molecular_profile	molecular_profile_id	disease	doid	phenotypes	therapies	therapy_interaction_type	evidence_type	evidence_direction	evidence_level	significance	evidence_statement	citation_id	source_type	asco_abstract_id	citation	nct_ids	rating	evidence_status	evidence_id	variant_origin	last_review_date	evidence_civic_url	molecular_profile_civic_url	is_flagged																			
JAK2 V617F	64	Lymphoid Leukemia	1037				Diagnostic	Supports	B	Negative	"JAK2 V617F is not associated with lymphoid leukemia (B-lineage ALL, T-ALL or CLL)."	16081687	PubMed		"Levine et al., 2005, Blood"		4	accepted	1	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/1	https://civicdb.org/links/molecular_profiles/64	FALSE	JAK2	3717	V617F		chr9	5073770	5073770	G	T	ENST00000381652.3	75		"missense_variant,gain_of_function_variant"	"NC_000009.11:g.5073770G>T,NM_004972.3:c.1849G>T,NP_004963.1:p.Val617Phe,ENST00000381652.3:c.1849G>T"	2023-01-27 17:02:22 UTC	CA124183	14662	"VAL617PHE,RS77375493"	FALSE
PDGFRA D842V	99	Gastrointestinal Stromal Tumor	9253				Diagnostic	Supports	B	Negative	GIST tumors harboring PDGFRA D842V mutation are more likely to be benign than malignant.	15146165	PubMed		"Lasota et al., 2004, Lab. Invest."		3	accepted	2	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/2	https://civicdb.org/links/molecular_profiles/99	FALSE	PDGFRA	5156	D842V	Imatinib Resistance	chr4	54285926	54285926	A	T	ENST00000257290.5	75		missense_variant	"NM_006206.4:c.2525A>T,NP_006197.1:p.Asp842Val,ENST00000257290.5:c.2525A>T,NC_000004.11:g.55152093A>T"	2023-01-27 17:02:33 UTC	CA123194	13543	"ASP842VAL,RS121908585"	FALSE
DNMT3A R882	32	Acute Myeloid Leukemia	9119				Diagnostic	Supports	B	Positive	DNMT3A R882 mutations occur most often in de novo AML patients with intermediate risk cytogenetics (39/194 intermediate risk patients vs 0/89 low and high risk).	22081665	PubMed		"LaRochelle et al., 2011, Oncotarget"		2	accepted	3	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/3	https://civicdb.org/links/molecular_profiles/32	FALSE	DNMT3A	1788	R882		chr2	25234372	25234374			ENST00000264709.3	75		missense_variant		2023-01-09 21:52:04 UTC		"375,881,375,880,375,000,000,000,000,000,000,000"	"R693,ARG882,ARG693"	FALSE
DNMT3A R882	32	Acute Myeloid Leukemia	9119				Diagnostic	Supports	B	Positive	"Young AML patients (<60 years old) with DNMT3A mutations (60% of which were R882) were older in age, had higher white blood cell counts and had higher platelet counts than patients wildtype for DNMT3A."	22490330	PubMed		"Ribeiro et al., 2012, Blood"		3	accepted	4	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/4	https://civicdb.org/links/molecular_profiles/32	FALSE	DNMT3A	1788	R882		chr2	25234372	25234374			ENST00000264709.3	75		missense_variant		2023-01-09 21:52:04 UTC		"375,881,375,880,375,000,000,000,000,000,000,000"	"R693,ARG882,ARG693"	FALSE
JAK2 V617F	64	Chronic Myeloid Leukemia	8552				Diagnostic	Supports	B	Positive	"JAK2 V617F is associated with myeloid malignanices (AML, MDS, CMML/atypical CML)."	16081687	PubMed		"Levine et al., 2005, Blood"		4	accepted	5	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/5	https://civicdb.org/links/molecular_profiles/64	FALSE	JAK2	3717	V617F		chr9	5073770	5073770	G	T	ENST00000381652.3	75		"missense_variant,gain_of_function_variant"	"NC_000009.11:g.5073770G>T,NM_004972.3:c.1849G>T,NP_004963.1:p.Val617Phe,ENST00000381652.3:c.1849G>T"	2023-01-27 17:02:22 UTC	CA124183	14662	"VAL617PHE,RS77375493"	FALSE
JAK2 V617F	64	Chronic Myeloid Leukemia	8552				Diagnostic	Supports	B	Positive	"JAK2 V617F is associated with myeloid neoplasms (AML, MDS, CMML/aCML)."	16081687	PubMed		"Levine et al., 2005, Blood"		4	accepted	6	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/6	https://civicdb.org/links/molecular_profiles/64	FALSE	JAK2	3717	V617F		chr9	5073770	5073770	G	T	ENST00000381652.3	75		"missense_variant,gain_of_function_variant"	"NC_000009.11:g.5073770G>T,NM_004972.3:c.1849G>T,NP_004963.1:p.Val617Phe,ENST00000381652.3:c.1849G>T"	2023-01-27 17:02:22 UTC	CA124183	14662	"VAL617PHE,RS77375493"	FALSE
JAK2 V617F	64	Bone Marrow Cancer	4960				Diagnostic	Supports	B	Positive	The SNP rs10974944 in the Jak2 locus is associated with increased predisposition for JAK2 V617F mutation and its associated cancer.	19287384	PubMed		"Kilpivaara et al., 2009, Nat. Genet."		4	accepted	7	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/7	https://civicdb.org/links/molecular_profiles/64	FALSE	JAK2	3717	V617F		chr9	5073770	5073770	G	T	ENST00000381652.3	75		"missense_variant,gain_of_function_variant"	"NC_000009.11:g.5073770G>T,NM_004972.3:c.1849G>T,NP_004963.1:p.Val617Phe,ENST00000381652.3:c.1849G>T"	2023-01-27 17:02:22 UTC	CA124183	14662	"VAL617PHE,RS77375493"	FALSE
KRAS G12	76	Acute Leukemia	12603				Diagnostic	Supports	B	Positive	Children with early age leukaemia who had second hand smoke exposure are more likely to harbor KRAS mutation.	24571676	PubMed		"Andrade et al., 2014, BMC Cancer"		3	accepted	8	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/8	https://civicdb.org/links/molecular_profiles/76	FALSE	KRAS	3845	G12		chr12	25245350	25245351			ENST00000256078.4	75		protein_altering_variant		2023-01-09 21:52:04 UTC		"451,221,257,812,582,000,000,000,000,000"	GLY12	FALSE
NRAS Q61	94	Melanoma	1909				Diagnostic	Supports	B	Positive	Melanoma associated with NRAS Q61 mutation was more often associated with those at the extremity than those at the trunk.	23861977	PubMed		"Tschandl et al., 2013, PLoS ONE"		3	accepted	10	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/10	https://civicdb.org/links/molecular_profiles/94	FALSE	NRAS	4893	Q61		chr1	114713907	114713909			ENST00000369535.4	75		missense_variant		2023-01-09 21:52:04 UTC		"7,305,813,900,375,870,000,000,000,000,000,000,000,000"	GLN61	FALSE
DNMT3A R882	32	Acute Myeloid Leukemia	9119		Daunorubicin		Predictive	Does Not Support	B	Resistance	Daunorubicin treatment resulted in similar overall survival and disease free survival in de novo AML patients with DNMT3A R882 mutation compared to those who do not harbor this mutation.	22081665	PubMed		"LaRochelle et al., 2011, Oncotarget"		4	accepted	11	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/11	https://civicdb.org/links/molecular_profiles/32	FALSE	DNMT3A	1788	R882		chr2	25234372	25234374			ENST00000264709.3	75		missense_variant		2023-01-09 21:52:04 UTC		"375,881,375,880,375,000,000,000,000,000,000,000"	"R693,ARG882,ARG693"	FALSE
MAP2K1 P124S	82	Melanoma	1909		Selumetinib		Predictive	Supports	D	Resistance	"A375 cells expressing MAP2K1 P124S mutation conferred an approximately 5-fold increased resistance to selumetinib (AZD6244) induced growth inhibition when compared to untransduced cells, cells expressing wild-type MAP2K1 or cells expressing a constitutively active form. This mutation also attenuated pERK inhibition by selumetinib in these cells."	19915144	PubMed		"Emery et al., 2009, Proc. Natl. Acad. Sci. U.S.A."		3	accepted	12	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/12	https://civicdb.org/links/molecular_profiles/82	FALSE	MAP2K1	5604	P124S		chr15	66436824	66436824	C	T	ENST00000307102.5	75		missense_variant	"ENST00000307102.5:c.370C>T,NC_000015.9:g.66729162C>T,NM_002755.3:c.370C>T,NP_002746.1:p.Pro124Ser"	2023-01-27 17:02:28 UTC	CA16602456	375981	PRO124SER	FALSE
MAP2K1 Q56P	83	Melanoma	1909		Selumetinib		Predictive	Supports	D	Resistance	"A375 cells expressing MAP2K1 Q56P mutation conferred an approximately 100-fold increased resistance to selumetinib (AZD6244) induced growth inhibition when compared to untransduced cells, cells expressing wild-type MAP2K1, or cells expressing a constitutively active form. This mutation also attenuated pERK inhibition by selumetinib in these cells."	19915144	PubMed		"Emery et al., 2009, Proc. Natl. Acad. Sci. U.S.A."		3	accepted	13	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/13	https://civicdb.org/links/molecular_profiles/83	FALSE	MAP2K1	5604	Q56P		chr15	66435113	66435113	A	C	ENST00000307102.5	75		missense_variant	"ENST00000307102.5:c.167A>C,NC_000015.9:g.66727451A>C,NM_002755.3:c.167A>C,NP_002746.1:p.Gln56Pro"	2023-01-27 17:02:29 UTC	CA16602453	375978	GLN56PRO	FALSE
NRAS Q61	94	Melanoma	1909		Vemurafenib		Predictive	Supports	B	Resistance	Vemurafenib resistance is associated with gain of Q61 mutation in NRAS.	23569304	PubMed		"Trunzer et al., 2013, J. Clin. Oncol."		4	accepted	14	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/14	https://civicdb.org/links/molecular_profiles/94	FALSE	NRAS	4893	Q61		chr1	114713907	114713909			ENST00000369535.4	75		missense_variant		2023-01-09 21:52:04 UTC		"7,305,813,900,375,870,000,000,000,000,000,000,000,000"	GLN61	FALSE
PDGFRA D842V	99	Gastrointestinal Stromal Tumor	9253		Imatinib		Predictive	Supports	B	Resistance	GIST cancer with D842V mutation is resistant to imatinib.	15928335	PubMed		"Corless et al., 2005, J. Clin. Oncol."		4	accepted	15	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/15	https://civicdb.org/links/molecular_profiles/99	FALSE	PDGFRA	5156	D842V	Imatinib Resistance	chr4	54285926	54285926	A	T	ENST00000257290.5	75		missense_variant	"NM_006206.4:c.2525A>T,NP_006197.1:p.Asp842Val,ENST00000257290.5:c.2525A>T,NC_000004.11:g.55152093A>T"	2023-01-27 17:02:33 UTC	CA123194	13543	"ASP842VAL,RS121908585"	FALSE
PDGFRA D842V	99	Gastrointestinal Stromal Tumor	9253		Imatinib		Predictive	Supports	B	Resistance	"While cancer with PDGFRA V561D mutation is known to be sensitive to Imatinib, double mutation of V561D and D842V mutants are resistant to imatinib."	16954519	PubMed		"Heinrich et al., 2006, J. Clin. Oncol."		4	accepted	16	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/16	https://civicdb.org/links/molecular_profiles/99	FALSE	PDGFRA	5156	D842V	Imatinib Resistance	chr4	54285926	54285926	A	T	ENST00000257290.5	75		missense_variant	"NM_006206.4:c.2525A>T,NP_006197.1:p.Asp842Val,ENST00000257290.5:c.2525A>T,NC_000004.11:g.55152093A>T"	2023-01-27 17:02:33 UTC	CA123194	13543	"ASP842VAL,RS121908585"	FALSE
ARAF S214C	10	Lung Non-small Cell Carcinoma	3908		Sorafenib		Predictive	Supports	C	Sensitivity/Response	"In one patient with S214C mutation, the use of sorafenib has led to more than 5 years of survival and near remission."	24569458	PubMed		"Imielinski et al., 2014, J. Clin. Invest."		2	accepted	17	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/17	https://civicdb.org/links/molecular_profiles/10	FALSE	ARAF	369	S214C		chrX	47566722	47566722	C	G	ENST00000377045.4	75		missense_variant	"NC_000023.10:g.47426121C>G,NM_001654.4:c.641C>G,NP_001645.1:p.Ser214Cys,ENST00000377045.4:c.641C>G"	2023-01-27 17:02:00 UTC	CA16602595	376137	"SER214CYS,RS1057519786"	FALSE
DNMT3A R882	32	Acute Myeloid Leukemia	9119		Idarubicin		Predictive	Supports	B	Sensitivity/Response	Idarubicin increases the overall survival and disease free survival in de novo AML patients with DNMT3A R882 mutation compared to those who do not harbor this mutation.	22081665	PubMed		"LaRochelle et al., 2011, Oncotarget"		4	accepted	18	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/18	https://civicdb.org/links/molecular_profiles/32	FALSE	DNMT3A	1788	R882		chr2	25234372	25234374			ENST00000264709.3	75		missense_variant		2023-01-09 21:52:04 UTC		"375,881,375,880,375,000,000,000,000,000,000,000"	"R693,ARG882,ARG693"	FALSE
JAK2 V617F	64	Polycythemia Vera	8997		Peginterferon Alfa-2b		Predictive	Supports	B	Sensitivity/Response	"In patients with JAK2 V617F, the use of pegylated IFN-alpha-2a leads to reduction in the percentage of cells harboring JAK2 V617F."	16709929	PubMed		"Kiladjian et al., 2006, Blood"	NCT00241241	4	accepted	19	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/19	https://civicdb.org/links/molecular_profiles/64	FALSE	JAK2	3717	V617F		chr9	5073770	5073770	G	T	ENST00000381652.3	75		"missense_variant,gain_of_function_variant"	"NC_000009.11:g.5073770G>T,NM_004972.3:c.1849G>T,NP_004963.1:p.Val617Phe,ENST00000381652.3:c.1849G>T"	2023-01-27 17:02:22 UTC	CA124183	14662	"VAL617PHE,RS77375493"	FALSE
JAK2 V617F	64	Polycythemia Vera	8997		Fedratinib		Predictive	Supports	D	Sensitivity/Response	TG101348 effectively inhibits STAT5 signaling in JAK2 V617F cells.	18394554	PubMed		"Wernig et al., 2008, Cancer Cell"		3	accepted	20	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/20	https://civicdb.org/links/molecular_profiles/64	FALSE	JAK2	3717	V617F		chr9	5073770	5073770	G	T	ENST00000381652.3	75		"missense_variant,gain_of_function_variant"	"NC_000009.11:g.5073770G>T,NM_004972.3:c.1849G>T,NP_004963.1:p.Val617Phe,ENST00000381652.3:c.1849G>T"	2023-01-27 17:02:22 UTC	CA124183	14662	"VAL617PHE,RS77375493"	FALSE
NRAS G13D	93	Melanoma	1909		Tanespimycin		Predictive	Supports	C	Sensitivity/Response	"Likely due to increased reliance of mutant NRAS on HSP90 for stabilization, inhibition of HSP90 by 17-AAG was shown to be effective in a patient with metastatic malignant melanoma with an NRAS G13D mutation."	18375819	PubMed		"Banerji et al., 2008, Mol. Cancer Ther."		2	accepted	21	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/21	https://civicdb.org/links/molecular_profiles/93	FALSE	NRAS	4893	G13D		chr1	114716123	114716123	C	T	ENST00000369535.4	75		missense_variant	"NM_002524.4:c.38G>A,NP_002515.1:p.Gly13Asp,NC_000001.10:g.115258744C>T,ENST00000369535.4:c.38G>A"	2023-01-27 17:02:30 UTC	CA123620	13901	"GLY13ASP,RS121434596"	FALSE
NRAS Q61L	95	Melanoma	1909		Temozolomide		Predictive	Supports	C	Sensitivity/Response	"In a melanoma patient with NRAS Q61L mutation, treatment with temozolomide resulted in disease free survival of 14 months."	21576590	PubMed		"Soon et al., 2011, Arch Dermatol"		2	accepted	22	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/22	https://civicdb.org/links/molecular_profiles/95	FALSE	NRAS	4893	Q61L		chr1	114713908	114713908	T	A	ENST00000369535.4	75		missense_variant	"NP_002515.1:p.Gln61Leu,NC_000001.10:g.115256529T>A,NM_002524.4:c.182A>T,ENST00000369535.4:c.182A>T"	2023-01-27 17:02:31 UTC	CA16602361	375874	"GLN61LEU,RS11554290"	FALSE
NRAS Q61R	96	Melanoma	1909		Temozolomide		Predictive	Supports	C	Sensitivity/Response	"In a melanoma patient with Q61R mutation, treatment with temozolomide resulted in overall survival of 16 months."	21576590	PubMed		"Soon et al., 2011, Arch Dermatol"		2	accepted	23	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/23	https://civicdb.org/links/molecular_profiles/96	FALSE	NRAS	4893	Q61R		chr1	114713908	114713908	T	C	ENST00000369535.4	75		missense_variant	"NM_002524.4:c.182A>G,NP_002515.1:p.Gln61Arg,NC_000001.10:g.115256529T>C,ENST00000369535.4:c.182A>G"	2023-01-27 17:02:32 UTC	CA123618	13900	"GLN61ARG,RS11554290"	FALSE
DNMT3A R882	32	Acute Myeloid Leukemia	9119				Prognostic	Does Not Support	B	N/A	There is no difference in the complete remission rate of de novo AML patients with DNMT3A mutation compared to those who are wild type for DNMT3A.	22081665	PubMed		"LaRochelle et al., 2011, Oncotarget"		4	accepted	24	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/24	https://civicdb.org/links/molecular_profiles/32	FALSE	DNMT3A	1788	R882		chr2	25234372	25234374			ENST00000264709.3	75		missense_variant		2023-01-09 21:52:04 UTC		"375,881,375,880,375,000,000,000,000,000,000,000"	"R693,ARG882,ARG693"	FALSE
DNMT3A R882	32	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	De novo AML patients with DNMT3A D882 mutation showed worse survival (event-free and overall) outcome than those without DNMT3A mutation.	21067377	PubMed		"Ley et al., 2010, N. Engl. J. Med."		4	accepted	25	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/25	https://civicdb.org/links/molecular_profiles/32	FALSE	DNMT3A	1788	R882		chr2	25234372	25234374			ENST00000264709.3	75		missense_variant		2023-01-09 21:52:04 UTC		"375,881,375,880,375,000,000,000,000,000,000,000"	"R693,ARG882,ARG693"	FALSE
KIT D816V	65	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	"In acute myloid leukemia patients, D816 mutation is associated with earlier relapse and poorer prognosis than wildtype KIT."	16384925	PubMed		"Cairoli et al., 2006, Blood"		4	accepted	26	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/26	https://civicdb.org/links/molecular_profiles/65	FALSE	KIT	3815	D816V	KIT Exon 17	chr4	54733155	54733155	A	T	ENST00000288135.5	75		missense_variant	"NM_000222.2:c.2447A>T,NP_000213.1:p.Asp816Val,ENST00000288135.5:c.2447A>T,NC_000004.11:g.55599321A>T"	2023-01-27 17:02:23 UTC	CA123513	13852	"ASP816VAL,RS121913507"	FALSE
NRAS Mutation	208	Colorectal Cancer	9256				Prognostic	Supports	B	Poor Outcome	Patients with colorectal cancer harboring NRAS mutation have poorer survival outcome and worse prognosis than patients with wildtype NRAS.	24666267	PubMed		"Therkildsen et al., 2014, Acta Oncol"		3	accepted	27	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/27	https://civicdb.org/links/molecular_profiles/208	FALSE	NRAS	4893	Mutation		chr1	114704469	114716894			ENST00000369535.4	75		"transcript_variant,gain_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
BRAF V600	17	Melanoma	1909				Diagnostic	Supports	B	Positive	BRAF mutations are associated with melanoma arising in non-chronic sun damaged skin and with superficial spreading melanoma.	21166657	PubMed		"Lee et al., 2011, Br. J. Dermatol."		4	accepted	30	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/30	https://civicdb.org/links/molecular_profiles/17	FALSE	BRAF	673	V600	Other BRAF V600's	chr7	140753336	140753337			ENST00000288602.6	75		protein_altering_variant		2023-01-09 21:52:04 UTC		"13,961,448,153,762,800,000,000,000,000,000"	VAL600	FALSE
DNMT3A R882	32	Acute Myeloid Leukemia	9119				Diagnostic	Supports	B	Positive	"DNMT3A R882 mutations were associated with older age, higher white blood cell count, and FAB M4 and M5 subtypes compared to wildtype DNMT3A in a cohort of cytogenetically normal AML patients."	24512939	PubMed		"El Ghannam et al., 2014, Blood Cells Mol Dis"		3	accepted	31	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/31	https://civicdb.org/links/molecular_profiles/32	FALSE	DNMT3A	1788	R882		chr2	25234372	25234374			ENST00000264709.3	75		missense_variant		2023-01-09 21:52:04 UTC		"375,881,375,880,375,000,000,000,000,000,000,000"	"R693,ARG882,ARG693"	FALSE
ALK F1174L	8	Inflammatory Myofibroblastic Tumor	50905		Crizotinib		Predictive	Supports	D	Resistance	Ba/F3 cells expressing the RANBP2-ALK fusion containing an F1174L mutation were more resistant to crizotinib treatment than Ba/F3 cells expressing RANBP2-ALK without this mutation.	21030459	PubMed		"Sasaki et al., 2010, Cancer Res."		3	accepted	32	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/32	https://civicdb.org/links/molecular_profiles/8	FALSE	ALK	238	F1174L	ALK Crizotinib Resistance	chr2	29220829	29220829	G	T	ENST00000389048.3	75		missense_variant	"NM_004304.4:c.3522C>A,NP_004295.2:p.Phe1174Leu,NC_000002.11:g.29443695G>T,ENST00000389048.3:c.3522C>A"	2023-01-27 17:01:58 UTC	CA279586	217851	"PHE1174LEU,RS863225281"	FALSE
ALK F1174L	8	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	D	Resistance	Ba/F3 cells expressing the EML4-ALK fusion containing an F1174L mutation were more resistant to crizotinib treatment than Ba/F3 cells expressing EML4-ALK without this mutation.	21030459	PubMed		"Sasaki et al., 2010, Cancer Res."		3	accepted	33	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/33	https://civicdb.org/links/molecular_profiles/8	FALSE	ALK	238	F1174L	ALK Crizotinib Resistance	chr2	29220829	29220829	G	T	ENST00000389048.3	75		missense_variant	"NM_004304.4:c.3522C>A,NP_004295.2:p.Phe1174Leu,NC_000002.11:g.29443695G>T,ENST00000389048.3:c.3522C>A"	2023-01-27 17:01:58 UTC	CA279586	217851	"PHE1174LEU,RS863225281"	FALSE
KIT L576P	72	Melanoma	1909		"Imatinib,Sorafenib,Nilotinib"	Substitutes	Predictive	Supports	D	Resistance	"The melanoma cell line WM3211, which harbors the L576P mutation, is not sensitive to imatinib, nilotinib, and sorafenib. Molecular modeling indicated the L576P mutation alters the conformation of KIT and reduces the binding affinity of imatinib."	19671763	PubMed		"Woodman et al., 2009, Mol. Cancer Ther."		3	accepted	34	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/34	https://civicdb.org/links/molecular_profiles/72	FALSE	KIT	3815	L576P	KIT Exon 11	chr4	54727495	54727495	T	C	ENST00000288135.5	75		missense_variant	"NM_000222.2:c.1727T>C,NP_000213.1:p.Leu576Pro,ENST00000288135.5:c.1727T>C,NC_000004.11:g.55593661T>C"	2023-01-27 17:02:24 UTC	CA16602401	375919	"RS121913513,LEU576PRO"	FALSE
KRAS G12/G13	77	Lung Non-small Cell Carcinoma	3908		"Gefitinib,Erlotinib"	Substitutes	Predictive	Supports	B	Resistance	"In 60 patients with NSCLC, Exon 2 KRAS mutations were associated with resistance to the EGFR kinase inhibitors gefitinib or erlotinib (9/38 refractory vs 0/21 sensitive patients; P=0.0201)."	15696205	PubMed		"Pao et al., 2005, PLoS Med."		3	accepted	35	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/35	https://civicdb.org/links/molecular_profiles/77	FALSE	KRAS	3845	G12/G13		chr12	25245346	25245351			ENST00000256078.4	75		protein_altering_variant		2023-01-09 21:52:04 UTC		"45,122,125,781,258,200,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000"		FALSE
NRAS Q61	94	Colorectal Cancer	9256		"Chemotherapy,Cetuximab"	Combination	Predictive	Supports	B	Resistance	"Chemotherapy-refractory patients with KRAS wt metastatic colorectal cancer harboring NRAS mutation (primarily Q61, n=10) have a significantly lower response rate to cetuximab than patients wildtype for NRAS (7.1% [1/14] vs 38.1% [110/289])."	20619739	PubMed		"De Roock et al., 2010, Lancet Oncol."		2	accepted	36	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/36	https://civicdb.org/links/molecular_profiles/94	FALSE	NRAS	4893	Q61		chr1	114713907	114713909			ENST00000369535.4	75		missense_variant		2023-01-09 21:52:04 UTC		"7,305,813,900,375,870,000,000,000,000,000,000,000,000"	GLN61	FALSE
ALK F1174L	8	Neuroblastoma	769		Alectinib		Predictive	Supports	D	Sensitivity/Response	CH5424802 (Alectinib) is effective in inhibiting the activity of the F1174L ALK mutant in a kinase activity assay and proliferation assay using neuroblastoma KELLY cells.	21575866	PubMed		"Sakamoto et al., 2011, Cancer Cell"		3	accepted	37	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/37	https://civicdb.org/links/molecular_profiles/8	FALSE	ALK	238	F1174L	ALK Crizotinib Resistance	chr2	29220829	29220829	G	T	ENST00000389048.3	75		missense_variant	"NM_004304.4:c.3522C>A,NP_004295.2:p.Phe1174Leu,NC_000002.11:g.29443695G>T,ENST00000389048.3:c.3522C>A"	2023-01-27 17:01:58 UTC	CA279586	217851	"PHE1174LEU,RS863225281"	FALSE
ALK F1174L	8	Neuroblastoma	769		Crizotinib		Predictive	Supports	D	Sensitivity/Response	High levels of crizotinib can overcome drug resistance of Ba/F3 cells expressing the EML4-ALK fusion containing the F1174L mutation.	21948233	PubMed		"Heuckmann et al., 2011, Clin. Cancer Res."		3	accepted	38	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/38	https://civicdb.org/links/molecular_profiles/8	FALSE	ALK	238	F1174L	ALK Crizotinib Resistance	chr2	29220829	29220829	G	T	ENST00000389048.3	75		missense_variant	"NM_004304.4:c.3522C>A,NP_004295.2:p.Phe1174Leu,NC_000002.11:g.29443695G>T,ENST00000389048.3:c.3522C>A"	2023-01-27 17:01:58 UTC	CA279586	217851	"PHE1174LEU,RS863225281"	FALSE
ALK R1275Q	9	Neuroblastoma	769		TAE684		Predictive	Supports	D	Sensitivity/Response	"TAE684 inhibits growth of Ba/F3 cells expressing ALK mutations; however, cells with the R1275Q mutation were inhibited at a higher IC50 than those expressing F1174L."	18923525	PubMed		"George et al., 2008, Nature"		3	accepted	39	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/39	https://civicdb.org/links/molecular_profiles/9	FALSE	ALK	238	R1275Q		chr2	29209798	29209798	C	T	ENST00000389048.3	75		missense_variant	"NM_004304.4:c.3824G>A,NP_004295.2:p.Arg1275Gln,NC_000002.11:g.29432664C>T,ENST00000389048.3:c.3824G>A"	2023-01-27 17:01:59 UTC	CA341482	18083	"ARG1275GLN,RS113994087"	FALSE
ARAF S214C	10	Lung Non-small Cell Carcinoma	3908		Sorafenib		Predictive	Supports	D	Sensitivity/Response	Sorafenib can inhibit ARF-mediated MEK phosphorylation and soft agar colony formation of AALE cells expressing ARAF S214C in vitro.	24569458	PubMed		"Imielinski et al., 2014, J. Clin. Invest."		3	accepted	40	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/40	https://civicdb.org/links/molecular_profiles/10	FALSE	ARAF	369	S214C		chrX	47566722	47566722	C	G	ENST00000377045.4	75		missense_variant	"NC_000023.10:g.47426121C>G,NM_001654.4:c.641C>G,NP_001645.1:p.Ser214Cys,ENST00000377045.4:c.641C>G"	2023-01-27 17:02:00 UTC	CA16602595	376137	"SER214CYS,RS1057519786"	FALSE
ARAF S214C	10	Lung Non-small Cell Carcinoma	3908		Trametinib		Predictive	Supports	D	Sensitivity/Response	Trametinib can inhibit ARF-mediated ERK phosphorylation and soft agar colony formation of AALE cells expressing ARAF S214C in vitro.	24569458	PubMed		"Imielinski et al., 2014, J. Clin. Invest."		3	accepted	41	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/41	https://civicdb.org/links/molecular_profiles/10	FALSE	ARAF	369	S214C		chrX	47566722	47566722	C	G	ENST00000377045.4	75		missense_variant	"NC_000023.10:g.47426121C>G,NM_001654.4:c.641C>G,NP_001645.1:p.Ser214Cys,ENST00000377045.4:c.641C>G"	2023-01-27 17:02:00 UTC	CA16602595	376137	"SER214CYS,RS1057519786"	FALSE
KIT L576P	72	Melanoma	1909		Dasatinib		Predictive	Supports	D	Sensitivity/Response	"The melanoma cell line WM3211, which harbors the L576P mutation, is sensitive to dasatinib. Molecular modeling indicated the L576P mutation alters the conformation of KIT but did not alter the binding affinity of dasatinib."	19671763	PubMed		"Woodman et al., 2009, Mol. Cancer Ther."		3	accepted	42	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/42	https://civicdb.org/links/molecular_profiles/72	FALSE	KIT	3815	L576P	KIT Exon 11	chr4	54727495	54727495	T	C	ENST00000288135.5	75		missense_variant	"NM_000222.2:c.1727T>C,NP_000213.1:p.Leu576Pro,ENST00000288135.5:c.1727T>C,NC_000004.11:g.55593661T>C"	2023-01-27 17:02:24 UTC	CA16602401	375919	"RS121913513,LEU576PRO"	FALSE
PDGFRA D842I	98	Gastrointestinal Stromal Tumor	9253		Crenolanib		Predictive	Supports	D	Sensitivity/Response	"In CHO cells with PDGFRA D842I mutation that have shown imatinib resistance, crenolanib was significantly more potent at inhibiting kinase activity than imatinib."	22745105	PubMed		"Heinrich et al., 2012, Clin. Cancer Res."		4	accepted	43	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/43	https://civicdb.org/links/molecular_profiles/98	FALSE	PDGFRA	5156	D842I	Imatinib Resistance	chr4	54285925	54285926	GA	AT	ENST00000257290.5	75		missense_variant	"ENST00000257290.5:c.2524_2525delinsAT,NC_000004.11:g.55152092_55152093delinsAT,NP_006197.1:p.Asp842Ile,NM_006206.5:c.2524_2525delGAinsAT"	2023-01-27 17:02:33 UTC	CA16602522	376055	ASP842ILE	FALSE
PDGFRA D842V	99	Gastrointestinal Stromal Tumor	9253		Crenolanib		Predictive	Supports	D	Sensitivity/Response	"In CHO cells with PDGFRA D842V mutation that have shown imatinib resistance, crenolanib was significantly more potent at inhibiting kinase activity than imatinib."	22745105	PubMed		"Heinrich et al., 2012, Clin. Cancer Res."		4	accepted	44	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/44	https://civicdb.org/links/molecular_profiles/99	FALSE	PDGFRA	5156	D842V	Imatinib Resistance	chr4	54285926	54285926	A	T	ENST00000257290.5	75		missense_variant	"NM_006206.4:c.2525A>T,NP_006197.1:p.Asp842Val,ENST00000257290.5:c.2525A>T,NC_000004.11:g.55152093A>T"	2023-01-27 17:02:33 UTC	CA123194	13543	"ASP842VAL,RS121908585"	FALSE
PDGFRA D842Y	100	Gastrointestinal Stromal Tumor	9253		Crenolanib		Predictive	Supports	D	Sensitivity/Response	"In CHO cells with PDGFRA D842Y mutation that have shown imatinib resistance, crenolanib was significantly more potent at inhibiting kinase activity than imatinib."	22745105	PubMed		"Heinrich et al., 2012, Clin. Cancer Res."		4	accepted	45	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/45	https://civicdb.org/links/molecular_profiles/100	FALSE	PDGFRA	5156	D842Y	Imatinib Resistance	chr4	54285925	54285925	G	T	ENST00000257290.5	75		missense_variant	"ENST00000257290.5:c.2524G>T,NC_000004.11:g.55152092G>T,NM_006206.5:c.2524G>T,NP_006197.1:p.Asp842Tyr"	2023-01-27 17:02:34 UTC	CA16602703	376250	"ASP842TYR,RS121913265"	FALSE
PDGFRA I843DEL	101	Gastrointestinal Stromal Tumor	9253		Crenolanib		Predictive	Supports	D	Sensitivity/Response	"In CHO cells with the PDGFRA deletion I843 mutation that have shown imatinib sensitivity, crenolanib showed no significant difference from imatinib in kinase activity inhibition."	22745105	PubMed		"Heinrich et al., 2012, Clin. Cancer Res."		3	accepted	46	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/46	https://civicdb.org/links/molecular_profiles/101	FALSE	PDGFRA	5156	I843DEL	Imatinib Resistance	chr4	54285928	54285930	ATC		ENST00000257290.5	75		inframe_deletion	"ENST00000257290.5:c.2527_2529delATC,NC_000004.11:g.55152095_55152097del"	2023-01-27 17:02:35 UTC	CA645526434	NONE FOUND	DELI843	FALSE
PDGFRA D842_I843delinsVM	102	Gastrointestinal Stromal Tumor	9253		Crenolanib		Predictive	Supports	D	Sensitivity/Response	"In CHO cells with PDGFRA DI842-843VM mutation that have shown imatinib resistance, crenolanib was significantly more potent at inhibiting kinase activity than imatinib."	22745105	PubMed		"Heinrich et al., 2012, Clin. Cancer Res."		4	accepted	47	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/47	https://civicdb.org/links/molecular_profiles/102	FALSE	PDGFRA	5156	D842_I843delinsVM	Imatinib Resistance	chr4	54285926	54285930	ACATC	TCATG	ENST00000257290.5	75		missense_variant	NC_000004.11:g.55152093_55152097delinsTCATG	2023-01-27 17:02:36 UTC	CA658820703	NONE FOUND		FALSE
ALK R1275Q	9	Neuroblastoma	769		TAE684		Predictive	Supports	D	Resistance	The SMS-KCNR cell line harboring the R1275Q mutation was resistant to TAE684.	18923525	PubMed		"George et al., 2008, Nature"		3	accepted	48	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/48	https://civicdb.org/links/molecular_profiles/9	FALSE	ALK	238	R1275Q		chr2	29209798	29209798	C	T	ENST00000389048.3	75		missense_variant	"NM_004304.4:c.3824G>A,NP_004295.2:p.Arg1275Gln,NC_000002.11:g.29432664C>T,ENST00000389048.3:c.3824G>A"	2023-01-27 17:01:59 UTC	CA341482	18083	"ARG1275GLN,RS113994087"	FALSE
DNMT3A R882	32	Acute Myeloid Leukemia	9119				Prognostic	Does Not Support	B	N/A	"In a large cohort of AML patients (mean = 48 years), DNMT3A mutation (64.5% of which were R882) had no prognostic value on overall, relapse free and event free survival."	23632886	PubMed		"Gaidzik et al., 2013, Blood"		3	accepted	49	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/49	https://civicdb.org/links/molecular_profiles/32	FALSE	DNMT3A	1788	R882		chr2	25234372	25234374			ENST00000264709.3	75		missense_variant		2023-01-09 21:52:04 UTC		"375,881,375,880,375,000,000,000,000,000,000,000"	"R693,ARG882,ARG693"	FALSE
DNMT3A R882	32	Acute Myeloid Leukemia	9119				Prognostic	Does Not Support	B	Poor Outcome	"In a large cohort (n=1770) of AML patients (18-60 years old), DNMT3A mutation status (65.4% of which were R882) had no prognostic value for overall, relapse free and event free survival. This was true for cytogenetically normal AML and the entire cohort."	23632886	PubMed		"Gaidzik et al., 2013, Blood"		3	accepted	50	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/50	https://civicdb.org/links/molecular_profiles/32	FALSE	DNMT3A	1788	R882		chr2	25234372	25234374			ENST00000264709.3	75		missense_variant		2023-01-09 21:52:04 UTC		"375,881,375,880,375,000,000,000,000,000,000,000"	"R693,ARG882,ARG693"	FALSE
DNMT3A R882	32	Acute Myeloid Leukemia	9119				Prognostic	Does Not Support	B	N/A	"In young AML patients (<60 years old), DNMT3A mutation status (60% of which were R882) was not predictive of overall and relapse free survival in patients with NPM1 mutations and wildtype FLT3 or wildtype NPM1 and FLT3-ITD."	22490330	PubMed		"Ribeiro et al., 2012, Blood"		4	accepted	51	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/51	https://civicdb.org/links/molecular_profiles/32	FALSE	DNMT3A	1788	R882		chr2	25234372	25234374			ENST00000264709.3	75		missense_variant		2023-01-09 21:52:04 UTC		"375,881,375,880,375,000,000,000,000,000,000,000"	"R693,ARG882,ARG693"	FALSE
FLT3 ITD	55	Acute Myeloid Leukemia	9119				Prognostic	Does Not Support	B	N/A	"In young AML patients (<60 years old), DNMT3A mutation status was not predictive of overall and relapse free survival in patients with NPM1 mutations and wildtype FLT3 or wildtype NPM1 and FLT3-ITD."	22490330	PubMed		"Ribeiro et al., 2012, Blood"		4	accepted	52	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/52	https://civicdb.org/links/molecular_profiles/55	FALSE	FLT3	2322	ITD		chr13	28034082	28034214			ENST00000241453.7	75		inframe_insertion		2023-01-09 21:52:04 UTC		16270		FALSE
KIT Exon 11 Mutation	66	Gastrointestinal Stromal Tumor	9253				Prognostic	Does Not Support	B	N/A	There is no significant association between wildtype KIT or KIT mutations in exon 9 or 11 in survival among GIST patients.	16551858	PubMed		"Wardelmann et al., 2006, Clin. Cancer Res."		3	accepted	53	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/53	https://civicdb.org/links/molecular_profiles/66	FALSE	KIT	3815	Exon 11 Mutation	KIT Exon 11	chr4	54727416	54727542			ENST00000288135.5	75		coding_sequence_variant		2023-01-09 21:52:04 UTC				FALSE
NRAS Mutation	208	Acute Myeloid Leukemia	9119				Prognostic	Does Not Support	B	N/A	"The presence of NRAS mutation in AML patients does not impact diease prognosis (resistant disease, disease-free survival, complete remission rate, relapse rate, induction death)."	15951308	PubMed		"Bowen et al., 2005, Blood"		3	accepted	56	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/56	https://civicdb.org/links/molecular_profiles/208	FALSE	NRAS	4893	Mutation		chr1	114704469	114716894			ENST00000369535.4	75		"transcript_variant,gain_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
NRAS G12	92	Acute Myeloid Leukemia	9119				Prognostic	Does Not Support	B	N/A	"NRAS mutation status does not impact overall, event-free or disease-free survival in patients with AML."	16434492	PubMed		"Bacher et al., 2006, Blood"		3	accepted	57	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/57	https://civicdb.org/links/molecular_profiles/92	FALSE	NRAS	4893	G12		chr1	114716126	114716127			ENST00000369535.4	75		missense_variant		2023-01-09 21:52:04 UTC		"40,468,396,481,777,700,000,000,000,000,000"		FALSE
KIT Exon 11 Mutation	66	Melanoma	1909		Imatinib		Predictive	Supports	B	Sensitivity/Response	Melanoma patients with KIT mutation but not KIT amplification showed response to imatinib treatment in a small cohort of patients.	23775962	PubMed		"Hodi et al., 2013, J. Clin. Oncol."	NCT00424515	3	accepted	58	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/58	https://civicdb.org/links/molecular_profiles/66	FALSE	KIT	3815	Exon 11 Mutation	KIT Exon 11	chr4	54727416	54727542			ENST00000288135.5	75		coding_sequence_variant		2023-01-09 21:52:04 UTC				FALSE
DNMT3A R882	32	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	"In a large cohort of young AML patients (18-60 years old), DNMT3A R882 mutations were associated with reduced relapse free survival in the entire cohort as well as the subset of patients with cytogenetically normal AML."	23632886	PubMed		"Gaidzik et al., 2013, Blood"		3	accepted	61	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/61	https://civicdb.org/links/molecular_profiles/32	FALSE	DNMT3A	1788	R882		chr2	25234372	25234374			ENST00000264709.3	75		missense_variant		2023-01-09 21:52:04 UTC		"375,881,375,880,375,000,000,000,000,000,000,000"	"R693,ARG882,ARG693"	FALSE
DNMT3A R882	32	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	AML patients with DNMT3A mutations (59% of which were R882) showed worse survival (event-free and overall) outcome than those without DNMT3A mutation.	21067377	PubMed		"Ley et al., 2010, N. Engl. J. Med."		5	accepted	62	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/62	https://civicdb.org/links/molecular_profiles/32	FALSE	DNMT3A	1788	R882		chr2	25234372	25234374			ENST00000264709.3	75		missense_variant		2023-01-09 21:52:04 UTC		"375,881,375,880,375,000,000,000,000,000,000,000"	"R693,ARG882,ARG693"	FALSE
DNMT3A R882	32	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	"DNMT3A R882 mutation was associated with reduced relapse free and overall survival in ELN-unfavorable, cytogenetically normal AMLs."	23632886	PubMed		"Gaidzik et al., 2013, Blood"		3	accepted	63	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/63	https://civicdb.org/links/molecular_profiles/32	FALSE	DNMT3A	1788	R882		chr2	25234372	25234374			ENST00000264709.3	75		missense_variant		2023-01-09 21:52:04 UTC		"375,881,375,880,375,000,000,000,000,000,000,000"	"R693,ARG882,ARG693"	FALSE
DNMT3A R882	32	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	"In AML patients with FLT3-ITD mutations, concurrent DNMT3A mutations (including R882) were associated with worse overall survival compared to those without DNMT3A mutation."	21067377	PubMed		"Ley et al., 2010, N. Engl. J. Med."		5	accepted	64	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/64	https://civicdb.org/links/molecular_profiles/32	FALSE	DNMT3A	1788	R882		chr2	25234372	25234374			ENST00000264709.3	75		missense_variant		2023-01-09 21:52:04 UTC		"375,881,375,880,375,000,000,000,000,000,000,000"	"R693,ARG882,ARG693"	FALSE
DNMT3A R882	32	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	"In cytogenetically normal AML patients, DNMT3A R882 mutations are associated with lower overall and disease free survival as compared to patients with wild type DNMT3A."	24512939	PubMed		"El Ghannam et al., 2014, Blood Cells Mol Dis"		5	accepted	65	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/65	https://civicdb.org/links/molecular_profiles/32	FALSE	DNMT3A	1788	R882		chr2	25234372	25234374			ENST00000264709.3	75		missense_variant		2023-01-09 21:52:04 UTC		"375,881,375,880,375,000,000,000,000,000,000,000"	"R693,ARG882,ARG693"	FALSE
DNMT3A R882	32	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	"In older cytogenetically normal AML patients (>59 years), DNMT3A R882 mutation is prognostic for shorter disease free survival and overall survival compared to patients without the mutation."	22291079	PubMed		"Marcucci et al., 2012, J. Clin. Oncol."		4	accepted	66	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/66	https://civicdb.org/links/molecular_profiles/32	FALSE	DNMT3A	1788	R882		chr2	25234372	25234374			ENST00000264709.3	75		missense_variant		2023-01-09 21:52:04 UTC		"375,881,375,880,375,000,000,000,000,000,000,000"	"R693,ARG882,ARG693"	FALSE
DNMT3A R882	32	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	"In young AML patients (<60 years old), DNMT3A mutations were associated with significantly reduced overall survival and relapse free survival in patients wildtype for NPM1 and FLT3."	22490330	PubMed		"Ribeiro et al., 2012, Blood"		4	accepted	67	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/67	https://civicdb.org/links/molecular_profiles/32	FALSE	DNMT3A	1788	R882		chr2	25234372	25234374			ENST00000264709.3	75		missense_variant		2023-01-09 21:52:04 UTC		"375,881,375,880,375,000,000,000,000,000,000,000"	"R693,ARG882,ARG693"	FALSE
DNMT3A R882	32	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	"In younger cytogenetically normal AML patients (<60 years), DNMT3A mutations other than R882 are prognostic for shorter disease free survival and overall survival compared to patients without the mutation."	22291079	PubMed		"Marcucci et al., 2012, J. Clin. Oncol."		4	accepted	68	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/68	https://civicdb.org/links/molecular_profiles/32	FALSE	DNMT3A	1788	R882		chr2	25234372	25234374			ENST00000264709.3	75		missense_variant		2023-01-09 21:52:04 UTC		"375,881,375,880,375,000,000,000,000,000,000,000"	"R693,ARG882,ARG693"	FALSE
FLT3 ITD	55	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	"In AML patients with FLT3-ITD mutations, concurrent DNMT3A mutations were associated with worse overall survival compared to those without DNMT3A mutation."	21067377	PubMed		"Ley et al., 2010, N. Engl. J. Med."		5	accepted	69	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/69	https://civicdb.org/links/molecular_profiles/55	FALSE	FLT3	2322	ITD		chr13	28034082	28034214			ENST00000241453.7	75		inframe_insertion		2023-01-09 21:52:04 UTC		16270		FALSE
KIT Exon 14 Mutation	69	Gastrointestinal Stromal Tumor	9253				Prognostic	Supports	B	Poor Outcome	GIST patients with exon 14 KIT mutations had reduced overall survival compared to patients wiltype for KIT.	16551858	PubMed		"Wardelmann et al., 2006, Clin. Cancer Res."		3	accepted	70	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/70	https://civicdb.org/links/molecular_profiles/69	FALSE	KIT	3815	Exon 14 Mutation		chr4	54729335	54729485			ENST00000288135.5	75		exon_variant		2023-01-09 21:52:04 UTC				FALSE
NRAS Mutation	208	Melanoma	1909				Prognostic	Supports	B	Poor Outcome	"In patients with stage IV melanoma, NRAS mutation was associated with reduced median survival compared to patients with wildtype NRAS."	22180178	PubMed		"Jakob et al., 2012, Cancer"		3	accepted	71	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/71	https://civicdb.org/links/molecular_profiles/208	FALSE	NRAS	4893	Mutation		chr1	114704469	114716894			ENST00000369535.4	75		"transcript_variant,gain_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
RET M918T	113	Thyroid Gland Medullary Carcinoma	3973				Diagnostic	Supports	B	Positive	"In patients with medullary carcinoma, the presence of RET M918T mutation is associated with increased probability of lymph node metastases."	18073307	PubMed		"Elisei et al., 2008, J. Clin. Endocrinol. Metab."		5	accepted	74	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/74	https://civicdb.org/links/molecular_profiles/113	FALSE	RET	5979	M918T	RET Motesanib Resistance	chr10	43121968	43121968	T	C	ENST00000355710.3	75		missense_variant	"NM_020975.4:c.2753T>C,NP_065681.1:p.Met918Thr,ENST00000355710.3:c.2753T>C,NC_000010.10:g.43617416T>C"	2023-01-27 17:02:41 UTC	CA009082	13919	"MET918THR,RS74799832"	FALSE
RET C634W	112	Thyroid Gland Medullary Carcinoma	3973		Motesanib		Predictive	Supports	D	Resistance	"Medullary thyroid cancer cells with RET C634W mutation are insensitive to motesanib, compared to wild-type RET."	21422803	PubMed		"Coxon et al., 2012, J. Endocrinol. Invest."		3	accepted	75	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/75	https://civicdb.org/links/molecular_profiles/112	FALSE	RET	5979	C634W	RET Motesanib Resistance	chr10	43114502	43114502	C	G	ENST00000355710.3	75		missense_variant	"NM_020975.4:c.1902C>G,NP_065681.1:p.Cys634Trp,ENST00000355710.3:c.1902C>G,NC_000010.10:g.43609950C>G"	2023-01-27 17:02:40 UTC	CA008378	13918	CYS634TRP	FALSE
RET M918T	113	Thyroid Gland Medullary Carcinoma	3973		Motesanib		Predictive	Supports	D	Resistance	"Medullary thyroid cancer cells with RET M918T mutation are insensitive to motesanib, compared to wild-type RET."	21422803	PubMed		"Coxon et al., 2012, J. Endocrinol. Invest."		3	accepted	76	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/76	https://civicdb.org/links/molecular_profiles/113	FALSE	RET	5979	M918T	RET Motesanib Resistance	chr10	43121968	43121968	T	C	ENST00000355710.3	75		missense_variant	"NM_020975.4:c.2753T>C,NP_065681.1:p.Met918Thr,ENST00000355710.3:c.2753T>C,NC_000010.10:g.43617416T>C"	2023-01-27 17:02:41 UTC	CA009082	13919	"MET918THR,RS74799832"	FALSE
RET M918T	113	Thyroid Gland Medullary Carcinoma	3973		JAK2 Inhibitor AZD1480		Predictive	Supports	D	Sensitivity/Response	The use of AZD1480 on RET-mutated/rearranged cell lines in vitro led to strong repression of tyroid cancer cell growth.	23056499	PubMed		"Couto et al., 2012, PLoS ONE"		3	accepted	77	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/77	https://civicdb.org/links/molecular_profiles/113	FALSE	RET	5979	M918T	RET Motesanib Resistance	chr10	43121968	43121968	T	C	ENST00000355710.3	75		missense_variant	"NM_020975.4:c.2753T>C,NP_065681.1:p.Met918Thr,ENST00000355710.3:c.2753T>C,NC_000010.10:g.43617416T>C"	2023-01-27 17:02:41 UTC	CA009082	13919	"MET918THR,RS74799832"	FALSE
RET M918T	113	Thyroid Gland Medullary Carcinoma	3973				Prognostic	Supports	B	Poor Outcome	"Compared to those who harbor a wild type RET, patients with RET M918T mutation develop larger and more aggressive medullary thyroid cancer."	9839497	PubMed		"Egawa et al., 1998, Jpn. J. Clin. Oncol."		4	accepted	78	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/78	https://civicdb.org/links/molecular_profiles/113	FALSE	RET	5979	M918T	RET Motesanib Resistance	chr10	43121968	43121968	T	C	ENST00000355710.3	75		missense_variant	"NM_020975.4:c.2753T>C,NP_065681.1:p.Met918Thr,ENST00000355710.3:c.2753T>C,NC_000010.10:g.43617416T>C"	2023-01-27 17:02:41 UTC	CA009082	13919	"MET918THR,RS74799832"	FALSE
BRAF V600E	12	Thyroid Gland Cancer	1781				Diagnostic	Supports	B	Positive	BRAF V600E is shown to be associated with the tall-cell variant of papillary thyroid cancer.	21594703	PubMed		"Howell et al., 2011, Ann. Surg. Oncol."		3	accepted	79	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/79	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
BRAF V600E	12	Thyroid Gland Papillary Carcinoma	3969				Diagnostic	Supports	B	Positive	Thyroid nodule with BRAF V600E mutation is highly correlated with papillary thyroid cancer.	24570209	PubMed		"Crescenzi et al., 2014, Horm. Metab. Res."		5	accepted	80	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/80	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
BRAF V600E	12	Melanoma	1909				Prognostic	Does Not Support	B	Poor Outcome	BRAF status does not predict outcome in patients treated with dacarbazine or temozolomide.	24586605	PubMed		"Meckbach et al., 2014, PLoS ONE"		2	accepted	82	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/82	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
PIK3CA E542K	103	Colorectal Cancer	9256		Regorafenib		Predictive	Does Not Support	B	Resistance	"This was a retrospective analysis of genetic markers in 503 metastatic colorectal cancer patients who participated in the CORRECT phase III trial of regorafenib. PIK3CA mutations were identified in the tumors of 84 patients, including 27 with PIK3CA E542K. Authors found a clinical benefit of regorafenib across PIK3CA mutated and wildtype subgroups (progression free survival with regorafenib vs placebo: mutant HR: 0.54, wildtype HR: 0.50, P=0.85). Authors do not provide direct comparison between patients with wildtype and PIK3CA E542K patients. Note that it's unclear how many PIK3CA wildtype patients harbor KRAS mutations, though authors' suggest that regorafenib induces clinical benefit regardless of KRAS or PIK3CA mutation status."	26184520	PubMed		"Tabernero et al., 2015, Lancet Oncol"	NCT01103323	3	accepted	83	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/83	https://civicdb.org/links/molecular_profiles/103	FALSE	PIK3CA	5290	E542K		chr3	179218294	179218294	G	A	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.1624G>A,NP_006209.2:p.Glu542Lys,ENST00000263967.3:c.1624G>A,NC_000003.11:g.178936082G>A"	2023-01-27 17:02:37 UTC	CA333572	31944	"GLU542LYS,RS121913273"	FALSE
BRAF V600E	12	Melanoma	1909		"Trametinib,Mirdametinib"	Substitutes	Predictive	Does Not Support	D	Resistance	"In the setting of BRAF(V600E), NF1 loss resulted in elevated activation of RAS-GTP but does not show resistance to MEK inhibitors."	24576830	PubMed		"Nissan et al., 2014, Cancer Res."		3	accepted	86	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/86	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
KRAS Exon 2 Mutation	75	Colorectal Cancer	9256		Regorafenib		Predictive	Does Not Support	B	Sensitivity/Response	"KRAS mutation status was not predictive of response to regorafenib treatment in patients that had received standard therapy and progressed within 3 months of their last treatment. KRAS exon 2 variants (G12A, C, D, R, S, V; G13D) were sequenced, among variants in other KRAS exons."	24559322	PubMed		"Sartore-Bianchi et al., 2014, Expert Rev Anticancer Ther"		1	accepted	87	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/87	https://civicdb.org/links/molecular_profiles/75	FALSE	KRAS	3845	Exon 2 Mutation		chr12	25245274	25245395			ENST00000256078.4	75		missense_variant		2023-01-09 21:52:04 UTC				FALSE
BRAF V600	17	Colorectal Cancer	9256		Panitumumab		Predictive	Supports	B	Resistance	"In metastatic colorectal cancer patients with wildtype KRAS, BRAF mutations were associated with poor progression free survival regardless of treatment (panitumumab with best supportive care or best supportive care alone)."	23325582	PubMed		"Peeters et al., 2013, Clin. Cancer Res."		3	accepted	88	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/88	https://civicdb.org/links/molecular_profiles/17	FALSE	BRAF	673	V600	Other BRAF V600's	chr7	140753336	140753337			ENST00000288602.6	75		protein_altering_variant		2023-01-09 21:52:04 UTC		"13,961,448,153,762,800,000,000,000,000,000"	VAL600	FALSE
BRAF V600E	12	Colorectal Cancer	9256		"Sorafenib,Panitumumab"	Combination	Predictive	Supports	D	Sensitivity/Response	Cetuximab or panitumumab may be ineffective in patients with BRAF mutation unless BRAF inhibitor such as Sorafenib is introduced.	19001320	PubMed		"Di Nicolantonio et al., 2008, J. Clin. Oncol."		3	accepted	89	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/89	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
BRAF V600E	12	Melanoma	1909		Vemurafenib		Predictive	Supports	D	Resistance	"In the setting of BRAF(V600E), NF1 loss resulted in elevated activation of RAS-GTP and resistance to RAF inhibitors."	24576830	PubMed		"Nissan et al., 2014, Cancer Res."		3	accepted	90	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/90	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
BRAF V600E	12	Lung Non-small Cell Carcinoma	3908		Dabrafenib		Predictive	Supports	C	Resistance	"In a patient with V600E-positive NSCLC, KRAS G12D seemed to confer resistance to dabrafenib."	23524406	PubMed		"Rudin et al., 2013, J Thorac Oncol"		2	accepted	91	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/91	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
BRAF V600	17	Melanoma	1909		"Trametinib,Dabrafenib"	Combination	Predictive	Supports	B	Sensitivity/Response	"This was a Phase I and II study (NCT01072175) of dabrafenib and trametinib combination therapy vs. dabrafenib monotherapy in patients with metastatic melanoma.    Cutaneous squamous-cell carcinoma was seen in 7% of patients receiving combination therapy in contrast to 19% in those receiving monotherapy (P = 0.09).  Of 162 patients with V600E or V600K mutation, 108 were given combination therapy and 54 monotherapy.  After 1 year, 41% of patients in the combination group were alive and progression free whereas this was 9% in the monotherapy group (P<0.001).   Median progression-free survival was 9.4 months with combination and 5.8 months with monotherapy. Hazard ratio for progression or death was 0.39 (95% CI, 0.25 to 0.62; P<0.001)."	23020132	PubMed		"Flaherty et al., 2012, N. Engl. J. Med."	NCT01072175	3	accepted	93	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/93	https://civicdb.org/links/molecular_profiles/17	FALSE	BRAF	673	V600	Other BRAF V600's	chr7	140753336	140753337			ENST00000288602.6	75		protein_altering_variant		2023-01-09 21:52:04 UTC		"13,961,448,153,762,800,000,000,000,000,000"	VAL600	FALSE
BRAF V600D	11	Melanoma	1909		Dabrafenib		Predictive	Supports	B	Sensitivity/Response	Patients with other BRAF V600 mutations also respond well to the V600E drug dabrafenib.	23463675	PubMed		"Ponti et al., 2013, J. Clin. Pathol."		5	accepted	94	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/94	https://civicdb.org/links/molecular_profiles/11	FALSE	BRAF	673	V600D	Other BRAF V600's	chr7	140753335	140753336	CA	AT	ENST00000288602.6	75		missense_variant	"NC_000007.13:g.140453135_140453136delinsAT,NM_004333.4:c.1799_1800delTGinsAT,NP_004324.2:p.Val600Asp,ENST00000288602.6:c.1799_1800delTGinsAT"	2023-01-27 17:02:01 UTC	CA16602419	375939	"RS121913377,VAL600ASP"	FALSE
BRAF V600E	12	Melanoma	1909		"Trametinib,Dabrafenib"	Combination	Predictive	Supports	B	Sensitivity/Response	Dabrafenib with trametinib provides higher response rate and lower toxicity (as compared to chemotherapy) in patients with melanoma.	24583796	PubMed		"Menzies et al., 2014, Clin. Cancer Res."		5	accepted	95	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/95	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
BRAF V600E	12	Colorectal Cancer	9256		"PLX4720,Pictilisib Bismesylate"	Combination	Predictive	Supports	D	Sensitivity/Response	Combined PI3K inhibitor GDC0941 and BRAF inhibitor PLX4720 administration to NSG mice subcutanousely injected with colorectal cell lines with a BRAF V600E mutation effectively inhibited tumor growth and reduced cellular proliferation.	23845441	PubMed		"Rad et al., 2013, Cancer Cell"		3	accepted	96	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/96	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
BRAF V600E	12	Colorectal Cancer	9256		"PLX4720,Nutlin-3"	Combination	Predictive	Supports	D	Sensitivity/Response	Combined nutlin-3 and PLX4720 administration to athymic nude mice subcutanousely injected with the A357 colorectal cell line with a BRAF V600E mutation effectively inhibited tumor growth significantly more than single agent therapy.	23812671	PubMed		"Ji et al., 2013, Clin. Cancer Res."		2	accepted	97	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/97	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
BRAF V600E	12	Colorectal Cancer	9256		"Bevacizumab,Vemurafenib,Capecitabine"	Combination	Predictive	Supports	D	Sensitivity/Response	"This in vivo study examined the efficacy of various treatments on athymic nude mice xenografted with colorectal cancer HT29 cells, which harbor BRAF V600E. The authors sought to understand whether the addition of vemurafenib (a BRAF V600E inhibitor) to agents approved for the treatment of metastatic colorectal cancer increased therapeutic efficacy, and which combinations worked best. Capecitabine, bevacizumab and vemurafenib combination therapy resulted in 100% tumor growth inhibition (TGI) and 190% increased lifespan (ILS) compared to vehicle treated controls. Seven mice experienced partial response and two experienced complete response. Triplet therapy resulted in better TGI and ILS compared to any agent in isolation or capecitabine + vemurafenib doublet therapy (p <0.05, p <0.0001, for all comparisons)."	22180495	PubMed		"Yang et al., 2012, Cancer Res."		3	accepted	98	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/98	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
BRAF V600E	12	Colorectal Cancer	9256		Vemurafenib		Predictive	Supports	D	Sensitivity/Response	"This preclinical study examined vemurafenib efficacy on various colorectal cancer cell lines and in mouse xenograft experiments. Of the cell lines tested, six harbored BRAF V600E (and WT KRAS) and three harbored BRAF WT (but mutant KRAS). Of the six BRAF V600E expressing cell lines, four were sensitive to vemurafenib (IC50 ranging between 0.025 and 0.35 uM; HT29, Colo205, Colo741, LS411N). Cell lines expressing the BRAF V600E mutation responded better to vemurafenib treatment than cells wildtype for BRAF as measured by reduced cellular proliferation and inhibition of MET and ERK phosphorylation (none of the three BRAF wt cell lines had IC50s less than 10uM). Authors note that one of the vemurafenib-resistant cell lines harboring BRAF V600E (RKO) harbored a concurrent activating PIK3CA H1047R mutation. Nude, athymic mice with HT29 xenografts treated with vemurafenib experienced substantial tumor inhibition and increased lifespan at every dose tested, though authors found 75 mg/kg twice daily to be optimal (95% tumor growth inhibition, 90% increased lifespan compared to vehicle treated controls)."	22180495	PubMed		"Yang et al., 2012, Cancer Res."		2	accepted	99	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/99	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
BRAF V600E	12	Thyroid Gland Papillary Carcinoma	3969				Prognostic	Does Not Support	B	Poor Outcome	"Unlike other studies that suggest a poorer outcome, BRAF mutation in this study was not correlated with poorer prognosis in papillary thyroid cancer."	24354346	PubMed		"Walczyk et al., 2014, Clin. Endocrinol. (Oxf)"		5	accepted	102	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/102	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
BRAF V600E	12	Colorectal Cancer	9256				Prognostic	Supports	B	Poor Outcome	V600E is associated with adverse pathological features of colorectal cancer. This can be concluded as a marker of poor prognosis.	24594804	PubMed		"Chen et al., 2014, PLoS ONE"		5	accepted	103	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/103	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
BRAF V600E	12	Melanoma	1909				Prognostic	Supports	B	Poor Outcome	BRAF V600E is correlated with shorter disease-free and overall Survival in a Spanish cohort of melanoma patients.	24388723	PubMed		"Nagore et al., 2014, J. Am. Acad. Dermatol."		3	accepted	104	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/104	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
BRAF V600E	12	Thyroid Gland Papillary Carcinoma	3969				Prognostic	Supports	B	Poor Outcome	BRAF mutation correlated with poor prognosis in papillary thyroid cancer in both older (>65 yo) and younger (<65 yo) cohorts.	21594703	PubMed		"Howell et al., 2011, Ann. Surg. Oncol."		3	accepted	105	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/105	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
BRAF V600E	12	Thyroid Gland Papillary Carcinoma	3969				Prognostic	Supports	B	Poor Outcome	BRAF V600E is correlated with poor prognosis in papillary thyroid cancer in a study of 187 patients with PTC and other thyroid diseases.	24396464	PubMed		"He et al., 2014, Oncol Lett"		3	accepted	106	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/106	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
BRAF V600E	12	Thyroid Gland Papillary Carcinoma	3969				Prognostic	Supports	B	Poor Outcome	V600E is correlated with disease recurrence in both age cohorts (>65 and <65 yo).	21594703	PubMed		"Howell et al., 2011, Ann. Surg. Oncol."		3	accepted	107	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/107	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
NPM1 EXON 12 MUTATION	86	Acute Myeloid Leukemia	9119				Diagnostic	Does Not Support	B	Positive	NPM1 mutations were not associated with the M3 acute myeloid leukemia FAB subtype (0/55).	16455956	PubMed		"Thiede et al., 2006, Blood"		3	accepted	108	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/108	https://civicdb.org/links/molecular_profiles/86	FALSE	NPM1	4869	EXON 12 MUTATION	NPM1 Exon 12	chr5	171410527	171410565			ENST00000517671.1	75		exon_variant		2023-01-09 21:52:04 UTC		N/A		FALSE
NPM1 W288FS	87	Acute Myeloid Leukemia	9119				Diagnostic	Does Not Support	B	Positive	No NPM1 mutations were identified in patients with favorable risk cytogenetics (79/215 patients).	21067377	PubMed		"Ley et al., 2010, N. Engl. J. Med."		4	accepted	109	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/109	https://civicdb.org/links/molecular_profiles/87	FALSE	NPM1	4869	W288FS	NPM1 Exon 12	chr5	171410543	171410544		TCTG	ENST00000517671.1	75		frameshift_elongation	"NM_002520.6:c.860_863dupTCTG,NC_000005.9:g.170837544_170837547dupTCTG,NP_002511.1:p.Trp288Cysfs,ENST00000517671.1:c.860_863dupTCTG"	2023-01-27 17:02:30 UTC	CA280199	13998	"NPM1-A,RS587776806,TRP288FS"	FALSE
DNMT3A R882	32	Acute Myeloid Leukemia	9119				Diagnostic	Supports	B	Negative	Therapy-related AML was less common in patients with DNMT3A mutations (64.5% of which were R882) than patients wildtype for DNMT3A in a large cohort of younger (18-60) AML patients.	23632886	PubMed		"Gaidzik et al., 2013, Blood"		3	accepted	110	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/110	https://civicdb.org/links/molecular_profiles/32	FALSE	DNMT3A	1788	R882		chr2	25234372	25234374			ENST00000264709.3	75		missense_variant		2023-01-09 21:52:04 UTC		"375,881,375,880,375,000,000,000,000,000,000,000"	"R693,ARG882,ARG693"	FALSE
NPM1 EXON 12 MUTATION	86	Acute Myeloid Leukemia	9119				Diagnostic	Supports	B	Negative	NPM1 mutations were not associated with the M2 FAB subtype of acute myeloid leukemia.	16076867	PubMed		"Schnittger et al., 2005, Blood"		4	accepted	111	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/111	https://civicdb.org/links/molecular_profiles/86	FALSE	NPM1	4869	EXON 12 MUTATION	NPM1 Exon 12	chr5	171410527	171410565			ENST00000517671.1	75		exon_variant		2023-01-09 21:52:04 UTC		N/A		FALSE
DNMT3A R882	32	Acute Myeloid Leukemia	9119				Diagnostic	Supports	B	Positive	"DNMT3A mutations (59% of which were R882) were associated with an intermediate risk cytogenetic profile, normal cytogenetic profile, and M4 and M5 FAB subtypes."	21067377	PubMed		"Ley et al., 2010, N. Engl. J. Med."		5	accepted	112	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/112	https://civicdb.org/links/molecular_profiles/32	FALSE	DNMT3A	1788	R882		chr2	25234372	25234374			ENST00000264709.3	75		missense_variant		2023-01-09 21:52:04 UTC		"375,881,375,880,375,000,000,000,000,000,000,000"	"R693,ARG882,ARG693"	FALSE
DNMT3A R882	32	Acute Myeloid Leukemia	9119				Diagnostic	Supports	B	Positive	DNMT3A mutations (59% of which were R882) were associated with intermediate risk cytogenetics (including normal karyotype).	21067377	PubMed		"Ley et al., 2010, N. Engl. J. Med."		4	accepted	113	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/113	https://civicdb.org/links/molecular_profiles/32	FALSE	DNMT3A	1788	R882		chr2	25234372	25234374			ENST00000264709.3	75		missense_variant		2023-01-09 21:52:04 UTC		"375,881,375,880,375,000,000,000,000,000,000,000"	"R693,ARG882,ARG693"	FALSE
DNMT3A R882	32	Acute Myeloid Leukemia	9119				Diagnostic	Supports	B	Positive	"DNMT3A mutations (64.5% R882) were associated with older age, higher white blood cell count and cytogenetically normal AML in a large cohort of younger (18-60) AML patients."	23632886	PubMed		"Gaidzik et al., 2013, Blood"		3	accepted	114	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/114	https://civicdb.org/links/molecular_profiles/32	FALSE	DNMT3A	1788	R882		chr2	25234372	25234374			ENST00000264709.3	75		missense_variant		2023-01-09 21:52:04 UTC		"375,881,375,880,375,000,000,000,000,000,000,000"	"R693,ARG882,ARG693"	FALSE
DNMT3A R882	32	Acute Myeloid Leukemia	9119				Diagnostic	Supports	B	Positive	DNMT3A R882 mutations were associated with cytogenetically normal AML in a large cohort of younger (18-60) AML patients.	23632886	PubMed		"Gaidzik et al., 2013, Blood"		3	accepted	115	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/115	https://civicdb.org/links/molecular_profiles/32	FALSE	DNMT3A	1788	R882		chr2	25234372	25234374			ENST00000264709.3	75		missense_variant		2023-01-09 21:52:04 UTC		"375,881,375,880,375,000,000,000,000,000,000,000"	"R693,ARG882,ARG693"	FALSE
NPM1 EXON 12 MUTATION	86	Acute Myeloid Leukemia	9119				Diagnostic	Supports	A	Positive	AML with mutated NPM1 is a provisional entity in the World Health Organization (WHO) classification of acute myeloid leukemia (AML). This mutation should be tested for in clinical trials and is recommended for testing in patients with cytogentically normal AML.	19357394	PubMed		"Vardiman et al., 2009, Blood"		5	accepted	116	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/116	https://civicdb.org/links/molecular_profiles/86	FALSE	NPM1	4869	EXON 12 MUTATION	NPM1 Exon 12	chr5	171410527	171410565			ENST00000517671.1	75		exon_variant		2023-01-09 21:52:04 UTC		N/A		FALSE
NPM1 EXON 12 MUTATION	86	Acute Myeloid Leukemia	9119				Diagnostic	Supports	B	Positive	NPM1 mutations were associated with de novo AML as well as M4 and M5 FAB subtypes.	17957027	PubMed		"Gale et al., 2008, Blood"		2	accepted	117	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/117	https://civicdb.org/links/molecular_profiles/86	FALSE	NPM1	4869	EXON 12 MUTATION	NPM1 Exon 12	chr5	171410527	171410565			ENST00000517671.1	75		exon_variant		2023-01-09 21:52:04 UTC		N/A		FALSE
NPM1 EXON 12 MUTATION	86	Acute Myeloid Leukemia	9119				Diagnostic	Supports	B	Positive	"NPM1 mutations were associated with M4, M5a and M5b FAB subtypes of acute myeloid leukemia."	16076867	PubMed		"Schnittger et al., 2005, Blood"		4	accepted	118	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/118	https://civicdb.org/links/molecular_profiles/86	FALSE	NPM1	4869	EXON 12 MUTATION	NPM1 Exon 12	chr5	171410527	171410565			ENST00000517671.1	75		exon_variant		2023-01-09 21:52:04 UTC		N/A		FALSE
NPM1 EXON 12 MUTATION	86	Acute Myeloid Leukemia	9119				Diagnostic	Supports	B	Positive	NPM1 mutations were associated with M5a and M5b FAB subtypes of acute myeloid leukemia.	16455956	PubMed		"Thiede et al., 2006, Blood"		3	accepted	119	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/119	https://civicdb.org/links/molecular_profiles/86	FALSE	NPM1	4869	EXON 12 MUTATION	NPM1 Exon 12	chr5	171410527	171410565			ENST00000517671.1	75		exon_variant		2023-01-09 21:52:04 UTC		N/A		FALSE
NPM1 EXON 12 MUTATION	86	Acute Myeloid Leukemia	9119				Diagnostic	Supports	B	Positive	NPM1 mutations were associated with normal karyotype in older (>60) patients.	19059939	PubMed		"Schlenk et al., 2009, Haematologica"	NCT00151242	3	accepted	120	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/120	https://civicdb.org/links/molecular_profiles/86	FALSE	NPM1	4869	EXON 12 MUTATION	NPM1 Exon 12	chr5	171410527	171410565			ENST00000517671.1	75		exon_variant		2023-01-09 21:52:04 UTC		N/A		FALSE
NPM1 W288FS	87	Acute Myeloid Leukemia	9119				Diagnostic	Supports	B	Positive	NPM1 mutations were associated with intermediate risk cytogenetics (including normal karyotype).	21067377	PubMed		"Ley et al., 2010, N. Engl. J. Med."		4	accepted	121	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/121	https://civicdb.org/links/molecular_profiles/87	FALSE	NPM1	4869	W288FS	NPM1 Exon 12	chr5	171410543	171410544		TCTG	ENST00000517671.1	75		frameshift_elongation	"NM_002520.6:c.860_863dupTCTG,NC_000005.9:g.170837544_170837547dupTCTG,NP_002511.1:p.Trp288Cysfs,ENST00000517671.1:c.860_863dupTCTG"	2023-01-27 17:02:30 UTC	CA280199	13998	"NPM1-A,RS587776806,TRP288FS"	FALSE
CEBPA Mutation	29	Acute Myeloid Leukemia	9119		Tretinoin		Predictive	Does Not Support	B	Sensitivity/Response	In a randomized trial of previously untreated younger (<60) patients with acute myeloid leukemia (excluding acute promyelocytic leukemia) and high-risk myelodysplastic syndrome CEBPA mutation status had no significant impact on patient response to ATRA (N=20) compared to randomized control (N=15).	19965647	PubMed		"Burnett et al., 2010, Blood"		3	accepted	122	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/122	https://civicdb.org/links/molecular_profiles/29	FALSE	CEBPA	1050	Mutation		chr19	33299934	33302564			ENST00000498907.2	75		"transcript_variant,loss_of_function_variant"		2023-01-09 21:52:04 UTC		N/A		FALSE
PIK3CA Exon 10 Mutation	106	Colorectal Cancer	9256		"Cetuximab,Chemotherapy"	Combination	Predictive	Does Not Support	B	Resistance	"In chemotherapy-refractory patients with metastatic colorectal cancer and KRAS wt tumors, Exon 10 PIK3CA mutations (listed as Exon 9 in the source) had no significant impact on response rate (6/21 [28.6%] vs 115/317 [36.3%]; OR: 0.70; p = 0.47), disease control rate, median progression free survival or median overall survival (46 vs 51 weeks, HR: 1.30, p=0.28) following cetuximab + chemotherapy than wildtype PIK3CA. In multivariate analysis of KRAS wildtype patients, PIK3CA was not significantly associated with patient outcome. Authors conclude that PIK3CA exon 10 mutation status does not appear relevant to treatment response."	20619739	PubMed		"De Roock et al., 2010, Lancet Oncol."		3	accepted	123	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/123	https://civicdb.org/links/molecular_profiles/106	FALSE	PIK3CA	5290	Exon 10 Mutation		chr3	179218210	179218334			ENST00000263967.3	75		exon_variant		2023-01-09 21:52:05 UTC		"3,194,413,655"	EXON 9 MUTATION	FALSE
NRAS Q61	94	Colorectal Cancer	9256		Cetuximab		Predictive	Does Not Support	B	Resistance	"In chemotherapy-refractory patients with colorectal cancer, NRAS mutation status (primarily Q61, N=13) was not informative for disease control rate, progression free survival or overall survival following cetuximab plus chemotherapy (N=480)."	20619739	PubMed		"De Roock et al., 2010, Lancet Oncol."		3	accepted	124	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/124	https://civicdb.org/links/molecular_profiles/94	FALSE	NRAS	4893	Q61		chr1	114713907	114713909			ENST00000369535.4	75		missense_variant		2023-01-09 21:52:04 UTC		"7,305,813,900,375,870,000,000,000,000,000,000,000,000"	GLN61	FALSE
ALK F1174L	8	Neuroblastoma	769		Crizotinib		Predictive	Supports	D	Resistance	Cells lines expressing ALK harboring the F1174L mutation are less sensitive to growth inhibition by crizotinib than cells expressing the R1275Q mutation. The authors conclude that this effect should be surmountable with higher doses of crizotinib and/or with higher-affinity inhibitors.	22072639	PubMed		"Bresler et al., 2011, Sci Transl Med"		3	accepted	125	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/125	https://civicdb.org/links/molecular_profiles/8	FALSE	ALK	238	F1174L	ALK Crizotinib Resistance	chr2	29220829	29220829	G	T	ENST00000389048.3	75		missense_variant	"NM_004304.4:c.3522C>A,NP_004295.2:p.Phe1174Leu,NC_000002.11:g.29443695G>T,ENST00000389048.3:c.3522C>A"	2023-01-27 17:01:58 UTC	CA279586	217851	"PHE1174LEU,RS863225281"	FALSE
BRAF V600E	12	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	B	Resistance	"This was a retrospective study of 691 cetuximab treated patients with metastatic, chemotherapy refractory colorectal cancer. Of those, 30 patients harbored BRAF V600E, were KRAS, NRAS and PIK3CA wt, and had individual response data. One patient (who harbored BRAF V600E in low copy number) responded, 11 had stable disease, and 18 progressed. Treatments included cetuximab + irinotecan (n=20), cetuximab monotherapy (n=5), cetuximab + FOLFIRI (n=4), and cetuximab + oxaliplatin + 5FU (n=1). Median PFS was 8 weeks (2-32 weeks), median OS was 25 weeks (4-237 weeks), and median number of previous chemotherapy lines was 2 (0-4). Median age was 61 years old (42-78) and there were 16 males and 14 females. Authors concluded that BRAF mutation (23/24 of mutants were BRAF V600E) was strongly associated with poor response to cetuximab and suggested that mutation status of BRAF is more informative than those of NRAS and PIK3CA exon 20 for predicting cetuximab response (second only to KRAS)."	20619739	PubMed		"De Roock et al., 2010, Lancet Oncol."		3	accepted	126	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/126	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
FLT3 ITD	55	Acute Myeloid Leukemia	9119		Tretinoin		Predictive	Supports	B	Resistance	ATRA treatment did not effect overall survival in patients <60 years old with FLT3-ITD mutation.	19965647	PubMed		"Burnett et al., 2010, Blood"		3	accepted	127	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/127	https://civicdb.org/links/molecular_profiles/55	FALSE	FLT3	2322	ITD		chr13	28034082	28034214			ENST00000241453.7	75		inframe_insertion		2023-01-09 21:52:04 UTC		16270		FALSE
FLT3 ITD	55	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	FLT3-ITD mutation without NPM1 was associated with increased relapse risk and reduced overall survival in young adult AML patients (median age 43).	17957027	PubMed		"Gale et al., 2008, Blood"		4	accepted	128	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/128	https://civicdb.org/links/molecular_profiles/55	FALSE	FLT3	2322	ITD		chr13	28034082	28034214			ENST00000241453.7	75		inframe_insertion		2023-01-09 21:52:04 UTC		16270		FALSE
FLT3 ITD	55	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	Increasing level of FLT3-ITD mutant correlated with reduced disease-free and overall survival as well as increased relapse rate.	17957027	PubMed		"Gale et al., 2008, Blood"		3	accepted	129	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/129	https://civicdb.org/links/molecular_profiles/55	FALSE	FLT3	2322	ITD		chr13	28034082	28034214			ENST00000241453.7	75		inframe_insertion		2023-01-09 21:52:04 UTC		16270		FALSE
FLT3 ITD	55	Acute Myeloid Leukemia	9119		Daunorubicin		Predictive	Supports	D	Resistance	Ba/F3 cells with both FLT3-ITD and TKD mutations on the same allele have more resistance to daunorubicin than cells with FLT3-ITD alone.	15626738	PubMed		"Bagrintseva et al., 2005, Blood"		3	accepted	130	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/130	https://civicdb.org/links/molecular_profiles/55	FALSE	FLT3	2322	ITD		chr13	28034082	28034214			ENST00000241453.7	75		inframe_insertion		2023-01-09 21:52:04 UTC		16270		FALSE
FLT3 ITD	55	Acute Myeloid Leukemia	9119		SU5614		Predictive	Supports	D	Resistance	Ba/F3 cells with both FLT3-ITD and TKD mutations on the same allele have more resistance to the protein tyrosine kinase (PTK) inhibitor SU5614 than cells with FLT3-ITD alone or FLT3 ITD and TKD mutations on opposing alleles.	15626738	PubMed		"Bagrintseva et al., 2005, Blood"		3	accepted	131	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/131	https://civicdb.org/links/molecular_profiles/55	FALSE	FLT3	2322	ITD		chr13	28034082	28034214			ENST00000241453.7	75		inframe_insertion		2023-01-09 21:52:04 UTC		16270		FALSE
KRAS G12/G13	77	Colorectal Cancer	9256		"Cetuximab,Chemotherapy"	Combination	Predictive	Supports	B	Resistance	"Chemotherapy-refractory patients with metastatic colorectal cancer harboring KRAS mutations (primarily G12/G13; n=230 out of 253 total KRAS mutant patients) had lower response rates (17/253; 6.7% vs KRAS wt 126/352; 35.8%; P < .0001), disease control rates and shorter progression free and overall survival following cetuximab plus chemotherapy than those with wildtype KRAS. Authors note that these patients were treated with cetuximab prior to widespead adoption of regular KRAS mutational status screening. Patients treated with cetuximab or panitumumab monotherapy were not included."	20619739	PubMed		"De Roock et al., 2010, Lancet Oncol."		3	accepted	134	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/134	https://civicdb.org/links/molecular_profiles/77	FALSE	KRAS	3845	G12/G13		chr12	25245346	25245351			ENST00000256078.4	75		protein_altering_variant		2023-01-09 21:52:04 UTC		"45,122,125,781,258,200,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000"		FALSE
KRAS G12/G13	77	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	D	Resistance	KRAS mutations were significantly associated with lack of response to cetuximab in patients with advanced colorectal cancer.	18202412	PubMed		"Livre et al., 2008, J. Clin. Oncol."		3	accepted	135	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/135	https://civicdb.org/links/molecular_profiles/77	FALSE	KRAS	3845	G12/G13		chr12	25245346	25245351			ENST00000256078.4	75		protein_altering_variant		2023-01-09 21:52:04 UTC		"45,122,125,781,258,200,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000"		FALSE
KRAS G12V	421	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	D	Resistance	Cells harboring KRAS G12V mutation were insensitive to cetuximab treatment in isogenic SW48 cells and in a mouse xenograft model.	20978259	PubMed		"De Roock et al., 2010, JAMA"		4	accepted	136	Somatic	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/136	https://civicdb.org/links/molecular_profiles/421	FALSE	KRAS	3845	G12V		chr12	25245350	25245350	C	A	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.35G>T,NP_004976.2:p.Gly12Val,NC_000012.11:g.25398284C>A,ENST00000256078.4:c.35G>T"	2023-01-27 17:03:41 UTC	CA122540	12583	"GLY12VAL,RS121913529"	FALSE
NPM1 EXON 12 MUTATION	86	Acute Myeloid Leukemia	9119		Tretinoin		Predictive	Does Not Support	B	Sensitivity/Response	"ATRA treatment plus chemotherapy (daunorubicin, Ara-C, and thioguanine, N=113) did not effect overall survival in patients <60 years old with NPM1 mutation regardless of FLT3-ITD status compared to chemotherapy alone (N=94)."	19965647	PubMed		"Burnett et al., 2010, Blood"		3	accepted	137	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/137	https://civicdb.org/links/molecular_profiles/86	FALSE	NPM1	4869	EXON 12 MUTATION	NPM1 Exon 12	chr5	171410527	171410565			ENST00000517671.1	75		exon_variant		2023-01-09 21:52:04 UTC		N/A		FALSE
PIK3CA Exon 21 Mutation	105	Colorectal Cancer	9256		"Chemotherapy,Cetuximab"	Combination	Predictive	Supports	B	Resistance	"Chemotherapy-refractory patients with metastatic colorectal cancer harboring wildtype KRAS and Exon 21 (listed as exon 20 in the source) PIK3CA mutations had lower response rates (0/9 vs 121/329; OR: 0.00; p=0.029) and disease control rates as well as shorter progression free and overall survival (median 34 vs 51 weeks; HR: 3.29, p=0.0057) following cetuximab plus chemotherapy than those with wildtype PIK3CA. In multivariate analysis of the KRAS wildtype population, significant associations between PIK3CA exon 21 mutations and poor response to cetuximab were retained. The authors concluded that PIK3CA exon 21 mutation status is more predictive of poor response to cetuximab than PIK3CA mutation status as a whole. They also recommended screening for mutations in the following gene order: KRAS, BRAF, NRAS, PIK3CA exon 21."	20619739	PubMed		"De Roock et al., 2010, Lancet Oncol."		3	accepted	138	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/138	https://civicdb.org/links/molecular_profiles/105	FALSE	PIK3CA	5290	Exon 21 Mutation		chr3	179234094	179234707			ENST00000263967.3	75		exon_variant		2023-01-09 21:52:05 UTC			EXON 20 MUTATION	FALSE
WT1 Exon 7 Mutation	129	Acute Myeloid Leukemia	9119		"Cytarabine,Daunorubicin"	Combination	Predictive	Supports	B	Resistance	"WT1 mutations were associated with an inferior response to induction chemotherapy with a higher rate of resistant disease in young (15-60+, median 45) patients with cytogenetically normal AML."	18591546	PubMed		"Virappane et al., 2008, J. Clin. Oncol."		3	accepted	139	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/139	https://civicdb.org/links/molecular_profiles/129	FALSE	WT1	7490	Exon 7 Mutation		chr11	32396257	32396407			ENST00000332351.3	75		exon_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
ALK F1174L	8	Neuroblastoma	769		TAE684		Predictive	Supports	D	Sensitivity/Response	SH-SY5Y and Kelly cells with mutant ALK (F1174L) and Ba/F3 cells overexpressing ALK harboring the F1174L mutation are sensitive to TAE684-mediated growth inhibition.	18923525	PubMed		"George et al., 2008, Nature"		4	accepted	142	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/142	https://civicdb.org/links/molecular_profiles/8	FALSE	ALK	238	F1174L	ALK Crizotinib Resistance	chr2	29220829	29220829	G	T	ENST00000389048.3	75		missense_variant	"NM_004304.4:c.3522C>A,NP_004295.2:p.Phe1174Leu,NC_000002.11:g.29443695G>T,ENST00000389048.3:c.3522C>A"	2023-01-27 17:01:58 UTC	CA279586	217851	"PHE1174LEU,RS863225281"	FALSE
ALK R1275Q	9	Neuroblastoma	769		Crizotinib		Predictive	Supports	D	Sensitivity/Response	Cells lines expressing ALK harboring the F1174L mutation are less sensitive to growth inhibition by crizotinib than cells expressing the R1275Q mutation.	22072639	PubMed		"Bresler et al., 2011, Sci Transl Med"		3	accepted	143	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/143	https://civicdb.org/links/molecular_profiles/9	FALSE	ALK	238	R1275Q		chr2	29209798	29209798	C	T	ENST00000389048.3	75		missense_variant	"NM_004304.4:c.3824G>A,NP_004295.2:p.Arg1275Gln,NC_000002.11:g.29432664C>T,ENST00000389048.3:c.3824G>A"	2023-01-27 17:01:59 UTC	CA341482	18083	"ARG1275GLN,RS113994087"	FALSE
FGFR3 FGFR3::BAIAP2L1	53	Bladder Carcinoma	4007		PD173074		Predictive	Supports	D	Sensitivity/Response	"Following identification of this fusion in a patient, this fusion was expressed in HEK 293T cells leading to oligomerization in the absence of ligand, induced morphologic changes in the cell and increased cellular proliferation consistent with FGFR activation. Mouse xenografts using the bladder cell line SW780 which harbors an FGFR3-BAIAP2L1 fusion showed reduced tumor burden when treated with the FGFR inhibitor PD173074."	23558953	PubMed		"Wu et al., 2013, Cancer Discov"		3	accepted	144	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/144	https://civicdb.org/links/molecular_profiles/53	FALSE	FGFR3	2261	FGFR3::BAIAP2L1	FGFR fusions	chr4	1793312	1808872			ENST00000340107.4	75	ENST00000005260.8	transcript_fusion		2023-01-09 21:52:04 UTC		N/A	FGFR3-BAIAP2L1	FALSE
KRAS G13D	81	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	D	Sensitivity/Response	Cells harboring KRAS G13D mutation were sensitive to cetuximab treatment in isogenic SW48 cells and in a mouse xenograft model.	20978259	PubMed		"De Roock et al., 2010, JAMA"		4	accepted	145	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/145	https://civicdb.org/links/molecular_profiles/81	FALSE	KRAS	3845	G13D		chr12	25245347	25245347	C	T	ENST00000256078.4	75		missense_variant	"NM_033360.3:c.38G>A,NP_004976.2:p.Gly13Asp,NC_000012.11:g.25398281C>T,ENST00000256078.4:c.38G>A"	2023-01-27 17:02:27 UTC	CA122534	12580	"GLY13ASP,RS112445441"	FALSE
NPM1 EXON 12 MUTATION	86	Acute Myeloid Leukemia	9119		Tretinoin		Predictive	Supports	B	Sensitivity/Response	ATRA treatment improved overall and relapse-free survival in older (>60) patients with mutant NPM1 and without FLT3-ITD.	19059939	PubMed		"Schlenk et al., 2009, Haematologica"	NCT00151242	2	accepted	146	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/146	https://civicdb.org/links/molecular_profiles/86	FALSE	NPM1	4869	EXON 12 MUTATION	NPM1 Exon 12	chr5	171410527	171410565			ENST00000517671.1	75		exon_variant		2023-01-09 21:52:04 UTC		N/A		FALSE
NPM1 EXON 12 MUTATION	86	Acute Myeloid Leukemia	9119		Daunorubicin		Predictive	Supports	B	Sensitivity/Response	"Young patients (18-60) with NPM1 mutations had improved overall survival following high-dose versus standard dose daunorubicin (p=0.01) in univariate analysis. However, the adjusted p-value for multiple testing is 0.11."	22417203	PubMed		"Patel et al., 2012, N. Engl. J. Med."		2	accepted	147	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/147	https://civicdb.org/links/molecular_profiles/86	FALSE	NPM1	4869	EXON 12 MUTATION	NPM1 Exon 12	chr5	171410527	171410565			ENST00000517671.1	75		exon_variant		2023-01-09 21:52:04 UTC		N/A		FALSE
NPM1 EXON 12 MUTATION	86	Acute Myeloid Leukemia	9119		Valproic Acid		Predictive	Supports	B	Sensitivity/Response	"For patients with NPM1 mutation that achieved CR following induction therapy, relapse-free survival was improved following treatment with valproic acid."	24797300	PubMed		"Tassara et al., 2014, Blood"	NCT00151255	2	accepted	148	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/148	https://civicdb.org/links/molecular_profiles/86	FALSE	NPM1	4869	EXON 12 MUTATION	NPM1 Exon 12	chr5	171410527	171410565			ENST00000517671.1	75		exon_variant		2023-01-09 21:52:04 UTC		N/A		FALSE
NPM1 EXON 12 MUTATION	86	Acute Myeloid Leukemia	9119		"NSC348884,Tretinoin"	Combination	Predictive	Supports	D	Sensitivity/Response	NSC348884 combined with ATRA treatment induces apoptosis in primary AML cells harboring mutant NPM1 but not in cells with wildtype NPM1 or both mutant NPM1 and FLT3-ITD.	21719597	PubMed		"Balusu et al., 2011, Blood"		3	accepted	149	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/149	https://civicdb.org/links/molecular_profiles/86	FALSE	NPM1	4869	EXON 12 MUTATION	NPM1 Exon 12	chr5	171410527	171410565			ENST00000517671.1	75		exon_variant		2023-01-09 21:52:04 UTC		N/A		FALSE
NPM1 EXON 12 MUTATION	86	Acute Myeloid Leukemia	9119		"Anti-CD123,Anti-CD33"	Combination	Predictive	Supports	E	Sensitivity/Response	"CD33 and CD123 expression was significantly increased in patients with NPM1 mutation with FLT3-ITD, indicating these patients may respond to combined anti-CD33 and anti-CD123 therapy."	24927407	PubMed		"Ehninger et al., 2014, Blood Cancer J"		2	accepted	150	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/150	https://civicdb.org/links/molecular_profiles/86	TRUE	NPM1	4869	EXON 12 MUTATION	NPM1 Exon 12	chr5	171410527	171410565			ENST00000517671.1	75		exon_variant		2023-01-09 21:52:04 UTC		N/A		FALSE
NPM1 EXON 12 MUTATION	86	Acute Myeloid Leukemia	9119		Anti-CD33		Predictive	Supports	E	Sensitivity/Response	"CD33 expression was significantly increased in patients with NPM1 mutation with or without FLT3-ITD, indicating these patients may respond to anti-CD33 therapy."	24927407	PubMed		"Ehninger et al., 2014, Blood Cancer J"		2	accepted	151	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/151	https://civicdb.org/links/molecular_profiles/86	FALSE	NPM1	4869	EXON 12 MUTATION	NPM1 Exon 12	chr5	171410527	171410565			ENST00000517671.1	75		exon_variant		2023-01-09 21:52:04 UTC		N/A		FALSE
NPM1 W288FS	87	Acute Myeloid Leukemia	9119		NSC348884		Predictive	Supports	D	Sensitivity/Response	NSC348884 induced apoptosis in OPI-AML3 cells harboring an NPM1 mutation.	21719597	PubMed		"Balusu et al., 2011, Blood"		3	accepted	152	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/152	https://civicdb.org/links/molecular_profiles/87	FALSE	NPM1	4869	W288FS	NPM1 Exon 12	chr5	171410543	171410544		TCTG	ENST00000517671.1	75		frameshift_elongation	"NM_002520.6:c.860_863dupTCTG,NC_000005.9:g.170837544_170837547dupTCTG,NP_002511.1:p.Trp288Cysfs,ENST00000517671.1:c.860_863dupTCTG"	2023-01-27 17:02:30 UTC	CA280199	13998	"NPM1-A,RS587776806,TRP288FS"	FALSE
NPM1 W288FS	87	Acute Myeloid Leukemia	9119		"Daunorubicin,Etoposide,Cytarabine"	Combination	Predictive	Supports	E	Sensitivity/Response	"NPM1 mutation (Type A, W288fs) causes cytoplasmic localization of NPM when transfected into a non-hematopoietic cell line (293T cells). Cytoplasmic localization of NPM in AML patients was associated with good response to induction therapy."	15659725	PubMed		"Falini et al., 2005, N. Engl. J. Med."		3	accepted	153	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/153	https://civicdb.org/links/molecular_profiles/87	FALSE	NPM1	4869	W288FS	NPM1 Exon 12	chr5	171410543	171410544		TCTG	ENST00000517671.1	75		frameshift_elongation	"NM_002520.6:c.860_863dupTCTG,NC_000005.9:g.170837544_170837547dupTCTG,NP_002511.1:p.Trp288Cysfs,ENST00000517671.1:c.860_863dupTCTG"	2023-01-27 17:02:30 UTC	CA280199	13998	"NPM1-A,RS587776806,TRP288FS"	FALSE
TSC1 Frameshift Truncation	124	Lung Non-small Cell Carcinoma	3908		Sirolimus		Predictive	Supports	D	Sensitivity/Response	"Following rapamycin treatment of mice with KrasG12D-induced lung tumors, mice with Tsc1 deletion (exon17/18 deletion resulting in frameshift) in the lung exhibit increased overall survival, increased apoptosis, reduced proliferation and reduced tumor burden compared to Tsc1 wildtype mice."	19966866	PubMed		"Liang et al., 2010, Oncogene"		3	accepted	154	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/154	https://civicdb.org/links/molecular_profiles/124	FALSE	TSC1	7248	Frameshift Truncation	TSC Loss	chr9	132891348	132944621			ENST00000298552.3	75		frameshift_truncation		2023-01-09 21:52:05 UTC				FALSE
TSC1 Loss-of-function	125	Bladder Carcinoma	4007		Everolimus		Predictive	Supports	B	Sensitivity/Response	Tumors expressing TSC1 or TSC2 mutations show notably more sensitivity to everolimus than their wild-type counterparts.	22923433	PubMed		"Iyer et al., 2012, Science"	NCT00805129	3	accepted	155	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/155	https://civicdb.org/links/molecular_profiles/125	FALSE	TSC1	7248	Loss-of-function	TSC Loss	chr9	132891348	132944621			ENST00000298552.3	75		loss_of_function_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
FLT3 Mutation	515	Acute Myeloid Leukemia	9119				Prognostic	Does Not Support	B	N/A	"FLT3 mutations did not alter overall survival or remission duration in younger (16-60), cytogenetically normal AML patients with CEBPA mutations. 10/36 patients with CEBPA mutations also had FLT3 mutations (8 FLT3-ITD, 2 FLT3-D835)."	14726504	PubMed		"Frhling et al., 2004, J. Clin. Oncol."		2	accepted	156	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/156	https://civicdb.org/links/molecular_profiles/515	FALSE	FLT3	2322	Mutation		chr13	28003274	28100592			ENST00000241453.7	75		"transcript_variant,gain_of_function_variant"		2023-01-09 21:52:07 UTC				FALSE
DNMT3A R882	32	Acute Myeloid Leukemia	9119				Prognostic	Does Not Support	B	N/A	Complete remission rates did not differ between patients with wildtype or mutant DNMT3A (62% of which affected R882) and cytogenetically normal AML.	22291079	PubMed		"Marcucci et al., 2012, J. Clin. Oncol."		4	accepted	157	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/157	https://civicdb.org/links/molecular_profiles/32	FALSE	DNMT3A	1788	R882		chr2	25234372	25234374			ENST00000264709.3	75		missense_variant		2023-01-09 21:52:04 UTC		"375,881,375,880,375,000,000,000,000,000,000,000"	"R693,ARG882,ARG693"	FALSE
FLT3 ITD	55	Acute Myeloid Leukemia	9119				Prognostic	Does Not Support	B	N/A	FLT3-ITD duplication length did not effect prognosis in patients with an NPM1 mutation.	21537333	PubMed		"Schnittger et al., 2011, Leukemia"		4	accepted	158	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/158	https://civicdb.org/links/molecular_profiles/55	FALSE	FLT3	2322	ITD		chr13	28034082	28034214			ENST00000241453.7	75		inframe_insertion		2023-01-09 21:52:04 UTC		16270		FALSE
FLT3 ITD	55	Acute Myeloid Leukemia	9119				Prognostic	Does Not Support	B	N/A	Size of the FLT3-ITD mutant duplication had no impact on overall survival or relapse rate.	17957027	PubMed		"Gale et al., 2008, Blood"		2	accepted	159	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/159	https://civicdb.org/links/molecular_profiles/55	FALSE	FLT3	2322	ITD		chr13	28034082	28034214			ENST00000241453.7	75		inframe_insertion		2023-01-09 21:52:04 UTC		16270		FALSE
IDH1 R132	58	Acute Myeloid Leukemia	9119				Prognostic	Does Not Support	B	N/A	Mutation status of IDH1 did not change event-free survival of patients with an NPM1 mutation.	20805365	PubMed		"Schnittger et al., 2010, Blood"		3	accepted	160	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/160	https://civicdb.org/links/molecular_profiles/58	FALSE	IDH1	3417	R132		chr2	208248387	208248389			ENST00000415913.1	75		protein_altering_variant	"NC_000002.11:g.209113113G>A,NC_000002.11:g.209113112C>T,NC_000002.11:g.209113113G>C,NC_000002.11:g.209113112C>A,NC_000002.11:g.209113113G>T,NC_000002.11:g.209113112C>G"	2023-01-09 21:52:04 UTC		"156,444,375,891,375,000,000,000,000,000,000,000"	ARG132	FALSE
WT1 Exon 7 Mutation	129	Acute Myeloid Leukemia	9119				Prognostic	Does Not Support	B	N/A	"No differences in relapse-free or overall survival were identified between young (16-60) patients with or without WT1 mutations (69% exon 7, 15% exon 9) in cytogenetically normal AML."	19221039	PubMed		"Gaidzik et al., 2009, Blood"		3	accepted	162	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/162	https://civicdb.org/links/molecular_profiles/129	FALSE	WT1	7490	Exon 7 Mutation		chr11	32396257	32396407			ENST00000332351.3	75		exon_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
WT1 Exon 7 Mutation	129	Acute Myeloid Leukemia	9119				Prognostic	Does Not Support	B	N/A	"Rates of complete remission and refractory disease are not different in patients with WT1 mutations (69% exon 7, 15% exon 9) than those without in young (16-60) patients with cytogenetically normal AML."	19221039	PubMed		"Gaidzik et al., 2009, Blood"		4	accepted	163	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/163	https://civicdb.org/links/molecular_profiles/129	FALSE	WT1	7490	Exon 7 Mutation		chr11	32396257	32396407			ENST00000332351.3	75		exon_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
WT1 Exon 9 Mutation	130	Acute Myeloid Leukemia	9119				Prognostic	Does Not Support	B	N/A	"Rates of complete remission and refractory disease are not different in patients with WT1 mutations (69% exon 7, 15% exon 9) than those without in young (16-60) patients with cytogenetically normal AML."	19221039	PubMed		"Gaidzik et al., 2009, Blood"		4	accepted	165	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/165	https://civicdb.org/links/molecular_profiles/130	FALSE	WT1	7490	Exon 9 Mutation		chr11	32391972	32392064			ENST00000332351.3	75		exon_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
CEBPA Mutation	29	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Better Outcome	"In a group of young (<60 years old) acute myeloid leukemia (exclude acute promyelocytic leukemia) and high-risk MDS patients, those with CEBPA mutations (35/423) showed marginally improved overall survival (36% vs 31%; P = .04) than those with wildtype CEBPA."	19965647	PubMed		"Burnett et al., 2010, Blood"		3	accepted	166	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/166	https://civicdb.org/links/molecular_profiles/29	FALSE	CEBPA	1050	Mutation		chr19	33299934	33302564			ENST00000498907.2	75		"transcript_variant,loss_of_function_variant"		2023-01-09 21:52:04 UTC		N/A		FALSE
CEBPA Mutation	29	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Better Outcome	"In young patients (age 16-60) with previously untreated, cytogenetically normal acute myeloid leukemia, CEBPA mutation was significantly associated with complete remission in multivariate analysis (odds ratio, 1.33; 95% confidence interval [CI], 1.01 to 1.74). Multivariate analysis was performed on all patients  that were evaluated for a mutation in at least 1 gene (CEBPA, FLT3-ITD or NPM1) totaling 693/872 patients in the study. Only 509 patients in the study were evaluated for CEBPA, 67 of which had a mutation."	18450602	PubMed		"Schlenk et al., 2008, N. Engl. J. Med."		4	accepted	167	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/167	https://civicdb.org/links/molecular_profiles/29	FALSE	CEBPA	1050	Mutation		chr19	33299934	33302564			ENST00000498907.2	75		"transcript_variant,loss_of_function_variant"		2023-01-09 21:52:04 UTC		N/A		FALSE
CEBPA Mutation	29	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Better Outcome	"Overall survival and remission duration were significantly longer (p=0.01 and p=0.05, respectively) in younger (16-60), cytogenetically normal acute myeloid leukemia patients with CEBPA mutations (21/236 patients)."	14726504	PubMed		"Frhling et al., 2004, J. Clin. Oncol."		3	accepted	168	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/168	https://civicdb.org/links/molecular_profiles/29	FALSE	CEBPA	1050	Mutation		chr19	33299934	33302564			ENST00000498907.2	75		"transcript_variant,loss_of_function_variant"		2023-01-09 21:52:04 UTC		N/A		FALSE
CEBPA N-TERMINAL FRAME SHIFT	28	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Better Outcome	"Remission duration was significantly longer in younger (16-60), cytogenetically normal AML patients with CEBPA"	14726504	PubMed		"Frhling et al., 2004, J. Clin. Oncol."		3	accepted	169	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/169	https://civicdb.org/links/molecular_profiles/28	FALSE	CEBPA	1050	N-TERMINAL FRAME SHIFT		chr19	33302055	33302564			ENST00000498907.2	75		"frameshift_truncation,dominant_negative_variant"		2023-01-09 21:52:04 UTC				FALSE
DNMT3A R882	32	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Better Outcome	DNMT3A mutations were associated with achievement of complete remission in a large cohort of younger (18-60) AML patients.	23632886	PubMed		"Gaidzik et al., 2013, Blood"		3	accepted	170	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/170	https://civicdb.org/links/molecular_profiles/32	FALSE	DNMT3A	1788	R882		chr2	25234372	25234374			ENST00000264709.3	75		missense_variant		2023-01-09 21:52:04 UTC		"375,881,375,880,375,000,000,000,000,000,000,000"	"R693,ARG882,ARG693"	FALSE
FLT3 TKD MUTATION	56	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Better Outcome	"Event-free survival was significantly improved in patients with both NPM1 and FLT3-TKD mutations compared to patients with 1) FLT3-TKD mutations alone 2) either NPM1 or FLT3-TKD when FLT3-ITD patients were excluded from the analysis 3) neither FLT3-TKD or NPM1 mutations or FLT3-TKD alone when only de novo, normal karyotype patients were analyzed."	17965322	PubMed		"Bacher et al., 2008, Blood"		3	accepted	171	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/171	https://civicdb.org/links/molecular_profiles/56	FALSE	FLT3	2322	TKD MUTATION		chr13	28018505	28018505	C	A	ENST00000241453.7	75		nonsynonymous_variant	NC_000013.10:g.28592642C>A	2023-01-27 17:02:18 UTC	CA126347	16276		TRUE
MGMT Promoter Methylation	85	Glioblastoma	3068				Prognostic	Supports	B	Better Outcome	MGMT promoter methylation was associated with increased overall and disease-free survival as well as tumor regression in patients with gliomas.	11070098	PubMed		"Esteller et al., 2000, N. Engl. J. Med."		4	accepted	172	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/172	https://civicdb.org/links/molecular_profiles/85	FALSE	MGMT	4255	Promoter Methylation		chr10	129466231	129467392			ENST00000306010.7	75		N/A		2023-01-09 21:52:04 UTC		N/A		FALSE
NPM1 EXON 12 MUTATION	86	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Better Outcome	NPM1 mutation without FLT3-ITD was associated with reduced relapse risk and increased overall survival in young adult acute myeloid leukemia patients (median age 43).	17957027	PubMed		"Gale et al., 2008, Blood"		4	accepted	173	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/173	https://civicdb.org/links/molecular_profiles/86	FALSE	NPM1	4869	EXON 12 MUTATION	NPM1 Exon 12	chr5	171410527	171410565			ENST00000517671.1	75		exon_variant		2023-01-09 21:52:04 UTC		N/A		FALSE
NPM1 EXON 12 MUTATION	86	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Better Outcome	"Patients with NPM1 mutations were associated with improved complete remission rates as well as overall and disease free survival when all ages and karyotype were analyzed; however, when only normal karyotype patients were analyzed, only complete remission rates were improved."	19059939	PubMed		"Schlenk et al., 2009, Haematologica"	NCT00151242	3	accepted	174	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/174	https://civicdb.org/links/molecular_profiles/86	FALSE	NPM1	4869	EXON 12 MUTATION	NPM1 Exon 12	chr5	171410527	171410565			ENST00000517671.1	75		exon_variant		2023-01-09 21:52:04 UTC		N/A		FALSE
NPM1 EXON 12 MUTATION	86	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Better Outcome	"Complete remission rates were higher (P<0.001) and both disease-free survival (N=205 vs 352, P=0.041) and overall survival (N=372 vs 956, P=0.022) were longer for AML patients with Exon 12 NPM1 mutations (irrespective of FLT3 status) than those with wildtype NPM1. Improved CR rates were also higher for those with NPM1 exon 12 mutations and normal karyotype. In multivariate analysis, NPM1 mutation alone (FLT3 wildtype) was associated with improved overall survival (but not DFS) in the entire cohort and in normal karyotype patients <60 years old."	16455956	PubMed		"Thiede et al., 2006, Blood"		3	accepted	175	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/175	https://civicdb.org/links/molecular_profiles/86	FALSE	NPM1	4869	EXON 12 MUTATION	NPM1 Exon 12	chr5	171410527	171410565			ENST00000517671.1	75		exon_variant		2023-01-09 21:52:04 UTC		N/A		FALSE
NPM1 EXON 12 MUTATION	86	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Better Outcome	"Complete remission rates were higher (70.5% vs 54.7%, P = 0.003) and event-free survival was longer (median, 428 vs 336 days; P = 0.012) for normal karyotype AML patients (median age 60.3 years) with Exon 12 NPM1 mutations (N=212) compared to those with wildtype NPM1 (N=189)."	16076867	PubMed		"Schnittger et al., 2005, Blood"		5	accepted	176	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/176	https://civicdb.org/links/molecular_profiles/86	FALSE	NPM1	4869	EXON 12 MUTATION	NPM1 Exon 12	chr5	171410527	171410565			ENST00000517671.1	75		exon_variant		2023-01-09 21:52:04 UTC		N/A		FALSE
NPM1 EXON 12 MUTATION	86	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Better Outcome	Cytoplasmic localization of NPM in AML patients was an independent prognositic factor associated with complete remission in response to induction therapy in a multivariate analysis (p=0.019) but not in a univariate analysis (p=0.07).	15659725	PubMed		"Falini et al., 2005, N. Engl. J. Med."		3	accepted	177	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/177	https://civicdb.org/links/molecular_profiles/86	FALSE	NPM1	4869	EXON 12 MUTATION	NPM1 Exon 12	chr5	171410527	171410565			ENST00000517671.1	75		exon_variant		2023-01-09 21:52:04 UTC		N/A		FALSE
NPM1 EXON 12 MUTATION	86	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Better Outcome	Intermediate risk patients with mutant NPM1 had improved overall survival with the presence of either IDH1 or IDH2 mutations than those wildtype for both IDH1 and IDH2.	22417203	PubMed		"Patel et al., 2012, N. Engl. J. Med."		2	accepted	179	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/179	https://civicdb.org/links/molecular_profiles/86	FALSE	NPM1	4869	EXON 12 MUTATION	NPM1 Exon 12	chr5	171410527	171410565			ENST00000517671.1	75		exon_variant		2023-01-09 21:52:04 UTC		N/A		FALSE
NPM1 EXON 12 MUTATION	86	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Better Outcome	"Normal karyotype patients with NPM1 mutation and without FLT3-ITD had improved overall and relapse-free survival, complete remission rates and remission duration compared to all other combinations of mutants."	19047294	PubMed		"Bchner et al., 2009, J. Clin. Oncol."		3	accepted	180	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/180	https://civicdb.org/links/molecular_profiles/86	FALSE	NPM1	4869	EXON 12 MUTATION	NPM1 Exon 12	chr5	171410527	171410565			ENST00000517671.1	75		exon_variant		2023-01-09 21:52:04 UTC		N/A		FALSE
NPM1 EXON 12 MUTATION	86	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Better Outcome	"NPM1 mutation (N=724) was associated with higher complete remission rates (92% vs 82%; P < 0.0001), lower cumulative incidence of relapse (42% vs 58%; P < 0.0001) and higher overall survival (48% vs 27%; P < .0001) than NPM1 wildtype status (N=885) in intermediate risk, young adult AML patients (median age 46 years)."	24855211	PubMed		"Linch et al., 2014, Blood"		4	accepted	181	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/181	https://civicdb.org/links/molecular_profiles/86	FALSE	NPM1	4869	EXON 12 MUTATION	NPM1 Exon 12	chr5	171410527	171410565			ENST00000517671.1	75		exon_variant		2023-01-09 21:52:04 UTC		N/A		FALSE
NPM1 EXON 12 MUTATION	86	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Better Outcome	"NPM1 mutation was associated with increased overall, event-free and relapse-free survival and remission after induction therapy in the entire cohort and in the cytogenetically normal subset of patients."	22430270	PubMed		"Gaidzik et al., 2012, J. Clin. Oncol."		3	accepted	182	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/182	https://civicdb.org/links/molecular_profiles/86	FALSE	NPM1	4869	EXON 12 MUTATION	NPM1 Exon 12	chr5	171410527	171410565			ENST00000517671.1	75		exon_variant		2023-01-09 21:52:04 UTC		N/A		FALSE
NPM1 EXON 12 MUTATION	86	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Better Outcome	"In young patients (age 16-60) with previously untreated, cytogenetically normal acute myeloid leukemia, NPM1 mutation without FLT3-ITD was significantly associated with complete remission in multivariate analysis (odds ratio, 1.48; 95% CI, 1.21 to 1.80). Multivariate analysis was performed on all patients that were evaluated for a mutation in at least 1 gene (CEBPA, FLT3-ITD or NPM1) totaling 693/872 patients in the study. 130 patients had NPM1 mutations without FLT3-ITD. NPM1 mutations were evaluated in 570 patients (310 mutated).  FLT3-ITD was evaluated in 531 patients (164 mutated)."	18450602	PubMed		"Schlenk et al., 2008, N. Engl. J. Med."		3	accepted	183	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/183	https://civicdb.org/links/molecular_profiles/86	FALSE	NPM1	4869	EXON 12 MUTATION	NPM1 Exon 12	chr5	171410527	171410565			ENST00000517671.1	75		exon_variant		2023-01-09 21:52:04 UTC		N/A		FALSE
NPM1 EXON 12 MUTATION	86	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Better Outcome	"NPM1 mutations were associated with increased complete remission rates as well as longer overall disease free survival in normal karyotype AML patients >59 years old, particularly in those >69 years old."	20026798	PubMed		"Becker et al., 2010, J. Clin. Oncol."		4	accepted	184	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/184	https://civicdb.org/links/molecular_profiles/86	FALSE	NPM1	4869	EXON 12 MUTATION	NPM1 Exon 12	chr5	171410527	171410565			ENST00000517671.1	75		exon_variant		2023-01-09 21:52:04 UTC		N/A		FALSE
NPM1 EXON 12 MUTATION	86	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Better Outcome	"Younger (16-60), normal karyotype AML patients with Exon 12 NPM1 mutation and without FLT3-ITD have increased overall survival (N=74, P = .001), relapse-free survival (N=86, P < .001) and response to induction chemotherapy. Multivariate analysis identified NPM1 mutation in the absence of FLT3-ITD as a prognostic marker for the achievement of CR (P=0.004)."	16051734	PubMed		"Dhner et al., 2005, Blood"		3	accepted	185	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/185	https://civicdb.org/links/molecular_profiles/86	FALSE	NPM1	4869	EXON 12 MUTATION	NPM1 Exon 12	chr5	171410527	171410565			ENST00000517671.1	75		exon_variant		2023-01-09 21:52:04 UTC		N/A		FALSE
DNMT3A R882	32	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	Complete remission rate was not different between young AML patients (<60 years old) with or without DNMT3A mutations (60% of which were R882).	22490330	PubMed		"Ribeiro et al., 2012, Blood"		3	accepted	186	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/186	https://civicdb.org/links/molecular_profiles/32	FALSE	DNMT3A	1788	R882		chr2	25234372	25234374			ENST00000264709.3	75		missense_variant		2023-01-09 21:52:04 UTC		"375,881,375,880,375,000,000,000,000,000,000,000"	"R693,ARG882,ARG693"	FALSE
DNMT3A R882	32	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	DNMT3A mutations (62% of which were R882) were associated with reduced disease-free survival in patients with cytogenetically normal AML.	22291079	PubMed		"Marcucci et al., 2012, J. Clin. Oncol."		4	accepted	187	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/187	https://civicdb.org/links/molecular_profiles/32	FALSE	DNMT3A	1788	R882		chr2	25234372	25234374			ENST00000264709.3	75		missense_variant		2023-01-09 21:52:04 UTC		"375,881,375,880,375,000,000,000,000,000,000,000"	"R693,ARG882,ARG693"	FALSE
DNMT3A Mutation	189	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	Young AML patients (415 patients; <60 years old) with any DNMT3A mutation (n=96) have shorter overall survival and relapse-free survival than patients with wildtype DNMT3A.	22490330	PubMed		"Ribeiro et al., 2012, Blood"		3	accepted	188	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/188	https://civicdb.org/links/molecular_profiles/189	FALSE	DNMT3A	1788	Mutation		chr2	25232976	25342590			ENST00000264709.3	75		transcript_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
DNMT3A R882	32	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	Young AML patients (415 patients; <60 years old) with DNMT3A R882 mutations (n=58) have shorter overall and relapse-free survival than patients with wildtype DNMT3A.	22490330	PubMed		"Ribeiro et al., 2012, Blood"		3	accepted	189	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/189	https://civicdb.org/links/molecular_profiles/32	FALSE	DNMT3A	1788	R882		chr2	25234372	25234374			ENST00000264709.3	75		missense_variant		2023-01-09 21:52:04 UTC		"375,881,375,880,375,000,000,000,000,000,000,000"	"R693,ARG882,ARG693"	FALSE
FLT3 ITD	55	Acute Myeloid Leukemia	9119				Prognostic	Supports	A	Poor Outcome	Meta-analysis of studies involving cytogentically normal younger (<60) patients showed reduced overall and relapse-free survival for patients with FLT3-ITD.	24801015	PubMed		"Port et al., 2014, Ann. Hematol."		3	accepted	190	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/190	https://civicdb.org/links/molecular_profiles/55	FALSE	FLT3	2322	ITD		chr13	28034082	28034214			ENST00000241453.7	75		inframe_insertion		2023-01-09 21:52:04 UTC		16270		FALSE
FLT3 ITD	55	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	A ratio of >0.49 FLT3-ITD/FLT3 wildtype level was associated with reduced event-free and overall survival in old (>59) and younger patients (<60) with an NPM1 mutation.	21537333	PubMed		"Schnittger et al., 2011, Leukemia"		4	accepted	191	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/191	https://civicdb.org/links/molecular_profiles/55	FALSE	FLT3	2322	ITD		chr13	28034082	28034214			ENST00000241453.7	75		inframe_insertion		2023-01-09 21:52:04 UTC		16270		FALSE
FLT3 ITD	55	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	Patients with NPM1 mutation and FLT3-ITD had reduced event-free survival compared to patients with wildtype FLT3.	21537333	PubMed		"Schnittger et al., 2011, Leukemia"		4	accepted	192	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/192	https://civicdb.org/links/molecular_profiles/55	FALSE	FLT3	2322	ITD		chr13	28034082	28034214			ENST00000241453.7	75		inframe_insertion		2023-01-09 21:52:04 UTC		16270		FALSE
FLT3 ITD	55	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	"Using a ratio of FLT3-ITD/FLT3 wildtype levels as a continuous variable, a higher ratio was associated with reduced event-free survival in patients with an NPM1 mutation."	21537333	PubMed		"Schnittger et al., 2011, Leukemia"		4	accepted	193	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/193	https://civicdb.org/links/molecular_profiles/55	FALSE	FLT3	2322	ITD		chr13	28034082	28034214			ENST00000241453.7	75		inframe_insertion		2023-01-09 21:52:04 UTC		16270		FALSE
KRAS G12/G13	77	Colorectal Cancer	9256				Prognostic	Supports	D	Poor Outcome	KRAS mutations were significantly associated with reduced progression-free and overall survival in patients with advanced colorectal cancer.	18202412	PubMed		"Livre et al., 2008, J. Clin. Oncol."		3	accepted	194	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/194	https://civicdb.org/links/molecular_profiles/77	FALSE	KRAS	3845	G12/G13		chr12	25245346	25245351			ENST00000256078.4	75		protein_altering_variant		2023-01-09 21:52:04 UTC		"45,122,125,781,258,200,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000"		FALSE
FLT3 ITD	55	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	"Coocurrence of FLT3-ITD mutations significantly reduced overall (N=74 vs 95, P=0.003) and disease-free survival (N=43 vs 67, P=0.02) of normal karyotype AML patients (<60 years old) compared to patients with NPM1 mutations alone."	16455956	PubMed		"Thiede et al., 2006, Blood"		4	accepted	195	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/195	https://civicdb.org/links/molecular_profiles/55	FALSE	FLT3	2322	ITD		chr13	28034082	28034214			ENST00000241453.7	75		inframe_insertion		2023-01-09 21:52:04 UTC		16270		FALSE
NPM1 EXON 12 MUTATION	86	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	Monitoring NPM1 mutation by cDNA-based RT-PCR effectively predicted relapse in 62/93 patients by >1 log increase in NPM1 levels (N=57) or lack of reduction in NPM1 levels following first line therapy (N=15).	19587375	PubMed		"Schnittger et al., 2009, Blood"		2	accepted	196	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/196	https://civicdb.org/links/molecular_profiles/86	FALSE	NPM1	4869	EXON 12 MUTATION	NPM1 Exon 12	chr5	171410527	171410565			ENST00000517671.1	75		exon_variant		2023-01-09 21:52:04 UTC		N/A		FALSE
FLT3 ITD	55	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	"Patients with NPM1 mutations and low (<25%, N=63), intermediate (25-50%, N=156) or high (>50%, N=66) levels of FLT3-ITD have worse overall survival (P<0.0001 for trend) and cumulative incidence of relapse (P<0.001) than those with NPM1 mutations alone (N=387) in young adult, intermediate risk AML patients."	24855211	PubMed		"Linch et al., 2014, Blood"		3	accepted	198	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/198	https://civicdb.org/links/molecular_profiles/55	FALSE	FLT3	2322	ITD		chr13	28034082	28034214			ENST00000241453.7	75		inframe_insertion		2023-01-09 21:52:04 UTC		16270		FALSE
NPM1 EXON 12 MUTATION	86	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	TET2 mutation reduces overall survival of normal karyotype patients with either an NPM1 mutation or NPM1 mutation without FLT3-ITD.	24859829	PubMed		"Tian et al., 2014, Int. J. Hematol."		3	accepted	199	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/199	https://civicdb.org/links/molecular_profiles/86	FALSE	NPM1	4869	EXON 12 MUTATION	NPM1 Exon 12	chr5	171410527	171410565			ENST00000517671.1	75		exon_variant		2023-01-09 21:52:04 UTC		N/A		FALSE
WT1 Exon 7 Mutation	129	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	Mutations  in WT1 were associated with increased risk of recurrence in young patients (15-50) with cytogenetically normal AML.	19536888	PubMed		"Renneville et al., 2009, Cancer"		2	accepted	201	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/201	https://civicdb.org/links/molecular_profiles/129	FALSE	WT1	7490	Exon 7 Mutation		chr11	32396257	32396407			ENST00000332351.3	75		exon_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
WT1 Exon 7 Mutation	129	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	"Mutations in WT1 were associated with a worse overall prognosis than patients wildtype for WT1 in young patients (15-50), primarily because of increased risk of disease recurrence."	19536888	PubMed		"Renneville et al., 2009, Cancer"		2	accepted	202	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/202	https://civicdb.org/links/molecular_profiles/129	FALSE	WT1	7490	Exon 7 Mutation		chr11	32396257	32396407			ENST00000332351.3	75		exon_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
WT1 Exon 7 Mutation	129	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	"Patients with WT1 (69% exon 7, 15% exon 9) and FLT3-ITD mutations had significantly lower complete remission and higher refractory disease rates than those with wildtype WT1 and without FLT3-ITD following induction therapy in young (16-60) patients with cytogenetically normal AML."	19221039	PubMed		"Gaidzik et al., 2009, Blood"		3	accepted	203	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/203	https://civicdb.org/links/molecular_profiles/129	FALSE	WT1	7490	Exon 7 Mutation		chr11	32396257	32396407			ENST00000332351.3	75		exon_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
WT1 Exon 7 Mutation	129	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	"WT mutations were associated with shorter overall and disease free survival in a cohort of cytogenetically normal, young (<60) AML patients."	18559874	PubMed		"Paschka et al., 2008, J. Clin. Oncol."		3	accepted	204	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/204	https://civicdb.org/links/molecular_profiles/129	FALSE	WT1	7490	Exon 7 Mutation		chr11	32396257	32396407			ENST00000332351.3	75		exon_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
WT1 Exon 7 Mutation	129	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	"WT1 mutations were a negative prognostic factor for overall survival in young (15-60+, median 45) patients with cytogenetically normal AML."	18591546	PubMed		"Virappane et al., 2008, J. Clin. Oncol."		3	accepted	205	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/205	https://civicdb.org/links/molecular_profiles/129	FALSE	WT1	7490	Exon 7 Mutation		chr11	32396257	32396407			ENST00000332351.3	75		exon_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
WT1 Exon 7 Mutation	129	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	"WT1 mutations were associated with a higher cumulative incidence of relapse and shorter relapse free survival in young (15-60+, median 45) patients with cytogenetically normal AML."	18591546	PubMed		"Virappane et al., 2008, J. Clin. Oncol."		3	accepted	206	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/206	https://civicdb.org/links/molecular_profiles/129	FALSE	WT1	7490	Exon 7 Mutation		chr11	32396257	32396407			ENST00000332351.3	75		exon_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
WT1 Exon 9 Mutation	130	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	"WT1 mutations were associated with shorter overall and disease free survival in a cohort of cytogenetically normal, young (<60) AML patients."	18559874	PubMed		"Paschka et al., 2008, J. Clin. Oncol."		3	accepted	210	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/210	https://civicdb.org/links/molecular_profiles/130	FALSE	WT1	7490	Exon 9 Mutation		chr11	32391972	32392064			ENST00000332351.3	75		exon_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
BRCA1 Loss-of-function	131	Ovarian Cancer	2394		Olaparib		Predictive	Supports	B	Sensitivity/Response	The combination of PARP inhibition (Olaparib) with BRCA mutation results in irreparable and lethal DNA damage. Response rates are higher in BRCA1 mutation positive women with high grade serous or undifferentiated ovarian cancer.	23346317	PubMed		"Goff, 2013, J Gynecol Oncol"		4	accepted	211	Rare Germline	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/211	https://civicdb.org/links/molecular_profiles/131	FALSE	BRCA1	672	Loss-of-function	BRCA Germline Variants	chr17	43045629	43125483			ENST00000471181.2	75		"loss_of_heterozygosity,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
BRCA2 Loss-of-function	132	Ovarian Cancer	2394		Olaparib		Predictive	Supports	B	Sensitivity/Response	The combination of PARP inhibition (Olaparib) with BRCA mutation results in irreparable and lethal DNA damage. Response rates are higher in BRCA2 mutation positive women with high grade serous or undifferentiated ovarian cancer.	23346317	PubMed		"Goff, 2013, J Gynecol Oncol"		4	accepted	212	Rare Germline	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/212	https://civicdb.org/links/molecular_profiles/132	FALSE	BRCA2	675	Loss-of-function	BRCA Germline Variants	chr13	32315474	32399210			ENST00000380152.3	75		loss_of_function_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
ABL1 BCR::ABL	1	Chronic Myeloid Leukemia	8552				Diagnostic	Does Not Support	C	Positive	"Data from deep sequencing of a Ph-negative clone of a Ph-positive CML patient has found a driving mutation in DNMT3A that preceeded the BCR-ABL fusion, and may imply the possibility that BCR-ABL is not universally the initiating event in CML."	25212276	PubMed		"Schmidt et al., 2014, Leukemia"		2	accepted	213	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/213	https://civicdb.org/links/molecular_profiles/1	FALSE	ABL1	25	BCR::ABL	ABL1 fusions in B-ALL	chr22	23180210	23290413			ENST00000305877.8	75	ENST00000318560.5	transcript_fusion	N/A	2023-01-09 21:52:04 UTC		N/A	"T(9;22)(Q34;Q11),BCR-ABL1,BCR-ABL"	FALSE
ABL1 BCR::ABL	1	Chronic Myeloid Leukemia	8552				Diagnostic	Does Not Support	C	Positive	"Data from deep sequencing of a Ph-negative clone of a Ph-positive CML patient has found a driving mutation in DNMT3A that preceeded the BCR-ABL fusion, and may imply the possibility that BCR-ABL is not universally the initiating event in CML."	25212276	PubMed		"Schmidt et al., 2014, Leukemia"		2	accepted	213	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/213	https://civicdb.org/links/molecular_profiles/1	FALSE	ABL1	25	BCR::ABL	ABL1 fusions in B-ALL	chr9	130854064	130887676			ENST00000305877.8	75	ENST00000318560.5	transcript_fusion	N/A	2023-01-09 21:52:04 UTC		N/A	"T(9;22)(Q34;Q11),BCR-ABL1,BCR-ABL"	FALSE
FLT3 TKD MUTATION	56	Acute Myeloid Leukemia	9119				Diagnostic	Does Not Support	B	Positive	WBC counts were not significantly different in AML patients with FLT3 D835 mutations compared to wild type.	11290608	PubMed		"Yamamoto et al., 2001, Blood"		3	accepted	214	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/214	https://civicdb.org/links/molecular_profiles/56	FALSE	FLT3	2322	TKD MUTATION		chr13	28018505	28018505	C	A	ENST00000241453.7	75		nonsynonymous_variant	NC_000013.10:g.28592642C>A	2023-01-27 17:02:18 UTC	CA126347	16276		TRUE
KRAS G12	76	Lung Non-small Cell Carcinoma	3908				Diagnostic	Does Not Support	B	Positive	"KRAS mutations in lung cancer patients are not associated with smoking history, age or gender."	18794081	PubMed		"Riely et al., 2008, Clin. Cancer Res."		3	accepted	215	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/215	https://civicdb.org/links/molecular_profiles/76	FALSE	KRAS	3845	G12		chr12	25245350	25245351			ENST00000256078.4	75		protein_altering_variant		2023-01-09 21:52:04 UTC		"451,221,257,812,582,000,000,000,000,000"	GLY12	FALSE
U2AF1 Q157P/R	127	Acute Myeloid Leukemia	9119				Diagnostic	Does Not Support	B	Positive	"Age, sex, FAB subtype and karyotypes were not statistically significant between AML patients with U2AF Q157P/R mutations and those who harbor wild type U2AF."	23029227	PubMed		"Qian et al., 2012, PLoS ONE"		3	accepted	217	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/217	https://civicdb.org/links/molecular_profiles/127	FALSE	U2AF1	7307	Q157P/R		chr21	43094667	43094667	T	G	ENST00000291552.4	75		missense_variant	NC_000021.8:g.44514777T>G	2023-01-09 21:52:05 UTC				FALSE
U2AF1 S34Y/F	128	Acute Myeloid Leukemia	9119				Diagnostic	Does Not Support	B	Positive	"Age, sex, FAB subtype and karyotypes were not statistically significant between AML patients with U2AF S34Y/F mutations and those who harbor wild type U2AF."	23029227	PubMed		"Qian et al., 2012, PLoS ONE"		3	accepted	218	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/218	https://civicdb.org/links/molecular_profiles/128	FALSE	U2AF1	7307	S34Y/F		chr21	43104346	43104346	G	A	ENST00000291552.4	75		missense_variant	NC_000021.8:g.44524456G>A	2023-01-09 21:52:05 UTC				FALSE
CCND2 PROMOTER DEMETHYLATION	22	Stomach Cancer	10534				Diagnostic	Supports	D	Negative	CCND2 hypomethylation is seen to be more common in stage III and IV gastric tumors than stage I and II.	14612939	PubMed		"Oshimo et al., 2003, Int. J. Oncol."		3	accepted	219	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/219	https://civicdb.org/links/molecular_profiles/22	FALSE	CCND2	894	PROMOTER DEMETHYLATION		chr12	4272271	4273771			ENST00000261254.3	75		N/A		2023-01-09 21:52:04 UTC				FALSE
ABL1 BCR::ABL	1	Chronic Myeloid Leukemia	8552				Diagnostic	Supports	A	Positive	"The presence of BCR-ABL fusion is considered the characterizing feature of chronic myeloid leukemia, and has been widely thought of as the initiating event in the disease."	20537386	PubMed		"An et al., 2010, Leuk. Res."		4	accepted	220	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/220	https://civicdb.org/links/molecular_profiles/1	FALSE	ABL1	25	BCR::ABL	ABL1 fusions in B-ALL	chr22	23180210	23290413			ENST00000305877.8	75	ENST00000318560.5	transcript_fusion	N/A	2023-01-09 21:52:04 UTC		N/A	"T(9;22)(Q34;Q11),BCR-ABL1,BCR-ABL"	FALSE
ABL1 BCR::ABL	1	Chronic Myeloid Leukemia	8552				Diagnostic	Supports	A	Positive	"The presence of BCR-ABL fusion is considered the characterizing feature of chronic myeloid leukemia, and has been widely thought of as the initiating event in the disease."	20537386	PubMed		"An et al., 2010, Leuk. Res."		4	accepted	220	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/220	https://civicdb.org/links/molecular_profiles/1	FALSE	ABL1	25	BCR::ABL	ABL1 fusions in B-ALL	chr9	130854064	130887676			ENST00000305877.8	75	ENST00000318560.5	transcript_fusion	N/A	2023-01-09 21:52:04 UTC		N/A	"T(9;22)(Q34;Q11),BCR-ABL1,BCR-ABL"	FALSE
CCND1 Overexpression	20	Breast Cancer	1612				Diagnostic	Supports	B	Positive	Cyclin D1 overexpression is associated with the ER-positive subtype of breast cancer.	15961768	PubMed		"Arnold et al., 2005, J. Clin. Oncol."		4	accepted	221	N/A	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/221	https://civicdb.org/links/molecular_profiles/20	FALSE	CCND1	595	Overexpression		chr11	69641087	69654474			ENST00000227507.2	75		N/A	N/A	2023-01-09 21:52:04 UTC		N/A		FALSE
FLT3 ITD	55	Acute Myeloid Leukemia	9119				Diagnostic	Supports	B	Positive	WBC counts were higher in AML patients with internal tandem repeat of Flt3 compared to wild type.	11290608	PubMed		"Yamamoto et al., 2001, Blood"		3	accepted	222	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/222	https://civicdb.org/links/molecular_profiles/55	FALSE	FLT3	2322	ITD		chr13	28034082	28034214			ENST00000241453.7	75		inframe_insertion		2023-01-09 21:52:04 UTC		16270		FALSE
IDH1 R132	58	Acute Myeloid Leukemia	9119				Diagnostic	Supports	B	Positive	"In leukemia patients, IDH1 R132 mutation is associated with adults and normal karyotype."	20376086	PubMed		"Ho et al., 2010, Leukemia"		2	accepted	223	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/223	https://civicdb.org/links/molecular_profiles/58	FALSE	IDH1	3417	R132		chr2	208248387	208248389			ENST00000415913.1	75		protein_altering_variant	"NC_000002.11:g.209113113G>A,NC_000002.11:g.209113112C>T,NC_000002.11:g.209113113G>C,NC_000002.11:g.209113112C>A,NC_000002.11:g.209113113G>T,NC_000002.11:g.209113112C>G"	2023-01-09 21:52:04 UTC		"156,444,375,891,375,000,000,000,000,000,000,000"	ARG132	FALSE
IDH1 R132C	59	Acute Myeloid Leukemia	9119				Diagnostic	Supports	B	Positive	"IDH1 R132 mutation is associated with patients of older age, high platelet count during diagnosis, cytogenic normalcy and NPM1 mutation."	20538800	PubMed		"Abbas et al., 2010, Blood"		3	accepted	224	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/224	https://civicdb.org/links/molecular_profiles/59	FALSE	IDH1	3417	R132C		chr2	208248389	208248389	G	A	ENST00000415913.1	75		missense_variant	"NM_005896.3:c.394C>T,NP_005887.2:p.Arg132Cys,NC_000002.11:g.209113113G>A,ENST00000415913.1:c.394C>T"	2023-01-27 17:02:19 UTC	CA16602374	375891	"RS121913499,ARG132CYS"	FALSE
KIT Exon 11 Mutation	66	Gastrointestinal Stromal Tumor	9253				Diagnostic	Supports	B	Positive	"KIT mutation is associated with larger, more invasive tumors, greater pathologic histology and older patients compared to tumors with wildtype KIT."	10485475	PubMed		"Taniguchi et al., 1999, Cancer Res."		2	accepted	225	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/225	https://civicdb.org/links/molecular_profiles/66	FALSE	KIT	3815	Exon 11 Mutation	KIT Exon 11	chr4	54727416	54727542			ENST00000288135.5	75		coding_sequence_variant		2023-01-09 21:52:04 UTC				FALSE
KRAS G12C	78	Lung Cancer	1324				Diagnostic	Supports	B	Positive	KRAS G12C occur more frequently in women than men.	23014527	PubMed		"Dogan et al., 2012, Clin. Cancer Res."		2	accepted	227	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/227	https://civicdb.org/links/molecular_profiles/78	FALSE	KRAS	3845	G12C	EGFR TKI Resistance	chr12	25245351	25245351	C	A	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.34G>T,NP_004976.2:p.Gly12Cys,NC_000012.11:g.25398285C>A,ENST00000256078.4:c.34G>T"	2023-01-27 17:02:26 UTC	CA122528	12578	"GLY12CYS,RS121913530"	FALSE
KRAS G12D	79	Lung Cancer	1324				Diagnostic	Supports	B	Positive	KRAS G12D mutation occurs in never smokers significantly more often than in smokers.	23014527	PubMed		"Dogan et al., 2012, Clin. Cancer Res."		3	accepted	228	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/228	https://civicdb.org/links/molecular_profiles/79	FALSE	KRAS	3845	G12D	EGFR TKI Resistance	chr12	25245350	25245350	C	T	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.35G>A,NP_004976.2:p.Gly12Asp,NC_000012.11:g.25398284C>T,ENST00000256078.4:c.35G>A"	2023-01-27 17:02:26 UTC	CA122538	12582	"GLY12ASP,RS121913529"	FALSE
EGFR L858R	33	Lung Non-small Cell Carcinoma	3908		"Gefitinib,Erlotinib"	Substitutes	Predictive	Supports	B	Sensitivity/Response	There is no statistical difference in progression free survival between lung cancer patients treated with gefitinib or erlotinib with EGFR L858R mutations (N=72/242; univariate: P=0.283; multivariate: P=0.250) compared to patients with Exon 19 mutations (N=170).	24736073	PubMed		"Lim et al., 2014, J Thorac Oncol"		3	accepted	229	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/229	https://civicdb.org/links/molecular_profiles/33	FALSE	EGFR	1956	L858R		chr7	55191822	55191822	T	G	ENST00000275493.2	75		missense_variant	"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg"	2023-01-27 17:02:04 UTC	CA126713	"16,609,376,282,376,200"	"LEU858ARG,RS121434568"	FALSE
AKT1 E17K	4	Breast Cancer	1612		Akt Inhibitor MK2206		Predictive	Does Not Support	D	Sensitivity/Response	"Breast cancer cell lines with the AKT1 E17K mutation did not show sensitivity to AKT inhibitor MK-2206, unlike cell lines with PIK3CA mutations."	23888070	PubMed		"Beaver et al., 2013, Clin. Cancer Res."		3	accepted	231	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/231	https://civicdb.org/links/molecular_profiles/4	FALSE	AKT1	207	E17K		chr14	104780214	104780214	C	T	ENST00000407796.2	75		missense_variant	"NC_000014.8:g.105246551C>T,NM_001014432.1:c.49G>A,NP_001014432.1:p.Glu17Lys,ENST00000407796.2:c.49G>A"	2023-01-27 17:01:56 UTC	CA123660	13983	"GLU17LYS,RS34409589"	FALSE
ABL1 BCR::ABL	1	Acute Myeloid Leukemia	9119		Imatinib		Predictive	Supports	D	Resistance	BCR-ABL fusions have been found to contribute to imatinib resistance in AML cell lines.	12476305	PubMed		"Nimmanapalli et al., 2002, Oncogene"		3	accepted	232	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/232	https://civicdb.org/links/molecular_profiles/1	FALSE	ABL1	25	BCR::ABL	ABL1 fusions in B-ALL	chr22	23180210	23290413			ENST00000305877.8	75	ENST00000318560.5	transcript_fusion	N/A	2023-01-09 21:52:04 UTC		N/A	"T(9;22)(Q34;Q11),BCR-ABL1,BCR-ABL"	FALSE
ABL1 BCR::ABL	1	Acute Myeloid Leukemia	9119		Imatinib		Predictive	Supports	D	Resistance	BCR-ABL fusions have been found to contribute to imatinib resistance in AML cell lines.	12476305	PubMed		"Nimmanapalli et al., 2002, Oncogene"		3	accepted	232	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/232	https://civicdb.org/links/molecular_profiles/1	FALSE	ABL1	25	BCR::ABL	ABL1 fusions in B-ALL	chr9	130854064	130887676			ENST00000305877.8	75	ENST00000318560.5	transcript_fusion	N/A	2023-01-09 21:52:04 UTC		N/A	"T(9;22)(Q34;Q11),BCR-ABL1,BCR-ABL"	FALSE
EGFR T790M	34	Lung Non-small Cell Carcinoma	3908		Erlotinib		Predictive	Supports	A	Resistance	"The T790M mutation in EGFR has been shown to confer resistance to the tyrosine kinase inhibitor erlotinib, and patients harboring this mutation that are placed on the drug are likely to relapse."	25668228	PubMed		"Denis et al., 2015, Clin. Chim. Acta"		5	accepted	238	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/238	https://civicdb.org/links/molecular_profiles/34	FALSE	EGFR	1956	T790M	EGFR TKI Resistance	chr7	55181378	55181378	C	T	ENST00000275493.2	75		missense_variant	"ENST00000275493.2:c.2369C>T,NM_005228.4:c.2369C>T,NP_005219.2:p.Thr790Met,NC_000007.13:g.55249071C>T"	2023-01-27 17:02:05 UTC	CA090928	16613	"THR790MET,RS121434569"	FALSE
EGFR T790M	34	Lung Non-small Cell Carcinoma	3908		Gefitinib		Predictive	Supports	B	Resistance	"In non-small cell lung cancer, the appearance of T790M mutation leads to resistance to gefitinib."	15728811	PubMed		"Kobayashi et al., 2005, N. Engl. J. Med."		3	accepted	239	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/239	https://civicdb.org/links/molecular_profiles/34	FALSE	EGFR	1956	T790M	EGFR TKI Resistance	chr7	55181378	55181378	C	T	ENST00000275493.2	75		missense_variant	"ENST00000275493.2:c.2369C>T,NM_005228.4:c.2369C>T,NP_005219.2:p.Thr790Met,NC_000007.13:g.55249071C>T"	2023-01-27 17:02:05 UTC	CA090928	16613	"THR790MET,RS121434569"	FALSE
EGFR T790M	34	Lung Non-small Cell Carcinoma	3908		Dacomitinib		Predictive	Supports	B	Resistance	"In Lung Cancer patients with acquired resistance to Dacomitinib (PF00299804), MET amplification and EGFR T790M were found to be the primary drivers of resistance."	21430269	PubMed		"Sequist et al., 2011, Sci Transl Med"		4	accepted	240	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/240	https://civicdb.org/links/molecular_profiles/34	FALSE	EGFR	1956	T790M	EGFR TKI Resistance	chr7	55181378	55181378	C	T	ENST00000275493.2	75		missense_variant	"ENST00000275493.2:c.2369C>T,NM_005228.4:c.2369C>T,NP_005219.2:p.Thr790Met,NC_000007.13:g.55249071C>T"	2023-01-27 17:02:05 UTC	CA090928	16613	"THR790MET,RS121434569"	FALSE
ERBB2 L755S	39	Breast Cancer	1612		Lapatinib		Predictive	Supports	D	Resistance	The L755S mutation was shown to confer resistance to lapatinib in MCF10A cell lines retrovirally transduced with wildtype or mutant ERBB2.	23220880	PubMed		"Bose et al., 2013, Cancer Discov"		5	accepted	241	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/241	https://civicdb.org/links/molecular_profiles/39	FALSE	ERBB2	2064	L755S		chr17	39723967	39723967	T	C	ENST00000269571.5	75		missense_variant	"ENST00000269571.5:c.2264T>C,NC_000017.10:g.37880220T>C,NM_004448.3:c.2264T>C,NP_004439.2:p.Leu755Ser"	2023-01-27 17:02:09 UTC	CA16602502	376035	"LEU755SER,L725S,L740S"	FALSE
ESR1 L536Q	46	Breast Cancer	1612		Hormone Therapy		Predictive	Supports	D	Resistance	MCF7 cell lines harboring the L536Q mutation in the ligand-binding domain of ESR1 have shown resistance to hormone therapy.	24185512	PubMed		"Toy et al., 2013, Nat. Genet."		3	accepted	242	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/242	https://civicdb.org/links/molecular_profiles/46	TRUE	ESR1	2099	L536Q	ESR1 Ligand-Binding Domain	chr6	152098785	152098786	TC	AG	ENST00000440973.1	75		missense_variant	"NC_000006.11:g.152419920_152419921delinsAG,ENST00000440973.1:c.1607_1608delinsAG"	2023-01-27 17:02:14 UTC	CA645542628	NONE FOUND	LEU536GLN	FALSE
ESR1 D538G	47	Breast Cancer	1612		Hormone Therapy		Predictive	Supports	D	Resistance	MCF7 cell lines harboring the D538G mutation in the ligand-binding domain of ESR1 have shown resistance to hormone therapy.	24185512	PubMed		"Toy et al., 2013, Nat. Genet."		3	accepted	243	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/243	https://civicdb.org/links/molecular_profiles/47	FALSE	ESR1	2099	D538G	ESR1 Ligand-Binding Domain	chr6	152098791	152098791	A	G	ENST00000206249.3	75		missense_variant	"ENST00000206249.3:c.1613A>G,NC_000006.11:g.152419926A>G,NM_000125.3:c.1613A>G,NP_000116.2:p.Asp538Gly"	2023-01-27 17:02:15 UTC	CA366085705	NONE FOUND	ASP538GLY	FALSE
ESR1 Y537C	48	Breast Cancer	1612		Hormone Therapy		Predictive	Supports	D	Resistance	MCF7 cell lines harboring the Y537C mutation in the ligand-binding domain of ESR1 have shown resistance to hormone therapy.	24185512	PubMed		"Toy et al., 2013, Nat. Genet."		3	accepted	244	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/244	https://civicdb.org/links/molecular_profiles/48	FALSE	ESR1	2099	Y537C	ESR1 Ligand-Binding Domain	chr6	152098788	152098788	A	G	ENST00000206249.3	75		missense_variant	"ENST00000206249.3:c.1610A>G,NC_000006.11:g.152419923A>G,NM_000125.3:c.1610A>G,NP_000116.2:p.Tyr537Cys"	2023-01-27 17:02:16 UTC	CA366085697	NONE FOUND	GLY537CYS	FALSE
ESR1 Y537N	49	Breast Cancer	1612		Hormone Therapy		Predictive	Supports	D	Resistance	MCF7 cell lines harboring the Y537N mutation in the ligand-binding domain of ESR1 have shown resistance to hormone therapy.	24185512	PubMed		"Toy et al., 2013, Nat. Genet."		3	accepted	245	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/245	https://civicdb.org/links/molecular_profiles/49	FALSE	ESR1	2099	Y537N	ESR1 Ligand-Binding Domain	chr6	152098787	152098787	T	A	ENST00000206249.3	75		missense_variant	"ENST00000206249.3:c.1609T>A,NC_000006.11:g.152419922T>A,NM_000125.3:c.1609T>A,NP_000116.2:p.Tyr537Asn"	2023-01-27 17:02:17 UTC	CA366085693	NONE FOUND	GLY537ASN	FALSE
ESR1 Y537S	50	Breast Cancer	1612		Hormone Therapy		Predictive	Supports	D	Resistance	MCF7 cell lines harboring the L537S mutation in the ligand-binding domain of ESR1 have shown resistance to hormone therapy.	24185512	PubMed		"Toy et al., 2013, Nat. Genet."		3	accepted	246	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/246	https://civicdb.org/links/molecular_profiles/50	FALSE	ESR1	2099	Y537S	ESR1 Ligand-Binding Domain	chr6	152098788	152098788	A	C	ENST00000206249.3	75		missense_variant	"ENST00000206249.3:c.1610A>C,NC_000006.11:g.152419923A>C,NM_000125.3:c.1610A>C,NP_000116.2:p.Tyr537Ser"	2023-01-27 17:02:18 UTC	CA366085696	NONE FOUND	GLY537SER	FALSE
FLT3 TKD MUTATION	56	Acute Myeloid Leukemia	9119		Sorafenib		Predictive	Supports	B	Resistance	Emergence of D835 mutation in AML patients with FLT3 tandem repeat is associated with sorafenib resistance.	22368270	PubMed		"Man et al., 2012, Blood"		4	accepted	247	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/247	https://civicdb.org/links/molecular_profiles/56	FALSE	FLT3	2322	TKD MUTATION		chr13	28018505	28018505	C	A	ENST00000241453.7	75		nonsynonymous_variant	NC_000013.10:g.28592642C>A	2023-01-27 17:02:18 UTC	CA126347	16276		TRUE
FLT3 TKD MUTATION	56	Acute Myeloid Leukemia	9119		Sorafenib		Predictive	Supports	B	Resistance	"Sorafenib is effective in patients with FLT3 internal tandem repeat mutations, but not in patients with wild type or D835 mutation."	18230792	PubMed		"Zhang et al., 2008, J. Natl. Cancer Inst."		4	accepted	248	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/248	https://civicdb.org/links/molecular_profiles/56	FALSE	FLT3	2322	TKD MUTATION		chr13	28018505	28018505	C	A	ENST00000241453.7	75		nonsynonymous_variant	NC_000013.10:g.28592642C>A	2023-01-27 17:02:18 UTC	CA126347	16276		TRUE
KIT V654A	73	Gastrointestinal Stromal Tumor	9253		Imatinib		Predictive	Supports	D	Resistance	KIT V654A results in imatinib resistance in GIST patient-derived cell lines.	16954519	PubMed		"Heinrich et al., 2006, J. Clin. Oncol."		3	accepted	249	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/249	https://civicdb.org/links/molecular_profiles/73	FALSE	KIT	3815	V654A		chr4	54728092	54728092	T	C	ENST00000288135.5	75		missense_variant	"NM_000222.2:c.1961T>C,NP_000213.1:p.Val654Ala,ENST00000288135.5:c.1961T>C,NC_000004.11:g.55594258T>C"	2023-01-27 17:02:25 UTC	CA16602402	375921	"RS121913523,VAL654ALA"	FALSE
KRAS Exon 2 Mutation	75	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	B	Resistance	Patients with colorectal cancer who harbor KRAS mutation have low response rate to cetuximab.	16618717	PubMed		"Livre et al., 2006, Cancer Res."		3	accepted	250	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/250	https://civicdb.org/links/molecular_profiles/75	FALSE	KRAS	3845	Exon 2 Mutation		chr12	25245274	25245395			ENST00000256078.4	75		missense_variant		2023-01-09 21:52:04 UTC				FALSE
KRAS G12A	148	Lung Adenocarcinoma	3910		"Erlotinib,Gefitinib"	Substitutes	Predictive	Supports	B	Resistance	"KRAS mutations (N=29 G12, N=1 G13) were the primary predictor of EGFR TKI resistance in patients with lung adenocarcinoma (N=83). Overall survival (P=0.001) and progression-free survival (P=0.005) were significantly shorter in mutated patients."	19794967	PubMed		"Marchetti et al., 2009, Neoplasia"		3	accepted	251	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/251	https://civicdb.org/links/molecular_profiles/148	FALSE	KRAS	3845	G12A	EGFR TKI Resistance	chr12	25245350	25245350	C	G	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.35G>C,NP_004976.2:p.Gly12Ala,NC_000012.11:g.25398284C>G,ENST00000256078.4:c.35G>C"	2023-01-27 17:02:57 UTC	CA135567	45122	"GLY12ALA,RS121913529"	FALSE
PIK3CA H1047R	107	Colorectal Cancer	9256		"Panitumumab,Cetuximab"	Substitutes	Predictive	Does Not Support	B	Resistance	"In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). KRAS PIK3CA and PTEN were tested for mutation; PIK3CA H1047R was the only variant noted in the primary tumor (located in rectum) of one patient who experienced partial response (patient 38; Supplemental Table 1), following treatment. In the larger cohort, patients with tumors harboring any PIK3CA mutation had significantly shorter progression free survival and decreased incidence of objective response than patients with wtPIK3CA tumors."	19223544	PubMed		"Sartore-Bianchi et al., 2009, Cancer Res."		2	accepted	258	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/258	https://civicdb.org/links/molecular_profiles/107	FALSE	PIK3CA	5290	H1047R		chr3	179234297	179234297	A	G	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.3140A>G,NP_006209.2:p.His1047Arg,ENST00000263967.3:c.3140A>G,NC_000003.11:g.178952085A>G"	2023-01-27 17:02:38 UTC	CA123326	13652	"HIS1047ARG,RS121913279"	FALSE
ABL1 BCR::ABL	1	Acute Myeloid Leukemia	9119		Imatinib		Predictive	Supports	A	Sensitivity/Response	Treatment of Philadelphia chromosome positive leukemias with imatinib results in high rates of complete remission in patients with CML.	12476305	PubMed		"Nimmanapalli et al., 2002, Oncogene"		5	accepted	259	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/259	https://civicdb.org/links/molecular_profiles/1	FALSE	ABL1	25	BCR::ABL	ABL1 fusions in B-ALL	chr22	23180210	23290413			ENST00000305877.8	75	ENST00000318560.5	transcript_fusion	N/A	2023-01-09 21:52:04 UTC		N/A	"T(9;22)(Q34;Q11),BCR-ABL1,BCR-ABL"	FALSE
ABL1 BCR::ABL	1	Acute Myeloid Leukemia	9119		Imatinib		Predictive	Supports	A	Sensitivity/Response	Treatment of Philadelphia chromosome positive leukemias with imatinib results in high rates of complete remission in patients with CML.	12476305	PubMed		"Nimmanapalli et al., 2002, Oncogene"		5	accepted	259	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/259	https://civicdb.org/links/molecular_profiles/1	FALSE	ABL1	25	BCR::ABL	ABL1 fusions in B-ALL	chr9	130854064	130887676			ENST00000305877.8	75	ENST00000318560.5	transcript_fusion	N/A	2023-01-09 21:52:04 UTC		N/A	"T(9;22)(Q34;Q11),BCR-ABL1,BCR-ABL"	FALSE
ABL1 BCR::ABL	1	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	A	Sensitivity/Response	The clinical use of imatinib in patients with BCR-ABL fusion has resulted in drastic prognostic improvements in patients with CML.	20537386	PubMed		"An et al., 2010, Leuk. Res."		5	accepted	260	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/260	https://civicdb.org/links/molecular_profiles/1	FALSE	ABL1	25	BCR::ABL	ABL1 fusions in B-ALL	chr22	23180210	23290413			ENST00000305877.8	75	ENST00000318560.5	transcript_fusion	N/A	2023-01-09 21:52:04 UTC		N/A	"T(9;22)(Q34;Q11),BCR-ABL1,BCR-ABL"	FALSE
ABL1 BCR::ABL	1	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	A	Sensitivity/Response	The clinical use of imatinib in patients with BCR-ABL fusion has resulted in drastic prognostic improvements in patients with CML.	20537386	PubMed		"An et al., 2010, Leuk. Res."		5	accepted	260	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/260	https://civicdb.org/links/molecular_profiles/1	FALSE	ABL1	25	BCR::ABL	ABL1 fusions in B-ALL	chr9	130854064	130887676			ENST00000305877.8	75	ENST00000318560.5	transcript_fusion	N/A	2023-01-09 21:52:04 UTC		N/A	"T(9;22)(Q34;Q11),BCR-ABL1,BCR-ABL"	FALSE
ABL1 BCR::ABL	1	Chronic Myeloid Leukemia	8552		"Dasatinib,Nilotinib"	Substitutes	Predictive	Supports	A	Sensitivity/Response	"The use of nilotinib and dasatinib, second-generation BCR-ABL targeted therapies, has been effective in patients resistant to imatinib, leading to their FDA-approval."	20537386	PubMed		"An et al., 2010, Leuk. Res."		4	accepted	261	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/261	https://civicdb.org/links/molecular_profiles/1	FALSE	ABL1	25	BCR::ABL	ABL1 fusions in B-ALL	chr22	23180210	23290413			ENST00000305877.8	75	ENST00000318560.5	transcript_fusion	N/A	2023-01-09 21:52:04 UTC		N/A	"T(9;22)(Q34;Q11),BCR-ABL1,BCR-ABL"	FALSE
ABL1 BCR::ABL	1	Chronic Myeloid Leukemia	8552		"Dasatinib,Nilotinib"	Substitutes	Predictive	Supports	A	Sensitivity/Response	"The use of nilotinib and dasatinib, second-generation BCR-ABL targeted therapies, has been effective in patients resistant to imatinib, leading to their FDA-approval."	20537386	PubMed		"An et al., 2010, Leuk. Res."		4	accepted	261	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/261	https://civicdb.org/links/molecular_profiles/1	FALSE	ABL1	25	BCR::ABL	ABL1 fusions in B-ALL	chr9	130854064	130887676			ENST00000305877.8	75	ENST00000318560.5	transcript_fusion	N/A	2023-01-09 21:52:04 UTC		N/A	"T(9;22)(Q34;Q11),BCR-ABL1,BCR-ABL"	FALSE
ALK EML4::ALK	5	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	C	Sensitivity/Response	A 28 year-old patient with non-small cell lung cancer that failed conventional therapy was found to harbor the EML4-ALK (E13;A20) fusion using reverse transcription PCR. Treatment with 250mg crizotinib twice daily resulted in rapid improvement of symptoms and disease control for 5 months.	20979473	PubMed		"Choi et al., 2010, N. Engl. J. Med."		4	accepted	262	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/262	https://civicdb.org/links/molecular_profiles/5	FALSE	ALK	238	EML4::ALK	ALK Fusion	chr2	42169350	42295516			ENST00000318522.5	75	ENST00000389048.3	transcript_fusion		2023-01-09 21:52:04 UTC		N/A	EML4-ALK	FALSE
ALK EML4::ALK	5	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	C	Sensitivity/Response	A 28 year-old patient with non-small cell lung cancer that failed conventional therapy was found to harbor the EML4-ALK (E13;A20) fusion using reverse transcription PCR. Treatment with 250mg crizotinib twice daily resulted in rapid improvement of symptoms and disease control for 5 months.	20979473	PubMed		"Choi et al., 2010, N. Engl. J. Med."		4	accepted	262	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/262	https://civicdb.org/links/molecular_profiles/5	FALSE	ALK	238	EML4::ALK	ALK Fusion	chr2	29192774	29223528			ENST00000318522.5	75	ENST00000389048.3	transcript_fusion		2023-01-09 21:52:04 UTC		N/A	EML4-ALK	FALSE
CCND3 Loss	23	T-cell Lymphoblastic Leukemia/lymphoma	715		Palbociclib		Predictive	Supports	D	Sensitivity/Response	Treatment of Notch-driven T-cell leukemia in Ccnd3 knockout mice with Palbociclib (PD-0332991) significantly increased median survival.	23079656	PubMed		"Sawai et al., 2012, Cancer Cell"		3	accepted	263	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/263	https://civicdb.org/links/molecular_profiles/23	TRUE	CCND3	896	Loss		chr6	41934933	41941848			ENST00000372991.4	75		loss_of_function_variant		2023-01-09 21:52:04 UTC		N/A		FALSE
CDK4 EXPRESSION	25	Estrogen-receptor Positive Breast Cancer	60075		Alpelisib		Predictive	Supports	D	Sensitivity/Response	"In mouse xenograft studies of PIK3CA mutant breast cancers, the combination of PI3K and CDK4/6 inhibitors overcomes intrinsic and adaptive resistance leading to tumor regressions."	25002028	PubMed		"Vora et al., 2014, Cancer Cell"	NCT01219699	4	accepted	264	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/264	https://civicdb.org/links/molecular_profiles/25	FALSE	CDK4	1019	EXPRESSION		chr12	57747727	57752521			ENST00000257904.6	75		N/A		2023-01-09 21:52:04 UTC		N/A		FALSE
DDR2 G253C	141	Lung Non-small Cell Carcinoma	3908		Dasatinib		Predictive	Supports	D	Sensitivity/Response	In 3T3 fibroblasts expressing the G253C mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib.	22328973	PubMed		"Hammerman et al., 2011, Cancer Discov"		4	accepted	266	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/266	https://civicdb.org/links/molecular_profiles/141	FALSE	DDR2	4921	G253C		chr1	162759881	162759881	G	T	ENST00000367922.3	75		missense_variant	"ENST00000367922.3:c.757G>T,NC_000001.10:g.162729671G>T"	2023-01-27 17:02:53 UTC	CA16602599	376142	GLY253CYS	FALSE
DDR2 G505S	142	Lung Non-small Cell Carcinoma	3908		Dasatinib		Predictive	Supports	D	Sensitivity/Response	In 3T3 fibroblasts expressing the G505S mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib.	22328973	PubMed		"Hammerman et al., 2011, Cancer Discov"		4	accepted	267	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/267	https://civicdb.org/links/molecular_profiles/142	FALSE	DDR2	4921	G505S		chr1	162772032	162772032	G	A	ENST00000367922.3	75		missense_variant	"NM_006182.2:c.1513G>A,NP_006173.2:p.Gly505Ser,ENST00000367922.3:c.1513G>A,NC_000001.10:g.162741822G>A"	2023-01-27 17:02:54 UTC	CA1217584	282994	"GLY505SER,RS115169993"	FALSE
DDR2 G774V	144	Lung Non-small Cell Carcinoma	3908		Dasatinib		Predictive	Supports	D	Sensitivity/Response	In 3T3 fibroblasts expressing the G774V mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib.	22328973	PubMed		"Hammerman et al., 2011, Cancer Discov"		4	accepted	268	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/268	https://civicdb.org/links/molecular_profiles/144	FALSE	DDR2	4921	G774V		chr1	162778617	162778617	G	T	ENST00000367922.3	75		missense_variant	"ENST00000367922.3:c.2321G>T,NC_000001.10:g.162748407G>T"	2023-01-27 17:02:56 UTC	CA16602601	376144	GLY774VAL	FALSE
DDR2 I638F	143	Lung Non-small Cell Carcinoma	3908		Dasatinib		Predictive	Supports	D	Sensitivity/Response	In 3T3 fibroblasts expressing the I638F mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib.	22328973	PubMed		"Hammerman et al., 2011, Cancer Discov"		4	accepted	269	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/269	https://civicdb.org/links/molecular_profiles/143	FALSE	DDR2	4921	I638F		chr1	162775707	162775707	A	T	ENST00000367922.3	75		missense_variant	"ENST00000367922.3:c.1912A>T,NC_000001.10:g.162745497A>T"	2023-01-27 17:02:55 UTC	CA16602600	376143	ILE638PHE	FALSE
DDR2 L239R	140	Lung Non-small Cell Carcinoma	3908		Dasatinib		Predictive	Supports	D	Sensitivity/Response	In 3T3 fibroblasts expressing the L239R mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib.	22328973	PubMed		"Hammerman et al., 2011, Cancer Discov"		4	accepted	270	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/270	https://civicdb.org/links/molecular_profiles/140	FALSE	DDR2	4921	L239R		chr1	162759840	162759840	T	G	ENST00000367922.3	75		missense_variant	"ENST00000367922.3:c.716T>G,NC_000001.10:g.162729630T>G"	2023-01-27 17:02:52 UTC	CA16602598	376141	LEU239ARG	FALSE
DDR2 L63V	139	Lung Non-small Cell Carcinoma	3908		Dasatinib		Predictive	Supports	D	Sensitivity/Response	In 3T3 fibroblasts expressing the L63V mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib.	22328973	PubMed		"Hammerman et al., 2011, Cancer Discov"		4	accepted	271	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/271	https://civicdb.org/links/molecular_profiles/139	FALSE	DDR2	4921	L63V		chr1	162754625	162754625	C	G	ENST00000367922.3	75		missense_variant	"NM_006182.2:c.187C>G,NP_006173.2:p.Leu63Val,ENST00000367922.3:c.187C>G,NC_000001.10:g.162724415C>G"	2023-01-27 17:02:52 UTC	CA1217196		LEU63VAL	FALSE
DDR2 S768R	145	Lung Non-small Cell Carcinoma	3908		"Erlotinib,Dasatinib"	Combination	Predictive	Supports	C	Sensitivity/Response	"In a patient expressing a DDR2 S768R mutation, treatment with dasatinib plus erlotinib acheived a partial response."	22328973	PubMed		"Hammerman et al., 2011, Cancer Discov"		3	accepted	272	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/272	https://civicdb.org/links/molecular_profiles/145	FALSE	DDR2	4921	S768R		chr1	162778600	162778600	T	A	ENST00000367922.3	75		missense_variant	"ENST00000367922.3:c.2304T>A,NC_000001.10:g.162748390T>A"	2023-01-27 17:02:56 UTC	CA16602365	375878	SER768ARG	FALSE
EGFR Exon 19 Deletion	133	Lung Non-small Cell Carcinoma	3908		Gefitinib		Predictive	Supports	D	Sensitivity/Response	Exon 19 deletion has been shown to be correlated with gefitinib response.	16730237	PubMed		"Ji et al., 2006, Cancer Cell"		4	accepted	273	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/273	https://civicdb.org/links/molecular_profiles/133	FALSE	EGFR	1956	Exon 19 Deletion		chr7	55174722	55174820			ENST00000275493.2	75		inframe_deletion	ENST00000275493.2:c.2185_2283del	2023-01-09 21:52:05 UTC		N/A		FALSE
EGFR G719S	134	Lung Non-small Cell Carcinoma	3908		Gefitinib		Predictive	Supports	D	Sensitivity/Response	Gefinitib has been shown to be effective in treating cell lines with G719S missense mutations.	15118125	PubMed		"Paez et al., 2004, Science"		4	accepted	274	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/274	https://civicdb.org/links/molecular_profiles/134	FALSE	EGFR	1956	G719S		chr7	55174014	55174014	G	A	ENST00000275493.2	75		missense_variant	"ENST00000275493.2:c.2155G>A,NC_000007.13:g.55241707G>A,NM_005228.4:c.2155G>A,NP_005219.2:p.Gly719Ser"	2023-01-27 17:02:49 UTC	CA126722	16612	"GLY719SER,RS28929495"	FALSE
EGFR L858R	33	Lung Non-small Cell Carcinoma	3908		"Erlotinib,Gefitinib"	Substitutes	Predictive	Supports	B	Sensitivity/Response	"In NSCLC patients treated with EGFR tyrosine kinase inhibitors, the presence of L858R mutation is prognostic for better progression free survival."	24457318	PubMed		"Fukihara et al., 2014, Oncology"		4	accepted	275	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/275	https://civicdb.org/links/molecular_profiles/33	FALSE	EGFR	1956	L858R		chr7	55191822	55191822	T	G	ENST00000275493.2	75		missense_variant	"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg"	2023-01-27 17:02:04 UTC	CA126713	"16,609,376,282,376,200"	"LEU858ARG,RS121434568"	FALSE
EGFR L858R	33	Lung Non-small Cell Carcinoma	3908		Gefitinib		Predictive	Supports	D	Sensitivity/Response	Gefinitib has been shown to be effective in treating cell lines with L858R missense mutations.	15118125	PubMed		"Paez et al., 2004, Science"		4	accepted	276	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/276	https://civicdb.org/links/molecular_profiles/33	FALSE	EGFR	1956	L858R		chr7	55191822	55191822	T	G	ENST00000275493.2	75		missense_variant	"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg"	2023-01-27 17:02:04 UTC	CA126713	"16,609,376,282,376,200"	"LEU858ARG,RS121434568"	FALSE
EGFR T790M	34	Lung Non-small Cell Carcinoma	3908		"Pemetrexed,Erlotinib"	Combination	Predictive	Supports	C	Sensitivity/Response	"In an NSCLC patient initially with L858R mutation, pemetrexed and cisplatin combination treatment was followed by erlotinib treatment. A slow progression developed which was found to be positive for L858R as well as T790M mutation which confers resistance to tyrosine kinase inhibitors. Due to slow tumor growth erlotinib was continued despite T790M, with re-addition of premetrexed, and this reduced tumor size and resulted in stable disease."	24636847	PubMed		"Li et al., 2014, Lung Cancer"		3	accepted	277	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/277	https://civicdb.org/links/molecular_profiles/34	FALSE	EGFR	1956	T790M	EGFR TKI Resistance	chr7	55181378	55181378	C	T	ENST00000275493.2	75		missense_variant	"ENST00000275493.2:c.2369C>T,NM_005228.4:c.2369C>T,NP_005219.2:p.Thr790Met,NC_000007.13:g.55249071C>T"	2023-01-27 17:02:05 UTC	CA090928	16613	"THR790MET,RS121434569"	FALSE
EGFR T790M	34	Lung Non-small Cell Carcinoma	3908		Staurosporine		Predictive	Supports	E	Sensitivity/Response	"In NSCLC containing a T790M mutation, staurosporine may be inhibitive of EGFR, especially when an L858R mutation is also present."	24658966	PubMed		"Ai et al., 2014, Amino Acids"		1	accepted	278	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/278	https://civicdb.org/links/molecular_profiles/34	FALSE	EGFR	1956	T790M	EGFR TKI Resistance	chr7	55181378	55181378	C	T	ENST00000275493.2	75		missense_variant	"ENST00000275493.2:c.2369C>T,NM_005228.4:c.2369C>T,NP_005219.2:p.Thr790Met,NC_000007.13:g.55249071C>T"	2023-01-27 17:02:05 UTC	CA090928	16613	"THR790MET,RS121434569"	FALSE
ERBB2 D769H	35	Breast Cancer	1612		"Neratinib,Lapatinib"	Substitutes	Predictive	Supports	D	Sensitivity/Response	"In MCF10A cell lines, the D769H mutation was shown to be sensitive to neratinib."	23220880	PubMed		"Bose et al., 2013, Cancer Discov"		4	accepted	279	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/279	https://civicdb.org/links/molecular_profiles/35	FALSE	ERBB2	2064	D769H	HER2 Activating	chr17	39724008	39724008	G	C	ENST00000269571.5	75		missense_variant	"NM_001289937.1:c.2305G>C,NP_001276866.1:p.Asp769His,ENST00000269571.5:c.2305G>C,NC_000017.10:g.37880261G>C"	2023-01-27 17:02:06 UTC	CA16602465	375991	"ASP769HIS,D739H,D754H,ASP739HIS,ASP754HIS,D769H,RS121913468"	FALSE
ERBB2 D769Y	36	Breast Cancer	1612		Neratinib		Predictive	Supports	D	Sensitivity/Response	"In MCF10A cell lines, the D769Y mutation was shown to be sensitive to neratinib."	23220880	PubMed		"Bose et al., 2013, Cancer Discov"		4	accepted	280	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/280	https://civicdb.org/links/molecular_profiles/36	FALSE	ERBB2	2064	D769Y	HER2 Activating	chr17	39724008	39724008	G	T	ENST00000269571.5	75		missense_variant	"ENST00000269571.5:c.2305G>T,NC_000017.10:g.37880261G>T,NM_004448.3:c.2305G>T,NP_004439.2:p.Asp769Tyr"	2023-01-27 17:02:06 UTC	CA16602466	375992	"D739Y,D754Y,RS121913468,ASP769TYR,D769Y,ASP754TYR,ASP739TYR"	FALSE
ERBB2 L755_T759del	37	Breast Cancer	1612		Neratinib		Predictive	Supports	D	Sensitivity/Response	"In MCF10A cell lines retrovirally transduced with wildtype or mutant ERBB2, cells expressing the in-frame deletion of amino acids 755-759 were shown to be sensitive to neratinib."	23220880	PubMed		"Bose et al., 2013, Cancer Discov"		5	accepted	281	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/281	https://civicdb.org/links/molecular_profiles/37	FALSE	ERBB2	2064	L755_T759del		chr17	39723966	39723980	TTGAGGGAAAACACA		ENST00000269571.5	75		inframe_deletion	"ENST00000269571.5:c.2263_2277del,NC_000017.10:g.37880219_37880233del,NP_004439.2:p.Leu755_Thr759del,NM_004448.3:c.2263_2277delTTGAGGGAAAACACA"	2023-01-27 17:02:07 UTC	CA645372623	375990	"RS1131692241,LEU755_THR759DEL"	FALSE
ERBB2 G309A	38	Breast Cancer	1612		Neratinib		Predictive	Supports	D	Sensitivity/Response	"In MCF10A cell lines, the G309A mutation was shown to be sensitive to neratinib."	23220880	PubMed		"Bose et al., 2013, Cancer Discov"		5	accepted	282	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/282	https://civicdb.org/links/molecular_profiles/38	FALSE	ERBB2	2064	G309A	HER2 Activating	chr17	39711952	39711952	G	C	ENST00000269571.5	75		missense_variant	"ENST00000269571.5:c.926G>C,NC_000017.10:g.37868205G>C,NM_004448.3:c.926G>C,NP_004439.2:p.Gly309Ala"	2023-01-27 17:02:08 UTC	CA16602660	376205	"GLY309ALA,GLY279ALA,GLY294ALA,G294A,G279A,RS1057519787"	FALSE
ERBB2 L755S	39	Breast Cancer	1612		Neratinib		Predictive	Supports	D	Sensitivity/Response	The L755S mutation showed mild response to neratinib in MCF10A cell lines retrovirally transduced with wildtype or mutant ERBB2.	23220880	PubMed		"Bose et al., 2013, Cancer Discov"		5	accepted	283	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/283	https://civicdb.org/links/molecular_profiles/39	FALSE	ERBB2	2064	L755S		chr17	39723967	39723967	T	C	ENST00000269571.5	75		missense_variant	"ENST00000269571.5:c.2264T>C,NC_000017.10:g.37880220T>C,NM_004448.3:c.2264T>C,NP_004439.2:p.Leu755Ser"	2023-01-27 17:02:09 UTC	CA16602502	376035	"LEU755SER,L725S,L740S"	FALSE
ERBB2 L755W	40	Breast Cancer	1612		Neratinib		Predictive	Supports	D	Sensitivity/Response	MCF10A cells transduced with ERBB2 harboring an L755W mutation were sensitive to the irreversible kinase inhibitor neratinib in an matrigel colony forming assay.	23220880	PubMed		"Bose et al., 2013, Cancer Discov"		5	accepted	284	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/284	https://civicdb.org/links/molecular_profiles/40	TRUE	ERBB2	2064	L755W		chr17	39723967	39723967	T	G	ENST00000269571.5	75		missense_variant	"ENST00000269571.5:c.2264T>G,NC_000017.10:g.37880220T>G,NM_004448.3:c.2264T>G,NP_004439.2:p.Leu755Trp"	2023-01-27 17:02:10 UTC	CA16602786	376343	"LEU755TRP,L725W,L740W,RS121913470"	FALSE
ERBB2 P780INS	41	Breast Cancer	1612		Neratinib		Predictive	Supports	D	Sensitivity/Response	"In MCF10A cell lines, the in-frame insertion of a single amino acid at position 780 was shown to be sensitive to neratinib."	23220880	PubMed		"Bose et al., 2013, Cancer Discov"		5	accepted	285	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/285	https://civicdb.org/links/molecular_profiles/41	FALSE	ERBB2	2064	P780INS	HER2 Activating	chr17	39724758	39724759		GGCTCCCCA	ENST00000269571.5	75		inframe_insertion	"ENST00000269571.5:c.2340_2341insGGCTCCCCA,NC_000017.10:g.37881011_37881012insGGCTCCCCA"	2023-01-27 17:02:11 UTC	CA135401	NONE FOUND	PRO780INS	TRUE
ERBB2 R678Q	42	Breast Cancer	1612		"Lapatinib,Neratinib"	Substitutes	Predictive	Supports	D	Sensitivity/Response	MCF10A cells transduced with ERBB2 harboring an R678Q mutation were sensitive to lapatinib and the irreversible kinase inhibitor neratinib in an matrigel colony forming assay.	23220880	PubMed		"Bose et al., 2013, Cancer Discov"		5	accepted	286	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/286	https://civicdb.org/links/molecular_profiles/42	FALSE	ERBB2	2064	R678Q		chr17	39723405	39723405	G	A	ENST00000269571.5	75		missense_variant	"ENST00000269571.5:c.2033G>A,NC_000017.10:g.37879658G>A,NM_004448.3:c.2033G>A,NP_004439.2:p.Arg678Gln"	2023-01-27 17:02:11 UTC	CA16602787	376344	"ARG678GLN,R648Q,R663Q,RS1057519862"	FALSE
ERBB2 R896C	43	Breast Cancer	1612		Neratinib		Predictive	Supports	D	Sensitivity/Response	"In MCF10A cell lines, the R896C mutation was shown to be sensitive to neratinib."	23220880	PubMed		"Bose et al., 2013, Cancer Discov"		5	accepted	287	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/287	https://civicdb.org/links/molecular_profiles/43	FALSE	ERBB2	2064	R896C	HER2 Activating	chr17	39725363	39725363	C	T	ENST00000269571.5	75		missense_variant	"ENST00000269571.5:c.2686C>T,NC_000017.10:g.37881616C>T,NM_004448.3:c.2686C>T,NP_004439.2:p.Arg896Cys"	2023-01-27 17:02:12 UTC	CA8534359	375995	"ARG896CYS,R866C,R881C,RS758222990"	FALSE
ERBB2 V777L	44	Breast Cancer	1612		Neratinib		Predictive	Supports	D	Sensitivity/Response	"In MCF10A cell lines, the V777L mutation was shown to be sensitive to neratinib."	23220880	PubMed		"Bose et al., 2013, Cancer Discov"		5	accepted	288	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/288	https://civicdb.org/links/molecular_profiles/44	FALSE	ERBB2	2064	V777L	HER2 Activating	chr17	39724747	39724747	G	T	ENST00000269571.5	75		missense_variant	"NM_004448.3:c.2329G>T,NP_004439.2:p.Val777Leu,ENST00000269571.5:c.2329G>T,NC_000017.10:g.37881000G>T"	2023-01-27 17:02:13 UTC	CA135387	44991	"V747L,V762L,VAL777LEU,RS121913471"	FALSE
ERBB2 V842I	45	Breast Cancer	1612		Neratinib		Predictive	Supports	D	Sensitivity/Response	"In MCF10A cell lines, the V842I mutation was shown to be sensitive to neratinib."	23220880	PubMed		"Bose et al., 2013, Cancer Discov"		5	accepted	289	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/289	https://civicdb.org/links/molecular_profiles/45	FALSE	ERBB2	2064	V842I	HER2 Activating	chr17	39725079	39725079	G	A	ENST00000269571.5	75		missense_variant	"ENST00000269571.5:c.2524G>A,NM_004448.3:c.2524G>A,NP_004439.2:p.Val842Ile,NC_000017.10:g.37881332G>A"	2023-01-27 17:02:14 UTC	CA16602468	375994	"VAL842ILE,V812I,V827I,VAL812ILE,VAL827ILE,RS1057519738"	FALSE
ESR1 L536Q	46	Breast Cancer	1612		"Tamoxifen,Fulvestrant"	Substitutes	Predictive	Supports	D	Sensitivity/Response	"Using an estrogen response element (ERE)-luciferase reporter system co-transfected with one of five ESR1 mutants, the L536Q ligand binding domain mutation was shown to result in constitutive activity (response in the absence of beta-estradiol ligand) and continued responsiveness (inhibition of downstream target activation) to anti-estrogen therapies (tamoxifen or fulvestrant) in HEK293T cell lines."	24185510	PubMed		"Robinson et al., 2013, Nat. Genet."		5	accepted	290	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/290	https://civicdb.org/links/molecular_profiles/46	FALSE	ESR1	2099	L536Q	ESR1 Ligand-Binding Domain	chr6	152098785	152098786	TC	AG	ENST00000440973.1	75		missense_variant	"NC_000006.11:g.152419920_152419921delinsAG,ENST00000440973.1:c.1607_1608delinsAG"	2023-01-27 17:02:14 UTC	CA645542628	NONE FOUND	LEU536GLN	FALSE
ESR1 D538G	47	Breast Cancer	1612		"Tamoxifen,Fulvestrant"	Substitutes	Predictive	Supports	D	Sensitivity/Response	"Using an estrogen response element (ERE)-luciferase reporter system co-transfected with one of five ESR1 mutants, the N538G ligand binding domain mutation was shown to result in constitutive activity (response in the absence of beta-estradiol ligand) and continued responsiveness (inhibition of downstream target activation) to anti-estrogen therapies (tamoxifen or fulvestrant) in HEK293T cell lines."	24185510	PubMed		"Robinson et al., 2013, Nat. Genet."		5	accepted	291	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/291	https://civicdb.org/links/molecular_profiles/47	FALSE	ESR1	2099	D538G	ESR1 Ligand-Binding Domain	chr6	152098791	152098791	A	G	ENST00000206249.3	75		missense_variant	"ENST00000206249.3:c.1613A>G,NC_000006.11:g.152419926A>G,NM_000125.3:c.1613A>G,NP_000116.2:p.Asp538Gly"	2023-01-27 17:02:15 UTC	CA366085705	NONE FOUND	ASP538GLY	FALSE
ESR1 Y537C	48	Breast Cancer	1612		"Fulvestrant,Tamoxifen"	Substitutes	Predictive	Supports	D	Sensitivity/Response	"Using an estrogen response element (ERE)-luciferase reporter system co-transfected with one of five ESR1 mutants, the Y537C ligand binding domain mutation was shown to result in constitutive activity (response in the absence of beta-estradiol ligand) and continued responsiveness (inhibition of downstream target activation) to anti-estrogen therapies (tamoxifen or fulvestrant) in HEK293T cell lines."	24185510	PubMed		"Robinson et al., 2013, Nat. Genet."		5	accepted	292	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/292	https://civicdb.org/links/molecular_profiles/48	FALSE	ESR1	2099	Y537C	ESR1 Ligand-Binding Domain	chr6	152098788	152098788	A	G	ENST00000206249.3	75		missense_variant	"ENST00000206249.3:c.1610A>G,NC_000006.11:g.152419923A>G,NM_000125.3:c.1610A>G,NP_000116.2:p.Tyr537Cys"	2023-01-27 17:02:16 UTC	CA366085697	NONE FOUND	GLY537CYS	FALSE
ESR1 Y537N	49	Breast Cancer	1612		"Tamoxifen,Fulvestrant"	Substitutes	Predictive	Supports	D	Sensitivity/Response	"Using an estrogen response element (ERE)-luciferase reporter system co-transfected with one of five ESR1 mutants, the Y537N ligand binding domain mutation was shown to result in constitutive activity (response in the absence of beta-estradiol ligand) and continued responsiveness (inhibition of downstream target activation) to anti-estrogen therapies (tamoxifen or fulvestrant) in HEK293T cell lines."	24185510	PubMed		"Robinson et al., 2013, Nat. Genet."		5	accepted	293	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/293	https://civicdb.org/links/molecular_profiles/49	FALSE	ESR1	2099	Y537N	ESR1 Ligand-Binding Domain	chr6	152098787	152098787	T	A	ENST00000206249.3	75		missense_variant	"ENST00000206249.3:c.1609T>A,NC_000006.11:g.152419922T>A,NM_000125.3:c.1609T>A,NP_000116.2:p.Tyr537Asn"	2023-01-27 17:02:17 UTC	CA366085693	NONE FOUND	GLY537ASN	FALSE
ESR1 Y537S	50	Breast Cancer	1612		"Tamoxifen,Fulvestrant"	Substitutes	Predictive	Supports	D	Sensitivity/Response	"Using an estrogen response element (ERE)-luciferase reporter system co-transfected with one of five ESR1 mutants, the Y537S ligand binding domain mutation was shown to result in constitutive activity (response in the absence of beta-estradiol ligand) and continued responsiveness (inhibition of downstream target activation) to anti-estrogen therapies (tamoxifen or fulvestrant) in HEK293T cell lines."	24185510	PubMed		"Robinson et al., 2013, Nat. Genet."		5	accepted	294	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/294	https://civicdb.org/links/molecular_profiles/50	FALSE	ESR1	2099	Y537S	ESR1 Ligand-Binding Domain	chr6	152098788	152098788	A	C	ENST00000206249.3	75		missense_variant	"ENST00000206249.3:c.1610A>C,NC_000006.11:g.152419923A>C,NM_000125.3:c.1610A>C,NP_000116.2:p.Tyr537Ser"	2023-01-27 17:02:18 UTC	CA366085696	NONE FOUND	GLY537SER	FALSE
FGFR2 FGFR2::MGEA5	52	Cholangiocarcinoma	4947		Ponatinib		Predictive	Supports	C	Sensitivity/Response	"In a single patient with this fusion in intrahepatic cholangiocarcinoma. Ponatinib treatment resulted in necrosis and shrinkage of the primary and metastatic sites and overall stable disease. However, this response did not meet criteria for RECIST partial response."	24550739	PubMed		"Borad et al., 2014, PLoS Genet."		2	accepted	295	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/295	https://civicdb.org/links/molecular_profiles/52	FALSE	FGFR2	2263	FGFR2::MGEA5	FGFR fusions	chr10	121483698	121598403			ENST00000457416.2	75	ENST00000361464.3	transcript_fusion		2023-01-09 21:52:04 UTC		N/A	FGFR2-MGEA5	FALSE
FGFR2 FGFR2::MGEA5	52	Cholangiocarcinoma	4947		Ponatinib		Predictive	Supports	C	Sensitivity/Response	"In a single patient with this fusion in intrahepatic cholangiocarcinoma. Ponatinib treatment resulted in necrosis and shrinkage of the primary and metastatic sites and overall stable disease. However, this response did not meet criteria for RECIST partial response."	24550739	PubMed		"Borad et al., 2014, PLoS Genet."		2	accepted	295	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/295	https://civicdb.org/links/molecular_profiles/52	FALSE	FGFR2	2263	FGFR2::MGEA5	FGFR fusions	chr10	101784452	101792943			ENST00000457416.2	75	ENST00000361464.3	transcript_fusion		2023-01-09 21:52:04 UTC		N/A	FGFR2-MGEA5	FALSE
FGFR2 FGFR2::TACC3	54	Cholangiocarcinoma	4947		"Pazopanib,Ponatinib"	Sequential	Predictive	Supports	C	Sensitivity/Response	In a 43 year old female patient with this fusion in intrahepatic cholangiocarcinoma. Both pazopanib and ponatinib separately resulted in minor tumor shrinkage. This fusion is also shown to be recurrent in multiple other cancer types.	24550739	PubMed		"Borad et al., 2014, PLoS Genet."		3	accepted	296	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/296	https://civicdb.org/links/molecular_profiles/54	FALSE	FGFR2	2263	FGFR2::TACC3	FGFR fusions	chr4	122322057	122436443			ENST00000358487.5	75	ENST00000313288.4	transcript_fusion		2023-01-09 21:52:04 UTC		N/A	FGFR2-TACC3	FALSE
FGFR2 FGFR2::TACC3	54	Cholangiocarcinoma	4947		"Pazopanib,Ponatinib"	Sequential	Predictive	Supports	C	Sensitivity/Response	In a 43 year old female patient with this fusion in intrahepatic cholangiocarcinoma. Both pazopanib and ponatinib separately resulted in minor tumor shrinkage. This fusion is also shown to be recurrent in multiple other cancer types.	24550739	PubMed		"Borad et al., 2014, PLoS Genet."		3	accepted	296	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/296	https://civicdb.org/links/molecular_profiles/54	FALSE	FGFR2	2263	FGFR2::TACC3	FGFR fusions	chr4	1721539	1739778			ENST00000358487.5	75	ENST00000313288.4	transcript_fusion		2023-01-09 21:52:04 UTC		N/A	FGFR2-TACC3	FALSE
FLT3 ITD	55	Acute Myeloid Leukemia	9119		Lestaurtinib		Predictive	Supports	B	Sensitivity/Response	CEP701 was effective in reducing blast counts of 5/14 heavily pre-treated AML patients with FLT3 mutations.	14726387	PubMed		"Smith et al., 2004, Blood"		4	accepted	297	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/297	https://civicdb.org/links/molecular_profiles/55	FALSE	FLT3	2322	ITD		chr13	28034082	28034214			ENST00000241453.7	75		inframe_insertion		2023-01-09 21:52:04 UTC		16270		FALSE
FLT3 ITD	55	Acute Myeloid Leukemia	9119		Sorafenib		Predictive	Supports	B	Sensitivity/Response	"Sorafenib is effective in patients with FLT3 internal tandem repeats, but not in wild type or D835 mutation."	18230792	PubMed		"Zhang et al., 2008, J. Natl. Cancer Inst."		4	accepted	298	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/298	https://civicdb.org/links/molecular_profiles/55	FALSE	FLT3	2322	ITD		chr13	28034082	28034214			ENST00000241453.7	75		inframe_insertion		2023-01-09 21:52:04 UTC		16270		FALSE
FLT3 ITD	55	Acute Myeloid Leukemia	9119		Tyrphostin AG 1296		Predictive	Supports	D	Sensitivity/Response	AG1296 is effective in triggering apoptosis in Ba/F3 and primary AML cells with FLT3 internal tandem repeat.	12357354	PubMed		"Tse et al., 2002, Leukemia"		4	accepted	299	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/299	https://civicdb.org/links/molecular_profiles/55	FALSE	FLT3	2322	ITD		chr13	28034082	28034214			ENST00000241453.7	75		inframe_insertion		2023-01-09 21:52:04 UTC		16270		FALSE
GATA2 EXPRESSION	57	Lung Adenocarcinoma	3910		"Bortezomib,Fasudil"	Combination	Predictive	Supports	D	Sensitivity/Response	Targeting overactive GATA2-mediated pathways with inhibitors bortezomib and fasudil led to dramatic tumor regression.	22541434	PubMed		"Kumar et al., 2012, Cell"		4	accepted	301	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/301	https://civicdb.org/links/molecular_profiles/57	FALSE	GATA2	2624	EXPRESSION		chr3	128479427	128493185			ENST00000341105.2	75		N/A		2023-01-09 21:52:04 UTC		N/A		FALSE
KIT Internal Duplication	67	Malignant Anus Melanoma	14145		Imatinib		Predictive	Supports	C	Sensitivity/Response	"In a case study, a patient with anal melanoma harboring a 7 codon duplication in the juxtamambrane region (exon 11) of KIT showed marked response 4 months after imatinib treatment."	18421059	PubMed		"Hodi et al., 2008, J. Clin. Oncol."		3	accepted	302	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/302	https://civicdb.org/links/molecular_profiles/67	FALSE	KIT	3815	Internal Duplication	KIT Exon 11	chr4	54727416	54727542			ENST00000288135.5	75		inframe_insertion		2023-01-09 21:52:04 UTC		N/A		FALSE
KIT L576P	72	Lung Non-small Cell Carcinoma	3908		"Dasatinib,Imatinib,Nilotinib"	Substitutes	Predictive	Supports	D	Sensitivity/Response	"Ba/F3 cells harboring the KIT L576P mutation are sensitive to nilotinib, imatinib and lower concentrations of dasatinib."	17372901	PubMed		"Antonescu et al., 2007, Int. J. Cancer"		3	accepted	303	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/303	https://civicdb.org/links/molecular_profiles/72	FALSE	KIT	3815	L576P	KIT Exon 11	chr4	54727495	54727495	T	C	ENST00000288135.5	75		missense_variant	"NM_000222.2:c.1727T>C,NP_000213.1:p.Leu576Pro,ENST00000288135.5:c.1727T>C,NC_000004.11:g.55593661T>C"	2023-01-27 17:02:24 UTC	CA16602401	375919	"RS121913513,LEU576PRO"	FALSE
KIT V654A	73	Gastrointestinal Stromal Tumor	9253		Sunitinib		Predictive	Supports	B	Sensitivity/Response	"In GIST tumor cells and patients harboring KIT V654A mutation, SU11248 is effective for those that are refractory to imatinib."	16638875	PubMed		"Prenen et al., 2006, Clin. Cancer Res."		3	accepted	304	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/304	https://civicdb.org/links/molecular_profiles/73	FALSE	KIT	3815	V654A		chr4	54728092	54728092	T	C	ENST00000288135.5	75		missense_variant	"NM_000222.2:c.1961T>C,NP_000213.1:p.Val654Ala,ENST00000288135.5:c.1961T>C,NC_000004.11:g.55594258T>C"	2023-01-27 17:02:25 UTC	CA16602402	375921	"RS121913523,VAL654ALA"	FALSE
KRAS G12D	79	Lung Non-small Cell Carcinoma	3908		"Dactolisib,Selumetinib"	Combination	Predictive	Supports	D	Sensitivity/Response	"The use of NVP-BEZ235 in conjunction with ARRY-142886, but not as monotherapy, in a lung cancer model with KRAS G12D mutation led to marked tumor regression."	19029981	PubMed		"Engelman et al., 2008, Nat. Med."		4	accepted	305	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/305	https://civicdb.org/links/molecular_profiles/79	FALSE	KRAS	3845	G12D	EGFR TKI Resistance	chr12	25245350	25245350	C	T	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.35G>A,NP_004976.2:p.Gly12Asp,NC_000012.11:g.25398284C>T,ENST00000256078.4:c.35G>A"	2023-01-27 17:02:26 UTC	CA122538	12582	"GLY12ASP,RS121913529"	FALSE
KRAS G13D	81	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	B	Sensitivity/Response	KRAS G13D mutation is associated with better response to Cetuximab with longer progression-free and overall survival in colorectal patients compared to other KRAS.	20978259	PubMed		"De Roock et al., 2010, JAMA"		4	accepted	306	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/306	https://civicdb.org/links/molecular_profiles/81	FALSE	KRAS	3845	G13D		chr12	25245347	25245347	C	T	ENST00000256078.4	75		missense_variant	"NM_033360.3:c.38G>A,NP_004976.2:p.Gly13Asp,NC_000012.11:g.25398281C>T,ENST00000256078.4:c.38G>A"	2023-01-27 17:02:27 UTC	CA122534	12580	"GLY13ASP,RS112445441"	FALSE
MGMT Promoter Methylation	85	Glioblastoma	3068		Temozolomide		Predictive	Supports	A	Sensitivity/Response	"In a randomized clinical trial, patients with MGMT promoter methylation benefitted from temozolomide. This benefit was also methylation status dependent, as those without methylation did not see increased survival."	15758010	PubMed		"Hegi et al., 2005, N. Engl. J. Med."		5	accepted	307	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/307	https://civicdb.org/links/molecular_profiles/85	FALSE	MGMT	4255	Promoter Methylation		chr10	129466231	129467392			ENST00000306010.7	75		N/A		2023-01-09 21:52:04 UTC		N/A		FALSE
MGMT Promoter Methylation	85	Glioblastoma	3068		Carmustine		Predictive	Supports	B	Sensitivity/Response	"MGMT promoter methylation has been shown to confer sensitivity to alkylating agents, such as carmustine, in glioblastoma cells."	11070098	PubMed		"Esteller et al., 2000, N. Engl. J. Med."		4	accepted	308	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/308	https://civicdb.org/links/molecular_profiles/85	FALSE	MGMT	4255	Promoter Methylation		chr10	129466231	129467392			ENST00000306010.7	75		N/A		2023-01-09 21:52:04 UTC		N/A		FALSE
MGMT Promoter Methylation	85	Glioblastoma	3068		O6-Benzylguanine		Predictive	Supports	E	Sensitivity/Response	"In patients lacking MGMT promoter methylation, the use of an MGMT inhibitor, such as O(6)-benzylguanine, in combination with alkylating agents (Carmustine) may be useful in treating patients with initial resistance to alkylating agents."	11070098	PubMed		"Esteller et al., 2000, N. Engl. J. Med."		4	accepted	309	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/309	https://civicdb.org/links/molecular_profiles/85	FALSE	MGMT	4255	Promoter Methylation		chr10	129466231	129467392			ENST00000306010.7	75		N/A		2023-01-09 21:52:04 UTC		N/A		FALSE
PIK3CA E542K	103	Breast Cancer	1612		PI3K-alpha Inhibitor MEN1611		Predictive	Supports	D	Sensitivity/Response	Breast cancer cell lines with E542K/E545K mutations showed increased sensitivity to CH5132799 than cells with wild-type PIK3CA gene.	21558396	PubMed		"Tanaka et al., 2011, Clin. Cancer Res."		4	accepted	310	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/310	https://civicdb.org/links/molecular_profiles/103	FALSE	PIK3CA	5290	E542K		chr3	179218294	179218294	G	A	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.1624G>A,NP_006209.2:p.Glu542Lys,ENST00000263967.3:c.1624G>A,NC_000003.11:g.178936082G>A"	2023-01-27 17:02:37 UTC	CA333572	31944	"GLU542LYS,RS121913273"	FALSE
PIK3CA E542K	103	Breast Cancer	1612		Sirolimus		Predictive	Supports	D	Sensitivity/Response	Rapamycin inhibits transformation induced by mutation in PIK3CA.	15647370	PubMed		"Kang et al., 2005, Proc. Natl. Acad. Sci. U.S.A."		3	accepted	311	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/311	https://civicdb.org/links/molecular_profiles/103	FALSE	PIK3CA	5290	E542K		chr3	179218294	179218294	G	A	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.1624G>A,NP_006209.2:p.Glu542Lys,ENST00000263967.3:c.1624G>A,NC_000003.11:g.178936082G>A"	2023-01-27 17:02:37 UTC	CA333572	31944	"GLU542LYS,RS121913273"	FALSE
PIK3CA H1047R	107	Breast Cancer	1612		PI3K-alpha Inhibitor MEN1611		Predictive	Supports	D	Sensitivity/Response	Breast cancer cell lines with H1047R mutation showed increased sensitivity to CH5132799 than cells with wild-type PIK3CA gene.	21558396	PubMed		"Tanaka et al., 2011, Clin. Cancer Res."		4	accepted	314	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/314	https://civicdb.org/links/molecular_profiles/107	FALSE	PIK3CA	5290	H1047R		chr3	179234297	179234297	A	G	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.3140A>G,NP_006209.2:p.His1047Arg,ENST00000263967.3:c.3140A>G,NC_000003.11:g.178952085A>G"	2023-01-27 17:02:38 UTC	CA123326	13652	"HIS1047ARG,RS121913279"	FALSE
PML PML::RARA	108	Acute Promyelocytic Leukemia	60318		Tretinoin		Predictive	Supports	B	Sensitivity/Response	Fusion protein degradation is accelerated upon ATRA treatment of acute promyelocytic cells at pharmalogical concentrations.	8674046	PubMed		"Yoshida et al., 1996, Cancer Res."		5	accepted	316	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/316	https://civicdb.org/links/molecular_profiles/108	FALSE	PML	5371	PML::RARA		chr15	73994717	74033414			ENST00000268058.3	75	ENST00000254066.5	transcript_fusion	N/A	2023-01-09 21:52:05 UTC		N/A	PML-RARA	FALSE
PML PML::RARA	108	Acute Promyelocytic Leukemia	60318		Tretinoin		Predictive	Supports	B	Sensitivity/Response	Fusion protein degradation is accelerated upon ATRA treatment of acute promyelocytic cells at pharmalogical concentrations.	8674046	PubMed		"Yoshida et al., 1996, Cancer Res."		5	accepted	316	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/316	https://civicdb.org/links/molecular_profiles/108	FALSE	PML	5371	PML::RARA		chr17	40348316	40356796			ENST00000268058.3	75	ENST00000254066.5	transcript_fusion	N/A	2023-01-09 21:52:05 UTC		N/A	PML-RARA	FALSE
PTEN R233*	110	Breast Cancer	1612		MTOR Inhibitor		Predictive	Supports	D	Sensitivity/Response	Cells with PTEN deficiency have been shown to exhibit slowed growth in reponse to PI3K-mTOR inhibitors.	20085938	PubMed		"Courtney et al., 2010, J. Clin. Oncol."		4	accepted	317	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/317	https://civicdb.org/links/molecular_profiles/110	FALSE	PTEN	5728	R233*	PTEN Loss-of-Function	chr10	87957915	87957915	C	T	ENST00000371953.3	75		"stop_gained,loss_of_function_variant"	"NM_000314.6:c.697C>T,NP_000305.3:p.Arg233Ter,ENST00000371953.3:c.697C>T,NC_000010.10:g.89717672C>T"	2023-01-27 17:02:39 UTC	CA000549	7813	"R233X,ARG233TER,RS121909219"	FALSE
TP53 R175H	116	Breast Cancer	1612		Doxorubicin		Predictive	Supports	D	Sensitivity/Response	Breast tumors in a mouse model with R172H mutation (homologous to human R175H) are more responsive to doxorubicin than breast tumors with wild type TP53.	22698404	PubMed		"Jackson et al., 2012, Cancer Cell"		3	accepted	319	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/319	https://civicdb.org/links/molecular_profiles/116	FALSE	TP53	7157	R175H		chr17	7675088	7675088	C	T	ENST00000269305.4	75		missense_variant	"NM_000546.5:c.524G>A,NP_000537.3:p.Arg175His,NC_000017.10:g.7578406C>T,ENST00000269305.4:c.524G>A"	2023-01-27 17:02:43 UTC	CA000251	12374	"ARG175HIS,RS28934578,R43H,R136H"	FALSE
TSC1 Frameshift Truncation	124	Invasive Bladder Transitional Cell Carcinoma	6477		Everolimus		Predictive	Supports	B	Sensitivity/Response	"A patient with metastatic bladder cancer that responded well to the mTOR inhibitor everolimus was shown to harbor a TSC1 frameshift truncation mutation (c.1907_1908del, p.Glu636fs) and a nonsense NF2 mutation. 2/3 additional patients with TSC1 mutations also had mild responses to everolimus."	22923433	PubMed		"Iyer et al., 2012, Science"	NCT00805129	3	accepted	320	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/320	https://civicdb.org/links/molecular_profiles/124	FALSE	TSC1	7248	Frameshift Truncation	TSC Loss	chr9	132891348	132944621			ENST00000298552.3	75		frameshift_truncation		2023-01-09 21:52:05 UTC				FALSE
FLT3 TKD MUTATION	56	Acute Myeloid Leukemia	9119				Prognostic	Does Not Support	B	N/A	AML patients with D835 mutation of FLT3 did not have worse overall survival than patients with wild type FLT3.	11290608	PubMed		"Yamamoto et al., 2001, Blood"		3	accepted	322	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/322	https://civicdb.org/links/molecular_profiles/56	FALSE	FLT3	2322	TKD MUTATION		chr13	28018505	28018505	C	A	ENST00000241453.7	75		nonsynonymous_variant	NC_000013.10:g.28592642C>A	2023-01-27 17:02:18 UTC	CA126347	16276		TRUE
IDH1 R132	58	Acute Myeloid Leukemia	9119				Prognostic	Does Not Support	B	N/A	The complete remission and overall survival rates in patients with IDH1 R132 mutation is not significantly different from those who do not have this mutation.	20368538	PubMed		"Wagner et al., 2010, J. Clin. Oncol."		2	accepted	323	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/323	https://civicdb.org/links/molecular_profiles/58	FALSE	IDH1	3417	R132		chr2	208248387	208248389			ENST00000415913.1	75		protein_altering_variant	"NC_000002.11:g.209113113G>A,NC_000002.11:g.209113112C>T,NC_000002.11:g.209113113G>C,NC_000002.11:g.209113112C>A,NC_000002.11:g.209113113G>T,NC_000002.11:g.209113112C>G"	2023-01-09 21:52:04 UTC		"156,444,375,891,375,000,000,000,000,000,000,000"	ARG132	FALSE
IDH1 R132C	59	Acute Myeloid Leukemia	9119				Prognostic	Does Not Support	B	N/A	IDH1 R132 mutation in patients with AML is not associated with any prognostic value compared to patients with wild-type IDH1.	20538800	PubMed		"Abbas et al., 2010, Blood"		2	accepted	324	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/324	https://civicdb.org/links/molecular_profiles/59	FALSE	IDH1	3417	R132C		chr2	208248389	208248389	G	A	ENST00000415913.1	75		missense_variant	"NM_005896.3:c.394C>T,NP_005887.2:p.Arg132Cys,NC_000002.11:g.209113113G>A,ENST00000415913.1:c.394C>T"	2023-01-27 17:02:19 UTC	CA16602374	375891	"RS121913499,ARG132CYS"	FALSE
IDH2 R140	62	Acute Myeloid Leukemia	9119				Prognostic	Does Not Support	B	N/A	"In this meta-analysis of adult non-promyelocytic AML (11 studies), patients with IDH2 R140 or R172 mutations had event free survival and overall survival similar to those with wild-type IDH2."	22616558	PubMed		"Zhou et al., 2012, Leuk. Lymphoma"		2	accepted	327	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/327	https://civicdb.org/links/molecular_profiles/62	FALSE	IDH2	3418	R140		chr15	90088702	90088702			ENST00000330062.3	75		protein_altering_variant		2023-01-09 21:52:04 UTC		"37,598,814,716,375,900"	ARG140	FALSE
IDH2 Mutation	566	Acute Myeloid Leukemia	9119				Prognostic	Does Not Support	B	N/A	"In patients with IDH2 R140 and R172 mutation, the presence of mutation does not impact overall survival or disease free survival."	20421455	PubMed		"Thol et al., 2010, Blood"	NCT00209833	3	accepted	328	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/328	https://civicdb.org/links/molecular_profiles/566	FALSE	IDH2	3418	Mutation		chr15	90083045	90102504			ENST00000330062.3	75		protein_altering_variant		2023-01-09 21:52:07 UTC		N/A		FALSE
IDH2 R140	62	Myelodysplastic Syndrome	50908				Prognostic	Does Not Support	B	N/A	"In patients with myelodysplastic syndrome, the presence of IDH2 R140Q (N=3) or IDH1 R132 (N=2) mutations did not confer prognostic value (overall survival) compared to wild-type IDH1/2 patients (N=61; P=0.794)."	21997850	PubMed		"Lin et al., 2012, Ann. Hematol."		2	accepted	329	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/329	https://civicdb.org/links/molecular_profiles/62	FALSE	IDH2	3418	R140		chr15	90088702	90088702			ENST00000330062.3	75		protein_altering_variant		2023-01-09 21:52:04 UTC		"37,598,814,716,375,900"	ARG140	FALSE
IDH2 R140	62	Myelodysplastic Syndrome	50908				Prognostic	Does Not Support	B	N/A	R140Q mutation in IDH2 does not have prognostic value in patients with MDS.	22033490	PubMed		"Patnaik et al., 2012, Leukemia"		3	accepted	330	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/330	https://civicdb.org/links/molecular_profiles/62	FALSE	IDH2	3418	R140		chr15	90088702	90088702			ENST00000330062.3	75		protein_altering_variant		2023-01-09 21:52:04 UTC		"37,598,814,716,375,900"	ARG140	FALSE
IDH2 R172K	63	Acute Myeloid Leukemia	9119				Prognostic	Does Not Support	B	N/A	AML patients with IDH2 mutations such as R172K have event free survival and overall survival similar to those with wild-type IDH2.	22616558	PubMed		"Zhou et al., 2012, Leuk. Lymphoma"		2	accepted	331	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/331	https://civicdb.org/links/molecular_profiles/63	FALSE	IDH2	3418	R172K		chr15	90088606	90088606	C	T	ENST00000330062.3	75		missense_variant	"NM_002168.3:c.515G>A,NP_002159.2:p.Arg172Lys,NC_000015.9:g.90631838C>T,ENST00000330062.3:c.515G>A"	2023-01-27 17:02:22 UTC	CA16602462	375987	"ARG172LYS,R120K,RS121913503"	FALSE
IDH2 R172K	63	Myelodysplastic Syndrome	50908				Prognostic	Does Not Support	B	N/A	"In patients suffering from MDS, the presence of IDH2 mutations such as R172K do not confer prognostic value (overall survival)."	21997850	PubMed		"Lin et al., 2012, Ann. Hematol."		2	accepted	332	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/332	https://civicdb.org/links/molecular_profiles/63	FALSE	IDH2	3418	R172K		chr15	90088606	90088606	C	T	ENST00000330062.3	75		missense_variant	"NM_002168.3:c.515G>A,NP_002159.2:p.Arg172Lys,NC_000015.9:g.90631838C>T,ENST00000330062.3:c.515G>A"	2023-01-27 17:02:22 UTC	CA16602462	375987	"ARG172LYS,R120K,RS121913503"	FALSE
KIT Exon 11 Mutation	66	Gastrointestinal Stromal Tumor	9253				Prognostic	Does Not Support	B	N/A	"KIT mutations were identified in morphologically benign, incidentally discovered GISTs at a rate similar to that seen in advanced, metastatic GIST patients indicating is not a prognostic marker for GIST."	12000708	PubMed		"Corless et al., 2002, Am. J. Pathol."		3	accepted	333	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/333	https://civicdb.org/links/molecular_profiles/66	FALSE	KIT	3815	Exon 11 Mutation	KIT Exon 11	chr4	54727416	54727542			ENST00000288135.5	75		coding_sequence_variant		2023-01-09 21:52:04 UTC				FALSE
KIT Exon 11 Mutation	66	Lung Cancer	1324				Prognostic	Does Not Support	B	N/A	KIT mutations detected in 5/60 patients showed no prognostic significance in patients with small cell lung cancer.	15217946	PubMed		"Boldrini et al., 2004, Clin. Cancer Res."		2	accepted	334	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/334	https://civicdb.org/links/molecular_profiles/66	FALSE	KIT	3815	Exon 11 Mutation	KIT Exon 11	chr4	54727416	54727542			ENST00000288135.5	75		coding_sequence_variant		2023-01-09 21:52:04 UTC				FALSE
KRAS G12	76	Colorectal Cancer	9256				Prognostic	Does Not Support	B	N/A	"In patients with stage III colorectal cancer undergoing chemotherapy, KRAS G12 mutation did not impact overall or disease free survival."	19934290	PubMed		"Ogino et al., 2009, Clin. Cancer Res."		4	accepted	336	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/336	https://civicdb.org/links/molecular_profiles/76	FALSE	KRAS	3845	G12		chr12	25245350	25245351			ENST00000256078.4	75		protein_altering_variant		2023-01-09 21:52:04 UTC		"451,221,257,812,582,000,000,000,000,000"	GLY12	FALSE
KRAS G12	76	Lung Non-small Cell Carcinoma	3908				Prognostic	Does Not Support	B	N/A	There is no strong association between KRAS mutation status and overall or progression free survival in patients with NSCLC.	11208838	PubMed		"Schiller et al., 2001, J. Clin. Oncol."		3	accepted	337	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/337	https://civicdb.org/links/molecular_profiles/76	FALSE	KRAS	3845	G12		chr12	25245350	25245351			ENST00000256078.4	75		protein_altering_variant		2023-01-09 21:52:04 UTC		"451,221,257,812,582,000,000,000,000,000"	GLY12	FALSE
U2AF1 Q157P/R	127	Acute Myeloid Leukemia	9119				Prognostic	Does Not Support	B	N/A	"In patients with AML, those who harbor Q157P/R mutation of U2AF1 do not show a statistically significant difference in complete remission rate compared to those who harbor wild type U2AF1."	23029227	PubMed		"Qian et al., 2012, PLoS ONE"		2	accepted	338	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/338	https://civicdb.org/links/molecular_profiles/127	FALSE	U2AF1	7307	Q157P/R		chr21	43094667	43094667	T	G	ENST00000291552.4	75		missense_variant	NC_000021.8:g.44514777T>G	2023-01-09 21:52:05 UTC				FALSE
U2AF1 Q157P/R	127	Myelodysplastic Syndrome	50908				Prognostic	Does Not Support	B	N/A	"In patients with MDS, those who harbor Q157P/R mutation of U2AF do not show statistical significance in complete remission rate compared to those who harbor wild type U2AF."	23029227	PubMed		"Qian et al., 2012, PLoS ONE"		2	accepted	339	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/339	https://civicdb.org/links/molecular_profiles/127	FALSE	U2AF1	7307	Q157P/R		chr21	43094667	43094667	T	G	ENST00000291552.4	75		missense_variant	NC_000021.8:g.44514777T>G	2023-01-09 21:52:05 UTC				FALSE
U2AF1 S34Y/F	128	Acute Myeloid Leukemia	9119				Prognostic	Does Not Support	B	N/A	"In patients with AML, complete remission rates are not different between patients who harbor the U2AF1 S34Y/F mutation and those with wild type U2AF1."	23029227	PubMed		"Qian et al., 2012, PLoS ONE"		2	accepted	340	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/340	https://civicdb.org/links/molecular_profiles/128	FALSE	U2AF1	7307	S34Y/F		chr21	43104346	43104346	G	A	ENST00000291552.4	75		missense_variant	NC_000021.8:g.44524456G>A	2023-01-09 21:52:05 UTC				FALSE
CCND1 Expression	19	Lung Non-small Cell Carcinoma	3908				Prognostic	Does Not Support	B	Poor Outcome	Three studies have found no significant survival impact for CCND1 in lung cancer.	17070615	PubMed		"Gautschi et al., 2007, Lung Cancer"		3	accepted	342	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/342	https://civicdb.org/links/molecular_profiles/19	FALSE	CCND1	595	Expression		chr11	69641087	69654474			ENST00000227507.2	75		N/A	N/A	2023-01-09 21:52:04 UTC		N/A		FALSE
PTEN R233*	110	Glioblastoma	3068				Prognostic	Does Not Support	B	Poor Outcome	"PTEN nonsense mutations, including R233*, have been shown to be inactivating and loss-of-function, but do not have prognostic value in glioblastoma multiforme patients."	22479427	PubMed		"Carico et al., 2012, PLoS ONE"		3	accepted	343	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/343	https://civicdb.org/links/molecular_profiles/110	FALSE	PTEN	5728	R233*	PTEN Loss-of-Function	chr10	87957915	87957915	C	T	ENST00000371953.3	75		"stop_gained,loss_of_function_variant"	"NM_000314.6:c.697C>T,NP_000305.3:p.Arg233Ter,ENST00000371953.3:c.697C>T,NC_000010.10:g.89717672C>T"	2023-01-27 17:02:39 UTC	CA000549	7813	"R233X,ARG233TER,RS121909219"	FALSE
ABL1 BCR::ABL	1	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	A	Sensitivity/Response	"BCR-ABL inhibitors such as imatinib have lead to significantly improved prognosis, response rate, overall survival, and patient outcome in CML patients compared to previous therapeutic regimens."	20537386	PubMed		"An et al., 2010, Leuk. Res."		5	accepted	344	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/344	https://civicdb.org/links/molecular_profiles/1	FALSE	ABL1	25	BCR::ABL	ABL1 fusions in B-ALL	chr22	23180210	23290413			ENST00000305877.8	75	ENST00000318560.5	transcript_fusion	N/A	2023-01-09 21:52:04 UTC		N/A	"T(9;22)(Q34;Q11),BCR-ABL1,BCR-ABL"	FALSE
ABL1 BCR::ABL	1	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	A	Sensitivity/Response	"BCR-ABL inhibitors such as imatinib have lead to significantly improved prognosis, response rate, overall survival, and patient outcome in CML patients compared to previous therapeutic regimens."	20537386	PubMed		"An et al., 2010, Leuk. Res."		5	accepted	344	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/344	https://civicdb.org/links/molecular_profiles/1	FALSE	ABL1	25	BCR::ABL	ABL1 fusions in B-ALL	chr9	130854064	130887676			ENST00000305877.8	75	ENST00000318560.5	transcript_fusion	N/A	2023-01-09 21:52:04 UTC		N/A	"T(9;22)(Q34;Q11),BCR-ABL1,BCR-ABL"	FALSE
EGFR L858R	33	Lung Non-small Cell Carcinoma	3908				Prognostic	Supports	B	Better Outcome	Median survival of patients with EGFR L858R mutation is better than those with wild type EGFR.	24662454	PubMed		"Douillard et al., 2014, J Thorac Oncol"		3	accepted	347	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/347	https://civicdb.org/links/molecular_profiles/33	FALSE	EGFR	1956	L858R		chr7	55191822	55191822	T	G	ENST00000275493.2	75		missense_variant	"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg"	2023-01-27 17:02:04 UTC	CA126713	"16,609,376,282,376,200"	"LEU858ARG,RS121434568"	FALSE
IDH1 R132	58	Malignant Astrocytoma	3069				Prognostic	Supports	B	Better Outcome	"In patients with astrocytoma, the presence of IDH1 R132 mutation is prognostic for better survival compared to patients who harbor wild type mutation."	19933982	PubMed		"Dubbink et al., 2009, Neurology"		3	accepted	348	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/348	https://civicdb.org/links/molecular_profiles/58	FALSE	IDH1	3417	R132		chr2	208248387	208248389			ENST00000415913.1	75		protein_altering_variant	"NC_000002.11:g.209113113G>A,NC_000002.11:g.209113112C>T,NC_000002.11:g.209113113G>C,NC_000002.11:g.209113112C>A,NC_000002.11:g.209113113G>T,NC_000002.11:g.209113112C>G"	2023-01-09 21:52:04 UTC		"156,444,375,891,375,000,000,000,000,000,000,000"	ARG132	FALSE
IDH1 R132	58	Glioblastoma	3068				Prognostic	Supports	B	Better Outcome	"In patients with glioblastoma, those harboring IDH1 R132 mutation has higher overall survival compared to those who do not have IDH1 mutation."	20127344	PubMed		"Bleeker et al., 2010, Acta Neuropathol."		3	accepted	349	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/349	https://civicdb.org/links/molecular_profiles/58	FALSE	IDH1	3417	R132		chr2	208248387	208248389			ENST00000415913.1	75		protein_altering_variant	"NC_000002.11:g.209113113G>A,NC_000002.11:g.209113112C>T,NC_000002.11:g.209113113G>C,NC_000002.11:g.209113112C>A,NC_000002.11:g.209113113G>T,NC_000002.11:g.209113112C>G"	2023-01-09 21:52:04 UTC		"156,444,375,891,375,000,000,000,000,000,000,000"	ARG132	FALSE
IDH2 R140	62	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Better Outcome	"In AML, patients with IDH2 R140 mutation have improved overall survival compared to those with wild-type IDH2."	21596855	PubMed		"Green et al., 2011, Blood"		3	accepted	350	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/350	https://civicdb.org/links/molecular_profiles/62	FALSE	IDH2	3418	R140		chr15	90088702	90088702			ENST00000330062.3	75		protein_altering_variant		2023-01-09 21:52:04 UTC		"37,598,814,716,375,900"	ARG140	FALSE
SF3B1 Mutation	215	Myelodysplastic Syndrome	50908				Prognostic	Supports	B	Better Outcome	"Patients with SF3B1 mutations had a statistically significant longer overall survival as well as event free-survival. Both before and after adjustment for age, karyotype and sex."	21995386	PubMed		"Papaemmanuil et al., 2011, N. Engl. J. Med."		3	accepted	352	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/352	https://civicdb.org/links/molecular_profiles/215	FALSE	SF3B1	23451	Mutation		chr2	197389784	197435091			ENST00000335508.6	75		protein_altering_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
CCND1 Amplification	18	Lung Non-small Cell Carcinoma	3908				Prognostic	Supports	B	Poor Outcome	Inceased copy number of CCND1 is associated with poorer overall survival.	17070615	PubMed		"Gautschi et al., 2007, Lung Cancer"		3	accepted	354	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/354	https://civicdb.org/links/molecular_profiles/18	FALSE	CCND1	595	Amplification		chr11	69641087	69654474			ENST00000227507.2	75		transcript_amplification	N/A	2023-01-09 21:52:04 UTC		N/A		FALSE
CCND1 Expression	19	Lung Non-small Cell Carcinoma	3908				Prognostic	Supports	B	Poor Outcome	Three studies have associated CCND1 expression with poorer survival.	17070615	PubMed		"Gautschi et al., 2007, Lung Cancer"		3	accepted	355	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/355	https://civicdb.org/links/molecular_profiles/19	FALSE	CCND1	595	Expression		chr11	69641087	69654474			ENST00000227507.2	75		N/A	N/A	2023-01-09 21:52:04 UTC		N/A		FALSE
CCND1 Overexpression	20	Breast Cancer	1612				Prognostic	Supports	B	Poor Outcome	"In ER-positive breast cancer patients, Cyclin D1 overexpression is associated with shorter overall survival and increased metastasis."	15961768	PubMed		"Arnold et al., 2005, J. Clin. Oncol."		4	accepted	356	N/A	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/356	https://civicdb.org/links/molecular_profiles/20	FALSE	CCND1	595	Overexpression		chr11	69641087	69654474			ENST00000227507.2	75		N/A	N/A	2023-01-09 21:52:04 UTC		N/A		FALSE
CCND1 Overexpression	20	Head And Neck Squamous Cell Carcinoma	5520				Prognostic	Supports	B	Poor Outcome	Cyclin D1 overexpression is associated with shorter overall survival and increased metastasis in head and neck squamous cell carcinoma.	16309541	PubMed		"Thomas et al., 2005, Int J Exp Pathol"		4	accepted	357	N/A	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/357	https://civicdb.org/links/molecular_profiles/20	FALSE	CCND1	595	Overexpression		chr11	69641087	69654474			ENST00000227507.2	75		N/A	N/A	2023-01-09 21:52:04 UTC		N/A		FALSE
CCND1 Overexpression	20	Mantle Cell Lymphoma	50746				Prognostic	Supports	B	Poor Outcome	Cyclin D1 overexpression is associated with shorter overall survival and increased metastasis in mantle cell lymphoma.	17891190	PubMed		"Jares et al., 2007, Nat. Rev. Cancer"		4	accepted	358	N/A	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/358	https://civicdb.org/links/molecular_profiles/20	FALSE	CCND1	595	Overexpression		chr11	69641087	69654474			ENST00000227507.2	75		N/A	N/A	2023-01-09 21:52:04 UTC		N/A		FALSE
CCND2 OVEREXPRESSION	21	Stomach Cancer	10534				Prognostic	Supports	D	Poor Outcome	Cyclin D2 overexpression is associated with poor prognosis in gastric cancers.	10547574	PubMed		"Takano et al., 1999, J. Pathol."		4	accepted	359	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/359	https://civicdb.org/links/molecular_profiles/21	FALSE	CCND2	894	OVEREXPRESSION		chr12	4273772	4305350			ENST00000261254.3	75		N/A		2023-01-09 21:52:04 UTC		N/A		FALSE
CCND2 OVEREXPRESSION	21	Stomach Cancer	10534				Prognostic	Supports	D	Poor Outcome	Cyclin D2 overexpression is associated with the increased depth of cancer invasion in gastric cancers.	10547574	PubMed		"Takano et al., 1999, J. Pathol."		4	accepted	360	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/360	https://civicdb.org/links/molecular_profiles/21	FALSE	CCND2	894	OVEREXPRESSION		chr12	4273772	4305350			ENST00000261254.3	75		N/A		2023-01-09 21:52:04 UTC		N/A		FALSE
CCND2 OVEREXPRESSION	21	Stomach Cancer	10534				Prognostic	Supports	D	Poor Outcome	Cyclin D2 overexpression is associated with the presence pf lymph node metastasis in gastric cancers.	10547574	PubMed		"Takano et al., 1999, J. Pathol."		4	accepted	361	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/361	https://civicdb.org/links/molecular_profiles/21	FALSE	CCND2	894	OVEREXPRESSION		chr12	4273772	4305350			ENST00000261254.3	75		N/A		2023-01-09 21:52:04 UTC		N/A		FALSE
CCND2 OVEREXPRESSION	21	Stomach Cancer	10534				Prognostic	Supports	D	Poor Outcome	Cyclin D2 overexpression is associated with vascular invasion by cancer cells in gastric cancers.	10547574	PubMed		"Takano et al., 1999, J. Pathol."		4	accepted	362	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/362	https://civicdb.org/links/molecular_profiles/21	FALSE	CCND2	894	OVEREXPRESSION		chr12	4273772	4305350			ENST00000261254.3	75		N/A		2023-01-09 21:52:04 UTC		N/A		FALSE
CCNE1 Overexpression	24	Breast Cancer	1612				Prognostic	Supports	B	Poor Outcome	"Patients with high expression of total cyclin E and low-molecular weight cyclin E is strongly associated with poor prognosis in breast cancer, and the hazard ratio for these patients in 13.3 times higher than those with normal cyclin E levels."	12432043	PubMed		"Keyomarsi et al., 2002, N. Engl. J. Med."		4	accepted	363	N/A	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/363	https://civicdb.org/links/molecular_profiles/24	FALSE	CCNE1	898	Overexpression		chr19	29811898	29824308			ENST00000262643.3	75		N/A		2023-01-09 21:52:04 UTC		N/A		FALSE
CCNE1 Overexpression	24	Gastric Adenosquamous Carcinoma	5635				Prognostic	Supports	B	Poor Outcome	Elevated levels of CCNE1 mRNA has been shown to be correlated with advanced stage gastric carcinoma.	10224221	PubMed		"Donnellan et al., 1999, FASEB J."		4	accepted	364	N/A	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/364	https://civicdb.org/links/molecular_profiles/24	FALSE	CCNE1	898	Overexpression		chr19	29811898	29824308			ENST00000262643.3	75		N/A		2023-01-09 21:52:04 UTC		N/A		FALSE
CCNE1 Overexpression	24	Gastric Adenosquamous Carcinoma	5635				Prognostic	Supports	B	Poor Outcome	Elevated levels of CCNE1 mRNA has been shown to be correlated with increased depth of tumor invasion in gastic carcinoma.	10224221	PubMed		"Donnellan et al., 1999, FASEB J."		4	accepted	365	N/A	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/365	https://civicdb.org/links/molecular_profiles/24	FALSE	CCNE1	898	Overexpression		chr19	29811898	29824308			ENST00000262643.3	75		N/A		2023-01-09 21:52:04 UTC		N/A		FALSE
CDKN2A Promoter Hypermethylation	27	Lung Non-small Cell Carcinoma	3908				Prognostic	Supports	B	Poor Outcome	"In NSCLC patients younger than 60 years at age of diagnosis, p16 (CDKN2A) promoter hypermethylation is associated with shorter time to recurrence and shorter overall survival."	23111194	PubMed		"Bradly et al., 2012, Diagn. Mol. Pathol."		3	accepted	367	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/367	https://civicdb.org/links/molecular_profiles/27	FALSE	CDKN2A	1029	Promoter Hypermethylation		chr9	21974828	21994592			ENST00000498124.1	75		N/A		2023-01-09 21:52:04 UTC				FALSE
CDKN2A Promoter Hypermethylation	27	Lung Non-small Cell Carcinoma	3908				Prognostic	Supports	B	Poor Outcome	"In NSCLC patients younger than 60 years at age of diagnosis, p16 (CDKN2A) promoter hypermethylation is associated with shorter time to recurrence."	23111194	PubMed		"Bradly et al., 2012, Diagn. Mol. Pathol."		3	accepted	368	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/368	https://civicdb.org/links/molecular_profiles/27	FALSE	CDKN2A	1029	Promoter Hypermethylation		chr9	21974828	21994592			ENST00000498124.1	75		N/A		2023-01-09 21:52:04 UTC				FALSE
EGFR T790M	34	Lung Non-small Cell Carcinoma	3908				Prognostic	Supports	B	Poor Outcome	"In NSCLC patients with T790M and another activating mutations, their progression free survival is shorter compared to those who do not possess T790M mutation."	24623981	PubMed		"Ding et al., 2014, Onco Targets Ther"		4	accepted	369	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/369	https://civicdb.org/links/molecular_profiles/34	FALSE	EGFR	1956	T790M	EGFR TKI Resistance	chr7	55181378	55181378	C	T	ENST00000275493.2	75		missense_variant	"ENST00000275493.2:c.2369C>T,NM_005228.4:c.2369C>T,NP_005219.2:p.Thr790Met,NC_000007.13:g.55249071C>T"	2023-01-27 17:02:05 UTC	CA090928	16613	"THR790MET,RS121434569"	FALSE
EGFR T790M	34	Lung Non-small Cell Carcinoma	3908				Prognostic	Supports	B	Poor Outcome	Patients with NSCLC harboring EGFR T790M mutation have statistically worse overall survival compared to patients with L858R or other exon 19 activating mutations.	24729716	PubMed		"Li et al., 2014, Onco Targets Ther"		4	accepted	370	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/370	https://civicdb.org/links/molecular_profiles/34	FALSE	EGFR	1956	T790M	EGFR TKI Resistance	chr7	55181378	55181378	C	T	ENST00000275493.2	75		missense_variant	"ENST00000275493.2:c.2369C>T,NM_005228.4:c.2369C>T,NP_005219.2:p.Thr790Met,NC_000007.13:g.55249071C>T"	2023-01-27 17:02:05 UTC	CA090928	16613	"THR790MET,RS121434569"	FALSE
FLT3 ITD	55	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	AML patients with internal tandem repeat of FLT3 has worse overall survival than patients with wild type FLT3.	11290608	PubMed		"Yamamoto et al., 2001, Blood"		3	accepted	371	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/371	https://civicdb.org/links/molecular_profiles/55	FALSE	FLT3	2322	ITD		chr13	28034082	28034214			ENST00000241453.7	75		inframe_insertion		2023-01-09 21:52:04 UTC		16270		FALSE
FLT3 ITD	55	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	Simultaneous tandem repeat of FLT3 with loss of wild type FLT3 leads to poor survival and inferior disease free survival in patients with AML.	11585760	PubMed		"Whitman et al., 2001, Cancer Res."		4	accepted	372	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/372	https://civicdb.org/links/molecular_profiles/55	FALSE	FLT3	2322	ITD		chr13	28034082	28034214			ENST00000241453.7	75		inframe_insertion		2023-01-09 21:52:04 UTC		16270		FALSE
FLT3 TKD MUTATION	56	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	"In AML patients, FLT3-TKD mutation was associated with poorer disease free survival compared to patients with wild type FLT3."	17940205	PubMed		"Whitman et al., 2008, Blood"		4	accepted	373	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/373	https://civicdb.org/links/molecular_profiles/56	FALSE	FLT3	2322	TKD MUTATION		chr13	28018505	28018505	C	A	ENST00000241453.7	75		nonsynonymous_variant	NC_000013.10:g.28592642C>A	2023-01-27 17:02:18 UTC	CA126347	16276		TRUE
IDH1 R132	58	Myelodysplastic Syndrome	50908				Prognostic	Supports	B	Poor Outcome	IDH1 R132 mutation in patients suffering from myelodysplastic syndromes is associated with worse overall survival.	20494930	PubMed		"Thol et al., 2010, Haematologica"		4	accepted	374	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/374	https://civicdb.org/links/molecular_profiles/58	FALSE	IDH1	3417	R132		chr2	208248387	208248389			ENST00000415913.1	75		protein_altering_variant	"NC_000002.11:g.209113113G>A,NC_000002.11:g.209113112C>T,NC_000002.11:g.209113113G>C,NC_000002.11:g.209113112C>A,NC_000002.11:g.209113113G>T,NC_000002.11:g.209113112C>G"	2023-01-09 21:52:04 UTC		"156,444,375,891,375,000,000,000,000,000,000,000"	ARG132	FALSE
IDH2 R172K	63	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	"In AML, patients with an IDH2 R172K mutation have worse overall survival compared to those with wild-type IDH2."	21596855	PubMed		"Green et al., 2011, Blood"		3	accepted	375	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/375	https://civicdb.org/links/molecular_profiles/63	FALSE	IDH2	3418	R172K		chr15	90088606	90088606	C	T	ENST00000330062.3	75		missense_variant	"NM_002168.3:c.515G>A,NP_002159.2:p.Arg172Lys,NC_000015.9:g.90631838C>T,ENST00000330062.3:c.515G>A"	2023-01-27 17:02:22 UTC	CA16602462	375987	"ARG172LYS,R120K,RS121913503"	FALSE
KIT Exon 11 Mutation	66	Gastrointestinal Stromal Tumor	9253				Prognostic	Supports	B	Poor Outcome	KIT mutation is associated with worse overall and cause-specific prognosis in patients with GIST compared to patients with wildtype KIT.	10485475	PubMed		"Taniguchi et al., 1999, Cancer Res."		3	accepted	376	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/376	https://civicdb.org/links/molecular_profiles/66	FALSE	KIT	3815	Exon 11 Mutation	KIT Exon 11	chr4	54727416	54727542			ENST00000288135.5	75		coding_sequence_variant		2023-01-09 21:52:04 UTC				FALSE
KRAS G12	76	Multiple Myeloma	9538				Prognostic	Supports	B	Poor Outcome	The presence of KRAS mutations in MM patients is prognostic for shorter overall and progression free survival.	18528420	PubMed		"Chng et al., 2008, Leukemia"		3	accepted	377	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/377	https://civicdb.org/links/molecular_profiles/76	FALSE	KRAS	3845	G12		chr12	25245350	25245351			ENST00000256078.4	75		protein_altering_variant		2023-01-09 21:52:04 UTC		"451,221,257,812,582,000,000,000,000,000"	GLY12	FALSE
KRAS G12	76	Lung Non-small Cell Carcinoma	3908				Prognostic	Supports	B	Poor Outcome	A meta-analysis showed KRAS mutation is associated with worse outcome in patients with NSCLC.	15597105	PubMed		"Mascaux et al., 2005, Br. J. Cancer"		3	accepted	378	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/378	https://civicdb.org/links/molecular_profiles/76	FALSE	KRAS	3845	G12		chr12	25245350	25245351			ENST00000256078.4	75		protein_altering_variant		2023-01-09 21:52:04 UTC		"451,221,257,812,582,000,000,000,000,000"	GLY12	FALSE
NOTCH1 D1642H	135	Lung Non-small Cell Carcinoma	3908				Prognostic	Supports	B	Poor Outcome	"NOTCH1 gain-of-function mutations, including D1642H (called D1643H in publication), have shown to be correlated with poor prognosis in lung cancer. This is in a TP53 wild-type context."	20007775	PubMed		"Westhoff et al., 2009, Proc. Natl. Acad. Sci. U.S.A."		4	accepted	380	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/380	https://civicdb.org/links/molecular_profiles/135	FALSE	NOTCH1	4851	D1642H		chr9	136504767	136504767	C	G	ENST00000277541.6	75		missense_variant	"ENST00000277541.6:c.4924G>C,NC_000009.11:g.139399219C>G,NM_017617.4:c.4924G>C,NP_060087.3:p.Asp1642His"	2023-01-27 17:02:49 UTC	CA16602788	376345	ASP1642HIS	FALSE
NOTCH1 R2327W	136	Lung Non-small Cell Carcinoma	3908				Prognostic	Supports	B	Poor Outcome	"NOTCH1 gain-of-function mutations, including R2327W (called R2328W in publication), have shown to be correlated to poor prognosis in lung cancer. This is in a TP53 wild-type context."	20007775	PubMed		"Westhoff et al., 2009, Proc. Natl. Acad. Sci. U.S.A."		4	accepted	381	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/381	https://civicdb.org/links/molecular_profiles/136	FALSE	NOTCH1	4851	R2327W		chr9	136496760	136496760	G	A	ENST00000277541.6	75		missense_variant	"NM_017617.4:c.6979C>T,NP_060087.3:p.Arg2327Trp,NC_000009.11:g.139391212G>A"	2023-01-27 17:02:50 UTC	CA5339772	376346	ARG2327TRP	FALSE
NOTCH1 S2275FS	138	Lung Non-small Cell Carcinoma	3908				Prognostic	Supports	B	Poor Outcome	"NOTCH1 gain-of-function mutations, including S2275fs, have shown to be correlated to poor prognosis in lung cancer. This is in a TP53 wild-type context."	20007775	PubMed		"Westhoff et al., 2009, Proc. Natl. Acad. Sci. U.S.A."		4	accepted	382	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/382	https://civicdb.org/links/molecular_profiles/138	FALSE	NOTCH1	4851	S2275FS		chr9	136496917	136496918		A	ENST00000277541.6	75		plus_1_frameshift_variant	"ENST00000277541.6:c.6821_6822insT,NC_000009.11:g.139391369_139391370insA"	2023-01-27 17:02:51 UTC	CA645544343	NONE FOUND		FALSE
NOTCH1 V2444FS	137	Lung Non-small Cell Carcinoma	3908				Prognostic	Supports	B	Poor Outcome	"NOTCH1 gain-of-function mutations, including V2444fs, have shown to be correlated to poor prognosis in lung cancer. This is in a TP53 wild-type context."	20007775	PubMed		"Westhoff et al., 2009, Proc. Natl. Acad. Sci. U.S.A."		4	accepted	383	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/383	https://civicdb.org/links/molecular_profiles/137	FALSE	NOTCH1	4851	V2444FS		chr9	136496409	136496409	G	TGT	ENST00000277541.6	75		frameshift_variant	ENST00000277541.6:c.7330delinsACA	2023-03-24 00:00:05 UTC	CA913157307	NONE FOUND	VAL2444FS	FALSE
PIK3CA Exon 10 Mutation	106	Colorectal Cancer	9256				Prognostic	Does Not Support	B	Poor Outcome	"This study analyzed tumor and patient characteristics from 1,170 colorectal cancer patients derived from the prospective cohort studies: Nurses' Health Study and Health Professionals Follow Up Study. PIK3CA mutations were found in 16% (189/1170) of patients via pyrosequencing of FFPE samples. Of patients with PIK3CA mutated tumors, 58% (109/189) had mutations in exon 10 (listed as exon 9 in the publication, as it was common at the time of its publication to exclude non-coding exon 1). The presence of an exon 10 mutation was not significantly associated with differences in colorectal cancer-specific or overall survival when compared to patients with wt PIK3CA (multivariate, stage-stratified HR = 1.15 vs 1). Authors note that they had limited data on cancer treatment data, but assume that treatment regimens did not differ substantially based on PIK3CA mutation status given that patients were diagnosed prior to clinical availability of PIK3CA genotype data. They further note that treatment decisions were typically based on cancer stage, for which their analyses adjusted."	22357840	PubMed		"Liao et al., 2012, Clin. Cancer Res."		2	accepted	384	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/384	https://civicdb.org/links/molecular_profiles/106	FALSE	PIK3CA	5290	Exon 10 Mutation		chr3	179218210	179218334			ENST00000263967.3	75		exon_variant		2023-01-09 21:52:05 UTC		"3,194,413,655"	EXON 9 MUTATION	FALSE
PIK3CA E545K	104	Colorectal Cancer	9256		"Panitumumab,Cetuximab"	Substitutes	Predictive	Supports	C	Resistance	"In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). KRAS PIK3CA and PTEN were tested for mutation, and 1 patient (patient 95, see supplemental table 1) had PIK3CA E545K in the primary tumor without co-occurring mutations in the other tested genes. This response was consistent with observations made of the larger cohort, where patients with tumors harboring any PIK3CA mutation had significantly shorter progression free survival and decreased incidence of objective response than patients with wtPIK3CA tumors. However, there was one patient (Patient 55, Table S1) who had E545K as the only noted variant, but experienced partial response."	19223544	PubMed		"Sartore-Bianchi et al., 2009, Cancer Res."		3	accepted	387	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/387	https://civicdb.org/links/molecular_profiles/104	FALSE	PIK3CA	5290	E545K		chr3	179218303	179218303	G	A	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.1633G>A,NP_006209.2:p.Glu545Lys,ENST00000263967.3:c.1633G>A,NC_000003.11:g.178936091G>A"	2023-01-27 17:02:37 UTC	CA123334	13655	"GLU545LYS,RS104886003"	FALSE
PIK3CA H1047R	107	Colorectal Cancer	9256		"Panitumumab,Cetuximab"	Substitutes	Predictive	Supports	C	Resistance	"In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). KRAS PIK3CA and PTEN were tested for mutation; PIK3CA H1047R was the only variant noted in the primary tumors of four patients (Patient Ids: 7, 42, 52, 64; Table S1) and the metastatic tumor of one patient (11; Table S1), who experienced disease progression following treatment. It was also noted in the primary tumors of 3 patients (25, 48, 88; Table S1) who experienced stable disease following treatment.This response was consistent with observations made of the larger cohort, where patients with tumors harboring any PIK3CA mutation had significantly shorter progression free survival and decreased incidence of objective response than patients with wtPIK3CA tumors. However, one patient (38, Table S1) had PIK3CA H1047R as the only noted variant, but experienced partial response."	19223544	PubMed		"Sartore-Bianchi et al., 2009, Cancer Res."		2	accepted	388	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/388	https://civicdb.org/links/molecular_profiles/107	FALSE	PIK3CA	5290	H1047R		chr3	179234297	179234297	A	G	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.3140A>G,NP_006209.2:p.His1047Arg,ENST00000263967.3:c.3140A>G,NC_000003.11:g.178952085A>G"	2023-01-27 17:02:38 UTC	CA123326	13652	"HIS1047ARG,RS121913279"	FALSE
TP53 R175H	116	Breast Cancer	1612				Prognostic	Supports	B	Poor Outcome	"Breast cancer patients who harbor R175H mutation have worse overall survival than those with wild type TP53, but have better prognosis than those with R248W mutation."	16489069	PubMed		"Olivier et al., 2006, Clin. Cancer Res."		3	accepted	389	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/389	https://civicdb.org/links/molecular_profiles/116	FALSE	TP53	7157	R175H		chr17	7675088	7675088	C	T	ENST00000269305.4	75		missense_variant	"NM_000546.5:c.524G>A,NP_000537.3:p.Arg175His,NC_000017.10:g.7578406C>T,ENST00000269305.4:c.524G>A"	2023-01-27 17:02:43 UTC	CA000251	12374	"ARG175HIS,RS28934578,R43H,R136H"	FALSE
TP53 R248Q	117	Breast Cancer	1612				Prognostic	Supports	B	Poor Outcome	"Breast cancer patients who harbor a R248Q mutation (N=18) have worse overall survival than those with wild type TP53 (N=1460), but have better prognosis than those with a R248W mutation (N=8)."	16489069	PubMed		"Olivier et al., 2006, Clin. Cancer Res."		3	accepted	390	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/390	https://civicdb.org/links/molecular_profiles/117	FALSE	TP53	7157	R248Q		chr17	7674220	7674220	C	T	ENST00000269305.4	75		missense_variant	"NM_000546.5:c.743G>A,NP_000537.3:p.Arg248Gln,NC_000017.10:g.7577538C>T,ENST00000269305.4:c.743G>A"	2023-01-27 17:02:44 UTC	CA000387	12356	"ARG248GLN,RS11540652"	FALSE
TP53 R248Q	117	Breast Cancer	1612				Prognostic	Supports	B	Poor Outcome	"In breast cancer patients harboring TP53 mutation, mutations in DNA contact regions such as R248 (N=10, 6 at R248) are prognostic for a worse relapse-free survival compared to other non-silent mutations in TP53 (N=43)."	9569050	PubMed		"Berns et al., 1998, Br. J. Cancer"		3	accepted	391	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/391	https://civicdb.org/links/molecular_profiles/117	FALSE	TP53	7157	R248Q		chr17	7674220	7674220	C	T	ENST00000269305.4	75		missense_variant	"NM_000546.5:c.743G>A,NP_000537.3:p.Arg248Gln,NC_000017.10:g.7577538C>T,ENST00000269305.4:c.743G>A"	2023-01-27 17:02:44 UTC	CA000387	12356	"ARG248GLN,RS11540652"	FALSE
TP53 R248W	118	Breast Cancer	1612				Prognostic	Supports	B	Poor Outcome	"In breast cancer patients harboring R248W mutation, the prognosis is worse than any other hotspot TP53 mutation, as well as worse than patients with wild type TP53."	16489069	PubMed		"Olivier et al., 2006, Clin. Cancer Res."		3	accepted	392	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/392	https://civicdb.org/links/molecular_profiles/118	FALSE	TP53	7157	R248W		chr17	7674221	7674221	G	A	ENST00000269305.4	75		missense_variant	"NM_000546.5:c.742C>T,NP_000537.3:p.Arg248Trp,NC_000017.10:g.7577539G>A,ENST00000269305.4:c.742C>T"	2023-01-27 17:02:45 UTC	CA000382	12347	"ARG248TRP,RS121912651"	FALSE
TP53 R249	119	Breast Cancer	1612				Prognostic	Supports	B	Poor Outcome	"In breast cancer patients harboring TP53 mutation, mutations in conserved regions such as R249 are prognostic for a worse overall survival compared to those harboring wild-type TP53."	9569050	PubMed		"Berns et al., 1998, Br. J. Cancer"		3	accepted	393	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/393	https://civicdb.org/links/molecular_profiles/119	FALSE	TP53	7157	R249		chr17	7674217	7674217	C	G	ENST00000269305.4	75		protein_altering_variant	NC_000017.10:g.7577535C>G	2023-01-27 17:02:45 UTC	CA16602484	376015	ARG249	FALSE
TP53 R273C	121	Breast Cancer	1612				Prognostic	Supports	B	Poor Outcome	"Breast cancer patients who harbor R273C mutation have worse overall survival than those with wild type TP53, but have better prognosis than those with R248W mutation."	16489069	PubMed		"Olivier et al., 2006, Clin. Cancer Res."		3	accepted	395	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/395	https://civicdb.org/links/molecular_profiles/121	FALSE	TP53	7157	R273C		chr17	7673803	7673803	G	A	ENST00000269305.4	75		missense_variant	"NM_000546.5:c.817C>T,NP_000537.3:p.Arg273Cys,NC_000017.10:g.7577121G>A,ENST00000269305.4:c.817C>T"	2023-01-27 17:02:47 UTC	CA000432	43594	"ARG273CYS,RS121913343"	FALSE
TP53 R273C	121	Breast Cancer	1612				Prognostic	Supports	B	Poor Outcome	"In breast cancer patients  harboring TP53 mutation, mutations in DNA contact regions such as R273 are prognostic for a worse relapse-free survival compared to other non-silent mutations in TP53."	9569050	PubMed		"Berns et al., 1998, Br. J. Cancer"		3	accepted	396	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/396	https://civicdb.org/links/molecular_profiles/121	FALSE	TP53	7157	R273C		chr17	7673803	7673803	G	A	ENST00000269305.4	75		missense_variant	"NM_000546.5:c.817C>T,NP_000537.3:p.Arg273Cys,NC_000017.10:g.7577121G>A,ENST00000269305.4:c.817C>T"	2023-01-27 17:02:47 UTC	CA000432	43594	"ARG273CYS,RS121913343"	FALSE
TP53 R273H	122	Breast Cancer	1612				Prognostic	Supports	B	Poor Outcome	"Breast cancer patients who harbor R273H mutation have worse overall survival than those with wild type TP53, but have better prognosis than those with R248W mutation."	16489069	PubMed		"Olivier et al., 2006, Clin. Cancer Res."		3	accepted	397	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/397	https://civicdb.org/links/molecular_profiles/122	FALSE	TP53	7157	R273H		chr17	7673802	7673802	C	T	ENST00000269305.4	75		missense_variant	"NM_000546.5:c.818G>A,NP_000537.3:p.Arg273His,NC_000017.10:g.7577120C>T,ENST00000269305.4:c.818G>A"	2023-01-27 17:02:48 UTC	CA000434	12366	"ARG273HIS,RS28934576"	FALSE
TP53 R273H	122	Breast Cancer	1612				Prognostic	Supports	B	Poor Outcome	"In breast cancer patients harboring TP53 mutation, mutations in DNA contact regions such as R273 are prognostic for a worse relapse-free survival compared to other non-silent mutations in TP53."	9569050	PubMed		"Berns et al., 1998, Br. J. Cancer"		3	accepted	398	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/398	https://civicdb.org/links/molecular_profiles/122	FALSE	TP53	7157	R273H		chr17	7673802	7673802	C	T	ENST00000269305.4	75		missense_variant	"NM_000546.5:c.818G>A,NP_000537.3:p.Arg273His,NC_000017.10:g.7577120C>T,ENST00000269305.4:c.818G>A"	2023-01-27 17:02:48 UTC	CA000434	12366	"ARG273HIS,RS28934576"	FALSE
TP53 R249	119	Breast Cancer	1612		Doxorubicin		Predictive	Supports	B	Sensitivity/Response	Breast tumors with R175H or R249 mutations are more responsive to doxorubicin than breast tumors with wild type TP53.	9569050	PubMed		"Berns et al., 1998, Br. J. Cancer"		3	accepted	399	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/399	https://civicdb.org/links/molecular_profiles/119	FALSE	TP53	7157	R249		chr17	7674217	7674217	C	G	ENST00000269305.4	75		protein_altering_variant	NC_000017.10:g.7577535C>G	2023-01-27 17:02:45 UTC	CA16602484	376015	ARG249	FALSE
U2AF1 Q157P/R	127	Myelodysplastic Syndrome	50908				Prognostic	Supports	B	Poor Outcome	"After adjusting for age and cancer stage, presence of U2AF mutation such as Q157P/R is prognostic for poorer survival outcomes in patients with MDS."	23861105	PubMed		"Wu et al., 2013, Am. J. Hematol."		3	accepted	400	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/400	https://civicdb.org/links/molecular_profiles/127	FALSE	U2AF1	7307	Q157P/R		chr21	43094667	43094667	T	G	ENST00000291552.4	75		missense_variant	NC_000021.8:g.44514777T>G	2023-01-09 21:52:05 UTC				FALSE
U2AF1 S34Y/F	128	Myelodysplastic Syndrome	50908				Prognostic	Supports	B	Poor Outcome	"After adjusting for age and cancer stage, the presence of U2AF mutations such as S34Y/F are prognostic for poorer survival outcomes in patients with MDS."	23861105	PubMed		"Wu et al., 2013, Am. J. Hematol."		3	accepted	401	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/401	https://civicdb.org/links/molecular_profiles/128	FALSE	U2AF1	7307	S34Y/F		chr21	43104346	43104346	G	A	ENST00000291552.4	75		missense_variant	NC_000021.8:g.44524456G>A	2023-01-09 21:52:05 UTC				FALSE
CSF1R MEF2D::CSF1R	30	Acute Lymphoblastic Leukemia	9952		"GW-2580,Imatinib"	Substitutes	Predictive	Supports	D	Sensitivity/Response	Cell lines with MEF2D-CSF1R fusion show sensitivity to the tyrosine kinase inhibitors Imatinib and GW-2580.	24186003	PubMed		"Lilljebjrn et al., 2014, Leukemia"		3	accepted	403	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/403	https://civicdb.org/links/molecular_profiles/30	FALSE	CSF1R	1436	MEF2D::CSF1R		chr1	156477012	156500828			ENST00000348159.4	75	ENST00000286301.3	transcript_fusion		2023-01-09 21:52:04 UTC		N/A	MEF2D-CSF1R	FALSE
CSF1R MEF2D::CSF1R	30	Acute Lymphoblastic Leukemia	9952		"GW-2580,Imatinib"	Substitutes	Predictive	Supports	D	Sensitivity/Response	Cell lines with MEF2D-CSF1R fusion show sensitivity to the tyrosine kinase inhibitors Imatinib and GW-2580.	24186003	PubMed		"Lilljebjrn et al., 2014, Leukemia"		3	accepted	403	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/403	https://civicdb.org/links/molecular_profiles/30	FALSE	CSF1R	1436	MEF2D::CSF1R		chr5	150054224	150061849			ENST00000348159.4	75	ENST00000286301.3	transcript_fusion		2023-01-09 21:52:04 UTC		N/A	MEF2D-CSF1R	FALSE
PRKACA DNAJB1::PRKACA	31	Fibrolamellar Carcinoma	5015				Diagnostic	Supports	B	Positive	"A head-to-tail in-frame fusion between exon1 of DNAJB1 and exon2 of PRKACA resulting from a ~400kb deletion was observed in 100% (15/15) fibrolamellar hepatocellular carcinomas examined. The fusion was confirmed at both RNA and DNA level in all primary and metastatic tumor samples but not in adjacent normal tissue. Immunoprecipitation and Western blot analyses confirmed that the chimeric protein is expressed in tumor tissue, and a cell culture assay indicated that it retains kinase activity."	24578576	PubMed		"Honeyman et al., 2014, Science"		4	accepted	405	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/405	https://civicdb.org/links/molecular_profiles/31	FALSE	PRKACA	5566	DNAJB1::PRKACA		chr19	14518139	14518420			ENST00000254322.2	75	ENST00000308677.4	transcript_fusion		2023-01-09 21:52:04 UTC		N/A	DNAJB1-PRKACA	FALSE
PRKACA DNAJB1::PRKACA	31	Fibrolamellar Carcinoma	5015				Diagnostic	Supports	B	Positive	"A head-to-tail in-frame fusion between exon1 of DNAJB1 and exon2 of PRKACA resulting from a ~400kb deletion was observed in 100% (15/15) fibrolamellar hepatocellular carcinomas examined. The fusion was confirmed at both RNA and DNA level in all primary and metastatic tumor samples but not in adjacent normal tissue. Immunoprecipitation and Western blot analyses confirmed that the chimeric protein is expressed in tumor tissue, and a cell culture assay indicated that it retains kinase activity."	24578576	PubMed		"Honeyman et al., 2014, Science"		4	accepted	405	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/405	https://civicdb.org/links/molecular_profiles/31	FALSE	PRKACA	5566	DNAJB1::PRKACA		chr19	14091688	14107409			ENST00000254322.2	75	ENST00000308677.4	transcript_fusion		2023-01-09 21:52:04 UTC		N/A	DNAJB1-PRKACA	FALSE
BCL2 IGH::BCL2	151	Diffuse Large B-cell Lymphoma	50745				Diagnostic	Supports	B	Positive	The t(14;18) transloaction of BCL2 is shown to be associated with germinal-center B-celllike diffuse large-B-cell lymphomas.	12075054	PubMed		"Rosenwald et al., 2002, N. Engl. J. Med."		4	accepted	407	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/407	https://civicdb.org/links/molecular_profiles/151	FALSE	BCL2	596	IGH::BCL2		chr14	105566277	106879844				75	ENST00000333681.4	"transcript_fusion,transcript_regulatory_region_fusion"		2023-01-09 21:52:05 UTC		N/A	"RECIPROCAL T(14;18)(Q32;Q21),IGH-BCL2"	FALSE
BCL2 IGH::BCL2	151	Diffuse Large B-cell Lymphoma	50745				Diagnostic	Supports	B	Positive	The t(14;18) transloaction of BCL2 is shown to be associated with germinal-center B-celllike diffuse large-B-cell lymphomas.	12075054	PubMed		"Rosenwald et al., 2002, N. Engl. J. Med."		4	accepted	407	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/407	https://civicdb.org/links/molecular_profiles/151	FALSE	BCL2	596	IGH::BCL2		chr18	63127035	63319786				75	ENST00000333681.4	"transcript_fusion,transcript_regulatory_region_fusion"		2023-01-09 21:52:05 UTC		N/A	"RECIPROCAL T(14;18)(Q32;Q21),IGH-BCL2"	FALSE
FOXP1 AMPLIFICATION	153	Diffuse Large B-cell Lymphoma	50745				Diagnostic	Supports	B	Positive	Amplification of FOXP1 is shown to be associated with ABC DLBCL.	18765795	PubMed		"Lenz et al., 2008, Proc. Natl. Acad. Sci. U.S.A."		3	accepted	408	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/408	https://civicdb.org/links/molecular_profiles/153	FALSE	FOXP1	27086	AMPLIFICATION		chr3	70954693	71583989			ENST00000318789.4	75		transcript_amplification		2023-01-09 21:52:05 UTC		N/A		FALSE
REL AMPLIFICATION	154	Diffuse Large B-cell Lymphoma	50745				Diagnostic	Supports	B	Positive	Amplification of REL is shown to be associated with germinal-center B-celllike diffuse large-B-cell lymphomas.	12075054	PubMed		"Rosenwald et al., 2002, N. Engl. J. Med."		4	accepted	409	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/409	https://civicdb.org/links/molecular_profiles/154	FALSE	REL	5966	AMPLIFICATION		chr2	60881574	60922665			ENST00000295025.8	75		transcript_amplification		2023-01-09 21:52:05 UTC		N/A		FALSE
RUNX1 Mutation	155	Acute Myeloid Leukemia	9119		Cytarabine		Predictive	Supports	B	Resistance	"In non-APL patients with AML (age 18-60), those who had mutations in RUNX1 had significantly shorter relapse-free survival following conventional post-remission treatment (repetitive cycles of high-dose cytarabine) than those treated with an allogeneic hematopoietic stem-cell transplantation (N=32) at first remission (4-year RFS; 0% vs 52%; P<0.0001)."	21343560	PubMed		"Gaidzik et al., 2011, J. Clin. Oncol."	"NCT00146120,NCT00151242"	4	accepted	411	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/411	https://civicdb.org/links/molecular_profiles/155	FALSE	RUNX1	861	Mutation		chr21	34787801	35049344			ENST00000300305.3	75		"transcript_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
IGF2 Overexpression	156	Prostate Cancer	10283		Linsitinib		Predictive	Does Not Support	D	Sensitivity/Response	"Increased IGF2 expression was shown to mediate chemotherapy resistance in several prostate cancer cell lines. The IGF1R/INSR inhibitor OSI-906 did not have a significant effect on chemotherapy resistant castration-resistant prostate cancer cell lines, as measured by colony formation assay. Similarly, in vivo experiments showed no difference between OSI-906 and control treatment in terms of tumor growth and survival."	25670080	PubMed		"Vidal et al., 2015, Cancer Cell"		3	accepted	412	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/412	https://civicdb.org/links/molecular_profiles/156	FALSE	IGF2	3481	Overexpression		chr11	2129118	2149603			ENST00000300632.5	75		N/A	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
EGFR Exon 19 Deletion	133	Lung Non-small Cell Carcinoma	3908		"Gefitinib,Erlotinib"	Substitutes	Predictive	Supports	B	Sensitivity/Response	NSCLC patients with exon 19 deletions in EGFR had longer overall survival than patients with an L858R mutation when treated with gefitinib or erlotinib (38 versus 17 months; P = 0.04).	16818686	PubMed		"Jackman et al., 2006, Clin. Cancer Res."		4	accepted	413	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/413	https://civicdb.org/links/molecular_profiles/133	FALSE	EGFR	1956	Exon 19 Deletion		chr7	55174722	55174820			ENST00000275493.2	75		inframe_deletion	ENST00000275493.2:c.2185_2283del	2023-01-09 21:52:05 UTC		N/A		FALSE
IGF2 Overexpression	156	Prostate Cancer	10283		"Linsitinib,Cabazitaxel,Docetaxel"	Substitutes	Predictive	Supports	D	Sensitivity/Response	"OSI-906, an IGF1R/INSR inhibitor, sensitizes cell lines to docetaxel and cabazitaxel, resulting in better overall survival in mouse xenografts of patient derived chemotherapy resistant castration-resistant prostate cancer cell lines."	25670080	PubMed		"Vidal et al., 2015, Cancer Cell"		3	accepted	414	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/414	https://civicdb.org/links/molecular_profiles/156	FALSE	IGF2	3481	Overexpression		chr11	2129118	2149603			ENST00000300632.5	75		N/A	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
TET2 Mutation	157	Acute Myeloid Leukemia	9119				Prognostic	Does Not Support	B	N/A	"In a cohort of 783 young adult patients with acute myeloid leukemia, those with TET2 mutations did not have significantly different rates of complete recovery, refractory disease, or hypoplastic death."	22430270	PubMed		"Gaidzik et al., 2012, J. Clin. Oncol."		4	accepted	415	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/415	https://civicdb.org/links/molecular_profiles/157	FALSE	TET2	54790	Mutation		chr4	105146293	105279816			ENST00000513237.1	75		"gene_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
AURKA EXPRESSION	158	Ovarian Carcinoma	4001				Prognostic	Supports	B	Better Outcome	"In patients with ovarian carcinomas, those with Aurora kinase A expression (as measured by immunohistochemistry) had increased progression-free and overall survival compared to those without expression."	19157502	PubMed		"Mendiola et al., 2009, Hum. Pathol."		3	accepted	416	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/416	https://civicdb.org/links/molecular_profiles/158	FALSE	AURKA	6790	EXPRESSION		chr20	56369390	56392337			ENST00000395913.3	75		N/A		2023-01-09 21:52:05 UTC		N/A		FALSE
TET2 Mutation	157	Myelodysplastic Syndrome	50908				Prognostic	Supports	B	Better Outcome	"In patients with myelodysplastic syndromes, those with TET2 mutations have been shown to have better overall survival than patients without TET2 mutations."	19666869	PubMed		"Kosmider et al., 2009, Blood"		4	accepted	417	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/417	https://civicdb.org/links/molecular_profiles/157	FALSE	TET2	54790	Mutation		chr4	105146293	105279816			ENST00000513237.1	75		"gene_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
VHL Mutation	160	Clear Cell Renal Cell Carcinoma	4467				Prognostic	Supports	B	Better Outcome	"In patients with renal clear cell carcinoma, patients with VHL mutations had longer cancer-specific survival."	18464292	PubMed		"Patard et al., 2008, Int. J. Cancer"		4	accepted	418	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/418	https://civicdb.org/links/molecular_profiles/160	FALSE	VHL	7428	Mutation		chr3	10141008	10152220			ENST00000256474.2	75		"gene_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
TET2 Mutation	157	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Better Outcome	"In patients with cytogenetically normal acute myeloid leukemia, those in the intermediate-I risk group with TET2 mutations had higher rates of complete remission."	22430270	PubMed		"Gaidzik et al., 2012, J. Clin. Oncol."		4	accepted	419	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/419	https://civicdb.org/links/molecular_profiles/157	FALSE	TET2	54790	Mutation		chr4	105146293	105279816			ENST00000513237.1	75		"gene_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
PBRM1 Mutation	161	Clear Cell Renal Cell Carcinoma	4467				Prognostic	Supports	B	N/A	"In renal clear cell carcinoma, patients with PBRM1 mutations did not have a significantly different cancer specific survival."	23620406	PubMed		"Hakimi et al., 2013, Clin. Cancer Res."		3	accepted	420	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/420	https://civicdb.org/links/molecular_profiles/161	FALSE	PBRM1	55193	Mutation		chr3	52547841	52685836			ENST00000394830.3	75		"transcription_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
TET2 Mutation	157	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	N/A	"In patients with cytogenetically normal acute myeloid leukemia, those in the intermediate-I risk group with TET2 mutations did not have significantly different rates of event-free survival, complete remission, disease-free survival, or overall survival."	21343549	PubMed		"Metzeler et al., 2011, J. Clin. Oncol."		4	accepted	421	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/421	https://civicdb.org/links/molecular_profiles/157	FALSE	TET2	54790	Mutation		chr4	105146293	105279816			ENST00000513237.1	75		"gene_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
VHL Mutation	160	Clear Cell Renal Cell Carcinoma	4467				Prognostic	Supports	B	N/A	"In renal clear cell carcinoma, patients with VHL mutations did not have a significant impact on cancer specific survival."	23620406	PubMed		"Hakimi et al., 2013, Clin. Cancer Res."		3	accepted	422	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/422	https://civicdb.org/links/molecular_profiles/160	FALSE	VHL	7428	Mutation		chr3	10141008	10152220			ENST00000256474.2	75		"gene_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
BCL2 Overexpression	152	Diffuse Large B-cell Lymphoma	50745				Prognostic	Supports	B	Poor Outcome	"In patients with Diffuse Large B-Cell Lymphoma, those with increased levels of BCL2 were shown to have decreased overall, disease-free, and relapse-free survival."	9207459	PubMed		"Gascoyne et al., 1997, Blood"		4	accepted	423	N/A	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/423	https://civicdb.org/links/molecular_profiles/152	FALSE	BCL2	596	Overexpression		chr18	63123346	63320128			ENST00000398117.1	75		N/A		2023-01-09 21:52:05 UTC		N/A		FALSE
EZH2 Mutation	163	Myelodysplastic Syndrome	50908				Prognostic	Supports	B	Poor Outcome	"In myelodysplastic syndrome, patients with point mutations in EZH2 have worse overall survival that their wild-type counterparts."	20601954	PubMed		"Nikoloski et al., 2010, Nat. Genet."		3	accepted	425	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/425	https://civicdb.org/links/molecular_profiles/163	FALSE	EZH2	2146	Mutation		chr7	148807385	148884278			ENST00000320356.2	75		protein_altering_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
TET2 Mutation	157	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	"In patients classified as intermediate-risk via cytogenetics, TET2 mutations have been shown to be correlated with poor prognosis."	21828143	PubMed		"Chou et al., 2011, Blood"		4	accepted	426	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/426	https://civicdb.org/links/molecular_profiles/157	FALSE	TET2	54790	Mutation		chr4	105146293	105279816			ENST00000513237.1	75		"gene_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
TET2 Mutation	157	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	"In patients with cytogenetically normal acute myeloid leukemia, those in the ELN favorable-risk group with TET2 mutations had shorter event-free survival, lower rates of complete remission, and shorter disease-free survival."	21343549	PubMed		"Metzeler et al., 2011, J. Clin. Oncol."		4	accepted	427	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/427	https://civicdb.org/links/molecular_profiles/157	FALSE	TET2	54790	Mutation		chr4	105146293	105279816			ENST00000513237.1	75		"gene_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
VHL Loss-of-function	159	Clear Cell Renal Cell Carcinoma	4467				Prognostic	Supports	B	Poor Outcome	"In patients with renal clear cell carcinoma, patients with loss of function VHL mutations had shorter tumor-specific survival."	11793370	PubMed		"Schraml et al., 2002, J. Pathol."		3	accepted	428	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/428	https://civicdb.org/links/molecular_profiles/159	FALSE	VHL	7428	Loss-of-function		chr3	10141008	10152220			ENST00000256474.2	75		loss_of_function_variant	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
RUNX1 Mutation	155	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	"In 878 non-APL patients with AML, those who had mutations in RUNX1 (N=53) had higher rates of refractory disease than those without (30% versus 19%; P = 0.047)."	21343560	PubMed		"Gaidzik et al., 2011, J. Clin. Oncol."	"NCT00146120,NCT00151242"	4	accepted	429	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/429	https://civicdb.org/links/molecular_profiles/155	FALSE	RUNX1	861	Mutation		chr21	34787801	35049344			ENST00000300305.3	75		"transcript_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
RUNX1 Mutation	155	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	"In 878 non-APL patients with AML (18-60 years), those who had mutations in RUNX1 (N=53) had shorter event-free survival (8% vs 30%, P<0.0001) and relapse-free survival (26% vs 44%, P=0.022) relative to wild-type. EFS was also shorter for the cytogenetically normal (CN) subgroup with RUNX1 mutations (N=34; 10% vs 34%; P<0.0001) compared to wild-type (N=499), but only trending for relapse-free survival (29% vs 43%; P=0.21). For multivariate analysis, RUNX1 was a significant marker of inferior EFS in the entire cohort (P=0.011) and the intermediate-risk (P=0.005) subgroup but not the CN subgroup."	21343560	PubMed		"Gaidzik et al., 2011, J. Clin. Oncol."	"NCT00146120,NCT00151242"	4	accepted	430	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/430	https://civicdb.org/links/molecular_profiles/155	FALSE	RUNX1	861	Mutation		chr21	34787801	35049344			ENST00000300305.3	75		"transcript_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
FLI1 EWSR1::FLI1 e7-e6	164	Ewing Sarcoma	3369				Prognostic	Supports	B	Better Outcome	"In patients with Ewing's sarcoma, those with type 1 EWS-FLI1 fusions had longer overall survival than those with other types of EWS-FLI1 fusions."	9552022	PubMed		"de Alava et al., 1998, J. Clin. Oncol."		4	accepted	431	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/431	https://civicdb.org/links/molecular_profiles/164	FALSE	FLI1	2313	EWSR1::FLI1 e7-e6		chr22	29268018	29287134			ENST00000397938.2	75	ENST00000527786.2	transcript_fusion		2023-01-09 21:52:05 UTC		N/A	"EWSR1-FLI1 TYPE 1,EWSR1-FLI1 E7-E6"	FALSE
FLI1 EWSR1::FLI1 e7-e6	164	Ewing Sarcoma	3369				Prognostic	Supports	B	Better Outcome	"In patients with Ewing's sarcoma, those with type 1 EWS-FLI1 fusions had longer overall survival than those with other types of EWS-FLI1 fusions."	9552022	PubMed		"de Alava et al., 1998, J. Clin. Oncol."		4	accepted	431	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/431	https://civicdb.org/links/molecular_profiles/164	FALSE	FLI1	2313	EWSR1::FLI1 e7-e6		chr11	128805366	128813267			ENST00000397938.2	75	ENST00000527786.2	transcript_fusion		2023-01-09 21:52:05 UTC		N/A	"EWSR1-FLI1 TYPE 1,EWSR1-FLI1 E7-E6"	FALSE
EZH2 Y646	165	Diffuse Large B-cell Lymphoma	50745				Diagnostic	Supports	B	Positive	"Heterozygous mutations in EZH2 at Y641 were the second most frequent genetic event (after BCL2 t(14;18)) associated with a diagnosis of GCB-DLBCL in 35 / 320 patient samples. In contrast, mutations in EZH2 Y641 are not observed in centroblast samples from healthy controls."	20081860	PubMed		"Morin et al., 2010, Nat. Genet."		4	accepted	432	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/432	https://civicdb.org/links/molecular_profiles/165	FALSE	EZH2	2146	Y646		chr7	148811634	148811636			ENST00000320356.2	75		protein_altering_variant		2023-01-09 21:52:05 UTC		"3,762,187,676,837,620,000,000"	"Y641,TYR646"	FALSE
EZH2 Y646	165	Follicular Lymphoma	50873				Diagnostic	Supports	B	Positive	"Heterozygous mutations in EZH2 at Y641 were the second most frequent genetic event (after BCL2 t(14;18)) associated with a diagnosis of Follicular non-Hodgkin Lymphoma in 18 / 251 patient samples. In contrast, mutations in EZH2 Y641 are not observed in centroblast samples from healthy controls."	20081860	PubMed		"Morin et al., 2010, Nat. Genet."		4	accepted	433	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/433	https://civicdb.org/links/molecular_profiles/165	FALSE	EZH2	2146	Y646		chr7	148811634	148811636			ENST00000320356.2	75		protein_altering_variant		2023-01-09 21:52:05 UTC		"3,762,187,676,837,620,000,000"	"Y641,TYR646"	FALSE
KMT2D Loss-of-function	167	Follicular Lymphoma	50873				Diagnostic	Supports	B	Positive	"MLL2 was found to be the most frequently mutated gene in a sample of 31/35 follicular lymphoma patients and was not mutated in normal centroblast samples. Furthermore, MLL2 mutations were as frequently observed as t(14;18) Igh-BCL2 translocations, which are the most common clinically significant genetic event observed in follicular lymphoma. Mutations were predicted to be loss-of-function."	21796119	PubMed		"Morin et al., 2011, Nature"		3	accepted	435	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/435	https://civicdb.org/links/molecular_profiles/167	FALSE	KMT2D	8085	Loss-of-function		chr12	49018975	49055324			ENST00000301067.7	75		loss_of_function_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
BTK C481S	168	Chronic Lymphocytic Leukemia	1040		Ibrutinib		Predictive	Supports	B	Resistance	Whole exome sequencing of 6 chronic lymphocytic leukemia patients with acquired resistance to ibrutinib determined 5/6 patients harbored a C481S mutation in BTK.	24869598	PubMed		"Woyach et al., 2014, N. Engl. J. Med."		4	accepted	436	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/436	https://civicdb.org/links/molecular_profiles/168	FALSE	BTK	695	C481S		chrX	101356177	101356177	A	T	ENST00000308731.7	75		missense_variant	"ENST00000308731.7:c.1441T>A,NC_000023.10:g.100611165A>T,NM_000061.2:c.1441T>A,NP_000052.1:p.Cys481Ser"	2023-01-27 17:02:58 UTC	CA16602659	376204	"CYS481SER,RS1057519826"	FALSE
AKT1 Q79K	169	Melanoma	1909		Vemurafenib		Predictive	Supports	D	Resistance	The AKT1 Q79K mutation has been shown to confer resistance to BRAF inhibitors (vemurafenib) in melanoma cell line M229.	24265152	PubMed		"Shi et al., 2014, Cancer Discov"		4	accepted	439	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/439	https://civicdb.org/links/molecular_profiles/169	FALSE	AKT1	207	Q79K		chr14	104776711	104776711	G	T	ENST00000407796.2	75		missense_variant	"NC_000014.8:g.105243048G>T,NM_001014432.1:c.235C>A,NP_001014432.1:p.Gln79Lys,ENST00000407796.2:c.235C>A"	2023-01-27 17:02:59 UTC	CA16602625	376168	"Q17K,GLN79LYS,RS1057519804"	FALSE
APC Mutation	174	Colon Carcinoma	1520		JW55		Predictive	Supports	D	Sensitivity/Response	Canonical Wnt signaling in colon carcinoma cells with APC mutation was inhibited by JW55 treatment.	22440753	PubMed		"Waaler et al., 2012, Cancer Res."		3	accepted	445	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/445	https://civicdb.org/links/molecular_profiles/174	FALSE	APC	324	Mutation		chr5	112707521	112846239			ENST00000457016.1	75				2023-01-09 21:52:05 UTC				FALSE
APC Mutation	174	Colorectal Cancer	9256		G007-LK		Predictive	Supports	D	Sensitivity/Response	G007-LK inhibits in vivo tumor growth in a subset of APC-mutant colorectal cancers xenograft models but may be limited by intestinal toxicity.	23539443	PubMed		"Lau et al., 2013, Cancer Res."		4	accepted	446	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/446	https://civicdb.org/links/molecular_profiles/174	FALSE	APC	324	Mutation		chr5	112707521	112846239			ENST00000457016.1	75				2023-01-09 21:52:05 UTC				FALSE
AR F877L	175	Prostate Cancer	10283		"Apalutamide,Enzalutamide"	Substitutes	Predictive	Supports	D	Resistance	"Mutations F876L in the ligand binding domain of the androgen receptor confered resistance to enzalutamide and ARN-509, causing these compounds to function as partial agonists in two prostate cancer cell lines."	23779130	PubMed		"Joseph et al., 2013, Cancer Discov"		4	accepted	447	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/447	https://civicdb.org/links/molecular_profiles/175	FALSE	AR	367	F877L		chrX	67723707	67723707	T	C	ENST00000374690.3	75		missense_variant	"ENST00000374690.3:c.2629T>C,NC_000023.10:g.66943549T>C,NM_000044.4:c.2629T>C,NP_000035.2:p.Phe877Leu"	2023-01-27 17:03:02 UTC	CA16602789	376347	PHE877LEU	FALSE
AR W742	176	Prostate Carcinoma	10286		Bicalutamide		Predictive	Supports	D	Resistance	"LNCaP-FGC cells with mutations at codon 741 (W741C, W741L) were able to use bicalutamide as an AR agonist, promoting cell growth and increased prostate-specific antigen secretion."	12517791	PubMed		"Hara et al., 2003, Cancer Res."		4	accepted	448	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/448	https://civicdb.org/links/molecular_profiles/176	FALSE	AR	367	W742		chrX	67717528	67717530			ENST00000374690.3	75		missense_variant		2023-01-09 21:52:05 UTC		NONE FOUND	TRP742	FALSE
ASXL1 Mutation	177	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	"In patients with acute myeloid leukemia, in a univariate analysis those with mutations in ASXL1 had worse overall survival than wild-type."	25412851	PubMed		"Ohgami et al., 2015, Mod. Pathol."		2	accepted	449	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/449	https://civicdb.org/links/molecular_profiles/177	FALSE	ASXL1	171023	Mutation		chr20	32358352	32439319			ENST00000375687.4	75		protein_altering_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
ASXL1 Mutation	177	Acute Myeloid Leukemia	9119				Diagnostic	Supports	B	Positive	"Among patients with AML, those with mutations in ASXL1 were more likely to have the AML with myelodysplasia-related changes (AML-MRC) subtype."	25412851	PubMed		"Ohgami et al., 2015, Mod. Pathol."		3	accepted	450	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/450	https://civicdb.org/links/molecular_profiles/177	FALSE	ASXL1	171023	Mutation		chr20	32358352	32439319			ENST00000375687.4	75		protein_altering_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
ASXL1 Mutation	177	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	"In a meta-analysis of six studies totalling 3311 patients with non-M3 acute myeloid leukemia, those with mutations in ASXL1 had worse overall survival than wild-type patients (Hazard ratio 1.86, 95% CI 1.49-2.33)."	25308295	PubMed		"Shivarov et al., 2015, Leuk. Lymphoma"		4	accepted	451	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/451	https://civicdb.org/links/molecular_profiles/177	FALSE	ASXL1	171023	Mutation		chr20	32358352	32439319			ENST00000375687.4	75		protein_altering_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
ATM Mutation	178	Glioblastoma	3068		Temozolomide		Predictive	Supports	D	Sensitivity/Response	Glioblastoma cell lines were shown to have increased sensitivity to Temozolomide when siRNA-induced ATM knockdown was applied.	23960094	PubMed		"Eich et al., 2013, Mol. Cancer Ther."		3	accepted	452	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/452	https://civicdb.org/links/molecular_profiles/178	FALSE	ATM	472	Mutation		chr11	108222832	108369099			ENST00000278616.4	75		"transcription_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
ATM Mutation	178	Melanoma	1909		Temozolomide		Predictive	Supports	D	Sensitivity/Response	Melanoma cell lines were shown to have increased sensitivity to Temozolomide when siRNA-induced ATM knockdown was applied.	23960094	PubMed		"Eich et al., 2013, Mol. Cancer Ther."		3	accepted	453	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/453	https://civicdb.org/links/molecular_profiles/178	FALSE	ATM	472	Mutation		chr11	108222832	108369099			ENST00000278616.4	75		"transcription_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
ATM Underexpression	179	Cancer	162		"NU7441,KU-0060648"	Substitutes	Predictive	Supports	D	Sensitivity/Response	ATM-deficient H1395 and HT144 cancer cell lines showed growth inhibition when treated with DNA PKcs inhibitors KU-0060648 and NU7441. These agents also increased the lifespan of mice transfused with ATM-deficient lymphoma cells when compared with etoposide or control.	23761041	PubMed		"Riabinska et al., 2013, Sci Transl Med"		5	accepted	454	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/454	https://civicdb.org/links/molecular_profiles/179	FALSE	ATM	472	Underexpression		chr11	108222832	108369099			ENST00000278616.4	75		N/A		2023-01-09 21:52:05 UTC		N/A		FALSE
ATM Mutation	178	Hematologic Cancer	2531		Olaparib		Predictive	Supports	D	Sensitivity/Response	"Olaparib was found to inhibit cancer cell growth in ATM mutant cell lines of several blood cancers including Lymphoblastoid Leukemia, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, and in a murine xenograft model of Mantle Cell Lymphoma."	20739657	PubMed		"Weston et al., 2010, Blood"		5	accepted	455	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/455	https://civicdb.org/links/molecular_profiles/178	FALSE	ATM	472	Mutation		chr11	108222832	108369099			ENST00000278616.4	75		"transcription_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
AURKA Amplification	180	Esophagus Adenocarcinoma	4914		"Cisplatin,Alisertib"	Combination	Predictive	Supports	E	Sensitivity/Response	Antitumour effect of alisertib treatment in esophageal adenocarcinomas can be intensified in combination with cisplatin.	22302096	PubMed		"Sehdev et al., 2012, Mol. Cancer Ther."		3	accepted	456	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/456	https://civicdb.org/links/molecular_profiles/180	FALSE	AURKA	6790	Amplification		chr20	56369390	56392337			ENST00000395913.3	75		transcript_amplification		2023-01-09 21:52:05 UTC		N/A		FALSE
AURKA Overexpression	181	Cervical Adenocarcinoma	3702		Paclitaxel		Predictive	Supports	D	Resistance	"In the cervial andenocarcinoma cell line HeLa, when AURK-A was overexpressed, the cells were resistant to the apoptotic effects of Taxol."	12559175	PubMed		"Anand et al., 2003, Cancer Cell"		3	accepted	457	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/457	https://civicdb.org/links/molecular_profiles/181	FALSE	AURKA	6790	Overexpression		chr20	56369390	56392337			ENST00000395913.3	75		N/A		2023-01-09 21:52:05 UTC		N/A		FALSE
BAP1 EXPRESSION	182	Uveal Melanoma	6039				Prognostic	Supports	B	Better Outcome	"In patients with uveal melanoma, those with BAP1 expression (determined by immunohistochemical staining) had better survival."	25147369	PubMed		"van Essen et al., 2014, Br J Ophthalmol"		3	accepted	458	N/A	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/458	https://civicdb.org/links/molecular_profiles/182	FALSE	BAP1	8314	EXPRESSION		chr3	52401013	52410350			ENST00000460680.1	75		N/A		2023-01-09 21:52:05 UTC		N/A		FALSE
BAP1 Mutation	183	Clear Cell Renal Cell Carcinoma	4467				Prognostic	Supports	B	Poor Outcome	"In patients with clear cell renal cell carcinoma, in a multivariate analysis those with mutations in BAP1 had worse overall survival than wild-type."	23797736	PubMed		"Sato et al., 2013, Nat. Genet."		5	accepted	459	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/459	https://civicdb.org/links/molecular_profiles/183	FALSE	BAP1	8314	Mutation		chr3	52401013	52410350			ENST00000460680.1	75		"protein_altering_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
BAP1 Mutation	183	Renal Cell Carcinoma	4450				Prognostic	Supports	B	Poor Outcome	"In patients with clear cell renal cell carcinoma, in a multivariate analysis those with mutations in BAP1 had worse overall survival than wild-type."	23797736	PubMed		"Sato et al., 2013, Nat. Genet."		5	accepted	460	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/460	https://civicdb.org/links/molecular_profiles/183	FALSE	BAP1	8314	Mutation		chr3	52401013	52410350			ENST00000460680.1	75		"protein_altering_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
BAP1 Mutation	183	Clear Cell Renal Cell Carcinoma	4467				Prognostic	Supports	B	Poor Outcome	"In patients with clear cell renal cell carcinoma, those with nonsilent mutations of BAP1 had worse overall survival than wild-type."	23792563	PubMed		"2013, Nature"		5	accepted	461	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/461	https://civicdb.org/links/molecular_profiles/183	FALSE	BAP1	8314	Mutation		chr3	52401013	52410350			ENST00000460680.1	75		"protein_altering_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
BRAF AKAP9::BRAF	184	Thyroid Gland Papillary Carcinoma	3969				Diagnostic	Supports	B	Positive	"The AKAP9-BRAF fusion gene was found in 3/28 tumor samples of radiation-associated papillary thyroid carcinoma, and no samples of non-radiation associated papillary thyroid carcinoma. This fusion was associated with elevated BRAF kinase activity, similar to the V600E variant."	15630448	PubMed		"Ciampi et al., 2005, J. Clin. Invest."		4	accepted	462	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/462	https://civicdb.org/links/molecular_profiles/184	FALSE	BRAF	673	AKAP9::BRAF	BRAF Fusions	chr7	91940867	91995800			ENST00000356239.3	75	ENST00000288602.6	transcript_fusion	N/A	2023-01-09 21:52:05 UTC		N/A	AKAP9-BRAF	FALSE
BRAF AKAP9::BRAF	184	Thyroid Gland Papillary Carcinoma	3969				Diagnostic	Supports	B	Positive	"The AKAP9-BRAF fusion gene was found in 3/28 tumor samples of radiation-associated papillary thyroid carcinoma, and no samples of non-radiation associated papillary thyroid carcinoma. This fusion was associated with elevated BRAF kinase activity, similar to the V600E variant."	15630448	PubMed		"Ciampi et al., 2005, J. Clin. Invest."		4	accepted	462	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/462	https://civicdb.org/links/molecular_profiles/184	FALSE	BRAF	673	AKAP9::BRAF	BRAF Fusions	chr7	140734479	140787584			ENST00000356239.3	75	ENST00000288602.6	transcript_fusion	N/A	2023-01-09 21:52:05 UTC		N/A	AKAP9-BRAF	FALSE
BRAF V600E	12	Multiple Myeloma	9538				Prognostic	Supports	B	Poor Outcome	"In patients with multiple myeloma, those with BRAF V600E had shorter overall survival than wild-type."	23612012	PubMed		"Andrulis et al., 2013, Cancer Discov"		3	accepted	463	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/463	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
BRCA1 Mutation	185	Epithelial Ovarian Cancer	2152				Prognostic	Supports	B	Better Outcome	"In patients with invasive epithelial ovarian cancer, those with mutations in BRCA1 had better five-year overall survival."	22274685	PubMed		"Bolton et al., 2012, JAMA"		3	accepted	464	Rare Germline	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/464	https://civicdb.org/links/molecular_profiles/185	FALSE	BRCA1	672	Mutation		chr17	43045629	43125483			ENST00000471181.2	75		"gene_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
BRCA2 Mutation	186	Epithelial Ovarian Cancer	2152				Prognostic	Supports	B	Better Outcome	"In patients with invasive epithelial ovarian cancer, those with mutations in BRCA2 had better five-year overall survival."	22274685	PubMed		"Bolton et al., 2012, JAMA"		3	accepted	465	Rare Germline	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/465	https://civicdb.org/links/molecular_profiles/186	FALSE	BRCA2	675	Mutation		chr13	32315474	32399210			ENST00000380152.3	75		"gene_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
CCNE1 Amplification	187	Ovarian Carcinoma	4001				Prognostic	Supports	B	Poor Outcome	"In a retrospective study of 88 ovarian carcinomas, 18 had amplification of CCNE1. Those with amplification had worse overall and disease-free survival."	20336784	PubMed		"Nakayama et al., 2010, Cancer"		4	accepted	466	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/466	https://civicdb.org/links/molecular_profiles/187	FALSE	CCNE1	898	Amplification		chr19	29811898	29824308			ENST00000262643.3	75		transcript_amplification	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
CEBPA Mutation	29	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Better Outcome	"In children with acute myeloid leukemia, those with mutations in CEBPA had better overall and event-free survival and decreased cummulative incidence of relapse."	19304957	PubMed		"Ho et al., 2009, Blood"	"NCT00002798,NCT00070174"	4	accepted	467	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/467	https://civicdb.org/links/molecular_profiles/29	FALSE	CEBPA	1050	Mutation		chr19	33299934	33302564			ENST00000498907.2	75		"transcript_variant,loss_of_function_variant"		2023-01-09 21:52:04 UTC		N/A		FALSE
CEBPA Mutation	29	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Better Outcome	"In a set of 315 pediatric patients with acute myeloid leukemia, 47 had mutations in CEBPA. Those with mutations had better overall survival than wild-type patients."	25014773	PubMed		"Matsuo et al., 2014, Blood Cancer J"		4	accepted	468	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/468	https://civicdb.org/links/molecular_profiles/29	FALSE	CEBPA	1050	Mutation		chr19	33299934	33302564			ENST00000498907.2	75		"transcript_variant,loss_of_function_variant"		2023-01-09 21:52:04 UTC		N/A		FALSE
DNMT3A Mutation	189	T-cell Acute Lymphoblastic Leukemia	5603				Prognostic	Supports	B	Poor Outcome	"In adult patients with early (n = 30), cortical (n = 30), mature (n = 3) or unknown (n = 8) T-cell acute lymphoblastic leukemia, those with mutations in DNMT3A (n=12) had shorter overall survival than wild-type patients (n=59; p=0.011). This was also true for the subset of patients with early T-ALL DNMT3A-mutated (n = 8) compared to wild-type patients (n = 22; p=0.005)."	23341344	PubMed		"Grossmann et al., 2013, Genes Chromosomes Cancer"		4	accepted	469	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/469	https://civicdb.org/links/molecular_profiles/189	FALSE	DNMT3A	1788	Mutation		chr2	25232976	25342590			ENST00000264709.3	75		transcript_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
EGFR Amplification	190	Barrett's Adenocarcinoma	7941				Prognostic	Supports	B	Poor Outcome	"In patients with Barrett's adenocarcinoma, those with amplification of EGFR had shorter disease-specific survial."	20840671	PubMed		"Marx et al., 2010, Histopathology"		3	accepted	470	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/470	https://civicdb.org/links/molecular_profiles/190	FALSE	EGFR	1956	Amplification		chr7	55019101	55211628			ENST00000275493.2	75		transcript_amplification	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
EGFR Amplification	190	Cervical Squamous Cell Carcinoma	3744				Prognostic	Supports	B	Poor Outcome	"In patients with cervical squamous cell carcinoma, those with gene amplification of EGFR had worse overall survival."	21730982	PubMed		"Iida et al., 2011, Br. J. Cancer"		3	accepted	471	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/471	https://civicdb.org/links/molecular_profiles/190	FALSE	EGFR	1956	Amplification		chr7	55019101	55211628			ENST00000275493.2	75		transcript_amplification	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
EGFR Copy Number Variation	191	Head And Neck Squamous Cell Carcinoma	5520				Prognostic	Supports	B	Poor Outcome	"In 134 patients with head and neck squamous cancer 32 had copy number variations. Tumors with variation (either increase or decrease) in copy number of EGFR had worse overall, cancer-specific, and disease-free survival."	17538160	PubMed		"Temam et al., 2007, J. Clin. Oncol."		4	accepted	472	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/472	https://civicdb.org/links/molecular_profiles/191	FALSE	EGFR	1956	Copy Number Variation		chr7	55019101	55211628			ENST00000275493.2	75		copy_number_change		2023-01-09 21:52:05 UTC		N/A		FALSE
EGFR Amplification	190	Head And Neck Squamous Cell Carcinoma	5520				Prognostic	Supports	B	Poor Outcome	The group of 43 out of 75 tumor samples with increased copy number or amplification of EGFR as determined by FISH (FISH-positive) had worse progression-free and overall survival than FISH-negative tumors.	16943533	PubMed		"Chung et al., 2006, J. Clin. Oncol."		4	accepted	473	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/473	https://civicdb.org/links/molecular_profiles/190	FALSE	EGFR	1956	Amplification		chr7	55019101	55211628			ENST00000275493.2	75		transcript_amplification	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
EGFR Overexpression	193	Brain Glioblastoma Multiforme	3073				Prognostic	Supports	B	Poor Outcome	"In patients with glioblastoma multiforme, those with overespression of wild-type EGFR had shorter overall survival."	14583498	PubMed		"Shinojima et al., 2003, Cancer Res."		3	accepted	474	N/A	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/474	https://civicdb.org/links/molecular_profiles/193	FALSE	EGFR	1956	Overexpression		chr7	55019101	55211628			ENST00000275493.2	75		N/A		2023-01-09 21:52:05 UTC		N/A		FALSE
ERG EWSR1::ERG	194	Ewing Sarcoma	3369				Diagnostic	Supports	B	Positive	t(21;22) rearrangements of EWSR1-ERG are associated with a diagnosis of Ewing sarcoma and are the second most common gene fusion reported in this disease.	23706910	PubMed		"Warren et al., 2013, Hum. Pathol."		5	accepted	475	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/475	https://civicdb.org/links/molecular_profiles/194	FALSE	ERG	2078	EWSR1::ERG		chr22	29268018	29287134			ENST00000397938.2	75	ENST00000398907.1	transcript_fusion		2023-01-09 21:52:05 UTC		N/A	EWSR1-ERG	FALSE
ERG EWSR1::ERG	194	Ewing Sarcoma	3369				Diagnostic	Supports	B	Positive	t(21;22) rearrangements of EWSR1-ERG are associated with a diagnosis of Ewing sarcoma and are the second most common gene fusion reported in this disease.	23706910	PubMed		"Warren et al., 2013, Hum. Pathol."		5	accepted	475	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/475	https://civicdb.org/links/molecular_profiles/194	FALSE	ERG	2078	EWSR1::ERG		chr21	38380027	38383923			ENST00000397938.2	75	ENST00000398907.1	transcript_fusion		2023-01-09 21:52:05 UTC		N/A	EWSR1-ERG	FALSE
ERG TMPRSS2::ERG	195	Prostate Carcinoma	10286				Diagnostic	Supports	B	Positive	"TMPRSS2/ERG gene fusion was observed in 23 of 29 (79%) of prostate carcinoma samples, and 90% of ERG expression positive prostate carcinoma samples."	16254181	PubMed		"Tomlins et al., 2005, Science"		3	accepted	476	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/476	https://civicdb.org/links/molecular_profiles/195	FALSE	ERG	2078	TMPRSS2::ERG		chr21	41507950	41508065			ENST00000398585.3	75	ENST00000398910.1	transcript_fusion		2023-01-09 21:52:05 UTC		N/A	TMPRSS2-ERG	FALSE
ERG TMPRSS2::ERG	195	Prostate Carcinoma	10286				Diagnostic	Supports	B	Positive	"TMPRSS2/ERG gene fusion was observed in 23 of 29 (79%) of prostate carcinoma samples, and 90% of ERG expression positive prostate carcinoma samples."	16254181	PubMed		"Tomlins et al., 2005, Science"		3	accepted	476	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/476	https://civicdb.org/links/molecular_profiles/195	FALSE	ERG	2078	TMPRSS2::ERG		chr21	38380027	38445621			ENST00000398585.3	75	ENST00000398910.1	transcript_fusion		2023-01-09 21:52:05 UTC		N/A	TMPRSS2-ERG	FALSE
FGFR3 Y373C	2277	Bladder Carcinoma	4007				Diagnostic	Supports	B	Positive	Y375C mutation results in activation of FGFR3 and is associated with bladder carcinoma. Patients with low-grade tumors were more likely to have FGFR3 mutations than those with high-grade tumors.	20542753	PubMed		"Bodoor et al., 2010, Cancer Epidemiol"		3	accepted	477	Somatic	2023-01-09 21:46:58 UTC	https://civicdb.org/links/evidence_items/477	https://civicdb.org/links/molecular_profiles/2277	FALSE	FGFR3	2261	Y373C		chr4	1804372	1804372	A	G	ENST00000440486.2	75		missense_variant	"NC_000004.11:g.1806099A>G,NM_001163213.1:c.1124A>G,NP_000133.1:p.Tyr373Cys,NM_000142.5:c.1118A>G,NC_000004.12:g.1804372A>G"	2023-01-27 17:16:37 UTC	CA341413	16342	"TYR375CYS,RS121913485,Y375C,TYR373CYS"	FALSE
EWSR1 EWSR1::FLI1	687	Ewing Sarcoma	3369				Diagnostic	Supports	B	Positive	"t(11;22) rearrangements of EWSR1-FLI1 are diagnostic of ewing sarcoma, and are observed in 90% of cytogenetic samples."	23706910	PubMed		"Warren et al., 2013, Hum. Pathol."		5	accepted	478	Somatic	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/478	https://civicdb.org/links/molecular_profiles/687	FALSE	EWSR1	2130	EWSR1::FLI1		chr22	29268318	29292169			ENST00000414183.2	75	ENST00000527786.2	transcript_fusion		2023-01-09 21:52:08 UTC		N/A	"EWS-FLI,T(11;22)(Q24;Q12),EWSR1-FLI1"	FALSE
EWSR1 EWSR1::FLI1	687	Ewing Sarcoma	3369				Diagnostic	Supports	B	Positive	"t(11;22) rearrangements of EWSR1-FLI1 are diagnostic of ewing sarcoma, and are observed in 90% of cytogenetic samples."	23706910	PubMed		"Warren et al., 2013, Hum. Pathol."		5	accepted	478	Somatic	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/478	https://civicdb.org/links/molecular_profiles/687	FALSE	EWSR1	2130	EWSR1::FLI1		chr11	128768118	128813267			ENST00000414183.2	75	ENST00000527786.2	transcript_fusion		2023-01-09 21:52:08 UTC		N/A	"EWS-FLI,T(11;22)(Q24;Q12),EWSR1-FLI1"	FALSE
FOXL2 C134W	198	Ovarian Granulosa Cell Tumor	2999				Diagnostic	Supports	B	Positive	"FOXL2 C134W mutation was found in 52 / 56 adult granulosa cell tumors, and is absent in other types of sex-cord stromal tumors, and juvenile granulosa tumors."	20693978	PubMed		"Jamieson et al., 2010, Mod. Pathol."		4	accepted	479	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/479	https://civicdb.org/links/molecular_profiles/198	FALSE	FOXL2	668	C134W		chr3	138946321	138946321	G	C	ENST00000330315.3	75		missense_variant	NC_000003.11:g.138665163G>C	2023-01-27 17:03:03 UTC	CA16602790			FALSE
IDH1 R132	58	Glioblastoma	3068				Prognostic	Supports	B	Better Outcome	"In patients with a glioblastoma, those with mutations at R132 of IDH1 had better overall survival than wild-type patients."	19228619	PubMed		"Yan et al., 2009, N. Engl. J. Med."		5	accepted	480	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/480	https://civicdb.org/links/molecular_profiles/58	FALSE	IDH1	3417	R132		chr2	208248387	208248389			ENST00000415913.1	75		protein_altering_variant	"NC_000002.11:g.209113113G>A,NC_000002.11:g.209113112C>T,NC_000002.11:g.209113113G>C,NC_000002.11:g.209113112C>A,NC_000002.11:g.209113113G>T,NC_000002.11:g.209113112C>G"	2023-01-09 21:52:04 UTC		"156,444,375,891,375,000,000,000,000,000,000,000"	ARG132	FALSE
IDH1 R132	58	Malignant Astrocytoma	3069				Prognostic	Supports	B	Better Outcome	"In patients with anaplastic astrocytoma, those with mutations at R132 of IDH1 had better overall survival than wild-type patients."	19228619	PubMed		"Yan et al., 2009, N. Engl. J. Med."		5	accepted	481	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/481	https://civicdb.org/links/molecular_profiles/58	FALSE	IDH1	3417	R132		chr2	208248387	208248389			ENST00000415913.1	75		protein_altering_variant	"NC_000002.11:g.209113113G>A,NC_000002.11:g.209113112C>T,NC_000002.11:g.209113113G>C,NC_000002.11:g.209113112C>A,NC_000002.11:g.209113113G>T,NC_000002.11:g.209113112C>G"	2023-01-09 21:52:04 UTC		"156,444,375,891,375,000,000,000,000,000,000,000"	ARG132	FALSE
IDH2 R172	199	Glioblastoma	3068				Prognostic	Supports	B	Better Outcome	"In patients with a glioblastoma, those with mutations at R172 of IDH2 had better overall survival than wild-type patients."	19228619	PubMed		"Yan et al., 2009, N. Engl. J. Med."		5	accepted	482	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/482	https://civicdb.org/links/molecular_profiles/199	FALSE	IDH2	3418	R172		chr15	90088605	90088607			ENST00000330062.3	75		protein_altering_variant		2023-01-09 21:52:05 UTC		N/A	ARG172	FALSE
IDH2 R172	199	Malignant Astrocytoma	3069				Prognostic	Supports	B	Better Outcome	"In patients with anaplastic astrocytoma, those with mutations at R172 of IDH2 had better overall survival than wild-type patients."	19228619	PubMed		"Yan et al., 2009, N. Engl. J. Med."		5	accepted	483	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/483	https://civicdb.org/links/molecular_profiles/199	FALSE	IDH2	3418	R172		chr15	90088605	90088607			ENST00000330062.3	75		protein_altering_variant		2023-01-09 21:52:05 UTC		N/A	ARG172	FALSE
KIT M541L	201	Chronic Myeloid Leukemia	8552				Diagnostic	Does Not Support	B	Positive	"M541L mutation was not associated with CML in caucasian patients, and was common among healthy controls (8.1%), in contrast to a previous study in a Japanese CML patient population in which M541L was strongly associated with CML disease."	16307017	PubMed		"Krger et al., 2006, Leukemia"		4	accepted	485	Common Germline	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/485	https://civicdb.org/links/molecular_profiles/201	FALSE	KIT	3815	M541L		chr4	54727298	54727298	A	C	ENST00000288135.5	75		missense_variant	"NM_000222.2:c.1621A>C,NP_000213.1:p.Met541Leu,ENST00000288135.5:c.1621A>C,NC_000004.11:g.55593464A>C"	2023-01-27 17:03:04 UTC	CA160347	41599	"MET541LEU,RS3822214"	FALSE
KIT V560DEL	202	Thymic Carcinoma	3284		Imatinib		Predictive	Supports	C	Sensitivity/Response	"In a patient with thymic carcinoma, the tumor expressing an activating mutation in exon 11 of KIT (V560del) was sensitive to imatinib."	15201427	PubMed		"Strbel et al., 2004, N. Engl. J. Med."		5	accepted	486	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/486	https://civicdb.org/links/molecular_profiles/202	FALSE	KIT	3815	V560DEL		chr4	54727446	54727448	GTT		ENST00000288135.5	75		"amino_acid_deletion,inframe_deletion"	"NC_000004.11:g.55593612_55593614del,ENST00000288135.5:c.1675_1677delGTT,NM_000222.2:c.1675_1677delGTT,NP_000213.1:p.Val560del"	2023-01-27 17:03:05 UTC	CA123529	13859	"VAL560DEL,V559DEL,V555DEL,V556DEL"	FALSE
KRAS G12	76	Multiple Myeloma	9538				Prognostic	Supports	B	Poor Outcome	"In a retrospective study of 439 patients with multiple myeloma enrolled in a clinical trial, 28 had mutations in KRAS (22/28 in G12/G13). Those with KRAS (but not NRAS) mutations had worse overall (median 19.9 vs 44.3 months, p=0.005) and progression free survival (median 14.7 vs 30.3 months, p<0.001) than those without mutations."	18528420	PubMed		"Chng et al., 2008, Leukemia"		4	accepted	487	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/487	https://civicdb.org/links/molecular_profiles/76	FALSE	KRAS	3845	G12		chr12	25245350	25245351			ENST00000256078.4	75		protein_altering_variant		2023-01-09 21:52:04 UTC		"451,221,257,812,582,000,000,000,000,000"	GLY12	FALSE
KRAS G13	80	Multiple Myeloma	9538				Prognostic	Supports	B	Poor Outcome	"In a retrospective study of 439 patients with multiple myeloma enrolled in a clinical trial, 28 had mutations in KRAS (22/28 in G12/G13). Those with KRAS (but not NRAS) mutations had worse overall (median 19.9 vs 44.3 months, p=0.005) and progression free survival (median 14.7 vs 30.3 months, p<0.001) than those without mutations."	18528420	PubMed		"Chng et al., 2008, Leukemia"		4	accepted	488	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/488	https://civicdb.org/links/molecular_profiles/80	FALSE	KRAS	3845	G13		chr12	25245347	25245348			ENST00000256078.4	75		"missense_variant,inframe_insertion"		2023-01-09 21:52:04 UTC		"1,258,045,123,125,930,000,000,000,000,000,000,000,000,000"	GLY13	FALSE
KRAS Q61	203	Multiple Myeloma	9538				Prognostic	Supports	B	Poor Outcome	"In a retrospective study of 439 patients with multiple myeloma enrolled in a clinical trial, 28 had mutaions in KRAS. Those with mutations had worse overall and progression free survival than those without mutations."	18528420	PubMed		"Chng et al., 2008, Leukemia"		4	accepted	489	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/489	https://civicdb.org/links/molecular_profiles/203	FALSE	KRAS	3845	Q61		chr12	25227341	25227343			ENST00000256078.4	75		protein_altering_variant		2023-01-09 21:52:05 UTC		"177,881,177,777,451,000,000,000,000,000,000,000,000"	GLN61	FALSE
MGMT Promoter Methylation	85	Oligodendroglioma	3181				Prognostic	Supports	B	Better Outcome	"In a study of 152 anaplastic oligodendroglial tumors, 121 samples had MGMT promoter methylation. Those with promoter methylation had better progression-free and overall survival."	19901104	PubMed		"van den Bent et al., 2009, J. Clin. Oncol."		4	accepted	490	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/490	https://civicdb.org/links/molecular_profiles/85	FALSE	MGMT	4255	Promoter Methylation		chr10	129466231	129467392			ENST00000306010.7	75		N/A		2023-01-09 21:52:04 UTC		N/A		FALSE
MGMT Promoter Methylation	85	Glioblastoma	3068				Prognostic	Supports	B	Better Outcome	"In patients with glioblastoma, those with methylated MGMT promoters have better overall survival than those with unmethylated promoters."	15758010	PubMed		"Hegi et al., 2005, N. Engl. J. Med."		5	accepted	491	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/491	https://civicdb.org/links/molecular_profiles/85	FALSE	MGMT	4255	Promoter Methylation		chr10	129466231	129467392			ENST00000306010.7	75		N/A		2023-01-09 21:52:04 UTC		N/A		FALSE
NCOA3 AMPLIFICATION	204	Breast Cancer	1612				Prognostic	Supports	B	Poor Outcome	"In patients with breast cancer, those with amplification of NCOA3 had shorter disease-specific survival."	23322234	PubMed		"Burandt et al., 2013, Breast Cancer Res. Treat."		3	accepted	492	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/492	https://civicdb.org/links/molecular_profiles/204	FALSE	NCOA3	8202	AMPLIFICATION		chr20	47501902	47656877			ENST00000372004.3	75		transcript_amplification	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
NCOA3 OVEREXPRESSION	205	Breast Cancer	1612				Prognostic	Supports	B	Poor Outcome	"High expression determined by immunohistochemistry of NCOA3 was found in 571 out of 1,836 breast cancer samples. Those with high expression had worse overall and disease-specific survival."	23322234	PubMed		"Burandt et al., 2013, Breast Cancer Res. Treat."		3	accepted	493	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/493	https://civicdb.org/links/molecular_profiles/205	FALSE	NCOA3	8202	OVEREXPRESSION		chr20	47501902	47656877			ENST00000372004.3	75		N/A	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
NOTCH1 Mutation	206	Mantle Cell Lymphoma	50746				Prognostic	Supports	B	Poor Outcome	"14 out of 121 patient samples contained mutations in NOTCH1. Those with mutations had worse overall survival than wild-type (median OS, 1.43 years vs. 3.86 years)."	22210878	PubMed		"Kridel et al., 2012, Blood"		3	accepted	494	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/494	https://civicdb.org/links/molecular_profiles/206	FALSE	NOTCH1	4851	Mutation		chr9	136494444	136545862			ENST00000277541.6	75		protein_altering_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
NOTCH1 P2514FS	207	Chronic Lymphocytic Leukemia	1040				Prognostic	Supports	B	Poor Outcome	"In a cohort of 120 patients with chronic lymphoytic leukemia, those with P2515 frameshift deletions in NOTCH1 at diagnosis had worse overall and treatment free survival. NOTCH1 mutations were also found to be an independent poor predictor of survival regardless of TP53 and IGHV status."	21670202	PubMed		"Fabbri et al., 2011, J. Exp. Med."		3	accepted	495	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/495	https://civicdb.org/links/molecular_profiles/207	FALSE	NOTCH1	4851	P2514FS		chr9	136496197	136496198			ENST00000277541.6	75		frameshift_truncation	NC_000009.11:g.139390649_139390650del	2023-01-09 21:52:05 UTC		NONE FOUND	PRO2514ARGFS	FALSE
NRAS Mutation	208	Multiple Myeloma	9538				Prognostic	Supports	B	N/A	"In patients with multiple myeloma, the presence of a mutation in NRAS was not significantly associated with progression-free or overall survival."	18528420	PubMed		"Chng et al., 2008, Leukemia"		4	accepted	496	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/496	https://civicdb.org/links/molecular_profiles/208	FALSE	NRAS	4893	Mutation		chr1	114704469	114716894			ENST00000369535.4	75		"transcript_variant,gain_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
NRAS Q61	94	Thyroid Gland Follicular Carcinoma	3962				Prognostic	Supports	B	N/A	"In patients with follicular thyroid carcinoma, those with mutations in NRAS at codon 61 did not have significantly different overall survival than patients with wild-type NRAS (p=0.36)."	22650231	PubMed		"Fukahori et al., 2012, Thyroid"		3	accepted	497	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/497	https://civicdb.org/links/molecular_profiles/94	FALSE	NRAS	4893	Q61		chr1	114713907	114713909			ENST00000369535.4	75		missense_variant		2023-01-09 21:52:04 UTC		"7,305,813,900,375,870,000,000,000,000,000,000,000,000"	GLN61	FALSE
PAX8 PAX8::PPARG	209	Thyroid Gland Follicular Carcinoma	3962				Diagnostic	Supports	B	Positive	"PAX8PPARG gene fusions were found in 12/33 follicular thyroid carcinoma tumor samples, but were rarely found in thyroid Hrthle cell tumors."	12727991	PubMed		"Nikiforova et al., 2003, J. Clin. Endocrinol. Metab."		3	accepted	498	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/498	https://civicdb.org/links/molecular_profiles/209	FALSE	PAX8	7849	PAX8::PPARG		chr2	113235394	113278944			ENST00000429538.3	75	ENST00000397015.2	transcript_fusion		2023-01-09 21:52:05 UTC		N/A	"T(2;3)(Q13;P25),PAX8-PPARG"	FALSE
PAX8 PAX8::PPARG	209	Thyroid Gland Follicular Carcinoma	3962				Diagnostic	Supports	B	Positive	"PAX8PPARG gene fusions were found in 12/33 follicular thyroid carcinoma tumor samples, but were rarely found in thyroid Hrthle cell tumors."	12727991	PubMed		"Nikiforova et al., 2003, J. Clin. Endocrinol. Metab."		3	accepted	498	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/498	https://civicdb.org/links/molecular_profiles/209	FALSE	PAX8	7849	PAX8::PPARG		chr3	12287901	12434311			ENST00000429538.3	75	ENST00000397015.2	transcript_fusion		2023-01-09 21:52:05 UTC		N/A	"T(2;3)(Q13;P25),PAX8-PPARG"	FALSE
PBRM1 Mutation	161	Renal Cell Carcinoma	4450				Prognostic	Supports	B	Better Outcome	"In patients with sporatic clear cell renal cell carcinoma, those with mutations in PBRM1 had better overall survival than patients with BAP1 mutations."	23333114	PubMed		"Kapur et al., 2013, Lancet Oncol."		3	accepted	499	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/499	https://civicdb.org/links/molecular_profiles/161	FALSE	PBRM1	55193	Mutation		chr3	52547841	52685836			ENST00000394830.3	75		"transcription_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
PGR Expression	210	Breast Cancer	1612				Prognostic	Supports	B	Better Outcome	"In patients with breast cancer, those with expression of PgR (determined by immunohistochemical staining) had better relapse-free survival than those without expression."	16497822	PubMed		"Dowsett et al., 2006, Ann. Oncol."		3	accepted	500	N/A	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/500	https://civicdb.org/links/molecular_profiles/210	FALSE	PGR	5241	Expression		chr11	101029624	101130524			ENST00000325455.5	75		N/A		2023-01-09 21:52:05 UTC		N/A		FALSE
PGR Expression	210	Breast Cancer	1612		Tamoxifen		Predictive	Does Not Support	B	Sensitivity/Response	"In patients with ER-Positive breast cancer, expression of PgR does not effect the outcome of treatment with tamoxifen."	23280579	PubMed		"Patani et al., 2013, Int. J. Cancer"		1	accepted	501	N/A	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/501	https://civicdb.org/links/molecular_profiles/210	FALSE	PGR	5241	Expression		chr11	101029624	101130524			ENST00000325455.5	75		N/A		2023-01-09 21:52:05 UTC		N/A		FALSE
PGR Expression	210	Breast Cancer	1612		"Exemestane,Tamoxifen"	Substitutes	Predictive	Does Not Support	B	Sensitivity/Response	"Multivariate Cox regression analysis showed no disease free survival benefit for exemestane compared with tamoxifen in either PgR-low (n=984; HR, 0.85; 95% CI, 0.61 to 1.19) or PgR-high (n=3,341; HR, 0.83; 95% CI, 0.65 to 1.05) breast cancer patients (P=.88 for interaction)."	21422407	PubMed		"Bartlett et al., 2011, J. Clin. Oncol."		4	accepted	502	N/A	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/502	https://civicdb.org/links/molecular_profiles/210	FALSE	PGR	5241	Expression		chr11	101029624	101130524			ENST00000325455.5	75		N/A		2023-01-09 21:52:05 UTC		N/A		FALSE
PGR Expression	210	Breast Cancer	1612				Prognostic	Supports	B	Poor Outcome	"In patients with breast cancer, those with low expression of PgR had worse disease-free survival than those with high expression."	21422407	PubMed		"Bartlett et al., 2011, J. Clin. Oncol."		4	accepted	503	N/A	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/503	https://civicdb.org/links/molecular_profiles/210	FALSE	PGR	5241	Expression		chr11	101029624	101130524			ENST00000325455.5	75		N/A		2023-01-09 21:52:05 UTC		N/A		FALSE
PIK3CA Amplification	212	Gastric Adenocarcinoma	3717				Prognostic	Supports	B	Poor Outcome	"In patients with gastric cancer, those with amplification of PIK3CA had shorter overall survival than those without amplification."	22292935	PubMed		"Shi et al., 2012, BMC Cancer"		3	accepted	504	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/504	https://civicdb.org/links/molecular_profiles/212	FALSE	PIK3CA	5290	Amplification		chr3	179148523	179240093			ENST00000263967.3	75		transcript_amplification	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
PTEN Deletion	213	Prostate Adenocarcinoma	2526				Prognostic	Supports	B	Poor Outcome	"In a study of 107 prostate adenocarcinomas, those with either hemi- or homozygous deletions of PTEN (as determined by interphase FISH) have shorter biochemical recurence-free survival than those without deletions."	17700571	PubMed		"Yoshimoto et al., 2007, Br. J. Cancer"		4	accepted	505	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/505	https://civicdb.org/links/molecular_profiles/213	FALSE	PTEN	5728	Deletion		chr10	87863113	87971930			ENST00000371953.3	75		transcript_ablation		2023-01-09 21:52:05 UTC		NONE FOUND		FALSE
PTEN Loss	214	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	B	Resistance	"In 27 patients with chemotherapy-naive or chemotherapy-refractory metastatic colorectal cancer who were treated with cetuximab and chemotherapy, PTEN loss was associated with non-response."	21163703	PubMed		"De Roock et al., 2011, Lancet Oncol."		3	accepted	506	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/506	https://civicdb.org/links/molecular_profiles/214	FALSE	PTEN	5728	Loss		chr10	87863113	87971930			ENST00000371953.3	75		loss_of_function_variant	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
PTEN Loss	214	Prostate Cancer	10283		Temsirolimus		Predictive	Supports	D	Sensitivity/Response	"In prostate cancer xenographs, PTEN null tumors had a significant decrease in cell size and proliferation when treated with Temsirolimus (CCI-779)."	11504908	PubMed		"Neshat et al., 2001, Proc. Natl. Acad. Sci. U.S.A."		4	accepted	507	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/507	https://civicdb.org/links/molecular_profiles/214	FALSE	PTEN	5728	Loss		chr10	87863113	87971930			ENST00000371953.3	75		loss_of_function_variant	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
RUNX1 Mutation	155	Acute Lymphoblastic Leukemia	9952				Prognostic	Supports	B	Poor Outcome	"In univariate analysis, mutations in RUNX1 were significantly associated with shorter overall survival compared to wildtype RUNX1 in adult (18-87 years old) T-cell acute lymphoblastic leukemia (N=9 mutated, 62 wild type patients; P=0.014) and the early subtype (N=7 mutated, 23 wild type patients; P=0.027). RUNX1 mutations were associated with other poor-risk parameters, early subtype and older age."	23341344	PubMed		"Grossmann et al., 2013, Genes Chromosomes Cancer"		3	accepted	508	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/508	https://civicdb.org/links/molecular_profiles/155	FALSE	RUNX1	861	Mutation		chr21	34787801	35049344			ENST00000300305.3	75		"transcript_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
RUNX1 Mutation	155	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	"In a study of patients with cytogenically normal acute myeloid leukemia, RUNX1 mutations were more frequent in patients 60 years old or older. Patients with RUNX1 mutations had shorter disease-free (younger, P = 0.058; older, P < 0.001), event-free (both, P < 0.001), and overall survival (younger, P = 0.003; older, P < 0.001) as well as lower complete remission rates (younger, P = 0.005; older, P = 0.006)."	22753902	PubMed		"Mendler et al., 2012, J. Clin. Oncol."		4	accepted	509	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/509	https://civicdb.org/links/molecular_profiles/155	FALSE	RUNX1	861	Mutation		chr21	34787801	35049344			ENST00000300305.3	75		"transcript_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
SF3B1 Mutation	215	Chronic Lymphocytic Leukemia	1040				Prognostic	Supports	B	Poor Outcome	"In patients with chronic lymphocytic leukemia, those with mutations in SF3B1 had shorter time to treatment, progression-free survival, and overall survival. A majority of the mutations are in the C-terminal domain with the most frequent location being K700E (50% of reported cases)."	23568491	PubMed		"Wan et al., 2013, Blood"		4	accepted	510	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/510	https://civicdb.org/links/molecular_profiles/215	FALSE	SF3B1	23451	Mutation		chr2	197389784	197435091			ENST00000335508.6	75		protein_altering_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
SMAD4 Mutation	216	Pancreatic Adenocarcinoma	4074				Prognostic	Supports	B	Poor Outcome	"In a study of 89 patients with adenocarcinoma of the pancreas who underwent a pancreaticoduodenectomy, those with mutations in SMAD4 had shorter overall survival than wild-type patients."	19584151	PubMed		"Blackford et al., 2009, Clin. Cancer Res."		3	accepted	511	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/511	https://civicdb.org/links/molecular_profiles/216	FALSE	SMAD4	4089	Mutation		chr18	51030213	51085039			ENST00000342988.3	75		"transcript_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
SMARCA4 MUTATION	217	Small-cell Carcinoma Of The Ovary Of Hypercalcemic Type	7651				Diagnostic	Supports	B	Positive	"Nonsense mutations in SMARCA4 were associated with small cell carcinoma of the ovary, hypercalcemic type in 10/10 tumor samples, and were rarely found in other solid tumor types catalogued by TCGA."	24658004	PubMed		"Jelinic et al., 2014, Nat. Genet."		5	accepted	512	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/512	https://civicdb.org/links/molecular_profiles/217	FALSE	SMARCA4	6597	MUTATION		chr19	10960922	11062282			ENST00000358026.2	75		"gene_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
SMARCA4 INACTIVATING MUTATION	218	Lung Adenocarcinoma	3910				Prognostic	Supports	B	Poor Outcome	"In patients with lung adenocarcinoma, those with loss-of-function mutations in SMARCA4 had worse overall survival than those with only missense or no mutations."	24658004	PubMed		"Jelinic et al., 2014, Nat. Genet."		4	accepted	513	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/513	https://civicdb.org/links/molecular_profiles/218	FALSE	SMARCA4	6597	INACTIVATING MUTATION		chr19	10960922	11062282			ENST00000358026.2	75		loss_of_function_variant		2023-01-09 21:52:05 UTC				FALSE
TERT Amplification	219	Acral Lentiginous Melanoma	6367				Prognostic	Supports	B	Poor Outcome	"In patients with acral lentiginous melanoma, those with amplification of TERT had shorter overall survival."	25219713	PubMed		"Diaz et al., 2014, J. Am. Acad. Dermatol."		3	accepted	514	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/514	https://civicdb.org/links/molecular_profiles/219	FALSE	TERT	7015	Amplification		chr5	1253167	1295047			ENST00000310581.5	75		transcript_amplification		2023-01-09 21:52:05 UTC		N/A		FALSE
TERT Promoter Mutation	220	Skin Melanoma	8923				Prognostic	Supports	B	Poor Outcome	"In patients with nonacral cutaneous melanoma, those with mutations in the TERT promoter had shorter overall survival than wild-type patients."	25217772	PubMed		"Griewank et al., 2014, J. Natl. Cancer Inst."		3	accepted	515	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/515	https://civicdb.org/links/molecular_profiles/220	FALSE	TERT	7015	Promoter Mutation		chr5	1295046	1295258			ENST00000310581.5	75		regulatory_region_variant		2023-01-09 21:52:05 UTC			"-124C>T,-146C>T"	FALSE
TERT Promoter Mutation	220	Glioblastoma	3068				Prognostic	Supports	B	Poor Outcome	"In 187 patients with glioblastoma, those with TERT promoter mutations had worse cummulative survival than wild-type patients. The most common mutation was C228T (73% of mutants) followed by C250T (27% of mutants). However, most of the Prognostic value of TERT mutations is thought to be derived from their inverse coorelation with IDH1 mutations."	23955565	PubMed		"Nonoguchi et al., 2013, Acta Neuropathol."		4	accepted	516	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/516	https://civicdb.org/links/molecular_profiles/220	FALSE	TERT	7015	Promoter Mutation		chr5	1295046	1295258			ENST00000310581.5	75		regulatory_region_variant		2023-01-09 21:52:05 UTC			"-124C>T,-146C>T"	FALSE
TP53 Deleterious Mutation	221	Head And Neck Squamous Cell Carcinoma	5520				Prognostic	Supports	B	Poor Outcome	"In a study of 74 patients with head and neck squamous cell carcinoma, those with disruptive mutations in TP53 had shorter overall survival and a higher rate of locoregional recurrence than those without mutations or with nondisruptive mutations."	22090360	PubMed		"Skinner et al., 2012, Clin. Cancer Res."		3	accepted	517	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/517	https://civicdb.org/links/molecular_profiles/221	FALSE	TP53	7157	Deleterious Mutation		chr17	7668402	7687538			ENST00000269305.4	75		N/A		2023-01-09 21:52:05 UTC				FALSE
TP53 Mutation	222	Head And Neck Squamous Cell Carcinoma	5520				Prognostic	Does Not Support	B	Poor Outcome	"Unlike other studies, in this study of 110 patients with head and neck squamous cell carcinoma, there was no significant difference in the overall survival of patients with and without any TP53 mutations."	8901856	PubMed		"Koch et al., 1996, J. Natl. Cancer Inst."		3	accepted	518	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/518	https://civicdb.org/links/molecular_profiles/222	FALSE	TP53	7157	Mutation		chr17	7668402	7687538			ENST00000269305.4	75		protein_altering_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
TP53 Mutation	222	Esophagus Squamous Cell Carcinoma	3748				Prognostic	Supports	B	Poor Outcome	"In a retrospective study of patients with esophageal carcinoma, those with mutations in TP53 had worse overall survival."	19941080	PubMed		"Yamasaki et al., 2010, Ann. Surg. Oncol."		4	accepted	519	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/519	https://civicdb.org/links/molecular_profiles/222	FALSE	TP53	7157	Mutation		chr17	7668402	7687538			ENST00000269305.4	75		protein_altering_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
TP53 Mutation	222	B-lymphoblastic Leukemia/lymphoma	80630				Prognostic	Supports	B	Poor Outcome	"In children with bone marrow relapsed B-cell precursor acute lymphoblastic leukemia, in multivariate analysis those with mutations in TP53 had worse event-free survival than patients without mutations."	22699455	PubMed		"Krentz et al., 2013, Leukemia"		4	accepted	520	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/520	https://civicdb.org/links/molecular_profiles/222	FALSE	TP53	7157	Mutation		chr17	7668402	7687538			ENST00000269305.4	75		protein_altering_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
TP53 Mutation	222	Myelodysplastic Syndrome	50908				Prognostic	Supports	B	Poor Outcome	"In patients with myelodysplastic syndrome, in a multivariate analysis those with mutations in TP53 had shorter overall survival than wild-type patients."	24836762	PubMed		"Bally et al., 2014, Leuk. Res."		4	accepted	521	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/521	https://civicdb.org/links/molecular_profiles/222	FALSE	TP53	7157	Mutation		chr17	7668402	7687538			ENST00000269305.4	75		protein_altering_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
TP53 Mutation	222	Myeloid Neoplasm	70004				Prognostic	Supports	B	Poor Outcome	"In patients with myeloma, those with mutations in TP53 had worse overall survival than those without."	17215851	PubMed		"Chng et al., 2007, Leukemia"		4	accepted	522	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/522	https://civicdb.org/links/molecular_profiles/222	FALSE	TP53	7157	Mutation		chr17	7668402	7687538			ENST00000269305.4	75		protein_altering_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
TP53 Mutation	222	Head And Neck Squamous Cell Carcinoma	5520				Prognostic	Does Not Support	B	Poor Outcome	"Tumors from 114 patients with head and neck squamous cell carcinoma were analyzed for TP53 mutations, 21 of which were treated with surgery. Unlike those treated with radiotherapy, those treated with surgery did not show a significant difference in rates of loco-regional control between those with and without mutations in TP53."	11325447	PubMed		"Alsner et al., 2001, Radiother Oncol"		4	accepted	523	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/523	https://civicdb.org/links/molecular_profiles/222	FALSE	TP53	7157	Mutation		chr17	7668402	7687538			ENST00000269305.4	75		protein_altering_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
TP53 Mutation	222	Head And Neck Squamous Cell Carcinoma	5520				Prognostic	Supports	B	Poor Outcome	"Tumors from 114 patients with head and neck squamous cell carcinoma were analyzed for TP53 mutations. Of the 93 patients treated with radiotherapy, patients with mutations in TP53 had lower rates of loco-regional control and shorter disease-free, disease-specific, and overall survival."	11325447	PubMed		"Alsner et al., 2001, Radiother Oncol"		4	accepted	524	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/524	https://civicdb.org/links/molecular_profiles/222	FALSE	TP53	7157	Mutation		chr17	7668402	7687538			ENST00000269305.4	75		protein_altering_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
TP53 Truncating Mutation	223	Head And Neck Squamous Cell Carcinoma	5520				Prognostic	Supports	B	Poor Outcome	"In patients with head and neck squamous cell carcinoma, in a multivariate analysis those with truncating mutations in TP53 had worse progression-free and overall survival than wild-type patients."	21467160	PubMed		"Lindenbergh-van der Plas et al., 2011, Clin. Cancer Res."		4	accepted	525	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/525	https://civicdb.org/links/molecular_profiles/223	FALSE	TP53	7157	Truncating Mutation		chr17	7670680	7676396			ENST00000269305.4	75		frameshift_truncation		2023-01-09 21:52:05 UTC		N/A		FALSE
TP53 Truncating Mutation	223	Head And Neck Squamous Cell Carcinoma	5520				Prognostic	Does Not Support	B	Poor Outcome	"In patients with head and neck squamous cell carcinoma, when comparing patients with any mutation in TP53 to wild-type, there was not a significant difference in overall survival in a multivariate analysis."	21467160	PubMed		"Lindenbergh-van der Plas et al., 2011, Clin. Cancer Res."		4	accepted	526	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/526	https://civicdb.org/links/molecular_profiles/223	FALSE	TP53	7157	Truncating Mutation		chr17	7670680	7676396			ENST00000269305.4	75		frameshift_truncation		2023-01-09 21:52:05 UTC		N/A		FALSE
TTF1 AMPLIFICATION	224	Lung Adenocarcinoma	3910				Prognostic	Does Not Support	B	N/A	6 of 89 patients with lung adenocarcinoma had amplification of TTF1. There was no statistical difference in overall survival between patients with and without gene amplification.	19040416	PubMed		"Barletta et al., 2009, J. Cell. Mol. Med."		3	accepted	527	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/527	https://civicdb.org/links/molecular_profiles/224	FALSE	TTF1	7270	AMPLIFICATION		chr9	132375621	132406822			ENST00000334270.2	75		transcript_amplification		2023-01-09 21:52:05 UTC		N/A		FALSE
ERBB2 Amplification	302	Her2-receptor Positive Breast Cancer	60079		Trastuzumab		Predictive	Supports	B	Sensitivity/Response	"A randomized clinical trial of 469 patients with previously untreated, HER2-positive, metastatic breast cancer demonstrated improved time to disease progression, objective response rate, and duration of response for patients who received trastuzumab in addition to chemotherapy compared to chemotherapy alone."	11248153	PubMed		"Slamon et al., 2001, N. Engl. J. Med."		5	accepted	528	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/528	https://civicdb.org/links/molecular_profiles/302	FALSE	ERBB2	2064	Amplification		chr17	39700080	39728662			ENST00000269571.5	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A	OVEREXPRESSION	FALSE
ERBB2 Amplification	302	Her2-receptor Positive Breast Cancer	60079		Trastuzumab		Predictive	Supports	B	Sensitivity/Response	"A randomized clinical trial of 186 patients with previously untreated, HER2-positive, metastatic breast cancer demonstrated improved overall survival, response rate, response duration, time to progression, and time to treatment failure for patients who received trastuzumab in addition to chemotherapy (docetaxel) compared to chemotherapy alone."	15911866	PubMed		"Marty et al., 2005, J. Clin. Oncol."		5	accepted	529	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/529	https://civicdb.org/links/molecular_profiles/302	FALSE	ERBB2	2064	Amplification		chr17	39700080	39728662			ENST00000269571.5	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A	OVEREXPRESSION	FALSE
CHEK2 Loss-of-function	227	Cancer	162				Predisposing	Supports	B	Predisposition	"Heterozygous germline truncating (frameshift) and missense mutations confer highly penetrant predisposition to multiple cancer types including sarcoma, breast cancer, and brain tumors. Screening of individuals with Li-Fraumeni syndrome but lacking TP53 mutations identified 1/4 classical and 2/18 LFS variant presentation. This included 1 large family pedigree with strong co-segregation of the mutation with cancer development."	10617473	PubMed		"Bell et al., 1999, Science"		5	accepted	531	Rare Germline	2023-02-07 20:29:12 UTC	https://civicdb.org/links/evidence_items/531	https://civicdb.org/links/molecular_profiles/227	FALSE	CHEK2	11200	Loss-of-function		chr22	28687744	28741844			ENST00000328354.6	75		loss_of_function_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
PRKACA DNAJB1::PRKACA	31	Fibrolamellar Carcinoma	5015				Diagnostic	Supports	B	Positive	"RT-PCR and FISH assays were developed for the detection of rearrangements of the PRKACA locus. A total of 106 primary liver tumors were studied by RT-PCR (26 fibrolamellar carcinomas, 25 conventional hepatocellular carcinomas, 25 cholangiocarcinomas, 25 hepatic adenomas, and 5 hepatoblastomas). FISH was tested in 19 fibrolamellar carcinomas and in 6 scirrhous hepatocellular carcinomas. Evidence of the DNAJB1-PRKACA fusion was found in all fibrolamellar cases but not in other tumor types for both methods indicating that detection of DNAJB1-PRKACA is a very sensitive and specific finding in support of the diagnosis of fibrolamellar carcinoma."	25698061	PubMed		"Graham et al., 2015, Mod. Pathol."		5	accepted	532	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/532	https://civicdb.org/links/molecular_profiles/31	FALSE	PRKACA	5566	DNAJB1::PRKACA		chr19	14518139	14518420			ENST00000254322.2	75	ENST00000308677.4	transcript_fusion		2023-01-09 21:52:04 UTC		N/A	DNAJB1-PRKACA	FALSE
PRKACA DNAJB1::PRKACA	31	Fibrolamellar Carcinoma	5015				Diagnostic	Supports	B	Positive	"RT-PCR and FISH assays were developed for the detection of rearrangements of the PRKACA locus. A total of 106 primary liver tumors were studied by RT-PCR (26 fibrolamellar carcinomas, 25 conventional hepatocellular carcinomas, 25 cholangiocarcinomas, 25 hepatic adenomas, and 5 hepatoblastomas). FISH was tested in 19 fibrolamellar carcinomas and in 6 scirrhous hepatocellular carcinomas. Evidence of the DNAJB1-PRKACA fusion was found in all fibrolamellar cases but not in other tumor types for both methods indicating that detection of DNAJB1-PRKACA is a very sensitive and specific finding in support of the diagnosis of fibrolamellar carcinoma."	25698061	PubMed		"Graham et al., 2015, Mod. Pathol."		5	accepted	532	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/532	https://civicdb.org/links/molecular_profiles/31	FALSE	PRKACA	5566	DNAJB1::PRKACA		chr19	14091688	14107409			ENST00000254322.2	75	ENST00000308677.4	transcript_fusion		2023-01-09 21:52:04 UTC		N/A	DNAJB1-PRKACA	FALSE
KRAS G12/G13	77	Pancreatic Adenocarcinoma	4074		"Trametinib,Gemcitabine"	Combination	Predictive	Supports	B	Resistance	"Adding trametinib to gemcitabine does not improve overall survival (OS), progression-free survival (PFS), overall response rate (ORR) or duration of response (DOR) in patients with untreated metastatic adenocarcinoma of the pancreas."	24915778	PubMed		"Infante et al., 2014, Eur. J. Cancer"	NCT01231581	4	accepted	622	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/622	https://civicdb.org/links/molecular_profiles/77	FALSE	KRAS	3845	G12/G13		chr12	25245346	25245351			ENST00000256078.4	75		protein_altering_variant		2023-01-09 21:52:04 UTC		"45,122,125,781,258,200,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000"		FALSE
CDK12 Loss-of-function	232	Ovarian Serous Carcinoma	50933		Olaparib		Predictive	Supports	D	Sensitivity/Response	"In models of high-grade serous ovarian cancer (HGS-OVCa), CDK12 attenuation was sufficient to confer sensitivity to PARP1/2 inhibition, suppression of DNA repair via homologous recombination, and reduced expression of BRCA1."	24240700	PubMed		"Bajrami et al., 2014, Cancer Res."		4	accepted	623	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/623	https://civicdb.org/links/molecular_profiles/232	FALSE	CDK12	51755	Loss-of-function		chr17	39462039	39535146			ENST00000447079.4	75		loss_of_function_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
IDH2 R172	199	Peripheral T-cell Lymphoma	50749				Prognostic	Does Not Support	B	Better Outcome	"In patients with angioimmunoblastic T-cell lymphoma (a subtype of peripheral T-cell lymphoma), IDH2 R172 mutations (N=16) had no impact on overall survival when compared to patients with wildtype IDH2 (N=24)."	26268241	PubMed		"Wang et al., 2015, Blood"		3	accepted	627	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/627	https://civicdb.org/links/molecular_profiles/199	FALSE	IDH2	3418	R172		chr15	90088605	90088607			ENST00000330062.3	75		protein_altering_variant		2023-01-09 21:52:05 UTC		N/A	ARG172	FALSE
IDH2 R172	199	Peripheral T-cell Lymphoma	50749				Diagnostic	Supports	B	Positive	IDH2 R172 mutations were frequently observed in patients with the angioimmunoblastic T-cell lymphoma subtype of peripheral T-cell lymphomas but not observed in other subtypes.	22215888	PubMed		"Cairns et al., 2012, Blood"		4	accepted	628	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/628	https://civicdb.org/links/molecular_profiles/199	FALSE	IDH2	3418	R172		chr15	90088605	90088607			ENST00000330062.3	75		protein_altering_variant		2023-01-09 21:52:05 UTC		N/A	ARG172	FALSE
NT5C2 R367Q	234	T-cell Acute Lymphoblastic Leukemia	5603		"Thioguanine,Mercaptopurine"	Substitutes	Predictive	Supports	D	Resistance	"CCRF-CEM and to a lesser extent CUTLL1 T-ALL cell lines expressing the NT5C2 R367Q mutation had increased resistance to 6-mercaptopurine and 6-thioguanine treatment than cells expressing wildtype NT5C2. Consistent with this, isolated mutant proteins also showed increased enzyme activity compared to wildtype proteins."	23377281	PubMed		"Tzoneva et al., 2013, Nat. Med."		4	accepted	630	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/630	https://civicdb.org/links/molecular_profiles/234	FALSE	NT5C2	22978	R367Q		chr10	103093198	103093198	C	T	ENST00000343289.5	75		missense_variant	NC_000010.10:g.104852955C>T	2023-01-27 17:03:06 UTC	CA16602791	376349	ARG367GLN	FALSE
NT5C2 K359Q	235	T-cell Acute Lymphoblastic Leukemia	5603		"Mercaptopurine,Thioguanine"	Substitutes	Predictive	Supports	D	Resistance	"CCRF-CEM and to a lesser extent CUTLL1 T-ALL cell lines expressing the NT5C2 K359Q mutation had increased resistance to 6-mercaptopurine and 6-thioguanine treatment than cells expressing wildtype NT5C2. Consistent with this, isolated mutant proteins also showed increased enzyme activity compared to wildtype proteins."	23377281	PubMed		"Tzoneva et al., 2013, Nat. Med."		4	accepted	631	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/631	https://civicdb.org/links/molecular_profiles/235	FALSE	NT5C2	22978	K359Q		chr10	103093223	103093223	T	G	ENST00000343289.5	75		missense_variant	"NC_000010.10:g.104852980T>G,NM_012229.4:c.1075A>C,NP_036361.1:p.Lys359Gln,ENST00000343289.5:c.1075A>C"	2023-01-27 17:03:07 UTC	CA16602792	376350	LYS359GLN	FALSE
NT5C2 D407A	236	T-cell Acute Lymphoblastic Leukemia	5603		"Mercaptopurine,Thioguanine"	Substitutes	Predictive	Supports	D	Resistance	"CCRF-CEM and to a lesser extent CUTLL1 T-ALL cell lines expressing the NT5C2 D407A mutation had increased resistance to 6-mercaptopurine and 6-thioguanine treatment than cells expressing wildtype NT5C2. Consistent with this, isolated mutant proteins also showed increased enzyme activity compared to wildtype protein."	23377281	PubMed		"Tzoneva et al., 2013, Nat. Med."		4	accepted	632	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/632	https://civicdb.org/links/molecular_profiles/236	FALSE	NT5C2	22978	D407A		chr10	103090988	103090988	T	G	ENST00000343289.5	75		missense_variant	"NC_000010.10:g.104850745T>G,NM_012229.4:c.1220A>C,NP_036361.1:p.Asp407Ala,ENST00000343289.5:c.1220A>C"	2023-01-27 17:03:07 UTC	CA16602793	376351	ASP407ALA	FALSE
NT5C2 R367Q	234	T-cell Acute Lymphoblastic Leukemia	5603		"Nelarabine,Arabinosylguanine"	Substitutes	Predictive	Does Not Support	D	Resistance	"CCRF-CEM and CUTLL1 T-ALL cell lines expressing NT5C2 mutant proteins (K359Q, R367Q or D407A) observed in relapsed T-ALL patients showed no difference in sensitivity to nelarabine or arabinosylguanine treatment when compared to cells expressing wildtype protein or vector alone."	23377281	PubMed		"Tzoneva et al., 2013, Nat. Med."		4	accepted	633	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/633	https://civicdb.org/links/molecular_profiles/234	FALSE	NT5C2	22978	R367Q		chr10	103093198	103093198	C	T	ENST00000343289.5	75		missense_variant	NC_000010.10:g.104852955C>T	2023-01-27 17:03:06 UTC	CA16602791	376349	ARG367GLN	FALSE
NT5C2 D407A	236	T-cell Acute Lymphoblastic Leukemia	5603		"Nelarabine,Arabinosylguanine"	Substitutes	Predictive	Does Not Support	D	Resistance	"CCRF-CEM and CUTLL1 T-ALL cell lines expressing NT5C2 mutant proteins (K359Q, R367Q or D407A) observed in relapsed T-ALL patients showed no difference in sensitivity to nelarabine or arabinosylguanine treatment when compared to cells expressing wildtype protein or vector alone."	23377281	PubMed		"Tzoneva et al., 2013, Nat. Med."		4	accepted	635	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/635	https://civicdb.org/links/molecular_profiles/236	FALSE	NT5C2	22978	D407A		chr10	103090988	103090988	T	G	ENST00000343289.5	75		missense_variant	"NC_000010.10:g.104850745T>G,NM_012229.4:c.1220A>C,NP_036361.1:p.Asp407Ala,ENST00000343289.5:c.1220A>C"	2023-01-27 17:03:07 UTC	CA16602793	376351	ASP407ALA	FALSE
NT5C2 K359Q	235	T-cell Acute Lymphoblastic Leukemia	5603		"Nelarabine,Arabinosylguanine"	Substitutes	Predictive	Does Not Support	D	Resistance	"CCRF-CEM and CUTLL1 T-ALL cell lines expressing NT5C2 mutant proteins (K359Q, R367Q or D407A) observed in relapsed T-ALL patients showed no difference in sensitivity to nelarabine or arabinosylguanine treatment when compared to cells expressing wildtype protein or vector alone."	23377281	PubMed		"Tzoneva et al., 2013, Nat. Med."		4	accepted	636	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/636	https://civicdb.org/links/molecular_profiles/235	FALSE	NT5C2	22978	K359Q		chr10	103093223	103093223	T	G	ENST00000343289.5	75		missense_variant	"NC_000010.10:g.104852980T>G,NM_012229.4:c.1075A>C,NP_036361.1:p.Lys359Gln,ENST00000343289.5:c.1075A>C"	2023-01-27 17:03:07 UTC	CA16602792	376350	LYS359GLN	FALSE
TP53 Mutation	222	B-lymphoblastic Leukemia/lymphoma	80630				Prognostic	Supports	B	Poor Outcome	"In relapsed B-ALL patients, TP53 mutations were associated with morphologic nonresponse to therapy (>5% blasts in the bone marrow after 9 weeks of treatment) as well as reduced event free and overall survival when compared to TP53 wildtype patients."	21747090	PubMed		"Hof et al., 2011, J. Clin. Oncol."		4	accepted	640	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/640	https://civicdb.org/links/molecular_profiles/222	FALSE	TP53	7157	Mutation		chr17	7668402	7687538			ENST00000269305.4	75		protein_altering_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
TP53 DNA Binding Domain Mutation	238	Oral Squamous Cell Carcinoma	50866				Prognostic	Supports	B	Poor Outcome	"Oral squamous cell carcinoma patients with TP53 mutations in the DNA binding domain (L2, L3 and the LSH motif) have significantly reduced cumulative survival when compared to patients with TP53 mutations outside of this DNA binding domain. These mutations were also significantly associated with locoregional failure, cervical lymph node metastasis and distant metastasis, likely contributing to this finding."	12509970	PubMed		"Yamazaki et al., 2003, Oral Oncol."		4	accepted	641	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/641	https://civicdb.org/links/molecular_profiles/238	FALSE	TP53	7157	DNA Binding Domain Mutation		chr17	7673831	7675125			ENST00000269305.4	75		DNA_binding_site		2023-01-09 21:52:05 UTC		N/A		FALSE
EGFR T790M	34	Lung Cancer	1324		"Gefitinib,Multikinase Inhibitor AEE788"	Sequential	Predictive	Supports	D	Resistance	"Lung cancers can accumulate activating mutations in oncogenes such as EGFR. The common L858R EGFR mutation has been shown previously to be sensitive to small molecular tyrosine kinase inhibitors (ie. erlotinib). In response, tumors may accumulate an additional 'gatekeeper' mutation in EGFR, T790M. Authors show that T790M retain low affinity for gefitinib and that introduction of T790M in the presence of L858R mutant increases the ATP affinity of L858R and activates wild-type EGFR, thus showing that increased ATP affinity is the primary mode of resistance in tumors with T790M, though irreversible ATP inhibitors (ie. HKI-272) are able to overcome this resistance via covalent bonding."	18227510	PubMed		"Yun et al., 2008, Proc. Natl. Acad. Sci. U.S.A."		5	accepted	642	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/642	https://civicdb.org/links/molecular_profiles/34	FALSE	EGFR	1956	T790M	EGFR TKI Resistance	chr7	55181378	55181378	C	T	ENST00000275493.2	75		missense_variant	"ENST00000275493.2:c.2369C>T,NM_005228.4:c.2369C>T,NP_005219.2:p.Thr790Met,NC_000007.13:g.55249071C>T"	2023-01-27 17:02:05 UTC	CA090928	16613	"THR790MET,RS121434569"	FALSE
PTEN Loss	214	Bladder Carcinoma	4007		Everolimus		Predictive	Supports	B	Resistance	PTEN loss is associated with reduced response to mTOR inhibitors in patients with bladder cancer.	23989949	PubMed		"Seront et al., 2013, Br. J. Cancer"		4	accepted	644	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/644	https://civicdb.org/links/molecular_profiles/214	FALSE	PTEN	5728	Loss		chr10	87863113	87971930			ENST00000371953.3	75		loss_of_function_variant	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
PTEN Loss	214	Breast Cancer	1612		Trastuzumab		Predictive	Supports	B	Resistance	"PTEN loss is associated with loss of sensitivity to the HER2-antibody trastuzumab in breast cancer in smaller trials, a phase III trial (NCCTG N9831) did not show an effect of PTEN on disease-free survival."	24387334	PubMed		"Dillon et al., 2014, Curr Drug Targets"		1	accepted	645	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/645	https://civicdb.org/links/molecular_profiles/214	FALSE	PTEN	5728	Loss		chr10	87863113	87971930			ENST00000371953.3	75		loss_of_function_variant	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
EGFR T790M	34	Lung Non-small Cell Carcinoma	3908		Rociletinib		Predictive	Supports	B	Sensitivity/Response	"In a phase1-2 study, patients with the T790M mutation were more sensitive to rocelitinib in comparison to patients with T790M-negative NSCLC."	25923550	PubMed		"Sequist et al., 2015, N. Engl. J. Med."	NCT01526928	4	accepted	646	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/646	https://civicdb.org/links/molecular_profiles/34	FALSE	EGFR	1956	T790M	EGFR TKI Resistance	chr7	55181378	55181378	C	T	ENST00000275493.2	75		missense_variant	"ENST00000275493.2:c.2369C>T,NM_005228.4:c.2369C>T,NP_005219.2:p.Thr790Met,NC_000007.13:g.55249071C>T"	2023-01-27 17:02:05 UTC	CA090928	16613	"THR790MET,RS121434569"	FALSE
ATM S2289*	239	Prostate Cancer	10283		Olaparib		Predictive	Supports	C	Sensitivity/Response	"Treatment with the PARP inhibitor olaparib in patients whose prostate cancers were no longer responding to standard treatments and who had defects in DNA-repair genes led to a high response rate. Overall, 4/6 patients (3/5 with no other identified aberrations in DNA repair genes) with several germline and somatic aberrations of ATM had a response. Responders included a single patient with a somatic frameshift mutation (ATM V2288fs*1) predicted to result in truncation prior to the PI3K catalytic domain and other domains for p53 recognition and response to DNA damage. No other alterations in ATM were observed; however, this patient also had frameshift mutations in MLH3, MRE11 and NBN."	26510020	PubMed		"Mateo et al., 2015, N. Engl. J. Med."	NCT01682772	3	accepted	647	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/647	https://civicdb.org/links/molecular_profiles/239	FALSE	ATM	472	S2289*		chr11	108326113	108326114	TC		ENST00000278616.4	75		frameshift_truncation	ENST00000278616.4:c.6863_6864delTC	2023-01-27 17:03:09 UTC	CA10588507	NONE FOUND	V2288FS*1	FALSE
ATM N2875H	240	Prostate Cancer	10283		Olaparib		Predictive	Supports	C	Sensitivity/Response	"Treatment with the PARP inhibitor olaparib in patients whose prostate cancers were no longer responding to standard treatments and who had defects in DNA-repair genes led to a high response rate. Overall, 4/6 patients (3/5 with no other identified aberrations in DNA repair genes) with several germline and somatic aberrations of ATM had a response. Responders included a single patient with a somatic missense mutation (ATM N2875H) and no other alterations in ATM or other DNA repair genes."	26510020	PubMed		"Mateo et al., 2015, N. Engl. J. Med."	NCT01682772	3	accepted	648	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/648	https://civicdb.org/links/molecular_profiles/240	FALSE	ATM	472	N2875H		chr11	108347317	108347317	A	C	ENST00000278616.4	75		missense_variant	"ENST00000278616.4:c.8623A>C,NC_000011.9:g.108218044A>C,NM_000051.3:c.8623A>C,NP_000042.3:p.Asn2875His"	2023-01-27 17:03:10 UTC	CA16602795	376353	"ASN2875HIS,RS1057519869"	FALSE
NF2 Y177fs	241	Peritoneal Mesothelioma	1788		"Cisplatin,Carboplatin"	Substitutes	Predictive	Supports	C	Resistance	"A frameshift mutation in NF2 at position Y177 was found in a patient who responded poorly to therapy and died within 8 months of diagnosis. Initially treated with 3 cycles of systemic chemotherapy with cisplatin and pemetrexed with modest response, 2 months after cytoreductive surgery the patient had no response to platinum doublet chemotherapy."	25798586	PubMed		"Sheffield et al., 2015, PLoS ONE"		3	accepted	649	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/649	https://civicdb.org/links/molecular_profiles/241	FALSE	NF2	4771	Y177fs		chr22	29655604	29655605		T	ENST00000338641.4	75		frameshift_elongation	"ENST00000338641.4:c.527_528insT,NC_000022.10:g.30051593_30051594insT"	2023-01-27 17:03:11 UTC	CA645601016	NONE FOUND	TYR177FS	FALSE
BRCA2 Loss-of-function	132	Prostate Cancer	10283		Olaparib		Predictive	Supports	B	Sensitivity/Response	"In a phase 2 trial of patients with metastatic, castration-resistant prostate cancer, treated with olaparib tablets at a dose of 400 mg twice a day, all 7 patients harbouring BRCA2 loss of function alleles (biallelic somatic loss or germline mutations in combination with somatic copy loss or copy neutral LOH) demonstrated a clinical response."	26510020	PubMed		"Mateo et al., 2015, N. Engl. J. Med."	NCT01682772	4	accepted	650	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/650	https://civicdb.org/links/molecular_profiles/132	FALSE	BRCA2	675	Loss-of-function	BRCA Germline Variants	chr13	32315474	32399210			ENST00000380152.3	75		loss_of_function_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
PDGFRA D842V	99	Gastrointestinal Stromal Tumor	9253		Imatinib		Predictive	Supports	D	Resistance	"When 293T cells stably transduced with PDGFRA A842V were treated with imatinib, tyrosine phosphorylation was maintained at 1 and 10umol/L concentrations that inhibited phosphorylation of wildtype PDGFRA, consistent with resistance to this inhibitor."	12949711	PubMed		"Hirota et al., 2003, Gastroenterology"		3	accepted	651	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/651	https://civicdb.org/links/molecular_profiles/99	FALSE	PDGFRA	5156	D842V	Imatinib Resistance	chr4	54285926	54285926	A	T	ENST00000257290.5	75		missense_variant	"NM_006206.4:c.2525A>T,NP_006197.1:p.Asp842Val,ENST00000257290.5:c.2525A>T,NC_000004.11:g.55152093A>T"	2023-01-27 17:02:33 UTC	CA123194	13543	"ASP842VAL,RS121908585"	FALSE
PDGFRA V561A	243	Gastrointestinal Stromal Tumor	9253		Imatinib		Predictive	Supports	D	Sensitivity/Response	"293T cells stably transduced with PDGFRA V561A showed constitutive tyrosine phosphorylation in the absense of ligand; however, when treated with imatinib, this phosphorylation was inhibited similarly to that of wildtype PDGFRA, consistent with sensitivity to this inhibitor."	12949711	PubMed		"Hirota et al., 2003, Gastroenterology"		3	accepted	652	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/652	https://civicdb.org/links/molecular_profiles/243	FALSE	PDGFRA	5156	V561A		chr4	54274869	54274869	T	C	ENST00000257290.5	75		missense_variant	"ENST00000257290.5:c.1682T>C,NC_000004.11:g.55141036T>C,NM_006206.5:c.1682T>C,NP_006197.1:p.Val561Ala"	2023-01-27 17:03:12 UTC	CA16602796	376354	"VAL561ALA,RS121908586"	FALSE
KIT Exon 11 Mutation	66	Gastrointestinal Stromal Tumor	9253		Imatinib		Predictive	Supports	A	Sensitivity/Response	"This prospective study of 127 pretreatment patients with metastatic gastrointestinal stromal tumors (GISTs) examined the relationship between kinase (KIT and PDGFRA) genotype and treatment outcome for patients enrolled in a randomized phase II trial of imatinib (CSTI571B 2222). 85 patients harbored KIT exon 11 mutated GISTs: 71 had an in-frame deletion and 15 had unspecified point mutations (3 codon 557 cases, 3 codon 559 cases, 6 codon 560 cases and 2 codon 576 cases). Of patients harboring KIT exon 11 mutated GISTs, 71 (83.5%) had a partial response, 7 had stable disease, 4 had progressive disease and 3 were nonassessable.  Patients with KIT exon 11 mutations were significantly more likely to have a partial response than those with KIT exon 9 mutations (P=.0006)  or double WT kinases (WT KIT and WT PDGFRA; P < .0001). The presence of a KIT exon 11 mutation was the strongest predictor of response (Hazard ratio= 7.85). Patients harboring KIT exon 11 mutant GISTs experienced longer event free survival (median: 687 days) than those with  KIT exon 9 mutant or double WT kinase GISTs (200 days and 82 days, respectively). Furthermore, patients whose tumors expressed an exon 11 mutant KIT had improved overall survival compared to patients whose tumor expressed an exon 9 mutant KIT (P = .0034)  or double WT kinases (P <.0001)."	14645423	PubMed		"Heinrich et al., 2003, J. Clin. Oncol."		4	accepted	654	Somatic	2023-03-02 22:34:01 UTC	https://civicdb.org/links/evidence_items/654	https://civicdb.org/links/molecular_profiles/66	FALSE	KIT	3815	Exon 11 Mutation	KIT Exon 11	chr4	54727416	54727542			ENST00000288135.5	75		coding_sequence_variant		2023-01-09 21:52:04 UTC				FALSE
TERT C228T	244	Thyroid Gland Papillary Carcinoma	3969				Prognostic	Supports	B	Poor Outcome	"In patients with papillary thyroid cancer harboring both BRAF V600E and the TERT promotor mutation C228T, recurrence-free survival is worse than in patients harboring one of these mutations or no mutations in either gene."	25024077	PubMed		"Xing et al., 2014, J. Clin. Oncol."		5	accepted	655	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/655	https://civicdb.org/links/molecular_profiles/244	FALSE	TERT	7015	C228T		chr5	1295113	1295113	G	A	ENST00000310581.5	75		regulatory_region_variant	NC_000005.9:g.1295228G>A	2023-01-27 17:03:12 UTC	CA557858711	NONE FOUND	-124C>T	FALSE
BRAF V600E	12	Thyroid Gland Papillary Carcinoma	3969				Prognostic	Supports	B	Poor Outcome	"In patients with papillary thyroid cancer harboring both BRAF V600E and the TERT promotor mutation C228T (N=35), recurrence-free survival is worse than in patients harboring one of these mutations (N=159 BRAF, N=26 TERT promoter mutated) or no mutations in either gene (N=287)(P<0.001)."	25024077	PubMed		"Xing et al., 2014, J. Clin. Oncol."		5	accepted	656	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/656	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
TERT Promoter Mutation	220	Thyroid Gland Cancer	1781				Diagnostic	Supports	B	Positive	TERT promoter mutations are prevalent in aggressive sub-types of thyroid cancers. This work showed that TERT promoter mutations were significantly more prevalent in the tall cell papillary thyroid carcinoma (PTC) samples than in the conventional PTC and follicular variant PTC samples.	23766237	PubMed		"Liu et al., 2013, Endocr. Relat. Cancer"		3	accepted	657	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/657	https://civicdb.org/links/molecular_profiles/220	FALSE	TERT	7015	Promoter Mutation		chr5	1295046	1295258			ENST00000310581.5	75		regulatory_region_variant		2023-01-09 21:52:05 UTC			"-124C>T,-146C>T"	FALSE
TERT Promoter Mutation	220	Thyroid Gland Cancer	1781				Prognostic	Supports	B	Poor Outcome	"TERT promoter mutation C228T is significantly associated with BRAF V600E mutation, a marker of more aggressive tumors, in papillary thyroid cancer (PTC). Conversely, the BRAF V600E mutation is significantly more common in PTC cases with the TERT C228T mutation than in cases with the wild-type allele of TERT. TERT promoter mutations were also enriched in the more aggressive tall cell PTC compared to follicular or conventional PTC (30.8% vs 10.3%, P=0.046) and in the worse outcome anaplastic thyroid cancer than differentiated thyroid cancers (46.3% vs 12.2%, P=310?)."	23766237	PubMed		"Liu et al., 2013, Endocr. Relat. Cancer"		3	accepted	658	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/658	https://civicdb.org/links/molecular_profiles/220	FALSE	TERT	7015	Promoter Mutation		chr5	1295046	1295258			ENST00000310581.5	75		regulatory_region_variant		2023-01-09 21:52:05 UTC			"-124C>T,-146C>T"	FALSE
XRCC1 R194W	245	Lung Non-small Cell Carcinoma	3908		"Docetaxel,Vinorelbine,Gemcitabine"	Substitutes	Predictive	Supports	B	Sensitivity/Response	The XRCC1 R194W variant was shown to be correlated with increased chance of response to platinum-based chemotherapy in Stage IV Non-small Cell Lung Carcinoma (NSCLC). 82 patients with Stage IV NSCLC who had not previously been treated with chemotherapy were used in this study.	19157633	PubMed		"Sun et al., 2009, Lung Cancer"		4	accepted	659	Rare Germline	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/659	https://civicdb.org/links/molecular_profiles/245	FALSE	XRCC1	7515	R194W		chr19	43553422	43553422	G	A	ENST00000262887.5	75		missense_variant	"NM_006297.2:c.580C>T,NP_006288.2:p.Arg194Trp,ENST00000262887.5:c.580C>T,NC_000019.9:g.44057574G>A"	2023-01-27 17:03:13 UTC	CA9488737	376355	"RS1799782,ARG194TRP"	FALSE
GSTP1 Deletion	246	Ovarian Carcinoma	4001		"Carboplatin,Paclitaxel,Cisplatin"	Substitutes	Predictive	Supports	D	Sensitivity/Response	"Stable GSTP1 knockdown in ovarian carcinoma A2780 cell lines showed increased sensitivity to platinum-based chemotherapy drugs carboplatin, cisplatinum, carboplatin, and paclitaxel. For each drug, 3 biological replicates were performed for this study, and effectiveness was evaluated using an MTT assay. There was not a significant difference in sensitivity to other chemotherapy drugs such as gemcitabine, topotecan, and doxorubicin."	25010864	PubMed		"Sawers et al., 2014, Br. J. Cancer"		4	accepted	660	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/660	https://civicdb.org/links/molecular_profiles/246	FALSE	GSTP1	2950	Deletion		chr11	67583595	67586660			ENST00000398606.3	75		transcript_ablation		2023-01-09 21:52:05 UTC				FALSE
BIRC7 Amplification	247	Colon Cancer	219		Cisplatin		Predictive	Supports	D	Resistance	"Livin (BIRC7) overexpression in two colon cancer cell lines (RKO and SW620) increased resistance of these cells to cisplatin. siRNA knockdown of Livin rendered the cells more sensitive to cisplatin. The study also further showed that cytoplasmic Livin levels increased in four colon cancer cell lines (RKO, SW620, HCT116, and KM12C) after cisplatin treatment in a dose-dependent manner. This study highlighted Livin as a potential player in colon cancer therapy."	23188704	PubMed		"Ding et al., 2013, Tumour Biol."		4	accepted	661	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/661	https://civicdb.org/links/molecular_profiles/247	FALSE	BIRC7	79444	Amplification		chr20	63235883	63240507			ENST00000217169.3	75		transcript_amplification		2023-01-09 21:52:05 UTC		N/A		FALSE
EGFR Exon 4 Deletion	248	Epithelial Ovarian Cancer	2152		Cisplatin		Predictive	Supports	D	Resistance	"A variant of EGFR with exon 4 deletion (de4 EGFR) enhanced the invasiveness and cisplatin resistance of epithelial ovarian cancer cell lines (SKOV3, CAOV3, ES2) in vitro when compared with wild-type EGFR. The three cell lines were infected with lentivirus for either EGFR or de4 EGFR, and lentivirus-infected cells were used to perform transwell migration assays, invasion assays, and cisplatin sensitivity assays."	23764753	PubMed		"Zhang et al., 2013, Carcinogenesis"		4	accepted	662	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/662	https://civicdb.org/links/molecular_profiles/248	FALSE	EGFR	1956	Exon 4 Deletion		chr7	55146606	55146740			ENST00000275493.2	75		exon_loss_variant	ENST00000275493.2:c.425_559del	2023-01-09 21:52:05 UTC		N/A		FALSE
KRAS RS61764370	250	Epithelial Ovarian Cancer	2152		"Paclitaxel,Carboplatin"	Substitutes	Predictive	Supports	B	Resistance	"The functional variant rs61764370 in the KRAS gene 3' UTR (KRAS-variant) was found to be correlated with platinum-based chemotherapy resistance in patients with Epithelial Ovarian Cancer (EOC). 291 EOC patients without BRCA mutations were used in this study. Furthermore, the researchers tested a KRAS-variant EOC cell line (BG1) and found it has much greater platinum-based chemotherapy resistance than a non-KRAS-variant cell line (CAOV3)."	22139083	PubMed		"Ratner et al., 2012, Oncogene"		3	accepted	664	Common Germline	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/664	https://civicdb.org/links/molecular_profiles/250	FALSE	KRAS	3845	RS61764370		chr12	25207290	25207290	A	C	ENST00000311936.3	75		3_prime_UTR_variant	"NM_004985.4:c.*2505T>G,NC_000012.11:g.25360224A>C,ENST00000311936.3:c.*2505T>G"	2023-01-27 17:03:14 UTC	CA10637079	308084		FALSE
ERCC5 RS751402	251	Parietal Lobe Ependymoma	50903				Prognostic	Supports	B	Poor Outcome	The rs751402 polymorphism in the 5' UTR of ERCC5 was correlated with reduced progression free-survival in children with ependymoma that had been treated with platinum-based therapies. 55 post-operative frozen samples were used in this study. The results were also confirmed in vitro by treating neuroblastoma and B-cell lines expressing the wild-type or rs751402 polymorphism and finding that the rs751402 polymorphism was correlated with higher survival.	26338418	PubMed		"Somers et al., 2015, Genes Dev."		3	accepted	665	Common Germline	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/665	https://civicdb.org/links/molecular_profiles/251	FALSE	ERCC5	2073	RS751402		chr13	102845848	102845848	A	G	ENST00000355739.4	75		"5_prime_UTR_variant,SNP"	NC_000013.10:g.103498198A>G	2023-01-27 17:03:15 UTC	CA10642711	310903		FALSE
KIT rs17084733	252	Acral Lentiginous Melanoma	6367				Diagnostic	Supports	B	Positive	The rs17084733 variant in the 3' UTR of KIT was correlated with susceptibility to melanoma when comparing 70 melanoma patients to 94 healthy individuals from the same community. This variant was most strongly correlated with acral lentigious melanoma.	21119596	PubMed		"Godshalk et al., 2011, Oncogene"		3	accepted	666	Common Germline	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/666	https://civicdb.org/links/molecular_profiles/252	FALSE	KIT	3815	rs17084733		chr4	54738774	54738774	G	A	ENST00000288135.5	75		3_prime_UTR_variant	NC_000004.11:g.55604940G>A	2023-01-27 17:03:15 UTC	CA10621234		3' UTR MUTATION	FALSE
NT5C2 K359Q	235	Acute Lymphoblastic Leukemia	9952				Prognostic	Supports	B	Poor Outcome	The K359Q somatic mutation was significantly correlated with early disease recurrence and relapse in 103 T-cell ALL regardless of treatment course. The data was obtained from Berlin Frankfurt Mnster Clinical Trials.	23377281	PubMed		"Tzoneva et al., 2013, Nat. Med."		4	accepted	667	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/667	https://civicdb.org/links/molecular_profiles/235	FALSE	NT5C2	22978	K359Q		chr10	103093223	103093223	T	G	ENST00000343289.5	75		missense_variant	"NC_000010.10:g.104852980T>G,NM_012229.4:c.1075A>C,NP_036361.1:p.Lys359Gln,ENST00000343289.5:c.1075A>C"	2023-01-27 17:03:07 UTC	CA16602792	376350	LYS359GLN	FALSE
EZH2 Intron 6 Mutation	253	Colorectal Cancer	9256				Prognostic	Supports	B	Poor Outcome	The rs3757441 variant in Intron 6 of EZH2 (C/C versus C/T or T/T) was significantly correlated with lower progression free survival and overall survival in patients with metastatic Colorectal Cancer (mCRC). Blood samples from 106 patients with mCRC before and after treatment were used for this study.	21926398	PubMed		"Crea et al., 2012, Ann. Oncol."		4	accepted	668	Common Germline	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/668	https://civicdb.org/links/molecular_profiles/253	FALSE	EZH2	2146	Intron 6 Mutation		chr7	148827660	148827660	C	C	ENST00000320356.2	75		intron_variant	"NC_000007.14:g.148827660C=,NC_000007.13:g.148524752C=,ENST00000320356.7:c.626-394G=,ENSP00000320147.2:n.626-394G=,NM_004456.5:c.626-394G=,NP_004447.2:n.626-394G="	2023-01-27 17:03:16 UTC	CA1139771703	NONE FOUND	RS3757441	FALSE
MTHFR A222V	254	Stomach Cancer	10534		Fluorouracil		Predictive	Supports	B	Sensitivity/Response	"The MTHFR C667T variant was associated with significantly lower relapse-free survival and overall survival in stomach cancer patients treated with 5-Fluorouracil-based therapies. 116 Chinese patients with histologically confirmed gastric cancer were used in this study, and all patients had radical surgery before treatment."	18704422	PubMed		"Huang et al., 2009, Cancer Chemother. Pharmacol."		3	accepted	669	Common Germline	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/669	https://civicdb.org/links/molecular_profiles/254	FALSE	MTHFR	4524	A222V		chr1	11796321	11796321	G	A	ENST00000376592.1	75		missense_variant	"NM_005957.4:c.665C>T,NP_005948.3:p.Ala222Val,ENST00000376592.1:c.665G>A,NC_000001.10:g.11856378G>A"	2023-01-27 17:03:17 UTC	CA170990	3520	"RS1801133,C677T,ALA222VAL"	FALSE
GSTP1 I105V	255	Colorectal Cancer	9256		FOLFOX Regimen		Predictive	Supports	B	Sensitivity/Response	"Patients with the GSTP1 I105V variant had greater response to FOLFOX-4 treatment, longer progression-free survival, and longer overall survival. 166 Chinese patients with metastatic colorectal carcinoma who had been treated with FOLFOX-4 were used in this study."	19922504	PubMed		"Chen et al., 2010, Cancer Sci."		4	accepted	670	Common Germline	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/670	https://civicdb.org/links/molecular_profiles/255	FALSE	GSTP1	2950	I105V		chr11	67585218	67585218	A	G	ENST00000398606.3	75		missense_variant	"NM_000852.3:c.313A>G,NP_000843.1:p.Ile105Val,ENST00000398606.3:c.313A>G,NC_000011.9:g.67352689A>G"	2023-01-27 17:03:18 UTC	CA6142790	37340	ILE105VAL	FALSE
ABCG2 Q141K	256	Ovarian Cancer	2394				Prognostic	Supports	B	Better Outcome	The ABCG2 Q141K variant was correlated with  higher progression-free survival and overall survival in 511 ovarian cancer patients treated with platinum + taxane-based chemotherapy.	22112610	PubMed		"Tian et al., 2012, Gynecol. Oncol."		3	accepted	671	Common Germline	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/671	https://civicdb.org/links/molecular_profiles/256	FALSE	ABCG2	9429	Q141K		chr4	88131171	88131171	G	T	ENST00000237612.3	75		missense_variant	"NC_000004.11:g.89052323G>T,NM_004827.2:c.421C>A,NP_004818.2:p.Gln141Lys,ENST00000237612.3:c.421C>A"	2023-01-27 17:03:19 UTC	CA129179	30389	"GLN141LYS,RS2231142"	FALSE
XRCC1 Q399R	257	Lung Non-small Cell Carcinoma	3908				Prognostic	Supports	B	Better Outcome	The XRCC1 R399Q variant was significantly correlated with higher overall survival in non-small cell lung carcinoma (NSCLC) patients treated with gemcitabine and platinum. 62 patients with either Stage IIIB or Stage IV NSCLC were used for this study.	22551904	PubMed		"Liao et al., 2012, J Thorac Oncol"		4	accepted	672	Rare Germline	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/672	https://civicdb.org/links/molecular_profiles/257	FALSE	XRCC1	7515	Q399R		chr19	43551574	43551574	T	C	ENST00000262887.5	75		missense_variant	"NM_006297.2:c.1196A>G,NP_006288.2:p.Gln399Arg,NC_000019.9:g.44055726T>C,ENST00000262887.5:c.1196A>G"	2023-01-27 17:03:19 UTC	CA9488516	225976	"GLN399ARG,RS25487"	FALSE
XRCC1 Q399R	257	Cervical Cancer	4362		"Cisplatin,Carboplatin"	Substitutes	Predictive	Supports	B	Sensitivity/Response	The XRCC1 R399Q variant was correlated with increased response to platinum-based neoadjuvant chemotherapy in patients with cervical cancer. Tumor samples from 36 patients with Stage IB or IIA bulky (greater than 4 cm in size) cervical carcinomas were used in this study.	16875718	PubMed		"Chung et al., 2006, Gynecol. Oncol."		4	accepted	673	Rare Germline	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/673	https://civicdb.org/links/molecular_profiles/257	FALSE	XRCC1	7515	Q399R		chr19	43551574	43551574	T	C	ENST00000262887.5	75		missense_variant	"NM_006297.2:c.1196A>G,NP_006288.2:p.Gln399Arg,NC_000019.9:g.44055726T>C,ENST00000262887.5:c.1196A>G"	2023-01-27 17:03:19 UTC	CA9488516	225976	"GLN399ARG,RS25487"	FALSE
ABCB1 S893T	258	Ovarian Cancer	2394		Paclitaxel		Predictive	Supports	B	Sensitivity/Response	"The ABCB1 G2677T/A (S893T, rs2032582) homozygous variant was positively correlated with response to paclitaxel treatment in ovarian cancer patients. 51 epithelial and 2 fallopian tube frozen tumors were analyzed for this study."	16467099	PubMed		"Gren et al., 2006, Clin. Cancer Res."		3	accepted	674	Rare Germline	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/674	https://civicdb.org/links/molecular_profiles/258	FALSE	ABCB1	5243	S893T		chr7	87531302	87531302	A	T	ENST00000265724.3	75		missense_variant	"NM_000927.4:c.2677T>A,NP_000918.2:p.Ser893Thr,NC_000007.13:g.87160618A>T,ENST00000265724.3:c.2677T>A"	2023-01-27 17:03:20 UTC	CA179696	166619	"A893S,SER893THR,RS2032582"	FALSE
ABCB1 I1145I	259	Lung Non-small Cell Carcinoma	3908		"Cisplatin,Carboplatin"	Substitutes	Predictive	Supports	B	Sensitivity/Response	"The mutation at codon 3435 (C>T) correlated with a significantly higher response rate to platinum-based chemotherapy in patients with advanced non small cell lung cancer (NSCLC).  103 Chinese patients with NSCLC were evaluated in this study. However, there was not a significant correlation between the mutation and overall survival."	22296372	PubMed		"Yan et al., 2011, Asian Pac. J. Cancer Prev."		2	accepted	675	Common Germline	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/675	https://civicdb.org/links/molecular_profiles/259	FALSE	ABCB1	5243	I1145I		chr7	87509329	87509329	A	G	ENST00000265724.3	75		synonymous_variant	"NM_000927.4:c.3435T>C,NP_000918.2:p.Ile1145=,NC_000007.13:g.87138645A>G,ENST00000265724.3:c.3435T>C"	2023-01-27 17:03:21 UTC	CA4327768	225939	"T3435C,RS1045642,3435C-T,ILE1145="	FALSE
ERCC2 K751Q	260	Osteosarcoma	3347		Cisplatin		Predictive	Supports	B	Resistance	The ERCC2 K751Q variant was significantly correlated with a lower response to cisplatin chemotherapy in osteosarcoma patients and shorter event-free survival. 91 osteosarcoma patients with a median age of 15 years were followed in this study.	19434073	PubMed		"Caronia et al., 2009, Pharmacogenomics J."		4	accepted	676	Rare Germline	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/676	https://civicdb.org/links/molecular_profiles/260	FALSE	ERCC2	2068	K751Q		chr19	45351661	45351661	T	G	ENST00000391945.4	75		missense_variant	NC_000019.9:g.45854919T>G	2023-01-27 17:03:22 UTC	CA158782	134105	LYS751GLN	FALSE
ERCC2 K751Q	260	Lung Non-small Cell Carcinoma	3908		"Carboplatin,Paclitaxel"	Combination	Predictive	Supports	B	Sensitivity/Response	The ERCC2 K751Q variant is significantly correlated with increased response to paclitaxel and carboplatin therapies in non small cell lung cancer (NSCLC). The researchers utilized data from three previous clinical trials in Japan and the United States with a total of 526 NSCLC patients.	19470925	PubMed		"Gandara et al., 2009, J. Clin. Oncol."		3	accepted	677	Rare Germline	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/677	https://civicdb.org/links/molecular_profiles/260	FALSE	ERCC2	2068	K751Q		chr19	45351661	45351661	T	G	ENST00000391945.4	75		missense_variant	NC_000019.9:g.45854919T>G	2023-01-27 17:03:22 UTC	CA158782	134105	LYS751GLN	FALSE
TYMS 5' TANDEM REPEAT	261	Colorectal Cancer	9256		"Irinotecan,Fluorouracil"	Combination	Predictive	Supports	B	Resistance	The TYMS 5' 3TPR germline variant was significantly correlated with lower response to irinotecan plus 5-fluorouracil treatment in colorectal cancer patients. 149 metastatic CRC patients treated with irinotecan/5FU as first-line chemotherapy were followed in this study.	20628391	PubMed		"Martinez-Balibrea et al., 2010, Br. J. Cancer"		3	accepted	678	Rare Germline	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/678	https://civicdb.org/links/molecular_profiles/261	FALSE	TYMS	7298	5' TANDEM REPEAT		chr18	657604	657742			ENST00000323274.10	75		"5_prime_UTR_variant,short_tandem_repeat_variation"		2023-01-09 21:52:05 UTC				FALSE
LRP1B EXON 12-22 DELETION	262	Ovarian Cancer	2394		Doxorubicin		Predictive	Supports	D	Resistance	"A minimum common region of deletion of 0.19Mb, encompassing exons 12?2 of LRP1B4 was observed in 4 patients exhibiting acquired treatment resistance. Transfection of mLRP1B4, a fully functional minigene of LRP1B, in IGROV1 and OVCAR4 ovarian cell lines with low expression of LRP1B4 increased sensitivity to liposomal doxorubicin but not doxorubicin. siRNA knockdown of LRP1B4 in JHOS3 and Kuramochi ovarian cancer cell lines decreased sensitivity to liposomal doxorubicin but not doxorubicin."	22896685	PubMed		"Cowin et al., 2012, Cancer Res."		3	accepted	679	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/679	https://civicdb.org/links/molecular_profiles/262	FALSE	LRP1B	53353	EXON 12-22 DELETION		chr2	140907877	141020102			ENST00000389484.3	75		exon_loss_variant	ENST00000389484.3:c.1790_3520del	2023-01-09 21:52:05 UTC		N/A		FALSE
FGFR1 Amplification	263	Lung Squamous Cell Carcinoma	3907		PD173074		Predictive	Supports	D	Sensitivity/Response	"Preclinical (in-vitro, in-vivo) evidence suggests predictive value of FGFR1 amplification for treatment with FGFR1-inhibitors. 4 of 83 cell lines exhibited FGFR1 amplification, and 3 of these were highly sensitive to PD173074. This sensitivity was confirmed in a mouse xenograft. Clinical trials are currently ongoing."	21160078	PubMed		"Weiss et al., 2010, Sci Transl Med"		5	accepted	680	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/680	https://civicdb.org/links/molecular_profiles/263	FALSE	FGFR1	2260	Amplification		chr8	38411138	38467845			ENST00000425967.3	75		transcript_amplification	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
FGFR1 Expression	264	Lung Cancer	1324		Ponatinib		Predictive	Supports	D	Sensitivity/Response	"Preclinical evidence (in-vitro) for predictive value of FGFR1 mRNA and protein expression as well as mRNA expression of FGF2 and FGF9 for sensitivity to FGFR1 inhibition. The authors suggested that FGFR1 expression is a better predictive marker than FGFR1 amplification and proposes a connection between KRAS and PIK3CA mutations. This study used 58 cell lines, of which 14 exhibited ponatinib sensitivity. This sensitivity was correlated with FGFR1 mRNA and protein expression."	24771645	PubMed		"Wynes et al., 2014, Clin. Cancer Res."		4	accepted	681	N/A	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/681	https://civicdb.org/links/molecular_profiles/264	FALSE	FGFR1	2260	Expression		chr8	38411138	38467845			ENST00000425967.3	75		N/A	N/A	2023-01-09 21:52:06 UTC		N/A		FALSE
FGFR1 Amplification	263	Lung Squamous Cell Carcinoma	3907				Prognostic	Supports	B	Poor Outcome	"In this study in surgically resected squamous cell lung cancer, FGFR1 amplification has been shown as an independent negative prognostic factor in Asian patients. FGFR1 amplification also correlates with cigarette smoking."	23182986	PubMed		"Kim et al., 2013, J. Clin. Oncol."		4	accepted	682	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/682	https://civicdb.org/links/molecular_profiles/263	FALSE	FGFR1	2260	Amplification		chr8	38411138	38467845			ENST00000425967.3	75		transcript_amplification	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
FGFR1 Amplification	263	Lung Squamous Cell Carcinoma	3907				Prognostic	Supports	B	Poor Outcome	"This study shows an association of FGFR1 amplification with shorter overall and disease-free survival. However, no statistically significant association is seen on multivariate analysis."	25086725	PubMed		"Seo et al., 2014, Virchows Arch."		3	accepted	683	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/683	https://civicdb.org/links/molecular_profiles/263	FALSE	FGFR1	2260	Amplification		chr8	38411138	38467845			ENST00000425967.3	75		transcript_amplification	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
FGFR1 Amplification	263	Lung Non-small Cell Carcinoma	3908				Prognostic	Supports	B	Better Outcome	This study shows a reduction in the risk of death for patients with FGFR1 copy-number between 4 and 6. No difference in survival is seen between amplified and non-amplified patients in general.	23806793	PubMed		"Tran et al., 2013, Lung Cancer"		2	accepted	684	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/684	https://civicdb.org/links/molecular_profiles/263	FALSE	FGFR1	2260	Amplification		chr8	38411138	38467845			ENST00000425967.3	75		transcript_amplification	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
FGFR1 Amplification	263	Cancer	162				Prognostic	Supports	B	Poor Outcome	"Meta-Analysis on prognostic value of FGFR1 amplification in different types of cancer shows significantly worse overall survival for patients with FGFR1 and FGFR2 amplification. However, larger studies are warranted for confirmation."	25171497	PubMed		"Chang et al., 2014, PLoS ONE"		4	accepted	685	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/685	https://civicdb.org/links/molecular_profiles/263	FALSE	FGFR1	2260	Amplification		chr8	38411138	38467845			ENST00000425967.3	75		transcript_amplification	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
FGFR1 Amplification	263	Lung Non-small Cell Carcinoma	3908		PD173074		Predictive	Supports	D	Sensitivity/Response	Preclinical study showing FGFR1 amplification in NSCLC and efficacy of FGFR-1 inhibition in one amplified cell line.	21666749	PubMed		"Dutt et al., 2011, PLoS ONE"		4	accepted	686	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/686	https://civicdb.org/links/molecular_profiles/263	FALSE	FGFR1	2260	Amplification		chr8	38411138	38467845			ENST00000425967.3	75		transcript_amplification	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
FGFR1 Amplification	263	Lung Squamous Cell Carcinoma	3907				Prognostic	Does Not Support	B	Poor Outcome	"Effect of FGFR1 amplification on survival unclear, no significant correlation with PFS and OS seen in this meta-analysis. However, FGFR1 amplification is significantly correlated with lymph node metastasis."	25433983	PubMed		"Jiang et al., 2015, Lung Cancer"		4	accepted	687	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/687	https://civicdb.org/links/molecular_profiles/263	FALSE	FGFR1	2260	Amplification		chr8	38411138	38467845			ENST00000425967.3	75		transcript_amplification	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
ROS1 Rearrangement	265	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	B	Sensitivity/Response	"An expansion cohort of a phase-1 Crizotinib study found a 72% objective response rate among 50 patients with ROS1 rearrangement. The study did not compare to patients without rearrangement that were treated with Crizotinib.  Several different ROS1 fusion partners were identified, but no clinical differences in outcome were associated with the identity of the 5' partner."	25264305	PubMed		"Shaw et al., 2014, N. Engl. J. Med."	NCT00585195	4	accepted	688	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/688	https://civicdb.org/links/molecular_profiles/265	FALSE	ROS1	6098	Rearrangement		chr6	117288300	117425855			ENST00000368508.3	75		transcript_fusion		2023-01-09 21:52:06 UTC		N/A		FALSE
MET Amplification	266	Gastric Adenocarcinoma	3717		Onartuzumab		Predictive	Supports	C	Sensitivity/Response	"A case-study describing a patient with MET polysomy, MET over-expression and evidence of autocrine HGF-production (the growth factor ligand of MET). The patient initially achieved a complete response on MET-Inhibitor MetMAb (Onartuzumab) for 2 years and mixed response after recurrence with resistance in some of the newly developing metastases."	22389872	PubMed		"Catenacci et al., 2011, Cancer Discov"		3	accepted	689	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/689	https://civicdb.org/links/molecular_profiles/266	FALSE	MET	4233	Amplification		chr7	116672405	116796342			ENST00000318493.6	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A		FALSE
ATR I774FS	267	Endometrial Cancer	1380				Prognostic	Supports	B	Poor Outcome	"Extension and reduction of the ATR exon 10 A10 repeat (alters codon I774) was associated with poorer overall and disease-free survival in patients with endometrioid endometrial cancer when compared to patients with wildtype ATR and with or without microsatellite instability. These ATR mutations were observed in 12 of 248 patients (4.8%, 3 insertions, 9 deletions)."	19470935	PubMed		"Zighelboim et al., 2009, J. Clin. Oncol."		4	accepted	690	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/690	https://civicdb.org/links/molecular_profiles/267	FALSE	ATR	545	I774FS		chr3	142555898	142555898			ENST00000350721.4	75		frameshift_truncation	NC_000003.11:g.142274740del	2023-01-09 21:52:06 UTC				FALSE
EGFR Amplification	190	Head And Neck Squamous Cell Carcinoma	5520		"Fluorouracil,Platinum Compound,Cetuximab"	Combination	Predictive	Does Not Support	B	Sensitivity/Response	EGFR amplification was not a predictor of response to cetuximab/5-FU/platinum in patients with recurrent or metastatic HNSSC from the EXTREME study.	21048039	PubMed		"Licitra et al., 2011, Ann. Oncol."		4	accepted	691	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/691	https://civicdb.org/links/molecular_profiles/190	FALSE	EGFR	1956	Amplification		chr7	55019101	55211628			ENST00000275493.2	75		transcript_amplification	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
EGFR Overexpression	193	Head And Neck Squamous Cell Carcinoma	5520		Cetuximab		Predictive	Does Not Support	B	Sensitivity/Response	EGFR expression level was not predicitive of response to cetuximab-containing first line regimens in recurrent or metastatic head and neck squamous cell carcinoma and KRAS-wild type colorectal carcinoma.	23265711	PubMed		"Licitra et al., 2013, Eur. J. Cancer"	"NCT00122460,NCT00154102"	4	accepted	692	N/A	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/692	https://civicdb.org/links/molecular_profiles/193	FALSE	EGFR	1956	Overexpression		chr7	55019101	55211628			ENST00000275493.2	75		N/A		2023-01-09 21:52:05 UTC		N/A		FALSE
EGFR Overexpression	193	Lung Non-small Cell Carcinoma	3908		Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor		Predictive	Supports	B	Sensitivity/Response	EGFR overexpression was correlated with longer overall survival in patients with advanced NSCLC treated with first line chemotherapy and cetuximab than those treated with first line chemotherapy alone.	22056021	PubMed		"Pirker et al., 2012, Lancet Oncol."	NCT00148798	4	accepted	693	N/A	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/693	https://civicdb.org/links/molecular_profiles/193	FALSE	EGFR	1956	Overexpression		chr7	55019101	55211628			ENST00000275493.2	75		N/A		2023-01-09 21:52:05 UTC		N/A		FALSE
CDKN2A p16 Expression	268	Head And Neck Squamous Cell Carcinoma	5520		Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor		Predictive	Does Not Support	B	Resistance	"In this retrospective analysis of the SPECTRUM trial, p16 (CDKN2A) expression (and HPV-infection) was not predictive of response to EGFR-targeted therapy in combination with chemotherapy (n = 416 patient tumors)."	24577117	PubMed		"Vermorken et al., 2014, Ann. Oncol."		3	accepted	694	N/A	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/694	https://civicdb.org/links/molecular_profiles/268	FALSE	CDKN2A	1029	p16 Expression		chr9	21968056	21974866			ENST00000498124.1	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
CDKN2A p16 Expression	268	Head And Neck Squamous Cell Carcinoma	5520				Prognostic	Supports	B	Better Outcome	"p16 positivity, as a surrogate marker for HPV-associated HNSSC was a favorable prognostic marker in recurrent or metastatic carcinoma."	24799460	PubMed		"Argiris et al., 2014, Ann. Oncol."	NCT01487733	4	accepted	695	N/A	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/695	https://civicdb.org/links/molecular_profiles/268	FALSE	CDKN2A	1029	p16 Expression		chr9	21968056	21974866			ENST00000498124.1	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
CDKN2A p16 Expression	268	Head And Neck Squamous Cell Carcinoma	5520		Panitumumab		Predictive	Supports	B	Resistance	"In this retrospective analysis of p16 status as surrogate marker for HPV in the SPECTRUM trial, p16 (CDKN2A) expression was not associated with improved response to EGFR-directed therapy (Panitumumab) in combination with chemotherapy compared to chemotherapy alone."	23746666	PubMed		"Vermorken et al., 2013, Lancet Oncol."	NCT00460265	3	accepted	696	N/A	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/696	https://civicdb.org/links/molecular_profiles/268	FALSE	CDKN2A	1029	p16 Expression		chr9	21968056	21974866			ENST00000498124.1	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
CDKN2A p16 Expression	268	Head And Neck Squamous Cell Carcinoma	5520		Cetuximab		Predictive	Does Not Support	B	Resistance	"In this study response to EGFR-inhibition by cetuximab was independent of HPV-status, represented by expression of p16 (CDKN2A, an established biomarker of HPV infection). Expression of p16 was assayed in 69 HNSCC patients by IHC."	24577089	PubMed		"Pogorzelski et al., 2014, Cell Death Dis"		4	accepted	697	N/A	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/697	https://civicdb.org/links/molecular_profiles/268	FALSE	CDKN2A	1029	p16 Expression		chr9	21968056	21974866			ENST00000498124.1	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
RET KIF5B::RET	269	Lung Adenocarcinoma	3910		Vandetanib		Predictive	Supports	C	Sensitivity/Response	"A case study of a patient with EGFR, KRAS, BRAF, HER2, ALK, ROS1 and MET negative adenocarcinoma of the lung. FISH analysis revealed a KIF5B-RET fusion. The RET inhibitor Vandetanib led to remission in the patient."	23584301	PubMed		"Gautschi et al., 2013, J Thorac Oncol"		2	accepted	698	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/698	https://civicdb.org/links/molecular_profiles/269	FALSE	RET	5979	KIF5B::RET		chr10	32017143	32056431			ENST00000302418.4	75	ENST00000355710.3	transcript_fusion		2023-01-09 21:52:06 UTC		N/A	KIF5B-RET	FALSE
RET KIF5B::RET	269	Lung Adenocarcinoma	3910		Vandetanib		Predictive	Supports	C	Sensitivity/Response	"A case study of a patient with EGFR, KRAS, BRAF, HER2, ALK, ROS1 and MET negative adenocarcinoma of the lung. FISH analysis revealed a KIF5B-RET fusion. The RET inhibitor Vandetanib led to remission in the patient."	23584301	PubMed		"Gautschi et al., 2013, J Thorac Oncol"		2	accepted	698	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/698	https://civicdb.org/links/molecular_profiles/269	FALSE	RET	5979	KIF5B::RET		chr10	43114480	43130351			ENST00000302418.4	75	ENST00000355710.3	transcript_fusion		2023-01-09 21:52:06 UTC		N/A	KIF5B-RET	FALSE
HRAS G13D	270	Colorectal Cancer	9256		Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor		Predictive	Supports	C	Resistance	Case report of a patient with metastatic colorectal carcinoma and a novel HRAS G13D mutation showed resistance to treatment with panitumumab. In vitro models of HRAS G13D confirmed resistance mechanism in the same study.	26561417	PubMed		"Boidot et al., 2016, Int J Colorectal Dis"		3	accepted	699	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/699	https://civicdb.org/links/molecular_profiles/270	FALSE	HRAS	3265	G13D		chr11	534285	534285	C	T	ENST00000451590.1	75		missense_variant	"NC_000011.9:g.534285C>T,NP_005334.1:p.Gly13Asp,NM_005343.3:c.38G>A,ENST00000451590.1:c.38G>A"	2023-01-27 17:03:22 UTC	CA256488	12604	"GLY13ASP,RS104894226"	FALSE
HRAS Mutation	271	Cancer	162		"MTOR Kinase Inhibitor AZD8055,Everolimus,Mirdametinib,Binimetinib,Selumetinib"	Substitutes	Predictive	Supports	D	Sensitivity/Response	"A pre-clinical study in 10 solid cancer cell lines. HRAS mutations (Q61L, Q61R and G12V) sensitized cell lines toward MEK inhibitors (AZD6244/selumetinib, MEK162 and PD0325901) and mTOR inhibitors (Everolimus and AZD8055)."	26544513	PubMed		"Kiessling et al., 2015, Oncotarget"		3	accepted	700	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/700	https://civicdb.org/links/molecular_profiles/271	FALSE	HRAS	3265	Mutation		chr11	533873	534289			ENST00000451590.1	75		coding_transcript_variant		2023-01-09 21:52:06 UTC		"376,033,126,131,260,000,000,000,000,000,000"		FALSE
CD274 Expression	272	Lung Non-small Cell Carcinoma	3908				Prognostic	Does Not Support	B	Poor Outcome	This meta-analysis did not find a significant connection between expression of PD-L1 and overall survival in patients with NSCLC.	26664143	PubMed		"Zhong et al., 2015, Onco Targets Ther"		4	accepted	701	N/A	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/701	https://civicdb.org/links/molecular_profiles/272	FALSE	CD274	29126	Expression		chr9	5450525	5470547			ENST00000381577.3	75		N/A	N/A	2023-01-09 21:52:06 UTC		N/A		FALSE
CD274 Expression	272	Lung Squamous Cell Carcinoma	3907				Prognostic	Supports	B	Better Outcome	"In this study, PD-L1 expression (measured by IHC) was associated with better overall survival in the subgroup of Lung Squamous Cell Carcinomas (149 of 321 patients in the study)."	26313362	PubMed		"Schmidt et al., 2015, PLoS ONE"		3	accepted	702	N/A	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/702	https://civicdb.org/links/molecular_profiles/272	FALSE	CD274	29126	Expression		chr9	5450525	5470547			ENST00000381577.3	75		N/A	N/A	2023-01-09 21:52:06 UTC		N/A		FALSE
CD274 Expression	272	Ovarian Serous Carcinoma	50933				Prognostic	Supports	B	Better Outcome	High expression of PD-L1 and PD-1 were associated with a favorable prognosis in patients with high grade serous ovarian carcinoma (n = 215 cases).	26625204	PubMed		"Darb-Esfahani et al., 2016, Oncotarget"		3	accepted	703	N/A	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/703	https://civicdb.org/links/molecular_profiles/272	FALSE	CD274	29126	Expression		chr9	5450525	5470547			ENST00000381577.3	75		N/A	N/A	2023-01-09 21:52:06 UTC		N/A		FALSE
CD274 Expression	272	Melanoma	1909		"Pembrolizumab,Nivolumab"	Substitutes	Predictive	Supports	B	Sensitivity/Response	"Based on a meta-analysis of 20 trials (1475 patients), of which 7 studies (636 patients) included melanoma, PD-L1 expression was associated with a higher ORR rate in patients with melanoma. Active drugs were Nivolumab and Pembrolizumab, PD-1 receptor targeting antibodies."	26086854	PubMed		"Carbognin et al., 2015, PLoS ONE"		4	accepted	704	N/A	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/704	https://civicdb.org/links/molecular_profiles/272	FALSE	CD274	29126	Expression		chr9	5450525	5470547			ENST00000381577.3	75		N/A	N/A	2023-01-09 21:52:06 UTC		N/A		FALSE
MTOR Mutation	273	Bladder Carcinoma	4007		"Everolimus,Pazopanib"	Combination	Predictive	Supports	C	Sensitivity/Response	A case-study of a patient with urothelial carcinoma reported exceptional response (14 months) in a phase 1 study of Everolimus and Pazopanib. Mutations E2014K and E2419K were shown to be activating in-vitro.	24625776	PubMed		"Wagle et al., 2014, Cancer Discov"		3	accepted	705	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/705	https://civicdb.org/links/molecular_profiles/273	FALSE	MTOR	2475	Mutation		chr1	11106535	11262507			ENST00000361445.4	75		protein_altering_variant		2023-01-09 21:52:06 UTC		N/A		FALSE
AKT2 EXPRESSION	274	Breast Cancer	1612		Trastuzumab		Predictive	Supports	B	Sensitivity/Response	"In HER2+ metastatic breast cancer treated with trastuzumab (n = 74 patients), the expression of AKT2 and pAkt-Thr308 and/or pAkt-Ser473 localized in nucleus+cytoplasm was associated with an improved time to progression (TTP) and overall survival (OS) compared to AKT2 negative tumors as measured by immunohistochemistry."	22842582	PubMed		"Grell et al., 2012, Int. J. Oncol."		3	accepted	706	N/A	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/706	https://civicdb.org/links/molecular_profiles/274	FALSE	AKT2	208	EXPRESSION		chr19	40230317	40285395			ENST00000392038.2	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
AKT1 E17K	4	Melanoma	1909		Uprosertib		Predictive	Supports	D	Sensitivity/Response	A cell line with AKT E17K mutation was found to be sensitive to AKT inhibition with GSK2141795B  in this study.	24735930	PubMed		"Lassen et al., 2014, Mol. Cancer"		2	accepted	707	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/707	https://civicdb.org/links/molecular_profiles/4	FALSE	AKT1	207	E17K		chr14	104780214	104780214	C	T	ENST00000407796.2	75		missense_variant	"NC_000014.8:g.105246551C>T,NM_001014432.1:c.49G>A,NP_001014432.1:p.Glu17Lys,ENST00000407796.2:c.49G>A"	2023-01-27 17:01:56 UTC	CA123660	13983	"GLU17LYS,RS34409589"	FALSE
PTEN Loss	214	Melanoma	1909		Uprosertib		Predictive	Supports	D	Sensitivity/Response	Most BRAF mutant cell lines (mostly V600E) with PTEN mutation or loss of expression were among those sensitive to inhibition with AKT inhibitor GSK2141795B.	24735930	PubMed		"Lassen et al., 2014, Mol. Cancer"		2	accepted	708	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/708	https://civicdb.org/links/molecular_profiles/214	FALSE	PTEN	5728	Loss		chr10	87863113	87971930			ENST00000371953.3	75		loss_of_function_variant	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
AKT1 E17K	4	Breast Cancer	1612		Capivasertib		Predictive	Supports	C	Sensitivity/Response	"In a phase-I study of AZD5363, partial response was observed in 2 patients with breast and ovarian carcinoma, respectively, and AKT1 E17K mutations. While full study results have not yet been published, this paper highlights in vitro results that further confirm the role of AKT E17K mutation."	26351323	PubMed		"Davies et al., 2015, Mol. Cancer Ther."	NCT01353781	3	accepted	709	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/709	https://civicdb.org/links/molecular_profiles/4	FALSE	AKT1	207	E17K		chr14	104780214	104780214	C	T	ENST00000407796.2	75		missense_variant	"NC_000014.8:g.105246551C>T,NM_001014432.1:c.49G>A,NP_001014432.1:p.Glu17Lys,ENST00000407796.2:c.49G>A"	2023-01-27 17:01:56 UTC	CA123660	13983	"GLU17LYS,RS34409589"	FALSE
PIK3CA E545K	104	Breast Cancer	1612		"Pictilisib,Akt Inhibitor MK2206"	Substitutes	Predictive	Supports	D	Sensitivity/Response	PIK3CA E545K mutation increased sensitivity to AKT inhibitor MK-2206 and PI3K inhibitor GDC-0941 in a breast cancer cell line model.	23888070	PubMed		"Beaver et al., 2013, Clin. Cancer Res."		3	accepted	710	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/710	https://civicdb.org/links/molecular_profiles/104	FALSE	PIK3CA	5290	E545K		chr3	179218303	179218303	G	A	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.1633G>A,NP_006209.2:p.Glu545Lys,ENST00000263967.3:c.1633G>A,NC_000003.11:g.178936091G>A"	2023-01-27 17:02:37 UTC	CA123334	13655	"GLU545LYS,RS104886003"	FALSE
PTEN Loss	214	Breast Cancer	1612		PI3Kbeta Inhibitor AZD8186		Predictive	Supports	D	Sensitivity/Response	Breast and prostate cancer cell lines responsive to AZD8186 were enriched for PTEN deficiency.	25398829	PubMed		"Hancox et al., 2015, Mol. Cancer Ther."		2	accepted	711	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/711	https://civicdb.org/links/molecular_profiles/214	FALSE	PTEN	5728	Loss		chr10	87863113	87971930			ENST00000371953.3	75		loss_of_function_variant	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
MTOR Mutation	273	Melanoma	1909				Prognostic	Supports	B	Poor Outcome	Median overall survival of patients with nonsynonymous mutations in mTOR was shorter.	26490311	PubMed		"Kong et al., 2016, Clin. Cancer Res."		3	accepted	712	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/712	https://civicdb.org/links/molecular_profiles/273	FALSE	MTOR	2475	Mutation		chr1	11106535	11262507			ENST00000361445.4	75		protein_altering_variant		2023-01-09 21:52:06 UTC		N/A		FALSE
MTOR H1968Y	279	Melanoma	1909		"PI3K/BET Inhibitor LY294002,Capivasertib"	Substitutes	Predictive	Supports	D	Sensitivity/Response	"In a cell line (HEK293T) with expression of H1968Y or P2213S mTOR mutations, LY294002 and AZD5363 were more effective than temsirolimus or BYL719 in suppressing cell growth."	26490311	PubMed		"Kong et al., 2016, Clin. Cancer Res."		3	accepted	713	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/713	https://civicdb.org/links/molecular_profiles/279	FALSE	MTOR	2475	H1968Y		chr1	11128462	11128462	G	A	ENST00000361445.4	75		"missense_variant,gain_of_function_variant"	"ENST00000361445.4:c.5902C>T,NC_000001.10:g.11188519G>A,NM_004958.3:c.5902C>T,NP_004949.1:p.His1968Tyr"	2023-01-27 17:03:24 UTC	CA16602797	376357	HIS1968TYR	FALSE
PTEN Loss	214	Cancer	162		"Buparlisib,Carboplatin,Paclitaxel"	Combination	Predictive	Supports	B	Sensitivity/Response	All three patients with PTEN loss had benefit from adding Buparlisib to carboplatin+paclitaxel therapy in a phase I study in advanced solid cancers.	25672916	PubMed		"Hyman et al., 2015, Cancer Chemother. Pharmacol."	NCT01297452	3	accepted	714	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/714	https://civicdb.org/links/molecular_profiles/214	FALSE	PTEN	5728	Loss		chr10	87863113	87971930			ENST00000371953.3	75		loss_of_function_variant	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
NF2 K159fs	275	Breast Cancer	1612		Temsirolimus		Predictive	Supports	C	Sensitivity/Response	23 patients were treated with temsirolimus containing regimens. 1 patient with a complete response >3 years had a K159fs*16 mutation in NF2. 2 patients were tested for NF2 mutations.	25878190	PubMed		"Moulder et al., 2015, Ann. Oncol."		3	accepted	715	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/715	https://civicdb.org/links/molecular_profiles/275	FALSE	NF2	4771	K159fs		chr22	29654685	29654685	A		ENST00000338641.4	75		frameshift_truncation	"NC_000022.10:g.30050674del,NC_000022.11:g.29654685del,NM_000268.3:c.476del,NP_000259.1:p.Lys159SerfsTer15"	2023-01-27 17:03:23 UTC	CA915940524	NONE FOUND	LYS159FS*16	FALSE
PTEN Loss	214	Breast Cancer	1612		Alpelisib		Predictive	Supports	D	Resistance	"A case report described a responder to PI3K inhibitor BYL719 for a tumor with PIK3CA E542K mutation. After partial response for 9.5 months, resistance developed. Sequencing in this and other patients as well as preclinical models showed loss of PTEN as the probable mechanism of resistance."	25409150	PubMed		"Juric et al., 2015, Nature"		4	accepted	716	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/716	https://civicdb.org/links/molecular_profiles/214	FALSE	PTEN	5728	Loss		chr10	87863113	87971930			ENST00000371953.3	75		loss_of_function_variant	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
EGFR S492R	449	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	C	Resistance	In-vitro studies found this mutation to confer resistance to cetuximab. 2 of 10 patients studied also harbored EGFR S492R and were resistant to cetuximab therapy. Panitumumab was still active in-vitro and in one patient.	22270724	PubMed		"Montagut et al., 2012, Nat. Med."		4	accepted	717	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/717	https://civicdb.org/links/molecular_profiles/449	FALSE	EGFR	1956	S492R	EGFR ECD MUTATION	chr7	55160316	55160316	C	A	ENST00000275493.2	75		missense_variant	"ENST00000275493.2:c.1476C>A,NC_000007.13:g.55228009C>A,NP_005219.2:p.Ser492Arg,NM_005228.4:c.1476C>A"	2023-01-27 17:03:46 UTC	CA16602784	376341	"SER492ARG,RS1057519860"	FALSE
FBXW7 Mutation	277	Colorectal Cancer	9256		"Cetuximab,Panitumumab"	Substitutes	Predictive	Supports	B	Resistance	65 patients were retrospectively analyzed for mutational profiles predictive of response to EGFR-inhibitors (cetuximab or panitumumab). FBXW7 mutation was found to be more prevalent in non-responders (5 mutations) than responders (1 mutation).	26508446	PubMed		"Lupini et al., 2015, BMC Cancer"		2	accepted	718	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/718	https://civicdb.org/links/molecular_profiles/277	FALSE	FBXW7	55294	Mutation		chr4	152324294	152411562			ENST00000281708.4	75		"protein_altering_variant,loss_of_function_variant"		2023-01-09 21:52:06 UTC				FALSE
SMAD4 Mutation	216	Colorectal Cancer	9256		"Panitumumab,Cetuximab"	Substitutes	Predictive	Supports	B	Resistance	"In a retrospective analysis of 65 patients with metastatic colorectal cancer, SMAD4 mutations were more common among patients with no benefit from EGFR-inhibition (cetuximab or panitumumab) (4 patients) than with patients with response to EGFR directed treatment (1 patient)."	26508446	PubMed		"Lupini et al., 2015, BMC Cancer"		2	accepted	719	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/719	https://civicdb.org/links/molecular_profiles/216	FALSE	SMAD4	4089	Mutation		chr18	51030213	51085039			ENST00000342988.3	75		"transcript_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
SMAD4 Underexpression	278	Head And Neck Squamous Cell Carcinoma	5520		Cetuximab		Predictive	Supports	D	Resistance	"In this study, SMAD4 underexpression was associated with an epithelial-to-mesenchymal transition and resistance to EGFR-directed treatment with Cetuximab."	26046389	PubMed		"Cheng et al., 2015, Cancer Biol. Ther."		3	accepted	720	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/720	https://civicdb.org/links/molecular_profiles/278	FALSE	SMAD4	4089	Underexpression		chr18	51030213	51085039			ENST00000342988.3	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
MTOR P2213S	280	Melanoma	1909		"PI3K/BET Inhibitor LY294002,Capivasertib"	Combination	Predictive	Supports	D	Sensitivity/Response	"In a cell line (HEK293T) with expression of H1968Y or P2213S mTOR mutations, LY294002 and AZD5363 were more effective than temsirolimus or BYL719 in suppressing cell growth."	26490311	PubMed		"Kong et al., 2016, Clin. Cancer Res."		3	accepted	722	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/722	https://civicdb.org/links/molecular_profiles/280	FALSE	MTOR	2475	P2213S		chr1	11124523	11124523	G	A	ENST00000361445.4	75		"missense_variant,gain_of_function_variant"	"ENST00000361445.4:c.6637C>T,NC_000001.10:g.11184580G>A,NM_004958.3:c.6637C>T,NP_004949.1:p.Pro2213Ser"	2023-01-27 17:03:25 UTC	CA16602798	376358	PRO2213SER	FALSE
BRAF AGK::BRAF	281	Melanoma	1909		Sorafenib		Predictive	Supports	C	Sensitivity/Response	BRAF fusion AGK-BRAF was associated with decreased sensitivity to vemurafenib and increased sensitivity to sorafenib in-vitro. A single patient with this fusion showed durable response to sorafenib.	23890088	PubMed		"Botton et al., 2013, Pigment Cell Melanoma Res"		2	accepted	723	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/723	https://civicdb.org/links/molecular_profiles/281	FALSE	BRAF	673	AGK::BRAF	BRAF Fusions	chr7	141551189	141555567			ENST00000355413.4	75	ENST00000288602.6	transcript_fusion	N/A	2023-01-09 21:52:06 UTC		N/A	AGK-BRAF	FALSE
BRAF AGK::BRAF	281	Melanoma	1909		Sorafenib		Predictive	Supports	C	Sensitivity/Response	BRAF fusion AGK-BRAF was associated with decreased sensitivity to vemurafenib and increased sensitivity to sorafenib in-vitro. A single patient with this fusion showed durable response to sorafenib.	23890088	PubMed		"Botton et al., 2013, Pigment Cell Melanoma Res"		2	accepted	723	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/723	https://civicdb.org/links/molecular_profiles/281	FALSE	BRAF	673	AGK::BRAF	BRAF Fusions	chr7	140734479	140794467			ENST00000355413.4	75	ENST00000288602.6	transcript_fusion	N/A	2023-01-09 21:52:06 UTC		N/A	AGK-BRAF	FALSE
BRAF AGK::BRAF	281	Melanoma	1909		Vemurafenib		Predictive	Supports	D	Resistance	A melanoma cell line with AGK-BRAF in-frame fusion showed decreased sensitivity towards Vemurafenib in comparison with BRAF mutated (V600E) cell lines.	23890088	PubMed		"Botton et al., 2013, Pigment Cell Melanoma Res"		2	accepted	724	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/724	https://civicdb.org/links/molecular_profiles/281	FALSE	BRAF	673	AGK::BRAF	BRAF Fusions	chr7	141551189	141555567			ENST00000355413.4	75	ENST00000288602.6	transcript_fusion	N/A	2023-01-09 21:52:06 UTC		N/A	AGK-BRAF	FALSE
BRAF AGK::BRAF	281	Melanoma	1909		Vemurafenib		Predictive	Supports	D	Resistance	A melanoma cell line with AGK-BRAF in-frame fusion showed decreased sensitivity towards Vemurafenib in comparison with BRAF mutated (V600E) cell lines.	23890088	PubMed		"Botton et al., 2013, Pigment Cell Melanoma Res"		2	accepted	724	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/724	https://civicdb.org/links/molecular_profiles/281	FALSE	BRAF	673	AGK::BRAF	BRAF Fusions	chr7	140734479	140794467			ENST00000355413.4	75	ENST00000288602.6	transcript_fusion	N/A	2023-01-09 21:52:06 UTC		N/A	AGK-BRAF	FALSE
BRAF PAPSS1::BRAF	282	Melanoma	1909		Vemurafenib		Predictive	Supports	D	Resistance	"BRAF-fusion in ""pan-negative"" melanomas were identified in TCGA data. Cell-lines with PAPSS1-BRAF fusion were resistant to treatment with Vemurafenib."	24345920	PubMed		"Hutchinson et al., 2013, Clin. Cancer Res."		3	accepted	725	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/725	https://civicdb.org/links/molecular_profiles/282	FALSE	BRAF	673	PAPSS1::BRAF	BRAF Fusions	chr4	107682015	107720452			ENST00000265174.4	75	ENST00000288602.6	"gene_fusion,transcript_fusion"		2023-01-09 21:52:06 UTC		N/A	"T(4;7)(Q24;Q34),PAPSS1-BRAF"	FALSE
BRAF PAPSS1::BRAF	282	Melanoma	1909		Vemurafenib		Predictive	Supports	D	Resistance	"BRAF-fusion in ""pan-negative"" melanomas were identified in TCGA data. Cell-lines with PAPSS1-BRAF fusion were resistant to treatment with Vemurafenib."	24345920	PubMed		"Hutchinson et al., 2013, Clin. Cancer Res."		3	accepted	725	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/725	https://civicdb.org/links/molecular_profiles/282	FALSE	BRAF	673	PAPSS1::BRAF	BRAF Fusions	chr7	140734479	140787584			ENST00000265174.4	75	ENST00000288602.6	"gene_fusion,transcript_fusion"		2023-01-09 21:52:06 UTC		N/A	"T(4;7)(Q24;Q34),PAPSS1-BRAF"	FALSE
BRAF PAPSS1::BRAF	282	Melanoma	1909		Trametinib		Predictive	Supports	D	Sensitivity/Response	"BRAF-fusion in ""pan-negative"" melanomas were identified in TCGA data. Cell-lines with a PAPSS1-BRAF fusion were resistant to treatment with Vemurafenib but sensitive to treatment with Trametinib. This fusion is believed to activate MAPK pathway signaling."	24345920	PubMed		"Hutchinson et al., 2013, Clin. Cancer Res."		3	accepted	726	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/726	https://civicdb.org/links/molecular_profiles/282	FALSE	BRAF	673	PAPSS1::BRAF	BRAF Fusions	chr4	107682015	107720452			ENST00000265174.4	75	ENST00000288602.6	"gene_fusion,transcript_fusion"		2023-01-09 21:52:06 UTC		N/A	"T(4;7)(Q24;Q34),PAPSS1-BRAF"	FALSE
BRAF PAPSS1::BRAF	282	Melanoma	1909		Trametinib		Predictive	Supports	D	Sensitivity/Response	"BRAF-fusion in ""pan-negative"" melanomas were identified in TCGA data. Cell-lines with a PAPSS1-BRAF fusion were resistant to treatment with Vemurafenib but sensitive to treatment with Trametinib. This fusion is believed to activate MAPK pathway signaling."	24345920	PubMed		"Hutchinson et al., 2013, Clin. Cancer Res."		3	accepted	726	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/726	https://civicdb.org/links/molecular_profiles/282	FALSE	BRAF	673	PAPSS1::BRAF	BRAF Fusions	chr7	140734479	140787584			ENST00000265174.4	75	ENST00000288602.6	"gene_fusion,transcript_fusion"		2023-01-09 21:52:06 UTC		N/A	"T(4;7)(Q24;Q34),PAPSS1-BRAF"	FALSE
BRAF TRIM24::BRAF	283	Melanoma	1909		Trametinib		Predictive	Supports	D	Sensitivity/Response	"A TRIM24-BRAF fusion was identified in a single patient with metastatic melanoma that was ""pan-negative"" for driver mutations. A cell-line (293H) ectopically expressing the TRIM24-BRAF fusion was found to be sensitive to the MEK-inhibitor Trametinib."	24345920	PubMed		"Hutchinson et al., 2013, Clin. Cancer Res."		3	accepted	727	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/727	https://civicdb.org/links/molecular_profiles/283	FALSE	BRAF	673	TRIM24::BRAF	BRAF Fusions	chr7	138460334	138554966			ENST00000343526.4	75	ENST00000288602.6	transcript_fusion		2023-01-09 21:52:06 UTC		N/A	TRIM24-BRAF	FALSE
BRAF TRIM24::BRAF	283	Melanoma	1909		Trametinib		Predictive	Supports	D	Sensitivity/Response	"A TRIM24-BRAF fusion was identified in a single patient with metastatic melanoma that was ""pan-negative"" for driver mutations. A cell-line (293H) ectopically expressing the TRIM24-BRAF fusion was found to be sensitive to the MEK-inhibitor Trametinib."	24345920	PubMed		"Hutchinson et al., 2013, Clin. Cancer Res."		3	accepted	727	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/727	https://civicdb.org/links/molecular_profiles/283	FALSE	BRAF	673	TRIM24::BRAF	BRAF Fusions	chr7	140734479	140787584			ENST00000343526.4	75	ENST00000288602.6	transcript_fusion		2023-01-09 21:52:06 UTC		N/A	TRIM24-BRAF	FALSE
BRAF L597R	284	Melanoma	1909		Vemurafenib		Predictive	Supports	C	Sensitivity/Response	A case report of a patient with BRAF L597R mutation and clinical response to BRAF-inhibition (Vemurafenib) that correlated to in-vitro models.	23715574	PubMed		"Bahadoran et al., 2013, J. Clin. Oncol."		4	accepted	728	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/728	https://civicdb.org/links/molecular_profiles/284	FALSE	BRAF	673	L597R	Other BRAF V600's	chr7	140753345	140753345	A	C	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1790T>G,NP_004324.2:p.Leu597Arg,NC_000007.13:g.140453145A>C,ENST00000288602.6:c.1790T>G"	2023-01-27 17:03:26 UTC	CA123649	13968	"LEU597ARG,RS121913366"	FALSE
ERBB3 Overexpression	285	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	B	Resistance	High expression of ERBB3 (her3) was associated with shorter overall survival (OS) from Cetuximab treatment in patients with metastatic colorectal cancer. Gene expression measures (qRT-PCR) were available for 103 patients.	25520391	PubMed		"Cushman et al., 2015, Clin. Cancer Res."		4	accepted	729	N/A	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/729	https://civicdb.org/links/molecular_profiles/285	FALSE	ERBB3	2065	Overexpression		chr12	56079861	56103505			ENST00000267101.3	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
NT5E Overexpression	286	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	B	Sensitivity/Response	CD73 high expression was identified as a potential marker of improved PFS from cetuximab treatment in patients with metastatic CRC.	25520391	PubMed		"Cushman et al., 2015, Clin. Cancer Res."		3	accepted	730	N/A	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/730	https://civicdb.org/links/molecular_profiles/286	FALSE	NT5E	4907	Overexpression		chr6	85450091	85495778			ENST00000257770.3	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
EZH2 Overexpression	287	Cancer	162				Prognostic	Supports	B	Poor Outcome	High expression of EZH2 was associated with poorer outcome in a meta-analysis encompassing 51 studies and 9444 patients.	26683709	PubMed		"Jiang et al., 2016, Oncotarget"		4	accepted	731	N/A	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/731	https://civicdb.org/links/molecular_profiles/287	FALSE	EZH2	2146	Overexpression		chr7	148807385	148884278			ENST00000320356.2	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
IDH1 R132C	59	Acute Myeloid Leukemia	9119		GSK321		Predictive	Supports	D	Sensitivity/Response	Newly developed allosteric inhibitors (GSK321) of IDH1 led to granulocytic differentiation in-vitro and in-vivo.	26436839	PubMed		"Okoye-Okafor et al., 2015, Nat. Chem. Biol."		3	accepted	732	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/732	https://civicdb.org/links/molecular_profiles/59	FALSE	IDH1	3417	R132C		chr2	208248389	208248389	G	A	ENST00000415913.1	75		missense_variant	"NM_005896.3:c.394C>T,NP_005887.2:p.Arg132Cys,NC_000002.11:g.209113113G>A,ENST00000415913.1:c.394C>T"	2023-01-27 17:02:19 UTC	CA16602374	375891	"RS121913499,ARG132CYS"	FALSE
MET Amplification	266	Lung Non-small Cell Carcinoma	3908		Gefitinib		Predictive	Supports	D	Resistance	"In this study a gefitinib-sensitive cell-line (HCC827), acquired gefitinib resistance (HCC827 GR) by a focal amplification of MET.  Resistance was conferred by the MET amplification driving ERBB3 (HER3)-dependent activation of PI3K."	17463250	PubMed		"Engelman et al., 2007, Science"		4	accepted	733	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/733	https://civicdb.org/links/molecular_profiles/266	FALSE	MET	4233	Amplification		chr7	116672405	116796342			ENST00000318493.6	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A		FALSE
MYD88 Overexpression	288	Breast Cancer	1612		Paclitaxel		Predictive	Supports	D	Resistance	"In this retrospective analysis of 211 breast cancer tissues, MYD88 overexpression was correlated  with poor survival. In-vitro experiments showed a decrease in sensitivity towards paclitaxel in cell-lines with high MYD88 expression."	26596839	PubMed		"Xiang et al., 2016, Tumour Biol."		2	accepted	734	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/734	https://civicdb.org/links/molecular_profiles/288	FALSE	MYD88	4615	Overexpression		chr3	38138478	38143019			ENST00000417037.2	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
MET Amplification	266	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	C	Sensitivity/Response	A case-study of an ALK-negative patient with MET amplification (MET/CEP7 ratio >5.0) who achieved a durable partial response to MET/ALK-inhibitor crizotinib.	21623265	PubMed		"Ou et al., 2011, J Thorac Oncol"	NCT00585195	3	accepted	735	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/735	https://civicdb.org/links/molecular_profiles/266	FALSE	MET	4233	Amplification		chr7	116672405	116796342			ENST00000318493.6	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A		FALSE
MET Exon 14 Skipping Mutation	320	Cancer	162		Crizotinib		Predictive	Supports	D	Sensitivity/Response	The creation of a cell line model (HEK293) with MET exon 14 deletion (using the CRISPR/Cas9 system) led to enhanced cellular growth and sensitivity to the MET inhibitor crizotinib. MET exon 14 deletion results in an in-frame deletion in the MET protein. Recurrent splice site mutations that result in exon 14 skipping have been observed in ~3% of all lung cancers.	26547802	PubMed		"Togashi et al., 2015, Lung Cancer"		3	accepted	736	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/736	https://civicdb.org/links/molecular_profiles/320	FALSE	MET	4233	Exon 14 Skipping Mutation		chr7	116771849	116771989			ENST00000318493.6	75		exon_loss_variant		2023-01-09 21:52:06 UTC		N/A		FALSE
EGFR Overexpression	193	Lung Non-small Cell Carcinoma	3908		Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor		Predictive	Supports	B	Sensitivity/Response	"In this prospective study in 37 patients of whom 34 were treated with different EGFR inhibitors (gefitinib, erlotinib, afatinib), EGFR mutations and a higher relative expression of EGFR in comparison to MET expression were correlated with longer PFS."	26439803	PubMed		"Park et al., 2015, Oncotarget"		3	accepted	737	N/A	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/737	https://civicdb.org/links/molecular_profiles/193	FALSE	EGFR	1956	Overexpression		chr7	55019101	55211628			ENST00000275493.2	75		N/A		2023-01-09 21:52:05 UTC		N/A		FALSE
PDGFRA D842V	99	Gastrointestinal Stromal Tumor	9253		Imatinib		Predictive	Supports	B	Resistance	"823 patients with GIST under therapy with imatinib were genotyped for this study. 18 patients (2%) with PDGFRA mutations were identified. In D842V-mutant GISTs, PFS (median 3.8 months) and OS (median 25.2 months) were significantly poorer than Non-D842V mutated (PFS median 29.5 months OS median 59.8 months)."	26130666	PubMed		"Yoo et al., 2016, Cancer Res Treat"		4	accepted	738	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/738	https://civicdb.org/links/molecular_profiles/99	FALSE	PDGFRA	5156	D842V	Imatinib Resistance	chr4	54285926	54285926	A	T	ENST00000257290.5	75		missense_variant	"NM_006206.4:c.2525A>T,NP_006197.1:p.Asp842Val,ENST00000257290.5:c.2525A>T,NC_000004.11:g.55152093A>T"	2023-01-27 17:02:33 UTC	CA123194	13543	"ASP842VAL,RS121908585"	FALSE
PIK3CA P471L	290	Merkel Cell Carcinoma	3965		Idelalisib		Predictive	Supports	C	Sensitivity/Response	A case report of an 86-year old patient with metastasized Merkel cell carcinoma who achieved a complete clinical response under therapy with the PI3K-inhibitor Idelalisib.	26466009	PubMed		"Shiver et al., 2015, N. Engl. J. Med."		3	accepted	739	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/739	https://civicdb.org/links/molecular_profiles/290	FALSE	PIK3CA	5290	P471L		chr3	179210438	179210438	C	T	ENST00000263967.3	75		missense_variant	"ENST00000263967.3:c.1412C>T,NC_000003.11:g.178928226C>T,NM_006218.3:c.1412C>T,NP_006209.2:p.Pro471Leu"	2023-01-27 17:03:26 UTC	CA16602799	376359	"PRO471LEU,RS1057519872"	FALSE
RET Overexpression	593	Breast Cancer	1612		Vandetanib		Predictive	Supports	D	Sensitivity/Response	"Vandetanib was tested in 4 murine models of patient-derived xenografts. In xenografts with high expression of EGFR or RET, vandetanib led to tumor regression, in those without high expression, vandetanib slowed tumor growth."	26686064	PubMed		"Hatem et al., 2016, Int. J. Cancer"		2	accepted	740	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/740	https://civicdb.org/links/molecular_profiles/593	FALSE	RET	5979	Overexpression		chr10	43077027	43130351			ENST00000355710.3	75		N/A		2023-01-09 21:52:08 UTC		N/A		FALSE
RIT1 OVEREXPRESSION	292	Endometrial Cancer	1380				Prognostic	Supports	B	Poor Outcome	"After preliminary studies in cell lines, GEO datasets and fresh frozen tissues, RIT1 expression was determined in 257 tumors and 31 normal tissues. Elevated expression of RIT1 was correlated with poorer overall survival, pathological type, clinical stage, grade and vascular invasion."	26617739	PubMed		"Xu et al., 2015, Int J Clin Exp Pathol"		3	accepted	741	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/741	https://civicdb.org/links/molecular_profiles/292	FALSE	RIT1	6016	OVEREXPRESSION		chr1	155900274	155910915			ENST00000368322.3	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
RIT1 Mutation	293	Lung Adenocarcinoma	3910		"Pictilisib,Selumetinib"	Substitutes	Predictive	Supports	D	Sensitivity/Response	"RIT1 mutations were identified in approx. 2% of lung adenocarcinomas (5/87 in the ""oncogene negative"" samples of TCGA - no RIT1 mutations were observed in 143 samples with a known driver mutation). GDC-0941 impaired tumor growth of NCI-H2110 (RIT1 M90I mutated) xenografts in nude mice. GDC-0941 and AZD-6244 (selumetinib) impaired colony formation in-vitro. Combined PI3K/MEK inhibition was more effective than single agent treatment in-vitro."	24469055	PubMed		"Berger et al., 2014, Oncogene"		3	accepted	742	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/742	https://civicdb.org/links/molecular_profiles/293	FALSE	RIT1	6016	Mutation		chr1	155900274	155910915			ENST00000368322.3	75		transcript_variant		2023-01-09 21:52:06 UTC		N/A		FALSE
CD274 Expression	272	Lung Non-small Cell Carcinoma	3908		"Nivolumab,Pembrolizumab"	Substitutes	Predictive	Supports	B	Sensitivity/Response	"Based on a meta-analysis of 20 trials (1475 patients), PD-L1 expression was associated with a higher ORR rate in patients with NSCLC. Active drugs were Nivolumab and Pembrolizumab, PD-1 receptor targeting antibodies."	26086854	PubMed		"Carbognin et al., 2015, PLoS ONE"		4	accepted	743	N/A	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/743	https://civicdb.org/links/molecular_profiles/272	FALSE	CD274	29126	Expression		chr9	5450525	5470547			ENST00000381577.3	75		N/A	N/A	2023-01-09 21:52:06 UTC		N/A		FALSE
MYCN Amplification	294	Neuroblastoma	769		FACT Complex-targeting Curaxin CBL0137		Predictive	Supports	D	Sensitivity/Response	"The drug CBL0137 (a drug that interacts with SSRP1 aka FACT) exhibited a synergistic effect with standard chemotherapy (cyclophosphamide, etoposide, cisplatin, vincristine, etc.) by blocking repair of DNA damage caused by genotoxic drugs, thus creating a synthetic lethal environment in MYCN-amplified neuroblastoma cells. High MYCN expression was found to sensitize neuroblastoma cells to CBL0137."	26537256	PubMed		"Carter et al., 2015, Sci Transl Med"		3	accepted	744	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/744	https://civicdb.org/links/molecular_profiles/294	FALSE	MYCN	4613	Amplification		chr2	15940564	15947007			ENST00000281043.3	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A		FALSE
SMO D473H	295	Medulloblastoma	50902		Vismodegib		Predictive	Supports	C	Resistance	"In this case report, the D473H mutation was reported as an acquired mechanism of resistance to the hedgehog pathway inhibitor GDC-0449 (vismodegib)."	19726788	PubMed		"Yauch et al., 2009, Science"		3	accepted	745	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/745	https://civicdb.org/links/molecular_profiles/295	FALSE	SMO	6608	D473H		chr7	129209348	129209348	G	C	ENST00000249373.3	75		missense_variant	"NM_005631.4:c.1417G>A,NP_005622.1:p.Asp473His,ENST00000249373.3:c.1417G>A,NC_000007.13:g.128849189G>C"	2023-01-27 17:03:27 UTC	CA16602418	375938	ASP473HIS	FALSE
SMO Mutation	296	Basal Cell Carcinoma	2513		Vismodegib		Predictive	Supports	B	Resistance	"In basal cell carcinoma, H231R, D473G, W281C and Q477E mutations conferred resistance to SMO-inhibitor vismodegib. SMO mutations were identified in 22 of 44 resistant basal cell carcinomas in 15 patients."	25759020	PubMed		"Atwood et al., 2015, Cancer Cell"		4	accepted	746	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/746	https://civicdb.org/links/molecular_profiles/296	FALSE	SMO	6608	Mutation		chr7	129188872	129213545			ENST00000249373.3	75		coding_transcript_variant		2023-01-09 21:52:06 UTC		N/A		FALSE
SMO Mutation	296	Basal Cell Carcinoma	2513		"Arsenic Trioxide,PSI"	Substitutes	Predictive	Supports	D	Sensitivity/Response	Basal cell carcinomas with ligand-binding pocket or constitutively active mutations in the SMO gene were sensitive to inhibition of downstream hedgehog signaling with PSI (aPKC-//GLI inhibitor) or arsenic trioxide.	25759020	PubMed		"Atwood et al., 2015, Cancer Cell"		4	accepted	747	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/747	https://civicdb.org/links/molecular_profiles/296	FALSE	SMO	6608	Mutation		chr7	129188872	129213545			ENST00000249373.3	75		coding_transcript_variant		2023-01-09 21:52:06 UTC		N/A		FALSE
PTCH1 Mutation	297	Medulloblastoma	50902		Sonidegib		Predictive	Supports	B	Sensitivity/Response	"133 sonic-hedghog driven medulloblastomas were sequenced for alterations (WGS or WES). 60 cases exhibited PTCH1 mutations, most of which were likely loss-of-function (spread across the gene and of types including: stop gain, splice site, frameshift, etc.). Functional models also showed PTCH1 mutant xenografts to be sensitive to SHH inhibition with sonidegib."	24651015	PubMed		"Kool et al., 2014, Cancer Cell"		4	accepted	748	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/748	https://civicdb.org/links/molecular_profiles/297	FALSE	PTCH1	5727	Mutation		chr9	95442980	95508661			ENST00000331920.6	75		"gene_variant,loss_of_function_variant"		2023-01-09 21:52:06 UTC				FALSE
PTCH1 LOH	298	Medulloblastoma	50902		Vismodegib		Predictive	Supports	B	Sensitivity/Response	"Loss-of-heterozygosity in SHH-driven medulloblastoma was associated with increased PFS under therapy with vismodegib (AKA HhAntag691, GDC0449, GDC-0449). 43 patients total were enrolled for this study."	26169613	PubMed		"Robinson et al., 2015, J. Clin. Oncol."	"NCT00939484,NCT01239316"	2	accepted	749	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/749	https://civicdb.org/links/molecular_profiles/298	FALSE	PTCH1	5727	LOH		chr9	95442980	95508661			ENST00000331920.6	75		loss_of_heterozygosity		2023-01-09 21:52:06 UTC		N/A		FALSE
STK11 EXON 1-2 MUTATION	299	Lung Non-small Cell Carcinoma	3908				Prognostic	Supports	B	Poor Outcome	"In a retrospective analysis of 567 non-squamous, non-small cell lung cancer patients, Exon 1-2 mutations in STK11 were significantly associated with shorter OS (24 vs. 69 months) also after multivariate analysis. Results were validated in public datasets."	26625312	PubMed		"Pcuchet et al., 2015, Oncotarget"		4	accepted	750	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/750	https://civicdb.org/links/molecular_profiles/299	FALSE	STK11	6794	EXON 1-2 MUTATION		chr19	1205741	1218500			ENST00000326873.7	75		exon_variant		2023-01-09 21:52:06 UTC				FALSE
STK11 Underexpression	300	Prostate Cancer	10283		SB202190		Predictive	Supports	D	Sensitivity/Response	STK11-deficient cells were sensitive to treatment with MAPK11 inhibitor SB202190.	26391455	PubMed		"Grossi et al., 2015, Autophagy"		2	accepted	751	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/751	https://civicdb.org/links/molecular_profiles/300	FALSE	STK11	6794	Underexpression		chr19	1205741	1228429			ENST00000326873.7	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
SYK OVEREXPRESSION	301	Ovarian Cancer	2394		Paclitaxel		Predictive	Supports	D	Resistance	Overexpression and high p-SYK/SYK ratio were associated with resistance to paclitaxel. Inhibition of SYK with R406 resensitized cell lines to paclitaxel.	26096845	PubMed		"Yu et al., 2015, Cancer Cell"		3	accepted	752	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/752	https://civicdb.org/links/molecular_profiles/301	FALSE	SYK	6850	OVEREXPRESSION		chr9	90801787	90898549			ENST00000375754.4	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
CDKN2A p16 Expression	268	Head And Neck Squamous Cell Carcinoma	5520		Panitumumab		Predictive	Supports	B	Sensitivity/Response	p16-negative patients (HPV negative) have a longer overall survival under panitumumab/chemotherapy in comparison to chemotherapy alone.	23746666	PubMed		"Vermorken et al., 2013, Lancet Oncol."	NCT00460265	3	accepted	753	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/753	https://civicdb.org/links/molecular_profiles/268	FALSE	CDKN2A	1029	p16 Expression		chr9	21968056	21974866			ENST00000498124.1	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
PRKACA DNAJB1::PRKACA	31	Fibrolamellar Carcinoma	5015				Diagnostic	Supports	B	Positive	The DNAJB1-PRKACA fusion was detected in 79% (58/73) of fibrolamellar hepatocellular carcinomas assayed.	25557953	PubMed		"Cornella et al., 2015, Gastroenterology"		4	accepted	754	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/754	https://civicdb.org/links/molecular_profiles/31	FALSE	PRKACA	5566	DNAJB1::PRKACA		chr19	14518139	14518420			ENST00000254322.2	75	ENST00000308677.4	transcript_fusion		2023-01-09 21:52:04 UTC		N/A	DNAJB1-PRKACA	FALSE
PRKACA DNAJB1::PRKACA	31	Fibrolamellar Carcinoma	5015				Diagnostic	Supports	B	Positive	The DNAJB1-PRKACA fusion was detected in 79% (58/73) of fibrolamellar hepatocellular carcinomas assayed.	25557953	PubMed		"Cornella et al., 2015, Gastroenterology"		4	accepted	754	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/754	https://civicdb.org/links/molecular_profiles/31	FALSE	PRKACA	5566	DNAJB1::PRKACA		chr19	14091688	14107409			ENST00000254322.2	75	ENST00000308677.4	transcript_fusion		2023-01-09 21:52:04 UTC		N/A	DNAJB1-PRKACA	FALSE
SMO D473H	295	Basal Cell Carcinoma	2513		Vismodegib		Predictive	Supports	D	Resistance	"D473 mutations were identified in 5/30 resistant basal cell carcinomas. Crystal structure indicated this mutation interacts with a water molecule in the ligand binding pocket, putatively altering its interaction with the SMO inhibitor vismodegib. SMO-/- mouse embryonic fibroblasts expressing the SMO D473G mutant maintained hedgehog signaling in the presence of the drug and had IC50 values >40 fold higher than cells expressing wildtype SMO."	25759020	PubMed		"Atwood et al., 2015, Cancer Cell"		3	accepted	755	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/755	https://civicdb.org/links/molecular_profiles/295	FALSE	SMO	6608	D473H		chr7	129209348	129209348	G	C	ENST00000249373.3	75		missense_variant	"NM_005631.4:c.1417G>A,NP_005622.1:p.Asp473His,ENST00000249373.3:c.1417G>A,NC_000007.13:g.128849189G>C"	2023-01-27 17:03:27 UTC	CA16602418	375938	ASP473HIS	FALSE
PIK3CA Amplification	212	Epithelial Ovarian Cancer	2152		Pictilisib		Predictive	Supports	C	Sensitivity/Response	One platinum-refractory epithelial ovarian cancer patient with PTEN loss and PIK3CA amplification had a partial response on treatment with PI3K inhibitor pictilisib (GDC-0941) in this phase 1 study. A total of 60 patients with advanced solid tumors were enrolled in this study.	25370471	PubMed		"Sarker et al., 2015, Clin. Cancer Res."		2	accepted	756	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/756	https://civicdb.org/links/molecular_profiles/212	FALSE	PIK3CA	5290	Amplification		chr3	179148523	179240093			ENST00000263967.3	75		transcript_amplification	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
BRAF V600E	12	Melanoma	1909		Pictilisib		Predictive	Supports	C	Sensitivity/Response	"One patient with BRAF V600E mutated melanoma (with no detected PI3K pathway deregulation) had a partial response on treatment with pictilisib, a PI3K inhibitor, for 9.5 months. Study was a phase-1 with 60 patients enrolled."	25370471	PubMed		"Sarker et al., 2015, Clin. Cancer Res."		2	accepted	757	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/757	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
CDKN2A p16 Expression	268	Oropharynx Cancer	8557				Prognostic	Supports	A	Better Outcome	720 patients with stage III/IV oropharyngeal cancer were retrospectively analyzed for p16 and HPV status. p16 and HPV-positivity correlated well and both showed improved overall-survival compared to patients with HPV-negative/p16 negative tumors. HPV/p16 status was shown to be a strong and independent risk factor in oropharyngeal carcinoma.	20530316	PubMed		"Ang et al., 2010, N. Engl. J. Med."	NCT00047008	4	accepted	758	N/A	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/758	https://civicdb.org/links/molecular_profiles/268	FALSE	CDKN2A	1029	p16 Expression		chr9	21968056	21974866			ENST00000498124.1	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
CDKN2A p16 Expression	268	Oropharynx Cancer	8557		Cetuximab		Predictive	Does Not Support	B	Resistance	This study shows that benefit of EGFR inhibition in addition to radiotherapy was independent of p16/HPV status. 182 patients were evaluated.	26712222	PubMed		"Rosenthal et al., 2016, J. Clin. Oncol."		4	accepted	759	N/A	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/759	https://civicdb.org/links/molecular_profiles/268	FALSE	CDKN2A	1029	p16 Expression		chr9	21968056	21974866			ENST00000498124.1	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
ERBB2 Amplification	302	Breast Cancer	1612		AKTi-1/2		Predictive	Supports	D	Sensitivity/Response	Xenografts established from breast cancer cell lines with ERBB2 amplification and PIK3CA mutation (BT474) or PIK3CA mutation alone (MCF7) were effectively inhibited in-vivo with an AKT1/2-inhibitor (AKTi-1/2; naphthyridinone).	18725974	PubMed		"She et al., 2008, PLoS ONE"		3	accepted	760	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/760	https://civicdb.org/links/molecular_profiles/302	FALSE	ERBB2	2064	Amplification		chr17	39700080	39728662			ENST00000269571.5	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A	OVEREXPRESSION	FALSE
ERBB2 Amplification	302	Her2-receptor Positive Breast Cancer	60079		Neratinib		Predictive	Supports	B	Sensitivity/Response	"Oral neratinib showed objective response rates of 24 and 56% respectively in prior-trastuzumab (n=63) and trastuzumab-naive (n=64) cohorts in a Phase II trial. As for the primary endpoint, the 16-week progression free survival was 59% in the prior-trastuzumab + neratibin patients and 78% in the trastuzumab-naive + neratinib patients. Overall, neratinib treatment results in substantial clinical activity and is well tolerated by patients."	20142587	PubMed		"Burstein et al., 2010, J. Clin. Oncol."		3	accepted	761	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/761	https://civicdb.org/links/molecular_profiles/302	FALSE	ERBB2	2064	Amplification		chr17	39700080	39728662			ENST00000269571.5	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A	OVEREXPRESSION	FALSE
EGFR T790M	34	Lung Non-small Cell Carcinoma	3908		Rociletinib		Predictive	Supports	D	Sensitivity/Response	CO-1686 (Rociletinib) more effectively induced apoptosis in EGFR mutated (T790M and others) NSCLC cell lines than those harboring wildtype EGFR. CO-1686 also more effectively reduced tumor volume of mouse xenografts harboring the T790M than those with wildtype EGFR.	24065731	PubMed		"Walter et al., 2013, Cancer Discov"		3	accepted	762	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/762	https://civicdb.org/links/molecular_profiles/34	FALSE	EGFR	1956	T790M	EGFR TKI Resistance	chr7	55181378	55181378	C	T	ENST00000275493.2	75		missense_variant	"ENST00000275493.2:c.2369C>T,NM_005228.4:c.2369C>T,NP_005219.2:p.Thr790Met,NC_000007.13:g.55249071C>T"	2023-01-27 17:02:05 UTC	CA090928	16613	"THR790MET,RS121434569"	FALSE
ERBB4 Mutation	306	Melanoma	1909		Lapatinib		Predictive	Supports	D	Sensitivity/Response	"ERBB4 was the most commonly mutated protein tyrosine kinase in this study in melanoma (19% in 79 patients). Seven of the identified mutations in ERBB4 (E317K, E452K, E542K, R544W, E563K, E836K and E872K) were transforming and activating in-vitro. ERBB4 inhibition with shRNA or lapatinib led to reduced cell growth."	19718025	PubMed		"Prickett et al., 2009, Nat. Genet."		4	accepted	770	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/770	https://civicdb.org/links/molecular_profiles/306	FALSE	ERBB4	2066	Mutation		chr2	211430972	211713583			ENST00000342788.4	75		"transcript_variant,gain_of_function_variant"		2023-01-09 21:52:06 UTC				FALSE
PIK3CA Mutation	307	Colorectal Cancer	9256		Cabozantinib		Predictive	Supports	D	Sensitivity/Response	"20 patient-derived colorectal cancer xenografts were treated with cabozantinib, a c-MET and VEGFR2 inhibitor. 16 xenografts showed sensitivity (as defined by TGII: tumor growth of treated compared to control?0%). Among the genes tested for mutations (KRAS, TP53, PIK3CA, MET, VEGFR2, RET and AXL), PIK3CA mutations (4 PDTX) showed a significant enrichment in sensitive xenografts. PIK3CA mutations were observed in 4/5 of the most responsive tumors. Treating xenografts derived from isogenic PIK3CA wildtype or mutant cell lines corroborated this finding with PIK3CA mutant xenografts showing greater sensitivity to cabozantinib."	25242168	PubMed		"Song et al., 2015, Int. J. Cancer"		3	accepted	771	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/771	https://civicdb.org/links/molecular_profiles/307	FALSE	PIK3CA	5290	Mutation		chr3	179148523	179240093			ENST00000263967.3	75		"transcript_variant,gain_of_function_variant"		2023-01-09 21:52:06 UTC		N/A		FALSE
EGFR VIII	308	Glioblastoma	3068		Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor		Predictive	Supports	B	Sensitivity/Response	49 patients (26 pretreatment tissues available for analysis) with recurrent glioblastomas who were treated with EGFR TKIs were analyzed in this study. Results were confirmed in an independent cohort of 33 patients. EGFRvIII and PTEN coexpression were associated with responsiveness to EGFR TKI.	16282176	PubMed		"Mellinghoff et al., 2005, N. Engl. J. Med."		4	accepted	772	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/772	https://civicdb.org/links/molecular_profiles/308	FALSE	EGFR	1956	VIII		chr7	55019365	55155830			ENST00000275493.2	75		disruptive_inframe_deletion	"NM_005228.3:c.89_881del,NP_005219.2:p.Val30_Arg297delinsGly,NC_000007.13:g.55209979_55221845del"	2023-01-09 21:52:06 UTC				FALSE
EGFR VIII	308	Glioblastoma	3068		Afatinib		Predictive	Supports	C	Sensitivity/Response	"Case report of a 58-year old patient with disease progression after radiotherapy and three temozolomide cycles. Afatinib and temozolomide led to disease regression. At last assessment 63 treatment cycles had been completed and the patient had survived for about 5 years since recurrence. Identified EGFR aberrations included EGFRvIII positivity, EGFR gene amplification and three somatic EGFR mutations."	26423602	PubMed		"Alshami et al., 2015, Oncotarget"		2	accepted	773	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/773	https://civicdb.org/links/molecular_profiles/308	FALSE	EGFR	1956	VIII		chr7	55019365	55155830			ENST00000275493.2	75		disruptive_inframe_deletion	"NM_005228.3:c.89_881del,NP_005219.2:p.Val30_Arg297delinsGly,NC_000007.13:g.55209979_55221845del"	2023-01-09 21:52:06 UTC				FALSE
PTEN Expression	309	Glioblastoma	3068		Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor		Predictive	Supports	B	Sensitivity/Response	49 patients (26 pretreatment tissues available for analysis) with recurrent glioblastomas who were treated with EGFR TKIs were analyzed in this study. Results were confirmed in an independent cohort of 33 patients. EGFRvIII and PTEN coexpression were associated with responsiveness to EGFR TKI.	16282176	PubMed		"Mellinghoff et al., 2005, N. Engl. J. Med."		4	accepted	774	N/A	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/774	https://civicdb.org/links/molecular_profiles/309	FALSE	PTEN	5728	Expression		chr10	87863113	87971930			ENST00000371953.3	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
PTEN Expression	309	Glioblastoma	3068		Dacomitinib		Predictive	Supports	D	Sensitivity/Response	"In this preclinical study, the EGFR inhibitor dacomitinib had an effect on cell viability, self-renewal and proliferation in EGFR amplified GBM cells in-vitro and in-vivo (with or without the EGFRvIII mutation). It was less effective in one cell-line with PTEN deletion."	25939761	PubMed		"Zahonero et al., 2015, Mol. Cancer Ther."		2	accepted	775	N/A	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/775	https://civicdb.org/links/molecular_profiles/309	FALSE	PTEN	5728	Expression		chr10	87863113	87971930			ENST00000371953.3	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
NRG1 Expression	310	Head And Neck Squamous Cell Carcinoma	5520		Lapatinib		Predictive	Supports	D	Sensitivity/Response	"In non-HER2 amplified cell lines, sensitivity to HER2 kinase inhibitor lapatinib was found mainly in cell-lines with elevated NRG1 expression and HER3 activation. This aberration was mainly identified in head and neck cancer cell lines."	21840482	PubMed		"Wilson et al., 2011, Cancer Cell"		4	accepted	776	N/A	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/776	https://civicdb.org/links/molecular_profiles/310	FALSE	NRG1	3084	Expression		chr8	31640426	32764776			ENST00000523534.1	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
NRG1 Expression	310	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	D	Resistance	NRG1 upregulation or ERBB2 amplification were the main causes of resistance to cetuximab in-vivo and in-vitro in this study. Inhibition of ERBB2/ERBB3 signaling restored cetuximab sensitivity.	21900593	PubMed		"Yonesaka et al., 2011, Sci Transl Med"		4	accepted	777	N/A	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/777	https://civicdb.org/links/molecular_profiles/310	FALSE	NRG1	3084	Expression		chr8	31640426	32764776			ENST00000523534.1	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
NRG1 Expression	310	Ovarian Cancer	2394		Seribantumab		Predictive	Supports	D	Sensitivity/Response	An NRG1-ERBB3 autocrine signal-transducing loop was identified in a subset of ovarian cancers and cell lines. Disruption of this loop led to decreased cell-growth in-vitro and prolonged survival in-vivo. An ERBB3 directed antibody (MM-121) inhibited tumor-growth in-vivo.	20227043	PubMed		"Sheng et al., 2010, Cancer Cell"		3	accepted	778	N/A	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/778	https://civicdb.org/links/molecular_profiles/310	FALSE	NRG1	3084	Expression		chr8	31640426	32764776			ENST00000523534.1	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
NRG1 Expression	310	Lung Non-small Cell Carcinoma	3908		"Carboplatin,Paclitaxel,Cisplatin,Gemcitabine"	Substitutes	Predictive	Supports	D	Sensitivity/Response	In-vivo studies of residual NSCLC tumors (xenografts of 5 cell lines) after chemotherapy found increased EGFR-family signaling and NRG1 expression. NRG1 inhibition (YW538.24.71 antibody) led to decreased tumor growth and enhanced magnitude and response to chemotherapy.	23390248	PubMed		"Hegde et al., 2013, Sci Transl Med"		3	accepted	779	N/A	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/779	https://civicdb.org/links/molecular_profiles/310	FALSE	NRG1	3084	Expression		chr8	31640426	32764776			ENST00000523534.1	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
AREG Expression	311	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	D	Resistance	A cell line (DFCI076) with EML1-ALK fusion and resistance mutation L1152R showed no response to ALK inhibition with crizotinib or TAE684. There was co-dependancy on AKT and EGFR-signaling and inhibition of both pathways led to decreased cell-growth. Amphiregulin (AREG) production was identified as a potential mediator of EGFR-activation (no other alterations detectable). The same mechanism could be reproduced in a cell line (H3122) without EML1-ALK mutation and resistance to crizotinib that was acquired in-vitro.	21791641	PubMed		"Sasaki et al., 2011, Cancer Res."		3	accepted	780	N/A	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/780	https://civicdb.org/links/molecular_profiles/311	FALSE	AREG	374	Expression		chr4	74445134	74455009			ENST00000395748.3	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
AREG Expression	311	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	B	Resistance	Five patients with acquired resistance to crizotinib showed high concentration of amphiregulin in malignant pleural effusions.	23344087	PubMed		"Kim et al., 2013, J Thorac Oncol"		2	accepted	781	N/A	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/781	https://civicdb.org/links/molecular_profiles/311	FALSE	AREG	374	Expression		chr4	74445134	74455009			ENST00000395748.3	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
EGFR Overexpression	193	Head And Neck Squamous Cell Carcinoma	5520				Prognostic	Supports	B	Poor Outcome	Primary tumors of 91 patients with head and neck squamous cell carcinoma were analyzed for expression of EGFR and TGF-alpha using IHC. Expression of EGFR or TGF-alpha were associated with reduced disease-free and cause-specific survival.	9625170	PubMed		"Rubin Grandis et al., 1998, J. Natl. Cancer Inst."		3	accepted	782	N/A	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/782	https://civicdb.org/links/molecular_profiles/193	FALSE	EGFR	1956	Overexpression		chr7	55019101	55211628			ENST00000275493.2	75		N/A		2023-01-09 21:52:05 UTC		N/A		FALSE
EGFR Overexpression	193	Esophagus Squamous Cell Carcinoma	3748		Nimotuzumab		Predictive	Does Not Support	B	Sensitivity/Response	55 tumor samples were analyzed for EGFR expression using IHC. The objective response rate to anti-EGFR antibody nimotuzumab did not differ significantly between EGFR high- (18 pts) and EGFR low to moderate groups (37 pts).	26459251	PubMed		"Jia et al., 2016, Clin Transl Oncol"		3	accepted	783	N/A	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/783	https://civicdb.org/links/molecular_profiles/193	FALSE	EGFR	1956	Overexpression		chr7	55019101	55211628			ENST00000275493.2	75		N/A		2023-01-09 21:52:05 UTC		N/A		FALSE
EGFR Overexpression	193	Esophagus Squamous Cell Carcinoma	3748				Prognostic	Supports	B	Poor Outcome	"55 tumor samples were analyzed for EGFR expression using IHC. PFS and OS was shorter for the EGFR high expressing group (18 pts) than for the low to moderate expression group (37 pts). PFS: 5.8  0.5 vs. 11.0  2.8 months, P = 0.007; OS: 9.7  0.5 vs. 21.5  1.5 months, P = 0.03."	26459251	PubMed		"Jia et al., 2016, Clin Transl Oncol"		3	accepted	784	N/A	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/784	https://civicdb.org/links/molecular_profiles/193	FALSE	EGFR	1956	Overexpression		chr7	55019101	55211628			ENST00000275493.2	75		N/A		2023-01-09 21:52:05 UTC		N/A		FALSE
TGFA EXPRESSION	312	Head And Neck Squamous Cell Carcinoma	5520				Prognostic	Supports	B	Poor Outcome	Primary tumors of 91 patients with head and neck squamous cell carcinoma were analyzed for expression of EGFR and TGF-alpha using IHC. Expression of EGFR or TGF-alpha were associated with reduced disease-free and cause-specific survival.	9625170	PubMed		"Rubin Grandis et al., 1998, J. Natl. Cancer Inst."		3	accepted	785	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/785	https://civicdb.org/links/molecular_profiles/312	FALSE	TGFA	7039	EXPRESSION		chr2	70447280	70554015			ENST00000295400.6	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
EGFR G724S	313	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	D	Sensitivity/Response	"Whole genome sequencing of a case of colon carcinoma revealed a G724S mutation in the EGFR gene. In-vitro, this mutation was shown to be oncogenic and sensitive to Cetuximab, yet relatively insensitive towards small molecules."	24894453	PubMed		"Cho et al., 2014, Mol. Cancer"		4	accepted	786	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/786	https://civicdb.org/links/molecular_profiles/313	FALSE	EGFR	1956	G724S		chr7	55174029	55174029	G	A	ENST00000275493.2	75		missense_variant	"ENST00000275493.2:c.2170G>A,NC_000007.13:g.55241722G>A,NM_005228.4:c.2170G>A,NP_005219.2:p.Gly724Ser"	2023-01-27 17:03:30 UTC	CA16602800	376360	"GLY724SER,RS1051753269"	FALSE
EGFR G719S	134	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	D	Sensitivity/Response	"Whole genome sequencing of a case of colon carcinoma revealed a G724S mutation in the EGFR gene. In-vitro, this mutation was shown to be oncogenic and sensitive to Cetuximab, yet relatively insensitive towards small molecules. The same in-vitro results could be reproduced for the G719S mutation."	24894453	PubMed		"Cho et al., 2014, Mol. Cancer"		4	accepted	787	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/787	https://civicdb.org/links/molecular_profiles/134	FALSE	EGFR	1956	G719S		chr7	55174014	55174014	G	A	ENST00000275493.2	75		missense_variant	"ENST00000275493.2:c.2155G>A,NC_000007.13:g.55241707G>A,NM_005228.4:c.2155G>A,NP_005219.2:p.Gly719Ser"	2023-01-27 17:02:49 UTC	CA126722	16612	"GLY719SER,RS28929495"	FALSE
AREG Expression	311	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	B	Sensitivity/Response	"226 cetuximab-treated patients with colorectal cancer (CRC) were analyzed for mRNA expression (by qPCR) of EGFR and its ligands (EGF, TGFA, AREG and EREG). High AREG mRNA expression in KRAS wild type tumours was a favorable predictor in a multivariate analysis (median survival 33 vs. 15months, p=0.0005).   Cetuximab-treated patients with AREG-low KRAS wild type CRC had poor survival, similar to KRAS mutated CRC."	23374602	PubMed		"Pentheroudakis et al., 2013, BMC Cancer"		3	accepted	788	N/A	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/788	https://civicdb.org/links/molecular_profiles/311	FALSE	AREG	374	Expression		chr4	74445134	74455009			ENST00000395748.3	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
EREG EXPRESSION	314	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	B	Sensitivity/Response	"226 cetuximab-treated patients with CRC were analyzed for mRNA expression of EGFR and its ligands. Favorable predictors in a multivariate analysis were high AREG mRNA in KRAS wild type tumours, high EREG mRNA and low Ephrin A2 receptor mRNA."	23374602	PubMed		"Pentheroudakis et al., 2013, BMC Cancer"		3	accepted	789	N/A	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/789	https://civicdb.org/links/molecular_profiles/314	FALSE	EREG	2069	EXPRESSION		chr4	74365143	74388751			ENST00000244869.2	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
MAPK1 E322K	316	Head And Neck Squamous Cell Carcinoma	5520		Erlotinib		Predictive	Supports	C	Sensitivity/Response	Case report of a patient with stage IVA HNSCC with near-complete histologic response after 13 days of neoadjuvant erlotinib. Whole-exome sequencing of the pre-treatment tumor revealed a MAPK1 E322K mutation (allelic fraction 0.13). In-vitro studies in two HNSCC cell lines showed enhanced EGFR phosphorylation and erlotinib sensitivity in the mutant line compared with the wild-type line.	26181029	PubMed		"Van Allen et al., 2015, JAMA Oncol"	NCT00779389	4	accepted	791	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/791	https://civicdb.org/links/molecular_profiles/316	FALSE	MAPK1	5594	E322K		chr22	21772875	21772875	C	T	ENST00000215832.6	75		"missense_variant,gain_of_function_variant"	"ENST00000215832.6:c.964G>A,NC_000002.11:g.22127164C>T,NP_002736.3:p.Glu322Lys,NM_002745.4:c.964G>A"	2023-01-27 17:03:30 UTC	CA16602885	376450	GLU322LYS	FALSE
MAPK1 Amplification	317	Lung Non-small Cell Carcinoma	3908		WZ4002		Predictive	Supports	D	Resistance	"Resistance to WZ4002 was induced in cell lines. Amplification of MAPK1 or downregulation of ERK-pathway inhibitors led to resistance to EGFR inhibition with WZ4002. Chemical inhibition (MEK inhibition with either CI-1040 or GSK1120212) or shRNA knockdown of MAPK1 resensitized cells to EGFR inhibition with WZ4002 in-vitro. Additionally, MAPK1 amplification was identified in 1/21 erlotinib-resistant NSCLC patients. MAPK1 amplification was not observed in the pretreatment tumor, only the post-treatment resistant tumor which lacked other more common drug-resistance mechanisms EGFR T790M or MET amplification."	22961667	PubMed		"Ercan et al., 2012, Cancer Discov"		4	accepted	792	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/792	https://civicdb.org/links/molecular_profiles/317	FALSE	MAPK1	5594	Amplification		chr22	21754500	21867629			ENST00000215832.6	75		transcript_amplification		2023-01-09 21:52:06 UTC		N/A		FALSE
FGFR1 Expression	264	Breast Cancer	1612				Prognostic	Supports	B	Poor Outcome	"FGFR1 expression, was assessed by IHC in 1,086 invasive breast cancers. FGFR1 expression was mainly associated with luminal cancer subtypes. Multivariate Cox regression analysis showed FGFR1 to be an independent poor prognostic marker in luminal A cancers for disease free survival (hazard ratio = 3.341, p = 0.008). In luminal A cancers, FGFR1 expression was also significantly associated with higher pN (lymph node metastases; p = 0.023) and pT (unfavorable tumor characteristics; p = 0.003) stages and lymphovascular invasion (p = 0.010)."	26673008	PubMed		"Shi et al., 2016, Oncotarget"		2	accepted	793	N/A	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/793	https://civicdb.org/links/molecular_profiles/264	FALSE	FGFR1	2260	Expression		chr8	38411138	38467845			ENST00000425967.3	75		N/A	N/A	2023-01-09 21:52:06 UTC		N/A		FALSE
KRAS A146V	318	Lung Non-small Cell Carcinoma	3908		Abemaciclib		Predictive	Supports	C	Sensitivity/Response	"Case report of a patient with metastatic lung adenocarcinoma. Whole exome sequencing of the metastatic tumor revealed KRAS A146V, STK11 frameshift deletion and ATM alteration. Preclinical evidence led to administration of CDK4 inhibitor LY2835219. Specifically, the PHIAL algorithm nominated this variant as actionable on the basis of a predicted synthetic lethal relationship between activated KRAS and CDK4. The patient achieved stable disease and was on treatment for 16 weeks which was the patients best and only clinical response to any cancer-directed therapy."	24836576	PubMed		"Van Allen et al., 2014, Nat. Med."		2	accepted	794	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/794	https://civicdb.org/links/molecular_profiles/318	FALSE	KRAS	3845	A146V		chr12	25225627	25225627	G	A	ENST00000256078.4	75		missense_variant	"ENST00000256078.4:c.437C>T,NC_000012.11:g.25378561G>A,NP_004976.2:p.Ala146Val,NM_004985.4:c.437C>T"	2023-01-27 17:03:31 UTC	CA16602440	375962	"ALA146VAL,RS1057519725"	FALSE
KRAS G12V	421	Lung Non-small Cell Carcinoma	3908		Palbociclib		Predictive	Supports	D	Sensitivity/Response	"In vivo studies confirmed the activity of PD0332991 (CDK4 inhibitor) on KRAS G12V mutant tumors. 17% (2/12) of mice treated with PD0332991 developed detectable lesions, whereas 75% of mice (3/4) treated with vehicle developed lesions at the end of the treatment."	20609353	PubMed		"Puyol et al., 2010, Cancer Cell"		1	accepted	795	Somatic	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/795	https://civicdb.org/links/molecular_profiles/421	FALSE	KRAS	3845	G12V		chr12	25245350	25245350	C	A	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.35G>T,NP_004976.2:p.Gly12Val,NC_000012.11:g.25398284C>A,ENST00000256078.4:c.35G>T"	2023-01-27 17:03:41 UTC	CA122540	12583	"GLY12VAL,RS121913529"	FALSE
MET Mutation	319	Papillary Renal Cell Carcinoma	4465		Foretinib		Predictive	Supports	B	Sensitivity/Response	"In a retrospective analysis of 74 patients with papillary renal cell carcinoma, treated with foretinib, MET germline mutation was associated with improved response rate.  A response was observed in 5 of 10 (50%) vs. 5 of 57 (8.8%) patients with and without germline MET mutations, respectively."	23213094	PubMed		"Choueiri et al., 2013, J. Clin. Oncol."	NCT00726323	3	accepted	796	Rare Germline	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/796	https://civicdb.org/links/molecular_profiles/319	FALSE	MET	4233	Mutation		chr7	116672405	116796342			ENST00000318493.6	75		"transcription_variant,gain_of_function_variant"		2023-01-09 21:52:06 UTC		N/A		FALSE
MET Exon 14 Skipping Mutation	320	Lung Adenocarcinoma	3910		Crizotinib		Predictive	Supports	C	Sensitivity/Response	We now report responses to the MET inhibitors crizotinib and cabozantinib in four patients with stage IV lung adenocarcinomas harboring mutations leading to MET exon 14 skipping.	25971939	PubMed		"Paik et al., 2015, Cancer Discov"		3	accepted	797	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/797	https://civicdb.org/links/molecular_profiles/320	FALSE	MET	4233	Exon 14 Skipping Mutation		chr7	116771849	116771989			ENST00000318493.6	75		exon_loss_variant		2023-01-09 21:52:06 UTC		N/A		FALSE
FGFR1 Expression	264	Head And Neck Squamous Cell Carcinoma	5520				Prognostic	Does Not Support	B	Poor Outcome	"This review identified 12 studies that addressed the prognostic role of FGFRs in HNSSC. Evidence was found for the expression of FGFR1 in cancer-associated fibroblasts, other results were conflicting. Significant risk of bias was reported for the included studies."	26115874	PubMed		"Ipenburg et al., 2016, Target Oncol"		2	accepted	798	N/A	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/798	https://civicdb.org/links/molecular_profiles/264	FALSE	FGFR1	2260	Expression		chr8	38411138	38467845			ENST00000425967.3	75		N/A	N/A	2023-01-09 21:52:06 UTC		N/A		FALSE
FGFR1 Expression	264	Head And Neck Squamous Cell Carcinoma	5520		Infigratinib		Predictive	Supports	D	Sensitivity/Response	"FGFR1 mRNA expression, rather than copy number alterations, were predictive of response to FGFR inhibitor BGJ398 in cell lines and patient derived xenografts."	26015511	PubMed		"Gke et al., 2015, Clin. Cancer Res."		3	accepted	799	N/A	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/799	https://civicdb.org/links/molecular_profiles/264	FALSE	FGFR1	2260	Expression		chr8	38411138	38467845			ENST00000425967.3	75		N/A	N/A	2023-01-09 21:52:06 UTC		N/A		FALSE
FGFR1 Expression	264	Gastric Adenocarcinoma	3717		Infigratinib		Predictive	Supports	D	Sensitivity/Response	FGFR inhibitor BGJ398 was most effective in a gastric cancer cell line model with high expression of FGFR1 and FGFR2IIIc.	26637881	PubMed		"Schmidt et al., 2015, Anticancer Res."		2	accepted	800	N/A	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/800	https://civicdb.org/links/molecular_profiles/264	FALSE	FGFR1	2260	Expression		chr8	38411138	38467845			ENST00000425967.3	75		N/A	N/A	2023-01-09 21:52:06 UTC		N/A		FALSE
FGFR1 Expression	264	Bladder Carcinoma	4007		"PD173074,Dovitinib"	Substitutes	Predictive	Supports	D	Sensitivity/Response	"One urothelial cell line (JMSU1) with high expression of FGFR1 was sensitive to treatment with FGFR inhibitors  (SU5402, TKI258 or PD173074). IC50 values for PD173074 and TKI-258 (Dovitinib) were in nanomolar range compared with micromolar concentration for SU5402."	21119661	PubMed		"Lamont et al., 2011, Br. J. Cancer"		2	accepted	801	N/A	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/801	https://civicdb.org/links/molecular_profiles/264	FALSE	FGFR1	2260	Expression		chr8	38411138	38467845			ENST00000425967.3	75		N/A	N/A	2023-01-09 21:52:06 UTC		N/A		FALSE
FGFR3 Overexpression	321	Bladder Carcinoma	4007		"PD173074,Tyrosine Kinase Inhibitor SU5402,Dovitinib"	Substitutes	Predictive	Supports	D	Sensitivity/Response	"The effects of FGFR inhibitors (PD173074, TKI-258 and SU5402) in bladder carcinoma cell lines were related to FGFR3 (and/or FGFR1) expression."	21119661	PubMed		"Lamont et al., 2011, Br. J. Cancer"		3	accepted	803	N/A	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/803	https://civicdb.org/links/molecular_profiles/321	FALSE	FGFR3	2261	Overexpression		chr4	1793312	1808872			ENST00000440486.2	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
CDKN2A p16 Expression	268	Head And Neck Squamous Cell Carcinoma	5520				Prognostic	Supports	B	Better Outcome	"Patients from three studies (RTOG 0129, 0234, and 0522; 85, 95 and 142 patients, respectively) were retrospectively analyzed for p16 (CDKN2A) expression (IHC) and HPV-high risk status (ISH). p16 expression in non-oropharyngeal HNSSC was also prognostic and associated with a better outcome. However, p16-positive oropharyngeal HNSSC still had better PFS and OS than p16-positive non-oropharyngeal HNSSC."	25267748	PubMed		"Chung et al., 2014, J. Clin. Oncol."		3	accepted	804	N/A	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/804	https://civicdb.org/links/molecular_profiles/268	FALSE	CDKN2A	1029	p16 Expression		chr9	21968056	21974866			ENST00000498124.1	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
CBLC EXPRESSION	322	Cancer	162		Olaparib		Predictive	Supports	D	Resistance	"The E3 ubiquitin ligase, CBLC, was identified as a candidate biomarker for olaparib sensitivity in a siRNA screen and further validated in-vitro. In other words, expression of CBLC is predicted to confer resistance to olaparib."	25883215	PubMed		"Frankum et al., 2015, Oncotarget"		2	accepted	805	N/A	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/805	https://civicdb.org/links/molecular_profiles/322	FALSE	CBLC	23624	EXPRESSION		chr19	44777869	44800634			ENST00000270279.3	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
KRAS G13D	81	Colorectal Cancer	9256		Cetuximab		Predictive	Does Not Support	B	Resistance	"This is a retrospective analysis of 98 patients with metastatic colorectal cancer and KRAS mutations. 23 (23.5%) had KRAS p.G13D-mutated tumors. Of the 98 patients, 31 patients received cetuximab, of these, 9 (29.0%) had KRAS p.G13D mutations. Univariate analysis did not show any differences between these groups. Multivariate analysis showed a trend towards better PFS among patients with a G13D mutation (PFS: HR=0.29; 95% CI: 0.08-1.10; P=0.07; OS: HR=0.23; 95% CI: 0.04-1.54; P=0.13)."	26623049	PubMed		"Osumi et al., 2015, Mol Clin Oncol"		2	accepted	806	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/806	https://civicdb.org/links/molecular_profiles/81	FALSE	KRAS	3845	G13D		chr12	25245347	25245347	C	T	ENST00000256078.4	75		missense_variant	"NM_033360.3:c.38G>A,NP_004976.2:p.Gly13Asp,NC_000012.11:g.25398281C>T,ENST00000256078.4:c.38G>A"	2023-01-27 17:02:27 UTC	CA122534	12580	"GLY13ASP,RS112445441"	FALSE
PTPRD Mutation	323	Head And Neck Carcinoma	1542		JSI-124		Predictive	Supports	D	Sensitivity/Response	"In this preclinical study, loss-of-function of PTPRD was mainly caused by mutation in head and neck cancer, as identified in TCGA data. PTPRD mutated cell-lines were more sensitive to STAT3 inhibition (JSI-124) than wild-type cells. The authors generated several representative HNSCC-derived PTPRD mutants by site-directed mutagenesis (S384R, K1502M, T1100M and L1147F)."	26267899	PubMed		"Peyser et al., 2015, PLoS ONE"		3	accepted	807	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/807	https://civicdb.org/links/molecular_profiles/323	FALSE	PTPRD	5789	Mutation		chr9	8314246	10033790			ENST00000381196.4	75		"transcript_variant,loss_of_function_variant"		2023-01-09 21:52:06 UTC		N/A		FALSE
DEFA1 EXPRESSION	324	Prostate Cancer	10283		Docetaxel		Predictive	Supports	B	Sensitivity/Response	"Blood mRNA levels of DEFA1, DEFA1B and DEFA3 were associated with response to docetaxel treatment in castration resistant prostate cancer. The discovery cohort consisted of 6 patients, results were validated in 10 patients."	26261420	PubMed		"Kohli et al., 2015, Onco Targets Ther"		2	accepted	808	N/A	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/808	https://civicdb.org/links/molecular_profiles/324	FALSE	DEFA1	1667	EXPRESSION		chr8	6977650	6980080			ENST00000382692.2	75		N/A		2023-01-09 21:52:06 UTC				FALSE
ERCC1 Expression	325	Bladder Carcinoma	4007		Cisplatin		Predictive	Does Not Support	B	Sensitivity/Response	Immunhistochemistry of ERCC1 expression in 432 patients revealed no correlation to response to cisplatin based chemotherapy. In-vitro studies also did not show any effects.	26162296	PubMed		"Klatte et al., 2015, J. Urol."		4	accepted	809	N/A	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/809	https://civicdb.org/links/molecular_profiles/325	FALSE	ERCC1	2067	Expression		chr19	45413434	45423566			ENST00000013807.5	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
ERCC1 Expression	325	Bladder Carcinoma	4007				Prognostic	Supports	B	Better Outcome	"ERCC1 expression as evaluated by IHC in 432 patients was associated with better disease-free survival (HR 0.70, p = 0.028) and cancer specific survival (HR 0.70, p = 0.032) on multivariable analysis."	26162296	PubMed		"Klatte et al., 2015, J. Urol."		2	accepted	810	N/A	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/810	https://civicdb.org/links/molecular_profiles/325	FALSE	ERCC1	2067	Expression		chr19	45413434	45423566			ENST00000013807.5	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
NOTCH1 Amplification	326	Colorectal Cancer	9256		NOTCH1 Antibody (PF-06293622)		Predictive	Supports	D	Sensitivity/Response	"NOTCH1 copy-number gain in a patient-derived tumor xenograft model of colorectal cancer, was associated with increased NOTCH1 and JAG1 activity and response to a NOTCH1-targeting antibody (PF-06293622)."	26152787	PubMed		"Arcaroli et al., 2016, Int. J. Cancer"		2	accepted	811	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/811	https://civicdb.org/links/molecular_profiles/326	FALSE	NOTCH1	4851	Amplification		chr9	136494444	136545862			ENST00000277541.6	75		transcript_amplification		2023-01-09 21:52:06 UTC		N/A		FALSE
NOTCH1 Amplification	326	Colorectal Cancer	9256				Prognostic	Supports	B	Poor Outcome	NOTCH1 amplifications (as determined by FISH) were significantly (log-rank p??.025) associated with worse survival in a cohort of 116 patients with colorectal cancer.	26152787	PubMed		"Arcaroli et al., 2016, Int. J. Cancer"		2	accepted	812	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/812	https://civicdb.org/links/molecular_profiles/326	FALSE	NOTCH1	4851	Amplification		chr9	136494444	136545862			ENST00000277541.6	75		transcript_amplification		2023-01-09 21:52:06 UTC		N/A		FALSE
NRG1 Expression	310	Lung Non-small Cell Carcinoma	3908		Patritumab		Predictive	Supports	B	Sensitivity/Response	"In this phase-2 study, 215 patients were randomized to either erlotinib and placebo or erlotinib and HER3 monoclonal antibody patritumab. HRG (NRG1) expression was retrospectively defined as predictive biomarker but prospectively assessed in 102 patients before unblinding. NRG1-high groups demonstrated clinical benefit from additional patritumab with hazard ratios of 0.37 (P = 0.0283) and 0.29 (P = 0.0027) in the high- and low-dose patritumab arms, respectively."	26137564	PubMed		"Mendell et al., 2015, EBioMedicine"		4	accepted	813	N/A	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/813	https://civicdb.org/links/molecular_profiles/310	FALSE	NRG1	3084	Expression		chr8	31640426	32764776			ENST00000523534.1	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
WEE1 RS3910384	327	Lung Non-small Cell Carcinoma	3908		"Gemcitabine,Platinum Compound"	Combination	Predictive	Supports	B	Sensitivity/Response	"The presence of the WEE1 polymorphism rs3910384 correlated with OS and PFS of NSCLC patients treated with platinum-based chemotherapy. Especially the combination of two DNA-damaging agents was associated with efficacy. 663 patients were tested. The authors showed that rs3910384 is closely linked with the putative functional WEE1 promoter at SNPs rs6486433, rs3763869 and rs3763868."	26057002	PubMed		"Liu et al., 2015, Sci Rep"		3	accepted	814	Common Germline	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/814	https://civicdb.org/links/molecular_profiles/327	FALSE	WEE1	7465	RS3910384		chr11	9578396	9578396	A	G	ENST00000450114.2	75		"intron_variant,polymorphic_sequence_variant"	"NC_000011.9:g.9599943A>G,ENST00000450114.2:c.1141+1133A>G"	2023-01-27 17:03:32 UTC	CA15681425	NONE FOUND	INTRON POLYMORPHISM	FALSE
FNTB RS11623866	328	Ovarian Cancer	2394		Lonafarnib		Predictive	Supports	B	Resistance	"57 from 105 patients in the AGo-OVAR-15 trial were retrospectively genotyped for FNTB polymorphisms. Resistance to lonafarnib-containing treatment was limited to patients with a FNTB rs11623866 (c.-609G?C) GG genotype (HRPFS 6.2, 95%CI??.01, 19.41, P??.002; HROS 9.6, 95%CI??.89, 48.54, P??.006)."	26033044	PubMed		"Bachmann et al., 2015, Br J Clin Pharmacol"		2	accepted	815	Common Germline	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/815	https://civicdb.org/links/molecular_profiles/328	FALSE	FNTB	2342	RS11623866		chr14	64986345	64986345	G	C	ENST00000246166.2	75		regulatory_region_variant	NC_000014.8:g.65453063G>C	2023-01-27 17:03:33 UTC	CA13941207			FALSE
BRAF V600E	12	Colorectal Cancer	9256		"Cetuximab,Panitumumab"	Substitutes	Predictive	Does Not Support	B	Resistance	"This meta-analysis of 7 randomized control trials evaluating overall survival (OS) (8 for progression free survival) could not definitely state that survival benefit of anti-EGFR monoclonal antibodies is limited to patients with wild type BRAF. In other words, the authors believe that there is insufficient data to justify the exclusion of anti-EGFR monoclonal antibody therapy for patients with mutant BRAF. In these studies, mutant BRAF specifically meant the V600E mutation."	25989278	PubMed		"Rowland et al., 2015, Br. J. Cancer"		4	accepted	816	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/816	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
VEGFA Decreased Peri-therapeutic Expression	330	Colorectal Cancer	9256		"Bevacizumab,Levoleucovorin,Irinotecan,Fluorouracil"	Combination	Predictive	Supports	B	Sensitivity/Response	Decreased peri- and post-therapeutic expression of VEGFA were significantly associated with response to FOLFIRI plus bevacizumab in 57 patients with metastatic CRC.	25973082	PubMed		"Tsai et al., 2015, Int J Clin Exp Pathol"		2	accepted	818	N/A	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/818	https://civicdb.org/links/molecular_profiles/330	FALSE	VEGFA	7422	Decreased Peri-therapeutic Expression		chr6	43770707	43784609			ENST00000372055.4	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
DNMT1 EXPRESSION	331	Ovarian Cancer	2394		Decitabine		Predictive	Supports	D	Sensitivity/Response	"DNMT1 expression (mRNA expression from an independent study) correlated with sensitivity to decitabine (, ?.443, Pearson regression analysis) in this preclinical study of 45 solid tumor cell lines. DNMT1 protein expression was also evaluated in two KRAS-mutant ovarian cancer cell lines pre and post-decitabine treatment showing downregulation following treatment."	25968887	PubMed		"Stewart et al., 2015, Cancer Res."		3	accepted	819	N/A	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/819	https://civicdb.org/links/molecular_profiles/331	FALSE	DNMT1	1786	EXPRESSION		chr19	10133346	10195135			ENST00000340748.4	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
KRAS Mutation	332	Ovarian Cancer	2394		Decitabine		Predictive	Supports	D	Sensitivity/Response	"KRAS mutation or amplification predicted sensitivity to decitabine in ovarian cancer cell lines. The authors profiled the response of 45 ovarian, melanoma, and breast cancer cell lines over 9 days of treatment with decitabine. 4 ovarian lines with KRAS mutation were among the most sensitive to decitabine."	25968887	PubMed		"Stewart et al., 2015, Cancer Res."		3	accepted	820	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/820	https://civicdb.org/links/molecular_profiles/332	FALSE	KRAS	3845	Mutation		chr12	25209431	25250803			ENST00000256078.4	75		protein_altering_variant		2023-01-09 21:52:06 UTC		N/A		FALSE
PDCD4 EXPRESSION	333	Lung Cancer	1324		Paclitaxel		Predictive	Supports	B	Sensitivity/Response	PDCD4 expression was associated with response to paclitaxel in a retrospective analysis of 77 patients after preclinical validation and mechanistic analysis of the biomarker.	25928036	PubMed		"Xu et al., 2015, J. Proteome Res."		4	accepted	821	N/A	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/821	https://civicdb.org/links/molecular_profiles/333	FALSE	PDCD4	27250	EXPRESSION		chr10	110871838	110900005			ENST00000393104.2	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
MGMT RS16906252	334	Glioblastoma	3068		Temozolomide		Predictive	Supports	B	Sensitivity/Response	"The T allele of the rs16906252 SNP was associated with MGMT methylation and low protein expression. Germline presence of the T allele increased the risk of glioblastoma development (adjusted odds ratio, 1.96; P = .013). Temozolomide treatment led to better survival in patients with the rs16906252 T genotype irrespective of methylation status."	25910840	PubMed		"Rapkins et al., 2015, Neuro-oncology"		3	accepted	822	Common Germline	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/822	https://civicdb.org/links/molecular_profiles/334	FALSE	MGMT	4255	RS16906252		chr10	129467281	129467281	C	T	ENST00000306010.7	75		synonymous_variant	NC_000010.10:g.131265545C>T	2023-01-27 17:03:33 UTC	CA5747879			FALSE
TFF3 EXPRESSION	335	Breast Cancer	1612		"Aminoglutethimide,Tamoxifen"	Substitutes	Predictive	Supports	B	Sensitivity/Response	"TFF3 expression was assessed by IHC in 75 patients, 187 patients were identified for the validation cohort. TFF3 expression was associated with response to endocrine therapy (tamoxifen, aminoglutethimide or oophorectomy) and outperformed ER, PR and TFF1 as biomarkers."	25900183	PubMed		"May et al., 2015, Endocr. Relat. Cancer"		3	accepted	823	N/A	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/823	https://civicdb.org/links/molecular_profiles/335	FALSE	TFF3	7033	EXPRESSION		chr21	42311667	42315651			ENST00000518498.1	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
DKK1 NUCLEAR EXPRESSION	336	Colorectal Cancer	9256		"Irinotecan,Levoleucovorin,Oxaliplatin,Fluorouracil"	Combination	Predictive	Supports	B	Resistance	"Nuclear expression of DICKKOPF-1 was identified in 15% of 699 patients with colorectal cancer and was associated with decreased progression-free survival (PFS) and overall survival (OS) after chemotherapy (FOLFOX, FOLFIRI, or 5-FU) [adjusted HR, 1.65; 95% confidence interval (CI), 1.23-2.21; P = 0.002)]."	25788273	PubMed		"Aguilera et al., 2015, Oncotarget"		3	accepted	824	N/A	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/824	https://civicdb.org/links/molecular_profiles/336	FALSE	DKK1	22943	NUCLEAR EXPRESSION		chr10	52314296	52317657			ENST00000373970.3	75		N/A		2023-01-09 21:52:06 UTC				FALSE
CD44 CD44s Expression	337	Cancer	162		RG7356		Predictive	Supports	D	Sensitivity/Response	"CD44 isoform expression (especially CD44s) was identified to predict response to CD44 antibody RG7356 preclinically. Retrospective evaluation of 13 patients from a phase 1 study, treated with RG7356, identified 3 patients with CD44s isoform. 2/3 patients with CD44s had SD as best response. Overall, 5 patients had an OR."	25762343	PubMed		"Birzele et al., 2015, Clin. Cancer Res."		3	accepted	825	N/A	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/825	https://civicdb.org/links/molecular_profiles/337	FALSE	CD44	960	CD44s Expression		chr11	35139181	35230027			ENST00000428726.2	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
EGF EXPRESSION	338	Head And Neck Squamous Cell Carcinoma	5520		Cetuximab		Predictive	Supports	D	Resistance	3 tongue cancer cell lines were used for this study. Addition of recombinant human EGF led to increased cetuximab resistance. EGF downregulation suppressed proliferation of cell lines. Results for amphiregulin and epiregulin were inconclusive.	25677871	PubMed		"Ansell et al., 2016, J. Oral Pathol. Med."		3	accepted	826	N/A	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/826	https://civicdb.org/links/molecular_profiles/338	FALSE	EGF	1950	EXPRESSION		chr4	109912891	110012266			ENST00000265171.5	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
MDM2 EXPRESSION	339	Malignant Pleural Mesothelioma	7474		"Pemetrexed,Cisplatin"	Combination	Predictive	Supports	B	Resistance	"72 patients with malignant pleural mesothelioma were analyzed, MDM2 immunoexpression was assessed in 65 patients. MDM2 mRNA and protein expression correlated with poor OS and PFS for patients treated with cisplatin and pemetrexed (standard of care therapy)."	25668009	PubMed		"Walter et al., 2015, Br. J. Cancer"		1	accepted	827	N/A	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/827	https://civicdb.org/links/molecular_profiles/339	FALSE	MDM2	4193	EXPRESSION		chr12	68808176	68845434			ENST00000462284.1	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
MDM2 EXPRESSION	339	Malignant Pleural Mesothelioma	7474				Prognostic	Supports	B	Poor Outcome	"72 patients with malignant pleural mesothelioma were analyzed, MDM2 immunoexpression was assessed in 65 patients. MDM2 mRNA and protein expression correlated with poor OS and PFS for patients treated with standard of care therapy (cisplatin and pemetrexed)."	25668009	PubMed		"Walter et al., 2015, Br. J. Cancer"		3	accepted	828	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/828	https://civicdb.org/links/molecular_profiles/339	FALSE	MDM2	4193	EXPRESSION		chr12	68808176	68845434			ENST00000462284.1	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
HMOX1 EXPRESSION	340	Renal Cell Carcinoma	4450		"Sunitinib,Sorafenib"	Substitutes	Predictive	Supports	B	Resistance	"In 66 patients with advanced renal cell carcinoma, high expression of heme oxygenase-1 (HO-1) was associated with poor overall response rate (2.6% versus 53.6%, P<0.01), clinical benefit rate (47.4% versus 92.9%, P<0.01), shorter progression-free survival (4.4 versus 42 months, P=0.022) and poor overall survival ( (2)=4.775, P=0.029) in patients receiving sorafenib or sunitinib."	26309414	PubMed		"Zheng et al., 2015, Onco Targets Ther"		3	accepted	829	N/A	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/829	https://civicdb.org/links/molecular_profiles/340	FALSE	HMOX1	3162	EXPRESSION		chr22	35380835	35394214			ENST00000216117.8	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
SPHK1 OVEREXPRESSION	341	Cervical Cancer	4362				Prognostic	Supports	B	Poor Outcome	"SPHK1 protein expression was assessed in 287 cervical cancer and 5 normal cervical tissue samples using IHC. Univariate analysis for OS showed SPHK1 expression (p = 0.033; Figure 1C), tumor size (p = 0.033), and lymph node metastasis (p = 0.008) as associated with OS. SPHK1 expression did not directly predict OS. High SPHK1 expression was also associated with larger tumor size (p < 0.001), deeper invasion depth (p < 0.001), presence of lymph node metastasis (p = 0.029), higher FIGO stage (p = 0.029), presence of lymphovascular invasion (p = 0.045), and higher preoperative squamous cell carcinoma (SCC) antigen level (p = 0.009)."	26311741	PubMed		"Kim et al., 2015, Oncotarget"		2	accepted	830	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/830	https://civicdb.org/links/molecular_profiles/341	FALSE	SPHK1	8877	OVEREXPRESSION		chr17	76384650	76387855			ENST00000323374.4	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
CASP8 Overexpression	342	Ewing Sarcoma Of Bone	3368		Conatumumab		Predictive	Supports	D	Sensitivity/Response	In-vitro and in-vivo sensitivity to DR5 antibody conatumumab was correlated with expression of caspase-8.	26291055	PubMed		"Kang et al., 2015, Br. J. Cancer"		3	accepted	831	N/A	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/831	https://civicdb.org/links/molecular_profiles/342	FALSE	CASP8	841	Overexpression		chr2	201258036	201287711			ENST00000358485.4	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
TYMS Overexpression	343	Lung Non-small Cell Carcinoma	3908		Pemetrexed		Predictive	Supports	B	Resistance	"mRNA expression of thymidylate synthase (TYMS) in 62 NSCLC patients correlated with response rate to pemetrexed mono- or combination therapy. Response rate with low TYMS expression was 0.29 compared with 0.03 in patients with overexpression (P = 0.025). Patients with low expression exhibited a benefit in time to progression (average TTP = 56 vs. 23 months, P = 0.001) and in overall survival (average OS = 60 vs. 25 months, P = 0.002)."	26502926	PubMed		"Chamizo et al., 2015, BMC Pulm Med"		3	accepted	832	N/A	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/832	https://civicdb.org/links/molecular_profiles/343	FALSE	TYMS	7298	Overexpression		chr18	657604	673578			ENST00000323274.10	75		N/A	N/A	2023-01-09 21:52:06 UTC		N/A		FALSE
PBK OVEREXPRESSION	344	Lung Non-small Cell Carcinoma	3908		Gefitinib		Predictive	Supports	D	Resistance	TOPK (PBK) silencing sensitized lung cancer cells to gefitinib in preclinical xenograft models. Over-expression was also associated with resistance in various lung cancer cell lines.	26745678	PubMed		"Li et al., 2016, Oncotarget"		3	accepted	835	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/835	https://civicdb.org/links/molecular_profiles/344	FALSE	PBK	55872	OVEREXPRESSION		chr8	27809620	27838095			ENST00000301905.4	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
MET Amplification	266	Lung Adenocarcinoma	3910		Crizotinib		Predictive	Supports	C	Sensitivity/Response	"Case report of a patient with MET amplification without high-level MET/CEP7 ratio, MET exon 14 mutation or overexpression who achieved rapid response to crizotinib."	26724472	PubMed		"Zhang et al., 2016, J Thorac Oncol"		2	accepted	836	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/836	https://civicdb.org/links/molecular_profiles/266	FALSE	MET	4233	Amplification		chr7	116672405	116796342			ENST00000318493.6	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A		FALSE
SMARCA4 Underexpression	345	Lung Non-small Cell Carcinoma	3908		"Vinorelbine,Cisplatin"	Combination	Predictive	Supports	B	Sensitivity/Response	"SMARCA4 expression was determined with gene expression microarray in 133 patients. Improved five-year disease-specific survival (DSS) was noted only in patients with low SMARCA4 expression when treated with adjuvant cisplatin/vinorelbine (n=36) (HR=0.1, 95% CI: 0.0-0.5, P=0.002 [low]; HR 1.0, 95% CI: 0.5-2.3, P=0.92 [high]) compared to patients in the observation arm (N=30)."	26671993	PubMed		"Bell et al., 2016, Clin. Cancer Res."		3	accepted	837	N/A	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/837	https://civicdb.org/links/molecular_profiles/345	FALSE	SMARCA4	6597	Underexpression		chr19	10960922	11062282			ENST00000358026.2	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
SMARCA4 Underexpression	345	Lung Non-small Cell Carcinoma	3908				Prognostic	Supports	B	Poor Outcome	"SMARCA4 expression was determined with gene expression microarray in 133 patients. Reduced overall survival was observed in patients with low SMARCA4 expression compared to intermediate (P<0 .001) or high expression (P=0.009). In multivariate analysis, compared to low, high SMARCA4 expression predicted a decrease in risk of death (HR=0.6, 95% CI: 0.4-0.8, P=0.002)."	26671993	PubMed		"Bell et al., 2016, Clin. Cancer Res."		3	accepted	838	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/838	https://civicdb.org/links/molecular_profiles/345	FALSE	SMARCA4	6597	Underexpression		chr19	10960922	11062282			ENST00000358026.2	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
SETBP1 Exon 4 Mutation	346	"Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative"	60597				Prognostic	Supports	B	Poor Outcome	"Atypical Chronic Myeloid Leukemia has the same symptoms as CML, but it lacks the BCR-ABL1 fusion. Targeted sequencing of 70 aCML patients identified SETBP1 mutations between codons 858 and 871 in 24.3% of the patients. Patients with this mutation had a 22 month median survival compared to 77 months in aCML patients without the mutation (P=.01)."	23222956	PubMed		"Piazza et al., 2013, Nat. Genet."		3	accepted	839	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/839	https://civicdb.org/links/molecular_profiles/346	FALSE	SETBP1	26040	Exon 4 Mutation		chr18	44951912	44951953			ENST00000282030.5	75		exon_variant		2023-01-09 21:52:06 UTC				FALSE
SETBP1 G870S	347	Chronic Myeloid Leukemia	8552				Prognostic	Supports	D	Poor Outcome	"Atypical Chronic Myeloid Leukemia has the same symptoms as CML, but it lacks the BCR-ABL1 fusion. The researchers transfected 293T cells with SETBP1 G870S, a variant found to be associated with poor prognosis in aCML, and found those cells had higher proliferation and higher expression of SET and SETBP1 proteins. This may be linked to the mutation abrogating a ubiquitination site."	23222956	PubMed		"Piazza et al., 2013, Nat. Genet."		3	accepted	840	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/840	https://civicdb.org/links/molecular_profiles/347	FALSE	SETBP1	26040	G870S		chr18	44951948	44951948	G	A	ENST00000282030.5	75		missense_variant	"NM_015559.2:c.2608G>A,NP_056374.2:p.Gly870Ser,ENST00000282030.5:c.2608G>A,NC_000018.9:g.42531913G>A"	2023-01-27 17:03:34 UTC	CA114719	1035	"GLY870SER,RS267607040"	FALSE
BRCA1 Loss-of-function	131	Prostate Cancer	10283		Olaparib		Predictive	Supports	C	Sensitivity/Response	1/1 patients with BRCA1 homozygous deletion had a response to olaparib in this phase 2 study.	26510020	PubMed		"Mateo et al., 2015, N. Engl. J. Med."	NCT01682772	2	accepted	845	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/845	https://civicdb.org/links/molecular_profiles/131	FALSE	BRCA1	672	Loss-of-function	BRCA Germline Variants	chr17	43045629	43125483			ENST00000471181.2	75		"loss_of_heterozygosity,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
AREG Expression	311	Head And Neck Squamous Cell Carcinoma	5520		"Cetuximab,Docetaxel"	Combination	Predictive	Supports	B	Resistance	"47 HNSCC patients treated with cetuximab/docetaxel were retrospectively analyzed for EGFRvIII, EGFR and AREG expression with IHC. 45% of cases expressed high level of AREG. High AREG expression in tumor cells was associated with reduced overall survival  (hazard ratio: 2.2, P = 0.002) and progression free survival (hazard ratio: 2.2, P = 0.016) compared to patients with low AREG expression score. AREG was an independent prognosticator of OS in multivariate Cox analysis. High EGFRvIII and AREG expression levels identified SCCHN (squamous cell carcinoma, head and neck) patients that were less likely to benefit from combination treatment with cetuximab and docetaxel."	21653686	PubMed		"Tinhofer et al., 2011, Clin. Cancer Res."		2	accepted	846	N/A	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/846	https://civicdb.org/links/molecular_profiles/311	FALSE	AREG	374	Expression		chr4	74445134	74455009			ENST00000395748.3	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
EGFR VIII	308	Head And Neck Squamous Cell Carcinoma	5520		"Cetuximab,Docetaxel"	Combination	Predictive	Supports	B	Resistance	"47 HNSCC patients treated with cetuximab/docetaxel were retrospectively analyzed for EGFRvIII, EGFR, and AREG expression by IHC. 17% of cases expressed high levels of EGFRvIII. High vIII expression was associated with reduced disease control rate (DCR) and shortened progression free survival (PFS) (HR: 3.3, P = 0.005) but not with OS."	21653686	PubMed		"Tinhofer et al., 2011, Clin. Cancer Res."		2	accepted	848	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/848	https://civicdb.org/links/molecular_profiles/308	FALSE	EGFR	1956	VIII		chr7	55019365	55155830			ENST00000275493.2	75		disruptive_inframe_deletion	"NM_005228.3:c.89_881del,NP_005219.2:p.Val30_Arg297delinsGly,NC_000007.13:g.55209979_55221845del"	2023-01-09 21:52:06 UTC				FALSE
EGFR Overexpression	193	Head And Neck Squamous Cell Carcinoma	5520		"Cetuximab,Docetaxel"	Combination	Predictive	Does Not Support	B	Sensitivity/Response	"47 HNSCC patients treated with cetuximab/docetaxel were retrospectively analyzed for EGFRvIII, EGFR and AREG expression with IHC. 73 % of cases expressed high level of EGFR. EGFR expression had no impact on PFS (P=0.73) or OS (P=0.75)."	21653686	PubMed		"Tinhofer et al., 2011, Clin. Cancer Res."		3	accepted	849	N/A	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/849	https://civicdb.org/links/molecular_profiles/193	FALSE	EGFR	1956	Overexpression		chr7	55019101	55211628			ENST00000275493.2	75		N/A		2023-01-09 21:52:05 UTC		N/A		FALSE
TP53 Mutation	222	Gastric Adenocarcinoma	3717		Chemotherapy		Predictive	Supports	B	Sensitivity/Response	In this meta-analysis of 13 studies (564 patients) p53 positivity as defined by high protein expression and/or p53 mutation was associated with improved response to chemotherapy (risk ratio [RR] = 0.704; 95% confidence intervals [CI] = 0.550-0.903; P = 0.006).	24740294	PubMed		"Xu et al., 2014, PLoS ONE"		3	accepted	850	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/850	https://civicdb.org/links/molecular_profiles/222	FALSE	TP53	7157	Mutation		chr17	7668402	7687538			ENST00000269305.4	75		protein_altering_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
TP53 Mutation	222	Breast Cancer	1612		Doxorubicin		Predictive	Supports	D	Sensitivity/Response	"In this preclinical study, MMTV-Wnt1 mammary tumors with mutant TP53 showed a better clinical response to chemotherapy (doxorubicin) than TP53 wild-type tumors. This was mediated by wild-type TP53-induced cell-arrest under chemotherapy even in the context of heterozygous TP53 point mutations or absence of p21. Thus the status of both TP53 alleles should be assessed because even one copy of wild-type TP53 may contribute to poor response to chemotherapy."	22698404	PubMed		"Jackson et al., 2012, Cancer Cell"		4	accepted	851	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/851	https://civicdb.org/links/molecular_profiles/222	FALSE	TP53	7157	Mutation		chr17	7668402	7687538			ENST00000269305.4	75		protein_altering_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
CDKN1A EXPRESSION	351	Colorectal Cancer	9256		Fluorouracil		Predictive	Supports	B	Resistance	"112 patients with rectal cancer who received 5-FU based chemotherapy and surgery were retrospectively analyzed for expression of Ki67, TS, BAX, EpCAM, p53, p21, EGFR, CD44, CD133, CD166, HIF1 and ALDH1. High pretreatment p21 (CDKN1A) expression was significantly associated with non-pCR (p??.022) and poor disease free survival (median DFS - low vs high p21: 75.8 vs 58.1 months, p??.002). Multivariate analysis was also significant (p??.001, HR 6.14; 95% CI 2.03, 18.55)."	24708484	PubMed		"Sim et al., 2014, BMC Cancer"		3	accepted	852	N/A	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/852	https://civicdb.org/links/molecular_profiles/351	FALSE	CDKN1A	1026	EXPRESSION		chr6	36678710	36687331			ENST00000405375.1	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
ALCAM EXPRESSION	352	Colorectal Cancer	9256		Fluorouracil		Predictive	Supports	B	Resistance	"112 patients with rectal cancer who received 5-FU based chemotherapy and surgery were retrospectively analyzed for expression of Ki67, TS, BAX, EpCAM, p53, p21, EGFR, CD44, CD133, CD166, HIF1 and ALDH1. Pretreatment CD166 (ALCAM) expression level was associated with poor disease free survival (p??.003; HR 5.61; 95% CI 1.81, 17.35)."	24708484	PubMed		"Sim et al., 2014, BMC Cancer"		3	accepted	853	N/A	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/853	https://civicdb.org/links/molecular_profiles/352	FALSE	ALCAM	214	EXPRESSION		chr3	105366909	105576900			ENST00000306107.5	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
EGFR Amplification	190	Colorectal Cancer	9256		"Cetuximab,Panitumumab"	Substitutes	Predictive	Supports	B	Sensitivity/Response	"In this meta-analysis (14 studies, 1021 patients), EGFR gene copy number (GCN) was predictive of improved progression free survival (PFS) and overall survival (OS) with cetuximab or panitumumab regardless of KRAS status. For the pooled analysis, the objective response rate (ORR) was 65.2% (167/256) in patients with high EFGR GCN, while in patients with low EFGR GCN, the pooled ORR was 12.2% (44/361). The odds ratio (OR) was 6.905 (95% CI: 4.489-10.620; Z=8.79, P=0.000). In wild type KRAS patients, the pooled OR was 8.133 (95% CI: 4.316-15.326; Z=6.48, P=0.000)."	24653627	PubMed		"Shen et al., 2014, Chin. J. Cancer Res."		3	accepted	854	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/854	https://civicdb.org/links/molecular_profiles/190	FALSE	EGFR	1956	Amplification		chr7	55019101	55211628			ENST00000275493.2	75		transcript_amplification	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
STMN1 EXPRESSION	353	Endometrial Carcinoma	2871		Paclitaxel		Predictive	Supports	B	Resistance	33 patients were retrospectively analyzed for Stathmin expression by IHC. High protein expression was correlated with poor response to paclitaxel but not other chemotherapy. The authors supported this conclusion with pre-clinical studies that showed that knock-down of stathmin improved sensitivity to paclitaxel in endometrial carcinoma cell lines with both naturally higher and lower sensitivity to paclitaxel.	24587245	PubMed		"Werner et al., 2014, PLoS ONE"		3	accepted	855	N/A	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/855	https://civicdb.org/links/molecular_profiles/353	FALSE	STMN1	3925	EXPRESSION		chr1	25885440	25906466			ENST00000426559.2	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
CCND1 Overexpression	20	Estrogen-receptor Positive Breast Cancer	60075		Tamoxifen		Predictive	Supports	B	Resistance	The authors performed a tissue microarray analysis of 167 postmenopausal breast cancers that had been randomized to treatment with or without tamoxifen.  ER +ve patients with high CCND1 tumor expression did not show any difference in survival between tamoxifen and no treatment.	15138475	PubMed		"Stendahl et al., 2004, Br. J. Cancer"		3	accepted	856	N/A	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/856	https://civicdb.org/links/molecular_profiles/20	FALSE	CCND1	595	Overexpression		chr11	69641087	69654474			ENST00000227507.2	75		N/A	N/A	2023-01-09 21:52:04 UTC		N/A		FALSE
RSF1 Amplification	354	Breast Cancer	1612		Tamoxifen		Predictive	Supports	B	Resistance	"In retrospective study, 413 patients were assessed for RSF1 amplification. 28 patients with RSF1 amplification did not show a benefit from adjuvant tamoxifen compared to placebo (12 treated vs 16 placebo). 381 patients without amplification did show a benefit compared to placebo (187 treated vs 194 placebo)."	24367492	PubMed		"Keilty et al., 2013, PLoS ONE"		2	accepted	857	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/857	https://civicdb.org/links/molecular_profiles/354	FALSE	RSF1	51773	Amplification		chr11	77659996	77821017			ENST00000308488.6	75		transcript_amplification		2023-01-09 21:52:06 UTC		N/A		FALSE
CCND1 Amplification	18	Breast Cancer	1612		Tamoxifen		Predictive	Does Not Support	B	Resistance	"In this retrospective analysis, CCND1 amplification was analyzed in 442 patients. No interaction with treatment was observed."	24367492	PubMed		"Keilty et al., 2013, PLoS ONE"		3	accepted	858	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/858	https://civicdb.org/links/molecular_profiles/18	FALSE	CCND1	595	Amplification		chr11	69641087	69654474			ENST00000227507.2	75		transcript_amplification	N/A	2023-01-09 21:52:04 UTC		N/A		FALSE
AR OVEREXPRESSION	355	Breast Cancer	1612		Dactolisib		Predictive	Supports	D	Sensitivity/Response	In-vitro and xenograft studies of response of breast cancer cell lines to PI3K/mTOR inhibitor NVP-BEZ235 showed that sensitivity correlated with expression of the androgen receptor (AR). Reintroduction of AR expression resensitized nonresponsive AR-negative cells to NVP-BEZ235. A dihydrotestosterone (DHT) and NVP-BEZ235 combination achieved tumor regression and complete response in AR/ER expressing tumors (xenografts).	24356815	PubMed		"Wang et al., 2014, Mol. Cancer Ther."		3	accepted	859	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/859	https://civicdb.org/links/molecular_profiles/355	FALSE	AR	367	OVEREXPRESSION		chrX	67544623	67730619			ENST00000374690.3	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
CDKN1B CYTOPLASMIC MISLOCALIZATION	356	Breast Cancer	1612		Lapatinib		Predictive	Supports	D	Resistance	Cytoplasmic localization of p27 (CDKN1B) leads to lapatinib resistance in HER2+ breast cancer cell lines. p27 knockout resensitiuzed cells to lapatinib.	25587029	PubMed		"Zhao et al., 2014, Oncotarget"		3	accepted	860	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/860	https://civicdb.org/links/molecular_profiles/356	FALSE	CDKN1B	1027	CYTOPLASMIC MISLOCALIZATION		chr12	12717124	12722371			ENST00000228872.4	75		N/A		2023-01-09 21:52:06 UTC				FALSE
NRG1 Expression	310	Cancer	162		Anti-ErbB3 Monoclonal Antibody AV-203		Predictive	Supports	D	Sensitivity/Response	This screening study in various tumor xenografts identified NRG1 expression to correlate with sensivity to ERBB3 inhibitory antibody AV-203. ERBB3 expression was not predictive of response.	25542901	PubMed		"Meetze et al., 2015, Clin. Cancer Res."		3	accepted	861	N/A	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/861	https://civicdb.org/links/molecular_profiles/310	FALSE	NRG1	3084	Expression		chr8	31640426	32764776			ENST00000523534.1	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
ERBB3 EXPRESSION	357	Cancer	162		Anti-ErbB3 Monoclonal Antibody AV-203		Predictive	Does Not Support	D	Sensitivity/Response	"The authors conducted an in vivo efficacy study of AV-203 (ERBB3 inhibitory antibody) using a panel of 32 xenograft models representing 12 human cancer types. To identify biomarkers that can predict response to AV-203, the relationship between tumor growth inhibition (TGI) by AV-203 and the expression levels of ERBB3 and NRG1 were evaluated in these tumor models. ERBB3 expression was not predictive of response."	25542901	PubMed		"Meetze et al., 2015, Clin. Cancer Res."		3	accepted	862	N/A	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/862	https://civicdb.org/links/molecular_profiles/357	FALSE	ERBB3	2065	EXPRESSION		chr12	56079861	56103505			ENST00000267101.3	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
AR V7 EXPRESSION	358	Prostate Cancer	10283		"Enzalutamide,Abiraterone"	Substitutes	Predictive	Supports	B	Resistance	"Detection of AR-V7 in circulating tumor cells of 62 patients treated with either enzalitamide (n=31) or arbiraterone (n=31), was correlated with lower PSA response rates and PSA PFS in men receiving enzalutamide or abiraterone."	25184630	PubMed		"Antonarakis et al., 2014, N. Engl. J. Med."		3	accepted	863	N/A	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/863	https://civicdb.org/links/molecular_profiles/358	FALSE	AR	367	V7 EXPRESSION		chrX	67544820	67696075			ENST00000504326.1	75				2023-01-09 21:52:06 UTC				FALSE
PTEN Loss	214	Gastric Adenocarcinoma	3717		"Trastuzumab,Lapatinib"	Substitutes	Predictive	Supports	B	Resistance	"In 48 patients with advanced gastric cancer, retrospectively analyzed for PTEN expression using IHC, PTEN loss was associated with a shorter duration of response (median 4.2 vs. 6.1 months, p = 0.04) to HER2-targeted therapy (trastuzumab, N=39; lapatinib, N=9). Response rates did not differ between groups."	25300346	PubMed		"Zhang et al., 2015, Oncology"		2	accepted	864	N/A	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/864	https://civicdb.org/links/molecular_profiles/214	FALSE	PTEN	5728	Loss		chr10	87863113	87971930			ENST00000371953.3	75		loss_of_function_variant	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
ERBB3 EXPRESSION	357	Pancreatic Ductal Adenocarcinoma	3498		"Pertuzumab,9F7-F11"	Combination	Predictive	Supports	D	Sensitivity/Response	In mice xenografts expressing ERBB3 (HER3) the combination of ERBB2 (HER2) and ERBB3 inhibitors pertuzumab and 9F7-F11enhanced tumor inhibition and the median survival time. Sensitivity to single-agent pertuzumab might also be increased through ERBB3 expression.	25216528	PubMed		"Thomas et al., 2014, Oncotarget"		3	accepted	865	N/A	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/865	https://civicdb.org/links/molecular_profiles/357	FALSE	ERBB3	2065	EXPRESSION		chr12	56079861	56103505			ENST00000267101.3	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
UGT1A EXPRESSION	359	Colorectal Cancer	9256		Ganetespib		Predictive	Supports	D	Resistance	Colorectal cancer cell lines were evaluated for response to the HSP90 inhibitor ganetespib.  Correlating cell line-specific IC50s with the corresponding gene expression patterns revealed a possible relationship to UGT1A expression. High UGT1A expression was correlated with ganetespib resistance. Knockdown of UGT1A sensitized HT29 cells to HSP90 inhibition. HCT116 and SW480 cell lines became resistant through UGT1A overexpression.	25210794	PubMed		"Landmann et al., 2014, Cell Death Dis"		3	accepted	866	N/A	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/866	https://civicdb.org/links/molecular_profiles/359	FALSE	UGT1A	7361	EXPRESSION		chr2	233617645	233773310			ENST00000373450.4	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
ERBB4 NUCLEAR TRANSLOCATION	360	Breast Cancer	1612		Trastuzumab		Predictive	Supports	D	Resistance	HER4 nuclear translocation was identified as a mediator of trastuzumab resistance in HER2 positive breast cancer cell lines. Increased nuclear staining was also identified in xenograft and patient samples after trastuzumab treatment.	25153719	PubMed		"Mohd Nafi et al., 2014, Oncotarget"		2	accepted	867	N/A	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/867	https://civicdb.org/links/molecular_profiles/360	FALSE	ERBB4	2066	NUCLEAR TRANSLOCATION		chr2	211375721	212538841			ENST00000342788.4	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
ERBB4 EXPRESSION	361	Breast Cancer	1612		Trastuzumab		Predictive	Supports	D	Resistance	siRNA knockdown of HER4 or inhibition with neratinib enhanced trastuzumab response in breast cancer cell lines.	25153719	PubMed		"Mohd Nafi et al., 2014, Oncotarget"		2	accepted	868	N/A	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/868	https://civicdb.org/links/molecular_profiles/361	FALSE	ERBB4	2066	EXPRESSION		chr2	211375721	212538841			ENST00000342788.4	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
ERBB4 EXPRESSION	361	Breast Cancer	1612		Lapatinib		Predictive	Supports	D	Resistance	"ERBB4 protein expression was identified in breast cancer cell lines with acquired lapatinib resistance. Genetic ablation of ERBB4 (not ERBB1-3) led to apoptosis in trastuzumab- and lapatinib resistant cells, probably through a decrease in the PI3K/Akt pathway."	25590338	PubMed		"Canfield et al., 2015, Cell Cycle"		3	accepted	869	N/A	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/869	https://civicdb.org/links/molecular_profiles/361	FALSE	ERBB4	2066	EXPRESSION		chr2	211375721	212538841			ENST00000342788.4	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
SLFN11 EXPRESSION	362	Colorectal Cancer	9256		7-Ethyl-10-Hydroxycamptothecin		Predictive	Supports	D	Sensitivity/Response	"In this study, SLFN11 expression was associated with sensitivity to SN-38 (an active metabolite of topoisomerase inhibitor irinotecan)."	25089570	PubMed		"Tian et al., 2014, Anticancer Drugs"		2	accepted	870	Somatic	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/870	https://civicdb.org/links/molecular_profiles/362	FALSE	SLFN11	91607	EXPRESSION		chr17	35350305	35373620			ENST00000394566.1	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
AURKA Overexpression	181	Lung Non-small Cell Carcinoma	3908		Cisplatin		Predictive	Supports	B	Resistance	High levels of Aurora-A expression (retrospectively assessed by IHC in 102 NSCLC patients) predicted poorer overall survival and progression free survival in a population treated with surgery and cisplatin-based chemotherapy. In-vitro data confirmed these results and overexpression or knockdown of AURKA decreased or increased in-vitro sensitivity to cisplatin.	25082261	PubMed		"Xu et al., 2014, J Transl Med"		4	accepted	871	N/A	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/871	https://civicdb.org/links/molecular_profiles/181	FALSE	AURKA	6790	Overexpression		chr20	56369390	56392337			ENST00000395913.3	75		N/A		2023-01-09 21:52:05 UTC		N/A		FALSE
KRAS RS61764370	250	Head And Neck Squamous Cell Carcinoma	5520		Cisplatin		Predictive	Supports	B	Resistance	"In the retrospective analysis of 103 HNSSC, the TG/GG rs61764370 variant was associated with poor response to cisplatin (log-rank P = 0.002).There seemed to be some improvement when cetuximab was added to their platinum-based regimen (log-rank P = 0.04)."	25081901	PubMed		"Chung et al., 2014, Ann. Oncol."	"NCT00003809,NCT00425750,NCT00503997"	3	accepted	872	Common Germline	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/872	https://civicdb.org/links/molecular_profiles/250	FALSE	KRAS	3845	RS61764370		chr12	25207290	25207290	A	C	ENST00000311936.3	75		3_prime_UTR_variant	"NM_004985.4:c.*2505T>G,NC_000012.11:g.25360224A>C,ENST00000311936.3:c.*2505T>G"	2023-01-27 17:03:14 UTC	CA10637079	308084		FALSE
RAC1 P29S	363	Melanoma	1909		"Vemurafenib,Dabrafenib"	Substitutes	Predictive	Supports	D	Resistance	Melanoma cell lines harboring the RAC1 P29S hotspot mutation were shown to be resistant to BRAF inhibition with vemurafenib or dabrafenib and knock-in or knock-out of this mutation decreased and increased sensitivity to these drugs.	25056119	PubMed		"Watson et al., 2014, Cancer Res."		4	accepted	873	Somatic	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/873	https://civicdb.org/links/molecular_profiles/363	FALSE	RAC1	5879	P29S		chr7	6387261	6387261	C	T	ENST00000356142.4	75		missense_variant	"ENST00000356142.4:c.85C>T,NC_000007.13:g.6426892C>T"	2023-01-27 17:03:35 UTC	CA16602801	376362	PRO29SER	FALSE
BIRC5 NUCLEAR EXPRESSION	364	Lung Non-small Cell Carcinoma	3908		"Taxane Compound,Platinum Compound"	Combination	Predictive	Supports	B	Sensitivity/Response	Patients with nuclear survivin (BIRC5) expression had significantly better responses to taxane-platinum chemotherapy than those with low tumor N-survivin expression (P < 0.001) in a retrospective analysis of 48 patients with non-small cell lung cancer.	24961465	PubMed		"Wu et al., 2014, Med. Oncol."		3	accepted	874	N/A	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/874	https://civicdb.org/links/molecular_profiles/364	FALSE	BIRC5	332	NUCLEAR EXPRESSION		chr17	78214186	78225636			ENST00000301633.4	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
TP53 Wildtype	365	Colorectal Cancer	9256		"Oxaliplatin,Cetuximab,Capecitabine"	Combination	Predictive	Supports	B	Sensitivity/Response	"In this retrospective biomarker analysis of the EXPERT-C trial, patients with TP53 wild-type status had a statistically significant better progression free survival (PFS) (89.3% vs 65.0% at 5 years; hazard ratio [HR] = 0.23; 95% confidence interval [CI] = 0.07 to 0.78; two-sided P = .02 by Cox regression) and overall survival (OS) (92.7% vs 67.5% at 5 years; HR = 0.16; 95% CI = 0.04 to 0.70; two-sided P = .02 by Cox regression) when treated with Cetuximab + CAPOX (Capecitabine, Oxaliplatin) than in the control arm without Cetuximab."	24957073	PubMed		"Sclafani et al., 2014, J. Natl. Cancer Inst."		3	accepted	875	N/A	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/875	https://civicdb.org/links/molecular_profiles/365	FALSE	TP53	7157	Wildtype		chr17	7668402	7687538			ENST00000269305.4	75		wild_type		2023-01-09 21:52:06 UTC		N/A		FALSE
MRE11 Loss	366	Endometrial Cancer	1380		Talazoparib		Predictive	Supports	D	Sensitivity/Response	One endometrial cell line with decreased MRE11 expression caused by a homozygous poly(T) mutation exhibited increased sensitivity to the PARP inhibitor BMN-673. Loss of MRE11 was identified in 30.7% of endometrial tumors (N=521).	24927325	PubMed		"Koppensteiner et al., 2014, PLoS ONE"		2	accepted	876	N/A	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/876	https://civicdb.org/links/molecular_profiles/366	FALSE	MRE11	4361	Loss		chr11	94419729	94493908			ENST00000323929.3	75		loss_of_function_variant		2023-01-09 21:52:06 UTC		N/A		FALSE
ATM Underexpression	179	Gastric Adenocarcinoma	3717		Olaparib		Predictive	Supports	D	Sensitivity/Response	Low ATM protein expression led to sensitivity to PARP inhibitors in TP53 -ve gastric cancer cell lines (8 lines were used for various aspects of this study).	24841718	PubMed		"Kubota et al., 2014, Cell Cycle"		4	accepted	878	N/A	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/878	https://civicdb.org/links/molecular_profiles/179	FALSE	ATM	472	Underexpression		chr11	108222832	108369099			ENST00000278616.4	75		N/A		2023-01-09 21:52:05 UTC		N/A		FALSE
EGFR L858R	33	Lung Adenocarcinoma	3910		Afatinib		Predictive	Supports	B	Sensitivity/Response	"A phase III clinical trial (NCT00949650) found that median progression free survival among patients with exon 19 deletions or L858R EGFR mutations (n = 308) was 13.6 months for afatinib and 6.9 months for chemotherapy (HR, 0.47; 95% CI, 0.34 to 0.65; P = 0.001)."	23816960	PubMed		"Sequist et al., 2013, J. Clin. Oncol."	NCT00949650	4	accepted	879	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/879	https://civicdb.org/links/molecular_profiles/33	FALSE	EGFR	1956	L858R		chr7	55191822	55191822	T	G	ENST00000275493.2	75		missense_variant	"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg"	2023-01-27 17:02:04 UTC	CA126713	"16,609,376,282,376,200"	"LEU858ARG,RS121434568"	FALSE
EGFR Exon 19 Deletion	133	Lung Adenocarcinoma	3910		Afatinib		Predictive	Supports	B	Sensitivity/Response	"A phase III clinical trial (NCT00949650) found that median progression free survival among patients with EGFR exon 19 deletion was 13.6 months for afatinib and 6.9 months for chemotherapy (HR, 0.47; 95% CI, 0.34 to 0.65; P = .001). 308 patients had either exon 19 or L858 mutations."	23816960	PubMed		"Sequist et al., 2013, J. Clin. Oncol."	NCT00949650	4	accepted	880	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/880	https://civicdb.org/links/molecular_profiles/133	FALSE	EGFR	1956	Exon 19 Deletion		chr7	55174722	55174820			ENST00000275493.2	75		inframe_deletion	ENST00000275493.2:c.2185_2283del	2023-01-09 21:52:05 UTC		N/A		FALSE
EGFR Exon 19 Deletion	133	Lung Non-small Cell Carcinoma	3908		Afatinib		Predictive	Supports	D	Sensitivity/Response	Stable HEK293 cell lines expressing mutant EGFR cDNAs were created (using a pQCLIN retroviral vector) and their drug sensitivities to afatinib were examined by MTT assay. Phorphorylation of EGFR was assayed by Western blot. The 50% inhibitory concentration (IC50) of afatinib was significantly lower in cells harboring EGFR exon 19 deletion than in cells harboring EGFR L858R.	25862853	PubMed		"Banno et al., 2015, Anticancer Res."		2	accepted	881	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/881	https://civicdb.org/links/molecular_profiles/133	FALSE	EGFR	1956	Exon 19 Deletion		chr7	55174722	55174820			ENST00000275493.2	75		inframe_deletion	ENST00000275493.2:c.2185_2283del	2023-01-09 21:52:05 UTC		N/A		FALSE
EGFR Exon 19 Deletion	133	Lung Adenocarcinoma	3910		Afatinib		Predictive	Supports	B	Sensitivity/Response	"In a phase 2 study (NCT00525148), patients with lung adenocarcinoma (stage IIIb with pleural effusion or stage IV) and EGFR mutations, treated with afatinib, were assessed by objective response. In total, 129 patients were treated with afatinib. 66% of the 106 patients with two common activating EGFR mutations (exon 19 deletion or L858R) had an objective response compared to 39% of 23 patients with less common EGFR mutations."	22452895	PubMed		"Yang et al., 2012, Lancet Oncol."	NCT00525148	3	accepted	882	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/882	https://civicdb.org/links/molecular_profiles/133	FALSE	EGFR	1956	Exon 19 Deletion		chr7	55174722	55174820			ENST00000275493.2	75		inframe_deletion	ENST00000275493.2:c.2185_2283del	2023-01-09 21:52:05 UTC		N/A		FALSE
EGFR L858R	33	Lung Adenocarcinoma	3910		Afatinib		Predictive	Supports	B	Sensitivity/Response	"In a phase 2 study of patients with lung adenocarcinoma (stage IIIb with pleural effusion or stage IV) and EGFR mutations, treated with afatinib were assessed by objective response. 129 patients were treated with afatinib. 66% of the 106 patients with two common activating EGFR mutations (deletion 19 or L858R) had an objective response compared to 39% of 23 patients with less common mutations."	22452895	PubMed		"Yang et al., 2012, Lancet Oncol."	NCT00525148	3	accepted	883	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/883	https://civicdb.org/links/molecular_profiles/33	FALSE	EGFR	1956	L858R		chr7	55191822	55191822	T	G	ENST00000275493.2	75		missense_variant	"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg"	2023-01-27 17:02:04 UTC	CA126713	"16,609,376,282,376,200"	"LEU858ARG,RS121434568"	FALSE
EGFR Exon 19 Deletion	133	Lung Non-small Cell Carcinoma	3908		Erlotinib		Predictive	Supports	B	Sensitivity/Response	"A randomized phase 3 trial involving 173 NSCLC patients with EGFR mutations (exon 19 deletion or L858R mutation in exon 21) with no history of chemotherapy for metastatic disease. Patients were randomly allocated (1:1) to receive either erlotinib or standard chemotherapy. The primary endpoint was progression-free survival (PFS). Median PFS was 9.7 months in the erlotinib group, compared with 5.2 months in the standard chemotherapy group."	22285168	PubMed		"Rosell et al., 2012, Lancet Oncol."	NCT00446225	3	accepted	884	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/884	https://civicdb.org/links/molecular_profiles/133	FALSE	EGFR	1956	Exon 19 Deletion		chr7	55174722	55174820			ENST00000275493.2	75		inframe_deletion	ENST00000275493.2:c.2185_2283del	2023-01-09 21:52:05 UTC		N/A		FALSE
EGFR L858R	33	Lung Non-small Cell Carcinoma	3908		Erlotinib		Predictive	Supports	B	Sensitivity/Response	"A randomized phase 3 trial (NCT00446225) involving 173 NSCLC patients with EGFR mutations (exon 19 deletion or L858R mutation in exon 21) with no history of chemotherapy for metastatic disease. Patients were randomly allocated (1:1) to receive either erlotinib or standard chemotherapy. The primary endpoint was progression-free survival (PFS). Median PFS was 9.7 months in the erlotinib group, compared with 5.2 months in the standard chemotherapy group."	22285168	PubMed		"Rosell et al., 2012, Lancet Oncol."	NCT00446225	3	accepted	885	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/885	https://civicdb.org/links/molecular_profiles/33	FALSE	EGFR	1956	L858R		chr7	55191822	55191822	T	G	ENST00000275493.2	75		missense_variant	"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg"	2023-01-27 17:02:04 UTC	CA126713	"16,609,376,282,376,200"	"LEU858ARG,RS121434568"	FALSE
ERBB2 Amplification	302	Uterine Corpus Endometrial Carcinoma	50939		Afatinib		Predictive	Supports	D	Sensitivity/Response	Eight uterine cancer cell lines (four with ERBB2 amplification and four without) were treated with scalar concentrations of afatinib. Primary chemotherapy-resistant USC cell lines harbouring ERBB2 gene amplification were sensitive to afatinib exposure and significantly more sensitive than non-amplified cell lines.	25268372	PubMed		"Schwab et al., 2014, Br. J. Cancer"		2	accepted	886	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/886	https://civicdb.org/links/molecular_profiles/302	FALSE	ERBB2	2064	Amplification		chr17	39700080	39728662			ENST00000269571.5	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A	OVEREXPRESSION	FALSE
ERBB2 Amplification	302	Her2-receptor Positive Breast Cancer	60079		"Trastuzumab,Afatinib,Lapatinib"	Substitutes	Predictive	Supports	B	Sensitivity/Response	"In this phase 2 trial, treatment-naive, ERBB2-positive (by IHC) breast cancer patients with stage IIIA, B, C or inflammatory disease were randomized 1:1:1 to afatinib (n = 10), lapatinib (n = 8), or trastuzumab (n = 11). The primary end point was objective response rate. Objective response was seen in 8 afatinib-, 6 lapatinib-, and 4 trastuzumab-treated patients. Afatinib demonstrated clinical activity that compared favorably to trastuzumab and lapatinib for neoadjuvant treatment of HER2-positive breast cancer."	25537159	PubMed		"Rimawi et al., 2015, Clin. Breast Cancer"		2	accepted	887	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/887	https://civicdb.org/links/molecular_profiles/302	FALSE	ERBB2	2064	Amplification		chr17	39700080	39728662			ENST00000269571.5	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A	OVEREXPRESSION	FALSE
TOP1 Amplification	367	Colorectal Cancer	9256		Irinotecan		Predictive	Supports	B	Sensitivity/Response	"FFPE tumor samples from 78 patients with colorectal cancer, who had received irinotecan monotherapy were analyzed with a FISH dual-probe. TOP1 gain was nonsignificantly associated with objective response to irinotecan Odds ratio (OR): 1.62; p = 0.07."	24256029	PubMed		"Nygrd et al., 2014, Scand. J. Gastroenterol."		1	accepted	888	Somatic	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/888	https://civicdb.org/links/molecular_profiles/367	FALSE	TOP1	7150	Amplification		chr20	41028818	41124487			ENST00000361337.2	75		transcript_amplification		2023-01-09 21:52:06 UTC		N/A		FALSE
CDKN1B EXPRESSION	368	Head And Neck Squamous Cell Carcinoma	5520		"Cisplatin,Fluorouracil"	Combination	Predictive	Supports	B	Sensitivity/Response	"41 HNSSC were analyzed by IHC for expression of EGFR, p53, CCND1, p16, p21, p27 (CDKN2B), p-AKT, HIF-1a, Caspase 3 and BCL2. p27 was the only protein that served as a predictive biomarker of response after multivariate analysis (p=0.025; n=41 patients)."	24239278	PubMed		"Moreno-Galindo et al., 2014, Oral Oncol."		2	accepted	889	N/A	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/889	https://civicdb.org/links/molecular_profiles/368	FALSE	CDKN1B	1027	EXPRESSION		chr12	12717124	12722371			ENST00000228872.4	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
MET Amplification	266	Lung Squamous Cell Carcinoma	3907		Crizotinib		Predictive	Supports	C	Sensitivity/Response	"Case report of a 73 year old patient with advanced squamous cell carcinoma of the lung that tested negative for EGFR, KRAS and PIK3CA mutations and ALK and ROS1 rearrangements. c-MET amplification was detected by FISH. Crizotinib led to a partial response."	24192513	PubMed		"Schwab et al., 2014, Lung Cancer"		2	accepted	890	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/890	https://civicdb.org/links/molecular_profiles/266	FALSE	MET	4233	Amplification		chr7	116672405	116796342			ENST00000318493.6	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A		FALSE
AGR2 EXPRESSION	369	Breast Cancer	1612		Tamoxifen		Predictive	Supports	B	Resistance	"mRNA expression of AGR2 in 61 patients with tamoxifen treated postmenopausal breast cancer was determined by qRT-PCR and was inversely associated with treatment response and progression free survival (p= 0.0011, p = 0.0366 respectively). AGR2 protein expression as assessed by IHC was not significantly associated with treatment outcome."	24167368	PubMed		"Hrstka et al., 2013, Dis. Markers"		1	accepted	891	N/A	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/891	https://civicdb.org/links/molecular_profiles/369	FALSE	AGR2	10551	EXPRESSION		chr7	16791811	16805080			ENST00000419304.2	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
PIK3CA Mutation	307	Endometrial Cancer	1380		"Ridaforolimus,Temsirolimus"	Substitutes	Predictive	Does Not Support	B	Sensitivity/Response	"94 endometrial cancer samples of women who had been treated with single agent mTOR inhibitors temsirolimus or ridaforolimus were retrospectively analyzed. No predictive biomarkers were identified, including PIK3CA mutations (N=21/73), KRAS mutations (10/73) or PTEN loss."	24166148	PubMed		"Mackay et al., 2014, Cancer"		3	accepted	892	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/892	https://civicdb.org/links/molecular_profiles/307	FALSE	PIK3CA	5290	Mutation		chr3	179148523	179240093			ENST00000263967.3	75		"transcript_variant,gain_of_function_variant"		2023-01-09 21:52:06 UTC		N/A		FALSE
PTEN Loss	214	Endometrial Cancer	1380		"Ridaforolimus,Temsirolimus"	Substitutes	Predictive	Does Not Support	B	Resistance	"94 endometrial cancer samples of women who had been treated with single agent mTOR inhibitors temsirolimus or ridaforolimus were retrospectively analyzed. No predictive biomarkers were identified, including PIK3CA mutations, KRAS mutations or PTEN loss."	24166148	PubMed		"Mackay et al., 2014, Cancer"		3	accepted	893	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/893	https://civicdb.org/links/molecular_profiles/214	FALSE	PTEN	5728	Loss		chr10	87863113	87971930			ENST00000371953.3	75		loss_of_function_variant	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
KRAS Mutation	332	Endometrial Cancer	1380		"Temsirolimus,Ridaforolimus"	Substitutes	Predictive	Does Not Support	B	Sensitivity/Response	"94 endometrial cancer samples of women who had been treated with single agent mTOR inhibitors temsirolimus or ridaforolimus were retrospectively analyzed. Mutations were found in 32 of 73 analyzed tumors, 10 of which were KRAS mutations. No predictive biomarkers were identified, including PIK3CA mutations, KRAS mutations or PTEN loss."	24166148	PubMed		"Mackay et al., 2014, Cancer"		2	accepted	894	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/894	https://civicdb.org/links/molecular_profiles/332	FALSE	KRAS	3845	Mutation		chr12	25209431	25250803			ENST00000256078.4	75		protein_altering_variant		2023-01-09 21:52:06 UTC		N/A		FALSE
ERBB2 Amplification	302	Colorectal Cancer	9256		"Capecitabine,Cetuximab,Oxaliplatin"	Combination	Predictive	Does Not Support	B	Resistance	"141 patients were analyzed for ERBB2 (HER2) positivity by FISH and/or IHC. Only 6 (4.3%) were ERBB2 positive. These patients did not show a difference in outcome after capecitabine, oxaliplatin and chemoradiotherapy, with or without cetuximab."	24146218	PubMed		"Sclafani et al., 2013, Ann. Oncol."		1	accepted	895	N/A	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/895	https://civicdb.org/links/molecular_profiles/302	FALSE	ERBB2	2064	Amplification		chr17	39700080	39728662			ENST00000269571.5	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A	OVEREXPRESSION	FALSE
FGFR1 Expression	264	Colorectal Cancer	9256		Infigratinib		Predictive	Supports	D	Sensitivity/Response	"In vitro studies showed efficacy of FGFR inhibitor NVP-BGJ398 in cell lines exhibiting high FGFR1 protein. Three cell lines (SNU-C1, HDC9, HCT116) were analyzed. FGFR1 amplification (24/454, assessed by FISH) and/or activated pFGFR1 protein (18/99, assessed by mRNA in situ hybridization) was identified in primary CRC tissue samples."	24135816	PubMed		"Gke et al., 2013, Digestion"		2	accepted	896	N/A	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/896	https://civicdb.org/links/molecular_profiles/264	FALSE	FGFR1	2260	Expression		chr8	38411138	38467845			ENST00000425967.3	75		N/A	N/A	2023-01-09 21:52:06 UTC		N/A		FALSE
EGFR Exon 18 Overexpression	371	Lung Non-small Cell Carcinoma	3908		"Bevacizumab,Erlotinib"	Combination	Predictive	Supports	B	Sensitivity/Response	"Overexpression of EGFR exon 18 (Affymetrix Human Exon 1.0 ST) in tumor or blood samples was associated with tumor shrinkage, independently of EGFR mutational status in NSCLC treated with bevacizumab and erlotinib. 76 patients were analyzed for this study."	24039832	PubMed		"Baty et al., 2013, PLoS ONE"		2	accepted	898	N/A	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/898	https://civicdb.org/links/molecular_profiles/371	FALSE	EGFR	1956	Exon 18 Overexpression		chr7	55170306	55171042			ENST00000344576.2	75		exon_variant		2023-01-09 21:52:06 UTC		N/A		FALSE
ZEB1 Expression	372	Mantle Cell Lymphoma	50746		"Cytarabine,Gemcitabine,Doxorubicin"	Substitutes	Predictive	Supports	D	Resistance	"Downregulation of ZEB1 expression in mantle cell lymphoma cell lines and mouse xenografts led to enhanced sensitivity towards treatment with doxorubicin, cytarabin and gemcitabine."	24013721	PubMed		"Snchez-Till et al., 2014, Cell Death Differ."		2	accepted	899	N/A	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/899	https://civicdb.org/links/molecular_profiles/372	FALSE	ZEB1	6935	Expression		chr10	31319172	31529813			ENST00000361642.5	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
ZEB1 Expression	372	Mantle Cell Lymphoma	50746		"Salinomycin,Doxorubicin"	Combination	Predictive	Supports	D	Sensitivity/Response	"Downregulation of ZEB1 expression in mantle cell lymphoma cell lines and mouse xenografts led to enhanced sensitivity towards treatment with doxorubicin, cytarabin and gemcitabine. the combination of salinomycin (downregulating ZEB1) and doxorubicin was syngergistic."	24013721	PubMed		"Snchez-Till et al., 2014, Cell Death Differ."		3	accepted	900	Somatic	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/900	https://civicdb.org/links/molecular_profiles/372	FALSE	ZEB1	6935	Expression		chr10	31319172	31529813			ENST00000361642.5	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
TIMP1 Overexpression	373	Breast Cancer	1612		Fulvestrant		Predictive	Supports	D	Resistance	TIMP1 overexpression was associated with resistance to fulvestrant in breast cancer cell lines.	23881388	PubMed		"Bjerre et al., 2013, Tumour Biol."		2	accepted	901	N/A	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/901	https://civicdb.org/links/molecular_profiles/373	FALSE	TIMP1	7076	Overexpression		chrX	47582313	47586789			ENST00000218388.4	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
PTP4A3 OVEREXPRESSION	374	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	D	Sensitivity/Response	"In-vitro studies linked PRL-3 (PP4A3) expression to hyperactivation and dependence on EGFR signaling (through downregulation of PTP1B, an inhibitory phosphatase of EGFR). Retrospective analysis of 68 patients showed improved clinical response to the EGFR inhibitor cetuximab in tumors expressing PRL-3."	23867504	PubMed		"Al-Aidaroos et al., 2013, J. Clin. Invest."		3	accepted	902	Somatic	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/902	https://civicdb.org/links/molecular_profiles/374	FALSE	PTP4A3	11156	OVEREXPRESSION		chr8	141391993	141431294			ENST00000521578.1	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
TYMS Amplification	375	Lung Adenocarcinoma	3910		Pemetrexed		Predictive	Supports	B	Resistance	TYMS copy number was lower in clinical samples responding to pemetrexed in combination with platinum (n=25). The same was found in 17 cell lines.	23645741	PubMed		"Kasai et al., 2013, Anticancer Res."		3	accepted	903	Somatic	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/903	https://civicdb.org/links/molecular_profiles/375	FALSE	TYMS	7298	Amplification		chr18	657604	673578			ENST00000323274.10	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A		FALSE
IGF1R EXPRESSION	376	Lung Non-small Cell Carcinoma	3908		Gefitinib		Predictive	Supports	D	Resistance	"Expression of IGF1R in NSCLC cell lines (n=17) was associated with resistance to EGFR inhibitor gefitinib, however, knock-in or knock-out of IGF1R did not affect gefitinib sensitivity. IGF1R expression was also higher in patients with disease progression after gefitinib therapy in a clinical cohort (n=98)."	23619944	PubMed		"Peled et al., 2013, Cell Oncol (Dordr)"		2	accepted	904	N/A	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/904	https://civicdb.org/links/molecular_profiles/376	FALSE	IGF1R	3480	EXPRESSION		chr15	98648971	98964530			ENST00000268035.6	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
EPHB4 EXPRESSION	377	Colorectal Cancer	9256		Bevacizumab		Predictive	Supports	B	Resistance	"EPHB4 expression, as assessed by quantitative RT-PCR in 13 colorectal cancer patients treated with bevacizumab, was higher in non-responders (p = 0.048). No difference was observed in a control group without bevacizumab treatment. qRT-PCR results were also shown to correlate with protein expression measured by IHC."	23579861	PubMed		"Guijarro-Muoz et al., 2013, Med. Oncol."		2	accepted	905	N/A	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/905	https://civicdb.org/links/molecular_profiles/377	FALSE	EPHB4	2050	EXPRESSION		chr7	100802565	100827499			ENST00000358173.3	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
TP53 Wildtype	365	Esophageal Carcinoma	1107		Chemotherapy		Predictive	Supports	B	Sensitivity/Response	"Patients with p53 wild type (as defined by low expression and/or wild-type tp53 gene) had a higher response rate to chemotherapy-based treatment (total major response [MR]: risk ratio [RR] = 1.09, 95 % CI = 1.03-1.16, P = .003; pathological MR: RR = 1.15, 95 % CI = 1.06-1.25, P = .001; total complete response [CR]: RR = 1.08, 95 % CI = 1.00-1.17, P = .040) in this meta-analysis (28 studies, 1497 cases)."	23515910	PubMed		"Zhang et al., 2013, Ann. Surg. Oncol."		3	accepted	906	N/A	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/906	https://civicdb.org/links/molecular_profiles/365	FALSE	TP53	7157	Wildtype		chr17	7668402	7687538			ENST00000269305.4	75		wild_type		2023-01-09 21:52:06 UTC		N/A		FALSE
TYMS Underexpression	378	Lung Non-small Cell Carcinoma	3908		Pemetrexed		Predictive	Supports	B	Sensitivity/Response	49 tumor specimens from 268 NSCLC patients treated with pemetrexed were evaluated for expression of TYMS and DHFR by IHC and compared to treatment outcomes. Patients with low TS (?50) expression had a longer median progression-free survival (PFS) than those with high TS (>150) expression (4.8 vs. 3.4 months; p=0.01).	21367480	PubMed		"Chen et al., 2011, Lung Cancer"		3	accepted	907	N/A	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/907	https://civicdb.org/links/molecular_profiles/378	FALSE	TYMS	7298	Underexpression		chr18	657604	673578			ENST00000323274.10	75		N/A	N/A	2023-01-09 21:52:06 UTC		N/A		FALSE
TYMS Underexpression	378	Prostate Cancer	10283		Pemetrexed		Predictive	Supports	C	Sensitivity/Response	Case report of a patient with metastatic prostate cancer and underexpression of TYMS who showed a nonspecified response to pemetrexed for at least 4 months.	24782778	PubMed		"Russell et al., 2014, Front Pharmacol"		2	accepted	908	N/A	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/908	https://civicdb.org/links/molecular_profiles/378	FALSE	TYMS	7298	Underexpression		chr18	657604	673578			ENST00000323274.10	75		N/A	N/A	2023-01-09 21:52:06 UTC		N/A		FALSE
TOP2A EXPRESSION	379	Breast Cancer	1612		Doxorubicin		Predictive	Supports	B	Sensitivity/Response	"In a retrospective study, TOP2A expression was assessed by IHC for 108 breast cancer patients (from TAX 303 trial). TOP2A expression was associated with a higher probability of response in doxorubicin treated but not in docetaxel treated breast cancer patients."	15486187	PubMed		"Durbecq et al., 2004, Mol. Cancer Ther."		2	accepted	909	N/A	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/909	https://civicdb.org/links/molecular_profiles/379	FALSE	TOP2A	7153	EXPRESSION		chr17	40388516	40417950			ENST00000423485.1	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
TOP1 EXPRESSION	380	Ovarian Cancer	2394		"Topotecan,Carboplatin,Cyclophosphamide"	Combination	Predictive	Supports	B	Sensitivity/Response	"Shorter progression free survival was observed in patients with low expression (IHC) of topoisomerase 1 in 16 patients with relapsed or persistent ovarian or peritoneal carcinoma after treatment with topotecan, cyclophosphamide and carboplatin followed by an autologous hematopoietic stem cell transplant."	19648970	PubMed		"Litzow et al., 2010, Bone Marrow Transplant."	NCT00652691	2	accepted	910	N/A	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/910	https://civicdb.org/links/molecular_profiles/380	FALSE	TOP1	7150	EXPRESSION		chr20	41028818	41124487			ENST00000361337.2	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
EGFR Amplification	190	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	B	Sensitivity/Response	"87 patients with metastatic colorectal cancer treated with cetuximab were retrospectively analyzed for EGFR amplifications by FISH. In multivariate analysis, EGFR amplification predicted response and overall survival independent of KRAS status."	18794099	PubMed		"Personeni et al., 2008, Clin. Cancer Res."		3	accepted	911	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/911	https://civicdb.org/links/molecular_profiles/190	FALSE	EGFR	1956	Amplification		chr7	55019101	55211628			ENST00000275493.2	75		transcript_amplification	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
TOP1 EXPRESSION	380	Colorectal Cancer	9256		Irinotecan		Predictive	Supports	B	Sensitivity/Response	"498 patients were retrospectively analyzed for topoisomerase 1 expression (IHC). In the subgroup of patients treated with irinotecan (38% of the 498), those patients expressing Topoisomerase I had a better overall survival according to multivariate analysis (HR = 0.47, 95% CI 0.23-0.94, p = 0.033)."	19775480	PubMed		"Kostopoulos et al., 2009, BMC Cancer"		3	accepted	912	N/A	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/912	https://civicdb.org/links/molecular_profiles/380	FALSE	TOP1	7150	EXPRESSION		chr20	41028818	41124487			ENST00000361337.2	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
PRKAA2 T172 PHOSPHORYLATION	381	Cancer	162		ACLY SiRNA		Predictive	Supports	E	Sensitivity/Response	"Low levels of baseline p-AMPK (PRKAA2, measured at Thr172) were predictive of efficacy of ACLY inhibition by siRNA in cell lines of various cancer histologies."	23506848	PubMed		"Migita et al., 2013, Am. J. Pathol."		2	accepted	913	N/A	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/913	https://civicdb.org/links/molecular_profiles/381	FALSE	PRKAA2	5563	T172 PHOSPHORYLATION		chr1	56693803	56693805			ENST00000371244.4	75		N/A		2023-01-09 21:52:06 UTC				FALSE
HSPA5 EXPRESSION	382	Colorectal Cancer	9256		Fluorouracil		Predictive	Supports	B	Sensitivity/Response	"Expression of GRP78 (HSPA5) in colorectal cancer patients (n=396, by IHC) showed improved benefit from adjuvant chemotherapy in stage III patients (52% vs. 28%; p = 0.026). In vitro, GRP78 inhibition reduced response to 5-FU."	23456958	PubMed		"Thornton et al., 2013, Int. J. Cancer"		4	accepted	914	N/A	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/914	https://civicdb.org/links/molecular_profiles/382	FALSE	HSPA5	3309	EXPRESSION		chr9	125234853	125241330			ENST00000324460.6	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
PIK3CA Mutation	307	Colorectal Cancer	9256		Anti-EGFR Monoclonal Antibody		Predictive	Supports	B	Resistance	"A meta-analysis of 8 metastatic colorectal cancer studies (839 patients) was performed. PIK3CA mutations were significantly associated with shorter PFS and OS following therapy with anti-EGFR monoclonal antibodies (PFS: 8 studies, 839 patients; HR = 1.53; 95 % confidence interval (CI) 1.28-1.84; P < 0.001; OS: 5 studies; 587 patients; HR = 1.28; 95 % CI 1.05-1.56; P = 0.015)."	23435830	PubMed		"Wu et al., 2013, J. Cancer Res. Clin. Oncol."		4	accepted	915	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/915	https://civicdb.org/links/molecular_profiles/307	FALSE	PIK3CA	5290	Mutation		chr3	179148523	179240093			ENST00000263967.3	75		"transcript_variant,gain_of_function_variant"		2023-01-09 21:52:06 UTC		N/A		FALSE
KRAS Exon 2 Mutation	75	Pancreatic Carcinoma	4905		Erlotinib		Predictive	Does Not Support	B	Resistance	KRAS exon 2 was mutated in 121 of 173 (70%) patients with advanced pancreatic cancer and did not show an association with response to erlotinib treatment.	23435671	PubMed		"Boeck et al., 2013, J. Gastroenterol."		3	accepted	916	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/916	https://civicdb.org/links/molecular_profiles/75	FALSE	KRAS	3845	Exon 2 Mutation		chr12	25245274	25245395			ENST00000256078.4	75		missense_variant		2023-01-09 21:52:04 UTC				FALSE
KRAS Exon 2 Mutation	75	Pancreatic Carcinoma	4905				Prognostic	Supports	B	Poor Outcome	"KRAS exon 2 was mutated in 121 of 173 patients with advanced pancreatic cancer. Patients with KRAS wildtype had an improved OS (HR 1.68, p = 0.005)."	23435671	PubMed		"Boeck et al., 2013, J. Gastroenterol."		3	accepted	917	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/917	https://civicdb.org/links/molecular_profiles/75	FALSE	KRAS	3845	Exon 2 Mutation		chr12	25245274	25245395			ENST00000256078.4	75		missense_variant		2023-01-09 21:52:04 UTC				FALSE
EIF4EBP1 PHOSPHORYLATION	383	Gastric Adenocarcinoma	3717		Everolimus		Predictive	Supports	D	Sensitivity/Response	"8 gastric cancer cell lines were treated with the MTOR inhibitor everolimus. Cell proliferation was effectively inhibited in 3 cell lines by everolimus. Phosphorylated EIF4EBP1 (T37/46, T70) levels were higher in cell lines and xenografts sensitive to everolimus."	23340172	PubMed		"Nishi et al., 2013, Cancer Lett."		2	accepted	918	N/A	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/918	https://civicdb.org/links/molecular_profiles/383	FALSE	EIF4EBP1	1978	PHOSPHORYLATION		chr8	38030682	38057145			ENST00000338825.4	75		N/A		2023-01-09 21:52:06 UTC				FALSE
KIT Mutation	384	Gastrointestinal Stromal Tumor	9253		"Imatinib,Pictilisib"	Combination	Predictive	Supports	D	Sensitivity/Response	"Human GISTs with different KIT mutations were grafted in 136 nude muce. Mice were then treated with control, imatinib, GDC-0941, or GDC-0941 + imatinib. The combination showed superior antitumor efficacy that was sustained after treatment withdrawal."	23231951	PubMed		"Floris et al., 2013, Clin. Cancer Res."		2	accepted	919	Somatic	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/919	https://civicdb.org/links/molecular_profiles/384	FALSE	KIT	3815	Mutation		chr4	54657918	54740715			ENST00000288135.5	75		transcript_variant		2023-01-09 21:52:06 UTC		N/A		FALSE
TUBB3 EXPRESSION	385	Cancer	162		Paclitaxel		Predictive	Supports	D	Resistance	"High expression of class 3 beta-tubulin led to decreased effect of paclitaxel on cell motility in HeLa, MCF-7 and CHO cell lines."	21576762	PubMed		"Ganguly et al., 2011, Oncotarget"		2	accepted	920	N/A	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/920	https://civicdb.org/links/molecular_profiles/385	FALSE	TUBB3	10381	EXPRESSION		chr16	89923279	89936097			ENST00000315491.7	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
TUBB3 EXPRESSION	385	Breast Cancer	1612		Taxane Compound		Predictive	Supports	B	Sensitivity/Response	"High expression of betaIII-tubulin, as assessed in 85 breast cancers by IHC, was associated with better pathological response."	23218766	PubMed		"Wang et al., 2013, Clin. Breast Cancer"		2	accepted	921	N/A	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/921	https://civicdb.org/links/molecular_profiles/385	FALSE	TUBB3	10381	EXPRESSION		chr16	89923279	89936097			ENST00000315491.7	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
TYMS Overexpression	343	Lung Non-small Cell Carcinoma	3908		Pemetrexed		Predictive	Supports	B	Resistance	"mRNA levels of TYMS, DHFR and GARFT were assessed (rt-PCR) in 50 patient samples of NSCLC. TYMS mRNA levels were lower in responders compared to non-responders to pemetrexed (1.671  0.844 versus 5.978  1.895, p=0.0142)."	23060591	PubMed		"Shimizu et al., 2012, Anticancer Res."		3	accepted	922	N/A	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/922	https://civicdb.org/links/molecular_profiles/343	FALSE	TYMS	7298	Overexpression		chr18	657604	673578			ENST00000323274.10	75		N/A	N/A	2023-01-09 21:52:06 UTC		N/A		FALSE
EGFR Y1092 PHOSPHORYLATION	386	Lung Non-small Cell Carcinoma	3908		"Gefitinib,Erlotinib"	Substitutes	Predictive	Supports	B	Sensitivity/Response	"While EGFR mutation is a strong predictive factor for EGFR inhibition, some patients with EGFR wild-type also respond.  The authors investigated whether phosphorylated EGFR could be a potential predictive biomarker in patients with wild-type EGFR. Phosphorylation of Y1068 (assessed by IHC) was associated with improved progression free survival (PFS) in 205 patients with stage IIb and IV NSCLC treated with EGFR tyrosine kinase inhibitors (gefitinib or erlotinib) compared to phospho-Y1068 negative patients (median PFS 7.0 months vs. 1.2 months, P??.001). In this group, 92 (44.9%) were EGFR mutant. In a subgroup of patients with wild-type EGFR, phospho-Y1068 expression positive patients had a significantly prolonged PFS (4.2months vs.1.2months P??.001) compared with those without phospho-Y1068 expression."	22901364	PubMed		"Wang et al., 2012, J. Exp. Clin. Cancer Res."		3	accepted	923	N/A	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/923	https://civicdb.org/links/molecular_profiles/386	FALSE	EGFR	1956	Y1092 PHOSPHORYLATION		chr7	55205258	55205260			ENST00000275493.2	75		N/A		2023-01-09 21:52:06 UTC			Y1039 PHOSPHORYLATION	FALSE
IGF1R NUCLEAR EXPRESSION	387	Sarcoma	1115		IGF1R Monoclonal Antibody		Predictive	Supports	B	Sensitivity/Response	"IGF-1R nuclear immunostaining (IHC) was observed in 9 out of 16 samples of patients with different sarcomas (osteosarcoma, ewing sarcoma, liposarcoma, synovialsarcoma, desmoplastic tumor, rhabdomyosarcoma). Exclusive nuclear immunostaining was associated with better progression free survival and overall survival after therapy with IGF1R antibodies (R1507, IMC-A12, SCH 717454 and CP-751.871)."	22682017	PubMed		"Asmane et al., 2012, Eur. J. Cancer"	"NCT00474760,NCT00617890,NCT00642941,NCT00668148"	2	accepted	924	N/A	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/924	https://civicdb.org/links/molecular_profiles/387	FALSE	IGF1R	3480	NUCLEAR EXPRESSION		chr15	98648971	98964530			ENST00000268035.6	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
CFLAR EXPRESSION	388	Prostate Cancer	10283		Bicalutamide		Predictive	Supports	D	Resistance	"Expression of c-FLIP (CFLAR) in 50 prostate specimens (assessed by IHC) was increased in castrate-resistant prostate cancer. In-vitro, silencing of CFLAR led to sensitization of two cell lines to bicalutamide."	22623731	PubMed		"McCourt et al., 2012, Clin. Cancer Res."		3	accepted	925	N/A	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/925	https://civicdb.org/links/molecular_profiles/388	FALSE	CFLAR	8837	EXPRESSION		chr2	201116104	201176687			ENST00000309955.3	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
PROM1 EXPRESSION	389	Hepatocellular Carcinoma	684		Sorafenib		Predictive	Supports	B	Resistance	"CD133 (PROM1) expression in 39 samples of hepatocellular carcinomas was correlated with JNK activity. Both were more highly expressed in patients not responding to sorafenib. CD133+ cells (sorted) were xenografted into mice, producing larger, more JNK inhibitor responsive tumors than CD133- xenografts."	22596232	PubMed		"Hagiwara et al., 2012, Br. J. Cancer"		2	accepted	926	N/A	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/926	https://civicdb.org/links/molecular_profiles/389	FALSE	PROM1	8842	EXPRESSION		chr4	15968234	16083701			ENST00000510224.1	75		N/A		2023-01-09 21:52:06 UTC				FALSE
TIMP1 Overexpression	373	Breast Cancer	1612		Paclitaxel		Predictive	Supports	B	Resistance	High expression of TIMP-1 was assessed by IHC in 99 primary breast cancers that had not spread beyond the breast after 6 postoperative courses of paclitaxel-based chemotherapy. High TIMP1 levels were associated with worse 5-year disease free survival (71.1%) than low levels (88.5 %; P = 0.020). High TIMP-1 levels were also associated with worse 5-year overall survival (78.9 %) than low levels (96.7 %; P = 0.004).	22544540	PubMed		"Zhu et al., 2012, Med. Oncol."		2	accepted	927	N/A	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/927	https://civicdb.org/links/molecular_profiles/373	FALSE	TIMP1	7076	Overexpression		chrX	47582313	47586789			ENST00000218388.4	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
FOXP3 EXPRESSION	390	Breast Cancer	1612		Epirubicin		Predictive	Supports	B	Sensitivity/Response	"1,097 patients with breast cancer were evaluated for FOXP3 expression by IHC. FOXP3 expression was found in 405 tumor samples and associated with improved OS in patients treated with anthracycline-based adjuvant chemotherapy (6 cycles of 'FEC100' aka epirubicin + cyclophosphamide + 5-fluorouracil) but not in patients treated with sequential anthracycline->taxane (3 cycles of FEC100 followed by 3 cycles of docetaxel). In-vitro experiments confirmed that FOXP3 expression enhance anthracycline efficacy. The in vitro data consisted of testing the sensitivity of various breast cancer cell lines to anthracyclines after treatment with valproic acid (which increases FOXP3 expression). The authors observed that, while valproic acid has no intrinsic cytotoxic effect on tumor cells, it enhanced the cytotoxic effect of epirubicin specifically in cell lines where FOXP3 expression was increased."	22431701	PubMed		"Ladoire et al., 2012, Ann. Oncol."		4	accepted	928	N/A	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/928	https://civicdb.org/links/molecular_profiles/390	FALSE	FOXP3	50943	EXPRESSION		chrX	49250436	49264826			ENST00000376207.4	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
TYMS Overexpression	343	Gastric Adenocarcinoma	3717		Raltitrexed		Predictive	Supports	B	Resistance	"In 125 gastric tumors, plasma and tissue mRNA levels of TYMS were lower in the raltitrexed sensitive group compared to the resistant group (p = 0.007 and 0.013, respectively)."	22422354	PubMed		"Shen et al., 2012, Int. J. Cancer"		2	accepted	929	N/A	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/929	https://civicdb.org/links/molecular_profiles/343	FALSE	TYMS	7298	Overexpression		chr18	657604	673578			ENST00000323274.10	75		N/A	N/A	2023-01-09 21:52:06 UTC		N/A		FALSE
RPS6 PHOSPHORYLATION	391	Gastric Adenocarcinoma	3717		Everolimus		Predictive	Supports	D	Sensitivity/Response	"54 patients with advanced gastric cancer were treated with everolimus. Two patient responsed and potential biomarkers were explored. High pre-treatment expression of phosphorylated RPS6 (pS6; at Ser240/4) was associated with higher disease control rate and progression free survival (P=0.043, P=0.001 respectively; N=28)."	22343617	PubMed		"Yoon et al., 2012, Br. J. Cancer"		2	accepted	930	N/A	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/930	https://civicdb.org/links/molecular_profiles/391	FALSE	RPS6	6194	PHOSPHORYLATION		chr9	19376311	19376325			ENST00000380394.4	75		N/A		2023-01-09 21:52:06 UTC				FALSE
JAK1 OVEREXPRESSION	392	Lung Non-small Cell Carcinoma	3908		Enzastaurin		Predictive	Supports	D	Sensitivity/Response	Overexpression of JAK1 in 22 lung cancer cell lines was associated with sensitivity to PKC-inhibitor enzastaurin. Silencing of JAK1 (by small molecule JAK 1/2/3 inhibitor) led to resistance.  Overexpression of JAK1 (lentiviral mediated) led to sensitivity to enzastaurin.	22333600	PubMed		"Shimokawa et al., 2012, Br. J. Cancer"		4	accepted	931	N/A	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/931	https://civicdb.org/links/molecular_profiles/392	FALSE	JAK1	3716	OVEREXPRESSION		chr1	64833229	64966504			ENST00000342505.4	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
EIF4EBP1 PHOSPHORYLATION	383	Colorectal Cancer	9256		"WYE354,MTOR Kinase Inhibitor PP242,Dactolisib"	Substitutes	Predictive	Supports	D	Resistance	"12 CRC cell lines were evaluated. 40% of these were intrinsically resistant to mTOR inhibition with  BEZ235, PP242 or WYE354. mTOR independent phosphorylation of EIF4EBP1 (T37/46) was associated with resistance to mTOR inhibitors in one analyzed cell line (SW620)."	22262166	PubMed		"Zhang et al., 2012, Cell Cycle"		2	accepted	932	N/A	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/932	https://civicdb.org/links/molecular_profiles/383	FALSE	EIF4EBP1	1978	PHOSPHORYLATION		chr8	38030682	38057145			ENST00000338825.4	75		N/A		2023-01-09 21:52:06 UTC				FALSE
BRCA1 Expression	393	Malignant Mesothelioma	1790		Vinorelbine		Predictive	Supports	D	Sensitivity/Response	Expression of BRCA1 in 6 mesothelioma cell lines was associated with sensitivity to vinorelbine in functional studies.	22190288	PubMed		"Busacca et al., 2012, J. Pathol."		2	accepted	933	N/A	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/933	https://civicdb.org/links/molecular_profiles/393	FALSE	BRCA1	672	Expression		chr17	43045629	43125483			ENST00000471181.2	75		N/A	N/A	2023-01-09 21:52:06 UTC		N/A		FALSE
DUSP6 EXPRESSION	394	Cancer	162		Trametinib		Predictive	Supports	D	Sensitivity/Response	Expression of DUSP6 was associated with sensitivity to MEK inhibitor GSK1120212 (Sensitivity: 79%; specificity: 82%: P = 0.0027) in 218 solid cancer cell lines.	22169769	PubMed		"Jing et al., 2012, Mol. Cancer Ther."		3	accepted	934	N/A	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/934	https://civicdb.org/links/molecular_profiles/394	FALSE	DUSP6	1848	EXPRESSION		chr12	89347232	89353271			ENST00000279488.7	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
KRAS Mutation	332	Cancer	162		Trametinib		Predictive	Supports	D	Sensitivity/Response	"In this screen of 218 solid cancer cell lines, KRAS and BRAF mutations were predictive of response to MEK inhibitor GSK1120212. 40 cell lines harbored a KRAS mutation. In RAF/RAS mutant colon cancer cell lines, co-occurring PIK3CA/PTEN mutations led to a cytostatic (9/10 cell lines) response rather than a cytotoxic response (1/10 cell lines)."	22169769	PubMed		"Jing et al., 2012, Mol. Cancer Ther."		4	accepted	935	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/935	https://civicdb.org/links/molecular_profiles/332	FALSE	KRAS	3845	Mutation		chr12	25209431	25250803			ENST00000256078.4	75		protein_altering_variant		2023-01-09 21:52:06 UTC		N/A		FALSE
BRAF Mutation	395	Cancer	162		Trametinib		Predictive	Supports	D	Sensitivity/Response	"In this screen of 218 solid cancer cell lines, BRAF mutations were predictive of response to the MEK inhibitor GSK1120212. 26 of these cell lines had the BRAF V600E mutation, one cell line had a G469A mutation, one had G596R mutation and one had an unspecified mutation. Also of note, in RAF/RAS mutant colon cancer cell lines, co-occurring PIK3CA/PTEN mutations led to a cytostatic response rather than a cytotoxic response."	22169769	PubMed		"Jing et al., 2012, Mol. Cancer Ther."		4	accepted	936	Somatic	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/936	https://civicdb.org/links/molecular_profiles/395	FALSE	BRAF	673	Mutation		chr7	140753336	140781603			ENST00000288602.6	75		"gene_variant,gain_of_function_variant"		2023-01-09 21:52:06 UTC				FALSE
KRAS G12D	79	Pancreatic Carcinoma	4905		Akt Inhibitor MK2206		Predictive	Supports	C	Sensitivity/Response	"Among 33 patients treated with pan-AKT inhibitor MK-2206 in this phase 1 study, one patient with pancreatic adenocarcinoma and PTEN loss and a KRAS G12D mutation experienced a decrease of approximately 60% in cancer antigen 19-9 levels and 23% shrinkage in tumor measurements."	22025163	PubMed		"Yap et al., 2011, J. Clin. Oncol."		2	accepted	937	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/937	https://civicdb.org/links/molecular_profiles/79	FALSE	KRAS	3845	G12D	EGFR TKI Resistance	chr12	25245350	25245350	C	T	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.35G>A,NP_004976.2:p.Gly12Asp,NC_000012.11:g.25398284C>T,ENST00000256078.4:c.35G>A"	2023-01-27 17:02:26 UTC	CA122538	12582	"GLY12ASP,RS121913529"	FALSE
PTEN Loss	214	Pancreatic Carcinoma	4905		Akt Inhibitor MK2206		Predictive	Supports	C	Sensitivity/Response	"Among 33 patients treated with pan-AKT inhibitor MK-2206 in this phase 1 study, one patient with pancreatic adenocarcinoma and PTEN loss/KRAS G12D mutation experienced a decrease of approximately 60% in cancer antigen 19-9 levels and 23% shrinkage in tumor measurements."	22025163	PubMed		"Yap et al., 2011, J. Clin. Oncol."		2	accepted	938	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/938	https://civicdb.org/links/molecular_profiles/214	FALSE	PTEN	5728	Loss		chr10	87863113	87971930			ENST00000371953.3	75		loss_of_function_variant	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
HSPB1 EXPRESSION	396	Pancreatic Ductal Adenocarcinoma	3498		Gemcitabine		Predictive	Supports	D	Sensitivity/Response	HSP27 (HSPB1) expression in pancreatic adenocarcinoma cell lines was associated with sensitivity to treatment with gemcitabine.	22004109	PubMed		"Schfer et al., 2012, J. Cell. Mol. Med."		2	accepted	939	N/A	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/939	https://civicdb.org/links/molecular_profiles/396	FALSE	HSPB1	3315	EXPRESSION		chr7	76302544	76304295			ENST00000248553.6	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
NQO1 EXPRESSION	397	Lung Cancer	1324		Amrubicin		Predictive	Supports	D	Resistance	Higher expression of NQO1 was correlated with decreased cytotoxicity of amrubicin (amrubicinol is the active metabolite) in 27 NSCLC and SCLC cell lines.  siRNA knockdown of NQO1 (in two cell lines) increased amrubicinol cytotoxicity.	21964527	PubMed		"Takakuwa et al., 2011, J Thorac Oncol"		2	accepted	940	N/A	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/940	https://civicdb.org/links/molecular_profiles/397	FALSE	NQO1	1728	EXPRESSION		chr16	69709401	69726951			ENST00000320623.5	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
NQO1 P187S	398	Lung Cancer	1324		Amrubicin		Predictive	Supports	D	Sensitivity/Response	"The presence of NQO1 C609T SNP (rs1800566) was associated with decreased protein expression and higher amrubicin sensitivity in 29 NSCLC and SCLC cell lines. 15 of these cell lines were genotyped for C609T (only 3 were T/T, and the rest were C/C or C/T). Cell lines with the T/T genotype had lower expression of NQ01 and greater response to amrubicinol."	21964527	PubMed		"Takakuwa et al., 2011, J Thorac Oncol"		2	accepted	941	Common Germline	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/941	https://civicdb.org/links/molecular_profiles/398	FALSE	NQO1	1728	P187S		chr16	69711242	69711242	G	A	ENST00000320623.5	75		missense_variant	"NM_000903.2:c.559C>T,NP_000894.1:p.Pro187Ser,NC_000016.9:g.69745145G>A"	2023-01-27 17:03:36 UTC	CA126904	16809	PRO187SER	FALSE
BRCA1 Underexpression	399	Ovarian Cancer	2394		"Platinum Compound,Taxane Compound"	Combination	Predictive	Supports	B	Sensitivity/Response	"Absent/low expression of BRCA1 (IHC) was associated with improved response to chemotherapy in 292 patients with sporadic ovarian cancer compared to patients with high expression (odds ratio 2.47: 95%CI 1.10-5.55, p=0.029)."	21920589	PubMed		"Carser et al., 2011, Gynecol. Oncol."		3	accepted	942	N/A	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/942	https://civicdb.org/links/molecular_profiles/399	FALSE	BRCA1	672	Underexpression		chr17	43045629	43125483			ENST00000471181.2	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
KRAS Mutation	332	Colorectal Cancer	9256		"Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor,Immunomodulatory Oligonucleotide"	Combination	Predictive	Supports	D	Sensitivity/Response	TLR9 agonist immunomodulatory oligonucleotide (IMO) led to inhibited survival of LS174T colorectal cancer and AsPC1 pancreatic cancer cell lines with KRAS mutations.	21890455	PubMed		"Rosa et al., 2011, Clin. Cancer Res."		2	accepted	943	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/943	https://civicdb.org/links/molecular_profiles/332	FALSE	KRAS	3845	Mutation		chr12	25209431	25250803			ENST00000256078.4	75		protein_altering_variant		2023-01-09 21:52:06 UTC		N/A		FALSE
ALK Fusion	495	Lung Non-small Cell Carcinoma	3908		Pemetrexed		Predictive	Supports	B	Sensitivity/Response	"Among 95 patients with NSCLC in this study, 15 had an ALK translocation. ORR of these patients compared to EGFR mutated or wild-type tumors was superior (46.7 versus 4.7 versus 16.2%, p = 0.001). TYMS expression was lower in ALK-positive cells."	21642865	PubMed		"Lee et al., 2011, J Thorac Oncol"		3	accepted	945	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/945	https://civicdb.org/links/molecular_profiles/495	FALSE	ALK	238	Fusion	ALK Fusion	chr2	29192774	29223528			ENST00000389048.3	75		transcript_fusion		2023-01-09 21:52:07 UTC		N/A	REARRANGEMENT	FALSE
DNMT1 EXPRESSION	331	Gastric Adenocarcinoma	3717		Cisplatin		Predictive	Supports	B	Resistance	"High DNMT1 expression was found in 105/127 (83%) or patients (by qPCR assay). Low DNMT1 expression was associated with improved histopathological and clinical response and OS in patients with gastric cancer  (P=0.03/P=0.008, P(log-rank)=0.001, respectively). In one cisplatin resistant cell line, DAC treatment and cisplatin had a synergistic effect."	21458988	PubMed		"Mutze et al., 2011, Eur. J. Cancer"		3	accepted	946	N/A	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/946	https://civicdb.org/links/molecular_profiles/331	FALSE	DNMT1	1786	EXPRESSION		chr19	10133346	10195135			ENST00000340748.4	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
KRAS Mutation	332	Colorectal Cancer	9256		"Cetuximab,Dasatinib"	Combination	Predictive	Supports	D	Sensitivity/Response	"Combined treatment with dasatinib and cetuximab, but not either agent in monotherapy, had an antitumor efficacy in-vitro and in xenografts. These results were based on three KRAS mutant cell lines (LS180, LoVo and HCT116) and two KRAS wild-type cell lines (SW48 and CaCo2)."	20956938	PubMed		"Dunn et al., 2011, Oncogene"		3	accepted	947	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/947	https://civicdb.org/links/molecular_profiles/332	FALSE	KRAS	3845	Mutation		chr12	25209431	25250803			ENST00000256078.4	75		protein_altering_variant		2023-01-09 21:52:06 UTC		N/A		FALSE
EGFR Amplification	190	Lung Non-small Cell Carcinoma	3908		Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor		Predictive	Supports	B	Sensitivity/Response	"A meta-analysis of EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment was performed. In total, 20 (1689 patients, 594 with increased gene copy number), 10 (822 patients, 290 with increased gene copy number) and 5 studies (294 patients, 129 with increased gene copy number) were analyzed for overall survival (OS), progression-free survival (PFS) and time-to-progression (TTP) meta-analyses respectively. EGFR amplification was associated with increased OS (HR = 0.77; 95% CI 0.66-0.89; P = 0.001), PFS (HR = 0.60; 95% CI 0.46-0.79; P<0.001) and TTP (HR = 0.50; 95% CI 0.28-0.91; P = 0.02). This effect was shown to influence survival in predominantly white patient populations but not patients of Asian descent."	20826716	PubMed		"Dahabreh et al., 2011, Ann. Oncol."		4	accepted	948	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/948	https://civicdb.org/links/molecular_profiles/190	FALSE	EGFR	1956	Amplification		chr7	55019101	55211628			ENST00000275493.2	75		transcript_amplification	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
CXCR4 EXPRESSION	401	Gastric Adenocarcinoma	3717		Docetaxel		Predictive	Supports	B	Resistance	"CXCR4 expression as assessed by microarray analysis, was associated with resistance to docetaxel in 11 cancer cell lines (R^2 = 0.23, p = 0.019). Expression levels (by qtPCR) were also higher in resistant tumors among 25 patient samples."	20651371	PubMed		"Xie et al., 2010, Anticancer Res."		2	accepted	949	N/A	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/949	https://civicdb.org/links/molecular_profiles/401	FALSE	CXCR4	7852	EXPRESSION		chr2	136114349	136116243			ENST00000409817.1	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
MAGEH1 EXPRESSION	402	Bile Duct Adenocarcinoma	4896		Gemcitabine		Predictive	Supports	D	Resistance	"10 biliary tract carcinoma cell lines were sorted based on their gemcitabine sensitivity. MAGEH1 protein expression was negatively correlated with sensitivity. In a clinical validation cohort, MAGEH protein expression was found in 4/4 ""non-effective"" cases and 2/5 effective cases based on RECIST criteria after gemcitabine treatment."	20088962	PubMed		"Ojima et al., 2010, Cancer Sci."		2	accepted	950	N/A	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/950	https://civicdb.org/links/molecular_profiles/402	FALSE	MAGEH1	28986	EXPRESSION		chrX	55452105	55453565			ENST00000342972.1	75		N/A		2023-01-09 21:52:06 UTC				FALSE
ABCC3 Amplification	403	Breast Cancer	1612		"Monomethyl Auristatin E,Paclitaxel"	Substitutes	Predictive	Supports	D	Resistance	44 cell lines and 145 patient samples were utilized in various aspects of this study. 31 breast cancer cell lines for in vitro sensitivity to paclitaxel and Monomethyl Auristatin E (MMAE). Genome wide amplification was assessed by Affymetrix SNP arrays and expression was assessed by Affymetrix gene expression arrays. ABCC3 amplification (and expression) in ERBB2 (HER2) amplified breast cancer cell lines was associated with resistance to paclitaxel and  MMAE. Three independently derived EVSA-T cell lines overexpressing ABCC3 were at least 20-fold less sensitive to paclitaxel and MMAE based on EC50 values.	18593940	PubMed		"O'Brien et al., 2008, Cancer Res."		3	accepted	951	Somatic	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/951	https://civicdb.org/links/molecular_profiles/403	FALSE	ABCC3	8714	Amplification		chr17	50634857	50692252			ENST00000285238.8	75		transcript_amplification		2023-01-09 21:52:06 UTC		N/A		FALSE
ABCC10 Overexpression	404	Lung Non-small Cell Carcinoma	3908		Paclitaxel		Predictive	Supports	D	Resistance	Increased expression of ABCC10 in 17 NSCLC cell lines was inversely correlated with paclitaxel sensitivity (r = 0.574; P < 0.05).	18445659	PubMed		"Oguri et al., 2008, Mol. Cancer Ther."		3	accepted	952	N/A	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/952	https://civicdb.org/links/molecular_profiles/404	FALSE	ABCC10	89845	Overexpression		chr6	43427554	43450430			ENST00000372530.4	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
ASNS Amplification	405	Ovarian Cancer	2394		Asparaginase		Predictive	Supports	D	Resistance	ASNS amplification and expression was associated with resistance to L-asparaginase in ovarian cancer and leukemia cell lines. ASNS silencing increased sensitivity to l-ASP in 2/3 of ovarian cancer cell lines.	17088436	PubMed		"Lorenzi et al., 2006, Mol. Cancer Ther."		2	accepted	953	Somatic	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/953	https://civicdb.org/links/molecular_profiles/405	FALSE	ASNS	440	Amplification		chr7	97852118	97872542			ENST00000175506.4	75		transcript_amplification		2023-01-09 21:52:06 UTC		N/A		FALSE
EGFR Overexpression	193	Lung Non-small Cell Carcinoma	3908		Gefitinib		Predictive	Supports	B	Sensitivity/Response	"82 patients treated with gefitinib were retrospectively analyzed for EGFR mRNA expression (rt-PCR in 64 patients). Patients with high EGFR mRNA expression (>5.01) had 43% response probability, whereas patients with low EGFR mRNA expression had 8% response probability (P = 0.006). PFS but not OS was also longer in patients with high EGFR mRNA expression."	16707605	PubMed		"Dziadziuszko et al., 2006, Clin. Cancer Res."		3	accepted	954	N/A	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/954	https://civicdb.org/links/molecular_profiles/193	FALSE	EGFR	1956	Overexpression		chr7	55019101	55211628			ENST00000275493.2	75		N/A		2023-01-09 21:52:05 UTC		N/A		FALSE
PTEN Expression	309	Breast Cancer	1612		Trastuzumab		Predictive	Supports	B	Sensitivity/Response	Trastuzumab was more effective in cell lines (SKBR3 vs. drug-resistant SKBR3/R) and 17 patient samples that exhibit elevated PTEN expression (by IHC).	16404430	PubMed		"Fujita et al., 2006, Br. J. Cancer"		3	accepted	955	N/A	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/955	https://civicdb.org/links/molecular_profiles/309	FALSE	PTEN	5728	Expression		chr10	87863113	87971930			ENST00000371953.3	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
CDX2 EXPRESSION	406	Colorectal Cancer	9256				Prognostic	Supports	B	Better Outcome	"Patients with stage II/III colorectal cancer were analyzed for expression of CDX2 (by microarray and IHC). In the discovery (466 patients) and validation sets (314 patients), 5-year DFS was lower among patients with CDX2 negative tumors (discovery set:hazard ratio for disease recurrence, 3.44; 95% confidence interval [CI], 1.60 to 7.38; P=0.002; validation set: hazard ratio, 2.42; 95% CI, 1.36 to 4.29; P=0.003)."	26789870	PubMed		"Dalerba et al., 2016, N. Engl. J. Med."		4	accepted	956	N/A	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/956	https://civicdb.org/links/molecular_profiles/406	FALSE	CDX2	1045	EXPRESSION		chr13	27962137	27971139			ENST00000381020.7	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
STAT3 SH2 DOMAIN MUTATION	407	T-cell Large Granular Lymphocyte Leukemia	50751				Diagnostic	Supports	B	Positive	"Mutations in the Src homology 2 (SH2) domain (exon 21) of STAT3 were found in 31 of 77 patients (40%) with large granular lymphocytic leukemia. Recurrent mutational hot spots included Y640F, D661V, D661Y, and N647I. Patients with these mutations presented more often with neutropenia and rheumatoid arthritis than did patients without."	22591296	PubMed		"Koskela et al., 2012, N. Engl. J. Med."		4	accepted	957	Somatic	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/957	https://civicdb.org/links/molecular_profiles/407	FALSE	STAT3	6774	SH2 DOMAIN MUTATION		chr17	42313324	42323354			ENST00000264657.5	75		protein_altering_variant		2023-01-09 21:52:06 UTC				FALSE
POU5F1 EXPRESSION	408	Colon Cancer	219		Oxaliplatin		Predictive	Supports	D	Resistance	OCT4B1 (POU5F1 splice variant) expression reduced sensitivity to oxaliplatin (via P-gp and ABCG2 differential expression) in vitro.	26398480	PubMed		"Wen et al., 2015, Oncol. Rep."		2	accepted	958	N/A	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/958	https://civicdb.org/links/molecular_profiles/408	FALSE	POU5F1	5460	EXPRESSION		chr6	31164343	31170693			ENST00000259915.8	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
ERBB2 Kinase Domain Mutation	409	Lung Adenocarcinoma	3910		Afatinib		Predictive	Supports	C	Sensitivity/Response	"A Phase II study for use of Afatinib in non- or light smokers with lung adenocarcinoma. Three patients with metastatic lung adenocarcinomas bearing mutations in the kinase domain of HER2 gene were identified (Y772_A775dup, G776L, and G778_P780dup). Objective response was observed in all three of these patients."	22325357	PubMed		"De Grve et al., 2012, Lung Cancer"	NCT00730925	3	accepted	959	Somatic	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/959	https://civicdb.org/links/molecular_profiles/409	FALSE	ERBB2	2064	Kinase Domain Mutation		chr17	39723610	39726617			ENST00000269571.5	75		protein_altering_variant		2023-01-09 21:52:06 UTC		N/A		FALSE
ERBB2 Y772_A775DUP	410	Lung Non-small Cell Carcinoma	3908		"Sirolimus,Afatinib"	Combination	Predictive	Supports	D	Sensitivity/Response	"In preclinical studies of transgenic mice and xenografts, continuous expression of mutant ERBB2 (M774insAYVM or the equivalent A775insYVMA) was found to be essential for tumor maintenance. Furthermore, preclinical in vivo studies assessing erlotinib, trastuzumab, afatinib (aka BIBW2992), and/or sirolimus (aka rapamycin) revealed that the combination of afatinib and sirolimus was most effective in shrinking tumors harboring this insertion."	19122144	PubMed		"Perera et al., 2009, Proc. Natl. Acad. Sci. U.S.A."		3	accepted	960	Somatic	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/960	https://civicdb.org/links/molecular_profiles/410	FALSE	ERBB2	2064	Y772_A775DUP		chr17	39724743	39724744		TACGTGATGGCT	ENST00000269571.5	75		inframe_insertion	"NM_001005862.2:c.2224_2235dupTACGTGATGGCT,ENST00000269571.5:c.2314_2325dupTACGTGATGGCT,NC_000017.10:g.37880985_37880996dupTACGTGATGGCT,NC_000017.10:g.37880993_37880994insGCTTACGTGATG"	2023-01-27 17:03:37 UTC	CA135369	44985	"A775INSYVMA,P.A775_G776INSYVMA,P.E770_A771INSAYVM,TYR772_ALA775DUP,A775_G776INSYVMA,M774INSAYVM"	FALSE
ERBB2 Amplification	302	Her2-receptor Positive Breast Cancer	60079		Afatinib		Predictive	Supports	B	Sensitivity/Response	"A phase II study involving adult female patients, >=18 years, with stage IIIB or IV HER2-positive (by IHC and/or in situ fluorescence) metastatic breast cancer. All patients were previously treated with trastuzumab and a median of three chemotherapy lines. 41 patients received 50 mg afatinib once-daily until disease progression and the primary endpoint was objective response rate. 4 patients (10% of 41 treated; 11% of evaluable patients) had partial response and 15 patients (37% of 41) had stable disease as best response. Thus a total of 19 (46% of 41) achieved clinical benefit. Median progression-free survival was 15.1 weeks."	22418700	PubMed		"Lin et al., 2012, Breast Cancer Res. Treat."		3	accepted	961	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/961	https://civicdb.org/links/molecular_profiles/302	FALSE	ERBB2	2064	Amplification		chr17	39700080	39728662			ENST00000269571.5	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A	OVEREXPRESSION	FALSE
ERBB2 Amplification	302	Pancreatic Adenocarcinoma	4074		Afatinib		Predictive	Supports	D	Sensitivity/Response	"Afatinib was growth-inhibitory for three pancreatic cancer cell lines but cytotoxic only toward BxPC3 (KRAS wt) and Capan-2 (KRAS mut) cells, both of which express high levels of EGFR, ERBB2, and ERBB3 receptors. Afatinib increased the radiosensitivity of BxPC3 and Capan-2 cells. In comparison, Panc-1 cells (KRAS mut) expressing low levels of EGFR family receptors were resistant to afatinib-induced radiosensitization."	26668065	PubMed		"Huguet et al., 2016, Target Oncol"		2	accepted	962	N/A	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/962	https://civicdb.org/links/molecular_profiles/302	FALSE	ERBB2	2064	Amplification		chr17	39700080	39728662			ENST00000269571.5	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A	OVEREXPRESSION	FALSE
EGFR T790M	34	Lung Non-small Cell Carcinoma	3908		Osimertinib		Predictive	Supports	D	Sensitivity/Response	"Cell line, xenograft, and transgenic models were used to establish Osimertinib as an inhibitor of both EGFR mutation sensitizing (L858M, del exon 19) and T790M resistance mutants. Preclinically, the drug inhibits signaling pathways and cellular growth in both EGFRm(+) and EGFRm(+)/T790M(+) mutant cell lines in vitro, with lower activity against wild-type EGFR lines. Sustained tumor regression was observed in EGFR-mutant tumor xenograft and transgenic models. Treatment of 2 patients with advanced EGFRm(+) T790M(+) NSCLC was reported as proof of principle."	24893891	PubMed		"Cross et al., 2014, Cancer Discov"		3	accepted	963	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/963	https://civicdb.org/links/molecular_profiles/34	FALSE	EGFR	1956	T790M	EGFR TKI Resistance	chr7	55181378	55181378	C	T	ENST00000275493.2	75		missense_variant	"ENST00000275493.2:c.2369C>T,NM_005228.4:c.2369C>T,NP_005219.2:p.Thr790Met,NC_000007.13:g.55249071C>T"	2023-01-27 17:02:05 UTC	CA090928	16613	"THR790MET,RS121434569"	FALSE
EGFR C797S	411	Lung Non-small Cell Carcinoma	3908		Osimertinib		Predictive	Supports	B	Resistance	"An EGFR resistance mutation, C797S, was discovered by deep sequencing of cell-free plasma DNA (cfDNA) from patients with advanced lung cancer whose tumors had developed resistance to osimertinib. Expression of this mutant EGFR construct in a cell line rendered it resistant to osimertinib. ddPCR on serial cfDNA specimens collected from 15 osimertinib-treated subjects (all positive for T790M before treatment) revealed 6 cases with acquired C797S mutation."	25939061	PubMed		"Thress et al., 2015, Nat. Med."		3	accepted	964	Somatic	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/964	https://civicdb.org/links/molecular_profiles/411	FALSE	EGFR	1956	C797S		chr7	55181398	55181398	T	A	ENST00000275493.2	75		missense_variant	"ENST00000275493.2:c.2389T>A,NC_000007.13:g.55249091T>A,NM_005228.4:c.2389T>A,NP_005219.2:p.Cys797Ser"	2023-01-27 17:03:38 UTC	CA16602785	376342	"CYS797SER,RS1057519861"	FALSE
EGFR T790M	34	Lung Non-small Cell Carcinoma	3908		Osimertinib		Predictive	Supports	B	Sensitivity/Response	"This phase I/II trial (NCT01802632) involved 253 non-small cell lung cancer patients with activating EGFR mutations, who had progressed on first generation tyrosine kinase inhibitor treatment, and were subsequently treated with Osimertinib (AZD9291). The overall objective tumor response rate was 51%. Among 127 patients with EGFR T790M who could be evaluated for response, the response rate was 61% (95% CI, 52 to 70). In contrast, among 61 patients without EGFR T790M, the response rate was 21% (95% CI, 12 to 34). The median progression-free survival was 9.6 months in EGFR T790M-positive patients and 2.8 months in EGFR T790M-negative patients."	25923549	PubMed		"Jnne et al., 2015, N. Engl. J. Med."	NCT01802632	4	accepted	965	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/965	https://civicdb.org/links/molecular_profiles/34	FALSE	EGFR	1956	T790M	EGFR TKI Resistance	chr7	55181378	55181378	C	T	ENST00000275493.2	75		missense_variant	"ENST00000275493.2:c.2369C>T,NM_005228.4:c.2369C>T,NP_005219.2:p.Thr790Met,NC_000007.13:g.55249071C>T"	2023-01-27 17:02:05 UTC	CA090928	16613	"THR790MET,RS121434569"	FALSE
EGFR T790M	34	Lung Non-small Cell Carcinoma	3908		Osimertinib		Predictive	Supports	B	Sensitivity/Response	"This study summarized 9 EGFR-mutant patients from two clinical trials involving rociletinib (NCT01526928) and subsequent osimertinib (NCT01802632). 8 were T790M-positive prior to treatment with osimertinib. 6 transitioned directly from rociletinib to osimertinib. 3 patients achieved PR and 4 achieved SD. The median PFS was 208 days (95% CI, 41-208 days). Among 6 patients who transitioned directly from rociletinib to osimertinib all derived clinical benefit from osimertinib with either prolonged SD or PR."	26720284	PubMed		"Sequist et al., 2016, JAMA Oncol"		3	accepted	966	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/966	https://civicdb.org/links/molecular_profiles/34	FALSE	EGFR	1956	T790M	EGFR TKI Resistance	chr7	55181378	55181378	C	T	ENST00000275493.2	75		missense_variant	"ENST00000275493.2:c.2369C>T,NM_005228.4:c.2369C>T,NP_005219.2:p.Thr790Met,NC_000007.13:g.55249071C>T"	2023-01-27 17:02:05 UTC	CA090928	16613	"THR790MET,RS121434569"	FALSE
EGFR T790M	34	Lung Non-small Cell Carcinoma	3908		"Osimertinib,Rociletinib"	Substitutes	Predictive	Supports	D	Sensitivity/Response	"For cell harboring EGFR T790M mutation, osimertinib and rociletinib showed potent inhibition compared to erlotinib or afatinib. This study performed drug response assays using five human NSCLC cell lines with various combinations of EGFR mutations. In order to directly compare the sensitivity of multiple EGFR mutations to EGFR-TKIs the authors also generated multiple EGFR transduced Ba/F3 stable cell lines and evaluated sensitivity to EGFR-TKIs by MTS assay."	26515464	PubMed		"Hirano et al., 2015, Oncotarget"		2	accepted	967	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/967	https://civicdb.org/links/molecular_profiles/34	FALSE	EGFR	1956	T790M	EGFR TKI Resistance	chr7	55181378	55181378	C	T	ENST00000275493.2	75		missense_variant	"ENST00000275493.2:c.2369C>T,NM_005228.4:c.2369C>T,NP_005219.2:p.Thr790Met,NC_000007.13:g.55249071C>T"	2023-01-27 17:02:05 UTC	CA090928	16613	"THR790MET,RS121434569"	FALSE
EGFR L858R	33	Lung Non-small Cell Carcinoma	3908		Afatinib		Predictive	Supports	D	Sensitivity/Response	Cells harboring L858R were sensitive to afatinib. This study performed drug response assays using five human NSCLC cell lines with various combinations of EGFR mutations. In order to directly compare the sensitivity of multiple EGFR mutations to EGFR-TKIs the authors also generated multiple EGFR transduced Ba/F3 stable cell lines and evaluated sensitivity to EGFR-TKIs by MTS assay.	26515464	PubMed		"Hirano et al., 2015, Oncotarget"		2	accepted	968	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/968	https://civicdb.org/links/molecular_profiles/33	FALSE	EGFR	1956	L858R		chr7	55191822	55191822	T	G	ENST00000275493.2	75		missense_variant	"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg"	2023-01-27 17:02:04 UTC	CA126713	"16,609,376,282,376,200"	"LEU858ARG,RS121434568"	FALSE
EGFR Exon 19 Deletion	133	Lung Non-small Cell Carcinoma	3908		Afatinib		Predictive	Supports	D	Sensitivity/Response	Cells harboring an exon 19 deletion were sensitive to afatinib. This study performed drug response assays using five human NSCLC cell lines with various combinations of EGFR mutations. In order to directly compare the sensitivity of multiple EGFR mutations to EGFR-TKIs the authors also generated multiple EGFR transduced Ba/F3 stable cell lines and evaluated sensitivity to EGFR-TKIs by MTS assay.	26515464	PubMed		"Hirano et al., 2015, Oncotarget"		2	accepted	969	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/969	https://civicdb.org/links/molecular_profiles/133	FALSE	EGFR	1956	Exon 19 Deletion		chr7	55174722	55174820			ENST00000275493.2	75		inframe_deletion	ENST00000275493.2:c.2185_2283del	2023-01-09 21:52:05 UTC		N/A		FALSE
FGFR1 Expression	264	Head And Neck Squamous Cell Carcinoma	5520				Prognostic	Supports	B	Poor Outcome	"Expression of bFGF and FGFR1 were evaluated in 61 biopsy specimens of primary OSCC (IHC). Expression was evaluated in both the cancer cells and fibroblasts at the invasive front of each tumor. bFGF and FGFR1 were expressed in all tumor specimens, whereas expression of these proteins in cancer-associated fibroblasts was associated with lymph node metastasis (P < 0.05) and worse patient survival."	16454808	PubMed		"Hase et al., 2006, J. Oral Pathol. Med."		2	accepted	970	N/A	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/970	https://civicdb.org/links/molecular_profiles/264	FALSE	FGFR1	2260	Expression		chr8	38411138	38467845			ENST00000425967.3	75		N/A	N/A	2023-01-09 21:52:06 UTC		N/A		FALSE
EGFR VIII	308	Glioblastoma	3068		Rindopepimut		Predictive	Supports	B	Sensitivity/Response	"In a Phase II clinical trial, patients with Glioblastoma Multiforme (GBM), positive for EGFR VIII deletion mutation (N=65), were treated with the Rindopepimut cancer vaccine,  and standard adjuvant temozolomide chemotherapy.  Median progression free survival (PFS) was 9.2 months, and median overall survival (OS) was 21.8 months.  A pivotal, randomized Phase III trial is currently underway."	25586468	PubMed		"Schuster et al., 2015, Neuro-oncology"		3	accepted	971	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/971	https://civicdb.org/links/molecular_profiles/308	FALSE	EGFR	1956	VIII		chr7	55019365	55155830			ENST00000275493.2	75		disruptive_inframe_deletion	"NM_005228.3:c.89_881del,NP_005219.2:p.Val30_Arg297delinsGly,NC_000007.13:g.55209979_55221845del"	2023-01-09 21:52:06 UTC				FALSE
ERBB2 SERUM LEVELS	412	Breast Cancer	1612		Lapatinib		Predictive	Supports	B	Sensitivity/Response	"Serum and tissue levels of HER2 (ERBB2) were analyzed in 1,902 breast cancer patients treated with lapatinib or control. Serum HER2 (sHER2) levels measured by ELISA were higher in patients with HER2 amplification (median sHER2 levels were 25.1 ng/mL in patients with HER2-positive tumors). Serum HER2 levels were Independent predictors of lapatinib progression free survival benefit (HR per 10-ng/mL increase in serum HER2: lapatinib-containing therapies, 1.009 v nonlapatinib-containing therapies, 1.044; P interaction < .001). Tissue HER2 levels were also predictive, but within this subgroup, serum HER2 still independently predicted lapatinib PFS benefit."	26811533	PubMed		"Lee et al., 2016, J. Clin. Oncol."		4	accepted	972	N/A	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/972	https://civicdb.org/links/molecular_profiles/412	FALSE	ERBB2	2064	SERUM LEVELS		chr17	39700080	39728662			ENST00000269571.5	75		N/A		2023-01-09 21:52:06 UTC		NONE FOUND		FALSE
ERBB2 SERUM LEVELS	412	Breast Cancer	1612				Prognostic	Supports	B	Poor Outcome	"Serum and tissue levels of HER2 (ERBB2) were analyzed in 1,902 breast cancer patients treated with lapatinib or control. In the control group (n = 936), higher serum HER2 (sHER2) was associated with worse prognosis in multivariable analyses (progression free survival hazard ratio per 10 ng/mL: PFS, 1.024; P < .001; and OS, 1.018; P < .001)."	26811533	PubMed		"Lee et al., 2016, J. Clin. Oncol."		3	accepted	973	N/A	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/973	https://civicdb.org/links/molecular_profiles/412	FALSE	ERBB2	2064	SERUM LEVELS		chr17	39700080	39728662			ENST00000269571.5	75		N/A		2023-01-09 21:52:06 UTC		NONE FOUND		FALSE
THBS2 UNDEREXPRESSION	413	Colorectal Cancer	9256				Prognostic	Supports	B	Poor Outcome	"172 patients treated with neoadjuvant concurrent chemoradiotherapy (CCRT) were retrospectively analyzed for expression of thrombospondin 2 (THBS2) using IHC (discovery set with 46 rectal cancer patients, GSE35452). Low expression was associated with advanced pretreatment tumor, nodal status, post-treatment tumor, vascular invasion and inferior regression grade. In multivariate analysis, low expression served as negative prognostic factor for disease-free survival (Hazard ratio=3.057, P=0.002)."	26807188	PubMed		"Lin et al., 2015, Am J Transl Res"		3	accepted	974	N/A	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/974	https://civicdb.org/links/molecular_profiles/413	FALSE	THBS2	7058	UNDEREXPRESSION		chr6	169215780	169254044			ENST00000366787.3	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
CD274 Expression	272	Lung Non-small Cell Carcinoma	3908				Prognostic	Supports	B	Poor Outcome	"74 patients with stage III NSCLC treated with concurrent chemoradiotherapy were retrospectively analyzed for PD-L1 expression and CD8+ tumour-infiltrating lymphocytes (TILs) density (IHC). CD8+ TIL density was an independent predictor of progression free survival (PFS) and overall survival (OS). Only when both TIL density and PD-L1 expression were both considered, was PD-L1 expression associated with survival. The subgroup, PD-L1+/CD8 low tumors had the shortest PFS (8.6 months, p = 0.02) and shortest, but not significantly different, OS (13.9 months, p = 0.11)."	26771872	PubMed		"Tokito et al., 2016, Eur. J. Cancer"		2	accepted	975	N/A	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/975	https://civicdb.org/links/molecular_profiles/272	FALSE	CD274	29126	Expression		chr9	5450525	5470547			ENST00000381577.3	75		N/A	N/A	2023-01-09 21:52:06 UTC		N/A		FALSE
TERT Promoter Mutation	220	Brain Glioma	60108				Diagnostic	Supports	B	Positive	"In this meta-analysis of 16 Trials, TERT mutations were more common in glioblastomas (69%), oligodendrogliomas (72%) in comparison to astrocytomas (24%) and oligoastrocytomas (38%)."	26765760	PubMed		"Yuan et al., 2016, J Clin Neurosci"		3	accepted	976	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/976	https://civicdb.org/links/molecular_profiles/220	FALSE	TERT	7015	Promoter Mutation		chr5	1295046	1295258			ENST00000310581.5	75		regulatory_region_variant		2023-01-09 21:52:05 UTC			"-124C>T,-146C>T"	FALSE
EGFR Amplification	190	Lung Non-small Cell Carcinoma	3908		"Erlotinib,Gefitinib"	Substitutes	Predictive	Does Not Support	B	Sensitivity/Response	"In 290 patients with advanced NSCLC, 177 of which were treated with EGFR TKI (erlotinib or gefitinib). EGFR amplification (Multiplex ligation-dependent probe amplification; MLPA) and Mutation (PCR) were analzed. EGFR amplification was associated with EGFR mutation but not independently with patient benefit from EGFR TKI (overall and progression-free survival)."	26722081	PubMed		"Fiala et al., 2016, Anticancer Res."		2	accepted	977	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/977	https://civicdb.org/links/molecular_profiles/190	FALSE	EGFR	1956	Amplification		chr7	55019101	55211628			ENST00000275493.2	75		transcript_amplification	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
NTRK1 Fusion	415	Colorectal Cancer	9256		Larotrectinib		Predictive	Supports	D	Sensitivity/Response	"NTRK1 fusions (one LMNA-NTRK1 and two TPM3-NTRK1) were identified in 2% of Korean colorectal cancer patients (147 patients). TrkA (NTRK1) protein expression was associated with presence of NTRK1 gene fusion. These fusions were mutually exclusive with other oncogenic drivers and showed in-vitro sensitivity to TrkA Inhibitor ARRY470  (Larotrectinib) (one cell line with fusion (KM12), one control cell line)."	26716414	PubMed		"Park et al., 2016, Oncotarget"		2	accepted	978	Somatic	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/978	https://civicdb.org/links/molecular_profiles/415	FALSE	NTRK1	4914	Fusion	NTRK1 Fusions	chr1	156874383	156881642			ENST00000524377.1	75		transcript_fusion		2023-01-09 21:52:06 UTC		N/A		FALSE
IDH1 R132H	416	Oligodendroglioma	3181		AGI-5198		Predictive	Supports	D	Sensitivity/Response	"In pre-clinical studies, an IDH1 inhibitor (AG-5198) impaired growth of glioma / anaplastic oligodendroglioma cell lines with IDH1 R132H mutations.  A phase I clinical trial of the AG-120 IDH1 inhibitor in IDH1 mutant positive solid tumors, including glioma is currently underway."	23558169	PubMed		"Rohle et al., 2013, Science"		4	accepted	979	Somatic	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/979	https://civicdb.org/links/molecular_profiles/416	FALSE	IDH1	3417	R132H		chr2	208248388	208248388	C	T	ENST00000415913.1	75		missense_variant	"NM_001282386.1:c.395G>A,NP_005887.2:p.Arg132His,NC_000002.11:g.209113112C>T,ENST00000415913.1:c.395G>A"	2023-01-27 17:03:38 UTC	CA170874	156444	"ARG132HIS,RS121913500"	FALSE
TERT RS2736100	417	Brain Glioma	60108				Predisposing	Supports	B	Positive	"Meta-analysis of 10 studies (9,411 patients, 13,708 controls) showed that TERT polymorphisms (rs2736100) were associated with an increased glioma risk (RR=1.28, 95% CI 1.23-1.33)."	26765760	PubMed		"Yuan et al., 2016, J Clin Neurosci"		2	accepted	980	Common Germline	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/980	https://civicdb.org/links/molecular_profiles/417	FALSE	TERT	7015	RS2736100		chr5	1286401	1286401	C	A	ENST00000310581.5	75		"coding_transcript_intron_variant,polymorphic_sequence_variant"	"NC_000005.9:g.1286516C>A,ENST00000310581.5:c.1574-3777G>T,NM_001193376.1:c.1574-3777G>T,NP_001180305.1:p.="	2023-01-27 17:03:39 UTC	CA11915794	375480		FALSE
EGFR Exon 19 Deletion	133	Lung Adenocarcinoma	3910		Afatinib		Predictive	Supports	B	Sensitivity/Response	Afatinib is an irreversible covalent inhibitor of EGFR (second generation). This Phase III clinical trial (LUX-Lung 6; NCT01121393) was performed in Asian patients with EGFR mutant advanced NSCLC. 364 eligible patients with EGFR mutations were assigned to afatinib (n=242) or gemcitabine and cisplatin (n=122) treatment. The trial observed significantly longer median progression-free survival with afatinib vs. gemcitabine and cisplatin treatment (11.0 vs. 5.6 months). Afatinib/Chemotherapy group compositions: 51.2/50.8 % del 19; 38/37.7 % Leu858Arg; 10.8/11.5 % Uncommon.	24439929	PubMed		"Wu et al., 2014, Lancet Oncol."	NCT01121393	4	accepted	981	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/981	https://civicdb.org/links/molecular_profiles/133	FALSE	EGFR	1956	Exon 19 Deletion		chr7	55174722	55174820			ENST00000275493.2	75		inframe_deletion	ENST00000275493.2:c.2185_2283del	2023-01-09 21:52:05 UTC		N/A		FALSE
EGFR L858R	33	Lung Adenocarcinoma	3910		Afatinib		Predictive	Supports	B	Sensitivity/Response	Afatinib is an irreversible covalent inhibitor of EGFR (second generation). This Phase III clinical trial (LUX-Lung 6; NCT01121393) was performed in Asian patients with EGFR mutant advanced NSCLC. 364 eligible patients with EGFR mutations were assigned to afatinib (n=242) or gemcitabine and cisplatin (n=122) treatment. The trial observed significantly longer median progression-free survival with afatinib vs. gemcitabine and cisplatin treatment (11.0 vs. 5.6 months). Afatinib/Chemotherapy group compositions: 51.2/50.8 % del 19; 38/37.7 % Leu858Arg; 10.8/11.5 % Uncommon.	24439929	PubMed		"Wu et al., 2014, Lancet Oncol."	NCT01121393	4	accepted	982	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/982	https://civicdb.org/links/molecular_profiles/33	FALSE	EGFR	1956	L858R		chr7	55191822	55191822	T	G	ENST00000275493.2	75		missense_variant	"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg"	2023-01-27 17:02:04 UTC	CA126713	"16,609,376,282,376,200"	"LEU858ARG,RS121434568"	FALSE
EGFR Exon 19 Deletion	133	Lung Adenocarcinoma	3910		Afatinib		Predictive	Supports	B	Sensitivity/Response	"In analysis of LUX-Lung 3 and LUX-Lung 6 trials (NCT00949650 and NCT01121393), of EGFR mutant NSCLC, median overall survival with afatinib treatment was seen to be significantly improved over chemotherapy (33.3 vs 21.1 and 31.4 vs 18.4 months in LUX-Lung 3 and LUX-Lung 6 respectively).  This effect was observed in the EGFR exon 19 deletion subgroup, but not in the L858R mutant subgroup."	25589191	PubMed		"Yang et al., 2015, Lancet Oncol."	"NCT00949650,NCT01121393"	4	accepted	983	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/983	https://civicdb.org/links/molecular_profiles/133	FALSE	EGFR	1956	Exon 19 Deletion		chr7	55174722	55174820			ENST00000275493.2	75		inframe_deletion	ENST00000275493.2:c.2185_2283del	2023-01-09 21:52:05 UTC		N/A		FALSE
STAG2 Underexpression	418	Bladder Carcinoma	4007				Prognostic	Supports	B	Better Outcome	Tumor samples from 125 patients with bladder cancer were assessed by IHC for STAG2 expression. STAG2-negativity was associated with lower histological grade (p??.009). Complete loss of STAG2 expression was associated with a lower risk of recurrence (P??.023) and diminished risk of death (P??.034) in log-rank analysis and was a beneficial factor in uni- and multivariate analysis.	26838030	PubMed		"Qiao et al., 2016, Tumour Biol."		2	accepted	984	N/A	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/984	https://civicdb.org/links/molecular_profiles/418	FALSE	STAG2	10735	Underexpression		chrX	123961718	124102656			ENST00000371157.3	75		N/A		2023-01-09 21:52:07 UTC		N/A		FALSE
HLA-DRA EXPRESSION	419	Skin Melanoma	8923		"Pembrolizumab,Nivolumab,Atezolizumab"	Substitutes	Predictive	Supports	B	Sensitivity/Response	"Melanoma patients treated with Anti-PD1 or anti-PD-L1(nivolumab, pembrolizumab, MPDL3280A) therapy were analyzed for expression of HLA-DRA (the primary antigen-presenting molecule of the MHC-II pathway). In a discovery cohort, 30 patients underwent IHC for HLA-DRA. 11/14 (79%) patients with positive HLA-DR staining, had complete (n=3) or partial (n=8) response. 6/16 (38%) HLA-DR non-expressing melanomas responded to therapy (overall response rate 79 versus 38%, Fishers exact test P=0.033). This finding was confirmed in a second independent data set of 23 melanoma patients with 6/8 (75%) of HLA-DR(+) tumours in comparison to 4/15 (27%) HLA-DR(? responding (Fishers exact test P=0.025). Preclinical models confirmed the result."	26822383	PubMed		"Johnson et al., 2016, Nat Commun"		3	accepted	985	N/A	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/985	https://civicdb.org/links/molecular_profiles/419	FALSE	HLA-DRA	3122	EXPRESSION		chr6	32439842	32445046			ENST00000395388.2	75		N/A		2023-01-09 21:52:07 UTC				FALSE
MYD88 L265P	420	Lymphoplasmacytic Lymphoma	60901		Ibrutinib		Predictive	Supports	B	Sensitivity/Response	A prospective study of ibrutinib in 63 symptomatic patients with Waldenstrm's macroglobulinemia who had received at least one previous treatment. The response rates were highest among patients with MYD88(L265P) and CXCR4(WT). The MYD88 L265P mutation was present in 56 patients (89%).	25853747	PubMed		"Treon et al., 2015, N. Engl. J. Med."	NCT01614821	4	accepted	986	Somatic	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/986	https://civicdb.org/links/molecular_profiles/420	FALSE	MYD88	4615	L265P		chr3	38141150	38141150	T	C	ENST00000396334.3	75		"missense_variant,gain_of_function_variant"	NC_000003.11:g.38182641T>C	2023-01-27 17:03:40 UTC	CA130043	37055	"LEU265PRO,L273P,LEU273PRO"	FALSE
KRAS G12V	421	Lung Non-small Cell Carcinoma	3908				Prognostic	Supports	B	Poor Outcome	"Retrospective analysis of data from 841 patients who underwent surgery and molecular testing for NSCLC.  Mutant KRAS was observed in 265 (31.5%) cases and 90 of these were G12V. Patients with KRAS G12V exhibited worse OS and TTR compared with the entire cohort. These results were confirmed using multivariate analyses (non-G12V status, hazard ratio (HR): 0.43 (confidence interval: 0.28?.65), P<0.0001 for OS. Risk of recurrence was significantly lower for non-KRAS G12V (HR: 0.01, (0.001?.08), P<0.0001)."	26372703	PubMed		"Renaud et al., 2015, Br. J. Cancer"		3	accepted	987	Somatic	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/987	https://civicdb.org/links/molecular_profiles/421	FALSE	KRAS	3845	G12V		chr12	25245350	25245350	C	A	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.35G>T,NP_004976.2:p.Gly12Val,NC_000012.11:g.25398284C>A,ENST00000256078.4:c.35G>T"	2023-01-27 17:03:41 UTC	CA122540	12583	"GLY12VAL,RS121913529"	FALSE
KRAS Mutation	332	Colorectal Cancer	9256		"B-Raf/VEGFR-2 Inhibitor RAF265,Selumetinib"	Combination	Predictive	Supports	D	Sensitivity/Response	"SiRNA Screening in 37 KRAS Mutant colorectal cancer cell lines identified RAF1 and MEK Inhibition as synergistic, whereas MEK Inhibition alone led to quick resistance via upregulation of RAF-signalling. This finding could be reproduced in colorectal and lung cancer cell lines in a second, independent screen."	25199829	PubMed		"Lamba et al., 2014, Cell Rep"		4	accepted	988	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/988	https://civicdb.org/links/molecular_profiles/332	FALSE	KRAS	3845	Mutation		chr12	25209431	25250803			ENST00000256078.4	75		protein_altering_variant		2023-01-09 21:52:06 UTC		N/A		FALSE
KRAS Mutation	332	Lung Non-small Cell Carcinoma	3908		"Selumetinib,B-Raf/VEGFR-2 Inhibitor RAF265"	Combination	Predictive	Supports	D	Sensitivity/Response	"SiRNA Screening in 37 KRAS Mutant colorectal cancer cell lines identified RAF1 and MEK Inhibition as synergistic, whereas MEK Inhibition alone led to quick resistance via upregulation of RAF-signalling. This finding was reproduced two NSCLC cell lines in a second, independent shRNA screen."	25199829	PubMed		"Lamba et al., 2014, Cell Rep"		2	accepted	989	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/989	https://civicdb.org/links/molecular_profiles/332	FALSE	KRAS	3845	Mutation		chr12	25209431	25250803			ENST00000256078.4	75		protein_altering_variant		2023-01-09 21:52:06 UTC		N/A		FALSE
KRAS G12/G13	77	Pancreatic Adenocarcinoma	4074		Trametinib		Predictive	Does Not Support	B	Sensitivity/Response	"KRAS G12/G13 status was evaluated in cell-free DNA (cfDNA) of patients with untreated metastatic adenocarcinoma of the pancreas that were randomised (1:1) to receive gemcitabine plus trametinib or placebo. KRAS mutations were identified in 103 patients using cfDNA. There was no difference betweeen overall survival of KRAS Mutation-positive and -negative patients. Of note, evaluation of KRAS mutations from archival tissue from 71/143 patients identified 8 patients with mutant KRAS (wildtype by cfDNA) and 3 patients with wildtype KRAS (mutant by cfDNA)."	24915778	PubMed		"Infante et al., 2014, Eur. J. Cancer"	NCT01231581	3	accepted	990	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/990	https://civicdb.org/links/molecular_profiles/77	FALSE	KRAS	3845	G12/G13		chr12	25245346	25245351			ENST00000256078.4	75		protein_altering_variant		2023-01-09 21:52:04 UTC		"45,122,125,781,258,200,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000"		FALSE
KRAS Mutation	332	Colorectal Cancer	9256		"Trametinib,Afatinib"	Combination	Predictive	Supports	D	Sensitivity/Response	An shDNA Screen identified synergy betwenn ERBB3 Inhibition and MEK Inhibition in KRAS mutated cell lines. Dual EGFR/ERBB2 Inhibitors afatinib and dacomitinib and MEK Inhibition was synergistic in colorectal and lung cancer cell lines. Induction of ERBB3 signalling was also identified in a patient with KRAS mutation after MEK inhibition with trametinib.	24685132	PubMed		"Sun et al., 2014, Cell Rep"		4	accepted	991	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/991	https://civicdb.org/links/molecular_profiles/332	FALSE	KRAS	3845	Mutation		chr12	25209431	25250803			ENST00000256078.4	75		protein_altering_variant		2023-01-09 21:52:06 UTC		N/A		FALSE
KRAS Mutation	332	Lung Non-small Cell Carcinoma	3908		"Afatinib,Trametinib"	Combination	Predictive	Supports	D	Sensitivity/Response	An shDNA screen identified synergy between ERBB3 Inhibition and MEK Inhibition in KRAS mutated cell lines. Dual EGFR/ERBB2 Inhibitors afatinib and dacomitinib and MEK Inhibition was synergistic in colorectal and lung cancer cell lines. Induction of ERBB3 signalling was also identified in a patient with KRAS mutation after MEK inhibition with trametinib.	24685132	PubMed		"Sun et al., 2014, Cell Rep"		2	accepted	992	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/992	https://civicdb.org/links/molecular_profiles/332	FALSE	KRAS	3845	Mutation		chr12	25209431	25250803			ENST00000256078.4	75		protein_altering_variant		2023-01-09 21:52:06 UTC		N/A		FALSE
KRAS Exon 2 Mutation	75	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	A	Resistance	"KRAS mutation status was assessed in 394 tumor samples from colorectal cancer patients who were randomly assigned to receive cetuximab plus best supportive care or best supportive care alone.   42% of the tumors evaluated had at least one mutation in exon 2. Patients with a colorectal tumor bearing mutated K-ras did not benefit from cetuximab, whereas patients with a tumor bearing wild-type K-ras did benefit from cetuximab. The effectiveness of cetuximab was significantly associated with K-ras mutation status (P=0.01 for overall survival and P<0.001 for progression-free survival). In patients with wild-type K-ras tumors, treatment with cetuximab as compared with supportive care alone significantly improved overall survival. The related clinical trial ID is NCT00079066."	18946061	PubMed		"Karapetis et al., 2008, N. Engl. J. Med."	NCT00079066	5	accepted	993	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/993	https://civicdb.org/links/molecular_profiles/75	FALSE	KRAS	3845	Exon 2 Mutation		chr12	25245274	25245395			ENST00000256078.4	75		missense_variant		2023-01-09 21:52:04 UTC				FALSE
BRAF V600E	12	Melanoma	1909		MEK Inhibitor RO4987655		Predictive	Does Not Support	B	Resistance	"This was a phase I expansion and pharmacodynamic study of oral MEK inhibitor RO4987655 on advanced cancer. Of 17 patients with BRAF V600E melanoma, 4 achieved partial response, 5 experienced stable disease lasting longer than 16 weeks, and 8 experienced disease progression (including 2 with prior vemurafenib treatment). One of the partial responders had a concomitant EGFR mutation, and two of the stable disease patients had other concomitant mutations (in RET or MET). The median days on treatment was 113 (18-366) for BRAF V600E melanoma patients and 107 (17-323) for BRAF V600 wildtype patients (n=23). Patients with BRAF V600E mutant melanoma experienced similar response rates (24% vs 20%) and rates of metabolic response measured by decrease in FDG uptake assessed by FDG-PET (86% vs 75%) compared to non-BRAF mutant patients. Patients with melanoma, either BRAF wt or V600E, experienced significant decreases in Ki67 expression by day 15 of MEK inhibitor treatment (P<0.02). The authors conclude that RO4987655 has clinical activity in BRAF V600E and BRAF wt melanoma."	24947927	PubMed		"Zimmer et al., 2014, Clin. Cancer Res."		2	accepted	994	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/994	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
BRAF WILD TYPE	422	Melanoma	1909		MEK Inhibitor RO4987655		Predictive	Does Not Support	B	Resistance	"Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655. Among 12 patients with melanoma BRAF wild type and non-NRAS or NRAS unknown status, seven patients experienced partial response (n=3) or stable disease (n=4). Authors conclude that RO4987655 has clinical activity in BRAF V600-wt (and BRAF V600E) melanoma. They suggest that other drugs such as immune check point inhibitors are preferred in BRAF wt melanoma, so the role of RO4987655 as a single agent is limited for BRAF WT patients with the possible exception of a small window of opportunity for combinations with MEK inhibitors after immunotherapy progression."	24947927	PubMed		"Zimmer et al., 2014, Clin. Cancer Res."		2	accepted	995	N/A	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/995	https://civicdb.org/links/molecular_profiles/422	FALSE	BRAF	673	WILD TYPE		chr7	140734479	140924764			ENST00000288602.6	75		wild_type	N/A	2023-01-09 21:52:07 UTC		N/A		FALSE
NRAS Mutation	208	Melanoma	1909		MEK Inhibitor RO4987655		Predictive	Does Not Support	C	Resistance	"Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655). Among 8 patients with NRAS mutated melanoma, 3 experienced clinical benefit: 2 stable disease and 1 partial response (1 Patient received study treatment for 323 days). Of 10 NRAS wt patients, 4 experienced clinical benefit. Authors note that RO4987655 demonstrates clinical efficacy in BRAF wildtype melanomas with NRAS mutations."	24947927	PubMed		"Zimmer et al., 2014, Clin. Cancer Res."		2	accepted	996	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/996	https://civicdb.org/links/molecular_profiles/208	FALSE	NRAS	4893	Mutation		chr1	114704469	114716894			ENST00000369535.4	75		"transcript_variant,gain_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
KRAS Mutation	332	Lung Non-small Cell Carcinoma	3908		MEK Inhibitor RO4987655		Predictive	Does Not Support	B	Resistance	"This was a phase I expansion and pharmacodynamic study of oral MEK inhibitor RO4987655 on advanced cancer. Of 18 patients with KRAS mutant non-small cell lung cancer (NSCLC), 10 experienced clinical benefit: 2 partial responses and 8 patients experiencing stable disease for longer than 8 weeks. The median days on treatment was 58.5 (13-394) with one patient ongoing treatment at the end of the study period (56 weeks). The response rate of patients with KRAS mutant NSCLC was 11%, and 71% showed decrease in metabolic response (less FDG uptake in FDG-PET analysis). All responders showed decreases in FDG-uptake. There was not a significant decrease in Ki67 expression between day 1 and day 15 of treatment. Authors conclude that RO4987655 has some clinical activity in KRAS mutated NSCLC, though patients with KRAS wild-type NSCLC were excluded from this expansion study, so it is not possible to determine whether activity of RO4987655 in NSCLC is related to KRAS mutation status."	24947927	PubMed		"Zimmer et al., 2014, Clin. Cancer Res."		3	accepted	997	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/997	https://civicdb.org/links/molecular_profiles/332	FALSE	KRAS	3845	Mutation		chr12	25209431	25250803			ENST00000256078.4	75		protein_altering_variant		2023-01-09 21:52:06 UTC		N/A		FALSE
KRAS Mutation	332	Colorectal Cancer	9256		MEK Inhibitor RO4987655		Predictive	Does Not Support	B	Sensitivity/Response	"Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655). All 25 patients with KRAS mutant colorectal cancer experienced PD. Median days on treatment was 57 (5-269). Among the patients with KRAS mutant cancer, 52% showed decrease in metabolic response (less FDG uptake in FDG-PET analysis). There was not a significant decrease in Ki67 expression between day 1 and day 15 of treatment. The authors concluded that RO4987655 does not have clinical activity in patients with KRAS mutant advanced colorectal cancer."	24947927	PubMed		"Zimmer et al., 2014, Clin. Cancer Res."		2	accepted	998	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/998	https://civicdb.org/links/molecular_profiles/332	FALSE	KRAS	3845	Mutation		chr12	25209431	25250803			ENST00000256078.4	75		protein_altering_variant		2023-01-09 21:52:06 UTC		N/A		FALSE
KRAS Mutation	332	Lung Non-small Cell Carcinoma	3908		"Selumetinib,Docetaxel"	Combination	Predictive	Supports	B	Sensitivity/Response	"87 patients with KRAS mutant stage IIB-IV NSCLC after first line therapy were randomly assigned (1:1) to oral selumetunib and docetaxel or docetaxel and Placebo. Median OS was 94 months (68-136) in selumetinib group and 52 months (95% CI 38-non-calculable) in placebo group (hazard ratio [HR] for death 080, 80% CI 056-114; one-sided p=021). Median PFS was 53 months (46-64) in selumetinib group and 21 months (95% CI 14-37) in placebo group (HR for progression 058, 80% CI 042-079; one-sided p=0014). An objective response was observed in 16 (37%) patients in the selumetinib group and none in the placebo group(p<00001)."	23200175	PubMed		"Jnne et al., 2013, Lancet Oncol."	NCT00890825	4	accepted	999	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/999	https://civicdb.org/links/molecular_profiles/332	FALSE	KRAS	3845	Mutation		chr12	25209431	25250803			ENST00000256078.4	75		protein_altering_variant		2023-01-09 21:52:06 UTC		N/A		FALSE
BRAF V600	17	Melanoma	1909		Refametinib		Predictive	Supports	C	Resistance	Phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766. 2 of 2 patients with BRAF mutant melanoma had moderate progressive disease (despite receiving the highest doses administered in the study).	23434733	PubMed		"Weekes et al., 2013, Clin. Cancer Res."		2	accepted	1000	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/1000	https://civicdb.org/links/molecular_profiles/17	FALSE	BRAF	673	V600	Other BRAF V600's	chr7	140753336	140753337			ENST00000288602.6	75		protein_altering_variant		2023-01-09 21:52:04 UTC		"13,961,448,153,762,800,000,000,000,000,000"	VAL600	FALSE
KRAS Mutation	332	Colorectal Cancer	9256		Refametinib		Predictive	Does Not Support	C	Sensitivity/Response	"Phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766. 4 patients with KRAS +/- PIK3CA mutant colorectal cancer. 3 with SD, 1 with PD."	23434733	PubMed		"Weekes et al., 2013, Clin. Cancer Res."		2	accepted	1001	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/1001	https://civicdb.org/links/molecular_profiles/332	FALSE	KRAS	3845	Mutation		chr12	25209431	25250803			ENST00000256078.4	75		protein_altering_variant		2023-01-09 21:52:06 UTC		N/A		FALSE
NRAS Q61K	423	Neuroblastoma	769		"Binimetinib,Everolimus"	Combination	Predictive	Supports	D	Sensitivity/Response	"In-vitro study in 5 neuroblastoma cell lines (2 with NRAS Q61K mutation). The combination of mTOR and MEK Inhibitors synergistically blocked cell growth in NRAS mutant but not wild type cell lines. Single agent MEK inhibition (AZD6244/selumetinib, MEK162 or PD0325901) and single agent mTOR inhibition (Everolimus or AZD8055) also blocked cell growth in NRAS mutant cell lines, whereas single agent PI3K inhibitors or MEK Inhibitors in combination with PIK3CA/AKT inhibitors did not show synergistic effects."	26821351	PubMed		"Kiessling et al., 2016, PLoS ONE"		3	accepted	1002	Somatic	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/1002	https://civicdb.org/links/molecular_profiles/423	FALSE	NRAS	4893	Q61K		chr1	114713909	114713909	G	T	ENST00000369535.4	75		missense_variant	"NM_002524.4:c.181C>A,NP_002515.1:p.Gln61Lys,NC_000001.10:g.115256530G>T,ENST00000369535.4:c.181C>A"	2023-01-27 17:03:41 UTC	CA151263	73058	"GLN61LYS,RS121913254"	FALSE
KRAS Mutation	332	Pancreatic Adenocarcinoma	4074		"PI3Kbeta Inhibitor AZD8186,SCH772984"	Combination	Predictive	Supports	D	Sensitivity/Response	"Inhibition of ERK in 11 KRAS mutant pancreatic cancer cell lines with SCH772984 was more effective than MEK Inhibition. Combined Treatment with PI3K Inhibitor AZD8186 was more effective than either agent alone. Chemical library screen in two cell lines also identified mTOR, AKT Family Inhibitors (Temsirolimus, Everolimus) to act synergistically with ERK Inhibition."	26725216	PubMed		"Hayes et al., 2016, Cancer Cell"		4	accepted	1003	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/1003	https://civicdb.org/links/molecular_profiles/332	FALSE	KRAS	3845	Mutation		chr12	25209431	25250803			ENST00000256078.4	75		protein_altering_variant		2023-01-09 21:52:06 UTC		N/A		FALSE
KRAS Mutation	332	Colorectal Cancer	9256		"Teprotumumab,Selumetinib"	Combination	Predictive	Supports	D	Sensitivity/Response	"Preclinial data from KRAS mutant colorectal cancer cell lines show syngergistic effect on cell viability and apoptosis in vitro and in vivo when MEK and IGF-IR are inhibited concomitantly. In other cell lines, activation of other RTKs (such as MET) were observed upon MEK Inhibition and combination of RTKi and METi also showed synergistic activity. A total of 16 cell lines were used in this study. 6 were KRAS wild type, and 10 harbored various KRAS mutations (G12C, G12D, G12V, G13D, and Q61L). Additional data was obtained from xenografts."	21985784	PubMed		"Ebi et al., 2011, J. Clin. Invest."		3	accepted	1004	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/1004	https://civicdb.org/links/molecular_profiles/332	FALSE	KRAS	3845	Mutation		chr12	25209431	25250803			ENST00000256078.4	75		protein_altering_variant		2023-01-09 21:52:06 UTC		N/A		FALSE
BRAF V600E	12	Melanoma	1909		"Dactolisib,Selumetinib"	Combination	Predictive	Supports	D	Sensitivity/Response	"49 BRAF-mutant melanoma cell lines from patients not previously treated with BRAF inhibition were analyzed. 21 exhibited primary resistance to BRAF inhibition using PLX4720. Inhibition of MEK1/2 (AZD6244 [selumetinib]) and PI3K/mTOR (BEZ235 [dactolisib]) was the most effective approach to counteract resistance in comparison to inhibition with the PLX4720 (progenitor of vemurafenib)-BEZ235 (where response was assessed by apoptosis, viability, p-ERK, p-Akt inhibition)."	26678033	PubMed		"Penna et al., 2016, Oncotarget"		2	accepted	1005	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/1005	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
ERBB2 Amplification	302	Breast Cancer	1612		"Trastuzumab,Lapatinib"	Combination	Predictive	Supports	D	Sensitivity/Response	"In-vitro studies using ERBB2 over-expressing breast cancer cell lines BT474 and SKBR3 (with ERBB2 amplification) showed apoptosis under either labatinib or trastuzumab treatment.  A marked synergistic apoptotic effect under lapatinib and trastuzumab co-treatment was observed in BT474 cells, and a milder synergistic effect was observed in SKBR3 cells."	16091755	PubMed		"Xia et al., 2005, Oncogene"		3	accepted	1006	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1006	https://civicdb.org/links/molecular_profiles/302	FALSE	ERBB2	2064	Amplification		chr17	39700080	39728662			ENST00000269571.5	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A	OVEREXPRESSION	FALSE
ERBB2 Amplification	302	Her2-receptor Positive Breast Cancer	60079		"Trastuzumab,Lapatinib"	Combination	Predictive	Supports	B	Sensitivity/Response	"In light of results showing increased PFS using mAB plus TKI in heavily pretreated patients, the efficacy of trastuzumab plus lapatinib in a neoadjuvant setting with untreated stage II or IIIA HER2 positive breast cancer was assessed.  In this randomized 3 arm phase II study (CHER-LOB), patients received (A) chemotherapy plus trastuzumab, (B) chemotherapy plus lapatinib, or (C) chemotherapy plus trastuzumab and lapatinib, with pathologic complete response (pCR) as endpoint.  From 121 patients, pCR rates were 25% in arm A, 26.3% in arm B, and 46.7% in arm C.  The authors conclude these results support the superiority of dual-HER2 inhibition in the neoadjuvant context of HER2 positive BC."	22493419	PubMed		"Guarneri et al., 2012, J. Clin. Oncol."		4	accepted	1007	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1007	https://civicdb.org/links/molecular_profiles/302	FALSE	ERBB2	2064	Amplification		chr17	39700080	39728662			ENST00000269571.5	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A	OVEREXPRESSION	FALSE
ERBB2 Amplification	302	Her2-receptor Positive Breast Cancer	60079		"Trastuzumab,Lapatinib"	Combination	Predictive	Does Not Support	B	Sensitivity/Response	"This Phase III trial compared the activity of lapatinib vs. trastuzumab vs. sequential trastuzumab followed by lapatinib vs. lapatinib plus trastuzumab in an adjuvant treatment setting.  8381 women were randomized to one of four treatment arms. Patients had HER2 positive non-metastatic operable BC. The primary endpoint was disease free survival.  First results report that after median 4.5 year follow up, a non significant 16% improvement in DFS was seen in trastuzumab + lapatinib vs. trastuzumab alone.  The results are interpreted as showing no added benefit for labatinib addition to trastuzumab in the adjuvant treatment context.  This trial is ongoing but not recruiting patients (NCT00490139)."	26255196	PubMed		"Zardavas et al., 2015, Breast"		4	accepted	1008	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1008	https://civicdb.org/links/molecular_profiles/302	FALSE	ERBB2	2064	Amplification		chr17	39700080	39728662			ENST00000269571.5	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A	OVEREXPRESSION	FALSE
ERBB2 Amplification	302	Her2-receptor Positive Breast Cancer	60079		"Trastuzumab,Lapatinib"	Combination	Predictive	Supports	B	Sensitivity/Response	"This Phase III study (EGF104900) was motivated by preclinical and other data demonstrating synergistic activity between lapatinib and trastuzumab against HER2 positive breast cancer (BC) cells.  In this study of HER2 positive metastatic BC which had progressed on trastuzumab, two arms were compared: lapatinib vs. lapatinib + trastuzumab. Progression free survival (PFS) was the primary endpoint. For 296 patients, 148 in each arm, median PFS of 8.1 weeks for lapatinib and 12.0 for combination therapy was observed (P=0.008).  The authors conclude that in the context of metastatic trastuzumab-progressed HER2 positive BC, trastuzumab with lapatinib TKI addition is a favorable treatment."	20124187	PubMed		"Blackwell et al., 2010, J. Clin. Oncol."		4	accepted	1009	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1009	https://civicdb.org/links/molecular_profiles/302	FALSE	ERBB2	2064	Amplification		chr17	39700080	39728662			ENST00000269571.5	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A	OVEREXPRESSION	FALSE
ERBB2 Amplification	302	Her2-receptor Positive Breast Cancer	60079		Afatinib		Predictive	Supports	B	Sensitivity/Response	"This Phase II trial (LUX-Breast 3 - NCT01441596) compared afatinib, afatinib plus vinorelbine, or investigator's choice of treatment.  121 patients with HER2 overexpressing breast cancer with CNS recurrence or regression who had previously progressed on trastuzumab or lapatinib were assigned to 3 arms, with endpoint in the intention-to-treat population being patient benefit at 12 weeks defined as absence of CNS or extra CNS progression, no tumor related worsening of neurological symptoms and no increase in corticosteroid dose. Benefit was seen in 30% of 40 patients assigned to afatinib alone, 34.2% of 38 assigned to afatinib plus vinorelbine, and 41.9% of 43 assigned to investigator's treatment choice.  Differences were not statistically significant, and afatanib patients experienced more adverse effects.  While Afatanib did show response in HER2 breast cancer patients, it was not better than investigator's treatment choice and the investigators state that no further development of afatinib for HER2 breast cancer will be planned."	26596672	PubMed		"Corts et al., 2015, Lancet Oncol."	NCT01441596	3	accepted	1011	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1011	https://civicdb.org/links/molecular_profiles/302	FALSE	ERBB2	2064	Amplification		chr17	39700080	39728662			ENST00000269571.5	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A	OVEREXPRESSION	FALSE
ERBB2 Amplification	302	Her2-receptor Positive Breast Cancer	60079		Afatinib		Predictive	Does Not Support	B	Sensitivity/Response	"LUX-Breast 1 is a phase 3 trial (NCT01125566) which enrolled 508 patients with metastatic HER2 positive BC who had progressed after adjuvant or first-line trastuzumab. It was thought that the wider range of ErbB family blocking and irreversible properties of afatinib could be beneficial in trastuzumab resistant cancer cells, since ErbB family members are thought to play a role in trastuzumab resistance. Primary endpoint was intention-to-treat group PFS. 339 patients were assigned to afatanib + vinorelbine and 169  to trastuzumab + vinorelbine.  Recruitment was stopped prematurely when it was deemed unlikely that the increased PFS would be seen in the afatinib group. Median PFS was 5.5 months in the afatinib group and 5.6 months in the trastuzumab group.  Afatanib plus vinorelbine was less well tolerated than trastuzumab plus vinorelbine, and the authors conclude that trastuzumab remains the best choice for treatment of trastuzumab-progressed HER2 positive metastatic BC."	26822398	PubMed		"Harbeck et al., 2016, Lancet Oncol."	NCT01125566	4	accepted	1012	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1012	https://civicdb.org/links/molecular_profiles/302	FALSE	ERBB2	2064	Amplification		chr17	39700080	39728662			ENST00000269571.5	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A	OVEREXPRESSION	FALSE
ERBB2 Amplification	302	Her2-receptor Positive Breast Cancer	60079		"Trastuzumab,Afatinib"	Combination	Predictive	Supports	B	Sensitivity/Response	"Trastuzumab resistance is thought to consist of multiple compensatory mechanisms involving ErbB family members such as increased signaling through ErbB family heterodimers.  The irreversible TKI afatinib blocks EGFR, HER2, ErbB3 and ErbB4.  Thus afatinib was studied in this Phase I trial of trastuzumab-progressed HER2 positive metastatic BC (MBC) in combination with continued trastuzumab treatment, where trastuzumab is still the perferred treatment for trastuzumab-progressed MBC.  Objective response and disease control rates were 11% and 39%.  The authors conclude that the clinical activity observed in this trial warrants further work with afatinib and trastuzumab combination therapy."	25370464	PubMed		"Ring et al., 2015, Clin. Cancer Res."		3	accepted	1013	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1013	https://civicdb.org/links/molecular_profiles/302	FALSE	ERBB2	2064	Amplification		chr17	39700080	39728662			ENST00000269571.5	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A	OVEREXPRESSION	FALSE
NOTCH1 P2514FS	207	Chronic Lymphocytic Leukemia	1040				Prognostic	Supports	B	Poor Outcome	"NOTCH1 mutations were found to be associated with worse overall survival (3.77-fold increase in the hazard of death, P < .001) in a series of 309 newly diagnosed CLL and confirmed in an additional set of 230 patients. NOTCH1 mutations were mostly represented (26/34, 76.5%) by a recurrent 2-bp frameshift deletion (c.7544_7545delCT), with the remaining being other frameshift deletions or insertions."	22077063	PubMed		"Rossi et al., 2012, Blood"		4	accepted	1014	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/1014	https://civicdb.org/links/molecular_profiles/207	FALSE	NOTCH1	4851	P2514FS		chr9	136496197	136496198			ENST00000277541.6	75		frameshift_truncation	NC_000009.11:g.139390649_139390650del	2023-01-09 21:52:05 UTC		NONE FOUND	PRO2514ARGFS	FALSE
EZH2 Mutation	163	Follicular Lymphoma	50873				Prognostic	Supports	B	Better Outcome	"In advanced stage follicular lymphoma patients receiving rituximab + chemotherapy (R-CHOP or R-CVP), EZH2 mutations were associated with better failure free survival in patients with high-risk FLIPI scores compared to patients that were EZH2 wildtype with high-risk FLIPI scores."	26256760	PubMed		"Pastore et al., 2015, Lancet Oncol."		4	accepted	1015	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/1015	https://civicdb.org/links/molecular_profiles/163	FALSE	EZH2	2146	Mutation		chr7	148807385	148884278			ENST00000320356.2	75		protein_altering_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
MRE11 Frameshift	424	Prostate Cancer	10283		Olaparib		Predictive	Supports	B	Sensitivity/Response	"One patient in a cohort of 50 patients with metastatic prostate cancer had a frameshift mutation in the MRE11, ATM, MLH3 and NBN genes and showed clinical response to PARP inhibitor olaparib (16 weeks on Treatment)."	26510020	PubMed		"Mateo et al., 2015, N. Engl. J. Med."	NCT01682772	2	accepted	1016	Somatic	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/1016	https://civicdb.org/links/molecular_profiles/424	FALSE	MRE11	4361	Frameshift		chr11	94419729	94493908			ENST00000323929.3	75		frameshift_variant		2023-01-09 21:52:07 UTC				FALSE
EGFR VIII	308	Brain Glioma	60108		Nimotuzumab		Predictive	Supports	D	Sensitivity/Response	"Two human glioma cell lines (U87MG or LNZ308) overexpressing either wild-type (wt) EGFR or EGFRvIII were treated with nimotuzumab, temozolomide, or both in vitro. Anti-tumor effects of nimotuzumab were greater in EGFRvIII in comparison to EGFRwt (as measured by antitumor effects, growth suppression, survival elongation and EGFR and Akt phosphorylation). Combination of nimotuzumab and temozolomide further increased efficacy."	26778701	PubMed		"Nitta et al., 2016, Cancer Med"		1	accepted	1017	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/1017	https://civicdb.org/links/molecular_profiles/308	FALSE	EGFR	1956	VIII		chr7	55019365	55155830			ENST00000275493.2	75		disruptive_inframe_deletion	"NM_005228.3:c.89_881del,NP_005219.2:p.Val30_Arg297delinsGly,NC_000007.13:g.55209979_55221845del"	2023-01-09 21:52:06 UTC				FALSE
TP53 Mutation	222	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	"In a study of 97 patients with AML  treated with HSCT, 40 had TP53 mutations comprising a total of 44 mutations. Patients with a TP53 mutation had a reduced three year probability of overall survival and event-free survival compared to patients with the wild-type TP53."	26771088	PubMed		"Middeke et al., 2016, Br. J. Haematol."		4	accepted	1018	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/1018	https://civicdb.org/links/molecular_profiles/222	FALSE	TP53	7157	Mutation		chr17	7668402	7687538			ENST00000269305.4	75		protein_altering_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
NTRK1 Fusion	415	Lung Adenocarcinoma	3910		"Lestaurtinib,Larotrectinib,Crizotinib"	Substitutes	Predictive	Supports	D	Sensitivity/Response	"Two patients were found to harbor gene fusions maintaining the kinase domain of NTRK1 (3' partner), specifically: MPRIP-NTRK1 and CD74-NTRK1.  Both of these fusions lead to constitutive kinase activity and were found to be oncogenic. Treatment of cells expressing NTRK1 fusions with inhibitors of TRKA kinase activity (ARRY-470, CEP-701 and, to a lesser extent, crizotinib) inhibited autophosphorylation of TRKA and cell growth."	24162815	PubMed		"Vaishnavi et al., 2013, Nat. Med."		3	accepted	1019	Somatic	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/1019	https://civicdb.org/links/molecular_profiles/415	FALSE	NTRK1	4914	Fusion	NTRK1 Fusions	chr1	156874383	156881642			ENST00000524377.1	75		transcript_fusion		2023-01-09 21:52:06 UTC		N/A		FALSE
AREG Expression	311	Colorectal Cancer	9256		Panitumumab		Predictive	Supports	B	Sensitivity/Response	"Prospectively planned retrospective biomarker study in archived tumor tissue from 323 patients from the PICCOLO trial (panitumumab plus irinotecan in CRC patients with KRAS wt). Tumors were classified as ""high expressor"" (either EREG or AREG mRNA level) or ""low expressor"" (neither EREG nor AREG in top tertile).  For RAS wild-type patients with high ligand expression, median PFS was 8.3 [4.0-11.0] months (irinotecan with panitumumab) vs 4.4 [2.8-6.7] months (irinotecan alone); HR, 0.38 [95% CI, 0.24-0.61]; P??001. In RAS wild-type patients with low ligand expression, median PFS was 3.2 [2.7-8.1] months (irinotecan with panitumumab) vs 4.0 [2.7-7.5] months (irinotecan); HR, 0.93 [95% CI, 0.64-1.37]; P??73; interaction test results were significant [P??01]). Results were less clear for response rate (interaction P??17) and OS (interaction P??11)."	26867820	PubMed		"Seligmann et al., 2016, JAMA Oncol"		4	accepted	1020	N/A	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/1020	https://civicdb.org/links/molecular_profiles/311	FALSE	AREG	374	Expression		chr4	74445134	74455009			ENST00000395748.3	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
EREG EXPRESSION	314	Colorectal Cancer	9256		Panitumumab		Predictive	Supports	B	Sensitivity/Response	"Prospectively planned retrospective biomarker study in archived tumor tissue from 323 patients from the PICCOLO trial (panitumumab plus irinotecan in CRC patients with KRAS wt). Tumors were classified as ""high expressor"" (either EREG or AREG mRNA level) or ""low expressor"" (neither EREG nor AREG in top tertile). For RAS wild-type patients with high ligand expression, median PFS was 8.3 [4.0-11.0] months (irinotecan with panitumumab) vs 4.4 [2.8-6.7] months (irinotecan alone); HR, 0.38 [95% CI, 0.24-0.61]; P??001. In RAS wild-type patients with low ligand expression, median PFS was 3.2 [2.7-8.1] months (irinotecan with panitumumab) vs 4.0 [2.7-7.5] months (irinotecan); HR, 0.93 [95% CI, 0.64-1.37]; P??73; interaction test results were significant [P??01]). Results were less clear for response rate (interaction P??17) and OS (interaction P??11)."	26867820	PubMed		"Seligmann et al., 2016, JAMA Oncol"		4	accepted	1021	N/A	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/1021	https://civicdb.org/links/molecular_profiles/314	FALSE	EREG	2069	EXPRESSION		chr4	74365143	74388751			ENST00000244869.2	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
ERBB2 Amplification	302	Gastric Adenocarcinoma	3717		Trastuzumab		Predictive	Supports	B	Sensitivity/Response	"ToGA, a Phase III study (NCT01041404) addressed use of trastuzumab in HER2 positive advanced gastric cancer, where chemotherapy using fluoropyrimidine-based and platinum-based combinations had been common practice.  Patients were given a chemotherapy regime containing capecitabine, flourouracil and cisplatin with (n=298) or without (n=296) trastuzumab, and had not been previously treated for metastatic cancer.  Study endpoint was overall survival, which was significantly different in the two populations (13.8 months with chemotherapy + trastuzumab and 11.1 months for chemotherapy alone).  The authors conclude that trastuzumab should be a standard option for HER2 positive advanced gastric cancer."	20728210	PubMed		"Bang et al., 2010, Lancet"	NCT01041404	4	accepted	1022	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1022	https://civicdb.org/links/molecular_profiles/302	FALSE	ERBB2	2064	Amplification		chr17	39700080	39728662			ENST00000269571.5	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A	OVEREXPRESSION	FALSE
ERBB2 Amplification	302	Gastric Adenocarcinoma	3717		Lapatinib		Predictive	Supports	B	Sensitivity/Response	"TyTAN, a Phase III study in Asian patients, looked at addition of tyrosine kinase inhibitor lapatinib to chemptherapy in advanced HER2 positive gastric cancer.  Primary endpoint was Overall Survival (OS).  Participants had progressed under previous treatment and only a small percentage had seen first line trastuzumab.  Patients were a mix of those having undergone gastrectomy and not.  OS was not significantly  different in the ITT population, but certain subpopulations showed significant differences.  In the subset of patients showing a stronger immunohistochemistry result for HER2 (IHC3+), progression free survival was significantly different at 5.6 months for lapatinib + pacitaxel vs. 4.2 months for pacitaxel alone.  The authors conclude that proof of concept for lapatanib addition to chemotherapy for certain subgroups is provided in this study."	24868024	PubMed		"Satoh et al., 2014, J. Clin. Oncol."		3	accepted	1023	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1023	https://civicdb.org/links/molecular_profiles/302	FALSE	ERBB2	2064	Amplification		chr17	39700080	39728662			ENST00000269571.5	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A	OVEREXPRESSION	FALSE
KIT EXPRESSION	425	Endometrial Cancer	1380		Imatinib		Predictive	Supports	C	Sensitivity/Response	Case Report of a 42-year old patient with low-grade endometrial stromal sarcoma. IHC was focally positive for CD117. Imatinib mesylate led to complete metabolic response (PET-CT).	18607592	PubMed		"Kalender et al., 2009, Cancer Chemother. Pharmacol."		2	accepted	1024	N/A	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/1024	https://civicdb.org/links/molecular_profiles/425	FALSE	KIT	3815	EXPRESSION		chr4	54657918	54740715			ENST00000288135.5	75		N/A		2023-01-09 21:52:07 UTC		N/A		FALSE
KIT EXPRESSION	425	Endometrial Cancer	1380		Imatinib		Predictive	Supports	C	Sensitivity/Response	Case Report of a 41-year old patient with high-grade stromal endometrial sarcoma and a large abdominal and retroperitoneal mass progressing after chemotherapy. IHC for c-Kit was positive and treatment with imatinib led to an objective Response. Surgery was performed and the patient was free of disease two years later.	16487996	PubMed		"Salvatierra et al., 2006, Gynecol. Oncol."		2	accepted	1025	N/A	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/1025	https://civicdb.org/links/molecular_profiles/425	FALSE	KIT	3815	EXPRESSION		chr4	54657918	54740715			ENST00000288135.5	75		N/A		2023-01-09 21:52:07 UTC		N/A		FALSE
CBFB CBFB::MYH11	427	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Better Outcome	The CBFB-MYH11 fusion has been shown to be associated with favorable prognosis in acute myeloid leukemia.	22180162	PubMed		"Estey, 2012, Am. J. Hematol."		4	accepted	1027	Somatic	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/1027	https://civicdb.org/links/molecular_profiles/427	FALSE	CBFB	865	CBFB::MYH11		chr16	67029245	67082308			ENST00000412916.2	75	ENST00000396324.3	transcript_fusion		2023-01-09 21:52:07 UTC		N/A	"INV(16)(P13.1;Q22),T(16;16)(P13.1;Q22),CBFB-MYH11"	FALSE
CBFB CBFB::MYH11	427	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Better Outcome	The CBFB-MYH11 fusion has been shown to be associated with favorable prognosis in acute myeloid leukemia.	22180162	PubMed		"Estey, 2012, Am. J. Hematol."		4	accepted	1027	Somatic	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/1027	https://civicdb.org/links/molecular_profiles/427	FALSE	CBFB	865	CBFB::MYH11		chr16	15703172	15727054			ENST00000412916.2	75	ENST00000396324.3	transcript_fusion		2023-01-09 21:52:07 UTC		N/A	"INV(16)(P13.1;Q22),T(16;16)(P13.1;Q22),CBFB-MYH11"	FALSE
TP53 Mutation	222	Adrenocortical Carcinoma	3948				Prognostic	Supports	B	Poor Outcome	"TP53 mutation was shown to be associated with shorter overall survival in patients with adrenocortical tumors (log-rank test; P=0.098). Of 20 patients studied, 5 had coding mutation in TP53. Four of the 5 patients with a TP53 mutation had metastases at diagnosis or detected soon thereafter, and 3 of 4 died of disease within 12 months of surgical resection."	15922892	PubMed		"Sidhu et al., 2005, Eur J Surg Oncol"		2	accepted	1028	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/1028	https://civicdb.org/links/molecular_profiles/222	FALSE	TP53	7157	Mutation		chr17	7668402	7687538			ENST00000269305.4	75		protein_altering_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
ROS1 Rearrangement	265	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	B	Sensitivity/Response	"In a retrospective study, 30 patients were evaluated after crizotinib treatment for stage IV NSCLC confirmed for ROS1 rearrangement. On crizotinib, 24 of the patients achieved objective responses including 5 complete responses. Median progression free survival was 9.1 months and all patients had  been pretreated with 1 or more lines of chemotherapy."	25667280	PubMed		"Mazires et al., 2015, J. Clin. Oncol."		3	accepted	1030	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1030	https://civicdb.org/links/molecular_profiles/265	FALSE	ROS1	6098	Rearrangement		chr6	117288300	117425855			ENST00000368508.3	75		transcript_fusion		2023-01-09 21:52:06 UTC		N/A		FALSE
HIF1A 3' UTR Polymorphism	429	Pancreatic Adenocarcinoma	4074				Prognostic	Supports	B	Poor Outcome	"The HIF1A rs2057482 SNP was genotyped in 410 pancreatic ductal adenocarcinoma cases and 490 healthy controls. The CC genotype was significantly correlated with PDAC risk (OR = 1.719, 95% CI: 1.293-2.286) and shorter overall survival (OS, P<0.0001), compared with the CT/TT alleles Group. After multivariate Analysis, CC-HIF1A and HIF-1 expression were still significantly associated with OS (P<0.0001).  This SNP is expected to reduce MiR-199a induced repression of HIF-1 Expression."	26872370	PubMed		"Wang et al., 2016, Oncotarget"		2	accepted	1031	Common Germline	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1031	https://civicdb.org/links/molecular_profiles/429	FALSE	HIF1A	3091	3' UTR Polymorphism		chr14	61747130	61747130	T	C	ENST00000394997.1	75		"3_prime_UTR_variant,SNP"	NC_000014.8:g.62213848T>C	2023-01-27 17:03:42 UTC	CA7216212			FALSE
HIF1A OVEREXPRESSION	430	Colorectal Cancer	9256				Prognostic	Supports	B	Poor Outcome	"HIF1A overexpression was assessed by IHC in 731 colorectal cancers from two prospective cohort studies. 142 (19%) tumors showed HIF1A overexpression. Overexpression of HIF1A was associated with higher colorectal cancer-specific mortality in Kaplan-Meier analysis (log-rank test, P < 0.0001), univariate Cox regression (hazard ratio = 1.84; 95% confidence interval, 1.37 to 2.47; P < 0.0001) and multivariate analysis (adjusted hazard ratio = 1.72; 95% confidence interval, 1.26 to 2.36; P = 0.0007, adjusted for clinical and tumoral features: microsatellite instability, TP53 (p53), PTGS2 (cyclooxygenase-2), CpG island methylator phenotype, and KRAS, BRAF, PIK3CA, and LINE-1 methylation)."	20363910	PubMed		"Baba et al., 2010, Am. J. Pathol."		3	accepted	1032	N/A	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1032	https://civicdb.org/links/molecular_profiles/430	FALSE	HIF1A	3091	OVEREXPRESSION		chr14	61695540	61748258			ENST00000394997.1	75		N/A		2023-01-09 21:52:07 UTC		N/A		FALSE
EPAS1 Overexpression	431	Colorectal Cancer	9256				Prognostic	Does Not Support	B	Poor Outcome	Expression of EPAS1 (HIF-2alpha) was assessed in 731 colorectal cancers from two prospective cohort studies. EPAS1 overexpression was found in 322 (46%) cancers by immunohistochemistry and not significantly associated with patient survival.	20363910	PubMed		"Baba et al., 2010, Am. J. Pathol."		3	accepted	1033	N/A	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1033	https://civicdb.org/links/molecular_profiles/431	FALSE	EPAS1	2034	Overexpression		chr2	46297402	46386697			ENST00000263734.3	75		N/A		2023-01-09 21:52:07 UTC		N/A		FALSE
HIF1A OVEREXPRESSION	430	Sarcoma	1115				Prognostic	Supports	B	Poor Outcome	"Expression of HIF1A was analyzed by IHC in 49 soft-tissue sarcomas (29 malignant fibrous histiocytomas, 12 synovial sarcomas, 4 leiomyosarcomas and 4 malignant peripheral nerve sheath tumors). High (18.4%) or moderate (35.4%) expression of HIF-1alpha was significatnly associated with shorter overall survival rate in comparison with those with a weak or negative expression in univariate analysis (P = 0.029; log-rank test) and multivariate analysis (P = 0.018)."	17103226	PubMed		"Shintani et al., 2006, Virchows Arch."		2	accepted	1034	N/A	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1034	https://civicdb.org/links/molecular_profiles/430	FALSE	HIF1A	3091	OVEREXPRESSION		chr14	61695540	61748258			ENST00000394997.1	75		N/A		2023-01-09 21:52:07 UTC		N/A		FALSE
VHL Loss	432	Renal Carcinoma	4451		Temsirolimus		Predictive	Supports	D	Sensitivity/Response	Preclinical studies linking the efficacy of mTOR inhibitor CCI-779 to VHL loss in vitro and in mouse models of kidney cancer. VHL-deficient tumors were more sensitive to mTOR inhibition than VHL-proficient tumors. Growth arrest caused by CCI-779 correlated with a block in translation of HIF1A mRNA. Expression of a VHL-resistant HIF1A cDNA lacking the 5' untranslated region rescued tumor growth.	16341243	PubMed		"Thomas et al., 2006, Nat. Med."		3	accepted	1035	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1035	https://civicdb.org/links/molecular_profiles/432	FALSE	VHL	7428	Loss		chr3	10141008	10152220			ENST00000256474.2	75		loss_of_function_variant	N/A	2023-01-09 21:52:07 UTC		N/A		FALSE
FLT3 D835	433	Acute Myeloid Leukemia	9119		"Quizartinib,Ponatinib"	Substitutes	Predictive	Supports	D	Resistance	"An in-vitro saturation mutagenesis screen of 50 independently derived FLT3-ITD clones was performed to identify mutations that confer resistance to ponatinib. Mutations at 3 AL residues (D835 [n = 31], D839 [n = 3], and Y842 [n = 16]), with varying degrees of resistance to ponatinib were identified. FLT3 D835 mutations were shown to confer resistance to the tyrosine kinase inhibitor AC220 and ponatinib.  This was especially found for D835Y and D835V mutations, whereas D835H mutations were found to confer moderate resistance to ponatinib but relatively minimal resistance to AC220."	23430109	PubMed		"Smith et al., 2013, Blood"		3	accepted	1036	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1036	https://civicdb.org/links/molecular_profiles/433	FALSE	FLT3	2322	D835		chr13	28018505	28018505	C	A	ENST00000241453.7	75		protein_altering_variant	NC_000013.10:g.28592642C>A	2023-01-27 17:03:43 UTC	CA126347	16276		FALSE
FLT3 D835	433	Acute Myeloid Leukemia	9119		SU5614		Predictive	Supports	D	Resistance	"An in-vitro cell-based screening approach generated FLT3-ITD-expressing cell lines resistant to the FLT3 inhibitors SU5614, PKC412, and sorafenib. SU5614 resistance mutations were limited to exchanges in the second part of the kinase domain (TK2), with exchanges of D835 predominating (D835E were most common). In clones that emerged at 1,500 nmol/L SU5614 after ENU (mutagen) treatment, 127 of 179 clones (71%) displayed mutations, generating 9 different exchanges affecting 6 positions in the activation loop of FLT3."	19318574	PubMed		"von Bubnoff et al., 2009, Cancer Res."		3	accepted	1037	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1037	https://civicdb.org/links/molecular_profiles/433	FALSE	FLT3	2322	D835		chr13	28018505	28018505	C	A	ENST00000241453.7	75		protein_altering_variant	NC_000013.10:g.28592642C>A	2023-01-27 17:03:43 UTC	CA126347	16276		FALSE
FLT3 D835	433	Acute Myeloid Leukemia	9119		"Quizartinib,Sorafenib"	Substitutes	Predictive	Supports	B	Resistance	"In an in-vitro study using an in vitro saturation mutagenesis assay, 4 residues with AC220 (quizartinib) resistance-conferring mutations in the kinase domain of FLT3-ITD were identified. Mutations at three of these amino acid positions conferred high degrees of in vitro AC220 resistance (based on proliferation and cell-based biochemical assays). Among these residues, two within the activation loop were found (D835, Y842).  Pre-treatment and relapse samples of 8 patients (treated with AC220) with FLT3-ITD+ acute myeloid leukemia were analyzed. The activation loop mutation D835Y was detected in three cases, D835V in two, and D835F was identified in a single patient. Cross-resistance to sorafenib was identified in-vitro."	22504184	PubMed		"Smith et al., 2012, Nature"		4	accepted	1038	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1038	https://civicdb.org/links/molecular_profiles/433	FALSE	FLT3	2322	D835		chr13	28018505	28018505	C	A	ENST00000241453.7	75		protein_altering_variant	NC_000013.10:g.28592642C>A	2023-01-27 17:03:43 UTC	CA126347	16276		FALSE
FLT3 D835	433	Acute Myeloid Leukemia	9119		Sorafenib		Predictive	Supports	B	Resistance	"13 patients with relapsed or chemo-refractory FLT3-ITD+ AML were treated with sorafenib (200-400 mg twice daily). 12 patients responded, but sorafenib response was lost in most patients after 72 (range 54-287) days. Leukemia initiating cells bearing the D835 mutation expanded during sorafenib treatment and dominated during the subsequent clinical resistance. Results were recapitulated in-vivo."	22368270	PubMed		"Man et al., 2012, Blood"		4	accepted	1039	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1039	https://civicdb.org/links/molecular_profiles/433	FALSE	FLT3	2322	D835		chr13	28018505	28018505	C	A	ENST00000241453.7	75		protein_altering_variant	NC_000013.10:g.28592642C>A	2023-01-27 17:03:43 UTC	CA126347	16276		FALSE
FLT3 ITD	55	Acute Myeloid Leukemia	9119		Sorafenib		Predictive	Supports	B	Sensitivity/Response	13 patients with relapsed or chemo-refractory FLT3-ITD+ AML were treated with sorafenib (200-400 mg twice daily). 12 patients showed clearance or near clearance of bone marrow myeloblasts after 27 (range 21-84) days with evidence of differentiation of leukemia cells. Sorafenib response was lost in most patients after 72 (range 54-287) days.	22368270	PubMed		"Man et al., 2012, Blood"		2	accepted	1040	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/1040	https://civicdb.org/links/molecular_profiles/55	FALSE	FLT3	2322	ITD		chr13	28034082	28034214			ENST00000241453.7	75		inframe_insertion		2023-01-09 21:52:04 UTC		16270		FALSE
ERBB2 Amplification	302	Lung Non-small Cell Carcinoma	3908		Trastuzumab		Predictive	Does Not Support	B	Sensitivity/Response	"In this phase II trial with 2 arms, 103 patients with untreated stage IIIB/IV HER2 positive NSCLC were given gemcitabine-cisplatin with or without trastuzumab.  HER2 positivity was broadly defined as IHC2+/3+, positive by FISH, or increased circulating HER2 extracellular domain.  Significant differences between the treatment arms were not observed, but in a small subset of IHC3+/FISH positive patients, 5 of 6 responded to trastuzumab and had increased PFS of 8.5 months in comparison to 6.1 months in the IHC2+ group.  Although from 2004, this study remains cited in 2016 literature when discussing the unclear efficacy of trastuzumab in wild-type HER2 overexpressing NSCLC. The authors conclude that future studies of trastuzumab in HER2 positive NSCLC should focus on high expressing subjects."	14679114	PubMed		"Gatzemeier et al., 2004, Ann. Oncol."		2	accepted	1041	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1041	https://civicdb.org/links/molecular_profiles/302	FALSE	ERBB2	2064	Amplification		chr17	39700080	39728662			ENST00000269571.5	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A	OVEREXPRESSION	FALSE
ERBB2 Amplification	302	Lung Non-small Cell Carcinoma	3908		Trastuzumab		Predictive	Does Not Support	B	Sensitivity/Response	"In this phase II trial a small group of patients with IHC2+ or IHC3+ HER2 NSCLC, in which primary platinum-based therapy had failed, were given either docetaxel or trastuzumab after which both groups were given docetaxel and trastuzumab together.  there was one partial response in the docetaxel group and none in the trastuzumab group.  The authors report that due to the limited clinical activity of trastuzumab-based therapy in this cohort, as well as similar results in other trastuzumab studies, that targets other than HER2 in NSCLC should be considered for future study.  This 2004 study remains cited in 2016 literature in discussing the unclear efficacy of trastuzumab in wild-type HER2 overexpressing NSCLC, but mutant HER2 in NSCLC has been further studied and a picture of different HER2 mutations being potentially responsive to specific targeted therapies is emerging."	14967075	PubMed		"Lara et al., 2004, Clin Lung Cancer"		3	accepted	1042	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1042	https://civicdb.org/links/molecular_profiles/302	FALSE	ERBB2	2064	Amplification		chr17	39700080	39728662			ENST00000269571.5	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A	OVEREXPRESSION	FALSE
ERBB2 Kinase Domain Mutation	409	Lung Adenocarcinoma	3910		Trastuzumab		Predictive	Supports	C	Sensitivity/Response	"This was a retrospective study of patients with advanced HER2-mutant NSCLC who had undergone varied courses of treatment.  All tumors were adenocarcinoma with in-frame HER2 exon 20 insertions.  In patients (n=57) that had been treated with trastuzumab plus chemotherapy, an overall response rate of 75% and progression free survival of 5.1 months were observed.  No standard of care currently exists for HER2-mutant NSCLC.  While trastuzumab has not shown clear benefit yet in wild-type HER2 overexpressed NSCLC, the authors conclude that further prospective studies should be done with trastuzumab plus chemotherapy in advanced HER2 mutant NSCLC, and that trastuzumab plus chemotherapy should be considered in current treatment courses of this cancer type."	26598547	PubMed		"Mazires et al., 2016, Ann. Oncol."		4	accepted	1043	Somatic	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/1043	https://civicdb.org/links/molecular_profiles/409	FALSE	ERBB2	2064	Kinase Domain Mutation		chr17	39723610	39726617			ENST00000269571.5	75		protein_altering_variant		2023-01-09 21:52:06 UTC		N/A		FALSE
ERBB2 Amplification	302	Lung Small Cell Carcinoma	5409		"Trastuzumab,Irinotecan"	Combination	Predictive	Supports	C	Sensitivity/Response	"This report details 2 case studies in relapsed HER2 positive SCLC.  In the first case, a 50 pack-year patient showed intense non-mutant HER2 expression by IHC without DNA amplification, and had undergone multiple prior lines of treatment.  With induction of trastuzumab and irinotecan treatment, tumor regression was observed with progression free survival of 4.5 months.  Case 2 involved a 68 year old never-smoker with relapsed SCLC.  Tumor showed HER2 positive SCLC cells with no amplification or mutation.  Third line trastuzumab plus irinotecan brought about some symptom improvement and PFS of 3.5 months.  While the efficacy of trastuzumab against NSCLC with elevated levels of wild-type HER2 expression remains unclear, the authors conclude that trastuzumab based therapy is a promising strategy for chemo-resistant SCLC."	25601188	PubMed		"Kinehara et al., 2015, Lung Cancer"		4	accepted	1044	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1044	https://civicdb.org/links/molecular_profiles/302	FALSE	ERBB2	2064	Amplification		chr17	39700080	39728662			ENST00000269571.5	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A	OVEREXPRESSION	FALSE
ERBB2 Y772_A775DUP	410	Lung Adenocarcinoma	3910		Afatinib		Predictive	Supports	C	Sensitivity/Response	"A 55 year old heavily pretreated patient with equivocal HER2 overexpression (IHC2+ and no amplification in FISH) was found to have the HER2 YMVA kinase domain insertion.  Afatinib monotherapy resulted in resolution of symptoms and 10 months before progressive disease.  The patient was subsequently given trastuzumab with no response.  The observed efficacy of afatinib against M774insAYVM, and studies reporting afatinib activity against other variants in the HER2 kinase domain, are cited by the authors as motivation for the arm of NCI-MATCH focusing on afatinib and activating HER2 mutations."	26559459	PubMed		"Li et al., 2015, Lung Cancer"		4	accepted	1045	Somatic	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/1045	https://civicdb.org/links/molecular_profiles/410	FALSE	ERBB2	2064	Y772_A775DUP		chr17	39724743	39724744		TACGTGATGGCT	ENST00000269571.5	75		inframe_insertion	"NM_001005862.2:c.2224_2235dupTACGTGATGGCT,ENST00000269571.5:c.2314_2325dupTACGTGATGGCT,NC_000017.10:g.37880985_37880996dupTACGTGATGGCT,NC_000017.10:g.37880993_37880994insGCTTACGTGATG"	2023-01-27 17:03:37 UTC	CA135369	44985	"A775INSYVMA,P.A775_G776INSYVMA,P.E770_A771INSAYVM,TYR772_ALA775DUP,A775_G776INSYVMA,M774INSAYVM"	FALSE
ERBB2 Y772_A775DUP	410	Lung Carcinoma	3905		Afatinib		Predictive	Supports	D	Sensitivity/Response	"Human HER2 with YVMA insertion was put under a clara cell specific, rtTA promoter system inducible via doxycycline.  Induction of mutant HER2 in these mice drove rapid development of adenosquamous lung tumors, where tumor maintenance was dependent on continued YMVA HER2 induction by doxycycline.  Administration of afatinib had a stronger effect than erlotinib or trastuzumab, as measured by histology and tumor volume regression.  Authors state that in the case of afatinib vs. trastuzumab, intracellular HER2 signaling may be blocked by afatanib but remain unaltered by trastuzumab."	19122144	PubMed		"Perera et al., 2009, Proc. Natl. Acad. Sci. U.S.A."		4	accepted	1047	Somatic	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/1047	https://civicdb.org/links/molecular_profiles/410	FALSE	ERBB2	2064	Y772_A775DUP		chr17	39724743	39724744		TACGTGATGGCT	ENST00000269571.5	75		inframe_insertion	"NM_001005862.2:c.2224_2235dupTACGTGATGGCT,ENST00000269571.5:c.2314_2325dupTACGTGATGGCT,NC_000017.10:g.37880985_37880996dupTACGTGATGGCT,NC_000017.10:g.37880993_37880994insGCTTACGTGATG"	2023-01-27 17:03:37 UTC	CA135369	44985	"A775INSYVMA,P.A775_G776INSYVMA,P.E770_A771INSAYVM,TYR772_ALA775DUP,A775_G776INSYVMA,M774INSAYVM"	FALSE
ERBB2 P780INS	41	Lung Adenocarcinoma	3910		Dacomitinib		Predictive	Supports	C	Sensitivity/Response	"In this phase II study (NCT00818441) of dacomitinib in HER2 amplified or mutant NSCLC tumors, three of 26 patients with HER2 p.P780_Y781insGSP or p.M774delinsWLV showed partial responses of duration between 3 and 14 months, while 13 patients with the more common HER2 p. A775_G776insYVMA showed no partial responses.  The authors conclude that in the set of activating HER2 mutations, benefits of an individual agent may be specific to certain mutations, and that ""HER2-positive lung cancers"" is not an adequate term to describe this group of distinguishable illnesses."	25899785	PubMed		"Kris et al., 2015, Ann. Oncol."	NCT00818441	3	accepted	1048	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/1048	https://civicdb.org/links/molecular_profiles/41	FALSE	ERBB2	2064	P780INS	HER2 Activating	chr17	39724758	39724759		GGCTCCCCA	ENST00000269571.5	75		inframe_insertion	"ENST00000269571.5:c.2340_2341insGGCTCCCCA,NC_000017.10:g.37881011_37881012insGGCTCCCCA"	2023-01-27 17:02:11 UTC	CA135401	NONE FOUND	PRO780INS	TRUE
ERBB2 Amplification	302	Lung Non-small Cell Carcinoma	3908		Trastuzumab Emtansine		Predictive	Supports	D	Sensitivity/Response	"Efficacy of trastuzumab in HER2 overexpressing NSCLC remains unclear.  In this study using a panel of NSCLC HER2 overexpressing cell lines, antiproliferative effects of trastuzumab emtansine (T-DM1) were observed in a HER2-expression dependant manner, with strongest effects in Calu-3 (high expressing) and no effects in Calu-6 (low expressing).  Trastuzumab did not show notable effects on cell growth in any tested cells.  HER2 positivity in NSCLC is fairly common at 2-20%.  A clinical trial (NCT02289833) is currently underway to asses TDM-1 in HER2 overexpressing lung cancer."	24898067	PubMed		"Cretella et al., 2014, Mol. Cancer"		4	accepted	1050	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1050	https://civicdb.org/links/molecular_profiles/302	FALSE	ERBB2	2064	Amplification		chr17	39700080	39728662			ENST00000269571.5	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A	OVEREXPRESSION	FALSE
PSMB8 NUCLEAR EXPRESSION	434	Gastric Adenocarcinoma	3717				Prognostic	Supports	B	Poor Outcome	"Microarray expression data from 48 patients with gastric adenocarcinoma were analyzed for genes differentially expressed with regard to overall survival. Expression of 294 and 116 genes was enriched in good and poor prognosis subtypes, respectively. Of these genes, upregulation of proteasome subunit beta type 8 PSMB8 and PDZ binding kinase PBK was confirmed by real-time reverse transcription-PCR Analysis. IHC in 385 gastric cancer patients showed that increased nuclear expression of PSMB8 and PBK was correlated with depth of invasion, lymph node metastasis, and lower survival rates (survival durations of the (-), (+), and (++) groups, classified according to nuclear PSMB8 expression, were 77.2, 70.6, and 62.2 months, respectively; P = 0.004). Cytoplasmic staining of PSMB8 and PBK were not statistically significant. In multivariate Analysis, nuclear expression of PSMB8 and PBK were not significant predictors of overall survival (P = 0.085, P = 0.083, respectively)."	26894977	PubMed		"Kwon et al., 2016, Oncotarget"		2	accepted	1051	N/A	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1051	https://civicdb.org/links/molecular_profiles/434	FALSE	PSMB8	5696	NUCLEAR EXPRESSION		chr6	32840717	32844703			ENST00000374881.2	75		N/A		2023-01-09 21:52:07 UTC		N/A		FALSE
PBK NUCLEAR EXPRESSION	435	Gastric Adenocarcinoma	3717				Prognostic	Supports	B	Poor Outcome	"Microarray expression data from 48 patients with gastric adenocarcinoma were analyzed for genes differentially expressed with regard to overall survival. Upregulation of proteasome subunit beta type 8 (PSMB8) and PDZ binding kinase (PBK) was confirmed by real-time reverse transcription-PCR Analysis. IHC in 385 gastric cancer patients showed that increased nuclear expression of PSMB8 and PBK was correlated with depth of invasion, lymph node metastasis, and lower survival rates (survival duration, months according to nuclear PBK Expression: -, 72.3  1.2; +, 66.2  3.4; ++, 53.1  9.2; P = 0.002). Cytoplasmic staining of PSMB8 and PBK were not statistically significant. In multivariate analysis, nuclear expression of PSMB8 and PBK were not significant predictors of overall survival (P = 0.085, P = 0.083, respectively)."	26894977	PubMed		"Kwon et al., 2016, Oncotarget"		2	accepted	1052	N/A	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1052	https://civicdb.org/links/molecular_profiles/435	FALSE	PBK	55872	NUCLEAR EXPRESSION		chr8	27809620	27838095			ENST00000301905.4	75		N/A		2023-01-09 21:52:07 UTC		N/A		FALSE
PTTG1 OVEREXPRESSION	436	Meningioma	3565				Prognostic	Supports	B	Poor Outcome	"144 cases (discovery set: N=62 discovery; independent validation set: N = 82) of meningiomas were analyzed for transcriptional features defining aggressive clinical course (recurrent, malignantly progressing, or WHO grade III). Meningiomas were categorized into non-recurrent (NR), recurrent (R), and tumors undergoing malignant progression (M). Unsupervised transcriptomic analysis in 62 meningiomas revealed a large set of differentially expressed genes in aggressive subgroups (R+M tumors and WHO grade III, n=332; p<0.01, FC>1.25). Multivariate analysis identified PTTG1 and LEPR mRNA expression independent of gender, WHO grade and extent of resection. The patient group with the longest progression free survival was characterized by co-occurrence of low PTTG1 and high LEPR mRNA expression. IHC in 36 tumors validated these results at the protein level."	26894859	PubMed		"Schmidt et al., 2016, Oncotarget"		2	accepted	1053	N/A	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1053	https://civicdb.org/links/molecular_profiles/436	FALSE	PTTG1	9232	OVEREXPRESSION		chr5	160421822	160428741			ENST00000352433.5	75		N/A		2023-01-09 21:52:07 UTC		N/A		FALSE
LEPR UNDEREXPRESSION	437	Meningioma	3565				Prognostic	Supports	B	Poor Outcome	"144 cases (discovery set: N=62 discovery; Independent validation set: N = 82) of meningiomas were analyzed for transcriptional features defining aggressive clinical course (recurrent, malignantly progressing or WHO grade III). Meningiomas were categorized into non-recurrent (NR), recurrent (R), and tumors undergoing malignant progression (M). Unsupervised transcriptomic analysis in 62 meningiomas revealed a large set of differentially expressed genes in aggressive subgroups (R+M tumors and WHO grade III, n=332; p<0.01, FC>1.25). Multivariate analysis identified PTTG1 and LEPR mRNA expression independent of gender, WHO grade and extent of resection. The patient group with the longest PFS was characterized by co-occurrence of low PTTG1 and high LEPR mRNA expression. IHC in 36 tumors validated these results on protein level."	26894859	PubMed		"Schmidt et al., 2016, Oncotarget"		2	accepted	1054	N/A	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1054	https://civicdb.org/links/molecular_profiles/437	FALSE	LEPR	3953	UNDEREXPRESSION		chr1	65420652	65641559			ENST00000349533.6	75		N/A		2023-01-09 21:52:07 UTC		N/A		FALSE
EREG EXPRESSION	314	Lung Adenocarcinoma	3910				Prognostic	Supports	E	Poor Outcome	"Study reporting an in-vivo two-stage initiation/promotion model, testing the hypothesis that Ereg deficiency would reduce lung tumor promotion in mice. Cancerogenesis with chemical initiators/promoters (3-methylcholanthrene or control, butylated hydroxytoluene) was assessed in mice lacking Ereg (Ereg-/-) and wildtype controls (BALB/ByJ; Ereg+/+) at multiple time points and endpoints (bronchoalveolar lavage analysis, tumor analysis, mRNA expression, ELISA, wound assay). Initially a significantly reduced amount of inflammation (macrophages, PMNs) was observed in the Ereg-/- mice. At 20wk, tumor multiplicity was also significantly decreased in the Ereg-/- mice."	26894620	PubMed		"Bauer et al., 2016, Mol. Carcinog."		2	accepted	1055	N/A	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/1055	https://civicdb.org/links/molecular_profiles/314	FALSE	EREG	2069	EXPRESSION		chr4	74365143	74388751			ENST00000244869.2	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
EGFR G465R	439	Colorectal Cancer	9256		Futuximab/Modotuximab Mixture		Predictive	Supports	C	Sensitivity/Response	"An EGFR G465R mutation (22% of mutant alleles) was detected in a biopsy from one patient which had been previously treated with cetuximab in the analysis of 15 patients with refractory, metastatic CRC after cetuximab/panitumumab, prior to Sym004 (Futuximab/Modotuximab mixture) treatment. Subsequent treatment of this patient with Sym004 yielded disease stabilization lasting 15 weeks. In vitro analysis in colorectal cancer cell line NIH3T3 with EGFR mutations S492R, R451C, K467T, and G465R showed that antibody mixture Sym004 effectively bound to all mutants, whereas cetuximab and panitumumab did not effectively bind to all mutants. In-vitro, Sym004 inhibited growth of S492R and G465R EGFR mutant cell lines. In-vivo analysis of S492R and G465R mutant cell lines showed regression of S492R and tumor growth delay of G465R mutant cell lines."	26888827	PubMed		"Snchez-Martn et al., 2016, Clin. Cancer Res."		4	accepted	1057	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1057	https://civicdb.org/links/molecular_profiles/439	FALSE	EGFR	1956	G465R	EGFR ECD MUTATION	chr7	55160233	55160233	G	A	ENST00000275493.2	75		missense_variant	"ENST00000275493.2:c.1393G>A,NC_000007.13:g.55227926G>A,NM_005228.3:c.1393G>A,NP_005219.2:p.Gly465Arg"	2023-01-27 17:03:44 UTC	CA367579504	NONE FOUND	GLY465ARG	FALSE
EGFR G465R	439	Colorectal Cancer	9256		"Cetuximab,Panitumumab"	Substitutes	Predictive	Supports	C	Resistance	"An EGFR G465R mutation (22% of mutant alleles) was detected in a biopsy from one patient which had been previously treated with cetuximab in the analysis of 15 patients with refractory, metastatic CRC after cetuximab/panitumumab, prior to Sym004 treatment. Treatment of this patient with Sym004 yielded disease stabilization lasting 15 weeks. Sym004 is a 1:1 mixture of two non-overlapping anti-EGFR monoclonal antibodies. In vitro analysis in the murine fibroblast cell line NIH3T3 with ectopic expression of EGFR mutations S492R, R451C, K467T, and G465R showed that Sym004 effectively bound to all mutants, whereas cetuximab and panitumumab did not effectively bind to all mutants. In-vitro, Sym004 inhibited growth of S492R and G465R EGFR mutant cell lines. In-vivo analysis of S492R and G465R mutant cell lines showed regression of S492R and tumor growth delay of G465R mutant cell lines. G465R mutant cell lines were resistant to treatment with panitumumab or cetuximab in-vitro."	26888827	PubMed		"Snchez-Martn et al., 2016, Clin. Cancer Res."		4	accepted	1058	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1058	https://civicdb.org/links/molecular_profiles/439	FALSE	EGFR	1956	G465R	EGFR ECD MUTATION	chr7	55160233	55160233	G	A	ENST00000275493.2	75		missense_variant	"ENST00000275493.2:c.1393G>A,NC_000007.13:g.55227926G>A,NM_005228.3:c.1393G>A,NP_005219.2:p.Gly465Arg"	2023-01-27 17:03:44 UTC	CA367579504	NONE FOUND	GLY465ARG	FALSE
NEDD9 EXPRESSION	440	Hepatocellular Carcinoma	684				Prognostic	Supports	B	Poor Outcome	"IHC was performed in 123 hepatocellular carcinoma tissues and their adjacent normal liver tissues for protein expression of HEF1 (NEDD9). Overexpression of HEF1 protein was observed in HCC tissue when compared with their adjacent non-malignant liver tissue. High expression of HEF1 correlated with higher advanced tumor, node, metastasis (TNM) stage and vascular invasion (P<0.05). In univariate and multivariate analysis, the expression of HEF1 was identified as an independent prognostic factor (Spearman's rank correlation, Kaplan-Meier plots and Cox regression model). In subgroup analysis, high expression of HEF1 correlated with a poorer prognosis in advanced (TNM III+IV) stages (P<0.05)."	26893853	PubMed		"Li et al., 2016, Mol Clin Oncol"		3	accepted	1059	N/A	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1059	https://civicdb.org/links/molecular_profiles/440	FALSE	NEDD9	4739	EXPRESSION		chr6	11184818	11382348			ENST00000504387.1	75		N/A		2023-01-09 21:52:07 UTC		N/A		FALSE
ETS2 RS461155	441	Lung Non-small Cell Carcinoma	3908		"Paclitaxel,Cisplatin"	Combination	Predictive	Supports	B	Sensitivity/Response	"Eighty SNPs in miRNA binding sites of cancer related genes selected from 18,500 miRNA:target bindings in crosslinking, ligation, and sequencing of hybrids (CLASH) data were investigated in 379 advanced NSCLC patients using a sequenom mass spectrometry-based genotype assay. 16 SNPs were significantly associated with the clinical outcomes after chemotherapy with paclitaxel-cisplatin: ETS2 SNP: OR = 1.34, 95% CI = 1.00?.81, P = 0.05; aHR = 0.80, 95% CI = 0.69?.94, P = 0.006, under additive model. ETS2 rs461155A>G was significantly associated with decreased ETS2 mRNA expression in both tumor and paired normal lung tissues (Ptrend = 4  10-7, and 3  10-4, respectively)."	26893365	PubMed		"Hong et al., 2016, Oncotarget"		2	accepted	1060	Common Germline	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1060	https://civicdb.org/links/molecular_profiles/441	FALSE	ETS2	2114	RS461155		chr21	38819714	38819714	A	G	ENST00000360214.3	75		synonymous_variant	"NC_000021.8:g.40191638A>G,NM_005239.5:c.1023A>G,ENST00000360214.3:c.1023A>G,NP_005230.1:p.Pro341="	2023-01-27 17:03:45 UTC	CA10025650	NONE FOUND	"P341P,P481P,PRO341="	FALSE
KRT18 UNDEREXPRESSION	442	Prostate Cancer	10283				Prognostic	Supports	D	Poor Outcome	"Comparison of nuclear matrix protein (NMP) patterns of paclitaxel-resistant PCa cells (DU145-TxR), with that of parental cell (DU145) using two-dimensional electrophoresis, identified cytokeratin 18 (CK18) as downregulated in DU145-TxR cells (validated at mRNA, NMP and total cellular protein levels). An in-vivo assay of xenograft transplantation showed higher tumorigenicity of DU145-TxR cells. Immunohistochemistry showed that CK18 expression in PCa tissues was statistically significant inversely correlated with tumor grade."	26892177	PubMed		"Yin et al., 2016, Int. J. Oncol."		2	accepted	1061	N/A	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1061	https://civicdb.org/links/molecular_profiles/442	FALSE	KRT18	3875	UNDEREXPRESSION		chr12	52948871	52952900			ENST00000388837.2	75		N/A		2023-01-09 21:52:07 UTC		N/A		FALSE
FGF13 CYTOPLASMIC EXPRESSION	443	Prostate Cancer	10283				Prognostic	Supports	B	Poor Outcome	"243 primary PCa, 37 metastatic PCa, and  20  castration-resistant  PCa  (CRPC) specimens underwent IHC and microarray analysis. Immunohistochemistry (IHC) showed that FGF13 was detectable in the majority of human PCa samples, and FGF13 IHC scores were higher in high-grade prostatic intraepithelial neoplasia, in primary PCa, and in metastatic PCa than in benign prostatic tissue. There was a significant association between high cytoplasmic FGF13 staining and a risk of biochemical recurrence (BCR) after radical prostatectomy. Multivariate regression analysis indicated that high cytoplasmic FGF13 staining was associated with BCR. Results were recapitulated in cell lines and public databases."	26891277	PubMed		"Yu et al., 2016, Int. J. Cancer"		3	accepted	1062	N/A	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1062	https://civicdb.org/links/molecular_profiles/443	FALSE	FGF13	2258	CYTOPLASMIC EXPRESSION		chrX	138632850	139204107			ENST00000370603.3	75		N/A		2023-01-09 21:52:07 UTC		N/A		FALSE
SSX4 SS18::SSX4	446	Synovial Sarcoma	5485				Diagnostic	Supports	C	Positive	"Three synovial sarcomas were assayed for SYT-SSX fusion messenger RNA by nested RT-PCR. In a single case an SYT-SSX4 (SS18-SSX4) fusion was detected. The majority of synovial sarcomas are characterized by SS18-SSX1 or SS18-SSX2, but other rare events such as this SS18-SSX4 may explain some or all of the synovial sarcomas that are negative for the most common fusions."	10359553	PubMed		"Skytting et al., 1999, J. Natl. Cancer Inst."		2	accepted	1074	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1074	https://civicdb.org/links/molecular_profiles/446	FALSE	SSX4	6759	SS18::SSX4	SYT-SSX fusions	chr18	26032399	26090625			ENST00000415083.2	75	ENST00000376884.2	transcript_fusion		2023-01-09 21:52:07 UTC			SS18-SSX4	FALSE
SSX4 SS18::SSX4	446	Synovial Sarcoma	5485				Diagnostic	Supports	C	Positive	"Three synovial sarcomas were assayed for SYT-SSX fusion messenger RNA by nested RT-PCR. In a single case an SYT-SSX4 (SS18-SSX4) fusion was detected. The majority of synovial sarcomas are characterized by SS18-SSX1 or SS18-SSX2, but other rare events such as this SS18-SSX4 may explain some or all of the synovial sarcomas that are negative for the most common fusions."	10359553	PubMed		"Skytting et al., 1999, J. Natl. Cancer Inst."		2	accepted	1074	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1074	https://civicdb.org/links/molecular_profiles/446	FALSE	SSX4	6759	SS18::SSX4	SYT-SSX fusions	chrX	48402082	48406079			ENST00000415083.2	75	ENST00000376884.2	transcript_fusion		2023-01-09 21:52:07 UTC			SS18-SSX4	FALSE
ABCB1 S893A/T	447	Breast Cancer	1612				Prognostic	Supports	B	Better Outcome	A total of 57 women with HER2-positive metastatic breast cancer were analyzed after taxane plus trastuzumab chemotherapy. ABCB1 G2677T carriers had a longer progression-free survival (p = 0.037) along with a tendency toward a longer overall survival (p = 0.057).	22906996	PubMed		"Kim et al., 2012, Oncology"		3	accepted	1075	Common Germline	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1075	https://civicdb.org/links/molecular_profiles/447	FALSE	ABCB1	5243	S893A/T		chr7	87531302	87531302	A	C	ENST00000265724.3	75		missense_variant	NC_000007.13:g.87160618A>C	2023-01-27 17:03:45 UTC	CA179699	"166,619,166,622"	RS2032582	FALSE
ABCB1 I1145I	259	Breast Cancer	1612				Prognostic	Supports	B	Better Outcome	A total of 57 women with HER2-positive metastatic breast cancer were analyzed after taxane plus trastuzumab chemotherapy. ABCB1 C3435T carriers had a longer progression-free survival (p = 0.039) along with a tendency toward a longer overall survival (p = 0.093).	22906996	PubMed		"Kim et al., 2012, Oncology"		3	accepted	1076	Common Germline	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/1076	https://civicdb.org/links/molecular_profiles/259	FALSE	ABCB1	5243	I1145I		chr7	87509329	87509329	A	G	ENST00000265724.3	75		synonymous_variant	"NM_000927.4:c.3435T>C,NP_000918.2:p.Ile1145=,NC_000007.13:g.87138645A>G,ENST00000265724.3:c.3435T>C"	2023-01-27 17:03:21 UTC	CA4327768	225939	"T3435C,RS1045642,3435C-T,ILE1145="	FALSE
ERBB2 Amplification	302	Her2-receptor Positive Breast Cancer	60079		"Docetaxel,Pertuzumab,Trastuzumab"	Combination	Predictive	Supports	B	Sensitivity/Response	"CLEOPATRA (NCT00567190) was a Phase III, randomized and double-blind, placebo-controlled study of 808 patients with HER2-positive metastatic breast cancer.  Patients were HER2-positive by IHC3+ or FISH, and patients who had received prior hormonal treatment or adjuvant/neo-adjuvant therapy with or without trastuzumab for longer than 12 months before randomization were also eligible.  The two arms of the study were trastuzumab and docetaxel with either placebo or pertuzumab.  Median PFS in the placebo arm was 12.4 months while in the petuzumab arm 18.5 months was achieved.  Median OS in the control arm was 40.8 months and 56.5 months with pertuzumab.  These strong results make a case for dual antibody blockade in first line treatments of HER2-positive metastatic breast cancer."	25693012	PubMed		"Swain et al., 2015, N. Engl. J. Med."	NCT00567190	5	accepted	1077	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1077	https://civicdb.org/links/molecular_profiles/302	FALSE	ERBB2	2064	Amplification		chr17	39700080	39728662			ENST00000269571.5	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A	OVEREXPRESSION	FALSE
EGFR S492R	449	Colorectal Cancer	9256		Panitumumab		Predictive	Supports	C	Sensitivity/Response	"Tumor sequencing in pre- and post-therapy specimens from ten individuals with mCRC who experienced disease progression after a prior response to cetuximab with chemotherapy was performed. The S492R mutation was identified in two persons. One of them had already died, the other received treatment with panitumumab and had a partial response (50% tumor reduction in all liver lesions) for 5 months."	22270724	PubMed		"Montagut et al., 2012, Nat. Med."		2	accepted	1078	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1078	https://civicdb.org/links/molecular_profiles/449	FALSE	EGFR	1956	S492R	EGFR ECD MUTATION	chr7	55160316	55160316	C	A	ENST00000275493.2	75		missense_variant	"ENST00000275493.2:c.1476C>A,NC_000007.13:g.55228009C>A,NP_005219.2:p.Ser492Arg,NM_005228.4:c.1476C>A"	2023-01-27 17:03:46 UTC	CA16602784	376341	"SER492ARG,RS1057519860"	FALSE
EGFR S492R	449	Colorectal Cancer	9256		"Panitumumab,Futuximab/Modotuximab Mixture"	Substitutes	Predictive	Supports	D	Sensitivity/Response	"In this preclinical study of cetuximab, panitumumab or sym004 on various EGFR mutations in colorectal cancer. The S492R mutation was sensitive to Sym004 and panitumumab treatment but resistant to cetuximab. Experiments include flow cytometry binding assay, kinase phosphorylation, cell viability, downstream signalling."	26888827	PubMed		"Snchez-Martn et al., 2016, Clin. Cancer Res."		4	accepted	1079	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1079	https://civicdb.org/links/molecular_profiles/449	FALSE	EGFR	1956	S492R	EGFR ECD MUTATION	chr7	55160316	55160316	C	A	ENST00000275493.2	75		missense_variant	"ENST00000275493.2:c.1476C>A,NC_000007.13:g.55228009C>A,NP_005219.2:p.Ser492Arg,NM_005228.4:c.1476C>A"	2023-01-27 17:03:46 UTC	CA16602784	376341	"SER492ARG,RS1057519860"	FALSE
EGFR S492R	449	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	D	Resistance	"In this preclinical study of the effects of cetuximab, panitumumab or sym004 on various EGFR mutations in colorectal cancer. The S492R mutation was sensitive to Sym004 and panitumumab treatment but resistant to cetuximab. Experiments include flow cytometry binding assay, kinase phosphorylation, cell viability, downstream signalling."	26888827	PubMed		"Snchez-Martn et al., 2016, Clin. Cancer Res."		4	accepted	1080	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1080	https://civicdb.org/links/molecular_profiles/449	FALSE	EGFR	1956	S492R	EGFR ECD MUTATION	chr7	55160316	55160316	C	A	ENST00000275493.2	75		missense_variant	"ENST00000275493.2:c.1476C>A,NC_000007.13:g.55228009C>A,NP_005219.2:p.Ser492Arg,NM_005228.4:c.1476C>A"	2023-01-27 17:03:46 UTC	CA16602784	376341	"SER492ARG,RS1057519860"	FALSE
EGFR R451C	450	Colorectal Cancer	9256		"Cetuximab,Panitumumab,Futuximab/Modotuximab Mixture"	Substitutes	Predictive	Supports	D	Sensitivity/Response	"In this preclinical study on the effects of cetuximab, panitumumab or sym004 on various EGFR mutations in colorectal cancer. The R451C mutation showed moderate drug-receptor binding with sym004, cetuximab and panitumumab treatment and inhibition of EGFR phosphorylation."	26888827	PubMed		"Snchez-Martn et al., 2016, Clin. Cancer Res."		2	accepted	1081	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1081	https://civicdb.org/links/molecular_profiles/450	FALSE	EGFR	1956	R451C		chr7	55160191	55160191	C	T	ENST00000275493.2	75		missense_variant	"ENST00000275493.2:c.1351C>T,NC_000007.13:g.55227884C>T,NM_001346898.1:c.1351C>T,NP_001333827.1:p.Arg451Cys"	2023-01-27 17:03:47 UTC	CA158917074	NONE FOUND	"ARG451CYS,RS377567759"	FALSE
EGFR K467T	451	Colorectal Cancer	9256		"Panitumumab,Futuximab/Modotuximab Mixture"	Substitutes	Predictive	Supports	D	Sensitivity/Response	"In this preclinical study on the effects of cetuximab, panitumumab or sym004 on various EGFR mutations in colorectal cancer. In NIH3T3 cells expressing EGFR with a K467T mutation, Sym004 and panitumumab bound the mutated receptor and inhibited EGFR phosphorylation in the presence of ligand while cetuximab neither bound to nor inhibited EGFR phosphorylation of the mutated receptor."	26888827	PubMed		"Snchez-Martn et al., 2016, Clin. Cancer Res."		3	accepted	1082	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1082	https://civicdb.org/links/molecular_profiles/451	FALSE	EGFR	1956	K467T	EGFR ECD MUTATION	chr7	55160240	55160240	A	C	ENST00000275493.2	75		missense_variant	"ENST00000275493.2:c.1400A>C,NC_000007.13:g.55227933A>C,NM_005228.3:c.1400A>C,NP_005219.2:p.Lys467Thr"	2023-01-27 17:03:48 UTC	CA367579521	NONE FOUND	LYS467THR	FALSE
EGFR K467T	451	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	D	Resistance	"In this preclinical study on the effects of cetuximab, panitumumab or sym004 on various EGFR mutations in colorectal cancer. In NIH3T3 cells expressing EGFR with a K467T mutation, Sym004 and panitumumab bound the mutated receptor and inhibited EGFR phosphorylation in the presence of ligand while cetuximab neither bound to nor inhibited EGFR phosphorylation of the mutated receptor."	26888827	PubMed		"Snchez-Martn et al., 2016, Clin. Cancer Res."		3	accepted	1083	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1083	https://civicdb.org/links/molecular_profiles/451	FALSE	EGFR	1956	K467T	EGFR ECD MUTATION	chr7	55160240	55160240	A	C	ENST00000275493.2	75		missense_variant	"ENST00000275493.2:c.1400A>C,NC_000007.13:g.55227933A>C,NM_005228.3:c.1400A>C,NP_005219.2:p.Lys467Thr"	2023-01-27 17:03:48 UTC	CA367579521	NONE FOUND	LYS467THR	FALSE
FCGR2A H167R	452	Breast Cancer	1612				Prognostic	Does Not Support	B	N/A	"A total of 57 women with HER2-positive metastatic breast cancer were analyzed after taxane plus trastuzumab chemotherapy. FCGR2A H131R carriers did not have a significantly different response rate, progression-free survival, or overall survival."	22906996	PubMed		"Kim et al., 2012, Oncology"		3	accepted	1084	Common Germline	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1084	https://civicdb.org/links/molecular_profiles/452	FALSE	FCGR2A	2212	H167R		chr1	161509955	161509955	A	G	ENST00000271450.6	75		missense_variant	"NM_001136219.1:c.500A>G,NP_001129691.1:p.His167Arg,ENST00000271450.6:c.500A>G,NC_000001.10:g.161479745A>G"	2023-01-27 17:03:48 UTC	CA124361	14823	"RS1801274,H131R,H166R,HIS167ARG"	FALSE
FCGR3A F212V	453	Breast Cancer	1612				Prognostic	Does Not Support	B	N/A	"A total of 57 women with HER2-positive metastatic breast cancer were analyzed after taxane plus trastuzumab chemotherapy. FCGR3A V158F carriers did not have a significantly different response rate, progression-free survival, or overall survival."	22906996	PubMed		"Kim et al., 2012, Oncology"		3	accepted	1085	Common Germline	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1085	https://civicdb.org/links/molecular_profiles/453	FALSE	FCGR3A	2214	F212V		chr1	161544752	161544752	A	C	ENST00000367969.3	75		missense_variant	"NC_000001.10:g.161514542A>C,NM_001127593.1:c.526T>G,NP_001121065.1:p.Phe176Val,ENST00000367969.3:c.526T>G"	2023-01-27 17:03:49 UTC	CA1211378	225994	"RS396991,V158F,PHE176VAL"	FALSE
FCGR2B I232T	454	Breast Cancer	1612				Prognostic	Supports	B	Poor Outcome	"1325 HER2-positive breast cancer patients treated with trastuzumab and chemotherapy from the N9831 clinical trial were analyzed. There was a difference in disease-free survival for FCGR2B I232T, with I/I patients deriving benefit from trastuzumab (p<0.001) compared to the T carriers who did not (p=0.81). The interaction between FCGR2B genotype and treatment was statistically significant (p=0.03)."	24989892	PubMed		"Norton et al., 2014, Cancer Immunol Res"		4	accepted	1086	Common Germline	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1086	https://civicdb.org/links/molecular_profiles/454	FALSE	FCGR2B	2213	I232T		chr1	161674008	161674008	T	C	ENST00000358671.5	75		missense_variant	"NM_004001.4:c.695T>C,NP_003992.3:p.Ile232Thr,ENST00000358671.5:c.695T>C,NC_000001.10:g.161643798T>C"	2023-01-27 17:03:50 UTC	CA117549	5467	"RS1050501,ILE232THR"	FALSE
FCGR3A F212V	453	Breast Cancer	1612		Trastuzumab		Predictive	Does Not Support	B	Sensitivity/Response	1325 HER2-positive breast cancer patients treated with trastuzumab and chemotherapy from the N9831 clinical trial were analyzed. There was no statistically significant difference in disease-free survival between trastuzumab-treated patients who had the FCGR3A 158 V/V high-affinity genotype and patients without that genotype (V/F and F/F).	24989892	PubMed		"Norton et al., 2014, Cancer Immunol Res"		4	accepted	1087	Common Germline	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1087	https://civicdb.org/links/molecular_profiles/453	FALSE	FCGR3A	2214	F212V		chr1	161544752	161544752	A	C	ENST00000367969.3	75		missense_variant	"NC_000001.10:g.161514542A>C,NM_001127593.1:c.526T>G,NP_001121065.1:p.Phe176Val,ENST00000367969.3:c.526T>G"	2023-01-27 17:03:49 UTC	CA1211378	225994	"RS396991,V158F,PHE176VAL"	FALSE
FCGR2A H167R	452	Breast Cancer	1612		Trastuzumab		Predictive	Does Not Support	B	Sensitivity/Response	1325 HER2-positive breast cancer patients treated with trastuzumab and chemotherapy from the N9831 clinical trial were analyzed. There was no statistical difference in disease-free survival between trastuzumab-treated patients who had the FCGR2A 131 H/H high-affinity genotype and patients without that genotype.	24989892	PubMed		"Norton et al., 2014, Cancer Immunol Res"		4	accepted	1088	Common Germline	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1088	https://civicdb.org/links/molecular_profiles/452	FALSE	FCGR2A	2212	H167R		chr1	161509955	161509955	A	G	ENST00000271450.6	75		missense_variant	"NM_001136219.1:c.500A>G,NP_001129691.1:p.His167Arg,ENST00000271450.6:c.500A>G,NC_000001.10:g.161479745A>G"	2023-01-27 17:03:48 UTC	CA124361	14823	"RS1801274,H131R,H166R,HIS167ARG"	FALSE
EGFR P753S	456	Skin Squamous Cell Carcinoma	3151		"Sirolimus,Cetuximab"	Combination	Predictive	Supports	C	Sensitivity/Response	72-year old male patient presents with SCC with a mutation profile consistent with UV exposure. Sequencing revealed a number of abnormalities including P753S mutation in EGFR. Patient began therapy with cetuximab and sirolimus and continued for 9 months. Disease burden was not measurable by Response Evaluation Criteria in Solid Tumors.	24934779	PubMed		"Ganesan et al., 2016, J. Clin. Oncol."		3	accepted	1089	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1089	https://civicdb.org/links/molecular_profiles/456	FALSE	EGFR	1956	P753S		chr7	55174794	55174794	C	T	ENST00000275493.2	75		missense_variant	"ENST00000275493.2:c.2257C>T,NC_000007.13:g.55242487C>T,NM_005228.4:c.2257C>T,NP_005219.2:p.Pro753Ser"	2023-01-27 17:03:51 UTC	CA4266020	376081	"PRO753SER,RS121913231"	FALSE
PML PML::RARA	108	Acute Promyelocytic Leukemia	60318				Diagnostic	Supports	A	Positive	"The presence of the PML-RARa fusion protein is a diagnostic marker of Acute Promyelocytic Leukemia, or M3 AML."	7628753	PubMed		"Diverio et al., 1995, Haematologica"		5	accepted	1090	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/1090	https://civicdb.org/links/molecular_profiles/108	FALSE	PML	5371	PML::RARA		chr15	73994717	74033414			ENST00000268058.3	75	ENST00000254066.5	transcript_fusion	N/A	2023-01-09 21:52:05 UTC		N/A	PML-RARA	FALSE
PML PML::RARA	108	Acute Promyelocytic Leukemia	60318				Diagnostic	Supports	A	Positive	"The presence of the PML-RARa fusion protein is a diagnostic marker of Acute Promyelocytic Leukemia, or M3 AML."	7628753	PubMed		"Diverio et al., 1995, Haematologica"		5	accepted	1090	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/1090	https://civicdb.org/links/molecular_profiles/108	FALSE	PML	5371	PML::RARA		chr17	40348316	40356796			ENST00000268058.3	75	ENST00000254066.5	transcript_fusion	N/A	2023-01-09 21:52:05 UTC		N/A	PML-RARA	FALSE
PML PML::RARA	108	Acute Promyelocytic Leukemia	60318		"Tretinoin,Arsenic Trioxide"	Combination	Predictive	Supports	A	Sensitivity/Response	ATRA/Arsenic combined with standard chemotherapy has been shown to induce a complete remission rate of greater than 75% of patients with acute promyelocytic leukemia harboring the PML-RARa fusion.	11704842	PubMed		"Degos et al., 2001, Oncogene"		5	accepted	1091	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/1091	https://civicdb.org/links/molecular_profiles/108	FALSE	PML	5371	PML::RARA		chr15	73994717	74033414			ENST00000268058.3	75	ENST00000254066.5	transcript_fusion	N/A	2023-01-09 21:52:05 UTC		N/A	PML-RARA	FALSE
PML PML::RARA	108	Acute Promyelocytic Leukemia	60318		"Tretinoin,Arsenic Trioxide"	Combination	Predictive	Supports	A	Sensitivity/Response	ATRA/Arsenic combined with standard chemotherapy has been shown to induce a complete remission rate of greater than 75% of patients with acute promyelocytic leukemia harboring the PML-RARa fusion.	11704842	PubMed		"Degos et al., 2001, Oncogene"		5	accepted	1091	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/1091	https://civicdb.org/links/molecular_profiles/108	FALSE	PML	5371	PML::RARA		chr17	40348316	40356796			ENST00000268058.3	75	ENST00000254066.5	transcript_fusion	N/A	2023-01-09 21:52:05 UTC		N/A	PML-RARA	FALSE
PML B2 DOMAIN MUTATION	457	Acute Promyelocytic Leukemia	60318		Tretinoin		Predictive	Supports	B	Resistance	Mutations in the B2 domain of PML in the PML-RARa fusion have been shown to be associated with resistance to standard ATRA treatment in patients with acute promyelocytic leukemia.	23670176	PubMed		"Tomita et al., 2013, Int. J. Hematol."		4	accepted	1092	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1092	https://civicdb.org/links/molecular_profiles/457	FALSE	PML	5371	B2 DOMAIN MUTATION	PML-RARa B2 Domain	chr15	74022872	74022878			ENST00000268058.3	75		missense_variant		2023-01-09 21:52:07 UTC				FALSE
PML PML::RARA A216V	458	Acute Promyelocytic Leukemia	60318		Tretinoin		Predictive	Supports	C	Resistance	The mutation A216V in the B2 domain of PML in the PML-RARa fusion was seen in a patient with ATRA-resistant acute promyelocytic leukemia.	21613260	PubMed		"Goto et al., 2011, Blood"		4	accepted	1093	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1093	https://civicdb.org/links/molecular_profiles/458	FALSE	PML	5371	PML::RARA A216V	PML-RARa B2 Domain	chr15	74022872	74022872	C	T	ENST00000268058.3	75		"missense_variant,transcript_fusion"	NC_000015.9:g.74315213C>T	2023-01-27 17:03:52 UTC	CA393121894	NONE FOUND	PML-RARA A216V	FALSE
PML PML::RARA L218P	459	Acute Promyelocytic Leukemia	60318		Tretinoin		Predictive	Supports	C	Resistance	"The PML L218P mutation in the PML-RARa fusion was observed in a patient with previously ATRA-treated, relapsed acute promyelocytic leukemia refractory to arsenic trioxide."	21613260	PubMed		"Goto et al., 2011, Blood"		3	accepted	1094	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1094	https://civicdb.org/links/molecular_profiles/459	FALSE	PML	5371	PML::RARA L218P	PML-RARa B2 Domain	chr15	74022878	74022878	T	C	ENST00000268058.3	75		"missense_variant,transcript_fusion"	NC_000015.9:g.74315219T>C	2023-01-27 17:03:52 UTC	CA393121927	NONE FOUND	PML-RARA L218P	FALSE
ERBB2 Amplification	302	Endometrial Serous Adenocarcinoma	5750				Prognostic	Supports	B	Poor Outcome	"In a study of 27 African American and caucasian patients, endometrial adenocarcinoma samples were assessed for HER2 via IHC staining, and association studies were performed using corresponding patient information.  Earlier deaths were seen with heavier HER2 expression.  Multivariate Cox regression indicated that shorter survival was associated with higher HER2 expression, and not with age or ethnicity, and that observed differences in survival rates between ethnicities can be ascribed to higher rates of HER2 overexpression in African American patients.  The authors conclude that high HER2 expression in USPC is associated with poor outcome and explains observed differences in outcome between ethnicities."	15746676	PubMed		"Santin et al., 2005, Am. J. Obstet. Gynecol."		4	accepted	1096	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1096	https://civicdb.org/links/molecular_profiles/302	FALSE	ERBB2	2064	Amplification		chr17	39700080	39728662			ENST00000269571.5	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A	OVEREXPRESSION	FALSE
ERBB2 Amplification	302	Endometrial Serous Adenocarcinoma	5750		Trastuzumab		Predictive	Supports	C	Sensitivity/Response	"HER2 expression in uterine serous papillary carcinoma (USPC) is thought to be associated with poor prognosis and may act as a targetable driver mutation in this cancer.  HER2 overexpression in USPC is more common in African American women.  This report covered 2 African American patients, the first of which presented high-grade endometrial adenocarcinoma with IHC3+ HER2-positivity as well as positivity by FISH.  Prior treatment involved surgery and chemotherapy.  Treatment with pacitaxel/carboplatin with trastuzumab showed clear clinical improvement assessed by CT scan and drop in CA-125 levels from 988 to 7.9 U/mL.  The second patient had USPC, and was treated with surgery and radiation.  Trastuzumab monotheraby was then administered.  After 7 months of treatment, the patient showed no sign of disease progression and CA-125 had dropped from 144 to 41 U/mL.  The investigators conclude there is promise in trastuzumab-based therapies in advanced endometrial cancers, including USPC."	18555254	PubMed		"Santin et al., 2008, Int J Gynaecol Obstet"		4	accepted	1097	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1097	https://civicdb.org/links/molecular_profiles/302	FALSE	ERBB2	2064	Amplification		chr17	39700080	39728662			ENST00000269571.5	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A	OVEREXPRESSION	FALSE
ERBB2 Amplification	302	Endometrial Cancer	1380		Trastuzumab		Predictive	Does Not Support	B	Sensitivity/Response	"This phase II single arm study assessed trastuzumab monotherapy in HER2 positive endometrial cancers with tumor response as primary endpoint.  Participants had stage III, IV or recurrent HER2 positive endometrial cancer.  During the trial's initial phase, 23 of 132 patients screened met the criteria of IHC2+ or 3+ or FISH positivity for HER2 status.  In the absence of results, the trial entered phase B, where only patients with HER2 amplification by FISH were admitted.  The trial ended early due to poor accrual with 11 of 154 screened meeting the phase B criteria. No major objective tumor responses were observed in the study.  28% of the cancers were of the serous type that had shown trastuzumab response in case studies.  The investigators note that in other HER2 cancers, such as breast and gastrointestinal, trastuzumab in combination with chemotherapy has been found most effective, and could warrant more study.  Currently a clinical trial (NCT01367002) is evaluating carboplatin/paclitaxel with or without trastuzumab in uterine serous cancer."	19840887	PubMed		"Fleming et al., 2010, Gynecol. Oncol."		2	accepted	1098	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1098	https://civicdb.org/links/molecular_profiles/302	FALSE	ERBB2	2064	Amplification		chr17	39700080	39728662			ENST00000269571.5	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A	OVEREXPRESSION	FALSE
SMO D473H	295	Medulloblastoma	50902		Patidegib		Predictive	Supports	D	Sensitivity/Response	"Saridegib treatment induced tumor reduction and significantly prolonged survival in a Shh-driven mouse medulloblastoma model, and was found to be active in cells with the D473H point mutation."	22550175	PubMed		"Lee et al., 2012, Proc. Natl. Acad. Sci. U.S.A."		3	accepted	1099	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1099	https://civicdb.org/links/molecular_profiles/295	FALSE	SMO	6608	D473H		chr7	129209348	129209348	G	C	ENST00000249373.3	75		missense_variant	"NM_005631.4:c.1417G>A,NP_005622.1:p.Asp473His,ENST00000249373.3:c.1417G>A,NC_000007.13:g.128849189G>C"	2023-01-27 17:03:27 UTC	CA16602418	375938	ASP473HIS	FALSE
ROS1 CD74::ROS1 G2032R	461	Lung Adenocarcinoma	3910		Crizotinib		Predictive	Supports	C	Resistance	"Resistance to crizotinib developed in a patient with metastatic lung adenocarcinoma harboring a CD74-ROS1 rearrangement who had initially shown a dramatic response to treatment. An acquired G2032R mutation in the ROS1 kinase domain was observed in the resistant tumor, and was found to confer resistance to ROS1 kinase inhibition through steric interference with drug binding."	23724914	PubMed		"Awad et al., 2013, N. Engl. J. Med."	NCT00585195	4	accepted	1100	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1100	https://civicdb.org/links/molecular_profiles/461	FALSE	ROS1	6098	CD74::ROS1 G2032R		chr6	117317184	117317184	C	T	ENST00000368508.3	75		"missense_variant,transcript_fusion"	NC_000006.11:g.117638347C>T	2023-01-27 17:03:53 UTC	CA16602597	376139	CD74-ROS1 G2032R	FALSE
ROS1 CD74::ROS1 G2032R	461	Lung Non-small Cell Carcinoma	3908		Cabozantinib		Predictive	Supports	D	Sensitivity/Response	"Cabozantinib was assessed in the CD74-ROS1-mutant Ba/F3 cells and crizotinib-resistant patient-derived cancer cells (MGH047) harboring G2032R-mutated CD74-ROS1. It effectively inhibited the survival of CD74-ROS1 wild-type (WT) and resistant mutants harboring Ba/F3 and MGH047 cells. Furthermore, cabozantinib could overcome all the resistance by all newly identified secondary mutations."	25351743	PubMed		"Katayama et al., 2015, Clin. Cancer Res."		3	accepted	1101	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1101	https://civicdb.org/links/molecular_profiles/461	FALSE	ROS1	6098	CD74::ROS1 G2032R		chr6	117317184	117317184	C	T	ENST00000368508.3	75		"missense_variant,transcript_fusion"	NC_000006.11:g.117638347C>T	2023-01-27 17:03:53 UTC	CA16602597	376139	CD74-ROS1 G2032R	FALSE
NPM1 EXON 12 MUTATION	86	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	"Peripheral blood from NPM1 mutated AMLs was assessed for NPM1 mutation status at multiple time points using RT-qPCR with primers designed to amplify different mutant NPM1 transcripts. The test development cohort consisted of 194 cases and an independent validation cohort consisted of 91 cases. Persistence of NPM1-mutated transcripts in blood was present in 15% of the patients after the second chemotherapy cycle. This persistence was associated with a greater risk of relapse after 3 years of follow-up than was an absence of such transcripts (82% vs. 30%; hazard ratio, 4.80; 95% confidence interval [CI], 2.95 to 7.80; P<0.001) and a lower rate of survival (24% vs. 75%; hazard ratio for death, 4.38; 95% CI, 2.57 to 7.47; P<0.001). The presence of minimal residual disease was the only independent prognostic factor for death in multivariate analysis (hazard ratio, 4.84; 95% CI, 2.57 to 9.15; P<0.001). On sequential monitoring of minimal residual disease, relapse was reliably predicted by a rising level of NPM1-mutated transcripts."	26789727	PubMed		"Ivey et al., 2016, N. Engl. J. Med."		4	accepted	1102	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/1102	https://civicdb.org/links/molecular_profiles/86	FALSE	NPM1	4869	EXON 12 MUTATION	NPM1 Exon 12	chr5	171410527	171410565			ENST00000517671.1	75		exon_variant		2023-01-09 21:52:04 UTC		N/A		FALSE
CEBPA N-TERMINAL FRAME SHIFT	28	Acute Myeloid Leukemia	9119		OICR-9429		Predictive	Supports	D	Sensitivity/Response	"This preclinical study establishes that the p30 isoform of CEBPA expressed as a result of N-terminal truncating mutations preferentially interacts with WRD5, a component of the SET/MLL complex. Knockdown of WRD5 in 32D cells (mouse hematopoietic cell line) or transplanted primary mouse bone marrow expressing the p30 isoform restored myeloid differentiation in these cells. OICR-9429, a small molecule inhibitor of WRD5, and anti-WRD5 siRNAs selectively inhibited colony formation of mouse fetal liver cells homozygous for N-terminal CEBPA mutations but not wildtype colony formation. Finally, OICR-9429 reduced viability of primary human AML blasts harboring N-terminal domain CEBPA mutations in culture but not AML blasts with other mutations. Taken together, WRD5 inhibition is a potential therapeutic method for patients harboring N-terminal CEBPA mutations."	26167872	PubMed		"Grebien et al., 2015, Nat. Chem. Biol."		3	accepted	1103	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/1103	https://civicdb.org/links/molecular_profiles/28	FALSE	CEBPA	1050	N-TERMINAL FRAME SHIFT		chr19	33302055	33302564			ENST00000498907.2	75		"frameshift_truncation,dominant_negative_variant"		2023-01-09 21:52:04 UTC				FALSE
FGFR1 Amplification	263	Breast Cancer	1612		Afimoxifene		Predictive	Supports	D	Resistance	"FGFR1-amplified breast cancer cell lines show resistance to 4-hydroxytamoxifen, which is reversed by small interfering RNA silencing of FGFR1."	20179196	PubMed		"Turner et al., 2010, Cancer Res."		3	accepted	1105	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/1105	https://civicdb.org/links/molecular_profiles/263	FALSE	FGFR1	2260	Amplification		chr8	38411138	38467845			ENST00000425967.3	75		transcript_amplification	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
KDR A1065T	463	Angiosarcoma	1816		"Sorafenib,Sunitinib"	Substitutes	Predictive	Supports	D	Sensitivity/Response	"COS-7 cells were transiently transfected with expression constructs encoding cDNAs for wild-type or A1065T-mutant KDR. Autophosphorylation was observed on tyrosine of mutant cells, but not wild-type cells, which were starved from serum for 6 hours without rhVEGF stimulation. Decreased phosphorylation in mutant cells was noted after treatment with either sunitinib or sorafenib."	19723655	PubMed		"Antonescu et al., 2009, Cancer Res."		3	accepted	1106	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1106	https://civicdb.org/links/molecular_profiles/463	FALSE	KDR	3791	A1065T		chr4	55089802	55089802	C	T	ENST00000263923.4	75		missense_variant	"NM_002253.2:c.3193G>A,NP_002244.1:p.Ala1065Thr,ENST00000263923.4:c.3193G>A,NC_000004.11:g.55955969C>T"	2023-01-27 17:03:54 UTC	CA2924178	NONE FOUND	"ALA1065THR,RS56302315"	FALSE
KDR D717V	464	Angiosarcoma	1816		"Sorafenib,Sunitinib"	Substitutes	Predictive	Supports	D	Sensitivity/Response	"COS-7 cells were transiently transfected with expression constructs encoding cDNAs for wild-type or D717V-mutant KDR. Autophosphorylation was observed on tyrosine of mutant cells, but not wild-type cells, which were starved from serum for 6 hours without rhVEGF stimulation. Decreased phosphorylation in mutant cells was noted after treatment with either sunitinib or sorafenib."	19723655	PubMed		"Antonescu et al., 2009, Cancer Res."		3	accepted	1107	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1107	https://civicdb.org/links/molecular_profiles/464	FALSE	KDR	3791	D717V		chr4	55102013	55102013	T	A	ENST00000263923.4	75		missense_variant	"ENST00000263923.4:c.2150A>T,NC_000004.11:g.55968180T>A"	2023-01-27 17:03:55 UTC	CA356908090	NONE FOUND	ASP717VAL	FALSE
TSC2 Q1178*	465	Thyroid Gland Carcinoma	3963		Everolimus		Predictive	Supports	C	Sensitivity/Response	"The pretreatment tumor contained a somatic nonsense mutation (Q1178*) in the tumor-suppressor gene TSC2 that inactivates the gene, allowing for activation of the mTOR pathway and resulting in sensitivity to mTOR inhibition by everolimus. The patient received a sustained response to everolimus for 18 months."	25295501	PubMed		"Wagle et al., 2014, N. Engl. J. Med."		5	accepted	1108	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1108	https://civicdb.org/links/molecular_profiles/465	FALSE	TSC2	7249	Q1178*		chr16	2080299	2080299	C	T	ENST00000219476.3	75		stop_gained	"NM_000548.4:c.3532C>T,NP_000539.2:p.Gln1178Ter,ENST00000219476.3:c.3532C>T,NC_000016.9:g.2130300C>T"	2023-01-27 17:03:56 UTC	CA019253	49263	"Q1178X,GLN1178TER,RS45517297"	FALSE
FLT3 ITD	55	Acute Promyelocytic Leukemia	60318				Prognostic	Supports	B	Poor Outcome	"In a study of 53 APL patients treated with combination ATRA/anthracycline chemotherapy, patients with the FLT3 ITD mutation (n=10) had higher rates of relapse (30% vs. 2.5%), lower rates of remission (70% vs 87.5%), and lower 3-year Leukemia-Free Survival (44.4% vs. 84.4%)."	21461300	PubMed		"Hong et al., 2011, Korean J Hematol"		3	accepted	1109	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/1109	https://civicdb.org/links/molecular_profiles/55	FALSE	FLT3	2322	ITD		chr13	28034082	28034214			ENST00000241453.7	75		inframe_insertion		2023-01-09 21:52:04 UTC		16270		FALSE
MTOR F2108L	466	Thyroid Gland Carcinoma	3963		Everolimus		Predictive	Supports	C	Resistance	"The pretreatment tumor contained a somatic nonsense mutation (Q1178*) in the tumor-suppressor gene TSC2 that inactivates the gene, allowing for activation of the mTOR pathway and resulting in sensitivity to mTOR inhibition by everolimus. The patient received a sustained response to everolimus for 18 months, after which time resistance developed. The resistant tumor had a somatic mutation in MTOR (F2108L), that was not detected in the pretreatment tumor."	25295501	PubMed		"Wagle et al., 2014, N. Engl. J. Med."		5	accepted	1110	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1110	https://civicdb.org/links/molecular_profiles/466	FALSE	MTOR	2475	F2108L		chr1	11127037	11127037	G	T	ENST00000361445.4	75		missense_variant	"ENST00000361445.4:c.6324C>A,NC_000001.10:g.11187094G>T"	2023-01-27 17:03:57 UTC	CA338391533	NONE FOUND	PHE2108LEU	FALSE
RAD51D R186*	467	Breast Cancer	1612				Predisposing	N/A	C	N/A	"A healthy, 36-year-old woman presented with a palpable right breast mass upon biopsy determined to be high-grade, triple negative invasive ductal carcinoma. Her family history was notable for multiple relatives on her maternal side with breast cancer, including a distant male relative with breast cancer. Multigene panel testing with an 18-gene panel revealed a germline truncating pathogenic mutation in RAD51D (p.R186X; c. 556C>T)."	25445424	PubMed		"Baker et al., 2015, Clin. Breast Cancer"		2	accepted	1111	Rare Germline	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1111	https://civicdb.org/links/molecular_profiles/467	FALSE	RAD51D	5892	R186*		chr17	35106406	35106406	G	A	ENST00000345365.6	75		stop_gained	NC_000017.10:g.33433425G>A	2023-01-27 17:03:58 UTC	CA129082	30285	"R186X,ARG186TER,RS387906843"	FALSE
FLT3 ITD	55	Acute Promyelocytic Leukemia	60318		"Anthracycline Antineoplastic Antibiotic,Tretinoin"	Combination	Predictive	Supports	B	Resistance	"In a study of 171 APL patients treated with combination ATRA/anthracycline chemotherapy, FLT3 ITD mutations (n=35) were associated with lower 3-year OS compared to the FLT3 ITD-negative group (62% vs. 82%), as well as higher CR achievement failure and early death."	24981688	PubMed		"Lucena-Araujo et al., 2014, Ann. Hematol."		4	accepted	1112	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/1112	https://civicdb.org/links/molecular_profiles/55	FALSE	FLT3	2322	ITD		chr13	28034082	28034214			ENST00000241453.7	75		inframe_insertion		2023-01-09 21:52:04 UTC		16270		FALSE
ERBB2 Amplification	302	Her2-receptor Positive Breast Cancer	60079		"Trastuzumab,Neratinib"	Sequential	Predictive	Supports	A	Sensitivity/Response	"In this two arm, Phase III study (NCT00878709) of the efficacy of a 12 month course of the TKI neratinib after trastuzumab-based adjuvant therapy of early stage HER2-positive breast cancer was assessed using invasive disease-free survival as primary endpoint. HER2 positivity was assessed via FISH. At 2 year follow-up, 70 vs. 109 disease-free survival events had occurred and disease-free survival rates were 93.9% vs. 91.6% (significant) in neratinib vs. placebo groups respectively. Distant disease-free survival and time to distant recurrence were similar in both groups. These results are an interesting contrast to results of long-term adjuvant therapy with trastuzumab (HERA) which did not show significant benefit."	26874901	PubMed		"Chan et al., 2016, Lancet Oncol."	NCT00878709	4	accepted	1113	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/1113	https://civicdb.org/links/molecular_profiles/302	FALSE	ERBB2	2064	Amplification		chr17	39700080	39728662			ENST00000269571.5	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A	OVEREXPRESSION	FALSE
ALDH1A2 Overexpression	468	Head And Neck Squamous Cell Carcinoma	5520				Prognostic	Supports	B	Better Outcome	"IHC for expression of ALDH1A2 and CRABP2 was performed in 89 patients with squamous cell carcinoma of the head and neck. High expression of both, ALDH1A2 and CRABP2 (in comparison to ALDH1A2 low or ALDH1A2 high and CRABP2 low) was significantly associated with OS and PFS in multivariate Cox analysis (OS, HR: 0.303, 95%CI 0.14?.63, p-value 0.002 PFS, HR: 0.395, 95%CI 0.20?.77, p-value 0.007)."	26634247	PubMed		"Seidensaal et al., 2015, Mol. Cancer"		3	accepted	1114	N/A	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1114	https://civicdb.org/links/molecular_profiles/468	FALSE	ALDH1A2	8854	Overexpression		chr15	57953424	58066418			ENST00000249750.4	75		N/A		2023-01-09 21:52:07 UTC		N/A		FALSE
ALDH1A2 Underexpression	469	Head And Neck Squamous Cell Carcinoma	5520		Tretinoin		Predictive	Supports	D	Sensitivity/Response	"FaDu (a high ALDH1A2 expression cell line) and Cal27 (a low expression cell line) were treated with all-trans retinoic acid (ATRA), Adapalene or Fenretinide. This led to concentration dependent decrease in the survival fraction in both cell lines with higher efficacy in Cal27 (ED50 ?1 M) as compared to FaDu cells (ED ?44 M). Treatment with 3 M ATRA sensitized Cal27 cells to irradiation at a dose of 2 Gy, but had no or only a minor effect on ALDH1A2-postitive cells."	26634247	PubMed		"Seidensaal et al., 2015, Mol. Cancer"		2	accepted	1115	N/A	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1115	https://civicdb.org/links/molecular_profiles/469	FALSE	ALDH1A2	8854	Underexpression		chr15	57953424	58066418			ENST00000249750.4	75		N/A		2023-01-09 21:52:07 UTC		N/A		FALSE
ALDH1A2 Overexpression	468	Head And Neck Squamous Cell Carcinoma	5520				Prognostic	Supports	B	Better Outcome	"ALDH1A2 protein levels were determined (IHC) in 115 patients with oropharyngeal squamous cell carcinoma with known HPV status (n = 89 nonHPV-driven; n = 26 HPV-driven). Low to moderate ALDH1A2 protein levels (combined as ALDH1A2low) were identified in keratinocytes of healthy mucosa as well as 73 (63.5%) primary tumors, and high ALDH1A2 protein levels in 42 (36.5%) primary tumors. Significantly higher ALDH1A2 protein levels were identified in HPV-driven than non-HPV-driven tumors. Moreover, PFS and OS strongly correlated with the ALDH1A2 protein expression level (OS, P < 0.001; PFS, P = 0.001; log-rank/Mantel-Cox test. Previous analyses in the same study identify hypermethylation of ALDH1A2 as the underlying mechanism of differential protein expression."	23635773	PubMed		"Kostareli et al., 2013, J. Clin. Invest."		3	accepted	1116	N/A	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1116	https://civicdb.org/links/molecular_profiles/468	FALSE	ALDH1A2	8854	Overexpression		chr15	57953424	58066418			ENST00000249750.4	75		N/A		2023-01-09 21:52:07 UTC		N/A		FALSE
CIP2A EXPRESSION	470	Pancreatic Ductal Adenocarcinoma	3498				Prognostic	Supports	B	Poor Outcome	"Expression of the protein CIP2A was investigated in 72 cases of pancreatic ductal adenocarcinoma and 27 cases of adjacent tissues. Immunohistochemistry revealed a significant difference in expression between tumor and adjacent normal samples. Furthermore, a statistically significant decrease in overall survival was discovered between positive and negative CIP2A expression."	26894380	PubMed		"Xu et al., 2016, Oncotarget"		3	accepted	1117	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1117	https://civicdb.org/links/molecular_profiles/470	FALSE	CIP2A	57650	EXPRESSION		chr3	108549869	108589452			ENST00000295746.8	75		N/A		2023-01-09 21:52:07 UTC		N/A		FALSE
CIP2A Underexpression	471	Pancreatic Ductal Adenocarcinoma	3498		Gemcitabine		Predictive	Supports	D	Sensitivity/Response	"Researchers studied the effect of CIP2A expression in relation to  gemcitabine sensitivity via SW1990 cell lines. SW1990 cells with CIP2A expression knocked-down displayed lower IC50 (p=.024), indicating a sensitivity to gemcitabine."	26894380	PubMed		"Xu et al., 2016, Oncotarget"		3	accepted	1118	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1118	https://civicdb.org/links/molecular_profiles/471	FALSE	CIP2A	57650	Underexpression		chr3	108549869	108589452			ENST00000295746.8	75		N/A		2023-01-09 21:52:07 UTC		N/A		FALSE
MIR218-1 EXPRESSION	472	Colorectal Cancer	9256				Prognostic	Supports	B	Better Outcome	"Researchers examined the prognostic role of miR-218 expression in CRC tumor samples when receiving 5-FU based treatment. CRC samples from patients who received first-line 5-FU-based adjuvant chemotherapy were stratified into two groups (complete/partial response and stable/progressive disease) based on RECIST criteria. miR-218 expression levels were found to be significantly higher in the complete/partial response group.  Further Kaplan-Meier survival analysis revealed that in groups with higher miR-218 expression, overall survival was significantly greater."	26442524	PubMed		"Li et al., 2015, Carcinogenesis"		3	accepted	1119	N/A	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1119	https://civicdb.org/links/molecular_profiles/472	FALSE	MIR218-1	407000	EXPRESSION		chr4	20528275	20528384			ENST00000384999.1	75		N/A		2023-01-09 21:52:07 UTC		N/A		FALSE
MIR218-1 EXPRESSION	472	Colorectal Cancer	9256				Prognostic	Supports	B	Better Outcome	"Researchers examined the overall and progression free survival of CRC patients receiving first line 5-Fluorouracil therapy.  Samples were stratified into two groups (low/high expressing miR-218). Kaplan-Meier survival analysis revealed that in groups with higher miR-218 expression, overall survival was significantly greater."	26442524	PubMed		"Li et al., 2015, Carcinogenesis"		3	accepted	1120	N/A	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1120	https://civicdb.org/links/molecular_profiles/472	FALSE	MIR218-1	407000	EXPRESSION		chr4	20528275	20528384			ENST00000384999.1	75		N/A		2023-01-09 21:52:07 UTC		N/A		FALSE
ALK EML4::ALK	5	Lung Acinar Adenocarcinoma	6482		Erlotinib		Predictive	Supports	C	Resistance	"A 39-year-old man presented was observed to have lung acinar adenocarcinoma. Treatment with chemotherapy produced no remarkable response. A EGFR L858R point mutation was observed; the patient was therefore treated with erlotinib, but the disease progressed after 30 days. A second biopsy identified a EML4-ALK fusion, which may explain the therapeutic resistance."	23181703	PubMed		"Tanaka et al., 2012, BMC Cancer"		2	accepted	1121	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/1121	https://civicdb.org/links/molecular_profiles/5	FALSE	ALK	238	EML4::ALK	ALK Fusion	chr2	42169350	42295516			ENST00000318522.5	75	ENST00000389048.3	transcript_fusion		2023-01-09 21:52:04 UTC		N/A	EML4-ALK	FALSE
ALK EML4::ALK	5	Lung Acinar Adenocarcinoma	6482		Erlotinib		Predictive	Supports	C	Resistance	"A 39-year-old man presented was observed to have lung acinar adenocarcinoma. Treatment with chemotherapy produced no remarkable response. A EGFR L858R point mutation was observed; the patient was therefore treated with erlotinib, but the disease progressed after 30 days. A second biopsy identified a EML4-ALK fusion, which may explain the therapeutic resistance."	23181703	PubMed		"Tanaka et al., 2012, BMC Cancer"		2	accepted	1121	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/1121	https://civicdb.org/links/molecular_profiles/5	FALSE	ALK	238	EML4::ALK	ALK Fusion	chr2	29192774	29223528			ENST00000318522.5	75	ENST00000389048.3	transcript_fusion		2023-01-09 21:52:04 UTC		N/A	EML4-ALK	FALSE
ERBB2 Amplification	302	Her2-receptor Positive Breast Cancer	60079		Trastuzumab		Predictive	Supports	A	Sensitivity/Response	"HERA was a Phase III trial assessing application of trastuzumab in an extended adjuvant setting.  Patients were HER2 positive with completely excised invasive BC, node positive or negative, and having undergone prior adjuvant or neo-adjuvant chemotherapy.  In the 3 arm study patients were given trastuzumab courses of 1 year, 2 years, or untreated.  At the first planned interim analysis, trastuzumab treatment for one year was compared with observation alone.  A significant difference in disease-free survival was seen with 220 DFS events out of 1693 in the observation arm versus 127 DFS events out of 1694 in the 1 year trastuzumab arm.  1 year adjuvant trastuzumab is currently the standard of care."	16236737	PubMed		"Piccart-Gebhart et al., 2005, N. Engl. J. Med."	NCT00045032	4	accepted	1122	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1122	https://civicdb.org/links/molecular_profiles/302	FALSE	ERBB2	2064	Amplification		chr17	39700080	39728662			ENST00000269571.5	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A	OVEREXPRESSION	FALSE
BRCA1 P968FS	473	Breast Cancer	1612				Predisposing	Supports	C	Predisposition	"A 55-year-old non-Ashkenazi Spanish female diagnosed with breast cancer (at 51 years old) and ovarian cancer. Sequencing of BRCA1 and BRCA2 revealed a 2-base frameshift insertion in BRCA1 (labeled 3020insCT/c.2901insCT in this paper, with the data shown corresponding to a GA insertion, reading left to right in the reference genome, between chr17:43092628-43092629 in GRCh38). This mutation ultimately causes a downstream premature stop codon and truncated BRCA1."	24137399	PubMed		"Salgado et al., 2013, Oncol Lett"		4	accepted	1123	Rare Germline	2023-03-30 18:54:44 UTC	https://civicdb.org/links/evidence_items/1123	https://civicdb.org/links/molecular_profiles/473	FALSE	BRCA1	672	P968FS		chr17	43092628	43092629		GA	ENST00000471181.2	75		frameshift_truncation	"NM_007294.3:c.2902_2903insTC,NP_009225.1:p.Pro968Leufs,NC_000017.10:g.41244645_41244646insGA,ENST00000471181.2:c.2902_2903insTC"	2023-01-27 17:03:58 UTC	CA001889	91602	"3021INSTC,PRO968LEUFS,RS398122670"	FALSE
BRCA1 P968FS	473	Ovarian Cancer	2394				Predisposing	Supports	C	Predisposition	"A 55-year-old non-Ashkenazi Spanish female diagnosed with breast cancer (at 51 years old) and ovarian cancer. Sequencing of BRCA1 and BRCA2 revealed a 2-base frameshift insertion in BRCA1 (labeled 3020insCT/c.2901insCT in this paper, with the data shown corresponding to a GA insertion, reading left to right in the reference genome, between chr17:43092628-43092629 in GRCh38). This mutation ultimately causes a downstream premature stop codon and truncated BRCA1."	24137399	PubMed		"Salgado et al., 2013, Oncol Lett"		4	accepted	1124	Rare Germline	2023-03-30 18:57:10 UTC	https://civicdb.org/links/evidence_items/1124	https://civicdb.org/links/molecular_profiles/473	FALSE	BRCA1	672	P968FS		chr17	43092628	43092629		GA	ENST00000471181.2	75		frameshift_truncation	"NM_007294.3:c.2902_2903insTC,NP_009225.1:p.Pro968Leufs,NC_000017.10:g.41244645_41244646insGA,ENST00000471181.2:c.2902_2903insTC"	2023-01-27 17:03:58 UTC	CA001889	91602	"3021INSTC,PRO968LEUFS,RS398122670"	FALSE
ERBB2 Y772_A775DUP	410	Lung Adenocarcinoma	3910		Trastuzumab Emtansine		Predictive	Supports	C	Sensitivity/Response	"A 51-year old female never smoker with stage IV lung adenocarcinoma carrying a HER2 insertion in exon 20 (p.A775_G776insYVMA) by sequencing archived material, HER2 overexpression by IHC (2+) and HER2 amplification by in situ hybridization was treated with T-DM1 (trastuzumab emtansine). Patient received two cycles off-label at 3.6mg/kg and was found to have morphologic response of lung and bone lesions by PET and CT. TDM-1 therapy was ongoing as of publication April 2015."	25789838	PubMed		"Weiler et al., 2015, J Thorac Oncol"		3	accepted	1125	Somatic	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/1125	https://civicdb.org/links/molecular_profiles/410	FALSE	ERBB2	2064	Y772_A775DUP		chr17	39724743	39724744		TACGTGATGGCT	ENST00000269571.5	75		inframe_insertion	"NM_001005862.2:c.2224_2235dupTACGTGATGGCT,ENST00000269571.5:c.2314_2325dupTACGTGATGGCT,NC_000017.10:g.37880985_37880996dupTACGTGATGGCT,NC_000017.10:g.37880993_37880994insGCTTACGTGATG"	2023-01-27 17:03:37 UTC	CA135369	44985	"A775INSYVMA,P.A775_G776INSYVMA,P.E770_A771INSAYVM,TYR772_ALA775DUP,A775_G776INSYVMA,M774INSAYVM"	FALSE
BRAF V600E	12	Hairy Cell Leukemia	285				Diagnostic	Supports	B	Positive	"In 47 patients with Hairy Cell Leukemia, sequencing discovered a V600E mutation in all 47 of the sequenced patients."	21663470	PubMed		"Tiacci et al., 2011, N. Engl. J. Med."		4	accepted	1127	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/1127	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
EGFR VIII	308	Glioblastoma	3068		"Erlotinib,Gefitinib"	Substitutes	Predictive	Supports	B	Sensitivity/Response	Expression of EGFRvIII and PTEN was evaluated in 26 patients with glioblastomas treated with erlotinib or gefitinib and no EGFR or Her2/neu kinase domain mutations. 7 patients responded to treatment while 19 progressed rapidly. Coexpression of EGFRvIII and PTEN was associated with clinical response (defined as 25% tumor shrinkage). These results were confirmed using IHC in an independent cohort of 33 patients (8 responders) treated with erlotinib at another institution.	16282176	PubMed		"Mellinghoff et al., 2005, N. Engl. J. Med."		3	accepted	1128	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/1128	https://civicdb.org/links/molecular_profiles/308	FALSE	EGFR	1956	VIII		chr7	55019365	55155830			ENST00000275493.2	75		disruptive_inframe_deletion	"NM_005228.3:c.89_881del,NP_005219.2:p.Val30_Arg297delinsGly,NC_000007.13:g.55209979_55221845del"	2023-01-09 21:52:06 UTC				FALSE
PTEN Expression	309	Glioblastoma	3068		"Gefitinib,Erlotinib"	Substitutes	Predictive	Supports	B	Sensitivity/Response	Expression of EGFRvIII and PTEN was evaluated in 26 patients with glioblastomas treated with erlotinib or gefitinib and no EGFR or Her2/neu kinase domain mutations. 7 patients responded to treatment while 19 progressed rapidly. Coexpression of EGFRvIII and PTEN was associated with clinical response (defined as 25% tumor shrinkage). These results were confirmed using IHC in an independent cohort of 33 patients (8 responders) treated with erlotinib at another institution.	16282176	PubMed		"Mellinghoff et al., 2005, N. Engl. J. Med."		3	accepted	1129	N/A	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/1129	https://civicdb.org/links/molecular_profiles/309	FALSE	PTEN	5728	Expression		chr10	87863113	87971930			ENST00000371953.3	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
KRAS Q22*	475	Colon Mucinous Adenocarcinoma	3029		Panitumumab		Predictive	Supports	C	Resistance	"A 43-year-old female was diagnosed with an adenocarcinoma of the ascending colon and received 6-months of adjuvant chemotherapy. After 5 years of completion of adjuvant chemotherapy, the disease relapsed. EGFR was assessed by immunohistochemistry, and the patient was subsequently treated with the anti-EGFR monoclonal antibody panitumumab. However, there was a rapid clinical worsening, which may possibly be attributed to a somatic mutation in KRAS (Q22*)."	19661358	PubMed		"Palmirotta et al., 2009, Anticancer Res."		2	accepted	1131	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1131	https://civicdb.org/links/molecular_profiles/475	FALSE	KRAS	3845	Q22*		chr12	25245321	25245321	G	A	ENST00000256078.4	75		stop_gained	"ENST00000256078.4:c.64C>T,NC_000012.11:g.25398255G>A,NM_004985.4:c.64C>T,NP_004976.2:p.Gln22Ter"	2023-01-27 17:03:59 UTC	CA384157370	NONE FOUND	"Q22X,GLN22TER"	FALSE
ERBB2 Amplification	302	Her2-receptor Positive Breast Cancer	60079		"Capecitabine,Lapatinib"	Combination	Predictive	Supports	B	Sensitivity/Response	"This Phase III trial took patients with locally advanced or metastatic HER2 (ERBB2) positive breast cancer that had progressed on prior trastuzumab treatment.  Patients were given capecitabine (n=161) or lapatinib plus capecitabine (n=163). The primary endpoint of the study was time to progression. Median time to progression was 4.4 months in the capecitabine group and 8.4 months in capecitabine plus lapatinib group (hazard ratio was 0.49 ; 95% confidence interval, 0.34 to 0.71; P<0.001).  The results indicated that lapatinib may be useful in addressing the problem of trastuzumab progression in HER2 breast cancer."	17192538	PubMed		"Geyer et al., 2006, N. Engl. J. Med."	NCT00078572	4	accepted	1132	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1132	https://civicdb.org/links/molecular_profiles/302	FALSE	ERBB2	2064	Amplification		chr17	39700080	39728662			ENST00000269571.5	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A	OVEREXPRESSION	FALSE
ERBB2 Amplification	302	Her2-receptor Positive Breast Cancer	60079		"Capecitabine,Trastuzumab"	Combination	Predictive	Supports	B	Sensitivity/Response	"In this Phase III trial, trastuzumab-based treatment was assessed in women with locally advanced or metastatic HER2 positive breast cancer who had progressed on trastuzumab.  Patients had 12 weeks or greater previous trastuzumab treatment with time since end of last cycle less than 6 weeks.  Primary endpoint was time to progression.  78 patients were assigned to each group, with median time to progression of 5.6 months in capecitabine group and 8.2 months in trastuzumab plus capecitabine group.  The results are in contrast to the principle of change of treatment on disease progression, and authors suggest that chemotherapy-sensitizing mechanisms of trastuzumab remain intact in HER2 breast cancer cells with trastuzumab progression."	19289619	PubMed		"von Minckwitz et al., 2009, J. Clin. Oncol."		4	accepted	1133	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1133	https://civicdb.org/links/molecular_profiles/302	FALSE	ERBB2	2064	Amplification		chr17	39700080	39728662			ENST00000269571.5	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A	OVEREXPRESSION	FALSE
DDX43 Overexpression	477	Uveal Melanoma	6039		"Selumetinib,Mirdametinib,Trametinib"	Substitutes	Predictive	Supports	D	Resistance	"MEK inhibitor-resistant (selumetinib, PD0325901, GSK1129212) uveal melanoma cell lines were created from two GNAQ Q209L mutant cell lines. Overexpression of DDX43 mediated RAS-induced selumetinib resistance as demonstrated by depletion of DDX43 decreasing RAS proteins and ectopic expression of DDX43 induced RAS protein levels. These results were confirmed using biopsies from liver metastases in 14 patients with uveal melanoma harboring GNAQ or GNA11 mutations who were treated on a phase II study of selumetinib. 6 patients with partial response or stable disease for ?6 weeks, were defined as responders?(R), 8 patients who had disease progression before 16 weeks were defined as nonresponders?(NR). DDX43 Expression (qPCR) was higher in nonresponders (P = 0.045). Liver metastasis biopsy samples (3 R and 3 NR) were immunoblotted for DDX43, pERK and RAS proteins with consistent results."	24899684	PubMed		"Ambrosini et al., 2014, Mol. Cancer Ther."		4	accepted	1135	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1135	https://civicdb.org/links/molecular_profiles/477	FALSE	DDX43	55510	Overexpression		chr6	73394748	73417569			ENST00000370336.4	75		N/A		2023-01-09 21:52:07 UTC		N/A		FALSE
KIT RS3733542	478	Acute Myeloid Leukemia	9119		Selumetinib		Predictive	Supports	B	Sensitivity/Response	"Patients with relapsed/refractory AML or 60 years old or more with untreated AML were enrolled on a phase II study of selumetinib and analyzed for mutations in KIT, NRAS, KRAS and FLT3. KIT mutation analysis (N=41) revealed the presence of a synonymous SNP rs3733542 (known population frequency of 20%) in exon 18 of the KIT gene in six of ten (60%) patients assessed as having a response or disease stabilization to selumetinib. In contrast, this SNP was detected in only seven of 31 (23%) patients without a response or disease stabilization (P = 0.027, Chi-squared test)."	24178622	PubMed		"Jain et al., 2014, Clin. Cancer Res."		1	accepted	1136	Common Germline	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1136	https://civicdb.org/links/molecular_profiles/478	FALSE	KIT	3815	RS3733542		chr4	54736599	54736599	G	C	ENST00000288135.5	75		synonymous_variant	"NM_000222.2:c.2586G>C,NP_000213.1:p.Leu862=,ENST00000288135.5:c.2586G>C,NC_000004.11:g.55602765G>C"	2023-01-27 17:04:01 UTC	CA2923796	255572	LEU862=	FALSE
FLT3 ITD	55	Acute Myeloid Leukemia	9119		Selumetinib		Predictive	Supports	B	Resistance	"Forty-seven patients with relapsed/refractory AML or 60+ years old with untreated AML were enrolled on a phase II study. In FLT3 wild-type patients, six out of 36 (17%) had a response (1 PR, 3 MR, 2 uMR) that lasted a median of 58 days (range, 33?73 days). No patient with FLT3-ITD (n = 10) responded. One patient with unknown FLT3 status also had no response. Of note, this study did not meet its primary endpoint of 6 responses (CR, CRi, PR or MR) in the first 35 patients enrolled."	24178622	PubMed		"Jain et al., 2014, Clin. Cancer Res."		2	accepted	1137	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/1137	https://civicdb.org/links/molecular_profiles/55	FALSE	FLT3	2322	ITD		chr13	28034082	28034214			ENST00000241453.7	75		inframe_insertion		2023-01-09 21:52:04 UTC		16270		FALSE
TBK1 Overexpression	479	Melanoma	1909		"Selumetinib,AZ909"	Combination	Predictive	Supports	D	Sensitivity/Response	"Preclinical study in melanoma cell lines. TBK1 depletion (siRNA) inhibited migration and invasion, whereas its constitutive overexpression led to an increase in invasion. In MEK-resistant NRAS mutant melanoma cell lines, TBK1 depletion or inhibition (AZ909) in combination with MEK inhibitors (selumetinib) promoted apoptosis in 3D culture."	24962318	PubMed		"Vu et al., 2014, Mol. Cancer Res."		2	accepted	1138	N/A	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1138	https://civicdb.org/links/molecular_profiles/479	FALSE	TBK1	29110	Overexpression		chr12	64451880	64502108			ENST00000331710.5	75		N/A		2023-01-09 21:52:07 UTC		N/A		FALSE
KRAS Mutation	332	Colorectal Cancer	9256		"Chemotherapy,Bevacizumab"	Combination	Predictive	Supports	B	Resistance	"Meta-Analysis of 12 studies with 2,266 patients (54 % were KRAS wt). The pooled response rates (RR) for KRAS wild-type (wt) versus mutated (mut) patients were 54.8 and 48.3 %, respectively (OR 1.42, P = 0.02). Median PFS in KRAS wild-type patients was significantly longer than in KRAS mut patients (HR = 0.85; 95 % confidence interval (CI) 0.74-0.98; P = 0.02). Median OS in wild-type KRAS patients compared was significantly better than in KRAS mut patients (HR = 0.65; 95 % CI 0.46-0.92; P = 0.01)."	23828442	PubMed		"Petrelli et al., 2013, Med. Oncol."		4	accepted	1139	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/1139	https://civicdb.org/links/molecular_profiles/332	FALSE	KRAS	3845	Mutation		chr12	25209431	25250803			ENST00000256078.4	75		protein_altering_variant		2023-01-09 21:52:06 UTC		N/A		FALSE
KRAS Mutation	332	Cancer	162		"MEK Inhibitor GDC-0623,G-573"	Substitutes	Predictive	Supports	D	Sensitivity/Response	"Preclinical study analyzing the differential response to MEK Inhibitors in KRAS and BRAF mutant cancer cell lines and mouse xenografts. Efficacy of MEK inhibitors (GDC-0623 and G-573) in KRAS-driven tumours is mediated by a hydrogen-bond interaction with S212 in MEK that is critical for blocking MEK feedback phosphorylation by wild-type RAF. This mechanism was distinct from GDC-0973 which is less potent in KRAS mutant tumors. Overall, this work indicates that MEK inhibitors with this mechanism of action will be most effective in patients with both BRAF and KRAS mutations."	23934108	PubMed		"Hatzivassiliou et al., 2013, Nature"		3	accepted	1140	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/1140	https://civicdb.org/links/molecular_profiles/332	FALSE	KRAS	3845	Mutation		chr12	25209431	25250803			ENST00000256078.4	75		protein_altering_variant		2023-01-09 21:52:06 UTC		N/A		FALSE
BRAF V600E	12	Cancer	162		Cobimetinib		Predictive	Supports	D	Sensitivity/Response	"Preclinical study analyzing the differential response to MEK inhibitors in KRAS and BRAF mutant cancer cell lines and mouse xenografts. Inhibition of active, phosphorylated MEK by GDC-0973 (cobimetinib) is required for strong inhibition of the MAPK pathway in BRAF-mutant tumours. This study provides mechanistic rationale for improved efficacy of cobimetinib in BRAF-mutant models compared to MEK inhibitors acting through an alternative mechanism (GDC-0623 and G-573)."	23934108	PubMed		"Hatzivassiliou et al., 2013, Nature"		3	accepted	1141	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/1141	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
KRAS G12C	78	Lung Non-small Cell Carcinoma	3908		"Selumetinib,Docetaxel"	Combination	Predictive	Supports	B	Sensitivity/Response	"83 patients from a phase II trial (docetaxel + placebo or MEK1/2 inhibitor selumetinib) with KRAS mutant tumors were retrospectively assessed for differences in OS, PFS, ORR and change in tumor size at week 6 according to type of KRAS mutation. G12C, G12D and G12V were the most common mutations (46%, 22%, 11%, respectively). Patients with G12C or G12V mutations receiving selumetinib and docetaxel combined treatment had a trend towards longer OS, PFS and ORR compared to other KRAS mutations, but the differences did not reach statistical significance. Changes in tumor size were similar between groups with the best responses in tumors with G12V mutations. Few differences were observed between groups when treated with docetaxel + placebo."	26125448	PubMed		"Jnne et al., 2015, Br. J. Cancer"	NCT00890825	2	accepted	1142	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/1142	https://civicdb.org/links/molecular_profiles/78	FALSE	KRAS	3845	G12C	EGFR TKI Resistance	chr12	25245351	25245351	C	A	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.34G>T,NP_004976.2:p.Gly12Cys,NC_000012.11:g.25398285C>A,ENST00000256078.4:c.34G>T"	2023-01-27 17:02:26 UTC	CA122528	12578	"GLY12CYS,RS121913530"	FALSE
KRAS G12V	421	Lung Non-small Cell Carcinoma	3908		"Docetaxel,Selumetinib"	Combination	Predictive	Supports	B	Sensitivity/Response	"83 patients from a phase II trial (docetaxel + placebo or selumetinib) with KRAS mutant tumors were retrospectively assessed for differences in OS, PFS, ORR and change in tumor size at week 6 according to type of KRAS mutation. G12C, G12D and G12V were the most common mutations (46%, 22%, 11%, respectively). Patients with G12C or G12V mutations receiving combination selumetinib and docetaxel had a trend towards longer OS, PFS and ORR compared to other KRAS mutations. Changes in tumor size were similar between groups with the best responses in tumors with G12V mutations. Few differences were observed between groups when treated with docetaxel + placebo."	26125448	PubMed		"Jnne et al., 2015, Br. J. Cancer"	NCT00890825	1	accepted	1143	Somatic	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/1143	https://civicdb.org/links/molecular_profiles/421	FALSE	KRAS	3845	G12V		chr12	25245350	25245350	C	A	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.35G>T,NP_004976.2:p.Gly12Val,NC_000012.11:g.25398284C>A,ENST00000256078.4:c.35G>T"	2023-01-27 17:03:41 UTC	CA122540	12583	"GLY12VAL,RS121913529"	FALSE
STK11 Loss	481	Lung Non-small Cell Carcinoma	3908		"Docetaxel,Selumetinib"	Combination	Predictive	Supports	D	Resistance	A clinical trial comparing selumetinib and docetaxel vs. docetaxel and placebo in KRAS mutant NSCLC was recapitulated in mice. Tumors were induced in lung epithelium by nasal instillation of CRE-bearing adenovirus in conditionally targeted mice. Kras(G12D) and Lkb1 (STK11) knockout mutant mice showed only mild response to combined treatment and very low response rates to docetaxel monotherapy compared to mice with Kras(G12D) alone or Kras(G12D) and Trp53 knockout. In a small number of human NSCLC patients with these genotypes FDG-PET signal intensity changes and pERK IHC staining correlated with mouse data.	22425996	PubMed		"Chen et al., 2012, Nature"		3	accepted	1144	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1144	https://civicdb.org/links/molecular_profiles/481	FALSE	STK11	6794	Loss		chr19	1205741	1228429			ENST00000326873.7	75		loss_of_function_variant		2023-01-09 21:52:07 UTC		N/A		FALSE
TP53 Mutation	222	Lung Non-small Cell Carcinoma	3908		"Docetaxel,Selumetinib"	Combination	Predictive	Supports	D	Sensitivity/Response	A clinical trial comparing selumetinib and docetaxel vs. docetaxel and placebo in KRAS mutant NSCLC was recapitulated in mice. Tumors were induced in lung epithelium by nasal instillation of CRE-bearing adenovirus in conditionally targeted mice. Kras(G12D) and Trp53 knockout mutant mice were resistant to docetaxel monotherapy but sensitive to combined treatment. In a small number of human NSCLC patients with these genotypes FDG-PET signal intensity changes and pERK IHC staining correlated with mouse data.	22425996	PubMed		"Chen et al., 2012, Nature"		3	accepted	1145	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/1145	https://civicdb.org/links/molecular_profiles/222	FALSE	TP53	7157	Mutation		chr17	7668402	7687538			ENST00000269305.4	75		protein_altering_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
TP53 Deleterious Mutation	221	Lung Non-small Cell Carcinoma	3908				Prognostic	Does Not Support	B	Poor Outcome	"Pooled analysis of TP53 mutations (exons 5-8) from 4 randomized trials (IALT, JBR10, CALGB-9633 and ANITA). Mutations (434; 36%) had no prognostic effect (OBS: HROS=0.99; [95%CI 0.77-1.28], p=0.95; HRDFS=0.99 [0.78-1.25], p=0.92) but were marginally predictive of benefit from ACT for OS (test for interaction: OS: p=0.06; DFS: p=0.11)."	26899019	PubMed		"Ma et al., 2016, J Thorac Oncol"		4	accepted	1147	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/1147	https://civicdb.org/links/molecular_profiles/221	FALSE	TP53	7157	Deleterious Mutation		chr17	7668402	7687538			ENST00000269305.4	75		N/A		2023-01-09 21:52:05 UTC				FALSE
TP53 Deleterious Mutation	221	Lung Non-small Cell Carcinoma	3908		Adjuvant Chemotherapy		Predictive	Does Not Support	B	Sensitivity/Response	"Pooled analysis of TP53 mutations (exons 5-8) from 4 randomized trials (IALT, JBR10, CALGB-9633 and ANITA) of platinum-based adjuvant chemotherapy (ACT) versus observation (OBS). Patients with TP53wt had significantly better PFS and OS with ACT vs. OBS (p=0.005, p=0.02, respectively) whereas patients with TP53 mutations did not show significant differences in PFS and OS between ACT and OBS (p=0.86, p=0.63)."	26899019	PubMed		"Ma et al., 2016, J Thorac Oncol"		2	accepted	1148	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/1148	https://civicdb.org/links/molecular_profiles/221	FALSE	TP53	7157	Deleterious Mutation		chr17	7668402	7687538			ENST00000269305.4	75		N/A		2023-01-09 21:52:05 UTC				FALSE
TP53 Wildtype	365	Lung Non-small Cell Carcinoma	3908		Adjuvant Chemotherapy		Predictive	Supports	B	Sensitivity/Response	"Pooled analysis of TP53 mutations (exons 5-8) from 4 randomized trials (IALT, JBR10, CALGB-9633 and ANITA, 1209 patients, median follow-up 5.5 years) of platinum-based adjuvant chemotherapy (ACT) versus observation (OBS). Patients with wild-type TP53 had better outcomes with ACT than OBS (HROS=0.77 [0.62-0.95], p=0.02; HRDFS=0.75 [0.62-0.92], p=0.005)."	26899019	PubMed		"Ma et al., 2016, J Thorac Oncol"		3	accepted	1149	N/A	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/1149	https://civicdb.org/links/molecular_profiles/365	FALSE	TP53	7157	Wildtype		chr17	7668402	7687538			ENST00000269305.4	75		wild_type		2023-01-09 21:52:06 UTC		N/A		FALSE
HAVCR2 Overexpression	482	Lung Non-small Cell Carcinoma	3908		PD1 Inhibitor		Predictive	Supports	C	Resistance	"In a preclinical study in an immunocompetent mouse model of lung adenocarcinoma, upregulation of alternative immune checkpoints, notably T-cell immunoglobulin mucin-3 (TIM-3, aka HAVCR2) was observed after progression under PD-1 antibody. A survival advantage was observed with the addition of a TIM-3 blocking antibody. Two patients who developed adaptive resistance to anti-PD-1 treatment also showed TIM-3 upregulation in blocking antibody-bound T cells at treatment failure."	26883990	PubMed		"Koyama et al., 2016, Nat Commun"		3	accepted	1150	N/A	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1150	https://civicdb.org/links/molecular_profiles/482	FALSE	HAVCR2	84868	Overexpression		chr5	157085832	157109714			ENST00000307851.4	75		N/A		2023-01-09 21:52:07 UTC		N/A		FALSE
HAVCR2 Overexpression	482	Lung Non-small Cell Carcinoma	3908		"PD1 Inhibitor,Anti-TIM-3 Monoclonal Antibody"	Combination	Predictive	Supports	D	Sensitivity/Response	"In a preclinical study in an immunocompetent mouse model of lung adenocarcinoma, upregulation of alternative immune checkpoints, notably T-cell immunoglobulin mucin-3 (TIM-3, aka HAVCR2) was observed after progression under PD-1 antibody. A survival advantage was observed with the addition of a TIM-3 blocking antibody."	26883990	PubMed		"Koyama et al., 2016, Nat Commun"		3	accepted	1151	N/A	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1151	https://civicdb.org/links/molecular_profiles/482	FALSE	HAVCR2	84868	Overexpression		chr5	157085832	157109714			ENST00000307851.4	75		N/A		2023-01-09 21:52:07 UTC		N/A		FALSE
ERBB3 Overexpression	285	Cancer	162		"Afatinib,Selumetinib"	Combination	Predictive	Supports	D	Sensitivity/Response	"Preclinical study in KRAS mutant lung and colon cancer models. A synthetic lethal screen using a total of 3,530 shRNAs to target 518 human kinases identified ERBB3 knockdown to confer sensitivity of selumetinib-resistant H358 cells (NSCLC cell line) to the MEK inhibitor selumetinib. The dual EGFR-ERBB2 inhibitors afatinib and dacomitinib each showed synergy with MEK Inhibition via selumetinib in 4 KRAS mutant cell lines. Western blot evaluation of 9 NSCLC and 12 CRC cell lines showed ERBB3 expression correlated with the synergy score for combination afatinib and trametinib treatment. I.e. the synergy score was low in cells having low basal levels of ERBB3 protein and high for cells having high basal ERBB3 expression. Using selumetinib in patient-derived CRC xenografts or trametinib in NSCLC xenografts, MEK inhibition by selumetinib or trametinib in combination with afatinib more effectively inhibited increases in tumor volume than either monotherapy."	24685132	PubMed		"Sun et al., 2014, Cell Rep"		3	accepted	1152	N/A	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1152	https://civicdb.org/links/molecular_profiles/285	FALSE	ERBB3	2065	Overexpression		chr12	56079861	56103505			ENST00000267101.3	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
ERBB3 Overexpression	285	Cancer	162		"Selumetinib,HER2 Inhibitor CP-724,714,Gefitinib"	Substitutes	Predictive	Supports	D	Resistance	Preclinical study in KRAS mutant lung and colon cancer models. A synthetic lethal screen identified ERBB3 blockade to confer sensitivity to MEK inhibitors. The dual EGFR-ERBB2 (both forming heterodimers with ERBB3) inhibitors afatinib and dacomitinib each showed strong synergy with MEK Inhibition (trametinib or selumetinib) in several KRAS mutant cell lines. MEK Inhibitors alone or the combination with gefitinib (EGFRi) or CP724714 (ERBB2i) showed strong synergy. Results were validated in-vivo. Basal ERBB3 expression was associated with higher synergy scores.	24685132	PubMed		"Sun et al., 2014, Cell Rep"		4	accepted	1153	N/A	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1153	https://civicdb.org/links/molecular_profiles/285	FALSE	ERBB3	2065	Overexpression		chr12	56079861	56103505			ENST00000267101.3	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
CDKN2A p16 Expression	268	Head And Neck Squamous Cell Carcinoma	5520		Afatinib		Predictive	Supports	B	Resistance	"Phase III trial to compare afatinib or metothrexate in recurrent or metastatic head and neck squamous cell carcinoma. 483 patients were randomized to either afatinib (n=322) or methotrexate (n=161). 285 patients were assessed for p16 Status (IHC). In the post-hoc analysis, benefit of afatinib compared with methotrexate was more pronounced in p16-negative disease (HR 069 [95% CI 050?96], p=0.022) than in p16-positive disease (HR 095 [CI 051?75], p=0.67, interaction test p=032)."	25892145	PubMed		"Machiels et al., 2015, Lancet Oncol."	NCT01345682	2	accepted	1155	N/A	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1155	https://civicdb.org/links/molecular_profiles/268	FALSE	CDKN2A	1029	p16 Expression		chr9	21968056	21974866			ENST00000498124.1	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
MMP2 SERUM LEVELS	483	Inflammatory Breast Carcinoma	6263		Bevacizumab		Predictive	Supports	B	Sensitivity/Response	"MMP2 serum levels were assessed (ELISA) at baseline (b) and before surgery in 45 available samples from patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant therapy. High bMMP2 was correlated with better disease-free survival (DFS, p=0.001) and overall survival (OS, p=0.032). Correlation to DFS was also found after multivariate analysis (p=0.003, Hazard Ratio [HR]: 0.115). bMMP2 was associated with relapse (p=0.002) and death (p=0.049). During treatment, significant increase in MMP2 was observed in 100% of patients."	26921265	PubMed		"Tabouret et al., 2016, Oncotarget"		3	accepted	1156	N/A	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1156	https://civicdb.org/links/molecular_profiles/483	FALSE	MMP2	4313	SERUM LEVELS		chr16	55478971	55506691			ENST00000219070.4	75		N/A		2023-01-09 21:52:07 UTC				FALSE
MMP9 SERUM LEVELS	484	Inflammatory Breast Carcinoma	6263		Bevacizumab		Predictive	Supports	B	Resistance	"MMP9 serum levels were assessed (ELISA) at baseline (b) and before surgery in 45 available samples from patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant therapy. Low bMMP9 was correlated with better OS (p=0.022) and non-significantly associated with longer DFS (p=0.071). Correlation to DFS was also found after multivariate analysis (p=0.041, HR: 3.511). bMMP9 was associated with death (p=0.035). During treatment, a significant decrease in MMP9 levels (p<0.001) was observed in 87% of patients."	26921265	PubMed		"Tabouret et al., 2016, Oncotarget"		3	accepted	1157	N/A	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1157	https://civicdb.org/links/molecular_profiles/484	FALSE	MMP9	4318	SERUM LEVELS		chr20	46008908	46016561			ENST00000372330.3	75		N/A		2023-01-09 21:52:07 UTC				FALSE
MMP2 SERUM LEVELS	483	Brain Glioma	60108		Bevacizumab		Predictive	Supports	B	Sensitivity/Response	"Plasma levels of 11 potential biomarkers were tested at baseline and 2 weeks after bevacizumab initiation in a prospective cohort of 26 patients with recurrent high-grade gliomas. Results were validated in a separate retrospective cohort (n = 50) and also tested in patients treated with cytotoxic agents without bevacizumab (n = 34). MMP2 level was correlated with PFS (hazard ratio, 3.92; 95% confidence interval [CI]:1.46-10.52; P = .007) and OS (hazard ratio, 4.62; 95% CI: 1.58-13.53; P = .005) in the discovery and validation cohorts but not in patients treated without bevacizumab."	24327581	PubMed		"Tabouret et al., 2014, Neuro-oncology"		2	accepted	1158	N/A	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1158	https://civicdb.org/links/molecular_profiles/483	FALSE	MMP2	4313	SERUM LEVELS		chr16	55478971	55506691			ENST00000219070.4	75		N/A		2023-01-09 21:52:07 UTC				FALSE
ERBB2 Amplification	302	Her2-receptor Positive Breast Cancer	60079		Trastuzumab Emtansine		Predictive	Supports	B	Sensitivity/Response	"The Phase III trial, TH3RESA (NCT01419197), was performed in patients with advanced HER2 breast cancer that was heavily pretreated.  Patients were required to have prior exposure to trastuzumab and lapatinib as well as a taxane.  This patient population has not seen many studies, responds poorly to late-line treatment with trastuzumab, and in this study was treated with trastuzumab emtansine (T-DM1, n=404) vs. physician's choice (usually trastuzumab plus chemotherapy, n=198).  Results showed progression free survival was 6.2 months in T-DM1 treatment vs. 3.3 months under physician's choice, along with lower incidence of grade 3 or worse events with T-DM1.  The authors conclude that their findings in this heavily pretreated population, along with findings in the EMILIA trial, indicate promise for antibody-drug conjugates.  The NCI-MATCH trial with further study T-DM1 in the context of HER2 amplification."	24793816	PubMed		"Krop et al., 2014, Lancet Oncol."	NCT01419197	4	accepted	1159	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1159	https://civicdb.org/links/molecular_profiles/302	FALSE	ERBB2	2064	Amplification		chr17	39700080	39728662			ENST00000269571.5	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A	OVEREXPRESSION	FALSE
ERBB2 Amplification	302	Her2-receptor Positive Breast Cancer	60079		Trastuzumab Emtansine		Predictive	Supports	B	Sensitivity/Response	"The EMILIA study (NCT00829166) was a Phase II trial to assess the efficacy of trastuzumab emtansine (T-DM1, n=495) in comparison to lapatinib plus capecitabine (n=496), in treatment of advanced HER2 positive breast cancer.  Patients were required to have progressed on or after treatments involving trastuzumab and a taxane, and no prior exposure to lapatinib or T-DM1.   Primary endpoints included independently assessed progression free survival (PFS) and safety. PFS was 9.6 months in T-DM1 group vs. 6.4 months in lapatinib plus capecitabine.  Rates of adverse events of grade 3 or higher were greater with lapatinib plus capecitabine.  These results, together with other trials such as TH3RESA indicate promise for T-DM1 therapy in HER2 amplification, and this will be further studied in an arm of the NCI-MATCH trial."	23020162	PubMed		"Verma et al., 2012, N. Engl. J. Med."	NCT00829166	4	accepted	1160	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1160	https://civicdb.org/links/molecular_profiles/302	FALSE	ERBB2	2064	Amplification		chr17	39700080	39728662			ENST00000269571.5	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A	OVEREXPRESSION	FALSE
ACTA1 EXPRESSION	542	Lung Adenocarcinoma	3910				Prognostic	Supports	B	Poor Outcome	"ActA level was measured in serum and plasma samples of 64/87 lung adenocarcinoma patients and 46/66 age- and gender-matched controls (ELISA). ActA Levels were higher in patients than in controls and were significantly correlated with disease stage and metastasis. Patients were stratified as having high or low ActA levels using the median expression level. LADC patients with high serum or plasma ActA levels had significantly shorter OS than those with low circulating ActA concentrations (p < 0.0001 in both) and were identified as an independent prognostic factor (p=0.004 and p=0.002, respectively)."	26950277	PubMed		"Hoda et al., 2016, Oncotarget"		2	accepted	1161	N/A	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1161	https://civicdb.org/links/molecular_profiles/542	FALSE	ACTA1	58	EXPRESSION		chr1	229431245	229434094			ENST00000366684.3	75		N/A	N/A	2023-01-09 21:52:07 UTC		N/A		FALSE
HSPH1 NUCLEAR EXPRESSION	486	Gastric Adenocarcinoma	3717				Prognostic	Supports	B	Poor Outcome	"HSP110 (HSPH1) expression was immunohistochemically assessed using a tissue microarray in 210 gastric cancer patients. The overall survival rate was significantly lower in patients with high nuclear expression (N=121, 2+ moderate/3+ strong staining) than patients with low nuclear staining (N=89, 0 no/1+ weak staining)(P = 0.0169). Multivariate regression analysis identified expression of nuclear HSP110 as an independent prognostic factor for gastric cancer outcome (P = 0.0068). This was not found for cytoplasmic expression."	26943774	PubMed		"Kimura et al., 2016, Oncotarget"		2	accepted	1162	N/A	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1162	https://civicdb.org/links/molecular_profiles/486	FALSE	HSPH1	10808	NUCLEAR EXPRESSION		chr13	31136628	31161927			ENST00000320027.5	75		N/A		2023-01-09 21:52:07 UTC				FALSE
HSPH1 NUCLEAR EXPRESSION	486	Gastric Adenocarcinoma	3717		"Cisplatin,Fluorouracil"	Substitutes	Predictive	Supports	D	Sensitivity/Response	"49 patients gastric cancer patients treated with adjuvant chemotherapy were immunohistochemically assessed for nuclear HSPH1 (HSP110) expression. Overall survival rate in the high expression group (2+ moderate/3+ strong staining) was significantly lower compared with the low expression group (0 no/1+ weak staining) (P = 0.0364). In gastric cancer cell lines (MKN7, MKN45), siRNA mediated HSP110 knockdown led to a higher sensitivity to 5-FU and cisplatin compared with the parent and control cells (p < 0.05)."	26943774	PubMed		"Kimura et al., 2016, Oncotarget"		1	accepted	1163	N/A	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1163	https://civicdb.org/links/molecular_profiles/486	FALSE	HSPH1	10808	NUCLEAR EXPRESSION		chr13	31136628	31161927			ENST00000320027.5	75		N/A		2023-01-09 21:52:07 UTC				FALSE
HSPH1 T17 DELETION	487	Colorectal Cancer	9256		"Oxaliplatin,Fluorouracil"	Combination	Predictive	Supports	B	Sensitivity/Response	"329 consecutive patients with stage IIIII colorectal tumors with MSI after surgical resection at tertiary medical centers were screened for HSP110 T(17) by PCR. Patients underwent adjuvant chemotherapy with 5-fluorouracil and oxaliplatin. Patients with large HSP110 T(17) deletions (? bp; 18 of 77 patients, 23.4%) had longer times of relapse-free survival than patients with small or no deletions (? bp; 59 of 77 patients, 76.6%) in multivariate analysis (hazard ratio, 0.16; 95% confidence interval, 0.012?.8; P = .03). A significant interaction between chemotherapy and T17 deletion was found (P =.009)."	24512910	PubMed		"Collura et al., 2014, Gastroenterology"		2	accepted	1164	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1164	https://civicdb.org/links/molecular_profiles/487	FALSE	HSPH1	10808	T17 DELETION		chr13	31148484	31148500			ENST00000320027.5	75		short_tandem_repeat_variation		2023-01-09 21:52:07 UTC				FALSE
ROBO4 EXPRESSION	489	Cancer	162		Angiogenesis Inhibitor		Predictive	Does Not Support	B	Sensitivity/Response	"Biomarkers for Response to antiangiogenic treatment were screened for in hepatocellular cancer (n = 11), renal cell cancer (n = 7) and non-small cell lung cancer (n = 2). Increased expression of tumor endothelial markers: Robo4 and ECSCR, nonsignificantly correlated with prolonged antiangiogenic time to progression (ECSCR high = 275 days vs. ECSCR low = 92.5 days; p = 0.07 and for Robo4 high = 387 days vs. Robo4 low = 90.0 days; p = 0.08)."	26956051	PubMed		"Pircher et al., 2016, Oncotarget"		1	accepted	1166	N/A	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1166	https://civicdb.org/links/molecular_profiles/489	FALSE	ROBO4	54538	EXPRESSION		chr11	124883691	124898281			ENST00000306534.3	75		N/A		2023-01-09 21:52:07 UTC				FALSE
CD274 Expression	272	Lung Non-small Cell Carcinoma	3908		"Pembrolizumab,Atezolizumab,Avelumab,Nivolumab"	Substitutes	Predictive	Supports	B	Sensitivity/Response	"Meta-Analysis of PD-L1 (CD274) Expression Status in 914 patients (7 studies) and response to PD-1/PD-L1 monoclonal antibodies. Patients with PD-L1 positive tumors (PD-L1 tumor cell staining ?%), had a significantly higher ORR, compared to patients with PD-L1 negative tumors (OR: 2.44; 95% CIs: 1.61-3.68)."	26918451	PubMed		"Passiglia et al., 2016, Oncotarget"		4	accepted	1167	N/A	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1167	https://civicdb.org/links/molecular_profiles/272	FALSE	CD274	29126	Expression		chr9	5450525	5470547			ENST00000381577.3	75		N/A	N/A	2023-01-09 21:52:06 UTC		N/A		FALSE
PIM1 NUCLEAR EXPRESSION	490	Lung Non-small Cell Carcinoma	3908				Prognostic	Supports	B	Poor Outcome	"The expression of PIM1, p-STAT3, and c-MYC was tested (IHC) in 194 NSCLC archival tumor samples. High nuclear expression of PIM1 was detected in 43.3% of cases and was significantly correlated with advanced clinical stage (p<0.001) and poor pathologic differentiation (P = 0.004) and was an independent unfavorable prognostic factors for overall and disease-free survival (OS, P=0.009; DFS, P=0.034)."	26918046	PubMed		"Jiang et al., 2016, J Cancer"		2	accepted	1168	N/A	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1168	https://civicdb.org/links/molecular_profiles/490	FALSE	PIM1	5292	NUCLEAR EXPRESSION		chr6	37170203	37175426			ENST00000373509.5	75		N/A		2023-01-09 21:52:07 UTC		N/A		FALSE
MDM2 SNP309	491	Head And Neck Cancer	11934				Prognostic	Supports	B	Poor Outcome	66 HNSCC patients treated with chemoradiation were assessed for survival after a follow-up time of 10 years. Median OS was significantly shorter in patients with MDM2 SNP309 GG or GT genotypes compared with the TT genotype (p = 0.002).	26916894	PubMed		"Vivenza et al., 2016, Int. J. Biol. Markers"		2	accepted	1169	Common Germline	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1169	https://civicdb.org/links/molecular_profiles/491	FALSE	MDM2	4193	SNP309		chr12	68808800	68808800	T	G	ENST00000462284.1	75		coding_transcript_intron_variant	NC_000012.11:g.69202580T>G	2023-01-27 17:04:02 UTC	CA123622	13904		FALSE
TP53 Deleterious Mutation	221	Sarcoma	1115		Pazopanib		Predictive	Supports	B	Sensitivity/Response	"19 advanced sarcoma patients treated with pazopanib were retrospectively assessed for mutations associated with response using the Foundation one sarcoma/heme panel. Progression-free survival (PFS) of patients with TP53 mutations (all predicted to be loss of function) was significantly greater than TP53 wild-type tumors with the median PFS of 208 versus 136 days, respectively [P = 0.036, hazards ratio 0.38 (95% confidence interval 0.09-0.83)]."	26646755	PubMed		"Koehler et al., 2016, Ann. Oncol."		2	accepted	1170	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/1170	https://civicdb.org/links/molecular_profiles/221	FALSE	TP53	7157	Deleterious Mutation		chr17	7668402	7687538			ENST00000269305.4	75		N/A		2023-01-09 21:52:05 UTC				FALSE
PIK3CA E545K	104	Lung Adenocarcinoma	3910		Gefitinib		Predictive	Supports	D	Resistance	"HCC827 cell lines harboring activated PI3K (HCC827 p110 E545K cells) were more resistant to gefitinib in vitro (IC50, 1 M) compared with those harboring GFP alone (IC50, 0.01 M). The presence of p110 E545K also protected HCC827 cells from gefitinib-mediated apoptosis."	16906227	PubMed		"Engelman et al., 2006, J. Clin. Invest."		2	accepted	1171	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/1171	https://civicdb.org/links/molecular_profiles/104	FALSE	PIK3CA	5290	E545K		chr3	179218303	179218303	G	A	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.1633G>A,NP_006209.2:p.Glu545Lys,ENST00000263967.3:c.1633G>A,NC_000003.11:g.178936091G>A"	2023-01-27 17:02:37 UTC	CA123334	13655	"GLU545LYS,RS104886003"	FALSE
CD274 Expression	272	Lung Non-small Cell Carcinoma	3908		Atezolizumab		Predictive	Supports	B	Sensitivity/Response	"Exploratory biomarker analysis from a phase-II randomized trial comparing atezolizumab (PD-L1) and docetaxel in previously treated, advanced or metastatic non-small cell lung cancer. Baseline PD-L1 expression (IHC) was assessed in tumour cells (as percentage of PD-L1-expressing tumour cells TC3?0%, TC2?% and <50%, TC1?% and <5%, and TC0<1%) and tumour-infiltrating immune cells (as percentage of tumour area: IC3?0%, IC2?% and <10%, IC1?% and <5%, and IC0<1%). Increasing PD-L1 Expression was associated with improved overall survival (TC3 or IC3 HR 049 [022-107; p=0068], TC2/3 or IC2/3 HR 054 [033-089; p=0014], TC1/2/3 or IC1/2/3 HR 059 [040-085; p=0005], TC0 and IC0 HR 104 [062-175; p=0871]) but not progression free survival or overall response rate."	26970723	PubMed		"Fehrenbacher et al., 2016, Lancet"	NCT01903993	4	accepted	1172	N/A	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1172	https://civicdb.org/links/molecular_profiles/272	FALSE	CD274	29126	Expression		chr9	5450525	5470547			ENST00000381577.3	75		N/A	N/A	2023-01-09 21:52:06 UTC		N/A		FALSE
KRAS G12C	78	Cancer	162		"Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor,ARS-853"	Combination	Predictive	Supports	D	Sensitivity/Response	"Preclinical study to investigate mechanisms of KRAS G12C activity and inhibition with ARS-853, a covalent (irreversible) inhibitor which binds KRAS G12C in the GDP-bound state to prevent activation. Results from a mass spectrometry-based assay to evaluate KRAS activity suggests that G12C mutant KRAS is in a hyperexcitable?rather than a statically active?state. ARS-853 targets the inactive state and inhibited proliferation in a subset  (3/11) of KRAS G12C mutant cell lines in 2-D growth assays and 11/11 cell lines in soft-agar colony formation and 3-D assays. This effect was specific for KRAS G12C as 12/12 cell lines with other KRAS mutations (including other G12 mutations V, D and A) were not inhibited in either soft-agar assay.  Relative resistance to ARS-853 developed after epidermal growth factor (50 ng/mL) administration and the combination of erlotinib or afatinib (EGFR-inhibitors) with ARS-853 greatly potentiated growth arrest, apoptosis and decrease of PI3K and MAPK-signaling over single-agent ARS-853 treatment, even in the presence of added EGF."	26739882	PubMed		"Patricelli et al., 2016, Cancer Discov"		3	accepted	1173	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/1173	https://civicdb.org/links/molecular_profiles/78	FALSE	KRAS	3845	G12C	EGFR TKI Resistance	chr12	25245351	25245351	C	A	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.34G>T,NP_004976.2:p.Gly12Cys,NC_000012.11:g.25398285C>A,ENST00000256078.4:c.34G>T"	2023-01-27 17:02:26 UTC	CA122528	12578	"GLY12CYS,RS121913530"	FALSE
ERBB2 V842I	45	Colon Cancer	219		"Lapatinib,Neratinib,Trastuzumab"	Combination	Predictive	Supports	D	Sensitivity/Response	Colon cancer patient derived xenografts with HER2 mutations are sensitive to HER2 targeted drugs and the greatest tumor reduction was seen with the combination of a tyrosine kinase inhibitor with trastuzumab.	26243863	PubMed		"Kavuri et al., 2015, Cancer Discov"		4	accepted	1174	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/1174	https://civicdb.org/links/molecular_profiles/45	FALSE	ERBB2	2064	V842I	HER2 Activating	chr17	39725079	39725079	G	A	ENST00000269571.5	75		missense_variant	"ENST00000269571.5:c.2524G>A,NM_004448.3:c.2524G>A,NP_004439.2:p.Val842Ile,NC_000017.10:g.37881332G>A"	2023-01-27 17:02:14 UTC	CA16602468	375994	"VAL842ILE,V812I,V827I,VAL812ILE,VAL827ILE,RS1057519738"	FALSE
ALK Fusion	495	Lung Non-small Cell Carcinoma	3908		Ceritinib		Predictive	Supports	B	Sensitivity/Response	"Updated results from ASCEND-1 trial assessing safety and activity of ceritinib in ALK rearranged locally advanced or metastatic NSCLC. 255 patients were enrolled and received at least one dose of ceritinib 750 mg/day, of whom 246 had ALK-rearranged NSCLC (Median follow-up: 11.1 months). Overall response rate was 72% [95% CI 61-82] of 83 ALK inhibitor-naive patients and 56% [49-64] of 163 ALK inhibitor-pretreated patients. Median duration of response was 170 months (95% CI 11.3-non-estimable [NE]) in ALK inhibitor-naive patients and 8.3 months (6.8-9.7) in ALK inhibitor-pretreated patients. Median progression-free survival was 18.4 months (95% CI 11.1-NE) in ALK inhibitor-naive patients and 6.9 months (5.6-8.7) in ALK inhibitor-pretreated patients. Brain metastases control was reported in 79% [95% CI 54-94] of 19 ALK inhibitor-naive patients and in 65% [54-76] of 75 ALK inhibitor-pretreated patients."	26973324	PubMed		"Kim et al., 2016, Lancet Oncol."	NCT01283516	4	accepted	1175	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1175	https://civicdb.org/links/molecular_profiles/495	FALSE	ALK	238	Fusion	ALK Fusion	chr2	29192774	29223528			ENST00000389048.3	75		transcript_fusion		2023-01-09 21:52:07 UTC		N/A	REARRANGEMENT	FALSE
ERBB2 L755S	39	Colon Cancer	219		"Lapatinib,Trastuzumab,Neratinib"	Combination	Predictive	Supports	D	Sensitivity/Response	Colon cancer patient derived xenografts with HER2 mutations are sensitive to HER2 targeted drugs and the greatest tumor reduction was seen with the combination of a tyrosine kinase inhibitor with trastuzumab.	26243863	PubMed		"Kavuri et al., 2015, Cancer Discov"		4	accepted	1176	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/1176	https://civicdb.org/links/molecular_profiles/39	FALSE	ERBB2	2064	L755S		chr17	39723967	39723967	T	C	ENST00000269571.5	75		missense_variant	"ENST00000269571.5:c.2264T>C,NC_000017.10:g.37880220T>C,NM_004448.3:c.2264T>C,NP_004439.2:p.Leu755Ser"	2023-01-27 17:02:09 UTC	CA16602502	376035	"LEU755SER,L725S,L740S"	FALSE
ERBB2 V777L	44	Colon Cancer	219		"Neratinib,Lapatinib,Trastuzumab"	Combination	Predictive	Supports	D	Sensitivity/Response	Colon cancer patient derived xenografts with HER2 mutations are sensitive to HER2 targeted drugs and the greatest tumor reduction was seen with the combination of a tyrosine kinase inhibitor with trastuzumab.	26243863	PubMed		"Kavuri et al., 2015, Cancer Discov"		4	accepted	1177	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/1177	https://civicdb.org/links/molecular_profiles/44	FALSE	ERBB2	2064	V777L	HER2 Activating	chr17	39724747	39724747	G	T	ENST00000269571.5	75		missense_variant	"NM_004448.3:c.2329G>T,NP_004439.2:p.Val777Leu,ENST00000269571.5:c.2329G>T,NC_000017.10:g.37881000G>T"	2023-01-27 17:02:13 UTC	CA135387	44991	"V747L,V762L,VAL777LEU,RS121913471"	FALSE
ERBB2 L866M	492	Colon Cancer	219		"Lapatinib,Neratinib,Trastuzumab"	Combination	Predictive	Supports	D	Sensitivity/Response	Colon cancer patient derived xenografts with HER2 mutations are sensitive to HER2 targeted drugs and the greatest tumor reduction was seen with the combination of a tyrosine kinase inhibitor with trastuzumab.	26243863	PubMed		"Kavuri et al., 2015, Cancer Discov"		4	accepted	1178	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1178	https://civicdb.org/links/molecular_profiles/492	FALSE	ERBB2	2064	L866M		chr17	39725151	39725151	C	A	ENST00000269571.5	75		missense_variant	"ENST00000269571.5:c.2596C>A,NC_000017.10:g.37881404C>A,NM_001289937.1:c.2596C>A,NP_001276866.1:p.Leu866Met"	2023-01-27 17:04:02 UTC	CA399304874	NONE FOUND	LEU866MET	FALSE
ERBB2 S310F/Y	493	Colon Cancer	219		"Lapatinib,Trastuzumab,Neratinib"	Combination	Predictive	Supports	D	Sensitivity/Response	Colon cancer patient derived xenografts with HER2 mutations are sensitive to HER2 targeted drugs and the greatest tumor reduction was seen with the combination of a tyrosine kinase inhibitor with trastuzumab.	26243863	PubMed		"Kavuri et al., 2015, Cancer Discov"		4	accepted	1179	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1179	https://civicdb.org/links/molecular_profiles/493	FALSE	ERBB2	2064	S310F/Y		chr17	39711955	39711955			ENST00000269571.5	75		missense_variant	"ENST00000269571.5:c.929C>T,NC_000017.10:g.37868208C>T"	2023-01-09 21:52:07 UTC		"376,189,376,188"		FALSE
KRAS G13D	81	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	B	Resistance	"12 patients with KRAS G13D mutant, metastatic colorectal cancer were treated with single agent cetuximab in a prospective phase II study. The primary endpoint of the trial was 4-month progression-free survival, with a benefit to treatment evaluated to be 50% of patients were progression free at this point. None of 12 patients achieved response by RECIST 1.1 criteria and three patients (25%) were progression-free at 4 months, with disease control rate at 6 months reaching 0%. Median PFS and OS were 1.9 (95% CI 1.7?.8) and 7.2 months (95% CI 5.7?.7)."	26371285	PubMed		"Schirripa et al., 2015, Ann. Oncol."		3	accepted	1180	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/1180	https://civicdb.org/links/molecular_profiles/81	FALSE	KRAS	3845	G13D		chr12	25245347	25245347	C	T	ENST00000256078.4	75		missense_variant	"NM_033360.3:c.38G>A,NP_004976.2:p.Gly13Asp,NC_000012.11:g.25398281C>T,ENST00000256078.4:c.38G>A"	2023-01-27 17:02:27 UTC	CA122534	12580	"GLY13ASP,RS112445441"	FALSE
KRAS G13D	81	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	B	Resistance	"Meta-analysis encompassing eight randomized controlled trials (n = 5967) for assessment of both overall survival (OS) and progression-free survival (PFS) of patients with KRAS mutant metastatic colorectal cancer. For other KRAS MT the hazard ratio for OS benefit with addition of anti-EGFR mAb therapy was 1.06 (95% confidence interval [CI]; 0.96, 1.17), compared to 1.08 (95% CI; 0.73, 1.60) for KRAS G13D [test for interaction p=0.99]. In contrast, the hazard ratio for KRAS wild-type (WT) tumours was 0.85 (95% CI; 0.76, 0.95). Regarding PFS benefit with anti-EGFR mAbs, the hazard ratio was 1.07 (95% CI; 0.92, 1.26) for other KRAS MT, 0.96 (95% CI; 0.73, 1.27) for KRAS G13D, and 0.68 (95% CI; 0.54, 0.85) for KRAS wild-type. Again, the test for interaction (p=0.46) demonstrated no significant difference in PFS benefit for anti-EGFR mAb therapy between KRAS G13D and other KRAS MT."	26812186	PubMed		"Rowland et al., 2016, Eur. J. Cancer"		4	accepted	1181	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/1181	https://civicdb.org/links/molecular_profiles/81	FALSE	KRAS	3845	G13D		chr12	25245347	25245347	C	T	ENST00000256078.4	75		missense_variant	"NM_033360.3:c.38G>A,NP_004976.2:p.Gly13Asp,NC_000012.11:g.25398281C>T,ENST00000256078.4:c.38G>A"	2023-01-27 17:02:27 UTC	CA122534	12580	"GLY13ASP,RS112445441"	FALSE
KRAS Mutation	332	Colorectal Cancer	9256		Ixazomib		Predictive	Supports	D	Resistance	"Preclinical study in colorectal cancer xenografts. KRAS-G13D or KRAS-G12V mutations were introduced into KRAS-WT SW48 cell line. KRAS wild-type, but not KRAS mutant tumors were sensitive to proteasome inhibitor ixazomib"	26709701	PubMed		"Chattopadhyay et al., 2015, PLoS ONE"		1	accepted	1182	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/1182	https://civicdb.org/links/molecular_profiles/332	FALSE	KRAS	3845	Mutation		chr12	25209431	25250803			ENST00000256078.4	75		protein_altering_variant		2023-01-09 21:52:06 UTC		N/A		FALSE
KRAS Mutation	332	Cancer	162		AZD5438		Predictive	Supports	D	Sensitivity/Response	"CDK1 was identified in a preclinical siRNA screen to identify targets in KRAS mutant tumors. Cell viability was evaluated following knockdown of 834 genes in isogenic LIM1215 colorectal cancer cell lines harboring wildtype (parental), G12S, G12D or G12V KRAS. 6 targets identified by this screen were evaluated in a second set of isogenic colorectal cancer cell lines (SW48) harboring wildtype (parental), G12S, G12D, G12V or G13D KRAS where only CDK1 knockdown more profoundly reduced survival in mutant cells compared to wildtype. Results were validated in 5 KRAS mutant (BRAF WT) and 10 KRAS WT colorectal cancer cell lines. Chemical inhibition of CDK1 by AZD5438 in KRAS mutant vs WT pancreatic and colorectal cancer cell lines showed increased efficacy in mutant cell lines. Finally, AZD5438 reduced tumor growth induced by SW620 (KRAS p.G12V) colorectal tumour cells xenografted into immunodeficient mice."	26881434	PubMed		"Costa-Cabral et al., 2016, PLoS ONE"		3	accepted	1183	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/1183	https://civicdb.org/links/molecular_profiles/332	FALSE	KRAS	3845	Mutation		chr12	25209431	25250803			ENST00000256078.4	75		protein_altering_variant		2023-01-09 21:52:06 UTC		N/A		FALSE
MIR218-1 UNDEREXPRESSION	494	Pancreatic Cancer	1793				Prognostic	Supports	D	Poor Outcome	"The study found mir-218 was significantly under-expressed when compared to matched adjacent normal tissue in 107 samples via qPCR. Further, low expression of mir-218 was revealed to be associated with lower overall survival (p < .001), and multivariate analysis revealed that low expression of mir-218 as an independent predictor of poor prognosis (p < .007)."	26662432	PubMed		"Li et al., 2015, Genet. Mol. Res."		3	accepted	1184	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1184	https://civicdb.org/links/molecular_profiles/494	FALSE	MIR218-1	407000	UNDEREXPRESSION		chr4	20528275	20528384			ENST00000384999.1	75		N/A		2023-01-09 21:52:07 UTC		N/A		FALSE
MET Exon 14 Skipping Mutation	320	Lung Adenocarcinoma	3910		Crizotinib		Predictive	Supports	C	Sensitivity/Response	A single patient with a MET c.3028G>A (splice donor site of exon 14) mutation exhibited clinical sensitivity to the c-Met inhibitor crizotinib. Exon 14 skipping was detected using qRT-PCR. Response to the therapy was demonstrated by comparing CAT scans obtained before treatment to those obtained during treatment (at 2 months of crizotinib therapy).	26729443	PubMed		"Awad et al., 2016, J. Clin. Oncol."		3	accepted	1185	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/1185	https://civicdb.org/links/molecular_profiles/320	FALSE	MET	4233	Exon 14 Skipping Mutation		chr7	116771849	116771989			ENST00000318493.6	75		exon_loss_variant		2023-01-09 21:52:06 UTC		N/A		FALSE
MET Exon 14 Skipping Mutation	320	Lung Adenocarcinoma	3910		Capmatinib		Predictive	Supports	C	Sensitivity/Response	"A patient with MET c.3028+1G>T mutation (METex14) had partial response (tumor reduction of 61%) after 13 months capmatinib. MET gene copy number was four, MET FISH 13.8 copy number, and IHC 3+."	25971938	PubMed		"Frampton et al., 2015, Cancer Discov"		3	accepted	1186	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/1186	https://civicdb.org/links/molecular_profiles/320	FALSE	MET	4233	Exon 14 Skipping Mutation		chr7	116771849	116771989			ENST00000318493.6	75		exon_loss_variant		2023-01-09 21:52:06 UTC		N/A		FALSE
ALK Fusion	495	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	A	Sensitivity/Response	"In the Phase I study PROFILE 1001 (NCT00585195), a recommended crizotinib dose of 250 mg twice daily for 28 day cycles was established. Among 1,500 advanced NSCLC patients who were screened for ALK-rearrangement using a break-apart FISH assay, 82 patients were eligible for crizotinib treatment. Overall response rate was 57%, with 46 partial responses and one complete response. Since crizotinib inhibits MET, 33 patients with available tissue were screened for MET amplification and were found negative, further indicating that patient response was due to ALK inhibition. 31 patients were tested via RT-PCR for known EML4-ALK fusions, and 13 were shown to have EML4-ALK variant 1, four cases had variant 3, and one instance of variants 2, 3b and 5 were seen. 9 were unidentified, suggesting other fusion partners in these instances."	20979469	PubMed		"Kwak et al., 2010, N. Engl. J. Med."	NCT00585195	5	accepted	1187	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1187	https://civicdb.org/links/molecular_profiles/495	FALSE	ALK	238	Fusion	ALK Fusion	chr2	29192774	29223528			ENST00000389048.3	75		transcript_fusion		2023-01-09 21:52:07 UTC		N/A	REARRANGEMENT	FALSE
ALK EML4::ALK	5	Lung Non-small Cell Carcinoma	3908		WHI-P154		Predictive	Supports	D	Sensitivity/Response	"A retroviral cDNA expression library was constructed using a lung adenocarcinoma specimen from a 67 year old NSCLC patient, and transfected into mouse 3T3 fibroblasts which were assessed for transformed foci.  Analysis of clones from one transformed focus yielded a novel fusion. This fusion generated a protein with N-terminal consisting of EML4 exons 1-13 and C-terminal consisting of ALK exons 20-29, which comprise the intracellular kinase domain of ALK. In subsequent experiments using EML4-ALK or altered versions, the transforming potential of EML4-ALK was found to be dependent on a functional ALK kinase activity as well as the EML4 basic domain, which was shown to have an important role in EML4-ALK dimer formation.  BA/F3 cells expressing EML4-ALK were able to grow independently of IL3 addition, but addition of ALK inhibitor WHI-P154 induced cell death and inhibited tyrosine phosphorylation of EML4-ALK. These results indicated that EML4-ALK may be a driver mutation in NSCLC,  and a target for ALK inhibitor treatment."	17625570	PubMed		"Soda et al., 2007, Nature"		5	accepted	1188	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/1188	https://civicdb.org/links/molecular_profiles/5	FALSE	ALK	238	EML4::ALK	ALK Fusion	chr2	42169350	42295516			ENST00000318522.5	75	ENST00000389048.3	transcript_fusion		2023-01-09 21:52:04 UTC		N/A	EML4-ALK	FALSE
ALK EML4::ALK	5	Lung Non-small Cell Carcinoma	3908		WHI-P154		Predictive	Supports	D	Sensitivity/Response	"A retroviral cDNA expression library was constructed using a lung adenocarcinoma specimen from a 67 year old NSCLC patient, and transfected into mouse 3T3 fibroblasts which were assessed for transformed foci.  Analysis of clones from one transformed focus yielded a novel fusion. This fusion generated a protein with N-terminal consisting of EML4 exons 1-13 and C-terminal consisting of ALK exons 20-29, which comprise the intracellular kinase domain of ALK. In subsequent experiments using EML4-ALK or altered versions, the transforming potential of EML4-ALK was found to be dependent on a functional ALK kinase activity as well as the EML4 basic domain, which was shown to have an important role in EML4-ALK dimer formation.  BA/F3 cells expressing EML4-ALK were able to grow independently of IL3 addition, but addition of ALK inhibitor WHI-P154 induced cell death and inhibited tyrosine phosphorylation of EML4-ALK. These results indicated that EML4-ALK may be a driver mutation in NSCLC,  and a target for ALK inhibitor treatment."	17625570	PubMed		"Soda et al., 2007, Nature"		5	accepted	1188	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/1188	https://civicdb.org/links/molecular_profiles/5	FALSE	ALK	238	EML4::ALK	ALK Fusion	chr2	29192774	29223528			ENST00000318522.5	75	ENST00000389048.3	transcript_fusion		2023-01-09 21:52:04 UTC		N/A	EML4-ALK	FALSE
ALK EML4::ALK e20-e20	496	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	C	Sensitivity/Response	"In the PROFILE 1001 study, from 31 NSCLC tumors positive for ALK fusions with sufficient material for RT-PCR aided exon breakpoint identification, 1 case of EML4-ALK variant 2 (EML4 exon 20 fused to ALK exon 20) was found. This patient had adenocarcinoma and a 9 pack year smoking history. Crizotinib treatment duration was over 16 weeks. The patient had multiple lines of prior treatment and showed a partial response to first-time crizotinib treatment. Overall, in the 82 ALK positive patients treated in the study, 46 had partial responses (including this patient) and 1 had a complete response for an overall response rate of 57%."	20979469	PubMed		"Kwak et al., 2010, N. Engl. J. Med."	NCT00585195	2	accepted	1189	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1189	https://civicdb.org/links/molecular_profiles/496	FALSE	ALK	238	EML4::ALK e20-e20	ALK Fusion	chr2	42169350	42325554			ENST00000318522.5	75	ENST00000389048.3	transcript_fusion		2023-01-09 21:52:07 UTC		N/A	EML4-ALK E20-E20	FALSE
ALK EML4::ALK e20-e20	496	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	C	Sensitivity/Response	"In the PROFILE 1001 study, from 31 NSCLC tumors positive for ALK fusions with sufficient material for RT-PCR aided exon breakpoint identification, 1 case of EML4-ALK variant 2 (EML4 exon 20 fused to ALK exon 20) was found. This patient had adenocarcinoma and a 9 pack year smoking history. Crizotinib treatment duration was over 16 weeks. The patient had multiple lines of prior treatment and showed a partial response to first-time crizotinib treatment. Overall, in the 82 ALK positive patients treated in the study, 46 had partial responses (including this patient) and 1 had a complete response for an overall response rate of 57%."	20979469	PubMed		"Kwak et al., 2010, N. Engl. J. Med."	NCT00585195	2	accepted	1189	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1189	https://civicdb.org/links/molecular_profiles/496	FALSE	ALK	238	EML4::ALK e20-e20	ALK Fusion	chr2	29192774	29223528			ENST00000318522.5	75	ENST00000389048.3	transcript_fusion		2023-01-09 21:52:07 UTC		N/A	EML4-ALK E20-E20	FALSE
ALK EML4::ALK e2-e20	497	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	E	Sensitivity/Response	"Multiplex RT-PCR to detect in-frame fusions of EML4 to ALK was performed on total RNA from 253 lung adenocarcinomas, and 9 samples were found to contain such fusions, one of which was a novel fusion containing EML4 exon 2 and exon 20 of ALK. This was called variant 5. Two versions of this variant were seen: 5a consisted of EML4 exon 2 fused to ALK exon 20 while 5b contained a 117bp intronic ALK region between the two exons. Genomic PCR showed that EML4-ALK variant 5 tumor cells contained a single EML4-ALK fusion, suggesting 5a and 5b arise from alternate splicing.  5a and 5b showed in-vitro kinase activity and transformed 3T3 cells in cell culture. 5a and 5b transformed 3T3 cells formed tumors when injected in 8/8 nude mice, but 3T3 transformed with ALK alone did not.  These results suggest that EML4-ALK variant 5 is a driver mutation in lung adenocarcinoma targetable by ALK inhibitors like crizotinib."	18927303	PubMed		"Takeuchi et al., 2008, Clin. Cancer Res."		4	accepted	1190	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1190	https://civicdb.org/links/molecular_profiles/497	FALSE	ALK	238	EML4::ALK e2-e20	ALK Fusion	chr2	42169350	42245687			ENST00000318522.5	75	ENST00000389048.3	transcript_fusion		2023-01-09 21:52:07 UTC		N/A	EML4-ALK E2-E20	FALSE
ALK EML4::ALK e2-e20	497	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	E	Sensitivity/Response	"Multiplex RT-PCR to detect in-frame fusions of EML4 to ALK was performed on total RNA from 253 lung adenocarcinomas, and 9 samples were found to contain such fusions, one of which was a novel fusion containing EML4 exon 2 and exon 20 of ALK. This was called variant 5. Two versions of this variant were seen: 5a consisted of EML4 exon 2 fused to ALK exon 20 while 5b contained a 117bp intronic ALK region between the two exons. Genomic PCR showed that EML4-ALK variant 5 tumor cells contained a single EML4-ALK fusion, suggesting 5a and 5b arise from alternate splicing.  5a and 5b showed in-vitro kinase activity and transformed 3T3 cells in cell culture. 5a and 5b transformed 3T3 cells formed tumors when injected in 8/8 nude mice, but 3T3 transformed with ALK alone did not.  These results suggest that EML4-ALK variant 5 is a driver mutation in lung adenocarcinoma targetable by ALK inhibitors like crizotinib."	18927303	PubMed		"Takeuchi et al., 2008, Clin. Cancer Res."		4	accepted	1190	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1190	https://civicdb.org/links/molecular_profiles/497	FALSE	ALK	238	EML4::ALK e2-e20	ALK Fusion	chr2	29192774	29223528			ENST00000318522.5	75	ENST00000389048.3	transcript_fusion		2023-01-09 21:52:07 UTC		N/A	EML4-ALK E2-E20	FALSE
KDR R961W	498	Colorectal Adenocarcinoma	50861		Regorafenib		Predictive	Supports	C	Sensitivity/Response	"Case Report of a 84-year-old woman with stage IVb CRC after progression under 5-fluorouracil and bevacizumab. NGS revealed a frameshift mutation in APC, a missense mutation in KRAS. Variants of uncertain significance were: a missense variant in ERBB2 and a missense variant in KDR at amino acid 961 converting the wild type residue, Arginine, to Tryptophan (frequency 28.25%). Because of the high frequency of the KDR (VEGFR2) mutation, the patient was considered a suitable candidate for a VEGFR inhibitor and received regorafenib monotherapy, which is approved for this situation, at 80mg daily which was later reduced to 40mg daily and had CEA normalization as well as partial metabolic and radiologic response. The patient remained almost asymptomatic and without disease progression after 39 weeks."	27004155	PubMed		"Loaiza-Bonilla et al., 2016, Cureus"		1	accepted	1191	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1191	https://civicdb.org/links/molecular_profiles/498	FALSE	KDR	3791	R961W		chr4	55094892	55094892	G	A	ENST00000263923.4	75		missense_variant	"NM_002253.2:c.2881C>T,NP_002244.1:p.Arg961Trp,ENST00000263923.4:c.2881C>T,NC_000004.11:g.55961059G>A"	2023-01-27 17:04:03 UTC	CA2924278	NONE FOUND	"ARG961TRP,RS530419081"	FALSE
ALK EML4::ALK e6-e20	499	Lung Non-small Cell Carcinoma	3908		"2,4-pyrimidinediamine"		Predictive	Supports	D	Sensitivity/Response	"In a cohort of 75 NSCLC patients that had tested positive for 3 EML4-ALK rearrangements, two individuals were identified via RT-PCR with a novel EML4-ALK translocation involving the first 6 exons of EML4 fused to the kinase domain of ALK. Genomic PCR resolved a single breakpoint, but 2 variants of the fusion were observed in cells. Variant 3a consisted of fusion at EML4 exon 6 and ALK exon 20, while variant 3b fused a 33 bp intronic EML4 region between EML4 exon 6 and ALK exon 20.  3a and 3b showed strong in-vitro kinase activity, transformed mouse 3T3 cells, and 3b-transformed 3T3 cells formed tumors in 8/8 nude mice.  The ALK inhibitor 2,4-pyrimidinediamine inhibited growth of the 3a/b containing NCI-H2228 NSCLC cell line.  The results indicate that 3a/b is a targetable driver-mutation as other EML4-ALK variants."	18593892	PubMed		"Choi et al., 2008, Cancer Res."		4	accepted	1192	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1192	https://civicdb.org/links/molecular_profiles/499	FALSE	ALK	238	EML4::ALK e6-e20	ALK Fusion	chr2	42169350	42264731			ENST00000318522.5	75	ENST00000389048.3	transcript_fusion		2023-01-09 21:52:07 UTC		N/A	EML4-ALK E6-E20	FALSE
ALK EML4::ALK e6-e20	499	Lung Non-small Cell Carcinoma	3908		"2,4-pyrimidinediamine"		Predictive	Supports	D	Sensitivity/Response	"In a cohort of 75 NSCLC patients that had tested positive for 3 EML4-ALK rearrangements, two individuals were identified via RT-PCR with a novel EML4-ALK translocation involving the first 6 exons of EML4 fused to the kinase domain of ALK. Genomic PCR resolved a single breakpoint, but 2 variants of the fusion were observed in cells. Variant 3a consisted of fusion at EML4 exon 6 and ALK exon 20, while variant 3b fused a 33 bp intronic EML4 region between EML4 exon 6 and ALK exon 20.  3a and 3b showed strong in-vitro kinase activity, transformed mouse 3T3 cells, and 3b-transformed 3T3 cells formed tumors in 8/8 nude mice.  The ALK inhibitor 2,4-pyrimidinediamine inhibited growth of the 3a/b containing NCI-H2228 NSCLC cell line.  The results indicate that 3a/b is a targetable driver-mutation as other EML4-ALK variants."	18593892	PubMed		"Choi et al., 2008, Cancer Res."		4	accepted	1192	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1192	https://civicdb.org/links/molecular_profiles/499	FALSE	ALK	238	EML4::ALK e6-e20	ALK Fusion	chr2	29192774	29223528			ENST00000318522.5	75	ENST00000389048.3	transcript_fusion		2023-01-09 21:52:07 UTC		N/A	EML4-ALK E6-E20	FALSE
ALK EML4::ALK e6-e20	499	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	C	Sensitivity/Response	"In a set of 31 patients with NSCLC, RT-PCR was performed to test for known EML4-ALK variants.  Five patients tested positive for the 3a/3b EML4-ALK variant.  Of these, 4 had partial response (PR), and one had disease progression (DP), and this was the only DP in the group of 31.  In contrast, of the 13 testing positive for EML4-ALK variant 1, 12 showed PR, and 1 showed stable disease.  These results potentially mirror findings in the H2228 3a/3b containing NSCLC cell line where some literature indicates it does respond as strongly to ALK inhibition as other EML4-ALK NSCLC cell lines."	20979469	PubMed		"Kwak et al., 2010, N. Engl. J. Med."	NCT00585195	4	accepted	1193	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1193	https://civicdb.org/links/molecular_profiles/499	FALSE	ALK	238	EML4::ALK e6-e20	ALK Fusion	chr2	42169350	42264731			ENST00000318522.5	75	ENST00000389048.3	transcript_fusion		2023-01-09 21:52:07 UTC		N/A	EML4-ALK E6-E20	FALSE
ALK EML4::ALK e6-e20	499	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	C	Sensitivity/Response	"In a set of 31 patients with NSCLC, RT-PCR was performed to test for known EML4-ALK variants.  Five patients tested positive for the 3a/3b EML4-ALK variant.  Of these, 4 had partial response (PR), and one had disease progression (DP), and this was the only DP in the group of 31.  In contrast, of the 13 testing positive for EML4-ALK variant 1, 12 showed PR, and 1 showed stable disease.  These results potentially mirror findings in the H2228 3a/3b containing NSCLC cell line where some literature indicates it does respond as strongly to ALK inhibition as other EML4-ALK NSCLC cell lines."	20979469	PubMed		"Kwak et al., 2010, N. Engl. J. Med."	NCT00585195	4	accepted	1193	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1193	https://civicdb.org/links/molecular_profiles/499	FALSE	ALK	238	EML4::ALK e6-e20	ALK Fusion	chr2	29192774	29223528			ENST00000318522.5	75	ENST00000389048.3	transcript_fusion		2023-01-09 21:52:07 UTC		N/A	EML4-ALK E6-E20	FALSE
ALK EML4::ALK e6-e20	499	Lung Non-small Cell Carcinoma	3908		TAE684		Predictive	Supports	D	Sensitivity/Response	"In a panel of 602 cancer cell lines, 3/134 NSCLC cell lines showed <0.5% cell viability following treatment with the ALK inhibitor TAE684. Of these, NCI-H2228 harbored EML4-ALK variant 3a/b (EML4 exon 6 and ALK exon 20). TAE684 inhibited Akt and Erk1/2 phosphorylation in H2228 cells and appeared to induce a cytostatic response."	18451166	PubMed		"McDermott et al., 2008, Cancer Res."		2	accepted	1194	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1194	https://civicdb.org/links/molecular_profiles/499	FALSE	ALK	238	EML4::ALK e6-e20	ALK Fusion	chr2	42169350	42264731			ENST00000318522.5	75	ENST00000389048.3	transcript_fusion		2023-01-09 21:52:07 UTC		N/A	EML4-ALK E6-E20	FALSE
ALK EML4::ALK e6-e20	499	Lung Non-small Cell Carcinoma	3908		TAE684		Predictive	Supports	D	Sensitivity/Response	"In a panel of 602 cancer cell lines, 3/134 NSCLC cell lines showed <0.5% cell viability following treatment with the ALK inhibitor TAE684. Of these, NCI-H2228 harbored EML4-ALK variant 3a/b (EML4 exon 6 and ALK exon 20). TAE684 inhibited Akt and Erk1/2 phosphorylation in H2228 cells and appeared to induce a cytostatic response."	18451166	PubMed		"McDermott et al., 2008, Cancer Res."		2	accepted	1194	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1194	https://civicdb.org/links/molecular_profiles/499	FALSE	ALK	238	EML4::ALK e6-e20	ALK Fusion	chr2	29192774	29223528			ENST00000318522.5	75	ENST00000389048.3	transcript_fusion		2023-01-09 21:52:07 UTC		N/A	EML4-ALK E6-E20	FALSE
ALK EML4::ALK e6-e20	499	Lung Non-small Cell Carcinoma	3908		TAE684		Predictive	Does Not Support	D	Sensitivity/Response	"Exon-array and RT-PCR was used to screen a panel of 83 NSCLC cell lines for EML4-ALK variants. The cell lines NCI-H3122 (containing EML4-ALK variant 1) and NCI-H2228 (containing the EML4 exon 6 and ALK exon 20 fusion-variant 3a/3b) were identified. TAE684 (0.1uM) appreciably inhibited growth as well as Akt and Erk1/2 phosphorylation in variant 1 containing H3122 cells. However, incomplete inhibition in 3a/3b containing H2228 cells was observed. H2228 growth inhibition by TAE684 was more similar to NSCLC cell lines harboring KRAS and EGFR mutations."	18594010	PubMed		"Koivunen et al., 2008, Clin. Cancer Res."		2	accepted	1195	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1195	https://civicdb.org/links/molecular_profiles/499	FALSE	ALK	238	EML4::ALK e6-e20	ALK Fusion	chr2	42169350	42264731			ENST00000318522.5	75	ENST00000389048.3	transcript_fusion		2023-01-09 21:52:07 UTC		N/A	EML4-ALK E6-E20	FALSE
ALK EML4::ALK e6-e20	499	Lung Non-small Cell Carcinoma	3908		TAE684		Predictive	Does Not Support	D	Sensitivity/Response	"Exon-array and RT-PCR was used to screen a panel of 83 NSCLC cell lines for EML4-ALK variants. The cell lines NCI-H3122 (containing EML4-ALK variant 1) and NCI-H2228 (containing the EML4 exon 6 and ALK exon 20 fusion-variant 3a/3b) were identified. TAE684 (0.1uM) appreciably inhibited growth as well as Akt and Erk1/2 phosphorylation in variant 1 containing H3122 cells. However, incomplete inhibition in 3a/3b containing H2228 cells was observed. H2228 growth inhibition by TAE684 was more similar to NSCLC cell lines harboring KRAS and EGFR mutations."	18594010	PubMed		"Koivunen et al., 2008, Clin. Cancer Res."		2	accepted	1195	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1195	https://civicdb.org/links/molecular_profiles/499	FALSE	ALK	238	EML4::ALK e6-e20	ALK Fusion	chr2	29192774	29223528			ENST00000318522.5	75	ENST00000389048.3	transcript_fusion		2023-01-09 21:52:07 UTC		N/A	EML4-ALK E6-E20	FALSE
ALK EML4::ALK e20-e20	496	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	D	Sensitivity/Response	"EML4-ALK variants v1 (E13;A20), v2 (E20;A20), v3a (E6;A20) and v3b (E6ins33;A20) were expressed in Ba/F3 cells using retrovirus.  While all constructs rendered Ba/F3 cells IL3-independant, marked differences in sensitivity to ALK inhibitors TAE684 and crizotinib were observed, where v2 was most sensitized to growth inhibition and v3a the least, with v1 and v3b intermediate.  While phospho-ALK western blots indicated that the ALK inhibitors acted similarly on both v2 and v3a EML4-ALK variants, blots of cyclohexamide-treated cells showed that v2 had a shorter half-life than 3a in the transduced cells, potentially explaining increased v2 sensitivity.  Assays with a panel of mutated EML4-ALK variants of varied length suggested that longer EML4-ALK variants are less stable in cells, although this tendency was not observed across other types of ALK fusion."	22912387	PubMed		"Heuckmann et al., 2012, Clin. Cancer Res."		2	accepted	1196	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1196	https://civicdb.org/links/molecular_profiles/496	FALSE	ALK	238	EML4::ALK e20-e20	ALK Fusion	chr2	42169350	42325554			ENST00000318522.5	75	ENST00000389048.3	transcript_fusion		2023-01-09 21:52:07 UTC		N/A	EML4-ALK E20-E20	FALSE
ALK EML4::ALK e20-e20	496	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	D	Sensitivity/Response	"EML4-ALK variants v1 (E13;A20), v2 (E20;A20), v3a (E6;A20) and v3b (E6ins33;A20) were expressed in Ba/F3 cells using retrovirus.  While all constructs rendered Ba/F3 cells IL3-independant, marked differences in sensitivity to ALK inhibitors TAE684 and crizotinib were observed, where v2 was most sensitized to growth inhibition and v3a the least, with v1 and v3b intermediate.  While phospho-ALK western blots indicated that the ALK inhibitors acted similarly on both v2 and v3a EML4-ALK variants, blots of cyclohexamide-treated cells showed that v2 had a shorter half-life than 3a in the transduced cells, potentially explaining increased v2 sensitivity.  Assays with a panel of mutated EML4-ALK variants of varied length suggested that longer EML4-ALK variants are less stable in cells, although this tendency was not observed across other types of ALK fusion."	22912387	PubMed		"Heuckmann et al., 2012, Clin. Cancer Res."		2	accepted	1196	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1196	https://civicdb.org/links/molecular_profiles/496	FALSE	ALK	238	EML4::ALK e20-e20	ALK Fusion	chr2	29192774	29223528			ENST00000318522.5	75	ENST00000389048.3	transcript_fusion		2023-01-09 21:52:07 UTC		N/A	EML4-ALK E20-E20	FALSE
ALK EML4::ALK e6-e20	499	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Does Not Support	D	Sensitivity/Response	"Ba/F3 cells transduced with EML4-ALK variants v1 (E13;A20), v2 (E20;A20), v3a (E6;A20) and v3b (E6ins33;A20) showed differential sensitivity to both crizotinib and TAE684, with variant 3a (E6;A20) being the least sensitive. The authors suggest that the type/structure of ALK fusion may have some impact on patient outcome in targeted therapy."	22912387	PubMed		"Heuckmann et al., 2012, Clin. Cancer Res."		2	accepted	1197	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1197	https://civicdb.org/links/molecular_profiles/499	FALSE	ALK	238	EML4::ALK e6-e20	ALK Fusion	chr2	42169350	42264731			ENST00000318522.5	75	ENST00000389048.3	transcript_fusion		2023-01-09 21:52:07 UTC		N/A	EML4-ALK E6-E20	FALSE
ALK EML4::ALK e6-e20	499	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Does Not Support	D	Sensitivity/Response	"Ba/F3 cells transduced with EML4-ALK variants v1 (E13;A20), v2 (E20;A20), v3a (E6;A20) and v3b (E6ins33;A20) showed differential sensitivity to both crizotinib and TAE684, with variant 3a (E6;A20) being the least sensitive. The authors suggest that the type/structure of ALK fusion may have some impact on patient outcome in targeted therapy."	22912387	PubMed		"Heuckmann et al., 2012, Clin. Cancer Res."		2	accepted	1197	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1197	https://civicdb.org/links/molecular_profiles/499	FALSE	ALK	238	EML4::ALK e6-e20	ALK Fusion	chr2	29192774	29223528			ENST00000318522.5	75	ENST00000389048.3	transcript_fusion		2023-01-09 21:52:07 UTC		N/A	EML4-ALK E6-E20	FALSE
ALK Fusion	495	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	A	Sensitivity/Response	"This two arm Phase III study named PROFILE 1007 (NCT00932893) was performed to assess crizotinib vs. established chemotherapy in non-small cell lung cancer patients positive for ALK rearrangement (assessed by break-apart FISH) with locally advanced or metastatic disease. 347 patients with disease progression after one round of platinum-based chemotherapy were randomized to receive crizotinib (N=173) or chemotherapy (N=174) consisting of pemetrexed in pemetrexed-naive patients and docetaxel for patients previously treated with pemetrexed. The primary endpoint - progression free survival (PFS) - was found to be significantly better for patients treated with crizotinib (median 7.7 months) than with chemotherapy (median 3.0 months) (hazard ratio for disease progression or death with crizotinib, 0.49; 95% CI, 0.37 to 0.64; P<0.001). Response rates were 65% for crizotinib treatment and 20% for chemotherapy (P<0.001). Improvements in quality of life were also reported."	23724913	PubMed		"Shaw et al., 2013, N. Engl. J. Med."	NCT00932893	5	accepted	1198	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1198	https://civicdb.org/links/molecular_profiles/495	FALSE	ALK	238	Fusion	ALK Fusion	chr2	29192774	29223528			ENST00000389048.3	75		transcript_fusion		2023-01-09 21:52:07 UTC		N/A	REARRANGEMENT	FALSE
ALK Fusion	495	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	A	Sensitivity/Response	"This phase 3 trial named PROFILE 1014 (NCT01154140) compared crizotinib to established chemotherapy in first-line treatment for this disease. The study consisted of 343 patients with advanced or metastatic NSCLC that tested positive for ALK rearrangement via break-apart FISH assay, and had no prior systemic treatment. Patients were assigned in a 1:1 ratio to crizotinib (N=172) or pemetrexed with cisplatin or carboplatin (N=171). Progression free survival was significantly longer with crizotinib treatment than chemotherapy (10.9 vs. 7.0 months; hazard ratio for progression or death with crizotinib, 0.45; 95% CI, 0.35 to 0.60;P<0.001), and objective response rate was higher with crizotinib treatment than chemotherapy (75% vs. 45%, P<0.001). Improvement in quality of life was also reported."	25470694	PubMed		"Solomon et al., 2014, N. Engl. J. Med."	NCT01154140	5	accepted	1199	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1199	https://civicdb.org/links/molecular_profiles/495	FALSE	ALK	238	Fusion	ALK Fusion	chr2	29192774	29223528			ENST00000389048.3	75		transcript_fusion		2023-01-09 21:52:07 UTC		N/A	REARRANGEMENT	FALSE
ALK Fusion	495	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	B	Sensitivity/Response	"This retrospective study of patients from the PROFILE 1001 and 1005 studies of crizotinib in advanced ALK-rearranged NSCLC assessed the potential benefit of crizotinib beyond progressive disease (CBPD), defined as continuation of crizotinib for 3 or more weeks after disease progression on crizotinib. 194 patients who had developed PD by data cutoff were studied, where 120 received crizotinib for a median duration of 19.4 weeks and 74 discontinued crizotinib after PD. No gross imbalances in clinicopathologic features of the two groups were evident.  Significantly longer overall survival was observed in the crizotinib continuing group from time of PD (16.4 vs. 3.9 months; hazard ratio 0.27, 95% CI: 0.17?.42; P < 0.0001), and from the time of initial crizotinib (29.6 vs. 10.8 months; HR 0.30, 95% CI: 0.19?.46; P < 0.0001)."	24478318	PubMed		"Ou et al., 2014, Ann. Oncol."		4	accepted	1200	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1200	https://civicdb.org/links/molecular_profiles/495	FALSE	ALK	238	Fusion	ALK Fusion	chr2	29192774	29223528			ENST00000389048.3	75		transcript_fusion		2023-01-09 21:52:07 UTC		N/A	REARRANGEMENT	FALSE
ALK Fusion	495	Lung Non-small Cell Carcinoma	3908	Brain neoplasm	Crizotinib		Predictive	Supports	B	Sensitivity/Response	"This prospective Phase III study named Profile 1014 on NSCLC ALK-rearranged patients assessed intracranial disease control rate (IC-DCR) in the subset of patients entering the study with preexisting treated brain metastasis (tBM). IC-DCR was significantly improved in the tBM group given crizotinib (N=39) over chemotherapy (pemetrexed + cisplatin or carboplatin; N=40) at 12 weeks (85% vs. 45%, P<0.001), and at 24 weeks (56% vs. 25%, P=0.006). Progression free survival was also significantly improved with crizotinib over chemotherapy in the tBM subgroup (9.0 vs. 4.0 months; HR 0.40; P<0.001), where in the intent to treat population it was 10.9 vs. 7.0 months (HR 0.45; P<0.001), indicating that the difficult to treat BM population obtained benefit from crizotinib at both the brain and systemic level."	27022118	PubMed		"Solomon et al., 2016, J. Clin. Oncol."	NCT01154140	4	accepted	1201	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1201	https://civicdb.org/links/molecular_profiles/495	FALSE	ALK	238	Fusion	ALK Fusion	chr2	29192774	29223528			ENST00000389048.3	75		transcript_fusion		2023-01-09 21:52:07 UTC		N/A	REARRANGEMENT	FALSE
ALK Fusion	495	Lung Non-small Cell Carcinoma	3908		Retaspimycin Hydrochloride		Predictive	Supports	C	Sensitivity/Response	"In this study, heavily pretreated advanced NSCLC patients with various molecular tumor makeup were treated with Hsp90 inhibitor IPI-504 to assess overall response rate. The study did not reach the targeted endpoint of 20% ORR. However, of 3/12 patients found to be ALK-rearranged via break apart FISH assay, 2 showed a partial response and the third stable disease, which was durable for 7.2 months. The authors note that the break apart FISH assay used to determine ALK-rearrangement status does not determine the identity of the ALK fusion partner and the promising results shown here may be dependent on the nature of the ALK fusion partner."	20940188	PubMed		"Sequist et al., 2010, J. Clin. Oncol."		2	accepted	1202	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1202	https://civicdb.org/links/molecular_profiles/495	FALSE	ALK	238	Fusion	ALK Fusion	chr2	29192774	29223528			ENST00000389048.3	75		transcript_fusion		2023-01-09 21:52:07 UTC		N/A	REARRANGEMENT	FALSE
ALK EML4::ALK	5	Lung Non-small Cell Carcinoma	3908		"Crizotinib,Retaspimycin Hydrochloride"	Combination	Predictive	Supports	D	Sensitivity/Response	"In preclinical work using H3122 NSCLC cells which contain the EML4-ALK variant 1, administration of the Hsp90 inhibitor IPI-504 caused marked decrease of EML4-ALK protein levels at concentrations lower than those used to knock down protein levels of drivers such as HER2 or EGFR in other cell lines, making it the most sensitive Hsp90 client protein the authors had encountered.  IPI-504 treatment caused regression of H3122 tumors in nude mice, whereas Hsp90 inhibitors usually only cause growth inhibition in these models.  Combined treatment of these mice with IPI-504 and crizotinib caused an even stronger tumor regression."	21258415	PubMed		"Normant et al., 2011, Oncogene"		4	accepted	1203	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/1203	https://civicdb.org/links/molecular_profiles/5	FALSE	ALK	238	EML4::ALK	ALK Fusion	chr2	42169350	42295516			ENST00000318522.5	75	ENST00000389048.3	transcript_fusion		2023-01-09 21:52:04 UTC		N/A	EML4-ALK	FALSE
ALK EML4::ALK	5	Lung Non-small Cell Carcinoma	3908		"Crizotinib,Retaspimycin Hydrochloride"	Combination	Predictive	Supports	D	Sensitivity/Response	"In preclinical work using H3122 NSCLC cells which contain the EML4-ALK variant 1, administration of the Hsp90 inhibitor IPI-504 caused marked decrease of EML4-ALK protein levels at concentrations lower than those used to knock down protein levels of drivers such as HER2 or EGFR in other cell lines, making it the most sensitive Hsp90 client protein the authors had encountered.  IPI-504 treatment caused regression of H3122 tumors in nude mice, whereas Hsp90 inhibitors usually only cause growth inhibition in these models.  Combined treatment of these mice with IPI-504 and crizotinib caused an even stronger tumor regression."	21258415	PubMed		"Normant et al., 2011, Oncogene"		4	accepted	1203	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/1203	https://civicdb.org/links/molecular_profiles/5	FALSE	ALK	238	EML4::ALK	ALK Fusion	chr2	29192774	29223528			ENST00000318522.5	75	ENST00000389048.3	transcript_fusion		2023-01-09 21:52:04 UTC		N/A	EML4-ALK	FALSE
ALK EML4::ALK e20-e20	496	Lung Non-small Cell Carcinoma	3908		"Alvespimycin,Crizotinib"	Combination	Predictive	Supports	D	Sensitivity/Response	"EML4-ALK fusions occur in 2-7% of lung adenocarcinomas. Transduction of Ba/F3 cells with EML4-ALK variant 2 (EML4 exon 20 fused to ALK exon 20) caused the cells to grow independently of IL3 addition.  EML4-ALK may be a client protein of Hsp90. Addition of Hsp90 inhibitor 17-DMAG to the EML4-ALK variant 2 cells induced cell death which was rescued at lower 17-DMAG concentrations by IL3 addition. This result suggests that 17-DMAG specifically  targeted the EML4-ALK driver in these cells. Finally, 17-DMAG and crizotinib showed a synergistic effect in killing EML4-ALK variant 2 cells."	22912387	PubMed		"Heuckmann et al., 2012, Clin. Cancer Res."		2	accepted	1204	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1204	https://civicdb.org/links/molecular_profiles/496	FALSE	ALK	238	EML4::ALK e20-e20	ALK Fusion	chr2	42169350	42325554			ENST00000318522.5	75	ENST00000389048.3	transcript_fusion		2023-01-09 21:52:07 UTC		N/A	EML4-ALK E20-E20	FALSE
ALK EML4::ALK e20-e20	496	Lung Non-small Cell Carcinoma	3908		"Alvespimycin,Crizotinib"	Combination	Predictive	Supports	D	Sensitivity/Response	"EML4-ALK fusions occur in 2-7% of lung adenocarcinomas. Transduction of Ba/F3 cells with EML4-ALK variant 2 (EML4 exon 20 fused to ALK exon 20) caused the cells to grow independently of IL3 addition.  EML4-ALK may be a client protein of Hsp90. Addition of Hsp90 inhibitor 17-DMAG to the EML4-ALK variant 2 cells induced cell death which was rescued at lower 17-DMAG concentrations by IL3 addition. This result suggests that 17-DMAG specifically  targeted the EML4-ALK driver in these cells. Finally, 17-DMAG and crizotinib showed a synergistic effect in killing EML4-ALK variant 2 cells."	22912387	PubMed		"Heuckmann et al., 2012, Clin. Cancer Res."		2	accepted	1204	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1204	https://civicdb.org/links/molecular_profiles/496	FALSE	ALK	238	EML4::ALK e20-e20	ALK Fusion	chr2	29192774	29223528			ENST00000318522.5	75	ENST00000389048.3	transcript_fusion		2023-01-09 21:52:07 UTC		N/A	EML4-ALK E20-E20	FALSE
ALK EML4::ALK e6-e20	499	Lung Non-small Cell Carcinoma	3908		Alvespimycin		Predictive	Does Not Support	D	Sensitivity/Response	"Transduction of Ba/F3 cells with EML4-ALK variant 3a caused the cells to grow independently of IL3 addition.  While incubation of Ba/F3 cells transduced with EML4-ALK variants 1 and 2 with Hsp90 inhibitor 17-DMAG caused cell death that was reversible with IL3 addition, Ba/F3 cells with variant 3a were not sensitized to 17-DMAG induced death, suggesting that 17-DMAG was effecting the EML4-ALK driver of IL3-independant proliferation. This in turn suggests that variant 3a may not rely on Hsp90 for stability in cancer cells to the extent of other variants."	22912387	PubMed		"Heuckmann et al., 2012, Clin. Cancer Res."		2	accepted	1205	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1205	https://civicdb.org/links/molecular_profiles/499	FALSE	ALK	238	EML4::ALK e6-e20	ALK Fusion	chr2	42169350	42264731			ENST00000318522.5	75	ENST00000389048.3	transcript_fusion		2023-01-09 21:52:07 UTC		N/A	EML4-ALK E6-E20	FALSE
ALK EML4::ALK e6-e20	499	Lung Non-small Cell Carcinoma	3908		Alvespimycin		Predictive	Does Not Support	D	Sensitivity/Response	"Transduction of Ba/F3 cells with EML4-ALK variant 3a caused the cells to grow independently of IL3 addition.  While incubation of Ba/F3 cells transduced with EML4-ALK variants 1 and 2 with Hsp90 inhibitor 17-DMAG caused cell death that was reversible with IL3 addition, Ba/F3 cells with variant 3a were not sensitized to 17-DMAG induced death, suggesting that 17-DMAG was effecting the EML4-ALK driver of IL3-independant proliferation. This in turn suggests that variant 3a may not rely on Hsp90 for stability in cancer cells to the extent of other variants."	22912387	PubMed		"Heuckmann et al., 2012, Clin. Cancer Res."		2	accepted	1205	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1205	https://civicdb.org/links/molecular_profiles/499	FALSE	ALK	238	EML4::ALK e6-e20	ALK Fusion	chr2	29192774	29223528			ENST00000318522.5	75	ENST00000389048.3	transcript_fusion		2023-01-09 21:52:07 UTC		N/A	EML4-ALK E6-E20	FALSE
ALK EML4::ALK	5	Lung Non-small Cell Carcinoma	3908		"Alvespimycin,Crizotinib"	Combination	Predictive	Supports	D	Sensitivity/Response	"Transduction of Ba/F3 cells with EML4-ALK variant 1 causes IL3 independent growth. Incubation of EML4-ALK variant 1 transduced Ba/F3 cells with Hsp90 inhibitor 17-DMAG caused cell death that was reversible with IL3 addition, suggesting that 17-DMAG was effecting the EML4-ALK driver of IL3-independant proliferation, and that EML4-ALK variant 1 is a client protein of Hsp90. The degree of Hsp90 dependence, and targetability of EML4-ALK for Hsp90 inhibition, may vary among ALK fusion variants.  Addition of crizotinib to 17-DMAG caused synergistic death effects, suggesting potential clinical benefit for this inhibitor combination in targeting EML4-ALK variant 1."	22912387	PubMed		"Heuckmann et al., 2012, Clin. Cancer Res."		2	accepted	1206	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/1206	https://civicdb.org/links/molecular_profiles/5	FALSE	ALK	238	EML4::ALK	ALK Fusion	chr2	42169350	42295516			ENST00000318522.5	75	ENST00000389048.3	transcript_fusion		2023-01-09 21:52:04 UTC		N/A	EML4-ALK	FALSE
ALK EML4::ALK	5	Lung Non-small Cell Carcinoma	3908		"Alvespimycin,Crizotinib"	Combination	Predictive	Supports	D	Sensitivity/Response	"Transduction of Ba/F3 cells with EML4-ALK variant 1 causes IL3 independent growth. Incubation of EML4-ALK variant 1 transduced Ba/F3 cells with Hsp90 inhibitor 17-DMAG caused cell death that was reversible with IL3 addition, suggesting that 17-DMAG was effecting the EML4-ALK driver of IL3-independant proliferation, and that EML4-ALK variant 1 is a client protein of Hsp90. The degree of Hsp90 dependence, and targetability of EML4-ALK for Hsp90 inhibition, may vary among ALK fusion variants.  Addition of crizotinib to 17-DMAG caused synergistic death effects, suggesting potential clinical benefit for this inhibitor combination in targeting EML4-ALK variant 1."	22912387	PubMed		"Heuckmann et al., 2012, Clin. Cancer Res."		2	accepted	1206	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/1206	https://civicdb.org/links/molecular_profiles/5	FALSE	ALK	238	EML4::ALK	ALK Fusion	chr2	29192774	29223528			ENST00000318522.5	75	ENST00000389048.3	transcript_fusion		2023-01-09 21:52:04 UTC		N/A	EML4-ALK	FALSE
ALK EML4::ALK	5	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	C	Sensitivity/Response	"In the PROFILE 1001 study of crizotinib in 82 patients with ALK-rearranged NSCLC, 31 patients with sufficient tumor material were tested using RT-PCR for the presence of certain EML4-ALK variants.  13/31 tested patients had the EML4-ALK variant 1. Of these, 12/13 had a partial response, and 1 had stable disease. This response rate of 92% is in contrast to the 57% response rate in the overall patient population, but the numbers of patients with specific EML4-ALK breakpoints were insufficient to correlate with patient response rate."	20979469	PubMed		"Kwak et al., 2010, N. Engl. J. Med."	NCT00585195	4	accepted	1207	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/1207	https://civicdb.org/links/molecular_profiles/5	FALSE	ALK	238	EML4::ALK	ALK Fusion	chr2	42169350	42295516			ENST00000318522.5	75	ENST00000389048.3	transcript_fusion		2023-01-09 21:52:04 UTC		N/A	EML4-ALK	FALSE
ALK EML4::ALK	5	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	C	Sensitivity/Response	"In the PROFILE 1001 study of crizotinib in 82 patients with ALK-rearranged NSCLC, 31 patients with sufficient tumor material were tested using RT-PCR for the presence of certain EML4-ALK variants.  13/31 tested patients had the EML4-ALK variant 1. Of these, 12/13 had a partial response, and 1 had stable disease. This response rate of 92% is in contrast to the 57% response rate in the overall patient population, but the numbers of patients with specific EML4-ALK breakpoints were insufficient to correlate with patient response rate."	20979469	PubMed		"Kwak et al., 2010, N. Engl. J. Med."	NCT00585195	4	accepted	1207	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/1207	https://civicdb.org/links/molecular_profiles/5	FALSE	ALK	238	EML4::ALK	ALK Fusion	chr2	29192774	29223528			ENST00000318522.5	75	ENST00000389048.3	transcript_fusion		2023-01-09 21:52:04 UTC		N/A	EML4-ALK	FALSE
KRAS Exon 2 Mutation	75	Colorectal Cancer	9256		Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor		Predictive	Supports	B	Resistance	"102 mCRC patients treated with anti-EGFR therapy were analyzed for 34 hotspot mutations in KRAS, NRAS and BRAF with nanofluidic digital PCR and quantitative PCR. dPCR and qPCR results were correlated to PFS and OS. Analysis of only KRAS exon 2 hotspot mutations showed that patients with more than 1% mutant allele fraction (n = 19/83) had a hazard ratio of 3.43 for PFS (95% CI, 1.67?.02; P=0.002) and 2.72 for OS (95% CI, 1.52?.88; P=0.002) compared to wild-type patients or patients with less than 1% mutant allele fraction. Considering all RAS and BRAF mutations, the patients with more than 1% mutant allele fraction (n = 37/65) had a hazard ratio of 4.52 for PFS (95% CI, 2.25?.07; P<0.001) and 2.5 for OS (95% CI, 1.57?.02; P<0.001). ROC analysis showed that a cut-off of 1% for any mutated allele offered the best predictive value."	27037411	PubMed		"Azuara et al., 2016, Mol. Cancer Ther."		3	accepted	1208	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/1208	https://civicdb.org/links/molecular_profiles/75	FALSE	KRAS	3845	Exon 2 Mutation		chr12	25245274	25245395			ENST00000256078.4	75		missense_variant		2023-01-09 21:52:04 UTC				FALSE
TP53 P47S	500	Cancer	162		Cisplatin		Predictive	Supports	E	Resistance	"The P47S (rs1800371) variant of TP53 is observed in 1.5% in African Americans and between 6% and 8% in certain African populations but has not been detected in Caucasian Americans. This paper reports functional studies of this variant. Mouse models with this variant show an increase in spontaneous tumor formation. 16 out of 20 (80%) of S47 homozygous mice developed cancer between 12 and 18 months of age. Cancers predominantly included hepatocellular carcinoma, B-cell lymphoma, and histiocytic sarcoma, as well as other tumor types. In S47/wild-type heterozygote mice an increased cancer incidence, with a predisposition for hepatocellular carcinoma, was also found. Mouse embryonic fibroblasts and human lymphoblastoid cell lines with S47 mutations were significantly less sensitive to cisplatinum treatment compared to TP53 wild-type cells (apoptosis and viability)."	27034505	PubMed		"Jennis et al., 2016, Genes Dev."		2	accepted	1209	Common Germline	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1209	https://civicdb.org/links/molecular_profiles/500	FALSE	TP53	7157	P47S		chr17	7676230	7676230	G	A	ENST00000269305.4	75		missense_variant	"NM_000546.5:c.139C>T,NP_000537.3:p.Pro47Ser,NC_000017.10:g.7579548G>A,ENST00000269305.4:c.139C>T"	2023-01-27 17:04:04 UTC	CA000053	43588	"PRO47SER,RS1800371"	FALSE
GNAQ Mutation	501	Uveal Melanoma	6039		JQ1		Predictive	Supports	D	Sensitivity/Response	"Preclinical study in uveal melanoma cell lines. Cell lines (n=4) with GNAQ mutation (92.1, Omm1.3, Mel270, Mel202) were more sensitive to BRD4 inhibition with JQ1 than GNAQ/GNA11 wild type (n=3) cell line. JQ1 also inhibited growth of a GNAQ mutant cell line (92.1) in a mouse xenograft model compared to vehicle (N=5 mice/group)."	26397223	PubMed		"Ambrosini et al., 2015, Oncotarget"		2	accepted	1210	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1210	https://civicdb.org/links/molecular_profiles/501	FALSE	GNAQ	2776	Mutation		chr9	77716087	78031458			ENST00000286548.4	75				2023-01-09 21:52:07 UTC				FALSE
GNA11 Mutation	502	Uveal Melanoma	6039		JQ1		Predictive	Supports	D	Sensitivity/Response	"Preclinical study in uveal melanoma cell lines. Cell lines (n=5) with GNAQ (92.1, Omm1.3, Mel270, Mel202) or GNA11 (Omm1) mutation were more sensitive to BRD4 inhibition with JQ1 than GNAQ/11 wild type (n=3) cell line."	26397223	PubMed		"Ambrosini et al., 2015, Oncotarget"		1	accepted	1211	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1211	https://civicdb.org/links/molecular_profiles/502	FALSE	GNA11	2767	Mutation		chr19	3094410	3124004			ENST00000078429.4	75				2023-01-09 21:52:07 UTC				FALSE
GNA11 Q209	554	Uveal Melanoma	6039		Selumetinib		Predictive	Does Not Support	B	Sensitivity/Response	"101 patients with metastatic uveal melanoma were randomized 1:1 to receive selumetinib or chemotherapy. Median PFS among patients randomized to chemotherapy was 7 weeks (95% CI, 4.3-8.4 weeks; median treatment duration, 8 weeks; interquartile range [IQR], 4.3-16 weeks) vs. 15.9 weeks with selumetinib (95% CI, 8.4-21.1 weeks; median treatment duration, 16.1 weeks; IQR, 8.1-25.3 weeks) (hazard ratio, 0.46; 95% CI, 0.30-0.71; P??.001). Most patients (80/96 evaluable harbored a mutation in exon 5 of GNAQ or GNA11) but PFS benefit from Selumetinib compared to chemotherapy was greater in the GNAQ and GNA11 wild-type population (25.9 weeks [range, 3.7-40.4 weeks] vs 15.4 weeks [range, 8.1-16.9 weeks]). However, PFS was still better with Selumetinib than chemotherapy in the GNA mutant population (hazard ratio 0.55, 95% CI, 0.34-0.87; P??.01). The difference was explained by potential GNAQ or GNA11 mutations outside of exon 5 in the GNA wild-type population. Another three mutations in exon 4 were retrospectively identified in the wild-type population and one had a major response."	24938562	PubMed		"Carvajal et al., 2014, JAMA"	NCT01143402	3	accepted	1212	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1212	https://civicdb.org/links/molecular_profiles/554	FALSE	GNA11	2767	Q209		chr19	3118944	3118944			ENST00000078429.4	75		missense_variant		2023-01-09 21:52:07 UTC		376001		FALSE
GNAQ Q209	503	Uveal Melanoma	6039		Selumetinib		Predictive	Does Not Support	B	Sensitivity/Response	"101 patients with metastatic uveal melanoma were randomized 1:1 to receive selumetinib or chemotherapy. Median PFS among patients randomized to chemotherapy was 7 weeks (95% CI, 4.3-8.4 weeks; median treatment duration, 8 weeks; interquartile range [IQR], 4.3-16 weeks) vs. 15.9 weeks with selumetinib (95% CI, 8.4-21.1 weeks; median treatment duration, 16.1 weeks; IQR, 8.1-25.3 weeks) (hazard ratio, 0.46; 95% CI, 0.30-0.71; P??.001). Most patients (80/96 evaluable harbored a mutation in exon 5 of GNAQ or GNA11) but PFS benefit from Selumetinib compared to chemotherapy was greater in the GNAQ and GNA11 wild-type population (25.9 weeks [range, 3.7-40.4 weeks] vs 15.4 weeks [range, 8.1-16.9 weeks]). However, PFS was still better with Selumetinib than chemotherapy in the GNA mutant population (hazard ratio 0.55, 95% CI, 0.34-0.87; P??.01). The difference was explained by potential GNAQ or GNA11 mutations outside of exon 5 in the GNA wild-type population. Another three mutations in exon 4 were retrospectively identified in the wild-type population and one had a major response."	24938562	PubMed		"Carvajal et al., 2014, JAMA"	NCT01143402	3	accepted	1213	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1213	https://civicdb.org/links/molecular_profiles/503	FALSE	GNAQ	2776	Q209		chr9	77794571	77794573			ENST00000286548.4	75		protein_altering_variant		2023-01-09 21:52:07 UTC		"375,957,375,956,375,000"	GLN209	FALSE
PMS2 K706FS*19	504	Glioblastoma	3068		Nivolumab		Predictive	Supports	C	Sensitivity/Response	"Two siblings (6 and 3.5 years) from nonconsanguineous parents were diagnosed with glioblastoma multiforme. Both tumors harbored TP53 mutations and lack of MGMT promoter hypermethylation as poor prognostic markers. Germline homozygous c.2117delA, p. Lys706SerfsX19 mutation in PMS2, loss of PMS2 staining in the tumor and normal tissue confirmed a diagnosis of biallelic mismatch repair deficiency (bMMRD). Both tumors harbored driver mutations in POLE and were found to harbor 24,680 and 21,919 mutations per exome. Neoantigen load was assessed in 37 bMMRD patients and all malignant tumors had high numbers of predicted neoantigens (7-16x as high as in melanoma, lung or other immunoresponsive cancers). Treatment with nivolumab was begun and both patients had radiologic response. After 9 and 5 months of therapy, respectively, the patient and her brother resumed normal schooling and daily activities."	27001570	PubMed		"Bouffet et al., 2016, J. Clin. Oncol."		4	accepted	1214	Rare Germline	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1214	https://civicdb.org/links/molecular_profiles/504	FALSE	PMS2	5395	K706FS*19		chr7	5982881	5982881			ENST00000265849.7	75		minus_1_frameshift_variant	"NM_000535.6:c.2117delA,NP_000526.2:p.Lys706Serfs,NC_000007.13:g.6022512del"	2023-01-09 21:52:07 UTC		142765	"RS587782704,LYS706SERFS"	FALSE
KRAS G12D	79	Colorectal Cancer	9256				Prognostic	Supports	B	Better Outcome	"In 119 metastatic colorectal cancer patients treated with cetuximab-based first-line chemotherapy, KRAS G12D mutations (N=44) were associated with longer overall patient survival when compared to other KRAS G12 mutations (23.3 vs 14-18 months; G12V, A, C, S, R)."	22948721	PubMed		"Modest et al., 2012, Oncology"		3	accepted	1215	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/1215	https://civicdb.org/links/molecular_profiles/79	FALSE	KRAS	3845	G12D	EGFR TKI Resistance	chr12	25245350	25245350	C	T	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.35G>A,NP_004976.2:p.Gly12Asp,NC_000012.11:g.25398284C>T,ENST00000256078.4:c.35G>A"	2023-01-27 17:02:26 UTC	CA122538	12582	"GLY12ASP,RS121913529"	FALSE
KRAS G12C	78	Colorectal Cancer	9256		"Gefitinib,Erlotinib"	Substitutes	Predictive	Supports	B	Resistance	"In a study of 448 metastatic colorectal cancer patients treated with EGFR-TKIs and tested for EGFR and KRAS mutations, 69 tested positive for KRAS mutations. In 38 EGFR wildtype patients treated with erlotinib or gefitinib, those with KRAS G12C mutations (n=24) had shorter progression free survival rates compared to patients with non-G12C KRAS mutations (n=14; 4.3 vs 9 weeks; P = 0.009; HR=2.7). This was true when restricted to patients with an adenocarcinoma subtype only (n=18 vs 12; 4.1 vs 9 weeks; P = 0.007; HR=3.1). Overall survival was not different between groups."	23313110	PubMed		"Fiala et al., 2013, Cancer Genet"		3	accepted	1216	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/1216	https://civicdb.org/links/molecular_profiles/78	FALSE	KRAS	3845	G12C	EGFR TKI Resistance	chr12	25245351	25245351	C	A	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.34G>T,NP_004976.2:p.Gly12Cys,NC_000012.11:g.25398285C>A,ENST00000256078.4:c.34G>T"	2023-01-27 17:02:26 UTC	CA122528	12578	"GLY12CYS,RS121913530"	FALSE
KRAS G12C	78	Lung Non-small Cell Carcinoma	3908				Prognostic	Supports	B	Poor Outcome	"In a study of 48 NSCLC patients, those with G12C or G12V mutant KRAS were associated with decreased progression free survival (1.84 months) compared with other KRAS mutants or with wild-type KRAS (3.35 and 1.95 months)."	22247021	PubMed		"Ihle et al., 2012, J. Natl. Cancer Inst."		3	accepted	1217	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/1217	https://civicdb.org/links/molecular_profiles/78	FALSE	KRAS	3845	G12C	EGFR TKI Resistance	chr12	25245351	25245351	C	A	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.34G>T,NP_004976.2:p.Gly12Cys,NC_000012.11:g.25398285C>A,ENST00000256078.4:c.34G>T"	2023-01-27 17:02:26 UTC	CA122528	12578	"GLY12CYS,RS121913530"	FALSE
KRAS Mutation	332	Lung Adenocarcinoma	3910		Salirasib		Predictive	Does Not Support	B	Sensitivity/Response	"In a study of 30 lung adenocarcinoma patients with documented KRAS mutations, farnesylthiosalicylic acid (Salirasib) mono-therapy resulted in no partial responses and did not improve overall survival rates compared to previously untreated patients."	21847063	PubMed		"Riely et al., 2011, J Thorac Oncol"		3	accepted	1218	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/1218	https://civicdb.org/links/molecular_profiles/332	FALSE	KRAS	3845	Mutation		chr12	25209431	25250803			ENST00000256078.4	75		protein_altering_variant		2023-01-09 21:52:06 UTC		N/A		FALSE
KRAS Exon 2 Mutation	75	Pancreatic Cancer	1793		"Gemcitabine,Erlotinib"	Combination	Predictive	Supports	B	Resistance	"In a retrospective study of 136 pancreatic cancer patients, point mutations in KRAS exon 2 were associated with worse overall survival compared to that of wild-type KRAS (5.8 vs 8.0 months; P = 0.001; multivariate analysis). This difference was largely driven by the subgroup of patients with reduced response to gemcitabine-erlotinib combination therapy (7.5% vs 23.3%) with overall survival of 5.2 vs 9.7 months (N=40 vs 30) compared to those that received other therapies with an overall survival of 7.0 months for both KRAS mutated (N=31) and KRAS wildtype (N=35) patients."	21862683	PubMed		"Kim et al., 2011, Mol. Cancer Ther."		4	accepted	1219	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/1219	https://civicdb.org/links/molecular_profiles/75	FALSE	KRAS	3845	Exon 2 Mutation		chr12	25245274	25245395			ENST00000256078.4	75		missense_variant		2023-01-09 21:52:04 UTC				FALSE
KRAS Mutation	332	Lung Non-small Cell Carcinoma	3908		Trametinib		Predictive	Supports	B	Sensitivity/Response	"In a phase 1 clinical trial for the use of trametinib for various advanced solid tumors, 22 out of 30 NSCLC patients harbored KRAS mutations. Of those 22 patients with mutant KRAS, 8 saw reductions in tumor size ranging from 6-52% including 2 partial responses."	22805291	PubMed		"Infante et al., 2012, Lancet Oncol."	NCT00687622	2	accepted	1220	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/1220	https://civicdb.org/links/molecular_profiles/332	FALSE	KRAS	3845	Mutation		chr12	25209431	25250803			ENST00000256078.4	75		protein_altering_variant		2023-01-09 21:52:06 UTC		N/A		FALSE
KIT Exon 9 Mutation	505	Gastrointestinal Stromal Tumor	9253		Imatinib		Predictive	Supports	A	Sensitivity/Response	"In a phase III clinical trial comparing different doses of imatinib in GIST patients, KIT exon 9 mutations were associated with significantly improved progression free survival (P=0.0013) and a 61% relative risk reduction in response to the higher dose regimen (N=31; 800mg/daily) when compared to the lower dose regimen (N=27; 400 mg/daily; HR 0.329; 95% CI 0.218?.706). The same dose dependent responses were not observed with KIT exon 11 mutations (N=130 vs 118; P=0.25; HR 0.821; 95% CI 0.585?.151) or with wild-type KIT (N=25 vs 27; P=0.07; HR 1.823; 95% CI 0.938?.543)."	16624552	PubMed		"Debiec-Rychter et al., 2006, Eur. J. Cancer"		4	accepted	1221	Somatic	2023-03-02 22:26:54 UTC	https://civicdb.org/links/evidence_items/1221	https://civicdb.org/links/molecular_profiles/505	FALSE	KIT	3815	Exon 9 Mutation		chr4	54725857	54726050			ENST00000288135.5	75		exon_variant		2023-01-09 21:52:07 UTC				FALSE
KIT Mutation	384	Melanoma	1909		Imatinib		Predictive	Supports	B	Sensitivity/Response	"In a phase II clinical trial of 43 melanoma patients harboring KIT mutations or amplifications, imatinib treatment exhibited significant anti-tumor activity with a median progression free survival of 3.5 months, tumor regression in 41.9% of patients, and a 1-year overall survival rate of 51%. 9/10 partial responses were in patients with exon 11 or 13 KIT mutations."	21690468	PubMed		"Guo et al., 2011, J. Clin. Oncol."		3	accepted	1222	Somatic	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/1222	https://civicdb.org/links/molecular_profiles/384	FALSE	KIT	3815	Mutation		chr4	54657918	54740715			ENST00000288135.5	75		transcript_variant		2023-01-09 21:52:06 UTC		N/A		FALSE
KIT Exon 9 Mutation	505	Gastrointestinal Stromal Tumor	9253		Sunitinib		Predictive	Supports	B	Sensitivity/Response	"Primary tumor genotyping of 89 patients with metastatic GIST given 2nd-line sunitinib treatment after prior imatinib therapy failure, revealed an improved response to sunitinib in patients with KIT exon 9 mutations or with wild-type KIT compared those with KIT exon 11 or PDGFRA mutations. 1-year progression free survival rates for exon 9 mutants and wild type were 68% and 57%, compared with 34% and 15% for exon 11 and PDGFRA mutants."	22439647	PubMed		"Rutkowski et al., 2012, BMC Cancer"		3	accepted	1223	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1223	https://civicdb.org/links/molecular_profiles/505	FALSE	KIT	3815	Exon 9 Mutation		chr4	54725857	54726050			ENST00000288135.5	75		exon_variant		2023-01-09 21:52:07 UTC				FALSE
KIT Exon 11 Mutation	66	Melanoma	1909		Sunitinib		Predictive	Supports	C	Sensitivity/Response	"10 melanoma patients were evaluated after sunitinib treatment, among which 3 out of the 4 patients with KIT exon 11 mutations showed either complete or partial response."	22261812	PubMed		"Minor et al., 2012, Clin. Cancer Res."		3	accepted	1224	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/1224	https://civicdb.org/links/molecular_profiles/66	FALSE	KIT	3815	Exon 11 Mutation	KIT Exon 11	chr4	54727416	54727542			ENST00000288135.5	75		coding_sequence_variant		2023-01-09 21:52:04 UTC				FALSE
NRAS Mutation	208	Skin Melanoma	8923		"Docetaxel,Trametinib"	Combination	Predictive	Supports	B	Sensitivity/Response	"Phase 1 trial of trametinib and docetaxel in patients with advanced melanoma lacking BRAF V600 mutations. 15 patients were enrolled (14 BRAF wt). Six patients had a partial response, including four out of eight patients with NRAS mutations."	25542057	PubMed		"Coupe et al., 2015, Eur. J. Cancer"		2	accepted	1225	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/1225	https://civicdb.org/links/molecular_profiles/208	FALSE	NRAS	4893	Mutation		chr1	114704469	114716894			ENST00000369535.4	75		"transcript_variant,gain_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
NRAS Q61	94	Skin Melanoma	8923		Binimetinib		Predictive	Supports	B	Sensitivity/Response	"Phase 2 study of MEK162 in patients with advanced melanoma and NRAS or BRAF mutation. 71 patients were enrolled, 6/30 patients with NRAS mutation had a partial response (Gln61Leu 1 Patient, Gln61Lys 9 Patients, Gln61Arg 15 Patients). Another 13 patients had stable disease (63% disease control rate)."	23414587	PubMed		"Ascierto et al., 2013, Lancet Oncol."	NCT01320085	2	accepted	1226	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/1226	https://civicdb.org/links/molecular_profiles/94	FALSE	NRAS	4893	Q61		chr1	114713907	114713909			ENST00000369535.4	75		missense_variant		2023-01-09 21:52:04 UTC		"7,305,813,900,375,870,000,000,000,000,000,000,000,000"	GLN61	FALSE
NRAS Mutation	208	Melanoma	1909		Trametinib		Predictive	Does Not Support	B	Sensitivity/Response	"Phase 1 trial in 97 patients with melanoma (81 cutaneous or unknown, 16 uveal). Seven patients were found to harbor an NRAS mutation and two of them experienced stable disease (one 48 weeks on treatment). Patients with concurrent BRAFV600wt/NRASwt (n=20) had a trend of higher response rates (20%) than BRAFV600wt/NRAS-mutant patients (n=11; RR=0%; p=0.27), as well as a trend of higher percentage of patients on study at Week 24 or at 1 year (40% vs. 18% [p=0.26] and 30% vs. 0% [p=0.07], respectively)."	22805292	PubMed		"Falchook et al., 2012, Lancet Oncol."	NCT00687622	2	accepted	1227	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/1227	https://civicdb.org/links/molecular_profiles/208	FALSE	NRAS	4893	Mutation		chr1	114704469	114716894			ENST00000369535.4	75		"transcript_variant,gain_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
GNA11 Mutation	502	Uveal Melanoma	6039		Trametinib		Predictive	Supports	C	Sensitivity/Response	"Phase 1 study of trametinib in 97 patients with melanoma (16 with uveal melanoma). Analysis in patients with uveal melanoma identified GNAQ and GNA11 mutations in six patients, in which three SD and three PD were the best responses. One patient with a GNA11 mutation identified by Illumina genotyping stayed on study treatment for >40 weeks."	22805292	PubMed		"Falchook et al., 2012, Lancet Oncol."	NCT00687622	2	accepted	1228	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1228	https://civicdb.org/links/molecular_profiles/502	FALSE	GNA11	2767	Mutation		chr19	3094410	3124004			ENST00000078429.4	75				2023-01-09 21:52:07 UTC				FALSE
GNAQ Mutation	501	Uveal Melanoma	6039		Trametinib		Predictive	Supports	B	Sensitivity/Response	"Phase 1 study of trametinib in 97 patients with melanoma (16 with uveal melanoma). Analysis in patients with uveal melanoma identified GNAQ and GNA11 mutations in six patients, in which three SD and three PD were the best responses. One patient with a GNA11 mutation identified by Illumina genotyping stayed on study treatment for >40 weeks."	22805292	PubMed		"Falchook et al., 2012, Lancet Oncol."	NCT00687622	2	accepted	1229	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1229	https://civicdb.org/links/molecular_profiles/501	FALSE	GNAQ	2776	Mutation		chr9	77716087	78031458			ENST00000286548.4	75				2023-01-09 21:52:07 UTC				FALSE
NRAS Mutation	208	Cancer	162		"Metformin,Trametinib"	Combination	Predictive	Supports	D	Sensitivity/Response	"Preclinical study in 16 NRAS mutant cell lines (melanoma, lung carcinoma, neuroblastoma with various Q61, G13, G12 mutations). The combination of metformin and trametinib shown synergistic effects in most tested cell lines (no antagonistic effects observed) and a melanoma xenograft model. Metformin-induced PI3K pathway suppression was identified as a potential mechanism."	25504439	PubMed		"Vujic et al., 2015, Oncotarget"		3	accepted	1230	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/1230	https://civicdb.org/links/molecular_profiles/208	FALSE	NRAS	4893	Mutation		chr1	114704469	114716894			ENST00000369535.4	75		"transcript_variant,gain_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
PTEN Deletion	213	Prostate Cancer	10283		Everolimus		Predictive	Supports	B	Sensitivity/Response	"In a phase II trial on castration-resistant prostate cancer patients, FISH detection of PTEN deletion was associated with increased progression free survival (p=0.07) and with improved PSA response (p=0.02) in response to everolimus, an mTOR pathway inhibitor."	23582881	PubMed		"Templeton et al., 2013, Eur. Urol."	NCT00976755	3	accepted	1231	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/1231	https://civicdb.org/links/molecular_profiles/213	FALSE	PTEN	5728	Deletion		chr10	87863113	87971930			ENST00000371953.3	75		transcript_ablation		2023-01-09 21:52:05 UTC		NONE FOUND		FALSE
PTEN Mutation	506	Endometrial Carcinoma	2871		Everolimus		Predictive	Does Not Support	B	Sensitivity/Response	"Tumors from 35 patients (12 with partial response or stable disease) with advanced endometrial carcinoma were assessed for PTEN mutational status, revealing 12 tumors with non-identical PTEN gene mutations. No mutations found in PTEN were effective in predicting tumor response to everolimus treatment. The clinical trial associated with this study is NCT00870337."	23238879	PubMed		"Trdan et al., 2013, Target Oncol"	NCT00870337	3	accepted	1232	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1232	https://civicdb.org/links/molecular_profiles/506	FALSE	PTEN	5728	Mutation		chr10	87863113	87971930			ENST00000371953.3	75		protein_altering_variant		2023-01-09 21:52:07 UTC		N/A		FALSE
GNAQ Q209	503	Uveal Melanoma	6039		Refametinib		Predictive	Supports	C	Sensitivity/Response	"Phase 1 study of MAPK1/2 inhibitor BAY 86-9766. 53 patients were evaluated for efficacy, one patients achieved a PR and 11 patients had stable disease. One ocular melanoma patient with prolonged stable disease, who later went on to complete 28 courses, was positive for GNAQ Q209L and PTEN R173S mutations. The PTEN mutation was identified only in the postdose biopsy and not in the predose biopsy."	23434733	PubMed		"Weekes et al., 2013, Clin. Cancer Res."		2	accepted	1233	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1233	https://civicdb.org/links/molecular_profiles/503	FALSE	GNAQ	2776	Q209		chr9	77794571	77794573			ENST00000286548.4	75		protein_altering_variant		2023-01-09 21:52:07 UTC		"375,957,375,956,375,000"	GLN209	FALSE
BAP1 Mutation	183	Uveal Melanoma	6039		"Valproic Acid,Panobinostat,Vorinostat,Trichostatin A"	Substitutes	Predictive	Supports	D	Sensitivity/Response	"Somatic and germline BAP1 mutations are associated with uveal melanoma. In this preclinical study, gene set enrichment analysis revealed HDAC inhibitors as potential drugs in BAP1 mutant uveal melanomas. HDAC inhibitors VPA, TSA, LBH-589, and SAHA (vorinostat) were tested in-vitro and led to decreased proliferation (all inhibitors) decreased viability and cytotoxicity (TSA, SAHA, LBH-589) in-vitro and in-vivo (VPA). RNAi mediated BAP1 knockdown increased sensitivity to HDAC inhibition (VPA)."	22038994	PubMed		"Landreville et al., 2012, Clin. Cancer Res."		3	accepted	1234	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/1234	https://civicdb.org/links/molecular_profiles/183	FALSE	BAP1	8314	Mutation		chr3	52401013	52410350			ENST00000460680.1	75		"protein_altering_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
BAP1 Mutation	183	Malignant Mesothelioma	1790		"Vorinostat,MC1568,Mocetinostat"	Substitutes	Predictive	Supports	E	Sensitivity/Response	"A siRNA screen identified BAP1 associated with HDAC1 and HDAC2 expression. HDAC2 or BAP1 depletion sensitized a mesothelioma cell line (MSTO-211H) to HDAC inhibitors MC1568, vorinostat or mocetinostat. The paper indicates however, that temporary BAP knockdown might not adequately reflect long-term BAP1 mutation."	25970771	PubMed		"Sacco et al., 2015, Oncotarget"		2	accepted	1235	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/1235	https://civicdb.org/links/molecular_profiles/183	FALSE	BAP1	8314	Mutation		chr3	52401013	52410350			ENST00000460680.1	75		"protein_altering_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
FGFR2 Mutation	507	Endometrial Cancer	1380		Ponatinib		Predictive	Supports	D	Sensitivity/Response	"Preclinical study in endometrial cancer cell lines (MFE-296, AN3CA, MFE-280 and Ishikawa). In cell proliferation assays, the three FGFR2 mutant cell lines were more sensitive to the pan-FGFR inhibitor ponatinib (AP24534) than the FGFR2 wild type cell line (Ishikawa) and human embryonic kidney cell line (HEK293). Ponatinib also inhibited FGFR2 kinase activity and phosphorylation (MFE-296 and MFE-280) as well as cell migration and invasion (MFE-296 and AN3CA) of FGFR2 mutated cancer cell lines."	26574622	PubMed		"Kim et al., 2016, Cancer Biol. Ther."		3	accepted	1236	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1236	https://civicdb.org/links/molecular_profiles/507	FALSE	FGFR2	2263	Mutation		chr10	121479857	121598403			ENST00000457416.2	75		"transcript_variant,gain_of_function_variant"		2023-01-09 21:52:07 UTC		"37,615,737,615,637,600,000,000"		FALSE
ALK Mutation	508	Lung Non-small Cell Carcinoma	3908		Ceritinib		Predictive	Supports	B	Sensitivity/Response	"In a phase 1 clinical trial (NCT01283516) 130 patients with advanced cancers all harboring ALK alterations were treated with ceritinib.  Of 114 NSCLC patients treated with at least 400 mg/daily ceritinib, 1 had a complete response, 65 had a partial response, 25 had stable disease, 12 had progressive disease, and 11 withdrew from the study early. Ceritinib dosed at 400 mg or higher had similar results in patients who had or had not received prior crizotinib treatment. Overall response rate for patients with prior crizotinib treatment (83 out of 122) was 56% with median progression free survival of 6.9 months. For patients who had no prior crizotinib treatment, median progression free survival was 10.4 months."	24670165	PubMed		"Shaw et al., 2014, N. Engl. J. Med."	NCT01283516	4	accepted	1237	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1237	https://civicdb.org/links/molecular_profiles/508	FALSE	ALK	238	Mutation		chr2	29192774	29921566			ENST00000389048.3	75		"gene_variant,gain_of_function_variant"		2023-01-09 21:52:07 UTC		N/A		FALSE
DNMT3A Mutation	189	Myelodysplastic Syndrome	50908				Prognostic	Supports	B	Poor Outcome	"12/150 patients with de novo myelodysplastic syndrome screened for DNMT3A mutations (bone marrow and paired normal skin) had heterozygous mutations with predicted translational consequences. 1 patient was identified with 2 nonsynonymous coding mutations. R882 mutations accounted for 4/13 reported mutations, P904L for 2/13 mutations and the remaining had not been previously reported at the time of this report. Overall and event-free survival were worse for DNMT3A mutant patients although transplantation status was not considered (log-rank p=0.005 and p=0.009). Transformation to AML was increased for mutant 7/12 (58%) versus wildtype 39/138 (28%) patients (p=0.007). The authors note larger cohorts will be required to confirm these results."	21415852	PubMed		"Walter et al., 2011, Leukemia"		3	accepted	1238	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/1238	https://civicdb.org/links/molecular_profiles/189	FALSE	DNMT3A	1788	Mutation		chr2	25232976	25342590			ENST00000264709.3	75		transcript_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
ALK NPM::ALK	509	Anaplastic Large Cell Lymphoma	50744		Crizotinib		Predictive	Supports	D	Sensitivity/Response	"NPM-ALK in anaplastic large cell lymphoma (ALCL) was the first ALK-fusion to be discovered and characterized.  In this study, targeted activity against NPM-ALK by the ALK and MET inhibitor crizotinib was assessed in cell lines and tumor xenograft models. Treatment of NPM-ALK positive ALCL cell lines Karpas299 and SU-DHL-1 potently inhibited growth, and this was seen to occur at concentrations which also inhibited NPM-ALK phosphorylation in these cells. Administration of 100mg/kg/d crizotinib resulted in complete regression of all tumors, indicating that NPM-ALK could be an effective target for crizotinib in ALCL."	18089725	PubMed		"Christensen et al., 2007, Mol. Cancer Ther."		5	accepted	1239	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1239	https://civicdb.org/links/molecular_profiles/509	FALSE	ALK	238	NPM::ALK	ALK Fusion	chr5	171387116	171391799			ENST00000517671.1	75	ENST00000389048.3	transcript_fusion		2023-01-09 21:52:07 UTC		N/A	"T(2;5)(P23;Q35),NPM-ALK"	FALSE
ALK NPM::ALK	509	Anaplastic Large Cell Lymphoma	50744		Crizotinib		Predictive	Supports	D	Sensitivity/Response	"NPM-ALK in anaplastic large cell lymphoma (ALCL) was the first ALK-fusion to be discovered and characterized.  In this study, targeted activity against NPM-ALK by the ALK and MET inhibitor crizotinib was assessed in cell lines and tumor xenograft models. Treatment of NPM-ALK positive ALCL cell lines Karpas299 and SU-DHL-1 potently inhibited growth, and this was seen to occur at concentrations which also inhibited NPM-ALK phosphorylation in these cells. Administration of 100mg/kg/d crizotinib resulted in complete regression of all tumors, indicating that NPM-ALK could be an effective target for crizotinib in ALCL."	18089725	PubMed		"Christensen et al., 2007, Mol. Cancer Ther."		5	accepted	1239	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1239	https://civicdb.org/links/molecular_profiles/509	FALSE	ALK	238	NPM::ALK	ALK Fusion	chr2	29192774	29223528			ENST00000517671.1	75	ENST00000389048.3	transcript_fusion		2023-01-09 21:52:07 UTC		N/A	"T(2;5)(P23;Q35),NPM-ALK"	FALSE
ALK Fusion	495	Anaplastic Large Cell Lymphoma	50744		Crizotinib		Predictive	Supports	C	Sensitivity/Response	"Crizotinib at 250mg daily was given to two patients with relapsed ALK-rearranged anaplastic large cell lymphoma (ALCL). Patient one, 26 yrs old, had been treated with the CHOP-15 chemotherapy regimen, then salvage chemotherapy to prepare for autologous bone marrow transplant but ultimately relapsed. After initiation of crizotinib, PET, CT and bone marrow aspirates showed complete remission of previous lesions at 28 days. At time of publication the patient continued to show persistent response at 6 months. A 20 year old patient relapsed after one month of CHOP, and was treated with further chemotherapy and autologous bone marrow transplantation resulting in partial response of 1 month. Crizotinib was initialized, and after 12 days PET scan showed complete regression of all lesions. On day 60 bone marrow aspirates were ALK-negative (pretreatment evaluation showed 8% ALK-positive). The authors conclude these two cases indicate sensitivity to crizotinib of relapsed ALK-rearranged ALCL."	21345110	PubMed		"Gambacorti-Passerini et al., 2011, N. Engl. J. Med."		4	accepted	1240	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1240	https://civicdb.org/links/molecular_profiles/495	FALSE	ALK	238	Fusion	ALK Fusion	chr2	29192774	29223528			ENST00000389048.3	75		transcript_fusion		2023-01-09 21:52:07 UTC		N/A	REARRANGEMENT	FALSE
ALK NPM::ALK	509	Anaplastic Large Cell Lymphoma	50744		Crizotinib		Predictive	Supports	B	Sensitivity/Response	"In the second part of this Phase I study NCT00939770, nine patients between the ages of 12 months and 22 years with anaplastic large cell lymphoma (ALCL), who were refractory to treatment and for whom no further known treatments were available, were treated with crizotinib. Six patients with detectable NPM-ALK transcript levels responded with partial response, 1 with complete response, and 1 with stable disease.  Crizotinib was well tolerated in these children."	23598171	PubMed		"Moss et al., 2013, Lancet Oncol."	NCT00939770	4	accepted	1241	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1241	https://civicdb.org/links/molecular_profiles/509	FALSE	ALK	238	NPM::ALK	ALK Fusion	chr5	171387116	171391799			ENST00000517671.1	75	ENST00000389048.3	transcript_fusion		2023-01-09 21:52:07 UTC		N/A	"T(2;5)(P23;Q35),NPM-ALK"	FALSE
ALK NPM::ALK	509	Anaplastic Large Cell Lymphoma	50744		Crizotinib		Predictive	Supports	B	Sensitivity/Response	"In the second part of this Phase I study NCT00939770, nine patients between the ages of 12 months and 22 years with anaplastic large cell lymphoma (ALCL), who were refractory to treatment and for whom no further known treatments were available, were treated with crizotinib. Six patients with detectable NPM-ALK transcript levels responded with partial response, 1 with complete response, and 1 with stable disease.  Crizotinib was well tolerated in these children."	23598171	PubMed		"Moss et al., 2013, Lancet Oncol."	NCT00939770	4	accepted	1241	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1241	https://civicdb.org/links/molecular_profiles/509	FALSE	ALK	238	NPM::ALK	ALK Fusion	chr2	29192774	29223528			ENST00000517671.1	75	ENST00000389048.3	transcript_fusion		2023-01-09 21:52:07 UTC		N/A	"T(2;5)(P23;Q35),NPM-ALK"	FALSE
ALK Fusion	495	Inflammatory Myofibroblastic Tumor	50905		Crizotinib		Predictive	Supports	B	Sensitivity/Response	"As part of a phase 1 dose-escalation trial (NCT00939770), seven patients between ages 12 months and 22 years with relapsed or refractory inflammatory myofibroblastic tumors with ALK-rearrangement were given crizotinib. In six patients with measurable disease, responses included 3 with partial response and 3 with stable disease. One patient with evaluable disease had stable disease with treatment ongoing at the time of publication. Crizotinib was well tolerated in this group of pediatric patients."	23598171	PubMed		"Moss et al., 2013, Lancet Oncol."	NCT00939770	3	accepted	1243	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1243	https://civicdb.org/links/molecular_profiles/495	FALSE	ALK	238	Fusion	ALK Fusion	chr2	29192774	29223528			ENST00000389048.3	75		transcript_fusion		2023-01-09 21:52:07 UTC		N/A	REARRANGEMENT	FALSE
ALK RANBP2::ALK	510	Inflammatory Myofibroblastic Tumor	50905		Crizotinib		Predictive	Supports	C	Sensitivity/Response	"ALK-rearrangements are seen in 50% of inflammatory myofibroblastic tumor (IMT) cases. A 44 year old man was diagnosed with IMT.  He was treated with surgery and catheter placement for administration of cisplatin, doxyrubicin and mitomycin C.  Break-apart FISH showed ALK rearrangement, and immunohistochemical staining was characteristic of RANBP2 rearrangement. After further chemotherapy along with maintenance imatinib, crizotinib was started at 200mg twice daily, and a maximal partial response was achieved 5 months later, with regrowth occurring 2 months later. After further surgery, crizotinib was restarted at 250mg twice daily and almost 2 years later the patient was in complete radiographic remission. Another patient with non-ALK rearranged IMT was administered crizotinib in this study but did not respond."	20979472	PubMed		"Butrynski et al., 2010, N. Engl. J. Med."	NCT00585195	4	accepted	1244	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1244	https://civicdb.org/links/molecular_profiles/510	FALSE	ALK	238	RANBP2::ALK	ALK Fusion	chr2	108719481	108758548			ENST00000283195.6	75	ENST00000389048.3	transcript_fusion		2023-01-09 21:52:07 UTC		N/A	RANBP2-ALK	FALSE
ALK RANBP2::ALK	510	Inflammatory Myofibroblastic Tumor	50905		Crizotinib		Predictive	Supports	C	Sensitivity/Response	"ALK-rearrangements are seen in 50% of inflammatory myofibroblastic tumor (IMT) cases. A 44 year old man was diagnosed with IMT.  He was treated with surgery and catheter placement for administration of cisplatin, doxyrubicin and mitomycin C.  Break-apart FISH showed ALK rearrangement, and immunohistochemical staining was characteristic of RANBP2 rearrangement. After further chemotherapy along with maintenance imatinib, crizotinib was started at 200mg twice daily, and a maximal partial response was achieved 5 months later, with regrowth occurring 2 months later. After further surgery, crizotinib was restarted at 250mg twice daily and almost 2 years later the patient was in complete radiographic remission. Another patient with non-ALK rearranged IMT was administered crizotinib in this study but did not respond."	20979472	PubMed		"Butrynski et al., 2010, N. Engl. J. Med."	NCT00585195	4	accepted	1244	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1244	https://civicdb.org/links/molecular_profiles/510	FALSE	ALK	238	RANBP2::ALK	ALK Fusion	chr2	29192774	29223528			ENST00000283195.6	75	ENST00000389048.3	transcript_fusion		2023-01-09 21:52:07 UTC		N/A	RANBP2-ALK	FALSE
ALK EML4::ALK e20-e20	496	Cancer	162		Crizotinib		Predictive	Supports	C	Sensitivity/Response	"This case study presented a 53-year-old never-smoker with a poorly differentiated malignant neoplasm. Morphology and immunohistochemistry were unable to establish the primary tumor site. Right upper extremity (RUE), scalp, and multiple lung lesions were apparent. A lung lesion sample with sufficient material for molecular profiling was not attainable but sufficient material was present from the RUE for hybrid capture genomic profiling  (FoundationOne kit was used). EML4-ALK variant 2 was found, and the patient was started on crizotinib. Rapid symptom improvement was seen. After 1 month, a CT scan showed significant size reduction in lung tumors, and after 5 months the patient was asymptomatic with an entirely negative examination."	25408655	PubMed		"Chung et al., 2014, Case Rep Oncol"		3	accepted	1245	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1245	https://civicdb.org/links/molecular_profiles/496	FALSE	ALK	238	EML4::ALK e20-e20	ALK Fusion	chr2	42169350	42325554			ENST00000318522.5	75	ENST00000389048.3	transcript_fusion		2023-01-09 21:52:07 UTC		N/A	EML4-ALK E20-E20	FALSE
ALK EML4::ALK e20-e20	496	Cancer	162		Crizotinib		Predictive	Supports	C	Sensitivity/Response	"This case study presented a 53-year-old never-smoker with a poorly differentiated malignant neoplasm. Morphology and immunohistochemistry were unable to establish the primary tumor site. Right upper extremity (RUE), scalp, and multiple lung lesions were apparent. A lung lesion sample with sufficient material for molecular profiling was not attainable but sufficient material was present from the RUE for hybrid capture genomic profiling  (FoundationOne kit was used). EML4-ALK variant 2 was found, and the patient was started on crizotinib. Rapid symptom improvement was seen. After 1 month, a CT scan showed significant size reduction in lung tumors, and after 5 months the patient was asymptomatic with an entirely negative examination."	25408655	PubMed		"Chung et al., 2014, Case Rep Oncol"		3	accepted	1245	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1245	https://civicdb.org/links/molecular_profiles/496	FALSE	ALK	238	EML4::ALK e20-e20	ALK Fusion	chr2	29192774	29223528			ENST00000318522.5	75	ENST00000389048.3	transcript_fusion		2023-01-09 21:52:07 UTC		N/A	EML4-ALK E20-E20	FALSE
FGFR1 N546K	511	Ewing Sarcoma Of Bone	3368		Ponatinib		Predictive	Supports	E	Sensitivity/Response	"116 Ewing's sarcoma tumor samples were analyzed in this study. 2 patient's samples underwent whole genome sequencing, tumor samples from 51 patients underwent exome sequencing and expression analysis, 63 samples underwent FGFR1 copy number analysis, mRNA analysis and IHC. A FGFR1 N546K mutation was detected in one patient. Gain of the FGFR1 locus (qPCR) was observed in 13 of 41 patients (31.7%) and Ewing sarcoma cell lines (A673, CADO, SK-NMC, SK-ES, and VH-64). FGFR1 was also highly expressed in Ewing sarcoma (mRNA and IHC) and correlated with copy number. Retroviral transduction of FGFR1 wild-type or the FGFR1 N546K mutant into NIH3T3 cells led to enhanced proliferation especially for cells harboring the FGFR1 mutation. ShRNA mediated knockdown of FGFR1 inhibited growth of Ewing sarcoma and other cancer cells (A549 lung carcinoma cell line or leukemia cell lines HL60 and Kasumi) with almost complete growth suppression only in the Ewing sarcoma cell lines and knockdown of FGFR1 abrogated growth of cell lines in xenograft. Ponatinib treatment inhibited growth of Ewing sarcoma cell lines."	26179511	PubMed		"Agelopoulos et al., 2015, Clin. Cancer Res."		2	accepted	1246	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1246	https://civicdb.org/links/molecular_profiles/511	FALSE	FGFR1	2260	N546K		chr8	38417331	38417331	G	T	ENST00000341462.5	75		missense_variant	"NM_023110.2:c.1638C>A,NP_075598.2:p.Asn546Lys,ENST00000341462.5:c.1638C>A,NC_000008.10:g.38274849G>T"	2023-01-27 17:04:05 UTC	CA357830	224896	"ASN546LYS,RS779707422"	FALSE
FGFR1 Amplification	263	Ewing Sarcoma Of Bone	3368		Ponatinib		Predictive	Supports	D	Sensitivity/Response	"116 Ewing's sarcoma tumor samples were analyzed in this study. 2 patient's samples underwent whole genome sequencing, tumor samples from 51 patients underwent exome sequencing and expression analysis, 63 samples underwent FGFR1 copy number analysis, mRNA analysis and IHC. A FGFR1 N546K mutation was detected in one patient. Gain of the FGFR1 locus (qPCR) was observed in 13 of 41 patients (31.7%) and Ewing sarcoma cell lines (A673, CADO, SK-NMC, SK-ES, and VH-64). FGFR1 was also highly expressed in Ewing sarcoma (mRNA and IHC) and correlated with copy number. Retroviral transduction of FGFR1 wild-type or the FGFR1 N546K mutant into NIH3T3 cells led to enhanced proliferation especially for cells harboring the FGFR1 mutation. ShRNA mediated knockdown of FGFR1 inhibited growth of Ewing sarcoma and other cancer cells (A549 lung carcinoma cell line or leukemia cell lines HL60 and Kasumi) with almost complete growth suppression only in the Ewing sarcoma cell lines and knockdown of FGFR1 abrogated growth of cell lines in xenograft. Ponatinib treatment inhibited growth of Ewing sarcoma cell lines."	26179511	PubMed		"Agelopoulos et al., 2015, Clin. Cancer Res."		3	accepted	1247	N/A	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/1247	https://civicdb.org/links/molecular_profiles/263	FALSE	FGFR1	2260	Amplification		chr8	38411138	38467845			ENST00000425967.3	75		transcript_amplification	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
ROS1 Rearrangement	265	Lung Adenocarcinoma	3910		Ceritinib		Predictive	Supports	C	Sensitivity/Response	"Case report of a 77-year old male patient with lung adenocarcinoma (T2aN1M0, stage IIA) without EGFR, KRAS, or BRAF mutations, and no ALK gene rearrangement. CD72-ROS1 was identified in sequencing after progression on chemotherapy. Crizotinib at 250 mg orally twice daily led to resolution of metastatic disease. The patient remained disease-free for 13 months when a CT-scan showed a relapse with two nodules in the right lower lobe. Stereotactic radiation therapy, gamma knife radiosurgery, and ipilimumab did not lead to a relevant response (new pleural nodules, new intracranial metastases). The patient next received ceritinib on a Signature Trial"" for tumors with aberrations in ALK or ROS1 that are treated with oral ceritinib (LDK378) at 750 mg daily (NCT02186821). Restaging scans after two cycles showed a partial response confirmed after four cycles (56% decrease) per RECIST1.1. MRI showed that his brain metastases decreased as well."	26917690	PubMed		"Subbiah et al., 2016, Proc. Natl. Acad. Sci. U.S.A."		1	accepted	1248	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1248	https://civicdb.org/links/molecular_profiles/265	FALSE	ROS1	6098	Rearrangement		chr6	117288300	117425855			ENST00000368508.3	75		transcript_fusion		2023-01-09 21:52:06 UTC		N/A		FALSE
ROS1 CD74::ROS1 G2032R	461	Lung Non-small Cell Carcinoma	3908		"Cabozantinib,Foretinib"	Substitutes	Predictive	Supports	D	Sensitivity/Response	"Preclinical study analyzing the efficacy of dual ROS1/ALK and more specific ROS1 inhibitors on cell lines (Ba/F3) expressing CD74-ROS1 with and without the G2032R mutation. Selective ROS1 inhibitors retained activity against the G2032R mutation (cabozatinib, foretinib), whereas dual ALK/ROS inhibitors (crizotinib, brigatinib, ceritinib, AZD3463) or ALK-selective inhibitors (alectinib) were ineffective."	26372962	PubMed		"Davare et al., 2015, Proc. Natl. Acad. Sci. U.S.A."		3	accepted	1249	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1249	https://civicdb.org/links/molecular_profiles/461	FALSE	ROS1	6098	CD74::ROS1 G2032R		chr6	117317184	117317184	C	T	ENST00000368508.3	75		"missense_variant,transcript_fusion"	NC_000006.11:g.117638347C>T	2023-01-27 17:03:53 UTC	CA16602597	376139	CD74-ROS1 G2032R	FALSE
ROS1 CD74::ROS1 G2032R	461	Lung Non-small Cell Carcinoma	3908		"Crizotinib,AZD3463,Ceritinib,Brigatinib"	Substitutes	Predictive	Supports	D	Resistance	"Preclinical study analyzing the efficacy of dual ROS1/ALK and more specific ROS1 inhibitors on cell lines (Ba/F3) expressing CD74-ROS1 with and without the G2032R mutation. Selective ROS1 inhibitors retained activity against the G2032R mutation (cabozatinib, foretinib), whereas dual ALK/ROS inhibitors (crizotinib, brigatinib, ceritinib, AZD3463) or ALK-selective inhibitors (alectinib) were ineffective."	26372962	PubMed		"Davare et al., 2015, Proc. Natl. Acad. Sci. U.S.A."		3	accepted	1250	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1250	https://civicdb.org/links/molecular_profiles/461	FALSE	ROS1	6098	CD74::ROS1 G2032R		chr6	117317184	117317184	C	T	ENST00000368508.3	75		"missense_variant,transcript_fusion"	NC_000006.11:g.117638347C>T	2023-01-27 17:03:53 UTC	CA16602597	376139	CD74-ROS1 G2032R	FALSE
ROS1 CD74::ROS1 G2032R	461	Lung Non-small Cell Carcinoma	3908		Lorlatinib		Predictive	Supports	D	Sensitivity/Response	"Preclinical study of PF-06463922 in NSCLC in-vitro, in-vivo and in enzyme assays. PF-06463922 showed inhibition of kinase activity, cell viability and tumor growth in wild-type, G2032R and L2026M mutations in ROS1."	25733882	PubMed		"Zou et al., 2015, Proc. Natl. Acad. Sci. U.S.A."		3	accepted	1251	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1251	https://civicdb.org/links/molecular_profiles/461	FALSE	ROS1	6098	CD74::ROS1 G2032R		chr6	117317184	117317184	C	T	ENST00000368508.3	75		"missense_variant,transcript_fusion"	NC_000006.11:g.117638347C>T	2023-01-27 17:03:53 UTC	CA16602597	376139	CD74-ROS1 G2032R	FALSE
ROS1 CD74::ROS1 L2026M	512	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	D	Resistance	"Preclinical study of PF-06463922 in NSCLC in-vitro, in-vivo and in enzyme assays. BaF3 cells expressing CD74-ROS1 L2026M were more resistant to crizotinib treatment than wildtype CD74-ROS1 in both cell viability and ROS1 phosphorylation. Crizotinib was also less effective at inhibiting kinase activity in ROS1 with L2026M mutation than wildtype. In contrast, PF-06463922 was effectively inhibited the fusion harboring this mutation in these assays."	25733882	PubMed		"Zou et al., 2015, Proc. Natl. Acad. Sci. U.S.A."		2	accepted	1252	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1252	https://civicdb.org/links/molecular_profiles/512	FALSE	ROS1	6098	CD74::ROS1 L2026M		chr6	117317202	117317202	G	T	ENST00000368508.3	75		"missense_variant,transcript_fusion"	"NC_000006.11:g.117638365G>T,ENST00000368508.3:c.6076C>A,NM_002944.2:c.6076C>A,NP_002935.2:p.Leu2026Met"	2023-01-27 17:04:05 UTC	CA365441006	NONE FOUND	CD74-ROS1 L2026M	FALSE
ROS1 CD74::ROS1 L2026M	512	Lung Non-small Cell Carcinoma	3908		Lorlatinib		Predictive	Supports	D	Sensitivity/Response	"Preclinical study of PF-06463922 in NSCLC in-vitro, in-vivo, and in enzyme assays. After establishing that the CD74-ROS1 L2026M mutation confers crizotinib resistance in kinase activity and cell viability assays (in transduced BaF3 cells), response to PF-06463922 was tested.  Wild-type CD74-ROS1, CD74-ROS1 G2032R, and CD74-ROS1 L2026M all showed sensitivity to PF-06463922 in these assays."	25733882	PubMed		"Zou et al., 2015, Proc. Natl. Acad. Sci. U.S.A."		3	accepted	1253	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1253	https://civicdb.org/links/molecular_profiles/512	FALSE	ROS1	6098	CD74::ROS1 L2026M		chr6	117317202	117317202	G	T	ENST00000368508.3	75		"missense_variant,transcript_fusion"	"NC_000006.11:g.117638365G>T,ENST00000368508.3:c.6076C>A,NM_002944.2:c.6076C>A,NP_002935.2:p.Leu2026Met"	2023-01-27 17:04:05 UTC	CA365441006	NONE FOUND	CD74-ROS1 L2026M	FALSE
ROS1 CD74::ROS1 G2032R	461	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	C	Resistance	ROS1 kinase domain mutations were assessed in two patients with stage IIIa/IV pulmonary adenocarcinoma and a cell line. The ROS1 G2032R mutation was identified in a crizotinib-resistant tumor from one of the patients harboring the CD74ROS1 fusion. Expression of CD74ROS1 G2032R in Ba/F3 cells conferred resistance to crizotinib combared to CD74ROS1 (IC50=353.62+/-20.15 vs. 2.76+/-0.82).	25688157	PubMed		"Song et al., 2015, Clin. Cancer Res."		3	accepted	1254	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1254	https://civicdb.org/links/molecular_profiles/461	FALSE	ROS1	6098	CD74::ROS1 G2032R		chr6	117317184	117317184	C	T	ENST00000368508.3	75		"missense_variant,transcript_fusion"	NC_000006.11:g.117638347C>T	2023-01-27 17:03:53 UTC	CA16602597	376139	CD74-ROS1 G2032R	FALSE
ROS1 CD74::ROS1 G2032R	461	Lung Non-small Cell Carcinoma	3908		Foretinib		Predictive	Supports	D	Sensitivity/Response	"Ba/F3 cells expressing CD74ROS1 G2032R showed resistance to crizotinib, compared with those expressing wild-type CD74ROS1 (~128 fold higher IC50); however, showed relative sensitivity to foretinib (only ~6 fold higher IC50 than WT)."	25688157	PubMed		"Song et al., 2015, Clin. Cancer Res."		2	accepted	1255	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1255	https://civicdb.org/links/molecular_profiles/461	FALSE	ROS1	6098	CD74::ROS1 G2032R		chr6	117317184	117317184	C	T	ENST00000368508.3	75		"missense_variant,transcript_fusion"	NC_000006.11:g.117638347C>T	2023-01-27 17:03:53 UTC	CA16602597	376139	CD74-ROS1 G2032R	FALSE
ROS1 CD74::ROS1 L2155S	513	Lung Non-small Cell Carcinoma	3908		"TAE684,Crizotinib,Foretinib"	Substitutes	Predictive	Supports	D	Resistance	"The L2155S mutation in ROS1 was identified in the HCC78CR1, -2 and -3 cell lines which harbor the SLC34A2ROS1 rearrangement and in 2 patients with NSCLC with progressive disease following crizotinib treatment and CD74ROS1 rearrangment. Crystal structure predicted ROS1 L2155S mutation to be highly destabilizating and cause protein structural modification. HCC78CR1, 2, and 3 cells and Ba/F3 cells transfected with CD74ROS1 L2155S, showed resistance to crizotinib compared with parental HCC78 and Ba/F3 cells. In addition, these cell lines showed resistance to foretinib, a potent ROS1 inhibitor that is effective against ROS1 G2032R-mutant cells (16), and TAE684, a potent ALK inhibitor"	25688157	PubMed		"Song et al., 2015, Clin. Cancer Res."		3	accepted	1256	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1256	https://civicdb.org/links/molecular_profiles/513	FALSE	ROS1	6098	CD74::ROS1 L2155S		chr6	117308899	117308899	A	G	ENST00000368508.3	75		"missense_variant,transcript_fusion"	"NC_000006.11:g.117630062A>G,NM_002944.2:c.6464T>C,NP_002935.2:p.Leu2155Ser,ENST00000368508.3:c.6464T>C"	2023-01-27 17:04:06 UTC	CA365440144	NONE FOUND	"CD74-ROS1 L2155S,CD74::ROS1 L2149S,CD74-ROS1 L2149S"	FALSE
ROS1 CD74::ROS1 L2026M	512	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	D	Resistance	"Ba/F3 cells expressing CD74ROS1 L2026M mutation showed resistance to crizotinib (~10 fold higher IC50 value), compared with those expressing wild-type CD74ROS1; however, showed similar sensitivity to foretinib."	25688157	PubMed		"Song et al., 2015, Clin. Cancer Res."		2	accepted	1257	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1257	https://civicdb.org/links/molecular_profiles/512	FALSE	ROS1	6098	CD74::ROS1 L2026M		chr6	117317202	117317202	G	T	ENST00000368508.3	75		"missense_variant,transcript_fusion"	"NC_000006.11:g.117638365G>T,ENST00000368508.3:c.6076C>A,NM_002944.2:c.6076C>A,NP_002935.2:p.Leu2026Met"	2023-01-27 17:04:05 UTC	CA365441006	NONE FOUND	CD74-ROS1 L2026M	FALSE
ROS1 CD74::ROS1 L2026M	512	Lung Non-small Cell Carcinoma	3908		Foretinib		Predictive	Supports	D	Sensitivity/Response	Ba/F3 cells expressing CD74ROS1 L2026M mutation showed similar sensitivity to foretinib compared with those expressing wild-type CD74ROS1. This is in contrast to the increased resistance to crizotinib associated with this mutation in the same assay.	25688157	PubMed		"Song et al., 2015, Clin. Cancer Res."		2	accepted	1258	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1258	https://civicdb.org/links/molecular_profiles/512	FALSE	ROS1	6098	CD74::ROS1 L2026M		chr6	117317202	117317202	G	T	ENST00000368508.3	75		"missense_variant,transcript_fusion"	"NC_000006.11:g.117638365G>T,ENST00000368508.3:c.6076C>A,NM_002944.2:c.6076C>A,NP_002935.2:p.Leu2026Met"	2023-01-27 17:04:05 UTC	CA365441006	NONE FOUND	CD74-ROS1 L2026M	FALSE
ROS1 CD74::ROS1 G2101A	514	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	D	Resistance	"Ba/F3 cells expressing CD74ROS1 G2101A showed resistance to crizotinib, compared with those expressing wild-type CD74ROS1, and were sensitive to foretinib."	25688157	PubMed		"Song et al., 2015, Clin. Cancer Res."		2	accepted	1259	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1259	https://civicdb.org/links/molecular_profiles/514	FALSE	ROS1	6098	CD74::ROS1 G2101A		chr6	117310213	117310213	C	G	ENST00000368508.3	75		"missense_variant,transcript_fusion"	NC_000006.11:g.117631376C>G	2023-01-27 17:04:07 UTC	CA365440505	NONE FOUND	CD74-ROS1 G2101A	FALSE
ROS1 CD74::ROS1 G2101A	514	Lung Non-small Cell Carcinoma	3908		Foretinib		Predictive	Supports	D	Sensitivity/Response	"Ba/F3 cells expressing CD74ROS1 G2101A showed resistance to crizotinib, compared with those expressing wild-type CD74ROS1, and were sensitive to foretinib."	25688157	PubMed		"Song et al., 2015, Clin. Cancer Res."		2	accepted	1260	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1260	https://civicdb.org/links/molecular_profiles/514	FALSE	ROS1	6098	CD74::ROS1 G2101A		chr6	117310213	117310213	C	G	ENST00000368508.3	75		"missense_variant,transcript_fusion"	NC_000006.11:g.117631376C>G	2023-01-27 17:04:07 UTC	CA365440505	NONE FOUND	CD74-ROS1 G2101A	FALSE
ALK CLTC::ALK	516	Diffuse Large B-cell Lymphoma	50745		TAE684		Predictive	Supports	D	Sensitivity/Response	"A cell line called LM1 was established from the bone marrow of a 13 year old female patient with relapsed CLTC-ALK positive diffuse large B-cell lymphoma (DLBCL). The patient had been heavily treated with chemotherapy before establishment of the cell line. The cell line maintained the tumor immunophenotype.  SNP analysis of patient bone marrow mononuclear cells and LM1 showed chromosomal changes associated with the cell line but 94.7% of SNPs were identically called.  ALK kinase inhibitor TAE684 induced cell death in LM1 cells at low nanomolar concentrations, while it did not significantly effect the ALK-rearrangement negative DLBCL cell line Karpas422.  LM1 cells formed tumors in 3/10 SCID and 9/10 NOD-SCID mice.  CD30 and CD138 immmunostaining were maintained between original tumor and LM1 xenografts. In mice, LM1 but not Karpas422 xenografts regressed with TAE684 administration, and complete remission for 13 weeks was observed before experiment was terminated."	21494621	PubMed		"Cerchietti et al., 2011, PLoS ONE"		4	accepted	1261	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1261	https://civicdb.org/links/molecular_profiles/516	FALSE	ALK	238	CLTC::ALK	ALK Fusion	chr17	59619858	59690711			ENST00000269122.3	75	ENST00000389048.3	transcript_fusion		2023-01-09 21:52:07 UTC		N/A	"T(2;17)(P23;Q23),CLTC-ALK"	FALSE
ALK CLTC::ALK	516	Diffuse Large B-cell Lymphoma	50745		TAE684		Predictive	Supports	D	Sensitivity/Response	"A cell line called LM1 was established from the bone marrow of a 13 year old female patient with relapsed CLTC-ALK positive diffuse large B-cell lymphoma (DLBCL). The patient had been heavily treated with chemotherapy before establishment of the cell line. The cell line maintained the tumor immunophenotype.  SNP analysis of patient bone marrow mononuclear cells and LM1 showed chromosomal changes associated with the cell line but 94.7% of SNPs were identically called.  ALK kinase inhibitor TAE684 induced cell death in LM1 cells at low nanomolar concentrations, while it did not significantly effect the ALK-rearrangement negative DLBCL cell line Karpas422.  LM1 cells formed tumors in 3/10 SCID and 9/10 NOD-SCID mice.  CD30 and CD138 immmunostaining were maintained between original tumor and LM1 xenografts. In mice, LM1 but not Karpas422 xenografts regressed with TAE684 administration, and complete remission for 13 weeks was observed before experiment was terminated."	21494621	PubMed		"Cerchietti et al., 2011, PLoS ONE"		4	accepted	1261	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1261	https://civicdb.org/links/molecular_profiles/516	FALSE	ALK	238	CLTC::ALK	ALK Fusion	chr2	29192774	29223528			ENST00000269122.3	75	ENST00000389048.3	transcript_fusion		2023-01-09 21:52:07 UTC		N/A	"T(2;17)(P23;Q23),CLTC-ALK"	FALSE
U2AF1 MUTATION	517	Myelofibrosis	4971				Prognostic	Supports	B	Poor Outcome	"In a large study of patients with primary myelofibrosis evaluating mutations associated with anemia, 457 patients were evaluated for U2AF1 mutations. U2AF1 mutations were significantly associated with anemia in univariate and multivariate analysis (72 mutated vs 385 wildtype; P<0.0001). U2AF1 mutations were significantly associated with shorter overall survival in univariate analysis (P < 0.0001) but not in multivariate analysis with adjustment for age and anemia (P=0.24)."	27058230	PubMed		"Barraco et al., 2016, Blood Cancer J"		4	accepted	1262	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1262	https://civicdb.org/links/molecular_profiles/517	FALSE	U2AF1	7307	MUTATION		chr21	43092956	43107587			ENST00000291552.4	75		protein_altering_variant		2023-01-09 21:52:07 UTC		N/A		FALSE
ALK CLTC::ALK	516	Diffuse Large B-cell Lymphoma	50745				Prognostic	Supports	C	Poor Outcome	"CLTC-ALK is one of the most common ALK fusions found in diffuse large B cell lymphoma (DLBCL). In a retrospective study of 38 patients with ALK-rearranged DLBCL, 3 were CD20 positive. Only one showed cytoplasmic, nuclear and nucleolar staining associated with NPM-ALK, while the others showed granular cytoplasmic ALK stain characteristic for CLTC-ALK.  Seven molecularly characterized cases were positive for CLTC-ALK.  6/7 patients were treated with CHOP chemotherapy with survival of 5, 10, 26 and 27 months, and two alive at end of study, and one CD20 positive patient was treated with CHOP chemotherapy supplemented with CD20-targeted rituximab, with survival of 8 months, resulting in median survival of 26 months for this group.  Although these numbers are not sufficient for statistical comparison, they compare unfavorably to 3.1 year overall survival and 45% 5 year survival of CHOP treated DLBCL patients, and even less favorably to R-CHOP standard of care for CD20 positive DLBCL, suggesting poor prognosis for CLTC-ALK DLBCL and need for updated treatment in this cohort."	19636007	PubMed		"Laurent et al., 2009, J. Clin. Oncol."		3	accepted	1263	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1263	https://civicdb.org/links/molecular_profiles/516	FALSE	ALK	238	CLTC::ALK	ALK Fusion	chr17	59619858	59690711			ENST00000269122.3	75	ENST00000389048.3	transcript_fusion		2023-01-09 21:52:07 UTC		N/A	"T(2;17)(P23;Q23),CLTC-ALK"	FALSE
ALK CLTC::ALK	516	Diffuse Large B-cell Lymphoma	50745				Prognostic	Supports	C	Poor Outcome	"CLTC-ALK is one of the most common ALK fusions found in diffuse large B cell lymphoma (DLBCL). In a retrospective study of 38 patients with ALK-rearranged DLBCL, 3 were CD20 positive. Only one showed cytoplasmic, nuclear and nucleolar staining associated with NPM-ALK, while the others showed granular cytoplasmic ALK stain characteristic for CLTC-ALK.  Seven molecularly characterized cases were positive for CLTC-ALK.  6/7 patients were treated with CHOP chemotherapy with survival of 5, 10, 26 and 27 months, and two alive at end of study, and one CD20 positive patient was treated with CHOP chemotherapy supplemented with CD20-targeted rituximab, with survival of 8 months, resulting in median survival of 26 months for this group.  Although these numbers are not sufficient for statistical comparison, they compare unfavorably to 3.1 year overall survival and 45% 5 year survival of CHOP treated DLBCL patients, and even less favorably to R-CHOP standard of care for CD20 positive DLBCL, suggesting poor prognosis for CLTC-ALK DLBCL and need for updated treatment in this cohort."	19636007	PubMed		"Laurent et al., 2009, J. Clin. Oncol."		3	accepted	1263	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1263	https://civicdb.org/links/molecular_profiles/516	FALSE	ALK	238	CLTC::ALK	ALK Fusion	chr2	29192774	29223528			ENST00000269122.3	75	ENST00000389048.3	transcript_fusion		2023-01-09 21:52:07 UTC		N/A	"T(2;17)(P23;Q23),CLTC-ALK"	FALSE
ALK Fusion	495	Diffuse Large B-cell Lymphoma	50745		Crizotinib		Predictive	Supports	C	Sensitivity/Response	"A 27 year old female patient with advanced-stage IV, CD20 negative diffuse large B cell lymphoma (DLBCL). ALK rearrangement was determined by FISH, but the ALK fusion partner was not determined due to limited tissue. The patient underwent treatment with CHOP chemotherapy regimen and radiation but did not respond. The patient progressed following salvage chemotherapy and autologous stem cell transplant. Crizotinib was then administered at 250 mg twice daily, and LDH levels rapidly dropped along with disappearance of palpable lymphadenopathy, but progression ensued after 21 days and the patient died soon after. The authors attribute the short response to crizotinib to the possibility of this tumor having an ALK fusion variant less responsive to ALK inhibition and to a high Ki-67 index in the patient, and deem that despite the brief response, crizotinib shows promise in ALK rearranged DLBCL."	24330038	PubMed		"Wass et al., 2014, Eur. J. Haematol."		2	accepted	1264	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1264	https://civicdb.org/links/molecular_profiles/495	FALSE	ALK	238	Fusion	ALK Fusion	chr2	29192774	29223528			ENST00000389048.3	75		transcript_fusion		2023-01-09 21:52:07 UTC		N/A	REARRANGEMENT	FALSE
ALK CLTC::ALK	516	Diffuse Large B-cell Lymphoma	50745		Crizotinib		Predictive	Supports	C	Sensitivity/Response	"A 21 year old male presented with lymphadenopathy and a low density mass in pancreas. Histopathological analysis showed diffuse tumor cell infiltrate (CD20/EMA negative) with cytoplasmic ALK. RT-PCR indicated CLTC-ALK fusion. The patient was diagnosed with splenic ALK + diffuse large B cell lymphoma (DLBCL), Stage III, Group A with an IPI of 3. CHOP-21 chemotherapy regimen was administered with improvement in abdominal lymph nodes but worsening in retroperitoneal lymph nodes assessed via standardized uptake values. Subsequent ICE chemotherapy regiment relieved some symptoms prompting the patient to refuse further treatment despite other indications of disease progression. Therapy was reinstated after worsening of disease. GEMOX chemotherapy was administered with dexamethasone and 250mg crizotinib twice daily resulting in symptom relief, decreased lymphadenopathy and LDH decline. The disease then progressed and the patient died 2 months after crizotinib initiation. The authors conclude that partial response to crizotinib was observed and that in future trials ALK rearranged DLBCL patients might see increased benefit with earlier application of targeted therapy during the treatment course."	26221234	PubMed		"Li et al., 2015, Int J Clin Exp Med"		3	accepted	1265	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1265	https://civicdb.org/links/molecular_profiles/516	FALSE	ALK	238	CLTC::ALK	ALK Fusion	chr17	59619858	59690711			ENST00000269122.3	75	ENST00000389048.3	transcript_fusion		2023-01-09 21:52:07 UTC		N/A	"T(2;17)(P23;Q23),CLTC-ALK"	FALSE
ALK CLTC::ALK	516	Diffuse Large B-cell Lymphoma	50745		Crizotinib		Predictive	Supports	C	Sensitivity/Response	"A 21 year old male presented with lymphadenopathy and a low density mass in pancreas. Histopathological analysis showed diffuse tumor cell infiltrate (CD20/EMA negative) with cytoplasmic ALK. RT-PCR indicated CLTC-ALK fusion. The patient was diagnosed with splenic ALK + diffuse large B cell lymphoma (DLBCL), Stage III, Group A with an IPI of 3. CHOP-21 chemotherapy regimen was administered with improvement in abdominal lymph nodes but worsening in retroperitoneal lymph nodes assessed via standardized uptake values. Subsequent ICE chemotherapy regiment relieved some symptoms prompting the patient to refuse further treatment despite other indications of disease progression. Therapy was reinstated after worsening of disease. GEMOX chemotherapy was administered with dexamethasone and 250mg crizotinib twice daily resulting in symptom relief, decreased lymphadenopathy and LDH decline. The disease then progressed and the patient died 2 months after crizotinib initiation. The authors conclude that partial response to crizotinib was observed and that in future trials ALK rearranged DLBCL patients might see increased benefit with earlier application of targeted therapy during the treatment course."	26221234	PubMed		"Li et al., 2015, Int J Clin Exp Med"		3	accepted	1265	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1265	https://civicdb.org/links/molecular_profiles/516	FALSE	ALK	238	CLTC::ALK	ALK Fusion	chr2	29192774	29223528			ENST00000269122.3	75	ENST00000389048.3	transcript_fusion		2023-01-09 21:52:07 UTC		N/A	"T(2;17)(P23;Q23),CLTC-ALK"	FALSE
ALK EML4::ALK e2-e20	497	Renal Cell Carcinoma	4450				Predictive	Supports	E	Sensitivity/Response	"Adenocarcinoma cells were detected via urinary cytology in a 53 year old woman. Cancer morphology suggested papillary renal cell carcinoma (RCC), type 2A.  EML4-ALK variant 5 was discovered in tumor tissue using PCR with EML4 and ALK specific primers. The authors conclude that their findings confirm the potential for ALK targeting therapy in select cases of RCC."	22252991	PubMed		"Sugawara et al., 2012, Cancer"		3	accepted	1266	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1266	https://civicdb.org/links/molecular_profiles/497	FALSE	ALK	238	EML4::ALK e2-e20	ALK Fusion	chr2	42169350	42245687			ENST00000318522.5	75	ENST00000389048.3	transcript_fusion		2023-01-09 21:52:07 UTC		N/A	EML4-ALK E2-E20	FALSE
ALK EML4::ALK e2-e20	497	Renal Cell Carcinoma	4450				Predictive	Supports	E	Sensitivity/Response	"Adenocarcinoma cells were detected via urinary cytology in a 53 year old woman. Cancer morphology suggested papillary renal cell carcinoma (RCC), type 2A.  EML4-ALK variant 5 was discovered in tumor tissue using PCR with EML4 and ALK specific primers. The authors conclude that their findings confirm the potential for ALK targeting therapy in select cases of RCC."	22252991	PubMed		"Sugawara et al., 2012, Cancer"		3	accepted	1266	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1266	https://civicdb.org/links/molecular_profiles/497	FALSE	ALK	238	EML4::ALK e2-e20	ALK Fusion	chr2	29192774	29223528			ENST00000318522.5	75	ENST00000389048.3	transcript_fusion		2023-01-09 21:52:07 UTC		N/A	EML4-ALK E2-E20	FALSE
BRAF DEL 485-490	518	Cancer	162		Pan-RAF Inhibitor LY3009120		Predictive	Supports	D	Sensitivity/Response	"Cells harboring in-frame deletions in BRAF in the L485-P490 amino acid region were found to be sensitive to the RAF dimer inhibitor LY3009120, but not sensitive to the BRAF-selective inhibitors vemurafenib or dabrafenib. These deletions were observed in KRAS wildtype pancreatic, ovarian, NSCLC, and thyroid cancers. In three cell lines H2405 (NSCLC with L485-P490>Y), BxPC-3 (pancreatic with V487-P492>A), and OV-90 (ovarian with N486-P490del), BRAF deletionmediated MAPK activation was found to be sensitive to LY3009120 as evidenced by dose-dependent inhibition of phospho-MEK and ERK and cell growth inhibition with IC50 values of 0.04, 0.087, and 0.007 mol/L in these three cell lines. LY3009120, but not vemurafenib, also inhibited tumor growth of both H2405 and BxPC-3 cells xenografted into mice."	26732095	PubMed		"Chen et al., 2016, Cancer Discov"		3	accepted	1267	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1267	https://civicdb.org/links/molecular_profiles/518	FALSE	BRAF	673	DEL 485-490		chr7	140778038	140778055	AGGTGCTGTCACATTCAA		ENST00000288602.6	75		inframe_deletion	ENST00000288602.6:c.1453_1470del	2023-01-09 21:52:07 UTC	unregistered	NONE FOUND		FALSE
ALK R1275Q	9	Neuroblastoma	769		Crizotinib		Predictive	Supports	C	Sensitivity/Response	"This Phase I study of crizotinib involved a cohort of pediatric neuroblastoma patients between ages 12 months and 22 years. In 11 patients with characterized ALK mutations, 4 had R1275Q mutations, and two of these were germline mutations.  Of these 2 germline patients, 1 showed stable disease (SD) and 1 complete response (CR). In contrast, in the 7 characterized patients with ALK mutations that were not R1275Q, 6 showed PD and 1 SD. The authors conclude this finding is promising and merits further study."	23598171	PubMed		"Moss et al., 2013, Lancet Oncol."	NCT00939770	2	accepted	1269	Rare Germline	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/1269	https://civicdb.org/links/molecular_profiles/9	FALSE	ALK	238	R1275Q		chr2	29209798	29209798	C	T	ENST00000389048.3	75		missense_variant	"NM_004304.4:c.3824G>A,NP_004295.2:p.Arg1275Gln,NC_000002.11:g.29432664C>T,ENST00000389048.3:c.3824G>A"	2023-01-27 17:01:59 UTC	CA341482	18083	"ARG1275GLN,RS113994087"	FALSE
ALK R1275Q	9	Neuroblastoma	769		Crizotinib		Predictive	Supports	C	Sensitivity/Response	"A cohort of pediatric neuroblastoma patients ages 12 months to 22 years were assessed for response to crizotinib in a Phase I study.  11 patients in this cohort had characterized ALK mutations, 4 of which were R1275Q mutation. Two of these R1275Q mutations were germline and two were somatic. Of these 2 somatic R1275Q patients, 1 showed progressive disease (PD) and 1 showed stable disease (SD). In contrast, of the 7 characterized patients with ALK mutations that were not R1275Q, 6 showed PD and 1 SD. The stable disease patient had an R1275L mutation in ALK. In general, patients with germline or somatic R1275Q mutations or R1275L mutations had 1 complete response, 3 SD and one PD, while patients with other ALK mutations had 6 PD."	23598171	PubMed		"Moss et al., 2013, Lancet Oncol."	NCT00939770	2	accepted	1270	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/1270	https://civicdb.org/links/molecular_profiles/9	FALSE	ALK	238	R1275Q		chr2	29209798	29209798	C	T	ENST00000389048.3	75		missense_variant	"NM_004304.4:c.3824G>A,NP_004295.2:p.Arg1275Gln,NC_000002.11:g.29432664C>T,ENST00000389048.3:c.3824G>A"	2023-01-27 17:01:59 UTC	CA341482	18083	"ARG1275GLN,RS113994087"	FALSE
ALK F1174L	8	Neuroblastoma	769		Crizotinib		Predictive	Does Not Support	C	Sensitivity/Response	"In a Phase I trial (NCT00939770) of the drug crizotinib in pediatric patients, a subset of 11 neuroblastoma patients were characterized for mutations in ALK. Of these 11 patients, 4 had the F1174L mutation. Among these 4 patients, stable disease (SD) was observed in one, and progressive disease (PD) was observed in 3 others after administration of crizotinib. In contrast, in the remaining 7 patients with mutations different than F1174L, 4 had PD, 2 had SD and one had complete response as best response after initiation of crizotinib."	23598171	PubMed		"Moss et al., 2013, Lancet Oncol."	NCT00939770	3	accepted	1271	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/1271	https://civicdb.org/links/molecular_profiles/8	FALSE	ALK	238	F1174L	ALK Crizotinib Resistance	chr2	29220829	29220829	G	T	ENST00000389048.3	75		missense_variant	"NM_004304.4:c.3522C>A,NP_004295.2:p.Phe1174Leu,NC_000002.11:g.29443695G>T,ENST00000389048.3:c.3522C>A"	2023-01-27 17:01:58 UTC	CA279586	217851	"PHE1174LEU,RS863225281"	FALSE
ALK Fusion	495	Lung Non-small Cell Carcinoma	3908		Alectinib		Predictive	Supports	B	Sensitivity/Response	"In this initial report of a single-arm Phase I and II study (JapicCTI-101264) of alectinib (CH5424802), 46 patients with advanced or metastatic ALK-rearranged non small cell lung cancer (NSCLC) were assessed for objective response during phase II. ALK positivity was assessed via IHC and verified with FISH or RT-PCR. Patients had received one or more rounds of previous chemotherapy, but no prior targeted therapy towards ALK. From the 46 patients, 41 showed partial response, and 2 showed complete response. CNS metastases in three patients which had not received prior brain irradiation showed response to alectinib. Alectinib was generally well tolerated, and the authors conclude that alectinib compared favorably to crizotinib and could be an effective and safe option in ALK-rearranged NSCLC."	23639470	PubMed		"Seto et al., 2013, Lancet Oncol."		3	accepted	1272	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1272	https://civicdb.org/links/molecular_profiles/495	FALSE	ALK	238	Fusion	ALK Fusion	chr2	29192774	29223528			ENST00000389048.3	75		transcript_fusion		2023-01-09 21:52:07 UTC		N/A	REARRANGEMENT	FALSE
ALK Fusion	495	Lung Non-small Cell Carcinoma	3908		Alectinib		Predictive	Supports	C	Sensitivity/Response	"In this case study of a critically ill 29 year old male nonsmoker with advanced metastatic ALK-positive NSCLC, alectinib (CH5424802), was administered as first line treatment. Where most clinical trials only admit patients with Eastern Cooperative Oncology Performance status (PS) of 0 or 1, this patient had PS 4 due to respiratory failure, multiple bone metastases and complications from disseminated intravascular coagulation (DIC). Administration of alectinib at 300 mg twice daily was followed by marked improvement seen in tests associated with DIC, pulmonary metastasis and change in PS from 4 to 0. Further improvements after a couple of months suggested a rapid complete response. Alectinib was well tolerated in this first line treatment of a critically ill ALK-positive NSCLC patient."	26938871	PubMed		"Yoshida et al., 2016, Anticancer Drugs"		3	accepted	1273	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1273	https://civicdb.org/links/molecular_profiles/495	FALSE	ALK	238	Fusion	ALK Fusion	chr2	29192774	29223528			ENST00000389048.3	75		transcript_fusion		2023-01-09 21:52:07 UTC		N/A	REARRANGEMENT	FALSE
CD274 Expression	272	Thyroid Gland Papillary Carcinoma	3969				Prognostic	Supports	B	Poor Outcome	"Immunohistochemical analyses of PD-L1 protein was retrospectively performed on 251 archived FFPE surgical tissues (66 benign thyroid nodules and 185 papillary thyroid carcinomas PTC, E1L3N antibody). Patients with increased PD-L1 protein had significantly shorter median DFS (36 months [membranous staining] and 49 months [cytoplasmic staining] vs. 186 months [negative], p < 0.001 and p < 0.01, respectively)."	27086918	PubMed		"Chowdhury et al., 2016, Oncotarget"		3	accepted	1274	N/A	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1274	https://civicdb.org/links/molecular_profiles/272	FALSE	CD274	29126	Expression		chr9	5450525	5470547			ENST00000381577.3	75		N/A	N/A	2023-01-09 21:52:06 UTC		N/A		FALSE
CD274 Expression	272	Stomach Carcinoma	5517				Prognostic	Supports	B	Better Outcome	"465 gastric cancer samples and 15 corresponding liver metastases underwent IHC for PD1/PD-L1 protein expression. PD-L1 positivity in tumor cells was defined by at least 2% tumor cells with membranous positivity, PD-L1 positivity in immune cells by at least 10% PD-L1 positive immune cells. Patients with PD-L1 positive tumor cells had a significant better overall (p=0.028) and tumor specific survival (p=0.018). The same applied for patients with PD-L1 positive immune cells (p<0.001 each)."	27009855	PubMed		"Bger et al., 2016, Oncotarget"		3	accepted	1275	N/A	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1275	https://civicdb.org/links/molecular_profiles/272	FALSE	CD274	29126	Expression		chr9	5450525	5470547			ENST00000381577.3	75		N/A	N/A	2023-01-09 21:52:06 UTC		N/A		FALSE
B4GALT1 Overexpression	521	Renal Cell Carcinoma	4450				Prognostic	Supports	B	Poor Outcome	438 patients with non-metastatic clear-cell renal carcinoma were were retrospectively analysed for B4GALT1 expression via IHC. High B4GALT1 expression was associated with poor overall survival (P<0.001 and P<0.001 in training and validation cohort) and identified as an independent adverse prognostic factor for survival (P=0.007 and P=0.002).	27092876	PubMed		"Xie et al., 2016, Oncotarget"		3	accepted	1278	N/A	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1278	https://civicdb.org/links/molecular_profiles/521	FALSE	B4GALT1	2683	Overexpression		chr9	33110637	33167356			ENST00000379731.4	75		N/A		2023-01-09 21:52:07 UTC		N/A		FALSE
ALK Fusion	495	Lung Non-small Cell Carcinoma	3908		Alectinib		Predictive	Supports	B	Sensitivity/Response	"In this Phase I trial (NCT01588028) in 47 patients, alectinib was assessed for its effectiveness in treating locally advanced or metastatic ALK-positive NSCLC that had progressed or been resistant to crizotinib treatment. ALK rearrangement was assessed via approved break apart FISH kit, and patients with asymptomatic CNS metastases were also included. Patients were divided into different cohorts receiving different doses of alectinib. In the 600 mg cohort (N=13), ten were assessable, and there were 4 confirmed partial responses, 3 unconfirmed partial responses and 3 instances of stable disease. Also, five of nine patients throughout the cohorts with measurable baseline CNS lesions showed partial response to alectinib. Cerebrospinal fluid levels of alectinib increased linearly with blood alectinib levels, indicating it effectively crossed the blood-brain barrier."	25153538	PubMed		"Gadgeel et al., 2014, Lancet Oncol."	NCT01588028	4	accepted	1279	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1279	https://civicdb.org/links/molecular_profiles/495	FALSE	ALK	238	Fusion	ALK Fusion	chr2	29192774	29223528			ENST00000389048.3	75		transcript_fusion		2023-01-09 21:52:07 UTC		N/A	REARRANGEMENT	FALSE
BCL2L11 Deletion Polymorphism	522	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	B	Resistance	"DNA sequencing was performed in five Ph+ CML samples with sensitivity or resistance to imatinib. A structural variation in BIM2 (BCL2L11) with an identical 2,903-bp genomic deletion was identified in all three resistant samples. 2,597 healthy individuals were screened and the deletion polymorphism was identified in 12.3% of East Asian Population but 0% in African or European Population. In-vitro, imatinib-induced apoptosis was reduced in cells harboring the BIM deletion polymorphism. Two East Asian CML cohorts (n=203) treated with imatinib were analzed for the polymorphism. Overall odds ratio for resistant disease among subjects with the deletion polymorphism compared to those without it was 2.94 (P = 0.02, 95% CI 1.17?.43). Patients with the polymorphism, compared to those without, were more likely to be resistant without BCR-ABL mutations than resistant with BCR-ABL mutation or sensitive (odds ratio = 1.90, 95% CI 1.08?.35)."	22426421	PubMed		"Ng et al., 2012, Nat. Med."		4	accepted	1280	Common Germline	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1280	https://civicdb.org/links/molecular_profiles/522	FALSE	BCL2L11	10018	Deletion Polymorphism		chr2	111125618	111128520			ENST00000393256.3	75		polymorphic_sequence_variant		2023-01-09 21:52:07 UTC				FALSE
BCL2L11 Deletion Polymorphism	522	Lung Non-small Cell Carcinoma	3908		Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor		Predictive	Supports	B	Resistance	"The BIM (BCL2L11) deletion polymorphism was identified in an EGFR Mutant NSCLC cell line with resistance to EGFR-TKI (HCC2779). Introduction of this polymorphism in a previously EGFR-inhibitor sensitive cell line led to TKI-resistance. In 141 NSCLC patients with EGFR mutations, the presence of the polymorphism (N=26) was predictive of a significantly shorter PFS under treatment with EGFR-TKI (6.6 months vs. 11.9 months, p = 0.0027). Patients received either gefitinib only (N=136) or erlotinib only (N=5)."	22426421	PubMed		"Ng et al., 2012, Nat. Med."		4	accepted	1281	Common Germline	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1281	https://civicdb.org/links/molecular_profiles/522	FALSE	BCL2L11	10018	Deletion Polymorphism		chr2	111125618	111128520			ENST00000393256.3	75		polymorphic_sequence_variant		2023-01-09 21:52:07 UTC				FALSE
ALK Fusion	495	Lung Non-small Cell Carcinoma	3908		Alectinib		Predictive	Supports	A	Sensitivity/Response	"In this Phase II trial of 87 patients (NCT01871805), alectinib was assayed for safety and efficacy in ALK positive NSCLC that had progressed on crizotinib. Of 69 patients with measurable disease, 35 achieved objective response, with median duration of response 13.5 months. Of 16 patients with measurable CNS disease, four achieved CNS complete response and 8 showed CNS partial response. median duration of CNS response was 11.1 months. 2 deaths were observed, and 1 was judged related to study treatment."	26708155	PubMed		"Shaw et al., 2016, Lancet Oncol."	NCT01871805	5	accepted	1282	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1282	https://civicdb.org/links/molecular_profiles/495	FALSE	ALK	238	Fusion	ALK Fusion	chr2	29192774	29223528			ENST00000389048.3	75		transcript_fusion		2023-01-09 21:52:07 UTC		N/A	REARRANGEMENT	FALSE
ALK I1171	523	Lung Non-small Cell Carcinoma	3908		Alectinib		Predictive	Supports	C	Resistance	"The I1171T mutation in ALK fusions was found in a NSCLC patient shown positive for ALK rearrangement via break apart FISH assay, who progressed after 8 months of crizotinib, and then progressed again after 4 months of alectinib. The MGH056-1 cell line was derived from this patient, and this cell line was resistant to alectinib. Sequencing of MGH056-1 cells revealed the I1171T mutation in ALK. In cell culture studies Ba/F3 cells with EML4-ALK I1171T required more that 10x the concentration of alectinib to significantly reduce viability that was required for EML4-ALK wild-type expressing cells. Computer simulation studies indicated that the I1171T mutation interfered with alectinib binding at the ALK active site."	25228534	PubMed		"Katayama et al., 2014, Clin. Cancer Res."		4	accepted	1283	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1283	https://civicdb.org/links/molecular_profiles/523	FALSE	ALK	238	I1171		chr2	29222347	29222347	A	G	ENST00000389048.3	75		missense_variant	"ENST00000389048.3:c.3512T>C,NC_000002.11:g.29445213A>G,NM_004304.4:c.3512T>C,NP_004295.2:p.Ile1171Thr"	2023-01-27 17:04:09 UTC	CA346462880	375888	ILE1171	FALSE
ALK I1171	523	Lung Non-small Cell Carcinoma	3908		Ceritinib		Predictive	Supports	C	Sensitivity/Response	"The MGH056-1 cell line was derived from an NSCLC patient with ALK-rearrangement who had progressed on crizotinib and then on alectinib. the cell line was also resistant to crizotinib and alectinib, and sequencing of ALK from the cell line revealed the I1171T mutation. Further testing of this mutation in BaF3 cells revealed that cells expressing EML4-ALk with I1171T mutation required 10x higher concentration to induce cell death than BaF3 cells with wild-type EML4-ALK. In contrast, ceritinib caused loss of viability in EML4-ALK wild-type and I1171T BaF3 cells at comparable concentrations. Ceritinib was also effective at killing MGH056-1 cells that were resistant to alectinib, and reduced Akt and ERK phosphorylation in these cells. Finally, administration of ceritinib to the crizotinib and alectinib resistant patient let to tumor regression and partial response lasting 7 months."	25228534	PubMed		"Katayama et al., 2014, Clin. Cancer Res."		4	accepted	1284	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1284	https://civicdb.org/links/molecular_profiles/523	FALSE	ALK	238	I1171		chr2	29222347	29222347	A	G	ENST00000389048.3	75		missense_variant	"ENST00000389048.3:c.3512T>C,NC_000002.11:g.29445213A>G,NM_004304.4:c.3512T>C,NP_004295.2:p.Ile1171Thr"	2023-01-27 17:04:09 UTC	CA346462880	375888	ILE1171	FALSE
ALK I1171	523	Lung Non-small Cell Carcinoma	3908		TAE684		Predictive	Supports	D	Sensitivity/Response	"The I1171T ALK kinase domain mutaion was found in the MGH056-1 cell line which was derived from an ALK rearranged NSCLC patient who had progressed on crizotinib and then on alectinib given at lower dose (300mg twice daily).  Ectopic expression of EML4-ALK I1171T in Ba/F3 cells made these cells moderately resistant to crizotinib and resistant to alectinib. In contrast, the frequently used tool compound TAE684 was equally effective against EML4-ALK wild-type and I1171T, causing cell death at 1000x lower concentration then in unaltered Ba/F3 cells supplemented with IL3."	25228534	PubMed		"Katayama et al., 2014, Clin. Cancer Res."		3	accepted	1285	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1285	https://civicdb.org/links/molecular_profiles/523	FALSE	ALK	238	I1171		chr2	29222347	29222347	A	G	ENST00000389048.3	75		missense_variant	"ENST00000389048.3:c.3512T>C,NC_000002.11:g.29445213A>G,NM_004304.4:c.3512T>C,NP_004295.2:p.Ile1171Thr"	2023-01-27 17:04:09 UTC	CA346462880	375888	ILE1171	FALSE
ALK I1171	523	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	D	Resistance	The MGH056-1 cell line was derived from a patient with ALK rearranged NSCLC who had progressed on crizotinib and then on lower dose alectinib (300 mg twice daily). The I1171T ALK kinase domain mutation was found in this cell line (established after alectinib resistance). MGH056-1 cells were resistant to crizotinib (IC50 236nmol/L; aproximately 50x higher than for ceritinib). About 50 fold higher concentration of crizotinib was required to inhibit Ba/F3 cells expressing EML4 ALK I1171T than was required for EML4 ALK wild-type.	25228534	PubMed		"Katayama et al., 2014, Clin. Cancer Res."		3	accepted	1287	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1287	https://civicdb.org/links/molecular_profiles/523	FALSE	ALK	238	I1171		chr2	29222347	29222347	A	G	ENST00000389048.3	75		missense_variant	"ENST00000389048.3:c.3512T>C,NC_000002.11:g.29445213A>G,NM_004304.4:c.3512T>C,NP_004295.2:p.Ile1171Thr"	2023-01-27 17:04:09 UTC	CA346462880	375888	ILE1171	FALSE
ATM Underexpression	179	Pancreatic Cancer	1793				Prognostic	Supports	B	Poor Outcome	"Absent expression of ATM, as assessed by IHC in 133 pancreatic ductal adenocarcinomas, was found to be associated with dismal prognosis (median survival, 9.6 months), whereas expression of ATM was associated with increased survival (17.7 months, P = 0.001). Furthermore loss of expression of nuclear phosphorylated Ser1981-ATM (IHC) was indicative of the worst prognosis (median survival, 10.8 vs 14.3 months [low expression] vs 31.1 months [high expression], P < 0.001)."	25423555	PubMed		"Kamphues et al., 2015, Pancreas"		2	accepted	1292	N/A	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/1292	https://civicdb.org/links/molecular_profiles/179	FALSE	ATM	472	Underexpression		chr11	108222832	108369099			ENST00000278616.4	75		N/A		2023-01-09 21:52:05 UTC		N/A		FALSE
SIRT1 Overexpression	525	Pancreatic Ductal Carcinoma	3587				Prognostic	Supports	B	Poor Outcome	"Nuclear Sirt1 expression was identified by IHC in 36 (27.9%) of 129 pancreatic ductal adenocarcinoma cases. SIRT1 expression was associated with poor survival in univariate (p??.002) and multivariate (HR 1.65, p??.045) analyses. Overexpression of Sirt1 in pancreas cancer cell lines MiaPaCa-2 and PANC-1 led to increased cell viability."	24088390	PubMed		"Stenzinger et al., 2013, BMC Cancer"		3	accepted	1293	N/A	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1293	https://civicdb.org/links/molecular_profiles/525	FALSE	SIRT1	23411	Overexpression		chr10	67884669	67918390			ENST00000212015.6	75		N/A		2023-01-09 21:52:07 UTC		N/A		FALSE
SIRT1 Overexpression	525	Pancreatic Cancer	1793		Niacinamide		Predictive	Supports	D	Resistance	"In-vitro study with MiaPaCa-2 and PANC-1 pancreatic cancer cell lines. Inhibition of Sirt1 by increasing concentrations of nicotinamide led to a decrease in viability. Gefitinib treatment with concentrations of 50 M showed similar effects as observed for the application of 25 mM nicotinamide. Combinatory treatment with gefitinib and nicotinamide showed a synergistic effect on cell viability. In cell lines overexpressing Sirt1, higher concentrations of nicotinamide were required to abrogate increased cell viability mediated by Sirt1 overexpression compared to controls."	24088390	PubMed		"Stenzinger et al., 2013, BMC Cancer"		1	accepted	1294	N/A	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1294	https://civicdb.org/links/molecular_profiles/525	FALSE	SIRT1	23411	Overexpression		chr10	67884669	67918390			ENST00000212015.6	75		N/A		2023-01-09 21:52:07 UTC		N/A		FALSE
FLT3 TKD MUTATION	56	Acute Myeloid Leukemia	9119		Midostaurin		Predictive	Supports	B	Sensitivity/Response	"In a phase 2 clinical study of 95 AML/high-risk MDS patients treated with either 50 or 100 mg midostaurin, 35 harbored FLT3 mutations (26 had FLT3 ITD, 9 had FLT3 D835Y mutations). A higher percentage of patients saw blast reductions in the FLT3 mutant group than in the FLT3 wild type group (71 vs 42%). Only one permanent response occurred in a FLT3 mutant patient receiving the 100 mg dose. No differences were observed in toxicity or response rate between the two doses of midostaurin."	20733134	PubMed		"Fischer et al., 2010, J. Clin. Oncol."		3	accepted	1295	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/1295	https://civicdb.org/links/molecular_profiles/56	FALSE	FLT3	2322	TKD MUTATION		chr13	28018505	28018505	C	A	ENST00000241453.7	75		nonsynonymous_variant	NC_000013.10:g.28592642C>A	2023-01-27 17:02:18 UTC	CA126347	16276		TRUE
PIK3CA Mutation	307	Her2-receptor Positive Breast Cancer	60079		Everolimus		Predictive	Supports	B	Sensitivity/Response	"Archival tumor samples from 549 patients from the BOLERO-1 and -3 trials were analyzed for alterations in the PI3K pathway using next-generation sequencing, immunohistochemistry (IHC) and Sanger sequencing. In the BOLERO trials, patients with HER2-overexpressing advanced breast cancer were treated with trastuzumab, chemotherapy and randomized to receive either everolimus or placebo. In the pooled analysis of both trials, patients with PI3K mutations had longer progression-free survival with everolimus compared to placebo (HR 0.67 95%CI 0.45 to 1.00, P=0.05) whereas patients with PI3K wild type status did not benefit significantly (HR 1.1, 95%CI 0.83 to 1.46, P=0.5). The same was found when PI3K mutations, PTEN loss and AKT E17K mutations were combinedly analyzed as hyperactive PI3K pathway. Patients with PI3K hyperactive pathway had a hazard ratio of 0.67 (95%CI 0.48 to 0.93, P=0.02) compared to HR 1.19 (95%CI 0.87 to 1.62, P=0.28) in patients with PI3K normal pathway. These trends were independently confirmed in both trials but only pooled results showed consistent statistical significance."	27091708	PubMed		"Andr et al., 2016, J. Clin. Oncol."		4	accepted	1296	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/1296	https://civicdb.org/links/molecular_profiles/307	FALSE	PIK3CA	5290	Mutation		chr3	179148523	179240093			ENST00000263967.3	75		"transcript_variant,gain_of_function_variant"		2023-01-09 21:52:06 UTC		N/A		FALSE
PTEN Loss	214	Her2-receptor Positive Breast Cancer	60079		Everolimus		Predictive	Supports	B	Sensitivity/Response	"Archival tumor samples from 549 patients from the BOLERO-1 and -3 trials were analyzed for alterations in the PI3K pathway using next-generation sequencing, immunohistochemistry (IHC) and Sanger sequencing. In the BOLERO trials, patients with HER2-overexpressing advanced breast cancer were treated with trastuzumab, chemotherapy and randomized to receive either everolimus or placebo. In the pooled analysis of both trials, patients with PTEN loss (as defined by IHC staining intensity and proportion of positive tumor cells) had a longer progression-free survival with everolimus compared to placebo (HR 0.54 (95%CI 0.31 to 0.96, P=0.04) whereas patients with PTEN normal status had a hazard ration of 1.00 (95%CI 0.8 to 1.26, P=0.97). The same was found when PI3K mutations, PTEN loss and AKT E17K mutations were combined and analyzed as hyperactive PI3K pathway. Patients with PI3K hyperactive pathway had a hazard ratio of 0.67 (95%CI 0.48 to 0.93, P=0.02) compared to HR 1.19 (95%CI 0.87 to 1.62, P=0.28) in patients with PI3K normal pathway. These trends were independently confirmed in both trials but only pooled results showed consistent statistical significance."	27091708	PubMed		"Andr et al., 2016, J. Clin. Oncol."		4	accepted	1297	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/1297	https://civicdb.org/links/molecular_profiles/214	FALSE	PTEN	5728	Loss		chr10	87863113	87971930			ENST00000371953.3	75		loss_of_function_variant	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
KRAS G12R	526	Pancreatic Cancer	1793				Prognostic	Supports	B	Poor Outcome	"In 242 patients with unresectable pancreatic cancer, the presence of KRAS G12R (N=17) or G12D (N=92) was associated with poorer prognosis (overall survival HR 1.6; 95% confidence interval 1.11-2.28)."	22983505	PubMed		"Ogura et al., 2013, J. Gastroenterol."		4	accepted	1298	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1298	https://civicdb.org/links/molecular_profiles/526	FALSE	KRAS	3845	G12R		chr12	25245351	25245351	C	G	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.34G>C,NP_004976.2:p.Gly12Arg,NC_000012.11:g.25398285C>G,ENST00000256078.4:c.34G>C"	2023-01-27 17:04:11 UTC	CA122531	12579	"GLY12ARG,RS121913530"	FALSE
KRAS G12D	79	Pancreatic Cancer	1793				Prognostic	Supports	B	Poor Outcome	"In 219 patients with metastatic pancreatic ductal adenocarcinoma, a multivariate analysis identified KRAS G12D mutations as an independent predictor of poorer prognosis both in patients that have received chemotherapy (N=49/162), and the entire series (N=73/219). HR of 1.84 (P=0.02) and 1.44 (P=0.01), respectively."	27010960	PubMed		"Bournet et al., 2016, Clin Transl Gastroenterol"		4	accepted	1300	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/1300	https://civicdb.org/links/molecular_profiles/79	FALSE	KRAS	3845	G12D	EGFR TKI Resistance	chr12	25245350	25245350	C	T	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.35G>A,NP_004976.2:p.Gly12Asp,NC_000012.11:g.25398284C>T,ENST00000256078.4:c.35G>A"	2023-01-27 17:02:26 UTC	CA122538	12582	"GLY12ASP,RS121913529"	FALSE
ROS1 Rearrangement	265	Colorectal Adenocarcinoma	50861		Crizotinib		Predictive	Supports	E	Sensitivity/Response	"A tissue microarray of 268 patients with histologically confirmed colorectal adenocarcinoma was performed to search for ROS1 gene fusion events to guide potential targeted therapy in future cases. Break apart FISH assay, which does not distinguish ROS1-fusion partner, was used on the tissue microarray to determine ROS1 fusion status. 2 cases of ROS1 fusions were found. 1 case was verified by RT-PCR to be a SLC34A2-ROS1 fusion, but this case was also positive for BRAF V600E.  The second case of ROS1 fusion was of undetermined fusion partner, where known ROS1 fusion parters SLC34A2, CD74 and SDC4 were tested. This case did not have KRAS or BRAF mutations, indicating that ROS1 fusion may act in a small subset of colorectal cancer as a driver targetable by crizotinib or other inhibitors."	24296758	PubMed		"Aisner et al., 2014, Mol. Cancer Res."		2	accepted	1301	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1301	https://civicdb.org/links/molecular_profiles/265	FALSE	ROS1	6098	Rearrangement		chr6	117288300	117425855			ENST00000368508.3	75		transcript_fusion		2023-01-09 21:52:06 UTC		N/A		FALSE
TP53 P72R	527	Breast Cancer	1612				Predisposing	Does Not Support	B	Positive	"Large meta-analysis of 5,191 breast cancer patients and 3,834 controls did not find a conclusive link between codon 72 allele and breast cancer susceptibility. Odds ratios were 0.98 (95% CI, 0.91?.05) for heterozygotes and 0.97 (95% CI, 0.86?.11) in homozygotes (per-allele OR, 0.98; 95% CI, 0.91?.04). Median age of onset was also not different between genotypes (GG: 49 years, GC: 50, CC: 50)."	17909070	PubMed		"Schmidt et al., 2007, Cancer Res."		4	accepted	1302	Common Germline	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1302	https://civicdb.org/links/molecular_profiles/527	FALSE	TP53	7157	P72R		chr17	7676154	7676154	G	C	ENST00000269305.4	75		missense_variant	"NM_000546.5:c.215C>G,NP_000537.3:p.Pro72Arg,NC_000017.10:g.7579472G>C,ENST00000269305.4:c.215C>G"	2023-01-27 17:04:11 UTC	CA000072	12351	"PRO72ARG,P33R,RS1042522"	FALSE
TP53 P72R	527	Lung Carcinoma	3905				Prognostic	Does Not Support	B	Poor Outcome	"Pooled data from 13 studies of patients with lung cancer found little effect of codon 72 allele on the overall survival of patients with lung cancer. Proline homozygous patients were correlated with slightly poorer outcome, odds ratio 1.18 with a 95% confidence interval of 0.99-1.41. Heterozygotes had an OR of 1.02 (95% CI 0.86-1.20). Authors conclude that the effect of these alleles on prognosis in lung cancer is inconclusive at best."	12840112	PubMed		"Matakidou et al., 2003, Mutagenesis"		3	accepted	1303	Common Germline	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1303	https://civicdb.org/links/molecular_profiles/527	FALSE	TP53	7157	P72R		chr17	7676154	7676154	G	C	ENST00000269305.4	75		missense_variant	"NM_000546.5:c.215C>G,NP_000537.3:p.Pro72Arg,NC_000017.10:g.7579472G>C,ENST00000269305.4:c.215C>G"	2023-01-27 17:04:11 UTC	CA000072	12351	"PRO72ARG,P33R,RS1042522"	FALSE
TP53 P72R	527	Cervical Cancer	4362				Prognostic	Does Not Support	B	Poor Outcome	"In a relatively small meta-analysis of 119 women with cervical cancer and 127 controls, associations with homozygosity for arginine, and heterozygosity at this locus were both associated with odds ratios above one (3.5 and 2.2, respectively) after adjusting for age and HPV infection. However, both confidence intervals had minimums below one (0.9 and 0.6, respectively). So the overall conclusion remains mixed on the significance of this polymorphism in the prognosis for cervical cancer."	11535556	PubMed		"Klug et al., 2001, Cancer Epidemiol. Biomarkers Prev."		2	accepted	1304	Common Germline	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1304	https://civicdb.org/links/molecular_profiles/527	FALSE	TP53	7157	P72R		chr17	7676154	7676154	G	C	ENST00000269305.4	75		missense_variant	"NM_000546.5:c.215C>G,NP_000537.3:p.Pro72Arg,NC_000017.10:g.7579472G>C,ENST00000269305.4:c.215C>G"	2023-01-27 17:04:11 UTC	CA000072	12351	"PRO72ARG,P33R,RS1042522"	FALSE
PALB2 Biallelic Inactivation	528	Pancreatic Cancer	1793		Mitomycin		Predictive	Supports	C	Sensitivity/Response	"In a patient with gemcitabine-refractory pancreatic cancer, a tumor-derived xenograft was found to be responsive to Mitomycin C. After disease progression, the patient was started on a regimen of mitomycin C, and the patient was shown to be asymptomatic after 3 years of follow-up."	21135251	PubMed		"Villarroel et al., 2011, Mol. Cancer Ther."	NCT00276744	4	accepted	1305	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1305	https://civicdb.org/links/molecular_profiles/528	FALSE	PALB2	79728	Biallelic Inactivation		chr16	23603170	23641310			ENST00000261584.4	75		loss_of_function_variant		2023-01-09 21:52:07 UTC		N/A		FALSE
SMAD4 Expression	529	Pancreatic Ductal Adenocarcinoma	3498				Prognostic	Supports	B	Better Outcome	"In 249 patients that have undergone a pancreaticoduodenectomy (Whipple) for the resection of pancreatic ductal adenocarcinoma, expression of SMAD4 is associated with favorable prognosis. SMAD4 was assessed by IHC in 56 of 249 (22%).  Relative hazard of mortality for cancers lacking SMAD4 after adjusting for other prognostic factors was 1.36 (95% confidence interval, 1.01-1.83; P = 0.04)."	11751510	PubMed		"Tascilar et al., 2001, Clin. Cancer Res."		3	accepted	1306	N/A	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1306	https://civicdb.org/links/molecular_profiles/529	FALSE	SMAD4	4089	Expression		chr18	51030213	51085039			ENST00000342988.3	75		N/A		2023-01-09 21:52:07 UTC		N/A		FALSE
FANCC Loss-of-function	530	Pancreatic Cancer	1793		"Chlorambucil,Gemcitabine,Cisplatin,Melphalan,Mitomycin"	Substitutes	Predictive	Supports	D	Sensitivity/Response	"In the pancreatic cell lines PL11 (FANCC homozygous deletion) and Hs766T (FANCG-mutated), sensitivity to DNA cross-linking agents was observed. PL11 cells (empty vector transduced) were more sensitive to mitomycin C (MMC), cisplatin, chlorambucil, and melphalan than PL11 cells transduced with a vector wildtype FANCC. Similarly, mouse xenografts of PL11 cells (empty vector) were more sensitive to MMC or gemcitabine than PL11 cells expressing a wildtype FANCC."	16243825	PubMed		"van der Heijden et al., 2005, Clin. Cancer Res."		3	accepted	1307	Unknown	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1307	https://civicdb.org/links/molecular_profiles/530	FALSE	FANCC	2176	Loss-of-function		chr9	95099054	95317702			ENST00000289081.3	75		loss_of_function_variant		2023-01-09 21:52:07 UTC		N/A		FALSE
BRCA2 Loss-of-function	132	Pancreatic Cancer	1793		Mitomycin		Predictive	Supports	D	Sensitivity/Response	"In pancreatic cell lines PL11 (FANCC-deficient) and CAPAN1 (BRCA2-mutated), sensitivity to DNA cross-linking agents was observed compared to FANCC/BRCA2 wildtype cell lines (Su86.86, CFPAC, AsPc1, and MiaPaCa2). Mitomycin C specifically led to regression in 8/11 xenografts of the CAPAN1 cell line compared to 2/9 in the CFPAC (BRCA2 wildtype) cell line."	16243825	PubMed		"van der Heijden et al., 2005, Clin. Cancer Res."		2	accepted	1308	Rare Germline	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/1308	https://civicdb.org/links/molecular_profiles/132	FALSE	BRCA2	675	Loss-of-function	BRCA Germline Variants	chr13	32315474	32399210			ENST00000380152.3	75		loss_of_function_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
PDGFRA I843DEL	101	Gastrointestinal Stromal Tumor	9253		Imatinib		Predictive	Supports	D	Sensitivity/Response	15/127 patients with KIT-WT metastatic gastrointestinal stromal tumors were tested for PDGFRA mutations. 6 GISTs harbored PDGFRA mutations. 1 patient had a deletion of I843. CHO cells expressing this variant showed similar sensitivity to imatinib as cells expressing wildtype PDGFRA. 2/3 patients with a mutation determined to be sensitive in vitro achieved partial response on imatinib treatment. It is not noted whether the patient whose GISTs harbored I843del had partial response or progressive disease.	14645423	PubMed		"Heinrich et al., 2003, J. Clin. Oncol."		2	accepted	1309	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/1309	https://civicdb.org/links/molecular_profiles/101	FALSE	PDGFRA	5156	I843DEL	Imatinib Resistance	chr4	54285928	54285930	ATC		ENST00000257290.5	75		inframe_deletion	"ENST00000257290.5:c.2527_2529delATC,NC_000004.11:g.55152095_55152097del"	2023-01-27 17:02:35 UTC	CA645526434	NONE FOUND	DELI843	FALSE
PDGFRB EBF1::PDGFRB	531	Childhood B-cell Acute Lymphoblastic Leukemia	80146	Juvenile onset	Imatinib		Predictive	Supports	C	Sensitivity/Response	"A 10-year-old boy with B-cell acute lymphoblastic leukemia refractory to conventional chemotherapy and harboring an EBF1-PDGFRB fusion responded to imatinib plus induction chemotherapy (vincristine, daunorubicin, prednisone, and intrathecal methotrexate). Complete remission was achieved with bone marrow MRD of 0.059% by flow cytometry and normal PDGFRB by FISH. Consolidation therapy with cyclophosphamide, cytarabine, mercaptopurine, and imatinib followed and the patient was still in remission 10 months after beginning imatinib."	23835704	PubMed		"Weston et al., 2013, J. Clin. Oncol."		3	accepted	1310	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1310	https://civicdb.org/links/molecular_profiles/531	FALSE	PDGFRB	5159	EBF1::PDGFRB		chr5	158707979	159099761			ENST00000517373.1	75	ENST00000261799.4	transcript_fusion		2023-01-09 21:52:07 UTC		N/A	EBF1-PDGFRB	FALSE
PDGFRB EBF1::PDGFRB	531	Childhood B-cell Acute Lymphoblastic Leukemia	80146	Juvenile onset	Imatinib		Predictive	Supports	C	Sensitivity/Response	"A 10-year-old boy with B-cell acute lymphoblastic leukemia refractory to conventional chemotherapy and harboring an EBF1-PDGFRB fusion responded to imatinib plus induction chemotherapy (vincristine, daunorubicin, prednisone, and intrathecal methotrexate). Complete remission was achieved with bone marrow MRD of 0.059% by flow cytometry and normal PDGFRB by FISH. Consolidation therapy with cyclophosphamide, cytarabine, mercaptopurine, and imatinib followed and the patient was still in remission 10 months after beginning imatinib."	23835704	PubMed		"Weston et al., 2013, J. Clin. Oncol."		3	accepted	1310	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1310	https://civicdb.org/links/molecular_profiles/531	FALSE	PDGFRB	5159	EBF1::PDGFRB		chr5	150113837	150125577			ENST00000517373.1	75	ENST00000261799.4	transcript_fusion		2023-01-09 21:52:07 UTC		N/A	EBF1-PDGFRB	FALSE
KRAS G12D	79	Malignant Exocrine Pancreas Neoplasm	1795				Prognostic	Supports	B	Poor Outcome	"In 171 patients with tumors of the exocrine pancreas, a KRAS G12D mutation (N=60) was associated with shorter overall survival than being wild-type for KRAS (N=21; Hazard Ratio: 95% CI between 1.14 and 2.67). Additionally, KRAS mutations combined with CDKN2A alterations (N=26) showed an even worse OS than those wild-type for both (N=17; HR: 95%CI 1.33-7.10)."	23565280	PubMed		"Rachakonda et al., 2013, PLoS ONE"		3	accepted	1311	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/1311	https://civicdb.org/links/molecular_profiles/79	FALSE	KRAS	3845	G12D	EGFR TKI Resistance	chr12	25245350	25245350	C	T	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.35G>A,NP_004976.2:p.Gly12Asp,NC_000012.11:g.25398284C>T,ENST00000256078.4:c.35G>A"	2023-01-27 17:02:26 UTC	CA122538	12582	"GLY12ASP,RS121913529"	FALSE
RB1 EXPRESSION	533	Lung Non-small Cell Carcinoma	3908				Prognostic	Supports	B	Poor Outcome	Positive RB1 expression (2+ by IHC) was associated with adverse outcomes in a cohort of 73 cases with stage I and II NSCLC (P<0.001) in this retrospective study. This finding was independent from other genomic and clinical factors explored by the authors.	22619677	PubMed		"Zhao et al., 2012, J Oncol"		2	accepted	1313	N/A	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1313	https://civicdb.org/links/molecular_profiles/533	FALSE	RB1	5925	EXPRESSION		chr13	48303775	48481986			ENST00000267163.4	75		N/A		2023-01-09 21:52:07 UTC		N/A		FALSE
CDKN2A p16 Expression	268	Lung Non-small Cell Carcinoma	3908				Prognostic	Supports	B	Poor Outcome	In a cohort of 73 patients with stage I or stage II NSCLC it was discovered that the CDKN2A protein (p16-INK4A) retrospectively evaluated via IHC was associated with adverse outcomes (p=0.004).	22619677	PubMed		"Zhao et al., 2012, J Oncol"		2	accepted	1314	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1314	https://civicdb.org/links/molecular_profiles/268	FALSE	CDKN2A	1029	p16 Expression		chr9	21968056	21974866			ENST00000498124.1	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
PTPN11 Overexpression	535	Laryngeal Carcinoma	2600				Prognostic	Supports	B	Poor Outcome	Study explored the expression of the PTPN11 protein (SHP2) and found that expression was increased in a cohort of 112 laryngeal cancer samples. Expression was also associated with poor survival (p=.02) and in vitro models showed SHP2 expression promoted tumor growth.	24297342	PubMed		"Gu et al., 2014, Int. J. Oncol."		2	accepted	1316	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1316	https://civicdb.org/links/molecular_profiles/535	FALSE	PTPN11	5781	Overexpression		chr12	112418914	112509913			ENST00000351677.2	75		N/A		2023-01-09 21:52:07 UTC		N/A		FALSE
FLT3 T227M	536	Renal Cell Carcinoma	4450		Sunitinib		Predictive	Supports	B	Adverse Response	"In 219 patients with mostly Renal Cell Carcinoma and some Gastrointestinal Stromal tumors given sunitinib treatment, FLT3 T227M (rs1933437) was associated with the development of leukopenia. 95% confidence interval of hazard ratio of between .17 and .77."	19667267	PubMed		"van Erp et al., 2009, J. Clin. Oncol."		3	accepted	1317	Common Germline	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1317	https://civicdb.org/links/molecular_profiles/536	FALSE	FLT3	2322	T227M		chr13	28050157	28050157	G	A	ENST00000241453.7	75		"missense_variant,SNP"	"NM_004119.2:c.680C>T,NP_004110.2:p.Thr227Met,NC_000013.10:g.28624294G>A,ENST00000241453.7:c.680C>T"	2023-01-27 17:04:12 UTC	CA159846	134447	"RS1933437,THR227MET"	FALSE
PALB2 L531FS*30	537	Breast Cancer	1612				Diagnostic	Supports	B	Positive	"Study explored the known PALB2 variant c.1592delT (p.L531C) in the context of breast cancer. The study found that among an augmented cohort of breast cancer patients with the variant, there was a hazard ratio of 6.1 (p=.01).  Further there is weak evidence to conclude that breast cancer risk for this variant decreases with age (p=.06)."	18628482	PubMed		"Erkko et al., 2008, Clin. Cancer Res."		3	accepted	1318	Common Germline	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1318	https://civicdb.org/links/molecular_profiles/537	FALSE	PALB2	79728	L531FS*30		chr16	23634955	23634955			ENST00000261584.4	75		"minus_1_frameshift_variant,SNP"		2023-01-09 21:52:07 UTC			LEU531FS*30	FALSE
MTOR S2215Y	538	Endometrial Adenocarcinoma	2870		Sirolimus		Predictive	Supports	D	Sensitivity/Response	Cell lines with various putative activating mutations were tested for sensitivity to rapamycin. The cell line JHUEM7 with the MTOR mutation S2215Y was hypersensitive to rapamycin treatment (IC50 of 0.23 nmol/L).	24631838	PubMed		"Grabiner et al., 2014, Cancer Discov"		2	accepted	1319	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1319	https://civicdb.org/links/molecular_profiles/538	FALSE	MTOR	2475	S2215Y		chr1	11124516	11124516	G	T	ENST00000361445.4	75		missense_variant	"ENST00000361445.4:c.6644C>A,NC_000001.10:g.11184573G>T,NM_004958.3:c.6644C>A,NP_004949.1:p.Ser2215Tyr"	2023-01-27 17:04:13 UTC	CA16602587	376129	SER2215TYR	FALSE
MTOR C1483Y	539	T-cell Acute Lymphoblastic Leukemia	5603		Sirolimus		Predictive	Supports	D	Sensitivity/Response	"Cell lines with various putative activating mutations were tested for sensitivity to rapamycin. The cell line MOLT16, with MTOR mutation C1483Y was hypersensitive to rapamycin treatment (IC50 of 0.75 nmol/L)."	24631838	PubMed		"Grabiner et al., 2014, Cancer Discov"		2	accepted	1320	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1320	https://civicdb.org/links/molecular_profiles/539	FALSE	MTOR	2475	C1483Y		chr1	11157173	11157173	C	T	ENST00000361445.4	75		missense_variant	"ENST00000361445.4:c.4448G>A,NC_000001.10:g.11217230C>T,NM_004958.3:c.4448G>A,NP_004949.1:p.Cys1483Tyr"	2023-01-27 17:04:14 UTC	CA16602888	376453	CYS1483TYR	FALSE
MTOR E1799K	540	Clear Cell Renal Cell Carcinoma	4467		Sirolimus		Predictive	Supports	D	Sensitivity/Response	"Cell lines with various putative activating mutations were tested for sensitivity to rapamycin. The cell line SNU349, with MTOR mutation E1799K was hypersensitive to rapamycin treatment (IC50 of 0.19 nmol/L)."	24631838	PubMed		"Grabiner et al., 2014, Cancer Discov"		2	accepted	1321	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1321	https://civicdb.org/links/molecular_profiles/540	FALSE	MTOR	2475	E1799K		chr1	11130747	11130747	C	T	ENST00000361445.4	75		missense_variant	"NM_004958.3:c.5395G>A,NP_004949.1:p.Glu1799Lys,NC_000001.10:g.11190804C>T,ENST00000361445.4:c.5395G>A"	2023-01-27 17:04:15 UTC	CA279594	217823	"GLU1799LYS,RS863225264"	FALSE
FGFR2 N550K	541	Endometrial Cancer	1380		PD173074		Predictive	Supports	D	Sensitivity/Response	"The endometrial cancer cell lines, AN3CA and MFE296, which carry the N550K FGFR2 mutation, were found to be sensitive to FGFR inhibition with PD174074 (10 to 40x more sensitive than cell lines with wild type FGFR2.)."	18757403	PubMed		"Byron et al., 2008, Cancer Res."		3	accepted	1322	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1322	https://civicdb.org/links/molecular_profiles/541	FALSE	FGFR2	2263	N550K		chr10	121498520	121498520	A	T	ENST00000457416.2	75		"missense_variant,gain_of_function_variant"	"NM_022970.3:c.1650T>A,NP_075259.4:p.Asn550Lys,ENST00000457416.2:c.1650T>A,NC_000010.10:g.123258034A>T"	2023-01-27 17:04:16 UTC	CA16602614	376157	"ASN550LYS,N549K,RS121913476"	FALSE
RB1 Overexpression	543	Pancreatic Adenocarcinoma	4074		"Mitomycin,Gemcitabine,Fluorouracil,Doxorubicin"	Substitutes	Predictive	Supports	D	Resistance	"In Capan-1 cell lines engineered to reduce pRB expression (by transfection with p16), resensitization to chemotherapy-induced apoptosis was observed. The effect was asserted to be specific to pRB depletion because, in two separate cell lines, also transfected with p16, that retained high pRB expression, chemotherapy resistance was still observed."	11792751	PubMed		"Plath et al., 2002, J. Natl. Cancer Inst."		2	accepted	1324	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1324	https://civicdb.org/links/molecular_profiles/543	FALSE	RB1	5925	Overexpression		chr13	48303775	48481986			ENST00000267163.4	75		N/A		2023-01-09 21:52:07 UTC		N/A		FALSE
PPP1R15A RS557806	544	Colorectal Cancer	9256		"FOLFIRI Regimen,Bevacizumab"	Combination	Predictive	Supports	B	Sensitivity/Response	"Exome and RNA sequencing was performed in tumor and matched normal tissue of 19 patients with metastatic colorectal cancer treated with chemotherapy and bevacizumab. The variant PPP1R15A (rs557806) showed the most significant association (P = 0.000401) with FOLFIRI-bevacizumab-driven tumor inhibition rate in exome sequencing data and the highest correlation (r = 0.74) with the drug responses in RNA sequencing data. Patients who were homozygous for the reference alleles (GG) of PPP1R15A rs557806 exhibited greater disease control rates and a tendency toward greater overall response rate than those with homozygous or heterozygous substitution alleles (GC and CC; P = 0.027 and 0.073) when treated with bevacizumab-containing regimens. PPP1R15A rs557806 nonsignificantly correlated with DCR in multivariate analysis (P = 0.054). In HCT116 xenograft tumors, tumor growth IR with FRB was 25 % in mock cells, 24 % in clones with reference alleles (G alleles) of PPP1R15A rs557806, and 17 % in clones with substitution alleles (C alleles) of PPP1R15A rs557806 (P = 0.004, day 13). FDG-PET imaging on day 7 showed FDG uptake (mean SUV max) of 0.219 and 0.500 in HCT116 xenografts expressing the reference allele (G) and substitution allele (C) of PPP1R15A rs557806, respectively (P = 0.032)."	27177629	PubMed		"Roh et al., 2016, J. Cancer Res. Clin. Oncol."		1	accepted	1325	Common Germline	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1325	https://civicdb.org/links/molecular_profiles/544	FALSE	PPP1R15A	23645	RS557806		chr19	48873985	48873985	G	C	ENST00000200453.5	75		"missense_variant,polymorphic_sequence_variant"	"NM_014330.3:c.752G>C,NP_055145.3:p.Arg251Pro,ENST00000200453.5:c.752G>C,NC_000019.9:g.49377242G>C"	2023-01-27 17:04:16 UTC	CA9560103	NONE FOUND	"ARG251PRO,R251P"	FALSE
KRAS Exon 2 Mutation	75	Colorectal Cancer	9256		"Irinotecan,Selumetinib"	Combination	Predictive	Supports	B	Sensitivity/Response	"31 patients with KRAS exon 2 mutation (codons 12 and 13) were treated with selumetinib and irinotecan. All patients had ECOG status 0 or 1 and confirmed progression after first line therapy with oxaliplatin-based chemotherapy and bevacizumab. Patients with more than one line of therapy, MEK or B-RAF inhibitor treatment or prior irinotecan treatment were excluded. The study was terminated before full accrual due to non-protocol considerations. Three patients had a PR, 16 patients had SD >= 4 weeks. Median PFS for all patients was 105 days, median OS was 267 days."	25322874	PubMed		"Hochster et al., 2015, Cancer Chemother. Pharmacol."		1	accepted	1326	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/1326	https://civicdb.org/links/molecular_profiles/75	FALSE	KRAS	3845	Exon 2 Mutation		chr12	25245274	25245395			ENST00000256078.4	75		missense_variant		2023-01-09 21:52:04 UTC				FALSE
ALK F1174L	8	Neuroblastoma	769		AZD3463		Predictive	Supports	D	Sensitivity/Response	"The SH-SY5Y neuroblastoma cell line containing the F1174L ALK mutation was found to undergo cell death when treated with the ALK/IGF1R inhibitor AZD3463. These cells were more sensitive than other neuroblastoma cell lines containing wild-type ALK. Marked inhibition of soft agar colony formation of SH-SY5Y cells was also observed with drug treatment. AZD3463 inhibited Akt signaling in these cells within two hours of treatment, and activated apoptosis and autophagy pathways. Treatment of SH-SY5Y cells implanted into left kidneys of nude mice resulted in almost complete tumor regression."	26786851	PubMed		"Wang et al., 2016, Sci Rep"		3	accepted	1327	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/1327	https://civicdb.org/links/molecular_profiles/8	FALSE	ALK	238	F1174L	ALK Crizotinib Resistance	chr2	29220829	29220829	G	T	ENST00000389048.3	75		missense_variant	"NM_004304.4:c.3522C>A,NP_004295.2:p.Phe1174Leu,NC_000002.11:g.29443695G>T,ENST00000389048.3:c.3522C>A"	2023-01-27 17:01:58 UTC	CA279586	217851	"PHE1174LEU,RS863225281"	FALSE
MYCN Amplification	294	Neuroblastoma	769				Prognostic	Supports	A	Poor Outcome	"In a cohort of 1596 diagnostic tumor samples taken from patients enrolled in the Children's oncology group (COG) neuroblastoma biology protocol ANBL00B1, 1579 samples were annotated with MYCN amplification status. 1239 (78%) were not MYCN amplified, and 349 (22%) were MYCN amplified. Five year event free survival was 74 +/- 1.6 months in non MYCN amplified cases and 39 +/- 4.1 months in amplified cases. Differences were significant with p<0.0001. Five year overall survival was 83 +/- 1.4 months and non MYCN amplified cases and 46 +/- 4.2 months in amplified cases, with p<0.0001, indicating poor prognosis for MYCN amplified cases."	25517749	PubMed		"Bresler et al., 2014, Cancer Cell"		4	accepted	1328	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1328	https://civicdb.org/links/molecular_profiles/294	FALSE	MYCN	4613	Amplification		chr2	15940564	15947007			ENST00000281043.3	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A		FALSE
ALK F1174L	8	Neuroblastoma	769		Lorlatinib		Predictive	Supports	D	Sensitivity/Response	"Efficacy of the second generation ALK inhibitor PF-06463922 was tested on ALK mutation F1174L containing neuroblastoma-derived cells.  COG-N-453x and SH-SY5Y xenografts showed some inhibition when treated with crizotinib, but showed complete growth inhibition with PF-06463922 treatment.  This corresponded to 0% event free survival (EFS) in these mice by 6 weeks with crizotinib treatment, but 100% EFS with PF-06463922 treatment. Comparison of crizotinib and PF-06463922 growth inhibition in F1174L cells SH-SY5Y, NBSD 415-IMDM and KELLY showed increased sensitivity to PF-06463922, as compared to crizotinib. Inhibition effects were not seen on neuroblastoma cells with wild type ALK (NB-EBc1, SK-N-BE(2)C). Decreased phosphorylation on ALK tyrosine 1278 was seen with PF-06463922 over crizotinib at 10 and 100 nM concentrations in SH-SY5Y cells. PF-06463922 was well tolerated in the in-vivo models."	26554404	PubMed		"Infarinato et al., 2016, Cancer Discov"		4	accepted	1329	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/1329	https://civicdb.org/links/molecular_profiles/8	FALSE	ALK	238	F1174L	ALK Crizotinib Resistance	chr2	29220829	29220829	G	T	ENST00000389048.3	75		missense_variant	"NM_004304.4:c.3522C>A,NP_004295.2:p.Phe1174Leu,NC_000002.11:g.29443695G>T,ENST00000389048.3:c.3522C>A"	2023-01-27 17:01:58 UTC	CA279586	217851	"PHE1174LEU,RS863225281"	FALSE
ALK F1245C	545	Neuroblastoma	769		Lorlatinib		Predictive	Supports	D	Sensitivity/Response	"Patient derived xenografts of neuroblastoma Felix cells with F1245C ALK mutation in CB17 SCID mice showed growth inhibition with crizotinib treatment over control, and mice had improved duration of event-free survival (EFS) with crizotinib treatment over vehicle, but EFS with crizotinib went down to 0% by six weeks.  In contrast, PF-06463922 treatment induced complete tumor regression and EFS rate of 100% at six weeks.  PF-06463922 inhibited viability in Felix cells at 37x efficacy over crizotinib, with IC50 values of 21.8 +/- 0.4 and 814.0 +/- 119 respectively.  PF-06463922 was well tolerated in the animal models."	26554404	PubMed		"Infarinato et al., 2016, Cancer Discov"		3	accepted	1330	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1330	https://civicdb.org/links/molecular_profiles/545	FALSE	ALK	238	F1245C		chr2	29213993	29213993	A	C	ENST00000389048.3	75		missense_variant	"NM_004304.4:c.3734T>G,NP_004295.2:p.Phe1245Cys,NC_000002.11:g.29436859A>C,ENST00000389048.3:c.3734T>G"	2023-01-27 17:04:17 UTC	CA279597	217856	"PHE1245CYS,RS863225283"	FALSE
ALK R1275Q	9	Neuroblastoma	769		Lorlatinib		Predictive	Supports	D	Sensitivity/Response	"In NB-1643 and LAN-5 neuroblastoma cell lines containing R1275Q mutation, PF-06463922 showed 51 and 19 fold greater effect on cell viability over crizotinib treatment respectively. ALK wild-type neuroblastoma cell lines did not show differential sensitivity to the treatments within the sensitivity range of R1275Q cells, and had IC50 values above 3800 nM to the inhibitors. NB-1653 cells induced tumors in CB17 SCID mice and crizotinib treatment inhibited tumor growth over vehicle treatment, but PF-06463922 induced complete tumor regression."	26554404	PubMed		"Infarinato et al., 2016, Cancer Discov"		4	accepted	1331	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/1331	https://civicdb.org/links/molecular_profiles/9	FALSE	ALK	238	R1275Q		chr2	29209798	29209798	C	T	ENST00000389048.3	75		missense_variant	"NM_004304.4:c.3824G>A,NP_004295.2:p.Arg1275Gln,NC_000002.11:g.29432664C>T,ENST00000389048.3:c.3824G>A"	2023-01-27 17:01:59 UTC	CA341482	18083	"ARG1275GLN,RS113994087"	FALSE
ALK EML4::ALK	5	Lung Non-small Cell Carcinoma	3908		Lorlatinib		Predictive	Supports	D	Sensitivity/Response	"EML4-ALK variant 1 containing H-3122 NSCLC cells were treated with second generation ALK inhibitor PF-06463922. PF-06463922 was 125x more potent at reducing cell viability than crizotinib. Control neuroblastoma cell lines with wild-type ALK did not show inhibition below 3800 nM with either drug. At values of 10 and 100 nM, PF-06463922 showed increased ability to inhibit ALK 1278 tyrosine phosphorylation in H3122 cells."	26554404	PubMed		"Infarinato et al., 2016, Cancer Discov"		2	accepted	1332	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/1332	https://civicdb.org/links/molecular_profiles/5	FALSE	ALK	238	EML4::ALK	ALK Fusion	chr2	42169350	42295516			ENST00000318522.5	75	ENST00000389048.3	transcript_fusion		2023-01-09 21:52:04 UTC		N/A	EML4-ALK	FALSE
ALK EML4::ALK	5	Lung Non-small Cell Carcinoma	3908		Lorlatinib		Predictive	Supports	D	Sensitivity/Response	"EML4-ALK variant 1 containing H-3122 NSCLC cells were treated with second generation ALK inhibitor PF-06463922. PF-06463922 was 125x more potent at reducing cell viability than crizotinib. Control neuroblastoma cell lines with wild-type ALK did not show inhibition below 3800 nM with either drug. At values of 10 and 100 nM, PF-06463922 showed increased ability to inhibit ALK 1278 tyrosine phosphorylation in H3122 cells."	26554404	PubMed		"Infarinato et al., 2016, Cancer Discov"		2	accepted	1332	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/1332	https://civicdb.org/links/molecular_profiles/5	FALSE	ALK	238	EML4::ALK	ALK Fusion	chr2	29192774	29223528			ENST00000318522.5	75	ENST00000389048.3	transcript_fusion		2023-01-09 21:52:04 UTC		N/A	EML4-ALK	FALSE
ALK F1245C	545	Neuroblastoma	769		Crizotinib		Predictive	Supports	C	Resistance	A participant in Children's Oncology Group (COG) study AVDL0912 with measurable neuroblastoma mutated at ALK F1245C was administered crizotinib at 100mg twice daily.  The patient showed progressive disease as best response after two 28-day cycles on crizotinib.	23598171	PubMed		"Moss et al., 2013, Lancet Oncol."	NCT00939770	3	accepted	1333	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1333	https://civicdb.org/links/molecular_profiles/545	FALSE	ALK	238	F1245C		chr2	29213993	29213993	A	C	ENST00000389048.3	75		missense_variant	"NM_004304.4:c.3734T>G,NP_004295.2:p.Phe1245Cys,NC_000002.11:g.29436859A>C,ENST00000389048.3:c.3734T>G"	2023-01-27 17:04:17 UTC	CA279597	217856	"PHE1245CYS,RS863225283"	FALSE
ALK Fusion	495	Colorectal Adenocarcinoma	50861		Crizotinib		Predictive	Supports	E	Sensitivity/Response	"26 colorectal adenocarcinoma samples were run on Affymetrix human Exon 1.0 arrays and a computational method that assessed differential 5' and 3' gene expression for each gene was used to find potential rearrangements.  One sample showed potential rearrangement and RT-PCR demonstrated an EML4-ALK fusion where EML4 exon 21 was fused to ALK exon 13. This EML4-ALK variant is different from those commonly found in NSCLC. Genomic PCR verified the existence of the fusion breakpoint in intronic space, indicating that some colorectal adenocarcinoma may have targetable ALK-fusion driver mutations."	19737969	PubMed		"Lin et al., 2009, Mol. Cancer Res."		1	accepted	1334	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1334	https://civicdb.org/links/molecular_profiles/495	FALSE	ALK	238	Fusion	ALK Fusion	chr2	29192774	29223528			ENST00000389048.3	75		transcript_fusion		2023-01-09 21:52:07 UTC		N/A	REARRANGEMENT	FALSE
ALK Fusion	495	Breast Cancer	1612		Crizotinib		Predictive	Supports	E	Sensitivity/Response	"84 breast cancer samples acquired from commercial sources were assayed on Affymetrix human exon 1.0 arrays. A computational method was used to find potential gene fusions which assessed differential exon expression between the 3' and 5' ends of each gene. Two potential fusions were found and assessed using RNA ligase mediated rapid amplifiation of cDNA ends and RT-PCR. The fusions were EML4-ALK variants 1 and 2. Genomic PCR identified fusion breakpoints, and these differed from breakpoints for these EML4-ALK variants reported in NSCLC."	19737969	PubMed		"Lin et al., 2009, Mol. Cancer Res."		1	accepted	1335	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1335	https://civicdb.org/links/molecular_profiles/495	FALSE	ALK	238	Fusion	ALK Fusion	chr2	29192774	29223528			ENST00000389048.3	75		transcript_fusion		2023-01-09 21:52:07 UTC		N/A	REARRANGEMENT	FALSE
ALK Exon 4-11 Deletion	546	Neuroblastoma	769		Brigatinib		Predictive	Supports	D	Sensitivity/Response	"The MYCN amplification positive relapsed neuroblastoma-derived cell line CLB-BAR contains the driver ALK DEL 11-14 mutation, which removes extracellular domain exons 4 through 11. Brigatinib treatment of CLB-BAR cells reduced MYCN protein levels and ALK phosphorylation (Y1604) similar to crizotnib. Brigatinib reduced CLB-BAR cellular proliferation more effectively than crizotinib (IC50 75.2 vs 186.4nM). CLB-BAR xenografts in BalbC/NUDE mice responded to brigatinib with reduced tumor volume and weight (N=8/group) as well as reduced ALK phosphorylation and MYCN levels compared to untreated controls. Release of brigatinib administration at day 15 resulted in tumor growth (N=2)."	27049722	PubMed		"Siaw et al., 2016, Oncotarget"		3	accepted	1336	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1336	https://civicdb.org/links/molecular_profiles/546	FALSE	ALK	238	Exon 4-11 Deletion		chr2	29251662	29630790			ENST00000389048.3	75		inframe_deletion	"NM_004304.5:c.953_2041del,NP_004295.2:p.Gly318_Val681delinsVal,NC_000002.11:g.29474528_29853656del"	2023-01-09 21:52:07 UTC				FALSE
ALK EML4::ALK e6-e20	499	Lung Non-small Cell Carcinoma	3908		Ceritinib		Predictive	Supports	D	Sensitivity/Response	"Ceritinib was 28x more potent (GI50 3.8nM) than crizotinib (GI50 107nM) at inhibiting growth of  H2228, an NSCLC cell line which harbors the EML4-ALK variant 3a/3b. SCID mice xenografted with H2228 were treated for 14 days with crizotinib (100 mg/kg) or ceritinib (25 or 50 mg/kg). All treatments caused tumor regression, but tumors recurred within 11 days after crizotinib treatment withdrawal. 4/8 mice treated with 25 mg/kg ceritinib showed regrowth after 1 month treatment withdrawal. The remaining 4/8 mice treated at 25 mg/kg ceritinib, and all mice treated at 50 mg/kg ceritinib maintained complete remission for four months. While 100 mg/kg crizotinib in mice approximates levels 3-5 times the maximal tolerated dose in humans, the authors state 25 to 50 mg/kg ceritinib in mice is predicted to approximate tolerable doses in humans."	24675041	PubMed		"Friboulet et al., 2014, Cancer Discov"		3	accepted	1340	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1340	https://civicdb.org/links/molecular_profiles/499	FALSE	ALK	238	EML4::ALK e6-e20	ALK Fusion	chr2	42169350	42264731			ENST00000318522.5	75	ENST00000389048.3	transcript_fusion		2023-01-09 21:52:07 UTC		N/A	EML4-ALK E6-E20	FALSE
ALK EML4::ALK e6-e20	499	Lung Non-small Cell Carcinoma	3908		Ceritinib		Predictive	Supports	D	Sensitivity/Response	"Ceritinib was 28x more potent (GI50 3.8nM) than crizotinib (GI50 107nM) at inhibiting growth of  H2228, an NSCLC cell line which harbors the EML4-ALK variant 3a/3b. SCID mice xenografted with H2228 were treated for 14 days with crizotinib (100 mg/kg) or ceritinib (25 or 50 mg/kg). All treatments caused tumor regression, but tumors recurred within 11 days after crizotinib treatment withdrawal. 4/8 mice treated with 25 mg/kg ceritinib showed regrowth after 1 month treatment withdrawal. The remaining 4/8 mice treated at 25 mg/kg ceritinib, and all mice treated at 50 mg/kg ceritinib maintained complete remission for four months. While 100 mg/kg crizotinib in mice approximates levels 3-5 times the maximal tolerated dose in humans, the authors state 25 to 50 mg/kg ceritinib in mice is predicted to approximate tolerable doses in humans."	24675041	PubMed		"Friboulet et al., 2014, Cancer Discov"		3	accepted	1340	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1340	https://civicdb.org/links/molecular_profiles/499	FALSE	ALK	238	EML4::ALK e6-e20	ALK Fusion	chr2	29192774	29223528			ENST00000318522.5	75	ENST00000389048.3	transcript_fusion		2023-01-09 21:52:07 UTC		N/A	EML4-ALK E6-E20	FALSE
ALK I1171	523	Lung Non-small Cell Carcinoma	3908		Ceritinib		Predictive	Supports	D	Sensitivity/Response	"Ba/F3 cells expressing EML4-ALK variant 3 with ALK I1171T mutation were treated with ceritinib, and survival IC50 of 2.6 nM was observed, which compares favorably with highly ceritinib sensitive EML4-ALK wild-type variant 1 survival IC50 of 1.7 nM reported from parallel experiments. Tumors from mice with EML4-ALK variant 3 H2228 NSCLC cell xenografts which had progressed after approximately 40 days of crizotinib treatment were sequenced for ALK mutations. I1171T was found as one of 6 ALK resistance mutations from 80 sequenced tumors. Treatment of these mouse xenograft models with ceritinib reduced tumor volume to zero, while in contrast tumor size increased with crizotinib treatment."	24675041	PubMed		"Friboulet et al., 2014, Cancer Discov"		4	accepted	1344	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1344	https://civicdb.org/links/molecular_profiles/523	FALSE	ALK	238	I1171		chr2	29222347	29222347	A	G	ENST00000389048.3	75		missense_variant	"ENST00000389048.3:c.3512T>C,NC_000002.11:g.29445213A>G,NM_004304.4:c.3512T>C,NP_004295.2:p.Ile1171Thr"	2023-01-27 17:04:09 UTC	CA346462880	375888	ILE1171	FALSE
ALK NPM::ALK	509	Cancer	162		Crizotinib		Predictive	Supports	D	Sensitivity/Response	"In Ba/F3 cells, crizotinib sensitivty of the NPM-ALK variant was compared to crizotinib sensitivity of EML4-ALK variant 3. 50% of maximal inhibitory concentration for NPM-ALK was 42 nM, which was approximately 4x greater than IC50 of 11 nM obtained for EML4-ALK. The IC50 for parental Ba/F3 supplemented with IL3 was 2299 nM, resulting in a fold difference of 209.2 for EML4-ALK and 55.1 for NPM-ALK, indicating some reduced sensitivity for NPM-ALK in direct comparison to EML4-ALK, but substantial sensitization to crizotinib for NPM-ALK in Ba/F3 cells."	25727400	PubMed		"Fontana et al., 2015, Cancer Med"		2	accepted	1356	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1356	https://civicdb.org/links/molecular_profiles/509	FALSE	ALK	238	NPM::ALK	ALK Fusion	chr5	171387116	171391799			ENST00000517671.1	75	ENST00000389048.3	transcript_fusion		2023-01-09 21:52:07 UTC		N/A	"T(2;5)(P23;Q35),NPM-ALK"	FALSE
ALK NPM::ALK	509	Cancer	162		Crizotinib		Predictive	Supports	D	Sensitivity/Response	"In Ba/F3 cells, crizotinib sensitivty of the NPM-ALK variant was compared to crizotinib sensitivity of EML4-ALK variant 3. 50% of maximal inhibitory concentration for NPM-ALK was 42 nM, which was approximately 4x greater than IC50 of 11 nM obtained for EML4-ALK. The IC50 for parental Ba/F3 supplemented with IL3 was 2299 nM, resulting in a fold difference of 209.2 for EML4-ALK and 55.1 for NPM-ALK, indicating some reduced sensitivity for NPM-ALK in direct comparison to EML4-ALK, but substantial sensitization to crizotinib for NPM-ALK in Ba/F3 cells."	25727400	PubMed		"Fontana et al., 2015, Cancer Med"		2	accepted	1356	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1356	https://civicdb.org/links/molecular_profiles/509	FALSE	ALK	238	NPM::ALK	ALK Fusion	chr2	29192774	29223528			ENST00000517671.1	75	ENST00000389048.3	transcript_fusion		2023-01-09 21:52:07 UTC		N/A	"T(2;5)(P23;Q35),NPM-ALK"	FALSE
PIK3CA Mutation	307	Cancer	162		"Pictilisib,Tanespimycin"	Substitutes	Predictive	Does Not Support	D	Sensitivity/Response	Analysis of drug response data from the Sanger center cell line screen. Cell lines with either PI3K and/or PTEN mutations did not show a significant difference in response to class I PI3K inhibitor GDC-0941 (p =0.07 for combined PI3K/PTEN aberrations with a trend towards lower IC50 for mutated cell lines). IC50 values with HSP90 inhibitor 17-AAG were significantly lower in PI3K and/or PTEN mutated cell lines in the sanger cell line screening but these results could not be reproduced in the cancer cell line encyclopedia screening.	25855885	PubMed		"Wirtz et al., 2015, JAMA Otolaryngol Head Neck Surg"		2	accepted	1358	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/1358	https://civicdb.org/links/molecular_profiles/307	FALSE	PIK3CA	5290	Mutation		chr3	179148523	179240093			ENST00000263967.3	75		"transcript_variant,gain_of_function_variant"		2023-01-09 21:52:06 UTC		N/A		FALSE
PTEN Mutation	506	Head And Neck Cancer	11934		"Tanespimycin,Pictilisib"	Substitutes	Predictive	Does Not Support	D	Sensitivity/Response	Analysis of drug response data from the Sanger center cell line screen. Cell lines with either PI3K and/or PTEN mutations did not show a significant difference in response to the class I PI3K inhibitor GDC-0941(p =0.07 for combined PI3K/PTEN aberrations with a trend towards lower IC50 for mutated cell lines). IC50 values with HSP90 inhibitor 17-AAG were significantly lower in PI3K and/or PTEN mutated cell lines in the Sanger cell line screening but these results could not be reproduced in the Broad cancer cell line encyclopedia screening.	25855885	PubMed		"Wirtz et al., 2015, JAMA Otolaryngol Head Neck Surg"		2	accepted	1359	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1359	https://civicdb.org/links/molecular_profiles/506	FALSE	PTEN	5728	Mutation		chr10	87863113	87971930			ENST00000371953.3	75		protein_altering_variant		2023-01-09 21:52:07 UTC		N/A		FALSE
PIK3CA Mutation	307	Head And Neck Cancer	11934		Dactolisib		Predictive	Supports	D	Sensitivity/Response	"Preclinical analysis of the predicitive value of PIK3CA mutations for mTOR/PI3K Inhibition with BEZ-235. Two cell lines with PIK3CA Mutation (H1047R) were more sensitive to BEZ-235 than two cell lines with wild-type PIK3CA (in-vitro, results from one cell line also confirmed in-vivo). Two patient-derived xenografts with PIK3CA mutations (E110K, E542K) showed sensitivity to BEZ-235."	23619167	PubMed		"Lui et al., 2013, Cancer Discov"		3	accepted	1360	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/1360	https://civicdb.org/links/molecular_profiles/307	FALSE	PIK3CA	5290	Mutation		chr3	179148523	179240093			ENST00000263967.3	75		"transcript_variant,gain_of_function_variant"		2023-01-09 21:52:06 UTC		N/A		FALSE
PIK3CA H1047R	107	Head And Neck Cancer	11934		Dactolisib		Predictive	Supports	D	Sensitivity/Response	Lentiviral transduction of PIK3CA H1047R mutation into head and neck cancer cell line SCC25 led to increased sensitivity to PI3K/mTOR inhibition with BEZ235 compared to unmanipulated cells (IC50 values 6 nM and 31 nM).	25855885	PubMed		"Wirtz et al., 2015, JAMA Otolaryngol Head Neck Surg"		1	accepted	1361	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/1361	https://civicdb.org/links/molecular_profiles/107	FALSE	PIK3CA	5290	H1047R		chr3	179234297	179234297	A	G	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.3140A>G,NP_006209.2:p.His1047Arg,ENST00000263967.3:c.3140A>G,NC_000003.11:g.178952085A>G"	2023-01-27 17:02:38 UTC	CA123326	13652	"HIS1047ARG,RS121913279"	FALSE
PIK3CA H1047R	107	Head And Neck Cancer	11934		Dactolisib		Predictive	Supports	D	Sensitivity/Response	"Two head and neck cancer cell lines with PIK3CA H1047R mutation were more sensitive to PI3K/mTOR inhibition with BEZ-235 (NVP-BEZ235, Dactolisib) than two wild type cell lines in vitro. One cell line with H1047R mutation was also found to be sensitive to BEZ-235 in vivo. PIK3CA (H1047R) mutation positive cell lines used were ""CAL-33"" and ""Detroit 562"". Wild type cell lines used here were ""SCC-9"" and ""PE/CA-PJ34(clone C12)""."	23619167	PubMed		"Lui et al., 2013, Cancer Discov"		2	accepted	1362	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/1362	https://civicdb.org/links/molecular_profiles/107	FALSE	PIK3CA	5290	H1047R		chr3	179234297	179234297	A	G	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.3140A>G,NP_006209.2:p.His1047Arg,ENST00000263967.3:c.3140A>G,NC_000003.11:g.178952085A>G"	2023-01-27 17:02:38 UTC	CA123326	13652	"HIS1047ARG,RS121913279"	FALSE
PIK3CA H1047R	107	Head And Neck Cancer	11934		"Cetuximab,Dactolisib"	Combination	Predictive	Supports	D	Sensitivity/Response	"Xenografts from one head and neck cancer cell line (CAL-33) with a PIK3CA H1047R mutation were more sensitive to the combined inhibition of PI3K/mTOR and EGFR with BEZ-235 and cetuximab (N=9) than cetuximab (N=9, P=0.0039) or BEZ-235 alone (N=9, P=0.0002) in-vivo."	23619167	PubMed		"Lui et al., 2013, Cancer Discov"		2	accepted	1363	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/1363	https://civicdb.org/links/molecular_profiles/107	FALSE	PIK3CA	5290	H1047R		chr3	179234297	179234297	A	G	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.3140A>G,NP_006209.2:p.His1047Arg,ENST00000263967.3:c.3140A>G,NC_000003.11:g.178952085A>G"	2023-01-27 17:02:38 UTC	CA123326	13652	"HIS1047ARG,RS121913279"	FALSE
PIK3CA Mutation	307	Head And Neck Cancer	11934		"Pictilisib,Trametinib,Tanespimycin"	Substitutes	Predictive	Does Not Support	D	Sensitivity/Response	"6 head and neck cancer cell lines were tested for Response to 17-AAG, GDC-0941. Two of the cell lines did not carry PIK3CA mutations. No clear difference was shown between PIK3CA-mutant and wild-type cell lines and there was a trend towards increased resistance. SCC25 cell line was lentivirally transduced with PIK3CA E545K or H1047R mutation. Engineered cells, compared to the parental cell line, showed decreased sensitivity to 17-AAG, GDC-0941 or trametinib."	25855885	PubMed		"Wirtz et al., 2015, JAMA Otolaryngol Head Neck Surg"		2	accepted	1364	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/1364	https://civicdb.org/links/molecular_profiles/307	FALSE	PIK3CA	5290	Mutation		chr3	179148523	179240093			ENST00000263967.3	75		"transcript_variant,gain_of_function_variant"		2023-01-09 21:52:06 UTC		N/A		FALSE
RET M918T	113	Thyroid Gland Medullary Carcinoma	3973		Sorafenib		Predictive	Supports	B	Sensitivity/Response	"In a phase 2 clinical trial of sorafenib in patients with hereditary or sporadic advanced medullary thyroid cancer, 10 out of 12 patients genotyped in arm B (sporadic MTC) tested positive for RET mutations. In response to sorafenib, 8 patients with RET M918T mutations had stable disease, 1 RET M918T mutant had partial response, and 1 patient with a RET C634R mutation had stable disease. Prior to study entry, all patients with RET M918T mutations had progressive disease or were newly diagnosed."	20368568	PubMed		"Lam et al., 2010, J. Clin. Oncol."		3	accepted	1365	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/1365	https://civicdb.org/links/molecular_profiles/113	FALSE	RET	5979	M918T	RET Motesanib Resistance	chr10	43121968	43121968	T	C	ENST00000355710.3	75		missense_variant	"NM_020975.4:c.2753T>C,NP_065681.1:p.Met918Thr,ENST00000355710.3:c.2753T>C,NC_000010.10:g.43617416T>C"	2023-01-27 17:02:41 UTC	CA009082	13919	"MET918THR,RS74799832"	FALSE
CDK4 Amplification	549	Liposarcoma	3382		Palbociclib		Predictive	Supports	B	Sensitivity/Response	"In a phase 2 clinical trial, NCT01209598, 30 patients with CDK4-amplified and RB-expressing well differentiated and dedifferentiated liposarcomas (WDLS/DDLS) were treated with a selective CDK 4/6 inhibitor, PD0332991. Treatment with PD0332991 was associated with favorable progression free survival rates (66% PFS rate, primary end point being greater than 40%) suggesting that CDK4 amplification is predictive of sensitivity to CDK4 inhibitor therapy."	23569312	PubMed		"Dickson et al., 2013, J. Clin. Oncol."	NCT01209598	3	accepted	1366	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1366	https://civicdb.org/links/molecular_profiles/549	FALSE	CDK4	1019	Amplification		chr12	57747727	57752521			ENST00000257904.6	75		transcript_amplification		2023-01-09 21:52:07 UTC		N/A		FALSE
ALK I1171	523	Lung Non-small Cell Carcinoma	3908		Alectinib		Predictive	Supports	C	Resistance	"A 51 year old female never-smoker was diagnosed with stage IV NSCLC with liver metastases. ALK rearrangement was verified via FISH. She was treated with crizotinib at 250 mg twice daily but discontinued due to adverse response. She then started alectinib at 600 mg twice daily with partial response, but new liver metastases then formed at 5 months. Liver tumor biopsy was performed and was estimated to be 15% tumor tissue. Next-generation sequencing discovered an ALK I1171N mutation. The tumor was not sequenced prior to alectinib resistance."	25736571	PubMed		"Ou et al., 2015, Lung Cancer"		2	accepted	1367	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1367	https://civicdb.org/links/molecular_profiles/523	FALSE	ALK	238	I1171		chr2	29222347	29222347	A	G	ENST00000389048.3	75		missense_variant	"ENST00000389048.3:c.3512T>C,NC_000002.11:g.29445213A>G,NM_004304.4:c.3512T>C,NP_004295.2:p.Ile1171Thr"	2023-01-27 17:04:09 UTC	CA346462880	375888	ILE1171	FALSE
ALK I1171	523	Lung Non-small Cell Carcinoma	3908		Ceritinib		Predictive	Supports	C	Sensitivity/Response	"A 51 year old female never smoker was diagnosed with stage IV NSCLC with liver metastases, and had adverse response to crizotinib treatment, after which she responded to alectinib until disease progressed after 5 months with new liver metastases. Liver tumor biopsy was taken and estimated to be 15% tumor. Hybrid capture next generation sequencing was performed and an I1171N mutation was found in rearranged ALK, and estimated to be in 33% of the tumor cells. Ceritinib was given at 750 mg once daily but dose reduction to 600 mg once daily was required due to persistent nausea. CT showed regression of liver lesions and primary lung lesion and ongoing response was seen at 3 months."	25736571	PubMed		"Ou et al., 2015, Lung Cancer"		3	accepted	1368	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1368	https://civicdb.org/links/molecular_profiles/523	FALSE	ALK	238	I1171		chr2	29222347	29222347	A	G	ENST00000389048.3	75		missense_variant	"ENST00000389048.3:c.3512T>C,NC_000002.11:g.29445213A>G,NM_004304.4:c.3512T>C,NP_004295.2:p.Ile1171Thr"	2023-01-27 17:04:09 UTC	CA346462880	375888	ILE1171	FALSE
NPM1 EXON 12 MUTATION	86	Acute Myeloid Leukemia	9119				Prognostic	Does Not Support	B	Better Outcome	"In normal karyotype patients with AML (15-65 years old), complete remission rates and overall, event-free and relapse-free survival were not different for patients harboring NPM1 exon 12 mutations (N=50) than those wildtype for NPM1 (N=56)."	16046528	PubMed		"Boissel et al., 2005, Blood"		3	accepted	1369	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/1369	https://civicdb.org/links/molecular_profiles/86	FALSE	NPM1	4869	EXON 12 MUTATION	NPM1 Exon 12	chr5	171410527	171410565			ENST00000517671.1	75		exon_variant		2023-01-09 21:52:04 UTC		N/A		FALSE
BRCA1 Mutation	185	Cancer	162		Olaparib		Predictive	Supports	B	Sensitivity/Response	"In this phase 1 trial, 60 patients with advanced solid tumors (ovarian, breast, colorectal, melanoma, sarcoma, prostate) were treated with PARP inhibitor olaparib. Durable antitumor activity was only observed in BRCA1/2 mutation carriers. 19 BRCA carriers had ovarian, breast, or prostate cancers; 12 of these (63%) had a clinical benefit from treatment with olaparib: radiologic or tumor-marker responses or meaningful disease stabilization (stable disease for a period of 4 months or more). Nine BRCA carriers had a response according to RECIST, with the response sustained for more than 76 weeks in one patient. No responses were seen in patients without BRCA mutation."	19553641	PubMed		"Fong et al., 2009, N. Engl. J. Med."	NCT00516373	4	accepted	1370	Rare Germline	2023-05-05 21:15:48 UTC	https://civicdb.org/links/evidence_items/1370	https://civicdb.org/links/molecular_profiles/185	FALSE	BRCA1	672	Mutation		chr17	43045629	43125483			ENST00000471181.2	75		"gene_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
BRCA2 Mutation	186	Cancer	162		Olaparib		Predictive	Supports	B	Sensitivity/Response	"In this phase 1 trial 60 patients with advanced solid tumors (ovarian, breast, colorectal, melanoma, sarcoma, prostate) were treated with PARP inhibitor olaparib. Durable antitumor activity was only observed in BRCA1/2 mutation carriers.19 BRCA carriers had ovarian, breast, or prostate cancers; 12 of these (63%) had a clinical benefit from treatment with olaparib: radiologic or tumor-marker responses or meaningful disease stabilization (stable disease for a period of 4 months or more). Nine BRCA carriers had a response according to RECIST, with the response sustained for more than 76 weeks in one patient. No responses were seen in patients without BRCA mutation."	19553641	PubMed		"Fong et al., 2009, N. Engl. J. Med."	NCT00516373	4	accepted	1371	Rare Germline	2023-05-05 21:15:38 UTC	https://civicdb.org/links/evidence_items/1371	https://civicdb.org/links/molecular_profiles/186	FALSE	BRCA2	675	Mutation		chr13	32315474	32399210			ENST00000380152.3	75		"gene_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
CDKN2A Loss	550	Skin Melanoma	8923		Alvocidib		Predictive	Supports	D	Sensitivity/Response	"Preclinical study in 9 melanoma cell lines. Three cell lines did not have CDKN2A (p16) mutations and showed expression of the protein on western blot analysis. Two of the other six cell lines had stop codons leading to a truncated protein, and three had missense mutations with evidence of protein expression on western blot (two cell lines with a P114L mutation and one with an E88K mutation). Mean IC50s of flavopiridol were significantly lower in cell lines with a mutated or non-expressed p16 (p16-) (mean 50% inhibitory concentration [IC(50)] = 12.5 nM), than in cell lines with intact p16 (p16+) (mean IC(50) = 25 nM)."	12777976	PubMed		"Robinson et al., 2003, Melanoma Res."		2	accepted	1372	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1372	https://civicdb.org/links/molecular_profiles/550	FALSE	CDKN2A	1029	Loss		chr9	21967753	21994624			ENST00000579755.1	75		loss_of_function_variant		2023-01-09 21:52:07 UTC		N/A		FALSE
CDKN2A Loss	550	Renal Cell Carcinoma	4450		Palbociclib		Predictive	Supports	D	Sensitivity/Response	"Preclinical study of CDK4/6 inhibitor PD-0332991 in 28 renal carcinoma cell lines (25 malignant RCC and three non-malignant, transformed cell lines derived from kidney epithelium). Both p15 and p16 loss (CGH) were tested for association with response to PD-0332991 using Fisher's exact test. Cell lines with p16 and p15 losses were significantly more likely to be classified as responders (defined by pharmacokinetic data-based concentration of <=400nM) to PD-0332991 (p=0.027, relative risk (RR)=2.06 and p=0.047, RR=1.71, respectively). Four cell lines had homozygous deletions of CDKN2A but not CDKN2B, and three of these lines were classified as being sensitive to PD-0332991. There were no cell lines with only CDKN2B deletion."	23898052	PubMed		"Logan et al., 2013, Anticancer Res."		3	accepted	1373	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1373	https://civicdb.org/links/molecular_profiles/550	FALSE	CDKN2A	1029	Loss		chr9	21967753	21994624			ENST00000579755.1	75		loss_of_function_variant		2023-01-09 21:52:07 UTC		N/A		FALSE
CDKN2B Loss	551	Renal Cell Carcinoma	4450		Palbociclib		Predictive	Supports	D	Sensitivity/Response	"Preclinical study of CDK4/6 inhibitor PD-0332991 in 28 renal carcinoma cell lines (25 malignant RCC and three non-malignant, transformed cell lines derived from kidney epithelium). Both p15 and p16 loss (CGH) were tested for association with response to PD-0332991 using Fisher's exact test. Cell lines with p16 and p15 losses were significantly more likely to be classified as responders (defined by pharmacokinetic data-based concentration of <=400nM) to PD-0332991 (p=0.027, relative risk (RR)=2.06 and p=0.047, RR=1.71, respectively). Four cell lines had homozygous deletions of CDKN2A but not CDKN2B, and three of these lines were classified as being sensitive to PD-0332991. There were no cell lines with only CDKN2B deletion."	23898052	PubMed		"Logan et al., 2013, Anticancer Res."		3	accepted	1374	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1374	https://civicdb.org/links/molecular_profiles/551	FALSE	CDKN2B	1030	Loss		chr9	22002903	22009363			ENST00000276925.6	75		transcript_ablation		2023-01-09 21:52:07 UTC		N/A		FALSE
CDKN2A Loss	550	Skin Melanoma	8923		Palbociclib		Predictive	Supports	D	Sensitivity/Response	"In a cohort of 143 patients with primary invasive melanoma hemizygous or homozygous loss of CDKN2A was observed (FISH) in 56% of cases. PD0332991 efficacy (proliferation assay) was assessed in a panel of 47 melanoma cell lines. Loss of functional p16INK4A (CDKN2A) due to gene deletion (49% of cells), methylation (4% of cells), or mutation (19% of cells) was the most prevalent alteration occurring in 71% of cell lines, and significantly correlated with PD0332991 sensitivity (Fisher's exact test P < 0.02)."	24495407	PubMed		"Young et al., 2014, Pigment Cell Melanoma Res"		3	accepted	1375	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1375	https://civicdb.org/links/molecular_profiles/550	FALSE	CDKN2A	1029	Loss		chr9	21967753	21994624			ENST00000579755.1	75		loss_of_function_variant		2023-01-09 21:52:07 UTC		N/A		FALSE
CDK4 R24C	552	Skin Melanoma	8923		Palbociclib		Predictive	Supports	D	Sensitivity/Response	"In a cohort of 143 patients with primary invasive melanoma, copy-number gain of CDK4 was observed (FISH) in 37% of cases. PD0332991 efficacy (proliferation assay) was assessed in a panel of 47 melanoma cell lines. Four cell lines had an R24C activating mutation in CDK4, three of these were sensitive to PD0332991 (palbociclib)."	24495407	PubMed		"Young et al., 2014, Pigment Cell Melanoma Res"		1	accepted	1376	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1376	https://civicdb.org/links/molecular_profiles/552	FALSE	CDK4	1019	R24C		chr12	57751648	57751648	G	A	ENST00000257904.6	75		missense_variant	"NM_000075.3:c.70C>T,NP_000066.1:p.Arg24Cys,ENST00000257904.6:c.70C>T,NC_000012.11:g.58145431G>A"	2023-01-27 17:04:19 UTC	CA126982	16928	"ARG24CYS,RS11547328"	FALSE
CDKN2A Loss	550	Ovarian Cancer	2394		Palbociclib		Predictive	Supports	D	Sensitivity/Response	"Preclinical study of the effects of PD-0332991 on proliferation, cell-cycle, apoptosis, and Rb phosphorylation in a panel of 40 human ovarian cancer cell lines. Concentration-dependent antiproliferative effects of PD-0332991 were seen in all ovarian cancer cell lines, but varied significantly between individual lines. Rb-proficient cell lines with low p16 expression were significantly more sensitive to PD-0332991 (as defined by IC50 < mean) in mRNA expression (Agilent), protein level (Western Blot) and copy number (Array CGH) analyses."	21278246	PubMed		"Konecny et al., 2011, Clin. Cancer Res."		3	accepted	1377	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1377	https://civicdb.org/links/molecular_profiles/550	FALSE	CDKN2A	1029	Loss		chr9	21967753	21994624			ENST00000579755.1	75		loss_of_function_variant		2023-01-09 21:52:07 UTC		N/A		FALSE
ASXL1 Mutation	177	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	"In older patients (>59 years) with cytogenetically normal acute myeloid leukemia classified as ELN favorable, multivariate analysis identified ASXL1 mutations (12/99 patients) were associated with lower complete remission rates (P = 0.03), disease-free survival (P < 0.001), overall survival (P < 0.001), and event-free survival (P < 0.001). This confirmed results from univariate analysis of patients not stratified by ELN category, but cytogenetically normal and older (38/220 patients)."	22031865	PubMed		"Metzeler et al., 2011, Blood"		3	accepted	1378	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/1378	https://civicdb.org/links/molecular_profiles/177	FALSE	ASXL1	171023	Mutation		chr20	32358352	32439319			ENST00000375687.4	75		protein_altering_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
ASXL1 EXON 12 MUTATION	553	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	"In patients with de novo AML who received intensive chemotherapy, ASXL1 mutations (N=51) were associated with shorter overall (P<0.001) and event free survival (P=0.012) compared to ASXL1 wild-type (N=430). Multivariate analysis identified ASXL1 mutations as an independent factor for adverse overall survival (P=0.032, relative risk: 1.70)."	23018865	PubMed		"Schnittger et al., 2013, Leukemia"		4	accepted	1379	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1379	https://civicdb.org/links/molecular_profiles/553	FALSE	ASXL1	171023	EXON 12 MUTATION		chr20	32433284	32433917			ENST00000375687.4	75		exon_variant		2023-01-09 21:52:07 UTC				FALSE
ERBB2 Amplification	302	Her2-receptor Positive Breast Cancer	60079		Pictilisib		Predictive	Supports	D	Sensitivity/Response	"The HER2/Neu mammary tumor mouse model MMTV-NeuT was employed to demonstrate dependence of HER2 tumor formation on PIK3 p110alpha isoform. MMTV-NeuT mice were crossed with floxed p110alpha mice. Diassacociated tumors cells from these mice were treated with Cre adenovirus to delete p110alpha, or GFP adenovirus, and cells were transplanted into athymic mice. GFP treated cells formed new tumors, while p110alpha deletion blocked tumor formation indicating tumor dependence on PI3KA. Next, MMTV-NeuT tumors were dissociated and treated with pan-PI3K inhibitor GDC-0941. Reduced lipid kinase activity and reduced phospho-Akt levels were seen in these cells. Administration of 125 mg/kg GDC-0941 to athymic mice with transplantation of tumor cells caused marked reduction of tumor cell volume in comparison to control treatment."	22802530	PubMed		"Utermark et al., 2012, Genes Dev."		3	accepted	1380	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1380	https://civicdb.org/links/molecular_profiles/302	FALSE	ERBB2	2064	Amplification		chr17	39700080	39728662			ENST00000269571.5	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A	OVEREXPRESSION	FALSE
ERBB2 Amplification	302	Her2-receptor Positive Breast Cancer	60079		A66		Predictive	Supports	D	Sensitivity/Response	"Pharmacologic (A66; p110alpha specific inhibitor) or genetic (cre-mediated knockout) ablation of the p110alpha PI3K isoform reduced tumor growth and tumor formation, respectively, in athymic mice transplanted with cells transduced by MMTV-NeuT (mammary specific overexpression of HER2 that effectively induces tumors). A66 treatment of cells from MMTV-NeuT mouse tumors resulted in decreased lipid kinase activity and phospho Akt levels."	22802530	PubMed		"Utermark et al., 2012, Genes Dev."		2	accepted	1381	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1381	https://civicdb.org/links/molecular_profiles/302	FALSE	ERBB2	2064	Amplification		chr17	39700080	39728662			ENST00000269571.5	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A	OVEREXPRESSION	FALSE
ERBB2 Amplification	302	Her2-receptor Positive Breast Cancer	60079		Tgx 221		Predictive	Does Not Support	D	Sensitivity/Response	"Treatment of cells obtained from MMTV-NeuT mouse mammary tumors with the p110beta selective inhibitor TGX-221 showed significant but minimal reductions in lipid kinase activity and negligible reductions in phospho Akt levels. In simmilar cells subjected to p110alpha isoform knockout, TGX-221 treatment fully blocked Akt activation, indicating that TGX-221 was fully inhibiting the p110beta isoform. Athymic mice recieved MMTV-NeuT tumor cell transplants and were treated with TGX-221, which resulted in significant but minimal reduction in tumor growth compared to controls."	22802530	PubMed		"Utermark et al., 2012, Genes Dev."		3	accepted	1382	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1382	https://civicdb.org/links/molecular_profiles/302	FALSE	ERBB2	2064	Amplification		chr17	39700080	39728662			ENST00000269571.5	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A	OVEREXPRESSION	FALSE
PTEN Loss	214	Her2-receptor Positive Breast Cancer	60079		Trastuzumab		Predictive	Supports	D	Resistance	"A large-scale RNAi genetic sereen in HER2 overexpressing breast cancer cell line BT-474 was performed to discover genes whose loss induced trastuzumab resistance. The most prominently enriched gene in trastuzumab resistant populations was PTEN. Subsequent knockdown of PTEN in BT-474 cells increased cell survival when treated with trastuzumab, and growth curves showed partial restoration of proliferation in PTEN knockdown BT-474 cells treated with trastuzumab."	17936563	PubMed		"Berns et al., 2007, Cancer Cell"		2	accepted	1383	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/1383	https://civicdb.org/links/molecular_profiles/214	FALSE	PTEN	5728	Loss		chr10	87863113	87971930			ENST00000371953.3	75		loss_of_function_variant	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
PIK3CA Mutation	307	Her2-receptor Positive Breast Cancer	60079		Trastuzumab		Predictive	Supports	B	Resistance	"The HER2 overexpressing breast cancer cell line BT-474 transduced with mutant PIK3CA H1047R demonstrated essentially normal proliferation under trastuzumab, while control cells showed negligible proliferation with trastuzumab. Sequencing of 55 HER2 breast cancer samples revealed 25% PIK3CA mutation rate and Kaplan Meier curves showed decreased time to progression for mutant PIK3CA at borderline statistical significance (p=0.052). This was potentially explained by presence of PTEN loss in wild-type PIK3CA sample and combining PTEN loss with PIK3CA mutation resulted in significant differences in time to progression (p=0.007)."	17936563	PubMed		"Berns et al., 2007, Cancer Cell"		2	accepted	1384	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/1384	https://civicdb.org/links/molecular_profiles/307	FALSE	PIK3CA	5290	Mutation		chr3	179148523	179240093			ENST00000263967.3	75		"transcript_variant,gain_of_function_variant"		2023-01-09 21:52:06 UTC		N/A		FALSE
PTEN Loss	214	Her2-receptor Positive Breast Cancer	60079		Trastuzumab		Predictive	Supports	B	Resistance	"A subgroup of HER2-positive breast cancer patients that received first-line trastuzumab treatment were assessed for PTEN loss via IHC of FFPE samples. 46 samples showed PTEN loss while 41 did not, and PTEN loss alone was found to be significantly associated with resistance to trastuzumab (p=0.028) and shorter overall survival (p=0.008)."	20813970	PubMed		"Esteva et al., 2010, Am. J. Pathol."		3	accepted	1385	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/1385	https://civicdb.org/links/molecular_profiles/214	FALSE	PTEN	5728	Loss		chr10	87863113	87971930			ENST00000371953.3	75		loss_of_function_variant	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
PTEN Loss	214	Her2-receptor Positive Breast Cancer	60079		Trastuzumab		Predictive	Does Not Support	B	Resistance	"While some reports indicate PTEN loss is associated with resistance to trastuzumab, in a subgroup of HER2 breast cancer FFPE samples from patients receiving trastuzumab as later line therapy (second or greater line therapy), with 25 PTEN loss and and 25 normal samples, no association was seen between trastuzumab response and PTEN status (p=1.000) or overall survival and PTEN status (p=0.863)."	20813970	PubMed		"Esteva et al., 2010, Am. J. Pathol."		3	accepted	1386	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/1386	https://civicdb.org/links/molecular_profiles/214	FALSE	PTEN	5728	Loss		chr10	87863113	87971930			ENST00000371953.3	75		loss_of_function_variant	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
CALR EXON 9 FRAMESHIFT	555	Myelofibrosis	4971				Prognostic	Supports	A	Better Outcome	"Study of 428 patients with primary Myelofibrosis found that those patients harboring CALR exon 9 mutations displayed significantly longer survival than those with JAK2 mutations (HR: 2.5, median survival yrs: CALR 15.9, JAK2 5.9)"	25037629	PubMed		"Tefferi et al., 2014, Blood"		4	accepted	1387	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1387	https://civicdb.org/links/molecular_profiles/555	FALSE	CALR	811	EXON 9 FRAMESHIFT		chr19	12943713	12943913			ENST00000316448.5	75		exon_variant		2023-01-09 21:52:07 UTC				FALSE
CSF3R Mutation	556	Chronic Neutrophilic Leukemia	80187				Diagnostic	Supports	B	Positive	"Study found that mutations in CSF3R are enriched in patients with Chronic Neutrophilic Leukemia (CNL) or Atypical Chronic Myeloid Leukemia (16/27, 59%) when compared to other blood disorders (AML=1/292, t-cell ALL=0/8, B-cell ALL=0/41)"	23656643	PubMed		"Maxson et al., 2013, N. Engl. J. Med."		3	accepted	1388	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1388	https://civicdb.org/links/molecular_profiles/556	FALSE	CSF3R	1441	Mutation		chr1	36466495	36467843			ENST00000373106.1	75		protein_altering_variant		2023-01-09 21:52:07 UTC		N/A		FALSE
CSF3R Mutation	556	"Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative"	60597				Diagnostic	Supports	B	Positive	"Study found that mutations in CSF3R are enriched in patients with Chronic Neutrophilic Leukemia (CNL) or Atypical Chronic Myeloid Leukemia (16/27, 59%) when compared to other blood disorders (AML=1/292, t-cell ALL=0/8, B-cell ALL=0/41)"	23656643	PubMed		"Maxson et al., 2013, N. Engl. J. Med."		3	accepted	1389	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1389	https://civicdb.org/links/molecular_profiles/556	FALSE	CSF3R	1441	Mutation		chr1	36466495	36467843			ENST00000373106.1	75		protein_altering_variant		2023-01-09 21:52:07 UTC		N/A		FALSE
EGFR T790M	34	Lung Adenocarcinoma	3910		"Erlotinib,Gefitinib"	Substitutes	Predictive	Supports	B	Resistance	"155 patients with lung adenocarcinomas underwent rebiopsy and genotyping (EGFR, AKT1, BRAF, ERBB2, KRAS, MEK1, NRAS, PIK3CA and FISH for MET and HER2) after the development of acquired resistance to EGFR inhibitors (gefitinib or erlotinib). 98 patients were found to have developed EGFR T790M mutations."	23470965	PubMed		"Yu et al., 2013, Clin. Cancer Res."		3	accepted	1391	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/1391	https://civicdb.org/links/molecular_profiles/34	FALSE	EGFR	1956	T790M	EGFR TKI Resistance	chr7	55181378	55181378	C	T	ENST00000275493.2	75		missense_variant	"ENST00000275493.2:c.2369C>T,NM_005228.4:c.2369C>T,NP_005219.2:p.Thr790Met,NC_000007.13:g.55249071C>T"	2023-01-27 17:02:05 UTC	CA090928	16613	"THR790MET,RS121434569"	FALSE
MET Amplification	266	Lung Adenocarcinoma	3910		"Erlotinib,Gefitinib"	Substitutes	Predictive	Supports	C	Resistance	"155 patients with lung adenocarcinomas underwent rebiopsy and genotyping (EGFR, AKT1, BRAF, ERBB2, KRAS, MEK1, NRAS, PIK3CA and FISH for MET and HER2) after the development of acquired resistance to EGFR inhibitors (gefitinib or erlotinib). MET amplification was seen in 4 of 75 patients tested (no baseline samples available). One patient had small cell transformation and MET amplification, two patients had EGFR T790M mutation and MET amplification."	23470965	PubMed		"Yu et al., 2013, Clin. Cancer Res."		2	accepted	1392	N/A	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1392	https://civicdb.org/links/molecular_profiles/266	FALSE	MET	4233	Amplification		chr7	116672405	116796342			ENST00000318493.6	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A		FALSE
ERBB2 Amplification	302	Lung Adenocarcinoma	3910		"Erlotinib,Gefitinib"	Substitutes	Predictive	Supports	C	Resistance	"155 patients with lung adenocarcinomas underwent rebiopsy and genotyping (EGFR, AKT1, BRAF, ERBB2, KRAS, MEK1, NRAS, PIK3CA and FISH for MET and HER2) after the development of acquired resistance to EGFR inhibitors (gefitinib or erlotinib). 2 of 24 patients tested were found to have HER2 amplification (but no baseline samples available for analysis). One patient of which had a metastasis sample which was reported to have only HER2 amplification whereas another autopsy specimen from the same patient was HER2 negative but EGFR T790M positive."	23470965	PubMed		"Yu et al., 2013, Clin. Cancer Res."		1	accepted	1393	N/A	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/1393	https://civicdb.org/links/molecular_profiles/302	FALSE	ERBB2	2064	Amplification		chr17	39700080	39728662			ENST00000269571.5	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A	OVEREXPRESSION	FALSE
EGFR S768I	558	Lung Adenocarcinoma	3910		Erlotinib		Predictive	Supports	C	Sensitivity/Response	A patient with metastatic lung adenocarcinoma was found to harbor EGFR T790M and S768I mutations when acquired resistance developed after 8 years of erlotinib treatment. Analysis of original tumor samples from 2001 and 2003 were found to also harbor the S768I (but not T790M) mutation. Three-dimensional visualization showed the 768 position to be outside of the erlotinib binding position.	25521405	PubMed		"Hellmann et al., 2014, J Thorac Oncol"		3	accepted	1394	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1394	https://civicdb.org/links/molecular_profiles/558	FALSE	EGFR	1956	S768I		chr7	55181312	55181312	G	T	ENST00000275493.2	75		missense_variant	"ENST00000275493.2:c.2303G>T,NC_000007.13:g.55249005G>T,NM_005228.4:c.2303G>T,NP_005219.2:p.Ser768Ile"	2023-01-27 17:04:20 UTC	CA135840	45251	"SER768ILE,RS121913465"	FALSE
EGFR S768I	558	Lung Adenocarcinoma	3910		Gefitinib		Predictive	Supports	C	Sensitivity/Response	Case report of an 81-year old man with lung adenocarcinoma and EGFR S768I mutation. The patient then received chemotheraoy (vinorelbine) and showed stable disease. Gefitinib was administered when disease progression was noted 4 months later and the patient was followed-up without signs of disease progression for 461 days.	20522446	PubMed		"Masago et al., 2010, Jpn. J. Clin. Oncol."		2	accepted	1395	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1395	https://civicdb.org/links/molecular_profiles/558	FALSE	EGFR	1956	S768I		chr7	55181312	55181312	G	T	ENST00000275493.2	75		missense_variant	"ENST00000275493.2:c.2303G>T,NC_000007.13:g.55249005G>T,NM_005228.4:c.2303G>T,NP_005219.2:p.Ser768Ile"	2023-01-27 17:04:20 UTC	CA135840	45251	"SER768ILE,RS121913465"	FALSE
EGFR C797S	411	Lung Adenocarcinoma	3910		Osimertinib		Predictive	Supports	C	Resistance	"Case report of a patient with stage IV lung adenocarcinoma and a 15base pair deletion in EGFR exon 19. Partial response with erlotinib was achieved for 15 months after initial chemotherapy. After further progression, rebiopsy additionally identified the EGFR T790M mutation and the patient received several cycles of chemotherapy and targeted therapy including afatinib, cetuximab, erlotinib, AZD9291. She was treated with AZD9291 for 9 months until disease progression. Repeat biopsy detected EGFRC797S mutation additionally to both aforementioned EGFR aberrations. In addition, PTEN Y27C and CTNNB1 S37F mutations were present in all 3 samples, and a TSC2 N486I was seen in the third biopsy sample only"	26181354	PubMed		"Yu et al., 2015, JAMA Oncol"	NCT01802632	1	accepted	1396	Somatic	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/1396	https://civicdb.org/links/molecular_profiles/411	FALSE	EGFR	1956	C797S		chr7	55181398	55181398	T	A	ENST00000275493.2	75		missense_variant	"ENST00000275493.2:c.2389T>A,NC_000007.13:g.55249091T>A,NM_005228.4:c.2389T>A,NP_005219.2:p.Cys797Ser"	2023-01-27 17:03:38 UTC	CA16602785	376342	"CYS797SER,RS1057519861"	FALSE
EGFR T790M	34	Lung Adenocarcinoma	3910		Osimertinib		Predictive	Supports	C	Sensitivity/Response	"Case report of a patient with stage IV lung adenocarcinoma and a 15base pair deletion in EGFR exon 19. Partial response with erlotinib was achieved for 15 months after initial chemotherapy. After further progression, rebiopsy additionally identified the EGFR T790M mutation and the patient received several cycles of chemotherapy and targeted therapy including afatinib, cetuximab, erlotinib, AZD9291. She was treated with AZD9291 for 9 months until disease progression."	26181354	PubMed		"Yu et al., 2015, JAMA Oncol"	NCT01802632	1	accepted	1397	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/1397	https://civicdb.org/links/molecular_profiles/34	FALSE	EGFR	1956	T790M	EGFR TKI Resistance	chr7	55181378	55181378	C	T	ENST00000275493.2	75		missense_variant	"ENST00000275493.2:c.2369C>T,NM_005228.4:c.2369C>T,NP_005219.2:p.Thr790Met,NC_000007.13:g.55249071C>T"	2023-01-27 17:02:05 UTC	CA090928	16613	"THR790MET,RS121434569"	FALSE
BRAF V600E	12	Melanoma	1909		Vemurafenib		Predictive	Supports	B	Sensitivity/Response	The BRIM-3 Phase III trial NCT01006980 assessed BRAF inhibitor vemurafenib versus dacarbazine in 598 patients with treatment naive metastatic melanoma and confirmed V600E mutation. Significant differences were seen in overall survival (13.3 months with vemurafenib vs. 10.0 months with dacarbazine) and median progression free survival (6.9 months  with vemurafenib vs. 1.6 months with dacarbazine)	24508103	PubMed		"McArthur et al., 2014, Lancet Oncol."	NCT01006980	5	accepted	1398	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/1398	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
BRAF V600K	559	Melanoma	1909		Vemurafenib		Predictive	Supports	B	Sensitivity/Response	"In the Phase III study of vemurafenib versus dacarbazine BRIM-3 (NCT01006980) in metastatic melanoma, 57 patients were confirmed to have V600K mutation. In this subgroup of treatment-naive patients, significant differences were seen in overall survival (14.5 months with vemurafenib vs. 7.6 months with dacarbazine), as well as median progression free survival (5.9 months with vemurafenib vs. 1.7 months with dacarbazine)."	24508103	PubMed		"McArthur et al., 2014, Lancet Oncol."	NCT01006980	4	accepted	1399	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1399	https://civicdb.org/links/molecular_profiles/559	FALSE	BRAF	673	V600K	Other BRAF V600's	chr7	140753336	140753337	AC	TT	ENST00000288602.6	75		missense_variant	"ENST00000288602.6:c.1798_1799delinsAA,NC_000007.13:g.140453136_140453137delinsTT,NM_004333.4:c.1798_1799delGTinsAA,NP_004324.2:p.Val600Lys"	2023-01-27 17:04:21 UTC	CA16602420	375941	"VAL600LYS,RS121913227"	FALSE
BRAF V600K	559	Melanoma	1909		Vemurafenib		Predictive	Supports	C	Sensitivity/Response	"A 53 year old male presented with a scalp lesion which was incompletely excised. Metastases were seen in lymph node biopsy and subsequently in CT. BRAF inhibitor vemurafenib was then administered at 960 mg twice daily and later at 720 mg twice daily and reduction in metastases was observed. After 2 years complete radiological response was seen, while treatment was discontinued due to cardiomyopathy. 12 months after stopping vemurafenib patient did not show evidence of metastatic melanoma."	26989536	PubMed		"Sahadudheen et al., 2016, Case Rep Oncol Med"		3	accepted	1400	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1400	https://civicdb.org/links/molecular_profiles/559	FALSE	BRAF	673	V600K	Other BRAF V600's	chr7	140753336	140753337	AC	TT	ENST00000288602.6	75		missense_variant	"ENST00000288602.6:c.1798_1799delinsAA,NC_000007.13:g.140453136_140453137delinsTT,NM_004333.4:c.1798_1799delGTinsAA,NP_004324.2:p.Val600Lys"	2023-01-27 17:04:21 UTC	CA16602420	375941	"VAL600LYS,RS121913227"	FALSE
PIK3CA H1047R	107	Head And Neck Cancer	11934		Alpelisib		Predictive	Supports	D	Sensitivity/Response	"In a panel of head and neck cancer cell lines, 2 lines containing the PIK3CA mutation H1047R (Detroit562 and SNU-1076) were more sensitive to growth inhibition (IC50 1.10 and 6.82) by the PI3Kalpha specific inhibitor BYL719 (Alepelisib) than 3 of 4 lines with wild type PI3K (SNU-1066 IC50 1.13 M; SNU-1041, 20.65 M; FaDu, 19.67 M; SCC25, 49.30 M). In the H1047R mutant cell lines and the wildtype cell line tested, phospho-Akt and phospho-S6 levels were diminished with increasing BYL719 levels."	25550549	PubMed		"Keam et al., 2015, Anticancer Res."		1	accepted	1401	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/1401	https://civicdb.org/links/molecular_profiles/107	FALSE	PIK3CA	5290	H1047R		chr3	179234297	179234297	A	G	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.3140A>G,NP_006209.2:p.His1047Arg,ENST00000263967.3:c.3140A>G,NC_000003.11:g.178952085A>G"	2023-01-27 17:02:38 UTC	CA123326	13652	"HIS1047ARG,RS121913279"	FALSE
PIK3CA Mutation	307	Cancer	162		Alpelisib		Predictive	Supports	D	Sensitivity/Response	"A set of 474 cell lines from the Cancer Cell Line Encyclopedia was tested for responsiveness to the PI3Kalpha specific inhibitor BYL719 (Alpelisib). In the PIK3CA wild type subroup of cell lines, 22% were assessed as responsive, while in the subgroup of cell lines with PIK3CA mutations, 64% were labeled as responders. 7 patient derived xenografts with PIK3CA mutations (H1047R, E545K, M1043I, C420R, Q546K) were transplanted into mice and treated with BYL719. 6/7 mice responded with strong tumor growth inhibition or regression, while one (H1047R) responded with weak growth inhibition."	24608574	PubMed		"Fritsch et al., 2014, Mol. Cancer Ther."		4	accepted	1402	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/1402	https://civicdb.org/links/molecular_profiles/307	FALSE	PIK3CA	5290	Mutation		chr3	179148523	179240093			ENST00000263967.3	75		"transcript_variant,gain_of_function_variant"		2023-01-09 21:52:06 UTC		N/A		FALSE
PIK3CA Amplification	212	Stomach Carcinoma	5517		Alpelisib		Predictive	Supports	D	Sensitivity/Response	474 cancer cell lines from the cancer cell line encyclopedia were assessed for response to the PI3Kalpha inhibitor BYL719 (Alpelisib). PIK3CA amplification was significanly associated with BYL719 response. A gastric cancer patient derived xenograft (PDX) was transplanted into two athymic mice and one was treated with BYL719. The untreated PDX grew by over 100 percent while the BYL719 tumor was reduced by 86 percent.	24608574	PubMed		"Fritsch et al., 2014, Mol. Cancer Ther."		3	accepted	1403	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/1403	https://civicdb.org/links/molecular_profiles/212	FALSE	PIK3CA	5290	Amplification		chr3	179148523	179240093			ENST00000263967.3	75		transcript_amplification	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
BRAF Mutation	395	Colorectal Cancer	9256		"Panitumumab,Cetuximab"	Substitutes	Predictive	Does Not Support	B	Sensitivity/Response	"A quantitative synthesis was performed on nine studies comparing treatment of metastatic colorectal cancer with cetuximab or panitumumab and chemotherapy, versus chemotherapy alone, or with other targeted inhibitors. It was found that in the patient subgroup with BRAF mutation (V600E in the majority of cases), there were no benefits to overall survival, progression free survival, or overall response rate with addition of cetuximab or panitumumab to treatment. This conclusion held in the first line treatment as well as general treatment setting."	25673558	PubMed		"Pietrantonio et al., 2015, Eur. J. Cancer"		3	accepted	1404	Somatic	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/1404	https://civicdb.org/links/molecular_profiles/395	FALSE	BRAF	673	Mutation		chr7	140753336	140781603			ENST00000288602.6	75		"gene_variant,gain_of_function_variant"		2023-01-09 21:52:06 UTC				FALSE
BRAF V600E	12	Colorectal Cancer	9256		Vemurafenib		Predictive	Does Not Support	B	Sensitivity/Response	"In this Phase II pilot study (NCT00405587) of BRAF V600 inhibitor vemurafenib in 21 metastatic colorectal cancer (CRC) patients with BRAF V600E, one patient had a durable 21 week partial response, and seven patients had 8 week stable disease as best response. Median progression free survival was 2.1 months and median overall survival was 7.7 months. The authors conclude that single agent vemurafenib did not show meaningful activity in V600E CRC, in contrast to the significant vemurafenib activity against V600 in melanoma."	26460303	PubMed		"Kopetz et al., 2015, J. Clin. Oncol."	NCT00405587	4	accepted	1405	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/1405	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
BRAF V600E	12	Colorectal Cancer	9256		Dabrafenib		Predictive	Does Not Support	B	Sensitivity/Response	"In trial NCT00880321, dabrafenib was tested in various solid tumor types harboring mutant BRAF after establishing dosage of 150 mg twice daily. In nine colorectal cancer patients with established V600E mutation, 1 confirmed response, 7 instances of stable disease, and 1 case of progressive disease was seen, which contrasted strongly with a 56% confirmed response rate seen in metastatic V600E melanoma patients similarly treated in the same study."	22608338	PubMed		"Falchook et al., 2012, Lancet"	NCT00880321	3	accepted	1406	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/1406	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
BRAF V600	17	Melanoma	1909	Brain neoplasm	Dabrafenib		Predictive	Supports	B	Sensitivity/Response	"In the NCT00880321 trial using mutant BRAF inhibitor dabrafenib in solid tumors, 10 cases of melanoma brain metastases were assessed for dabrafenib response. In nine patients a decrease in size of metastases was seen, and in four cases a complete resolution of brain lesions was observed. This subset of patients had median progression free survival of 4.2 months."	22608338	PubMed		"Falchook et al., 2012, Lancet"	NCT00880321	4	accepted	1407	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/1407	https://civicdb.org/links/molecular_profiles/17	FALSE	BRAF	673	V600	Other BRAF V600's	chr7	140753336	140753337			ENST00000288602.6	75		protein_altering_variant		2023-01-09 21:52:04 UTC		"13,961,448,153,762,800,000,000,000,000,000"	VAL600	FALSE
BRAF V600E	12	Colorectal Cancer	9256		"Cetuximab,Gefitinib,Vemurafenib"	Combination	Predictive	Supports	D	Sensitivity/Response	"5 of 7 colorectal cancer (CRC) cell lines with BRAF V600E mutation were resistant to treatment with the BRAF inhibitor vemurafenib. An RNAi screen in the WiDr cell line (a V600E CRC line) identified EGFR as an enhancer for survival when exposed to vemurafenib.  Treatment with vemurafenib and EGFR inhibitor (cetuximab or gefitinib) in V600E CRC cells (WiDr, VACO432 and KM20) showed inhibited growth as well as induction of the cleaved PARP apoptotic marker. WiDr and VACO432 cells were injected into immunodeficient mice. Modest response was seen with vemurafenib treatment, while combination treatment showed considerable tumor growth inhibition as compared to control."	22281684	PubMed		"Prahallad et al., 2012, Nature"		3	accepted	1408	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/1408	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
BRAF V600E	12	Skin Melanoma	8923		Vemurafenib		Predictive	Supports	A	Sensitivity/Response	"Phase 3 randomized clinical trial comparing vemurafenib with dacarbazine in 675 patients with previously untreated, metastatic melanoma with the BRAF V600E mutation. At 6 months, overall survival was 84% (95% confidence interval [CI], 78 to 89) in the vemurafenib group and 64% (95% CI, 56 to 73) in the dacarbazine group. A relative reduction of 63% in the risk of death and of 74% in the risk of either death or disease progression was observed with vemurafenib as compared with dacarbazine (P<0.001 for both comparisons)."	21639808	PubMed		"Chapman et al., 2011, N. Engl. J. Med."	NCT01006980	5	accepted	1409	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/1409	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
BRAF V600E	12	Skin Melanoma	8923		Vemurafenib		Predictive	Supports	B	Sensitivity/Response	"Phase 2 trial in 132 patients with previously treated metastatic melanoma with BRAF V600E mutation.  Confirmed overall response rate was 53% (95% confidence interval [CI], 44 to 62; 6% with a complete response and 47% with a partial response), median duration of response was 6.7 months (95% CI, 5.6 to 8.6), and median progression-free survival was 6.8 months (95% CI, 5.6 to 8.1). Median overall survival was 15.9 months (95% CI, 11.6 to 18.3)."	22356324	PubMed		"Sosman et al., 2012, N. Engl. J. Med."	NCT00949702	3	accepted	1410	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/1410	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
BRAF V600	17	Skin Melanoma	8923		"Trametinib,Dabrafenib"	Combination	Predictive	Supports	A	Sensitivity/Response	"The Combi-v (NCT01597908) open-label, randomized phase 3 trial had 704 patients with metastatic melanoma with a BRAF V600 mutation. Patients were randomized to receive either a combination of dabrafenib and trametinib or vemurafenib orally as first-line therapy. At preplanned interim analysis the overall survival rate at 12 months was 72% (95% confidence interval [CI], 67 to 77) in the combination-therapy group and 65% (95% CI, 59 to 70) in the vemurafenib group (hazard ratio for death in the combination-therapy group, 0.69; 95% CI, 0.53 to 0.89; P=0.005). Median progression-free survival was 11.4 months in the combination-therapy group and 7.3 months in the vemurafenib group (hazard ratio, 0.56; 95% CI, 0.46 to 0.69; P<0.001). Cutaneous squamous-cell carcinoma and keratoacanthoma occurred at 1% with combination-therapy and 18% in the vemurafenib group."	25399551	PubMed		"Robert et al., 2015, N. Engl. J. Med."	NCT01597908	5	accepted	1411	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/1411	https://civicdb.org/links/molecular_profiles/17	FALSE	BRAF	673	V600	Other BRAF V600's	chr7	140753336	140753337			ENST00000288602.6	75		protein_altering_variant		2023-01-09 21:52:04 UTC		"13,961,448,153,762,800,000,000,000,000,000"	VAL600	FALSE
SMAD4 LOSS	560	Pancreatic Cancer	1793				Prognostic	Supports	B	Poor Outcome	"Study employed a rapid autopsy technique on a cohort of 76 patients with pancreatic cancer and explored the status of several genes. 63% (41/65) of carcinomas analyzed showed inactivation of SMAD4 (DPC4) via immunolabeling. Among the patterns of failure ""metastatic and locally destructive"", It was discovered that DPC4 loss was significantly associated with metastatic disease (p=.007)."	19273710	PubMed		"Iacobuzio-Donahue et al., 2009, J. Clin. Oncol."		3	accepted	1412	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1412	https://civicdb.org/links/molecular_profiles/560	FALSE	SMAD4	4089	LOSS		chr18	51030213	51085039			ENST00000342988.3	75		loss_of_function_variant		2023-01-09 21:52:07 UTC		N/A		FALSE
BRAF V600E	12	Colorectal Cancer	9256		"Panitumumab,Vemurafenib"	Combination	Predictive	Does Not Support	B	Sensitivity/Response	"Treatment response to mutant BRAF inhibitor vemurafenib and EGFR inhibitor panitumumab was assayed in 12 patients with metastatic colorectal cancer (CRC) who had progressed on chemotherapy. Two patients had confirmed partial responses, and 2 showed stable disease over 6 months. The authors conclude that although some efficacy is seen, only a small subset of patients respond to this treatment and the responses are not durable."	25589621	PubMed		"Yaeger et al., 2015, Clin. Cancer Res."		3	accepted	1413	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/1413	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
BRAF V600E	12	Thyroid Gland Papillary Carcinoma	3969		Vemurafenib		Predictive	Supports	C	Sensitivity/Response	"A 73 year old patient with prior history of breast cancer presented with metastatic papillary thyroid carcinoma. After two treatments of I-131 a comprehensive tumor profile revealed BRAF V600E as the only genetic alteration on a near diploid genome with trisomy 1q. Vemurafenib treatment resulted in improvement of symptoms and considerable reductions in tumor mass, and after 23 months the patient remained on therapy with well controlled disease."	24987354	PubMed		"Ali et al., 2014, Case Rep Oncol"		4	accepted	1414	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/1414	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
BRAF V600	17	Colorectal Cancer	9256		"Trametinib,Dabrafenib"	Combination	Predictive	Supports	B	Sensitivity/Response	"In clinical trial NCT01072175, 43 patients with BRAF V600 metastatic colorectal cancer (CRC) received mutant BRAF inhibitor dabrafenib and MEK inhibitor trametinib. Only 12% of patients showed  partial response or better, with one complete response lasting 36 months and ongoing after data cutoff. 56% of patients achieved stable disease. The median progression free survival (PFS) was 3.5 months, longer than the median PFS (2.5 months) reported for metastatic CRC treated with standard chemotherapy. The authors conclude that MAPK targeting in CRC is a valid approach that can produce meaningful responses but additional work is required to more effectively inhibit the pathway."	26392102	PubMed		"Corcoran et al., 2015, J. Clin. Oncol."	NCT01072175	2	accepted	1415	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/1415	https://civicdb.org/links/molecular_profiles/17	FALSE	BRAF	673	V600	Other BRAF V600's	chr7	140753336	140753337			ENST00000288602.6	75		protein_altering_variant		2023-01-09 21:52:04 UTC		"13,961,448,153,762,800,000,000,000,000,000"	VAL600	FALSE
BRAF TRIM24::BRAF	283	Skin Melanoma	8923		Vemurafenib		Predictive	Supports	D	Resistance	Foundation One NGS assay and targeted RNAseq identified PAPSS1-BRAF fusion in a melanoma sample. Further BRAF fusions (TRIM24-BRAF) were identified in TCGA and additional samples. Ectopic expression of engineered cDNA in 293H cells showed that trametinib led to reduced ERK1/2 phosphorylation in fusion positive cells whereas vemurafenib was not effective.	24345920	PubMed		"Hutchinson et al., 2013, Clin. Cancer Res."		3	accepted	1416	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1416	https://civicdb.org/links/molecular_profiles/283	FALSE	BRAF	673	TRIM24::BRAF	BRAF Fusions	chr7	138460334	138554966			ENST00000343526.4	75	ENST00000288602.6	transcript_fusion		2023-01-09 21:52:06 UTC		N/A	TRIM24-BRAF	FALSE
BRAF TRIM24::BRAF	283	Skin Melanoma	8923		Vemurafenib		Predictive	Supports	D	Resistance	Foundation One NGS assay and targeted RNAseq identified PAPSS1-BRAF fusion in a melanoma sample. Further BRAF fusions (TRIM24-BRAF) were identified in TCGA and additional samples. Ectopic expression of engineered cDNA in 293H cells showed that trametinib led to reduced ERK1/2 phosphorylation in fusion positive cells whereas vemurafenib was not effective.	24345920	PubMed		"Hutchinson et al., 2013, Clin. Cancer Res."		3	accepted	1416	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1416	https://civicdb.org/links/molecular_profiles/283	FALSE	BRAF	673	TRIM24::BRAF	BRAF Fusions	chr7	140734479	140787584			ENST00000343526.4	75	ENST00000288602.6	transcript_fusion		2023-01-09 21:52:06 UTC		N/A	TRIM24-BRAF	FALSE
SF3B1 K700E	561	Breast Cancer	1612		Spliceostatin A		Predictive	Supports	D	Sensitivity/Response	"Mutations in SF3B1 were identified in 21/936 ER positive vs. 1/289 ER negative breast cancers. Mutation was recurrent (K700E in 74% or K666Q or K666E in another 9% of tumors). Treatment of two SF3B1 mutant cell lines (pancreatic and endometrial with K700 and K666 mutation, respectively) and six wild-type controls showed that mutant cell lines were significantly more sensitive to spliceostatin A (SF3b complex inhibitor)."	25424858	PubMed		"Maguire et al., 2015, J. Pathol."		2	accepted	1417	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1417	https://civicdb.org/links/molecular_profiles/561	FALSE	SF3B1	23451	K700E	SF3B1 HEAT domain mutation	chr2	197402110	197402110	T	C	ENST00000335508.6	75		missense_variant	"NM_012433.3:c.2098A>G,NP_036565.2:p.Lys700Glu,ENST00000335508.6:c.2098A>G,NC_000002.11:g.198266834T>C"	2023-01-27 17:04:22 UTC	CA2042597	376004	"LYS700GLU,RS559063155"	FALSE
SF3B1 K666N	114	Breast Cancer	1612		Spliceostatin A		Predictive	Supports	D	Sensitivity/Response	"Mutations in SF3B1 were identified in 21/936 ER positive vs. 1/289 ER negative breast cancers. Mutation was recurrent (K700E in 74% or K666Q or K666E in another 9% of tumors). Treatment of two SF3B1 mutant cell lines (pancreatic and endometrial with K700 and K666 mutation, respectively) and six wild-type controls showed that mutant cell lines were significantly more sensitive to spliceostatin A (SF3b complex inhibitor)."	25424858	PubMed		"Maguire et al., 2015, J. Pathol."		2	accepted	1418	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/1418	https://civicdb.org/links/molecular_profiles/114	FALSE	SF3B1	23451	K666N	SF3B1 HEAT domain mutation	chr2	197402635	197402635	C	A	ENST00000335508.6	75		missense_variant	"NM_012433.3:c.1998G>T,NP_036565.2:p.Lys666Asn,ENST00000335508.6:c.1998G>T,NC_000002.11:g.198267359C>A"	2023-01-27 17:02:41 UTC	CA280929	219098	"LYS666ASN,RS377023736"	FALSE
ALK Fusion	495	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	B	Sensitivity/Response	"In a retrospective study comparing survival outcomes in a subgroup of 82 ALK-positive crizotinib-treated patients enrolled in a phase 1 clinical trial (NCT00585195), crizotinib therapy was associated with improved survival. For the crizotinib-treated, ALK-positive patient group, 1 year survival was 74% and 2 year overall survival was 54%, compared with 72% and 36% for the control group (ALK-positive crizotinib naive patients)."	21933749	PubMed		"Shaw et al., 2011, Lancet Oncol."	NCT00585195	3	accepted	1419	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1419	https://civicdb.org/links/molecular_profiles/495	FALSE	ALK	238	Fusion	ALK Fusion	chr2	29192774	29223528			ENST00000389048.3	75		transcript_fusion		2023-01-09 21:52:07 UTC		N/A	REARRANGEMENT	FALSE
MAP2K7 E116K	562	Lung Cancer	1324				Prognostic	Supports	B	Poor Outcome	Study examined rare SNPs on MAP2K7 among a discovery and two validation cohorts. It was discovered that the E116K genotype was associated with a reduced median survival time of 4 and 7 months for E/K or K/K genotypes (P=2.61E-7) and an increased cancer death risk for heterozygous (HR=1.49) and homozygous (HR=1.94) genotypes for a pooled cohort. Further nude mice harboring this variant showed increased xenograft growth and metastasis.	27028764	PubMed		"Qiu et al., 2016, PLoS Genet."		5	accepted	1420	Common Germline	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1420	https://civicdb.org/links/molecular_profiles/562	FALSE	MAP2K7	5609	E116K		chr19	7910272	7910272	G	A	ENST00000397979.3	75		missense_variant	NC_000019.9:g.7975157G>A	2023-01-27 17:04:23 UTC	CA304968685	NONE FOUND	GLU116LYS	FALSE
BRAF V600E	12	Melanoma	1909		"Vemurafenib,Cobimetinib"	Combination	Predictive	Supports	B	Sensitivity/Response	"In this Phase III trial (coBRIM, NCT01689519) of 495 V600 mutant melanoma patients, 344 had V600E mutation. 174 patients were treated with vemurafenib and placebo, and 170 were treated with vemurafenib and cobimetinib and tested for progression free survival. 88 of 174 monotherapy group patients had an event with median progression free survival of 6.5 months. In the combination group 58 of 174 patients had an event with median progression-free survival not met, however, when in combination with other V600 mutations median progression-free survival was 9.9 months with combination treatment. Median time to followup for the whole cohort was 7.3 months. Hazard Ratio for progression or death was 0.57 (0.41-0.80)."	25265494	PubMed		"Larkin et al., 2014, N. Engl. J. Med."	NCT01689519	4	accepted	1421	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/1421	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
BRAF V600	17	Melanoma	1909		"Cobimetinib,Vemurafenib"	Combination	Predictive	Supports	B	Sensitivity/Response	"In a randomized phase 3 study, previously untreated advanced or metastatic BRAF V600 mutation-positive melanoma patients treated with combination vemurafenib and cobimetinib showed improved progression free survival (9.9 vs 6.2 months), increased rate of complete or partial response (68% vs 45%), and improved overall survival at 9 months ( 81% vs 73%) compared to the vemurafenib and placebo control group."	25265494	PubMed		"Larkin et al., 2014, N. Engl. J. Med."	NCT01689519	4	accepted	1422	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/1422	https://civicdb.org/links/molecular_profiles/17	FALSE	BRAF	673	V600	Other BRAF V600's	chr7	140753336	140753337			ENST00000288602.6	75		protein_altering_variant		2023-01-09 21:52:04 UTC		"13,961,448,153,762,800,000,000,000,000,000"	VAL600	FALSE
KIT M541L	201	Chronic Leukemia	1036		Imatinib		Predictive	Supports	C	Sensitivity/Response	"In 5 patients with KIT M541L mutation-positive chronic eosinophilic leukemia (4 somatic and 1 germline mutation), treatment with low dose imatinib resulted in complete and lasting remission with a median follow up of 74 months and 1 patient relapse at 50 months."	25015329	PubMed		"Iurlo et al., 2014, Oncotarget"		2	accepted	1423	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/1423	https://civicdb.org/links/molecular_profiles/201	FALSE	KIT	3815	M541L		chr4	54727298	54727298	A	C	ENST00000288135.5	75		missense_variant	"NM_000222.2:c.1621A>C,NP_000213.1:p.Met541Leu,ENST00000288135.5:c.1621A>C,NC_000004.11:g.55593464A>C"	2023-01-27 17:03:04 UTC	CA160347	41599	"MET541LEU,RS3822214"	FALSE
KIT Exon 9 Mutation	505	Gastrointestinal Stromal Tumor	9253		Sunitinib		Predictive	Supports	B	Sensitivity/Response	"In a study of 78 patients with gastrointestinal stromal tumors treated with sunitinib, patients with Kit exon 9 mutations or wildtype (lacking KIT or PDGFRA mutations) showed increased progression free survival and overall survival compared to patients with Kit exon 11 mutations."	18955458	PubMed		"Heinrich et al., 2008, J. Clin. Oncol."		3	accepted	1424	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1424	https://civicdb.org/links/molecular_profiles/505	FALSE	KIT	3815	Exon 9 Mutation		chr4	54725857	54726050			ENST00000288135.5	75		exon_variant		2023-01-09 21:52:07 UTC				FALSE
FGFR1 Fusion	565	Chronic Myelomonocytic Leukemia	80188				Diagnostic	Supports	A	Negative	"The 2016 World Health Organization guidelines for the classification of myeloid malignancies uses the detection of PCM1-JAK2 or rearrangements involving PDGFRA, PDGFRB, or FGFR1 as recommended exclusion criteria for a diagnosis of chronic myelomonocytic leukemia, particularly in patients with evidence of eosinophilia."	27069254	PubMed		"Arber et al., 2016, Blood"		5	accepted	1427	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1427	https://civicdb.org/links/molecular_profiles/565	FALSE	FGFR1	2260	Fusion		chr8	38411138	38467845			ENST00000425967.3	75		transcript_fusion	N/A	2023-01-09 21:52:07 UTC		N/A		FALSE
BRAF V600E	12	Colorectal Cancer	9256		"Dactolisib,GDC-0879"	Combination	Predictive	Supports	D	Sensitivity/Response	"In a mouse model of BRAF V600E colorectal cancer, western blots from tumors in mice treated with BRAF inhibitor GDC-0879 and PI3K/mTOR inhibitor BEZ235 showed stronger reduction in phospho-Akt and phospho-S6 than PI3K/mTOR inhibitor alone, and combination inhibition also resulted in stronger phospho-ERK inhibition in tumors than did BRAF inhibition alone. Increased apoptosis in tumors was seen in dual treatment conditions with increased TUNEL-positive cells. In vehicle treated mice, area of colon covered by tumor increased, while treatment with single agent inhibitors caused growth inhibition resulting in no change in colon area covered by tumors. Administration of dual inhibitors induced tumor regression apparent in a decrease of colonic area covered by tumors over the course of treatment."	23549875	PubMed		"Coffee et al., 2013, Clin. Cancer Res."		3	accepted	1428	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/1428	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
NRAS Mutation	208	Melanoma	1909		"Trametinib,Omipalisib"	Combination	Predictive	Supports	D	Sensitivity/Response	"In six NRAS mutant melanoma cell lines, concomitant use of MEK inhibitor and PI3K/mTOR inhibitor resulted in greater decrease in cell viability than either alone, with the synergistic effect being marked in 4/6 cell lines. MEK inhibitor JTP-74057 and PI3K/mTOR inhibitor GSK2126458 together induced synergistic increase in apoptotic Annexin V+/PI+ cells in these cell lines. Tumor xenografts in nude mice were established with 5 of the 6 cell lines. Effects of single agent treatment with JTP-74057 or GSK2126458 ranged from minor inhibition to tumor stasis, while dual inhibitor treatment showed synergistic effects in each case, with marked tumor reductions in 2/5 cases and the authors report one compete response in a MaMel301 cell line xenograft mouse."	23431193	PubMed		"Posch et al., 2013, Proc. Natl. Acad. Sci. U.S.A."		4	accepted	1429	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/1429	https://civicdb.org/links/molecular_profiles/208	FALSE	NRAS	4893	Mutation		chr1	114704469	114716894			ENST00000369535.4	75		"transcript_variant,gain_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
BRAF V600E	12	Gastrointestinal Neuroendocrine Tumor	50626		"Trametinib,Vemurafenib,Dabrafenib"	Combination	Predictive	Supports	C	Sensitivity/Response	"BRAF mutations were identified in 9% of 108 cases of high-grade colorectal neuroendocrine tumors (80% V600E). Two patients were treated with a combination of BRAF and MEK inhibition and exhibited durable response (beyond 7 and 9 months, respectively). Urinary BRAF V600E tumor DNA correlated with disease response in one of the patients. BRAF and MEK inhibition was either dabrafenib+trametinib (case 1) or vemurafenib+trametinib (case 2)."	27048246	PubMed		"Klempner et al., 2016, Cancer Discov"		3	accepted	1430	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/1430	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
ERBB2 Amplification	302	Her2-receptor Positive Breast Cancer	60079		Trastuzumab Emtansine		Predictive	Supports	B	Sensitivity/Response	"In a randomized phase II study, first line treatment of HER2-positive metastatic breast cancer with trastuzumab emtansine (T-DM1) resulted in improved progression free survival and fewer serious adverse effects when compared to treatment with combination trastuzumab plus docetaxel (HT) (median follow up 14 months, median PFS with T-DM1 14.2 vs 9.2 with HT)."	23382472	PubMed		"Hurvitz et al., 2013, J. Clin. Oncol."	NCT00679341	3	accepted	1432	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1432	https://civicdb.org/links/molecular_profiles/302	FALSE	ERBB2	2064	Amplification		chr17	39700080	39728662			ENST00000269571.5	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A	OVEREXPRESSION	FALSE
FGFR1 Fusion	565	Hematologic Cancer	2531				Diagnostic	Supports	A	Positive	"The 2016 World Health Organization guidelines for the classification of myeloid malignancies and acute leukemia describes a new class of disease defined by myeloid or lymphoid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, or FGFR1 or with PCM1-JAK2."	27069254	PubMed		"Arber et al., 2016, Blood"		5	accepted	1435	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1435	https://civicdb.org/links/molecular_profiles/565	FALSE	FGFR1	2260	Fusion		chr8	38411138	38467845			ENST00000425967.3	75		transcript_fusion	N/A	2023-01-09 21:52:07 UTC		N/A		FALSE
ERBB2 Amplification	302	Her2-receptor Positive Breast Cancer	60079		"Trastuzumab,Docetaxel,Pertuzumab"	Combination	Predictive	Supports	B	Sensitivity/Response	"In a randomized phase 3 trial, HER2 positive metastatic breast cancer patients given first-line treatment of pertuzumab plus trastuzumb plus docetaxel experienced improved progression free survival (18.5 vs 12.4 months,  P<0.001) and increased objective response rate (80.2% vs 69.3%, P=0.001) than the control group given placebo plus trastuzumab plus docetaxel."	22149875	PubMed		"Baselga et al., 2012, N. Engl. J. Med."	NCT00567190	4	accepted	1437	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1437	https://civicdb.org/links/molecular_profiles/302	FALSE	ERBB2	2064	Amplification		chr17	39700080	39728662			ENST00000269571.5	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A	OVEREXPRESSION	FALSE
ERBB2 Amplification	302	Her2-receptor Positive Breast Cancer	60079		"Trastuzumab,Lapatinib"	Combination	Predictive	Supports	B	Sensitivity/Response	"In a randomized open label phase 3 study (NCT00553358), women with HER2 positive primary breast cancer treated with lapatinib plus trasuzumab had higher rates of pathological complete responses than seen in control groups receiving either IV trastuzumab or oral lapatinib alone (combination treatment pCR rate of 51% vs 29.5% and 24.7% for trastuzumab and lapatinib alone, respectively)."	22257673	PubMed		"Baselga et al., 2012, Lancet"	NCT00553358	4	accepted	1439	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1439	https://civicdb.org/links/molecular_profiles/302	FALSE	ERBB2	2064	Amplification		chr17	39700080	39728662			ENST00000269571.5	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A	OVEREXPRESSION	FALSE
RICTOR Amplification	569	Lung Adenocarcinoma	3910		"Sapanisertib,Onatasertib"	Substitutes	Predictive	Supports	C	Sensitivity/Response	Study describes an 18 year old never smoker patient presenting with lung adenocarcinoma. A genomic profiling assay (FoundationOne) revealed a 7-copy amplification of RICTOR as the only somatic alteration. RICTOR amplification was confirmed via FISH and IHC. On two separate treatments with dual mTOR1/2 inhibitors patient exhibited stable disease for more than 18 months.	26370156	PubMed		"Cheng et al., 2015, Cancer Discov"		2	accepted	1440	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1440	https://civicdb.org/links/molecular_profiles/569	FALSE	RICTOR	253260	Amplification		chr5	38937919	39074408			ENST00000357387.3	75		transcript_amplification	N/A	2023-01-09 21:52:08 UTC		N/A		FALSE
PDGFRA FIP1L1::PDGFRA	570	"Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1"	80164		Imatinib		Predictive	Supports	B	Sensitivity/Response	A cohort of seven male patients with myeloproliferative hypereosinophilic syndrome and elevated serum tryptase levels were enrolled in a study of imatinib mesylate therapy. All seven patients demonstrated improvement in clinical symptoms and resolution of laboratory abnormalities and bone marrow pathology in response to treatment. Complete molecular remission of FIP1L1-PDGFRA was observed in 5 of 6 patients tested post-therapy.	14504092	PubMed		"Klion et al., 2004, Blood"		4	accepted	1441	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1441	https://civicdb.org/links/molecular_profiles/570	FALSE	PDGFRA	5156	FIP1L1::PDGFRA		chr4	53377645	53428183			ENST00000337488.6	75	ENST00000257290.5	transcript_fusion		2023-01-09 21:52:08 UTC		N/A	FIP1L1-PDGFRA	FALSE
PDGFRA FIP1L1::PDGFRA	570	"Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1"	80164		Imatinib		Predictive	Supports	B	Sensitivity/Response	A cohort of seven male patients with myeloproliferative hypereosinophilic syndrome and elevated serum tryptase levels were enrolled in a study of imatinib mesylate therapy. All seven patients demonstrated improvement in clinical symptoms and resolution of laboratory abnormalities and bone marrow pathology in response to treatment. Complete molecular remission of FIP1L1-PDGFRA was observed in 5 of 6 patients tested post-therapy.	14504092	PubMed		"Klion et al., 2004, Blood"		4	accepted	1441	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1441	https://civicdb.org/links/molecular_profiles/570	FALSE	PDGFRA	5156	FIP1L1::PDGFRA		chr4	54274841	54298247			ENST00000337488.6	75	ENST00000257290.5	transcript_fusion		2023-01-09 21:52:08 UTC		N/A	FIP1L1-PDGFRA	FALSE
ROS1 Rearrangement	265	Bronchiolo-alveolar Adenocarcinoma	4926		Crizotinib		Predictive	Supports	C	Sensitivity/Response	"Study describes a 31-year old male, never-smoker patient with advanced NSCLC with a ROS1 rearrangement. The patient was treated with crizotinib with marked response at 1 week and resolution of the tumor confirmed at 8 and 12 weeks via CT-scans. It was also demonstrated that crizotinib inhibits ROS1 phosphorylation in HEK 293 cells transfected with a CD14-ROS1 fusion gene, and crizotinib inhibited growth in the HCC78 cell line containing a ROS1 rearrangement to a similar degree as ALK-fusion positive cell lines."	22215748	PubMed		"Bergethon et al., 2012, J. Clin. Oncol."		3	accepted	1443	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1443	https://civicdb.org/links/molecular_profiles/265	FALSE	ROS1	6098	Rearrangement		chr6	117288300	117425855			ENST00000368508.3	75		transcript_fusion		2023-01-09 21:52:06 UTC		N/A		FALSE
ROS1 TFG::ROS1	572	Inflammatory Myofibroblastic Tumor	50905		Crizotinib		Predictive	Supports	C	Sensitivity/Response	Case report of a pediatric patient with treatment-refactory inflammatory myofibroblastic tumor negative for ALK expression and rearrangement. Next generation sequencing of the patient revealed a TFG-ROS1 fusion. CT scans after 3 cycles of crizotinib treatment showed a reduction of the tumor mass which continued to decrease at the time of publication after 4 months of crizonitib treatment.	24875859	PubMed		"Lovly et al., 2014, Cancer Discov"		3	accepted	1444	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1444	https://civicdb.org/links/molecular_profiles/572	FALSE	ROS1	6098	TFG::ROS1		chr3	100709425	100728858			ENST00000240851.4	75	ENST00000368508.3	transcript_fusion		2023-01-09 21:52:08 UTC		N/A	TFG-ROS1	FALSE
ROS1 TFG::ROS1	572	Inflammatory Myofibroblastic Tumor	50905		Crizotinib		Predictive	Supports	C	Sensitivity/Response	Case report of a pediatric patient with treatment-refactory inflammatory myofibroblastic tumor negative for ALK expression and rearrangement. Next generation sequencing of the patient revealed a TFG-ROS1 fusion. CT scans after 3 cycles of crizotinib treatment showed a reduction of the tumor mass which continued to decrease at the time of publication after 4 months of crizonitib treatment.	24875859	PubMed		"Lovly et al., 2014, Cancer Discov"		3	accepted	1444	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1444	https://civicdb.org/links/molecular_profiles/572	FALSE	ROS1	6098	TFG::ROS1		chr6	117288300	117321394			ENST00000240851.4	75	ENST00000368508.3	transcript_fusion		2023-01-09 21:52:08 UTC		N/A	TFG-ROS1	FALSE
PDGFRA FIP1L1::PDGFRA	570	"Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1"	80164		Imatinib		Predictive	Supports	A	Sensitivity/Response	"Of eleven patients prospectively accrued with hypereosinophilic syndrome, nine had favorable responses to imatinib that lasted >3 months post-treatment. Of these nine patients, five were found to have a FIP1L1-PDGFRA fusion."	12660384	PubMed		"Cools et al., 2003, N. Engl. J. Med."		3	accepted	1445	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1445	https://civicdb.org/links/molecular_profiles/570	FALSE	PDGFRA	5156	FIP1L1::PDGFRA		chr4	53377645	53428183			ENST00000337488.6	75	ENST00000257290.5	transcript_fusion		2023-01-09 21:52:08 UTC		N/A	FIP1L1-PDGFRA	FALSE
PDGFRA FIP1L1::PDGFRA	570	"Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1"	80164		Imatinib		Predictive	Supports	A	Sensitivity/Response	"Of eleven patients prospectively accrued with hypereosinophilic syndrome, nine had favorable responses to imatinib that lasted >3 months post-treatment. Of these nine patients, five were found to have a FIP1L1-PDGFRA fusion."	12660384	PubMed		"Cools et al., 2003, N. Engl. J. Med."		3	accepted	1445	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1445	https://civicdb.org/links/molecular_profiles/570	FALSE	PDGFRA	5156	FIP1L1::PDGFRA		chr4	54274841	54298247			ENST00000337488.6	75	ENST00000257290.5	transcript_fusion		2023-01-09 21:52:08 UTC		N/A	FIP1L1-PDGFRA	FALSE
PDGFRA FIP1L1::PDGFRA T674I	573	"Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1"	80164		Imatinib		Predictive	Supports	C	Resistance	"A patient treated with imatinib for a FIP1L1-PDGFRA mutation relapsed during treatment. A T674I mutation in the PDGFRA split kinase domain was hypothesized to confer resistance, due to the strong evidence of this fusion in driving myeloproliferative hypereosinophilic syndrome and the contextual similarity to T315I mutations in BCR-ABL."	12660384	PubMed		"Cools et al., 2003, N. Engl. J. Med."		2	accepted	1446	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1446	https://civicdb.org/links/molecular_profiles/573	FALSE	PDGFRA	5156	FIP1L1::PDGFRA T674I		chr4	54278380	54278380	C	T	ENST00000257290.5	75		"missense_variant,transcript_fusion"	"NC_000004.11:g.55144547C>T,ENST00000257290.5:c.2021C>T,NM_006206.5:c.2021C>T,NP_006197.1:p.Thr674Ile"	2023-01-27 17:04:23 UTC	CA123215	13550	"THR674ILE,RS121908587,FIP1L1-PDGFRA T674I"	FALSE
PIK3CA H1047R	107	Lung Adenocarcinoma	3910		Dactolisib		Predictive	Supports	D	Sensitivity/Response	"Doxycycline dependent expression of the PIK3CA H1047R mutation in mouse type II alveolar epithelial cells drove lung cancer in a reversible fashion, indicating the driver properties of this p110alpha catalytic domain mutation. Administration of pan-p110 isoform and mTOR inhibitor BEZ235 to H1047R mice with established tumors resulted in reduced tumor phospho-Akt and phosoho-S6 levels, and significant regression of tumor volume."	19029981	PubMed		"Engelman et al., 2008, Nat. Med."		3	accepted	1447	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/1447	https://civicdb.org/links/molecular_profiles/107	FALSE	PIK3CA	5290	H1047R		chr3	179234297	179234297	A	G	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.3140A>G,NP_006209.2:p.His1047Arg,ENST00000263967.3:c.3140A>G,NC_000003.11:g.178952085A>G"	2023-01-27 17:02:38 UTC	CA123326	13652	"HIS1047ARG,RS121913279"	FALSE
ERBB2 Amplification	302	Her2-receptor Positive Breast Cancer	60079		"Pilaralisib,Trastuzumab"	Combination	Predictive	Supports	D	Sensitivity/Response	"In 5 trastuzumab resistant HER2 overexpressing breast cancer cell lines, combination of the pan-PI3K inhibitor XL147 (pilaralisib) and trastuzumab treatment induced cell death to similar or greater levels than XL147 alone. In three trastuzumab resistant cell lines tested, colony formation in matrigel was markedly inhibited by combination treatment. Apoptotic markers were apparent with combination treatment. In athymic mice, trastuzumab resistant cell line HR6 was used in tumor xenografts and tumors were allowed to form. Mice subsequently treated with trastuzumab or XL147 showed continued tumor growth without marked difference from control, while combination treatment essentially halted tumor growth rate."	23204226	PubMed		"Chakrabarty et al., 2013, Cancer Res."		4	accepted	1448	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1448	https://civicdb.org/links/molecular_profiles/302	FALSE	ERBB2	2064	Amplification		chr17	39700080	39728662			ENST00000269571.5	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A	OVEREXPRESSION	FALSE
BIRC5 Overexpression	574	Her2-receptor Positive Breast Cancer	60079		Trastuzumab		Predictive	Supports	B	Resistance	"13 HER2 breast cancer patients were treated with trastuzumab and then trastuzumab + docetaxel prior to surgery. Pretreatment biopsies and post-treatment surgical samples were obtained, and microarray performed. 5 of 13 patients responded to treatment, and pretreatment biopsies from non-responders showed significantly higher survivin (BIRC5) mRNA (p=0.026) levels than responders. In HER2 positive, trastuzumab-sensitive BT474 cells, overexpression of survivin blunted sensitivity to trastuzumab. In HER2 positive trastuzumab-resistant breast cancer cell lines, knockdown of survivin with RNAi or with YM155 induced growth inhibition and apoptosis."	23204226	PubMed		"Chakrabarty et al., 2013, Cancer Res."		4	accepted	1449	N/A	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1449	https://civicdb.org/links/molecular_profiles/574	FALSE	BIRC5	332	Overexpression		chr17	78214186	78225636			ENST00000301633.4	75		N/A		2023-01-09 21:52:08 UTC		N/A		FALSE
TP53 Mutation	222	Chronic Lymphocytic Leukemia	1040				Prognostic	Supports	B	Poor Outcome	A study of 53 patients with B-CLL found a significant resistance to chemotherapy and corresponding poor clinical outcomes among the 7 treated patients with p53 mutations compared to the 29 treated patients without.	8241511	PubMed		"el Rouby et al., 1993, Blood"		3	accepted	1450	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/1450	https://civicdb.org/links/molecular_profiles/222	FALSE	TP53	7157	Mutation		chr17	7668402	7687538			ENST00000269305.4	75		protein_altering_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
TP53 Mutation	222	Chronic Lymphocytic Leukemia	1040				Prognostic	Supports	B	Poor Outcome	"In a study of 126 patients with long-term follow-up, TP53 mutations were significantly associated with shorter median survival in patients (P = 0.002) from time of diagnosis. The median survival from the time of first observation of a TP53 mutation was much more pronounced (P = <0.001). These findings were statistically independent of 17p deletions."	18689542	PubMed		"Zenz et al., 2008, Blood"		4	accepted	1451	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/1451	https://civicdb.org/links/molecular_profiles/222	FALSE	TP53	7157	Mutation		chr17	7668402	7687538			ENST00000269305.4	75		protein_altering_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
TP53 Mutation	222	Chronic Lymphocytic Leukemia	1040				Prognostic	Supports	B	Poor Outcome	"The authors analyzed 328 patients with CLL, of which 28 were identified to have TP53 mutations. Patients with TP53 mutations were found to have significantly shorter progression-free (HR = 3.8; P < 0.001) and overall survival (HR = 7.2; P < 0.001)."	20697090	PubMed		"Zenz et al., 2010, J. Clin. Oncol."		5	accepted	1452	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/1452	https://civicdb.org/links/molecular_profiles/222	FALSE	TP53	7157	Mutation		chr17	7668402	7687538			ENST00000269305.4	75		protein_altering_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
PIK3CA E545K	104	Her2-receptor Positive Breast Cancer	60079		Trastuzumab		Predictive	Supports	D	Resistance	"PI3K mutant E545K was overexpressed in the trastuzumab sensitive HER2 BT474 breast cancer cell line, and significant resistance to trastuzumab was induced in comparison to control cells."	18829560	PubMed		"Serra et al., 2008, Cancer Res."		2	accepted	1453	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/1453	https://civicdb.org/links/molecular_profiles/104	FALSE	PIK3CA	5290	E545K		chr3	179218303	179218303	G	A	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.1633G>A,NP_006209.2:p.Glu545Lys,ENST00000263967.3:c.1633G>A,NC_000003.11:g.178936091G>A"	2023-01-27 17:02:37 UTC	CA123334	13655	"GLU545LYS,RS104886003"	FALSE
BRAF D594A	575	Skin Melanoma	8923		"Sorafenib,Mitogen-Activated Protein Kinase Kinase Inhibitor"	Substitutes	Predictive	Supports	E	Sensitivity/Response	"Preclinical study in melanoma cell lines. Inactivity of BRAF as mediated by specific mutation (D594A, D594V or K483M) or selective pharmacological inhibition leads to MEK hyperactivation through CRAF binding in NRAS mutant D04 cells. Either pan-RAF (e.g. sorafenib in the abscence of CRAF T421N gatekeeper mutation) or MEK inhibitors (e.g., trametinib) could instead block ERK pathway hyperactivation in RAS mutated cancers."	20141835	PubMed		"Heidorn et al., 2010, Cell"		3	accepted	1454	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1454	https://civicdb.org/links/molecular_profiles/575	FALSE	BRAF	673	D594A	Kinase Dead BRAF Mutation	chr7	140753354	140753354	T	G	ENST00000288602.6	75		missense_variant	"ENST00000288602.6:c.1781A>C,NC_000007.13:g.140453154T>G,NM_004333.4:c.1781A>C,NP_004324.2:p.Asp594Ala"	2023-01-27 17:04:24 UTC	CA16602532	376070	"ASP594ALA,RS121913338"	FALSE
PTEN Loss	214	Her2-receptor Positive Breast Cancer	60079		"PI3K/BET Inhibitor LY294002,Trastuzumab"	Combination	Predictive	Supports	D	Sensitivity/Response	"Knockdown of PTEN in trastuzumab sensitive HER2 breast cancer BT474 cells induced trastuzumab resistance. PTEN null cells treated with PI3K inhibitor LY294002 also did not show substantial inhibition, but co-treatment with trastuzumab and LY294002 induced growth inhibition comparable to trastuzumab alone in normal BT474 cells. BT474 mouse xenograft tumors were injected with PTEN antisense (AS) oligonucleotides and this resulted in trastuzumab resitance. Co-treatment of PTEN AS tumor mice with LY294002 and trastuzumab inhibited tumor growth in comparison to PTEN AS tumors treated with trastuzumab or LY294002 alone."	15324695	PubMed		"Nagata et al., 2004, Cancer Cell"		3	accepted	1455	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/1455	https://civicdb.org/links/molecular_profiles/214	FALSE	PTEN	5728	Loss		chr10	87863113	87971930			ENST00000371953.3	75		loss_of_function_variant	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
BRAF D594V	576	Skin Melanoma	8923		"Trametinib,Sorafenib"	Substitutes	Predictive	Supports	E	Sensitivity/Response	"Preclinical study in melanoma cell lines. Inactivity of BRAF as mediated by specific mutation (D594A, D594V or K483M) or selective pharmacological inhibition leads to MEK hyperactivation through CRAF binding in NRAS mutant D04 cells. Either pan-RAF (e.g. sorafenib in the abscence of CRAF T421N gatekeeper mutation) or MEK inhibitors could instead block ERK pathway hyperactivation in RAS mutated cancers."	20141835	PubMed		"Heidorn et al., 2010, Cell"		3	accepted	1456	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1456	https://civicdb.org/links/molecular_profiles/576	FALSE	BRAF	673	D594V	Kinase Dead BRAF Mutation	chr7	140753354	140753354	T	A	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1781A>T,NP_004324.2:p.Asp594Val,NC_000007.13:g.140453154T>A,ENST00000288602.6:c.1781A>T"	2023-01-27 17:04:25 UTC	CA16602425	375946	"ASP594VAL,RS121913338"	FALSE
BRAF K483M	577	Skin Melanoma	8923		"Sorafenib,Mitogen-Activated Protein Kinase Kinase Inhibitor"	Substitutes	Predictive	Supports	E	Sensitivity/Response	"Preclinical study in melanoma cell lines. Inactivity of BRAF as mediated by specific mutation (D594A, D594V or K483M) or selective pharmacological inhibition leads to MEK hyperactivation through CRAF binding in NRAS mutant D04 cells. Either pan-RAF (e.g. sorafenib in the abscence of CRAF T421N gatekeeper mutation) or MEK inhibitors (e.g., trametinib) could instead block ERK pathway hyperactivation in RAS mutated cancers."	20141835	PubMed		"Heidorn et al., 2010, Cell"		3	accepted	1457	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1457	https://civicdb.org/links/molecular_profiles/577	FALSE	BRAF	673	K483M	Kinase Dead BRAF Mutation	chr7	140778059	140778060	TT	CA	ENST00000288602.6	75		"missense_variant,loss_of_function_variant"	"NC_000007.13:g.140477859_140477860delinsCA,ENST00000288602.6:c.1448_1449delinsTG"	2023-01-27 17:04:26 UTC	CA913112072	NONE FOUND	LYS483MET	FALSE
BRAF L597R	284	Skin Melanoma	8923		"Trametinib,Vemurafenib"	Substitutes	Predictive	Supports	D	Sensitivity/Response	"Preclinical study in 293H cell line. Ectopic expression of V600E, L597R/Q/S, and K601E mutants elevated phospho-MEK and ERK levels. Vemurafenib treatment of all of the BRAF mutantexpressing cells led to a decrease in phospho-MEK and ERK protein levels. Treatment with MEK inhibitor GSK1120212 led to a more dramatic decrease in phospho-ERK signaling."	22798288	PubMed		"Dahlman et al., 2012, Cancer Discov"		2	accepted	1458	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1458	https://civicdb.org/links/molecular_profiles/284	FALSE	BRAF	673	L597R	Other BRAF V600's	chr7	140753345	140753345	A	C	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1790T>G,NP_004324.2:p.Leu597Arg,NC_000007.13:g.140453145A>C,ENST00000288602.6:c.1790T>G"	2023-01-27 17:03:26 UTC	CA123649	13968	"LEU597ARG,RS121913366"	FALSE
BRAF L597S	578	Skin Melanoma	8923		"Vemurafenib,Trametinib"	Substitutes	Predictive	Supports	D	Sensitivity/Response	"Preclinical study in 293H cell line. Ectopic expression of V600E, L597R/Q/S, and K601E mutants elevated phospho-MEK and ERK levels. Vemurafenib treatment of all of the BRAF mutantexpressing cells led to a decrease in phospho-MEK and ERK protein levels. Treatment with MEK inhibitor GSK1120212 led to a more dramatic decrease in phospho-ERK signaling."	22798288	PubMed		"Dahlman et al., 2012, Cancer Discov"		2	accepted	1459	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1459	https://civicdb.org/links/molecular_profiles/578	FALSE	BRAF	673	L597S		chr7	140753345	140753346	AG	GA	ENST00000288602.6	75		missense_variant	"NC_000007.13:g.140453145_140453146delinsGA,NM_004333.4:c.1789_1790delCTinsTC,NP_004324.2:p.Leu597Ser,ENST00000288602.6:c.1789_1790delCTinsTC"	2023-01-27 17:04:27 UTC	CA16602421	375942	LEU597SER	FALSE
BRAF L597S	578	Skin Melanoma	8923		MEK Inhibitor TAK-733		Predictive	Supports	C	Sensitivity/Response	Case report of a 69 year old patient with metastatic melanoma treated with MEK inhibitor TAK-733 in a clinical trial. A partial radiographic response with a decrease of 31% in the sum of maximum diameters of target metastatic lesions in the liver and spleen was noted after 2 cycles of therapy and remained progression free at more than 24 weeks. Follow-up sequencing analysis of DNA from the patient's tumor revealed a somatic BRAF L597S mutation.	22798288	PubMed		"Dahlman et al., 2012, Cancer Discov"		3	accepted	1460	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1460	https://civicdb.org/links/molecular_profiles/578	FALSE	BRAF	673	L597S		chr7	140753345	140753346	AG	GA	ENST00000288602.6	75		missense_variant	"NC_000007.13:g.140453145_140453146delinsGA,NM_004333.4:c.1789_1790delCTinsTC,NP_004324.2:p.Leu597Ser,ENST00000288602.6:c.1789_1790delCTinsTC"	2023-01-27 17:04:27 UTC	CA16602421	375942	LEU597SER	FALSE
BRAF L597Q	579	Skin Melanoma	8923		"Vemurafenib,Trametinib"	Substitutes	Predictive	Supports	D	Sensitivity/Response	"Preclinical study in 293H cell line. Ectopic expression of V600E, L597R/Q/S, and K601E mutants elevated phospho-MEK and ERK levels. Vemurafenib treatment of all of the BRAF mutantexpressing cells led to a decrease in phospho-MEK and ERK protein levels. Treatment with MEK inhibitor GSK1120212 led to a more dramatic decrease in phospho-ERK signaling."	22798288	PubMed		"Dahlman et al., 2012, Cancer Discov"		2	accepted	1461	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1461	https://civicdb.org/links/molecular_profiles/579	FALSE	BRAF	673	L597Q		chr7	140753345	140753345	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1790T>A,NP_004324.2:p.Leu597Gln,NC_000007.13:g.140453145A>T,ENST00000288602.6:c.1790T>A"	2023-01-27 17:04:27 UTC	CA16602257	76687	"LEU597GLN,RS121913366"	FALSE
BRAF K601E	580	Skin Melanoma	8923		"Trametinib,Vemurafenib"	Substitutes	Predictive	Supports	D	Sensitivity/Response	"Preclinical study in 293H cell line. Ectopic expression of V600E, L597R/Q/S, and K601E mutants elevated phospho-MEK and ERK levels. Vemurafenib treatment of all of the BRAF mutantexpressing cells led to a decrease in phospho-MEK and ERK protein levels. Treatment with MEK inhibitor GSK1120212 led to a more dramatic decrease in phospho-ERK signaling."	22798288	PubMed		"Dahlman et al., 2012, Cancer Discov"		3	accepted	1462	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1462	https://civicdb.org/links/molecular_profiles/580	FALSE	BRAF	673	K601E		chr7	140753334	140753334	T	C	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1801A>G,NP_004324.2:p.Lys601Glu,NC_000007.13:g.140453134T>C,ENST00000288602.6:c.1801A>G"	2023-01-27 17:04:28 UTC	CA123645	13966	"LYS601GLU,RS121913364"	FALSE
BRAF L597V	581	Skin Melanoma	8923		Trametinib		Predictive	Supports	C	Sensitivity/Response	Case report of a phase 1 study in advanced melanoma patients. 97 patients with melanoma were enrolled and treated with trametinib. One patient with a BRAF Leu597Val had a confirmed partial response with 60% tumour reduction and received study treatment for more than 2 years.	22805292	PubMed		"Falchook et al., 2012, Lancet Oncol."	NCT00687622	3	accepted	1463	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1463	https://civicdb.org/links/molecular_profiles/581	FALSE	BRAF	673	L597V		chr7	140753346	140753346	G	C	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1789C>G,NP_004324.2:p.Leu597Val,NC_000007.13:g.140453146G>C,ENST00000288602.6:c.1789C>G"	2023-01-27 17:04:29 UTC	CA123651	13969	"LEU597VAL,RS121913369"	FALSE
PIK3CA Amplification	212	Head And Neck Squamous Cell Carcinoma	5520		Taselisib		Predictive	Supports	D	Sensitivity/Response	"The HNSCC cell line LB771 with PIK3CA amplification was shown to have low antiproliferative IC50 for the p110beta-sparing PI3K inhibitor taselisib. Under increasing taselisib concentrations, reduction in phospho-Akt pro-survival signal was apparent, along with increased levels of pro-apoptotic marker cleaved PARP. A general tendency for taselisib sensitivity to PI3K activation (mutation/amplification) was also seen in a panel of 26 HNSCC cell lines"	26589432	PubMed		"Zumsteg et al., 2016, Clin. Cancer Res."		1	accepted	1464	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/1464	https://civicdb.org/links/molecular_profiles/212	FALSE	PIK3CA	5290	Amplification		chr3	179148523	179240093			ENST00000263967.3	75		transcript_amplification	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
PIK3CA H1047R	107	Head And Neck Squamous Cell Carcinoma	5520		Taselisib		Predictive	Supports	D	Sensitivity/Response	"The Cal-33 HNSCC cell line with H1047R mutation was found to have a low antiproliferative IC50 value for the alpha, gamma and delta isoform-specific PI3K inhibitor taselisib. Increasing taselisib concentration induced reduction of phospho-Akt levels in Call-33 cells, while upregulating the cleaved PARP apoptotic marker. Among a panel of 26 HNSCC cell lines, activating PI3K mutations were associated with taselisib sensitivity in comparison to wild-type PI3K or PTEN mutant cell lines."	26589432	PubMed		"Zumsteg et al., 2016, Clin. Cancer Res."		2	accepted	1465	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/1465	https://civicdb.org/links/molecular_profiles/107	FALSE	PIK3CA	5290	H1047R		chr3	179234297	179234297	A	G	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.3140A>G,NP_006209.2:p.His1047Arg,ENST00000263967.3:c.3140A>G,NC_000003.11:g.178952085A>G"	2023-01-27 17:02:38 UTC	CA123326	13652	"HIS1047ARG,RS121913279"	FALSE
KIT Amplification	582	Mucosal Melanoma	50929		Imatinib		Predictive	Supports	B	Resistance	"Phase 2 trial in metastatic mucosal, acral or chronically sun-damaged melanoma. Twenty-five patients were enrolled (24 evaluable). Eight patients (33%) had tumors with KIT mutations, 11 (46%) with KIT amplifications, and five (21%) with both. Median follow-up was 10.6 months. Best overall response rate was statistically significantly different by mutation status: 7 of 13 or 54% KIT mutated v 0% KIT amplified only."	23775962	PubMed		"Hodi et al., 2013, J. Clin. Oncol."	NCT00424515	3	accepted	1466	N/A	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1466	https://civicdb.org/links/molecular_profiles/582	FALSE	KIT	3815	Amplification		chr4	54657918	54740715			ENST00000288135.5	75		transcript_amplification		2023-01-09 21:52:08 UTC		N/A		FALSE
PTEN Mutation	506	Head And Neck Squamous Cell Carcinoma	5520		Taselisib		Predictive	Supports	D	Resistance	"In a panel of 26 HNSCC cell lines tested for sensitivity to taselisib (an alpha, delta and gamma isoform-specific PI3K inhibitor) the UD-SCC-2 cell line with homozygous PTEN deletion had considerably higher antiproliferative IC50 than taselisib sensitized cell lines. Western blots of UD-SCC-3 cells with increasing taselisib concentration showed reduction of phospho-Akt only at micro-molar doses, in contrast to nano-molar range for sensitized cells. Slight induction of the apoptotic marker cleaved PARP was only apparent at 4 micro-molar dose. Similar results were reported with the PTEN mutant HNSCC cell line UPCI-SCC-90, and 4 of the 6 most taselisib resistant cell lines had PTEN mutation."	26589432	PubMed		"Zumsteg et al., 2016, Clin. Cancer Res."		3	accepted	1467	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1467	https://civicdb.org/links/molecular_profiles/506	FALSE	PTEN	5728	Mutation		chr10	87863113	87971930			ENST00000371953.3	75		protein_altering_variant		2023-01-09 21:52:07 UTC		N/A		FALSE
NF1 Mutation	583	Skin Melanoma	8923		Vemurafenib		Predictive	Supports	D	Resistance	"Preclinical study of mouse melanoma in-vitro and in-vivo. In-vitro treament of Braf-mutant melanomas were 10-fold more sensitive to vermurafenib (PLX4032) treatment than Braf/Nf1-mutant melanomas. In vivo treatment of mice with Braf/Nf1-mutant allografts showed less sensitivity to vemurafenib (PLX4032) than the MEK inhibitor, PD0325901."	23171796	PubMed		"Maertens et al., 2013, Cancer Discov"		2	accepted	1468	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1468	https://civicdb.org/links/molecular_profiles/583	FALSE	NF1	4763	Mutation		chr17	31094927	31377677			ENST00000358273.4	75		"protein_altering_variant,loss_of_function_variant"		2023-01-09 21:52:08 UTC		N/A		FALSE
NF1 Mutation	583	Skin Melanoma	8923		"Mirdametinib,Sirolimus"	Combination	Predictive	Supports	D	Sensitivity/Response	"Preclinical study of mouse melanoma both in-vitro and in-vivo. Braf/Nf1-mutant melanomas were less sensitive to vemurafenib than the MEK inhibitor PD0325901. mTOR inhibition with rapamycin had a more pronounced effect than GDC-0941 on mouse melanoma, but synergized with PD0325901(but not vemurafenib) to promote tumor regression."	23171796	PubMed		"Maertens et al., 2013, Cancer Discov"		3	accepted	1469	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1469	https://civicdb.org/links/molecular_profiles/583	FALSE	NF1	4763	Mutation		chr17	31094927	31377677			ENST00000358273.4	75		"protein_altering_variant,loss_of_function_variant"		2023-01-09 21:52:08 UTC		N/A		FALSE
NF1 Mutation	583	Skin Melanoma	8923		Vemurafenib		Predictive	Supports	C	Resistance	"NF1 was identified in an unbiased RNAi screen as mediator of resistance to BRAF inhibition in BRAF mutant melanoma. Knockdown of NF1 led to PLX4720 resistance in-vitro. MEK inhibition with AZD6244 (selumetinib) had some efficacy but was also less active than in NF1 proficient cells.  4 patients with mutant alleles of NF1 were identified among patients relapsed after vemurafenib. Of these, one was a nonsense mutation (p.R2450*) present in both pretreatment and postrelapse biopsies. The patient had a progression-free survival (PFS) of about 10 weeks. The other NF1 mutations were silent events (patient 15, c.135T>C, patient 45 c.4023G>A, and patient 50 c3018C>T) located within candidate splicing motifs. Patients 15 and 50 exhibited response rates of relatively short duration (10 and 12 weeks, respectively) and the mutations were observed in both the pretreatment and postrelapse biopsies. Patient 45 experienced a PFS of 5 months, and the NF1 mutation was only present in the postrelapse biopsy indicative of acquired resistance."	23288408	PubMed		"Whittaker et al., 2013, Cancer Discov"		4	accepted	1470	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1470	https://civicdb.org/links/molecular_profiles/583	FALSE	NF1	4763	Mutation		chr17	31094927	31377677			ENST00000358273.4	75		"protein_altering_variant,loss_of_function_variant"		2023-01-09 21:52:08 UTC		N/A		FALSE
NF1 Mutation	583	Skin Melanoma	8923		"VTX-11e,AZ628"	Substitutes	Predictive	Supports	D	Sensitivity/Response	"NF1 was identified in an unbiased RNAi screen as mediator of resistance to BRAF inhibition in BRAF mutant melanoma. BRAF V600E/NF1 mutant cell lines were sensitive to ERK inhibition with VTX-11e, modest resistance was observed against RAF inhibitor AZ628. Combined PLX4720 and AZD6244 (selumetinib) achieved greater efficacy than either agent alone but NF1 knockdown was still associated with residual resistance to combined RAF/MEK inhibition in vitro."	23288408	PubMed		"Whittaker et al., 2013, Cancer Discov"		2	accepted	1471	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1471	https://civicdb.org/links/molecular_profiles/583	FALSE	NF1	4763	Mutation		chr17	31094927	31377677			ENST00000358273.4	75		"protein_altering_variant,loss_of_function_variant"		2023-01-09 21:52:08 UTC		N/A		FALSE
NRAS Mutation	208	Skin Melanoma	8923		Binimetinib		Predictive	Supports	B	Sensitivity/Response	Phase II study in 71 patients with NRAS or BRAF V600 mutant melanoma treated with MEK162. Six (20%) of 30 patients with NRAS-mutated melanoma had a partial response (three confirmed).	23414587	PubMed		"Ascierto et al., 2013, Lancet Oncol."	NCT01320085	2	accepted	1472	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/1472	https://civicdb.org/links/molecular_profiles/208	FALSE	NRAS	4893	Mutation		chr1	114704469	114716894			ENST00000369535.4	75		"transcript_variant,gain_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
NRAS Q61	94	Skin Melanoma	8923		Selumetinib		Predictive	Supports	C	Sensitivity/Response	Phase 1 trial in 57 patients with advanced cancers treated with selumetinib. 4 melanoma patients had NRAS Q61 mutations. One patient with NRAS mutation had 70% tumor shrinkage after three cycles of selumetinib (AZD6244) but developed symptomatic brain metastases before confirmatory scans could be performed.	18390968	PubMed		"Adjei et al., 2008, J. Clin. Oncol."		2	accepted	1473	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/1473	https://civicdb.org/links/molecular_profiles/94	FALSE	NRAS	4893	Q61		chr1	114713907	114713909			ENST00000369535.4	75		missense_variant		2023-01-09 21:52:04 UTC		"7,305,813,900,375,870,000,000,000,000,000,000,000,000"	GLN61	FALSE
NRAS Q61K	423	Skin Melanoma	8923		Vemurafenib		Predictive	Supports	D	Resistance	"Preclinical study in melanoma cell lines. NRAS Q61K, in addition to the BRAF V600E mutation was associated with resistance to vemurafenib but sensitivity to AZD6244 (selumetinib) in vitro in the acquired resistant cell line M249-AR4 and in the patient-derived acquired resistant cell line M376."	22194965	PubMed		"Atefi et al., 2011, PLoS ONE"		2	accepted	1474	Somatic	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/1474	https://civicdb.org/links/molecular_profiles/423	FALSE	NRAS	4893	Q61K		chr1	114713909	114713909	G	T	ENST00000369535.4	75		missense_variant	"NM_002524.4:c.181C>A,NP_002515.1:p.Gln61Lys,NC_000001.10:g.115256530G>T,ENST00000369535.4:c.181C>A"	2023-01-27 17:03:41 UTC	CA151263	73058	"GLN61LYS,RS121913254"	FALSE
NRAS Q61K	423	Skin Melanoma	8923		Selumetinib		Predictive	Supports	D	Sensitivity/Response	"Preclinical study in melanoma cell lines. NRAS Q61K, in addition to the BRAF V600E mutation was associated with resistance to vemurafenib but sensitivity to AZD6244 (selumetinib) in vitro in the acquired resistant cell line M249-AR4 and in the patient-derived acquired resistant cell line M376."	22194965	PubMed		"Atefi et al., 2011, PLoS ONE"		2	accepted	1475	Somatic	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/1475	https://civicdb.org/links/molecular_profiles/423	FALSE	NRAS	4893	Q61K		chr1	114713909	114713909	G	T	ENST00000369535.4	75		missense_variant	"NM_002524.4:c.181C>A,NP_002515.1:p.Gln61Lys,NC_000001.10:g.115256530G>T,ENST00000369535.4:c.181C>A"	2023-01-27 17:03:41 UTC	CA151263	73058	"GLN61LYS,RS121913254"	FALSE
NRAS Mutation	208	Skin Melanoma	8923		Amuvatinib		Predictive	Supports	D	Sensitivity/Response	"Preclinical study in melanoma cell lines. Cell lines (2-5/assay) with NRAS mutation were more sensitive to Amuvatinib (inhibitor targets multiple tyrosine kinases) than BRAF mutant cell lines in growth inhibition, tyrosine phosphorylation inhibition, cell cycle and apoptotic (Annexin V) assays."	24950457	PubMed		"Fedorenko et al., 2014, Melanoma Res."		1	accepted	1476	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/1476	https://civicdb.org/links/molecular_profiles/208	FALSE	NRAS	4893	Mutation		chr1	114704469	114716894			ENST00000369535.4	75		"transcript_variant,gain_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
SMO Mutation	296	Basal Cell Carcinoma	2513		"Vismodegib,Sonidegib"	Sequential	Predictive	Supports	B	Resistance	"Study explored the response to the SMO inhibitor sonidegib (LDE225) in a cohort of 9 patients with advanced basal cell carcinoma  that exhibited treatment resistance with vismodegib (GDC0449). Sequencing revealed that 5 of these patients harbored SMO mutations known to confer resistance to the Smoothened inhibitors (D473G, D473H, Q477E, S533N, W535L) an additional patient harbored a SMO mutation of unknown consequence (R168H). Of these patients, 4 with a SMO mutation displayed progressive disease and 1 stable disease for 58 weeks according to RECIST v1.1 criteria."	26546616	PubMed		"Danial et al., 2016, Clin. Cancer Res."		2	accepted	1477	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1477	https://civicdb.org/links/molecular_profiles/296	FALSE	SMO	6608	Mutation		chr7	129188872	129213545			ENST00000249373.3	75		coding_transcript_variant		2023-01-09 21:52:06 UTC		N/A		FALSE
TP53 Mutation	222	Chronic Lymphocytic Leukemia	1040				Prognostic	Supports	B	Poor Outcome	"In the CLL4 trial assessing first line treatment with chlorambucil or fludarabine with or without cyclophosphamide, patients with TP53 mutations experienced poorer overall response rates (27% vs 83%), shorter progression free survival (5 year PFS 5% vs 17%), and overall survival (20% vs 59%) compared to patients without TP53 mutations."	21483000	PubMed		"Gonzalez et al., 2011, J. Clin. Oncol."		3	accepted	1478	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/1478	https://civicdb.org/links/molecular_profiles/222	FALSE	TP53	7157	Mutation		chr17	7668402	7687538			ENST00000269305.4	75		protein_altering_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
NOTCH1 Mutation	206	Chronic Lymphocytic Leukemia	1040				Prognostic	Supports	B	Poor Outcome	"In the randomized UK LRF CCL4 phase 3 trial comparing first-line treatment with chlorambucil, fludarabine, or fludarabine plus cyclophosphamide, univariate analysis of patients with NOTCH1 mutations (within amino acids 2405-2525, a 399bp region of the PEST domain) demonstrated poorer overall survival (54.8 vs 74.6 months, P=0.02) and progression free survival (22 vs 26.4 months, P=0.02) compared to patients with wild-type NOTCH1. Progression-free survival was not significant (P = 0.21), however, overall survival remained significant (P = 0.03) under multivariate analysis."	23086750	PubMed		"Oscier et al., 2013, Blood"		2	accepted	1479	Unknown	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/1479	https://civicdb.org/links/molecular_profiles/206	FALSE	NOTCH1	4851	Mutation		chr9	136494444	136545862			ENST00000277541.6	75		protein_altering_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
SF3B1 Mutation	215	Chronic Lymphocytic Leukemia	1040				Prognostic	Supports	B	Poor Outcome	"In the randomized phase 3 UK LRF CCL4 trial comparing first-line treatment with chlorambucil, fludarabine, or fludarabine plus cyclophosphamide, SF3B1 mutations (73/437 patients) were associated with poorer overall survival (median 54.3 vs 79 months, P <0.001), independent of treatment. Additionally, controlling for cases with TP53 deletions/mutations, SF3B1 mutations were associated with reduced progression free survival for patients in the fludarabine plus cyclophosphamide treatment arm when compared to wildtype SF3B1 (29.4 vs 46 months, P=0.002)."	23086750	PubMed		"Oscier et al., 2013, Blood"		4	accepted	1480	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/1480	https://civicdb.org/links/molecular_profiles/215	FALSE	SF3B1	23451	Mutation		chr2	197389784	197435091			ENST00000335508.6	75		protein_altering_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
TP53 Mutation	222	Chronic Lymphocytic Leukemia	1040		Alemtuzumab		Predictive	Supports	B	Sensitivity/Response	"Thirty-six patients with CLL were treated with alemtuzumab. Partial or complete response was achieved in 6 of 15 patients with p53 mutations, compared to 4 of 21 without. These findings are not statistically significant, but the authors suggest that alemtuzumab is an effective therapy for patients with p53 mutations or deletions."	14726385	PubMed		"Lozanski et al., 2004, Blood"		2	accepted	1481	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/1481	https://civicdb.org/links/molecular_profiles/222	FALSE	TP53	7157	Mutation		chr17	7668402	7687538			ENST00000269305.4	75		protein_altering_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
CALR EXON 9 FRAMESHIFT	555	Essential Thrombocythemia	2224		Peginterferon Alfa-2a		Predictive	Supports	B	Sensitivity/Response	"Study explored the hematologic and molecular responses in a cohort of 31 patients presenting with thrombocythemia and CALR exon 9 frameshift mutations. All 31 patients exhibited a hematologic response at the time of followup (European LeukemiaNet criteria). In regards to molecular response, before treatment the CALR mutant allele displayed a median frequency of 41% across the cohort, during treatment a significant decrease was observed in comparison to controls treated with hydroxyurea and aspirin."	26486786	PubMed		"Verger et al., 2015, Blood"		4	accepted	1482	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1482	https://civicdb.org/links/molecular_profiles/555	FALSE	CALR	811	EXON 9 FRAMESHIFT		chr19	12943713	12943913			ENST00000316448.5	75		exon_variant		2023-01-09 21:52:07 UTC				FALSE
TP53 Mutation	222	Chronic Lymphocytic Leukemia	1040				Prognostic	Supports	B	Poor Outcome	"In a multivariate analysis of 774 CLL patients, TP53 aberrations were significantly correlated with shorter time to first treatment (HR=2.081; 95% CI=1.431-3.021). This finding was independent of IGHV mutation status."	24943832	PubMed		"Baliakas et al., 2015, Leukemia"		5	accepted	1485	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/1485	https://civicdb.org/links/molecular_profiles/222	FALSE	TP53	7157	Mutation		chr17	7668402	7687538			ENST00000269305.4	75		protein_altering_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
NOTCH1 Mutation	206	Chronic Lymphocytic Leukemia	1040				Prognostic	Does Not Support	B	Poor Outcome	"In a multivariate analysis of 774 CLL patients, NOTCH1 mutations were not significantly correlated with shorter time to first treatment (HR=1.305; 95% CI=0.923-1.847)."	24943832	PubMed		"Baliakas et al., 2015, Leukemia"		5	accepted	1486	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/1486	https://civicdb.org/links/molecular_profiles/206	FALSE	NOTCH1	4851	Mutation		chr9	136494444	136545862			ENST00000277541.6	75		protein_altering_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
SF3B1 Mutation	215	Chronic Lymphocytic Leukemia	1040				Prognostic	Supports	B	Poor Outcome	"In a multivariate analysis of 774 CLL patients, SF3B1 mutations were significantly correlated with shorter time to first treatment (HR=1.644; 95% CI=1.134-2.383). This finding was independent of IGHV mutation status."	24943832	PubMed		"Baliakas et al., 2015, Leukemia"		5	accepted	1487	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/1487	https://civicdb.org/links/molecular_profiles/215	FALSE	SF3B1	23451	Mutation		chr2	197389784	197435091			ENST00000335508.6	75		protein_altering_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
BIRC3 TRUNCATING MUTATION	586	Chronic Lymphocytic Leukemia	1040				Prognostic	Supports	B	Poor Outcome	"BIRC3 mutations were identified in 23 of 919 screened  CLLs. They are strongly linked to non-mutated IGHV genes (18/23, P = 0.0001), a widely recognized prognostic signature for poor outcome."	24943832	PubMed		"Baliakas et al., 2015, Leukemia"		2	accepted	1488	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1488	https://civicdb.org/links/molecular_profiles/586	FALSE	BIRC3	330	TRUNCATING MUTATION		chr11	102330999	102337102			ENST00000263464.3	75		frameshift_variant		2023-01-09 21:52:08 UTC				FALSE
MYD88 L265P	420	Chronic Lymphocytic Leukemia	1040				Prognostic	Supports	B	Better Outcome	"MYD88 mutations were identified in 24 of 1080 screened  CLLs. They were exclusively seen in instances of mutated IGHV genes (18/23, P = 0.0001), a widely recognized prognostic signature for better outcome in CLL."	24943832	PubMed		"Baliakas et al., 2015, Leukemia"		2	accepted	1489	Somatic	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/1489	https://civicdb.org/links/molecular_profiles/420	FALSE	MYD88	4615	L265P		chr3	38141150	38141150	T	C	ENST00000396334.3	75		"missense_variant,gain_of_function_variant"	NC_000003.11:g.38182641T>C	2023-01-27 17:03:40 UTC	CA130043	37055	"LEU265PRO,L273P,LEU273PRO"	FALSE
PIK3CA Mutation	307	Head And Neck Squamous Cell Carcinoma	5520		"Taselisib,Radiation Therapy"	Combination	Predictive	Supports	D	Sensitivity/Response	"A panel of 26 HNSCC cell lines was tested for efficacy of the p110 alpha, delta and gamma isoform inhibitor taselisib (GDC-0032). Cell lines with PIK3CA mutation or amplification were the most sensitive. Four HNSCC cell lines with activating PIK3CA alterations showed synergistic cell death response to the combination of drug with radiation treatment. This synergism was not apparent in 4 tested HNSCC cell lines with wild-type PIK3CA or PTEN mutation. Nude mouse xenografts were established with Cal-33 PIK3CA H1047R cells. Radiation and taselisib treatments alone showed some growth inhibition in comparison to control, but only the combined treatment led durable tumor regressions."	26589432	PubMed		"Zumsteg et al., 2016, Clin. Cancer Res."		3	accepted	1490	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/1490	https://civicdb.org/links/molecular_profiles/307	FALSE	PIK3CA	5290	Mutation		chr3	179148523	179240093			ENST00000263967.3	75		"transcript_variant,gain_of_function_variant"		2023-01-09 21:52:06 UTC		N/A		FALSE
PTEN Mutation	506	Cancer	162		Ipatasertib		Predictive	Supports	D	Sensitivity/Response	"IC50 for the pan-Akt inhibitor ipatasertib (GDC-0068) was determined over a panel of 100 cancer cell lines. Loss or mutation of PTEN (e.g. PTEN deletion, T319fsX1/Y155C, etc.) was significantly associated with ipatasertib sensitivity (p=0.000071). Non-transformed human mammary epithelial MCF10A cells were compared to an isogenic line with PTEN knockout. With low or high EGF culture conditions, a 4x or 3.5x decrease in IC50 for ipatasertib was seen in PTEN knockout cells, respectively."	23287563	PubMed		"Lin et al., 2013, Clin. Cancer Res."		3	accepted	1491	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1491	https://civicdb.org/links/molecular_profiles/506	FALSE	PTEN	5728	Mutation		chr10	87863113	87971930			ENST00000371953.3	75		protein_altering_variant		2023-01-09 21:52:07 UTC		N/A		FALSE
PTEN Loss	214	Ovarian Cancer	2394		Cisplatin		Predictive	Supports	D	Resistance	"A cisplatin resistant derivative of ovarian cancer cell line OVCAR-3 was generated by long term passage with increasing cisplatin levels. Western blot showed decreased PTEN level in the resistant cell line, and siRNA against PTEN in parent OVCAR-3 cells induced cisplatin resistance."	15790433	PubMed		"Lee et al., 2005, Gynecol. Oncol."		2	accepted	1492	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/1492	https://civicdb.org/links/molecular_profiles/214	FALSE	PTEN	5728	Loss		chr10	87863113	87971930			ENST00000371953.3	75		loss_of_function_variant	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
PTEN Loss	214	Stomach Carcinoma	5517		Chemotherapy		Predictive	Supports	B	Resistance	"Cancer and normal tissue samples were taken from 68 gastric cancer patients undergoing surgery without prior chemotherapy. Tissue samples were divided into high grade and low grade for phospho Akt (p-Akt) expression, and tested for PTEN LOH by sequencing. Patients with PTEN LOH were significantly more likely to have elevated p-Akt (p=0.0081), and high p-Akt samples were significantly less sensitive to chemotherapy agents 5-flourouracil, adriamycin, mitomycin and cis-platinum in MTT assay."	15900596	PubMed		"Oki et al., 2005, Int. J. Cancer"		2	accepted	1493	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/1493	https://civicdb.org/links/molecular_profiles/214	FALSE	PTEN	5728	Loss		chr10	87863113	87971930			ENST00000371953.3	75		loss_of_function_variant	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
EZH2 Y646	165	Skin Melanoma	8923		GSK126		Predictive	Supports	D	Sensitivity/Response	Preclinical study in melanoma cell lines. EZH2 expression was higher in EZH2 mutant (N=3) and wild-type melanoma cell lines (N=12) than untransformed cells (human epithelial melanocytes and human dermal fibroblasts). EZH2 mutant cell lines were the most sensitive to GSK126 compared to wild-type and untransformed.	26304929	PubMed		"Tiffen et al., 2015, Oncotarget"		2	accepted	1494	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/1494	https://civicdb.org/links/molecular_profiles/165	FALSE	EZH2	2146	Y646		chr7	148811634	148811636			ENST00000320356.2	75		protein_altering_variant		2023-01-09 21:52:05 UTC		"3,762,187,676,837,620,000,000"	"Y641,TYR646"	FALSE
CCND1 Amplification	18	Skin Melanoma	8923		"Paclitaxel,Carboplatin,Sorafenib"	Combination	Predictive	Supports	B	Sensitivity/Response	"Retrospective analysis of somatic mutations and copy number changes in 119 patient treated with carboplatin, paclitaxel,  sorafenib (CPS) in the E2603 trial. CPS therapy was associated with improved progression-free survival (PFS) compared with CP in patients with tumors with CCND1 gene copy gains (HR, 0.45; P = 0.035)."	26307133	PubMed		"Wilson et al., 2016, Clin. Cancer Res."		2	accepted	1495	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/1495	https://civicdb.org/links/molecular_profiles/18	FALSE	CCND1	595	Amplification		chr11	69641087	69654474			ENST00000227507.2	75		transcript_amplification	N/A	2023-01-09 21:52:04 UTC		N/A		FALSE
RAF1 Amplification	587	Skin Melanoma	8923		"Carboplatin,Paclitaxel,Sorafenib"	Combination	Predictive	Supports	B	Sensitivity/Response	"Retrospective analysis of somatic mutations and copy number changes in 119 patients treated with carboplatin, paclitaxel,  sorafenib (CPS) in the E2603 trial. CPS therapy was associated with improved progression-free survival (PFS) compared with CP in patients with tumors that were positive for RAF1 gene copy gains (HR = 0.372; P = 0.025)."	26307133	PubMed		"Wilson et al., 2016, Clin. Cancer Res."		2	accepted	1496	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1496	https://civicdb.org/links/molecular_profiles/587	FALSE	RAF1	5894	Amplification		chr3	12583601	12664226			ENST00000251849.4	75		transcript_amplification		2023-01-09 21:52:08 UTC		N/A		FALSE
KRAS Amplification	588	Skin Melanoma	8923		"Sorafenib,Docetaxel,Carboplatin"	Combination	Predictive	Supports	B	Sensitivity/Response	"Retrospective analysis of somatic mutations and copy number changes in 119 patients treated with carboplatin, paclitaxel,  sorafenib (CPS) in the E2603 trial. CPS therapy was associated with improved overall survival compared with CP in patients with tumors positive for KRAS gene copy gains (HR = 0.25; P = 0.035)."	26307133	PubMed		"Wilson et al., 2016, Clin. Cancer Res."		2	accepted	1497	N/A	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1497	https://civicdb.org/links/molecular_profiles/588	FALSE	KRAS	3845	Amplification		chr12	25209431	25250803			ENST00000256078.4	75		transcript_amplification	N/A	2023-01-09 21:52:08 UTC		N/A		FALSE
ERBB2 Amplification	302	Gastric Adenocarcinoma	3717		Trastuzumab		Predictive	Supports	A	Sensitivity/Response	"ToGA, a Phase III study (NCT01041404) addressed use of trastuzumab in HER2 positive (overexpression or amplification) advanced gastric cancer, where chemotherapy using fluoropyrimidine-based and platinum-based combinations had been common practice.  Patients were given a chemotherapy regime containing capecitabine, flourouracil and cisplatin with (n=298) or without (n=296) trastuzumab, and had not been previously treated for metastatic cancer.  Study endpoint was overall survival, which was significantly different in the two populations (13.8 months with chemotherapy + trastuzumab and 11.1 months for chemotherapy alone).  The authors conclude that trastuzumab should be a standard option for HER2 positive advanced gastric cancer."	20728210	PubMed		"Bang et al., 2010, Lancet"	NCT01041404	4	accepted	1499	N/A	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1499	https://civicdb.org/links/molecular_profiles/302	FALSE	ERBB2	2064	Amplification		chr17	39700080	39728662			ENST00000269571.5	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A	OVEREXPRESSION	FALSE
PTEN Loss	214	Stomach Cancer	10534		"Docetaxel,Capivasertib"	Combination	Predictive	Supports	D	Sensitivity/Response	"A patient derived mouse xenograft model was established with gastric cancer cells having PTEN loss. The xenograft was resistant to monotherapy with both the pan-Akt inhibitor AZD5363, and also to the commonly used gastric cancer chemotheraputic docetaxel. When used in combination, AZD5363 and docetaxel induced significant tumor growth inhibition in comparison to monotherapy and vehicle control."	24088382	PubMed		"Li et al., 2013, J Transl Med"		1	accepted	1500	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/1500	https://civicdb.org/links/molecular_profiles/214	FALSE	PTEN	5728	Loss		chr10	87863113	87971930			ENST00000371953.3	75		loss_of_function_variant	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
PIK3CA Mutation	307	Stomach Cancer	10534		Capivasertib		Predictive	Supports	D	Sensitivity/Response	"In a panel of 22 gastric cancer cell lines, 4 of 6 cell lines having the highest sensitivity to AZD5363 contained a PIK3CA mutation (E542K, E453K, E545K). A patient derived gastric cancer xenograft mouse model was established with PIK3CA H1047R mutant cells, and treatment with AZD5363 induced significant tumor growth inhibition in comparison to vehicle control."	24088382	PubMed		"Li et al., 2013, J Transl Med"		3	accepted	1501	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/1501	https://civicdb.org/links/molecular_profiles/307	FALSE	PIK3CA	5290	Mutation		chr3	179148523	179240093			ENST00000263967.3	75		"transcript_variant,gain_of_function_variant"		2023-01-09 21:52:06 UTC		N/A		FALSE
PTEN Loss	214	Cancer	162		Capivasertib		Predictive	Supports	D	Sensitivity/Response	"In a panel of 182 cell lines (162 with PIK3CA mutation status known) from solid and hematological tumors, significant correlation was found between AZD5363 (pan-Akt inhibitor) sensitivity and PIK3CA mutation status (N=33, p=0.0059). In the subpopulation free of RAS mutation (N=19) the correlation was increased."	22294718	PubMed		"Davies et al., 2012, Mol. Cancer Ther."		3	accepted	1502	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/1502	https://civicdb.org/links/molecular_profiles/214	FALSE	PTEN	5728	Loss		chr10	87863113	87971930			ENST00000371953.3	75		loss_of_function_variant	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
PIK3CA Mutation	307	Cancer	162		Capivasertib		Predictive	Supports	D	Sensitivity/Response	"Sensitivity to pan-Akt inhibitor AZD5363 was assessed in a panel of 182 cell lines (160 with PTEN evaluated) derived from solid and hematological tumors. PTEN loss of function due to loss or mutation (N=32) was found to be significantly correlated with AZD5363 sensitivity (p=0.0099), and correlation improved in the subpopulation free of RAS mutation. Mouse xenografts with 786-0 (PTEN-null renal cancer) cells were established. 75 mg/kg twice daily AZD5363 caused tumor growth inhibition while 150 mg/kg twice daily induced moderate tumor regression."	22294718	PubMed		"Davies et al., 2012, Mol. Cancer Ther."		3	accepted	1503	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/1503	https://civicdb.org/links/molecular_profiles/307	FALSE	PIK3CA	5290	Mutation		chr3	179148523	179240093			ENST00000263967.3	75		"transcript_variant,gain_of_function_variant"		2023-01-09 21:52:06 UTC		N/A		FALSE
PIK3CA Mutation	307	Her2-receptor Positive Breast Cancer	60079		Capivasertib		Predictive	Supports	D	Sensitivity/Response	"HER2 overexpressing breast cancer cell lines with PIK3CA mutation BT474c (K111N) and HCC-1954 (H1047R) were used to establish mouse tumor xenografts. In BT474c xenografts, three dosing schedules of AZD5363 caused significant tumor inhibition (200 mg/kg twice daily > 200 mg/kg once daily > 100 mg/kg once daily). In HCC-1954 xenografts two doses of AZD5363 induced significant tumor inhibition (150 mg/kg twice daily > 75 mg/kg twice daily) while 30 mg/kg twice weekly trastuzumab was inactive."	22294718	PubMed		"Davies et al., 2012, Mol. Cancer Ther."		2	accepted	1504	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/1504	https://civicdb.org/links/molecular_profiles/307	FALSE	PIK3CA	5290	Mutation		chr3	179148523	179240093			ENST00000263967.3	75		"transcript_variant,gain_of_function_variant"		2023-01-09 21:52:06 UTC		N/A		FALSE
PIK3CA H1047R	107	Her2-receptor Positive Breast Cancer	60079		"Capivasertib,Trastuzumab"	Combination	Predictive	Supports	D	Sensitivity/Response	"Tumor xenografts in mice were established with the KPL4 HER2 positive breast cancer cell line with PIK3CA H1047R mutation. KPL4 has suboptimal responses to trastuzumab and lapatinib. Xengraft treatment with trastuzumab and AZD5363 monotherapy induced moderate growth inhibition which was significant for AZD5363, but co-treatment with trastuzumab and AZD5363 induced significant tumor regression and enhanced growth delay upon removal of treatment."	22294718	PubMed		"Davies et al., 2012, Mol. Cancer Ther."		3	accepted	1505	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/1505	https://civicdb.org/links/molecular_profiles/107	FALSE	PIK3CA	5290	H1047R		chr3	179234297	179234297	A	G	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.3140A>G,NP_006209.2:p.His1047Arg,ENST00000263967.3:c.3140A>G,NC_000003.11:g.178952085A>G"	2023-01-27 17:02:38 UTC	CA123326	13652	"HIS1047ARG,RS121913279"	FALSE
PIK3CA H1047R	107	Her2-receptor Positive Breast Cancer	60079		"Capivasertib,Lapatinib"	Combination	Predictive	Supports	D	Sensitivity/Response	"The HER2 breast cancer cell line KPL4 with PIK3CA H1047R shows sub-optimal responses to trastuzumab and lapatinib, and was used to establish mouse xenografts. Treatment of mice with monotherapy of AZD5363 or lapatinib alone induced growth inhibition (37%, not significant; 65%, P = 0.004), but treatment with AZD5363 and lapatinib together induced significant tumor regression (109%, P < 0.0001) as well as delayed tumor regrowth after removal of therapy."	22294718	PubMed		"Davies et al., 2012, Mol. Cancer Ther."		3	accepted	1506	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/1506	https://civicdb.org/links/molecular_profiles/107	FALSE	PIK3CA	5290	H1047R		chr3	179234297	179234297	A	G	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.3140A>G,NP_006209.2:p.His1047Arg,ENST00000263967.3:c.3140A>G,NC_000003.11:g.178952085A>G"	2023-01-27 17:02:38 UTC	CA123326	13652	"HIS1047ARG,RS121913279"	FALSE
TP53 Mutation	222	Chronic Lymphocytic Leukemia	1040				Prognostic	Supports	A	Poor Outcome	"In a cohort of 406 patients with CLL, those patients with clonal or sub-clonal mutations in TP53 had significantly shorter overall survival (HR: 1.71; 95% CI: 1.28-2.26; P = .0001)."	26837699	PubMed		"Nadeu et al., 2016, Blood"		5	accepted	1507	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/1507	https://civicdb.org/links/molecular_profiles/222	FALSE	TP53	7157	Mutation		chr17	7668402	7687538			ENST00000269305.4	75		protein_altering_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
ASXL1 Mutation	177	Myelofibrosis	4971				Prognostic	Supports	B	Poor Outcome	"An ASXL1 mutation, especially in conjunction with DNMT3A and EZH2 mutations, results in a fourfold increase in resistance to treatment with ruxolitinib and a reduced time to treatment discontinuation (TTD) for patients with myelofibrosis."	26124496	PubMed		"Patel et al., 2015, Blood"		3	accepted	1508	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/1508	https://civicdb.org/links/molecular_profiles/177	FALSE	ASXL1	171023	Mutation		chr20	32358352	32439319			ENST00000375687.4	75		protein_altering_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
NRAS Mutation	208	Melanoma	1909		Binimetinib		Predictive	Supports	D	Sensitivity/Response	"In a panel of 7 NRAS mutant melanoma cell lines, all 7 were found to be sensitive to the MEK inhibitor MEK162, whereas 3 of 5 melanoma cell lines that were wild type for BRAF and NRAS were not sensitive to MEK162. In further tests using two of the seven NRAS mutant cell lines (YUDOSO Q16K/wt and YUKIM Q16R), colony forming capacity was reduced with increased MEK162 treatment, and MEK162 induced apoptotic markers in these cells."	24588908	PubMed		"Thumar et al., 2014, Mol. Cancer"		3	accepted	1509	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/1509	https://civicdb.org/links/molecular_profiles/208	FALSE	NRAS	4893	Mutation		chr1	114704469	114716894			ENST00000369535.4	75		"transcript_variant,gain_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
IDH2 R172	199	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Better Outcome	"In a study of 1,540 patients with Acute Myeloid Leukemia, 18 patients had a mutation in IDH2(R172).  IDH2(R172) mutations rarely showed co-mutation with NPM1 (odds ratio= 0.06; P=4x10-5), whereas IDH2(R140) mutations showed strong co-mutation with NPM1 (odds ratio= 3.6; P=5x10-10).  In an absence of gene fusion products, patients with IDH2(R172) mutations showed higher survival rates when compared to mutations in NPM1, chromatin-spliceosome mutations and TP53aneuploidy.  Patients with IDH2(R172) mutations showed worse prognosis when compared to CEBPA(biallelic) mutations."	27276561	PubMed		"Papaemmanuil et al., 2016, N. Engl. J. Med."	NCT00146120	4	accepted	1511	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/1511	https://civicdb.org/links/molecular_profiles/199	FALSE	IDH2	3418	R172		chr15	90088605	90088607			ENST00000330062.3	75		protein_altering_variant		2023-01-09 21:52:05 UTC		N/A	ARG172	FALSE
CEBPA BIALLELIC INACTIVATION	590	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Better Outcome	"In a study of 1,540 patients with Acute Myeloid Leukemia, 66 patients (4%) had a CEBPA (biallelic) mutation.  In the absence of gene fusion products, patients with biallelic CEBPA mutations showed the highest rate of survival (~78%) when compared to IDH2 (R172) mutations, NPM1(W288fs) mutations, chromatin-spliceosome mutations and TP53aneuploidy."	27276561	PubMed		"Papaemmanuil et al., 2016, N. Engl. J. Med."	NCT00146120	5	accepted	1512	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1512	https://civicdb.org/links/molecular_profiles/590	FALSE	CEBPA	1050	BIALLELIC INACTIVATION		chr19	33299934	33302564			ENST00000498907.2	75		loss_of_function_variant		2023-01-09 21:52:08 UTC		N/A		FALSE
ASXL1 Mutation	177	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	"Patients with Acute Myeloid Leukemia showed an synergistic mortality rate with ASXL1 and SRSF2 co-mutations such that individual mutations of either ASXL1 or SRSF2 resulted in ~20% probability of survival after 10 years, whereas co-mutations resulted in a 100% mortality rate after 4 years."	27276561	PubMed		"Papaemmanuil et al., 2016, N. Engl. J. Med."	NCT00146120	5	accepted	1513	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/1513	https://civicdb.org/links/molecular_profiles/177	FALSE	ASXL1	171023	Mutation		chr20	32358352	32439319			ENST00000375687.4	75		protein_altering_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
SRSF2 MUTATION	591	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	"Patients with Acute Myeloid Leukemia showed an synergistic mortality rate with ASXL1 and SRSF2 co-mutations such that individual mutations of either ASXL1 or SRSF2 resulted in ~20% probability of survival after 10 years, whereas co-mutations resulted in a 100% mortality rate after 4 years."	27276561	PubMed		"Papaemmanuil et al., 2016, N. Engl. J. Med."	NCT00146120	5	accepted	1514	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1514	https://civicdb.org/links/molecular_profiles/591	FALSE	SRSF2	6427	MUTATION		chr17	76736320	76737031			ENST00000392485.2	75		gene_variant		2023-01-09 21:52:08 UTC				FALSE
FLT3 ITD	55	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	"In the absence of a FLT3 (ITD) mutation, a co-mutation of NPM1 and DNMT3A had a 50% 10-year survival rate, whereas triple-mutation of NPM1, DNMT3A, and FLT3 (ITD) had a 20% 10-year survival rate."	27276561	PubMed		"Papaemmanuil et al., 2016, N. Engl. J. Med."	NCT00146120	5	accepted	1515	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/1515	https://civicdb.org/links/molecular_profiles/55	FALSE	FLT3	2322	ITD		chr13	28034082	28034214			ENST00000241453.7	75		inframe_insertion		2023-01-09 21:52:04 UTC		16270		FALSE
NRAS G12/G13	592	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	"Patients with a triple mutation of NPM1, DNMT3A, and NRAS (G12/13) (three-way interaction p=0.04) showed a relatively benign prognosis with an 8-year survival rate of 75% and a 10-year survival rate of 55%.  Conversely, patients with a concomitant NPM1/DNMT3A co-mutation, in the absence of an NRAS (G12/13) mutation, showed a clinically unfavorable 10-year survival rate of 30%."	27276561	PubMed		"Papaemmanuil et al., 2016, N. Engl. J. Med."	NCT00146120	4	accepted	1516	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1516	https://civicdb.org/links/molecular_profiles/592	FALSE	NRAS	4893	G12/G13		chr1	114716123	114716127			ENST00000369535.4	75		protein_altering_variant		2023-01-09 21:52:08 UTC		"13,901,404,683,964,800,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000"		FALSE
CD274 Expression	272	Cancer	162		Nivolumab		Predictive	Supports	B	Sensitivity/Response	"Trial NCT00730639 tested monoclonal antibody nivolumab against the PD-1 immune checkpoint receptor in pretreated patients with various cancer types. PD-L1 expression was tested in 42 patients by ICH from tumor FFPE biopsies. (18 melanoma, 10 NSCLC, 7 colorectal cancer, 5 renal cell cancer, 2 prostate cancer). 9 of 25 PD-L1 expressing patients showed objective response, and zero of 17 PD-L1 negative patients showed objective response (p=0.006). Biopsies were optional, and therefore not fully randomized."	22658127	PubMed		"Topalian et al., 2012, N. Engl. J. Med."	NCT00730639	2	accepted	1517	N/A	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1517	https://civicdb.org/links/molecular_profiles/272	FALSE	CD274	29126	Expression		chr9	5450525	5470547			ENST00000381577.3	75		N/A	N/A	2023-01-09 21:52:06 UTC		N/A		FALSE
RET Overexpression	593	Papillary Adenocarcinoma	3112		Sunitinib		Predictive	Supports	C	Sensitivity/Response	"A 78-year-old man presented with oral papillary adenocarcinoma and lung metastases that were refractory to standard treatment.  Tumor sequencing showed increased MAPK activity due to RET over-expression and PTEN deletion, therefore sunitinib (RET inhibitor) was initiated.  After 28 days post-administration, the lung metastases decreased in size by 22% (28mm to 21mm) and no new metastatic lesions had appeared.  After 4 months, the patient grew resistant to treatment."	20696054	PubMed		"Jones et al., 2010, Genome Biol."		3	accepted	1518	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1518	https://civicdb.org/links/molecular_profiles/593	FALSE	RET	5979	Overexpression		chr10	43077027	43130351			ENST00000355710.3	75		N/A		2023-01-09 21:52:08 UTC		N/A		FALSE
PML PML::RARA	108	Acute Promyelocytic Leukemia	60318		Tretinoin		Predictive	Supports	C	Sensitivity/Response	"A 39-year old woman who presented with acute myeloid leukemia revealed a complicated genetic profile using conventional metaphase cytogenetics and FISH analysis.  Whole genome sequencing elucidated a PML-RARA fusion, which can be successfully treated with ATRA. Uncovering this mutation prevented an unnecessary allogeneic transplant and the patient remained in remission 15 months post-treatment (date of publication)."	21505136	PubMed		"Welch et al., 2011, JAMA"		3	accepted	1519	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/1519	https://civicdb.org/links/molecular_profiles/108	FALSE	PML	5371	PML::RARA		chr15	73994717	74033414			ENST00000268058.3	75	ENST00000254066.5	transcript_fusion	N/A	2023-01-09 21:52:05 UTC		N/A	PML-RARA	FALSE
PML PML::RARA	108	Acute Promyelocytic Leukemia	60318		Tretinoin		Predictive	Supports	C	Sensitivity/Response	"A 39-year old woman who presented with acute myeloid leukemia revealed a complicated genetic profile using conventional metaphase cytogenetics and FISH analysis.  Whole genome sequencing elucidated a PML-RARA fusion, which can be successfully treated with ATRA. Uncovering this mutation prevented an unnecessary allogeneic transplant and the patient remained in remission 15 months post-treatment (date of publication)."	21505136	PubMed		"Welch et al., 2011, JAMA"		3	accepted	1519	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/1519	https://civicdb.org/links/molecular_profiles/108	FALSE	PML	5371	PML::RARA		chr17	40348316	40356796			ENST00000268058.3	75	ENST00000254066.5	transcript_fusion	N/A	2023-01-09 21:52:05 UTC		N/A	PML-RARA	FALSE
CTLA4 CTLA4::CD28	595	Sezary's Disease	8541		Ipilimumab		Predictive	Supports	C	Sensitivity/Response	"A 67-year-old Caucasian female with stage IVA Sezary syndrome presented refractory to traditional therapy and was enrolled in a whole genome study trial. Sequencing revealed a CTLA4-CD28 fusion protein such that the inhibitory CTLA4 receptor activated a stimulatory CD28 intracellular domain that promoted proliferation. The patient was treated with iplimumab, a CTLA4 receptor inhibitor, and after 10 days, there was a reduction in erythema and ulceration by 50%, a reduction in tumor size by 75%, and overall improved quality of life. However, during the sixth week of therapy, the patient rapidly developed skin tumors and died 3 months later."	25802883	PubMed		"Sekulic et al., 2015, Mol Genet Genomic Med"		2	accepted	1520	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1520	https://civicdb.org/links/molecular_profiles/595	FALSE	CTLA4	1493	CTLA4::CD28		chr2	203867786	203871487			ENST00000302823.3	75	ENST00000324106.8	transcript_fusion		2023-01-09 21:52:08 UTC		N/A	CTLA4-CD28	FALSE
CTLA4 CTLA4::CD28	595	Sezary's Disease	8541		Ipilimumab		Predictive	Supports	C	Sensitivity/Response	"A 67-year-old Caucasian female with stage IVA Sezary syndrome presented refractory to traditional therapy and was enrolled in a whole genome study trial. Sequencing revealed a CTLA4-CD28 fusion protein such that the inhibitory CTLA4 receptor activated a stimulatory CD28 intracellular domain that promoted proliferation. The patient was treated with iplimumab, a CTLA4 receptor inhibitor, and after 10 days, there was a reduction in erythema and ulceration by 50%, a reduction in tumor size by 75%, and overall improved quality of life. However, during the sixth week of therapy, the patient rapidly developed skin tumors and died 3 months later."	25802883	PubMed		"Sekulic et al., 2015, Mol Genet Genomic Med"		2	accepted	1520	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1520	https://civicdb.org/links/molecular_profiles/595	FALSE	CTLA4	1493	CTLA4::CD28		chr2	203734784	203738912			ENST00000302823.3	75	ENST00000324106.8	transcript_fusion		2023-01-09 21:52:08 UTC		N/A	CTLA4-CD28	FALSE
AR Mutation	596	Prostate Cancer	10283		"Bicalutamide,Flutamide,Cyproterone Acetate,Nilutamide"	Substitutes	Predictive	Supports	B	Resistance	"In a study of 150 patients with metastatic castration resistant prostate cancer (mCRPC), 71.3% of cases (n=107) harbored androgen receptor (AR) pathway aberrations.   Within the AR mutation cohort, 78 patients had AR amplification mutations, 16 patients had AR missense mutations, and 13 patients had mutations in ZBTB16, NCOR1, FOXA1, and SPOP, which are all AR regulators or downstream effectors.  All AR mutations were exclusive to mCRPC neoplasms and were not found in primary prostate cancer."	26000489	PubMed		"Robinson et al., 2015, Cell"		4	accepted	1521	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1521	https://civicdb.org/links/molecular_profiles/596	FALSE	AR	367	Mutation		chrX	67544623	67730619			ENST00000374690.3	75		transcript_variant		2023-01-09 21:52:08 UTC		N/A		FALSE
PTEN Mutation	506	Prostate Cancer	10283		"Alpelisib,PI3Kbeta Inhibitor AZD8186,Enzalutamide"	Combination	Predictive	Supports	D	Sensitivity/Response	"Castrated mice bearing androgen-sensitive human prostate adenocarcinomas (LNCaP tumors) were treated with PI3K inhibitors (AZD8186, BYL719) and an androgen receptor inhibitor (MDV3100).  Mice treated with single therapy of either MDV3100, BYL719, or AZD8186 resulted in mild tumor growth inhibition of 90%, 36%, and 40% respectively (n=5 mice/group).  However, triple therapy of MDV300, BYL719, and AZD8186 resulted in tumor regression of 113% (n=5 mice)."	25544636	PubMed		"Schwartz et al., 2015, Cancer Cell"		3	accepted	1522	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1522	https://civicdb.org/links/molecular_profiles/506	FALSE	PTEN	5728	Mutation		chr10	87863113	87971930			ENST00000371953.3	75		protein_altering_variant		2023-01-09 21:52:07 UTC		N/A		FALSE
BRCA1 Loss-of-function	131	Prostate Cancer	10283				Prognostic	Supports	B	Poor Outcome	"In a study of 2,019 patients with prostate cancer, 18 had germline BRCA1 mutations, 61 had germline BRCA2 mutations and 1,940 were non-carriers.  Patients with BRCA1/2 mutations had a 2-fold higher incidence of poorly differentiated cancer (Gleason score >8), a higher incidence of advanced stage (37% vs. 28%; P=0.003), a higher incidence of nodal involvement (15% vs. 5%; P=0.0005), and a higher incidence of metastatic spread (18% vs. 9%; P=0.005)."	23569316	PubMed		"Castro et al., 2013, J. Clin. Oncol."		3	accepted	1523	Rare Germline	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/1523	https://civicdb.org/links/molecular_profiles/131	FALSE	BRCA1	672	Loss-of-function	BRCA Germline Variants	chr17	43045629	43125483			ENST00000471181.2	75		"loss_of_heterozygosity,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
BRCA2 Loss-of-function	132	Prostate Cancer	10283				Prognostic	Supports	B	Poor Outcome	"In a study of 2,019 patients with prostate cancer, 18 had germ-line BRCA1 mutations, 61 had germ-line BRCA2 mutations and 1,940 were non-carriers.  Patients with BRCA1/2 mutations had a 2-fold higher incidence of poorly differentiated cancer (Gleason score >8), a higher incidence of advanced stage (37% vs. 28%; P=0.003), a higher incidence of nodal involvement (15% vs. 5%; P=0.0005), and a higher incidence of metastatic spread (18% vs. 9%; P=0.005)."	23569316	PubMed		"Castro et al., 2013, J. Clin. Oncol."		3	accepted	1524	Rare Germline	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/1524	https://civicdb.org/links/molecular_profiles/132	FALSE	BRCA2	675	Loss-of-function	BRCA Germline Variants	chr13	32315474	32399210			ENST00000380152.3	75		loss_of_function_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
NOTCH1 Loss-of-function	597	Head And Neck Squamous Cell Carcinoma	5520		Porcupine Inhibitor WNT974		Predictive	Supports	D	Sensitivity/Response	"In an evaluation of 96 head and neck squamous cell carcinoma (HNSCC) cell lines, 31 were responsive to LGK974 (PORCN inhibitor). Of 40 cell lines (25 responsive, 15 non-responsive) that were exome sequenced, 6 cell lines had NOTCH1 loss-of-function mutations (N-terminal frameshift/nonsense) and 5/6 cell lines that had NOTCH1 mutations were susceptible to LGK974 (PORCN inhibitor)."	24277854	PubMed		"Liu et al., 2013, Proc. Natl. Acad. Sci. U.S.A."		2	accepted	1525	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1525	https://civicdb.org/links/molecular_profiles/597	FALSE	NOTCH1	4851	Loss-of-function		chr9	136494444	136545862			ENST00000277541.6	75		loss_of_function_variant		2023-01-09 21:52:08 UTC		N/A		FALSE
CDK6 Overexpression	598	Estrogen-receptor Positive Breast Cancer	60075		Fulvestrant		Predictive	Supports	B	Resistance	"In two cohorts (n=45 and n=46) of ER+ breast cancer patients who had received fulvestrant, CDK6 overexpression correlated with shorter median time to progression in both cohorts (2.5 vs. 8.2 months and 3.4 vs. 8.9 months for CDK6 overexpression vs. normal expression). CDK6 expression did not correlate with other lines of treatment (N=68, tamoxifen or endocrine therapy). Four fulvestrant-resistant cell lines were derived from estrogen responsive and fulvestrant sensitive parental breast cancer cell line MCF-7/SO.5. Gene expression profiling showed upregulation of CDK6 in the fulvestrant resistant derivatives. Knockdown of CDK6 in these derivative cells resulted in fulvestrant sensitivity."	27252418	PubMed		"Alves et al., 2016, Clin. Cancer Res."		4	accepted	1526	N/A	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1526	https://civicdb.org/links/molecular_profiles/598	FALSE	CDK6	1021	Overexpression		chr7	92604921	92833917			ENST00000265734.4	75		N/A		2023-01-09 21:52:08 UTC		N/A		FALSE
CDK6 Overexpression	598	Estrogen-receptor Positive Breast Cancer	60075		"Fulvestrant,Palbociclib"	Combination	Predictive	Supports	D	Sensitivity/Response	"Four fulvestrant (estrogen receptor degrader) resistant cell lines were derived from parent fulvestrant sensitive ER+ MCF-7/SO.5 breast cancer cell line. Derivative cell lines showed some sensitivity to CDK4/6 inhibitor palbociclib, and increased growth inhibition when treated with fulvestrant and palbociclib together."	27252418	PubMed		"Alves et al., 2016, Clin. Cancer Res."		2	accepted	1527	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1527	https://civicdb.org/links/molecular_profiles/598	FALSE	CDK6	1021	Overexpression		chr7	92604921	92833917			ENST00000265734.4	75		N/A		2023-01-09 21:52:08 UTC		N/A		FALSE
FLT3 Overexpression	599	B-cell Adult Acute Lymphocytic Leukemia	60592		Sunitinib		Predictive	Supports	C	Sensitivity/Response	"A 25-year-old Caucasian male presented with a second relapse of B-ALL. RNA sequencing revealed FLT3 overexpression (also confirmed by IHC). The patient was treated with 22 days of sunitinib, permitting the patient to undergo a bone marrow transplant. A bone marrow biopsy showed complete clearance by variant allele frequency and the patient remains in remission 4-years post matched-unrelated donor allograft."	27181063	PubMed		"Griffith et al., 2016, Exp. Hematol."		3	accepted	1528	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1528	https://civicdb.org/links/molecular_profiles/599	FALSE	FLT3	2322	Overexpression		chr13	28003274	28100592			ENST00000241453.7	75		N/A		2023-01-09 21:52:08 UTC		N/A		FALSE
BRCA1 Mutation	185	Ovarian Carcinoma	4001		Platinum Compound		Predictive	Supports	B	Sensitivity/Response	"In a study of ovarian carcinomas, 81% of tumors with germline BRCA1/2 mutations were platinum sensitive, whereas only 60% of tumors with non-BRCA1/2 mutations were platinum sensitive (N=47; N=158; P=0.01). Sensitivity was defined by maintenance of complete response greater than 6 months post platinum-based therapy."	24240112	PubMed		"Pennington et al., 2014, Clin. Cancer Res."		3	accepted	1529	Rare Germline	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/1529	https://civicdb.org/links/molecular_profiles/185	FALSE	BRCA1	672	Mutation		chr17	43045629	43125483			ENST00000471181.2	75		"gene_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
BRCA2 Mutation	186	Ovarian Carcinoma	4001		Platinum Compound		Predictive	Supports	B	Sensitivity/Response	"In a study of ovarian carcinomas, 81% of tumors with germline BRCA1/2 mutations were platinum sensitive, whereas only 60% of tumors with non-BRCA1/2 mutations were platinum sensitive (N=47; N=158; P=0.01). Sensitivity was defined by maintenance of complete response greater than 6 months post platinum-based therapy."	24240112	PubMed		"Pennington et al., 2014, Clin. Cancer Res."		3	accepted	1530	Rare Germline	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/1530	https://civicdb.org/links/molecular_profiles/186	FALSE	BRCA2	675	Mutation		chr13	32315474	32399210			ENST00000380152.3	75		"gene_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
BRCA1 Mutation	185	Ovarian Carcinoma	4001		Platinum Compound		Predictive	Supports	B	Sensitivity/Response	"In a study of ovarian carcinomas, 87% of tumors with somatic BRCA1/2 mutations were platinum sensitive, whereas only 60% of tumors with non-BRCA1/2 mutations were platinum sensitive (N=38; N=158; P=0.002). Sensitivity to platinum was defined by maintenance of complete response greater than 6 months post platinum-based therapy."	24240112	PubMed		"Pennington et al., 2014, Clin. Cancer Res."		3	accepted	1531	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/1531	https://civicdb.org/links/molecular_profiles/185	FALSE	BRCA1	672	Mutation		chr17	43045629	43125483			ENST00000471181.2	75		"gene_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
BRCA2 Mutation	186	Ovarian Carcinoma	4001		Platinum Compound		Predictive	Supports	B	Sensitivity/Response	"In a study of ovarian carcinomas, 87% of tumors with somatic BRCA1/2 mutations were platinum sensitive, whereas only 60% of tumors with non-BRCA1/2 mutations were platinum sensitive (N=38; N=158; P=0.002). Sensitivity to platinum was defined by maintenance of complete response greater than 6 months post platinum therapy."	24240112	PubMed		"Pennington et al., 2014, Clin. Cancer Res."		3	accepted	1532	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/1532	https://civicdb.org/links/molecular_profiles/186	FALSE	BRCA2	675	Mutation		chr13	32315474	32399210			ENST00000380152.3	75		"gene_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
GNAQ Q209P	600	Skin Melanoma	8923		Vemurafenib		Predictive	Supports	C	Resistance	A 26-year old patient presented with vemurafenib resistant BRAF-mutated (V600E) cutaneous melanoma. Five of his metastases were evaluated using whole genome sequencing. A GNAQ (Q209P) mutation was identified as unanimously present in all five tumors.	24504448	PubMed		"Turajlic et al., 2014, Ann. Oncol."		2	accepted	1533	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1533	https://civicdb.org/links/molecular_profiles/600	FALSE	GNAQ	2776	Q209P		chr9	77794572	77794572	T	G	ENST00000286548.4	75		missense_variant	"NC_000009.11:g.80409488T>G,NM_002072.4:c.626A>C,NP_002063.2:p.Gln209Pro,ENST00000286548.4:c.626A>C"	2023-01-27 17:04:31 UTC	CA16602436	375957	"GLN209PRO,RS121913492"	FALSE
PTEN V317FS	601	Skin Melanoma	8923		"MEK Inhibitor CI-1040,Akt Inhibitor MK2206"	Combination	Predictive	Supports	D	Sensitivity/Response	"A 26-year old patient presented with vemurafenib resistant BRAF V600E-mutated cutaneous melanoma. Five metastases were evaluated using whole genome sequencing and a 4-bp deletion in PTEN (frameshift mutation at V317) was identified as unanimously present in all five tumors and a pre-treatment biopsy. The other copy of PTEN was lost with a chromosome-wide loss of chr 10. Subsequently, a patient-derived tumor cell line (designated 22 092) was suspended in a solution of PD184352/MK2206 combination therapy and cell growth inhibition confirmed tumor sensitivity to MEK/AKT inhibitors compared to the BRAF V600E-containing A375P cell line. ERK inhibitor resistance was demonstrated as a result of a GNAQ Q209P mutation also identified in the patient. This cell line showed overexpression of AKT and no expression of PTEN."	24504448	PubMed		"Turajlic et al., 2014, Ann. Oncol."		3	accepted	1534	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1534	https://civicdb.org/links/molecular_profiles/601	FALSE	PTEN	5728	V317FS		chr10	87961042	87961045	TACT		ENST00000371953.3	75		frameshift_variant	"ENST00000371953.3:c.950_953delTACT,NC_000010.10:g.89720799_89720802del"	2023-01-27 17:04:32 UTC	CA000646	NONE FOUND	VAL317FS	FALSE
RB1 Loss-of-function	602	Breast Cancer	1612		Palbociclib		Predictive	Supports	D	Resistance	"In 3 ER positive and 2 ER negative breast cancer cell lines with intact Rb, significant growth inhibition, as measured by BrdU incorporation, was seen with incubation in CDK4/6 inhibitor palbociclib (PD-0332991). In contrast, two ER negative cell lines lacking detectable Rb were fully resistant to palbociclib. Knockdown of Rb in 3 of the tested Rb positive cell lines led to moderate palbociclib resistance in short term incubation experiments.  In longer term (15 day) palbociclib incubations of ER negative MDA-MB-231 cells and ER positive MCF-7 cells, significant resistance to palbociclib was seen in Rb knockdown conditions while wild-type Rb cells maintained sensitivity."	20473330	PubMed		"Dean et al., 2010, Oncogene"		3	accepted	1535	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1535	https://civicdb.org/links/molecular_profiles/602	FALSE	RB1	5925	Loss-of-function		chr13	48303775	48481986			ENST00000267163.4	75		loss_of_function_variant		2023-01-09 21:52:08 UTC		N/A		FALSE
CCND1 Overexpression	20	Mantle Cell Lymphoma	50746		Palbociclib		Predictive	Does Not Support	B	Sensitivity/Response	"A pharmacodynamic study (NCT00420056) of 17 mantle cell lymphoma MCL patients was performed using the CDK4/6 inhibitor palbociclib (PD0332991). Patients were verified by IHC, FISH or molecular testing for the t(11:14) rearrangement causing Cyclin D overexpression in MCL. 1 patient demonstrated complete response, and 2 showed partial response for an 18% overall response rate. 7 patients showed stable disease. Patient population was heavily pretreated."	22383795	PubMed		"Leonard et al., 2012, Blood"	NCT00420056	2	accepted	1536	N/A	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/1536	https://civicdb.org/links/molecular_profiles/20	FALSE	CCND1	595	Overexpression		chr11	69641087	69654474			ENST00000227507.2	75		N/A	N/A	2023-01-09 21:52:04 UTC		N/A		FALSE
GNAQ Q209P	600	Skin Melanoma	8923		PLX4720		Predictive	Supports	D	Resistance	"Cells were derived from a 26-year old patient with vemurafenib resistant BRAF-mutated (V600E) cutaneous melanoma (designated 20 092 cells). Five of his metastases evaluated using whole genome sequencing contained a GNAQ (Q209P) mutation. 20 092 cells were insensitive to BRAF inhibition (PLX4720) in both proliferation assays and evaluation of pERK compared to BRAF V600E mutated, GNAQ wild-type A375P cells. Using GNAQ (Q209P) siRNA in 22 092 cells, ERK activity was suppressed and cell sensitivity to PLX4720 was increased."	24504448	PubMed		"Turajlic et al., 2014, Ann. Oncol."		3	accepted	1537	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1537	https://civicdb.org/links/molecular_profiles/600	FALSE	GNAQ	2776	Q209P		chr9	77794572	77794572	T	G	ENST00000286548.4	75		missense_variant	"NC_000009.11:g.80409488T>G,NM_002072.4:c.626A>C,NP_002063.2:p.Gln209Pro,ENST00000286548.4:c.626A>C"	2023-01-27 17:04:31 UTC	CA16602436	375957	"GLN209PRO,RS121913492"	FALSE
NOTCH1 Mutation	206	Chronic Lymphocytic Leukemia	1040				Prognostic	Supports	A	Poor Outcome	"In a study of 406 previously untreated CLL cases, a multivariate analysis indicated clonal NOTCH1 mutations (N=55) were significantly associated with reduced overall survival (HR: 1.5; 95%CI: 1.13-1.99; P = 0.0049). Subclonal mutations (VAF <12%) were not associated with reduced OS (N=29, P=0.94, univariate analysis)."	26837699	PubMed		"Nadeu et al., 2016, Blood"		5	accepted	1538	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/1538	https://civicdb.org/links/molecular_profiles/206	FALSE	NOTCH1	4851	Mutation		chr9	136494444	136545862			ENST00000277541.6	75		protein_altering_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
ATM Mutation	178	Chronic Lymphocytic Leukemia	1040				Prognostic	Supports	A	Poor Outcome	"In a study of 406 previously untreated CLL cases, a multivariate analysis indicated that aberrations (N=44; mixed pathogenic germline and somatic) in exons 2-63 of ATM were significantly associated with shorter time to first treatment (HR: 1.36; 95% CI: 1.05-1.76; P = 0.021). These mutations were not significantly associated with overall survival."	26837699	PubMed		"Nadeu et al., 2016, Blood"		5	accepted	1539	N/A	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/1539	https://civicdb.org/links/molecular_profiles/178	FALSE	ATM	472	Mutation		chr11	108222832	108369099			ENST00000278616.4	75		"transcription_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
SF3B1 Mutation	215	Chronic Lymphocytic Leukemia	1040				Prognostic	Supports	A	Poor Outcome	"In a study of 406 previously untreated CLL cases, a multivariate analysis indicated SF3B1 mutations (N=51) were significantly associated with reduced time to first treatment (HR: 1.73; 95%CI: 1.05-2.86; P = 0.031). While clonal mutations (VAF >= 12%) were associated with reduced time to first treatment by univariate analysis (N=28, P<0.0001), subclonal mutations were not (N=21, P=0.22)."	26837699	PubMed		"Nadeu et al., 2016, Blood"		5	accepted	1540	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/1540	https://civicdb.org/links/molecular_profiles/215	FALSE	SF3B1	23451	Mutation		chr2	197389784	197435091			ENST00000335508.6	75		protein_altering_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
ESR1 Overexpression	603	Breast Cancer	1612		"Letrozole,Palbociclib"	Combination	Predictive	Supports	B	Sensitivity/Response	"A phase 2 clinical trial evaluated 165 patients with oestrogen receptor positive and HER2-negative breast cancer such that 84 patients received combination therapy of palbociclib plus letrozole and 81 patients received letrozole alone. The combination therapy arm had higher median duration of progression-free survival when compared to the letrozole only group (20.2 months vs. 10.2 months; p<0.0004). A subcategory of patients taking combination therapy, who lacked mutations in p16 or CCND1 (n=34), had an even higher median free survival of 26.1 months. Noticeable side effects in the combination therapy group included neutropenia (54%) leucopenia (19%), fatigue (4%) back pain (2%), diarrhea (2%) and pulmonary embolism (4%)."	25524798	PubMed		"Finn et al., 2015, Lancet Oncol."	NCT00721409	4	accepted	1541	N/A	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1541	https://civicdb.org/links/molecular_profiles/603	FALSE	ESR1	2099	Overexpression		chr6	151807551	152103271			ENST00000206249.3	75		N/A		2023-01-09 21:52:08 UTC		N/A		FALSE
IDH2 R140	62	Acute Myeloid Leukemia	9119				Prognostic	Does Not Support	B	N/A	"In patients with acute myeloid leukemia, the presence of IDH2 R140Q (n??), IDH2 R172K (n??) or IDH1 R132 (N=4) mutations did not confer prognostic value (overall survival) compared to wild-type IDH1/2 patients overall (N=102; P=0.177). IDH1/2 mutations were significantly more common in cytogenetically normal AML (P=0.004). IDH1/2 mutations did also not confer an overall survival benefit in patients with an intermediate risk karyotype (N=68, P=0.484)."	21997850	PubMed		"Lin et al., 2012, Ann. Hematol."		2	accepted	1542	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/1542	https://civicdb.org/links/molecular_profiles/62	FALSE	IDH2	3418	R140		chr15	90088702	90088702			ENST00000330062.3	75		protein_altering_variant		2023-01-09 21:52:04 UTC		"37,598,814,716,375,900"	ARG140	FALSE
MTOR F2108L	466	Breast Cancer	1612		Sirolimus		Predictive	Supports	D	Resistance	MCF-7 breast cancer cell line was exposed to mTOR inhibitors AZD8055 or rapamycin until resistance developed. Deep sequencing revealed an MTOR F2108L mutation in rapamycin-resistant clones (RR2 cells). Downstream signalling was independent of inhibitor presence in these clones and expression of the mutations in MDA-MB-468 cells led to resistance.	27279227	PubMed		"Rodrik-Outmezguine et al., 2016, Nature"		4	accepted	1543	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1543	https://civicdb.org/links/molecular_profiles/466	FALSE	MTOR	2475	F2108L		chr1	11127037	11127037	G	T	ENST00000361445.4	75		missense_variant	"ENST00000361445.4:c.6324C>A,NC_000001.10:g.11187094G>T"	2023-01-27 17:03:57 UTC	CA338391533	NONE FOUND	PHE2108LEU	FALSE
MTOR M2327I	605	Breast Cancer	1612		MTOR Kinase Inhibitor AZD8055		Predictive	Supports	D	Resistance	MCF-7 breast cancer cell line was exposed to mTOR inhibitor AZD8055 until resistance developed. Deep sequencing revealed an MTOR M2327I mutation in the AZD8055-resistant clone. Downstream signalling was independent of inhibitor presence in these clones and expression of the mutation in MDA-MB-468 cells led to resistance. Tumor volume grew more rapidly in mice with xenografts of M2327I mTOR mutant MCF7 cells treated with AZD8055 than rapamycin or RapaLink-1 treatment.	27279227	PubMed		"Rodrik-Outmezguine et al., 2016, Nature"		4	accepted	1544	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1544	https://civicdb.org/links/molecular_profiles/605	FALSE	MTOR	2475	M2327I		chr1	11117039	11117039	C	A	ENST00000361445.4	75		missense_variant	"ENST00000361445.4:c.6981G>T,NC_000001.10:g.11177096C>A"	2023-01-27 17:04:33 UTC	CA338383476	NONE FOUND	MET2327ILE	FALSE
MTOR M2327I	605	Breast Cancer	1612		"Sirolimus,RapaLink-1"	Substitutes	Predictive	Does Not Support	D	Resistance	MCF-7 breast cancer cell line was exposed to mTOR inhibitor AZD8055 until resistance developed. Deep sequencing revealed an MTOR M2327I mutation in the AZD8055-resistant clone. These cells remained sensitive to rapamycin and RapaLink-1 in vitro and in mouse xenografts. Expression of the mutation in MDA-MB-468 cells led to AZD8055 resistance and these cells were also rapamycin and RapaLink-1 sensitive.	27279227	PubMed		"Rodrik-Outmezguine et al., 2016, Nature"		3	accepted	1545	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1545	https://civicdb.org/links/molecular_profiles/605	FALSE	MTOR	2475	M2327I		chr1	11117039	11117039	C	A	ENST00000361445.4	75		missense_variant	"ENST00000361445.4:c.6981G>T,NC_000001.10:g.11177096C>A"	2023-01-27 17:04:33 UTC	CA338383476	NONE FOUND	MET2327ILE	FALSE
MTOR A2034V	606	Breast Cancer	1612		Sirolimus		Predictive	Supports	D	Resistance	MCF-7 breast cancer cell line was exposed to mTOR inhibitor rapamycin until resistance developed. Deep sequencing revealed an MTOR A2034V mutation in the resistant clone. Downstream signalling was independent of inhibitor presence in these clones and expression of the mutation in MDA-MB-468 cells led to resistance. Xenografts of these cells were more resistant to rapamycin than AZD8055 or RapaLink-1 treatment.	27279227	PubMed		"Rodrik-Outmezguine et al., 2016, Nature"		4	accepted	1547	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1547	https://civicdb.org/links/molecular_profiles/606	FALSE	MTOR	2475	A2034V		chr1	11127739	11127739	G	A	ENST00000361445.4	75		missense_variant	"ENST00000361445.4:c.6101C>T,NC_000001.10:g.11187796G>A"	2023-01-27 17:04:34 UTC	CA338393920	NONE FOUND	ALA2034VAL	FALSE
MTOR A2034V	606	Breast Cancer	1612		"RapaLink-1,MTOR Kinase Inhibitor AZD8055"	Substitutes	Predictive	Does Not Support	D	Resistance	MCF-7 breast cancer cell line was exposed to mTOR inhibitor rapamycin until resistance developed. Deep sequencing revealed an MTOR A2034V mutation in the resistant clone (RR1). Downstream signalling was independent of inhibitor presence in these clones and expression of the mutation in MDA-MB-468 cells led to resistance to rapamycin but maintained sensistivity to AZD8055. A novel mTOR inhibitor RapaLink-1 was designed and showed efficacy in A2034V mTOR mutant cell lines in-vivo and in-vitro. AZD8055 also retained efficacy in these clones in xenograft.	27279227	PubMed		"Rodrik-Outmezguine et al., 2016, Nature"		4	accepted	1548	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1548	https://civicdb.org/links/molecular_profiles/606	FALSE	MTOR	2475	A2034V		chr1	11127739	11127739	G	A	ENST00000361445.4	75		missense_variant	"ENST00000361445.4:c.6101C>T,NC_000001.10:g.11187796G>A"	2023-01-27 17:04:34 UTC	CA338393920	NONE FOUND	ALA2034VAL	FALSE
PIK3CA E542K	103	Head And Neck Squamous Cell Carcinoma	5520		Apitolisib		Predictive	Supports	C	Sensitivity/Response	"Phase 1 study with the dual PI3K/mTOR inhibitor apitolisib. 120 patients were treated at doses between 2 and 70mg. Of the 14 evaluable patients with PIK3CA mutations total, there were 3 PRs (1 confirmed), 8 SD, and 3 PD as best radiological responses. One of the partial responses harbored a PIK3CA E542K mutation."	26787751	PubMed		"Dolly et al., 2016, Clin. Cancer Res."		2	accepted	1549	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/1549	https://civicdb.org/links/molecular_profiles/103	FALSE	PIK3CA	5290	E542K		chr3	179218294	179218294	G	A	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.1624G>A,NP_006209.2:p.Glu542Lys,ENST00000263967.3:c.1624G>A,NC_000003.11:g.178936082G>A"	2023-01-27 17:02:37 UTC	CA333572	31944	"GLU542LYS,RS121913273"	FALSE
PIK3CA E545K	104	Cancer	162		Apitolisib		Predictive	Supports	C	Sensitivity/Response	"Phase 1 study with the dual PI3K/mTOR inhibitor apitolisib. 120 patients were treated at doses between 2 and 70mg. Of 45 evaluable patients receiving 40mg, two patients with E545K PIK3CA mutation (one head and neck squamous cell carcinoma patient and a patient with ovarian cancer) had unconfirmed partial responses. Of the 14 evaluable patients with PIK3CA mutations total, there were 3 PRs (1 confirmed), 8 SD, and 3 PD as best radiological responses."	26787751	PubMed		"Dolly et al., 2016, Clin. Cancer Res."		1	accepted	1550	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/1550	https://civicdb.org/links/molecular_profiles/104	FALSE	PIK3CA	5290	E545K		chr3	179218303	179218303	G	A	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.1633G>A,NP_006209.2:p.Glu545Lys,ENST00000263967.3:c.1633G>A,NC_000003.11:g.178936091G>A"	2023-01-27 17:02:37 UTC	CA123334	13655	"GLU545LYS,RS104886003"	FALSE
BRAF D594G	607	Colorectal Cancer	9256				Prognostic	Supports	B	Poor Outcome	"In a study of 908 patients with colorectal cancer, 7 patients had BRAF (D594G) mutations and 45 patients had BRAF (V600E) mutations. Overall clinicopathological implications of BRAF V600E and D594G mutant tumors were similar but BRAF D594G mutations were more likely to be left-sided tumors (85.7% vs. 31.1%; p<0.0098) and they were more likely to present as metastatic tumors (71.4% vs. 28.9%; p<0.04) than BRAF V600E mutant tumors. The overall log-rank was p < 0.001 when all three groups were calculated simultaneously; p < 0.0001 comparing BRAF wild-type and BRAF V600E survival, p = 0.015 comparing BRAF wild-type and BRAF D594G survival, and p = 0.98 comparing BRAF V600E and BRAF D594G.  There was no statistically significant difference in OS between BRAF D594G and BRAF wt but BRAF V600E mutant patients had significantly worse survival when only stage IV patients (BRAF D594G N=5) were analyzed."	27404270	PubMed		"Amaki-Takao et al., 2016, Oncology"		1	accepted	1551	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1551	https://civicdb.org/links/molecular_profiles/607	FALSE	BRAF	673	D594G		chr7	140753354	140753354	T	C	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1781A>G,NP_004324.2:p.Asp594Gly,NC_000007.13:g.140453154T>C,ENST00000288602.6:c.1781A>G"	2023-01-27 17:04:35 UTC	CA123657	13972	"ASP594GLY,RS121913338"	FALSE
BRAF V600E	12	Colorectal Cancer	9256				Prognostic	Supports	B	Poor Outcome	"In a study of 908 patients with colorectal cancer, 45 patients had BRAF V600E mutations and 589 patients were BRAF wild type.  BRAF V600E mutations were more likely to be proximal tumors (68.9%, 20.7%; p<0.0001), they were more likely to be poorly differentiated (17.7%, 1.9%; p<0.0001), they were more likely to be mucinous carcinoma type (20.0%, 4.2%; p=0.0003), they were more likely to have lymphatic invasion (77.6%, 49.9%; p=0.0003), and they had a shorter survival time (31.1 mo, 41.6 mo; p=0.001).  The 3-year survival rate was significantly poorer in the V600E group when compared to the wild type group (63.8%, 87.9%; p<0.0001)."	27404270	PubMed		"Amaki-Takao et al., 2016, Oncology"		3	accepted	1552	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/1552	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
BRAF D594G	607	Colorectal Cancer	9256				Prognostic	Supports	B	Poor Outcome	"In a study of 908 patients with colorectal cancer (CRC), 7 patients had BRAF D595G mutations and 589 patients were BRAF wild type. The survival rate of CRC patients at 3 years was significantly poorer in the BRAF D595G mutations when compared to the wild type group (50%, 87.9%; p<0.00152)."	27404270	PubMed		"Amaki-Takao et al., 2016, Oncology"		2	accepted	1553	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1553	https://civicdb.org/links/molecular_profiles/607	FALSE	BRAF	673	D594G		chr7	140753354	140753354	T	C	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1781A>G,NP_004324.2:p.Asp594Gly,NC_000007.13:g.140453154T>C,ENST00000288602.6:c.1781A>G"	2023-01-27 17:04:35 UTC	CA123657	13972	"ASP594GLY,RS121913338"	FALSE
BRAF D594G	607	Colorectal Cancer	9256		"Cetuximab,Panitumumab"	Substitutes	Predictive	Does Not Support	C	Resistance	Two patients with stage IV BRAF (D594G) mutations received anti-EGFR antibody therapy (cetuximab and panitumumab). The first patient was on FOLFOX plus bevacizumab and showed no signs of progression for 10 months. No response was observed after cetuximab was given as a third line therapy. The second patient received panitumumab with FOLFOX and showed no signs of progression for 8 months with reduction of the size of metastases.	27404270	PubMed		"Amaki-Takao et al., 2016, Oncology"		1	accepted	1554	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1554	https://civicdb.org/links/molecular_profiles/607	FALSE	BRAF	673	D594G		chr7	140753354	140753354	T	C	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1781A>G,NP_004324.2:p.Asp594Gly,NC_000007.13:g.140453154T>C,ENST00000288602.6:c.1781A>G"	2023-01-27 17:04:35 UTC	CA123657	13972	"ASP594GLY,RS121913338"	FALSE
FLT3 ITD	55	Acute Myeloid Leukemia	9119		Sorafenib		Predictive	Supports	C	Sensitivity/Response	"Six children with relapsed or refractory FLT3-ITD-positive AML received initial therapy with sorafenib (alone or in combination with clofarabine and cytarabine).  Four of the patients initially achieved morphological complete remission (bone marrow blasts <5%), however, 3 patients developed resistance within 14-37 weeks and and 1 required a bone marrow transplant.  Two patients did not have any clinical response to sorafenib upon initial treatment."	23969938	PubMed		"Baker et al., 2013, Clin. Cancer Res."		1	accepted	1555	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/1555	https://civicdb.org/links/molecular_profiles/55	FALSE	FLT3	2322	ITD		chr13	28034082	28034214			ENST00000241453.7	75		inframe_insertion		2023-01-09 21:52:04 UTC		16270		FALSE
FLT3 D835H	608	Acute Myeloid Leukemia	9119		Sorafenib		Predictive	Supports	C	Resistance	"Three children with relapsed or refractory FLT3-ITD-positive AML were treated with sorafenib. FLT3 mutations were assessed before treatment and at the time of resistance. During the initiation of the treatment, all three patients had undetectable levels of FLT3 (D835H) mutations, however, after resistance developed, the mutation frequency rose to 33.1%, 35.7%, and 11.0% in the three patients. Ba/F3 cells expressing FLT3 mutants were resistant to sorafenib-dependent inhibition of cell viability"	23969938	PubMed		"Baker et al., 2013, Clin. Cancer Res."		3	accepted	1556	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1556	https://civicdb.org/links/molecular_profiles/608	FALSE	FLT3	2322	D835H		chr13	28018505	28018505	C	G	ENST00000241453.7	75		missense_variant	"NM_004119.2:c.2503G>C,NP_004110.2:p.Asp835His,ENST00000241453.7:c.2503G>C,NC_000013.10:g.28592642C>G"	2023-01-27 17:04:35 UTC	CA280208	16273	"ASP835HIS,RS121913488"	FALSE
FLT3 D835H/Y	609	Acute Myeloid Leukemia	9119		Sorafenib		Predictive	Supports	D	Resistance	Mouse Ba/F3 cells with FLT3 mutations were evaluated for sorafenib resistance.  Cells with single FLT3 (D835H/Y) mutants were resistant to sorafenib (IC50 81 nm/210 nM) whereas cells with FLT3 (ITD) mutants were not resistant to sorafenib (IC50 1.1 nM).  Cells with double mutants (ITD-D835H/Y or ITD F691L) were highly resistant to sorafenib (IC50 460-3300 nM).	23969938	PubMed		"Baker et al., 2013, Clin. Cancer Res."		1	accepted	1557	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1557	https://civicdb.org/links/molecular_profiles/609	FALSE	FLT3	2322	D835H/Y		chr13	28018505	28018505	C	G/A	ENST00000241453.7	75		missense_variant	"NM_004119.2:c.2503G>C,NP_004110.2:p.Asp835His,NM_004119.2:c.2503G>T,NP_004110.2:p.Asp835Tyr,ENST00000241453.7:c.2503G>C,ENST00000241453.7:c.2503G>T"	2023-01-09 21:52:08 UTC		"1,627,316,276"	"ASP835HIS,ASP835TYR"	FALSE
RUNX1 Mutation	155	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	"In patients with acute myeloid leukemia, those with RUNX1 mutations (n=245) had significantly worse outcomes when compared to those with RUNX1 wild-type alleles (n=2,194).  The complete remission rate for patients with RUNX1 mutations was significantly lower (48.4% vs. 68.1%; p <0.0001), the refractory disease rate was significantly higher (40.6% 23.4%; p=0.03), the 5-year event free survival rate was significantly lower (9%, 24%; p<0.0001), the 5-year relapse free survival rate was significantly lower (22%, 36%; p=0.0007), and the 5-year overall survival rate was significantly lower (22%, 37%; p=0.0001)."	27137476	PubMed		"Gaidzik et al., 2016, Leukemia"		3	accepted	1558	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/1558	https://civicdb.org/links/molecular_profiles/155	FALSE	RUNX1	861	Mutation		chr21	34787801	35049344			ENST00000300305.3	75		"transcript_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
CCND1 Amplification	18	Renal Cell Carcinoma	4450		Palbociclib		Predictive	Does Not Support	D	Sensitivity/Response	"28 renal cell carcinoma cell lines were tested for sensitivity to CDK4/6 inhibitor Palbociclib (PD0332991). 19 were reported sensitive, and 9 resistant. 15 of the 28 cell lines had high levels of Cyclin D1 (CCND1) expression which did not correlate significantly with palbociclib sensitivity (p=0.348)."	23898052	PubMed		"Logan et al., 2013, Anticancer Res."		2	accepted	1560	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/1560	https://civicdb.org/links/molecular_profiles/18	FALSE	CCND1	595	Amplification		chr11	69641087	69654474			ENST00000227507.2	75		transcript_amplification	N/A	2023-01-09 21:52:04 UTC		N/A		FALSE
ERBB2 Amplification	302	Her2-receptor Positive Breast Cancer	60079		"Palbociclib,Trastuzumab"	Combination	Predictive	Supports	D	Sensitivity/Response	"In a panel of 47 breast cancer cell lines, HER2 overexpressing cells were among those more sensitive to CDK4/6 inhibitor Palbociclib (PD0332991). In the trastuzumab sensitive cell line Bt474, palbociclib synergized with trastuzumab in growth inhibition, while in 2 trastuzumab resistant cell lines, addition of trastuzumab to palbociclib treatment resulted in increased growth inhibition over palbociclib alone."	19874578	PubMed		"Finn et al., 2009, Breast Cancer Res."		2	accepted	1561	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1561	https://civicdb.org/links/molecular_profiles/302	FALSE	ERBB2	2064	Amplification		chr17	39700080	39728662			ENST00000269571.5	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A	OVEREXPRESSION	FALSE
CCND1 Amplification	18	Breast Cancer	1612		Palbociclib		Predictive	Supports	D	Sensitivity/Response	"A panel of 47 breast cancer cell lines was tested for sensitivty/resistance to CDK4/6 inhibitor Palbociclib (PD0332991),  where IC50 below 150nM was sensitive, and above 1000nM resistant. Cyclin D1 had higher expression levels in sensitive cell lines."	19874578	PubMed		"Finn et al., 2009, Breast Cancer Res."		2	accepted	1562	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/1562	https://civicdb.org/links/molecular_profiles/18	FALSE	CCND1	595	Amplification		chr11	69641087	69654474			ENST00000227507.2	75		transcript_amplification	N/A	2023-01-09 21:52:04 UTC		N/A		FALSE
CCND1 Overexpression	20	Mantle Cell Lymphoma	50746		Palbociclib		Predictive	Supports	D	Sensitivity/Response	"In Mantle Cell Lymphoma (MCL), t(11:14)-induced overexpression of cyclin D1 was targeted by CDK4/6 inhibitor Palbociclib (PD0332991). Palbociclib caused Rb dephosphorylation in MCL cell lines and patient derived tumor cells. MCL cell lines overexpressing cyclin D1 showed growth inhibition with Palbociclib. The VAL DLBCL cell line was used as control to verify cyclin D1 overexpression but was not used as a control in Palbociclib inhibitor experiments. Instead, the investigators report that other publications report cell lines without cyclin D1 overexpression had higher IC50 values for palbociclib, suggesting overexpresssed cyclin D1 targetability in MCL."	16690963	PubMed		"Marzec et al., 2006, Blood"		1	accepted	1563	N/A	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/1563	https://civicdb.org/links/molecular_profiles/20	FALSE	CCND1	595	Overexpression		chr11	69641087	69654474			ENST00000227507.2	75		N/A	N/A	2023-01-09 21:52:04 UTC		N/A		FALSE
ATM Underexpression	179	Chronic Lymphocytic Leukemia	1040				Prognostic	Supports	B	Poor Outcome	"43 B-CLL patients with LoH or reduced protein levels (<50% normal expression, radioimmunoassay, western blot) of ATM were found to have significantly shorter overall survival (35.6 vs. 97.3 months; P=0.003) when compared to 108 patients with normal expression levels."	9788599	PubMed		"Starostik et al., 1998, Cancer Res."		3	accepted	1564	N/A	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/1564	https://civicdb.org/links/molecular_profiles/179	FALSE	ATM	472	Underexpression		chr11	108222832	108369099			ENST00000278616.4	75		N/A		2023-01-09 21:52:05 UTC		N/A		FALSE
MET Amplification	266	Glioblastoma	3068		Crizotinib		Predictive	Supports	C	Sensitivity/Response	"A 62 year old female was diagnosed with glioblastoma (GBM) WHO grade 4. Treatment included radiation, temozolomide and cediranib. MET amplification was found by FISH, and ALK and MET inhibitor crizotinib treatment was started. A 40% reduction in size of contrast enhancing lesion was seen. After 6 months, progressive disease was seen and crizotinib withdrawn. The authors state this is a first report of response to prospective MET targeted therapy in GBM."	22162573	PubMed		"Chi et al., 2012, J. Clin. Oncol."		3	accepted	1565	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1565	https://civicdb.org/links/molecular_profiles/266	FALSE	MET	4233	Amplification		chr7	116672405	116796342			ENST00000318493.6	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A		FALSE
MET Amplification	266	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	D	Sensitivity/Response	"2 MET amplified NSCLC cell lines (EBC-1 and H1993), as well as 2 EGFR mutant and 2 MET and EGFR wild type cell lines were treated with ALK and MET inhibitor crizotinib, and the MET amplified cells had IC50 100 fold lower than the non MET amplified cell lines. Both crizotinib treatment and siRNA against MET increased apoptotic markers in MET amplified cells but not controls, indicating that crizotinib targeting of amplified MET was inducing the apoptotic effects. Tumors caused by MET amplified EBC-1 cells injected into mice were significantly inhibited with crizotinib treatment, while tumors from non-MET amplified cells showed no substantial effect."	21716144	PubMed		"Tanizaki et al., 2011, J Thorac Oncol"		4	accepted	1566	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1566	https://civicdb.org/links/molecular_profiles/266	FALSE	MET	4233	Amplification		chr7	116672405	116796342			ENST00000318493.6	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A		FALSE
JAK1 Q503*	610	Skin Melanoma	8923		Pembrolizumab		Predictive	Supports	C	Resistance	"Paired tumor samples were analyzed from four patients with metastatic melanoma and initial response with a subsequent relapse under pembrolizumab (PD-1 checkpoint inhibitor) therapy. Baseline biopsies were obtained before therapy initiation with pembrolizumab (before prior vemurafenib treatment in patient 1). A JAK1 Q503* mutation was observed at the time of relapse in patient 1. This mutation was one of 3 new homozygous mutations in this patient (53 new mutations total) and the tumor was described to be genetically similar to the pre-treatment tumor. CRIPR-Cas9 mediated modelling of the JAK1 mutation in a melanoma cell line led to a loss of response to interferon alpha, beta and gamma."	27433843	PubMed		"Zaretsky et al., 2016, N. Engl. J. Med."		4	accepted	1567	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1567	https://civicdb.org/links/molecular_profiles/610	FALSE	JAK1	3716	Q503*		chr1	64855650	64855650	G	A	ENST00000342505.4	75		stop_gained	"NC_000001.10:g.65321333G>A,ENST00000342505.4:c.1507C>T"	2023-01-27 17:04:36 UTC	CA340669637	NONE FOUND	"Q503X,GLN503TER"	FALSE
JAK2 c.1641+1dup	611	Skin Melanoma	8923		Pembrolizumab		Predictive	Supports	C	Resistance	Paired tumor samples were analyzed from four patients with metastatic melanoma and initial response with a subsequent relapse under pembrolizumab (PD-1 checkpoint inhibitor) therapy. Baseline biopsies were obtained before therapy initiation with pembrolizumab. A JAK2 F547 splice site mutation was observed at the time of relapse in patient 2. RNA sequencing revealed an in-frame stop codon after exon 12. The JAK2 mutation was the only homozygous mutation (allele frequency >85%) of 76 new nonsynonymous mutations in patient 2. Cell line modelling of baseline and relapse JAK2 mutational status revealed a loss of response to interferon gamma and  loss of JAK2 protein. This loss of response was also modeled in another cell line.	27433843	PubMed		"Zaretsky et al., 2016, N. Engl. J. Med."		4	accepted	1568	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1568	https://civicdb.org/links/molecular_profiles/611	FALSE	JAK2	3717	c.1641+1dup		chr9	5070053	5070054		G	ENST00000381652.3	75			NC_000009.11:g.5070053_5070054insG	2023-01-27 17:04:37 UTC	CA913189235			FALSE
B2M S14FS	612	Skin Melanoma	8923		Pembrolizumab		Predictive	Supports	C	Resistance	Paired tumor samples were analyzed from four patients with metastatic melanoma and initial response with a subsequent relapse under pembrolizumab (PD-1 checkpoint inhibitor) therapy. Baseline biopsies were obtained before therapy initiation with pembrolizumab. A B2M frame-shift deletion in exon 1 was identified as the only new homozygous mutation among 24 new relapse-specific mutations. Immunohistochemistry revealed loss of MHC1 outer-membrane localization.	27433843	PubMed		"Zaretsky et al., 2016, N. Engl. J. Med."		3	accepted	1569	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1569	https://civicdb.org/links/molecular_profiles/612	FALSE	B2M	567	S14FS		chr15	44711588	44711591	TCTT		ENST00000558401.1	75		frameshift_truncation	"ENST00000558401.1:c.42_45delTCTT,NC_000015.9:g.45003786_45003789del"	2023-01-27 17:04:38 UTC	CA645576720			FALSE
BRAF PPFIBP2::BRAF	613	Skin Melanoma	8923		Trametinib		Predictive	Supports	C	Sensitivity/Response	"Case report of a 47year old female patient with metastatic melanoma (BRAF, NRAS, KIT negative). A PPFIBP2-BRAF fusion was identified from DNA from a brain metastasis (inton 3 of PPFIBP2 fused to intron 10 of BRAF). Trametinib was introduced and anemia and ECOG status improved. Imaging revealed a 90% decrease in extracranial and 19% decrease in intracranial metastases with no new metastases and no progressing sites at 6 weeks. Trametinib was stopped and pembrolizumab introduced at this time. Progressive disease was noted after 5 cycles of pembrolizumab but re-introduction of trametinib did not show an effect."	26072686	PubMed		"Menzies et al., 2015, Pigment Cell Melanoma Res"		2	accepted	1570	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1570	https://civicdb.org/links/molecular_profiles/613	FALSE	BRAF	673	PPFIBP2::BRAF	BRAF Fusions	chr11	7513770	7565767			ENST00000299492.4	75	ENST00000288602.6	transcript_fusion		2023-01-09 21:52:08 UTC		N/A	PPFIBP2-BRAF	FALSE
BRAF PPFIBP2::BRAF	613	Skin Melanoma	8923		Trametinib		Predictive	Supports	C	Sensitivity/Response	"Case report of a 47year old female patient with metastatic melanoma (BRAF, NRAS, KIT negative). A PPFIBP2-BRAF fusion was identified from DNA from a brain metastasis (inton 3 of PPFIBP2 fused to intron 10 of BRAF). Trametinib was introduced and anemia and ECOG status improved. Imaging revealed a 90% decrease in extracranial and 19% decrease in intracranial metastases with no new metastases and no progressing sites at 6 weeks. Trametinib was stopped and pembrolizumab introduced at this time. Progressive disease was noted after 5 cycles of pembrolizumab but re-introduction of trametinib did not show an effect."	26072686	PubMed		"Menzies et al., 2015, Pigment Cell Melanoma Res"		2	accepted	1570	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1570	https://civicdb.org/links/molecular_profiles/613	FALSE	BRAF	673	PPFIBP2::BRAF	BRAF Fusions	chr7	140734479	140781693			ENST00000299492.4	75	ENST00000288602.6	transcript_fusion		2023-01-09 21:52:08 UTC		N/A	PPFIBP2-BRAF	FALSE
BRAF KIAA1549::BRAF	614	Skin Melanoma	8923		Trametinib		Predictive	Supports	C	Sensitivity/Response	"A 65 yr old male patient with metastatic acral lentiginous melanoma (BRAF, NRAS, KIT negative) was found to harbor a KIAA1549-BRAF (intron 15-intron 8) fusion in a subcutaneous metastasis sample after disease progression. Trametinib was started and fatigue and ECOG status improved but imaging revealed slight disease progression after 2 weeks (15 sites measurable, 9 stable, 6 progressive). No new metastases were identified. The patient was switched to pembrolizumab and major disease progression was noted."	26072686	PubMed		"Menzies et al., 2015, Pigment Cell Melanoma Res"		1	accepted	1571	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1571	https://civicdb.org/links/molecular_profiles/614	FALSE	BRAF	673	KIAA1549::BRAF	BRAF Fusions	chr7	138861139	138981318			ENST00000440172.1	75	ENST00000288602.6	transcript_fusion		2023-01-09 21:52:08 UTC		N/A	KIAA1549-BRAF	FALSE
BRAF KIAA1549::BRAF	614	Skin Melanoma	8923		Trametinib		Predictive	Supports	C	Sensitivity/Response	"A 65 yr old male patient with metastatic acral lentiginous melanoma (BRAF, NRAS, KIT negative) was found to harbor a KIAA1549-BRAF (intron 15-intron 8) fusion in a subcutaneous metastasis sample after disease progression. Trametinib was started and fatigue and ECOG status improved but imaging revealed slight disease progression after 2 weeks (15 sites measurable, 9 stable, 6 progressive). No new metastases were identified. The patient was switched to pembrolizumab and major disease progression was noted."	26072686	PubMed		"Menzies et al., 2015, Pigment Cell Melanoma Res"		1	accepted	1571	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1571	https://civicdb.org/links/molecular_profiles/614	FALSE	BRAF	673	KIAA1549::BRAF	BRAF Fusions	chr7	140734479	140787584			ENST00000440172.1	75	ENST00000288602.6	transcript_fusion		2023-01-09 21:52:08 UTC		N/A	KIAA1549-BRAF	FALSE
EGFR Expression	350	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	B	Sensitivity/Response	"Patients with refractory colorectal cancer expressing immunohistochemically detectable EGFR were randomly assigned to receive treatment with cetuximab (n=287) or receive supportive care alone (n=285). Patients receiving cetuximab had increased overall survival (HR=0.77, 95%CI 0.64-0.92; p=0.005), increased progression-free survival (HR=0.68, 95%CI 0.57-0.80; p<0.001), and improved quality of life at 4 months measured by survey on physical deterioration (-5.9 vs -12.5; p=0.03) and global health status (-3.6 vs. -15.2; p<0.001)."	18003960	PubMed		"Jonker et al., 2007, N. Engl. J. Med."	NCT00079066	4	accepted	1572	N/A	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/1572	https://civicdb.org/links/molecular_profiles/350	FALSE	EGFR	1956	Expression		chr7	55019101	55211628			ENST00000275493.2	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
BRAF V600	17	Lung Non-small Cell Carcinoma	3908		Vemurafenib		Predictive	Supports	B	Sensitivity/Response	"Patients with BRAF-V600 mutated cancers were identified (n=122) and clinical response to vemurafenib was evaluated. Of the 20 patients with non-small-cell-lung cancer (17 with BRAF V600E, one with BRAF V600G and one with BRAF V600 unknown status), 19 were evaluable and the response rate to vemurafenib was 42%, tumor regression was observed in 14/19 patients, progression-free survival was 7.3 months, and 12-month overall survival was 66%."	26287849	PubMed		"Hyman et al., 2015, N. Engl. J. Med."	NCT01524978	3	accepted	1574	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/1574	https://civicdb.org/links/molecular_profiles/17	FALSE	BRAF	673	V600	Other BRAF V600's	chr7	140753336	140753337			ENST00000288602.6	75		protein_altering_variant		2023-01-09 21:52:04 UTC		"13,961,448,153,762,800,000,000,000,000,000"	VAL600	FALSE
BRAF V600	17	Langerhans-cell Histiocytosis	2571		Vemurafenib		Predictive	Supports	B	Sensitivity/Response	"Patients with BRAF-V600 mutated cancers were identified (n=122) and clinical response to vemurafenib was evaluated.  Of the 14 patients with Langerhans?cell histiocytosis, 43% of patients had a response to vemurafenib (1 complete and 5 partial responses), disease regression was observed in 12/14 patients, all patients detailed improvement in disease-related symptoms, 0 patients had progressive disease during treatment, 12-month progression free survival was 91%, and overall survival rate was 100%. Among all 18 patients with Erdheim-Chester disease or Langerhans histiocytosis, 94% had BRAF V600E mutations and the remaining 6 percent (1 patient) had an unknown V600 mutation."	26287849	PubMed		"Hyman et al., 2015, N. Engl. J. Med."	NCT01524978	3	accepted	1575	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/1575	https://civicdb.org/links/molecular_profiles/17	FALSE	BRAF	673	V600	Other BRAF V600's	chr7	140753336	140753337			ENST00000288602.6	75		protein_altering_variant		2023-01-09 21:52:04 UTC		"13,961,448,153,762,800,000,000,000,000,000"	VAL600	FALSE
BRAF V600	17	Colorectal Cancer	9256		Vemurafenib		Predictive	Supports	B	Resistance	"Patients with BRAF-V600 mutated cancers were identified (n=122) and clinical response to vemurafenib was evaluated.  Of the 10 patients with colorectal cancer (80% BRAF V600E, 20% V600 unknown status), no responses were observed and overall survival was 9.3 months with a median progression-free survival of 4.5 months."	26287849	PubMed		"Hyman et al., 2015, N. Engl. J. Med."	NCT01524978	3	accepted	1576	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/1576	https://civicdb.org/links/molecular_profiles/17	FALSE	BRAF	673	V600	Other BRAF V600's	chr7	140753336	140753337			ENST00000288602.6	75		protein_altering_variant		2023-01-09 21:52:04 UTC		"13,961,448,153,762,800,000,000,000,000,000"	VAL600	FALSE
ALK Fusion	495	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	B	Sensitivity/Response	"A phase-3 clinical trial evaluated 347 patients with ALK-positive lung cancer.  The study compared crizotinib treatment (n=173) with chemotherapy treatment of either pemetrexed or docetaxel (n=174).  In the crizotinib arm, the response rate was significantly higher (65% vs 20%; P<0.001), the progression-free survival was increased (7.7 months vs. 3.0 months; HR=0.49, 95%CI:14 months-26 months; p<0.001), however, there was no significant improvement in overall survival (HR=1.02; 95%CI:0.68-1.54; P=0.54).  Of the patients on crizotinib treatment, global quality of life was improved relative to baseline when compared to chemotherapy patients (+5 mean change, -5 mean change; P<0.001)."	26466010	PubMed		"2015, N Engl J Med"		3	accepted	1577	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1577	https://civicdb.org/links/molecular_profiles/495	FALSE	ALK	238	Fusion	ALK Fusion	chr2	29192774	29223528			ENST00000389048.3	75		transcript_fusion		2023-01-09 21:52:07 UTC		N/A	REARRANGEMENT	FALSE
CD274 Expression	272	Merkel Cell Carcinoma	3965		Pembrolizumab		Predictive	Does Not Support	B	Sensitivity/Response	"Patients with Merkel Cell Carcinoma (n=26) were enrolled to receive pembrolizumab. Of these patients, 25 were evaluated for response rate to pembrolizumab and PD-L1 (CD274) expression. The response rate to pembrolizumab was 56% (95%CI: 35-76%), however, there was no correlation between PD-L1 expression (cutoff >1%) on tumor cells or on infiltrating immune cells and clinical response to pembrolizumab (P=0.61)."	27093365	PubMed		"Nghiem et al., 2016, N. Engl. J. Med."	NCT02267603	2	accepted	1578	N/A	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1578	https://civicdb.org/links/molecular_profiles/272	FALSE	CD274	29126	Expression		chr9	5450525	5470547			ENST00000381577.3	75		N/A	N/A	2023-01-09 21:52:06 UTC		N/A		FALSE
BRAF V600E	12	Hairy Cell Leukemia	285		Vemurafenib		Predictive	Supports	B	Sensitivity/Response	"Two clinical trials evaluated the effects of vemurafenib in 54 patients with BRAF (V600E) positive hairy-cell leukemia.  The overall response rate was 98% with 19/54 having a complete response and 34/54 having a partial response.  In the Italian study (n=25), the median relapse-free survival was 9 months and in the U.S. study (n=24), rate of progression-free survival was 73% with overall survival rate of 91%."	26352686	PubMed		"Tiacci et al., 2015, N. Engl. J. Med."	NCT01711632	2	accepted	1579	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/1579	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
KRAS G12D	79	Hairy Cell Leukemia	285		Vemurafenib		Predictive	Supports	C	Resistance	"One patient enrolled in a clinical study to evaluate vemurafenib treatment of BRAF V600E mutant hairy-cell leukemia developed resistance to vemurafenib retreatment. 300-gene targeted sequencing of the patients genome revealed activating subclonal KRAS mutations (KRAS G12D, 15.2% allele frequency; KRAS K117N, 1.2%), as well as a RUNX1 A55E mutation (5.9%) that had not been seen prior to vemurafenib treatment or at remission. BRAF V600E allele frequency was detectable (2.4%) at the time of remission but dramatically increased at relapse (64.9%)."	26352686	PubMed		"Tiacci et al., 2015, N. Engl. J. Med."	NCT01711632	2	accepted	1580	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/1580	https://civicdb.org/links/molecular_profiles/79	FALSE	KRAS	3845	G12D	EGFR TKI Resistance	chr12	25245350	25245350	C	T	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.35G>A,NP_004976.2:p.Gly12Asp,NC_000012.11:g.25398284C>T,ENST00000256078.4:c.35G>A"	2023-01-27 17:02:26 UTC	CA122538	12582	"GLY12ASP,RS121913529"	FALSE
MET Overexpression	617	Skin Melanoma	8923		Vemurafenib		Predictive	Supports	B	Resistance	"Whole exome sequencing, transcriptome and methylome alterations in 48 melanoma samples with acquired resistance to BRAFi +/- MEKi therapy compared to patient-matched baseline melanoma tissues were analyzed. 39% of resistant melanomas were not accounted for by any validated mutational mechanism. c-MET was overexpressed in 21 of 48 (44%) resistant samples. Methylome analysis revealed three CpG clusters (C1?) with differential methylation to be negatively correlated with differential c-MET mRNA expression. In nearly all (90%) pairwise comparisons of tumors and cell lines, differential c-MET mRNA expression could be accounted for by at least one differential CpG cluster methylation ( ?10% and FDR adjusted p ?0.05). In contrast, only 48% displayed a concordant differential expression pattern of at least one c-MET transcription factor. In an independent study, c-MET was overexpressed in 8 of 35 (23%) MAPKi-resistant tumors from 7 of 26 (27%) patients. In two human BRAF V600E mutant cell lines, BRAFi treatment led to progressive methylation-expression changes akin to observations across MAPKi-sensitive versus resistant tumors."	26359985	PubMed		"Hugo et al., 2015, Cell"		4	accepted	1581	N/A	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1581	https://civicdb.org/links/molecular_profiles/617	FALSE	MET	4233	Overexpression		chr7	116672405	116796342			ENST00000318493.6	75		N/A	N/A	2023-01-09 21:52:08 UTC		N/A		FALSE
MET Overexpression	617	Uveal Melanoma	6039		Crizotinib		Predictive	Supports	D	Sensitivity/Response	"c-MET and ligand HGF were expressed by 6 uveal melanoma cell lines in-vitro. GNA-mutant cell lines (n=3) showed stronger expression of ligand and receptor as well as more receptor phosphorylation. SiRNA mediated MET-knockdown reduced cell migration but not cell growth. Crizotinib treatment led to a decrease in cell growth and migration. At 25 nmol/L of crizotinib, only the migration of G-protein mutant cells lines and not G-protein wild type cell lines was decreased. Crizotinib did not lead to a reduction in tumor volume of two cell lines in vivo but reduced the formation of macrometastases (luciferase activity, p=0.03)."	24140933	PubMed		"Surriga et al., 2013, Mol. Cancer Ther."		1	accepted	1583	N/A	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1583	https://civicdb.org/links/molecular_profiles/617	FALSE	MET	4233	Overexpression		chr7	116672405	116796342			ENST00000318493.6	75		N/A	N/A	2023-01-09 21:52:08 UTC		N/A		FALSE
MET Overexpression	617	Skin Melanoma	8923		Vemurafenib		Predictive	Does Not Support	B	Resistance	"FFPE tumours from patients enrolled in the BRIM2 (n = 59) and BRIM3 (n = 150) trials of vemurafenib in advanced BRAF mutant (V600E/K) melanoma were analyzed for MET expression (IHC). Pretreatment MET expression was frequent at the ? + cutoff (BRIM3, 31%; BRIM2, 49%), but relatively infrequent at the ? + cutoff (BRIM3, 9%; BRIM2, 19%). Retrospective subset analyses showed that, irrespective of the cutoff used or the treatment arm, MET expression did not show prognostic significance, in terms of objective response rate, progression-free survival, or overall survival."	23802768	PubMed		"Jubb et al., 2013, Histopathology"		3	accepted	1584	N/A	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1584	https://civicdb.org/links/molecular_profiles/617	FALSE	MET	4233	Overexpression		chr7	116672405	116796342			ENST00000318493.6	75		N/A	N/A	2023-01-09 21:52:08 UTC		N/A		FALSE
DNMT3A Mutation	189	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	"In AML patients aged <60years, presence of a DNMT3A mutation associated with inferior CR rate (HR, 0.54; P=.05) and shorter OS (HR, 1.84; P<.001) in multivariate analyses. Mutated DNMT3A associated with shorter RFS (HR 1.38; P=.034) irrespective of patient age."	27288520	PubMed		"Metzeler et al., 2016, Blood"		4	accepted	1585	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/1585	https://civicdb.org/links/molecular_profiles/189	FALSE	DNMT3A	1788	Mutation		chr2	25232976	25342590			ENST00000264709.3	75		transcript_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
DNMT3A Mutation	189	Acute Myeloid Leukemia	9119				Prognostic	Supports	B	Poor Outcome	"DNMT3A mutations associate with adverse overall survival in acute myeloid leukemia patients if they occur in the context of mutated NPM1 and  FLT3-ITD (NPM1-FLT3ITD-DNMT3A phenotype), and in the context of IDH2 codon R140 mutations."	27276561	PubMed		"Papaemmanuil et al., 2016, N. Engl. J. Med."	NCT00146120	4	accepted	1586	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/1586	https://civicdb.org/links/molecular_profiles/189	FALSE	DNMT3A	1788	Mutation		chr2	25232976	25342590			ENST00000264709.3	75		transcript_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
DNMT3A Mutation	189	Acute Myeloid Leukemia	9119		Decitabine		Predictive	Supports	B	Sensitivity/Response	"Among 46 AML patients treated with decitabine, the response rate was 75% (6/8) among DNMT3A mutated and 34% (13/38) among DNMT3A wild-type patients (P=.008)"	22124213	PubMed		"Metzeler et al., 2012, Leukemia"		3	accepted	1587	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/1587	https://civicdb.org/links/molecular_profiles/189	FALSE	DNMT3A	1788	Mutation		chr2	25232976	25342590			ENST00000264709.3	75		transcript_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
MET Amplification	266	Colorectal Cancer	9256		"Vemurafenib,Crizotinib"	Combination	Predictive	Supports	C	Sensitivity/Response	"Case report of a patient with BRAF V600E mutant metastatic colorectal cancer. Combined EGFR and BRAF inhibition (panitumumab and vemurafenib) showed an initial partial response for 4 months. Re-biopsy at the time of progression showed a MET amplification and overexpression (IHC, ISH) but no secondary mutations in candidate resistance genes (EGFR, KRAS, NRAS, MAP2K1). MET amplification was also present in a subset of tumor cells in the pretreatment sample. MET amplification was also identified in 3/17 (18%) chemonaive BRAF V600E colorectal cancer tumor tissues. Overexpression of MET in a BRAF mutant CRC cell line (WiDr) confered resistance to combined vemurafenib and panitumumab. The addition of crizotinib to this combination restored sensitivity in vitro. The patient was started on combined vemurafenib and crizotinib in January 2016 and had a metabolic, clinical and tumor marker response that was ongoing at the time of publication (06/16) without significant toxicity."	27325282	PubMed		"Pietrantonio et al., 2016, Cancer Discov"		4	accepted	1588	N/A	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1588	https://civicdb.org/links/molecular_profiles/266	FALSE	MET	4233	Amplification		chr7	116672405	116796342			ENST00000318493.6	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A		FALSE
BRAF V600E	12	Colorectal Cancer	9256		"Vemurafenib,Panitumumab"	Combination	Predictive	Supports	C	Sensitivity/Response	Case report of a patient with BRAF V600E mutant metastatic colorectal cancer. Combined EGFR and BRAF inhibition (panitumumab and vemurafenib) showed an initial partial response for 4 months with subsequent disease progression.	27325282	PubMed		"Pietrantonio et al., 2016, Cancer Discov"		2	accepted	1589	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/1589	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
POT1 MUTATION	619	Chronic Lymphocytic Leukemia	1040				Prognostic	Supports	B	Poor Outcome	"In previously untreated patients with chronic lymphocytic leukemia, POT1 mutations (N=13) were associated with shorter overall survival than wildtype POT1 (N=148) in univariate and multivariate analysis (HR, 4.0; 95% CI, 1.6-10.1; P = .003) independent of IGHV mutation status, Binet stage, and serum beta-2-microglobulin."	27226433	PubMed		"Herling et al., 2016, Blood"		3	accepted	1590	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1590	https://civicdb.org/links/molecular_profiles/619	FALSE	POT1	25913	MUTATION		chr7	124822386	124929981			ENST00000357628.3	75		"protein_altering_variant,loss_of_function_variant"		2023-01-09 21:52:08 UTC		N/A		FALSE
BRAF V600E	12	Thyroid Gland Papillary Carcinoma	3969		Vemurafenib		Predictive	Supports	B	Sensitivity/Response	"Open-label non-randomised phase 2 trial in patients with recurrent or metastatic BRAF V600E mutant papillary thyroid cancer refractory to radioactive iodine. Patients had (cohort 2) or had not (cohort 1) previously been treated with VEGFR inhibitors. 51 patients were enrolled (26 cohort 1, 25 cohort 2). In cohort 1, partial response was achieved in ten (38.5%) patients. Nine patients achieved stable disease for at least 6 months (35%). Median PFS was 18.2 months and median OS not reached after a median follow-up pf 18.8 months. In cohort 2, six patients (27.3%) achieved a partial response and another six patients achieved stable disease for at least six months. Median PFS was 8.9 months and median OS was 14.4. months."	27460442	PubMed		"Brose et al., 2016, Lancet Oncol."	NCT01286753	3	accepted	1591	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/1591	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
EGFR T790M	34	Lung Non-small Cell Carcinoma	3908		Osimertinib		Predictive	Supports	A	Sensitivity/Response	Osimertinib has been approved for the treatment of EGFR T790M mutant NSCLC.	26729184	PubMed		"Greig, 2016, Drugs"		5	accepted	1592	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/1592	https://civicdb.org/links/molecular_profiles/34	FALSE	EGFR	1956	T790M	EGFR TKI Resistance	chr7	55181378	55181378	C	T	ENST00000275493.2	75		missense_variant	"ENST00000275493.2:c.2369C>T,NM_005228.4:c.2369C>T,NP_005219.2:p.Thr790Met,NC_000007.13:g.55249071C>T"	2023-01-27 17:02:05 UTC	CA090928	16613	"THR790MET,RS121434569"	FALSE
MKI67 EXPRESSION	620	Breast Cancer	1612				Prognostic	Supports	B	Poor Outcome	"A quantitative meta-analysis was performed to assess optimal IHC-calculated cutoff values for the prognostic use of proliferative biomarker Ki67 in breast cancer. The studies included ER positive and negative cases, and the MIB-1 antibody was used in the large majority of studies. 25 studies that employed multivariate analysis were used, and a hazard ratio of 2.05 for overall survival was obtained when Ki67 cutoff value was set at greater or equal to 25%."	26341751	PubMed		"Petrelli et al., 2015, Breast Cancer Res. Treat."		4	accepted	1593	N/A	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1593	https://civicdb.org/links/molecular_profiles/620	FALSE	MKI67	4288	EXPRESSION		chr10	128096659	128126385			ENST00000368654.3	75		N/A		2023-01-09 21:52:08 UTC		N/A		FALSE
MKI67 EXPRESSION	620	Prostate Cancer	10283				Prognostic	Supports	B	Poor Outcome	"293 cases of clinically localized prostate cancer were analyzed on needle-biopsy FFPE tissue microarray, using the MIB-1 antibody against the Ki67 marker of proliferation. IHC staining was used to generate a Ki67 score, and cases were divided into 2 groups with Ki67 score greater or less than 10%. Primary endpoint was death due to prostate cancer. A hazard ratio for high Ki67 values of 3.42 was seen in univariate analysis, and  Ki67 score also added significant predictive value in multivariate analysis, with a hazard ratio of 2.78."	23329234	PubMed		"Fisher et al., 2013, Br. J. Cancer"		3	accepted	1594	N/A	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1594	https://civicdb.org/links/molecular_profiles/620	FALSE	MKI67	4288	EXPRESSION		chr10	128096659	128126385			ENST00000368654.3	75		N/A		2023-01-09 21:52:08 UTC		N/A		FALSE
RB1 Loss-of-function	602	Glioblastoma	3068		Palbociclib		Predictive	Supports	D	Resistance	"A panel of 21 glioblastoma cell lines harboring various mutations was treated with palbociclib. 16 of the cell lines with intact Rb showed decreased proliferation (bromodeoxyuridine incorporation, BrdU flow cytometry) and growth arrest characteristic of senescence, while the 5 cell lines that did not show a palbociclib response had homozygous deletion of Rb. Rb positive and palbociclib responsive GBM cell line U87MG was treated with shRNA against Rb. shRb treated cells showed restoration of cell proliferation (BrdU incorporation) under palbociclib treatment, indicating resistance."	20354191	PubMed		"Michaud et al., 2010, Cancer Res."		3	accepted	1595	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1595	https://civicdb.org/links/molecular_profiles/602	FALSE	RB1	5925	Loss-of-function		chr13	48303775	48481986			ENST00000267163.4	75		loss_of_function_variant		2023-01-09 21:52:08 UTC		N/A		FALSE
KRAS Mutation	332	Pseudomyxoma Peritonei	3559				Prognostic	Supports	B	Poor Outcome	40 patients with pseudomyxoma peritonei underwent panel sequencing after cytoreductive surgery and hypertermic intraperitoneal chemotherapy (HIPEC). KRAS mutations were found in 72% of samples and KRAS mutations were independently associated with PFS (p=0.012) after multivariate analysis.	27502722	PubMed		"Pietrantonio et al., 2016, Ann. Oncol."		3	accepted	1596	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/1596	https://civicdb.org/links/molecular_profiles/332	FALSE	KRAS	3845	Mutation		chr12	25209431	25250803			ENST00000256078.4	75		protein_altering_variant		2023-01-09 21:52:06 UTC		N/A		FALSE
RAD23B EXPRESSION	621	Sarcoma	1115		Vorinostat		Predictive	Supports	D	Sensitivity/Response	"Western blot analyses were performed for HR23b (RAD23B) expression sarcoma cell lines after treatment with vorinostat, belinostat, mocetinostat and entinostat. All HDACi were able to regulate proliferation and apoptosis in vitro. Sensitivity to vorinostat correlated significantly with HR23b protein expression. IHC in 523 patient samples revealed high HR23b expression in 12.5% of sarcomas (among them malignant peripheral nerve sheath tumours, pleomorphic liposarcomas, leiomyosarcomas, dedifferentiated liposarcomas, synovial sarcomas and angiosarcomas) and 23.2% of GIST."	27499916	PubMed		"Angelika Ihle et al., 2016, J Pathol Clin Res"		2	accepted	1597	N/A	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1597	https://civicdb.org/links/molecular_profiles/621	FALSE	RAD23B	5887	EXPRESSION		chr9	107283279	107332194			ENST00000358015.3	75		N/A		2023-01-09 21:52:08 UTC		N/A		FALSE
BRAF V600	17	Colorectal Cancer	9256		"Cetuximab,Vemurafenib"	Combination	Predictive	Does Not Support	B	Sensitivity/Response	"Patients with BRAF-V600 mutated cancers were identified (n=122) and subsequently underwent targeted therapy. 27 patients with colorectal cancer were treated with vemurafenib and cetuximab (N=24 with BRAF V600E mutation, N=3 with V600 unknown status). One response was observed; however, approximately half the patients had tumor regression that did not meet the standard criteria for a partial response. Median progression-free survival and overall survival for patients receiving combination therapy were 3.7 months (95% CI, 1.8 to 5.1) and 7.1 months (95% CI, 4.4 to not reached), respectively. Patients were heavily pretreated, with a median of two lines of previous therapy (range, one to six)."	26287849	PubMed		"Hyman et al., 2015, N. Engl. J. Med."	NCT01524978	2	accepted	1598	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/1598	https://civicdb.org/links/molecular_profiles/17	FALSE	BRAF	673	V600	Other BRAF V600's	chr7	140753336	140753337			ENST00000288602.6	75		protein_altering_variant		2023-01-09 21:52:04 UTC		"13,961,448,153,762,800,000,000,000,000,000"	VAL600	FALSE
CCND1 Amplification	18	Ovarian Cancer	2394		Palbociclib		Predictive	Does Not Support	D	Sensitivity/Response	A panel of 40 ovarian cancer cell lines with varied mutation profiles was assayed for sensitivity to the cdk4/6 inhibitor palbociclib (PD0332991) via measurement of IC50 values for inhibition of proliferation. Large variation in palbociclib sensitivity was observed and cell lines (N=40) were classified as above (resistant) or below (sensitive) the mean log of all IC50 values. 6/18 (33%) of the resistant lines and in only 1/22 (5%) of the sensitive lines (P = 0.017) had CCND1 copy number gain. Increased CCND1 expression was not correlated with sensitivity to palbociclib (p=0.671).	21278246	PubMed		"Konecny et al., 2011, Clin. Cancer Res."		3	accepted	1599	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/1599	https://civicdb.org/links/molecular_profiles/18	FALSE	CCND1	595	Amplification		chr11	69641087	69654474			ENST00000227507.2	75		transcript_amplification	N/A	2023-01-09 21:52:04 UTC		N/A		FALSE
PIK3CA Mutation	307	Breast Cancer	1612		"Ribociclib,Phosphatidylinositide 3-Kinase Inhibitor"	Combination	Predictive	Supports	D	Sensitivity/Response	"Three PI3K mutant breast cancer cell lines were rendered resistant to PI3K inhibitors (BYL719 or GDC-0941), and a panel of 42 inhibitor compounds was tested on the cells for ability to resensitize the cells to PI3K inhibition. The CDK4/6 inhibitor ribociclib (LEE011) acted synergistically with PI3K inhibitor to reduce viability in all three resistant cell lines. In a panel of 12 PIK3CA mutant and 10 wild type cell lines, synergistic effects between P110alpha inhibitor BYL719 and ribociclib were significantly stronger (weighted synergy score calculation, ANOVA, p=0.012) in PIK3CA mutant cells, indicating variant specific sensitization. Mouse xenografts of 4 different PIK3CA mutant breast cancer cells resistant to PI3K inhibitor showed stronger regression under dual PI3K inhibitor and ribociclib treatment than with either treatment alone."	25002028	PubMed		"Vora et al., 2014, Cancer Cell"	NCT01219699	4	accepted	1600	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/1600	https://civicdb.org/links/molecular_profiles/307	FALSE	PIK3CA	5290	Mutation		chr3	179148523	179240093			ENST00000263967.3	75		"transcript_variant,gain_of_function_variant"		2023-01-09 21:52:06 UTC		N/A		FALSE
MAP2K1 C121S	623	Melanoma	1909		Vemurafenib		Predictive	Supports	C	Resistance	A patient with BRAF-mutant melanoma relapsed after treatment with PLX4032 (vemurafenib). The MAP2K1 C121S mutation was identified as a relapse-specific variant and was undetectable in the pre-treatment tumor. In vitro experiments showed that the C121S mutation increased kinase activity and conferred resistance to PLX4032.	21383288	PubMed		"Wagle et al., 2011, J. Clin. Oncol."		4	accepted	1602	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1602	https://civicdb.org/links/molecular_profiles/623	FALSE	MAP2K1	5604	C121S		chr15	66436816	66436816	G	C	ENST00000307102.5	75		missense_variant	"ENST00000307102.5:c.362G>C,NC_000015.9:g.66729154G>C,NM_002755.3:c.362G>C,NP_002746.1:p.Cys121Ser"	2023-01-27 17:04:39 UTC	CA16602455	375980	CYS121SER	FALSE
FGFR3 S249C	624	Transitional Cell Carcinoma	2671		Pazopanib		Predictive	Supports	C	Sensitivity/Response	"Case report of a 67 year old woman with high-grade papillary urothelial carcinoma. The patient underwent chemotherapy and palliative cystectomy followed by tumor progression and pulmonary lesion enlargement. Genomic profiling of the cystectomy specimen identified FGFR3, CCND1 and FGF19 amplification as well as an FGFR3 S249C mutation (allele frequency 58%). Pazopanib was initiated on the basis of these findings and a partial response was achieved for >6 months."	25766722	PubMed		"Palma et al., 2015, Eur. Urol."		2	accepted	1603	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1603	https://civicdb.org/links/molecular_profiles/624	FALSE	FGFR3	2261	S249C		chr4	1801841	1801841	C	G	ENST00000340107.4	75		missense_variant	"NC_000004.11:g.1803568C>G,NM_000142.4:c.746C>G,NP_000133.1:p.Ser249Cys,ENST00000340107.4c.746C>G"	2023-01-27 17:04:39 UTC	CA126380	16339	"SER249CYS,RS121913483"	FALSE
FGFR1 Amplification	263	Breast Cancer	1612		Dovitinib		Predictive	Supports	B	Sensitivity/Response	"Dovitinib was evaluated in-vitro, in xenograft and in a phase 2 study. Dovitinib inhibited proliferation in one FGFR1- and one FGFR2-amplified breast cancer cell lines at higher IC50 values than in 11 nonamplified cell lines. Dovitinib inhibited tumor growth and caused regression in both a FGFR1- and FGFR2-amplified xenograft model. 81 patients were enrolled in the trial and treated with dovitinib. Unconfirmed response or stable disease >6 months was observed in 25% of FGFR1-amplified/HR-positive vs. 3% FGFR1-nonamplified/HR-positive breast cancer patientes. When FGF3 and FGFR2 amplifications were also assessed, a combined FGF-pathway amplified patient group had a higher mean reduction in target lesion size than patients with FGF-non-amplified tumors."	23658459	PubMed		"Andr et al., 2013, Clin. Cancer Res."		2	accepted	1604	N/A	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/1604	https://civicdb.org/links/molecular_profiles/263	FALSE	FGFR1	2260	Amplification		chr8	38411138	38467845			ENST00000425967.3	75		transcript_amplification	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
FGFR2 Amplification	625	Breast Cancer	1612		Dovitinib		Predictive	Supports	B	Sensitivity/Response	"Dovitinib was evaluated in-vitro, in xenograft and in a phase 2 study. Dovitinib inhibited proliferation in one FGFR1- and one FGFR2-amplified breast cancer cell lines at higher IC50 values than in 11 nonamplified cell lines. Dovitinib inhibited tumor growth and caused regression in both a FGFR1- and FGFR2-amplified xenograft model. 81 patients were enrolled in the trial and treated with dovitinib. 2 patients were reported to harbor FGFR2 amplifications and both had a reduction in tumor size of 18.5 and 28.2%, respectively. When FGFR1, FGF3 and FGFR2 amplifications were combined, a combined FGF-pathway amplified patient group had a higher mean reduction in target lesion size than patients with FGF-non-amplified tumors."	23658459	PubMed		"Andr et al., 2013, Clin. Cancer Res."		2	accepted	1605	N/A	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1605	https://civicdb.org/links/molecular_profiles/625	FALSE	FGFR2	2263	Amplification		chr10	121479857	121598403			ENST00000457416.2	75		transcript_amplification	N/A	2023-01-09 21:52:08 UTC		N/A		FALSE
FGF3 Amplification	626	Breast Cancer	1612		Dovitinib		Predictive	Supports	B	Sensitivity/Response	"81 patients were enrolled in a clinical trial with the FGFR inhibitor dovitinib. Four of these patients had FGF3 amplifications (qPCR) and showed tumor reductions of 100%, 30.8%, 23.0%, and 7.5%, respectively. 3 of these 4 patients also had FGFR1 amplifications (? copies by qPCR) and the fourth presented with FGFR1-gene gain (3.4 copies of FGFR1 by qPCR and SISH negative)."	23658459	PubMed		"Andr et al., 2013, Clin. Cancer Res."		2	accepted	1606	N/A	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1606	https://civicdb.org/links/molecular_profiles/626	FALSE	FGF3	2248	Amplification		chr11	69810224	69819024			ENST00000334134.2	75		transcript_amplification		2023-01-09 21:52:08 UTC		N/A		FALSE
PIK3CA Mutation	307	Breast Cancer	1612		"Phosphatidylinositide 3-Kinase Inhibitor,Palbociclib"	Combination	Predictive	Supports	D	Sensitivity/Response	"Three PIK3CA mutant breast cancer cell lines were rendered resistant to PI3K inhibitors (BYL719 or GDC-0941) by chronic exposure. Co-treatment of all three cell lines with PI3K inhibitor and CDK4/6 inhibitor palbociclib resulted in synergistic reductions in cell viability which were not seen with treatment of either compound alone, and resulted in similar suppression to viability as seen in the respective PI3K inhibitor sensitive parental cell lines."	25002028	PubMed		"Vora et al., 2014, Cancer Cell"	NCT01219699	3	accepted	1607	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/1607	https://civicdb.org/links/molecular_profiles/307	FALSE	PIK3CA	5290	Mutation		chr3	179148523	179240093			ENST00000263967.3	75		"transcript_variant,gain_of_function_variant"		2023-01-09 21:52:06 UTC		N/A		FALSE
VHL R200W (c.598C>T)	627	Chuvash Polycythemia	60474	Polycythemia	Ruxolitinib		Predictive	Supports	C	Sensitivity/Response	Homozygous VHL R200W mutations result in a rare congenital polycythemia known as Chuvash polycythemia. Treatment of 3 patients with this disease with the JAK1/2 inhibitor ruxolitinib led to symptomatic and hematologic improvements in all patients through 21-78 weeks of treatment.	27518686	PubMed		"Zhou et al., 2016, N. Engl. J. Med."		4	accepted	1608	Rare Germline	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1608	https://civicdb.org/links/molecular_profiles/627	FALSE	VHL	7428	R200W (c.598C>T)		chr3	10149921	10149921	C	T	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.598C>T,NP_000542.1:p.Arg200Trp,ENST00000256474.2:c.598C>T,NC_000003.11:g.10191605C>T"	2023-01-27 17:04:40 UTC	CA020510	2232	"ARG200TRP,C.598C>T,RS28940298"	FALSE
RB1 PHOSPHORYLATION	628	Breast Cancer	1612		Alpelisib		Predictive	Supports	B	Resistance	"The p110alpha-specific PI3K inhibitor BYL719 (Alpelisib) was used on a panel of five PI3K inhibitor sensitive and five resistant breast cancer cell lines. Sensitive cells (IC50<400nM) showed reduced phospho-Rb (p-Rb) western blot levels in response to BYL719 treatment, while resistant cell lines (IC50>800nM) showed significantly less reduction in p-Rb after BYL719. Paired biopsies before and after treatment were taken from a set of eight patients classified as either responder or non-responder to BYL719. Responder samples showed significantly reduced p-Rb staining after treatment in comparison to non-responder biopsies. In biopsies taken from a group of three responders who progressed, p-Rb levels were increased after progression."	25002028	PubMed		"Vora et al., 2014, Cancer Cell"	NCT01219699	3	accepted	1609	N/A	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1609	https://civicdb.org/links/molecular_profiles/628	FALSE	RB1	5925	PHOSPHORYLATION		chr13	48303775	48481986			ENST00000267163.4	75		N/A		2023-01-09 21:52:08 UTC				FALSE
PIK3CA Mutation	307	Breast Cancer	1612		"Everolimus,MTOR Kinase Inhibitor PP242"	Substitutes	Predictive	Supports	D	Sensitivity/Response	A panel of 31 breast cancer cell lines was tested for sensitivity to mTORC1 inhibitor everolimus and mTORC1/mTORC2 inhibitor PP242. Inhibitor concentrations for 50% survival fraction (SF50) were measured and SF50 less than one micro molar was considered sensitive. PIK3CA mutant cell lines were significantly more sensitive to both everolimus and PP242 than PIK3CA wild type cell lines. Apoptotic indicators and cell cycle analysis indicated that the mTOR inhibitors induced G1 arrest instead of apoptosis in the cell lines.	21358673	PubMed		"Weigelt et al., 2011, Oncogene"		3	accepted	1610	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/1610	https://civicdb.org/links/molecular_profiles/307	FALSE	PIK3CA	5290	Mutation		chr3	179148523	179240093			ENST00000263967.3	75		"transcript_variant,gain_of_function_variant"		2023-01-09 21:52:06 UTC		N/A		FALSE
PTEN Loss	214	Breast Cancer	1612		"MTOR Kinase Inhibitor PP242,Everolimus"	Substitutes	Predictive	Does Not Support	D	Sensitivity/Response	"In a panel of 31 breast cancer cell lines, 11 had loss of PTEN function. Cells were tested for sensitivity to mTORC1 inhibitor everolimus and mTORC1/2 inhibitor PP242, and no significant correlation was found between PTEN status and sensitivity to mTORC inhibition."	21358673	PubMed		"Weigelt et al., 2011, Oncogene"		3	accepted	1611	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/1611	https://civicdb.org/links/molecular_profiles/214	FALSE	PTEN	5728	Loss		chr10	87863113	87971930			ENST00000371953.3	75		loss_of_function_variant	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
PIK3R1 Mutation	629	Breast Cancer	1612		MTOR Kinase Inhibitor PP242		Predictive	Supports	D	Sensitivity/Response	"Sensitivity to mTORC1/2 inhibitor PP242 was assessed in a panel of breast cancer cell lines with various mutation backgrounds. PTEN and PIK3CA mutations were heavily represented in the panel. However, a PTEN and PIK3CA wild type cell line 'HS578T' was found to harbor a mutation in the PI3K regulatory protein PIK3R1. Like PIK3CA mutant cell lines, the PIK3R1 mutant HS578T line was also determined to be sensitive to PP242. Approximately 70% of PIK3CA wild type lines were not sensitive to PP242. This suggests that mutations in the PI3K holoenzyme may be targetable by mTORC1/2 inhibition."	21358673	PubMed		"Weigelt et al., 2011, Oncogene"		2	accepted	1612	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1612	https://civicdb.org/links/molecular_profiles/629	FALSE	PIK3R1	5295	Mutation		chr5	68215720	68301821			ENST00000521381.1	75		"missense_variant,gain_of_function_variant"		2023-01-09 21:52:08 UTC				FALSE
ERBB2 Amplification	302	Breast Cancer	1612		MTOR Kinase Inhibitor PP242		Predictive	Supports	D	Sensitivity/Response	"In a panel of 31 breast cancer cell lines with varied mutation backgrounds, 10 cell lines harbored HER2 (ERBB2) amplification. Sensitivity to the mTORC1/2 inhibitor PP242 was assessed, and 8/10 HER2 positive cell lines were reported to be sensitive (IC50 < 1 micro molar PP242).  8/21 without HER2 amplification were reported as resistant (IC50 > 1 micro molar PP242). This pattern of HER2 positive cell sensitivity was not reported with the rapamycin analog  mTORC1 inhibitor everolimus."	21358673	PubMed		"Weigelt et al., 2011, Oncogene"		2	accepted	1613	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1613	https://civicdb.org/links/molecular_profiles/302	FALSE	ERBB2	2064	Amplification		chr17	39700080	39728662			ENST00000269571.5	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A	OVEREXPRESSION	FALSE
PTEN Loss	214	Endometrial Cancer	1380		Temsirolimus		Predictive	Supports	D	Sensitivity/Response	"A panel of 24 endometroid endometrial cancer (EEC) cell lines was characterized for mutations and 18 cell lines were found to have mutations in PTEN or absence of expression. Cell lines were assessed for sensitivity to mTORC1 allosteric inhibitor temsirolimus, and it was reported that PTEN loss had significant association with temsirolimus sensitivity. ."	23674493	PubMed		"Weigelt et al., 2013, Clin. Cancer Res."		3	accepted	1614	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/1614	https://civicdb.org/links/molecular_profiles/214	FALSE	PTEN	5728	Loss		chr10	87863113	87971930			ENST00000371953.3	75		loss_of_function_variant	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
CD274 Expression	272	Melanoma	1909		"Nivolumab,Ipilimumab"	Combination	Predictive	Does Not Support	B	Sensitivity/Response	"A clinical trial of 86 patients evaluated concurrent (n=53) or sequential (n=33) treatment of ipilimumab (anti-CTLA4) and nivolumab (anti-PD1). In the concurrent regimen cohort, 65% of patients showed clinical activity with no correlation between PD-L1 expression and response (6 of 13 patients were PD-L1 positive versus 9 of 22 patients were PD-L1 negative). In the sequential regimen cohort, 20% of patients had an objective response with a potential correlation between PD-L1 expression and response (4 of 8 patients were PD-L1 positive versus 1 of 13 patients were PD-L1 negative)."	23724867	PubMed		"Wolchok et al., 2013, N. Engl. J. Med."	NCT01024231	3	accepted	1615	N/A	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1615	https://civicdb.org/links/molecular_profiles/272	FALSE	CD274	29126	Expression		chr9	5450525	5470547			ENST00000381577.3	75		N/A	N/A	2023-01-09 21:52:06 UTC		N/A		FALSE
PIK3CA Mutation	307	Endometrial Cancer	1380		Pictilisib		Predictive	Supports	D	Sensitivity/Response	"A panel of 24 endometrioid endometrial cancer (EEC) cell lines was characterized for a set of mutations and sensitivity to pan PI3K class I inhibitor GDC-0941 (pictilisib) was assessed. EEC cell lines with PIK3CA mutations were significantly more sensitive to GDC-0941 (Fishers exact test, two-tailed, P=0.038). Some of the PIK3CA mutant cells contained PTEN and KRAS mutations, but in these cells, these mutations did not effect sensitivity."	23674493	PubMed		"Weigelt et al., 2013, Clin. Cancer Res."		3	accepted	1616	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/1616	https://civicdb.org/links/molecular_profiles/307	FALSE	PIK3CA	5290	Mutation		chr3	179148523	179240093			ENST00000263967.3	75		"transcript_variant,gain_of_function_variant"		2023-01-09 21:52:06 UTC		N/A		FALSE
STK11 D194E	630	Pancreatic Cancer	1793		Everolimus		Predictive	Supports	C	Sensitivity/Response	Case study of a 46-year old male patient with Peutz-Jeghers Syndrome and pancreatic cancer. A germline STK11 D194E mutation was identified with LOH in the tumor sample. phospho-S6 ribosomal protein staining was observed in the tumor indicating mTOR pathway activation. Everolimus treatement led to partial response (but no change in phospho-S6 ribosomal protein staining) for 9 months.	21189378	PubMed		"Klmpen et al., 2011, J. Clin. Oncol."		2	accepted	1617	Rare Germline	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1617	https://civicdb.org/links/molecular_profiles/630	FALSE	STK11	6794	D194E		chr19	1220490	1220490	C	A	ENST00000326873.7	75		"missense_variant,loss_of_heterozygosity"	"NM_000455.4:c.582C>A,NP_000446.1:p.Asp194Glu,ENST00000326873.7:c.582C>A,NC_000019.9:g.1220489C>A"	2023-01-27 17:04:41 UTC	CA023096	185384	"ASP194GLU,RS786202134"	FALSE
STK11 Loss	481	Peutz-Jeghers Syndrome	3852		Sirolimus		Predictive	Supports	D	Sensitivity/Response	"Preclinical study in a mouse model of Peutz-Jeghers syndrome. Heterozygous Lkb1 (STK11) knockout mice were generated and treated with rapamycin after the onset of polyposis at 9 months of age. Rapamycin treatment significantly suppressed polyposis (p=0.017) and pS6 staining (IHC, p=0.011)."	18281551	PubMed		"Wei et al., 2008, Clin. Cancer Res."		1	accepted	1618	Rare Germline	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1618	https://civicdb.org/links/molecular_profiles/481	FALSE	STK11	6794	Loss		chr19	1205741	1228429			ENST00000326873.7	75		loss_of_function_variant		2023-01-09 21:52:07 UTC		N/A		FALSE
STK11 Loss	481	Peutz-Jeghers Syndrome	3852		Sirolimus		Predictive	Supports	D	Sensitivity/Response	Treatment of mice with a heterozygous loss of Lkb1 (STK11) with rapamycin led to reduction in polyp size (p < 0.0001) and number of polyps (p=0.00022). pS6 staining was also reduced after rapamycin treatment. Rapamycin treatment abolished FDG-PET signal on imaging.	19541609	PubMed		"Shackelford et al., 2009, Proc. Natl. Acad. Sci. U.S.A."		1	accepted	1619	Rare Germline	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1619	https://civicdb.org/links/molecular_profiles/481	FALSE	STK11	6794	Loss		chr19	1205741	1228429			ENST00000326873.7	75		loss_of_function_variant		2023-01-09 21:52:07 UTC		N/A		FALSE
STK11 Loss	481	Lung Non-small Cell Carcinoma	3908		"Everolimus,Sirolimus"	Substitutes	Predictive	Does Not Support	D	Sensitivity/Response	Preclinical study in 5 NSCLC cell lines. Two LKB1 (STK11) mutant cell lines had higher basal levels of mTOR activity (pS6K and p4EBP1 levels) but were not more sensitive to mTOR inhibitors (everolimus or rapamycin) than two wild type cell lines. Knockdown of LKB1 in one additional cell line did not lead to an increase in sensitivity to mTOR inhibitors.	26027660	PubMed		"Xiao et al., 2015, Acta Pharmacol. Sin."		3	accepted	1620	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1620	https://civicdb.org/links/molecular_profiles/481	FALSE	STK11	6794	Loss		chr19	1205741	1228429			ENST00000326873.7	75		loss_of_function_variant		2023-01-09 21:52:07 UTC		N/A		FALSE
AKT2 Amplification	631	Lung Adenocarcinoma	3910		"Everolimus,Vandetanib"	Combination	Predictive	Supports	C	Sensitivity/Response	"Case report of a 74-year old woman with EGFR- and ALK-negative lung adenocarcinoma. FISH identified a deletion of 5'RET (FISH, indicating RET-gene rearrangement) and genomic testing confirmed a fusion of KIF5B and RET, as well as an AKT2 gene amplification. The patient was enrolled in a clinical trial with vandetanib and everolimus (NCT01582191) with everolimus used to enhance brain accumulation of vandetanib. After two cycles of therapy a repeat MRI brain showed a decrease in the intracranial disease burden and PET/CT showed systemic response as well."	25982012	PubMed		"Subbiah et al., 2015, Lung Cancer"	NCT01582191	1	accepted	1621	N/A	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1621	https://civicdb.org/links/molecular_profiles/631	FALSE	AKT2	208	Amplification		chr19	40230317	40285395			ENST00000392038.2	75		transcript_amplification		2023-01-09 21:52:08 UTC		N/A		FALSE
RET KIF5B::RET	269	Lung Adenocarcinoma	3910		"Everolimus,Vandetanib"	Combination	Predictive	Supports	C	Sensitivity/Response	"Case report of a 74-year old woman with EGFR- and ALK-negative lung adenocarcinoma. FISH identified a deletion of 5'RET (FISH, indicating RET-gene rearrangement) and genomic testing confirmed a fusion of KIF5B and RET. The patient was enrolled in a clinical trial with vandetanib and everolimus (NCT01582191) with everolimus used to enhance brain accumulation of vandetanib. After two cycles of therapy a repeat MRI brain showed a decrease in the intracranial disease burden and PET/CT showed systemic response as well."	25982012	PubMed		"Subbiah et al., 2015, Lung Cancer"	NCT01582191	2	accepted	1622	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1622	https://civicdb.org/links/molecular_profiles/269	FALSE	RET	5979	KIF5B::RET		chr10	32017143	32056431			ENST00000302418.4	75	ENST00000355710.3	transcript_fusion		2023-01-09 21:52:06 UTC		N/A	KIF5B-RET	FALSE
RET KIF5B::RET	269	Lung Adenocarcinoma	3910		"Everolimus,Vandetanib"	Combination	Predictive	Supports	C	Sensitivity/Response	"Case report of a 74-year old woman with EGFR- and ALK-negative lung adenocarcinoma. FISH identified a deletion of 5'RET (FISH, indicating RET-gene rearrangement) and genomic testing confirmed a fusion of KIF5B and RET. The patient was enrolled in a clinical trial with vandetanib and everolimus (NCT01582191) with everolimus used to enhance brain accumulation of vandetanib. After two cycles of therapy a repeat MRI brain showed a decrease in the intracranial disease burden and PET/CT showed systemic response as well."	25982012	PubMed		"Subbiah et al., 2015, Lung Cancer"	NCT01582191	2	accepted	1622	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1622	https://civicdb.org/links/molecular_profiles/269	FALSE	RET	5979	KIF5B::RET		chr10	43114480	43130351			ENST00000302418.4	75	ENST00000355710.3	transcript_fusion		2023-01-09 21:52:06 UTC		N/A	KIF5B-RET	FALSE
PIK3CA H1047R	107	Her2-receptor Positive Breast Cancer	60079		"Fulvestrant,Everolimus"	Combination	Predictive	Supports	C	Sensitivity/Response	"Case report of a 44-year-old patient with recurrent HER2-positive breast cancer. The primary tumor was HR positive; however, the metastatic tumor was HR negative. The patient was resistant to classical chemotherapeutic agents and anti-HER2 treatment. Thus, the combination of everolimus and fulvestrant was administered. The patient experienced stable disease and PFS of 10 months. Genetic testing of pleural effusion after disease progression revealed a PIK3CA H1047R gene mutation but was positive for PTEN expression (IHC)."	27445490	PubMed		"Sun et al., 2016, Onco Targets Ther"		2	accepted	1623	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/1623	https://civicdb.org/links/molecular_profiles/107	FALSE	PIK3CA	5290	H1047R		chr3	179234297	179234297	A	G	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.3140A>G,NP_006209.2:p.His1047Arg,ENST00000263967.3:c.3140A>G,NC_000003.11:g.178952085A>G"	2023-01-27 17:02:38 UTC	CA123326	13652	"HIS1047ARG,RS121913279"	FALSE
PTEN Expression	309	Her2-receptor Positive Breast Cancer	60079		"Everolimus,Fulvestrant"	Combination	Predictive	Supports	C	Resistance	"Case report of a 44-year-old patient with recurrent HER2-positive breast cancer. The primary tumor was HR positive; however, the metastatic tumor was HR negative. The patient was resistant to classical chemotherapeutic agents and anti-HER2 treatment. Thus, the combination of everolimus and fulvestrant was administered. The patient experienced stable disease and PFS of 10 months. Genetic testing of pleural effusion after disease progression revealed a PIK3CA H1047R gene mutation but was positive for PTEN expression (IHC)."	27445490	PubMed		"Sun et al., 2016, Onco Targets Ther"		1	accepted	1624	N/A	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/1624	https://civicdb.org/links/molecular_profiles/309	FALSE	PTEN	5728	Expression		chr10	87863113	87971930			ENST00000371953.3	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
PIK3CA H1047R	107	Thyroid Gland Cancer	1781		"Temsirolimus,Perifosine"	Substitutes	Predictive	Supports	D	Sensitivity/Response	"Preclinical study in thyroid cancer cell lines. 6 cell lines with alterations of the PI3K/Akt pathway were more sensitive to Akt inhibitor perifosine or MTOR inhibitor temsirolimus than 5 cell lines without genetic alterations in the PI3K/Akt pathway. Among the alterations, One cell line harbored a PIK3CA H1047R mutation. Transfection of another cell line with this mutation led to lower IC50 values to perifosine and temsirolimus than in a cell line transfected with a control vector. Perifosine treatment also increased apoptosis of a thyroid tumor xenograft with PIK3CA H1047R mutation."	19706758	PubMed		"Liu et al., 2009, Cancer Res."		3	accepted	1625	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/1625	https://civicdb.org/links/molecular_profiles/107	FALSE	PIK3CA	5290	H1047R		chr3	179234297	179234297	A	G	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.3140A>G,NP_006209.2:p.His1047Arg,ENST00000263967.3:c.3140A>G,NC_000003.11:g.178952085A>G"	2023-01-27 17:02:38 UTC	CA123326	13652	"HIS1047ARG,RS121913279"	FALSE
PIK3CA E542K	103	Thyroid Gland Cancer	1781		"Perifosine,Temsirolimus"	Substitutes	Predictive	Supports	D	Sensitivity/Response	"Preclinical study in thyroid cancer cell lines. 6 cell lines with alterations of the PI3K/Akt pathway were more sensitive to Akt inhibitor perifosine or MTOR inhibitor temsirolimus than 5 cell lines without genetic alterations in the PI3K/Akt pathway. Among the alterations, One cell line harbored a PIK3CA E542K mutation. Transfection of another cell line with this mutation led to lower IC50 values to perifosine and temsirolimus than in a cell line transfected with a control vector"	19706758	PubMed		"Liu et al., 2009, Cancer Res."		3	accepted	1626	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/1626	https://civicdb.org/links/molecular_profiles/103	FALSE	PIK3CA	5290	E542K		chr3	179218294	179218294	G	A	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.1624G>A,NP_006209.2:p.Glu542Lys,ENST00000263967.3:c.1624G>A,NC_000003.11:g.178936082G>A"	2023-01-27 17:02:37 UTC	CA333572	31944	"GLU542LYS,RS121913273"	FALSE
PTEN R130*	632	Thyroid Gland Cancer	1781		"Perifosine,Temsirolimus"	Substitutes	Predictive	Supports	D	Sensitivity/Response	"Preclinical study in thyroid cancer cell lines. 6 cell lines with alterations of the PI3K/Akt pathway were more sensitive to Akt inhibitor perifosine or MTOR inhibitor temsirolimus than 5 cell lines without genetic alterations in the PI3K/Akt pathway. Among the alterations, one cell line harbored a PTEN allele deletion and R130* mutation. This cell line harbored the lowest IC50 values to both perifosine and temsirolimus and also showed increased apoptosis with perifosine in a xenograft model."	19706758	PubMed		"Liu et al., 2009, Cancer Res."		2	accepted	1627	N/A	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1627	https://civicdb.org/links/molecular_profiles/632	FALSE	PTEN	5728	R130*		chr10	87933147	87933147	C	T	ENST00000371953.3	75		stop_gained	"NM_000314.6:c.388C>T,NP_000305.3:p.Arg130Ter,ENST00000371953.3:c.388C>T,NC_000010.10:g.89692904C>T"	2023-01-27 17:04:42 UTC	CA000433	7819	"R130X,ARG130TER,RS121909224"	FALSE
FBXW7 Loss-of-function	633	Renal Cell Carcinoma	4450		Everolimus		Predictive	Supports	E	Sensitivity/Response	mTOR protein levels were found to underly a circadian 24-hour rhythm regulated by time-dependent Fbxw7-mediated ubiquitination. Survival rates of tumor-bearing mice with everolimus showed time-dependency consistent with mTOR protein levels. It could be hypothesized that FBXW7 loss leads to an increase in mTOR protein levels independent of circadian regulation and higher sensitivity to mTOR inhibitors.	24253377	PubMed		"Okazaki et al., 2014, Cancer Res."		2	accepted	1628	N/A	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1628	https://civicdb.org/links/molecular_profiles/633	FALSE	FBXW7	55294	Loss-of-function		chr4	152321258	152536101			ENST00000281708.4	75		loss_of_function_variant		2023-01-09 21:52:08 UTC		N/A		FALSE
CCNE1 Amplification	187	Estrogen-receptor Positive Breast Cancer	60075		Palbociclib		Predictive	Supports	D	Resistance	"Preclinical study in breast cancer cell lines treated with CDK4/6 inhibitor palbociclib. Cell lines with acquired resistance to palbociclib were developed. Two palbociclib-resistant cell lines were derived through chronic exposure to 1 mol/L palbociclib during 3 to 4 months. Copy number profiling from exome sequencing of MCF-7 and MCF-7pR, confirmed relative amplification of CCNE1. Silencing of CCNE1 or CDK2 alone in MCF-7pR cells had no effect on cell-cycle arrest, but resulted in substantially increased cell-cycle arrest and reduction in cell growth in combination with palbociclib."	27020857	PubMed		"Herrera-Abreu et al., 2016, Cancer Res."		3	accepted	1629	N/A	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/1629	https://civicdb.org/links/molecular_profiles/187	FALSE	CCNE1	898	Amplification		chr19	29811898	29824308			ENST00000262643.3	75		transcript_amplification	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
RB1 M695FS*26	634	Estrogen-receptor Positive Breast Cancer	60075		Palbociclib		Predictive	Supports	D	Resistance	"Preclinical study in breast cancer cell lines treated with CDK4/6 inhibitor palbociclib. Palbociclib-resistant xenografts from one cell line (PDX244) were developed in-vivo. In resistant xenografts, western blot analysis showed a decrease of pRb protein levels in 4 of 7 CDK4/6-acquired resistant tumors and a sustained expression of the E2F target cyclin E2, in contrast to CDK4/6 inhibitor-sensitive PDX244. Genomic characterization of PDX244LR1 showed the acquisition of an RB1 frameshift mutation (RB1 p.M695fs*26)."	27020857	PubMed		"Herrera-Abreu et al., 2016, Cancer Res."		2	accepted	1630	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1630	https://civicdb.org/links/molecular_profiles/634	FALSE	RB1	5925	M695FS*26		chr13	48459810	48459811		A	ENST00000267163.4	75		frameshift_truncation	"ENST00000267163.4:c.2083_2084insA,NC_000013.10:g.49033946_49033947insA"	2023-01-27 17:04:43 UTC	CA913189236	NONE FOUND		FALSE
FBXW7 Mutation	277	Cancer	162		MTOR Inhibitor		Predictive	Supports	B	Sensitivity/Response	"418 patients with advanced cancer were screened for FBXW7 mutations using a multiplex gene panel. 17 FBXW7 mutations were detected (isolated mutation in 2 patients). Ten patients were treated with an mTOR inhibitor with 7 patients having stable disease as best responses and a median time to treatment failure of 2.8 months, two patients had prolonged stable disease of >16 weeks."	24586741	PubMed		"Jardim et al., 2014, PLoS ONE"		2	accepted	1631	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1631	https://civicdb.org/links/molecular_profiles/277	FALSE	FBXW7	55294	Mutation		chr4	152324294	152411562			ENST00000281708.4	75		"protein_altering_variant,loss_of_function_variant"		2023-01-09 21:52:06 UTC				FALSE
FBXW7 Loss-of-function	633	Cancer	162		Sirolimus		Predictive	Supports	D	Sensitivity/Response	"FBXW7 was shown to target mTOR for ubiquitination and degradation.  A reciprocal relationship between FBXW7 or PTEN loss was identified in breast cancer tumors and cell lines (mutual exclusivity of these two events).  In total only 4 out of 450 tumor and cell line samples had concomitant loss of both genes (p=4.9x10^-7). Cell lines (n=5) with FBXW7 mutations or deletions were significantly sensitive to rapamycin and downregulation of FBXW7 (shRNA) increased the sensitivity to rapamycin. In summary, this evidence suggests that FBXW7 may be a biomarker for cancers sensitivity to inhibitors of the mTOR pathway."	18787170	PubMed		"Mao et al., 2008, Science"		4	accepted	1632	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1632	https://civicdb.org/links/molecular_profiles/633	FALSE	FBXW7	55294	Loss-of-function		chr4	152321258	152536101			ENST00000281708.4	75		loss_of_function_variant		2023-01-09 21:52:08 UTC		N/A		FALSE
JUN Overexpression	635	Colorectal Adenocarcinoma	50861		Irbesartan		Predictive	Supports	C	Sensitivity/Response	"A 67-year-old female presents with recurrent metastatic colonic adenocarcinoma.  Immunohistochemical and genetic workup showed overexpression of c-JUN and FOS, which presumably signals through the RAAS pathway. The patient was treated with irbesartan and after 5 weeks of therapy, the CEA value decreased from 18 to 3.1 and there was radiological resolution of the disease.  Her 10 month CEA was 1.4."	27022066	PubMed		"Jones et al., 2016, Ann. Oncol."		2	accepted	1633	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1633	https://civicdb.org/links/molecular_profiles/635	FALSE	JUN	3725	Overexpression		chr1	58780793	58784113			ENST00000371222.2	75		N/A		2023-01-09 21:52:08 UTC		N/A		FALSE
FOS Overexpression	636	Colon Adenocarcinoma	234		Irbesartan		Predictive	Supports	C	Sensitivity/Response	"A 67-year-old female presents with recurrent metastatic colonic adenocarcinoma.  Immunohistochemical and genetic workup showed overexpression of c-JUN and FOS, which presumably signals through the RAAS pathway. The patient was treated with Irbesartan and after 5 weeks of therapy, the CEA value decreased from 18 to 3.1 and there was radiological resolution of the disease.  Her 10 month CEA was 1.4."	27022066	PubMed		"Jones et al., 2016, Ann. Oncol."		2	accepted	1634	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1634	https://civicdb.org/links/molecular_profiles/636	FALSE	FOS	2353	Overexpression		chr14	75278774	75282230			ENST00000303562.4	75		N/A		2023-01-09 21:52:08 UTC		N/A		FALSE
CDKN2A RS3814960	637	Esophagus Squamous Cell Carcinoma	3748				Prognostic	Supports	B	Poor Outcome	"124 esophageal squamous cell carcinoma patients with radical resection were genotyped using MassArray.  The TC/CC genotype of p14ARF at rs3814960 had decreased overall survival (HR = 2.77, 95% CI: 1.33?.75, P = 0.006, Pc = 0.030) and decreased disease-free survival (DFS) (HR = 2.45, 95% CI: 1.30?.61, P = 0.005) compared to patients without this mutation."	27414035	PubMed		"Li et al., 2016, PLoS ONE"		3	accepted	1635	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1635	https://civicdb.org/links/molecular_profiles/637	FALSE	CDKN2A	1029	RS3814960		chr9	21975018	21975018	C	T	ENST00000498124.1	75		5_prime_UTR_exon_variant	"NC_000009.11:g.21975017C>T,NM_000077.4:c.-191G>A"	2023-01-27 17:04:43 UTC	CA12951936	NONE FOUND		FALSE
MDM2 RS34886328	638	Esophagus Squamous Cell Carcinoma	3748				Prognostic	Supports	B	Better Outcome	"124 esophageal squamous cell carcinoma patients with radical resection were genotyped using MassArray.  Patients with the DEL/A +AA genotype of MDM2 rs34886328 had a notably increased overall survival (HR = 0.27, 95% CI: 0.13?.56, P = 4.710?, Pc = 0.003) and increased disease free survival (HR = 0.22, 95% CI: 0.11?.43, P < .0001) when compared to patients without this mutation."	27414035	PubMed		"Li et al., 2016, PLoS ONE"		2	accepted	1636	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1636	https://civicdb.org/links/molecular_profiles/638	FALSE	MDM2	4193	RS34886328		chr12	68841208	68841208	A		ENST00000462284.1	75		3_prime_UTR_truncation		2023-01-27 17:04:44 UTC	CA238461468			FALSE
CBLB RS2305035	639	Lung Non-small Cell Carcinoma	3908				Prognostic	Supports	B	Better Outcome	"Samples from 393 patients with NSCLC were evaluated for 3 SNPs in CBLB (rs1042852, rs2305035, and rs7649466).  Genotypes rs7649466 and rs1042852 were not associated with a change in clinical outcome compared to wildtype however, rs2305035 A genotype  (A/A or A/G) had better local recurrence-free survival, metastasis-free survival and overall survival when compared to GG genotype (n=186)."	26732495	PubMed		"Li et al., 2016, Clin Lung Cancer"		2	accepted	1637	Common Germline	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1637	https://civicdb.org/links/molecular_profiles/639	FALSE	CBLB	868	RS2305035		chr3	105720182	105720182	G	A	ENST00000264122.4	75		"synonymous_variant,polymorphic_sequence_variant"	"NC_000003.11:g.105439026G>A,NM_001321788.1:c.1272C>T,ENST00000264122.4:c.1272C>T"	2023-01-27 17:04:45 UTC	CA2524814	NONE FOUND	D424D	FALSE
PRDM1 MUTATION	640	Diffuse Large B-cell Lymphoma	50745				Prognostic	Supports	B	Poor Outcome	"Biopsies from 520 DLBCL patients treated with R-CHOP were evaluated for PRDM1 mutations or protein (BLIMP-1) expression. Patients with a homozygous deletion of PRDM1 (7%, N=19) had a significantly shorter overall survival and poorer progression free survival compared to heterozygous or wildtype PRDM1."	27568520	PubMed		"Xia et al., 2016, Leukemia"		2	accepted	1638	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1638	https://civicdb.org/links/molecular_profiles/640	FALSE	PRDM1	639	MUTATION		chr6	106086320	106109938			ENST00000369096.4	75		"transcript_variant,loss_of_function_variant"		2023-01-09 21:52:08 UTC		N/A		FALSE
IDH1 Mutation	641	Brain Glioma	60108				Prognostic	Supports	B	Better Outcome	Genomewide analysis of 250 low-grade adult gliomas revealed that patients with a wildtype IDH1/2 had significantly shorter overall survival than those with a mutated IDH gene (HR 7.4; 95%CI: 4.0-13.8). The median survival for patients with low grade gliomas was 1.7 years for patients with wild-type IDH (N=55); 6.3 years for patients with mutated IDH and no 1p/19q co-deletion (N=139); and 8.0 years for patients with IDH mutation and a 1p/19q co-deletion (N=84).	26061751	PubMed		"2015, N. Engl. J. Med."		3	accepted	1639	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1639	https://civicdb.org/links/molecular_profiles/641	FALSE	IDH1	3417	Mutation		chr2	208237079	208251551			ENST00000415913.1	75		transcript_variant		2023-01-09 21:52:08 UTC				FALSE
IDH2 Mutation	566	Brain Glioma	60108				Prognostic	Supports	B	Better Outcome	Genomewide analysis of 250 low-grade adult gliomas revealed that patients with a wildtype IDH1/2 had significantly shorter overall survival than those with a mutated IDH gene (HR 7.4; 95%CI: 4.0-13.8). The median survival for patients with low grade gliomas was 1.7 years for patients with wild-type IDH (N=55); 6.3 years for patients with mutated IDH and no 1p/19q co-deletion (N=139); and 8.0 years for patients with IDH mutation and a 1p/19q co-deletion (N=84).	26061751	PubMed		"2015, N. Engl. J. Med."		3	accepted	1640	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1640	https://civicdb.org/links/molecular_profiles/566	FALSE	IDH2	3418	Mutation		chr15	90083045	90102504			ENST00000330062.3	75		protein_altering_variant		2023-01-09 21:52:07 UTC		N/A		FALSE
MYD88 L265P	420	Lymphoplasmacytic Lymphoma	60901		"IRAK-1/4 Inhibitor,IMG-2005-5"	Substitutes	Predictive	Supports	D	Sensitivity/Response	"In a study of 30 patients with Waldenstrms macroglobulinemia, 87% had MYD88(L265P) mutations.  Waldenstrom macroglobulinemia cells expressing MYD88(L265P) were treated with an MYD88 homodimerization inhibitor or an IRAK 1/4 kinase inhibitor.  The cells showed a decrease in staining of NF-kappa-B p65 phosphorylation."	22931316	PubMed		"Treon et al., 2012, N. Engl. J. Med."		1	accepted	1641	Somatic	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/1641	https://civicdb.org/links/molecular_profiles/420	FALSE	MYD88	4615	L265P		chr3	38141150	38141150	T	C	ENST00000396334.3	75		"missense_variant,gain_of_function_variant"	NC_000003.11:g.38182641T>C	2023-01-27 17:03:40 UTC	CA130043	37055	"LEU265PRO,L273P,LEU273PRO"	FALSE
KRAS Mutation	332	Hepatocellular Carcinoma	684		"Refametinib,Sorafenib"	Combination	Predictive	Supports	B	Sensitivity/Response	"Phase 2 study in Asian patients with unresectable hepatocellular carcinoma. 70 patients received refametinib (BAY 86-9766) plus sorafenib as study treatment. A retrospective biomarker analysis was performed in 69 patients for KRAS, NRAS and BRAF mutations (BEAM technology). 4 patients were identified to harbor RAS mutations. 3 of whom still received study treatment at the cutoff date used for the final data analysis. These 3 patients had achieved confirmed PR, with duration responses ranging from 128 to 382 days. The fourth patient with a RAS mutation discontinued study treatment after 41 days on therapy due to PD. An overall of 4 (6 by modified RECIST) patients achieved PR."	25294897	PubMed		"Lim et al., 2014, Clin. Cancer Res."	NCT01204177	2	accepted	1642	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/1642	https://civicdb.org/links/molecular_profiles/332	FALSE	KRAS	3845	Mutation		chr12	25209431	25250803			ENST00000256078.4	75		protein_altering_variant		2023-01-09 21:52:06 UTC		N/A		FALSE
PRKACA DNAJB1::PRKACA	31	Mixed Fibrolamellar Hepatocellular Carcinoma	80182				Diagnostic	Supports	C	Positive	"A DNAJB1:PRKACA fusion transcript was detected at very high expression levels by RNA-Seq in a case of mixed fibrolamellar hepatocellular carcinoma. Subsequent analysis revealed the presence of this fusion in all primary and metastatic samples, including those with mixed or conventional HCC pathology. A second case of mFL-HCC confirmed that the fusion was detectable in conventional components. An expanded screen of 112 additional HCC samples and 44 adjacent non-tumor liver samples was positive for a third case of HCC with both conventional and fibrolamellar features but negative for all conventional HCC and adjacent non-tumor liver samples."	27029710	PubMed		"Griffith et al., 2016, Ann. Oncol."		4	accepted	1643	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/1643	https://civicdb.org/links/molecular_profiles/31	FALSE	PRKACA	5566	DNAJB1::PRKACA		chr19	14518139	14518420			ENST00000254322.2	75	ENST00000308677.4	transcript_fusion		2023-01-09 21:52:04 UTC		N/A	DNAJB1-PRKACA	FALSE
PRKACA DNAJB1::PRKACA	31	Mixed Fibrolamellar Hepatocellular Carcinoma	80182				Diagnostic	Supports	C	Positive	"A DNAJB1:PRKACA fusion transcript was detected at very high expression levels by RNA-Seq in a case of mixed fibrolamellar hepatocellular carcinoma. Subsequent analysis revealed the presence of this fusion in all primary and metastatic samples, including those with mixed or conventional HCC pathology. A second case of mFL-HCC confirmed that the fusion was detectable in conventional components. An expanded screen of 112 additional HCC samples and 44 adjacent non-tumor liver samples was positive for a third case of HCC with both conventional and fibrolamellar features but negative for all conventional HCC and adjacent non-tumor liver samples."	27029710	PubMed		"Griffith et al., 2016, Ann. Oncol."		4	accepted	1643	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/1643	https://civicdb.org/links/molecular_profiles/31	FALSE	PRKACA	5566	DNAJB1::PRKACA		chr19	14091688	14107409			ENST00000254322.2	75	ENST00000308677.4	transcript_fusion		2023-01-09 21:52:04 UTC		N/A	DNAJB1-PRKACA	FALSE
SMAD4 Deletion	642	Colorectal Cancer	9256		Fluorouracil		Predictive	Supports	B	Resistance	"A retrospective study with 202 colorectal cancer patients found that SMAD4 deletion was associated with worse outcomes during 5-fluorouracil treatment. The hazard ratio for disease-free survival was 2.89 times greater for patients with SMAD4 deletion as compared to those  with normal SMAD4 diploidy (P = .045).  For overall survival, the hazard ratio was 3.23 times greater for SMAD4 deletion (P = .056)."	12237773	PubMed		"Boulay et al., 2002, Br. J. Cancer"		3	accepted	1644	N/A	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1644	https://civicdb.org/links/molecular_profiles/642	FALSE	SMAD4	4089	Deletion		chr18	51030213	51085039			ENST00000342988.3	75		transcript_ablation		2023-01-09 21:52:08 UTC				FALSE
LRP1B DELETION	643	Glioblastoma	3068				Prognostic	Supports	B	Poor Outcome	"A retrospective study of 178 glioblastoma patients found that LRP1B deletion (complete transcript, N=4 or focal transcript deletion of >150kb, N=13) was associated with a lower progress free survival (6.4 months vs. 10.1 months; P = 0.004) and overall free survival (13.4 months vs. 17.8 months; P = 0.001). Multivariate analysis adjusting for age and type of surgery also supported LRP1B deletion being associated with a higher hazard ratio."	26428308	PubMed		"Tabouret et al., 2015, J. Neurol. Sci."		4	accepted	1645	N/A	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1645	https://civicdb.org/links/molecular_profiles/643	FALSE	LRP1B	53353	DELETION		chr2	140231423	142131701			ENST00000389484.3	75		transcript_ablation		2023-01-09 21:52:08 UTC				FALSE
TERT C228T	244	Thyroid Gland Cancer	1781				Diagnostic	Supports	B	Positive	"In 308 thyroid fine-needle aspiration biopsies, 0 of the 179 benign tumors displayed either the C228T or the C250T TERT promoter mutation; however, 9 of the 129 differentiated thyroid cancers had either of these mutations. The biomarker displayed 100% diagnostic specificity and 7% sensitivity."	25121551	PubMed		"Liu et al., 2014, Endocr. Relat. Cancer"		3	accepted	1646	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/1646	https://civicdb.org/links/molecular_profiles/244	FALSE	TERT	7015	C228T		chr5	1295113	1295113	G	A	ENST00000310581.5	75		regulatory_region_variant	NC_000005.9:g.1295228G>A	2023-01-27 17:03:12 UTC	CA557858711	NONE FOUND	-124C>T	FALSE
ATRX Underexpression	644	Malignant Astrocytoma	3069		"PCV Regimen,Temozolomide"	Substitutes	Predictive	Supports	B	Sensitivity/Response	"A retrospective tumor sample study found that the loss of ATRX expression (less than 10% of nuclei) in IDH-mutant astrocytomas treated with temozolomide or a combination of procarbazine, lomustine and vincristine (PCV) was associated with better outcomes. Patients with IDH-mutant tumors and ATRX expression loss (n=40) experienced greater time to treatment failure (55.6 months vs. 31.8 months; P = 0.0168) and a greater progression-free survival (37.1 months vs. 18.1 months; P = 0.038) compared to patients with IDH-mutant tumors with ATRX expression (n=9)."	23904111	PubMed		"Wiestler et al., 2013, Acta Neuropathol."		3	accepted	1647	N/A	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1647	https://civicdb.org/links/molecular_profiles/644	FALSE	ATRX	546	Underexpression		chrX	77504878	77786216			ENST00000373344.5	75		N/A		2023-01-09 21:52:08 UTC		N/A	UNDEREXPRESSION	FALSE
ATRX Underexpression	644	Glioblastoma	3068				Prognostic	Supports	D	Poor Outcome	"In a glioblastoma mouse model induced by NRAS and p53 knockdown, ATRX loss was associated with a decreased median survival (69 days vs. 84 days; P = .0032). Also, the tumors grew to a larger size at earlier time points. ATRX loss was also associated with greater microsatellite instability."	26936505	PubMed		"Koschmann et al., 2016, Sci Transl Med"		4	accepted	1648	N/A	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1648	https://civicdb.org/links/molecular_profiles/644	FALSE	ATRX	546	Underexpression		chrX	77504878	77786216			ENST00000373344.5	75		N/A		2023-01-09 21:52:08 UTC		N/A	UNDEREXPRESSION	FALSE
CALR EXON 9 FRAMESHIFT	555	Myelofibrosis	4971				Prognostic	Supports	B	Better Outcome	"In patients with primary myelofibrosis CALR mutations were associated with improved median survival. For 277 patients, CALR mutated, ASXL1 wildtype patients (median survival, 10.4 years, N=46); CALR wildtype, ASXL1 mutant patients (2.3 years; HR, 5.9; 95% CI, 3.5?0.0, N=62); and either CALR/ASXL1wildtype or CALR/ASXL1 mutant patients (5.8 years; HR, 2.5; 95% CI, 1.5?.0, N=169). These results were independent of DIPSS-plus risk but added prognostic information to this risk categorization. These results were also validated in an independent cohort of 293 patients."	24496303	PubMed		"Tefferi et al., 2014, Leukemia"		4	accepted	1649	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1649	https://civicdb.org/links/molecular_profiles/555	FALSE	CALR	811	EXON 9 FRAMESHIFT		chr19	12943713	12943913			ENST00000316448.5	75		exon_variant		2023-01-09 21:52:07 UTC				FALSE
AURKA Overexpression	181	Ovarian Serous Carcinoma	50933		Platinum Compound		Predictive	Supports	B	Resistance	A study of 41 patients with high-grade ovarian serous carcinoma found that high expression levels of AURKA correlated with poorer overall survival (P??.001; HR 0.14) and platinum therapy resistance (P < 0.001). Expression of AURKA was measured using immunohistochemical techniques on tumor samples.	27209210	PubMed		"Mignogna et al., 2016, J Ovarian Res"		3	accepted	1650	N/A	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/1650	https://civicdb.org/links/molecular_profiles/181	FALSE	AURKA	6790	Overexpression		chr20	56369390	56392337			ENST00000395913.3	75		N/A		2023-01-09 21:52:05 UTC		N/A		FALSE
MET Exon 14 Skipping Mutation	320	Lung Adenocarcinoma	3910		Crizotinib		Predictive	Supports	C	Sensitivity/Response	Case report of a patient with lung adenocarcinoma harboring a MET exon 14 skipping mutation and major response to crizotinib.	26845194	PubMed		"Shea et al., 2016, J Thorac Oncol"		2	accepted	1651	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/1651	https://civicdb.org/links/molecular_profiles/320	FALSE	MET	4233	Exon 14 Skipping Mutation		chr7	116771849	116771989			ENST00000318493.6	75		exon_loss_variant		2023-01-09 21:52:06 UTC		N/A		FALSE
MET D1228N	645	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	C	Resistance	Case report of a patient with NSCLC harboring a MET exon 14 skipping mutation and initial response to crizotinib. A second biopsy at the time of progression revealed an acquired MET D1228N mutation.	27343442	PubMed		"Heist et al., 2016, J Thorac Oncol"		2	accepted	1652	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1652	https://civicdb.org/links/molecular_profiles/645	FALSE	MET	4233	D1228N		chr7	116783353	116783353	G	A	ENST00000397752.3	75		missense_variant	"NC_000007.13:g.116423407G>A,NC_000007.14:g.116783353G>A,ENST00000397752.8:c.3682G>A,ENSP00000380860.3:p.Asp1228Asn,ENSP00000380860.3:p.Asp1228Asn,ENST00000397752.7:c.3682G>A,NM_000245.4:c.3682G>A,NP_000236.2:p.Asp1228Asn,NP_000236.2:p.Asp1228Asn,NM_000245.3:c.3682G>A"	2023-01-27 17:04:46 UTC	CA257000	13884	"D1246N,ASP1246ASN,ASP1228ASN"	FALSE
AURKA EXPRESSION	158	Esophagus Squamous Cell Carcinoma	3748		"Radiation Therapy,Cisplatin,Fluorouracil"	Combination	Predictive	Supports	B	Sensitivity/Response	"A retrospective study examining the expression of AURKA in tumor samples of 78 esophageal squamous cell carcinoma patients found that positive expression of AURKA (>10% of cells by IHC) was correlated with increased clinical response to chemoradiation therapy consisting of cisplatin, 5-fluorouracil, and 40 gy radiation (P = 0.0003)."	25924824	PubMed		"Tamotsu et al., 2015, BMC Cancer"		3	accepted	1653	N/A	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/1653	https://civicdb.org/links/molecular_profiles/158	FALSE	AURKA	6790	EXPRESSION		chr20	56369390	56392337			ENST00000395913.3	75		N/A		2023-01-09 21:52:05 UTC		N/A		FALSE
CASP8 D302H	646	Neuroblastoma	769				Prognostic	Supports	B	Poor Outcome	"21 SNPs were analyzed using qRT-PCR genotyping assays in 500 Neuroblastoma tumor samples, and the CASP8 D302H missense variant was found to be associated with worse overall survival (P = 0.0006; Q = 0.049) and worse event-free survival (P = 0.0002; Q = 0.042) in those samples that had MYCN amplification (N = 94)."	25502557	PubMed		"Rihani et al., 2014, PLoS ONE"		3	accepted	1654	Common Germline	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1654	https://civicdb.org/links/molecular_profiles/646	FALSE	CASP8	841	D302H		chr2	201284866	201284866	G	C	ENST00000264275.5	75		"missense_variant,polymorphic_sequence_variant"	"NM_001228.4:c.904G>C,NP_001219.2:p.Asp302His,ENST00000264275.5:c.904G>C,NC_000002.11:g.202149589G>C"	2023-01-27 17:04:46 UTC	CA119051	7762	"RS1045485,D285H,ASP302HIS"	FALSE
AXL EXPRESSION	647	Esophagus Squamous Cell Carcinoma	3748				Prognostic	Supports	B	Poor Outcome	"Immunohistochemical analysis of tumors from 116 esophageal squamous cell carcinoma found that expression of AXL was associated with increased progression of the tumor (P < 0.0001), increased risk of death (HR = 2.09 ; P = 0.028), and increased risk of distant metastasis (OR = 3.96 ; P = 0.029)."	27172793	PubMed		"Hsieh et al., 2016, Oncotarget"		4	accepted	1655	N/A	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1655	https://civicdb.org/links/molecular_profiles/647	FALSE	AXL	558	EXPRESSION		chr19	41219203	41261766			ENST00000301178.4	75		N/A	N/A	2023-01-09 21:52:08 UTC		N/A		FALSE
GAS6 EXPRESSION	648	Prostate Cancer	10283		Docetaxel		Predictive	Supports	D	Resistance	"Prostate Cancer (PCa) cell lines were either cultured alone, co-cultured with osteoblasts expressing GAS6, or cultured in the presence of media with GAS6 to examine their response to therapy with docetaxel. Docetaxel efficiently induced apoptosis in the cells cultured without any GAS6, but it was not able to do so in the cells that were in media with GAS6 present or that were co-cultured with osteoblasts expressing GAS6. PCa cells in the presence of GAS6 were found to be in G1 phase for a greater duration which may help explain the increased resistance to docetaxel."	27153245	PubMed		"Lee et al., 2016, J. Cell. Biochem."		3	accepted	1656	N/A	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/1656	https://civicdb.org/links/molecular_profiles/648	FALSE	GAS6	2621	EXPRESSION		chr13	113820551	113864073			ENST00000357389.3	75		N/A		2023-01-09 21:52:08 UTC		N/A		FALSE
GAS6 EXPRESSION	648	Oral Squamous Cell Carcinoma	50866				Prognostic	Supports	B	Poor Outcome	"128 patients with oral squamous cell carcinoma (OSCC) and 145 normal control subjects were evaluated for the concentration of GAS6 in their plasma serum. OSCC patients were found to be associated with a significantly higher level of GAS6 in serum ( P = .05 ). Furthermore, within the OSCC patients, increased GAS6 serum concentration was associated with higher stage tumors ( P < .01) , poorly differentiated tumors ( P < .01 ), and increased lymph node metastasis ( OR = 2.79 ; CI = 1.72-4.48 )."	26207647	PubMed		"Jiang et al., 2015, PLoS ONE"		4	accepted	1657	N/A	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/1657	https://civicdb.org/links/molecular_profiles/648	FALSE	GAS6	2621	EXPRESSION		chr13	113820551	113864073			ENST00000357389.3	75		N/A		2023-01-09 21:52:08 UTC		N/A		FALSE
ETV4 Overexpression	649	Prostate Cancer	10283				Prognostic	Supports	B	Poor Outcome	"Immunohistochemical methods were used to evaluate the expression levels of ETV4 in prostate cancer (PCa) tumor samples. Increased expression of ETV4 was associated with greater Gleason score (P = 0.045) , pathological tumor stage (P = 0.041),  and an unfavorable prognosis (P = 0.040)."	25544710	PubMed		"Qi et al., 2015, Tumour Biol."		3	accepted	1658	N/A	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/1658	https://civicdb.org/links/molecular_profiles/649	FALSE	ETV4	2118	Overexpression		chr17	43527844	43546432			ENST00000319349.5	75		N/A		2023-01-09 21:52:08 UTC		N/A		FALSE
STAG2 Underexpression	418	Melanoma	1909		Vemurafenib		Predictive	Supports	D	Resistance	A375 melanoma cells containing an inducible shRNA for STAG2 were grown as xenograft tumors in nude mice. The mice in which STAG2 was silenced had tumors that were less sensitive to vemurafenib-induced tumor shrinkage than the tumors of the control mice (P < .01).	27500726	PubMed		"Shen et al., 2016, Nat. Med."		4	accepted	1659	N/A	2023-02-01 18:07:29 UTC	https://civicdb.org/links/evidence_items/1659	https://civicdb.org/links/molecular_profiles/418	FALSE	STAG2	10735	Underexpression		chrX	123961718	124102656			ENST00000371157.3	75		N/A		2023-01-09 21:52:07 UTC		N/A		FALSE
STAG3 Underexpression	650	Melanoma	1909		Vemurafenib		Predictive	Supports	D	Resistance	A375 melanoma cells containing an inducible shRNA for STAG3 were grown as xenograft tumors in nude mice. The mice in which STAG3 was silenced had tumors that were less sensitive to vemurafenib-induced tumor shrinkage than the tumors of the control mice (P < .01).	27500726	PubMed		"Shen et al., 2016, Nat. Med."		4	accepted	1660	N/A	2023-02-01 18:08:05 UTC	https://civicdb.org/links/evidence_items/1660	https://civicdb.org/links/molecular_profiles/650	FALSE	STAG3	10734	Underexpression		chr7	100177563	100214380			ENST00000426455.1	75		N/A		2023-01-09 21:52:08 UTC		N/A		FALSE
MAP2K1 Q56_V60del	651	Ovarian Serous Carcinoma	50933		Selumetinib		Predictive	Supports	C	Sensitivity/Response	Case report of a 51-year old patient with recurrent low-grade serous ovarian cancer. Selumetinib treatment in a phase-II trial led to a complete and durable response > 5 years. Sequencing (MSK-IMPACT Panel) was performed on the patients tumor and germline and identified a 15-bp in-frame deletion of MAP2K1 (8.3% of tumor reads but 0% in germline). In-silico modelling suggested loss of negative feedback on kinase activity from this deletion.In-vitro expression of the MEK1 Q56_V60 deletion as well as the previously characterized MEK1 F53L mutation in 293H cells resulted in elevated levels of phosphorylated ERK and phosphorylated ribosomal protein S6 kinase as compared with wild-type MEK1 as well as increased colony formation and tumor growth in-vivo. Selumetinib treatment of MEK1-transfected cells confirmed retained sensitivity to MEK inhibition and inhibition of colony formation.	26324360	PubMed		"Grisham et al., 2015, J. Clin. Oncol."		4	accepted	1661	Somatic	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/1661	https://civicdb.org/links/molecular_profiles/651	FALSE	MAP2K1	5604	Q56_V60del		chr15	66435111	66435125	CCAGAAGCAGAAGGT		ENST00000307102.5	75		inframe_deletion	"ENST00000307102.5:c.165_179del,NC_000015.9:g.66727449_66727463del"	2023-01-27 17:04:47 UTC	CA912992484	NONE FOUND		FALSE
BRAF BRAF::CUL1	652	Ovarian Serous Carcinoma	50933		Mitogen-Activated Protein Kinase Kinase Inhibitor		Predictive	Supports	C	Sensitivity/Response	"One patient with low-grade serous ovarian cancer had an in-frame fusion between the BRAF kinase domain and CUL1 identified by panel sequencing (MSK-IMPACT), with expression confirmed by whole-transcriptome sequencing. This patient with metastatic disease after treatment with carboplatin and paclitaxel, was enrolled onto a study of paclitaxel in combination with an oral MEK inhibitor and achieved a CR. She continued to receive therapy for 7 months, until discontinuation because of the development of pneumonitis. At publication, sustained CR had lasted > 18 months."	26324360	PubMed		"Grisham et al., 2015, J. Clin. Oncol."		2	accepted	1662	Somatic	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/1662	https://civicdb.org/links/molecular_profiles/652	FALSE	BRAF	673	BRAF::CUL1	BRAF Fusions	chr7	140734479	140787584			ENST00000288602.6	75	ENST00000602748.1	transcript_fusion		2023-01-09 21:52:08 UTC		N/A	BRAF-CUL1	FALSE
BRAF BRAF::CUL1	652	Ovarian Serous Carcinoma	50933		Mitogen-Activated Protein Kinase Kinase Inhibitor		Predictive	Supports	C	Sensitivity/Response	"One patient with low-grade serous ovarian cancer had an in-frame fusion between the BRAF kinase domain and CUL1 identified by panel sequencing (MSK-IMPACT), with expression confirmed by whole-transcriptome sequencing. This patient with metastatic disease after treatment with carboplatin and paclitaxel, was enrolled onto a study of paclitaxel in combination with an oral MEK inhibitor and achieved a CR. She continued to receive therapy for 7 months, until discontinuation because of the development of pneumonitis. At publication, sustained CR had lasted > 18 months."	26324360	PubMed		"Grisham et al., 2015, J. Clin. Oncol."		2	accepted	1662	Somatic	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/1662	https://civicdb.org/links/molecular_profiles/652	FALSE	BRAF	673	BRAF::CUL1	BRAF Fusions	chr7	148698645	148760496			ENST00000288602.6	75	ENST00000602748.1	transcript_fusion		2023-01-09 21:52:08 UTC		N/A	BRAF-CUL1	FALSE
BRAF ZKSCAN1::BRAF	653	Melanoma	1909		Trametinib		Predictive	Supports	C	Sensitivity/Response	"Analysis of BRAF fusions in 20,573 tumors, across 12 distinct tumor types. BRAF fusions were identified in 55 (0.3%) patients and enriched in spitzoid melanoma, pilocytic astrocytomas, pancreatic acinar and papillary thyroid cancers. Clinical data were available for two patients. Among them one 46-year old woman with spitzoid melanoma that  harbored  a ZKSCAN1-BRAF fusion responded to treatment with the MEK inhibitor trametinib. Subcutaneous  tumor  nodules  exhibited  clinical responses within 14 days of therapy, and her dominant bulky right lung metastases showed significant response by Day 45. Subsequent robotic-assisted lobectomy was able to remove the previously unresectable tumor with clean surgical margins."	26314551	PubMed		"Ross et al., 2016, Int. J. Cancer"		3	accepted	1663	Somatic	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/1663	https://civicdb.org/links/molecular_profiles/653	FALSE	BRAF	673	ZKSCAN1::BRAF	BRAF Fusions	chr7	100015599	100029952			ENST00000426572.1	75	ENST00000288602.6	transcript_fusion		2023-01-09 21:52:08 UTC		N/A	ZKSCAN1-BRAF	FALSE
BRAF ZKSCAN1::BRAF	653	Melanoma	1909		Trametinib		Predictive	Supports	C	Sensitivity/Response	"Analysis of BRAF fusions in 20,573 tumors, across 12 distinct tumor types. BRAF fusions were identified in 55 (0.3%) patients and enriched in spitzoid melanoma, pilocytic astrocytomas, pancreatic acinar and papillary thyroid cancers. Clinical data were available for two patients. Among them one 46-year old woman with spitzoid melanoma that  harbored  a ZKSCAN1-BRAF fusion responded to treatment with the MEK inhibitor trametinib. Subcutaneous  tumor  nodules  exhibited  clinical responses within 14 days of therapy, and her dominant bulky right lung metastases showed significant response by Day 45. Subsequent robotic-assisted lobectomy was able to remove the previously unresectable tumor with clean surgical margins."	26314551	PubMed		"Ross et al., 2016, Int. J. Cancer"		3	accepted	1663	Somatic	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/1663	https://civicdb.org/links/molecular_profiles/653	FALSE	BRAF	673	ZKSCAN1::BRAF	BRAF Fusions	chr7	140734479	140783157			ENST00000426572.1	75	ENST00000288602.6	transcript_fusion		2023-01-09 21:52:08 UTC		N/A	ZKSCAN1-BRAF	FALSE
BRAF KIAA1549::BRAF	614	Spindle Cell Sarcoma	4235		"Bevacizumab,Temsirolimus,Sorafenib"	Combination	Predictive	Supports	C	Sensitivity/Response	"A patient with a malignant spindle cell tumor of the chest wall treated as a soft tissue sarcoma was identified to harbor a KIAA1549-BRAF fusion. This patient responded to treatment with the pan-kinase inhibitor sorafenib in combination with bevacizumab and temsirolimus, achieving stable disease after 2 cycles extending into 11 cycles at which time she expired due to co-morbidities (acute myocardial infarction, hypotension). Of note, sequencing of 236 cancer-related genes identified CDKN2A A68fs*51, SUFU E283fs*3, MAP3K1 N325fs*3 and homozygous deletion of PTEN as well."	24422672	PubMed		"Subbiah et al., 2014, J Hematol Oncol"	NCT01187199	2	accepted	1664	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1664	https://civicdb.org/links/molecular_profiles/614	FALSE	BRAF	673	KIAA1549::BRAF	BRAF Fusions	chr7	138861139	138981318			ENST00000440172.1	75	ENST00000288602.6	transcript_fusion		2023-01-09 21:52:08 UTC		N/A	KIAA1549-BRAF	FALSE
BRAF KIAA1549::BRAF	614	Spindle Cell Sarcoma	4235		"Bevacizumab,Temsirolimus,Sorafenib"	Combination	Predictive	Supports	C	Sensitivity/Response	"A patient with a malignant spindle cell tumor of the chest wall treated as a soft tissue sarcoma was identified to harbor a KIAA1549-BRAF fusion. This patient responded to treatment with the pan-kinase inhibitor sorafenib in combination with bevacizumab and temsirolimus, achieving stable disease after 2 cycles extending into 11 cycles at which time she expired due to co-morbidities (acute myocardial infarction, hypotension). Of note, sequencing of 236 cancer-related genes identified CDKN2A A68fs*51, SUFU E283fs*3, MAP3K1 N325fs*3 and homozygous deletion of PTEN as well."	24422672	PubMed		"Subbiah et al., 2014, J Hematol Oncol"	NCT01187199	2	accepted	1664	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1664	https://civicdb.org/links/molecular_profiles/614	FALSE	BRAF	673	KIAA1549::BRAF	BRAF Fusions	chr7	140734479	140787584			ENST00000440172.1	75	ENST00000288602.6	transcript_fusion		2023-01-09 21:52:08 UTC		N/A	KIAA1549-BRAF	FALSE
EGFR L858R	33	Lung Non-small Cell Carcinoma	3908		Gefitinib		Predictive	Supports	B	Sensitivity/Response	"90 NSCLC patients with stage IIIB/IV chemotherapy-resistant tumors were treated with gefitinib, and the L858R EGFR mutation was associated with longer time to treatment failure than those with wild-type EGFR (median 9.1 versus 2.1). In multivariate analysis, L858R mutations plus adenocarcinoma was a significant predictive factor for time to treatment failure (HR = 0.1030; P = .0004)."	18509184	PubMed		"Yang et al., 2008, J. Clin. Oncol."		3	accepted	1665	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/1665	https://civicdb.org/links/molecular_profiles/33	FALSE	EGFR	1956	L858R		chr7	55191822	55191822	T	G	ENST00000275493.2	75		missense_variant	"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg"	2023-01-27 17:02:04 UTC	CA126713	"16,609,376,282,376,200"	"LEU858ARG,RS121434568"	FALSE
EGFR Exon 19 Deletion	133	Lung Non-small Cell Carcinoma	3908		Gefitinib		Predictive	Supports	B	Sensitivity/Response	"90 NSCLC patients with stage IIIB/IV chemotherapy-resistant tumors were treated with gefitinib, and exon 19 deletion of EGFR was associated with longer time to treatment failure than those with wild-type EGFR (median 8.9 versus 2.1). In multivariate analysis, exon 19 deletion was a significant predictive factor for TTF (HR = 0.0320; P < .0001)."	18509184	PubMed		"Yang et al., 2008, J. Clin. Oncol."		3	accepted	1666	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/1666	https://civicdb.org/links/molecular_profiles/133	FALSE	EGFR	1956	Exon 19 Deletion		chr7	55174722	55174820			ENST00000275493.2	75		inframe_deletion	ENST00000275493.2:c.2185_2283del	2023-01-09 21:52:05 UTC		N/A		FALSE
EGFR T790M	34	Lung Non-small Cell Carcinoma	3908		"Erlotinib,Gefitinib"	Substitutes	Predictive	Supports	B	Resistance	"48 tumor samples from 41 patients with EGFR mutant lung adenocarcinoma that were resistant to tyrosine kinase inhibition by gefitinib (n=1) or erlotinib (n=40) underwent next generation sequencing (NGS failed in 5 samples leading to a remaining 43 specimens from 39 patients). The prevalence of various mutations post-treatment was analyzed. 79%, or 31 out of the 39 patients, had the T790M EGFR mutation present, indicating its importance in the development of resistance."	27304188	PubMed		"Belchis et al., 2016, Oncotarget"		3	accepted	1667	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/1667	https://civicdb.org/links/molecular_profiles/34	FALSE	EGFR	1956	T790M	EGFR TKI Resistance	chr7	55181378	55181378	C	T	ENST00000275493.2	75		missense_variant	"ENST00000275493.2:c.2369C>T,NM_005228.4:c.2369C>T,NP_005219.2:p.Thr790Met,NC_000007.13:g.55249071C>T"	2023-01-27 17:02:05 UTC	CA090928	16613	"THR790MET,RS121434569"	FALSE
BRAF L505H	654	Melanoma	1909		Vemurafenib		Predictive	Supports	D	Resistance	"Using a mutation screen in the BRAFV600E melanoma cell line A375, the L505H variant was identified as conferring resistance to vemurafenib. Analysis of the mutation in T293 cell lines found that the L505H mutant alone or with V600e had greater kinase activity and increased the levels of phospho-MEK. Finally, transduction of Ba/F3 cells with BRAF V600E/L505H IL3 independent proliferation."	24112705	PubMed		"Wagenaar et al., 2014, Pigment Cell Melanoma Res"		4	accepted	1668	Somatic	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/1668	https://civicdb.org/links/molecular_profiles/654	FALSE	BRAF	673	L505H		chr7	140777994	140777994	A	T	ENST00000288602.6	75		missense_variant	"ENST00000288602.6:c.1514T>A,NC_000007.13:g.140477794A>T,NM_004333.4:c.1514T>A,NP_004324.2:p.Leu505His"	2023-01-27 17:04:48 UTC	CA369588358	NONE FOUND	LEU505HIS	FALSE
BRAF L505H	654	Melanoma	1909		Vemurafenib		Predictive	Supports	B	Resistance	"In this study, the investigators followed 10 patients treated with vemurafenib, and then they collected biopsies of lesions that progressed. In one of these patients, they identified the L505H mutation."	25515853	PubMed		"Hoogstraat et al., 2015, Pigment Cell Melanoma Res"		3	accepted	1669	Somatic	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/1669	https://civicdb.org/links/molecular_profiles/654	FALSE	BRAF	673	L505H		chr7	140777994	140777994	A	T	ENST00000288602.6	75		missense_variant	"ENST00000288602.6:c.1514T>A,NC_000007.13:g.140477794A>T,NM_004333.4:c.1514T>A,NP_004324.2:p.Leu505His"	2023-01-27 17:04:48 UTC	CA369588358	NONE FOUND	LEU505HIS	FALSE
PIK3CA E545K	104	Lung Adenocarcinoma	3910		"Gefitinib,Erlotinib"	Substitutes	Predictive	Supports	C	Resistance	"48 tumor samples from 41 patients with EGFR mutant lung adenocarcinoma that were resistant to tyrosine kinase inhibition underwent next generation sequencing (AmpliSeq Cancer Hotspot Panel (v2) failed in 5 samples leading to a remaining 43 specimens from 39 patients). The prevalence of various mutations post-treatment was analyzed. 2 out of the 39 patients had the E545K PIK3CA mutation in the absence of EGFR T790M, indicating that E545K may be an alternative mutation contributing to resistance."	27304188	PubMed		"Belchis et al., 2016, Oncotarget"		2	accepted	1670	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/1670	https://civicdb.org/links/molecular_profiles/104	FALSE	PIK3CA	5290	E545K		chr3	179218303	179218303	G	A	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.1633G>A,NP_006209.2:p.Glu545Lys,ENST00000263967.3:c.1633G>A,NC_000003.11:g.178936091G>A"	2023-01-27 17:02:37 UTC	CA123334	13655	"GLU545LYS,RS104886003"	FALSE
VHL Mutation	160	Renal Cell Carcinoma	4450		Pazopanib		Predictive	Does Not Support	B	Sensitivity/Response	"VHL mutations were evaluated in 78 tumors samples of patients with metastatic RCC treated with pazopanib as part of a clinical trial. Overall, 87% had one VHL mutation, 12% showed promoter hypermethylation, and 6 patients had both. 8 patients exhibited neither mutation nor methylation of VHL. There was no correlation between VHL status and overall response rate or progression free survival under pazopanib therapy."	23881929	PubMed		"Choueiri et al., 2013, Clin. Cancer Res."		2	accepted	1672	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/1672	https://civicdb.org/links/molecular_profiles/160	FALSE	VHL	7428	Mutation		chr3	10141008	10152220			ENST00000256474.2	75		"gene_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
EPAS1 Overexpression	431	Renal Cell Carcinoma	4450		Pazopanib		Predictive	Does Not Support	B	Sensitivity/Response	"HIF2A (EPAS1) staining was conducted on tumors from 66 patients, of which 27 were classified as low expression and 39 were classified as high expression. The response rates of patients with low and high HIF2A expression to pazopanib were 44% and 33% (p=0.36) respectively and no significant difference in PFS between the two groups (p=0.76) was observed. The authors concluded that HIF2A expression levels are not associated with clinical response to pazopanib."	23881929	PubMed		"Choueiri et al., 2013, Clin. Cancer Res."		2	accepted	1673	N/A	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1673	https://civicdb.org/links/molecular_profiles/431	FALSE	EPAS1	2034	Overexpression		chr2	46297402	46386697			ENST00000263734.3	75		N/A		2023-01-09 21:52:07 UTC		N/A		FALSE
HIF1A EXPRESSION	656	Renal Cell Carcinoma	4450		Pazopanib		Predictive	Does Not Support	B	Sensitivity/Response	"Immunohistochemical staining for HIF1A was performed on tumor samples from 65 patients that received pazopanib as part of VEG102616, of which 17 were classified as low expression and 48 were classified as high expression. The response rates of patients with low and high HIF1a expression to pazopanib were 52.9% and 29.1% (p=0.13), and there was no significant difference in PFS between the two groups (p=0.25). The authors concluded that HIF1a expression levels are not associated with clinical response to pazopanib."	23881929	PubMed		"Choueiri et al., 2013, Clin. Cancer Res."		2	accepted	1674	N/A	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/1674	https://civicdb.org/links/molecular_profiles/656	FALSE	HIF1A	3091	EXPRESSION		chr14	61697622	61747771			ENST00000539097.1	75		N/A		2023-01-09 21:52:08 UTC		N/A		FALSE
BRCA1 Mutation	185	Ovarian Cancer	2394				Prognostic	Supports	B	Better Outcome	"664 patients with non-bulky FIGO Stage II-IV ovarian cancer were evaluated for PFS when treated with Pazopanib versus placebo.  Of the 664 patients, 10% (n=68) were BRCA1+, 4% were BRCA 2+ (n=29) and 85% (n=567) were BCRA1/2 negative.  Longer progression free survival was observed in BRCA1/2 positive carriers versus BRCA1/2 negative carriers in both the Pazopanib arm and the placebo arm, however, due to small sample size, the PFS increase in the Pazopanib arm was not statistically significant."	26740259	PubMed		"Harter et al., 2016, Gynecol. Oncol."		3	accepted	1675	Rare Germline	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/1675	https://civicdb.org/links/molecular_profiles/185	FALSE	BRCA1	672	Mutation		chr17	43045629	43125483			ENST00000471181.2	75		"gene_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
BRCA2 Mutation	186	Ovarian Cancer	2394				Prognostic	Supports	B	Better Outcome	"664 patients with non-bulky FIGO Stage II-IV ovarian cancer were evaluated for PFS when treated with Pazopanib versus placebo.  Of the 664 patients, 10% (n=68) were BRCA1+, 4% were BRCA 2+ (n=29) and 85% (n=567) were BCRA1/2 negative.  Longer progression free survival was observed in BRCA1/2 positive carriers versus BRCA1/2 negative carriers in both the Pazopanib arm and the placebo arm, however, due to small sample size, the PFS increase in the Pazopanib arm was not statistically significant."	26740259	PubMed		"Harter et al., 2016, Gynecol. Oncol."		3	accepted	1676	Rare Germline	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/1676	https://civicdb.org/links/molecular_profiles/186	FALSE	BRCA2	675	Mutation		chr13	32315474	32399210			ENST00000380152.3	75		"gene_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
BRCA1 Mutation	185	Ovarian Cancer	2394		"Olaparib,Cediranib"	Combination	Predictive	Supports	B	Sensitivity/Response	"46 women with platinum-sensitive, high-grade, BRCA1/2+ ovarian cancer received either olaparib monotherapy or olaparib/cediranib combination therapy.  Median PFS was increased in combination therapy (17.7 months versus 9.0 months; HR=0.42; 95%CI 0.23-0.76; p=0.005); overall response rate was increased in the combination therapy (79.6% versus 47.8%; p=0.002); and total deaths were reduced in combination therapy (6 patients versus 10 patients)."	25218906	PubMed		"Liu et al., 2014, Lancet Oncol."	NCT01116648	3	accepted	1677	Rare Germline	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/1677	https://civicdb.org/links/molecular_profiles/185	FALSE	BRCA1	672	Mutation		chr17	43045629	43125483			ENST00000471181.2	75		"gene_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
BRCA2 Mutation	186	Ovarian Cancer	2394		"Olaparib,Cediranib"	Combination	Predictive	Supports	B	Sensitivity/Response	"46 women with platinum-sensitive, high-grade, BRCA1/2+ ovarian cancer received either olaparib monotherapy or olaparib/cediranib combination therapy.  Median PFS was increased in combination therapy (17.7 months versus 9.0 months; HR=0.42; 95%CI 0.23-0.76; p=0.005); overall response rate was increased in the combination therapy (79.6% versus 47.8%; p=0.002); and total deaths were reduced in combination therapy (6 patients versus 10 patients)."	25218906	PubMed		"Liu et al., 2014, Lancet Oncol."	NCT01116648	3	accepted	1678	Rare Germline	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/1678	https://civicdb.org/links/molecular_profiles/186	FALSE	BRCA2	675	Mutation		chr13	32315474	32399210			ENST00000380152.3	75		"gene_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
BRCA2 D3095E	657	Breast Cancer	1612				Predisposing	Supports	C	Predisposition	"49-year old woman diagnosed with breast cancer was assessed for BRCA2 mutations. Algorithms including Align-GVGD predicted pathogenicity, however PolyPhen predicted that this variant was benign. The authors assessment of the factors predicts a pathogenicity probability of 0.73 and an Odds Ratio of 2.7."	18951446	PubMed		"Plon et al., 2008, Hum. Mutat."		3	accepted	1679	Rare Germline	2023-03-30 19:20:21 UTC	https://civicdb.org/links/evidence_items/1679	https://civicdb.org/links/molecular_profiles/657	FALSE	BRCA2	675	D3095E		chr13	32394717	32394717	C	A	ENST00000544455.1	75		missense_variant	"NM_000059.3:c.9285C>A,NP_000050.2:p.Asp3095Glu,ENST00000544455.1:c.9285C>A,NC_000013.10:g.32968854C>A"	2023-01-27 17:04:49 UTC	CA10586089	252859	"ASP3095GLU,RS80359198"	FALSE
MLH1 EXPRESSION	658	Stomach Carcinoma	5517				Prognostic	Supports	B	Poor Outcome	"46 patients with poorly cohesive, signet-cell ring, gastric carcinoma were evaluated for genetic mutations and MLH1 expression (immunohistochemistry). Overall survival rate of MLH1 negative cases were significantly better than MLH1 positive cases (p=0.020)."	27313181	PubMed		"Rokutan et al., 2016, J. Pathol."		3	accepted	1680	Somatic	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/1680	https://civicdb.org/links/molecular_profiles/658	FALSE	MLH1	4292	EXPRESSION		chr3	36993332	37050918			ENST00000231790.2	75		N/A		2023-01-09 21:52:08 UTC		N/A		FALSE
BCOR Mutation	659	Stomach Cancer	10534				Prognostic	Supports	B	Better Outcome	"46 patients with poorly cohesive, signet-cell ring, gastric carcinoma were evaluated for genetic mutations.  Overall survival rate of BCOR positive cases were significantly better than BCOR negative cases cases (p=0.038)."	27313181	PubMed		"Rokutan et al., 2016, J. Pathol."		3	accepted	1681	Somatic	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/1681	https://civicdb.org/links/molecular_profiles/659	FALSE	BCOR	54880	Mutation		chrX	40051248	40177329			ENST00000342274.4	75		transcript_variant		2023-01-09 21:52:08 UTC				FALSE
CDH1 MUTATION	660	Stomach Carcinoma	5517				Prognostic	Supports	E	Poor Outcome	"285 intestinal-type tumors and 183 diffuse-type tumors were evaluated for mutational profiles.  CDH1 mutations are associated with diffuse type mucinous gastric carcinoma, which indicate worse prognosis when compared to intestinal type (p<0.001)."	27313181	PubMed		"Rokutan et al., 2016, J. Pathol."		2	accepted	1682	Somatic	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/1682	https://civicdb.org/links/molecular_profiles/660	FALSE	CDH1	999	MUTATION		chr16	68737225	68835548			ENST00000261769.5	75		transcription_variant		2023-01-09 21:52:08 UTC		N/A		FALSE
RHOA MUTATION	661	Stomach Carcinoma	5517				Prognostic	Supports	E	Poor Outcome	"285 intestinal-type tumors and 183 diffuse-type tumors were evaluated for mutational profiles.  RHOA mutations are associated with diffuse type mucinous gastric carcinoma, which indicate worse prognosis when compared to intestinal type (p<0.001)."	27313181	PubMed		"Rokutan et al., 2016, J. Pathol."		2	accepted	1683	Somatic	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/1683	https://civicdb.org/links/molecular_profiles/661	FALSE	RHOA	387	MUTATION		chr3	49359145	49412202			ENST00000418115.1	75		"transcription_variant,gain_of_function_variant"		2023-01-09 21:52:08 UTC				FALSE
BRCA1 Mutation	185	Triple-receptor Negative Breast Cancer	60081		"Cisplatin,Carboplatin"	Substitutes	Predictive	Supports	B	Sensitivity/Response	"In an evaluation of 77 patients, those who had BRCA1/2 germline mutations (n=11) had an increase response rate to cisplatin when compared to those without germline mutations (54.5% versus 19.7%; P=0.022) although progression free survival and overall survival was not significantly different."	25847936	PubMed		"Isakoff et al., 2015, J. Clin. Oncol."	NCT00483223	3	accepted	1684	Rare Germline	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/1684	https://civicdb.org/links/molecular_profiles/185	FALSE	BRCA1	672	Mutation		chr17	43045629	43125483			ENST00000471181.2	75		"gene_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
BRCA2 Mutation	186	Triple-receptor Negative Breast Cancer	60081		"Carboplatin,Cisplatin"	Substitutes	Predictive	Supports	B	Sensitivity/Response	"In an evaluation of 77 patients, those who had BRCA1/2 germline mutations (n=11) had an increase response rate to cisplatin when compared to those without germline mutations (54.5% versus 19.7%; P=0.022) although progression free survival and overall survival was not significantly different."	25847936	PubMed		"Isakoff et al., 2015, J. Clin. Oncol."	NCT00483223	3	accepted	1685	Rare Germline	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/1685	https://civicdb.org/links/molecular_profiles/186	FALSE	BRCA2	675	Mutation		chr13	32315474	32399210			ENST00000380152.3	75		"gene_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
ERBB2 Amplification	302	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	B	Resistance	"A cohort of patient-derived xenografts (PDX) from 85 patients with metastatic colorectal cancer was created. PDX were treated with cetuximab and mechanisms of resistance investigated. None of the xenografts harboring KRAS (N=18), NRAS (N=7) or BRAF (N=3) mutations showed a response to cetuximab whereas 1 out of 4 xenografts with a PIK3CA mutation responded to cetuximab. Among 11 quadruple-negative samples with resistance to cetuximab, HER2 overexpression and amplification (N=3) and amplification (N=1) were identified. In an independent second retrospective patient cohort, 3 out of 17 patients with KRAS wt, cetuximab resitant CRC were found to harbor HER2 overexpression and amplification. In this cohort no HER2 overexpression or amplification was identified in 14 KRAS wt patients with response to cetuximab."	22586653	PubMed		"Bertotti et al., 2011, Cancer Discov"		4	accepted	1686	N/A	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1686	https://civicdb.org/links/molecular_profiles/302	FALSE	ERBB2	2064	Amplification		chr17	39700080	39728662			ENST00000269571.5	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A	OVEREXPRESSION	FALSE
ERBB2 Amplification	302	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	B	Resistance	"A cohort of patient-derived xenografts (PDX) from 85 patients with metastatic colorectal cancer was created. PDX were treated with cetuximab and mechanisms of resistance investigated. None of the xenografts harboring KRAS (N=18), NRAS (N=7) or BRAF (N=3) mutations showed resistance whereas 1 out of 4 xenografts with a PIK3CA mutation responded to cetuximab. Among 11 quadruple-negative samples with resistance to cetuximab, HER2 overexpression and amplification (N=3) and amplification (N=1) were identified. In an independent second retrospective cohort, 3 out of 17 patients with KRAS wt, cetuximab resitant CRC were found to harbor HER2 overexpression and amplification. In this cohort no HER2 overexpression or amplification was identified in 14 KRAS wt patients with response to cetuximab."	22586653	PubMed		"Bertotti et al., 2011, Cancer Discov"		4	accepted	1687	N/A	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1687	https://civicdb.org/links/molecular_profiles/302	FALSE	ERBB2	2064	Amplification		chr17	39700080	39728662			ENST00000269571.5	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A	OVEREXPRESSION	FALSE
ERBB2 Amplification	302	Colorectal Cancer	9256		"Cetuximab,Panitumumab"	Substitutes	Predictive	Supports	B	Resistance	"HER2 amplification (FISH) was assessed in 170 KRAS wt mCRC patients treated with cetuximab or panitumumab. HER2 copy number status was significantly correlated with response rate, PFS and OS. Patients with amplification in all neoplastic cells (4%) had worse outcome compared to patients without amplification (35%, intermediate outcome) or amplification in minor clones (61%, highest survival probability)."	23348520	PubMed		"Martin et al., 2013, Br. J. Cancer"		2	accepted	1688	N/A	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1688	https://civicdb.org/links/molecular_profiles/302	FALSE	ERBB2	2064	Amplification		chr17	39700080	39728662			ENST00000269571.5	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A	OVEREXPRESSION	FALSE
ERBB2 Amplification	302	Colorectal Cancer	9256		"Lapatinib,Trastuzumab"	Combination	Predictive	Supports	B	Sensitivity/Response	"Phase 2 study in 27 patients with HER2 positive (IHC, FISH), KRAS wt metastatic colorectal cancer refractory to standard of care received trastuzumab and lapatinib. After a median follow-up of 94 weeks, eight (30%, 95% CI 14-50) of 27 patients had achieved an objective response, with one patient (4%, 95% CI -3 to 11) achieving a complete response, and seven (26%, 95% CI 9-43) achieving partial responses; 12 (44%, 95% CI 25-63) patients had stable disease. A total of 914 patients with KRAS wt were screened for this study, 48 patients (5%) were identified to have HER2-positive tumors."	27108243	PubMed		"Sartore-Bianchi et al., 2016, Lancet Oncol."		4	accepted	1689	N/A	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1689	https://civicdb.org/links/molecular_profiles/302	FALSE	ERBB2	2064	Amplification		chr17	39700080	39728662			ENST00000269571.5	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A	OVEREXPRESSION	FALSE
ROS1 Rearrangement	265	Lung Adenocarcinoma	3910		Crizotinib		Predictive	Supports	C	Sensitivity/Response	"In an evaluation of a patient and never smoker with crizotinib-sensitive lung adenocarcinoma, an SDC4-ROS1 rearrangement was identified using comprehensive genomic profiling. The patient attained a decrease in RESIST target lesions by 26.8% (stable disease); however, the patient relapsed 4 months later. This patient also harbored a TP53 mutation, MCL1 amplification and CDKN2A deletion."	25922291	PubMed		"Le et al., 2015, Clin Lung Cancer"		3	accepted	1690	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1690	https://civicdb.org/links/molecular_profiles/265	FALSE	ROS1	6098	Rearrangement		chr6	117288300	117425855			ENST00000368508.3	75		transcript_fusion		2023-01-09 21:52:06 UTC		N/A		FALSE
ALK Fusion	495	Lung Adenocarcinoma	3910		Crizotinib		Predictive	Supports	C	Sensitivity/Response	"In an evaluation of a patient with crizotinib-sensitive lung adenocarcinoma, an EML4-ALK-E13;A20 rearrangement was identified using CGP.  The patient attained a reduction in the target lesions by 14.2%, however, the patient relapsed 17 months later."	25922291	PubMed		"Le et al., 2015, Clin Lung Cancer"		3	accepted	1691	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1691	https://civicdb.org/links/molecular_profiles/495	FALSE	ALK	238	Fusion	ALK Fusion	chr2	29192774	29223528			ENST00000389048.3	75		transcript_fusion		2023-01-09 21:52:07 UTC		N/A	REARRANGEMENT	FALSE
MET Amplification	266	Lung Adenocarcinoma	3910		Crizotinib		Predictive	Supports	C	Sensitivity/Response	"In an evaluation of a patient with crizotinib-sensitive lung adenocarcinoma, an MET-Amplification was identified using CGP.  The patient attained a reduction in the target lesions by 38.7%, and the patient maintained response for at least 5 months post-treatment."	25922291	PubMed		"Le et al., 2015, Clin Lung Cancer"		3	accepted	1692	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1692	https://civicdb.org/links/molecular_profiles/266	FALSE	MET	4233	Amplification		chr7	116672405	116796342			ENST00000318493.6	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A		FALSE
ERBB2 Amplification	302	Scrotum Paget's Disease	3444		Trastuzumab		Predictive	Supports	C	Sensitivity/Response	"A 71-year old male with metastatic extramammary Pagets disease of the scrotum overexpressing Her2/neu was treated with trastuzumab, achieving a complete response. At 12 months, he maintains stable disease."	25692060	PubMed		"Barth et al., 2015, Case Rep Oncol Med"		2	accepted	1693	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1693	https://civicdb.org/links/molecular_profiles/302	FALSE	ERBB2	2064	Amplification		chr17	39700080	39728662			ENST00000269571.5	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A	OVEREXPRESSION	FALSE
ERBB2 Mutation	662	Bladder Carcinoma	4007		Platinum Compound		Predictive	Supports	C	Sensitivity/Response	"In patients with muscle-invasive bladder chancer, a cohort of complete responders to platinum chemotherapy (n=38) and non-responders to platinum chemotherapy (n=33) were evaluated for 178 cancer-associated genes. Of the complete responders, 24% had an ERBB2 missense mutations and no non-responders had ERBB2 mutations (p=0.003)."	25636205	PubMed		"Groenendijk et al., 2016, Eur. Urol."		3	accepted	1694	Somatic	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/1694	https://civicdb.org/links/molecular_profiles/662	FALSE	ERBB2	2064	Mutation		chr17	39711943	39725079			ENST00000269571.5	75		missense_variant		2023-01-09 21:52:08 UTC				FALSE
MEN1 FRAMESHIFT TRUNCATION	663	Thyroid Gland Hurthle Cell Carcinoma	8161				Diagnostic	Supports	C	Positive	Two patients diagnosed with oncocytic thyroid carcinoma (hurthle cell thyroid carcinoma) were evaluated for MEN1 mutations.  One tumor showed 592-end deletion of MEN1 and the other showed a 521 frameshift mutation.  These mutations are similar to the ones seen in MEN1 syndrome inducing endocrine gland tumors.	25625803	PubMed		"Kasaian et al., 2015, J. Clin. Endocrinol. Metab."		2	accepted	1695	Somatic	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/1695	https://civicdb.org/links/molecular_profiles/663	FALSE	MEN1	4221	FRAMESHIFT TRUNCATION		chr11	64804620	64804620	C		ENST00000337652.1	75		frameshift_truncation	NC_000011.9:g.64572092del	2023-01-27 17:04:50 UTC	CA16044439			FALSE
KMT2C MUTATION	664	Skin Squamous Cell Carcinoma	3151				Prognostic	Supports	B	Poor Outcome	Evaluation of 39 aggressive cutaneous squamous cell carcinomas revealed that tumors with a KMT2C mutation were 5x more likely to invade the bone (53% versus 10%; p=0.008).  Patients with KMT2C mutations also had significantly shorter recurrent free survival (21.6 versus 167.5; p=0.003) and an increased hazards ratio for death (HR=5.16; 95%CI:1.55 to 17.18).  This worse prognosis did not appear to be correlated with bone invasion (p=0.98).	25303977	PubMed		"Pickering et al., 2014, Clin. Cancer Res."		3	accepted	1696	Somatic	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/1696	https://civicdb.org/links/molecular_profiles/664	FALSE	KMT2C	58508	MUTATION		chr7	152134925	152436005			ENST00000262189.6	75		"transcription_variant,loss_of_function_variant"		2023-01-09 21:52:08 UTC				FALSE
STAG2 MUTATION	665	Ewing Sarcoma Of Bone	3368				Prognostic	Supports	B	Poor Outcome	"In a study of 96 Ewing sarcoma tumors, 15% showed heterogenous loss of STAG2 expression in IHC analysis.  Of those with STAG2 expression loss, 88% presented with metastatic disease compared to only 27% of patients who expressed STAG2 on IHC (P=0.002)."	25186949	PubMed		"Crompton et al., 2014, Cancer Discov"		4	accepted	1697	N/A	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/1697	https://civicdb.org/links/molecular_profiles/665	FALSE	STAG2	10735	MUTATION		chrX	124042568	124083458			ENST00000218089.9	75		protein_altering_variant		2023-01-09 21:52:08 UTC		N/A		FALSE
BRAF V600E	12	Multiple Myeloma	9538		Vemurafenib		Predictive	Supports	C	Sensitivity/Response	"A 65-year-old man presented with stage II myeloma.  He was initially treated with chemotherapy and he received an autologous stem cell transplant. Sequencing of the recurrent tumor harbored BRAF V600E mutation and he was treated with vemurafenib.  After 7 weeks of treatment, the patient relapsed and died."	24997557	PubMed		"Sharman et al., 2014, Clin Lymphoma Myeloma Leuk"		3	accepted	1698	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/1698	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
BRAF V600E	12	Multiple Myeloma	9538		Vemurafenib		Predictive	Supports	C	Sensitivity/Response	A 54-year-old man presented with stage II myeloma.  He was initially treated with chemotherapy and received an autologous stem cell transplant.  Genomic profiling of the bone biopsy revealed BRAF V600E activating mutation and the patient was treated with vemurafenib.  At 4-months post treatment (time of case study report) the patient maintains near-resolution of hypermetabolic lesions.	24997557	PubMed		"Sharman et al., 2014, Clin Lymphoma Myeloma Leuk"		2	accepted	1699	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/1699	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
KRAS Mutation	332	Lung Adenocarcinoma	3910				Prognostic	Supports	B	Poor Outcome	"In a study of 1036 patients with lung adenocarcinoma, patients with KRAS mutations (n=241) showed worse prognosis (OS: 19 months versus 23 months; HR=1.21; P=0.048)."	22810899	PubMed		"Johnson et al., 2013, Cancer"		4	accepted	1700	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/1700	https://civicdb.org/links/molecular_profiles/332	FALSE	KRAS	3845	Mutation		chr12	25209431	25250803			ENST00000256078.4	75		protein_altering_variant		2023-01-09 21:52:06 UTC		N/A		FALSE
EGFR Mutation	438	Lung Adenocarcinoma	3910				Prognostic	Supports	B	Better Outcome	"In a study of 1036 patients with lung adenocarcinomas, patients with EGFR mutations (n=275) showed better prognosis (OS: 34 months versus 23 months; HR=0.6; P<0.001)."	22810899	PubMed		"Johnson et al., 2013, Cancer"		4	accepted	1701	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1701	https://civicdb.org/links/molecular_profiles/438	FALSE	EGFR	1956	Mutation		chr7	55019101	55211628			ENST00000275493.2	75		inframe_variant		2023-01-09 21:52:07 UTC		N/A		FALSE
KRAS Mutation	332	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	D	Resistance	"A cohort of patient-derived xenografts (PDX) from 85 patients with metastatic colorectal cancer was created. PDX were treated with cetuximab and mechanisms of resistance investigated. None of the xenografts harboring KRAS (N=18), NRAS (N=7) or BRAF (N=3) mutations showed a response to cetuximab whereas 1 out of 4 xenografts with a PIK3CA mutation responded to cetuximab."	22586653	PubMed		"Bertotti et al., 2011, Cancer Discov"		3	accepted	1702	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/1702	https://civicdb.org/links/molecular_profiles/332	FALSE	KRAS	3845	Mutation		chr12	25209431	25250803			ENST00000256078.4	75		protein_altering_variant		2023-01-09 21:52:06 UTC		N/A		FALSE
NRAS Mutation	208	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	D	Resistance	"A cohort of patient-derived xenografts (PDX) from 85 patients with metastatic colorectal cancer was created. PDX were treated with cetuximab and mechanisms of resistance investigated. None of the xenografts harboring KRAS (N=18), NRAS (N=7) or BRAF (N=3) mutations showed a response to cetuximab whereas 1 out of 4 xenografts with a PIK3CA mutation responded to cetuximab."	22586653	PubMed		"Bertotti et al., 2011, Cancer Discov"		2	accepted	1703	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/1703	https://civicdb.org/links/molecular_profiles/208	FALSE	NRAS	4893	Mutation		chr1	114704469	114716894			ENST00000369535.4	75		"transcript_variant,gain_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
BRAF Mutation	395	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	D	Resistance	"A cohort of patient-derived xenografts (PDX) from 85 patients with metastatic colorectal cancer was created. PDX were treated with cetuximab and mechanisms of resistance investigated. None of the xenografts harboring KRAS (N=18), NRAS (N=7) or BRAF (N=3) mutations showed a response to cetuximab whereas 1 out of 4 xenografts with a PIK3CA mutation responded to cetuximab."	22586653	PubMed		"Bertotti et al., 2011, Cancer Discov"		2	accepted	1704	Somatic	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/1704	https://civicdb.org/links/molecular_profiles/395	FALSE	BRAF	673	Mutation		chr7	140753336	140781603			ENST00000288602.6	75		"gene_variant,gain_of_function_variant"		2023-01-09 21:52:06 UTC				FALSE
PIK3CA Mutation	307	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	D	Resistance	"A cohort of patient-derived xenografts (PDX) from 85 patients with metastatic colorectal cancer was created. PDX were treated with cetuximab and mechanisms of resistance investigated. None of the xenografts harboring KRAS (N=18), NRAS (N=7) or BRAF (N=3) mutations showed a response to cetuximab and only 1 out of 4 xenografts with a PIK3CA mutation responded to cetuximab."	22586653	PubMed		"Bertotti et al., 2011, Cancer Discov"		1	accepted	1705	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/1705	https://civicdb.org/links/molecular_profiles/307	FALSE	PIK3CA	5290	Mutation		chr3	179148523	179240093			ENST00000263967.3	75		"transcript_variant,gain_of_function_variant"		2023-01-09 21:52:06 UTC		N/A		FALSE
MYCL EXPRESSION	666	Multiple Myeloma	9538		"I-BET151,JQ1"	Substitutes	Predictive	Supports	D	Sensitivity/Response	"Four myeloma cell lines were treated with two different BET inhibitors (I-BET151 or JQ1). Proliferation of three cell lines (KMS11, RPMI8226 and MM1S) but not U266 (only partial inhibition) was strongly inhibited by the BET inhibitors. Microarray analysis showed a downregulation of MYC-dependent genes after treatment. qRT-PCR showed that MYCL1 but not c-MYC and MYCN was expressed in U266 cells and I-BET151 induced downregulation of MYCL1. In contrast, c-MYC but not MYCL was expressed in the other cell lines and I-BET151 induced downregulation of c-MYC."	27276402	PubMed		"Suzuki et al., 2016, Anticancer Drugs"		1	accepted	1706	N/A	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/1706	https://civicdb.org/links/molecular_profiles/666	FALSE	MYCL	4610	EXPRESSION		chr1	39895426	39902013			ENST00000397332.2	75		N/A		2023-01-09 21:52:08 UTC				FALSE
HGF EXPRESSION	667	Glioblastoma	3068		MET Tyrosine Kinase Inhibitor SGX523		Predictive	Supports	D	Sensitivity/Response	Three metastatic glioblastoma cell lines were compared with their parental cell lines with regard to differential gene expression. HGF signalling was among the top pathways identified. Exogenous HFG led to an increase in MET activity (except in one cell line with high endogenous HGF levels) which was abrogated by MET inhibitor SGX523. Three HGF autocrine cell lines were grown in mice and showed significantly increased sensitivity to SGX523 than three non-HGF autocrine cell lines (P<0.05).	22203985	PubMed		"Xie et al., 2012, Proc. Natl. Acad. Sci. U.S.A."		2	accepted	1707	N/A	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/1707	https://civicdb.org/links/molecular_profiles/667	FALSE	HGF	3082	EXPRESSION		chr7	81699006	81770198			ENST00000222390.5	75		N/A		2023-01-09 21:52:08 UTC				FALSE
EGFR Expression	350	Colorectal Cancer	9256		Panitumumab		Predictive	Supports	B	Sensitivity/Response	"463 patients with 1% or more EGFR tumor cell membrane staining, with metastatic CRC progressive after standard chemotherapy were randomized to panitumumab plus best supportive care (BSC, n = 231) or BSC alone (n = 232). Panitumumab significantly prolonged PFS (hazard ratio [HR], 0.54; 95% CI, 0.44 to 0.66, [P < .0001]). Objective response rates favored panitumumab over BSC; after a 12-month minimum follow-up, response rates were 10% for panitumumab and 0% for BSC (P < .0001). No difference was observed in OS (HR, 1.00; 95% CI, 0.82 to 1.22), but 76% of BSC patients entered the cross-over study."	17470858	PubMed		"Van Cutsem et al., 2007, J. Clin. Oncol."		2	accepted	1708	N/A	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/1708	https://civicdb.org/links/molecular_profiles/350	FALSE	EGFR	1956	Expression		chr7	55019101	55211628			ENST00000275493.2	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
EGFR Expression	350	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	B	Sensitivity/Response	"57 patients with chemorefractory colorectal cancer expressing EGFR (IHC staining) were treated with single-agent cetuximab in this phase 2 study. Five patients (9%; 95% CI, 3% to 19%) achieved a partial response. Twenty-one additional patients had stable disease or minor responses. The median survival in these previously treated patients with chemotherapy-refractory colorectal cancer was 6.4 months."	14993230	PubMed		"Saltz et al., 2004, J. Clin. Oncol."		1	accepted	1709	N/A	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/1709	https://civicdb.org/links/molecular_profiles/350	FALSE	EGFR	1956	Expression		chr7	55019101	55211628			ENST00000275493.2	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
SOX10 Loss	668	Melanoma	1909		Vemurafenib		Predictive	Supports	D	Resistance	FACS-assisted shRNA genetic screen identified SOX10 as a determinant of vemurafenib resistance. Suppression of SOX10 in melanoma cells confers resistance to BRAF and MEK inhibitors through activation of TGF- signalling and upregulation of EGFR and PDGFRB. EGFR expression or exposure to TGF- becomes beneficial for proliferation of melanoma cells in the presence of BRAF or MEK inhibitors. Melanoma cells with low SOX10 and consequently high EGFR expression are enriched in the presence of vemurafenib. This study finds evidence for SOX10 loss (N=2) and/or activation of TGF- signalling (N=2) in 4 of the 6 EGFR-positive drug-resistant melanoma patient samples.	24670642	PubMed		"Sun et al., 2014, Nature"		4	accepted	1710	N/A	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/1710	https://civicdb.org/links/molecular_profiles/668	FALSE	SOX10	6663	Loss		chr22	37972300	37984537			ENST00000396884.2	75		loss_of_function_variant		2023-01-09 21:52:08 UTC		N/A		FALSE
FGF2 EXPRESSION	669	Acute Myeloid Leukemia	9119		Quizartinib		Predictive	Supports	D	Resistance	"AML MOLM14 cells were cocultured with FLT3 inhibitor AC220 (10 nM) and selected proteins expressed in the bone marrow microenvironment. FL and FGF2 were the only proteins that increased viability >2 standard deviations. FGFR inhibitor PD173074 (and FGFR1 siRNA) was able to attenuate the protective effect of FGF2.  Removing FL or FGF2 from ligand-dependent resistant cultures transiently restored sensitivity to AC220, but accelerated acquisition of secondary resistance mutations. 10 FLT3-ITD AML patients treated with AC220 developed increased FGF2 expression (IHC) in marrow stromal cells, which peaked prior to overt clinical relapse and detection of resistance mutations"	27671675	PubMed		"Traer et al., 2016, Cancer Res."		4	accepted	1711	N/A	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/1711	https://civicdb.org/links/molecular_profiles/669	FALSE	FGF2	2247	EXPRESSION		chr4	122826708	122898236			ENST00000264498.3	75		N/A		2023-01-09 21:52:08 UTC				FALSE
EIF1AX MUTATION	670	Uveal Melanoma	6039				Prognostic	Supports	C	Better Outcome	"EIF1AX was identified as a uveal melanoma (UM) driver gene by whole-exome sequencing. Approximately 14%?0% of UM carry a mutation in EIF1AX, with most mutations found in exons 1 and 2. EIF1AX mutations are associated with a good prognosis, and are inversely associated with metastasis. This assertion is based on observed survival for 19 EIF1AX mutant UM cases compared to 69 EIF1AX wildtype cases."	23793026	PubMed		"Martin et al., 2013, Nat. Genet."		4	accepted	1712	Somatic	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/1712	https://civicdb.org/links/molecular_profiles/670	FALSE	EIF1AX	1964	MUTATION		chrX	20138595	20141636			ENST00000379607.5	75		transcript_variant		2023-01-09 21:52:08 UTC				FALSE
MET Amplification	266	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	C	Sensitivity/Response	Case report of two patients with MET amplification (MET:CEP7 ratio ?) and no concomitant MET exon 14 deletion. A response to crizotinib was observed in both cases suggesting that MET amplification may predict response to this drug even in the absence of MET exon 14 mutations.	27664533	PubMed		"Caparica et al., 2017, J Thorac Oncol"		2	accepted	1713	N/A	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1713	https://civicdb.org/links/molecular_profiles/266	FALSE	MET	4233	Amplification		chr7	116672405	116796342			ENST00000318493.6	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A		FALSE
MET Amplification	266	Cancer	162		Crizotinib		Predictive	Supports	C	Sensitivity/Response	"Case report of a 59-year-old white female patient (60 pack-years) with a CUP-syndrome. Molecular profiling identified both MET amplification (16 copies) and a KRAS G12V mutation. The patient was treated with crizotinib and experienced a complete normalization of tumor metabolic activity for more than 19 months. Other identified aberrations include CCND1 amplification (8 copies), MYC amplification (9 copies) as well as KRAS G12V, TP53 R273L and CARD11 N184S."	25232318	PubMed		"Palma et al., 2014, Case Rep Oncol"		3	accepted	1714	N/A	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1714	https://civicdb.org/links/molecular_profiles/266	FALSE	MET	4233	Amplification		chr7	116672405	116796342			ENST00000318493.6	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A		FALSE
KRAS G12V	421	Cancer	162		Crizotinib		Predictive	Does Not Support	C	Resistance	"Case report of a 59-year-old white female patient (60 pack-years) with a CUP-syndrome. Molecular profiling identified both MET amplification (16 copies) and a KRAS G12V mutation. The patient was treated with crizotinib and experienced a complete normalization of tumor metabolic activity for more than 19 months. Other identified aberrations include CCND1 amplification (8 copies), MYC amplification (9 copies) as well as KRAS G12V, TP53 R273L and CARD11 N184S."	25232318	PubMed		"Palma et al., 2014, Case Rep Oncol"		2	accepted	1715	Somatic	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/1715	https://civicdb.org/links/molecular_profiles/421	FALSE	KRAS	3845	G12V		chr12	25245350	25245350	C	A	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.35G>T,NP_004976.2:p.Gly12Val,NC_000012.11:g.25398284C>A,ENST00000256078.4:c.35G>T"	2023-01-27 17:03:41 UTC	CA122540	12583	"GLY12VAL,RS121913529"	FALSE
PAX8 Expression	671	Female Reproductive Organ Cancer	120				Diagnostic	Supports	A	Positive	The authors explored the viability of PAX8 expression as a biomarker for differentiating mullerian from non-mullerian tumors. 74 tumors (37 Mullerian/37 non-Mullerian) were examined for PAX8 expression via IHC. Of these 29/37 Mullerian and 1/37 non-Mullerian tumors exhibited PAX8 expression. The sensitivity and specificity of using this as a biomarker to differentiate between the two tumor types was 78.4% and 97.3% respectively.	24800185	PubMed		"Heidarpour et al., 2014, Adv Biomed Res"		4	accepted	1716	N/A	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/1716	https://civicdb.org/links/molecular_profiles/671	FALSE	PAX8	7849	Expression		chr2	113215997	113278950			ENST00000429538.3	75		N/A	N/A	2023-01-09 21:52:08 UTC		N/A		FALSE
PRDM1 MUTATION	640	Diffuse Large B-cell Lymphoma	50745				Prognostic	Supports	B	Poor Outcome	"In 177 patients with activated B-cell diffuse large B-cell lymphoma (ABC-DLBCL), PRDM1 mutations (N=46) were associated with worse overall (P=0.016) and progression-free (P=0.023) survival compared to wildtype patients. This may have been driven by patients with exon1-2 mutations (N=15; P=0.021 for OS; P=0.024 for PFS) versus those with exon 3-7 mutations (N=31; P=0.16 for OS; P=0.24 for PFS) when compared to wildtype patients. Multivariate analysis did not identify PRDM1 mutations as an independent prognostic factor."	27568520	PubMed		"Xia et al., 2016, Leukemia"		2	accepted	1717	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1717	https://civicdb.org/links/molecular_profiles/640	FALSE	PRDM1	639	MUTATION		chr6	106086320	106109938			ENST00000369096.4	75		"transcript_variant,loss_of_function_variant"		2023-01-09 21:52:08 UTC		N/A		FALSE
ERRFI1 E384*	672	Cholangiocarcinoma	4947		Erlotinib		Predictive	Supports	C	Sensitivity/Response	"An ERRFI1 (E384X) was detected in a patient with metastatic, recurrent/refractory cholangiocarcinoma (allelic fraction 11%) without any mutations or amplifications in other EGFR signaling members such as EGFR and BRAF. The patient was treated with erlotinib 150 mg orally/daily. After 3 months, RECIST v1.1 partial response evidenced by a decrease of 58% in the sum of largest diameters was observed."	24550739	PubMed		"Borad et al., 2014, PLoS Genet."		2	accepted	1724	Somatic	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/1724	https://civicdb.org/links/molecular_profiles/672	FALSE	ERRFI1	54206	E384*		chr1	8013449	8013449	C	A	ENST00000377482.5	75		"stop_gained,loss_of_function_variant"	NC_000001.10:g.8073509C>A	2023-01-27 17:04:50 UTC	CA338219584	NONE FOUND	"E384X,GLU384TER"	FALSE
KIT D816V	65	Systemic Mastocytosis	349		Midostaurin		Predictive	Supports	B	Sensitivity/Response	"In a phase II clinical trial, 60% of patients (N=89) with advanced systemic mastocytosis responded to treatment with midostaurin."	27355533	PubMed		"Gotlib et al., 2016, N. Engl. J. Med."	NCT00782067	4	accepted	1725	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/1725	https://civicdb.org/links/molecular_profiles/65	FALSE	KIT	3815	D816V	KIT Exon 17	chr4	54733155	54733155	A	T	ENST00000288135.5	75		missense_variant	"NM_000222.2:c.2447A>T,NP_000213.1:p.Asp816Val,ENST00000288135.5:c.2447A>T,NC_000004.11:g.55599321A>T"	2023-01-27 17:02:23 UTC	CA123513	13852	"ASP816VAL,RS121913507"	FALSE
KIT D816V	65	Systemic Mastocytosis	349				Prognostic	Supports	B	Poor Outcome	"The D816V+ advanced systemic mastocytosis patients with additional mutations in SRSF2 (N=30), ASLX1 (N=20), or RUNX1 (N=16) exhibited lower overall survival over 14 years as compared to D816V+ patients with wildtype SRSF2 (N=40), ASXL1(N=50), or RUNX1 (N=54)."	26464169	PubMed		"Jawhar et al., 2016, Leukemia"		4	accepted	1726	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/1726	https://civicdb.org/links/molecular_profiles/65	FALSE	KIT	3815	D816V	KIT Exon 17	chr4	54733155	54733155	A	T	ENST00000288135.5	75		missense_variant	"NM_000222.2:c.2447A>T,NP_000213.1:p.Asp816Val,ENST00000288135.5:c.2447A>T,NC_000004.11:g.55599321A>T"	2023-01-27 17:02:23 UTC	CA123513	13852	"ASP816VAL,RS121913507"	FALSE
ESR1 S463P	673	Estrogen-receptor Positive Breast Cancer	60075		Aromatase Inhibitor		Predictive	Supports	D	Resistance	ESR1 S463P variants were observed after extensive treatment with hormonal therapy (aromatase inhibition). Expression of the S463P mutant was found to induce modest activity in the absence of hormone. This mutation displayed elevated levels of Ser118 phosphorylation compared to wild-type ER and appeared to possess estrogen-independent activity.	24185512	PubMed		"Toy et al., 2013, Nat. Genet."		2	accepted	1727	Somatic	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/1727	https://civicdb.org/links/molecular_profiles/673	FALSE	ESR1	2099	S463P		chr6	152094402	152094402	T	C	ENST00000440973.1	75		missense_variant	"ENST00000440973.1:c.1387T>C,NC_000006.11:g.152415537T>C,NM_000125.3:c.1387T>C,NP_000116.2:p.Ser463Pro"	2023-01-27 17:04:51 UTC	CA16602414	375934	"SER463PRO,RS1057519714"	FALSE
EGFR Mutation	438	Lung Non-small Cell Carcinoma	3908		Afatinib		Predictive	Supports	B	Sensitivity/Response	"In the LUX-LUNG 7 trial, (NCT01466660) stage IIIB or IV NSCLC patients with EGFR exon 19 deletion, (n=186) Leu858Arg mutation, (n=132) or both (n=1) were divided into equal groups and treated with first line reversible EGFR inhibitor gefitinib or irreversible pan-ErbB family inhibitor afatinib in order to obtain a direct comparison of these two approved first line treatments. Significant difference was seen in objective response with 70%  of cases with afatinib vs. 56% of cases with gefitinib. Median progression free survival was 11.0 months (10.6-12.9) with afatinib and 10.9 months (9.1-11.5) with gefitinib, HR 0.73 [0.57-0.95] p=0.017."	27083334	PubMed		"Park et al., 2016, Lancet Oncol."	NCT01466660	4	accepted	1728	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1728	https://civicdb.org/links/molecular_profiles/438	FALSE	EGFR	1956	Mutation		chr7	55019101	55211628			ENST00000275493.2	75		inframe_variant		2023-01-09 21:52:07 UTC		N/A		FALSE
SGK1 Overexpression	674	Breast Cancer	1612		Alpelisib		Predictive	Supports	D	Resistance	SGK1 mRNA expression was elevated in five breast cancer cell lines which were resistant to PI3Kalpha inhibitor alpelisib (NVP-BYL719) in comparison to five sensitive cell lines. Western blots showed clear elevation of protein levels in 3/5 resistant cell lines. Ectopic SGK1 expression in sensitive MDA-MB-361 cells resulted in alpelisib resistance and preservation of phopho-S6K and phospho-4EBP with alpelisib treatment. Knockdown of SGK1 in resistant HCC1954 cells increased alpelisib sensitivity and reduced p-S6K and p-4EBP levels with alpelisib treatment. Promoter methylation at SGK1 was increased in sensitive cells compared to alpelisib resistant cell lines.	27451907	PubMed		"Castel et al., 2016, Cancer Cell"		5	accepted	1729	Somatic	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/1729	https://civicdb.org/links/molecular_profiles/674	FALSE	SGK1	6446	Overexpression		chr6	134169246	134318058			ENST00000367858.5	75		N/A		2023-01-09 21:52:08 UTC		N/A		FALSE
SGK1 Overexpression	674	Breast Cancer	1612		Alpelisib		Predictive	Supports	B	Resistance	"A group of 18 breast cancer patients were treated with PI3Kalpha inhibitor alpelisib (NVP-BYL719) plus an aromatase inhbitor (NCT01870505). 3 out of 3 patients expressing high tumor SGK1 mRNA had disease progression as best response with median progression free survival (PFS) of 56 days, while 15 patients classified with low to medium SGK1 mRNA had median PFS 111 days with 4/15 having disease progression as best response."	27451907	PubMed		"Castel et al., 2016, Cancer Cell"		3	accepted	1730	N/A	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/1730	https://civicdb.org/links/molecular_profiles/674	FALSE	SGK1	6446	Overexpression		chr6	134169246	134318058			ENST00000367858.5	75		N/A		2023-01-09 21:52:08 UTC		N/A		FALSE
SGK1 Overexpression	674	Breast Cancer	1612		"Alpelisib,SGK1-Inh"	Combination	Predictive	Supports	D	Sensitivity/Response	"The alpelisib (PI3Kalpha inhibitor) resistant breast cancer cell line HCC1954 was treated with alpelsisb alone or in combination with the SGK1 kinase inhibitor SGK1-Inh. Addition of SGK1 reduced viability over alpelisib alone, and phospho-S6K as well as phospho-4EBP1 levels decreased with combination treatment. HCC1954 xenografts showed increased tumor volume with treatment of alpelisib or SGK1-Inh alone, but only combination treatment resulted in lack of volume increase and decreased phospho-S6K levels in tumors by IHC."	27451907	PubMed		"Castel et al., 2016, Cancer Cell"		4	accepted	1731	Somatic	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/1731	https://civicdb.org/links/molecular_profiles/674	FALSE	SGK1	6446	Overexpression		chr6	134169246	134318058			ENST00000367858.5	75		N/A		2023-01-09 21:52:08 UTC		N/A		FALSE
KRAS G12D	79	Pancreatic Ductal Carcinoma	3587				Prognostic	Supports	B	Poor Outcome	"Exon-2 KRAS mutation status was analyzed in 219 patients with pancreatic ductal carcinoma, excluding those who had previously undergone chemotherapy, first-line pancreatic resection, or neoadjuvant treatment with chemotherapy or radiotherapy. 72 patients had wild-type KRAS, 147 had a codon-12 KRAS mutation (G12D, G12V, or G12R) and 73 had a G12D KRAS mutation, specifically. There was no significant difference in overall survival between wild-type patients and patients with any type of exon-12 mutation. However, patients with the G12D mutation exhibited significantly lower overall survival compared to wild-type patients in univariate and multivariate analyses. This difference in overall survival between wild-type and G12D patients persisted in the subset of patients who underwent chemotherapy at any point after enrollment."	27010960	PubMed		"Bournet et al., 2016, Clin Transl Gastroenterol"		3	accepted	1732	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/1732	https://civicdb.org/links/molecular_profiles/79	FALSE	KRAS	3845	G12D	EGFR TKI Resistance	chr12	25245350	25245350	C	T	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.35G>A,NP_004976.2:p.Gly12Asp,NC_000012.11:g.25398284C>T,ENST00000256078.4:c.35G>A"	2023-01-27 17:02:26 UTC	CA122538	12582	"GLY12ASP,RS121913529"	FALSE
CD274 Expression	272	Lung Non-small Cell Carcinoma	3908		Pembrolizumab		Predictive	Supports	B	Sensitivity/Response	"This open-label, randomized, phase-3 clinical trial compared pembrolizumab to chemotherapy in treating NSCLC patients with PD-L1 expression on at least 50% of tumor cells and no sensitizing mutation of EGFR or translocation of ALK. Patients in the pembrolizumab group exhibited significantly better progression-free survival and overall survival compared to patients in the chemotherapy group."	27718847	PubMed		"Reck et al., 2016, N. Engl. J. Med."	NCT02142738	3	accepted	1733	N/A	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1733	https://civicdb.org/links/molecular_profiles/272	FALSE	CD274	29126	Expression		chr9	5450525	5470547			ENST00000381577.3	75		N/A	N/A	2023-01-09 21:52:06 UTC		N/A		FALSE
CCNE1 Overexpression	24	Ovarian Cancer	2394		CDK Inhibitor SNS-032		Predictive	Supports	D	Sensitivity/Response	Four ovarian cancer cell lines with elevated CCNE1 expression were 40x more sensitive to Cdk2 inhibitor SNS-032 than four cell lines without CCNE1 overexpression. SNS-032 greatly prolonged the survival of mice with CCNE1 overexpressing xenografts.	26204491	PubMed		"Yang et al., 2015, Oncotarget"		2	accepted	1734	N/A	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/1734	https://civicdb.org/links/molecular_profiles/24	FALSE	CCNE1	898	Overexpression		chr19	29811898	29824308			ENST00000262643.3	75		N/A		2023-01-09 21:52:04 UTC		N/A		FALSE
CCNE1 Amplification	187	Ovarian Serous Cystadenocarcinoma	5746		"Dinaciclib,Akt Inhibitor MK2206"	Combination	Predictive	Supports	D	Sensitivity/Response	"A high throughput compound screen identified synergistic combinations in CCNE1 amplified high grade serous ovarian carcinoma, including dinaciclib and AKT inhibitors"	27663592	PubMed		"Au-Yeung et al., 2016, Clin. Cancer Res."		4	accepted	1735	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/1735	https://civicdb.org/links/molecular_profiles/187	FALSE	CCNE1	898	Amplification		chr19	29811898	29824308			ENST00000262643.3	75		transcript_amplification	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
EGFR G719S	134	Lung Non-small Cell Carcinoma	3908		"Gefitinib,Erlotinib"	Substitutes	Predictive	Supports	B	Sensitivity/Response	"This small clinical (n=56) study suggests that patients with minor mutations of EGFR, like G719S, are likely to have a moderate response to Tyrosine kinase inhibitors like Gefitinib and Erlotinib. In this study 44 of 56 patients were treated with either gefitinib or erlotinib. 35 patients had a G719 mutation but the majority of these were G719S (20 with G719S, 9 with G719A, 3 with G719C)."	26124334	PubMed		"Otsuka et al., 2015, Anticancer Res."		3	accepted	1736	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/1736	https://civicdb.org/links/molecular_profiles/134	FALSE	EGFR	1956	G719S		chr7	55174014	55174014	G	A	ENST00000275493.2	75		missense_variant	"ENST00000275493.2:c.2155G>A,NC_000007.13:g.55241707G>A,NM_005228.4:c.2155G>A,NP_005219.2:p.Gly719Ser"	2023-01-27 17:02:49 UTC	CA126722	16612	"GLY719SER,RS28929495"	FALSE
STK11 Loss	481	Peutz-Jeghers Syndrome	3852				Predisposing	Supports	B	Predisposition	"In a series of 33 patients with Peutz-Jeghers Syndrome, 17 mutations in STK11/LKB1 were observed in exons 1-8 (none in exon 9). 11 of these mutations were predicted to be truncating. These mutations occurred in 10/13 patients with familial PJS and 7/20 patients with sporadic PJS."	12865922	PubMed		"Lim et al., 2003, Br. J. Cancer"		3	accepted	1737	Rare Germline	2023-01-31 23:19:04 UTC	https://civicdb.org/links/evidence_items/1737	https://civicdb.org/links/molecular_profiles/481	FALSE	STK11	6794	Loss		chr19	1205741	1228429			ENST00000326873.7	75		loss_of_function_variant		2023-01-09 21:52:07 UTC		N/A		FALSE
BRAF G596C	675	Lung Non-small Cell Carcinoma	3908		"Trametinib,Dabrafenib"	Combination	Predictive	Supports	D	Sensitivity/Response	"non-V600 BRAF mutations can be sensitive to clinically relevant doses of Dabrafenib and Trametinib in HEK293T cells, in lung epithelial cellular model (BEAS-2B) and in human cancer cell lines harboring non-V600 BRAF mutations"	27577079	PubMed		"Noeparast et al., 2016, Oncotarget"			accepted	1738	Somatic	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/1738	https://civicdb.org/links/molecular_profiles/675	TRUE	BRAF	673	G596C		chr7	140753349	140753349	C	A	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1786G>T,NP_004324.2:p.Gly596Cys,NC_000007.13:g.140453149C>A,ENST00000288602.6:c.1786G>T"	2023-01-27 17:04:52 UTC	CA135098	44814	"GLY596CYS,RS121913361"	FALSE
SMARCB1 Underexpression	676	Synovial Sarcoma	5485		Tazemetostat		Predictive	Supports	D	Sensitivity/Response	"Treatment with tazemetostat , a small-molecule inhibitor of EZH2, results in concentration-dependent cell growth inhibition and cell death specifically in SS18-SSX-positive, SMARCB1-deficient synovial sarcomas."	27391784	PubMed		"Kawano et al., 2016, PLoS ONE"		2	accepted	1739	N/A	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/1739	https://civicdb.org/links/molecular_profiles/676	FALSE	SMARCB1	6598	Underexpression		chr22	23786963	23834516			ENST00000344921.6	75		N/A		2023-01-09 21:52:08 UTC		N/A		FALSE
SMARCB1 Deletion	677	Rhabdoid Cancer	3672		Tazemetostat		Predictive	Supports	D	Sensitivity/Response	EPZ-6438 (Tazemetostat) induces apoptosis and differentiation specifically in SMARCB1-deleted malignant rhabdoid tumors (MRT) cells. This study compared in vitro EPZ-6438 treatment of four SMARCB1-deleted MRT cell lines to three control (wild-type) cell lines. These data demonstrate the dependency of SMARCB1 mutant MRTs on EZH2 enzymatic activity and suggest treatment of these genetically defined cancers with EZH2 inhibitors.	23620515	PubMed		"Knutson et al., 2013, Proc. Natl. Acad. Sci. U.S.A."		3	accepted	1740	Somatic	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/1740	https://civicdb.org/links/molecular_profiles/677	FALSE	SMARCB1	6598	Deletion		chr22	23786963	23834516			ENST00000344921.6	75		transcript_ablation		2023-01-09 21:52:08 UTC				FALSE
PTEN Deletion	213	Prostate Cancer	10283				Prognostic	Supports	B	Poor Outcome	"A meta-analysis of 26 published studies including 8097 prostate cancer patients showed that, compared to patients with normal PTEN, patients with PTEN deletion exhibited a greater aggressive Gleason score (OR: 1.284, 95% CI = 1.145?.439), pathological stage (OR: 1.628, 95% CI = 1.270?.087), and risk for recurrence of prostate cancer (HR: 1.738, 95% CI = 1.264?.390)."	27470558	PubMed		"Gao et al., 2016, Biomed. Pharmacother."		4	accepted	1741	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/1741	https://civicdb.org/links/molecular_profiles/213	FALSE	PTEN	5728	Deletion		chr10	87863113	87971930			ENST00000371953.3	75		transcript_ablation		2023-01-09 21:52:05 UTC		NONE FOUND		FALSE
NF2 Loss	678	Thyroid Gland Carcinoma	3963		Selumetinib		Predictive	Supports	D	Sensitivity/Response	"NF2 loss promotes oncogenic RAS-signaling via YAP-dependent transactivation of RAS and sensitizes to MEK inhibition. The authors demonstrate this in (A) isogenic lines derived from C643 cells (HRASG13R, NF2-WT) modified to stably express shNF2, (B) in set of 7 RAS-mutant thyroid cancer cell lines that differ in their NF2 expression levels, and (C) in a Hras-G12V/Nf2-null mouse model."	26359368	PubMed		"Garcia-Rendueles et al., 2015, Cancer Discov"		4	accepted	1742	Somatic	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/1742	https://civicdb.org/links/molecular_profiles/678	FALSE	NF2	4771	Loss		chr22	29603558	29698598			ENST00000338641.4	75		loss_of_function_variant		2023-01-09 21:52:08 UTC		N/A		FALSE
NF1 Loss	679	Malignant Peripheral Nerve Sheath Tumor	5940		JQ1 Compound		Predictive	Supports	D	Sensitivity/Response	"BRD4 inhibition supressess growth and tumorigenesis of NF1-/-, TP53-/- MPNST cells in mouse xenografts"	24373973	PubMed		"Patel et al., 2014, Cell Rep"		3	accepted	1743	Somatic	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/1743	https://civicdb.org/links/molecular_profiles/679	FALSE	NF1	4763	Loss		chr17	31094927	31377677			ENST00000358273.4	75		loss_of_function_variant		2023-01-09 21:52:08 UTC		N/A		FALSE
SH2B3 RS3184504	680	Colorectal Cancer	9256				Predisposing	Supports	B	Positive	"A genome wide association study (GWAS) meta-analysis of 13,265 cancer cases (colorectal cancer and endometrial cancer) and 40,245 controls found this variant to be associated with colorectal cancer (OR??.10, P??.23?0?). The authors speculated that since this polymorphism, a missense variant in the gene SH2B3, is also associated with haematological and autoimmune disorders, it might influence cancer risk through its role in the immune response."	26621817	PubMed		"Cheng et al., 2015, Sci Rep"		2	accepted	1744	Common Germline	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/1744	https://civicdb.org/links/molecular_profiles/680	FALSE	SH2B3	10019	RS3184504		chr12	111446804	111446804	T	C	ENST00000341259.2	75		"missense_variant,polymorphic_sequence_variant"	"NC_000012.11:g.111884608T>C,NM_005475.2:c.784T>C,ENST00000341259.2:c.784T>C"	2023-01-27 17:04:53 UTC	CA6789733	NONE FOUND	"ARG262TRP,R262W,TRP262ARG"	FALSE
KIF23 EXPRESSION	681	Hepatocellular Carcinoma	684				Prognostic	Supports	B	Better Outcome	"KIF23 variant 1 was found to be expressed in the cDNA of tumor tissues from a large cohort of HCC patients of chinese descent via PCR. This expression was absent in the normal tissues of these patients for this isoform. Using IHC and custom generated antibody, the overall survival with respect to KIF23 V1 expression was evaluated using the kaplan-meier method with a log rank test. It was found that positive KIF23 V1 staining was correlated with longer overall survival over a period of 5 years (p=.0052). This pattern was seen to a lesser degree over a period of 3 years (p=.1604). KIF23 V1 expression was independent of gender, age, tumor size, or TNM stage (multivariate cox regression)."	26674738	PubMed		"Sun et al., 2015, BMC Cancer"		3	accepted	1745	Somatic	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/1745	https://civicdb.org/links/molecular_profiles/681	FALSE	KIF23	9493	EXPRESSION		chr15	69414349	69448417			ENST00000260363.4	75		N/A		2023-01-09 21:52:08 UTC		N/A		FALSE
ERBB3 V104M	682	Transitional Cell Carcinoma	2671		Afatinib		Predictive	Supports	B	Sensitivity/Response	"In this phase II trial, patients with metastatic platinum-refractory urothelial carcinoma (UC) received afatinib (40 mg/day). Among the 21 tumors, five of six patients (83.3%) with ERBB2 (HER2) and/or ERBB3 alterations achieved 3-month progression-free survival (PFS3) versus none of 15 patients without alterations (P < .001). Three of three patients with ERBB3 somatic mutations (G284R, V104M, and R103G) achieved PFS3."	27044931	PubMed		"Choudhury et al., 2016, J. Clin. Oncol."		3	accepted	1746	Somatic	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/1746	https://civicdb.org/links/molecular_profiles/682	FALSE	ERBB3	2065	V104M		chr12	56085070	56085070	G	A	ENST00000267101.3	75		missense_variant	NC_000012.11:g.56478854G>A	2023-01-27 17:04:54 UTC	CA16602847	376410	VAL104MET	FALSE
ERBB3 R103G	683	Transitional Cell Carcinoma	2671		Afatinib		Predictive	Supports	B	Sensitivity/Response	"In this phase II trial, patients with metastatic platinum-refractory urothelial carcinoma (UC) received afatinib (40 mg/day). Among the 21 tumors, five of six patients (83.3%) with ERBB2 (HER2) and/or ERBB3 alterations achieved 3-month progression-free survival (PFS3) versus none of 15 patients without alterations (P < .001). Three of three patients with ERBB3 somatic mutations (G284R, V104M, and R103G) achieved PFS3."	27044931	PubMed		"Choudhury et al., 2016, J. Clin. Oncol."		3	accepted	1747	Somatic	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/1747	https://civicdb.org/links/molecular_profiles/683	FALSE	ERBB3	2065	R103G		chr12	56085067	56085067	C	G	ENST00000267101.3	75		missense_variant	NC_000012.11:g.56478851C>G	2023-01-27 17:04:54 UTC	CA385279657	NONE FOUND	ARG103GLY	FALSE
ERBB3 G284R	684	Transitional Cell Carcinoma	2671		Afatinib		Predictive	Supports	B	Sensitivity/Response	"In this phase II trial, patients with metastatic platinum-refractory urothelial carcinoma (UC) received afatinib (40 mg/day). Among the 21 tumors, five of six patients (83.3%) with ERBB2 (HER2) and/or ERBB3 alterations achieved 3-month progression-free survival (PFS3) versus none of 15 patients without alterations (P < .001). Three of three patients with ERBB3 somatic mutations (G284R, V104M, and R103G) achieved PFS3."	27044931	PubMed		"Choudhury et al., 2016, J. Clin. Oncol."		3	accepted	1748	Somatic	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/1748	https://civicdb.org/links/molecular_profiles/684	FALSE	ERBB3	2065	G284R		chr12	56088138	56088138	G	A	ENST00000267101.3	75		missense_variant	NC_000012.11:g.56481922G>A	2023-01-27 17:04:55 UTC	CA16602624	376167	GLY284ARG	FALSE
BRAF V600E	12	Melanoma	1909		Vemurafenib		Predictive	Supports	B	Sensitivity/Response	"Multicenter, phase 1, dose-escalation trial of PLX4032 (Vemurafenib). Treatment of metastatic melanoma with PLX4032 in patients with tumors that carry the V600E BRAF mutation resulted in complete or partial tumor regression in the majority of patients (N=37/48). Patients without the V600E mutation had evidence of tumor regression."	20818844	PubMed		"Flaherty et al., 2010, N. Engl. J. Med."		4	accepted	1749	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/1749	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
BRAF V600	17	Melanoma	1909		Trametinib		Predictive	Supports	B	Sensitivity/Response	"Patients who had histologically confirmed, unresectable stage IIIC or IV cutaneous melanoma with a V600E or V600K BRAF mutation were eligible for the study. 322 eligible patients (281 with the V600E mutation, 40 with the V600K mutation, and 1 with both mutations) in a 2:1 ratio to receive oral trametinib (2 mg once daily) or intravenous chemotherapy consisting of either dacarbazine (1000 mg per square meter of body-surface area) or paclitaxel (175 mg per square meter), at the discretion of the investigator, every 3 weeks. The primary end point was progression-free survival; secondary end points included overall survival, overall response rate, duration of response, and safety. Treatment continued until disease progression, death, or withdrawal from the study. In the intention-to-treat population, the median duration of progression-free survival was 4.8 months in the trametinib group as compared with 1.5 months in the chemotherapy group (hazard ratio for progression, 0.45; 95% confidence interval [CI], 0.33 to 0.63; P<0.001).  The 6-month overall survival rate in the intention-to-treat population was 81% in the trametinib group and 67% in the chemotherapy group."	22663011	PubMed		"Flaherty et al., 2012, N. Engl. J. Med."	NCT01245062	3	accepted	1750	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/1750	https://civicdb.org/links/molecular_profiles/17	FALSE	BRAF	673	V600	Other BRAF V600's	chr7	140753336	140753337			ENST00000288602.6	75		protein_altering_variant		2023-01-09 21:52:04 UTC		"13,961,448,153,762,800,000,000,000,000,000"	VAL600	FALSE
GADD45A rs681673	686	Ovarian Cancer	2394				Predisposing	Supports	B	Predisposition	"GADD45A (1506T>C) association with ovarian cancer was investigated with 258 ovarian cancer patients and 332 age matched healthy women as controls using sequence analysis. A significant difference in genotype distribution was observed between cases and controls  (TT vs. TC vs. CC, P = 0.0021). A statistically significant difference in the GADD454A (1506T>C) variant between the controls groups was found in correlation with an increased risk of ovarian cancer (P<0.001, OR = 1.71, 95% CI 1.28?.29).  Presence of the GADD45A (1506T>C) variant was also found to have higher GADD45A mRNA expression, longer ovarian cancer relapse free survival and overall survival."	26422378	PubMed		"Yuan et al., 2015, PLoS ONE"		3	accepted	1751	Common Germline	2023-01-12 05:36:01 UTC	https://civicdb.org/links/evidence_items/1751	https://civicdb.org/links/molecular_profiles/686	FALSE	GADD45A	1647	rs681673		chr1	67686705	67686705	T	C	ENST00000370986.4	75		coding_transcript_intron_variant		2023-01-27 17:04:56 UTC	CA10728634		1506T>C	FALSE
EWSR1 EWSR1::FLI1	687	Ewing Sarcoma Of Bone	3368				Diagnostic	Supports	B	Positive	A total of 85 unrelated cases of Ewing's sarcoma were examined and 83% we found to harbor the t(11;22)(q24;q12) chromosomal abnormality (EWS/FLI).	3163261	PubMed		"Turc-Carel et al., 1988, Cancer Genet. Cytogenet."		4	accepted	1752	Somatic	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/1752	https://civicdb.org/links/molecular_profiles/687	FALSE	EWSR1	2130	EWSR1::FLI1		chr22	29268318	29292169			ENST00000414183.2	75	ENST00000527786.2	transcript_fusion		2023-01-09 21:52:08 UTC		N/A	"EWS-FLI,T(11;22)(Q24;Q12),EWSR1-FLI1"	FALSE
EWSR1 EWSR1::FLI1	687	Ewing Sarcoma Of Bone	3368				Diagnostic	Supports	B	Positive	A total of 85 unrelated cases of Ewing's sarcoma were examined and 83% we found to harbor the t(11;22)(q24;q12) chromosomal abnormality (EWS/FLI).	3163261	PubMed		"Turc-Carel et al., 1988, Cancer Genet. Cytogenet."		4	accepted	1752	Somatic	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/1752	https://civicdb.org/links/molecular_profiles/687	FALSE	EWSR1	2130	EWSR1::FLI1		chr11	128768118	128813267			ENST00000414183.2	75	ENST00000527786.2	transcript_fusion		2023-01-09 21:52:08 UTC		N/A	"EWS-FLI,T(11;22)(Q24;Q12),EWSR1-FLI1"	FALSE
EWSR1 EWSR1::FLI1	687	Ewing Sarcoma Of Bone	3368				Diagnostic	Supports	B	Positive	"The authors propose RT-PCR as a diagnostic test for Ewing sarcoma using FFPE materials.  Starting with 40 cases, intact RNA could be isolated from 6, and of these the EWS-FLI event was detected in 2 by nested PCR. Alternative diagnostic assays for this event are also considered."	9741544	PubMed		"Park et al., 1998, J. Korean Med. Sci."		2	accepted	1753	Somatic	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/1753	https://civicdb.org/links/molecular_profiles/687	FALSE	EWSR1	2130	EWSR1::FLI1		chr22	29268318	29292169			ENST00000414183.2	75	ENST00000527786.2	transcript_fusion		2023-01-09 21:52:08 UTC		N/A	"EWS-FLI,T(11;22)(Q24;Q12),EWSR1-FLI1"	FALSE
EWSR1 EWSR1::FLI1	687	Ewing Sarcoma Of Bone	3368				Diagnostic	Supports	B	Positive	"The authors propose RT-PCR as a diagnostic test for Ewing sarcoma using FFPE materials.  Starting with 40 cases, intact RNA could be isolated from 6, and of these the EWS-FLI event was detected in 2 by nested PCR. Alternative diagnostic assays for this event are also considered."	9741544	PubMed		"Park et al., 1998, J. Korean Med. Sci."		2	accepted	1753	Somatic	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/1753	https://civicdb.org/links/molecular_profiles/687	FALSE	EWSR1	2130	EWSR1::FLI1		chr11	128768118	128813267			ENST00000414183.2	75	ENST00000527786.2	transcript_fusion		2023-01-09 21:52:08 UTC		N/A	"EWS-FLI,T(11;22)(Q24;Q12),EWSR1-FLI1"	FALSE
EWSR1 EWSR1::FLI1	687	Ewing Sarcoma Of Bone	3368				Diagnostic	Supports	B	Positive	"An evaluation of alternative strategies for detection of EWS-FLI (FISH break apart, FISH fusion, and RT-PCR).  Of the 22 informative EWS/PNETs, 20 cases (91%) were positive by FISH break apart, FISH fusion, or both."	16258512	PubMed		"Bridge et al., 2006, Mod. Pathol."		3	accepted	1754	Somatic	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/1754	https://civicdb.org/links/molecular_profiles/687	FALSE	EWSR1	2130	EWSR1::FLI1		chr22	29268318	29292169			ENST00000414183.2	75	ENST00000527786.2	transcript_fusion		2023-01-09 21:52:08 UTC		N/A	"EWS-FLI,T(11;22)(Q24;Q12),EWSR1-FLI1"	FALSE
EWSR1 EWSR1::FLI1	687	Ewing Sarcoma Of Bone	3368				Diagnostic	Supports	B	Positive	"An evaluation of alternative strategies for detection of EWS-FLI (FISH break apart, FISH fusion, and RT-PCR).  Of the 22 informative EWS/PNETs, 20 cases (91%) were positive by FISH break apart, FISH fusion, or both."	16258512	PubMed		"Bridge et al., 2006, Mod. Pathol."		3	accepted	1754	Somatic	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/1754	https://civicdb.org/links/molecular_profiles/687	FALSE	EWSR1	2130	EWSR1::FLI1		chr11	128768118	128813267			ENST00000414183.2	75	ENST00000527786.2	transcript_fusion		2023-01-09 21:52:08 UTC		N/A	"EWS-FLI,T(11;22)(Q24;Q12),EWSR1-FLI1"	FALSE
MTHFR A222V	254	Pancreatic Cancer	1793				Prognostic	Supports	B	Better Outcome	Study of 1817 PCa cases and 2026 cancer free controls to clarify the association of (MTHFR)c.677C>T (and c.1298A>C ) of pancreatic cancer risk in a population of Han Chinese in Shanghai. Results indicated a lower risk for the heterozygous CT genotype and homozygous TT genotype carriers of (MTHFR)c.677C>T which had a significantly lower risk of developing pancreatic cancer compared with the wild-type CC genotype.	27819322	PubMed		"Wu et al., 2016, Sci Rep"		4	accepted	1756	Common Germline	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/1756	https://civicdb.org/links/molecular_profiles/254	FALSE	MTHFR	4524	A222V		chr1	11796321	11796321	G	A	ENST00000376592.1	75		missense_variant	"NM_005957.4:c.665C>T,NP_005948.3:p.Ala222Val,ENST00000376592.1:c.665G>A,NC_000001.10:g.11856378G>A"	2023-01-27 17:03:17 UTC	CA170990	3520	"RS1801133,C677T,ALA222VAL"	FALSE
MTHFR A222V	254	Rectum Cancer	1993		Fluorouracil		Predictive	Supports	B	Sensitivity/Response	"Patients with the wild type (C/C) MTHFR gene are 2.91 times (95% CI: [1.23, 6.89]) more likely to have a positive response to neoadjuvant CRT and  3.25 times more likely not to experience relapse (95% CI: [1.37, 7.72]) than patients with the heterozygous  MTHFR [rs1801133 (C>T)] mutation or  the homzygous (T/T)."	26693073	PubMed		"Nikas et al., 2015, Am J Cancer Res"		4	accepted	1757	Common Germline	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/1757	https://civicdb.org/links/molecular_profiles/254	FALSE	MTHFR	4524	A222V		chr1	11796321	11796321	G	A	ENST00000376592.1	75		missense_variant	"NM_005957.4:c.665C>T,NP_005948.3:p.Ala222Val,ENST00000376592.1:c.665G>A,NC_000001.10:g.11856378G>A"	2023-01-27 17:03:17 UTC	CA170990	3520	"RS1801133,C677T,ALA222VAL"	FALSE
HOXB13 G84E	753	Prostate Cancer	10283				Predisposing	Supports	B	Predisposition	"G84E (rs138213197) substitution in HOXB13 is associated with an increased risk for prostate cancer. 49 out of 9012 male patients in the Mayo Clinic Biobank were carriers. 31% of patients were diagnosed with cancer (n=2,595). Cancer diagnosis was more common in G84E carriers than in non-carriers (51.5% vs 30.6%, P = 0.004). G84E was highly prevalent in patients with prostate cancer than those without cancer (P < 0.0001). Evidence also supported a possible link between G84E with bladder cancer (P = 0.06) and leukemia (P = 0.01). Patient family history indicated a history of prostate cancer with a first degree relative was more common when compared to non-carriers (36.2% vs. 16.0%, P = 0.0003)."	26108461	PubMed		"Beebe-Dimmer et al., 2015, Cancer Epidemiol. Biomarkers Prev."		4	accepted	1760	Common Germline	2023-01-12 05:42:12 UTC	https://civicdb.org/links/evidence_items/1760	https://civicdb.org/links/molecular_profiles/753	FALSE	HOXB13	10481	G84E		chr17	48728343	48728343	C	T	ENST00000290295.7	75		missense_variant	"NC_000017.10:g.46805705C>T,NM_006361.5:c.251G>A,NP_006352.2:p.Gly84Glu,ENST00000290295.7:c.251G>A"	2023-01-27 17:05:32 UTC	CA288225	128031	"RS138213197,GLY84GLU"	FALSE
EGFR D761Y	693	Lung Non-small Cell Carcinoma	3908		"Gefitinib,Erlotinib"	Substitutes	Predictive	Supports	C	Resistance	D761Y as a secondary mutation was reported to be associated with resistance to gefitinib and erlotinib in NSCLC cells that contain the L858R-EGFR mutation. This mutation combination was observed in a single patient with lung cancer and specifically in a metastatic brain lesion following gefitinib treatment. Functional validation of its role in drug sensitivity was examined in cell lines (293T and Ba/F3 cells).	17085664	PubMed		"Balak et al., 2006, Clin. Cancer Res."		3	accepted	1763	Somatic	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/1763	https://civicdb.org/links/molecular_profiles/693	FALSE	EGFR	1956	D761Y		chr7	55174818	55174818	G	T	ENST00000275493.2	75		missense_variant	"ENST00000275493.2:c.2281G>T,NM_005228.4:c.2281G>T,NP_005219.2:p.Asp761Tyr,NC_000007.13:g.55242511G>T"	2023-01-27 17:04:57 UTC	CA135827	45244	"ASP761TYR,RS121913418"	FALSE
ERBB2 Amplification	302	Her2-receptor Positive Breast Cancer	60079		Trastuzumab Emtansine		Predictive	Supports	B	Sensitivity/Response	"In the single arm Phase II study (TDM4258g) breast cancer patients who had progressed on previous anti-HER2 therapy were given transtuzumab emtansine (T-DM1), a HER2 monoclonal antibody and antimicrotubule drug conjugate. 95 trial participants with archival primary tumor were reassessed for HER2 status (positivity defined by FISH or IHC 3+), and 74 patients were confirmed for HER2 positivity and 21 were normal. Overall response rate was 33.8% (95% CI, 23.2% to 44.9%) in patients with confirmed HER2-positive tumors and 4.8% (95% CI, 1.0% to 21.8%) in HER2 normal patients. Median PFS was 8.2 months (95% CI, 4.4 months to not estimable) in patients with confirmed HER2-positive tumors and 2.6 months (95% CI, 1.4 to 3.9 months) in HER2 normal patients."	21172893	PubMed		"Burris et al., 2011, J. Clin. Oncol."		4	accepted	1764	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1764	https://civicdb.org/links/molecular_profiles/302	FALSE	ERBB2	2064	Amplification		chr17	39700080	39728662			ENST00000269571.5	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A	OVEREXPRESSION	FALSE
CDKN2A Loss	550	Her2-receptor Negative Breast Cancer	60080		"Letrozole,Palbociclib"	Combination	Predictive	Supports	C	Sensitivity/Response	"A patient with metastatic ER-positive, her2-negative breast cancer with CDKN2A loss experienced a short-lived (~3-month) clinical response to palbociclib when given in combination with letrozole."	26715889	PubMed		"Gao et al., 2015, Curr Oncol"		3	accepted	1765	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1765	https://civicdb.org/links/molecular_profiles/550	FALSE	CDKN2A	1029	Loss		chr9	21967753	21994624			ENST00000579755.1	75		loss_of_function_variant		2023-01-09 21:52:07 UTC		N/A		FALSE
CRBN Mutation	694	Multiple Myeloma	9538		"Lenalidomide,Pomalidomide"	Substitutes	Predictive	Supports	C	Resistance	"A 37 year old, heavily pretreated (including thalidomide and lenalidomide) patient with IgG-kappa multiple myeloma was sequenced following extramedullary relapse. A high number of alterations were observed including 38 rearrangements, 35 translocations, 4 indels, and 271 nonsynonymous point mutations. Two mutations altering CRBN (Q99* and R283K), a gene previously described as being necessary for immunomodulatory drug response, were observed and thought to be responsible for resistance to the pomalidomide and dexamethasone treatment she received but failed to respond to following sequencing."	23480694	PubMed		"Egan et al., 2013, Br. J. Haematol."		3	accepted	1766	Somatic	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/1766	https://civicdb.org/links/molecular_profiles/694	FALSE	CRBN	51185	Mutation		chr3	3150011	3179710			ENST00000231948.4	75				2023-01-09 21:52:08 UTC				FALSE
FGFR1 Amplification	263	Estrogen-receptor Positive Breast Cancer	60075		Ponatinib		Predictive	Supports	D	Sensitivity/Response	In MDA-MB-134 cells (ER-positive breast cancer cells with amplified FGFR1) ponatinib potently inhibited cell growth with a GI50 value of 23 nmol/L and inhibited FGFR1 phosphorylation with an IC50 value of 7 nmol/L.	22238366	PubMed		"Gozgit et al., 2012, Mol. Cancer Ther."		3	accepted	1767	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/1767	https://civicdb.org/links/molecular_profiles/263	FALSE	FGFR1	2260	Amplification		chr8	38411138	38467845			ENST00000425967.3	75		transcript_amplification	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
TSC1 R1062W	695	Tuberous Sclerosis	13515				Predisposing	Supports	C	Uncertain Significance	"Deep sequencing of TSC1 and TSC2 was performed on blood from a group of 38 sporadic Tuberous Sclerosis patients who had been previously studied with no mutation identified in TSC1 or TSC2. Five patients had readily observable mutations in these genes, one of which was a previously unidentified TSC1 missense change R1062W. The authors indicate that the mutation may not be pathogenic."	20165957	PubMed		"Qin et al., 2010, Hum. Genet."		2	accepted	1768	Rare Germline	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/1768	https://civicdb.org/links/molecular_profiles/695	FALSE	TSC1	7248	R1062W		chr9	132896546	132896546	G	A	ENST00000298552.3	75		missense_variant	"NM_000368.3:c.3184C>T,NP_000359.1:p.Arg1062Trp,ENST00000298552.3:c.3184C>T,NC_000009.11:g.135771933G>A"	2023-01-27 17:04:57 UTC	CA007223	49015	ARG1062TRP	FALSE
STK11 Mutation	696	Peutz-Jeghers Syndrome	3852				Predisposing	Supports	B	Predisposition	"Retrospective analysis of the Danish tumor bank. 43 patients with Peutz-Jeghers Syndrome were identified (clinical criteria + STK11 mutations). STK11 mutations were detected in 86% of those tested (18 of 21 probands) and included eight nonsense mutations, five frameshift mutations, two splice site mutations, two large genomic rearrangements, and one missense mutation."	26979979	PubMed		"Jelsig et al., 2016, Int J Colorectal Dis"		4	accepted	1769	Rare Germline	2023-01-12 05:51:34 UTC	https://civicdb.org/links/evidence_items/1769	https://civicdb.org/links/molecular_profiles/696	FALSE	STK11	6794	Mutation		chr19	1205741	1223075			ENST00000326873.7	75		gene_variant		2023-01-09 21:52:08 UTC		N/A		FALSE
BTK C481S	168	Chronic Lymphocytic Leukemia	1040		Ibrutinib		Predictive	Supports	B	Resistance	"In a trial of 308 patients with chronic lymphocytic leukemia treated with ibrutinib, 31 discontinued treatment due to disease progression (13 CLL progression, 18 Richters transformation). 11/13 patients were deep sequenced for BTK and PLCG2. 9 patients were identified with BTK mutations (C481S in 8 patients). In 5 patients, C481S was the sole abnormality."	26182309	PubMed		"Maddocks et al., 2015, JAMA Oncol"	"NCT01105247,NCT01217749,NCT01578707,NCT01589302"	4	accepted	1770	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/1770	https://civicdb.org/links/molecular_profiles/168	FALSE	BTK	695	C481S		chrX	101356177	101356177	A	T	ENST00000308731.7	75		missense_variant	"ENST00000308731.7:c.1441T>A,NC_000023.10:g.100611165A>T,NM_000061.2:c.1441T>A,NP_000052.1:p.Cys481Ser"	2023-01-27 17:02:58 UTC	CA16602659	376204	"CYS481SER,RS1057519826"	FALSE
PDGFRA Amplification	697	Lung Non-small Cell Carcinoma	3908		Sunitinib		Predictive	Supports	D	Sensitivity/Response	"In a high-throughput cell line screen of 637 cell lines, only 2 sunitinib sensitive cell lines were identified. In the sunitinib-sensitive adenosquamous NSCLC cell line (NCI-H1703), PDGFRA expression was associated with focal PDGFRA gene amplification. This alteration was detected in a small fraction of primary squamous cell NSCLC tumor specimens. Focal amplification of PDGFC, the gene encoding the PDGFR ligand, was also detected."	19366796	PubMed		"McDermott et al., 2009, Cancer Res."		3	accepted	1771	Somatic	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/1771	https://civicdb.org/links/molecular_profiles/697	FALSE	PDGFRA	5156	Amplification		chr4	54229097	54298247			ENST00000257290.5	75		transcript_amplification		2023-01-09 21:52:08 UTC		N/A		FALSE
BRCA1 Mutation	185	Ovarian Cancer	2394		Olaparib		Predictive	Supports	B	Sensitivity/Response	"In a study of 63 patients with ovarian cancer, 17 patients had BRCA1 or BRCA2 mutations and 46 patients had no BRCA mutations.  Of the BRCA-positive patients, 7/17(41%; 95%CI 22-64) showed objective response to olaparib whereas only 11/46 BRCA-negative patients (24%; 95%CI 14-38) showed objective response to olaparib."	21862407	PubMed		"Gelmon et al., 2011, Lancet Oncol."	NCT00679783	3	accepted	1772	Rare Germline	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/1772	https://civicdb.org/links/molecular_profiles/185	FALSE	BRCA1	672	Mutation		chr17	43045629	43125483			ENST00000471181.2	75		"gene_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
BRCA2 Mutation	186	Ovarian Cancer	2394		Olaparib		Predictive	Supports	B	Sensitivity/Response	"In a study of 63 patients with ovarian cancer, 17 patients had BRCA1 or BRCA2 mutations and 46 patients had no BRCA mutations.  Of the BRCA-positive patients, 7/17(41%; 95%CI 22-64) showed objective response to olaparib whereas only 11/46 BRCA-negative patients (24%; 95%CI 14-38) showed objective response to olaparib."	21862407	PubMed		"Gelmon et al., 2011, Lancet Oncol."	NCT00679783	3	accepted	1773	Rare Germline	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/1773	https://civicdb.org/links/molecular_profiles/186	FALSE	BRCA2	675	Mutation		chr13	32315474	32399210			ENST00000380152.3	75		"gene_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
PDGFRA FIP1L1::PDGFRA	570	"Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1"	80164		Imatinib		Predictive	Supports	C	Sensitivity/Response	"A patient with monoblastic myeloid sarcoma harbouring a PCR confirmed FIP1L1-PDGFRA rearrangement was treated with imatinib monotherapy. The patient demonstrated a durable response (10 wks) while on therapy which was reversed when the patient discontinued treatment. Imatinib therapy was subsequently restarted, with peripheral blood and BM analyses returning to normal after 4 weeks."	24456122	PubMed		"Srinivas et al., 2014, Br. J. Haematol."		3	accepted	1774	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1774	https://civicdb.org/links/molecular_profiles/570	FALSE	PDGFRA	5156	FIP1L1::PDGFRA		chr4	53377645	53428183			ENST00000337488.6	75	ENST00000257290.5	transcript_fusion		2023-01-09 21:52:08 UTC		N/A	FIP1L1-PDGFRA	FALSE
PDGFRA FIP1L1::PDGFRA	570	"Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1"	80164		Imatinib		Predictive	Supports	C	Sensitivity/Response	"A patient with monoblastic myeloid sarcoma harbouring a PCR confirmed FIP1L1-PDGFRA rearrangement was treated with imatinib monotherapy. The patient demonstrated a durable response (10 wks) while on therapy which was reversed when the patient discontinued treatment. Imatinib therapy was subsequently restarted, with peripheral blood and BM analyses returning to normal after 4 weeks."	24456122	PubMed		"Srinivas et al., 2014, Br. J. Haematol."		3	accepted	1774	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1774	https://civicdb.org/links/molecular_profiles/570	FALSE	PDGFRA	5156	FIP1L1::PDGFRA		chr4	54274841	54298247			ENST00000337488.6	75	ENST00000257290.5	transcript_fusion		2023-01-09 21:52:08 UTC		N/A	FIP1L1-PDGFRA	FALSE
BRCA1 Mutation	185	Triple-receptor Negative Breast Cancer	60081		Olaparib		Predictive	Supports	B	Resistance	"In a study of 26 patients with breast cancer, 10 patients were BRCA-positive and 16 patients were BRCA-negative.  Regardless of BRCA status, none showed objective response when treated with olaparib."	21862407	PubMed		"Gelmon et al., 2011, Lancet Oncol."	NCT00679783	3	accepted	1775	Rare Germline	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/1775	https://civicdb.org/links/molecular_profiles/185	FALSE	BRCA1	672	Mutation		chr17	43045629	43125483			ENST00000471181.2	75		"gene_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
BRCA2 Mutation	186	Triple-receptor Negative Breast Cancer	60081		Olaparib		Predictive	Does Not Support	B	Sensitivity/Response	"In a study of 26 patients with breast cancer, 10 patients were BRCA-positive and 16 patients were BRCA-negative.  Regardless of BRCA status, none showed objective response when treated with olaparib."	21862407	PubMed		"Gelmon et al., 2011, Lancet Oncol."	NCT00679783	3	accepted	1776	Rare Germline	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/1776	https://civicdb.org/links/molecular_profiles/186	FALSE	BRCA2	675	Mutation		chr13	32315474	32399210			ENST00000380152.3	75		"gene_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
PDGFRA FIP1L1::PDGFRA	570	"Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1"	80164		Ponatinib		Predictive	Supports	D	Sensitivity/Response	"In a FIP1L1-PDGFRA positive eosinophil cell line growth-inhibitory effects were seen with all PDGFR-blocking agents, (ponatinib, sorafenib, masitinib, nilotinib, dasatinib, sunitinib, midostaurin) with ponatinib found to be the most potent compound."	24407160	PubMed		"Sadovnik et al., 2014, Exp. Hematol."		3	accepted	1777	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1777	https://civicdb.org/links/molecular_profiles/570	FALSE	PDGFRA	5156	FIP1L1::PDGFRA		chr4	53377645	53428183			ENST00000337488.6	75	ENST00000257290.5	transcript_fusion		2023-01-09 21:52:08 UTC		N/A	FIP1L1-PDGFRA	FALSE
PDGFRA FIP1L1::PDGFRA	570	"Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1"	80164		Ponatinib		Predictive	Supports	D	Sensitivity/Response	"In a FIP1L1-PDGFRA positive eosinophil cell line growth-inhibitory effects were seen with all PDGFR-blocking agents, (ponatinib, sorafenib, masitinib, nilotinib, dasatinib, sunitinib, midostaurin) with ponatinib found to be the most potent compound."	24407160	PubMed		"Sadovnik et al., 2014, Exp. Hematol."		3	accepted	1777	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1777	https://civicdb.org/links/molecular_profiles/570	FALSE	PDGFRA	5156	FIP1L1::PDGFRA		chr4	54274841	54298247			ENST00000337488.6	75	ENST00000257290.5	transcript_fusion		2023-01-09 21:52:08 UTC		N/A	FIP1L1-PDGFRA	FALSE
DDIT3 EWSR1::DDIT3	698	Myxoid Liposarcoma	5363				Diagnostic	Supports	C	Positive	Identified two cases of myxoid liposarcoma with translocations (between 12q13 and 22q12) giving rise to EWSR1-DDIT3 (EWS-CHOP) fusions instead of the more common FUS-DDIT3.	8637704	PubMed		"Panagopoulos et al., 1996, Oncogene"		3	accepted	1778	Somatic	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/1778	https://civicdb.org/links/molecular_profiles/698	FALSE	DDIT3	1649	EWSR1::DDIT3		chr22	29268318	29291599			ENST00000414183.2	75	ENST00000346473.3	transcript_fusion		2023-01-09 21:52:08 UTC		N/A	"T(12;22)(Q13;Q12),EWS-CHOP,EWSR1-DDIT3"	FALSE
DDIT3 EWSR1::DDIT3	698	Myxoid Liposarcoma	5363				Diagnostic	Supports	C	Positive	Identified two cases of myxoid liposarcoma with translocations (between 12q13 and 22q12) giving rise to EWSR1-DDIT3 (EWS-CHOP) fusions instead of the more common FUS-DDIT3.	8637704	PubMed		"Panagopoulos et al., 1996, Oncogene"		3	accepted	1778	Somatic	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/1778	https://civicdb.org/links/molecular_profiles/698	FALSE	DDIT3	1649	EWSR1::DDIT3		chr12	57516593	57517753			ENST00000414183.2	75	ENST00000346473.3	transcript_fusion		2023-01-09 21:52:08 UTC		N/A	"T(12;22)(Q13;Q12),EWS-CHOP,EWSR1-DDIT3"	FALSE
PDGFRA FIP1L1::PDGFRA T674I	573	"Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1"	80164		Ponatinib		Predictive	Supports	D	Sensitivity/Response	"Ba/F3 cells expressing two clinically relevant, imatinib-resistant, mutant forms of FIP1L1-PDGFRA, namely T674I and D842V were tested for growth inhibition by 8 PDGFR-blocking TKIs. Strong inhibitory effects on both mutants were seen only with ponatinib."	24407160	PubMed		"Sadovnik et al., 2014, Exp. Hematol."		3	accepted	1779	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1779	https://civicdb.org/links/molecular_profiles/573	FALSE	PDGFRA	5156	FIP1L1::PDGFRA T674I		chr4	54278380	54278380	C	T	ENST00000257290.5	75		"missense_variant,transcript_fusion"	"NC_000004.11:g.55144547C>T,ENST00000257290.5:c.2021C>T,NM_006206.5:c.2021C>T,NP_006197.1:p.Thr674Ile"	2023-01-27 17:04:23 UTC	CA123215	13550	"THR674ILE,RS121908587,FIP1L1-PDGFRA T674I"	FALSE
EGFR G719	699	Lung Adenocarcinoma	3910		Erlotinib		Predictive	Supports	B	Sensitivity/Response	"In a meta-analysis of 7 clinical trials of erlotinib (some vs placebo or other treatment), 10/24 patients with Exon 18 mutations harbored a G719 variant. These variants were associated with improved progression-free and overall survival. No statistical analysis was reported for this variant and PFS or OS, citing small sample size across the studies."	26773740	PubMed		"Klughammer et al., 2016, J Thorac Oncol"		2	accepted	1780	Somatic	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/1780	https://civicdb.org/links/molecular_profiles/699	FALSE	EGFR	1956	G719		chr7	55174014	55174015			ENST00000275493.2	75		protein_altering_variant		2023-01-09 21:52:08 UTC		"16,612,452,254,522,400,000,000,000"	"GLY719,G719X"	FALSE
EGFR S720	701	Lung Adenocarcinoma	3910		Erlotinib		Predictive	Supports	C	Resistance	"Efficacy of erlotinib treatment was evaluated by meta-analysis of results from seven trials and literature review. Two patients with p.S270P, and one patient with p.S720F were observed to have poor survival outcomes."	26773740	PubMed		"Klughammer et al., 2016, J Thorac Oncol"		3	accepted	1782	Somatic	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/1782	https://civicdb.org/links/molecular_profiles/701	FALSE	EGFR	1956	S720		chr7	55174017	55174018			ENST00000275493.2	75		protein_altering_variant		2023-01-09 21:52:08 UTC		NONE FOUND	SER720	FALSE
ALK Fusion	495	Inflammatory Myofibroblastic Tumor	50905				Diagnostic	Supports	C	Positive	"Fluorescence in situ hybridization with a probe flanking the ALK gene at 2p23 and immunohistochemistry revealed ALK expression, suggesting ALK fusions in three cases of IMT."	10383129	PubMed		"Griffin et al., 1999, Cancer Res."		4	accepted	1783	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1783	https://civicdb.org/links/molecular_profiles/495	FALSE	ALK	238	Fusion	ALK Fusion	chr2	29192774	29223528			ENST00000389048.3	75		transcript_fusion		2023-01-09 21:52:07 UTC		N/A	REARRANGEMENT	FALSE
CYP2D6 Loss-of-function	702	Breast Cancer	1612				Prognostic	Does Not Support	B	Poor Outcome	"Meta-analysis of 25 studies involving 13,629 women with tamoxifen treated breast cancer. The meta-analysis investigated the association between CYP2D6 genotypes and response to tamoxifen treatment (loss/reduced function vs. unchanged/increased function). The authors examine a prevailing hypothesis that individuals carrying a reduced function CYP2D6 allele have poorer outcomes due to less metabolism of tamoxifen to active metabolites. The study concludes that there is insufficient evidence to support use of CYP2D6 genotyping as a guide for tamoxifen use in breast cancer."	24098545	PubMed		"Lum et al., 2013, PLoS ONE"		4	accepted	1784	Common Germline	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/1784	https://civicdb.org/links/molecular_profiles/702	FALSE	CYP2D6	1565	Loss-of-function		chr22	42126499	42130906			ENST00000360608.5	75		loss_of_function_variant		2023-01-09 21:52:08 UTC		N/A		FALSE
EGFR K757R	704	Lung Adenocarcinoma	3910		Erlotinib		Predictive	Supports	C	Sensitivity/Response	"In a meta-analysis of 7 clinical trials evaluating the efficacy of erlotinib, one patient was described with the exon 19 mutation K757R from the MERIT study. Progression-free (250 days) and overall (435 days) survival suggested sensitivity in this patient. Literature analysis did not identify additional reports of patients harboring this mutation."	26773740	PubMed		"Klughammer et al., 2016, J Thorac Oncol"		3	accepted	1786	Somatic	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/1786	https://civicdb.org/links/molecular_profiles/704	FALSE	EGFR	1956	K757R		chr7	55174807	55174807	A	G	ENST00000275493.2	75		missense_variant	"ENST00000275493.2:c.2270A>G,NC_000007.13:g.55242500A>G,NM_005228.3:c.2270A>G,NP_005219.2:p.Lys757Arg,NM_005228.5:c.2270A>G,NC_000007.14:g.55174807A>G"	2023-01-27 17:04:58 UTC	CA4266023	560009	"LYS757ARG,RS397517102"	FALSE
EGFR E746G	705	Lung Adenocarcinoma	3910		Erlotinib		Predictive	Supports	C	Sensitivity/Response	"In a meta-analysis of 7 clinical trials evaluating the efficacy of erlotinib, one patient was described with the exon 19 mutation E746G from the BeTa study. Progression-free (415 days) and overall (462 days) survival suggested sensitivity in this patient. No statistical analysis was reported for this variant and PFS or OS, citing small sample size across the studies."	26773740	PubMed		"Klughammer et al., 2016, J Thorac Oncol"		1	accepted	1787	Somatic	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/1787	https://civicdb.org/links/molecular_profiles/705	FALSE	EGFR	1956	E746G		chr7	55174774	55174774	A	G	ENST00000275493.2	75		missense_variant	"ENST00000275493.2:c.2237A>G,NC_000007.13:g.55242467A>G,NM_005228.3:c.2237A>G,NP_005219.2:p.Glu746Gly"	2023-01-27 17:04:59 UTC	CA367584149	NONE FOUND	GLU746GLY	FALSE
MLH1 E13fs	706	Endometrial Cancer	1380				Oncogenic	Supports	C	Oncogenicity	"MLH1 E13fs (c.37del), identified in a case of microsatellite-unstable endometrial cancer, was confirmed to be somatic in a 46 year old female patient (sLS-1) with suspected Lynch Syndrome (LS). The patient was therefore negative for LS. This patient also harbored MLH1 p.G606fs."	25111426	PubMed		"Geurts-Giele et al., 2014, J. Pathol."		1	accepted	1788	Somatic	2023-01-10 20:04:34 UTC	https://civicdb.org/links/evidence_items/1788	https://civicdb.org/links/molecular_profiles/706	FALSE	MLH1	4292	E13fs		chr3	36993584	36993584	G		ENST00000231790.2	75		"minus_1_frameshift_variant,frameshift_truncation"	"NM_000249.3:c.37delG,NP_000240.1:p.Glu13Argfs,ENST00000231790.2:c.37delG,NC_000003.11:g.37035075del"	2023-01-27 17:05:00 UTC	CA010006	90190	"GLU13ARGFS,RS63750081,E13FS*3"	FALSE
MSH2 R383*	708	Endometrial Cancer	1380				Oncogenic	Supports	C	Oncogenicity	"This variant (R383*), identified in two patients, was confirmed to be a somatic mutation in both patients' microsatellite-unstable tumors (39 year-old female with endometrial cancer & 34 year-old female with ovarian cancer) with suspected Lynch Syndrome (LS). These patients were therefore negative for LS, which is by definition a germline condition. LOH of the WT allele was confirmed in the case of ovarian cancer."	25111426	PubMed		"Geurts-Giele et al., 2014, J. Pathol."		1	accepted	1790	Somatic	2023-01-10 20:21:24 UTC	https://civicdb.org/links/evidence_items/1790	https://civicdb.org/links/molecular_profiles/708	FALSE	MSH2	4436	R383*		chr2	47429812	47429812	C	T	ENST00000233146.2	75		stop_gained	"NM_000251.2:c.1147C>T,NP_000242.1:p.Arg383Ter,ENST00000233146.2:c.1147C>T,NC_000002.11:g.47656951C>T"	2023-01-27 17:05:01 UTC	CA017356	90554	"R383X,ARG383TER,RS63749849"	FALSE
MLH1 V534R	709	Colorectal Cancer	9256				Oncogenic	Supports	C	Oncogenicity	"MLH1 V534R (c.1600_1601delinsAG), identified in a case of microsatellite-unstable colorectal cancer, was confirmed to be a somatic variant in a 27 year old male patient (id: sLS-24) with suspected Lynch syndrome (LS). The patient was therefore negative for LS which is germline by definition. Authors note that this patient's tumor retained MLH1 heterozygosity and wildtype BRAF."	25111426	PubMed		"Geurts-Giele et al., 2014, J. Pathol."		1	accepted	1791	Somatic	2023-01-10 20:23:18 UTC	https://civicdb.org/links/evidence_items/1791	https://civicdb.org/links/molecular_profiles/709	FALSE	MLH1	4292	V534R		chr3	37040227	37040228	GT	AG	ENST00000231790.2	75		missense_variant	"ENST00000231790.2:c.1600_1601delinsAG,NC_000003.11:g.37081718_37081719delinsAG"	2023-01-27 17:05:01 UTC	CA913102764	NONE FOUND	VAL534ARG	FALSE
UGT1A1 UGT1A1*28	710	Cancer	162		Belinostat		Predictive	Supports	A	Adverse Response	The FDA approved package insert for Belinostat recommends dose adjustment for UGT1A1*28 allele homozygotes.	26313268	PubMed		"Goey et al., 2016, J Clin Pharmacol"		5	accepted	1792	Common Germline	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/1792	https://civicdb.org/links/molecular_profiles/710	FALSE	UGT1A1	54658	UGT1A1*28		chr2	233760235	233760236		TATATATATATATA	ENST00000305208.5	75		microsatellite	NC_000002.11:g.234668881_234668882TA[7]	2023-01-09 21:52:08 UTC	unregistered	226028	RS8175347	FALSE
MLH1 G606FS*2	711	Endometrial Cancer	1380				Oncogenic	Supports	C	Oncogenicity	"MLH1 G606fs*2 (c.1816_1817del), identified in a case of microsatellite-unstable endometrial cancer, was confirmed to be somatic in a 46 year old female patient (sLS-1) with suspected Lynch Syndrome (LS). The patient was therefore negative for LS, which is by definition a germline condition. This patient also harbored a MLH1 p.E13fs*3 mutation."	25111426	PubMed		"Geurts-Giele et al., 2014, J. Pathol."		1	accepted	1793	Somatic	2023-01-10 20:23:56 UTC	https://civicdb.org/links/evidence_items/1793	https://civicdb.org/links/molecular_profiles/711	FALSE	MLH1	4292	G606FS*2		chr3	37047603	37047604	GG		ENST00000231790.2	75		frameshift_truncation	"ENST00000231790.2:c.1816_1817delGG,NC_000003.11:g.37089094_37089095del"	2023-01-27 17:05:03 UTC	CA913102766	NONE FOUND	GLY606FS	FALSE
MLH1 c.790+1G>A	712	Colorectal Cancer	9256				Oncogenic	Supports	C	Oncogenicity	"MLH1 c.790+1G > A, identified in a case of microsatellite-unstable colorectal cancer, was confirmed to be somatic in a 61 year old male patient (sLS-2) with suspected Lynch Syndrome (LS). The patient was therefore negative for LS, as the disease is germline by definition. This patient's tumor also harbored a p.K618del mutation and was wildtype for BRAF."	25111426	PubMed		"Geurts-Giele et al., 2014, J. Pathol."		1	accepted	1794	Somatic	2023-01-10 20:24:31 UTC	https://civicdb.org/links/evidence_items/1794	https://civicdb.org/links/molecular_profiles/712	FALSE	MLH1	4292	c.790+1G>A		chr3	37014545	37014545	G	A	ENST00000231790.2	75		splice_donor_variant	"NM_000249.3:c.790+1G>A,NC_000003.11:g.37056036G>A,ENST00000231790.2:c.790+1G>A"	2023-01-27 17:05:04 UTC	CA012109	90356	RS267607789	FALSE
MLH1 K618DEL	714	Colorectal Cancer	9256				Oncogenic	Supports	C	Oncogenicity	"MLH1 K618del (c.1852_1854del), identified in two cases of microsatellite-unstable colorectal cancer, was confirmed to be somatic in both patients with suspected Lynch Syndrome (LS). Both patients were therefore negative for LS, as it is germline by definition. sLS-2 was a 61 year old male whose tumor harbored MLH1 c.790 + 1G>A concomitantly, retained MLH1 heterozygosity and was wildtype for BRAF. sLS-8 was a 73 year old female whose tumor harbored MLH1 M1L and was wildtype for BRAF."	25111426	PubMed		"Geurts-Giele et al., 2014, J. Pathol."		1	accepted	1796	Somatic	2023-01-10 20:25:33 UTC	https://civicdb.org/links/evidence_items/1796	https://civicdb.org/links/molecular_profiles/714	FALSE	MLH1	4292	K618DEL		chr3	37047639	37047641	AAG		ENST00000231790.2	75		inframe_deletion	"NC_000003.11:g.37089130_37089132del,ENST00000231790.2:c.1852_1854delAAG,NM_000249.3:c.1852_1854delAAG,NP_000240.1:p.Lys618del"	2023-01-27 17:05:04 UTC	CA007087	17080	"RS63751247,LYS618DEL"	FALSE
MLH1 R687FS	716	Colorectal Cancer	9256				Oncogenic	Supports	C	Oncogenicity	"MLH1 R687fs (c.2059del), identified in a case of microsatellite-unstable colorectal cancer, was confirmed to be somatic in a 33 year old male patient (patient id: sLS-3) with suspected Lynch Syndrome (LS). The patient was therefore negative for LS which is germline by definition. Loss of heterozygosity of the wildtype allele was demonstrated. Patient also had a BRAF p.D594G mutation."	25111426	PubMed		"Geurts-Giele et al., 2014, J. Pathol."		1	accepted	1798	Somatic	2023-01-10 20:40:16 UTC	https://civicdb.org/links/evidence_items/1798	https://civicdb.org/links/molecular_profiles/716	FALSE	MLH1	4292	R687FS		chr3	37048973	37048973	C		ENST00000231790.2	75		frameshift_variant	"NM_000249.3:c.2059delC,NP_000240.1:p.Arg687Glyfs,ENST00000231790.2:c.2059delC,NC_000003.11:g.37090464del"	2023-01-27 17:05:05 UTC	CA279809	218022	"ARG687GLYFS,RS863225381"	FALSE
EGFR V769_D770insASV	717	Lung Adenocarcinoma	3910		Erlotinib		Predictive	Supports	C	Sensitivity/Response	"In this meta-analysis of 7 clinical trials evaluating the efficacy of erlotinib, 1 patient with V769_770insASV had overall and progression-free survival of 642 days. From this and literature review it was concluded that although EGFR exon 20 insertions may confer reduced sensitivity to erlotinib, patients with this particular mutation appeared to benefit from therapy."	26773740	PubMed		"Klughammer et al., 2016, J Thorac Oncol"		3	accepted	1799	Somatic	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/1799	https://civicdb.org/links/molecular_profiles/717	FALSE	EGFR	1956	V769_D770insASV		chr7	55181316	55181317		GCCAGCGTG	ENST00000275493.2	75		direct_tandem_duplication	"NM_005228.4:c.2300_2308dupCCAGCGTGG,NP_005219.2:p.Val769_Asp770insAlaSerVal,ENST00000275493.2:c.2300_2308dupCCAGCGTGG"	2023-01-27 17:05:06 UTC	CA180588	177678	"VAL769_ASP770INSALASERVAL, V769_770INSASV"	FALSE
DPYD DPYD*2A HOMOZYGOSITY	718	Cancer	162		"Capecitabine,Tegafur,Fluorouracil"	Substitutes	Predictive	Supports	A	Adverse Response	"The Clinical Pharmacogenomics Implementation Consortium Guidelines for DPYD genotype and 5-FU dosing does not recommend the use of 5-FU or capecitabine in patients with homozygous DPYD*2A, *13 or rs67376798 and the FDA drug labels warn to use precautions in this patient population."	23988873	PubMed		"Caudle et al., 2013, Clin. Pharmacol. Ther."		5	accepted	1800	Common Germline	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/1800	https://civicdb.org/links/molecular_profiles/718	FALSE	DPYD	1806	DPYD*2A HOMOZYGOSITY		chr1	97450058	97450058	C	T	ENST00000370192.3	75		splice_donor_variant	"NC_000001.10:g.97915614C>T,NM_000110.3:c.1905+1G>A,ENST00000370192.3:c.1905+1G>A"	2023-01-27 17:05:07 UTC	CA114277	432	"RS3918290,DPYD*2A,DPYD:IVS14 + 1G>A,C.1905+1G>A"	FALSE
DPYD DPYD*13 HOMOZYGOSITY	719	Cancer	162		"Capecitabine,Tegafur,Fluorouracil"	Substitutes	Predictive	Supports	A	Adverse Response	"The Clinical Pharmacogenomics Implementation Consortium Guidelines for DPYD genotype and 5-FU dosing does not recommend the use of 5-FU or capecitabine in patients with homozygous DPYD*2A, *13 or rs67376798 and the FDA drug labels warn to use precautions in this patient population."	23988873	PubMed		"Caudle et al., 2013, Clin. Pharmacol. Ther."		5	accepted	1801	Common Germline	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/1801	https://civicdb.org/links/molecular_profiles/719	FALSE	DPYD	1806	DPYD*13 HOMOZYGOSITY		chr1	97515787	97515787	A	C	ENST00000370192.3	75		missense_variant	"NM_000110.3:c.1679T>G,NP_000101.2:p.Ile560Ser,ENST00000370192.3:c.1679T>G,NC_000001.10:g.97981343A>C"	2023-01-27 17:05:08 UTC	CA228118	88975	"RS55886062,ILE560SER,I560S"	FALSE
FOS TRUNCATING FUSION	720	Bone Epithelioid Hemangioma	6610				Diagnostic	Supports	C	Positive	"FOS was found fused  with 3 different genes in 3 cases of bone epithelioid hemangioma. The fusion partners were not recurrent, respectively MBNL1, VIM and a lincRNA. The truncation of the FOS gene would result in the loss of the transactivation domain (TAD) in all three cases. Extension of this analysis identified FOS rearrangements in 5/7 additional classic epithelioid hemangiomas of bone."	26173738	PubMed		"van IJzendoorn et al., 2015, Genes Chromosomes Cancer"		3	accepted	1802	Somatic	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/1802	https://civicdb.org/links/molecular_profiles/720	FALSE	FOS	2353	TRUNCATING FUSION		chr14	75278774	75281424			ENST00000303562.4	75		"stop_gained,transcript_fusion"		2023-01-09 21:52:08 UTC				FALSE
MLH1 R100*	722	Colorectal Cancer	9256				Oncogenic	Supports	C	Oncogenicity	"R100* (c.298C > T), identified in a case of microsatellite-unstable colorectal cancer, was confirmed to be somatic in a 46 year old female patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS, which is by definition a germline condition. Loss of heterozygosity of the wildtype allele was confirmed."	25111426	PubMed		"Geurts-Giele et al., 2014, J. Pathol."		1	accepted	1804	Somatic	2023-01-10 20:42:58 UTC	https://civicdb.org/links/evidence_items/1804	https://civicdb.org/links/molecular_profiles/722	FALSE	MLH1	4292	R100*		chr3	37001045	37001045	C	T	ENST00000231790.2	75		stop_gained	"NM_000249.3:c.298C>T,NP_000240.1:p.Arg100Ter,ENST00000231790.2:c.298C>T,NC_000003.11:g.37042536C>T"	2023-01-27 17:05:08 UTC	CA009575	36550	"ARG100TER,R100X,RS63751221"	FALSE
WWTR1 WWTR1::CAMTA1	723	Malignant Epithelioid Hemangioendothelioma	80190				Diagnostic	Supports	B	Positive	"Performed a systematic molecular analysis of 17 epithelioid hemangioendothelioma (EHE) and compared to 13 epithelioid hemangiomas, five epithelioid angiosarcomas, and four epithelioid sarcoma-like EHE. A FISH positional cloning strategy, and RT-PCR analysis identified WWTR1-CAMTA1 in all EHE cases and none of the other benign or malignant epithelioid vascular tumors examined."	21584898	PubMed		"Errani et al., 2011, Genes Chromosomes Cancer"		4	accepted	1805	Somatic	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/1805	https://civicdb.org/links/molecular_profiles/723	FALSE	WWTR1	25937	WWTR1::CAMTA1		chr3	149517235	149573000			ENST00000465804.1	75	ENST00000303635.7	transcript_fusion		2023-01-09 21:52:08 UTC		N/A	"T(1;3)(P36.3;Q25),WWTR1-CAMTA1"	FALSE
WWTR1 WWTR1::CAMTA1	723	Malignant Epithelioid Hemangioendothelioma	80190				Diagnostic	Supports	B	Positive	"Performed a systematic molecular analysis of 17 epithelioid hemangioendothelioma (EHE) and compared to 13 epithelioid hemangiomas, five epithelioid angiosarcomas, and four epithelioid sarcoma-like EHE. A FISH positional cloning strategy, and RT-PCR analysis identified WWTR1-CAMTA1 in all EHE cases and none of the other benign or malignant epithelioid vascular tumors examined."	21584898	PubMed		"Errani et al., 2011, Genes Chromosomes Cancer"		4	accepted	1805	Somatic	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/1805	https://civicdb.org/links/molecular_profiles/723	FALSE	WWTR1	25937	WWTR1::CAMTA1		chr1	7661726	7769706			ENST00000465804.1	75	ENST00000303635.7	transcript_fusion		2023-01-09 21:52:08 UTC		N/A	"T(1;3)(P36.3;Q25),WWTR1-CAMTA1"	FALSE
MLH1 T117M	724	Colorectal Cancer	9256				Oncogenic	Supports	C	Oncogenicity	"MLH1 T117M (c.350C > T), identified in three cases of microsatellite-unstable colorectal cancer, was confirmed to be somatic in patients with suspected Lynch Syndrome (LS). The patients were therefore negative for LS, as the disease is germline by definition. Patient sLS-6 was a 59 year old female whose tumor harbored BRAF V600E and had loss of heterozygosity of MLH1. Patient sLS-19 was a 62 year old female whose tumor harbored loss of heterozygosity at MLH1 and wildtype BRAF. Patient sLS-20 was a 65 year old male whose tumor harbored concomitant MLH1 I68S and BRAF wildtype."	25111426	PubMed		"Geurts-Giele et al., 2014, J. Pathol."		1	accepted	1806	Somatic	2023-01-10 21:05:23 UTC	https://civicdb.org/links/evidence_items/1806	https://civicdb.org/links/molecular_profiles/724	FALSE	MLH1	4292	T117M		chr3	37004444	37004444	C	T	ENST00000231790.2	75		missense_variant	"NM_000249.3:c.350C>T,NP_000240.1:p.Thr117Met,ENST00000231790.2:c.350C>T,NC_000003.11:g.37045935C>T"	2023-01-27 17:05:09 UTC	CA009872	17094	"THR117MET,RS63750781"	FALSE
MLH1 Q426FS	725	Colorectal Cancer	9256				Oncogenic	Supports	C	Oncogenicity	"MLH1 Q426fs (c.1276del), identified in a case of microsatellite-unstable colorectal cancer, was confirmed to be a somatic mutation in a 46 year old male patient (patient id: sLS-5) with suspected Lynch syndrome (LS). The patient was therefore negative for LS as it is a germline disease, by definition. Loss of heterozygosity of the wildtype allele and wildtype BRAF was observed."	25111426	PubMed		"Geurts-Giele et al., 2014, J. Pathol."		1	accepted	1807	Somatic	2023-01-10 21:14:36 UTC	https://civicdb.org/links/evidence_items/1807	https://civicdb.org/links/molecular_profiles/725	FALSE	MLH1	4292	Q426FS		chr3	37025874	37025874	C		ENST00000231790.2	75		frameshift_truncation	"ENST00000231790.2:c.1276delC,NC_000003.11:g.37067365del"	2023-01-27 17:05:10 UTC	CA913102760	NONE FOUND	GLN426FS	FALSE
MLH1 V49A	726	Colorectal Cancer	9256				Oncogenic	Supports	C	Oncogenicity	"MLH1 V49A (c.146 T > C), identified in a case of microsatellite-unstable colorectal cancer, was confirmed to be somatic in a 68 year old female patient (id: sLS-7) with suspected Lynch Syndrome (LS). The patient was therefore negative for LS as the disease is germline by definition. The patient also harbored a second MLH1 mutation (p.D667fs) which demonstrated loss of heterozygosity and BRAF wildtype."	25111426	PubMed		"Geurts-Giele et al., 2014, J. Pathol."		1	accepted	1808	Somatic	2023-01-10 21:17:26 UTC	https://civicdb.org/links/evidence_items/1808	https://civicdb.org/links/molecular_profiles/726	FALSE	MLH1	4292	V49A		chr3	36996648	36996648	T	C	ENST00000231790.2	75		missense_variant	"ENST00000231790.2:c.146T>C,NC_000003.11:g.37038139T>C"	2023-01-27 17:05:11 UTC	CA352035388	NONE FOUND	VAL49ALA	FALSE
EGFR Exon 20 Insertion	707	Lung Adenocarcinoma	3910		Afatinib		Predictive	Supports	B	Resistance	"In retrospective analysis of trials, afatinib conferred limited clinical benefit to patients with EGFR exon 20 insertion mutations (N=23). Only 2 patients had objective responses."	26051236	PubMed		"Yang et al., 2015, Lancet Oncol."	"NCT00525148,NCT00949650,NCT01121393"	3	accepted	1809	Somatic	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/1809	https://civicdb.org/links/molecular_profiles/707	FALSE	EGFR	1956	Exon 20 Insertion		chr7	55181298	55181329			ENST00000275493.2	75		inframe_insertion		2023-01-09 21:52:08 UTC				FALSE
MLH1 D667FS	727	Colorectal Cancer	9256				Oncogenic	Supports	C	Oncogenicity	"This variant (D667fs), identified in a case of microsatellite-unstable colorectal cancer, was confirmed to be somatic in a 68 year old female patient (id: sLS-7) with suspected Lynch Syndrome (LS). The patient was therefore negative for LS, which is by definition a germline condition. Loss of heterozygosity leading to primarily the D667fs allele detected (90% VAF). This patient also harbored a heterozygous p.V49A variant."	25111426	PubMed		"Geurts-Giele et al., 2014, J. Pathol."		1	accepted	1810	Somatic	2023-01-10 21:21:07 UTC	https://civicdb.org/links/evidence_items/1810	https://civicdb.org/links/molecular_profiles/727	FALSE	MLH1	4292	D667FS		chr3	37048915	37048915	C		ENST00000231790.2	75		frameshift_truncation	"NC_000003.11:g.37090406del,ENST00000231790.2:c.2001del"	2023-01-27 17:05:12 UTC	CA913102767	NONE FOUND	ASP667FS	FALSE
MLH1 M1L	728	Colorectal Cancer	9256				Oncogenic	Supports	C	Oncogenicity	"MLH1 M1L (c.1A>T), identified in a case of microsatellite-unstable colorectal cancer, was confirmed to be somatic in a 73 year old female patient (patient id: sLS-8) with suspected Lynch Syndrome (LS). The patient was therefore negative for LS, which is by definition a germline condition. Loss of heterozygosity resulting in overrepresentation of the M1L allele was observed. Additionally, this patient's tumor harbored a heterozygous MLH1 p.K618del mutation and was wildtype for BRAF."	25111426	PubMed		"Geurts-Giele et al., 2014, J. Pathol."		1	accepted	1811	Somatic	2023-01-10 21:23:52 UTC	https://civicdb.org/links/evidence_items/1811	https://civicdb.org/links/molecular_profiles/728	FALSE	MLH1	4292	M1L		chr3	36993548	36993548	A	T	ENST00000231790.2	75		missense_variant	"ENST00000231790.2:c.1A>T,NC_000003.11:g.37035039A>T"	2023-01-27 17:05:12 UTC	CA352059785	NONE FOUND	MET1LEU	FALSE
MLH1 *757L	729	Villous Adenoma					Oncogenic	Supports	C	Oncogenicity	"MLH1 *757 L (c.2270A > T), identified in a case of microsatellite-unstable villous adenoma, was confirmed to be somatic in a 39 year old male patient (id: sLS-9) with suspected Lynch Syndrome (LS). The patient was therefore negative for LS, as the disease is germline by definition. The patient also harbored an MLH1 c.453+1G > A mutation."	25111426	PubMed		"Geurts-Giele et al., 2014, J. Pathol."		1	accepted	1812	Somatic	2023-01-10 21:25:47 UTC	https://civicdb.org/links/evidence_items/1812	https://civicdb.org/links/molecular_profiles/729	TRUE	MLH1	4292	*757L		chr3	37050652	37050652	A	T	ENST00000231790.2	75		stop_lost	"ENST00000231790.2:c.2270A>T,NC_000003.11:g.37092143A>T"	2023-01-27 17:05:13 UTC	CA352069936	NONE FOUND	X757L	FALSE
MLH1 R265G	730	Colorectal Cancer	9256				Oncogenic	Supports	C	Oncogenicity	"MLH1 R265G (c.793C > G), identified in a case of microsatellite-unstable colorectal cancer, was confirmed to be somatic in a 65 year old female patient (id: sLS-10) with suspected Lynch Syndrome (LS). The patient was therefore negative for LS, as the disease is germline by definition. Loss of heterozygosity of the wildtype allele and BRAF wildtype was observed."	25111426	PubMed		"Geurts-Giele et al., 2014, J. Pathol."		1	accepted	1813	Somatic	2023-01-11 15:30:03 UTC	https://civicdb.org/links/evidence_items/1813	https://civicdb.org/links/molecular_profiles/730	FALSE	MLH1	4292	R265G		chr3	37017508	37017508	C	G	ENST00000231790.2	75		missense_variant	"ENST00000231790.2:c.793C>G,NC_000003.11:g.37058999C>G"	2023-01-27 17:05:14 UTC	CA352045752	NONE FOUND	ARG265GLY	FALSE
MLH1 V213FS	731	Colorectal Cancer	9256				Oncogenic	Supports	C	Oncogenicity	"This variant (V213fs), identified in two cases of microsatellite-unstable colorectal cancer, was confirmed to be somatic in both patients (40 year-old female & 70 year-old male) with suspected Lynch Syndrome (LS). The patients were therefore negative for LS, which is by definition a germline disorder."	25111426	PubMed		"Geurts-Giele et al., 2014, J. Pathol."		1	accepted	1814	Somatic	2023-01-12 17:29:52 UTC	https://civicdb.org/links/evidence_items/1814	https://civicdb.org/links/molecular_profiles/731	FALSE	MLH1	4292	V213FS		chr3	37012060	37012060	T		ENST00000231790.2	75		frameshift_truncation	"ENST00000231790.2:c.638delT,NC_000003.11:g.37053551del"	2023-01-27 17:05:15 UTC	CA913102758	NONE FOUND	VAL213FS	FALSE
MLH1 N551T	732	Colorectal Cancer	9256				Oncogenic	Supports	C	Oncogenicity	MLH1 N551T (c.1652A > C) identified in a case of microsatellite-unstable colorectal cancer was confirmed to be somatic in a 51 year old female patient (id: sLS-12) with suspected Lynch Syndrome (LS). The patient was therefore negative for LS as the disease is germline by definition.	25111426	PubMed		"Geurts-Giele et al., 2014, J. Pathol."		1	accepted	1815	Somatic	2023-01-12 17:30:21 UTC	https://civicdb.org/links/evidence_items/1815	https://civicdb.org/links/molecular_profiles/732	FALSE	MLH1	4292	N551T		chr3	37040279	37040279	A	C	ENST00000231790.2	75		missense_variant	"NM_000249.3:c.1652A>C,NP_000240.1:p.Asn551Thr,ENST00000231790.2:c.1652A>C,NC_000003.11:g.37081770A>C"	2023-01-27 17:05:15 UTC	CA006238	89819	"ASN551THR,RS63750271"	FALSE
MLH1 A424T	733	Colorectal Cancer	9256				Oncogenic	Supports	C	Oncogenicity	"MLH1 A424T (c.1270G>A), identified in a case of microsatellite-unstable colorectal cancer, was confirmed to be somatic in a 45 year old male patient (id: sLS-13) with suspected Lynch Syndrome (LS). The patient was therefore negative for LS which is germline by definition. Patient also harbored a BRAF V600E mutation."	25111426	PubMed		"Geurts-Giele et al., 2014, J. Pathol."		1	accepted	1816	Somatic	2023-01-12 17:31:04 UTC	https://civicdb.org/links/evidence_items/1816	https://civicdb.org/links/molecular_profiles/733	FALSE	MLH1	4292	A424T		chr3	37025868	37025868	G	A	ENST00000231790.2	75		missense_variant	"NM_000249.3:c.1270G>A,NP_000240.1:p.Ala424Thr,ENST00000231790.2:c.1270G>A,NC_000003.11:g.37067359G>A"	2023-01-27 17:05:16 UTC	CA028060	220203	"ALA424THR,RS377433038"	FALSE
MLH1 Q149*	734	Colorectal Cancer	9256				Oncogenic	Supports	C	Oncogenicity	"MLH1 Q149* (c.445C > T), identified in a case of microsatellite-unstable colorectal cancer, was confirmed to be somatic in a 65 year old female patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS, which is a germline disease by definition. This patient also harbored MLH1 p.R226* and MSH6 p.I972F mutations at similar variant allele frequencies. Authors note that the tumor retained MLH1 heterozygosity, was wildtype for BRAF, and harbored two pathogenic variants in MMR."	25111426	PubMed		"Geurts-Giele et al., 2014, J. Pathol."		1	accepted	1817	Somatic	2023-01-12 17:35:36 UTC	https://civicdb.org/links/evidence_items/1817	https://civicdb.org/links/molecular_profiles/734	FALSE	MLH1	4292	Q149*		chr3	37007055	37007055	C	T	ENST00000231790.2	75		stop_gained	"NM_000249.3:c.445C>T,NP_000240.1:p.Gln149Ter,ENST00000231790.2:c.445C>T,NC_000003.11:g.37048546C>T"	2023-01-27 17:05:17 UTC	CA010427	90219	"Q149X,GLN149TER,RS63751302"	FALSE
MLH1 R226*	735	Colorectal Cancer	9256				Oncogenic	Supports	C	Oncogenicity	"MLH1 R226* (c.676C > T), identified in a case of microsatellite-unstable colorectal cancer, was confirmed to be somatic in a 65 year old female patient (sLS-14) with suspected Lynch Syndrome (LS). The patient was therefore negative for LS, which is by definition a germline condition. This patient also harbored MLH1 p.Q149* and MSH6 p.I972F mutations as similar variant allele frequencies. Authors note that the tumor of this patient was wildtype for BRAF."	25111426	PubMed		"Geurts-Giele et al., 2014, J. Pathol."		1	accepted	1818	Somatic	2023-01-12 17:36:31 UTC	https://civicdb.org/links/evidence_items/1818	https://civicdb.org/links/molecular_profiles/735	FALSE	MLH1	4292	R226*		chr3	37012098	37012098	C	T	ENST00000231790.2	75		stop_gained	"NM_000249.3:c.676C>T,NP_000240.1:p.Arg226Ter,ENST00000231790.2:c.676C>T,NC_000003.11:g.37053589C>T"	2023-01-27 17:05:18 UTC	CA011496	17087	"R226X,ARG226TER,R128*,RS63751615"	FALSE
MLH1 P536FS	737	Colorectal Cancer	9256				Oncogenic	Supports	C	Oncogenicity	"This variant (P536fs), identified in a case of microsatellite-unstable colorectal cancer, was confirmed to be somatic in a 59 year-old female patient (sLS-17) with suspected Lynch Syndrome (LS). The patient was therefore negative for LS, which is by definition a germline condition. Loss of heterozygosity of the wildtype allele was demonstrated resulting in higher mutated allele representation (80% variant allele frequency)."	25111426	PubMed		"Geurts-Giele et al., 2014, J. Pathol."		1	accepted	1820	Somatic	2023-01-13 04:40:56 UTC	https://civicdb.org/links/evidence_items/1820	https://civicdb.org/links/molecular_profiles/737	FALSE	MLH1	4292	P536FS		chr3	37040235	37040235	T		ENST00000231790.2	75		frameshift_truncation	"NC_000003.11:g.37081726del,ENST00000231790.2:c.1608del"	2023-01-27 17:05:20 UTC	CA913102765	NONE FOUND	PRO536FS	FALSE
MLH1 G67R	738	Colorectal Cancer	9256				Oncogenic	Supports	C	Oncogenicity	"This variant (G67R), identified in a case of microsatellite-unstable colorectal cancer was confirmed to be somatic in a 61 year-old male patient (sLS-18) with suspected Lynch Syndrome (LS). The patient was therefore negative for LS, which is by definition a germline condition. Loss of heterozygosity of the wildtype allele was demonstrated."	25111426	PubMed		"Geurts-Giele et al., 2014, J. Pathol."		1	accepted	1821	Somatic	2023-01-13 04:43:23 UTC	https://civicdb.org/links/evidence_items/1821	https://civicdb.org/links/molecular_profiles/738	FALSE	MLH1	4292	G67R		chr3	36996701	36996701	G	A	ENST00000231790.2	75		missense_variant	"NM_000249.3:c.199G>A,NP_000240.1:p.Gly67Arg,ENST00000231790.2:c.199G>A,NC_000003.11:g.37038192G>A"	2023-01-27 17:05:20 UTC	CA008104	89992	"GLY67ARG,RS63750206"	FALSE
MLH1 I68S	739	Colorectal Cancer	9256				Oncogenic	Supports	C	Oncogenicity	"MLH1 I68S (c.203 T > G), identified in a case of microsatellite-unstable colorectal cancer, was confirmed to be somatic in a 65 year old male patient (id: sLS-20) with suspected Lynch Syndrome (LS). The patient was therefore negative for LS, as the disease is germline by definition. Loss of heterozygosity leading to p.I68S at 77% variant allele frequency was demonstrated. The patient also harbored a heterozygous MLH1 p.T117M mutation (38% VAF)."	25111426	PubMed		"Geurts-Giele et al., 2014, J. Pathol."		1	accepted	1822	Somatic	2023-01-13 04:43:57 UTC	https://civicdb.org/links/evidence_items/1822	https://civicdb.org/links/molecular_profiles/739	FALSE	MLH1	4292	I68S		chr3	36996705	36996705	T	G	ENST00000231790.2	75		missense_variant	"ENST00000231790.2:c.203T>G,NC_000003.11:g.37038196T>G"	2023-01-27 17:05:21 UTC	CA352035494	NONE FOUND	ILE68SER	FALSE
MLH1 G65D	740	Colorectal Cancer	9256				Oncogenic	Supports	C	Oncogenicity	"This variant (G65D), identified in a case of microsatellite-unstable colorectal cancer, was confirmed to be somatic in a 71 year-old male patient (sLS-21) with suspected Lynch Syndrome (LS). The patient was therefore negative for LS, which is by definition a germline condition. This patient also had loss of heterozygosity."	25111426	PubMed		"Geurts-Giele et al., 2014, J. Pathol."		1	accepted	1823	Somatic	2023-01-17 17:56:58 UTC	https://civicdb.org/links/evidence_items/1823	https://civicdb.org/links/molecular_profiles/740	FALSE	MLH1	4292	G65D		chr3	36996696	36996696	G	A	ENST00000231790.2	75		missense_variant	"NM_000249.3:c.194G>A,NP_000240.1:p.Gly65Asp,ENST00000231790.2:c.194G>A,NC_000003.11:g.37038187G>A"	2023-01-27 17:05:22 UTC	CA007735	89955	"GLY65ASP,RS63751465"	FALSE
MLH1 A681V	741	Colorectal Cancer	9256				Oncogenic	Supports	C	Oncogenicity	"This variant (A681V), identified in a case of microsatellite-unstable colorectal cancer was confirmed to be somatic in a 52 year-old male patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS, which is by definition a germline condition. Loss of heterozygosity (wildtype allele loss) was also demonstrated."	25111426	PubMed		"Geurts-Giele et al., 2014, J. Pathol."		1	accepted	1824	Somatic	2023-01-17 17:59:03 UTC	https://civicdb.org/links/evidence_items/1824	https://civicdb.org/links/molecular_profiles/741	FALSE	MLH1	4292	A681V		chr3	37048956	37048956	C	T	ENST00000231790.2	75		missense_variant	"NM_000249.3:c.2042C>T,NP_000240.1:p.Ala681Val,ENST00000231790.2:c.2042C>T,NC_000003.11:g.37090447C>T"	2023-01-27 17:05:23 UTC	CA008313	90011	"ALA681VAL,A440V,RS63750864"	FALSE
MSH6 P138T	742	Colorectal Cancer	9256				Oncogenic	Supports	C	Oncogenicity	"This variant, identified in a case of microsatellite-unstable colorectal cancer was confirmed to be somatic in a patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS."	25111426	PubMed		"Geurts-Giele et al., 2014, J. Pathol."		1	accepted	1825	Somatic	2023-01-17 17:59:36 UTC	https://civicdb.org/links/evidence_items/1825	https://civicdb.org/links/molecular_profiles/742	FALSE	MSH6	2956	P138T		chr2	47791078	47791078	C	A	ENST00000234420.5	75		missense_variant	"ENST00000234420.5:c.412C>A,NC_000002.11:g.48018217C>A"	2023-01-27 17:05:24 UTC	CA346737117	NONE FOUND	PRO138THR	FALSE
MSH2 V273FS	743	Colorectal Cancer	9256				Oncogenic	Supports	C	Oncogenicity	"This variant (V273fs), identified in a case of microsatellite-unstable colorectal cancer, was confirmed to be a somatic mutation in a 61 year-old male patient (sLS-27) with suspected Lynch Syndrome (LS). The patient was therefore negative for LS, which is by definition a germline condition. LOH of the WT allele was demonstrated."	25111426	PubMed		"Geurts-Giele et al., 2014, J. Pathol."		1	accepted	1826	Somatic	2023-01-17 18:00:48 UTC	https://civicdb.org/links/evidence_items/1826	https://civicdb.org/links/molecular_profiles/743	FALSE	MSH2	4436	V273FS		chr2	47414294	47414294	T		ENST00000233146.2	75		frameshift_variant	"ENST00000233146.2:c.818delT,NC_000002.11:g.47641433del"	2023-01-27 17:05:24 UTC	CA913090558			FALSE
MSH2 E28FS	744	Colorectal Cancer	9256				Oncogenic	Supports	C	Oncogenicity	"This variant (E28fs), identified in a case of microsatellite-unstable colorectal cancer was confirmed to be somatic in a 66 year-old male patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS, which by definition is a germline condition.. This patient had two somatic mutations in MSH2 (E28fs, K172*)."	25111426	PubMed		"Geurts-Giele et al., 2014, J. Pathol."		1	accepted	1827	Somatic	2023-01-17 18:02:42 UTC	https://civicdb.org/links/evidence_items/1827	https://civicdb.org/links/molecular_profiles/744	FALSE	MSH2	4436	E28FS		chr2	47403274	47403275		G	ENST00000233146.2	75		frameshift_elongation	NC_000002.11:g.47630414dupG	2023-01-27 17:05:25 UTC	CA913189237	NONE FOUND		FALSE
VHL E55FS (c.163_164delGA)	745	Renal Cell Carcinoma	4450				Oncogenic	Supports	C	Oncogenicity	"In a 54 year old male patient with sporadic renal cell carcinoma, VHL c.163_164delGA causing a p.Glu55 Stop at 130 frameshift mutation was observed. Loss of heterozygosity analysis was non-informative. This result suggests a potential oncogenic role for VHL c.163_164delGA in Renal Cell Carcinoma."	10408776	PubMed		"Gallou et al., 1999, Hum. Mutat."		1	accepted	1828	Somatic	2023-01-17 21:23:05 UTC	https://civicdb.org/links/evidence_items/1828	https://civicdb.org/links/molecular_profiles/745	FALSE	VHL	7428	E55FS (c.163_164delGA)		chr3	10142010	10142011	GA		ENST00000256474.2	75		frameshift_truncation	"NP_000542.1:p.Glu55fs,NC_000003.11:g.10183694_10183695del,ENST00000256474.2:c.163_164delGA"	2023-01-27 17:05:26 UTC	CA645524641	NONE FOUND	"C.163_164DELGA,GLU55FS"	FALSE
MSH6 I891FS	746	Colorectal Cancer	9256				Oncogenic	Supports	C	Oncogenicity	"This variant (I891fs), identified in a case of microsatellite-unstable colorectal cancer was confirmed to be somatic in a 79 year-old male patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS, which is by definition a germline condition."	25111426	PubMed		"Geurts-Giele et al., 2014, J. Pathol."		1	accepted	1829	Somatic	2023-02-03 16:10:36 UTC	https://civicdb.org/links/evidence_items/1829	https://civicdb.org/links/molecular_profiles/746	FALSE	MSH6	2956	I891FS		chr2	47800655	47800656	TC		ENST00000234420.5	75		frameshift_truncation	"ENST00000234420.5:c.2672_2673delTC,NC_000002.11:g.48027794_48027795del"	2023-01-27 17:05:27 UTC	CA913090565	NONE FOUND	ILE891FS	FALSE
VHL E55RfsTer11 (c.163delG)	747	Von Hippel-Lindau Disease	14175	"Hemangioblastoma,Renal cell carcinoma,Retinal capillary hemangioma"			Predisposing	Supports	C	Uncertain Significance	"This is a frameshift mutation that results in a stop at codon 66.   Family 3682 in this publication, variant segregates with disease.  VHL Type 1 disease is reported: CNS tumors, retinal angioma, renal cell carcinoma but no pheochromocytoma"	8956040	PubMed		"Zbar et al., 1996, Hum. Mutat."		3	accepted	1830	Rare Germline	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/1830	https://civicdb.org/links/molecular_profiles/747	FALSE	VHL	7428	E55RfsTer11 (c.163delG)		chr3	10142010	10142010	G		ENST00000256474.2	75		frameshift_truncation	"NP_000542.1:p.Glu55fs,NP_000542.1:p.Glu55ArgfsTer11,NM_000551.2:c.163delG,NC_000003.11:g.10183694del,ENST00000256474.2:c.163delG"	2023-01-27 17:05:27 UTC	CA432536363	428800	"C.163DELG,GLU55ARGFS"	FALSE
MSH6 R1242H	748	Colorectal Cancer	9256				Oncogenic	Supports	C	Oncogenicity	"This variant (R1242H), identified in a case of microsatellite-unstable colorectal cancer was confirmed to be somatic in a 79 year-old male patient (sLS-37) with suspected Lynch Syndrome (LS). The patient was therefore negative for LS, which is by definition a germline condition."	25111426	PubMed		"Geurts-Giele et al., 2014, J. Pathol."		1	accepted	1831	Somatic	2023-02-03 16:10:52 UTC	https://civicdb.org/links/evidence_items/1831	https://civicdb.org/links/molecular_profiles/748	FALSE	MSH6	2956	R1242H		chr2	47806282	47806282	G	A	ENST00000234420.5	75		missense_variant	"NM_000179.2:c.3725G>A,NP_000170.1:p.Arg1242His,ENST00000234420.5:c.3725G>A,NC_000002.11:g.48033421G>A"	2023-01-27 17:05:28 UTC	CA014077	140866	"ARG1242HIS,RS63750119"	FALSE
PMS2 R315*	749	Endometrial Cancer	1380				Oncogenic	Supports	C	Oncogenicity	"This variant (R315*), identified in a case of microsatellite-unstable endometrial cancer, was confirmed to be somatic in a 69 year-old female patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS, which is by definition a germline condition. This patient also harbored MLH1 M490T, MSH2 E483G, and MSH6 V352I mutations."	25111426	PubMed		"Geurts-Giele et al., 2014, J. Pathol."		1	accepted	1832	Somatic	2023-02-03 16:13:00 UTC	https://civicdb.org/links/evidence_items/1832	https://civicdb.org/links/molecular_profiles/749	FALSE	PMS2	5395	R315*		chr7	5992018	5992018	G	A	ENST00000265849.7	75		stop_gained	"NM_000535.6:c.943C>T,NP_000526.2:p.Arg315Ter,NC_000007.13:g.6031649G>A"	2023-01-27 17:05:29 UTC	CA013335	91382	"ARG315TER,RS200640585,R315X"	FALSE
MLH1 M490T	750	Endometrial Cancer	1380				Oncogenic	Supports	C	Oncogenicity	"This variant (M490T), identified in a case of microsatellite-unstable endometrial cancer was confirmed to be somatic in a 69 year-old female patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS, which by definition is a germline condition. The patient also harbored PMS2 R315*, MSH2 p.E483G and MSH6 p.V352I mutations."	25111426	PubMed		"Geurts-Giele et al., 2014, J. Pathol."		1	accepted	1833	Somatic	2023-02-03 16:13:21 UTC	https://civicdb.org/links/evidence_items/1833	https://civicdb.org/links/molecular_profiles/750	FALSE	MLH1	4292	M490T		chr3	37028843	37028843	T	C	ENST00000231790.2	75		missense_variant	"ENST00000231790.2:c.1469T>C,NC_000003.11:g.37070334T>C"	2023-01-27 17:05:30 UTC	CA352056416	NONE FOUND	MET490THR	FALSE
MSH2 K172*	751	Colorectal Cancer	9256				Oncogenic	Supports	C	Oncogenicity	"MSH2 K172*, identified in a case of microsatellite-unstable colorectal cancer, was confirmed to be somatic in a 66 year old male patient (id: sLS-32) with suspected Lynch Syndrome (LS). The patient was therefore negative for LS. This patient had two somatic mutations in MSH2 (E28fs, K172*)."	25111426	PubMed		"Geurts-Giele et al., 2014, J. Pathol."		1	accepted	1834	Somatic	2023-02-03 16:14:58 UTC	https://civicdb.org/links/evidence_items/1834	https://civicdb.org/links/molecular_profiles/751	FALSE	MSH2	4436	K172*		chr2	47410241	47410241	A	T	ENST00000233146.2	75		stop_gained	"ENST00000233146.2:c.514A>T,NC_000002.11:g.47637380A>T"	2023-01-27 17:05:31 UTC	CA346730730	NONE FOUND	"K172X,LYS172TER"	FALSE
VHL A56FS (c.164_165insG)	752	Von Hippel-Lindau Disease	14175	"Renal cell carcinoma,Pheochromocytoma,Retinal capillary hemangioma,Hemangioblastoma"			Predisposing	Supports	C	Uncertain Significance	"c.164insG causes a framehift and truncation allele. One family is described with this allele segregating with disease; 10 affected individuals: 2  patients with renal cell carcinoma, 3 with pheochromocytoma, 7 with retinal angioma, 3 with central nervous system hemangioma. ACMG evidence codes supported by this paper are possibly PVS1 and PP1."	17024664	PubMed		"Ong et al., 2007, Hum. Mutat."		3	accepted	1835	Rare Germline	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/1835	https://civicdb.org/links/molecular_profiles/752	FALSE	VHL	7428	A56FS (c.164_165insG)		chr3	10142011	10142012		G	ENST00000256474.2	75		frameshift_truncation	"NP_000542.1:p.Ala56fs,NP_000542.1:p.Ala56GlyfsTer74,NM_000551.2:c.164_165insG,NC_000003.11:g.10183695_10183696insG,NC_000003.11:g.10183697dupG"	2023-01-27 17:05:32 UTC	CA645524645	NONE FOUND	"164INSG,C.164_165INSG,377_378INSG"	FALSE
HOXB13 G84E	753	Prostate Cancer	10283				Predisposing	Supports	B	Predisposition	"Meta-analysis of prostate cancer with sixteen case-control studies including 50,048 cases and 123,211 controls.  In a random effect model the pooled OR (3.38 (95% CI: 2.45?.66)) of the studies supported the link between HOXB13 G84E variant and a susceptibility to prostate cancer."	27626483	PubMed		"Zhang et al., 2016, Oncotarget"		4	accepted	1836	Rare Germline	2023-01-12 05:56:57 UTC	https://civicdb.org/links/evidence_items/1836	https://civicdb.org/links/molecular_profiles/753	FALSE	HOXB13	10481	G84E		chr17	48728343	48728343	C	T	ENST00000290295.7	75		missense_variant	"NC_000017.10:g.46805705C>T,NM_006361.5:c.251G>A,NP_006352.2:p.Gly84Glu,ENST00000290295.7:c.251G>A"	2023-01-27 17:05:32 UTC	CA288225	128031	"RS138213197,GLY84GLU"	FALSE
MSH2 E483G	754	Endometrial Cancer	1380				Oncogenic	Supports	C	Oncogenicity	"MSH2 E483G (c.1448A > G), identified in a case of microsatellite-unstable endometrial cancer was confirmed to be somatic in a 69 year old female patient (sLS-39) with suspected Lynch Syndrome (LS). The patient was therefore negative for LS, as LS is a germline condition by definition. This patient also harbored PMS2 p.R315*, MLH1 p.M490T and MSH6 p.V352I mutations. Authors note that this patient's tumor harbored wildtype BRAF."	25111426	PubMed		"Geurts-Giele et al., 2014, J. Pathol."		1	accepted	1837	Somatic	2023-02-03 16:16:48 UTC	https://civicdb.org/links/evidence_items/1837	https://civicdb.org/links/molecular_profiles/754	FALSE	MSH2	4436	E483G		chr2	47463092	47463092	A	G	ENST00000233146.2	75		missense_variant	"NC_000002.11:g.47690231A>G,ENST00000233146.2:c.1448A>G"	2023-01-27 17:05:33 UTC	CA346726930	NONE FOUND	GLU483GLY	FALSE
PDGFRA TNKS2::PDGFRA	755	"Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1"	80164		Imatinib		Predictive	Supports	C	Sensitivity/Response	A patient harbouring a novel TNKS2PDGFRA fusion in a myeloid neoplasm with eosinophilia demonstrated a dramatic and durable response upon treatment with Imatinib mono therapy.	25658984	PubMed		"Chalmers et al., 2015, Blood Cancer J"		3	accepted	1838	Somatic	2023-01-09 21:46:38 UTC	https://civicdb.org/links/evidence_items/1838	https://civicdb.org/links/molecular_profiles/755	FALSE	PDGFRA	5156	TNKS2::PDGFRA		chr10	91798312	91859648			ENST00000371627.4	75	ENST00000257290.5	transcript_fusion		2023-01-09 21:52:09 UTC		N/A	TNKS2-PDGFRA	FALSE
PDGFRA TNKS2::PDGFRA	755	"Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1"	80164		Imatinib		Predictive	Supports	C	Sensitivity/Response	A patient harbouring a novel TNKS2PDGFRA fusion in a myeloid neoplasm with eosinophilia demonstrated a dramatic and durable response upon treatment with Imatinib mono therapy.	25658984	PubMed		"Chalmers et al., 2015, Blood Cancer J"		3	accepted	1838	Somatic	2023-01-09 21:46:38 UTC	https://civicdb.org/links/evidence_items/1838	https://civicdb.org/links/molecular_profiles/755	FALSE	PDGFRA	5156	TNKS2::PDGFRA		chr4	54274841	54298247			ENST00000371627.4	75	ENST00000257290.5	transcript_fusion		2023-01-09 21:52:09 UTC		N/A	TNKS2-PDGFRA	FALSE
MSH6 V352I	756	Endometrial Cancer	1380				Oncogenic	Supports	C	Oncogenicity	"This variant (V352I), identified in a case of microsatellite-unstable endometrial cancer, was confirmed to be somatic in a 69 year-old female patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS, which is by definition a germline condition. This patient also harbored PMS2 p.R315*, MLH1 p.M490T and MSH2 p.E483G mutations."	25111426	PubMed		"Geurts-Giele et al., 2014, J. Pathol."		1	accepted	1839	Somatic	2023-02-03 16:17:22 UTC	https://civicdb.org/links/evidence_items/1839	https://civicdb.org/links/molecular_profiles/756	FALSE	MSH6	2956	V352I		chr2	47799037	47799037	G	A	ENST00000234420.5	75		missense_variant	"NM_000179.2:c.1054G>A,NP_000170.1:p.Val352Ile,ENST00000234420.5:c.1054G>A,NC_000002.11:g.48026176G>A"	2023-01-27 17:05:34 UTC	CA007915	182617	"VAL352ILE,RS730881787"	FALSE
MSH6 R1242C	757	Colorectal Cancer	9256				Oncogenic	Supports	C	Oncogenicity	"MSH6 R1242C (c.3724C > T), identified in a case of microsatellite-unstable colorectal cancer, was confirmed to be somatic in a 53 year old male patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS, as LS is a germline condition by definition. The authors note that this patient's tumor was not deficient in mismatch repair (MMR) protein and retained heterozygosity in MSH6."	25111426	PubMed		"Geurts-Giele et al., 2014, J. Pathol."		1	accepted	1840	Somatic	2023-02-03 16:18:26 UTC	https://civicdb.org/links/evidence_items/1840	https://civicdb.org/links/molecular_profiles/757	FALSE	MSH6	2956	R1242C		chr2	47806281	47806281	C	T	ENST00000234420.5	75		missense_variant	"NM_000179.2:c.3724C>T,NP_000170.1:p.Arg1242Cys,ENST00000234420.5:c.3724C>T,NC_000002.11:g.48033420C>T"	2023-01-27 17:05:35 UTC	CA10578156	232375	"ARG1242CYS,RS587779285"	FALSE
SLCO1B1 RS4149056	758	Cancer	162		Methotrexate		Predictive	Supports	B	Adverse Response	499 children from ALL trials treated with methotrexate were genotyped for 8 SNPs in 5 genes. The SLCO1B1 rs4149056 variant was significantly associated with MTX AUC0-48h and as such associated with increased toxicity.	23652803	PubMed		"Radtke et al., 2013, Blood"		3	accepted	1841	Common Germline	2023-01-09 21:46:38 UTC	https://civicdb.org/links/evidence_items/1841	https://civicdb.org/links/molecular_profiles/758	FALSE	SLCO1B1	10599	RS4149056		chr12	21178615	21178615	T	C	ENST00000256958.2	75		"missense_variant,polymorphic_sequence_variant"	"NC_000012.11:g.21331549T>C,NM_006446.4:c.521T>C,NP_006437.3:p.Val174Ala,ENST00000256958.2:c.521T>C"	2023-01-27 17:05:36 UTC	CA6476722	37346	"VAL174ALA,V174A"	FALSE
SLCO1B1 N130D	759	Cancer	162		Methotrexate		Predictive	Supports	B	Adverse Response	499 children from ALL trials treated with methotrexate were genotyped for 8 SNPs in 5 genes. The SLCO1B1 RS2306283 variant was significantly associated with MTX AUC0-48h and as such associated with increased toxicity.	23652803	PubMed		"Radtke et al., 2013, Blood"		3	accepted	1842	Common Germline	2023-01-09 21:46:38 UTC	https://civicdb.org/links/evidence_items/1842	https://civicdb.org/links/molecular_profiles/759	FALSE	SLCO1B1	10599	N130D		chr12	21176804	21176804	A	G	ENST00000256958.2	75		missense_variant	NC_000012.11:g.21329738A>G	2023-01-27 17:05:36 UTC	CA6476674	259983	"ASN130ASP,RS2306283"	FALSE
TYMS RS34743033	760	Cancer	162		Methotrexate		Predictive	Supports	B	Adverse Response	"499 children from ALL trials treated with methotrexate were genotyped for 8 SNPs in 5 genes. The TYMS rs34743033 tandem repeat polymorphism was the only significant predictor of stomatitis in a multiple regression model considering sex, age, MRD class, WBC, MTX AUC0-48h, and genotypes as independent variables (B = ?.48; 95% CI, ?.84, ?.12; R2 = 0.018; P = .009). Stomatitis toxicity was reduced with increasing *3 (3R) alleles as the *2/*2 (2R/2R) genotype displayed the highest incidence of stomatitis, *2/*3 (2R/3R) showed intermediate toxicity, and *3/*3 (3R/3R) had the lowest incidence of stomatitis."	23652803	PubMed		"Radtke et al., 2013, Blood"		3	accepted	1843	Common Germline	2023-01-09 21:46:38 UTC	https://civicdb.org/links/evidence_items/1843	https://civicdb.org/links/molecular_profiles/760	FALSE	TYMS	7298	RS34743033		chr18	657646	657646	C	T	ENST00000323274.10	75				2023-01-09 21:52:09 UTC				FALSE
ERBB3 V855A	762	Lung Non-small Cell Carcinoma	3908		"Afatinib,Pertuzumab"	Substitutes	Predictive	Supports	D	Sensitivity/Response	Case report on a novel V855A mutation located in exon 21 of the HER3 tyrosine kinase domain and found in the tumor specimen of an adolescent patient with a chemotherapy-resistant advanced NSCLC. Protein alignments indicated this mutation was analogous to EGFR-L858R and BRAF-L597V. Co-expression of wildtype HER2 and HER3-V855A in Ba/F3 cells led to sensitivity to afatinib and pertuzumab.	26689995	PubMed		"Umelo et al., 2016, Oncotarget"		2	accepted	1845	Somatic	2023-01-09 21:46:38 UTC	https://civicdb.org/links/evidence_items/1845	https://civicdb.org/links/molecular_profiles/762	FALSE	ERBB3	2065	V855A		chr12	56097888	56097888	T	C	ENST00000267101.3	75		missense_variant	"NC_000012.11:g.56491672T>C,ENST000000267101.3:c.2564T>C"	2023-01-27 17:05:37 UTC	CA385313732	NONE FOUND	VAL855ALA	FALSE
FGFR2 FGFR2::BICC1	763	Cholangiocarcinoma	4947				Diagnostic	Supports	B	Positive	"Massively parallel whole transcriptome sequencing in eight specimens from cholangiocarcinoma patients identified two fusion kinase genes, FGFR2-AHCYL1 and FGFR2-BICC1. In RT-PCR screening, the FGFR2 fusion was detected in nine patients with cholangiocarcinoma (9/102), exclusively in the intrahepatic subtype (9/66, 13.6%)."	24122810	PubMed		"Arai et al., 2014, Hepatology"		4	accepted	1846	Somatic	2023-01-09 21:46:38 UTC	https://civicdb.org/links/evidence_items/1846	https://civicdb.org/links/molecular_profiles/763	FALSE	FGFR2	2263	FGFR2::BICC1		chr10	121479857	121598403			ENST00000457416.2	75	ENST00000373886.3	transcript_fusion		2023-01-09 21:52:09 UTC		N/A	FGFR2-BICC1	FALSE
FGFR2 FGFR2::BICC1	763	Cholangiocarcinoma	4947				Diagnostic	Supports	B	Positive	"Massively parallel whole transcriptome sequencing in eight specimens from cholangiocarcinoma patients identified two fusion kinase genes, FGFR2-AHCYL1 and FGFR2-BICC1. In RT-PCR screening, the FGFR2 fusion was detected in nine patients with cholangiocarcinoma (9/102), exclusively in the intrahepatic subtype (9/66, 13.6%)."	24122810	PubMed		"Arai et al., 2014, Hepatology"		4	accepted	1846	Somatic	2023-01-09 21:46:38 UTC	https://civicdb.org/links/evidence_items/1846	https://civicdb.org/links/molecular_profiles/763	FALSE	FGFR2	2263	FGFR2::BICC1		chr10	58702074	58831435			ENST00000457416.2	75	ENST00000373886.3	transcript_fusion		2023-01-09 21:52:09 UTC		N/A	FGFR2-BICC1	FALSE
FGFR2 FGFR2::AHCYL1	764	Cholangiocarcinoma	4947				Diagnostic	Supports	B	Positive	"Massively parallel whole transcriptome sequencing in eight specimens from cholangiocarcinoma patients identified two fusion kinase genes, FGFR2-AHCYL1 and FGFR2-BICC1. In RT-PCR screening, the FGFR2 fusion was detected in nine patients with cholangiocarcinoma (9/102), exclusively in the intrahepatic subtype (9/66, 13.6%)."	24122810	PubMed		"Arai et al., 2014, Hepatology"		4	accepted	1847	Somatic	2023-01-09 21:46:38 UTC	https://civicdb.org/links/evidence_items/1847	https://civicdb.org/links/molecular_profiles/764	FALSE	FGFR2	2263	FGFR2::AHCYL1		chr10	121479857	121598403			ENST00000457416.2	75	ENST00000369799.5	transcript_fusion		2023-01-09 21:52:09 UTC		N/A	FGFR2-AHCYL1	FALSE
FGFR2 FGFR2::AHCYL1	764	Cholangiocarcinoma	4947				Diagnostic	Supports	B	Positive	"Massively parallel whole transcriptome sequencing in eight specimens from cholangiocarcinoma patients identified two fusion kinase genes, FGFR2-AHCYL1 and FGFR2-BICC1. In RT-PCR screening, the FGFR2 fusion was detected in nine patients with cholangiocarcinoma (9/102), exclusively in the intrahepatic subtype (9/66, 13.6%)."	24122810	PubMed		"Arai et al., 2014, Hepatology"		4	accepted	1847	Somatic	2023-01-09 21:46:38 UTC	https://civicdb.org/links/evidence_items/1847	https://civicdb.org/links/molecular_profiles/764	FALSE	FGFR2	2263	FGFR2::AHCYL1		chr1	110012362	110023735			ENST00000457416.2	75	ENST00000369799.5	transcript_fusion		2023-01-09 21:52:09 UTC		N/A	FGFR2-AHCYL1	FALSE
CDKN2B METHYLATION	765	Acute Promyelocytic Leukemia	60318				Prognostic	Supports	B	Poor Outcome	"This study analyses 45 new acute promyelocytic leukemia patients (22 male and 23 female). CDKN2B was found to be a negative prognostic biomarker for disease free survival (DFS). The 5-year DFS was 9.6% in methylated and 62.5% in unmethylated samples. While methylation also associated with young age, a multivariate analysis found CDKN2B methylation to be the only independent marker with significance (P=0.008) for DFS."	16307009	PubMed		"Chim et al., 2006, Leukemia"		4	accepted	1848	Somatic	2023-01-09 21:46:38 UTC	https://civicdb.org/links/evidence_items/1848	https://civicdb.org/links/molecular_profiles/765	FALSE	CDKN2B	1030	METHYLATION		chr9	22009122	22009173			ENST00000276925.6	75		N/A		2023-01-09 21:52:09 UTC		N/A		FALSE
CHEK2 1100DELC	766	Prostate Cancer	10283				Predisposing	Supports	B	Predisposition	Meta-analysis linking CHEK2 1100delC to a higher risk of prostate cancer (OR 3.29; 95% confidence interval: 1.85-5.85; P = 0.00).	26629066	PubMed		"Wang et al., 2015, Int J Clin Exp Med"		3	accepted	1850	Rare Germline	2023-01-12 05:58:15 UTC	https://civicdb.org/links/evidence_items/1850	https://civicdb.org/links/molecular_profiles/766	FALSE	CHEK2	11200	1100DELC		chr22	28695869	28695869	G		ENST00000328354.6	75		frameshift_truncation	"NC_000022.10:g.29091857delG,NM_007194.3:c.1100delC,NP_009125.1:p.Thr367Metfs,ENST00000328354.6:c.1100delC,NC_000022.10:g.29091857del"	2023-01-27 17:05:38 UTC	CA288251	128042	"THR367METFS,RS555607708"	FALSE
FGFR2 FGFR2::BICC1	763	Cholangiocarcinoma	4947		"Infigratinib,PD173074"	Substitutes	Predictive	Supports	D	Sensitivity/Response	Expression of the FGFR2-BICC1 fusion kinase in NIH3T3 cells demonstrated transforming ability that was effectively suppressed with the fibroblast growth factor receptor (FGFR) kinase inhibitors BGJ398 and PD173074.	24122810	PubMed		"Arai et al., 2014, Hepatology"		3	accepted	1851	Somatic	2023-01-09 21:46:38 UTC	https://civicdb.org/links/evidence_items/1851	https://civicdb.org/links/molecular_profiles/763	FALSE	FGFR2	2263	FGFR2::BICC1		chr10	121479857	121598403			ENST00000457416.2	75	ENST00000373886.3	transcript_fusion		2023-01-09 21:52:09 UTC		N/A	FGFR2-BICC1	FALSE
FGFR2 FGFR2::BICC1	763	Cholangiocarcinoma	4947		"Infigratinib,PD173074"	Substitutes	Predictive	Supports	D	Sensitivity/Response	Expression of the FGFR2-BICC1 fusion kinase in NIH3T3 cells demonstrated transforming ability that was effectively suppressed with the fibroblast growth factor receptor (FGFR) kinase inhibitors BGJ398 and PD173074.	24122810	PubMed		"Arai et al., 2014, Hepatology"		3	accepted	1851	Somatic	2023-01-09 21:46:38 UTC	https://civicdb.org/links/evidence_items/1851	https://civicdb.org/links/molecular_profiles/763	FALSE	FGFR2	2263	FGFR2::BICC1		chr10	58702074	58831435			ENST00000457416.2	75	ENST00000373886.3	transcript_fusion		2023-01-09 21:52:09 UTC		N/A	FGFR2-BICC1	FALSE
CHEK2 I157T	768	Prostate Cancer	10283				Predisposing	Supports	B	Predisposition	Meta-analysis of 4 retrospective studies linked CHEK2 I157T to a higher risk of prostate cancer (OR 1.80; 95% confidence interval: 1.51-2.14; P = 0.00).	26629066	PubMed		"Wang et al., 2015, Int J Clin Exp Med"		3	accepted	1852	Rare Germline	2023-01-12 05:58:48 UTC	https://civicdb.org/links/evidence_items/1852	https://civicdb.org/links/molecular_profiles/768	FALSE	CHEK2	11200	I157T		chr22	28725099	28725099	A	G	ENST00000328354.6	75		missense_variant	"NM_007194.3:c.470T>C,NP_009125.1:p.Ile157Thr,ENST00000328354.6:c.470T>C,NC_000022.10:g.29121087A>G"	2023-01-27 17:05:39 UTC	CA117630	5591	"ILE157THR,I200T,RS17879961"	FALSE
FGFR2 FGFR2::AHCYL1	764	Cholangiocarcinoma	4947		"Infigratinib,PD173074"	Substitutes	Predictive	Supports	D	Sensitivity/Response	Expression of the FGFR2-AHCYL1 fusion kinase in NIH3T3 cells demonstrated transforming ability that was effectively suppressed with the fibroblast growth factor receptor (FGFR) kinase inhibitors BGJ398 and PD173074.	24122810	PubMed		"Arai et al., 2014, Hepatology"		3	accepted	1853	Somatic	2023-01-09 21:46:38 UTC	https://civicdb.org/links/evidence_items/1853	https://civicdb.org/links/molecular_profiles/764	FALSE	FGFR2	2263	FGFR2::AHCYL1		chr10	121479857	121598403			ENST00000457416.2	75	ENST00000369799.5	transcript_fusion		2023-01-09 21:52:09 UTC		N/A	FGFR2-AHCYL1	FALSE
FGFR2 FGFR2::AHCYL1	764	Cholangiocarcinoma	4947		"Infigratinib,PD173074"	Substitutes	Predictive	Supports	D	Sensitivity/Response	Expression of the FGFR2-AHCYL1 fusion kinase in NIH3T3 cells demonstrated transforming ability that was effectively suppressed with the fibroblast growth factor receptor (FGFR) kinase inhibitors BGJ398 and PD173074.	24122810	PubMed		"Arai et al., 2014, Hepatology"		3	accepted	1853	Somatic	2023-01-09 21:46:38 UTC	https://civicdb.org/links/evidence_items/1853	https://civicdb.org/links/molecular_profiles/764	FALSE	FGFR2	2263	FGFR2::AHCYL1		chr1	110012362	110023735			ENST00000457416.2	75	ENST00000369799.5	transcript_fusion		2023-01-09 21:52:09 UTC		N/A	FGFR2-AHCYL1	FALSE
PTPRD V253I	770	Ewing Sarcoma Of Bone	3368		"Teprotumumab,Cixutumumab"	Substitutes	Predictive	Supports	C	Sensitivity/Response	"Report of complete response to IGF1-R antibody, with or without mTOR inhibitor tensirolimus in 2/3 Ewing Sarcoma patients with germline PTPRD mutations (V253I and W775*, R995C). The third patient had stable disease (T781A mutant). Four wildtype patients had stable or progressive disease."	23800680	PubMed		"Jiang et al., 2013, Oncotarget"		4	accepted	1856	Rare Germline	2023-01-09 21:46:38 UTC	https://civicdb.org/links/evidence_items/1856	https://civicdb.org/links/molecular_profiles/770	FALSE	PTPRD	5789	V253I		chr9	8521481	8521481	C	T	ENST00000381196.4	75		missense_variant	"NM_002839.3:c.757G>A,NP_002830.1:p.Val253Ile,NC_000009.11:g.8521481C>T"	2023-01-27 17:05:40 UTC	CA4984656	NONE FOUND	VAL253ILE	FALSE
VHL A56fs (c.164_165insA)	771	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Predisposition	A variants resulting in A56G frameshift (with stop introduced at position 131) was observed in a single patient of a VHL family. (family #146 in the publication). Neither the VHL phenotype details or segregation data were provided by this publication. Since this is a frameshift occurring early in the protein sequence we can assign an ACMG evidence code of 'PVS1'.	7987306	PubMed		"Crossey et al., 1994, Hum. Mol. Genet."		2	accepted	1857	Rare Germline	2023-01-12 06:02:11 UTC	https://civicdb.org/links/evidence_items/1857	https://civicdb.org/links/molecular_profiles/771	FALSE	VHL	7428	A56fs (c.164_165insA)		chr3	10142011	10142012		A	ENST00000256474.2	75		frameshift_truncation	"NP_000542.1:p.Ala56fs,NP_000542.1:p.Ala56GlyfsTer74,NM_000551.2:c.164_165insA,NC_000003.11:g.10183695_10183696insA,NC_000003.11:g.10183695dupA,NC_000003.12:g.10142011dup"	2023-01-27 17:05:40 UTC	CA658795187	NONE FOUND	"165INSA,C.164_165INSA"	FALSE
VHL E55= (c.165G>A)	772	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	"c.165G>A results in synonymous change Glu55Glu. This is family V5 in the paper (VHL Type 1, no phechromocytoma)."	9829912	PubMed		"Olschwang et al., 1998, Hum. Mutat."		2	accepted	1858	Rare Germline	2023-01-09 21:46:38 UTC	https://civicdb.org/links/evidence_items/1858	https://civicdb.org/links/molecular_profiles/772	FALSE	VHL	7428	E55= (c.165G>A)		chr3	10142012	10142012	G	A	ENST00000256474.2	75		synonymous_variant	"NM_000551.2:c.165G>A,NC_000003.11:g.10183696G>A,ENST00000256474.2:c.165G>A,NP_000542.1:p.Glu55="	2023-01-27 17:05:41 UTC	CA432536364	486721	"GLU55GLU,C.165G>A,RS1553619391,GLU55=,E55E (C.165G>A)"	FALSE
RRM1 Overexpression	773	Pancreatic Cancer	1793		Gemcitabine		Predictive	Supports	D	Resistance	The mRNA expression level of RRM1 was analyzed by RT-PCR in 3 human pancreatic cancer cell lines cultured in incrementally increased concentrations of gemcitabine. Expression levels of RRM1 progressively increased during the development of gemcitabine resistance.	17224927	PubMed		"Nakano et al., 2007, Br. J. Cancer"		2	accepted	1859	N/A	2023-01-09 21:46:38 UTC	https://civicdb.org/links/evidence_items/1859	https://civicdb.org/links/molecular_profiles/773	FALSE	RRM1	6240	Overexpression		chr11	4094809	4138876			ENST00000300738.5	75		N/A	N/A	2023-01-09 21:52:09 UTC		N/A		FALSE
RRM2 OVEREXPRESSION	774	Pancreatic Cancer	1793		Gemcitabine		Predictive	Supports	D	Resistance	The mRNA expression level of RRM2 was analyzed by RT-PCR in 3 human pancreatic cancer cell lines  cultured in incrementally increased concentrations of gemcitabine. Expression levels of RRM2 progressively increased during the development of gemcitabine resistance.	17224927	PubMed		"Nakano et al., 2007, Br. J. Cancer"		2	accepted	1860	N/A	2023-01-09 21:46:38 UTC	https://civicdb.org/links/evidence_items/1860	https://civicdb.org/links/molecular_profiles/774	FALSE	RRM2	6241	OVEREXPRESSION		chr2	10122328	10131418			ENST00000360566.2	75		N/A		2023-01-09 21:52:09 UTC		N/A		FALSE
POLE Mutation	775	Glioblastoma	3068		Pembrolizumab		Predictive	Supports	C	Sensitivity/Response	Case report of a patient with glioblastoma multiforme and POLE germline mutation. The patient was treated with pembrolizumab and lymphocyte infiltration was noted after resection of a spinal metastasis. An objective radiographic response was noted in the intracranial lesion. A high neoantigen load was identified.	27683556	PubMed		"Johanns et al., 2016, Cancer Discov"		3	accepted	1861	Rare Germline	2023-01-09 21:46:38 UTC	https://civicdb.org/links/evidence_items/1861	https://civicdb.org/links/molecular_profiles/775	FALSE	POLE	5426	Mutation		chr12	132626314	132680037			ENST00000320574.5	75		gene_variant		2023-01-09 21:52:09 UTC		N/A		FALSE
POLE Mutation	775	Endometrial Cancer	1380		Pembrolizumab		Predictive	Supports	C	Sensitivity/Response	Case report of a patient with endometrial cancer and exceptional response to pembrolizumab (maintained at 14 months). POLE mutations V411L (exonuclease domain) and R114* were identified in the primary tumor as well as a resected lymph node metastasis. The tumor harbored a high mutational load as assessed by panel sequencing. Analysis of TCGA RNA-seq data revealed an association between POLE mutations and high immune marker expression.	27159395	PubMed		"Mehnert et al., 2016, J. Clin. Invest."		3	accepted	1862	Somatic	2023-01-09 21:46:38 UTC	https://civicdb.org/links/evidence_items/1862	https://civicdb.org/links/molecular_profiles/775	FALSE	POLE	5426	Mutation		chr12	132626314	132680037			ENST00000320574.5	75		gene_variant		2023-01-09 21:52:09 UTC		N/A		FALSE
EGFR T790M	34	Lung Non-small Cell Carcinoma	3908		Afatinib		Predictive	Supports	B	Resistance	"Patients with advanced NSCLC and acquired resistance to EGFR TKI (gefitinib or erlotinib) were analyzed for T790M mutations.  Of the 70 patients analyzed, 36 (51%) had the T790M mutation and 34 (49%) were T790M-negative.  There was no significant difference in the median post-progression or overall survival between patients with T790M mutation and without T790M mutation for initial TKI treatment.  However, subsequent treatment with afatinib showed partial response in six patients where 1/21(5%) were in the T790M-positive group and 5/13 (38%) were in the T790M-negative group (P=0.01)."	24035188	PubMed		"Sun et al., 2013, Lung Cancer"		4	accepted	1863	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/1863	https://civicdb.org/links/molecular_profiles/34	FALSE	EGFR	1956	T790M	EGFR TKI Resistance	chr7	55181378	55181378	C	T	ENST00000275493.2	75		missense_variant	"ENST00000275493.2:c.2369C>T,NM_005228.4:c.2369C>T,NP_005219.2:p.Thr790Met,NC_000007.13:g.55249071C>T"	2023-01-27 17:02:05 UTC	CA090928	16613	"THR790MET,RS121434569"	FALSE
MET D1228V	776	Lung Non-small Cell Carcinoma	3908		Cabozantinib		Predictive	Supports	C	Sensitivity/Response	"Case report of a patient with lung adenocarcinoma harboring both a mutation in EGFR and an amplification of MET. After progression on erlotinib the patient was treated with combined type I MET (savolitinib) and EGFR (osimertinib) inhibition and responded. When resistance developed, a new MET kinase domain mutation, D1228V, was detected. Drug binding predictions and in vitro studies demonstrated that the D1228V mutation induces resistance to type I but not type II MET TKIs. The patient was treated with erlotinib (EGFR TKI) combined with cabozantinib, a type II MET inhibitor, and had a response which continued at the time of report (5 months)."	27694386	PubMed		"Bahcall et al., 2016, Cancer Discov"		4	accepted	1864	Somatic	2023-01-09 21:46:38 UTC	https://civicdb.org/links/evidence_items/1864	https://civicdb.org/links/molecular_profiles/776	FALSE	MET	4233	D1228V		chr7	116783354	116783354	A	T	ENST00000397752.3	75		missense_variant	"ENST00000318493.11:c.3737A>T,ENSP00000317272.6:p.Asp1246Val,NM_001127500.3:c.3737A>T,NP_001120972.1:p.Asp1246Val"	2023-01-27 17:05:42 UTC	CA368991571	NONE FOUND	"ASP1228VAL,D1246V,ASP1246VAL"	FALSE
MET D1228V	776	Lung Non-small Cell Carcinoma	3908		Savolitinib		Predictive	Supports	C	Resistance	"Case report of a patient with lung adenocarcinoma harboring both a mutation in EGFR and an amplification of MET. After progression on erlotinib the patient was treated with combined type I MET (savolitinib) and EGFR (osimertinib) inhibition and responded. When resistance developed, a new MET kinase domain mutation, D1228V, was detected. Drug binding predictions and in vitro studies demonstrated that the D1228V mutation induces resistance to type I but not type II MET TKIs. The patient was treated with erlotinib (EGFR TKI) combined with cabozantinib, a type II MET inhibitor, and had a response which continued at the time of report (5 months)."	27694386	PubMed		"Bahcall et al., 2016, Cancer Discov"		4	accepted	1865	Somatic	2023-01-09 21:46:38 UTC	https://civicdb.org/links/evidence_items/1865	https://civicdb.org/links/molecular_profiles/776	FALSE	MET	4233	D1228V		chr7	116783354	116783354	A	T	ENST00000397752.3	75		missense_variant	"ENST00000318493.11:c.3737A>T,ENSP00000317272.6:p.Asp1246Val,NM_001127500.3:c.3737A>T,NP_001120972.1:p.Asp1246Val"	2023-01-27 17:05:42 UTC	CA368991571	NONE FOUND	"ASP1228VAL,D1246V,ASP1246VAL"	FALSE
RB1 Mutation	777	Lung Small Cell Carcinoma	5409		Chemotherapy		Predictive	Supports	B	Sensitivity/Response	"Study evaluated a total of 50 small cell lung cancer patients with extensive stage disease. Multivariate analysis identified RB1 as a factor in predicting response to first-line chemotherapy (odds ratio 5.58 compared to WT, p=.038). Kaplan-Meier survival analysis revealed patients with RB1 mutations exhibited better overall survival (p = .04, 11.7 versus 9.1 months, CI = 1.1-28.2)."	26802149	PubMed		"Dowlati et al., 2016, Ann. Oncol."		2	accepted	1866	Somatic	2023-01-09 21:46:38 UTC	https://civicdb.org/links/evidence_items/1866	https://civicdb.org/links/molecular_profiles/777	FALSE	RB1	5925	Mutation		chr13	48303775	48481986			ENST00000267163.4	75		gene_variant		2023-01-09 21:52:09 UTC				FALSE
EGFR T790M	34	Lung Non-small Cell Carcinoma	3908		Osimertinib		Predictive	Supports	A	Sensitivity/Response	"Randomized, international, open-label, phase 3 trial (NCT02151981) in 419 patients with T790M-positive advanced NSCLC and disease progression after first-line EGFR-TKI therapy. Patients were randomized, in a 2:1 ratio, to oral osimertinib or chemotherapy (pemetrexed plus either carboplatin or cisplatin every 3 weeks for up to six cycles, maintenance pemetrexed was allowed). Primary end point was PFS, which was significantly longer with osimertinib than with chemotherapy (10.1 months vs. 4.4 months; HR 0.30; 95% CI: 0.23 to 0.41; P<0.001). Objective response rate was significantly better with osimertinib (71%; 95% CI, 65 to 76) than with chemotherapy (31%; 95% CI, 24 to 40) (odds ratio for objective response, 5.39; 95% CI, 3.47 to 8.48; P<0.001)."	27959700	PubMed		"Mok et al., 2016, N. Engl. J. Med."	NCT02151981	5	accepted	1867	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/1867	https://civicdb.org/links/molecular_profiles/34	FALSE	EGFR	1956	T790M	EGFR TKI Resistance	chr7	55181378	55181378	C	T	ENST00000275493.2	75		missense_variant	"ENST00000275493.2:c.2369C>T,NM_005228.4:c.2369C>T,NP_005219.2:p.Thr790Met,NC_000007.13:g.55249071C>T"	2023-01-27 17:02:05 UTC	CA090928	16613	"THR790MET,RS121434569"	FALSE
NTRK3 ETV6::NTRK3	779	Mammary Analogue Secretory Carcinoma	80808		Entrectinib		Predictive	Supports	C	Sensitivity/Response	Case report of a patient with mammary analogue secretory carcinoma (MASC) harboring an ETV6-NTRK3 fusion. The patient was treated with entrectinib and exhibited a partial response for 7 months followed by disease progression.	26884591	PubMed		"Drilon et al., 2016, Ann. Oncol."	NCT02097810	3	accepted	1869	Somatic	2023-01-09 21:46:38 UTC	https://civicdb.org/links/evidence_items/1869	https://civicdb.org/links/molecular_profiles/779	FALSE	NTRK3	4916	ETV6::NTRK3		chr12	11649854	11869969			ENST00000396373.4	75	ENST00000394480.2	transcript_fusion		2023-01-09 21:52:09 UTC		N/A	ETV6-NTRK3	FALSE
NTRK3 ETV6::NTRK3	779	Mammary Analogue Secretory Carcinoma	80808		Crizotinib		Predictive	Does Not Support	C	Sensitivity/Response	Case report of a patient with mammary analogue secretory carcinoma (MASC) harboring an ETV6-NTRK3 fusion. The patient was treated with crizotinib and had stable disease but disease progression after 18 weeks. The patient was subsequently treated with entrectinib and exhibited a partial response for 7 months followed by disease progression.	26884591	PubMed		"Drilon et al., 2016, Ann. Oncol."	NCT02097810	2	accepted	1870	Somatic	2023-01-09 21:46:38 UTC	https://civicdb.org/links/evidence_items/1870	https://civicdb.org/links/molecular_profiles/779	FALSE	NTRK3	4916	ETV6::NTRK3		chr12	11649854	11869969			ENST00000396373.4	75	ENST00000394480.2	transcript_fusion		2023-01-09 21:52:09 UTC		N/A	ETV6-NTRK3	FALSE
RUNX1 K83E	780	Acute Myeloid Leukemia	9119				Predisposing	Supports	C	Predisposition	A pedigree of 48 individuals with multiple instances of bleeding and platelet disorders and 8 cases of leukemia showed an A>G substitution in RUNX1 exon 3 which segregated with Familial Platelet Disorder and Acute Myeloid Leukemia. The mutation was not present in 188 unrelated control chromosomes. Functional assay suggested the mutant RUNX1 transcription factor had impaired DNA binding.	11830488	PubMed		"Michaud et al., 2002, Blood"		4	accepted	1871	Rare Germline	2023-01-12 06:04:11 UTC	https://civicdb.org/links/evidence_items/1871	https://civicdb.org/links/molecular_profiles/780	FALSE	RUNX1	861	K83E		chr21	34886866	34886866	T	C	ENST00000344691.4	75		missense_variant	"NC_000021.8:g.36259163T>C,NP_001001890.1:p.Lys83Glu,NM_001001890.2:c.247A>G,ENST00000344691.4:c.247A>G"	2023-01-27 17:05:43 UTC	CA248613	14465	"LYS83GLU,K110E,RS121912498"	FALSE
RUNX1 Y260*	781	Acute Myeloid Leukemia	9119				Predisposing	Supports	C	Predisposition	"A pedigree (Pedigree number 3) with 24 members with multiple instances of bleeding disorder and three cases of familial leukemia showed a C>A substitution in exon 7B of the transcription factor RUNX1.  This mutation resulted in a nonsense mutation, and the mutation segregated with familial platelet disorder and acute myeloid leukemia in the pedigree."	11830488	PubMed		"Michaud et al., 2002, Blood"		3	accepted	1872	Rare Germline	2023-01-12 06:05:04 UTC	https://civicdb.org/links/evidence_items/1872	https://civicdb.org/links/molecular_profiles/781	FALSE	RUNX1	861	Y260*		chr21	34799407	34799407	G	T	ENST00000344691.4	75		stop_gained	"NM_001001890.2:c.780C>A,NP_001001890.1:p.Tyr260Ter,NC_000021.8:g.36171704G>T,ENST00000344691.4:c.780C>A"	2023-01-27 17:05:44 UTC	CA248619	14467	"Y260X,TYR260TER,RS121912499"	FALSE
NTRK3 ETV6::NTRK3 G623R	783	Mammary Analogue Secretory Carcinoma	80808		Entrectinib		Predictive	Supports	C	Resistance	Case report of a patient with mammary analogue secretory carcinoma (MASC) harboring an etv6-ntrk3 fusion. The patient was treated with entrectinib and exhibited a partial response for 7 months followed by disease progression. A NTRK3 exon 16 G623R (c.1867G>A) mutation was identified in the progressive tumor. Cell line and structural models revealed that this mutation conferred relative resistance to entrectinib.	26884591	PubMed		"Drilon et al., 2016, Ann. Oncol."	NCT02097810	4	accepted	1874	Somatic	2023-01-09 21:46:38 UTC	https://civicdb.org/links/evidence_items/1874	https://civicdb.org/links/molecular_profiles/783	FALSE	NTRK3	4916	ETV6::NTRK3 G623R		chr15	87933034	87933034	C	T	ENST00000394480.2	75		"missense_variant,transcript_fusion"	"NC_000015.9:g.88476265C>T,ENST00000394480.2:c.1867G>A"	2023-01-27 17:05:44 UTC	CA393914380	NONE FOUND	"GLY623ARG,ETV6-NTRK3 G623R"	FALSE
RUNX1 D198Y	784	Acute Myeloid Leukemia	9119				Predisposing	Supports	C	Uncertain Significance	"In a pedigree with familial platelet disorder with predisposition to acute myeloid leukemia (FPD/AML) spanning three generations, five members of generation II were sequenced at exons 3, 4 and 5 of the RUNX1 (or CBFA2) gene and the D198Y mutation (in the DNA binding RUNT domain) was found in 3/5 of the individuals with FPD/AML but not in 2/5 without FPD/AML. The mutation was not found in 108 control subjects."	11675361	PubMed		"Buijs et al., 2001, Blood"		3	accepted	1875	Rare Germline	2023-01-09 21:46:38 UTC	https://civicdb.org/links/evidence_items/1875	https://civicdb.org/links/molecular_profiles/784	FALSE	RUNX1	861	D198Y		chr21	34859495	34859495	C	A	ENST00000300305.3	75		"missense_variant,loss_of_function_variant"	NC_000021.8:g.36231792C>A	2023-01-27 17:05:45 UTC	CA410207975	NONE FOUND	ASP198TYR	FALSE
RUNX1 A107P	785	Acute Myeloid Leukemia	9119				Predisposing	Supports	C	Predisposition	"A pedigree of 3 generations and 8 individuals with familial platelet disease with propensity to acute myeloid leukemia (FPD/AML) was assessed for mutation in RUNX1 exons 3, 4, 5 and 6. Mutation was found in DNA binding RUNT domain at amino acid 107 from alanine to proline. This mutation was found in 5/8 individuals with FPD/AML but not in 3/8 unaffected individuals as well as 10 unrelated control samples."	12060124	PubMed		"Walker et al., 2002, Br. J. Haematol."		5	accepted	1876	Rare Germline	2023-01-12 06:07:12 UTC	https://civicdb.org/links/evidence_items/1876	https://civicdb.org/links/molecular_profiles/785	FALSE	RUNX1	861	A107P		chr21	34880665	34880665	C	G	ENST00000344691.4	75		missense_variant	"NM_001754.4:c.400G>C,NP_001745.2:p.Ala134Pro,NC_000021.8:g.36252962C>G,ENST00000344691.4:c.400G>C"	2023-01-27 17:05:46 UTC	CA248623	14468	"A134P,ALA134PRO,RS74315451"	FALSE
MSH2 Loss	786	Transitional Cell Carcinoma	2671		"Durvalumab,Anti-PD-1 Monoclonal Antibody MEDI0680"	Combination	Predictive	Supports	C	Sensitivity/Response	"Case report of a 45-year old woman of Japanese descent with recurrent urothelial carcinoma. The patient was identified to harbor mutations in MSH2 (A913fs*2, E226*, E580*) and in MSH6 (R361H) by panel sequencing as well as loss of expression of these genes as confirmed by IHC. Testing also revealed a high mutational load as well as 2+ PD-L1 expression in 80% of the cells.  The patient was treated with anti-PD-L1 inhibitor MEDI4736 and MEDI0680 in a phase 1 trial and had a complete remission within 2 months of treatment that was ongoing after 11 months."	26674132	PubMed		"Castro et al., 2015, J Immunother Cancer"	NCT00938834	3	accepted	1877	Somatic	2023-01-09 21:46:38 UTC	https://civicdb.org/links/evidence_items/1877	https://civicdb.org/links/molecular_profiles/786	FALSE	MSH2	4436	Loss		chr2	47402969	47483228			ENST00000233146.2	75		loss_of_function_variant		2023-01-09 21:52:09 UTC		N/A		FALSE
MSH6 LOSS	787	Transitional Cell Carcinoma	2671		"Anti-PD-1 Monoclonal Antibody MEDI0680,Durvalumab"	Combination	Predictive	Supports	C	Sensitivity/Response	"Case report of a 45-year old woman of Japanese descent with recurrent urothelial carcinoma. The patient was identified to harbor mutations in MSH2 (A913fs*2, E226*, E580*) and in MSH6 (R361H) by panel sequencing as well as loss of expression of these genes as confirmed by IHC. Testing also revealed a high mutational load as well as 2+ PD-L1 expression in 80% of the cells. The patient was treated with anti-PD-L1 inhibitor MEDI4736 and MEDI0680 in a phase 1 trial and had a complete remission within 2 months of treatment that was ongoing after 11 months."	26674132	PubMed		"Castro et al., 2015, J Immunother Cancer"	NCT00938834	3	accepted	1878	Somatic	2023-01-09 21:46:38 UTC	https://civicdb.org/links/evidence_items/1878	https://civicdb.org/links/molecular_profiles/787	FALSE	MSH6	2956	LOSS		chr2	47783082	47810101			ENST00000234420.5	75		loss_of_function_variant		2023-01-09 21:52:09 UTC		N/A		FALSE
CDKN2A Loss	550	Ewing Sarcoma	3369		"Linsitinib,Palbociclib"	Substitutes	Predictive	Supports	D	Sensitivity/Response	"A patient-derived xenograft (PDX) from a patient with cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) loss and FUS-ERG fusion positive Ewing's sarcoma was created. The PDX was treated in four cohorts (each N=6) with control, doxorubicin, CDK4/6 inhibitor palbociclib or IGF-1R inhibitor linsitinib. Both linsitinib and palbociclib cohorts were significantly more effective than control and doxorubicin. Doxorubicin was part of the patient's treatment (Neoadjuvant chemotherapy with DOX, vincristine, and cyclophosphamide) and was noted by authors as failing to control tumor growth."	27286459	PubMed		"Murakami et al., 2016, Oncotarget"		2	accepted	1879	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1879	https://civicdb.org/links/molecular_profiles/550	FALSE	CDKN2A	1029	Loss		chr9	21967753	21994624			ENST00000579755.1	75		loss_of_function_variant		2023-01-09 21:52:07 UTC		N/A		FALSE
CDKN2B Loss	551	Ewing Sarcoma	3369		"Linsitinib,Palbociclib"	Substitutes	Predictive	Supports	D	Sensitivity/Response	"A patient-derived xenograft (PDX) from a patient with cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) loss and FUS-ERG fusion positive Ewing's sarcoma was created. The PDX was treated in four cohorts (each N=6) with control, doxorubicin, CDK4/6 inhibitor palbociclib or IGF-1R inhibitor linsitinib. Both linsitinib and palbociclib cohorts were significantly more effective than control and doxorubicin. Doxorubicin was part of the patient's treatment (Neoadjuvant chemotherapy with DOX, vincristine, and cyclophosphamide) and was noted by authors as failing to control tumor growth."	27286459	PubMed		"Murakami et al., 2016, Oncotarget"		2	accepted	1880	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1880	https://civicdb.org/links/molecular_profiles/551	FALSE	CDKN2B	1030	Loss		chr9	22002903	22009363			ENST00000276925.6	75		transcript_ablation		2023-01-09 21:52:07 UTC		N/A		FALSE
CDKN2A Loss	550	Dermatofibrosarcoma Protuberans	3507		Palbociclib		Predictive	Supports	D	Sensitivity/Response	"An imatinib-resistant cell line, DFSP105, was established from a dermatofibrosarcoma protuberans which had progressed to a high-grade fibrosarcomatous DFSP. The disease-associated COL1A1-PDGFB fusion was consistent with the most common form, a supernumerary ring chromosome. Genetic characterization of the cell line with a SNP array identified a homozygous CDKN2A/B deletion. Treatment of this cell line with CDK4/6 inhibitor palbociclib led to growth inhibition and reduced RB1 phosphorylation in vitro and in-vivo."	25852058	PubMed		"Eilers et al., 2015, Mol. Cancer Ther."		2	accepted	1881	Unknown	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1881	https://civicdb.org/links/molecular_profiles/550	FALSE	CDKN2A	1029	Loss		chr9	21967753	21994624			ENST00000579755.1	75		loss_of_function_variant		2023-01-09 21:52:07 UTC		N/A		FALSE
RUNX1 T148HFSX9	788	Acute Myeloid Leukemia	9119				Predisposing	Supports	C	Uncertain Significance	A 2 year old male presented with easy bruising and bleeding. At 6 years old he was diagnosed with AML. The patients mother showed mile thrombocytopenia. Sequencing of RUNX1 exons 3-6 revealed an 8 bp deletion which was hypothesized to result in a null allele. The mutation was found in the mother and son. The patient's maternal grandparents were haematologicaly  normal. Relevant ACMG codes from this paper are 'PVS1' (frameshift/null variant) and 'PP1' (limited segregation data).	18478040	PubMed		"Bri-Dexheimer et al., 2008, Eur. J. Hum. Genet."		2	accepted	1882	Rare Germline	2023-01-09 21:46:38 UTC	https://civicdb.org/links/evidence_items/1882	https://civicdb.org/links/molecular_profiles/788	FALSE	RUNX1	861	T148HFSX9		chr21	34880616	34880623	GCTGCGGT		ENST00000300305.3	75		frameshift_truncation	"NM_001754.4:c.442_449delACCGCAGC,NP_001745.2:p.Thr148Hisfs,NC_000021.8:g.36252913_36252920del,ENST00000300305.3:c.442_449delACCGCAGC"	2023-01-27 17:05:47 UTC	CA248627	14470	"C.442_449DEL,THR148HISFSX9,RS587776811"	FALSE
DDX41 R164W	792	Hematologic Cancer	2531				Predisposing	Supports	C	Predisposition	"Eight members of larger pedigree spanning four generations with inherited hematological cancers were sequenced with whole exome sequencing or sanger sequencing of DDX41 exons 5 and 6. A mutation c.490C>T or R164W was found in 5/5 members with Non Hodkin's lymphoma, Hodgkin lymphoma, or multiple myeloma but not in 3/3 unaffected individuals. The site of mutation is reported to potentially be important for DDX41 helicase activity."	26712909	PubMed		"Lewinsohn et al., 2016, Blood"		3	accepted	1887	Rare Germline	2023-01-12 06:14:28 UTC	https://civicdb.org/links/evidence_items/1887	https://civicdb.org/links/molecular_profiles/792	FALSE	DDX41	51428	R164W		chr5	177515766	177515766	G	A	ENST00000507955.1	75		missense_variant		2023-01-27 17:05:50 UTC	CA358665			FALSE
ERBB2 Y772_A775DUP	410	Lung Adenocarcinoma	3910		Afatinib		Predictive	Supports	C	Sensitivity/Response	"A Phase II study for use of Afatinib in non- or light smokers with lung adenocarcinoma. Three patients with metastatic lung adenocarcinomas bearing mutations in the kinase domain of HER2 gene were identified (Y772_A775dup, G776L, and G778_P780dup). Objective response was observed in all three of these patients. The patient with Y772_A775dup (Case 1 in the paper), maintained a metabolic complete response for 3 months, ultimately received a total of 9 months of Afatinib, and survived one year from study entry."	22325357	PubMed		"De Grve et al., 2012, Lung Cancer"	NCT00730925	3	accepted	1888	Somatic	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/1888	https://civicdb.org/links/molecular_profiles/410	FALSE	ERBB2	2064	Y772_A775DUP		chr17	39724743	39724744		TACGTGATGGCT	ENST00000269571.5	75		inframe_insertion	"NM_001005862.2:c.2224_2235dupTACGTGATGGCT,ENST00000269571.5:c.2314_2325dupTACGTGATGGCT,NC_000017.10:g.37880985_37880996dupTACGTGATGGCT,NC_000017.10:g.37880993_37880994insGCTTACGTGATG"	2023-01-27 17:03:37 UTC	CA135369	44985	"A775INSYVMA,P.A775_G776INSYVMA,P.E770_A771INSAYVM,TYR772_ALA775DUP,A775_G776INSYVMA,M774INSAYVM"	FALSE
ERBB2 G776L	794	Lung Adenocarcinoma	3910		Afatinib		Predictive	Supports	C	Sensitivity/Response	"A Phase II study for use of Afatinib in non- or light smokers with lung adenocarcinoma. Three patients with metastatic lung adenocarcinomas bearing mutations in the kinase domain of HER2 gene were identified (Y772_A775dup, G776L, and G778_P780dup). Objective response was observed in all three of these patients. The patient with G776L (Case 2 in the paper) achieved a partial response after two months of afatinib (50 mg/day). The time to progression of this single agent was four months. The patient was also noted to have a EGFR kinase domain (exon 21: p.Ala859Thr) mutation."	22325357	PubMed		"De Grve et al., 2012, Lung Cancer"	NCT00730925	3	accepted	1889	Somatic	2023-01-09 21:46:38 UTC	https://civicdb.org/links/evidence_items/1889	https://civicdb.org/links/molecular_profiles/794	FALSE	ERBB2	2064	G776L		chr17	39724744	39724745	GG	CT	ENST00000269571.5	75		missense_variant	"ENST00000269571.5:c.2326_2327delinsCT,NC_000017.10:g.37880997_37880998delinsCT,NP_001276866.1:p.Gly776Leu,NM_001289937.1:c.2326_2327delinsCT"	2023-01-27 17:05:51 UTC	CA913189238	NONE FOUND	GLY776LEU	FALSE
ERBB2 G778_P780DUP	795	Lung Adenocarcinoma	3910		Afatinib		Predictive	Supports	C	Sensitivity/Response	"A Phase II study for use of Afatinib in non- or light smokers with lung adenocarcinoma. Three patients with metastatic lung adenocarcinomas bearing mutations in the kinase domain of HER2 gene were identified (Y772_A775dup, G776L, and G778_P780dup). Objective response was observed in all three of these patients. The patient with G778_P780dup (Case 3 in the paper), had a rapid clinical and symptomatic response to Afatinib and stable disease which lasted for 3 months. Progressive disease at 4 months led to the addition of paclitaxel, resulting in partial response. Total Afatinib treatment was 15 months (11 in combination) at which time the patient developed a brain metastasis but no other progressive disease."	22325357	PubMed		"De Grve et al., 2012, Lung Cancer"	NCT00730925	3	accepted	1890	Somatic	2023-01-09 21:46:38 UTC	https://civicdb.org/links/evidence_items/1890	https://civicdb.org/links/molecular_profiles/795	FALSE	ERBB2	2064	G778_P780DUP		chr17	39724758	39724759		GGCTCCCCA	ENST00000269571.5	75		inframe_insertion	"NM_004448.3:c.2332_2340dupGGCTCCCCA,ENST00000269571.5:c.2332_2340dupGGCTCCCCA"	2023-01-27 17:05:52 UTC	CA135401	44993	GLY778_PRO780DUP	FALSE
ERBB2 Amplification	302	Lung Non-small Cell Carcinoma	3908		Dacomitinib		Predictive	Does Not Support	B	Sensitivity/Response	"Phase 2 trial of ERBB-inhibitor dacomitinib in stage IIIB/IV lung cancers with HER2 mutations or amplification. 4 patients with HER2 amplified NSCLC were enrolled in the trial, no one among them had a response."	25899785	PubMed		"Kris et al., 2015, Ann. Oncol."	NCT00818441	3	accepted	1891	N/A	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1891	https://civicdb.org/links/molecular_profiles/302	FALSE	ERBB2	2064	Amplification		chr17	39700080	39728662			ENST00000269571.5	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A	OVEREXPRESSION	FALSE
ERBB2 G778_P780DUP	795	Lung Non-small Cell Carcinoma	3908		Dacomitinib		Predictive	Supports	C	Sensitivity/Response	"Phase 2 trial of ERBB-inhibitor dacomitinib in stage IIIB/IV lung cancers with HER2 mutations or amplification. Two patients were identified with identical HER2 p.G778_P780dup mutations (p. P780_Y781insGSP, c. 2339_2340ins GGCTCCCCA) and no amplification. Both had a confirmed partial response lasting 11 and 14 months. Only 3/30 patients on this trial had a partial response (no complete responses)."	25899785	PubMed		"Kris et al., 2015, Ann. Oncol."	NCT00818441	3	accepted	1892	Somatic	2023-01-09 21:46:38 UTC	https://civicdb.org/links/evidence_items/1892	https://civicdb.org/links/molecular_profiles/795	FALSE	ERBB2	2064	G778_P780DUP		chr17	39724758	39724759		GGCTCCCCA	ENST00000269571.5	75		inframe_insertion	"NM_004448.3:c.2332_2340dupGGCTCCCCA,ENST00000269571.5:c.2332_2340dupGGCTCCCCA"	2023-01-27 17:05:52 UTC	CA135401	44993	GLY778_PRO780DUP	FALSE
ERBB2 Y772_A775DUP	410	Lung Non-small Cell Carcinoma	3908		Dacomitinib		Predictive	Does Not Support	B	Sensitivity/Response	"Phase 2 trial of ERBB-inhibitor dacomitinib in stage IIIB/IV lung cancers with HER2 mutations or amplification (N=30). Thirteen tumors harbored identical 12 base pair exon 20 insertions [A775_G776insYVMA, alternative nomenclature p.Y772_A775dup(c.2313_2324dup)]. No partial responses were found in this subgroup even though some were on study treatment for >2 years and 3 patients with other HER2 mutations achieved PRs."	25899785	PubMed		"Kris et al., 2015, Ann. Oncol."	NCT00818441	2	accepted	1893	Somatic	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/1893	https://civicdb.org/links/molecular_profiles/410	FALSE	ERBB2	2064	Y772_A775DUP		chr17	39724743	39724744		TACGTGATGGCT	ENST00000269571.5	75		inframe_insertion	"NM_001005862.2:c.2224_2235dupTACGTGATGGCT,ENST00000269571.5:c.2314_2325dupTACGTGATGGCT,NC_000017.10:g.37880985_37880996dupTACGTGATGGCT,NC_000017.10:g.37880993_37880994insGCTTACGTGATG"	2023-01-27 17:03:37 UTC	CA135369	44985	"A775INSYVMA,P.A775_G776INSYVMA,P.E770_A771INSAYVM,TYR772_ALA775DUP,A775_G776INSYVMA,M774INSAYVM"	FALSE
ERBB2 M774DELINSWLV	796	Lung Non-small Cell Carcinoma	3908		Dacomitinib		Predictive	Supports	C	Sensitivity/Response	"Phase 2 trial of ERBB-inhibitor dacomitinib in stage IIIB/IV lung cancers with HER2 mutations or amplification (N=30). One patient was found to harbor a unique Exon 20 indel (p. M774delinsWLV, c.2320A>TGGCT GG; p. M774delinsWLV, c.2320delins TGGCTGG) and was among the three patients that had a partial response."	25899785	PubMed		"Kris et al., 2015, Ann. Oncol."	NCT00818441	3	accepted	1894	Somatic	2023-01-09 21:46:38 UTC	https://civicdb.org/links/evidence_items/1894	https://civicdb.org/links/molecular_profiles/796	FALSE	ERBB2	2064	M774DELINSWLV		chr17	39724738	39724738	A	TGGCTGG	ENST00000269571.5	75		inframe_indel		2023-03-24 00:00:08 UTC	unregistered	NONE FOUND		FALSE
PTPRB Loss-of-function	797	Angiosarcoma	1816		"Vatalanib,Sunitinib"	Substitutes	Predictive	Supports	D	Sensitivity/Response	"The endothelial phosphatase PTPRB, a negative regulator of vascular growth factor tyrosine kinases, harbored truncating mutations in 10 of 39 angiosarcomas (26%) which correlated with MYC amplifications. In HUVEC cell line model, silencing of PTPRB induced features of angiogenesis which were abolished in the presence of sunitinib or vatalinib, inhibitors of VEGFR."	24633157	PubMed		"Behjati et al., 2014, Nat. Genet."		3	accepted	1895	Somatic	2023-01-09 21:46:38 UTC	https://civicdb.org/links/evidence_items/1895	https://civicdb.org/links/molecular_profiles/797	FALSE	PTPRB	5787	Loss-of-function		chr12	70516850	70637440			ENST00000334414.6	75		loss_of_function_variant		2023-01-09 21:52:09 UTC		N/A		FALSE
VHL A149S (c.445G>T)	798	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	"Study of a large kindred with von Hippel-Lindau disease (VHLD) and pheochromocytoma (spread over four generations). 25 proven cases of VHLD and 17 cases with pheochromocytoma were identified. Mutation analysis was performed in 14 family members (7 affected, 7 unaffected).  11 cases had the same mutation resulting in a predicted amino acid substitution of A149S.  The cases with mutation that appeared unaffected were all very young (before the likely age of onset). The three cases without the mutation that appeared unaffected were aged 18, 54, and 69.  ACMG evidence codes: 'PP1' based on segregation results, 'PM5' because the authors describe a prior report of a similar mutation at the same site (A149T), 'PP2' because they observe a missense variant in gene where missense variants are common mechanism of disease, and 'PP4' because the patients phenotypes and family history are highly specific for a disease with single genetic etiology."	9435426	PubMed		"Atuk et al., 1998, J. Clin. Endocrinol. Metab."		4	accepted	1896	Rare Germline	2023-01-09 21:46:38 UTC	https://civicdb.org/links/evidence_items/1896	https://civicdb.org/links/molecular_profiles/798	FALSE	VHL	7428	A149S (c.445G>T)		chr3	10146618	10146618	G	T	ENST00000256474.2	75		missense_variant	"NP_000542.1:p.Ala149Ser,NM_000551.2:c.445G>T,ENST00000256474.2:c.445G>T,NC_000003.11:g.10188302G>T"	2023-01-27 17:05:52 UTC	CA020355	127829	"ALA149SER,C.445G>T,RS587780077"	FALSE
BRCA1 Mutation	185	Ovarian Cancer	2394		Rucaparib		Predictive	Supports	B	Sensitivity/Response	"A phase 2 trial on patients with relapsed, platinum-sensitive high grade ovarian, fallopian tube or primary peritoneal carcinoma (ARIEL2 Part1, NCT01891344) was held to assess PARP inhibitor rucaparib on 3 genetically defined subsets of patients. Out of 40 BRCA mutant (BRCA1 or BRCA2) patients, 14 had homozygous somatic BRCA1 mutation or deletion. Confirmed objective response was seen in 71% (10/14) of the somatic BRCA1 mutant subgroup. Authors note that response rate was similar regardless of whether the BRCA mutation was somatic or germline, in BRCA 1 or BRCA 2. In a BRCA wild-type subgroup, with low levels of loss of heterozygosity (LOH), confirmed objective response was observed in 10% (7/70) of the patients. Patients with BRCA mutant tumors experienced significantly longer median progression free survival than patients with BRCA wildtype, LOH low tumors (12.8 vs 5.2 mo, HR: 0.27, P<0.0001)."	27908594	PubMed		"Swisher et al., 2017, Lancet Oncol."	NCT01891344	3	accepted	1897	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/1897	https://civicdb.org/links/molecular_profiles/185	FALSE	BRCA1	672	Mutation		chr17	43045629	43125483			ENST00000471181.2	75		"gene_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
KRAS G12D	79	Colorectal Cancer	9256		Therapeutic Tumor Infiltrating Lymphocytes		Predictive	Supports	C	Sensitivity/Response	"A patient with metastatic colorectal cancer was enrolled in a phase 2 clinical trial (NCT01174121). 24 cultures of tumor-infiltrating lymphocytes were expanded from 3 lung metastasis resections. After cultures were tested for reactivity, the patient was infused with 1.48 x 10^11 tumor-infiltrating lymphocytes (75% CD8+ T cells) that were specifically reactive to KRAS G12D. All 7 metastatic lung lesions regressed 40 days after therapy, and the patient had a 9-month partial response."	27959684	PubMed		"Tran et al., 2016, N. Engl. J. Med."		3	accepted	1898	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/1898	https://civicdb.org/links/molecular_profiles/79	FALSE	KRAS	3845	G12D	EGFR TKI Resistance	chr12	25245350	25245350	C	T	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.35G>A,NP_004976.2:p.Gly12Asp,NC_000012.11:g.25398284C>T,ENST00000256078.4:c.35G>A"	2023-01-27 17:02:26 UTC	CA122538	12582	"GLY12ASP,RS121913529"	FALSE
JAK1 S703I	800	Hepatocellular Carcinoma	684		Ruxolitinib		Predictive	Supports	D	Sensitivity/Response	A JAK1 S703I mutation was found to activate the JAK-STAT signaling pathway in vitro and in vivo in hepatocellular carcinoma. Ruxolitinib causes the suppression of JAK-STAT signaling pathway in PDX models bearing JAK1 S703I mutation and delays tumor progression.	26701727	PubMed		"Yang et al., 2016, Oncotarget"		4	accepted	1900	Somatic	2023-01-09 21:46:38 UTC	https://civicdb.org/links/evidence_items/1900	https://civicdb.org/links/molecular_profiles/800	FALSE	JAK1	3716	S703I		chr1	64845520	64845520	C	A	ENST00000342505.4	75		missense_variant	"ENST00000342505.4:c.2108G>T,NC_000001.10:g.65311203C>A"	2023-01-27 17:05:53 UTC	CA340667333	NONE FOUND	SER703ILE	FALSE
EPCAM 3' Exon Deletion	801	Lynch Syndrome	3883				Predisposing	Supports	B	Predisposition	"Rare but recurring germline truncating mutations of the 3?end of EPCAM, were reported for 27 independent families, shown to lead to epigenetic silencing of a neighbouring gene, MSH2, and suggested to cause Lynch syndrome."	21309036	PubMed		"Kuiper et al., 2011, Hum. Mutat."		4	accepted	1901	Rare Germline	2023-01-12 06:17:51 UTC	https://civicdb.org/links/evidence_items/1901	https://civicdb.org/links/molecular_profiles/801	FALSE	EPCAM	4072	3' Exon Deletion		chr2	47385166	47387034			ENST00000263735	75		disruptive_inframe_deletion		2023-01-09 21:52:09 UTC				FALSE
BRAF V600E	12	Colorectal Cancer	9256		"Vemurafenib,Cetuximab,Irinotecan"	Combination	Predictive	Supports	B	Sensitivity/Response	"Phase 1b study of vemurafenib, cetuximab and irinotecan in 19 patients with colorectal cancer (1 with appendiceal cancer). Six of 17 evaluable patients achieved an objective response, 15 patients total had either stable disease or radiographic response (the patient with appendiceal cancer had disease progression). Estimated median PFS was 7.7 months. Effect of the combined treatment was also observed in xenograft and cell line studies."	27729313	PubMed		"Hong et al., 2016, Cancer Discov"	NCT01787500	4	accepted	1902	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/1902	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
ARAF S490T	803	Colorectal Cancer	9256		"Vemurafenib,Cetuximab,Irinotecan"	Combination	Predictive	Supports	C	Resistance	"Phase 1b study of vemurafenib, cetuximab and irinotecan in 19 BRAF V600E mutant colorectal cancer patients. cfDNA panel sequencing was performed in 10 patients after disease progression. One patient had an acquired ARAF S490T mutation that was not identified before treatment initiation."	27729313	PubMed		"Hong et al., 2016, Cancer Discov"	NCT01787500	1	accepted	1905	Somatic	2023-01-09 21:46:38 UTC	https://civicdb.org/links/evidence_items/1905	https://civicdb.org/links/molecular_profiles/803	FALSE	ARAF	369	S490T		chrX	47569941	47569941	T	A	ENST00000377045.4	75		missense_variant		2023-01-27 17:05:55 UTC	CA412818377	NONE FOUND	SER490THR	FALSE
GNAS R201C	804	Colorectal Cancer	9256		"Cetuximab,Irinotecan,Vemurafenib"	Combination	Predictive	Supports	C	Resistance	"Phase 1b study of vemurafenib, cetuximab and irinotecan in 19 BRAF V600E mutant colorectal cancer patients. cfDNA panel sequencing was performed in 10 patients after disease progression. One patient acquired a novel GNAS1 R201C mutation at disease progression."	27729313	PubMed		"Hong et al., 2016, Cancer Discov"	NCT01787500	2	accepted	1906	Somatic	2023-01-09 21:46:38 UTC	https://civicdb.org/links/evidence_items/1906	https://civicdb.org/links/molecular_profiles/804	FALSE	GNAS	2778	R201C		chr20	58909365	58909365	C	T	ENST00000371085.3	75		missense_variant	"NM_000516.5:c.601C>T,NP_000507.1:p.Arg201Cys,NC_000020.10:g.57484420C>T,ENST00000371085.3:c.601C>T"	2023-01-27 17:05:55 UTC	CA126067	15933	"ARG201CYS,R202C,RS11554273"	FALSE
ATM Mutation	178	Mantle Cell Lymphoma	50746		Olaparib		Predictive	Supports	D	Sensitivity/Response	Two ATM deficient mantle cell lymphoma (MCL) cell lines were more sensitive to PARP-1 inhibition with olaparib or PJ-34 than 4 other MCL cell lines. shRNA mediated ATM knockdown in a cell line increased sensitivity to olaparib. These results were confirmed in a xenograft model.	20124459	PubMed		"Williamson et al., 2010, Mol. Cancer Ther."		3	accepted	1907	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/1907	https://civicdb.org/links/molecular_profiles/178	FALSE	ATM	472	Mutation		chr11	108222832	108369099			ENST00000278616.4	75		"transcription_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
FGFR1 Amplification	263	Lung Squamous Cell Carcinoma	3907		Infigratinib		Predictive	Supports	B	Sensitivity/Response	"Phase 1 study of FGFR-inhibitor BGJ398 (infigratinib) in advanced cancer with FGFR-aberrations (n=132). In the subgroup of FGFR1-amplified squamous NSCLC (as classified by FISH), 36 patients were treated at doses >100mg continuously and disease control was achieved in 50% of patients (4 PR and 14 SD) with 6 patients receiving treatment after 16 weeks. Of the 27 patients who had evaluable pre- and post- treatment target lesion assessments, 11 had reduced tumor burden."	27870574	PubMed		"Nogova et al., 2017, J. Clin. Oncol."		3	accepted	1908	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1908	https://civicdb.org/links/molecular_profiles/263	FALSE	FGFR1	2260	Amplification		chr8	38411138	38467845			ENST00000425967.3	75		transcript_amplification	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
FGFR1 Amplification	263	Breast Cancer	1612		Infigratinib		Predictive	Does Not Support	B	Resistance	"Phase 1 study of FGFR-inhibitor BGJ398 (infigratinib) in advanced cancer with FGFR-aberrations (n=132). Among the 21 continuously treated (>100mg) patients with breast cancer and FGFR1 amplification (as classified by FISH), 9 had a best response of SD, three of which experienced reductions in tumor burden."	27870574	PubMed		"Nogova et al., 2017, J. Clin. Oncol."		2	accepted	1909	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1909	https://civicdb.org/links/molecular_profiles/263	FALSE	FGFR1	2260	Amplification		chr8	38411138	38467845			ENST00000425967.3	75		transcript_amplification	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
FGFR3 Mutation	805	Bladder Carcinoma	4007		Infigratinib		Predictive	Supports	B	Sensitivity/Response	"Phase 1 study evaluated 132 patients who had advanced cancer with FGFR-aberrations treated with FGFR-inhibitor BGJ398. In the subgroup of eight patients with FGFR3-mutated bladder/urothelial cancer treated at doses ?100 mg, the disease control rate (SD + PR) was 75%. Three patients achieved partial response and 3 patients had stable disease. Of the six patients with disease control, the time on treatment ranged from 15.1 to ?101 weeks, with one ongoing at data cutoff."	27870574	PubMed		"Nogova et al., 2017, J. Clin. Oncol."		3	accepted	1910	Somatic	2023-01-09 21:46:38 UTC	https://civicdb.org/links/evidence_items/1910	https://civicdb.org/links/molecular_profiles/805	FALSE	FGFR3	2261	Mutation		chr4	1793312	1808872			ENST00000340107.4	75				2023-01-09 21:52:09 UTC				FALSE
FGFR1 Amplification	263	Bladder Carcinoma	4007		Infigratinib		Predictive	Does Not Support	C	Sensitivity/Response	"Phase 1 study of FGFR-inhibitor BGJ398 in advanced cancer with FGFR-aberrations. Of the eight patients with FGFR3-mutated bladder/urothelial cancer, one patient with FGFR1 amplification was treated with 125 mg and progressed rapidly in cycle 1 after 11 days of treatment."	27870574	PubMed		"Nogova et al., 2017, J. Clin. Oncol."		2	accepted	1911	N/A	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1911	https://civicdb.org/links/molecular_profiles/263	FALSE	FGFR1	2260	Amplification		chr8	38411138	38467845			ENST00000425967.3	75		transcript_amplification	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
FGFR2 Mutation	507	Cholangiocarcinoma	4947		Infigratinib		Predictive	Supports	C	Sensitivity/Response	"Phase 1 study of FGFR-inhibitor BGJ398 in advanced cancer with FGFR-aberrations. Among three patients with cholangiocarcinoma and FGFR2 aberrations (2 fusions, 1 mutation), all three had stable disease with a reduced tumor burden."	27870574	PubMed		"Nogova et al., 2017, J. Clin. Oncol."		2	accepted	1912	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1912	https://civicdb.org/links/molecular_profiles/507	FALSE	FGFR2	2263	Mutation		chr10	121479857	121598403			ENST00000457416.2	75		"transcript_variant,gain_of_function_variant"		2023-01-09 21:52:07 UTC		"37,615,737,615,637,600,000,000"		FALSE
VHL M54IFS (c.162_166delGGAGG)	807	Clear Cell Renal Cell Carcinoma	4467				Oncogenic	Supports	C	Oncogenicity	A study of sporadic renal cell carcinoma identified this frameshift confirmed somatic variant along with LOH of the VHL gene in a case with clear cell renal carcinoma (case #152 in the study).	8187067	PubMed		"Shuin et al., 1994, Cancer Res."		1	accepted	1914	Somatic	2023-02-03 16:19:51 UTC	https://civicdb.org/links/evidence_items/1914	https://civicdb.org/links/molecular_profiles/807	FALSE	VHL	7428	M54IFS (c.162_166delGGAGG)		chr3	10142009	10142013	GGAGG		ENST00000256474.2	75		frameshift_truncation	"NM_000551.2:c.162_166delGGAGG,NP_000542.1:p.Met54IlefsTer76,NC_000003.11:g.10183693_10183697del,ENST00000256474.2:c.162_166delGGAGG"	2023-01-27 17:05:56 UTC	CA645524639	NONE FOUND	"C.162_166DELGGAGG,MET54ILEFS"	FALSE
FGFR2 FGFR2::BICC1	763	Transitional Cell Carcinoma	2671		Erdafitinib		Predictive	Supports	C	Sensitivity/Response	"Phase 1 study of pan-FGFR inhibitor JNJ-42756493 in patients with solid tumors. No responses were seen 36 patients without known FGFR pathway aberrations. Among 23 patients with FGFR pathway aberrations, 4 partial responses as well as 16 with stable disease were seen. In patients with FGFR2-BICC1 fusions, 1 patient with urothelial cancer harboring FGFR2-BICC1/FGFR2-CASP7 fusions had a PR."	26324363	PubMed		"Tabernero et al., 2015, J. Clin. Oncol."	NCT01703481	3	accepted	1917	Somatic	2023-01-09 21:46:38 UTC	https://civicdb.org/links/evidence_items/1917	https://civicdb.org/links/molecular_profiles/763	FALSE	FGFR2	2263	FGFR2::BICC1		chr10	121479857	121598403			ENST00000457416.2	75	ENST00000373886.3	transcript_fusion		2023-01-09 21:52:09 UTC		N/A	FGFR2-BICC1	FALSE
FGFR2 FGFR2::BICC1	763	Transitional Cell Carcinoma	2671		Erdafitinib		Predictive	Supports	C	Sensitivity/Response	"Phase 1 study of pan-FGFR inhibitor JNJ-42756493 in patients with solid tumors. No responses were seen 36 patients without known FGFR pathway aberrations. Among 23 patients with FGFR pathway aberrations, 4 partial responses as well as 16 with stable disease were seen. In patients with FGFR2-BICC1 fusions, 1 patient with urothelial cancer harboring FGFR2-BICC1/FGFR2-CASP7 fusions had a PR."	26324363	PubMed		"Tabernero et al., 2015, J. Clin. Oncol."	NCT01703481	3	accepted	1917	Somatic	2023-01-09 21:46:38 UTC	https://civicdb.org/links/evidence_items/1917	https://civicdb.org/links/molecular_profiles/763	FALSE	FGFR2	2263	FGFR2::BICC1		chr10	58702074	58831435			ENST00000457416.2	75	ENST00000373886.3	transcript_fusion		2023-01-09 21:52:09 UTC		N/A	FGFR2-BICC1	FALSE
FGFR3 FGFR3::TACC3	808	Cancer	162		Erdafitinib		Predictive	Supports	B	Sensitivity/Response	"Phase 1 study of pan-FGFR inhibitor JNJ-42756493 in patients with solid tumors. No responses were seen 36 patients without FGFR pathway aberrations. Among 23 patients with FGFR pathway aberrations, 5 partial responses (PR) and 16 with stable disease were seen. In patients harboring FGFR3-TACC3, there were 2 urothelial cancer patients with PRs, 1 endometrial cancer patient with PR (also had FGFR2-BICC1/FGFR2-OFD1 fusions), and tumor shrinkage in a patient with adrenal carcinoma (also had FGFR2-CCDC6 fusion)."	26324363	PubMed		"Tabernero et al., 2015, J. Clin. Oncol."	NCT01703481	3	accepted	1919	Somatic	2023-01-09 21:46:38 UTC	https://civicdb.org/links/evidence_items/1919	https://civicdb.org/links/molecular_profiles/808	FALSE	FGFR3	2261	FGFR3::TACC3		chr4	1793312	1806934			ENST00000340107.4	75	ENST00000313288.4	transcript_fusion		2023-01-09 21:52:09 UTC		495323	FGFR3-TACC3	FALSE
FGFR3 FGFR3::TACC3	808	Cancer	162		Erdafitinib		Predictive	Supports	B	Sensitivity/Response	"Phase 1 study of pan-FGFR inhibitor JNJ-42756493 in patients with solid tumors. No responses were seen 36 patients without FGFR pathway aberrations. Among 23 patients with FGFR pathway aberrations, 5 partial responses (PR) and 16 with stable disease were seen. In patients harboring FGFR3-TACC3, there were 2 urothelial cancer patients with PRs, 1 endometrial cancer patient with PR (also had FGFR2-BICC1/FGFR2-OFD1 fusions), and tumor shrinkage in a patient with adrenal carcinoma (also had FGFR2-CCDC6 fusion)."	26324363	PubMed		"Tabernero et al., 2015, J. Clin. Oncol."	NCT01703481	3	accepted	1919	Somatic	2023-01-09 21:46:38 UTC	https://civicdb.org/links/evidence_items/1919	https://civicdb.org/links/molecular_profiles/808	FALSE	FGFR3	2261	FGFR3::TACC3		chr4	1739702	1745171			ENST00000340107.4	75	ENST00000313288.4	transcript_fusion		2023-01-09 21:52:09 UTC		495323	FGFR3-TACC3	FALSE
FGFR2 FGFR2::BICC1	763	Endometrial Cancer	1380		Erdafitinib		Predictive	Supports	C	Sensitivity/Response	"Phase 1 study of pan-FGFR inhibitor JNJ-42756493 in patients with solid tumors. No responses were seen 36 patients without FGFR pathway aberrations. Among 23 patients with FGFR pathway aberrations, 4 partial responses as well as 16 with stable disease were seen. A patient with endometrial cancer with synchronous FGFR3-TACC3 and FGFR2-BICC1/FGFR2-OFD1 fusions had a PR."	26324363	PubMed		"Tabernero et al., 2015, J. Clin. Oncol."	NCT01703481	3	accepted	1920	Somatic	2023-01-09 21:46:38 UTC	https://civicdb.org/links/evidence_items/1920	https://civicdb.org/links/molecular_profiles/763	FALSE	FGFR2	2263	FGFR2::BICC1		chr10	121479857	121598403			ENST00000457416.2	75	ENST00000373886.3	transcript_fusion		2023-01-09 21:52:09 UTC		N/A	FGFR2-BICC1	FALSE
FGFR2 FGFR2::BICC1	763	Endometrial Cancer	1380		Erdafitinib		Predictive	Supports	C	Sensitivity/Response	"Phase 1 study of pan-FGFR inhibitor JNJ-42756493 in patients with solid tumors. No responses were seen 36 patients without FGFR pathway aberrations. Among 23 patients with FGFR pathway aberrations, 4 partial responses as well as 16 with stable disease were seen. A patient with endometrial cancer with synchronous FGFR3-TACC3 and FGFR2-BICC1/FGFR2-OFD1 fusions had a PR."	26324363	PubMed		"Tabernero et al., 2015, J. Clin. Oncol."	NCT01703481	3	accepted	1920	Somatic	2023-01-09 21:46:38 UTC	https://civicdb.org/links/evidence_items/1920	https://civicdb.org/links/molecular_profiles/763	FALSE	FGFR2	2263	FGFR2::BICC1		chr10	58702074	58831435			ENST00000457416.2	75	ENST00000373886.3	transcript_fusion		2023-01-09 21:52:09 UTC		N/A	FGFR2-BICC1	FALSE
TSC1 R1062W	695	Tuberous Sclerosis	13515				Predisposing	Supports	D	Uncertain Significance	The authors used a transfection based immunoblot assay to assess the impact of TSC1 (and TSC2) variants. Numerous variants were tested independently across 4 replicates and the mean and s.e.m. were plotted relative to wild type TSC1. The R1062W variant does not display a significant functional impact relative to the wildtype.  The authors state that SIFT (an in-silico missense functional prediction program) predicts the variant is tolerated.	21309039	PubMed		"Hoogeveen-Westerveld et al., 2011, Hum. Mutat."		3	accepted	1921	Rare Germline	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/1921	https://civicdb.org/links/molecular_profiles/695	FALSE	TSC1	7248	R1062W		chr9	132896546	132896546	G	A	ENST00000298552.3	75		missense_variant	"NM_000368.3:c.3184C>T,NP_000359.1:p.Arg1062Trp,ENST00000298552.3:c.3184C>T,NC_000009.11:g.135771933G>A"	2023-01-27 17:04:57 UTC	CA007223	49015	ARG1062TRP	FALSE
BRCA1 Loss-of-function	131	Breast Cancer	1612		"Quarfloxin,Pidnarulex"	Substitutes	Predictive	Supports	D	Sensitivity/Response	"The authors show that in the CX-5461 and CX-3543, G-quadruplex stabilizing agents, demonstrate specific toxicity against BRCA deficient breast cancer derived cells and polyclonal patient-derived xenograft models. Xenografts harbored both a germline BRCA and a somatic BRCA mutation leading to disruption of both. The BRCA and NHEJ pathways are required for the repair of CX-5461 and CX-3543-induced DNA damage and failure to do so leads to lethality."	28211448	PubMed		"Xu et al., 2017, Nat Commun"	NCT02719977	4	accepted	1924	Unknown	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/1924	https://civicdb.org/links/molecular_profiles/131	FALSE	BRCA1	672	Loss-of-function	BRCA Germline Variants	chr17	43045629	43125483			ENST00000471181.2	75		"loss_of_heterozygosity,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
BRCA2 Loss-of-function	132	Breast Cancer	1612		"Pidnarulex,Quarfloxin"	Substitutes	Predictive	Supports	D	Sensitivity/Response	"The authors show that in the CX-5461 and CX-3543, G-quadruplex stabilizing agents, demonstrate specific toxicity against BRCA deficient breast cancer derived cells and polyclonal patient-derived xenograft models. The BRCA and NHE J pathways are required for the repair of CX-5461 and CX-3543-induced DNA damage and failure to do so leads to lethality."	28211448	PubMed		"Xu et al., 2017, Nat Commun"	NCT02719977	4	accepted	1925	Unknown	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/1925	https://civicdb.org/links/molecular_profiles/132	FALSE	BRCA2	675	Loss-of-function	BRCA Germline Variants	chr13	32315474	32399210			ENST00000380152.3	75		loss_of_function_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
PTEN R173C	812	Cancer	162				Predisposing	Supports	D	Uncertain Significance	"Han et al functionally tested the R173C mutation in PTEN using an expression vector construct, assessing phosphatase activity of the mutant construct with two phosphoinositide substrates (""with[ PtdIns(3,4,5)P3] or without[ Ins(1,3,4,5)P4] a diacylglycerol chain""). R173C resides in the NH2-terminal phosphatase domain of PTEN. R173C was one of four mutations (out of 42 tested) that displayed no significant phosphatase activity against either substrate, indicating, by this assay, that the mutation negatively impacts the function of PTEN.   However this mutation did not affect the ability of PTEN to bind lipid membranes in-vivo.  This data justifies PS3 level evidence for pathogenicity according to ACMG guidelines."	10866302	PubMed		"Han et al., 2000, Cancer Res."		3	accepted	1930	N/A	2023-01-09 21:46:38 UTC	https://civicdb.org/links/evidence_items/1930	https://civicdb.org/links/molecular_profiles/812	FALSE	PTEN	5728	R173C		chr10	87952142	87952142	C	T	ENST00000371953.3	75		missense_variant	"NM_000314.6:c.517C>T,NP_000305.3:p.Arg173Cys,ENST00000371953.3:c.517C>T,NC_000010.10:g.89711899C>T"	2023-01-27 17:05:58 UTC	CA000498	189500	"ARG173CYS,RS121913293"	FALSE
PTEN Mutation	506	Glioblastoma	3068				Diagnostic	Supports	C	Positive	"Rasheed et al. identified that PTEN mutations occur with significantly greater frequency in adults with high-grade gliomas (42 adult glioblastoma multiforme and 13 adult anaplastic astrocytoma) compared to low-grade and child gliomas (68 others, varied). Mutation analysis performed using SSCP. No further testing was done."	9331072	PubMed		"Rasheed et al., 1997, Cancer Res."		2	accepted	1931	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1931	https://civicdb.org/links/molecular_profiles/506	FALSE	PTEN	5728	Mutation		chr10	87863113	87971930			ENST00000371953.3	75		protein_altering_variant		2023-01-09 21:52:07 UTC		N/A		FALSE
PTEN R173C	812	Endometrial Hyperplasia	80365				Oncogenic	Supports	C	Oncogenicity	"Maxwell et al identified R173C in 1 subject (of 51 endometrial hyperplasias assayed for mutations in PTEN), and identified 10 mutations of 51 in PTEN overall (20%). No additional functional testing or clinical description was given."	9635567	PubMed		"Maxwell et al., 1998, Cancer Res."		1	accepted	1934	Somatic	2023-02-03 16:21:43 UTC	https://civicdb.org/links/evidence_items/1934	https://civicdb.org/links/molecular_profiles/812	FALSE	PTEN	5728	R173C		chr10	87952142	87952142	C	T	ENST00000371953.3	75		missense_variant	"NM_000314.6:c.517C>T,NP_000305.3:p.Arg173Cys,ENST00000371953.3:c.517C>T,NC_000010.10:g.89711899C>T"	2023-01-27 17:05:58 UTC	CA000498	189500	"ARG173CYS,RS121913293"	FALSE
PTEN R173C	812	PTEN Hamartoma Tumor Syndrome	80191	"Chylothorax,Dyspnea,Venous malformation"			Predisposing	Supports	C	Predisposition	"Hopman et al presents a case study with an affected proband carrying PTEN R173C, and meeting the pediatric criteria for PTEN testing of Tan et al (2011). The proband died at 2 years due to a fatal chylothorax, having been seen at 1 year with progressive dyspnoea and displaying extensive lymphatic and venus malformations that displaced the right lung, as well as osteolytic lesions of the bones. Proband's mother and two siblings (one 7 years and one 7 months) also carried the PTEN R173C mutation and were thus far asymptomatic. The mother's parents did not carry the R173C mutation. PP4 ACMG evidence criteria are met as PTEN hamartoma tumor syndrome is a disease with a single genetic etiology."	22628360	PubMed		"Hopman et al., 2012, Am. J. Med. Genet. A"		3	accepted	1935	Rare Germline	2023-04-22 17:37:40 UTC	https://civicdb.org/links/evidence_items/1935	https://civicdb.org/links/molecular_profiles/812	FALSE	PTEN	5728	R173C		chr10	87952142	87952142	C	T	ENST00000371953.3	75		missense_variant	"NM_000314.6:c.517C>T,NP_000305.3:p.Arg173Cys,ENST00000371953.3:c.517C>T,NC_000010.10:g.89711899C>T"	2023-01-27 17:05:58 UTC	CA000498	189500	"ARG173CYS,RS121913293"	FALSE
EGFR Mutation	438	Lung Non-small Cell Carcinoma	3908		Gefitinib		Predictive	Supports	B	Sensitivity/Response	"This open label Phase 3 Trial performed across 36 centers in Japan (WJTOG3405) assessed patients with postoperative recurrent or stage IIIB/IV NSCLC and activating EGFR mutations (Exon 19 deletion and L858R).  88 patients were treated with EGFR inhibitor gefitinib, while 89 were treated with cisplatin/docetaxel. Progression free survival was significantly longer with gefitinib treatment with a median of 9.2 months vs. 6.3 with cisplatin/docetaxel (HR 0.48; 95% CI 0.336-0.710; p<0.0001). Difference in response to gefitinib between the two EGFR mutation types was not observed."	20022809	PubMed		"Mitsudomi et al., 2010, Lancet Oncol."		5	accepted	1937	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1937	https://civicdb.org/links/molecular_profiles/438	FALSE	EGFR	1956	Mutation		chr7	55019101	55211628			ENST00000275493.2	75		inframe_variant		2023-01-09 21:52:07 UTC		N/A		FALSE
BRAF V600E	12	Colorectal Cancer	9256				Prognostic	Supports	B	Poor Outcome	"In a study of 468 colorectal cancer samples, 61 patients had micro-satellite instability and there was a statistically significantly better prognosis for BRAF WT patients relative to BRAF (V600E)-mutated patients (Log-rank P=0.0903)."	27302369	PubMed		"Schell et al., 2016, Nat Commun"		4	accepted	1940	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/1940	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
VHL Exon 1-3 Deletion	817	Von Hippel-Lindau Disease	14175	"Retinal capillary hemangioma,Pancreatic cysts,Renal cell carcinoma,Renal cyst,Hemangioblastoma,Hepatic cysts"			Predisposing	N/A	C	N/A	"Mutation detected in 4 separate cases. Two cases show CNS hemangioblastoma, pancreatic/hepatic/renal cysts, and renal cell carcinoma. One case shows CNS hemangioblastoma, pancreatic cysts, and Grawitz One shows CNS HB, pancreatic/renal cysts and retinal angioma. ACMG evidence codes: 'PVS1' based on deletion of all exons, 'PP1' based on segregation results, 'PP4' because the patients phenotypes are highly specific for a disease with single genetic etiology."	20151405	PubMed		"Nordstrom-O'Brien et al., 2010, Hum. Mutat."		4	accepted	1942	Rare Germline	2023-01-09 21:46:38 UTC	https://civicdb.org/links/evidence_items/1942	https://civicdb.org/links/molecular_profiles/817	FALSE	VHL	7428	Exon 1-3 Deletion		chr3	10141848	10149965			ENST00000256474.2	75		exon_loss_variant	ENST00000256474.2:c.1-?_642+?del	2023-01-09 21:52:09 UTC				FALSE
VHL Exon 1 Deletion	818	Von Hippel-Lindau Disease	14175	Hemangioblastoma			Predisposing	Supports	C	Pathogenic	"Mutation detected in one case. Case shows CNS hemangioblastoma. ACMG evidence codes: 'PVS1' for a single exon deletion, 'PP1' based on segregation results, 'PP4' because patients phenotypes are highly specific for a disease with single genetic etiology."	20151405	PubMed		"Nordstrom-O'Brien et al., 2010, Hum. Mutat."		3	accepted	1943	Rare Germline	2023-01-09 21:46:38 UTC	https://civicdb.org/links/evidence_items/1943	https://civicdb.org/links/molecular_profiles/818	FALSE	VHL	7428	Exon 1 Deletion		chr3	10141848	10142187			ENST00000256474.2	75		exon_loss_variant	ENST00000256474.2:c.1-?_340+?del	2023-01-09 21:52:09 UTC				FALSE
VHL Exon 1-2 Deletion	819	Von Hippel-Lindau Disease	14175	Renal cell carcinoma			Predisposing	Supports	C	Uncertain Significance	"Mutation detected in one case. Case shows renal cell carcinoma. ACMG evidence codes:Mutation detected in one case. Case shows renal cell carcinoma. ACMG evidence codes: 'PVS1' based on deletion of exon 1+2, 'PP4' since the patients phenotypes are highly specific for a disease with single genetic etiology."	20151405	PubMed		"Nordstrom-O'Brien et al., 2010, Hum. Mutat."		3	accepted	1944	Rare Germline	2023-01-09 21:46:38 UTC	https://civicdb.org/links/evidence_items/1944	https://civicdb.org/links/molecular_profiles/819	FALSE	VHL	7428	Exon 1-2 Deletion		chr3	10141848	10146636			ENST00000256474.2	75		exon_loss_variant	ENST00000256474.2:c.1-?_463+?del	2023-01-09 21:52:09 UTC				FALSE
VHL M1FS (c.1_17del17)	820	Chromophobe Renal Cell Carcinoma	4471				Oncogenic	Supports	C	Oncogenicity	This somatic mutation was detected in two samples from a single patient with chromophobe renal cell carcinoma (a 74 year old male). The tumor also harbored a silent T157= (c.471T>A) somatic variant.	15932632	PubMed		"van Houwelingen et al., 2005, BMC Cancer"		1	accepted	1945	Somatic	2023-02-03 16:22:44 UTC	https://civicdb.org/links/evidence_items/1945	https://civicdb.org/links/molecular_profiles/820	FALSE	VHL	7428	M1FS (c.1_17del17)		chr3	10141848	10141864	ATGCCCCGGAGGGCGGA		ENST00000256474.2	75		start_lost	"ENST00000256474.2:c.1_17del17,NC_000003.11:g.10183532_10183548del,NM_000551.3:c.1_17del"	2023-01-27 17:06:00 UTC	CA645524623	NONE FOUND	"C.1_17DEL17,MET1FS"	FALSE
VHL M1? (c.1-1_20del21)	821	Clear Cell Renal Cell Carcinoma	4467				Oncogenic	Supports	C	Oncogenicity	"This variant was detected in a single case with clear-cell renal cell carcinoma. The tumor had two somatic variants (c.1-1_20del21 and c.291_310del20). Either of these variants is predicted to be quite deleterious. While they were observed in a somatic context in an RCC, we can infer that they could be predisposing for VHL in a germline context."	15932632	PubMed		"van Houwelingen et al., 2005, BMC Cancer"		1	accepted	1946	Somatic	2023-02-03 16:23:52 UTC	https://civicdb.org/links/evidence_items/1946	https://civicdb.org/links/molecular_profiles/821	FALSE	VHL	7428	M1? (c.1-1_20del21)		chr3	10141847	10141867	AATGCCCCGGAGGGCGGAGAA		ENST00000256474.2	75		start_lost	"NP_000542.1:p.0,NP_000542.1:p.Met1?,NM_000551.3:c.1-1_20del21,ENST00000256474.2:c.1-1_20del21,NC_000003.11:g.10183531_10183551del"	2023-01-27 17:06:01 UTC	CA645524624	NONE FOUND	"MET1 LOSS,START LOSS,NO INITIATION,C.1-1_20DEL21"	FALSE
VHL M1? (c.3G>A)	822	Clear Cell Renal Cell Carcinoma	4467				Oncogenic	Supports	C	Oncogenicity	Mutation detected in one case. Case shows clear-cell renal cell carcinoma. This case also harbored a second somatic variant in VHL: 209-210delAG (Stop130).	11505222	PubMed		"Gallou et al., 2001, Pharmacogenetics"		1	accepted	1947	Somatic	2023-02-03 16:24:24 UTC	https://civicdb.org/links/evidence_items/1947	https://civicdb.org/links/molecular_profiles/822	FALSE	VHL	7428	M1? (c.3G>A)		chr3	10141850	10141850	G	A	ENST00000256474.2	75		start_lost	"NP_000542.1:p.0,NP_000542.1:p.Met1?,NM_000551.3:c.3G>A,ENST00000256474.2:c.3G>A,NC_000003.11:g.10183534G>A"	2023-01-27 17:06:02 UTC	CA020331	135406	"MET1 LOSS,START LOSS,NO INITIATION,C.3G>A,RS578091032"	FALSE
VHL N7D (c.19A>G)	823	Renal Cell Carcinoma	4450				Oncogenic	Supports	C	Oncogenicity	"A somatic mutation (N7D) detected in one case, a 79ya patient with renal cell carcinoma (case '1VT'). The patient had a second in-frame deletion of 5 amino acids (41-45), but the author speculate that it could be an inherited polymorphism."	11536052	PubMed		"Ma et al., 2001, Oncogene"		1	accepted	1948	Somatic	2023-02-03 16:25:13 UTC	https://civicdb.org/links/evidence_items/1948	https://civicdb.org/links/molecular_profiles/823	FALSE	VHL	7428	N7D (c.19A>G)		chr3	10141866	10141866	A	G	ENST00000256474.2	75		missense_variant	"NC_000003.11:g.10183550A>G,NM_000551.3:c.19A>G,ENST00000256474.2:c.19A>G,NP_000542.1:c.Asn7Asp"	2023-01-27 17:06:02 UTC	CA351747044	NONE FOUND	"ASN7ASP,C.19A>G,RS1311403806"	FALSE
VHL P25L (c.74C>T)	824	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Mutation was detected in three unaffected members of Polish VHL families. Described as being in the non-conserved portion of the VHL coding region where mutations are not typically seen according to these authors. Possibly benign but appears to have fairly low global mutation allele frequency.	12114495	PubMed		"Cybulski et al., 2002, J. Med. Genet."		3	accepted	1949	Rare Germline	2023-01-09 21:46:39 UTC	https://civicdb.org/links/evidence_items/1949	https://civicdb.org/links/molecular_profiles/824	FALSE	VHL	7428	P25L (c.74C>T)		chr3	10141921	10141921	C	T	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.74C>T,NP_000542.1:p.Pro25Leu,ENST00000256474.2:c.74C>T,NC_000003.11:g.10183605C>T"	2023-01-27 17:06:03 UTC	CA020538	93330	"PRO25LEU,C.74C>T,RS35460768"	FALSE
VHL P59fs (c.173_174insC)	825	Von Hippel-Lindau Disease	14175	"Pancreatic endocrine tumor,Hemangioblastoma,Neoplasm of the central nervous system,Pancreatic cysts,Renal cyst"			Predisposing	Supports	C	Predisposition	"Mutation was detected in one patient. Patient shows CNS hemangioblastoma and pancreatic neuroendocrine tumors, renal and pancreatic cysts, or central nervous system tumors. ACMG evidence codes: 'PVS1' because the variant is an early frameshift and 'PP4' because the patients phenotypes and family history are highly specific for a disease with single genetic etiology."	19270817	PubMed		"Cho et al., 2009, J. Korean Med. Sci."		3	accepted	1950	Rare Germline	2023-01-09 21:46:39 UTC	https://civicdb.org/links/evidence_items/1950	https://civicdb.org/links/molecular_profiles/825	FALSE	VHL	7428	P59fs (c.173_174insC)		chr3	10142020	10142021		C	ENST00000256474.2	75		"plus_1_frameshift_variant,frameshift_truncation"	"ENST00000256474.2:c.173_174insC,NP_000542.1:p.Pro59AlafsTer73,NM_000551.3:c.173_174insC,NC_000003.11:g.10183704_10183705insC"	2023-01-27 17:06:04 UTC	CA658795188	NONE FOUND	"PRO59FS,C.173_174INSC"	FALSE
VHL Y98FS (c.291_310del20)	826	Clear Cell Renal Cell Carcinoma	4467				Oncogenic	Supports	C	Oncogenicity	This variant was detected in a single case with clear-cell renal cell carcinoma. The tumor had two somatic variants (c.1-1_20del21 and c.291_310del20). Either of these variants is predicted to be quite deleterious.	15932632	PubMed		"van Houwelingen et al., 2005, BMC Cancer"		1	accepted	1951	Somatic	2023-01-27 18:16:53 UTC	https://civicdb.org/links/evidence_items/1951	https://civicdb.org/links/molecular_profiles/826	FALSE	VHL	7428	Y98FS (c.291_310del20)		chr3	10142138	10142157	CTACCCAACGCTGCCGCCTG		ENST00000256474.2	75		frameshift_truncation	"ENST00000256474.2:c.291_310del,NC_000003.11:g.10183822_10183841del,NM_000551.3:c.291_310del,NP_000542.1:p.Tyr98HisfsTer27"	2023-01-27 17:06:05 UTC	CA645524819	NONE FOUND	"C.291_310DEL20,TYR98FS"	FALSE
GNA11 Mutation	502	Uveal Melanoma	6039		"Mirdametinib,Sotrastaurin Acetate"	Combination	Predictive	Supports	D	Sensitivity/Response	Preclinical study in uveal melanoma. Increased PKC activity was found in uveal melanoma cell lines with GNA11 or GNAQ mutations (n=6) compared to GNA wt cell lines (n=4) and could be induced by introducing these mutations into wt cell lines. Cell lines carrying GNA mutations were more sensitive to PKC inhibition with AEB071 and AHT956 in vitro and in vivo. Combined inhibition of MEK and PKC with AEB071 and PD0325901led to sustained MAPK-signalling blockade and induced apoptosis.	24141786	PubMed		"Chen et al., 2014, Oncogene"		3	accepted	1952	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1952	https://civicdb.org/links/molecular_profiles/502	FALSE	GNA11	2767	Mutation		chr19	3094410	3124004			ENST00000078429.4	75				2023-01-09 21:52:07 UTC				FALSE
GNAQ Mutation	501	Uveal Melanoma	6039		"Sotrastaurin Acetate,Mirdametinib"	Combination	Predictive	Supports	D	Sensitivity/Response	Preclinical study in uveal melanoma. Increased PKC activity was found in uveal melanoma cell lines with GNA11 or GNAQ mutations (n=6) compared to GNA wt cell lines (n=4) and could be induced by introducing these mutations into wt cell lines. Cell lines carrying GNA mutations were more sensitive to PKC inhibition with AEB071 and AHT956 in vitro and in vivo. Combined inhibition of MEK and PKC with AEB071 and PD0325901led to sustained MAPK-signalling blockade and induced apoptosis.	24141786	PubMed		"Chen et al., 2014, Oncogene"		4	accepted	1953	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/1953	https://civicdb.org/links/molecular_profiles/501	FALSE	GNAQ	2776	Mutation		chr9	77716087	78031458			ENST00000286548.4	75				2023-01-09 21:52:07 UTC				FALSE
NF1 Mutation	583	Plexiform Neurofibroma	5151		Selumetinib		Predictive	Supports	A	Sensitivity/Response	"Treatment with selumetinib (NCT01362803) resulted in confirmed partial, long term responses in 17 of the 24 children with NF1 associated plexiform fibromas (71%) and decreases from baseline in neurofibroma volume in 12 of 18 mice (67%)."	28029918	PubMed		"Dombi et al., 2016, N. Engl. J. Med."	NCT01362803	3	accepted	1958	Rare Germline	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1958	https://civicdb.org/links/molecular_profiles/583	FALSE	NF1	4763	Mutation		chr17	31094927	31377677			ENST00000358273.4	75		"protein_altering_variant,loss_of_function_variant"		2023-01-09 21:52:08 UTC		N/A		FALSE
ATM Mutation	178	Prostate Cancer	10283		Olaparib		Predictive	Supports	C	Sensitivity/Response	Response to olaparib was observed in 4 of 5 with prostate cancer patients with ATM aberrations (2 germline).	26510020	PubMed		"Mateo et al., 2015, N. Engl. J. Med."	NCT01682772	3	accepted	1960	Rare Germline	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/1960	https://civicdb.org/links/molecular_profiles/178	FALSE	ATM	472	Mutation		chr11	108222832	108369099			ENST00000278616.4	75		"transcription_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
PALB2 Biallelic Inactivation	528	Prostate Cancer	10283		Olaparib		Predictive	Supports	C	Sensitivity/Response	"From 14 prostate cancer patients (88%) who had a response to olaparib, 7 patients had BRCA2 loss (4 with biallelic somatic loss, and 3 with germline mutations), 4 of 5 with had ATM aberrations and one had a biallelic inactivation of PALB2 (frameshift mutation and deletion)."	26510020	PubMed		"Mateo et al., 2015, N. Engl. J. Med."	NCT01682772	3	accepted	1963	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/1963	https://civicdb.org/links/molecular_profiles/528	FALSE	PALB2	79728	Biallelic Inactivation		chr16	23603170	23641310			ENST00000261584.4	75		loss_of_function_variant		2023-01-09 21:52:07 UTC		N/A		FALSE
MET Amplification	266	Colorectal Cancer	9256		Anti-EGFR Monoclonal Antibody		Predictive	Supports	D	Resistance	"Functional studies show that MET activation confers resistance to anti-EGFR therapy both in vitro and in vivo. Notably, in patient-derived colorectal cancer xenografts, MET amplification correlated with resistance to EGFR blockade, which could be overcome by MET kinase inhibitors."	23729478	PubMed		"Bardelli et al., 2013, Cancer Discov"		3	accepted	1971	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1971	https://civicdb.org/links/molecular_profiles/266	FALSE	MET	4233	Amplification		chr7	116672405	116796342			ENST00000318493.6	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A		FALSE
NTRK1 Overexpression	834	Neuroblastoma	769				Prognostic	Supports	B	Better Outcome	A high level of expression of the TRK proto-oncogene in a neuroblastoma is strongly predictive of a favorable outcome. A tumor with a functional nerve growth factor receptor may be dependent on the neurotrophin nerve growth factor for survival and may regress in its absence.	8441429	PubMed		"Nakagawara et al., 1993, N. Engl. J. Med."		4	accepted	1972	N/A	2023-01-09 21:46:39 UTC	https://civicdb.org/links/evidence_items/1972	https://civicdb.org/links/molecular_profiles/834	FALSE	NTRK1	4914	Overexpression		chr1	156860894	156881642			ENST00000524377.1	75		N/A		2023-01-09 21:52:09 UTC		N/A		FALSE
PDGFRA P577S	836	Melanoma	1909		"Imatinib,Crenolanib"	Substitutes	Predictive	Supports	D	Sensitivity/Response	"PDGFRA mutations (exon 12, 14, 18) were assessed in 351 melanoma patient samples. 18 different mutations were detected in 4,6% of samples (all without chronic sun-induced damage and mainly in acral and mucosal melanoma, mutually exclusive with KIT). 12 novel missense mutations were tested for functional significance (western blot of autophosphorylation in transduced 293T cell line). Five PDGFRA Mutations (P577S, V658A, R841K, H845Y, and G853D)  resulted in strong autophosphorylation of PDGFRA. Crenolanib showed higher potency than imatinib in inhibiting the kinase activity of PDGFRA. Except for the  imatinib-resistant V658A mutation, all the other mutations were sensitive to both imatinib and crenolanib."	24132921	PubMed		"Dai et al., 2013, Clin. Cancer Res."		3	accepted	1974	Somatic	2023-01-09 21:46:39 UTC	https://civicdb.org/links/evidence_items/1974	https://civicdb.org/links/molecular_profiles/836	FALSE	PDGFRA	5156	P577S		chr4	54274916	54274916	C	T	ENST00000257290.5	75		missense_variant	"NM_006206.4:c.1729C>T,NP_006197.1:p.Pro577Ser,NC_000004.11:g.55141083C>T,ENST00000257290.5:c.1729C>T"	2023-01-27 17:06:08 UTC	CA16602636	376181	"PRO577SER,RS1057519811"	FALSE
PDGFRA R841K	837	Melanoma	1909		"Imatinib,Crenolanib"	Substitutes	Predictive	Supports	D	Sensitivity/Response	"PDGFRA mutations (exon 12, 14, 18) were assessed in 351 melanoma patient samples. 18 different mutations were detected in 4.6% of samples (all without chronic sun-induced damage and mainly in acral and mucosal melanoma, mutually exclusive with KIT). 12 novel missense mutations were tested for functional significance (western blot of autophosphorylation in transduced 293T cell line). PDGFRA R841K was detected in one sample of mucosal melanoma. In vitro, PDGFRA R841K expressed in IL-3 dependent Ba/F3 cells resulted in strong auto-phosphorylation and cell growth of PDGFRA independent of the presence of IL-3, suggesting oncogenicity. Crenolanib showed higher potency than imatinib in inhibiting the kinase activity of PDGFRA and cell proliferation. The authors concluded that PDGFRA R841K is sensitive to imatinib and crenolanib."	24132921	PubMed		"Dai et al., 2013, Clin. Cancer Res."		3	accepted	1975	Somatic	2023-01-09 21:46:39 UTC	https://civicdb.org/links/evidence_items/1975	https://civicdb.org/links/molecular_profiles/837	FALSE	PDGFRA	5156	R841K		chr4	54285923	54285923	G	A	ENST00000257290.5	75		missense_variant	"NM_006206.4:c.2522G>A,NP_006197.1:p.Arg841Lys,NC_000004.11:g.55152090G>A,ENST00000257290.5:c.2522G>A"	2023-01-27 17:06:09 UTC	CA16602638	376183	"ARG841LYS,RS1057519813"	FALSE
PDGFRA H845Y	838	Melanoma	1909		"Imatinib,Crenolanib"	Substitutes	Predictive	Supports	D	Sensitivity/Response	"PDGFRA mutations (exon 12, 14, 18) were assessed in 351 melanoma patient samples. 18 different mutations were detected in 4,6% of samples (all without chronic sun-induced damage and mainly in acral and mucosal melanoma, mutually exclusive with KIT). 12 novel missense mutations were tested for functional significance (western blot of autophosphorylation in transduced 293T cell line). Five PDGFRA Mutations (P577S, V658A, R841K, H845Y, and G853D) resulted in strong autophosphorylation of PDGFRA. Crenolanib showed higher potency than imatinib in inhibiting the kinase activity of PDGFRA. Except for the imatinib-resistant V658A mutation, all the other mutations were sensitive to both imatinib and crenolanib."	24132921	PubMed		"Dai et al., 2013, Clin. Cancer Res."		3	accepted	1976	Somatic	2023-01-09 21:46:39 UTC	https://civicdb.org/links/evidence_items/1976	https://civicdb.org/links/molecular_profiles/838	FALSE	PDGFRA	5156	H845Y		chr4	54285934	54285934	C	T	ENST00000257290.5	75		missense_variant	"NM_006206.4:c.2533C>T,NP_006197.1:p.His845Tyr,NC_000004.11:g.55152101C>T,ENST00000257290.5:c.2533C>T"	2023-01-27 17:06:10 UTC	CA16602639	376184	"HIS845TYR,RS1057519814"	FALSE
PDGFRA G853D	839	Melanoma	1909		"Crenolanib,Imatinib"	Substitutes	Predictive	Supports	D	Sensitivity/Response	"PDGFRA mutations (exon 12, 14, 18) were assessed in 351 melanoma patient samples. 18 different mutations were detected in 4,6% of samples (all without chronic sun-induced damage and mainly in acral and mucosal melanoma, mutually exclusive with KIT). 12 novel missense mutations were tested for functional significance (western blot of autophosphorylation in transduced 293T cell line). Five PDGFRA Mutations (P577S, V658A, R841K, H845Y, and G853D) resulted in strong autophosphorylation of PDGFRA. Crenolanib showed higher potency than imatinib in inhibiting the kinase activity of PDGFRA. Except for the imatinib-resistant V658A mutation, all the other mutations were sensitive to both imatinib and crenolanib."	24132921	PubMed		"Dai et al., 2013, Clin. Cancer Res."		3	accepted	1977	Somatic	2023-01-09 21:46:39 UTC	https://civicdb.org/links/evidence_items/1977	https://civicdb.org/links/molecular_profiles/839	FALSE	PDGFRA	5156	G853D		chr4	54285959	54285959	G	A	ENST00000257290.5	75		missense_variant	"NM_006206.4:c.2558G>A,NP_006197.1:p.Gly853Asp,NC_000004.11:g.55152126G>A,ENST00000257290.5:c.2558G>A"	2023-01-27 17:06:10 UTC	CA16602640	376185	"GLY853ASP,RS763576329"	FALSE
MET Amplification	266	Colorectal Cancer	9256		"Crizotinib,Cetuximab"	Combination	Predictive	Supports	D	Sensitivity/Response	"Functional studies show that MET activation confers resistance to anti-EGFR therapy both in vitro and in vivo. Notably, in patient-derived colorectal cancer xenografts, MET amplification correlated with resistance to EGFR blockade, which could be overcome by MET kinase inhibitors."	23729478	PubMed		"Bardelli et al., 2013, Cancer Discov"		3	accepted	1979	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1979	https://civicdb.org/links/molecular_profiles/266	FALSE	MET	4233	Amplification		chr7	116672405	116796342			ENST00000318493.6	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A		FALSE
VPS37A Underexpression	842	Ovarian Cancer	2394		Cetuximab		Predictive	Supports	D	Resistance	Vps37A-deficient ovarian cancer cells become irresponsive to inhibition by the therapeutic antibody cetuximab in-vitro.	22016507	PubMed		"Wittinger et al., 2011, Clin. Cancer Res."		3	accepted	1981	Somatic	2023-01-09 21:46:39 UTC	https://civicdb.org/links/evidence_items/1981	https://civicdb.org/links/molecular_profiles/842	FALSE	VPS37A	137492	Underexpression		chr8	17246571	17298024			ENST00000324849.4	75		N/A		2023-01-09 21:52:09 UTC		N/A		FALSE
EGFR Expression	350	Chordoma	3302		Lapatinib		Predictive	Supports	B	Sensitivity/Response	"18 advanced progressing chordoma patients that were positive for EGFR by at least one technique (immunohistochemistry and/or phospho-arrays, real-time polymerase chain reaction for EGFR ligands, FISH) entered this phase 2 study investigating the efficacy of lapatinib (median age: 61 years; disease extent: metastatic 72% and locally advanced 28%). Of the 25 patients screened, three tested negative for EGFR. Six (33.3%) patients had PR and 7 (38.9%) SD, as their best Choi responses, corresponding to RECIST SD in all cases. Median PFS by Choi was 6 [interquartile (IQ) range 3-8] months. Median PFS by RECIST was 8 (IQ range 4-12) months, with a 22% CBR. This phase II study showed a modest antitumor activity of lapatinib in chordoma"	23559153	PubMed		"Stacchiotti et al., 2013, Ann. Oncol."		2	accepted	1984	N/A	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/1984	https://civicdb.org/links/molecular_profiles/350	FALSE	EGFR	1956	Expression		chr7	55019101	55211628			ENST00000275493.2	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
BTK T316A	844	Chronic Lymphocytic Leukemia	1040		Ibrutinib		Predictive	Supports	C	Resistance	"Case report of a patient with CLL and Richter-transformed relapse under ibrutinib (after an initial partial response for 10 months). Sequencing of sequential samples of this patient revealed a novel BTK T316 mutation at relapse (allele frequency of 75%). Characterization of this mutation showed that is was located on the SH2 domain, not associated with Ibrutinib binding. Introduction of this mutation in an Ibrutinib-sensitive lymphoma cell line showed resistance comparable to the known C481 resistance mutations, which was also confirmed by absence of downstream signaling."	27626698	PubMed		"Sharma et al., 2016, Oncotarget"		4	accepted	1985	Somatic	2023-01-09 21:46:39 UTC	https://civicdb.org/links/evidence_items/1985	https://civicdb.org/links/molecular_profiles/844	FALSE	BTK	695	T316A		chrX	101358645	101358645	T	C	ENST00000308731.7	75		missense_variant	"ENST00000308731.7:c.946T>C,NM_000061.2:c.946T>C,NC_000023.10:g.100613633T>C"	2023-01-27 17:06:11 UTC	CA413928923	NONE FOUND	THR316ALA	FALSE
ERBB2 T862A	845	Stomach Carcinoma	5517		Lapatinib		Predictive	Supports	D	Sensitivity/Response	"Cell proliferation analysis showed that the ERBB2-H878Y mutant had the highest sensitivity against lapatinib among all mutations tested. Another mutation, ERBB2-V777L also remained sensitive to lapatinib with a cellular IC50 value similar to that of wild type ERBB2. Remaining mutations showed a shift towards significant higher cellular IC50 values compared to the wild type receptor. Since levels of up to 1 M of lapatinib may be achieved in patients, ERBB2-V773A, ERBB2-T862A and ERBB2-N857S mutations might respond to higher doses of lapatinib. In contrast, ERBB2-L755S, ERBB2-L755P and ERBB2-T798M caused strong lapatinib resistance."	22046346	PubMed		"Kancha et al., 2011, PLoS ONE"		3	accepted	1986	Somatic	2023-01-09 21:46:39 UTC	https://civicdb.org/links/evidence_items/1986	https://civicdb.org/links/molecular_profiles/845	FALSE	ERBB2	2064	T862A		chr17	39725139	39725139	A	G	ENST00000269571.5	75		missense_variant	"ENST00000269571.5:c.2584A>G,NC_000017.10:g.37881392A>G,NM_001289937.1:c.2584A>G,NP_001276866.1:p.Thr862Ala"	2023-01-27 17:06:12 UTC	CA399304738	NONE FOUND	THR862ALA	FALSE
ERBB2 V773A	846	Breast Cancer	1612		Lapatinib		Predictive	Supports	D	Sensitivity/Response	"The IC90 of ERBB2-V773A cell lines was approximately 0.5 M and was considered as lapatinib-sensitive. Since levels of up to 1 M of lapatinib may be achieved in patients, ERBB2-T773A might respond to higher doses of lapatinib."	22046346	PubMed		"Kancha et al., 2011, PLoS ONE"		1	accepted	1987	Somatic	2023-01-09 21:46:39 UTC	https://civicdb.org/links/evidence_items/1987	https://civicdb.org/links/molecular_profiles/846	FALSE	ERBB2	2064	V773A		chr17	39724736	39724736	T	C	ENST00000269571.5	75		missense_variant	"ENST00000269571.5:c.2318T>C,NC_000017.10:g.37880989T>C,NM_004448.3:c.2318T>C,NP_004439.2:p.Val773Ala"	2023-01-27 17:06:13 UTC	CA399302815	NONE FOUND	VAL773ALA	FALSE
ERBB2 N857S	847	Breast Cancer	1612		Lapatinib		Predictive	Supports	D	Sensitivity/Response	"The IC90 of ERBB2-N857S cell lines was approximately 0.5 M and was considered as lapatinib-sensitive. Since levels of up to 1 M of lapatinib may be achieved in patients, ERBB2-N857S might respond to higher doses of lapatinib."	22046346	PubMed		"Kancha et al., 2011, PLoS ONE"		1	accepted	1988	Somatic	2023-01-09 21:46:39 UTC	https://civicdb.org/links/evidence_items/1988	https://civicdb.org/links/molecular_profiles/847	FALSE	ERBB2	2064	N857S		chr17	39725125	39725125	A	G	ENST00000269571.5	75		missense_variant	"NC_000017.10:g.37881378A>G,NP_004439.2:p.Asn857Ser,NM_004448.3:c.2570A>G,ENST00000269571.5:c.2570A>G"	2023-01-27 17:06:13 UTC	CA123601	13880	"ASN857SER,N827S,N842S,RS28933370"	FALSE
ERBB2 H878Y	848	Hepatocellular Carcinoma	684		Lapatinib		Predictive	Supports	D	Sensitivity/Response	"Cell proliferation analysis of ERBB2 mutant expressing cell lines showed that the ERBB2-H878Y mutant, which is observed in 11% of hepatocellular carcinoma patients, had the highest sensitivity against lapatinib among all mutations tested (IC50<30nM)."	22046346	PubMed		"Kancha et al., 2011, PLoS ONE"		1	accepted	1989	Somatic	2023-01-09 21:46:39 UTC	https://civicdb.org/links/evidence_items/1989	https://civicdb.org/links/molecular_profiles/848	FALSE	ERBB2	2064	H878Y		chr17	39725187	39725187	C	T	ENST00000269571.5	75		missense_variant	"ENST00000269571.5:c.2632C>T,NC_000017.10:g.37881440C>T,NM_001289937.1:c.2632C>T,NP_001276866.1:p.His878Tyr"	2023-01-27 17:06:14 UTC	CA399305170	NONE FOUND	HIS878TYR	FALSE
FGFR2 Amplification	625	Stomach Carcinoma	5517		FGFR Inhibitor AZD4547		Predictive	Supports	B	Sensitivity/Response	"Nine patients with FGFR2-amplified gastroesophageal cancer were treated with AZD4547.  Of these 9 patients, 3 showed confirmed responses to AZD4547. Median progression-free survival was 6.6 months (range=6.2-10.5). Two additional patients had a response in day 15 using FDG-PET but were not considered complete responders by RECIST criteria. High-level FGFR2-amplified (arbitrarily defined as FISH-ratio > 5) cancers had a higher likelihood of response and were associated with a substantially higher expression of both FGFR2 mRNA and FGFR2 protein (IHC). In vitro and in PDX models, FGFR2-amplified cell lines were sensitive to FGFR inhibition. Further preclinical analyses suggested, that FGFR2 amplification mainly signals via the PI3K pathway."	27179038	PubMed		"Pearson et al., 2016, Cancer Discov"		3	accepted	1990	N/A	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/1990	https://civicdb.org/links/molecular_profiles/625	FALSE	FGFR2	2263	Amplification		chr10	121479857	121598403			ENST00000457416.2	75		transcript_amplification	N/A	2023-01-09 21:52:08 UTC		N/A		FALSE
FGFR1 Amplification	263	Breast Cancer	1612		FGFR Inhibitor AZD4547		Predictive	Supports	C	Sensitivity/Response	"Activity of the FGFR-selective inhibitor AZD4547 in FGFR1-amplified breast cancer and FGFR2-amplified gastroesophageal cancer was analyzed in this study. 341 patients with advanced cancer were screened by FISH, identifying FGFR1 amplification in 18% of advanced HER2-negative breast cancers and FGFR2 amplification in 9% of advanced gastroesophageal cancer. 1 patient had a confirmed response among 8 patients treated with FGFR1-amplified breast cancer. In a preclinical model, FGFR1 amplification in breast cancer cell lines was less pronounced than FGFR2-amplifications in gastroesophageal cancers, which also had a higher response rate in the trial, indicating that high level amplification is associated with response and less common in FGFR1-amplified breast cancer."	27179038	PubMed		"Pearson et al., 2016, Cancer Discov"		2	accepted	1991	N/A	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1991	https://civicdb.org/links/molecular_profiles/263	FALSE	FGFR1	2260	Amplification		chr8	38411138	38467845			ENST00000425967.3	75		transcript_amplification	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
ERBB2 Amplification	302	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	B	Resistance	"We identified 142 patients with metastatic colorectal cancer whose tumors harbored both wild-type exons 2, 3, and 4 in KRAS and NRAS, and wild-type exon 15 in BRAF. All patients received cetuximab after oxaliplatin, irinotecan, and fluoropyrimidine failure. HER2 status was determined using immunohistochemistry and silver in situ hybridization and correlated with cetuximab efficacy. Of 142 RAS and BRAF wild-type tumors, we observed 7 cases (4.9%) of HER2 amplification by SISH. After a median follow-up of 13.2 months (range, 1.4-78.1 months), median progression-free survival (PFS) was significantly different according to HER2 status: 3.1 months in patients with HER2 amplification compared with 5.6 months in those with non-amplified HER2 (HR = 2.73; 95% CI = 1.18-6.31; P = 0.019). Overall survival (OS) was not significantly different between groups, although there was a tendency towards shorter OS in patients with HER2-amplified tumors (HR = 0.31; 95% CI = 0.61-2.82; 10.1 vs. 13.5 months; P = 0.488)."	28223103	PubMed		"Jeong et al., 2017, Clin Colorectal Cancer"		3	accepted	1993	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/1993	https://civicdb.org/links/molecular_profiles/302	FALSE	ERBB2	2064	Amplification		chr17	39700080	39728662			ENST00000269571.5	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A	OVEREXPRESSION	FALSE
GNAS c.393T>C	851	Lung Non-small Cell Carcinoma	3908		"Gefitinib,Erlotinib"	Substitutes	Predictive	Supports	B	Resistance	"The disease control rate of patients with GNAS1 T393C CC genotype was lower than that of patients with variant genotype (TT or CT) (46.2% vs 73.8%, P=0.039). Univariate analysis identified gender, smoking history, histology and GNAS1 T393C polymorphism as predictive marker of PFS (P=0.04, P<0.001, P<0.001 and P=0.005). Multivariate analysis of factors, including smoking history, performance status score, histology, GNAS1 T393C polymorphism demonstrated that GNAS1 T393C polymorphism was correlated independently with PFS (P=0.007). The data suggests the role of GNAS1 T393C CC genotype as a poor predictive marker both of DCR and PFS in advanced NSCLC patients treated with tyrosine kinase inhibitor."	24758907	PubMed		"Hong et al., 2014, Zhongguo Fei Ai Za Zhi"		2	accepted	1995	Common Germline	2023-01-09 21:46:39 UTC	https://civicdb.org/links/evidence_items/1995	https://civicdb.org/links/molecular_profiles/851	FALSE	GNAS	2778	c.393T>C		chr20	58853658	58853658	T	C	ENST00000371100.4	75		synonymous_variant	"NC_000020.11:g.58903752C>T,NC_000020.10:g.57478807C>T,NM_000516.4:c.393C>T,NP_000507.1:p.Ile131="	2023-01-27 17:06:15 UTC	CA409455494	197681	"I131=,RS7121,L131="	FALSE
GNAS c.393T>C	851	Intrahepatic Cholangiocarcinoma	4928				Prognostic	Supports	B	Poor Outcome	Intrahepatic cholangiocarcinomas of patients with homozygous TT genotypes revealed a higher proliferation rate and a lower apoptotic rate.This study demonstrated a significant association of both disease-specific OS and recurrence-free survival with the homozygous TT genotype of the GNAS1 gene (hazard ratio = 2.47; 95% CI = 1.03?.28). Patients with T393 homozygosity exhibit a decreased survival time regardless of their resection status and show earlier tumor recurrence.	17356712	PubMed		"Schmitz et al., 2007, Neoplasia"		3	accepted	1996	Common Germline	2023-01-09 21:46:39 UTC	https://civicdb.org/links/evidence_items/1996	https://civicdb.org/links/molecular_profiles/851	FALSE	GNAS	2778	c.393T>C		chr20	58853658	58853658	T	C	ENST00000371100.4	75		synonymous_variant	"NC_000020.11:g.58903752C>T,NC_000020.10:g.57478807C>T,NM_000516.4:c.393C>T,NP_000507.1:p.Ile131="	2023-01-27 17:06:15 UTC	CA409455494	197681	"I131=,RS7121,L131="	FALSE
GNAS c.393T>C	851	Breast Carcinoma	3459				Prognostic	Supports	B	Poor Outcome	"This study showed that the carriers of the T allele had a significantly less favourable course of the disease when compared to carriers of the homozygous CC genotype. GNAS 393C homozygous patients of pT2-4 stages displayed a significantly lower risk for death than T393 homozygous patients, with heterozygous patients being at intermediate risk. Ten-year survival rates were 63% for CC, 40% for TC and 23% for TT genotypes, respectively."	17186357	PubMed		"Otterbach et al., 2007, Breast Cancer Res. Treat."		4	accepted	1997	Common Germline	2023-01-09 21:46:39 UTC	https://civicdb.org/links/evidence_items/1997	https://civicdb.org/links/molecular_profiles/851	FALSE	GNAS	2778	c.393T>C		chr20	58853658	58853658	T	C	ENST00000371100.4	75		synonymous_variant	"NC_000020.11:g.58903752C>T,NC_000020.10:g.57478807C>T,NM_000516.4:c.393C>T,NP_000507.1:p.Ile131="	2023-01-27 17:06:15 UTC	CA409455494	197681	"I131=,RS7121,L131="	FALSE
PIK3CA C420R	905	Colorectal Cancer	9256		Cetuximab		Predictive	Does Not Support	C	Resistance	"One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored PIK3CA C420R and was wildtype for KRAS, BRAF and NRAS. This patient was was a 60 year old female treated with cetuximab monotherapy as 5th line therapy who experienced partial response and had PFS of 31 weeks and OS of 59 weeks."	20619739	PubMed		"De Roock et al., 2010, Lancet Oncol."		3	accepted	1999	Somatic	2023-01-09 21:46:40 UTC	https://civicdb.org/links/evidence_items/1999	https://civicdb.org/links/molecular_profiles/905	FALSE	PIK3CA	5290	C420R		chr3	179210192	179210192	T	C	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.1258T>C,NP_006209.2:p.Cys420Arg,NC_000003.11:g.178927980T>C,ENST00000263967.3:c.1258T>C"	2023-01-27 17:06:45 UTC	CA180900	31945	"RS121913272,CYS420ARG"	FALSE
KRAS G12V	421	Colorectal Cancer	9256		"Selumetinib,Dactolisib"	Combination	Predictive	Supports	D	Sensitivity/Response	"In 28 out of 40 (70%) metastatic colorectal cancer tumors harboring KRAS, NRAS, BRAF, or PIK3CA mutations and implanted into mice, the therapeutic combination of the MEK inhibitor AZD6244 and the PI3K/mTor inhibitor BEZ235 resulted in disease stabilization. Mean tumor growth was lower in the tumors treated with AZD6244+ BEZ235 (+77% vs. +267%, P=1E-6) compared to AZD6244 alone and (+77% vs. +222%, P=0.0014) BEZ235 alone. 32/40 tumors harbored KRAS mutations including 8 G12V mutations (3 with PIK3CA mutations) where progressive disease occurred in only 1 tumor upon doublet treatment but 6 tumors in monotherapy."	22392911	PubMed		"Migliardi et al., 2012, Clin. Cancer Res."		3	accepted	2001	Somatic	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/2001	https://civicdb.org/links/molecular_profiles/421	FALSE	KRAS	3845	G12V		chr12	25245350	25245350	C	A	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.35G>T,NP_004976.2:p.Gly12Val,NC_000012.11:g.25398284C>A,ENST00000256078.4:c.35G>T"	2023-01-27 17:03:41 UTC	CA122540	12583	"GLY12VAL,RS121913529"	FALSE
NRAS G12D	852	Colorectal Cancer	9256		"Cetuximab,Irinotecan"	Combination	Predictive	Supports	C	Resistance	"One patient participating in a large retrospective trial of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored NRAS G12D and was wild type for KRAS, PIK3CA, and BRAF. This patient was a 64 year old male treated with cetuximab and irinotecan as 5th line therapy who experienced stable disease and had PFS of 64 weeks and OS of 84 weeks."	20619739	PubMed		"De Roock et al., 2010, Lancet Oncol."		3	accepted	2002	Somatic	2023-01-09 21:46:39 UTC	https://civicdb.org/links/evidence_items/2002	https://civicdb.org/links/molecular_profiles/852	FALSE	NRAS	4893	G12D		chr1	114716126	114716126	C	T	ENST00000369535.4	75		missense_variant	"NM_002524.4:c.35G>A,NP_002515.1:p.Gly12Asp,NC_000001.10:g.115258747C>T,ENST00000369535.4:c.35G>A"	2023-01-27 17:06:16 UTC	CA130425	39648	"RS121913237,GLY12ASP"	FALSE
KRAS G12/G13	77	Colorectal Cancer	9256		Panitumumab		Predictive	Supports	B	Resistance	"In a retrospective study of 427 chemotherapy-refractory metastatic colorectal patients treated with either panitumumab monotherapy or best supportive care (BSC), KRAS codon 12 or 13 mutations were observed in 43% of the tumor samples. The effect of panitumumab on PFS in the KRAS wt group was significantly greater than in the KRAS mutant group (HR:0.45, 95% CI:0.34-0.59 vs HR:0.99, 95% CI:0.73-1.36; P<0.0001). None of the 84 panitumumab-treated patients with KRAS mutant tumors responded to treatment (100% positive predictive value for nonresponse in mutant group). In the KRAS wt group treated with panitumumab (n=124), 21 patients had partial response (17%), 42 experienced stable disease (34%). Additionally, patients with KRAS mutations showed no significant improvement between treatment with panitumumab and BSC alone (PFS: 7.4 wk vs 7.3 wk). The authors concluded that their findings support the hypothesis that KRAS mutations confer primary resistance to anti-EGFR antibodies and recommend that KRAS status be evaluated prior to panitumumab administration."	18316791	PubMed		"Amado et al., 2008, J. Clin. Oncol."	"NCT00113763,NCT00113776"	3	accepted	2004	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/2004	https://civicdb.org/links/molecular_profiles/77	FALSE	KRAS	3845	G12/G13		chr12	25245346	25245351			ENST00000256078.4	75		protein_altering_variant		2023-01-09 21:52:04 UTC		"45,122,125,781,258,200,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000"		FALSE
KRAS G12A	148	Lung Cancer	1324		Gefitinib		Predictive	Supports	B	Resistance	"In recurrent lung cancer patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib, patients with KRAS mutations had a lower frequency of partial response (PR) and stable disease (SD) and a higher rate of progressive disease (PD) (PR:0, SD:1, PD:15 vs. PR:24, SD:8, PD:14; P=0.0274) compared to wildtype KRAS patients. Patients with KRAS mutations also had a shorter overall survival compared to wildtype KRAS patients (HR:2.542, 95% CI:1.048-6.168, P=0.0390)."	17409929	PubMed		"Endoh et al., 2006, J Thorac Oncol"		2	accepted	2008	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/2008	https://civicdb.org/links/molecular_profiles/148	FALSE	KRAS	3845	G12A	EGFR TKI Resistance	chr12	25245350	25245350	C	G	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.35G>C,NP_004976.2:p.Gly12Ala,NC_000012.11:g.25398284C>G,ENST00000256078.4:c.35G>C"	2023-01-27 17:02:57 UTC	CA135567	45122	"GLY12ALA,RS121913529"	FALSE
KRAS G12A	148	Multiple Myeloma	9538		Melphalan		Predictive	Supports	B	Resistance	"In a study of patients receiving melphalan-based therapy, those with KRAS codon 12 mutations were less likely to have a positive response than those with wildtype KRAS (26.9% vs. 58.3%, P=0.015)."	19284554	PubMed		"Greco et al., 2009, J. Exp. Clin. Cancer Res."		2	accepted	2009	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/2009	https://civicdb.org/links/molecular_profiles/148	FALSE	KRAS	3845	G12A	EGFR TKI Resistance	chr12	25245350	25245350	C	G	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.35G>C,NP_004976.2:p.Gly12Ala,NC_000012.11:g.25398284C>G,ENST00000256078.4:c.35G>C"	2023-01-27 17:02:57 UTC	CA135567	45122	"GLY12ALA,RS121913529"	FALSE
KRAS G12A	148	Multiple Myeloma	9538		Melphalan		Predictive	Supports	D	Resistance	"In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS."	11050000	PubMed		"Rowley et al., 2000, Blood"		2	accepted	2012	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/2012	https://civicdb.org/links/molecular_profiles/148	FALSE	KRAS	3845	G12A	EGFR TKI Resistance	chr12	25245350	25245350	C	G	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.35G>C,NP_004976.2:p.Gly12Ala,NC_000012.11:g.25398284C>G,ENST00000256078.4:c.35G>C"	2023-01-27 17:02:57 UTC	CA135567	45122	"GLY12ALA,RS121913529"	FALSE
KRAS G12A	148	Multiple Myeloma	9538		Melphalan		Predictive	Supports	D	Resistance	"In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS."	12483530	PubMed		"Rowley et al., 2002, Oncogene"		2	accepted	2013	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/2013	https://civicdb.org/links/molecular_profiles/148	FALSE	KRAS	3845	G12A	EGFR TKI Resistance	chr12	25245350	25245350	C	G	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.35G>C,NP_004976.2:p.Gly12Ala,NC_000012.11:g.25398284C>G,ENST00000256078.4:c.35G>C"	2023-01-27 17:02:57 UTC	CA135567	45122	"GLY12ALA,RS121913529"	FALSE
KRAS G12A	148	Multiple Myeloma	9538		Melphalan		Predictive	Supports	D	Resistance	"In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS."	16497971	PubMed		"Hoang et al., 2006, Blood"		2	accepted	2014	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/2014	https://civicdb.org/links/molecular_profiles/148	FALSE	KRAS	3845	G12A	EGFR TKI Resistance	chr12	25245350	25245350	C	G	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.35G>C,NP_004976.2:p.Gly12Ala,NC_000012.11:g.25398284C>G,ENST00000256078.4:c.35G>C"	2023-01-27 17:02:57 UTC	CA135567	45122	"GLY12ALA,RS121913529"	FALSE
IDH1 R132	58	High Grade Glioma	3070		"Sunitinib,Bevacizumab"	Substitutes	Predictive	Supports	B	Sensitivity/Response	"In a clinical study of 63 recurrent glioma patients, the combined cohort of patients treated with either bevacizumab or sunitinib showed that those harboring IDH1 codon 132 mutation were associated with improved overall survival (OS 7.53 vs. 4.83 months; P=0.04), as compared to patients with wild-type IDH1."	22199315	PubMed		"Lv et al., 2011, Anticancer Res."		2	accepted	2020	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/2020	https://civicdb.org/links/molecular_profiles/58	FALSE	IDH1	3417	R132		chr2	208248387	208248389			ENST00000415913.1	75		protein_altering_variant	"NC_000002.11:g.209113113G>A,NC_000002.11:g.209113112C>T,NC_000002.11:g.209113113G>C,NC_000002.11:g.209113112C>A,NC_000002.11:g.209113113G>T,NC_000002.11:g.209113112C>G"	2023-01-09 21:52:04 UTC		"156,444,375,891,375,000,000,000,000,000,000,000"	ARG132	FALSE
PIK3CA E542K	103	Her2-receptor Positive Breast Cancer	60079		Pictilisib		Predictive	Supports	D	Sensitivity/Response	"This preclinical study tested the efficacy on several breast cancer cell lines of GDC-0941 (pictilisib), a selective inhibitor of all four isoforms of class I PI3-kinases at a range of IC50 values. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. HCC202 is a HER2 positive, ER/PR negative breast cancer cell line harboring PIK3CA E542K, and it had an IC50 of 0.80uM. Authors further note that HER2 amplified cell lines were generally more sensitive, regardless of mutation, to pictilisib than basal-like cell lines (p=0.002)."	20453058	PubMed		"O'Brien et al., 2010, Clin. Cancer Res."		2	accepted	2022	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/2022	https://civicdb.org/links/molecular_profiles/103	FALSE	PIK3CA	5290	E542K		chr3	179218294	179218294	G	A	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.1624G>A,NP_006209.2:p.Glu542Lys,ENST00000263967.3:c.1624G>A,NC_000003.11:g.178936082G>A"	2023-01-27 17:02:37 UTC	CA333572	31944	"GLU542LYS,RS121913273"	FALSE
PIK3CA Mutation	307	Breast Cancer	1612				Prognostic	Supports	B	Better Outcome	"Prognostic significance of PIK3CA mutations was evaluated in a retrospective study of 590 patients with surgically resected invasive breast cancer. Patients with tumors harboring PIK3CA mutations (n=192, 32.5%; 14.9% with H1047R; 4.2% with E542K; 4.9% with E545K; 8.5% across all other variants) experienced longer PFS, OS, and breast cancer specific survival than patients with PIK3CA wt tumors (p=0.06; p=0.03; p=0.004). PIK3CA mutations were positively associated with lymph node negativity, lower tumor stage, hormone receptor positivity, and HER2 negativity. Patients with PIK3CA mutated tumors experienced a 2 fold decrease in death due to breast cancer at 5 and 10 years. Tumors with hot spot mutations (E542K, E545K, H10447), were strongly correlated with lower grade (2), ER-positive, PR-positive, HR-positive, HER2-negative compared to PIK3CA wt tumors."	19671852	PubMed		"Kalinsky et al., 2009, Clin. Cancer Res."		3	accepted	2025	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/2025	https://civicdb.org/links/molecular_profiles/307	FALSE	PIK3CA	5290	Mutation		chr3	179148523	179240093			ENST00000263967.3	75		"transcript_variant,gain_of_function_variant"		2023-01-09 21:52:06 UTC		N/A		FALSE
PIK3CA E542K	103	Breast Cancer	1612		Pictilisib		Predictive	Supports	D	Sensitivity/Response	"This preclinical study tested the efficacy on several breast cancer cell lines of GDC-0941 (pictilisib), which is a selective inhibitor of all four isoforms of class I PI3-kinases over a range of IC50 values. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. KPL-1 is a luminal-like breast cancer cell line harboring PIK3CA E542K, and it had an IC50 of 0.72uM. Authors note that luminal-like cell lines were generally more sensitive, regardless of mutation, to pictilisib than basal-like cell lines (p=0.02)."	20453058	PubMed		"O'Brien et al., 2010, Clin. Cancer Res."		2	accepted	2026	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/2026	https://civicdb.org/links/molecular_profiles/103	FALSE	PIK3CA	5290	E542K		chr3	179218294	179218294	G	A	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.1624G>A,NP_006209.2:p.Glu542Lys,ENST00000263967.3:c.1624G>A,NC_000003.11:g.178936082G>A"	2023-01-27 17:02:37 UTC	CA333572	31944	"GLU542LYS,RS121913273"	FALSE
PIK3CA E545K	104	Breast Cancer	1612		Pictilisib		Predictive	Supports	D	Sensitivity/Response	"This preclinical study tested the efficacy on several breast cancer cell lines of GDC-0941 (pictilisib), a selective inhibitor of all four isoforms of class I PI3-kinases over a range of IC50 values. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. MCF7 is a luminal type breast cancer cell line harboring PIK3CA E545K, and it had an IC50 of 0.34uM. To evaluate in vivo efficacy, MCF7 cells were injected in the mammary fat pad of SCID mice and allowed to grow. Mice treated with 100mg/kg pictilisib experienced a 62% tumor reduction, and those treated with 150mg/kg experienced a 70% tumor reduction, with respect to untreated control. Authors note that pictilisib was well tolerated and observed no toxicities or significant weight loss. Authors further note that luminal-like cell lines were generally more sensitive, regardless of mutation, to pictilisib than basal-like (p=0.02)."	20453058	PubMed		"O'Brien et al., 2010, Clin. Cancer Res."		2	accepted	2034	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/2034	https://civicdb.org/links/molecular_profiles/104	FALSE	PIK3CA	5290	E545K		chr3	179218303	179218303	G	A	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.1633G>A,NP_006209.2:p.Glu545Lys,ENST00000263967.3:c.1633G>A,NC_000003.11:g.178936091G>A"	2023-01-27 17:02:37 UTC	CA123334	13655	"GLU545LYS,RS104886003"	FALSE
PTEN Loss	214	Her2-receptor Positive Breast Cancer	60079		Trastuzumab		Predictive	Supports	B	Resistance	"In a retrospective study of 111 HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapy, PTEN loss (as measured by IHC) was associated with shorter survival as measured from initiation of trastuzumab (HR = 1.92, P = 0.017) and diagnosis of first metastasis (HR = 1.69, P = 0.047)."	21594665	PubMed		"Razis et al., 2011, Breast Cancer Res. Treat."		2	accepted	2035	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/2035	https://civicdb.org/links/molecular_profiles/214	FALSE	PTEN	5728	Loss		chr10	87863113	87971930			ENST00000371953.3	75		loss_of_function_variant	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
PIK3CA E545K	104	Her2-receptor Positive Breast Cancer	60079		Trastuzumab Emtansine		Predictive	Does Not Support	D	Resistance	"As part of a pre-clinical experiment, the efficacy of ado-trastuzumab emtansine (T-DM1) was compared to that of trastuzumab against various HER2 positive cell lines. MCF7-neo/HER2 cell line harboring PIK3CA E545K was associated with similar sensitivity to T-DM1 as PIK3CA wild-type cell line SK-BR-3; reduced cell viability was observed at concentrations >0.01 ug/mL in both cell lines. Conversely, the cell line harboring PIK3CA E545K was resistant to trastuzumab in vitro at all concentrations tested (0-10 ug/mL). Further, treatment with T-DM1 on nude mice xenografted with PIK3CA E545K-harboring cells resulted in inhibition of tumor growth. A single dose of T-DM1 >3mg/kg was sufficient to induce tumor suppression lasting >20 days after administration."	26920887	PubMed		"Baselga et al., 2016, Clin. Cancer Res."		3	accepted	2036	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/2036	https://civicdb.org/links/molecular_profiles/104	FALSE	PIK3CA	5290	E545K		chr3	179218303	179218303	G	A	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.1633G>A,NP_006209.2:p.Glu545Lys,ENST00000263967.3:c.1633G>A,NC_000003.11:g.178936091G>A"	2023-01-27 17:02:37 UTC	CA123334	13655	"GLU545LYS,RS104886003"	FALSE
PIK3CA E545K	104	Colorectal Cancer	9256		"Cetuximab,Panitumumab"	Substitutes	Predictive	Does Not Support	C	Resistance	"In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). PIK3CA E545K was the only variant noted in the primary tumor (found in the sigma-rectum junction) of one patient who experienced partial response following treatment. In the larger cohort, patients with tumors harboring any PIK3CA mutation had significantly shorter progression free survival and decreased incidence of objective response than patients with wtPIK3CA tumors. See Patient 55 from Supplemental Table 1 for more information on this patient."	19223544	PubMed		"Sartore-Bianchi et al., 2009, Cancer Res."		2	accepted	2037	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/2037	https://civicdb.org/links/molecular_profiles/104	FALSE	PIK3CA	5290	E545K		chr3	179218303	179218303	G	A	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.1633G>A,NP_006209.2:p.Glu545Lys,ENST00000263967.3:c.1633G>A,NC_000003.11:g.178936091G>A"	2023-01-27 17:02:37 UTC	CA123334	13655	"GLU545LYS,RS104886003"	FALSE
PIK3CA Wildtype	2463	Colorectal Cancer	9256		Aspirin		Predictive	Does Not Support	B	Sensitivity/Response	"This was a retrospective study of 964 colorectal cancer patients who participated in the Nurses' Health Study and the Health Professionals Follow-up Study. Of 964 patients, 803 patients had wildtype PIK3CA (aspirin use: 337/803, no aspirin use: 466/803) and 161 had mutated PIK3CA (aspirin use: 66/161, no aspirin use: 95/161). Among patients with wild-type PIK3CA, regular use of aspirin after diagnosis was not significantly associated with increased survival. The 5-year cumulative colorectal cancer specific mortality was the same (15%) for users and nonusers of aspirin after diagnosis (P = 0.92)."	23094721	PubMed		"Liao et al., 2012, N. Engl. J. Med."		3	accepted	2038	Somatic	2023-01-09 21:47:00 UTC	https://civicdb.org/links/evidence_items/2038	https://civicdb.org/links/molecular_profiles/2463	FALSE	PIK3CA	5290	Wildtype		chr3	179148523	179240093			ENST00000263967.3	75		wild_type		2023-01-09 21:52:20 UTC				FALSE
PIK3CA E545K	104	Lung Non-small Cell Carcinoma	3908		PI103		Predictive	Supports	D	Sensitivity/Response	"H460, a gefitinib-resistant NSCLC cell line harboring PIK3CA E545K (a PIK3CA activating mutation), was used to test the anti-tumor effects of PI103. Without treatment, H460 cells expressed high levels of phosphorylated AKT. Following treatment, p-AKT decreased which correlated with cell senescence. PI103 treatment resulted in greater cell senescence in the PIK3CA E545K cell line than in A549, a wildtype PIK3CA gefinitib-resistant NSCLC cell line."	19513541	PubMed		"Zou et al., 2009, Int. J. Mol. Med."		2	accepted	2040	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/2040	https://civicdb.org/links/molecular_profiles/104	FALSE	PIK3CA	5290	E545K		chr3	179218303	179218303	G	A	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.1633G>A,NP_006209.2:p.Glu545Lys,ENST00000263967.3:c.1633G>A,NC_000003.11:g.178936091G>A"	2023-01-27 17:02:37 UTC	CA123334	13655	"GLU545LYS,RS104886003"	FALSE
KRAS G13D	81	Breast Cancer	1612		Pictilisib		Predictive	Supports	D	Resistance	"This preclinical study tested the efficacy on several breast cancer cell lines of GDC-0941 (pictilisib), a selective inhibitor of all four isoforms of class I PI3-kinases over a range of IC50 values. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. MDA-MB-231 is a basal-type breast cancer cell line which harbors KRAS G13D, and it had an ICD50 of 20uM. To evaluate in vivo efficacy, cells were injected in the mammary fat pad of SCID mice and allowed to grow. Mice injected with MDA-MB-231 and treated with pictilisib saw no reduction in tumor volume compared to untreated control. There was no effect on G1 arrest in pictilisib treated cells; however, phosphorylated AKT (S473) was substantially reduced following pictilisib. Authors note that basal breast cancer cell lines were generally more resistant to pictilisib than luminal lines (p=0.02), and concluded that this cell line was resistant to pictilisib."	20453058	PubMed		"O'Brien et al., 2010, Clin. Cancer Res."		4	accepted	2041	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/2041	https://civicdb.org/links/molecular_profiles/81	FALSE	KRAS	3845	G13D		chr12	25245347	25245347	C	T	ENST00000256078.4	75		missense_variant	"NM_033360.3:c.38G>A,NP_004976.2:p.Gly13Asp,NC_000012.11:g.25398281C>T,ENST00000256078.4:c.38G>A"	2023-01-27 17:02:27 UTC	CA122534	12580	"GLY13ASP,RS112445441"	FALSE
PIK3CA Rare Mutation	3091	Breast Cancer	1612				Prognostic	Supports	B	Better Outcome	"Prognostic significance of PIK3CA mutations was evaluated in a retrospective study of 590 patients with surgically resected invasive breast cancer. Tumors harboring rare PIK3CA mutations (N345K: 2.4%, C420R: 1.2%, E545A: 1.2%, E545Q: 0.3%, E545G: 0.3%, Q546R: 0.7%, Q546P: 0.2%, H1047L: 2.2%) were significantly associated with lower grade, HER2 negativity, and lymph-node negative status compared with WT."	19671852	PubMed		"Kalinsky et al., 2009, Clin. Cancer Res."		2	accepted	2042	Somatic	2023-01-09 21:47:07 UTC	https://civicdb.org/links/evidence_items/2042	https://civicdb.org/links/molecular_profiles/3091	FALSE	PIK3CA	5290	Rare Mutation		chr3	179148523	179240093			ENST00000263967.3	75				2023-01-09 21:52:24 UTC				FALSE
PTEN Loss	214	Breast Cancer	1612		Trastuzumab		Predictive	Supports	B	Resistance	"In a retrospective study of 182 metastatic breast cancer patients of mixed HER2 status treated with trastuzumab-based therapy, PTEN loss (as measured by IHC) was associated with a higher risk of death measured from initiation of trastuzumab (HR = 1.64, P = 0.029) and diagnosis of first metastasis (HR = 1.85, P = 0.003)."	21594665	PubMed		"Razis et al., 2011, Breast Cancer Res. Treat."		2	accepted	2043	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/2043	https://civicdb.org/links/molecular_profiles/214	FALSE	PTEN	5728	Loss		chr10	87863113	87971930			ENST00000371953.3	75		loss_of_function_variant	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
PTEN Loss	214	Her2-receptor Positive Breast Cancer	60079		Pictilisib		Predictive	Supports	D	Sensitivity/Response	"This preclinical study tested the efficacy of GDC-0941, a selective inhibitor of class I PI3K, on several cell lines of breast cancer. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. HCC1569 is a PTEN null, HER2 amplified breast cancer cell line. It had an IC50 of 0.46. Authors note that HER2 amplified breast cancer cell lines are generally more sensitive to GDC-0941 than basal-type cell lines (p = 0.002)."	20453058	PubMed		"O'Brien et al., 2010, Clin. Cancer Res."		3	accepted	2045	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/2045	https://civicdb.org/links/molecular_profiles/214	FALSE	PTEN	5728	Loss		chr10	87863113	87971930			ENST00000371953.3	75		loss_of_function_variant	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
EGFR Mutation	438	Lung Non-small Cell Carcinoma	3908		"Gefitinib,Erlotinib"	Substitutes	Predictive	Supports	B	Sensitivity/Response	"In a retrospective study, 166 non-small cell lung cancer (NSCLC) patients that tended to have selected characteristics known to be predictive for TKI sensitivity (i.e. women, never smokers, and patients with ADC) were treated with either gefitinib or erlotinib. EGFR mutations (n=42) were associated with improved objective response to drug treatment (71.4% vs. 20.1%, p<0.0001), improved but not significant overall survival (36.9 vs. 24.8 months, p=0.09), and longer median time to progression (not reached vs. 3.7 months, p<0.0001) when compared to wild-type EGFR. Through multivariate analyses, it was shown that EGFR mutations are independent predictive favorable factors of response to drug treatment (p<0.0001) and are significant predictors of longer time to progression (HR: 0.27, 95% CI: 0.14-0.52, p=0.0001)"	21258250	PubMed		"Ludovini et al., 2011, J Thorac Oncol"		4	accepted	2053	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/2053	https://civicdb.org/links/molecular_profiles/438	FALSE	EGFR	1956	Mutation		chr7	55019101	55211628			ENST00000275493.2	75		inframe_variant		2023-01-09 21:52:07 UTC		N/A		FALSE
PIK3CA E542K	103	Her2-receptor Positive Breast Cancer	60079		PI-103		Predictive	Supports	D	Sensitivity/Response	"As part of a preclinical study, the efficacy of PI-103 (a dual inhibitor of MTOR and Class IA PI3Ks) was evaluated for several cell lines of breast cancer. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. HCC202 is a HER2 receptor amplified breast cancer cell line harboring PIK3CA E542K, and it had an IC50 of 0.43uM."	20453058	PubMed		"O'Brien et al., 2010, Clin. Cancer Res."		1	accepted	2058	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/2058	https://civicdb.org/links/molecular_profiles/103	FALSE	PIK3CA	5290	E542K		chr3	179218294	179218294	G	A	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.1624G>A,NP_006209.2:p.Glu542Lys,ENST00000263967.3:c.1624G>A,NC_000003.11:g.178936082G>A"	2023-01-27 17:02:37 UTC	CA333572	31944	"GLU542LYS,RS121913273"	FALSE
PIK3CA E545K	104	Her2-receptor Positive Breast Cancer	60079		Pictilisib		Predictive	Supports	D	Sensitivity/Response	"This preclinical study tested the efficacy on several breast cancer cell lines of GDC-0941 (pictilisib), a selective inhibitor of all four isoforms of class I PI3-kinases at a range of IC50 values. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. MDA-MB-361 is a HER2 amplified breast cancer cell line harboring PIK3CA E545K, and it had an IC50 of 0.14uM. To asses the effect of pictilisib on cell cycle progression and apoptosis, fluorescence based cell cycle and flow cytometry were used to measure the proportion of cells in various phases and the relative presence of Annexin V, a marker of apoptosis. Untreated, 68% of cells were in G1 or sub-G1. Following treatment with 1.0uM pictilisib, the proportion of cells in G1 or sub-G1 rose to 78%, and the amount of Annexin V detected rose 3 fold. A substantial reduction in phosphorylated AKT (S473) was also noted. Authors concluded that pictilisib had a modest effect on cell cycle progression and encouraged apoptosis in this cell line, and that this cell line is sensitive to pictilisib. Authors further noted that HER2 amplified cell lines were generally more sensitive, regardless of mutation, to pictilisib than basal-like breast cancer cell lines (p=0.002)."	20453058	PubMed		"O'Brien et al., 2010, Clin. Cancer Res."		4	accepted	2062	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/2062	https://civicdb.org/links/molecular_profiles/104	FALSE	PIK3CA	5290	E545K		chr3	179218303	179218303	G	A	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.1633G>A,NP_006209.2:p.Glu545Lys,ENST00000263967.3:c.1633G>A,NC_000003.11:g.178936091G>A"	2023-01-27 17:02:37 UTC	CA123334	13655	"GLU545LYS,RS104886003"	FALSE
ERBB2 Amplification	302	Breast Cancer	1612		Pictilisib		Predictive	Supports	D	Sensitivity/Response	"This preclinical study tested the efficacy of GDC-0941, a selective inhibitor of class I PI3K, on several cell lines of breast cancer. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. Authors tested six HER2 amplified breast cancer cell lines for sensitivity to GDC-0941. Their IC50s ranged from 0.19uM to 1.29uM (5/6 cell lines had IC50s below 1umol/L). Authors further note that HER2 amplified breast cancer cell lines are generally more sensitive to GDC-0941 than basal-type cell lines (p = 0.002)."	20453058	PubMed		"O'Brien et al., 2010, Clin. Cancer Res."		3	accepted	2071	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/2071	https://civicdb.org/links/molecular_profiles/302	FALSE	ERBB2	2064	Amplification		chr17	39700080	39728662			ENST00000269571.5	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A	OVEREXPRESSION	FALSE
PTEN Loss	214	Breast Cancer	1612		Pictilisib		Predictive	Does Not Support	D	Sensitivity/Response	"This preclinical study tested the efficacy of GDC-0941, a selective inhibitor of class I PI3K, on several cell lines of breast cancer. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. The authors tested several basal and luminal cell lines harboring PTEN loss for sensitivity to GDC-0941. ZR-75-1, a luminal-type cell line, had an IC50 of 0.15uM and reduction in phosphorylated AKT was noted following administration of GDC-0941. EVSTA-T, a luminal-type cell line, had an IC50 of 0.36uM; treatment resulted in an relative increase of Sub-G and G phase cells from 49% to 78% of total cells evaluated; there was a 12fold increase in annexin V (an apoptotic marker), and a substantial reduction in phosphorylated AKT following GDC-0941 administration. Seven basal-like cell lines harbored PTEN loss and had IC50s ranging fom 0.30uM to 20.00uM (4/7 had IC50s greater than 1 uM). There was a varied reduction in phosphorylated AKT among basal-like cell lines. Authors note that PTEN status may have low predictive power for response, and suggested that other factors such as basal/luminal characteristics may be more informative for GDC-0941 response. Authors further note that luminal type cell lines are generally more sensitive to GDC-0941 than basal type cell lines (p=0.02)."	20453058	PubMed		"O'Brien et al., 2010, Clin. Cancer Res."		2	accepted	2074	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/2074	https://civicdb.org/links/molecular_profiles/214	FALSE	PTEN	5728	Loss		chr10	87863113	87971930			ENST00000371953.3	75		loss_of_function_variant	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
PIK3CA C420R	905	Her2-receptor Positive Breast Cancer	60079		Pictilisib		Predictive	Supports	D	Sensitivity/Response	"This preclinical study tested the efficacy on several HER2 amplified breast cancer cell lines of GDC-0941 (pictilisib), a selective inhibitor of all four isoforms of class I PI3-kinases at a range of IC50 values. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. Two HER2 amplified breast cancer cell lines harboring PIK3CA C420R were tested for sensitivity to pictilisib. EFM-192A had an IC50 of 0.32uM and JIMT-1 had an IC50 of 0.86uM. Authors note that HER2 amplified cell lines were generally more sensitive, regardless of mutation, to pictilisib than basal-like cell lines (p=0.002)."	20453058	PubMed		"O'Brien et al., 2010, Clin. Cancer Res."		3	accepted	2078	Somatic	2023-01-09 21:46:40 UTC	https://civicdb.org/links/evidence_items/2078	https://civicdb.org/links/molecular_profiles/905	FALSE	PIK3CA	5290	C420R		chr3	179210192	179210192	T	C	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.1258T>C,NP_006209.2:p.Cys420Arg,NC_000003.11:g.178927980T>C,ENST00000263967.3:c.1258T>C"	2023-01-27 17:06:45 UTC	CA180900	31945	"RS121913272,CYS420ARG"	FALSE
PIK3CA K111N	1208	Her2-receptor Positive Breast Cancer	60079		Pictilisib		Predictive	Supports	D	Sensitivity/Response	"This preclinical study tested the efficacy on several breast cancer cell lines of GDC-0941 (pictilisib), a selective inhibitor of all four isoforms of class I PI3-kinases at a range of IC50 values. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. BT-474 is a HER2 amplified breast cancer cell line harboring PIK3CA K111N, and it had an IC50 of 0.23uM. To evaluate in vivo efficacy, cells were injected in the mammary fat pad of SCID mice and allowed to grow. Mice subsequently treated with 100mg/kg pictilisib experienced a 69% tumor reduction, and those treated with 150mg/kg experienced an 82% tumor reduction, with respect to untreated control. Authors note that pictilisib was well tolerated and observed no toxicities or significant weight loss. Authors further note that HER2 amplified cell lines were generally more sensitive, regardless of mutation, to pictilisib than basal-like cell lines (p=0.002)."	20453058	PubMed		"O'Brien et al., 2010, Clin. Cancer Res."		4	accepted	2085	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/2085	https://civicdb.org/links/molecular_profiles/1208	FALSE	PIK3CA	5290	K111N		chr3	179199158	179199158	G	C	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.333G>C,NP_006209.2:p.Lys111Asn,NC_000003.11:g.178916946G>C,ENST00000263967.3:c.333G>C"	2023-01-27 17:08:48 UTC	CA16602917	376483	"LYS111ASN,RS1057519934"	FALSE
PIK3CA Mutation	307	Breast Cancer	1612		Trastuzumab		Predictive	Supports	B	Resistance	"In retrospective study of 175 metastatic breast cancer patients treated with trastuzumab-based therapy, the presence of a PIK3CA mutation (E542K, E545K, or H1047R) was associated with a greater risk of progression (HR = 1.86, P = 0.014, multivariate analysis ) compared to wildtype PIK3CA."	21594665	PubMed		"Razis et al., 2011, Breast Cancer Res. Treat."		3	accepted	2087	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/2087	https://civicdb.org/links/molecular_profiles/307	FALSE	PIK3CA	5290	Mutation		chr3	179148523	179240093			ENST00000263967.3	75		"transcript_variant,gain_of_function_variant"		2023-01-09 21:52:06 UTC		N/A		FALSE
PIK3CA H1047L	1125	Breast Cancer	1612		Pictilisib		Predictive	Supports	D	Sensitivity/Response	"This preclinical study tested the efficacy on several breast cancer cell lines of GDC-0941 (pictilisib), a selective inhibitor of all four isoforms of class I PI3-kinases at a range of IC50 values. Sensitivity and resistance was categorized as less than and more than an IC50 of 1 umol/L, respectively, with a maximum tested concentration of 20 umol/L. EFM-19 is a luminal type breast cancer cell line harboring PIK3CA H1047L, and it had an IC50 of 0.09uM, suggesting sensitivity. Authors note that luminal-like cell lines were generally more sensitive, regardless of mutation, to pictilisib than basal-like (p=.02)"	20453058	PubMed		"O'Brien et al., 2010, Clin. Cancer Res."		3	accepted	2089	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/2089	https://civicdb.org/links/molecular_profiles/1125	FALSE	PIK3CA	5290	H1047L		chr3	179234297	179234297	A	T	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.3140A>T,NP_006209.2:p.His1047Leu,NC_000003.11:g.178952085A>T,ENST00000263967.3:c.3140A>T"	2023-01-27 17:08:14 UTC	CA123328	13653	"RS121913279,HIS1047LEU"	FALSE
PIK3CA H1047R	107	Her2-receptor Positive Breast Cancer	60079		Pictilisib		Predictive	Supports	D	Sensitivity/Response	"This preclinical study tested the efficacy on several breast cancer cell lines of GDC-0941 (pictilisib), a selective inhibitor of all four isoforms of class I PI3-kinases at a range of IC50 values. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. KPL4 is a HER2 amplified breast cancer cell line harboring PIK3CA H1047R, and it had an IC50 of 0.28uM. To evaluate in vivo efficacy, cells were injected in the mammary fat pad of SCID mice, and allowed to grow. Subsequently, pictilisib was administered orally daily for 14 days. Mice treated with 100mg/kg experienced a 76% tumor reduction, and those treated with 150mg/kg experienced a 90% tumor reduction, with respect to untreated control. Phosphorylated AKT (S473) was substantially reduced with pictilisib administration. Three other HER2 amplified breast cancer cell lines harbored PIK3CA H1047R: UACC-893, HCC1954, MDA-MB-453, which had IC50s of 0.41uM, 0.49uM, and 0.64uM, suggesting that PIK3CA H1047R induces sensitivity to pictilisib in HER2 amplified breast cancer. Authors note that pictilisib was well tolerated in vivo and further note that HER2 amplified cell lines were generally more sensitive, regardless of mutation, to pictilisib than basal-like cell lines (p=0.002)."	20453058	PubMed		"O'Brien et al., 2010, Clin. Cancer Res."		4	accepted	2096	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/2096	https://civicdb.org/links/molecular_profiles/107	FALSE	PIK3CA	5290	H1047R		chr3	179234297	179234297	A	G	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.3140A>G,NP_006209.2:p.His1047Arg,ENST00000263967.3:c.3140A>G,NC_000003.11:g.178952085A>G"	2023-01-27 17:02:38 UTC	CA123326	13652	"HIS1047ARG,RS121913279"	FALSE
PIK3CA H1047R	107	Breast Cancer	1612				Prognostic	Supports	B	Better Outcome	"Prognostic significance of PIK3CA mutations was evaluated in a retrospective study of 590 patients with surgically resected invasive breast cancer. Patients whose tumors harbored PIK3CA H1047R (n=88, 14.9%) experienced significantly higher 10-year overall survival rate (76% vs 62%) and lower 10-year probability of breast cancer specific death (11% vs 23%) compared to those with wildtype PIK3CA. They also experienced a 2.8 and 2 fold reduction in probability of death due to breast cancer at 5 and 10 years. Authors found that PIK3CA H1047R was specifically associated with lymph node-negative status: 64% of H1047R patients were lymph-node negative compared to 48% of patients with PIK3CA WT and helical domain mutated tumors (P=0.007). PIK3CA H1047R was positively associated with lymph node negative status, lower nodal stage, lower overall stage, and smaller tumor size compared to WT PIK3CA"	19671852	PubMed		"Kalinsky et al., 2009, Clin. Cancer Res."		2	accepted	2097	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/2097	https://civicdb.org/links/molecular_profiles/107	FALSE	PIK3CA	5290	H1047R		chr3	179234297	179234297	A	G	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.3140A>G,NP_006209.2:p.His1047Arg,ENST00000263967.3:c.3140A>G,NC_000003.11:g.178952085A>G"	2023-01-27 17:02:38 UTC	CA123326	13652	"HIS1047ARG,RS121913279"	FALSE
PIK3CA Mutation	307	Her2-receptor Positive Breast Cancer	60079		Trastuzumab		Predictive	Supports	B	Resistance	"In a retrospective study of 105 HER2-positive metastic breast cancer patients treated with trastuzumab-based therapy, the presence of a PIK3CA mutation (E542K, E545K, or H1047R) was associated with a greater risk of progression (HR = 2.50, P = 0.003, multivariate analysis) compared to wildtype PIK3CA."	21594665	PubMed		"Razis et al., 2011, Breast Cancer Res. Treat."		3	accepted	2098	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/2098	https://civicdb.org/links/molecular_profiles/307	FALSE	PIK3CA	5290	Mutation		chr3	179148523	179240093			ENST00000263967.3	75		"transcript_variant,gain_of_function_variant"		2023-01-09 21:52:06 UTC		N/A		FALSE
PIK3CA H1047R	107	Breast Cancer	1612				Prognostic	Supports	B	Better Outcome	"In Japanese invasive breast cancer patients, PIK3CA mutation was associated with improved relapse-free survival (p < .05)."	17202311	PubMed		"Maruyama et al., 2007, Clin. Cancer Res."		2	accepted	2100	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/2100	https://civicdb.org/links/molecular_profiles/107	FALSE	PIK3CA	5290	H1047R		chr3	179234297	179234297	A	G	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.3140A>G,NP_006209.2:p.His1047Arg,ENST00000263967.3:c.3140A>G,NC_000003.11:g.178952085A>G"	2023-01-27 17:02:38 UTC	CA123326	13652	"HIS1047ARG,RS121913279"	FALSE
PIK3CA H1047R	107	Breast Cancer	1612		Pictilisib		Predictive	Supports	D	Sensitivity/Response	"This preclinical study tested the efficacy of GDC-0941, a selective inhibitor of class I PI3K, on several cell lines of breast cancer. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. Three cell lines harbored PIK3CA H1047R. T-47D is a luminal type breast cancer cell line, and it had an IC50 of 0.22uM. Treatment with GDC-0941 resulted in a substantial reduction of phosphorylated AKT. BT-20 is a basal breast cancer cell line which had an ICD50 of 0.62uM. MFM-223 is basal cell line that had an ICD50 of 2.10uM, and experienced some reduction in pAKT. Authors note that luminal-like cell lines were generally more sensitive to GDC-0941 than basal-like (p=0.02)."	20453058	PubMed		"O'Brien et al., 2010, Clin. Cancer Res."		2	accepted	2102	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/2102	https://civicdb.org/links/molecular_profiles/107	FALSE	PIK3CA	5290	H1047R		chr3	179234297	179234297	A	G	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.3140A>G,NP_006209.2:p.His1047Arg,ENST00000263967.3:c.3140A>G,NC_000003.11:g.178952085A>G"	2023-01-27 17:02:38 UTC	CA123326	13652	"HIS1047ARG,RS121913279"	FALSE
PIK3CA H1047R	107	Her2-receptor Positive Breast Cancer	60079		Trastuzumab Emtansine		Predictive	Does Not Support	D	Resistance	"As part of a pre-clinical experiment, the efficacy of ado-trastuzumab emtansine (T-DM1) was compared to that of trastuzumab against various HER2 positive cell lines. HCC1954 and KPL-4 cell lines expressing PIK3CA H1047R were associated with similar sensitivity to T-DM1 as PIK3CA wild-type cell line SK-BR-3; reduced cell viability was observed at concentrations > 0.01 ug/mL in all three cell lines. Conversely, the cell lines harboring PIK3CA H1047R were resistant to trastuzumab in vitro at all concentrations tested (0-10 ug/mL). Further, treatment with T-DM1 on SCID mice xenografted with KPL-4 (PIK3CA H1047R cells) resulted in inhibition of tumor growth. A single dose of T-DM1 >5mg/kg was sufficient to induce tumor regression >20 days after administration."	26920887	PubMed		"Baselga et al., 2016, Clin. Cancer Res."		3	accepted	2103	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/2103	https://civicdb.org/links/molecular_profiles/107	FALSE	PIK3CA	5290	H1047R		chr3	179234297	179234297	A	G	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.3140A>G,NP_006209.2:p.His1047Arg,ENST00000263967.3:c.3140A>G,NC_000003.11:g.178952085A>G"	2023-01-27 17:02:38 UTC	CA123326	13652	"HIS1047ARG,RS121913279"	FALSE
PIK3CA Mutation	307	Colorectal Cancer	9256				Prognostic	Supports	B	Poor Outcome	"This retrospective study examines outcomes of 158 primary sporadic colorectal cancer patients who had undergone surgical resection and were treated with 5-fluorouracil based chemotherapy. PIK3CA mutations were associated with reduced relapse-free survival in stage II/III patients (HR:2.587, 95% CI:1.108-6.039, P=0.0280, univariate analysis; HR:2.478, 95% CI:1.028-5.973, P=0.0433, multivariate analysis) and reduced disease-specific survival in patients of any stage (n=18 vs. n=140, P=0.0357) compared to wildtype PIK3CA. Authors noted that the tumors of 6 patients harbored both PIK3CA and KRAS mutations, but stated that the presence of PIK3CA mutations did not correlate with the presence of KRAS mutations."	17590872	PubMed		"Kato et al., 2007, Int. J. Cancer"		3	accepted	2105	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/2105	https://civicdb.org/links/molecular_profiles/307	FALSE	PIK3CA	5290	Mutation		chr3	179148523	179240093			ENST00000263967.3	75		"transcript_variant,gain_of_function_variant"		2023-01-09 21:52:06 UTC		N/A		FALSE
PIK3CA E545K	104	Rectum Cancer	1993				Prognostic	Supports	B	Poor Outcome	"This study examined outcomes of 240 rectum cancer patients treated with total mesorectal excision therapy. Tumor samples were obtained at the time of surgery and genotyped for PIK3CA exon 10 and 21 mutations (listed as exon 9 and 20 in the publication, as it was common at the time of its publication to exclude non-coding exon 1). Of the 19 patients whose tumors harbored PIK3CA mutations, nine harbored PIK3CA E545K. PIK3CA E545K was associated with poor outcome compared to other PIK3CA mutations for local and distant recurrences (HR: 11.6, P < 0.001; HR 3.7, P = 0.006). Additionally, 89% of patients whose tumors harbored PIK3CA E545K experienced a relapse."	19903786	PubMed		"He et al., 2009, Clin. Cancer Res."		2	accepted	2106	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/2106	https://civicdb.org/links/molecular_profiles/104	FALSE	PIK3CA	5290	E545K		chr3	179218303	179218303	G	A	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.1633G>A,NP_006209.2:p.Glu545Lys,ENST00000263967.3:c.1633G>A,NC_000003.11:g.178936091G>A"	2023-01-27 17:02:37 UTC	CA123334	13655	"GLU545LYS,RS104886003"	FALSE
BRAF V600E	12	Colorectal Cancer	9256		"Cetuximab,Panitumumab"	Substitutes	Predictive	Supports	B	Resistance	"In metastatic colorectal cancer patients with wildtype KRAS status, those with a BRAF V600E mutation were less likely to respond to treatment with cetuximab or panitumumab than  those with wildtype BRAF (0%  vs. 32% , P=0.029). Regardless of KRAS status, patients with BRAF mutations had reduced progression-free and overall survival (P=0.0107 and P <0.0001, respectively). Transfection of the colorectal cancer cell line DiFi with a BRAF V600E expression vector conferred decreased sensitivity to cetuximab and panitumumab in comparison to cells transfected with empty vector."	19001320	PubMed		"Di Nicolantonio et al., 2008, J. Clin. Oncol."		3	accepted	2115	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/2115	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
BRAF V600E	12	Colorectal Cancer	9256				Predictive	Supports	B	Resistance	"In a study of metastatic colorectal cancer patients who received 5-FU-based first-line chemotherapy, those with BRAF V600E mutations had reduced progression-free survival (4.3mo vs. 12.5mo, HR:4.9, 95%CI:2.7-9.0, P<0.0001, univariate analysis; HR:4.0, 95%CI:2.2-7.4, P<0.0001, multivariate analysis) and reduced overall survival (10.9mo vs. 40.5mo, HR:4.5, 95%CI:2.4-8.4, P<0.0001, univariate analysis; HR:4.1, 95%CI:2.1-8.0, P<0.0001, multivariate analysis) compared to those with wildtype BRAF."	19603024	PubMed		"Souglakos et al., 2009, Br. J. Cancer"			accepted	2116	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/2116	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
BRAF V600E	12	Colorectal Cancer	9256		Oxaliplatin		Predictive	Supports	B	Resistance	"Of 100 metastatic colorectal cancer patients treated with oxaliplatin-based first-line therapy, the 6 patients with either BRAF V600E or D594K had reduced progression-free survival compared to 94 patients with wildtype BRAF (5.0mo vs. 11.7mo, HR:6.4, 95%CI:2.6-15.6, P<0.0001)."	19603024	PubMed		"Souglakos et al., 2009, Br. J. Cancer"		3	accepted	2117	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/2117	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
BRAF V600E	12	Colorectal Cancer	9256		Irinotecan		Predictive	Supports	B	Resistance	"The presence of BRAF V600E or D594K was associated with reduced progression-free survival in 5 patients with metastatic colorectal cancer treated with irinotecan-based first line therapy (3.5mo vs. 12.8mo, HR:4.1, 95%CI:1.5-11.3, P=0.006) when compared to 39 patients with wildtype BRAF."	19603024	PubMed		"Souglakos et al., 2009, Br. J. Cancer"		3	accepted	2118	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/2118	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
BRAF V600E	12	Colorectal Cancer	9256		"Oxaliplatin,Capecitabine,Bevacizumab"	Combination	Predictive	Supports	B	Resistance	"In a study of metastatic colorectal cancer patients treated with capecitabine, oxaliplatin, and bevacizumab, those with BRAF V600E mutations had reduced progression-free survival (5.9mo vs. 12.2mo, P=0.003) and reduced overall survival (15.0mo vs. 24.6mo, P=0.002) compared to those with wildtype BRAF."	19571295	PubMed		"Tol et al., 2009, N. Engl. J. Med."		3	accepted	2121	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/2121	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
BRAF V600E	12	Melanoma	1909		Trametinib		Predictive	Supports	B	Sensitivity/Response	"In a study of 322 advanced melanoma patients with BRAF-V600E (N=281), BRAF-V600K (N=40), or both mutations (N=1), treatment with trametinib was associated with improved progression-free survival (4.8mo vs. 1.5mo; HR: 0.45, 95% CI: 0.33-0.63, P<0.001) compared to chemotherapy control group. Additionally, treatment with trametinib was associated with increased 6-month overall survival (HR: 0.54, 95% CI: 0.32-0.92, P=0.01). The authors note similar outcomes for the primary efficacy population (V600E only) and the intention-to-treat population."	22663011	PubMed		"Flaherty et al., 2012, N. Engl. J. Med."	NCT01245062	4	accepted	2135	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/2135	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
BRAF V600E	12	Thyroid Gland Papillary Carcinoma	3969				Prognostic	Supports	B	Poor Outcome	"In a study of 102 papillary thyroid cancer patients with a 15 year median follow-up time, those with BRAF V600E mutations had reduced overall survival compared to those with wildtype BRAF (P=0.015, log-rank test). The presence of BRAF V600E was associated with poorer outcome as defined by persistent disease or death (Odds ratio:14.63, 95%CI:1.28-167.29, P=0.03, multivariate analysis."	18682506	PubMed		"Elisei et al., 2008, J. Clin. Endocrinol. Metab."		4	accepted	2137	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/2137	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
EGFR Mutation	438	Lung Non-small Cell Carcinoma	3908		Gefitinib		Predictive	Supports	B	Sensitivity/Response	"In a phase 3 clinical trial of East Asian advanced pulmonary adenocarcinoma patients, a subset of patients with EGFR mutations (n=261) treated with gefitinib were associated with improved response (HR:0.48, 95% CI:0.36-0.64, P<0.001), compared to carboplatin plus paclitaxel treatment. The frequency of mutation in exon 19 deletion and L858R was 53.6% (140/261) and 42.5% (111/261), respectively."	19692680	PubMed		"Mok et al., 2009, N. Engl. J. Med."	NCT00322452	5	accepted	2148	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/2148	https://civicdb.org/links/molecular_profiles/438	FALSE	EGFR	1956	Mutation		chr7	55019101	55211628			ENST00000275493.2	75		inframe_variant		2023-01-09 21:52:07 UTC		N/A		FALSE
EGFR Mutation	438	Lung Non-small Cell Carcinoma	3908		Afatinib		Predictive	Supports	B	Sensitivity/Response	"In a phase 2b/3 study of 585 stage IIIB-IV lung adenocarcinoma patients who had a previous round of EGFR-TKI treatment, archival material was available for 141 patients. EGFR mutational analysis revealed that 96 tumors had an EGFR mutation, of which 76 (79%) were positive for either L858R or a deletion in exon 19. These mutations were associated with improved progression-free survival (median 3.3 months  vs 1.0 month ; HR:0.51, 95% CI:0.31-0.85, P<0.009) compared to placebo control. No difference was reported between the treatment groups for EGFR mutation negative subgroup."	22452896	PubMed		"Miller et al., 2012, Lancet Oncol."	NCT00656136	4	accepted	2153	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/2153	https://civicdb.org/links/molecular_profiles/438	FALSE	EGFR	1956	Mutation		chr7	55019101	55211628			ENST00000275493.2	75		inframe_variant		2023-01-09 21:52:07 UTC		N/A		FALSE
EGFR T790M	34	Lung Adenocarcinoma	3910		Osimertinib		Predictive	Supports	C	Sensitivity/Response	"In a lung adenocarcinoma patient harboring an EGFR E746_A750 mutation and an acquired EGFR T790M co-mutation, EGFR T790M was associated with sensitivity to osimertinib monotherapy. Prior to the development of the EGFR T790M mutation, the patient was treated with gefitinib and achieved a partial response, but subsequently tumor progression occurred; however, osimertinib treatment resulted a favorable tumor response with the extinguishment of the EGFR T790M mutation. In a stage IV lung adenocarcinoma patient harboring an EGFR L858R mutation and an acquired EGFR T790M co-mutation, EGFR T790M was associated with sensitivity to osimertinib monotherapy. Prior to the development of the EGFR T790M mutation, the patient was treated with erlotinib, followed by gefitinib for 12 months and achieved stable disease, but subsequently metastasis occurred; the EGFR T790M was then identified and subsequent 10 month treatment with osimertinib monotherapy resulted in a 45% disease regression."	26269204	PubMed		"Planchard et al., 2015, Ann. Oncol."		2	accepted	2157	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/2157	https://civicdb.org/links/molecular_profiles/34	FALSE	EGFR	1956	T790M	EGFR TKI Resistance	chr7	55181378	55181378	C	T	ENST00000275493.2	75		missense_variant	"ENST00000275493.2:c.2369C>T,NM_005228.4:c.2369C>T,NP_005219.2:p.Thr790Met,NC_000007.13:g.55249071C>T"	2023-01-27 17:02:05 UTC	CA090928	16613	"THR790MET,RS121434569"	FALSE
EGFR T790M	34	Lung Non-small Cell Carcinoma	3908		"Erlotinib,Gefitinib"	Substitutes	Predictive	Supports	C	Resistance	"In a study of 6 patients with progressive non-small cell lung cancer during gefitinib or erlotinib therapy, comparison of DNA sequences from the original diagnostic biopsy specimen and a post-treatment biopsy specimen demonstrated that 3 patients acquired a new EGFR-T790M mutation. Analysis of EGFR sequence from 155 NSCLC samples prior to treatment with an EGFR inhibitor showed no T790M mutations, suggesting that T790M is associated with progression on gefitinib or erlotinib. In vitro experiments showed that the addition of T790M drastically reduced sensitivity to gefitinib or erlotinib in cells containing the sensitizing EGFR mutation L858R."	15737014	PubMed		"Pao et al., 2005, PLoS Med."		4	accepted	2158	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/2158	https://civicdb.org/links/molecular_profiles/34	FALSE	EGFR	1956	T790M	EGFR TKI Resistance	chr7	55181378	55181378	C	T	ENST00000275493.2	75		missense_variant	"ENST00000275493.2:c.2369C>T,NM_005228.4:c.2369C>T,NP_005219.2:p.Thr790Met,NC_000007.13:g.55249071C>T"	2023-01-27 17:02:05 UTC	CA090928	16613	"THR790MET,RS121434569"	FALSE
EGFR T790M	34	Lung Non-small Cell Carcinoma	3908		Gefitinib		Predictive	Supports	B	Resistance	"In a study of 14 patients with progressive non-small cell lung cancer during gefitinib treatment, comparison of DNA sequences from the original diagnostic biopsy specimen and the post-treatment biopsy specimen demonstrated that 7 patients acquired a new EGFR-T790M mutation. In addition, 52 pre-treatment tumours were examined with a sensitive real-time PCR assay and found no evidence of low frequency T790M mutation prior to gefitinib treatment."	17020982	PubMed		"Kosaka et al., 2006, Clin. Cancer Res."		3	accepted	2159	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/2159	https://civicdb.org/links/molecular_profiles/34	FALSE	EGFR	1956	T790M	EGFR TKI Resistance	chr7	55181378	55181378	C	T	ENST00000275493.2	75		missense_variant	"ENST00000275493.2:c.2369C>T,NM_005228.4:c.2369C>T,NP_005219.2:p.Thr790Met,NC_000007.13:g.55249071C>T"	2023-01-27 17:02:05 UTC	CA090928	16613	"THR790MET,RS121434569"	FALSE
EGFR T790M	34	Lung Non-small Cell Carcinoma	3908		Lapatinib		Predictive	Supports	D	Resistance	"In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H1975 cells (EGFR-L858R/T790M), inhibition of cell growth was used as an assay to determine sensitivity to reversible tyrosine kinase inhibitor drugs. Cells with an EGFR L858R/T790M mutation demonstrated a reduced response to lapatinib (IC50: >4000nM vs. 534nM) compared to wildtype EGFR cells. Similarly, NIH-3T3 ectopically expression EGFR-L858R/T790M showed reduced sensistivity to lapatinib compared to EGFR wt or L585R mutant cells. These results were further confirmed in a Ba/F3 cell line model"	18408761	PubMed		"Li et al., 2008, Oncogene"		4	accepted	2160	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/2160	https://civicdb.org/links/molecular_profiles/34	FALSE	EGFR	1956	T790M	EGFR TKI Resistance	chr7	55181378	55181378	C	T	ENST00000275493.2	75		missense_variant	"ENST00000275493.2:c.2369C>T,NM_005228.4:c.2369C>T,NP_005219.2:p.Thr790Met,NC_000007.13:g.55249071C>T"	2023-01-27 17:02:05 UTC	CA090928	16613	"THR790MET,RS121434569"	FALSE
EGFR T790M	34	Lung Non-small Cell Carcinoma	3908		Dacomitinib		Predictive	Supports	D	Sensitivity/Response	"In an in vitro study using NCI-H322 cells (wildtype EGFR) and NCI-H1975 cells (EGFR-L858R/T790M), inhibition of cell growth was used as an assay to determine sensitivity to irreversible tyrosine kinase inhibitor (TKI) drugs. PF00299804 inhibited the growth of Ba/F3 cell lines containing the EFGR T790M resistance mutation as well as H1975 and H3255 cell lines that contain both EGFR L858R and T790M mutations and H820 containing an EGFR exon 19 deletion (Del 747_L751, Ins S) and a T790M mutation. All three cell lines were resistant to gefitinib in vitro, but sensitive to PF00299804 (IC50 <1 mol/L for all three cell lines)."	18089823	PubMed		"Engelman et al., 2007, Cancer Res."		3	accepted	2161	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/2161	https://civicdb.org/links/molecular_profiles/34	FALSE	EGFR	1956	T790M	EGFR TKI Resistance	chr7	55181378	55181378	C	T	ENST00000275493.2	75		missense_variant	"ENST00000275493.2:c.2369C>T,NM_005228.4:c.2369C>T,NP_005219.2:p.Thr790Met,NC_000007.13:g.55249071C>T"	2023-01-27 17:02:05 UTC	CA090928	16613	"THR790MET,RS121434569"	FALSE
EGFR T790M	34	Lung Non-small Cell Carcinoma	3908		Neratinib		Predictive	Supports	D	Sensitivity/Response	"The NSCLC cell line NCI-H1975 carrying the EGFR T790M mutation was resistant to erlotinib but showed increased sensitivity to HKI-272 (neratinib, IC50: 0.29 mol/L). In an in vitro study Ba/F3 cells transfected with either EGFR-L858R or EGFR-L858R/T790M were used to assay cell growth. Ba/F3 cells require IL-3 in order to proliferate, but cells transfected with an activated oncogene are IL-3 independent. Cells with an EGFR L858R/T790M mutation demonstrated an improved response to neratinib (IC50: 0.185umol/L vs. >10umol/L) compared to the same cells treated with erlotinib."	16818618	PubMed		"Shimamura et al., 2006, Cancer Res."		2	accepted	2162	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/2162	https://civicdb.org/links/molecular_profiles/34	FALSE	EGFR	1956	T790M	EGFR TKI Resistance	chr7	55181378	55181378	C	T	ENST00000275493.2	75		missense_variant	"ENST00000275493.2:c.2369C>T,NM_005228.4:c.2369C>T,NP_005219.2:p.Thr790Met,NC_000007.13:g.55249071C>T"	2023-01-27 17:02:05 UTC	CA090928	16613	"THR790MET,RS121434569"	FALSE
EGFR T790M	34	Lung Non-small Cell Carcinoma	3908		Afatinib		Predictive	Supports	D	Sensitivity/Response	"In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H1975 cells (EGFR-L858R/T790M), inhibition of cell growth was used as an assay to determine sensitivity to tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R/T790M mutation demonstrated an improved response to afatinib (IC50: 99nM vs. >4000nM) compared to the same cells treated with erlotinib. In an in vivo mouse xenograft study, the growth of cells with an EGFR-L858R/T790M mutation were more sensitive to treatment of afatinib (concentration: 15-20mg/kg) (median tumor volume = 75-150mm^3 vs. 1000mm^3), compared to reversible TKI lapatinib-treated xenografts. However, no complete responses were observed with afatinib alone."	18408761	PubMed		"Li et al., 2008, Oncogene"		2	accepted	2163	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/2163	https://civicdb.org/links/molecular_profiles/34	FALSE	EGFR	1956	T790M	EGFR TKI Resistance	chr7	55181378	55181378	C	T	ENST00000275493.2	75		missense_variant	"ENST00000275493.2:c.2369C>T,NM_005228.4:c.2369C>T,NP_005219.2:p.Thr790Met,NC_000007.13:g.55249071C>T"	2023-01-27 17:02:05 UTC	CA090928	16613	"THR790MET,RS121434569"	FALSE
EGFR T790M	34	Lung Non-small Cell Carcinoma	3908		Afatinib		Predictive	Supports	D	Sensitivity/Response	"In an in vitro study using purified EGFR protein, kinase activity was assayed and compared for wildtype EGFR, EGFR-T790M and EGFR-T790M/L858R using both reversible and irreversible TKI drugs. EFGR proteins with T790M or T790M/L858R mutations were more sensitive to afatinib treatment (IC50: 9.8nM and 24nM, respectively vs. IC50: >1000nM and >1000nM, respectively) compared to treatment with erlotinib or lapatinib treatment. In an in vitro study using NCI-H358 cells (wildtype EGFR) and NCI-H1975 cells (EGFR-L858R/T790M), inhibition of cell growth was used as an assay to determine sensitivity to tyrosine kinase inhibitor drugs. Cells with an EGFR L858R/T790M mutation demonstrated an improved response to afatinib (GI50: 42.0nM vs. >1000nM) compared to the same cells treated with erlotinib. However, IC50s were intermediate compared to a more potent pan-HER inhibitor."	21732342	PubMed		"Cha et al., 2012, Int. J. Cancer"		2	accepted	2164	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/2164	https://civicdb.org/links/molecular_profiles/34	FALSE	EGFR	1956	T790M	EGFR TKI Resistance	chr7	55181378	55181378	C	T	ENST00000275493.2	75		missense_variant	"ENST00000275493.2:c.2369C>T,NM_005228.4:c.2369C>T,NP_005219.2:p.Thr790Met,NC_000007.13:g.55249071C>T"	2023-01-27 17:02:05 UTC	CA090928	16613	"THR790MET,RS121434569"	FALSE
EGFR T790M	34	Lung Non-small Cell Carcinoma	3908		Canertinib		Predictive	Supports	D	Sensitivity/Response	"In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H1975 cells (EGFR-L858R/T790M), inhibition of cell growth was used as an assay to determine sensitivity to tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R/T790M mutation demonstrated an improved response to canertinib (IC50: 101nM vs. >4000nM) compared to the same cells treated with erlotinib. IC50 values of canertinib were comparable to afatinib."	18408761	PubMed		"Li et al., 2008, Oncogene"		2	accepted	2165	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/2165	https://civicdb.org/links/molecular_profiles/34	FALSE	EGFR	1956	T790M	EGFR TKI Resistance	chr7	55181378	55181378	C	T	ENST00000275493.2	75		missense_variant	"ENST00000275493.2:c.2369C>T,NM_005228.4:c.2369C>T,NP_005219.2:p.Thr790Met,NC_000007.13:g.55249071C>T"	2023-01-27 17:02:05 UTC	CA090928	16613	"THR790MET,RS121434569"	FALSE
ABL1 BCR::ABL F359V	866	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	D	Resistance	"A panel of 18 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL protein and were grouped according to their anti-proliferative activity. Mutant cell lines that exhibited a greater than 4-fold increase in IC50 value were considered resistant to drug, 2-4 fold increase in IC50 were moderately resistant and less than 2-fold change in IC50 was sensitive to drug treatment. The F359V mutation was moderately resistant to imatinib."	19075254	PubMed		"Redaelli et al., 2009, J. Clin. Oncol."		2	accepted	2167	Somatic	2023-01-09 21:46:39 UTC	https://civicdb.org/links/evidence_items/2167	https://civicdb.org/links/molecular_profiles/866	FALSE	ABL1	25	BCR::ABL F359V		chr9	130873027	130873027	T	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.1075T>G,NP_005148.2:p.Phe359Val,NC_000009.11:g.133748414T>G,ENST00000318560.5:c.1075T>G"	2023-01-27 17:06:25 UTC	CA16602557	376096	"RS121913452,BCR-ABL F378V,BCR-ABL PHE359VAL,BCR-ABL1 F359V,BCR-ABL1 PHE359VAL,BCR-ABL F359V"	FALSE
ABL1 BCR::ABL F359V	866	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	C	Resistance	"In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. An accelerated-phase (AP) patient improved to chronic phase. M351T, E255K, and F359V variants were each present in ~25% of transcripts beginning at 6, 11, and 14 months, respectively. At 20 months, the patient returned to accelerated phase with an increase in the proportion of E255K variants to ~75% of transcripts. Another AP patient had a complete hematologic response with the M351T variant present in ~25 to ~75% of transcripts and the F359V variant present in ~25% to ~50% of transcripts between 8 and 16 months after therapy initiation but prior to resistance. At 17 months, the patient progressed to myeloid blast crisis and there was cytogenetic evidence of a double Ph-chromosome. At that time, no secondary variants could be detected."	12623848	PubMed		"Branford et al., 2003, Blood"		2	accepted	2168	Somatic	2023-01-09 21:46:39 UTC	https://civicdb.org/links/evidence_items/2168	https://civicdb.org/links/molecular_profiles/866	FALSE	ABL1	25	BCR::ABL F359V		chr9	130873027	130873027	T	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.1075T>G,NP_005148.2:p.Phe359Val,NC_000009.11:g.133748414T>G,ENST00000318560.5:c.1075T>G"	2023-01-27 17:06:25 UTC	CA16602557	376096	"RS121913452,BCR-ABL F378V,BCR-ABL PHE359VAL,BCR-ABL1 F359V,BCR-ABL1 PHE359VAL,BCR-ABL F359V"	FALSE
ABL1 BCR::ABL F359V	866	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	C	Resistance	"In two cell-based studies, a panel of either 18 or 16 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL protein and were grouped according to their anti-proliferative activity. Mutant cell lines that exhibited a greater than 4-fold increase in IC50 value were considered resistant to drug, 2-4 fold increase in IC50 were moderately resistant and less than 2-fold change in IC50 was sensitive to drug treatment. The F359V mutation was  moderately resistant to imatinib ."	15930265	PubMed		"O'Hare et al., 2005, Cancer Res."			accepted	2169	Somatic	2023-01-09 21:46:39 UTC	https://civicdb.org/links/evidence_items/2169	https://civicdb.org/links/molecular_profiles/866	FALSE	ABL1	25	BCR::ABL F359V		chr9	130873027	130873027	T	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.1075T>G,NP_005148.2:p.Phe359Val,NC_000009.11:g.133748414T>G,ENST00000318560.5:c.1075T>G"	2023-01-27 17:06:25 UTC	CA16602557	376096	"RS121913452,BCR-ABL F378V,BCR-ABL PHE359VAL,BCR-ABL1 F359V,BCR-ABL1 PHE359VAL,BCR-ABL F359V"	FALSE
ABL1 BCR::ABL F359V	866	Chronic Myeloid Leukemia	8552		Nilotinib		Predictive	Supports	D	Resistance	"In an in vitro study, a Ba/F3  cell line stably expressing the F359V mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to nilotinib treatment (IC50: 5.16-fold), as compared to Ba/F3 cells expressing BCR-ABL1 fusion protein (reported to be sensitizing to nilotinib). Sensitivity was determined by assessing cell proliferation."	19075254	PubMed		"Redaelli et al., 2009, J. Clin. Oncol."		3	accepted	2170	Somatic	2023-01-09 21:46:39 UTC	https://civicdb.org/links/evidence_items/2170	https://civicdb.org/links/molecular_profiles/866	FALSE	ABL1	25	BCR::ABL F359V		chr9	130873027	130873027	T	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.1075T>G,NP_005148.2:p.Phe359Val,NC_000009.11:g.133748414T>G,ENST00000318560.5:c.1075T>G"	2023-01-27 17:06:25 UTC	CA16602557	376096	"RS121913452,BCR-ABL F378V,BCR-ABL PHE359VAL,BCR-ABL1 F359V,BCR-ABL1 PHE359VAL,BCR-ABL F359V"	FALSE
KRAS G13D	81	Colorectal Cancer	9256		Panitumumab		Predictive	Supports	C	Resistance	"Three patients participating in a large retrospective study of EGFR monoclonal antibodies in metastatic, treatment refractory colorectal cancer had tumors which harbored KRAS G13D, were wildtype for NRAS, BRAF and PIK3CA, and had individual response data. All three patients were males treated with panitumumab monotherapy. Their characteristics are as follows: 51 year old who experienced progressive disease (PFS: 8 weeks; OS: 24 weeks) and had three prior lines of chemotherapy; 54 year old who experienced progressive disease (PFS: 8 weeks; OS: 17 weeks) and had two prior lines of chemotherapy; 52 year old who experienced stable disease (PFS: 12 weeks; OS: 46 weeks) and had two prior lines of chemotherapy. Per the authors criteria, the clinical benefit rate is 1/3 and the response rate is 0/3."	20619739	PubMed		"De Roock et al., 2010, Lancet Oncol."		3	accepted	2178	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/2178	https://civicdb.org/links/molecular_profiles/81	FALSE	KRAS	3845	G13D		chr12	25245347	25245347	C	T	ENST00000256078.4	75		missense_variant	"NM_033360.3:c.38G>A,NP_004976.2:p.Gly13Asp,NC_000012.11:g.25398281C>T,ENST00000256078.4:c.38G>A"	2023-01-27 17:02:27 UTC	CA122534	12580	"GLY13ASP,RS112445441"	FALSE
NRAS Q61L	95	Colorectal Cancer	9256		"Cetuximab,Irinotecan"	Combination	Predictive	Supports	C	Resistance	"Two patients participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored NRAS Q61L and were wildtype for KRAS, BRAF and PIK3CA. Both patients experienced stable disease, which the authors classified as non-response. The two patients whose tumors harbored NRAS Q61L included a 53 year old female treated with cetuximab and irinotecan as a 6th line treatment who had PFS of 12 weeks and OS of 25 weeks; and a 64 year old female treated with cetuximab and ironotecan as a 3rd line therapy who had PFS of 12 weeks and OS of 46 weeks."	20619739	PubMed		"De Roock et al., 2010, Lancet Oncol."		3	accepted	2181	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/2181	https://civicdb.org/links/molecular_profiles/95	FALSE	NRAS	4893	Q61L		chr1	114713908	114713908	T	A	ENST00000369535.4	75		missense_variant	"NP_002515.1:p.Gln61Leu,NC_000001.10:g.115256529T>A,NM_002524.4:c.182A>T,ENST00000369535.4:c.182A>T"	2023-01-27 17:02:31 UTC	CA16602361	375874	"GLN61LEU,RS11554290"	FALSE
KRAS G13D	81	Colorectal Cancer	9256		"Dactolisib,Selumetinib"	Combination	Predictive	Supports	D	Sensitivity/Response	"In 28 out of 40 (70%) metastatic colorectal cancer tumors harboring KRAS, NRAS, PIK3CA or BRAF mutations and implanted into mice, the therapeutic combination of the MEK inhibitor AZD6244 and the PI3K/mTor inhibitor BEZ235 resulted in disease stabilization. Mean tumor growth was lower in the tumors treated with AZD6244+ BEZ235 (+77% vs. +267%, P=1E-6) compared to AZD6244 alone and (+77% vs. +222%, P=0.0014) BEZ235 alone. 32/40 mice harbored KRAS mutations including 5 G13D mutations where disease stabilization was achieved in 2/5 mice treated with AZD6244 or combination therapy and 0/5 mice treated with BEZ235 alone."	22392911	PubMed		"Migliardi et al., 2012, Clin. Cancer Res."		2	accepted	2183	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/2183	https://civicdb.org/links/molecular_profiles/81	FALSE	KRAS	3845	G13D		chr12	25245347	25245347	C	T	ENST00000256078.4	75		missense_variant	"NM_033360.3:c.38G>A,NP_004976.2:p.Gly13Asp,NC_000012.11:g.25398281C>T,ENST00000256078.4:c.38G>A"	2023-01-27 17:02:27 UTC	CA122534	12580	"GLY13ASP,RS112445441"	FALSE
NRAS Q61R	96	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	C	Resistance	"Five patients participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored NRAS Q61R and were wildtype for KRAS, BRAF and PIK3CA. Overall, one patient experienced stable disease, and the other four experienced progressive disease.The five patients whose tumors harbored NRAS Q61R included a 65 year old male treated with cetuximab monotherapy as a 3rd line treatment who experienced progressive disease and had PFS of 6 weeks and OS of 41 weeks; a 47 year old female treated with cetuximab and ironotecan as a 5th line therapy who experienced progressive disease and had PFS of 4 weeks and OS of 10 weeks; a 60 year old female treated with cetuximab and ironotecan as a 3rd line therapy who experienced stable disease and had PFS of 24 weeks and OS of 38 weeks; a 47 year old female treated with cetuximab and ironotecan as a 3rd line therapy who experienced progressive disease and had PFS of 14 weeks and OS of 18 weeks; and a 77 year old male treated with cetuximab monotherapy as a 1st line therapy who experienced progressive disease and had PFS of 7 weeks and OS of 67 weeks."	20619739	PubMed		"De Roock et al., 2010, Lancet Oncol."		2	accepted	2184	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/2184	https://civicdb.org/links/molecular_profiles/96	FALSE	NRAS	4893	Q61R		chr1	114713908	114713908	T	C	ENST00000369535.4	75		missense_variant	"NM_002524.4:c.182A>G,NP_002515.1:p.Gln61Arg,NC_000001.10:g.115256529T>C,ENST00000369535.4:c.182A>G"	2023-01-27 17:02:32 UTC	CA123618	13900	"GLN61ARG,RS11554290"	FALSE
BRAF Mutation	395	Colorectal Cancer	9256		"Chemotherapy,Cetuximab"	Combination	Predictive	Supports	B	Resistance	"This was a retrospective study of 350 patients with metastatic, chemotherapy refractory colorectal cancer treated with cetuximab + chemotherapy who had individual response data and whose tumors were KRAS wildtype and BRAF assessable. Patients harboring BRAF mutations (total n=24, V600E n=23, D594G n=1) had a lower response rate than did patients with wildtype BRAF (n=326; 2/24 [4.3%] vs 124/326 [38%], OR: 0.15, p=0.0012). BRAF mutant patients also experienced significantly lower disease control rate, PFS, and OS (median 26 vs 54 weeks, HR: 3.03 p<0.0001) in response to cetuximab treatment. In multivariate analysis, the significant associations between BRAF mutations and poor outcome were confirmed. The authors noted that two responders had the following genotypes: V600E mutation in low copy number, and BRAF D594G, and suggested that mutation status of BRAF is more informative than those of NRAS and PIK3CA exon 20 for predicting cetuximab response (second only to KRAS)."	20619739	PubMed		"De Roock et al., 2010, Lancet Oncol."		3	accepted	2187	Somatic	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/2187	https://civicdb.org/links/molecular_profiles/395	FALSE	BRAF	673	Mutation		chr7	140753336	140781603			ENST00000288602.6	75		"gene_variant,gain_of_function_variant"		2023-01-09 21:52:06 UTC				FALSE
NRAS Q61K	423	Colorectal Cancer	9256		"Cetuximab,Chemotherapy"	Combination	Predictive	Supports	C	Resistance	"Four patients participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored NRAS Q61K and were wildtype for KRAS, BRAF and PIK3CA. One patient experienced partial response and three patients experienced progressive disease. The four patients whose tumors harbored NRAS Q61K included an 80 year old male treated with cetuximab and irinotecan as a 3rd line treatment who experienced progressive disease and had PFS of 6 weeks and OS of 43 weeks; a 51 year old male treated with cetuximab and ironotecan as a 3rd line therapy who experienced a partial response and had PFS of 24 weeks and OS of 54 weeks; a 64 year old male treated with cetuximab and ironotecan as a 5th line therapy who experienced progressive disease and had PFS of 8 weeks and OS of 33 weeks; and a 65 year old female treated with cetuximab, oxaliplatin and 5FU as a 2nd line therapy who experienced progressive disease and had PFS of 31 weeks and OS of 50 weeks."	20619739	PubMed		"De Roock et al., 2010, Lancet Oncol."		3	accepted	2189	Somatic	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/2189	https://civicdb.org/links/molecular_profiles/423	FALSE	NRAS	4893	Q61K		chr1	114713909	114713909	G	T	ENST00000369535.4	75		missense_variant	"NM_002524.4:c.181C>A,NP_002515.1:p.Gln61Lys,NC_000001.10:g.115256530G>T,ENST00000369535.4:c.181C>A"	2023-01-27 17:03:41 UTC	CA151263	73058	"GLN61LYS,RS121913254"	FALSE
NRAS Q61K	423	Colorectal Cancer	9256		"Dactolisib,Selumetinib"	Combination	Predictive	Supports	D	Sensitivity/Response	"In 28 out of 40 (70%) metastatic colorectal cancer tumors harboring mutations in KRAS, NRAS, BRAF, or PIK3CA and implanted into mice, the therapeutic combination of the MEK inhibitor AZD6244 and the PI3K/mTor inhibitor BEZ235 resulted in disease stabilization. Mean tumor growth was lower in the tumors treated with AZD6244+ BEZ235 (+77% vs. +267%, P=1E-6) compared to AZD6244 alone and (+77% vs. +222%, P=0.0014) BEZ235 alone. NRAS mutations were in 4/40 tumors (three Q61K, one G12D)."	22392911	PubMed		"Migliardi et al., 2012, Clin. Cancer Res."		3	accepted	2192	Somatic	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/2192	https://civicdb.org/links/molecular_profiles/423	FALSE	NRAS	4893	Q61K		chr1	114713909	114713909	G	T	ENST00000369535.4	75		missense_variant	"NM_002524.4:c.181C>A,NP_002515.1:p.Gln61Lys,NC_000001.10:g.115256530G>T,ENST00000369535.4:c.181C>A"	2023-01-27 17:03:41 UTC	CA151263	73058	"GLN61LYS,RS121913254"	FALSE
KRAS G12D	79	Colorectal Cancer	9256		Panitumumab		Predictive	Supports	C	Resistance	"One patient participating in a large retrospective study of EGFR monoclonal antibodies in metastatic, treatment refractory colorectal cancer had a tumor which harbored KRAS G12D, was wildtype for NRAS, BRAF and PIK3CA, and had individual response data. This patient was was a 55 year old female treated with panitumumab monotherapy as 3rd line therapy who experienced progressive disease (PFS: 8 weeks; OS: 9 weeks)."	20619739	PubMed		"De Roock et al., 2010, Lancet Oncol."		3	accepted	2193	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/2193	https://civicdb.org/links/molecular_profiles/79	FALSE	KRAS	3845	G12D	EGFR TKI Resistance	chr12	25245350	25245350	C	T	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.35G>A,NP_004976.2:p.Gly12Asp,NC_000012.11:g.25398284C>T,ENST00000256078.4:c.35G>A"	2023-01-27 17:02:26 UTC	CA122538	12582	"GLY12ASP,RS121913529"	FALSE
PIK3CA Q546K	859	Colorectal Cancer	9256		"Cetuximab,Irinotecan"	Combination	Predictive	Does Not Support	C	Resistance	"One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored PIK3CA Q546K (exon 10), was wildtype for KRAS, BRAF and NRAS, and had individual response data. This patient was was a 75 year old female treated with cetuximab and irinotecan as 2nd line therapy (discontinued for toxic/biochemical reasons) who experienced a partial response (PFS: 43 weeks, OS: 57 weeks). Using clinical data compiled from the larger cohort, authors concluded that PIK3CA exon 10 (listed as exon 9 in the source) mutations predict weak or no resistance to cetuximab."	20619739	PubMed		"De Roock et al., 2010, Lancet Oncol."		2	accepted	2198	Somatic	2023-01-09 21:46:39 UTC	https://civicdb.org/links/evidence_items/2198	https://civicdb.org/links/molecular_profiles/859	FALSE	PIK3CA	5290	Q546K		chr3	179218306	179218306	C	A	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.1636C>A,NP_006209.2:p.Gln546Lys,NC_000003.11:g.178936094C>A,ENST00000263967.3:c.1636C>A"	2023-01-27 17:06:21 UTC	CA123338	13657	"RS121913286,GLN546LYS"	FALSE
BRAF D594G	607	Colorectal Cancer	9256		"Cetuximab,Irinotecan"	Combination	Predictive	Does Not Support	C	Resistance	"One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored BRAF D594G and was wildtype for KRAS, NRAS and PIK3CA. This patient was a 63 year old female treated with cetuximab and irinotecan (3rd line) who was one of two patients harboring a BRAF mutant tumor to experience a partial response. Progression free survival was 36 weeks and overall survival was 42 weeks from time of cetuximab administration. Authors note that cetuximab response is in accordance with cell line data suggesting that D594G cannot directly activate MAPK signaling, and that D594G mutants have low levels of p-MEK and are resistant to MEK inhibition."	20619739	PubMed		"De Roock et al., 2010, Lancet Oncol."		3	accepted	2201	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/2201	https://civicdb.org/links/molecular_profiles/607	FALSE	BRAF	673	D594G		chr7	140753354	140753354	T	C	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1781A>G,NP_004324.2:p.Asp594Gly,NC_000007.13:g.140453154T>C,ENST00000288602.6:c.1781A>G"	2023-01-27 17:04:35 UTC	CA123657	13972	"ASP594GLY,RS121913338"	FALSE
NRAS G13R	870	Colorectal Cancer	9256		"Irinotecan,Cetuximab"	Combination	Predictive	Supports	C	Resistance	"One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored NRAS G13R, was wildtype for KRAS, BRAF and PIK3CA, and had individual response data. This patient was was a 68 year old male treated with cetuximab + irinotecan as 3rd line therapy who experienced stable disease (PFS: 18 weeks; OS: 34 weeks). Authors considered stable disease as both clinical benefit and non response."	20619739	PubMed		"De Roock et al., 2010, Lancet Oncol."		1	accepted	2204	Somatic	2023-01-09 21:46:39 UTC	https://civicdb.org/links/evidence_items/2204	https://civicdb.org/links/molecular_profiles/870	FALSE	NRAS	4893	G13R		chr1	114716124	114716124	C	G	ENST00000369535.4	75		missense_variant	"NM_002524.4:c.37G>C,NP_002515.1:p.Gly13Arg,NC_000001.10:g.115258745C>G,ENST00000369535.4:c.37G>C"	2023-01-27 17:06:28 UTC	CA151261	13899	"RS121434595,GLY13ARG"	FALSE
KRAS A146T	880	Colorectal Cancer	9256		"Dactolisib,Selumetinib"	Combination	Predictive	Supports	D	Sensitivity/Response	"In 28 out of 40 (70%) metastatic colorectal cancer tumors implanted into mice, the therapeutic combination of the MEK inhibitor AZD6244 and the PI3K/mTor inhibitor BEZ235 resulted in disease stabilization. Mean tumor growth was lower in the tumors treated with AZD6244+ BEZ235 (+77% vs. +267%, P=1E-6) compared to AZD6244 alone and (+77% vs. +222%, P=0.0014) BEZ235 alone. 32/40 tumors harbored KRAS mutations including 2 A146T tumors (1 also harboring PIK3CA E545K) which both showed disease stabilization during doublet therapy but progression on either single agent."	22392911	PubMed		"Migliardi et al., 2012, Clin. Cancer Res."		3	accepted	2206	Somatic	2023-01-09 21:46:39 UTC	https://civicdb.org/links/evidence_items/2206	https://civicdb.org/links/molecular_profiles/880	FALSE	KRAS	3845	A146T		chr12	25225628	25225628	C	T	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.436G>A,NP_004976.2:p.Ala146Thr,NC_000012.11:g.25378562C>T,ENST00000256078.4:c.436G>A"	2023-01-27 17:06:34 UTC	CA245262	197243	"RS121913527,ALA146THR"	FALSE
KRAS G12D	79	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	B	Resistance	"This was a retrospective study of 691 cetuximab treated patients with metastatic colorectal cancer. Of those, 76 patients harbored KRAS G12D, were BRAF, NRAS and PIK3CA wt, and had individual response data. Five patients had partial response, 34 had stable disease, and 37 progressed. Treatments included cetuximab + irinotecan (n=61), cetuximab + FOLFIRI (n=6), cetuximab monotherapy (n=5), cetuximab + oxaliplatin + 5FU (n=2), cetuximab + 5FU (n=1), cetuximab + oxaliplatin + bevacizumab (n=1). Median PFS was 12 weeks (3-169 weeks), median OS was 31 weeks (6-232 weeks), and median number of previous chemotherapy lines was 2 (0-5). Median age was 62 years old (32-86), and there were 43 males and 33 females. Using these data and data from the larger cohort, authors concluded that KRAS mutation was strongly associated with poor response to cetuximab and suggested that mutation status of KRAS is the most informative compared to BRAF, NRAS, and PIK3CA exon 20 for predicting cetuximab response."	20619739	PubMed		"De Roock et al., 2010, Lancet Oncol."		3	accepted	2207	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/2207	https://civicdb.org/links/molecular_profiles/79	FALSE	KRAS	3845	G12D	EGFR TKI Resistance	chr12	25245350	25245350	C	T	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.35G>A,NP_004976.2:p.Gly12Asp,NC_000012.11:g.25398284C>T,ENST00000256078.4:c.35G>A"	2023-01-27 17:02:26 UTC	CA122538	12582	"GLY12ASP,RS121913529"	FALSE
KRAS A146V	318	Colorectal Cancer	9256		"Dactolisib,Selumetinib"	Combination	Predictive	Supports	D	Sensitivity/Response	"In 28 out of 40 (70%) metastatic colorectal cancer tumors harboring NRAS, KRAS, BRAF or PIK3CA mutations and implanted into mice, the therapeutic combination of the MEK inhibitor AZD6244 and the PI3K/mTor inhibitor BEZ235 resulted in disease stabilization. Mean tumor growth was lower in the tumors treated with AZD6244+ BEZ235 (+77% vs. +267%, P=1E-6) compared to AZD6244 alone and (+77% vs. +222%, P=0.0014) BEZ235 alone. 32/40 tumors harbored KRAS mutations including 2 tumors with A146V mutations which achieved stable disease with combined therapy but progressive disease in either monotherapy."	22392911	PubMed		"Migliardi et al., 2012, Clin. Cancer Res."		3	accepted	2209	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/2209	https://civicdb.org/links/molecular_profiles/318	FALSE	KRAS	3845	A146V		chr12	25225627	25225627	G	A	ENST00000256078.4	75		missense_variant	"ENST00000256078.4:c.437C>T,NC_000012.11:g.25378561G>A,NP_004976.2:p.Ala146Val,NM_004985.4:c.437C>T"	2023-01-27 17:03:31 UTC	CA16602440	375962	"ALA146VAL,RS1057519725"	FALSE
NRAS Mutation	208	Colorectal Cancer	9256		"Cetuximab,Chemotherapy"	Combination	Predictive	Supports	B	Resistance	"This was a retrospective study of 605 patients with metastatic, chemotherapy refractory colorectal cancer treated with cetuximab + chemotherapy. Patients with KRAS wildtype, NRAS assessable tumors, and individual response data (n=301) were genotyped for NRAS mutations. Patients harboring NRAS mutant tumors (n=13) had a significantly lower response rate than did patients with wildtype NRAS (n=289; 1/13 [7.7%] vs 110/289 [77.9%]; p =.013). However, there was no significant difference between patients with mutant or wildtype NRAS in disease control rate, progression free survival, or overall survival. Authors note that their small sample size of patients with NRAS mutant tumors made it difficult to assess the effect of NRAS mutation on survival thus the large confidence intervals. Authors further note that the close relationship between KRAS and NRAS, and the lack of NRAS response to another EGFR inhibitor (panitumumab) support the inclusion of NRAS genotyping prior to cetuximab treatment. Authors suggest screening for mutations in the following gene order: KRAS, BRAF, NRAS, PIK3CA exon 21 (listed as PIK3CA exon 20 in the source)."	20619739	PubMed		"De Roock et al., 2010, Lancet Oncol."		2	accepted	2210	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/2210	https://civicdb.org/links/molecular_profiles/208	FALSE	NRAS	4893	Mutation		chr1	114704469	114716894			ENST00000369535.4	75		"transcript_variant,gain_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
KRAS G12C	78	Colorectal Cancer	9256		"Selumetinib,Dactolisib"	Combination	Predictive	Supports	D	Sensitivity/Response	"In 28 out of 40 (70%) metastatic colorectal cancer tumors harboring BRAF, KRAS, NRAS or PIK3CA mutations and implanted into mice, the therapeutic combination of the MEK inhibitor AZD6244 and the PI3K/mTor inhibitor BEZ235 resulted in disease stabilization. Mean tumor growth was lower in the tumors treated with AZD6244+ BEZ235 (+77% vs. +267%, P=1E-6) compared to AZD6244 alone and (+77% vs. +222%, P=0.0014) BEZ235 alone. 32/40 tumors harbored KRAS mutations including 4 G12C mutations where disease stabilization occurred in 3/4 treated with BEZ235 or doublet therapy and 2/4 treated with AZD6244 only."	22392911	PubMed		"Migliardi et al., 2012, Clin. Cancer Res."		2	accepted	2212	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/2212	https://civicdb.org/links/molecular_profiles/78	FALSE	KRAS	3845	G12C	EGFR TKI Resistance	chr12	25245351	25245351	C	A	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.34G>T,NP_004976.2:p.Gly12Cys,NC_000012.11:g.25398285C>A,ENST00000256078.4:c.34G>T"	2023-01-27 17:02:26 UTC	CA122528	12578	"GLY12CYS,RS121913530"	FALSE
PIK3CA E545Q	855	Colorectal Cancer	9256		"Irinotecan,Cetuximab"	Combination	Predictive	Does Not Support	C	Resistance	"Two patients participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored PIK3CA E545Q (exon 10), were wildtype for NRAS, BRAF and PIK3CA, and had individual response data. Both were treated with cetuximab and irinotecan and experienced partial responses. One patient was a 44 year old female, on 5th line therapy, with a PFS of 67 weeks and an OS of 209 weeks. The other patient was a 46 year old male, on 2nd line therapy, with a PFS of 22 weeks and an OS of 105 weeks. Using these and data from the larger cohort, authors concluded that PIK3CA exon 10 (listed as exon 9 in source) mutations are associated with weak or no resistance to cetuximab."	20619739	PubMed		"De Roock et al., 2010, Lancet Oncol."		3	accepted	2213	Somatic	2023-01-09 21:46:39 UTC	https://civicdb.org/links/evidence_items/2213	https://civicdb.org/links/molecular_profiles/855	FALSE	PIK3CA	5290	E545Q		chr3	179218303	179218303	G	C	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.1633G>C,NP_006209.2:p.Glu545Gln,NC_000003.11:g.178936091G>C,ENST00000263967.3:c.1633G>C"	2023-01-27 17:06:18 UTC	CA16602379	375896	"RS104886003,GLU545GLN"	FALSE
PIK3CA E545K	104	Colorectal Cancer	9256		Cetuximab		Predictive	Does Not Support	C	Resistance	"This was a retrospective study of 691 cetuximab treated patients with metastatic, chemotherapy refractory colorectal cancer. Of those, 16 patients harbored PIK3CA E545K (exon 10), were wt for BRAF, NRAS and PIK3CA, and had individual response data. Five patients had partial response, six had stable disease, and five progressed, resulting in a response rate of 5/16 and a clinical benefit rate of 11/16 according to author criteria. Treatments included cetuximab + irinotecan (n=13), cetuximab monotherapy (n=1), cetuximab + bevacizumab (n=1), and cetuximab + oxaliplatin + 5FU (n=1). Median PFS was 24 weeks (2-60 weeks), median OS was 43 weeks (9-107 weeks), and median number of previous chemotherapy lines was 2 (1-5). Median age was 58 years old (43-79), and there were 10 males and 6 females. Using these and data from the larger cohort, authors concluded that PIK3CA exon 10 (listed as exon 9 in source) mutations are associated with weak or no resistance to cetuximab."	20619739	PubMed		"De Roock et al., 2010, Lancet Oncol."		3	accepted	2217	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/2217	https://civicdb.org/links/molecular_profiles/104	FALSE	PIK3CA	5290	E545K		chr3	179218303	179218303	G	A	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.1633G>A,NP_006209.2:p.Glu545Lys,ENST00000263967.3:c.1633G>A,NC_000003.11:g.178936091G>A"	2023-01-27 17:02:37 UTC	CA123334	13655	"GLU545LYS,RS104886003"	FALSE
KRAS G12D	79	Colorectal Cancer	9256		"Selumetinib,Dactolisib"	Combination	Predictive	Supports	D	Sensitivity/Response	"In 28 out of 40 (70%) metastatic colorectal cancer tumors harboring KRAS, NRAS, BRAF or PIK3CA mutations and implanted into mice, the therapeutic combination of the MEK inhibitor AZD6244 and the PI3K/mTor inhibitor BEZ235 resulted in disease stabilization. Mean tumor growth was lower in the tumors treated with AZD6244+ BEZ235 (+77% vs. +267%, P=1E-6) compared to AZD6244 alone and (+77% vs. +222%, P=0.0014) BEZ235 alone. 32/40 tumors studied had KRAS mutations with 9 G12D (2 with PIK3CA H1047R) and 13 other G12 mutations."	22392911	PubMed		"Migliardi et al., 2012, Clin. Cancer Res."		3	accepted	2218	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/2218	https://civicdb.org/links/molecular_profiles/79	FALSE	KRAS	3845	G12D	EGFR TKI Resistance	chr12	25245350	25245350	C	T	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.35G>A,NP_004976.2:p.Gly12Asp,NC_000012.11:g.25398284C>T,ENST00000256078.4:c.35G>A"	2023-01-27 17:02:26 UTC	CA122538	12582	"GLY12ASP,RS121913529"	FALSE
KRAS G12V	421	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	B	Resistance	"This was a retrospective study of 691 cetuximab treated patients with metastatic colorectal cancer. Of those, 39 patients harbored KRAS G12V, were BRAF, NRAS and PIK3CA wt, and had individual response data. Three patients had partial response, 16 had stable disease, and 20 progressed. Treatments included cetuximab + irinotecan (n=30), cetuximab + FOLFIRI (n=2), cetuximab monotherapy (n=2), cetuximab + oxaliplatin + 5FU (n=2), cetuximab + 5FU (n=1), cetuximab + irinotecan + oxaliplatin + 5FU + bevacizumab (n=1), and cetuximab+irinotecan+oxaliplatin+5FU (n=1). Median PFS was 12 weeks (1-37 weeks), median OS was 32 weeks (4-77 weeks), and median number of previous chemotherapy lines was 2 (0-5). Median age was 63 years old (34-76), and there were 21 males and 18 females. Authors concluded that KRAS mutation was strongly associated with poor response to cetuximab and suggested that mutation status of KRAS is the most informative compared to BRAF, NRAS, and PIK3CA exon 20 for predicting cetuximab response."	20619739	PubMed		"De Roock et al., 2010, Lancet Oncol."		3	accepted	2219	Somatic	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/2219	https://civicdb.org/links/molecular_profiles/421	FALSE	KRAS	3845	G12V		chr12	25245350	25245350	C	A	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.35G>T,NP_004976.2:p.Gly12Val,NC_000012.11:g.25398284C>A,ENST00000256078.4:c.35G>T"	2023-01-27 17:03:41 UTC	CA122540	12583	"GLY12VAL,RS121913529"	FALSE
ATM T2666A	875	Chronic Lymphocytic Leukemia	1040		Doxorubicin		Predictive	Supports	D	Resistance	"Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. Cells were treated with doxorubicin to induce double-strand (DSB) and p21 induction was monitored by qPCR. To confirm wild type p53, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for adequate p21 induction. A patient sample had the T2666A variant of ATM, confirmed by sanger sequencing, in trans with a loss of function 11q deletion found in 91% of cells by FISH. Western blot showed null ATM expression. Treatment with doxorubicin resulted in a p21 expression level of less than 300% that of untreated wild-type controls. This was much lower than the median expression level of treated controls which was 815% that of untreated controls, supporting resistance."	23585524	PubMed		"Navrkalova et al., 2013, Haematologica"		3	accepted	2221	Somatic	2023-01-09 21:46:39 UTC	https://civicdb.org/links/evidence_items/2221	https://civicdb.org/links/molecular_profiles/875	FALSE	ATM	472	T2666A		chr11	108333954	108333954	A	G	ENST00000278616.4	75		missense_variant	NC_000011.9:g.108204681A>G	2023-01-27 17:06:30 UTC	CA349494	219594		FALSE
ATM Mutation	178	Chronic Lymphocytic Leukemia	1040		Doxorubicin		Predictive	Supports	D	Resistance	"Primary cells from chronic lymphocytic leukemia patients were treated with doxorubicin to induce double-strand (DSB). In this setting, cells harboring rare ATM variants (n=8) had significantly higher viability, measured by mitochondrial dehydrogenase activity, compared to wildtype cells (n=8, p < 0.001) suggesting resistance. A qPCR functional assay showed that samples with rare ATM variants (n= 20) had significantly less p21 expression after treatment with doxorubicin compared to treated wildtype controls (n=31, p < 0.001). Furthermore, there was significantly decreased expression of BBC3, BAX, and GADD45 genes which are downstream of ATM in the DNA damage response. In the above studies, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for p21 induction to confirm wildtype p53."	23585524	PubMed		"Navrkalova et al., 2013, Haematologica"		4	accepted	2222	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/2222	https://civicdb.org/links/molecular_profiles/178	FALSE	ATM	472	Mutation		chr11	108222832	108369099			ENST00000278616.4	75		"transcription_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
ATM R3008C	877	Chronic Lymphocytic Leukemia	1040		Doxorubicin		Predictive	Supports	D	Resistance	"Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. The effect of the R3008C variant on ATM expression was tested by western blot, and the effect on ATM function was tested by treating with doxorubicin to induce double-strand breaks (DSB) and monitoring p21 induction. To confirm wild type p53, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for adequate p21 induction. In a patient sample with the R3008C variant of ATM in trans with a wild-type allele, confirmed by sanger sequencing, western blot showed stable ATM expression. Treatment with doxorubicin resulted in a p21 expression level of less than 300% that of untreated wild-type controls. This was much lower than the median expression level of treated controls which was 815% that of untreated controls, supporting resistance. The authors propose that this variant has a dominant-negative effect."	23585524	PubMed		"Navrkalova et al., 2013, Haematologica"		3	accepted	2223	Somatic	2023-01-09 21:46:39 UTC	https://civicdb.org/links/evidence_items/2223	https://civicdb.org/links/molecular_profiles/877	FALSE	ATM	472	R3008C		chr11	108365359	108365359	C	T	ENST00000278616.4	75		missense_variant	NC_000011.9:g.108236086C>T	2023-01-27 17:06:32 UTC	CA294307			FALSE
KRAS A146P	879	Colorectal Cancer	9256		"Cetuximab,Irinotecan"	Combination	Predictive	Supports	C	Resistance	"In a retrospective study of 68 irinotecan-refractory metastatic colorectal cancer patients, one patient's tumor harbored a KRAS codon 146 mutation but was wildtype for BRAF, and KRAS codons 12, 13, and 61. This patient did not respond to irinotecan and cetuximab combination therapy and experienced progression free survival (PFS) lasting less than 10 months and overall survival (OS) lasting less than 30 months. Median PFS for patients with BRAF, KRAS G12/G13 wildtype tumors harboring mutations in either KRAS codon 146 (n=1) or KRAS codon 61 (n=7) was lower than patients whose tumors were additionally wildtype for KRAS A146 and Q61 (PFS: 3.8 vs 5.3mo, p= 0.023), though there wasn't a significant difference in overall survival (OS: 9.7 vs 14.8 mo, p=0.320)."	19603018	PubMed		"Loupakis et al., 2009, Br. J. Cancer"		3	accepted	2225	Somatic	2023-01-09 21:46:39 UTC	https://civicdb.org/links/evidence_items/2225	https://civicdb.org/links/molecular_profiles/879	FALSE	KRAS	3845	A146P		chr12	25225628	25225628	C	G	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.436G>C,NP_004976.2:p.Ala146Pro,NC_000012.11:g.25378562C>G,ENST00000256078.4:c.436G>C"	2023-01-27 17:06:33 UTC	CA16602441	375963	"RS121913527,ALA146PRO"	FALSE
KRAS G12/G13	77	Colorectal Cancer	9256				Prognostic	Does Not Support	B	Poor Outcome	"In a retrospective study of 427 chemotherapy-refractory metastatic colorectal patients treated with either panitumumab monotherapy or best supportive care (BSC), KRAS codon 12 or 13 mutations were observed in 43% of the tumor samples. The effect of BSC on PFS was the same in the KRAS mutant group as in the KRAS wildtype group (7.3 vs 7.3 weeks), suggesting that the presence of KRAS mutations does not support worse outcome compared to wildtype KRAS."	18316791	PubMed		"Amado et al., 2008, J. Clin. Oncol."	"NCT00113763,NCT00113776"	3	accepted	2231	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/2231	https://civicdb.org/links/molecular_profiles/77	FALSE	KRAS	3845	G12/G13		chr12	25245346	25245351			ENST00000256078.4	75		protein_altering_variant		2023-01-09 21:52:04 UTC		"45,122,125,781,258,200,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000"		FALSE
KRAS G12V	421	Colorectal Cancer	9256		Panitumumab		Predictive	Supports	C	Resistance	"In a retrospective study of 427 metastatic colorectal patients, KRAS mutations were observed in 43% of the tumor samples. Patients with mutations in codon 12 or 13 of KRAS were associated with reduced response to panitumumab compared to wildtype KRAS (HR:0.99, 95% CI:0.73-1.36 vs. HR:0.45, 95% CI:0.34-0.59; P<0.0001). Additionally, patients with KRAS mutations showed no significant improvement between treatment with panitumumab and best supportive care alone (PFS: 7.4 wk vs 7.3 wk)."	18316791	PubMed		"Amado et al., 2008, J. Clin. Oncol."	"NCT00113763,NCT00113776"		accepted	2232	Somatic	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/2232	https://civicdb.org/links/molecular_profiles/421	FALSE	KRAS	3845	G12V		chr12	25245350	25245350	C	A	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.35G>T,NP_004976.2:p.Gly12Val,NC_000012.11:g.25398284C>A,ENST00000256078.4:c.35G>T"	2023-01-27 17:03:41 UTC	CA122540	12583	"GLY12VAL,RS121913529"	FALSE
KRAS G12D	79	Colorectal Cancer	9256		Panitumumab		Predictive	Supports	C	Resistance	"In a retrospective study of 427 metastatic colorectal patients, KRAS mutations were observed in 43% of the tumor samples. Patients with mutations in codon 12 or 13 of KRAS were associated with reduced response to panitumumab compared to wildtype KRAS (HR:0.99, 95% CI:0.73-1.36 vs. HR:0.45, 95% CI:0.34-0.59; P<0.0001). Additionally, patients with KRAS mutations showed no significant improvement between treatment with panitumumab and best supportive care alone (PFS: 7.4 wk vs 7.3 wk)."	18316791	PubMed		"Amado et al., 2008, J. Clin. Oncol."	"NCT00113763,NCT00113776"		accepted	2236	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/2236	https://civicdb.org/links/molecular_profiles/79	FALSE	KRAS	3845	G12D	EGFR TKI Resistance	chr12	25245350	25245350	C	T	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.35G>A,NP_004976.2:p.Gly12Asp,NC_000012.11:g.25398284C>T,ENST00000256078.4:c.35G>A"	2023-01-27 17:02:26 UTC	CA122538	12582	"GLY12ASP,RS121913529"	FALSE
KRAS G12D	79	Lung Cancer	1324		Gefitinib		Predictive	Supports	B	Resistance	"In recurrent lung cancer patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib, patients with KRAS mutations had a lower frequency of partial response (PR) and stable disease (SD) and a higher rate of progressive disease (PD) (PR:0, SD:1, PD:15 vs. PR:24, SD:8, PD:14; P=0.0274) compared to wildtype KRAS patients. Patients with KRAS mutations also had a shorter overall survival compared to wildtype KRAS patients (HR:2.542, 95% CI:1.048-6.168, P=0.0390)."	17409929	PubMed		"Endoh et al., 2006, J Thorac Oncol"		2	accepted	2240	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/2240	https://civicdb.org/links/molecular_profiles/79	FALSE	KRAS	3845	G12D	EGFR TKI Resistance	chr12	25245350	25245350	C	T	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.35G>A,NP_004976.2:p.Gly12Asp,NC_000012.11:g.25398284C>T,ENST00000256078.4:c.35G>A"	2023-01-27 17:02:26 UTC	CA122538	12582	"GLY12ASP,RS121913529"	FALSE
KRAS Mutation	332	Lung Non-small Cell Carcinoma	3908		Erlotinib		Predictive	Supports	B	Resistance	"In advanced-stage (IIIB or IV) non-small cell lung cancer patients treated with erlotinib and placebo, patients whose tumors harbored KRAS mutations (n=8) had a lower 12-week progression-free survival rate (0% vs. 37%, P=0.0390) compared to wildtype KRAS patients (n=35). Authors concluded that KRAS mutation was associated with poor response to erlotinib monotherapy."	22025157	PubMed		"Ramalingam et al., 2011, J. Clin. Oncol."	NCT00760929	2	accepted	2242	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/2242	https://civicdb.org/links/molecular_profiles/332	FALSE	KRAS	3845	Mutation		chr12	25209431	25250803			ENST00000256078.4	75		protein_altering_variant		2023-01-09 21:52:06 UTC		N/A		FALSE
KRAS G12D	79	Multiple Myeloma	9538		Melphalan		Predictive	Supports	B	Resistance	"In a study of patients receiving melphalan-based therapy, those with KRAS codon 12 mutations were less likely to have a positive response than those with wildtype KRAS (26.9% vs. 58.3%, P=0.015)."	19284554	PubMed		"Greco et al., 2009, J. Exp. Clin. Cancer Res."		2	accepted	2247	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/2247	https://civicdb.org/links/molecular_profiles/79	FALSE	KRAS	3845	G12D	EGFR TKI Resistance	chr12	25245350	25245350	C	T	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.35G>A,NP_004976.2:p.Gly12Asp,NC_000012.11:g.25398284C>T,ENST00000256078.4:c.35G>A"	2023-01-27 17:02:26 UTC	CA122538	12582	"GLY12ASP,RS121913529"	FALSE
KRAS G12D	79	Multiple Myeloma	9538		Melphalan		Predictive	Supports	D	Resistance	"In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS."	11050000	PubMed		"Rowley et al., 2000, Blood"		2	accepted	2250	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/2250	https://civicdb.org/links/molecular_profiles/79	FALSE	KRAS	3845	G12D	EGFR TKI Resistance	chr12	25245350	25245350	C	T	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.35G>A,NP_004976.2:p.Gly12Asp,NC_000012.11:g.25398284C>T,ENST00000256078.4:c.35G>A"	2023-01-27 17:02:26 UTC	CA122538	12582	"GLY12ASP,RS121913529"	FALSE
KRAS G12D	79	Multiple Myeloma	9538		Melphalan		Predictive	Supports	D	Resistance	"In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS."	12483530	PubMed		"Rowley et al., 2002, Oncogene"			accepted	2251	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/2251	https://civicdb.org/links/molecular_profiles/79	FALSE	KRAS	3845	G12D	EGFR TKI Resistance	chr12	25245350	25245350	C	T	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.35G>A,NP_004976.2:p.Gly12Asp,NC_000012.11:g.25398284C>T,ENST00000256078.4:c.35G>A"	2023-01-27 17:02:26 UTC	CA122538	12582	"GLY12ASP,RS121913529"	FALSE
KRAS G12D	79	Multiple Myeloma	9538		Melphalan		Predictive	Supports	D	Resistance	"In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS."	16497971	PubMed		"Hoang et al., 2006, Blood"		2	accepted	2252	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/2252	https://civicdb.org/links/molecular_profiles/79	FALSE	KRAS	3845	G12D	EGFR TKI Resistance	chr12	25245350	25245350	C	T	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.35G>A,NP_004976.2:p.Gly12Asp,NC_000012.11:g.25398284C>T,ENST00000256078.4:c.35G>A"	2023-01-27 17:02:26 UTC	CA122538	12582	"GLY12ASP,RS121913529"	FALSE
KRAS G12C	78	Colorectal Cancer	9256		Panitumumab		Predictive	Supports	C	Resistance	"In a retrospective study of 427 metastatic colorectal patients, KRAS mutations were observed in 43% of the tumor samples. Patients with mutations in codon 12 or 13 of KRAS were associated with reduced response to panitumumab compared to wildtype KRAS (HR:0.99, 95% CI:0.73-1.36 vs. HR:0.45, 95% CI:0.34-0.59; P<0.0001). Additionally, patients with KRAS mutations showed no significant improvement between treatment with panitumumab and best supportive care alone (PFS: 7.4 wk vs 7.3 wk)."	18316791	PubMed		"Amado et al., 2008, J. Clin. Oncol."	"NCT00113763,NCT00113776"		accepted	2253	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/2253	https://civicdb.org/links/molecular_profiles/78	FALSE	KRAS	3845	G12C	EGFR TKI Resistance	chr12	25245351	25245351	C	A	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.34G>T,NP_004976.2:p.Gly12Cys,NC_000012.11:g.25398285C>A,ENST00000256078.4:c.34G>T"	2023-01-27 17:02:26 UTC	CA122528	12578	"GLY12CYS,RS121913530"	FALSE
KRAS G12C	78	Lung Cancer	1324		Gefitinib		Predictive	Supports	B	Resistance	"In recurrent lung cancer patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib, patients with KRAS mutations had a lower frequency of partial response (PR) and stable disease (SD) and a higher rate of progressive disease (PD) (PR:0, SD:1, PD:15 vs. PR:24, SD:8, PD:14; P=0.0274) compared to wildtype KRAS patients. Patients with KRAS mutations also had a shorter overall survival compared to wildtype KRAS patients (HR:2.542, 95% CI:1.048-6.168, P=0.0390)."	17409929	PubMed		"Endoh et al., 2006, J Thorac Oncol"		2	accepted	2257	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/2257	https://civicdb.org/links/molecular_profiles/78	FALSE	KRAS	3845	G12C	EGFR TKI Resistance	chr12	25245351	25245351	C	A	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.34G>T,NP_004976.2:p.Gly12Cys,NC_000012.11:g.25398285C>A,ENST00000256078.4:c.34G>T"	2023-01-27 17:02:26 UTC	CA122528	12578	"GLY12CYS,RS121913530"	FALSE
KRAS G12C	78	Multiple Myeloma	9538		Melphalan		Predictive	Supports	B	Resistance	"In a study of patients receiving melphalan-based therapy, those with KRAS codon 12 mutations were less likely to have a positive response than those with wildtype KRAS (26.9% vs. 58.3%, P=0.015)."	19284554	PubMed		"Greco et al., 2009, J. Exp. Clin. Cancer Res."			accepted	2258	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/2258	https://civicdb.org/links/molecular_profiles/78	FALSE	KRAS	3845	G12C	EGFR TKI Resistance	chr12	25245351	25245351	C	A	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.34G>T,NP_004976.2:p.Gly12Cys,NC_000012.11:g.25398285C>A,ENST00000256078.4:c.34G>T"	2023-01-27 17:02:26 UTC	CA122528	12578	"GLY12CYS,RS121913530"	FALSE
KRAS G12C	78	Multiple Myeloma	9538		Melphalan		Predictive	Supports	D	Resistance	"In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS."	11050000	PubMed		"Rowley et al., 2000, Blood"		2	accepted	2261	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/2261	https://civicdb.org/links/molecular_profiles/78	FALSE	KRAS	3845	G12C	EGFR TKI Resistance	chr12	25245351	25245351	C	A	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.34G>T,NP_004976.2:p.Gly12Cys,NC_000012.11:g.25398285C>A,ENST00000256078.4:c.34G>T"	2023-01-27 17:02:26 UTC	CA122528	12578	"GLY12CYS,RS121913530"	FALSE
KRAS G12C	78	Multiple Myeloma	9538		Melphalan		Predictive	Supports	D	Resistance	"In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS."	12483530	PubMed		"Rowley et al., 2002, Oncogene"			accepted	2262	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/2262	https://civicdb.org/links/molecular_profiles/78	FALSE	KRAS	3845	G12C	EGFR TKI Resistance	chr12	25245351	25245351	C	A	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.34G>T,NP_004976.2:p.Gly12Cys,NC_000012.11:g.25398285C>A,ENST00000256078.4:c.34G>T"	2023-01-27 17:02:26 UTC	CA122528	12578	"GLY12CYS,RS121913530"	FALSE
KRAS G12C	78	Multiple Myeloma	9538		Melphalan		Predictive	Supports	D	Resistance	"In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS."	16497971	PubMed		"Hoang et al., 2006, Blood"		2	accepted	2263	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/2263	https://civicdb.org/links/molecular_profiles/78	FALSE	KRAS	3845	G12C	EGFR TKI Resistance	chr12	25245351	25245351	C	A	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.34G>T,NP_004976.2:p.Gly12Cys,NC_000012.11:g.25398285C>A,ENST00000256078.4:c.34G>T"	2023-01-27 17:02:26 UTC	CA122528	12578	"GLY12CYS,RS121913530"	FALSE
KRAS G12R	526	Colorectal Cancer	9256		Panitumumab		Predictive	Supports	C	Resistance	"In a retrospective study of 427 metastatic colorectal patients, KRAS mutations were observed in 43% of the tumor samples. Patients with mutations in codon 12 or 13 of KRAS were associated with reduced response to panitumumab compared to wildtype KRAS (HR:0.99, 95% CI:0.73-1.36 vs. HR:0.45, 95% CI:0.34-0.59; P<0.0001). Additionally, patients with KRAS mutations showed no significant improvement between treatment with panitumumab and best supportive care alone (PFS: 7.4 wk vs 7.3 wk)."	18316791	PubMed		"Amado et al., 2008, J. Clin. Oncol."	"NCT00113763,NCT00113776"		accepted	2264	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/2264	https://civicdb.org/links/molecular_profiles/526	FALSE	KRAS	3845	G12R		chr12	25245351	25245351	C	G	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.34G>C,NP_004976.2:p.Gly12Arg,NC_000012.11:g.25398285C>G,ENST00000256078.4:c.34G>C"	2023-01-27 17:04:11 UTC	CA122531	12579	"GLY12ARG,RS121913530"	FALSE
KRAS G12V	421	Lung Cancer	1324		Gefitinib		Predictive	Supports	C	Resistance	"In recurrent lung cancer patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib, patients with KRAS mutations had a lower frequency of partial response (PR) and stable disease (SD) and a higher rate of progressive disease (PD) (PR:0, SD:1, PD:15 vs. PR:24, SD:8, PD:14; P=0.0274) compared to wildtype KRAS patients. Patients with KRAS mutations also had a shorter overall survival compared to wildtype KRAS patients (HR:2.542, 95% CI:1.048-6.168, P=0.0390)."	17409929	PubMed		"Endoh et al., 2006, J Thorac Oncol"		2	accepted	2268	Somatic	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/2268	https://civicdb.org/links/molecular_profiles/421	FALSE	KRAS	3845	G12V		chr12	25245350	25245350	C	A	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.35G>T,NP_004976.2:p.Gly12Val,NC_000012.11:g.25398284C>A,ENST00000256078.4:c.35G>T"	2023-01-27 17:03:41 UTC	CA122540	12583	"GLY12VAL,RS121913529"	FALSE
KRAS G12S	887	Colorectal Cancer	9256		Panitumumab		Predictive	Supports	C	Resistance	"In a retrospective study of 427 metastatic colorectal patients, KRAS mutations were observed in 43% of the tumor samples. Patients with mutations in codon 12 or 13 of KRAS were associated with reduced response to panitumumab compared to wildtype KRAS (HR:0.99, 95% CI:0.73-1.36 vs. HR:0.45, 95% CI:0.34-0.59; P<0.0001). Additionally, patients with KRAS mutations showed no significant improvement between treatment with panitumumab and best supportive care alone (PFS: 7.4 wk vs 7.3 wk)."	18316791	PubMed		"Amado et al., 2008, J. Clin. Oncol."	"NCT00113763,NCT00113776"		accepted	2269	Somatic	2023-01-09 21:46:39 UTC	https://civicdb.org/links/evidence_items/2269	https://civicdb.org/links/molecular_profiles/887	FALSE	KRAS	3845	G12S		chr12	25245351	25245351	C	T	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.34G>A,NP_004976.2:p.Gly12Ser,NC_000012.11:g.25398285C>T,ENST00000256078.4:c.34G>A"	2023-01-27 17:06:39 UTC	CA135565	12584	"RS121913530,GLY12SER"	FALSE
KRAS G12S	887	Lung Cancer	1324		Gefitinib		Predictive	Supports	B	Resistance	"In recurrent lung cancer patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib, patients with KRAS mutations had a lower frequency of partial response (PR) and stable disease (SD) and a higher rate of progressive disease (PD) (PR:0, SD:1, PD:15 vs. PR:24, SD:8, PD:14; P=0.0274) compared to wildtype KRAS patients. Patients with KRAS mutations also had a shorter overall survival compared to wildtype KRAS patients (HR:2.542, 95% CI:1.048-6.168, P=0.0390)."	17409929	PubMed		"Endoh et al., 2006, J Thorac Oncol"		2	accepted	2273	Somatic	2023-01-09 21:46:39 UTC	https://civicdb.org/links/evidence_items/2273	https://civicdb.org/links/molecular_profiles/887	FALSE	KRAS	3845	G12S		chr12	25245351	25245351	C	T	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.34G>A,NP_004976.2:p.Gly12Ser,NC_000012.11:g.25398285C>T,ENST00000256078.4:c.34G>A"	2023-01-27 17:06:39 UTC	CA135565	12584	"RS121913530,GLY12SER"	FALSE
KRAS G12S	887	Multiple Myeloma	9538		Melphalan		Predictive	Supports	B	Resistance	"In a study of patients receiving melphalan-based therapy, those with KRAS codon 12 mutations were less likely to have a positive response than those with wildtype KRAS (26.9% vs. 58.3%, P=0.015)."	19284554	PubMed		"Greco et al., 2009, J. Exp. Clin. Cancer Res."			accepted	2274	Somatic	2023-01-09 21:46:39 UTC	https://civicdb.org/links/evidence_items/2274	https://civicdb.org/links/molecular_profiles/887	FALSE	KRAS	3845	G12S		chr12	25245351	25245351	C	T	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.34G>A,NP_004976.2:p.Gly12Ser,NC_000012.11:g.25398285C>T,ENST00000256078.4:c.34G>A"	2023-01-27 17:06:39 UTC	CA135565	12584	"RS121913530,GLY12SER"	FALSE
KRAS G12S	887	Multiple Myeloma	9538		Melphalan		Predictive	Supports	D	Resistance	"In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS."	11050000	PubMed		"Rowley et al., 2000, Blood"		2	accepted	2277	Somatic	2023-01-09 21:46:39 UTC	https://civicdb.org/links/evidence_items/2277	https://civicdb.org/links/molecular_profiles/887	FALSE	KRAS	3845	G12S		chr12	25245351	25245351	C	T	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.34G>A,NP_004976.2:p.Gly12Ser,NC_000012.11:g.25398285C>T,ENST00000256078.4:c.34G>A"	2023-01-27 17:06:39 UTC	CA135565	12584	"RS121913530,GLY12SER"	FALSE
KRAS G12S	887	Multiple Myeloma	9538		Melphalan		Predictive	Supports	D	Resistance	"In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS."	12483530	PubMed		"Rowley et al., 2002, Oncogene"		2	accepted	2278	Somatic	2023-01-09 21:46:39 UTC	https://civicdb.org/links/evidence_items/2278	https://civicdb.org/links/molecular_profiles/887	FALSE	KRAS	3845	G12S		chr12	25245351	25245351	C	T	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.34G>A,NP_004976.2:p.Gly12Ser,NC_000012.11:g.25398285C>T,ENST00000256078.4:c.34G>A"	2023-01-27 17:06:39 UTC	CA135565	12584	"RS121913530,GLY12SER"	FALSE
KRAS G12S	887	Multiple Myeloma	9538		Melphalan		Predictive	Supports	D	Resistance	"In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS."	16497971	PubMed		"Hoang et al., 2006, Blood"		2	accepted	2279	Somatic	2023-01-09 21:46:39 UTC	https://civicdb.org/links/evidence_items/2279	https://civicdb.org/links/molecular_profiles/887	FALSE	KRAS	3845	G12S		chr12	25245351	25245351	C	T	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.34G>A,NP_004976.2:p.Gly12Ser,NC_000012.11:g.25398285C>T,ENST00000256078.4:c.34G>A"	2023-01-27 17:06:39 UTC	CA135565	12584	"RS121913530,GLY12SER"	FALSE
TP53 R273L	892	Ovarian Cancer	2394		"Cisplatin,Carboplatin"	Substitutes	Predictive	Supports	C	Resistance	"Ovarian cancer patients with TP53 missense mutations were refractory to platinum-based chemotherapy (66% vs. 34% in wildtype, P=0.008) and had a shorter time to disease progression (n=54, P=0.037). A study of ovarian carcinoma patients (n=178) reported a reduced overall survival (HR:1.59, 95% CI:1.09-2.33, P=0.014) for patients with mutations in TP53."	11595686	PubMed		"Reles et al., 2001, Clin. Cancer Res."			accepted	2286	Somatic	2023-01-09 21:46:40 UTC	https://civicdb.org/links/evidence_items/2286	https://civicdb.org/links/molecular_profiles/892	FALSE	TP53	7157	R273L		chr17	7673802	7673802	C	A	ENST00000269305.4	75		missense_variant	"NM_000546.5:c.818G>T,NP_000537.3:p.Arg273Leu,NC_000017.10:g.7577120C>A,ENST00000269305.4:c.818G>T"	2023-01-27 17:06:40 UTC	CA001530	376655	"RS28934576,ARG273LEU"	FALSE
TP53 R273C	121	Stomach Carcinoma	5517		"Cisplatin,Etoposide,Mitomycin"	Combination	Predictive	Does Not Support	C	Sensitivity/Response	"A female patient taking part in a 25 patient gastric cancer trial was diagnosed at age 46, and received preoperative high dose chemotherapy (HDCT). Japanese Society for Gastric Cancer Response Score was 0. Resection was performed on patients with greater than 50% size reduction of the lesion. This patient did not undergo resection, and had on overall survival of 7.4 months."	14514923	PubMed		"Bataille et al., 2003, MP, Mol. Pathol."		3	accepted	2292	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/2292	https://civicdb.org/links/molecular_profiles/121	FALSE	TP53	7157	R273C		chr17	7673803	7673803	G	A	ENST00000269305.4	75		missense_variant	"NM_000546.5:c.817C>T,NP_000537.3:p.Arg273Cys,NC_000017.10:g.7577121G>A,ENST00000269305.4:c.817C>T"	2023-01-27 17:02:47 UTC	CA000432	43594	"ARG273CYS,RS121913343"	FALSE
TP53 Y220C	896	Stomach Carcinoma	5517		"Etoposide,Cisplatin,Mitomycin"	Combination	Predictive	Supports	C	Sensitivity/Response	"A male patient taking part in a 25 patient gastric cancer trial was diagnosed at age 50, harbored a TP53 mutation and received preoperative high dose chemotherapy (HDCT). Japanese Society for Gastric Cancer Response Score was 2. Resection was performed on patients with >50% size reduction of the lesion. Consistent with response to preoperative chemotherapy, this patient did undergo resection, and had an overall survival of 12.6 months."	14514923	PubMed		"Bataille et al., 2003, MP, Mol. Pathol."		3	accepted	2306	Somatic	2023-01-09 21:46:40 UTC	https://civicdb.org/links/evidence_items/2306	https://civicdb.org/links/molecular_profiles/896	FALSE	TP53	7157	Y220C		chr17	7674872	7674872	T	C	ENST00000269305.4	75		missense_variant	"NM_000546.5:c.659A>G,NP_000537.3:p.Tyr220Cys,NC_000017.10:g.7578190T>C,ENST00000269305.4:c.659A>G"	2023-01-27 17:06:41 UTC	CA000315	127819	"RS121912666,TYR220CYS"	FALSE
TP53 R175H	116	Stomach Carcinoma	5517		EAP Protocol		Predictive	Supports	C	Sensitivity/Response	"In a study of 25 patients with advanced gastric cancer, mutations in TP53 were identified in 32% of primary tumors. TP53 mutations were associated with an improved response to preoperative treatment of a modified EAP protocol (combination of doxorubicin, etoposide and cisplatin). Patients with mutations in TP53 had an increased median survival compared to patients with wildtype TP53 (18.5mo vs. 10.2mo, P=0.044)."	14514923	PubMed		"Bataille et al., 2003, MP, Mol. Pathol."			accepted	2310	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/2310	https://civicdb.org/links/molecular_profiles/116	FALSE	TP53	7157	R175H		chr17	7675088	7675088	C	T	ENST00000269305.4	75		missense_variant	"NM_000546.5:c.524G>A,NP_000537.3:p.Arg175His,NC_000017.10:g.7578406C>T,ENST00000269305.4:c.524G>A"	2023-01-27 17:02:43 UTC	CA000251	12374	"ARG175HIS,RS28934578,R43H,R136H"	FALSE
IDH1 R132C	59	Brain Glioma	60108		Temozolomide		Predictive	Supports	B	Sensitivity/Response	"In a study of 189 low-grade gliomas, IDH (IDH1 or IDH2) mutations were found in 132 patients (70%). IDH mutations were associated with improved rate of response to temozolomide as compared to patients with wildtype IDH (61%  vs. 17% , P=0.01)."	20975057	PubMed		"Houillier et al., 2010, Neurology"		2	accepted	2327	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/2327	https://civicdb.org/links/molecular_profiles/59	FALSE	IDH1	3417	R132C		chr2	208248389	208248389	G	A	ENST00000415913.1	75		missense_variant	"NM_005896.3:c.394C>T,NP_005887.2:p.Arg132Cys,NC_000002.11:g.209113113G>A,ENST00000415913.1:c.394C>T"	2023-01-27 17:02:19 UTC	CA16602374	375891	"RS121913499,ARG132CYS"	FALSE
IDH1 R132C	59	High Grade Glioma	3070		AGI-5198		Predictive	Supports	D	Sensitivity/Response	"In an experimental in vitro study, glioma cells expressing IDH1 R132C were associated with sensitivity to AGI-5198 (IC50: 0.16M vs. IC50 > 100.00M), as compared to cells expressing wild-type IDH1. Sensitivity was determined by assessing cell growth."	23558169	PubMed		"Rohle et al., 2013, Science"		2	accepted	2329	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/2329	https://civicdb.org/links/molecular_profiles/59	FALSE	IDH1	3417	R132C		chr2	208248389	208248389	G	A	ENST00000415913.1	75		missense_variant	"NM_005896.3:c.394C>T,NP_005887.2:p.Arg132Cys,NC_000002.11:g.209113113G>A,ENST00000415913.1:c.394C>T"	2023-01-27 17:02:19 UTC	CA16602374	375891	"RS121913499,ARG132CYS"	FALSE
IDH1 R132C	59	Acute Myeloid Leukemia	9119		Ivosidenib		Predictive	Supports	B	Sensitivity/Response	"In a clinical study of 17 relapsed or refractory AML patients harboring IDH1 mutations, these patients were associated with response to AG-120 monotherapy; 4/7 patients who achieved a response experienced complete remission."	25583779	PubMed		"2015, Cancer Discov"		2	accepted	2331	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/2331	https://civicdb.org/links/molecular_profiles/59	FALSE	IDH1	3417	R132C		chr2	208248389	208248389	G	A	ENST00000415913.1	75		missense_variant	"NM_005896.3:c.394C>T,NP_005887.2:p.Arg132Cys,NC_000002.11:g.209113113G>A,ENST00000415913.1:c.394C>T"	2023-01-27 17:02:19 UTC	CA16602374	375891	"RS121913499,ARG132CYS"	FALSE
IDH1 R132C	59	Acute Myeloid Leukemia	9119		BPTES		Predictive	Supports	D	Sensitivity/Response	"In an experimental study of acute myeloid leukemia (AML) cell lines expressing IDH1 R132C, IDH1 R132G, or IDH1 R132H mutations were associated with increased sensitivity to small molecule glutaminase inhibitor, bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES) as compared to AML cell lines expressing wild-type IDH1. Sensitivity was determined by assessing cell growth."	24333121	PubMed		"Emadi et al., 2014, Exp. Hematol."		3	accepted	2332	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/2332	https://civicdb.org/links/molecular_profiles/59	FALSE	IDH1	3417	R132C		chr2	208248389	208248389	G	A	ENST00000415913.1	75		missense_variant	"NM_005896.3:c.394C>T,NP_005887.2:p.Arg132Cys,NC_000002.11:g.209113113G>A,ENST00000415913.1:c.394C>T"	2023-01-27 17:02:19 UTC	CA16602374	375891	"RS121913499,ARG132CYS"	FALSE
PIK3CA C420R	905	Her2-receptor Positive Breast Cancer	60079		Trastuzumab Emtansine		Predictive	Does Not Support	D	Resistance	"As part of a pre-clinical experiment, the efficacy of ado-trastuzumab emtansine (T-DM1) was compared to that of trastuzumab against various HER2 positive cell lines. EFM-192A cell line expressing PIK3CA C420R was associated with similar sensitivity to T-DM1 as PIK3CA wild-type cell line SK-BR-3; substantially reduced cell viability was observed at concentrations > 0.01 ug/mL in both cell lines. Conversely, when treated with trastuzumab, the cell line harboring PIK3CA C420R experienced a smaller reduction in cell viability."	26920887	PubMed		"Baselga et al., 2016, Clin. Cancer Res."		3	accepted	2346	Somatic	2023-01-09 21:46:40 UTC	https://civicdb.org/links/evidence_items/2346	https://civicdb.org/links/molecular_profiles/905	FALSE	PIK3CA	5290	C420R		chr3	179210192	179210192	T	C	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.1258T>C,NP_006209.2:p.Cys420Arg,NC_000003.11:g.178927980T>C,ENST00000263967.3:c.1258T>C"	2023-01-27 17:06:45 UTC	CA180900	31945	"RS121913272,CYS420ARG"	FALSE
PIK3CA Mutation	307	Lung Non-small Cell Carcinoma	3908		"Gefitinib,Erlotinib"	Substitutes	Predictive	Supports	B	Resistance	"In a retrospective study, 166 non-small cell lung cancer (NSCLC) patients that tended to have selected characteristics known to be predictive for TKI sensitivity (i.e. women, never smokers, and patients with ADC) were treated with either gefitinib or erlotinib. PIK3CA mutations (n=6) were associated with no difference in objective response to drug treatment (16.6% vs. 35.2%, p=0.61), shorter overall survival (9.9 vs. 30.2 months, p<0.001), and shorter median time to progression (2.3 vs. 6.0 months, p=0.01) when compared to wild-type PIK3CA. Through multivariate analyses, it was shown that PIK3CA mutations are significant predictors of worse overall survival (HR: 5.81, 95% CI: 2.43-13.91, p=0.0001) and shorter time to progression (HR: 2.71 95% CI: 1.23-4.79, p=0.03)."	21258250	PubMed		"Ludovini et al., 2011, J Thorac Oncol"		3	accepted	2355	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/2355	https://civicdb.org/links/molecular_profiles/307	FALSE	PIK3CA	5290	Mutation		chr3	179148523	179240093			ENST00000263967.3	75		"transcript_variant,gain_of_function_variant"		2023-01-09 21:52:06 UTC		N/A		FALSE
KRAS Exon 2 Mutation	75	Colorectal Cancer	9256				Prognostic	Does Not Support	B	Poor Outcome	"This retrospective study examines outcomes of 158 primary sporadic colorectal cancer patients who had undergone surgical resection and were treated with 5-fluorouracil based chemotherapy. KRAS exon 2 mutations (listed as KRAS exon 1 as it was common at the time of source publication to exclude non-coding exon 1) were not associated with differences in disease specific survival compared to wt KRAS (n = 50 mutant, n = 108 wt; p =0.6077) or in relapse free survival. Authors noted that the tumors of 6 patients harbored both PIK3CA and KRAS mutations, but stated that the presence of PIK3CA mutations did not correlate with the presence of KRAS mutations."	17590872	PubMed		"Kato et al., 2007, Int. J. Cancer"		3	accepted	2361	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/2361	https://civicdb.org/links/molecular_profiles/75	FALSE	KRAS	3845	Exon 2 Mutation		chr12	25245274	25245395			ENST00000256078.4	75		missense_variant		2023-01-09 21:52:04 UTC				FALSE
BRAF V600E	12	Colorectal Cancer	9256				Prognostic	Does Not Support	C	Poor Outcome	This study examined outcomes of 240 rectum cancer patients treated with total mesorectal excision therapy. Tumor samples were obtained at the time of surgery and genotyped for BRAF exon 15 mutations. BRAF V600E was identified in 5 cases. The authors reported that no differences were found in overall survival between patients with and without BRAF mutations (P > 0.1).	19903786	PubMed		"He et al., 2009, Clin. Cancer Res."		2	accepted	2362	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/2362	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
KRAS Mutation	332	Lung Non-small Cell Carcinoma	3908		"Gefitinib,Erlotinib"	Substitutes	Predictive	Supports	B	Resistance	"In a retrospective study, 166 non-small cell lung cancer (NSCLC) patients that tended to have selected characteristics known to be predictive for TKI sensitivity (i.e. women, never smokers, and patients with ADC) were treated with either gefitinib or erlotinib. KRAS mutations (n=11) were associated with lack of objective response to drug treatment (0.0% vs. 35.7%, p=0.03), no significant difference in overall survival (19.3 vs. 28.6 months, p=0.47), and shorter median time to progression (2.7 vs. 5.6 months, p=0.003) when compared to wild-type KRAS. Through multivariate analyses, it was shown that KRAS mutations were significant predictors of shorter time to progression (HR: 2.43, 95% CI: 1.23-4.79, p=0.01)."	21258250	PubMed		"Ludovini et al., 2011, J Thorac Oncol"		3	accepted	2385	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/2385	https://civicdb.org/links/molecular_profiles/332	FALSE	KRAS	3845	Mutation		chr12	25209431	25250803			ENST00000256078.4	75		protein_altering_variant		2023-01-09 21:52:06 UTC		N/A		FALSE
KIT F506_F508DUP	2494	Gastrointestinal Stromal Tumor	9253		Imatinib		Predictive	Does Not Support	C	Sensitivity/Response	This patient was part of a larger cohort of 397 patients with incurable (i.e. metastatic or unresectable) CD117-positive Gastrointestinal stromal tumors (GISTs) enrolled in the North American phase III study SWOG S0033/CALGB 150105. Patients in the study were treated with either 400mg or 800mg of imatinib per day. This patient's GIST harbored a tandem reduplication of KIT codons 506 to 508 (FAF) after F508 (F506_F508dup). The patient's response to imatinib was not assessed but the TTP was 10.6 months.	18955451	PubMed		"Heinrich et al., 2008, J. Clin. Oncol."		1	accepted	2441	Somatic	2023-01-09 21:47:00 UTC	https://civicdb.org/links/evidence_items/2441	https://civicdb.org/links/molecular_profiles/2494	FALSE	KIT	3815	F506_F508DUP		chr4	54726026	54726034		TTTGCATTT	ENST00000288135.5	75			"p.Phe506_Phe508dup,c.55592192_55592200dup"	2023-01-09 21:52:20 UTC				FALSE
KIT N822H	961	Cancer	162		Imatinib		Predictive	Does Not Support	D	Resistance	"In an in vitro study of imatinib sensitivity, KIT N822H was cloned into a plasmid by site-directed mutagenesis of KIT WT cDNA. Chinese hamster ovary cells were transiently transfected with the plasmid. Cells were treated with control media or media containing various concentrations of imatinib for 90 minutes. Protein lysates from the transfected cells were examined for phosphorylated tyrosine, a measure of KIT activation. Cells expressing KIT N822H were as sensitive to imatinib as ligand activated wildtype KIT (IC50: 100-200 nmol/L)."	14645423	PubMed		"Heinrich et al., 2003, J. Clin. Oncol."		2	accepted	2445	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/2445	https://civicdb.org/links/molecular_profiles/961	FALSE	KIT	3815	N822H	KIT Exon 17	chr4	54733172	54733172	A	C				missense_variant		2023-01-27 17:07:25 UTC	CA356911968			FALSE
KIT N822K	1237	Cancer	162		Imatinib		Predictive	Does Not Support	D	Sensitivity/Response	"In an in vitro study of imatinib sensitivity, KIT N822K was cloned into a plasmid by site-directed mutagenesis of KIT WT cDNA. Chinese hamster ovary cells were transiently transfected with the plasmid. Cells were treated with control media or media containing various concentrations of imatinib for 90 minutes. Protein lysates from the transfected cells were examined for phosphorylated tyrosine, a measure of KIT activation. Cells expressing KIT N822K were as sensitive to imatinib as ligand activated wildtype KIT (IC50: 100-200 nmol/L)."	14645423	PubMed		"Heinrich et al., 2003, J. Clin. Oncol."		2	accepted	2448	Somatic	2023-01-09 21:46:44 UTC	https://civicdb.org/links/evidence_items/2448	https://civicdb.org/links/molecular_profiles/1237	FALSE	KIT	3815	N822K	KIT Exon 17	chr4	54733174	54733174	T	A	ENST00000288135.5	75		missense_variant	"NM_000222.2:c.2466T>A,NP_000213.1:p.Asn822Lys,NC_000004.11:g.55599340T>A,ENST00000288135.5:c.2466T>A"	2023-01-27 17:09:06 UTC	CA16602411	375931	"ASN822LYS,RS121913514"	FALSE
KIT D816V	65	Cancer	162		Imatinib		Predictive	Supports	D	Resistance	"In an in vitro study of imatinib sensitivity, KIT D816V was cloned into a plasmid by site-directed mutagenesis of KIT WT cDNA. Chinese hamster ovary cells were transiently transfected with the plasmid. Cells were treated with control media or media containing various concentrations of imatinib for 90 minutes. Protein lysates from the transfected cells were examined for phosphorylated tyrosine, a measure of KIT activation. Cells expressing KIT D816V were resistant to imatinib up to 10 umol/L."	14645423	PubMed		"Heinrich et al., 2003, J. Clin. Oncol."		2	accepted	2451	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/2451	https://civicdb.org/links/molecular_profiles/65	FALSE	KIT	3815	D816V	KIT Exon 17	chr4	54733155	54733155	A	T	ENST00000288135.5	75		missense_variant	"NM_000222.2:c.2447A>T,NP_000213.1:p.Asp816Val,ENST00000288135.5:c.2447A>T,NC_000004.11:g.55599321A>T"	2023-01-27 17:02:23 UTC	CA123513	13852	"ASP816VAL,RS121913507"	FALSE
PDGFRA V561D	915	Cancer	162		Imatinib		Predictive	Does Not Support	D	Resistance	"In an in vitro study of imatinib sensitivity, PDGFRA V561D was cloned into a plasmid by site-directed mutagenesis of PDGFRA WT cDNA. Chinese hamster ovary cells were transiently transfected with the plasmid. The cells were treated with control media or media containing various concentrations of imatinib for 90 minutes. Protein lysates from the transfected cells were examined for phosphorylated tyrosine, a measure of PDGFRA activation. Cells expressing PDGFRA V561D were as sensitive to imatinib as ligand activated wildtype PDGFRA (IC50: 100-200 nmol/L)."	14645423	PubMed		"Heinrich et al., 2003, J. Clin. Oncol."		2	accepted	2454	Somatic	2023-01-09 21:46:40 UTC	https://civicdb.org/links/evidence_items/2454	https://civicdb.org/links/molecular_profiles/915	FALSE	PDGFRA	5156	V561D		chr4	54274869	54274869	T	A	ENST00000257290.5	75		missense_variant	"NM_006206.5:c.1682T>A,NP_006197.1:p.Val561Asp,NC_000004.11:g.55141036T>A,ENST00000257290.5:c.1682T>A"	2023-01-27 17:06:52 UTC	CA123203	13546	RS121908586	FALSE
PDGFRA D842V	99	Cancer	162		Imatinib		Predictive	Supports	D	Resistance	"In an in vitro study of imatinib sensitivity, PDGFRA D842V was cloned into a plasmid by site-directed mutagenesis of PDGFRA WT cDNA. Chinese hamster ovary cells were transiently transfected with the plasmid. The cells were treated with control media or media containing various concentrations of imatinib for 90 minutes. Protein lysates from the transfected cells were examined for phosphorylated tyrosine, a measure of PDGFRA activation. Cells expressing PDGFRA D842V required 10-20 fold higher concentrations of imatinib as ligand activated wildtype PDGFRA (IC50: 1-2 umol/L)."	14645423	PubMed		"Heinrich et al., 2003, J. Clin. Oncol."		2	accepted	2463	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/2463	https://civicdb.org/links/molecular_profiles/99	FALSE	PDGFRA	5156	D842V	Imatinib Resistance	chr4	54285926	54285926	A	T	ENST00000257290.5	75		missense_variant	"NM_006206.4:c.2525A>T,NP_006197.1:p.Asp842Val,ENST00000257290.5:c.2525A>T,NC_000004.11:g.55152093A>T"	2023-01-27 17:02:33 UTC	CA123194	13543	"ASP842VAL,RS121908585"	FALSE
KIT Exon 9 Mutation	505	Gastrointestinal Stromal Tumor	9253		Imatinib		Predictive	Supports	B	Sensitivity/Response	"This prospective study of 127 patients with metastatic gastrointestinal stromal tumors (GISTs) examined the relationship between KIT genotype and treatment outcome for patients enrolled in a randomized phase II trial of imatinib (CSTI571B 2222). 23 patients harbored KIT exon 9 mutated GISTs: 22 harbored A502_503Ydup and 1 harbored F506_F508dup. Of patients harboring KIT exon 9 mutated GISTs, 11 (47.8%) had a partial response, 6 had stable disease, 4 had progressive disease and 2 were nonassessable. Patients with KIT exon 9 mutant GISTs were significantly more likely to have a partial response than those with WT KIT (P = .013), though significantly less likely than those with KIT exon 11 mutated GISTs (P = .0006). Patients harboring KIT exon 9 mutant GISTs experienced longer event free survival (median: 200 days) than those with WT KIT GISTs (82 days). Furthermore, there was a signficant difference in overall survival between patients with KIT exon 9 mutant and double WT kinase GISTs (P = .0067). There was no significant difference in the rate of treatment failure for patients with exon 9 mutation compared with those with no KIT or PDGFRA mutation (P = .14)."	14645423	PubMed		"Heinrich et al., 2003, J. Clin. Oncol."		3	accepted	2466	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/2466	https://civicdb.org/links/molecular_profiles/505	FALSE	KIT	3815	Exon 9 Mutation		chr4	54725857	54726050			ENST00000288135.5	75		exon_variant		2023-01-09 21:52:07 UTC				FALSE
KIT V560G	946	Cancer	162		Imatinib		Predictive	Does Not Support	D	Resistance	"In an in vitro study of imatinib sensitivity, KIT V560G was cloned into a plasmid by site-directed mutagenesis of KIT WT cDNA. Chinese hamster ovary cells were transiently transfected with the plasmid. The cells were treated with control media or media containing various concentrations of imatinib for 90 minutes. Protein lysates from the transfected cells were examined for the presence of phosphorylated tyrosine, a measure of KIT activation. Cells expressing KIT V560G were as sensitive to imatinib as ligand activated wildtype KIT (IC50: 100-200 nmol/L)."	14645423	PubMed		"Heinrich et al., 2003, J. Clin. Oncol."		2	accepted	2469	Somatic	2023-01-09 21:46:40 UTC	https://civicdb.org/links/evidence_items/2469	https://civicdb.org/links/molecular_profiles/946	FALSE	KIT	3815	V560G		chr4	54727447	54727447	T	G	ENST00000288135.5	75		missense_variant	"NM_000222.2:c.1679T>G,NP_000213.1:p.Val560Gly,NC_000004.11:g.55593613T>G,ENST00000288135.5:c.1679T>G"	2023-01-27 17:07:14 UTC	CA16602398	"375,916,376,735"	"RS121913521,VAL560GLY"	FALSE
KIT Exon 11 Mutation	66	Gastrointestinal Stromal Tumor	9253		Imatinib		Predictive	Supports	B	Sensitivity/Response	"This prospective study of 397 patients with incurable (i.e. metastatic or unresectable) CD117-positive Gastrointestinal stromal tumors (GISTs) examined the relationship between KIT genotype and treatment outcome for patients enrolled in the North American phase III study SWOG S0033/CALGB 150105 who were treated with either 400mg or 800mg of imatinib per day. The study found that patients whose tumors harbored mutations in KIT exon 11 had signficantly superior responses to imatinib, regardless of dose,  than those whose tumors harbored wildtype KIT or KIT exon 9 mutations. This is evidenced by the findings that imatinib-treated patients whose tumors contained KIT exon 11 mutations had longer overall survival compared to those with exon 9 mutations (60.0mo vs.38.4mo, P=0.011) or wildtype KIT (60mo vs. 49.0mo, P=0.049). Patients with exon 11 mutations had improved progression-free survival in comparison to those with exon 9 mutations (24.7mo vs. 16.7mo, P=0.0013) or wildtype KIT (24.7mo vs. 12.8mo, P=0.005)."	18955451	PubMed		"Heinrich et al., 2008, J. Clin. Oncol."		4	accepted	2471	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/2471	https://civicdb.org/links/molecular_profiles/66	FALSE	KIT	3815	Exon 11 Mutation	KIT Exon 11	chr4	54727416	54727542			ENST00000288135.5	75		coding_sequence_variant		2023-01-09 21:52:04 UTC				FALSE
KIT K642E	952	Cancer	162		Imatinib		Predictive	Does Not Support	D	Resistance	"In an in vitro study of imatinib sensitivity, KIT K642E was cloned into a plasmid by site-directed mutagenesis of KIT WT cDNA. Chinese hamster ovary cells were transiently transfected with the plasmid. Cells were treated with control media or media containing various concentrations of imatinib for 90 minutes. Then, protein lysates from the transfected cells were examined for phosphorylated tyrosine, a measure of KIT activation. Cells expressing KIT K642E were as sensitive to imatinib as ligand activated wildtype KIT (IC50: 100-200 nmol/L)."	14645423	PubMed		"Heinrich et al., 2003, J. Clin. Oncol."		2	accepted	2472	Somatic	2023-01-09 21:46:40 UTC	https://civicdb.org/links/evidence_items/2472	https://civicdb.org/links/molecular_profiles/952	FALSE	KIT	3815	K642E		chr4	54728055	54728055	A	G	ENST00000288135.5	75		missense_variant	"NM_000222.2:c.1924A>G,NP_000213.1:p.Lys642Glu,NC_000004.11:g.55594221A>G,ENST00000288135.5:c.1924A>G"	2023-01-27 17:07:18 UTC	CA123547	13866	"RS121913512,LYS642GLU"	FALSE
PDGFRA V561D	915	Gastrointestinal Stromal Tumor	9253		Imatinib		Predictive	Supports	C	Sensitivity/Response	"This case study examines one patient from a larger cohort of 397 patients with incurable (i.e. metastatic or unresectable) CD117-positive Gastrointestinal stromal tumors (GISTs) enrolled in the North American phase III study SWOG S0033/CALGB 150105. Patients in this cohort were treated with either 400mg or 800mg of imatinib per day. This patient's GIST harbored PDGFRA exon 12 V561D. The patient was treated with 800mg of imatinib per day, and had not progressed or died as of 31 months of follow up (vs median TTP of 12.8 months for WT)."	18955451	PubMed		"Heinrich et al., 2008, J. Clin. Oncol."		1	accepted	2474	Somatic	2023-01-09 21:46:40 UTC	https://civicdb.org/links/evidence_items/2474	https://civicdb.org/links/molecular_profiles/915	FALSE	PDGFRA	5156	V561D		chr4	54274869	54274869	T	A	ENST00000257290.5	75		missense_variant	"NM_006206.5:c.1682T>A,NP_006197.1:p.Val561Asp,NC_000004.11:g.55141036T>A,ENST00000257290.5:c.1682T>A"	2023-01-27 17:06:52 UTC	CA123203	13546	RS121908586	FALSE
KIT Exon 13 Mutation	2512	Gastrointestinal Stromal Tumor	9253		Imatinib		Predictive	Supports	C	Sensitivity/Response	"This prospective study of 127 patients with metastatic gastrointestinal stromal tumors (GISTs) examined the relationship between kinase (KIT and PDGFRA) genotype and treatment outcome for patients enrolled in a randomized phase II trial of imatinib (CSTI571B 2222). Two patients' GISTs harbored KIT exon 13 mutations, and both experienced partial responses to imatinib. The authors conclude that this uncommon variant is sensitive to imatinib."	14645423	PubMed		"Heinrich et al., 2003, J. Clin. Oncol."		2	accepted	2475	Somatic	2023-01-09 21:47:01 UTC	https://civicdb.org/links/evidence_items/2475	https://civicdb.org/links/molecular_profiles/2512	FALSE	KIT	3815	Exon 13 Mutation		chr4	54728011	54728121			ENST00000288135.5	75				2023-01-09 21:52:20 UTC				FALSE
KIT Exon 9 Mutation	505	Gastrointestinal Stromal Tumor	9253		Imatinib		Predictive	Supports	B	Reduced Sensitivity	"This prospective study of 397 patients with incurable (i.e. metastatic or unresectable) CD117-positive Gastrointestinal stromal tumors (GISTs) examined the relationship between KIT genotype and treatment outcome for patients enrolled in the North American phase III study SWOG S0033/CALGB 150105 who were treated with either 400mg or 800mg of imatinib per day. Of 33 patients with KIT exon-9 mutant GISTs, 31 harbored KIT A502_Y503 internal tandom duplication, one harbored K484_G487del (KHNG).  Of the KIT exon 9 mutant patients, 14 were treated with 400mg daily and 19 were treated with 800mg daily. Patients with KIT exon-9 mutant GISTs had a significantly higher response rate when treated with 800mg compared with 400mg (CR/PR 17% vs 67% for 400mg and 800mg, respectively; OR, 9.05; p = .02). However, the authors report that there was not a significant difference in time to progression or overall survival between the two dose groups for patients harboring KIT exon-9 mutant GISTs."	18955451	PubMed		"Heinrich et al., 2008, J. Clin. Oncol."		2	accepted	2477	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/2477	https://civicdb.org/links/molecular_profiles/505	FALSE	KIT	3815	Exon 9 Mutation		chr4	54725857	54726050			ENST00000288135.5	75		exon_variant		2023-01-09 21:52:07 UTC				FALSE
PDGFRA D842V	99	Gastrointestinal Stromal Tumor	9253		Imatinib		Predictive	Supports	C	Resistance	This prospective study of 127 patients with metastatic gastrointestinal stromal tumors (GISTs) examined the relationship between kinase (KIT and PDGFRA) genotype and treatment outcome for patients enrolled in a randomized phase II trial of imatinib (CSTI571B 2222). Three patients' GISTs harbored PDGFRA D842V. Two of these patients experienced progressive disease and one was unassessable. The authors conclude that this finding is consistent with the work of others suggesting that PDGFRA D842V is an imatinib resistant variant in GIST.	14645423	PubMed		"Heinrich et al., 2003, J. Clin. Oncol."		2	accepted	2478	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/2478	https://civicdb.org/links/molecular_profiles/99	FALSE	PDGFRA	5156	D842V	Imatinib Resistance	chr4	54285926	54285926	A	T	ENST00000257290.5	75		missense_variant	"NM_006206.4:c.2525A>T,NP_006197.1:p.Asp842Val,ENST00000257290.5:c.2525A>T,NC_000004.11:g.55152093A>T"	2023-01-27 17:02:33 UTC	CA123194	13543	"ASP842VAL,RS121908585"	FALSE
KIT EXPRESSION	425	Gastrointestinal Stromal Tumor	9253		Imatinib		Predictive	Supports	B	Sensitivity/Response	"In a prospective phase III study (SWOG S0033/CALGB 150105) of 407 patients with gastrointestinal stromal tumors (GISTs), 397 patients were observed to be CD117-positive (i.e. KIT-positive) and 10 patients were CD117-negative. Patients were treated with either 400mg or 800mg of imatinib per day. When compared to CD117-positive, GISTs, CD117-negative GISTs did not show significant difference in median time to progression (18.3 months vs. 20.5 months; P = 0.46), however, CD-117-negative GISTs showed reduced overall survival relative to CD-117-positive GISTs (25.8 months vs. 57.1 months; P= 0.01)."	18955451	PubMed		"Heinrich et al., 2008, J. Clin. Oncol."		2	accepted	2480	Somatic	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/2480	https://civicdb.org/links/molecular_profiles/425	FALSE	KIT	3815	EXPRESSION		chr4	54657918	54740715			ENST00000288135.5	75		N/A		2023-01-09 21:52:07 UTC		N/A		FALSE
KIT W557_K558del	935	Cancer	162		Imatinib		Predictive	Does Not Support	D	Resistance	"In an in vitro study of imatinib sensitivity, KIT W557_K558del was cloned into a plasmid by site-directed mutagenesis of KIT WT cDNA. Chinese hamster ovary cells were transiently transfected with the plasmid. Cells were treated with control media or media containing various concentrations of imatinib for 90 minutes. Protein lysates from the transfected cells were examined for phosphorylated tyrosine, a measure of KIT activation. Cells expressing KIT W557_K558del were as sensitive to imatinib as ligand activated wildtype KIT (IC50: 100-200 nmol/L)."	14645423	PubMed		"Heinrich et al., 2003, J. Clin. Oncol."		2	accepted	2481	Somatic	2023-01-09 21:46:40 UTC	https://civicdb.org/links/evidence_items/2481	https://civicdb.org/links/molecular_profiles/935	FALSE	KIT	3815	W557_K558del		chr4	54727437	54727442	TGGAAG		ENST00000288135.5	75		conservative_inframe_deletion		2023-01-27 17:07:05 UTC	CA356974	222957		FALSE
KIT Y503_F504insAY	920	Cancer	162		Imatinib		Predictive	Does Not Support	D	Resistance	"In an in vitro study of imatinib sensitivity, KIT Y503_F504insAY was cloned into a plasmid by site-directed mutagenesis of KIT WT cDNA. Chinese hamster ovary cells were transiently transfected with the plasmid. Cells were treated with control media or media containing various concentrations of imatinib for 90 minutes. Then, protein lysates from the transfected cells were examined for phosphorylated tyrosine, a measure of KIT activation. Cells expressing KIT Y503_F504insAY were as sensitive to imatinib as ligand activated wildtype KIT (IC50: 100-200 nmol/L)."	14645423	PubMed		"Heinrich et al., 2003, J. Clin. Oncol."		2	accepted	2484	Somatic	2023-01-09 21:46:40 UTC	https://civicdb.org/links/evidence_items/2484	https://civicdb.org/links/molecular_profiles/920	FALSE	KIT	3815	Y503_F504insAY		chr4	54726019	54726020		GCCTAT	ENST00000288135.5	75		inframe_insertion	NC_000004.11:g.55592185_55592186insGCCTAT	2023-01-27 17:06:53 UTC	CA645516719			FALSE
BRAF V600E	12	Thyroid Gland Papillary Carcinoma	3969				Prognostic	Supports	B	Poor Outcome	"In a meta-analysis of 8 studies, papillary thyroid cancer patients with BRAF V600E mutation had a higher frequency of recurrence and persistent disease compared to those with wildtype BRAF (28.5%  vs. 12.8% ,  Risk ratio:2.14, 95%CI:1.67-2.74, P<0.00001)."	21882184	PubMed		"Kim et al., 2012, Cancer"		3	accepted	2503	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/2503	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
BRAF V600K	559	Melanoma	1909		Dabrafenib		Predictive	Supports	B	Sensitivity/Response	"Patients were treated with a specific RAF inhibitor (dabrafenib), which improved overall survival of patients with BRAF mutations (P<0.003), compared to non-treated patients with BRAF mutations. Patients having BRAF mutations were associated with reduced overall survival (11.1 mo vs. 46.1 mo for wild-type, P=0.006). BRAF mutations were more frequent in tumors with superficially spreading histological sub-type (43%  vs. 19% , P<0.001) compared to BRAF wild-type tumors."	21343559	PubMed		"Long et al., 2011, J. Clin. Oncol."			accepted	2505	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/2505	https://civicdb.org/links/molecular_profiles/559	FALSE	BRAF	673	V600K	Other BRAF V600's	chr7	140753336	140753337	AC	TT	ENST00000288602.6	75		missense_variant	"ENST00000288602.6:c.1798_1799delinsAA,NC_000007.13:g.140453136_140453137delinsTT,NM_004333.4:c.1798_1799delGTinsAA,NP_004324.2:p.Val600Lys"	2023-01-27 17:04:21 UTC	CA16602420	375941	"VAL600LYS,RS121913227"	FALSE
BRAF V600K	559	Melanoma	1909		Trametinib		Predictive	Supports	B	Sensitivity/Response	"In a study of 322 advanced melanoma patients with BRAF-V600E (N=281), BRAF-V600K (N=40), or both mutations (N=1), treatment with trametinib was associated with improved progression-free survival (4.8mo vs. 1.5mo; HR: 0.45, 95% CI: 0.33-0.63, P<0.001) compared to chemotherapy control group. Additionally, treatment with trametinib was associated with increased 6-month overall survival (HR: 0.54, 95% CI: 0.32-0.92, P=0.01). The authors note similar outcomes for the primary efficacy population (V600E only) and the intention-to-treat population, however, sub-group analysis for patients with V600K did not show significant improvement in PFS (HR: 0.50, 95% CI:0.18-1.35)."	22663011	PubMed		"Flaherty et al., 2012, N. Engl. J. Med."	NCT01245062	2	accepted	2506	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/2506	https://civicdb.org/links/molecular_profiles/559	FALSE	BRAF	673	V600K	Other BRAF V600's	chr7	140753336	140753337	AC	TT	ENST00000288602.6	75		missense_variant	"ENST00000288602.6:c.1798_1799delinsAA,NC_000007.13:g.140453136_140453137delinsTT,NM_004333.4:c.1798_1799delGTinsAA,NP_004324.2:p.Val600Lys"	2023-01-27 17:04:21 UTC	CA16602420	375941	"VAL600LYS,RS121913227"	FALSE
EGFR G719A	973	Lung Non-small Cell Carcinoma	3908		Gefitinib		Predictive	Supports	C	Sensitivity/Response	"In a study of 297 non-small cell lung cancer patients, 15% of the analyzed tumors had  EGFR mutations including deletions in exon 19 (n=22), L858R (n=16) and G719A (n=2). Patients with EGFR mutations treated with gefitinib were associated with improved response rates (42.1% vs. 6.6%, P=0.04) compared to wildtype EGFR patients."	20038723	PubMed		"Douillard et al., 2010, J. Clin. Oncol."	NCT00076388		accepted	2508	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/2508	https://civicdb.org/links/molecular_profiles/973	FALSE	EGFR	1956	G719A		chr7	55174015	55174015	G	C	ENST00000275493.2	75		missense_variant	"NM_005228.4:c.2156G>C,NP_005219.2:p.Gly719Ala,NC_000007.13:g.55241708G>C,ENST00000275493.2:c.2156G>C"	2023-01-27 17:07:33 UTC	CA135775	45225	"RS121913428,GLY719ALA"	FALSE
EGFR Wildtype	2050	Lung Non-small Cell Carcinoma	3908		Gefitinib		Predictive	Supports	B	Resistance	"In a phase 3 clinical trial of East Asian pulmonary adenocarcinoma patients, a subset of patients with EGFR mutations (n=261) treated with gefitinib were associated with improved response compared to carboplatin plus paclitaxel treatment, but in patients shown to be negative for EGFR mutation (n=176), patients given gefitinib fared worse than those given carboplatin and paclitaxel: Hazard ratio 2.85 (85% CI 2.05-3.98) p<0.001"	19692680	PubMed		"Mok et al., 2009, N. Engl. J. Med."	NCT00322452	4	accepted	2512	Somatic	2023-01-09 21:46:56 UTC	https://civicdb.org/links/evidence_items/2512	https://civicdb.org/links/molecular_profiles/2050	FALSE	EGFR	1956	Wildtype		chr7	55019101	55211628			ENST00000275493.2	75		wild_type		2023-01-09 21:52:17 UTC		N/A		FALSE
EGFR E746_A750del	976	Bronchiolo-alveolar Adenocarcinoma	4926		Erlotinib		Predictive	Supports	C	Sensitivity/Response	"EGFR exons 18-24 were analyzed in 7 patients who had shown a partial response to erlotinib in a phase II trial for bronchioloalveolar carcinoma (BAC, or in situ pulmonary adenocarcinoma). One patient (Patient E2) had the E746_A750del mutation. The patient was a male never smoker, and demonstrated response for 8.5 months. Overall survival was 21+ months as the patient was alive at study end."	15329413	PubMed		"Pao et al., 2004, Proc. Natl. Acad. Sci. U.S.A."		3	accepted	2513	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/2513	https://civicdb.org/links/molecular_profiles/976	FALSE	EGFR	1956	E746_A750del		chr7	55174772	55174786	GGAATTAAGAGAAGC		ENST00000275493.2	75		inframe_deletion		2023-01-27 17:07:34 UTC	CA175996	163343	"RS121913421,E746_A750DELELREA"	FALSE
EGFR Exon 19 Deletion	133	Lung Adenocarcinoma	3910		Gefitinib		Predictive	Supports	B	Sensitivity/Response	"In a phase 3 clinical trial of Korean, never-smoker, lung adenocarcinoma patients, a subset of patients with EGFR mutations (n=42) treated with gefitinib were associated with improved overall response rate compared to gemcitabine plus cisplatin treatment (84.6%, 22/26, vs. 37.5%, 6/16, P=0.002). By contrast, in EGFR mutation negative cases, the response rate was much lower (25.9%, 7/27). The frequency of mutation in exon 19 deletion and L858R was 64.3% (27/42) and 36.4% (16/42), respectively. Exon 19 and L858R mutations were mutually exclusive in this cohort."	22370314	PubMed		"Han et al., 2012, J. Clin. Oncol."		3	accepted	2519	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/2519	https://civicdb.org/links/molecular_profiles/133	FALSE	EGFR	1956	Exon 19 Deletion		chr7	55174722	55174820			ENST00000275493.2	75		inframe_deletion	ENST00000275493.2:c.2185_2283del	2023-01-09 21:52:05 UTC		N/A		FALSE
EGFR Mutation	438	Lung Non-small Cell Carcinoma	3908		Gefitinib		Predictive	Supports	B	Sensitivity/Response	"Mutational profiling was performed on EGFR exons 18-24 from a group of 10 retrospectively chosen patients who had shown partial response or clinical imporvement in response to gefitinib, and in 8 patients who had not shown gefitinib response. 7 of 10 sensitive patients had mutations in EGFR, while none of the 8 gefitinib refractory patients showed EGFR mutation in these exons (p=0.004)"	15329413	PubMed		"Pao et al., 2004, Proc. Natl. Acad. Sci. U.S.A."		3	accepted	2559	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/2559	https://civicdb.org/links/molecular_profiles/438	FALSE	EGFR	1956	Mutation		chr7	55019101	55211628			ENST00000275493.2	75		inframe_variant		2023-01-09 21:52:07 UTC		N/A		FALSE
EGFR L858R	33	Lung Non-small Cell Carcinoma	3908		Gefitinib		Predictive	Supports	B	Sensitivity/Response	"In a phase 3 clinical trial of non-small cell lung cancer (NSCLC) patients, a subset of patients with EGFR mutations (n=44) treated with gefitinib were associated with improved progression free survival (HR: 0.16, 95% CI: 0.05-0.49, P=0.001), and a higher objective response rate (ORR: 42.1% vs 21.1%, p=0.04) compared to patients treated with docetaxel. Of the 44 patients, 22 had an exon 19 deletion, 16 had an L858R mutation, one patient had an exon 20 T790M mutation, two had an exon G719A mutation and four had other mutations."	20038723	PubMed		"Douillard et al., 2010, J. Clin. Oncol."	NCT00076388	4	accepted	2621	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/2621	https://civicdb.org/links/molecular_profiles/33	FALSE	EGFR	1956	L858R		chr7	55191822	55191822	T	G	ENST00000275493.2	75		missense_variant	"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg"	2023-01-27 17:02:04 UTC	CA126713	"16,609,376,282,376,200"	"LEU858ARG,RS121434568"	FALSE
EGFR L858R	33	Lung Adenocarcinoma	3910		Gefitinib		Predictive	Supports	C	Sensitivity/Response	"Mutational profiling was performed on EGFR exons 18-24 from a group of 10 retrospectively chosen patients who had shown partial response or clinical improvement in response to gefitinib. Of 7 tumors with EGFR mutations, 1 was L858R. The patient was a female former smoker who had lung adenocarcinoma histology, and demonstrated response for 5 months, with overall survival 8 months."	15329413	PubMed		"Pao et al., 2004, Proc. Natl. Acad. Sci. U.S.A."		1	accepted	2624	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/2624	https://civicdb.org/links/molecular_profiles/33	FALSE	EGFR	1956	L858R		chr7	55191822	55191822	T	G	ENST00000275493.2	75		missense_variant	"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg"	2023-01-27 17:02:04 UTC	CA126713	"16,609,376,282,376,200"	"LEU858ARG,RS121434568"	FALSE
EGFR E746_A750del	976	Lung Non-small Cell Carcinoma	3908		Gefitinib		Predictive	Supports	D	Sensitivity/Response	"In an in vitro study using PC9 cells (EGFR exon 19 deletion), inhibition of cell viability was used as an assay to determine sensitivity to EGFR tyrosine kinase inhibitors. PC9 cells demonstrated an increased sensitivity to gefitinib (IC50: 23.0 nmol/L vs 200.0 nmol/L) compared to NCI-H2073 cells (EGFR wild type)."	24893891	PubMed		"Cross et al., 2014, Cancer Discov"		2	accepted	2625	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/2625	https://civicdb.org/links/molecular_profiles/976	FALSE	EGFR	1956	E746_A750del		chr7	55174772	55174786	GGAATTAAGAGAAGC		ENST00000275493.2	75		inframe_deletion		2023-01-27 17:07:34 UTC	CA175996	163343	"RS121913421,E746_A750DELELREA"	FALSE
EGFR L858R	33	Lung Non-small Cell Carcinoma	3908		Lapatinib		Predictive	Supports	D	Sensitivity/Response	"In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H3255 cells (EGFR-L858R), inhibition of cell growth was used as an assay to determine sensitivity to reversible tyrosine kinase inhibitor drugs. Cells with an EGFR L858R mutation demonstrated an improved response to lapatinib (IC50: 63nM vs. 534nM) compared to wildtype EGFR cells."	18408761	PubMed		"Li et al., 2008, Oncogene"		3	accepted	2626	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/2626	https://civicdb.org/links/molecular_profiles/33	FALSE	EGFR	1956	L858R		chr7	55191822	55191822	T	G	ENST00000275493.2	75		missense_variant	"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg"	2023-01-27 17:02:04 UTC	CA126713	"16,609,376,282,376,200"	"LEU858ARG,RS121434568"	FALSE
EGFR L858R	33	Lung Non-small Cell Carcinoma	3908		Dacomitinib		Predictive	Supports	D	Sensitivity/Response	"In an in vitro study using NCI-H322 cells (wildtype EGFR) and NCI-H3255 cells (EGFR-L858R), inhibition of cell growth was used as an assay to determine sensitivity to irreversible tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R mutation demonstrated an improved response to Dacomitinib (IC50: 0.007umol/L vs. >10umol/L) compared to wildtype EGFR cells or compared to reversible TKI drug gefitinib (IC50: 0.075umol/L vs. wild-type >10umol/L)."	18089823	PubMed		"Engelman et al., 2007, Cancer Res."		3	accepted	2627	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/2627	https://civicdb.org/links/molecular_profiles/33	FALSE	EGFR	1956	L858R		chr7	55191822	55191822	T	G	ENST00000275493.2	75		missense_variant	"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg"	2023-01-27 17:02:04 UTC	CA126713	"16,609,376,282,376,200"	"LEU858ARG,RS121434568"	FALSE
EGFR L858R	33	Lung Non-small Cell Carcinoma	3908		Neratinib		Predictive	Supports	D	Sensitivity/Response	"In an in vitro study using NCI-H3255 cells (EGFR L858R), inhibition of cell growth was used as an assay to determine sensitivity to tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R mutation demonstrated sensitivity to neratinib (IC50: 0.0049 mol/L) compared to EGFRwt A549 cells (IC50 > 1 mol/L)."	16818618	PubMed		"Shimamura et al., 2006, Cancer Res."		3	accepted	2628	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/2628	https://civicdb.org/links/molecular_profiles/33	FALSE	EGFR	1956	L858R		chr7	55191822	55191822	T	G	ENST00000275493.2	75		missense_variant	"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg"	2023-01-27 17:02:04 UTC	CA126713	"16,609,376,282,376,200"	"LEU858ARG,RS121434568"	FALSE
EGFR L858R	33	Lung Non-small Cell Carcinoma	3908		Afatinib		Predictive	Supports	D	Sensitivity/Response	"In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H3255 cells (EGFR-L858R), inhibition of cell growth was used as an assay to determine sensitivity to irreversible tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R mutation demonstrated an improved response to afatinib (IC50: 0.7nM vs. 60nM) compared to wildtype EGFR cells."	18408761	PubMed		"Li et al., 2008, Oncogene"		2	accepted	2629	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/2629	https://civicdb.org/links/molecular_profiles/33	FALSE	EGFR	1956	L858R		chr7	55191822	55191822	T	G	ENST00000275493.2	75		missense_variant	"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg"	2023-01-27 17:02:04 UTC	CA126713	"16,609,376,282,376,200"	"LEU858ARG,RS121434568"	FALSE
EGFR L858R	33	Lung Non-small Cell Carcinoma	3908		Canertinib		Predictive	Supports	D	Sensitivity/Response	"In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H3255 cells (EGFR-L858R), inhibition of cell growth was used as an assay to determine sensitivity to irreversible tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R mutation demonstrated an improved response to canertinib (IC50: 1nM vs. 198nM) compared to wildtype EGFR cells."	18408761	PubMed		"Li et al., 2008, Oncogene"		3	accepted	2631	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/2631	https://civicdb.org/links/molecular_profiles/33	FALSE	EGFR	1956	L858R		chr7	55191822	55191822	T	G	ENST00000275493.2	75		missense_variant	"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg"	2023-01-27 17:02:04 UTC	CA126713	"16,609,376,282,376,200"	"LEU858ARG,RS121434568"	FALSE
EGFR L858R	33	Lung Non-small Cell Carcinoma	3908		Erlotinib		Predictive	Supports	C	Sensitivity/Response	"In a phase II trial for bronchioloalveolar carcinoma (BAC, or in situ pulmonary adenocarcinoma), EGFR exons 18-24 were analyzed in 7 patients who had shown a partial response to erlotinib. Two patients had the del L858R mutation. One patient was a male former smoker who demonstrated response for 3 months with overall survival of 3.5 months, and the other patient was a female never smoker who had response for 6 months and overall survival of 17+ months as the patient was alive at study end."	15329413	PubMed		"Pao et al., 2004, Proc. Natl. Acad. Sci. U.S.A."		2	accepted	2632	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/2632	https://civicdb.org/links/molecular_profiles/33	FALSE	EGFR	1956	L858R		chr7	55191822	55191822	T	G	ENST00000275493.2	75		missense_variant	"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg"	2023-01-27 17:02:04 UTC	CA126713	"16,609,376,282,376,200"	"LEU858ARG,RS121434568"	FALSE
EGFR L858R	33	Lung Adenocarcinoma	3910		Gefitinib		Predictive	Supports	B	Sensitivity/Response	"In a phase 3 clinical trial of Korean, never-smoker, lung adenocarcinoma patients, a subset of patients with EGFR mutations (n=42) treated with gefitinib were associated with improved overall response rate compared to gemcitabine plus cisplatin treatment (84.6%, 22/26, vs. 37.5%, 6/16, P=0.002). By contrast, in EGFR mutation negative cases, the response rate was much lower (25.9%, 7/27). The frequency of mutation in exon 19 deletion and L858R was 64.3% (27/42) and 36.4% (16/42), respectively. Exon 19 and L858R mutations were mutually exclusive in this cohort."	22370314	PubMed		"Han et al., 2012, J. Clin. Oncol."		3	accepted	2634	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/2634	https://civicdb.org/links/molecular_profiles/33	FALSE	EGFR	1956	L858R		chr7	55191822	55191822	T	G	ENST00000275493.2	75		missense_variant	"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg"	2023-01-27 17:02:04 UTC	CA126713	"16,609,376,282,376,200"	"LEU858ARG,RS121434568"	FALSE
ABL1 BCR::ABL M244V	995	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Does Not Support	C	Resistance	"In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. A late-chronic phase patient had only a partial hematologic response which improved to a major cytogenetic response after dose escalation 18 months after therapy initiation. At months 7 and 8, the M244V was present in 100% of transcripts. No further testing for secondary variants was performed. At 18 months, 25% of cells were Ph-positive, but this did not meet the authors' threshold for loss of MCR which is >65% Ph-positive cells or an increase of 30%."	12623848	PubMed		"Branford et al., 2003, Blood"		3	accepted	2636	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/2636	https://civicdb.org/links/molecular_profiles/995	FALSE	ABL1	25	BCR::ABL M244V		chr9	130862943	130862943	A	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.730A>G,NP_005148.2:p.Met244Val,NC_000009.11:g.133738330A>G,ENST00000318560.5:c.730A>G"	2023-01-27 17:07:41 UTC	CA16602545	376084	"RS121913456,M263V,MET263VAL,BCR-ABL MET244VAL,BCR-ABL1 M244V,BCR-ABL1 MET244VAL,BCR-ABL M244V"	FALSE
ABL1 BCR::ABL M244V	995	Cancer	162		Imatinib		Predictive	Supports	D	Sensitivity/Response	"A panel of 16 mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL protein and evaluated for antiproliferative activity and substrate or auto-phosphorylation assays. The authors considered the M244V mutation sensitive to imatinib (IC50: 2000 vs. 260 nmol/L, 8x fold change, in a proliferative assay compared to Ba/F3 cells with unmutated BCR-ABL fusions)."	15930265	PubMed		"O'Hare et al., 2005, Cancer Res."		3	accepted	2638	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/2638	https://civicdb.org/links/molecular_profiles/995	FALSE	ABL1	25	BCR::ABL M244V		chr9	130862943	130862943	A	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.730A>G,NP_005148.2:p.Met244Val,NC_000009.11:g.133738330A>G,ENST00000318560.5:c.730A>G"	2023-01-27 17:07:41 UTC	CA16602545	376084	"RS121913456,M263V,MET263VAL,BCR-ABL MET244VAL,BCR-ABL1 M244V,BCR-ABL1 MET244VAL,BCR-ABL M244V"	FALSE
ABL1 BCR::ABL M244V	995	Cancer	162		"Dasatinib,Nilotinib"	Substitutes	Predictive	Does Not Support	D	Resistance	"In an in vitro study, a Ba/F3 cell line stably expressing the M244V mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with similar sensitivity to dasatinib and nilotinib treatment (IC50: 93.1 nM and 891.4 nM) as compared to wild-type BCR-ABL1 expressing Ba/F3 cells (IC50: 87.6 nM and 642.3 nM). Sensitivity was determined by assessing cell proliferation using the MTT assay."	18191450	PubMed		"Deguchi et al., 2008, Leuk. Res."		3	accepted	2640	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/2640	https://civicdb.org/links/molecular_profiles/995	FALSE	ABL1	25	BCR::ABL M244V		chr9	130862943	130862943	A	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.730A>G,NP_005148.2:p.Met244Val,NC_000009.11:g.133738330A>G,ENST00000318560.5:c.730A>G"	2023-01-27 17:07:41 UTC	CA16602545	376084	"RS121913456,M263V,MET263VAL,BCR-ABL MET244VAL,BCR-ABL1 M244V,BCR-ABL1 MET244VAL,BCR-ABL M244V"	FALSE
ABL1 BCR::ABL L248V	996	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	D	Resistance	"A panel of 18 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL protein and were grouped according to their anti-proliferative activity. Mutant cell lines that exhibited a greater than 4-fold increase in IC50 value were considered resistant to drug, 2-4 fold increase in IC50 were moderately resistant and less than 2-fold change in IC50 was sensitive to drug treatment. The L248V mutation was moderately resistant to imatinib."	19075254	PubMed		"Redaelli et al., 2009, J. Clin. Oncol."		2	accepted	2641	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/2641	https://civicdb.org/links/molecular_profiles/996	FALSE	ABL1	25	BCR::ABL L248V		chr9	130862955	130862955	C	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.742C>G,NP_005148.2:p.Leu248Val,NC_000009.11:g.133738342C>G,ENST00000318560.5:c.742C>G"	2023-01-27 17:07:42 UTC	CA16602546	376085	"RS121913455,L267V,LEU248VAL,BCR-ABL L248V"	FALSE
ABL1 BCR::ABL L248V	996	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	C	Resistance	"In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. A late-chronic phase (CP) patient had a complete hematologic response but acquired resistance after 7 months of therapy and discontinued imatinib 3 months later. At month 11, the L248V, G250E, S417Y, E459K variants were present in approximately 25, 25, 25, and 50% of transcripts, respectively. The patient died in myeloid blast crisis at month 14 after a bone marrow transplant."	12623848	PubMed		"Branford et al., 2003, Blood"		2	accepted	2642	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/2642	https://civicdb.org/links/molecular_profiles/996	FALSE	ABL1	25	BCR::ABL L248V		chr9	130862955	130862955	C	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.742C>G,NP_005148.2:p.Leu248Val,NC_000009.11:g.133738342C>G,ENST00000318560.5:c.742C>G"	2023-01-27 17:07:42 UTC	CA16602546	376085	"RS121913455,L267V,LEU248VAL,BCR-ABL L248V"	FALSE
ABL1 BCR::ABL L248V	996	Chronic Myeloid Leukemia	8552		"Dasatinib,Nilotinib,Imatinib Mesylate"	Substitutes	Predictive	Supports	D	Resistance	"In an in vitro study, a Ba/F3-p210BCR-ABL1 cell line was ENU-mutated and exposed to graded concentrations of imatinib, nilotinib or dasatinib to identify resistance mutations. The L248V mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to 2 M imatinib (3 clones recovered, ~2% of viable clones in this treatment), 50nM nilotinib (1 clone, ~2%), and 5nM dasatinib (3 clones, ~9%). In a review of 20 publications, this mutation was described in imatinib resistant patients."	16772610	PubMed		"Bradeen et al., 2006, Blood"		2	accepted	2644	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/2644	https://civicdb.org/links/molecular_profiles/996	FALSE	ABL1	25	BCR::ABL L248V		chr9	130862955	130862955	C	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.742C>G,NP_005148.2:p.Leu248Val,NC_000009.11:g.133738342C>G,ENST00000318560.5:c.742C>G"	2023-01-27 17:07:42 UTC	CA16602546	376085	"RS121913455,L267V,LEU248VAL,BCR-ABL L248V"	FALSE
ABL1 BCR::ABL G250E	997	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	D	Resistance	"A panel of 18 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL protein and were grouped according to their anti-proliferative activity. Mutant cell lines that exhibited a greater than 4-fold increase in IC50 value were considered resistant to drug, 2-4 fold increase in IC50 were moderately resistant and less than 2-fold change in IC50 was sensitive to drug treatment. The G250E mutation was resistant to imatinib."	19075254	PubMed		"Redaelli et al., 2009, J. Clin. Oncol."		3	accepted	2645	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/2645	https://civicdb.org/links/molecular_profiles/997	FALSE	ABL1	25	BCR::ABL G250E		chr9	130862962	130862962	G	A	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.749G>A,NP_005148.2:p.Gly250Glu,NC_000009.11:g.133738349G>A,ENST00000318560.5:c.749G>A"	2023-01-27 17:07:43 UTC	CA16602547	376086	"RS121913453,BCR-ABL G269E,BCR-ABL GLY250GLU,BCR-ABL1 G250E,BCR-ABL1 GLY250GLU,BCR-ABL G250E"	FALSE
ABL1 BCR::ABL G250E	997	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	C	Resistance	"In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. A late-chronic phase (CP) patient had a complete hematologic response (CHR) but acquired resistance 7 months after therapy initiation. At month 11, the L248V, G250E, S417Y, E459K variants were present in approximately 25, 25, 25, and 50% of transcripts, respectively. The patient died in accelerated phase at month 14. An accelerated-phase patient had a CHR but progressed to partial hematologic response concurrent with the appearance of the G250E variant in ~25% of transcripts and the M351T variant in ~50% of transcripts. The patient died at 12 months."	12623848	PubMed		"Branford et al., 2003, Blood"		2	accepted	2646	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/2646	https://civicdb.org/links/molecular_profiles/997	FALSE	ABL1	25	BCR::ABL G250E		chr9	130862962	130862962	G	A	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.749G>A,NP_005148.2:p.Gly250Glu,NC_000009.11:g.133738349G>A,ENST00000318560.5:c.749G>A"	2023-01-27 17:07:43 UTC	CA16602547	376086	"RS121913453,BCR-ABL G269E,BCR-ABL GLY250GLU,BCR-ABL1 G250E,BCR-ABL1 GLY250GLU,BCR-ABL G250E"	FALSE
ABL1 BCR::ABL G250E	997	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	C	Resistance	"In two cell-based studies, a panel of either 18 or 16 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL protein and were grouped according to their anti-proliferative activity. Mutant cell lines that exhibited a greater than 4-fold increase in IC50 value were considered resistant to drug, 2-4 fold increase in IC50 were moderately resistant and less than 2-fold change in IC50 was sensitive to drug treatment. The G250E mutation was  resistant to imatinib ."	15930265	PubMed		"O'Hare et al., 2005, Cancer Res."			accepted	2647	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/2647	https://civicdb.org/links/molecular_profiles/997	FALSE	ABL1	25	BCR::ABL G250E		chr9	130862962	130862962	G	A	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.749G>A,NP_005148.2:p.Gly250Glu,NC_000009.11:g.133738349G>A,ENST00000318560.5:c.749G>A"	2023-01-27 17:07:43 UTC	CA16602547	376086	"RS121913453,BCR-ABL G269E,BCR-ABL GLY250GLU,BCR-ABL1 G250E,BCR-ABL1 GLY250GLU,BCR-ABL G250E"	FALSE
ABL1 BCR::ABL G250E	997	Chronic Myeloid Leukemia	8552		Nilotinib		Predictive	Supports	D	Resistance	"In an in vitro study, a Ba/F3 cell line stably expressing the G250E mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to nilotinib treatment (IC50: 4.56-fold), as compared to Ba/F3 cells expressing BCR-ABL1 fusion protein (reported to be sensitizing to nilotinib). Sensitivity was determined by assessing cell proliferation."	19075254	PubMed		"Redaelli et al., 2009, J. Clin. Oncol."		2	accepted	2648	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/2648	https://civicdb.org/links/molecular_profiles/997	FALSE	ABL1	25	BCR::ABL G250E		chr9	130862962	130862962	G	A	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.749G>A,NP_005148.2:p.Gly250Glu,NC_000009.11:g.133738349G>A,ENST00000318560.5:c.749G>A"	2023-01-27 17:07:43 UTC	CA16602547	376086	"RS121913453,BCR-ABL G269E,BCR-ABL GLY250GLU,BCR-ABL1 G250E,BCR-ABL1 GLY250GLU,BCR-ABL G250E"	FALSE
ABL1 BCR::ABL G250E	997	Cancer	162		Nilotinib		Predictive	Does Not Support	D	Resistance	"In an in vitro study, a Ba/F3 cell line stably expressing the G250E mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with similar sensitivity to nilotinib treatment (IC50: 866 nM) as compared to wild-type BCR-ABL1 expressing Ba/F3 cells (IC50: 642.3 nM). Sensitivity was determined by assessing cell proliferation using the MTT assay."	18191450	PubMed		"Deguchi et al., 2008, Leuk. Res."		3	accepted	2649	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/2649	https://civicdb.org/links/molecular_profiles/997	FALSE	ABL1	25	BCR::ABL G250E		chr9	130862962	130862962	G	A	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.749G>A,NP_005148.2:p.Gly250Glu,NC_000009.11:g.133738349G>A,ENST00000318560.5:c.749G>A"	2023-01-27 17:07:43 UTC	CA16602547	376086	"RS121913453,BCR-ABL G269E,BCR-ABL GLY250GLU,BCR-ABL1 G250E,BCR-ABL1 GLY250GLU,BCR-ABL G250E"	FALSE
ABL1 BCR::ABL Q252H	998	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	D	Sensitivity/Response	"A panel of 18 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL protein and were grouped according to their anti-proliferative activity. Mutant cell lines that exhibited a greater than 4-fold increase in IC50 value were considered resistant to drug, 2-4 fold increase in IC50 were moderately resistant and less than 2-fold change in IC50 was sensitive to drug treatment. The Q252H mutation was sensitive to imatinib."	19075254	PubMed		"Redaelli et al., 2009, J. Clin. Oncol."		3	accepted	2650	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/2650	https://civicdb.org/links/molecular_profiles/998	FALSE	ABL1	25	BCR::ABL Q252H		chr9	130862969	130862969	G	C	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.756G>C,NP_005148.2:p.Gln252His,NC_000009.11:g.133738356G>C,ENST00000318560.5:c.756G>C"	2023-01-27 17:07:44 UTC	CA16602548	376087	"RS121913458,BCR-ABL Q271H,BCR-ABL1 Q252H,BCR-ABL1 GLN252HIS,BCR-ABL Q252H"	FALSE
ABL1 BCR::ABL Q252H	998	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	C	Resistance	"In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. A chronic-phase (CP) patient achieved a complete hematologic response (CHR). The Q252H variant was detected but was absent when the patient progressed to myeloid blast crisis (MBC) with a double Philadelphia chromosome and died. A second CP patient had a partial hematologic response (PHR) with the Q252H and M351T variants. They progressed to MBC and the double Ph-chromosome was later detected without any secondary variants prior to death. The third CP patient had a PHR but became resistant. The Q252H variant was later detected and the patient died in MBC. An accelerated-phase (AP) patient had a CHR but progressed to MBC with the appearance of the Q252H variant. The patient died in MBC after a bone marrow transplant."	12623848	PubMed		"Branford et al., 2003, Blood"		3	accepted	2651	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/2651	https://civicdb.org/links/molecular_profiles/998	FALSE	ABL1	25	BCR::ABL Q252H		chr9	130862969	130862969	G	C	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.756G>C,NP_005148.2:p.Gln252His,NC_000009.11:g.133738356G>C,ENST00000318560.5:c.756G>C"	2023-01-27 17:07:44 UTC	CA16602548	376087	"RS121913458,BCR-ABL Q271H,BCR-ABL1 Q252H,BCR-ABL1 GLN252HIS,BCR-ABL Q252H"	FALSE
ABL1 BCR::ABL Q252H	998	Cancer	162		"Dasatinib,Nilotinib"	Substitutes	Predictive	Does Not Support	D	Resistance	"In an in vitro study, a Ba/F3 cell line stably expressing the Q252H mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with similar sensitivity to dasatinib and nilotinib treatment (IC50: 62.3 nM and 895.5 nM) as compared to wild-type expressing Ba/F3 cells (IC50: 87.6 nM and 642.3 nM). Sensitivity was determined by assessing cell proliferation using the MTT assay."	18191450	PubMed		"Deguchi et al., 2008, Leuk. Res."		3	accepted	2653	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/2653	https://civicdb.org/links/molecular_profiles/998	FALSE	ABL1	25	BCR::ABL Q252H		chr9	130862969	130862969	G	C	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.756G>C,NP_005148.2:p.Gln252His,NC_000009.11:g.133738356G>C,ENST00000318560.5:c.756G>C"	2023-01-27 17:07:44 UTC	CA16602548	376087	"RS121913458,BCR-ABL Q271H,BCR-ABL1 Q252H,BCR-ABL1 GLN252HIS,BCR-ABL Q252H"	FALSE
ABL1 BCR::ABL Y253H	999	Chronic Myeloid Leukemia	8552		"Nilotinib,Imatinib Mesylate"	Substitutes	Predictive	Supports	D	Resistance	"In an in vitro study, a Ba/F3-p210BCR-ABL1 cell line was ENU-mutated and exposed to graded concentrations of imatinib, nilotinib or dasatinib to identify resistance mutations. The Y253H mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to 50nM nilotinib (14 clones recovered, ~30% of viable clones in this treatment), 500nM nilotinib (50 clones, ~63%), and 16 nM imatinib (16 clones; ~48%). Resistant clones were also found at 2, 4, and 8 M imatinib. In a review of 20 publications, this mutation was described in imatinib resistant patients."	16772610	PubMed		"Bradeen et al., 2006, Blood"		3	accepted	2654	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/2654	https://civicdb.org/links/molecular_profiles/999	FALSE	ABL1	25	BCR::ABL Y253H		chr9	130862970	130862970	T	C	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.757T>C,NP_005148.2:p.Tyr253His,NC_000009.11:g.133738357T>C,ENST00000318560.5:c.757T>C"	2023-01-27 17:07:45 UTC	CA122584	12627	"RS121913461,Y272H,TYR272HIS,BCR-ABL TYR253HIS,BCR-ABL1 Y253H,BCR-ABL1 TYR253HIS,BCR-ABL Y253H"	FALSE
ABL1 BCR::ABL Y253F	1000	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	D	Resistance	"A panel of 18 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL protein and were grouped according to their anti-proliferative activity. Mutant cell lines that exhibited a greater than 4-fold increase in IC50 value were considered resistant to drug, 2-4 fold increase in IC50 were moderately resistant and less than 2-fold change in IC50 was sensitive to drug treatment. The Y253F mutation was moderately resistant to imatinib."	19075254	PubMed		"Redaelli et al., 2009, J. Clin. Oncol."		2	accepted	2655	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/2655	https://civicdb.org/links/molecular_profiles/1000	FALSE	ABL1	25	BCR::ABL Y253F		chr9	130862971	130862971	A	T	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"ENST00000318560.5:c.758A>T,NM_005157.5:c.758A>T,NP_005148.2:p.Tyr253Phe,NC_000009.11:g.133738358A>T"	2023-01-27 17:07:45 UTC	CA16602550	376089	"RS121913460,Y272F,TYR253PHE,TYR272PHE,BCR-ABL Y253F"	FALSE
ABL1 BCR::ABL E255V	1147	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	C	Resistance	"In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. An AP patient had a complete hematologic response. After 9 months of therapy, the patient progressed returning to chronic phase. Concurrently, the Y253F and E255V variants were found in ~50% and ~50% of BCR-ABL1 transcripts, respectively. Imatinib was withdrawn at 10 months and the patient died 14 months after treatment initiation."	12623848	PubMed		"Branford et al., 2003, Blood"		3	accepted	2656	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/2656	https://civicdb.org/links/molecular_profiles/1147	FALSE	ABL1	25	BCR::ABL E255V		chr9	130862977	130862977	A	T	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.764A>T,NP_005148.2:p.Glu255Val,NC_000009.11:g.133738364A>T,ENST00000318560.5:c.764A>T"	2023-01-27 17:08:31 UTC	CA16602552	376091	"RS121913449,BCR-ABL E274V,BCR-ABL GLU255VAL,BCR-ABL1 E274V,BCR-ABL1 GLU255VAL,BCR-ABL E255V"	FALSE
ABL1 BCR::ABL Y253F	1000	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	C	Resistance	"In two cell-based studies, a panel of either 18 or 16 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL protein and were grouped according to their anti-proliferative activity. Mutant cell lines that exhibited a greater than 4-fold increase in IC50 value were considered resistant to drug, 2-4 fold increase in IC50 were moderately resistant and less than 2-fold change in IC50 was sensitive to drug treatment. The Y253F mutation was  moderately resistant to imatinib ."	15930265	PubMed		"O'Hare et al., 2005, Cancer Res."			accepted	2657	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/2657	https://civicdb.org/links/molecular_profiles/1000	FALSE	ABL1	25	BCR::ABL Y253F		chr9	130862971	130862971	A	T	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"ENST00000318560.5:c.758A>T,NM_005157.5:c.758A>T,NP_005148.2:p.Tyr253Phe,NC_000009.11:g.133738358A>T"	2023-01-27 17:07:45 UTC	CA16602550	376089	"RS121913460,Y272F,TYR253PHE,TYR272PHE,BCR-ABL Y253F"	FALSE
ABL1 BCR::ABL Y253F	1000	Cancer	162		"Nilotinib,Dasatinib,Bafetinib"	Substitutes	Predictive	Does Not Support	D	Resistance	"In an in vitro study, a Ba/F3 cell line stably expressing the Y253F mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with similar sensitivity to nilotinib, dasatinib, and bafetinib (INNO-406) treatment (IC50: 975.3 nM, 16.8 nM, and 490.8 nM) as compared to wild-type BCR-ABL1 expressing Ba/F3 cells (IC50: 642.3 nM, 87.6 nM, and 152.9 nM). Sensitivity was determined by assessing cell proliferation using the MTT assay."	18191450	PubMed		"Deguchi et al., 2008, Leuk. Res."		3	accepted	2658	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/2658	https://civicdb.org/links/molecular_profiles/1000	FALSE	ABL1	25	BCR::ABL Y253F		chr9	130862971	130862971	A	T	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"ENST00000318560.5:c.758A>T,NM_005157.5:c.758A>T,NP_005148.2:p.Tyr253Phe,NC_000009.11:g.133738358A>T"	2023-01-27 17:07:45 UTC	CA16602550	376089	"RS121913460,Y272F,TYR253PHE,TYR272PHE,BCR-ABL Y253F"	FALSE
ABL1 BCR::ABL D276G	1001	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	D	Resistance	"A panel of 18 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL protein and were grouped according to their anti-proliferative activity. Mutant cell lines that exhibited a greater than 4-fold increase in IC50 value were considered resistant to drug, 2-4 fold increase in IC50 were moderately resistant and less than 2-fold change in IC50 was sensitive to drug treatment. The D276G mutation was moderately resistant to imatinib."	19075254	PubMed		"Redaelli et al., 2009, J. Clin. Oncol."		2	accepted	2663	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/2663	https://civicdb.org/links/molecular_profiles/1001	FALSE	ABL1	25	BCR::ABL D276G		chr9	130872133	130872133	A	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"ENST00000318560.5:c.827A>G,NP_005148.2:p.Asp276Gly,NM_005157.5:c.827A>G,NC_000009.11:g.133747520A>G"	2023-01-27 17:07:46 UTC	CA200645023	NONE FOUND	"RS121913447,BCR-ABL ASP276GLY,BCR-ABL D295G,BCR-ABL1 D295G,BCR-ABL D276G"	FALSE
ABL1 BCR::ABL E355G	1395	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Does Not Support	C	Resistance	"In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. A CP patient had complete cytogenetic response until progressing to accelerated phase with concurrent detection of the E355G variant. After dose escalation, this patient achieved a major cytogenetic response with continued presence of E355G. Another CP patient had a major cytogenetic response to imatinib which was maintained after the detection of the E355G variant."	12623848	PubMed		"Branford et al., 2003, Blood"		3	accepted	2664	Somatic	2023-01-09 21:46:45 UTC	https://civicdb.org/links/evidence_items/2664	https://civicdb.org/links/molecular_profiles/1395	FALSE	ABL1	25	BCR::ABL E355G		chr9	130873016	130873016	A	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.1064A>G,NP_005148.2:p.Glu355Gly,NC_000009.11:g.133748403A>G,ENST00000318560.5:c.1064A>G"	2023-01-27 17:09:47 UTC	CA16602556	376095	"RS121913450,BCR-ABL GLU355GLY,BCR-ABL1 E355G,BCR-ABL1 GLU355GLY,BCR-ABL E355G"	FALSE
ABL1 BCR::ABL D276G	1001	Chronic Myeloid Leukemia	8552		Nilotinib		Predictive	Supports	D	Sensitivity/Response	"In an in vitro study, a Ba/F3  cell line stably expressing the D276G mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with sensitivity to nilotinib treatment (IC50: 2.00-fold), as compared to Ba/F3 cells expressing BCR-ABL1 fusion protein (reported to be sensitizing to nilotinib). Sensitivity was determined by assessing cell proliferation."	19075254	PubMed		"Redaelli et al., 2009, J. Clin. Oncol."		2	accepted	2666	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/2666	https://civicdb.org/links/molecular_profiles/1001	FALSE	ABL1	25	BCR::ABL D276G		chr9	130872133	130872133	A	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"ENST00000318560.5:c.827A>G,NP_005148.2:p.Asp276Gly,NM_005157.5:c.827A>G,NC_000009.11:g.133747520A>G"	2023-01-27 17:07:46 UTC	CA200645023	NONE FOUND	"RS121913447,BCR-ABL ASP276GLY,BCR-ABL D295G,BCR-ABL1 D295G,BCR-ABL D276G"	FALSE
ABL1 BCR::ABL S417Y	1521	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	C	Resistance	"In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. A late-chronic phase (CP) patient had a complete hematologic response but acquired resistance 7 months after therapy initiation. At month 11, the L248V, G250E, S417Y, E459K variants were present in approximately 25, 25, 25, and 50% of transcripts, respectively. The patient died in accelerated phase at month 14."	12623848	PubMed		"Branford et al., 2003, Blood"		2	accepted	2679	Somatic	2023-01-09 21:46:46 UTC	https://civicdb.org/links/evidence_items/2679	https://civicdb.org/links/molecular_profiles/1521	FALSE	ABL1	25	BCR::ABL S417Y		chr9	130875032	130875032	C	A	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"ENST00000318560.5:c.1250C>A,NC_000009.11:g.133750419C>A,NM_005157.5:c.1250C>A,NP_005148.2:p.Ser417Tyr"	2023-01-27 17:10:53 UTC	CA375250115	NONE FOUND	"SER417TYR,BCR-ABL1 S436Y,BCR-ABL S417Y"	FALSE
ABL1 BCR::ABL M351T	1003	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	D	Sensitivity/Response	"A panel of 18 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL protein and were grouped according to their anti-proliferative activity. Mutant cell lines that exhibited a greater than 4-fold increase in IC50 value were considered resistant to drug, 2-4 fold increase in IC50 were moderately resistant and less than 2-fold change in IC50 was sensitive to drug treatment. The M351T mutation was sensitive to imatinib."	19075254	PubMed		"Redaelli et al., 2009, J. Clin. Oncol."		3	accepted	2682	Somatic	2023-01-09 21:46:42 UTC	https://civicdb.org/links/evidence_items/2682	https://civicdb.org/links/molecular_profiles/1003	FALSE	ABL1	25	BCR::ABL M351T		chr9	130873004	130873004	T	C	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.1052T>C,NP_005148.2:p.Met351Thr,NC_000009.11:g.133748391T>C,ENST00000318560.5:c.1052T>C"	2023-01-27 17:07:48 UTC	CA122590	12629	"RS121913457,BCR-ABL M370T,BCR-ABL MET351THR,BCR-ABL MET370THR,BCR-ABL M351T"	FALSE
ABL1 BCR::ABL M351T	1003	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	C	Resistance	"In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. Three CP patients, with the M351T variants detected prior to resistance, had hematologic responses prior to progression. One patient became resistant after the appearance of the M351T variant but responded to dose escalation. The last patient, who also had the Q252H variant, progressed to myeloid blast crisis (MBC) after which there was cytogenetic evidence of a double Ph-chromosome and no detectable secondary variants. Three accelerated-phase (AP) patients returned to CP and had M351T variants. One of these patients also had E255K and F359V variants and progressed to AP. The remaining two, one of whom also had H396R variant, progressed to MBC and died. Two additional AP patients also had M351T variants but initially had CHRs. One who also had the G250E variant died from disease progression. The other also had the F359V variant progressed to MBC with cytogenetic evidence of the double Ph-chromosome and no detectable secondary variants at progression."	12623848	PubMed		"Branford et al., 2003, Blood"		4	accepted	2683	Somatic	2023-01-09 21:46:42 UTC	https://civicdb.org/links/evidence_items/2683	https://civicdb.org/links/molecular_profiles/1003	FALSE	ABL1	25	BCR::ABL M351T		chr9	130873004	130873004	T	C	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.1052T>C,NP_005148.2:p.Met351Thr,NC_000009.11:g.133748391T>C,ENST00000318560.5:c.1052T>C"	2023-01-27 17:07:48 UTC	CA122590	12629	"RS121913457,BCR-ABL M370T,BCR-ABL MET351THR,BCR-ABL MET370THR,BCR-ABL M351T"	FALSE
ABL1 BCR::ABL M351T	1003	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	C	Sensitivity/Response	"In two cell-based studies, a panel of either 18 or 16 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL protein and were grouped according to their anti-proliferative activity. Mutant cell lines that exhibited a greater than 4-fold increase in IC50 value were considered resistant to drug, 2-4 fold increase in IC50 were moderately resistant and less than 2-fold change in IC50 was sensitive to drug treatment. The M351T mutation was  sensitive to imatinib ."	15930265	PubMed		"O'Hare et al., 2005, Cancer Res."			accepted	2684	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/2684	https://civicdb.org/links/molecular_profiles/1003	FALSE	ABL1	25	BCR::ABL M351T		chr9	130873004	130873004	T	C	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.1052T>C,NP_005148.2:p.Met351Thr,NC_000009.11:g.133748391T>C,ENST00000318560.5:c.1052T>C"	2023-01-27 17:07:48 UTC	CA122590	12629	"RS121913457,BCR-ABL M370T,BCR-ABL MET351THR,BCR-ABL MET370THR,BCR-ABL M351T"	FALSE
ABL1 BCR::ABL M351T	1003	Chronic Myeloid Leukemia	8552		Nilotinib		Predictive	Supports	D	Sensitivity/Response	"In an in vitro study, Ba/F3 cell line stably expressing the M351T mutation in the ABL1 portion of the BCR-ABL1 gene fusion was associated with sensitivity to nilotinib treatment (IC50: 0.44-fold), comparable to Ba/F3 cells expressing BCR-ABL1 fusion protein (reported to be sensitizing to nilotinib). Sensitivity was determined by assessing cell proliferation."	19075254	PubMed		"Redaelli et al., 2009, J. Clin. Oncol."		3	accepted	2685	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/2685	https://civicdb.org/links/molecular_profiles/1003	FALSE	ABL1	25	BCR::ABL M351T		chr9	130873004	130873004	T	C	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.1052T>C,NP_005148.2:p.Met351Thr,NC_000009.11:g.133748391T>C,ENST00000318560.5:c.1052T>C"	2023-01-27 17:07:48 UTC	CA122590	12629	"RS121913457,BCR-ABL M370T,BCR-ABL MET351THR,BCR-ABL MET370THR,BCR-ABL M351T"	FALSE
ABL1 BCR::ABL M351T	1003	Cancer	162		"Dasatinib,Bafetinib,Nilotinib"	Substitutes	Predictive	Does Not Support	D	Resistance	"In an in vitro study, a Ba/F3 cell line stably expressing the M351T mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with similar sensitivity to nilotinib, dasatinib, and bafetinib treatment (IC50: 580.4 nM, 88 nM, 582.9 nM) as compared to wild-type BCR-ABL1 expressing Ba/F3 cells (IC50: 642.3 nM, 87.6 nM, 152.9 nM). Sensitivity was determined by assessing cell proliferation using the MTT assay."	18191450	PubMed		"Deguchi et al., 2008, Leuk. Res."		3	accepted	2686	Somatic	2023-01-09 21:46:42 UTC	https://civicdb.org/links/evidence_items/2686	https://civicdb.org/links/molecular_profiles/1003	FALSE	ABL1	25	BCR::ABL M351T		chr9	130873004	130873004	T	C	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.1052T>C,NP_005148.2:p.Met351Thr,NC_000009.11:g.133748391T>C,ENST00000318560.5:c.1052T>C"	2023-01-27 17:07:48 UTC	CA122590	12629	"RS121913457,BCR-ABL M370T,BCR-ABL MET351THR,BCR-ABL MET370THR,BCR-ABL M351T"	FALSE
ABL1 BCR::ABL H396R	1004	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	D	Resistance	"A panel of 18 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL protein and were grouped according to their anti-proliferative activity. Mutant cell lines that exhibited a greater than 4-fold increase in IC50 value were considered resistant to drug, 2-4 fold increase in IC50 were moderately resistant and less than 2-fold change in IC50 was sensitive to drug treatment. The H396R mutation was resistant to imatinib."	19075254	PubMed		"Redaelli et al., 2009, J. Clin. Oncol."		2	accepted	2687	Somatic	2023-01-09 21:46:42 UTC	https://civicdb.org/links/evidence_items/2687	https://civicdb.org/links/molecular_profiles/1004	FALSE	ABL1	25	BCR::ABL H396R		chr9	130874969	130874969	A	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.1187A>G,NP_005148.2:p.His396Arg,NC_000009.11:g.133750356A>G,ENST00000318560.5:c.1187A>G"	2023-01-27 17:07:48 UTC	CA16602558	376097	"RS121913454,BCR-ABL HIS415ARG,BCR-ABL HIS396ARG,BCR-ABL H415R,BCR-ABL1 H396R,BCR-ABL1 HIS396ARG,BCR-ABL H396R"	FALSE
ABL1 BCR::ABL H396R	1004	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	C	Resistance	"In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. An accelerated-phase patient had a return to chronic phase but progressed to myeloid blast crisis after 5 months of therapy. At that time, the M351T and H396R variants were detected in ~50% and ~25% of transcripts, respectively. At 10 months, the patient died."	12623848	PubMed		"Branford et al., 2003, Blood"		2	accepted	2688	Somatic	2023-01-09 21:46:42 UTC	https://civicdb.org/links/evidence_items/2688	https://civicdb.org/links/molecular_profiles/1004	FALSE	ABL1	25	BCR::ABL H396R		chr9	130874969	130874969	A	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.1187A>G,NP_005148.2:p.His396Arg,NC_000009.11:g.133750356A>G,ENST00000318560.5:c.1187A>G"	2023-01-27 17:07:48 UTC	CA16602558	376097	"RS121913454,BCR-ABL HIS415ARG,BCR-ABL HIS396ARG,BCR-ABL H415R,BCR-ABL1 H396R,BCR-ABL1 HIS396ARG,BCR-ABL H396R"	FALSE
ABL1 BCR::ABL H396R	1004	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	C	Resistance	"In two cell-based studies, a panel of either 18 or 16 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL protein and were grouped according to their anti-proliferative activity. Mutant cell lines that exhibited a greater than 4-fold increase in IC50 value were considered resistant to drug, 2-4 fold increase in IC50 were moderately resistant and less than 2-fold change in IC50 was sensitive to drug treatment. The H396R mutation was  resistant to imatinib ."	15930265	PubMed		"O'Hare et al., 2005, Cancer Res."			accepted	2689	Somatic	2023-01-09 21:46:42 UTC	https://civicdb.org/links/evidence_items/2689	https://civicdb.org/links/molecular_profiles/1004	FALSE	ABL1	25	BCR::ABL H396R		chr9	130874969	130874969	A	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.1187A>G,NP_005148.2:p.His396Arg,NC_000009.11:g.133750356A>G,ENST00000318560.5:c.1187A>G"	2023-01-27 17:07:48 UTC	CA16602558	376097	"RS121913454,BCR-ABL HIS415ARG,BCR-ABL HIS396ARG,BCR-ABL H415R,BCR-ABL1 H396R,BCR-ABL1 HIS396ARG,BCR-ABL H396R"	FALSE
TP53 Overexpression	1280	Ovarian Cancer	2394				Prognostic	Supports	B	Poor Outcome	p53 overexpression (>10% positive stained nuclei) was found in 110 cases from a 178 patient cohort with invasive ovarian carcinoma who had undergone surgery. Overexpression of p53 was correlated with poor differentiation (p<0.001) and high S-phase fraction (p<0.001).	11595686	PubMed		"Reles et al., 2001, Clin. Cancer Res."		3	accepted	2697	N/A	2023-01-09 21:46:44 UTC	https://civicdb.org/links/evidence_items/2697	https://civicdb.org/links/molecular_profiles/1280	FALSE	TP53	7157	Overexpression		chr17	7668402	7687538			ENST00000269305.4	75		N/A		2023-01-09 21:52:12 UTC		N/A		FALSE
TP53 Y234C	1042	Ovarian Cancer	2394		"Cisplatin,Carboplatin"	Substitutes	Predictive	Supports	C	Resistance	"Ovarian cancer patients with TP53 missense mutations were refractory to platinum-based chemotherapy (66% vs. 34% in wildtype, P=0.008) and had a shorter time to disease progression (n=54, P=0.037). A study of ovarian carcinoma patients (n=178) reported a reduced overall survival (HR:1.59, 95% CI:1.09-2.33, P=0.014) for patients with mutations in TP53."	11595686	PubMed		"Reles et al., 2001, Clin. Cancer Res."			accepted	2745	Somatic	2023-01-09 21:46:42 UTC	https://civicdb.org/links/evidence_items/2745	https://civicdb.org/links/molecular_profiles/1042	FALSE	TP53	7157	Y234C		chr17	7674262	7674262	T	C	ENST00000269305.4	75		missense_variant	"NM_000546.5:c.701A>G,NP_000537.3:p.Tyr234Cys,NC_000017.10:g.7577580T>C,ENST00000269305.4:c.701A>G"	2023-01-27 17:07:56 UTC	CA000337	127820	"TYR234CYS,Y102C,Y195C,RS587780073"	FALSE
TP53 ALTERATION	1281	Ovarian Cancer	2394		"Cisplatin,Carboplatin"	Substitutes	Predictive	Supports	B	Resistance	"In a group of patients with invasive ovarian carcinoma who had undergone surgery, a subset of 74 patients treated with platinum based chemotherapy were assessed for  p53 alteration (p53 mutation or p53 overexpression by immunostaining >10% positive). Significant decreased time to progression (p=0.037) was seen in the subset of  patients with p53 alteration (n=54) in comparison to the group with normatl p53 (n=20)"	11595686	PubMed		"Reles et al., 2001, Clin. Cancer Res."		4	accepted	2771	Somatic	2023-01-09 21:46:44 UTC	https://civicdb.org/links/evidence_items/2771	https://civicdb.org/links/molecular_profiles/1281	FALSE	TP53	7157	ALTERATION		chr17	7668402	7687538			ENST00000269305.4	75				2023-01-09 21:52:12 UTC		N/A		FALSE
TP53 DNA Binding Domain Mutation	238	Breast Cancer	1612		Tamoxifen		Predictive	Supports	B	Resistance	"In a study 202 breast cancer patients undergoing first line tamoxifen treatment, 65 patients had mutations in TP53. Among the p53 wild type population a 66% response rate was reported, where response was considered as complete response, partial response or stable disease. In a patient subgroup with mutations in p53 amino acids that directly interact with DNA, 2 of 11 (18%) of patients responded to tamoxifen."	10786679	PubMed		"Berns et al., 2000, Cancer Res."		3	accepted	2783	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/2783	https://civicdb.org/links/molecular_profiles/238	FALSE	TP53	7157	DNA Binding Domain Mutation		chr17	7673831	7675125			ENST00000269305.4	75		DNA_binding_site		2023-01-09 21:52:05 UTC		N/A		FALSE
TP53 Mutation	222	Breast Cancer	1612		Tamoxifen		Predictive	Supports	C	Resistance	"In a study 202 breast cancer patients undergoing tamoxifen treatment, a higher frequency of wildtype TP53 patients responded to treatment compared to those with mutations in TP53 (66% wild-type vs. 31%, odds ratio (OR):0.22, 95CI:0.12-0.42, P<0.0001, univariate analysis; OR:0.29, 95% CI:0.12-0.42, P=0.0014, multivariate analysis). The median survival after start of therapy was shorter in patients with mutations in TP53 than for patients with wild-type TP53 (20mo vs. 29mo, HR:1.99,95% CI:1.43-2.75, P<0.001). Breast cancer patients with TP53 mutations also had a decrease in progression-free survival (HR:2.61, 95% CI:1.90-3.6, P<0.001)."	10786679	PubMed		"Berns et al., 2000, Cancer Res."		1	accepted	2784	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/2784	https://civicdb.org/links/molecular_profiles/222	FALSE	TP53	7157	Mutation		chr17	7668402	7687538			ENST00000269305.4	75		protein_altering_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
TP53 Overexpression	1280	Stomach Cancer	10534		"Cisplatin,Etoposide,Mitomycin"	Combination	Predictive	Supports	B	Sensitivity/Response	"In a Phase II trial of 25 patients with metastaic gastric cancer, patients received preoperative high dose chemotherapy (HDCT) consisting of etoposide, cisplatin and mitomycin. Patients with greater than 50% regression in response to HDCT received surgery. TP53 overexpression was assayed by immunohistochemistry. 14 patients showed p53 overexpression, and 12 of these qualified for resection. Overall survival in patients with p53 overexpression was 17.3 months in contrast to patients with negative p53 immunohistochemistry, where it was 7.2 months (p=0.0003)."	14514923	PubMed		"Bataille et al., 2003, MP, Mol. Pathol."		4	accepted	2799	N/A	2023-01-09 21:46:44 UTC	https://civicdb.org/links/evidence_items/2799	https://civicdb.org/links/molecular_profiles/1280	FALSE	TP53	7157	Overexpression		chr17	7668402	7687538			ENST00000269305.4	75		N/A		2023-01-09 21:52:12 UTC		N/A		FALSE
TP53 R282L	1082	Stomach Carcinoma	5517		EAP Protocol		Predictive	Supports	C	Sensitivity/Response	"In a study of 25 patients with advanced gastric cancer, mutations in TP53 were identified in 32% of primary tumors. TP53 mutations were associated with an improved response to preoperative treatment of a modified EAP protocol (combination of doxorubicin, etoposide and cisplatin). Patients with mutations in TP53 had an increased median survival compared to patients with wildtype TP53 (18.5mo vs. 10.2mo, P=0.044)."	14514923	PubMed		"Bataille et al., 2003, MP, Mol. Pathol."			accepted	2818	Somatic	2023-01-09 21:46:42 UTC	https://civicdb.org/links/evidence_items/2818	https://civicdb.org/links/molecular_profiles/1082	FALSE	TP53	7157	R282L		chr17	7673775	7673775	C	A	ENST00000269305.4	75		missense_variant	"NM_000546.5:c.845G>T,NP_000537.3:p.Arg282Leu,NC_000017.10:g.7577093C>A,ENST00000269305.4:c.845G>T"	2023-01-27 17:08:04 UTC	CA000456	182938	"ARG282LEU,R150L,R243L,RS730882008"	FALSE
TP53 R213P	1083	Stomach Carcinoma	5517		EAP Protocol		Predictive	Supports	C	Sensitivity/Response	"In a study of 25 patients with advanced gastric cancer, mutations in TP53 were identified in 32% of primary tumors. TP53 mutations were associated with an improved response to preoperative treatment of a modified EAP protocol (combination of doxorubicin, etoposide and cisplatin). Patients with mutations in TP53 had an increased median survival compared to patients with wildtype TP53 (18.5mo vs. 10.2mo, P=0.044)."	14514923	PubMed		"Bataille et al., 2003, MP, Mol. Pathol."			accepted	2819	Somatic	2023-01-09 21:46:42 UTC	https://civicdb.org/links/evidence_items/2819	https://civicdb.org/links/molecular_profiles/1083	FALSE	TP53	7157	R213P		chr17	7674893	7674893	C	G	ENST00000269305.4	75		missense_variant	"NM_000546.5:c.638G>C,NP_000537.3:p.Arg213Pro,NC_000017.10:g.7578211C>G,ENST00000269305.4:c.638G>C"	2023-01-27 17:08:04 UTC	CA10580932	231214	"ARG213PRO,R174P,R81P,RS587778720"	FALSE
TP53 Mutation	222	Stomach Carcinoma	5517		"Doxorubicin,Cisplatin,Etoposide"	Combination	Predictive	Supports	C	Sensitivity/Response	"In a study of 25 patients with advanced gastric cancer, mutations in TP53 were identified in 32% of primary tumors. TP53 mutations were associated with an improved response to preoperative treatment of a modified EAP protocol (combination of doxorubicin, etoposide and cisplatin). Patients with mutations in TP53 had an increased median survival compared to patients with wildtype TP53 (18.5mo vs. 10.2mo, P=0.044)."	14514923	PubMed		"Bataille et al., 2003, MP, Mol. Pathol."		1	accepted	2820	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/2820	https://civicdb.org/links/molecular_profiles/222	FALSE	TP53	7157	Mutation		chr17	7668402	7687538			ENST00000269305.4	75		protein_altering_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
ABL1 BCR::ABL F486S	1126	Chronic Myeloid Leukemia	8552		Nilotinib		Predictive	Supports	D	Sensitivity/Response	"In an in vitro study, a Ba/F3 cell line stably expressing the F486S mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with sensitivity to nilotinib treatment (IC50: 1.85-fold), comparable to Ba/F3 cells expressing BCR-ABL fusion protein. Sensitivity was determined by assessing cell proliferation."	19075254	PubMed		"Redaelli et al., 2009, J. Clin. Oncol."		3	accepted	2829	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/2829	https://civicdb.org/links/molecular_profiles/1126	FALSE	ABL1	25	BCR::ABL F486S		chr9	130880101	130880101	T	C	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"ENST00000318560.5:c.1457T>C,NC_000009.11:g.133755488T>C,NM_005157.5:c.1457T>C,NP_005148.2:p.Phe486Ser"	2023-01-27 17:08:15 UTC	CA375251598	NONE FOUND	"BCR-ABL F505S,BCR-ABL PHE486SER,BCR-ABL1 PHE486SER,BCR-ABL1 F486S,BCR-ABL F486S"	FALSE
ATM K293*	1129	Chronic Lymphocytic Leukemia	1040		Doxorubicin		Predictive	Supports	D	Resistance	"Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. The effect of the K293* variant on ATM expression was tested by western blot, and the effect on ATM function was tested by treating with doxorubicin to induce double-strand breaks (DSB) and monitoring p21 induction. To confirm wild type p53, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for adequate p21 induction. A patient sample had the K293* variant of ATM, confirmed by sanger sequencing, in trans with a loss of function 11q deletion found in 92% of cells by FISH. Western blot showed null ATM expression. Treatment with doxorubicin resulted in a p21 expression level of less than 300% that of untreated wild-type controls. This was much lower than the median expression level of treated controls which was 815% that of untreated controls, supporting resistance."	23585524	PubMed		"Navrkalova et al., 2013, Haematologica"		3	accepted	2832	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/2832	https://civicdb.org/links/molecular_profiles/1129	FALSE	ATM	472	K293*		chr11	108245002	108245002	A	T	ENST00000278616.4	75		stop_gained	"ENST00000278616.4:c.877A>T,NM_000051.3:c.877A>T,NP_000042.3:p.Lys293Ter,NC_000011.9:g.108115729A>T"	2023-01-27 17:08:17 UTC	CA16041383	370378	"K293X,LYS293TER,RS1057516442"	FALSE
ATM F1025L	1132	Chronic Lymphocytic Leukemia	1040		Doxorubicin		Predictive	Supports	D	Resistance	"Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. The effect of the F1025L variant on ATM expression was tested by western blot, and the effect on ATM function was tested by treating with doxorubicin to induce double-strand breaks (DSB) and monitoring p21 induction. To confirm wild type p53, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for adequate p21 induction. A patient sample had the F1025L variant of ATM, confirmed by sanger sequencing, in trans with a loss of function 11q deletion found in 93% of cells by FISH. Western blot showed stable ATM expression. Treatment with doxorubicin resulted in a p21 expression level of less than 300% that of untreated wild-type controls. This was much lower than the median expression level of treated controls which was 815% that of untreated controls, supporting resistance."	23585524	PubMed		"Navrkalova et al., 2013, Haematologica"		3	accepted	2835	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/2835	https://civicdb.org/links/molecular_profiles/1132	FALSE	ATM	472	F1025L		chr11	108271404	108271404	T	G	ENST00000278616.4	75		missense_variant	"ENST00000278616.4:c.3075T>G,NC_000011.9:g.108142131T>G,NM_000051.3:c.3075T>G,NP_000042.3:p.Phe1025Leu"	2023-01-27 17:08:19 UTC	CA382547708	NONE FOUND	PHE1025LEU	FALSE
ATM D1930V	1134	Chronic Lymphocytic Leukemia	1040		Doxorubicin		Predictive	Supports	D	Resistance	"Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. The effect of the D1930V variant on ATM expression was tested by western blot, and the effect on ATM function was tested by treating with doxorubicin to induce double-strand breaks (DSB) and monitoring p21 induction. To confirm wild type p53, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for adequate p21 induction. A patient sample had the D1930V variant of ATM, confirmed by sanger sequencing, in trans with a loss of function 11q deletion found in 88% of cells by FISH. Western blot showed null ATM expression. Treatment with doxorubicin resulted in p21 expression greater than 300% that of untreated wild-type controls. This was considered by the authors to be similar to treated wild-type controls with a median expression level 815% that of untreated controls suggesting this variant does not support resistance."	23585524	PubMed		"Navrkalova et al., 2013, Haematologica"		2	accepted	2837	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/2837	https://civicdb.org/links/molecular_profiles/1134	FALSE	ATM	472	D1930V		chr11	108310186	108310186	A	T	ENST00000278616.4	75		missense_variant	"ENST00000278616.4:c.5789A>T,NC_000011.9:g.108180913A>T,NM_000051.3:c.5789A>T,NP_000042.3:p.Asp1930Val"	2023-01-27 17:08:21 UTC	CA382548326	NONE FOUND	"M72L,ASP1930VAL,MET72LEU"	FALSE
ATM E2187*	1136	Chronic Lymphocytic Leukemia	1040		Doxorubicin		Predictive	Supports	D	Resistance	"Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. The effect of the E2187* variant on ATM expression was tested by western blot, and the effect on ATM function was tested by treating with doxorubicin to induce double-strand breaks (DSB) and monitoring p21 induction. To confirm wild type p53, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for adequate p21 induction. A patient sample had the E2187* variant of ATM, confirmed by sanger sequencing, in trans with a loss of function 11q deletion found in 96% of cells by FISH. Western blot showed null ATM expression. Treatment with doxorubicin resulted in a p21 expression level of less than 300% that of untreated wild-type controls. This was much lower than the median expression level of treated controls which was 815% that of untreated controls, supporting resistance."	23585524	PubMed		"Navrkalova et al., 2013, Haematologica"		3	accepted	2839	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/2839	https://civicdb.org/links/molecular_profiles/1136	FALSE	ATM	472	E2187*		chr11	108321407	108321407	G	T	ENST00000278616.4	75		stop_gained	"ENST00000278616.4:c.6559G>T,NC_000011.9:g.108192134G>T,NM_000051.3:c.6559G>T,NP_000042.3:p.Glu2187Ter"	2023-01-27 17:08:23 UTC	CA382554382	NONE FOUND	"E2187X,GLU2187TER"	FALSE
ATM L2427P	1137	Chronic Lymphocytic Leukemia	1040		Doxorubicin		Predictive	Supports	D	Resistance	"Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. The effect of the L2427P variant on ATM expression was tested by western blot, and the effect on ATM function was tested by treating with doxorubicin to induce double-strand breaks (DSB) and monitoring p21 induction. To confirm wild type p53, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for adequate p21 induction. A patient sample had the L2427P variant of ATM, confirmed by sanger sequencing, in trans with a loss of function 11q deletion found in 94% of cells by FISH. Western blot showed stable ATM expression. Treatment with doxorubicin resulted in a p21 expression level of less than 300% that of untreated wild-type controls. This was much lower than the median expression level of treated controls which was 815% that of untreated controls, supporting resistance."	23585524	PubMed		"Navrkalova et al., 2013, Haematologica"		3	accepted	2840	Unknown	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/2840	https://civicdb.org/links/molecular_profiles/1137	FALSE	ATM	472	L2427P		chr11	108329211	108329211	T	C	ENST00000278616.4	75		missense_variant	"ENST00000278616.4:c.7280T>C,NC_000011.9:g.108199938T>C,NM_000051.3:c.7280T>C,NP_000042.3:p.Leu2427Pro"	2023-01-27 17:08:24 UTC	CA382559785	NONE FOUND	LEU2427PRO	FALSE
ATM F2732V	1138	Chronic Lymphocytic Leukemia	1040		Doxorubicin		Predictive	Supports	D	Resistance	"Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. The effect of the F2732V variant on ATM expression was tested by western blot, and the effect on ATM function was tested by treating with doxorubicin to induce double-strand breaks (DSB) and monitoring p21 induction. To confirm wild type p53, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for adequate p21 induction. A patient sample had the F2732V variant of ATM, confirmed by sanger sequencing, in trans with a loss of function 11q deletion found in 98% of cells by FISH. Western blot showed stable ATM expression. Treatment with doxorubicin resulted in a p21 expression level of less than 300% that of untreated wild-type controls. This was much lower than the median expression level of treated controls which was 815% that of untreated controls, supporting resistance."	23585524	PubMed		"Navrkalova et al., 2013, Haematologica"		3	accepted	2841	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/2841	https://civicdb.org/links/molecular_profiles/1138	FALSE	ATM	472	F2732V		chr11	108335887	108335887	T	G	ENST00000278616.4	75		missense_variant	"ENST00000278616.4:c.8194T>G,NC_000011.9:g.108206614T>G,NM_000051.3:c.8194T>G,NP_000042.3:p.Phe2732Val"	2023-01-27 17:08:24 UTC	CA16619250	422531	"PHE2732VAL,RS876659619"	FALSE
ATM K468FS	1140	Chronic Lymphocytic Leukemia	1040		Doxorubicin		Predictive	Does Not Support	D	Resistance	"Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. The effect of the K468FS variant on ATM expression was tested by western blot, and the effect on ATM function was tested by treating with doxorubicin to induce double-strand breaks (DSB) and monitoring p21 induction. To confirm wild type p53, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for adequate p21 induction. A patient sample had the K468FS variant of ATM, confirmed by sanger sequencing, in trans with a loss of function 11q deletion found in 91% of cells by FISH. Western blot showed null ATM expression. Treatment with doxorubicin resulted in p21 expression greater than 300% that of untreated wild-type controls. This was considered by the authors to be similar to treated wild-type controls with a median expression level 815% that of untreated controls suggesting this variant does not support resistance."	23585524	PubMed		"Navrkalova et al., 2013, Haematologica"		2	accepted	2843	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/2843	https://civicdb.org/links/molecular_profiles/1140	FALSE	ATM	472	K468FS		chr11	108250867	108250868	AA		ENST00000278616.4	75		frameshift_variant	"NM_000051.3:c.1402_1403delAA,NP_000042.3:p.Lys468Glufs,NC_000011.9:g.108121594_108121595delAA,ENST00000278616.4:c.1402_1403delAA,NC_000011.9:g.108121594_108121595del"	2023-01-27 17:08:26 UTC	CA163840	140889	LYS468GLUFS	FALSE
ATM D1682H	1142	Chronic Lymphocytic Leukemia	1040		Doxorubicin		Predictive	Supports	D	Resistance	"Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. The effect of the D1682H variant on ATM expression was tested by western blot, and the effect on ATM function was tested by treating with doxorubicin to induce double-strand breaks (DSB) and monitoring p21 induction. To confirm wild type p53, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for adequate p21 induction. A patient sample had the D1682H variant of ATM, confirmed by sanger sequencing, in trans with a loss of function 11q deletion found in 93% of cells by FISH. Western blot showed stable ATM expression. Treatment with doxorubicin resulted in a p21 expression level of less than 300% that of untreated wild-type controls. This was much lower than the median expression level of treated controls which was 815% that of untreated controls, supporting resistance."	23585524	PubMed		"Navrkalova et al., 2013, Haematologica"		3	accepted	2845	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/2845	https://civicdb.org/links/molecular_profiles/1142	FALSE	ATM	472	D1682H		chr11	108299752	108299752	G	C	ENST00000278616.4	75		missense_variant	"NM_000051.3:c.5044G>C,NP_000042.3:p.Asp1682His,NC_000011.9:g.108170479G>C,ENST00000278616.4:c.5044G>C"	2023-01-27 17:08:27 UTC	CA115932	3026	"RS121434217,ASP1682HIS"	FALSE
ATM A2062V	1143	Chronic Lymphocytic Leukemia	1040		Doxorubicin		Predictive	Supports	D	Resistance	"Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. The effect of the A2062V variant on ATM expression was tested by western blot, and the effect on ATM function was tested by treating with doxorubicin to induce double-strand breaks (DSB) and monitoring p21 induction. To confirm wild type p53, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for adequate p21 induction. A patient sample had the A2062V variant of ATM, confirmed by sanger sequencing, in trans with a loss of function 11q deletion found in 87% of cells by FISH. Western blot showed stable ATM expression. Treatment with doxorubicin resulted in a p21 expression level of less than 300% that of untreated wild-type controls. This was much lower than the median expression level of treated controls which was 815% that of untreated controls, supporting resistance."	23585524	PubMed		"Navrkalova et al., 2013, Haematologica"		3	accepted	2846	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/2846	https://civicdb.org/links/molecular_profiles/1143	FALSE	ATM	472	A2062V		chr11	108316100	108316100	C	T	ENST00000278616.4	75		missense_variant	"ENST00000278616.4:c.6185C>T,NC_000011.9:g.108186827C>T,NM_000051.3:c.6185C>T,NP_000042.3:p.Ala2062Val"	2023-01-27 17:08:28 UTC	CA382550752	NONE FOUND	ALA2062VAL	FALSE
ATM C2488Y	1146	Chronic Lymphocytic Leukemia	1040		Doxorubicin		Predictive	Supports	D	Resistance	"Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. The effect of the C2488Y variant on ATM expression was tested by western blot, and the effect on ATM function was tested by treating with doxorubicin to induce double-strand breaks (DSB) and monitoring p21 induction. To confirm wild type p53, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for adequate p21 induction. A patient sample had the C2488Y variant of ATM, confirmed by sanger sequencing, in trans with a loss of function 11q deletion found in 90% of cells by FISH. Western blot showed stable ATM expression. Treatment with doxorubicin resulted in a p21 expression level of less than 300% that of untreated wild-type controls. This was much lower than the median expression level of treated controls which was 815% that of untreated controls, supporting resistance."	23585524	PubMed		"Navrkalova et al., 2013, Haematologica"		3	accepted	2849	Rare Germline	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/2849	https://civicdb.org/links/molecular_profiles/1146	FALSE	ATM	472	C2488Y		chr11	108330369	108330369	G	A	ENST00000278616.4	75		missense_variant	"NM_000051.3:c.7463G>A,NP_000042.3:p.Cys2488Tyr,NC_000011.9:g.108201096G>A,ENST00000278616.4:c.7463G>A"	2023-01-27 17:08:30 UTC	CA196568	187037	"CYS2488TYR,RS774281788"	FALSE
ABL1 BCR::ABL E255V	1147	Chronic Myeloid Leukemia	8552		Nilotinib		Predictive	Supports	D	Resistance	"In an in vitro study, a Ba/F3  cell line stably expressing the E255V mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to nilotinib treatment (IC50: 10.31-fold), as compared to Ba/F3 cells expressing BCR-ABL1 fusion protein. Sensitivity was determined by assessing cell proliferation."	19075254	PubMed		"Redaelli et al., 2009, J. Clin. Oncol."		3	accepted	2850	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/2850	https://civicdb.org/links/molecular_profiles/1147	FALSE	ABL1	25	BCR::ABL E255V		chr9	130862977	130862977	A	T	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.764A>T,NP_005148.2:p.Glu255Val,NC_000009.11:g.133738364A>T,ENST00000318560.5:c.764A>T"	2023-01-27 17:08:31 UTC	CA16602552	376091	"RS121913449,BCR-ABL E274V,BCR-ABL GLU255VAL,BCR-ABL1 E274V,BCR-ABL1 GLU255VAL,BCR-ABL E255V"	FALSE
ABL1 BCR::ABL E255V	1147	Chronic Myeloid Leukemia	8552		"Nilotinib,Imatinib Mesylate"	Substitutes	Predictive	Supports	D	Resistance	"In an in vitro study, a Ba/F3-p210BCR-ABL1 cell line was ENU-mutated and exposed to graded concentrations of imatinib, nilotinib or dasatinib to identify resistance mutations. The E255V mutation in the ABL1 portion of the BCR-ABL1 fusion protein was identified and associated with resistance to imatinib (1 clone, 0.43% of viable clones in this treatment, recovered in 4 M but none at 2, 8, or 16 M) and nilotinib (1 clone, 1.25%, recovered at 500nM but none at 50, 2000 or 5000nM). In a review of 20 publications, this mutation was described in imatinib resistant patients."	16772610	PubMed		"Bradeen et al., 2006, Blood"		2	accepted	2851	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/2851	https://civicdb.org/links/molecular_profiles/1147	FALSE	ABL1	25	BCR::ABL E255V		chr9	130862977	130862977	A	T	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.764A>T,NP_005148.2:p.Glu255Val,NC_000009.11:g.133738364A>T,ENST00000318560.5:c.764A>T"	2023-01-27 17:08:31 UTC	CA16602552	376091	"RS121913449,BCR-ABL E274V,BCR-ABL GLU255VAL,BCR-ABL1 E274V,BCR-ABL1 GLU255VAL,BCR-ABL E255V"	FALSE
ABL1 BCR::ABL E292V	1157	Chronic Myeloid Leukemia	8552		Nilotinib		Predictive	Supports	D	Resistance	"In an in vitro study, a Ba/F3-p210BCR-ABL1 cell line was ENU-mutated and exposed to graded concentrations of imatinib, nilotinib or dasatinib. The E292V mutation in the ABL1 portion of the BCR-ABL1 fusion protein was identified and associated with resistance to nilotinib treatment (1 clone recovered at 50nM). In a review of 20 publications, this mutation was not previously described in imatinib resistant patients."	16772610	PubMed		"Bradeen et al., 2006, Blood"		2	accepted	2853	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/2853	https://civicdb.org/links/molecular_profiles/1157	FALSE	ABL1	25	BCR::ABL E292V		chr9	130872181	130872181	A	T	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"ENST00000318560.5:c.875A>T,NC_000009.11:g.133747568A>T,NM_005157.5:c.875A>T,NP_005148.2:p.Glu292Val"	2023-01-27 17:08:35 UTC	CA375249260	NONE FOUND	"E311V,GLU311VAL,BCR-ABL GLU292VAL,BCR-ABL1 E292V,BCR-ABL1 GLU292VAL,BCR-ABL E292V"	FALSE
ABL1 BCR::ABL F359C	1158	Chronic Myeloid Leukemia	8552		"Nilotinib,Imatinib Mesylate"	Substitutes	Predictive	Supports	D	Resistance	"In an in vitro study, a Ba/F3-p210BCR-ABL1 cell line was ENU-mutated and exposed to graded concentrations of imatinib, nilotinib or dasatinib to identify resistance mutations. The F359C mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to 50nM nilotinib (6 clones recovered, ~13% of viable clones in this treatment) and 2 M imatinib (6 clones, ~4%). In a review of 20 publications, this mutation was described in imatinib resistant patients."	16772610	PubMed		"Bradeen et al., 2006, Blood"		2	accepted	2854	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/2854	https://civicdb.org/links/molecular_profiles/1158	FALSE	ABL1	25	BCR::ABL F359C		chr9	130873028	130873028	T	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.1076T>G,NP_005148.2:p.Phe359Cys,NC_000009.11:g.133748415T>G,ENST00000318560.5:c.1076T>G"	2023-01-27 17:08:36 UTC	CA16602582	376124	"F378C,RS1057519775,BCR-ABL PHE359CYS,BCR-ABL1 F359C,BCR-ABL1 PHE359CYS,BCR-ABL F359C"	FALSE
ABL1 BCR::ABL L384M	1204	Chronic Myeloid Leukemia	8552		"Nilotinib,Imatinib Mesylate"	Substitutes	Predictive	Supports	D	Resistance	"In an in vitro study, a Ba/F3-p210BCR-ABL1 cell line was ENU-mutated and exposed to graded concentrations of imatinib, nilotinib or dasatinib to identify resistance mutations. The L384M mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance in 50nM nilotinib (1 clone recovered, ~2% of viable clones in this treatment) and 2 M imatinib (1 clone, ~0.7%). L384M was one of 3 novel mutations that were not identified in imatinib resistant patients from a review of 20 publications."	16772610	PubMed		"Bradeen et al., 2006, Blood"		1	accepted	2861	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/2861	https://civicdb.org/links/molecular_profiles/1204	FALSE	ABL1	25	BCR::ABL L384M		chr9	130874932	130874932	C	A	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"ENST00000318560.5:c.1150C>A,NC_000009.11:g.133750319C>A,NM_005157.5:c.1150C>A,NP_005148.2:p.Leu384Met"	2023-01-27 17:08:45 UTC	CA375249885	NONE FOUND	"L403M,LEU403MET,LEU384MET,BCR-ABL1 L384M,BCR-ABL1 LEU384MET,BCR-ABL L384M"	FALSE
ABL1 BCR::ABL V299L	1205	Chronic Myeloid Leukemia	8552		Nilotinib		Predictive	Supports	D	Sensitivity/Response	"In an in vitro study, a Ba/F3 cell line stably expressing the V299L mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with sensitivity to nilotinib treatment (IC50: 1.34-fold), comparable to Ba/F3 cells expressing BCR-ABL1 fusion protein. Sensitivity was determined by assessing cell proliferation."	19075254	PubMed		"Redaelli et al., 2009, J. Clin. Oncol."		3	accepted	2862	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/2862	https://civicdb.org/links/molecular_profiles/1205	FALSE	ABL1	25	BCR::ABL V299L		chr9	130872201	130872201	G	C	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.895G>C,NP_005148.2:p.Val299Leu,NC_000009.11:g.133747588G>C,ENST00000318560.5:c.895G>C"	2023-01-27 17:08:46 UTC	CA16602575	376117	"BCR-ABL VAL299LEU,BCR-ABL V318L,RS1057519771,BCR-ABL1 V299L,BCR-ABL1 VAL299LEU,BCR-ABL V299L"	FALSE
ABL1 BCR::ABL L387F	1206	Chronic Myeloid Leukemia	8552		Nilotinib		Predictive	Supports	D	Resistance	"In an in vitro study, a Ba/F3-p210BCR-ABL1 cell line was ENU-mutated and exposed to graded concentrations of imatinib, nilotinib or dasatinib. The L387F mutation in the ABL1 portion of the BCR-ABL1 fusion protein was identified and associated with resistance to nilotinib treatment (1 clone recovered at 50nM)."	16772610	PubMed		"Bradeen et al., 2006, Blood"		2	accepted	2863	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/2863	https://civicdb.org/links/molecular_profiles/1206	FALSE	ABL1	25	BCR::ABL L387F		chr9	130874943	130874943	G	C	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"ENST00000318560.5:c.1161G>C,NC_000009.11:g.133750330G>C,NM_005157.5:c.1161G>C,NP_005148.2:p.Leu387Phe"	2023-01-27 17:08:47 UTC	CA375249910	NONE FOUND	"L406F,LEU406PHE,LEU387PHE,BCR-ABL1 L387F,BCR-ABL1 LEU387PHE,BCR-ABL L387F"	FALSE
ABL1 BCR::ABL G398R	1207	Chronic Myeloid Leukemia	8552		Nilotinib		Predictive	Supports	D	Sensitivity/Response	"In an in vitro study, a Ba/F3 cell line stably expressing the G398R mutation in the ABL1 portion of the BCR-ABL1 gene fusion was associated with sensitivity to nilotinib treatment (IC50: 0.49-fold), comparable to Ba/F3 cells expressing BCR-ABL1 fusion protein (reported to be sensitizing to nilotinib). Sensitivity was determined by assessing cell proliferation."	19075254	PubMed		"Redaelli et al., 2009, J. Clin. Oncol."		3	accepted	2864	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/2864	https://civicdb.org/links/molecular_profiles/1207	FALSE	ABL1	25	BCR::ABL G398R		chr9	130874974	130874974	G	C	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"ENST00000318560.5:c.1192G>C,NC_000009.11:g.133750361G>C,NM_005157.5:c.1192G>C,NP_005148.2:p.Gly398Arg"	2023-01-27 17:08:47 UTC	CA375249980	NONE FOUND	"BCR-ABL G417R,BCR-ABL GLY417ARG,BCR-ABL GLY398ARG,BCR-ABL1 G398R,BCR-ABL1 GLY398ARG,BCR-ABL G398R"	FALSE
PIK3CA K111N	1208	Her2-receptor Positive Breast Cancer	60079		Trastuzumab Emtansine		Predictive	Does Not Support	D	Resistance	"As part of a pre-clinical experiment, the efficacy of ado-trastuzumab emtansine (T-DM1) was evaluated against various HER2 positive cell lines. BT-474 cell line expressing PIK3CA K111N was associated with similar sensitivity to T-DM1 as PIK3CA wild-type cell line SK-BR-3; reduced cell viability was observed at concentrations > 0.01 ug/mL in both cell lines. Conversely, when treated with trastuzumab, the cell line harboring PIK3CA K111N experienced a smaller reduction in cell viability. Further, treatment with T-DM1 on SCID mice xenografted with PIK3CA K111N cells resulted in inhibition of tumor growth. A single dose of T-DM1 >5mg/kg was sufficient to induce tumor regression >20 days after administration."	26920887	PubMed		"Baselga et al., 2016, Clin. Cancer Res."		3	accepted	2866	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/2866	https://civicdb.org/links/molecular_profiles/1208	FALSE	PIK3CA	5290	K111N		chr3	179199158	179199158	G	C	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.333G>C,NP_006209.2:p.Lys111Asn,NC_000003.11:g.178916946G>C,ENST00000263967.3:c.333G>C"	2023-01-27 17:08:48 UTC	CA16602917	376483	"LYS111ASN,RS1057519934"	FALSE
PIK3CA I391M	1209	Her2-receptor Positive Breast Cancer	60079		Trastuzumab Emtansine		Predictive	Does Not Support	D	Resistance	"As part of a pre-clinical experiment, the efficacy of ado-trastuzumab emtansine (T-DM1) was evaluated against various HER2 positive cell lines. ZR-75-30 cell line expressing PIK3CA I391M was associated with similar sensitivity to T-DM1 as PIK3CA wild-type cell line SK-BR-3; reduced cell viability was observed at concentrations > 0.01 ug/mL in both cell lines. When treated with trastuzumab, the cell line harboring PIK3CA I391M experienced similar reduction in cell viability."	26920887	PubMed		"Baselga et al., 2016, Clin. Cancer Res."		3	accepted	2867	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/2867	https://civicdb.org/links/molecular_profiles/1209	FALSE	PIK3CA	5290	I391M		chr3	179209622	179209622	A	G	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.1173A>G,NP_006209.2:p.Ile391Met,NC_000003.11:g.178927410A>G,ENST00000263967.3:c.1173A>G"	2023-01-27 17:08:49 UTC	CA161490	135038	"ILE391MET,RS2230461"	FALSE
BRCA2 Mutation	186	Ovarian Cancer	2394		Rucaparib		Predictive	Supports	B	Sensitivity/Response	"A phase 2 trial on patients with relapsed, platinum-sensitive high grade ovarian, fallopian tube or primary peritoneal carcinoma (ARIEL2 Part1, NCT01891344) was held to assess PARP inhibitor rucaparib on 3 genetically defined subsets of patients. Out of 40 BRCA (BRCA1 or BRCA2) mutant patients, 5 had somatic BRCA2 mutation, 4 of which were homozygous mutations and one had unknown zygosity. Confirmed objective response was seen in 80% (4/5) of the somatic BRCA2 mutant subgroup. Authors note that response rate was similar regardless of whether the BRCA mutation was somatic or germline, in BRCA 1 or BRCA 2. In a BRCA wild-type subgroup, with low levels of loss of heterozygosity (LOH), confirmed objective response was observed in 10% (7/70) of the patients. Patients with BRCA mutant tumors experienced significantly longer median progression free survival than patients with BRCA wildtype, LOH low tumors (12.8 vs 5.2 mo, HR: 0.27, P<0.0001)."	27908594	PubMed		"Swisher et al., 2017, Lancet Oncol."	NCT01891344	2	accepted	2868	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/2868	https://civicdb.org/links/molecular_profiles/186	FALSE	BRCA2	675	Mutation		chr13	32315474	32399210			ENST00000380152.3	75		"gene_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
BRCA1 Q1467*	1220	Ovarian Cancer	2394		Rucaparib		Predictive	Supports	C	Sensitivity/Response	"In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5)."	27908594	PubMed		"Swisher et al., 2017, Lancet Oncol."	NCT01891344		accepted	2878	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/2878	https://civicdb.org/links/molecular_profiles/1220	FALSE	BRCA1	672	Q1467*		chr17	43076573	43076573	G	A	ENST00000357654.3	75		stop_gained	"NM_007294.3:c.4399C>T,NP_009225.1:p.Gln1467Ter,NC_000017.10:g.41228590G>A,ENST00000357654.3:c.4399C>T"	2023-01-27 17:08:58 UTC	CA002821	55191	"Q1467X,GLN1467TER,RS397509171"	FALSE
BRCA2 M1R	1221	Ovarian Cancer	2394		Rucaparib		Predictive	Supports	C	Sensitivity/Response	"In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5)."	27908594	PubMed		"Swisher et al., 2017, Lancet Oncol."	NCT01891344		accepted	2879	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/2879	https://civicdb.org/links/molecular_profiles/1221	FALSE	BRCA2	675	M1R		chr13	32316462	32316462	T	G	ENST00000544455.1			missense_variant	"NM_000059.3:c.2T>G,NC_000013.10:g.32890599T>G,NP_000050.2:p.Met1Arg,ENST00000544455.1:c.2T>G"	2023-01-27 17:08:59 UTC	CA017013	51385	"MET1ARG,RS80358547"	FALSE
BRCA2 M1I	1222	Ovarian Cancer	2394		Rucaparib		Predictive	Supports	C	Sensitivity/Response	"In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5)."	27908594	PubMed		"Swisher et al., 2017, Lancet Oncol."	NCT01891344		accepted	2880	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/2880	https://civicdb.org/links/molecular_profiles/1222	FALSE	BRCA2	675	M1I		chr13	32316463	32316463	G	T	ENST00000544455.1	75		missense_variant	"NC_000013.10:g.32890600G>T,NM_000059.3:c.3G>T,NP_000050.2:p.Met1Ile,ENST00000544455.1:c.3G>T"	2023-01-27 17:08:59 UTC	CA019369	37871	"MET1ILE,RS80358650"	FALSE
BRCA2 V159M	1223	Ovarian Cancer	2394		Rucaparib		Predictive	Supports	C	Sensitivity/Response	"In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5)."	27908594	PubMed		"Swisher et al., 2017, Lancet Oncol."	NCT01891344		accepted	2881	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/2881	https://civicdb.org/links/molecular_profiles/1223	FALSE	BRCA2	675	V159M		chr13	32326150	32326150	G	A	ENST00000544455.1	75		missense_variant	"ENST00000544455.1:c.475G>A,NM_000059.3:c.475G>A,NP_000050.2:p.Val159Met,NC_000013.10:g.32900287G>A"	2023-01-27 17:09:00 UTC	CA020781	51711	"VAL159MET,RS80358702"	FALSE
BRCA2 V211L	1224	Ovarian Cancer	2394		Rucaparib		Predictive	Supports	C	Sensitivity/Response	"In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5)."	27908594	PubMed		"Swisher et al., 2017, Lancet Oncol."	NCT01891344		accepted	2882	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/2882	https://civicdb.org/links/molecular_profiles/1224	FALSE	BRCA2	675	V211L		chr13	32326614	32326614	G	C				missense_variant	NC_000013.10:g.32900751G>C	2023-01-27 17:09:01 UTC	CA16619647			FALSE
BRCA2 V211I	1225	Ovarian Cancer	2394		Rucaparib		Predictive	Supports	C	Sensitivity/Response	"In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5)."	27908594	PubMed		"Swisher et al., 2017, Lancet Oncol."	NCT01891344		accepted	2883	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/2883	https://civicdb.org/links/molecular_profiles/1225	FALSE	BRCA2	675	V211I		chr13	32326614	32326614	G	A				missense_variant	NC_000013.10:g.32900751G>A	2023-01-27 17:09:02 UTC	CA023848			FALSE
BRCA2 R2336P	1226	Ovarian Cancer	2394		Rucaparib		Predictive	Supports	C	Sensitivity/Response	"In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5)."	27908594	PubMed		"Swisher et al., 2017, Lancet Oncol."	NCT01891344		accepted	2884	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/2884	https://civicdb.org/links/molecular_profiles/1226	FALSE	BRCA2	675	R2336P		chr13	32346896	32346896	G	C	ENST00000544455.1	75		missense_variant	"NM_000059.3:c.7007G>C,NP_000050.2:p.Arg2336Pro,NC_000013.10:g.32921033G>C,ENST00000544455.1:c.7007G>C"	2023-01-27 17:09:03 UTC	CA024716	52241	"ARG2336PRO,RS28897743"	FALSE
KIT D820Y	960	Melanoma	1909		Imatinib		Predictive	Supports	C	Resistance	"FFPE tumor specimens from 295 melanoma patients were screened for KIT amplification and mutation. Of these, 51 patients had variants in KIT and 28 of these were treated with imatinib mesylate at 400 mg orally, twice daily with 25 patients eligible for response evaluation. None of the patients had mutations in BRAF, NRAS, or GNAQ. Two patients achieved a durable complete response, two achieved a durable partial response, and 5 achieved stable disease >12 weeks with a median survival of 46.3 weeks. One patient harboring a somatic D820Y mutation at roughly 50% variant allele frequency (1:1 with wild type) displayed Imatinib mesylateresistance and disease progression, which is consistent with resistant mechanisms described in Gastro-Intestinal Stromal Tumors."	21642685	PubMed		"Carvajal et al., 2011, JAMA"	NCT00470470	3	accepted	2886	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/2886	https://civicdb.org/links/molecular_profiles/960	FALSE	KIT	3815	D820Y	KIT Exon 17	chr4	54733166	54733166	G	T	ENST00000288135.5	75		missense_variant	"NM_000222.2:c.2458G>T,NP_000213.1:p.Asp820Tyr,NC_000004.11:g.55599332G>T,ENST00000288135.5:c.2458G>T"	2023-01-27 17:07:24 UTC	CA16602408	375928	"ASP820TYR,RS1057519710"	FALSE
KIT D820Y	960	Melanoma	1909		Sunitinib		Predictive	Supports	D	Sensitivity/Response	"28 acral or mucosal melanomas were examined for KIT expression and mutations (exons 11, 13, 17, and 18). Two of 19 melanomas examined harbored KIT mutations, with one subject harboring a D820Y mutation. Western blotting showed KIT phosphorylation (Y219) in this case and the SM3 cell line harboring the D820Y mutation. The SM3 cell line showed significant growth inhibition with sunitinib exposures of 1uM and 10uM while imatinib showed no activity. The authors comment that this indicates a potential role for sunitinib in growth inhibition of acral melanomas."	19035443	PubMed		"Ashida et al., 2009, Int. J. Cancer"		2	accepted	2888	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/2888	https://civicdb.org/links/molecular_profiles/960	FALSE	KIT	3815	D820Y	KIT Exon 17	chr4	54733166	54733166	G	T	ENST00000288135.5	75		missense_variant	"NM_000222.2:c.2458G>T,NP_000213.1:p.Asp820Tyr,NC_000004.11:g.55599332G>T,ENST00000288135.5:c.2458G>T"	2023-01-27 17:07:24 UTC	CA16602408	375928	"ASP820TYR,RS1057519710"	FALSE
KIT K642E	952	Mucosal Melanoma	50929		Imatinib		Predictive	Supports	C	Sensitivity/Response	"A 69 y.o. woman presented with metastatic mucosal melanoma of the anus. KIT was amplified in the tumor and harbored the K642E mutation. Post surgery with extensive margins, she was given a dose of anti-CTLA-4 antibody and adjuvant radiation therapy for 2.5 weeks.  Two weeks post radiation she developed nodules in the same region and testing indicated they were malignant melanoma with high KIT expression. She enrolled in a clinical trial with a dose of 400mg imatinib per day (Nov 2006). Less than 4 weeks later, all nodules had disappeared. Upon a lowered dosage to 200mg of imatinib, the nodules returned and subsequently the dosage was increased to 600mg/day. The patient remained melanoma-free on 600mg imatinib until a follow up in Jan 2008. The authors do not provide further details on patient outcome."	18510589	PubMed		"Lutzky et al., 2008, Pigment Cell Melanoma Res"		2	accepted	2889	Somatic	2023-01-09 21:46:40 UTC	https://civicdb.org/links/evidence_items/2889	https://civicdb.org/links/molecular_profiles/952	FALSE	KIT	3815	K642E		chr4	54728055	54728055	A	G	ENST00000288135.5	75		missense_variant	"NM_000222.2:c.1924A>G,NP_000213.1:p.Lys642Glu,NC_000004.11:g.55594221A>G,ENST00000288135.5:c.1924A>G"	2023-01-27 17:07:18 UTC	CA123547	13866	"RS121913512,LYS642GLU"	FALSE
GNAS c.393T>C	851	Bladder Urothelial Carcinoma	4006				Prognostic	Supports	B	Better Outcome	"This study demostrated that the progression-free survival, metastasis-free survival, and cancer-specific survival was significantly increased in patients with T393 homozygosity i.e. TT genotypes (56%, 84%, 82%) compared with CC genotypes (35%, 53%, 58%). In multivariate Cox proportional hazard analysis, the T393C polymorphism was an independent prognostic factor for clinical outcome. Homozygous CC patients were at highest risk for progression [odds ratio (OR), 1.94; P = 0.020], metastasis (OR, 3.49; P = 0.005), and tumor-related death (OR, 2.49; P = 0.031) compared with TT genotypes."	15824158	PubMed		"Frey et al., 2005, Cancer Epidemiol. Biomarkers Prev."		4	accepted	2892	Common Germline	2023-01-09 21:46:39 UTC	https://civicdb.org/links/evidence_items/2892	https://civicdb.org/links/molecular_profiles/851	FALSE	GNAS	2778	c.393T>C		chr20	58853658	58853658	T	C	ENST00000371100.4	75		synonymous_variant	"NC_000020.11:g.58903752C>T,NC_000020.10:g.57478807C>T,NM_000516.4:c.393C>T,NP_000507.1:p.Ile131="	2023-01-27 17:06:15 UTC	CA409455494	197681	"I131=,RS7121,L131="	FALSE
GNAS c.393T>C	851	Colorectal Cancer	9256				Prognostic	Supports	B	Better Outcome	"In a retrospective study of 151 patients with sporadic colorectal cancer, 5-year survival rate was significantly higher in patients with International Union Against Cancer (UICC) stages I to II (mean follow-up, 43 months) and the GNAS1 T393C polymorphism-associated TT genotypes (87.8%) compared with TC (71.0%) and CC genotypes (50.0%; P = 0.009). No genotype effect could be observed for UICC stages III to IV. In multivariate Cox proportional analysis the T393C polymorphism was an independent prognostic factor for survival. Compatible with a gene-dose effect, homozygous CC patients were at highest risk for death (hazard ratio, 12.1; P = 0.006) compared with TT genotypes and heterozygous patients had an intermediate risk."	16033819	PubMed		"Frey et al., 2005, Clin. Cancer Res."		4	accepted	2893	Common Germline	2023-01-09 21:46:39 UTC	https://civicdb.org/links/evidence_items/2893	https://civicdb.org/links/molecular_profiles/851	FALSE	GNAS	2778	c.393T>C		chr20	58853658	58853658	T	C	ENST00000371100.4	75		synonymous_variant	"NC_000020.11:g.58903752C>T,NC_000020.10:g.57478807C>T,NM_000516.4:c.393C>T,NP_000507.1:p.Ile131="	2023-01-27 17:06:15 UTC	CA409455494	197681	"I131=,RS7121,L131="	FALSE
GNAS c.393T>C	851	Esophageal Cancer	5041		"Cisplatin,Fluorouracil"	Combination	Predictive	Supports	B	Resistance	"Overall, 63% of the patients in the T-allele group (TT + CT), i.e with the T393C genotype, were minor responders with more than 10% residual vital tumor cells in resection specimens, whereas T(-) genotypes (CC) showed a major histopathological response with less than 10% residual vital tumor cells in 80%."	19274060	PubMed		"Alakus et al., 2009, Pharmacogenomics J."		4	accepted	2895	Common Germline	2023-01-09 21:46:39 UTC	https://civicdb.org/links/evidence_items/2895	https://civicdb.org/links/molecular_profiles/851	FALSE	GNAS	2778	c.393T>C		chr20	58853658	58853658	T	C	ENST00000371100.4	75		synonymous_variant	"NC_000020.11:g.58903752C>T,NC_000020.10:g.57478807C>T,NM_000516.4:c.393C>T,NP_000507.1:p.Ile131="	2023-01-27 17:06:15 UTC	CA409455494	197681	"I131=,RS7121,L131="	FALSE
GNAS c.393T>C	851	Clear Cell Renal Cell Carcinoma	4467				Prognostic	Supports	B	Better Outcome	"In this study, Kaplan-Meier curves for tumor progression, development of metastasis, and tumor-related death showed a significant association of the T393C polymorphism with outcome (5-year cancer-specific survival rates: TT, 91%; TC, 81%; CC, 69%; P = 0.015). Multivariate Cox proportional analysis of a 10-year follow-up confirmed the T393C polymorphism as an independent prognostic factor in clear cell renal cell carcinoma. Homozygous CC patients were at highest risk for progression (hazard ratio, 2.48; P = 0.009) or tumor-related death (hazard ratio, 3.15; P = 0.018) compared with T-allele carriers."	16467086	PubMed		"Frey et al., 2006, Clin. Cancer Res."		4	accepted	2896	Common Germline	2023-01-09 21:46:39 UTC	https://civicdb.org/links/evidence_items/2896	https://civicdb.org/links/molecular_profiles/851	FALSE	GNAS	2778	c.393T>C		chr20	58853658	58853658	T	C	ENST00000371100.4	75		synonymous_variant	"NC_000020.11:g.58903752C>T,NC_000020.10:g.57478807C>T,NM_000516.4:c.393C>T,NP_000507.1:p.Ile131="	2023-01-27 17:06:15 UTC	CA409455494	197681	"I131=,RS7121,L131="	FALSE
GNAS c.393T>C	851	Chronic Lymphocytic Leukemia	1040				Prognostic	Supports	B	Better Outcome	"In a retrospective study of 144 patients with B-cell chronic lymphocytic leukemia, the median progression-free survival was significantly different between GNAS T393C genotypes (TT 130 months; TC 100 months; CC 31 months; P = 0.0066) and an independent prognostic factor for progression-free survival by multivariable analysis [hazard ratio (HR) CC versus TT 2.7; P = 0.010]. CC genotypes were at highest risk for death compared with T-alleles (median overall survival 197 vs 310 months, respectively) in both univariate (HR, 4.8; P < 0.0001) and multivariable analysis (HR, 5.6; P = 0.002)."	17020971	PubMed		"Frey et al., 2006, Clin. Cancer Res."		4	accepted	2897	Common Germline	2023-01-09 21:46:39 UTC	https://civicdb.org/links/evidence_items/2897	https://civicdb.org/links/molecular_profiles/851	FALSE	GNAS	2778	c.393T>C		chr20	58853658	58853658	T	C	ENST00000371100.4	75		synonymous_variant	"NC_000020.11:g.58903752C>T,NC_000020.10:g.57478807C>T,NM_000516.4:c.393C>T,NP_000507.1:p.Ile131="	2023-01-27 17:06:15 UTC	CA409455494	197681	"I131=,RS7121,L131="	FALSE
GNAS c.393T>C	851	Melanoma	1909				Prognostic	Supports	B	Poor Outcome	"This study showed that GNAS1 T393C SNP represents a genetic host factor for predicting tumor progression in patients with malignant melanoma. Carriers of the C-allele showed a significantly more severe tumor progression as estimated from the time period to develop metastasis (HR 2.2, 95% CI 1.1-3.2, p = 0.017). Proportions of 5-year metastasis-free intervals were 87.1% for TT genotypes and 66.0% for C-allele carriers. Moreover, multivariable Cox regression analysis including tumor stage and melanoma subtype proved the T393C polymorphism to be an independent factor for metastasis (p = 0.012)."	21156401	PubMed		"Frey et al., 2010, Eur. J. Med. Res."		4	accepted	2898	Common Germline	2023-05-03 21:15:03 UTC	https://civicdb.org/links/evidence_items/2898	https://civicdb.org/links/molecular_profiles/851	FALSE	GNAS	2778	c.393T>C		chr20	58853658	58853658	T	C	ENST00000371100.4	75		synonymous_variant	"NC_000020.11:g.58903752C>T,NC_000020.10:g.57478807C>T,NM_000516.4:c.393C>T,NP_000507.1:p.Ile131="	2023-01-27 17:06:15 UTC	CA409455494	197681	"I131=,RS7121,L131="	FALSE
MGMT Underexpression	1229	Glioblastoma	3068		Temozolomide		Predictive	Supports	B	Sensitivity/Response	"In this study, patients with low MGMT expression, compared with patients with high MGMT expression, had a significantly higher response rate (55% v 7%, respectively; P = .004) and improved PFS (median, 5.5 v 1.9 months, respectively; P = .009) and OS (median, 16 v 5 months, respectively; P = .003). Among patients with MGMT data available for analysis, radiotherapy was started and completed in 91% of patients with low MGMT expression. In contrast, among patients with high MGMT expression, only 64% started radiotherapy, and 43% completed it. These results suggest that neoadjuvant chemotherapy may be feasible for inoperable glioblastoma patients expressing low levels of MGMT without compromising subsequent treatment with radiotherapy, whereas patients with high MGMT expression are less likely to respond and more likely to experience progression before or during radiotherapy."	17442989	PubMed		"Chinot et al., 2007, J. Clin. Oncol."		3	accepted	2899	N/A	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/2899	https://civicdb.org/links/molecular_profiles/1229	FALSE	MGMT	4255	Underexpression		chr10	129467184	129768007			ENST00000306010.7	75		N/A		2023-01-09 21:52:12 UTC		N/A		FALSE
MGMT Underexpression	1229	High Grade Glioma	3070		Temozolomide		Predictive	Supports	B	Sensitivity/Response	"This study showed that low MGMT mRNA expression was strongly predictive for prolonged time to progression, treatment response, and length of survival in univariate and multivariate models (p<0.0001). The degree of MGMT mRNA expression was highly correlated with the MGMT promoter methylation status (p<0.0001); however, discordant findings were seen in 12 glioblastoma patients. Patients with methylated tumors with high MGMT mRNA expression (N = 6) did significantly worse than those with low transcriptional activity (p<0.01). Conversely, unmethylated tumors with low MGMT mRNA expression (N = 6) did better than their counterparts."	21365007	PubMed		"Kreth et al., 2011, PLoS ONE"		3	accepted	2901	N/A	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/2901	https://civicdb.org/links/molecular_profiles/1229	FALSE	MGMT	4255	Underexpression		chr10	129467184	129768007			ENST00000306010.7	75		N/A		2023-01-09 21:52:12 UTC		N/A		FALSE
MGMT Underexpression	1229	Oligodendroglioma	3181		Temozolomide		Predictive	Supports	B	Sensitivity/Response	"In this study, loss of chromosome 1p and low MGMT protein expression were associated with objective response (P < .003 and P < .04, respectively). However, only 54% of the study group had evaluation of 1p/19q status, and MGMT protein expression was studied in only 33%. Therefore, the association between 1p deletion and low MGMT protein expression was statistically significant when evaluated further and verified in the extended group of 31 patients with low-grade oligodendrogliomas."	16541434	PubMed		"Levin et al., 2006, Cancer"		2	accepted	2902	N/A	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/2902	https://civicdb.org/links/molecular_profiles/1229	FALSE	MGMT	4255	Underexpression		chr10	129467184	129768007			ENST00000306010.7	75		N/A		2023-01-09 21:52:12 UTC		N/A		FALSE
MGMT Underexpression	1229	Glioblastoma	3068		Temozolomide		Predictive	Supports	B	Sensitivity/Response	"In 41 glioblastomas treated with temozolomide (TMZ) therapy (MGMT-immunopositive: n = 22, negative: n = 19), both progression free survival and overall survival were significantly better in MGMT-immunonegative glioblastomas. (PFS: P = 0.0015, OS: P = 0.0384)."	21331613	PubMed		"Watanabe et al., 2011, Brain Tumor Pathol"		3	accepted	2903	N/A	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/2903	https://civicdb.org/links/molecular_profiles/1229	FALSE	MGMT	4255	Underexpression		chr10	129467184	129768007			ENST00000306010.7	75		N/A		2023-01-09 21:52:12 UTC		N/A		FALSE
MGMT Underexpression	1229	Neuroendocrine Tumor	169		Temozolomide		Predictive	Supports	B	Sensitivity/Response	"Among those patients who received temozolomide-based therapy in this study, the median progression-free survival for patients whose tumors showed intact MGMT expression was 9.3 months compared with 19.2 months for patients with MGMT-deficient tumors (P = 0.11). The median overall survival for patients whose tumors showed intact MGMT expression was 19.1 months; the median overall survival for patients with MGMT deficient tumors was not reached."	19118063	PubMed		"Kulke et al., 2009, Clin. Cancer Res."		2	accepted	2904	N/A	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/2904	https://civicdb.org/links/molecular_profiles/1229	FALSE	MGMT	4255	Underexpression		chr10	129467184	129768007			ENST00000306010.7	75		N/A		2023-01-09 21:52:12 UTC		N/A		FALSE
RRM1 Underexpression	1231	Lung Non-small Cell Carcinoma	3908		"Cisplatin,Gemcitabine"	Combination	Predictive	Supports	B	Sensitivity/Response	"In the personalized therapy group of this study, patients received chemotherapy based on RRM-1 IHC expression levels, whereas the standard therapy group received non-customized chemotherapy. There were statistically significant improvements between the personalized therapy group versus the standard therapy group in disease control rate (82.9% vs 55.3%, P=0.004), and progression-free survival (median: 5.5 months vs 3.0 months, P=0.005). Besides, the overall survival had a tendency to become more prolonged (median: 16.0 months vs 12.4 months, P=0.286)."	24595080	PubMed		"Nie et al., 2013, Cancer Biomark"		4	accepted	2905	N/A	2023-01-09 21:46:44 UTC	https://civicdb.org/links/evidence_items/2905	https://civicdb.org/links/molecular_profiles/1231	FALSE	RRM1	6240	Underexpression		chr11	4094809	4138876			ENST00000300738.5	75		N/A		2023-01-09 21:52:12 UTC		N/A		FALSE
EGFR S768I	558	Lung Non-small Cell Carcinoma	3908		Erlotinib		Predictive	Does Not Support	C	Sensitivity/Response	"S768I mutations in exon 20 of the EGFR gene are rare and are typically seen in conjunction with sensitizing EGFR mutations. Because of this mutation's rarity and the variability of responses of treated cases, its exact prognostic and predictive role is not fully understood. In our experience, S768I mutations in isolation do not necessarily confer sensitivity to erlotinib, but in conjunction with sensitizing EGFR mutations, S768I mutations do not restrict efficacy."	27211795	PubMed		"Leventakos et al., 2016, J Thorac Oncol"		2	accepted	2906	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/2906	https://civicdb.org/links/molecular_profiles/558	FALSE	EGFR	1956	S768I		chr7	55181312	55181312	G	T	ENST00000275493.2	75		missense_variant	"ENST00000275493.2:c.2303G>T,NC_000007.13:g.55249005G>T,NM_005228.4:c.2303G>T,NP_005219.2:p.Ser768Ile"	2023-01-27 17:04:20 UTC	CA135840	45251	"SER768ILE,RS121913465"	FALSE
NRAS Q61K	423	Lung Non-small Cell Carcinoma	3908		"Selumetinib,Trametinib"	Substitutes	Predictive	Supports	D	Sensitivity/Response	"Of the 4,562 patients with lung cancers, 30 showed NRAS mutations, which corresponded to 9 different amino acid substitutions. Cell lines were developed for 6 of these mutations (one harboring Q61L, two Q61R, and three Q61K mutations) and 5/6 were sensitive to MEK inhibitors selumetinib and trametinib. One Q61K line was not sensitive to these inhibitors."	23515407	PubMed		"Ohashi et al., 2013, Clin. Cancer Res."		2	accepted	2907	Somatic	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/2907	https://civicdb.org/links/molecular_profiles/423	FALSE	NRAS	4893	Q61K		chr1	114713909	114713909	G	T	ENST00000369535.4	75		missense_variant	"NM_002524.4:c.181C>A,NP_002515.1:p.Gln61Lys,NC_000001.10:g.115256530G>T,ENST00000369535.4:c.181C>A"	2023-01-27 17:03:41 UTC	CA151263	73058	"GLN61LYS,RS121913254"	FALSE
RET C609Y	1234	Thyroid Gland Medullary Carcinoma	3973				Predisposing	Supports	B	Predisposition	"Study of a family with three generations of history indicating co-segregation of RET C609Y and multiple endocrine neoplasia type 2A, many of whom exhibited medullary thyroid cancers specifically.  22 individuals in this family were carriers of C609Y. Of these, 9 exhibited medullary thyroid cancers. While the variant is strongly suspected of being pathogenic for these tumors, this variant appears to result in later onset of cancer than some other variants and the authors recommend delaying prophylactic thyroidectomy until 10-15 years of age. In addition to this large family, the authors also provide an extensive review of prior reports of C609 variants, identifying a total of 111 patients from 19 publications, representing 21 affected kindreds and 15 sporadic cases. 89 of these cases had C609Y specifically.  The authors also summarize prior functional work that suggests that C609Y has transforming activity that is significant but not as strong as some other variants. Based on all of this analysis, the authors conclude that C609Y causes medullary thyroid cancers but a milder form than some other variants. Based on this paper, the following ACMG evidence codes seem potentially valid: 'PS1', 'PS3',  'PM5', 'PP1', 'PP4', and 'PP5'."	19472011	PubMed		"Calva et al., 2009, Ann. Surg. Oncol."		4	accepted	2913	Rare Germline	2023-01-12 06:23:20 UTC	https://civicdb.org/links/evidence_items/2913	https://civicdb.org/links/molecular_profiles/1234	FALSE	RET	5979	C609Y		chr10	43113622	43113622	G	A	ENST00000355710.3	75		missense_variant	"NM_020630.4:c.1826G>A,NC_000010.10:g.43609070G>A,NP_065681.1:p.Cys609Tyr,ENST00000355710.3:c.1826G>A"	2023-01-27 17:09:05 UTC	CA007824	13933	CYS609TYR	FALSE
FGFR1 Expression	264	Sarcoma	1115		"Infigratinib,FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074,FGFR Inhibitor AZD4547"	Substitutes	Predictive	Supports	D	Sensitivity/Response	"Targeting of FGFR1 by RNA interference and small-molecule inhibitors (PD173074, AZD4547, BGJ398) revealed that the requirement for FGFR1 signaling in STS cells is dictated by FGFR1 expression levels, and identified the MAPK-ERK1/2 axis as critical FGFR1 effector pathway."	27535980	PubMed		"Chudasama et al., 2017, Clin. Cancer Res."		3	accepted	2915	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/2915	https://civicdb.org/links/molecular_profiles/264	FALSE	FGFR1	2260	Expression		chr8	38411138	38467845			ENST00000425967.3	75		N/A	N/A	2023-01-09 21:52:06 UTC		N/A		FALSE
KIT N822K	1237	Gastrointestinal Stromal Tumor	9253		Imatinib		Predictive	Supports	C	Resistance	"147 patients with advanced, unresectable GISTs were enrolled onto a randomized, phase II clinical study of imatinib (CSTI571-B2222). Specimens from 43 pretreatment and/or imatinib-resistant tumors were analyzed to identify molecular correlates of imatinib resistance. N822K was observed as a secondary KIT mutation in two patients with secondary imatinib resistance and one patient with primary resistance, and also as a primary mutation in a patient with primary resistance. The mutation was shown to occur at a hotspot (N822) of previously reported secondary KIT mutations in imatinib resistant GISTs. When co-expressed with V560D (imatinib sensitive) in vitro N822K showed moderate imatinib resistance."	16954519	PubMed		"Heinrich et al., 2006, J. Clin. Oncol."		3	accepted	2918	Somatic	2023-01-09 21:46:44 UTC	https://civicdb.org/links/evidence_items/2918	https://civicdb.org/links/molecular_profiles/1237	FALSE	KIT	3815	N822K	KIT Exon 17	chr4	54733174	54733174	T	A	ENST00000288135.5	75		missense_variant	"NM_000222.2:c.2466T>A,NP_000213.1:p.Asn822Lys,NC_000004.11:g.55599340T>A,ENST00000288135.5:c.2466T>A"	2023-01-27 17:09:06 UTC	CA16602411	375931	"ASN822LYS,RS121913514"	FALSE
KIT Y823D	963	Gastrointestinal Stromal Tumor	9253		Imatinib		Predictive	Supports	C	Resistance	"147 patients with advanced, unresectable GISTs were enrolled onto a randomized, phase II clinical study of imatinib (CSTI571-B2222). Specimens from 43 pretreatment and/or imatinib-resistant tumors were analyzed to identify molecular correlates of imatinib resistance. Y823D was observed as a secondary KIT mutation in five patients with secondary imatinib resistance. The mutation was shown to occur at a hotspot (Y823) of previously reported secondary KIT mutations in imatinib resistant GISTs. When co-expressed with V560D (imatinib sensitive) in vitro Y823D showed ""extreme"" imatinib resistance."	16954519	PubMed		"Heinrich et al., 2006, J. Clin. Oncol."		3	accepted	2919	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/2919	https://civicdb.org/links/molecular_profiles/963	FALSE	KIT	3815	Y823D	KIT Exon 17	chr4	54733175	54733175	T	G	ENST00000288135.5	75		missense_variant	"NM_000222.2:c.2467T>G,NP_000213.1:p.Tyr823Asp,NC_000004.11:g.55599341T>G,ENST00000288135.5:c.2467T>G"	2023-01-27 17:07:25 UTC	CA16602561	376101	"TYR823ASP,RS1057519761"	FALSE
KIT C809G	1238	Gastrointestinal Stromal Tumor	9253		Imatinib		Predictive	Supports	C	Resistance	"147 patients with advanced, unresectable GISTs were enrolled onto a randomized, phase II clinical study of imatinib (CSTI571-B2222). Specimens from 43 pretreatment and/or imatinib-resistant tumors were analyzed to identify molecular correlates of imatinib resistance. C809G was observed as a secondary KIT mutation in one patient with secondary imatinib resistance. In vitro, C809G showed imatinib resistance both in isolation and when coexpressed with K642E + N822H (the primary KIT mutations, found on the same allele, for this patient)."	16954519	PubMed		"Heinrich et al., 2006, J. Clin. Oncol."		3	accepted	2920	Somatic	2023-01-09 21:46:44 UTC	https://civicdb.org/links/evidence_items/2920	https://civicdb.org/links/molecular_profiles/1238	FALSE	KIT	3815	C809G	KIT Exon 17	chr4	54733133	54733133	T	G	ENST00000288135.5	75		missense_variant	"ENST00000288135.5:c.2425T>G,NC_000004.11:g.55599299T>G,NM_000222.2:c.2425T>G,NP_000213.1:p.Cys809Gly"	2023-01-27 17:09:06 UTC	CA356911727	NONE FOUND	CYS809GLY	FALSE
KIT D820A	1239	Gastrointestinal Stromal Tumor	9253		Imatinib		Predictive	Supports	C	Resistance	"147 patients with advanced, unresectable GISTs were enrolled onto a randomized, phase II clinical study of imatinib (CSTI571-B2222). Specimens from 43 pretreatment and/or imatinib-resistant tumors were analyzed to identify molecular correlates of imatinib resistance. D820A was observed as a secondary KIT mutation in one patient with secondary imatinib resistance. The mutation was shown to occur at a hotspot (D820) of previously reported secondary KIT mutations in imatinib resistant GISTs. A cell line derived from a separate patient with the same primary (V560D) and secondary (D820A) mutations showed moderately increased resistance to imatinib compared to reports for GIST lines with primary exon 11 KIT mutations alone."	16954519	PubMed		"Heinrich et al., 2006, J. Clin. Oncol."		3	accepted	2921	Somatic	2023-01-09 21:46:44 UTC	https://civicdb.org/links/evidence_items/2921	https://civicdb.org/links/molecular_profiles/1239	FALSE	KIT	3815	D820A	KIT Exon 17	chr4	54733167	54733167	A	C	ENST00000288135.5	75		missense_variant	"ENST00000288135.5:c.2459A>C,NC_000004.11:g.55599333A>C,NM_000222.2:c.2459A>C,NP_000213.1:p.Asp820Ala"	2023-01-27 17:09:07 UTC	CA356911952	NONE FOUND	ASP820ALA	FALSE
KIT D820G	1240	Gastrointestinal Stromal Tumor	9253		Imatinib		Predictive	Supports	C	Resistance	"147 patients with advanced, unresectable GISTs were enrolled onto a randomized, phase II clinical study of imatinib (CSTI571-B2222). Specimens from 43 pretreatment and/or imatinib-resistant tumors were analyzed to identify molecular correlates of imatinib resistance. D820G was observed as a secondary KIT mutation in two patients with secondary imatinib resistance. The mutation was shown to occur at a hotspot (D820) of previously reported secondary KIT mutations in imatinib resistant GISTs. When co-expressed with V560D (imatinib sensitive) in vitro D820G showed ""extreme"" imatinib resistance."	16954519	PubMed		"Heinrich et al., 2006, J. Clin. Oncol."		3	accepted	2922	Somatic	2023-01-09 21:46:44 UTC	https://civicdb.org/links/evidence_items/2922	https://civicdb.org/links/molecular_profiles/1240	FALSE	KIT	3815	D820G	KIT Exon 17	chr4	54733167	54733167	A	G	ENST00000288135.5	75		missense_variant	"NM_000222.2:c.2459A>G,NP_000213.1:p.Asp820Gly,NC_000004.11:g.55599333A>G,ENST00000288135.5:c.2459A>G"	2023-01-27 17:09:08 UTC	CA123516	13853	"ASP820GLY,RS121913682"	FALSE
KIT D816H	957	Gastrointestinal Stromal Tumor	9253		Imatinib		Predictive	Supports	C	Resistance	"147 patients with advanced, unresectable GISTs were enrolled onto a randomized, phase II clinical study of imatinib (CSTI571-B2222). Specimens from 43 pretreatment and/or imatinib-resistant tumors were analyzed to identify molecular correlates of imatinib resistance. D816H was observed as a secondary KIT mutation in two patients with secondary imatinib resistance. The mutation was shown to occur at a hotspot (D816) of previously reported secondary KIT mutations in imatinib resistant GISTs. When co-expressed with V560D (imatinib sensitive) in vitro D816H showed ""extreme"" imatinib resistance. It was also highly resistant in isolation."	16954519	PubMed		"Heinrich et al., 2006, J. Clin. Oncol."		3	accepted	2923	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/2923	https://civicdb.org/links/molecular_profiles/957	FALSE	KIT	3815	D816H	KIT Exon 17	chr4	54733154	54733154	G	C	ENST00000288135.5	75		missense_variant	"NM_000222.2:c.2446G>C,NP_000213.1:p.Asp816His,NC_000004.11:g.55599320G>C,ENST00000288135.5:c.2446G>C"	2023-01-27 17:07:22 UTC	CA123540	13863	"ASP816HIS,RS121913506"	FALSE
KIT T670I	1241	Gastrointestinal Stromal Tumor	9253		Imatinib		Predictive	Supports	C	Resistance	"147 patients with advanced, unresectable GISTs were enrolled onto a randomized, phase II clinical study of imatinib (CSTI571-B2222). Specimens from 43 pretreatment and/or imatinib-resistant tumors were analyzed to identify molecular correlates of imatinib resistance. T670I was observed as a secondary KIT mutation in one patient with secondary imatinib resistance. The mutation was shown to occur at a hotspot (T670) of previously reported secondary KIT mutations in imatinib resistant GISTs. When co-expressed with V560D (imatinib sensitive) in vitro T670I showed ""extreme"" imatinib resistance. It also showed resistance in isolation."	16954519	PubMed		"Heinrich et al., 2006, J. Clin. Oncol."		3	accepted	2924	Somatic	2023-01-09 21:46:44 UTC	https://civicdb.org/links/evidence_items/2924	https://civicdb.org/links/molecular_profiles/1241	FALSE	KIT	3815	T670I		chr4	54729353	54729353	C	T	ENST00000288135.5	75		missense_variant	"NM_000222.2:c.2009C>T,NP_000213.1:p.Thr670Ile,NC_000004.11:g.55595519C>T,ENST00000288135.5:c.2009C>T"	2023-01-27 17:09:09 UTC	CA16602525	376058	"THR670ILE,RS121913516"	FALSE
DNMT3A Mutation	189	Cancer	162		"Nivolumab,Pembrolizumab,Atezolizumab"	Substitutes	Predictive	Supports	B	Resistance	"A subset of patients receiving PD1/PD-L1 inhibition appear to be ""hyper-progressors,"" with a greatly accelerated rate of tumor growth and clinical deterioration compared to pre-therapy. The current study investigated potential genomic markers associated with ""hyper-progression"". Consecutive stage IV cancer patients who received immunotherapies (CTLA-4, PD-1/PD-L1 inhibitors or other [investigational] agents) and had their tumor evaluated by next-generation sequencing Amongst 155 patients, TTF (time to treatment failure) <2 months was seen in 4/5 individuals harbouring DNMT3A alteration."	28351930	PubMed		"Kato et al., 2017, Clin. Cancer Res."		2	accepted	2926	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/2926	https://civicdb.org/links/molecular_profiles/189	FALSE	DNMT3A	1788	Mutation		chr2	25232976	25342590			ENST00000264709.3	75		transcript_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
ATM Mutation	178	Chronic Lymphocytic Leukemia	1040				Prognostic	Supports	B	Poor Outcome	"ATM point mutations were found in 8/57 patients with CLL and were associated with a shorter treatment-free interval, suggesting a more aggressive course."	21993670	PubMed		"Guarini et al., 2012, Haematologica"		3	accepted	2927	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/2927	https://civicdb.org/links/molecular_profiles/178	FALSE	ATM	472	Mutation		chr11	108222832	108369099			ENST00000278616.4	75		"transcription_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
BRAF Amplification	1243	Colorectal Cancer	9256		"Panitumumab,Dabrafenib"	Combination	Predictive	Supports	C	Resistance	"Paired pre-treatment and post-progression tumor biopsies from BRAF-mutant CRC patients treated with RAF inhibitor combinations were analyzed. Alterations in MAPK pathway genes were found in resistant tumors not present in matched pre-treatment tumors, including KRAS amplification, BRAF amplification, and a MEK1 mutation."	25673644	PubMed		"Ahronian et al., 2015, Cancer Discov"		3	accepted	2929	Somatic	2023-01-09 21:46:44 UTC	https://civicdb.org/links/evidence_items/2929	https://civicdb.org/links/molecular_profiles/1243	FALSE	BRAF	673	Amplification		chr7	140734479	140924764			ENST00000288602.6	75		transcript_amplification	N/A	2023-01-09 21:52:12 UTC		N/A		FALSE
NRAS Mutation	208	Skin Melanoma	8923		"Binimetinib,Ribociclib"	Combination	Predictive	Supports	B	Sensitivity/Response	"Inhibition of CDK4 and 6, regulators of the G1/S cell cycle checkpoint, arrests the cell cycle in the G1 phase, suppresses DNA synthesis, and inhibits cancer cell growth. There is an ongoing phase 1/2 trial of binimetinib with the CDK4/6 inhibitor ribociclib (LEE011) in mutant NRAS melanoma patients (NCT01781572). Early results from the 21 evaluable patients were very promising, with 7 patients achieving a partial response (33%) and 11 patients with stable disease (52%)"	26987942	PubMed		"Vu et al., 2016, Pharmacol. Res."		3	accepted	2931	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/2931	https://civicdb.org/links/molecular_profiles/208	FALSE	NRAS	4893	Mutation		chr1	114704469	114716894			ENST00000369535.4	75		"transcript_variant,gain_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
IDH1 Mutation	641	Brain Glioma	60108		Olaparib		Predictive	Supports	D	Sensitivity/Response	"Mutations in isocitrate dehydrogenase 1 and 2, which result in overproduction of 2-hydroxyglutarate (2HG). 2HG is considered to be an oncometabolite, or a metabolite that promotes carcinogenesis, and inhibitors of mutant isocitrate dehydrogenase are in development to target this process. The authors discovered that 2HG overproduction impairs homologous recombination used in DNA repair and sensitizes cancer cells to treatment with PARP inhibitors, another class of cancer drugs that are already in clinical use."	28148839	PubMed		"Sulkowski et al., 2017, Sci Transl Med"		3	accepted	2933	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/2933	https://civicdb.org/links/molecular_profiles/641	FALSE	IDH1	3417	Mutation		chr2	208237079	208251551			ENST00000415913.1	75		transcript_variant		2023-01-09 21:52:08 UTC				FALSE
ROS1 G2032R	1245	Lung Adenocarcinoma	3910		Crizotinib		Predictive	Supports	C	Resistance	"Resistance to crizotinib developed in a patient with metastatic lung adenocarcinoma harboring a CD74-ROS1 rearrangement who had initially shown a dramatic response to treatment. A biopsy of a resistant tumor showed an acquired G2032R mutation in the ROS1 kinase domain. Although this mutation does not lie at the gatekeeper residue, it confers resistance to ROS1 kinase inhibition through steric interference with drug binding. The same resistance mutation was observed at all the metastatic sites that were examined at autopsy, suggesting that this mutation was an early event in the clonal evolution of resistance."	23724914	PubMed		"Awad et al., 2013, N. Engl. J. Med."	NCT00585195	1	accepted	2934	Somatic	2023-01-09 21:46:44 UTC	https://civicdb.org/links/evidence_items/2934	https://civicdb.org/links/molecular_profiles/1245	FALSE	ROS1	6098	G2032R		chr6	117317184	117317184	C	T	ENST00000368508.3	75		missense_variant	"NC_000006.11:g.117638347C>T,NM_002944.2:c.6094G>A,NP_002935.2:p.Gly2032Arg,ENST00000368508.3:c.6094G>A"	2023-01-27 17:09:10 UTC	CA16602597	376139	GLY2032ARG	TRUE
MAP2K1 K57N	1246	Lung Adenocarcinoma	3910				Prognostic	Supports	B	Poor Outcome	"In a study of 6,024 lung adenocarcinomas, 36 conferred MEK1 mutations whereby 64% (n=23) were K57N and 19% (n=7) were Q56P.  Median overall survival of MEK1-mutated tumors was not significantly different from KRAS-mutated tumors (14.9 vs 13.7 months) or BRAP-mutated tumors (14.9 vs. 20.9 months).  MEK1-mutated tumors were significantly inferior compared to EGFR-mutated tumors (14.9 vs. 35.9 months; HR=2.64, p=0.01), ALK-rearranged tumors (14.9 vs. 35.9 months; HR, 2.64; P = 0.01), ROS1-rearranged tumors (14.9 vs. 76 months; HR, 4.00; P = 0.02), and RET-rearranged tumors (14.9 months vs. not reached; HR, 3.25; P = 0.03)."	25351745	PubMed		"Arcila et al., 2015, Clin. Cancer Res."		3	accepted	2935	Somatic	2023-01-09 21:46:44 UTC	https://civicdb.org/links/evidence_items/2935	https://civicdb.org/links/molecular_profiles/1246	FALSE	MAP2K1	5604	K57N		chr15	66435117	66435117	G	T	ENST00000307102.5	75		missense_variant	"NM_002755.3:c.171G>T,NP_002746.1:p.Lys57Asn,NC_000015.9:g.66727455G>T,ENST00000307102.5:c.171G>T,NG_008305.1:g.53245G>T"	2023-01-27 17:09:11 UTC	CA356995	223140	"LYS57ASN,RS869025608"	FALSE
MAP2K1 K57N	1246	Lung Adenocarcinoma	3910		Selumetinib		Predictive	Supports	D	Sensitivity/Response	"Mutational profiling of 207 lung adenocarcinomas identified in 2 of with activating mutation in exon 2 of MEK1 (K57N) in the nonkinase portion of the kinase. Neither of these two tumors harbored known mutations in other genes encoding components of the EGFR signaling pathway (i.e., EGFR, HER2, KRAS, PIK3CA, and BRAF). Expression of mutant, but not wild-type, MEK1 leads to constitutive activity of extracellular signal-regulated kinase (ERK)-1/2 in human 293T cells and to growth factor-independent proliferation of murine Ba/F3 cells. A selective MEK inhibitor, AZD6244, inhibits mutant-induced ERK activity in 293T cells and growth of mutant-bearing Ba/F3 cells."	18632602	PubMed		"Marks et al., 2008, Cancer Res."		2	accepted	2936	Somatic	2023-01-09 21:46:44 UTC	https://civicdb.org/links/evidence_items/2936	https://civicdb.org/links/molecular_profiles/1246	FALSE	MAP2K1	5604	K57N		chr15	66435117	66435117	G	T	ENST00000307102.5	75		missense_variant	"NM_002755.3:c.171G>T,NP_002746.1:p.Lys57Asn,NC_000015.9:g.66727455G>T,ENST00000307102.5:c.171G>T,NG_008305.1:g.53245G>T"	2023-01-27 17:09:11 UTC	CA356995	223140	"LYS57ASN,RS869025608"	FALSE
NRAS Mutation	208	Skin Melanoma	8923		Binimetinib		Predictive	Supports	B	Sensitivity/Response	"NEMO is an ongoing, randomised, open-label phase 3 study of patients with advanced, unresectable, AJCC IIIC/IV NRAS-mutant melanoma. 402 patients that were previously untreated or progressed on or after previous immunotherapy were randomised to receive either binimetinib (269) or dacarbazine (133). The study's primary endpoint was progression free survival. Median follow-up was 1.7 months (IQR 1.4-4.1). Median progression-free survival was 2.8 months (95% CI 2.8-3.6) in the binimetinib group and 1.5 months (1.5-1.7) in the dacarbazine group, demonstrating improved progression-free survival of binimetinib compared with dacarbazine."	28284557	PubMed		"Dummer et al., 2017, Lancet Oncol."	NCT01763164	5	accepted	2937	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/2937	https://civicdb.org/links/molecular_profiles/208	FALSE	NRAS	4893	Mutation		chr1	114704469	114716894			ENST00000369535.4	75		"transcript_variant,gain_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
EGFR Mutation	438	Lung Cancer	1324		Gefitinib		Predictive	Supports	B	Sensitivity/Response	"In a study of 52 patients with recurrent lung cancer, 27 individuals had EGFR mutation including 2 point mutations in exon 18 (G719A and G1719C), 23 deletions in exon 19, two insertions in exon 19 (I744KIPVAI), on mutation in exon 20 (S768I), and 16 point mutations in exon 21 (L858R and E709H). Patients were treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib, and tumors harboring an EGFR mutation had an increased frequency of partial response (PR) and a lower rate of progressive disease (PD) (PR:22, PD:2 vs. PR:2, PD:17; P<0.0001) compared to wildtype EGFR patients. Patients with KRAS mutations also had a longer overall survival compared to wildtype EGFR patients (HR:2.526, 95% CI:1.314-4.858, P=0.0055)."	17409929	PubMed		"Endoh et al., 2006, J Thorac Oncol"		2	accepted	2939	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/2939	https://civicdb.org/links/molecular_profiles/438	FALSE	EGFR	1956	Mutation		chr7	55019101	55211628			ENST00000275493.2	75		inframe_variant		2023-01-09 21:52:07 UTC		N/A		FALSE
CTAG1B Overexpression	1247	Multiple Myeloma	9538		Letetresgene Autoleucel		Predictive	Supports	B	Sensitivity/Response	Clinical responses to NY-ESO-1/LAGE-1 TCR-engineered T-cells were observed in 16 of 20 patients (80%) with advanced multiple myeloma expressing NY-ESO-1 and/or LAGE-1 in this Phase 1/2a trial showing a median progression free survival of 19.1 months.	26193344	PubMed		"Rapoport et al., 2015, Nat. Med."		3	accepted	2940	N/A	2023-01-09 21:46:44 UTC	https://civicdb.org/links/evidence_items/2940	https://civicdb.org/links/molecular_profiles/1247	FALSE	CTAG1B	1485	Overexpression		chrX	154617609	154619271			ENST00000328435.2	75		N/A		2023-01-09 21:52:12 UTC		N/A		FALSE
CTAG2 Overexpression	1248	Multiple Myeloma	9538		Letetresgene Autoleucel		Predictive	Supports	B	Sensitivity/Response	Clinical responses to NY-ESO-1/LAGE-1 TCR-engineered T-cells were observed in 16 of 20 patients (80%) with advanced multiple myeloma expressing NY-ESO-1 and/or LAGE-1 in this Phase 1/2a trial showing a median progression free survival of 19.1 months.	26193344	PubMed		"Rapoport et al., 2015, Nat. Med."		3	accepted	2941	N/A	2023-01-09 21:46:44 UTC	https://civicdb.org/links/evidence_items/2941	https://civicdb.org/links/molecular_profiles/1248	FALSE	CTAG2	30848	Overexpression		chrX	154651972	154653579			ENST00000247306.4	75		N/A		2023-01-09 21:52:12 UTC		N/A		FALSE
KRAS A146T	880	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	D	Resistance	"Preclinical data supporting resistance of Exon 4 mutations, in particular A146T, to cetuximab and sensitivity to PD0325901. This study involved treatment of mice bearing A146T KRAS xenografts treated with PD0325901 or cetuximab."	20570890	PubMed		"Janakiraman et al., 2010, Cancer Res."		3	accepted	2943	Somatic	2023-01-09 21:46:39 UTC	https://civicdb.org/links/evidence_items/2943	https://civicdb.org/links/molecular_profiles/880	FALSE	KRAS	3845	A146T		chr12	25225628	25225628	C	T	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.436G>A,NP_004976.2:p.Ala146Thr,NC_000012.11:g.25378562C>T,ENST00000256078.4:c.436G>A"	2023-01-27 17:06:34 UTC	CA245262	197243	"RS121913527,ALA146THR"	FALSE
NTRK1 Fusion	415	Cancer	162		Entrectinib		Predictive	Supports	B	Sensitivity/Response	"in two phase I studies in patients with advanced or metastatic solid tumors, including patients with active central nervous system (CNS) disease. Here, we summarize the overall safety and report the antitumor activity of entrectinib in a cohort of patients with tumors harboring NTRK1/2/3, ROS1, or ALK gene fusions Responses were observed in non-small cell lung cancer, colorectal cancer, mammary analogue secretory carcinoma, melanoma, and renal cell carcinoma, as early as 4 weeks after starting treatment and lasting as long as >2 years. Notably, a complete CNS response was achieved in a patient with SQSTM1-NTRK1-rearranged lung cancer."	28183697	PubMed		"Drilon et al., 2017, Cancer Discov"		3	accepted	2948	Somatic	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/2948	https://civicdb.org/links/molecular_profiles/415	FALSE	NTRK1	4914	Fusion	NTRK1 Fusions	chr1	156874383	156881642			ENST00000524377.1	75		transcript_fusion		2023-01-09 21:52:06 UTC		N/A		FALSE
ROS1 Rearrangement	265	Cancer	162		Entrectinib		Predictive	Supports	B	Sensitivity/Response	"Two phase I studies included 119 patients with advanced or metastatic solid tumors, which included 28 patients with ROS1 rearrangements (n=28) where the overall safety and antitumor activity of entrectinib was examined. Entrectinib was shown to be safe and well tolerated. For phase 2, 14 ROS1-rearranged solid tumors were eligible and demonstrated an overall objective response rate of 86% (95% CI: 60?6) to entrectinib. Of the 14, 13 were Non-small cell lung cancer cases, 12 of which showed response with 2 of these patients demonstrated a complete response. A single melanoma case with a ROS1 rearrangement also showed a response to treatment."	28183697	PubMed		"Drilon et al., 2017, Cancer Discov"		3	accepted	2951	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/2951	https://civicdb.org/links/molecular_profiles/265	FALSE	ROS1	6098	Rearrangement		chr6	117288300	117425855			ENST00000368508.3	75		transcript_fusion		2023-01-09 21:52:06 UTC		N/A		FALSE
ALK Fusion	495	Cancer	162		Entrectinib		Predictive	Supports	B	Sensitivity/Response	"Two phase I studies in patients with advanced or metastatic solid tumors, including patients with active central nervous system (CNS) disease. Here, we summarize the overall safety and report the antitumor activity of entrectinib in a cohort of patients with tumors harboring NTRK1/2/3, ROS1, or ALK gene fusions Responses were observed in non-small cell lung cancer, colorectal cancer, mammary analogue secretory carcinoma, melanoma, and renal cell carcinoma, as early as 4 weeks after starting treatment and lasting as long as >2 years. Notably, a complete CNS response was achieved in a patient with SQSTM1-NTRK1-rearranged lung cancer."	28183697	PubMed		"Drilon et al., 2017, Cancer Discov"		3	accepted	2952	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/2952	https://civicdb.org/links/molecular_profiles/495	FALSE	ALK	238	Fusion	ALK Fusion	chr2	29192774	29223528			ENST00000389048.3	75		transcript_fusion		2023-01-09 21:52:07 UTC		N/A	REARRANGEMENT	FALSE
NTRK1 Fusion	415	Cancer	162		Larotrectinib		Predictive	Supports	C	Sensitivity/Response	"Results from a phase I study show that the TRK inhibitor LOXO-101 is well tolerated and effective, with patients whose tumors bear NTRK fusions responding well and durably to this targeted therapy. This publication reported results from an AACR meeting for an ongoing study that had enrolled six patients with NTRK fusions, three of whom could be evaluated at the time. Each had a different, heavily pretreated advanced disease: soft-tissue sarcoma; gastrointestinal stromal tumor (GIST); and MASC. All three patients experienced partial responses by 3-4 months with resolution of key tumour-related symptoms within two weeks. One of three patients experienced near-complete response by 8 months."	26603524	PubMed		"2016, Cancer Discov"		2	accepted	2953	Somatic	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/2953	https://civicdb.org/links/molecular_profiles/415	FALSE	NTRK1	4914	Fusion	NTRK1 Fusions	chr1	156874383	156881642			ENST00000524377.1	75		transcript_fusion		2023-01-09 21:52:06 UTC		N/A		FALSE
NTRK1 Amplification	1254	Cancer	162		Entrectinib		Predictive	Does Not Support	B	Sensitivity/Response	"Entrectinib, a potent oral inhibitor of the tyrosine kinases TRKA/B/C, ROS1, and ALK, was evaluated in two phase I studies in patients with advanced or metastatic solid tumors, including CNS disease. Responses were observed in non-small cell lung cancer, colorectal cancer, mammary analogue secretory carcinoma, melanoma, and renal cell carcinoma, as early as 4 weeks after starting treatment and lasting as long as >2 years. No objective responses (per RECIST v1.1) were observed in patients whose tumors did not harbor gene fusions involving NTRK1/2/3, ROS1, or ALK, with the exception of 1 patient with an ALKF1245V mutant neuroblastoma."	28183697	PubMed		"Drilon et al., 2017, Cancer Discov"		1	accepted	2958	Somatic	2023-01-09 21:46:44 UTC	https://civicdb.org/links/evidence_items/2958	https://civicdb.org/links/molecular_profiles/1254	FALSE	NTRK1	4914	Amplification		chr1	156860894	156881642			ENST00000524377.1	75		transcript_amplification		2023-01-09 21:52:12 UTC		N/A		FALSE
NTRK3 Amplification	1255	Cancer	162		Entrectinib		Predictive	Does Not Support	B	Sensitivity/Response	"Entrectinib, a potent oral inhibitor of the tyrosine kinases TRKA/B/C, ROS1, and ALK, was evaluated in two phase I studies in patients with advanced or metastatic solid tumors, including CNS disease. Responses were observed in non-small cell lung cancer, colorectal cancer, mammary analogue secretory carcinoma, melanoma, and renal cell carcinoma, as early as 4 weeks after starting treatment and lasting as long as >2 years. No objective responses (per RECIST v1.1) were observed in patients whose tumors did not harbor gene fusions involving NTRK1/2/3, ROS1, or ALK, with the exception of 1 patient with an ALKF1245V mutant neuroblastoma. Only 9 of 119 patients had NTRK Amplifications."	28183697	PubMed		"Drilon et al., 2017, Cancer Discov"		1	accepted	2959	Somatic	2023-01-09 21:46:44 UTC	https://civicdb.org/links/evidence_items/2959	https://civicdb.org/links/molecular_profiles/1255	FALSE	NTRK3	4916	Amplification		chr15	87874999	88256747			ENST00000394480.2	75		transcript_amplification	N/A	2023-01-09 21:52:12 UTC		N/A		FALSE
NTRK1 LMNA::NTRK1 e11-e10	3094	Colorectal Adenocarcinoma	50861		Entrectinib		Predictive	Supports	C	Sensitivity/Response	"A gene fusion between exon 11 of LMNA and exon 10 of NTRK1 was observed in a patient with metastatic colorectal cancer after therapy with first-line FOLFOX, second-line FOLFIRI/cetuximab, and third-line irinotecan. The patient treated in a clinical trial with pan-TRK kinase inhibitor entrectinib. Treatment was well tolerated and led to a partial response (PR) with 30% tumor shrinkage of multiple liver metastases. Clinical response lasted 4 months."	26546295	PubMed		"Russo et al., 2016, Cancer Discov"		3	accepted	2960	Somatic	2023-01-09 21:47:07 UTC	https://civicdb.org/links/evidence_items/2960	https://civicdb.org/links/molecular_profiles/3094	FALSE	NTRK1	4914	LMNA::NTRK1 e11-e10		chr1	156114707	156138757			ENST00000368300.4	75	ENST00000524377.1	transcript_fusion		2023-01-09 21:52:24 UTC			LMNA-NTRK1 E11-E10	FALSE
NTRK1 LMNA::NTRK1 e11-e10	3094	Colorectal Adenocarcinoma	50861		Entrectinib		Predictive	Supports	C	Sensitivity/Response	"A gene fusion between exon 11 of LMNA and exon 10 of NTRK1 was observed in a patient with metastatic colorectal cancer after therapy with first-line FOLFOX, second-line FOLFIRI/cetuximab, and third-line irinotecan. The patient treated in a clinical trial with pan-TRK kinase inhibitor entrectinib. Treatment was well tolerated and led to a partial response (PR) with 30% tumor shrinkage of multiple liver metastases. Clinical response lasted 4 months."	26546295	PubMed		"Russo et al., 2016, Cancer Discov"		3	accepted	2960	Somatic	2023-01-09 21:47:07 UTC	https://civicdb.org/links/evidence_items/2960	https://civicdb.org/links/molecular_profiles/3094	FALSE	NTRK1	4914	LMNA::NTRK1 e11-e10		chr1	156874571	156881642			ENST00000368300.4	75	ENST00000524377.1	transcript_fusion		2023-01-09 21:52:24 UTC			LMNA-NTRK1 E11-E10	FALSE
NTRK1 LMNA::NTRK1 G595R and G667C	1256	Colorectal Adenocarcinoma	50861		Entrectinib		Predictive	Supports	C	Resistance	"A gene fusion between exon 10 of NTRK1 and exon 11 of the LMNA genes was observed in a patient with metastatic colorectal cancer after therapy with first-line FOLFOX, second-line FOLFIRI/cetuximab, and third-line irinotecan. The patient treated in a clinical trial with pan-TRK kinase inhibitor entrectinib. Treatment was well tolerated and led to a partial response (PR) with 30% tumor shrinkage of multiple liver metastases. Clinical response lasted 4 months. Longitudinal analysis of ctDNA in plasma samples revealed a p.G595R- and p.G667C mutation in NTRK1 that were absent before treatment initiation but  emerged 4 weeks upon initiation of treatment with entrectinib. These mutations were also validated using xenograft, in vitro and 3D-modeling."	26546295	PubMed		"Russo et al., 2016, Cancer Discov"		4	accepted	2961	Somatic	2023-01-09 21:46:44 UTC	https://civicdb.org/links/evidence_items/2961	https://civicdb.org/links/molecular_profiles/1256	FALSE	NTRK1	4914	LMNA::NTRK1 G595R and G667C		chr1	156876550	156879315			ENST00000524377.1	75		"missense_variant,transcript_fusion"		2023-01-09 21:52:12 UTC		NONE FOUND	LMNA-NTRK1 G595R AND G667C	FALSE
TP53 Wildtype	365	Cancer	162		Rebemadlin		Predictive	Supports	D	Sensitivity/Response	"MDM2 Inhibitor Nutlin-3a induced senescence in presence of functional TP53 in murine primary fibroblasts, oncogenically transformed fibroblasts, and fibrosarcoma cell lines. Cells lacking functional TP53 were completely insensitive to the drug."	17671205	PubMed		"Efeyan et al., 2007, Cancer Res."		4	accepted	2963	N/A	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/2963	https://civicdb.org/links/molecular_profiles/365	FALSE	TP53	7157	Wildtype		chr17	7668402	7687538			ENST00000269305.4	75		wild_type		2023-01-09 21:52:06 UTC		N/A		FALSE
TP53 Wildtype	365	Cancer	162		MDM2 Inhibitor AMGMDS3		Predictive	Supports	D	Sensitivity/Response	MDM2 Inhibitor screen in a panel of 260 cancer cell lines with well characterized TP53 status shows that only cancer cell lines with unaltered TP53 may be sensitive to MDM2 Inhibitor.	25730903	PubMed		"Saiki et al., 2015, Oncotarget"		4	accepted	2964	N/A	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/2964	https://civicdb.org/links/molecular_profiles/365	FALSE	TP53	7157	Wildtype		chr17	7668402	7687538			ENST00000269305.4	75		wild_type		2023-01-09 21:52:06 UTC		N/A		FALSE
TP53 Wildtype	365	Leukemia	1240		RG7112		Predictive	Supports	B	Sensitivity/Response	"Phase I Trial of RG7112 in 116 heavily pretreated patients with AML, ALL, CML, CLL, sCLL demonstrated sustained clinical improvement and induction of TP53 target genes in subset of patients with wild type TP53. 96 patients were tested for TP53 mutation and 19 cases of mutation were detected. No sustained clinical improvement or induction of TP53 target genes was observed in patients with mutant TP53."	26459177	PubMed		"Andreeff et al., 2016, Clin. Cancer Res."		3	accepted	2965	N/A	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/2965	https://civicdb.org/links/molecular_profiles/365	FALSE	TP53	7157	Wildtype		chr17	7668402	7687538			ENST00000269305.4	75		wild_type		2023-01-09 21:52:06 UTC		N/A		FALSE
TP53 Deleterious Mutation	221	Leukemia	1240		RG7112		Predictive	Supports	B	Resistance	"Phase I Trial of MDM2 inhibitor RG7112 in 116 patients with AML, ALL, CML, CLL, sCLL demonstrated sustained clinical improvement and induction of TP53 target genes in subset of patients with wild type TP53. No sustained clinical improvement or induction of TP53 target genes was observed in patients with mutant TP53."	26459177	PubMed		"Andreeff et al., 2016, Clin. Cancer Res."		3	accepted	2966	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/2966	https://civicdb.org/links/molecular_profiles/221	FALSE	TP53	7157	Deleterious Mutation		chr17	7668402	7687538			ENST00000269305.4	75		N/A		2023-01-09 21:52:05 UTC				FALSE
TP53 Deleterious Mutation	221	Cancer	162		MDM2 Inhibitor AMGMDS3		Predictive	Supports	D	Resistance	"MDM2 Inhibitor screen in a panel of 260 cancer cell lines with well characterized TP53 status shows that only cancer cell lines with unaltered TP53 may be sensitive to MDM2 Inhibitor AMGMDS3, while those with p53 mutations demonstrated resistance."	25730903	PubMed		"Saiki et al., 2015, Oncotarget"		4	accepted	2967	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/2967	https://civicdb.org/links/molecular_profiles/221	FALSE	TP53	7157	Deleterious Mutation		chr17	7668402	7687538			ENST00000269305.4	75		N/A		2023-01-09 21:52:05 UTC				FALSE
TP53 Deleterious Mutation	221	Cancer	162		Rebemadlin		Predictive	Supports	D	Resistance	"MDM2 Inhibitor Nutlin-3a induced senescence in presence of functional TP53 in murine primary fibroblasts, oncogenically transformed fibroblasts, and fibrosarcoma cell lines. TP53 mutant cells lacking functional TP53 were completely insensitive to the drug."	17671205	PubMed		"Efeyan et al., 2007, Cancer Res."		4	accepted	2968	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/2968	https://civicdb.org/links/molecular_profiles/221	FALSE	TP53	7157	Deleterious Mutation		chr17	7668402	7687538			ENST00000269305.4	75		N/A		2023-01-09 21:52:05 UTC				FALSE
CTNNB1 T41A	1259	Desmoid Tumor	80366				Diagnostic	Supports	B	Positive	"Desmoid fibromatosis is a rare, nonmetastatic neoplasm marked by local invasiveness and relentless recurrence. Beta-Catenin deregulation has been commonly identified in sporadic desmoids. CTNNB1 mutations were observed in 117 of 138 (85%) of desmoids. Three discrete mutations in two codons of CTNNB1 exon 3 were identified: T41A (59%), S45F (33%), and S45P (8%). Five-year recurrence-free survival was significantly poorer in S45F-mutated desmoids (23%, P < 0.0001) versus either T41A (57%) or nonmutated tumors (65%). In conclusion, CTNNB1 mutations are highly common in desmoid tumors. Furthermore, patients harboring CTNNB1 (45F) mutations are at particular risk for recurrence and therefore may especially benefit from adjuvant therapeutic approaches."	18832571	PubMed		"Lazar et al., 2008, Am. J. Pathol."		4	accepted	2973	Somatic	2023-01-09 21:46:44 UTC	https://civicdb.org/links/evidence_items/2973	https://civicdb.org/links/molecular_profiles/1259	FALSE	CTNNB1	1499	T41A		chr3	41224633	41224633	A	G	ENST00000349496.5	75		missense_variant	"NM_001904.3:c.121A>G,NP_001895.1:p.Thr41Ala,NC_000003.11:g.41266124A>G,ENST00000349496.5:c.121A>G"	2023-01-27 17:09:13 UTC	CA127269	17580	"THR41ALA,RS121913412"	FALSE
CTNNB1 S45F	1260	Desmoid Tumor	80366				Diagnostic	Supports	B	Positive	"Desmoid fibromatosis is a rare, nonmetastatic neoplasm marked by local invasiveness and relentless recurrence. Beta-Catenin deregulation has been commonly identified in sporadic desmoids. CTNNB1 mutations were observed in 117 of 138 (85%) of desmoids. Three discrete mutations in two codons of CTNNB1 exon 3 were identified: T41A (59%), S45F (33%), and S45P (8%). Five-year recurrence-free survival was significantly poorer in S45F-mutated desmoids (23%, P < 0.0001) versus either T41A (57%) or nonmutated tumors (65%). In conclusion, CTNNB1 mutations are highly common in desmoid tumors. Furthermore, patients harboring CTNNB1 (S45F) mutations are at particular risk for recurrence and therefore may especially benefit from adjuvant therapeutic approaches."	18832571	PubMed		"Lazar et al., 2008, Am. J. Pathol."		4	accepted	2974	Somatic	2023-01-09 21:46:44 UTC	https://civicdb.org/links/evidence_items/2974	https://civicdb.org/links/molecular_profiles/1260	FALSE	CTNNB1	1499	S45F		chr3	41224646	41224646	C	T	ENST00000349496.5	75		missense_variant	"NM_001904.3:c.134C>T,NP_001895.1:p.Ser45Phe,NC_000003.11:g.41266137C>T,ENST00000349496.5:c.134C>T"	2023-01-27 17:09:14 UTC	CA127283	17588	"SER45PHE,RS121913409"	FALSE
CTNNB1 S45P	1261	Desmoid Tumor	80366				Diagnostic	Supports	B	Positive	"Desmoid fibromatosis is a rare, nonmetastatic neoplasm marked by local invasiveness and relentless recurrence. Beta-Catenin deregulation has been commonly identified in sporadic desmoids. CTNNB1 mutations were observed in 117 of 138 (85%) of desmoids. Three discrete mutations in two codons of CTNNB1 exon 3 were identified: T41A (59%), S45F (33%), and S45P (8%). In conclusion, CTNNB1 mutations are highly common in desmoid tumors."	18832571	PubMed		"Lazar et al., 2008, Am. J. Pathol."		3	accepted	2975	Somatic	2023-01-09 21:46:44 UTC	https://civicdb.org/links/evidence_items/2975	https://civicdb.org/links/molecular_profiles/1261	FALSE	CTNNB1	1499	S45P		chr3	41224645	41224645	T	C	ENST00000349496.5	75		missense_variant	"NM_001904.3:c.133T>C,NP_001895.1:p.Ser45Pro,NC_000003.11:g.41266136T>C,ENST00000349496.5:c.133T>C"	2023-01-27 17:09:14 UTC	CA127285	17589	"SER45PRO,RS121913407"	FALSE
CTNNB1 S45F	1260	Desmoid Tumor	80366				Prognostic	Supports	B	Poor Outcome	"Desmoid fibromatosis is a rare, nonmetastatic neoplasm marked by local invasiveness and relentless recurrence. Beta-Catenin deregulation has been commonly identified in sporadic desmoids. CTNNB1 mutations were observed in 117 of 138 (85%) of desmoids. Three discrete mutations in two codons of CTNNB1 exon 3 were identified: T41A (59%), S45F (33%), and S45P (8%). Five-year recurrence-free survival was significantly poorer in S45F-mutated desmoids (23%, P < 0.0001) versus either T41A (57%) or nonmutated tumors (65%). In conclusion, CTNNB1 mutations are highly common in desmoid tumors. Furthermore, patients harboring CTNNB1 (S45F) mutations are at particular risk for recurrence and therefore may especially benefit from adjuvant therapeutic approaches."	18832571	PubMed		"Lazar et al., 2008, Am. J. Pathol."		3	accepted	2976	Somatic	2023-01-09 21:46:44 UTC	https://civicdb.org/links/evidence_items/2976	https://civicdb.org/links/molecular_profiles/1260	FALSE	CTNNB1	1499	S45F		chr3	41224646	41224646	C	T	ENST00000349496.5	75		missense_variant	"NM_001904.3:c.134C>T,NP_001895.1:p.Ser45Phe,NC_000003.11:g.41266137C>T,ENST00000349496.5:c.134C>T"	2023-01-27 17:09:14 UTC	CA127283	17588	"SER45PHE,RS121913409"	FALSE
ARID1A Loss-of-function	1267	Ovarian Clear Cell Carcinoma	50934		Dasatinib		Predictive	Supports	D	Sensitivity/Response	"High-throughput  drug screens in OCCC tumor cell model identified synthetic lethal (SL) interaction between the kinase inhibitor dasatinib and ARID1A mutation. Imposing ARID1A deficiency upon a variety of human or mouse cells induced dasatinib sensitivity, both in vitro and in vivo."	27364904	PubMed		"Miller et al., 2016, Mol. Cancer Ther."		3	accepted	2982	Somatic	2023-01-09 21:46:44 UTC	https://civicdb.org/links/evidence_items/2982	https://civicdb.org/links/molecular_profiles/1267	FALSE	ARID1A	8289	Loss-of-function		chr1	26696033	26782104			ENST00000324856.7	75				2023-01-09 21:52:12 UTC		N/A		FALSE
ARID1A Loss-of-function	1267	Ovarian Clear Cell Carcinoma	50934		GSK126		Predictive	Supports	D	Sensitivity/Response	"Inhibition of the EZH2 methyltransferase acts in a synthetic lethal manner in ARID1A mutated ovarian cancer cells. ARID1A mutational status correlates with response to the EZH2 inhibitor. Significantly, EZH2 inhibition causes regression of ARID1A mutated ovarian tumors in vivo."	25686104	PubMed		"Bitler et al., 2015, Nat. Med."		4	accepted	2983	Somatic	2023-01-09 21:46:44 UTC	https://civicdb.org/links/evidence_items/2983	https://civicdb.org/links/molecular_profiles/1267	FALSE	ARID1A	8289	Loss-of-function		chr1	26696033	26782104			ENST00000324856.7	75				2023-01-09 21:52:12 UTC		N/A		FALSE
PIK3CA E545K	104	Cervix Carcinoma	2893		"Pictilisib,Cisplatin"	Combination	Predictive	Supports	D	Sensitivity/Response	"CaSki cells that are heterozygous for the PIK3CA-E545K mutation are more resistant to cisplatin or cisplatin plus radiation than either HeLa or SiHa cells that express only wild-type PIK3CA. Similarly, HeLa cells engineered to stably express PIK3CA-E545K were more resistant to cisplatin or cisplatin plus radiation than cells expressing only wild-type PIK3CA or with PIK3CA depleted. Cells expressing the PIK3CA-E545K mutation also had constitutive PI3K pathway activation and increased cellular migration and each of these phenotypes was reversed by treatment with the PI3K inhibitor GDC-0941/Pictilisib. In addition, GDC-0941 restored sensitivity of E545K mutant cell lines to cisplatin as combination treatment had a larger impact on cell survival than either drug alone."	27489350	PubMed		"Arjumand et al., 2016, Oncotarget"		3	accepted	2984	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/2984	https://civicdb.org/links/molecular_profiles/104	FALSE	PIK3CA	5290	E545K		chr3	179218303	179218303	G	A	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.1633G>A,NP_006209.2:p.Glu545Lys,ENST00000263967.3:c.1633G>A,NC_000003.11:g.178936091G>A"	2023-01-27 17:02:37 UTC	CA123334	13655	"GLU545LYS,RS104886003"	FALSE
PIK3CA E545K	104	Cervical Cancer	4362		Cisplatin		Predictive	Supports	D	Resistance	"Authors tested various cervical cancer cell lines (CaSki, SiHa and HeLa) for their responses to cisplatin, radiation therapy, and GDC-0941. CaSki cells that are heterozygous for the PIK3CA-E545K mutation were significantly more resistant to cisplatin or cisplatin plus radiation than either HeLa or SiHa cells that express only wild-type PIK3CA. Similarly, HeLa cells engineered to stably express PIK3CA E545K were more resistant to cisplatin or cisplatin plus radiation than cells expressing only wild-type PIK3CA or with PIK3CA depleted. Cells expressing the PIK3CA-E545K mutation also had constitutive PI3K pathway activation and increased cellular migration and each of these phenotypes was reversed by treatment with the PI3K inhibitor GDC-0941 (pictilisib)."	27489350	PubMed		"Arjumand et al., 2016, Oncotarget"		3	accepted	2985	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/2985	https://civicdb.org/links/molecular_profiles/104	FALSE	PIK3CA	5290	E545K		chr3	179218303	179218303	G	A	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.1633G>A,NP_006209.2:p.Glu545Lys,ENST00000263967.3:c.1633G>A,NC_000003.11:g.178936091G>A"	2023-01-27 17:02:37 UTC	CA123334	13655	"GLU545LYS,RS104886003"	FALSE
VHL W8* (c.24G>A)	1268	Renal Cell Carcinoma	4450				Oncogenic	Supports	C	Oncogenicity	"A single case (70 year-old named ""3GT"" in this study) with sporadic grade 3 renal cell carcinoma was observed with both W8* and G44D somatic variants."	11536052	PubMed		"Ma et al., 2001, Oncogene"		1	accepted	2986	Somatic	2023-02-03 16:29:01 UTC	https://civicdb.org/links/evidence_items/2986	https://civicdb.org/links/molecular_profiles/1268	FALSE	VHL	7428	W8* (c.24G>A)		chr3	10141871	10141871	G	A	ENST00000256474.2	75		stop_gained	"NM_000551.3:c.24G>A,ENST00000256474.2:c.24G>A,NC_000003.11:g.10183555G>A,NP_000542.1:p.Trp8Ter"	2023-01-27 17:09:19 UTC	CA351747069	NONE FOUND	"TRP8X,TRP8STOP,C.24G>A"	FALSE
ALK F1245V	1269	Neuroblastoma	769		Entrectinib		Predictive	Supports	C	Sensitivity/Response	"Clinical trial of entrectinib in patients with ALK/ROS/TRK altered tumors. One patient with an ALK F1245V-mutant neuroblastoma achieved a durable, confirmed partial response (PR) lasting 8.3 months. The patient remained on study treatment for more than 3.5 years because of clinical benefit."	28183697	PubMed		"Drilon et al., 2017, Cancer Discov"		3	accepted	2987	Somatic	2023-01-09 21:46:44 UTC	https://civicdb.org/links/evidence_items/2987	https://civicdb.org/links/molecular_profiles/1269	FALSE	ALK	238	F1245V		chr2	29213994	29213994	A	C	ENST00000389048.3	75		missense_variant	"NM_004304.4:c.3733T>G,NP_004295.2:p.Phe1245Val,NC_000002.11:g.29436860A>C,ENST00000389048.3:c.3733T>G"	2023-01-27 17:09:20 UTC	CA345003	65671	"PHE1245VAL,RS281864720"	FALSE
CTNNB1 Activating Mutation	1270	Melanoma	1909		"Anti-CTLA-4 Monoclonal Antibody,Anti-PD-L1 Monoclonal Antibody"	Substitutes	Predictive	Supports	D	Resistance	Activation of melanoma-cell-intrinsic WNT/-catenin signalling pathway contributes to a lack of T-cell infiltration in melanoma. Molecular analysis of human metastatic melanoma samples revealed a correlation between activation of the WNT/-catenin signalling pathway and absence of a T-cell gene expression signature. In autochthonous mouse melanoma models active -catenin signalling results in T-cell exclusion and resistance to anti-PD-L1/anti-CTLA-4 monoclonal antibody therapy.	25970248	PubMed		"Spranger et al., 2015, Nature"		4	accepted	2988	Somatic	2023-01-09 21:46:44 UTC	https://civicdb.org/links/evidence_items/2988	https://civicdb.org/links/molecular_profiles/1270	FALSE	CTNNB1	1499	Activating Mutation		chr3	41199439	41240445			ENST00000349496.5	75		"transcript_variant,gain_of_function_variant"		2023-01-09 21:52:12 UTC		N/A		FALSE
MERTK OVEREXPRESSION	1273	Melanoma	1909		UNC1062		Predictive	Supports	D	Sensitivity/Response	"Highest MERTK expression was observed in metastatic melanomas, followed by primary melanomas, and lowest in benign nevi. Over half of melanoma cell lines overexpressed MERTK compared with normal human melanocytes; however, overexpression did not correlate with mutations in BRAF or RAS. MERTK inhibition via shRNA reduced MERTK-mediated downstream signaling, reduced colony formation by up to 59%, and diminished tumor volume by 60% in a human melanoma murine xenograft model. Treatment of melanoma cells with UNC1062, a novel MERTK-selective small-molecule tyrosine kinase inhibitor, reduced activation of MERTK-mediated downstream signaling, induced apoptosis in culture, reduced colony formation in soft agar, and inhibited invasion of melanoma cells."	23585477	PubMed		"Schlegel et al., 2013, J. Clin. Invest."		3	accepted	2991	Somatic	2023-01-09 21:46:44 UTC	https://civicdb.org/links/evidence_items/2991	https://civicdb.org/links/molecular_profiles/1273	FALSE	MERTK	10461	OVEREXPRESSION		chr2	111898479	112029561			ENST00000295408.4	75		N/A		2023-01-09 21:52:12 UTC		N/A		FALSE
TP53 CONSERVED DOMAIN MUT	1274	Ovarian Cancer	2394				Prognostic	Supports	B	Poor Outcome	"Patients with conserved domain p53 mutation (n=61) were compared with those with wild type or non-conserved domain p53 mutation (n=117) in a cohort of 178 invasive ovarian carcinoma patients who had undergone surgery. Overall survival was decreased in the cohort with conserved domian mutation (p=0.005).  Conserved domain mutation was an independent factor in univariate (but not multivariate) analysis of overall survival with relative risk 1.70 (1.17-2.47, p<0.007)."	11595686	PubMed		"Reles et al., 2001, Clin. Cancer Res."		3	accepted	2993	Somatic	2023-01-09 21:46:44 UTC	https://civicdb.org/links/evidence_items/2993	https://civicdb.org/links/molecular_profiles/1274	FALSE	TP53	7157	CONSERVED DOMAIN MUT		chr17	7673744	7676080			ENST00000269305.4	75				2023-01-09 21:52:12 UTC				FALSE
EGFR L858R	33	Lung Non-small Cell Carcinoma	3908		Erlotinib		Predictive	Supports	A	Sensitivity/Response	"On May 14, 2013, the U.S. Food and Drug Administration approved erlotinib (Tarceva) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations."	24868098	PubMed		"Khozin et al., 2014, Oncologist"		5	accepted	2994	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/2994	https://civicdb.org/links/molecular_profiles/33	FALSE	EGFR	1956	L858R		chr7	55191822	55191822	T	G	ENST00000275493.2	75		missense_variant	"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg"	2023-01-27 17:02:04 UTC	CA126713	"16,609,376,282,376,200"	"LEU858ARG,RS121434568"	FALSE
EGFR Exon 19 Deletion	133	Lung Non-small Cell Carcinoma	3908		Erlotinib		Predictive	Supports	A	Sensitivity/Response	"On May 14, 2013, the U.S. Food and Drug Administration approved erlotinib (Tarceva) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations."	24868098	PubMed		"Khozin et al., 2014, Oncologist"		5	accepted	2995	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/2995	https://civicdb.org/links/molecular_profiles/133	FALSE	EGFR	1956	Exon 19 Deletion		chr7	55174722	55174820			ENST00000275493.2	75		inframe_deletion	ENST00000275493.2:c.2185_2283del	2023-01-09 21:52:05 UTC		N/A		FALSE
EGFR Exon 19 Deletion	133	Lung Non-small Cell Carcinoma	3908		Afatinib		Predictive	Supports	A	Sensitivity/Response	"Afatinib, an irreversible inhibitor of the ErbB family of tyrosine kinases has been approved in the US for the first-line treatment of patients with metastatic non-small-cell lung cancer (NSCLC) who have tumours with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by a US FDA-approved test"	23982599	PubMed		"Dungo et al., 2013, Drugs"		5	accepted	2996	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/2996	https://civicdb.org/links/molecular_profiles/133	FALSE	EGFR	1956	Exon 19 Deletion		chr7	55174722	55174820			ENST00000275493.2	75		inframe_deletion	ENST00000275493.2:c.2185_2283del	2023-01-09 21:52:05 UTC		N/A		FALSE
EGFR L858R	33	Lung Non-small Cell Carcinoma	3908		Afatinib		Predictive	Supports	A	Sensitivity/Response	"Afatinib, an irreversible inhibitor of the ErbB family of tyrosine kinases has been approved in the US for the first-line treatment of patients with metastatic non-small-cell lung cancer (NSCLC) who have tumours with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by a US FDA-approved test"	23982599	PubMed		"Dungo et al., 2013, Drugs"		5	accepted	2997	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/2997	https://civicdb.org/links/molecular_profiles/33	FALSE	EGFR	1956	L858R		chr7	55191822	55191822	T	G	ENST00000275493.2	75		missense_variant	"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg"	2023-01-27 17:02:04 UTC	CA126713	"16,609,376,282,376,200"	"LEU858ARG,RS121434568"	FALSE
KRAS Mutation	332	Lung Non-small Cell Carcinoma	3908		"Docetaxel,Selumetinib"	Combination	Predictive	Supports	A	Resistance	"A phase 3 study of selumetinib and docetaxel in KRAS mutant, previously treated NSCLC. 866 were enrolled and 510 randomized. Median progression-free survival was 3.9 months with selumetinib?docetaxel and 2.8 months with placebo?docetaxel. Median overall survival was 8.7 months with selumetinib?docetaxel and 7.9 months with placebo?docetaxel. Objective response rate was 20.1% with selumetinib?docetaxel and 13.7% with placebo?docetaxel."	28492898	PubMed		"Jnne et al., 2017, JAMA"	NCT01933932	5	accepted	2998	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/2998	https://civicdb.org/links/molecular_profiles/332	FALSE	KRAS	3845	Mutation		chr12	25209431	25250803			ENST00000256078.4	75		protein_altering_variant		2023-01-09 21:52:06 UTC		N/A		FALSE
TP53 Mutation	222	Lung Non-small Cell Carcinoma	3908				Prognostic	Supports	B	N/A	"A pooled analysis to investigate the prognostic and predictive roles of TP53/KRAS and TP53/EGFR comutations (cm) in randomized trials of adjuvant chemotherapy compared to observational therapy encompassing a total of 3,553 patients. TP53/KRAS cm showed no prognostic effects but a borderline predictive effect (p=0,04) for negative effect of chemotherapy as compared to tp53/KRAS wt/wt. TP53/EGFR cm in was neither prognostic ( P = .83), nor significantly predictive ( P = .86). Similar results were observed for both groups for disease-free survival."	28453411	PubMed		"Shepherd et al., 2017, J. Clin. Oncol."		5	accepted	2999	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/2999	https://civicdb.org/links/molecular_profiles/222	FALSE	TP53	7157	Mutation		chr17	7668402	7687538			ENST00000269305.4	75		protein_altering_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
CD274 Expression	272	Head And Neck Squamous Cell Carcinoma	5520		Radiation Therapy		Predictive	Supports	B	Resistance	"Radiation-resistant cell lines exhibited upregulation and increased activation of Axl, PI3 kinase signalling as well as increased expression of PD-L1. In 3 cohorts of HPV-negative head and neck squamous cell carcinoma patient samples evaluated with different methods [reverse phase protein array (N=68), mRNA expression array (N=97) or immunohistochemistry (N=114), respectively], increased expression of PD-L1 was also correlated with local failure following radiotherapy as compared to the PD-L1low expression group (P = 0.01, 1.9  10?, and 9  10?, respectively)."	28476872	PubMed		"Skinner et al., 2017, Clin. Cancer Res."		4	accepted	3000	N/A	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/3000	https://civicdb.org/links/molecular_profiles/272	FALSE	CD274	29126	Expression		chr9	5450525	5470547			ENST00000381577.3	75		N/A	N/A	2023-01-09 21:52:06 UTC		N/A		FALSE
FLT3 D835V	1276	Acute Myeloid Leukemia	9119		Tandutinib		Predictive	Supports	D	Resistance	Murine Ba/F3 cells with FLT3-D835V mutations were evaluated as non-responsive to MLN518 (Tandutinib). Cells with single FLT3 (D835V) mutants were resistant to MLN518(IC50 > 10uM) whereas cells with FLT3 (ITD) mutants were not resistant to MLN518 (IC50 0.55uM).	15256420	PubMed		"Clark et al., 2004, Blood"		3	accepted	3007	Somatic	2023-01-09 21:46:44 UTC	https://civicdb.org/links/evidence_items/3007	https://civicdb.org/links/molecular_profiles/1276	FALSE	FLT3	2322	D835V		chr13	28018504	28018504	T	A	ENST00000241453.7	75		missense_variant	"ENST00000241453.7:c.2504A>T,NM_004119.2:c.2504A>T,NP_004110.2:p.Asp835Val,NC_000013.10:g.28592641T>A"	2023-01-27 17:09:21 UTC	CA126344	16272	"RS121909646,ASP835VAL"	FALSE
FLT3 D835V	1276	Acute Myeloid Leukemia	9119		Sunitinib		Predictive	Does Not Support	D	Sensitivity/Response	Murine Ba/F3 cells with FLT3 D835V mutation were assessed as not sensitive to SU11248 (Sunitinib) with dose required to inhibit proliferation of cells to 50% of untreated controls ED50 = 110nM.	15304385	PubMed		"Yee et al., 2004, Blood"		3	accepted	3008	Somatic	2023-01-09 21:46:44 UTC	https://civicdb.org/links/evidence_items/3008	https://civicdb.org/links/molecular_profiles/1276	FALSE	FLT3	2322	D835V		chr13	28018504	28018504	T	A	ENST00000241453.7	75		missense_variant	"ENST00000241453.7:c.2504A>T,NM_004119.2:c.2504A>T,NP_004110.2:p.Asp835Val,NC_000013.10:g.28592641T>A"	2023-01-27 17:09:21 UTC	CA126344	16272	"RS121909646,ASP835VAL"	FALSE
FLT3 D835V	1276	Acute Myeloid Leukemia	9119		"Cytarabine,Sunitinib"	Combination	Predictive	Supports	D	Sensitivity/Response	"SU11248 + Cytarabin has a synergic effect on Murine Ba/F3 cells with FLT3 D835V mutation (Combination Index = 0.59 for ED50, Combination Index = 0.71 for ED75, Combination Index = 0.82 for ED90)"	15304385	PubMed		"Yee et al., 2004, Blood"		2	accepted	3009	Somatic	2023-01-09 21:46:44 UTC	https://civicdb.org/links/evidence_items/3009	https://civicdb.org/links/molecular_profiles/1276	FALSE	FLT3	2322	D835V		chr13	28018504	28018504	T	A	ENST00000241453.7	75		missense_variant	"ENST00000241453.7:c.2504A>T,NM_004119.2:c.2504A>T,NP_004110.2:p.Asp835Val,NC_000013.10:g.28592641T>A"	2023-01-27 17:09:21 UTC	CA126344	16272	"RS121909646,ASP835VAL"	FALSE
FLT3 D835V	1276	Acute Myeloid Leukemia	9119		"Daunorubicin,Sunitinib"	Combination	Predictive	Supports	D	Sensitivity/Response	"SU11248 + Daunorubicin has a synergic effect on Murine Ba/F3 cells with FLT3 D835V mutation. (Combination Index = 0.82 for ED50, Combination Index = 0.72 for ED75, Combination Index = 0.64 for ED90)"	15304385	PubMed		"Yee et al., 2004, Blood"		2	accepted	3010	Somatic	2023-01-09 21:46:44 UTC	https://civicdb.org/links/evidence_items/3010	https://civicdb.org/links/molecular_profiles/1276	FALSE	FLT3	2322	D835V		chr13	28018504	28018504	T	A	ENST00000241453.7	75		missense_variant	"ENST00000241453.7:c.2504A>T,NM_004119.2:c.2504A>T,NP_004110.2:p.Asp835Val,NC_000013.10:g.28592641T>A"	2023-01-27 17:09:21 UTC	CA126344	16272	"RS121909646,ASP835VAL"	FALSE
FLT3 D835V	1276	Acute Myeloid Leukemia	9119		Quizartinib		Predictive	Does Not Support	D	Sensitivity/Response	"Murine Ba/F3 cell line has a restrictive sensitivity to Quizartinib (AC220), a second generation class II tyrosine kinase inhibitor (IC50 for proliferation = 172nM, IC50 for induction of apoptosis = 888nM)."	23497317	PubMed		"Kampa-Schittenhelm et al., 2013, Mol. Cancer"		4	accepted	3012	Somatic	2023-01-09 21:46:44 UTC	https://civicdb.org/links/evidence_items/3012	https://civicdb.org/links/molecular_profiles/1276	FALSE	FLT3	2322	D835V		chr13	28018504	28018504	T	A	ENST00000241453.7	75		missense_variant	"ENST00000241453.7:c.2504A>T,NM_004119.2:c.2504A>T,NP_004110.2:p.Asp835Val,NC_000013.10:g.28592641T>A"	2023-01-27 17:09:21 UTC	CA126344	16272	"RS121909646,ASP835VAL"	FALSE
TP53 Overexpression	1280	Ovarian Cancer	2394		"Carboplatin,Cisplatin"	Substitutes	Predictive	Supports	B	Resistance	"In a study involving patients with invasive ovarian carcinoma who had undergone surgery, a subset of 73 patients were classified via response to platinum-based chemotherapy as sensitive or resistant/refractory and tested for p53 overexpression (>10% postive stained nuclei). 78% of p53 negative patients were classified as sensitive, in compariston to 39% of p53 positive patients (p=0.001)."	11595686	PubMed		"Reles et al., 2001, Clin. Cancer Res."		3	accepted	3013	N/A	2023-01-09 21:46:44 UTC	https://civicdb.org/links/evidence_items/3013	https://civicdb.org/links/molecular_profiles/1280	FALSE	TP53	7157	Overexpression		chr17	7668402	7687538			ENST00000269305.4	75		N/A		2023-01-09 21:52:12 UTC		N/A		FALSE
TP53 ALTERATION	1281	Ovarian Cancer	2394				Prognostic	Supports	B	Poor Outcome	"In a study of invasive ovarian carcinoma patients who had undergone surgery, the p53 alteration variant was defined as p53 mutation or p53 overexpression by immunostain (>10% positive). Patients with p53 alterations showed increase in poor tumor cell differentiation (p<0.001) and increase in tumor cellular S-phase fraction (p<0.001). Out of 178 patients, p53 alteration (n=132) was associated with decreased overall survival in comparison to normal p53 (n=46), p=0.007."	11595686	PubMed		"Reles et al., 2001, Clin. Cancer Res."		4	accepted	3014	Somatic	2023-01-09 21:46:44 UTC	https://civicdb.org/links/evidence_items/3014	https://civicdb.org/links/molecular_profiles/1281	FALSE	TP53	7157	ALTERATION		chr17	7668402	7687538			ENST00000269305.4	75				2023-01-09 21:52:12 UTC		N/A		FALSE
EGFR Amplification	190	Lung Non-small Cell Carcinoma	3908		"Osimertinib,Rociletinib"	Substitutes	Predictive	Supports	D	Resistance	"Evidence of wild-type allele-mediated resistance, a novel concept of acquired resistance in response to mutation-selective inhibitor therapy in cancer treatment. This study reports that the Src-AKT pathway contributes to acquired resistance to third generation EGFR TKIs. In addition, amplification of EGFR wild-type alleles but not mutant alleles was sufficient to confer acquired resistance."	28202511	PubMed		"Nukaga et al., 2017, Cancer Res."		3	accepted	3015	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/3015	https://civicdb.org/links/molecular_profiles/190	FALSE	EGFR	1956	Amplification		chr7	55019101	55211628			ENST00000275493.2	75		transcript_amplification	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
EGFR Mutation	438	Lung Non-small Cell Carcinoma	3908		Gefitinib		Predictive	Supports	B	Sensitivity/Response	"In a phase 3 clinical trial of non-small cell lung cancer (NSCLC) patients, a subset of patients with EGFR mutations (n=44) treated with gefitinib were associated with improved progression free survival (HR: 0.16, 95% CI: 0.05-0.49, P=0.001), and a higher objective response rate (ORR: 42.1% vs 21.1%, p=0.04) compared to patients treated with docetaxel. Of the 44 patients, 22 had an exon 19 deletion, 16 had an L858R mutation, one patient had an exon 20 T790M mutation, two had an exon G719A mutation and four had other mutations."	20038723	PubMed		"Douillard et al., 2010, J. Clin. Oncol."	NCT00076388	3	accepted	3016	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/3016	https://civicdb.org/links/molecular_profiles/438	FALSE	EGFR	1956	Mutation		chr7	55019101	55211628			ENST00000275493.2	75		inframe_variant		2023-01-09 21:52:07 UTC		N/A		FALSE
BRAF V600E	12	Lung Non-small Cell Carcinoma	3908		"Dabrafenib,Trametinib"	Combination	Predictive	Supports	A	Sensitivity/Response	"Patients with BRAF V600E-mutant NSCLC (n=57) were enrolled into a phase 2, multicentre, non-randomised, open-label study, administering dabrafenib plus trametinib. The overall response rate was 36/57 (63.2%, [95% CI 49.3-75.6]) and the median progression-free survival was 9.7 months (95% CI 6.9-19.6). At data cutoff (11.6 months of follow-up), 18/36  (50%) confirmed responses were ongoing and 23/57 (40%) of patients had died."	27283860	PubMed		"Planchard et al., 2016, Lancet Oncol."	NCT01336634	4	accepted	3017	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/3017	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
FGFR1 Amplification	263	Lung Non-small Cell Carcinoma	3908		Dovitinib		Predictive	Supports	B	Sensitivity/Response	"Clinical trial studied the efficacy of Dovitinib on 26 patients with FGFR1 amplifications. Objective response for the cohort was 11.5%, disease control rate was 50%. 11.5% of patients exhibited partial response, 38.5% exhibited stable disease. Median PFS was 2.9 months, median OS was 5 months, this trend was worse with increases in FGFR1 amplification above average."	27315356	PubMed		"Lim et al., 2016, Cancer"		2	accepted	3027	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/3027	https://civicdb.org/links/molecular_profiles/263	FALSE	FGFR1	2260	Amplification		chr8	38411138	38467845			ENST00000425967.3	75		transcript_amplification	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
KIT V559D	942	Gastrointestinal Stromal Tumor	9253		Imatinib		Predictive	Supports	C	Sensitivity/Response	A patient with an uncontrolled relapse of c-kit-positive mesenchymal tumor in descending part of the duodenum had received 400mg Imatinib daily for more than 10 years at the time of publication. He responded well to therapy (Karnofsky index 90%). KIT V559D (Exon 11) was identified in the diagnostic biopsy and indicated as a positive predictor of imatinib response with long term usage.	22114577	PubMed		"Cameron et al., 2011, Case Rep Oncol"		3	accepted	3028	Somatic	2023-01-09 21:46:40 UTC	https://civicdb.org/links/evidence_items/3028	https://civicdb.org/links/molecular_profiles/942	FALSE	KIT	3815	V559D		chr4	54727444	54727444	T	A	ENST00000288135.5	75		missense_variant	"NM_000222.2:c.1676T>A,NP_000213.1:p.Val559Asp,NC_000004.11:g.55593610T>A,ENST00000288135.5:c.1676T>A"	2023-01-27 17:07:10 UTC	CA123522	13856	"RS121913517,VAL559ASP"	FALSE
KIT V559D	942	Cancer	162		"Dasatinib,Imatinib,Tandutinib,Sunitinib,PD-180970"	Substitutes	Predictive	Supports	D	Sensitivity/Response	"KIT(V559D) were expressed in HEK-293 cells (in vitro). Imatinib, BMS-354825 (dasatinib), PD-180970, MLN-518 (tandutinib), and SU-11248 bind variant V559D with high affinity (Kd =< 20 nM), and inhibit KIT autophosphorylation. Despite similar binding affinities, the cellular activity of BMS-354825 was >10-fold greater than that of SU-11248 or PD-180970, and the authors hypothesize that additional pharmaceutical properties may contribute to the greater cellular potency."	16046538	PubMed		"Carter et al., 2005, Proc. Natl. Acad. Sci. U.S.A."		2	accepted	3029	Somatic	2023-01-09 21:46:40 UTC	https://civicdb.org/links/evidence_items/3029	https://civicdb.org/links/molecular_profiles/942	FALSE	KIT	3815	V559D		chr4	54727444	54727444	T	A	ENST00000288135.5	75		missense_variant	"NM_000222.2:c.1676T>A,NP_000213.1:p.Val559Asp,NC_000004.11:g.55593610T>A,ENST00000288135.5:c.1676T>A"	2023-01-27 17:07:10 UTC	CA123522	13856	"RS121913517,VAL559ASP"	FALSE
FLT3 D835V	1276	Acute Myeloid Leukemia	9119		"Tyrphostin AG 1296,AS602868"	Substitutes	Predictive	Supports	D	Sensitivity/Response	"Murine Ba/F3 cells with FLT3 D835V mutation were assessed as sensitive to both AS602868 and AG1296.(IC50 = 1.85uM and IC50 = 4.55uM, respectively)"	17330097	PubMed		"Griessinger et al., 2007, Leukemia"		3	accepted	3034	Somatic	2023-01-09 21:46:44 UTC	https://civicdb.org/links/evidence_items/3034	https://civicdb.org/links/molecular_profiles/1276	FALSE	FLT3	2322	D835V		chr13	28018504	28018504	T	A	ENST00000241453.7	75		missense_variant	"ENST00000241453.7:c.2504A>T,NM_004119.2:c.2504A>T,NP_004110.2:p.Asp835Val,NC_000013.10:g.28592641T>A"	2023-01-27 17:09:21 UTC	CA126344	16272	"RS121909646,ASP835VAL"	FALSE
MET Overexpression	617	Uveal Melanoma	6039		"Selumetinib,Trametinib"	Substitutes	Predictive	Supports	D	Resistance	"In this study the authors screened for growth factors that elicited resistance in newly characterized metastatic uveal melanoma cell lines to clinical-grade MEK inhibitors, trametinib and selumetinib, showing that neuregulin 1 (NRG1) and hepatocyte growth factor (HGF) provide resistance to MEK inhibition. Trametinib enhances the responsiveness to NRG1 and sustained HGF-mediated activation of AKT. Targeting ERBB3 and cMET could overcome resistance to trametinib."	25952648	PubMed		"Cheng et al., 2015, Cancer Res."		3	accepted	3038	N/A	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/3038	https://civicdb.org/links/molecular_profiles/617	FALSE	MET	4233	Overexpression		chr7	116672405	116796342			ENST00000318493.6	75		N/A	N/A	2023-01-09 21:52:08 UTC		N/A		FALSE
AKT1 E17K	4	Cancer	162		Capivasertib		Predictive	Supports	B	Sensitivity/Response	"AKT1 E17K mutations are oncogenic and occur in many cancers at a low prevalence. We performed a multihistology basket study of AZD5363. 58 patients with advanced solid tumors were treated. In patients with AKT1 E17K-mutant tumors (n = 52) and a median of 5 lines of prior therapy, the median PFS was 5.5 months , 6.6 months and 4.2 months in patients with ER+ breast, gynecologic, and other solid tumors, respectively. In an exploratory biomarker analysis, imbalance of the AKT1 E17K-mutant allele, most frequently caused by copy-neutral loss-of-heterozygosity targeting the wild-type allele, was associated with longer PFS as was the presence of coincident PI3K pathway hotspot mutations. Persistent declines in AKT1 E17K in cfDNA were associated with improved PFS and response. Responses were not restricted to patients with detectable AKT1 E17K in pretreatment cfDNA."	28489509	PubMed		"Hyman et al., 2017, J. Clin. Oncol."		4	accepted	3039	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/3039	https://civicdb.org/links/molecular_profiles/4	FALSE	AKT1	207	E17K		chr14	104780214	104780214	C	T	ENST00000407796.2	75		missense_variant	"NC_000014.8:g.105246551C>T,NM_001014432.1:c.49G>A,NP_001014432.1:p.Glu17Lys,ENST00000407796.2:c.49G>A"	2023-01-27 17:01:56 UTC	CA123660	13983	"GLU17LYS,RS34409589"	FALSE
PIK3CA Mutation	307	Cancer	162		Capivasertib		Predictive	Supports	B	Sensitivity/Response	"In a study of 37 patients with AKT1 (E13K) mutations, 5 patients harbored a concurrent PI3K/mTOR pathway alteration. The PFS of patients with a concurrent PI3K/mTOR pathway alteration was significantly longer than those without when treated with AZD-5363 (median PFS, not reached v 4.3 months, respectively; HR, 0.21; P = 0.045)."	28489509	PubMed		"Hyman et al., 2017, J. Clin. Oncol."		4	accepted	3040	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/3040	https://civicdb.org/links/molecular_profiles/307	FALSE	PIK3CA	5290	Mutation		chr3	179148523	179240093			ENST00000263967.3	75		"transcript_variant,gain_of_function_variant"		2023-01-09 21:52:06 UTC		N/A		FALSE
TP53 R248Q	117	Cancer	162		MDM2 Inhibitor AMGMDS3		Predictive	Supports	D	Resistance	Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 R248Q loss of function mutation is present in 5 cell lines and all are insensitive to MDM2 Inhibitor AMGMDS3.	25730903	PubMed		"Saiki et al., 2015, Oncotarget"		4	accepted	3042	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/3042	https://civicdb.org/links/molecular_profiles/117	FALSE	TP53	7157	R248Q		chr17	7674220	7674220	C	T	ENST00000269305.4	75		missense_variant	"NM_000546.5:c.743G>A,NP_000537.3:p.Arg248Gln,NC_000017.10:g.7577538C>T,ENST00000269305.4:c.743G>A"	2023-01-27 17:02:44 UTC	CA000387	12356	"ARG248GLN,RS11540652"	FALSE
CTNNB1 S45P	1261	Desmoid Tumor	80366				Prognostic	Supports	B	Better Outcome	"Desmoid fibromatosis is a rare, nonmetastatic neoplasm marked by local invasiveness and relentless recurrence. Beta-Catenin deregulation has been commonly identified in sporadic desmoids. CTNNB1 mutations were observed in 117 of 138 (85%) of desmoids. Three discrete mutations in two codons of CTNNB1 exon 3 were identified: T41A (59%), S45F (33%), and S45P (8%). Five-year recurrence-free survival was significantly poorer in S45F-mutated desmoids (23%, P < 0.0001) versus either T41A (57%) or nonmutated tumors (65%). Because of their low frequency, patients with S45P mutations were excluded from these analyses but showed a recurrence course similar to T41A or wild type patients."	18832571	PubMed		"Lazar et al., 2008, Am. J. Pathol."		1	accepted	3043	Somatic	2023-01-09 21:46:44 UTC	https://civicdb.org/links/evidence_items/3043	https://civicdb.org/links/molecular_profiles/1261	FALSE	CTNNB1	1499	S45P		chr3	41224645	41224645	T	C	ENST00000349496.5	75		missense_variant	"NM_001904.3:c.133T>C,NP_001895.1:p.Ser45Pro,NC_000003.11:g.41266136T>C,ENST00000349496.5:c.133T>C"	2023-01-27 17:09:14 UTC	CA127285	17589	"SER45PRO,RS121913407"	FALSE
CTNNB1 T41A	1259	Desmoid Tumor	80366				Prognostic	Supports	B	Better Outcome	"In an analysis of 138 desmoid fibromatosis tumors, which is a rare, nonmetastatic neoplasm marked by local invasiveness and relentless recurrence, 117 tumors (85%) had CTNNB1 mutations. Three discrete mutations in two codons of CTNNB1 exon 3 were identified: T41A (59%), S45F (33%), and S45P (8%). Five-year recurrence-free survival was significantly poorer in S45F-mutated desmoids (23%, P < 0.0001) versus either T41A (57%) or nonmutated tumors."	18832571	PubMed		"Lazar et al., 2008, Am. J. Pathol."		3	accepted	3044	Somatic	2023-01-09 21:46:44 UTC	https://civicdb.org/links/evidence_items/3044	https://civicdb.org/links/molecular_profiles/1259	FALSE	CTNNB1	1499	T41A		chr3	41224633	41224633	A	G	ENST00000349496.5	75		missense_variant	"NM_001904.3:c.121A>G,NP_001895.1:p.Thr41Ala,NC_000003.11:g.41266124A>G,ENST00000349496.5:c.121A>G"	2023-01-27 17:09:13 UTC	CA127269	17580	"THR41ALA,RS121913412"	FALSE
GNA11 Mutation	502	Uveal Melanoma	6039		Cabozantinib		Predictive	Supports	B	Sensitivity/Response	"In total, 77 patients with metastatic melanoma (62% cutaneous, 30% uveal, 8% mucosal) were admitted into a randomized phase II trial assessing the efficacy of Cabozantinib. Patients received cabozantinib 100mg/d during a 12-week lead-in. Patients with stable disease (SD; RECIST) at week 12 were randomized to cabozantinib or placebo. During lead-in phase, 55% of evaluable patients showed reduction in target lesion size (59% uveal melanoma). Uveal melanoma cohort included 23 patients, 9 with GNAQ (n=5) and GNA11 (n=4) mutations. Responses were reported in mutational patients. In the uveal melanoma cohort, 61% of patients (14/23) had SD at week 12, and no patient had a PR, resulting in an overall disease control rate of 61%. The median PFS for the 23 patients with uveal melanoma was 4.8 months."	28103611	PubMed		"Daud et al., 2017, Br. J. Cancer"		3	accepted	3049	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/3049	https://civicdb.org/links/molecular_profiles/502	FALSE	GNA11	2767	Mutation		chr19	3094410	3124004			ENST00000078429.4	75				2023-01-09 21:52:07 UTC				FALSE
NRAS Q61H	867	Colorectal Cancer	9256		"Irinotecan,Cetuximab"	Combination	Predictive	Supports	C	Resistance	"One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored NRAS Q61H was wildtype for KRAS, BRAF and PIK3CA. This patient was was a 73 year old male treated with cetuximab and irinotecan as 4th line therapy who experienced progressive disease and had PFS of 10 weeks and OS of 36 weeks."	20619739	PubMed		"De Roock et al., 2010, Lancet Oncol."		2	accepted	3690	Somatic	2023-01-09 21:46:39 UTC	https://civicdb.org/links/evidence_items/3690	https://civicdb.org/links/molecular_profiles/867	FALSE	NRAS	4893	Q61H		chr1	114713907	114713907	T	G	ENST00000369535.4	75		missense_variant	"NM_002524.4:c.183A>C,NP_002515.1:p.Gln61His,NC_000001.10:g.115256528T>G,ENST00000369535.4:c.183A>C"	2023-01-27 17:06:26 UTC	CA16602358	375871	"RS121913255,GLN61HIS"	FALSE
NRAS G12D	852	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	B	Resistance	"In a retrospective study of 148 treatment naive metastatic colorectal cancer patients, patients with RAS mutations (n=10), including KRAS A146T, KRAS G13D, NRAS G12D and NRAS Q179*, treated with FOLFOX4 plus cetuximab were associated with decreased overall survival (16.3mo vs. 28.5mo, HR:0.43, 95% CI:0.20-0.89, P=0.020) and decreased progression free survival (7.2mo vs. 9.7mo, HR:0.56, 95% CI:0.27-1.16, P=0.11), as compared to patients with wild-type KRAS and NRAS."	25666295	PubMed		"Kaczirek et al., 2015, Clin Colorectal Cancer"			accepted	3693	Somatic	2023-01-09 21:46:39 UTC	https://civicdb.org/links/evidence_items/3693	https://civicdb.org/links/molecular_profiles/852	FALSE	NRAS	4893	G12D		chr1	114716126	114716126	C	T	ENST00000369535.4	75		missense_variant	"NM_002524.4:c.35G>A,NP_002515.1:p.Gly12Asp,NC_000001.10:g.115258747C>T,ENST00000369535.4:c.35G>A"	2023-01-27 17:06:16 UTC	CA130425	39648	"RS121913237,GLY12ASP"	FALSE
KRAS Mutation	332	Colorectal Cancer	9256		"Cetuximab,Chemotherapy"	Combination	Predictive	Supports	B	Resistance	"This was a retrospective study of 605 patients with metastatic, chemotherapy refractory colorectal cancer treated with cetuximab + chemotherapy. Patients with KRAS mutant tumors (total [n = 253], codon 12 [n=183], 13 [n=47], 59 [n=1], 61 [n=13], 146 [n=9]) had a significantly lower response rate (17/253; 6.7%) compared to patients with KRAS wt tumors (126/352; 35.8%; OR: .13; P < .0001). Patients with KRAS mutant tumors also experienced significant lower disease control rate, shorter median progression free survival and overall survival. Association between KRAS mutation status and outcome was confirmed in multivariate analysis. Authors note that these patients were treated with cetuximab prior to widespread adoption of regular KRAS mutational status screening. Patients treated with cetuximab or panitumumab monotherapy were not included."	20619739	PubMed		"De Roock et al., 2010, Lancet Oncol."		4	accepted	3704	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/3704	https://civicdb.org/links/molecular_profiles/332	FALSE	KRAS	3845	Mutation		chr12	25209431	25250803			ENST00000256078.4	75		protein_altering_variant		2023-01-09 21:52:06 UTC		N/A		FALSE
KRAS G12A	148	Colorectal Cancer	9256		Regorafenib		Predictive	Supports	D	Resistance	"In an in vitro study, a human colon adenocarcinoma SW48 cell line virally transduced to express KRAS G12A demonstrated resistance to regorafenib treatment (IC50: 330.13 nM vs. 114.28 nM, P<0.01, reported errantly as 3301.13nM in the source) compared to SW48 cells expressing KRAS wild-type. Resistance was determined by assessing cell viability. Authors concluded that KRAS G12A was more strongly resistant to regorafenib than KRAS wt and other KRAS G12/G13 mutations."	26161928	PubMed		"Camaj et al., 2015, Future Oncol"		2	accepted	3710	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/3710	https://civicdb.org/links/molecular_profiles/148	FALSE	KRAS	3845	G12A	EGFR TKI Resistance	chr12	25245350	25245350	C	G	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.35G>C,NP_004976.2:p.Gly12Ala,NC_000012.11:g.25398284C>G,ENST00000256078.4:c.35G>C"	2023-01-27 17:02:57 UTC	CA135567	45122	"GLY12ALA,RS121913529"	FALSE
KRAS Mutation	332	Lung Non-small Cell Carcinoma	3908		"Erlotinib,Teprotumumab"	Combination	Predictive	Supports	B	Sensitivity/Response	"In advanced-stage (IIIB or IV) non-small cell lung cancer patients treated with erlotinib daily and teprotumumab (R1507) weekly or every three weeks, patients whose tumors harbored KRAS mutations had similar progression free survival rates compared to patients with wt KRAS. Among patients given R1507 weekly, those whose tumors had KRAS mutations (n=16) had a 12-week progression free survival (PFS) rate of 25% compared to 30% for KRAS wt patients (n=27; p = 0.7436). For patients given R1507 (teprotumumab) every three weeks, 12-week PFS rate for patients with KRAS mt tumors (n=12) was 50% compared to 27% for patients with KRAS wt tumors (n=34; p=0.1350). Authors concluded that KRAS mutation was predictive of a favorable response to erlotinib + R1507 combination therapy."	22025157	PubMed		"Ramalingam et al., 2011, J. Clin. Oncol."	NCT00760929	2	accepted	3713	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/3713	https://civicdb.org/links/molecular_profiles/332	FALSE	KRAS	3845	Mutation		chr12	25209431	25250803			ENST00000256078.4	75		protein_altering_variant		2023-01-09 21:52:06 UTC		N/A		FALSE
KRAS Mutation	332	Lung Non-small Cell Carcinoma	3908				Prognostic	Supports	B	Poor Outcome	"Analysis was performed on the placebo group (n=451) of the Phase III study SATURN using erlotinib maintenance therapy for patients with advanced NSCLC who were selected for response or stable disease after first line chemotherpy. The study was not powered for prognostic tests, but it was still found that KRAS Mutant status was a significant negative prognostic factor on progression free survival. (HR, 1.50; 95% CI, 1.06 to 2.12; P=0.20)"	21969500	PubMed		"Brugger et al., 2011, J. Clin. Oncol."		3	accepted	3715	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/3715	https://civicdb.org/links/molecular_profiles/332	FALSE	KRAS	3845	Mutation		chr12	25209431	25250803			ENST00000256078.4	75		protein_altering_variant		2023-01-09 21:52:06 UTC		N/A		FALSE
PIK3CA E545K	104	Melanoma	1909		Vemurafenib		Predictive	Supports	D	Resistance	"An in vitro study of M229 (a human melanoma cell line) endogenously expressing wildtype PIK3CA and BRAF V600E (a known BRAF inhibitor sensitizing mutation) used PIK3CA E545K as a positive control for testing resistance to BRAF inhibition by vemurafenib. M229 cells virally transduced with PIK3CA E545K were significantly more resistant to vemurafenib-mediated growth suppression than cells transduced with empty vectors (50% vs 20% survival at the highest concentration, p <.0001). Furthermore, E545K appears to confer more resistance to vemurafenib than PIK3CA D350G and similar levels of resistance as E545G. Resistance was determined by assessing cell survival."	24265155	PubMed		"Shi et al., 2014, Cancer Discov"		2	accepted	3722	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/3722	https://civicdb.org/links/molecular_profiles/104	FALSE	PIK3CA	5290	E545K		chr3	179218303	179218303	G	A	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.1633G>A,NP_006209.2:p.Glu545Lys,ENST00000263967.3:c.1633G>A,NC_000003.11:g.178936091G>A"	2023-01-27 17:02:37 UTC	CA123334	13655	"GLU545LYS,RS104886003"	FALSE
PIK3CA E545G	857	Melanoma	1909		Vemurafenib		Predictive	Supports	D	Resistance	"An in vitro study of M229 (a human melanoma cell line) endogenously expressing wildtype PIK3CA and BRAF V600E (a known BRAF inhibitor sensitizing mutation) found that cells virally induced to stably over-express PIK3CA E545G were significantly more resistant to BRAF inhibition by vemurafenib than cells transduced with an empty vector (50% vs 20% survival at the highest concentration, p < .0001). Though statistics were not provided, E545G appears to confer similar levels of resistance to vemurafenib as the positive control variant, PIK3CA E545K."	24265155	PubMed		"Shi et al., 2014, Cancer Discov"		2	accepted	3724	Somatic	2023-01-09 21:46:39 UTC	https://civicdb.org/links/evidence_items/3724	https://civicdb.org/links/molecular_profiles/857	FALSE	PIK3CA	5290	E545G		chr3	179218304	179218304	A	G	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.1634A>G,NP_006209.2:p.Glu545Gly,NC_000003.11:g.178936092A>G,ENST00000263967.3:c.1634A>G"	2023-01-27 17:06:20 UTC	CA123336	13656	"RS121913274,GLU545GLY"	FALSE
PIK3CA Exon 21 Mutation	105	Colorectal Cancer	9256				Prognostic	Does Not Support	B	Poor Outcome	"This study analyzed tumor and patient characteristics from 1,170 colorectal cancer patients derived from the prospective cohort studies: Nurses' Health Study and Health Professionals Follow Up Study. PIK3CA mutations were found in 16% (189/1170) of patients via pyrosequencing of FFPE samples. Of patients with PIK3CA mutations, 39% (73/189) had mutations in exon 21 (listed as exon 20 in the publication, as it was common at the time of its publication to exclude non-coding exon 1). The presence of an exon 21 mutation was not significantly associated with colorectal cancer-specific or overall survival when compared to patients with wt PIK3CA (multivariate, stage-stratified HR = 1.11 vs 1). Authors note that they had limited data on cancer treatment data, but assume that treatment regimens did not differ substantially based on PIK3CA mutation status given that patients were diagnosed prior to clinical availability of PIK3CA genotype data. They further note that treatment decisions were typically based on cancer stage, for which their analyses adjusted."	22357840	PubMed		"Liao et al., 2012, Clin. Cancer Res."		2	accepted	3729	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/3729	https://civicdb.org/links/molecular_profiles/105	FALSE	PIK3CA	5290	Exon 21 Mutation		chr3	179234094	179234707			ENST00000263967.3	75		exon_variant		2023-01-09 21:52:05 UTC			EXON 20 MUTATION	FALSE
PIK3CA Mutation	307	Colorectal Cancer	9256		"Chemotherapy,Cetuximab"	Combination	Predictive	Does Not Support	B	Resistance	"This was a retrospective study of 605 patients with metastatic, chemotherapy refractory colorectal cancer treated with cetuximab + chemotherapy. Patients with KRAS wildtype, PIK3CA assessable tumors, and individual response data (n=339) were genotyped for PIK3CA mutations. Patients harboring PIK3CA mutant tumors (n=34) had a significantly lower response rate than did patients with wildtype PIK3CA (6/34 [17.7%] vs 115/305 [37.7%]; p =.015). Patients with mutant PIK3CA also experienced lower disease control rate in response to cetuximab treatment. However, there was no significant difference between patients with mutant or wildtype PIK3CA in progression free or overall survival (median PFS: 18 vs 24 weeks; median OS: 39 vs 51 weeks). Authors suggest that PIK3CA exon 21 mutations are more relevant to cetuximab response than PIK3CA mutations as a whole, as PIK3CA exon 10 mutations do not appear to effect cetuximab response (exons are listed as exon 20 and exon 9 in the source)."	20619739	PubMed		"De Roock et al., 2010, Lancet Oncol."		2	accepted	3732	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/3732	https://civicdb.org/links/molecular_profiles/307	FALSE	PIK3CA	5290	Mutation		chr3	179148523	179240093			ENST00000263967.3	75		"transcript_variant,gain_of_function_variant"		2023-01-09 21:52:06 UTC		N/A		FALSE
PIK3CA H1047R	107	Colorectal Cancer	9256		Vemurafenib		Predictive	Supports	D	Resistance	"In an in vitro study, a RKO cell line expressing BRAF V600E (a known vemurafenib sensitizing mutation) and PIK3CA H1047R co-mutation demonstrated reduced sensitivity to vemurafenib treatment. Resistance was determined by assessing cellular proliferation and AKT phosphorylation."	22180495	PubMed		"Yang et al., 2012, Cancer Res."		3	accepted	3733	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/3733	https://civicdb.org/links/molecular_profiles/107	FALSE	PIK3CA	5290	H1047R		chr3	179234297	179234297	A	G	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.3140A>G,NP_006209.2:p.His1047Arg,ENST00000263967.3:c.3140A>G,NC_000003.11:g.178952085A>G"	2023-01-27 17:02:38 UTC	CA123326	13652	"HIS1047ARG,RS121913279"	FALSE
BRAF V600E	12	Colorectal Cancer	9256		"FOLFOX-4 Regimen,Cetuximab"	Combination	Predictive	Supports	B	Resistance	"In a retrospective study of 148 treatment naive metastatic colorectal cancer patients, patients with BRAF V600E and wildtype NRAS/KRAS (n=14) mutation treated with FOLFOX4 plus cetuximab were associated with a decreased progression free survival (7.2mo vs. 9.7mo, HR:0.39, 95% CI:0.21-0.72, P=0.0017), and decreased overall survival (11.7mo vs. 28.5mo, HR:0.23, 95% CI:0.12-0.41, P<0.0001), as compared to patients with wildtype BRAF, NRAS and KRAS."	25666295	PubMed		"Kaczirek et al., 2015, Clin Colorectal Cancer"		4	accepted	3739	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/3739	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
BRAF V600E	12	Melanoma	1909		Vemurafenib		Predictive	Supports	B	Sensitivity/Response	"In a phase 2 clinical trial (NCT00949702) of 132 BRAF mutation positive metastatic melanoma patients treated with vemurafenib monotherapy, patients harboring BRAF V600E (n=123) or V600K (n=9) mutations were associated with a favorable objective response rate (53% per RECIST v1.1 criteria, 70/132), with 6% (8/132) and 47% (62/132) of patients achieving complete response and partial response, respectively."	23569304	PubMed		"Trunzer et al., 2013, J. Clin. Oncol."		4	accepted	3750	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/3750	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
BRAF V600E	12	Melanoma	1909		Vemurafenib		Predictive	Supports	B	Sensitivity/Response	"In a clinical study (NCT01307397) of Polish, stage IIIC/IV, melanoma patients with metastases (n=75) harboring BRAF V600 mutation (as detected by cobas 4800 BRAF V600 Mutation Test), median overall survival was 61.9% (95% CI: 50.1-73.6) and median progression free survival was 7.4 months (95% CI: 5.5-9.2). Median duration of response was 7.4 months (95% CI: 5.7-9.2), with 3% (2/75) and 43% (29/75) of patients achieving a complete and partial response, respectively."	26557775	PubMed		"Rutkowski et al., 2015, Contemp Oncol (Pozn)"		3	accepted	3755	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/3755	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
BRAF V600E	12	Melanoma	1909		Vemurafenib		Predictive	Supports	B	Sensitivity/Response	"In a retrospective study of 300 stage IV melanoma patients, patients with BRAF V600E mutation (n=175) were associated with a 4.8% (8/167) complete response, a 58.1% (97/167) partial response and stable disease in 22.2% (37/167) of cases, while 15% (25/167) of patients harboring BRAF V600E experienced progressive disease."	25524477	PubMed		"Ugurel et al., 2015, Ann. Oncol."		3	accepted	3757	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/3757	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
BRAF V600E	12	Skin Melanoma	8923		"Dabrafenib,Trametinib"	Combination	Predictive	Supports	B	Sensitivity/Response	"In a clinical trial (NCT01597908) of 704 metastatic melanoma patients, patients harboring a BRAF V600E mutation and treated with vemurafenib (n=317) were associated with a 51% response rate, as compared to a 64% response rate (p<0.001) in V600E mutation positive patients treated with dabrafenib and trametinib combination therapy (n=312). Median progression-free survival was 11.4 months in the combination-therapy group and 7.3 months in the vemurafenib group (hazard ratio, 0.56; 95% CI, 0.46 to 0.69; P<0.001)."	25399551	PubMed		"Robert et al., 2015, N. Engl. J. Med."	NCT01597908	4	accepted	3758	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/3758	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
BRAF V600E	12	Childhood Pilocytic Astrocytoma	6812		Vemurafenib		Predictive	Supports	C	Sensitivity/Response	"In a case report, a 28 month old patient with a cervicomedullary low grade glioma compatible with pilocytic astrocytoma which was resected had a second lesion consistent with a ganglioglioma 3 years later. This mass progressed under treatment at which point PCR amplification of BRAF exon 15 and subsequent Sanger sequencing the initial biopsy revealed the tumor harbored a BRAF V600E mutation. Based on these results, vemurafenib monotherapy was started and radiological and clinical response was noted after 3 months of treatment, which was sustained after 6 months of therapy. Prior to vemurafenib treatment, the patient had undergone tracheotomy, was treated with standard chemotherapy and underwent another surgery, but had developed progressive disease."	25524464	PubMed		"del Bufalo et al., 2014, J Transl Med"		3	accepted	3777	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/3777	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
BRAF V600E	12	Ovarian Serous Carcinoma	50933		Vemurafenib		Predictive	Supports	C	Sensitivity/Response	"A stage 4B, low-grade papillary serous ovarian adenocarcinoma patient, harboring a BRAF V600E mutation was associated with response to vemurafenib monotherapy. The patient was treated with standard chemotherapy, hormone therapy and bevacizumab prior to the identification of the BRAF V600E mutation; next, the patient was treated with paclitaxel and an anti-HER3 antibody and finally with vemurafenib, obtaining a partial response of greater than 1 year."	26490654	PubMed		"Combe et al., 2015, Invest New Drugs"		3	accepted	3787	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/3787	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
EGFR Mutation	438	Lung Adenocarcinoma	3910				Prognostic	Supports	B	Better Outcome	"Analysis was performed on the placebo group (n=451) of the Phase III study SATURN using erlotinib maintenance therapy for patients with advanced NSCLC who were selected for response or stable disease after first line chemotherapy. It was found that EGFR Mutant status was a significant positive prognostic factor for overall survival. (HR, 0.33; 95% CI, 0.19 to 0.59; P<0.01)"	21969500	PubMed		"Brugger et al., 2011, J. Clin. Oncol."		3	accepted	3792	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/3792	https://civicdb.org/links/molecular_profiles/438	FALSE	EGFR	1956	Mutation		chr7	55019101	55211628			ENST00000275493.2	75		inframe_variant		2023-01-09 21:52:07 UTC		N/A		FALSE
EGFR Mutation	438	Lung Non-small Cell Carcinoma	3908		Erlotinib		Predictive	Supports	B	Sensitivity/Response	"In a phase II trial for Bronchioloalveolar carcinoma (BAC, or in situ pulmonary adenocarcinoma), EGFR exons 18-24 were analyzed in 7 patients who had shown a partial response to Erlotinib, and 10 patients who did not.  EGFR mutations were seen in 5/7 responders but not in any of the non-responders, which was a significant result (p=0.003)."	15329413	PubMed		"Pao et al., 2004, Proc. Natl. Acad. Sci. U.S.A."		3	accepted	3794	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/3794	https://civicdb.org/links/molecular_profiles/438	FALSE	EGFR	1956	Mutation		chr7	55019101	55211628			ENST00000275493.2	75		inframe_variant		2023-01-09 21:52:07 UTC		N/A		FALSE
EGFR L861Q	994	Lung Non-small Cell Carcinoma	3908		Gefitinib		Predictive	Supports	C	Sensitivity/Response	"In a study, a group of 6 participants, 5 with stage IV and one with stage IIIB lung adenocarcinoma, were sequenced at EGFR exons 18 to 21. All patients had L861Q mutation and were treated with the 1st generation TKI gefitinib. 4 patients had partial response with progression free survival (PFS) of 4.3, 19.3, 10.0, 8.7 months; overall survival (OS) of 4.3, 34.9, 15.7, 15.7 months; and all 4 were alive at study end. One patient had stable disease, PFS 6.5 months, OS 15.2 months, and was not alive at study end. One patient had progressive disease as response, with PFS of 2.8 months, OS of 10.7 months, and was not alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type."	21531810	PubMed		"Wu et al., 2011, Clin. Cancer Res."		3	accepted	3802	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/3802	https://civicdb.org/links/molecular_profiles/994	FALSE	EGFR	1956	L861Q		chr7	55191831	55191831	T	A	ENST00000275493.2	75		missense_variant	"NM_005228.4:c.2582T>A,NP_005219.2:p.Leu861Gln,NC_000007.13:g.55259524T>A,ENST00000275493.2:c.2582T>A"	2023-01-27 17:07:41 UTC	CA176021	163380	RS121913444	FALSE
EGFR T790M	34	Cancer	162		"Gefitinib,Multikinase Inhibitor AEE788,Erlotinib"	Substitutes	Predictive	Supports	D	Resistance	"Experimental - EGFR T790M mutation has been associated with resistance to first generation EGFR tyrosine kinase inhibitors, including erlotinib and gefitinib. In an in vitro study, Ba/F3 cells stably expressing EGFR T790M demonstrated resistance to gefitinib and erlotinib and the tool construct AEE788. These cells had very high IC50 nmol/L values for all three inhibitors in comparison to other constructs (Gefitinib>2000, Erlotinib>2000, AEE788>2000), indicating resitance to all three inhibitors."	19147750	PubMed		"Kancha et al., 2009, Clin. Cancer Res."		3	accepted	3810	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/3810	https://civicdb.org/links/molecular_profiles/34	FALSE	EGFR	1956	T790M	EGFR TKI Resistance	chr7	55181378	55181378	C	T	ENST00000275493.2	75		missense_variant	"ENST00000275493.2:c.2369C>T,NM_005228.4:c.2369C>T,NP_005219.2:p.Thr790Met,NC_000007.13:g.55249071C>T"	2023-01-27 17:02:05 UTC	CA090928	16613	"THR790MET,RS121434569"	FALSE
EGFR L858R	33	Cancer	162		"Multikinase Inhibitor AEE788,Gefitinib,Erlotinib"	Substitutes	Predictive	Supports	D	Sensitivity/Response	"EGFR L858R was expressed in Ba/F3 cells which do not contain endogenous EGFR, and conferred growth factor independance to the cells. Cells were plated and treated with 1st generation EGFR inhibitors Gefitinib, Erlotinib, or the the tool compound AEE788, and IC50 values were measured. L858R EGFR cells had very low IC50 nmol/L values for all three inhibitors in comparison to other constructs (Gefitinib=12, Erlotinib=6, AEE788=6), indicating sensitivity to all three constructs."	19147750	PubMed		"Kancha et al., 2009, Clin. Cancer Res."		3	accepted	3811	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/3811	https://civicdb.org/links/molecular_profiles/33	FALSE	EGFR	1956	L858R		chr7	55191822	55191822	T	G	ENST00000275493.2	75		missense_variant	"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg"	2023-01-27 17:02:04 UTC	CA126713	"16,609,376,282,376,200"	"LEU858ARG,RS121434568"	FALSE
ABL1 BCR::ABL F359V	866	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Does Not Support	C	Resistance	"In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with F359V evaluated, 6/6 had complete hematologic responses and 4/7 had major cytogenetic responses."	21865346	PubMed		"Cortes et al., 2011, Blood"	NCT00261846	2	accepted	3815	Somatic	2023-01-09 21:46:39 UTC	https://civicdb.org/links/evidence_items/3815	https://civicdb.org/links/molecular_profiles/866	FALSE	ABL1	25	BCR::ABL F359V		chr9	130873027	130873027	T	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.1075T>G,NP_005148.2:p.Phe359Val,NC_000009.11:g.133748414T>G,ENST00000318560.5:c.1075T>G"	2023-01-27 17:06:25 UTC	CA16602557	376096	"RS121913452,BCR-ABL F378V,BCR-ABL PHE359VAL,BCR-ABL1 F359V,BCR-ABL1 PHE359VAL,BCR-ABL F359V"	FALSE
ABL1 BCR::ABL F359V	866	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Does Not Support	C	Resistance	"This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chronic phase CML and BCR-ABL fusions. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. Of patients with F359V, 0/2 had a CHR and 1/2 had a MCyR. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occuring."	22371878	PubMed		"Khoury et al., 2012, Blood"	NCT00261846	1	accepted	3816	Somatic	2023-01-09 21:46:39 UTC	https://civicdb.org/links/evidence_items/3816	https://civicdb.org/links/molecular_profiles/866	FALSE	ABL1	25	BCR::ABL F359V		chr9	130873027	130873027	T	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.1075T>G,NP_005148.2:p.Phe359Val,NC_000009.11:g.133748414T>G,ENST00000318560.5:c.1075T>G"	2023-01-27 17:06:25 UTC	CA16602557	376096	"RS121913452,BCR-ABL F378V,BCR-ABL PHE359VAL,BCR-ABL1 F359V,BCR-ABL1 PHE359VAL,BCR-ABL F359V"	FALSE
ABL1 BCR::ABL F359V	866	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Supports	C	Reduced Sensitivity	"In this phase II multinational study, patients with accelerated phase CML and BCR-ABL fusions were treated with dasatinib monotherapy. Response rate among 60 imatinib-resistant patients with BCR-ABL mutations did not differ from the rate of the total population of 100 imatinib-resistant or -intolerant patients. 44 (73%) of 60 BCR-ABL mutant patients achieved major hematologic responses (MaHRs) and 18 (30%) of 60 achieved major cytogenetic responses (MCyRs). Of patients with F359V, 5/7 had MaHRs which was comparable to response rates among wild type patients, and 1/7 had MCyRs which which was lower than response rates among wild type patients."	17264298	PubMed		"Guilhot et al., 2007, Blood"		1	accepted	3817	Somatic	2023-01-09 21:46:39 UTC	https://civicdb.org/links/evidence_items/3817	https://civicdb.org/links/molecular_profiles/866	FALSE	ABL1	25	BCR::ABL F359V		chr9	130873027	130873027	T	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.1075T>G,NP_005148.2:p.Phe359Val,NC_000009.11:g.133748414T>G,ENST00000318560.5:c.1075T>G"	2023-01-27 17:06:25 UTC	CA16602557	376096	"RS121913452,BCR-ABL F378V,BCR-ABL PHE359VAL,BCR-ABL1 F359V,BCR-ABL1 PHE359VAL,BCR-ABL F359V"	FALSE
ABL1 BCR::ABL F359V	866	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	B	Resistance	"This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase) patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Of the 27 with F359V mutations, 14, 17, and 25 achieved CCyR, MCyR, and CHR with dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations."	19779040	PubMed		"Mller et al., 2009, Blood"	"NCT00101660,NCT00103844,NCT00123474"	3	accepted	3819	Somatic	2023-01-09 21:46:39 UTC	https://civicdb.org/links/evidence_items/3819	https://civicdb.org/links/molecular_profiles/866	FALSE	ABL1	25	BCR::ABL F359V		chr9	130873027	130873027	T	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.1075T>G,NP_005148.2:p.Phe359Val,NC_000009.11:g.133748414T>G,ENST00000318560.5:c.1075T>G"	2023-01-27 17:06:25 UTC	CA16602557	376096	"RS121913452,BCR-ABL F378V,BCR-ABL PHE359VAL,BCR-ABL1 F359V,BCR-ABL1 PHE359VAL,BCR-ABL F359V"	FALSE
ABL1 BCR::ABL F359V	866	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Supports	C	Resistance	"Prior to dasatinib treatment, two imatinib-resistant patients with chronic myeloid leukemia (CML) in chronic phase had the BCR-ABL1 fusion, one with the T315I, F359V, M244V, and G250E variants in 2/10, 6/10, 1/10, and 1/10 clones, respectively, and the other with F359V, F359V/F486S, F359V/L273M, and L273M variants in 6/10, 1/10, 2/10, and 1/10 clones, respectively. Clones were generated using peripheral blood RNA. The patients had no best cytogenetic responses and no or complete best hematologic responses to dasatinib. Two additional patients with CML, in myeloid blast crisis,  had F359V in 1/10 and 9/10 clones. They had no hematologic and no cytogenetic responses. Overall, responses were poor compared to responses in patients with unmutated BCR-ABL1."	16775234	PubMed		"Talpaz et al., 2006, N. Engl. J. Med."	NCT00064233	2	accepted	3820	Somatic	2023-01-09 21:46:39 UTC	https://civicdb.org/links/evidence_items/3820	https://civicdb.org/links/molecular_profiles/866	FALSE	ABL1	25	BCR::ABL F359V		chr9	130873027	130873027	T	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.1075T>G,NP_005148.2:p.Phe359Val,NC_000009.11:g.133748414T>G,ENST00000318560.5:c.1075T>G"	2023-01-27 17:06:25 UTC	CA16602557	376096	"RS121913452,BCR-ABL F378V,BCR-ABL PHE359VAL,BCR-ABL1 F359V,BCR-ABL1 PHE359VAL,BCR-ABL F359V"	FALSE
ABL1 BCR::ABL F359V	866	Chronic Myeloid Leukemia	8552		Axitinib		Predictive	Does Not Support	D	Resistance	"In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed similar incorporation when harboring fusions with the F359V variant of ABL1 compared to fusions with wildtype ABL1 (IC50 of 933nM vs. 823 nM), indicating that the variant does not induce resistance."	25686603	PubMed		"Pemovska et al., 2015, Nature"		2	accepted	3822	Somatic	2023-01-09 21:46:39 UTC	https://civicdb.org/links/evidence_items/3822	https://civicdb.org/links/molecular_profiles/866	FALSE	ABL1	25	BCR::ABL F359V		chr9	130873027	130873027	T	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.1075T>G,NP_005148.2:p.Phe359Val,NC_000009.11:g.133748414T>G,ENST00000318560.5:c.1075T>G"	2023-01-27 17:06:25 UTC	CA16602557	376096	"RS121913452,BCR-ABL F378V,BCR-ABL PHE359VAL,BCR-ABL1 F359V,BCR-ABL1 PHE359VAL,BCR-ABL F359V"	FALSE
KRAS G12V	421	Colorectal Cancer	9256		Panitumumab		Predictive	Supports	C	Resistance	"One patient participating in a large retrospective study of EGFR monoclonal antibodies in metastatic, treatment refractory colorectal cancer had a tumor which harbored KRAS G12V, was wildtype for NRAS, BRAF and PIK3CA, and had individual response data. This patient was was a 78 year old female treated with panitumumab monotherapy as 2nd line therapy who experienced progressive disease (PFS: 5 weeks)."	20619739	PubMed		"De Roock et al., 2010, Lancet Oncol."		3	accepted	3824	Somatic	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/3824	https://civicdb.org/links/molecular_profiles/421	FALSE	KRAS	3845	G12V		chr12	25245350	25245350	C	A	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.35G>T,NP_004976.2:p.Gly12Val,NC_000012.11:g.25398284C>A,ENST00000256078.4:c.35G>T"	2023-01-27 17:03:41 UTC	CA122540	12583	"GLY12VAL,RS121913529"	FALSE
BRAF V600E	12	Colorectal Cancer	9256		Panitumumab		Predictive	Supports	C	Resistance	"One patient participating in a large retrospective study of EGFR monoclonal antibodies in metastatic colorectal cancer had a tumor which harbored BRAF V600E, was wildtype for NRAS, KRAS and PIK3CA, and had individual response data. This patient was was a male treated with panitumumab monotherapy as 1st line therapy who experienced progressive disease (PFS: 7 weeks; OS: 10 weeks)."	20619739	PubMed		"De Roock et al., 2010, Lancet Oncol."		3	accepted	3827	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/3827	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
PIK3CA R88Q	903	Colorectal Cancer	9256		"Irinotecan,Cetuximab"	Combination	Predictive	Does Not Support	C	Resistance	"One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored PIK3CA R88Q, was wildtype for KRAS, BRAF and NRAS, and had individual response data. This patient was was a 56 year old female treated with cetuximab and irinotecan as 2nd line therapy who experienced a partial response (PFS: 32 weeks, OS: 32 weeks)."	20619739	PubMed		"De Roock et al., 2010, Lancet Oncol."		3	accepted	3832	Somatic	2023-01-09 21:46:40 UTC	https://civicdb.org/links/evidence_items/3832	https://civicdb.org/links/molecular_profiles/903	FALSE	PIK3CA	5290	R88Q		chr3	179199088	179199088	G	A	ENST00000263967.3	75		missense_variant	"NC_000003.12:g.179199088G>A,NC_000003.11:g.178916876G>A,NM_006218.4:c.263G>A,NP_006209.2:p.Arg88Gln"	2023-01-27 17:06:44 UTC	CA16602516	376049	"RS121913287,ARG88GLN"	FALSE
PIK3CA H1047R	107	Colorectal Cancer	9256		"Irinotecan,Cetuximab"	Combination	Predictive	Supports	C	Resistance	"Five patients participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored PIK3CA H1047R (exon 21), were wildtype for KRAS, BRAF and NRAS, and had individual response data. All patients were treated with cetuximab and irinotecan, four as 3rd line therapy, one as 4th line. Patient characteristics are as follows: a 65 year old female who experienced stable disease (PFS: 33 weeks, OS: 37 weeks); a 56 year old female who experienced stable disease (PFS: 28 weeks, OS: 43 weeks); a 69 year old female who experienced progressive disease (PFS: 10 weeks, OS: 28 weeks); a 63 year old male who experienced progressive disease (PFS:11 weeks, OS: 18 weeks); a 60 year old female who experienced progressive disease (PFS: 12 weeks, OS: 34 weeks). Based off this information and clinical data compiled from the larger cohort, authors concluded that PIK3CA exon 21 (listed as exon 20 in source) mutations predict poor response to cetuximab."	20619739	PubMed		"De Roock et al., 2010, Lancet Oncol."		3	accepted	3841	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/3841	https://civicdb.org/links/molecular_profiles/107	FALSE	PIK3CA	5290	H1047R		chr3	179234297	179234297	A	G	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.3140A>G,NP_006209.2:p.His1047Arg,ENST00000263967.3:c.3140A>G,NC_000003.11:g.178952085A>G"	2023-01-27 17:02:38 UTC	CA123326	13652	"HIS1047ARG,RS121913279"	FALSE
NRAS G13R	870	Colorectal Cancer	9256		Panitumumab		Predictive	Supports	C	Resistance	"One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored NRAS G13R, was wildtype for KRAS, BRAF and PIK3CA, and had individual response data. This patient was was a 50 year old male treated with panitumumab monotherapy as 3rd line therapy (discontinued for toxic/biochemical reasons) who experienced stable disease (PFS: 22 weeks; OS: 74 weeks). Authors considered stable disease as both clinical benefit and non-response"	20619739	PubMed		"De Roock et al., 2010, Lancet Oncol."		1	accepted	3842	Somatic	2023-01-09 21:46:39 UTC	https://civicdb.org/links/evidence_items/3842	https://civicdb.org/links/molecular_profiles/870	FALSE	NRAS	4893	G13R		chr1	114716124	114716124	C	G	ENST00000369535.4	75		missense_variant	"NM_002524.4:c.37G>C,NP_002515.1:p.Gly13Arg,NC_000001.10:g.115258745C>G,ENST00000369535.4:c.37G>C"	2023-01-27 17:06:28 UTC	CA151261	13899	"RS121434595,GLY13ARG"	FALSE
NRAS G12C	871	Colorectal Cancer	9256		"Chemotherapy,Cetuximab"	Combination	Predictive	Supports	C	Resistance	"Two patients participating in a large retrospective trial of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored NRAS G12C and were wild type for KRAS, PIK3CA, and BRAF. Both experienced stable disease, which the authors classified as non-response. The two patients whose tumors harbored NRAS G12C included a 63 year old female treated with cetuximab and irinotecan as a 3rd line treatment who had PFS of 34 weeks and OS of 55 weeks; and a 38 year old female treated with cetuximab, oxaliplatin and 5FU as a 2nd line therapy who had PFS of 12 weeks."	20619739	PubMed		"De Roock et al., 2010, Lancet Oncol."		3	accepted	3845	Somatic	2023-01-09 21:46:39 UTC	https://civicdb.org/links/evidence_items/3845	https://civicdb.org/links/molecular_profiles/871	FALSE	NRAS	4893	G12C		chr1	114716127	114716127	C	A	ENST00000369535.4	75		missense_variant	"NM_002524.4:c.34G>T,NP_002515.1:p.Gly12Cys,NC_000001.10:g.115258748C>A,ENST00000369535.4:c.34G>T"	2023-01-27 17:06:29 UTC	CA297020	40468	"RS121913250,GLY12CYS"	FALSE
PIK3CA G1049R	914	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	C	Resistance	"One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored PIK3CA G1049R (exon 20), was wildtype for KRAS, BRAF and NRAS, and had individual response data. This patient was was a 69 year old male treated with cetuximab + FOLFIRI as 3rd line therapy who experienced progressive disease and had PFS of 13 weeks and OS of 36 weeks. Using this information and data from the larger cohort, authors concluded that PIK3CA exon 21 (listed as exon 20 in source) mutations predict poor response to cetuximab."	20619739	PubMed		"De Roock et al., 2010, Lancet Oncol."		3	accepted	3847	Somatic	2023-01-09 21:46:40 UTC	https://civicdb.org/links/evidence_items/3847	https://civicdb.org/links/molecular_profiles/914	FALSE	PIK3CA	5290	G1049R		chr3	179234302	179234302	G	C	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.3145G>C,NP_006209.2:p.Gly1049Arg,NC_000003.11:g.178952090G>C,ENST00000263967.3:c.3145G>C"	2023-01-27 17:06:51 UTC	CA16602520	376053	"RS121913277,GLY1049ARG"	FALSE
HRAS G13D	270	Skin Squamous Cell Carcinoma	3151		Vemurafenib		Predictive	Supports	C	Resistance	"In a retrospective study of 23 patients with BRAF V600 mutation (a known vemurafenib sensitizing mutation) that developed cutaneous squamous-cell carcinoma upon treatment with vemurafenib monotherapy, a patient harboring HRAS G13D co-mutation (n=1) was reported to be resistant to vemurafenib treatment."	22256804	PubMed		"Su et al., 2012, N. Engl. J. Med."	"NCT00405587,NCT00949702,NCT01001299,NCT01006980"		accepted	3851	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/3851	https://civicdb.org/links/molecular_profiles/270	FALSE	HRAS	3265	G13D		chr11	534285	534285	C	T	ENST00000451590.1	75		missense_variant	"NC_000011.9:g.534285C>T,NP_005334.1:p.Gly13Asp,NM_005343.3:c.38G>A,ENST00000451590.1:c.38G>A"	2023-01-27 17:03:22 UTC	CA256488	12604	"GLY13ASP,RS104894226"	FALSE
HRAS G13D	270	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	D	Resistance	"In an in vitro study, Colo-320, SW48, and CaCO2 cell lines expressing HRAS G13D mutation were associated with resistance to cetuximab treatment, as compared to Colo-320, SW48, and CaCO2 cells expressing wild-type HRAS."	26561417	PubMed		"Boidot et al., 2016, Int J Colorectal Dis"			accepted	3852	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/3852	https://civicdb.org/links/molecular_profiles/270	FALSE	HRAS	3265	G13D		chr11	534285	534285	C	T	ENST00000451590.1	75		missense_variant	"NC_000011.9:g.534285C>T,NP_005334.1:p.Gly13Asp,NM_005343.3:c.38G>A,ENST00000451590.1:c.38G>A"	2023-01-27 17:03:22 UTC	CA256488	12604	"GLY13ASP,RS104894226"	FALSE
KRAS A146T	880	Colorectal Cancer	9256		"FOLFOX-4 Regimen,Cetuximab"	Combination	Predictive	Supports	B	Resistance	"In a retrospective study of 148 treatment naive metastatic colorectal cancer patients, patients with RAS mutations and wildtype BRAF (n=10), including A146T (N=3), G15D (N=1), and V152M/NRAS V160A, treated with FOLFOX4 plus cetuximab were associated with decreased overall survival (16.3mo vs. 28.5mo, HR:0.43, 95% CI:0.20-0.89, P=0.020) and decreased progression free survival (7.2mo vs. 9.7mo, HR:0.56, 95% CI:0.27-1.16, P=0.11), as compared to patients with wild-type KRAS, NRAS and BRAF."	25666295	PubMed		"Kaczirek et al., 2015, Clin Colorectal Cancer"		3	accepted	3858	Somatic	2023-01-09 21:46:39 UTC	https://civicdb.org/links/evidence_items/3858	https://civicdb.org/links/molecular_profiles/880	FALSE	KRAS	3845	A146T		chr12	25225628	25225628	C	T	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.436G>A,NP_004976.2:p.Ala146Thr,NC_000012.11:g.25378562C>T,ENST00000256078.4:c.436G>A"	2023-01-27 17:06:34 UTC	CA245262	197243	"RS121913527,ALA146THR"	FALSE
KRAS Q61H	881	Colorectal Cancer	9256		"Cetuximab,Chemotherapy"	Combination	Predictive	Supports	C	Resistance	"Seven patients participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored KRAS Q61H (either c.183A > C or >T) and were wildtype for BRAF and PIK3CA mutations. A 73 year old man who was treated with cetixumab and irinotecan as a fourth line therapy experienced stable disease, with a PFS of 36 weeks and OS of 57 weeks. A 65 year old man who was treated with cetuximab and irinotecan as a 3rd line therapy experienced stable disease with a PFS of 32 weeks and an OS of 51 weeks. A 70 year old female who was treated with cetuximab, oxaliplatin and 5FU as a second line therapy experienced progressive disease after 4 weeks of treatment. A 66 year old male who was treated with cetuximab and irinotecan as a 4th line therapy experienced progression after 6 week and had an OS of 21 weeks. A 71 year old female who was treated with cetuximab and folfiri as a 3rd line therapy experienced progression after 8 weeks and had an OS of 116 weeks. A 77 year old male who was treated with cetuximab and irinotecan as a 4th line therapy experienced progression after 8 weeks and had an overall survival of 17 weeks. A 66 year old male who was treated with cetuximab and irinotecan as a 3rd line therapy experienced stable disease (11 weeks) and an OS of 14 weeks. In this study, authors considered stable disease to be non-response to treatment."	20619739	PubMed		"De Roock et al., 2010, Lancet Oncol."		3	accepted	3861	Somatic	2023-01-09 21:46:39 UTC	https://civicdb.org/links/evidence_items/3861	https://civicdb.org/links/molecular_profiles/881	FALSE	KRAS	3845	Q61H		chr12	25227341	25227341	T	G	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.183A>C,NP_004976.2:p.Gln61His,NC_000012.11:g.25380275T>G,ENST00000256078.4:c.183A>C"	2023-01-27 17:06:35 UTC	CA180922	177881	"RS17851045,GLN61HIS"	FALSE
KRAS Q61H	881	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	C	Resistance	"In a colorectal cancer patient with a KRAS Q61H mutation, KRAS Q61H was reported to be refractory to cetuximab treatment. The patient was treated with cetuximab and irinotecan for 18 months, had a partial response to therapy and then experienced progressive disease with a re-biopsy of the tumor identifying a KRAS Q61H mutation."	22722830	PubMed		"Misale et al., 2012, Nature"			accepted	3862	Somatic	2023-01-09 21:46:39 UTC	https://civicdb.org/links/evidence_items/3862	https://civicdb.org/links/molecular_profiles/881	FALSE	KRAS	3845	Q61H		chr12	25227341	25227341	T	G	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.183A>C,NP_004976.2:p.Gln61His,NC_000012.11:g.25380275T>G,ENST00000256078.4:c.183A>C"	2023-01-27 17:06:35 UTC	CA180922	177881	"RS17851045,GLN61HIS"	FALSE
EGFR Mutation	438	Lung Cancer	1324		Erlotinib		Predictive	Supports	B	Sensitivity/Response	"In advanced-stage (IIIB or IV) non-small cell lung cancer patients treated with erlotinib, patients whose tumors harbored EGFR mutations (n=3) had a higher 12-week progression-free survival rate compared to wildtype EGFR patients (n=54; 100% vs. 25%, P=0.0064)."	22025157	PubMed		"Ramalingam et al., 2011, J. Clin. Oncol."	NCT00760929	2	accepted	3864	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/3864	https://civicdb.org/links/molecular_profiles/438	FALSE	EGFR	1956	Mutation		chr7	55019101	55211628			ENST00000275493.2	75		inframe_variant		2023-01-09 21:52:07 UTC		N/A		FALSE
KRAS Q61L	882	Colorectal Cancer	9256		"Chemotherapy,Cetuximab"	Combination	Predictive	Supports	C	Resistance	"Two patients participating in a large retrospective trial of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored KRAS Q61L. One patient, a 67 year old male, whose tumor was wildtype for BRAF and PIK3CA, was treated with cetuximab and irinotecan as a fourth line therapy. Cetuximab was discontinued due to toxicity and the patient experienced stable disease for 17 weeks and an overall survival of 23 weeks following treatment. The other patient was a 44 year old female whose tumor was wildtype for PIK3CA, BRAF and NRAS. The patient was treated with cetuximab and irinotecan as a third line therapy, and experienced progressive disease 23 weeks following treatment; overall survival was 30 weeks. Both patients experienced progressive disease following treatment."	20619739	PubMed		"De Roock et al., 2010, Lancet Oncol."		3	accepted	3867	Somatic	2023-01-09 21:46:39 UTC	https://civicdb.org/links/evidence_items/3867	https://civicdb.org/links/molecular_profiles/882	FALSE	KRAS	3845	Q61L		chr12	25227342	25227342	T	A	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.182A>T,NP_004976.2:p.Gln61Leu,NC_000012.11:g.25380276T>A,ENST00000256078.4:c.182A>T"	2023-01-27 17:06:36 UTC	CA210876	45116	"RS121913240,GLN61LEU"	FALSE
KRAS Q61R	883	Colorectal Cancer	9256		"Irinotecan,Cetuximab"	Combination	Predictive	Supports	C	Resistance	"Two patients participating in a large retrospective trial of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored KRAS Q61R and were wild type for PIK3CA, BRAF, and NRAS. Both were treated with cetuximab and irinotecan as 3rd line treatments. One patient was a 72 year old female who experienced progressive disease 12 weeks following treatment; OS was 20 weeks. The other patient was a 43 year old female who experienced stable disease for the duration of the study and did not progress."	20619739	PubMed		"De Roock et al., 2010, Lancet Oncol."		3	accepted	3870	Somatic	2023-01-09 21:46:39 UTC	https://civicdb.org/links/evidence_items/3870	https://civicdb.org/links/molecular_profiles/883	FALSE	KRAS	3845	Q61R		chr12	25227342	25227342	T	C	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.182A>G,NP_004976.2:p.Gln61Arg,NC_000012.11:g.25380276T>C,ENST00000256078.4:c.182A>G"	2023-01-27 17:06:37 UTC	CA261702	45115	"RS121913240,GLN61ARG"	FALSE
KRAS Q61K	884	Colorectal Cancer	9256		"Cetuximab,Chemotherapy"	Combination	Predictive	Supports	C	Resistance	"Two patients participating in a large retrospective trial of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored KRAS Q61K. One patient was a 61 year old female whose tumor was wildtype for BRAF and PIK3CA. This patient was treated with cetuximab, oxaliplatin, and 5FU, as a second line therapy, and experienced progressive disease 6 weeks following cetuximab administration; overall survival was 90 weeks. The other patient was a 65 year old female whose tumor was wildtype for PIK3CA. The patient was treated with cetuximab and irinotecan as a third line therapy, and experienced progressive disease 10 week following cetuximab. Both patients experienced progressive disease following treatment."	20619739	PubMed		"De Roock et al., 2010, Lancet Oncol."		3	accepted	3872	Somatic	2023-01-09 21:46:39 UTC	https://civicdb.org/links/evidence_items/3872	https://civicdb.org/links/molecular_profiles/884	FALSE	KRAS	3845	Q61K		chr12	25227343	25227343	G	T	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.181C>A,NP_004976.2:p.Gln61Lys,NC_000012.11:g.25380277G>T,ENST00000256078.4:c.181C>A"	2023-01-27 17:06:37 UTC	CA180750	177777	"RS121913238,GLN61LYS"	FALSE
KRAS G13D	81	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	D	Resistance	"In an in vitro study, a Lim1215 colorectal cancer cell line endogenously expressing KRAS G13D mutation demonstrated resistance to cetuximab treatment, compared to Lim1215 parental cells expressing wild-type KRAS. Resistance was determined by assessing cell viability."	22722830	PubMed		"Misale et al., 2012, Nature"			accepted	3878	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/3878	https://civicdb.org/links/molecular_profiles/81	FALSE	KRAS	3845	G13D		chr12	25245347	25245347	C	T	ENST00000256078.4	75		missense_variant	"NM_033360.3:c.38G>A,NP_004976.2:p.Gly13Asp,NC_000012.11:g.25398281C>T,ENST00000256078.4:c.38G>A"	2023-01-27 17:02:27 UTC	CA122534	12580	"GLY13ASP,RS112445441"	FALSE
KRAS G13D	81	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	B	Resistance	"This was a retrospective study of 691 cetuximab treated patients with metastatic colorectal cancer. Of those, 50 patients harbored KRAS G13D, were BRAF, NRAS and PIK3CA wt, and had individual response data. Nine patients had partial response, 19 had stable disease, and 22 progressed. Treatments included cetuximab + irinotecan (n=38), cetuximab + FOLFIRI (n=5), cetuximab monotherapy (n=4), cetuximab + oxaliplatin + 5FU (n=2), and cetuximab + irinotecan + oxaliplatin + 5FU (n=1). Median PFS was 16 weeks (3-101 weeks), median OS was 33 weeks (3-161 weeks), and median number of previous chemotherapy lines was 2 (0-4). Median age was 65 years old (34-78), and there were 29 males and 20 females. Authors concluded that KRAS mutation was strongly associated with poor response to cetuximab and suggested that mutation status of KRAS is the most informative compared to BRAF, NRAS, and PIK3CA exon 20 for predicting cetuximab response."	20619739	PubMed		"De Roock et al., 2010, Lancet Oncol."		3	accepted	3881	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/3881	https://civicdb.org/links/molecular_profiles/81	FALSE	KRAS	3845	G13D		chr12	25245347	25245347	C	T	ENST00000256078.4	75		missense_variant	"NM_033360.3:c.38G>A,NP_004976.2:p.Gly13Asp,NC_000012.11:g.25398281C>T,ENST00000256078.4:c.38G>A"	2023-01-27 17:02:27 UTC	CA122534	12580	"GLY13ASP,RS112445441"	FALSE
KRAS G13D	81	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	B	Resistance	"In a retrospective study of 148 treatment naive metastatic colorectal cancer patients, patients with RAS mutations (n=10), including KRAS A146T, KRAS G13D, NRAS G12D and NRAS Q179*, treated with FOLFOX4 plus cetuximab were associated with decreased overall survival (16.3mo vs. 28.5mo, HR:0.43, 95% CI:0.20-0.89, P=0.020) and decreased progression free survival (7.2mo vs. 9.7mo, HR:0.56, 95% CI:0.27-1.16, P=0.11), as compared to patients with wild-type KRAS and NRAS."	25666295	PubMed		"Kaczirek et al., 2015, Clin Colorectal Cancer"			accepted	3882	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/3882	https://civicdb.org/links/molecular_profiles/81	FALSE	KRAS	3845	G13D		chr12	25245347	25245347	C	T	ENST00000256078.4	75		missense_variant	"NM_033360.3:c.38G>A,NP_004976.2:p.Gly13Asp,NC_000012.11:g.25398281C>T,ENST00000256078.4:c.38G>A"	2023-01-27 17:02:27 UTC	CA122534	12580	"GLY13ASP,RS112445441"	FALSE
KRAS G13D	81	Colorectal Cancer	9256		Regorafenib		Predictive	Supports	D	Resistance	"In an in vitro study, a human colon adenocarcinoma SW48 cell line expressing KRAS G13D mutation demonstrated resistance to regorafenib treatment (IC50: 172.23 nM vs. 114.28 nM, P<0.01) compared to SW48 cells expressing KRAS wild-type. Resistance was determined by assessing cell viability. Authors concluded that KRAS G13D is more resistant to regorafenib than KRAS wt, but more sensitive than common KRAS G12 mutations."	26161928	PubMed		"Camaj et al., 2015, Future Oncol"		1	accepted	3889	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/3889	https://civicdb.org/links/molecular_profiles/81	FALSE	KRAS	3845	G13D		chr12	25245347	25245347	C	T	ENST00000256078.4	75		missense_variant	"NM_033360.3:c.38G>A,NP_004976.2:p.Gly13Asp,NC_000012.11:g.25398281C>T,ENST00000256078.4:c.38G>A"	2023-01-27 17:02:27 UTC	CA122534	12580	"GLY13ASP,RS112445441"	FALSE
KRAS Mutation	332	Lung Non-small Cell Carcinoma	3908		Erlotinib		Predictive	Supports	B	Resistance	"In the placebo-controlled Phase III study SATURN, using erlotinib maintenance therapy for patients with advanced NSCLC who were selected for response or stable disease after first line chemotherapy, KRAS mutation was assessed. In the KRAS wildtype group, erlotinib showed a significant benefit for progression free survival (PFS) over placebo (HR, 0.70; 95% CI, 0.57 to 0.87, P<0.001). No statistically significant improvement in PFS was seen with erlotinib in the KRAS mutant group over placebo. Significant difference in PFS between erlotinib treated KRAS WT and MUT patients was not seen.  Overall, in the intent to treat population erlotinib significantly improved PFS over placebo (HR, 0.71; 95% CI, 0.62 to 0.82; P<0.001)."	21969500	PubMed		"Brugger et al., 2011, J. Clin. Oncol."		3	accepted	3895	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/3895	https://civicdb.org/links/molecular_profiles/332	FALSE	KRAS	3845	Mutation		chr12	25209431	25250803			ENST00000256078.4	75		protein_altering_variant		2023-01-09 21:52:06 UTC		N/A		FALSE
KRAS Q61	203	Colorectal Cancer	9256		"Chemotherapy,Cetuximab"	Combination	Predictive	Supports	B	Resistance	"This was a retrospective study of 605 patients with metastatic, chemotherapy refractory colorectal cancer treated with cetuximab + chemotherapy. Patients harboring KRAS codon 61 mutations (n=13) had a significantly lower response rate than did patients with KRAS wildtype tumors (0/13 vs 123/345; p= .0055). Authors consider KRAS codon 61 mutations as supporting resistance to cetuximab and suggest that it should be included in KRAS mutation screening. Authors note that these patients were treated with cetuximab prior to widespread adoption of regular KRAS mutational status screening. Patients treated with cetuximab monotherapy were not included."	20619739	PubMed		"De Roock et al., 2010, Lancet Oncol."		4	accepted	3917	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/3917	https://civicdb.org/links/molecular_profiles/203	FALSE	KRAS	3845	Q61		chr12	25227341	25227343			ENST00000256078.4	75		protein_altering_variant		2023-01-09 21:52:05 UTC		"177,881,177,777,451,000,000,000,000,000,000,000,000"	GLN61	FALSE
KRAS G12V	421	Colorectal Cancer	9256		Regorafenib		Predictive	Supports	D	Resistance	"In an in vitro study, a human colon adenocarcinoma SW48 cell line expressing KRAS G12V mutation demonstrated resistance to regorafenib treatment (IC50: 241.90 nM vs. 114.28 nM, P<0.01) compared to SW48 cells expressing KRAS wildtype. Resistance was determined by assessing cell viability. Regorafenib significantly reduced BRAF, Erk1/2 and Elk phosphorylation compared to wildtype, as assessed by western blot. Authors concluded that KRAS G12A was more resistant to regorafenib than KRAS wt, and intermediately resistant compared to other common KRAS mutations."	26161928	PubMed		"Camaj et al., 2015, Future Oncol"		2	accepted	3924	Somatic	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/3924	https://civicdb.org/links/molecular_profiles/421	FALSE	KRAS	3845	G12V		chr12	25245350	25245350	C	A	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.35G>T,NP_004976.2:p.Gly12Val,NC_000012.11:g.25398284C>A,ENST00000256078.4:c.35G>T"	2023-01-27 17:03:41 UTC	CA122540	12583	"GLY12VAL,RS121913529"	FALSE
KRAS G12D	79	Colorectal Cancer	9256		Regorafenib		Predictive	Supports	D	Resistance	"In an in vitro study, a human colon adenocarcinoma SW48 cell line expressing KRAS G12D mutation demonstrated resistance to regorafenib treatment (IC50: 195.01nM vs. 114.28 nM P<0.01) compared to SW48 cells expressing KRAS wild-type. Resistance was determined by assessing cell viability. Authors concluded that KRAS G12D was more resistant to regorafenib than KRAS wt, and intermediately resistant compared to other common KRAS G12/G13 mutations."	26161928	PubMed		"Camaj et al., 2015, Future Oncol"		1	accepted	3946	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/3946	https://civicdb.org/links/molecular_profiles/79	FALSE	KRAS	3845	G12D	EGFR TKI Resistance	chr12	25245350	25245350	C	T	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.35G>A,NP_004976.2:p.Gly12Asp,NC_000012.11:g.25398284C>T,ENST00000256078.4:c.35G>A"	2023-01-27 17:02:26 UTC	CA122538	12582	"GLY12ASP,RS121913529"	FALSE
KRAS G12D	79	Melanoma	1909		Vemurafenib		Predictive	Supports	D	Resistance	In vitro studies of M229 (a human melanoma cell line) endogenously expressing wildtype KRAS and BRAF V600E (a known BRAF inhibitor sensitizing mutation) found that cells virally induced to stably over-express KRAS4a G12D or KRAS4b G12D  were more resistant to vemurafenib (a BRAF inhibitor) than cells transduced with empty vectors (90% vs 10% survival).	24265155	PubMed		"Shi et al., 2014, Cancer Discov"		2	accepted	3957	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/3957	https://civicdb.org/links/molecular_profiles/79	FALSE	KRAS	3845	G12D	EGFR TKI Resistance	chr12	25245350	25245350	C	T	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.35G>A,NP_004976.2:p.Gly12Asp,NC_000012.11:g.25398284C>T,ENST00000256078.4:c.35G>A"	2023-01-27 17:02:26 UTC	CA122538	12582	"GLY12ASP,RS121913529"	FALSE
KRAS G12D	79	Ovarian Cancer	2394		Cetuximab		Predictive	Supports	D	Resistance	"In an in vitro study, a MCAS cell line expressing KRAS G12D mutation was associated with reduced sensitivity to cetuximab treatment as compared to RMUG-L and OMC-1 cells expressing wild-type KRAS. Resistance was determined by assessing cell growth. Further, in an in vivo experiment, KRAS G12D expressing MCAS xenografts in nude mice had reduced response to cetuximab, as compared to KRAS wild-type expressing RMUG-L xenografts. Resistance was determined by assessing tumor growth."	22246397	PubMed		"Sato et al., 2012, Oncol. Rep."		3	accepted	3958	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/3958	https://civicdb.org/links/molecular_profiles/79	FALSE	KRAS	3845	G12D	EGFR TKI Resistance	chr12	25245350	25245350	C	T	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.35G>A,NP_004976.2:p.Gly12Asp,NC_000012.11:g.25398284C>T,ENST00000256078.4:c.35G>A"	2023-01-27 17:02:26 UTC	CA122538	12582	"GLY12ASP,RS121913529"	FALSE
KRAS G12C	78	Colorectal Cancer	9256		"Cetuximab,Chemotherapy"	Combination	Predictive	Supports	B	Resistance	"This was a retrospective study of 691 cetuximab treated patients with metastatic, chemotherapy refractory colorectal cancer. Of those, 16 patients harbored KRAS G12C, were BRAF, NRAS and PIK3CA wt, and had individual response data. One patient had a partial response, 6 had stable disease, and 9 progressed. Treatments included cetuximab + irinotecan (n=15) and cetuximab + FOLFIRI (n=1). Median PFS was 11 weeks (6-65 weeks), median OS was 24 weeks (14-91 weeks), and median number of previous chemotherapy lines was 2 (1-6). Median age was 62 years old (46-73), and there were 8 males and 8 females. Using these data and data from the larger cohort, authors concluded that KRAS mutation was strongly associated with poor response to cetuximab and suggested that mutation status of KRAS is the most informative compared to BRAF, NRAS, and PIK3CA exon 20 for predicting cetuximab response."	20619739	PubMed		"De Roock et al., 2010, Lancet Oncol."		3	accepted	3967	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/3967	https://civicdb.org/links/molecular_profiles/78	FALSE	KRAS	3845	G12C	EGFR TKI Resistance	chr12	25245351	25245351	C	A	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.34G>T,NP_004976.2:p.Gly12Cys,NC_000012.11:g.25398285C>A,ENST00000256078.4:c.34G>T"	2023-01-27 17:02:26 UTC	CA122528	12578	"GLY12CYS,RS121913530"	FALSE
KRAS G12C	78	Colorectal Cancer	9256		Regorafenib		Predictive	Supports	D	Resistance	"In an in vitro study, a human colon adenocarcinoma SW48 cell line expressing KRAS G12C mutation demonstrated resistance to regorafenib treatment (IC50: 386.22 nM vs. 114.28 nM, P<0.01) compared to SW48 cells expressing KRAS wild-type. Resistance was determined by assessing cell viability. In vivo, KRAS G12C expressing SW48 cells were injected into NOD/SCID mice. Treatment with regorafenib did not lead to a significant delay of tumor growth. Mice injected with KRAS wt cells did not significantly respond to regorafenib, although a trend was seen toward better response. IHC analysis of mouse tissue revealed no significant change in markers of proliferation (Ki67), angiogenesis (CD31) and apoptosis (TUNEL) in KRAS G12C expressing mice treated with regorafenib compared to KRAS wt expressing mice whose tumors displayed more pronounced changes. Authors concluded that G12C was more resistant to regorafenib than KRAS wt and other common KRAS G12/G13 mutants."	26161928	PubMed		"Camaj et al., 2015, Future Oncol"		2	accepted	3973	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/3973	https://civicdb.org/links/molecular_profiles/78	FALSE	KRAS	3845	G12C	EGFR TKI Resistance	chr12	25245351	25245351	C	A	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.34G>T,NP_004976.2:p.Gly12Cys,NC_000012.11:g.25398285C>A,ENST00000256078.4:c.34G>T"	2023-01-27 17:02:26 UTC	CA122528	12578	"GLY12CYS,RS121913530"	FALSE
KRAS G12R	526	Colorectal Cancer	9256		"Cetuximab,Chemotherapy"	Combination	Predictive	Supports	C	Resistance	"Three patients participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored KRAS G12R, were wildtype for NRAS, BRAF and PIK3CA, and had individual response data. One patient experienced stable disease, and two patients experienced progressive disease. Patient characteristics were as follows: a 67 year old female treated with cetuximab + irinotecan as a 4th line treatment who experienced progressive disease and had PFS of 8 weeks and OS of 17 weeks; a 78 year old female treated with cetuximab + irinotecan as a 3rd line therapy who experienced progressive disease and had PFS of 3 weeks and OS of 10 weeks; and a 55 year old male treated with cetuximab + FOLFIRI as a 3rd line therapy who experienced stable disease and had PFS of 13 weeks and OS of 15 weeks."	20619739	PubMed		"De Roock et al., 2010, Lancet Oncol."		3	accepted	3987	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/3987	https://civicdb.org/links/molecular_profiles/526	FALSE	KRAS	3845	G12R		chr12	25245351	25245351	C	G	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.34G>C,NP_004976.2:p.Gly12Arg,NC_000012.11:g.25398285C>G,ENST00000256078.4:c.34G>C"	2023-01-27 17:04:11 UTC	CA122531	12579	"GLY12ARG,RS121913530"	FALSE
KRAS G12R	526	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	D	Resistance	"In an in vitro study to identify cetuximab-resistant clones following continuous drug treatment, a resistant clone of the Lim1215 colorectal cancer cell line was identified to have the KRAS G12R mutation. No G12R was detected in the parental line despite high-resolution evaluation. Additionally, endogenously expressing KRAS G12R (knock-in) mutation demonstrated resistance to cetuximab treatment, compared to Lim1215 parental cells expressing wild-type KRAS. Resistance was determined by assessing cell viability."	22722830	PubMed		"Misale et al., 2012, Nature"		4	accepted	3989	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/3989	https://civicdb.org/links/molecular_profiles/526	FALSE	KRAS	3845	G12R		chr12	25245351	25245351	C	G	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.34G>C,NP_004976.2:p.Gly12Arg,NC_000012.11:g.25398285C>G,ENST00000256078.4:c.34G>C"	2023-01-27 17:04:11 UTC	CA122531	12579	"GLY12ARG,RS121913530"	FALSE
KRAS G12R	526	Colorectal Cancer	9256		Regorafenib		Predictive	Supports	D	Resistance	"In an in vitro study, a human colon adenocarcinoma SW48 cell line expressing KRAS G12R mutation demonstrated resistance to regorafenib treatment (IC50: 181.77 nM vs. 114.28 nM, P<0.01) compared to SW48 cells expressing KRAS wild-type. Resistance was determined by assessing cell viability. Authors concluded that KRAS G12R was resistant to regorafenib compared to wildtype but was less resistant than other common KRAS G12/G13 mutations."	26161928	PubMed		"Camaj et al., 2015, Future Oncol"		1	accepted	3991	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/3991	https://civicdb.org/links/molecular_profiles/526	FALSE	KRAS	3845	G12R		chr12	25245351	25245351	C	G	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.34G>C,NP_004976.2:p.Gly12Arg,NC_000012.11:g.25398285C>G,ENST00000256078.4:c.34G>C"	2023-01-27 17:04:11 UTC	CA122531	12579	"GLY12ARG,RS121913530"	FALSE
KRAS G12S	887	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	B	Resistance	"This was a retrospective study of 691 cetuximab treated patients with metastatic, chemotherapy refractory colorectal cancer. Of those, 16 patients harbored KRAS G12S, were BRAF, NRAS and PIK3CA wt, and had individual response data. Nine patients had stable disease and seven progressed. Treatments included cetuximab + irinotecan (n=13), cetuximab + FOLFIRI (n=1), cetuximab+5FU (n=1), cetuximab + irinotecan + oxaliplatin + bevacizumab (n=1). Median PFS was 12 weeks (2-50 weeks), median OS was 25 weeks (10-135 weeks), and median number of previous chemotherapy lines was 2 (1-6). Median age was 59 years old (31-69), and there were 9 males and 7 females. Using these data and data from the larger cohort, authors concluded that KRAS mutation was strongly associated with poor response to cetuximab and suggested that mutation status of KRAS is the most informative compared to BRAF, NRAS, and PIK3CA exon 20 for predicting cetuximab response."	20619739	PubMed		"De Roock et al., 2010, Lancet Oncol."		3	accepted	4006	Somatic	2023-01-09 21:46:39 UTC	https://civicdb.org/links/evidence_items/4006	https://civicdb.org/links/molecular_profiles/887	FALSE	KRAS	3845	G12S		chr12	25245351	25245351	C	T	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.34G>A,NP_004976.2:p.Gly12Ser,NC_000012.11:g.25398285C>T,ENST00000256078.4:c.34G>A"	2023-01-27 17:06:39 UTC	CA135565	12584	"RS121913530,GLY12SER"	FALSE
KRAS G12S	887	Colorectal Cancer	9256		Regorafenib		Predictive	Supports	D	Resistance	"In an in vitro study, a human colon adenocarcinoma SW48 cell line expressing KRAS G12S mutation demonstrated resistance to regorafenib treatment (IC50: 264.23 nM vs. 114.28 nM, P<0.01) compared to SW48 cells expressing KRAS wild-type. Resistance was determined by assessing cell viability. Authors concluded that KRAS G12S was more resistant to regorafenib than KRAS wt, and intermediately resistant compared to other common KRAS G12/G13 mutations."	26161928	PubMed		"Camaj et al., 2015, Future Oncol"		2	accepted	4012	Somatic	2023-01-09 21:46:39 UTC	https://civicdb.org/links/evidence_items/4012	https://civicdb.org/links/molecular_profiles/887	FALSE	KRAS	3845	G12S		chr12	25245351	25245351	C	T	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.34G>A,NP_004976.2:p.Gly12Ser,NC_000012.11:g.25398285C>T,ENST00000256078.4:c.34G>A"	2023-01-27 17:06:39 UTC	CA135565	12584	"RS121913530,GLY12SER"	FALSE
FLT3 D835V	1276	Acute Myeloid Leukemia	9119		Sunitinib		Predictive	Supports	C	Sensitivity/Response	"In a retrospective study of 15 acute myeloid leukemia patients, the patients with FLT3 D835 mutation (n=2) were associated with improved response to sunitinib treatment (2/2 vs. 2/7) compared to FLT3 wild-type patients. The FLT3 D835 mutation positive patients were treated with sunitinib after failure of standard chemotherapy. After 4wk of sunitinib therapy, one patient showed morphological response and the other patient showed partial response to sunitinib therapy."	15459012	PubMed		"Fiedler et al., 2005, Blood"			accepted	4022	Somatic	2023-01-09 21:46:44 UTC	https://civicdb.org/links/evidence_items/4022	https://civicdb.org/links/molecular_profiles/1276	FALSE	FLT3	2322	D835V		chr13	28018504	28018504	T	A	ENST00000241453.7	75		missense_variant	"ENST00000241453.7:c.2504A>T,NM_004119.2:c.2504A>T,NP_004110.2:p.Asp835Val,NC_000013.10:g.28592641T>A"	2023-01-27 17:09:21 UTC	CA126344	16272	"RS121909646,ASP835VAL"	FALSE
AKT1 E17K	4	Melanoma	1909		Vemurafenib		Predictive	Supports	D	Resistance	"In an in vitro study, a M229 cell line endogenously expressing BRAF V600E mutation (a known vemurafenib sensitizing mutation) and overexpressing AKT1 E17K mutation was associated with resistance to vemurafenib treatment, as compared to cells expressing BRAF V600E mutation and wildtype AKT1. Resistance was determined by assessing cell survival."	24265155	PubMed		"Shi et al., 2014, Cancer Discov"		1	accepted	4029	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/4029	https://civicdb.org/links/molecular_profiles/4	FALSE	AKT1	207	E17K		chr14	104780214	104780214	C	T	ENST00000407796.2	75		missense_variant	"NC_000014.8:g.105246551C>T,NM_001014432.1:c.49G>A,NP_001014432.1:p.Glu17Lys,ENST00000407796.2:c.49G>A"	2023-01-27 17:01:56 UTC	CA123660	13983	"GLU17LYS,RS34409589"	FALSE
PIK3CA N345K	904	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	C	Resistance	"Three patients participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored PIK3CA N345K, were wildtype for KRAS, BRAF and NRAS, and had individual response data. Patient characteristics are as follows: a 48 year old female treated with cetuximab + irinotecan as 3rd line therapy who experienced stable disease (PFS: 72 weeks, OS: 105 weeks); a 46 year old male treated with cetuximab monotherapy as 5th line therapy who experienced stable disease (PFS: 24 weeks, OS: 57 weeks); a 61 year old female treated with cetuximab + irinotecan as 3rd line therapy who experienced progressive disease (PFS: 12 weeks, OS: 45 weeks). The response rate was 0/3 and the clinical benefit rate was 2/3 according to author criteria."	20619739	PubMed		"De Roock et al., 2010, Lancet Oncol."		1	accepted	4047	Somatic	2023-01-09 21:46:40 UTC	https://civicdb.org/links/evidence_items/4047	https://civicdb.org/links/molecular_profiles/904	FALSE	PIK3CA	5290	N345K		chr3	179203765	179203765	T	A	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.1035T>A,NP_006209.2:p.Asn345Lys,NC_000003.11:g.178921553T>A,ENST00000263967.3:c.1035T>A"	2023-01-27 17:06:45 UTC	CA16602517	376050	"RS121913284,ASN345LYS"	FALSE
KRAS Exon 2 Mutation	75	Rectum Cancer	1993				Prognostic	Does Not Support	B	Poor Outcome	"This study examined outcomes of 240 rectum cancer patients treated with total mesorectal excision therapy. Tumor samples were obtained at the time of surgery and genotyped for KRAS exon 2 mutations (listed as exon 1 in the source, as it was common at the time of publication to exclude non-coding exon 1). KRAS exon 2 mutations were identified in 81 cases. The authors reported that no differences were found in overall survival between patients with and without KRAS exon 2 mutations (P > 0.1)."	19903786	PubMed		"He et al., 2009, Clin. Cancer Res."		2	accepted	4052	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/4052	https://civicdb.org/links/molecular_profiles/75	FALSE	KRAS	3845	Exon 2 Mutation		chr12	25245274	25245395			ENST00000256078.4	75		missense_variant		2023-01-09 21:52:04 UTC				FALSE
PDGFRA V561D	915	Cancer	162		Sunitinib		Predictive	Does Not Support	D	Resistance	"In an in vitro study, Chinese hamster ovary cells expressing PDGFRA V561D mutation demonstrated sensitivity to sunitinib treatment (IC50<100), though this sensitivity was indistinguishable from Chinese hamster ovary cells expressing wild-type PDGFRA. Sensitivity was determined by assessing PDGFRA auto-phosphorylation."	18955458	PubMed		"Heinrich et al., 2008, J. Clin. Oncol."		2	accepted	4056	Somatic	2023-01-09 21:46:40 UTC	https://civicdb.org/links/evidence_items/4056	https://civicdb.org/links/molecular_profiles/915	FALSE	PDGFRA	5156	V561D		chr4	54274869	54274869	T	A	ENST00000257290.5	75		missense_variant	"NM_006206.5:c.1682T>A,NP_006197.1:p.Val561Asp,NC_000004.11:g.55141036T>A,ENST00000257290.5:c.1682T>A"	2023-01-27 17:06:52 UTC	CA123203	13546	RS121908586	FALSE
PDGFRA D842V	99	Cancer	162		Sunitinib		Predictive	Supports	D	Resistance	"In an in vitro study, Chinese hamster ovary cells expressing PDGFRA D842V mutation demonstrated reduced sensitivity to sunitinib treatment (IC50>1000 vs. IC50<100), compared to Chinese hamster ovary cells expressing wild-type PDGFRA. Sensitivity was determined by assessing PDGFRA auto-phosphorylation."	18955458	PubMed		"Heinrich et al., 2008, J. Clin. Oncol."		2	accepted	4060	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/4060	https://civicdb.org/links/molecular_profiles/99	FALSE	PDGFRA	5156	D842V	Imatinib Resistance	chr4	54285926	54285926	A	T	ENST00000257290.5	75		missense_variant	"NM_006206.4:c.2525A>T,NP_006197.1:p.Asp842Val,ENST00000257290.5:c.2525A>T,NC_000004.11:g.55152093A>T"	2023-01-27 17:02:33 UTC	CA123194	13543	"ASP842VAL,RS121908585"	FALSE
KIT V560_L576DEL	1458	Gastrointestinal Stromal Tumor	9253		Regorafenib		Predictive	Supports	D	Sensitivity/Response	A GIST430 patient derived cell line expressing KIT V560_L576del primary activating mutation demonstrated insensitivity to regorafenib (IC50: 191nmol/L) treatment. IC50 was determined by assessing cell viability.	25239608	PubMed		"Garner et al., 2014, Clin. Cancer Res."		2	accepted	4061	Somatic	2023-01-09 21:46:46 UTC	https://civicdb.org/links/evidence_items/4061	https://civicdb.org/links/molecular_profiles/1458	FALSE	KIT	3815	V560_L576DEL		chr4	54727446	54727496						inframe_deletion		2023-01-09 21:52:14 UTC				FALSE
KIT K550_K558del	923	Gastrointestinal Stromal Tumor	9253		Sunitinib		Predictive	Supports	C	Resistance	"Patient 3 from a larger cohort of genotyped patients (n= 78) with imatinib resistant or intolerant gastrointestinal stromal tumors (GISTs) harbored a primary (pre-imatinib treatment) KIT K550_K558 deletion. Following failure of imatinib, the GIST was again genotyped, but no secondary mutations were found. The patient started on 50mg sunitinib on a schedule of two weeks on/two weeks off. This patient experienced stable disease less than 6 months; time to progresssion of 14 weeks and overall survival of 17 weeks (Table A1)."	18955458	PubMed		"Heinrich et al., 2008, J. Clin. Oncol."		2	accepted	4062	Somatic	2023-01-09 21:46:40 UTC	https://civicdb.org/links/evidence_items/4062	https://civicdb.org/links/molecular_profiles/923	FALSE	KIT	3815	K550_K558del		chr4	54727416	54727442	AAACCCATGTATGAAGTACAGTGGAAG		ENST00000288135.5	75		inframe_deletion	"NM_000222.2:c.1648_1674del27,NP_000213.1:p.Lys550_Lys558del,NC_000004.11:g.55593582_55593608del27,ENST00000288135.5:c.1648_1674del27"	2023-01-27 17:06:56 UTC	CA123524	13857	"RS121913234,KPMYEVQWK550-558DEL"	FALSE
KIT Exon 11 Mutation	66	Gastrointestinal Stromal Tumor	9253		Sunitinib		Predictive	Supports	B	Resistance	"In a phase I/II trial of sunitinib efficacy on imatinib resistant or intolerant gastrointestinal stromal tumor (GIST) patients (n=77), patients harboring primary (pre-imatinib treatment) KIT exon 11 mutant GISTs (n=44) treated with sunitinib experienced shorter progression free survival (5.1 vs 19.0 months, P = .0356) and overall survival (12.3 vs 30.5 months, P=0.0132) as compared to patients with wild-type KIT (n=9)."	18955458	PubMed		"Heinrich et al., 2008, J. Clin. Oncol."		3	accepted	4072	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/4072	https://civicdb.org/links/molecular_profiles/66	FALSE	KIT	3815	Exon 11 Mutation	KIT Exon 11	chr4	54727416	54727542			ENST00000288135.5	75		coding_sequence_variant		2023-01-09 21:52:04 UTC				FALSE
KIT V560D	945	Cancer	162		Sunitinib		Predictive	Does Not Support	D	Resistance	"In an in vitro study, Chinese hamster ovary cells expressing KIT V560D demonstrated comparable sensitivity to sunitinib treatment compared to cells expressing ligand activated wild-type KIT (IC50<100 nmol/L). Sensitivity was determined by assessing KIT auto-phosphorylation."	18955458	PubMed		"Heinrich et al., 2008, J. Clin. Oncol."		2	accepted	4077	Somatic	2023-01-09 21:46:40 UTC	https://civicdb.org/links/evidence_items/4077	https://civicdb.org/links/molecular_profiles/945	FALSE	KIT	3815	V560D		chr4	54727447	54727447	T	A	ENST00000288135.5	75		missense_variant	"ENST00000288135.5:c.1679T>A,NM_000222.2:c.1679T>A,NP_000213.1:p.Val560Asp,NC_000004.11:g.55593613T>A"	2023-01-27 17:07:13 UTC	CA16602396	375914	"VAL560ASP,RS121913521"	FALSE
KIT W557_K558del	935	Gastrointestinal Stromal Tumor	9253		Sunitinib		Predictive	Supports	C	Resistance	"Patients 11, 69, and 73 from a larger cohort of genotyped patients (n= 78) with imatinib resistant or intolerant gastrointestinal stromal tumors (GISTs) harbored a primary (pre-imatinib treatment) KIT W557_K558 deletion. Following failure of imatinib, the GIST was again genotyped, but no secondary mutations were found. Patient 11 started on 25 mg sunitinib daily, for a two week on/two week off schedule. Patients 69 and 73 were on a 50 mg sunitib per day for four weeks on/ two weeks off. All three patients experienced stable disease for less than 6 months. Time to progression for patients 11, 69, and 73: 8, 22, and 10 weeks. Overall survival for patients 11, 69, and 73: 10, 38, and 19 weeks (Table A1)."	18955458	PubMed		"Heinrich et al., 2008, J. Clin. Oncol."		3	accepted	4082	Somatic	2023-01-09 21:46:40 UTC	https://civicdb.org/links/evidence_items/4082	https://civicdb.org/links/molecular_profiles/935	FALSE	KIT	3815	W557_K558del		chr4	54727437	54727442	TGGAAG		ENST00000288135.5	75		conservative_inframe_deletion		2023-01-27 17:07:05 UTC	CA356974	222957		FALSE
KIT W557_K558del	935	Gastrointestinal Stromal Tumor	9253		"Ponatinib,Imatinib"	Substitutes	Predictive	Supports	D	Sensitivity/Response	"In an in vitro study, an IL3 independent Ba/F3 cell line expressing KIT W557_K558del primary activating mutation demonstrated sensitivity to imatinib (IC50: 27nmol/L) and ponatinib (IC50: 3nmol/L) treatments. IC50 was determined by assessing cell viability. In mice treated in vivo with Ba/F3 cells expressing KIT W557_K558 mutation, tumor volume was significantly reduced in response to both ponatinib and imatinib treatments."	25239608	PubMed		"Garner et al., 2014, Clin. Cancer Res."		3	accepted	4084	Somatic	2023-01-09 21:46:40 UTC	https://civicdb.org/links/evidence_items/4084	https://civicdb.org/links/molecular_profiles/935	FALSE	KIT	3815	W557_K558del		chr4	54727437	54727442	TGGAAG		ENST00000288135.5	75		conservative_inframe_deletion		2023-01-27 17:07:05 UTC	CA356974	222957		FALSE
KIT W557_K558del	935	Gastrointestinal Stromal Tumor	9253		"Regorafenib,Sunitinib"	Substitutes	Predictive	Supports	D	Sensitivity/Response	"In an in vitro study, an IL3 independent Ba/F3 cell line expressing KIT W557_K558del primary activating mutation demonstrated sensitivity to sunitinib (IC50: 7 +/-  2nmol/L) and regorafenib (IC50: 30 +/- 14nmol/L) treatments. IC50 was determined by assessing cell viability."	25239608	PubMed		"Garner et al., 2014, Clin. Cancer Res."		2	accepted	4087	Somatic	2023-01-09 21:46:40 UTC	https://civicdb.org/links/evidence_items/4087	https://civicdb.org/links/molecular_profiles/935	FALSE	KIT	3815	W557_K558del		chr4	54727437	54727442	TGGAAG		ENST00000288135.5	75		conservative_inframe_deletion		2023-01-27 17:07:05 UTC	CA356974	222957		FALSE
KIT K558_V559del	938	Gastrointestinal Stromal Tumor	9253		Sunitinib		Predictive	Supports	C	Resistance	"Patient 47 from a larger cohort of genotyped patients (n= 78) with imatinib resistant or intolerant gastrointestinal stromal tumors (GISTs) harbored a primary (pre-imatinib treatment) KIT K558_V559 deletion. Following failure of imatinib, the GIST was again genotyped, but no secondary mutations were found. The patient took 50 mg sunitinib per day on a treatment schedule of two weeks on/one week off.  The patient experienced progressive disease. Time to progression was censored at 5 weeks, and overall survival was 60 weeks."	18955458	PubMed		"Heinrich et al., 2008, J. Clin. Oncol."		2	accepted	4095	Somatic	2023-01-09 21:46:40 UTC	https://civicdb.org/links/evidence_items/4095	https://civicdb.org/links/molecular_profiles/938	FALSE	KIT	3815	K558_V559del		chr4	54727440	54727445	AAGGTT		ENST00000288135.5	75			ENST00000288135.5:c.1672_1677delAAGGTT	2023-01-27 17:07:07 UTC	CA645516838	NONE FOUND		FALSE
KIT A502_Y503insAY	1466	Cancer	162		Sunitinib		Predictive	Does Not Support	D	Resistance	"In an in vitro study, Chinese hamster ovary cells expressing KIT A502_Y503INSAY demonstrated comparable sensitivity to sunitinib treatment compared to CHO cells expressing ligand activated wild-type KIT (IC50<100 nmol/L). Sensitivity was determined by assessing KIT auto-phosphorylation."	18955458	PubMed		"Heinrich et al., 2008, J. Clin. Oncol."		2	accepted	4100	Somatic	2023-01-09 21:46:46 UTC	https://civicdb.org/links/evidence_items/4100	https://civicdb.org/links/molecular_profiles/1466	FALSE	KIT	3815	A502_Y503insAY		chr4	54726016	54726017		GCCTAT				inframe_insertion		2023-01-09 21:52:14 UTC	unregistered			FALSE
KIT Exon 9 Mutation	505	Gastrointestinal Stromal Tumor	9253		Regorafenib		Predictive	Supports	C	Reduced Sensitivity	"This phase II clinical trial of regorafenib (NCT01068769) examined the long term safety and efficacy of regorafenib monotherapy in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GISTs) who failed previous treatments with imatinib. In response to regorafenib monotherapy, patients whose GISTs harbored KIT exon 9 mutations experienced lower rates of clinical benefit (defined as complete response, partial response, or stable disease lasting >16 weeks) than patients whose GISTs harbored KIT exon 11 mutations or KIT/PDGFR wildtype SDH-deficient patients. Of 3 patients with KIT exon 9 mutant GISTs, 2 experienced clinical benefit (including one PR), and the median progression free survival was 5.7 months."	27371698	PubMed		"Ben-Ami et al., 2016, Ann. Oncol."	NCT01068769	3	accepted	4104	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/4104	https://civicdb.org/links/molecular_profiles/505	FALSE	KIT	3815	Exon 9 Mutation		chr4	54725857	54726050			ENST00000288135.5	75		exon_variant		2023-01-09 21:52:07 UTC				FALSE
KIT V560D	945	Gastrointestinal Stromal Tumor	9253		Sunitinib		Predictive	Supports	C	Resistance	"Patient 72 from a larger cohort of genotyped patients (n= 78) with imatinib resistant or intolerant gastrointestinal stromal tumors (GISTs) harbored a primary (pre-imatinib treatment) KIT V560D mutation. Following failure of imatinib, the GIST was again genotyped, but no secondary mutations were found. The patient took 50 mg sunitinib per day on a treatment schedule of four weeks on/two weeks off. The patient experienced progressive disease. Time to progression and overall survival were 9 and 33 weeks."	18955458	PubMed		"Heinrich et al., 2008, J. Clin. Oncol."		3	accepted	4122	Somatic	2023-01-09 21:46:40 UTC	https://civicdb.org/links/evidence_items/4122	https://civicdb.org/links/molecular_profiles/945	FALSE	KIT	3815	V560D		chr4	54727447	54727447	T	A	ENST00000288135.5	75		missense_variant	"ENST00000288135.5:c.1679T>A,NM_000222.2:c.1679T>A,NP_000213.1:p.Val560Asp,NC_000004.11:g.55593613T>A"	2023-01-27 17:07:13 UTC	CA16602396	375914	"VAL560ASP,RS121913521"	FALSE
KIT P551_E554delPMYE	1405	Gastrointestinal Stromal Tumor	9253		Ponatinib		Predictive	Supports	D	Sensitivity/Response	"In an in vitro study, an IL3 independent Ba/F3 cell line expressing KIT P551_E554delPMYE primary activating mutation demonstrated sensitivity to ponatinib treatment (IC50: 15nM). IC50 was determined by assessing cell viability."	25239608	PubMed		"Garner et al., 2014, Clin. Cancer Res."		3	accepted	4125	Somatic	2023-01-09 21:46:45 UTC	https://civicdb.org/links/evidence_items/4125	https://civicdb.org/links/molecular_profiles/1405	FALSE	KIT	3815	P551_E554delPMYE		chr4	54727419	54727430						inframe_deletion		2023-01-09 21:52:13 UTC				FALSE
KIT V560D	945	Gastrointestinal Stromal Tumor	9253		"Sunitinib,Ponatinib,Regorafenib,Imatinib"	Substitutes	Predictive	Supports	D	Sensitivity/Response	"In an in vitro study, an IL3 independent Ba/F3 cell line expressing KIT V560D primary activating mutation demonstrated sensitivity to imatinib (IC50: 3nmol/L), sunitinib (IC50: 2nmol/L), regorafenib (IC50: 3nmol/L), and ponatinib (IC50: 2nmol/L) treatments. IC50 was determined by assessing cell viability."	25239608	PubMed		"Garner et al., 2014, Clin. Cancer Res."		3	accepted	4127	Somatic	2023-01-09 21:46:40 UTC	https://civicdb.org/links/evidence_items/4127	https://civicdb.org/links/molecular_profiles/945	FALSE	KIT	3815	V560D		chr4	54727447	54727447	T	A	ENST00000288135.5	75		missense_variant	"ENST00000288135.5:c.1679T>A,NM_000222.2:c.1679T>A,NP_000213.1:p.Val560Asp,NC_000004.11:g.55593613T>A"	2023-01-27 17:07:13 UTC	CA16602396	375914	"VAL560ASP,RS121913521"	FALSE
KIT L576P	72	Gastrointestinal Stromal Tumor	9253		Sunitinib		Predictive	Supports	C	Resistance	"Patient 29 from a larger cohort of genotyped patients (n= 78) with imatinib resistant or intolerant gastrointestinal stromal tumors (GISTs) harbored a primary (pre-imatinib treatment) KIT L576P mutation. Following failure of imatinib, the GIST was again genotyped, but no secondary mutations were found. The patient took 50 mg sunitinib per day on a treatment schedule of two weeks on/two weeks off.  The patient experienced stable disease for less than 6 months. Time to progression and overall survival were 31 and 29 weeks."	18955458	PubMed		"Heinrich et al., 2008, J. Clin. Oncol."		2	accepted	4136	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/4136	https://civicdb.org/links/molecular_profiles/72	FALSE	KIT	3815	L576P	KIT Exon 11	chr4	54727495	54727495	T	C	ENST00000288135.5	75		missense_variant	"NM_000222.2:c.1727T>C,NP_000213.1:p.Leu576Pro,ENST00000288135.5:c.1727T>C,NC_000004.11:g.55593661T>C"	2023-01-27 17:02:24 UTC	CA16602401	375919	"RS121913513,LEU576PRO"	FALSE
KIT Exon 9 Mutation	505	Gastrointestinal Stromal Tumor	9253		Regorafenib		Predictive	Supports	B	Reduced Sensitivity	"This retrospective study of a phase 2 clinical trial (NCT01068769) examined regorafenib safety and efficacy in advanced gastrointestinal stromal tumor (GIST) patients who failed previous treatments with at least imatinib and sunitinib. Of 30 genotyped patients treated with regorafenib, those with KIT exon 9 mutant GISTs (n=3) experienced decreased progression free survival as compared to patients with KIT exon 11 mutated GISTs (n=19) or wildtype (lacking KIT or PDGFRA mutations) GISTs (n= 8). The difference in PFS was significant between Exon 9 and 11 mutant GISTs (P = .01). Median PFS for the whole cohort was 10.0 months. Regorafenib treatment induced clinical benefit (defined as complete response, partial response, stable disease <16 weeks) in 2/3 patients with KIT exon 9 mutant GISTs."	22614970	PubMed		"George et al., 2012, J. Clin. Oncol."		2	accepted	4139	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/4139	https://civicdb.org/links/molecular_profiles/505	FALSE	KIT	3815	Exon 9 Mutation		chr4	54725857	54726050			ENST00000288135.5	75		exon_variant		2023-01-09 21:52:07 UTC				FALSE
KIT L576P	72	Cancer	162		"Dasatinib,Imatinib"	Substitutes	Predictive	Supports	D	Sensitivity/Response	"In an in vitro study, COS-7 cells expressing KIT L576P activating mutation demonstrated sensitivity to imatinib and dasatinib treatments. Sensitivity was determined by assessing reduced mutant KIT auto-phosphorylation via western blotting with addition of inhibitors."	25317746	PubMed		"Vita et al., 2014, JAMA Dermatol"		2	accepted	4141	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/4141	https://civicdb.org/links/molecular_profiles/72	FALSE	KIT	3815	L576P	KIT Exon 11	chr4	54727495	54727495	T	C	ENST00000288135.5	75		missense_variant	"NM_000222.2:c.1727T>C,NP_000213.1:p.Leu576Pro,ENST00000288135.5:c.1727T>C,NC_000004.11:g.55593661T>C"	2023-01-27 17:02:24 UTC	CA16602401	375919	"RS121913513,LEU576PRO"	FALSE
KIT D579del	951	Gastrointestinal Stromal Tumor	9253		Sunitinib		Predictive	Supports	C	Resistance	"Patient 74 from a larger cohort of genotyped patients (n= 78) with imatinib resistant or intolerant gastrointestinal stromal tumors (GISTs) harbored a primary (pre-imatinib treatment) KIT D579 deletion. Following failure of imatinib, the GIST was again genotyped, but no secondary mutations were found. The patient took 50 mg sunitinib per day on a treatment schedule of four weeks on/two weeks off. The patient experienced stable disease for less than six months. Time to progression was censored at 10 weeks and overall survival was 85 weeks."	18955458	PubMed		"Heinrich et al., 2008, J. Clin. Oncol."		2	accepted	4142	Somatic	2023-01-09 21:46:40 UTC	https://civicdb.org/links/evidence_items/4142	https://civicdb.org/links/molecular_profiles/951	FALSE	KIT	3815	D579del		chr4	54727503	54727505	GAT		ENST00000288135.5	75		conservative_inframe_deletion	"ENST00000288135.5:c.1735_1737delGAT,NM_000222.2:c.1735_1737delGAT,NP_000213.1:p.Asp579del,NC_000004.11:g.55593669_55593671delGAT"	2023-01-27 17:07:18 UTC	CA16611553	409725	"ASP579DEL,RS1060502543"	FALSE
KIT WILDTYPE	2520	Gastrointestinal Stromal Tumor	9253		Regorafenib		Predictive	Supports	B	Sensitivity/Response	"This phase II clinical trial of regorafenib (NCT01068769) examined the long term safety and efficacy of regorafenib in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GISTs) who failed previous treatments with imatinib. Patients whose GISTs were wildtype for KIT and PDGFR and who were succinate dehydrogenase (SDH) deficient (n=6) experienced higher rates of clinical benefit (defined as complete response, partial response, or stable disease lasting >16 weeks) than patients whose GISTs were wildtype for KIT and PDGFR but were not SDH deficient (n=2). 6/6 patients with SDH deficient GISTs had clinical benefit (including 2 PRs), and their median PFS was 10 months vs 1.6 months for patients with non-SDH deficient GISTs."	27371698	PubMed		"Ben-Ami et al., 2016, Ann. Oncol."	NCT01068769	2	accepted	4144	Somatic	2023-01-09 21:47:01 UTC	https://civicdb.org/links/evidence_items/4144	https://civicdb.org/links/molecular_profiles/2520	TRUE	KIT	3815	WILDTYPE		chr4	54657918	54740715			ENST00000288135.5	75		wild_type		2023-01-09 21:52:20 UTC		N/A		FALSE
KIT K642E	952	Melanoma	1909		Dasatinib		Predictive	Supports	C	Sensitivity/Response	"In a phase 2 clinical trial of 39 stage 3/4 chemotherapy-naive unresectable melanoma patients, a subungual melanoma patient harboring the KIT K642E mutation was reported to have a partial response to dasatinib monotherapy of 24 weeks with a 56% tumor reduction."	21523734	PubMed		"Kluger et al., 2011, Cancer"			accepted	4147	Somatic	2023-01-09 21:46:40 UTC	https://civicdb.org/links/evidence_items/4147	https://civicdb.org/links/molecular_profiles/952	FALSE	KIT	3815	K642E		chr4	54728055	54728055	A	G	ENST00000288135.5	75		missense_variant	"NM_000222.2:c.1924A>G,NP_000213.1:p.Lys642Glu,NC_000004.11:g.55594221A>G,ENST00000288135.5:c.1924A>G"	2023-01-27 17:07:18 UTC	CA123547	13866	"RS121913512,LYS642GLU"	FALSE
KIT N822K	1237	Gastrointestinal Stromal Tumor	9253		Ponatinib		Predictive	Does Not Support	D	Resistance	"A preclinical study tested the effect of a tyrosine kinase inhibitor (TKI) on Ba/F3 cell lines with primary ponatinib-sensitizing del 557-558 mutation, which induced IL-3 independent growth, and secondary mutation N822K. The cells were tested for Ponatinib resistance. Ba/F3 cells with del 557-558 and N822K mutations did not show resistance towards Ponatinib (IC50 for growth inhibition: 3 nM) compared to Ba/F3 cells with del 557-558  alone (IC50: 3 nM). Ponatinib inhibited KIT phosphorylation at moderate concentrations. The results suggest that N822K does not induce Ponatinib resistance."	25239608	PubMed		"Garner et al., 2014, Clin. Cancer Res."		3	accepted	4167	Somatic	2023-01-09 21:46:44 UTC	https://civicdb.org/links/evidence_items/4167	https://civicdb.org/links/molecular_profiles/1237	FALSE	KIT	3815	N822K	KIT Exon 17	chr4	54733174	54733174	T	A	ENST00000288135.5	75		missense_variant	"NM_000222.2:c.2466T>A,NP_000213.1:p.Asn822Lys,NC_000004.11:g.55599340T>A,ENST00000288135.5:c.2466T>A"	2023-01-27 17:09:06 UTC	CA16602411	375931	"ASN822LYS,RS121913514"	FALSE
KIT N822K	1237	Gastrointestinal Stromal Tumor	9253		Regorafenib		Predictive	Supports	D	Resistance	"A preclinical study tested the effects of tyrosine kinase inhibitor (TKI) on Ba/F3 cell lines with primary regorafenib-sensitizing mutation del 557-558, which induced IL-3 independent growth, and secondary mutation N822K. The cells were tested for Regorafenib resistance. Ba/F3 cells with del 557-558 and N822K mutations did show resistance towards Regorafenib (IC50 for growth inhibition: 131 +- 9 nM) compared to Ba/F3 cells with the del 557-558 mutation (IC50 for growth inhibition: 30 +- 14 nM). Regorafenib inhibited KIT phosphorylation only at high concentrations. The results suggest that N822K does induce Regorafenib resistance."	25239608	PubMed		"Garner et al., 2014, Clin. Cancer Res."		3	accepted	4169	Somatic	2023-01-09 21:46:44 UTC	https://civicdb.org/links/evidence_items/4169	https://civicdb.org/links/molecular_profiles/1237	FALSE	KIT	3815	N822K	KIT Exon 17	chr4	54733174	54733174	T	A	ENST00000288135.5	75		missense_variant	"NM_000222.2:c.2466T>A,NP_000213.1:p.Asn822Lys,NC_000004.11:g.55599340T>A,ENST00000288135.5:c.2466T>A"	2023-01-27 17:09:06 UTC	CA16602411	375931	"ASN822LYS,RS121913514"	FALSE
BRAF V600K	559	Melanoma	1909		Vemurafenib		Predictive	Supports	B	Sensitivity/Response	"In a retrospective study of 300 stage IV melanoma patients, patients with BRAF V600K mutation (n=18) were associated with a 5.6% (1/18) complete response, a 22.2% (4/18) partial response and stable disease in 44.4% (8/18) of cases; however, 27.8% (5/18) of patients harboring BRAF V600K experienced progressive disease and patients with BRAF V600E mutation achieved a more impressive clinical benefit, as compared to patients with BRAF V600K mutation (P=0.016)."	25524477	PubMed		"Ugurel et al., 2015, Ann. Oncol."		3	accepted	4180	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/4180	https://civicdb.org/links/molecular_profiles/559	FALSE	BRAF	673	V600K	Other BRAF V600's	chr7	140753336	140753337	AC	TT	ENST00000288602.6	75		missense_variant	"ENST00000288602.6:c.1798_1799delinsAA,NC_000007.13:g.140453136_140453137delinsTT,NM_004333.4:c.1798_1799delGTinsAA,NP_004324.2:p.Val600Lys"	2023-01-27 17:04:21 UTC	CA16602420	375941	"VAL600LYS,RS121913227"	FALSE
BRAF V600K	559	Skin Melanoma	8923		"Trametinib,Dabrafenib"	Combination	Predictive	Supports	B	Sensitivity/Response	"In a clinical trial (NCT01597908) of 704 metastatic melanoma patients, patients harboring a BRAF V600K mutation and treated with vemurafenib (n=34) were associated with a 44% response rate, as compared to a 65% response rate in V600E mutation positive patients treated with dabrafenib and trametinib combination therapy (n=34)."	25399551	PubMed		"Robert et al., 2015, N. Engl. J. Med."	NCT01597908	3	accepted	4181	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/4181	https://civicdb.org/links/molecular_profiles/559	FALSE	BRAF	673	V600K	Other BRAF V600's	chr7	140753336	140753337	AC	TT	ENST00000288602.6	75		missense_variant	"ENST00000288602.6:c.1798_1799delinsAA,NC_000007.13:g.140453136_140453137delinsTT,NM_004333.4:c.1798_1799delGTinsAA,NP_004324.2:p.Val600Lys"	2023-01-27 17:04:21 UTC	CA16602420	375941	"VAL600LYS,RS121913227"	FALSE
EGFR R108K	968	High Grade Glioma	3070		Erlotinib		Predictive	Supports	D	Sensitivity/Response	"In an in vitro study, a Ba/F3 cell line expressing EGFR R108K demonstrated increased sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing EGFR wild-type. Variant function was assessed by EGFR auto-phosphorylation. Sensitivity was assessed by cell viability assay using stable transfection of each variant and increasing concentrations of erlotinib (0?0 uM)."	17177598	PubMed		"Lee et al., 2006, PLoS Med."		3	accepted	4186	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/4186	https://civicdb.org/links/molecular_profiles/968	FALSE	EGFR	1956	R108K		chr7	55143387	55143387	G	A	ENST00000275493.2	75		missense_variant	"NM_005228.4:c.323G>A,NP_005219.2:p.Arg108Lys,NC_000007.13:g.55211080G>A,ENST00000275493.2:c.323G>A"	2023-01-27 17:07:29 UTC	CA16602662	376207	ARG108LYS	FALSE
EGFR T263P	969	High Grade Glioma	3070		Erlotinib		Predictive	Supports	D	Sensitivity/Response	"In an in vitro study, a Ba/F3 cell line expressing EGFR T263P demonstrated increased sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing EGFR wild-type. Variant function was assessed by EGFR auto-phosphorylation. Sensitivity was assessed by cell viability assay using stable transfection of each variant and increasing concentrations of erlotinib (0?0 uM)."	17177598	PubMed		"Lee et al., 2006, PLoS Med."		3	accepted	4187	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/4187	https://civicdb.org/links/molecular_profiles/969	FALSE	EGFR	1956	T263P		chr7	55154050	55154050	A	C	ENST00000275493.2	75		missense_variant	"NM_005228.4:c.787A>C,NP_005219.2:p.Thr263Pro,NC_000007.13:g.55221743A>C,ENST00000275493.2:c.787A>C"	2023-01-27 17:07:30 UTC	CA16602663	376208	THR263PRO	FALSE
EGFR A289V	970	High Grade Glioma	3070		Erlotinib		Predictive	Supports	D	Sensitivity/Response	"In an in vitro study, a Ba/F3 cell line expressing EGFR A289V demonstrated increased sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing EGFR wild-type. Variant function was assessed by EGFR auto-phosphorylation. Sensitivity was assessed by cell viability assay using stable transfection of each variant and increasing concentrations of erlotinib (0?0 uM)."	17177598	PubMed		"Lee et al., 2006, PLoS Med."		3	accepted	4188	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/4188	https://civicdb.org/links/molecular_profiles/970	FALSE	EGFR	1956	A289V		chr7	55154129	55154129	C	T	ENST00000275493.2	75		missense_variant	"NM_005228.4:c.866C>T,NP_005219.2:p.Ala289Val,NC_000007.13:g.55221822C>T,ENST00000275493.2:c.866C>T"	2023-01-27 17:07:31 UTC	CA16602664	376209	"RS149840192,ALA289VAL"	FALSE
EGFR G719	699	Lung Non-small Cell Carcinoma	3908		"Gefitinib,Erlotinib"	Substitutes	Predictive	Supports	B	Sensitivity/Response	"EGFR G719 mutations have been associated with increased sensitivity to first generation EGFR tyrosine kinase inhibitors, including erlotinib and gefitinib. In a study of patients treated with erlotinib or gefitinib, a subset of patients with EGFR mutation at codons G719 or L861 (n=30) was associated with improved response rate (47.5% vs 16.5%, P<0.001) median progression free survival (5.0 vs 2.0 months, P<0.001), and overall survival (15.0 vs. 10.4 months, P =0.030), compared to patients with wild-type EGFR (n=272). For the subset of patients with G719, the response rate was 53.3% (8 of 15), median PFS was 8.1 months, and median overall survival was 16.4 months."	21531810	PubMed		"Wu et al., 2011, Clin. Cancer Res."		3	accepted	4189	Somatic	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/4189	https://civicdb.org/links/molecular_profiles/699	FALSE	EGFR	1956	G719		chr7	55174014	55174015			ENST00000275493.2	75		protein_altering_variant		2023-01-09 21:52:08 UTC		"16,612,452,254,522,400,000,000,000"	"GLY719,G719X"	FALSE
EGFR G719S	134	Lung Non-small Cell Carcinoma	3908		Erlotinib		Predictive	Supports	D	Sensitivity/Response	"In an in vitro study, a Ba/F3 cell line expressing EGFR G719S demonstrated increased sensitivity to erlotinib treatment comparable to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). Sensitivity was determined by assessing cell proliferation, the IC50 of erlotinib for EGFR G719S and EGFR L858R expressing cells were 16 nmol/L and 6 nmol/L, respectively."	19147750	PubMed		"Kancha et al., 2009, Clin. Cancer Res."			accepted	4190	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/4190	https://civicdb.org/links/molecular_profiles/134	FALSE	EGFR	1956	G719S		chr7	55174014	55174014	G	A	ENST00000275493.2	75		missense_variant	"ENST00000275493.2:c.2155G>A,NC_000007.13:g.55241707G>A,NM_005228.4:c.2155G>A,NP_005219.2:p.Gly719Ser"	2023-01-27 17:02:49 UTC	CA126722	16612	"GLY719SER,RS28929495"	FALSE
EGFR V742A	975	Lung Non-small Cell Carcinoma	3908		Erlotinib		Predictive	Supports	D	Sensitivity/Response	"In an in vitro study, a Ba/F3 cell line expressing EGFR V742A demonstrated increased sensitivity to erlotinib treatment comparable to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). Sensitivity was determined by assessing cell proliferation, the IC50 of erlotinib for EGFR V742A and EGFR L858R expressing cells were 21 nmol/L and 6 nmol/L, respectively."	19147750	PubMed		"Kancha et al., 2009, Clin. Cancer Res."			accepted	4197	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/4197	https://civicdb.org/links/molecular_profiles/975	FALSE	EGFR	1956	V742A		chr7	55174762	55174762	T	C	ENST00000275493.2	75		missense_variant	"NM_005228.4:c.2225T>C,NP_005219.2:p.Val742Ala,NC_000007.13:g.55242455T>C,ENST00000275493.2:c.2225T>C"	2023-01-27 17:07:33 UTC	CA16602541	376079	RS121913466	FALSE
EGFR E746_A750del	976	Lung Non-small Cell Carcinoma	3908		Gefitinib		Predictive	Supports	C	Sensitivity/Response	"Mutational profiling was performed on EGFR exons 18-24 from a group of 10 retrospectively chosen patients who had shown partial response or clinical improvement in response to gefitinib. Of 7 tumors with EGFR mutations, 4 were del E746-A750. 3 had adenocarcinoma with bronchioloalveolar carcinoma (BAC) features, with response duration and overall survival of 8 and 15 months, 5+ and 5+ months (treatment ongoing at study end) and 28 and 30+ months (alive at study end), and one former smoker with adenocarcinoma with BAC features, who had response duration of 5+ months with treatment ongoing at study end."	15329413	PubMed		"Pao et al., 2004, Proc. Natl. Acad. Sci. U.S.A."		4	accepted	4198	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/4198	https://civicdb.org/links/molecular_profiles/976	FALSE	EGFR	1956	E746_A750del		chr7	55174772	55174786	GGAATTAAGAGAAGC		ENST00000275493.2	75		inframe_deletion		2023-01-27 17:07:34 UTC	CA175996	163343	"RS121913421,E746_A750DELELREA"	FALSE
EGFR Mutation	438	Lung Non-small Cell Carcinoma	3908		Erlotinib		Predictive	Supports	C	Sensitivity/Response	"In the placebo-controlled Phase III study SATURN, using erlotinib maintenance therapy for patients with advanced NSCLC who were selected for response or stable disease after first line chemotherapy, EGFR mutation was assessed. In patients with EGFR mutation, erlotinib maintenance reduced progression and death significantly with median progression free survival (PFS) of 44.6 vs. 13 weeks over placebo. Erlotinib also significantly improved PFS in EGFR wildtype patients, but EGFR mutant tumors treated with erlotinib had significant better PFS than EGFR wildtype. Overall, in the intent to treat population erlotinib significantly improved PFS over placebo (HR, 0.71; 95% CI, 0.62 to 0.82; P<0.001)."	21969500	PubMed		"Brugger et al., 2011, J. Clin. Oncol."		4	accepted	4201	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/4201	https://civicdb.org/links/molecular_profiles/438	FALSE	EGFR	1956	Mutation		chr7	55019101	55211628			ENST00000275493.2	75		inframe_variant		2023-01-09 21:52:07 UTC		N/A		FALSE
EGFR G719D	1328	Lung Non-small Cell Carcinoma	3908		"Gefitinib,Erlotinib"	Substitutes	Predictive	Supports	C	Sensitivity/Response	"In a study, 2 participants with stage IV lung adenocarcinoma were sequenced at EGFR exons 18 to 21. Both patients were found to have G719D mutation and were treated with the 1st generation TKIs gefitinib or erlotinib. The first patient (M, 81, smoker) was treated with gefitinib and had a partial response, progression free survival (PFS) of 21.7 months, overall survival (OS) of 22.5 months and was alive at study end. The second patient (M, 76, smoker) was treated with erlotinib and had stable disease as response, PFS of 2.6 months, OS of 2.6 months and was alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type."	21531810	PubMed		"Wu et al., 2011, Clin. Cancer Res."		3	accepted	4210	Somatic	2023-01-09 21:46:45 UTC	https://civicdb.org/links/evidence_items/4210	https://civicdb.org/links/molecular_profiles/1328	FALSE	EGFR	1956	G719D		chr7	55174015	55174015	G	A				missense_variant	"NC_000007.14:g.55174015G>A,NC_000007.13:g.55241708G>A,ENST00000275493.7:c.2156G>A,ENSP00000275493.2:p.Gly719Asp,NM_005228.5:c.2156G>A,NP_005219.2:p.Gly719Asp"	2023-01-27 17:09:36 UTC	CA16602537	376075	"RS121913428,GLY719ASP"	FALSE
EGFR L747P	1767	Lung Non-small Cell Carcinoma	3908		"Erlotinib,Gefitinib"	Substitutes	Predictive	Does Not Support	C	Sensitivity/Response	"In a study, 2 participants with stage IV adenocarcinoma were sequenced at EGFR exons 18 to 21.  Both patients were found to have L747P mutation and were treated with the 1st generation TKIs gefitinib or erlotinib. The first patient (M, 62, nonsmoker) was treated with gefitinib and had progressive disease, progression free survival (PFS) of 1.0 months, overall survival (OS) of 7.7 months and was not alive at study end. The second patient (M, 39, nonsmoker) was treated with erlotinib and had progressive disease as response, PFS of 2.3 months, OS of 7.2 months and was alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type."	21531810	PubMed		"Wu et al., 2011, Clin. Cancer Res."		2	accepted	4220	Somatic	2023-01-09 21:46:52 UTC	https://civicdb.org/links/evidence_items/4220	https://civicdb.org/links/molecular_profiles/1767	FALSE	EGFR	1956	L747P		chr7	55174776	55174777	TT	CC	ENST00000275493.2	75		missense_variant	"NM_005228.4:c.2239_2240delTTinsCC,NP_005219.2:p.Leu747Pro,NC_000007.13:g.55242469_55242470delTTinsCC,ENST00000275493.2:c.2239_2240delTTinsCC"	2023-01-27 17:13:09 UTC	CA135800	45235	LEU747PRO	FALSE
EGFR V774A	1768	Lung Non-small Cell Carcinoma	3908		Gefitinib		Predictive	Supports	C	Sensitivity/Response	"In a study, 1 participant with stage IV adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have V774A mutation, and was treated with the 1st generation TKI gefitinib. The patient (F, 51, nonsmoker) had a partial response, progression free survival (PFS) of 6.9 months, overall survival (OS) of 29.7 months and was alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type."	21531810	PubMed		"Wu et al., 2011, Clin. Cancer Res."		3	accepted	4226	Somatic	2023-01-09 21:46:52 UTC	https://civicdb.org/links/evidence_items/4226	https://civicdb.org/links/molecular_profiles/1768	FALSE	EGFR	1956	V774A		chr7	55181330	55181330	T	C	ENST00000275493.2	75		missense_variant	ENST00000275493.2:c.2321T>C	2023-01-27 17:13:10 UTC	CA367578723	NONE FOUND	VAL774ALA	FALSE
EGFR V774M	1770	Lung Non-small Cell Carcinoma	3908		Erlotinib		Predictive	Does Not Support	C	Sensitivity/Response	"In a study, 1 participant with stage IV squamous cell lung carcinoma was sequenced at EGFR exons 18 to 21 and was found to have V774M mutation, and was treated with the 1st generation TKI erlotinib. The patient (M, 80, smoker) had progressive disease as response, progression free survival (PFS) of 1.6 months, overall survival (OS) of 6.7 months and was not alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type."	21531810	PubMed		"Wu et al., 2011, Clin. Cancer Res."		2	accepted	4231	Somatic	2023-01-09 21:46:52 UTC	https://civicdb.org/links/evidence_items/4231	https://civicdb.org/links/molecular_profiles/1770	FALSE	EGFR	1956	V774M		chr7	55181329	55181329	G	A	ENST00000275493.2	75		missense_variant	ENST00000275493.2:c.2320G>A	2023-01-27 17:13:10 UTC	CA158928427	NONE FOUND	VAL774MET	FALSE
EGFR K806E	1771	Lung Non-small Cell Carcinoma	3908		Gefitinib		Predictive	Does Not Support	C	Sensitivity/Response	"In a study, 1 participant with stage IIIB lung adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have K806E mutation, and was treated with the 1st generation TKI gefitinib. The patient (M, 77, nonsmoker) had progressive disease as response, progression free survival (PFS) of 1.6 months, overall survival (OS) of 28.1 months and was alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type."	21531810	PubMed		"Wu et al., 2011, Clin. Cancer Res."		2	accepted	4239	Somatic	2023-01-09 21:46:52 UTC	https://civicdb.org/links/evidence_items/4239	https://civicdb.org/links/molecular_profiles/1771	FALSE	EGFR	1956	K806E		chr7	55181425	55181425	A	G	ENST00000275493.2	75		missense_variant	"ENST00000275493.2:c.2416A>G,NM_001346898.1:c.2416A>G,NP_001333827.1:p.Lys806Glu,NC_000007.13:g.55249118A>G"	2023-01-27 17:13:11 UTC	CA4266068	NONE FOUND	"LYS806GLU,RS754652044"	FALSE
EGFR N826Y	1772	Lung Non-small Cell Carcinoma	3908		Gefitinib		Predictive	Does Not Support	C	Sensitivity/Response	"In a study, 1 participant with stage IV lung adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have N826Y mutation, and was treated with the 1st generation TKI gefitinib. The patient (F, 46, nonsmoker) had progressive disease as response, progression free survival (PFS) of 3.3 months, overall survival (OS) of 13.9 months and was not alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type."	21531810	PubMed		"Wu et al., 2011, Clin. Cancer Res."		2	accepted	4244	Somatic	2023-01-09 21:46:52 UTC	https://civicdb.org/links/evidence_items/4244	https://civicdb.org/links/molecular_profiles/1772	FALSE	EGFR	1956	N826Y		chr7	55191725	55191725	A	T	ENST00000275493.2	75		missense_variant	"ENST00000275493.2:c.2476A>T,NC_000007.13:g.55259418A>T,NC_000007.14:g.55191725A>T,NM_005228.3:c.2476A>T,NP_005219.2:p.Asn826Tyr"	2023-01-27 17:13:12 UTC	CA367580076	NONE FOUND	ASN826TYR	FALSE
EGFR L838P	1365	Lung Non-small Cell Carcinoma	3908		Gefitinib		Predictive	Supports	C	Sensitivity/Response	"In a study, 1 participant with stage IV lung adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have L838P mutation, and was treated with the 1st generation TKI gefitinib. The patient (F, 66, nonsmoker) had a partial response, progression free survival (PFS) of 15.2 months, overall survival (OS) of 29.3 months and was not alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type."	21531810	PubMed		"Wu et al., 2011, Clin. Cancer Res."		3	accepted	4252	Somatic	2023-01-09 21:46:45 UTC	https://civicdb.org/links/evidence_items/4252	https://civicdb.org/links/molecular_profiles/1365	FALSE	EGFR	1956	L838P		chr7	55191762	55191762	T	C	ENST00000275493.2	75		missense_variant	"NC_000007.14:g.55191762T>C,NC_000007.13:g.55259455T>C,ENST00000275493.7:c.2513T>C,ENSP00000275493.2:p.Leu838Pro,NM_005228.5:c.2513T>C,NP_005219.2:p.Leu838Pro"	2023-01-27 17:09:40 UTC	CA367580150	NONE FOUND	LEU838PRO	FALSE
EGFR N842S	1775	Lung Non-small Cell Carcinoma	3908		Gefitinib		Predictive	Does Not Support	C	Sensitivity/Response	"In a study, 1 participant with stage IV lung adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have N842S mutation, and was treated with the 1st generation TKI gefitinib. The patient (F, 73, nonsmoker) progressive disease as response, progression free survival (PFS) of 0.9 months, overall survival (OS) of 9.7 months and was not alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type."	21531810	PubMed		"Wu et al., 2011, Clin. Cancer Res."		2	accepted	4256	Somatic	2023-01-09 21:46:52 UTC	https://civicdb.org/links/evidence_items/4256	https://civicdb.org/links/molecular_profiles/1775	FALSE	EGFR	1956	N842S		chr7	55191774	55191774	A	G	ENST00000275493.2	75		missense_variant	ENST00000275493.2:c.2525A>G	2023-01-27 17:13:13 UTC	CA367580172	NONE FOUND	ASN842SER	FALSE
EGFR T847I	1371	Lung Non-small Cell Carcinoma	3908		Gefitinib		Predictive	Does Not Support	C	Sensitivity/Response	"In a study, 1 participant with stage IIIB lung adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have T847I mutation, and was treated with the 1st generation TKI gefitinib. The patient (M, 77, smoker) progressive disease as response, progression free survival (PFS) of 1.1 months, overall survival (OS) of 1.1 months and was not alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type."	21531810	PubMed		"Wu et al., 2011, Clin. Cancer Res."		2	accepted	4260	Somatic	2023-01-09 21:46:45 UTC	https://civicdb.org/links/evidence_items/4260	https://civicdb.org/links/molecular_profiles/1371	FALSE	EGFR	1956	T847I		chr7	55191789	55191789	C	T				missense_variant		2023-01-27 17:09:41 UTC	CA367580204			FALSE
EGFR V851I	1374	Lung Non-small Cell Carcinoma	3908		Gefitinib		Predictive	Does Not Support	C	Sensitivity/Response	"In a study, 1 participant with stage IV lung adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have V851I mutation, and was treated with the 1st generation TKI gefitinib. The patient (F, 69, nonsmoker) progressive disease as response, progression free survival (PFS) of 0.7 months, overall survival (OS) of 1.6 months and was not alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common mutations (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type."	21531810	PubMed		"Wu et al., 2011, Clin. Cancer Res."		2	accepted	4264	Somatic	2023-01-09 21:46:45 UTC	https://civicdb.org/links/evidence_items/4264	https://civicdb.org/links/molecular_profiles/1374	FALSE	EGFR	1956	V851I		chr7	55191800	55191800	G	A				missense_variant		2023-01-27 17:09:42 UTC	CA367580229			FALSE
EGFR L858R	33	Cancer	162		Erlotinib		Predictive	Supports	D	Sensitivity/Response	"MCF-7 cells were transduced with YFP tagged EGFR with E746_A750delELREA mutation, or YFP EGFR wildtype, and stained for ectopic YFP EGFR and phospho-Akt as a readout for EGFR pathway activity. Increased p-Akt stain was seen with ectopic mutant EGFR over wildtype cells. Parallel erlotinib incubations of cells with wildtype EGFR induced recompartmentalization of ectopic EGFR protien only at high concentration (10uM). Addition of erlotinib to mutant EGFR cell incubations reduced p-Akt signal and induced recompartmentalization of ectopic EGFR protien at considerably lower conecntration (100 nM) erlotinib.  These results indicate the EGFR L858R variant as a growth pathway driver targetable by erlotinib."	17877814	PubMed		"de Gunst et al., 2007, Mol. Cancer"		3	accepted	4265	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/4265	https://civicdb.org/links/molecular_profiles/33	FALSE	EGFR	1956	L858R		chr7	55191822	55191822	T	G	ENST00000275493.2	75		missense_variant	"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg"	2023-01-27 17:02:04 UTC	CA126713	"16,609,376,282,376,200"	"LEU858ARG,RS121434568"	FALSE
EGFR L747_P753delinsS	986	Lung Non-small Cell Carcinoma	3908		Erlotinib		Predictive	Supports	D	Sensitivity/Response	"In an in vitro study, a Ba/F3 cell line expressing EGFR L747_P753>S demonstrated increased sensitivity to erlotinib treatment comparable to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). Sensitivity was determined by assessing cell proliferation, the IC50 of erlotinib for EGFR L747_P753>S and EGFR L858R expressing cells were 5 nmol/L and 6 nmol/L, respectively."	19147750	PubMed		"Kancha et al., 2009, Clin. Cancer Res."			accepted	4266	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/4266	https://civicdb.org/links/molecular_profiles/986	FALSE	EGFR	1956	L747_P753delinsS		chr7	55174777	55174794	TAAGAGAAGCAACATCTC		ENST00000275493.2	75		inframe_deletion		2023-01-27 17:07:37 UTC	CA126710	16608	RS121913438	FALSE
EGFR S768I	558	Lung Adenocarcinoma	3910		Erlotinib		Predictive	Supports	C	Resistance	"In stage IV lung adenocarcinoma patients (n=2) harboring EGFR S768I mutation, EGFR S768I was associated with progressive disease after 1 month of erlotinib monotherapy; the patient was previously treated with standard chemotherapy."	22895145	PubMed		"Lund-Iversen et al., 2012, J Thorac Oncol"			accepted	4273	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/4273	https://civicdb.org/links/molecular_profiles/558	FALSE	EGFR	1956	S768I		chr7	55181312	55181312	G	T	ENST00000275493.2	75		missense_variant	"ENST00000275493.2:c.2303G>T,NC_000007.13:g.55249005G>T,NM_005228.4:c.2303G>T,NP_005219.2:p.Ser768Ile"	2023-01-27 17:04:20 UTC	CA135840	45251	"SER768ILE,RS121913465"	FALSE
EGFR S768I	558	Cancer	162		"Gefitinib,Erlotinib"	Substitutes	Predictive	Does Not Support	D	Sensitivity/Response	"In an in vitro study, a Ba/F3 cell line expressing EGFR S768I demonstrated reduced sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). Sensitivity was determined by assessing cell proliferation, the IC50 of erlotinib for EGFR S768I and EGFR L858R expressing cells were 250 nmol/L and 6 nmol/L, respectively. Gefitinib was similarly tested and IC50 of 315 nanomolar was obtained, indicating non-response and potential resistance"	19147750	PubMed		"Kancha et al., 2009, Clin. Cancer Res."		3	accepted	4274	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/4274	https://civicdb.org/links/molecular_profiles/558	FALSE	EGFR	1956	S768I		chr7	55181312	55181312	G	T	ENST00000275493.2	75		missense_variant	"ENST00000275493.2:c.2303G>T,NC_000007.13:g.55249005G>T,NM_005228.4:c.2303G>T,NP_005219.2:p.Ser768Ile"	2023-01-27 17:04:20 UTC	CA135840	45251	"SER768ILE,RS121913465"	FALSE
EGFR D770_N771insSVD	1353	Lung Non-small Cell Carcinoma	3908		Erlotinib		Predictive	Supports	D	Resistance	"In an in vitro study, a Ba/F3 cell line expressing EGFR D770_N771insSVD demonstrated reduced sensitivity to erlotinib treatment (IC50=3.187M), comparable to Ba/F3 cells expressing EGFR L858R and T790M co-mutation (T790M is a known resistant mutation to 1st and 2nd generation EGFR tyrosine kinase inhibitors; IC50=4.155M). Resistance was determined by assessing cell proliferation, EGFR, AKT and ERK phosphorylation."	24353160	PubMed		"Yasuda et al., 2013, Sci Transl Med"			accepted	4275	Somatic	2023-01-09 21:46:45 UTC	https://civicdb.org/links/evidence_items/4275	https://civicdb.org/links/molecular_profiles/1353	FALSE	EGFR	1956	D770_N771insSVD		chr7	55181320	55181321		GCGTGGACA	ENST00000275493.2				"NC_000007.14:g.55181312_55181320dup,NC_000007.13:g.55249005_55249013dup,ENST00000275493.7:c.2303_2311dup,ENSP00000275493.2:p.Asp770_Asn771insSerValAsp,NM_005228.5:c.2303_2311dup,NP_005219.2:p.Asp770_Asn771insSerValAsp"	2023-01-27 17:09:38 UTC	CA135844	45253	"S768_D770DUP,ASP770_ASN771INSSERVALASP"	FALSE
EGFR H773_V774insH	1354	Lung Non-small Cell Carcinoma	3908		Erlotinib		Predictive	Supports	D	Resistance	"In an in vitro study, a Ba/F3 cell line expressing EGFR H773_V774insH demonstrated reduced sensitivity to erlotinib treatment (IC50=3.902M), comparable to Ba/F3 cells expressing EGFR L858R and T790M co-mutation (T790M is a known resistant mutation to 1st and 2nd generation EGFR tyrosine kinase inhibitors; IC50=4.155M). Resistance was determined by assessing cell proliferation, EGFR, AKT and ERK phosphorylation."	24353160	PubMed		"Yasuda et al., 2013, Sci Transl Med"			accepted	4276	Somatic	2023-01-09 21:46:45 UTC	https://civicdb.org/links/evidence_items/4276	https://civicdb.org/links/molecular_profiles/1354	FALSE	EGFR	1956	H773_V774insH		chr7	55181328	55181329		CAC	ENST00000275493.2	75			"p.His773dup,c.55249019_55249021dup"	2023-01-27 17:09:39 UTC	CA135866			FALSE
EGFR R831H	991	Cancer	162		Erlotinib		Predictive	Supports	D	Sensitivity/Response	"In an in vitro study performed after identification of the mutation in a malignant peritoneal mesothelioma patient, COS-7 cells expressing EGFR R831H demonstrated increased EGFR phosphotyrosine after EGF treatment over wildtype EGFR expressing cells. Cells expressing mutant EGFR also showed increased sensitivity to erlotinib treatment compared to cells expressing EGFR wild-type. Sensitivity was determined by assessing EGFR auto-phosphorylation."	20942962	PubMed		"Foster et al., 2010, World J Surg Oncol"		3	accepted	4279	Somatic	2023-01-26 23:29:15 UTC	https://civicdb.org/links/evidence_items/4279	https://civicdb.org/links/molecular_profiles/991	FALSE	EGFR	1956	R831H		chr7	55191741	55191741	G	A	ENST00000275493.2	75		missense_variant	"ENST00000275493.2:c.2492G>A,NC_000007.13:g.55259434G>A,NM_005228.4:c.2492G>A,NP_005219.2:p.Arg831His,NC_000007.14:g.55191741G>A"	2023-01-27 17:07:39 UTC	CA4266102	560007	"RS150036236,ARG831HIS"	FALSE
EGFR L838V	992	Cancer	162		"Gefitinib,Erlotinib"	Substitutes	Predictive	Supports	D	Resistance	"In an in vitro study, a Ba/F3 cell line expressing EGFR L838V demonstrated reduced sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). Sensitivity was determined by assessing cell proliferation, the IC50 of erlotinib for EGFR L838V and EGFR L858R expressing cells were 160 nmol/L and 6 nmol/L, respectively. Similarly, gefitinib was tested and 187 nanomolar IC50 was seen, suggesting lack of sensitivity and potential resistance."	19147750	PubMed		"Kancha et al., 2009, Clin. Cancer Res."		2	accepted	4280	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/4280	https://civicdb.org/links/molecular_profiles/992	FALSE	EGFR	1956	L838V		chr7	55191761	55191761	C	G	ENST00000275493.2	75		missense_variant	"NM_005228.4:c.2512C>G,NP_005219.2:p.Leu838Val,NC_000007.13:g.55259454C>G,ENST00000275493.2:c.2512C>G"	2023-01-27 17:07:40 UTC	CA350916	208822	LEU838VAL	FALSE
EGFR L858R	33	Lung Non-small Cell Carcinoma	3908		Erlotinib		Predictive	Supports	D	Sensitivity/Response	"In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H3255 cells (EGFR-L858R), inhibition of cell growth was used as an assay to determine sensitivity to reversible tyrosine kinase inhibitor drugs. Cells with an EGFR L858R mutation demonstrated an improved response to erlotinib (IC50: 40nM vs. 110nM) compared to EGFR wild type cells."	18408761	PubMed		"Li et al., 2008, Oncogene"		2	accepted	4284	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/4284	https://civicdb.org/links/molecular_profiles/33	FALSE	EGFR	1956	L858R		chr7	55191822	55191822	T	G	ENST00000275493.2	75		missense_variant	"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg"	2023-01-27 17:02:04 UTC	CA126713	"16,609,376,282,376,200"	"LEU858ARG,RS121434568"	FALSE
EGFR L858R	33	Cancer	162		Erlotinib		Predictive	Supports	D	Sensitivity/Response	"In an in vitro study, a MCF-7 cell line expressing EGFR L858R mutation demonstrated sensitivity to erlotinib treatment, compared to MCF-7 cells expressing EGFR wild-type. Sensitivity was determined by assessing YFP signal-EGFR relocation."	21132006	PubMed		"Harada et al., 2011, Oncogene"		2	accepted	4285	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/4285	https://civicdb.org/links/molecular_profiles/33	FALSE	EGFR	1956	L858R		chr7	55191822	55191822	T	G	ENST00000275493.2	75		missense_variant	"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg"	2023-01-27 17:02:04 UTC	CA126713	"16,609,376,282,376,200"	"LEU858ARG,RS121434568"	FALSE
EGFR L858R	33	Lung Non-small Cell Carcinoma	3908		Erlotinib		Predictive	Supports	D	Sensitivity/Response	"In an in vitro study, Ba/F3 and NCI-H3255 cell lines expressing EGFR L858R demonstrated increased sensitivity to erlotinib treatment (IC50=0.006 and 0.068 M). Sensitivity was determined by assessing cell proliferation, EGFR, AKT and ERK phosphorylation, levels of BIM (a marker of EGFR TKI-induced cell killing) and cell viability."	24353160	PubMed		"Yasuda et al., 2013, Sci Transl Med"		3	accepted	4286	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/4286	https://civicdb.org/links/molecular_profiles/33	FALSE	EGFR	1956	L858R		chr7	55191822	55191822	T	G	ENST00000275493.2	75		missense_variant	"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg"	2023-01-27 17:02:04 UTC	CA126713	"16,609,376,282,376,200"	"LEU858ARG,RS121434568"	FALSE
EGFR L858R	33	Lung Non-small Cell Carcinoma	3908		Erlotinib		Predictive	Supports	D	Sensitivity/Response	"In an in vitro study, CHO and NCI-H3255 cells expressing EGFR L858R mutation were associated with sensitivity to erlotinib treatment. Sensitivity was determined by assessing cell density."	27612423	PubMed		"Ray et al., 2016, Oncotarget"		1	accepted	4287	Somatic	2023-02-01 17:39:24 UTC	https://civicdb.org/links/evidence_items/4287	https://civicdb.org/links/molecular_profiles/33	FALSE	EGFR	1956	L858R		chr7	55191822	55191822	T	G	ENST00000275493.2	75		missense_variant	"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg"	2023-01-27 17:02:04 UTC	CA126713	"16,609,376,282,376,200"	"LEU858ARG,RS121434568"	FALSE
EGFR L858R	33	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	C	Resistance	"This study analyzed patients with non small cell lung cancer (NSCLC) who were positive for EML4-ALK fusions (ALK+) and progressed on crizotinib monotherapy. One patient was biopsied twice following crizotinib progression and once pre-treatment. This patient was a 27 year old female with one pack year who experienced partial response on crizotinib as 4th line therapy. The patient's pre-crizotinib biopsy was ALK+ and lacked the EGFR mutation. A biopsy taken after 63 days on crizotinib showed EGFR L858R mutation and lacked ALK gene rearrangement by FISH (ALK Loss). Of note, a second post-treatment biopsy (after 113 on crizotinib) showed ALK rearrangement but lacked EGFR mutation. The authors interpreted the emergence of an ALK negative tumor (first post-critozitinib biopsy) as evidence of a separate oncogenic driver (EGFR L858R)."	22235099	PubMed		"Doebele et al., 2012, Clin. Cancer Res."		3	accepted	4288	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/4288	https://civicdb.org/links/molecular_profiles/33	FALSE	EGFR	1956	L858R		chr7	55191822	55191822	T	G	ENST00000275493.2	75		missense_variant	"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg"	2023-01-27 17:02:04 UTC	CA126713	"16,609,376,282,376,200"	"LEU858ARG,RS121434568"	FALSE
EGFR L858R	33	Lung Adenocarcinoma	3910		Erlotinib		Predictive	Supports	B	Sensitivity/Response	"In a prospective study of 46 Caucasian, advanced lung adenocarcinoma patients harboring EGFR mutations, first-line erlotinib treatment was assessed. Average PFS and OS for these 46 patients was 11 months (95% CI: 9.7-12.3 months) and 23 months (95% CI: 21.3-28.6+ months), respectively. A PFS rate of 81% at three months met the primary endpoint of presumed superiority over chemotherapy. Clinical benefit (CR+PR+SD) rate was 81%. Fifteen patients harbored EGFR L858R mutations, which was the only mutation found in exon 21. The authors note similar response profiles for exon 19 (27/46) and exon 21 mutations (15/46) to the overall population."	27032107	PubMed		"De Grve et al., 2016, PLoS ONE"	NCT00339586	2	accepted	4290	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/4290	https://civicdb.org/links/molecular_profiles/33	FALSE	EGFR	1956	L858R		chr7	55191822	55191822	T	G	ENST00000275493.2	75		missense_variant	"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg"	2023-01-27 17:02:04 UTC	CA126713	"16,609,376,282,376,200"	"LEU858ARG,RS121434568"	FALSE
EGFR L858R	33	Lung Adenocarcinoma	3910		Erlotinib		Predictive	Supports	D	Sensitivity/Response	"In an in vitro study, Ba/F3 cell line expressing EGFR L858R was associated with sensitivity to erlotinib treatment (IC50 26.9  12.4). Sensitivity was determined by assessing cell viability, AKT and ERK phosphorylation, and EGFR auto-phosphorylation."	27102076	PubMed		"Konduri et al., 2016, Cancer Discov"		2	accepted	4291	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/4291	https://civicdb.org/links/molecular_profiles/33	FALSE	EGFR	1956	L858R		chr7	55191822	55191822	T	G	ENST00000275493.2	75		missense_variant	"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg"	2023-01-27 17:02:04 UTC	CA126713	"16,609,376,282,376,200"	"LEU858ARG,RS121434568"	FALSE
EGFR L858R	33	Lung Adenocarcinoma	3910		Cetuximab		Predictive	Does Not Support	D	Sensitivity/Response	"In an in vitro study, Ba/F3 cell line expressing EGFR L858R did not show sensitivity to cetuximab treatment, while cells expressing EGFR-RAD51 fusion were sensitive. Sensitivity was determined by assessing cell viability, AKT and ERK phosphorylation and EGFR auto-phosphorylation."	27102076	PubMed		"Konduri et al., 2016, Cancer Discov"		3	accepted	4292	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/4292	https://civicdb.org/links/molecular_profiles/33	FALSE	EGFR	1956	L858R		chr7	55191822	55191822	T	G	ENST00000275493.2	75		missense_variant	"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg"	2023-01-27 17:02:04 UTC	CA126713	"16,609,376,282,376,200"	"LEU858ARG,RS121434568"	FALSE
EGFR L858R	33	Lung Small Cell Carcinoma	5409		Erlotinib		Predictive	Supports	D	Sensitivity/Response	"In an in vitro study using NCI-H3255 cells (EGFR L858R mutation), inhibition of EGFR phosphorylation was used as an assay to determine sensitivity to EGFR tyrosine kinase inhibitors. NCI-H3255 cells demonstrated increased sensitivity to erlotinib (IC50: 8 and 11 nM) compared to EGFRwt NCI-H2073 cells (IC50: 108 nM; 95%CI 52-223 nM)."	24893891	PubMed		"Cross et al., 2014, Cancer Discov"		2	accepted	4293	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/4293	https://civicdb.org/links/molecular_profiles/33	FALSE	EGFR	1956	L858R		chr7	55191822	55191822	T	G	ENST00000275493.2	75		missense_variant	"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg"	2023-01-27 17:02:04 UTC	CA126713	"16,609,376,282,376,200"	"LEU858ARG,RS121434568"	FALSE
EGFR L858R	33	Lung Non-small Cell Carcinoma	3908		Osimertinib		Predictive	Supports	D	Sensitivity/Response	"In an in vitro study using NCI-H3255 cells (EGFR L858R mutation), inhibition of EGFR phosphorylation was used as an assay to determine sensitivity to EGFR tyrosine kinase inhibitors. NCI-H3255 cells demonstrated increased sensitivity to AZD9291 (IC50: 60 and 49 nM) compared to EGFRwt NCI-H2073 cells (IC50: 1865 nM; 95%CI 872-3988 nM). In vivo experiments with NCI-H3255 xenograft models showed drastic tumour volume reduction upon treatment with 5mg/kg/day AZD9291."	24893891	PubMed		"Cross et al., 2014, Cancer Discov"		2	accepted	4294	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/4294	https://civicdb.org/links/molecular_profiles/33	FALSE	EGFR	1956	L858R		chr7	55191822	55191822	T	G	ENST00000275493.2	75		missense_variant	"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg"	2023-01-27 17:02:04 UTC	CA126713	"16,609,376,282,376,200"	"LEU858ARG,RS121434568"	FALSE
EGFR L858R	33	High Grade Glioma	3070		Erlotinib		Predictive	Supports	D	Sensitivity/Response	"In an in vitro study, a Ba/F3 cell line expressing EGFR L858R demonstrated increased sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing EGFR wild-type. Variant function was assessed by EGFR auto-phosphorylation. Sensitivity was assessed by cell viability assay using stable transfection of each variant and increasing concentrations of erlotinib (0?0 uM)."	17177598	PubMed		"Lee et al., 2006, PLoS Med."		3	accepted	4295	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/4295	https://civicdb.org/links/molecular_profiles/33	FALSE	EGFR	1956	L858R		chr7	55191822	55191822	T	G	ENST00000275493.2	75		missense_variant	"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg"	2023-01-27 17:02:04 UTC	CA126713	"16,609,376,282,376,200"	"LEU858ARG,RS121434568"	FALSE
EGFR L861Q	994	High Grade Glioma	3070		Erlotinib		Predictive	Supports	D	Sensitivity/Response	"In an in vitro study, a Ba/F3 cell line expressing EGFR L861Q demonstrated increased sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing EGFR wild-type. Variant function was assessed by EGFR auto-phosphorylation. Sensitivity was assessed by cell viability assay using stable transfection of each variant and increasing concentrations of erlotinib (0?0 uM)."	17177598	PubMed		"Lee et al., 2006, PLoS Med."		3	accepted	4299	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/4299	https://civicdb.org/links/molecular_profiles/994	FALSE	EGFR	1956	L861Q		chr7	55191831	55191831	T	A	ENST00000275493.2	75		missense_variant	"NM_005228.4:c.2582T>A,NP_005219.2:p.Leu861Gln,NC_000007.13:g.55259524T>A,ENST00000275493.2:c.2582T>A"	2023-01-27 17:07:41 UTC	CA176021	163380	RS121913444	FALSE
EGFR E868G	1390	Cancer	162		Erlotinib		Predictive	Supports	D	Sensitivity/Response	"In an in vitro study performed after identification of the mutation in a malignant peritoneal mesothelioma patient, COS-7 cells expressing EGFR E868G demonstrated increased EGFR phosphotyrosine after EGF treatment over wildtype EGFR expressing cells. Cells expressing mutant EGFR also showed increased sensitivity to erlotinib treatment compared to cells expressing EGFR wild-type. Sensitivity was determined by assessing EGFR auto-phosphorylation."	20942962	PubMed		"Foster et al., 2010, World J Surg Oncol"		3	accepted	4301	Somatic	2023-01-26 23:28:50 UTC	https://civicdb.org/links/evidence_items/4301	https://civicdb.org/links/molecular_profiles/1390	FALSE	EGFR	1956	E868G		chr7	55191852	55191852	A	G	ENST00000275493.2	75		missense_variant	"ENST00000275493.2:c.2603A>G,NC_000007.14:g.55191852A>G,NC_000007.13:g.55259545A>G,ENST00000275493.7:c.2603A>G,ENSP00000275493.2:p.Glu868Gly,NM_005228.5:c.2603A>G,NP_005219.2:p.Glu868Gly"	2023-01-27 17:09:46 UTC	CA367580333	NONE FOUND	GLU868GLY	FALSE
ABL1 BCR::ABL M244V	995	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	B	Resistance	"This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation  had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Out of 46 patients with M244V mutations,  20, 27, and 45 achieved a CCyR, MCyR, and CHR with dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations."	19779040	PubMed		"Mller et al., 2009, Blood"	"NCT00101660,NCT00103844,NCT00123474"	3	accepted	4302	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/4302	https://civicdb.org/links/molecular_profiles/995	FALSE	ABL1	25	BCR::ABL M244V		chr9	130862943	130862943	A	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.730A>G,NP_005148.2:p.Met244Val,NC_000009.11:g.133738330A>G,ENST00000318560.5:c.730A>G"	2023-01-27 17:07:41 UTC	CA16602545	376084	"RS121913456,M263V,MET263VAL,BCR-ABL MET244VAL,BCR-ABL1 M244V,BCR-ABL1 MET244VAL,BCR-ABL M244V"	FALSE
ABL1 BCR::ABL M244V	995	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	C	Resistance	"In this phase II multinational study, 60 imatinib-resistant patients with accelerated phase CML and BCR-ABL fusions were treated with dasatinib monotherapy. 44 (73%) of 60 BCR-ABL mutant patients achieved major hematologic responses (MaHRs) and 18 (30%) of 60 achieved major cytogenetic responses (MCyRs). Of patients with M244V, 4/5 had MaHRs which was higher than response rates among wild type patients, and 2/5 had MCyRs which was comparable to response rates among wild type patients."	17264298	PubMed		"Guilhot et al., 2007, Blood"		1	accepted	4304	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/4304	https://civicdb.org/links/molecular_profiles/995	FALSE	ABL1	25	BCR::ABL M244V		chr9	130862943	130862943	A	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.730A>G,NP_005148.2:p.Met244Val,NC_000009.11:g.133738330A>G,ENST00000318560.5:c.730A>G"	2023-01-27 17:07:41 UTC	CA16602545	376084	"RS121913456,M263V,MET263VAL,BCR-ABL MET244VAL,BCR-ABL1 M244V,BCR-ABL1 MET244VAL,BCR-ABL M244V"	FALSE
ABL1 BCR::ABL M244V	995	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	C	Resistance	"Prior to dasatinib treatment, one imatinib-resistant patient with chronic myeloid leukemia in chronic phase had the BCR-ABL1 fusion with the M244V secondary variant in 12/12 bacterial clones generated using peripheral blood RNA. They had complete best hematologic and no cytogenetic responses to dasatinib which were comparable to responses in patients with unmutated BCR-ABL1."	16775234	PubMed		"Talpaz et al., 2006, N. Engl. J. Med."	NCT00064233	2	accepted	4305	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/4305	https://civicdb.org/links/molecular_profiles/995	FALSE	ABL1	25	BCR::ABL M244V		chr9	130862943	130862943	A	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.730A>G,NP_005148.2:p.Met244Val,NC_000009.11:g.133738330A>G,ENST00000318560.5:c.730A>G"	2023-01-27 17:07:41 UTC	CA16602545	376084	"RS121913456,M263V,MET263VAL,BCR-ABL MET244VAL,BCR-ABL1 M244V,BCR-ABL1 MET244VAL,BCR-ABL M244V"	FALSE
ABL1 BCR::ABL M244V	995	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Does Not Support	C	Resistance	"In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with M244V evaluated, 2/2 had complete hematologic responses and 2/3 had major cytogenetic responses."	21865346	PubMed		"Cortes et al., 2011, Blood"	NCT00261846	2	accepted	4307	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/4307	https://civicdb.org/links/molecular_profiles/995	FALSE	ABL1	25	BCR::ABL M244V		chr9	130862943	130862943	A	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.730A>G,NP_005148.2:p.Met244Val,NC_000009.11:g.133738330A>G,ENST00000318560.5:c.730A>G"	2023-01-27 17:07:41 UTC	CA16602545	376084	"RS121913456,M263V,MET263VAL,BCR-ABL MET244VAL,BCR-ABL1 M244V,BCR-ABL1 MET244VAL,BCR-ABL M244V"	FALSE
ABL1 BCR::ABL M244V	995	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Does Not Support	C	Resistance	"This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chronic phase CML and BCR-ABL fusions. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. Of patients with M244V evaluated, 3/3 had CHR and 2/3 had MCyR. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occuring."	22371878	PubMed		"Khoury et al., 2012, Blood"	NCT00261846	2	accepted	4308	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/4308	https://civicdb.org/links/molecular_profiles/995	FALSE	ABL1	25	BCR::ABL M244V		chr9	130862943	130862943	A	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.730A>G,NP_005148.2:p.Met244Val,NC_000009.11:g.133738330A>G,ENST00000318560.5:c.730A>G"	2023-01-27 17:07:41 UTC	CA16602545	376084	"RS121913456,M263V,MET263VAL,BCR-ABL MET244VAL,BCR-ABL1 M244V,BCR-ABL1 MET244VAL,BCR-ABL M244V"	FALSE
ABL1 BCR::ABL L248V	996	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Does Not Support	C	Resistance	"In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with L248V evaluated, 3/3 had complete hematologic responses and 2/3 had major cytogenetic responses."	21865346	PubMed		"Cortes et al., 2011, Blood"	NCT00261846	2	accepted	4310	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/4310	https://civicdb.org/links/molecular_profiles/996	FALSE	ABL1	25	BCR::ABL L248V		chr9	130862955	130862955	C	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.742C>G,NP_005148.2:p.Leu248Val,NC_000009.11:g.133738342C>G,ENST00000318560.5:c.742C>G"	2023-01-27 17:07:42 UTC	CA16602546	376085	"RS121913455,L267V,LEU248VAL,BCR-ABL L248V"	FALSE
ABL1 BCR::ABL L248V	996	Chronic Myeloid Leukemia	8552		Axitinib		Predictive	Supports	D	Resistance	"In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed decreased incorporation when harboring fusions with the L248V variant of ABL1 compared to fusions with wildtype ABL1 (IC50 of 1393nM vs. 823 nM), indicating resistance."	25686603	PubMed		"Pemovska et al., 2015, Nature"		2	accepted	4311	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/4311	https://civicdb.org/links/molecular_profiles/996	FALSE	ABL1	25	BCR::ABL L248V		chr9	130862955	130862955	C	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.742C>G,NP_005148.2:p.Leu248Val,NC_000009.11:g.133738342C>G,ENST00000318560.5:c.742C>G"	2023-01-27 17:07:42 UTC	CA16602546	376085	"RS121913455,L267V,LEU248VAL,BCR-ABL L248V"	FALSE
ABL1 BCR::ABL G250E	997	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Does Not Support	C	Resistance	"In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with G250E evaluated, 1/1 had a complete hematologic response and 2/2 had major cytogenetic responses."	21865346	PubMed		"Cortes et al., 2011, Blood"	NCT00261846	2	accepted	4313	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/4313	https://civicdb.org/links/molecular_profiles/997	FALSE	ABL1	25	BCR::ABL G250E		chr9	130862962	130862962	G	A	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.749G>A,NP_005148.2:p.Gly250Glu,NC_000009.11:g.133738349G>A,ENST00000318560.5:c.749G>A"	2023-01-27 17:07:43 UTC	CA16602547	376086	"RS121913453,BCR-ABL G269E,BCR-ABL GLY250GLU,BCR-ABL1 G250E,BCR-ABL1 GLY250GLU,BCR-ABL G250E"	FALSE
ABL1 BCR::ABL G250E	997	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Supports	C	Reduced Sensitivity	"This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chronic phase CML and BCR-ABL fusions. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. Of patients with G250E, 3/6 had a CHR and 0/5 had a MCyR. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occuring."	22371878	PubMed		"Khoury et al., 2012, Blood"	NCT00261846	2	accepted	4314	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/4314	https://civicdb.org/links/molecular_profiles/997	FALSE	ABL1	25	BCR::ABL G250E		chr9	130862962	130862962	G	A	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.749G>A,NP_005148.2:p.Gly250Glu,NC_000009.11:g.133738349G>A,ENST00000318560.5:c.749G>A"	2023-01-27 17:07:43 UTC	CA16602547	376086	"RS121913453,BCR-ABL G269E,BCR-ABL GLY250GLU,BCR-ABL1 G250E,BCR-ABL1 GLY250GLU,BCR-ABL G250E"	FALSE
ABL1 BCR::ABL G250E	997	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	B	Resistance	"This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation  had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Of 60 patients with G250E mutations, 20, 29, and 56 achieved a CCyR, MCyR, and CHR with dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations."	19779040	PubMed		"Mller et al., 2009, Blood"	"NCT00101660,NCT00103844,NCT00123474"	3	accepted	4316	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/4316	https://civicdb.org/links/molecular_profiles/997	FALSE	ABL1	25	BCR::ABL G250E		chr9	130862962	130862962	G	A	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.749G>A,NP_005148.2:p.Gly250Glu,NC_000009.11:g.133738349G>A,ENST00000318560.5:c.749G>A"	2023-01-27 17:07:43 UTC	CA16602547	376086	"RS121913453,BCR-ABL G269E,BCR-ABL GLY250GLU,BCR-ABL1 G250E,BCR-ABL1 GLY250GLU,BCR-ABL G250E"	FALSE
ABL1 BCR::ABL G250E	997	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Supports	C	Reduced Sensitivity	"In this phase II multinational study, patients with accelerated phase CML and BCR-ABL fusions were treated with dasatinib monotherapy. Response rate among 60 imatinib-resistant patients with BCR-ABL mutations did not differ from the rate of the total population of 100 imatinib-resistant or -intolerant patients. 44 (73%) of 60 BCR-ABL mutant patients achieved major hematologic responses (MaHRs) and 18 (30%) of 60 achieved major cytogenetic responses (MCyRs). Of patients with G250E, 6/9 had MaHRs which was comparable to response rates among wild type patients, and 1/9 had MCyRs which was lower than response rates among wild type patients."	17264298	PubMed		"Guilhot et al., 2007, Blood"		1	accepted	4318	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/4318	https://civicdb.org/links/molecular_profiles/997	FALSE	ABL1	25	BCR::ABL G250E		chr9	130862962	130862962	G	A	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.749G>A,NP_005148.2:p.Gly250Glu,NC_000009.11:g.133738349G>A,ENST00000318560.5:c.749G>A"	2023-01-27 17:07:43 UTC	CA16602547	376086	"RS121913453,BCR-ABL G269E,BCR-ABL GLY250GLU,BCR-ABL1 G250E,BCR-ABL1 GLY250GLU,BCR-ABL G250E"	FALSE
ABL1 BCR::ABL G250E	997	Chronic Myeloid Leukemia	8552		Axitinib		Predictive	Supports	D	Resistance	"In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed higher incorporation when harboring fusions with the G250E variant of ABL1 compared to fusions with wildtype ABL1 (IC50 of 1295nM vs. 823 nM), indicating resistance."	25686603	PubMed		"Pemovska et al., 2015, Nature"		2	accepted	4320	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/4320	https://civicdb.org/links/molecular_profiles/997	FALSE	ABL1	25	BCR::ABL G250E		chr9	130862962	130862962	G	A	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.749G>A,NP_005148.2:p.Gly250Glu,NC_000009.11:g.133738349G>A,ENST00000318560.5:c.749G>A"	2023-01-27 17:07:43 UTC	CA16602547	376086	"RS121913453,BCR-ABL G269E,BCR-ABL GLY250GLU,BCR-ABL1 G250E,BCR-ABL1 GLY250GLU,BCR-ABL G250E"	FALSE
ABL1 BCR::ABL Q252H	998	Chronic Myeloid Leukemia	8552		Axitinib		Predictive	Supports	D	Resistance	"In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed increased incorporation when harboring fusions with the Q252H variant of ABL1 compared to fusions with wildtype ABL1 (IC50 of 1155nM vs. 823 nM), indicating resistance."	25686603	PubMed		"Pemovska et al., 2015, Nature"		2	accepted	4323	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/4323	https://civicdb.org/links/molecular_profiles/998	FALSE	ABL1	25	BCR::ABL Q252H		chr9	130862969	130862969	G	C	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.756G>C,NP_005148.2:p.Gln252His,NC_000009.11:g.133738356G>C,ENST00000318560.5:c.756G>C"	2023-01-27 17:07:44 UTC	CA16602548	376087	"RS121913458,BCR-ABL Q271H,BCR-ABL1 Q252H,BCR-ABL1 GLN252HIS,BCR-ABL Q252H"	FALSE
ABL1 BCR::ABL Q252H	998	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	C	Resistance	"This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation  had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Of 6 patients with  Q252H mutations, 1, 1, and 3 achieved CCyR, MCyR, and CHR with dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations. The authors identify Q252H as one of 4 variants with a low CCyR but advise caution when interpreting these results due to low sample size."	19779040	PubMed		"Mller et al., 2009, Blood"	"NCT00101660,NCT00103844,NCT00123474"	3	accepted	4327	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/4327	https://civicdb.org/links/molecular_profiles/998	FALSE	ABL1	25	BCR::ABL Q252H		chr9	130862969	130862969	G	C	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.756G>C,NP_005148.2:p.Gln252His,NC_000009.11:g.133738356G>C,ENST00000318560.5:c.756G>C"	2023-01-27 17:07:44 UTC	CA16602548	376087	"RS121913458,BCR-ABL Q271H,BCR-ABL1 Q252H,BCR-ABL1 GLN252HIS,BCR-ABL Q252H"	FALSE
ABL1 BCR::ABL Y253H	999	Chronic Myeloid Leukemia	8552		Axitinib		Predictive	Does Not Support	D	Resistance	"In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed similar incorporation when harboring fusions with the Y253H variant of ABL1 compared to fusions with wildtype ABL1 (IC50 of 867nM vs. 823 nM), indicating that the variant does not induce resistance."	25686603	PubMed		"Pemovska et al., 2015, Nature"		2	accepted	4329	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/4329	https://civicdb.org/links/molecular_profiles/999	FALSE	ABL1	25	BCR::ABL Y253H		chr9	130862970	130862970	T	C	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.757T>C,NP_005148.2:p.Tyr253His,NC_000009.11:g.133738357T>C,ENST00000318560.5:c.757T>C"	2023-01-27 17:07:45 UTC	CA122584	12627	"RS121913461,Y272H,TYR272HIS,BCR-ABL TYR253HIS,BCR-ABL1 Y253H,BCR-ABL1 TYR253HIS,BCR-ABL Y253H"	FALSE
ABL1 BCR::ABL Y253H	999	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Does Not Support	C	Resistance	"In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with Y253H evaluated, 1/1 had a complete hematologic response and 1/1 had a major cytogenetic response."	21865346	PubMed		"Cortes et al., 2011, Blood"	NCT00261846	2	accepted	4331	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/4331	https://civicdb.org/links/molecular_profiles/999	FALSE	ABL1	25	BCR::ABL Y253H		chr9	130862970	130862970	T	C	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.757T>C,NP_005148.2:p.Tyr253His,NC_000009.11:g.133738357T>C,ENST00000318560.5:c.757T>C"	2023-01-27 17:07:45 UTC	CA122584	12627	"RS121913461,Y272H,TYR272HIS,BCR-ABL TYR253HIS,BCR-ABL1 Y253H,BCR-ABL1 TYR253HIS,BCR-ABL Y253H"	FALSE
ABL1 BCR::ABL Y253H	999	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Does Not Support	C	Resistance	"This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chronic phase CML and BCR-ABL fusions. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. Of patients with Y253H evaluated, 5/6 had CHR and 4/6 had MCyR. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occuring."	22371878	PubMed		"Khoury et al., 2012, Blood"	NCT00261846	3	accepted	4332	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/4332	https://civicdb.org/links/molecular_profiles/999	FALSE	ABL1	25	BCR::ABL Y253H		chr9	130862970	130862970	T	C	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.757T>C,NP_005148.2:p.Tyr253His,NC_000009.11:g.133738357T>C,ENST00000318560.5:c.757T>C"	2023-01-27 17:07:45 UTC	CA122584	12627	"RS121913461,Y272H,TYR272HIS,BCR-ABL TYR253HIS,BCR-ABL1 Y253H,BCR-ABL1 TYR253HIS,BCR-ABL Y253H"	FALSE
ABL1 BCR::ABL Y253H	999	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	C	Resistance	"In this phase II multinational study, 60 imatinib-resistant patients with accelerated phase CML and BCR-ABL fusions were treated with dasatinib monotherapy. 44 (73%) of 60 BCR-ABL mutant patients achieved major hematologic responses (MaHRs) and 18 (30%) of 60 achieved major cytogenetic responses (MCyRs). Of patients with Y253H, 5/6 had MaHRs which was higher than response rates among wild type patients and 2/6 had MCyRs which was comparable to response rates among wild type patients."	17264298	PubMed		"Guilhot et al., 2007, Blood"		1	accepted	4334	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/4334	https://civicdb.org/links/molecular_profiles/999	FALSE	ABL1	25	BCR::ABL Y253H		chr9	130862970	130862970	T	C	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.757T>C,NP_005148.2:p.Tyr253His,NC_000009.11:g.133738357T>C,ENST00000318560.5:c.757T>C"	2023-01-27 17:07:45 UTC	CA122584	12627	"RS121913461,Y272H,TYR272HIS,BCR-ABL TYR253HIS,BCR-ABL1 Y253H,BCR-ABL1 TYR253HIS,BCR-ABL Y253H"	FALSE
ABL1 BCR::ABL Y253H	999	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	B	Resistance	"This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation  had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Out of 23 patients with the Y253H mutation, 14, 15, and 20 achieved CCyR, MCyR, and CHR with dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations."	19779040	PubMed		"Mller et al., 2009, Blood"	"NCT00101660,NCT00103844,NCT00123474"	3	accepted	4335	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/4335	https://civicdb.org/links/molecular_profiles/999	FALSE	ABL1	25	BCR::ABL Y253H		chr9	130862970	130862970	T	C	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.757T>C,NP_005148.2:p.Tyr253His,NC_000009.11:g.133738357T>C,ENST00000318560.5:c.757T>C"	2023-01-27 17:07:45 UTC	CA122584	12627	"RS121913461,Y272H,TYR272HIS,BCR-ABL TYR253HIS,BCR-ABL1 Y253H,BCR-ABL1 TYR253HIS,BCR-ABL Y253H"	FALSE
ABL1 BCR::ABL Y253H	999	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	C	Resistance	"Prior to dasatinib treatment, one imatinib-resistant patient with chronic myeloid leukemia in chronic phase had the BCR-ABL1 fusion with the Y253H secondary variant in 11/11 bacterial clones generated using peripheral blood RNA. They had complete response as best hematologic response and complete response as best cytogenetic response to dasatinib which were improved compared to responses in patients with unmutated BCR-ABL1."	16775234	PubMed		"Talpaz et al., 2006, N. Engl. J. Med."	NCT00064233	4	accepted	4336	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/4336	https://civicdb.org/links/molecular_profiles/999	FALSE	ABL1	25	BCR::ABL Y253H		chr9	130862970	130862970	T	C	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.757T>C,NP_005148.2:p.Tyr253His,NC_000009.11:g.133738357T>C,ENST00000318560.5:c.757T>C"	2023-01-27 17:07:45 UTC	CA122584	12627	"RS121913461,Y272H,TYR272HIS,BCR-ABL TYR253HIS,BCR-ABL1 Y253H,BCR-ABL1 TYR253HIS,BCR-ABL Y253H"	FALSE
ABL1 BCR::ABL Y253F	1000	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Does Not Support	C	Resistance	"In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with Y253F evaluated, 1/1 had a complete hematologic response and 0/1 had a major cytogenetic response."	21865346	PubMed		"Cortes et al., 2011, Blood"	NCT00261846	1	accepted	4340	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/4340	https://civicdb.org/links/molecular_profiles/1000	FALSE	ABL1	25	BCR::ABL Y253F		chr9	130862971	130862971	A	T	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"ENST00000318560.5:c.758A>T,NM_005157.5:c.758A>T,NP_005148.2:p.Tyr253Phe,NC_000009.11:g.133738358A>T"	2023-01-27 17:07:45 UTC	CA16602550	376089	"RS121913460,Y272F,TYR253PHE,TYR272PHE,BCR-ABL Y253F"	FALSE
ABL1 BCR::ABL Y253F	1000	Chronic Myeloid Leukemia	8552		Axitinib		Predictive	Supports	D	Resistance	"In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed increased incorporation when harboring fusions with the Y253F variant of ABL1 compared to fusions with wildtype ABL1 (IC50 of 1275nM vs. 823 nM), indicating resistance."	25686603	PubMed		"Pemovska et al., 2015, Nature"		2	accepted	4345	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/4345	https://civicdb.org/links/molecular_profiles/1000	FALSE	ABL1	25	BCR::ABL Y253F		chr9	130862971	130862971	A	T	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"ENST00000318560.5:c.758A>T,NM_005157.5:c.758A>T,NP_005148.2:p.Tyr253Phe,NC_000009.11:g.133738358A>T"	2023-01-27 17:07:45 UTC	CA16602550	376089	"RS121913460,Y272F,TYR253PHE,TYR272PHE,BCR-ABL Y253F"	FALSE
ABL1 BCR::ABL D276G	1001	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Does Not Support	C	Resistance	"In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with D276G evaluated, 1/1 had a complete hematologic responses and 0/1 had a major cytogenetic response."	21865346	PubMed		"Cortes et al., 2011, Blood"	NCT00261846	1	accepted	4357	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/4357	https://civicdb.org/links/molecular_profiles/1001	FALSE	ABL1	25	BCR::ABL D276G		chr9	130872133	130872133	A	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"ENST00000318560.5:c.827A>G,NP_005148.2:p.Asp276Gly,NM_005157.5:c.827A>G,NC_000009.11:g.133747520A>G"	2023-01-27 17:07:46 UTC	CA200645023	NONE FOUND	"RS121913447,BCR-ABL ASP276GLY,BCR-ABL D295G,BCR-ABL1 D295G,BCR-ABL D276G"	FALSE
ABL1 BCR::ABL D276G	1001	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	C	Resistance	"This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Out of 8 patients with D276G mutations, 3, 4, and 7 achieved CCyR, MCyR, and CHR with dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations."	19779040	PubMed		"Mller et al., 2009, Blood"	"NCT00101660,NCT00103844,NCT00123474"	3	accepted	4359	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/4359	https://civicdb.org/links/molecular_profiles/1001	FALSE	ABL1	25	BCR::ABL D276G		chr9	130872133	130872133	A	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"ENST00000318560.5:c.827A>G,NP_005148.2:p.Asp276Gly,NM_005157.5:c.827A>G,NC_000009.11:g.133747520A>G"	2023-01-27 17:07:46 UTC	CA200645023	NONE FOUND	"RS121913447,BCR-ABL ASP276GLY,BCR-ABL D295G,BCR-ABL1 D295G,BCR-ABL D276G"	FALSE
ABL1 BCR::ABL D276G	1001	Chronic Myeloid Leukemia	8552		Axitinib		Predictive	Supports	D	Resistance	"In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed increased incorporations when harboring fusions with the D276G variant of ABL1 compared to fusions with wildtype ABL1 (IC50 of 1105nM vs. 823 nM), indicating resistance."	25686603	PubMed		"Pemovska et al., 2015, Nature"		2	accepted	4360	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/4360	https://civicdb.org/links/molecular_profiles/1001	FALSE	ABL1	25	BCR::ABL D276G		chr9	130872133	130872133	A	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"ENST00000318560.5:c.827A>G,NP_005148.2:p.Asp276Gly,NM_005157.5:c.827A>G,NC_000009.11:g.133747520A>G"	2023-01-27 17:07:46 UTC	CA200645023	NONE FOUND	"RS121913447,BCR-ABL ASP276GLY,BCR-ABL D295G,BCR-ABL1 D295G,BCR-ABL D276G"	FALSE
ABL1 BCR::ABL M351T	1003	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Supports	C	Reduced Sensitivity	"This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chronic phase CML and BCR-ABL fusions. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. Of patients with M351T, 1/1 had a CHR and 0/1 had a MCyR. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occuring."	22371878	PubMed		"Khoury et al., 2012, Blood"	NCT00261846	1	accepted	4394	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/4394	https://civicdb.org/links/molecular_profiles/1003	FALSE	ABL1	25	BCR::ABL M351T		chr9	130873004	130873004	T	C	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.1052T>C,NP_005148.2:p.Met351Thr,NC_000009.11:g.133748391T>C,ENST00000318560.5:c.1052T>C"	2023-01-27 17:07:48 UTC	CA122590	12629	"RS121913457,BCR-ABL M370T,BCR-ABL MET351THR,BCR-ABL MET370THR,BCR-ABL M351T"	FALSE
ABL1 BCR::ABL M351T	1003	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	B	Resistance	"This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Out of 54 patients with M351T mutations, 25, 28, and 51 achieved CCyR, MCyR, and CHR with dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations."	19779040	PubMed		"Mller et al., 2009, Blood"	"NCT00101660,NCT00103844,NCT00123474"	4	accepted	4396	Somatic	2023-01-09 21:46:42 UTC	https://civicdb.org/links/evidence_items/4396	https://civicdb.org/links/molecular_profiles/1003	FALSE	ABL1	25	BCR::ABL M351T		chr9	130873004	130873004	T	C	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.1052T>C,NP_005148.2:p.Met351Thr,NC_000009.11:g.133748391T>C,ENST00000318560.5:c.1052T>C"	2023-01-27 17:07:48 UTC	CA122590	12629	"RS121913457,BCR-ABL M370T,BCR-ABL MET351THR,BCR-ABL MET370THR,BCR-ABL M351T"	FALSE
ABL1 BCR::ABL M351T	1003	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Supports	C	Reduced Sensitivity	"In this phase II multinational study, patients with accelerated phase CML and BCR-ABL fusions were treated with dasatinib monotherapy. Response rate among 60 imatinib-resistant patients with BCR-ABL mutations did not differ from the rate of the total population of 100 imatinib-resistant or -intolerant patients. 44 (73%) of 60 BCR-ABL mutant patients achieved major hematologic responses (MaHRs) and 18 (30%) of 60 achieved major cytogenetic responses (MCyRs). Of patients with M351T, 3/6 had MaHRs which was comparable to response rates among wild type patients, and 1/6 had MCyRs which was lower than response rates among wild type patients."	17264298	PubMed		"Guilhot et al., 2007, Blood"		1	accepted	4397	Somatic	2023-01-09 21:46:42 UTC	https://civicdb.org/links/evidence_items/4397	https://civicdb.org/links/molecular_profiles/1003	FALSE	ABL1	25	BCR::ABL M351T		chr9	130873004	130873004	T	C	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.1052T>C,NP_005148.2:p.Met351Thr,NC_000009.11:g.133748391T>C,ENST00000318560.5:c.1052T>C"	2023-01-27 17:07:48 UTC	CA122590	12629	"RS121913457,BCR-ABL M370T,BCR-ABL MET351THR,BCR-ABL MET370THR,BCR-ABL M351T"	FALSE
ABL1 BCR::ABL M351T	1003	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	C	Resistance	"Prior to dasatinib treatment, four imatinib-resistant patients with chronic myeloid leukemia in chronic phase had the BCR-ABL1 fusion with the M351T and M351S; M351T; M351T; and M351T secondary variants in 8/9 and 1/9; 4/10; 10/10; and 11/11 bacterial clones, respectively. Clones were generated using peripheral blood RNA. They had complete response as best hematologic response and complete (n = 3) or partial (n = 1) responses as best cytogenetic response to dasatinib. An additional patient, in myeloid blast crisis, had the M351T variant in 10/10 clones with complete response as best hematologic response and complete response as best cytogenetic response to dasatinib. An additional patient in accelerated phase had the M351T and M351A variants in 6/10 and 1/10 clones, respectively, with complete response as best hematologic response and none as best cytogenetic response to dasatinib. Overall, responses among these patients were comparable to those among patients with unmutated BCR-ABL1."	16775234	PubMed		"Talpaz et al., 2006, N. Engl. J. Med."	NCT00064233	3	accepted	4398	Somatic	2023-01-09 21:46:42 UTC	https://civicdb.org/links/evidence_items/4398	https://civicdb.org/links/molecular_profiles/1003	FALSE	ABL1	25	BCR::ABL M351T		chr9	130873004	130873004	T	C	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.1052T>C,NP_005148.2:p.Met351Thr,NC_000009.11:g.133748391T>C,ENST00000318560.5:c.1052T>C"	2023-01-27 17:07:48 UTC	CA122590	12629	"RS121913457,BCR-ABL M370T,BCR-ABL MET351THR,BCR-ABL MET370THR,BCR-ABL M351T"	FALSE
ABL1 BCR::ABL E355G	1395	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Does Not Support	C	Resistance	"In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with E355G evaluated, 2/2 had complete hematologic responses and 1/2 had major cytogenetic responses."	21865346	PubMed		"Cortes et al., 2011, Blood"	NCT00261846	1	accepted	4400	Somatic	2023-01-09 21:46:45 UTC	https://civicdb.org/links/evidence_items/4400	https://civicdb.org/links/molecular_profiles/1395	FALSE	ABL1	25	BCR::ABL E355G		chr9	130873016	130873016	A	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.1064A>G,NP_005148.2:p.Glu355Gly,NC_000009.11:g.133748403A>G,ENST00000318560.5:c.1064A>G"	2023-01-27 17:09:47 UTC	CA16602556	376095	"RS121913450,BCR-ABL GLU355GLY,BCR-ABL1 E355G,BCR-ABL1 GLU355GLY,BCR-ABL E355G"	FALSE
ABL1 BCR::ABL E355G	1395	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	C	Resistance	"In this phase II multinational study, patients with accelerated phase CML and BCR-ABL fusions were treated with dasatinib monotherapy. Response rate among 60 imatinib-resistant patients with BCR-ABL mutations did not differ from the rate of the total population of 100 imatinib-resistant or -intolerant patients. 44 (73%) of 60 BCR-ABL mutant patients achieved major hematologic responses (MaHRs) and 18 (30%) of 60 achieved major cytogenetic responses (MCyRs). Of patients with E355G, 2/4 had MaHRs and 2/4 had MCyRs which were comparable to response rates among wild type."	17264298	PubMed		"Guilhot et al., 2007, Blood"		1	accepted	4402	Somatic	2023-01-09 21:46:45 UTC	https://civicdb.org/links/evidence_items/4402	https://civicdb.org/links/molecular_profiles/1395	FALSE	ABL1	25	BCR::ABL E355G		chr9	130873016	130873016	A	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.1064A>G,NP_005148.2:p.Glu355Gly,NC_000009.11:g.133748403A>G,ENST00000318560.5:c.1064A>G"	2023-01-27 17:09:47 UTC	CA16602556	376095	"RS121913450,BCR-ABL GLU355GLY,BCR-ABL1 E355G,BCR-ABL1 GLU355GLY,BCR-ABL E355G"	FALSE
ABL1 BCR::ABL E355G	1395	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	B	Resistance	"This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Out of 19 patients with E355G mutations, 4, 9, and 17 achieved CCyR, MCyR, and CHR with dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations."	19779040	PubMed		"Mller et al., 2009, Blood"	"NCT00101660,NCT00103844,NCT00123474"	2	accepted	4403	Somatic	2023-01-09 21:46:45 UTC	https://civicdb.org/links/evidence_items/4403	https://civicdb.org/links/molecular_profiles/1395	FALSE	ABL1	25	BCR::ABL E355G		chr9	130873016	130873016	A	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.1064A>G,NP_005148.2:p.Glu355Gly,NC_000009.11:g.133748403A>G,ENST00000318560.5:c.1064A>G"	2023-01-27 17:09:47 UTC	CA16602556	376095	"RS121913450,BCR-ABL GLU355GLY,BCR-ABL1 E355G,BCR-ABL1 GLU355GLY,BCR-ABL E355G"	FALSE
ABL1 BCR::ABL E355G	1395	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	C	Resistance	"Prior to dasatinib treatment, three imatinib-resistant patients with chronic myeloid leukemia had the BCR-ABL1 fusion with the E355G secondary variant in one or more bacterial clones. Clones were generated using peripheral blood RNA. The first two, in chronic and accelerated phases, had minimal or no best cytogenetic responses but had complete or no evidence of leukemia best hematologic responses, respectively. Of these, the first had E355G and E355G/Q252R variants in 8/10 and 1/10 clones, respectively, and the second had E355G, E355G/L324Q, and L324Q variants in 6/10, 1/10, and 3/10 clones, respectively. The third patient, in lymphoid blast crisis with the E355G variant in 10/10 clones, had complete best hematologic and partial best cytogenetic responses to dasatinib. All responses were comparable to responses in patients with unmutated BCR-ABL1."	16775234	PubMed		"Talpaz et al., 2006, N. Engl. J. Med."	NCT00064233	3	accepted	4404	Somatic	2023-01-09 21:46:45 UTC	https://civicdb.org/links/evidence_items/4404	https://civicdb.org/links/molecular_profiles/1395	FALSE	ABL1	25	BCR::ABL E355G		chr9	130873016	130873016	A	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.1064A>G,NP_005148.2:p.Glu355Gly,NC_000009.11:g.133748403A>G,ENST00000318560.5:c.1064A>G"	2023-01-27 17:09:47 UTC	CA16602556	376095	"RS121913450,BCR-ABL GLU355GLY,BCR-ABL1 E355G,BCR-ABL1 GLU355GLY,BCR-ABL E355G"	FALSE
ABL1 BCR::ABL L387M	1396	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	C	Resistance	"This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Out of 5 patients with L387M mutations, 4, 4, and 5 achieved CCyR, MCyR, and CHR with dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations."	19779040	PubMed		"Mller et al., 2009, Blood"	"NCT00101660,NCT00103844,NCT00123474"	3	accepted	4406	Somatic	2023-01-09 21:46:45 UTC	https://civicdb.org/links/evidence_items/4406	https://civicdb.org/links/molecular_profiles/1396	FALSE	ABL1	25	BCR::ABL L387M		chr9	130874941	130874941	T	A	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"ENST00000318560.5:c.1159T>A,NC_000009.11:g.133750328T>A,NM_005157.5:c.1159T>A,NP_005148.2:p.Leu387Met"	2023-01-27 17:09:48 UTC	CA375249905	NONE FOUND	"BCR-ABL LEU387MET,BCR-ABL1 L387M,BCR-ABL1 LEU387MET,BCR-ABL L387M"	FALSE
ABL1 BCR::ABL L387M	1396	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	C	Resistance	"Prior to dasatinib treatment, one imatinib-resistant patient with chronic myeloid leukemia in chronic phase had the BCR-ABL1 fusion with L387M, L387M/F192L, and E450G variants in 7/10, 2/10, and 1/10 clones, respectively. Clones were generated using peripheral blood RNA. The patient had minimal best cytogenetic and complete best hematologic responses to dasatinib which were comparable to responses in patients with unmutated BCR-ABL1."	16775234	PubMed		"Talpaz et al., 2006, N. Engl. J. Med."	NCT00064233	3	accepted	4407	Somatic	2023-01-09 21:46:45 UTC	https://civicdb.org/links/evidence_items/4407	https://civicdb.org/links/molecular_profiles/1396	FALSE	ABL1	25	BCR::ABL L387M		chr9	130874941	130874941	T	A	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"ENST00000318560.5:c.1159T>A,NC_000009.11:g.133750328T>A,NM_005157.5:c.1159T>A,NP_005148.2:p.Leu387Met"	2023-01-27 17:09:48 UTC	CA375249905	NONE FOUND	"BCR-ABL LEU387MET,BCR-ABL1 L387M,BCR-ABL1 LEU387MET,BCR-ABL L387M"	FALSE
ABL1 BCR::ABL H396R	1004	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Supports	C	Resistance	"This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chronic phase CML and BCR-ABL fusions. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. Of patients with H396R, 0/1 had a CHR and 0/1 had a MCyR. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occuring."	22371878	PubMed		"Khoury et al., 2012, Blood"	NCT00261846	1	accepted	4410	Somatic	2023-01-09 21:46:42 UTC	https://civicdb.org/links/evidence_items/4410	https://civicdb.org/links/molecular_profiles/1004	FALSE	ABL1	25	BCR::ABL H396R		chr9	130874969	130874969	A	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.1187A>G,NP_005148.2:p.His396Arg,NC_000009.11:g.133750356A>G,ENST00000318560.5:c.1187A>G"	2023-01-27 17:07:48 UTC	CA16602558	376097	"RS121913454,BCR-ABL HIS415ARG,BCR-ABL HIS396ARG,BCR-ABL H415R,BCR-ABL1 H396R,BCR-ABL1 HIS396ARG,BCR-ABL H396R"	FALSE
ABL1 BCR::ABL H396R	1004	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Does Not Support	C	Resistance	"In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with H396R evaluated, 1/1 had a complete hematologic response."	21865346	PubMed		"Cortes et al., 2011, Blood"	NCT00261846	1	accepted	4411	Somatic	2023-01-09 21:46:42 UTC	https://civicdb.org/links/evidence_items/4411	https://civicdb.org/links/molecular_profiles/1004	FALSE	ABL1	25	BCR::ABL H396R		chr9	130874969	130874969	A	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.1187A>G,NP_005148.2:p.His396Arg,NC_000009.11:g.133750356A>G,ENST00000318560.5:c.1187A>G"	2023-01-27 17:07:48 UTC	CA16602558	376097	"RS121913454,BCR-ABL HIS415ARG,BCR-ABL HIS396ARG,BCR-ABL H415R,BCR-ABL1 H396R,BCR-ABL1 HIS396ARG,BCR-ABL H396R"	FALSE
ABL1 BCR::ABL H396R	1004	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	B	Resistance	"This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Out of 33 patients with H396R mutations, 13, 17, and 30 achieved CCyR, MCyR, and CHR with dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations."	19779040	PubMed		"Mller et al., 2009, Blood"	"NCT00101660,NCT00103844,NCT00123474"	3	accepted	4413	Somatic	2023-01-09 21:46:42 UTC	https://civicdb.org/links/evidence_items/4413	https://civicdb.org/links/molecular_profiles/1004	FALSE	ABL1	25	BCR::ABL H396R		chr9	130874969	130874969	A	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.1187A>G,NP_005148.2:p.His396Arg,NC_000009.11:g.133750356A>G,ENST00000318560.5:c.1187A>G"	2023-01-27 17:07:48 UTC	CA16602558	376097	"RS121913454,BCR-ABL HIS415ARG,BCR-ABL HIS396ARG,BCR-ABL H415R,BCR-ABL1 H396R,BCR-ABL1 HIS396ARG,BCR-ABL H396R"	FALSE
ABL1 BCR::ABL H396R	1004	Chronic Myeloid Leukemia	8552		Axitinib		Predictive	Supports	D	Resistance	"In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed increased incorporation when harboring fusions with the H396R variant of ABL1 compared to fusions with wildtype ABL1 (IC50 of 1247nM vs. 823 nM), indicating resistance."	25686603	PubMed		"Pemovska et al., 2015, Nature"		2	accepted	4417	Somatic	2023-01-09 21:46:42 UTC	https://civicdb.org/links/evidence_items/4417	https://civicdb.org/links/molecular_profiles/1004	FALSE	ABL1	25	BCR::ABL H396R		chr9	130874969	130874969	A	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.1187A>G,NP_005148.2:p.His396Arg,NC_000009.11:g.133750356A>G,ENST00000318560.5:c.1187A>G"	2023-01-27 17:07:48 UTC	CA16602558	376097	"RS121913454,BCR-ABL HIS415ARG,BCR-ABL HIS396ARG,BCR-ABL H415R,BCR-ABL1 H396R,BCR-ABL1 HIS396ARG,BCR-ABL H396R"	FALSE
PIK3CA E542K	103	Colorectal Cancer	9256		Cetuximab		Predictive	Does Not Support	C	Resistance	"This was a retrospective study of 691 cetuximab treated patients with metastatic colorectal cancer. Of those, 7 patients harbored PIK3CA E542K (exon 10), were wt for BRAF, NRAS and PIK3CA, and had individual response data. Two patients had partial response, three had stable disease, and two progressed, resulting in a response rate of 2/7 and a clinical benefit rate of 5/7 according to author criteria. Treatments included cetuximab + irinotecan (n=5), cetuximab + FOLFIRI (n=1), and cetuximab monotherapy (n=1). Median PFS was 34 weeks (17-48 weeks), median OS was 46 weeks (27-91 weeks), and median number of previous chemotherapy lines was 2 (0-4). Median age was 59 years old (53-74), and there were 6 females and one male. Using these and data from the larger cohort, authors concluded that PIK3CA exon 10 (listed as exon 9 in source) mutations are associated with weak or no resistance to cetuximab."	20619739	PubMed		"De Roock et al., 2010, Lancet Oncol."		3	accepted	4424	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/4424	https://civicdb.org/links/molecular_profiles/103	FALSE	PIK3CA	5290	E542K		chr3	179218294	179218294	G	A	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.1624G>A,NP_006209.2:p.Glu542Lys,ENST00000263967.3:c.1624G>A,NC_000003.11:g.178936082G>A"	2023-01-27 17:02:37 UTC	CA333572	31944	"GLU542LYS,RS121913273"	FALSE
KRAS G12A	148	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	B	Resistance	"This was a retrospective study of 691 cetuximab treated patients with metastatic colorectal cancer. Of those, 22 patients harbored KRAS G12A, were BRAF, NRAS and PIK3CA wt, and had individual response data. Three patients had partial response, 12 had stable disease, and seven progressed. Treatments included cetuximab + irinotecan (n=18), cetuximab monotherapy (n=1), cetuximab + FOLFIRI (n=2), and cetuximab + oxaliplatin + 5FU (n=1). Median PFS was 18 weeks (1-34 weeks), median OS was 35 weeks (1-143 weeks), and median number of previous chemotherapy lines was 2 (0-5). Median age was 62 years old (22-77) and there were 11 males and 11 females. Using these data and data from the larger cohort, authors concluded that KRAS mutation was strongly associated with poor response to cetuximab and suggested that mutation status of KRAS is the most informative compared to BRAF, NRAS, and PIK3CA exon 20 for predicting cetuximab response."	20619739	PubMed		"De Roock et al., 2010, Lancet Oncol."		3	accepted	4429	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/4429	https://civicdb.org/links/molecular_profiles/148	FALSE	KRAS	3845	G12A	EGFR TKI Resistance	chr12	25245350	25245350	C	G	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.35G>C,NP_004976.2:p.Gly12Ala,NC_000012.11:g.25398284C>G,ENST00000256078.4:c.35G>C"	2023-01-27 17:02:57 UTC	CA135567	45122	"GLY12ALA,RS121913529"	FALSE
PIK3CA H1047L	1125	Colorectal Cancer	9256		"Cetuximab,Irinotecan"	Combination	Predictive	Supports	C	Resistance	"Two patients participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored PIK3CA H1047L (exon 21), were wildtype for NRAS, BRAF and PIK3CA, and had individual response data. Both were males treated with cetuximab + irinotecan as 3rd line therapy and experienced progressive disease. One patient was 73 years old with a PFS of 11 weeks and an OS of 31 weeks. The other patient was 61 years old with a PFS and OS of 4 weeks. Authors concluded from this information and data from larger cohort that PIK3CA exon 21 (listed as exon 20 in source) mutations predict poor response to cetuximab."	20619739	PubMed		"De Roock et al., 2010, Lancet Oncol."		3	accepted	4432	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/4432	https://civicdb.org/links/molecular_profiles/1125	FALSE	PIK3CA	5290	H1047L		chr3	179234297	179234297	A	T	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.3140A>T,NP_006209.2:p.His1047Leu,NC_000003.11:g.178952085A>T,ENST00000263967.3:c.3140A>T"	2023-01-27 17:08:14 UTC	CA123328	13653	"RS121913279,HIS1047LEU"	FALSE
ABL1 BCR::ABL	1	Acute Lymphoblastic Leukemia	9952		Dasatinib		Predictive	Supports	C	Sensitivity/Response	"Prior to dasatinib treatment, one imatinib-resistant patient with acute lymphoblastic leukemia had the BCR-ABL1 fusion with no secondary variants in at least ten bacterial clones generated using peripheral blood RNA. They had NEL (no evidence of leukemia) best hematologic and minor best cytogenetic responses to dasatinib."	16775234	PubMed		"Talpaz et al., 2006, N. Engl. J. Med."	NCT00064233	3	accepted	4436	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/4436	https://civicdb.org/links/molecular_profiles/1	FALSE	ABL1	25	BCR::ABL	ABL1 fusions in B-ALL	chr22	23180210	23290413			ENST00000305877.8	75	ENST00000318560.5	transcript_fusion	N/A	2023-01-09 21:52:04 UTC		N/A	"T(9;22)(Q34;Q11),BCR-ABL1,BCR-ABL"	FALSE
ABL1 BCR::ABL	1	Acute Lymphoblastic Leukemia	9952		Dasatinib		Predictive	Supports	C	Sensitivity/Response	"Prior to dasatinib treatment, one imatinib-resistant patient with acute lymphoblastic leukemia had the BCR-ABL1 fusion with no secondary variants in at least ten bacterial clones generated using peripheral blood RNA. They had NEL (no evidence of leukemia) best hematologic and minor best cytogenetic responses to dasatinib."	16775234	PubMed		"Talpaz et al., 2006, N. Engl. J. Med."	NCT00064233	3	accepted	4436	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/4436	https://civicdb.org/links/molecular_profiles/1	FALSE	ABL1	25	BCR::ABL	ABL1 fusions in B-ALL	chr9	130854064	130887676			ENST00000305877.8	75	ENST00000318560.5	transcript_fusion	N/A	2023-01-09 21:52:04 UTC		N/A	"T(9;22)(Q34;Q11),BCR-ABL1,BCR-ABL"	FALSE
ABL1 BCR::ABL F486S	1126	Chronic Myeloid Leukemia	8552		Axitinib		Predictive	Does Not Support	D	Resistance	"In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed similar incorporation when harboring fusions with the F486S variant of ABL1 compared to fusions with wildtype ABL1 (IC50 of 897nM vs. 823 nM), indicating baseline sensitivity."	25686603	PubMed		"Pemovska et al., 2015, Nature"		2	accepted	4438	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/4438	https://civicdb.org/links/molecular_profiles/1126	FALSE	ABL1	25	BCR::ABL F486S		chr9	130880101	130880101	T	C	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"ENST00000318560.5:c.1457T>C,NC_000009.11:g.133755488T>C,NM_005157.5:c.1457T>C,NP_005148.2:p.Phe486Ser"	2023-01-27 17:08:15 UTC	CA375251598	NONE FOUND	"BCR-ABL F505S,BCR-ABL PHE486SER,BCR-ABL1 PHE486SER,BCR-ABL1 F486S,BCR-ABL F486S"	FALSE
ABL1 BCR::ABL F486S	1126	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Supports	C	Resistance	"This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chronic phase CML and BCR-ABL fusions. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. Of patients with F486S, 0/1 had a CHR and 0/1 had a MCyR. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occuring."	22371878	PubMed		"Khoury et al., 2012, Blood"	NCT00261846	1	accepted	4440	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/4440	https://civicdb.org/links/molecular_profiles/1126	FALSE	ABL1	25	BCR::ABL F486S		chr9	130880101	130880101	T	C	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"ENST00000318560.5:c.1457T>C,NC_000009.11:g.133755488T>C,NM_005157.5:c.1457T>C,NP_005148.2:p.Phe486Ser"	2023-01-27 17:08:15 UTC	CA375251598	NONE FOUND	"BCR-ABL F505S,BCR-ABL PHE486SER,BCR-ABL1 PHE486SER,BCR-ABL1 F486S,BCR-ABL F486S"	FALSE
ABL1 BCR::ABL E255V	1147	Chronic Myeloid Leukemia	8552		Axitinib		Predictive	Supports	D	Resistance	"In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed increased incorporation when harboring fusions with the E255V variant of ABL1 compared to fusions with wildtype ABL1 (IC50 of 1350nM vs. 823 nM), indicating resistance."	25686603	PubMed		"Pemovska et al., 2015, Nature"		2	accepted	4441	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/4441	https://civicdb.org/links/molecular_profiles/1147	FALSE	ABL1	25	BCR::ABL E255V		chr9	130862977	130862977	A	T	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.764A>T,NP_005148.2:p.Glu255Val,NC_000009.11:g.133738364A>T,ENST00000318560.5:c.764A>T"	2023-01-27 17:08:31 UTC	CA16602552	376091	"RS121913449,BCR-ABL E274V,BCR-ABL GLU255VAL,BCR-ABL1 E274V,BCR-ABL1 GLU255VAL,BCR-ABL E255V"	FALSE
ABL1 BCR::ABL E255V	1147	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Does Not Support	C	Resistance	"In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with E255V evaluated, 1/1 had a complete hematologic response and 1/1 had a major cytogenetic response."	21865346	PubMed		"Cortes et al., 2011, Blood"	NCT00261846	2	accepted	4443	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/4443	https://civicdb.org/links/molecular_profiles/1147	FALSE	ABL1	25	BCR::ABL E255V		chr9	130862977	130862977	A	T	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.764A>T,NP_005148.2:p.Glu255Val,NC_000009.11:g.133738364A>T,ENST00000318560.5:c.764A>T"	2023-01-27 17:08:31 UTC	CA16602552	376091	"RS121913449,BCR-ABL E274V,BCR-ABL GLU255VAL,BCR-ABL1 E274V,BCR-ABL1 GLU255VAL,BCR-ABL E255V"	FALSE
ABL1 BCR::ABL E255V	1147	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Supports	C	Reduced Sensitivity	"This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chronic phase CML and BCR-ABL fusions. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. Of patients with E255V, 1/1 had a CHR and 0/1 had a MCyR. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occuring."	22371878	PubMed		"Khoury et al., 2012, Blood"	NCT00261846	1	accepted	4444	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/4444	https://civicdb.org/links/molecular_profiles/1147	FALSE	ABL1	25	BCR::ABL E255V		chr9	130862977	130862977	A	T	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.764A>T,NP_005148.2:p.Glu255Val,NC_000009.11:g.133738364A>T,ENST00000318560.5:c.764A>T"	2023-01-27 17:08:31 UTC	CA16602552	376091	"RS121913449,BCR-ABL E274V,BCR-ABL GLU255VAL,BCR-ABL1 E274V,BCR-ABL1 GLU255VAL,BCR-ABL E255V"	FALSE
ABL1 BCR::ABL E255V	1147	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	B	Resistance	"This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Out of 11 patients with E255V mutations, 4, 4, and 9 achieved a CCyR, MCyR, and CHR with dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations."	19779040	PubMed		"Mller et al., 2009, Blood"	"NCT00101660,NCT00103844,NCT00123474"	3	accepted	4447	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/4447	https://civicdb.org/links/molecular_profiles/1147	FALSE	ABL1	25	BCR::ABL E255V		chr9	130862977	130862977	A	T	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.764A>T,NP_005148.2:p.Glu255Val,NC_000009.11:g.133738364A>T,ENST00000318560.5:c.764A>T"	2023-01-27 17:08:31 UTC	CA16602552	376091	"RS121913449,BCR-ABL E274V,BCR-ABL GLU255VAL,BCR-ABL1 E274V,BCR-ABL1 GLU255VAL,BCR-ABL E255V"	FALSE
ABL1 BCR::ABL E255V	1147	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	C	Resistance	"Three chronic myeloid leukemia patients had the BCR-ABL1 fusion with the E255V secondary variant in one or more bacterial clones generated using peripheral blood RNA. They had no best cytogenetic responses but had complete (n = 2) or minor best hematologic responses to dasatinib which were comparable to responses in patients with unmutated BCR-ABL1. The first patient, in chronic phase, had E255V, E255V/Q447R, E255V/T345A, and E255V/T345A/H396R variants in 6/10, 2/10, 1/10, and 1/10 clones, respectively. The second patient, in chronic phase, had E255V and E255K variants in 10/11 and 1/11 clones, respectively. The third patient, in myeloid blast crisis, had E255V and E292V variants in 10/12 and 2/12 clones, respectively."	16775234	PubMed		"Talpaz et al., 2006, N. Engl. J. Med."	NCT00064233	3	accepted	4448	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/4448	https://civicdb.org/links/molecular_profiles/1147	FALSE	ABL1	25	BCR::ABL E255V		chr9	130862977	130862977	A	T	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.764A>T,NP_005148.2:p.Glu255Val,NC_000009.11:g.133738364A>T,ENST00000318560.5:c.764A>T"	2023-01-27 17:08:31 UTC	CA16602552	376091	"RS121913449,BCR-ABL E274V,BCR-ABL GLU255VAL,BCR-ABL1 E274V,BCR-ABL1 GLU255VAL,BCR-ABL E255V"	FALSE
KIT P551_E554delPMYE	1405	Gastrointestinal Stromal Tumor	9253		"Regorafenib,Sunitinib,Imatinib"	Substitutes	Predictive	Does Not Support	D	Sensitivity/Response	"In an in vitro study, an IL3 independent Ba/F3 cell line expressing KIT P551_E554delPMYE primary activating mutation demonstrated insensitivity to regorafenib (IC50: 141nmol/L), imatinib (IC50: 90nmol/L), and sunitinib (IC50: 42nmol/L) treatments. In comparison, sensitizing KIT mutation del550-557 showed IC50 22, 13 and 5 nmol/L for these drugs respectively. IC50 was determined by assessing cell viability."	25239608	PubMed		"Garner et al., 2014, Clin. Cancer Res."		3	accepted	4455	Somatic	2023-01-09 21:46:45 UTC	https://civicdb.org/links/evidence_items/4455	https://civicdb.org/links/molecular_profiles/1405	FALSE	KIT	3815	P551_E554delPMYE		chr4	54727419	54727430						inframe_deletion		2023-01-09 21:52:13 UTC				FALSE
KIT V559D	942	Gastrointestinal Stromal Tumor	9253		"Regorafenib,Ponatinib,Imatinib"	Substitutes	Predictive	Supports	D	Sensitivity/Response	"In an in vitro kinase study, a KIT V559D primary activating mutant kinase demonstrated sensitivity to imatinib (IC50: 36nmol/L vs. 640nmol/L), regorafenib (IC50: 57nmol/L vs. 533nmol/L), and ponatinib (IC50: 0.8nmol/L vs. 6nmol/L) treatments compared to the wild-type KIT. IC50 was determined by assessing kinase activity."	25239608	PubMed		"Garner et al., 2014, Clin. Cancer Res."		2	accepted	4459	Somatic	2023-01-09 21:46:40 UTC	https://civicdb.org/links/evidence_items/4459	https://civicdb.org/links/molecular_profiles/942	FALSE	KIT	3815	V559D		chr4	54727444	54727444	T	A	ENST00000288135.5	75		missense_variant	"NM_000222.2:c.1676T>A,NP_000213.1:p.Val559Asp,NC_000004.11:g.55593610T>A,ENST00000288135.5:c.1676T>A"	2023-01-27 17:07:10 UTC	CA123522	13856	"RS121913517,VAL559ASP"	FALSE
PIK3CA S158L	1407	Colorectal Cancer	9256		"Cetuximab,Irinotecan"	Combination	Predictive	Supports	C	Resistance	"One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored PIK3CA S158L, was wildtype for KRAS, BRAF and NRAS, and had individual response data. This patient was was a 53 year old male treated with cetuximab + irinotecan as 3rd line therapy who experienced progressive disease (PFS: 1 week; OS: 3 weeks)."	20619739	PubMed		"De Roock et al., 2010, Lancet Oncol."		3	accepted	4463	Somatic	2023-01-09 21:46:45 UTC	https://civicdb.org/links/evidence_items/4463	https://civicdb.org/links/molecular_profiles/1407	FALSE	PIK3CA	5290	S158L		chr3	179199810	179199810	C	T	ENST00000263967.3	75		missense_variant	"ENST00000263967.3:c.473C>T,NC_000003.11:g.178917598C>T,NM_006218.2:c.473C>T,NP_006209.2:p.Ser158Leu"	2023-01-27 17:09:54 UTC	CA355274155	NONE FOUND	SER158LEU	FALSE
PIK3CA E81K	1408	Colorectal Cancer	9256		"Fluorouracil,Cetuximab,Oxaliplatin"	Combination	Predictive	Does Not Support	C	Resistance	"Two patients participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored PIK3CA E81K, were wildtype for NRAS, BRAF and PIK3CA, and had individual response data. Both were treated with cetuximab + oxaliplatin + 5FU as 2nd line therapy and experienced stable disease, resulting in a response rate of 0/2 and a clinical benefit rate of 2/2 according to author criteria. One patient was a 57 year old female with a PFS of 24 weeks and an OS of 100 weeks. The other patient was a 60 year old male with a PFS of 23 weeks."	20619739	PubMed		"De Roock et al., 2010, Lancet Oncol."		2	accepted	4464	Somatic	2023-01-09 21:46:45 UTC	https://civicdb.org/links/evidence_items/4464	https://civicdb.org/links/molecular_profiles/1408	FALSE	PIK3CA	5290	E81K		chr3	179199066	179199066	G	A	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.241G>A,NP_006209.2:p.Glu81Lys,NC_000003.11:g.178916854G>A,ENST00000263967.3:c.241G>A"	2023-01-27 17:09:55 UTC	CA16602912	376478	"GLU81LYS,RS1057519929"	FALSE
PIK3CA R93W	1152	Colorectal Cancer	9256		"Oxaliplatin,Cetuximab,Fluorouracil"	Combination	Predictive	Supports	C	Resistance	"One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored PIK3CA R93W, was wildtype for KRAS, BRAF and NRAS, and had individual response data. This patient was was a 56 year old male treated with cetuximab + oxaliplatin + 5FU as 2nd line therapy who experienced progressive disease (PFS: 8 weeks)."	20619739	PubMed		"De Roock et al., 2010, Lancet Oncol."		2	accepted	4467	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/4467	https://civicdb.org/links/molecular_profiles/1152	FALSE	PIK3CA	5290	R93W		chr3	179199102	179199102	C	T	ENST00000263967.3	75		missense_variant	"ENST00000263967.3:c.277C>T,NC_000003.11:g.178916890C>T,NM_006218.2:c.277C>T,NP_006209.2:p.Arg93Trp"	2023-01-27 17:08:33 UTC	CA355272477	NONE FOUND	ARG93TRP	FALSE
EGFR R776C	1155	Lung Non-small Cell Carcinoma	3908		Erlotinib		Predictive	Supports	D	Sensitivity/Response	"In an in vitro study, a Ba/F3 cell line expressing EGFR R776C demonstrated increased sensitivity to erlotinib treatment comparable to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). Sensitivity was determined by assessing cell proliferation, the IC50 of erlotinib for EGFR V742A and EGFR L858R expressing cells were 47 nmol/L and 6 nmol/L, respectively."	19147750	PubMed		"Kancha et al., 2009, Clin. Cancer Res."			accepted	4468	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/4468	https://civicdb.org/links/molecular_profiles/1155	FALSE	EGFR	1956	R776C		chr7	55181335	55181335	C	T	ENST00000275493.2	75		missense_variant	ENST00000275493.2:c.2326C>T	2023-01-27 17:08:34 UTC	CA367578749	NONE FOUND	"R723C,R731C"	FALSE
BRAF D594G	607	Colorectal Cancer	9256		"Cetuximab,Irinotecan"	Combination	Predictive	Supports	C	Resistance	"In a retrospective study of 53, KRAS exon 2 wild-type, metastatic colorectal cancer patients, patients harboring BRAF G466A (n=1), G469A (n=2), D594G (n=1), or V600E (n=2) mutations were reported to be non-responders to cetuximab in combination with irinotecan, (BRAF mutation positive: responders vs. non-responders = 0 vs. 6; BRAF wild-type: responders vs. non-responders 30 vs. 17; P=0.004), as compared to patients with wild-type BRAF."	26989027	PubMed		"Hsu et al., 2016, Oncotarget"		3	accepted	4472	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/4472	https://civicdb.org/links/molecular_profiles/607	FALSE	BRAF	673	D594G		chr7	140753354	140753354	T	C	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1781A>G,NP_004324.2:p.Asp594Gly,NC_000007.13:g.140453154T>C,ENST00000288602.6:c.1781A>G"	2023-01-27 17:04:35 UTC	CA123657	13972	"ASP594GLY,RS121913338"	FALSE
ABL1 L298V	1414	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Does Not Support	C	Resistance	"In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with L298V evaluated, 1/1 had a complete hematologic response and 0/1 had a major cytogenetic response."	21865346	PubMed		"Cortes et al., 2011, Blood"	NCT00261846	1	accepted	4475	Somatic	2023-01-09 21:46:45 UTC	https://civicdb.org/links/evidence_items/4475	https://civicdb.org/links/molecular_profiles/1414	FALSE	ABL1	25	L298V		chr9	130872198	130872198	C	G	ENST00000318560.5	75		missense_variant	"ENST00000318560.5:c.892C>G,NC_000009.11:g.133747585C>G,NM_005157.5:c.892C>G,NP_005148.2:p.Leu298Val"	2023-01-27 17:09:57 UTC	CA375249299	NONE FOUND	"L317V,LEU298VAL"	FALSE
ABL1 BCR::ABL F359C	1158	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Does Not Support	C	Resistance	"This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chronic phase CML and BCR-ABL fusions. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. Of patients with F359C, 2/2 had a CHR and 1/2 had a MCyR. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occuring."	22371878	PubMed		"Khoury et al., 2012, Blood"	NCT00261846	1	accepted	4480	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/4480	https://civicdb.org/links/molecular_profiles/1158	FALSE	ABL1	25	BCR::ABL F359C		chr9	130873028	130873028	T	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.1076T>G,NP_005148.2:p.Phe359Cys,NC_000009.11:g.133748415T>G,ENST00000318560.5:c.1076T>G"	2023-01-27 17:08:36 UTC	CA16602582	376124	"F378C,RS1057519775,BCR-ABL PHE359CYS,BCR-ABL1 F359C,BCR-ABL1 PHE359CYS,BCR-ABL F359C"	FALSE
ABL1 BCR::ABL F359C	1158	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	C	Resistance	"In this phase II multinational study, patients with accelerated phase CML and BCR-ABL fusions were treated with dasatinib monotherapy. Response rate among 60 imatinib-resistant patients with BCR-ABL mutations did not differ from the rate of the total population of 100 imatinib-resistant or -intolerant patients. 44 (73%) of 60 BCR-ABL mutant patients achieved major hematologic responses (MaHRs) and 18 (30%) of 60 achieved major cytogenetic responses (MCyRs). Of patients with F359C, 2/2 had MaHRs and 2/2 had MCyRs which were comparable to response rates among wild type patients."	17264298	PubMed		"Guilhot et al., 2007, Blood"		2	accepted	4481	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/4481	https://civicdb.org/links/molecular_profiles/1158	FALSE	ABL1	25	BCR::ABL F359C		chr9	130873028	130873028	T	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.1076T>G,NP_005148.2:p.Phe359Cys,NC_000009.11:g.133748415T>G,ENST00000318560.5:c.1076T>G"	2023-01-27 17:08:36 UTC	CA16602582	376124	"F378C,RS1057519775,BCR-ABL PHE359CYS,BCR-ABL1 F359C,BCR-ABL1 PHE359CYS,BCR-ABL F359C"	FALSE
ABL1 BCR::ABL F359C	1158	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	C	Resistance	"This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Out of 5 patients with F359C mutations, 3, 3, and 4 achieved CCyR, MCyR, and CHR with dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations."	19779040	PubMed		"Mller et al., 2009, Blood"	"NCT00101660,NCT00103844,NCT00123474"	3	accepted	4482	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/4482	https://civicdb.org/links/molecular_profiles/1158	FALSE	ABL1	25	BCR::ABL F359C		chr9	130873028	130873028	T	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.1076T>G,NP_005148.2:p.Phe359Cys,NC_000009.11:g.133748415T>G,ENST00000318560.5:c.1076T>G"	2023-01-27 17:08:36 UTC	CA16602582	376124	"F378C,RS1057519775,BCR-ABL PHE359CYS,BCR-ABL1 F359C,BCR-ABL1 PHE359CYS,BCR-ABL F359C"	FALSE
ABL1 BCR::ABL F359C	1158	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	C	Resistance	"Prior to dasatinib treatment, one imatinib-resistant patient with chronic myeloid leukemia in chronic phase had the BCR-ABL1 fusion with G250E and F359C variants in 3/10 and 5/10 clones, respectively. Clones were generated using peripheral blood RNA. The patient had complete best cytogenetic and complete best hematologic responses to dasatinib which were improved compared to responses in patients with unmutated BCR-ABL1."	16775234	PubMed		"Talpaz et al., 2006, N. Engl. J. Med."	NCT00064233	4	accepted	4483	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/4483	https://civicdb.org/links/molecular_profiles/1158	FALSE	ABL1	25	BCR::ABL F359C		chr9	130873028	130873028	T	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.1076T>G,NP_005148.2:p.Phe359Cys,NC_000009.11:g.133748415T>G,ENST00000318560.5:c.1076T>G"	2023-01-27 17:08:36 UTC	CA16602582	376124	"F378C,RS1057519775,BCR-ABL PHE359CYS,BCR-ABL1 F359C,BCR-ABL1 PHE359CYS,BCR-ABL F359C"	FALSE
ABL1 BCR::ABL E453Q	1417	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Does Not Support	C	Resistance	"In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with E453Q evaluated, 1/1 had a complete hematologic response and 1/1 had a major cytogenetic response."	21865346	PubMed		"Cortes et al., 2011, Blood"	NCT00261846	2	accepted	4486	Somatic	2023-01-09 21:46:45 UTC	https://civicdb.org/links/evidence_items/4486	https://civicdb.org/links/molecular_profiles/1417	FALSE	ABL1	25	BCR::ABL E453Q		chr9	130878501	130878501	G	C	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"ENST00000318560.5:c.1357G>C,NC_000009.11:g.133753888G>C,NM_005157.5:c.1357G>C,NP_005148.2:p.Glu453Gln"	2023-01-27 17:10:00 UTC	CA375251170	NONE FOUND	"E472Q,BCR-ABL GLU453GLN,BCR-ABL1 E453Q,BCR-ABL1 GLU453GLN,BCR-ABL E453Q"	FALSE
ARID1A Q456*	1418	Ovarian Clear Cell Carcinoma	50934		Dasatinib		Predictive	Supports	D	Sensitivity/Response	"In an in vitro study, a HCT116 cell line expressing ARID1A Q456* mutation demonstrated increased sensitivity to dasatinib treatment, compared to HCT116 cells expressing wild-type ARID1A. Sensitivity was determined by assessing cell survival."	27364904	PubMed		"Miller et al., 2016, Mol. Cancer Ther."			accepted	4487	Somatic	2023-01-09 21:46:45 UTC	https://civicdb.org/links/evidence_items/4487	https://civicdb.org/links/molecular_profiles/1418	TRUE	ARID1A	8289	Q456*		chr1	26731167	26731167	C	T	ENST00000324856.7	75		stop_gained	ENST00000324856.7:c.1366C>T	2023-01-27 17:10:01 UTC	CA339267901	NONE FOUND	Q73X	FALSE
BRAF V600D	11	Melanoma	1909		Vemurafenib		Predictive	Supports	D	Sensitivity/Response	"In an in vitro study, WM2664, a BRAF V600D expressing cell line, demonstrated improved sensitivity to vemurafenib treatment, compared to BRAF wild-type expressing cells. Sensitivity was determined by assessing cell proliferation (WM2664, GI50: 1.5uM; vs. BRAF expressing cells (n=9) GI50: 10-41uM)."	18287029	PubMed		"Tsai et al., 2008, Proc. Natl. Acad. Sci. U.S.A."		3	accepted	4488	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/4488	https://civicdb.org/links/molecular_profiles/11	FALSE	BRAF	673	V600D	Other BRAF V600's	chr7	140753335	140753336	CA	AT	ENST00000288602.6	75		missense_variant	"NC_000007.13:g.140453135_140453136delinsAT,NM_004333.4:c.1799_1800delTGinsAT,NP_004324.2:p.Val600Asp,ENST00000288602.6:c.1799_1800delTGinsAT"	2023-01-27 17:02:01 UTC	CA16602419	375939	"RS121913377,VAL600ASP"	FALSE
BRAF V600D	11	Melanoma	1909		Vemurafenib		Predictive	Supports	D	Sensitivity/Response	"In an in vitro study, the WM2664 and WM239A cell lines expressing BRAF V600D were associated with increased sensitivity to vemurafenib treatment, as compared to cell lines expressing BRAF wild-type. Sensitivity was determined by proliferation assay. In addition, vemurafenib treatment strongly inhibited MEK and ERK phosphorylation in WM2664 cells."	20551065	PubMed		"Yang et al., 2010, Cancer Res."		4	accepted	4489	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/4489	https://civicdb.org/links/molecular_profiles/11	FALSE	BRAF	673	V600D	Other BRAF V600's	chr7	140753335	140753336	CA	AT	ENST00000288602.6	75		missense_variant	"NC_000007.13:g.140453135_140453136delinsAT,NM_004333.4:c.1799_1800delTGinsAT,NP_004324.2:p.Val600Asp,ENST00000288602.6:c.1799_1800delTGinsAT"	2023-01-27 17:02:01 UTC	CA16602419	375939	"RS121913377,VAL600ASP"	FALSE
EGFR H773_V774insNPH	1421	Lung Adenocarcinoma	3910		Erlotinib		Predictive	Supports	C	Resistance	"A 61 year old male never smoker with EGFR H773_V774insNPH mutant lung adenocarcinoma was treated with fourth line erlotinib and had progressive disease as best response, progression free survival of 1.6 months, and overall survival of 4.4 months."	24353160	PubMed		"Yasuda et al., 2013, Sci Transl Med"		3	accepted	4493	Somatic	2023-01-09 21:46:45 UTC	https://civicdb.org/links/evidence_items/4493	https://civicdb.org/links/molecular_profiles/1421	FALSE	EGFR	1956	H773_V774insNPH		chr7	55181319	55181320		AACCCCCAC	ENST00000275493.2			inframe_insertion		2023-01-27 17:10:02 UTC	CA180983	177911		FALSE
EGFR D770_N771insGL	1422	Lung Adenocarcinoma	3910		Erlotinib		Predictive	Supports	C	Resistance	"2 patients with EGFR D770_N771insGL mutant lung adenocarcinoma were treated with first line erlotinib.  A 45 year old male never smoker had progressive disease as best response with +24% change to target lesions, progression free survival of 3.8 months, and still alive at study end after 39.3 months.   A 79 year old female never smoker had progressive disease as best response with +13% change to target lesions, progression free survival of 6 months and overall survival of 14 months."	24353160	PubMed		"Yasuda et al., 2013, Sci Transl Med"		4	accepted	4494	Somatic	2023-01-09 21:46:45 UTC	https://civicdb.org/links/evidence_items/4494	https://civicdb.org/links/molecular_profiles/1422	FALSE	EGFR	1956	D770_N771insGL		chr7	55181319	55181320		GGGTTA	ENST00000275493.2			inframe_insertion	"NC_000007.13:g.55249012_55249013insGGGTTA,NM_005228.3:c.2310_2311insGGGTTA,NP_005219.2:p.Asp770_Asn771insGlyLeu"	2023-01-27 17:10:03 UTC	CA645561585	45257	RS397517111	FALSE
EGFR A864T	1161	Lung Non-small Cell Carcinoma	3908		Erlotinib		Predictive	Supports	D	Sensitivity/Response	"In an in vitro study, a Ba/F3 cell line expressing EGFR A864T demonstrated increased sensitivity to erlotinib treatment comparable to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). Sensitivity was determined by assessing cell proliferation, the IC50 of erlotinib for EGFR A864T and EGFR L858R expressing cells were 49 nmol/L and 6 nmol/L, respectively."	19147750	PubMed		"Kancha et al., 2009, Clin. Cancer Res."			accepted	4495	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/4495	https://civicdb.org/links/molecular_profiles/1161	FALSE	EGFR	1956	A864T		chr7	55191839	55191839	G	A	ENST00000275493.2	75		missense_variant	"ENST00000275493.2:c.2590G>A,NC_000007.13:g.55259532G>A,NM_005228.3:c.2590G>A,NP_005219.2:p.Ala864Thr"	2023-01-27 17:08:38 UTC	CA367580302	NONE FOUND	"A811T,A819T,ALA864THR,RS1171287261"	FALSE
EGFR N826S	1162	Lung Non-small Cell Carcinoma	3908		Erlotinib		Predictive	Supports	D	Resistance	"In an in vitro study, a Ba/F3 cell line expressing EGFR N826S demonstrated reduced sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). Sensitivity was determined by assessing cell proliferation, the IC50 of erlotinib for EGFR N826S and EGFR L858R expressing cells were 505 nmol/L and 6 nmol/L, respectively."	19147750	PubMed		"Kancha et al., 2009, Clin. Cancer Res."			accepted	4496	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/4496	https://civicdb.org/links/molecular_profiles/1162	FALSE	EGFR	1956	N826S		chr7	55191726	55191726	A	G	ENST00000275493.2	75		missense_variant	ENST00000275493.2:c.2477A>G	2023-01-27 17:08:39 UTC	CA367580077	NONE FOUND	"N773S,N781S"	FALSE
EGFR A763_Y764insFQEA	1423	Lung Non-small Cell Carcinoma	3908		Erlotinib		Predictive	Supports	D	Sensitivity/Response	"In an in vitro study, Ba/F3 and BID007 cell lines expressing EGFR A763_Y764insFQEA demonstrated increased sensitivity to erlotinib treatment (IC50=0.048M and 0.082M, respectively), comparable to Ba/F3 and NCI-H3255 cells expressing EGFR L858R (a known sensitizing mutation to EGFR tyrosine kinase inhibitors; IC50=0.006M and 0.068M, respectively). Sensitivity was determined by assessing cell proliferation, EGFR, AKT and ERK phosphorylation, levels of BIM (a marker of EGFR TKI-induced cell killing) and cell viability."	24353160	PubMed		"Yasuda et al., 2013, Sci Transl Med"			accepted	4497	Somatic	2023-01-09 21:46:45 UTC	https://civicdb.org/links/evidence_items/4497	https://civicdb.org/links/molecular_profiles/1423	FALSE	EGFR	1956	A763_Y764insFQEA		chr7	55181299	55181300		TCCAGGAAGCCT	ENST00000275493.2			inframe_insertion	"NP_001333827.1:p.Ala763_Tyr764insPheGlnGluAla,NC_000007.13:g.55248992_55248993insTCCAGGAAGCCT,NM_001346898.1:c.2290_2291insTCCAGGAAGCCT"	2023-01-27 17:10:04 UTC	CA135833	NONE FOUND	RS397517106	FALSE
AKT1 Q79K	169	Melanoma	1909		Vemurafenib		Predictive	Supports	D	Resistance	"In an in vitro study, a M229 cell line endogenously expressing BRAF V600E mutation (a known vemurafenib sensitizing mutation) and overexpressing AKT1 Q79K mutation was associated with resistance to vemurafenib treatment, as compared to cells expressing BRAF V600E mutation and wildtype AKT1. Resistance was determined by assessing cell survival."	24265155	PubMed		"Shi et al., 2014, Cancer Discov"		2	accepted	4498	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/4498	https://civicdb.org/links/molecular_profiles/169	FALSE	AKT1	207	Q79K		chr14	104776711	104776711	G	T	ENST00000407796.2	75		missense_variant	"NC_000014.8:g.105243048G>T,NM_001014432.1:c.235C>A,NP_001014432.1:p.Gln79Lys,ENST00000407796.2:c.235C>A"	2023-01-27 17:02:59 UTC	CA16602625	376168	"Q17K,GLN79LYS,RS1057519804"	FALSE
EGFR VIII	308	High Grade Glioma	3070		Erlotinib		Predictive	Supports	D	Sensitivity/Response	"In an in vitro study, a Ba/F3 cell line expressing EGFR vIII demonstrated increased sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing EGFR wild-type. Variant function was assessed by EGFR auto-phosphorylation. Sensitivity was assessed by cell viability assay using stable transfection of each variant and increasing concentrations of erlotinib (0?0 uM)."	17177598	PubMed		"Lee et al., 2006, PLoS Med."		3	accepted	4500	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/4500	https://civicdb.org/links/molecular_profiles/308	FALSE	EGFR	1956	VIII		chr7	55019365	55155830			ENST00000275493.2	75		disruptive_inframe_deletion	"NM_005228.3:c.89_881del,NP_005219.2:p.Val30_Arg297delinsGly,NC_000007.13:g.55209979_55221845del"	2023-01-09 21:52:06 UTC				FALSE
KIT T670I	1241	Gastrointestinal Stromal Tumor	9253		Regorafenib		Predictive	Supports	D	Resistance	"A preclinical study tested the effects of a tyrosine kinase inhibitor (TKI) on Ba/F3 cell lines with representative primary regorafenib-sensitizing mutation del 557-558, which induced IL-3 independent growth, and secondary mutation T670I. The cells were tested for Regorafenib resistance. Ba/F3 cells with del 557-558/T670I mutations (IC50 = 132 +- 25 nM) did show resistance towards  Regorafenib  compared to Ba/F3 cells with del 557-558 alone (IC50 = 30 +- 14 nM). In addition, Ba/F3 cells were mutagenized with N-ethyl-N-nitrosourea and incubated with varying concentrations of Regorafenib. In Regorafenib incubated cells, T670I mutations were seen in approximately 10% of the resistant cell populations. The results suggest that T670I does induce regorafenib resistance in del 557-558/T670I cells."	25239608	PubMed		"Garner et al., 2014, Clin. Cancer Res."		4	accepted	4510	Somatic	2023-01-09 21:46:44 UTC	https://civicdb.org/links/evidence_items/4510	https://civicdb.org/links/molecular_profiles/1241	FALSE	KIT	3815	T670I		chr4	54729353	54729353	C	T	ENST00000288135.5	75		missense_variant	"NM_000222.2:c.2009C>T,NP_000213.1:p.Thr670Ile,NC_000004.11:g.55595519C>T,ENST00000288135.5:c.2009C>T"	2023-01-27 17:09:09 UTC	CA16602525	376058	"THR670ILE,RS121913516"	FALSE
AKT3 E17K	1201	Melanoma	1909		Vemurafenib		Predictive	Supports	D	Resistance	"An in vitro study of M229 (a human melanoma cell line) endogenously expressing wildtype AKT3 and BRAF V600E (a known BRAF inhibitor sensitizing mutation) found that cells virally induced to stably over-express AKT3 E17K were significantly more resistant to BRAF inhibition via vemurafenib than cells transduced with empty vectors (40% vs 20% survival, p = .0033)."	24265155	PubMed		"Shi et al., 2014, Cancer Discov"		3	accepted	4521	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/4521	https://civicdb.org/links/molecular_profiles/1201	FALSE	AKT3	10000	E17K		chr1	243695714	243695714	C	T	ENST00000366539.1	75		missense_variant	"NM_001206729.1:c.49G>A,NP_001193658.1:p.Glu17Lys,NC_000001.10:g.243859016C>T,ENST00000366539.1:c.49G>A"	2023-01-27 17:08:44 UTC	CA130584	39816	"RS397514606,GLU17LYS"	FALSE
ABL1 BCR::ABL L384M	1204	Chronic Myeloid Leukemia	8552		Axitinib		Predictive	Does Not Support	D	Resistance	"In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed similar incorporation when harboring fusions with the L384M variant of ABL1 compared to fusions with wildtype ABL1 (IC50 of 916nM vs. 823 nM), indicating baseline sensitivity."	25686603	PubMed		"Pemovska et al., 2015, Nature"		2	accepted	4525	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/4525	https://civicdb.org/links/molecular_profiles/1204	FALSE	ABL1	25	BCR::ABL L384M		chr9	130874932	130874932	C	A	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"ENST00000318560.5:c.1150C>A,NC_000009.11:g.133750319C>A,NM_005157.5:c.1150C>A,NP_005148.2:p.Leu384Met"	2023-01-27 17:08:45 UTC	CA375249885	NONE FOUND	"L403M,LEU403MET,LEU384MET,BCR-ABL1 L384M,BCR-ABL1 LEU384MET,BCR-ABL L384M"	FALSE
ABL1 BCR::ABL L384M	1204	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Supports	C	Resistance	"This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, a majority of patients with and without ABL1 mutation had comparable complete hematologic response, major cytogenetic response, complete cytogenetic response (CCyR), and major molecular response. However, out of 2 patients with the L384M mutation, 0 achieved CCyR with dasatinib monotherapy. Analyses by variant included patients with multiple kinase domain mutations."	19779040	PubMed		"Mller et al., 2009, Blood"	"NCT00101660,NCT00103844,NCT00123474"	1	accepted	4527	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/4527	https://civicdb.org/links/molecular_profiles/1204	FALSE	ABL1	25	BCR::ABL L384M		chr9	130874932	130874932	C	A	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"ENST00000318560.5:c.1150C>A,NC_000009.11:g.133750319C>A,NM_005157.5:c.1150C>A,NP_005148.2:p.Leu384Met"	2023-01-27 17:08:45 UTC	CA375249885	NONE FOUND	"L403M,LEU403MET,LEU384MET,BCR-ABL1 L384M,BCR-ABL1 LEU384MET,BCR-ABL L384M"	FALSE
ABL1 BCR::ABL F359I	1431	Chronic Myeloid Leukemia	8552		Axitinib		Predictive	Does Not Support	D	Resistance	"In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed similar incorporation when harboring fusions with the F359I variant of ABL1 compared to fusions with wildtype ABL1 (IC50 of 975nM vs. 823 nM), indicating that the variant does not induce resistance."	25686603	PubMed		"Pemovska et al., 2015, Nature"		2	accepted	4529	Somatic	2023-01-09 21:46:45 UTC	https://civicdb.org/links/evidence_items/4529	https://civicdb.org/links/molecular_profiles/1431	FALSE	ABL1	25	BCR::ABL F359I		chr9	130873027	130873027	T	A	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.1075T>A,NP_005148.2:p.Phe359Ile,NC_000009.11:g.133748414T>A,ENST00000318560.5:c.1075T>A"	2023-01-27 17:10:08 UTC	CA16602580	376122	"RS121913452,F378I,BCR-ABL PHE359ILE,BCR-ABL1 F359I,BCR-ABL1 PHE359ILE,BCR-ABL F359I"	FALSE
ABL1 BCR::ABL F359I	1431	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Does Not Support	C	Resistance	"In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with F359I evaluated, 1/1 had a complete hematologic response and 1/1 had a major cytogenetic response."	21865346	PubMed		"Cortes et al., 2011, Blood"	NCT00261846	2	accepted	4530	Somatic	2023-01-09 21:46:45 UTC	https://civicdb.org/links/evidence_items/4530	https://civicdb.org/links/molecular_profiles/1431	FALSE	ABL1	25	BCR::ABL F359I		chr9	130873027	130873027	T	A	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.1075T>A,NP_005148.2:p.Phe359Ile,NC_000009.11:g.133748414T>A,ENST00000318560.5:c.1075T>A"	2023-01-27 17:10:08 UTC	CA16602580	376122	"RS121913452,F378I,BCR-ABL PHE359ILE,BCR-ABL1 F359I,BCR-ABL1 PHE359ILE,BCR-ABL F359I"	FALSE
ABL1 BCR::ABL F359I	1431	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Does Not Support	C	Resistance	"This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chronic phase CML and BCR-ABL fusions. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. Of patients with F359I evaluated, 2/2 had CHR and 2/2 had MCyR. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were occurring."	22371878	PubMed		"Khoury et al., 2012, Blood"	NCT00261846	2	accepted	4531	Somatic	2023-01-09 21:46:45 UTC	https://civicdb.org/links/evidence_items/4531	https://civicdb.org/links/molecular_profiles/1431	FALSE	ABL1	25	BCR::ABL F359I		chr9	130873027	130873027	T	A	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.1075T>A,NP_005148.2:p.Phe359Ile,NC_000009.11:g.133748414T>A,ENST00000318560.5:c.1075T>A"	2023-01-27 17:10:08 UTC	CA16602580	376122	"RS121913452,F378I,BCR-ABL PHE359ILE,BCR-ABL1 F359I,BCR-ABL1 PHE359ILE,BCR-ABL F359I"	FALSE
ABL1 BCR::ABL F359I	1431	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	B	Resistance	"This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Out of 12 patients with F359I mutations, 7, 10, and 12 achieved CCyR, MCyR, and CHR with dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations."	19779040	PubMed		"Mller et al., 2009, Blood"	"NCT00101660,NCT00103844,NCT00123474"	3	accepted	4532	Somatic	2023-01-09 21:46:45 UTC	https://civicdb.org/links/evidence_items/4532	https://civicdb.org/links/molecular_profiles/1431	FALSE	ABL1	25	BCR::ABL F359I		chr9	130873027	130873027	T	A	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.1075T>A,NP_005148.2:p.Phe359Ile,NC_000009.11:g.133748414T>A,ENST00000318560.5:c.1075T>A"	2023-01-27 17:10:08 UTC	CA16602580	376122	"RS121913452,F378I,BCR-ABL PHE359ILE,BCR-ABL1 F359I,BCR-ABL1 PHE359ILE,BCR-ABL F359I"	FALSE
ABL1 BCR::ABL F359I	1431	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	C	Resistance	"Prior to dasatinib treatment, one imatinib-resistant patient with chronic myeloid leukemia in chronic phase had the BCR-ABL1 fusion with the F359I secondary variant in 9/9 bacterial clones generated using peripheral blood RNA. They had complete best hematologic and no cytogenetic responses to dasatinib which were comparable to responses in patients with unmutated BCR-ABL1."	16775234	PubMed		"Talpaz et al., 2006, N. Engl. J. Med."	NCT00064233	3	accepted	4533	Somatic	2023-01-09 21:46:45 UTC	https://civicdb.org/links/evidence_items/4533	https://civicdb.org/links/molecular_profiles/1431	FALSE	ABL1	25	BCR::ABL F359I		chr9	130873027	130873027	T	A	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.1075T>A,NP_005148.2:p.Phe359Ile,NC_000009.11:g.133748414T>A,ENST00000318560.5:c.1075T>A"	2023-01-27 17:10:08 UTC	CA16602580	376122	"RS121913452,F378I,BCR-ABL PHE359ILE,BCR-ABL1 F359I,BCR-ABL1 PHE359ILE,BCR-ABL F359I"	FALSE
ABL1 BCR::ABL M343T	1432	Chronic Myeloid Leukemia	8552		Axitinib		Predictive	Supports	D	Resistance	"In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed increased incorporation when harboring fusions with the M343T variant of ABL1 compared to fusions with wildtype ABL1 (IC50 of 1175nM vs. 823 nM), indicating resistance."	25686603	PubMed		"Pemovska et al., 2015, Nature"		2	accepted	4534	Somatic	2023-01-09 21:46:45 UTC	https://civicdb.org/links/evidence_items/4534	https://civicdb.org/links/molecular_profiles/1432	FALSE	ABL1	25	BCR::ABL M343T		chr9	130872980	130872980	T	C	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"ENST00000318560.5:c.1028T>C,NC_000009.11:g.133748367T>C,NM_005157.5:c.1028T>C,NP_005148.2:p.Met343Thr"	2023-01-27 17:10:09 UTC	CA375249596	NONE FOUND	"M362T,BCR-ABL MET343THR,BCR-ABL1 M343T,BCR-ABL1 MET343THR,BCR-ABL M343T"	FALSE
ABL1 BCR::ABL V299L	1205	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Supports	C	Reduced Sensitivity	"This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chronic phase CML and BCR-ABL fusions. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. Of patients with V299L, 1/2 had a CHR and 0/2 had a MCyR. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occuring."	22371878	PubMed		"Khoury et al., 2012, Blood"	NCT00261846	1	accepted	4538	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/4538	https://civicdb.org/links/molecular_profiles/1205	FALSE	ABL1	25	BCR::ABL V299L		chr9	130872201	130872201	G	C	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.895G>C,NP_005148.2:p.Val299Leu,NC_000009.11:g.133747588G>C,ENST00000318560.5:c.895G>C"	2023-01-27 17:08:46 UTC	CA16602575	376117	"BCR-ABL VAL299LEU,BCR-ABL V318L,RS1057519771,BCR-ABL1 V299L,BCR-ABL1 VAL299LEU,BCR-ABL V299L"	FALSE
ABL1 BCR::ABL V299L	1205	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Supports	C	Resistance	"This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation had comparable complete hematologic response, major cytogenetic response, complete cytogenetic response (CCyR), and major molecular response. There was 1 patient with a V299L mutation who did not achieved CCyR with dasatinib monotherapy. Analyses by variant included patients with multiple kinase domain mutations. Of the 63 variants considered, the authors associate T315I, F317L, and V299L with resistance to dasatinib or lower levels of response due to clinical resistance and low in vitro sensitivity. They suggest considering alternative treatment options for patients with these variants."	19779040	PubMed		"Mller et al., 2009, Blood"	"NCT00101660,NCT00103844,NCT00123474"	1	accepted	4540	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/4540	https://civicdb.org/links/molecular_profiles/1205	FALSE	ABL1	25	BCR::ABL V299L		chr9	130872201	130872201	G	C	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.895G>C,NP_005148.2:p.Val299Leu,NC_000009.11:g.133747588G>C,ENST00000318560.5:c.895G>C"	2023-01-27 17:08:46 UTC	CA16602575	376117	"BCR-ABL VAL299LEU,BCR-ABL V318L,RS1057519771,BCR-ABL1 V299L,BCR-ABL1 VAL299LEU,BCR-ABL V299L"	FALSE
ABL1 BCR::ABL E279K	1434	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	C	Resistance	"This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Out of 8 patients with E279K mutations, 5, 5, and 8 achieved CCyR, MCyR, and CHR with dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations."	19779040	PubMed		"Mller et al., 2009, Blood"	"NCT00101660,NCT00103844,NCT00123474"	3	accepted	4543	Somatic	2023-01-09 21:46:45 UTC	https://civicdb.org/links/evidence_items/4543	https://civicdb.org/links/molecular_profiles/1434	FALSE	ABL1	25	BCR::ABL E279K		chr9	130872141	130872141	G	A	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"ENST00000318560.5:c.835G>A,NC_000009.11:g.133747528G>A,NM_005157.5:c.835G>A,NP_005148.2:p.Glu279Lys"	2023-01-27 17:10:10 UTC	CA375249162	NONE FOUND	"BCR-ABL1 E279K,BCR-ABL GLU279LYS,BCR-ABL1 GLU279LYS,BCR-ABL E298K,BCR-ABL E279K"	FALSE
ABL1 BCR::ABL Q300R	1435	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Does Not Support	C	Resistance	"This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chronic phase CML and BCR-ABL fusions. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. Of patients with Q300R, 1/1 had a CHR and 1/1 had a MCyR. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occuring."	22371878	PubMed		"Khoury et al., 2012, Blood"	NCT00261846	1	accepted	4545	Somatic	2023-01-09 21:46:45 UTC	https://civicdb.org/links/evidence_items/4545	https://civicdb.org/links/molecular_profiles/1435	FALSE	ABL1	25	BCR::ABL Q300R		chr9	130872205	130872205	A	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"ENST00000318560.5:c.899A>G,NC_000009.11:g.133747592A>G,NM_005157.5:c.899A>G,NP_005148.2:p.Gln300Arg"	2023-01-27 17:10:11 UTC	CA375249312	NONE FOUND	"Q319R,BCR-ABL GLN300ARG,BCR-ABL1 Q300R,BCR-ABL1 GLN300ARG,BCR-ABL Q300R"	FALSE
ABL1 BCR::ABL F311L	1436	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Does Not Support	C	Resistance	"In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with F311L evaluated, 1/1 had a complete hematologic response and 1/1 had a major cytogenetic response."	21865346	PubMed		"Cortes et al., 2011, Blood"	NCT00261846	2	accepted	4546	Somatic	2023-01-09 21:46:45 UTC	https://civicdb.org/links/evidence_items/4546	https://civicdb.org/links/molecular_profiles/1436	FALSE	ABL1	25	BCR::ABL F311L		chr9	130872883	130872883	T	C	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.931T>C,NP_005148.2:p.Phe311Leu,NC_000009.11:g.133748270T>C,ENST00000318560.5:c.931T>C"	2023-01-27 17:10:12 UTC	CA122587	12628	"RS137853304,F330L,BCR-ABL PHE311LEU,BCR-ABL1 F311L,BCR-ABL1 PHE311LEU,BCR-ABL F311L"	FALSE
ABL1 BCR::ABL N331S	1437	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Does Not Support	C	Resistance	"In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with N331S evaluated, 1/1 had a major cytogenetic response."	21865346	PubMed		"Cortes et al., 2011, Blood"	NCT00261846	1	accepted	4549	Somatic	2023-01-09 21:46:45 UTC	https://civicdb.org/links/evidence_items/4549	https://civicdb.org/links/molecular_profiles/1437	FALSE	ABL1	25	BCR::ABL N331S		chr9	130872944	130872944	A	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"ENST00000318560.5:c.992A>G,NC_000009.11:g.133748331A>G,NM_005157.5:c.992A>G,NP_005148.2:p.Asn331Ser"	2023-01-27 17:10:13 UTC	CA5285356	NONE FOUND	"N350S,RS144448357,BCR-ABL ASN331SER,BCR-ABL1 N331S,BCR-ABL1 ASN331SER,BCR-ABL N331S"	FALSE
ABL1 BCR::ABL L364P	1438	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Does Not Support	C	Resistance	"In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with L364P evaluated, 1/1 had a major cytogenetic response."	21865346	PubMed		"Cortes et al., 2011, Blood"	NCT00261846	1	accepted	4551	Somatic	2023-01-09 21:46:45 UTC	https://civicdb.org/links/evidence_items/4551	https://civicdb.org/links/molecular_profiles/1438	FALSE	ABL1	25	BCR::ABL L364P		chr9	130874873	130874873	T	C	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"ENST00000318560.5:c.1091T>C,NC_000009.11:g.133750260T>C,NM_005157.5:c.1091T>C,NP_005148.2:p.Leu364Pro"	2023-01-27 17:10:13 UTC	CA375249757	NONE FOUND	"L383P,BCR-ABL LEU364PRO,BCR-ABL1 L364P,BCR-ABL1 LEU364PRO,BCR-ABL L364P"	FALSE
ABL1 BCR::ABL L387F	1206	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Supports	C	Resistance	"This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chronic phase CML and BCR-ABL fusions. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. Of patients with L387F, 1/1 had a CHR and 0/1 had a MCyR. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occuring."	22371878	PubMed		"Khoury et al., 2012, Blood"	NCT00261846	1	accepted	4552	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/4552	https://civicdb.org/links/molecular_profiles/1206	FALSE	ABL1	25	BCR::ABL L387F		chr9	130874943	130874943	G	C	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"ENST00000318560.5:c.1161G>C,NC_000009.11:g.133750330G>C,NM_005157.5:c.1161G>C,NP_005148.2:p.Leu387Phe"	2023-01-27 17:08:47 UTC	CA375249910	NONE FOUND	"L406F,LEU406PHE,LEU387PHE,BCR-ABL1 L387F,BCR-ABL1 LEU387PHE,BCR-ABL L387F"	FALSE
ABL1 BCR::ABL H396P	1439	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Does Not Support	C	Resistance	"In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with H396P evaluated, 1/1 had a complete hematologic response and 2/2 had major cytogenetic responses."	21865346	PubMed		"Cortes et al., 2011, Blood"	NCT00261846	2	accepted	4554	Somatic	2023-01-09 21:46:45 UTC	https://civicdb.org/links/evidence_items/4554	https://civicdb.org/links/molecular_profiles/1439	FALSE	ABL1	25	BCR::ABL H396P		chr9	130874969	130874969	A	C	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"ENST00000318560.5:c.1187A>C,NC_000009.11:g.133750356A>C,NM_005157.5:c.1187A>C,NP_005148.2:p.His396Pro"	2023-01-27 17:10:14 UTC	CA375249969	NONE FOUND	"BCR-ABL HIS396PRO,BCR-ABL1 H396P,BCR-ABL1 HIS396PRO,BCR-ABL H396P"	FALSE
ABL1 BCR::ABL D421G	1440	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Does Not Support	C	Resistance	"In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with D421G evaluated, 1/1 had a complete hematologic response and 0/1 had a major cytogenetic response."	21865346	PubMed		"Cortes et al., 2011, Blood"	NCT00261846	1	accepted	4559	Somatic	2023-01-09 21:46:45 UTC	https://civicdb.org/links/evidence_items/4559	https://civicdb.org/links/molecular_profiles/1440	FALSE	ABL1	25	BCR::ABL D421G		chr9	130875044	130875044	A	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"ENST00000318560.5:c.1262A>G,NC_000009.11:g.133750431A>G,NM_005157.5:c.1262A>G,NP_005148.2:p.Asp421Gly"	2023-01-27 17:10:15 UTC	CA375250143	NONE FOUND	"BCR-ABL1 D421G,BCR-ABL ASP421GLY,BCR-ABL1 ASP421GLY,BCR-ABL D421G"	FALSE
ABL1 BCR::ABL G398R	1207	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Supports	D	Sensitivity/Response	"In an in vitro study, a Ba/F3  cell line stably expressing the G398R mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with sensitivity to dasatinib treatment (IC50: 1.27nM vs. IC50: 1.83nM), comparable to Ba/F3 cells expressing BCR-ABL1 fusion protein. Sensitivity was determined by assessing cell proliferation."	19075254	PubMed		"Redaelli et al., 2009, J. Clin. Oncol."		2	accepted	4561	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/4561	https://civicdb.org/links/molecular_profiles/1207	FALSE	ABL1	25	BCR::ABL G398R		chr9	130874974	130874974	G	C	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"ENST00000318560.5:c.1192G>C,NC_000009.11:g.133750361G>C,NM_005157.5:c.1192G>C,NP_005148.2:p.Gly398Arg"	2023-01-27 17:08:47 UTC	CA375249980	NONE FOUND	"BCR-ABL G417R,BCR-ABL GLY417ARG,BCR-ABL GLY398ARG,BCR-ABL1 G398R,BCR-ABL1 GLY398ARG,BCR-ABL G398R"	FALSE
ABL1 BCR::ABL E450V	1442	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Does Not Support	C	Resistance	"In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with E450V evaluated, 1/1 had a complete hematologic response and 1/1 had a major cytogenetic response."	21865346	PubMed		"Cortes et al., 2011, Blood"	NCT00261846	2	accepted	4563	Somatic	2023-01-09 21:46:46 UTC	https://civicdb.org/links/evidence_items/4563	https://civicdb.org/links/molecular_profiles/1442	FALSE	ABL1	25	BCR::ABL E450V		chr9	130878493	130878493	A	T	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"ENST00000318560.5:c.1349A>T,NC_000009.11:g.133753880A>T,NM_005157.5:c.1349A>T,NP_005148.2:p.Glu450Val"	2023-01-27 17:10:16 UTC	CA375251155	NONE FOUND	"E469V,BCR-ABL GLU450VAL,BCR-ABL1 GLU450VAL,BCR-ABL1 E450V,BCR-ABL E450V"	FALSE
ABL1 BCR::ABL E453K	1443	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Does Not Support	C	Resistance	"In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with E453K evaluated, 1/1 had a major cytogenetic response."	21865346	PubMed		"Cortes et al., 2011, Blood"	NCT00261846	1	accepted	4565	Somatic	2023-01-09 21:46:46 UTC	https://civicdb.org/links/evidence_items/4565	https://civicdb.org/links/molecular_profiles/1443	FALSE	ABL1	25	BCR::ABL E453K		chr9	130878501	130878501	G	A	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"ENST00000318560.5:c.1357G>A,NC_000009.11:g.133753888G>A,NM_005157.5:c.1357G>A,NP_005148.2:p.Glu453Lys"	2023-01-27 17:10:17 UTC	CA375251169	NONE FOUND	"E472K,BCR-ABL GLU453LYS,BCR-ABL1 E453K,BCR-ABL1 GLU453LYS,BCR-ABL E453K"	FALSE
ABL1 BCR::ABL E453A	1444	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Does Not Support	C	Resistance	"This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chronic phase CML and BCR-ABL fusions. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. Of patients with E453A, 1/1 had a CHR and 0/0 had a MCyR. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occuring."	22371878	PubMed		"Khoury et al., 2012, Blood"	NCT00261846	1	accepted	4567	Somatic	2023-01-09 21:46:46 UTC	https://civicdb.org/links/evidence_items/4567	https://civicdb.org/links/molecular_profiles/1444	FALSE	ABL1	25	BCR::ABL E453A		chr9	130878502	130878502	A	C	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"ENST00000318560.5:c.1358A>C,NC_000009.11:g.133753889A>C,NM_005157.5:c.1358A>C,NP_005148.2:p.Glu453Ala"	2023-01-27 17:10:18 UTC	CA375251172	NONE FOUND	"E472A,GLU453ALA,BCR-ABL1 E453A,BCR-ABL1 GLU453ALA,BCR-ABL E453A"	FALSE
ABL1 BCR::ABL P480A	1445	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Does Not Support	C	Resistance	"In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with P480A evaluated, 1/1 had a major cytogenetic response."	21865346	PubMed		"Cortes et al., 2011, Blood"	NCT00261846	1	accepted	4568	Somatic	2023-01-09 21:46:46 UTC	https://civicdb.org/links/evidence_items/4568	https://civicdb.org/links/molecular_profiles/1445	FALSE	ABL1	25	BCR::ABL P480A		chr9	130880082	130880082	C	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"ENST00000318560.5:c.1438C>G,NC_000009.11:g.133755469C>G,NM_005157.5:c.1438C>G,NP_005148.2:p.Pro480Ala"	2023-01-27 17:10:19 UTC	CA375251559	NONE FOUND	"P499A,BCR-ABL PRO480ALA,BCR-ABL1 P480A,BCR-ABL1 PRO480ALA,BCR-ABL P480A"	FALSE
ABL1 BCR::ABL F486S	1126	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	B	Resistance	"This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Out of 13 patients with F486S mutations, 5, 6, and 12 achieved CCyR, MCyR, and CHR with dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations."	19779040	PubMed		"Mller et al., 2009, Blood"	"NCT00101660,NCT00103844,NCT00123474"	3	accepted	4571	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/4571	https://civicdb.org/links/molecular_profiles/1126	FALSE	ABL1	25	BCR::ABL F486S		chr9	130880101	130880101	T	C	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"ENST00000318560.5:c.1457T>C,NC_000009.11:g.133755488T>C,NM_005157.5:c.1457T>C,NP_005148.2:p.Phe486Ser"	2023-01-27 17:08:15 UTC	CA375251598	NONE FOUND	"BCR-ABL F505S,BCR-ABL PHE486SER,BCR-ABL1 PHE486SER,BCR-ABL1 F486S,BCR-ABL F486S"	FALSE
KIT K550_W557del	922	Gastrointestinal Stromal Tumor	9253		"Sunitinib,Ponatinib,Regorafenib,Imatinib"	Substitutes	Predictive	Supports	D	Sensitivity/Response	"In an in vitro study, an IL3 independent Ba/F3 cell line expressing KIT K550_W557del primary activating mutation demonstrated sensitivity to imatinib (IC50: 13nmol/L), sunitinib (IC50: 5nmol/L), regorafenib (IC50: 22nmol/L), and ponatinib (IC50: 3nmol/L) treatments. IC50 was determined by assessing cell viability."	25239608	PubMed		"Garner et al., 2014, Clin. Cancer Res."		2	accepted	4583	Somatic	2023-01-09 21:46:40 UTC	https://civicdb.org/links/evidence_items/4583	https://civicdb.org/links/molecular_profiles/922	FALSE	KIT	3815	K550_W557del		chr4	54727416	54727439	AAACCCATGTATGAAGTACAGTGG		ENST00000288135.5	75		inframe_deletion	ENST00000288135.5:c.1648_1671del AAACCCATGTATGAAGTACAGTGG	2023-01-27 17:06:55 UTC	CA645516733	NONE FOUND		FALSE
KIT D820Y	960	Gastrointestinal Stromal Tumor	9253		Regorafenib		Predictive	Supports	C	Sensitivity/Response	"This retrospective study of a phase 2 clinical trial (NCT01068769) examined regorafenib safety and efficacy in advanced gastrointestinal stromal tumor (GIST) patients refractory to at least imatinib and sunitinib. Three patients whose GIST harbored KIT D820Y experienced clinical benefit (defined as complete response, partial response, stable disease >16 weeks) in response to regorafenib. One patient remained on study without disease progression for >11 months, one patient developed disease progression at 5.7 months, and the other patient underwent surgical removal of all residual disease after 7 months, but continued on regorafenib. Immunoblotting of matched pre- and post- treatment GIST biopsies from these patients demonstrated decreased levels of KIT phosphorylation in response to regorafenib."	22614970	PubMed		"George et al., 2012, J. Clin. Oncol."		2	accepted	4589	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/4589	https://civicdb.org/links/molecular_profiles/960	FALSE	KIT	3815	D820Y	KIT Exon 17	chr4	54733166	54733166	G	T	ENST00000288135.5	75		missense_variant	"NM_000222.2:c.2458G>T,NP_000213.1:p.Asp820Tyr,NC_000004.11:g.55599332G>T,ENST00000288135.5:c.2458G>T"	2023-01-27 17:07:24 UTC	CA16602408	375928	"ASP820TYR,RS1057519710"	FALSE
KIT K558delinsNP	1457	Gastrointestinal Stromal Tumor	9253		"Imatinib,Regorafenib,Ponatinib,Sunitinib"	Substitutes	Predictive	Supports	D	Sensitivity/Response	"In an in vitro study, an IL3 independent Ba/F3 cell line expressing KIT K558NP primary activating mutation demonstrated sensitivity to imatinib (IC50: 2nmol/L), sunitinib (IC50: 2nmol/L ), regorafenib (IC50: 4nmol/L), and ponatinib (IC50: 1nmol/L) treatments. IC50 was determined by assessing cell viability."	25239608	PubMed		"Garner et al., 2014, Clin. Cancer Res."		3	accepted	4594	Somatic	2023-01-09 21:46:46 UTC	https://civicdb.org/links/evidence_items/4594	https://civicdb.org/links/molecular_profiles/1457	FALSE	KIT	3815	K558delinsNP		chr4	54727442	54727442	G	TCCT				delins		2023-03-24 00:00:08 UTC	CA645516857			FALSE
KIT N822K	1237	Gastrointestinal Stromal Tumor	9253		Regorafenib		Predictive	Supports	C	Sensitivity/Response	This retrospective study of a phase 2 clinical trial (NCT01068769) examined regorafenib safety and efficacy in advanced gastrointestinal stromal tumor (GIST) patients refractory to at least imatinib and sunitinib. One patient whose GIST harbored KIT N882K did not experienced disease progression for >7 months following treatment by regorafenib. Immunoblotting of matched pre- and post- treatment GIST biopsies from this patient demonstrated decreased levels of KIT phosphorylation in response to regorafenib.	22614970	PubMed		"George et al., 2012, J. Clin. Oncol."		2	accepted	4595	Somatic	2023-01-09 21:46:44 UTC	https://civicdb.org/links/evidence_items/4595	https://civicdb.org/links/molecular_profiles/1237	FALSE	KIT	3815	N822K	KIT Exon 17	chr4	54733174	54733174	T	A	ENST00000288135.5	75		missense_variant	"NM_000222.2:c.2466T>A,NP_000213.1:p.Asn822Lys,NC_000004.11:g.55599340T>A,ENST00000288135.5:c.2466T>A"	2023-01-27 17:09:06 UTC	CA16602411	375931	"ASN822LYS,RS121913514"	FALSE
PDGFRA D842V	99	Gastrointestinal Stromal Tumor	9253		Sunitinib		Predictive	Supports	C	Resistance	"Patients 29 and 66 from a larger cohort of genotyped patients (n= 78) with imatinib resistant or intolerant gastrointestinal stromal tumors (GISTs) harbored a primary (pre-imatinib treatment) PDGFRA D842V mutation. Following failure of imatinib, the GIST was again genotyped, but no secondary mutations were found. Patients took 50 mg sunitib per day. Patient 29 was on a treatment schedule of two weeks on/two weeks off, and patient 66 was scheduled for four weeks on/two weeks off.  Patient 29 experienced stable disease for less than 6 months and patient 66 experienced disease progression. Time to progression was censored at 0.1 weeks for patient 29 and was 10 weeks for patient 66. Overall survival was 99 and censored at 129 weeks for patients 29 and 66."	18955458	PubMed		"Heinrich et al., 2008, J. Clin. Oncol."		3	accepted	4597	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/4597	https://civicdb.org/links/molecular_profiles/99	FALSE	PDGFRA	5156	D842V	Imatinib Resistance	chr4	54285926	54285926	A	T	ENST00000257290.5	75		missense_variant	"NM_006206.4:c.2525A>T,NP_006197.1:p.Asp842Val,ENST00000257290.5:c.2525A>T,NC_000004.11:g.55152093A>T"	2023-01-27 17:02:33 UTC	CA123194	13543	"ASP842VAL,RS121908585"	FALSE
KIT Exon 11 Mutation	66	Gastrointestinal Stromal Tumor	9253		Regorafenib		Predictive	Supports	B	Sensitivity/Response	"This international, placebo controlled prospective phase 3 clinical trial (NCT01271712) examined safety and efficacy of regorafenib in patients with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) who failed previous treatments with at least imatinib or sunitinib. Progression free survival was measured for 199 patients treated with either daily 160mg regorafenib (n=133) or a matching placebo (n= 66). Overall, median PFS was 7.4 months in the regorafenib group and 1.7 months in the placebo group (HR= .22, P <.001). Patients with KIT exon 11 mutations (n=51) treated with regorafenib were associated with similarly favorable progression free survival (HR: 0.212), as compared to patients with treated with placebo."	23177515	PubMed		"Demetri et al., 2013, Lancet"	NCT01271712	2	accepted	4599	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/4599	https://civicdb.org/links/molecular_profiles/66	FALSE	KIT	3815	Exon 11 Mutation	KIT Exon 11	chr4	54727416	54727542			ENST00000288135.5	75		coding_sequence_variant		2023-01-09 21:52:04 UTC				FALSE
BRCA1 W1815X	1463	Endometrioid Ovary Carcinoma	5828		Olaparib		Predictive	Supports	D	Sensitivity/Response	"In an in vitro study, a SNU-251 cell line expressing BRCA1 W1815X truncating mutation demonstrated increased sensitivity to olaparib treatment with long-term exposure, compared to ovarian cell lines expressing BRCA1 wild-type. Sensitivity was determined by assessing cytotoxicity and doubling time. The authors note that the slow doubling time of SNU-251 cells was compensated for with a 2 week cytotoxicity assay as compared to the 1 week assay used for all other cell lines."	23415752	PubMed		"Stordal et al., 2013, Mol Oncol"		2	accepted	4623	Somatic	2023-01-09 21:46:46 UTC	https://civicdb.org/links/evidence_items/4623	https://civicdb.org/links/molecular_profiles/1463	FALSE	BRCA1	672	W1815X		chr17	43047665	43047665	C	T				stop_gained		2023-01-27 17:10:24 UTC	CA003600		"W125X,W1519X,W1550X,W1576X,W1768X,W1836X,W306X,W48X,W632X,W664X,W673X,W711X"	FALSE
KIT Exon 9 Mutation	505	Gastrointestinal Stromal Tumor	9253		Regorafenib		Predictive	Supports	B	Sensitivity/Response	"This international, placebo controlled prospective phase 3 clinical trial (NCT01271712) examined safety and efficacy of regorafenib in patients with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) who failed previous treatments with at least imatinib or sunitinib. Progression free survival was measured for 199 patients treated with either daily 160mg regorafenib (n=133) or a matching placebo (n= 66).  Overall, median PFS was 7.4 months in the regorafenib group and 1.7 months in the placebo group (HR= .22, P <.001). Patients with KIT exon 9 mutations (n=15) treated with regorafenib were associated with a similarly favorable progression free survival (HR: 0.239), as compared to patients with treated with placebo."	23177515	PubMed		"Demetri et al., 2013, Lancet"	NCT01271712	2	accepted	4628	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/4628	https://civicdb.org/links/molecular_profiles/505	FALSE	KIT	3815	Exon 9 Mutation		chr4	54725857	54726050			ENST00000288135.5	75		exon_variant		2023-01-09 21:52:07 UTC				FALSE
KIT Exon 11 Mutation	66	Gastrointestinal Stromal Tumor	9253		Regorafenib		Predictive	Supports	B	Sensitivity/Response	"This retrospective study of a phase 2 clinical trial (NCT01068769) examined regorafenib safety and efficacy in advanced gastrointestinal stromal tumor (GIST) patients who failed previous treatments with imatinib and sunitinib. Of 30 genotyped patients treated with regorafenib, those with KIT exon 11 mutant GISTs (n=19) experienced significantly increased progression free survival (P=0.01), as compared to patients with KIT exon 9 mutant GISTs (n=3). Median PFS for the entire cohort was 10.0 months. Regorafenib treatment induced clinical benefit (defined as complete response, partial response, stable disease > 16 weeks) in 16/19 patients with KIT exon 11 mutant GISTs."	22614970	PubMed		"George et al., 2012, J. Clin. Oncol."		2	accepted	4629	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/4629	https://civicdb.org/links/molecular_profiles/66	FALSE	KIT	3815	Exon 11 Mutation	KIT Exon 11	chr4	54727416	54727542			ENST00000288135.5	75		coding_sequence_variant		2023-01-09 21:52:04 UTC				FALSE
KIT A502_Y503insAY	1466	Gastrointestinal Stromal Tumor	9253		"Ponatinib,Regorafenib,Imatinib"	Substitutes	Predictive	Does Not Support	D	Sensitivity/Response	"In an in vitro study, an IL3 independent Ba/F3 cell line expressing KIT A502_Y503insAY primary activating mutation demonstrated insensitivity to regorafenib (IC50: 138nmol/L), imatinib (IC50: 143nmol/L), and ponatinib (IC50: 56nmol/L) treatments. In comparison, sensitizing KIT mutation del550-557 showed IC50 22, 13 and 3 nmol/L for these drugs respectively. IC50 was determined by assessing cell viability."	25239608	PubMed		"Garner et al., 2014, Clin. Cancer Res."		3	accepted	4630	Somatic	2023-01-09 21:46:46 UTC	https://civicdb.org/links/evidence_items/4630	https://civicdb.org/links/molecular_profiles/1466	FALSE	KIT	3815	A502_Y503insAY		chr4	54726016	54726017		GCCTAT				inframe_insertion		2023-01-09 21:52:14 UTC	unregistered			FALSE
KIT D816E	1467	Gastrointestinal Stromal Tumor	9253		"Sunitinib,Imatinib"	Substitutes	Predictive	Supports	D	Resistance	"Several preclinical studies were done in order to test the effects of various tyrosine kinase inhibitors (TKIs) on KIT-mutant cell lines derived from Gastrointestinal Stromal Tumor (GIST) patients with primary mutation 560-578 deletion and secondary mutation D816E. The cells were tested for Imatinib and Sunitinib resistances. GIST-T1/816 cells with 560-578 deletion and D816E mutations were resistant towards Imatinib and Sunitinib (Imatinib IC50: 604 nM and Sunitinib IC50: 3111 nM) compared to GIST-T1 cells with the 560-578 deletion mutation alone (Imatinib IC50: 30 nM and Sunitinib IC50: 15 nM). Imatinib inhibited phosphorylation in KIT and ERK at high concentrations. Sunitinib did not inhibit phosphorylation in KIT, ERK, or AKT at all. Additionally, Ba/F3 cells were mutagenized with N-ethyl-N-nitrosourea and incubated with varying concentrations of Sunitinib and Imatinib separately. In Imatinib incubated cells, D816E mutations were seen in less than 5% of resistant Ba/F3 cell clones only in the lowest concentration. In Imatinib incubated cells, D816E mutations were seen in approximately 10% of resistant Ba/F3 cell clones."	25239608	PubMed		"Garner et al., 2014, Clin. Cancer Res."		4	accepted	4631	Somatic	2023-01-09 21:46:46 UTC	https://civicdb.org/links/evidence_items/4631	https://civicdb.org/links/molecular_profiles/1467	FALSE	KIT	3815	D816E		chr4	54733156	54733156	C	G	ENST00000288135.5	75		missense_variant	"ENST00000288135.5:c.2448C>G,NC_000004.11:g.55599322C>G,NM_000222.2:c.2448C>G,NP_000213.1:p.Asp816Glu"	2023-01-27 17:10:27 UTC	CA356911882	NONE FOUND	"D812E,ASP816GLU"	FALSE
EGFR D770_N771insGT	1474	Lung Adenocarcinoma	3910		Erlotinib		Predictive	Supports	C	Resistance	"In a lung adenocarcinoma patient harboring EGFR D770_N771insGT mutation, EGFR D770_N771insGT was associated with lack of response to treatment with erlotinib monotherapy."	23371856	PubMed		"Arcila et al., 2013, Mol. Cancer Ther."			accepted	4643	Somatic	2023-01-09 21:46:46 UTC	https://civicdb.org/links/evidence_items/4643	https://civicdb.org/links/molecular_profiles/1474	FALSE	EGFR	1956	D770_N771insGT		chr7	55181319	55181320		GGCACA	ENST00000275493.2			inframe_insertion	"NC_000007.13:g.55249012_55249013insGGCACA,NM_005228.3:c.2310_2311insGGCACA,NP_005219.2:p.Cys770_Gly771insGlyThr,NC_000007.14:g.55181319_55181320insGGCACA,ENST00000275493.7:c.2310_2311insGGCACA,ENSP00000275493.2:p.Asp770_Asn771insGlyThr"	2023-01-27 17:10:27 UTC	CA645561586	NONE FOUND	ASP770_ASN771INSGLYTHR	FALSE
EGFR Exon 20 Insertion	707	Lung Adenocarcinoma	3910		Erlotinib		Predictive	Supports	C	Resistance	"In stage IV lung adenocarcinoma patients (n=2) harboring EGFR inframe exon 20 insertion mutation, EGFR exon 20 insertion was associated with progressive disease after 1 and 3 months of erlotinib monotherapy, respectively; both patients were previously treated with standard chemotherapy."	22895145	PubMed		"Lund-Iversen et al., 2012, J Thorac Oncol"			accepted	4650	Somatic	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/4650	https://civicdb.org/links/molecular_profiles/707	FALSE	EGFR	1956	Exon 20 Insertion		chr7	55181298	55181329			ENST00000275493.2	75		inframe_insertion		2023-01-09 21:52:08 UTC				FALSE
SMO L412F	1478	Basal Cell Carcinoma	2513		Vismodegib		Predictive	Supports	D	Resistance	"In an in vitro study, mouse embryonic fibroblasts (MEFs), null for the Smo mouse gene expressing SMO L412F mutation, demonstrated resistance to vismodegib treatment (IC50: >320 nmol/L vs. 8.23 nmol/L) compared to MEFs expressing wild-type SMO. Resistance was determined by assessing GLI1 mRNA expression levels."	25759020	PubMed		"Atwood et al., 2015, Cancer Cell"			accepted	4653	Somatic	2023-01-09 21:46:46 UTC	https://civicdb.org/links/evidence_items/4653	https://civicdb.org/links/molecular_profiles/1478	FALSE	SMO	6608	L412F		chr7	129206557	129206557	C	T	ENST00000249373.3	75		missense_variant	"NM_005631.4:c.1234C>T,NP_005622.1:p.Leu412Phe,NC_000007.13:g.128846398C>T,ENST00000249373.3:c.1234C>T"	2023-01-27 17:10:30 UTC	CA10584652	245609		FALSE
SMO L412F	1478	Basal Cell Carcinoma	2513		Vismodegib		Predictive	Supports	C	Resistance	"An Arab basal cell carcinoma patient harboring SMO L412F mutation was associated with response to vismodegib monotherapy. Prior to the identification of the mutation, the patient was treated with acitretin, but did not achieve any response."	26822128	PubMed		"Khamaysi et al., 2016, Br. J. Dermatol."			accepted	4654	Somatic	2023-01-09 21:46:46 UTC	https://civicdb.org/links/evidence_items/4654	https://civicdb.org/links/molecular_profiles/1478	FALSE	SMO	6608	L412F		chr7	129206557	129206557	C	T	ENST00000249373.3	75		missense_variant	"NM_005631.4:c.1234C>T,NP_005622.1:p.Leu412Phe,NC_000007.13:g.128846398C>T,ENST00000249373.3:c.1234C>T"	2023-01-27 17:10:30 UTC	CA10584652	245609		FALSE
EGFR W731L	1479	Cancer	162		Erlotinib		Predictive	Supports	D	Sensitivity/Response	"In an in vitro study performed after identification of the mutation in a malignant peritoneal mesothelioma patient, COS-7 cells expressing EGFR W731L demonstrated increased EGFR phosphotyrosine after EGF treatment over wildtype EGFR expressing cells. Cells expressing mutant EGFR also showed increased sensitivity to erlotinib treatment compared to cells expressing EGFR wild-type. Sensitivity was determined by assessing EGFR auto-phosphorylation."	20942962	PubMed		"Foster et al., 2010, World J Surg Oncol"		3	accepted	4655	Somatic	2023-01-09 21:46:46 UTC	https://civicdb.org/links/evidence_items/4655	https://civicdb.org/links/molecular_profiles/1479	FALSE	EGFR	1956	W731L		chr7	55174729	55174729	G	T	ENST00000275493.2	75		missense_variant	ENST00000275493.2:c.2192G>T	2023-01-27 17:10:31 UTC	CA367583965	NONE FOUND	"W678L,W686L,RS397517089"	FALSE
EGFR E734Q	1480	Cancer	162		Erlotinib		Predictive	Supports	D	Sensitivity/Response	"In an in vitro study performed after identification of the mutation in a malignant peritoneal mesothelioma patient, COS-7 cells expressing EGFR E734Q demonstrated increased EGFR phosphotyrosine after EGF treatment over wildtype EGFR expressing cells. Cells expressing mutant EGFR also showed increased sensitivity to erlotinib treatment compared to cells expressing EGFR wild-type. Sensitivity was determined by assessing EGFR auto-phosphorylation."	20942962	PubMed		"Foster et al., 2010, World J Surg Oncol"		3	accepted	4656	Somatic	2023-01-27 03:32:05 UTC	https://civicdb.org/links/evidence_items/4656	https://civicdb.org/links/molecular_profiles/1480	FALSE	EGFR	1956	E734Q		chr7	55174737	55174737	G	C	ENST00000	75		missense_variant	ENST00000275493.2:c.2200G>C	2023-01-27 17:10:31 UTC	CA367583997	NONE FOUND	"RS121913420,E681Q,E689Q"	FALSE
EGFR T785A	1481	Cancer	162		Erlotinib		Predictive	Supports	D	Sensitivity/Response	"In an in vitro study performed after identification of the mutation in a malignant peritoneal mesothelioma patient, COS-7 cells expressing EGFR T785A demonstrated increased EGFR phosphotyrosine after EGF treatment over wildtype EGFR expressing cells. Cells expressing mutant EGFR also showed increased sensitivity to erlotinib treatment compared to cells expressing EGFR wild-type. Sensitivity was determined by assessing EGFR auto-phosphorylation."	20942962	PubMed		"Foster et al., 2010, World J Surg Oncol"		3	accepted	4657	Somatic	2023-01-27 03:35:14 UTC	https://civicdb.org/links/evidence_items/4657	https://civicdb.org/links/molecular_profiles/1481	FALSE	EGFR	1956	T785A		chr7	55181362	55181362	A	G	ENST00000275493.2	75		missense_variant	ENST00000275493.2:c.2353A>G	2023-01-27 17:10:32 UTC	CA367578819	NONE FOUND	"T732A,T740A"	FALSE
EGFR C797Y	1482	Cancer	162		Erlotinib		Predictive	Supports	D	Sensitivity/Response	"In an in vitro study performed after identification of the mutation in a malignant peritoneal mesothelioma patient, COS-7 cells expressing EGFR C797Y demonstrated increased EGFR phosphotyrosine after EGF treatment over wildtype EGFR expressing cells. Cells expressing mutant EGFR also showed increased sensitivity to erlotinib treatment compared to cells expressing EGFR wild-type. Sensitivity was determined by assessing EGFR auto-phosphorylation."	20942962	PubMed		"Foster et al., 2010, World J Surg Oncol"		3	accepted	4658	Somatic	2023-01-27 03:38:56 UTC	https://civicdb.org/links/evidence_items/4658	https://civicdb.org/links/molecular_profiles/1482	FALSE	EGFR	1956	C797Y		chr7	55181399	55181399	G	A	ENST00000275493.2	75		missense_variant	"ENST00000275493.2:c.2390G>A,NM_005228.3:c.2390G>A,NC_000007.13:g.55249092G>A,NP_005219.2:p.Cys797Tyr"	2023-01-27 17:10:33 UTC	CA367578897	NONE FOUND	"C744Y,C752Y,CYS797TYR"	FALSE
EGFR Y801H	1483	Cancer	162		Erlotinib		Predictive	Supports	D	Sensitivity/Response	"In an in vitro study performed after identification of the mutation in a malignant peritoneal mesothelioma patient, COS-7 cells expressing EGFR Y801H demonstrated increased EGFR phosphotyrosine after EGF treatment over wildtype EGFR expressing cells. Cells expressing mutant EGFR also showed increased sensitivity to erlotinib treatment compared to cells expressing EGFR wild-type. Sensitivity was determined by assessing EGFR auto-phosphorylation."	20942962	PubMed		"Foster et al., 2010, World J Surg Oncol"		3	accepted	4659	Somatic	2023-01-09 21:46:46 UTC	https://civicdb.org/links/evidence_items/4659	https://civicdb.org/links/molecular_profiles/1483	FALSE	EGFR	1956	Y801H		chr7	55181410	55181410	T	C	ENST00000275493.2	75		missense_variant	ENST00000275493.2:c.2401T>C	2023-01-27 17:10:34 UTC	CA4266065	NONE FOUND	"Y748H,Y756H"	FALSE
EGFR A767_V769dupASV	1487	Lung Adenocarcinoma	3910		Erlotinib		Predictive	Supports	C	Resistance	"In a study of 19 non-small cell lung carcinoma patients with EGFR exon 20 insertion mutations and treated with erlotinib monotherapy, patients with EGFR A767_V769dupASV mutation (n=3) experienced progressive disease."	24353160	PubMed		"Yasuda et al., 2013, Sci Transl Med"			accepted	4665	Somatic	2023-01-09 21:46:46 UTC	https://civicdb.org/links/evidence_items/4665	https://civicdb.org/links/molecular_profiles/1487	FALSE	EGFR	1956	A767_V769dupASV		chr7	55181307	55181308		GCCAGCGTG	ENST00000275493.2			inframe_insertion		2023-01-27 17:10:35 UTC	CA180588			FALSE
EGFR L747_S752delinsQ	1488	Lung Adenocarcinoma	3910		Erlotinib		Predictive	Supports	C	Sensitivity/Response	"EGFR exons 18-24 were analyzed in 7 patients who had shown a partial response to erlotinib in a phase II trial for bronchioloalveolar carcinoma (BAC, or in situ pulmonary adenocarcinoma). One patient (Patient E1) had the del L747-S752 insQ mutation. The patient was a male never smoker and demonstrated response for 8 months. He continued to show response and remain on the drug when the manuscript was written."	15329413	PubMed		"Pao et al., 2004, Proc. Natl. Acad. Sci. U.S.A."		3	accepted	4667	Somatic	2023-01-09 21:46:46 UTC	https://civicdb.org/links/evidence_items/4667	https://civicdb.org/links/molecular_profiles/1488	FALSE	EGFR	1956	L747_S752delinsQ		chr7	55174776	55174793	TTAAGAGAAGCAACATCT	CAA				"inframe_insertion,inframe_deletion,delins"	"NC_000007.14:g.55174776_55174793delinsCAA,NC_000007.13:g.55242469_55242486delinsCAA,ENST00000275493.7:c.2239_2256delinsCAA,ENSP00000275493.2:p.Leu747_Ser752delinsGln,NM_005228.5:c.2239_2256delinsCAA,NP_005219.2:p.Leu747_Ser752delinsGln"	2023-01-27 17:10:36 UTC	CA645561524	NONE FOUND	"DEL L747-S752INSQ,LEU747_SER752DELINSGLN"	FALSE
EGFR L861R	1385	Lung Non-small Cell Carcinoma	3908		Gefitinib		Predictive	Supports	C	Sensitivity/Response	"In a study, 1 participant with stage IV lung adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have L861R mutation, and was treated with the 1st generation TKI gefitinib. The patient (M, 83, nonsmoker) had a partial response, progression free survival (PFS) of 37.5 months, overall survival (OS) of 53.3 months and was alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type."	21531810	PubMed		"Wu et al., 2011, Clin. Cancer Res."		3	accepted	4669	Somatic	2023-01-09 21:46:45 UTC	https://civicdb.org/links/evidence_items/4669	https://civicdb.org/links/molecular_profiles/1385	FALSE	EGFR	1956	L861R		chr7	55191831	55191831	T	G	ENST00000	75		missense_variant	"NM_005228.4:c.2582T>G,NP_005219.2:p.Leu861Arg,NC_000007.13:g.55259524T>G,ENST00000275493.2:c.2582T>G"	2023-01-27 17:09:45 UTC	CA135940	45287	RS121913444	FALSE
ABL1 BCR::ABL V379I	1517	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	C	Resistance	"Prior to dasatinib treatment, one imatinib-resistant patient with chronic myeloid leukemia in accelerated phase had the BCR-ABL1 fusion with E279K, V379I, and V379I/F317L/M351T variants in 3/11, 5/11, and 1/11 clones, respectively. Clones were generated using peripheral blood RNA. The patient had complete response as best cytogenetic response and no evidence of leukemia as best hematologic response to dasatinib which were improved compared to responses in patients with unmutated BCR-ABL1. An additional patient, in myeloid blast crisis, had V379I in 9/10 bacterial clones generated using peripheral blood RNA. They had complete response as best hematologic response and none as best cytogenetic response to dasatinib which were comparable to responses in patients with unmutated BCR-ABL1."	16775234	PubMed		"Talpaz et al., 2006, N. Engl. J. Med."	NCT00064233	3	accepted	4702	Somatic	2023-01-09 21:46:46 UTC	https://civicdb.org/links/evidence_items/4702	https://civicdb.org/links/molecular_profiles/1517	FALSE	ABL1	25	BCR::ABL V379I		chr9	130874917	130874917	G	A	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"ENST00000318560.5:c.1135G>A,NC_000009.11:g.133750304G>A,NM_005157.5:c.1135G>A,NP_005148.2:p.Val379Ile"	2023-01-27 17:10:50 UTC	CA375249852	NONE FOUND	"V398I,BCR-ABL VAL379ILE,BCR-ABL1 V379I,BCR-ABL1 VAL379ILE,BCR-ABL V379I"	FALSE
ABL1 BCR::ABL V379I	1517	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	C	Resistance	"In this phase II multinational study, patients with accelerated phase CML and BCR-ABL fusions were treated with dasatinib monotherapy. Response rate among 60 imatinib-resistant patients with BCR-ABL mutations did not differ from the rate of the total population of 100 imatinib-resistant or -intolerant patients. 44 (73%) of 60 BCR-ABL mutant patients achieved major hematologic responses (MaHRs) and 18 (30%) of 60 achieved major cytogenetic responses (MCyRs). Of patients with V379I, 3/4 had MaHRs and 2/4 had MCyRs which were comparable to response rates among wild type patients."	17264298	PubMed		"Guilhot et al., 2007, Blood"		1	accepted	4704	Somatic	2023-01-09 21:46:46 UTC	https://civicdb.org/links/evidence_items/4704	https://civicdb.org/links/molecular_profiles/1517	FALSE	ABL1	25	BCR::ABL V379I		chr9	130874917	130874917	G	A	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"ENST00000318560.5:c.1135G>A,NC_000009.11:g.133750304G>A,NM_005157.5:c.1135G>A,NP_005148.2:p.Val379Ile"	2023-01-27 17:10:50 UTC	CA375249852	NONE FOUND	"V398I,BCR-ABL VAL379ILE,BCR-ABL1 V379I,BCR-ABL1 VAL379ILE,BCR-ABL V379I"	FALSE
ABL1 BCR::ABL	1	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Supports	C	Sensitivity/Response	"Prior to dasatanib treatment, fifteen imatinib-resistant patients with chronic myeloid leukemia in various phases had the BCR-ABL1 fusion with no secondary variants in at least ten clones generated using peripheral blood RNA. They had no evidence of leukemia (n = 3), complete (9), minor (2), and no (1) best hematologic responses to dasatinib and complete (3), partial (3), minor (2), minimal (2), and no (5) best cytogenetic responses to dasatinib."	16775234	PubMed		"Talpaz et al., 2006, N. Engl. J. Med."	NCT00064233	4	accepted	4706	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/4706	https://civicdb.org/links/molecular_profiles/1	FALSE	ABL1	25	BCR::ABL	ABL1 fusions in B-ALL	chr22	23180210	23290413			ENST00000305877.8	75	ENST00000318560.5	transcript_fusion	N/A	2023-01-09 21:52:04 UTC		N/A	"T(9;22)(Q34;Q11),BCR-ABL1,BCR-ABL"	FALSE
ABL1 BCR::ABL	1	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Supports	C	Sensitivity/Response	"Prior to dasatanib treatment, fifteen imatinib-resistant patients with chronic myeloid leukemia in various phases had the BCR-ABL1 fusion with no secondary variants in at least ten clones generated using peripheral blood RNA. They had no evidence of leukemia (n = 3), complete (9), minor (2), and no (1) best hematologic responses to dasatinib and complete (3), partial (3), minor (2), minimal (2), and no (5) best cytogenetic responses to dasatinib."	16775234	PubMed		"Talpaz et al., 2006, N. Engl. J. Med."	NCT00064233	4	accepted	4706	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/4706	https://civicdb.org/links/molecular_profiles/1	FALSE	ABL1	25	BCR::ABL	ABL1 fusions in B-ALL	chr9	130854064	130887676			ENST00000305877.8	75	ENST00000318560.5	transcript_fusion	N/A	2023-01-09 21:52:04 UTC		N/A	"T(9;22)(Q34;Q11),BCR-ABL1,BCR-ABL"	FALSE
ABL1 BCR::ABL A397P	1520	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	C	Resistance	"In this phase II multinational study, patients with accelerated phase CML and BCR-ABL fusions were treated with dasatinib monotherapy. Response rate among 60 imatinib-resistant patients with BCR-ABL mutations did not differ from the rate of the total population of 100 imatinib-resistant or -intolerant patients. 44 (73%) of 60 BCR-ABL mutant patients achieved major hematologic responses (MaHRs) and 18 (30%) of 60 achieved major cytogenetic responses (MCyRs). Of patients with A397P,  2/2 had MaHRs and 1/2 had MCyRs which were comparable to response rates among wild type patients."	17264298	PubMed		"Guilhot et al., 2007, Blood"		1	accepted	4710	Somatic	2023-01-09 21:46:46 UTC	https://civicdb.org/links/evidence_items/4710	https://civicdb.org/links/molecular_profiles/1520	FALSE	ABL1	25	BCR::ABL A397P		chr9	130874971	130874971	G	C	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"ENST00000318560.5:c.1189G>C,NC_000009.11:g.133750358G>C,NM_005157.5:c.1189G>C,NP_005148.2:p.Ala397Pro"	2023-01-27 17:10:52 UTC	CA375249974	NONE FOUND	"A416P,ALA397PRO,BCR-ABL1 A397P,BCR-ABL A397P"	FALSE
BRAF G596R	1535	Colorectal Cancer	9256		Vemurafenib		Predictive	Does Not Support	D	Sensitivity/Response	"In an in vitro study, an NCI-H508 cell line expressing BRAF G596R demonstrated insensitivity to vemurafenib treatment compared to HT29 cells expressing BRAF V600E (a known vemurafenib sensitizing mutation; IC50 9.89 uM vs 0.025-0.35uM for BRAF V600E expressing cell lines). Note that NCI-H508 also expresses PIK3CA E545K."	22180495	PubMed		"Yang et al., 2012, Cancer Res."		1	accepted	4729	Somatic	2023-01-09 21:46:46 UTC	https://civicdb.org/links/evidence_items/4729	https://civicdb.org/links/molecular_profiles/1535	FALSE	BRAF	673	G596R		chr7	140753349	140753349	C	G	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1786G>C,NP_004324.2:p.Gly596Arg,NC_000007.13:g.140453149C>G,ENST00000288602.6:c.1786G>C"	2023-01-27 17:11:04 UTC	CA16602422	375943	"RS121913361,G204R,G24R,GLY596ARG"	FALSE
EGFR Exon 19 Deletion	133	Lung Adenocarcinoma	3910		Erlotinib		Predictive	Supports	C	Sensitivity/Response	"In a stage IV lung adenocarcinoma patient harboring EGFR exon 19 deletion, EGFR exon 19 deletion was associated with sensitivity to erlotinib monotherapy. Prior to identification of the EGFR exon 19 deletion, the patient was underwent complex treatments with standard chemotherapy and experienced disease progression; upon identification of EGFR exon 19 deletion and treatment with erlotinib, the patient achieved a clinical response."	27566387	PubMed		"Kanemaru et al., 2016, Respir Investig"			accepted	4766	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/4766	https://civicdb.org/links/molecular_profiles/133	FALSE	EGFR	1956	Exon 19 Deletion		chr7	55174722	55174820			ENST00000275493.2	75		inframe_deletion	ENST00000275493.2:c.2185_2283del	2023-01-09 21:52:05 UTC		N/A		FALSE
ABL1 BCR::ABL N336S	1548	Chronic Myeloid Leukemia	8552		Bosutinib		Predictive	Does Not Support	C	Resistance	"This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chronic phase CML and BCR-ABL fusions. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. Of patients with N336S, 1/1 had a CHR and 0/1 had a MCyR. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occuring."	22371878	PubMed		"Khoury et al., 2012, Blood"	NCT00261846	1	accepted	4769	Somatic	2023-01-09 21:46:47 UTC	https://civicdb.org/links/evidence_items/4769	https://civicdb.org/links/molecular_profiles/1548	FALSE	ABL1	25	BCR::ABL N336S		chr9	130872959	130872959	A	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"ENST00000318560.5:c.1007A>G,NC_000009.11:g.133748346A>G,NM_005157.5:c.1007A>G,NP_005148.2:p.Asn336Ser"	2023-01-27 17:11:06 UTC	CA375249553	NONE FOUND	"N355S,BCR-ABL1 ASN336SER,BCR-ABL N336S,BCR-ABL1 N336S,BCR-ABL N336S"	FALSE
PIK3CA D350G	1561	Melanoma	1909		Vemurafenib		Predictive	Supports	D	Resistance	"An in vitro study of M229 (a human melanoma cell line) endogenously expressing wildtype PIK3CA and BRAF V600E (a known BRAF inhibitor sensitizing mutation) found that cells virally induced to stably over-express PIK3CA D350G were significantly more resistant to BRAF inhibition by vemurafenib  than cells transduced with empty vectors (40% vs 20% survival at the highest concentration, p=.0148). Though statistics were not provided, D350G appears to confer less resistance to vemurafenib than the positive control variant, PIK3CA E545K."	24265155	PubMed		"Shi et al., 2014, Cancer Discov"		2	accepted	4784	Somatic	2023-01-09 21:46:47 UTC	https://civicdb.org/links/evidence_items/4784	https://civicdb.org/links/molecular_profiles/1561	FALSE	PIK3CA	5290	D350G		chr3	179203779	179203779	A	G	ENST00000263967.3	75		missense_variant	"ENST00000263967.3:c.1049A>G,NC_000003.11:g.178921567A>G,NM_006218.2:c.1049A>G,NP_006209.2:p.Asp350Gly"	2023-01-27 17:11:09 UTC	CA355281594	521363	ASP350GLY	FALSE
MET Exon 14 Skipping Mutation	320	Lung Adenocarcinoma	3910		Crizotinib		Predictive	Supports	C	Sensitivity/Response	"In a never-smoking metastatic lung adenocarcinoma patient harboring a MET splice site mutation (c.2887-18_2887-7del12)  treated with crizotinib monotherapy, was  associated with a response as evident by the reduced size of tumors. Prior to identification of the MET splice site mutation, the patient was treated with stereotactic radiotherapy, palliative radiation, and a single cycle of pemetrexed; subsequently, the patient was treated with crizotinib, but progressed at 8 weeks of treatment."	25769807	PubMed		"Jenkins et al., 2015, Clin Lung Cancer"		1	accepted	4786	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/4786	https://civicdb.org/links/molecular_profiles/320	FALSE	MET	4233	Exon 14 Skipping Mutation		chr7	116771849	116771989			ENST00000318493.6	75		exon_loss_variant		2023-01-09 21:52:06 UTC		N/A		FALSE
ABL1 R351W	1564	Lung Non-small Cell Carcinoma	3908		Dasatinib		Predictive	Supports	D	Sensitivity/Response	"In this in vitro study, the H1915 non-small cell lung cancer cell line (homozygous for a R351W mutation) was shown to be susceptible to dasatinib. This line showed a significant reduction in colony formation (P < 0.001) and MTT assay, which tests for NADH activity (P = 1.09 x 10^5), with dasatinib vs vehicle treatment. There was no significant difference in a lung cancer cell line without a known driver (H2126) nor in an immortalized bronchial epithelial line (Beas-2B) with either drug treatment in colony forming and MTT assays. Additionally, reduction in cell viability upon kinase inhibitor treatment could be rescued with tetracycline-induced overexpression of resistant ABL1-T315I (P < 0.001) confirming the genetic dependency of this cell line on ABL1. Moreover, a significant increased in cytotoxicity was noted with siRNA facilitated depletion of ABL1 (P < 0.005) with no significant change in H2126 or Beas-2B lines supporting ABL1 as the primary drug target."	26758680	PubMed		"Testoni et al., 2016, EMBO Mol Med"		4	accepted	4787	Somatic	2023-01-09 21:46:47 UTC	https://civicdb.org/links/evidence_items/4787	https://civicdb.org/links/molecular_profiles/1564	FALSE	ABL1	25	R351W		chr9	130872946	130872946	C	T	ENST00000372348.2	75		missense_variant	"ENST00000372348.2:c.1051C>T,NC_000009.11:g.133748333C>T,NM_007313.2:c.1051C>T,NP_009297.2:p.Arg351Trp"	2023-01-27 17:11:10 UTC	CA5285359	NONE FOUND	"R332W,ARG351TRP,RS779478267"	FALSE
ABL1 G340L	1565	Lung Non-small Cell Carcinoma	3908		"Dasatinib,Imatinib Mesylate"	Substitutes	Predictive	Supports	D	Sensitivity/Response	"In this in vitro study, the H2110 non-small cell lung cancer cell line (heterozygous for a G340L mutation) was shown to be susceptible to imatinib and dasatinib monotherapies. This line showed a significant reduction in colony formation (P = 0.0001) and MTT assay, which tests for NADH activity (P < 0.001), with imatinib vs vehicle treatment. A significant reduction in colony formation (P < 0.001) with dasatinib treatment vs vehicle was also observed. There was no significant difference in a lung cancer cell line without a known driver (H2126) nor in an immortalized bronchial epithelial line (Beas-2B) with either drug treatment in colony forming and MTT assays. Moreover, a significant increase in cytotoxicity was noted with siRNA facilitated depletion of ABL1 (P < 0.001) with no significant change in H2126 or Beas-2B lines supporting ABL1 as the primary drug target."	26758680	PubMed		"Testoni et al., 2016, EMBO Mol Med"		3	accepted	4788	Somatic	2023-01-09 21:46:47 UTC	https://civicdb.org/links/evidence_items/4788	https://civicdb.org/links/molecular_profiles/1565	FALSE	ABL1	25	G340L		chr9	130872913	130872914	GG	CT	ENST00000372348.2	75		coding_sequence_variant		2023-01-09 21:52:14 UTC	unregistered		GLY340LEU	FALSE
KIT S628N	1567	Cancer	162		"Dasatinib,Imatinib"	Substitutes	Predictive	Supports	D	Sensitivity/Response	"In an in vitro study, COS-7 cells expressing KIT S628N activating mutation demonstrated sensitivity to imatinib and dasatinib treatments when compared to the KIT L576P, which was used as an imatinib-sensitive control. Sensitivity was determined by assessing reduced mutant KIT auto-phosphorylation via western blotting with addition of inhibitors."	25317746	PubMed		"Vita et al., 2014, JAMA Dermatol"		2	accepted	4791	Somatic	2023-01-09 21:46:47 UTC	https://civicdb.org/links/evidence_items/4791	https://civicdb.org/links/molecular_profiles/1567	FALSE	KIT	3815	S628N		chr4	54728014	54728014	G	A				missense_variant		2023-01-27 17:11:12 UTC	CA356908374		S624N	FALSE
EGFR M766_A767insAI	1572	Lung Non-small Cell Carcinoma	3908		Erlotinib		Predictive	Supports	D	Resistance	"In an in vitro study, a Ba/F3 cell line expressing EGFR M766_A767insAI demonstrated reduced sensitivity to erlotinib treatment (IC50=3.403M), comparable to Ba/F3 cells expressing EGFR L858R and T790M co-mutation (T790M is a known resistant mutation to 1st and 2nd generation EGFR tyrosine kinase inhibitors; IC50=4.155M). Resistance was determined by assessing cell proliferation, EGFR, AKT and ERK phosphorylation."	24353160	PubMed		"Yasuda et al., 2013, Sci Transl Med"			accepted	4799	Somatic	2023-01-09 21:46:47 UTC	https://civicdb.org/links/evidence_items/4799	https://civicdb.org/links/molecular_profiles/1572	FALSE	EGFR	1956	M766_A767insAI		chr7	55181307	55181308		GCCATA	ENST00000275493.2	75		inframe_insertion		2023-01-27 17:11:15 UTC	CA645561560			FALSE
EGFR Y764_V765insHH	1573	Lung Non-small Cell Carcinoma	3908		Erlotinib		Predictive	Supports	D	Resistance	"In an in vitro study, a Ba/F3 cell line expressing EGFR Y764_V765insHH demonstrated reduced sensitivity to erlotinib treatment (IC50=3.845M), comparable to Ba/F3 cells expressing EGFR L858R and T790M co-mutation (T790M is a known resistant mutation to 1st and 2nd generations EGFR tyrosine kinase inhibitors; IC50=4.155M). Resistance was determined by assessing cell proliferation, EGFR, AKT and ERK phosphorylation."	24353160	PubMed		"Yasuda et al., 2013, Sci Transl Med"			accepted	4800	Somatic	2023-01-09 21:46:47 UTC	https://civicdb.org/links/evidence_items/4800	https://civicdb.org/links/molecular_profiles/1573	FALSE	EGFR	1956	Y764_V765insHH		chr7	55181301	55181302		CACCAC	ENST00000275493.2	75		inframe_insertion		2023-01-27 17:11:15 UTC	CA2573051277			FALSE
EGFR P772_H773insYNP	1575	Lung Non-small Cell Carcinoma	3908		Erlotinib		Predictive	Supports	C	Resistance	"A 79 year old Asian male never smoker with not otherwise specified NSCLC harboring EGFR P772_H773insYNP mutation was given erlotinib as first line treatment, and had progressive disease as best response with +2.3% change to target lesions, progression free survival of 2.1 months and overall survival of 16.5 months."	24353160	PubMed		"Yasuda et al., 2013, Sci Transl Med"		3	accepted	4802	Somatic	2023-01-09 21:46:47 UTC	https://civicdb.org/links/evidence_items/4802	https://civicdb.org/links/molecular_profiles/1575	FALSE	EGFR	1956	P772_H773insYNP		chr7	55181325	55181326		TATAATCCC				inframe_insertion		2023-01-27 17:11:17 UTC	CA2573051294			FALSE
ESR1 D538G	47	Breast Cancer	1612		"Palbociclib,Letrozole"	Combination	Predictive	Does Not Support	B	Sensitivity/Response	"In a study of 16 patients with metastatic breast cancer (NCT02142868) treated with palbociclib in combination with letrozole, patients with ESR1 mutations (5/16), including ESR1 D538G (n=2), detected at any time or at initial blood draw, were associated with reduced progression free survival (HR=0.31, 95% CI: 0.05-0.95, P=0.047), as compared with patients with wildtype ESR1 (n=11). There was no significant difference in overall survival (median; 14.1 versus 12.8 months, HR=0.40; 95% CI: 0.06-2.0, P-value=0.24)."	27556863	PubMed		"Gyanchandani et al., 2016, Oncotarget"		2	accepted	4814	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/4814	https://civicdb.org/links/molecular_profiles/47	FALSE	ESR1	2099	D538G	ESR1 Ligand-Binding Domain	chr6	152098791	152098791	A	G	ENST00000206249.3	75		missense_variant	"ENST00000206249.3:c.1613A>G,NC_000006.11:g.152419926A>G,NM_000125.3:c.1613A>G,NP_000116.2:p.Asp538Gly"	2023-01-27 17:02:15 UTC	CA366085705	NONE FOUND	ASP538GLY	FALSE
JAK2 Splice Site (c.1641+2T>G)	1589	Melanoma	1909		Pembrolizumab		Predictive	Supports	C	Resistance	"In a retrospective study of four relapsed, malignant melanoma patients, JAK2 (c.1641+2T>G) F547 splice site mutation was associated with acquired resistance to pembrolizumab monotherapy in one patient."	27433843	PubMed		"Zaretsky et al., 2016, N. Engl. J. Med."		3	accepted	4825	Somatic	2023-01-09 21:46:47 UTC	https://civicdb.org/links/evidence_items/4825	https://civicdb.org/links/molecular_profiles/1589	FALSE	JAK2	3717	Splice Site (c.1641+2T>G)		chr9	5070054	5070054	T	G				splice_donor_variant	"NC_000009.11:g.5070054T>G,NM_004972.3:c.1641+2T>G,NP_004963.1:p.="	2023-01-27 17:11:19 UTC	CA372825751	NONE FOUND	"F547 SPLICE SITE MUTATION,(C.1641+2T>G) F547 SPLICE SITE"	FALSE
VHL Mutation	160	Renal Cell Carcinoma	4450		Anti-VEGF Monoclonal Antibody		Predictive	Does Not Support	B	Sensitivity/Response	"A meta-analysis to evaluate the association between the VHL alteration and clinical outcomes in patients with RCC. There were six studies including a total of 633 patients: 244 patients who received anti-VEGF therapy in the predictive value analysis and 419 in the prognostic value analysis. 410 (61.8%) had VHL alteration. The meta-analysis showed no association between the VHL gene alteration and ORR or PFS, as well as no correlation to OS. VEGFR inhibition included: Sunitinib, Sorafenib, Axitinib, Pazopanib, Bevacizumab."	28103578	PubMed		"Kim et al., 2017, Oncotarget"		4	accepted	4832	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/4832	https://civicdb.org/links/molecular_profiles/160	FALSE	VHL	7428	Mutation		chr3	10141008	10152220			ENST00000256474.2	75		"gene_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
IDH2 Mutation	566	Acute Myeloid Leukemia	9119		Enasidenib		Predictive	Supports	D	Sensitivity/Response	"Mutations in IDH1 or IDH2 are identified in approximately 20% of patients with AML.This study report the discovery and characterization of AG-221, orally available, selective, potent inhibitor of the mutant IDH2 enzyme. AG-221 suppressed oncometobolite 2HG production and induced cellular differentiation in primary human IDH2 mutated AML cells in vivo and in xenograft mouse models, providing a statistically significant benefit in an aggressive IDH2 R140Q-mutant AML xenograft mouse model. Clinical trials are ongoing."	28193778	PubMed		"Yen et al., 2017, Cancer Discov"		4	accepted	4833	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/4833	https://civicdb.org/links/molecular_profiles/566	FALSE	IDH2	3418	Mutation		chr15	90083045	90102504			ENST00000330062.3	75		protein_altering_variant		2023-01-09 21:52:07 UTC		N/A		FALSE
ALK Fusion	495	Lung Non-small Cell Carcinoma	3908		Brigatinib		Predictive	Supports	B	Sensitivity/Response	"In a phase II randomized trial we evaluated two regimens of Brigatinib in Crizotinib-refractory ALK-pos. NSCLC. They were randomly assigned (1:1) to oral Brigatinib 90 mg once daily (arm A) or 180 mg once daily with a 7-day lead-in at 90 mg. Of 222 patients enrolled (arm A: n = 112, arm B: n = 110), 154 (69%) had baseline brain metastases and 164 of 222 (74%) had received prior chemotherapy. ORR was 45 (arm A) and 54% (B). Investigator-assessed median PFS was 9.2 months (A) and 12.9 months (B). Independent review committee-assessed intracranial ORR in patients with measurable brain metastases at baseline was 42% (11/26, A) and 67% (12/18, B). Brigatinib yielded substantial whole-body and intracranial responses as well as robust PFS; 180 mg (with lead-in) showed consistently better efficacy than 90 mg, with acceptable safety."	28475456	PubMed		"Kim et al., 2017, J. Clin. Oncol."		4	accepted	4835	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/4835	https://civicdb.org/links/molecular_profiles/495	FALSE	ALK	238	Fusion	ALK Fusion	chr2	29192774	29223528			ENST00000389048.3	75		transcript_fusion		2023-01-09 21:52:07 UTC		N/A	REARRANGEMENT	FALSE
BRCA1 Loss-of-function	131	Breast Cancer	1612		Talazoparib		Predictive	Supports	B	Sensitivity/Response	"In part 2 of a two-part dose-escalation phase I trial (NCT01286987), 71 patients with Ewings sarcoma, breast, ovarian, small cell lung, or pancreatic cancers received 1.0 mg/day talazoparib treatment. Of patients with BRCA mutation-associated breast and ovarian cancers, confirmed responses were observed in 7 of 14 (50%) and 5 of 12 (42%) patients, respectively."	28242752	PubMed		"de Bono et al., 2017, Cancer Discov"		4	accepted	4838	Rare Germline	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/4838	https://civicdb.org/links/molecular_profiles/131	FALSE	BRCA1	672	Loss-of-function	BRCA Germline Variants	chr17	43045629	43125483			ENST00000471181.2	75		"loss_of_heterozygosity,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
BRCA2 Loss-of-function	132	Breast Cancer	1612		Talazoparib		Predictive	Supports	B	Sensitivity/Response	"In part 2 of a two-part dose-escalation phase I trial (NCT01286987), 71 patients with Ewings sarcoma, breast, ovarian, small cell lung, or pancreatic cancers received 1.0 mg/day talazoparib treatment. Of patients with BRCA mutation-associated breast and ovarian cancers, confirmed responses were observed in 7 of 14 (50%) and 5 of 12 (42%) patients, respectively."	28242752	PubMed		"de Bono et al., 2017, Cancer Discov"		4	accepted	4839	Rare Germline	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/4839	https://civicdb.org/links/molecular_profiles/132	FALSE	BRCA2	675	Loss-of-function	BRCA Germline Variants	chr13	32315474	32399210			ENST00000380152.3	75		loss_of_function_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
CDK4 Amplification	549	Liposarcoma	3382		Palbociclib		Predictive	Supports	B	Sensitivity/Response	"A total of 59 patients with well-differentiated or dedifferentiated liposarcomas were enrolled in a phase 2 study to evaluate palbociclib efficacy. Half of the patients had received prior treatment and half were treatment naive. Of the 59 patients, at least 34 conferred CDK4 amplification and the remaining were not tested for CDK4 amplification. In the initial cohort (n=28), where all patients had confirmed CDK4 amplification, at least 14 of the patients were progression free at 12 weeks. Overall progression-free survival at 12 weeks was 57.2% and overall median PFS was 17.9 weeks. There was 1 complete response. Toxic effects were primarily hematologic and included neutropenia (grade 3, n??0 [33%]; grade 4, n?? [3%]) but no neutropenic fever."	27124835	PubMed		"Dickson et al., 2016, JAMA Oncol"	NCT01209598	3	accepted	4841	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/4841	https://civicdb.org/links/molecular_profiles/549	FALSE	CDK4	1019	Amplification		chr12	57747727	57752521			ENST00000257904.6	75		transcript_amplification		2023-01-09 21:52:07 UTC		N/A		FALSE
KRAS Mutation	332	Lung Non-small Cell Carcinoma	3908		Abemaciclib		Predictive	Supports	B	Sensitivity/Response	"In this multicenter phase I study of abemaciclib, a total of 225 patients were enrolled: 33 in dose escalation and 192 in tumor-specific cohorts. Radiographic responses were achieved in previously treated patients with breast cancer, NSCLC, and melanoma. The disease control rate for the KRAS-mutant population was 55% (16/29) compared to 39% (13/33)  in KRAS wildtype cohort. Stable disease lasting ?4 weeks was achieved for 31% (9/29) with KRAS-mutant disease vs 12% (4/33) with KRAS wild-type disease. Median PFS was 2.8 months and 1.9 months for the KRAS-mutant and KRAS wild-type populations, respectively."	27217383	PubMed		"Patnaik et al., 2016, Cancer Discov"		3	accepted	4842	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/4842	https://civicdb.org/links/molecular_profiles/332	FALSE	KRAS	3845	Mutation		chr12	25209431	25250803			ENST00000256078.4	75		protein_altering_variant		2023-01-09 21:52:06 UTC		N/A		FALSE
CD274 Expression	272	Breast Cancer	1612				Prognostic	Supports	B	Poor Outcome	"A meta-analysis of the role of PD-L1 expression in breast cancer found nine relevant studies with a total 8583 patients. PD-L1 expression was found to be associated with several poor prognostic indicators, such as ductal cancer, high tumor grade, ER negativity, PR negativity, HER2 positivity and aggressive molecular subtypes. PD-L1 overexpression had no significant impact on metastasis-free survival (HR 0.924, 95% CI = 0.747-1.141, p = 0.462), disease-free survival (HR 1.122, 95% CI = 0.878-1.434, p = 0.357) and overall specific survival (HR 0.837, 95% CI = 0.640-1.093, p = 0.191), but significantly correlated with shortened overall survival (HR 1.573, 95% CI = 1.010-2.451, p = 0.045)."	28079291	PubMed		"Wang et al., 2017, Breast J"		2	accepted	4844	N/A	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/4844	https://civicdb.org/links/molecular_profiles/272	FALSE	CD274	29126	Expression		chr9	5450525	5470547			ENST00000381577.3	75		N/A	N/A	2023-01-09 21:52:06 UTC		N/A		FALSE
ACVR1 G328V	1594	"Diffuse Midline Glioma, H3 K27M-mutant"	80684				Diagnostic	Supports	B	Positive	"Sequencing of 39 pediatric midline high-grade astrocytomas identified 5 patients with ACVR1 mutations. The authors identified an increase in endogenous phospho-SMAD1/5/8 signal in diffuse intrinsic pontine glioma (DIPG) cells harboring ACVR1 G328V, with corresponding increase in phospho-SMAD1/5/8 staining as well. By PCR, the authors show strong increase in fold change of mRNA expression in downstream proteins of the ACVR1/BMP pathway, ID, ID2, ID3 and SNAI1 in ACVR1-mutant DIPG cell line compared to glioblastoma cells (KNS42 cells). These activating ACVR1 mutations were exclusively in midline high grade astrocytomas (P = 0.0040, Fisher's exact test)."	24705250	PubMed		"Fontebasso et al., 2014, Nat. Genet."		3	accepted	4846	Somatic	2023-01-09 21:46:47 UTC	https://civicdb.org/links/evidence_items/4846	https://civicdb.org/links/molecular_profiles/1594	FALSE	ACVR1	90	G328V	ACVR1 kinase domain mutation	chr2	157766004	157766004	C	A	ENST00000434821.1	75		missense_variant	"NM_001105.4:c.983G>T,NP_001096.1:p.Gly328Val,NC_000002.11:g.158622516C>A,ENST00000434821.1:c.983G>T"	2023-01-27 17:11:21 UTC	CA16602802	376363	"GLY328VAL,RS387906589"	FALSE
CD274 Expression	272	Breast Cancer	1612				Prognostic	Supports	B	Poor Outcome	"In this meta-analysis, 5 studies totalling 2,546 cases were combined to assess the prognostic association of PD-L1 expression in breast cancer. The combined hazard ratio (HR) for PD-L1 overexpression was 1.76 (OS). The pooled odds ratios (ORs) indicated that PD-L1 expression was associated with positive lymph node metastasis, higher histological grades, estrogen receptor (ER)-negativity, and triple-negative breast cancer (TNBC)."	28430626	PubMed		"Zhang et al., 2017, Oncotarget"		3	accepted	4855	N/A	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/4855	https://civicdb.org/links/molecular_profiles/272	FALSE	CD274	29126	Expression		chr9	5450525	5470547			ENST00000381577.3	75		N/A	N/A	2023-01-09 21:52:06 UTC		N/A		FALSE
CD274 Expression	272	Cancer	162				Prognostic	Supports	B	Better Outcome	"PD-L1 is not only expressed in tumor cells (TCs) but also upregulated in tumor-infiltrating immune cells (TIICs). This meta-analysis evaluated the prognostic value of PD-L1 expression in TIICs in different types of cancers. 18 studies involving 3674 patients were included. PD-L1 positivity in TIICs related to a lower risk of death (HR = 0.784, p=0.047), and TIICs indicated a better prognosis especially in breast cancer patients (HR = 0.359, p=0.002)."	28453554	PubMed		"Zhao et al., 2017, PLoS ONE"		2	accepted	4856	N/A	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/4856	https://civicdb.org/links/molecular_profiles/272	FALSE	CD274	29126	Expression		chr9	5450525	5470547			ENST00000381577.3	75		N/A	N/A	2023-01-09 21:52:06 UTC		N/A		FALSE
CD274 Expression	272	Lung Non-small Cell Carcinoma	3908		"Nivolumab,Atezolizumab,Avelumab,Pembrolizumab,Durvalumab"	Substitutes	Predictive	Supports	B	Sensitivity/Response	"In this meta-analysis of 14 studies with 2857 patients, the immunotherapy response rate was higher among PD-L1-positive patients (RR: 2.19, 95% CI: 1.63-2.94). PD-L1 expression was also related to better progression-free survival (HR: 0.69, 95% CI: 0.57-0.85) and better overall survival (HR: 0.77, 95% CI: 0.67-0.89)."	28472902	PubMed		"Aguiar et al., 2017, Immunotherapy"		3	accepted	4857	N/A	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/4857	https://civicdb.org/links/molecular_profiles/272	FALSE	CD274	29126	Expression		chr9	5450525	5470547			ENST00000381577.3	75		N/A	N/A	2023-01-09 21:52:06 UTC		N/A		FALSE
ALK Fusion	495	Lung Non-small Cell Carcinoma	3908		"Crizotinib,Alectinib"	Substitutes	Predictive	Supports	B	Sensitivity/Response	"In a randomized, open-label phase 3 trial 303 patients with ALK-positive, previously untreated NSCLC (including asympt. CNS disease) were randomized to reiceive either Alectinib or Crizotinib. During a median follow-up of 17.6 months (crizotinib) and 18.6 months (alectinib), an event of disease progression/death occurred in 41% (62/152  pt) in the alectinib group and 68% (102/151 patients) in the crizotinib group. 12-month event-free survival rate 68.4% with alectinib vs. 48.7% with crizotinib. A total of 18 patients (12%) in the alectinib group had an event of CNS progression, compared to 68 patients (45%) in the crizotinib group. Response rates were 82.9% (Alectinib) and 75.5% (crizotinib)."	28586279	PubMed		"Peters et al., 2017, N. Engl. J. Med."	NCT02075840	5	accepted	4858	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/4858	https://civicdb.org/links/molecular_profiles/495	FALSE	ALK	238	Fusion	ALK Fusion	chr2	29192774	29223528			ENST00000389048.3	75		transcript_fusion		2023-01-09 21:52:07 UTC		N/A	REARRANGEMENT	FALSE
EGFR Exon 19 Deletion	133	Lung Non-small Cell Carcinoma	3908		"Dacomitinib,Erlotinib"	Substitutes	Predictive	Supports	B	Sensitivity/Response	"Non-small cell cancer patients from two studies [The ARCHER 1009 (NCT01360554) and A7471028 (NCT00769067)] with exon 19 deletion and L858R EGFR (Exon 21) mutations were pooled to compare the efficacy of dacomitinib to erlotinib. 121 patients with any EGFR mutation were enrolled, 101 had activating mutations in exon 19 or 21. Median progression-free survival and median survival were better following dacomitinib treatment (14.6 and 26.6 months, N=53) than erlotinib (9.6 and 23.2, P = 0.146 and P = 0.265, N=48). In exon 19 mutated patients (N=32 and 36) PFS was better for dacomitinib treated patients (HR of 0.585 [95% CI 0.335?.024], two-sided log-rank, P = 0.058) but did not reach significance."	26768165	PubMed		"Ramalingam et al., 2016, Ann. Oncol."	"NCT00769067,NCT01360554,NCT01774721"	3	accepted	4859	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/4859	https://civicdb.org/links/molecular_profiles/133	FALSE	EGFR	1956	Exon 19 Deletion		chr7	55174722	55174820			ENST00000275493.2	75		inframe_deletion	ENST00000275493.2:c.2185_2283del	2023-01-09 21:52:05 UTC		N/A		FALSE
EGFR L858R	33	Lung Non-small Cell Carcinoma	3908		Dacomitinib		Predictive	Supports	B	Sensitivity/Response	"The authors pooled patients with exon 19 deletion and L858R EGFR (Exon 21) mutations from both studies (The ARCHER 1009 (NCT01360554) and A7471028 (NCT00769067)) to compare the efficacy of dacomitinib to erlotinib. 121 patients with any EGFR mutation were enrolled, 101 had activating mutations in exon 19 or 21. For those (exon19/21), the median PFS was 14.6 months with dacomitinib and 9.6 months with erlotinib The median survival was 26.6 months with dacomitinib versus 23.2 months with erlotinib."	26768165	PubMed		"Ramalingam et al., 2016, Ann. Oncol."	"NCT00769067,NCT01360554,NCT01774721"	5	accepted	4860	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/4860	https://civicdb.org/links/molecular_profiles/33	FALSE	EGFR	1956	L858R		chr7	55191822	55191822	T	G	ENST00000275493.2	75		missense_variant	"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg"	2023-01-27 17:02:04 UTC	CA126713	"16,609,376,282,376,200"	"LEU858ARG,RS121434568"	FALSE
KRAS Mutation	332	Lung Non-small Cell Carcinoma	3908		"Trametinib,Pemetrexed,Docetaxel"	Combination	Predictive	Supports	B	Sensitivity/Response	"This phase I/Ib two-part study evaluated trametinib in combination with anticancer agents docetaxel or pemetrexed in NSCLC with and without KRAS mutations. Confirmed partial response (PR) was observed in 21% (10/47) patients receiving trametinib/docetaxel. The ORR was 18% (4 PR in 22 patients) in KRAS wild-type versus 24% (six PR in 25 patients) in KRAS-mutant NSCLC. Of the 42 patients treated with trametinib/pemetrexed, 14% (6/42) had a PR; the ORR was 17% (4/23) in KRAS-mutated NSCLC versus 11% (2/19) in KRAS wild-type NSCLC."	27876675	PubMed		"Gandara et al., 2017, J Thorac Oncol"	NCT01192165	3	accepted	4862	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/4862	https://civicdb.org/links/molecular_profiles/332	FALSE	KRAS	3845	Mutation		chr12	25209431	25250803			ENST00000256078.4	75		protein_altering_variant		2023-01-09 21:52:06 UTC		N/A		FALSE
KRAS Mutation	332	Lung Non-small Cell Carcinoma	3908		"Nivolumab,Atezolizumab"	Substitutes	Predictive	Supports	B	Sensitivity/Response	"A meta-analysis of randomized trials to investigate if KRAS mutation status affects survival benefits of immune checkpoint inhibition (ICI) in patients with advanced NSCLC. Of 3 eligible studies using either nivolumab or atezolizumab, 138 patients with KRAS mutant NSCLC and 371 with KRAS wild-type were included. ICI improved overall survival over that with docetaxel in KRAS mutant, previously-treated advanced NSCLC (hazard ratio=0.64 [95% confidence interval, 0.43-0.96], P = 0.03) but not in those with KRAS wild-type tumor (HR = 0.88 [95% CI, 0.68-1.13], P = 0.30). These results suggest that KRAS mutation status may be a potential biomarker for survival benefits to ICIs."	28525386	PubMed		"Kim et al., 2017, Oncotarget"		3	accepted	4863	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/4863	https://civicdb.org/links/molecular_profiles/332	FALSE	KRAS	3845	Mutation		chr12	25209431	25250803			ENST00000256078.4	75		protein_altering_variant		2023-01-09 21:52:06 UTC		N/A		FALSE
KRAS Mutation	332	Lung Non-small Cell Carcinoma	3908		Immune Checkpoint Inhibitor		Predictive	Supports	E	Sensitivity/Response	This meta-analysis of 5 studies with 752 non-small cell lung cancer patients examined the association between PD-L1 expression and KRAS mutation status. KRAS-mutant tumors were marginally more likely to be PD-L1 positive than KRAS-wild type tumors (51% vs 36%; odds ratio: 1.69; 95% CI 1.01-2.84; p = 0.045). Authors concluded that this result contributes to a theoretical basis for including PD-L1 inhibitors in combination with other molecularly targeted drugs in the treatment of patients with KRAS mutations.	28259530	PubMed		"Li et al., 2017, Eur J Surg Oncol"		2	accepted	4864	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/4864	https://civicdb.org/links/molecular_profiles/332	FALSE	KRAS	3845	Mutation		chr12	25209431	25250803			ENST00000256078.4	75		protein_altering_variant		2023-01-09 21:52:06 UTC		N/A		FALSE
KRAS Mutation	332	Colorectal Cancer	9256		"Selumetinib,Cetuximab"	Combination	Predictive	Does Not Support	B	Sensitivity/Response	"A phase I study  to determine the tolerability and pharmacokinetics of Selumetinib and Cetuximab with an expanded cohort in KRAS-mutant CRC. In the KRAS-mutant CRC dose expansion cohort 14 patients were evaluable for response. Five patients experienced stable disease, nine had progressive disease.  Minimal anti-tumor activity was observed in KRAS-mutant refractory metastatic CRC."	26666244	PubMed		"Deming et al., 2016, Invest New Drugs"	NCT01287130	3	accepted	4866	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/4866	https://civicdb.org/links/molecular_profiles/332	FALSE	KRAS	3845	Mutation		chr12	25209431	25250803			ENST00000256078.4	75		protein_altering_variant		2023-01-09 21:52:06 UTC		N/A		FALSE
KRAS Mutation	332	Lung Non-small Cell Carcinoma	3908		Trametinib		Predictive	Does Not Support	B	Sensitivity/Response	"In this phase II trial, trametinib or docetaxel was given to patients with advanced KRAS-mutant NSCLC. Median PFS was 12 weeks in the trametinib arm and 11 weeks in the docetaxel arm (HR 1.14; p = 0.5197). Median OS, while the data are immature, was 8 months in the trametinib arm and was not reached in the docetaxel arm (HR 0.97; P = 0.934). There were 10 (12%) partial responses (PRs) in the trametinib arm and 5 (12%) PRs in the docetaxel arm (P = 1.0000). These data suggest that trametinib is associated with similar PFS and response rates as docetaxel."	25722381	PubMed		"Blumenschein et al., 2015, Ann. Oncol."	NCT01362296	4	accepted	4867	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/4867	https://civicdb.org/links/molecular_profiles/332	FALSE	KRAS	3845	Mutation		chr12	25209431	25250803			ENST00000256078.4	75		protein_altering_variant		2023-01-09 21:52:06 UTC		N/A		FALSE
KRAS Mutation	332	Lung Non-small Cell Carcinoma	3908		"Erlotinib,Selumetinib"	Combination	Predictive	Does Not Support	B	Sensitivity/Response	38 KRAS wild-type patients were randomized to erlotinib or combination of selumetinib with erlotinib. 41 KRAS mutant patients were randomized to selumetinib or the combination. The primary end points were progression-free survival (PFS) for the KRAS wild-type cohort and objective response rate (ORR) for the KRAS mutant cohort. Median PFS in the KRAS wild-type arm was 2.4 months for erlotinib alone and 2.1 months for the combination. The ORR in the KRAS mutant group was 0% for selumetinib alone and 10% for the combination. These data suggest no difference in ORR or PFS with combination therapy of over monotherapy in KRAS mutant and KRAS wild-type advanced NSCLC.	26802155	PubMed		"Carter et al., 2016, Ann. Oncol."	NCT01229150	4	accepted	4868	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/4868	https://civicdb.org/links/molecular_profiles/332	FALSE	KRAS	3845	Mutation		chr12	25209431	25250803			ENST00000256078.4	75		protein_altering_variant		2023-01-09 21:52:06 UTC		N/A		FALSE
KRAS Mutation	332	Colorectal Cancer	9256		"Palbociclib,Binimetinib"	Combination	Predictive	Supports	D	Sensitivity/Response	"A preclinical study to investigate the efficacy of Binimetinib, Palbociclib and the combination on KRAS mutant colorectal cancer cell lines, cell line-derived and patient-derived xenografts.   The combination of MEK and CDK4/6 inhibition inhibited cancer cell growth and caused cell regression in a synergistic manner Combination therapy markedly decreased levels of phosphorylated ribosomal protein S6 both in vitro and in vivo and decreased Ki67 staining in vivo."	27167191	PubMed		"Lee et al., 2016, Oncotarget"		4	accepted	4869	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/4869	https://civicdb.org/links/molecular_profiles/332	FALSE	KRAS	3845	Mutation		chr12	25209431	25250803			ENST00000256078.4	75		protein_altering_variant		2023-01-09 21:52:06 UTC		N/A		FALSE
CDK4 EXPRESSION	25	Sarcoma	1115		Palbociclib		Predictive	Supports	D	Sensitivity/Response	"A preclinical study to explore the efficacy of CDK4/6 inhibition with palbociclib, in a panel of sarcoma cell lines and sarcoma tumor xenografts (PDXs). The responsiveness of these cell lines correlated with their levels of CDK4 mRNA as well as in vivo PDX, but not against sarcomas displaying low levels of CDK4 and high levels of p16ink4a (CDKN2A)."	26528855	PubMed		"Perez et al., 2015, Oncotarget"		4	accepted	4872	N/A	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/4872	https://civicdb.org/links/molecular_profiles/25	FALSE	CDK4	1019	EXPRESSION		chr12	57747727	57752521			ENST00000257904.6	75		N/A		2023-01-09 21:52:04 UTC		N/A		FALSE
BRCA2 Loss-of-function	132	Ovarian Cancer	2394		Talazoparib		Predictive	Supports	B	Sensitivity/Response	"In part 2 of a two-part dose-escalation phase I trial (NCT01286987), 71 patients with Ewings sarcoma, breast, ovarian, small cell lung, or pancreatic cancers received 1.0 mg/day talazoparib treatment. Of patients with BRCA mutation-associated breast and ovarian cancers, confirmed responses were observed in 7 of 14 (50%) and 5 of 12 (42%) patients, respectively."	28242752	PubMed		"de Bono et al., 2017, Cancer Discov"		3	accepted	4875	Rare Germline	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/4875	https://civicdb.org/links/molecular_profiles/132	FALSE	BRCA2	675	Loss-of-function	BRCA Germline Variants	chr13	32315474	32399210			ENST00000380152.3	75		loss_of_function_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
BRCA1 Loss-of-function	131	Ovarian Cancer	2394		Talazoparib		Predictive	Supports	B	Sensitivity/Response	"In part 2 of a two-part dose-escalation phase I trial (NCT01286987), 71 patients with Ewings sarcoma, breast, ovarian, small cell lung, or pancreatic cancers received 1.0 mg/day talazoparib treatment. Of patients with BRCA mutation-associated breast and ovarian cancers, confirmed responses were observed in 7 of 14 (50%) and 5 of 12 (42%) patients, respectively."	28242752	PubMed		"de Bono et al., 2017, Cancer Discov"		3	accepted	4876	Rare Germline	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/4876	https://civicdb.org/links/molecular_profiles/131	FALSE	BRCA1	672	Loss-of-function	BRCA Germline Variants	chr17	43045629	43125483			ENST00000471181.2	75		"loss_of_heterozygosity,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
EGFR Expression	350	Lung Non-small Cell Carcinoma	3908		Gefitinib		Predictive	Supports	B	Sensitivity/Response	"Double blind Phase II clinical trial evaluated 208 patients for efficacy of gefitinib against non-small cell lung cancer. For individuals taking 250mg/day, they observed an objective response rate of 18.4%, a PFS of 2.7 months and a median overall survival of 7.6 months. For individuals taking 500mg/day objective response rate was 19%, PFS was 2.8 months, and median overall survival was 8.0 months. For those who responded, median duration of the response was 3 months (ranges=1-5.5 months). The disease control rate was found to be 54.4% and 51.4% for the two groups."	12748244	PubMed		"Fukuoka et al., 2003, J. Clin. Oncol."		3	accepted	4877	N/A	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/4877	https://civicdb.org/links/molecular_profiles/350	FALSE	EGFR	1956	Expression		chr7	55019101	55211628			ENST00000275493.2	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
TP53 R248W	118	Cancer	162		MDM2 Inhibitor AMGMDS3		Predictive	Supports	D	Resistance	Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 R248W loss of function mutation is present in 4 cell lines and all are insensitive to MDM2 Inhibitor AMGMDS3.	25730903	PubMed		"Saiki et al., 2015, Oncotarget"		4	accepted	4879	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/4879	https://civicdb.org/links/molecular_profiles/118	FALSE	TP53	7157	R248W		chr17	7674221	7674221	G	A	ENST00000269305.4	75		missense_variant	"NM_000546.5:c.742C>T,NP_000537.3:p.Arg248Trp,NC_000017.10:g.7577539G>A,ENST00000269305.4:c.742C>T"	2023-01-27 17:02:45 UTC	CA000382	12347	"ARG248TRP,RS121912651"	FALSE
TP53 R175H	116	Cancer	162		MDM2 Inhibitor AMGMDS3		Predictive	Supports	D	Resistance	Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 R175H loss of function mutation is present in 4 cell lines and all are insensitive to MDM2 Inhibitor AMGMDS3.	25730903	PubMed		"Saiki et al., 2015, Oncotarget"		4	accepted	4880	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/4880	https://civicdb.org/links/molecular_profiles/116	FALSE	TP53	7157	R175H		chr17	7675088	7675088	C	T	ENST00000269305.4	75		missense_variant	"NM_000546.5:c.524G>A,NP_000537.3:p.Arg175His,NC_000017.10:g.7578406C>T,ENST00000269305.4:c.524G>A"	2023-01-27 17:02:43 UTC	CA000251	12374	"ARG175HIS,RS28934578,R43H,R136H"	FALSE
TP53 R273C	121	Cancer	162		MDM2 Inhibitor AMGMDS3		Predictive	Supports	D	Resistance	Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 R273C loss of function mutation is present in 2 cell lines and all are insensitive to MDM2 Inhibitor AMGMDS3.	25730903	PubMed		"Saiki et al., 2015, Oncotarget"		4	accepted	4881	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/4881	https://civicdb.org/links/molecular_profiles/121	FALSE	TP53	7157	R273C		chr17	7673803	7673803	G	A	ENST00000269305.4	75		missense_variant	"NM_000546.5:c.817C>T,NP_000537.3:p.Arg273Cys,NC_000017.10:g.7577121G>A,ENST00000269305.4:c.817C>T"	2023-01-27 17:02:47 UTC	CA000432	43594	"ARG273CYS,RS121913343"	FALSE
TP53 R273H	122	Cancer	162		MDM2 Inhibitor AMGMDS3		Predictive	Supports	D	Resistance	Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 R273H loss of function mutation is present in 7 cell lines and all are insensitive to MDM2 Inhibitor AMGMDS3.	25730903	PubMed		"Saiki et al., 2015, Oncotarget"		4	accepted	4882	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/4882	https://civicdb.org/links/molecular_profiles/122	FALSE	TP53	7157	R273H		chr17	7673802	7673802	C	T	ENST00000269305.4	75		missense_variant	"NM_000546.5:c.818G>A,NP_000537.3:p.Arg273His,NC_000017.10:g.7577120C>T,ENST00000269305.4:c.818G>A"	2023-01-27 17:02:48 UTC	CA000434	12366	"ARG273HIS,RS28934576"	FALSE
TP53 G245S	853	Cancer	162		MDM2 Inhibitor AMGMDS3		Predictive	Supports	D	Resistance	Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 G245S loss of function mutation is present in 3 cell lines and all are insensitive to MDM2 Inhibitor AMGMDS3.	25730903	PubMed		"Saiki et al., 2015, Oncotarget"		4	accepted	4883	Somatic	2023-01-09 21:46:39 UTC	https://civicdb.org/links/evidence_items/4883	https://civicdb.org/links/molecular_profiles/853	FALSE	TP53	7157	G245S		chr17	7674230	7674230	C	T	ENST00000269305.4	75		missense_variant	"NC_000017.10:g.7577548C>T,NM_000546.5:c.733G>A,NP_000537.3:p.Gly245Ser,ENST00000269305.4:c.733G>A"	2023-01-27 17:06:17 UTC	CA000367	12365	RS28934575	FALSE
TP53 Y220C	896	Cancer	162		MDM2 Inhibitor AMGMDS3		Predictive	Supports	D	Resistance	Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 Y220C loss of function mutation is present in 1 cell line and it is insensitive to MDM2 Inhibitor AMGMDS3.	25730903	PubMed		"Saiki et al., 2015, Oncotarget"		4	accepted	4884	Somatic	2023-01-09 21:46:40 UTC	https://civicdb.org/links/evidence_items/4884	https://civicdb.org/links/molecular_profiles/896	FALSE	TP53	7157	Y220C		chr17	7674872	7674872	T	C	ENST00000269305.4	75		missense_variant	"NM_000546.5:c.659A>G,NP_000537.3:p.Tyr220Cys,NC_000017.10:g.7578190T>C,ENST00000269305.4:c.659A>G"	2023-01-27 17:06:41 UTC	CA000315	127819	"RS121912666,TYR220CYS"	FALSE
TP53 M237I	1040	Glioblastoma	3068		MDM2 Inhibitor AMGMDS3		Predictive	Supports	D	Resistance	"Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 M237I loss of function mutation is present in 1 cell line (T98G, glioblastoma) and it is insensitive to MDM2 Inhibitor AMGMDS3 (IC50: 49.97uM)."	25730903	PubMed		"Saiki et al., 2015, Oncotarget"		3	accepted	4885	Somatic	2023-01-09 21:46:42 UTC	https://civicdb.org/links/evidence_items/4885	https://civicdb.org/links/molecular_profiles/1040	FALSE	TP53	7157	M237I		chr17	7674252	7674252	C	A	ENST00000269305.4	75		missense_variant	ENST00000269305.4:c.711G>T	2023-01-27 17:07:55 UTC	CA287488024	NONE FOUND	MET237ILE	FALSE
TP53 R158H	1603	Vulva Squamous Cell Carcinoma	2101		MDM2 Inhibitor AMGMDS3		Predictive	Supports	D	Resistance	Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 R158H loss of function mutation is present in 1 cell line (SW954) and it is insensitive to MDM2 Inhibitor AMGMDS3.	25730903	PubMed		"Saiki et al., 2015, Oncotarget"		3	accepted	4886	Somatic	2023-01-09 21:46:47 UTC	https://civicdb.org/links/evidence_items/4886	https://civicdb.org/links/molecular_profiles/1603	FALSE	TP53	7157	R158H		chr17	7675139	7675139	C	T	ENST00000269305.4	75		missense_variant	ENST00000269305.4:c.473G>A	2023-01-27 17:11:23 UTC	CA000227	141963	ARG158HIS	FALSE
TP53 V157F	1066	Cancer	162		MDM2 Inhibitor AMGMDS3		Predictive	Supports	D	Resistance	Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 V157F loss of function mutation is present in 1 cell line and it is insensitive to MDM2 Inhibitor AMGMDS3.	25730903	PubMed		"Saiki et al., 2015, Oncotarget"		4	accepted	4887	Somatic	2023-01-09 21:46:42 UTC	https://civicdb.org/links/evidence_items/4887	https://civicdb.org/links/molecular_profiles/1066	FALSE	TP53	7157	V157F		chr17	7675143	7675143	C	A	ENST00000269305.4	75		missense_variant	"NM_000546.5:c.469G>T,NP_000537.3:p.Val157Phe,NC_000017.10:g.7578461C>A,ENST00000269305.4:c.469G>T"	2023-01-27 17:08:00 UTC	CA000222	12353	"RS121912654,VAL157PHE"	FALSE
TP53 R158L	1607	Cancer	162		MDM2 Inhibitor AMGMDS3		Predictive	Supports	D	Resistance	Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 R158L loss of function mutation is present in 2 cell lines and all are insensitive to MDM2 Inhibitor AMGMDS3.	25730903	PubMed		"Saiki et al., 2015, Oncotarget"		4	accepted	4891	Somatic	2023-01-09 21:46:47 UTC	https://civicdb.org/links/evidence_items/4891	https://civicdb.org/links/molecular_profiles/1607	FALSE	TP53	7157	R158L		chr17	7675139	7675139	C	A	ENST00000269305.4	75		missense_variant	ENST00000269305.4:c.473G>T	2023-01-27 17:11:24 UTC	CA397842028	528248	ARG158LEU	FALSE
VHL E46* (c.136G>T)	1609	Von Hippel-Lindau Disease	14175	Retinal capillary hemangioma			Predisposing	Supports	C	Predisposition	"A study of 103 patients with VHL retinal manifestations and 108 patients without VHL retinal manifestations extracted from the French VHL database revealed that the number of hemangioblastomas appeared higher in patients who had a substitution when compared with patients with a truncated protein. Detected by PCR and SSCP, this stop mutation (E46*) was found in a single patient with VHL retinal manifestation, which coincides with mutations confirmed to be associated with VHL type 1 in this study. No family information was provided. Only moderate evidence of pathogenicity since the protein length changes as a result of in-frame deletions/insertions in a nonrepeat region or stop-loss variants (AMCG code: PM4)."	12202531	PubMed		"Dollfus et al., 2002, Invest. Ophthalmol. Vis. Sci."		4	accepted	4895	Rare Germline	2023-02-03 19:08:58 UTC	https://civicdb.org/links/evidence_items/4895	https://civicdb.org/links/molecular_profiles/1609	FALSE	VHL	7428	E46* (c.136G>T)		chr3	10141983	10141983	G	T	ENST00000256474.2	75		stop_gained	"ENST00000256474.2:c.136G>T,NC_000003.11:g.10183667G>T,NM_000551.3:c.136G>T,NP_000542.1:p.Glu46Ter"	2023-01-27 17:11:25 UTC	CA351748085	NONE FOUND	"GLU46TER,E46X,C.136G>T"	FALSE
VHL E52K (c.154G>A)	1610	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Predisposition	"A study of 103 patients with VHL retinal manifestations and 108 patients without VHL retinal manifestations revealed that the number of hemangioblastomas appeared higher in patients who had a substitution when compared with patients with a truncated protein. Detected by PCR and SSCP, the missense mutation (E52K (c.154G>A)) was found in a single patient with no VHL retinal manifestation."	12202531	PubMed		"Dollfus et al., 2002, Invest. Ophthalmol. Vis. Sci."		4	accepted	4896	Rare Germline	2023-02-03 19:11:18 UTC	https://civicdb.org/links/evidence_items/4896	https://civicdb.org/links/molecular_profiles/1610	FALSE	VHL	7428	E52K (c.154G>A)		chr3	10142001	10142001	G	A	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.154G>A,NP_000542.1:p.Glu52Lys,NC_000003.11:g.10183685G>A,ENST00000256474.2:c.154G>A"	2023-01-27 17:11:26 UTC	CA020056	161402	"GLU52LYS,C.154G>A,RS373068386"	FALSE
VHL E55* (c.163G>T)	1612	Von Hippel-Lindau Disease	14175	"Retinal capillary hemangioma,Renal cell carcinoma,Retinal detachment"			Predisposing	Supports	C	Likely Pathogenic	"Genetic analysis of 7 Hungarian individuals from 5 unrelated families affected with type von Hippel-Lindau disease revealed 5 different mutations, 3 of which were novel. The mutations could not be found within 100 healthy controls. One germline truncation mutation was found in a 15-year-old male patient with bilateral renal cell carcinoma and retinal hemangioblastoma with serious retinal detachment. Neither of his parents displayed any mutations in the VHL gene indicating a de novo mutation. ACMG evidence codes: 'PS2' because they observe a de novo mutation (maternity and paternity confirmed), 'PP4' because the patient's phenotypes or family history are highly specific for a disease with single genetic etiology, 'PVS1' because they observe a nonsense variant in a gene where loss of function is a known mechanism of disease. Relevant HPO terms: Renal cell carcinoma, Retinal hemangioblastoma"	23298237	PubMed		"Losonczy et al., 2013, BMC Med. Genet."		3	accepted	4898	Rare Germline	2023-01-09 21:46:47 UTC	https://civicdb.org/links/evidence_items/4898	https://civicdb.org/links/molecular_profiles/1612	FALSE	VHL	7428	E55* (c.163G>T)		chr3	10142010	10142010	G	T	ENST00000256474.2	75		stop_gained	"ENST00000256474.2:c.163G>T,NC_000003.11:g.10183694G>T,NC_000003.12:g.10142010G>T,NM_000551.4:c.163G>T,NP_000542.1:p.Glu55Ter"	2023-01-27 17:11:26 UTC	CA351748495	NONE FOUND	GLU55TER	FALSE
BRAF L597Q	579	Skin Melanoma	8923		Trametinib		Predictive	Supports	C	Sensitivity/Response	Case study report including one patient with L597Q mutation-positive metastatic melanoma (M1b disease) treated with the MEK inhibitor trametinib. The L597Q patient achieved a RECIST partial response and showed maximum tumor shrinkage of 33% with trametinib as the first-line treatment and had a partial response for 6.2 months.	24933606	PubMed		"Bowyer et al., 2014, Melanoma Res."		3	accepted	4905	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/4905	https://civicdb.org/links/molecular_profiles/579	FALSE	BRAF	673	L597Q		chr7	140753345	140753345	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1790T>A,NP_004324.2:p.Leu597Gln,NC_000007.13:g.140453145A>T,ENST00000288602.6:c.1790T>A"	2023-01-27 17:04:27 UTC	CA16602257	76687	"LEU597GLN,RS121913366"	FALSE
VHL Y98H (c.292T>C)	1617	Von Hippel-Lindau Disease	14175	"Retinal capillary hemangioma,Cerebellar hemangioblastoma,Pheochromocytoma"			Predisposing	Supports	C	Uncertain Significance	"In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. Missense mutation found in two VHL type 2A families of 55 individuals altogether (family IDs 3476, 3127). 26 of 55 individuals were identified with retinal hemangioblastomas, 5 with cerebellar hemangioblastomas, and 30 with pheochromocytomas. Supporting evidence of pathogenicity because cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1)."	7728151	PubMed		"Chen et al., 1995, Hum. Mutat."		3	accepted	4906	Rare Germline	2023-01-09 21:46:48 UTC	https://civicdb.org/links/evidence_items/4906	https://civicdb.org/links/molecular_profiles/1617	FALSE	VHL	7428	Y98H (c.292T>C)		chr3	10142139	10142139	T	C	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.292T>C,NP_000542.1:p.Tyr98His,NC_000003.11:g.10183823T>C,ENST00000256474.2:c.292T>C"	2023-01-27 17:11:30 UTC	CA020246	2223	"C.292T>C,TYR98HIS,RS5030809"	FALSE
VHL H115Q (c.345C>A)	1618	Von Hippel-Lindau Disease	14175	"Cerebellar hemangioblastoma,Pheochromocytoma,Renal cell carcinoma,Retinal capillary hemangioma"			Predisposing	Supports	C	Uncertain Significance	"In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This missense mutation was found in a VHL type 2B family of 12 individuals (Family ID 4486 in publication). All 12 family members identified with cerebellar hemangioblastomas, 2 of 12 family members with retinal hemangioblastomas, one with renal cell carcinoma and one with pheochromocytoma. Supporting evidence of pathogenicity because cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1).  Relevant HPO terms: Cerebellar hemangioblastoma, Retinal hemangioblastoma, Renal cell carcinoma, Pheochromocytoma."	7728151	PubMed		"Chen et al., 1995, Hum. Mutat."		2	accepted	4907	Rare Germline	2023-01-09 21:46:48 UTC	https://civicdb.org/links/evidence_items/4907	https://civicdb.org/links/molecular_profiles/1618	FALSE	VHL	7428	H115Q (c.345C>A)		chr3	10146518	10146518	C	A	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.345C>A,NP_000542.1:p.His115Gln,NC_000003.11:g.10188202C>A,NM_000551.3:c.345C>A"	2023-01-27 17:11:31 UTC	CA351753631	496057	"C.345C>A,HIS115GLN,RS864622646"	FALSE
VHL F119L (c.357C>G)	1619	Von Hippel-Lindau Disease	14175	"Cerebellar hemangioblastoma,Retinal capillary hemangioma,Pheochromocytoma,Renal cell carcinoma"			Predisposing	Supports	C	Uncertain Significance	"In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This missense mutation was found in a VHL type 2B family of 7 individuals (Family ID 4414 in publication). Two of seven individuals were identified with retinal hemangioblastomas, 3 with cerebellar hemangioblastomas, one with renal cell carcinoma, and one with pheochromocytomas. Supporting evidence of pathogenicity because cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1)."	7728151	PubMed		"Chen et al., 1995, Hum. Mutat."		2	accepted	4908	Rare Germline	2023-01-09 21:46:48 UTC	https://civicdb.org/links/evidence_items/4908	https://civicdb.org/links/molecular_profiles/1619	FALSE	VHL	7428	F119L (c.357C>G)		chr3	10146530	10146530	C	G	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.357C>G,NC_000003.11:g.10188214C>G,NM_000551.3:c.357C>G,NP_000542.1:p.Phe119Leu"	2023-01-27 17:11:32 UTC	CA351753726	625240	"C.357C>G,PHE119LEU,RS1559428077"	FALSE
VHL A149T (c.445G>A)	1620	Von Hippel-Lindau Disease	14175	"Pheochromocytoma,Retinal capillary hemangioma"			Predisposing	Supports	C	Uncertain Significance	"In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This missense mutation was found in 2 family members with VHL (Family ID 3969 in publication). One carried pheochromocytoma, while both carried angiomas."	7728151	PubMed		"Chen et al., 1995, Hum. Mutat."		2	accepted	4909	Rare Germline	2023-01-09 21:46:48 UTC	https://civicdb.org/links/evidence_items/4909	https://civicdb.org/links/molecular_profiles/1620	FALSE	VHL	7428	A149T (c.445G>A)		chr3	10146618	10146618	G	A	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.445G>A,NM_000551.3:c.445G>A,NP_000542.1:p.Ala149Thr,NC_000003.11:g.10188302G>A"	2023-01-27 17:11:33 UTC	CA357066	223213	"C.445G>A,ALA149THR,RS587780077"	FALSE
VHL T157I (c.470C>T)	1621	Von Hippel-Lindau Disease	14175	"Pheochromocytoma,Retinal capillary hemangioma"			Predisposing	Supports	C	Uncertain Significance	"In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This mutation was found in 2 family members with VHL disease (family ID 4402). One carried pheochromocytoma and both carried retinal hemangioblastoma. Supporting evidence of pathogenicity because cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1)."	7728151	PubMed		"Chen et al., 1995, Hum. Mutat."		4	accepted	4910	Rare Germline	2023-01-09 21:46:48 UTC	https://civicdb.org/links/evidence_items/4910	https://civicdb.org/links/molecular_profiles/1621	FALSE	VHL	7428	T157I (c.470C>T)		chr3	10149793	10149793	C	T	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.470C>T,NP_000542.1:p.Thr157Ile,NC_000003.11:g.10191477C>T,ENST00000256474.2:c.470C>T"	2023-01-27 17:11:33 UTC	CA357133	223223	"C.470C>T,THR157ILE,RS869025660"	FALSE
VHL R161Q (c.482G>A)	1622	Von Hippel-Lindau Disease	14175	"Pheochromocytoma,Renal cell carcinoma,Retinal capillary hemangioma"			Predisposing	Supports	C	Uncertain Significance	"In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This missense mutation was detected in a VHL type 2B patient with retinal hemangioblastoma, renal cell carcinoma, and pheochromocytoma (family ID 4422). Only supporting evidence for pathogenicity because patient's phenotyoe is highly specific for a disease with a single genetic etiology (ACMG code: PP4)."	7728151	PubMed		"Chen et al., 1995, Hum. Mutat."		4	accepted	4911	Rare Germline	2023-01-09 21:46:48 UTC	https://civicdb.org/links/evidence_items/4911	https://civicdb.org/links/molecular_profiles/1622	FALSE	VHL	7428	R161Q (c.482G>A)		chr3	10149805	10149805	G	A	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.482G>A,NP_000542.1:p.Arg161Gln,NC_000003.11:g.10191489G>A,ENST00000256474.2:c.482G>A"	2023-01-27 17:11:34 UTC	CA020413	182983	"C.482G>A,ARG161GLN,RS730882035"	FALSE
VHL R167W (c.499C>T)	1623	Von Hippel-Lindau Disease	14175	"Renal cell carcinoma,Retinal capillary hemangioma,Cerebellar hemangioblastoma,Pheochromocytoma"			Predisposing	Supports	C	Uncertain Significance	"In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This missense mutation was found in four VHL type 2 families of 51 individuals altogether (family IDs 2338, 3490, 4477, 4405). 36 of 51 individuals had retinal hemangioblastomas, 17 had cerebellar hemangioblastomas, 16 with renal cell carcinoma, and 36 with pheochromocytomas. This mutation was also detected in a VHL type 1 patient with angiomas (family ID 3699). Supporting evidence of pathogenicity because cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1)."	7728151	PubMed		"Chen et al., 1995, Hum. Mutat."		3	accepted	4912	Rare Germline	2023-01-09 21:46:48 UTC	https://civicdb.org/links/evidence_items/4912	https://civicdb.org/links/molecular_profiles/1623	FALSE	VHL	7428	R167W (c.499C>T)		chr3	10149822	10149822	C	T	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.499C>T,NP_000542.1:p.Arg167Trp,NC_000003.11:g.10191506C>T,ENST00000256474.2:c.499C>T"	2023-01-27 17:11:35 UTC	CA020450	2218	"C.499C>T,ARG167TRP,R126W,RS5030820"	FALSE
VHL R167Q (c.500G>A)	1615	Von Hippel-Lindau Disease	14175	"Pheochromocytoma,Retinal capillary hemangioma,Cerebellar hemangioblastoma,Renal cell carcinoma"			Predisposing	Supports	C	Uncertain Significance	"In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This missense mutation was found in six VHL type 2 families (including one family with 9 affected individuals) and one VHL type 1 family totaling 23 individuals altogether (family IDs 4421, 3718, 3767, 3493, 3731, 3517, 3739). Twelve of 23 individuals had retinal hemangioblastomas, 12 carried cerebellar hemangioblastomas, 8 carried renal cell carcinoma and 12 carried pheochromocytomas. Supporting evidence of pathogenicity because cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1)."	7728151	PubMed		"Chen et al., 1995, Hum. Mutat."		3	accepted	4913	Rare Germline	2023-01-09 21:46:47 UTC	https://civicdb.org/links/evidence_items/4913	https://civicdb.org/links/molecular_profiles/1615	FALSE	VHL	7428	R167Q (c.500G>A)		chr3	10149823	10149823	G	A	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.500G>A,NP_000542.1:p.Arg167Gln,NC_000003.11:g.10191507G>A,ENST00000256474.2:c.500G>A"	2023-01-27 17:11:29 UTC	CA020454	2216	"C.500G>A,ARG167GLN,RS5030821"	FALSE
VHL L178P (c.533T>C)	1624	Von Hippel-Lindau Disease	14175	"Renal cell carcinoma,Pheochromocytoma,Retinal capillary hemangioma,Cerebellar hemangioblastoma"			Predisposing	Supports	C	Uncertain Significance	"In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This missense mutation was found in 2 family members with VHL disease type 2A, who both had retinal hemangioblastomas and cerebellar hemangioblastomas (family ID 3786). One of 2 individuals carried pheochromocytomas as well. Mutation also found in 8 individuals with VHL type 1 phenotype (family IDs 3314, 4419, 4403, 3708). Three of 8 individuals were identified with retinal hemangioblastomas, 5 with cerebellar hemangioblastomas, and 2 with renal cell carcinoma. Supporting evidence of pathogenicity because cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1)."	7728151	PubMed		"Chen et al., 1995, Hum. Mutat."		4	accepted	4914	Rare Germline	2023-01-09 21:46:48 UTC	https://civicdb.org/links/evidence_items/4914	https://civicdb.org/links/molecular_profiles/1624	FALSE	VHL	7428	L178P (c.533T>C)		chr3	10149856	10149856	T	C	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.533T>C,NM_000551.3:c.533T>C,NP_000542.1:p.Leu178Pro,NC_000003.11:g.10191540T>C"	2023-01-27 17:11:36 UTC	CA351756245	428795	"C.533T>C,LEU178PRO,RS5030822"	FALSE
VHL S65W (c.194C>G)	1663	Von Hippel-Lindau Disease	14175	"Retinal capillary hemangioma,Cerebellar hemangioblastoma"			Predisposing	Supports	C	Uncertain Significance	"In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This missense mutation was found in a VHL type 1 family of four individuals (family ID 4325). Three of 4 individuals were identified with retinal hemangioblastomas and one with cerebellar hemangioblastomas. Relevant HPO terms: Cerebellar hemangioblastoma, Retinal hemangioblastoma."	7728151	PubMed		"Chen et al., 1995, Hum. Mutat."		2	accepted	4917	Rare Germline	2023-01-09 21:46:49 UTC	https://civicdb.org/links/evidence_items/4917	https://civicdb.org/links/molecular_profiles/1663	FALSE	VHL	7428	S65W (c.194C>G)		chr3	10142041	10142041	C	G	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.194C>G,NM_000551.3:c.194C>G,NP_000542.1:p.Ser65Trp,NC_000003.11:g.10183725C>G"	2023-01-27 17:12:02 UTC	CA020099	43597	"C.194C>G,SER65TRP,RS5030826"	FALSE
VHL Q73* (c.217C>T)	1628	Von Hippel-Lindau Disease	14175	"Cerebellar hemangioblastoma,Retinal capillary hemangioma,Renal cell carcinoma"			Predisposing	Supports	C	Uncertain Significance	"In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This nonsense mutation was found in a VHL type 1 family of 7 individuals (family ID 2753). Six of 7 individuals were identified with retinal hemangioblastomas, 3 with cerebellar hemangioblastomas and one with renal cell carcinoma. Supporting evidence of pathogenicity because cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1)."	7728151	PubMed		"Chen et al., 1995, Hum. Mutat."		4	accepted	4918	Rare Germline	2023-01-09 21:46:48 UTC	https://civicdb.org/links/evidence_items/4918	https://civicdb.org/links/molecular_profiles/1628	FALSE	VHL	7428	Q73* (c.217C>T)		chr3	10142064	10142064	C	T	ENST00000256474.2	75		stop_gained	"NM_000551.3:c.217C>T,NP_000542.1:p.Gln73Ter,NC_000003.11:g.10183748C>T,ENST00000256474.2:c.217C>T"	2023-01-27 17:11:39 UTC	CA357036	223164	"Q73X,C.217C>T,GLN73TER,RS869025619"	FALSE
VHL F76del (c.224_226delTCT)	1964	Von Hippel-Lindau Disease	14175	"Renal cell carcinoma,Retinal capillary hemangioma,Cerebellar hemangioblastoma"			Predisposing	Supports	C	Uncertain Significance	"This deletion mutation was found in two VHL type 1 families of 15 individuals altogether (Family IDs 2693 and 2956 in publication). Five of 7 individuals were identified with retinal hemangioblastomas, 8 with cerebellar hemangioblastomas, and 7 with renal cell carcinoma. Supporting evidence of pathogenicity because cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1)."	7728151	PubMed		"Chen et al., 1995, Hum. Mutat."		4	accepted	4919	Rare Germline	2023-01-09 21:46:55 UTC	https://civicdb.org/links/evidence_items/4919	https://civicdb.org/links/molecular_profiles/1964	FALSE	VHL	7428	F76del (c.224_226delTCT)		chr3	10142071	10142073	TCT		ENST00000256474.2	75		inframe_deletion	"NP_000542.1:p.Phe76del,ENST00000256474.2:c.224_226delTCT,NC_000003.11:g.10183758_10183760del,NC_000003.12:g.10142074_10142076del,NM_000551.3:c.227_229del,ENSP00000256474.2:p.Phe76del"	2023-01-27 17:15:01 UTC	CA357012	223166	"PHE76DEL,C.224_226DELTCT,C.226_228DELTTC,C.227_229DELTCT,DELPHE76"	FALSE
VHL N78H (c.232A>C)	1630	Von Hippel-Lindau Disease	14175	"Retinal capillary hemangioma,Cerebellar hemangioblastoma,Renal cell carcinoma"			Predisposing	Supports	C	Uncertain Significance	"In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This missense mutation was detected in a type 1 VHL patient (family ID 4389) with retinal hemangioblastomas, cerebellar hemangioblastomas, and renal cell carcinoma. Only supporting evidence for pathogenicity because patient's phenotype is highly specific for a disease with a single genetic etiology (ACMG code: PP4)."	7728151	PubMed		"Chen et al., 1995, Hum. Mutat."		4	accepted	4920	Rare Germline	2023-01-09 21:46:48 UTC	https://civicdb.org/links/evidence_items/4920	https://civicdb.org/links/molecular_profiles/1630	FALSE	VHL	7428	N78H (c.232A>C)		chr3	10142079	10142079	A	C	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.232A>C,NC_000003.11:g.10183763A>C,NM_000551.3:c.232A>C,NP_000542.1:p.Asn78His"	2023-01-27 17:11:40 UTC	CA351749283	NONE FOUND	"C.232A>C,ASN78HIS"	FALSE
VHL N78S (c.233A>G)	1631	Von Hippel-Lindau Disease	14175	"Cerebellar hemangioblastoma,Renal cell carcinoma"			Predisposing	Supports	C	Uncertain Significance	"In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This missense mutation was found in 3 family members with VHL type 1 phenotype (family ID 4327). All 3 individuals carried cerebellar hemangioblastomas and one also carried renal cell carcinoma. Supporting evidence of pathogenicity because cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1)."	7728151	PubMed		"Chen et al., 1995, Hum. Mutat."		2	accepted	4921	Rare Germline	2023-01-09 21:46:48 UTC	https://civicdb.org/links/evidence_items/4921	https://civicdb.org/links/molecular_profiles/1631	FALSE	VHL	7428	N78S (c.233A>G)		chr3	10142080	10142080	A	G	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.233A>G,NP_000542.1:p.Asn78Ser,NC_000003.11:g.10183764A>G,ENST00000256474.2:c.233A>G"	2023-01-27 17:11:40 UTC	CA020131	93326	"C.233A>G,ASN78SER,RS5030804"	FALSE
VHL N78T (c.233A>C)	1632	Von Hippel-Lindau Disease	14175	"Retinal capillary hemangioma,Cerebellar hemangioblastoma"			Predisposing	Supports	C	Uncertain Significance	"In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This missense mutation was found in 3 family members with VHL type 1 phenotype (family ID 3101). One of 3 members carried retinal hemangioblastomas and 2 carried cerebellar hemangioblastomas."	7728151	PubMed		"Chen et al., 1995, Hum. Mutat."		2	accepted	4922	Rare Germline	2023-01-09 21:46:49 UTC	https://civicdb.org/links/evidence_items/4922	https://civicdb.org/links/molecular_profiles/1632	FALSE	VHL	7428	N78T (c.233A>C)		chr3	10142080	10142080	A	C	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.233A>C,NP_000542.1:p.Asn78Thr,NC_000003.11:g.10183764A>C,ENST00000256474.2:c.233A>C"	2023-01-27 17:11:41 UTC	CA357095	223168	"C.233A>C,ASN78THR,RS5030804"	FALSE
VHL S80I (c.239G>T)	1633	Von Hippel-Lindau Disease	14175	"Cerebellar hemangioblastoma,Retinal capillary hemangioma"			Predisposing	Supports	C	Uncertain Significance	"In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This missense mutation was detected in a type 1 VHL patient with retinal hemangioblastomas and cerebellar hemangioblastomas (family ID 3630). Only supporting evidence for pathogenicity because patient's phenotype is highly specific for a disease with a single genetic etiology (ACMG code: PP4)."	7728151	PubMed		"Chen et al., 1995, Hum. Mutat."		4	accepted	4923	Rare Germline	2023-01-09 21:46:49 UTC	https://civicdb.org/links/evidence_items/4923	https://civicdb.org/links/molecular_profiles/1633	FALSE	VHL	7428	S80I (c.239G>T)		chr3	10142086	10142086	G	T	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.239G>T,NM_000551.3:c.239G>T,NP_000542.1:p.Ser80Ile,NC_000003.11:g.10183770G>T"	2023-01-27 17:11:42 UTC	CA16621914	NONE FOUND	"C.239G>T,SER80ILE,RS5030805"	FALSE
VHL P86fs (c.254_255insC)	1634	Von Hippel-Lindau Disease	14175	"Cerebellar hemangioblastoma,Retinal capillary hemangioma,Renal cell carcinoma"			Predisposing	Supports	C	Predisposition	"In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This frameshift mutation was found in 3 family members with VHL type 1 phenotype (family ID 3312). All 3 individuals carried retinal hemangioblastomas, 2 of 3 carried cerebellar hemangioblastomas and one carried renal cell carcinoma. Supporting evidence of pathogenicity because cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1)."	7728151	PubMed		"Chen et al., 1995, Hum. Mutat."		4	accepted	4924	Rare Germline	2023-01-12 21:37:21 UTC	https://civicdb.org/links/evidence_items/4924	https://civicdb.org/links/molecular_profiles/1634	FALSE	VHL	7428	P86fs (c.254_255insC)		chr3	10142101	10142102		C	ENST00000256474.2	75		"plus_1_frameshift_variant,frameshift_truncation"	"NC_000003.11:g.10183785_10183786insC,NM_000551.3:c.254_255insC,NC_000003.12:g.10142101_10142102insC,NP_000542.1:p.Pro86fs"	2023-01-27 17:11:43 UTC	CA2497028737	NONE FOUND	P86AFS*46	FALSE
VHL P86L (c.257C>T)	1636	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	"In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This missense mutation was found in two VHL type 1 families of 12 individuals altogether (family IDs 2612 and 3568). Nine of 12 individuals were identified with cerebellar hemangioblastomas, 6 with retinal hemangioblastomas, and 6 with renal cell carcinoma. Supporting evidence of pathogenicity because cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1). Relevant HPO terms: Cerebellar hemangioblastoma, Retinal hemangioblastoma, Renal cell carcinoma."	7728151	PubMed		"Chen et al., 1995, Hum. Mutat."		4	accepted	4926	Rare Germline	2023-01-09 21:46:49 UTC	https://civicdb.org/links/evidence_items/4926	https://civicdb.org/links/molecular_profiles/1636	FALSE	VHL	7428	P86L (c.257C>T)		chr3	10142104	10142104	C	T	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.257C>T,NP_000542.1:p.Pro86Leu,NC_000003.11:g.10183788C>T,ENST00000256474.2:c.257C>T"	2023-01-27 17:11:44 UTC	CA020186	182977	"C.257C>T,PRO86LEU,RS730882034"	FALSE
VHL W88R (c.262T>A)	1637	Von Hippel-Lindau Disease	14175	"Renal cell carcinoma,Retinal capillary hemangioma,Cerebellar hemangioblastoma"			Predisposing	Supports	C	Uncertain Significance	"In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This missense mutation was found in 3 family members with VHL type 1 phenotype (family ID 1255). All 3 individuals carried cerebellar hemangioblastomas and retinal hemangioblastomas. Two of 3 also carried renal cell carcinoma. Supporting evidence of pathogenicity because cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1). Relevant HPO terms: Cerebellar hemangioblastoma, Retinal hemangioblastoma, Renal cell carcinoma."	7728151	PubMed		"Chen et al., 1995, Hum. Mutat."		2	accepted	4927	Rare Germline	2023-01-09 21:46:49 UTC	https://civicdb.org/links/evidence_items/4927	https://civicdb.org/links/molecular_profiles/1637	FALSE	VHL	7428	W88R (c.262T>A)		chr3	10142109	10142109	T	A	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.262T>A,NP_000542.1:p.Trp88Arg,NC_000003.11:g.10183793T>A,NM_000551.3:c.262T>A"	2023-01-27 17:11:45 UTC	CA351750671	456577	"C.262T>A,TRP88ARG,RS1553619431"	FALSE
VHL S111FS (c.331delA)	1638	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	"In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This frameshift mutation was detected in a VHL type 1 patient with cerebellar hemangioblastomas (family ID 3669). Only supporting evidence for pathogenicity because the patient's phenotype is highly specific for a disease with a single genetic etiology (ACMG code: PP4). Relevant HPO terms: Cerebellar hemangioblastoma."	7728151	PubMed		"Chen et al., 1995, Hum. Mutat."		4	accepted	4928	Rare Germline	2023-01-09 21:46:49 UTC	https://civicdb.org/links/evidence_items/4928	https://civicdb.org/links/molecular_profiles/1638	FALSE	VHL	7428	S111FS (c.331delA)		chr3	10142178	10142178	A		ENST00000256474.2	75		frameshift_truncation	"NC_000003.12:g.10142178del,NC_000003.11:g.10183862del,NM_000551.3:c.331del,NM_198156.2:c.331del,NP_937799.1:p.Ser111AlafsTer7,NM_001354723.1:c.331del,NP_001341652.1:p.Ser111AlafsTer6,ENST00000256474.2:c.331del"	2023-01-27 17:11:46 UTC	CA432420649	NONE FOUND	"C.331DELA,SER111FS"	FALSE
VHL S111N (c.332G>A)	1639	Von Hippel-Lindau Disease	14175	"Cerebellar hemangioblastoma,Renal cell carcinoma,Retinal capillary hemangioma"			Predisposing	Supports	C	Uncertain Significance	"In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This missense mutation was found in a VHL type 1 family of 4 individuals (family ID 3315). One of the 4 individuals was identified with retinal hemangioblastomas, 2 with cerebellar hemangioblastomas and 2 with renal cell carcinoma. Supporting evidence of pathogenicity because cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1)."	7728151	PubMed		"Chen et al., 1995, Hum. Mutat."		2	accepted	4929	Rare Germline	2023-01-09 21:46:49 UTC	https://civicdb.org/links/evidence_items/4929	https://civicdb.org/links/molecular_profiles/1639	FALSE	VHL	7428	S111N (c.332G>A)		chr3	10142179	10142179	G	A	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.332G>A,NP_000542.1:p.Ser111Asn,NC_000003.11:g.10183863G>A,ENST00000256474.2:c.332G>A"	2023-01-27 17:11:47 UTC	CA357091	223186	"C.332G>A,SER111ASN,RS869025631"	FALSE
VHL S111R (c.333C>G)	1640	Von Hippel-Lindau Disease	14175	Cerebellar hemangioblastoma			Predisposing	Supports	C	Uncertain Significance	"In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This missense mutation was detected in a VHL type 1 patient with cerebellar hemangioblastomas (family ID 4401). Only supporting evidence for pathogenicity because patient's phenotype is highly specific for a disease with a single genetic etiology (ACMG code: PP4)."	7728151	PubMed		"Chen et al., 1995, Hum. Mutat."		4	accepted	4930	Rare Germline	2023-01-09 21:46:49 UTC	https://civicdb.org/links/evidence_items/4930	https://civicdb.org/links/molecular_profiles/1640	FALSE	VHL	7428	S111R (c.333C>G)		chr3	10142180	10142180	C	G	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.333C>G,NP_000542.1:p.Ser111Arg,NC_000003.11:g.10183864C>G,ENST00000256474.2:c.333C>G"	2023-01-27 17:11:47 UTC	CA040305	223187	"C.333C>G,SER111ARG,RS765978945"	FALSE
VHL Y112* (c.336C>A)	1642	Von Hippel-Lindau Disease	14175	"Hemangioma,Cerebellar hemangioblastoma,Renal cell carcinoma"			Predisposing	Supports	C	Uncertain Significance	"In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This nonsense mutation was found in a VHL type 1 patient and familiy of 4 individuals (family IDs 3759 and 3760). Four of 5 individuals were identified with angiomas, 2 with cerebellar hemangioblastomas, and one with renal cell carcinoma. ACMG codes as follows: Cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (PP1). Patient's phenotype is highly specific for a disease with a single genetic etiology (PP4)."	7728151	PubMed		"Chen et al., 1995, Hum. Mutat."		4	accepted	4932	Rare Germline	2023-01-09 21:46:49 UTC	https://civicdb.org/links/evidence_items/4932	https://civicdb.org/links/molecular_profiles/1642	FALSE	VHL	7428	Y112* (c.336C>A)		chr3	10142183	10142183	C	A	ENST00000256474.2	75		stop_gained	"ENST00000256474.2:c.336C>A,NC_000003.11:g.10183867C>A,NM_000551.3:c.336C>A,NP_000542.1:p.Tyr112Ter"	2023-01-27 17:11:48 UTC	CA16602183	NONE FOUND	"C.336C>A,Y112X,TYR112TER"	FALSE
VHL W117C (c.351G>T)	1643	Von Hippel-Lindau Disease	14175	"Retinal capillary hemangioma,Cerebellar hemangioblastoma,Renal cell carcinoma"			Predisposing	Supports	C	Uncertain Significance	"In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This missense mutation was found in a VHL type 1 family of 10 individuals (family ID 1239). Seven of 10 individuals were identified with cerebellar hemangioblastomas and renal cell carcinoma. One identified with retinal hemangioblastomas. Supporting evidence of pathogenicity because cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1)."	7728151	PubMed		"Chen et al., 1995, Hum. Mutat."		4	accepted	4933	Rare Germline	2023-01-09 21:46:49 UTC	https://civicdb.org/links/evidence_items/4933	https://civicdb.org/links/molecular_profiles/1643	FALSE	VHL	7428	W117C (c.351G>T)		chr3	10146524	10146524	G	T	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.351G>T,NP_000542.1:p.Trp117Cys,NC_000003.11:g.10188208G>T,ENST00000256474.2:c.351G>T"	2023-01-27 17:11:49 UTC	CA020294	167827	"C.351G>T,TRP117CYS,RS727504215"	FALSE
VHL L135* (c.404T>A)	1645	Von Hippel-Lindau Disease	14175	"Cerebellar hemangioblastoma,Renal cell carcinoma,Hemangioma"			Predisposing	Supports	C	Uncertain Significance	"In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This nonsense mutation was found in a VHL type 1 family of 6 individuals (family ID 3720). All 6 individuals were identified with cerebellar hemangioblastomas, 4 with angiomas and 3 with renal cell carcinoma. Supporting evidence of pathogenicity because cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1)."	7728151	PubMed		"Chen et al., 1995, Hum. Mutat."		4	accepted	4935	Rare Germline	2023-01-09 21:46:49 UTC	https://civicdb.org/links/evidence_items/4935	https://civicdb.org/links/molecular_profiles/1645	FALSE	VHL	7428	L135* (c.404T>A)		chr3	10146577	10146577	T	A	ENST00000256474.2	75		stop_gained	"ENST00000256474.2:c.404T>A,NC_000003.11:g.10188261T>A,NM_000551.3:c.404T>A,NP_000542.1:p.Leu135Ter"	2023-01-27 17:11:50 UTC	CA351754021	NONE FOUND	"C.404T>A,L135X,LEU135TER"	FALSE
VHL P154fs (c.462delA)	1647	Von Hippel-Lindau Disease	14175	"Retinal capillary hemangioma,Renal cell carcinoma"			Predisposing	Supports	C	Uncertain Significance	"In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. Mutation causes a stop codon at amino acid 158. This mutation was also found in 4 family members with VHL type 1 phenotype (family ID 3616). Two of 4 members carried retinal hemangioblastomas and 2 with renal cell carcinoma. Supporting evidence of pathogenicity because of the introduction of an early stop codon in a gene where loss of function is an established mechanism of disease (ACMG code: PVS1)."	7728151	PubMed		"Chen et al., 1995, Hum. Mutat."		3	accepted	4937	Rare Germline	2023-01-09 21:46:49 UTC	https://civicdb.org/links/evidence_items/4937	https://civicdb.org/links/molecular_profiles/1647	FALSE	VHL	7428	P154fs (c.462delA)		chr3	10146635	10146635	A		ENST00000256474.2	75		frameshift_truncation	"ENST00000256474.2:c.462delA,NC_000003.11:g.10188319del,NM_000551.3:c.462del,NP_000542.1:p.Val155CysfsTer4"	2023-01-27 17:11:51 UTC	CA432421926	NONE FOUND	"C.462DELA,PRO154FS"	FALSE
VHL C162R (c.484T>C)	1648	Von Hippel-Lindau Disease	14175	"Cerebellar hemangioblastoma,Hemangioma,Renal cell carcinoma"			Predisposing	Supports	C	Uncertain Significance	"In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. Missense mutation detected in a VHL type 1 patient (Family ID 3509 in publication) with angiomas, cerebellar hemangioblastomas, and renal cell carcinoma. Only supporting evidence for pathogenicity because patient's phenotype is highly specific for a disease with a single genetic etiology (ACMG code: PP4)."	7728151	PubMed		"Chen et al., 1995, Hum. Mutat."		2	accepted	4939	Rare Germline	2023-01-09 21:46:49 UTC	https://civicdb.org/links/evidence_items/4939	https://civicdb.org/links/molecular_profiles/1648	FALSE	VHL	7428	C162R (c.484T>C)		chr3	10149807	10149807	T	C	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.484T>C,NM_000551.3:c.484T>C,NC_000003.11:g.10191491T>C,NP_000542.1:p.Cys162Arg"	2023-01-27 17:11:51 UTC	CA351756117	496067	"RS1553620313,C.484T>C,CYS162ARG"	FALSE
VHL C162F (c.485G>T)	1649	Von Hippel-Lindau Disease	14175	"Renal cell carcinoma,Cerebellar hemangioblastoma,Retinal capillary hemangioma"			Predisposing	Supports	C	Uncertain Significance	"In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This missense mutation was found in 4 family members with VHL type 1 phenotype (Family ID 3820 in publication). All 4 family members carried cerebellar hemangioblastomas, 2 of 4 carried retinal hemangioblastomas and one carried renal cell carcinoma. Supporting evidence of pathogenicity because cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1). Relevant HPO terms: Cerebellar hemangioblastoma, Retinal hemangioblastoma, Renal cell carcinoma."	7728151	PubMed		"Chen et al., 1995, Hum. Mutat."		4	accepted	4940	Rare Germline	2023-01-09 21:46:49 UTC	https://civicdb.org/links/evidence_items/4940	https://civicdb.org/links/molecular_profiles/1649	FALSE	VHL	7428	C162F (c.485G>T)		chr3	10149808	10149808	G	T	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.485G>T,NP_000542.1:p.Cys162Phe,NC_000003.11:g.10191492G>T,ENST00000256474.2:c.485G>T"	2023-01-27 17:11:52 UTC	CA020418	43604	"C.485G>T,CYS162PHE,RS397516444"	FALSE
VHL C162W (c.486C>G)	1650	Von Hippel-Lindau Disease	14175	Cerebellar hemangioblastoma			Predisposing	Supports	C	Uncertain Significance	"In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This missense mutation was detected in VHL type 1 patient (Family ID 3618 in publication) with cerebellar hemangioblastomas. Only supporting evidence for pathogenicity because patient's phenotype is highly specific for a disease with a single genetic etiology (ACMG code: PP4). Relevant HPO terms: Cerebellar hemangioblastoma."	7728151	PubMed		"Chen et al., 1995, Hum. Mutat."		2	accepted	4941	Rare Germline	2023-01-09 21:46:49 UTC	https://civicdb.org/links/evidence_items/4941	https://civicdb.org/links/molecular_profiles/1650	FALSE	VHL	7428	C162W (c.486C>G)		chr3	10149809	10149809	C	G	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.486C>G,NP_000542.1:p.Cys162Trp,NC_000003.11:g.10191493C>G,ENST00000256474.2:c.486C>G"	2023-01-27 17:11:53 UTC	CA357016	223227	"C.486C>G,CYS162TRP,RS869025662"	FALSE
VHL V166D (c.497T>A)	1651	Von Hippel-Lindau Disease	14175	"Cerebellar hemangioblastoma,Retinal capillary hemangioma"			Predisposing	Supports	C	Uncertain Significance	"In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This missense mutation was found in 2 family members with VHL type 1 phenotype (family ID 4480). Both individuals were identified with cerebellar hemangioblastomas and one with retinal hemangioblastoma. Supporting evidence of pathogenicity because cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1)."	7728151	PubMed		"Chen et al., 1995, Hum. Mutat."		4	accepted	4942	Rare Germline	2023-01-09 21:46:49 UTC	https://civicdb.org/links/evidence_items/4942	https://civicdb.org/links/molecular_profiles/1651	FALSE	VHL	7428	V166D (c.497T>A)		chr3	10149820	10149820	T	A	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.497T>A,NC_000003.11:g.10191504T>A,NM_000551.3:c.497T>A,NP_000542.1:p.Val166Asp"	2023-01-27 17:11:54 UTC	CA351756176	625254	"C.497T>A,VAL166ASP"	FALSE
VHL L184P (c.551T>C)	1652	Von Hippel-Lindau Disease	14175	"Hemangioblastoma,Renal cell carcinoma"			Predisposing	N/A	C	N/A	"In a study of 114 unrelated VHL affected families, germline mutations in the VHL gene were identified in 85 of the families. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals, however it seems unaffected family members were not tested genetically for the mutations. Mutations in the VHL gene were detected by SSCP and DNA sequencing. Haplotypes were determined with four microsatellite polymorphic probes. The missense mutation L184P (c.551T>C) (In the paper noted as nucleotide position 764 and codon position 255 due to old reference transcript), was found in 2 individuals in family 3708. Both individuals were identified with renal cell carcinoma and one also presented with a CNS hemangioblastoma. Additional information regarding the family information, including a pedigree, were not provided. ACMG evidence codes: 'flag for PP4' since the patients phenotype and family history is consistent with VHL, 'flag for PP1' because there is co-segregation of variant with the phenotype in two members of the family."	7728151	PubMed		"Chen et al., 1995, Hum. Mutat."		2	accepted	4943	Rare Germline	2023-01-09 21:46:49 UTC	https://civicdb.org/links/evidence_items/4943	https://civicdb.org/links/molecular_profiles/1652	FALSE	VHL	7428	L184P (c.551T>C)		chr3	10149874	10149874	T	C	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.551T>C,NP_000542.1:p.Leu184Pro,NC_000003.11:g.10191558T>C,ENST00000256474.2:c.551T>C"	2023-01-27 17:11:54 UTC	CA16617792	419447	"C.551T>C,LEU184PRO,RS1064793878"	FALSE
VHL E186* (c.556G>T)	1653	Von Hippel-Lindau Disease	14175	"Renal cell carcinoma,Cerebellar hemangioblastoma,Retinal capillary hemangioma"			Predisposing	Supports	C	Uncertain Significance	"In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals .This nonsense mutation was found in a VHL type 1 family of 6 individuals (Family ID 3770 in publication). All 6 individuals were identified with cerebellar hemangioblastomas, 4 with retinal hemangioblastomas, and 5 with renal cell carcinoma. Supporting evidence of pathogenicity because of the introduction of an early stop codon in a gene where loss of function is an established mechanism of disease (ACMG code: PVS1)."	7728151	PubMed		"Chen et al., 1995, Hum. Mutat."		3	accepted	4944	Rare Germline	2023-01-09 21:46:49 UTC	https://civicdb.org/links/evidence_items/4944	https://civicdb.org/links/molecular_profiles/1653	FALSE	VHL	7428	E186* (c.556G>T)		chr3	10149879	10149879	G	T	ENST00000256474.2	75		stop_gained	"NM_000551.3:c.556G>T,NP_000542.1:p.Glu186Ter,NC_000003.11:g.10191563G>T,ENST00000256474.2:c.556G>T"	2023-01-27 17:11:55 UTC	CA16604432	381602	"C.556G>T,E186X,GLU186TER,RS367545984"	FALSE
VHL E186K (c.556G>A)	1654	Von Hippel-Lindau Disease	14175	"Renal cell carcinoma,Cerebellar hemangioblastoma,Retinal capillary hemangioma"			Predisposing	Supports	C	Uncertain Significance	"In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This missense mutation was found in 2 family members with VHL type 1 phenotype (Family ID 3736 in publication). One of 2 individuals were identified with retinal hemangioblastomas, one with cerebellar hemangioblastomas, and one with renal cell carcinoma. Only supporting evidence for pathogenicity because patient's phenotype is highly specific for a disease with a single genetic etiology (ACMG code: PP4)."	7728151	PubMed		"Chen et al., 1995, Hum. Mutat."		2	accepted	4945	Rare Germline	2023-01-09 21:46:49 UTC	https://civicdb.org/links/evidence_items/4945	https://civicdb.org/links/molecular_profiles/1654	FALSE	VHL	7428	E186K (c.556G>A)		chr3	10149879	10149879	G	A	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.556G>A,NP_000542.1:p.Glu186Lys,NC_000003.11:g.10191563G>A,ENST00000256474.2:c.556G>A"	2023-01-27 17:11:56 UTC	CA020480	161403	"C.556G>A,GLU186LYS,RS367545984"	FALSE
ERBB2 L755S	39	Colorectal Adenocarcinoma	50861		"Leucovorin,Fluorouracil,Trastuzumab"	Combination	Predictive	Does Not Support	C	Sensitivity/Response	Patient was a 35 year old male who was treated with pseudoadjuvant FOLFOX chemotherapy. Patient relapsed and was found to have an ERBB2 L755S kinase domain mutation along with mutations in APC and BRAF. He was then treated with trastuzumab combined with infusional 5-Fu and leucovorin but exhibited no response.	27626067	PubMed		"Aung et al., 2016, Cold Spring Harb Mol Case Stud"		3	accepted	4955	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/4955	https://civicdb.org/links/molecular_profiles/39	FALSE	ERBB2	2064	L755S		chr17	39723967	39723967	T	C	ENST00000269571.5	75		missense_variant	"ENST00000269571.5:c.2264T>C,NC_000017.10:g.37880220T>C,NM_004448.3:c.2264T>C,NP_004439.2:p.Leu755Ser"	2023-01-27 17:02:09 UTC	CA16602502	376035	"LEU755SER,L725S,L740S"	FALSE
VHL A56fs (c.166_167insA)	1661	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the mutation segregated with the disease. Large deletions or intragenic mutations predicted to cause a truncated protein were found in 36 of 53 families without pheochromocytoma (VHL type 1) and 2 of 12 families with pheochromocytoma (VHL type 2). This mutation causes a frameshift and premature stop codon at amino acid 131 and was found in a VHL type 1 patient (kindred no. 110). This variant is likely to cause a dramatic alteration in protein function in a gene where loss-of-function mutations are a known mechanism (ACMG code: PVS1). Relevant HPO terms: Pheochromocytoma.	7987306	PubMed		"Crossey et al., 1994, Hum. Mol. Genet."		2	accepted	4956	Rare Germline	2023-01-09 21:46:49 UTC	https://civicdb.org/links/evidence_items/4956	https://civicdb.org/links/molecular_profiles/1661	FALSE	VHL	7428	A56fs (c.166_167insA)		chr3	10142013	10142014		A	ENST00000256474.2	75		frameshift_truncation	"NC_000003.11:g.10183697_10183698insA,NC_000003.12:g.10142013_10142014insA,NM_000551.3:c.166_167insA,NP_000542.1:p.Ala56AspfsTer?,ENST00000256474.2:c.166_167insA"	2023-01-27 17:12:01 UTC	CA432536366	NONE FOUND	"L15409.1:380INSA,380INSA"	FALSE
VHL S65W (c.194C>G)	1663	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. This mutation was found in a VHL type 1 patient (kindred no. 25). Supporting evidence for pathogenicity because of a missense mutation in a gene where missense variants are a common mechanism of disease (ACMG code: PP2).	7987306	PubMed		"Crossey et al., 1994, Hum. Mol. Genet."		3	accepted	4958	Rare Germline	2023-01-09 21:46:49 UTC	https://civicdb.org/links/evidence_items/4958	https://civicdb.org/links/molecular_profiles/1663	FALSE	VHL	7428	S65W (c.194C>G)		chr3	10142041	10142041	C	G	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.194C>G,NM_000551.3:c.194C>G,NP_000542.1:p.Ser65Trp,NC_000003.11:g.10183725C>G"	2023-01-27 17:12:02 UTC	CA020099	43597	"C.194C>G,SER65TRP,RS5030826"	FALSE
VHL S65L (c.194C>T)	1664	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. This mutation was found in a VHL type 1 patient (kindred no. 52).	7987306	PubMed		"Crossey et al., 1994, Hum. Mol. Genet."		3	accepted	4959	Rare Germline	2023-01-09 21:46:49 UTC	https://civicdb.org/links/evidence_items/4959	https://civicdb.org/links/molecular_profiles/1664	FALSE	VHL	7428	S65L (c.194C>T)		chr3	10142041	10142041	C	T	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.194C>T,NP_000542.1:p.Ser65Leu,NC_000003.11:g.10183725C>T,ENST00000256474.2:c.194C>T"	2023-01-27 17:12:03 UTC	CA020104	182975	"C.194C>T,SER65LEU,RS5030826"	FALSE
VHL C77fs (c.228dup)	2008	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	"An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. This mutation causes a stop codon at amino acid 131 and was found in a VHL type 2 and a VHL type 1 patient (kindred no. 71, 85). A frameshift variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1). Relevant HPO terms: Pheochromocytoma."	7987306	PubMed		"Crossey et al., 1994, Hum. Mol. Genet."		3	accepted	4961	Rare Germline	2023-01-09 21:46:56 UTC	https://civicdb.org/links/evidence_items/4961	https://civicdb.org/links/molecular_profiles/2008	FALSE	VHL	7428	C77fs (c.228dup)		chr3	10142074	10142075		C	ENST00000256474.2	75			"NC_000003.11:g.10183759dup,NC_000003.12:g.10142075dup,NM_000551.3:c.228dup,ENST00000256474.2:c.228dup,NP_000542.1:p.Cys77LeufsTer?,ENSP00000256474.2:p.Cys77LeufsTer?"	2023-01-27 17:15:24 UTC	CA658795177	NONE FOUND	"440_441INSC,C.227_228INSC,F76FS,C.227INSC"	FALSE
VHL N78H (c.232A>C)	1630	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. Missense mutations were found to be more frequent among families affected by pheochromocytoma (VHL type 2) than in those in which pheochromocytoma had not occurred (VHL type1). This mutation was found in a VHL type 1 patient (kindred no. 34).	7987306	PubMed		"Crossey et al., 1994, Hum. Mol. Genet."		3	accepted	4962	Rare Germline	2023-01-09 21:46:48 UTC	https://civicdb.org/links/evidence_items/4962	https://civicdb.org/links/molecular_profiles/1630	FALSE	VHL	7428	N78H (c.232A>C)		chr3	10142079	10142079	A	C	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.232A>C,NC_000003.11:g.10183763A>C,NM_000551.3:c.232A>C,NP_000542.1:p.Asn78His"	2023-01-27 17:11:40 UTC	CA351749283	NONE FOUND	"C.232A>C,ASN78HIS"	FALSE
VHL R79P (c.236G>C)	1667	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. Missense mutations were found to be more frequent among families affected by pheochromocytoma (VHL type 2) than in those in which pheochromocytoma had not occurred (VHL type 1). This mutation was found in a VHL patient (kindred no. 150). The presence of pheochromocytoma was not indicated.	7987306	PubMed		"Crossey et al., 1994, Hum. Mol. Genet."		3	accepted	4963	Rare Germline	2023-01-09 21:46:49 UTC	https://civicdb.org/links/evidence_items/4963	https://civicdb.org/links/molecular_profiles/1667	FALSE	VHL	7428	R79P (c.236G>C)		chr3	10142083	10142083	G	C	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.236G>C,NC_000003.11:g.10183767G>C,NM_000551.3:c.236G>C,NP_000542.1:p.Arg79Pro"	2023-01-27 17:12:05 UTC	CA351749311	NONE FOUND	"C.236G>C,ARG79PRO"	FALSE
VHL S80R (c.240T>G)	1668	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. Missense mutations were found to be more frequent among families affected by pheochromocytoma (VHL type 2) than in those which pheochromocytoma had not occurred (VHL type 1). This mutation was found in a VHL type 1 patient (kindred no. 103).	7987306	PubMed		"Crossey et al., 1994, Hum. Mol. Genet."		3	accepted	4964	Rare Germline	2023-01-09 21:46:49 UTC	https://civicdb.org/links/evidence_items/4964	https://civicdb.org/links/molecular_profiles/1668	FALSE	VHL	7428	S80R (c.240T>G)		chr3	10142087	10142087	T	G	ENST00000256474.2	75		missense_variant	ENST00000256474.2:c.240T>G	2023-01-27 17:12:06 UTC	CA351750515	NONE FOUND	"C.240T>G,SER80ARG"	FALSE
VHL L89P (c.266T>C)	1669	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. Missense mutations were found to be more frequent among families affected by pheochromocytoma (VHL type 2) than in those which pheochromocytoma had not occurred (VHL type 1). This mutation was found in VHL type 1 patient (kindred no. 59).	7987306	PubMed		"Crossey et al., 1994, Hum. Mol. Genet."		3	accepted	4965	Rare Germline	2023-01-09 21:46:49 UTC	https://civicdb.org/links/evidence_items/4965	https://civicdb.org/links/molecular_profiles/1669	FALSE	VHL	7428	L89P (c.266T>C)		chr3	10142113	10142113	T	C	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.266T>C,NP_000542.1:p.Leu89Pro,NC_000003.11:g.10183797T>C,ENST00000256474.2:c.266T>C"	2023-01-27 17:12:07 UTC	CA020207	182979	"C.266T>C,LEU89PRO,RS5030807"	FALSE
VHL Y98H (c.292T>C)	1617	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. This mutation was found in a VHL family (kindred no. 22). Incidence of pheochromocytoma was unknown. Supporting evidence for pathogenicity because of a missense mutation in a gene where missense variants are a common mechanism of disease (ACMG code: PP2).	7987306	PubMed		"Crossey et al., 1994, Hum. Mol. Genet."		3	accepted	4967	Rare Germline	2023-01-09 21:46:48 UTC	https://civicdb.org/links/evidence_items/4967	https://civicdb.org/links/molecular_profiles/1617	FALSE	VHL	7428	Y98H (c.292T>C)		chr3	10142139	10142139	T	C	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.292T>C,NP_000542.1:p.Tyr98His,NC_000003.11:g.10183823T>C,ENST00000256474.2:c.292T>C"	2023-01-27 17:11:30 UTC	CA020246	2223	"C.292T>C,TYR98HIS,RS5030809"	FALSE
VHL G114C (c.340G>T)	1673	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	"An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. This mutation was found in 2 unrelated VHL families (kindred no. 40, 133). One was identified with pheochromocytoma, the other was unknown. Supporting evidence for pathogenicity because of a missense mutation in a gene where missense variants are a common mechanism of disease (ACMG code: PP2). Relevant HPO term: pheochromocytoma."	7987306	PubMed		"Crossey et al., 1994, Hum. Mol. Genet."		3	accepted	4970	Rare Germline	2023-01-09 21:46:50 UTC	https://civicdb.org/links/evidence_items/4970	https://civicdb.org/links/molecular_profiles/1673	FALSE	VHL	7428	G114C (c.340G>T)		chr3	10142187	10142187	G	T	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.340G>T,NC_000003.11:g.10183871G>T,NM_000551.3:c.340G>T,NP_000542.1:p.Gly114Cys"	2023-01-27 17:12:10 UTC	CA351751376	NONE FOUND	"C.340G>T,GLY114CYS"	FALSE
VHL L118P (c.353T>C)	1674	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. Missense mutations were found to be more frequent among families affected by pheochromocytoma (VHL type 2) than in those which pheochromocytoma had not occurred (VHL type 1). This mutation was found in a VHL type 1 patient (kindred no. 19).	7987306	PubMed		"Crossey et al., 1994, Hum. Mol. Genet."		3	accepted	4971	Rare Germline	2023-01-09 21:46:50 UTC	https://civicdb.org/links/evidence_items/4971	https://civicdb.org/links/molecular_profiles/1674	FALSE	VHL	7428	L118P (c.353T>C)		chr3	10146526	10146526	T	C	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.353T>C,NM_000551.3:c.353T>C,NP_000542.1:p.Leu118Pro,NC_000003.11:g.10188210T>C"	2023-01-27 17:12:11 UTC	CA70049399	428807	"C.353T>C,LEU118PRO,RS5030830"	FALSE
VHL N131fs (c.390_391del)	1676	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. Large deletions or intragenic mutations predicted to cause a truncated protein were found in 36 of 53 families without pheochromocytoma (VHL type 1) and 2 of 12 families with pheochromocytoma (VHL type 2). This mutation causes stop codon at amino acid 133 and was found in VHL type 1 patient (kindred no. 64). This study contains very strong evidence for pathogenicity in the form of a frameshift mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).	7987306	PubMed		"Crossey et al., 1994, Hum. Mol. Genet."		3	accepted	4973	Rare Germline	2023-01-09 21:46:50 UTC	https://civicdb.org/links/evidence_items/4973	https://civicdb.org/links/molecular_profiles/1676	FALSE	VHL	7428	N131fs (c.390_391del)		chr3	10146563	10146564	TA		ENST00000256474.2	75		minus_2_frameshift_variant	"ENST00000256474.2:c.390_391delTA,NC_000003.11:g.10188247_10188248del,NC_000003.12:g.10146563_10146564del,NM_000551.3:c.390_391delTA,NP_000542.1:p.Asn131fs,NP_000542.1:p.Asn131ProfsTer3"	2023-01-27 17:12:13 UTC	CA658795179	NONE FOUND	"C.390_391DELTA,ASN131PRO,N131PFS*3,ASN131PROFSTER3"	FALSE
VHL F136S (c.407T>C)	1677	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. Missense mutations were found to be more frequent among families affected by pheochromocytoma (VHL type 2) than in those which pheochromocytoma had not occurred (VHL type 1). This mutation was found in a VHL patient (kindred no. 27).	7987306	PubMed		"Crossey et al., 1994, Hum. Mol. Genet."		3	accepted	4974	Rare Germline	2023-01-09 21:46:50 UTC	https://civicdb.org/links/evidence_items/4974	https://civicdb.org/links/molecular_profiles/1677	FALSE	VHL	7428	F136S (c.407T>C)		chr3	10146580	10146580	T	C	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.407T>C,NC_000003.11:g.10188264T>C,NM_000551.3:c.407T>C,NP_000542.1:p.Phe136Ser"	2023-01-27 17:12:13 UTC	CA040847	496064	"C.407T>C,PHE136SER,RS5030833"	FALSE
VHL L153fs (c.457delC)	1678	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	"An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. Large deletions or intragenic mutations predicted to cause a truncated protein were found in 36 of 53 families without pheochromocytoma (VHL type 1) and 2 of 12 families with pheochromocytoma (VHL type 2). This mutation causes stop codon at amino acid 158 and was found in  2 unrelated VHL patients (kindred no. 41, 99). One patient did not have pheochromocytoma."	7987306	PubMed		"Crossey et al., 1994, Hum. Mol. Genet."		3	accepted	4975	Rare Germline	2023-01-09 21:46:50 UTC	https://civicdb.org/links/evidence_items/4975	https://civicdb.org/links/molecular_profiles/1678	FALSE	VHL	7428	L153fs (c.457delC)		chr3	10146633	10146633	C		ENST00000256474.2	75		deletion	NM_000551.3:c.457delC	2023-01-27 17:12:14 UTC	CA432421924	NONE FOUND	"C.457DELC,LEU153FS"	FALSE
VHL P154L (c.461C>T)	1658	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. Missense mutations were found to be more frequent among families affected by pheochromocytoma (VHL type 2) than in those which pheochromocytoma had not occurred (VHL type 1). This mutation was found in VHL type 2 patient (kindred no. 49).	7987306	PubMed		"Crossey et al., 1994, Hum. Mol. Genet."		3	accepted	4976	Rare Germline	2023-01-09 21:46:49 UTC	https://civicdb.org/links/evidence_items/4976	https://civicdb.org/links/molecular_profiles/1658	FALSE	VHL	7428	P154L (c.461C>T)		chr3	10146634	10146634	C	T	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.461C>T,NC_000003.11:g.10188318C>T,NM_000551.3:c.461C>T,NP_000542.1:p.Pro154Leu"	2023-01-27 17:11:58 UTC	CA351754410	NONE FOUND	"C.461C>T,PRO154LEU"	FALSE
VHL L158V (c.472C>G)	1679	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. Missense mutations were found to be more frequent among families affected by pheochromocytoma (VHL type 2) than in those which pheochromocytoma had not occurred (VHL type 1). This mutation was found in VHL type 1 patient (kindred no. 91).	7987306	PubMed		"Crossey et al., 1994, Hum. Mol. Genet."		3	accepted	4977	Rare Germline	2023-01-09 21:46:50 UTC	https://civicdb.org/links/evidence_items/4977	https://civicdb.org/links/molecular_profiles/1679	FALSE	VHL	7428	L158V (c.472C>G)		chr3	10149795	10149795	C	G	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.472C>G,NC_000003.11:g.10191479C>G,NM_000551.3:c.472C>G,NP_000542.1:p.Leu158Val"	2023-01-27 17:12:15 UTC	CA351756068	NONE FOUND	"C.472C>G,LEU158VAL"	FALSE
VHL V170F (c.508G>T)	1682	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. This mutation was found in a VHL type 2 patient (kindred no. 26). Supporting evidence of pathogenicity because of a missense mutation in a gene in which missense variants are a common mechanism of disease. Relevant HPO terms: Pheochomocytoma.	7987306	PubMed		"Crossey et al., 1994, Hum. Mol. Genet."		3	accepted	4982	Rare Germline	2023-01-09 21:46:50 UTC	https://civicdb.org/links/evidence_items/4982	https://civicdb.org/links/molecular_profiles/1682	FALSE	VHL	7428	V170F (c.508G>T)		chr3	10149831	10149831	G	T	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.508G>T,NC_000003.11:g.10191515G>T,NM_000551.3:c.508G>T,NP_000542.1:p.Val170Phe"	2023-01-27 17:12:17 UTC	CA351756193	NONE FOUND	"C.508G>T,VAL170PHE"	FALSE
VHL L178P (c.533T>C)	1624	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. Missense mutations were found to be more frequent among families affected by pheochromocytoma (VHL type 2) than in those which pheochromocytoma had not occurred (VHL type 1). This mutation was found in a VHL type 1 patient (kindred no. 44).	7987306	PubMed		"Crossey et al., 1994, Hum. Mol. Genet."		3	accepted	4983	Rare Germline	2023-01-09 21:46:48 UTC	https://civicdb.org/links/evidence_items/4983	https://civicdb.org/links/molecular_profiles/1624	FALSE	VHL	7428	L178P (c.533T>C)		chr3	10149856	10149856	T	C	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.533T>C,NM_000551.3:c.533T>C,NP_000542.1:p.Leu178Pro,NC_000003.11:g.10191540T>C"	2023-01-27 17:11:36 UTC	CA351756245	428795	"C.533T>C,LEU178PRO,RS5030822"	FALSE
VHL I180V (c.538A>G)	1683	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. Missense mutations were found to be more frequent among families affected by pheochromocytoma (VHL type 2) than in those which pheochromocytoma had not occurred (VHL type 1). This mutation was found in a VHL type 1 patient (kindred no. 79).	7987306	PubMed		"Crossey et al., 1994, Hum. Mol. Genet."		3	accepted	4984	Rare Germline	2023-01-09 21:46:50 UTC	https://civicdb.org/links/evidence_items/4984	https://civicdb.org/links/molecular_profiles/1683	FALSE	VHL	7428	I180V (c.538A>G)		chr3	10149861	10149861	A	G	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.538A>G,NP_000542.1:p.Ile180Val,NC_000003.11:g.10191545A>G,ENST00000256474.2:c.538A>G"	2023-01-27 17:12:18 UTC	CA020469	161401	"C.538A>G,ILE180VAL,RS377715747"	FALSE
VHL Q195* (c.583C>T)	1686	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. This mutation was found in a VHL type 1 patient (kindred no. 21). This study contains very strong evidence for pathogenicity in the form of a nonsense mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).	7987306	PubMed		"Crossey et al., 1994, Hum. Mol. Genet."		3	accepted	4987	Rare Germline	2023-01-09 21:46:50 UTC	https://civicdb.org/links/evidence_items/4987	https://civicdb.org/links/molecular_profiles/1686	FALSE	VHL	7428	Q195* (c.583C>T)		chr3	10149906	10149906	C	T	ENST00000256474.2	75		stop_gained	"NM_000551.3:c.583C>T,NP_000542.1:p.Gln195Ter,NC_000003.11:g.10191590C>T,ENST00000256474.2:c.583C>T"	2023-01-27 17:12:20 UTC	CA70052558	428794	"C.583C>T,Q195X,GLN195TER,RS5030825"	FALSE
KRAS Mutation	332	Lung Non-small Cell Carcinoma	3908		"Docetaxel,Erlotinib"	Substitutes	Predictive	Does Not Support	B	Sensitivity/Response	"222 EGFR-wt patients with advanced NSCLC were randomized to receive docetaxel or erlotinib In this study (4 patients not eligible, leaving 109 in each arm). KRAS was mutated in 25 and 26 out of 109 patients in the erlotinib and docetaxel arm, respectively. KRAS was neither prognostic nor predictive of benefit for either docetaxel or erlotinib."	26209642	PubMed		"Rulli et al., 2015, Ann. Oncol."	NCT00637910	4	accepted	4996	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/4996	https://civicdb.org/links/molecular_profiles/332	FALSE	KRAS	3845	Mutation		chr12	25209431	25250803			ENST00000256078.4	75		protein_altering_variant		2023-01-09 21:52:06 UTC		N/A		FALSE
KRAS Mutation	332	Lung Non-small Cell Carcinoma	3908		Docetaxel		Predictive	Does Not Support	B	Sensitivity/Response	"Of the 275 patients assessable for KRAS mutation status, 49 (18%) were positive for KRAS mutation. There were no differences between treatments in OS, PFS, or response rates according to KRAS mutation status, and no evidence that KRAS mutation is a predictive factor for a differential survival effect between gefitinib and docetaxel."	20038723	PubMed		"Douillard et al., 2010, J. Clin. Oncol."	NCT00076388	4	accepted	4997	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/4997	https://civicdb.org/links/molecular_profiles/332	FALSE	KRAS	3845	Mutation		chr12	25209431	25250803			ENST00000256078.4	75		protein_altering_variant		2023-01-09 21:52:06 UTC		N/A		FALSE
VHL S65W (c.194C>G)	1663	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	"In a study of 138 unrelated VHL families, 109 germline mutations were found. Missense mutations were more frequently found in families with pheochromocytoma. Deletions. Nonsense, and frameshift mutations were more frequently found in families without pheochromocytoma. Large deletions and mutations predicted to cause truncated protein were associated with lower risk pheochromocytoma. This missense mutation was found in one of the VHL families (family ID 39)."	8730290	PubMed		"Maher et al., 1996, J. Med. Genet."		3	accepted	4998	Rare Germline	2023-01-09 21:46:49 UTC	https://civicdb.org/links/evidence_items/4998	https://civicdb.org/links/molecular_profiles/1663	FALSE	VHL	7428	S65W (c.194C>G)		chr3	10142041	10142041	C	G	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.194C>G,NM_000551.3:c.194C>G,NP_000542.1:p.Ser65Trp,NC_000003.11:g.10183725C>G"	2023-01-27 17:12:02 UTC	CA020099	43597	"C.194C>G,SER65TRP,RS5030826"	FALSE
VHL V170D (c.509T>A)	1702	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	"In a study of 138 unrelated VHL families, 109 germline mutations were found. Missense mutations were more frequently found in families with pheochromocytoma (PC). Deletions. Nonsense, and frameshift mutations were more frequently found in families without PC. Large deletions and mutations predicted to cause truncated protein were associated with lower risk of PC. This missense mutation was found in a VHL family (family ID 77). No phenotype described."	8730290	PubMed		"Maher et al., 1996, J. Med. Genet."		3	accepted	5013	Rare Germline	2023-01-09 21:46:50 UTC	https://civicdb.org/links/evidence_items/5013	https://civicdb.org/links/molecular_profiles/1702	FALSE	VHL	7428	V170D (c.509T>A)		chr3	10149832	10149832	T	A	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.509T>A,NC_000003.11:g.10191516T>A,NM_000551.3:c.509T>A,NP_000542.1:p.Val170Asp"	2023-01-27 17:12:32 UTC	CA351756195	625256	"C.509T>A,VAL170ASP"	FALSE
VHL N78S (c.233A>G)	1631	Von Hippel-Lindau Disease	14175	"Renal cell carcinoma,Retinal capillary hemangioma,Cerebellar hemangioblastoma"			Predisposing	Supports	C	Uncertain Significance	"Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of VHL gene product (pVHL). Missense mutation, affecting an amino acid within pVHL protein core, was found in 6 VHL type 1 families with 12 affected individuals altogether. Nine of 12 patients had retinal angioma, 5 had cerebellar hemangioblastoma, and 2 had renal cell carcinoma."	17024664	PubMed		"Ong et al., 2007, Hum. Mutat."		4	accepted	5020	Rare Germline	2023-01-09 21:46:48 UTC	https://civicdb.org/links/evidence_items/5020	https://civicdb.org/links/molecular_profiles/1631	FALSE	VHL	7428	N78S (c.233A>G)		chr3	10142080	10142080	A	G	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.233A>G,NP_000542.1:p.Asn78Ser,NC_000003.11:g.10183764A>G,ENST00000256474.2:c.233A>G"	2023-01-27 17:11:40 UTC	CA020131	93326	"C.233A>G,ASN78SER,RS5030804"	FALSE
VHL L116V (c.346C>G)	1696	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	"Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). A missense mutation, affecting residue with pVHL protein core, was detected in a VHL type 1 family with 3 affected individuals. All 3 patients had retinal angioma."	17024664	PubMed		"Ong et al., 2007, Hum. Mutat."		4	accepted	5022	Rare Germline	2023-01-09 21:46:50 UTC	https://civicdb.org/links/evidence_items/5022	https://civicdb.org/links/molecular_profiles/1696	FALSE	VHL	7428	L116V (c.346C>G)		chr3	10146519	10146519	C	G	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.346C>G,NC_000003.11:g.10188203C>G,NM_000551.3:c.346C>G,NP_000542.1:p.Leu116Val"	2023-01-27 17:12:28 UTC	CA351753642	NONE FOUND	"C.346C>G,LEU116VAL"	FALSE
VHL V166F (c.496G>T)	1701	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	"Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). A missense mutation, affecting surface residue of pVHL protein core, was found in 2 VHL type 2A families with 5 affected individuals altogether. Two of 5 patients had retinal angioma, 2 had cerebellar hemangioblastoma, and 4 had pheochromocytoma."	17024664	PubMed		"Ong et al., 2007, Hum. Mutat."		4	accepted	5024	Rare Germline	2023-01-09 21:46:50 UTC	https://civicdb.org/links/evidence_items/5024	https://civicdb.org/links/molecular_profiles/1701	FALSE	VHL	7428	V166F (c.496G>T)		chr3	10149819	10149819	G	T	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.496G>T,NP_000542.1:p.Val166Phe,NC_000003.11:g.10191503G>T,ENST00000256474.2:c.496G>T"	2023-01-27 17:12:32 UTC	CA020436	2224	"C.496G>T,VAL166PHE,RS104893825"	FALSE
VHL S65W (c.194C>G)	1663	Von Hippel-Lindau Disease	14175	"Cerebellar hemangioblastoma,Multiple renal cysts,Retinal capillary hemangioma,Pancreatic cysts,Renal cell carcinoma"			Predisposing	Supports	C	Uncertain Significance	"Molecular analysis of VHL gene in 146 probands, 103 with and 43 without a positive family history, resulted in the detection of 43 germline VHL mutations. Majority of mutations were found in patients with classic or multi-organ manifestations of VHL disease, but mutations were also found in patients with limited or single-organ manifestations of VHL disease. Follow-up of families with germline mutations and limited VHL manifestations was recommended. This missense mutation was detected in a VHL type 1 patient with retinal and cerebellar hemangioblastoma, renal cell carcinoma, and renal and pancreatic cysts (family no. 3).  ACMG codes: PP4."	17661816	PubMed		"Hes et al., 2007, Clin. Genet."		3	accepted	5026	Rare Germline	2023-01-09 21:46:49 UTC	https://civicdb.org/links/evidence_items/5026	https://civicdb.org/links/molecular_profiles/1663	FALSE	VHL	7428	S65W (c.194C>G)		chr3	10142041	10142041	C	G	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.194C>G,NM_000551.3:c.194C>G,NP_000542.1:p.Ser65Trp,NC_000003.11:g.10183725C>G"	2023-01-27 17:12:02 UTC	CA020099	43597	"C.194C>G,SER65TRP,RS5030826"	FALSE
VHL N78S (c.233A>G)	1631	Von Hippel-Lindau Disease	14175	"Multiple renal cysts,Cerebellar hemangioblastoma,Pancreatic cysts"			Predisposing	Supports	C	Uncertain Significance	"Molecular analysis of VHL gene in 146 probands, 103 with and 43 without a positive family history, resulted in the detection of 43 germline VHL mutations. Majority of mutations were found in patients with classic or multi-organ manifestations of VHL disease, but mutations were also found in patients with limited or single-organ manifestations of VHL disease. Follow-up of families with germline mutations and limited VHL manifestations was recommended. This missense mutation was detected in a VHL type 1 patient with cerebellar hemangioblastoma, renal cysts and pancreatic cysts (family no. 6)."	17661816	PubMed		"Hes et al., 2007, Clin. Genet."		3	accepted	5027	Rare Germline	2023-01-09 21:46:48 UTC	https://civicdb.org/links/evidence_items/5027	https://civicdb.org/links/molecular_profiles/1631	FALSE	VHL	7428	N78S (c.233A>G)		chr3	10142080	10142080	A	G	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.233A>G,NP_000542.1:p.Asn78Ser,NC_000003.11:g.10183764A>G,ENST00000256474.2:c.233A>G"	2023-01-27 17:11:40 UTC	CA020131	93326	"C.233A>G,ASN78SER,RS5030804"	FALSE
VHL V170D (c.509T>A)	1702	Von Hippel-Lindau Disease	14175	"Renal cell carcinoma,Pheochromocytoma,Pancreatic cysts,Retinal capillary hemangioma,Cerebellar hemangioblastoma"			Predisposing	Supports	C	Uncertain Significance	"Molecular analysis of VHL gene in 146 probands, 103 with and 43 without a positive family history, resulted in the detection of 43 germline VHL mutations. Majority of mutations were found in patients with classic or multi-organ manifestations of VHL disease, but mutations were also found in patients with limited or single-organ manifestations of VHL disease. Follow-up of families with germline mutations and limited VHL manifestations was recommended. This missense mutation was identified in 14 VHL patients (family no. 18). Six had retinal hemangioblastoma, 9 had cerebellar hemangioblastoma, 7 had renal cell carcinoma, 8 had renal cysts, 4 had pheochromocytoma, and 5 had pancreatic cysts."	17661816	PubMed		"Hes et al., 2007, Clin. Genet."		3	accepted	5029	Rare Germline	2023-01-09 21:46:50 UTC	https://civicdb.org/links/evidence_items/5029	https://civicdb.org/links/molecular_profiles/1702	FALSE	VHL	7428	V170D (c.509T>A)		chr3	10149832	10149832	T	A	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.509T>A,NC_000003.11:g.10191516T>A,NM_000551.3:c.509T>A,NP_000542.1:p.Val170Asp"	2023-01-27 17:12:32 UTC	CA351756195	625256	"C.509T>A,VAL170ASP"	FALSE
VHL S65* (c.194C>A)	1687	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Predisposition	Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This nonsense mutation found in VHL type 1 family (lineage 80). This provides strong evidence of pathogenicity as it is a null variant in a gene where loss of function is a known mechanism of disease (ACMG code: PVS1).	9829911	PubMed		"Stolle et al., 1998, Hum. Mutat."		3	accepted	5033	Rare Germline	2023-02-03 16:51:24 UTC	https://civicdb.org/links/evidence_items/5033	https://civicdb.org/links/molecular_profiles/1687	FALSE	VHL	7428	S65* (c.194C>A)		chr3	10142041	10142041	C	A	ENST00000256474.2	75		stop_gained	"NM_000551.3:c.194C>A,NP_000542.1:p.Ser65Ter,NC_000003.11:g.10183725C>A,ENST00000256474.2:c.194C>A"	2023-01-27 17:12:21 UTC	CA357085	223161	"C.194C>A,S65X,SER65TER,RS5030826"	FALSE
VHL S65W (c.194C>G)	1663	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Predisposition	Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This missense mutation was found in a VHL type 1 family (lineage 53).	9829911	PubMed		"Stolle et al., 1998, Hum. Mutat."		3	accepted	5034	Rare Germline	2023-02-03 17:36:53 UTC	https://civicdb.org/links/evidence_items/5034	https://civicdb.org/links/molecular_profiles/1663	FALSE	VHL	7428	S65W (c.194C>G)		chr3	10142041	10142041	C	G	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.194C>G,NM_000551.3:c.194C>G,NP_000542.1:p.Ser65Trp,NC_000003.11:g.10183725C>G"	2023-01-27 17:12:02 UTC	CA020099	43597	"C.194C>G,SER65TRP,RS5030826"	FALSE
VHL E70* (c.208G>T)	1710	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Predisposition	Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This nonsense mutation was found in a VHL type 1 family (lineage 179). This provides strong evidence of pathogenicity as it is a null variant in a gene where loss of function is a known mechanism of disease (ACMG code: PVS1).	9829911	PubMed		"Stolle et al., 1998, Hum. Mutat."		3	accepted	5035	Rare Germline	2023-02-03 17:37:36 UTC	https://civicdb.org/links/evidence_items/5035	https://civicdb.org/links/molecular_profiles/1710	FALSE	VHL	7428	E70* (c.208G>T)		chr3	10142055	10142055	G	T	ENST00000256474.2	75		stop_gained	"NM_000551.3:c.208G>T,NP_000542.1:p.Glu70Ter,NC_000003.11:g.10183739G>T,ENST00000256474.2:c.208G>T"	2023-01-27 17:12:36 UTC	CA16602179	428806	"C.208G>T,E70X,GLU70TER,RS5030802"	FALSE
VHL F76S (c.227T>C)	1711	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Predisposition	Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This missense mutation was found in a VHL type 1 family (lineage 132).	9829911	PubMed		"Stolle et al., 1998, Hum. Mutat."		3	accepted	5037	Rare Germline	2023-02-03 17:39:00 UTC	https://civicdb.org/links/evidence_items/5037	https://civicdb.org/links/molecular_profiles/1711	FALSE	VHL	7428	F76S (c.227T>C)		chr3	10142074	10142074	T	C	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.227T>C,NC_000003.11:g.10183758T>C,NM_000551.3:c.227T>C,NP_000542.1:p.Phe76Ser"	2023-01-27 17:12:37 UTC	CA020125	182976	"PHE76SER,C.277T>C,RS730882033"	FALSE
VHL L101G (c.301_302delinsGG)	1714	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Predisposition	Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This missense mutation was found in a VHL type 1 family (lineage 103).	9829911	PubMed		"Stolle et al., 1998, Hum. Mutat."		2	accepted	5040	Rare Germline	2023-02-03 18:07:57 UTC	https://civicdb.org/links/evidence_items/5040	https://civicdb.org/links/molecular_profiles/1714	FALSE	VHL	7428	L101G (c.301_302delinsGG)		chr3	10142148	10142149	CT	GG	ENST00000256474.2	75		delins	"NM_000551.3:c.301_302delinsGG,NP_000542.1:p.Leu101Gly,ENST00000256474.2:c.301_302delinsGG,ENSP00000256474.2:p.Leu101Gly,NC_000003.11:g.10183832_10183833delinsGG,NC_000003.12:g.10142148_10142149delinsGG"	2023-01-27 17:12:39 UTC	CA915940707	NONE FOUND	C.301_302CT>GG	FALSE
VHL T105P (c.313A>C)	1715	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Predisposition	Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This missense mutation was found in VHL type 1 family (lineage 208).	9829911	PubMed		"Stolle et al., 1998, Hum. Mutat."		2	accepted	5041	Rare Germline	2023-02-03 18:08:58 UTC	https://civicdb.org/links/evidence_items/5041	https://civicdb.org/links/molecular_profiles/1715	FALSE	VHL	7428	T105P (c.313A>C)		chr3	10142160	10142160	A	C	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.313A>C,NC_000003.11:g.10183844A>C,NM_000551.3:c.313A>C,NP_000542.1:p.Thr105Pro"	2023-01-27 17:12:40 UTC	CA351751116	496055	"C.313A>C,THR105PRO,RS1553619461"	FALSE
VHL R107P (c.320G>C)	1716	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Predisposition	Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This missense mutation was found in a VHL type 1 family (lineage 76).	9829911	PubMed		"Stolle et al., 1998, Hum. Mutat."		3	accepted	5042	Rare Germline	2023-02-03 17:42:06 UTC	https://civicdb.org/links/evidence_items/5042	https://civicdb.org/links/molecular_profiles/1716	FALSE	VHL	7428	R107P (c.320G>C)		chr3	10142167	10142167	G	C	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.320G>C,NP_000542.1:p.Arg107Pro,NC_000003.11:g.10183851G>C,ENST00000256474.2:c.320G>C"	2023-01-27 17:12:41 UTC	CA020262	36900	"C.320G>C,ARG107PRO,RS193922609"	FALSE
VHL R113* (c.337C>T)	1672	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Predisposition	Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This nonsense mutation was found in a VHL type 1 family (lineage 81).	9829911	PubMed		"Stolle et al., 1998, Hum. Mutat."		3	accepted	5043	Rare Germline	2023-02-03 20:56:38 UTC	https://civicdb.org/links/evidence_items/5043	https://civicdb.org/links/molecular_profiles/1672	FALSE	VHL	7428	R113* (c.337C>T)		chr3	10142184	10142184	C	T	ENST00000256474.2	75		stop_gained	"NM_000551.3:c.337C>T,NP_000542.1:p.Arg113Ter,NC_000003.11:g.10183868C>T,ENST00000256474.2:c.337C>T"	2023-01-27 17:12:09 UTC	CA348491	220414	"C.337C>T,R113X,ARG113TER,RS5030810"	FALSE
VHL W117C (c.351G>T)	1643	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Predisposition	Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This missense mutation was found in 2 VHL type 1 families (lineage 83 and 146). Family 146 was previously described in another publication.	9829911	PubMed		"Stolle et al., 1998, Hum. Mutat."		2	accepted	5044	Rare Germline	2023-02-03 17:53:53 UTC	https://civicdb.org/links/evidence_items/5044	https://civicdb.org/links/molecular_profiles/1643	FALSE	VHL	7428	W117C (c.351G>T)		chr3	10146524	10146524	G	T	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.351G>T,NP_000542.1:p.Trp117Cys,NC_000003.11:g.10188208G>T,ENST00000256474.2:c.351G>T"	2023-01-27 17:11:49 UTC	CA020294	167827	"C.351G>T,TRP117CYS,RS727504215"	FALSE
VHL L118fs (c.352_353insA)	1717	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Predisposition	"Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This mutation causes stop codon at amino acid 131 and was found in a VHL type 1 family (lineage 13). This provides strong evidence of pathogenicity as it is a null variant in a gene where loss of function is a known mechanism of disease (ACMG code: PVS1). Relevant HPO terms: hemangioblastoma, Renal cell carcinoma, Pheochromocytoma."	9829911	PubMed		"Stolle et al., 1998, Hum. Mutat."		3	accepted	5045	Rare Germline	2023-02-03 17:57:34 UTC	https://civicdb.org/links/evidence_items/5045	https://civicdb.org/links/molecular_profiles/1717	FALSE	VHL	7428	L118fs (c.352_353insA)		chr3	10146525	10146526		A	ENST00000256474.2	75		plus_1_frameshift_variant	"NC_000003.11:g.10188209_10188210insA,NC_000003.12:g.10146525_10146526insA,NM_000551.3:c.352_353insA,NP_000542.1:p.Leu118fs"	2023-01-27 17:12:42 UTC	CA357125	223198	"LEU118FS,RS869025641"	FALSE
VHL N131T (c.392A>C)	2453	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Predisposition	Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This missense mutation was found in a VHL type 1 family (lineage 86).	9829911	PubMed		"Stolle et al., 1998, Hum. Mutat."		3	accepted	5046	Rare Germline	2023-02-03 18:01:28 UTC	https://civicdb.org/links/evidence_items/5046	https://civicdb.org/links/molecular_profiles/2453	FALSE	VHL	7428	N131T (c.392A>C)		chr3	10146565	10146565	A	C	ENST00000256474.2	75		non_conservative_missense_variant	"NC_000003.11:g.10188249A>C,CM000665.1:g.10188249A>C,NP_000542.1:p.Asn131Thr,NM_000551.3:c.392A>C"	2023-01-27 17:17:35 UTC	CA351753944	NONE FOUND		FALSE
VHL T133fs (c.397del)	1719	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Predisposition	Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This mutation causes an early stop codon at position 158 and was found in a VHL type 1 family (lineage 64). This provides strong evidence of pathogenicity as it is a null variant in a gene where loss of function is a known mechanism of disease (ACMG code: PVS1).	9829911	PubMed		"Stolle et al., 1998, Hum. Mutat."		3	accepted	5047	Rare Germline	2023-02-03 18:02:00 UTC	https://civicdb.org/links/evidence_items/5047	https://civicdb.org/links/molecular_profiles/1719	FALSE	VHL	7428	T133fs (c.397del)		chr3	10146568	10146568	A		ENST00000256474.2	75		"minus_1_frameshift_variant,frameshift_truncation"	"NC_000003.11:g.10188254del,NP_000542.1:p.Thr133LeufsTer26,NP_000542.1:p.Thr133fs,NC_000003.12:g.10146570del,NM_000551.4:c.397del"	2023-01-27 17:12:43 UTC	CA432421843	625244	"Q132FS (C.395DELA),T133LFS*26"	FALSE
VHL R161* (c.481C>T)	1680	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Predisposition	"Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This nonsense mutation was found in 3 VHL type 1 families and one VHL type 2 family (lineages 184, 93, 22, 92). Only moderate evidence for pathogenicity because protein length changes as a result of stop-loss variant (ACMG code: PM4)."	9829911	PubMed		"Stolle et al., 1998, Hum. Mutat."		3	accepted	5049	Rare Germline	2023-02-03 18:03:58 UTC	https://civicdb.org/links/evidence_items/5049	https://civicdb.org/links/molecular_profiles/1680	FALSE	VHL	7428	R161* (c.481C>T)		chr3	10149804	10149804	C	T	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.481C>T,NP_000542.1:p.Arg161Ter,NC_000003.11:g.10191488C>T,ENST00000256474.2:c.481C>T"	2023-01-27 17:12:16 UTC	CA020408	2217	"C.481C>T,R161X,ARG161TER,RS5030818"	FALSE
VHL C162F (c.485G>T)	1649	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Predisposition	Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This missense mutation was found in a VHL type 1 family (lineage 69).	9829911	PubMed		"Stolle et al., 1998, Hum. Mutat."		2	accepted	5050	Rare Germline	2023-02-03 18:09:23 UTC	https://civicdb.org/links/evidence_items/5050	https://civicdb.org/links/molecular_profiles/1649	FALSE	VHL	7428	C162F (c.485G>T)		chr3	10149808	10149808	G	T	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.485G>T,NP_000542.1:p.Cys162Phe,NC_000003.11:g.10191492G>T,ENST00000256474.2:c.485G>T"	2023-01-27 17:11:52 UTC	CA020418	43604	"C.485G>T,CYS162PHE,RS397516444"	FALSE
VHL Q164* (c.490C>T)	1721	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Predisposition	Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This nonsense mutation was found in a VHL type 1 family (lineage 141). This provides strong evidence of pathogenicity as it is a null variant in a gene where loss of function is a known mechanism of disease (ACMG code: PVS1).	9829911	PubMed		"Stolle et al., 1998, Hum. Mutat."		3	accepted	5051	Rare Germline	2023-02-03 18:04:37 UTC	https://civicdb.org/links/evidence_items/5051	https://civicdb.org/links/molecular_profiles/1721	FALSE	VHL	7428	Q164* (c.490C>T)		chr3	10149813	10149813	C	T	ENST00000256474.2	75		stop_gained	"NM_000551.3:c.490C>T,NP_000542.1:p.Gln164Ter,NC_000003.11:g.10191497C>T,ENST00000256474.2:c.490C>T"	2023-01-27 17:12:43 UTC	CA357060	223228	"C.490C>T,Q164X,GLN164TER,RS5030819"	FALSE
VHL R167W (c.499C>T)	1623	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Predisposition	"Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This missense mutation was found in six VHL type 2 families (lineages 202, 47, 102, 106, 153, 109). Two of these families (47 and 109) were previously reported in Chen et al 1995 or Zbar et al 1996."	9829911	PubMed		"Stolle et al., 1998, Hum. Mutat."		4	accepted	5052	Rare Germline	2023-02-03 16:29:43 UTC	https://civicdb.org/links/evidence_items/5052	https://civicdb.org/links/molecular_profiles/1623	FALSE	VHL	7428	R167W (c.499C>T)		chr3	10149822	10149822	C	T	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.499C>T,NP_000542.1:p.Arg167Trp,NC_000003.11:g.10191506C>T,ENST00000256474.2:c.499C>T"	2023-01-27 17:11:35 UTC	CA020450	2218	"C.499C>T,ARG167TRP,R126W,RS5030820"	FALSE
VHL Y175D (c.523T>G)	1722	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Predisposition	Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This missense mutation was found in a VHL type 1 family (lineage 7).	9829911	PubMed		"Stolle et al., 1998, Hum. Mutat."		3	accepted	5053	Rare Germline	2023-02-03 18:05:11 UTC	https://civicdb.org/links/evidence_items/5053	https://civicdb.org/links/molecular_profiles/1722	FALSE	VHL	7428	Y175D (c.523T>G)		chr3	10149846	10149846	T	G	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.523T>G,NC_000003.11:g.10191530T>G,NM_000551.3:c.523T>G,NP_000542.1:p.Tyr175Asp"	2023-01-27 17:12:44 UTC	CA351756228	NONE FOUND	"C.523T>G,TYR175ASP"	FALSE
VHL V181fs (c.540_543del)	1723	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Predisposition	Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This mutation causes an early stop codon at amino acid 200 and was found in a VHL type 1 family (lineage 25). Only moderate evidence for pathogenicity because protein length changes as a result of deletions in a nonrepeat region and stop-loss variant (ACMG code: PM4).	9829911	PubMed		"Stolle et al., 1998, Hum. Mutat."		3	accepted	5054	Rare Germline	2023-02-03 18:05:51 UTC	https://civicdb.org/links/evidence_items/5054	https://civicdb.org/links/molecular_profiles/1723	FALSE	VHL	7428	V181fs (c.540_543del)		chr3	10149863	10149866	CGTC		ENST00000256474.2	75		"minus_1_frameshift_variant,frameshift_truncation"	"NC_000003.11:g.10191547_10191550del,NC_000003.12:g.10149863_10149866del,NM_000551.3:c.540_543del,NP_000542.1:p.Val181fs"	2023-01-27 17:12:45 UTC	CA357022	223230	"VAL181FS,C.540_543DELCGTC,RS869025664"	FALSE
VHL L184P (c.551T>C)	1652	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Predisposition	"93 families that fulfilled the clinical criteria of VHL disease were assessed for germline mutations in the VHL gene, and mutations were found in all affected family members. The c.551T>C (p.L184P) mutation was found in a family (Lineage 14) in which members were clinically diagnosed with VHL presenting without pheochromocytoma (VHL type 1), however, no further phenotypic information about specific patients was provided. This mutation was recorded as c.764T>C in the paper, due to the use of an older VHL reference transcript (AF010238.1). Genomic DNA was extracted from whole blood for analysis. Polymorphisms in the VHL gene were detected by southern blotting, and were further investigated by PCR and Sanger sequencing. Partial and total deletions of the VHL gene were investigated by southern blot. Relevant ACMG codes include: PP4, because the patients phenotype is highly specific for a disease with a single genetic etiology."	9829911	PubMed		"Stolle et al., 1998, Hum. Mutat."		2	accepted	5055	Rare Germline	2023-02-03 18:07:04 UTC	https://civicdb.org/links/evidence_items/5055	https://civicdb.org/links/molecular_profiles/1652	FALSE	VHL	7428	L184P (c.551T>C)		chr3	10149874	10149874	T	C	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.551T>C,NP_000542.1:p.Leu184Pro,NC_000003.11:g.10191558T>C,ENST00000256474.2:c.551T>C"	2023-01-27 17:11:54 UTC	CA16617792	419447	"C.551T>C,LEU184PRO,RS1064793878"	FALSE
VHL Y185* (c.555C>G)	1685	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Predisposition	Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This nonsense mutation was found in a VHL type 1 family (lineage 50). Only moderate evidence for pathogenicity because protein length changes as a result of stop-loss variant (ACMG code: PM4).	9829911	PubMed		"Stolle et al., 1998, Hum. Mutat."		3	accepted	5056	Rare Germline	2023-02-03 18:10:42 UTC	https://civicdb.org/links/evidence_items/5056	https://civicdb.org/links/molecular_profiles/1685	FALSE	VHL	7428	Y185* (c.555C>G)		chr3	10149878	10149878	C	G	ENST00000256474.2	75		stop_gained	"NM_000551.3:c.555C>G,NP_000542.1:p.Tyr185Ter,NC_000003.11:g.10191562C>G,ENST00000256474.2:c.555C>G"	2023-01-27 17:12:20 UTC	CA357075	223233	"C.555C>G,Y185X,TYR185TER,RS864622109"	FALSE
VHL E186* (c.556G>T)	1653	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Predisposition	Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This nonsense mutation was found in a VHL type 1 family (lineage 78). Only moderate evidence for pathogenicity because protein length changes as a result of stop-loss variant (ACMG code: PM4).	9829911	PubMed		"Stolle et al., 1998, Hum. Mutat."		3	accepted	5057	Rare Germline	2023-02-03 18:10:17 UTC	https://civicdb.org/links/evidence_items/5057	https://civicdb.org/links/molecular_profiles/1653	FALSE	VHL	7428	E186* (c.556G>T)		chr3	10149879	10149879	G	T	ENST00000256474.2	75		stop_gained	"NM_000551.3:c.556G>T,NP_000542.1:p.Glu186Ter,NC_000003.11:g.10191563G>T,ENST00000256474.2:c.556G>T"	2023-01-27 17:11:55 UTC	CA16604432	381602	"C.556G>T,E186X,GLU186TER,RS367545984"	FALSE
VHL Q96* (c.286C>T)	1724	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Predisposition	Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This nonsense mutation was found in a VHL type 1 family (lineage 48). Only moderate evidence for pathogenicity because protein length changes as a result of stop-loss variant (ACMG code: PM4).	9829911	PubMed		"Stolle et al., 1998, Hum. Mutat."		3	accepted	5058	Rare Germline	2023-02-03 18:11:42 UTC	https://civicdb.org/links/evidence_items/5058	https://civicdb.org/links/molecular_profiles/1724	FALSE	VHL	7428	Q96* (c.286C>T)		chr3	10142133	10142133	C	T	ENST00000256474.2	75		stop_gained	"NM_000551.3:c.286C>T,NP_000542.1:p.Gln96Ter,NC_000003.11:g.10183817C>T,ENST00000256474.2:c.286C>T"	2023-01-27 17:12:46 UTC	CA351750811	428804	"C.286C>T,Q96X,GLN96TER,RS1131690959"	FALSE
VHL P86R (c.257C>G)	1725	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Predisposition	Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This missense mutation was found in a VHL type 1 family (lineage 128).	9829911	PubMed		"Stolle et al., 1998, Hum. Mutat."		3	accepted	5059	Rare Germline	2023-02-03 18:12:14 UTC	https://civicdb.org/links/evidence_items/5059	https://civicdb.org/links/molecular_profiles/1725	FALSE	VHL	7428	P86R (c.257C>G)		chr3	10142104	10142104	C	G	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.257C>G,NP_000542.1:p.Pro86Arg,NC_000003.11:g.10183788C>G,ENST00000256474.2:c.257C>G"	2023-01-27 17:12:46 UTC	CA357142	223170	"C.257C>G,PRO86ARG,RS730882034"	FALSE
VHL R161Q (c.482G>A)	1622	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Predisposition	Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This missense mutation was found in a VHL type 2 family (lineage 3).	9829911	PubMed		"Stolle et al., 1998, Hum. Mutat."		3	accepted	5061	Rare Germline	2023-02-03 18:13:23 UTC	https://civicdb.org/links/evidence_items/5061	https://civicdb.org/links/molecular_profiles/1622	FALSE	VHL	7428	R161Q (c.482G>A)		chr3	10149805	10149805	G	A	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.482G>A,NP_000542.1:p.Arg161Gln,NC_000003.11:g.10191489G>A,ENST00000256474.2:c.482G>A"	2023-01-27 17:11:34 UTC	CA020413	182983	"C.482G>A,ARG161GLN,RS730882035"	FALSE
VHL R167Q (c.500G>A)	1615	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Predisposition	"Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This missense mutation was found in six VHL type 2 families (lineages 100, 42, 44, 88, 105, 135). Only supporting evidence for pathogenicity because patient's phenotype is highly specific for a disease with a single genetic etiology (ACMG code: PP4)."	9829911	PubMed		"Stolle et al., 1998, Hum. Mutat."		4	accepted	5062	Rare Germline	2023-02-03 16:31:46 UTC	https://civicdb.org/links/evidence_items/5062	https://civicdb.org/links/molecular_profiles/1615	FALSE	VHL	7428	R167Q (c.500G>A)		chr3	10149823	10149823	G	A	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.500G>A,NP_000542.1:p.Arg167Gln,NC_000003.11:g.10191507G>A,ENST00000256474.2:c.500G>A"	2023-01-27 17:11:29 UTC	CA020454	2216	"C.500G>A,ARG167GLN,RS5030821"	FALSE
VHL G144* (c.430G>T)	1726	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Predisposition	Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This nonsense mutation was found in a VHL type 2 family (lineage 65). Only moderate evidence for pathogenicity because protein length changes as a result of stop-loss variant (ACMG code: PM4).	9829911	PubMed		"Stolle et al., 1998, Hum. Mutat."		3	accepted	5064	Rare Germline	2023-02-03 18:17:35 UTC	https://civicdb.org/links/evidence_items/5064	https://civicdb.org/links/molecular_profiles/1726	FALSE	VHL	7428	G144* (c.430G>T)		chr3	10146603	10146603	G	T	ENST00000256474.2	75		stop_gained	"NM_000551.3:c.430G>T,NP_000542.1:p.Gly144Ter,NC_000003.11:g.10188287G>T,ENST00000256474.2:c.430G>T"	2023-01-27 17:12:47 UTC	CA357109	223208	"C.430G>T,G144X,GLY144TER,RS869025650"	FALSE
VHL L188P (c.563T>C)	1728	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Predisposition	Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This missense mutation was found in a VHL type 2 family (lineage 73).	9829911	PubMed		"Stolle et al., 1998, Hum. Mutat."		3	accepted	5066	Rare Germline	2023-02-03 18:18:15 UTC	https://civicdb.org/links/evidence_items/5066	https://civicdb.org/links/molecular_profiles/1728	FALSE	VHL	7428	L188P (c.563T>C)		chr3	10149886	10149886	T	C	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.563T>C,NC_000003.11:g.10191570T>C,NM_000551.3:c.563T>C,NP_000542.1:p.Leu188Pro"	2023-01-27 17:12:49 UTC	CA351756399	625266	"C.563T>C,LEU188PRO"	FALSE
VHL S111C (c.330_331delinsTT)	1729	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Predisposition	Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This missense mutation was found in a VHL type 2 family (lineage 174).	9829911	PubMed		"Stolle et al., 1998, Hum. Mutat."		3	accepted	5067	Rare Germline	2023-02-03 18:25:40 UTC	https://civicdb.org/links/evidence_items/5067	https://civicdb.org/links/molecular_profiles/1729	FALSE	VHL	7428	S111C (c.330_331delinsTT)		chr3	10142177	10142178	CA	TT	ENST00000256474.2	75		delins	"NP_000542.1:p.Ser111Cys,NP_001341652.1:p.Ser111Cys,NC_000003.11:g.10183861_10183862delinsTT,NC_000003.12:g.10142177_10142178delinsTT"	2023-01-27 17:12:50 UTC	CA2573106137	NONE FOUND	S111C (C.330_331CA>TT)	FALSE
GNAQ Mutation	501	Uveal Melanoma	6039		Cabozantinib		Predictive	Supports	B	Sensitivity/Response	"Patients with metastatic melanoma (n=77; 48 cutaneous, 23 uveal, 6 mucosal) were enrolled in a phase II randomised discontinuation trial assessing cabozantinib. Patients received 100 mg cabozantinib daily for 12 weeks. Patients with stable disease (SD; RECIST; n=26) were randomly assigned to cabozantinib (n=13) or placebo (n=13). In the uveal melanoma cohort, 61% of patients (14/23, 61%) had SD at week 12. 9 patients had either a GNAQ (n=5) or GNA11 (n=4) mutation; only 10 patients were analyzed. Patients with GNAQ mutations remained on the study treatment from 1.4-10.3 months. The median PFS for the 23 patients with uveal melanoma was 4.8 months (41% PFS at 6 months) and median OS was 12.6 months. In the entire cohort, median overall PFS was 3.8 months (33% PFS at 6 months). After randomisation, median PFS for cabozantinib patients was 4.1 months and 2.8 months for placebo (HR 0.59, p=0.284)."	28103611	PubMed		"Daud et al., 2017, Br. J. Cancer"		2	accepted	5068	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/5068	https://civicdb.org/links/molecular_profiles/501	FALSE	GNAQ	2776	Mutation		chr9	77716087	78031458			ENST00000286548.4	75				2023-01-09 21:52:07 UTC				FALSE
IDH2 Mutation	566	Acute Myeloid Leukemia	9119		Enasidenib		Predictive	Supports	A	Sensitivity/Response	"A first-in-human phase 1/2 trial assessing the pharmacology, safety and activity of Enasidenib in IDH2-mutant myeloid hematoblastosis patients. In the AML subgroup (n=176, (n=130 R140; n=45 R172; n=1 Other)) of included patients (n=239) the overall response rate was 40.3%, with median response duration of 5.8 months. Responses were associated with cellular differentiation and maturation, typically without evidence of aplasia. Median overall survival among relapsed/refractory patients was 9.3 months, and for the 34 patients (19.3%) with complete response was 19.7 months."	28588020	PubMed		"Stein et al., 2017, Blood"	NCT01915498	4	accepted	5069	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/5069	https://civicdb.org/links/molecular_profiles/566	FALSE	IDH2	3418	Mutation		chr15	90083045	90102504			ENST00000330062.3	75		protein_altering_variant		2023-01-09 21:52:07 UTC		N/A		FALSE
CTNNB1 T41A	1259	Desmoid Tumor	80366				Diagnostic	Supports	B	Positive	In this study a collection of 254 sporadic desmoid tumors were analysed for presence of mutations in CTNNB1. A mutation in exon 3 of the CTNNB1 gene was identified in 223 (88%) of the 254 cases. The CTNNB1 mutation spectra concerned mainly three point mutations in two codons (41 and 45): T41A was identified in 132 cases (59%); S45F was identified in 49 samples (22%); and S45P was identified in 27 samples (12%). None of the 175 lesions mimicking desmoid tumors analyzed harbored any CTNNB1 mutations.	22766794	PubMed		"Le Guellec et al., 2012, Mod. Pathol."		4	accepted	5070	Somatic	2023-01-09 21:46:44 UTC	https://civicdb.org/links/evidence_items/5070	https://civicdb.org/links/molecular_profiles/1259	FALSE	CTNNB1	1499	T41A		chr3	41224633	41224633	A	G	ENST00000349496.5	75		missense_variant	"NM_001904.3:c.121A>G,NP_001895.1:p.Thr41Ala,NC_000003.11:g.41266124A>G,ENST00000349496.5:c.121A>G"	2023-01-27 17:09:13 UTC	CA127269	17580	"THR41ALA,RS121913412"	FALSE
CTNNB1 S45F	1260	Desmoid Tumor	80366				Diagnostic	Supports	B	Positive	In this study a collection of 254 sporadic desmoid tumors were analysed for presence of mutations in CTNNB1. A mutation in exon 3 of the CTNNB1 gene was identified in 223 (88%) of the 254 cases. The CTNNB1 mutation spectra concerned mainly three point mutations in two codons (41 and 45): T41A was identified in 132 cases (59%); S45F was identified in 49 samples (22%); and S45P was identified in 27 samples (12%). None of the 175 lesions mimicking desmoid tumors analyzed harbored any CTNNB1 mutations.	22766794	PubMed		"Le Guellec et al., 2012, Mod. Pathol."		4	accepted	5071	Somatic	2023-01-09 21:46:44 UTC	https://civicdb.org/links/evidence_items/5071	https://civicdb.org/links/molecular_profiles/1260	FALSE	CTNNB1	1499	S45F		chr3	41224646	41224646	C	T	ENST00000349496.5	75		missense_variant	"NM_001904.3:c.134C>T,NP_001895.1:p.Ser45Phe,NC_000003.11:g.41266137C>T,ENST00000349496.5:c.134C>T"	2023-01-27 17:09:14 UTC	CA127283	17588	"SER45PHE,RS121913409"	FALSE
CTNNB1 S45P	1261	Desmoid Tumor	80366				Diagnostic	Supports	B	Positive	In this study a collection of 254 sporadic desmoid tumors were analysed for presence of mutations in CTNNB1. A mutation in exon 3 of the CTNNB1 gene was identified in 223 (88%) of the 254 cases. The CTNNB1 mutation spectra concerned mainly three point mutations in two codons (41 and 45): T41A was identified in 132 cases (59%); S45F was identified in 49 samples (22%); and S45P was identified in 27 samples (12%). None of the 175 lesions mimicking desmoid tumors analyzed harbored any CTNNB1 mutations.	22766794	PubMed		"Le Guellec et al., 2012, Mod. Pathol."		3	accepted	5072	Somatic	2023-01-09 21:46:44 UTC	https://civicdb.org/links/evidence_items/5072	https://civicdb.org/links/molecular_profiles/1261	FALSE	CTNNB1	1499	S45P		chr3	41224645	41224645	T	C	ENST00000349496.5	75		missense_variant	"NM_001904.3:c.133T>C,NP_001895.1:p.Ser45Pro,NC_000003.11:g.41266136T>C,ENST00000349496.5:c.133T>C"	2023-01-27 17:09:14 UTC	CA127285	17589	"SER45PRO,RS121913407"	FALSE
VHL V170D (c.509T>A)	1702	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	"Germline mutation analysis of 469 VHL families reveled 300 mutations. The most common germline mutations were identified between codons 75-82, between codons 157-189 (Elongin binding domain) and at the splice site between exons 2 and 3. The association between mutations in codon 167 and pheochromocytoma was detected in all nationalities tested. This missense mutation was found in a VHL type 2 family (family ID R-D)."	8956040	PubMed		"Zbar et al., 1996, Hum. Mutat."		3	accepted	5092	Rare Germline	2023-01-09 21:46:50 UTC	https://civicdb.org/links/evidence_items/5092	https://civicdb.org/links/molecular_profiles/1702	FALSE	VHL	7428	V170D (c.509T>A)		chr3	10149832	10149832	T	A	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.509T>A,NC_000003.11:g.10191516T>A,NM_000551.3:c.509T>A,NP_000542.1:p.Val170Asp"	2023-01-27 17:12:32 UTC	CA351756195	625256	"C.509T>A,VAL170ASP"	FALSE
VHL R64P (c.191G>C)	1743	Von Hippel-Lindau Disease	14175	"Pheochromocytoma,Renal cell carcinoma,Paraganglioma"			Predisposing	Supports	C	Uncertain Significance	"Molecular analysis of VHL gene in 146 probands, 103 with and 43 without a positive family history, resulted in the detection of 43 germline VHL mutations. Majority of mutations were found in patients with classic or multi-organ manifestations of VHL disease, but mutations were also found in patients with limited or single-organ manifestations of VHL disease. Follow-up of families with germline mutations and limited VHL manifestations was recommended. This missense mutation was found in a VHL type 2B family of 6 patients with the mutation, but incomplete penetrance (family no. 1; pedigree in Figure 2). A 59 yo carrier had no VHL manifestations but 2 unaffected children without the mutation and 2 children with the mutation, 1 with pheochromocytoma aged 32 and a 40 yo with no clinical manifestations. The 59 year old also had an affected family with the mutation - a parent (renal cell carcinoma) and a affected sibling (pheochromocytoma) and their child (paraganglioma) - and 4 unaffected siblings without the mutation. Only supporting evidence for pathogenicity because of cosegregation of the disease with multiple affected family in a gene definitively known to cause the disease (ACMG code: PP1)."	17661816	PubMed		"Hes et al., 2007, Clin. Genet."		3	accepted	5094	Rare Germline	2023-01-09 21:46:51 UTC	https://civicdb.org/links/evidence_items/5094	https://civicdb.org/links/molecular_profiles/1743	FALSE	VHL	7428	R64P (c.191G>C)		chr3	10142038	10142038	G	C	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.191G>C,NP_000542.1:p.Arg64Pro,NC_000003.11:g.10183722G>C,ENST00000256474.2:c.191G>C"	2023-01-27 17:12:58 UTC	CA020089	2226	"C.191G>C,ARG64PRO,RS104893826"	FALSE
VHL Q164* (c.490C>T)	1721	Von Hippel-Lindau Disease	14175	"Epididymal cyst,Cerebellar hemangioblastoma,Renal cell carcinoma"			Predisposing	Supports	C	Uncertain Significance	"Molecular analysis of VHL gene in 146 probands, 103 with and 43 without a positive family history, resulted in the detection of 43 germline VHL mutations. Majority of mutations were found in patients with classic or multi-organ manifestations of VHL disease, but mutations were also found in patients with limited or single-organ manifestations of VHL disease. Follow-up of families with germline mutations and limited VHL manifestations was recommended. This mutation was found in a VHL type 1 patient with cerebellar hemangioblastomas, epididymal cyst, and renal cell carcinoma (family no. 21)."	17661816	PubMed		"Hes et al., 2007, Clin. Genet."		3	accepted	5096	Rare Germline	2023-01-09 21:46:51 UTC	https://civicdb.org/links/evidence_items/5096	https://civicdb.org/links/molecular_profiles/1721	FALSE	VHL	7428	Q164* (c.490C>T)		chr3	10149813	10149813	C	T	ENST00000256474.2	75		stop_gained	"NM_000551.3:c.490C>T,NP_000542.1:p.Gln164Ter,NC_000003.11:g.10191497C>T,ENST00000256474.2:c.490C>T"	2023-01-27 17:12:43 UTC	CA357060	223228	"C.490C>T,Q164X,GLN164TER,RS5030819"	FALSE
VHL Q195* (c.583C>T)	1686	Von Hippel-Lindau Disease	14175	"Retinal capillary hemangioma,Pheochromocytoma,Cerebellar hemangioblastoma"			Predisposing	Supports	C	Uncertain Significance	"Molecular analysis of VHL gene in 146 probands, 103 with and 43 without a positive family history, resulted in the detection of 43 germline VHL mutations. Majority of mutations were found in patients with classic or multi-organ manifestations of VHL disease, but mutations were also found in patients with limited or single-organ manifestations of VHL disease. Follow-up of families with germline mutations and limited VHL manifestations was recommended. This mutation was found in 2 VHL type 2A family members (family no. 23). Both had retinal hemangioblastomas, one had cerebellar hemangioblastomas, and one had pheochromocytoma.  Only supportive evidence for pathogenicity because patients phenotype or family history is highly specific for a disease with a single genetic etiology (ACMG code: PP4)."	17661816	PubMed		"Hes et al., 2007, Clin. Genet."		3	accepted	5097	Rare Germline	2023-01-09 21:46:50 UTC	https://civicdb.org/links/evidence_items/5097	https://civicdb.org/links/molecular_profiles/1686	FALSE	VHL	7428	Q195* (c.583C>T)		chr3	10149906	10149906	C	T	ENST00000256474.2	75		stop_gained	"NM_000551.3:c.583C>T,NP_000542.1:p.Gln195Ter,NC_000003.11:g.10191590C>T,ENST00000256474.2:c.583C>T"	2023-01-27 17:12:20 UTC	CA70052558	428794	"C.583C>T,Q195X,GLN195TER,RS5030825"	FALSE
VHL E189fs (c.565del)	1745	Von Hippel-Lindau Disease	14175	"Cerebellar hemangioblastoma,Multiple renal cysts"			Predisposing	Supports	C	Uncertain Significance	"Molecular analysis of VHL gene in 146 probands, 103 with and 43 without a positive family history, resulted in the detection of 43 germline VHL mutations. Majority of mutations were found in patients with classic or multi-organ manifestations of VHL disease, but mutations were also found in patients with limited or single-organ manifestations of VHL disease. Follow-up of families with germline mutations and limited VHL manifestations was recommended. This mutation causes an early stop codon at amino acid 201 and was found in a VHL type 1 patient with cerebellar hemangioblastomas and renal cysts (family no. 27)."	17661816	PubMed		"Hes et al., 2007, Clin. Genet."		3	accepted	5098	Rare Germline	2023-01-09 21:46:51 UTC	https://civicdb.org/links/evidence_items/5098	https://civicdb.org/links/molecular_profiles/1745	FALSE	VHL	7428	E189fs (c.565del)		chr3	10149888	10149888	G		ENST00000256474.2	75		"minus_1_frameshift_variant,frameshift_truncation"	"NC_000003.11:g.10191572del,NC_000003.12:g.10149888del,NM_000551.4:c.565del,NP_000542.1:p.Glu189fs"	2023-01-27 17:12:59 UTC	CA432423686	625267	"E189FS (C.565DELG),E189KFS*13 (C.565DEL),GLU189LYSFS*13"	FALSE
VHL Splice Site (c.340+1G>A)	1990	Von Hippel-Lindau Disease	14175	Renal cell carcinoma			Predisposing	Supports	C	Uncertain Significance	"Molecular analysis of VHL gene in 146 probands, 103 with and 43 without a positive family history, resulted in the detection of 43 germline VHL mutations. Majority of mutations were found in patients with classic or multi-organ manifestations of VHL disease, but mutations were also found in patients with limited or single-organ manifestations of VHL disease. Follow-up of families with germline mutations and limited VHL manifestations was recommended. This mutation was detected in a VHL patient with renal cell carcinoma (family no. 31)."	17661816	PubMed		"Hes et al., 2007, Clin. Genet."		3	accepted	5099	Rare Germline	2023-01-09 21:46:55 UTC	https://civicdb.org/links/evidence_items/5099	https://civicdb.org/links/molecular_profiles/1990	FALSE	VHL	7428	Splice Site (c.340+1G>A)		chr3	10142188	10142188	G	A	ENST00000256474.2	75		splice_donor_variant	"NM_000551.3:c.340+1G>A,NC_000003.11:g.10183872G>A,ENST00000256474.2:c.340+1G>A"	2023-01-27 17:15:13 UTC	CA357042	223190	"C.340+1G>A,C.553+1G>A"	FALSE
VHL G93S (c.277G>A)	1735	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	"Molecular analysis of VHL gene in 146 probands, 103 with and 43 without a positive family history, resulted in the detection of 43 germline VHL mutations. Majority of mutations were found in patients with classic or multi-organ manifestations of VHL disease, but mutations were also found in patients with limited or single-organ manifestations of VHL disease. Follow-up of families with germline mutations and limited VHL manifestations was recommended. This mutation was found in 2 VHL type 2C family members (family no. 9), both with pheochromocytoma."	17661816	PubMed		"Hes et al., 2007, Clin. Genet."		3	accepted	5100	Rare Germline	2023-01-09 21:46:51 UTC	https://civicdb.org/links/evidence_items/5100	https://civicdb.org/links/molecular_profiles/1735	FALSE	VHL	7428	G93S (c.277G>A)		chr3	10142124	10142124	G	A	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.277G>A,NP_000542.1:p.Gly93Ser,NC_000003.11:g.10183808G>A,ENST00000256474.2:c.277G>A"	2023-01-27 17:12:54 UTC	CA020230	2237	"C.277G>A,GLY93SER,RS5030808"	FALSE
VHL I151T (c.452T>C)	1747	Von Hippel-Lindau Disease	14175	"Renal cell carcinoma,Cerebellar hemangioblastoma"			Predisposing	Supports	C	Uncertain Significance	"Molecular analysis of VHL gene in 146 probands, 103 with and 43 without a positive family history, resulted in the detection of 43 germline VHL mutations. Majority of mutations were found in patients with classic or multi-organ manifestations of VHL disease, but mutations were also found in patients with limited or single-organ manifestations of VHL disease. Follow-up of families with germline mutations and limited VHL manifestations was recommended. This mutation was detected in a VHL patient with cerebellar hemangioblastomas and renal cell carcinoma (family no. 11). Only supporting evidence for pathogenicity because Patients phenotype or family history is highly specific for a disease with a single genetic etiology (ACMG code: PP4). Relevant HPO terms: Cerebellar hemangioblastoma, Renal cell carcinoma."	17661816	PubMed		"Hes et al., 2007, Clin. Genet."		3	accepted	5101	Rare Germline	2023-01-09 21:46:51 UTC	https://civicdb.org/links/evidence_items/5101	https://civicdb.org/links/molecular_profiles/1747	FALSE	VHL	7428	I151T (c.452T>C)		chr3	10146625	10146625	T	C	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.452T>C,NP_000542.1:p.Ile151Thr,NC_000003.11:g.10188309T>C,ENST00000256474.2:c.452T>C"	2023-01-27 17:13:00 UTC	CA351754359	428803	"C.452T>C,ILE151THR,RS869025655"	FALSE
VHL L158P (c.473T>C)	1614	Von Hippel-Lindau Disease	14175	Retinal capillary hemangioma			Predisposing	Supports	C	Uncertain Significance	"Molecular analysis of VHL gene in 146 probands, 103 with and 43 without a positive family history, resulted in the detection of 43 germline VHL mutations. Majority of mutations were found in patients with classic or multi-organ manifestations of VHL disease, but mutations were also found in patients with limited or single-organ manifestations of VHL disease. Follow-up of families with germline mutations and limited VHL manifestations was recommended. This mutation was found in 2 VHL family members with retinal hemangioblastomas (family no.13)."	17661816	PubMed		"Hes et al., 2007, Clin. Genet."		3	accepted	5103	Rare Germline	2023-01-09 21:46:47 UTC	https://civicdb.org/links/evidence_items/5103	https://civicdb.org/links/molecular_profiles/1614	FALSE	VHL	7428	L158P (c.473T>C)		chr3	10149796	10149796	T	C	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.473T>C,NP_000542.1:p.Leu158Pro,NC_000003.11:g.10191480T>C,ENST00000256474.2:c.473T>C"	2023-01-27 17:11:28 UTC	CA020399	182980	"C.473T>C,LEU158PRO,RS121913346"	FALSE
VHL S65L (c.194C>T)	1664	Von Hippel-Lindau Disease	14175	"Epididymal cyst,Cerebellar hemangioblastoma,Renal cell carcinoma,Pancreatic cysts,Multiple renal cysts"			Predisposing	Supports	C	Uncertain Significance	"Molecular analysis of VHL gene in 146 probands, 103 with and 43 without a positive family history, resulted in the detection of 43 germline VHL mutations. Majority of mutations were found in patients with classic or multi-organ manifestations of VHL disease, but mutations were also found in patients with limited or single-organ manifestations of VHL disease. Follow-up of families with germline mutations and limited VHL manifestations was recommended.  This mutation was found in a VHL type 1 patient with cerebellar hemangioblastomas, renal cell carcinoma, renal cysts, epididymal cyst, and pancreatic cysts (family no. 2)."	17661816	PubMed		"Hes et al., 2007, Clin. Genet."		3	accepted	5104	Rare Germline	2023-01-09 21:46:49 UTC	https://civicdb.org/links/evidence_items/5104	https://civicdb.org/links/molecular_profiles/1664	FALSE	VHL	7428	S65L (c.194C>T)		chr3	10142041	10142041	C	T	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.194C>T,NP_000542.1:p.Ser65Leu,NC_000003.11:g.10183725C>T,ENST00000256474.2:c.194C>T"	2023-01-27 17:12:03 UTC	CA020104	182975	"C.194C>T,SER65LEU,RS5030826"	FALSE
VHL S68P (c.202T>C)	1749	Von Hippel-Lindau Disease	14175	Retinal capillary hemangioma			Predisposing	Supports	C	Uncertain Significance	"Molecular analysis of VHL gene in 146 probands, 103 with and 43 without a positive family history, resulted in the detection of 43 germline VHL mutations. Majority of mutations were found in patients with classic or multi-organ manifestations of VHL disease, but mutations were also found in patients with limited or single-organ manifestations of VHL disease. Follow-up of families with germline mutations and limited VHL manifestations was recommended. This mutation was detected in a VHL family with 2 individuals with retinal hemangioblastomas (family no. 4)."	17661816	PubMed		"Hes et al., 2007, Clin. Genet."		3	accepted	5105	Rare Germline	2023-01-09 21:46:51 UTC	https://civicdb.org/links/evidence_items/5105	https://civicdb.org/links/molecular_profiles/1749	FALSE	VHL	7428	S68P (c.202T>C)		chr3	10142049	10142049	T	C	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.202T>C,NC_000003.11:g.10183733T>C,NM_000551.3:c.202T>C,NP_000542.1:p.Ser68Pro"	2023-01-27 17:13:01 UTC	CA16621912	NONE FOUND	"C.202T>C,SER68PRO"	FALSE
VHL R161Q (c.482G>A)	1622	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	"Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). A missense mutation, affecting a residue on surface of pVHL protein core, was found in 2 VHL type 2C families with 4 patients altogether. All 4 patients had pheochromocytoma."	17024664	PubMed		"Ong et al., 2007, Hum. Mutat."		3	accepted	5125	Rare Germline	2023-01-09 21:46:48 UTC	https://civicdb.org/links/evidence_items/5125	https://civicdb.org/links/molecular_profiles/1622	FALSE	VHL	7428	R161Q (c.482G>A)		chr3	10149805	10149805	G	A	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.482G>A,NP_000542.1:p.Arg161Gln,NC_000003.11:g.10191489G>A,ENST00000256474.2:c.482G>A"	2023-01-27 17:11:34 UTC	CA020413	182983	"C.482G>A,ARG161GLN,RS730882035"	FALSE
VHL N131fs (c.390_391del)	1676	Von Hippel-Lindau Disease	14175	Cerebellar hemangioblastoma			Predisposing	Supports	C	Uncertain Significance	Genotype-phenotype correlations of 573 VHL patients from 200 kindreds were analyzed. Higher risk of pheochromocytoma was associated with missense mutations that result in substitution of a surface amino acid (p<=0.004) than for patients with missense mutations that disrupt the structural integrity of the VHL gene product (pVHL) or other  loss of function mutations (either germline deletions or truncating mutations). Age-related risks of retinal angiomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This frameshift mutation causes an early stop codon at amino acid 133 and was found in a VHL patient with cerebellar hemangioblastomas. This study contains very strong evidence for pathogenicity in the form of a frameshift mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1). Relevant HPO terms: Cerebellar hemangioblastoma.	17024664	PubMed		"Ong et al., 2007, Hum. Mutat."		3	accepted	5128	Rare Germline	2023-01-09 21:46:50 UTC	https://civicdb.org/links/evidence_items/5128	https://civicdb.org/links/molecular_profiles/1676	FALSE	VHL	7428	N131fs (c.390_391del)		chr3	10146563	10146564	TA		ENST00000256474.2	75		minus_2_frameshift_variant	"ENST00000256474.2:c.390_391delTA,NC_000003.11:g.10188247_10188248del,NC_000003.12:g.10146563_10146564del,NM_000551.3:c.390_391delTA,NP_000542.1:p.Asn131fs,NP_000542.1:p.Asn131ProfsTer3"	2023-01-27 17:12:13 UTC	CA658795179	NONE FOUND	"C.390_391DELTA,ASN131PRO,N131PFS*3,ASN131PROFSTER3"	FALSE
VHL N78H (c.232A>C)	1630	Renal Cell Carcinoma	4450	"Retinal capillary hemangioma,Cerebellar hemangioblastoma,Renal cell carcinoma"			Predisposing	Supports	C	Uncertain Significance	"Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). A missense mutation, affecting a residue within the pVHL protein core, was found in 2 VHL family members. Both had retinal angiomas and cerebellar hemangioblastomas. One had renal cell carcinoma."	17024664	PubMed		"Ong et al., 2007, Hum. Mutat."		4	accepted	5130	Rare Germline	2023-01-09 21:46:48 UTC	https://civicdb.org/links/evidence_items/5130	https://civicdb.org/links/molecular_profiles/1630	FALSE	VHL	7428	N78H (c.232A>C)		chr3	10142079	10142079	A	C	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.232A>C,NC_000003.11:g.10183763A>C,NM_000551.3:c.232A>C,NP_000542.1:p.Asn78His"	2023-01-27 17:11:40 UTC	CA351749283	NONE FOUND	"C.232A>C,ASN78HIS"	FALSE
VHL Q132P (c.395A>C)	2001	Von Hippel-Lindau Disease	14175	"Cerebellar hemangioblastoma,Renal cell carcinoma,Retinal capillary hemangioma"			Predisposing	Supports	C	Uncertain Significance	"Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). A missense mutation, affecting a residue on surface of pVHL, was found in a VHL family with retinal angiomas, cerebellar hemangioblastomas, and renal cell carcinoma."	17024664	PubMed		"Ong et al., 2007, Hum. Mutat."		4	accepted	5131	Rare Germline	2023-01-09 21:46:56 UTC	https://civicdb.org/links/evidence_items/5131	https://civicdb.org/links/molecular_profiles/2001	FALSE	VHL	7428	Q132P (c.395A>C)		chr3	10146568	10146568	A	C	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.395A>C,NC_000003.11:g.10188252A>C,NM_000551.3:c.395A>C,NP_000542.1:p.Gln132Pro"	2023-01-27 17:15:20 UTC	CA351753958	496063	"C.395A>C,GLN132PRO,RS1347416980"	FALSE
VHL Q164R (c.491A>G)	1732	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	"Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). This missense mutation was found in a VHL patient with retinal hemangioblastomas and pheochromocytoma. Relevant HPO terms: Retinal hemangioblastoma, Pheochromocytoma."	17024664	PubMed		"Ong et al., 2007, Hum. Mutat."		4	accepted	5133	Rare Germline	2023-01-09 21:46:51 UTC	https://civicdb.org/links/evidence_items/5133	https://civicdb.org/links/molecular_profiles/1732	FALSE	VHL	7428	Q164R (c.491A>G)		chr3	10149814	10149814	A	G	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.491A>G,NP_000542.1:p.Gln164Arg,NC_000003.11:g.10191498A>G,ENST00000256474.2:c.491A>G"	2023-01-27 17:12:51 UTC	CA020429	2238	"C.491A>G,GLN164ARG,RS267607170"	FALSE
VHL Q195* (c.583C>T)	1686	Von Hippel-Lindau Disease	14175	"Pheochromocytoma,Retinal capillary hemangioma,Cerebellar hemangioblastoma,Renal cell carcinoma"			Predisposing	Supports	C	Uncertain Significance	"Genotype-phenotype correlations of 573 VHL patients from 200 kindreds were analyzed. Age-related risks of retinal angiomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This nonsense mutation was found in 2 VHL families with 9 patients altogether. Eight had retinal hemangioblastoma, one had cerebellar hemangioblastomas, 3 had renal cell carcinoma, and 5 had pheochromcytoma. This study contains very strong evidence for pathogenicity in the form of a frameshift mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1)."	17024664	PubMed		"Ong et al., 2007, Hum. Mutat."		4	accepted	5134	Rare Germline	2023-01-09 21:46:50 UTC	https://civicdb.org/links/evidence_items/5134	https://civicdb.org/links/molecular_profiles/1686	FALSE	VHL	7428	Q195* (c.583C>T)		chr3	10149906	10149906	C	T	ENST00000256474.2	75		stop_gained	"NM_000551.3:c.583C>T,NP_000542.1:p.Gln195Ter,NC_000003.11:g.10191590C>T,ENST00000256474.2:c.583C>T"	2023-01-27 17:12:20 UTC	CA70052558	428794	"C.583C>T,Q195X,GLN195TER,RS5030825"	FALSE
VHL Q73* (c.217C>T)	1628	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	"Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). Age-related risks of retinal hemangioblastomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This nonsense mutation was found in 3 VHL families with 9 patients altogether. Seven had retinal hemangioblastomas, 3 had cerebellar hemangioblastomas, and 5 had renal cell carcinoma. Only moderate evidence of pathogenicity since the protein length changes as a result of a stop-loss variants (ACMG code: PM4). Relevant HPO terms: Cerebellar hemangioblastoma, Retinal hemangioblastoma, Renal cell carcinoma."	17024664	PubMed		"Ong et al., 2007, Hum. Mutat."		4	accepted	5135	Rare Germline	2023-01-09 21:46:48 UTC	https://civicdb.org/links/evidence_items/5135	https://civicdb.org/links/molecular_profiles/1628	FALSE	VHL	7428	Q73* (c.217C>T)		chr3	10142064	10142064	C	T	ENST00000256474.2	75		stop_gained	"NM_000551.3:c.217C>T,NP_000542.1:p.Gln73Ter,NC_000003.11:g.10183748C>T,ENST00000256474.2:c.217C>T"	2023-01-27 17:11:39 UTC	CA357036	223164	"Q73X,C.217C>T,GLN73TER,RS869025619"	FALSE
VHL E94* (c.280G>T)	1670	Von Hippel-Lindau Disease	14175	"Retinal capillary hemangioma,Cerebellar hemangioblastoma"			Predisposing	Supports	C	Uncertain Significance	"Genotype-phenotype correlations of 573 VHL patients from 200 kindreds were analyzed. Age-related risks of retinal hemangioblastomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This nonsense mutation was found in 2 VHL families with 6 patients altogether. All six had retinal hemangioblastomas and 2 had cerebellar hemangioblastomas. This study contains very strong evidence for pathogenicity in the form of a nonsense mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1). Relevant HPO terms: Cerebellar hemangioblastoma, Retinal hemangioblastoma."	17024664	PubMed		"Ong et al., 2007, Hum. Mutat."		3	accepted	5137	Rare Germline	2023-01-09 21:46:49 UTC	https://civicdb.org/links/evidence_items/5137	https://civicdb.org/links/molecular_profiles/1670	FALSE	VHL	7428	E94* (c.280G>T)		chr3	10142127	10142127	G	T	ENST00000256474.2	75		stop_gained	"ENST00000256474.2:c.280G>T,NM_198156.2:c.280G>T,NP_000542.1:p.Glu94Ter,NC_000003.11:g.10183811G>T"	2023-01-27 17:12:08 UTC	CA70046202	584477	"C.280G>T,E94X,GLU94TER,RS5030829"	FALSE
VHL P103FS (c.309_310delTG)	1671	Von Hippel-Lindau Disease	14175	"Cerebellar hemangioblastoma,Renal cell carcinoma,Retinal capillary hemangioma"			Predisposing	Supports	C	Uncertain Significance	"Genotype-phenotype correlations of 573 VHL patients from 200 kindreds were analyzed. Age-related risks of retinal hemangioblastomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This frameshift mutation causes an early stop codon at amino acid 130 and was found in a VHL type 1 family of 16 patients. Six patients had retinal hemangioblastomas, 10 had cerebellar hemangioblastomas, and 2 had renal cell carcinoma. This study contains very strong evidence for pathogenicity in the form of a frameshift mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1)."	17024664	PubMed		"Ong et al., 2007, Hum. Mutat."		3	accepted	5138	Rare Germline	2023-01-09 21:46:50 UTC	https://civicdb.org/links/evidence_items/5138	https://civicdb.org/links/molecular_profiles/1671	FALSE	VHL	7428	P103FS (c.309_310delTG)		chr3	10142156	10142157	TG		ENST00000256474.2	75		frameshift_variant	"ENST00000256474.2:c.309_310delTG,NC_000003.11:g.10183840_10183841del,NM_000551.3:c.309_310del,NP_000542.1:p.Gly104HisfsTer27"	2023-01-27 17:12:09 UTC	CA658795178	NONE FOUND	"C.309_310DELTG,PRO103FS"	FALSE
VHL G114C (c.340G>T)	1673	Von Hippel-Lindau Disease	14175	Cerebellar hemangioblastoma			Predisposing	Supports	C	Uncertain Significance	"Genotype-phenotype correlations of 573 VHL patients from 200 kindreds were analyzed. Higher risk of pheochromocytoma was associated with missense mutations that result in substitution of a surface amino acid (p<=0.004) than for patients with missense mutations that disrupt the structural integrity of the VHL gene product (pVHL) or other  loss of function mutations (either germline deletions or truncating mutations). This missense mutation, affecting residue within the pVHL protein core, was found in a VHL patient with cerebellar hemangioblastomas. ACMG codes as follows: Supporting evidence of pathogenicity because Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease."	17024664	PubMed		"Ong et al., 2007, Hum. Mutat."		2	accepted	5139	Rare Germline	2023-01-09 21:46:50 UTC	https://civicdb.org/links/evidence_items/5139	https://civicdb.org/links/molecular_profiles/1673	FALSE	VHL	7428	G114C (c.340G>T)		chr3	10142187	10142187	G	T	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.340G>T,NC_000003.11:g.10183871G>T,NM_000551.3:c.340G>T,NP_000542.1:p.Gly114Cys"	2023-01-27 17:12:10 UTC	CA351751376	NONE FOUND	"C.340G>T,GLY114CYS"	FALSE
VHL H115P (c.344A>C)	1761	Von Hippel-Lindau Disease	14175	"Cerebellar hemangioblastoma,Retinal capillary hemangioma"			Predisposing	Supports	C	Uncertain Significance	"Genotype-phenotype correlations of 573 VHL patients from 200 kindreds were analyzed. Higher risk of pheochromocytoma was associated with missense mutations that result in substitution of a surface amino acid (p<=0.004) than for patients with missense mutations that disrupt the structural integrity of the VHL gene product (pVHL) or other  loss of function mutations (either germline deletions or truncating mutations). This missense mutation, affecting residue on the surface of pVHL, was found in a VHL type 1 patient with retinal hemangioblastomas and cerebellar hemangioblastomas. ACMG codes as follows: Supporting evidence of pathogenicity because missense variant in a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease (PP2)."	17024664	PubMed		"Ong et al., 2007, Hum. Mutat."		3	accepted	5140	Rare Germline	2023-01-09 21:46:52 UTC	https://civicdb.org/links/evidence_items/5140	https://civicdb.org/links/molecular_profiles/1761	FALSE	VHL	7428	H115P (c.344A>C)		chr3	10146517	10146517	A	C	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.344A>C,NC_000003.11:g.10188201A>C,NM_000551.3:c.344A>C,NP_000542.1:p.His115Pro"	2023-01-27 17:13:05 UTC	CA351753626	560744	"C.344A>C,HIS115PRO,RS5030812"	FALSE
VHL I151T (c.452T>C)	1747	Von Hippel-Lindau Disease	14175	Retinal capillary hemangioma			Predisposing	Supports	C	Uncertain Significance	"Genotype-phenotype correlations of 573 VHL patients from 200 kindreds were analyzed. Higher risk of pheochromocytoma was associated with missense mutations that result in substitution of a surface amino acid (p<=0.004) than for patients with missense mutations that disrupt the structural integrity of the VHL gene product (pVHL) or other loss of function mutations (either germline deletions or truncating mutations). A missense mutation, affecting residue within the pVHL protein core, was found in 2 VHL families with 4 patients. Two had retinal hemangioblastomas. ACMG codes as follows: Supporting evidence of pathogenicity because a missense variant in a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease (PP2). Relevant HPO terms: Retinal hemangioblastoma."	17024664	PubMed		"Ong et al., 2007, Hum. Mutat."		2	accepted	5141	Rare Germline	2023-01-09 21:46:51 UTC	https://civicdb.org/links/evidence_items/5141	https://civicdb.org/links/molecular_profiles/1747	FALSE	VHL	7428	I151T (c.452T>C)		chr3	10146625	10146625	T	C	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.452T>C,NP_000542.1:p.Ile151Thr,NC_000003.11:g.10188309T>C,ENST00000256474.2:c.452T>C"	2023-01-27 17:13:00 UTC	CA351754359	428803	"C.452T>C,ILE151THR,RS869025655"	FALSE
VHL L118P (c.353T>C)	1674	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	"Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). A missense mutation, affecting residue within the pVHL protein core, was found in 3 VHL families of 7 patients altogether. Six had retinal hemangioblastomas, one had renal cell carcinoma, 6 had cerebellar hemangioblastomas, and 4 pheochromocytoma. ACMG codes as follows: Supporting evidence of pathogenicity because Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a  common mechanism of disease (PP2). Relevant HPO terms: Renal cell carcinoma. retinal hemangioblastoma cerebellar hemangioblastoma, pheochromocytoma."	17024664	PubMed		"Ong et al., 2007, Hum. Mutat."		4	accepted	5143	Rare Germline	2023-01-09 21:46:50 UTC	https://civicdb.org/links/evidence_items/5143	https://civicdb.org/links/molecular_profiles/1674	FALSE	VHL	7428	L118P (c.353T>C)		chr3	10146526	10146526	T	C	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.353T>C,NM_000551.3:c.353T>C,NP_000542.1:p.Leu118Pro,NC_000003.11:g.10188210T>C"	2023-01-27 17:12:11 UTC	CA70049399	428807	"C.353T>C,LEU118PRO,RS5030830"	FALSE
VHL L128R (c.383T>G)	1762	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	"Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). A missense mutation, affecting residue within the pVHL protein core, was found in a VHL type 1 family with retinal hemangioblastomas and cerebellar hemangioblastomas. ACMG codes as follows: Supporting evidence of pathogenicity because Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a  common mechanism of disease (PP2). Relevant HPO terms: Cerebellar hemanioblastoma and retinal hemangioblastoma."	17024664	PubMed		"Ong et al., 2007, Hum. Mutat."		4	accepted	5144	Rare Germline	2023-01-09 21:46:52 UTC	https://civicdb.org/links/evidence_items/5144	https://civicdb.org/links/molecular_profiles/1762	FALSE	VHL	7428	L128R (c.383T>G)		chr3	10146556	10146556	T	G	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.383T>G,NC_000003.11:g.10188240T>G,NM_000551.3:c.383T>G,NP_000542.1:p.Leu128Arg"	2023-01-27 17:13:06 UTC	CA351753891	NONE FOUND	"C.383T>G,LEU128ARG"	FALSE
VHL L153fs (c.457delC)	1678	Von Hippel-Lindau Disease	14175	"Cerebellar hemangioblastoma,Retinal capillary hemangioma,Renal cell carcinoma"			Predisposing	Supports	C	Uncertain Significance	"Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). Age-related risks of retinal angiomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This frameshift mutation causes an early stop codon at amino acid 158 and was found in 2 VHL families with 5 patients altogether. Three had retinal angiomas, 5 had cerebellar hemangioblastomas, and 2 had renal cell carcinoma."	17024664	PubMed		"Ong et al., 2007, Hum. Mutat."		4	accepted	5145	Rare Germline	2023-01-09 21:46:50 UTC	https://civicdb.org/links/evidence_items/5145	https://civicdb.org/links/molecular_profiles/1678	FALSE	VHL	7428	L153fs (c.457delC)		chr3	10146633	10146633	C		ENST00000256474.2	75		deletion	NM_000551.3:c.457delC	2023-01-27 17:12:14 UTC	CA432421924	NONE FOUND	"C.457DELC,LEU153FS"	FALSE
VHL L158V (c.472C>G)	1679	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	"Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). This mutation was found in a VHL type 1 patient with retinal hemangioblastomas and cerebellar hemangioblastomas. ACMG codes as follows: Supporting evidence of pathogenicity because Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease (PP2).Relevant HPO terms: Cerebellar hemangioblastoma, Retinal hemangioblastoma."	17024664	PubMed		"Ong et al., 2007, Hum. Mutat."		4	accepted	5146	Rare Germline	2023-01-09 21:46:50 UTC	https://civicdb.org/links/evidence_items/5146	https://civicdb.org/links/molecular_profiles/1679	FALSE	VHL	7428	L158V (c.472C>G)		chr3	10149795	10149795	C	G	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.472C>G,NC_000003.11:g.10191479C>G,NM_000551.3:c.472C>G,NP_000542.1:p.Leu158Val"	2023-01-27 17:12:15 UTC	CA351756068	NONE FOUND	"C.472C>G,LEU158VAL"	FALSE
VHL L169P (c.506T>C)	1763	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	"Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). A missense mutation, affecting residue on the surface of pVHL, was found in a VHL type 1 family with retinal hemangioblastomas and renal cell carcinoma. ACMG codes as follows: Supporting evidence of pathogenicity because Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a  common mechanism of disease (PP2).  Relevant HPO terms: Cerebellar hemangioblastoma, Retinal hemangioblastoma"	17024664	PubMed		"Ong et al., 2007, Hum. Mutat."		4	accepted	5147	Rare Germline	2023-01-09 21:46:52 UTC	https://civicdb.org/links/evidence_items/5147	https://civicdb.org/links/molecular_profiles/1763	FALSE	VHL	7428	L169P (c.506T>C)		chr3	10149829	10149829	T	C	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.506T>C,NP_000542.1:p.Leu169Pro,NC_000003.11:g.10191513T>C,ENST00000256474.2:c.506T>C"	2023-01-27 17:13:07 UTC	CA351756191	428809	"C.506T>C,LEU169PRO,RS1131690962"	FALSE
VHL L178R (c.533T>G)	1764	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	"Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). A missense mutation, affecting residue on the surface of pVHL protein core, was found in a VHL type 1 patient with retinal hemanioblastomas and cerebellar hemangioblastomas. ACMG codes as follows: Supporting evidence of pathogenicity because Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a  common mechanism of disease (PP2). Relevant HPO terms: Cerebellar hemangioblastoma."	17024664	PubMed		"Ong et al., 2007, Hum. Mutat."		4	accepted	5148	Rare Germline	2023-01-09 21:46:52 UTC	https://civicdb.org/links/evidence_items/5148	https://civicdb.org/links/molecular_profiles/1764	FALSE	VHL	7428	L178R (c.533T>G)		chr3	10149856	10149856	T	G	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.533T>G,NC_000003.11:g.10191540T>G,NM_000551.3:c.533T>G,NP_000542.1:p.Leu178Arg"	2023-01-27 17:13:08 UTC	CA351756248	625261	"C.533T>G,LEU178ARG"	FALSE
VHL L178P (c.533T>C)	1624	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	"Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). A missense mutation, affecting residue on the surface of pVHL, was found in a VHL type 1 family of 3. All family members had retinal hemangioblastomas and cerebellar hemangioblastomas. Two had renal cell carcinoma. ACMG codes as follows: Supporting evidence of pathogenicity because Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a  common mechanism of disease (PP2).  Relevant HPO terms: Cerebellar hemangioblastoma, Retinal hemangioblastoma, Renal cell carcinoma."	17024664	PubMed		"Ong et al., 2007, Hum. Mutat."		4	accepted	5149	Rare Germline	2023-01-09 21:46:48 UTC	https://civicdb.org/links/evidence_items/5149	https://civicdb.org/links/molecular_profiles/1624	FALSE	VHL	7428	L178P (c.533T>C)		chr3	10149856	10149856	T	C	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.533T>C,NM_000551.3:c.533T>C,NP_000542.1:p.Leu178Pro,NC_000003.11:g.10191540T>C"	2023-01-27 17:11:36 UTC	CA351756245	428795	"C.533T>C,LEU178PRO,RS5030822"	FALSE
VHL L89P (c.266T>C)	1669	Von Hippel-Lindau Disease	14175	"Retinal capillary hemangioma,Renal cell carcinoma,Cerebellar hemangioblastoma"			Predisposing	Supports	C	Uncertain Significance	"Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). A missense mutation, affecting residue within the pVHL protein core, was found in a VHL type 1 patient with retinal hemangioblastomas, cerebellar hemangioblastomas, and renal cell carcinoma. ACMG codes as follows: Supporting evidence of pathogenicity because Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease (PP2)."	17024664	PubMed		"Ong et al., 2007, Hum. Mutat."		2	accepted	5150	Rare Germline	2023-01-09 21:46:49 UTC	https://civicdb.org/links/evidence_items/5150	https://civicdb.org/links/molecular_profiles/1669	FALSE	VHL	7428	L89P (c.266T>C)		chr3	10142113	10142113	T	C	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.266T>C,NP_000542.1:p.Leu89Pro,NC_000003.11:g.10183797T>C,ENST00000256474.2:c.266T>C"	2023-01-27 17:12:07 UTC	CA020207	182979	"C.266T>C,LEU89PRO,RS5030807"	FALSE
VHL M54fs (c.161dup)	1765	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). This mutation was found in 2 VHL type 1 family members with cerebellar hemangioblastomas. ACMG codes as follows: Protein length changes as a result of insertion in a nonrepeat region and stop-loss variant (PM4). Cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (PP1). Relevant HPO terms: Cerebellar hemangioblastoma.	17024664	PubMed		"Ong et al., 2007, Hum. Mutat."		4	accepted	5151	Rare Germline	2023-01-09 21:46:52 UTC	https://civicdb.org/links/evidence_items/5151	https://civicdb.org/links/molecular_profiles/1765	FALSE	VHL	7428	M54fs (c.161dup)		chr3	10142007	10142008	T		ENST00000256474.2	75		"plus_1_frameshift_variant,frameshift_truncation"	"NC_000003.11:g.10183692dup,NM_000551.3:c.161dup,NP_000542.1:p.Met54IlefsTer?,NC_000003.12:g.10142008dup"	2023-01-09 21:52:16 UTC	unregistered	NONE FOUND	"M54IFS*78 (C.161DUP),M54FS (C.161INST),M54FS (C.161DUPT)"	FALSE
VHL F136S (c.407T>C)	1677	Von Hippel-Lindau Disease	14175	"Cerebellar hemangioblastoma,Retinal capillary hemangioma,Renal cell carcinoma"			Predisposing	Supports	C	Uncertain Significance	"Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). A missense mutation, affecting residue within the pVHL protein core, was found in 2 VHL families of 5 patients altogether. Three had retinal hemangioblastomas, 4 had cerebellar hemangioblastomas, 3 had renal cell carcinoma. ACMG codes as follows:  supporting evidence for pathogenicity because of cosegregation of disease with multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1). Supporting evidence of pathogenicity because Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a  common mechanism of disease (PP2)."	17024664	PubMed		"Ong et al., 2007, Hum. Mutat."		4	accepted	5152	Rare Germline	2023-01-09 21:46:50 UTC	https://civicdb.org/links/evidence_items/5152	https://civicdb.org/links/molecular_profiles/1677	FALSE	VHL	7428	F136S (c.407T>C)		chr3	10146580	10146580	T	C	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.407T>C,NC_000003.11:g.10188264T>C,NM_000551.3:c.407T>C,NP_000542.1:p.Phe136Ser"	2023-01-27 17:12:13 UTC	CA040847	496064	"C.407T>C,PHE136SER,RS5030833"	FALSE
VHL P154L (c.461C>T)	1658	Von Hippel-Lindau Disease	14175	"Renal cell carcinoma,Pheochromocytoma,Retinal capillary hemangioma,Cerebellar hemangioblastoma"			Predisposing	Supports	C	Uncertain Significance	"Genotype-phenotype correlations of 573 VHL patients from 200 kindreds were analyzed. Higher risk of pheochromocytoma was associated with missense mutations that result in substitution of a surface amino acid (p<=0.004) than for patients with missense mutations that disrupt the structural integrity of the VHL gene product (pVHL) or other loss of function mutations (either germline deletions or truncating mutations). This missense mutation is within the protein core and was found in a VHL family with 6 patients. One patient had retinal hemangioblastomas, 2 had cerebellar hemangioblastomas, 3 had renal cell carcinoma, 2 had pheochromocytoma. Only supporting evidence of pathogenicity because of cosegregation of disease with multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1)."	17024664	PubMed		"Ong et al., 2007, Hum. Mutat."		2	accepted	5154	Rare Germline	2023-01-09 21:46:49 UTC	https://civicdb.org/links/evidence_items/5154	https://civicdb.org/links/molecular_profiles/1658	FALSE	VHL	7428	P154L (c.461C>T)		chr3	10146634	10146634	C	T	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.461C>T,NC_000003.11:g.10188318C>T,NM_000551.3:c.461C>T,NP_000542.1:p.Pro154Leu"	2023-01-27 17:11:58 UTC	CA351754410	NONE FOUND	"C.461C>T,PRO154LEU"	FALSE
VHL P59fs (c.176delC)	1805	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	"Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). Age-related risks of retinal hemangioblastomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This frameshift mutation, affecting residue within the pVHL protein core, was found in a VHL type 1 family of 5 patients. Three had retinal hemangioblastomas, 4 had cerebellar hemangioblastomas, and 2 had renal cell carcinoma. This mutation also causes an early stop codon at amino acid 66. ACMG codes as follows: Protein length changes as a result of in-frame deletions in a nonrepeat region and stop-loss variant (PM4). Cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (PP1).  Relevant HPO terms: Cerebellar hemangioblastoma, Retinal hemangioblastoma, Renal cell carcinoma."	17024664	PubMed		"Ong et al., 2007, Hum. Mutat."		4	accepted	5155	Rare Germline	2023-01-09 21:46:52 UTC	https://civicdb.org/links/evidence_items/5155	https://civicdb.org/links/molecular_profiles/1805	FALSE	VHL	7428	P59fs (c.176delC)		chr3	10142023	10142023	C		ENST00000256474.2	75		"minus_1_frameshift_variant,frameshift_truncation"	"ENST00000256474.2:c.176delC,NC_000003.11:g.10183707del,NM_000551.3:c.176del,NP_000542.1:p.Pro59ArgfsTer8"	2023-01-27 17:13:34 UTC	CA432536374	NONE FOUND	"PRO59FS,C.176DELC,P59RFS*8 (C.176DELC)"	FALSE
VHL P86R (c.257C>G)	1725	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	"Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). A missense mutation, affecting residue within the pVHL protein core, was found in a VHL type 1 family with retinal hemangiolastomas and renal cell carcinoma. Only supporting evidence of pathogenicity because of cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1).  Relevant HPO terms: retinal hemangioblastoma and renal cell carcinoma."	17024664	PubMed		"Ong et al., 2007, Hum. Mutat."		4	accepted	5156	Rare Germline	2023-01-09 21:46:51 UTC	https://civicdb.org/links/evidence_items/5156	https://civicdb.org/links/molecular_profiles/1725	FALSE	VHL	7428	P86R (c.257C>G)		chr3	10142104	10142104	C	G	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.257C>G,NP_000542.1:p.Pro86Arg,NC_000003.11:g.10183788C>G,ENST00000256474.2:c.257C>G"	2023-01-27 17:12:46 UTC	CA357142	223170	"C.257C>G,PRO86ARG,RS730882034"	FALSE
VHL P86L (c.257C>T)	1636	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	"Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). A missense mutation, affecting residue within the pVHL protein core, was found in a VHL patient with retinal hemangioblastomas and cerebellar hemangioblastomas. ACMG codes as follows:  Supporting evidence of pathogenicity because Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a  common mechanism of disease (PP2).  Relevant HPO terms: Cerebellar hemangioblastoma, Retinal hemangioblastoma."	17024664	PubMed		"Ong et al., 2007, Hum. Mutat."		4	accepted	5157	Rare Germline	2023-01-09 21:46:49 UTC	https://civicdb.org/links/evidence_items/5157	https://civicdb.org/links/molecular_profiles/1636	FALSE	VHL	7428	P86L (c.257C>T)		chr3	10142104	10142104	C	T	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.257C>T,NP_000542.1:p.Pro86Leu,NC_000003.11:g.10183788C>T,ENST00000256474.2:c.257C>T"	2023-01-27 17:11:44 UTC	CA020186	182977	"C.257C>T,PRO86LEU,RS730882034"	FALSE
VHL P86S (c.256C>T)	1778	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	"Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). A missense mutation, affecting residue within the pVHL protein core, was found in a VHL patient with cerebellar hemangioblastomas. ACMG codes as follows:  Supporting evidence of pathogenicity because Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a  common mechanism of disease (PP2).  Relevant HPO terms: Cerebellar hemangioblastoma."	17024664	PubMed		"Ong et al., 2007, Hum. Mutat."		4	accepted	5158	Rare Germline	2023-01-09 21:46:52 UTC	https://civicdb.org/links/evidence_items/5158	https://civicdb.org/links/molecular_profiles/1778	FALSE	VHL	7428	P86S (c.256C>T)		chr3	10142103	10142103	C	T	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.256C>T,NP_000542.1:p.Pro86Ser,NC_000003.11:g.10183787C>T,ENST00000256474.2:c.256C>T"	2023-01-27 17:13:14 UTC	CA020180	178692	"C.256C>T,PRO86SER,RS398123481"	FALSE
VHL S65L (c.194C>T)	1664	Von Hippel-Lindau Disease	14175	"Cerebellar hemangioblastoma,Retinal capillary hemangioma,Renal cell carcinoma"			Predisposing	N/A	C	N/A	"Genotype-phenotype correlations of 573 VHL patients from 200 kindreds were analyzed. This missense mutation was found in 4 VHL families of 11 patients altogether. Ten had retinal hemangioblastomas, 4 had cerebellar hemangioblastomas, and 2 had renal cell carcinoma. ACMG codes as follows: supporting evidence for pathogenicity because of cosegregation of disease with multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1). Two other amino acid changes at this site were also reported in this publication in association with disease (S65W and S65P). Relevant HPO terms: Cerebellar hemangioblastoma, Retinal hemangioblastoma, Renal cell carcinoma."	17024664	PubMed		"Ong et al., 2007, Hum. Mutat."		2	accepted	5159	Rare Germline	2023-01-09 21:46:49 UTC	https://civicdb.org/links/evidence_items/5159	https://civicdb.org/links/molecular_profiles/1664	FALSE	VHL	7428	S65L (c.194C>T)		chr3	10142041	10142041	C	T	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.194C>T,NP_000542.1:p.Ser65Leu,NC_000003.11:g.10183725C>T,ENST00000256474.2:c.194C>T"	2023-01-27 17:12:03 UTC	CA020104	182975	"C.194C>T,SER65LEU,RS5030826"	FALSE
VHL S65P (c.193T>C)	1779	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	"Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). This missense mutation was found in a VHL patient with retinal hemangioblastomas and cerebellar hemangioblastomas. ACMG codes as follows:  Supporting evidence of pathogenicity because Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a  common mechanism of disease (PP2).  Relevant HPO terms: Cerebellar hemangioblastoma, Retinal hemangioblastoma."	17024664	PubMed		"Ong et al., 2007, Hum. Mutat."		4	accepted	5160	Rare Germline	2023-01-09 21:46:52 UTC	https://civicdb.org/links/evidence_items/5160	https://civicdb.org/links/molecular_profiles/1779	FALSE	VHL	7428	S65P (c.193T>C)		chr3	10142040	10142040	T	C	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.193T>C,NC_000003.11:g.10183724T>C,NM_000551.3:c.193T>C,NP_000542.1:p.Ser65Pro"	2023-01-27 17:13:14 UTC	CA351748798	547829	"C.193T>C,SER65PRO,RS869025616"	FALSE
VHL S65W (c.194C>G)	1663	Von Hippel-Lindau Disease	14175	"Cerebellar hemangioblastoma,Retinal capillary hemangioma,Renal cell carcinoma"			Predisposing	Supports	C	Uncertain Significance	"Genotype-phenotype correlations of 573 VHL patients from 200 kindreds were analyzed. Higher risk of pheochromocytoma was associated with missense mutations that result in substitution of a surface amino acid (p<=0.004) than for patients with missense mutations that disrupt the structural integrity of the VHL gene product (pVHL) or other  loss of function mutations (either germline deletions or truncating mutations). A missense mutation, affecting residue within the pVHL protein core, was found in a VHL family with 8 affected individuals including 6 with retinal hemangioblastomas, 5 with cerebellar hemangioblastomas, and 1 with renal cell carcinoma. ACMG codes as follows:  supporting evidence for pathogenicity because of cosegregation of disease with multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1)."	17024664	PubMed		"Ong et al., 2007, Hum. Mutat."		3	accepted	5161	Rare Germline	2023-01-09 21:46:49 UTC	https://civicdb.org/links/evidence_items/5161	https://civicdb.org/links/molecular_profiles/1663	FALSE	VHL	7428	S65W (c.194C>G)		chr3	10142041	10142041	C	G	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.194C>G,NM_000551.3:c.194C>G,NP_000542.1:p.Ser65Trp,NC_000003.11:g.10183725C>G"	2023-01-27 17:12:02 UTC	CA020099	43597	"C.194C>G,SER65TRP,RS5030826"	FALSE
VHL S72P (c.214T>C)	1780	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	"Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). A missense mutation, affecting residue on the surface of pVHL, was found in two VHL families of 4 patients altogether. One patient had retinal hemagioblastomas and two had cerebellar hemangioblastomas. ACMG codes as follows:  Supporting evidence of pathogenicity because Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a  common mechanism of disease (PP2).  Relevant HPO terms: Cerebellar hemangioblastoma, Retinal hemangioblastoma."	17024664	PubMed		"Ong et al., 2007, Hum. Mutat."		4	accepted	5162	Rare Germline	2023-01-09 21:46:52 UTC	https://civicdb.org/links/evidence_items/5162	https://civicdb.org/links/molecular_profiles/1780	FALSE	VHL	7428	S72P (c.214T>C)		chr3	10142061	10142061	T	C	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.214T>C,NP_000542.1:p.Ser72Pro,NC_000003.11:g.10183745T>C,ENST00000256474.2:c.214T>C"	2023-01-27 17:13:15 UTC	CA357006	223163	"C.214T>C,SER72PRO,RS869025618"	FALSE
VHL S72fs (c.214del)	1692	Von Hippel-Lindau Disease	14175	"Retinal capillary hemangioma,Cerebellar hemangioblastoma,Renal cell carcinoma"			Predisposing	N/A	C	N/A	"Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). Age-related risks of retinal hemangioblastoma and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This mutation causes a frameshift, an early stop codon at amino acid 158, and was found in a VHL family with 3 affected members: 2 had retinal hemangioblastoma, 2 had cerebellar hemangioblastomas, and 1 had renal cell carcinoma. There is very strong evidence for pathogenicity in the form of a frameshift variant in a gene where loss-of-function is known mechanism of disease (ACMG code: PSV1)."	17024664	PubMed		"Ong et al., 2007, Hum. Mutat."		4	accepted	5163	Rare Germline	2023-01-09 21:46:50 UTC	https://civicdb.org/links/evidence_items/5163	https://civicdb.org/links/molecular_profiles/1692	FALSE	VHL	7428	S72fs (c.214del)		chr3	10142061	10142061	T		ENST00000256474.2	75		"minus_1_frameshift_variant,frameshift_truncation"	"ENST00000256474.2:c.214delT,NC_000003.12:g.10142061del,NM_000551.4:c.214del,NP_000542.1:p.Ser72ProfsTer?,NC_000003.11:g.10183745del"	2023-01-27 17:12:25 UTC	CA658795180	NONE FOUND	"C.214DELT,SER72FS,S72FS (C.214DELT)"	FALSE
VHL L135fs (c.404del)	1782	Von Hippel-Lindau Disease	14175	"Retinal capillary hemangioma,Cerebellar hemangioblastoma"			Predisposing	Supports	C	Predisposition	"Genotype-phenotype correlations of 573 VHL patients from 200 kindreds were analyzed. Age-related risks of retinal angiomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. VHL L135FS (c.404del) results in a frameshift, an early stop codon at amino acid 158, and was found in a VHL family of 2, both with retinal hemangioblastomas and 1 with cerebellar hemangioblastomas. There is very strong evidence for pathogenicity in the form of a frameshift variant in a gene where loss-of-function is known mechanism of disease (ACMG code: PVS1)."	17024664	PubMed		"Ong et al., 2007, Hum. Mutat."		3	accepted	5165	Rare Germline	2023-01-10 21:29:28 UTC	https://civicdb.org/links/evidence_items/5165	https://civicdb.org/links/molecular_profiles/1782	FALSE	VHL	7428	L135fs (c.404del)		chr3	10146576	10146576	T		ENST00000256474.2	75		"minus_1_frameshift_variant,frameshift_truncation"	"NC_000003.11:g.10188261del,NP_000542.1:p.Leu135TyrfsTer24,ENST00000256474.2:c.404del,NM_000551.3:c.404del,NC_000003.12:g.10146577del"	2023-01-27 17:13:17 UTC	CA432421852	NONE FOUND	"C.404DELT,LEU135FS,L135Y*24"	FALSE
VHL R176fs (c.526del)	1656	Von Hippel-Lindau Disease	14175	"Cerebellar hemangioblastoma,Renal cell carcinoma,Retinal capillary hemangioma"			Predisposing	Supports	C	Predisposition	"Genotype-phenotype correlations of 573 VHL patients from 200 kindreds were analyzed. Age-related risks of retinal hemangioblastomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. VHL R176fs (c.526del) causes a frameshift, an early stop codon at amino acid 201, and was found in two VHL families of 3 patients. One patient had retinal hemangioblastomas, three had cerebellar hemangioblastomas, and one had renal cell carcinoma. There is very strong evidence for pathogenicity in the form of a frameshift variant in a gene where loss-of-function is known mechanism of disease (ACMG code: PVS1)."	17024664	PubMed		"Ong et al., 2007, Hum. Mutat."		4	accepted	5166	Rare Germline	2023-01-10 21:30:52 UTC	https://civicdb.org/links/evidence_items/5166	https://civicdb.org/links/molecular_profiles/1656	FALSE	VHL	7428	R176fs (c.526del)		chr3	10149849	10149849	A		ENST00000256474.2	75		frameshift_truncation	"ENST00000256474.2:c.526delA,NC_000003.11:g.10191533del,NM_000551.3:c.526del,NP_000542.1:p.Arg176GlyfsTer26"	2023-01-27 17:11:57 UTC	CA16602180	625257	"C.526DELA,ARG176FS,RS1559429711,R176GFS*26 (C.526DEL)"	FALSE
VHL R177fs (c.528del)	1783	Von Hippel-Lindau Disease	14175	"Cerebellar hemangioblastoma,Renal cell carcinoma"			Predisposing	Supports	C	Predisposition	"Genotype-phenotype correlations of 573 VHL patients from 200 kindreds were analyzed. Age-related risks of retinal hemangioblastomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. VHL R177fs (c.528del) causes a frameshift, a stop codon at amino acid 201, and was found in a VHL family of 7, 3 with cerebellar hemangioblastomas and 3 with renal cell carcinoma. There is very strong evidence for pathogenicity in the form of a frameshift variant in a gene where loss-of-function is known mechanism of disease (ACMG code: PVS1)."	17024664	PubMed		"Ong et al., 2007, Hum. Mutat."		3	accepted	5167	Rare Germline	2023-01-10 21:32:10 UTC	https://civicdb.org/links/evidence_items/5167	https://civicdb.org/links/molecular_profiles/1783	FALSE	VHL	7428	R177fs (c.528del)		chr3	10149851	10149851	G		ENST00000256474.2	75		"minus_1_frameshift_variant,frameshift_truncation"	"ENST00000256474.2:c.528delG,NC_000003.11:g.10191535del,NM_000551.3:c.528del,NP_000542.1:p.Arg177AspfsTer25"	2023-01-27 17:13:18 UTC	CA432423454	NONE FOUND	"ARG176FS,C.528DELG,R177DFS*25 (C.528DELG),R176FS (C.528DELG),R176FS (C.528DEL)"	FALSE
VHL W88R (c.262T>A)	1637	Von Hippel-Lindau Disease	14175	"Renal cell carcinoma,Retinal capillary hemangioma,Cerebellar hemangioblastoma"			Predisposing	Supports	C	Predisposition	"Genotype-phenotype correlations of 573 VHL patients from 200 kindreds were analyzed. This missense mutation, affecting residue on the surface of pVHL, was found in a VHL type 1 patient with retinal hemangioblastoms, cerebellar hemangioblastomas, and renal cell carcinoma. ACMG codes as follows: Supporting evidence of pathogenicity because of a missense variant in a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease (PP2). Relevant HPO terms: Cerebellar hemangioblastoma, Retinal hemangioblastoma, Renal cell carcinoma."	17024664	PubMed		"Ong et al., 2007, Hum. Mutat."		2	accepted	5168	Rare Germline	2023-01-10 21:35:06 UTC	https://civicdb.org/links/evidence_items/5168	https://civicdb.org/links/molecular_profiles/1637	FALSE	VHL	7428	W88R (c.262T>A)		chr3	10142109	10142109	T	A	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.262T>A,NP_000542.1:p.Trp88Arg,NC_000003.11:g.10183793T>A,NM_000551.3:c.262T>A"	2023-01-27 17:11:45 UTC	CA351750671	456577	"C.262T>A,TRP88ARG,RS1553619431"	FALSE
VHL W88* (c.264G>A)	1784	Von Hippel-Lindau Disease	14175	"Cerebellar hemangioblastoma,Renal cell carcinoma,Retinal capillary hemangioma,Pheochromocytoma"			Predisposing	Supports	C	Predisposition	"Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). Age-related risks of retinal hemangoblastomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This nonsense mutation was found in a VHL family with 3 affected members, 1 had retinal hemangioblastomas, 1 had cerebellar hemangioblastomas, 2 had renal cell carcinoma, and 1 had pheochromocytoma. There is very strong evidence for pathogenicity in the form of a nonsense variant in a gene where loss-of-function is known mechanism of disease (ACMG code: PSV1)."	17024664	PubMed		"Ong et al., 2007, Hum. Mutat."		3	accepted	5169	Rare Germline	2023-01-10 21:36:04 UTC	https://civicdb.org/links/evidence_items/5169	https://civicdb.org/links/molecular_profiles/1784	FALSE	VHL	7428	W88* (c.264G>A)		chr3	10142111	10142111	G	A	ENST00000256474.2	75		stop_gained	"ENST00000256474.2:c.264G>A,NP_000542.1:p.Trp88Ter,NC_000003.11:g.10183795G>A,NM_000551.3:c.264G>A"	2023-01-27 17:13:18 UTC	CA351750677	936684	"C.264G>A,W88X,TRP88TER"	FALSE
VHL Y185* (c.555C>G)	1685	Von Hippel-Lindau Disease	14175	"Renal cell carcinoma,Cerebellar hemangioblastoma,Retinal capillary hemangioma"			Predisposing	Supports	C	Predisposition	Genotype-phenotype correlations of 573 VHL patients from 200 kindreds were analyzed. Age-related risks of retinal hemangiobastomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This mutation was found in 3 VHL families with 4 patients altogether. All four had retinal hemangioblastomas and cerebellar hemangioblastomas. Two had renal cell carcinoma. There is very strong evidence for pathogenicity in the form of a nonsense variant in a gene where loss-of-function is known mechanism of disease (ACMG code: PVS1).	17024664	PubMed		"Ong et al., 2007, Hum. Mutat."		3	accepted	5170	Rare Germline	2023-01-10 21:36:32 UTC	https://civicdb.org/links/evidence_items/5170	https://civicdb.org/links/molecular_profiles/1685	FALSE	VHL	7428	Y185* (c.555C>G)		chr3	10149878	10149878	C	G	ENST00000256474.2	75		stop_gained	"NM_000551.3:c.555C>G,NP_000542.1:p.Tyr185Ter,NC_000003.11:g.10191562C>G,ENST00000256474.2:c.555C>G"	2023-01-27 17:12:20 UTC	CA357075	223233	"C.555C>G,Y185X,TYR185TER,RS864622109"	FALSE
VHL V155E (c.464T>A)	1785	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Predisposition	"Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). This missense mutation was found in a VHL type 2B family with retinal hemangioblastomas, cerebellar hemangioblastomas, and pheochromocytoma. ACMG codes as follows:   Supporting evidence of pathogenicity because Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a  common mechanism of disease (PP2).  Relevant HPO terms: Cerebellar hemangioblastoma, Retinal hemangioblastoma, Pheochromocytoma."	17024664	PubMed		"Ong et al., 2007, Hum. Mutat."		4	accepted	5171	Rare Germline	2023-01-10 21:36:59 UTC	https://civicdb.org/links/evidence_items/5171	https://civicdb.org/links/molecular_profiles/1785	FALSE	VHL	7428	V155E (c.464T>A)		chr3	10149787	10149787	T	A	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.464T>A,NC_000003.11:g.10191471T>A,NM_000551.3:c.464T>A,NP_000542.1:p.Val155Glu"	2023-01-27 17:13:19 UTC	CA351756032	NONE FOUND	"C.464T>A,VAL155GLU"	FALSE
VHL V170G (c.509T>G)	1811	Von Hippel-Lindau Disease	14175	"Pheochromocytoma,Renal cell carcinoma,Retinal capillary hemangioma"			Predisposing	Supports	C	Predisposition	"Genotype-phenotype correlations of 573 VHL patients from 200 kindreds were analyzed. Higher risk of pheochromocytoma was associated with missense mutations that result in substitution of a surface amino acid (p<=0.004) than for patients with missense mutations that disrupt the structural integrity of the VHL gene product (pVHL) or other loss of function mutations (either germline deletions or truncating mutations). A missense mutation, affecting residue on the surface of pVHL, was found in a VHL family of 4, 3 with retinal hemangioblastomas, 1 with renal cell carcinoma, and 1 with pheochromocytoma. ACMG codes as follows:  supporting evidence for pathogenicity because of cosegregation of disease with multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1). Supporting evidence of pathogenicity because missense variant in a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease (PP2)."	17024664	PubMed		"Ong et al., 2007, Hum. Mutat."		2	accepted	5172	Rare Germline	2023-01-10 21:37:21 UTC	https://civicdb.org/links/evidence_items/5172	https://civicdb.org/links/molecular_profiles/1811	FALSE	VHL	7428	V170G (c.509T>G)		chr3	10149832	10149832	T	G	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.509T>G,NC_000003.11:g.10191516T>G,NM_000551.3:c.509T>G,NP_000542.1:p.Val170Gly"	2023-01-27 17:13:39 UTC	CA351756196	NONE FOUND	"C.509T>G,VAL170GLY"	FALSE
VHL F76fs (c.223_224insT)	1788	Von Hippel-Lindau Disease	14175	"Hemangioblastoma,Retinal capillary hemangioma"			Predisposing	Supports	C	Predisposition	"Germline VHL mutations were found in all Korean patients who fulfilled clinical criteria for VHL disease. No mutation of VHL was detected in other patients who did not meet clinical criteria. In all cases, samples from both parents were not available and evidence of de novo mutations could not further be evaluated. This variant is predicted to cause a frameshift and premature stop codon. This variant was found in a 24 year old Korean female with hemangioblastomas of the central nervous system and retinal hemangioblastomas (patient no. 4). There is very strong evidence of pathogenicity in the form of a frameshift variant in a gene where loss-of-function is known mechanism of disease (ACMG code: PSV1)."	19270817	PubMed		"Cho et al., 2009, J. Korean Med. Sci."		3	accepted	5174	Rare Germline	2023-01-10 21:38:27 UTC	https://civicdb.org/links/evidence_items/5174	https://civicdb.org/links/molecular_profiles/1788	FALSE	VHL	7428	F76fs (c.223_224insT)		chr3	10142070	10142071		T	ENST00000256474.2	75		frameshift_truncation	"NC_000003.11:g.10183755dupT,NM_000551.3:c.224dupT,NP_000542.1:p.F76Lfs*56,NC_000003.12:g.10142071dupT,NP_937799.1:p.Phe76LeufsTer?,NP_001341652.1:p.Phe76LeufsTer?"	2023-01-27 17:13:21 UTC	CA913189239		"ILE75FS,C.224DUPT,C.223_224INST"	FALSE
VHL C162R (c.484T>C)	1648	Von Hippel-Lindau Disease	14175	"Renal cell carcinoma,Hemangioblastoma,Retinal capillary hemangioma"			Predisposing	Supports	C	Predisposition	"Germline VHL mutations were found in all Korean patients who fulfilled clinical criteria for VHL disease. No mutation of VHL was detected in other patients who did not meet clinical criteria. In all cases, samples from both parents were not available and evidence of de novo mutations could not further be evaluated. This missense mutation (p.C162R) was found in a 30 year old Korean female with hemangioblastomas of the central nervous system, retinal hemangioblastomas, and renal cell carcinoma (patient no. 7). This patient's phenotype is highly specific for a disease with a single etiology (ACMG code: PP4). Relevant HPO terms: hemangioblastoma, Retinal hemangioblastoma, Renal cell carcinoma."	19270817	PubMed		"Cho et al., 2009, J. Korean Med. Sci."		2	accepted	5175	Rare Germline	2023-01-10 21:39:03 UTC	https://civicdb.org/links/evidence_items/5175	https://civicdb.org/links/molecular_profiles/1648	FALSE	VHL	7428	C162R (c.484T>C)		chr3	10149807	10149807	T	C	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.484T>C,NM_000551.3:c.484T>C,NC_000003.11:g.10191491T>C,NP_000542.1:p.Cys162Arg"	2023-01-27 17:11:51 UTC	CA351756117	496067	"RS1553620313,C.484T>C,CYS162ARG"	FALSE
VHL K196* (c.586A>T)	1789	Von Hippel-Lindau Disease	14175	Hemangioblastoma			Predisposing	Supports	C	Predisposition	"Germline VHL mutations were found in all Korean patients who fulfilled clinical criteria for VHL disease. No mutation of VHL was detected in other patients who did not meet clinical criteria. In all cases, samples from both parents were not available and evidence of de novo mutations could not further be evaluated. This nonsense mutation was found in a 22 year old Korean female with hemangioblastomas of the central nervous system (patient no. 3). There is very strong evidence of pathogenicity in the form of a nonsense variant in a gene where loss-of-function is known mechanism of disease (ACMG code: PVS1)."	19270817	PubMed		"Cho et al., 2009, J. Korean Med. Sci."		2	accepted	5176	Rare Germline	2023-01-14 07:34:43 UTC	https://civicdb.org/links/evidence_items/5176	https://civicdb.org/links/molecular_profiles/1789	FALSE	VHL	7428	K196* (c.586A>T)		chr3	10149909	10149909	A	T	ENST00000256474.2	75		stop_gained	"NM_000551.3:c.586A>T,NP_000542.1:p.Lys196Ter,NC_000003.11:g.10191593A>T,ENST00000256474.2:c.586A>T"	2023-01-27 17:13:22 UTC	CA020507	196284	"C.586A>T,K196X,LYS196TER,RS281860296"	FALSE
VHL R113* (c.337C>T)	1672	Von Hippel-Lindau Disease	14175	Hemangioblastoma			Predisposing	Supports	C	Predisposition	"In a study of 426 unrelated VHL patients, 111 were discovered to have alterations in the VHL gene. 18 novel variants were identified in VHL patients, but none were present in 200 unaffected control individuals. This nonsense mutation was found in a 23 year old VHL patient with no family history and hemangioblastomas of the central nervous system (index case 77). There is very strong evidence for pathogenicity in the form of a nonsense variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1)."	21463266	PubMed		"Leonardi et al., 2011, Ann. Hum. Genet."		3	accepted	5177	Rare Germline	2023-01-14 07:33:49 UTC	https://civicdb.org/links/evidence_items/5177	https://civicdb.org/links/molecular_profiles/1672	FALSE	VHL	7428	R113* (c.337C>T)		chr3	10142184	10142184	C	T	ENST00000256474.2	75		stop_gained	"NM_000551.3:c.337C>T,NP_000542.1:p.Arg113Ter,NC_000003.11:g.10183868C>T,ENST00000256474.2:c.337C>T"	2023-01-27 17:12:09 UTC	CA348491	220414	"C.337C>T,R113X,ARG113TER,RS5030810"	FALSE
VHL R120G (c.358A>G)	1790	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Predisposition	"In a study of 426 unrelated VHL patients, 111 were discovered to have alterations in the VHL gene. 18 novel variants were identified in VHL patients, but none were present in 200 unaffected control individuals. This missense mutation was found in a 24 year old VHL patient with hemangioblastomas of the central nervous system, retinal hemangioblastomas, pancreatic cysts, clear cell renal cell carcinoma, and multiple renal cysts (index case 100). ACMG codes as follows: Supporting evidence of pathogenicity because Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a  common mechanism of disease (PP2).  Patients phenotype or family history is highly specific for a disease with a single genetic etiology (PP4)Relevant HPO terms: Renal cell carcinoma, hemangioblastoma, retinal hemangioblastoma, pheochromocytoma, multiple pancreatic cysts and multiple renal cysts."	21463266	PubMed		"Leonardi et al., 2011, Ann. Hum. Genet."		3	accepted	5178	Rare Germline	2023-01-14 07:32:52 UTC	https://civicdb.org/links/evidence_items/5178	https://civicdb.org/links/molecular_profiles/1790	FALSE	VHL	7428	R120G (c.358A>G)		chr3	10146531	10146531	A	G	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.358A>G,NP_000542.1:p.Arg120Gly,NC_000003.11:g.10188215A>G,ENST00000256474.2:c.358A>G"	2023-01-27 17:13:23 UTC	CA357028	223199	"C.358A>G,ARG120GLY,RS869025642"	FALSE
VHL R161Q (c.482G>A)	1622	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Predisposition	"In a study of 426 unrelated VHL patients, 111 were discovered to have alterations in the VHL gene. 18 novel variants were identified in VHL patients, but none were present in 200 unaffected control individuals. This missense mutation was found in a 8 year old VHL patient with pheochromocytoma (index case 244). ACMG codes as follows: Supporting evidence of pathogenicity because this is a missense variant in a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease (PP2)."	21463266	PubMed		"Leonardi et al., 2011, Ann. Hum. Genet."		3	accepted	5179	Rare Germline	2023-01-14 07:30:59 UTC	https://civicdb.org/links/evidence_items/5179	https://civicdb.org/links/molecular_profiles/1622	FALSE	VHL	7428	R161Q (c.482G>A)		chr3	10149805	10149805	G	A	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.482G>A,NP_000542.1:p.Arg161Gln,NC_000003.11:g.10191489G>A,ENST00000256474.2:c.482G>A"	2023-01-27 17:11:34 UTC	CA020413	182983	"C.482G>A,ARG161GLN,RS730882035"	FALSE
VHL R167L (c.500G>T)	1792	Von Hippel-Lindau Disease	14175	"Retinal capillary hemangioma,Pheochromocytoma,Hemangioblastoma"			Predisposing	Supports	C	Predisposition	"In a study of 426 unrelated VHL patients, 111 were discovered to have alterations in the VHL gene. 18 novel variants were identified in VHL patients, but none were present in 200 unaffected control individuals. A novel, missense mutation, was found in 57 year old and 31 year old patients with hemangioblastomas of the central nervous system, retinal hemangioblastomas and pheochromocytoma (index cases 24, 232). This mutation was predicted to alter the linker region between beta and alpha domains of VHL protein. ACMG codes as follows: Novel missense change at an amino acid residue where a different missense change determined to be pathogenic has been seen before (PM5). Patient's phenotype is highly specific for a disease with a single genetic etiology (PP4)."	21463266	PubMed		"Leonardi et al., 2011, Ann. Hum. Genet."		2	accepted	5183	Rare Germline	2023-01-14 07:39:10 UTC	https://civicdb.org/links/evidence_items/5183	https://civicdb.org/links/molecular_profiles/1792	FALSE	VHL	7428	R167L (c.500G>T)		chr3	10149823	10149823	G	T	ENST00000256474.2	75		missense_variant	"NC_000003.11:g.10191507G>T,NM_000551.3:c.500G>T,NP_000542.1:p.Arg167Leu,ENST00000256474.2:c.500G>T"	2023-01-27 17:13:25 UTC	CA351756178	526685	"RS5030821,C.500G>T,ARG167LEU"	FALSE
VHL R167W (c.499C>T)	1623	Von Hippel-Lindau Disease	14175	"Retinal capillary hemangioma,Hemangioblastoma,Pheochromocytoma,Renal cyst"			Predisposing	Supports	C	Predisposition	"In a study of 426 unrelated VHL patients, 111 were discovered to have alterations in the VHL gene. 18 novel variants were identified in VHL patients, but none were present in 200 unaffected control individuals. This missense mutation was found in five VHL patients. The 13 yr old patient had pheochromocytoma (PH) (index case 164). The 25 yr old patient had pheochromocytoma and multiple renal cysts (index case 260). The 27 yr old patient had pheochromocytoma, hemangioblastomas of the central nervous system (CNS) and retinal hemangioblastoma (index case 6). The 30 yr old patient had CNS hemangioblastomas and pheochromocytoma (index case 217). The 33 yr old patient had retinal hemangioblastomas and multiple renal cysts (index case 44). Only supporting evidence for pathogenicity because patient's phenotype is highly specific for a disease with a single genetic etiology (ACMG code: PP4)."	21463266	PubMed		"Leonardi et al., 2011, Ann. Hum. Genet."		2	accepted	5184	Rare Germline	2023-01-14 07:38:40 UTC	https://civicdb.org/links/evidence_items/5184	https://civicdb.org/links/molecular_profiles/1623	FALSE	VHL	7428	R167W (c.499C>T)		chr3	10149822	10149822	C	T	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.499C>T,NP_000542.1:p.Arg167Trp,NC_000003.11:g.10191506C>T,ENST00000256474.2:c.499C>T"	2023-01-27 17:11:35 UTC	CA020450	2218	"C.499C>T,ARG167TRP,R126W,RS5030820"	FALSE
VHL D126FS (c.375_376insC)	1794	Von Hippel-Lindau Disease	14175	"Retinal capillary hemangioma,Hemangioblastoma"			Predisposing	Supports	C	Predisposition	"In a study of 426 unrelated VHL patients, 111 were discovered to have alterations in the VHL gene. 18 novel variants were identified in VHL patients, but none were present in 200 unaffected control individuals. This de novo frameshift mutation was found in a 24 yr old VHL patient with no family history and central nervous system and retinal hemangioblastomas (index case 107). This variant also potentially alters the beta domain of the VHL protein. ACMG codes as follows: Frameshift variant in a gene where loss-of-function is a known mechanism of disease (PVS1). De novo in a patient with the disease and no family history (PS2)."	21463266	PubMed		"Leonardi et al., 2011, Ann. Hum. Genet."		2	accepted	5188	Rare Germline	2023-01-14 07:49:25 UTC	https://civicdb.org/links/evidence_items/5188	https://civicdb.org/links/molecular_profiles/1794	FALSE	VHL	7428	D126FS (c.375_376insC)		chr3	10146548	10146549		C	ENST00000256474.2	75		inframe_insertion	ENST00000256474.2:c.375_376insC	2023-01-27 17:13:26 UTC	CA16621931	NONE FOUND	"C.375_376INSC,ASP126FS"	FALSE
VHL C162F (c.485G>T)	1649	Von Hippel-Lindau Disease	14175	"Retinal capillary hemangioma,Multiple renal cysts,Hemangioblastoma,Pheochromocytoma,Pancreatic cysts"			Predisposing	Supports	C	Predisposition	"In a study of 426 unrelated VHL patients, 111 were discovered to have alterations in the VHL gene. 18 novel variants were identified in VHL patients, but none were present in 200 unaffected control individuals. This missense mutation was found in a 34 yr old VHL patient with multiple pancreatic cysts, pheochromocytoma, multiple renal cysts, and central nervous system and retinal hemangioblastomas (index case 74). There is supporting evidence for pathogenicity because the patient's phenotype is highly specific for a disease with a single genetic etiology (ACMG code: PP4). Relevant HPO terms: Hemangioblastoma, retinal hemangioblastoma, multiple renal cysts, multiple pancreatic cysts, pheochromocytoma."	21463266	PubMed		"Leonardi et al., 2011, Ann. Hum. Genet."		2	accepted	5189	Rare Germline	2023-01-14 07:49:01 UTC	https://civicdb.org/links/evidence_items/5189	https://civicdb.org/links/molecular_profiles/1649	FALSE	VHL	7428	C162F (c.485G>T)		chr3	10149808	10149808	G	T	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.485G>T,NP_000542.1:p.Cys162Phe,NC_000003.11:g.10191492G>T,ENST00000256474.2:c.485G>T"	2023-01-27 17:11:52 UTC	CA020418	43604	"C.485G>T,CYS162PHE,RS397516444"	FALSE
VHL E160FS (c.479_480delAG)	1795	Von Hippel-Lindau Disease	14175	"Clear cell renal cell carcinoma,Hemangioblastoma"			Predisposing	Supports	C	Predisposition	"In a study of 426 unrelated VHL patients, 111 were discovered to have alterations in the VHL gene. 18 novel variants were identified in VHL patients, but none were present in 200 unaffected control individuals. This frameshift mutation introduces a premature stop codon at amino acid 172 and was found in a 35 yr old VHL patient with hemangioblastomas of the central nervous system and clear cell renal cell carcinoma (index case 182). There is very strong evidence for pathogenicity in the form of a frameshift mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code : PVS1). Relevant HPO terms: hemangioblastoma, clear cell renal cell carcinoma."	21463266	PubMed		"Leonardi et al., 2011, Ann. Hum. Genet."		2	accepted	5191	Rare Germline	2023-01-14 07:47:35 UTC	https://civicdb.org/links/evidence_items/5191	https://civicdb.org/links/molecular_profiles/1795	FALSE	VHL	7428	E160FS (c.479_480delAG)		chr3	10149802	10149803	AG		ENST00000256474.2	75		frameshift_truncation	"ENST00000256474.2:c.479_480delAG,NC_000003.11:g.10191486_10191487delAG,NM_000551.3:c.479_480delAG,NP_000542.1:p.Glu160AlafsTer13"	2023-01-27 17:13:27 UTC	CA16621940	NONE FOUND	"GLU160FS,C.479_480DELAG"	FALSE
VHL H115Y (c.343C>T)	1797	Von Hippel-Lindau Disease	14175	"Pancreatic cysts,Hemangioblastoma,Retinal capillary hemangioma"			Predisposing	Supports	C	Predisposition	"In a study of 426 unrelated VHL patients, 111 were discovered to have alterations in the VHL gene. 18 novel variants were identified in VHL patients, but none were present in 200 unaffected control individuals. This missense mutation was found in a 36 yr old VHL patient with multiple pancreatic cysts as well as central nervous system and retinal hemangioblastomas (index case 118). ACMG codes as follows: Supporting evidence of pathogenicity because this is a missense variant in a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease (PP2)."	21463266	PubMed		"Leonardi et al., 2011, Ann. Hum. Genet."		2	accepted	5193	Rare Germline	2023-01-14 07:46:19 UTC	https://civicdb.org/links/evidence_items/5193	https://civicdb.org/links/molecular_profiles/1797	FALSE	VHL	7428	H115Y (c.343C>T)		chr3	10146516	10146516	C	T	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.343C>T,NC_000003.11:g.10188200C>T,NM_000551.3:c.343C>T,NP_000542.1:p.His115Tyr"	2023-01-27 17:13:29 UTC	CA16621930	NONE FOUND	"C.343C>T,HIS115TYR,RS5030811"	FALSE
VHL L153P (c.458T>C)	1799	Von Hippel-Lindau Disease	14175	"Renal cyst,Hemangioblastoma,Retinal capillary hemangioma,Multiple renal cysts"			Predisposing	Supports	C	Predisposition	"In a study of 426 unrelated VHL patients, 111 were discovered to have alterations in the VHL gene. 18 novel variants were identified in VHL patients, but none were present in 200 unaffected control individuals. This missense mutation was found in a 36 yr old VHL patient with multiple renal cysts as well as central nervous system and retinal hemangioblastoma (index case 191). ACMG codes as follows: Supporting evidence of pathogenicity because this is a missense variant in a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease (PP2). Relevant HPO terms: hemangioblastoma, retinal hemangioblastoma, multiple renal cysts"	21463266	PubMed		"Leonardi et al., 2011, Ann. Hum. Genet."		2	accepted	5196	Rare Germline	2023-01-14 07:44:59 UTC	https://civicdb.org/links/evidence_items/5196	https://civicdb.org/links/molecular_profiles/1799	FALSE	VHL	7428	L153P (c.458T>C)		chr3	10146631	10146631	T	C	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.458T>C,NC_000003.11:g.10188315T>C,NM_000551.3:c.458T>C,NP_000542.1:p.Leu153Pro"	2023-01-27 17:13:30 UTC	CA16621942	NONE FOUND	"C.458T>C,LEU153PRO"	FALSE
VHL L169P (c.506T>C)	1763	Von Hippel-Lindau Disease	14175	Retinal capillary hemangioma			Predisposing	Supports	C	Predisposition	"In a study of 426 unrelated VHL patients, 111 were discovered to have alterations in the VHL gene. 18 novel variants were identified in VHL patients, but none were present in 200 unaffected control individuals. This missense mutation was found in a 21 yr old VHL patient with retinal hemangioblastomas (index case 344). ACMG codes as follows: Supporting evidence of pathogenicity because Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease (PP2)."	21463266	PubMed		"Leonardi et al., 2011, Ann. Hum. Genet."		2	accepted	5197	Rare Germline	2023-01-14 07:44:38 UTC	https://civicdb.org/links/evidence_items/5197	https://civicdb.org/links/molecular_profiles/1763	FALSE	VHL	7428	L169P (c.506T>C)		chr3	10149829	10149829	T	C	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.506T>C,NP_000542.1:p.Leu169Pro,NC_000003.11:g.10191513T>C,ENST00000256474.2:c.506T>C"	2023-01-27 17:13:07 UTC	CA351756191	428809	"C.506T>C,LEU169PRO,RS1131690962"	FALSE
VHL L178P (c.533T>C)	1624	Von Hippel-Lindau Disease	14175	"Multiple renal cysts,Retinal capillary hemangioma,Pheochromocytoma,Pancreatic cysts,Renal cyst"			Predisposing	Supports	C	Predisposition	"In a study of 426 unrelated VHL patients, 111 were discovered to have alterations in the VHL gene. 18 novel variants were identified in VHL patients, but none were present in 200 unaffected control individuals. This missense mutation was found in a 14 yr old VHL patient with retinal hemangioblastomas, multiple pancreatic cysts, pheochromocytoma, and multiple renal cysts (index case 160). This patient's phenotype is highly specific for a disease with a single genetic etiology (ACMG code: PP4)."	21463266	PubMed		"Leonardi et al., 2011, Ann. Hum. Genet."		2	accepted	5198	Rare Germline	2023-01-14 07:44:14 UTC	https://civicdb.org/links/evidence_items/5198	https://civicdb.org/links/molecular_profiles/1624	FALSE	VHL	7428	L178P (c.533T>C)		chr3	10149856	10149856	T	C	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.533T>C,NM_000551.3:c.533T>C,NP_000542.1:p.Leu178Pro,NC_000003.11:g.10191540T>C"	2023-01-27 17:11:36 UTC	CA351756245	428795	"C.533T>C,LEU178PRO,RS5030822"	FALSE
VHL L184R (c.551T>G)	1684	Von Hippel-Lindau Disease	14175	"Clear cell renal cell carcinoma,Retinal capillary hemangioma,Hemangioblastoma"			Predisposing	Supports	C	Predisposition	"In a study of 426 unrelated VHL patients, 111 were discovered to have alterations in the VHL gene. 18 novel variants were identified in VHL patients, but none were present in 200 unaffected control individuals. This missense mutation was found in a 44 yr old VHL patient with clear cell renal cell carcinoma as well as central nervous system and retinal hemangioblastomas (index case 363). ACMG codes as follows: Supporting evidence of pathogenicity because this is a missense variant in a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease (PP2)."	21463266	PubMed		"Leonardi et al., 2011, Ann. Hum. Genet."		2	accepted	5199	Rare Germline	2023-01-14 07:43:10 UTC	https://civicdb.org/links/evidence_items/5199	https://civicdb.org/links/molecular_profiles/1684	FALSE	VHL	7428	L184R (c.551T>G)		chr3	10149874	10149874	T	G	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.551T>G,NC_000003.11:g.10191558T>G,NM_000551.3:c.551T>G,NP_000542.1:p.Leu184Arg"	2023-01-27 17:12:19 UTC	CA351756355	NONE FOUND	"C.551T>G,LEU184ARG"	FALSE
VHL L188R (c.563T>G)	1800	Von Hippel-Lindau Disease	14175	"Multiple renal cysts,Renal cyst,Hemangioblastoma"			Predisposing	Supports	C	Predisposition	"In a study of 426 unrelated VHL patients, 111 were discovered to have alterations in the VHL gene. 18 novel variants were identified in VHL patients, but none were present in 200 unaffected control individuals. This novel, missense mutation was found in a 48 yr old VHL patient with multiple renal cysts and hemangioblastomas of the central nervous system (index case 109). This variant potentially alters the alpha domain core of the VHL protein. ACMG codes as follows: Supporting evidence of pathogenicity because this is a missense variant in a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease (PP2)."	21463266	PubMed		"Leonardi et al., 2011, Ann. Hum. Genet."		2	accepted	5200	Rare Germline	2023-01-18 05:23:17 UTC	https://civicdb.org/links/evidence_items/5200	https://civicdb.org/links/molecular_profiles/1800	FALSE	VHL	7428	L188R (c.563T>G)		chr3	10149886	10149886	T	G	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.563T>G,NC_000003.11:g.10191570T>G,NM_000551.3:c.563T>G,NP_000542.1:p.Leu188Arg"	2023-01-27 17:13:31 UTC	CA351756400	NONE FOUND	"C.563T>G,LEU188ARG"	FALSE
VHL F136S (c.407T>C)	1677	Von Hippel-Lindau Disease	14175	Hemangioblastoma			Predisposing	Supports	C	Predisposition	"In a study of 426 unrelated VHL patients, 111 were discovered to have alterations in the VHL gene. 18 novel variants were identified in VHL patients, but none were present in 200 unaffected control individuals. This missense mutation was found in a 30 yr old VHL patient with hemangioblastomas of the central nervous system (index case 207). ACMG codes as follows: Supporting evidence of pathogenicity because this is a missense variant in a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease (PP2)."	21463266	PubMed		"Leonardi et al., 2011, Ann. Hum. Genet."		2	accepted	5202	Rare Germline	2023-01-18 05:24:12 UTC	https://civicdb.org/links/evidence_items/5202	https://civicdb.org/links/molecular_profiles/1677	FALSE	VHL	7428	F136S (c.407T>C)		chr3	10146580	10146580	T	C	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.407T>C,NC_000003.11:g.10188264T>C,NM_000551.3:c.407T>C,NP_000542.1:p.Phe136Ser"	2023-01-27 17:12:13 UTC	CA040847	496064	"C.407T>C,PHE136SER,RS5030833"	FALSE
VHL F76del (c.224_226delTCT)	1964	Von Hippel-Lindau Disease	14175	"Hemangioblastoma,Pancreatic cysts"			Predisposing	Supports	C	Predisposition	"In a study of 426 unrelated VHL patients, 111 were discovered to have alterations in the VHL gene. 18 novel variants were identified in VHL patients, but none were present in 200 unaffected control individuals. This deletion mutation was found in a 25 yr old VHL patient with multiple pancreatic cysts and hemangioblastomas of the central nervous system (index case 280). This study contains moderate support for pathogenicity because the protein length changes as a result changes as a result of in-frame deletions in a nonrepeat region (ACMG code: PM4)."	21463266	PubMed		"Leonardi et al., 2011, Ann. Hum. Genet."		2	accepted	5203	Rare Germline	2023-01-18 05:24:43 UTC	https://civicdb.org/links/evidence_items/5203	https://civicdb.org/links/molecular_profiles/1964	FALSE	VHL	7428	F76del (c.224_226delTCT)		chr3	10142071	10142073	TCT		ENST00000256474.2	75		inframe_deletion	"NP_000542.1:p.Phe76del,ENST00000256474.2:c.224_226delTCT,NC_000003.11:g.10183758_10183760del,NC_000003.12:g.10142074_10142076del,NM_000551.3:c.227_229del,ENSP00000256474.2:p.Phe76del"	2023-01-27 17:15:01 UTC	CA357012	223166	"PHE76DEL,C.224_226DELTCT,C.226_228DELTTC,C.227_229DELTCT,DELPHE76"	FALSE
VHL P138T (c.412C>A)	1804	Von Hippel-Lindau Disease	14175	"Retinal capillary hemangioma,Pheochromocytoma"			Predisposing	Supports	C	Predisposition	"In a study of 426 unrelated VHL patients, 111 were discovered to have alterations in the VHL gene. 18 novel variants were identified in VHL patients, but none were present in 200 unaffected control individuals. This novel, missense mutation was found in a 21 yr old VHL patient with retinal hemangioblastomas and pheochromocytoma (index case 115). This variant potentially alters the beta domain core of the VHL protein. ACMG codes as follows: Supporting evidence of pathogenicity because this is a missense variant in a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease (PP2)."	21463266	PubMed		"Leonardi et al., 2011, Ann. Hum. Genet."		2	accepted	5205	Rare Germline	2023-01-18 05:26:45 UTC	https://civicdb.org/links/evidence_items/5205	https://civicdb.org/links/molecular_profiles/1804	FALSE	VHL	7428	P138T (c.412C>A)		chr3	10146585	10146585	C	A	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.412C>A,NC_000003.11:g.10188269C>A,NM_000551.3:c.412C>A,NP_000542.1:p.Pro138Thr"	2023-01-27 17:13:33 UTC	CA16621932	NONE FOUND	"PRO138THR,C.412C>A"	FALSE
VHL S65W (c.194C>G)	1663	Von Hippel-Lindau Disease	14175	"Renal cyst,Hemangioblastoma,Pancreatic cysts"			Predisposing	Supports	C	Predisposition	"In a study of 426 unrelated VHL patients, 111 were discovered to have alterations in the VHL gene. 18 novel variants were identified in VHL patients, and none were present in 200 unaffected control individuals. This missense variant was found in a 33 yr old VHL patient with pancreatic cyst or tumour, renal cystic lesion and CNS hemangioblastoma (index case 214). ACMG codes as follows: supporting evidence of pathogenicity because Patients phenotype or family history is highly specific for a disease with a single genetic etiology (PP4)."	21463266	PubMed		"Leonardi et al., 2011, Ann. Hum. Genet."		2	accepted	5212	Rare Germline	2023-01-19 06:26:29 UTC	https://civicdb.org/links/evidence_items/5212	https://civicdb.org/links/molecular_profiles/1663	FALSE	VHL	7428	S65W (c.194C>G)		chr3	10142041	10142041	C	G	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.194C>G,NM_000551.3:c.194C>G,NP_000542.1:p.Ser65Trp,NC_000003.11:g.10183725C>G"	2023-01-27 17:12:02 UTC	CA020099	43597	"C.194C>G,SER65TRP,RS5030826"	FALSE
ATM Underexpression	179	Stomach Cancer	10534		"Paclitaxel,Olaparib"	Combination	Predictive	Supports	B	Sensitivity/Response	"A randomized phase 2 trial investigating the efficiency of Olaparib plus Paclitaxel vs. Placebo plus Paclitaxel in recurrent or metastatic gastric cancer patients. 123 patients received treatment. Combination treatment did not significantly improve ORR (26,4% vs 19,1%) or PFS (3,91m vs 3,55 m) but OS (13,8 m vs. 8,3 m) in the overall cohort.  A subcohort of ATM low expressing tumours (14%) experienced a greater improvement of OS (not reached vs. 8,2 m) and a trend towards improved PFS (5,29 m vs 3,68 m)."	26282658	PubMed		"Bang et al., 2015, J. Clin. Oncol."		1	accepted	5215	N/A	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/5215	https://civicdb.org/links/molecular_profiles/179	FALSE	ATM	472	Underexpression		chr11	108222832	108369099			ENST00000278616.4	75		N/A		2023-01-09 21:52:05 UTC		N/A		FALSE
VHL Y98C  (c.293A>G)	1809	Von Hippel-Lindau Disease	14175	"Retinal capillary hemangioma,Pheochromocytoma"			Predisposing	Supports	C	Predisposition	"In a study of 426 unrelated VHL patients, 111 were discovered to have alterations in the VHL gene. 18 novel variants were identified in VHL patients, but none were present in 200 unaffected control individuals. This missense mutation was found in a 30 yr old VHL patient with retinal hemangioblastomas and pheochromocytoma (index case 183). ACMG codes as follows:  Supporting evidence of pathogenicity because Patients phenotype or family history is highly specific for a disease with a single genetic etiology (PP4)."	21463266	PubMed		"Leonardi et al., 2011, Ann. Hum. Genet."		2	accepted	5217	Rare Germline	2023-01-19 06:29:08 UTC	https://civicdb.org/links/evidence_items/5217	https://civicdb.org/links/molecular_profiles/1809	FALSE	VHL	7428	Y98C  (c.293A>G)		chr3	10142140	10142140	A	G	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.293A>G,NP_000542.1:p.Tyr98Cys,NC_000003.11:g.10183824A>G,ENST00000256474.2:c.293A>G"	2023-01-27 17:13:37 UTC	CA357072	223176	"C.293A>G,TYR98CYS,RS864321643"	FALSE
VHL Splice Region (c.340+5G>C)	1980	Von Hippel-Lindau Disease	14175	"Pheochromocytoma,Hemangioblastoma"			Predisposing	Supports	C	Predisposition	Germline mutation analysis of seven east-Chinese families revealed 6 mutations. This splice-site alteration was found in two VHL type 2A female family members with hemangioblastomas of the central nervous system. Mutation was also found in a male VHL type 2A family member with hemangioblastomas of the central nervous system and pheochromocytomas (family C). This study contains very strong evidence for pathogenicity in the form of a splice-site variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).	21972040	PubMed		"Huang et al., 2012, Int. J. Mol. Med."		2	accepted	5246	Rare Germline	2023-01-24 09:15:41 UTC	https://civicdb.org/links/evidence_items/5246	https://civicdb.org/links/molecular_profiles/1980	FALSE	VHL	7428	Splice Region (c.340+5G>C)		chr3	10142192	10142192	G	C	ENST00000256474.2	75		intron_variant	"NM_000551.3:c.340+5G>C,NC_000003.11:g.10183876G>C,ENST00000256474.2:c.340+5G>C,NP_000542.1:p.?,NC_000003.12:g.10142192G>C"	2023-01-27 17:15:07 UTC	CA020288	36901	"C.340+5G>C,C.533+5G>C,IVS1+5G>C"	FALSE
VHL Q145* (c.433C>T)	1759	Von Hippel-Lindau Disease	14175	"Pancreatic cysts,Hemangioblastoma"			Predisposing	Supports	C	Predisposition	Germline mutation analysis of seven east-Chinese families revealed 6 mutations. This nonsense mutation was found in two separate families. One female VHL type 1 patient with hemangioblastomas of the central nervous system and an asymptomatic son (family D). Two male VHL type 1 family members with hemangioblastomas of the central nervous system and pancreatic cysts (family F). This study contains very strong evidence for pathogenicity in the form of a nonsense variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).	21972040	PubMed		"Huang et al., 2012, Int. J. Mol. Med."		2	accepted	5248	Rare Germline	2023-01-24 09:16:19 UTC	https://civicdb.org/links/evidence_items/5248	https://civicdb.org/links/molecular_profiles/1759	FALSE	VHL	7428	Q145* (c.433C>T)		chr3	10146606	10146606	C	T	ENST00000256474.2	75		stop_gained	"ENST00000256474.2:c.433C>T,NC_000003.11:g.10188290C>T,NM_000551.3:c.433C>T,NP_000542.1:p.Gln145Ter"	2023-01-27 17:13:04 UTC	CA351754219	625249	"C.433C>T,Q145X,GLN145TER"	FALSE
VHL Exon 1 Deletion	818	Von Hippel-Lindau Disease	14175	Hemangioblastoma			Predisposing	Supports	C	Predisposition	Germline mutation analysis of seven east-Chinese families revealed 6 mutations. This mutation was found two separate VHL families. One family contained a male VHL type 1 patient with hemangioblastomas of the central nervous system and a male asymptomatic patient (family A). The other family contained two male VHL type patients with hemangioblastomas of the central nervous system and 4 asymptomatic family members (family E). This study contains very strong evidence for pathogenicity in the form of a single exon deletion variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).	21972040	PubMed		"Huang et al., 2012, Int. J. Mol. Med."		2	accepted	5249	Rare Germline	2023-01-24 09:17:30 UTC	https://civicdb.org/links/evidence_items/5249	https://civicdb.org/links/molecular_profiles/818	FALSE	VHL	7428	Exon 1 Deletion		chr3	10141848	10142187			ENST00000256474.2	75		exon_loss_variant	ENST00000256474.2:c.1-?_340+?del	2023-01-09 21:52:09 UTC				FALSE
VHL N78S (c.233A>G)	1631	Von Hippel-Lindau Disease	14175	"Pancreatic cysts,Retinal capillary hemangioma,Hemangioblastoma"			Predisposing	Supports	C	Predisposition	"43 Italian patients were molecularly analyzed for Von Hippel-Lindau disease based on clinical suspicion. 2 of the 43 patients were found to have the above mutation. Clinical manifestations associated with this mutation include: CNS hemangioblastomas, pancreatic cysts, and retinal hemangioblastomas. ACMG evidence codes:  'PP2' because they observe a missense variant in gene where missense variants are common mechanism of disease."	19464396	PubMed		"Ciotti et al., 2009, Eur J Med Genet"		3	accepted	5250	Rare Germline	2023-02-16 19:23:03 UTC	https://civicdb.org/links/evidence_items/5250	https://civicdb.org/links/molecular_profiles/1631	FALSE	VHL	7428	N78S (c.233A>G)		chr3	10142080	10142080	A	G	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.233A>G,NP_000542.1:p.Asn78Ser,NC_000003.11:g.10183764A>G,ENST00000256474.2:c.233A>G"	2023-01-27 17:11:40 UTC	CA020131	93326	"C.233A>G,ASN78SER,RS5030804"	FALSE
VHL R113* (c.337C>T)	1672	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Predisposition	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This mutation was found in a VHL type 1 patient (patient V59). This study contains very strong evidence for pathogenicity in the form of a nonsense mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).	9829912	PubMed		"Olschwang et al., 1998, Hum. Mutat."		3	accepted	5260	Rare Germline	2023-02-16 19:28:04 UTC	https://civicdb.org/links/evidence_items/5260	https://civicdb.org/links/molecular_profiles/1672	FALSE	VHL	7428	R113* (c.337C>T)		chr3	10142184	10142184	C	T	ENST00000256474.2	75		stop_gained	"NM_000551.3:c.337C>T,NP_000542.1:p.Arg113Ter,NC_000003.11:g.10183868C>T,ENST00000256474.2:c.337C>T"	2023-01-27 17:12:09 UTC	CA348491	220414	"C.337C>T,R113X,ARG113TER,RS5030810"	FALSE
FLT3 Mutation	515	Acute Myeloid Leukemia	9119		Midostaurin		Predictive	Supports	A	Sensitivity/Response	Midostaurin is FDA-approved for the treatment of newly-diagnosed acute myeloid leukemia patients harboring FLT3 mutations.	28546144	PubMed		"Levis, 2017, Blood"		3	accepted	5261	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/5261	https://civicdb.org/links/molecular_profiles/515	FALSE	FLT3	2322	Mutation		chr13	28003274	28100592			ENST00000241453.7	75		"transcript_variant,gain_of_function_variant"		2023-01-09 21:52:07 UTC				FALSE
VHL R161Q (c.482G>A)	1622	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Predisposition	"Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in 3 unrelated VHL type 2A patients (patients V32, V60, V97). This study contains strong evidence of pathogenicity for this variant because the prevalence of the variant in affected individuals is significantly increased compared with the prevalence In controls (ACMG code: PS4). An additional 0, 4 or 1 unaffected family members, respectively, were negative for the R161Q mutation across the 3 families described."	9829912	PubMed		"Olschwang et al., 1998, Hum. Mutat."		3	accepted	5262	Rare Germline	2023-02-16 19:28:22 UTC	https://civicdb.org/links/evidence_items/5262	https://civicdb.org/links/molecular_profiles/1622	FALSE	VHL	7428	R161Q (c.482G>A)		chr3	10149805	10149805	G	A	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.482G>A,NP_000542.1:p.Arg161Gln,NC_000003.11:g.10191489G>A,ENST00000256474.2:c.482G>A"	2023-01-27 17:11:34 UTC	CA020413	182983	"C.482G>A,ARG161GLN,RS730882035"	FALSE
VHL R161* (c.481C>T)	1680	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Predisposition	"Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This mutation was found in 2 unrelated VHL type 1 patients (patient V3, V46). ACMG codes as follows: A null, nonsense mutation in a gene where loss-of-function is a known mechanism of disease (PVS1). The prevalence of the variant in affected individuals is significantly increased compared with the prevalence in controls (PS4)."	9829912	PubMed		"Olschwang et al., 1998, Hum. Mutat."		3	accepted	5263	Rare Germline	2023-02-16 19:28:45 UTC	https://civicdb.org/links/evidence_items/5263	https://civicdb.org/links/molecular_profiles/1680	FALSE	VHL	7428	R161* (c.481C>T)		chr3	10149804	10149804	C	T	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.481C>T,NP_000542.1:p.Arg161Ter,NC_000003.11:g.10191488C>T,ENST00000256474.2:c.481C>T"	2023-01-27 17:12:16 UTC	CA020408	2217	"C.481C>T,R161X,ARG161TER,RS5030818"	FALSE
VHL R167Q (c.500G>A)	1615	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Predisposition	"Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in a VHL type 1 patient and two VHL type 2B patients (patient no. V322, V36, V262). This study contains strong evidence of pathogenicity for this variant because the prevalence of the variant in affected individuals is significantly increased compared with the prevalence In controls (ACMG code: PS4). No additional family members were screened in all 3 cases."	9829912	PubMed		"Olschwang et al., 1998, Hum. Mutat."		3	accepted	5264	Rare Germline	2023-02-21 00:24:42 UTC	https://civicdb.org/links/evidence_items/5264	https://civicdb.org/links/molecular_profiles/1615	FALSE	VHL	7428	R167Q (c.500G>A)		chr3	10149823	10149823	G	A	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.500G>A,NP_000542.1:p.Arg167Gln,NC_000003.11:g.10191507G>A,ENST00000256474.2:c.500G>A"	2023-01-27 17:11:29 UTC	CA020454	2216	"C.500G>A,ARG167GLN,RS5030821"	FALSE
VHL R167W (c.499C>T)	1623	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Predisposition	"Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in a VHL type 2A patient, a VHL type 2B patient and a family with 5 VHL type 2B patients (patient no. V30, V23, V1). This study contains strong evidence of pathogenicity for this variant because the prevalence of the variant in affected individuals is significantly increased compared with the prevalence In controls (ACMG code: PS4). The first two individuals had no family screened but 14 unaffected family members showed no evidence of this mutation in the family with 5 mutation-positive affected members."	9829912	PubMed		"Olschwang et al., 1998, Hum. Mutat."		4	accepted	5265	Rare Germline	2023-02-21 00:25:17 UTC	https://civicdb.org/links/evidence_items/5265	https://civicdb.org/links/molecular_profiles/1623	FALSE	VHL	7428	R167W (c.499C>T)		chr3	10149822	10149822	C	T	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.499C>T,NP_000542.1:p.Arg167Trp,NC_000003.11:g.10191506C>T,ENST00000256474.2:c.499C>T"	2023-01-27 17:11:35 UTC	CA020450	2218	"C.499C>T,ARG167TRP,R126W,RS5030820"	FALSE
VHL N131K (c.393C>A)	1829	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Predisposition	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in a VHL type 2A patient (patient no. V233). A single unaffected family member available for screening did not have the N131K mutation.	9829912	PubMed		"Olschwang et al., 1998, Hum. Mutat."		2	accepted	5266	Rare Germline	2023-02-21 00:26:02 UTC	https://civicdb.org/links/evidence_items/5266	https://civicdb.org/links/molecular_profiles/1829	FALSE	VHL	7428	N131K (c.393C>A)		chr3	10146566	10146566	C	A	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.393C>A,NP_000542.1:p.Asn131Lys,NC_000003.11:g.10188250C>A,ENST00000256474.2:c.393C>A"	2023-01-27 17:13:45 UTC	CA16617789	420074	"C.393C>A,ASN131LYS,RS1064794272"	FALSE
VHL C162W (c.486C>G)	1650	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Predisposition	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in a VHL type 2B patient (patient no. V345). No additional family was screened for this mutation.	9829912	PubMed		"Olschwang et al., 1998, Hum. Mutat."		2	accepted	5267	Rare Germline	2023-02-21 00:26:39 UTC	https://civicdb.org/links/evidence_items/5267	https://civicdb.org/links/molecular_profiles/1650	FALSE	VHL	7428	C162W (c.486C>G)		chr3	10149809	10149809	C	G	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.486C>G,NP_000542.1:p.Cys162Trp,NC_000003.11:g.10191493C>G,ENST00000256474.2:c.486C>G"	2023-01-27 17:11:53 UTC	CA357016	223227	"C.486C>G,CYS162TRP,RS869025662"	FALSE
VHL Q73* (c.217C>T)	1628	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Predisposition	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This mutation was found in a VHL type 1 patient (patient no. V64). This study contains very strong evidence for pathogenicity in the form of a nonsense mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).	9829912	PubMed		"Olschwang et al., 1998, Hum. Mutat."		3	accepted	5270	Rare Germline	2023-02-21 00:28:08 UTC	https://civicdb.org/links/evidence_items/5270	https://civicdb.org/links/molecular_profiles/1628	FALSE	VHL	7428	Q73* (c.217C>T)		chr3	10142064	10142064	C	T	ENST00000256474.2	75		stop_gained	"NM_000551.3:c.217C>T,NP_000542.1:p.Gln73Ter,NC_000003.11:g.10183748C>T,ENST00000256474.2:c.217C>T"	2023-01-27 17:11:39 UTC	CA357036	223164	"Q73X,C.217C>T,GLN73TER,RS869025619"	FALSE
VHL Q96* (c.286C>T)	1724	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Predisposition	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This mutation was found in a VHL type 1 patient (patient no. V77). This study contains very strong evidence for pathogenicity in the form of a nonsense mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).	9829912	PubMed		"Olschwang et al., 1998, Hum. Mutat."		3	accepted	5271	Rare Germline	2023-02-21 00:28:22 UTC	https://civicdb.org/links/evidence_items/5271	https://civicdb.org/links/molecular_profiles/1724	FALSE	VHL	7428	Q96* (c.286C>T)		chr3	10142133	10142133	C	T	ENST00000256474.2	75		stop_gained	"NM_000551.3:c.286C>T,NP_000542.1:p.Gln96Ter,NC_000003.11:g.10183817C>T,ENST00000256474.2:c.286C>T"	2023-01-27 17:12:46 UTC	CA351750811	428804	"C.286C>T,Q96X,GLN96TER,RS1131690959"	FALSE
VHL E52K (c.154G>A)	1610	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Predisposition	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in a VHL type 1 patient (patient no. V285). No additional family members were screened.	9829912	PubMed		"Olschwang et al., 1998, Hum. Mutat."		2	accepted	5272	Rare Germline	2023-02-21 00:28:45 UTC	https://civicdb.org/links/evidence_items/5272	https://civicdb.org/links/molecular_profiles/1610	FALSE	VHL	7428	E52K (c.154G>A)		chr3	10142001	10142001	G	A	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.154G>A,NP_000542.1:p.Glu52Lys,NC_000003.11:g.10183685G>A,ENST00000256474.2:c.154G>A"	2023-01-27 17:11:26 UTC	CA020056	161402	"GLU52LYS,C.154G>A,RS373068386"	FALSE
VHL E70K (c.208G>A)	1832	Von Hippel-Lindau Disease	14175	Retinal capillary hemangioma			Predisposing	Supports	C	Predisposition	"Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in a VHL type 1 patient (patient no. V374). This patient was further described in Hes et al 2007 (family no. 5) to have bilateral, retinal hemangioblastoma."	9829912	PubMed		"Olschwang et al., 1998, Hum. Mutat."		2	accepted	5273	Rare Germline	2023-02-21 00:29:47 UTC	https://civicdb.org/links/evidence_items/5273	https://civicdb.org/links/molecular_profiles/1832	FALSE	VHL	7428	E70K (c.208G>A)		chr3	10142055	10142055	G	A	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.208G>A,NP_000542.1:p.Glu70Lys,NC_000003.11:g.10183739G>A,ENST00000256474.2:c.208G>A"	2023-01-27 17:13:46 UTC	CA020108	43598	"C.208G>A,GLU70LYS,RS5030802"	FALSE
VHL H115Q (c.345C>G)	1833	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Predisposition	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in a VHL type 1 patient (patient no. V48). No unaffected family members were screened.	9829912	PubMed		"Olschwang et al., 1998, Hum. Mutat."		2	accepted	5274	Rare Germline	2023-02-21 00:33:46 UTC	https://civicdb.org/links/evidence_items/5274	https://civicdb.org/links/molecular_profiles/1833	FALSE	VHL	7428	H115Q (c.345C>G)		chr3	10146518	10146518	C	G	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.345C>G,NC_000003.11:g.10188202C>G,NM_000551.3:c.345C>G,NP_000542.1:p.His115Gln"	2023-01-27 17:13:47 UTC	CA351753634	496058	"HIS115GLN,C.345C>G,RS864622646"	FALSE
VHL H191FS (c.571delC)	1834	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Predisposition	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This mutation causes a premature stop codon at amino acid 201 and was found in a VHL type 2B patient (patient no. V51). This study contains very strong evidence for pathogenicity in the form of a frameshift mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1)	9829912	PubMed		"Olschwang et al., 1998, Hum. Mutat."		3	accepted	5275	Rare Germline	2023-02-21 00:37:26 UTC	https://civicdb.org/links/evidence_items/5275	https://civicdb.org/links/molecular_profiles/1834	FALSE	VHL	7428	H191FS (c.571delC)		chr3	10149894	10149894	C		ENST00000256474.2	75		frameshift_truncation	"ENST00000256474.2:c.571delC,NC_000003.11:g.10191578del,NM_000551.3:c.571delC,NP_000542.1:p.His191ThrfsTer11"	2023-01-27 17:13:47 UTC	CA658795182	NONE FOUND	"C.571DELC,HIS191FS"	FALSE
VHL L118P (c.353T>C)	1674	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Predisposition	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in 3 VHL type 1 family members (patient no. V27). Ten unaffected family members were screened with no evidence of the L188P variant. This study contains strong evidence of pathogenicity for this variant because the prevalence of the variant in affected individuals is significantly increased compared with the prevalence in controls (ACMG code: PS4).	9829912	PubMed		"Olschwang et al., 1998, Hum. Mutat."		3	accepted	5276	Rare Germline	2023-02-21 00:42:05 UTC	https://civicdb.org/links/evidence_items/5276	https://civicdb.org/links/molecular_profiles/1674	FALSE	VHL	7428	L118P (c.353T>C)		chr3	10146526	10146526	T	C	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.353T>C,NM_000551.3:c.353T>C,NP_000542.1:p.Leu118Pro,NC_000003.11:g.10188210T>C"	2023-01-27 17:12:11 UTC	CA70049399	428807	"C.353T>C,LEU118PRO,RS5030830"	FALSE
VHL K159fs (c.473dup)	1748	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This mutation causes a premature stop codon at amino acid 173 and was found in a VHL type 1 patient (patient no. V235). This study contains very strong evidence for pathogenicity in the form of a frameshift mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).	9829912	PubMed		"Olschwang et al., 1998, Hum. Mutat."		3	accepted	5280	Rare Germline	2023-01-09 21:46:51 UTC	https://civicdb.org/links/evidence_items/5280	https://civicdb.org/links/molecular_profiles/1748	FALSE	VHL	7428	K159fs (c.473dup)		chr3	10149796	10149796		T	ENST00000256474.2	75		frameshift_variant	"NM_000551.3:c.473dup,NP_000542.1:p.Lys159GlufsTer15,ENST00000256474.2:c.473dup,ENSP00000256474.2:p.Lys159GlufsTer15,NC_000003.11:g.10191480dup,NC_000003.12:g.10149796dup"	2023-01-09 21:52:16 UTC		NONE FOUND	"C.473INST,C.473DUPT"	FALSE
VHL L158P (c.473T>C)	1614	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Predisposition	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in two VHL type 1 family members (patient no. V252). One unaffected individual family member did not have the L158P mutation.	9829912	PubMed		"Olschwang et al., 1998, Hum. Mutat."		3	accepted	5281	Rare Germline	2023-02-21 00:44:22 UTC	https://civicdb.org/links/evidence_items/5281	https://civicdb.org/links/molecular_profiles/1614	FALSE	VHL	7428	L158P (c.473T>C)		chr3	10149796	10149796	T	C	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.473T>C,NP_000542.1:p.Leu158Pro,NC_000003.11:g.10191480T>C,ENST00000256474.2:c.473T>C"	2023-01-27 17:11:28 UTC	CA020399	182980	"C.473T>C,LEU158PRO,RS121913346"	FALSE
VHL L188P (c.563T>C)	1728	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Predisposition	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in a VHL type 1 patient (patient no. V269). Five unaffected family members were negative for the L188P variant.	9829912	PubMed		"Olschwang et al., 1998, Hum. Mutat."		3	accepted	5282	Rare Germline	2023-02-23 07:35:48 UTC	https://civicdb.org/links/evidence_items/5282	https://civicdb.org/links/molecular_profiles/1728	FALSE	VHL	7428	L188P (c.563T>C)		chr3	10149886	10149886	T	C	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.563T>C,NC_000003.11:g.10191570T>C,NM_000551.3:c.563T>C,NP_000542.1:p.Leu188Pro"	2023-01-27 17:12:49 UTC	CA351756399	625266	"C.563T>C,LEU188PRO"	FALSE
VHL M54fs (c.161dup)	1765	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Predisposition	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This mutation causes a premature stop codon at amino acid 131 and was found in a VHL type 2A patient (patient no. V69). This study contains very strong evidence for pathogenicity in the form of a frameshift mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).	9829912	PubMed		"Olschwang et al., 1998, Hum. Mutat."		3	accepted	5283	Rare Germline	2023-02-23 07:36:55 UTC	https://civicdb.org/links/evidence_items/5283	https://civicdb.org/links/molecular_profiles/1765	FALSE	VHL	7428	M54fs (c.161dup)		chr3	10142007	10142008	T		ENST00000256474.2	75		"plus_1_frameshift_variant,frameshift_truncation"	"NC_000003.11:g.10183692dup,NM_000551.3:c.161dup,NP_000542.1:p.Met54IlefsTer?,NC_000003.12:g.10142008dup"	2023-01-09 21:52:16 UTC	unregistered	NONE FOUND	"M54IFS*78 (C.161DUP),M54FS (C.161INST),M54FS (C.161DUPT)"	FALSE
VHL F136S (c.407T>C)	1677	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Predisposition	"Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in two unrelated VHL type 1 patients (patient no. V53, V94). No unaffected individuals from either family were tested for this mutation."	9829912	PubMed		"Olschwang et al., 1998, Hum. Mutat."		3	accepted	5284	Rare Germline	2023-02-23 07:37:22 UTC	https://civicdb.org/links/evidence_items/5284	https://civicdb.org/links/molecular_profiles/1677	FALSE	VHL	7428	F136S (c.407T>C)		chr3	10146580	10146580	T	C	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.407T>C,NC_000003.11:g.10188264T>C,NM_000551.3:c.407T>C,NP_000542.1:p.Phe136Ser"	2023-01-27 17:12:13 UTC	CA040847	496064	"C.407T>C,PHE136SER,RS5030833"	FALSE
VHL P154= (c.462A>C)	1838	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Predisposition	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This silent mutation was found in two VHL type 2A family members (patient no. V78). Two unaffected family members did not harbor this synonymous mutation.	9829912	PubMed		"Olschwang et al., 1998, Hum. Mutat."		2	accepted	5285	Rare Germline	2023-02-23 07:38:12 UTC	https://civicdb.org/links/evidence_items/5285	https://civicdb.org/links/molecular_profiles/1838	FALSE	VHL	7428	P154= (c.462A>C)		chr3	10146635	10146635	A	C	ENST00000256474.2	75		synonymous_variant	"ENST00000256474.2:c.462A>C,NC_000003.11:g.10188319A>C,NM_000551.3:c.462A>C,NP_000542.1:p.Pro154="	2023-01-27 17:13:48 UTC	CA16621934	NONE FOUND	"C.462A>C,PRO154PRO,P154P (C.462A>C)"	FALSE
VHL P86S (c.256C>T)	1778	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Predisposition	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in 3 VHL type 2B family members (patient no. V11). One unaffected family member was negative for the P86S mutation.	9829912	PubMed		"Olschwang et al., 1998, Hum. Mutat."		3	accepted	5286	Rare Germline	2023-02-23 07:38:32 UTC	https://civicdb.org/links/evidence_items/5286	https://civicdb.org/links/molecular_profiles/1778	FALSE	VHL	7428	P86S (c.256C>T)		chr3	10142103	10142103	C	T	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.256C>T,NP_000542.1:p.Pro86Ser,NC_000003.11:g.10183787C>T,ENST00000256474.2:c.256C>T"	2023-01-27 17:13:14 UTC	CA020180	178692	"C.256C>T,PRO86SER,RS398123481"	FALSE
VHL S65L (c.194C>T)	1664	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Predisposition	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in a VHL type 2 patient (patient no. V209).	9829912	PubMed		"Olschwang et al., 1998, Hum. Mutat."		2	accepted	5287	Rare Germline	2023-02-23 07:38:51 UTC	https://civicdb.org/links/evidence_items/5287	https://civicdb.org/links/molecular_profiles/1664	FALSE	VHL	7428	S65L (c.194C>T)		chr3	10142041	10142041	C	T	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.194C>T,NP_000542.1:p.Ser65Leu,NC_000003.11:g.10183725C>T,ENST00000256474.2:c.194C>T"	2023-01-27 17:12:03 UTC	CA020104	182975	"C.194C>T,SER65LEU,RS5030826"	FALSE
VHL S80R (c.238A>C)	1839	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Predisposition	"Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in a VHL type 1 patient (patient no. V259). This S80R variant was not detected in 2 unaffected family members. An additional 2 unrelated, affected individuals had the similar S80N missense mutation in this study."	9829912	PubMed		"Olschwang et al., 1998, Hum. Mutat."		3	accepted	5288	Rare Germline	2023-02-23 07:39:10 UTC	https://civicdb.org/links/evidence_items/5288	https://civicdb.org/links/molecular_profiles/1839	FALSE	VHL	7428	S80R (c.238A>C)		chr3	10142085	10142085	A	C	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.238A>C,NC_000003.11:g.10183769A>C,NM_000551.3:c.238A>C,NP_000542.1:p.Ser80Arg"	2023-01-27 17:13:49 UTC	CA16621913	496052	"SER80ARG,C.238A>C,RS786202787"	FALSE
VHL S80N (c.239G>A)	1750	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Predisposition	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in two VHL type 1 family members (patient no. V19).	9829912	PubMed		"Olschwang et al., 1998, Hum. Mutat."		3	accepted	5289	Rare Germline	2023-02-23 07:39:35 UTC	https://civicdb.org/links/evidence_items/5289	https://civicdb.org/links/molecular_profiles/1750	FALSE	VHL	7428	S80N (c.239G>A)		chr3	10142086	10142086	G	A	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.239G>A,NC_000003.11:g.10183770G>A,NM_000551.3:c.239G>A,NP_000542.1:p.Ser80Asn"	2023-01-27 17:13:01 UTC	CA70046108	NONE FOUND	"C.239G>A,SER80ASN,RS5030805"	FALSE
VHL R60FS (c.179delG)	1840	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Predisposition	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation causes a premature stop codon at amino acid 66 and was found in a VHL type 1 patient (patient no. V9). This study contains very strong evidence for pathogenicity in the form of a frameshift mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).	9829912	PubMed		"Olschwang et al., 1998, Hum. Mutat."		3	accepted	5290	Rare Germline	2023-02-23 07:39:54 UTC	https://civicdb.org/links/evidence_items/5290	https://civicdb.org/links/molecular_profiles/1840	FALSE	VHL	7428	R60FS (c.179delG)		chr3	10142026	10142026	G		ENST00000256474.2	75		frameshift_truncation	ENST00000256474.2:c.179delG	2023-01-27 17:13:50 UTC	CA020069	NONE FOUND	"C.179DELG,ARG60FS"	FALSE
VHL T105P (c.313A>C)	1715	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Predisposition	"Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in 14 VHL type 1 family members (patient no. V8).  This study contains supporting evidence of pathogenicity due to cosegregation with disease in multiple affected family members (14 affected, 13 unaffected) in a gene definitively known to cause the disease (ACMG code: PP1)."	9829912	PubMed		"Olschwang et al., 1998, Hum. Mutat."		3	accepted	5293	Rare Germline	2023-02-23 07:42:36 UTC	https://civicdb.org/links/evidence_items/5293	https://civicdb.org/links/molecular_profiles/1715	FALSE	VHL	7428	T105P (c.313A>C)		chr3	10142160	10142160	A	C	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.313A>C,NC_000003.11:g.10183844A>C,NM_000551.3:c.313A>C,NP_000542.1:p.Thr105Pro"	2023-01-27 17:12:40 UTC	CA351751116	496055	"C.313A>C,THR105PRO,RS1553619461"	FALSE
VHL T157I (c.470C>T)	1621	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Predisposition	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in a VHL type 2A patient (patient no. V240). No unaffected family members were tested.	9829912	PubMed		"Olschwang et al., 1998, Hum. Mutat."		2	accepted	5294	Rare Germline	2023-02-23 07:42:58 UTC	https://civicdb.org/links/evidence_items/5294	https://civicdb.org/links/molecular_profiles/1621	FALSE	VHL	7428	T157I (c.470C>T)		chr3	10149793	10149793	C	T	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.470C>T,NP_000542.1:p.Thr157Ile,NC_000003.11:g.10191477C>T,ENST00000256474.2:c.470C>T"	2023-01-27 17:11:33 UTC	CA357133	223223	"C.470C>T,THR157ILE,RS869025660"	FALSE
VHL W117C (c.351G>T)	1643	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Predisposition	"Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in 4 VHL type 1 family members (patient no. V13). This study contains supporting evidence of pathogenicity for this variant due to cosegregation of disease with multiple family members (4 affected, 4 unaffected) in a gene definitively known to cause disease (ACMG code: PP1)."	9829912	PubMed		"Olschwang et al., 1998, Hum. Mutat."		3	accepted	5295	Rare Germline	2023-02-23 07:43:29 UTC	https://civicdb.org/links/evidence_items/5295	https://civicdb.org/links/molecular_profiles/1643	FALSE	VHL	7428	W117C (c.351G>T)		chr3	10146524	10146524	G	T	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.351G>T,NP_000542.1:p.Trp117Cys,NC_000003.11:g.10188208G>T,ENST00000256474.2:c.351G>T"	2023-01-27 17:11:49 UTC	CA020294	167827	"C.351G>T,TRP117CYS,RS727504215"	FALSE
VHL W88S (c.263G>C)	1842	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Predisposition	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in a VHL type 1 patient (patient no. V266). No unaffected family members were evaluated.	9829912	PubMed		"Olschwang et al., 1998, Hum. Mutat."		2	accepted	5296	Rare Germline	2023-02-23 07:43:52 UTC	https://civicdb.org/links/evidence_items/5296	https://civicdb.org/links/molecular_profiles/1842	FALSE	VHL	7428	W88S (c.263G>C)		chr3	10142110	10142110	G	C	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.263G>C,NP_000542.1:p.Trp88Ser,NC_000003.11:g.10183794G>C,ENST00000256474.2:c.263G>C"	2023-01-27 17:13:51 UTC	CA020202	2220	"C.263G>C,TRP88SER,RS119103277"	FALSE
VHL Y156D (c.466T>G)	1843	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Predisposition	"Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in a VHL type 2B patient (patient no.V87). No unaffected family members were evaluated. An additional type 1 patient had a similar missense mutation (Y156C, patient no. V265)."	9829912	PubMed		"Olschwang et al., 1998, Hum. Mutat."		3	accepted	5297	Rare Germline	2023-02-23 07:47:24 UTC	https://civicdb.org/links/evidence_items/5297	https://civicdb.org/links/molecular_profiles/1843	FALSE	VHL	7428	Y156D (c.466T>G)		chr3	10149789	10149789	T	G	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.466T>G,NC_000003.11:g.10191473T>G,NM_000551.3:c.466T>G,NP_000542.1:p.Tyr156Asp"	2023-01-27 17:13:52 UTC	CA351756043	NONE FOUND	"C.466T>G,TYR156ASP"	FALSE
VHL Y156C (c.467A>G)	1822	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Predisposition	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in a VHL type 1 patient (patient no. V265). One unaffected family member was negative for this mutation.	9829912	PubMed		"Olschwang et al., 1998, Hum. Mutat."		3	accepted	5298	Rare Germline	2023-02-23 07:48:57 UTC	https://civicdb.org/links/evidence_items/5298	https://civicdb.org/links/molecular_profiles/1822	FALSE	VHL	7428	Y156C (c.467A>G)		chr3	10149790	10149790	A	G	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.467A>G,NP_000542.1:p.Tyr156Cys,NC_000003.11:g.10191474A>G,ENST00000256474.2:c.467A>G"	2023-01-27 17:13:44 UTC	CA020394	43600	"C.467A>G,TYR156CYS,RS397516441"	FALSE
VHL Y156* (c.468T>G)	1844	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Predisposition	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This mutation was found in a VHL type 1 patient (patient no. V41). This study contains very strong evidence for pathogenicity in the form of a nonsense mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).	9829912	PubMed		"Olschwang et al., 1998, Hum. Mutat."		3	accepted	5299	Rare Germline	2023-02-23 07:51:05 UTC	https://civicdb.org/links/evidence_items/5299	https://civicdb.org/links/molecular_profiles/1844	FALSE	VHL	7428	Y156* (c.468T>G)		chr3	10149791	10149791	T	G	ENST00000256474.2	75		stop_gained	"ENST00000256474.2:c.468T>G,NC_000003.11:g.10191475T>G,NM_000551.3:c.468T>G,NP_000542.1:p.Tyr156Ter"	2023-01-27 17:13:53 UTC	CA351756053	NONE FOUND	"C.468T>G,Y156X,TYR156TER"	FALSE
VHL Y175* (c.525C>G)	1845	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Predisposition	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This mutation was found in a VHL type 1 patient (patient no. V63). This study contains very strong evidence for pathogenicity in the form of a nonsense mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).	9829912	PubMed		"Olschwang et al., 1998, Hum. Mutat."		3	accepted	5300	Rare Germline	2023-02-23 07:51:36 UTC	https://civicdb.org/links/evidence_items/5300	https://civicdb.org/links/molecular_profiles/1845	FALSE	VHL	7428	Y175* (c.525C>G)		chr3	10149848	10149848	C	G	ENST00000256474.2	75		stop_gained	"ENST00000256474.2:c.525C>G,NC_000003.11:g.10191532C>G,NM_000551.3:c.525C>G,NP_000542.1:p.Tyr175Ter"	2023-01-27 17:13:54 UTC	CA020466	182974	"C.525C>G,Y175X,TYR175TER,RS5030835"	FALSE
VHL V130L (c.388G>C)	1846	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Predisposition	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in a VHL type 1 patient (patient no. V91). No unaffected family members were tested.	9829912	PubMed		"Olschwang et al., 1998, Hum. Mutat."		2	accepted	5301	Rare Germline	2023-02-23 07:51:54 UTC	https://civicdb.org/links/evidence_items/5301	https://civicdb.org/links/molecular_profiles/1846	FALSE	VHL	7428	V130L (c.388G>C)		chr3	10146561	10146561	G	C	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.388G>C,NP_000542.1:p.Val130Leu,NC_000003.11:g.10188245G>C,ENST00000256474.2:c.388G>C"	2023-01-27 17:13:54 UTC	CA020325	2229	"C.388G>C,VAL130LEU,RS104893830"	FALSE
VHL V166F (c.496G>T)	1701	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Predisposition	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in a VHL type 2A patient (patient no. V49). This variant was not found in 8 unaffected family members and previously reported in patients with VHL.	9829912	PubMed		"Olschwang et al., 1998, Hum. Mutat."		3	accepted	5302	Rare Germline	2023-02-23 07:52:19 UTC	https://civicdb.org/links/evidence_items/5302	https://civicdb.org/links/molecular_profiles/1701	FALSE	VHL	7428	V166F (c.496G>T)		chr3	10149819	10149819	G	T	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.496G>T,NP_000542.1:p.Val166Phe,NC_000003.11:g.10191503G>T,ENST00000256474.2:c.496G>T"	2023-01-27 17:12:32 UTC	CA020436	2224	"C.496G>T,VAL166PHE,RS104893825"	FALSE
VHL V170G (c.509T>G)	1811	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Predisposition	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in a VHL type 1 patient (patient no. V81). No unaffected family members were tested but this mutation was reported in other unrelated patients previously.	9829912	PubMed		"Olschwang et al., 1998, Hum. Mutat."		3	accepted	5303	Rare Germline	2023-02-23 07:53:22 UTC	https://civicdb.org/links/evidence_items/5303	https://civicdb.org/links/molecular_profiles/1811	FALSE	VHL	7428	V170G (c.509T>G)		chr3	10149832	10149832	T	G	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.509T>G,NC_000003.11:g.10191516T>G,NM_000551.3:c.509T>G,NP_000542.1:p.Val170Gly"	2023-01-27 17:13:39 UTC	CA351756196	NONE FOUND	"C.509T>G,VAL170GLY"	FALSE
VHL G114R (c.340G>C)	1733	Von Hippel-Lindau Disease	14175	"Hemangioblastoma,Pancreatic cysts"			Predisposing	Supports	C	Predisposition	43 Italian patients were molecularly analyzed for Von Hippel-Lindau disease based on clinical suspicion. 2 of the 43 patients (VHL-6 and -16) were found to have the above mutation. Clinical manifestations associated with this mutation include: CNS hemangioblastomas and pancreatic cysts. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease.	19464396	PubMed		"Ciotti et al., 2009, Eur J Med Genet"		3	accepted	5305	Rare Germline	2023-02-23 07:54:17 UTC	https://civicdb.org/links/evidence_items/5305	https://civicdb.org/links/molecular_profiles/1733	FALSE	VHL	7428	G114R (c.340G>C)		chr3	10142187	10142187	G	C	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.340G>C,NP_000542.1:p.Gly114Arg,NC_000003.11:g.10183871G>C,ENST00000256474.2:c.340G>C"	2023-01-27 17:12:52 UTC	CA357101	223193	"C.340G>C,GLY114ARG,RS869025636"	FALSE
VHL Mutation	160	Renal Cell Carcinoma	4450		Everolimus		Predictive	Supports	B	Sensitivity/Response	"A randomized, open-label phase 2 study, encompassing 85 patients, to compare the efficacy of dual PIK3/mTOR Inhibitor Apitolisib and mTORC1 inhibitor Everolimus in patients who progressed on or after antiangiogenetic therapy (VEGFR). There was a trend towards association between deleterious VHL alterations and progression-free-survival in the Everolimus arm only."	26951309	PubMed		"Powles et al., 2016, J. Clin. Oncol."	NCT01442090	4	accepted	5323	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/5323	https://civicdb.org/links/molecular_profiles/160	FALSE	VHL	7428	Mutation		chr3	10141008	10152220			ENST00000256474.2	75		"gene_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
VHL S65W (c.194C>G)	1663	Von Hippel-Lindau Disease	14175	"Retinal capillary hemangioma,Hemangioblastoma"			Predisposing	Supports	C	Predisposition	14 Chinese patients from 10 families were diagnosed with Von Hippel-Lindau disease based on clinical criteria. Genetic testing demonstrated 2 members (Patient 1 and 2) of a single family (Family I) harbored the above mutation. Clinical manifestations in this family included: CNS hemangioblastoma and retinal hemangioblastoma. ACMG evidence codes: PP4 - because the patients' phenotypes and family history are highly specific for a disease with single genetic etiology; PP1 - cosegregation with disease in multiple affected family members in a gene definitively known to cause disease.	20518900	PubMed		"Zhou et al., 2010, Pathol. Int."		3	accepted	5328	Rare Germline	2023-03-09 03:41:26 UTC	https://civicdb.org/links/evidence_items/5328	https://civicdb.org/links/molecular_profiles/1663	FALSE	VHL	7428	S65W (c.194C>G)		chr3	10142041	10142041	C	G	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.194C>G,NM_000551.3:c.194C>G,NP_000542.1:p.Ser65Trp,NC_000003.11:g.10183725C>G"	2023-01-27 17:12:02 UTC	CA020099	43597	"C.194C>G,SER65TRP,RS5030826"	FALSE
VHL R177* (c.529A>T)	1703	Von Hippel-Lindau Disease	14175	"Retinal capillary hemangioma,Pancreatic endocrine tumor,Hemangioblastoma"			Predisposing	Supports	C	Predisposition	"14 Chinese patients from 10 VHL Type I families were diagnosed with Von Hippel-Lindau disease based on clinical criteria. Germline mutations were identified in 7/10 families. In all 14 patients, the first manifestation of VHL disease was a central nervous system hemangioblastoma. Their mean age of neurological symptom onset was 24.5 years (range: 12?8 years). Genetic testing demonstrated that Patient 10 (from family VI) and Patient 11 (from family VII) carried this mutation. Patient 10 was reported to have a retinal hemangioblastoma, and patient 11 had a pancreatic tumor. ACMG evidence codes:  'PP4' because the patients' phenotypes and family history are highly specific for a disease with single genetic etiology."	20518900	PubMed		"Zhou et al., 2010, Pathol. Int."		3	accepted	5331	Rare Germline	2023-03-09 04:10:51 UTC	https://civicdb.org/links/evidence_items/5331	https://civicdb.org/links/molecular_profiles/1703	FALSE	VHL	7428	R177* (c.529A>T)		chr3	10149852	10149852	A	T	ENST00000256474.2	75		stop_gained	"ENST00000256474.2:c.529A>T,NC_000003.11:g.10191536A>T,NM_000551.3:c.529A>T,NP_000542.1:p.Arg177Ter"	2023-01-27 17:12:33 UTC	CA351756239	625258	"C.529A>T,R177X,ARG177TER,RS1559429717"	FALSE
VHL Splice Site (c.340+1G>A)	1990	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Predisposition	14 Chinese patients from 10 families were diagnosed with Von Hippel-Lindau disease based on clinical criteria. Genetic testing demonstrated 1 member of a single family harbored the above mutation. Clinical manifestations in this family included: CNS hemangioblastoma. ACMG evidence codes: 'PVS1' because they observe a canonical +1 splice site variant in a gene where loss of function is a known mechanism of disease. Relevant HPO terms: Hemangioblastoma.	20518900	PubMed		"Zhou et al., 2010, Pathol. Int."		3	accepted	5332	Rare Germline	2023-03-09 04:11:09 UTC	https://civicdb.org/links/evidence_items/5332	https://civicdb.org/links/molecular_profiles/1990	FALSE	VHL	7428	Splice Site (c.340+1G>A)		chr3	10142188	10142188	G	A	ENST00000256474.2	75		splice_donor_variant	"NM_000551.3:c.340+1G>A,NC_000003.11:g.10183872G>A,ENST00000256474.2:c.340+1G>A"	2023-01-27 17:15:13 UTC	CA357042	223190	"C.340+1G>A,C.553+1G>A"	FALSE
VHL *214L (c.641G>T)	1862	Von Hippel-Lindau Disease	14175	"Pheochromocytoma,Neuroendocrine neoplasm,Retinal capillary hemangioma"			Predisposing	Supports	C	Predisposition	"This paper identified run-on mutations in 5 members of 4 distinct families. More specifically, genetic testing demonstrated the above mutation (X214LextX15) in 3 individuals in 2 separate families. Clinical evidence suggested an additional 1 family member was affected with VHL, but genetic testing was not conducted on this individual. Clinical manifestations associated with this mutation include: pheochromocytoma, retinal hemangioblastoma, and pancreatic neuroendocrine tumor. ACMG evidence codes:  'PP4' because the patients' phenotypes and family history are highly specific for a disease with single genetic etiology, 'PP1' because of segregation results, and 'PS3' because in-vitro studies demonstrated this variant was unable to perform normal cellular functions (downregulate JunB)."	20560986	PubMed		"Sorrell et al., 2011, Clin. Genet."		4	accepted	5334	Rare Germline	2023-03-09 04:11:46 UTC	https://civicdb.org/links/evidence_items/5334	https://civicdb.org/links/molecular_profiles/1862	FALSE	VHL	7428	*214L (c.641G>T)		chr3	10149964	10149964	G	T	ENST00000256474.2	75		stop_lost	"NM_000551:c.641G>T,ENST00000256474.2:c.641G>T,NP_000542.1:p.Ter214Leu,NC_000003.11:g.10191648G>T"	2023-01-27 17:13:59 UTC	CA357103	223236	"X214L,*214LEXT*15,RS869025668"	FALSE
VHL *214W (c.642A>G)	1863	Von Hippel-Lindau Disease	14175	"Pheochromocytoma,Pancreatic cysts"			Predisposing	Supports	C	Predisposition	"This paper identified run-on mutations in 5 members of 4 distinct families. More specifically, genetic testing demonstrated the above mutation (X214WextX15) in 1 individual in a single family. Clinical manifestations included: pheochromocytoma and pancreatic cysts."	20560986	PubMed		"Sorrell et al., 2011, Clin. Genet."		2	accepted	5335	Rare Germline	2023-03-09 04:12:21 UTC	https://civicdb.org/links/evidence_items/5335	https://civicdb.org/links/molecular_profiles/1863	FALSE	VHL	7428	*214W (c.642A>G)		chr3	10149965	10149965	A	G	ENST00000256474.2	75		stop_lost	"NM_000551.3:c.642A>G,NP_000542.1:p.Ter214Trp,ENST00000256474.2:c.642A>G,NC_000003.11:g.10191649A>G"	2023-01-27 17:14:00 UTC	CA351756723	"36,907,625,269"	"C.642A>G,TER214TRP,NM_000551:*214WEXT*14"	FALSE
VHL *214C (c.642A>T)	1864	Von Hippel-Lindau Disease	14175	"Clear cell renal cell carcinoma,Pheochromocytoma,Hemangioblastoma,Neuroendocrine neoplasm,Retinal capillary hemangioma,Pancreatic endocrine tumor"			Predisposing	Supports	C	Predisposition	"This paper identified run-on mutations in 5 members of 4 distinct families. More specifically, genetic testing demonstrated the above mutation (X214CextX15) in 1 individual in a single family. Clinical manifestations included: pheochromocytoma, CNS hemangioblastoma, retinal hemangioblastoma, clear cell renal cell carcinoma, and pancreatic neuroendocrine tumor. Relevant HPO terms: Pheochromocytoma, Hemangioblastoma, Retinal hemangioblastoma, Clear cell renal cell carcinoma, Neuroendocrine neoplasm."	20560986	PubMed		"Sorrell et al., 2011, Clin. Genet."		2	accepted	5336	Rare Germline	2023-03-09 04:13:10 UTC	https://civicdb.org/links/evidence_items/5336	https://civicdb.org/links/molecular_profiles/1864	FALSE	VHL	7428	*214C (c.642A>T)		chr3	10149965	10149965	A	T	ENST00000256474.2	75		stop_lost	"ENST00000256474.2:c.642A>T,NC_000003.11:g.10191649A>T,NM_000551.3:c.642A>T,NP_000542.1:p.Ter214Cys"	2023-01-27 17:14:00 UTC	CA351756724	625270	"C.642A>T,X214C,TER214CYS,RS1559430011"	FALSE
ERBB2 Mutation	662	Breast Cancer	1612		Neratinib		Predictive	Supports	B	Sensitivity/Response	"16 patients with HER2-mutated metastatic breast cancer were treated with neratinib monotherapy. Of these 16 patients, 14 had known-activating mutations and 2 had mutations of unknown significance. Five of the 16 patients achieved clinical benefit including 1 complete response (6%), 1 partial response (6%) and 3 with stable disease >24 weeks (19%). Clinical benefit was observed across different HER2 mutations including L755S, V777_G778 insGSP, P780_Y781 insGSP, V842I, S310F, and L869R."	28679771	PubMed		"Ma et al., 2017, Clin. Cancer Res."		4	accepted	5338	Somatic	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/5338	https://civicdb.org/links/molecular_profiles/662	FALSE	ERBB2	2064	Mutation		chr17	39711943	39725079			ENST00000269571.5	75		missense_variant		2023-01-09 21:52:08 UTC				FALSE
BAP1 Mutation	183	Renal Cell Carcinoma	4450		"Sunitinib,Everolimus"	Sequential	Predictive	Supports	B	Resistance	"This study evaluated the effects of everolimus and sunitinib on patients with metastatic renal cell carcinoma. A total of 220 patients with RCC were evaluated for 341 genes at 540x coverage. Of all 220 patients, 19% of had BAP1 mutations. Patients with BAP1 mutations treated with first line everolimus followed by sunitinib (N=87 wildtype, 22 mutant) were associated with shorter progression free survival (median [95% CI] 4.9 [2.9 - 8.1] vs 10.5 [7.3 - 12.9] mo; HR 1.84 [1.1-3.2]; P=0.02). For patients treated with sunitinib followed by everolimus (N=91 wildtype, 20 mutant) were associated with a trend towards shorter progression free survival (median [95% CI] 8.1 [3.1-11.3] vs 11.0 [8.3-13.8] mo; HR 1.69 [0.9-3.2]; P=0.06)."	27751729	PubMed		"Hsieh et al., 2017, Eur. Urol."		4	accepted	5339	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/5339	https://civicdb.org/links/molecular_profiles/183	FALSE	BAP1	8314	Mutation		chr3	52401013	52410350			ENST00000460680.1	75		"protein_altering_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
VHL F76del (c.224_226delTCT)	1964	Von Hippel-Lindau Disease	14175	"Hemangioblastoma,Retinal capillary hemangioma"			Predisposing	Supports	C	Predisposition	"Blood samples from 5 Japanese families revealed 4 germline mutations. This mutation was found in a family of 3 individuals (Family B). Only one patient in this family developed symtoms, which included a brain stem hemangioblastoma and retinal angioma discovered at age 30. Parents of this individual showed no manifestations of VHL disease and were negative for bands via single-strand conformational polymorphism (SSCP) analysis where the proband showed extra bands. This study contains moderate evidence of pathogenicity because the protein length changes as a result of an in-frame deletion in a nonrepeat region (ACMG code: PM4)."	8641976	PubMed		"Kanno et al., 1996, Jpn. J. Cancer Res."		2	accepted	5340	Rare Germline	2023-03-09 04:14:01 UTC	https://civicdb.org/links/evidence_items/5340	https://civicdb.org/links/molecular_profiles/1964	FALSE	VHL	7428	F76del (c.224_226delTCT)		chr3	10142071	10142073	TCT		ENST00000256474.2	75		inframe_deletion	"NP_000542.1:p.Phe76del,ENST00000256474.2:c.224_226delTCT,NC_000003.11:g.10183758_10183760del,NC_000003.12:g.10142074_10142076del,NM_000551.3:c.227_229del,ENSP00000256474.2:p.Phe76del"	2023-01-27 17:15:01 UTC	CA357012	223166	"PHE76DEL,C.224_226DELTCT,C.226_228DELTTC,C.227_229DELTCT,DELPHE76"	FALSE
VHL N78H (c.232A>C)	1630	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Predisposition	"Blood samples from 5 Japanese families revealed 4 germline mutations. This missense mutation was found in a family of five individuals. Only one VHL patient was identified with hemangioblastomas of the cerebellum and spinal cord, retinal angiomas, and renal cysts (family A)."	8641976	PubMed		"Kanno et al., 1996, Jpn. J. Cancer Res."		2	accepted	5341	Rare Germline	2023-03-09 04:14:42 UTC	https://civicdb.org/links/evidence_items/5341	https://civicdb.org/links/molecular_profiles/1630	FALSE	VHL	7428	N78H (c.232A>C)		chr3	10142079	10142079	A	C	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.232A>C,NC_000003.11:g.10183763A>C,NM_000551.3:c.232A>C,NP_000542.1:p.Asn78His"	2023-01-27 17:11:40 UTC	CA351749283	NONE FOUND	"C.232A>C,ASN78HIS"	FALSE
VHL Splice Site (c.464-1G>T)	1866	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Predisposition	Blood samples from 5 Japanese families revealed 4 germline mutations. This mutation was found in a family of 10 individuals. Three VHL patients were identified with hemangioblastomas of the central nervous system and retinal angiomas (family C). The eldest patient also had renal cell carcinoma (listed as C-1 in publication). This study contains very strong evidence of pathogenicity in the form of a canonical -1 splice site mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).	8641976	PubMed		"Kanno et al., 1996, Jpn. J. Cancer Res."		2	accepted	5343	Rare Germline	2023-03-09 04:15:18 UTC	https://civicdb.org/links/evidence_items/5343	https://civicdb.org/links/molecular_profiles/1866	FALSE	VHL	7428	Splice Site (c.464-1G>T)		chr3	10149786	10149786	G	T	ENST00000256474.2	75		splice_acceptor_variant	"NC_000003.11:g.10191470G>T,NM_000551.3:c.464-1G>T,ENST00000256474.2:c.464-1G>T,NC_000003.12:g.10149786G>T,NP_000542.1:p.?"	2023-01-27 17:14:02 UTC	CA357144	223221	"C.464-1G>T,RS5030817,IVS2-1G>T"	FALSE
NRAS Mutation	208	Colorectal Cancer	9256		"Cetuximab,Panitumumab"	Substitutes	Predictive	Supports	A	Resistance	NCCN guidelines indicate colorectal cancer patients with NRAS mutations should not be treated with EGFR inhibitors cetuximab or panitumumab.	28275037	PubMed		"Benson et al., 2017, J Natl Compr Canc Netw"		4	accepted	5344	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/5344	https://civicdb.org/links/molecular_profiles/208	FALSE	NRAS	4893	Mutation		chr1	114704469	114716894			ENST00000369535.4	75		"transcript_variant,gain_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
KRAS Mutation	332	Colorectal Cancer	9256		"Cetuximab,Panitumumab"	Substitutes	Predictive	Supports	A	Resistance	NCCN guidelines indicate colorectal cancer patients with KRAS mutations should not be treated with the anti-EGFR therapies cetuximab or panitumumab.	28275037	PubMed		"Benson et al., 2017, J Natl Compr Canc Netw"		5	accepted	5345	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/5345	https://civicdb.org/links/molecular_profiles/332	FALSE	KRAS	3845	Mutation		chr12	25209431	25250803			ENST00000256078.4	75		protein_altering_variant		2023-01-09 21:52:06 UTC		N/A		FALSE
PDGFRA D842V	99	Cancer	162		Imatinib Mesylate		Predictive	Supports	D	Resistance	"In an in vitro study, Chinese hamster ovary cells expressing PDGFRA D842V mutation demonstrated reduced sensitivity to imatinib treatment (IC50=2,500 vs. IC50<100), compared to Chinese hamster ovary cells expressing wild-type PDGFRA. Sensitivity was determined by assessing PDGFRA auto-phosphorylation."	18955458	PubMed		"Heinrich et al., 2008, J. Clin. Oncol."		2	accepted	5346	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/5346	https://civicdb.org/links/molecular_profiles/99	FALSE	PDGFRA	5156	D842V	Imatinib Resistance	chr4	54285926	54285926	A	T	ENST00000257290.5	75		missense_variant	"NM_006206.4:c.2525A>T,NP_006197.1:p.Asp842Val,ENST00000257290.5:c.2525A>T,NC_000004.11:g.55152093A>T"	2023-01-27 17:02:33 UTC	CA123194	13543	"ASP842VAL,RS121908585"	FALSE
PDGFRA V561D	915	Cancer	162		Imatinib Mesylate		Predictive	Does Not Support	D	Resistance	"In an in vitro study, Chinese hamster ovary cells expressing PDGFRA V561D mutation demonstrated sensitivity to imatinib treatment (IC50<100), though this sensitivity was indistinguishable from Chinese hamster ovary cells expressing wild-type PDGFRA. Sensitivity was determined by assessing PDGFRA auto-phosphorylation."	18955458	PubMed		"Heinrich et al., 2008, J. Clin. Oncol."		2	accepted	5347	Somatic	2023-01-09 21:46:40 UTC	https://civicdb.org/links/evidence_items/5347	https://civicdb.org/links/molecular_profiles/915	FALSE	PDGFRA	5156	V561D		chr4	54274869	54274869	T	A	ENST00000257290.5	75		missense_variant	"NM_006206.5:c.1682T>A,NP_006197.1:p.Val561Asp,NC_000004.11:g.55141036T>A,ENST00000257290.5:c.1682T>A"	2023-01-27 17:06:52 UTC	CA123203	13546	RS121908586	FALSE
KIT V560D	945	Cancer	162		Imatinib Mesylate		Predictive	Supports	D	Sensitivity/Response	"In an in vitro study, Chinese hamster ovary cells expressing KIT V560D mutation demonstrated sensitivity to imatinib treatment (IC50 = 100 vs IC50 = 1000) when compared to Chinese hamster ovary cells expressing ligand-activated wild-type KIT. Sensitivity was determined by assessing KIT auto-phosphorylation."	18955458	PubMed		"Heinrich et al., 2008, J. Clin. Oncol."		2	accepted	5348	Somatic	2023-01-09 21:46:40 UTC	https://civicdb.org/links/evidence_items/5348	https://civicdb.org/links/molecular_profiles/945	FALSE	KIT	3815	V560D		chr4	54727447	54727447	T	A	ENST00000288135.5	75		missense_variant	"ENST00000288135.5:c.1679T>A,NM_000222.2:c.1679T>A,NP_000213.1:p.Val560Asp,NC_000004.11:g.55593613T>A"	2023-01-27 17:07:13 UTC	CA16602396	375914	"VAL560ASP,RS121913521"	FALSE
VHL C162R (c.484T>C)	1648	Von Hippel-Lindau Disease	14175	"Renal cell carcinoma,Retinal capillary hemangioma,Hemangioblastoma"			Predisposing	Supports	C	Predisposition	"Blood samples from 5 Japanese families revealed 4 germline mutations. This missense mutation was found in a family of 7 individuals. Two VHL patients were identified, 1 with brain stem hemangioblastomas and retinal angiomas, the other with renal cell carcinoma (family D). Single-strand conformational polymorphism (SSCP) analysis showed bands for the 2 affected individuals that were absent from 5 normal individuals. Direct sequencing was performed on SSCP positive patients. Supporting evidence for pathogenicity due to cosegregation with disease in multiple affected family members (ACMG code: PP1)."	8641976	PubMed		"Kanno et al., 1996, Jpn. J. Cancer Res."		2	accepted	5349	Rare Germline	2023-03-09 04:15:31 UTC	https://civicdb.org/links/evidence_items/5349	https://civicdb.org/links/molecular_profiles/1648	FALSE	VHL	7428	C162R (c.484T>C)		chr3	10149807	10149807	T	C	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.484T>C,NM_000551.3:c.484T>C,NC_000003.11:g.10191491T>C,NP_000542.1:p.Cys162Arg"	2023-01-27 17:11:51 UTC	CA351756117	496067	"RS1553620313,C.484T>C,CYS162ARG"	FALSE
VHL Splice Site (c.464-2A>T)	1868	Von Hippel-Lindau Disease	14175	"Pancreatic cysts,Renal cell carcinoma,Hemangioblastoma"			Predisposing	Supports	C	Predisposition	"Of 65 VHL families from central Europe, 53 were identified with germline mutations. This splice mutation was found in a German, VHL type 1 family. Only one affected patient was identified with hemangioblastomas of the central nervous system, renal cell carcinoma, and pancreatic cysts. (family VHL 57). This study contains very strong evidence of pathogenicity in the form of a canonical -2 splice variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1)."	8707293	PubMed		"Glavac et al., 1996, Hum. Genet."		2	accepted	5351	Rare Germline	2023-03-09 04:16:14 UTC	https://civicdb.org/links/evidence_items/5351	https://civicdb.org/links/molecular_profiles/1868	FALSE	VHL	7428	Splice Site (c.464-2A>T)		chr3	10149785	10149785	A	T	ENST00000256474.2	75		splice_acceptor_variant	"NM_000551.3:c.464-2A>T,NC_000003.11:g.10191469A>T,ENST00000256474.2:c.464-2A>T,NP_000542.1:p.="	2023-01-27 17:14:03 UTC	CA70052157	NONE FOUND	"C.464-2A>T,RS5030816"	FALSE
VHL R113* (c.337C>T)	1672	Von Hippel-Lindau Disease	14175	"Hemangioblastoma,Retinal capillary hemangioma"			Predisposing	Supports	C	Predisposition	"Of 65 VHL families from central Europe, 53 were identified with germline mutations using SSCP analysis of PCR products by peripheral blood. The R113* (c.337C>T) mutation was detected in the patient, referred to in the paper by R113* (c.550C>T) due to a difference in transcript sequence. This nonsense mutation was found in a German, VHL type 1 family (family VHL 55). Two patients were identified with retinal angiomas and hemangioblastomas of the central nervous system. This study contains very strong evidence of pathogenicity in the form of a nonsense mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1)."	8707293	PubMed		"Glavac et al., 1996, Hum. Genet."		3	accepted	5352	Rare Germline	2023-03-09 04:16:39 UTC	https://civicdb.org/links/evidence_items/5352	https://civicdb.org/links/molecular_profiles/1672	FALSE	VHL	7428	R113* (c.337C>T)		chr3	10142184	10142184	C	T	ENST00000256474.2	75		stop_gained	"NM_000551.3:c.337C>T,NP_000542.1:p.Arg113Ter,NC_000003.11:g.10183868C>T,ENST00000256474.2:c.337C>T"	2023-01-27 17:12:09 UTC	CA348491	220414	"C.337C>T,R113X,ARG113TER,RS5030810"	FALSE
VHL R161G (c.481C>G)	1791	Von Hippel-Lindau Disease	14175	"Hemangioblastoma,Pheochromocytoma,Renal cell carcinoma,Retinal capillary hemangioma"			Predisposing	Supports	C	Predisposition	"Of 65 VHL families from central Europe, 53 were identified with germline mutations. This missense mutation was found in a German, VHL type 2B family. Only one patient was identified with retinal angiomas, hemangioblastomas of the central nervous system, pheochromocytoma, and renal cell carcinoma. This patient's phenotype is highly specific for a disease with a single etiology (ACMG code: PP4)."	8707293	PubMed		"Glavac et al., 1996, Hum. Genet."		2	accepted	5353	Rare Germline	2023-03-09 04:16:50 UTC	https://civicdb.org/links/evidence_items/5353	https://civicdb.org/links/molecular_profiles/1791	FALSE	VHL	7428	R161G (c.481C>G)		chr3	10149804	10149804	C	G	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.481C>G,NC_000003.11:g.10191488C>G,NM_000551.3:c.481C>G,NP_000542.1:p.Arg161Gly"	2023-01-27 17:13:24 UTC	CA16621941	NONE FOUND	"C.481C>G,ARG161GLY,RS5030818"	FALSE
VHL R167Q (c.500G>A)	1615	Von Hippel-Lindau Disease	14175	"Cerebellar hemangioblastoma,Renal cell carcinoma,Retinal capillary hemangioma"			Predisposing	Supports	C	Predisposition	"Of 65 VHL families from central Europe, 53 were identified with germline mutations. This missense mutation was found in a German, VHL type 2B family with 5 affected individuals (family VHL 43). Each patient had retinal angiomas, 2 had hemangioblastomas of the central nervous system, and 2 had renal cell carcinoma. The patients phenotype and family history are highly specific for a disease with a single gene etiology (ACMG code: PP4)."	8707293	PubMed		"Glavac et al., 1996, Hum. Genet."		2	accepted	5354	Rare Germline	2023-03-09 03:48:37 UTC	https://civicdb.org/links/evidence_items/5354	https://civicdb.org/links/molecular_profiles/1615	FALSE	VHL	7428	R167Q (c.500G>A)		chr3	10149823	10149823	G	A	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.500G>A,NP_000542.1:p.Arg167Gln,NC_000003.11:g.10191507G>A,ENST00000256474.2:c.500G>A"	2023-01-27 17:11:29 UTC	CA020454	2216	"C.500G>A,ARG167GLN,RS5030821"	FALSE
VHL C162W (c.486C>G)	1650	Von Hippel-Lindau Disease	14175	"Pancreatic cysts,Hemangioblastoma,Retinal capillary hemangioma,Renal cell carcinoma"			Predisposing	Supports	C	Predisposition	"Of 65 VHL families from central Europe, 53 were identified with germline mutations. This missense mutation was found in a German, VHL type 1 patient with retinal angiomas, hemangioblastomas of the central nervous system, renal cell carcinoma, and pancreatic cysts (family VHL 42). HPO terms: retinal hemangioblastoma, hemangioblastoma, renal cell carcinoma, multiple pancreatic cysts."	8707293	PubMed		"Glavac et al., 1996, Hum. Genet."		2	accepted	5355	Rare Germline	2023-03-09 03:49:48 UTC	https://civicdb.org/links/evidence_items/5355	https://civicdb.org/links/molecular_profiles/1650	FALSE	VHL	7428	C162W (c.486C>G)		chr3	10149809	10149809	C	G	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.486C>G,NP_000542.1:p.Cys162Trp,NC_000003.11:g.10191493C>G,ENST00000256474.2:c.486C>G"	2023-01-27 17:11:53 UTC	CA357016	223227	"C.486C>G,CYS162TRP,RS869025662"	FALSE
VHL Splice Site (c.463+2T>C)	1951	Von Hippel-Lindau Disease	14175	"Pancreatic cysts,Hemangioblastoma,Retinal capillary hemangioma,Renal cell carcinoma"			Predisposing	Supports	C	Predisposition	"Of 65 VHL families from central Europe, 53 were identified with germline mutations. This splice mutation was found in a Croatian, VHL type 1 family of 3. Each individual had retinal angiomas, one had hemangioblastomas of the central nervous system, one had renal cell carcinoma, and one had pancreatic cysts (family VHL 7). This study contains very strong evidence of pathogenicity in the form of a canonical +2 splice site variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1)."	8707293	PubMed		"Glavac et al., 1996, Hum. Genet."		2	accepted	5356	Rare Germline	2023-03-09 03:50:04 UTC	https://civicdb.org/links/evidence_items/5356	https://civicdb.org/links/molecular_profiles/1951	FALSE	VHL	7428	Splice Site (c.463+2T>C)		chr3	10146638	10146638	T	C	ENST00000256474.2	75		splice_donor_variant	"NM_000551.3:c.463+2T>C,NC_000003.11:g.10188322T>C,ENST00000256474.2:c.463+2T>C,NP_000542.1:p.?,NC_000003.12:g.10146638T>C"	2023-01-27 17:14:55 UTC	CA16621936	569414	"C.463+2T>C,RS5030814"	FALSE
VHL Splice Site (c.464-1G>A)	1850	Von Hippel-Lindau Disease	14175	Hemangioblastoma			Predisposing	Supports	C	Predisposition	"Of 65 VHL families from central Europe, 53 were identified with germline mutations. This splice mutation was found in a German, VHL type 1 patient with hemangioblastomas of the central nervous system (family VHL 48). This study contains very strong evidence of pathogenicity in the form of a canonical -1 splice site variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1)."	8707293	PubMed		"Glavac et al., 1996, Hum. Genet."		2	accepted	5357	Rare Germline	2023-03-09 03:50:26 UTC	https://civicdb.org/links/evidence_items/5357	https://civicdb.org/links/molecular_profiles/1850	FALSE	VHL	7428	Splice Site (c.464-1G>A)		chr3	10149786	10149786	G	A	ENST00000256474.2	75		splice_acceptor_variant	"NM_000551.3:c.464-1G>A,NC_000003.11:g.10191470G>A,ENST00000256474.2:c.464-1G>A"	2023-01-27 17:13:56 UTC	CA020389	43603	"C.464-1G>A,RS5030817"	FALSE
VHL Q132* (c.394C>T)	1870	Von Hippel-Lindau Disease	14175	"Pancreatic cysts,Retinal capillary hemangioma,Hemangioblastoma"			Predisposing	Supports	C	Predisposition	"Of 65 VHL families from central Europe, 53 were identified with germline mutations. This nonsense mutation was found in a German, VHL type 1 patient with retinal angiomas, hemangioblastomas of the central nervous system, and pancreatic cysts (family VHL 30). This study contains very strong evidence of pathogenicity in the form of a nonsense variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1)."	8707293	PubMed		"Glavac et al., 1996, Hum. Genet."		2	accepted	5358	Rare Germline	2023-03-09 03:50:46 UTC	https://civicdb.org/links/evidence_items/5358	https://civicdb.org/links/molecular_profiles/1870	FALSE	VHL	7428	Q132* (c.394C>T)		chr3	10146567	10146567	C	T	ENST00000256474.2	75		stop_gained	"NM_000551.3:c.394C>T,NP_000542.1:p.Gln132Ter,NC_000003.11:g.10188251C>T,ENST00000256474.2:c.394C>T"	2023-01-27 17:14:04 UTC	CA10606205	288749	"C.394C>T,Q132X,GLN132TER,RS5030813"	FALSE
VHL Q164* (c.490C>T)	1721	Von Hippel-Lindau Disease	14175	"Renal cell carcinoma,Pancreatic cysts,Pancreatic endocrine tumor,Hemangioblastoma,Retinal capillary hemangioma"			Predisposing	Supports	C	Predisposition	"Of 65 VHL families from central Europe, 53 were identified with germline mutations. This nonsense mutation was found in an Iranian, VHL type 1 patient with retinal angiomas, hemangioblastomas of the central nervous system, renal cell carcinoma, pancreatic cysts, and pancreatic islet cell tumors (family VHL 65). This study contains very strong evidence of pathogenicity in the form of a nonsense variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1)."	8707293	PubMed		"Glavac et al., 1996, Hum. Genet."		2	accepted	5359	Rare Germline	2023-03-09 03:51:35 UTC	https://civicdb.org/links/evidence_items/5359	https://civicdb.org/links/molecular_profiles/1721	FALSE	VHL	7428	Q164* (c.490C>T)		chr3	10149813	10149813	C	T	ENST00000256474.2	75		stop_gained	"NM_000551.3:c.490C>T,NP_000542.1:p.Gln164Ter,NC_000003.11:g.10191497C>T,ENST00000256474.2:c.490C>T"	2023-01-27 17:12:43 UTC	CA357060	223228	"C.490C>T,Q164X,GLN164TER,RS5030819"	FALSE
VHL Q195* (c.583C>T)	1686	Von Hippel-Lindau Disease	14175	"Hemangioblastoma,Retinal capillary hemangioma"			Predisposing	Supports	C	Predisposition	"Of 65 VHL families from central Europe, 53 were identified with germline mutations. This nonsense mutation was found in 2 German, VHL type 1 family members with retinal angiomas and hemangioblastomas of the central nervous system (family VHL 56). This study contains very strong evidence of pathogenicity in the form of a nonsense variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1)."	8707293	PubMed		"Glavac et al., 1996, Hum. Genet."		2	accepted	5360	Rare Germline	2023-03-09 03:51:54 UTC	https://civicdb.org/links/evidence_items/5360	https://civicdb.org/links/molecular_profiles/1686	FALSE	VHL	7428	Q195* (c.583C>T)		chr3	10149906	10149906	C	T	ENST00000256474.2	75		stop_gained	"NM_000551.3:c.583C>T,NP_000542.1:p.Gln195Ter,NC_000003.11:g.10191590C>T,ENST00000256474.2:c.583C>T"	2023-01-27 17:12:20 UTC	CA70052558	428794	"C.583C>T,Q195X,GLN195TER,RS5030825"	FALSE
VHL E70* (c.208G>T)	1710	Von Hippel-Lindau Disease	14175	Hemangioblastoma			Predisposing	Supports	C	Predisposition	"Of 65 VHL families from central Europe, 53 were identified with germline mutations. This nonsense mutation was found in a Filipino, VHL type 1 patient with hemangioblastomas of the central nervous system (family VHL 50). This study contains very strong evidence of pathogenicity in the form of a frameshift variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1)."	8707293	PubMed		"Glavac et al., 1996, Hum. Genet."		2	accepted	5361	Rare Germline	2023-03-09 03:52:16 UTC	https://civicdb.org/links/evidence_items/5361	https://civicdb.org/links/molecular_profiles/1710	FALSE	VHL	7428	E70* (c.208G>T)		chr3	10142055	10142055	G	T	ENST00000256474.2	75		stop_gained	"NM_000551.3:c.208G>T,NP_000542.1:p.Glu70Ter,NC_000003.11:g.10183739G>T,ENST00000256474.2:c.208G>T"	2023-01-27 17:12:36 UTC	CA16602179	428806	"C.208G>T,E70X,GLU70TER,RS5030802"	FALSE
VHL H115Y (c.343C>T)	1797	Von Hippel-Lindau Disease	14175	Retinal capillary hemangioma			Predisposing	Supports	C	Predisposition	"Of 65 VHL families from central Europe, 53 were identified with germline mutations. This missense mutation was found in a German, VHL type 1 patient with retinal angiomas (family VHL 59)."	8707293	PubMed		"Glavac et al., 1996, Hum. Genet."		2	accepted	5363	Rare Germline	2023-03-09 03:53:55 UTC	https://civicdb.org/links/evidence_items/5363	https://civicdb.org/links/molecular_profiles/1797	FALSE	VHL	7428	H115Y (c.343C>T)		chr3	10146516	10146516	C	T	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.343C>T,NC_000003.11:g.10188200C>T,NM_000551.3:c.343C>T,NP_000542.1:p.His115Tyr"	2023-01-27 17:13:29 UTC	CA16621930	NONE FOUND	"C.343C>T,HIS115TYR,RS5030811"	FALSE
VHL C77_N78insL (c.230_231insTCT)	2965	Von Hippel-Lindau Disease	14175	"Pancreatic cysts,Hemangioblastoma,Renal cell carcinoma"			Predisposing	Supports	C	Predisposition	"Of 65 VHL families from central Europe, 53 were identified with germline mutations.  This mutation was found in 2 Croatian, VHL type 1 family members (family VHL 26). Both have hemangioblastomas of the central nervous system, one has renal cell carcinoma, and one with pancreatic cysts."	8707293	PubMed		"Glavac et al., 1996, Hum. Genet."		2	accepted	5364	Rare Germline	2023-03-09 03:48:10 UTC	https://civicdb.org/links/evidence_items/5364	https://civicdb.org/links/molecular_profiles/2965	FALSE	VHL	7428	C77_N78insL (c.230_231insTCT)		chr3	10142077	10142078		TCT	ENST00000256474.2	75		disruptive_inframe_insertion	"NC_000003.12:g.10142077_10142078insTCT,NC_000003.11:g.10183761_10183762insTCT,NM_000551.3:c.230_231insTCT,NP_000542.1:p.Cys77_Asn78insLeu"	2023-01-27 17:18:21 UTC	CA2499214029	NONE FOUND	77INSL	FALSE
VHL L129fs (c.384delT)	1872	Von Hippel-Lindau Disease	14175	"Pancreatic cysts,Renal cell carcinoma,Hemangioblastoma"			Predisposing	Supports	C	Predisposition	"Of 65 VHL families from central Europe, 53 were identified with germline mutations. This mutation was found in 2 German, VHL type 1 family members with hemangioblastomas of the central nervous system, renal cell carcinoma, and pancreatic cysts (family VHL 44). This study contains very strong evidence of pathogenicity in the form of a frameshift variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1)."	8707293	PubMed		"Glavac et al., 1996, Hum. Genet."		3	accepted	5365	Rare Germline	2023-03-09 03:47:30 UTC	https://civicdb.org/links/evidence_items/5365	https://civicdb.org/links/molecular_profiles/1872	FALSE	VHL	7428	L129fs (c.384delT)		chr3	10146557	10146557	T		ENST00000256474.2	75		frameshift_variant	ENST00000256474.2:c.384delT	2023-01-27 17:14:04 UTC	CA70049452	NONE FOUND	"C.384DELT,LEU129FS"	FALSE
VHL L178Q (c.533T>A)	1873	Von Hippel-Lindau Disease	14175	"Hemangioblastoma,Retinal capillary hemangioma,Pheochromocytoma"			Predisposing	Supports	C	Predisposition	"Of 65 VHL families from central Europe, 53 were identified with germline mutations. This missense mutation was found in 2 German, VHL type 2 family members with retinal angiomas, hemangioblastomas of the central nervous system, and pheochromocytomas (family VHL 29). Each patient's phenotype is highly specific for a disease with a single genetic etiology (ACMG code: PP4)."	8707293	PubMed		"Glavac et al., 1996, Hum. Genet."		2	accepted	5366	Rare Germline	2023-03-09 03:48:22 UTC	https://civicdb.org/links/evidence_items/5366	https://civicdb.org/links/molecular_profiles/1873	FALSE	VHL	7428	L178Q (c.533T>A)		chr3	10149856	10149856	T	A	ENST00000256474.2	75		missense_variant	"NC_000003.11:g.10191540T>A,NM_000551.3:c.533T>A,NP_000542.1:p.Leu178Gln,ENST00000256474.2:c.533T>A"	2023-01-27 17:14:05 UTC	CA70052370	625260	"C.533T>A,LEU178GLN,RS5030822"	FALSE
VHL L89P (c.266T>C)	1669	Von Hippel-Lindau Disease	14175	"Retinal capillary hemangioma,Hemangioblastoma,Pancreatic cysts,Renal cell carcinoma"			Predisposing	Supports	C	Uncertain Significance	"Of 65 VHL families from central Europe, 53 were identified with germline mutations. This missense mutation was found in a German, VHL type 1 family of 11. Three patients had retinal angiomas, 7 hand hemangioblastomas of the central nervous system, 7 had renal cell carcinoma, and 6 had pancreatic cysts (family VHL 3). This study contains supporting evidence of pathogenicity due to cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1)."	8707293	PubMed		"Glavac et al., 1996, Hum. Genet."		2	accepted	5368	Rare Germline	2023-01-09 21:46:49 UTC	https://civicdb.org/links/evidence_items/5368	https://civicdb.org/links/molecular_profiles/1669	FALSE	VHL	7428	L89P (c.266T>C)		chr3	10142113	10142113	T	C	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.266T>C,NP_000542.1:p.Leu89Pro,NC_000003.11:g.10183797T>C,ENST00000256474.2:c.266T>C"	2023-01-27 17:12:07 UTC	CA020207	182979	"C.266T>C,LEU89PRO,RS5030807"	FALSE
VHL P81S (c.241C>T)	1713	Von Hippel-Lindau Disease	14175	"Pancreatic cysts,Renal cell carcinoma,Hemangioblastoma"			Predisposing	Supports	C	Uncertain Significance	"Of 65 VHL families from central Europe, 53 were identified with germline mutations. This missense mutation was found in a German, VHL type 1 patient with hemangioblastomas of the central nervous system, renal cell carcinoma, and pancreatic cysts (family VHL 23)."	8707293	PubMed		"Glavac et al., 1996, Hum. Genet."		2	accepted	5369	Rare Germline	2023-01-09 21:46:51 UTC	https://civicdb.org/links/evidence_items/5369	https://civicdb.org/links/molecular_profiles/1713	FALSE	VHL	7428	P81S (c.241C>T)		chr3	10142088	10142088	C	T	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.241C>T,NP_000542.1:p.Pro81Ser,NC_000003.11:g.10183772C>T,ENST00000256474.2:c.241C>T"	2023-01-27 17:12:39 UTC	CA020148	2233	"C.241C>T,PRO81SER,RS104893829"	FALSE
VHL S183* (c.548C>A)	1660	Renal Cell Carcinoma	4450	"Retinal capillary hemangioma,Pancreatic cysts,Hemangioblastoma,Renal cell carcinoma"			Predisposing	Supports	C	Uncertain Significance	"Of 65 VHL families from central Europe, 53 were identified with germline mutations. This nonsense mutation was found in 3 Italian, VHL type 1 family members. Two had retinal angiomas, 2 had hemangioblastomas of the central nervous system, 2 had renal cell carcinoma, and all three had pancreatic cysts. This study contains very strong evidence of pathogenicity in the form of a nonsense variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1)."	8707293	PubMed		"Glavac et al., 1996, Hum. Genet."		3	accepted	5370	Rare Germline	2023-01-09 21:46:49 UTC	https://civicdb.org/links/evidence_items/5370	https://civicdb.org/links/molecular_profiles/1660	FALSE	VHL	7428	S183* (c.548C>A)		chr3	10149871	10149871	C	A	ENST00000256474.2	75		stop_gained	"NM_000551.3:c.548C>A,NP_000542.1:p.Ser183Ter,NC_000003.11:g.10191555C>A,ENST00000256474.2:c.548C>A"	2023-01-27 17:12:00 UTC	CA020473	2215	"C.548C>A,S183X,SER183TER,RS5030823"	FALSE
VHL S80N (c.239G>A)	1750	Renal Cell Carcinoma	4450	"Pancreatic endocrine tumor,Pancreatic cysts,Renal cell carcinoma,Retinal capillary hemangioma,Hemangioblastoma"			Predisposing	Supports	C	Uncertain Significance	"Of 65 VHL families from central Europe, 53 were identified with germline mutations. This missense mutation was found in a Slovakian, VHL type 1 family of 13 affected individuals. Seven had retinal angiomas, 7 had hemangioblastomas of the central nervous system, 5 had renal cell carcinoma, one had pancreatic cysts, and one had  pancreatic islet cell tumors (family VHL 39). This study contains supporting evidence for pathogenicity due to cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1)."	8707293	PubMed		"Glavac et al., 1996, Hum. Genet."		2	accepted	5371	Rare Germline	2023-01-09 21:46:51 UTC	https://civicdb.org/links/evidence_items/5371	https://civicdb.org/links/molecular_profiles/1750	FALSE	VHL	7428	S80N (c.239G>A)		chr3	10142086	10142086	G	A	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.239G>A,NC_000003.11:g.10183770G>A,NM_000551.3:c.239G>A,NP_000542.1:p.Ser80Asn"	2023-01-27 17:13:01 UTC	CA70046108	NONE FOUND	"C.239G>A,SER80ASN,RS5030805"	FALSE
VHL Y98H (c.292T>C)	1617	Von Hippel-Lindau Disease	14175	"Hemangioblastoma,Pheochromocytoma,Renal cell carcinoma,Retinal capillary hemangioma"			Predisposing	Supports	C	Uncertain Significance	"Of 65 VHL families from central Europe, 53 were identified with germline mutations. This missense mutation was found 3 unrelated, German families, 2 of which had been previously described (Neumann et al. 1995). The newly-identified VHL type 2 patient had retinal angiomas and pheochromocytoma (family VHL 54). As previously described, one VHL type 2A family of 52 affected individuals had 26 patients with retinal angiomas, 6 with hemangioblastomas of the central nervous system, and 41 with pheochromocytoma (family VHL*). A VHL type 1 family of 3 had 2 patients with retinal angiomas and one with renal cell carcinoma (family VHL 47). This study contains supporting evidence for pathogenicity due to cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1)."	8707293	PubMed		"Glavac et al., 1996, Hum. Genet."		2	accepted	5372	Rare Germline	2023-01-09 21:46:48 UTC	https://civicdb.org/links/evidence_items/5372	https://civicdb.org/links/molecular_profiles/1617	FALSE	VHL	7428	Y98H (c.292T>C)		chr3	10142139	10142139	T	C	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.292T>C,NP_000542.1:p.Tyr98His,NC_000003.11:g.10183823T>C,ENST00000256474.2:c.292T>C"	2023-01-27 17:11:30 UTC	CA020246	2223	"C.292T>C,TYR98HIS,RS5030809"	FALSE
VHL Splice Site (c.463+1G>C)	1874	Renal Cell Carcinoma	4450	"Hemangioblastoma,Retinal capillary hemangioma,Renal cell carcinoma,Pancreatic cysts"			Predisposing	Supports	C	Uncertain Significance	"Of 65 VHL families from central Europe, 53 were identified with germline mutations. This splice mutation was found in a German, VHL type 1 patient with retinal angiomas, hemangioblastomas of the central nervous system, renal cell carcinoma, and pancreatic cysts (family VHL 45). This study contains very strong evidence of pathogenicity in the form of a canonical +1 splice site variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1)."	8707293	PubMed		"Glavac et al., 1996, Hum. Genet."		2	accepted	5373	Rare Germline	2023-01-09 21:46:54 UTC	https://civicdb.org/links/evidence_items/5373	https://civicdb.org/links/molecular_profiles/1874	FALSE	VHL	7428	Splice Site (c.463+1G>C)		chr3	10146637	10146637	G	C	ENST00000256474.2	75		splice_donor_variant	"NM_000551.3:c.463+1G>C,NC_000003.11:g.10188321G>C,ENST00000256474.2:c.463+1G>C"	2023-01-27 17:14:06 UTC	CA357023	223217	"C.463+1G>C,RS869025657"	FALSE
VHL V74G (c.221T>G)	1875	Von Hippel-Lindau Disease	14175	"Renal cell carcinoma,Pheochromocytoma,Pancreatic cysts,Retinal capillary hemangioma,Hemangioblastoma"			Predisposing	Supports	C	Uncertain Significance	"Of 65 VHL families from central Europe, 53 were identified with germline mutations. This missense mutation was found in 2 unrelated, German families. The VHL type 1 family of 4 affected individuals had 2 patients with retinal angiomas, 5 with hemangioblastomas of the central nervous system, and one with renal cell carcinoma (family VHL 53). The VHL type 2B family of 3 affected individuals had one patient with retinal angioma, 3 with hemangioblastomas of the central nervous system, one with pheochromocytoma, one with renal cell carcinoma, one with pancreatic cysts, and one with cystadenomas of the epididymis (family VHL 9). This study contains supporting evidence of pathogenicity due to cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1). HPO terms: papillary cystadenomas of the broad ligament"	8707293	PubMed		"Glavac et al., 1996, Hum. Genet."		2	accepted	5374	Rare Germline	2023-01-09 21:46:54 UTC	https://civicdb.org/links/evidence_items/5374	https://civicdb.org/links/molecular_profiles/1875	FALSE	VHL	7428	V74G (c.221T>G)		chr3	10142068	10142068	T	G	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.221T>G,NM_000551.3:c.221T>G,NP_000542.1:p.Val74Gly,NC_000003.11:g.10183752T>G"	2023-01-27 17:14:07 UTC	CA70042528	NONE FOUND	"C.221T>G,VAL74GLY,RS5030803"	FALSE
VHL R161* (c.481C>T)	1680	Renal Cell Carcinoma	4450	"Pancreatic cysts,Retinal capillary hemangioma,Hemangioblastoma,Renal cell carcinoma"			Predisposing	Supports	C	Uncertain Significance	"Of 65 VHL families from central Europe, 53 were identified with germline mutations. This nonsense mutation was found in 2 unrelated, German families. One VHL type 1 family of 2 affected individuals had one patient with retinal angiomas, 2 with hemangioblastomas of the central nervous system, one with renal cell carcinoma, one with pancreatic cysts, and  one with cystadenomas of the epididymis (family VHL 32). Another VHL type 1 family of 3 affected individuals had 3 patients with retinal angiomas, one with hemangioblastomas of the central nervous system, 2 with renal cell carcinoma, one with pancreatic cysts, and one with cystadenomas of the epididymis (family VHL 49). ACMG codes as follows: A nonsense mutation in a gene where loss-of-function is a known mechanism of disease (PVS1). Cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (PP1). HPO terms:  papillary cystadenomas of the broad ligament."	8707293	PubMed		"Glavac et al., 1996, Hum. Genet."		3	accepted	5375	Rare Germline	2023-01-09 21:46:50 UTC	https://civicdb.org/links/evidence_items/5375	https://civicdb.org/links/molecular_profiles/1680	FALSE	VHL	7428	R161* (c.481C>T)		chr3	10149804	10149804	C	T	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.481C>T,NP_000542.1:p.Arg161Ter,NC_000003.11:g.10191488C>T,ENST00000256474.2:c.481C>T"	2023-01-27 17:12:16 UTC	CA020408	2217	"C.481C>T,R161X,ARG161TER,RS5030818"	FALSE
VHL N78S (c.233A>G)	1631	Von Hippel-Lindau Disease	14175	Hemangioblastoma			Predisposing	Supports	C	Uncertain Significance	"Of 65 VHL families from central Europe, 53 were identified with germline mutations. This missense mutation was found in a German, VHL type 1 family of 6. Each patient had hemangioblastomas of the central nervous system and 4 had cystadenomas of the epididymis (family VHL 51). This study contains supporting evidence of pathogenicity due to cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1). HPO terms: papillary cystadenomas of the broad ligament."	8707293	PubMed		"Glavac et al., 1996, Hum. Genet."		2	accepted	5376	Rare Germline	2023-01-09 21:46:48 UTC	https://civicdb.org/links/evidence_items/5376	https://civicdb.org/links/molecular_profiles/1631	FALSE	VHL	7428	N78S (c.233A>G)		chr3	10142080	10142080	A	G	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.233A>G,NP_000542.1:p.Asn78Ser,NC_000003.11:g.10183764A>G,ENST00000256474.2:c.233A>G"	2023-01-27 17:11:40 UTC	CA020131	93326	"C.233A>G,ASN78SER,RS5030804"	FALSE
VHL H115R (c.344A>G)	1876	Von Hippel-Lindau Disease	14175	"Pancreatic cysts,Hemangioblastoma,Retinal capillary hemangioma,Renal cell carcinoma"			Predisposing	Supports	C	Uncertain Significance	"Of 65 VHL families from central Europe, 53 were identified with germline mutations. This missense mutation was found in a German, VHL type 1 family of 2. Both patients had hemangioblastomas of the central nervous system, renal cell carcinoma, pancreatic cysts, and cystadenomas of the epididymis (family VHL 60). One patient also had retinal angiomas. This study contains supporting evidence of pathogenicity due to cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1).  HPO terms:  papillary cystadenomas of the broad ligament."	8707293	PubMed		"Glavac et al., 1996, Hum. Genet."		2	accepted	5377	Rare Germline	2023-01-09 21:46:54 UTC	https://civicdb.org/links/evidence_items/5377	https://civicdb.org/links/molecular_profiles/1876	FALSE	VHL	7428	H115R (c.344A>G)		chr3	10146517	10146517	A	G	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.344A>G,NC_000003.11:g.10188201A>G,NM_000551.3:c.344A>G,NP_000542.1:p.His115Arg"	2023-01-27 17:14:07 UTC	CA70049376	664415	"C.344A>G,HIS115ARG,RS5030812"	FALSE
VHL R113* (c.337C>T)	1672	Von Hippel-Lindau Disease	14175	"Pheochromocytoma,Hemangioblastoma,Pancreatic cysts,Renal cell carcinoma"			Predisposing	Supports	C	Predisposition	"A previous study of 26 Japanese, VHL families was extended to 41 additional families. Germline mutations were detected in 55 of 77 Japanese families, using SSCP, direct sequencing, and Southern Blot analysis of peripheral blood samples. Renal cell carcinoma occurred predominantly in non-missense mutations predicted to lead to gross alteration or complete loss of the VHL protein. This stop-gain mutation, c.337C>T (stated as c.550C>T in the paper which used the Latif sequence as reference), was found in a VHL type 2 patient, who was previously diagnosed with VHL type 1. The patient had a hemangioblastoma of the central nervous system, pancreatic cysts, renal cell carcinoma, and pheochromocytoma (family ID 47). This study contains very strong evidence for pathogenicity in the form of a nonsense variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1)."	10761708	PubMed		"Yoshida et al., 2000, Jpn. J. Cancer Res."		3	accepted	5379	Rare Germline	2023-01-20 17:45:00 UTC	https://civicdb.org/links/evidence_items/5379	https://civicdb.org/links/molecular_profiles/1672	FALSE	VHL	7428	R113* (c.337C>T)		chr3	10142184	10142184	C	T	ENST00000256474.2	75		stop_gained	"NM_000551.3:c.337C>T,NP_000542.1:p.Arg113Ter,NC_000003.11:g.10183868C>T,ENST00000256474.2:c.337C>T"	2023-01-27 17:12:09 UTC	CA348491	220414	"C.337C>T,R113X,ARG113TER,RS5030810"	FALSE
VHL N131S (c.392A>G)	1877	Von Hippel-Lindau Disease	14175	"Retinal capillary hemangioma,Pheochromocytoma,Hemangioblastoma,Abnormality of the pancreas"			Predisposing	Supports	C	Predisposition	"A previous study of 26 Japanese, VHL families was extended to 41 additional families. Germline mutations were detected in 55 of 77 Japanese families using SSCP, direct sequencing, and Southern Blot analysis of peripheral blood samples. The N131S (c.392A>G) missense mutation was found in 1 VHL type 2 family with both family members having retinal angiomas and pheochromocytomas (family ID 87). 1/2 individuals had hemangioblastomas of the central nervous system and 1/2 had pancreatic cysts or tumor (unspecified)."	10761708	PubMed		"Yoshida et al., 2000, Jpn. J. Cancer Res."		3	accepted	5380	Rare Germline	2023-01-20 19:35:14 UTC	https://civicdb.org/links/evidence_items/5380	https://civicdb.org/links/molecular_profiles/1877	FALSE	VHL	7428	N131S (c.392A>G)		chr3	10146565	10146565	A	G	ENST00000256474.2	75		missense_variant	"NC_000003.11:g.10188249A>G,NC_000003.12:g.10146565A>G,NP_000542.1:p.Asn131Ser"	2023-01-27 17:14:08 UTC	CA351753941	496062		FALSE
VHL R167Q (c.500G>A)	1615	Von Hippel-Lindau Disease	14175	"Retinal capillary hemangioma,Pancreatic cysts,Pheochromocytoma,Hemangioblastoma"			Predisposing	Supports	C	Predisposition	"A previous study of 26 Japanese, VHL families was extended to 41 additional families. Germline mutations were detected in 55 of 77 Japanese families using SSCP, direct sequencing, and Southern Blot analysis of peripheral blood samples. This missense mutation, c.500G>A (reported as 713G>A in the paper which used the Latif sequence as reference) was found in 3 unrelated VHL families (Family ID 5, 77, 79). Family 5 was previously reported in paper 8634692. In family 5, there were two patients who both presented with hemangioblastoma and retinal capillary hemangioma but only one patient had renal cell carcinoma. In the VHL family of 3, one affected individual had hemangioblastomas of the central nervous system, one had retinal angiomas, two had pancreatic cysts, and one had pheochromocytoma (family ID 77). The unrelated, VHL type 2 patient had retinal angiomas and pheochromocytoma (family ID 79). ACMG codes as follows: Cosegregation with the disease in multiple affected family members in a gene definitively known to cause the disease (PP1). Patient's phenotype is highly specific for a disease with a single genetic etiology (PP4)."	10761708	PubMed		"Yoshida et al., 2000, Jpn. J. Cancer Res."		3	accepted	5381	Rare Germline	2023-01-20 17:50:46 UTC	https://civicdb.org/links/evidence_items/5381	https://civicdb.org/links/molecular_profiles/1615	FALSE	VHL	7428	R167Q (c.500G>A)		chr3	10149823	10149823	G	A	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.500G>A,NP_000542.1:p.Arg167Gln,NC_000003.11:g.10191507G>A,ENST00000256474.2:c.500G>A"	2023-01-27 17:11:29 UTC	CA020454	2216	"C.500G>A,ARG167GLN,RS5030821"	FALSE
VHL R167W (c.499C>T)	1623	Von Hippel-Lindau Disease	14175	"Hemangioblastoma,Renal cell carcinoma,Pheochromocytoma,Retinal capillary hemangioma"			Predisposing	Supports	C	Predisposition	"A previous study of 26 Japanese, VHL families was extended to 41 additional families. Germline mutations were detected in 55 of 77 Japanese families using SSCP, direct sequencing, and Southern Blot analysis of peripheral blood samples. This missense mutation was found in 4 unrelated VHL families. Family 19: 1 individual presenting with pheochromocytoma, renal cell carcinoma, CNS hemangioblastoma and retinal angioma. Family 31: pheochromocytoma (2/2), CNS hemangioblastoma (2/2) and renal cell carcinoma (1/2). Family 66: pheochromocytoma (1/2), CNS hemangioblastoma (1/2) and renal cell carcinoma (1/2). Family 102: pheochromocytoma (2/2), CNS hemangioblastoma (1/2) and retinal angioma (1/2). Patients from families 19 and 31 were previously published in PMID 8634692. ACMG codes as follows: Cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (PP1). Patient's phenotype is highly specific for a disease with a single genetic etiology (PP4)."	10761708	PubMed		"Yoshida et al., 2000, Jpn. J. Cancer Res."		3	accepted	5382	Rare Germline	2023-01-20 17:55:14 UTC	https://civicdb.org/links/evidence_items/5382	https://civicdb.org/links/molecular_profiles/1623	FALSE	VHL	7428	R167W (c.499C>T)		chr3	10149822	10149822	C	T	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.499C>T,NP_000542.1:p.Arg167Trp,NC_000003.11:g.10191506C>T,ENST00000256474.2:c.499C>T"	2023-01-27 17:11:35 UTC	CA020450	2218	"C.499C>T,ARG167TRP,R126W,RS5030820"	FALSE
VHL C162Y (c.485G>A)	1700	Von Hippel-Lindau Disease	14175	"Abnormality of the pancreas,Pheochromocytoma,Retinal capillary hemangioma,Hemangioblastoma"			Predisposing	Supports	C	Predisposition	"A previous study of 26 Japanese, VHL families was extended to 41 additional families. Germline mutations were detected in 55 of 77 Japanese families using SSCP, direct sequencing, and Southern Blot analysis of peripheral blood samples. The C162Y (c.485G>A) germline missense mutation of the VHL gene was found in a VHL patient with retinal angiomas, pancreatic cysts or tumor (unspecified), renal cell carcinoma, and pheochromocytoma (family ID 104). The variant was also found in a family of 4 individuals all presenting with CNS hemangioblastoma (family ID 11). This family was previously reported in PMID 8634692. This patient's phenotype is highly specific for a disease with a single genetic etiology (ACMG code: PP4)."	10761708	PubMed		"Yoshida et al., 2000, Jpn. J. Cancer Res."		3	accepted	5383	Rare Germline	2023-01-20 18:02:29 UTC	https://civicdb.org/links/evidence_items/5383	https://civicdb.org/links/molecular_profiles/1700	FALSE	VHL	7428	C162Y (c.485G>A)		chr3	10149808	10149808	G	A	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.485G>A,NP_000542.1:p.Cys162Tyr,NC_000003.11:g.10191492G>A,ENST00000256474.2:c.485G>A"	2023-01-27 17:12:31 UTC	CA357010	223225	"C.485G>A,CYS162TYR,RS397516444"	FALSE
VHL F76del (c.224_226delTCT)	1964	Von Hippel-Lindau Disease	14175	"Pancreatic cysts,Hemangioblastoma,Renal cell carcinoma"			Predisposing	Supports	C	Predisposition	"A previous study of 26 Japanese, VHL families was extended to 41 additional families. Germline mutations were detected in 55 of 77 Japanese families. Renal cell carcinoma occurred predominantly in non-missense mutations predicted to lead to gross alteration or complete loss of the VHL protein. This mutation was found in a VHL type 1 patient with hemangioblastomas of the central nervous system, pancreatic cyst or tumor, and renal cell carcinoma (family ID 80)."	10761708	PubMed		"Yoshida et al., 2000, Jpn. J. Cancer Res."		3	accepted	5386	Rare Germline	2023-02-03 15:29:57 UTC	https://civicdb.org/links/evidence_items/5386	https://civicdb.org/links/molecular_profiles/1964	FALSE	VHL	7428	F76del (c.224_226delTCT)		chr3	10142071	10142073	TCT		ENST00000256474.2	75		inframe_deletion	"NP_000542.1:p.Phe76del,ENST00000256474.2:c.224_226delTCT,NC_000003.11:g.10183758_10183760del,NC_000003.12:g.10142074_10142076del,NM_000551.3:c.227_229del,ENSP00000256474.2:p.Phe76del"	2023-01-27 17:15:01 UTC	CA357012	223166	"PHE76DEL,C.224_226DELTCT,C.226_228DELTTC,C.227_229DELTCT,DELPHE76"	FALSE
VHL R107G  (c.319C>G)	1883	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	"Peripheral blood from unrelated patients with pheochromocytoma was tested for mutations of proto-oncogene RET, tumor suppressor gene VHL, succinate dehydrogenase subunit D (SDHD) gene, and the succinate dehydrogenase subunit B (SDHB) gene. Of 271 patients with nonsydromic pheochromocytoma and no family history of the disease, 30 mutations were found in VHL. Multiple pheochromocytomas were statistically more frequent among patients with mutations than among patients without mutations (21 of 66 vs. 5 of 205, P<0.001). This missense mutation was found in the VHL gene and one patient with pheochromocytoma."	12000816	PubMed		"Neumann et al., 2002, N. Engl. J. Med."		3	accepted	5399	Rare Germline	2023-01-09 21:46:54 UTC	https://civicdb.org/links/evidence_items/5399	https://civicdb.org/links/molecular_profiles/1883	FALSE	VHL	7428	R107G  (c.319C>G)		chr3	10142166	10142166	C	G	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.319C>G,NP_000542.1:p.Arg107Gly,NC_000003.11:g.10183850C>G,ENST00000256474.2:c.319C>G"	2023-01-27 17:14:13 UTC	CA020257	43599	"C.319C>G,ARG107GLY,RS397516440"	FALSE
VHL R161Q (c.482G>A)	1622	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	"Peripheral blood from unrelated patients with pheochromocytoma was tested for mutations of proto-oncogene RET, tumor suppressor gene VHL, succinate dehydrogenase subunit D (SDHD) gene, and the succinate dehydrogenase subunit B (SDHB) gene. Of 271 patients with nonsydromic pheochromocytoma and no family history of the disease, 30 mutations were found in VHL. Multiple pheochromocytomas were statistically more frequent among patients with mutations than among patients without mutations (21 of 66 vs. 5 of 205, P<0.001). This missense mutation was found in the VHL gene and two patients with pheochromocytoma."	12000816	PubMed		"Neumann et al., 2002, N. Engl. J. Med."		3	accepted	5400	Rare Germline	2023-01-09 21:46:48 UTC	https://civicdb.org/links/evidence_items/5400	https://civicdb.org/links/molecular_profiles/1622	FALSE	VHL	7428	R161Q (c.482G>A)		chr3	10149805	10149805	G	A	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.482G>A,NP_000542.1:p.Arg161Gln,NC_000003.11:g.10191489G>A,ENST00000256474.2:c.482G>A"	2023-01-27 17:11:34 UTC	CA020413	182983	"C.482G>A,ARG161GLN,RS730882035"	FALSE
VHL R161P (c.482G>C)	1731	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	"Peripheral blood from unrelated patients with pheochromocytoma was tested for mutations of proto-oncogene RET, tumor suppressor gene VHL, succinate dehydrogenase subunit D (SDHD) gene, and the succinate dehydrogenase subunit B (SDHB) gene. Of 271 patients with nonsydromic pheochromocytoma and no family history of the disease, 30 mutations were found in VHL. Multiple pheochromocytomas were statistically more frequent among patients with mutations than among patients without mutations (21 of 66 vs. 5 of 205, P<0.001). This missense mutation was found in the VHL gene and one patient with pheochromocytoma."	12000816	PubMed		"Neumann et al., 2002, N. Engl. J. Med."		3	accepted	5401	Rare Germline	2023-01-09 21:46:51 UTC	https://civicdb.org/links/evidence_items/5401	https://civicdb.org/links/molecular_profiles/1731	FALSE	VHL	7428	R161P (c.482G>C)		chr3	10149805	10149805	G	C	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.482G>C,NC_000003.11:g.10191489G>C,NM_000551.3:c.482G>C,NP_000542.1:p.Arg161Pro"	2023-01-27 17:12:50 UTC	CA351756111	NONE FOUND	"C.482G>C,ARG161PRO"	FALSE
VHL R167Q (c.500G>A)	1615	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	"Peripheral blood from unrelated patients with pheochromocytoma was tested for mutations of proto-oncogene RET, tumor suppressor gene VHL, succinate dehydrogenase subunit D (SDHD) gene, and the succinate dehydrogenase subunit B (SDHB) gene. Of 271 patients with nonsydromic pheochromocytoma and no family history of the disease, 30 mutations were found in VHL. Multiple pheochromocytomas were statistically more frequent among patients with mutations than among patients without mutations (21 of 66 vs. 5 of 205, P<0.001). This missense mutation was found in the VHL gene and one patient with pheochromocytoma."	12000816	PubMed		"Neumann et al., 2002, N. Engl. J. Med."		3	accepted	5402	Rare Germline	2023-01-09 21:46:47 UTC	https://civicdb.org/links/evidence_items/5402	https://civicdb.org/links/molecular_profiles/1615	FALSE	VHL	7428	R167Q (c.500G>A)		chr3	10149823	10149823	G	A	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.500G>A,NP_000542.1:p.Arg167Gln,NC_000003.11:g.10191507G>A,ENST00000256474.2:c.500G>A"	2023-01-27 17:11:29 UTC	CA020454	2216	"C.500G>A,ARG167GLN,RS5030821"	FALSE
VHL Q164* (c.490C>T)	1721	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	"Peripheral blood from unrelated patients with pheochromocytoma was tested for mutations of proto-oncogene RET, tumor suppressor gene VHL, succinate dehydrogenase subunit D (SDHD) gene, and the succinate dehydrogenase subunit B (SDHB) gene. Of 271 patients with nonsydromic pheochromocytoma and no family history of the disease, 30 mutations were found in VHL. Multiple pheochromocytomas were statistically more frequent among patients with mutations than among patients without mutations (21 of 66 vs. 5 of 205, P<0.001). This nonsense mutation was found in the VHL gene and one patient with pheochromocytoma. This study contains very strong evidence of pathogenicity in the form of a nonsense variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1)."	12000816	PubMed		"Neumann et al., 2002, N. Engl. J. Med."		3	accepted	5403	Rare Germline	2023-01-09 21:46:51 UTC	https://civicdb.org/links/evidence_items/5403	https://civicdb.org/links/molecular_profiles/1721	FALSE	VHL	7428	Q164* (c.490C>T)		chr3	10149813	10149813	C	T	ENST00000256474.2	75		stop_gained	"NM_000551.3:c.490C>T,NP_000542.1:p.Gln164Ter,NC_000003.11:g.10191497C>T,ENST00000256474.2:c.490C>T"	2023-01-27 17:12:43 UTC	CA357060	223228	"C.490C>T,Q164X,GLN164TER,RS5030819"	FALSE
VHL Q195* (c.583C>T)	1686	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	"Peripheral blood from unrelated patients with pheochromocytoma was tested for mutations of proto-oncogene RET, tumor suppressor gene VHL, succinate dehydrogenase subunit D (SDHD) gene, and the succinate dehydrogenase subunit B (SDHB) gene. Of 271 patients with nonsydromic pheochromocytoma and no family history of the disease, 30 mutations were found in VHL. Multiple pheochromocytomas were statistically more frequent among patients with mutations than among patients without mutations (21 of 66 vs. 5 of 205, P<0.001). This nonsense mutation was found in the VHL gene and one patient with pheochromocytoma. This study contains very strong evidence of pathogenicity in the form of a nonsense variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1)."	12000816	PubMed		"Neumann et al., 2002, N. Engl. J. Med."		3	accepted	5404	Rare Germline	2023-01-09 21:46:50 UTC	https://civicdb.org/links/evidence_items/5404	https://civicdb.org/links/molecular_profiles/1686	FALSE	VHL	7428	Q195* (c.583C>T)		chr3	10149906	10149906	C	T	ENST00000256474.2	75		stop_gained	"NM_000551.3:c.583C>T,NP_000542.1:p.Gln195Ter,NC_000003.11:g.10191590C>T,ENST00000256474.2:c.583C>T"	2023-01-27 17:12:20 UTC	CA70052558	428794	"C.583C>T,Q195X,GLN195TER,RS5030825"	FALSE
VHL E94* (c.280G>T)	1670	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	"Peripheral blood from unrelated patients with pheochromocytoma was tested for mutations of proto-oncogene RET, tumor suppressor gene VHL, succinate dehydrogenase subunit D (SDHD) gene, and the succinate dehydrogenase subunit B (SDHB) gene. Of 271 patients with nonsydromic pheochromocytoma and no family history of the disease, 30 mutations were found in VHL. Multiple pheochromocytomas were statistically more frequent among patients with mutations than among patients without mutations (21 of 66 vs. 5 of 205, P<0.001). This nonsense mutation was found in the VHL gene and one patient with pheochromocytoma. This study contains very strong evidence of pathogenicity in the form of a nonsense variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1)."	12000816	PubMed		"Neumann et al., 2002, N. Engl. J. Med."		3	accepted	5405	Rare Germline	2023-01-09 21:46:49 UTC	https://civicdb.org/links/evidence_items/5405	https://civicdb.org/links/molecular_profiles/1670	FALSE	VHL	7428	E94* (c.280G>T)		chr3	10142127	10142127	G	T	ENST00000256474.2	75		stop_gained	"ENST00000256474.2:c.280G>T,NM_198156.2:c.280G>T,NP_000542.1:p.Glu94Ter,NC_000003.11:g.10183811G>T"	2023-01-27 17:12:08 UTC	CA70046202	584477	"C.280G>T,E94X,GLU94TER,RS5030829"	FALSE
VHL G93C (c.277G>T)	1884	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	"Peripheral blood from unrelated patients with pheochromocytoma was tested for mutations of proto-oncogene RET, tumor suppressor gene VHL, succinate dehydrogenase subunit D (SDHD) gene, and the succinate dehydrogenase subunit B (SDHB) gene. Of 271 patients with nonsydromic pheochromocytoma and no family history of the disease, 30 mutations were found in VHL. Multiple pheochromocytomas were statistically more frequent among patients with mutations than among patients without mutations (21 of 66 vs. 5 of 205, P<0.001). This missense mutation was found in the VHL gene and one patient with pheochromocytoma."	12000816	PubMed		"Neumann et al., 2002, N. Engl. J. Med."		3	accepted	5406	Rare Germline	2023-01-09 21:46:54 UTC	https://civicdb.org/links/evidence_items/5406	https://civicdb.org/links/molecular_profiles/1884	FALSE	VHL	7428	G93C (c.277G>T)		chr3	10142124	10142124	G	T	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.277G>T,NM_000551.3:c.277G>T,NP_000542.1:p.Gly93Cys,NC_000003.11:g.10183808G>T"	2023-01-27 17:14:14 UTC	CA357106	223175	"C.277G>T,GLY93CYS,RS5030808"	FALSE
VHL G93S (c.277G>A)	1735	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	"Peripheral blood from unrelated patients with pheochromocytoma was tested for mutations of proto-oncogene RET, tumor suppressor gene VHL, succinate dehydrogenase subunit D (SDHD) gene, and the succinate dehydrogenase subunit B (SDHB) gene. Of 271 patients with nonsydromic pheochromocytoma and no family history of the disease, 30 mutations were found in VHL. Multiple pheochromocytomas were statistically more frequent among patients with mutations than among patients without mutations (21 of 66 vs. 5 of 205, P<0.001). This missense mutation was found in the VHL gene and two patients with pheochromocytoma."	12000816	PubMed		"Neumann et al., 2002, N. Engl. J. Med."		3	accepted	5407	Rare Germline	2023-01-09 21:46:51 UTC	https://civicdb.org/links/evidence_items/5407	https://civicdb.org/links/molecular_profiles/1735	FALSE	VHL	7428	G93S (c.277G>A)		chr3	10142124	10142124	G	A	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.277G>A,NP_000542.1:p.Gly93Ser,NC_000003.11:g.10183808G>A,ENST00000256474.2:c.277G>A"	2023-01-27 17:12:54 UTC	CA020230	2237	"C.277G>A,GLY93SER,RS5030808"	FALSE
VHL G93V (c.278G>T)	1885	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	"Peripheral blood from unrelated patients with pheochromocytoma was tested for mutations of proto-oncogene RET, tumor suppressor gene VHL, succinate dehydrogenase subunit D (SDHD) gene, and the succinate dehydrogenase subunit B (SDHB) gene. Of 271 patients with nonsydromic pheochromocytoma and no family history of the disease, 30 mutations were found in VHL. Multiple pheochromocytomas were statistically more frequent among patients with mutations than among patients without mutations (21 of 66 vs. 5 of 205, P<0.001). This missense mutation was found in the VHL gene and one patient with pheochromocytoma."	12000816	PubMed		"Neumann et al., 2002, N. Engl. J. Med."		3	accepted	5408	Rare Germline	2023-01-09 21:46:54 UTC	https://civicdb.org/links/evidence_items/5408	https://civicdb.org/links/molecular_profiles/1885	FALSE	VHL	7428	G93V (c.278G>T)		chr3	10142125	10142125	G	T	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.278G>T,NC_000003.11:g.10183809G>T,NM_000551.3:c.278G>T,NP_000542.1:p.Gly93Val"	2023-01-27 17:14:15 UTC	CA351750779	625232	"C.278G>T,GLY93VAL"	FALSE
VHL L188V (c.562C>G)	1712	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	"Peripheral blood from unrelated patients with pheochromocytoma was tested for mutations of proto-oncogene RET, tumor suppressor gene VHL, succinate dehydrogenase subunit D (SDHD) gene, and the succinate dehydrogenase subunit B (SDHB) gene. Of 271 patients with nonsydromic pheochromocytoma and no family history of the disease, 30 mutations were found in VHL. Multiple pheochromocytomas were statistically more frequent among patients with mutations than among patients without mutations (21 of 66 vs. 5 of 205, P<0.001). This missense mutation was found in the VHL gene and one patient with pheochromocytoma."	12000816	PubMed		"Neumann et al., 2002, N. Engl. J. Med."		3	accepted	5409	Rare Germline	2023-01-09 21:46:51 UTC	https://civicdb.org/links/evidence_items/5409	https://civicdb.org/links/molecular_profiles/1712	FALSE	VHL	7428	L188V (c.562C>G)		chr3	10149885	10149885	C	G	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.562C>G,NP_000542.1:p.Leu188Val,NC_000003.11:g.10191569C>G,ENST00000256474.2:c.562C>G"	2023-01-27 17:12:38 UTC	CA020488	2225	"C.562C>G,LEU188VAL,RS5030824"	FALSE
VHL L198Q  (c.593T>A)	1886	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	"Peripheral blood from unrelated patients with pheochromocytoma was tested for mutations of proto-oncogene RET, tumor suppressor gene VHL, succinate dehydrogenase subunit D (SDHD) gene, and the succinate dehydrogenase subunit B (SDHB) gene. Of 271 patients with nonsydromic pheochromocytoma and no family history of the disease, 30 mutations were found in VHL. Multiple pheochromocytomas were statistically more frequent among patients with mutations than among patients without mutations (21 of 66 vs. 5 of 205, P<0.001). This missense mutation was found in the VHL gene and one patient with pheochromocytoma."	12000816	PubMed		"Neumann et al., 2002, N. Engl. J. Med."		3	accepted	5410	Rare Germline	2023-01-09 21:46:54 UTC	https://civicdb.org/links/evidence_items/5410	https://civicdb.org/links/molecular_profiles/1886	FALSE	VHL	7428	L198Q  (c.593T>A)		chr3	10149916	10149916	T	A	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.593T>A,NC_000003.11:g.10191600T>A,NM_000551.3:c.593T>A,NP_000542.1:p.Leu198Gln"	2023-01-27 17:14:15 UTC	CA351756548	NONE FOUND	"C.593T>A,LEU198GLN"	FALSE
VHL F119L (c.357C>G)	1619	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	"Peripheral blood from unrelated patients with pheochromocytoma was tested for mutations of proto-oncogene RET, tumor suppressor gene VHL, succinate dehydrogenase subunit D (SDHD) gene, and the succinate dehydrogenase subunit B (SDHB) gene. Of 271 patients with nonsydromic pheochromocytoma and no family history of the disease, 30 mutations were found in VHL. Multiple pheochromocytomas were statistically more frequent among patients with mutations than among patients without mutations (21 of 66 vs. 5 of 205, P<0.001). This missense mutation was found in the VHL gene and one patient with pheochromocytoma."	12000816	PubMed		"Neumann et al., 2002, N. Engl. J. Med."		3	accepted	5411	Rare Germline	2023-01-09 21:46:48 UTC	https://civicdb.org/links/evidence_items/5411	https://civicdb.org/links/molecular_profiles/1619	FALSE	VHL	7428	F119L (c.357C>G)		chr3	10146530	10146530	C	G	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.357C>G,NC_000003.11:g.10188214C>G,NM_000551.3:c.357C>G,NP_000542.1:p.Phe119Leu"	2023-01-27 17:11:32 UTC	CA351753726	625240	"C.357C>G,PHE119LEU,RS1559428077"	FALSE
VHL F136C (c.407T>G)	1690	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	"Peripheral blood from unrelated patients with pheochromocytoma was tested for mutations of proto-oncogene RET, tumor suppressor gene VHL, succinate dehydrogenase subunit D (SDHD) gene, and the succinate dehydrogenase subunit B (SDHB) gene. Of 271 patients with nonsydromic pheochromocytoma and no family history of the disease, 30 mutations were found in VHL. Multiple pheochromocytomas were statistically more frequent among patients with mutations than among patients without mutations (21 of 66 vs. 5 of 205, P<0.001). This missense mutation was found in the VHL gene and one patient with pheochromocytoma."	12000816	PubMed		"Neumann et al., 2002, N. Engl. J. Med."		3	accepted	5412	Rare Germline	2023-01-09 21:46:50 UTC	https://civicdb.org/links/evidence_items/5412	https://civicdb.org/links/molecular_profiles/1690	FALSE	VHL	7428	F136C (c.407T>G)		chr3	10146580	10146580	T	G	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.407T>G,NC_000003.11:g.10188264T>G,NM_000551.3:c.407T>G,NP_000542.1:p.Phe136Cys"	2023-01-27 17:12:24 UTC	CA70049495	496065	"C.407T>G,PHE136CYS,RS5030833"	FALSE
VHL S65A (c.193T>G)	1887	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	"Peripheral blood from unrelated patients with pheochromocytoma was tested for mutations of proto-oncogene RET, tumor suppressor gene VHL, succinate dehydrogenase subunit D (SDHD) gene, and the succinate dehydrogenase subunit B (SDHB) gene. Of 271 patients with nonsydromic pheochromocytoma and no family history of the disease, 30 mutations were found in VHL. Multiple pheochromocytomas were statistically more frequent among patients with mutations than among patients without mutations (21 of 66 vs. 5 of 205, P<0.001). This missense mutation was found in the VHL gene and one patient with pheochromocytoma."	12000816	PubMed		"Neumann et al., 2002, N. Engl. J. Med."		3	accepted	5413	Rare Germline	2023-01-09 21:46:54 UTC	https://civicdb.org/links/evidence_items/5413	https://civicdb.org/links/molecular_profiles/1887	FALSE	VHL	7428	S65A (c.193T>G)		chr3	10142040	10142040	T	G	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.193T>G,NP_000542.1:p.Ser65Ala,NC_000003.11:g.10183724T>G,ENST00000256474.2:c.193T>G"	2023-01-27 17:14:16 UTC	CA357048	223160	"C.193T>G,SER65ALA,RS869025616"	FALSE
VHL S68W (c.203C>G)	1888	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	"Peripheral blood from unrelated patients with pheochromocytoma was tested for mutations of proto-oncogene RET, tumor suppressor gene VHL, succinate dehydrogenase subunit D (SDHD) gene, and the succinate dehydrogenase subunit B (SDHB) gene. Of 271 patients with nonsydromic pheochromocytoma and no family history of the disease, 30 mutations were found in VHL. Multiple pheochromocytomas were statistically more frequent among patients with mutations than among patients without mutations (21 of 66 vs. 5 of 205, P<0.001). This missense mutation was found in the VHL gene and one patient with pheochromocytoma."	12000816	PubMed		"Neumann et al., 2002, N. Engl. J. Med."		3	accepted	5414	Rare Germline	2023-01-09 21:46:54 UTC	https://civicdb.org/links/evidence_items/5414	https://civicdb.org/links/molecular_profiles/1888	FALSE	VHL	7428	S68W (c.203C>G)		chr3	10142050	10142050	C	G	ENST00000256474.2			missense_variant	"NP_000542.1:p.Ser68Trp,NC_000003.11:g.10183734C>G,NC_000003.12:g.10142050C>G,NM_000551.3:c.203C>G"	2023-01-27 17:14:17 UTC	CA351748895	NONE FOUND		FALSE
VHL S80N (c.239G>A)	1750	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	"Peripheral blood from unrelated patients with pheochromocytoma was tested for mutations of proto-oncogene RET, tumor suppressor gene VHL, succinate dehydrogenase subunit D (SDHD) gene, and the succinate dehydrogenase subunit B (SDHB) gene. Of 271 patients with nonsydromic pheochromocytoma and no family history of the disease, 30 mutations were found in VHL. Multiple pheochromocytomas were statistically more frequent among patients with mutations than among patients without mutations (21 of 66 vs. 5 of 205, P<0.001). This missense mutation was found in the VHL gene and one patient with pheochromocytoma."	12000816	PubMed		"Neumann et al., 2002, N. Engl. J. Med."		3	accepted	5415	Rare Germline	2023-01-09 21:46:51 UTC	https://civicdb.org/links/evidence_items/5415	https://civicdb.org/links/molecular_profiles/1750	FALSE	VHL	7428	S80N (c.239G>A)		chr3	10142086	10142086	G	A	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.239G>A,NC_000003.11:g.10183770G>A,NM_000551.3:c.239G>A,NP_000542.1:p.Ser80Asn"	2023-01-27 17:13:01 UTC	CA70046108	NONE FOUND	"C.239G>A,SER80ASN,RS5030805"	FALSE
VHL Y156N (c.466T>A)	1889	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	"Peripheral blood from unrelated patients with pheochromocytoma was tested for mutations of proto-oncogene RET, tumor suppressor gene VHL, succinate dehydrogenase subunit D (SDHD) gene, and the succinate dehydrogenase subunit B (SDHB) gene. Of 271 patients with nonsydromic pheochromocytoma and no family history of the disease, 30 mutations were found in VHL. Multiple pheochromocytomas were statistically more frequent among patients with mutations than among patients without mutations (21 of 66 vs. 5 of 205, P<0.001). This missense mutation was found in the VHL gene and one patient with pheochromocytoma."	12000816	PubMed		"Neumann et al., 2002, N. Engl. J. Med."		3	accepted	5416	Rare Germline	2023-01-09 21:46:54 UTC	https://civicdb.org/links/evidence_items/5416	https://civicdb.org/links/molecular_profiles/1889	FALSE	VHL	7428	Y156N (c.466T>A)		chr3	10149789	10149789	T	A	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.466T>A,NC_000003.11:g.10191473T>A,NM_000551.3:c.466T>A,NP_000542.1:p.Tyr156Asn"	2023-01-27 17:14:18 UTC	CA351756038	NONE FOUND	"C.466T>A,TYR156ASN"	FALSE
VHL Y156C (c.467A>G)	1822	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	"Peripheral blood from unrelated patients with pheochromocytoma was tested for mutations of proto-oncogene RET, tumor suppressor gene VHL, succinate dehydrogenase subunit D (SDHD) gene, and the succinate dehydrogenase subunit B (SDHB) gene. Of 271 patients with nonsydromic pheochromocytoma and no family history of the disease, 30 mutations were found in VHL. Multiple pheochromocytomas were statistically more frequent among patients with mutations than among patients without mutations (21 of 66 vs. 5 of 205, P<0.001). This missense mutation was found in the VHL gene and two patients with pheochromocytoma."	12000816	PubMed		"Neumann et al., 2002, N. Engl. J. Med."		3	accepted	5417	Rare Germline	2023-01-09 21:46:53 UTC	https://civicdb.org/links/evidence_items/5417	https://civicdb.org/links/molecular_profiles/1822	FALSE	VHL	7428	Y156C (c.467A>G)		chr3	10149790	10149790	A	G	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.467A>G,NP_000542.1:p.Tyr156Cys,NC_000003.11:g.10191474A>G,ENST00000256474.2:c.467A>G"	2023-01-27 17:13:44 UTC	CA020394	43600	"C.467A>G,TYR156CYS,RS397516441"	FALSE
VHL Y98H (c.292T>C)	1617	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	"Peripheral blood from unrelated patients with pheochromocytoma was tested for mutations of proto-oncogene RET, tumor suppressor gene VHL, succinate dehydrogenase subunit D (SDHD) gene, and the succinate dehydrogenase subunit B (SDHB) gene. Of 271 patients with nonsydromic pheochromocytoma and no family history of the disease, 30 mutations were found in VHL. Multiple pheochromocytomas were statistically more frequent among patients with mutations than among patients without mutations (21 of 66 vs. 5 of 205, P<0.001). This missense mutation was found in the VHL gene and one patient with pheochromocytoma."	12000816	PubMed		"Neumann et al., 2002, N. Engl. J. Med."		3	accepted	5418	Rare Germline	2023-01-09 21:46:48 UTC	https://civicdb.org/links/evidence_items/5418	https://civicdb.org/links/molecular_profiles/1617	FALSE	VHL	7428	Y98H (c.292T>C)		chr3	10142139	10142139	T	C	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.292T>C,NP_000542.1:p.Tyr98His,NC_000003.11:g.10183823T>C,ENST00000256474.2:c.292T>C"	2023-01-27 17:11:30 UTC	CA020246	2223	"C.292T>C,TYR98HIS,RS5030809"	FALSE
VHL S65* (c.194C>A)	1687	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	43 unrelated VHL patients with previously sequenced VHL germline mutations and 36 suspected VHL mutation carriers were subject to denaturing high performance liquid chromatography (DHPLC) mutation screening. This nonsense mutation was found in a previously diagnosed VHL patient by DHPLC (family VHL 83). This study contains very strong evidence of pathogenicity in the form of a nonsense variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).	11409863	PubMed		"Klein et al., 2001, Hum. Genet."		3	accepted	5422	Rare Germline	2023-01-09 21:46:50 UTC	https://civicdb.org/links/evidence_items/5422	https://civicdb.org/links/molecular_profiles/1687	FALSE	VHL	7428	S65* (c.194C>A)		chr3	10142041	10142041	C	A	ENST00000256474.2	75		stop_gained	"NM_000551.3:c.194C>A,NP_000542.1:p.Ser65Ter,NC_000003.11:g.10183725C>A,ENST00000256474.2:c.194C>A"	2023-01-27 17:12:21 UTC	CA357085	223161	"C.194C>A,S65X,SER65TER,RS5030826"	FALSE
VHL V74G (c.221T>G)	1875	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	43 unrelated VHL patients with previously sequenced VHL germline mutations and 36 suspected VHL mutation carriers were subject to denaturing high performance liquid chromatography (DHPLC) mutation screening. This missense mutation was found in a previously diagnosed VHL patient by DHPLC (family VHL 92). This was the same missense mutation as was described in the previously published Glava et al. (1996) study included in this study (VHL 9 and 53).	11409863	PubMed		"Klein et al., 2001, Hum. Genet."		2	accepted	5424	Rare Germline	2023-01-09 21:46:54 UTC	https://civicdb.org/links/evidence_items/5424	https://civicdb.org/links/molecular_profiles/1875	FALSE	VHL	7428	V74G (c.221T>G)		chr3	10142068	10142068	T	G	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.221T>G,NM_000551.3:c.221T>G,NP_000542.1:p.Val74Gly,NC_000003.11:g.10183752T>G"	2023-01-27 17:14:07 UTC	CA70042528	NONE FOUND	"C.221T>G,VAL74GLY,RS5030803"	FALSE
VHL F76del (c.224_226delTCT)	1964	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	"43 unrelated VHL patients with previously sequenced VHL germline mutations and 36 suspected VHL mutation carriers were subject to denaturing high performance liquid chromatography (DHPLC) mutation screening. This mutation was found in 2  previously diagnosed VHL patients and a suspect VHL mutation carrier by DHPLC (family VHL 26, VHL 63, VHL 77). This variant results in an in frame deletion providing moderate evidence for pathogenicity (PM4)."	11409863	PubMed		"Klein et al., 2001, Hum. Genet."		2	accepted	5426	Rare Germline	2023-01-09 21:46:55 UTC	https://civicdb.org/links/evidence_items/5426	https://civicdb.org/links/molecular_profiles/1964	FALSE	VHL	7428	F76del (c.224_226delTCT)		chr3	10142071	10142073	TCT		ENST00000256474.2	75		inframe_deletion	"NP_000542.1:p.Phe76del,ENST00000256474.2:c.224_226delTCT,NC_000003.11:g.10183758_10183760del,NC_000003.12:g.10142074_10142076del,NM_000551.3:c.227_229del,ENSP00000256474.2:p.Phe76del"	2023-01-27 17:15:01 UTC	CA357012	223166	"PHE76DEL,C.224_226DELTCT,C.226_228DELTTC,C.227_229DELTCT,DELPHE76"	FALSE
VHL S80N (c.239G>A)	1750	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	43 unrelated VHL patients with previously sequenced VHL germline mutations and 36 suspected VHL mutation carriers were subject to denaturing high performance liquid chromatography (DHPLC) mutation screening. This missense mutation was found in a previously diagnosed VHL patient by DHPLC (family VHL 82).	11409863	PubMed		"Klein et al., 2001, Hum. Genet."		2	accepted	5427	Rare Germline	2023-01-09 21:46:51 UTC	https://civicdb.org/links/evidence_items/5427	https://civicdb.org/links/molecular_profiles/1750	FALSE	VHL	7428	S80N (c.239G>A)		chr3	10142086	10142086	G	A	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.239G>A,NC_000003.11:g.10183770G>A,NM_000551.3:c.239G>A,NP_000542.1:p.Ser80Asn"	2023-01-27 17:13:01 UTC	CA70046108	NONE FOUND	"C.239G>A,SER80ASN,RS5030805"	FALSE
VHL S80I (c.239G>T)	1633	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	43 unrelated VHL patients with previously sequenced VHL germline mutations and 36 suspected VHL mutation carriers were subject to denaturing high performance liquid chromatography (DHPLC) mutation screening. This missense mutation was found in a previously diagnosed VHL patient by DHPLC (family VHL 104).	11409863	PubMed		"Klein et al., 2001, Hum. Genet."		2	accepted	5428	Rare Germline	2023-01-09 21:46:49 UTC	https://civicdb.org/links/evidence_items/5428	https://civicdb.org/links/molecular_profiles/1633	FALSE	VHL	7428	S80I (c.239G>T)		chr3	10142086	10142086	G	T	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.239G>T,NM_000551.3:c.239G>T,NP_000542.1:p.Ser80Ile,NC_000003.11:g.10183770G>T"	2023-01-27 17:11:42 UTC	CA16621914	NONE FOUND	"C.239G>T,SER80ILE,RS5030805"	FALSE
VHL V84L (c.250G>T)	1691	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	43 unrelated VHL patients with previously sequenced VHL germline mutations and 36 suspected VHL mutation carriers were subject to denaturing high performance liquid chromatography (DHPLC) mutation screening. This nonsense mutation was found in a suspect VHL mutation carrier by DHPLC (family VHL 110).	11409863	PubMed		"Klein et al., 2001, Hum. Genet."		2	accepted	5430	Rare Germline	2023-01-09 21:46:50 UTC	https://civicdb.org/links/evidence_items/5430	https://civicdb.org/links/molecular_profiles/1691	FALSE	VHL	7428	V84L (c.250G>T)		chr3	10142097	10142097	G	T	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.250G>T,NP_000542.1:p.Val84Leu,NC_000003.11:g.10183781G>T,ENST00000256474.2:c.250G>T"	2023-01-27 17:12:24 UTC	CA020170	2236	"C.250G>T,VAL84LEU,RS5030827"	FALSE
VHL L85P (c.254T>C)	1896	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	43 unrelated VHL patients with previously sequenced VHL germline mutations and 36 suspected VHL mutation carriers were subject to denaturing high performance liquid chromatography (DHPLC) mutation screening. This missense mutation was found in a previously diagnosed VHL patient by DHPLC (family VHL 66).	11409863	PubMed		"Klein et al., 2001, Hum. Genet."		2	accepted	5431	Rare Germline	2023-01-09 21:46:54 UTC	https://civicdb.org/links/evidence_items/5431	https://civicdb.org/links/molecular_profiles/1896	FALSE	VHL	7428	L85P (c.254T>C)		chr3	10142101	10142101	T	C	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.254T>C,NP_000542.1:p.Leu85Pro,NC_000003.11:g.10183785T>C,ENST00000256474.2:c.254T>C"	2023-01-27 17:14:21 UTC	CA16602675	376222	"C.254T>C,LEU85PRO,RS5030828"	FALSE
VHL G93R (c.277G>C)	1796	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	43 unrelated VHL patients with previously sequenced VHL germline mutations and 36 suspected VHL mutation carriers were subject to denaturing high performance liquid chromatography (DHPLC) mutation screening. This missense mutation was found in a suspected VHL mutation carrier by DHPLC (family VHL 106).	11409863	PubMed		"Klein et al., 2001, Hum. Genet."		2	accepted	5432	Rare Germline	2023-01-09 21:46:52 UTC	https://civicdb.org/links/evidence_items/5432	https://civicdb.org/links/molecular_profiles/1796	FALSE	VHL	7428	G93R (c.277G>C)		chr3	10142124	10142124	G	C	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.277G>C,NP_000542.1:p.Gly93Arg,NC_000003.11:g.10183808G>C,ENST00000256474.2:c.277G>C"	2023-01-27 17:13:28 UTC	CA357130	223174	"C.277G>C,GLY93ARG,RS5030808"	FALSE
VHL E94* (c.280G>T)	1670	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	43 unrelated VHL patients with previously sequenced VHL germline mutations and 36 suspected VHL mutation carriers were subject to denaturing high performance liquid chromatography (DHPLC) mutation screening. This nonsense mutation was found in a previously diagnosed VHL patient by DHPLC (family VHL 85). This study contains very strong evidence of pathogenicity in the form of a nonsense variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).	11409863	PubMed		"Klein et al., 2001, Hum. Genet."		2	accepted	5433	Rare Germline	2023-01-09 21:46:49 UTC	https://civicdb.org/links/evidence_items/5433	https://civicdb.org/links/molecular_profiles/1670	FALSE	VHL	7428	E94* (c.280G>T)		chr3	10142127	10142127	G	T	ENST00000256474.2	75		stop_gained	"ENST00000256474.2:c.280G>T,NM_198156.2:c.280G>T,NP_000542.1:p.Glu94Ter,NC_000003.11:g.10183811G>T"	2023-01-27 17:12:08 UTC	CA70046202	584477	"C.280G>T,E94X,GLU94TER,RS5030829"	FALSE
VHL R108dup (c.322_324dup)	1897	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	43 unrelated VHL patients with previously sequenced VHL germline mutations and 36 suspected VHL mutation carriers were subject to denaturing high performance liquid chromatography (DHPLC) mutation screening. This mutation was found in a previously diagnosed VHL patient by DHPLC (family VHL 86). Protein length changes as a result of in-frame insertion in a nonrepeat region (ACMG code: PM4).	11409863	PubMed		"Klein et al., 2001, Hum. Genet."		2	accepted	5434	Rare Germline	2023-01-09 21:46:54 UTC	https://civicdb.org/links/evidence_items/5434	https://civicdb.org/links/molecular_profiles/1897	FALSE	VHL	7428	R108dup (c.322_324dup)		chr3	10142165	10142166		CGC	ENST00000256474.2	75		conservative_inframe_insertion	"NC_000003.11:g.10183853_10183855dup,NC_000003.12:g.10142169_10142171dup,NP_000542.1:p.Arg108dup,NM_000551.4:c.322_324dup,NM_000551.3:c.322_324dup"	2023-01-27 17:14:22 UTC	CA916832608	NONE FOUND	"R107DUP,R108INS (C.324INSCGC)"	FALSE
VHL L118P (c.353T>C)	1674	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	43 unrelated VHL patients with previously sequenced VHL germline mutations and 36 suspected VHL mutation carriers were subject to denaturing high performance liquid chromatography (DHPLC) mutation screening. This missense mutation was found in a previously diagnosed VHL patient by DHPLC (family VHL 94).	11409863	PubMed		"Klein et al., 2001, Hum. Genet."		2	accepted	5435	Rare Germline	2023-01-09 21:46:50 UTC	https://civicdb.org/links/evidence_items/5435	https://civicdb.org/links/molecular_profiles/1674	FALSE	VHL	7428	L118P (c.353T>C)		chr3	10146526	10146526	T	C	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.353T>C,NM_000551.3:c.353T>C,NP_000542.1:p.Leu118Pro,NC_000003.11:g.10188210T>C"	2023-01-27 17:12:11 UTC	CA70049399	428807	"C.353T>C,LEU118PRO,RS5030830"	FALSE
VHL F119L (c.357C>G)	1619	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	43 unrelated VHL patients with previously sequenced VHL germline mutations and 36 suspected VHL mutation carriers were subject to denaturing high performance liquid chromatography (DHPLC) mutation screening. This missense mutation was found in a previously diagnosed VHL patient by DHPLC (family VHL 99).	11409863	PubMed		"Klein et al., 2001, Hum. Genet."		2	accepted	5436	Rare Germline	2023-01-09 21:46:48 UTC	https://civicdb.org/links/evidence_items/5436	https://civicdb.org/links/molecular_profiles/1619	FALSE	VHL	7428	F119L (c.357C>G)		chr3	10146530	10146530	C	G	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.357C>G,NC_000003.11:g.10188214C>G,NM_000551.3:c.357C>G,NP_000542.1:p.Phe119Leu"	2023-01-27 17:11:32 UTC	CA351753726	625240	"C.357C>G,PHE119LEU,RS1559428077"	FALSE
VHL D121G (c.362A>G)	1689	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	43 unrelated VHL patients with previously sequenced VHL germline mutations and 36 suspected VHL mutation carriers were subject to denaturing high performance liquid chromatography (DHPLC) mutation screening. This missense mutation was found in a previously diagnosed VHL patient by DHPLC (family VHL 105).	11409863	PubMed		"Klein et al., 2001, Hum. Genet."		2	accepted	5437	Rare Germline	2023-01-09 21:46:50 UTC	https://civicdb.org/links/evidence_items/5437	https://civicdb.org/links/molecular_profiles/1689	FALSE	VHL	7428	D121G (c.362A>G)		chr3	10146535	10146535	A	G	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.362A>G,NP_000542.1:p.Asp121Gly,NC_000003.11:g.10188219A>G,ENST00000256474.2:c.362A>G"	2023-01-27 17:12:23 UTC	CA357083	223200	"C.362A>G,ASP121GLY,RS5030832"	FALSE
VHL Y175* (c.525C>G)	1845	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	43 unrelated VHL patients with previously sequenced VHL germline mutations and 36 suspected VHL mutation carriers were subject to denaturing high performance liquid chromatography (DHPLC) mutation screening. This nonsense mutation was found in a previously diagnosed VHL patient by DHPLC (family VHL 103). This study contains very strong evidence of pathogenicity in the form of a nonsense variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).	11409863	PubMed		"Klein et al., 2001, Hum. Genet."		3	accepted	5440	Rare Germline	2023-01-09 21:46:53 UTC	https://civicdb.org/links/evidence_items/5440	https://civicdb.org/links/molecular_profiles/1845	FALSE	VHL	7428	Y175* (c.525C>G)		chr3	10149848	10149848	C	G	ENST00000256474.2	75		stop_gained	"ENST00000256474.2:c.525C>G,NC_000003.11:g.10191532C>G,NM_000551.3:c.525C>G,NP_000542.1:p.Tyr175Ter"	2023-01-27 17:13:54 UTC	CA020466	182974	"C.525C>G,Y175X,TYR175TER,RS5030835"	FALSE
VHL V194fs (c.581_582del)	1853	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	43 unrelated VHL patients with previously sequenced VHL germline mutations and 36 suspected VHL mutation carriers were subject to denaturing high performance liquid chromatography (DHPLC) mutation screening. This mutation was found in a previously diagnosed VHL patient by DHPLC (family VHL 79). This study contains very strong evidence of pathogenicity in the form of a frameshift variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).	11409863	PubMed		"Klein et al., 2001, Hum. Genet."		3	accepted	5441	Rare Germline	2023-01-09 21:46:54 UTC	https://civicdb.org/links/evidence_items/5441	https://civicdb.org/links/molecular_profiles/1853	FALSE	VHL	7428	V194fs (c.581_582del)		chr3	10149903	10149904	TG		ENST00000256474.2	75		minus_2_frameshift_variant	ENST00000256474.2:c.579_580delTG	2023-01-27 17:13:57 UTC	CA70052556	NONE FOUND	"C.579_580DELTG,VAL194FSX39,C.581_582DELTG,V153FS,V194FS (C.581_582DELTG)"	FALSE
VHL 3'UTR alteration (c.639+10C>G)	1900	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	43 unrelated VHL patients with previously sequenced VHL germline mutations and 36 suspected VHL mutation carriers were subject to denaturing high performance liquid chromatography (DHPLC) mutation screening. This mutation was found in a previously diagnosed VHL patient by DHPLC (family VHL 80).	11409863	PubMed		"Klein et al., 2001, Hum. Genet."		2	accepted	5443	Rare Germline	2023-01-09 21:46:54 UTC	https://civicdb.org/links/evidence_items/5443	https://civicdb.org/links/molecular_profiles/1900	FALSE	VHL	7428	3'UTR alteration (c.639+10C>G)		chr3	10149972	10149972	C	G	ENST00000256474.2	75		3_prime_UTR_variant	ENST00000256474.2:c.639+10C>G	2023-01-27 17:14:23 UTC	CA16042064	NONE FOUND	C.639+10C>G	FALSE
VHL Q164R (c.491A>G)	1732	Von Hippel-Lindau Disease	14175	"Renal cyst,Simple renal cyst,Epididymal cyst,Retinal capillary hemangioma,Pheochromocytoma"			Predisposing	N/A	C	N/A	"A 2.75 year old patient (32 month-old girl) presented with a pheochromocytoma. Genetic sequencing revealed a c.491A>G (p.Gln164Arg) heterozygous germline mutation in exon 3 of the VHL gene. Sequencing of her mother, father, a sibling, and her paternal grandparents revealed that the mutation was present only in her father, and was de-novo in her father. Upon screening, her father (a 31 year old male) presented with a retinal angioma, an adenoma of right adrenal gland, a right-sided renal cyst, an epidydymal cyst, a contrast-enhancing lesion in the pancreas, and bilateral pheochromocytomas. ACMG evidence codes: 'PP1'- Cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease, and 'PP4'- patients' phenotypes or family history are highly specific for a disease with a single genetic etiology."	20583150	PubMed		"Sovinz et al., 2010, Am. J. Med. Genet. A"		4	accepted	5444	Rare Germline	2023-01-09 21:46:51 UTC	https://civicdb.org/links/evidence_items/5444	https://civicdb.org/links/molecular_profiles/1732	FALSE	VHL	7428	Q164R (c.491A>G)		chr3	10149814	10149814	A	G	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.491A>G,NP_000542.1:p.Gln164Arg,NC_000003.11:g.10191498A>G,ENST00000256474.2:c.491A>G"	2023-01-27 17:12:51 UTC	CA020429	2238	"C.491A>G,GLN164ARG,RS267607170"	FALSE
VHL E70* (c.208G>T)	1710	Von Hippel-Lindau Disease	14175	Pancreatic endocrine tumor			Predisposing	Supports	C	Predisposition	"53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 1 patient was found to have the above mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes:  'PVS1' because they observe a nonsense variant in a gene where loss of function is a known mechanism of disease."	20660572	PubMed		"Erlic et al., 2010, Endocr. Relat. Cancer"		2	accepted	5445	Rare Germline	2023-02-18 00:20:37 UTC	https://civicdb.org/links/evidence_items/5445	https://civicdb.org/links/molecular_profiles/1710	FALSE	VHL	7428	E70* (c.208G>T)		chr3	10142055	10142055	G	T	ENST00000256474.2	75		stop_gained	"NM_000551.3:c.208G>T,NP_000542.1:p.Glu70Ter,NC_000003.11:g.10183739G>T,ENST00000256474.2:c.208G>T"	2023-01-27 17:12:36 UTC	CA16602179	428806	"C.208G>T,E70X,GLU70TER,RS5030802"	FALSE
VHL V74G (c.221T>G)	1875	Von Hippel-Lindau Disease	14175	Pancreatic endocrine tumor			Predisposing	Supports	C	Predisposition	"53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 1 patient was found to have the above mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease ."	20660572	PubMed		"Erlic et al., 2010, Endocr. Relat. Cancer"		2	accepted	5446	Rare Germline	2023-02-18 00:21:22 UTC	https://civicdb.org/links/evidence_items/5446	https://civicdb.org/links/molecular_profiles/1875	FALSE	VHL	7428	V74G (c.221T>G)		chr3	10142068	10142068	T	G	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.221T>G,NM_000551.3:c.221T>G,NP_000542.1:p.Val74Gly,NC_000003.11:g.10183752T>G"	2023-01-27 17:14:07 UTC	CA70042528	NONE FOUND	"C.221T>G,VAL74GLY,RS5030803"	FALSE
VHL F76del (c.224_226delTCT)	1964	Von Hippel-Lindau Disease	14175	Pancreatic endocrine tumor			Predisposing	Supports	C	Predisposition	"53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 1 patient was found to have the above mutation. More specifically, the mutation causes the following protein change: F76Cfs*83. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PVS1' because they observe a frameshift variant in a gene where loss of function is a known mechanism of disease."	20660572	PubMed		"Erlic et al., 2010, Endocr. Relat. Cancer"		2	accepted	5447	Rare Germline	2023-02-18 00:26:01 UTC	https://civicdb.org/links/evidence_items/5447	https://civicdb.org/links/molecular_profiles/1964	FALSE	VHL	7428	F76del (c.224_226delTCT)		chr3	10142071	10142073	TCT		ENST00000256474.2	75		inframe_deletion	"NP_000542.1:p.Phe76del,ENST00000256474.2:c.224_226delTCT,NC_000003.11:g.10183758_10183760del,NC_000003.12:g.10142074_10142076del,NM_000551.3:c.227_229del,ENSP00000256474.2:p.Phe76del"	2023-01-27 17:15:01 UTC	CA357012	223166	"PHE76DEL,C.224_226DELTCT,C.226_228DELTTC,C.227_229DELTCT,DELPHE76"	FALSE
VHL S80R (c.240T>G)	1668	Von Hippel-Lindau Disease	14175	Pancreatic endocrine tumor			Predisposing	Supports	C	Predisposition	"53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 1 patient was found to have the above mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease ."	20660572	PubMed		"Erlic et al., 2010, Endocr. Relat. Cancer"		2	accepted	5448	Rare Germline	2023-02-18 00:28:18 UTC	https://civicdb.org/links/evidence_items/5448	https://civicdb.org/links/molecular_profiles/1668	FALSE	VHL	7428	S80R (c.240T>G)		chr3	10142087	10142087	T	G	ENST00000256474.2	75		missense_variant	ENST00000256474.2:c.240T>G	2023-01-27 17:12:06 UTC	CA351750515	NONE FOUND	"C.240T>G,SER80ARG"	FALSE
VHL L89P (c.266T>C)	1669	Von Hippel-Lindau Disease	14175	Pancreatic endocrine tumor			Predisposing	Supports	C	Predisposition	"53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 1 patient was found to have the above mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease ."	20660572	PubMed		"Erlic et al., 2010, Endocr. Relat. Cancer"		2	accepted	5449	Rare Germline	2023-02-18 00:29:36 UTC	https://civicdb.org/links/evidence_items/5449	https://civicdb.org/links/molecular_profiles/1669	FALSE	VHL	7428	L89P (c.266T>C)		chr3	10142113	10142113	T	C	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.266T>C,NP_000542.1:p.Leu89Pro,NC_000003.11:g.10183797T>C,ENST00000256474.2:c.266T>C"	2023-01-27 17:12:07 UTC	CA020207	182979	"C.266T>C,LEU89PRO,RS5030807"	FALSE
VHL G93R (c.277G>C)	1796	Von Hippel-Lindau Disease	14175	Pancreatic endocrine tumor			Predisposing	Supports	C	Predisposition	"53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 1 patient was found to have the above mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease ."	20660572	PubMed		"Erlic et al., 2010, Endocr. Relat. Cancer"		2	accepted	5450	Rare Germline	2023-02-18 00:32:54 UTC	https://civicdb.org/links/evidence_items/5450	https://civicdb.org/links/molecular_profiles/1796	FALSE	VHL	7428	G93R (c.277G>C)		chr3	10142124	10142124	G	C	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.277G>C,NP_000542.1:p.Gly93Arg,NC_000003.11:g.10183808G>C,ENST00000256474.2:c.277G>C"	2023-01-27 17:13:28 UTC	CA357130	223174	"C.277G>C,GLY93ARG,RS5030808"	FALSE
VHL Y98H (c.292T>C)	1617	Von Hippel-Lindau Disease	14175	Pancreatic endocrine tumor			Predisposing	Supports	C	Predisposition	"53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 2 patients were found to have the above mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease ."	20660572	PubMed		"Erlic et al., 2010, Endocr. Relat. Cancer"		2	accepted	5451	Rare Germline	2023-02-18 00:34:10 UTC	https://civicdb.org/links/evidence_items/5451	https://civicdb.org/links/molecular_profiles/1617	FALSE	VHL	7428	Y98H (c.292T>C)		chr3	10142139	10142139	T	C	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.292T>C,NP_000542.1:p.Tyr98His,NC_000003.11:g.10183823T>C,ENST00000256474.2:c.292T>C"	2023-01-27 17:11:30 UTC	CA020246	2223	"C.292T>C,TYR98HIS,RS5030809"	FALSE
VHL G114S (c.340G>A)	1902	Von Hippel-Lindau Disease	14175	Pancreatic endocrine tumor			Predisposing	Supports	C	Predisposition	"53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 1 patient was found to have the above mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease ."	20660572	PubMed		"Erlic et al., 2010, Endocr. Relat. Cancer"		2	accepted	5452	Rare Germline	2023-02-18 00:34:51 UTC	https://civicdb.org/links/evidence_items/5452	https://civicdb.org/links/molecular_profiles/1902	FALSE	VHL	7428	G114S (c.340G>A)		chr3	10142187	10142187	G	A	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.340G>A,NC_000003.11:g.10183871G>A,NM_000551.3:c.340G>A,NP_000542.1:p.Gly114Ser"	2023-01-27 17:14:24 UTC	CA351751372	583094	"C.340G>A,GLY114SER"	FALSE
VHL W117fs (c.349dup)	1903	Von Hippel-Lindau Disease	14175	Pancreatic endocrine tumor			Predisposing	Supports	C	Predisposition	"53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 1 patient was found to have the above mutation. More specifically, the mutation causes the following protein change W117LfsX1. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PVS1' because they observe a frameshift variant in a gene where loss of function is a known mechanism of disease."	20660572	PubMed		"Erlic et al., 2010, Endocr. Relat. Cancer"		2	accepted	5453	Rare Germline	2023-02-18 00:36:03 UTC	https://civicdb.org/links/evidence_items/5453	https://civicdb.org/links/molecular_profiles/1903	FALSE	VHL	7428	W117fs (c.349dup)		chr3	10146522	10146523		T	ENST00000256474.2	75		"plus_1_frameshift_variant,frameshift_truncation"	"NC_000003.11:g.10188206dup,ENST00000256474.2:c.349dupT,NM_000551.3:c.349dup,NP_000542.1:p.cTrp117LeufsTer15"	2023-01-27 17:14:25 UTC	CA432421788	NONE FOUND	"TRP117LEUFS,C.349DUPT"	FALSE
VHL F119L (c.357C>G)	1619	Von Hippel-Lindau Disease	14175	Pancreatic endocrine tumor			Predisposing	Supports	C	Predisposition	"53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 2 patients were found to have the above mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease ."	20660572	PubMed		"Erlic et al., 2010, Endocr. Relat. Cancer"		2	accepted	5454	Rare Germline	2023-02-18 00:37:19 UTC	https://civicdb.org/links/evidence_items/5454	https://civicdb.org/links/molecular_profiles/1619	FALSE	VHL	7428	F119L (c.357C>G)		chr3	10146530	10146530	C	G	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.357C>G,NC_000003.11:g.10188214C>G,NM_000551.3:c.357C>G,NP_000542.1:p.Phe119Leu"	2023-01-27 17:11:32 UTC	CA351753726	625240	"C.357C>G,PHE119LEU,RS1559428077"	FALSE
VHL D121G (c.362A>G)	1689	Von Hippel-Lindau Disease	14175	Pancreatic endocrine tumor			Predisposing	Supports	C	Predisposition	"53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 1 patient was found to have the above mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease ."	20660572	PubMed		"Erlic et al., 2010, Endocr. Relat. Cancer"		2	accepted	5455	Rare Germline	2023-02-18 00:38:04 UTC	https://civicdb.org/links/evidence_items/5455	https://civicdb.org/links/molecular_profiles/1689	FALSE	VHL	7428	D121G (c.362A>G)		chr3	10146535	10146535	A	G	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.362A>G,NP_000542.1:p.Asp121Gly,NC_000003.11:g.10188219A>G,ENST00000256474.2:c.362A>G"	2023-01-27 17:12:23 UTC	CA357083	223200	"C.362A>G,ASP121GLY,RS5030832"	FALSE
VHL A122I (c.364_365GC>AT)	1904	Von Hippel-Lindau Disease	14175	Pancreatic endocrine tumor			Predisposing	Supports	C	Predisposition	"53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 1 patient was found to have the A122I mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease."	20660572	PubMed		"Erlic et al., 2010, Endocr. Relat. Cancer"		2	accepted	5456	Rare Germline	2023-02-18 00:40:39 UTC	https://civicdb.org/links/evidence_items/5456	https://civicdb.org/links/molecular_profiles/1904	FALSE	VHL	7428	A122I (c.364_365GC>AT)		chr3	10146537	10146538	GC	AT	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.364_365delinsAT,ENST00000256474.2:c.364_365delinsAT,NC_000003.11:g.10188221_10188222delinsAT,NC_000003.12:g.10146537_10146538delinsAT"	2023-01-27 17:14:25 UTC	CA658820874	NONE FOUND	"C.364_365GC>AT,ALA122ILE"	FALSE
VHL N131K (c.393C>A)	1829	Von Hippel-Lindau Disease	14175	Pancreatic endocrine tumor			Predisposing	Supports	C	Predisposition	"53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 1 patient was found to have the above mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease ."	20660572	PubMed		"Erlic et al., 2010, Endocr. Relat. Cancer"		2	accepted	5457	Rare Germline	2023-02-18 00:44:36 UTC	https://civicdb.org/links/evidence_items/5457	https://civicdb.org/links/molecular_profiles/1829	FALSE	VHL	7428	N131K (c.393C>A)		chr3	10146566	10146566	C	A	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.393C>A,NP_000542.1:p.Asn131Lys,NC_000003.11:g.10188250C>A,ENST00000256474.2:c.393C>A"	2023-01-27 17:13:45 UTC	CA16617789	420074	"C.393C>A,ASN131LYS,RS1064794272"	FALSE
VHL Q132* (c.394C>T)	1870	Von Hippel-Lindau Disease	14175	Pancreatic endocrine tumor			Predisposing	Supports	C	Predisposition	"53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 1 patient was found to have the above mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PVS1' because they observe a nonsense variant in a gene where loss of function is a known mechanism of disease."	20660572	PubMed		"Erlic et al., 2010, Endocr. Relat. Cancer"		2	accepted	5458	Rare Germline	2023-02-18 00:45:51 UTC	https://civicdb.org/links/evidence_items/5458	https://civicdb.org/links/molecular_profiles/1870	FALSE	VHL	7428	Q132* (c.394C>T)		chr3	10146567	10146567	C	T	ENST00000256474.2	75		stop_gained	"NM_000551.3:c.394C>T,NP_000542.1:p.Gln132Ter,NC_000003.11:g.10188251C>T,ENST00000256474.2:c.394C>T"	2023-01-27 17:14:04 UTC	CA10606205	288749	"C.394C>T,Q132X,GLN132TER,RS5030813"	FALSE
VHL N150fs (c.445_458del)	1905	Von Hippel-Lindau Disease	14175	Pancreatic endocrine tumor			Predisposing	Supports	C	Predisposition	"53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 1 patient was found to have the above mutation. More specifically, this mutation causes the following protein change: N150SfsX19. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PVS1' because they observe a frameshift variant in a gene where loss of function is a known mechanism of disease. Relevant HPO terms: Neuroendocrine neoplasm."	20660572	PubMed		"Erlic et al., 2010, Endocr. Relat. Cancer"		2	accepted	5459	Rare Germline	2023-02-18 00:47:10 UTC	https://civicdb.org/links/evidence_items/5459	https://civicdb.org/links/molecular_profiles/1905	FALSE	VHL	7428	N150fs (c.445_458del)		chr3	10146618	10146631	GCCAATATCACACT		ENST00000256474.2	75		frameshift_variant	ENST00000256474.2:c.445_458delGCCAATATCACACT	2023-01-27 17:14:26 UTC	CA658820719	NONE FOUND	"C.445_458DEL,ASN150FS"	FALSE
VHL I151M (c.453C>G)	1906	Von Hippel-Lindau Disease	14175	Pancreatic endocrine tumor			Predisposing	Supports	C	Predisposition	"53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 1 patient was found to have the above mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease ."	20660572	PubMed		"Erlic et al., 2010, Endocr. Relat. Cancer"		2	accepted	5460	Rare Germline	2023-02-18 00:49:45 UTC	https://civicdb.org/links/evidence_items/5460	https://civicdb.org/links/molecular_profiles/1906	FALSE	VHL	7428	I151M (c.453C>G)		chr3	10146626	10146626	C	G	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.453C>G,NC_000003.11:g.10188310C>G,NM_000551.3:c.453C>G,NP_000542.1:p.Ile151Met"	2023-01-27 17:14:27 UTC	CA351754364	NONE FOUND	"C.453C>G,ILE151MET"	FALSE
VHL P154L (c.461C>T)	1658	Von Hippel-Lindau Disease	14175	Pancreatic endocrine tumor			Predisposing	Supports	C	Predisposition	"53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 1 patient was found to have the above mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease ."	20660572	PubMed		"Erlic et al., 2010, Endocr. Relat. Cancer"		2	accepted	5461	Rare Germline	2023-02-18 00:52:05 UTC	https://civicdb.org/links/evidence_items/5461	https://civicdb.org/links/molecular_profiles/1658	FALSE	VHL	7428	P154L (c.461C>T)		chr3	10146634	10146634	C	T	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.461C>T,NC_000003.11:g.10188318C>T,NM_000551.3:c.461C>T,NP_000542.1:p.Pro154Leu"	2023-01-27 17:11:58 UTC	CA351754410	NONE FOUND	"C.461C>T,PRO154LEU"	FALSE
VHL Splice Site (c.464-2A>G)	1954	Von Hippel-Lindau Disease	14175	Pancreatic endocrine tumor			Predisposing	Supports	C	Predisposition	"53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 2 patients were found to have the above mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed."	20660572	PubMed		"Erlic et al., 2010, Endocr. Relat. Cancer"		2	accepted	5462	Rare Germline	2023-02-18 00:59:12 UTC	https://civicdb.org/links/evidence_items/5462	https://civicdb.org/links/molecular_profiles/1954	FALSE	VHL	7428	Splice Site (c.464-2A>G)		chr3	10149785	10149785	A	G	ENST00000256474.2	75		splice_acceptor_variant	"NM_000551.3:c.464-2A>G,NC_000003.11:g.10191469A>G,ENST00000256474.2:c.464-2A>G"	2023-01-27 17:14:57 UTC	CA357046	223222	"C.464-2A>G,RS5030816"	FALSE
VHL Y156C (c.467A>G)	1822	Von Hippel-Lindau Disease	14175	Pancreatic endocrine tumor			Predisposing	Supports	C	Predisposition	"53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 1 patient was found to have the above mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease ."	20660572	PubMed		"Erlic et al., 2010, Endocr. Relat. Cancer"		2	accepted	5463	Rare Germline	2023-02-18 01:02:49 UTC	https://civicdb.org/links/evidence_items/5463	https://civicdb.org/links/molecular_profiles/1822	FALSE	VHL	7428	Y156C (c.467A>G)		chr3	10149790	10149790	A	G	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.467A>G,NP_000542.1:p.Tyr156Cys,NC_000003.11:g.10191474A>G,ENST00000256474.2:c.467A>G"	2023-01-27 17:13:44 UTC	CA020394	43600	"C.467A>G,TYR156CYS,RS397516441"	FALSE
VHL L158V (c.472C>G)	1679	Von Hippel-Lindau Disease	14175	Pancreatic endocrine tumor			Predisposing	Supports	C	Predisposition	"53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 1 patient was found to have the above mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease ."	20660572	PubMed		"Erlic et al., 2010, Endocr. Relat. Cancer"		2	accepted	5464	Rare Germline	2023-02-18 01:04:18 UTC	https://civicdb.org/links/evidence_items/5464	https://civicdb.org/links/molecular_profiles/1679	FALSE	VHL	7428	L158V (c.472C>G)		chr3	10149795	10149795	C	G	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.472C>G,NC_000003.11:g.10191479C>G,NM_000551.3:c.472C>G,NP_000542.1:p.Leu158Val"	2023-01-27 17:12:15 UTC	CA351756068	NONE FOUND	"C.472C>G,LEU158VAL"	FALSE
VHL E160FS (c.479_480delAG)	1795	Von Hippel-Lindau Disease	14175	Pancreatic endocrine tumor			Predisposing	Supports	C	Predisposition	"53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 2 patients were found to have the above mutation. More specifically, this mutation causes the following protein change: E160AfsX12. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PVS1' because they observe a frameshift variant in a gene where loss of function is a known mechanism of disease ."	20660572	PubMed		"Erlic et al., 2010, Endocr. Relat. Cancer"		2	accepted	5465	Rare Germline	2023-02-18 01:10:22 UTC	https://civicdb.org/links/evidence_items/5465	https://civicdb.org/links/molecular_profiles/1795	FALSE	VHL	7428	E160FS (c.479_480delAG)		chr3	10149802	10149803	AG		ENST00000256474.2	75		frameshift_truncation	"ENST00000256474.2:c.479_480delAG,NC_000003.11:g.10191486_10191487delAG,NM_000551.3:c.479_480delAG,NP_000542.1:p.Glu160AlafsTer13"	2023-01-27 17:13:27 UTC	CA16621940	NONE FOUND	"GLU160FS,C.479_480DELAG"	FALSE
VHL R161Q (c.482G>A)	1622	Von Hippel-Lindau Disease	14175	Pancreatic endocrine tumor			Predisposing	Supports	C	Predisposition	"53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 5 patients were found to have the above mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease ."	20660572	PubMed		"Erlic et al., 2010, Endocr. Relat. Cancer"		2	accepted	5466	Rare Germline	2023-02-18 00:19:18 UTC	https://civicdb.org/links/evidence_items/5466	https://civicdb.org/links/molecular_profiles/1622	FALSE	VHL	7428	R161Q (c.482G>A)		chr3	10149805	10149805	G	A	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.482G>A,NP_000542.1:p.Arg161Gln,NC_000003.11:g.10191489G>A,ENST00000256474.2:c.482G>A"	2023-01-27 17:11:34 UTC	CA020413	182983	"C.482G>A,ARG161GLN,RS730882035"	FALSE
VHL L163H (c.488T>A)	1909	Von Hippel-Lindau Disease	14175	Pancreatic endocrine tumor			Predisposing	Supports	C	Predisposition	"53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 1 patient was found to have the above mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease ."	20660572	PubMed		"Erlic et al., 2010, Endocr. Relat. Cancer"		2	accepted	5467	Rare Germline	2023-02-18 01:13:45 UTC	https://civicdb.org/links/evidence_items/5467	https://civicdb.org/links/molecular_profiles/1909	FALSE	VHL	7428	L163H (c.488T>A)		chr3	10149811	10149811	T	A	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.488T>A,NC_000003.11:g.10191495T>A,NM_000551.3:c.488T>A,NP_000542.1:p.Leu163His"	2023-01-27 17:14:29 UTC	CA351756137	NONE FOUND	"C.488T>A,LEU163HIS"	FALSE
VHL R167W (c.499C>T)	1623	Von Hippel-Lindau Disease	14175	Pancreatic endocrine tumor			Predisposing	Supports	C	Predisposition	"53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 7 patients were found to have the above mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease."	20660572	PubMed		"Erlic et al., 2010, Endocr. Relat. Cancer"		3	accepted	5468	Rare Germline	2023-02-18 00:23:08 UTC	https://civicdb.org/links/evidence_items/5468	https://civicdb.org/links/molecular_profiles/1623	FALSE	VHL	7428	R167W (c.499C>T)		chr3	10149822	10149822	C	T	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.499C>T,NP_000542.1:p.Arg167Trp,NC_000003.11:g.10191506C>T,ENST00000256474.2:c.499C>T"	2023-01-27 17:11:35 UTC	CA020450	2218	"C.499C>T,ARG167TRP,R126W,RS5030820"	FALSE
VHL R167Q (c.500G>A)	1615	Von Hippel-Lindau Disease	14175	Pancreatic endocrine tumor			Predisposing	Supports	C	Predisposition	"53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 4 patients were found to have the above mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease."	20660572	PubMed		"Erlic et al., 2010, Endocr. Relat. Cancer"		2	accepted	5469	Rare Germline	2023-02-18 01:14:42 UTC	https://civicdb.org/links/evidence_items/5469	https://civicdb.org/links/molecular_profiles/1615	FALSE	VHL	7428	R167Q (c.500G>A)		chr3	10149823	10149823	G	A	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.500G>A,NP_000542.1:p.Arg167Gln,NC_000003.11:g.10191507G>A,ENST00000256474.2:c.500G>A"	2023-01-27 17:11:29 UTC	CA020454	2216	"C.500G>A,ARG167GLN,RS5030821"	FALSE
VHL L178P (c.533T>C)	1624	Von Hippel-Lindau Disease	14175	Pancreatic endocrine tumor			Predisposing	Supports	C	Predisposition	"53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 1 patient was found to have the above mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease ."	20660572	PubMed		"Erlic et al., 2010, Endocr. Relat. Cancer"		2	accepted	5470	Rare Germline	2023-02-18 01:15:00 UTC	https://civicdb.org/links/evidence_items/5470	https://civicdb.org/links/molecular_profiles/1624	FALSE	VHL	7428	L178P (c.533T>C)		chr3	10149856	10149856	T	C	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.533T>C,NM_000551.3:c.533T>C,NP_000542.1:p.Leu178Pro,NC_000003.11:g.10191540T>C"	2023-01-27 17:11:36 UTC	CA351756245	428795	"C.533T>C,LEU178PRO,RS5030822"	FALSE
VHL S183* (c.548C>A)	1660	Von Hippel-Lindau Disease	14175	Pancreatic endocrine tumor			Predisposing	Supports	C	Predisposition	"53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 1 patient was found to have the above mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PVS1' because they observe a nonsense variant in a gene where loss of function is a known mechanism of disease ."	20660572	PubMed		"Erlic et al., 2010, Endocr. Relat. Cancer"		2	accepted	5471	Rare Germline	2023-02-18 01:16:05 UTC	https://civicdb.org/links/evidence_items/5471	https://civicdb.org/links/molecular_profiles/1660	FALSE	VHL	7428	S183* (c.548C>A)		chr3	10149871	10149871	C	A	ENST00000256474.2	75		stop_gained	"NM_000551.3:c.548C>A,NP_000542.1:p.Ser183Ter,NC_000003.11:g.10191555C>A,ENST00000256474.2:c.548C>A"	2023-01-27 17:12:00 UTC	CA020473	2215	"C.548C>A,S183X,SER183TER,RS5030823"	FALSE
VHL Q195* (c.583C>T)	1686	Von Hippel-Lindau Disease	14175	Pancreatic endocrine tumor			Predisposing	Supports	C	Predisposition	"53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 1 patient was found to have the above mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PVS1' because they observe a nonsense variant in a gene where loss of function is a known mechanism of disease ."	20660572	PubMed		"Erlic et al., 2010, Endocr. Relat. Cancer"		2	accepted	5472	Rare Germline	2023-02-18 01:16:35 UTC	https://civicdb.org/links/evidence_items/5472	https://civicdb.org/links/molecular_profiles/1686	FALSE	VHL	7428	Q195* (c.583C>T)		chr3	10149906	10149906	C	T	ENST00000256474.2	75		stop_gained	"NM_000551.3:c.583C>T,NP_000542.1:p.Gln195Ter,NC_000003.11:g.10191590C>T,ENST00000256474.2:c.583C>T"	2023-01-27 17:12:20 UTC	CA70052558	428794	"C.583C>T,Q195X,GLN195TER,RS5030825"	FALSE
VHL L198Q  (c.593T>A)	1886	Von Hippel-Lindau Disease	14175	Pancreatic endocrine tumor			Predisposing	Supports	C	Predisposition	"53 patients with a molecularly confirmed VHL mutation and a pancreatic neuroendocrine tumor were collected from the German NET-Registry and the German VHL-registry. 2 patients were found to have the above mutation. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease ."	20660572	PubMed		"Erlic et al., 2010, Endocr. Relat. Cancer"		2	accepted	5473	Rare Germline	2023-02-18 01:17:59 UTC	https://civicdb.org/links/evidence_items/5473	https://civicdb.org/links/molecular_profiles/1886	FALSE	VHL	7428	L198Q  (c.593T>A)		chr3	10149916	10149916	T	A	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.593T>A,NC_000003.11:g.10191600T>A,NM_000551.3:c.593T>A,NP_000542.1:p.Leu198Gln"	2023-01-27 17:14:15 UTC	CA351756548	NONE FOUND	"C.593T>A,LEU198GLN"	FALSE
VHL Y98H (c.292T>C)	1617	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	"26 VHL patients from 18 families, who had undergone a partial adrenalectomy for pheochromocytoma were retrospectively analyzed. 1 patient from a single family was confirmed to have the above mutation. Additional manifestations aside from pheochromocytoma are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease."	20846682	PubMed		"Benhammou et al., 2010, J. Urol."		2	accepted	5474	Rare Germline	2023-01-09 21:46:48 UTC	https://civicdb.org/links/evidence_items/5474	https://civicdb.org/links/molecular_profiles/1617	FALSE	VHL	7428	Y98H (c.292T>C)		chr3	10142139	10142139	T	C	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.292T>C,NP_000542.1:p.Tyr98His,NC_000003.11:g.10183823T>C,ENST00000256474.2:c.292T>C"	2023-01-27 17:11:30 UTC	CA020246	2223	"C.292T>C,TYR98HIS,RS5030809"	FALSE
VHL Y112H (c.334T>C)	1741	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	"26 VHL patients from 18 families, who had undergone a partial adrenalectomy for pheochromocytoma were retrospectively analyzed. 1 patient from a single family was confirmed to have the above mutation. Additional manifestations aside from pheochromocytoma are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease."	20846682	PubMed		"Benhammou et al., 2010, J. Urol."		2	accepted	5475	Rare Germline	2023-01-09 21:46:51 UTC	https://civicdb.org/links/evidence_items/5475	https://civicdb.org/links/molecular_profiles/1741	FALSE	VHL	7428	Y112H (c.334T>C)		chr3	10142181	10142181	T	C	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.334T>C,NP_000542.1:p.Tyr112His,NC_000003.11:g.10183865T>C,ENST00000256474.2:c.334T>C"	2023-01-27 17:12:57 UTC	CA020277	2222	"C.334T>C,TYR112HIS,RS104893824"	FALSE
VHL G114R (c.340G>C)	1733	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	"26 VHL patients from 18 families, who had undergone a partial adrenalectomy for pheochromocytoma were retrospectively analyzed. 1 patient from a single family was confirmed to have the above mutation. Additional manifestations aside from pheochromocytoma are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease."	20846682	PubMed		"Benhammou et al., 2010, J. Urol."		2	accepted	5476	Rare Germline	2023-01-09 21:46:51 UTC	https://civicdb.org/links/evidence_items/5476	https://civicdb.org/links/molecular_profiles/1733	FALSE	VHL	7428	G114R (c.340G>C)		chr3	10142187	10142187	G	C	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.340G>C,NP_000542.1:p.Gly114Arg,NC_000003.11:g.10183871G>C,ENST00000256474.2:c.340G>C"	2023-01-27 17:12:52 UTC	CA357101	223193	"C.340G>C,GLY114ARG,RS869025636"	FALSE
VHL L118P (c.353T>C)	1674	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	"26 VHL patients from 18 families, who had undergone a partial adrenalectomy for pheochromocytoma were retrospectively analyzed. 1 patient from a single family was confirmed to have the above mutation. Additional manifestations aside from pheochromocytoma are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease."	20846682	PubMed		"Benhammou et al., 2010, J. Urol."		2	accepted	5477	Rare Germline	2023-01-09 21:46:50 UTC	https://civicdb.org/links/evidence_items/5477	https://civicdb.org/links/molecular_profiles/1674	FALSE	VHL	7428	L118P (c.353T>C)		chr3	10146526	10146526	T	C	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.353T>C,NM_000551.3:c.353T>C,NP_000542.1:p.Leu118Pro,NC_000003.11:g.10188210T>C"	2023-01-27 17:12:11 UTC	CA70049399	428807	"C.353T>C,LEU118PRO,RS5030830"	FALSE
VHL L128F (c.382C>T)	2935	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	"26 VHL patients from 18 families, who had undergone a partial adrenalectomy for pheochromocytoma were retrospectively analyzed. 1 patient from a single family was confirmed to have the above mutation. Additional manifestations aside from pheochromocytoma are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease."	20846682	PubMed		"Benhammou et al., 2010, J. Urol."		2	accepted	5478	Rare Germline	2023-01-09 21:47:05 UTC	https://civicdb.org/links/evidence_items/5478	https://civicdb.org/links/molecular_profiles/2935	FALSE	VHL	7428	L128F (c.382C>T)		chr3	10146555	10146555	C	T	ENST00000256474.2	75		missense_variant		2023-01-27 17:18:19 UTC	CA351753886			FALSE
VHL L129P (c.386T>C)	2381	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	"26 VHL patients from 18 families, who had undergone a partial adrenalectomy for pheochromocytoma were retrospectively analyzed. 1 patient from a single family was confirmed to have the above mutation. Additional manifestations aside from pheochromocytoma are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease."	20846682	PubMed		"Benhammou et al., 2010, J. Urol."		2	accepted	5479	Rare Germline	2023-01-09 21:46:59 UTC	https://civicdb.org/links/evidence_items/5479	https://civicdb.org/links/molecular_profiles/2381	FALSE	VHL	7428	L129P (c.386T>C)		chr3	10146559	10146559	T	C	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.386T>C,NC_000003.11:g.10188243T>C,NM_000551.3:c.386T>C,NP_000542.1:p.Leu129Pro,ENSP00000256474.2:p.Leu129Pro,NC_000003.12:g.10146559T>C"	2023-03-09 20:48:19 UTC	CA351753904	625242	L129P (C.386T>G)	FALSE
VHL F136C (c.407T>G)	1690	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	"26 VHL patients, from 18 families, who had undergone a partial adrenalectomy for pheochromocytoma were retrospectively analyzed. 1 patient from a single family was confirmed to have the above mutation. Additional manifestations aside from pheochromocytoma are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease."	20846682	PubMed		"Benhammou et al., 2010, J. Urol."		2	accepted	5480	Rare Germline	2023-01-09 21:46:50 UTC	https://civicdb.org/links/evidence_items/5480	https://civicdb.org/links/molecular_profiles/1690	FALSE	VHL	7428	F136C (c.407T>G)		chr3	10146580	10146580	T	G	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.407T>G,NC_000003.11:g.10188264T>G,NM_000551.3:c.407T>G,NP_000542.1:p.Phe136Cys"	2023-01-27 17:12:24 UTC	CA70049495	496065	"C.407T>G,PHE136CYS,RS5030833"	FALSE
VHL R161Q (c.482G>A)	1622	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	"26 VHL patients, from 18 families, who had undergone a partial adrenalectomy for pheochromocytoma were retrospectively analyzed. 1 patient from a single family was confirmed to have the above mutation. Additional manifestations aside from pheochromocytoma are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease."	20846682	PubMed		"Benhammou et al., 2010, J. Urol."		2	accepted	5481	Rare Germline	2023-01-09 21:46:48 UTC	https://civicdb.org/links/evidence_items/5481	https://civicdb.org/links/molecular_profiles/1622	FALSE	VHL	7428	R161Q (c.482G>A)		chr3	10149805	10149805	G	A	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.482G>A,NP_000542.1:p.Arg161Gln,NC_000003.11:g.10191489G>A,ENST00000256474.2:c.482G>A"	2023-01-27 17:11:34 UTC	CA020413	182983	"C.482G>A,ARG161GLN,RS730882035"	FALSE
VHL C162fs (c.483del)	1911	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	"26 VHL patients, from 18 families, who had undergone a partial adrenalectomy for pheochromocytoma were retrospectively analyzed. 1 patient from a single family was confirmed to have the above mutation. More specifically, this mutation causes the following protein change: C162AfsX8. Additional manifestations aside from pheochromocytoma are possible, but were not discussed. ACMG evidence codes: 'PVS1' because they observe a frameshift variant in a gene where loss of function is a known mechanism of disease. Relevant HPO terms: Pheochromocytoma."	20846682	PubMed		"Benhammou et al., 2010, J. Urol."		2	accepted	5482	Rare Germline	2023-01-09 21:46:54 UTC	https://civicdb.org/links/evidence_items/5482	https://civicdb.org/links/molecular_profiles/1911	FALSE	VHL	7428	C162fs (c.483del)		chr3	10149806	10149806	A		ENST00000256474.2	75		"minus_1_frameshift_variant,frameshift_truncation"	"NC_000003.11:g.10191490del,NP_000542.1:p.Cys162AlafsTer8,ENST00000256474.2:c.483del,NM_000551.3:c.483del,NC_000003.12:g.10149806del"	2023-01-27 17:14:30 UTC	CA658795183	928822	"C.483DELA,CYS162FS,C162AFS*8"	FALSE
VHL R161* (c.481C>T)	1680	Von Hippel-Lindau Disease	14175	"Retinal capillary hemangioma,Hemangioblastoma,Renal cell carcinoma"			Predisposing	Supports	C	Uncertain Significance	"A study of 34 Polish families revealed germline mutations in 30 families. Mutations were not detected in 4 probands fulfilling clinical criteria for von Hippel-Lindau disease (VHLD). This nonsense mutation was found in a VHL patient with hemangioblastomas of the central nervous system and retina, and renal cell carcinoma (family no. 15). This study contains very strong evidence of pathogenicity in the form of a nonsense variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1)."	12114495	PubMed		"Cybulski et al., 2002, J. Med. Genet."		3	accepted	5483	Rare Germline	2023-01-09 21:46:50 UTC	https://civicdb.org/links/evidence_items/5483	https://civicdb.org/links/molecular_profiles/1680	FALSE	VHL	7428	R161* (c.481C>T)		chr3	10149804	10149804	C	T	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.481C>T,NP_000542.1:p.Arg161Ter,NC_000003.11:g.10191488C>T,ENST00000256474.2:c.481C>T"	2023-01-27 17:12:16 UTC	CA020408	2217	"C.481C>T,R161X,ARG161TER,RS5030818"	FALSE
VHL R167W (c.499C>T)	1623	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	"26 VHL patients from 18 families, who had undergone a partial adrenalectomy for pheochromocytoma were retrospectively analyzed. 2 patients from 2 families were confirmed to have the above mutation. Additional manifestations aside from pheochromocytoma are possible, but were not discussed."	20846682	PubMed		"Benhammou et al., 2010, J. Urol."		2	accepted	5484	Rare Germline	2023-01-09 21:46:48 UTC	https://civicdb.org/links/evidence_items/5484	https://civicdb.org/links/molecular_profiles/1623	FALSE	VHL	7428	R167W (c.499C>T)		chr3	10149822	10149822	C	T	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.499C>T,NP_000542.1:p.Arg167Trp,NC_000003.11:g.10191506C>T,ENST00000256474.2:c.499C>T"	2023-01-27 17:11:35 UTC	CA020450	2218	"C.499C>T,ARG167TRP,R126W,RS5030820"	FALSE
VHL R167Q (c.500G>A)	1615	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	"26 VHL patients from 18 families, who had undergone a partial adrenalectomy for pheochromocytoma were retrospectively analyzed. 12 patients from 4 families were confirmed to have the above mutation. Additional manifestations aside from pheochromocytoma are possible, but were not discussed."	20846682	PubMed		"Benhammou et al., 2010, J. Urol."		2	accepted	5485	Rare Germline	2023-01-09 21:46:47 UTC	https://civicdb.org/links/evidence_items/5485	https://civicdb.org/links/molecular_profiles/1615	FALSE	VHL	7428	R167Q (c.500G>A)		chr3	10149823	10149823	G	A	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.500G>A,NP_000542.1:p.Arg167Gln,NC_000003.11:g.10191507G>A,ENST00000256474.2:c.500G>A"	2023-01-27 17:11:29 UTC	CA020454	2216	"C.500G>A,ARG167GLN,RS5030821"	FALSE
VHL R167Q (c.500G>A)	1615	Von Hippel-Lindau Disease	14175	"Pheochromocytoma,Cerebellar hemangioblastoma,Retinal capillary hemangioma"			Predisposing	Supports	C	Uncertain Significance	"A study of 34 Polish families revealed germline mutations in 30 families. Mutations were not detected in 4 probands fulfilling clinical criteria for von Hippel-Lindau disease (VHLD). Arg167Trp and Arg167Gln mutations conferred a high (62%) risk for pheochromocytoma. Pheochromocytoma was diagnosed in all families with Arg167Gln mutation. This missense mutation was found in a VHL patient with retinal hemangioblastomas and pheochromocytoma (family no. 17). This mutation was also found in a VHL family of 8 affected patients (family no. 18). Seven had retinal hemangioblastomas, six had hemangioblastomas of the central nervous system, and 2 had pheochromocytoma. Cosegregation of the disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1)."	12114495	PubMed		"Cybulski et al., 2002, J. Med. Genet."		2	accepted	5487	Rare Germline	2023-01-09 21:46:47 UTC	https://civicdb.org/links/evidence_items/5487	https://civicdb.org/links/molecular_profiles/1615	FALSE	VHL	7428	R167Q (c.500G>A)		chr3	10149823	10149823	G	A	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.500G>A,NP_000542.1:p.Arg167Gln,NC_000003.11:g.10191507G>A,ENST00000256474.2:c.500G>A"	2023-01-27 17:11:29 UTC	CA020454	2216	"C.500G>A,ARG167GLN,RS5030821"	FALSE
VHL N78I (c.233A>T)	1913	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	"A study of 34 Polish families revealed germline mutations in 30 families. Mutations were not detected in 4 probands fulfilling clinical criteria for von Hippel-Lindau disease (VHLD). This missense mutation was found in a VHLD family of 4 affected patients (family no. 10). All 4 patients had retinal hemangioblastomas, 3 had hemangioblastomas of the central nervous system, and one had renal cell carcinoma. Cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1).  HPO terms: retinal hemangioblastoma, hemangioblastoma, renal cell carcinoma."	12114495	PubMed		"Cybulski et al., 2002, J. Med. Genet."		2	accepted	5489	Rare Germline	2023-01-09 21:46:54 UTC	https://civicdb.org/links/evidence_items/5489	https://civicdb.org/links/molecular_profiles/1913	FALSE	VHL	7428	N78I (c.233A>T)		chr3	10142080	10142080	A	T	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.233A>T,NP_000542.1:p.Asn78Ile,NC_000003.11:g.10183764A>T,ENST00000256474.2:c.233A>T"	2023-01-27 17:14:31 UTC	CA357063	223169	"C.233A>T,ASN78ILE,RS5030804"	FALSE
VHL N78S (c.233A>G)	1631	Von Hippel-Lindau Disease	14175	"Retinal capillary hemangioma,Renal cell carcinoma,Hemangioblastoma"			Predisposing	Supports	C	Uncertain Significance	A study of 34 Polish families revealed germline mutations in 30 families. Mutations were not detected in 4 probands fulfilling clinical criteria for von Hippel-Lindau disease (VHLD). This missense mutation was found in a VHL patient and 2 VHL family members. The single patient had hemangioblastomas of the central nervous system and retina (family no. 8). One of the family members had retinal hemangioblastomas and the other had renal cell carcinoma (family no. 9).	12114495	PubMed		"Cybulski et al., 2002, J. Med. Genet."		2	accepted	5491	Rare Germline	2023-01-09 21:46:48 UTC	https://civicdb.org/links/evidence_items/5491	https://civicdb.org/links/molecular_profiles/1631	FALSE	VHL	7428	N78S (c.233A>G)		chr3	10142080	10142080	A	G	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.233A>G,NP_000542.1:p.Asn78Ser,NC_000003.11:g.10183764A>G,ENST00000256474.2:c.233A>G"	2023-01-27 17:11:40 UTC	CA020131	93326	"C.233A>G,ASN78SER,RS5030804"	FALSE
VHL C162Y (c.485G>A)	1700	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	"A study of 34 Polish families revealed germline mutations in 30 families. Mutations were not detected in 4 probands fulfilling clinical criteria for von Hippel-Lindau disease (VHLD). This missense mutation was found in a VHL family of 5 affected patients (family no. 16). Four had retinal hemangioblastomas and 4 had hemangioblastomas of the central nervous system. Cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1). HPO terms: hemangioblastoma, retinal hemangioblastoma."	12114495	PubMed		"Cybulski et al., 2002, J. Med. Genet."		2	accepted	5493	Rare Germline	2023-01-09 21:46:50 UTC	https://civicdb.org/links/evidence_items/5493	https://civicdb.org/links/molecular_profiles/1700	FALSE	VHL	7428	C162Y (c.485G>A)		chr3	10149808	10149808	G	A	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.485G>A,NP_000542.1:p.Cys162Tyr,NC_000003.11:g.10191492G>A,ENST00000256474.2:c.485G>A"	2023-01-27 17:12:31 UTC	CA357010	223225	"C.485G>A,CYS162TYR,RS397516444"	FALSE
VHL W88FS (c.263_265delGGCinsTT)	1915	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	"A study of 34 Polish families revealed germline mutations in 30 families. Mutations were not detected in 4 probands fulfilling clinical criteria for von Hippel-Lindau disease (VHLD). This mutation was found in a VHL patient with hemangioblastomas of the central nervous system and retina (family no. 11). This study contains very strong evidence of pathogenicity in the form of a frameshift variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).  HPO terms: hemangioblastoma, retinal hemangioblastoma."	12114495	PubMed		"Cybulski et al., 2002, J. Med. Genet."		2	accepted	5495	Rare Germline	2023-01-09 21:46:54 UTC	https://civicdb.org/links/evidence_items/5495	https://civicdb.org/links/molecular_profiles/1915	FALSE	VHL	7428	W88FS (c.263_265delGGCinsTT)		chr3	10142110	10142112	GGC	TT	ENST00000256474.2	75		"frameshift_variant,delins"	"ENST00000256474.2:c.263_265delGGCinsTT,NC_000003.11:g.10183794_10183796delinsTT,NM_000551.3:c.263_265delinsTT,NP_000542.1:p.Trp88PhefsTer?"	2023-01-27 17:14:33 UTC	CA658683075	NONE FOUND	"C.263_265DELGGCINSTT,TRP88FS"	FALSE
VHL K159fs (c.477_478insCA)	1916	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	"A study of 34 Polish families revealed germline mutations in 30 families. Mutations were not detected in 4 probands fulfilling clinical criteria for von Hippel-Lindau disease (VHLD). This mutation was found in VHL patient with hemangioblastomas of the retina and central nervous system (family no. 14). This study contains very strong evidence of pathogenicity in the form of a frameshift variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).  HPO terms: hemangioblastoma, retinal hemangioblastoma."	12114495	PubMed		"Cybulski et al., 2002, J. Med. Genet."		2	accepted	5496	Rare Germline	2023-01-09 21:46:54 UTC	https://civicdb.org/links/evidence_items/5496	https://civicdb.org/links/molecular_profiles/1916	FALSE	VHL	7428	K159fs (c.477_478insCA)		chr3	10149800	10149801		CA	ENST00000256474.2	75		frameshift_variant	ENST00000256474.2:c.477_478insCA	2023-01-27 17:14:33 UTC	CA645525053	NONE FOUND	"LYS159FS,C.477_478INSCA"	FALSE
VHL S111R (c.333C>G)	1640	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	"A study of 34 Polish families revealed germline mutations in 30 families. Mutations were not detected in 4 probands fulfilling clinical criteria for von Hippel-Lindau disease (VHLD). This missense mutation was found in a VHL patient with hemangioblastomas of the central nervous system and retina (family no. 12). HPO terms: hemangioblastoma, retinal hemangioblastoma."	12114495	PubMed		"Cybulski et al., 2002, J. Med. Genet."		2	accepted	5498	Rare Germline	2023-01-09 21:46:49 UTC	https://civicdb.org/links/evidence_items/5498	https://civicdb.org/links/molecular_profiles/1640	FALSE	VHL	7428	S111R (c.333C>G)		chr3	10142180	10142180	C	G	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.333C>G,NP_000542.1:p.Ser111Arg,NC_000003.11:g.10183864C>G,ENST00000256474.2:c.333C>G"	2023-01-27 17:11:47 UTC	CA040305	223187	"C.333C>G,SER111ARG,RS765978945"	FALSE
VHL S65L (c.194C>T)	1664	Von Hippel-Lindau Disease	14175	"Hemangioblastoma,Renal cell carcinoma,Retinal capillary hemangioma"			Predisposing	Supports	C	Uncertain Significance	"A study of 34 Polish families revealed germline mutations in 30 families. Mutations were not detected in 4 probands fulfilling clinical criteria for von Hippel-Lindau disease (VHLD). This missense mutation was found in a single VHL patient and 2 VHL families with multiple affected individuals. The patient had hemangioblastomas of the central nervous system (family no. 1). A VHL family of 4 affected individuals had one patient with retinal hemangioblastomas, 3 with hemangioblastomas of the central nervous system, and one with renal cell carcinoma (family no. 2). A VHL family of 12 individuals had 10 with retinal hemangioblastomas, 3 with renal cell carcinoma, and 12 with hemangioblastomas of the central nervous system (family no. 3). Supporting evidence of pathogenicity since there is cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1). HPO terms: hemangioblastoma, retinal hemangioblastoma, renal cell carcinoma."	12114495	PubMed		"Cybulski et al., 2002, J. Med. Genet."		2	accepted	5499	Rare Germline	2023-01-09 21:46:49 UTC	https://civicdb.org/links/evidence_items/5499	https://civicdb.org/links/molecular_profiles/1664	FALSE	VHL	7428	S65L (c.194C>T)		chr3	10142041	10142041	C	T	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.194C>T,NP_000542.1:p.Ser65Leu,NC_000003.11:g.10183725C>T,ENST00000256474.2:c.194C>T"	2023-01-27 17:12:03 UTC	CA020104	182975	"C.194C>T,SER65LEU,RS5030826"	FALSE
VHL Q73FS (c.217delC)	1917	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	"A study of 34 Polish families revealed germline mutations in 30 families. Mutations were not detected in 4 probands fulfilling clinical criteria for von Hippel-Lindau disease (VHLD). This mutation was found in a VHL patient with hemangioblastomas of the central nervous system and retina (family no. 4). This study contains very strong evidence of pathogenicity in the form of a frameshift variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).  HPO terms: hemangioblastoma, retinal hemangioblastoma."	12114495	PubMed		"Cybulski et al., 2002, J. Med. Genet."		2	accepted	5500	Rare Germline	2023-01-09 21:46:54 UTC	https://civicdb.org/links/evidence_items/5500	https://civicdb.org/links/molecular_profiles/1917	FALSE	VHL	7428	Q73FS (c.217delC)		chr3	10142064	10142064	C		ENST00000256474.2	75		frameshift_truncation	"ENST00000256474.2:c.217delC,NC_000003.11:g.10183748del,NM_000551.3:c.217del,NP_000542.1:p.Gln73ArgfsTer?"	2023-01-27 17:14:34 UTC	CA432536422	NONE FOUND	"C.217DELC,GLN73FS"	FALSE
VHL A149fs (c.445delG)	1918	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	"A study of 34 Polish families revealed germline mutations in 30 families. Mutations were not detected in 4 probands fulfilling clinical criteria for von Hippel-Lindau disease (VHLD). This mutation was found in a VHL family of 3 individuals. All 3 had retinal hemangioblastomas, 2 had hemangioblastomas of the central nervous system, and one had renal cell carcinoma (family no. 13). ACMG codes as follows: A frameshift variant in a gene where loss-of-function is a known mechanism of disease (PVS1). HPO terms: hemangioblastoma, retinal hemangioblastoma, renal cell carcinoma."	12114495	PubMed		"Cybulski et al., 2002, J. Med. Genet."		2	accepted	5501	Rare Germline	2023-01-09 21:46:54 UTC	https://civicdb.org/links/evidence_items/5501	https://civicdb.org/links/molecular_profiles/1918	FALSE	VHL	7428	A149fs (c.445delG)		chr3	10146618	10146618	G		ENST00000256474.2	75		"frameshift_variant,minus_1_frameshift_variant"	"ENST00000256474.2:c.445delG,NC_000003.11:g.10188302delG,NM_000551.3:c.445delG,NP_000542.1:p.Ala149ProfsTer10"	2023-01-27 17:14:35 UTC	CA432421902	NONE FOUND	"C.445DELG,ALA149FS"	FALSE
RRM1 Underexpression	1231	Pancreatic Cancer	1793		Gemcitabine		Predictive	Supports	B	Sensitivity/Response	"There were 68 patients enrolled in this study, 28 of which were treated with gemcitabine.  Of those 28, 14 patients had a low RRM1 expression and 14 had a high RRM1 expression. Only the patients with low RRM1 expression received a significant benefit from gemcitabine (p=0.0010) whereas the benefit for those with a high RRM1 expression was not significantly better (p=0.3309).  The study also tested the role of ERCC1 expression and its correlation to RRM1 expression. It was found that patients with a combined high RRM1 and ERCC1 expression had good prognosis with the highest survival rate (P=0.0127)."	19543324	PubMed		"Akita et al., 2009, Oncogene"		3	accepted	5506	N/A	2023-01-09 21:46:44 UTC	https://civicdb.org/links/evidence_items/5506	https://civicdb.org/links/molecular_profiles/1231	FALSE	RRM1	6240	Underexpression		chr11	4094809	4138876			ENST00000300738.5	75		N/A		2023-01-09 21:52:12 UTC		N/A		FALSE
CD274 Expression	272	Cancer	162				Prognostic	Supports	B	Poor Outcome	"A meta analysis of 60 research studies involving 10,310 solid tumors indicated that CD274 over expression results in poor overall survival (HR??.58, P?.001) and poor disease free/progression free survival (DFS/PFS) (HR??.72, P?0?001). When split into sub groups by cancer type overall survival  was poor for breast (HR??.98, P?0?014), urothelial (HR??.24, P?0.001), renal (HR??.30,  P?0.001), and gastric cancers (HR??.56, P?0?040). DFS/PFS was poor in patients with hepatocellular carcinoma (HR??.72,  P??.003), melanoma (HR??.39,  P?0.001), and renal carcinoma, (HR??.04,  P?0.001)."	28471952	PubMed		"Wang et al., 2017, Medicine (Baltimore)"		4	accepted	5507	N/A	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/5507	https://civicdb.org/links/molecular_profiles/272	FALSE	CD274	29126	Expression		chr9	5450525	5470547			ENST00000381577.3	75		N/A	N/A	2023-01-09 21:52:06 UTC		N/A		FALSE
RRM1 Underexpression	1231	Pancreatic Cancer	1793		Gemcitabine		Predictive	Supports	B	Sensitivity/Response	"In this study, human pancreatic carcinoma cell line MiaPaCa2, which is a gemcitabine-sensitive cell line, was used for the establishment of chemoresistant cells MiaPaCa2-RG. Analysis for identifying genetic alterations relating to gemcitabine resistance revealed that RRM1 was the most upregulated gene with a 4.5 fold expression. RRM1-specic RNAi transfection significantly reduced the gemcitabine chemoresistance of MiaPaCa2-RG to the same level as that of gemcitabine sensitive MiaPaCa2. Moreover, gemcitabine response of MiaPaCa2 also became more sensitive.  Next, patients with pancreatic cancer were recruited and 18 tissue samples were taken. The patients with a low RRM1 expression had a significantly better outcome after gemcitabine treatment than those patients with high RRM1 expression (P=0.016)."	17131328	PubMed		"Nakahira et al., 2007, Int. J. Cancer"		3	accepted	5508	N/A	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/5508	https://civicdb.org/links/molecular_profiles/1231	FALSE	RRM1	6240	Underexpression		chr11	4094809	4138876			ENST00000300738.5	75		N/A		2023-01-09 21:52:12 UTC		N/A		FALSE
VHL S80R (c.238A>C)	1839	Von Hippel-Lindau Disease	14175	Retinal capillary hemangioma			Predisposing	Supports	C	Predisposition	Study of 103 patients with VHL retinal manifestations and 108 patients without VHL retinal manifestations revealed that the number of hemangioblastomas appeared higher in patients who had a substitution when compared with patients with a truncated protein. This missense mutation was found in a VHL patient with retinal hemangioblastomas.	12202531	PubMed		"Dollfus et al., 2002, Invest. Ophthalmol. Vis. Sci."		4	accepted	5510	Rare Germline	2023-02-03 19:15:48 UTC	https://civicdb.org/links/evidence_items/5510	https://civicdb.org/links/molecular_profiles/1839	FALSE	VHL	7428	S80R (c.238A>C)		chr3	10142085	10142085	A	C	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.238A>C,NC_000003.11:g.10183769A>C,NM_000551.3:c.238A>C,NP_000542.1:p.Ser80Arg"	2023-01-27 17:13:49 UTC	CA16621913	496052	"SER80ARG,C.238A>C,RS786202787"	FALSE
VHL R82P (c.245G>C)	1856	Von Hippel-Lindau Disease	14175	Retinal capillary hemangioma			Predisposing	Supports	C	Predisposition	"A study of 103 patients with VHL retinal manifestations and 108 patients without VHL retinal manifestations extracted from the French VHL database revealed that the number of hemangioblastomas appeared higher in patients who had a substitution when compared with patients with a truncated protein. Detected by PCR and SSCP, this mutation was found in 3 VHL patients. 1 member was said to have retinal hemangioblastomas, while the other 2 were said not to have this phenotype. Other manifestations are not clearly stated. No family information or relation was provided."	12202531	PubMed		"Dollfus et al., 2002, Invest. Ophthalmol. Vis. Sci."		4	accepted	5511	Rare Germline	2023-02-03 19:16:31 UTC	https://civicdb.org/links/evidence_items/5511	https://civicdb.org/links/molecular_profiles/1856	FALSE	VHL	7428	R82P (c.245G>C)		chr3	10142092	10142092	G	C	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.245G>C,NP_000542.1:p.Arg82Pro,NC_000003.11:g.10183776G>C,ENST00000256474.2:c.245G>C"	2023-01-27 17:13:58 UTC	CA020159	193118	"C.245G>C,ARG82PRO,RS794726890"	FALSE
VHL G104A (c.311G>C)	1919	Von Hippel-Lindau Disease	14175	Retinal capillary hemangioma			Predisposing	Supports	C	Predisposition	"A study of 103 patients with VHL retinal manifestations and 108 patients without VHL retinal manifestations extracted from the French VHL database revealed that the number of hemangioblastomas appeared higher in patients who had a substitution when compared with patients with a truncated protein. Detected by PCR and SSCP, this missense mutation was found in a VHL patient with retinal hemangioblastomas. Other manifestations are not clearly stated. No family information or relation was provided."	12202531	PubMed		"Dollfus et al., 2002, Invest. Ophthalmol. Vis. Sci."		4	accepted	5512	Rare Germline	2023-02-03 19:17:38 UTC	https://civicdb.org/links/evidence_items/5512	https://civicdb.org/links/molecular_profiles/1919	FALSE	VHL	7428	G104A (c.311G>C)		chr3	10142158	10142158	G	C	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.311G>C,NP_000542.1:p.Gly104Ala,NC_000003.11:g.10183842G>C,ENST00000256474.2:c.311G>C"	2023-01-27 17:14:36 UTC	CA16611067	411966	"C.311G>C,GLY104ALA,RS869025630"	FALSE
VHL R107H (c.320G>A)	1920	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Predisposition	"A study of 103 patients with VHL retinal manifestations and 108 patients without VHL retinal manifestations extracted from the French VHL database revealed that the number of hemangioblastomas appeared higher in patients who had a substitution when compared with patients with a truncated protein. Detected by PCR and SSCP, this mutation was found in a 1 patient, without retinal hemangioblastomas, but other manifestations are not clearly stated. No family information or relation was provided."	12202531	PubMed		"Dollfus et al., 2002, Invest. Ophthalmol. Vis. Sci."		4	accepted	5513	Rare Germline	2023-02-03 19:18:54 UTC	https://civicdb.org/links/evidence_items/5513	https://civicdb.org/links/molecular_profiles/1920	FALSE	VHL	7428	R107H (c.320G>A)		chr3	10142167	10142167	G	A	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.320G>A,NP_000542.1:p.Arg107His,NC_000003.11:g.10183851G>A,ENST00000256474.2:c.320G>A"	2023-01-27 17:14:37 UTC	CA357135	223184	"C.320G>A,ARG107HIS,RS193922609"	FALSE
VHL S111C (c.331A>T)	1921	Von Hippel-Lindau Disease	14175	Retinal capillary hemangioma			Predisposing	Supports	C	Predisposition	"A study of 103 patients with VHL retinal manifestations and 108 patients without VHL retinal manifestations extracted from the French VHL database revealed that the number of hemangioblastomas appeared higher in patients who had a substitution when compared with patients with a truncated protein. Detected by PCR and SSCP, this mutation was found in 3 VHL patients. All 3 members were said to have retinal hemangioblastomas, while other manifestations are not clearly stated. No family information or relation was provided."	12202531	PubMed		"Dollfus et al., 2002, Invest. Ophthalmol. Vis. Sci."		4	accepted	5514	Rare Germline	2023-02-03 19:20:01 UTC	https://civicdb.org/links/evidence_items/5514	https://civicdb.org/links/molecular_profiles/1921	FALSE	VHL	7428	S111C (c.331A>T)		chr3	10142178	10142178	A	T	ENST00000256474.2	75		missense_variant	"NC_000003.11:g.10183862A>T,NM_000551.3:c.331A>T,NP_000542.1:p.Ser111Cys"	2023-01-27 17:14:37 UTC	CA351751322	565557	"SER111CYS,RS1559426203,C.331A>T"	FALSE
VHL H115Q (c.345C>G)	1833	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Predisposition	"A study of 103 patients with VHL retinal manifestations and 108 patients without VHL retinal manifestations extracted from the French VHL database revealed that the number of hemangioblastomas appeared higher in patients who had a substitution when compared with patients with a truncated protein. Detected by PCR and SSCP, this missense mutation (c.343C>T) was found in a VHL patient without retinal hemangioblastomas. Other manifestations are not clearly stated. No family information was provided."	12202531	PubMed		"Dollfus et al., 2002, Invest. Ophthalmol. Vis. Sci."		4	accepted	5515	Rare Germline	2023-02-03 20:08:30 UTC	https://civicdb.org/links/evidence_items/5515	https://civicdb.org/links/molecular_profiles/1833	FALSE	VHL	7428	H115Q (c.345C>G)		chr3	10146518	10146518	C	G	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.345C>G,NC_000003.11:g.10188202C>G,NM_000551.3:c.345C>G,NP_000542.1:p.His115Gln"	2023-01-27 17:13:47 UTC	CA351753634	496058	"HIS115GLN,C.345C>G,RS864622646"	FALSE
RRM1 Underexpression	1231	Lung Non-small Cell Carcinoma	3908		Gemcitabine		Predictive	Supports	B	Sensitivity/Response	"In this study, 229 tumors were analyzed for RRM1 expression. This resulted in 146 that were negative for RRM1 expression and 83 that were positive. These tumors were studied for a relationship between RRM1 expression and chemotherapy regimens, gemcitabine, docetaxel and carboplatin, and vinorelbine and carboplatin. In the patients receiving gemcitabine treatment, the progression-free survival of RRM1-negative patients was significantly higher than that of RRM1-positive patients (8.8 months vs. 7.6 months, P = 0.01). The patients that were positive for RRM1 expression, had a better response to docetaxel or vinorelbine treatment than gemcitabine (P=0.047 and P=0.047). However, there were no differences of response to docetaxel and vinorelbine in regards to RRM1 expression."	24647522	PubMed		"Dong et al., 2014, PLoS ONE"		4	accepted	5530	N/A	2023-01-09 21:46:44 UTC	https://civicdb.org/links/evidence_items/5530	https://civicdb.org/links/molecular_profiles/1231	FALSE	RRM1	6240	Underexpression		chr11	4094809	4138876			ENST00000300738.5	75		N/A		2023-01-09 21:52:12 UTC		N/A		FALSE
DICER1 E1705K	1926	Sertoli-Leydig Cell Tumor	2997				Diagnostic	Supports	B	Positive	"Sanger sequencing identified DICER1 hotspot mutations in 20 of 32 (63%) ovarian SertoliLeydig cell tumors. These mutations were unrelated to tumor differentiation and mostly (16/20, 80%) were E1705K. Additionally, DICER1 E1705K mutations were identified in 5/8 (63%) Sertoli cell tumors and 2/5 (40%) gynandroblastomas. However, no mutations were identified in 15 testicular sex cord-stromal tumors (8 classical Sertoli cell tumors, 3 Sertoli cell tumors-large cell calcifying variant, 4 sex cord-stromal tumors not otherwise specified)."	26428316	PubMed		"Conlon et al., 2015, Mod. Pathol."		4	accepted	5533	Somatic	2023-01-09 21:46:54 UTC	https://civicdb.org/links/evidence_items/5533	https://civicdb.org/links/molecular_profiles/1926	FALSE	DICER1	23405	E1705K		chr14	95094139	95094139	C	T	ENST00000526495.1	75		missense_variant	ENST00000526495.1:c.5113G>A	2023-01-27 17:14:39 UTC	CA390865421	NONE FOUND	GLU1705LYS	FALSE
DICER1 E1813Q	1928	Sertoli-Leydig Cell Tumor	2997				Diagnostic	Does Not Support	B	Positive	"In this exploratory study of Sertoli-Leydig cell tumors, DICER1 mutations were found in over half of the samples sequenced, but were not found to have any role in tumorigenesis, contrary to what was previously believed. "	26428316	PubMed		"Conlon et al., 2015, Mod. Pathol."		4	accepted	5535	Somatic	2023-01-09 21:46:54 UTC	https://civicdb.org/links/evidence_items/5535	https://civicdb.org/links/molecular_profiles/1928	FALSE	DICER1	23405	E1813Q		chr14	95091293	95091293	C	G	ENST00000526495.1	75		missense_variant	ENST00000526495.1:c.5437G>C	2023-01-27 17:14:40 UTC	CA390864655	NONE FOUND	GLU1813GLN	FALSE
VHL F136S (c.407T>C)	1677	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	"Germline mutations were found in 20 Brazilian, VHL probands and their families. This missense mutation was found in a VHL type 1 family of 8 affected individuals (VHL family 12). Seven had hemangioblastomas of the central nervous system, one had retinal angiomas, and 2 had renal carcinoma. Cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1). HPO terms: hemangioblastoma, retinal hemangioblastoma, renal cell carcinoma."	12624160	PubMed		"Rocha et al., 2003, J. Med. Genet."		3	accepted	5543	Rare Germline	2023-01-09 21:46:50 UTC	https://civicdb.org/links/evidence_items/5543	https://civicdb.org/links/molecular_profiles/1677	FALSE	VHL	7428	F136S (c.407T>C)		chr3	10146580	10146580	T	C	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.407T>C,NC_000003.11:g.10188264T>C,NM_000551.3:c.407T>C,NP_000542.1:p.Phe136Ser"	2023-01-27 17:12:13 UTC	CA040847	496064	"C.407T>C,PHE136SER,RS5030833"	FALSE
VHL P146fs (c.437del)	1931	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	"Germline mutations were found in 20 Brazilian, VHL probands and their families. This mutation causes a premature stop codon at amino acid 158 and was found in a VHL type 1 patient with hemangioblastomas of the central nervous system, retinal angiomas, and renal carcinoma (VHL family 13). This study contains very strong evidence for pathogenicity in the form of a frameshift mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1). HPO terms: hemangioblastoma, retinal hemangioblastoma, renal cell carcinoma."	12624160	PubMed		"Rocha et al., 2003, J. Med. Genet."		3	accepted	5544	Rare Germline	2023-01-09 21:46:54 UTC	https://civicdb.org/links/evidence_items/5544	https://civicdb.org/links/molecular_profiles/1931	FALSE	VHL	7428	P146fs (c.437del)		chr3	10146609	10146609	C		ENST00000256474.2	75		"minus_1_frameshift_variant,frameshift_truncation"	"NC_000003.12:g.10146610del,ENST00000256474.2:c.437del,NC_000003.11:g.10188294del,NM_000551.3:c.437del,NP_000542.1:p.Pro146LeufsTer13"	2023-01-27 17:14:42 UTC	CA432421892	NONE FOUND	"C.436DELC,PRO146FS,C.437DELC,P146LFS*13"	FALSE
VHL R167W (c.499C>T)	1623	Von Hippel-Lindau Disease	14175	"Pheochromocytoma,Hemangioblastoma"			Predisposing	Supports	C	Uncertain Significance	"Germline mutations were found in 20 Brazilian, VHL probands and their families. This missense mutation was found in 2 affected family members with pheochromocytoma (VHL family 15). One also had hemangioblastomas of the central nervous system."	12624160	PubMed		"Rocha et al., 2003, J. Med. Genet."		3	accepted	5545	Rare Germline	2023-01-09 21:46:48 UTC	https://civicdb.org/links/evidence_items/5545	https://civicdb.org/links/molecular_profiles/1623	FALSE	VHL	7428	R167W (c.499C>T)		chr3	10149822	10149822	C	T	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.499C>T,NP_000542.1:p.Arg167Trp,NC_000003.11:g.10191506C>T,ENST00000256474.2:c.499C>T"	2023-01-27 17:11:35 UTC	CA020450	2218	"C.499C>T,ARG167TRP,R126W,RS5030820"	FALSE
VHL R167Q (c.500G>A)	1615	Von Hippel-Lindau Disease	14175	"Pheochromocytoma,Hemangioblastoma"			Predisposing	Supports	C	Predisposition	"Germline mutations were found in 20 Brazilian, VHL probands and their families. This missense mutation was found in a VHL type 2 family of 4 affected individuals (VHL family 16). Two patients had hemangioblastomas of the central nervous system and three had pheochromocytoma. ACMG codes as follows: Cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (PP1)."	12624160	PubMed		"Rocha et al., 2003, J. Med. Genet."		3	accepted	5546	Rare Germline	2023-01-09 21:46:47 UTC	https://civicdb.org/links/evidence_items/5546	https://civicdb.org/links/molecular_profiles/1615	FALSE	VHL	7428	R167Q (c.500G>A)		chr3	10149823	10149823	G	A	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.500G>A,NP_000542.1:p.Arg167Gln,NC_000003.11:g.10191507G>A,ENST00000256474.2:c.500G>A"	2023-01-27 17:11:29 UTC	CA020454	2216	"C.500G>A,ARG167GLN,RS5030821"	FALSE
VHL S80R (c.238A>C)	1839	Von Hippel-Lindau Disease	14175	"Retinal capillary hemangioma,Renal cell carcinoma,Hemangioblastoma"			Predisposing	Supports	C	Uncertain Significance	"Germline mutations were found in 20 Brazilian, VHL probands and their families. This missense mutation was found in a VHL type 1 family of 10 affected individuals (VHL family 2). Seven had hemangioblastomas of the central nervous system, 3 had retinal angiomas, and 3 had renal carcinoma. Cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1)."	12624160	PubMed		"Rocha et al., 2003, J. Med. Genet."		3	accepted	5547	Rare Germline	2023-01-09 21:46:53 UTC	https://civicdb.org/links/evidence_items/5547	https://civicdb.org/links/molecular_profiles/1839	FALSE	VHL	7428	S80R (c.238A>C)		chr3	10142085	10142085	A	C	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.238A>C,NC_000003.11:g.10183769A>C,NM_000551.3:c.238A>C,NP_000542.1:p.Ser80Arg"	2023-01-27 17:13:49 UTC	CA16621913	496052	"SER80ARG,C.238A>C,RS786202787"	FALSE
VHL S80R (c.238A>C)	1839	Von Hippel-Lindau Disease	14175	"Renal cell carcinoma,Hemangioblastoma,Retinal capillary hemangioma"			Predisposing	Supports	C	Uncertain Significance	"Germline mutations were found in 20 Brazilian, VHL probands and their families. This missense mutation was found in a VHL type 1 family of 10 affected individuals (VHL family 2). Seven had hemangioblastomas of the central nervous system, 3 had retinal angiomas, and 3 had renal carcinoma. Cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1)."	12624160	PubMed		"Rocha et al., 2003, J. Med. Genet."		3	accepted	5548	Rare Germline	2023-01-09 21:46:53 UTC	https://civicdb.org/links/evidence_items/5548	https://civicdb.org/links/molecular_profiles/1839	FALSE	VHL	7428	S80R (c.238A>C)		chr3	10142085	10142085	A	C	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.238A>C,NC_000003.11:g.10183769A>C,NM_000551.3:c.238A>C,NP_000542.1:p.Ser80Arg"	2023-01-27 17:13:49 UTC	CA16621913	496052	"SER80ARG,C.238A>C,RS786202787"	FALSE
VHL W88R (c.262T>C)	1932	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	"Germline mutations were found in 20 Brazilian, VHL probands and their families. This missense mutation was found in 2 VHL family members (VHL family 3). One had hemangioblastomas of the central nervous system and the other had retinal angiomas. HPO terms: hemangioblastoma, retinal hemangioblastoma."	12624160	PubMed		"Rocha et al., 2003, J. Med. Genet."		3	accepted	5549	Rare Germline	2023-01-09 21:46:54 UTC	https://civicdb.org/links/evidence_items/5549	https://civicdb.org/links/molecular_profiles/1932	FALSE	VHL	7428	W88R (c.262T>C)		chr3	10142109	10142109	T	C	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.262T>C,NC_000003.11:g.10183793T>C,NM_000551.3:c.262T>C,NP_000542.1:p.Trp88Arg"	2023-01-27 17:14:43 UTC	CA351750667	496053	"TRP88ARG,C.262T>C,RS1553619431"	FALSE
VHL E94* (c.280G>T)	1670	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	"Germline mutations were found in 20 Brazilian, VHL probands and their families. This nonsense mutation was found in a VHL type 1 family of 3 affected individuals. All three family members had retinal angiomas and 2 also had hemangioblastomas of the central nervous system (VHL family 4). A nonsense mutation in a gene where loss-of-function is a known mechanism of disease (PVS1). HPO terms: hemangioblastoma, retinal hemangioblastoma."	12624160	PubMed		"Rocha et al., 2003, J. Med. Genet."		3	accepted	5550	Rare Germline	2023-01-09 21:46:49 UTC	https://civicdb.org/links/evidence_items/5550	https://civicdb.org/links/molecular_profiles/1670	FALSE	VHL	7428	E94* (c.280G>T)		chr3	10142127	10142127	G	T	ENST00000256474.2	75		stop_gained	"ENST00000256474.2:c.280G>T,NM_198156.2:c.280G>T,NP_000542.1:p.Glu94Ter,NC_000003.11:g.10183811G>T"	2023-01-27 17:12:08 UTC	CA70046202	584477	"C.280G>T,E94X,GLU94TER,RS5030829"	FALSE
VHL H115fs (c.344del)	1933	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	"Germline mutations were found in 20 Brazilian, VHL probands and their families. This mutstaion was found in a VHL type 1 family of 3 affected individuals (VHL family 9). One had hemangioblastomas of the central nervous system, one with retinal angiomas, and one with renal carcinoma. ACMG codes as follows: A frameshift mutation in a gene where loss-of-function is a known mechanism of disease (PVS1). Cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (PP1). HPO terms: hemangioblastoma, retinal hemangioblastoma, renal cell carcinoma."	12624160	PubMed		"Rocha et al., 2003, J. Med. Genet."		3	accepted	5553	Rare Germline	2023-01-09 21:46:55 UTC	https://civicdb.org/links/evidence_items/5553	https://civicdb.org/links/molecular_profiles/1933	FALSE	VHL	7428	H115fs (c.344del)		chr3	10146517	10146517	A		ENST00000256474.2	75		"minus_1_frameshift_variant,frameshift_truncation"	"NC_000003.11:g.10188201del,NM_000551.3:c.344delA,ENST00000256474.2:c.344del,NP_000542.1:p.His115ProfsTer44"	2023-01-27 17:14:44 UTC	CA70049370	NONE FOUND	"C.344DELA,HIS115FS,RS1553619937,HIS115PROFSTER44 (C.344DEL),H115FS (C.344DELA),H115PFS*44 (C.344DEL)"	FALSE
VHL P102fs (c.305delC)	1934	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	"Germline mutations were found in 20 Brazilian, VHL probands and their families. This mutation causes a premature stop codon at amino acid 142 and was found in a VHL type 1 patient with hemangioblastomas of the central nervous system (VHL family 6). This study contains very strong evidence for pathogenicity in the form of a frameshift mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1). HPO terms: hemangioblastoma."	12624160	PubMed		"Rocha et al., 2003, J. Med. Genet."		3	accepted	5554	Rare Germline	2023-01-09 21:46:55 UTC	https://civicdb.org/links/evidence_items/5554	https://civicdb.org/links/molecular_profiles/1934	FALSE	VHL	7428	P102fs (c.305delC)		chr3	10142152	10142152	C		ENST00000256474.2	75		frameshift_truncation	"ENST00000256474.2:c.305delC,NC_000003.11:g.10183836del,NM_000551.3:c.305del,NP_000542.1:p.Pro102ArgfsTer?"	2023-01-27 17:14:44 UTC	CA658820710	NONE FOUND	"C.305DELC,PRO102FS"	FALSE
VHL E94* (c.280G>T)	1670	Von Hippel-Lindau Disease	14175	"Pancreatic cysts,Spinal hemangioblastoma"			Predisposing	N/A	C	N/A	"Case report of a female VHL patient presenting with spinal hemangioblastoma at the age of 32. Further workup showed the presence of pancreatic cysts and a history of spinal hemangioblastoma in the mother. Genetic testing confirmed the presence of the above mutation in the proband. There was no mention of genetic testing performed on her mother in this paper. ACMG evidence codes: 'PVS1' because they observe a nonsense variant in a gene where loss of function is a known mechanism of disease, 'PP4' because the patients' phenotypes or family history are highly specific for a disease with single genetic etiology. Relevant HPO terms: Spinal hemangioblastoma, Multiple pancreatic cysts."	22133049	PubMed		"Sun et al., 2012, Br J Neurosurg"		3	accepted	5561	Rare Germline	2023-01-09 21:46:49 UTC	https://civicdb.org/links/evidence_items/5561	https://civicdb.org/links/molecular_profiles/1670	FALSE	VHL	7428	E94* (c.280G>T)		chr3	10142127	10142127	G	T	ENST00000256474.2	75		stop_gained	"ENST00000256474.2:c.280G>T,NM_198156.2:c.280G>T,NP_000542.1:p.Glu94Ter,NC_000003.11:g.10183811G>T"	2023-01-27 17:12:08 UTC	CA70046202	584477	"C.280G>T,E94X,GLU94TER,RS5030829"	FALSE
VHL Y175N (c.523T>A)	1942	Von Hippel-Lindau Disease	14175	"Pheochromocytoma,Retinal capillary hemangioma"			Predisposing	Supports	C	Predisposition	"Thirty-five unrelated patients suspected of having von Hippel-Lindau disease were analyzed and 32 VHL gene variants were found in 35 patients. An association of clear cell renal carcinoma development with a relatively high loss of structural stability in VHL protein missense mutations was discovered. This missense mutation (Y175N (c.523T>A)) was found in a 32 year old patient with retinal hemangioblastomas and pheochromocytomas (patient no. F11). ACMG evidence code: ""flag for PP4"" because patients phenotype is highly specific for the disease."	14722919	PubMed		"Ruiz-Llorente et al., 2004, Hum. Mutat."		3	accepted	5576	Rare Germline	2023-02-17 03:03:56 UTC	https://civicdb.org/links/evidence_items/5576	https://civicdb.org/links/molecular_profiles/1942	FALSE	VHL	7428	Y175N (c.523T>A)		chr3	10149846	10149846	T	A	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.523T>A,NC_000003.11:g.10191530T>A,NM_000551.3:c.523T>A,NP_000542.1:p.Tyr175Asn"	2023-01-27 17:14:50 UTC	CA351756226	NONE FOUND	"C.523T>A,TYR175ASN"	FALSE
VHL Y175C (c.524A>G)	1943	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Predisposition	Thirty-five unrelated patients suspected of having von Hippel-Lindau disease were analyzed and 32 VHL gene variants were found in 35 patients. An association of clear cell renal carcinoma development with a relatively high loss of structural stability in VHL protein missense mutations was discovered. This missense mutation was found in a 32 year old patient with unilateral pheochromocytoma (patient no. F15). The patient also had a family history of pheochromocytoma. ACMG evidence codes: none	14722919	PubMed		"Ruiz-Llorente et al., 2004, Hum. Mutat."		3	accepted	5577	Rare Germline	2023-02-17 03:05:32 UTC	https://civicdb.org/links/evidence_items/5577	https://civicdb.org/links/molecular_profiles/1943	FALSE	VHL	7428	Y175C (c.524A>G)		chr3	10149847	10149847	A	G	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.524A>G,NP_000542.1:p.Tyr175Cys,NC_000003.11:g.10191531A>G,ENST00000256474.2:c.524A>G"	2023-01-27 17:14:51 UTC	CA020462	36905	"C.524A>G,TYR175CYS,RS193922613"	FALSE
VHL D121G (c.362A>G)	1689	Von Hippel-Lindau Disease	14175	"Renal cyst,Pheochromocytoma,Hemangioblastoma,Retinal capillary hemangioma"			Predisposing	N/A	C	N/A	"Thirty-five unrelated patients suspected of having von Hippel-Lindau disease were analyzed and 32 VHL gene variants were found in 35 patients. An association of clear cell renal carcinoma development with a relatively high loss of structural stability in VHL protein missense mutations was discovered. This missense mutation was found in a 31 year old patient with retinal hemangioblastomas and renal cysts (patient no. F26). Patient had family history of pheochromocytomas and hemangioblastomas of the central nervous system. ACMG evidence code: ""flag for PP4"" because patients phenotype is highly specific for the disease."	14722919	PubMed		"Ruiz-Llorente et al., 2004, Hum. Mutat."		3	accepted	5578	Rare Germline	2023-01-09 21:46:50 UTC	https://civicdb.org/links/evidence_items/5578	https://civicdb.org/links/molecular_profiles/1689	FALSE	VHL	7428	D121G (c.362A>G)		chr3	10146535	10146535	A	G	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.362A>G,NP_000542.1:p.Asp121Gly,NC_000003.11:g.10188219A>G,ENST00000256474.2:c.362A>G"	2023-01-27 17:12:23 UTC	CA357083	223200	"C.362A>G,ASP121GLY,RS5030832"	FALSE
VHL S65L (c.194C>T)	1664	Von Hippel-Lindau Disease	14175	"Clear cell renal cell carcinoma,Cerebellar hemangioblastoma"			Predisposing	Supports	C	Predisposition	"Thirty-five unrelated patients suspected of having von Hippel-Lindau disease were analyzed and 32 VHL gene variants were found in 35 patients. An association of clear cell renal carcinoma development with a relatively high loss of structural stability in VHL protein missense mutations was discovered. This germline missense mutation was found in a 25 year old patient with cerebellar hemangioblastomas, and clear cell renal carcinoma (patient no. F62). The patient's family history was negative for VHL features. This evidence supports the following ACMG Code: PP4- Patient's phenotype is specific for a disease with a single genetic etiology."	14722919	PubMed		"Ruiz-Llorente et al., 2004, Hum. Mutat."		3	accepted	5582	Rare Germline	2023-02-17 03:12:15 UTC	https://civicdb.org/links/evidence_items/5582	https://civicdb.org/links/molecular_profiles/1664	FALSE	VHL	7428	S65L (c.194C>T)		chr3	10142041	10142041	C	T	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.194C>T,NP_000542.1:p.Ser65Leu,NC_000003.11:g.10183725C>T,ENST00000256474.2:c.194C>T"	2023-01-27 17:12:03 UTC	CA020104	182975	"C.194C>T,SER65LEU,RS5030826"	FALSE
VHL Q96* (c.286C>T)	1724	Von Hippel-Lindau Disease	14175	Retinal capillary hemangioma			Predisposing	Supports	C	Predisposition	Thirty-five unrelated patients suspected of having von Hippel-Lindau disease were analyzed and 32 VHL gene variants were found in 35 patients. An association of clear cell renal carcinoma development with a relatively high loss of structural stability in VHL protein missense mutations was discovered. This nonsense mutation was found in a patient with retinal hemangioblastoma (patient no. F66). Patient has family history of pancreatic cysts. This study contains very strong evidence for pathogenicity in the form of a nonsense mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).	14722919	PubMed		"Ruiz-Llorente et al., 2004, Hum. Mutat."		3	accepted	5583	Rare Germline	2023-02-17 03:15:35 UTC	https://civicdb.org/links/evidence_items/5583	https://civicdb.org/links/molecular_profiles/1724	FALSE	VHL	7428	Q96* (c.286C>T)		chr3	10142133	10142133	C	T	ENST00000256474.2	75		stop_gained	"NM_000551.3:c.286C>T,NP_000542.1:p.Gln96Ter,NC_000003.11:g.10183817C>T,ENST00000256474.2:c.286C>T"	2023-01-27 17:12:46 UTC	CA351750811	428804	"C.286C>T,Q96X,GLN96TER,RS1131690959"	FALSE
VHL S65W (c.194C>G)	1663	Von Hippel-Lindau Disease	14175	Renal cell carcinoma			Predisposing	Supports	C	Uncertain Significance	"The study looked to evaluate growth kinetic in VHL-associated renal cell carcinoma.  Of the 64 VHL patients with renal involvement, 61 were confirmed to have a germline variant. This variant was identified in one patient (Patient #3 - supplementary table). Clinical manifestations included renal cell carcinoma; other manifestations were not discussed."	22156657	PubMed		"Jilg et al., 2012, Urol. Int."		2	accepted	5592	Rare Germline	2023-01-09 21:46:49 UTC	https://civicdb.org/links/evidence_items/5592	https://civicdb.org/links/molecular_profiles/1663	FALSE	VHL	7428	S65W (c.194C>G)		chr3	10142041	10142041	C	G	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.194C>G,NM_000551.3:c.194C>G,NP_000542.1:p.Ser65Trp,NC_000003.11:g.10183725C>G"	2023-01-27 17:12:02 UTC	CA020099	43597	"C.194C>G,SER65TRP,RS5030826"	FALSE
RRM1 Underexpression	1231	Lung Non-small Cell Carcinoma	3908		"Vinorelbine,Paclitaxel,Gemcitabine"	Substitutes	Predictive	Supports	B	Sensitivity/Response	"The study began with a total of 443 patients that were randomly assigned to either regimen A (Paclitaxel and cisplatin with gemcitabine) or regimen B ( cisplatin and vinorelbine). Of those patients, 261 had tissue available for RRM1 evaluation. In regimen B, survival increased significantly in patients with low RRM1 expression as compared to those with a high expression (P=0.046). However, in regimen A, the increase in survival for patients with low RRM1 expression as opposed to those with a high RRM1 expression was not as significant (P=0.366)."	23038758	PubMed		"Vilmar et al., 2013, Ann. Oncol."		3	accepted	5599	N/A	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/5599	https://civicdb.org/links/molecular_profiles/1231	FALSE	RRM1	6240	Underexpression		chr11	4094809	4138876			ENST00000300738.5	75		N/A		2023-01-09 21:52:12 UTC		N/A		FALSE
VHL Splice Site (c.463+2T>C)	1951	Von Hippel-Lindau Disease	14175	Renal cell carcinoma			Predisposing	Supports	C	Uncertain Significance	"64 VHL patients with renal involvement were analyzed. 61 of the 64 patients had a known germline mutation. The above mutation was found in 2 patients. Clinical manifestations included renal cell carcinoma; other manifestations are possible, but not discussed. ACMG evidence codes: 'PSV1' because they observe a canonical +2 splice site variant in a gene where loss of function is a known mechanism of disease."	22156657	PubMed		"Jilg et al., 2012, Urol. Int."		3	accepted	5610	Rare Germline	2023-01-09 21:46:55 UTC	https://civicdb.org/links/evidence_items/5610	https://civicdb.org/links/molecular_profiles/1951	FALSE	VHL	7428	Splice Site (c.463+2T>C)		chr3	10146638	10146638	T	C	ENST00000256474.2	75		splice_donor_variant	"NM_000551.3:c.463+2T>C,NC_000003.11:g.10188322T>C,ENST00000256474.2:c.463+2T>C,NP_000542.1:p.?,NC_000003.12:g.10146638T>C"	2023-01-27 17:14:55 UTC	CA16621936	569414	"C.463+2T>C,RS5030814"	FALSE
VHL R82_V84del (c.243_251del)	1965	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. Large deletions or intragenic mutations predicted to cause a truncated protein were found in 36 of 53 families without pheochromocytoma (VHL type 1) and 2 of 12 families with pheochromocytoma (VHL type 2). This mutation was found in a VHL type 1 patient (kindred no. 35). Only moderate support for pathogenicity because protein length changes as a result of in-frame deletions in a nonrepeat region (ACMG code: PM4).	7987306	PubMed		"Crossey et al., 1994, Hum. Mol. Genet."		3	accepted	5637	Rare Germline	2023-01-09 21:46:55 UTC	https://civicdb.org/links/evidence_items/5637	https://civicdb.org/links/molecular_profiles/1965	FALSE	VHL	7428	R82_V84del (c.243_251del)		chr3	10142090	10142098	GCGCGTCGT		ENST00000256474.2	75		inframe_deletion	"NC_000003.11:g.10183774_10183782del,NC_000003.12:g.10142092_10142100del,NM_000551.4:c.245_253del,NP_000542.1:p.Arg82_Val84del"	2023-01-27 17:15:02 UTC	CA658820713	NONE FOUND	"P81DELRVV (C.243_251DELGCGCGTCGT),ARG82_VAL84DEL"	FALSE
VHL F76del (c.224_226delTCT)	1964	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	"An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. This mutation was found in 2 VHL type 1 patients (kindred no. 48, 75). Only moderate support for pathogenicity because protein length changes as a result of in-frame deletion in a nonrepeat region (ACMG code: PM4)."	7987306	PubMed		"Crossey et al., 1994, Hum. Mol. Genet."		3	accepted	5641	Rare Germline	2023-01-09 21:46:55 UTC	https://civicdb.org/links/evidence_items/5641	https://civicdb.org/links/molecular_profiles/1964	FALSE	VHL	7428	F76del (c.224_226delTCT)		chr3	10142071	10142073	TCT		ENST00000256474.2	75		inframe_deletion	"NP_000542.1:p.Phe76del,ENST00000256474.2:c.224_226delTCT,NC_000003.11:g.10183758_10183760del,NC_000003.12:g.10142074_10142076del,NM_000551.3:c.227_229del,ENSP00000256474.2:p.Phe76del"	2023-01-27 17:15:01 UTC	CA357012	223166	"PHE76DEL,C.224_226DELTCT,C.226_228DELTTC,C.227_229DELTCT,DELPHE76"	FALSE
VHL Splice Site (c.464-1G>T)	1866	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. Large deletions or intragenic mutations predicted to cause a truncated protein were found in 36 of 53 families without pheochromocytoma (VHL type 1) and 2 of 12 families with pheochromocytoma (VHL type 2). This splice mutation was found in a VHL type 1 patient (kindred no. 143). This study contains very strong evidence for pathogenicity in the form of a canonical -1 splice site mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).	7987306	PubMed		"Crossey et al., 1994, Hum. Mol. Genet."		3	accepted	5642	Rare Germline	2023-01-09 21:46:54 UTC	https://civicdb.org/links/evidence_items/5642	https://civicdb.org/links/molecular_profiles/1866	FALSE	VHL	7428	Splice Site (c.464-1G>T)		chr3	10149786	10149786	G	T	ENST00000256474.2	75		splice_acceptor_variant	"NC_000003.11:g.10191470G>T,NM_000551.3:c.464-1G>T,ENST00000256474.2:c.464-1G>T,NC_000003.12:g.10149786G>T,NP_000542.1:p.?"	2023-01-27 17:14:02 UTC	CA357144	223221	"C.464-1G>T,RS5030817,IVS2-1G>T"	FALSE
VHL R177fs (c.528del)	1783	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	An investigation of 94 VHL patients without large deletions for intragenic mutations revealed 40 different mutations in 55 unrelated individuals. In all patients with multiple affected family members the missense mutation segregated with the disease. This mutation was found in a VHL type 1 family (kindred no. 54). This study contains very strong evidence for pathogenicity in the form of a frameshift mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1).	7987306	PubMed		"Crossey et al., 1994, Hum. Mol. Genet."		3	accepted	5643	Rare Germline	2023-01-09 21:46:52 UTC	https://civicdb.org/links/evidence_items/5643	https://civicdb.org/links/molecular_profiles/1783	FALSE	VHL	7428	R177fs (c.528del)		chr3	10149851	10149851	G		ENST00000256474.2	75		"minus_1_frameshift_variant,frameshift_truncation"	"ENST00000256474.2:c.528delG,NC_000003.11:g.10191535del,NM_000551.3:c.528del,NP_000542.1:p.Arg177AspfsTer25"	2023-01-27 17:13:18 UTC	CA432423454	NONE FOUND	"ARG176FS,C.528DELG,R177DFS*25 (C.528DELG),R176FS (C.528DELG),R176FS (C.528DEL)"	FALSE
VHL L158fs (c.471dupT)	1659	Von Hippel-Lindau Disease	14175				Predisposing	N/A	C	N/A	"Germline mutation analysis of 469 VHL families reveled 300 mutations. The most common germline mutations were identified between codons 75-82, between codons 157-189 (Elongin binding domain) and at the splice site between exons 2 and 3. The association between mutations in codon 167 and pheochromocytoma was detected in all nationalities tested. This mutation was found in a VHL family (family ID 6BMS). No phenotype described. This study contains very strong evidence for pathogenicity in the form of a frameshift mutation in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1)."	8956040	PubMed		"Zbar et al., 1996, Hum. Mutat."		2	accepted	5646	Rare Germline	2023-01-09 21:46:49 UTC	https://civicdb.org/links/evidence_items/5646	https://civicdb.org/links/molecular_profiles/1659	FALSE	VHL	7428	L158fs (c.471dupT)		chr3	10149794	10149795		T	ENST00000256474.2	75		frameshift_variant	"NC_000003.11:g.10191478dup,NC_000003.12:g.10149794dup,NM_000551.3:c.471dup,NP_000542.1:p.Leu158SerfsTer16,ENST00000256474.2:c.471dup,ENSP00000256474.2:p.Leu158SerfsTer16"	2023-01-27 17:11:59 UTC	CA357050	NONE FOUND	C.685INST	FALSE
VHL G93_Y98del (c.275_292del)	1973	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Predisposition	Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This mutation was found in VHL type 1 family (lineage 11). Only moderate evidence for pathogenicity because protein length changes as a result of in-frame deletion in a nonrepeat region (ACMG code: PM4).	9829911	PubMed		"Stolle et al., 1998, Hum. Mutat."		3	accepted	5649	Rare Germline	2023-02-03 16:24:57 UTC	https://civicdb.org/links/evidence_items/5649	https://civicdb.org/links/molecular_profiles/1973	FALSE	VHL	7428	G93_Y98del (c.275_292del)		chr3	10142122	10142139	ACGGCGAGCCGCAGCCC		ENST00000256474.2	75		frameshift_variant		2023-01-27 17:15:03 UTC	CA891843321	574427	D92_Y98DEL	FALSE
VHL F76del (c.224_226delTCT)	1964	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Predisposition	"Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This mutation was found in 2 VHL type 1 families (lineages 136, 183). Only moderate evidence for pathogenicity because protein length changes as a result of in-frame deletion in a nonrepeat region (ACMG code: PM4)."	9829911	PubMed		"Stolle et al., 1998, Hum. Mutat."		3	accepted	5650	Rare Germline	2023-02-03 18:26:37 UTC	https://civicdb.org/links/evidence_items/5650	https://civicdb.org/links/molecular_profiles/1964	FALSE	VHL	7428	F76del (c.224_226delTCT)		chr3	10142071	10142073	TCT		ENST00000256474.2	75		inframe_deletion	"NP_000542.1:p.Phe76del,ENST00000256474.2:c.224_226delTCT,NC_000003.11:g.10183758_10183760del,NC_000003.12:g.10142074_10142076del,NM_000551.3:c.227_229del,ENSP00000256474.2:p.Phe76del"	2023-01-27 17:15:01 UTC	CA357012	223166	"PHE76DEL,C.224_226DELTCT,C.226_228DELTTC,C.227_229DELTCT,DELPHE76"	FALSE
VHL E160fs (c.477del)	1974	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Predisposition	Germline mutations were found in all 93 families that fulfilled clinical criteria of VHL disease. Mutations predicted to inactivate the VHL protein were associated with renal cell carcinoma and hemangioblastomas of the central nervous system (VHL type 1); mutations predicted to produce full length VHL proteins were associated with pheochromocytoma (VHL type 2). This mutation causes a premature stop codon at amino acid 170 and was found in a VHL type 1 family (lineage 16). There is very strong evidence of pathogenicity in the form of a frameshift variant in a gene where loss-of-function is known mechanism of disease (ACMG code: PVS1).	9829911	PubMed		"Stolle et al., 1998, Hum. Mutat."		3	accepted	5651	Rare Germline	2023-02-03 18:33:53 UTC	https://civicdb.org/links/evidence_items/5651	https://civicdb.org/links/molecular_profiles/1974	FALSE	VHL	7428	E160fs (c.477del)		chr3	10149798	10149798	A		ENST00000256474.2	75		"minus_1_frameshift_variant,frameshift_truncation"	"ENST00000256474.2:c.475del,NP_000542.1:p.Glu160SerfsTer10,NM_000551.3:c.477del,NC_000003.12:g.10149800del,NC_000003.11:g.10191484del"	2023-01-27 17:15:04 UTC	CA020404	182959	"C.475DELA,LYS159FS,E160SFS*10"	FALSE
VHL V66del (c.197_220del)	1975	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This mutation was found in a VHL type 1 patient (patient no. V287). Only moderate evidence of pathogenicity since the protein length changes as a result of an in-frame deletion in a nonrepeat region (AMCG code: PM4). One unaffected family member was tested and negative for this mutation.	9829912	PubMed		"Olschwang et al., 1998, Hum. Mutat."		2	accepted	5653	Rare Germline	2023-01-09 21:46:55 UTC	https://civicdb.org/links/evidence_items/5653	https://civicdb.org/links/molecular_profiles/1975	FALSE	VHL	7428	V66del (c.197_220del)		chr3	10142044	10142058	TGAACTCGCGCGAGC		ENST00000256474.2	75		inframe_deletion		2023-01-09 21:52:17 UTC	unregistered		197DEL24	FALSE
VHL F76del (c.224_226delTCT)	1964	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This mutation was found in a VHL type 1 patient (patient no. V67). Only moderate evidence of pathogenicity since the protein length changes as a result of an in-frame deletion in a nonrepeat region (AMCG code: PM4).	9829912	PubMed		"Olschwang et al., 1998, Hum. Mutat."		2	accepted	5654	Rare Germline	2023-01-09 21:46:55 UTC	https://civicdb.org/links/evidence_items/5654	https://civicdb.org/links/molecular_profiles/1964	FALSE	VHL	7428	F76del (c.224_226delTCT)		chr3	10142071	10142073	TCT		ENST00000256474.2	75		inframe_deletion	"NP_000542.1:p.Phe76del,ENST00000256474.2:c.224_226delTCT,NC_000003.11:g.10183758_10183760del,NC_000003.12:g.10142074_10142076del,NM_000551.3:c.227_229del,ENSP00000256474.2:p.Phe76del"	2023-01-27 17:15:01 UTC	CA357012	223166	"PHE76DEL,C.224_226DELTCT,C.226_228DELTTC,C.227_229DELTCT,DELPHE76"	FALSE
VHL V84M (c.250G>A)	1977	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	This study examined 182 patients with non-syndromic pheochromocytoma or paraganglioma for the presence of VHL mutations. VHL mutations were found in 3 of the 182 patients. The above mutation was found in 1 patient with pheochromocytoma. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease.	22438210	PubMed		"Eisenhofer et al., 2012, Horm. Metab. Res."		2	accepted	5660	Rare Germline	2023-01-09 21:46:55 UTC	https://civicdb.org/links/evidence_items/5660	https://civicdb.org/links/molecular_profiles/1977	FALSE	VHL	7428	V84M (c.250G>A)		chr3	10142097	10142097	G	A	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.250G>A,NP_000542.1:p.Val84Met,NC_000003.11:g.10183781G>A,ENST00000256474.2:c.250G>A"	2023-01-27 17:15:06 UTC	CA351750580	428813	"C.250G>A,VAL84MET,RS5030827"	FALSE
ARID1A Underexpression	1984	Stomach Cancer	10534				Prognostic	Supports	D	Poor Outcome	"In this study, real-time quantitative RT-PCR assays were used in 66 pairs of cancerous and matched adjacent normal tissues. In 43 of those pairs, the expression level of ARID1A was significantly lower in the cancerous tissue than in the normal tissue (P=0.0029). This was then again tested using Western Blotting. Consistent with the real-time PCR results, there was a lower expression of ARID1A in 13 of the tumor tissue samples compared to the normal tissue samples (P=0.0015). In an immunohistochemical analysis of 224 tissue blocks, 115 of those had a decreased ARID1A expression. The data conveyed that lower ARID1A expression was correlated with depth of tumor infiltration (P=0.001). Lastly, cell proliferation in regards to ARID1A expression was tested in cell lines. The cells with silenced expression of ARID1A had a much greater growth than those with greater expression of the protein."	22808142	PubMed		"Wang et al., 2012, PLoS ONE"		4	accepted	5675	N/A	2023-01-09 21:46:55 UTC	https://civicdb.org/links/evidence_items/5675	https://civicdb.org/links/molecular_profiles/1984	FALSE	ARID1A	8289	Underexpression		chr1	26696033	26782104			ENST00000324856.7	75		N/A		2023-01-09 21:52:17 UTC		N/A		FALSE
ARID1A Underexpression	1984	Clear Cell Renal Cell Carcinoma	4467				Prognostic	Supports	B	Poor Outcome	"This study included 290 patients with Clear Cell Renal Cell Carcinoma whose tumor tissues were sampled and then analyzed. These samples were then divided according to ARID1A expression after immunohistochemical staining. Of the 290 patients, 213 had a low ARID1A expression and 77 patients had a high expression. Low ARID1A expression was associated with higher nuclear grade (P<0.001), advanced pTNM stage (P=0.013), shorter cancer-specific survival (p=0.001) and progression-free survival (P<0.001). After a multivariate analysis using Cox proportional hazards, it was found that ARID1A expression levels are an independent predictor of progression-free survival in patients with CCRCC, although no significant correlation was found between the expression levels and cancer-specific survival."	25628030	PubMed		"Park et al., 2015, Hum. Pathol."		3	accepted	5676	N/A	2023-01-09 21:46:55 UTC	https://civicdb.org/links/evidence_items/5676	https://civicdb.org/links/molecular_profiles/1984	FALSE	ARID1A	8289	Underexpression		chr1	26696033	26782104			ENST00000324856.7	75		N/A		2023-01-09 21:52:17 UTC		N/A		FALSE
VHL A149S (c.445G>T)	798	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	"49 family members from three generations of a Turkish family were examined. A clinical presentation of VHL type 2B was noted. Genetic testing was performed on 17 family members. 11 members with the mutation had manifestations, while 6 members with the mutation were asymptomatic. 1 of the asymptomatic individuals belonged to generation 2, while the remaining 5 belonged to the fourth generation, suggesting they may be too young to present manifestations. From the members that had manifestations: 9 had pheochromocytoma (5 bilateral),  1 had lumbar spine hemangioblastoma, 1 had retinal hemangioblastoma, 4 had renal cell carcinoma (2 bilateral), and 3 had pancreatic neuroendocrine tumours (1 also had a serous cystadenoma in addition to the neuroendocrine tumour). ACMG evidence codes: 'PP1' because of segregation results, 'PP2' because there is a missense variant in a gene that has a low rate of benign missense variation and in which missense variants are a common mechanism of disease, 'PP4' because the patient's phenotype or family history is highly specific for a disease with a single genetic etiology. Relevant HPO terms: Renal cell carcinoma, Spinal hemangioblastoma, Multiple pancreatic cysts, Pheochromocytoma, Neuroendocrine neoplasm, Retinal hemangioblastoma."	23673869	PubMed		"Mete et al., 2014, Endocrine"		3	accepted	5679	Rare Germline	2023-01-09 21:46:38 UTC	https://civicdb.org/links/evidence_items/5679	https://civicdb.org/links/molecular_profiles/798	FALSE	VHL	7428	A149S (c.445G>T)		chr3	10146618	10146618	G	T	ENST00000256474.2	75		missense_variant	"NP_000542.1:p.Ala149Ser,NM_000551.2:c.445G>T,ENST00000256474.2:c.445G>T,NC_000003.11:g.10188302G>T"	2023-01-27 17:05:52 UTC	CA020355	127829	"ALA149SER,C.445G>T,RS587780077"	FALSE
VHL F76del (c.224_226delTCT)	1964	Von Hippel-Lindau Disease	14175	"Multiple renal cysts,Hemangioblastoma,Retinal capillary hemangioma,Renal cell carcinoma,Pancreatic cysts"			Predisposing	Supports	C	Uncertain Significance	"This paper reports on 4 Chinese kindreds with VHL. The VHL gene was screened using direct DNA sequencing and MLPA in 44 volunteers among the 4 families. The above mutation was found in 1 kindred; 10 members were tested and 3 were found to harbour the mutation. The 7 members without a mutation were asymptomatic, while the 3 members with a mutation had manifestations. In addition to the 3 members who tested positive, there were 2 additional members who displayed manifestations, but died before testing could be performed. Clinical manifestations in this kindred included: renal cell carcinoma, CNS hemangioblastoma, pancreatic cysts, renal cysts, and retinal hemangioblastoma. ACMG evidence codes: 'PP1' because of segregation results, 'PP4' because the patient's phenotypes or family history are highly specific for a disease with single genetic etiology."	23143947	PubMed		"Chen et al., 2013, Clin Transl Oncol"		4	accepted	5682	Rare Germline	2023-01-09 21:46:55 UTC	https://civicdb.org/links/evidence_items/5682	https://civicdb.org/links/molecular_profiles/1964	FALSE	VHL	7428	F76del (c.224_226delTCT)		chr3	10142071	10142073	TCT		ENST00000256474.2	75		inframe_deletion	"NP_000542.1:p.Phe76del,ENST00000256474.2:c.224_226delTCT,NC_000003.11:g.10183758_10183760del,NC_000003.12:g.10142074_10142076del,NM_000551.3:c.227_229del,ENSP00000256474.2:p.Phe76del"	2023-01-27 17:15:01 UTC	CA357012	223166	"PHE76DEL,C.224_226DELTCT,C.226_228DELTTC,C.227_229DELTCT,DELPHE76"	FALSE
VHL Splice Site (c.340+1G>A)	1990	Von Hippel-Lindau Disease	14175	"Retinal capillary hemangioma,Clear cell renal cell carcinoma,Cerebellar hemangioblastoma,Spinal hemangioblastoma"			Predisposing	Supports	C	Uncertain Significance	"Genetic analysis of 7 Hungarian individuals from 5 unrelated families affected with von Hippel-Lindau disease revealed 5 different mutations, 3 of which were novel. The mutations could not be found within 100 healthy controls. The above mutation was found in 2 members (father and daughter) of a single family. The mutation was absent in two healthy family members. The mutation destroys the conserved intronic donor splice site and likely leads to premature protein termination (G114Dfs*6). The 12-year-old daughter had retinal and spinal hemangioblastoma, while the 34-year-old father had retinal, spinal, and cerebellar hemangioblastoma, and bilateral clear cell renal cell carcinoma. ACMG evidence codes: 'PVS1' because they observe a canonical +1 splice site variant in a gene where loss of function is a known mechanism of disease, 'PP4' because the patient's phenotypes or family history are highly specific for a disease with single genetic etiology, 'PP1' because of segregation results."	23298237	PubMed		"Losonczy et al., 2013, BMC Med. Genet."		4	accepted	5689	Rare Germline	2023-01-09 21:46:55 UTC	https://civicdb.org/links/evidence_items/5689	https://civicdb.org/links/molecular_profiles/1990	FALSE	VHL	7428	Splice Site (c.340+1G>A)		chr3	10142188	10142188	G	A	ENST00000256474.2	75		splice_donor_variant	"NM_000551.3:c.340+1G>A,NC_000003.11:g.10183872G>A,ENST00000256474.2:c.340+1G>A"	2023-01-27 17:15:13 UTC	CA357042	223190	"C.340+1G>A,C.553+1G>A"	FALSE
VHL Q195* (c.583C>T)	1686	Von Hippel-Lindau Disease	14175	"Retinal capillary hemangioma,Cerebellar hemangioblastoma"			Predisposing	Supports	C	Uncertain Significance	"Genetic analysis of 7 Hungarian individuals from 5 unrelated families affected with von Hippel-Lindau disease revealed 5 different mutations, 3 of which were novel. All 7 patients were found to have Type 1 VHL disease. The mutations could not be found within 100 healthy controls. The above mutation was found in 1 member of a single family. The patient developed retinal and cerebellar hemangioblastoma. ACMG evidence codes: 'PP4' because the patient's phenotypes or family history are highly specific for a disease with single genetic etiology, 'PVS1' because they observe a nonsense variant in a gene where loss of function is a known mechanism of disease."	23298237	PubMed		"Losonczy et al., 2013, BMC Med. Genet."		3	accepted	5691	Rare Germline	2023-01-09 21:46:50 UTC	https://civicdb.org/links/evidence_items/5691	https://civicdb.org/links/molecular_profiles/1686	FALSE	VHL	7428	Q195* (c.583C>T)		chr3	10149906	10149906	C	T	ENST00000256474.2	75		stop_gained	"NM_000551.3:c.583C>T,NP_000542.1:p.Gln195Ter,NC_000003.11:g.10191590C>T,ENST00000256474.2:c.583C>T"	2023-01-27 17:12:20 UTC	CA70052558	428794	"C.583C>T,Q195X,GLN195TER,RS5030825"	FALSE
VHL S65W (c.194C>G)	1663	Von Hippel-Lindau Disease	14175	"Spinal hemangioblastoma,Pancreatic cysts,Renal cell carcinoma,Multiple renal cysts,Renal cyst"			Predisposing	Supports	C	Uncertain Significance	"A case report of a Chinese family with mosaic VHL is described. The proband first came to medical attention with bilateral renal cell carcinoma, renal cysts, and pancreatic cysts. However, she initially tested negative for VHL. Her daughter presented with spinal hemangioblastoma, and upon genetic testing was found to have the above mutation. The probands' DNA was reexamined and was determined to harbour the above mutation in approximately 18% of peripheral leukocytes. ACMG evidence codes:   'PP4' because the patient's phenotypes or family history are highly specific for a disease with single genetic etiology, 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease."	23384228	PubMed		"Wu et al., 2013, Clin. Genet."		3	accepted	5693	Rare Germline	2023-01-09 21:46:49 UTC	https://civicdb.org/links/evidence_items/5693	https://civicdb.org/links/molecular_profiles/1663	FALSE	VHL	7428	S65W (c.194C>G)		chr3	10142041	10142041	C	G	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.194C>G,NM_000551.3:c.194C>G,NP_000542.1:p.Ser65Trp,NC_000003.11:g.10183725C>G"	2023-01-27 17:12:02 UTC	CA020099	43597	"C.194C>G,SER65TRP,RS5030826"	FALSE
VHL I151T (c.452T>C)	1747	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	A cohort of 141 patients with hemangioblastomas of the central nervous system was analyzed. 81 patients had germline mutations in the VHL gene. This missense mutation was found in one patient with hemangioblastomas of the central nervous system. No other phenotype described.  HPO terms: hemangioblastoma.	10567493	PubMed		"Glsker et al., 1999, J. Neurol. Neurosurg. Psychiatry"		2	accepted	5720	Rare Germline	2023-01-09 21:46:51 UTC	https://civicdb.org/links/evidence_items/5720	https://civicdb.org/links/molecular_profiles/1747	FALSE	VHL	7428	I151T (c.452T>C)		chr3	10146625	10146625	T	C	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.452T>C,NP_000542.1:p.Ile151Thr,NC_000003.11:g.10188309T>C,ENST00000256474.2:c.452T>C"	2023-01-27 17:13:00 UTC	CA351754359	428803	"C.452T>C,ILE151THR,RS869025655"	FALSE
VHL E94FS (c.279delC)	2003	Von Hippel-Lindau Disease	14175	"Pancreatic cysts,Renal cell carcinoma,Hemangioblastoma"			Predisposing	Supports	C	Uncertain Significance	"This mutation was found in a 51 year old female with hemangioblastomas of the cerebellum, pancreatic cysts, and bilateral renal adenocarcinomas. Patient's mother died of a brain tumor. Mutation was not found in 55 normal individuals. This study contains very strong evidence for pathogenicity in the form of a frameshift variant in a gene where loss-of-function is a known mechanism of disease (ACMG code: PVS1)."	10862095	PubMed		"Moore et al., 2000, Hum. Mutat."		2	accepted	5722	Rare Germline	2023-01-09 21:46:56 UTC	https://civicdb.org/links/evidence_items/5722	https://civicdb.org/links/molecular_profiles/2003	FALSE	VHL	7428	E94FS (c.279delC)		chr3	10142126	10142126	C		ENST00000256474.2	75		frameshift_truncation	"ENST00000256474.2:c.279delC,NC_000003.11:g.10183810del,NM_000551.3:c.279del,NP_000542.1:p.Glu94SerfsTer?"	2023-01-27 17:15:22 UTC	CA658820711	NONE FOUND	"C.279DELC,GLY93FS,GLU94FS"	FALSE
VHL Splice Site (c.464-2A>G)	1954	Von Hippel-Lindau Disease	14175	"Cerebellar hemangioblastoma,Retinal capillary hemangioma"			Predisposing	N/A	C	N/A	"Genotype-phenotype correlations of 573 VHL patients from 200 kindreds were analyzed. This splice mutation was found in a VHL type 1 family of 3 individuals. One family member had retinal angiomas and 2 had hemangioblastomas of the central nervous system. There is very strong evidence for pathogenicity in the form of a splice-site variant in a gene where loss-of-function is known mechanism of disease (ACMG code: PSV1). HPO terms: retinal hemangioblastoma, hemangioblastoma."	17024664	PubMed		"Ong et al., 2007, Hum. Mutat."		2	accepted	5724	Rare Germline	2023-01-09 21:46:55 UTC	https://civicdb.org/links/evidence_items/5724	https://civicdb.org/links/molecular_profiles/1954	FALSE	VHL	7428	Splice Site (c.464-2A>G)		chr3	10149785	10149785	A	G	ENST00000256474.2	75		splice_acceptor_variant	"NM_000551.3:c.464-2A>G,NC_000003.11:g.10191469A>G,ENST00000256474.2:c.464-2A>G"	2023-01-27 17:14:57 UTC	CA357046	223222	"C.464-2A>G,RS5030816"	FALSE
VHL R82_V84del (c.243_251del)	1965	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	"Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). This mutation was found in a VHL type 1 family of 5 individuals. Four family members had retinal angiomas and 3 had hemangioblastomas of the central nervous system. Cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1). HPO terms: retinal hemangioblastoma, hemangioblastoma."	17024664	PubMed		"Ong et al., 2007, Hum. Mutat."		4	accepted	5726	Rare Germline	2023-01-09 21:46:55 UTC	https://civicdb.org/links/evidence_items/5726	https://civicdb.org/links/molecular_profiles/1965	FALSE	VHL	7428	R82_V84del (c.243_251del)		chr3	10142090	10142098	GCGCGTCGT		ENST00000256474.2	75		inframe_deletion	"NC_000003.11:g.10183774_10183782del,NC_000003.12:g.10142092_10142100del,NM_000551.4:c.245_253del,NP_000542.1:p.Arg82_Val84del"	2023-01-27 17:15:02 UTC	CA658820713	NONE FOUND	"P81DELRVV (C.243_251DELGCGCGTCGT),ARG82_VAL84DEL"	FALSE
VHL S65FS (c.194delC)	2006	Von Hippel-Lindau Disease	14175	"Renal cell carcinoma,Retinal capillary hemangioma,Cerebellar hemangioblastoma,Pheochromocytoma"			Predisposing	N/A	C	N/A	"Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). Age-related risks of retinal angiomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This mutation was found in a VHL type 2 family of 7 individuals. Three family members had retinal angiomas, 2 had hemangioblastomas of the cerebellum, 2 had renal cell carcinoma, and one had pheochromocytoma. ACMG codes as follows: A frameshift variant in a gene where loss-of-function is known mechanism of disease (PSV1). Cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (PP1)."	17024664	PubMed		"Ong et al., 2007, Hum. Mutat."		3	accepted	5727	Rare Germline	2023-01-09 21:46:56 UTC	https://civicdb.org/links/evidence_items/5727	https://civicdb.org/links/molecular_profiles/2006	FALSE	VHL	7428	S65FS (c.194delC)		chr3	10142041	10142041	C		ENST00000256474.2	75		frameshift_truncation	"ENST00000256474.2:c.194delC,NC_000003.11:g.10183725delC,NM_000551.3:c.194delC,NP_000542.1:p.Ser65TrpfsTer2"	2023-01-27 17:15:23 UTC	CA432536395	NONE FOUND	"C.194DELC,SER65FS"	FALSE
VHL C77fs (c.228dup)	2008	Von Hippel-Lindau Disease	14175	"Renal cell carcinoma,Cerebellar hemangioblastoma,Pheochromocytoma,Retinal capillary hemangioma"			Predisposing	N/A	C	N/A	"Genotype-phenotype correlations of 573 VHL patients from 200 kindreds were analyzed. Age-related risks of retinal angiomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This frameshift mutation was found in 3 VHL type 1 families of 7 individuals total. Five patients had retinal angiomas, 3 had hemangioblastomas of the central nervous system, 3 had renal cell carcinoma and 2 had pheochromocytoma. There is very strong evidence for pathogenicity in the form of a frameshift variant in a gene where loss-of-function is known mechanism of disease (ACMG code: PSV1)."	17024664	PubMed		"Ong et al., 2007, Hum. Mutat."		4	accepted	5729	Rare Germline	2023-01-09 21:46:56 UTC	https://civicdb.org/links/evidence_items/5729	https://civicdb.org/links/molecular_profiles/2008	FALSE	VHL	7428	C77fs (c.228dup)		chr3	10142074	10142075		C	ENST00000256474.2	75			"NC_000003.11:g.10183759dup,NC_000003.12:g.10142075dup,NM_000551.3:c.228dup,ENST00000256474.2:c.228dup,NP_000542.1:p.Cys77LeufsTer?,ENSP00000256474.2:p.Cys77LeufsTer?"	2023-01-27 17:15:24 UTC	CA658795177	NONE FOUND	"440_441INSC,C.227_228INSC,F76FS,C.227INSC"	FALSE
VHL Splice Site (c.341-2A>C)	2009	Renal Cell Carcinoma	4450	"Pheochromocytoma,Retinal capillary hemangioma,Renal cell carcinoma,Hemangioblastoma"			Predisposing	Supports	C	Uncertain Significance	"Genotype-phenotype correlations of 573 VHL patients from 200 kindreds were analyzed. This mutation was found in a VHL type 2 patient with retinal angiomas, hemangioblastomas of the central nervous system, renal cell carcinoma, and pheochromocytoma. There is very strong evidence for pathogenicity in the form of a splice-site variant in a gene where loss-of-function is known mechanism of disease (ACMG code: PSV1)."	17024664	PubMed		"Ong et al., 2007, Hum. Mutat."		2	accepted	5730	Rare Germline	2023-01-09 21:46:56 UTC	https://civicdb.org/links/evidence_items/5730	https://civicdb.org/links/molecular_profiles/2009	FALSE	VHL	7428	Splice Site (c.341-2A>C)		chr3	10146512	10146512	A	C	ENST00000256474.2	75		splice_acceptor_variant	"NC_000003.11:g.10188196A>C,NM_000551.3:c.341-2A>C,ENST00000256474.2:c.341-2A>C"	2023-01-27 17:15:25 UTC	CA351753579	NONE FOUND	C.341-2A>C	FALSE
VHL G123fs (c.369_375delGACACAC)	2011	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	"Genotype-phenotype correlations of 573 VHL patients from 200 kindreds were analyzed. Age-related risks of retinal angiomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This mutation was found in a patient with no clinical manifestations of VHL disease as described in their supplemental table (retinal angioma, cerebellar hemangioblastoma, renal cell carcinoma, pheochromocytoma). There is very strong evidence for pathogenicity in the form of a frameshift variant in a gene where loss-of-function is known mechanism of disease (ACMG code: PSV1)."	17024664	PubMed		"Ong et al., 2007, Hum. Mutat."		1	accepted	5732	Rare Germline	2023-01-09 21:46:56 UTC	https://civicdb.org/links/evidence_items/5732	https://civicdb.org/links/molecular_profiles/2011	FALSE	VHL	7428	G123fs (c.369_375delGACACAC)		chr3	10146542	10146548	GACACAC		ENST00000256474.2	75		frameshift_variant	ENST00000256474.2:c.369_375delGACACAC	2023-01-27 17:15:25 UTC	CA913189240	NONE FOUND	"GLY123FS,C.369_375DELGACACAC"	FALSE
VHL K159fs (c.474_476delGAAinsC)	2013	Von Hippel-Lindau Disease	14175	"Renal cell carcinoma,Cerebellar hemangioblastoma"			Predisposing	N/A	C	N/A	Genotype-phenotype correlations of 573 VHL patients from 200 kindreds were analyzed. Age-related risks of retinal angiomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. VHL K159fs (c.474_476delGAAinsC) frameshift mutation was found in a VHL type 1 family of 5 individuals. Three had cerebellar hemangioblastomas and one had renal cell carcinoma. There is very strong evidence for pathogenicity in the form of a frameshift variant in a gene where loss-of-function is known mechanism of disease (ACMG code: PVS1).	17024664	PubMed		"Ong et al., 2007, Hum. Mutat."		3	accepted	5735	Rare Germline	2023-01-09 21:46:56 UTC	https://civicdb.org/links/evidence_items/5735	https://civicdb.org/links/molecular_profiles/2013	FALSE	VHL	7428	K159fs (c.474_476delGAAinsC)		chr3	10149797	10149799	GAA	C	ENST00000256474.2	75		frameshift_variant	ENST00000256474.2:c.474_476delGAAinsC	2023-03-24 00:00:14 UTC	CA658683298	NONE FOUND	"C.474_476DELGAAINSC,LEU158FS,LYS159FS,K159FS"	FALSE
VHL Y175* (c.525delC)	2014	Von Hippel-Lindau Disease	14175	"Hemangioblastoma,Retinal capillary hemangioma"			Predisposing	Supports	C	Uncertain Significance	Genotype-phenotype correlations of 573 VHL patients from 200 kindreds were analyzed. Age-related risks of retinal angiomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This mutation was found in 2 family members. One family member had retinal angiomas and the other had hemangioblastomas of the central nervous system. There is very strong evidence for pathogenicity in the form of a frameshift variant in a gene where loss-of-function is known mechanism of disease (ACMG code: PVS1).	17024664	PubMed		"Ong et al., 2007, Hum. Mutat."		3	accepted	5736	Rare Germline	2023-01-09 21:46:56 UTC	https://civicdb.org/links/evidence_items/5736	https://civicdb.org/links/molecular_profiles/2014	FALSE	VHL	7428	Y175* (c.525delC)		chr3	10149848	10149848	C		ENST00000256474.2	75		frameshift_truncation	"ENST00000256474.2:c.525delC,NP_000542.1:p.Tyr175Ter,NC_000003.11:g.10191532del,NM_000551.3:c.525del"	2023-01-27 17:15:26 UTC	CA913185019	NONE FOUND	"TYR175FS,C.525DELC"	FALSE
VHL L188fs (c.562delC)	2015	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	"Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). Age-related risks of retinal angiomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This mutation was found in 2 family members with renal cell carcinomas. One relative also had retinal angiomas, while the other had hemangioblastomas of the central nervous system. HPO terms: retinal hemangioblastoma, hemangioblastoma, renal cell carcinoma."	17024664	PubMed		"Ong et al., 2007, Hum. Mutat."		4	accepted	5737	Rare Germline	2023-01-09 21:46:56 UTC	https://civicdb.org/links/evidence_items/5737	https://civicdb.org/links/molecular_profiles/2015	FALSE	VHL	7428	L188fs (c.562delC)		chr3	10149885	10149885	C		ENST00000256474.2	75		frameshift_truncation	"ENST00000256474.2:c.562delC,NC_000003.11:g.10191569del,NM_000551.3:c.562delC,NP_000542.1:p.Leu188TrpfsTer14"	2023-01-27 17:15:27 UTC	CA432423671	NONE FOUND	"C.562DELC,LEU188FS"	FALSE
VHL K196fs (c.584_585delAG)	2016	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	"Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). Age-related risks of retinal angiomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This mutation was found in a VHL type 1 patient with retinal angiomas, hemangioblastomas of the central nervous system, and renal cell carcinoma. HPO terms: hemangioblastoma, retinal hemangioblastoma, renal cell carcinoma."	17024664	PubMed		"Ong et al., 2007, Hum. Mutat."		4	accepted	5738	Rare Germline	2023-01-09 21:46:56 UTC	https://civicdb.org/links/evidence_items/5738	https://civicdb.org/links/molecular_profiles/2016	FALSE	VHL	7428	K196fs (c.584_585delAG)		chr3	10149907	10149908	AG		ENST00000256474.2	75		frameshift_variant	ENST00000256474.2:c.584_585delAG	2023-01-27 17:15:28 UTC	CA645529570	NONE FOUND	"C.584_585DELAG,GLN195FS"	FALSE
VHL D197FS (c.589delG)	2017	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	"Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). Age-related risks of retinal angiomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This mutation was found in a VHL type 1 family with 3 individuals, 1 with retinal angiomas and 1 with renal cell carcinoma. Supporting evidence of pathogenicity because of the introduction of a frame shift in a gene where loss of function is an established mechanism of disease (ACMG code: PVS1). HPO terms: retinal hemangioblastoma, renal cell carcinoma."	17024664	PubMed		"Ong et al., 2007, Hum. Mutat."		3	accepted	5739	Rare Germline	2023-01-09 21:46:56 UTC	https://civicdb.org/links/evidence_items/5739	https://civicdb.org/links/molecular_profiles/2017	FALSE	VHL	7428	D197FS (c.589delG)		chr3	10149912	10149912	G		ENST00000256474.2	75		frameshift_truncation	"ENST00000256474.2:c.589delG,NC_000003.11:g.10191596del,NM_000551.3:c.589del,NP_000542.1:p.Asp197ThrfsTer5"	2023-01-27 17:15:28 UTC	CA913189233	NONE FOUND	"C.589DELG,ASP197FS"	FALSE
VHL R113FS (c.337delC)	2019	Von Hippel-Lindau Disease	14175	Retinal capillary hemangioma			Predisposing	Supports	C	Uncertain Significance	Genotype-phenotype correlations of 573 VHL patients from 200 kindreds were analyzed. Age-related risks of retinal angiomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This mutation was found in a patient with retinal hemangioblastomas. There is very strong evidence for pathogenicity in the form of a frameshift variant in a gene where loss-of-function is known mechanism of disease (ACMG code: PSV1).	17024664	PubMed		"Ong et al., 2007, Hum. Mutat."		3	accepted	5741	Rare Germline	2023-01-09 21:46:56 UTC	https://civicdb.org/links/evidence_items/5741	https://civicdb.org/links/molecular_profiles/2019	FALSE	VHL	7428	R113FS (c.337delC)		chr3	10142184	10142184	C		ENST00000256474.2	75		frameshift_truncation	"ENST00000256474.2:c.337delC,NC_000003.11:g.10183868delC,NM_000551.3:c.337delC,NP_000542.1:p.Arg113GlufsTer?"	2023-01-27 17:15:29 UTC	CA432420675	NONE FOUND	"C.337DELC,ARG113FS"	FALSE
VHL A56fs (c.166dup)	2020	Von Hippel-Lindau Disease	14175	"Cerebellar hemangioblastoma,Retinal capillary hemangioma"			Predisposing	N/A	C	N/A	"Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). Age-related risks of retinal angiomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This mutation was found in a VHL patient with retinal angiomas at 24Y old and cerebellar hemangioblastoma at 15Y old. There is very strong evidence for pathogenicity in the form of a frameshift variant in a gene where loss-of-function is known mechanism of disease (ACMG code: PSV1). HPO terms: retinal hemangioblastoma, hemangioblastoma."	17024664	PubMed		"Ong et al., 2007, Hum. Mutat."		3	accepted	5742	Rare Germline	2023-01-09 21:46:56 UTC	https://civicdb.org/links/evidence_items/5742	https://civicdb.org/links/molecular_profiles/2020	FALSE	VHL	7428	A56fs (c.166dup)		chr3	10142012	10142013		G	ENST00000256474.2	75		plus_1_frameshift_variant	"NP_000542.1:p.Ala56fs,NC_000003.11:g.10183697dup,NC_000003.12:g.10142013dup,NM_000551.3:c.166dup"	2023-01-27 17:15:30 UTC	CA645524645	NONE FOUND	"C.165DUP,C.165_166DUPG,A56GFS*76 (C.166DUP)"	FALSE
VHL P61FS (c.182_185delCCGT)	2021	Von Hippel-Lindau Disease	14175	"Retinal capillary hemangioma,Hemangioblastoma"			Predisposing	N/A	C	N/A	Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). Age-related risks of retinal angiomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This mutation was found in a VHL patient with retinal angiomas and hemangioblastomas of the central nervous system. There is very strong evidence for pathogenicity in the form of a frameshift variant in a gene where loss-of-function is known mechanism of disease (ACMG code: PSV1).	17024664	PubMed		"Ong et al., 2007, Hum. Mutat."		4	accepted	5743	Rare Germline	2023-01-09 21:46:56 UTC	https://civicdb.org/links/evidence_items/5743	https://civicdb.org/links/molecular_profiles/2021	FALSE	VHL	7428	P61FS (c.182_185delCCGT)		chr3	10142029	10142032	CCGT		ENST00000256474.2	75		frameshift_variant	"ENST00000256474.2:c.182_185delCCGT,NC_000003.11:g.10183713_10183716del,NM_000551.3:c.182_185delCCGT,NP_000542.1:p.Pro61ArgfsTer5"	2023-01-27 17:15:31 UTC	CA658820712	NONE FOUND	"C.182_185DELCCGT,PRO61FS"	FALSE
VHL F76del (c.224_226delTCT)	1964	Von Hippel-Lindau Disease	14175	"Cerebellar hemangioblastoma,Retinal capillary hemangioma,Renal cell carcinoma"			Predisposing	N/A	C	N/A	"Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). Age-related risks of retinal angiomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This mutation was found in 4 unrelated families of 8 individuals total. 5 individuals had retinal hemangioblastomas, 4 had hemangioblastomas of the cerebellum, and 3 had renal cell carcinoma. ACMG evidence codes: 'PM4' because they observe a protein length change as a result of an in-frame deletion in a nonrepeat region or stop-loss variants, 'PP4' because the patients' phenotypes or family history are highly specific for a disease with single genetic etiology."	17024664	PubMed		"Ong et al., 2007, Hum. Mutat."		3	accepted	5744	Rare Germline	2023-01-09 21:46:55 UTC	https://civicdb.org/links/evidence_items/5744	https://civicdb.org/links/molecular_profiles/1964	FALSE	VHL	7428	F76del (c.224_226delTCT)		chr3	10142071	10142073	TCT		ENST00000256474.2	75		inframe_deletion	"NP_000542.1:p.Phe76del,ENST00000256474.2:c.224_226delTCT,NC_000003.11:g.10183758_10183760del,NC_000003.12:g.10142074_10142076del,NM_000551.3:c.227_229del,ENSP00000256474.2:p.Phe76del"	2023-01-27 17:15:01 UTC	CA357012	223166	"PHE76DEL,C.224_226DELTCT,C.226_228DELTTC,C.227_229DELTCT,DELPHE76"	FALSE
VHL Splice Site (c.464-1G>C)	1953	Von Hippel-Lindau Disease	14175	"Retinal capillary hemangioma,Renal cell carcinoma,Cerebellar hemangioblastoma"			Predisposing	N/A	C	N/A	"Genotype-phenotype correlations of 573 VHL patients were analyzed and confirmed that higher risk of pheochromocytoma is associated with missense mutations that result in substitution of a surface amino acid or that disrupt the structural integrity of the VHL gene product (pVHL). Age-related risks of retinal angiomas and renal cell carcinoma were higher in patients with nonsense or frameshift mutations. This mutation was found in 2 unrelated VHL families with 4 individuals total. Three had hemangioblastomas of the cerebellum, 4 had retinal angiomas, and 2 had renal cell carcinoma. There is very strong evidence for pathogenicity in the form of a splice-site variant in a gene where loss-of-function is known mechanism of disease (ACMG code: PSV1)."	17024664	PubMed		"Ong et al., 2007, Hum. Mutat."		2	accepted	5745	Rare Germline	2023-01-09 21:46:55 UTC	https://civicdb.org/links/evidence_items/5745	https://civicdb.org/links/molecular_profiles/1953	FALSE	VHL	7428	Splice Site (c.464-1G>C)		chr3	10149786	10149786	G	C	ENST00000256474.2	75		splice_acceptor_variant	"NM_000551.3:c.464-1G>C,NC_000003.11:g.10191470G>C,ENST00000256474.2:c.464-1G>C,NP_000542.1:p.=,NC_000003.12:g.10149786G>C"	2023-01-27 17:14:56 UTC	CA357081	223220	"C.464-1G>C,RS5030817,IVS2-1G>C"	FALSE
VHL Splice Site (c.341-2A>C)	2009	Von Hippel-Lindau Disease	14175	"Retinal capillary hemangioma,Pancreatic cysts,Renal cell carcinoma,Hemangioblastoma"			Predisposing	Supports	C	Uncertain Significance	"Molecular analysis of VHL gene in 146 probands, 103 with and 43 without a positive family history, resulted in the detection of 43 germline VHL mutations. Majority of mutations were found in patients with classic or multi-organ manifestations of VHL disease, but mutations were also found in patients with limited or single-organ manifestations of VHL disease. Follow-up of families with germline mutations and limited VHL manifestations was recommended. This splice mutation was found in VHL patient with hemangioblastomas of the retina and central nervous system, renal cell carcinoma, and pancreatic cysts (family no. 32). ACMG evidence codes: 'PSV1' because they observe a splice-site variant in a gene where loss-of-function is known mechanism of disease, 'PP4' because the patients' phenotypes or family history are highly specific for a disease with single genetic etiology."	17661816	PubMed		"Hes et al., 2007, Clin. Genet."		3	accepted	5748	Rare Germline	2023-01-09 21:46:56 UTC	https://civicdb.org/links/evidence_items/5748	https://civicdb.org/links/molecular_profiles/2009	FALSE	VHL	7428	Splice Site (c.341-2A>C)		chr3	10146512	10146512	A	C	ENST00000256474.2	75		splice_acceptor_variant	"NC_000003.11:g.10188196A>C,NM_000551.3:c.341-2A>C,ENST00000256474.2:c.341-2A>C"	2023-01-27 17:15:25 UTC	CA351753579	NONE FOUND	C.341-2A>C	FALSE
VHL F76del (c.224_226delTCT)	1964	Von Hippel-Lindau Disease	14175	"Renal cell carcinoma,Retinal capillary hemangioma,Hemangioblastoma"			Predisposing	Supports	C	Uncertain Significance	"Molecular analysis of VHL gene in 146 probands, 103 with and 43 without a positive family history, resulted in the detection of 43 germline VHL mutations. Majority of mutations were found in patients with classic or multi-organ manifestations of VHL disease, but mutations were also found in patients with limited or single-organ manifestations of VHL disease. Follow-up of families with germline mutations and limited VHL manifestations was recommended. This mutation was found in 2 family members with retinal hemangioblastomas and renal cell carcinoma (family no. 25). One family member also had central nervous system hemangioblastoma. ACMG evidence codes: 'PM4' because they observe a protein length change as a result of an in-frame deletion in a nonrepeat region."	17661816	PubMed		"Hes et al., 2007, Clin. Genet."		3	accepted	5749	Rare Germline	2023-01-09 21:46:55 UTC	https://civicdb.org/links/evidence_items/5749	https://civicdb.org/links/molecular_profiles/1964	FALSE	VHL	7428	F76del (c.224_226delTCT)		chr3	10142071	10142073	TCT		ENST00000256474.2	75		inframe_deletion	"NP_000542.1:p.Phe76del,ENST00000256474.2:c.224_226delTCT,NC_000003.11:g.10183758_10183760del,NC_000003.12:g.10142074_10142076del,NM_000551.3:c.227_229del,ENSP00000256474.2:p.Phe76del"	2023-01-27 17:15:01 UTC	CA357012	223166	"PHE76DEL,C.224_226DELTCT,C.226_228DELTTC,C.227_229DELTCT,DELPHE76"	FALSE
VHL F76del (c.224_226delTCT)	1964	Von Hippel-Lindau Disease	14175	"Hemangioblastoma,Renal cell carcinoma,Retinal capillary hemangioma"			Predisposing	N/A	C	N/A	"This study reports 1,548 germline and somatic mutations from 945 VHL families. Mutation was detected in a VHL kindred with hemangioblastomas of the central nervous system, retinal hemangioblastomas and Grawitz tumor (also known as RCC) (case no. 2034). Protein length changes as a result of an in-frame deletion in a nonrepeat region (ACMG code: PM4). Patient's phenotypes or family history are highly specific for a disease with a single genetic etiology (ACMG code: PP4)."	20151405	PubMed		"Nordstrom-O'Brien et al., 2010, Hum. Mutat."		3	accepted	5750	Rare Germline	2023-01-09 21:46:55 UTC	https://civicdb.org/links/evidence_items/5750	https://civicdb.org/links/molecular_profiles/1964	FALSE	VHL	7428	F76del (c.224_226delTCT)		chr3	10142071	10142073	TCT		ENST00000256474.2	75		inframe_deletion	"NP_000542.1:p.Phe76del,ENST00000256474.2:c.224_226delTCT,NC_000003.11:g.10183758_10183760del,NC_000003.12:g.10142074_10142076del,NM_000551.3:c.227_229del,ENSP00000256474.2:p.Phe76del"	2023-01-27 17:15:01 UTC	CA357012	223166	"PHE76DEL,C.224_226DELTCT,C.226_228DELTTC,C.227_229DELTCT,DELPHE76"	FALSE
VHL R161* (c.481C>T)	1680	Von Hippel-Lindau Disease	14175	"Pancreatic cysts,Retinal capillary hemangioma"			Predisposing	Supports	C	Uncertain Significance	"This study reports 1,548 germline and somatic mutations from 945 VHL families. This nonsense mutation was found in a VHL patient with retinal angiomas and pancreatic cysts (case no. 306). There is very strong evidence of pathogenicity in the form of a nonsense variant in a gene where loss-of-function is known mechanism of disease (ACMG code: PSV1)."	20151405	PubMed		"Nordstrom-O'Brien et al., 2010, Hum. Mutat."		4	accepted	5761	Rare Germline	2023-01-09 21:46:50 UTC	https://civicdb.org/links/evidence_items/5761	https://civicdb.org/links/molecular_profiles/1680	FALSE	VHL	7428	R161* (c.481C>T)		chr3	10149804	10149804	C	T	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.481C>T,NP_000542.1:p.Arg161Ter,NC_000003.11:g.10191488C>T,ENST00000256474.2:c.481C>T"	2023-01-27 17:12:16 UTC	CA020408	2217	"C.481C>T,R161X,ARG161TER,RS5030818"	FALSE
VHL S65W (c.194C>G)	1663	Von Hippel-Lindau Disease	14175	"Pancreatic cysts,Renal cell carcinoma,Hemangioblastoma"			Predisposing	Supports	C	Predisposition	"Mutational analysis for 16 patients with clinically diagnosed VHL disease, revealed 12 germline mutations. This missense mutation was found in a 40 year old type 1 VHL patient with hemangioblastomas of the central nervous system, renal cell carcinoma, and pancreatic cysts (proband no. 1) but no family history."	22357542	PubMed		"Wu et al., 2012, J. Hum. Genet."		3	accepted	5765	Rare Germline	2023-04-07 19:00:17 UTC	https://civicdb.org/links/evidence_items/5765	https://civicdb.org/links/molecular_profiles/1663	FALSE	VHL	7428	S65W (c.194C>G)		chr3	10142041	10142041	C	G	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.194C>G,NM_000551.3:c.194C>G,NP_000542.1:p.Ser65Trp,NC_000003.11:g.10183725C>G"	2023-01-27 17:12:02 UTC	CA020099	43597	"C.194C>G,SER65TRP,RS5030826"	FALSE
VHL F76del (c.224_226delTCT)	1964	Von Hippel-Lindau Disease	14175	"Renal cell carcinoma,Pancreatic cysts,Hemangioblastoma"			Predisposing	Supports	C	Predisposition	"Mutational analysis for 16 patients with clinically diagnosed VHL disease, revealed 12 germline mutations. This mutation was found in a 42-year-old VHL patient with hemangioblastomas of the central nervous system, renal cell carcinoma, and pancreatic cysts (proband no. 12). ACMG evidence codes: 'PP4' because the patient's phenotypes or family history are highly specific for a disease with single genetic etiology."	22357542	PubMed		"Wu et al., 2012, J. Hum. Genet."		3	accepted	5766	Rare Germline	2023-04-07 19:01:12 UTC	https://civicdb.org/links/evidence_items/5766	https://civicdb.org/links/molecular_profiles/1964	FALSE	VHL	7428	F76del (c.224_226delTCT)		chr3	10142071	10142073	TCT		ENST00000256474.2	75		inframe_deletion	"NP_000542.1:p.Phe76del,ENST00000256474.2:c.224_226delTCT,NC_000003.11:g.10183758_10183760del,NC_000003.12:g.10142074_10142076del,NM_000551.3:c.227_229del,ENSP00000256474.2:p.Phe76del"	2023-01-27 17:15:01 UTC	CA357012	223166	"PHE76DEL,C.224_226DELTCT,C.226_228DELTTC,C.227_229DELTCT,DELPHE76"	FALSE
VHL Exon 3 Deletion	1815	Von Hippel-Lindau Disease	14175	"Renal cell carcinoma,Retinal capillary hemangioma,Hemangioblastoma,Pancreatic cysts"			Predisposing	Supports	C	Predisposition	"Mutational analysis for 16 patients with clinically diagnosed VHL disease, revealed 12 germline mutations. This mutation was found in 3 family members and an unrelated patient. All three family members had hemangioblastomas of the central nervous system (proband no. 13). The 32-year-old sister and 27-year-old proband had renal cell carcinoma and pancreatic cysts. The proband also had retinal angiomas. The unrelated, 45-year-old VHL patient had hemangioblastomas of the central nervous system and retina, renal cell carcinoma, and pancreatic cysts (proband no. 14). ACMG codes as follows: A single exon deletion variant in a gene where loss-of-function is known mechanism of disease (PSV1). Cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (PP1)."	22357542	PubMed		"Wu et al., 2012, J. Hum. Genet."		2	accepted	5767	Rare Germline	2023-04-07 19:32:18 UTC	https://civicdb.org/links/evidence_items/5767	https://civicdb.org/links/molecular_profiles/1815	FALSE	VHL	7428	Exon 3 Deletion		chr3	10149787	10152220			ENST00000256474.2	75				2023-01-09 21:52:16 UTC				FALSE
VHL R161= (c.481C>A)	2024	Von Hippel-Lindau Disease	14175	"Renal cell carcinoma,Pancreatic cysts,Hemangioblastoma"			Predisposing	Supports	C	Predisposition	"Mutational analysis for 16 patients with clinically diagnosed VHL disease, revealed 12 germline mutations. This silent mutation was found in a 34-year-old VHL patient with hemangioblastomas of the central nervous system, renal cell carcinoma, and pancreatic cysts (proband no. 15)."	22357542	PubMed		"Wu et al., 2012, J. Hum. Genet."		2	accepted	5768	Rare Germline	2023-04-07 19:33:05 UTC	https://civicdb.org/links/evidence_items/5768	https://civicdb.org/links/molecular_profiles/2024	FALSE	VHL	7428	R161= (c.481C>A)		chr3	10149804	10149804	C	A	ENST00000256474.2	75		synonymous_variant	"NC_000003.11:g.10191488C>A,NC_000003.12:g.10149804C>A,NP_000542.1:p.Arg161="	2023-01-27 17:15:33 UTC	CA432423146	NONE FOUND	R161R (C.481C>A)	FALSE
VHL R167W (c.499C>T)	1623	Von Hippel-Lindau Disease	14175	"Hemangioblastoma,Epididymal cyst,Renal cell carcinoma,Retinal capillary hemangioma"			Predisposing	Supports	C	Predisposition	"Mutational analysis for 16 patients with clinically diagnosed VHL disease, revealed 12 germline mutations. This missense mutation was found in 4 VHL family members (proband no. 6). The 65-year-old father had renal cell carcinoma; The 37-year old sister had pancreatic cysts and the 33-year old sister had retinal angiomas. The 38-year-old proband had hemangioblastomas of the central nervous system, renal cell carcinoma, pancreatic cysts, and epididymal cystadenoma. Cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1)."	22357542	PubMed		"Wu et al., 2012, J. Hum. Genet."		2	accepted	5769	Rare Germline	2023-04-07 19:33:25 UTC	https://civicdb.org/links/evidence_items/5769	https://civicdb.org/links/molecular_profiles/1623	FALSE	VHL	7428	R167W (c.499C>T)		chr3	10149822	10149822	C	T	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.499C>T,NP_000542.1:p.Arg167Trp,NC_000003.11:g.10191506C>T,ENST00000256474.2:c.499C>T"	2023-01-27 17:11:35 UTC	CA020450	2218	"C.499C>T,ARG167TRP,R126W,RS5030820"	FALSE
VHL E94* (c.280G>T)	1670	Von Hippel-Lindau Disease	14175	"Renal cell carcinoma,Epididymal cyst,Hemangioblastoma,Pancreatic cysts"			Predisposing	Supports	C	Predisposition	"Mutational analysis for 16 patients with clinically diagnosed VHL disease, revealed 12 germline mutations. This nonsense mutation was found in 2 unrelated families. One family of 3 had a asymptomatic 27-year-old female, a 27-year-old male with epididymal cystadenoma, and a 55-year old with hemangioblastomas of the central nervous system, renal cell carcinoma, and pancreatic cysts (proband no. 10). The other VHL family had 2 individuals with hemangioblastomas of the central nervous system (proband no. 11). ACMG codes as follows: A nonsense variant in a gene where loss-of-function is a known mechanism of disease (PSV1). Cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (PP1)."	22357542	PubMed		"Wu et al., 2012, J. Hum. Genet."		2	accepted	5771	Rare Germline	2023-04-07 19:55:54 UTC	https://civicdb.org/links/evidence_items/5771	https://civicdb.org/links/molecular_profiles/1670	FALSE	VHL	7428	E94* (c.280G>T)		chr3	10142127	10142127	G	T	ENST00000256474.2	75		stop_gained	"ENST00000256474.2:c.280G>T,NM_198156.2:c.280G>T,NP_000542.1:p.Glu94Ter,NC_000003.11:g.10183811G>T"	2023-01-27 17:12:08 UTC	CA70046202	584477	"C.280G>T,E94X,GLU94TER,RS5030829"	FALSE
VHL H115R (c.344A>G)	1876	Von Hippel-Lindau Disease	14175	"Hemangioblastoma,Pancreatic cysts,Renal cell carcinoma"			Predisposing	Supports	C	Uncertain Significance	"Mutational analysis for 16 patients with clinically diagnosed VHL disease, revealed 12 germline mutations. This missense mutation was found in a 45-year-old VHL type 1 patient with hemangioblastomas of the central nervous system, renal cell carcinoma, and pancreatic cysts (proband no. 4) and no family history. HPO terms: hemangioblastoma, renal cell carcinoma, multiple pancreatic cysts."	22357542	PubMed		"Wu et al., 2012, J. Hum. Genet."		2	accepted	5772	Rare Germline	2023-01-09 21:46:54 UTC	https://civicdb.org/links/evidence_items/5772	https://civicdb.org/links/molecular_profiles/1876	FALSE	VHL	7428	H115R (c.344A>G)		chr3	10146517	10146517	A	G	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.344A>G,NC_000003.11:g.10188201A>G,NM_000551.3:c.344A>G,NP_000542.1:p.His115Arg"	2023-01-27 17:14:07 UTC	CA70049376	664415	"C.344A>G,HIS115ARG,RS5030812"	FALSE
VHL I151F (c.451A>T)	2026	Von Hippel-Lindau Disease	14175	"Epididymal cyst,Renal cell carcinoma,Pancreatic cysts,Endolymphatic sac tumor"			Predisposing	Supports	C	Uncertain Significance	"Mutational analysis for 16 patients with clinically diagnosed VHL disease, revealed 12 germline mutations. This missense mutation was found in a 43-year-old VHL type 1 patient with renal cell carcinoma, pancreatic cysts, an endolymphatic sac tumor, and an epididymal /ovarian cystadenoma (proband no. 5) and no family history. HPO terms: renal cell carcinoma, multiple pancreatic cysts, epididymal cysts, endolymphatic sac tumors."	22357542	PubMed		"Wu et al., 2012, J. Hum. Genet."		2	accepted	5773	Rare Germline	2023-01-09 21:46:56 UTC	https://civicdb.org/links/evidence_items/5773	https://civicdb.org/links/molecular_profiles/2026	FALSE	VHL	7428	I151F (c.451A>T)		chr3	10146624	10146624	A	T	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.451A>T,NC_000003.11:g.10188308A>T,NM_000551.3:c.451A>T,NP_000542.1:p.Ile151Phe"	2023-01-27 17:15:35 UTC	CA351754353	NONE FOUND	"C.451A>T,ILE151PHE"	FALSE
VHL L178R (c.533T>G)	1764	Von Hippel-Lindau Disease	14175	"Hemangioblastoma,Renal cell carcinoma,Pancreatic cysts,Retinal capillary hemangioma"			Predisposing	Supports	C	Uncertain Significance	"Mutational analysis for 16 patients with clinically diagnosed VHL disease, revealed 12 germline mutations. This missense mutation was found in a VHL family of 6 individuals (proband no. 7). A 62-year-old female carrying the mutation and a male with an unknown mutation had hemangioblastomas of the central nervous system (CNS). A 58-year-old male family member had retinal angiomas and renal cell carcinoma. The 60 year-old proband had CNS hemangioblastomas, retinal angiomas, renal cell carcinoma, and pancreatic cysts. Cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1)."	22357542	PubMed		"Wu et al., 2012, J. Hum. Genet."		2	accepted	5774	Rare Germline	2023-01-09 21:46:52 UTC	https://civicdb.org/links/evidence_items/5774	https://civicdb.org/links/molecular_profiles/1764	FALSE	VHL	7428	L178R (c.533T>G)		chr3	10149856	10149856	T	G	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.533T>G,NC_000003.11:g.10191540T>G,NM_000551.3:c.533T>G,NP_000542.1:p.Leu178Arg"	2023-01-27 17:13:08 UTC	CA351756248	625261	"C.533T>G,LEU178ARG"	FALSE
VHL P86S (c.256C>T)	1778	Von Hippel-Lindau Disease	14175	"Retinal capillary hemangioma,Renal cell carcinoma,Pheochromocytoma,Pancreatic cysts"			Predisposing	N/A	C	N/A	"Mutational analysis for 16 patients with clinically diagnosed VHL disease, revealed 12 germline variants. VHL P86S (c.256C>T) was found in a type 2B VHL patient (proband no. 2). The 33-year-old proband had retinal angiomas, renal cell carcinoma, pancreatic cysts, and pheochromocytoma. The proband's 8-year-old daughter also carried this variant but had no clinical manifestations of VHL disease."	22357542	PubMed		"Wu et al., 2012, J. Hum. Genet."		2	accepted	5775	Rare Germline	2023-01-09 21:46:52 UTC	https://civicdb.org/links/evidence_items/5775	https://civicdb.org/links/molecular_profiles/1778	FALSE	VHL	7428	P86S (c.256C>T)		chr3	10142103	10142103	C	T	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.256C>T,NP_000542.1:p.Pro86Ser,NC_000003.11:g.10183787C>T,ENST00000256474.2:c.256C>T"	2023-01-27 17:13:14 UTC	CA020180	178692	"C.256C>T,PRO86SER,RS398123481"	FALSE
VHL W88* (c.263G>A)	2027	Von Hippel-Lindau Disease	14175	"Epididymal cyst,Renal cell carcinoma,Pancreatic cysts,Hemangioblastoma"			Predisposing	Supports	C	Predisposition	"Mutational analysis for 16 patients with clinically diagnosed VHL disease, revealed 12 germline mutations. This nonsense mutation was found in 2 unrelated VHL type 1 families. One family had a 32-year-old with hemangioblastomas of the central nervous system, renal cell carcinoma, pancreatic cysts, and epididymal cystadenoma with an 8-year-old asymptomatic son (proband no. 8). The other family had a 39-year-old with renal cell carcinoma and pancreatic cysts and their 81-year-old mother with CNS hemangioblastomas (proband no. 9). There is very strong evidence of pathogenicity in the form of a nonsense variant in a gene where loss-of-function is known mechanism of disease (ACMG code: PVS1)."	22357542	PubMed		"Wu et al., 2012, J. Hum. Genet."		3	accepted	5776	Rare Germline	2023-04-07 19:02:33 UTC	https://civicdb.org/links/evidence_items/5776	https://civicdb.org/links/molecular_profiles/2027	FALSE	VHL	7428	W88* (c.263G>A)		chr3	10142110	10142110	G	A	ENST00000256474.2	75		stop_gained	"NM_000551.3:c.263G>A,NP_000542.1:p.Trp88Ter,NC_000003.11:g.10183794G>A,ENST00000256474.2:c.263G>A"	2023-01-27 17:15:35 UTC	CA020197	182978	"W88X,TRP88TER,C.263G>A,RS119103277"	FALSE
VHL 3'UTR alteration (c.*70C>A)	2028	Von Hippel-Lindau Disease	14175	"Pancreatic cysts,Hemangioblastoma,Retinal capillary hemangioma,Renal cell carcinoma"			Predisposing	Supports	C	Uncertain Significance	"Mutational analysis for 16 patients with clinically diagnosed VHL disease, revealed 12 germline mutations. This mutation was found in a 30-year-old VHL patient with hemangioblastomas of the central nervous system, retinal angiomas, renal cell carcinoma, and pancreatic cysts (proband no. 16). HPO terms: hemangioblastoma, retinal hemangioblastoma, renal cell carcinoma, multiple pancreatic cysts."	22357542	PubMed		"Wu et al., 2012, J. Hum. Genet."		2	accepted	5777	Rare Germline	2023-01-09 21:46:56 UTC	https://civicdb.org/links/evidence_items/5777	https://civicdb.org/links/molecular_profiles/2028	FALSE	VHL	7428	3'UTR alteration (c.*70C>A)		chr3	10150035	10150035	C	A				3_prime_UTR_variant	"NC_000003.11:g.10191719C>A,ENST00000256474.2:c.*70C>A,NM_000551.3:c.*70C>A,NP_000542.1:p.="	2023-01-27 17:15:36 UTC	CA658820858	NONE FOUND	"C.*70C>A,(C.642+70C>A)"	FALSE
VHL E70K (c.208G>A)	1832	Von Hippel-Lindau Disease	14175	Pancreatic endocrine tumor			Predisposing	Supports	C	Uncertain Significance	"In the analysis of 63 clinically diagnosed VHL patients, 55 patients were found with pancreatic involvement. Genetic tests on 35 of 55 VHL patients revealed VHL variants in 28 patients. Of the 55 enrolled patients, hemangioblastomas of the central nervous system were previously documented in 47 patients, renal cell carcinoma in 25, and pheochromocytoma in 11 patients. This missense variant was found in 37-year-old female with reported VHL type 1 phenotype and pancreatic lesions (case no. 1)."	25562111	PubMed		"Park et al., 2015, Scand. J. Gastroenterol."		2	accepted	5780	Rare Germline	2023-01-09 21:46:53 UTC	https://civicdb.org/links/evidence_items/5780	https://civicdb.org/links/molecular_profiles/1832	FALSE	VHL	7428	E70K (c.208G>A)		chr3	10142055	10142055	G	A	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.208G>A,NP_000542.1:p.Glu70Lys,NC_000003.11:g.10183739G>A,ENST00000256474.2:c.208G>A"	2023-01-27 17:13:46 UTC	CA020108	43598	"C.208G>A,GLU70LYS,RS5030802"	FALSE
ARID1A Underexpression	1984	Ovarian Clear Cell Carcinoma	50934				Prognostic	Supports	B	Poor Outcome	"In a study of 60 individuals with ovarian clear cell carcinoma, ARID1A expression was analyzed using immunohistochemistry. Of these 60 patients, 9 (15%) patients had a loss of ARID1A expression. Results showed that a low ARID1A expression was significantly related to advanced FIGO stages (P=0.02) and high CA125 levels (P=0.01). Patients with low expression experienced shorter progression free survival than those with no loss of expression (P<0.01). In a multivariate analysis it was found that a loss of ARID1A expression was significant for shorter disease free survival (P=0.03) and shorter overall survival for patients whose ovarian clear cell carcinoma was treated with platinum-based chemotherapy (P=0.015). Lastly, tumors with low expression were significantly more likely to be resistant to primary adjuvant chemotherapy than tumors with a higher expression (P=0.04)."	22101352	PubMed		"Katagiri et al., 2012, Mod. Pathol."		3	accepted	5787	N/A	2023-01-09 21:46:55 UTC	https://civicdb.org/links/evidence_items/5787	https://civicdb.org/links/molecular_profiles/1984	FALSE	ARID1A	8289	Underexpression		chr1	26696033	26782104			ENST00000324856.7	75		N/A		2023-01-09 21:52:17 UTC		N/A		FALSE
VHL Y98FS (c.291delC)	2036	Von Hippel-Lindau Disease	14175	"Pancreatic cysts,Multiple renal cysts,Renal cyst,Spinal hemangioblastoma,Cerebellar hemangioblastoma,Clear cell renal cell carcinoma"			Predisposing	Supports	C	Uncertain Significance	"A case report of a female Korean patient with VHL. She presented initially with gestational diabetes mellitus, and on routine abdominal scan displayed renal and pancreatic cysts. Family history demonstrated 2 family members with features consistent with VHL (cerebellar hemangioblastoma), which prompted genetic testing. Molecular analysis revealed the presence of the above mutation. Subsequently, she developed spinal hemangioblastoma and clear cell renal cell carcinoma. ACMG evidence codes: 'PP4' because the patient's phenotype or family history is highly specific for a disease with a single genetic etiology, 'PVS1' because they observe a frameshift variant in a gene where loss of function is a known mechanism of disease."	24396697	PubMed		"Ku et al., 2013, Endocrinol Metab (Seoul)"		4	accepted	5794	Rare Germline	2023-01-09 21:46:56 UTC	https://civicdb.org/links/evidence_items/5794	https://civicdb.org/links/molecular_profiles/2036	FALSE	VHL	7428	Y98FS (c.291delC)		chr3	10142138	10142138	C		ENST00000256474.2	75		frameshift_truncation	"ENST00000256474.2:c.291delC,NC_000003.11:g.10183822delC,NM_000551.3:c.291delC,NP_000542.1:p.Tyr98ThrfsTer"	2023-01-27 17:15:41 UTC	CA432420512	NONE FOUND	"TYR98FS,C.291DELC"	FALSE
VHL Q145* (c.433C>T)	1759	Von Hippel-Lindau Disease	14175	Polycythemia			Predisposing	Supports	C	Uncertain Significance	"This is a case report on a 9-month-old female with polycythemia. The patient carries a paternally inherited missense mutation (EID5799) and this de novo, nonsense mutation. ACMG codes as follows: A nonsense mutation in a gene where loss-of-function is a known mechanism of disease (PVS1). Assumed de novo, but without confirmation of paternity and maternity (PM6)."	25586603	PubMed		"Sidhu et al., 2015, Pediatr Blood Cancer"		2	accepted	5798	Rare Germline	2023-01-09 21:46:52 UTC	https://civicdb.org/links/evidence_items/5798	https://civicdb.org/links/molecular_profiles/1759	FALSE	VHL	7428	Q145* (c.433C>T)		chr3	10146606	10146606	C	T	ENST00000256474.2	75		stop_gained	"ENST00000256474.2:c.433C>T,NC_000003.11:g.10188290C>T,NM_000551.3:c.433C>T,NP_000542.1:p.Gln145Ter"	2023-01-27 17:13:04 UTC	CA351754219	625249	"C.433C>T,Q145X,GLN145TER"	FALSE
VHL N150S (c.449A>G)	2038	Von Hippel-Lindau Disease	14175	Polycythemia			Predisposing	Supports	C	Uncertain Significance	"This is a case report on a 9-month-old female with polycythemia. The patient carries a de novo nonsense mutation [Q145* (c.433C>T)] and this paternally inherited, missense mutation. The authors of this paper believed this missense mutation was the cause of the aforementioned clinical manifestations. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease."	25586603	PubMed		"Sidhu et al., 2015, Pediatr Blood Cancer"		2	accepted	5799	Rare Germline	2023-01-09 21:46:56 UTC	https://civicdb.org/links/evidence_items/5799	https://civicdb.org/links/molecular_profiles/2038	FALSE	VHL	7428	N150S (c.449A>G)		chr3	10146622	10146622	A	G	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.449A>G,NP_000542.1:p.Asn150Ser,NC_000003.11:g.10188306A>G,ENST00000256474.2:c.449A>G"	2023-01-27 17:15:43 UTC	CA041030	371992	"C.449A>G,ASN150SER,RS760184234"	FALSE
VHL V84L (c.250G>T)	1691	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	A case report of African American twin sisters with VHL type 2C is presented. 1 twin presented at the age of 16 with unilateral vision loss determined to be caused by a Rathke's cleft cyst. Further imaging identified bilateral pheochromocytoma. The other twin presented with pheochromocytoma at the age of 7. Radiological studies identified a similar sellar lesion to the Rathke's cleft cyst found in twin 1. Genetic testing discovered the above mutation in both twins. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease.	24877602	PubMed		"Huff et al., 2014, J Neurosurg Pediatr"		2	accepted	5801	Rare Germline	2023-01-09 21:46:50 UTC	https://civicdb.org/links/evidence_items/5801	https://civicdb.org/links/molecular_profiles/1691	FALSE	VHL	7428	V84L (c.250G>T)		chr3	10142097	10142097	G	T	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.250G>T,NP_000542.1:p.Val84Leu,NC_000003.11:g.10183781G>T,ENST00000256474.2:c.250G>T"	2023-01-27 17:12:24 UTC	CA020170	2236	"C.250G>T,VAL84LEU,RS5030827"	FALSE
VHL E70K (c.208G>A)	1832	Von Hippel-Lindau Disease	14175	"Cerebellar hemangioblastoma,Clear cell renal cell carcinoma,Spinal hemangioblastoma,Adenocarcinoma of the colon"			Predisposing	Supports	C	Uncertain Significance	"A case report of a 74-year-old male with colorectal adenocarcinoma, clear cell renal cell carcinoma, and hemangioblastomas of the central nervous system. The spinal hemangioblastoma was histopathologically confirmed. Bilateral multifocal cerebellar hemangioblastomas were inferred on brain MRI. Family history included a mother with a brain tumor of unconfirmed pathology, 2 brothers with the E70K variant and renal cell carcinoma, and an asymptomatic son in his 40s who was also found to have this variant. ACMG evidence codes: 'PP1' because of cosegregation with disease in multiple affected family members in a gene known to cause the disease, 'PP4' because the patient's phenotype and family history are highly specific for a disease with a single genetic etiology."	25715769	PubMed		"Heo et al., 2016, Cancer Res Treat"		3	accepted	5805	Rare Germline	2023-01-09 21:46:53 UTC	https://civicdb.org/links/evidence_items/5805	https://civicdb.org/links/molecular_profiles/1832	FALSE	VHL	7428	E70K (c.208G>A)		chr3	10142055	10142055	G	A	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.208G>A,NP_000542.1:p.Glu70Lys,NC_000003.11:g.10183739G>A,ENST00000256474.2:c.208G>A"	2023-01-27 17:13:46 UTC	CA020108	43598	"C.208G>A,GLU70LYS,RS5030802"	FALSE
VHL Y98H (c.292T>C)	1617	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	"Genetic analysis of 21 patients with known germline mutations in an inherited pheochromocytoma/paraganglioma gene, ten of which were in the VHL gene. This missense mutation was found in 8 unrelated patients with pheochromocytoma (tumor IDs P5, P6, P7, P8, P9, P10, P11, P12). ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease."	25883647	PubMed		"Luchetti et al., 2015, Int J Endocrinol"		2	accepted	5807	Rare Germline	2023-01-09 21:46:48 UTC	https://civicdb.org/links/evidence_items/5807	https://civicdb.org/links/molecular_profiles/1617	FALSE	VHL	7428	Y98H (c.292T>C)		chr3	10142139	10142139	T	C	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.292T>C,NP_000542.1:p.Tyr98His,NC_000003.11:g.10183823T>C,ENST00000256474.2:c.292T>C"	2023-01-27 17:11:30 UTC	CA020246	2223	"C.292T>C,TYR98HIS,RS5030809"	FALSE
CD274 Expression	272	Lung Non-small Cell Carcinoma	3908		Pembrolizumab		Predictive	Supports	B	Sensitivity/Response	PD-L1 expression in at least 50% of tumor cells correlated with improved efficacy of pembrolizumab.	25891174	PubMed		"Garon et al., 2015, N. Engl. J. Med."	NCT01295827	4	accepted	5811	N/A	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/5811	https://civicdb.org/links/molecular_profiles/272	FALSE	CD274	29126	Expression		chr9	5450525	5470547			ENST00000381577.3	75		N/A	N/A	2023-01-09 21:52:06 UTC		N/A		FALSE
BRCA1 Loss-of-function	131	Her2-receptor Negative Breast Cancer	60080		Olaparib		Predictive	Supports	B	Sensitivity/Response	"302 patients (234 with progression events) with HER2-negative metastatic breast cancer and with a confirmed deleterious or suspected deleterious germline BRCA mutation (164 BRCA1, 129 BRCA2) had significantly improved progression-free survival and better response rate to olaparib (PARP inhibitor) than standard therapy (7.0 mo vs 4.2 mo, hazard ratio 0.58, 95% CI 0.43-0.8) in this randomized phase 3 trial (NCT02000622). For BRCA1 patients specifically, the hazard ratio was 0.54, 95% CI 0.37-0.79)."	28578601	PubMed		"Robson et al., 2017, N. Engl. J. Med."	NCT02000622	5	accepted	5815	Rare Germline	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/5815	https://civicdb.org/links/molecular_profiles/131	FALSE	BRCA1	672	Loss-of-function	BRCA Germline Variants	chr17	43045629	43125483			ENST00000471181.2	75		"loss_of_heterozygosity,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
BRCA2 Loss-of-function	132	Her2-receptor Negative Breast Cancer	60080		Olaparib		Predictive	Supports	B	Sensitivity/Response	"302 patients (234 with progression events) with HER2-negative metastatic breast cancer and with a confirmed deleterious or suspected deleterious germline BRCA mutation (164 BRCA1, 129 BRCA2) had significantly improved progression-free survival and better response rate to olaparib (PARP inhibitor) than standard therapy (7.0 mo vs 4.2 mo, hazard ratio 0.58, 95% CI 0.43-0.8) in this randomized phase 3 trial (NCT02000622). For BRCA2 patients specifically, the hazard ratio was 0.68, 95% CI 0.45-0.1.07."	28578601	PubMed		"Robson et al., 2017, N. Engl. J. Med."	NCT02000622	3	accepted	5816	Rare Germline	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/5816	https://civicdb.org/links/molecular_profiles/132	FALSE	BRCA2	675	Loss-of-function	BRCA Germline Variants	chr13	32315474	32399210			ENST00000380152.3	75		loss_of_function_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
BRCA1 Mutation	185	Her2-receptor Negative Breast Cancer	60080		Olaparib		Predictive	Supports	B	Sensitivity/Response	"Randomized, open-label, phase 3 trial in which olaparib monotherapy was compared with standard therapy in patients with a germline BRCA mutation HER2negative metastatic breast cancer. 205 patients were assigned to receive olaparib and 97 were assigned to receive standard therapy. Median progression-free survival was significantly longer in the olaparib group than in the standard-therapy group (7.0 months vs. 4.2 months; hazard ratio 0.58; 95%CI 0.43 to 0.80; P<0.001). A response to treatment occurred in 100 of the 167 patients who had measurable disease in the olaparib group (59.9%; 95% CI, 52.0 to 67.4) and in 19 of the 66 patients in the standard-therapy group (28.8%; 95% CI, 18.3 to 41.3). A complete response was seen in 9.0% of the patients who had measurable disease in the olaparib group and in 1.5% in the standard-therapy group."	28792849	PubMed		"2017, N Engl J Med"		4	accepted	5830	Rare Germline	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/5830	https://civicdb.org/links/molecular_profiles/185	FALSE	BRCA1	672	Mutation		chr17	43045629	43125483			ENST00000471181.2	75		"gene_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
BRCA2 Mutation	186	Breast Cancer	1612		Olaparib		Predictive	Supports	B	Sensitivity/Response	"Randomized, open-label, phase 3 trial in which olaparib monotherapy was compared with standard therapy in patients with a germline BRCA mutation HER2negative metastatic breast cancer. 205 patients were assigned to receive olaparib and 97 were assigned to receive standard therapy. Median progression-free survival was significantly longer in the olaparib group than in the standard-therapy group (7.0 months vs. 4.2 months; hazard ratio 0.58; 95%CI 0.43 to 0.80; P<0.001). A response to treatment occurred in 100 of the 167 patients who had measurable disease in the olaparib group (59.9%; 95% CI, 52.0 to 67.4) and in 19 of the 66 patients in the standard-therapy group (28.8%; 95% CI, 18.3 to 41.3). A complete response was seen in 9.0% of the patients who had measurable disease in the olaparib group and in 1.5% in the standard-therapy group."	28792849	PubMed		"2017, N Engl J Med"		4	accepted	5831	Rare Germline	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/5831	https://civicdb.org/links/molecular_profiles/186	FALSE	BRCA2	675	Mutation		chr13	32315474	32399210			ENST00000380152.3	75		"gene_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
MET Overexpression	617	Stomach Carcinoma	5517		Rilotumumab		Predictive	Does Not Support	B	Sensitivity/Response	"In this randomised, double-blind, placebo-controlled phase 3 trial, 609 patients with MET+ (expression of at least 1+ intensity on 25% or more tumor cells) gastric cancer or gastroesophageal adenocarcinoma were randomized to chemotherapy (epirubicin, cisplatin, capecitabine) with placebo or MET inhibitor rilotumumab. Study treatment was stopped early because of a higher number of deaths in the rilotumumab arm. Median overall survival was 88 months (95% CI 77-102) in the rilotumumab group compared with 107 months (96-124) in the placebo group (stratified hazard ratio 134, 95% CI 110-163; p=0003)."	28958504	PubMed		"Catenacci et al., 2017, Lancet Oncol."	NCT01697072	5	accepted	5835	N/A	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/5835	https://civicdb.org/links/molecular_profiles/617	FALSE	MET	4233	Overexpression		chr7	116672405	116796342			ENST00000318493.6	75		N/A	N/A	2023-01-09 21:52:08 UTC		N/A		FALSE
KRAS Amplification	588	Endometrial Cancer	1380				Prognostic	Supports	B	Poor Outcome	"In this study, KRAS gain (KRAS/CEP12q ratio >1 and <2) or amplification (ratio >2) was detected in 3% (13 of 414) of the primary endometrial carcinomas investigated. Presence of KRAS gain or amplification were highly significantly associated with poor prognosis with a 46% 5-year survival compared with 87% for patients with unamplified status (P<0.001). Amplification of KRAS maintains its independent prognostic impact in Cox multivariate analysis when adjusted for age, histological subtype, grade and FIGO stage (HR=2.6, 95% CI: 1.2?.8, P=0.02). In contrast, presence of KRAS mutation did not influence prognosis (P=0.67)"	23099803	PubMed		"Birkeland et al., 2012, Br. J. Cancer"		3	accepted	5836	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/5836	https://civicdb.org/links/molecular_profiles/588	FALSE	KRAS	3845	Amplification		chr12	25209431	25250803			ENST00000256078.4	75		transcript_amplification	N/A	2023-01-09 21:52:08 UTC		N/A		FALSE
PTEN Loss	214	Cancer	162		Everolimus		Predictive	Does Not Support	B	Sensitivity/Response	"In a single-arm, open label phase 2 trial in PIK3CA amplified/mutated and/or PTEN loss encompassing 10 patients, no objective responses were observed but a stable disease response in 4 patients, resulting in a median PFS of 1.4 months. Everolimus failed to meet its enpoint."	28330462	PubMed		"Kim et al., 2017, BMC Cancer"	NCT02449538	3	accepted	5840	N/A	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/5840	https://civicdb.org/links/molecular_profiles/214	FALSE	PTEN	5728	Loss		chr10	87863113	87971930			ENST00000371953.3	75		loss_of_function_variant	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
VHL Splice Site (c.340+1G>A)	1990	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	"A study describing phenotypic and genotypic characteristics of VHL in an Indian population of 31 subjects, from 15 families diagnosed with VHL. Multi-cystic pancreas and CNS hemangioblastomas were the most common manifestations in this population. This splice site mutation was found in a VHL family of 8 individuals(family ID AD). 3 family members had renal cell carcinoma, 4 had hemangioblastomas of the central nervous system, 7 had multi-cystic pancreatic lesions, and 1 had retinal hemangioblastomas. ACMG codes as follows: A splice-site variant in a gene where loss-of-function is a known mechanism of disease (PVS1), patient's phenotypes or family history are highly specific for a disease with single genetic etiology (PP4), cosegregation with the disease in multiple affected family members in a gene definitively known to cause the disease (PP1). Relevant HPO terms: Hemangioblastoma, Retinal hemangioblastoma, Renal cell carcinoma, Multiple pancreatic cysts."	25952756	PubMed		"Vikkath et al., 2015, Fam. Cancer"		4	accepted	5845	Rare Germline	2023-01-09 21:46:55 UTC	https://civicdb.org/links/evidence_items/5845	https://civicdb.org/links/molecular_profiles/1990	FALSE	VHL	7428	Splice Site (c.340+1G>A)		chr3	10142188	10142188	G	A	ENST00000256474.2	75		splice_donor_variant	"NM_000551.3:c.340+1G>A,NC_000003.11:g.10183872G>A,ENST00000256474.2:c.340+1G>A"	2023-01-27 17:15:13 UTC	CA357042	223190	"C.340+1G>A,C.553+1G>A"	FALSE
VHL Splice Site (c.464-2A>G)	1954	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	"Of 65 VHL families from central Europe, 53 were identified with germline mutations. This splice mutation was found in a German, VHL type 1 family. Only one affected patient was identified with retinal angiomas, hemangioblastomas of the central nervous system, renal cell carcinoma, pancreatic cysts and cystadenomas of the epididymis. (family VHL 31).  HPO terms: hemangioblastomas, retinal hemangioblastomas, renal cell carcinoma, multiple pancreatic cysts, papillary cystadenomas of the broad ligament."	8707293	PubMed		"Glavac et al., 1996, Hum. Genet."		2	accepted	5851	Rare Germline	2023-01-09 21:46:55 UTC	https://civicdb.org/links/evidence_items/5851	https://civicdb.org/links/molecular_profiles/1954	FALSE	VHL	7428	Splice Site (c.464-2A>G)		chr3	10149785	10149785	A	G	ENST00000256474.2	75		splice_acceptor_variant	"NM_000551.3:c.464-2A>G,NC_000003.11:g.10191469A>G,ENST00000256474.2:c.464-2A>G"	2023-01-27 17:14:57 UTC	CA357046	223222	"C.464-2A>G,RS5030816"	FALSE
VHL V170D (c.509T>A)	1702	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	"20 patients from 6 families in the Netherlands were analyzed for Von Hippel Lindau manifestations. 1 family consisting of 12 members had the above mutation. Manifestations in this family included: renal cell carcinoma, cerebellar hemangioblastoma, pancreatic cyst, retinal hemangioblastoma, and pheochromocytoma. ACMG evidence codes: 'PP1' based on segregation results, 'PP2' because they observe a missense variant in gene where missense variants are common mechanism of disease, 'PP4' because the patients phenotypes and family history are highly specific for a disease with single genetic etiology. Relevant HPO terms: Renal cell carcinoma, Cerebellar hemangioblastoma, Multiple pancreatic cysts, Retinal hemangioblastoma, Pheochromocytoma."	9681858	PubMed		"Wittebol-Post et al., 1998, J. Intern. Med."		4	accepted	5863	Rare Germline	2023-01-09 21:46:50 UTC	https://civicdb.org/links/evidence_items/5863	https://civicdb.org/links/molecular_profiles/1702	FALSE	VHL	7428	V170D (c.509T>A)		chr3	10149832	10149832	T	A	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.509T>A,NC_000003.11:g.10191516T>A,NM_000551.3:c.509T>A,NP_000542.1:p.Val170Asp"	2023-01-27 17:12:32 UTC	CA351756195	625256	"C.509T>A,VAL170ASP"	FALSE
VHL R82P (c.245G>C)	1856	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	N/A	C	N/A	"Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in 3 VHL type 2B family members (kindred no. V12), but not in 7 unaffected family members. ACMG evidence codes: 'PP2' because they observe a missense variant in gene where missense variants are common mechanism of disease."	9829912	PubMed		"Olschwang et al., 1998, Hum. Mutat."		3	accepted	5864	Rare Germline	2023-01-09 21:46:54 UTC	https://civicdb.org/links/evidence_items/5864	https://civicdb.org/links/molecular_profiles/1856	FALSE	VHL	7428	R82P (c.245G>C)		chr3	10142092	10142092	G	C	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.245G>C,NP_000542.1:p.Arg82Pro,NC_000003.11:g.10183776G>C,ENST00000256474.2:c.245G>C"	2023-01-27 17:13:58 UTC	CA020159	193118	"C.245G>C,ARG82PRO,RS794726890"	FALSE
DICER1 E1813Q	1928	Sertoli-Leydig Cell Tumor	2997				Predisposing	Supports	C	Likely Pathogenic	DICER1 mutations in the RNase IIIb domain were found in 29% of nonepithelial ovarian tumors (n=103) with high predominance in Sertoli-Lydig cell tumors (26/43; 60%). There were two mutations in E1813Q.	22187960	PubMed		"Heravi-Moussavi et al., 2012, N. Engl. J. Med."		2	accepted	5892	Rare Germline	2023-01-09 21:46:54 UTC	https://civicdb.org/links/evidence_items/5892	https://civicdb.org/links/molecular_profiles/1928	FALSE	DICER1	23405	E1813Q		chr14	95091293	95091293	C	G	ENST00000526495.1	75		missense_variant	ENST00000526495.1:c.5437G>C	2023-01-27 17:14:40 UTC	CA390864655	NONE FOUND	GLU1813GLN	FALSE
BRAF V600E	12	Cholangiocarcinoma	4947		"Trametinib,Dabrafenib"	Combination	Predictive	Supports	C	Sensitivity/Response	"Chemotherapy-refractory, metastatic cholangiocarcinoma with CNS involvement and a BRAF V600E mutation had a partial response at 8 weeks to dabrafenib and trametinib combination with complete radiologic regression at 12 weeks. At 6 months the patient was still on treatment."	28480077	PubMed		"Kocsis et al., 2017, J Gastrointest Oncol"		3	accepted	5902	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/5902	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
BRAF V600E	12	Intrahepatic Cholangiocarcinoma	4928		"Dabrafenib,Trametinib"	Combination	Predictive	Supports	C	Sensitivity/Response	"Two cases of patients with BRAF V600E positive, refractory intrahepatic cholangiocarcinoma showed excellent clinical and radiographic response to combination dabrafenib and trametinib treatment. One patient achieved complete remission at 6 months with progression at 9 months and the other partial remission at 2 months and no progression as of 5 months."	28078132	PubMed		"Lavingia et al., 2016, J Gastrointest Oncol"		3	accepted	5903	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/5903	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
BRAF V600E	12	Intrahepatic Cholangiocarcinoma	4928		"Trametinib,Dabrafenib"	Combination	Predictive	Supports	C	Sensitivity/Response	"Dabrafenib and trametinib combination showed durable response for a patient with standard chemotherapy and radiation refractory, poorly differentiated, intrahepatic cholangiocarcinoma harboring BRAF V600E. At time of publication, 8.5 months, the patient was still on treatment."	25435907	PubMed		"Loaiza-Bonilla et al., 2014, Ecancermedicalscience"		3	accepted	5904	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/5904	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
BRAF V600	17	Cholangiocarcinoma	4947		Vemurafenib		Predictive	Supports	B	Sensitivity/Response	"Eight patients with BRAF V600 (7 with V600E, 1 with V600 unknown) mutated cholangiocarcinoma received vemurafenib. Only one patients showed partial response and duration of response of this patient was longer than 12 months."	26287849	PubMed		"Hyman et al., 2015, N. Engl. J. Med."	NCT01524978	4	accepted	5905	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/5905	https://civicdb.org/links/molecular_profiles/17	FALSE	BRAF	673	V600	Other BRAF V600's	chr7	140753336	140753337			ENST00000288602.6	75		protein_altering_variant		2023-01-09 21:52:04 UTC		"13,961,448,153,762,800,000,000,000,000,000"	VAL600	FALSE
BRAF V600E	12	Cholangiocarcinoma	4947		"Panitumumab,Vemurafenib,Irinotecan"	Combination	Predictive	Supports	C	Sensitivity/Response	"A 31 year old patient with metastatic cholangiocarcinoma with BRAF V600E was treated with vemurafenib, panitumumab and irinotecan triplet therapy. By 2 months, 50% reduction of tumor volume was noted, including multiple lung metastases, complete clinical response was noted by CT 6 months post therapy and this treatment was continued."	26687137	PubMed		"Silkin et al., 2016, J Gastrointest Cancer"		3	accepted	5906	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/5906	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
FGFR2 Mutation	507	Cholangiocarcinoma	4947		Infigratinib		Predictive	Supports	B	Sensitivity/Response	"Eight patients with cholangiocarcinoma haboring FGFR2 mutations received BGJ398. No response was observed, but one tumor showed a 23% reduction in  size. Water fall plot of this article showed 5 patients with stable disease."	29182496	PubMed		"Javle et al., 2018, J. Clin. Oncol."	NCT02150967	4	accepted	5912	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/5912	https://civicdb.org/links/molecular_profiles/507	FALSE	FGFR2	2263	Mutation		chr10	121479857	121598403			ENST00000457416.2	75		"transcript_variant,gain_of_function_variant"		2023-01-09 21:52:07 UTC		"37,615,737,615,637,600,000,000"		FALSE
BRCA2 Mutation	186	Pancreatic Cancer	1793		Olaparib		Predictive	Supports	B	Sensitivity/Response	"Twenty-three patients with pancreatic cancer havoring BRCA1/2 germline mutations received olaparib. Eighteen (78%) patients had a BRCA2 mutation.  In total of patients with BRCA1/2 mutation , all but one had received prior gemcitabine, and 65% had received prior platinum. Tumor response rate was 21.7% and stable disease more than 8 weeks was 35%."	25366685	PubMed		"Kaufman et al., 2015, J. Clin. Oncol."		4	accepted	5913	Rare Germline	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/5913	https://civicdb.org/links/molecular_profiles/186	FALSE	BRCA2	675	Mutation		chr13	32315474	32399210			ENST00000380152.3	75		"gene_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
BRCA1 Mutation	185	Pancreatic Cancer	1793		Olaparib		Predictive	Supports	B	Sensitivity/Response	"Twenty-three patients with pancreatic cancer havoring BRCA1/2 germline mutations received olaparib. Five (21.7%) patients had a BRCA1 mutation. All but one had received prior gemcitabine, and 65% had received prior platinum. Tumor response rate was 21.7% and stable disease more than 8 weeks was 35%."	25366685	PubMed		"Kaufman et al., 2015, J. Clin. Oncol."		3	accepted	5914	Rare Germline	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/5914	https://civicdb.org/links/molecular_profiles/185	FALSE	BRCA1	672	Mutation		chr17	43045629	43125483			ENST00000471181.2	75		"gene_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
BRCA1 Mutation	185	Pancreatic Cancer	1793		"Oxaliplatin,Cisplatin"	Substitutes	Predictive	Supports	B	Sensitivity/Response	"Patients with BRCA1/2 associated pancreatic adenocarcinoma were evaluated retrospectively. In patients with stage 3 and 4, the median overall survival (mOS) was 22 months for the platinum exposed (n=22), compared with 9 months for the non-platinum (n=21) treatment groups (p<0.039)"	25072261	PubMed		"Golan et al., 2014, Br. J. Cancer"		4	accepted	5915	Rare Germline	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/5915	https://civicdb.org/links/molecular_profiles/185	FALSE	BRCA1	672	Mutation		chr17	43045629	43125483			ENST00000471181.2	75		"gene_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
BRCA2 Mutation	186	Pancreatic Cancer	1793		Platinum Compound		Predictive	Supports	B	Sensitivity/Response	"Patients with BRCA1/2 associated pancreatic adenocarcinoma were evaluated retrospectively. In patients with stage 3 and 4, the median overall survival (mOS) was 22 months for the platinum exposed (n=22), compared with 9 months for the non-platinum (n=21) treatment groups (p<0.039)"	25072261	PubMed		"Golan et al., 2014, Br. J. Cancer"		4	accepted	5916	Rare Germline	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/5916	https://civicdb.org/links/molecular_profiles/186	FALSE	BRCA2	675	Mutation		chr13	32315474	32399210			ENST00000380152.3	75		"gene_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
EGFR L858R	33	Cancer	162		Erlotinib		Predictive	Supports	D	Sensitivity/Response	"In an in vitro study performed after identification of the mutation in a malignant peritoneal mesothelioma patient, COS-7 cells expressing EGFR L858R demonstrated increased EGFR phosphotyrosine after EGF treatment over wildtype EGFR   expressing cells. Cells expressing mutant EGFR also showed increased sensitivity to erlotinib treatment compared to cells expressing EGFR wild-type. Sensitivity was determined by assessing EGFR auto-phosphorylation."	20942962	PubMed		"Foster et al., 2010, World J Surg Oncol"		3	accepted	5922	Somatic	2023-01-27 03:51:19 UTC	https://civicdb.org/links/evidence_items/5922	https://civicdb.org/links/molecular_profiles/33	FALSE	EGFR	1956	L858R		chr7	55191822	55191822	T	G	ENST00000275493.2	75		missense_variant	"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg"	2023-01-27 17:02:04 UTC	CA126713	"16,609,376,282,376,200"	"LEU858ARG,RS121434568"	FALSE
EGFR Mutation	438	Peritoneal Mesothelioma	1788		"Cytoreductive Surgery,Hyperthermic Intraperitoneal Chemotherapy"	Combination	Predictive	Supports	B	Sensitivity/Response	"25 patients with metastatic peritoneal mesothelioma were treated with surgical cytoreduction consolidated with intraperitoneal hyperthermic chemotherapy (CRS/IPHC). 8 of the patients carried EGFR mutations in the tyrosine kinase domain. Each mutation was not found in 100 unrelated controls. At study end 10/18 wildtype patients had died with median survival of 14 months, while 2/7 EGFR mutant patients had died and median survival was not yet reached. Median time to progression (TTP) was 12 months in the wildtype group and in the mutant group median TTP was not yet reached. 3 year progression free survival was 71% in the mutant group and 28% in the wildtype group."	20942962	PubMed		"Foster et al., 2010, World J Surg Oncol"		4	accepted	5923	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/5923	https://civicdb.org/links/molecular_profiles/438	FALSE	EGFR	1956	Mutation		chr7	55019101	55211628			ENST00000275493.2	75		inframe_variant		2023-01-09 21:52:07 UTC		N/A		FALSE
EGFR Amplification	190	Lung Non-small Cell Carcinoma	3908		"Erlotinib,Gefitinib"	Substitutes	Predictive	Supports	B	Sensitivity/Response	"The result of the analysis found that EGFR gene copy number was associated with increased OS and PFS, supporting the idea that EGFR gene copy number is a biomarker for response to EGFR-TKI therapy in patients with advanced NSCLC."	20826716	PubMed		"Dahabreh et al., 2011, Ann. Oncol."		4	accepted	5924	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/5924	https://civicdb.org/links/molecular_profiles/190	FALSE	EGFR	1956	Amplification		chr7	55019101	55211628			ENST00000275493.2	75		transcript_amplification	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
EGFR Amplification	190	Lung Non-small Cell Carcinoma	3908		"Gefitinib,Erlotinib"	Substitutes	Predictive	Supports	B	Sensitivity/Response	"Among TKI-treated patients, increased EGFR gene copy number appears to be associated with improved survival outcomes."	27664271	PubMed		"Zhang et al., 2017, J. Investig. Med."		4	accepted	5925	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/5925	https://civicdb.org/links/molecular_profiles/190	FALSE	EGFR	1956	Amplification		chr7	55019101	55211628			ENST00000275493.2	75		transcript_amplification	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
BRCA1 Mutation	185	Pancreatic Cancer	1793		"Cisplatin,Gemcitabine,Veliparib"	Combination	Predictive	Supports	B	Sensitivity/Response	In Phase I study for pancreatic cancer patients GEM 600 mg/m2 + CDDP 25 mg/m2 + Veliparib 20 - 80 mg twice daily showed response rate of  77.8% (7/9) and mOS of 23.3 months in germline BRCA mutation-positive patients with stage IV disease.	29338080	PubMed		"O'Reilly et al., 2018, Cancer"		3	accepted	5932	Rare Germline	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/5932	https://civicdb.org/links/molecular_profiles/185	FALSE	BRCA1	672	Mutation		chr17	43045629	43125483			ENST00000471181.2	75		"gene_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
BRCA2 Mutation	186	Pancreatic Cancer	1793		"Gemcitabine,Veliparib,Cisplatin"	Combination	Predictive	Supports	B	Sensitivity/Response	In Phase I study for pancreatic cancer patients GEM 600 mg/m2 + CDDP 25 mg/m2 + Veliparib 20 - 80 mg twice daily showed response rate of  77.8% (7/9) and mOS of 23.3 months in germline BRCA mutation-positive patients with stage IV disease.	29338080	PubMed		"O'Reilly et al., 2018, Cancer"		3	accepted	5933	Rare Germline	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/5933	https://civicdb.org/links/molecular_profiles/186	FALSE	BRCA2	675	Mutation		chr13	32315474	32399210			ENST00000380152.3	75		"gene_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
BRCA1 Mutation	185	Pancreatic Cancer	1793		Veliparib		Predictive	Does Not Support	B	Sensitivity/Response	Veliparib 400mg BID was administered to patients with germline BRCA1/2-mutated pancreatic cancer. Sixteen patients were enrolled. All except two (12.5%) had previously been treated with platinum therapy. No confirmed partial response was observed. One patient who had received prior single-agent gemcitabine only had an unconfirmed PR.	29223478	PubMed		"Lowery et al., 2018, Eur. J. Cancer"	"NCT01585805,NCT02184195"	3	accepted	5934	Rare Germline	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/5934	https://civicdb.org/links/molecular_profiles/185	FALSE	BRCA1	672	Mutation		chr17	43045629	43125483			ENST00000471181.2	75		"gene_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
BRCA2 Mutation	186	Pancreatic Cancer	1793		Veliparib		Predictive	Does Not Support	B	Sensitivity/Response	Veliparib 400mg bid was administered to patients with germline BRCA1/2 mutated pancreatic cancer. Sixteen pts was enrolled. All except two pts (12.5%) had previously been treated with platinum therapy. No confirmed PR was observed. One patient who had received prior single-agent gemcitabine only had an unconfirmed PR.	29223478	PubMed		"Lowery et al., 2018, Eur. J. Cancer"	"NCT01585805,NCT02184195"	3	accepted	5935	Rare Germline	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/5935	https://civicdb.org/links/molecular_profiles/186	FALSE	BRCA2	675	Mutation		chr13	32315474	32399210			ENST00000380152.3	75		"gene_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
BRCA2 Mutation	186	Pancreatic Cancer	1793		Iniparib		Predictive	Supports	C	Sensitivity/Response	"Patient with germline BRCA2 mutation underwent resection of pancreatic cancer. Around three years later, tumor recurrence was detected by MRI and PET-CT confirmed it. She was treated with gemcitabine plus iniparib in clinical trial. Excellent response to therapy was observed and surgery was performed but no residual tumor tissue was detected"	21508395	PubMed		"Fogelman et al., 2011, Anticancer Res."		3	accepted	5936	Rare Germline	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/5936	https://civicdb.org/links/molecular_profiles/186	FALSE	BRCA2	675	Mutation		chr13	32315474	32399210			ENST00000380152.3	75		"gene_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
EGFR D770_N771insNPG	1477	Lung Non-small Cell Carcinoma	3908		"Afatinib,Gefitinib"	Substitutes	Predictive	Does Not Support	D	Sensitivity/Response	"Ba/F3 cells transduced with EGFR D770_N771insNPG were IL3 growth independent, suggesting a driver mutation.  Gefitinib growth inhibition IC50 in D770_N771insNPG transduced Ba/F3 cells was 3.356 micro molar, which was higher than cells transduced with resistance mutation T790M (IC50=2.752). Similarly, afatinib growth inhibition IC50 was 0.0724 micro molar, which was higher than cells transduced with resistance mutation T790M (IC50=0.0629)."	24353160	PubMed		"Yasuda et al., 2013, Sci Transl Med"		3	accepted	5947	Somatic	2023-01-09 21:46:46 UTC	https://civicdb.org/links/evidence_items/5947	https://civicdb.org/links/molecular_profiles/1477	FALSE	EGFR	1956	D770_N771insNPG		chr7	55181319	55181320		AACCCCGGC				inframe_insertion		2023-01-27 17:10:29 UTC	CA2573051057			FALSE
ALK Fusion	495	Thyroid Gland Anaplastic Carcinoma	80522		Crizotinib		Predictive	Supports	C	Sensitivity/Response	"A patient with anaplastic thyroid carcinoma harboring ALK rearrangement received crizotinib after chemotherapy for pulmonary recurrence. Crizotinib showed confirmed response of more than 90% by tumor volume, and her response has been stable on follow-up."	24687827	PubMed		"Godbert et al., 2015, J. Clin. Oncol."		3	accepted	5954	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/5954	https://civicdb.org/links/molecular_profiles/495	FALSE	ALK	238	Fusion	ALK Fusion	chr2	29192774	29223528			ENST00000389048.3	75		transcript_fusion		2023-01-09 21:52:07 UTC		N/A	REARRANGEMENT	FALSE
PTEN Loss	214	Solid Tumor			"Paclitaxel,Buparlisib,Carboplatin"	Combination	Predictive	Does Not Support	B	Sensitivity/Response	"In one arm of this phase 1b study, 7 patients with PTEN deficient tumors were treated with continuous buparlisib (100 mg/daily) orally plus standard dose carboplatin AUC 5 and paclitaxel 175 mg/m2. No objective responses were observed. 2 patients had stable disease for ?6 cycles. The authors recommended against the addition of buparlisib to carboplatin and paclitaxel, citing toxicity. Authors noted that combination therapy did not produce significant clinical activity amongst a small and heterogenous group of PTEN deficient tumors."	28281183	PubMed		"Smyth et al., 2017, Invest New Drugs"	NCT01297452	2	accepted	5957	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/5957	https://civicdb.org/links/molecular_profiles/214	FALSE	PTEN	5728	Loss		chr10	87863113	87971930			ENST00000371953.3	75		loss_of_function_variant	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
BRAF V600E	12	Lung Non-small Cell Carcinoma	3908		Vemurafenib		Predictive	Supports	B	Sensitivity/Response	"The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Within the BRAF mutant group, fourteen patients had refractory BRAF V600E-mutated NSCLC (adenocarcinoma, n = 13; sarcomatoid, n = 1). Six patients (43%; 95% CI, 18% to 71%) had objective responses (one CR, five PR), and two additional patients had SD > 120 days. The median DOR was 5 months (range, 4 to 14 months)."	29320312	PubMed		"Hainsworth et al., 2018, J. Clin. Oncol."	NCT02091141	4	accepted	5958	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/5958	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
BRAF V600E	12	Ovarian Cancer	2394		Vemurafenib		Predictive	Supports	B	Sensitivity/Response	"The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Among 4 patients with BRAF V600E mutant ovarian cancer, 2 had a partial response and one had stable disease > 120days."	29320312	PubMed		"Hainsworth et al., 2018, J. Clin. Oncol."	NCT02091141	3	accepted	5959	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/5959	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
BRAF V600E	12	Colorectal Cancer	9256		Vemurafenib		Predictive	Supports	C	Sensitivity/Response	"The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Among 2 patients with BRAF V600E mutant colorectal cancer, 1 had a partial response."	29320312	PubMed		"Hainsworth et al., 2018, J. Clin. Oncol."	NCT02091141	2	accepted	5960	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/5960	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
BRAF V600E	12	Thyroid Gland Anaplastic Carcinoma	80522		"Pertuzumab,Vemurafenib"	Combination	Predictive	Supports	C	Sensitivity/Response	"The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. One patient with BRAF V600E mutant anaplastic thyroid cancer had a complete response."	29320312	PubMed		"Hainsworth et al., 2018, J. Clin. Oncol."	NCT02091141	3	accepted	5961	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/5961	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
BRAF V600E	12	Laryngeal Squamous Cell Carcinoma	2876		Vemurafenib		Predictive	Supports	C	Sensitivity/Response	"The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. One patient with BRAF V600E mutant laryngeal cancer had a partial response with vemurafenib."	29320312	PubMed		"Hainsworth et al., 2018, J. Clin. Oncol."	NCT02091141	3	accepted	5962	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/5962	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
BRAF G464V	1080	Cancer	162		Vemurafenib		Predictive	Does Not Support	C	Sensitivity/Response	"The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patients with BRAF V600E mutations, objective responses were seen in 12 patients (46%; 95% CI, 27% to 67%). Only one of 23 patients (4%; 95% CI, 0% to 22%) with other non-V600 BRAF mutations had a PR (pancreas cancer with a CUX1-BRAF fusion). Nonresponding BRAF mutations included: K601E (n = 6), G464V (n = 2), G469A (n = 2), G496A (n = 2), N581S (n = 2), and one each for G466V, G596R, G606E, L597Q, P731T, intron 9 rearrangement, intron 10 rearrangement, and MACF1- and WASFL-BRAF fusion."	29320312	PubMed		"Hainsworth et al., 2018, J. Clin. Oncol."	NCT02091141	2	accepted	5964	Somatic	2023-01-09 21:46:42 UTC	https://civicdb.org/links/evidence_items/5964	https://civicdb.org/links/molecular_profiles/1080	FALSE	BRAF	673	G464V		chr7	140781617	140781617	C	A	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1391G>T,NP_004324.2:p.Gly464Val,NC_000007.13:g.140481417C>A,ENST00000288602.6:c.1391G>T"	2023-01-27 17:08:02 UTC	CA135076	40364	"RS121913348,GLY464VAL"	FALSE
BRAF G469A	966	Cancer	162		Vemurafenib		Predictive	Does Not Support	C	Sensitivity/Response	"The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patients with BRAF V600E mutations, objective responses were seen in 12 patients (46%; 95% CI, 27% to 67%). Only one of 23 patients (4%; 95% CI, 0% to 22%) with other non-V600 BRAF mutations had a PR (pancreas cancer with a CUX1-BRAF fusion). Nonresponding BRAF mutations included: K601E (n = 6), G464V (n = 2), G469A (n = 2), G496A (n = 2), N581S (n = 2), and one each for G466V, G596R, G606E, L597Q, P731T, intron 9 rearrangement, intron 10 rearrangement, and MACF1- and WASFL-BRAF fusion."	29320312	PubMed		"Hainsworth et al., 2018, J. Clin. Oncol."	NCT02091141	2	accepted	5965	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/5965	https://civicdb.org/links/molecular_profiles/966	FALSE	BRAF	673	G469A		chr7	140781602	140781602	C	G	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1406G>C,NP_004324.2:p.Gly469Ala,NC_000007.13:g.140481402C>G,ENST00000288602.6:c.1406G>C"	2023-01-27 17:07:28 UTC	CA123655	13971	"RS121913355,GLY469ALA"	FALSE
BRAF N581S	1160	Cancer	162		Vemurafenib		Predictive	Does Not Support	C	Sensitivity/Response	"The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patients with BRAF V600E mutations, objective responses were seen in 12 patients (46%; 95% CI, 27% to 67%). Only one of 23 patients (4%; 95% CI, 0% to 22%) with other non-V600 BRAF mutations had a PR (pancreas cancer with a CUX1-BRAF fusion). Nonresponding BRAF mutations included: K601E (n = 6), G464V (n = 2), G469A (n = 2), G496A (n = 2), N581S (n = 2), and one each for G466V, G596R, G606E, L597Q, P731T, intron 9 rearrangement, intron 10 rearrangement, and MACF1- and WASFL-BRAF fusion."	29320312	PubMed		"Hainsworth et al., 2018, J. Clin. Oncol."	NCT02091141	2	accepted	5967	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/5967	https://civicdb.org/links/molecular_profiles/1160	FALSE	BRAF	673	N581S		chr7	140753393	140753393	T	C				missense_variant		2023-01-27 17:08:37 UTC	CA180747		"N189S,N9S,RS121913370"	FALSE
BRAF G466V	2098	Cancer	162		Vemurafenib		Predictive	Does Not Support	C	Sensitivity/Response	"The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patients with BRAF V600E mutations, objective responses were seen in 12 patients (46%; 95% CI, 27% to 67%). Only one of 23 patients (4%; 95% CI, 0% to 22%) with other non-V600 BRAF mutations had a PR (pancreas cancer with a CUX1-BRAF fusion). Nonresponding BRAF mutations included: K601E (n = 6), G464V (n = 2), G469A (n = 2), G496A (n = 2), N581S (n = 2), and one each for G466V, G596R, G606E, L597Q, P731T, intron 9 rearrangement, intron 10 rearrangement, and MACF1- and WASFL-BRAF fusion."	29320312	PubMed		"Hainsworth et al., 2018, J. Clin. Oncol."	NCT02091141	2	accepted	5968	Somatic	2023-01-09 21:46:57 UTC	https://civicdb.org/links/evidence_items/5968	https://civicdb.org/links/molecular_profiles/2098	FALSE	BRAF	673	G466V		chr7	140781611	140781611	C	A	ENST00000288602.6	75		missense_variant	"NC_000007.13:g.140481411C>A,NM_004333.4:c.1397G>T,NP_004324.2:p.Gly466Val,ENST00000288602.6:c.1397G>T"	2023-01-27 17:15:52 UTC	CA123647	13967	"GLY466VAL,RS121913351"	FALSE
BRAF G596R	1535	Cancer	162		Vemurafenib		Predictive	Does Not Support	C	Sensitivity/Response	"The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patients with BRAF V600E mutations, objective responses were seen in 12 patients (46%; 95% CI, 27% to 67%). Only one of 23 patients (4%; 95% CI, 0% to 22%) with other non-V600 BRAF mutations had a PR (pancreas cancer with a CUX1-BRAF fusion). Nonresponding BRAF mutations included: K601E (n = 6), G464V (n = 2), G469A (n = 2), G496A (n = 2), N581S (n = 2), and one each for G466V, G596R, G606E, L597Q, P731T, intron 9 rearrangement, intron 10 rearrangement, and MACF1- and WASFL-BRAF fusion."	29320312	PubMed		"Hainsworth et al., 2018, J. Clin. Oncol."	NCT02091141	2	accepted	5969	Somatic	2023-01-09 21:46:46 UTC	https://civicdb.org/links/evidence_items/5969	https://civicdb.org/links/molecular_profiles/1535	FALSE	BRAF	673	G596R		chr7	140753349	140753349	C	G	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1786G>C,NP_004324.2:p.Gly596Arg,NC_000007.13:g.140453149C>G,ENST00000288602.6:c.1786G>C"	2023-01-27 17:11:04 UTC	CA16602422	375943	"RS121913361,G204R,G24R,GLY596ARG"	FALSE
BRAF G606E	2099	Cancer	162		Vemurafenib		Predictive	Does Not Support	C	Sensitivity/Response	"The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patients with BRAF V600E mutations, objective responses were seen in 12 patients (46%; 95% CI, 27% to 67%). Only one of 23 patients (4%; 95% CI, 0% to 22%) with other non-V600 BRAF mutations had a PR (pancreas cancer with a CUX1-BRAF fusion). Nonresponding BRAF mutations included: K601E (n = 6), G464V (n = 2), G469A (n = 2), G496A (n = 2), N581S (n = 2), and one each for G466V, G596R, G606E, L597Q, P731T, intron 9 rearrangement, intron 10 rearrangement, and MACF1- and WASFL-BRAF fusion."	29320312	PubMed		"Hainsworth et al., 2018, J. Clin. Oncol."	NCT02091141	2	accepted	5970	Somatic	2023-01-09 21:46:57 UTC	https://civicdb.org/links/evidence_items/5970	https://civicdb.org/links/molecular_profiles/2099	FALSE	BRAF	673	G606E		chr7	140753318	140753318	C	T	ENST00000288602.6	75		missense_variant		2023-01-27 17:15:53 UTC	CA369542941	NONE FOUND	GLY606GLU	FALSE
BRAF L597Q	579	Cancer	162		Vemurafenib		Predictive	Does Not Support	C	Sensitivity/Response	"The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patients with BRAF V600E mutations, objective responses were seen in 12 patients (46%; 95% CI, 27% to 67%). Only one of 23 patients (4%; 95% CI, 0% to 22%) with other non-V600 BRAF mutations had a PR (pancreas cancer with a CUX1-BRAF fusion). Nonresponding BRAF mutations included: K601E (n = 6), G464V (n = 2), G469A (n = 2), G496A (n = 2), N581S (n = 2), and one each for G466V, G596R, G606E, L597Q, P731T, intron 9 rearrangement, intron 10 rearrangement, and MACF1- and WASFL-BRAF fusion."	29320312	PubMed		"Hainsworth et al., 2018, J. Clin. Oncol."	NCT02091141	2	accepted	5971	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/5971	https://civicdb.org/links/molecular_profiles/579	FALSE	BRAF	673	L597Q		chr7	140753345	140753345	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1790T>A,NP_004324.2:p.Leu597Gln,NC_000007.13:g.140453145A>T,ENST00000288602.6:c.1790T>A"	2023-01-27 17:04:27 UTC	CA16602257	76687	"LEU597GLN,RS121913366"	FALSE
BRAF P731T	2100	Cancer	162		Vemurafenib		Predictive	Does Not Support	C	Sensitivity/Response	"The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patients with BRAF V600E mutations, objective responses were seen in 12 patients (46%; 95% CI, 27% to 67%). Only one of 23 patients (4%; 95% CI, 0% to 22%) with other non-V600 BRAF mutations had a PR (pancreas cancer with a CUX1-BRAF fusion). Nonresponding BRAF mutations included: K601E (n = 6), G464V (n = 2), G469A (n = 2), G496A (n = 2), N581S (n = 2), and one each for G466V, G596R, G606E, L597Q, P731T, intron 9 rearrangement, intron 10 rearrangement, and MACF1- and WASFL-BRAF fusion."	29320312	PubMed		"Hainsworth et al., 2018, J. Clin. Oncol."	NCT02091141	2	accepted	5972	Somatic	2023-01-09 21:46:57 UTC	https://civicdb.org/links/evidence_items/5972	https://civicdb.org/links/molecular_profiles/2100	FALSE	BRAF	673	P731T		chr7	140734707	140734707	G	T	ENST00000288602.6	75		missense_variant	ENST00000288602.6:c.2193G>T	2023-01-27 17:15:54 UTC	CA369537254	NONE FOUND	PRO731THR	FALSE
PTCH1 Mutation	297	Cancer	162		Vismodegib		Predictive	Supports	B	Sensitivity/Response	"The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Twenty-one patients had mutations in the Hedgehog pathway (PTCH-1, n = 18; SMO, n = 3). Three patients with PTCH1 mutations had PRs to vismodegib (17%; unknown primary cancer, n = 1; squamous skin cancer, n = 1; salivary gland cancer, n = 1)."	29320312	PubMed		"Hainsworth et al., 2018, J. Clin. Oncol."	NCT02091141	1	accepted	5978	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/5978	https://civicdb.org/links/molecular_profiles/297	FALSE	PTCH1	5727	Mutation		chr9	95442980	95508661			ENST00000331920.6	75		"gene_variant,loss_of_function_variant"		2023-01-09 21:52:06 UTC				FALSE
SMO Mutation	296	Cancer	162		Vismodegib		Predictive	Does Not Support	B	Sensitivity/Response	"The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Twenty-one patients had mutations in the Hedgehog pathway (PTCH-1, n = 18; SMO, n = 3). None of the patients with SMO mutations responded to SHH-inhibition with vismodegib."	29320312	PubMed		"Hainsworth et al., 2018, J. Clin. Oncol."	NCT02091141	2	accepted	5979	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/5979	https://civicdb.org/links/molecular_profiles/296	FALSE	SMO	6608	Mutation		chr7	129188872	129213545			ENST00000249373.3	75		coding_transcript_variant		2023-01-09 21:52:06 UTC		N/A		FALSE
ERBB2 Mutation	662	Lung Non-small Cell Carcinoma	3908		"Trastuzumab,Pertuzumab"	Combination	Predictive	Supports	B	Sensitivity/Response	"The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Among thirty-six patients that received treatment with trastuzumab plus pertuzumab because of a HER2 mutation (without amplification/overexpression) four patients (11%; 95% CI, 3% to 26%) had objective responses.  Fourteen of the 36 patients with HER2-mutated tumors had NSCLC (adenocarcinoma, n = 13; adenosquamous, n = 1); in this group, three patients (21%; 95% CI, 5% to 51%) had PR and three had SD > 120 days. Only one of the other 22 patients with HER2-mutated tumors responded to treatment with pertuzumab plus trastuzumab (biliary cancer)."	29320312	PubMed		"Hainsworth et al., 2018, J. Clin. Oncol."	NCT02091141	2	accepted	5980	Somatic	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/5980	https://civicdb.org/links/molecular_profiles/662	FALSE	ERBB2	2064	Mutation		chr17	39711943	39725079			ENST00000269571.5	75		missense_variant		2023-01-09 21:52:08 UTC				FALSE
ERBB2 Amplification	302	Colorectal Cancer	9256		"Trastuzumab,Pertuzumab"	Combination	Predictive	Supports	B	Sensitivity/Response	"The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively.  Thirty of 114 patients (26%; 95% CI, 19% to 35%) with HER2 amplification/overexpression had objective responses to treatment with trastuzumab plus pertuzumab (two CR, 28 PR).  Patients with HER2-amplified/overexpressing metastatic colorectal cancer composed the largest tumor-pathway cohort. In this group of 37 patients with refractory disease (median, four previous lines of therapy), treatment with trastuzumab plus pertuzumab produced PRs in 14 patients (38%; 95% CI, 23% to 55%; Fig 2A). An additional four patients had SD > 120 days. The median DOR was 11 months (range, < 1 to 16+ months; 95% CI, 2.8 months to not estimable)."	29320312	PubMed		"Hainsworth et al., 2018, J. Clin. Oncol."	NCT02091141	4	accepted	5981	N/A	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/5981	https://civicdb.org/links/molecular_profiles/302	FALSE	ERBB2	2064	Amplification		chr17	39700080	39728662			ENST00000269571.5	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A	OVEREXPRESSION	FALSE
ERBB2 Amplification	302	Bladder Carcinoma	4007		"Trastuzumab,Pertuzumab"	Combination	Predictive	Supports	B	Sensitivity/Response	"The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Three of nine patients (33%; 95% CI, 8% to 70%) with advanced bladder cancer and HER2 amplification/overexpression had responses (one CR ongoing at 15 months; two PR lasting 1 and 6 months), and two patients had SD > 120 days."	29320312	PubMed		"Hainsworth et al., 2018, J. Clin. Oncol."	NCT02091141	3	accepted	5982	N/A	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/5982	https://civicdb.org/links/molecular_profiles/302	FALSE	ERBB2	2064	Amplification		chr17	39700080	39728662			ENST00000269571.5	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A	OVEREXPRESSION	FALSE
ERBB2 Amplification	302	Biliary Tract Cancer	4607		"Pertuzumab,Trastuzumab"	Combination	Predictive	Supports	B	Sensitivity/Response	"The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Two of seven patients (29%; 95% CI, 4% to 71%) with biliary cancer and HER2 amplification/overexpression had PR, and three had SD > 120 days"	29320312	PubMed		"Hainsworth et al., 2018, J. Clin. Oncol."	NCT02091141	2	accepted	5983	N/A	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/5983	https://civicdb.org/links/molecular_profiles/302	FALSE	ERBB2	2064	Amplification		chr17	39700080	39728662			ENST00000269571.5	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A	OVEREXPRESSION	FALSE
ERBB2 Amplification	302	Salivary Gland Carcinoma	50904		"Pertuzumab,Trastuzumab"	Combination	Predictive	Supports	B	Sensitivity/Response	"The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Four of five patients with HER2 amplified/overexpressing salivary gland carcinoma (80%; 95% CI, 28% to > 99%) had responses (all PR)."	29320312	PubMed		"Hainsworth et al., 2018, J. Clin. Oncol."	NCT02091141	2	accepted	5984	N/A	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/5984	https://civicdb.org/links/molecular_profiles/302	FALSE	ERBB2	2064	Amplification		chr17	39700080	39728662			ENST00000269571.5	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A	OVEREXPRESSION	FALSE
ERBB2 Amplification	302	Pancreatic Cancer	1793		"Trastuzumab,Pertuzumab"	Combination	Predictive	Supports	B	Sensitivity/Response	"The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Two of nine patients (22%) with HER2 amplified/overexpressing pancreatic cancer had a PR with trastuzumab/pertuzumab combination. Another patient had SD > 120days."	29320312	PubMed		"Hainsworth et al., 2018, J. Clin. Oncol."	NCT02091141	2	accepted	5985	N/A	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/5985	https://civicdb.org/links/molecular_profiles/302	FALSE	ERBB2	2064	Amplification		chr17	39700080	39728662			ENST00000269571.5	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A	OVEREXPRESSION	FALSE
ERBB2 Amplification	302	Uterine Cancer	363		"Trastuzumab,Pertuzumab"	Combination	Predictive	Does Not Support	B	Sensitivity/Response	"The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. None of the 7 patients with HER2 amplified/overexpressing uterus cancer responded to pertuzumab/trastuzumab."	29320312	PubMed		"Hainsworth et al., 2018, J. Clin. Oncol."	NCT02091141	2	accepted	5986	N/A	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/5986	https://civicdb.org/links/molecular_profiles/302	FALSE	ERBB2	2064	Amplification		chr17	39700080	39728662			ENST00000269571.5	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A	OVEREXPRESSION	FALSE
IDH1 R132H	416	Pancreatic Ductal Adenocarcinoma	3498		Ivosidenib		Predictive	Does Not Support	C	Sensitivity/Response	"A 48-year-old female was diagnosed with metastatic pancreatic ductal adenocarcinoma and subsequently started on standard of care chemotherapy, during which her hepatic lesions progressed. Detailed molecular profiling was performed on a biopsy from a liver lesion that demonstrated an IDH1 mutation, R132H. The patient subsequently received a mutant IDH1 inhibitor (AG-120), but with no response."	27466707	PubMed		"Brody et al., 2016, Cancer Biol. Ther."		2	accepted	5987	Somatic	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/5987	https://civicdb.org/links/molecular_profiles/416	FALSE	IDH1	3417	R132H		chr2	208248388	208248388	C	T	ENST00000415913.1	75		missense_variant	"NM_001282386.1:c.395G>A,NP_005887.2:p.Arg132His,NC_000002.11:g.209113112C>T,ENST00000415913.1:c.395G>A"	2023-01-27 17:03:38 UTC	CA170874	156444	"ARG132HIS,RS121913500"	FALSE
BCL2 Mutation	2109	Follicular Lymphoma	50873				Prognostic	Supports	B	Poor Outcome	"In a multivariate analysis, BCL2 mutations and high FL international prognostic index were independent risk factors for transformation and death due to lymphoma. Some mutant Bcl-2 proteins exhibited enhanced antiapoptotic capacity in vitro."	25452615	PubMed		"Correia et al., 2015, Blood"		3	accepted	5992	Somatic	2023-01-09 21:46:57 UTC	https://civicdb.org/links/evidence_items/5992	https://civicdb.org/links/molecular_profiles/2109	FALSE	BCL2	596	Mutation		chr18	63123346	63320128			ENST00000398117.1	75				2023-01-09 21:52:18 UTC		N/A		FALSE
BRAF D594G	607	Skin Melanoma	8923		Sorafenib		Predictive	Supports	D	Sensitivity/Response	"In this preclinical study, melanoma cell lines harboring the kinase-dead G469E- and D594G mutations were identified. These cell lines were resitant to MEK-Inhibition but underwent apoptosis after shRNA-mediated CRAF knowdown or Treatment with the pan-RAF Inhibitor sorafenib."	18794803	PubMed		"Smalley et al., 2009, Oncogene"		3	accepted	6001	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/6001	https://civicdb.org/links/molecular_profiles/607	FALSE	BRAF	673	D594G		chr7	140753354	140753354	T	C	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1781A>G,NP_004324.2:p.Asp594Gly,NC_000007.13:g.140453154T>C,ENST00000288602.6:c.1781A>G"	2023-01-27 17:04:35 UTC	CA123657	13972	"ASP594GLY,RS121913338"	FALSE
BRAF D594G	607	Skin Melanoma	8923		U0126		Predictive	Supports	D	Resistance	"In this preclinical study, melanoma cell lines harboring the kinase-dead G469E- and D594G mutations were identified. These cell lines were resitant to MEK-Inhibition but underwent apoptosis after shRNA-mediated CRAF knowdown or Treatment with the pan-RAF Inhibitor sorafenib."	18794803	PubMed		"Smalley et al., 2009, Oncogene"		3	accepted	6002	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/6002	https://civicdb.org/links/molecular_profiles/607	FALSE	BRAF	673	D594G		chr7	140753354	140753354	T	C	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1781A>G,NP_004324.2:p.Asp594Gly,NC_000007.13:g.140453154T>C,ENST00000288602.6:c.1781A>G"	2023-01-27 17:04:35 UTC	CA123657	13972	"ASP594GLY,RS121913338"	FALSE
BRAF G469E	967	Skin Melanoma	8923		Sorafenib		Predictive	Supports	D	Sensitivity/Response	"In this preclinical study, melanoma cell lines harboring the kinase-dead G469E- and D594G mutations were identified. These cell lines were resitant to MEK-Inhibition but underwent apoptosis after shRNA-mediated CRAF knowdown or Treatment with the pan-RAF Inhibitor sorafenib."	18794803	PubMed		"Smalley et al., 2009, Oncogene"		3	accepted	6003	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/6003	https://civicdb.org/links/molecular_profiles/967	FALSE	BRAF	673	G469E		chr7	140781602	140781602	C	T				missense_variant		2023-01-27 17:07:28 UTC	CA279970		RS121913355	FALSE
BRAF G469E	967	Skin Melanoma	8923		U0126		Predictive	Supports	D	Resistance	"In this preclinical study, melanoma cell lines harboring the kinase-dead G469E- and D594G mutations were identified. These cell lines were resitant to MEK-Inhibition (U0126) but underwent apoptosis after shRNA-mediated CRAF knowdown or treatment with the pan-RAF inhibitor sorafenib."	18794803	PubMed		"Smalley et al., 2009, Oncogene"		3	accepted	6004	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/6004	https://civicdb.org/links/molecular_profiles/967	FALSE	BRAF	673	G469E		chr7	140781602	140781602	C	T				missense_variant		2023-01-27 17:07:28 UTC	CA279970		RS121913355	FALSE
EGFR L747_P753delinsS	986	Pancreatic Adenocarcinoma	4074		Erlotinib		Predictive	Supports	C	Sensitivity/Response	"Patients with recurrent pancreatic adenocarcinoma was treated with gemcitabine + nab-paclitaxel, FOLFIRINOX and docetaxel + irinotecan. After failure of these treatment, a tumor specimen from the pancreaticoduodenectomy was analyzed, which revealed an activating mutation in exon 19 (L747_P753>S) of EGFR. Mutations were also detected in CDKN2A, TP53, and amplifications of PRKCI and TERC. He began erlotinib at 150mg daily. CT imaging revealed a partial response by RECIST at 8, 24 and 32 weeks after starting erlotinib. At 40 weeks CT imaging revealed unequivocal disease progression. After disease progression to erlotinib, a repeat liver biopsy revealed an EGFR T790M mutation. He began treatment with osimertinib at 80mg daily. After 8 weeks of this treatment CT imaging revealed unequivocal disease progression."	28874593	PubMed		"Cecchini et al., 2017, J Natl Compr Canc Netw"		3	accepted	6005	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/6005	https://civicdb.org/links/molecular_profiles/986	FALSE	EGFR	1956	L747_P753delinsS		chr7	55174777	55174794	TAAGAGAAGCAACATCTC		ENST00000275493.2	75		inframe_deletion		2023-01-27 17:07:37 UTC	CA126710	16608	RS121913438	FALSE
EGFR T790M	34	Pancreatic Adenocarcinoma	4074		Osimertinib		Predictive	Does Not Support	C	Sensitivity/Response	"Patients with recurrent pancreatic adenocarcinoma was treated with gemcitabine + nab-paclitaxel, FOLFIRINOX and docetaxel + irinotecan. After failure of these treatment, a tumor specimen from the pancreaticoduodenectomy was analysed, which revealed an activating mutation in exon 19 (L747_P753>S) of EGFR. Mutations were also detected in CDKN2A, TP53, and amplifications of PRKCI and TERC. He began erlotinib at 150mg daily. CT imaging  revealed a partial response by RECIST at 8, 24 and 32 weeks after starting erlotinib. At 40 weeks CT imaging revealed unequivocal disease progression. After disease progression to erlotinib, a repeat liver biopsy revealed an EGFR T790M mutation. He began treatment with osimertinib at 80mg daily. After 8 weeks of this treatment CT imaging revealed unequivocal disease progression."	28874593	PubMed		"Cecchini et al., 2017, J Natl Compr Canc Netw"		2	accepted	6006	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/6006	https://civicdb.org/links/molecular_profiles/34	FALSE	EGFR	1956	T790M	EGFR TKI Resistance	chr7	55181378	55181378	C	T	ENST00000275493.2	75		missense_variant	"ENST00000275493.2:c.2369C>T,NM_005228.4:c.2369C>T,NP_005219.2:p.Thr790Met,NC_000007.13:g.55249071C>T"	2023-01-27 17:02:05 UTC	CA090928	16613	"THR790MET,RS121434569"	FALSE
MYCN Amplification	294	Neuroblastoma	769		"JQ1,Panobinostat"	Combination	Predictive	Supports	D	Sensitivity/Response	"JQ1 and panobinostat synergistically reduced LIN28B gene and N-Myc protein expression, and synergistically induced growth inhibition and apoptosis in neuroblastoma cells, but not normal nonmalignant cells in vitro In neuroblastoma-bearing mice, JQ1 and panobinostat synergistically and considerably reduced N-Myc protein expression in tumor tissues and blocked tumor progression."	26733615	PubMed		"Shahbazi et al., 2016, Clin. Cancer Res."		3	accepted	6019	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/6019	https://civicdb.org/links/molecular_profiles/294	FALSE	MYCN	4613	Amplification		chr2	15940564	15947007			ENST00000281043.3	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A		FALSE
VHL L184P (c.551T>C)	1652	Renal Cell Carcinoma	4450	"Renal cell carcinoma,Sporadic"			Diagnostic	Supports	C	Positive	"In a study of 31 kidney tumors from France, 14 somatic VHL mutations were found. Most tumors were found to have heterozygous pattern of mutation likely due to contamination of renal cancer tissues with non-tumor cells. Genomic DNA was extracted from tumors, lymphocytes and cell lines using standard phenol/chloroform extraction or salt extraction protocols. Three sets of primers were designed to amplify the entire exons 2 and 3 and the last one third 3'-region of exon 1, the genotyping method used was PCR-SSCP (polymerase chain reaction-single-strand conformation polymorphism). A metastatic clear cell renal cell carcinoma sample (sample 3087) was obtained from a 68 year old male who was known to smoke one pack of cigarettes per day and had intense alcohol drinking habits. In this patient's tumor (sample 3087), a c.551T>C variant (noted in the paper as nucleotide 764) was identified as a somatic mutation, found only in the tumor. The second mutation, a C>G transversion, c.183C>G (p.P61=) (noted in the paper at nucleotide 396) was present in the non-tumor DNA, a germline synonymous mutation. The patient had no metastasis after nephrectomy and patients survival was >4 months. ACMG codes: none."	7591282	PubMed		"Bailly et al., 1995, Int. J. Cancer"		1	accepted	6027	Somatic	2023-01-09 21:46:49 UTC	https://civicdb.org/links/evidence_items/6027	https://civicdb.org/links/molecular_profiles/1652	FALSE	VHL	7428	L184P (c.551T>C)		chr3	10149874	10149874	T	C	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.551T>C,NP_000542.1:p.Leu184Pro,NC_000003.11:g.10191558T>C,ENST00000256474.2:c.551T>C"	2023-01-27 17:11:54 UTC	CA16617792	419447	"C.551T>C,LEU184PRO,RS1064793878"	FALSE
FOXL2 C134W	198	Ovarian Sex-cord Stromal Tumor	80369				Diagnostic	Supports	A	Positive	"FOXL2 mutations were found in 94% of pathologically confirmed A-GCTs (95/101), in one of eight juvenile granulosa cell tumours (J-GCTs), and in two of 19 SLCTs."	26033501	PubMed		"Goulvent et al., 2016, Histopathology"		5	accepted	6034	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/6034	https://civicdb.org/links/molecular_profiles/198	FALSE	FOXL2	668	C134W		chr3	138946321	138946321	G	C	ENST00000330315.3	75		missense_variant	NC_000003.11:g.138665163G>C	2023-01-27 17:03:03 UTC	CA16602790			FALSE
ALK Fusion	495	Vagina Sarcoma	1901		Crizotinib		Predictive	Supports	C	Sensitivity/Response	"Patient was 34-year-old woman with vaginal sarcoma, which was excised with positive surgical margins. Fluorescence in situ hybridization testing of her tumor revealed  anaplastic lymphoma kinase gene rearrangements. A 3-cm mass recurred 1 month later. Treatment with crizotinib resulted in complete regression of all visible or palpable tumor within 3 weeks."	26942346	PubMed		"Forde et al., 2016, Obstet Gynecol"		2	accepted	6042	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/6042	https://civicdb.org/links/molecular_profiles/495	FALSE	ALK	238	Fusion	ALK Fusion	chr2	29192774	29223528			ENST00000389048.3	75		transcript_fusion		2023-01-09 21:52:07 UTC		N/A	REARRANGEMENT	FALSE
ALK Fusion	495	Epithelioid Inflammatory Myofibroblastic Sarcoma	80372		Crizotinib		Predictive	Supports	C	Sensitivity/Response	"This is a case report of a  22-year-old Japanese man with a pelvic mesenchymal neoplasm. Tumor analysis include IHC and RT-PCR led to diagnosis of epithelioid inflammatory myofibroblastic sarcoma with RANBP2-ALK fusion. Despite two surgical excision procedures, local recurrence rapidly occurred, and the tumor developed resistance to conventional chemotherapy with doxorubicin. Subsequent administration of crizotinib resulted in relief of severe pain and durable tumor shrinkage at least 10 months."	25028698	PubMed		"Kimbara et al., 2014, Jpn. J. Clin. Oncol."		2	accepted	6043	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/6043	https://civicdb.org/links/molecular_profiles/495	FALSE	ALK	238	Fusion	ALK Fusion	chr2	29192774	29223528			ENST00000389048.3	75		transcript_fusion		2023-01-09 21:52:07 UTC		N/A	REARRANGEMENT	FALSE
BRAF V600	17	Melanoma	1909		"Cobimetinib,Vemurafenib"	Combination	Predictive	Supports	A	Sensitivity/Response	"In this double-blind, randomized, placebo-controlled, multicentre study, adult patients with histologically confirmed BRAF(V600) mutation-positive unresectable stage IIIC or stage IV melanoma were randomly assigned (1:1) to receive cobimetinib or placebo, in combination with oral vemurafenib. Progression-free survival was the primary endpoint. Between Jan 8, 2013, and Jan 31, 2014, 495 eligible adult patients were enrolled and randomly assigned to the cobimetinib plus vemurafenib group (n=247) or placebo plus vemurafenib group (n=248). Investigator-assessed median progression-free survival was 12.3 months for cobimetinib and vemurafenib versus 7.2 months for placebo and vemurafenib (HR 0.58 [95% CI 0.46-0.72], p<0.0001). Median overall survival was 22.3 months for cobimetinib and vemurafenib versus 17.4 months for placebo and vemurafenib (HR 0.70, 95% CI 0.55-0.90; p=0.005). The safety profile for cobimetinib and vemurafenib was tolerable and manageable, and no new safety signals were observed with longer follow-up."	27480103	PubMed		"Ascierto et al., 2016, Lancet Oncol."	NCT01689519	5	accepted	6044	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/6044	https://civicdb.org/links/molecular_profiles/17	FALSE	BRAF	673	V600	Other BRAF V600's	chr7	140753336	140753337			ENST00000288602.6	75		protein_altering_variant		2023-01-09 21:52:04 UTC		"13,961,448,153,762,800,000,000,000,000,000"	VAL600	FALSE
BRAF V600E	12	Thyroid Gland Anaplastic Carcinoma	80522		Vemurafenib		Predictive	Supports	B	Sensitivity/Response	"In a phase 2 basket?study of vemurafenib in BRAF V600-positive non-melanoma cancers, seven patients with anaplastic thyroid cancer were enrolled. All 7 patients had V600E mutations. One complete response and one partial response was observed, for a response rate of 29%."	26287849	PubMed		"Hyman et al., 2015, N. Engl. J. Med."	NCT01524978	3	accepted	6045	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/6045	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
BRAF V600	17	Colorectal Cancer	9256		"Encorafenib,Cetuximab"	Combination	Predictive	Supports	B	Sensitivity/Response	"In a Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab, Twenty-six patients with refractory BRAF V600 mutant metastatic CRC (mCRC) were treated with a selective RAF kinase inhibitor (encorafenib) plus a monoclonal antibody targeting EGFR (cetuximab).  Confirmed overall response rates of 19% were observed and median progression-free survival was 3.7 months."	28363909	PubMed		"van Geel et al., 2017, Cancer Discov"		4	accepted	6046	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/6046	https://civicdb.org/links/molecular_profiles/17	FALSE	BRAF	673	V600	Other BRAF V600's	chr7	140753336	140753337			ENST00000288602.6	75		protein_altering_variant		2023-01-09 21:52:04 UTC		"13,961,448,153,762,800,000,000,000,000,000"	VAL600	FALSE
BRAF V600	17	Colorectal Cancer	9256		"Encorafenib,Cetuximab,Alpelisib"	Combination	Predictive	Supports	B	Sensitivity/Response	"In a phase Ib dose-escalation study of encorafenib, cetuximab and alpelisib, twenty-eight patients with refractory BRAF V600-mutant metastatic CRC (mCRC) were treated with a selective RAF kinase inhibitor (encorafenib) plus a monoclonal antibody targeting EGFR (cetuximab) with a PI3K inhibitor (alpelisib).  Confirmed overall response rates of 18% were observed and median progression-free survival was 4.2 months"	28363909	PubMed		"van Geel et al., 2017, Cancer Discov"		3	accepted	6047	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/6047	https://civicdb.org/links/molecular_profiles/17	FALSE	BRAF	673	V600	Other BRAF V600's	chr7	140753336	140753337			ENST00000288602.6	75		protein_altering_variant		2023-01-09 21:52:04 UTC		"13,961,448,153,762,800,000,000,000,000,000"	VAL600	FALSE
CTNNB1 S45F	1260	Desmoid Tumor	80366		Meloxicam		Predictive	Does Not Support	C	Sensitivity/Response	"Of the 33 patients with desmoid fibromatosis treated with meloxicam, a COX-2 selective inhibitor, one showed complete remission (CR), 7 partial remission (PR), 12 stable disease (SD), and 13 progressive disease (PD). The following 3 point mutations were identified in 21 of the 33 cases (64%): T41A (16 cases), S45F (4 cases) and S45P (one case). All four cases with S45F mutation exhibited strong nuclear expression of -catenin. S45F mutation was significantly associated with a poor response (all cases; PD) (p = 0.017)"	24788118	PubMed		"Hamada et al., 2014, PLoS ONE"		2	accepted	6049	Somatic	2023-01-09 21:46:44 UTC	https://civicdb.org/links/evidence_items/6049	https://civicdb.org/links/molecular_profiles/1260	FALSE	CTNNB1	1499	S45F		chr3	41224646	41224646	C	T	ENST00000349496.5	75		missense_variant	"NM_001904.3:c.134C>T,NP_001895.1:p.Ser45Phe,NC_000003.11:g.41266137C>T,ENST00000349496.5:c.134C>T"	2023-01-27 17:09:14 UTC	CA127283	17588	"SER45PHE,RS121913409"	FALSE
VHL E70* (c.208G>T)	1710	Von Hippel-Lindau Disease	14175	"Hemangioblastoma,Spinal hemangioblastoma,Cerebellar hemangioblastoma"			Predisposing	Supports	C	Uncertain Significance	"In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This nonsense variant was found in a VHL type 1 patient  with CNS hemangioblastomas (family ID 4479)."	7728151	PubMed		"Chen et al., 1995, Hum. Mutat."		4	accepted	6059	N/A	2023-01-09 21:46:51 UTC	https://civicdb.org/links/evidence_items/6059	https://civicdb.org/links/molecular_profiles/1710	FALSE	VHL	7428	E70* (c.208G>T)		chr3	10142055	10142055	G	T	ENST00000256474.2	75		stop_gained	"NM_000551.3:c.208G>T,NP_000542.1:p.Glu70Ter,NC_000003.11:g.10183739G>T,ENST00000256474.2:c.208G>T"	2023-01-27 17:12:36 UTC	CA16602179	428806	"C.208G>T,E70X,GLU70TER,RS5030802"	FALSE
VHL R82_V84del (c.244_252del)	2140	Von Hippel-Lindau Disease	14175	"Cerebellar hemangioblastoma,Hemangioblastoma"			Predisposing	Supports	C	Uncertain Significance	"In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This in-frame deletion was  found in a VHL type 1 family of 6 individuals (family ID 3177). Four of 6 individuals were identified with angiomas and 3 had CNS hemangioblastomas."	7728151	PubMed		"Chen et al., 1995, Hum. Mutat."		4	accepted	6060	N/A	2023-01-09 21:46:57 UTC	https://civicdb.org/links/evidence_items/6060	https://civicdb.org/links/molecular_profiles/2140	FALSE	VHL	7428	R82_V84del (c.244_252del)		chr3	10142091	10142099	CGCGTCGTG		ENST00000256474.2	75		inframe_deletion		2023-01-27 17:16:04 UTC	CA658820713	NONE FOUND	"C.244_252DEL,C.245_253DEL"	FALSE
VHL L188Q (c.563T>A)	1737	Von Hippel-Lindau Disease	14175	"Retinal capillary hemangioma,Renal cell carcinoma,Cerebellar hemangioblastoma"			Predisposing	Supports	C	Uncertain Significance	"In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This missense variant was found in 2 family members with VHL type 1 phenotype (family ID 3513). Both individuals were identified with cerebellar hemangioblastomas and renal cell carcinoma. One also had angiomas."	7728151	PubMed		"Chen et al., 1995, Hum. Mutat."		4	accepted	6061	Rare Germline	2023-01-09 21:46:51 UTC	https://civicdb.org/links/evidence_items/6061	https://civicdb.org/links/molecular_profiles/1737	FALSE	VHL	7428	L188Q (c.563T>A)		chr3	10149886	10149886	T	A	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.563T>A,NC_000003.11:g.10191570T>A,NM_000551.3:c.563T>A,NP_000542.1:p.Leu188Gln"	2023-01-27 17:12:55 UTC	CA351756398	625265	"C.563T>A,LEU188GLN"	FALSE
NTRK3 ETV6::NTRK3	779	Congenital Fibrosarcoma	8418		Larotrectinib		Predictive	Supports	A	Sensitivity/Response	"Four out of six patients with infantile fibrosarcoma and a ETV6-NTRK3 fusion had a partial response, the remaining two had a complete response with larotrectinib. Treatment was done within a multicentre, open-label, phase 1/2 study and enrolled infants, children, and adolescents aged 1 month to 21 years with locally advanced or metastatic solid tumours or CNS tumours that had relapsed, progressed, or were non-responsive to available therapies regardless of TRK fusion Status. In total, 24 patients (n=17 with tumours harbouring TRK fusions, n=7 without a documented TRK fusion) were enrolled. Among the fusion-positive patients, eight (47%) had infantile fibrosarcoma, seven (41%) had other soft tissue sarcomas, and two (12%) had papillary thyroid cancer. 14 (93%) of 15 patients with TRK fusion-positive cancers achieved an objective response; the remaining patient had tumour regression that did not meet the criteria for objective response. None of the seven patients with TRK fusion-negative cancers had an objective response."	29606586	PubMed		"Laetsch et al., 2018, Lancet Oncol."	NCT02637687	4	accepted	6099	Somatic	2023-01-09 21:46:38 UTC	https://civicdb.org/links/evidence_items/6099	https://civicdb.org/links/molecular_profiles/779	FALSE	NTRK3	4916	ETV6::NTRK3		chr12	11649854	11869969			ENST00000396373.4	75	ENST00000394480.2	transcript_fusion		2023-01-09 21:52:09 UTC		N/A	ETV6-NTRK3	FALSE
NTRK1 LMNA::NTRK1	1252	Sarcoma	1115		Larotrectinib		Predictive	Supports	C	Sensitivity/Response	"One Patient with soft tissue sarcoma and a NTRK1-LMNA fusion had a partial response with larotrectinib. Treatment was done within a multicentre, open-label, phase 1/2 study and enrolled infants, children, and adolescents aged 1 month to 21 years with locally advanced or metastatic solid tumours or CNS tumours that had relapsed, progressed, or were non-responsive to available therapies regardless of TRK fusion Status. In total, 24 patients (n=17 with tumours harbouring TRK fusions, n=7 without a documented TRK fusion) were enrolled. Among the fusion-positive patients, eight (47%) had infantile fibrosarcoma, seven (41%) had other soft tissue sarcomas, and two (12%) had papillary thyroid cancer. 14 (93%) of 15 patients with TRK fusion-positive cancers achieved an objective response; the remaining patient had tumour regression that did not meet the criteria for objective response. None of the seven patients with TRK fusion-negative cancers had an objective response."	29606586	PubMed		"Laetsch et al., 2018, Lancet Oncol."	NCT02637687	3	accepted	6100	Somatic	2023-01-09 21:46:44 UTC	https://civicdb.org/links/evidence_items/6100	https://civicdb.org/links/molecular_profiles/1252	FALSE	NTRK1	4914	LMNA::NTRK1	NTRK1 Fusions	chr1	156114707	156138757			ENST00000368300.4	75	ENST00000524377.1	transcript_fusion		2023-01-09 21:52:12 UTC		N/A	LMNA-NTRK1	FALSE
NTRK1 LMNA::NTRK1	1252	Sarcoma	1115		Larotrectinib		Predictive	Supports	C	Sensitivity/Response	"One Patient with soft tissue sarcoma and a NTRK1-LMNA fusion had a partial response with larotrectinib. Treatment was done within a multicentre, open-label, phase 1/2 study and enrolled infants, children, and adolescents aged 1 month to 21 years with locally advanced or metastatic solid tumours or CNS tumours that had relapsed, progressed, or were non-responsive to available therapies regardless of TRK fusion Status. In total, 24 patients (n=17 with tumours harbouring TRK fusions, n=7 without a documented TRK fusion) were enrolled. Among the fusion-positive patients, eight (47%) had infantile fibrosarcoma, seven (41%) had other soft tissue sarcomas, and two (12%) had papillary thyroid cancer. 14 (93%) of 15 patients with TRK fusion-positive cancers achieved an objective response; the remaining patient had tumour regression that did not meet the criteria for objective response. None of the seven patients with TRK fusion-negative cancers had an objective response."	29606586	PubMed		"Laetsch et al., 2018, Lancet Oncol."	NCT02637687	3	accepted	6100	Somatic	2023-01-09 21:46:44 UTC	https://civicdb.org/links/evidence_items/6100	https://civicdb.org/links/molecular_profiles/1252	FALSE	NTRK1	4914	LMNA::NTRK1	NTRK1 Fusions	chr1	156874571	156881642			ENST00000368300.4	75	ENST00000524377.1	transcript_fusion		2023-01-09 21:52:12 UTC		N/A	LMNA-NTRK1	FALSE
VHL G144E (c.431G>A)	2166	Adrenal Gland Pheochromocytoma	50892	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	"Screening of 68 patients, who had been operated on for apparently sporadic pheochromocytomas, for germline mutations in the VHL gene. This missense mutation was found in a 51 year-old female with unilateral, benign, adrenal pheochromocytoma (patient no. 48)."	9663592	PubMed		"van der Harst et al., 1998, Int. J. Cancer"		2	accepted	6106	Rare Germline	2023-01-09 21:46:57 UTC	https://civicdb.org/links/evidence_items/6106	https://civicdb.org/links/molecular_profiles/2166	FALSE	VHL	7428	G144E (c.431G>A)		chr3	10146604	10146604	G	A	ENST00000256474.2	75				2023-01-27 17:16:09 UTC	CA351754206			FALSE
VHL Splice Region (c.463+8C>T)	2168	Adrenal Gland Pheochromocytoma	50892	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	"Screening of 68 patients, who had been operated on for apparently sporadic pheochromocytomas, for germline mutations in the VHL gene. This splice variant causes a premature stop codon at amino acid 66 and was found in a 33 year-old male with unilateral, benign, adrenal pheochromocytoma (patient no. 54)."	9663592	PubMed		"van der Harst et al., 1998, Int. J. Cancer"		2	accepted	6108	Rare Germline	2023-01-09 21:46:57 UTC	https://civicdb.org/links/evidence_items/6108	https://civicdb.org/links/molecular_profiles/2168	FALSE	VHL	7428	Splice Region (c.463+8C>T)		chr3	10146644	10146644	C	T	ENST00000256474.2	75		splicing_variant	"NC_000003.11:g.10188328C>T,ENST00000256474.2:c.463+8C>T,NM_000551.3:c.463+8C>T"	2023-01-27 17:16:11 UTC	CA020379	127830		FALSE
VHL G104A (c.311G>C)	1919	Von Hippel-Lindau Disease	14175	Retinal capillary hemangioma			Predisposing	N/A	C	N/A	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in the germline of a female patient (patient no. S6150) with apparently sporadic retinal hemangioblastoma diagnosed at 42Y old. No unaffected family members were tested.	9829912	PubMed		"Olschwang et al., 1998, Hum. Mutat."		2	accepted	6109	Rare Germline	2023-01-09 21:46:54 UTC	https://civicdb.org/links/evidence_items/6109	https://civicdb.org/links/molecular_profiles/1919	FALSE	VHL	7428	G104A (c.311G>C)		chr3	10142158	10142158	G	C	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.311G>C,NP_000542.1:p.Gly104Ala,NC_000003.11:g.10183842G>C,ENST00000256474.2:c.311G>C"	2023-01-27 17:14:36 UTC	CA16611067	411966	"C.311G>C,GLY104ALA,RS869025630"	FALSE
VHL G104= (c.312C>G)	2169	Von Hippel-Lindau Disease	14175				Predisposing	N/A	C	N/A	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This silent variant was found in a VHL patient (patient no. V95). No unaffected family members were tested.	9829912	PubMed		"Olschwang et al., 1998, Hum. Mutat."		1	accepted	6110	Rare Germline	2023-01-09 21:46:57 UTC	https://civicdb.org/links/evidence_items/6110	https://civicdb.org/links/molecular_profiles/2169	FALSE	VHL	7428	G104= (c.312C>G)		chr3	10142159	10142159	C	G	ENST00000256474.2	75		synonymous_variant	"NC_000003.11:g.10183843C>G,NC_000003.12:g.10142159C>G,NP_000542.1:p.Gly104=,NP_001341652.1:p.Gly104="	2023-01-27 17:16:11 UTC	CA432420538	NONE FOUND	G104G (C.312C>G)	FALSE
VHL F91L (c.273C>G)	2170	Von Hippel-Lindau Disease	14175	Cerebellar hemangioblastoma			Predisposing	N/A	C	N/A	Screening of 92 unrelated patients with VHL disease revealed 61 DNA variants. No variants were found in 96 control cases. This missense mutation was found in the germline of a male VHL patient (patient no. S3940) with apparently sporadic cerebellar hemangioblastoma diagnosed at 56Y old. No unaffected family members were tested.	9829912	PubMed		"Olschwang et al., 1998, Hum. Mutat."		2	accepted	6111	Rare Germline	2023-01-09 21:46:57 UTC	https://civicdb.org/links/evidence_items/6111	https://civicdb.org/links/molecular_profiles/2170	FALSE	VHL	7428	F91L (c.273C>G)		chr3	10142120	10142120	C	G	ENST00000256474.2	75		missense_variant	"NC_000003.11:g.10183804C>G,NC_000003.12:g.10142120C>G,NP_000542.1:p.Phe91Leu"	2023-01-27 17:16:12 UTC	CA351750747	NONE FOUND	"C.273C>G,PHE91LEU"	FALSE
VHL Y156D (c.466T>G)	1843	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Predisposition	"A study of 103 patients with VHL retinal manifestations and 108 patients without VHL retinal manifestations extracted from the French VHL database revealed that the number of hemangioblastomas appeared higher in patients who had a substitution when compared with patients with a truncated protein. Detected by PCR and SSCP, this mutation (c.466T>G) was found in a VHL patient without retinal hemangioblastomas. Other manifestations are not clearly stated. No family information was provided."	12202531	PubMed		"Dollfus et al., 2002, Invest. Ophthalmol. Vis. Sci."		4	accepted	6112	Rare Germline	2023-02-03 20:10:07 UTC	https://civicdb.org/links/evidence_items/6112	https://civicdb.org/links/molecular_profiles/1843	FALSE	VHL	7428	Y156D (c.466T>G)		chr3	10149789	10149789	T	G	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.466T>G,NC_000003.11:g.10191473T>G,NM_000551.3:c.466T>G,NP_000542.1:p.Tyr156Asp"	2023-01-27 17:13:52 UTC	CA351756043	NONE FOUND	"C.466T>G,TYR156ASP"	FALSE
VHL L128R (c.383T>G)	1762	Von Hippel-Lindau Disease	14175	"Pancreatic cysts,Cerebellar hemangioblastoma,Retinal capillary hemangioma,Renal cyst"			Predisposing	Supports	C	Predisposition	"Thirty-five unrelated patients suspected of having von Hippel-Lindau disease were analyzed and 32 VHL gene variants were found in 35 patients. An association of clear cell renal carcinoma development with a relatively high loss of structural stability in VHL protein missense mutations was discovered. This missense variant was found in a 22 year old patient with retinal and cerebellar hemangioblastomas, renal cysts, and pancreatic cysts (patient no. F41)."	14722919	PubMed		"Ruiz-Llorente et al., 2004, Hum. Mutat."		3	accepted	6114	Rare Germline	2023-02-17 03:34:08 UTC	https://civicdb.org/links/evidence_items/6114	https://civicdb.org/links/molecular_profiles/1762	FALSE	VHL	7428	L128R (c.383T>G)		chr3	10146556	10146556	T	G	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.383T>G,NC_000003.11:g.10188240T>G,NM_000551.3:c.383T>G,NP_000542.1:p.Leu128Arg"	2023-01-27 17:13:06 UTC	CA351753891	NONE FOUND	"C.383T>G,LEU128ARG"	FALSE
VHL V130L (c.388G>C)	1846	Von Hippel-Lindau Disease	14175	"Cerebellar hemangioblastoma,Pancreatic cysts"			Predisposing	Supports	C	Predisposition	Thirty-five unrelated patients suspected of having von Hippel-Lindau disease were analyzed and 32 VHL gene variants were found in 35 patients. An association of clear cell renal carcinoma development with a relatively high loss of structural stability in VHL protein missense mutations was discovered. This missense mutation was found in a 26 year old patient with cerebellar hemangioblastomas and a pancreatic cyst (patient no. F2).	14722919	PubMed		"Ruiz-Llorente et al., 2004, Hum. Mutat."		3	accepted	6115	Rare Germline	2023-02-17 03:43:56 UTC	https://civicdb.org/links/evidence_items/6115	https://civicdb.org/links/molecular_profiles/1846	FALSE	VHL	7428	V130L (c.388G>C)		chr3	10146561	10146561	G	C	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.388G>C,NP_000542.1:p.Val130Leu,NC_000003.11:g.10188245G>C,ENST00000256474.2:c.388G>C"	2023-01-27 17:13:54 UTC	CA020325	2229	"C.388G>C,VAL130LEU,RS104893830"	FALSE
VHL R161* (c.481C>T)	1680	Von Hippel-Lindau Disease	14175	"Pancreatic cysts,Cerebellar hemangioblastoma,Retinal capillary hemangioma"			Predisposing	Supports	C	Predisposition	"Thirty-five unrelated patients suspected of having von Hippel-Lindau disease were analyzed and 32 VHL gene variants were found in 35 patients. An association of clear cell renal carcinoma development with a relatively high loss of structural stability in VHL protein missense mutations was discovered. This nonsense variant was found in a 20 year old patient with retinal and cerebellar hemangioblastomas and pancreatic cysts (patient no. F9). ACMG codes: ""flag for PP4"" since patients phenotype is specific for gene."	14722919	PubMed		"Ruiz-Llorente et al., 2004, Hum. Mutat."		3	accepted	6116	Rare Germline	2023-02-17 03:44:31 UTC	https://civicdb.org/links/evidence_items/6116	https://civicdb.org/links/molecular_profiles/1680	FALSE	VHL	7428	R161* (c.481C>T)		chr3	10149804	10149804	C	T	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.481C>T,NP_000542.1:p.Arg161Ter,NC_000003.11:g.10191488C>T,ENST00000256474.2:c.481C>T"	2023-01-27 17:12:16 UTC	CA020408	2217	"C.481C>T,R161X,ARG161TER,RS5030818"	FALSE
VHL L184P (c.551T>C)	1652	Von Hippel-Lindau Disease	14175	"Cerebellar hemangioblastoma,Spinal hemangioblastoma,Retinal capillary hemangioma,Renal cyst,Pancreatic cysts"			Predisposing	Supports	C	Predisposition	"Thirty-five unrelated patients suspected of having von Hippel-Lindau disease had genomic DNA from peripheral blood leukocytes analyzed using sequence analysis of the coding region for VHL / Southern blot analyses. 32 VHL gene variants were found in 35 patients. An association of clear cell renal carcinoma development with a relatively high loss of structural stability in VHL protein missense mutations was discovered, although this only reached significance when combining data from other studies (p=0.101 for present study; p=0.0086 for present study + other study data). This missense variant was found in a patient with spinal and cerebellar hemangioblastomas, retinal hemangioblastomas, pancreatic cysts, renal cysts, and cysts of the broad ligament (patient no. F43). The patient was 27 years old. ACMG PP4 as patient's phenotypes are highly specific for VHL disease."	14722919	PubMed		"Ruiz-Llorente et al., 2004, Hum. Mutat."		3	accepted	6119	Rare Germline	2023-02-17 03:55:51 UTC	https://civicdb.org/links/evidence_items/6119	https://civicdb.org/links/molecular_profiles/1652	FALSE	VHL	7428	L184P (c.551T>C)		chr3	10149874	10149874	T	C	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.551T>C,NP_000542.1:p.Leu184Pro,NC_000003.11:g.10191558T>C,ENST00000256474.2:c.551T>C"	2023-01-27 17:11:54 UTC	CA16617792	419447	"C.551T>C,LEU184PRO,RS1064793878"	FALSE
VHL F76del (c.224_226delTCT)	1964	Von Hippel-Lindau Disease	14175	"Cerebellar hemangioblastoma,Pheochromocytoma,Renal cell carcinoma,Epididymal cyst"			Predisposing	Supports	C	Uncertain Significance	"Molecular analysis of VHL gene in 146 probands, 103 with and 43 without a positive family history, resulted in the detection of 43 germline VHL mutations. Majority of mutations were found in patients with classic or multi-organ manifestations of VHL disease, but mutations were also found in patients with limited or single-organ manifestations of VHL disease. Follow-up of families with germline mutations and limited VHL manifestations was recommended. This in-frame deletion variant was detected in a VHL type 2 patient with cerebellar hemangioblastoma, pheochromocytoma, renal cell carcinoma, and epididymal cysts (family no. 24)."	17661816	PubMed		"Hes et al., 2007, Clin. Genet."		3	accepted	6121	Rare Germline	2023-01-09 21:46:55 UTC	https://civicdb.org/links/evidence_items/6121	https://civicdb.org/links/molecular_profiles/1964	TRUE	VHL	7428	F76del (c.224_226delTCT)		chr3	10142071	10142073	TCT		ENST00000256474.2	75		inframe_deletion	"NP_000542.1:p.Phe76del,ENST00000256474.2:c.224_226delTCT,NC_000003.11:g.10183758_10183760del,NC_000003.12:g.10142074_10142076del,NM_000551.3:c.227_229del,ENSP00000256474.2:p.Phe76del"	2023-01-27 17:15:01 UTC	CA357012	223166	"PHE76DEL,C.224_226DELTCT,C.226_228DELTTC,C.227_229DELTCT,DELPHE76"	FALSE
VHL W88fs (c.261dup)	2172	Von Hippel-Lindau Disease	14175	"Renal cell carcinoma,Retinal capillary hemangioma,Cerebellar hemangioblastoma"			Predisposing	Supports	C	Uncertain Significance	"Molecular analysis of VHL gene in 146 probands, 103 with and 43 without a positive family history, resulted in the detection of 43 germline VHL mutations. Majority of mutations were found in patients with classic or multi-organ manifestations of VHL disease, but mutations were also found in patients with limited or single-organ manifestations of VHL disease. Follow-up of families with germline mutations and limited VHL manifestations was recommended. This variant was detected in a VHL type 1 patient with cerebellar hemangioblastoma, retinal hemangioblastomas, and renal cell carcinoma (family no. 28)."	17661816	PubMed		"Hes et al., 2007, Clin. Genet."		3	accepted	6122	Rare Germline	2023-01-09 21:46:57 UTC	https://civicdb.org/links/evidence_items/6122	https://civicdb.org/links/molecular_profiles/2172	FALSE	VHL	7428	W88fs (c.261dup)		chr3	10142107	10142108		A	ENST00000256474.3	75		"plus_1_frameshift_variant,frameshift_truncation"	"NC_000003.11:g.10183792dup,NM_000551.3:c.261dup,NP_000542.1:p.Trp88MetfsTer44,ENST00000256474.3:c.261dup,NC_000003.12:g.10142108dup"	2023-01-27 17:16:14 UTC	CA2573050932	NONE FOUND	"C.261DUP,C.261INSA,TRP88METFSTER44,W88MFS*44"	FALSE
BRAF V600E	12	Colorectal Cancer	9256		"Dabrafenib,Trametinib,Panitumumab"	Combination	Predictive	Supports	B	Sensitivity/Response	"In this trial, 142 patients with metastatic, BRAF V600E mutant colorectal cancer were randomized to receive either BRAF inhibitor dabrafenib (D) + EGFR inhibitor panitumumab (P); or a triple therapy of D + P and MEK inhibition with trametinib (T) or T + P. Confirmed response rates for D+P (n=20), D+T+P (n=91), and T+P (n=31) were 10%, 21%, and 0%, respectively."	29431699	PubMed		"Corcoran et al., 2018, Cancer Discov"		4	accepted	6123	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/6123	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
BRAF V600E	12	Colorectal Adenocarcinoma	50861		"Trametinib,Panitumumab"	Combination	Predictive	Does Not Support	B	Sensitivity/Response	"In this trial, 142 patients with metastatic, BRAF V600E mutant colorectal cancer were randomized to receive either BRAF inhibitor dabrafenib (D) + EGFR inhibitor panitumumab (P); or a triple therapy of D + P and MEK inhibition with trametinib (T) or T + P. Confirmed response rates for D+P (n=20), D+T+P (n=91), and T+P (n=31) were 10%, 21%, and 0%, respectively."	29431699	PubMed		"Corcoran et al., 2018, Cancer Discov"		3	accepted	6124	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/6124	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
VHL S65L (c.194C>T)	1664	Clear Cell Renal Cell Carcinoma	4467	"Clear cell renal cell carcinoma,Sporadic"			Oncogenic	Supports	C	Oncogenicity	This study analyzed tumor and non-tumor kidney tissue from 195 unrelated patients with sporadic clear cell renal cell carcinoma (CCRCC) for a relationship between VHL variants in sporadic CCRCC and 'genotypes for genes encoding several carcinogen-metabolizing enzymes.' This missense variant was found in a 68 year-old male (tumour 311).	11505222	PubMed		"Gallou et al., 2001, Pharmacogenetics"		1	accepted	6131	Somatic	2023-02-03 16:44:36 UTC	https://civicdb.org/links/evidence_items/6131	https://civicdb.org/links/molecular_profiles/1664	FALSE	VHL	7428	S65L (c.194C>T)		chr3	10142041	10142041	C	T	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.194C>T,NP_000542.1:p.Ser65Leu,NC_000003.11:g.10183725C>T,ENST00000256474.2:c.194C>T"	2023-01-27 17:12:03 UTC	CA020104	182975	"C.194C>T,SER65LEU,RS5030826"	FALSE
VHL L184P (c.551T>C)	1652	Clear Cell Renal Cell Carcinoma	4467	"Clear cell renal cell carcinoma,Sporadic"			Diagnostic	Supports	C	Positive	"195 patients with sporadic clear cell renal cell carcinoma (sporadic CCRCC) were investigated for variants in the VHL gene, in order to determine the possible relationship between VHL mutations in CCRCC patients and polymorphisms in genes encoding enzymes involved in carcinogen metabolism. For each patient, fragments of tumor and non-tumoral kidney tissue were sampled, and DNA was extracted for analysis. PCR, SSCP (single strand conformation polymorphism,) and direct sequencing were used to investigate VHL variants. Tumor number 347 (a cytological grade 1 stage I tumor) was taken from a 60 year old female, and found to have the c.551T>C (p.L184P) somatic mutation in exon 3 of the VHL gene. No other phenotypic information was available for any of the patients included in this study. Relevant ACMG evidence codes: none."	11505222	PubMed		"Gallou et al., 2001, Pharmacogenetics"		2	accepted	6167	Somatic	2023-01-09 21:46:49 UTC	https://civicdb.org/links/evidence_items/6167	https://civicdb.org/links/molecular_profiles/1652	FALSE	VHL	7428	L184P (c.551T>C)		chr3	10149874	10149874	T	C	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.551T>C,NP_000542.1:p.Leu184Pro,NC_000003.11:g.10191558T>C,ENST00000256474.2:c.551T>C"	2023-01-27 17:11:54 UTC	CA16617792	419447	"C.551T>C,LEU184PRO,RS1064793878"	FALSE
ERBB2 T798I	2204	Breast Cancer	1612		Osimertinib		Predictive	Does Not Support	D	Sensitivity/Response	"Efficacy of osimertinib and its metabolite, AZ5104, at reducing phosphorylation of key proteins was evaluated by western blot. Osimertinib failed to induce substantial reductions in phosphorylated ERBB2 in NR6 mouse fibroblast cells transduced to co-express ERBB2 L869R and T798I or ERBB2 wt. AZ5104 blocked phosphorylation to a greater extent in the mutant and wildtype cells. MCF10A cells transduced with ERBB2 wt, ERBB2 T798I alone or ERBB2 L869R and T798I co-expressed did not show substantial reductions in phosphorylated ERBB2, AKT, ERK or S6. AZ5104 induced greater reductions. Authors note that AZ5104 is not being developed independently of osimertinib and only 10% of osimertinib is metabolized into AZ5104 in humans. Authors concluded that ERBB2 T798I is not sensitive to osimertinib."	28274957	PubMed		"Hanker et al., 2017, Cancer Discov"	NCT01953926	3	accepted	6174	Somatic	2023-01-09 21:46:58 UTC	https://civicdb.org/links/evidence_items/6174	https://civicdb.org/links/molecular_profiles/2204	FALSE	ERBB2	2064	T798I		chr17	39724811	39724811	C	T	ENST00000269571.5	75		missense_variant	"ENST00000269571.5:c.2393C>T,NC_000017.10:g.37881064C>T,NM_001289937.1:c.2393C>T,NP_001276866.1:p.Thr798Ile"	2023-01-27 17:16:23 UTC	CA399303242	NONE FOUND	THR798ILE	FALSE
BRAF V600E	12	Melanoma	1909		"Dabrafenib,Trametinib"	Combination	Predictive	Supports	B	Sensitivity/Response	"Adjuvant dual treatment with BRAF inhibitor dabrafenib and MEK inhibitor trametinib was administered to patients with stage III resected melenoma with V600E or V600K mutation in this stage III trial (COMBO-AD, NCT01682083). 792 (91%) patients had V600E, and were administered dabrafenib and trametinib or placebo for 12 months. In subsequent analysis, relapse or death occurred in 150/397 patients (38%) in the treatment group and 229/395 patients (58%) in the placebo group for a 95% CI Hazard Ratio of 0.48 (0.39-0.58)."	28891408	PubMed		"Long et al., 2017, N. Engl. J. Med."	NCT01682083	5	accepted	6178	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/6178	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
BRAF V600K	559	Melanoma	1909		"Dabrafenib,Trametinib"	Combination	Predictive	Supports	B	Sensitivity/Response	"Adjuvant dual treatment with BRAF inhibitor dabrafenib and MEK inhibitor trametinib was administered to patients with stage III resected melenoma with V600E or V600K mutation in this stage III trial (COMBO-AD, NCT01682083). 78 (9%) patients had V600K, and were administered dabrafenib and trametinib or placebo for 12 months. In subsequent analysis, relapse or death occurred in 16/41 patients (39%) in the treatment group and 19/37 patients (51%) in the placebo group for a 95% CI Hazard Ratio of 0.54 (0.27-1.06)."	28891408	PubMed		"Long et al., 2017, N. Engl. J. Med."	NCT01682083	4	accepted	6179	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/6179	https://civicdb.org/links/molecular_profiles/559	FALSE	BRAF	673	V600K	Other BRAF V600's	chr7	140753336	140753337	AC	TT	ENST00000288602.6	75		missense_variant	"ENST00000288602.6:c.1798_1799delinsAA,NC_000007.13:g.140453136_140453137delinsTT,NM_004333.4:c.1798_1799delGTinsAA,NP_004324.2:p.Val600Lys"	2023-01-27 17:04:21 UTC	CA16602420	375941	"VAL600LYS,RS121913227"	FALSE
BRAF V600	17	Melanoma	1909		"Trametinib,Dabrafenib"	Combination	Predictive	Supports	B	Sensitivity/Response	"Combination Dabrafenib and Trametinib treatment was assessed for adjuvant treatment of stage III resected BRAF V600 mutant melanoma in the COMBI-AD trial NCT01682083. Patients were treated with combination therapy or placebo for 12 months. The estimated 3-year rate of relapse-free survival was 58% in the treated group and 39% in the placebo group  with hazard ratio for relapse or death of 0.47 (95% CI, 0.39 to 0.58; P<0.001). 3-year overall survival rate for treated group was 86%, and 77% in the placebo group (hazard ratio for death, 0.57; 95% CI, 0.42-0.79; P=0.0006). The level of improvement observed did not cross the prespecified interim analysis boundary of P=0.000019. Distant metastasis-free survival and freedom from relapse was higher in the combination-treated group."	28891408	PubMed		"Long et al., 2017, N. Engl. J. Med."	NCT01682083	5	accepted	6180	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/6180	https://civicdb.org/links/molecular_profiles/17	FALSE	BRAF	673	V600	Other BRAF V600's	chr7	140753336	140753337			ENST00000288602.6	75		protein_altering_variant		2023-01-09 21:52:04 UTC		"13,961,448,153,762,800,000,000,000,000,000"	VAL600	FALSE
EGFR G719A	973	Lung Non-small Cell Carcinoma	3908		"Erlotinib,Gefitinib"	Substitutes	Predictive	Does Not Support	C	Sensitivity/Response	"In a large retrospective study, EGFR exons 18-21 were assessed using direct sequencing in 753 French NSCLC cases. Clinical details and patient outcomes were taken, including whether the first generation TKIs erlotinib or gefitinib were administered. One patient was found to have a G719A mutation, was administered a TKI, and an NSCLC progression was observed."	23749122	PubMed		"Locatelli-Sanchez et al., 2013, Lung"		2	accepted	6181	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/6181	https://civicdb.org/links/molecular_profiles/973	FALSE	EGFR	1956	G719A		chr7	55174015	55174015	G	C	ENST00000275493.2	75		missense_variant	"NM_005228.4:c.2156G>C,NP_005219.2:p.Gly719Ala,NC_000007.13:g.55241708G>C,ENST00000275493.2:c.2156G>C"	2023-01-27 17:07:33 UTC	CA135775	45225	"RS121913428,GLY719ALA"	FALSE
EGFR R705K	2206	Lung Non-small Cell Carcinoma	3908		"Erlotinib,Gefitinib"	Substitutes	Predictive	Does Not Support	C	Sensitivity/Response	"In a large retrospective study, EGFR exons 18-21 were assessed using direct sequencing in 753 French NSCLC cases. Clinical details and patient outcomes were taken, including whether the first generation TKIs erlotinib or gefitinib were administered. One patient was found to have a R705K mutation, was administered a TKI, and an NSCLC progression was observed."	23749122	PubMed		"Locatelli-Sanchez et al., 2013, Lung"		2	accepted	6182	Somatic	2023-01-09 21:46:58 UTC	https://civicdb.org/links/evidence_items/6182	https://civicdb.org/links/molecular_profiles/2206	FALSE	EGFR	1956	R705K		chr7	55173973	55173973	G	A	ENST00000275493.2	75		missense_variant	"ENST00000275493.2:c.2114G>A,NC_000007.13:g.55241666G>A,NM_005228.3:c.2114G>A,NP_005219.2:p.Arg705Lys"	2023-01-27 17:16:25 UTC	CA367583561	NONE FOUND	ARG705LYS	FALSE
EGFR L858R	33	Lung Adenocarcinoma	3910		Gefitinib		Predictive	Supports	B	Sensitivity/Response	"In a Japanese Phase III clinical trial, noninferiority of Gefitinib as compared to Erlotinib was assessed in 561 postoperative recurrent or stage IIIb/VI patients who had undergone prior chemotherapy treatment but no tyrosine kinase inhibitor therapy. In a subset of patients with sole EGFR L858R, there was an insignificant difference between the objective response and disease control rates for patients treated with erlotinib (N=67) and gefitinib (N=78). Progression free survival was also not significantly different and did not meet the noninferiority endpoint with Gefitinib and Erlotinib arms at 8.1 and 8.5 months, respectively (HR, 0.938; 95% CI, 0.675 to 1.304; P = .704)."	27022112	PubMed		"Urata et al., 2016, J. Clin. Oncol."		2	accepted	6183	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/6183	https://civicdb.org/links/molecular_profiles/33	FALSE	EGFR	1956	L858R		chr7	55191822	55191822	T	G	ENST00000275493.2	75		missense_variant	"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg"	2023-01-27 17:02:04 UTC	CA126713	"16,609,376,282,376,200"	"LEU858ARG,RS121434568"	FALSE
EGFR Exon 19 Deletion	133	Lung Adenocarcinoma	3910		Gefitinib		Predictive	Supports	B	Sensitivity/Response	"A Japanese Phase III clinical study assessed the noninferiority of gefitinib in comparison to erlotinib in 561 patients with postoperative or recurrent stage IIIB/IV lung adenocarcinoma. Patients were pretreated with at least one chemotherapy regimen, but no tyrosine kinase inhibitors. In the subgroup of 156 patients with exon 19 deletions as their sole EGFR mutation, 83 and 78 were treated with erlotinib and gefitinib, respectively. Objective response (defined as complete + partial response) was approximately 65 percent for both erlotinib gefitinib and non significantly different  (p= .965). Disease control rate (defined as complete response + partial response + stable disease) was 91.6 and 83.3 percent for erlotinib and gefitinib, respectively (p=.113). The study was unable to demonstrate statistical noninferiority via the planned end point; however, the lack of statistically significant differences between erlotinib and gefitinib responses, and the milder adverse effects experienced by gefitinib treated patients, led the authors to conclude that gefitinib is a feasible alternative to erlotinib in treating patients with ex19del EGFR positive, advanced lung adenocarcinoma."	27022112	PubMed		"Urata et al., 2016, J. Clin. Oncol."		3	accepted	6184	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/6184	https://civicdb.org/links/molecular_profiles/133	FALSE	EGFR	1956	Exon 19 Deletion		chr7	55174722	55174820			ENST00000275493.2	75		inframe_deletion	ENST00000275493.2:c.2185_2283del	2023-01-09 21:52:05 UTC		N/A		FALSE
EGFR Rare Mutation	2207	Lung Adenocarcinoma	3910		Gefitinib		Predictive	Supports	C	Sensitivity/Response	"A Japanese Phase III clinical study assessed the noninferiority of gefitinib as compared to erlotinib in 561 advanced stage (IIIB and IV) postoperative lung adenocarcinoma patients. All patients had prior chemotherapy but no treatment with TKIs. 19 patients had unspecified uncommon EGFR mutations, including single mutations other than ex19del and L858R and double mutations. Of those 19 patients, 7 were treated with erlotinib and 12 were treated with gefitinib. Objective response (42.9% for erlotinib and 25% for gefitinib) and disease control rate (71.4% with eflotinib and 66.7% with gefitinib) between were not significantly different between the treatments. The study failed to satisfy the primary endpoint of demonstrating statistical noninferiority in PFS of gefitinib."	27022112	PubMed		"Urata et al., 2016, J. Clin. Oncol."		2	accepted	6186	Somatic	2023-01-09 21:46:58 UTC	https://civicdb.org/links/evidence_items/6186	https://civicdb.org/links/molecular_profiles/2207	FALSE	EGFR	1956	Rare Mutation		chr7	55019101	55211628			ENST00000275493.2	75				2023-01-09 21:52:18 UTC				FALSE
PIK3CA Mutation	307	Breast Cancer	1612				Prognostic	Supports	B	Better Outcome	"This was a Swedish study of 270 breast tumors removed from patients with unilateral operable breast cancer, and either lymph node metastases or a tumor diameter >30mm. PIK3CA missense mutations were found in 66/270 (24%) tumors. Of these, 36 tumors (55%) harbored mutations in exon 20?33 H1047R, 1 Y1021C, 1 G1049R, and 1 H1047P. The other 30 were missense mutations in exon 9?11 E542K, 18 E545K, 1 Q546P. The study found that the risk of relapse with a local recurrence was significantly lower among patients with a PIK3CA mutation in comparison with those who carried wild-type PIK3CA (p= 0.023). When adjusting for other factors, including ER status, node status, tumor size, and treatment (tamoxifen vs no tamoxifen or radiotherapy vs chemotherapy), mutations in the PIK3CA gene were associated with approximately half the risk for local recurrence in comparison with wtPIK3CA (p = .07)."	17575221	PubMed		"Prez-Tenorio et al., 2007, Clin. Cancer Res."		3	accepted	6188	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/6188	https://civicdb.org/links/molecular_profiles/307	FALSE	PIK3CA	5290	Mutation		chr3	179148523	179240093			ENST00000263967.3	75		"transcript_variant,gain_of_function_variant"		2023-01-09 21:52:06 UTC		N/A		FALSE
PIK3CA Mutation	307	Estrogen-receptor Positive Breast Cancer	60075		Tamoxifen		Predictive	Does Not Support	B	Sensitivity/Response	"This was a Swedish study of 270 breast tumors removed from patients with unilateral operable breast cancer, and either lymph node metastases or a tumor diameter >30mm. PIK3CA missense mutations were found in 65/270 (24%) tumors. Of these, 36 (55%) were in exon 20?33 H1047R, 1 Y10121C, 1 G1049R, and 1 H1047P. The other 30 were missense mutations in exon 9?11 E542K, 18 E545K, 1 Q546P. Within the group of 188 patients with ER+ tumors, PIK3CA mutation status did not predict response to tamoxifen."	17575221	PubMed		"Prez-Tenorio et al., 2007, Clin. Cancer Res."		3	accepted	6189	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/6189	https://civicdb.org/links/molecular_profiles/307	FALSE	PIK3CA	5290	Mutation		chr3	179148523	179240093			ENST00000263967.3	75		"transcript_variant,gain_of_function_variant"		2023-01-09 21:52:06 UTC		N/A		FALSE
ABL1 BCR::ABL T315A	2208	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Supports	D	Resistance	"In an in vitro study, stochastic mutations in the ABL1 region of a stably expressed p210 BCR-ABL fusion were generated in Ba/F3 cell lines from five independently derived, mutagenized libraries. Dasatinib resistant subclones were identified using ?0 nM dasatinib in liquid culture. 201 individual clones were identified representing 10 different mutations at 6 different residues. 60 of these clones had T315A mutations. To validate resistance to dasatinib, Ba/F3 cell lines stably expressing a T315A mutation in the ABL1 region of the BCR-ABL fusion were generated. T315A was associated with higher dasatinib IC50 of 125 nM vs 1.34 nM in wildtype as determined by dose response curves."	15705718	PubMed		"Burgess et al., 2005, Proc. Natl. Acad. Sci. U.S.A."		3	accepted	6190	Somatic	2023-01-09 21:46:58 UTC	https://civicdb.org/links/evidence_items/6190	https://civicdb.org/links/molecular_profiles/2208	FALSE	ABL1	25	BCR::ABL T315A		chr9	130872895	130872895	A	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.943A>G,NP_005148.2:p.Thr315Ala,NC_000009.11:g.133748282A>G,ENST00000318560.5:c.943A>G"	2023-01-27 17:16:25 UTC	CA16602576	376118	"THR315ALA,T334A,RS1057519772,BCR-ABL T315A"	FALSE
PIK3CA Mutation	307	Breast Cancer	1612		"Paclitaxel,Fluorouracil,Cyclophosphamide,Epirubicin,Doxorubicin"	Combination	Predictive	Does Not Support	B	Resistance	"This study of 140 patients with stage II-III breast cancer assessed the response of patients with PIK3CA mutations to 6 months of preoperative chemotherapy. 23/170 patients had PIK3CA mutations. Of those patients, 12 received six courses of chemotherapy composed of 5-fluorouracil, doxorubicin (or epirubicin), and cyclophosphamide. This treatment group represented patients with the following mutations (number of patients in parentheses): E545K (7), E542K (1), and H1047R (4). The other 11 patients received 12 weekly courses of paclitaxel followed by four courses of the chemotherapy described above. This treatment group represented patients with the following mutations: E545K (1), Q546R (1), E542K (1), E542V (1), H1047R (5), G1049R (1), H1047T (1). The study did not find evidence that PIK3CA mutations are associated with resistance to preoperative chemotherapy in breast cancer, regardless of whether paclitaxel was also administered. The lack of association was true of estrogen receptor (ER)-positive and ER-negative tumors."	18371219	PubMed		"Liedtke et al., 2008, Breast Cancer Res."		3	accepted	6191	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/6191	https://civicdb.org/links/molecular_profiles/307	FALSE	PIK3CA	5290	Mutation		chr3	179148523	179240093			ENST00000263967.3	75		"transcript_variant,gain_of_function_variant"		2023-01-09 21:52:06 UTC		N/A		FALSE
PIK3CA Exon 21 Mutation	105	Breast Cancer	1612				Prognostic	Supports	B	Better Outcome	"An Italian study of 163 malignant breast tumors assessed the association between PIK3CA mutations and clinical outcome. Of the 163 tumors sequenced, 118 had wild-type (wt) PIK3CA, 24 had exon 9 (helical domain) missense mutations, and 21 had exon 20 (kinase domain) missense mutations. The study found that patients with exon 20 mutations showed significantly better 5-year overall survival (OS) and 5-year disease free survival (DFS) compared to patients with wt PIK3CA (P=.011 and P = .01, respectively). Furthermore, patients with exon 20 mut showed especially better OS and DFS than patients with exon 9 mutations (P=.0018 and P=.0017, respectively). The 21 cases with exon 20 mutations had excellent prognosis with no recurrences or deaths, whereas there were 10 recurrences and 9 deaths among the 24 cases of exon 9 mutations, in observed period. Note these exons are now referred to as exons 10 and 21 rather than as exons 9 and 20, as it was common at the time of publication to exclude non-coding exon 1."	17947469	PubMed		"Barbareschi et al., 2007, Clin. Cancer Res."		4	accepted	6198	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/6198	https://civicdb.org/links/molecular_profiles/105	FALSE	PIK3CA	5290	Exon 21 Mutation		chr3	179234094	179234707			ENST00000263967.3	75		exon_variant		2023-01-09 21:52:05 UTC			EXON 20 MUTATION	FALSE
PIK3CA Exon 10 Mutation	106	Breast Cancer	1612				Prognostic	Supports	B	Poor Outcome	"An Italian study of 163 malignant breast tumors assessed the association between PIK3CA mutations and clinical outcome. Of the 163 tumors sequenced, 118 had wild-type (wt) PIK3CA, 24 had exon 9 (helical domain) missense mutations, and 21 had exon 20 (kinase domain) missense mutations. The study found that patients with exon 9 mutations showed significantly worse 5-year overall survival (OS) and 5-year disease free survival (DFS) compared to patients with wt PIK3CA (P=.018 and P = .04, respectively). Furthermore, patients with exon 9 mut showed especially worse OS and DFS than patients with exon 20 mutations (P=.0018 and P=.0017, respectively). The 21 cases with exon 20 mutations had excellent prognosis with no recurrences or deaths, whereas there were 10 recurrences and 9 deaths among the 24 cases of exon 9 mutations, in observed period. Note these exons are now referred to as exons 10 and 21 rather than as exons 9 and 20, as it was common at the time of publication to exclude non-coding exon 1."	17947469	PubMed		"Barbareschi et al., 2007, Clin. Cancer Res."		4	accepted	6199	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/6199	https://civicdb.org/links/molecular_profiles/106	FALSE	PIK3CA	5290	Exon 10 Mutation		chr3	179218210	179218334			ENST00000263967.3	75		exon_variant		2023-01-09 21:52:05 UTC		"3,194,413,655"	EXON 9 MUTATION	FALSE
ABL1 BCR::ABL Y253H	999	Chronic Myeloid Leukemia	8552		"Nilotinib,Imatinib Mesylate"	Substitutes	Predictive	Supports	C	Resistance	"In this open-label, phase II registration trial, patients that were imatinib resistant or intolerant underwent nilotinib monotherapy. Within 12 months of nilotinib therapy, there was no significant difference in response to nilotinib treatment between patients with mutations in the Abl1 kinase domain versus without. However, the authors identify Y253H, E255K/V, and F359C/V variants as resistant as they had an IC50 of >150 nM. In patients with Y253H mutations prior to nilotinib treatment, complete hematologic response was achieved in 0 of 6 patients, major cytogenetic response in 1 of 8 patients, complete cytogenetic response in 0 of 8 patients, and major molecular response in 0 of 7 patients. After median follow-up of 15.5 months, 3 of 8 patients with this mutation progressed or died. The Y253H mutation was present in two patients at baseline and newly emerged in two patients at progression."	19652056	PubMed		"Hughes et al., 2009, J. Clin. Oncol."		3	accepted	6200	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/6200	https://civicdb.org/links/molecular_profiles/999	FALSE	ABL1	25	BCR::ABL Y253H		chr9	130862970	130862970	T	C	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.757T>C,NP_005148.2:p.Tyr253His,NC_000009.11:g.133738357T>C,ENST00000318560.5:c.757T>C"	2023-01-27 17:07:45 UTC	CA122584	12627	"RS121913461,Y272H,TYR272HIS,BCR-ABL TYR253HIS,BCR-ABL1 Y253H,BCR-ABL1 TYR253HIS,BCR-ABL Y253H"	FALSE
VHL R161* (c.481C>T)	1680	Von Hippel-Lindau Disease	14175	"Multiple renal cysts,Cerebellar hemangioblastoma,Hemangioblastoma,Retinal capillary hemangioma,Renal cyst,Pancreatic cysts"			Predisposing	N/A	C	N/A	"A case report of a 32 year old male patient presenting with bilateral retinal hemangioblastoma, loss of vision in the left eye, and a history of cerebral hemangioblastoma revealed a R161X mutation in VHL. Two family members (daughter and sister) were confirmed to heterozygously harbor R161X. The patient's 12 year old daughter had no clinical presentations. The patient's sister had an optic nerve head hemangioblastoma in the left eye, peripheral temporal retina hemangioblastoma in left eye, and cystic lesions in the pancreas and kidney. The patient's mother was recalled to have advanced unilateral vision loss and dying due to renal cancer, but no genetic confirmation of VHL mutation status could be completed. ACMG codes: PVS1 (nonsense variant where LOF is a known mechanism of disease), PP4 (patient's phenotype and family history is specific for a disease with a single genetic etiology)"	28630796	PubMed		"ahin Atik et al., 2017, Turk J Ophthalmol"		2	accepted	6201	Rare Germline	2023-01-09 21:46:50 UTC	https://civicdb.org/links/evidence_items/6201	https://civicdb.org/links/molecular_profiles/1680	FALSE	VHL	7428	R161* (c.481C>T)		chr3	10149804	10149804	C	T	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.481C>T,NP_000542.1:p.Arg161Ter,NC_000003.11:g.10191488C>T,ENST00000256474.2:c.481C>T"	2023-01-27 17:12:16 UTC	CA020408	2217	"C.481C>T,R161X,ARG161TER,RS5030818"	FALSE
PIK3CA H1047R	107	Her2-receptor Positive Breast Cancer	60079		"Trastuzumab,Lapatinib"	Combination	Predictive	Supports	D	Resistance	"In a preclinical study, efficacy of lapatinib and trastuzumab was evaluated in vitro against HER2 amplified breast cancer cell line BT474 (heterozygous for PIK3CA K111N) retrovirally transduced with PIK3CA H1047R. The study found that H1047R abrogated the growth inhibitory effects of lapatinib and trastuzumab, either in isolation or in combination, though somewhat increased cell death was observed with combination therapy relative to monotherapy. The authors concluded that the PIK3CA H1047R induces resistance to lapatinib and trastuzumab in HER2-positive breast cancer cells."	19010894	PubMed		"Eichhorn et al., 2008, Cancer Res."		4	accepted	6204	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/6204	https://civicdb.org/links/molecular_profiles/107	FALSE	PIK3CA	5290	H1047R		chr3	179234297	179234297	A	G	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.3140A>G,NP_006209.2:p.His1047Arg,ENST00000263967.3:c.3140A>G,NC_000003.11:g.178952085A>G"	2023-01-27 17:02:38 UTC	CA123326	13652	"HIS1047ARG,RS121913279"	FALSE
PIK3CA H1047R	107	Her2-receptor Positive Breast Cancer	60079		Dactolisib		Predictive	Does Not Support	D	Resistance	"This preclinical study tested the sensitivity of HER2-positive breast cancer cell line BT-474 (heterozygous for PIK3CA K111N) retrovirally transduced with PIK3CA H1047R to NVP-BEZ235 (dactolisib; a dual PI3K/mTOR inhibitor). The study found that dactolisib was effective in inhibiting outgrowth of H1047R mutant-containing cells. Dactolisib was also combined with trastuzumab and/or lapatinib with similar abrogation of growth for PIK3CA H1047R expressing cells. Additionally, growth of untransduced BT-474 control cells was prevented by treatment with any monotherapy or combination of trastuzumab, lapatinib, or dactolisib. Authors concluded that PIK3CA H1047R induces resistance to lapatinib and trastuzumab in HER2 positive breast cancer cells, but resistance can be reversed by dactolisib."	19010894	PubMed		"Eichhorn et al., 2008, Cancer Res."		4	accepted	6206	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/6206	https://civicdb.org/links/molecular_profiles/107	FALSE	PIK3CA	5290	H1047R		chr3	179234297	179234297	A	G	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.3140A>G,NP_006209.2:p.His1047Arg,ENST00000263967.3:c.3140A>G,NC_000003.11:g.178952085A>G"	2023-01-27 17:02:38 UTC	CA123326	13652	"HIS1047ARG,RS121913279"	FALSE
ABL1 BCR::ABL L248R	2213	Chronic Myeloid Leukemia	8552		"Dasatinib,Imatinib Mesylate"	Substitutes	Predictive	Supports	D	Resistance	"In an in vitro study, stochastic mutations in the ABL1 region of a stably expressed p210 BCR-ABL fusion were generated in Ba/F3 cell lines from five independently derived, mutagenized libraries. Dasatinib resistant subclones were identified using ?0 nM dasatinib in liquid culture. 201 individual clones were identified representing 10 different mutations at 6 different residues. 1 of these clones had an L248R mutation. To validate resistance to dasatinib, a Ba/F3 cell line stably expressing the L248R mutation in the ABL1 region of the BCR-ABL fusion was generated. The L248R variants was associated with higher dasatinib IC50 of 16 nM vs 1.34 nM in wildtype and higher imatinib IC50 of >10,000 nM vs 323 nM in wildtype as determined by dose response curves."	15705718	PubMed		"Burgess et al., 2005, Proc. Natl. Acad. Sci. U.S.A."		3	accepted	6210	Somatic	2023-01-09 21:46:58 UTC	https://civicdb.org/links/evidence_items/6210	https://civicdb.org/links/molecular_profiles/2213	FALSE	ABL1	25	BCR::ABL L248R		chr9	130862956	130862956	T	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"ENST00000318560.5:c.743T>G,NC_000009.11:g.133738343T>G,NM_005157.6:c.743T>G,NP_005148.2:p.Leu248Arg"	2023-01-27 17:16:26 UTC	CA375263224	NONE FOUND	"LEU248ARG,BCR-ABL L248R"	FALSE
PIK3CA E545K	104	Her2-receptor Positive Breast Cancer	60079		"Trastuzumab,Lapatinib"	Combination	Predictive	Supports	D	Resistance	"In a preclinical study, efficacy of lapatinib and trastuzumab was evaluated in vitro against HER2 amplified breast cancer cell line BT474 (heterozygous for PIK3CA K111N) retrovirally transduced with PIK3CA E45K. The study found that E545K abrogated the growth inhibitory effects of lapatinib and trastuzumab, either in isolation or in combination, though increased cell death was observed with combination therapy relative to monotherapy. The authors concluded that the PIK3CA E545K induces resistance to lapatinib and trastuzumab in HER2-positive breast cancer cells."	19010894	PubMed		"Eichhorn et al., 2008, Cancer Res."		3	accepted	6211	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/6211	https://civicdb.org/links/molecular_profiles/104	FALSE	PIK3CA	5290	E545K		chr3	179218303	179218303	G	A	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.1633G>A,NP_006209.2:p.Glu545Lys,ENST00000263967.3:c.1633G>A,NC_000003.11:g.178936091G>A"	2023-01-27 17:02:37 UTC	CA123334	13655	"GLU545LYS,RS104886003"	FALSE
PIK3CA E545K	104	Her2-receptor Positive Breast Cancer	60079		Dactolisib		Predictive	Does Not Support	D	Resistance	"This preclinical study tested the sensitivity of HER2-positive breast cancer cell line BT-474 (heterozygous for PIK3CA K111N) retrovirally transduced with PIK3CA E545K to NVP-BEZ235 (dactolisib; a dual PI3K/mTOR inhibitor). The study found that dactolisib was effective in inhibiting outgrowth of E545K mutant-containing cells. Dactolisib was also combined with trastuzumab and/or lapatinib with similar abrogation of growth for PIK3CA E545K expressing cells. Growth of untransduced BT-474 control cells was prevented by treatment with any monotherapy or combination of trastuzumab, lapatinib, or dactolisib."	19010894	PubMed		"Eichhorn et al., 2008, Cancer Res."		3	accepted	6213	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/6213	https://civicdb.org/links/molecular_profiles/104	FALSE	PIK3CA	5290	E545K		chr3	179218303	179218303	G	A	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.1633G>A,NP_006209.2:p.Glu545Lys,ENST00000263967.3:c.1633G>A,NC_000003.11:g.178936091G>A"	2023-01-27 17:02:37 UTC	CA123334	13655	"GLU545LYS,RS104886003"	FALSE
ABL1 BCR::ABL V299L	1205	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Supports	D	Resistance	"In an in vitro study, stochastic mutations in the ABL1 region of a stably expressed p210 BCR-ABL fusion were generated in Ba/F3 cell lines from five independently derived, mutagenized libraries. Dasatinib resistant subclones were identified using ?0 nM dasatinib in liquid culture. 201 individual clones were identified representing 10 different mutations at 6 different residues. 1 of these clones had an V299L mutation. To validate resistance to dasatinib, a Ba/F3 cell line stably expressing the V299L mutation in the ABL1 region of the BCR-ABL fusion was generated and associated with higher dasatinib IC50 of 18 nM vs 1.34 nM in wildtype as determined by dose response curves."	15705718	PubMed		"Burgess et al., 2005, Proc. Natl. Acad. Sci. U.S.A."		3	accepted	6216	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/6216	https://civicdb.org/links/molecular_profiles/1205	FALSE	ABL1	25	BCR::ABL V299L		chr9	130872201	130872201	G	C	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.895G>C,NP_005148.2:p.Val299Leu,NC_000009.11:g.133747588G>C,ENST00000318560.5:c.895G>C"	2023-01-27 17:08:46 UTC	CA16602575	376117	"BCR-ABL VAL299LEU,BCR-ABL V318L,RS1057519771,BCR-ABL1 V299L,BCR-ABL1 VAL299LEU,BCR-ABL V299L"	FALSE
ABL1 BCR::ABL F317I	1533	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Supports	D	Resistance	"In an in vitro study, stochastic mutations in the ABL1 region of a stably expressed p210 BCR-ABL fusion were generated in Ba/F3 cell lines from five independently derived, mutagenized libraries. Dasatinib resistant subclones were identified using ?0 nM dasatinib in liquid culture. 201 individual clones were identified representing 10 different mutations at 6 different residues. 1 of these clones had an F317I mutation."	15705718	PubMed		"Burgess et al., 2005, Proc. Natl. Acad. Sci. U.S.A."		1	accepted	6217	Somatic	2023-01-09 21:46:46 UTC	https://civicdb.org/links/evidence_items/6217	https://civicdb.org/links/molecular_profiles/1533	FALSE	ABL1	25	BCR::ABL F317I		chr9	130872901	130872901	T	A	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.949T>A,NP_005148.2:p.Phe317Ile,NC_000009.11:g.133748288T>A,ENST00000318560.5:c.949T>A"	2023-01-27 17:11:02 UTC	CA16602577	376119	"F336I,RS1057519773,BCR-ABL PHE317ILE,BCR-ABL1 F317I,BCR-ABL1 PHE317ILE,BCR-ABL F317I"	FALSE
ABL1 BCR::ABL F317S	2216	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Supports	D	Resistance	"In an in vitro study, stochastic mutations in the ABL1 region of a stably expressed p210 BCR-ABL fusion were generated in Ba/F3 cell lines from five independently derived, mutagenized libraries. Dasatinib resistant subclones were identified using ?0 nM dasatinib in liquid culture. 201 individual clones were identified representing 10 different mutations at 6 different residues. 1 of these clones had an F317S mutation."	15705718	PubMed		"Burgess et al., 2005, Proc. Natl. Acad. Sci. U.S.A."		1	accepted	6218	Somatic	2023-01-09 21:46:58 UTC	https://civicdb.org/links/evidence_items/6218	https://civicdb.org/links/molecular_profiles/2216	FALSE	ABL1	25	BCR::ABL F317S		chr9	130872902	130872902	T	C	ENST00000318560.5	75		"missense_variant,transcript_fusion"	ENST00000318560.5:c.950T>C	2023-01-27 17:16:27 UTC	CA375249431	NONE FOUND	"PHE317SER,BCR-ABL F317S"	FALSE
ABL1 BCR::ABL Q252H	998	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Supports	D	Resistance	"In an in vitro study, stochastic mutations in the ABL1 region of a stably expressed p210 BCR-ABL fusion were generated in Ba/F3 cell lines from five independently derived, mutagenized libraries. Dasatinib resistant subclones were identified using ?0 nM dasatinib in liquid culture. 201 individual clones were identified representing 10 different mutations at 6 different residues. 1 of these clones had an Q252H mutation."	15705718	PubMed		"Burgess et al., 2005, Proc. Natl. Acad. Sci. U.S.A."		1	accepted	6219	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/6219	https://civicdb.org/links/molecular_profiles/998	FALSE	ABL1	25	BCR::ABL Q252H		chr9	130862969	130862969	G	C	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.756G>C,NP_005148.2:p.Gln252His,NC_000009.11:g.133738356G>C,ENST00000318560.5:c.756G>C"	2023-01-27 17:07:44 UTC	CA16602548	376087	"RS121913458,BCR-ABL Q271H,BCR-ABL1 Q252H,BCR-ABL1 GLN252HIS,BCR-ABL Q252H"	FALSE
VHL R161* (c.481C>T)	1680	Von Hippel-Lindau Disease	14175	"Hemangioblastoma,Endolymphatic sac tumor,Retinal capillary hemangioma,Epididymal cyst,Renal cyst,Clear cell renal cell carcinoma,Pancreatic cysts"			Predisposing	N/A	C	N/A	"A retrospective cohort study was conducted at a public childrens hospital (Buenos Aires, Argentina). Eligible patients were all index cases with clinical diagnosis or clinical suspicion of type 1 VHL referred for genetic testing from 2003 to 2015. A nonsense germline mutation c.481C>T resulting in p.R161* was confirmed in 4 patients, all of which fulfilled the requirements for diagnosis of type 1 VHL, and none of which had family history of VHL disease. Patient #1 was clinically diagnosed at age 13, and presented with retinal angioma (16Y) and endolymphatic sac tumors (13Y). Patient #3 was diagnosed at age 20Y, and presented with CNS hemangioblastoma at 20Y, 25Y, 26Y, clear cell renal cancer at 27Y, pancreatic cysts at 25Y, renal cysts at 25Y, and epididymal cysts at 31Y. Patient #4 was diagnosed at 21Y and presented with CNS hemangioblastoma at 22Y, retinal angioma at 21Y, pancreatic cysts at 23Y, and epididymal cysts since birth. Patient #9 was diagnosed at 25Y and presented with CNS hemangioblastoma at 22Y, clear cell renal cell carcinoma at 22Y, renal cysts at 22Y, and pancreatic cysts at 22Y. ACMG: PVS1 (nonsense variant in gene where LOF is a known mechanism of disease), PM6 (mutations assumed de novo, without confirmation)."	27617348	PubMed		"Math et al., 2016, Genet Test Mol Biomarkers"		3	accepted	6221	Rare Germline	2023-01-09 21:46:50 UTC	https://civicdb.org/links/evidence_items/6221	https://civicdb.org/links/molecular_profiles/1680	FALSE	VHL	7428	R161* (c.481C>T)		chr3	10149804	10149804	C	T	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.481C>T,NP_000542.1:p.Arg161Ter,NC_000003.11:g.10191488C>T,ENST00000256474.2:c.481C>T"	2023-01-27 17:12:16 UTC	CA020408	2217	"C.481C>T,R161X,ARG161TER,RS5030818"	FALSE
VHL R167Q (c.500G>A)	1615	Von Hippel-Lindau Disease	14175	"Clear cell renal cell carcinoma,Hemangioblastoma,Pancreatic endocrine tumor,Pheochromocytoma,Spinal hemangioblastoma"			Predisposing	N/A	C	N/A	"A case report of a 51Y male patient presenting with headaches and a family history of VHL disease revealed multiple CNS hemangioblastomas, bilateral clear cell renal cell carcinomas, pheochromocytoma, and a pancreatic neuroendocrine tumor. A germline mutation of p.Arg167Trp was confirmed in the patient's VHL gene. ACMG: PP4 as patients phenotype and family history are highly specific for a disease with a single genetic etiology."	29396065	PubMed		"Taylor et al., 2018, J Clin Neurosci"		3	accepted	6222	Rare Germline	2023-01-09 21:46:47 UTC	https://civicdb.org/links/evidence_items/6222	https://civicdb.org/links/molecular_profiles/1615	FALSE	VHL	7428	R167Q (c.500G>A)		chr3	10149823	10149823	G	A	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.500G>A,NP_000542.1:p.Arg167Gln,NC_000003.11:g.10191507G>A,ENST00000256474.2:c.500G>A"	2023-01-27 17:11:29 UTC	CA020454	2216	"C.500G>A,ARG167GLN,RS5030821"	FALSE
VHL Exon 3 Deletion	1815	Von Hippel-Lindau Disease	14175	"Endolymphatic sac tumor,Hemangioblastoma,Epididymal cyst,Pancreatic cysts,Multiple renal cysts,Renal cell carcinoma"			Predisposing	N/A	C	N/A	"A 33Y male presented with multiple bilateral renal masses, epididymis cyst, pancreatic cysts and renal cysts. The patient previously underwent resections of medullary hemangioblastoma and endolymphatic sac tumors. Genetic evaluation by MLPA revealed a germline deletion of exon 3 in the VHL gene, confirming the diagnosis of VHL disease. Family history was unremarkable, and both parents tested negative for the mutation, suggesting the mutation occurred de novo in the patient. ACMG: PVS1 exon deletion, PS2 de novo mutation confirmed absent in parents, PP4 phenotype specific for disease"	28256701	PubMed		"Allasia et al., 2017, Urologia"		2	accepted	6223	Rare Germline	2023-01-09 21:46:53 UTC	https://civicdb.org/links/evidence_items/6223	https://civicdb.org/links/molecular_profiles/1815	FALSE	VHL	7428	Exon 3 Deletion		chr3	10149787	10152220			ENST00000256474.2	75				2023-01-09 21:52:16 UTC				FALSE
ABL1 BCR::ABL F359C	1158	Chronic Myeloid Leukemia	8552		"Nilotinib,Imatinib Mesylate"	Substitutes	Predictive	Supports	C	Resistance	"In this open-label, phase II registration trial, patients that were imatinib resistant or intolerant underwent nilotinib monotherapy. Within 12 months of nilotinib therapy, there was no significant difference in response to nilotinib treatment between patients with mutations in the Abl1 kinase domain versus without. However, the authors identify Y253H, E255K/V, and F359C/V variants as resistant as they had an IC50 of >150nM. In patients with F359C and/or F359V mutations prior to nilotinib treatment, complete hematological responses were achieved in 3 of 10 patients, a major cytogenetic response in 1 of 11 patients, a complete cytogenetic response in 0 of 11 patients, and major molecular response in 0 of 10 patients. After a median follow-up of 15.5 months, 9 of 11 patients with this mutation progressed or died. The F359C mutation was present in 1 patient at baseline and newly emerged in 1 patient at progression. The F359V mutation was present in 4 patients at baseline and newly emerged in 1 patient at progression."	19652056	PubMed		"Hughes et al., 2009, J. Clin. Oncol."		3	accepted	6233	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/6233	https://civicdb.org/links/molecular_profiles/1158	FALSE	ABL1	25	BCR::ABL F359C		chr9	130873028	130873028	T	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.1076T>G,NP_005148.2:p.Phe359Cys,NC_000009.11:g.133748415T>G,ENST00000318560.5:c.1076T>G"	2023-01-27 17:08:36 UTC	CA16602582	376124	"F378C,RS1057519775,BCR-ABL PHE359CYS,BCR-ABL1 F359C,BCR-ABL1 PHE359CYS,BCR-ABL F359C"	FALSE
ABL1 BCR::ABL L248V	996	Chronic Myeloid Leukemia	8552		"Imatinib Mesylate,Nilotinib"	Combination	Predictive	Supports	D	Resistance	"In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. 61 clones grew in a combination of 400 nM imatinib and 50 nM nilotinib. Of these, 19 were sequenced and 2 (~11%) were found to have L248V mutations."	16772610	PubMed		"Bradeen et al., 2006, Blood"		2	accepted	6236	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/6236	https://civicdb.org/links/molecular_profiles/996	FALSE	ABL1	25	BCR::ABL L248V		chr9	130862955	130862955	C	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.742C>G,NP_005148.2:p.Leu248Val,NC_000009.11:g.133738342C>G,ENST00000318560.5:c.742C>G"	2023-01-27 17:07:42 UTC	CA16602546	376085	"RS121913455,L267V,LEU248VAL,BCR-ABL L248V"	FALSE
ABL1 BCR::ABL Y253H	999	Chronic Myeloid Leukemia	8552		"Nilotinib,Imatinib Mesylate"	Combination	Predictive	Supports	D	Resistance	"In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. 61 clones grew in a combination of 400 nM imatinib and 50 nM nilotinib. Of these, 19 were sequenced and 5 (~26%) were found to have Y253H mutations."	16772610	PubMed		"Bradeen et al., 2006, Blood"		2	accepted	6237	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/6237	https://civicdb.org/links/molecular_profiles/999	FALSE	ABL1	25	BCR::ABL Y253H		chr9	130862970	130862970	T	C	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.757T>C,NP_005148.2:p.Tyr253His,NC_000009.11:g.133738357T>C,ENST00000318560.5:c.757T>C"	2023-01-27 17:07:45 UTC	CA122584	12627	"RS121913461,Y272H,TYR272HIS,BCR-ABL TYR253HIS,BCR-ABL1 Y253H,BCR-ABL1 TYR253HIS,BCR-ABL Y253H"	FALSE
ABL1 BCR::ABL F311L	1436	Chronic Myeloid Leukemia	8552		"Nilotinib,Imatinib Mesylate"	Combination	Predictive	Supports	D	Resistance	"In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. 61 clones grew in a combination of 400 nM imatinib and 50 nM nilotinib. Of these, 19 were sequenced and 1 (~5%) was found to have an F311L mutation."	16772610	PubMed		"Bradeen et al., 2006, Blood"		2	accepted	6238	Somatic	2023-01-09 21:46:45 UTC	https://civicdb.org/links/evidence_items/6238	https://civicdb.org/links/molecular_profiles/1436	FALSE	ABL1	25	BCR::ABL F311L		chr9	130872883	130872883	T	C	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.931T>C,NP_005148.2:p.Phe311Leu,NC_000009.11:g.133748270T>C,ENST00000318560.5:c.931T>C"	2023-01-27 17:10:12 UTC	CA122587	12628	"RS137853304,F330L,BCR-ABL PHE311LEU,BCR-ABL1 F311L,BCR-ABL1 PHE311LEU,BCR-ABL F311L"	FALSE
ABL1 BCR::ABL F359C	1158	Chronic Myeloid Leukemia	8552		"Imatinib Mesylate,Nilotinib"	Combination	Predictive	Supports	D	Resistance	"In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. 61 clones grew in a combination of 400 nM imatinib and 50 nM nilotinib. Of these, 19 were sequenced and 7 (~37%) were found to have F359C mutations."	16772610	PubMed		"Bradeen et al., 2006, Blood"		2	accepted	6239	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/6239	https://civicdb.org/links/molecular_profiles/1158	FALSE	ABL1	25	BCR::ABL F359C		chr9	130873028	130873028	T	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.1076T>G,NP_005148.2:p.Phe359Cys,NC_000009.11:g.133748415T>G,ENST00000318560.5:c.1076T>G"	2023-01-27 17:08:36 UTC	CA16602582	376124	"F378C,RS1057519775,BCR-ABL PHE359CYS,BCR-ABL1 F359C,BCR-ABL1 PHE359CYS,BCR-ABL F359C"	FALSE
ABL1 BCR::ABL H396P	1439	Chronic Myeloid Leukemia	8552		"Imatinib Mesylate,Nilotinib"	Combination	Predictive	Supports	D	Resistance	"In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. 61 clones grew in a combination of 400 nM imatinib and 50 nM nilotinib. Of these, 19 were sequenced and 1 (~5%) was found to have an H396P mutation."	16772610	PubMed		"Bradeen et al., 2006, Blood"		2	accepted	6240	Somatic	2023-01-09 21:46:45 UTC	https://civicdb.org/links/evidence_items/6240	https://civicdb.org/links/molecular_profiles/1439	FALSE	ABL1	25	BCR::ABL H396P		chr9	130874969	130874969	A	C	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"ENST00000318560.5:c.1187A>C,NC_000009.11:g.133750356A>C,NM_005157.5:c.1187A>C,NP_005148.2:p.His396Pro"	2023-01-27 17:10:14 UTC	CA375249969	NONE FOUND	"BCR-ABL HIS396PRO,BCR-ABL1 H396P,BCR-ABL1 HIS396PRO,BCR-ABL H396P"	FALSE
ABL1 BCR::ABL V299L	1205	Chronic Myeloid Leukemia	8552		"Imatinib Mesylate,Dasatinib"	Combination	Predictive	Supports	D	Resistance	"In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. Of the 11 clones that grew in a combination of 400 nM imatinib and 10 nM dasatinib, 1 (9%) was found to have a V299L mutation."	16772610	PubMed		"Bradeen et al., 2006, Blood"		2	accepted	6241	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/6241	https://civicdb.org/links/molecular_profiles/1205	FALSE	ABL1	25	BCR::ABL V299L		chr9	130872201	130872201	G	C	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.895G>C,NP_005148.2:p.Val299Leu,NC_000009.11:g.133747588G>C,ENST00000318560.5:c.895G>C"	2023-01-27 17:08:46 UTC	CA16602575	376117	"BCR-ABL VAL299LEU,BCR-ABL V318L,RS1057519771,BCR-ABL1 V299L,BCR-ABL1 VAL299LEU,BCR-ABL V299L"	FALSE
ABL1 BCR::ABL M244V	995	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	D	Resistance	"In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The M244V mutation was associated with resistance in 2 M imatinib (1 clone recovered, 0.71%). In a review of 20 publications, this mutation was described in imatinib resistant patients."	16772610	PubMed		"Bradeen et al., 2006, Blood"		2	accepted	6242	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/6242	https://civicdb.org/links/molecular_profiles/995	FALSE	ABL1	25	BCR::ABL M244V		chr9	130862943	130862943	A	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.730A>G,NP_005148.2:p.Met244Val,NC_000009.11:g.133738330A>G,ENST00000318560.5:c.730A>G"	2023-01-27 17:07:41 UTC	CA16602545	376084	"RS121913456,M263V,MET263VAL,BCR-ABL MET244VAL,BCR-ABL1 M244V,BCR-ABL1 MET244VAL,BCR-ABL M244V"	FALSE
ABL1 BCR::ABL L248R	2213	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	D	Resistance	"In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The L248R mutation was associated with resistance in 2 M imatinib (1 clone recovered, ~1%) and 8 M imatinib (1 clone, ~2%). In a review of 20 publications, this mutation had not been described in imatinib resistant patients."	16772610	PubMed		"Bradeen et al., 2006, Blood"		2	accepted	6243	Somatic	2023-01-09 21:46:58 UTC	https://civicdb.org/links/evidence_items/6243	https://civicdb.org/links/molecular_profiles/2213	FALSE	ABL1	25	BCR::ABL L248R		chr9	130862956	130862956	T	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"ENST00000318560.5:c.743T>G,NC_000009.11:g.133738343T>G,NM_005157.6:c.743T>G,NP_005148.2:p.Leu248Arg"	2023-01-27 17:16:26 UTC	CA375263224	NONE FOUND	"LEU248ARG,BCR-ABL L248R"	FALSE
ABL1 BCR::ABL G250E	997	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	D	Resistance	"In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The G250E mutation was associated with resistance in 2 M imatinib (3 clone recovered, ~2%), 4 M imatinib (1 clone recovered, ~0.74%), and 50 nM nilotinib (5 clone, ~11%). In a review of 20 publications, this mutation was previously described in imatinib resistant patients."	16772610	PubMed		"Bradeen et al., 2006, Blood"		2	accepted	6244	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/6244	https://civicdb.org/links/molecular_profiles/997	FALSE	ABL1	25	BCR::ABL G250E		chr9	130862962	130862962	G	A	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.749G>A,NP_005148.2:p.Gly250Glu,NC_000009.11:g.133738349G>A,ENST00000318560.5:c.749G>A"	2023-01-27 17:07:43 UTC	CA16602547	376086	"RS121913453,BCR-ABL G269E,BCR-ABL GLY250GLU,BCR-ABL1 G250E,BCR-ABL1 GLY250GLU,BCR-ABL G250E"	FALSE
ABL1 BCR::ABL Q252H	998	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	D	Resistance	"In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The Q252H mutation was associated with resistance to 4 M and 16 M imatinib (4 clones [~3%] and 1 clone [~3%] recovered, respectively) as well as 10 nM dasatinib (1 clone [~2%]). No clones recovered at 2 M/8 M imatinib or 5 nM dasatinib. In a review of 20 publications, this mutation was previously described in imatinib resistant patients."	16772610	PubMed		"Bradeen et al., 2006, Blood"		2	accepted	6245	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/6245	https://civicdb.org/links/molecular_profiles/998	FALSE	ABL1	25	BCR::ABL Q252H		chr9	130862969	130862969	G	C	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.756G>C,NP_005148.2:p.Gln252His,NC_000009.11:g.133738356G>C,ENST00000318560.5:c.756G>C"	2023-01-27 17:07:44 UTC	CA16602548	376087	"RS121913458,BCR-ABL Q271H,BCR-ABL1 Q252H,BCR-ABL1 GLN252HIS,BCR-ABL Q252H"	FALSE
ABL1 BCR::ABL D276G	1001	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	D	Resistance	"In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The D276G mutation was associated with resistance in 2 M imatinib (1 clone recovered, ~0.71%). In a review of 20 publications, this mutation was previously described in imatinib resistant patients."	16772610	PubMed		"Bradeen et al., 2006, Blood"		2	accepted	6246	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/6246	https://civicdb.org/links/molecular_profiles/1001	FALSE	ABL1	25	BCR::ABL D276G		chr9	130872133	130872133	A	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"ENST00000318560.5:c.827A>G,NP_005148.2:p.Asp276Gly,NM_005157.5:c.827A>G,NC_000009.11:g.133747520A>G"	2023-01-27 17:07:46 UTC	CA200645023	NONE FOUND	"RS121913447,BCR-ABL ASP276GLY,BCR-ABL D295G,BCR-ABL1 D295G,BCR-ABL D276G"	FALSE
ABL1 BCR::ABL V299L	1205	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Supports	D	Resistance	"In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The V299L mutation was associated with resistance in 10 nM dasatinib (3 clone recovered, ~5%). No clones were recovered in 5 nM dasatinib. In a review of 20 publications, this mutation was described in imatinib resistant patients."	16772610	PubMed		"Bradeen et al., 2006, Blood"		2	accepted	6247	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/6247	https://civicdb.org/links/molecular_profiles/1205	FALSE	ABL1	25	BCR::ABL V299L		chr9	130872201	130872201	G	C	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.895G>C,NP_005148.2:p.Val299Leu,NC_000009.11:g.133747588G>C,ENST00000318560.5:c.895G>C"	2023-01-27 17:08:46 UTC	CA16602575	376117	"BCR-ABL VAL299LEU,BCR-ABL V318L,RS1057519771,BCR-ABL1 V299L,BCR-ABL1 VAL299LEU,BCR-ABL V299L"	FALSE
ABL1 BCR::ABL F317C	2232	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Supports	D	Resistance	"In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The F317C mutation was associated with resistance in 5 nM dasatinib (1 clone recovered, ~ 3%) and 10 nM dasatinib (6 clones, ~11%). In a review of 20 publications, this mutation was previously described in imatinib resistant patients."	16772610	PubMed		"Bradeen et al., 2006, Blood"		2	accepted	6250	Somatic	2023-01-09 21:46:58 UTC	https://civicdb.org/links/evidence_items/6250	https://civicdb.org/links/molecular_profiles/2232	FALSE	ABL1	25	BCR::ABL F317C		chr9	130872902	130872902	T	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	ENST00000318560:c.950T>G	2023-01-27 17:16:28 UTC	CA16602579	376121	"PHE317CYS,F336C,BCR-ABL F317C"	FALSE
ABL1 BCR::ABL F317I	1533	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Supports	D	Resistance	"In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The F317I mutation was associated with resistance in 5 nM dasatinib (2 clone recovered, ~ 6%) and 10 nM dasatinib (10 clones, ~18%)."	16772610	PubMed		"Bradeen et al., 2006, Blood"		2	accepted	6251	Somatic	2023-01-09 21:46:46 UTC	https://civicdb.org/links/evidence_items/6251	https://civicdb.org/links/molecular_profiles/1533	FALSE	ABL1	25	BCR::ABL F317I		chr9	130872901	130872901	T	A	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.949T>A,NP_005148.2:p.Phe317Ile,NC_000009.11:g.133748288T>A,ENST00000318560.5:c.949T>A"	2023-01-27 17:11:02 UTC	CA16602577	376119	"F336I,RS1057519773,BCR-ABL PHE317ILE,BCR-ABL1 F317I,BCR-ABL1 PHE317ILE,BCR-ABL F317I"	FALSE
ABL1 BCR::ABL M351T	1003	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	D	Resistance	"In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The M351T mutation was associated with resistance in 2 M imatinib (1 clone recovered, ~0.71%). In a review of 20 publications, this mutation was previously described in imatinib resistant patients."	16772610	PubMed		"Bradeen et al., 2006, Blood"		2	accepted	6254	Somatic	2023-01-09 21:46:42 UTC	https://civicdb.org/links/evidence_items/6254	https://civicdb.org/links/molecular_profiles/1003	FALSE	ABL1	25	BCR::ABL M351T		chr9	130873004	130873004	T	C	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.1052T>C,NP_005148.2:p.Met351Thr,NC_000009.11:g.133748391T>C,ENST00000318560.5:c.1052T>C"	2023-01-27 17:07:48 UTC	CA122590	12629	"RS121913457,BCR-ABL M370T,BCR-ABL MET351THR,BCR-ABL MET370THR,BCR-ABL M351T"	FALSE
ABL1 BCR::ABL E355G	1395	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	D	Resistance	"In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The E355G mutation was associated with resistance in 2 M imatinib (1 clone recovered, ~0.71%). In a review of 20 publications, this mutation was previously described in imatinib resistant patients."	16772610	PubMed		"Bradeen et al., 2006, Blood"		2	accepted	6255	Somatic	2023-01-09 21:46:45 UTC	https://civicdb.org/links/evidence_items/6255	https://civicdb.org/links/molecular_profiles/1395	FALSE	ABL1	25	BCR::ABL E355G		chr9	130873016	130873016	A	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.1064A>G,NP_005148.2:p.Glu355Gly,NC_000009.11:g.133748403A>G,ENST00000318560.5:c.1064A>G"	2023-01-27 17:09:47 UTC	CA16602556	376095	"RS121913450,BCR-ABL GLU355GLY,BCR-ABL1 E355G,BCR-ABL1 GLU355GLY,BCR-ABL E355G"	FALSE
ABL1 BCR::ABL F359V	866	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	D	Resistance	"In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The F359V mutation was associated with resistance in 2 M imatinib (3 clones recovered, ~2%). In a review of 20 publications, this mutation was previously described in imatinib resistant patients."	16772610	PubMed		"Bradeen et al., 2006, Blood"		2	accepted	6256	Somatic	2023-01-09 21:46:39 UTC	https://civicdb.org/links/evidence_items/6256	https://civicdb.org/links/molecular_profiles/866	FALSE	ABL1	25	BCR::ABL F359V		chr9	130873027	130873027	T	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.1075T>G,NP_005148.2:p.Phe359Val,NC_000009.11:g.133748414T>G,ENST00000318560.5:c.1075T>G"	2023-01-27 17:06:25 UTC	CA16602557	376096	"RS121913452,BCR-ABL F378V,BCR-ABL PHE359VAL,BCR-ABL1 F359V,BCR-ABL1 PHE359VAL,BCR-ABL F359V"	FALSE
ABL1 BCR::ABL V379I	1517	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	D	Resistance	"In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The V379I mutation was associated with resistance in 2 M imatinib (2 clones recovered, ~1%). In a review of 20 publications, this mutation was previously described in imatinib resistant patients."	16772610	PubMed		"Bradeen et al., 2006, Blood"		2	accepted	6257	Somatic	2023-01-09 21:46:46 UTC	https://civicdb.org/links/evidence_items/6257	https://civicdb.org/links/molecular_profiles/1517	FALSE	ABL1	25	BCR::ABL V379I		chr9	130874917	130874917	G	A	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"ENST00000318560.5:c.1135G>A,NC_000009.11:g.133750304G>A,NM_005157.5:c.1135G>A,NP_005148.2:p.Val379Ile"	2023-01-27 17:10:50 UTC	CA375249852	NONE FOUND	"V398I,BCR-ABL VAL379ILE,BCR-ABL1 V379I,BCR-ABL1 VAL379ILE,BCR-ABL V379I"	FALSE
ABL1 BCR::ABL H396R	1004	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	D	Resistance	"In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The H396R mutation was associated with resistance in 2 M imatinib (1 clone recovered, ~0.71%) and 4 M imatinib (1 clone, ~0.74%). In a review of 20 publications, this mutation was previously described in imatinib resistant patients."	16772610	PubMed		"Bradeen et al., 2006, Blood"		2	accepted	6258	Somatic	2023-01-09 21:46:42 UTC	https://civicdb.org/links/evidence_items/6258	https://civicdb.org/links/molecular_profiles/1004	FALSE	ABL1	25	BCR::ABL H396R		chr9	130874969	130874969	A	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.1187A>G,NP_005148.2:p.His396Arg,NC_000009.11:g.133750356A>G,ENST00000318560.5:c.1187A>G"	2023-01-27 17:07:48 UTC	CA16602558	376097	"RS121913454,BCR-ABL HIS415ARG,BCR-ABL HIS396ARG,BCR-ABL H415R,BCR-ABL1 H396R,BCR-ABL1 HIS396ARG,BCR-ABL H396R"	FALSE
AKT1 Q79K	169	Melanoma	1909		Dabrafenib		Predictive	Supports	C	Resistance	"In a retrospective study of 44 relapsed melanoma patients with BRAF V600E/K (known BRAF inhibitor sensitizing mutations), AKT1 Q79K was associated with acquired resistance to BRAF inhibitor (dabrafenib) monotherapy in one patient. This patient was a 38 year old female with stage IV M1a melanoma who took dabrafenib (35 mg twice daily to 100 mg three times a day). The best overall response was a 100% reduction in the sum of target lesions, and progression free survival lasted 119 days. Prior to dabrafenib monotherapy, this patient's baseline tumor harbored BRAF V600Kno other somatic alterations were noted. Following relapse, the patient gained AKT1 Q79K in one of two disease progressive tumors. Whole exome sequencing and Sanger re-sequencing were used for all tumors. The authors hypothesized that disruptions in the PI3K-PTEN-AKT pathway represent a core mechanism of acquired resistance to BRAF inhibitor therapy."	24265155	PubMed		"Shi et al., 2014, Cancer Discov"		4	accepted	6260	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/6260	https://civicdb.org/links/molecular_profiles/169	FALSE	AKT1	207	Q79K		chr14	104776711	104776711	G	T	ENST00000407796.2	75		missense_variant	"NC_000014.8:g.105243048G>T,NM_001014432.1:c.235C>A,NP_001014432.1:p.Gln79Lys,ENST00000407796.2:c.235C>A"	2023-01-27 17:02:59 UTC	CA16602625	376168	"Q17K,GLN79LYS,RS1057519804"	FALSE
NRAS Mutation	208	Melanoma	1909		"Vemurafenib,Dabrafenib"	Substitutes	Predictive	Supports	B	Resistance	"In a retrospective study of 44 relapsed melanoma patients harboring BRAF V600E or V600K (known BRAF inhibitor sensitizing mutations), MAPK pathway reactivation mechanisms were implicated in acquired resistance to BRAF inhibitor (vemurafenib or dabrafenib) monotherapy. The following MAPK pathway variants were found in progressive tumors with patient matched baseline tumors (some patients donated samples from multiple geographically/temporally distinct progressive tumors): NRAS mutations (G12D, G12R, G13R, Q61K, Q61R, Q61L) in 13/71 (18%) of progressive tumors, KRAS mutations (G12C, G12R, Q61H) in 5/71 (7%) of progressive tumors, mutant BRAF amplification (2-15 fold or 4-75 copies) in 11/57 (19%) of progressive tumors, mutant BRAF alternative splice variants (novel exon boundaries between 1/9, 1/11, 3/9) in 6/48 (13%) of progressive tumor RNA."	24265155	PubMed		"Shi et al., 2014, Cancer Discov"		2	accepted	6263	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/6263	https://civicdb.org/links/molecular_profiles/208	FALSE	NRAS	4893	Mutation		chr1	114704469	114716894			ENST00000369535.4	75		"transcript_variant,gain_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
KRAS Mutation	332	Melanoma	1909		"Dabrafenib,Vemurafenib"	Substitutes	Predictive	Supports	B	Resistance	"In a retrospective study of 44 relapsed melanoma patients harboring BRAF V600E or V600K (known BRAF inhibitor sensitizing mutations), MAPK pathway reactivation mechanisms were implicated in acquired resistance to BRAF inhibitor (vemurafenib or dabrafenib) monotherapy. The following MAPK pathway variants were found in progressive tumors with patient matched baseline tumors (some patients donated samples from multiple geographically/temporally distinct progressive tumors): NRAS mutations (G12D, G12R, G13R, Q61K, Q61R, Q61L) in 13/71 (18%) of progressive tumors, KRAS mutations (G12C, G12R, Q61H) in 5/71 (7%) of progressive tumors, mutant BRAF amplification (2-15 fold or 4-75 copies) in 11/57 (19%) of progressive tumors, mutant BRAF alternative splice variants (novel exon boundaries between 1/9, 1/11, 3/9) in 6/48 (13%) of progressive tumor RNA."	24265155	PubMed		"Shi et al., 2014, Cancer Discov"		2	accepted	6264	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/6264	https://civicdb.org/links/molecular_profiles/332	FALSE	KRAS	3845	Mutation		chr12	25209431	25250803			ENST00000256078.4	75		protein_altering_variant		2023-01-09 21:52:06 UTC		N/A		FALSE
ABL1 BCR::ABL G250E	997	Chronic Myeloid Leukemia	8552		Nilotinib		Predictive	Supports	D	Resistance	"In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The G250E mutation was associated with resistance in 2 M imatinib (3 clone recovered, ~2%), 4 M imatinib (1 clone recovered, ~0.74%), and 50 nM nilotinib (5 clone, ~11%). In a review of 20 publications, this mutation was previously described in imatinib resistant patients."	16772610	PubMed		"Bradeen et al., 2006, Blood"		2	accepted	6267	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/6267	https://civicdb.org/links/molecular_profiles/997	FALSE	ABL1	25	BCR::ABL G250E		chr9	130862962	130862962	G	A	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.749G>A,NP_005148.2:p.Gly250Glu,NC_000009.11:g.133738349G>A,ENST00000318560.5:c.749G>A"	2023-01-27 17:07:43 UTC	CA16602547	376086	"RS121913453,BCR-ABL G269E,BCR-ABL GLY250GLU,BCR-ABL1 G250E,BCR-ABL1 GLY250GLU,BCR-ABL G250E"	FALSE
PREX2 R172I	2237	Melanoma	1909		Vemurafenib		Predictive	Supports	C	Resistance	"In a retrospective study of 44 relapsed melanoma patients harboring BRAF V600E/K (known BRAF inhibitor sensitizing mutations), PREX2 R172I was associated with a case of acquired resistance to BRAF inhibitor (vemurafenib) monotherapy in one patient. This patient was an 83 year old male with stage IV M1c melanoma who took vemurafenib (960mg twice daily). The best overall response was a 5% increase in sum of target lesions, and progression free survival lasted 132 days. Prior to vemurafenib monotherapy, this patient harbored BRAF V600K and no other somatic genetic alterations noted in the baseline tumor. Following relapse, the patient gained PREX2 R172I in one of two disease progressive tumors. Whole exome sequencing and Sanger re-sequencing were used for all tumors. The authors indicated that the biology behind this potential resistance mutation was unknown."	24265155	PubMed		"Shi et al., 2014, Cancer Discov"		4	accepted	6268	Somatic	2023-01-09 21:46:58 UTC	https://civicdb.org/links/evidence_items/6268	https://civicdb.org/links/molecular_profiles/2237	FALSE	PREX2	80243	R172I		chr8	68027295	68027295	G	T	ENST00000288368.4	75		missense_variant		2023-01-27 17:16:28 UTC	CA371196220	NONE FOUND	ARG172ILE	FALSE
PTEN Loss	214	Melanoma	1909		Vemurafenib		Predictive	Supports	D	Resistance	"An in vitro study of M229 (a human melanoma cell line) endogenously expressing wildtype PTEN and BRAF V600E (a known BRAF inhibitor sensitizing mutation) found that PTEN knockdown cells (achieved via lentiviral transduction of shPTEN) were more resistant to vemurafenib (a BRAF inhibitor) than cells expressing wildtype PTEN. Lentiviral mediated reintroduction of PTEN restored vemurafenib sensitivity in WM2664, a vemurafenib resistant, PTEN non-expressing and BRAF V600D mutated human melanoma cell line."	24265155	PubMed		"Shi et al., 2014, Cancer Discov"		4	accepted	6271	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/6271	https://civicdb.org/links/molecular_profiles/214	FALSE	PTEN	5728	Loss		chr10	87863113	87971930			ENST00000371953.3	75		loss_of_function_variant	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
ABL1 BCR::ABL Q252H	998	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Supports	D	Resistance	"In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The Q252H mutation was associated with resistance to 4 M and 16 M imatinib (4 clones [~3%] and 1 clone [~3%] recovered, respectively) as well as 10 nM dasatinib (1 clone [~2%]). No clones recovered at 2 M/8 M imatinib or 5 nM dasatinib. In a review of 20 publications, this mutation was previously described in imatinib resistant patients."	16772610	PubMed		"Bradeen et al., 2006, Blood"		2	accepted	6274	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/6274	https://civicdb.org/links/molecular_profiles/998	FALSE	ABL1	25	BCR::ABL Q252H		chr9	130862969	130862969	G	C	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.756G>C,NP_005148.2:p.Gln252His,NC_000009.11:g.133738356G>C,ENST00000318560.5:c.756G>C"	2023-01-27 17:07:44 UTC	CA16602548	376087	"RS121913458,BCR-ABL Q271H,BCR-ABL1 Q252H,BCR-ABL1 GLN252HIS,BCR-ABL Q252H"	FALSE
PIK3CA Amplification	212	Melanoma	1909		Vemurafenib		Predictive	Supports	D	Resistance	"An in vitro study of M229 (a human melanoma cell line) endogenously expressing wildtype PIK3CA and BRAF V600E (a known BRAF inhibitor sensitizing mutation) found that cells induced to stably over-express PIK3CA (via viral transduction with additional copies of wild type PIK3CA) were significantly more resistant to vemurafenib (a BRAFi) than cells transduced with an empty vector (30% vs 20% survival, p < .0001). Though statistics were not provided, it appears that amplification of wildtype PIK3CA confers less resistance than the positive control variant, PIK3CA E545K."	24265155	PubMed		"Shi et al., 2014, Cancer Discov"		2	accepted	6275	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/6275	https://civicdb.org/links/molecular_profiles/212	FALSE	PIK3CA	5290	Amplification		chr3	179148523	179240093			ENST00000263967.3	75		transcript_amplification	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
VHL N78S (c.233A>G)	1631	Von Hippel-Lindau Disease	14175	"Pancreatic endocrine tumor,Pancreatic cysts,Multiple renal cysts,Retinal capillary hemangioma,Hemangioblastoma"			Predisposing	Supports	C	Uncertain Significance	"A male patient with Type 1 VHL disease  presented with vision loss and retinal angiomatosis in the right eye at 19Y, left retinal angiomatosis at 23Y as well as CNS hemangioblastomas, neuroendocrine tumor of the pancreas which metastases to the liver, and renal tumors at 25Y. Patient was found to carry c.233A>G (p.Asn78Ser) mutation in the VHL gene. Patient had a positive family history of VHL clinical manifestations, although the genotype of affected family members was not confirmed. His mother presented with pancreatic and renal cysts at 37Y and retinal angiomatosis at 47Y. Patient's grandmother suffered from loss of vision  in her 30s, and renal cancer and brain tumour at 58Y. ACMG: PP2, PP4"	26984080	PubMed		"Kobayashi et al., 2016, Intern. Med."		2	accepted	6289	Rare Germline	2023-01-09 21:46:48 UTC	https://civicdb.org/links/evidence_items/6289	https://civicdb.org/links/molecular_profiles/1631	FALSE	VHL	7428	N78S (c.233A>G)		chr3	10142080	10142080	A	G	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.233A>G,NP_000542.1:p.Asn78Ser,NC_000003.11:g.10183764A>G,ENST00000256474.2:c.233A>G"	2023-01-27 17:11:40 UTC	CA020131	93326	"C.233A>G,ASN78SER,RS5030804"	FALSE
VHL Exon 3 Deletion	1815	Von Hippel-Lindau Disease	14175	"Pheochromocytoma,Clear cell renal cell carcinoma,Cerebellar hemangioblastoma,Retinal capillary hemangioma,Spinal hemangioblastoma,Pancreatic cysts"			Predisposing	N/A	C	N/A	"A 22-year-old woman diagnosed in childhood with type IIb VHL, with known multiple retinal angiomas, pancreatic cysts, and spinal and cerebellar hemangioblastomas presented to the ER with signs of acute decompensated heart failure leading to the discovery of dilated left ventricle with severely depressed ejection fraction. Pheochromocytoma and clear cell renal carcinoma was also discovered at this time. Genetic analysis revealed a de novo germline exon 3 deletion mutation in the VHL gene, with no family history of disease. ACMG: PVS1, PS2, PP4"	26584481	PubMed		"Valero et al., 2016, Med Princ Pract"		3	accepted	6290	Rare Germline	2023-01-09 21:46:53 UTC	https://civicdb.org/links/evidence_items/6290	https://civicdb.org/links/molecular_profiles/1815	FALSE	VHL	7428	Exon 3 Deletion		chr3	10149787	10152220			ENST00000256474.2	75				2023-01-09 21:52:16 UTC				FALSE
KRAS G12/G13	77	Colorectal Cancer	9256				Prognostic	Does Not Support	B	Poor Outcome	"This was a retrospective clinical study of 168 metastatic colorectal cancer patients who received first line chemotherapy (5-fluorouracil (5-FU) only, 5-FU + oxaliplatin, 5-FU + irinotecan, or 5-FU + oxaliplatin + irinotecan) alone or with monoclonal antibodies (bevacizumab or cetuximab). It assessed the relationship between KRAS mutation status in primary tumors and post treatment progression free survival (PFS) and overall survival (OS). Of the 168 patients, 106 had wildtype KRAS and 62 had mutations in KRASincluding G12A, G12C, G12D, G12R, G12S, G12V, and G13D. Regardless of first line chemotherapy regimen or use of monoclonal antibody treatment, patients with KRAS-mutated tumors did not have a significantly worse outcome than patients with wtKRAS tumors,  as evidenced by non-significant differences in PFS (12.3 vs 11.8 months, respectively) and OS (35.8 and 40.5 months, respectively)."	19603024	PubMed		"Souglakos et al., 2009, Br. J. Cancer"		3	accepted	6292	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/6292	https://civicdb.org/links/molecular_profiles/77	FALSE	KRAS	3845	G12/G13		chr12	25245346	25245351			ENST00000256078.4	75		protein_altering_variant		2023-01-09 21:52:04 UTC		"45,122,125,781,258,200,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000"		FALSE
KRAS G12/G13	77	Colorectal Cancer	9256		Oxaliplatin		Predictive	Does Not Support	B	Resistance	"This was a retrospective clinical study of 100 metastatic colorectal cancer patients who received FOLFOX (oxaliplatin + 5-fluorouracil + folinic acid) first-line therapy alone or with monoclonal antibodies (bevacizumab or cetuximab). It assessed the relationship between KRAS mutation status in primary tumors and response to oxaliplatin-based first-line therapy, as measured by post treatment PFS. Of 100 patients, 61 had wildtype KRAS and 39 had mutations in KRASincluding G12A, G12C, G12D, G12R, G12S, G12V, and G13D. The study found that patients with KRAS-mutated tumors were not significantly more resistant to oxaliplatin-based first-line therapy than patients with wildtype KRAS, as evidenced by a nonsignificant difference in PFS (11.7 and 11.4 months, respectively)."	19603024	PubMed		"Souglakos et al., 2009, Br. J. Cancer"		3	accepted	6293	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/6293	https://civicdb.org/links/molecular_profiles/77	FALSE	KRAS	3845	G12/G13		chr12	25245346	25245351			ENST00000256078.4	75		protein_altering_variant		2023-01-09 21:52:04 UTC		"45,122,125,781,258,200,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000"		FALSE
KRAS G12/G13	77	Colorectal Cancer	9256		Irinotecan		Predictive	Does Not Support	B	Resistance	"This was a retrospective clinical study of 44 metastatic colorectal cancer patients who recieved FOLFIRI (5-Fluorouacil + Folinic acid + irinotecan) first-line therapy alone or with bevacizumab. It assessed the relationship between KRAS mutation status in primary tumors and response to irinotecan-based first line therapy, as measured by PFS. Of the 44 patients, 26 had wildtype KRAS and 18 had mutations in KRASincluding G12A, G12C, G12D, G12R, G12S, G12V, and G13D. The study found that patients harboring a KRAS mutation were not significantly more resistant to irinotecan-based first-line therapy than patients with wildtype KRAS. The difference in PFS between patients with KRAS-mutated tumors and the patients with wtKRAS tumors was nonsignificant (PFS: 13.7 and 12.0 months; p= 0.074)."	19603024	PubMed		"Souglakos et al., 2009, Br. J. Cancer"		3	accepted	6294	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/6294	https://civicdb.org/links/molecular_profiles/77	FALSE	KRAS	3845	G12/G13		chr12	25245346	25245351			ENST00000256078.4	75		protein_altering_variant		2023-01-09 21:52:04 UTC		"45,122,125,781,258,200,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000"		FALSE
KRAS G12/G13	77	Colorectal Cancer	9256		Bevacizumab		Predictive	Does Not Support	B	Resistance	"This was a retrospective clinical study of 97 metastatic colorectal cancer patients who received bevacizumab in conjunction with first-line chemotherapy (composed of 5-fluorouracil (5-FU) only, 5-FU + oxaliplatin, 5-FU + irinotecan, or 5-FU + oxaliplatin + irinotecan). It assessed the relationship between KRAS mutation status in primary tumors and response to bevacizumab-containing first line chemotherapy, as measured by PFS. Of the 97 patients, 58 had wildtype KRAS and 39 had mutations in KRASincluding G12A, G12C, G12D, G12R, G12S, G12V, and G13D. The study found that patients with KRAS-mutated tumors were not significantly more resistant to bevacizumab-containing first-line chemotherapy than patients with wildtype KRAS, as evidenced by a non-significant difference in PFS between the two groups (12.1 and 11.7 months, respectively)."	19603024	PubMed		"Souglakos et al., 2009, Br. J. Cancer"		3	accepted	6295	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/6295	https://civicdb.org/links/molecular_profiles/77	FALSE	KRAS	3845	G12/G13		chr12	25245346	25245351			ENST00000256078.4	75		protein_altering_variant		2023-01-09 21:52:04 UTC		"45,122,125,781,258,200,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000"		FALSE
KRAS G12/G13	77	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	B	Resistance	"This was a retrospective clinical study of 92 metastatic colorectal cancer patients who received cetuximab in conjunction with salvage chemotherapy (refractory to at least one line of treatment). Salvage chemotherapy was composed of 5-fluorouracil (5-FU) only, 5-FU + oxaliplatin, 5-FU + irinotecan, or 5-FU + oxaliplatin + irinotecan. The study assessed the relationship between KRAS mutation status in primary tumors and response to cetuximab-containing salvage chemotherapy, as measured by PFS. Of the 92 patients, 60 had wildtype KRAS and 32 had mutations in KRASincluding G12A, G12C, G12D, G12R, G12S, G12V, and G13D. The study found that patients harboring a KRAS mutation were trending toward resistance to cetuximab-containing salvage chemotherapy as compared to patients with wildtype KRAS (p=0.094). Note: while differences in PFS were nonsignificant between patients with wildtype or mutant KRAS, differences in objective response (defined as reduction by at least 30% in the sum of the longest diameters of target lesions compared to baseline) were significantly different. Of the 32 patients with mutant KRAS, none responded to cetuximab-containing salvage therapy, while 14/60 of the patients with wildtype KRAS (23%) responded (p=.002)."	19603024	PubMed		"Souglakos et al., 2009, Br. J. Cancer"		3	accepted	6296	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/6296	https://civicdb.org/links/molecular_profiles/77	FALSE	KRAS	3845	G12/G13		chr12	25245346	25245351			ENST00000256078.4	75		protein_altering_variant		2023-01-09 21:52:04 UTC		"45,122,125,781,258,200,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000"		FALSE
PIK3CA Mutation	307	Colorectal Cancer	9256				Prognostic	Does Not Support	B	Poor Outcome	"This was a retrospective clinical study of 168 metastatic colorectal cancer patients who received first line chemotherapy (made up of 5-fluorouracil (5-FU) only, 5-FU + oxaliplatin, 5-FU + irinotecan, or 5-FU + oxaliplatin + irinotecan) alone or with monoclonal antibodies (bevacizumab or cetuximab). It assessed the relationship between PIK3CA mutation status in primary tumors and post treatment PFS. Of 168 patients, 142 had wildtype PIK3CA and 26 had mutations in PIK3CA on either exon 9 or 20 (exon 9 mutations: E542K, E545K, E545G, E545D, Q546K, D549N. Exon 20 mutations: R1023Q, H1047R, H1047L, G1049A). The study found that patients harboring a PIK3CA mutation did not have a significantly worse outcome than patients expressing wildtype PIK3CA, regardless of first line chemotherapy regimen or use of monoclonal antibody treatment."	19603024	PubMed		"Souglakos et al., 2009, Br. J. Cancer"		3	accepted	6297	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/6297	https://civicdb.org/links/molecular_profiles/307	FALSE	PIK3CA	5290	Mutation		chr3	179148523	179240093			ENST00000263967.3	75		"transcript_variant,gain_of_function_variant"		2023-01-09 21:52:06 UTC		N/A		FALSE
PIK3CA Mutation	307	Colorectal Cancer	9256		Oxaliplatin		Predictive	Does Not Support	B	Resistance	"This was a retrospective clinical study of 100 metastatic colorectal cancer patients who received FOLFOX (oxaliplatin + 5-fluorouracil + folinic acid) first-line therapy alone or with monoclonal antibodies (bevacizumab or cetuximab). It assessed the relationship between PIK3CA mutation status in primary tumors and response to oxaliplatin-based first-line therapy, as measured by post treatment PFS. Of 100 patients, 81 had wildtype PIK3CA and 19 had mutations in PIK3CA on either exon 9 or 20 (exon 9 mutations: E542K, E545K, E545G, E545D, Q546K, D549N. Exon 20 mutations: R1023Q, H1047R, H1047L, G1049A). The study found that patients harboring a PIK3CA mutation were not significantly more resistant to oxaliplatin-based first-line therapy than patients with wildtype PIK3CA, as evidenced by a nonsignificant difference in PFS between the two groups (10.7 and 11.7 months, respectively)."	19603024	PubMed		"Souglakos et al., 2009, Br. J. Cancer"		3	accepted	6298	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/6298	https://civicdb.org/links/molecular_profiles/307	FALSE	PIK3CA	5290	Mutation		chr3	179148523	179240093			ENST00000263967.3	75		"transcript_variant,gain_of_function_variant"		2023-01-09 21:52:06 UTC		N/A		FALSE
PIK3CA Mutation	307	Colorectal Cancer	9256		Irinotecan		Predictive	Does Not Support	B	Resistance	"This was a retrospective clinical study of 44 metastatic colorectal cancer patients who received FOLFIRI (5-Fluorouacil + Folinic acid + irinotecan) first-line therapy alone or with bevacizumab. It assessed the relationship between PIK3CA mutation status in primary tumors and response to irinotecan-based first line therapy, as measured by PFS. Of the 44 patients, 40 had wildtype PIK3CA and 4 had mutations in PIK3CA on either exon 9 or 20 (exon 9 mutations: E542K, E545K, E545G, E545D, Q546K, D549N. Exon 20 mutations: R1023Q, H1047R, H1047L, G1049A). The study found that patients harboring a PIK3CA mutation were not significantly more resistant to irinotecan-based first-line therapy than patients with wildtype PIK3CA, as evidenced by a nonsignificant difference in PFS between the two groups."	19603024	PubMed		"Souglakos et al., 2009, Br. J. Cancer"		3	accepted	6299	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/6299	https://civicdb.org/links/molecular_profiles/307	FALSE	PIK3CA	5290	Mutation		chr3	179148523	179240093			ENST00000263967.3	75		"transcript_variant,gain_of_function_variant"		2023-01-09 21:52:06 UTC		N/A		FALSE
PIK3CA Mutation	307	Colorectal Cancer	9256		Bevacizumab		Predictive	Does Not Support	B	Resistance	"This was a retrospective clinical study of 97 metastatic colorectal cancer patients who received bevacizumab in conjunction with first-line chemotherapy (composed of 5-fluorouracil (5-FU) only, 5-FU + oxaliplatin, 5-FU + irinotecan, or 5-FU + oxaliplatin + irinotecan). It assessed the relationship between PIK3CA mutation status in primary tumors and response to bevacizumab-containing first line chemotherapy, as measured by PFS. Of the 97 patients, 83 had wildtype PIK3CA and 14 had mutations in PIK3CA on either exon 9 or 20 (exon 9 mutations: E542K, E545K, E545G, E545D, Q546K, D549N. Exon 20 mutations: R1023Q, H1047R, H1047L, G1049A). The study found that patients harboring a PIK3CA mutation were not significantly more resistant to bevacizumab-containing first-line chemotherapy than patients with wildtype PIK3CA, as evidenced by a nonsignificant difference in PFS between the two groups."	19603024	PubMed		"Souglakos et al., 2009, Br. J. Cancer"		3	accepted	6300	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/6300	https://civicdb.org/links/molecular_profiles/307	FALSE	PIK3CA	5290	Mutation		chr3	179148523	179240093			ENST00000263967.3	75		"transcript_variant,gain_of_function_variant"		2023-01-09 21:52:06 UTC		N/A		FALSE
PIK3CA Mutation	307	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	B	Resistance	"This was a retrospective clinical study of 92 metastatic colorectal cancer patients who received cetuximab in conjunction with salvage chemotherapy (refractory to at least one line of treatment). Salvage chemotherapy was composed of 5-fluorouracil (5-FU) only, 5-FU + oxaliplatin, 5-FU + irinotecan, or 5-FU + oxaliplatin + irinotecan. The study assessed the relationship between PIK3CA mutation status in primary tumors and response to cetuximab-containing salvage chemotherapy, as measured by PFS. Of the 92 patients, 79 had wildtype PIK3CA and 19 had mutations in PIK3CA on either exon 9 or 20 (exon 9 mutations: E542K, E545K, E545G, E545D, Q546K, D549N. Exon 20 mutations: R1023Q, H1047R, H1047L, G1049A). The study found that patients harboring a PIK3CA mutation were significantly more resistant to cetuximab-containing salvage chemotherapy than patients with wildtype PIK3CA (Median PFS: 2.5 and 3.9 months, respectively; p = .014)."	19603024	PubMed		"Souglakos et al., 2009, Br. J. Cancer"		3	accepted	6301	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/6301	https://civicdb.org/links/molecular_profiles/307	FALSE	PIK3CA	5290	Mutation		chr3	179148523	179240093			ENST00000263967.3	75		"transcript_variant,gain_of_function_variant"		2023-01-09 21:52:06 UTC		N/A		FALSE
BRAF Mutation	395	Colorectal Cancer	9256				Prognostic	Supports	B	Poor Outcome	"This was a retrospective clinical study of 168 metastatic colorectal cancer patients who received first line chemotherapy (made up of 5-fluorouracil (5-FU) only, 5-FU + oxaliplatin, 5-FU + irinotecan, or 5-FU + oxaliplatin + irinotecan) alone or with monoclonal antibodies (bevacizumab or cetuximab). It assessed the relationship between BRAF mutation status in primary tumors and post treatment PFS. Of 168 patients, 155 had wildtype BRAF and 13 had mutations in BRAFincluding V600E and D594K. The study found that patients harboring a BRAF mutation had a significantly worse outcome than patients expressing wildtype BRAF, regardless of first line chemotherapy regimen or use of monoclonal antibody treatment (Median PFS: 4.3 and 12.5 months, respectively; p <.0001)."	19603024	PubMed		"Souglakos et al., 2009, Br. J. Cancer"		3	accepted	6302	Somatic	2023-02-03 00:05:19 UTC	https://civicdb.org/links/evidence_items/6302	https://civicdb.org/links/molecular_profiles/395	TRUE	BRAF	673	Mutation		chr7	140753336	140781603			ENST00000288602.6	75		"gene_variant,gain_of_function_variant"		2023-01-09 21:52:06 UTC				FALSE
BRAF Mutation	395	Colorectal Cancer	9256		Oxaliplatin		Predictive	Supports	B	Resistance	"This was a retrospective clinical study of 100 metastatic colorectal cancer patients who received FOLFOX (oxaliplatin + 5-fluorouracil + folinic acid) first-line therapy alone or with monoclonal antibodies (bevacizumab or cetuximab). It assessed the relationship between BRAF mutation status in primary tumors and response to oxaliplatin-based first-line therapy, as measured by post treatment PFS. Of 100 patients, 94 had wildtype BRAF and 6 had mutations in BRAFincluding V600E and D594K. The study found that patients harboring a BRAF mutation were significantly more resistant to oxaliplatin-based first-line therapy than patients with wildtype BRAF (Median PFS: 5.0 and 11. 7 months, respectively; p < .0001)."	19603024	PubMed		"Souglakos et al., 2009, Br. J. Cancer"		3	accepted	6303	Somatic	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/6303	https://civicdb.org/links/molecular_profiles/395	FALSE	BRAF	673	Mutation		chr7	140753336	140781603			ENST00000288602.6	75		"gene_variant,gain_of_function_variant"		2023-01-09 21:52:06 UTC				FALSE
BRAF Mutation	395	Colorectal Cancer	9256		Irinotecan		Predictive	Supports	B	Resistance	"This was a retrospective clinical study of 44 metastatic colorectal cancer patients who received FOLFIRI (5-Fluorouacil + Folinic acid + irinotecan) first-line therapy alone or with bevacizumab. It assessed the relationship between BRAF mutation status in primary tumors and response to irinotecan-based first line therapy, as measured by PFS. Of the 44 patients, 39 had wildtype BRAF and 5 had mutations in BRAFincluding V600E and D594K. The study found that patients harboring a BRAF mutation were significantly more resistant to irinotecan-based first-line therapy than patients with wildtype BRAF (Median PFS: 3.5 and 12.8 months, respectively; p = .006)."	19603024	PubMed		"Souglakos et al., 2009, Br. J. Cancer"		3	accepted	6304	Somatic	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/6304	https://civicdb.org/links/molecular_profiles/395	FALSE	BRAF	673	Mutation		chr7	140753336	140781603			ENST00000288602.6	75		"gene_variant,gain_of_function_variant"		2023-01-09 21:52:06 UTC				FALSE
BRAF Mutation	395	Colorectal Cancer	9256		Bevacizumab		Predictive	Supports	B	Resistance	"This was a retrospective clinical study of 97 metastatic colorectal cancer patients who received bevacizumab in conjunction with first-line chemotherapy (composed of 5-fluorouracil (5-FU) only, 5-FU + oxaliplatin, 5-FU + irinotecan, or 5-FU + oxaliplatin + irinotecan). It assessed the relationship between BRAF mutation status in primary tumors and response to bevacizumab-containing first line chemotherapy, as measured by PFS. Of the 97 patients,89 had wildtype BRAF and 8 had mutations in BRAFincluding V600E and D594K. The study found that patients harboring a BRAF mutation were significantly more resistant to bevacizumab-containing first-line chemotherapy than patients with wildtype BRAF (Median PFS: 4.2 and 12.5 months, respectively; p < .0001)."	19603024	PubMed		"Souglakos et al., 2009, Br. J. Cancer"		3	accepted	6305	Somatic	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/6305	https://civicdb.org/links/molecular_profiles/395	FALSE	BRAF	673	Mutation		chr7	140753336	140781603			ENST00000288602.6	75		"gene_variant,gain_of_function_variant"		2023-01-09 21:52:06 UTC				FALSE
BRAF Mutation	395	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	B	Resistance	"This was a retrospective clinical study of 92 metastatic colorectal cancer patients who received cetuximab in conjunction with salvage chemotherapy (refractory to at least one line of treatment). Salvage chemotherapy was composed of 5-fluorouracil (5-FU) only, 5-FU + oxaliplatin, 5-FU + irinotecan, or 5-FU + oxaliplatin + irinotecan. The study assessed the relationship between BRAF mutation status in primary tumors and response to cetuximab-containing salvage chemotherapy, as measured by PFS. Of the 92 patients, 83 had wildtype BRAF and 9 had mutations in BRAFincluding V600E and D594K. The study found that patients harboring a BRAF mutation were significantly more resistant to cetuximab-containing salvage chemotherapy than patients with wildtype BRAF (Median PFS: 2.0 and 3.9, respectively; p = .0005)."	19603024	PubMed		"Souglakos et al., 2009, Br. J. Cancer"		3	accepted	6306	Somatic	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/6306	https://civicdb.org/links/molecular_profiles/395	FALSE	BRAF	673	Mutation		chr7	140753336	140781603			ENST00000288602.6	75		"gene_variant,gain_of_function_variant"		2023-01-09 21:52:06 UTC				FALSE
BRAF Mutation	395	Colorectal Cancer	9256				Prognostic	Supports	B	Poor Outcome	"This was a retrospective clinical study of 168 metastatic colorectal cancer patients who received first line chemotherapy (made up of 5-fluorouracil (5-FU) only, 5-FU + oxaliplatin, 5-FU + irinotecan, or 5-FU + oxaliplatin + irinotecan) alone or with monoclonal antibodies (bevacizumab or cetuximab). It assessed the relationship between BRAF mutation status in primary tumors and post treatment OS. Of 168 patients, 155 had wildtype BRAF and 13 had mutations in BRAFincluding V600E and D594K. The study found that patients harboring a BRAF mutation had a significantly worse outcome than patients expressing wildtype BRAF, regardless of first line chemotherapy regimen or use of monoclonal antibody treatment (Median OS: 10.9 and 40.5 months, respectively; p <.0001)."	19603024	PubMed		"Souglakos et al., 2009, Br. J. Cancer"		3	accepted	6307	Somatic	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/6307	https://civicdb.org/links/molecular_profiles/395	FALSE	BRAF	673	Mutation		chr7	140753336	140781603			ENST00000288602.6	75		"gene_variant,gain_of_function_variant"		2023-01-09 21:52:06 UTC				FALSE
ABL1 BCR::ABL L248V	996	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	B	Resistance	"This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Out of 15 patients with L248V mutations, 6, 10, and 15 achieved CCyR, MCyR, and CHR with dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations."	19779040	PubMed		"Mller et al., 2009, Blood"	"NCT00101660,NCT00103844,NCT00123474"	3	accepted	6308	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/6308	https://civicdb.org/links/molecular_profiles/996	FALSE	ABL1	25	BCR::ABL L248V		chr9	130862955	130862955	C	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.742C>G,NP_005148.2:p.Leu248Val,NC_000009.11:g.133738342C>G,ENST00000318560.5:c.742C>G"	2023-01-27 17:07:42 UTC	CA16602546	376085	"RS121913455,L267V,LEU248VAL,BCR-ABL L248V"	FALSE
ABL1 BCR::ABL E459K	2243	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	B	Resistance	"This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Out of 12 patients with the E459K mutations, 4, 6, and 11 achieved CCyR, MCyR, and CHR with dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations."	19779040	PubMed		"Mller et al., 2009, Blood"	"NCT00101660,NCT00103844,NCT00123474"	3	accepted	6310	Somatic	2023-01-09 21:46:58 UTC	https://civicdb.org/links/evidence_items/6310	https://civicdb.org/links/molecular_profiles/2243	FALSE	ABL1	25	BCR::ABL E459K		chr9	130878519	130878519	G	A	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"ENST00000318560.5:c.1375G>A,NC_000009.11:g.133753906G>A,NM_005157.5:c.1375G>A,NP_005148.2:p.Glu459Lys"	2023-01-27 17:16:31 UTC	CA200648598	NONE FOUND	"BCR-ABL GLU459LYS,RS1064156,BCR-ABL1 E459K,BCR-ABL1 GLU459LYS,BCR-ABL E459K"	FALSE
KRAS G13V	1425	Colorectal Cancer	9256		"Cetuximab,Panitumumab"	Substitutes	Predictive	Supports	C	Resistance	"In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). KRAS PIK3CA and PTEN were tested for mutation; KRAS G13V was the only variant noted in the primary colon tumor of one patient who experienced disease progression (Patient 4; Supplemental Table 1) following treatment. In the larger cohort, patients with tumors harboring any KRAS mutation had significantly decreased incidence of objective response than patients with wtKRAS tumors. Authors noted that patients with tumors harboring KRAS mutations tended to have decreased PFS and OS compared to those with wild-type tumors though the differences were not statistically significant."	19223544	PubMed		"Sartore-Bianchi et al., 2009, Cancer Res."		2	accepted	6312	Somatic	2023-01-09 21:46:45 UTC	https://civicdb.org/links/evidence_items/6312	https://civicdb.org/links/molecular_profiles/1425	FALSE	KRAS	3845	G13V		chr12	25245346	25245347	GC	AA	ENST00000256078.4	75		missense_variant	"NC_000012.11:g.25398280_25398281delinsAA,ENST00000256078.4:c.38_39delinsTT,NM_004985.4:c.38_39delinsTT,NP_004976.2:p.Gly13Val"	2023-01-27 17:10:05 UTC	CA645572107	45124	"RS397517040,GLY13VAL"	FALSE
KRAS G12S	887	Colorectal Cancer	9256		"Cetuximab,Panitumumab"	Substitutes	Predictive	Supports	C	Resistance	"In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). KRAS PIK3CA and PTEN were tested for mutation; KRAS G12S was the only variant noted in the primary tumor of one patient who experienced disease progression following treatment (colon tumor of patient 20; Supplemental Table 1). In the larger cohort, patients with tumors harboring any KRAS mutation had significantly decreased incidence of objective response than patients with wtKRAS tumors. Authors noted that patients with tumors harboring KRAS mutations tended to have decreased PFS and OS compared to those with wild-type tumors though the differences were not statistically significant."	19223544	PubMed		"Sartore-Bianchi et al., 2009, Cancer Res."		2	accepted	6314	Somatic	2023-01-09 21:46:39 UTC	https://civicdb.org/links/evidence_items/6314	https://civicdb.org/links/molecular_profiles/887	FALSE	KRAS	3845	G12S		chr12	25245351	25245351	C	T	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.34G>A,NP_004976.2:p.Gly12Ser,NC_000012.11:g.25398285C>T,ENST00000256078.4:c.34G>A"	2023-01-27 17:06:39 UTC	CA135565	12584	"RS121913530,GLY12SER"	FALSE
PTEN Loss	214	Colorectal Cancer	9256		"Cetuximab,Panitumumab"	Substitutes	Predictive	Supports	B	Resistance	"In this study, 81 metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). Multivariate analysis demonstrated a significant association between PTEN protein expression loss and lack of response to panitumumab or cetuximab (P = 0.0012). Patients with PTEN non-expressing tumors (32/80) had shorter overall survival, compared to those with PTEN expressing tumors (P = 0.0048), though they had a nonsignificant difference in progression free survival (p = .0681).  PIK3CA, PTEN, and KRAS were evaluated for mutations; PTEN loss was the only variant noted in 17 of the patients who experienced either stable disease or disease progression, while the other patients experienced PTEN loss in combination with a KRAS or PIK3CA mutation."	19223544	PubMed		"Sartore-Bianchi et al., 2009, Cancer Res."		3	accepted	6315	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/6315	https://civicdb.org/links/molecular_profiles/214	FALSE	PTEN	5728	Loss		chr10	87863113	87971930			ENST00000371953.3	75		loss_of_function_variant	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
KRAS G12D	79	Colorectal Cancer	9256		"Panitumumab,Cetuximab"	Substitutes	Predictive	Supports	C	Resistance	"In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). KRAS, PIK3CA, and PTEN were tested for mutation; KRAS G12D was the only variant noted in the primary tumor of two patients who experienced stable disease  following treatment (Patients 22 and 36; colon and rectum tumors; Supplemental Table 1). In the larger cohort, patients with tumors harboring any KRAS mutation had significantly decreased incidence of objective response than patients with wtKRAS tumors. Authors noted that patients with tumors harboring KRAS mutations tended to have decreased PFS and OS compared to those with wild-type tumors though the differences were not statistically significant."	19223544	PubMed		"Sartore-Bianchi et al., 2009, Cancer Res."		2	accepted	6316	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/6316	https://civicdb.org/links/molecular_profiles/79	FALSE	KRAS	3845	G12D	EGFR TKI Resistance	chr12	25245350	25245350	C	T	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.35G>A,NP_004976.2:p.Gly12Asp,NC_000012.11:g.25398284C>T,ENST00000256078.4:c.35G>A"	2023-01-27 17:02:26 UTC	CA122538	12582	"GLY12ASP,RS121913529"	FALSE
KRAS Amplification	588	Melanoma	1909		Vemurafenib		Predictive	Supports	D	Resistance	In vitro studies of M229 (a human melanoma cell line) endogenously expressing wildtype KRAS and BRAF V600E (a known BRAF sensitizing mutation) found that cells induced to stably over-express wildtype KRAS4a or KRAS4b (via viral transduction with additional copies of KRAS4a or KRAS4b) were more resistant to vemurafenib (a BRAFi) than cells transduced with empty vectors. Resistance was determined by assessing cell survival.	24265155	PubMed		"Shi et al., 2014, Cancer Discov"		2	accepted	6317	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/6317	https://civicdb.org/links/molecular_profiles/588	FALSE	KRAS	3845	Amplification		chr12	25209431	25250803			ENST00000256078.4	75		transcript_amplification	N/A	2023-01-09 21:52:08 UTC		N/A		FALSE
KRAS G12A	148	Colorectal Cancer	9256		"Panitumumab,Cetuximab"	Substitutes	Predictive	Supports	C	Resistance	"In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). KRAS, PIK3CA, and PTEN were tested for mutation; KRAS G12A was the only variant noted in the both the primary and metastatic colon tumors of one patient (Patient 29; Supplemental table 1) , and the primary colon tumor of another patient (104; Table S1),  who both experienced stable disease following treatment. In the larger cohort, patients with tumors harboring any KRAS mutation had significantly decreased incidence of objective response than patients with wtKRAS tumors. Authors noted that patients with tumors harboring KRAS mutations tended to have decreased PFS and OS compared to those with wild-type tumors though the differences were not statistically significant."	19223544	PubMed		"Sartore-Bianchi et al., 2009, Cancer Res."		2	accepted	6319	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/6319	https://civicdb.org/links/molecular_profiles/148	FALSE	KRAS	3845	G12A	EGFR TKI Resistance	chr12	25245350	25245350	C	G	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.35G>C,NP_004976.2:p.Gly12Ala,NC_000012.11:g.25398284C>G,ENST00000256078.4:c.35G>C"	2023-01-27 17:02:57 UTC	CA135567	45122	"GLY12ALA,RS121913529"	FALSE
KRAS G13D	81	Colorectal Cancer	9256		"Cetuximab,Panitumumab"	Substitutes	Predictive	Does Not Support	C	Resistance	"In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). KRAS, PIK3CA, and PTEN were tested for mutation; KRAS G13D was the only variant noted in the primary colon tumors of two patients who experienced partial response following treatment (Patients 37, 47; Supplemental Table 1). In the larger cohort, patients with tumors harboring any KRAS mutation had significantly decreased incidence of objective response than patients with wtKRAS tumors. Authors noted that patients with tumors harboring KRAS mutations tended to have decreased PFS and OS compared to those with wild-type tumors though the differences were not statistically significant."	19223544	PubMed		"Sartore-Bianchi et al., 2009, Cancer Res."		2	accepted	6320	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/6320	https://civicdb.org/links/molecular_profiles/81	FALSE	KRAS	3845	G13D		chr12	25245347	25245347	C	T	ENST00000256078.4	75		missense_variant	"NM_033360.3:c.38G>A,NP_004976.2:p.Gly13Asp,NC_000012.11:g.25398281C>T,ENST00000256078.4:c.38G>A"	2023-01-27 17:02:27 UTC	CA122534	12580	"GLY13ASP,RS112445441"	FALSE
KRAS G13D	81	Colorectal Cancer	9256		"Panitumumab,Cetuximab"	Substitutes	Predictive	Supports	C	Resistance	"In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). KRAS G13D was the only variant noted in the primary rectal tumor of one patient who experienced disease progression following treatment (Patient 45; Supplemental Table 1). This is response is consistent with observations made of the larger cohort, where patients with tumors harboring any KRAS mutation had significantly decreased incidence of objective response than patients with wtKRAS tumors. Authors noted that patients with tumors harboring KRAS mutations tended to have decreased PFS and OS compared to those with wild-type tumors though the differences were not statistically significant. However, two other patients (37 and 47; Table S1) had G13D as their only noted variant, but experienced partial response."	19223544	PubMed		"Sartore-Bianchi et al., 2009, Cancer Res."		2	accepted	6322	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/6322	https://civicdb.org/links/molecular_profiles/81	FALSE	KRAS	3845	G13D		chr12	25245347	25245347	C	T	ENST00000256078.4	75		missense_variant	"NM_033360.3:c.38G>A,NP_004976.2:p.Gly13Asp,NC_000012.11:g.25398281C>T,ENST00000256078.4:c.38G>A"	2023-01-27 17:02:27 UTC	CA122534	12580	"GLY13ASP,RS112445441"	FALSE
KRAS G12V	421	Colorectal Cancer	9256		"Panitumumab,Cetuximab"	Substitutes	Predictive	Supports	C	Resistance	"In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). KRAS, PIK3CA, and PTEN were tested for mutation; KRAS G12V was the only variant noted in the primary rectal tumor of one patient who experienced disease progression (patient 56; Supplemental Table 1), and the primary colon tumors of two patients (9, 13; Supplemental Table 1) who experienced stable disease following treatment. In the larger cohort, patients with tumors harboring any KRAS mutation had significantly decreased incidence of objective response than patients with wtKRAS tumors. Authors noted that patients with tumors harboring KRAS mutations tended to have decreased PFS and OS compared to those with wild-type tumors though the differences were not statistically significant."	19223544	PubMed		"Sartore-Bianchi et al., 2009, Cancer Res."		2	accepted	6323	Somatic	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/6323	https://civicdb.org/links/molecular_profiles/421	FALSE	KRAS	3845	G12V		chr12	25245350	25245350	C	A	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.35G>T,NP_004976.2:p.Gly12Val,NC_000012.11:g.25398284C>A,ENST00000256078.4:c.35G>T"	2023-01-27 17:03:41 UTC	CA122540	12583	"GLY12VAL,RS121913529"	FALSE
BRCA1 Mutation	185	Ovarian Cancer	2394		Rucaparib		Predictive	Supports	B	Sensitivity/Response	"A phase 2 trial on patients with relapsed, platinum-sensitive high grade ovarian, fallopian tube or primary peritoneal carcinoma (ARIEL2 Part1, NCT01891344) was held to assess PARP inhibitor rucaparib on 3 genetically defined subsets of patients. Out of 40 BRCA (BRCA1 or BRCA2) mutant patients, 14 had germline BRCA1 mutation, 13 of which were homozygous mutation and one with unknown zygosity. Confirmed objective response was seen in 86% (12/14) of the germline BRCA1 mutant subgroup. Authors note that response rate was similar regardless of whether the BRCA mutation was somatic or germline, in BRCA 1 or BRCA 2. In a BRCA wild-type subgroup, with low levels of loss of heterozygosity (LOH), confirmed objective response was observed in 10% (7/70) of the patients. Patients with BRCA mutant tumors experienced significantly longer median progression free survival than patients with BRCA wildtype, LOH low tumors (12.8 vs 5.2 mo, HR: 0.27, P<0.0001)."	27908594	PubMed		"Swisher et al., 2017, Lancet Oncol."	NCT01891344	3	accepted	6341	Rare Germline	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/6341	https://civicdb.org/links/molecular_profiles/185	FALSE	BRCA1	672	Mutation		chr17	43045629	43125483			ENST00000471181.2	75		"gene_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
BRCA2 Mutation	186	Ovarian Cancer	2394		Rucaparib		Predictive	Supports	B	Sensitivity/Response	"A phase 2 trial on patients with relapsed, platinum-sensitive high grade ovarian, fallopian tube or primary peritoneal carcinoma (ARIEL2 Part1, NCT01891344) was held to assess PARP inhibitor rucaparib on 3 genetically defined subsets of patients. Out of 40 BRCA (BRCA1 or BRCA2) mutant patients, 6 had germline homozygous BRCA2 mutation. Confirmed objective response was seen in 83% (5/6) of the germline BRCA2 mutant subgroup. Authors note that response rate was similar regardless of whether the BRCA mutation was somatic or germline, in BRCA 1 or BRCA 2. In a BRCA wild-type subgroup, with low levels of loss of heterozygosity (LOH), confirmed objective response was observed in 10% (7/70) of the patients. Patients with BRCA mutant tumors experienced significantly longer median progression free survival than patients with BRCA wildtype, LOH low tumors (12.8 vs 5.2 mo, HR: 0.27, P<0.0001)."	27908594	PubMed		"Swisher et al., 2017, Lancet Oncol."	NCT01891344	3	accepted	6343	Rare Germline	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/6343	https://civicdb.org/links/molecular_profiles/186	FALSE	BRCA2	675	Mutation		chr13	32315474	32399210			ENST00000380152.3	75		"gene_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
VHL S65W (c.194C>G)	1663	Von Hippel-Lindau Disease	14175	"Retinal capillary hemangioma,Pancreatic cysts,Hemangioblastoma"			Predisposing	Supports	C	Uncertain Significance	"37 Danish patients diagnosed with VHL before 18 years from a prospective cohort study from Denmark's National vHL Research Database (Binderup et al., 2013) were assessed. Two families  (Family ID 9 and 13) were found with a germline missense mutation in the VHL gene (S65W; c.194C>G). Family ID9 had 3 patients: Patient 1 and 2 were both diagnosed at 0Y and had no manifestations by the end of the study at 5Y and 10Y respectively. Patient 3 was diagnosed at 16Y and developed 2 CNS hemangioblastomas at 16Y and 2 pancreatic cysts at 16Y. Family ID13 had 1 patient who was diagnosed at age 13Y and had 8 retinal hemangioblastomas at 13Y, 16Y, 17Y, and 18Y, 1 pancreatic cyst at 17Y, and 1 CNS hemangioblastoma at 17Y.  ACMG codes: PM1, PM5, PS3; and PP5."	28650583	PubMed		"Launbjerg et al., 2017, Am. J. Med. Genet. A"		3	accepted	6352	Rare Germline	2023-01-09 21:46:49 UTC	https://civicdb.org/links/evidence_items/6352	https://civicdb.org/links/molecular_profiles/1663	FALSE	VHL	7428	S65W (c.194C>G)		chr3	10142041	10142041	C	G	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.194C>G,NM_000551.3:c.194C>G,NP_000542.1:p.Ser65Trp,NC_000003.11:g.10183725C>G"	2023-01-27 17:12:02 UTC	CA020099	43597	"C.194C>G,SER65TRP,RS5030826"	FALSE
PIK3CA Mutation	307	Colorectal Cancer	9256		"Cetuximab,Panitumumab"	Substitutes	Predictive	Supports	B	Resistance	"Mutational analysis of 110 metastatic colorectal cancer patients was used to examine objective tumor response, progression free survival (PFS), and overall survival (OS) following treatment with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). In univariate analysis, PIK3CA mutations (H1047R or E545K) were significantly associated with lack of response to panitumumab or cetuximab (objective response rate: 0/15 vs 22/95 for patients harboring PIK3CA mutated or wildtype tumors, respectively; P = 0.038). Multivariate logistic regression of KRAS mutations, PIK3CA mutations and PTEN protein expression also confirmed an independent effect of PIK3CA mutation on objective response (P = 0.0337; OR = 0.1153; CI for OR: 0.000?.865). Patients with tumors harboring either PIK3CA H1047R or E545K mutations (15/109) had decreased PFS, compared to those with wild-type tumors (P = 0.0035), though they had a nonsignificant difference in OS. Authors note a trend in decreasing OS in patients with PIK3CA mutated tumors."	19223544	PubMed		"Sartore-Bianchi et al., 2009, Cancer Res."		3	accepted	6362	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/6362	https://civicdb.org/links/molecular_profiles/307	FALSE	PIK3CA	5290	Mutation		chr3	179148523	179240093			ENST00000263967.3	75		"transcript_variant,gain_of_function_variant"		2023-01-09 21:52:06 UTC		N/A		FALSE
KRAS G12/G13	77	Colorectal Cancer	9256		"Cetuximab,Panitumumab"	Substitutes	Predictive	Supports	B	Resistance	"Mutational analysis of 109 metastatic colorectal cancer patients was used to examine objective tumor response, progression free survival (PFS), and overall survival (OS) following treatment with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). In univariate analysis, KRAS mutations (G12V, G12S, G12D, G12A, G13V, G13D) were significantly associated with lack of response to panitumumab or cetuximab (objective response rate: 2/32 vs 20/77 for patients harboring KRAS mutated or wildtype tumors, respectively; P = 0.019). Multivariate logistic regression of KRAS mutations, PIK3CA mutations and PTEN protein expression also confirmed an independent effect of KRAS mutations on objective response (p = 0.0029). Authors noted that patients with tumors harboring KRAS mutations (32/108) tended to have decreased PFS and OS compared to those with wild-type tumors though the differences were not statistically significant."	19223544	PubMed		"Sartore-Bianchi et al., 2009, Cancer Res."		3	accepted	6363	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/6363	https://civicdb.org/links/molecular_profiles/77	FALSE	KRAS	3845	G12/G13		chr12	25245346	25245351			ENST00000256078.4	75		protein_altering_variant		2023-01-09 21:52:04 UTC		"45,122,125,781,258,200,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000"		FALSE
PIK3CA Mutation	307	Colorectal Cancer	9256		Aspirin		Predictive	Supports	B	Sensitivity/Response	"This was a retrospective study of 964 colorectal cancer patients who participated in the Nurses' Health Study and the Health Professionals Follow-up Study. Of 964 patients, 803 patients had wildtype PIK3CA (aspirin use: 337/803, no aspirin use: 466/803)  and 161 had mutated PIK3CA (aspirin use: 66/161, no aspirin use: 95/161). This study found thatamong patients with mutated PIK3CA cancer?regular use of aspirin following diagnosis was correlated with superior colorectal cancer specific survival (multivariate hazard ratio, 0.18; 95% CI, 0.06-0.61; P<0.001) and overall survival (multivariate hazard ratio, 0.54; 95% CI, 0.31-0.94; P = 0.01). Conversely, among patients with wild-type PIK3CA, regular use of aspirin after diagnosis was not significantly associated with colorectal cancerspecific survival or overall survival. Among patients with mutated-PIK3CA tumors, 23 of 90 patients who did not use aspirin after diagnosis (26%) died within 5 years after diagnosis, whereas only 2 of 62 regular users of aspirin after diagnosis (3%) died within 5 years after diagnosis (P<0.001). In contrast, among patients with wild-type PIK3CA tumors, the 5-year cumulative colorectal cancerspecific mortality was the same (15%) for users and nonusers of aspirin after diagnosis (P = 0.92). The authors conclude that PIK3CA mutation may predict response to aspirin therapy in patients with newly diagnosed colorectal cancer."	23094721	PubMed		"Liao et al., 2012, N. Engl. J. Med."		3	accepted	6375	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/6375	https://civicdb.org/links/molecular_profiles/307	FALSE	PIK3CA	5290	Mutation		chr3	179148523	179240093			ENST00000263967.3	75		"transcript_variant,gain_of_function_variant"		2023-01-09 21:52:06 UTC		N/A		FALSE
ABL1 R351W	1564	Lung Non-small Cell Carcinoma	3908		Imatinib		Predictive	Supports	D	Sensitivity/Response	"In this in vitro study, the H1915 non-small cell lung cancer cell line (homozygous for a R351W mutation) was shown to be susceptible to imatinib. This line showed a significant reduction in colony formation (P = 0.0004) and MTT assay, which tests for NADH activity (P < 0.001), with imatinib vs vehicle treatment. There was no significant difference in a lung cancer cell line without a known driver (H2126) nor in an immortalized bronchial epithelial line (Beas-2B) with either drug treatment in colony forming and MTT assays. Additionally, reduction in cell viability upon kinase inhibitor treatment was rescued with tetracycline-induced overexpression of resistant ABL1-T315I (P < 0.001) confirming the genetic dependency of this cell line on ABL1. Moreover, siRNA facilitated depletion of ABL1 expression resulted in significantly increased cytotoxicity (P < 0.004) with no significant change in H2126 or Beas-2B lines for 2/3 siRNAs supporting ABL1 as the primary drug target. Significant tumor reduction was observed in murine NSCLC xenografts of the H1915 cell line treated with imatinib compared to vehicle treatment (P = 0.0016). No change in tumor growth was observed in xenografts of the H650 cell line containing a wildtype ABL1 locus. In both in vitro and in vivo experiments, doxycycline-inducible expression of drug-resistant ABL1-T315I rescued imatinib-mediated inhibitory effects supporting the specificity of drug responses."	26758680	PubMed		"Testoni et al., 2016, EMBO Mol Med"		5	accepted	6376	Somatic	2023-01-09 21:46:47 UTC	https://civicdb.org/links/evidence_items/6376	https://civicdb.org/links/molecular_profiles/1564	FALSE	ABL1	25	R351W		chr9	130872946	130872946	C	T	ENST00000372348.2	75		missense_variant	"ENST00000372348.2:c.1051C>T,NC_000009.11:g.133748333C>T,NM_007313.2:c.1051C>T,NP_009297.2:p.Arg351Trp"	2023-01-27 17:11:10 UTC	CA5285359	NONE FOUND	"R332W,ARG351TRP,RS779478267"	FALSE
KIT Exon 11 Mutation	66	Gastrointestinal Stromal Tumor	9253		Regorafenib		Predictive	Supports	B	Sensitivity/Response	"This phase II clinical trial of regorafenib (NCT01068769) examined the long term safety and efficacy of regorafenib in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GISTs) who failed previous treatments with imatinib. Patients whose GISTs harbored KIT exon 11 mutations (n=19) experienced higher rates of clinical benefit (defined as complete response, partial response, or stable disease lasting >16 weeks) than patients whose GISTs harbored KIT exon 9 mutations.  15/19 patients with exon 11 mutant GISTs experienced clinical benefit (including 2 PRs). KIT exon 11 mutant GISTs treated with regorafenib monotherapy were associated with improved median progression free survival (13.4 months vs. 5.7 and 1.6 months, P<0.0001), as compared to patients with KIT exon 9 mutation (n=2) and patients with KIT wildtype, non-succinate dehydrogenase-deficient tumors (n=2)."	27371698	PubMed		"Ben-Ami et al., 2016, Ann. Oncol."	NCT01068769	3	accepted	6377	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/6377	https://civicdb.org/links/molecular_profiles/66	FALSE	KIT	3815	Exon 11 Mutation	KIT Exon 11	chr4	54727416	54727542			ENST00000288135.5	75		coding_sequence_variant		2023-01-09 21:52:04 UTC				FALSE
CSF3R T618I	2260	Chronic Neutrophilic Leukemia	80187		Ruxolitinib		Predictive	Supports	D	Sensitivity/Response	Demonstrates that activating mutations in CSF3R are sufficient to drive a myeloproliferative disorder resembling aCML and CNL that is sensitive to pharmacologic JAK inhibition.	24081659	PubMed		"Fleischman et al., 2013, Blood"		4	accepted	6380	Somatic	2023-01-09 21:46:58 UTC	https://civicdb.org/links/evidence_items/6380	https://civicdb.org/links/molecular_profiles/2260	FALSE	CSF3R	1441	T618I		chr1	36467833	36467833	G	A	ENST00000373103.1	75		missense_variant	"NP_724781.1:p.Thr618Ile,NM_156039.3:c.1853C>T,ENST00000373103.1:c.1853G>A,NC_000001.10:g.36933434G>A,NC_000001.11:g.36467833G>A"	2023-01-27 17:16:32 UTC	CA204418	208339	THR618ILE	FALSE
CSF3R T618I	2260	Chronic Neutrophilic Leukemia	80187		Ruxolitinib		Predictive	Supports	C	Sensitivity/Response	"Case report of a patient treated with ruxolitinib, an FDA-approved JAK1/2 inhibitor, which resulted in dramatic improvement of his blood counts. He also had significant reduction of spleen volume and constitutional symptoms."	25180155	PubMed		"Dao et al., 2014, Leuk Res Rep"	NCT02092324	4	accepted	6381	Somatic	2023-01-09 21:46:58 UTC	https://civicdb.org/links/evidence_items/6381	https://civicdb.org/links/molecular_profiles/2260	FALSE	CSF3R	1441	T618I		chr1	36467833	36467833	G	A	ENST00000373103.1	75		missense_variant	"NP_724781.1:p.Thr618Ile,NM_156039.3:c.1853C>T,ENST00000373103.1:c.1853G>A,NC_000001.10:g.36933434G>A,NC_000001.11:g.36467833G>A"	2023-01-27 17:16:32 UTC	CA204418	208339	THR618ILE	FALSE
NTRK1 LMNA::NTRK1	1252	Lipofibromatosis-like Neural Tumor	80894				Diagnostic	Supports	C	Positive	"A 14-month-old boy presented with a slow-growing, asymptomatic back plaque, which was biopsied and found to have S100 positivity, sparse CD34 staining, and no significant mitotic activity, nuclear pleomorphism, or necrosis; genetic workup found LMNA-NTRK1 gene fusion, overall consistent with lipofibromatosis-like neural tumor (LPF-NT). LPF-NT is rare, with 14 cases previously reported, and this patient was the first report of this diagnosis in infancy. This case report and literature review includes comparison of similar diagnoses including lipofibromatosis, low-grade malignant peripheral nerve sheath tumor, infantile fibrosarcoma, and dermatofibrosarcoma protuberans and serves to aid detection of LPF-NT presenting in pediatric patients by highlighting similarities and differences that should prompt consideration. LPF-NT shows locally aggressive behavior only and should not be confused with conditions that have potential for distant spread. However, case reports of metastasizing LMNA-NTRK1 tumors draw into question whether growths with this gene fusion exist on a spectrum of disease severity. The patient was treated with wide local excision and has developed no complications or evidence of recurrence with 6 months of follow-up time."	29892662	PubMed		"Bartenstein et al., 2018, JAAD Case Rep"		4	accepted	6391	Somatic	2023-02-04 18:36:22 UTC	https://civicdb.org/links/evidence_items/6391	https://civicdb.org/links/molecular_profiles/1252	FALSE	NTRK1	4914	LMNA::NTRK1	NTRK1 Fusions	chr1	156114707	156138757			ENST00000368300.4	75	ENST00000524377.1	transcript_fusion		2023-01-09 21:52:12 UTC		N/A	LMNA-NTRK1	FALSE
NTRK1 LMNA::NTRK1	1252	Lipofibromatosis-like Neural Tumor	80894				Diagnostic	Supports	C	Positive	"A 14-month-old boy presented with a slow-growing, asymptomatic back plaque, which was biopsied and found to have S100 positivity, sparse CD34 staining, and no significant mitotic activity, nuclear pleomorphism, or necrosis; genetic workup found LMNA-NTRK1 gene fusion, overall consistent with lipofibromatosis-like neural tumor (LPF-NT). LPF-NT is rare, with 14 cases previously reported, and this patient was the first report of this diagnosis in infancy. This case report and literature review includes comparison of similar diagnoses including lipofibromatosis, low-grade malignant peripheral nerve sheath tumor, infantile fibrosarcoma, and dermatofibrosarcoma protuberans and serves to aid detection of LPF-NT presenting in pediatric patients by highlighting similarities and differences that should prompt consideration. LPF-NT shows locally aggressive behavior only and should not be confused with conditions that have potential for distant spread. However, case reports of metastasizing LMNA-NTRK1 tumors draw into question whether growths with this gene fusion exist on a spectrum of disease severity. The patient was treated with wide local excision and has developed no complications or evidence of recurrence with 6 months of follow-up time."	29892662	PubMed		"Bartenstein et al., 2018, JAAD Case Rep"		4	accepted	6391	Somatic	2023-02-04 18:36:22 UTC	https://civicdb.org/links/evidence_items/6391	https://civicdb.org/links/molecular_profiles/1252	FALSE	NTRK1	4914	LMNA::NTRK1	NTRK1 Fusions	chr1	156874571	156881642			ENST00000368300.4	75	ENST00000524377.1	transcript_fusion		2023-01-09 21:52:12 UTC		N/A	LMNA-NTRK1	FALSE
FGFR3 V555M	2273	Myeloid Neoplasm	70004		"FGFR Inhibitor AZD4547,PD173074,AZ12908010"	Substitutes	Predictive	Supports	D	Resistance	"Preclinical study of FGFR Inhibitors AZ12908010, PD173074 and AZD4547 in cancer cell lines. Cell lines with aberrant FGFR signalling were more sensitive to FGFR Inhibition. Sequencing of a myeloma cell line KMS-11R with acquired resistance to FGFR inhibition revealed a FGFR3 V555M Mutation. These cells were cross-resistant to AZD4547 and PD173074."	22869148	PubMed		"Chell et al., 2013, Oncogene"		2	accepted	6408	Somatic	2023-01-09 21:46:58 UTC	https://civicdb.org/links/evidence_items/6408	https://civicdb.org/links/molecular_profiles/2273	FALSE	FGFR3	2261	V555M		chr4	1805767	1805767	G	A	ENST00000440486.8			missense_variant	"NM_022965.4:c.1327G>A,NC_000004.11:g.1807494G>A,NM_000142.5:c.1663G>A ,NP_000133.1:p.Val555Met,ENST00000440486.8:c.1663G>A,ENSP00000414914.2:p.Val555Met "	2023-01-27 17:16:34 UTC	CA355981674		"VAL443MET,V443M,VAL555MET,ENSP00000414914.2:P.VAL555MET "	FALSE
FGFR3 FGFR3::TACC3	808	Transitional Cell Carcinoma	2671		Infigratinib		Predictive	Supports	C	Sensitivity/Response	"In this one-arm study, 67 patients with metastastic urothelial carcinoma and diverse FGFR3 alterations were treated with pan-FGFR Inhibitor BGJ398. The majority of patients (70.1%) had received two or more prior antineoplastic therapies. An overall response rate of 25.4% was observed and an additional 38.8% of patients had disease stabilization. No clear differences between type of FGFR3 aberration and response could be seen. Four of five patients with FGFR3-TACC3 fusions had response data, with three achieving stable disease and one having a complete response. The authors conclude that BGJ398 appears to have moderate anticancer activity in patients with metastatic urothelial carcinoma, that response rates and disease control rate exceed outcomes with most agents in this setting, and that enriching for patients with activating FGFR3 mutations together with the high specificity of BGJ398 for FGFR3 likely explains this improved response."	29848605	PubMed		"Pal et al., 2018, Cancer Discov"		3	accepted	6409	Somatic	2023-01-09 21:46:38 UTC	https://civicdb.org/links/evidence_items/6409	https://civicdb.org/links/molecular_profiles/808	FALSE	FGFR3	2261	FGFR3::TACC3		chr4	1793312	1806934			ENST00000340107.4	75	ENST00000313288.4	transcript_fusion		2023-01-09 21:52:09 UTC		495323	FGFR3-TACC3	FALSE
FGFR3 FGFR3::TACC3	808	Transitional Cell Carcinoma	2671		Infigratinib		Predictive	Supports	C	Sensitivity/Response	"In this one-arm study, 67 patients with metastastic urothelial carcinoma and diverse FGFR3 alterations were treated with pan-FGFR Inhibitor BGJ398. The majority of patients (70.1%) had received two or more prior antineoplastic therapies. An overall response rate of 25.4% was observed and an additional 38.8% of patients had disease stabilization. No clear differences between type of FGFR3 aberration and response could be seen. Four of five patients with FGFR3-TACC3 fusions had response data, with three achieving stable disease and one having a complete response. The authors conclude that BGJ398 appears to have moderate anticancer activity in patients with metastatic urothelial carcinoma, that response rates and disease control rate exceed outcomes with most agents in this setting, and that enriching for patients with activating FGFR3 mutations together with the high specificity of BGJ398 for FGFR3 likely explains this improved response."	29848605	PubMed		"Pal et al., 2018, Cancer Discov"		3	accepted	6409	Somatic	2023-01-09 21:46:38 UTC	https://civicdb.org/links/evidence_items/6409	https://civicdb.org/links/molecular_profiles/808	FALSE	FGFR3	2261	FGFR3::TACC3		chr4	1739702	1745171			ENST00000340107.4	75	ENST00000313288.4	transcript_fusion		2023-01-09 21:52:09 UTC		495323	FGFR3-TACC3	FALSE
VHL R167W (c.499C>T)	1623	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	Supports	C	Uncertain Significance	"Peripheral blood from unrelated patients with pheochromocytoma was tested for mutations of proto-oncogene RET, tumor suppressor gene VHL, succinate dehydrogenase subunit D (SDHD) gene, and the succinate dehydrogenase subunit B (SDHB) gene. Of 271 patients with nonsydromic pheochromocytoma and no family history of the disease, 30 mutations were found in VHL. Multiple pheochromocytomas were statistically more frequent among patients with mutations than among patients without mutations (21 of 66 vs. 5 of 205, P<0.001). This missense mutation was found in the VHL gene and six patients with pheochromocytoma."	12000816	PubMed		"Neumann et al., 2002, N. Engl. J. Med."		4	accepted	6416	Rare Germline	2023-01-09 21:46:48 UTC	https://civicdb.org/links/evidence_items/6416	https://civicdb.org/links/molecular_profiles/1623	FALSE	VHL	7428	R167W (c.499C>T)		chr3	10149822	10149822	C	T	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.499C>T,NP_000542.1:p.Arg167Trp,NC_000003.11:g.10191506C>T,ENST00000256474.2:c.499C>T"	2023-01-27 17:11:35 UTC	CA020450	2218	"C.499C>T,ARG167TRP,R126W,RS5030820"	FALSE
VHL A122I (c.364_365GC>AT)	1904	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	"Peripheral blood from unrelated patients with pheochromocytoma was tested for mutations of proto-oncogene RET, tumor suppressor gene VHL, succinate dehydrogenase subunit D (SDHD) gene, and the succinate dehydrogenase subunit B (SDHB) gene. Of 271 patients with nonsydromic pheochromocytoma and no family history of the disease, 30 mutations were found in VHL. Multiple pheochromocytomas were statistically more frequent among patients with mutations than among patients without mutations (21 of 66 vs. 5 of 205, P<0.001). This mutation was found in the VHL gene and one patient with pheochromocytoma."	12000816	PubMed		"Neumann et al., 2002, N. Engl. J. Med."		3	accepted	6417	Rare Germline	2023-01-09 21:46:54 UTC	https://civicdb.org/links/evidence_items/6417	https://civicdb.org/links/molecular_profiles/1904	FALSE	VHL	7428	A122I (c.364_365GC>AT)		chr3	10146537	10146538	GC	AT	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.364_365delinsAT,ENST00000256474.2:c.364_365delinsAT,NC_000003.11:g.10188221_10188222delinsAT,NC_000003.12:g.10146537_10146538delinsAT"	2023-01-27 17:14:25 UTC	CA658820874	NONE FOUND	"C.364_365GC>AT,ALA122ILE"	FALSE
IDH1 R132	58	Intrahepatic Cholangiocarcinoma	4928		Dasatinib		Predictive	Supports	D	Sensitivity/Response	"Through a high-throughput drug screen of a large panel of cancer cell lines, including 17 biliary tract cancers, this work found that IDH mutant (IDHm) ICC cells demonstrate a striking response to the multikinase inhibitor dasatinib,  identifying SRC as a critical dasatinib target in IDHm ICC. Dasatinib-treated IDHm xenografts exhibited pronounced apoptosis and tumor regression."	27231123	PubMed		"Saha et al., 2016, Cancer Discov"		4	accepted	6439	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/6439	https://civicdb.org/links/molecular_profiles/58	FALSE	IDH1	3417	R132		chr2	208248387	208248389			ENST00000415913.1	75		protein_altering_variant	"NC_000002.11:g.209113113G>A,NC_000002.11:g.209113112C>T,NC_000002.11:g.209113113G>C,NC_000002.11:g.209113112C>A,NC_000002.11:g.209113113G>T,NC_000002.11:g.209113112C>G"	2023-01-09 21:52:04 UTC		"156,444,375,891,375,000,000,000,000,000,000,000"	ARG132	FALSE
STK11 Mutation	696	Lung Adenocarcinoma	3910		"Pembrolizumab,Atezolizumab,Nivolumab"	Substitutes	Predictive	Supports	B	Resistance	"In a retrospective analysis in two separate datasets (Stand Up To Cancer 2 Cohort and Checkmate-057), patients with concomitant KRAS and STK11 mutations had significantly worse response rates, PFS and OS compares to KRAS only and KRAS-TP53 Mutant Patients. This work identifies STK11/LKB1 alterations as the most prevalent genomic driver of primary resistance to PD-1 axis inhibitors in KRAS-mutant lung adenocarcinoma. Genomic profiling may enhance the predictive utility of PD-L1 expression and tumor mutation burden and facilitate establishment of personalized combination immunotherapy approaches for genomically defined LUAC subsets."	29773717	PubMed		"Skoulidis et al., 2018, Cancer Discov"		4	accepted	6441	Somatic	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/6441	https://civicdb.org/links/molecular_profiles/696	FALSE	STK11	6794	Mutation		chr19	1205741	1223075			ENST00000326873.7	75		gene_variant		2023-01-09 21:52:08 UTC		N/A		FALSE
SDHB p.193_196dupSTSC (c.577_588dupAGCACCAGCTGC)	2284	Paraganglioma	50773				Predisposing	Supports	C	Uncertain Significance	"An in-frame duplication of 12 nucleotides resulting in the insertion of 4 amino acids within exon 6 of the SDHB gene was found in a single female case (a 13-year-old) with confirmed paraganglioma. The patient also exhibited refractory hypertension, sweating and headaches, and elevated norepinephrine concentrations in plasma and urine. The same mutation was in four other family members with no evidence of disease."	20193854	PubMed		"Musil et al., 2010, Cancer Genet. Cytogenet."		2	accepted	6442	Rare Germline	2023-01-09 21:46:58 UTC	https://civicdb.org/links/evidence_items/6442	https://civicdb.org/links/molecular_profiles/2284	FALSE	SDHB	6390	p.193_196dupSTSC (c.577_588dupAGCACCAGCTGC)		chr1	17024026	17024027		GCAGCTGGTGCT	ENST00000375499.3	75		inframe_insertion	"NM_003000.2:c.577_588dupAGCACCAGCTGC,NP_002991.2:p.193_196dupSTSC,NC_000001.10:g.17350522_17350533dup"	2023-01-27 17:16:40 UTC	CA658820851		C.589_600DUP	FALSE
H3-3A K28M	2289	"Diffuse Midline Glioma, H3 K27M-mutant"	80684				Diagnostic	Supports	B	Positive	"Wu et al analyzed 127 pediatric HGGs, including diffuse intrinsic pontine gliomas (DIPGs) and non-brainstem HGGs (NBS-HGGs) by whole genome, whole exome, and/or transcriptome sequencing. In addition to ACVR1, they identified 41 recurrent K27M mutations in H3F3A (H3.3, 41/112 = 36.6%), and in 14 HIST1H3B (H3.1, 14/112, 12.5%) in NBS-HGGs and DIPGs. The authors focus on ACVR1 mutations, as H3F3A and HIST1H3A mutations in pediatric gliomas have previously been reported. However, this evidence helps confirm potential diagnostic utility of H3F3A K27M mutations."	24705251	PubMed		"Wu et al., 2014, Nat. Genet."		3	accepted	6450	Somatic	2023-01-09 21:46:58 UTC	https://civicdb.org/links/evidence_items/6450	https://civicdb.org/links/molecular_profiles/2289	FALSE	H3-3A	3020	K28M		chr1	225876734	225876734	A	T	ENST00000366813.1	105		non_conservative_missense_variant	"ENST00000366813.1:c.83A>T,ENSP00000355778.1:p.Lys28Met"	2023-01-27 17:16:41 UTC	CA16602870	376435	K27M	FALSE
H3-3A K28M	2289	"Diffuse Midline Glioma, H3 K27M-mutant"	80684	Pediatric onset			Diagnostic	Supports	B	Positive	"Whole genome sequencing (WGS) was performed on the diffuse intrinsic pontine gliomas (DIPGs) and matched germline DNA of 7 pediatric patients. Targeted sequencing was performed on an additional 43 DIPGs and 36 non-brainstem pediatric glioblastomas (non-BS-PGs). Authors identified K27M mutations in 30/50 (60%) of pediatric DIPGs (including 4/7 WGS samples) and 7/36 (19%) pediatric non-brainstem glioblastomas. The authors comment that the K27M mutation appeared exclusive to pediatric high grade gliomas, with H3F3A p.K27M mutation in one of 9 pediatric anaplastic astrocytomas (Grade III), but no histone H3 mutations found in any other pediatric brain tumors including 7 low-grade brainstem gliomas, 15 low-grade non-brainstem gliomas, 38 medulloblastomas, and 22 ependymomas. H3 K27M was not found in an additional 170 non-central nervous system pediatric tumors."	22286216	PubMed		"Wu et al., 2012, Nat. Genet."		3	accepted	6453	Somatic	2023-01-09 21:46:58 UTC	https://civicdb.org/links/evidence_items/6453	https://civicdb.org/links/molecular_profiles/2289	FALSE	H3-3A	3020	K28M		chr1	225876734	225876734	A	T	ENST00000366813.1	105		non_conservative_missense_variant	"ENST00000366813.1:c.83A>T,ENSP00000355778.1:p.Lys28Met"	2023-01-27 17:16:41 UTC	CA16602870	376435	K27M	FALSE
VHL S65W (c.194C>G)	1663	Von Hippel-Lindau Disease	14175	"Epididymal cyst,Renal cell carcinoma,Retinal capillary hemangioma"			Predisposing	Supports	C	Uncertain Significance	"A 33 year old Asian male patient presented with advanced bilateral multicentric renal carcinoma. Genetic testing confirmed a de novo missense variant at c.194C>G of the VHL gene. The patient was diagnosed with an epididymal cyst at age 23, bilateral retinal angiomatosis at age 26, and bilateral clear cell renal cell carcinoma at age 33. ACMG codes:PM1; PM5; and PP4."	26622630	PubMed		"Zhang et al., 2015, Oncol Lett"		3	accepted	6468	Rare Germline	2023-01-09 21:46:49 UTC	https://civicdb.org/links/evidence_items/6468	https://civicdb.org/links/molecular_profiles/1663	FALSE	VHL	7428	S65W (c.194C>G)		chr3	10142041	10142041	C	G	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.194C>G,NM_000551.3:c.194C>G,NP_000542.1:p.Ser65Trp,NC_000003.11:g.10183725C>G"	2023-01-27 17:12:02 UTC	CA020099	43597	"C.194C>G,SER65TRP,RS5030826"	FALSE
NTRK3 ETV6::NTRK3	779	Congenital Fibrosarcoma	8418		Larotrectinib		Predictive	Supports	C	Sensitivity/Response	"Nagasubramanian et al reports on a case of refractory infantile fibrosarcoma (IFS) with constitutive activation of the tropomyosinrelated kinase (TRK) signaling pathway from an ETS variant gene 6neurotrophin 3 receptor gene (ETV6NTRK3) gene fusion. The patient was diagnosed with IFS at 6 months of age. At 16 months the patient enrolled in a pediatric Phase 1 trial of LOXO?01 (Larotrectinib, ARRY-470), an experimental, highly selective inhibitor of TRK. The patient experienced a rapid, radiographic response, demonstrating the potential for LOXO?01 to provide benefit for IFS harboring NTRK gene fusions."	27093299	PubMed		"Nagasubramanian et al., 2016, Pediatr Blood Cancer"		2	accepted	6473	Somatic	2023-01-09 21:46:38 UTC	https://civicdb.org/links/evidence_items/6473	https://civicdb.org/links/molecular_profiles/779	FALSE	NTRK3	4916	ETV6::NTRK3		chr12	11649854	11869969			ENST00000396373.4	75	ENST00000394480.2	transcript_fusion		2023-01-09 21:52:09 UTC		N/A	ETV6-NTRK3	FALSE
NTRK3 ETV6::NTRK3	779	Thyroid Gland Papillary Carcinoma	3969				Prognostic	Supports	B	Poor Outcome	"Prasad et al queried the histopathology of 28 Papillary Thyroid Carcinomas (PTCs) from patients ages 6-18 years (20 females, 8 males). None had significant exposure to radiation. 5 / 27 PTCs (18.5%) had NTRK3-ETV6 fusion oncogenes. The authors compare NTRK3-ETV6 (and include 2 other NTRK fusion samples) to PTCs with BRAF(V) (600E) and find they are associated with large size (mean, 2.2 cm vs 1.5 cm, respectively; P = .05), solid and diffuse variants (11 of 13 vs 0 of 13 tumors, respectively; P < .001), and lymphovascular invasion (12 of 13 vs 6 of 13 tumors, respectively; P = .02); The authors conclude that NTRK fusion oncogene PTC presents with more extensive disease and aggressive pathology than BRAF(V) (600E) PTC in the pediatric population."	26784937	PubMed		"Prasad et al., 2016, Cancer"		3	accepted	6474	Somatic	2023-01-09 21:46:38 UTC	https://civicdb.org/links/evidence_items/6474	https://civicdb.org/links/molecular_profiles/779	FALSE	NTRK3	4916	ETV6::NTRK3		chr12	11649854	11869969			ENST00000396373.4	75	ENST00000394480.2	transcript_fusion		2023-01-09 21:52:09 UTC		N/A	ETV6-NTRK3	FALSE
NTRK3 ETV6::NTRK3	779	Breast Secretory Carcinoma	4922		Larotrectinib	Substitutes	Predictive	Supports	C	Sensitivity/Response	"Shukla et al report on a remarkable case study of a 14 year old pediatric patient with refractory secretory breast carcinoma first presenting as a fibroadenoma at 8 yo. Over the next years, she experienced recurrence, multiple rounds of chemotherapy and metastasis -- until her case was presented at a virtual multidisciplinary tumor board organized by the Global Cancer Institute which recommended testing for ETV6-NTRK3 fusion. This fusion was confirmed by RNA-seq, targeted DNA and WGS sequencing as well as immunohistochemistry staining with a TRK antibody. The patient was treated with LOXO-101 (larotrectinib) in a single patient use protocol. Within two months, she experienced near complete resolution of a 10.4  8.5 cm fungating chest mass with multiple satellite lesions (See Figure 2). The authors note that TERT promoter mutation and a reciprocal inversion including CDKN2A were also identified, but given what is known about LOXO-101 and ETV6-NTRK3, they  infer ETV6-NTRK3 fusion as the primary mitogenic driver in this patient."	29623306	PubMed		"Shukla et al., 2017, JCO Precis Oncol"		3	accepted	6475	Somatic	2023-01-09 21:46:38 UTC	https://civicdb.org/links/evidence_items/6475	https://civicdb.org/links/molecular_profiles/779	FALSE	NTRK3	4916	ETV6::NTRK3		chr12	11649854	11869969			ENST00000396373.4	75	ENST00000394480.2	transcript_fusion		2023-01-09 21:52:09 UTC		N/A	ETV6-NTRK3	FALSE
VHL E70K (c.208G>A)	1832	Von Hippel-Lindau Disease	14175	Retinal capillary hemangioma			Predisposing	Supports	C	Uncertain Significance	Data was collected from 82 VHL mutation carriers in the Dutch VHL surveillance program. One patient age 20Y at the last follow-up had retinal hemangioblastoma and a germline c.208G>A (p.Glu70Lys) mutation in the VHL gene. Family history was not described.	24132471	PubMed		"Kruizinga et al., 2014, Endocr. Relat. Cancer"		2	accepted	6503	Rare Germline	2023-01-09 21:46:53 UTC	https://civicdb.org/links/evidence_items/6503	https://civicdb.org/links/molecular_profiles/1832	FALSE	VHL	7428	E70K (c.208G>A)		chr3	10142055	10142055	G	A	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.208G>A,NP_000542.1:p.Glu70Lys,NC_000003.11:g.10183739G>A,ENST00000256474.2:c.208G>A"	2023-01-27 17:13:46 UTC	CA020108	43598	"C.208G>A,GLU70LYS,RS5030802"	FALSE
VHL P81S (c.241C>T)	1713	Von Hippel-Lindau Disease	14175	"Cerebellar hemangioblastoma,Pancreatic endocrine tumor,Multiple renal cysts,Pheochromocytoma,Renal cell carcinoma,Retinal capillary hemangioma"			Predisposing	N/A	C	N/A	"Data was collected from 82 VHL mutation carriers in the Dutch VHL surveillance program. Two patients were found with this missense mutation in the VHL gene. One patient was 34Y and the other was 59Y at last follow-up. Their phenotypes were grouped together: retinal hemangioblastoma, cerebellar hemangioblastoma, spinal cord hemangioblastoma, renal cell carcinoma, pancreatic neuroendocrine tumour, pheochromocytoma, and renal cysts. Family history was not described."	24132471	PubMed		"Kruizinga et al., 2014, Endocr. Relat. Cancer"		3	accepted	6505	Rare Germline	2023-01-09 21:46:51 UTC	https://civicdb.org/links/evidence_items/6505	https://civicdb.org/links/molecular_profiles/1713	FALSE	VHL	7428	P81S (c.241C>T)		chr3	10142088	10142088	C	T	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.241C>T,NP_000542.1:p.Pro81Ser,NC_000003.11:g.10183772C>T,ENST00000256474.2:c.241C>T"	2023-01-27 17:12:39 UTC	CA020148	2233	"C.241C>T,PRO81SER,RS104893829"	FALSE
VHL V87fs (c.259_260insA)	2305	Von Hippel-Lindau Disease	14175	"Renal cell carcinoma,Cerebellar hemangioblastoma,Retinal capillary hemangioma,Spinal hemangioblastoma,Multiple renal cysts,Pancreatic cysts"			Predisposing	Supports	C	Uncertain Significance	"Data was collected from 82 VHL mutation carriers in the Dutch VHL surveillance program. One patient was found with this insertion in the VHL gene. The patient was 42Y at the last follow-up and presented with: retinal hemangioblastoma, cerebellar hemangioblastoma, spinal cord hemangioblastoma, renal cell carcinoma, renal cysts and pancreatic cysts. Family history was not described."	24132471	PubMed		"Kruizinga et al., 2014, Endocr. Relat. Cancer"		3	accepted	6506	Rare Germline	2023-01-09 21:46:59 UTC	https://civicdb.org/links/evidence_items/6506	https://civicdb.org/links/molecular_profiles/2305	FALSE	VHL	7428	V87fs (c.259_260insA)		chr3	10142106	10142107		A	ENST00000256474.2	75		"plus_1_frameshift_variant,frameshift_truncation"	"ENST00000256474.2:c.259_260insA,NC_000003.11:g.10183790_10183791insA,NM_000551.3:c.259_260insA,NP_000542.1:p.Val87AspfsTer?,NC_000003.12:g.10142106_10142107insA"	2023-01-27 17:16:46 UTC	CA913189242	NONE FOUND	"C.259_260INSA,VAL87FS,V87DFS*45"	FALSE
VHL G93S (c.277G>A)	1735	Von Hippel-Lindau Disease	14175	"Pancreatic cysts,Retinal capillary hemangioma,Spinal hemangioblastoma,Multiple renal cysts,Pheochromocytoma"			Predisposing	Supports	C	Uncertain Significance	"Data was collected from 82 VHL mutation carriers in the Dutch VHL surveillance program. Two patients were found with this missense mutation in the VHL gene. One patient was 35Y and the other was 60Y at last follow-up. Their phenotypes were grouped together: retinal hemangioblastoma, spinal cord hemangioblastoma, pheochromocytoma, renal cysts, and pancreatic cysts. Family history was not described."	24132471	PubMed		"Kruizinga et al., 2014, Endocr. Relat. Cancer"		3	accepted	6507	Rare Germline	2023-01-09 21:46:51 UTC	https://civicdb.org/links/evidence_items/6507	https://civicdb.org/links/molecular_profiles/1735	FALSE	VHL	7428	G93S (c.277G>A)		chr3	10142124	10142124	G	A	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.277G>A,NP_000542.1:p.Gly93Ser,NC_000003.11:g.10183808G>A,ENST00000256474.2:c.277G>A"	2023-01-27 17:12:54 UTC	CA020230	2237	"C.277G>A,GLY93SER,RS5030808"	FALSE
VHL Splice Site (c.340+1G>A)	1990	Von Hippel-Lindau Disease	14175	"Renal cell carcinoma,Multiple renal cysts,Cerebellar hemangioblastoma,Retinal capillary hemangioma,Pancreatic cysts,Spinal hemangioblastoma"			Predisposing	Supports	C	Uncertain Significance	"Data was collected from 82 VHL mutation carriers in the Dutch VHL surveillance program. One patient was found with this splice varaint in the VHL gene. The patient was 32Y at the last follow-up and presented with: retinal hemangioblastoma, cerebellar hemangioblastoma, spinal cord hemangioblastoma, renal cell carcinoma, renal cysts and pancreatic cysts. Family history was not described."	24132471	PubMed		"Kruizinga et al., 2014, Endocr. Relat. Cancer"		3	accepted	6509	Rare Germline	2023-01-09 21:46:55 UTC	https://civicdb.org/links/evidence_items/6509	https://civicdb.org/links/molecular_profiles/1990	FALSE	VHL	7428	Splice Site (c.340+1G>A)		chr3	10142188	10142188	G	A	ENST00000256474.2	75		splice_donor_variant	"NM_000551.3:c.340+1G>A,NC_000003.11:g.10183872G>A,ENST00000256474.2:c.340+1G>A"	2023-01-27 17:15:13 UTC	CA357042	223190	"C.340+1G>A,C.553+1G>A"	FALSE
VHL R120G (c.358A>G)	1790	Von Hippel-Lindau Disease	14175	Spinal hemangioblastoma			Predisposing	Supports	C	Uncertain Significance	Data was collected from 82 VHL mutation carriers in the Dutch VHL surveillance program. One patient was found with this missense varaint in the VHL gene. The patient was 15Y at the last follow-up and presented with: spinal cord hemangioblastoma. Family history was not described.	24132471	PubMed		"Kruizinga et al., 2014, Endocr. Relat. Cancer"		3	accepted	6511	Rare Germline	2023-01-09 21:46:52 UTC	https://civicdb.org/links/evidence_items/6511	https://civicdb.org/links/molecular_profiles/1790	FALSE	VHL	7428	R120G (c.358A>G)		chr3	10146531	10146531	A	G	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.358A>G,NP_000542.1:p.Arg120Gly,NC_000003.11:g.10188215A>G,ENST00000256474.2:c.358A>G"	2023-01-27 17:13:23 UTC	CA357028	223199	"C.358A>G,ARG120GLY,RS869025642"	FALSE
VHL F136S (c.407T>C)	1677	Von Hippel-Lindau Disease	14175	"Cerebellar hemangioblastoma,Pancreatic cysts,Renal cell carcinoma,Spinal hemangioblastoma,Multiple renal cysts"			Predisposing	Supports	C	Uncertain Significance	"Data was collected from 82 VHL mutation carriers in the Dutch VHL surveillance program. One patient was found with this missense varaint in the VHL gene. The patient was 41Y at the last follow-up and presented with: cerebellar hemangioblastoma, spinal cord hemangioblastoma, renal cell carcinoma, renal cysts and pancreatic cysts. Family history was not described."	24132471	PubMed		"Kruizinga et al., 2014, Endocr. Relat. Cancer"		3	accepted	6512	Rare Germline	2023-01-09 21:46:50 UTC	https://civicdb.org/links/evidence_items/6512	https://civicdb.org/links/molecular_profiles/1677	FALSE	VHL	7428	F136S (c.407T>C)		chr3	10146580	10146580	T	C	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.407T>C,NC_000003.11:g.10188264T>C,NM_000551.3:c.407T>C,NP_000542.1:p.Phe136Ser"	2023-01-27 17:12:13 UTC	CA040847	496064	"C.407T>C,PHE136SER,RS5030833"	FALSE
VHL P154= (c.462A>C)	1838	Von Hippel-Lindau Disease	14175	"Pheochromocytoma,Multiple renal cysts,Cerebellar hemangioblastoma"			Predisposing	Supports	C	Uncertain Significance	"Data was collected from 82 VHL mutation carriers in the Dutch VHL surveillance program. One patient was found with this missense varaint in the VHL gene. The patient was 71Y at the last follow-up and presented with:  cerebellar hemangioblastoma, pheochromocytoma, and renal cysts. Family history was not described."	24132471	PubMed		"Kruizinga et al., 2014, Endocr. Relat. Cancer"		3	accepted	6513	Rare Germline	2023-01-09 21:46:53 UTC	https://civicdb.org/links/evidence_items/6513	https://civicdb.org/links/molecular_profiles/1838	FALSE	VHL	7428	P154= (c.462A>C)		chr3	10146635	10146635	A	C	ENST00000256474.2	75		synonymous_variant	"ENST00000256474.2:c.462A>C,NC_000003.11:g.10188319A>C,NM_000551.3:c.462A>C,NP_000542.1:p.Pro154="	2023-01-27 17:13:48 UTC	CA16621934	NONE FOUND	"C.462A>C,PRO154PRO,P154P (C.462A>C)"	FALSE
VHL Splice Site (c.463+2T>C)	1951	Von Hippel-Lindau Disease	14175	"Retinal capillary hemangioma,Spinal hemangioblastoma,Multiple renal cysts,Renal cell carcinoma,Cerebellar hemangioblastoma"			Predisposing	Supports	C	Uncertain Significance	"Data was collected from 82 VHL mutation carriers in the Dutch VHL surveillance program. One patient was found with this splice varaint in the VHL gene. The patient was 31Y at the last follow-up and presented with: retinal hemangioblastoma, cerebellar hemangioblastoma, spinal cord hemangioblastoma, renal cell carcinoma, and renal cysts. Family history was not described."	24132471	PubMed		"Kruizinga et al., 2014, Endocr. Relat. Cancer"		3	accepted	6514	Rare Germline	2023-01-09 21:46:55 UTC	https://civicdb.org/links/evidence_items/6514	https://civicdb.org/links/molecular_profiles/1951	FALSE	VHL	7428	Splice Site (c.463+2T>C)		chr3	10146638	10146638	T	C	ENST00000256474.2	75		splice_donor_variant	"NM_000551.3:c.463+2T>C,NC_000003.11:g.10188322T>C,ENST00000256474.2:c.463+2T>C,NP_000542.1:p.?,NC_000003.12:g.10146638T>C"	2023-01-27 17:14:55 UTC	CA16621936	569414	"C.463+2T>C,RS5030814"	FALSE
VHL Y156C (c.467A>G)	1822	Von Hippel-Lindau Disease	14175	"Pheochromocytoma,Multiple renal cysts"			Predisposing	N/A	C	N/A	"Data was collected from 82 VHL mutation carriers in the Dutch VHL surveillance program. Seven patients were found with this missense varaint in the VHL gene. The ages of the patients was represented as a range 7-88 (mean 45). Phenotypes were grouped together: phenochromocytoma and renal cysts, although it is unclear if only one of the seven patients had renal cysts. Family history was not described."	24132471	PubMed		"Kruizinga et al., 2014, Endocr. Relat. Cancer"		3	accepted	6516	Rare Germline	2023-01-09 21:46:53 UTC	https://civicdb.org/links/evidence_items/6516	https://civicdb.org/links/molecular_profiles/1822	FALSE	VHL	7428	Y156C (c.467A>G)		chr3	10149790	10149790	A	G	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.467A>G,NP_000542.1:p.Tyr156Cys,NC_000003.11:g.10191474A>G,ENST00000256474.2:c.467A>G"	2023-01-27 17:13:44 UTC	CA020394	43600	"C.467A>G,TYR156CYS,RS397516441"	FALSE
VHL V166A (c.497T>C)	2310	Von Hippel-Lindau Disease	14175	"Pancreatic endocrine tumor,Pheochromocytoma"			Predisposing	Supports	C	Uncertain Significance	Data was collected from 82 VHL mutation carriers in the Dutch VHL surveillance program. One patient was found with this missense varaint in the VHL gene. The patient was 27Y at the last follow-up and presented with: pancreatic neuroendocrine tumour and pheochromocytoma. Family history was not described.	24132471	PubMed		"Kruizinga et al., 2014, Endocr. Relat. Cancer"		3	accepted	6518	Rare Germline	2023-01-09 21:46:59 UTC	https://civicdb.org/links/evidence_items/6518	https://civicdb.org/links/molecular_profiles/2310	FALSE	VHL	7428	V166A (c.497T>C)		chr3	10149820	10149820	T	C	ENST00000256474.2	75		missense_variant	"NC_000003.11:g.10191504T>C,NM_000551.3:c.497T>C,NP_000542.1:p.Val166Ala,ENST00000256474.2:c.497T>C"	2023-01-27 17:16:47 UTC	CA020442	43605	VAL166ALA	FALSE
VHL R167W (c.499C>T)	1623	Von Hippel-Lindau Disease	14175	"Retinal capillary hemangioma,Spinal hemangioblastoma,Multiple renal cysts,Pheochromocytoma,Renal cell carcinoma"			Predisposing	Supports	C	Uncertain Significance	"Data was collected from 82 VHL mutation carriers in the Dutch VHL surveillance program. One patient was found with this missense varaint in the VHL gene. The patient was 43Y at the last follow-up and presented with: retinal hemangioblastoma, spinal cord hemangioblastoma, renal cell carcinoma, pheochromocytoma, and renal cysts. Family history was not described."	24132471	PubMed		"Kruizinga et al., 2014, Endocr. Relat. Cancer"		3	accepted	6519	Rare Germline	2023-01-09 21:46:48 UTC	https://civicdb.org/links/evidence_items/6519	https://civicdb.org/links/molecular_profiles/1623	FALSE	VHL	7428	R167W (c.499C>T)		chr3	10149822	10149822	C	T	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.499C>T,NP_000542.1:p.Arg167Trp,NC_000003.11:g.10191506C>T,ENST00000256474.2:c.499C>T"	2023-01-27 17:11:35 UTC	CA020450	2218	"C.499C>T,ARG167TRP,R126W,RS5030820"	FALSE
VHL R167Q (c.500G>A)	1615	Von Hippel-Lindau Disease	14175	"Pheochromocytoma,Pancreatic cysts,Multiple renal cysts,Renal cell carcinoma,Cerebellar hemangioblastoma,Retinal capillary hemangioma,Spinal hemangioblastoma,Pancreatic endocrine tumor"			Predisposing	Supports	C	Uncertain Significance	"Data was collected from 82 VHL mutation carriers in the Dutch VHL surveillance program. Eleven patients were found with this missense varaint in the VHL gene. The ages of the patient was represented as a range, 21-65Y. The phenotypes were presented together: retinal hemangioblastoma, cerebellar hemangioblastoma, spinal cord hemangioblastoma, renal cell carcinoma, pancreatic neuroendocrine tumour, phenchromocytoma, renal cysts, and pancreatic cysts. Family history was not described."	24132471	PubMed		"Kruizinga et al., 2014, Endocr. Relat. Cancer"		3	accepted	6520	Rare Germline	2023-01-09 21:46:47 UTC	https://civicdb.org/links/evidence_items/6520	https://civicdb.org/links/molecular_profiles/1615	FALSE	VHL	7428	R167Q (c.500G>A)		chr3	10149823	10149823	G	A	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.500G>A,NP_000542.1:p.Arg167Gln,NC_000003.11:g.10191507G>A,ENST00000256474.2:c.500G>A"	2023-01-27 17:11:29 UTC	CA020454	2216	"C.500G>A,ARG167GLN,RS5030821"	FALSE
VHL V170D (c.509T>A)	1702	Von Hippel-Lindau Disease	14175	"Spinal hemangioblastoma,Pheochromocytoma,Pancreatic cysts,Pancreatic endocrine tumor,Retinal capillary hemangioma,Multiple renal cysts,Cerebellar hemangioblastoma,Renal cell carcinoma"			Predisposing	N/A	C	N/A	"Data was collected from 82 VHL mutation carriers in the Dutch VHL surveillance program. 15 patients were found with this missense varaint in the VHL gene. The ages of the patients were represented as a range, 16-71Y (mean 45). The phenotypes were presented together: retinal hemangioblastoma, cerebellar hemangioblastoma, spinal cord hemangioblastoma, renal cell carcinoma, pancreatic neuroendocrine tumour, phenchromocytoma, renal cysts, and pancreatic cysts. Family history was not described."	24132471	PubMed		"Kruizinga et al., 2014, Endocr. Relat. Cancer"		3	accepted	6522	Rare Germline	2023-01-09 21:46:50 UTC	https://civicdb.org/links/evidence_items/6522	https://civicdb.org/links/molecular_profiles/1702	FALSE	VHL	7428	V170D (c.509T>A)		chr3	10149832	10149832	T	A	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.509T>A,NC_000003.11:g.10191516T>A,NM_000551.3:c.509T>A,NP_000542.1:p.Val170Asp"	2023-01-27 17:12:32 UTC	CA351756195	625256	"C.509T>A,VAL170ASP"	FALSE
VHL E189fs (c.565del)	1745	Von Hippel-Lindau Disease	14175	"Cerebellar hemangioblastoma,Multiple renal cysts"			Predisposing	N/A	C	N/A	Data was collected from 82 VHL mutation carriers in the Dutch VHL surveillance program. One patient was found with this frameshift mutation in the VHL gene. The patient was 30Y at the last follow-up and presented with: cerebellar hemangioblastoma and renal cysts. Family history was not described.	24132471	PubMed		"Kruizinga et al., 2014, Endocr. Relat. Cancer"		3	accepted	6523	Rare Germline	2023-01-09 21:46:51 UTC	https://civicdb.org/links/evidence_items/6523	https://civicdb.org/links/molecular_profiles/1745	FALSE	VHL	7428	E189fs (c.565del)		chr3	10149888	10149888	G		ENST00000256474.2	75		"minus_1_frameshift_variant,frameshift_truncation"	"NC_000003.11:g.10191572del,NC_000003.12:g.10149888del,NM_000551.4:c.565del,NP_000542.1:p.Glu189fs"	2023-01-27 17:12:59 UTC	CA432423686	625267	"E189FS (C.565DELG),E189KFS*13 (C.565DEL),GLU189LYSFS*13"	FALSE
VHL F76del (c.224_226delTCT)	1964	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	Supports	C	Uncertain Significance	"Patients with ELSTs were identified and included in the International Endolymphatic Sac Tumor Registry. The registry contained 93 patients as of July 2014, and of those, 25 were sporadic, and 68 associated with VHL.  statistics of the VHL subgroup is as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. In the data from this study, only endolymphatic sac tumours can be confirmed as a phenotype for this mutation (p.Phe76del), which was found in 4 individuals from Germany or France."	25867206	PubMed		"Bausch et al., 2016, Head Neck"		2	accepted	6547	Rare Germline	2023-01-09 21:46:55 UTC	https://civicdb.org/links/evidence_items/6547	https://civicdb.org/links/molecular_profiles/1964	FALSE	VHL	7428	F76del (c.224_226delTCT)		chr3	10142071	10142073	TCT		ENST00000256474.2	75		inframe_deletion	"NP_000542.1:p.Phe76del,ENST00000256474.2:c.224_226delTCT,NC_000003.11:g.10183758_10183760del,NC_000003.12:g.10142074_10142076del,NM_000551.3:c.227_229del,ENSP00000256474.2:p.Phe76del"	2023-01-27 17:15:01 UTC	CA357012	223166	"PHE76DEL,C.224_226DELTCT,C.226_228DELTTC,C.227_229DELTCT,DELPHE76"	FALSE
VHL N78S (c.233A>G)	1631	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	Supports	C	Uncertain Significance	"Patients with ELSTs were identified and included in the International Endolymphatic Sac Tumor Registry. The registry contained 93 patients as of July 2014, and of those, 25 were sporadic, and 68 associated with VHL.  statistics of the VHL subgroup is as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. In the data from this study, only endolymphatic sac tumours can be confirmed as a phenotype for this mutation (p.Asn78Ser), which was found in 2 individuals, one from Germany and the other from Japan."	25867206	PubMed		"Bausch et al., 2016, Head Neck"		2	accepted	6548	Rare Germline	2023-01-09 21:46:48 UTC	https://civicdb.org/links/evidence_items/6548	https://civicdb.org/links/molecular_profiles/1631	FALSE	VHL	7428	N78S (c.233A>G)		chr3	10142080	10142080	A	G	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.233A>G,NP_000542.1:p.Asn78Ser,NC_000003.11:g.10183764A>G,ENST00000256474.2:c.233A>G"	2023-01-27 17:11:40 UTC	CA020131	93326	"C.233A>G,ASN78SER,RS5030804"	FALSE
VHL P86A (c.256C>G)	1635	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	Supports	C	Uncertain Significance	"Patients with ELSTs were identified and included in the International Endolymphatic Sac Tumor Registry. The registry contained 93 patients as of July 2014, and of those, 25 were sporadic, and 68 associated with VHL.  statistics of the VHL subgroup is as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. In the data from this study, only endolymphatic sac tumours can be confirmed as a phenotype for this mutation, which was found in 1 individual from Italy."	25867206	PubMed		"Bausch et al., 2016, Head Neck"		2	accepted	6550	Rare Germline	2023-01-09 21:46:49 UTC	https://civicdb.org/links/evidence_items/6550	https://civicdb.org/links/molecular_profiles/1635	FALSE	VHL	7428	P86A (c.256C>G)		chr3	10142103	10142103	C	G	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.256C>G,NP_000542.1:p.Pro86Ala,NC_000003.11:g.10183787C>G,ENST00000256474.2:c.256C>G"	2023-01-27 17:11:44 UTC	CA020174	93327	"C.256C>G,PRO86ALA,RS398123481"	FALSE
VHL P86S (c.256C>T)	1778	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	Supports	C	Uncertain Significance	"Patients with ELSTs were identified and included in the International Endolymphatic Sac Tumor Registry. The registry contained 93 patients as of July 2014, and of those, 25 were sporadic, and 68 associated with VHL.  statistics of the VHL subgroup is as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. In the data from this study, only endolymphatic sac tumours can be confirmed as a phenotype for this mutation, which was found in 1 individual from France."	25867206	PubMed		"Bausch et al., 2016, Head Neck"		2	accepted	6551	Rare Germline	2023-01-09 21:46:52 UTC	https://civicdb.org/links/evidence_items/6551	https://civicdb.org/links/molecular_profiles/1778	FALSE	VHL	7428	P86S (c.256C>T)		chr3	10142103	10142103	C	T	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.256C>T,NP_000542.1:p.Pro86Ser,NC_000003.11:g.10183787C>T,ENST00000256474.2:c.256C>T"	2023-01-27 17:13:14 UTC	CA020180	178692	"C.256C>T,PRO86SER,RS398123481"	FALSE
VHL L89P (c.266T>C)	1669	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	Supports	C	Uncertain Significance	"Patients with ELSTs were identified and included in the International Endolymphatic Sac Tumor Registry. The registry contained 93 patients as of July 2014, and of those, 25 were sporadic, and 68 associated with VHL.  statistics of the VHL subgroup is as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. In the data from this study, only endolymphatic sac tumours can be confirmed as a phenotype for this mutation, which was found in 1 individual from France."	25867206	PubMed		"Bausch et al., 2016, Head Neck"		2	accepted	6552	Rare Germline	2023-01-09 21:46:49 UTC	https://civicdb.org/links/evidence_items/6552	https://civicdb.org/links/molecular_profiles/1669	FALSE	VHL	7428	L89P (c.266T>C)		chr3	10142113	10142113	T	C	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.266T>C,NP_000542.1:p.Leu89Pro,NC_000003.11:g.10183797T>C,ENST00000256474.2:c.266T>C"	2023-01-27 17:12:07 UTC	CA020207	182979	"C.266T>C,LEU89PRO,RS5030807"	FALSE
VHL D92G (c.275A>G)	2322	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	Supports	C	Uncertain Significance	"Patients with ELSTs were identified and included in the International Endolymphatic Sac Tumor Registry. The registry contained 93 patients as of July 2014, and of those, 25 were sporadic, and 68 associated with VHL.  statistics of the VHL subgroup is as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. In the data from this study, only endolymphatic sac tumours can be confirmed as a phenotype for this mutation, which was found in 1 individual from France."	25867206	PubMed		"Bausch et al., 2016, Head Neck"		2	accepted	6553	Rare Germline	2023-01-09 21:46:59 UTC	https://civicdb.org/links/evidence_items/6553	https://civicdb.org/links/molecular_profiles/2322	FALSE	VHL	7428	D92G (c.275A>G)		chr3	10142122	10142122	A	G	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.275A>G,NC_000003.11:g.10183806A>G,NM_000551.3:c.275A>G,NP_000542.1:p.Asp92Gly"	2023-01-27 17:16:49 UTC	CA351750765	NONE FOUND	"C.275A>G,ASP92GLY"	FALSE
VHL Y98H (c.292T>C)	1617	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	Supports	C	Uncertain Significance	"Patients with ELSTs were identified and included in the International Endolymphatic Sac Tumor Registry. The registry contained 93 patients as of July 2014, and of those, 25 were sporadic, and 68 associated with VHL.  statistics of the VHL subgroup is as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. In the data from this study, only endolymphatic sac tumours can be confirmed as a phenotype for this mutation, which was found in 1 individual from Germany."	25867206	PubMed		"Bausch et al., 2016, Head Neck"		2	accepted	6554	Rare Germline	2023-01-09 21:46:48 UTC	https://civicdb.org/links/evidence_items/6554	https://civicdb.org/links/molecular_profiles/1617	FALSE	VHL	7428	Y98H (c.292T>C)		chr3	10142139	10142139	T	C	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.292T>C,NP_000542.1:p.Tyr98His,NC_000003.11:g.10183823T>C,ENST00000256474.2:c.292T>C"	2023-01-27 17:11:30 UTC	CA020246	2223	"C.292T>C,TYR98HIS,RS5030809"	FALSE
VHL F76del (c.224_226delTCT)	1964	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	"A prospective study followed 128 participants affected by VHL syndrome for 12 years in Padova, Italy. Individual patient data was not available, but frequency of specific mutations was presented. An in-frame deletion (TCT) at nucleotide 227 was present in 1 individual of the 122 total number of variants captured in this population."	26763786	PubMed		"Feletti et al., 2016, Neuro-oncology"		1	accepted	6557	Rare Germline	2023-01-09 21:46:55 UTC	https://civicdb.org/links/evidence_items/6557	https://civicdb.org/links/molecular_profiles/1964	FALSE	VHL	7428	F76del (c.224_226delTCT)		chr3	10142071	10142073	TCT		ENST00000256474.2	75		inframe_deletion	"NP_000542.1:p.Phe76del,ENST00000256474.2:c.224_226delTCT,NC_000003.11:g.10183758_10183760del,NC_000003.12:g.10142074_10142076del,NM_000551.3:c.227_229del,ENSP00000256474.2:p.Phe76del"	2023-01-27 17:15:01 UTC	CA357012	223166	"PHE76DEL,C.224_226DELTCT,C.226_228DELTTC,C.227_229DELTCT,DELPHE76"	FALSE
NTRK1 Fusion	415	Solid Tumor			Larotrectinib		Predictive	Supports	A	Sensitivity/Response	This was a Phase 1/2 study of 55 patients from 4 months to 76 years old with TRK-fusion positive tumors given NTRK inhibitor Larotrectinib. Patients had 17 unique NTRK fusion types. Patient overall response rate was 75% according to independent review and 80% according to investigator assessment. Authors state that Larotrectinib had durable anti tumor activity regardless of age or tumor type. 17/23 patients with NTRK1-fusion showed maximum percent change in tumor size between -30% and -100%.	29466156	PubMed		"Drilon et al., 2018, N. Engl. J. Med."	"NCT02576431,NCT02122913,NCT02637687"	4	accepted	6567	Somatic	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/6567	https://civicdb.org/links/molecular_profiles/415	FALSE	NTRK1	4914	Fusion	NTRK1 Fusions	chr1	156874383	156881642			ENST00000524377.1	75		transcript_fusion		2023-01-09 21:52:06 UTC		N/A		FALSE
NTRK1 Fusion	415	Sarcoma	1115		Larotrectinib		Predictive	Supports	B	Sensitivity/Response	"In a Phase 1/2 study involving 15 pediatric patients with infantile fibrosarcoma or soft tissue sarcoma, 8 patients had NTRK1 fusions. The patients were administered Larotrectinib, and 7 out of 8 patients showed objective response, with 2 complete and 5 partial responses. The patient without objective response had soft tissue sarcoma, and showed stable disease."	29606586	PubMed		"Laetsch et al., 2018, Lancet Oncol."	NCT02637687	4	accepted	6569	Somatic	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/6569	https://civicdb.org/links/molecular_profiles/415	FALSE	NTRK1	4914	Fusion	NTRK1 Fusions	chr1	156874383	156881642			ENST00000524377.1	75		transcript_fusion		2023-01-09 21:52:06 UTC		N/A		FALSE
VHL F136S (c.407T>C)	1677	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	"A prospective study followed 128 participants affected by VHL syndrome for 12 years in Padova, Italy. Individual patient data was not available, but frequency of specific mutations was presented. This mutation was present in 2 individuals of the 122 total number of variants captured in this population."	26763786	PubMed		"Feletti et al., 2016, Neuro-oncology"		1	accepted	6573	Rare Germline	2023-01-09 21:46:50 UTC	https://civicdb.org/links/evidence_items/6573	https://civicdb.org/links/molecular_profiles/1677	FALSE	VHL	7428	F136S (c.407T>C)		chr3	10146580	10146580	T	C	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.407T>C,NC_000003.11:g.10188264T>C,NM_000551.3:c.407T>C,NP_000542.1:p.Phe136Ser"	2023-01-27 17:12:13 UTC	CA040847	496064	"C.407T>C,PHE136SER,RS5030833"	FALSE
VHL P138T (c.412C>A)	1804	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	"A prospective study followed 128 participants affected by VHL syndrome for 12 years in Padova, Italy. Individual patient data was not available, but frequency of specific mutations was presented. This mutation was present in 5 individuals of the 122 total number of variants captured in this population."	26763786	PubMed		"Feletti et al., 2016, Neuro-oncology"		2	accepted	6574	Rare Germline	2023-01-09 21:46:52 UTC	https://civicdb.org/links/evidence_items/6574	https://civicdb.org/links/molecular_profiles/1804	FALSE	VHL	7428	P138T (c.412C>A)		chr3	10146585	10146585	C	A	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.412C>A,NC_000003.11:g.10188269C>A,NM_000551.3:c.412C>A,NP_000542.1:p.Pro138Thr"	2023-01-27 17:13:33 UTC	CA16621932	NONE FOUND	"PRO138THR,C.412C>A"	FALSE
VHL L153P (c.458T>C)	1799	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	"A prospective study followed 128 participants affected by VHL syndrome for 12 years in Padova, Italy. Individual patient data was not available, but frequency of specific mutations was presented. This mutation was present in 1 individual of the 122 total number of variants captured in this population."	26763786	PubMed		"Feletti et al., 2016, Neuro-oncology"		1	accepted	6576	Rare Germline	2023-01-09 21:46:52 UTC	https://civicdb.org/links/evidence_items/6576	https://civicdb.org/links/molecular_profiles/1799	FALSE	VHL	7428	L153P (c.458T>C)		chr3	10146631	10146631	T	C	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.458T>C,NC_000003.11:g.10188315T>C,NM_000551.3:c.458T>C,NP_000542.1:p.Leu153Pro"	2023-01-27 17:13:30 UTC	CA16621942	NONE FOUND	"C.458T>C,LEU153PRO"	FALSE
VHL P154= (c.462A>C)	1838	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	"A prospective study followed 128 participants affected by VHL syndrome for 12 years in Padova, Italy. Individual patient data was not available, but frequency of specific mutations was presented. This mutation was present in 2 individuals of the 122 total number of variants captured in this population."	26763786	PubMed		"Feletti et al., 2016, Neuro-oncology"		1	accepted	6577	Rare Germline	2023-01-09 21:46:53 UTC	https://civicdb.org/links/evidence_items/6577	https://civicdb.org/links/molecular_profiles/1838	FALSE	VHL	7428	P154= (c.462A>C)		chr3	10146635	10146635	A	C	ENST00000256474.2	75		synonymous_variant	"ENST00000256474.2:c.462A>C,NC_000003.11:g.10188319A>C,NM_000551.3:c.462A>C,NP_000542.1:p.Pro154="	2023-01-27 17:13:48 UTC	CA16621934	NONE FOUND	"C.462A>C,PRO154PRO,P154P (C.462A>C)"	FALSE
VHL V155G (c.464T>G)	1810	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	"A prospective study followed 128 participants affected by VHL syndrome for 12 years in Padova, Italy. Individual patient data was not available, but frequency of specific mutations was presented. This mutation was present in 2 individuals of the 122 total number of variants captured in this population."	26763786	PubMed		"Feletti et al., 2016, Neuro-oncology"		1	accepted	6579	Rare Germline	2023-01-09 21:46:53 UTC	https://civicdb.org/links/evidence_items/6579	https://civicdb.org/links/molecular_profiles/1810	FALSE	VHL	7428	V155G (c.464T>G)		chr3	10149787	10149787	T	G	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.464T>G,NC_000003.11:g.10191471T>G,NM_000551.3:c.464T>G,NP_000542.1:p.Val155Gly"	2023-01-27 17:13:38 UTC	CA16621938	NONE FOUND	"C.464T>G,VAL155GLY"	FALSE
VHL T157I (c.470C>T)	1621	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	"A prospective study followed 128 participants affected by VHL syndrome for 12 years in Padova, Italy. Individual patient data was not available, but frequency of specific mutations was presented. This mutation was present in 2 individuals of the 122 total number of variants captured in this population."	26763786	PubMed		"Feletti et al., 2016, Neuro-oncology"		1	accepted	6581	Rare Germline	2023-01-09 21:46:48 UTC	https://civicdb.org/links/evidence_items/6581	https://civicdb.org/links/molecular_profiles/1621	FALSE	VHL	7428	T157I (c.470C>T)		chr3	10149793	10149793	C	T	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.470C>T,NP_000542.1:p.Thr157Ile,NC_000003.11:g.10191477C>T,ENST00000256474.2:c.470C>T"	2023-01-27 17:11:33 UTC	CA357133	223223	"C.470C>T,THR157ILE,RS869025660"	FALSE
VHL R161G (c.481C>G)	1791	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	"A prospective study followed 128 participants affected by VHL syndrome for 12 years in Padova, Italy. Individual patient data was not available, but frequency of specific mutations was presented. This mutation was present in 2 individuals of the 122 total number of variants captured in this population."	26763786	PubMed		"Feletti et al., 2016, Neuro-oncology"		1	accepted	6582	Rare Germline	2023-01-09 21:46:52 UTC	https://civicdb.org/links/evidence_items/6582	https://civicdb.org/links/molecular_profiles/1791	FALSE	VHL	7428	R161G (c.481C>G)		chr3	10149804	10149804	C	G	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.481C>G,NC_000003.11:g.10191488C>G,NM_000551.3:c.481C>G,NP_000542.1:p.Arg161Gly"	2023-01-27 17:13:24 UTC	CA16621941	NONE FOUND	"C.481C>G,ARG161GLY,RS5030818"	FALSE
VHL R161* (c.481C>T)	1680	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	"A prospective study followed 128 participants affected by VHL syndrome for 12 years in Padova, Italy. Individual patient data was not available, but frequency of specific mutations was presented. This mutation was present in 2 individuals of the 122 total number of variants captured in this population."	26763786	PubMed		"Feletti et al., 2016, Neuro-oncology"		1	accepted	6583	Rare Germline	2023-01-09 21:46:50 UTC	https://civicdb.org/links/evidence_items/6583	https://civicdb.org/links/molecular_profiles/1680	FALSE	VHL	7428	R161* (c.481C>T)		chr3	10149804	10149804	C	T	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.481C>T,NP_000542.1:p.Arg161Ter,NC_000003.11:g.10191488C>T,ENST00000256474.2:c.481C>T"	2023-01-27 17:12:16 UTC	CA020408	2217	"C.481C>T,R161X,ARG161TER,RS5030818"	FALSE
VHL C162F (c.485G>T)	1649	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	"A prospective study followed 128 participants affected by VHL syndrome for 12 years in Padova, Italy. Individual patient data was not available, but frequency of specific mutations was presented. This mutation was present in 1 individual of the 122 total number of variants captured in this population."	26763786	PubMed		"Feletti et al., 2016, Neuro-oncology"		1	accepted	6584	Rare Germline	2023-01-09 21:46:49 UTC	https://civicdb.org/links/evidence_items/6584	https://civicdb.org/links/molecular_profiles/1649	FALSE	VHL	7428	C162F (c.485G>T)		chr3	10149808	10149808	G	T	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.485G>T,NP_000542.1:p.Cys162Phe,NC_000003.11:g.10191492G>T,ENST00000256474.2:c.485G>T"	2023-01-27 17:11:52 UTC	CA020418	43604	"C.485G>T,CYS162PHE,RS397516444"	FALSE
VHL C162W (c.486C>G)	1650	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	"A prospective study followed 128 participants affected by VHL syndrome for 12 years in Padova, Italy. Individual patient data was not available, but frequency of specific mutations was presented. This mutation was present in 1 individual of the 122 total number of variants captured in this population."	26763786	PubMed		"Feletti et al., 2016, Neuro-oncology"		1	accepted	6585	Rare Germline	2023-01-09 21:46:49 UTC	https://civicdb.org/links/evidence_items/6585	https://civicdb.org/links/molecular_profiles/1650	FALSE	VHL	7428	C162W (c.486C>G)		chr3	10149809	10149809	C	G	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.486C>G,NP_000542.1:p.Cys162Trp,NC_000003.11:g.10191493C>G,ENST00000256474.2:c.486C>G"	2023-01-27 17:11:53 UTC	CA357016	223227	"C.486C>G,CYS162TRP,RS869025662"	FALSE
VHL R167Q (c.500G>A)	1615	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	"A prospective study followed 128 participants affected by VHL syndrome for 12 years in Padova, Italy. Individual patient data was not available, but frequency of specific mutations was presented. This mutation was present in 9 individuals of the 122 total number of variants captured in this population."	26763786	PubMed		"Feletti et al., 2016, Neuro-oncology"		2	accepted	6587	Rare Germline	2023-01-09 21:46:47 UTC	https://civicdb.org/links/evidence_items/6587	https://civicdb.org/links/molecular_profiles/1615	FALSE	VHL	7428	R167Q (c.500G>A)		chr3	10149823	10149823	G	A	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.500G>A,NP_000542.1:p.Arg167Gln,NC_000003.11:g.10191507G>A,ENST00000256474.2:c.500G>A"	2023-01-27 17:11:29 UTC	CA020454	2216	"C.500G>A,ARG167GLN,RS5030821"	FALSE
VHL R167L (c.500G>T)	1792	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	"A prospective study followed 128 participants affected by VHL syndrome for 12 years in Padova, Italy. Individual patient data was not available, but frequency of specific mutations was presented. The c.500 G>T mutation was present in 3 individuas of the 122 total number of variants captured in this population."	26763786	PubMed		"Feletti et al., 2016, Neuro-oncology"		1	accepted	6588	Rare Germline	2023-01-09 21:46:52 UTC	https://civicdb.org/links/evidence_items/6588	https://civicdb.org/links/molecular_profiles/1792	FALSE	VHL	7428	R167L (c.500G>T)		chr3	10149823	10149823	G	T	ENST00000256474.2	75		missense_variant	"NC_000003.11:g.10191507G>T,NM_000551.3:c.500G>T,NP_000542.1:p.Arg167Leu,ENST00000256474.2:c.500G>T"	2023-01-27 17:13:25 UTC	CA351756178	526685	"RS5030821,C.500G>T,ARG167LEU"	FALSE
VHL L169P (c.506T>C)	1763	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	"A prospective study followed 128 participants affected by VHL syndrome for 12 years in Padova, Italy. Individual patient data was not available, but frequency of specific mutations was presented. The c.506 T>C mutation was present in 1 individual of the 122 total number of variants captured in this population."	26763786	PubMed		"Feletti et al., 2016, Neuro-oncology"		1	accepted	6589	Rare Germline	2023-01-09 21:46:52 UTC	https://civicdb.org/links/evidence_items/6589	https://civicdb.org/links/molecular_profiles/1763	FALSE	VHL	7428	L169P (c.506T>C)		chr3	10149829	10149829	T	C	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.506T>C,NP_000542.1:p.Leu169Pro,NC_000003.11:g.10191513T>C,ENST00000256474.2:c.506T>C"	2023-01-27 17:13:07 UTC	CA351756191	428809	"C.506T>C,LEU169PRO,RS1131690962"	FALSE
VHL V170G (c.509T>G)	1811	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	"A prospective study followed 128 participants affected by VHL syndrome for 12 years in Padova, Italy. Individual patient data was not available, but frequency of specific mutations presented. The c.509 T>G mutation was present in 3 individuals of the 122 total number of variants captured in this population."	26763786	PubMed		"Feletti et al., 2016, Neuro-oncology"		1	accepted	6590	Rare Germline	2023-01-09 21:46:53 UTC	https://civicdb.org/links/evidence_items/6590	https://civicdb.org/links/molecular_profiles/1811	FALSE	VHL	7428	V170G (c.509T>G)		chr3	10149832	10149832	T	G	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.509T>G,NC_000003.11:g.10191516T>G,NM_000551.3:c.509T>G,NP_000542.1:p.Val170Gly"	2023-01-27 17:13:39 UTC	CA351756196	NONE FOUND	"C.509T>G,VAL170GLY"	FALSE
VHL S183* (c.548C>A)	1660	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	"A prospective study followed 128 participants affected by VHL syndrome for 12 years in Padova, Italy. Individual patient data was not available, but frequency of specific mutations was presented. The c.548 C>A mutation was present in 3 individuals of the 122 total number of variants captured in this population."	26763786	PubMed		"Feletti et al., 2016, Neuro-oncology"		1	accepted	6592	Rare Germline	2023-01-09 21:46:49 UTC	https://civicdb.org/links/evidence_items/6592	https://civicdb.org/links/molecular_profiles/1660	FALSE	VHL	7428	S183* (c.548C>A)		chr3	10149871	10149871	C	A	ENST00000256474.2	75		stop_gained	"NM_000551.3:c.548C>A,NP_000542.1:p.Ser183Ter,NC_000003.11:g.10191555C>A,ENST00000256474.2:c.548C>A"	2023-01-27 17:12:00 UTC	CA020473	2215	"C.548C>A,S183X,SER183TER,RS5030823"	FALSE
VHL L184R (c.551T>G)	1684	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	"A prospective study followed 128 participants affected by VHL syndrome for 12 years in Padova, Italy. Individual patient data was not available, but frequency of specific mutations was presented. The c.551 T>G mutation was present in 1 individual of the 122 total number of variants captured in this population."	26763786	PubMed		"Feletti et al., 2016, Neuro-oncology"		1	accepted	6593	Rare Germline	2023-01-09 21:46:50 UTC	https://civicdb.org/links/evidence_items/6593	https://civicdb.org/links/molecular_profiles/1684	FALSE	VHL	7428	L184R (c.551T>G)		chr3	10149874	10149874	T	G	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.551T>G,NC_000003.11:g.10191558T>G,NM_000551.3:c.551T>G,NP_000542.1:p.Leu184Arg"	2023-01-27 17:12:19 UTC	CA351756355	NONE FOUND	"C.551T>G,LEU184ARG"	FALSE
VHL L188R (c.563T>G)	1800	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	"A prospective study followed 128 participants affected by VHL syndrome for 12 years in Padova, Italy. Individual patient data was not available, but frequency of specific mutations was presented. The c.563 T>G mutation was present in 3 individuals of the 122 total number of variants captured in this population."	26763786	PubMed		"Feletti et al., 2016, Neuro-oncology"		1	accepted	6595	Rare Germline	2023-01-09 21:46:52 UTC	https://civicdb.org/links/evidence_items/6595	https://civicdb.org/links/molecular_profiles/1800	FALSE	VHL	7428	L188R (c.563T>G)		chr3	10149886	10149886	T	G	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.563T>G,NC_000003.11:g.10191570T>G,NM_000551.3:c.563T>G,NP_000542.1:p.Leu188Arg"	2023-01-27 17:13:31 UTC	CA351756400	NONE FOUND	"C.563T>G,LEU188ARG"	FALSE
VHL Q195* (c.583C>T)	1686	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	"A prospective study followed 128 participants affected by VHL syndrome for 12 years in Padova, Italy. Individual patient data was not available, but frequency of specific mutations was presented. The c.583 C>T mutation was present in 2 individuals of the 122 total number of variants captured in this population."	26763786	PubMed		"Feletti et al., 2016, Neuro-oncology"		1	accepted	6596	Rare Germline	2023-01-09 21:46:50 UTC	https://civicdb.org/links/evidence_items/6596	https://civicdb.org/links/molecular_profiles/1686	FALSE	VHL	7428	Q195* (c.583C>T)		chr3	10149906	10149906	C	T	ENST00000256474.2	75		stop_gained	"NM_000551.3:c.583C>T,NP_000542.1:p.Gln195Ter,NC_000003.11:g.10191590C>T,ENST00000256474.2:c.583C>T"	2023-01-27 17:12:20 UTC	CA70052558	428794	"C.583C>T,Q195X,GLN195TER,RS5030825"	FALSE
VHL S111C (c.331A>T)	1921	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	N/A	C	N/A	"Patients with ELSTs were identified and included in the International Endolymphatic Sac Tumor Registry. The registry contained 93 patients as of July 2014, and of those, 25 were sporadic, and 68 associated with VHL. Statistics of the VHL subgroup are as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. In the data from this study, only endolymphatic sac tumours can be confirmed as a phenotype for this mutation, which was found in 1 individual from France."	25867206	PubMed		"Bausch et al., 2016, Head Neck"		3	accepted	6600	Rare Germline	2023-01-09 21:46:54 UTC	https://civicdb.org/links/evidence_items/6600	https://civicdb.org/links/molecular_profiles/1921	FALSE	VHL	7428	S111C (c.331A>T)		chr3	10142178	10142178	A	T	ENST00000256474.2	75		missense_variant	"NC_000003.11:g.10183862A>T,NM_000551.3:c.331A>T,NP_000542.1:p.Ser111Cys"	2023-01-27 17:14:37 UTC	CA351751322	565557	"SER111CYS,RS1559426203,C.331A>T"	FALSE
VHL S111N (c.332G>A)	1639	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	N/A	C	N/A	"Patients with ELSTs were identified and included in the International Endolymphatic Sac Tumor Registry. The registry contained 93 patients as of July 2014, and of those, 25 were sporadic, and 68 associated with VHL. Statistics of the VHL subgroup are as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. In the data from this study, only endolymphatic sac tumours can be confirmed as a phenotype for this mutation, which was found in 2 individuals from the UK."	25867206	PubMed		"Bausch et al., 2016, Head Neck"		3	accepted	6601	Rare Germline	2023-01-09 21:46:49 UTC	https://civicdb.org/links/evidence_items/6601	https://civicdb.org/links/molecular_profiles/1639	FALSE	VHL	7428	S111N (c.332G>A)		chr3	10142179	10142179	G	A	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.332G>A,NP_000542.1:p.Ser111Asn,NC_000003.11:g.10183863G>A,ENST00000256474.2:c.332G>A"	2023-01-27 17:11:47 UTC	CA357091	223186	"C.332G>A,SER111ASN,RS869025631"	FALSE
VHL R113* (c.337C>T)	1672	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	Supports	C	Uncertain Significance	"Patients with ELSTs were identified and included in the International Endolymphatic Sac Tumor Registry. The registry contained 93 patients as of July 2014, and of those, 25 were sporadic, and 68 associated with VHL.  statistics of the VHL subgroup is as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. In the data from this study, only endolymphatic sac tumours can be confirmed as a phenotype for this mutation, which was found in 1 individual from France."	25867206	PubMed		"Bausch et al., 2016, Head Neck"		3	accepted	6602	Rare Germline	2023-01-09 21:46:50 UTC	https://civicdb.org/links/evidence_items/6602	https://civicdb.org/links/molecular_profiles/1672	FALSE	VHL	7428	R113* (c.337C>T)		chr3	10142184	10142184	C	T	ENST00000256474.2	75		stop_gained	"NM_000551.3:c.337C>T,NP_000542.1:p.Arg113Ter,NC_000003.11:g.10183868C>T,ENST00000256474.2:c.337C>T"	2023-01-27 17:12:09 UTC	CA348491	220414	"C.337C>T,R113X,ARG113TER,RS5030810"	FALSE
VHL H115Q (c.345C>G)	1833	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	N/A	C	N/A	"Patients with ELSTs were identified and included in the International Endolymphatic Sac Tumor Registry. The registry contained 93 patients as of July 2014, and of those, 25 were sporadic, and 68 associated with VHL. The statistics of the VHL subgroup are as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. In the data from this study, only endolymphatic sac tumours can be confirmed as a phenotype for this mutation, which was found in 1 individual from France."	25867206	PubMed		"Bausch et al., 2016, Head Neck"		3	accepted	6604	Rare Germline	2023-01-09 21:46:53 UTC	https://civicdb.org/links/evidence_items/6604	https://civicdb.org/links/molecular_profiles/1833	FALSE	VHL	7428	H115Q (c.345C>G)		chr3	10146518	10146518	C	G	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.345C>G,NC_000003.11:g.10188202C>G,NM_000551.3:c.345C>G,NP_000542.1:p.His115Gln"	2023-01-27 17:13:47 UTC	CA351753634	496058	"HIS115GLN,C.345C>G,RS864622646"	FALSE
VHL R120G (c.358A>G)	1790	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	Supports	C	Uncertain Significance	"Patients with ELSTs were identified and included in the International Endolymphatic Sac Tumor Registry. The registry contained 93 patients as of July 2014, and of those, 25 were sporadic, and 68 associated with VHL.  statistics of the VHL subgroup is as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. In the data from this study, only endolymphatic sac tumours can be confirmed as a phenotype for this mutation, which was found in 1 individual from Italy."	25867206	PubMed		"Bausch et al., 2016, Head Neck"		3	accepted	6605	Rare Germline	2023-01-09 21:46:52 UTC	https://civicdb.org/links/evidence_items/6605	https://civicdb.org/links/molecular_profiles/1790	FALSE	VHL	7428	R120G (c.358A>G)		chr3	10146531	10146531	A	G	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.358A>G,NP_000542.1:p.Arg120Gly,NC_000003.11:g.10188215A>G,ENST00000256474.2:c.358A>G"	2023-01-27 17:13:23 UTC	CA357028	223199	"C.358A>G,ARG120GLY,RS869025642"	FALSE
VHL N131T (c.392A>C)	2453	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	Supports	C	Uncertain Significance	"Patients with ELSTs were identified and included in the International Endolymphatic Sac Tumor Registry. The registry contained 93 patients as of July 2014, and of those, 25 were sporadic, and 68 associated with VHL.  statistics of the VHL subgroup is as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. In the data from this study, only endolymphatic sac tumours can be confirmed as a phenotype for this mutation, which was found in 1 individual from Germany."	25867206	PubMed		"Bausch et al., 2016, Head Neck"		3	accepted	6606	Rare Germline	2023-01-09 21:47:00 UTC	https://civicdb.org/links/evidence_items/6606	https://civicdb.org/links/molecular_profiles/2453	FALSE	VHL	7428	N131T (c.392A>C)		chr3	10146565	10146565	A	C	ENST00000256474.2	75		non_conservative_missense_variant	"NC_000003.11:g.10188249A>C,CM000665.1:g.10188249A>C,NP_000542.1:p.Asn131Thr,NM_000551.3:c.392A>C"	2023-01-27 17:17:35 UTC	CA351753944	NONE FOUND		FALSE
VHL T133fs (c.397del)	1719	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	Supports	C	Uncertain Significance	"Patients with ELSTs were identified and included in the International Endolymphatic Sac Tumor Registry. The registry contained 93 patients as of July 2014, and of those, 25 were sporadic, and 68 associated with VHL.  statistics of the VHL subgroup is as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. In the data from this study, only endolymphatic sac tumours can be confirmed as a phenotype for this mutation, which was found in 1 individual from France."	25867206	PubMed		"Bausch et al., 2016, Head Neck"		3	accepted	6607	Rare Germline	2023-01-09 21:46:51 UTC	https://civicdb.org/links/evidence_items/6607	https://civicdb.org/links/molecular_profiles/1719	FALSE	VHL	7428	T133fs (c.397del)		chr3	10146568	10146568	A		ENST00000256474.2	75		"minus_1_frameshift_variant,frameshift_truncation"	"NC_000003.11:g.10188254del,NP_000542.1:p.Thr133LeufsTer26,NP_000542.1:p.Thr133fs,NC_000003.12:g.10146570del,NM_000551.4:c.397del"	2023-01-27 17:12:43 UTC	CA432421843	625244	"Q132FS (C.395DELA),T133LFS*26"	FALSE
VHL L135* (c.404T>A)	1645	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	Supports	C	Uncertain Significance	"Patients with ELSTs in the VHL registries of the participating centers in Europe were identified and included in the International Endolymphatic Sac Tumor Registry. The statistics of this registry is as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. Only endolymphatic sac tumours can be confirmed as a phenotype for this mutation, which was found in 1 individual from Spain."	25867206	PubMed		"Bausch et al., 2016, Head Neck"		3	accepted	6608	Rare Germline	2023-01-09 21:46:49 UTC	https://civicdb.org/links/evidence_items/6608	https://civicdb.org/links/molecular_profiles/1645	FALSE	VHL	7428	L135* (c.404T>A)		chr3	10146577	10146577	T	A	ENST00000256474.2	75		stop_gained	"ENST00000256474.2:c.404T>A,NC_000003.11:g.10188261T>A,NM_000551.3:c.404T>A,NP_000542.1:p.Leu135Ter"	2023-01-27 17:11:50 UTC	CA351754021	NONE FOUND	"C.404T>A,L135X,LEU135TER"	FALSE
VHL P154L (c.461C>T)	1658	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	Supports	C	Uncertain Significance	"Patients with ELSTs were identified and included in the International Endolymphatic Sac Tumor Registry. The registry contained 93 patients as of July 2014, and of those, 25 were sporadic, and 68 associated with VHL.  statistics of the VHL subgroup is as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. In the data from this study, only endolymphatic sac tumours can be confirmed as a phenotype for this mutation, which was found in 2 individuals from Germany."	25867206	PubMed		"Bausch et al., 2016, Head Neck"		3	accepted	6609	Rare Germline	2023-01-09 21:46:49 UTC	https://civicdb.org/links/evidence_items/6609	https://civicdb.org/links/molecular_profiles/1658	FALSE	VHL	7428	P154L (c.461C>T)		chr3	10146634	10146634	C	T	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.461C>T,NC_000003.11:g.10188318C>T,NM_000551.3:c.461C>T,NP_000542.1:p.Pro154Leu"	2023-01-27 17:11:58 UTC	CA351754410	NONE FOUND	"C.461C>T,PRO154LEU"	FALSE
VHL Splice Site (c.463+2T>C)	1951	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	Supports	C	Uncertain Significance	"Patients with ELSTs were identified and included in the International Endolymphatic Sac Tumor Registry. The registry contained 93 patients as of July 2014, and of those, 25 were sporadic, and 68 associated with VHL.  statistics of the VHL subgroup is as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. In the data from this study, only endolymphatic sac tumours can be confirmed as a phenotype for this mutation, which was found in 2 individuals from Germany."	25867206	PubMed		"Bausch et al., 2016, Head Neck"		3	accepted	6610	Rare Germline	2023-01-09 21:46:55 UTC	https://civicdb.org/links/evidence_items/6610	https://civicdb.org/links/molecular_profiles/1951	FALSE	VHL	7428	Splice Site (c.463+2T>C)		chr3	10146638	10146638	T	C	ENST00000256474.2	75		splice_donor_variant	"NM_000551.3:c.463+2T>C,NC_000003.11:g.10188322T>C,ENST00000256474.2:c.463+2T>C,NP_000542.1:p.?,NC_000003.12:g.10146638T>C"	2023-01-27 17:14:55 UTC	CA16621936	569414	"C.463+2T>C,RS5030814"	FALSE
VHL T157I (c.470C>T)	1621	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	Supports	C	Uncertain Significance	"Patients with ELSTs in the VHL registries of the participating centers in Europe were identified and included in the International Endolymphatic Sac Tumor Registry. The statistics of this registry is as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. Only endolymphatic sac tumours can be confirmed as a phenotype for this mutation, which was found in 1 individual from Italy."	25867206	PubMed		"Bausch et al., 2016, Head Neck"		3	accepted	6612	Rare Germline	2023-01-09 21:46:48 UTC	https://civicdb.org/links/evidence_items/6612	https://civicdb.org/links/molecular_profiles/1621	FALSE	VHL	7428	T157I (c.470C>T)		chr3	10149793	10149793	C	T	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.470C>T,NP_000542.1:p.Thr157Ile,NC_000003.11:g.10191477C>T,ENST00000256474.2:c.470C>T"	2023-01-27 17:11:33 UTC	CA357133	223223	"C.470C>T,THR157ILE,RS869025660"	FALSE
VHL L158P (c.473T>C)	1614	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	Supports	C	Uncertain Significance	"Patients with ELSTs in the VHL registries of the participating centers in Europe were identified and included in the International Endolymphatic Sac Tumor Registry. The statistics of this registry is as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. Only endolymphatic sac tumours can be confirmed as a phenotype for this mutation, which was found in 1 individual from France."	25867206	PubMed		"Bausch et al., 2016, Head Neck"		3	accepted	6613	Rare Germline	2023-01-09 21:46:47 UTC	https://civicdb.org/links/evidence_items/6613	https://civicdb.org/links/molecular_profiles/1614	FALSE	VHL	7428	L158P (c.473T>C)		chr3	10149796	10149796	T	C	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.473T>C,NP_000542.1:p.Leu158Pro,NC_000003.11:g.10191480T>C,ENST00000256474.2:c.473T>C"	2023-01-27 17:11:28 UTC	CA020399	182980	"C.473T>C,LEU158PRO,RS121913346"	FALSE
VHL R161* (c.481C>T)	1680	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	Supports	C	Uncertain Significance	"Patients with ELSTs were identified and included in the International Endolymphatic Sac Tumor Registry. The registry contained 93 patients as of July 2014, and of those, 25 were sporadic, and 68 associated with VHL.  statistics of the VHL subgroup is as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. In the data from this study, only endolymphatic sac tumours can be confirmed as a phenotype for this mutation, which was found in 3 individuals from France or Argentina."	25867206	PubMed		"Bausch et al., 2016, Head Neck"		3	accepted	6614	Rare Germline	2023-01-09 21:46:50 UTC	https://civicdb.org/links/evidence_items/6614	https://civicdb.org/links/molecular_profiles/1680	FALSE	VHL	7428	R161* (c.481C>T)		chr3	10149804	10149804	C	T	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.481C>T,NP_000542.1:p.Arg161Ter,NC_000003.11:g.10191488C>T,ENST00000256474.2:c.481C>T"	2023-01-27 17:12:16 UTC	CA020408	2217	"C.481C>T,R161X,ARG161TER,RS5030818"	FALSE
VHL C162Y (c.485G>A)	1700	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	Supports	C	Uncertain Significance	"Patients with ELSTs were identified and included in the International Endolymphatic Sac Tumor Registry. The registry contained 93 patients as of July 2014, and of those, 25 were sporadic, and 68 associated with VHL.  statistics of the VHL subgroup is as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. In the data from this study, only endolymphatic sac tumours can be confirmed as a phenotype for this mutation, which was found in 1 individual from France."	25867206	PubMed		"Bausch et al., 2016, Head Neck"		3	accepted	6615	Rare Germline	2023-01-09 21:46:50 UTC	https://civicdb.org/links/evidence_items/6615	https://civicdb.org/links/molecular_profiles/1700	FALSE	VHL	7428	C162Y (c.485G>A)		chr3	10149808	10149808	G	A	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.485G>A,NP_000542.1:p.Cys162Tyr,NC_000003.11:g.10191492G>A,ENST00000256474.2:c.485G>A"	2023-01-27 17:12:31 UTC	CA357010	223225	"C.485G>A,CYS162TYR,RS397516444"	FALSE
VHL C162W (c.486C>G)	1650	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	Supports	C	Uncertain Significance	"Patients with ELSTs were identified and included in the International Endolymphatic Sac Tumor Registry. The registry contained 93 patients as of July 2014, and of those, 25 were sporadic, and 68 associated with VHL.  statistics of the VHL subgroup is as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. In the data from this study, only endolymphatic sac tumours can be confirmed as a phenotype for this mutation (p.Cys162Trp), which was found in 2 individuals from France."	25867206	PubMed		"Bausch et al., 2016, Head Neck"		3	accepted	6616	Rare Germline	2023-01-09 21:46:49 UTC	https://civicdb.org/links/evidence_items/6616	https://civicdb.org/links/molecular_profiles/1650	FALSE	VHL	7428	C162W (c.486C>G)		chr3	10149809	10149809	C	G	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.486C>G,NP_000542.1:p.Cys162Trp,NC_000003.11:g.10191493C>G,ENST00000256474.2:c.486C>G"	2023-01-27 17:11:53 UTC	CA357016	223227	"C.486C>G,CYS162TRP,RS869025662"	FALSE
VHL Q164L (c.491A>T)	1955	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	Supports	C	Uncertain Significance	"Patients with ELSTs were identified and included in the International Endolymphatic Sac Tumor Registry. The registry contained 93 patients as of July 2014, and of those, 25 were sporadic, and 68 associated with VHL.  statistics of the VHL subgroup is as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. In the data from this study, only endolymphatic sac tumours can be confirmed as a phenotype for this mutation, which was found in 1 individual from Germany."	25867206	PubMed		"Bausch et al., 2016, Head Neck"		3	accepted	6617	Rare Germline	2023-01-09 21:46:55 UTC	https://civicdb.org/links/evidence_items/6617	https://civicdb.org/links/molecular_profiles/1955	FALSE	VHL	7428	Q164L (c.491A>T)		chr3	10149814	10149814	A	T	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.491A>T,NC_000003.11:g.10191498A>T,NM_000551.3:c.491A>T,NP_000542.1:p.Gln164Leu"	2023-01-27 17:14:58 UTC	CA351756149	NONE FOUND	"C.491A>T,GLN164LEU"	FALSE
VHL R167W (c.499C>T)	1623	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	Supports	C	Uncertain Significance	"Patients with ELSTs were identified and included in the International Endolymphatic Sac Tumor Registry. The registry contained 93 patients as of July 2014, and of those, 25 were sporadic, and 68 associated with VHL.  statistics of the VHL subgroup is as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. In the data from this study, only endolymphatic sac tumours can be confirmed as a phenotype for this mutation, which was found in 3 individuals each from France, UK, and Germany."	25867206	PubMed		"Bausch et al., 2016, Head Neck"		3	accepted	6618	Rare Germline	2023-01-09 21:46:48 UTC	https://civicdb.org/links/evidence_items/6618	https://civicdb.org/links/molecular_profiles/1623	FALSE	VHL	7428	R167W (c.499C>T)		chr3	10149822	10149822	C	T	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.499C>T,NP_000542.1:p.Arg167Trp,NC_000003.11:g.10191506C>T,ENST00000256474.2:c.499C>T"	2023-01-27 17:11:35 UTC	CA020450	2218	"C.499C>T,ARG167TRP,R126W,RS5030820"	FALSE
VHL R167Q (c.500G>A)	1615	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	Supports	C	Uncertain Significance	"Patients with ELSTs were identified and included in the International Endolymphatic Sac Tumor Registry. The registry contained 93 patients as of July 2014, and of those, 25 were sporadic, and 68 associated with VHL.  statistics of the VHL subgroup is as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. In the data from this study, only endolymphatic sac tumours can be confirmed as a phenotype for this mutation, which was found in 4 individuals from France or Italy."	25867206	PubMed		"Bausch et al., 2016, Head Neck"		3	accepted	6619	Rare Germline	2023-01-09 21:46:47 UTC	https://civicdb.org/links/evidence_items/6619	https://civicdb.org/links/molecular_profiles/1615	FALSE	VHL	7428	R167Q (c.500G>A)		chr3	10149823	10149823	G	A	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.500G>A,NP_000542.1:p.Arg167Gln,NC_000003.11:g.10191507G>A,ENST00000256474.2:c.500G>A"	2023-01-27 17:11:29 UTC	CA020454	2216	"C.500G>A,ARG167GLN,RS5030821"	FALSE
VHL R167P (c.500G>C)	2331	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	Supports	C	Uncertain Significance	"Patients with ELSTs were identified and included in the International Endolymphatic Sac Tumor Registry. The registry contained 93 patients as of July 2014, and of those, 25 were sporadic, and 68 associated with VHL.  statistics of the VHL subgroup is as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. In the data from this study, only endolymphatic sac tumours can be confirmed as a phenotype for this mutation, which was found in 1 individual from France."	25867206	PubMed		"Bausch et al., 2016, Head Neck"		3	accepted	6620	Rare Germline	2023-01-09 21:46:59 UTC	https://civicdb.org/links/evidence_items/6620	https://civicdb.org/links/molecular_profiles/2331	FALSE	VHL	7428	R167P (c.500G>C)		chr3	10149823	10149823	G	C	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.500G>C,NM_000551.3:c.500G>C,NP_000542.1:p.Arg167Pro,NC_000003.11:g.10191507G>C"	2023-01-27 17:16:52 UTC	CA351756177	428799	"RS5030821,C.500G>C,ARG167PRO"	FALSE
VHL Y175* (c.525C>A)	1808	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	Supports	C	Uncertain Significance	"Patients with ELSTs were identified and included in the International Endolymphatic Sac Tumor Registry. The registry contained 93 patients as of July 2014, and of those, 25 were sporadic, and 68 associated with VHL.  statistics of the VHL subgroup is as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. In the data from this study, only endolymphatic sac tumours can be confirmed as a phenotype for this mutation, which was found in 1 individual from France."	25867206	PubMed		"Bausch et al., 2016, Head Neck"		2	accepted	6621	Rare Germline	2023-01-09 21:46:53 UTC	https://civicdb.org/links/evidence_items/6621	https://civicdb.org/links/molecular_profiles/1808	FALSE	VHL	7428	Y175* (c.525C>A)		chr3	10149848	10149848	C	A	ENST00000256474.2	75		stop_gained	"ENST00000256474.2:c.525C>A,NP_000542.1:p.Tyr175Ter,NC_000003.11:g.10191532C>A,NM_000551.3:c.525C>A"	2023-01-27 17:13:36 UTC	CA351756231	NONE FOUND	"Y175X,TYR175TER,C.525C>A"	FALSE
VHL Q195* (c.583C>T)	1686	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	Supports	C	Uncertain Significance	"Patients with ELSTs were identified and included in the International Endolymphatic Sac Tumor Registry. The registry contained 93 patients as of July 2014, and of those, 25 were sporadic, and 68 associated with VHL.  statistics of the VHL subgroup is as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. In the data from this study, only endolymphatic sac tumours can be confirmed as a phenotype for this mutation, which was found in 2 individuals from France."	25867206	PubMed		"Bausch et al., 2016, Head Neck"		3	accepted	6623	Rare Germline	2023-01-09 21:46:50 UTC	https://civicdb.org/links/evidence_items/6623	https://civicdb.org/links/molecular_profiles/1686	FALSE	VHL	7428	Q195* (c.583C>T)		chr3	10149906	10149906	C	T	ENST00000256474.2	75		stop_gained	"NM_000551.3:c.583C>T,NP_000542.1:p.Gln195Ter,NC_000003.11:g.10191590C>T,ENST00000256474.2:c.583C>T"	2023-01-27 17:12:20 UTC	CA70052558	428794	"C.583C>T,Q195X,GLN195TER,RS5030825"	FALSE
VHL Exon 1 Deletion	818	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	Supports	C	Uncertain Significance	"Patients with ELSTs were identified and included in the International Endolymphatic Sac Tumor Registry. The registry contained 93 patients as of July 2014, and of those, 25 were sporadic, and 68 associated with VHL.  statistics of the VHL subgroup is as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. In the data from this study, only endolymphatic sac tumours can be confirmed as a phenotype for this mutation, which was found in 1 individual from the Netherlands."	25867206	PubMed		"Bausch et al., 2016, Head Neck"		3	accepted	6624	Rare Germline	2023-01-09 21:46:38 UTC	https://civicdb.org/links/evidence_items/6624	https://civicdb.org/links/molecular_profiles/818	FALSE	VHL	7428	Exon 1 Deletion		chr3	10141848	10142187			ENST00000256474.2	75		exon_loss_variant	ENST00000256474.2:c.1-?_340+?del	2023-01-09 21:52:09 UTC				FALSE
VHL Exon 3 Deletion	1815	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	N/A	C	N/A	"Patients with ELSTs were identified and included in the International Endolymphatic Sac Tumor Registry. The registry contained 93 patients as of July 2014, and of those, 25 were sporadic, and 68 associated with VHL. Statistics of the VHL subgroup are as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. In the data from this study, only endolymphatic sac tumours can be confirmed as a phenotype for this mutation, which was found in 4 individuals from France, Germany, or Italy."	25867206	PubMed		"Bausch et al., 2016, Head Neck"		3	accepted	6626	Rare Germline	2023-01-09 21:46:53 UTC	https://civicdb.org/links/evidence_items/6626	https://civicdb.org/links/molecular_profiles/1815	FALSE	VHL	7428	Exon 3 Deletion		chr3	10149787	10152220			ENST00000256474.2	75				2023-01-09 21:52:16 UTC				FALSE
VHL Exon 1-3 Deletion	817	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	N/A	C	N/A	"Patients with ELSTs were identified and included in the International Endolymphatic Sac Tumor Registry. The registry contained 93 patients as of July 2014, and of those, 25 were sporadic, and 68 associated with VHL. Statistics of the VHL subgroup are as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. In the data from this study, only endolymphatic sac tumours can be confirmed as a phenotype for this mutation, which was found in 6 individuals from France, Germany, the Netherlands, or Spain."	25867206	PubMed		"Bausch et al., 2016, Head Neck"		3	accepted	6628	Rare Germline	2023-01-09 21:46:38 UTC	https://civicdb.org/links/evidence_items/6628	https://civicdb.org/links/molecular_profiles/817	FALSE	VHL	7428	Exon 1-3 Deletion		chr3	10141848	10149965			ENST00000256474.2	75		exon_loss_variant	ENST00000256474.2:c.1-?_642+?del	2023-01-09 21:52:09 UTC				FALSE
VHL S65L (c.194C>T)	1664	Von Hippel-Lindau Disease	14175	Cerebellar hemangioblastoma			Predisposing	N/A	C	N/A	"Thirty-two surgically resected HB specimens from 28 patients treated at the University of Tokyo Hospital between 1995 and 2012 were analyzed retrospectively. Of the 32 specimens, 11 were VHL-related HBs from 7 patients, and 21 were sporadic HBs from 21 patients. One of the 7 VHL patients was a female patient with a c.194C>T (p.Ser65Leu) mutation in the VHL gene. She developed a CNS hemangioblastoma in the cerebellum at 19Y. It is unclear whether she had germline testing. However, the patient met clinical criteria for VHL (Losner et al., 2003). Interestingly, the HB from this patient was noted to have LOH of chromosome 3p. No other phenotypic information was available."	28379443	PubMed		"Takayanagi et al., 2017, Neuro-oncology"		2	accepted	6644	Unknown	2023-01-09 21:46:49 UTC	https://civicdb.org/links/evidence_items/6644	https://civicdb.org/links/molecular_profiles/1664	FALSE	VHL	7428	S65L (c.194C>T)		chr3	10142041	10142041	C	T	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.194C>T,NP_000542.1:p.Ser65Leu,NC_000003.11:g.10183725C>T,ENST00000256474.2:c.194C>T"	2023-01-27 17:12:03 UTC	CA020104	182975	"C.194C>T,SER65LEU,RS5030826"	FALSE
VHL S65W (c.194C>G)	1663	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	"The national cohort study describes how the rate of new tumor development varies through the lifetimes of VHL patients and how it is influenced by age and genotype.  This study included 52 VHL mutation carriers who were retrospectively followed for a total of 799 person-years. From birth to current age, 581 manifestations were diagnosed during 2,583 examinations in the study subjects.   Genetic testing confirmed a germline variant at c.194C>G of the VHL gene in two patients. Detailed phenotype, demographic, and family history information was not available for the 2 patients."	25834951	PubMed		"Binderup et al., 2016, Genet. Med."		3	accepted	6661	Rare Germline	2023-01-09 21:46:49 UTC	https://civicdb.org/links/evidence_items/6661	https://civicdb.org/links/molecular_profiles/1663	FALSE	VHL	7428	S65W (c.194C>G)		chr3	10142041	10142041	C	G	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.194C>G,NM_000551.3:c.194C>G,NP_000542.1:p.Ser65Trp,NC_000003.11:g.10183725C>G"	2023-01-27 17:12:02 UTC	CA020099	43597	"C.194C>G,SER65TRP,RS5030826"	FALSE
VHL S65L (c.194C>T)	1664	Von Hippel-Lindau Disease	14175				Predisposing	Supports	C	Uncertain Significance	"This retrospective study of 52 Danish patients with genetically confirmed VHL mutations analyzed the results of each individual's VHL-related examinations and manifestations diagnosed up to the time of study inclusion. All patients were enrolled in the Danish vHL surveillance program. Data was collected through detailed interviews and subsequent evaluation of each subjects clinical, radiographic, and histological records. Genetic testing confirmed a germline VHL mutation at c.194C>T  in four patients. Associated phenotypes, demographic, and family history is unknown."	25834951	PubMed		"Binderup et al., 2016, Genet. Med."		2	accepted	6662	Rare Germline	2023-01-09 21:46:49 UTC	https://civicdb.org/links/evidence_items/6662	https://civicdb.org/links/molecular_profiles/1664	FALSE	VHL	7428	S65L (c.194C>T)		chr3	10142041	10142041	C	T	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.194C>T,NP_000542.1:p.Ser65Leu,NC_000003.11:g.10183725C>T,ENST00000256474.2:c.194C>T"	2023-01-27 17:12:03 UTC	CA020104	182975	"C.194C>T,SER65LEU,RS5030826"	FALSE
VHL I151T (c.452T>C)	1747	Von Hippel-Lindau Disease	14175	"Renal cell carcinoma,Renal cyst,Epididymal cyst,Hemangioblastoma,Pancreatic cysts"			Predisposing	N/A	C	N/A	"A retrospective medical chart review was performed on patients referred to the genetics service. Two unrelated probands were genetically confirmed with a non-familial mutation at c.452T>C of the VHL gene. The first, a 30 year old male, presented with central nervous system hemangioblastoma, renal cell carcinoma, and a pancreatic cyst. The second, a 37 year old male, presented with central nervous system hemangioblastoma, renal cyst, pancreatic cyst, and epididymal cyst. Family histories are both negative."	28469506	PubMed		"Sriphrapradang et al., 2017, Clin Med Insights Endocrinol Diabetes"		3	accepted	6696	Rare Germline	2023-01-09 21:46:51 UTC	https://civicdb.org/links/evidence_items/6696	https://civicdb.org/links/molecular_profiles/1747	FALSE	VHL	7428	I151T (c.452T>C)		chr3	10146625	10146625	T	C	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.452T>C,NP_000542.1:p.Ile151Thr,NC_000003.11:g.10188309T>C,ENST00000256474.2:c.452T>C"	2023-01-27 17:13:00 UTC	CA351754359	428803	"C.452T>C,ILE151THR,RS869025655"	FALSE
VHL S65L (c.194C>T)	1664	Von Hippel-Lindau Disease	14175	"Retinal capillary hemangioma,Hemangioblastoma,Renal cell carcinoma"			Predisposing	Supports	C	Uncertain Significance	"A retrospective study reviewed cases of 23 patients with advanced and complicated VHL eye disease who underwent pars plana vitrectomy in the years 1999 to 2012. These inidiviuals were part of 223 VHL patients consulted at the International Hereditary Cancer Center and Polish VHL Registry. 22/23 patients received genetic molecular testing to identify germline mutations in the VHL gene. 24 eyes from 23 patients were studied. Patient #6 (35 years old) had the p.Ser65Leu (c.194C>T) mutation and a previous history of HbCNS and RCC.  Patient # 16 (44 year old) also had this mutation, and had a previous history of HbCNS and RCC. Patient # 17 (20 year old) had this mutation, and had a previous history of HbCNS. Since patients were listed 'by eye' it is impossible to determine whether the three patients listed above actually represent 2 or 3 unique patients."	26308528	PubMed		"Krzystolik et al., 2016, Retina (Philadelphia, Pa.)"		3	accepted	6710	Rare Germline	2023-01-09 21:46:49 UTC	https://civicdb.org/links/evidence_items/6710	https://civicdb.org/links/molecular_profiles/1664	FALSE	VHL	7428	S65L (c.194C>T)		chr3	10142041	10142041	C	T	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.194C>T,NP_000542.1:p.Ser65Leu,NC_000003.11:g.10183725C>T,ENST00000256474.2:c.194C>T"	2023-01-27 17:12:03 UTC	CA020104	182975	"C.194C>T,SER65LEU,RS5030826"	FALSE
VHL *214G (c.640T>G)	2361	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	N/A	C	N/A	A 49 year old female (Patient 3) from Europe presented with a unilateral adrenal pheochromocytoma. Genetic testing confirmed germline missense mutation found at c.640T>G in the VHL gene (reported as T852G in the paper). Family history and patient demographic is unknown. This patient underwent surgical resection.	12673678	PubMed		"Dannenberg et al., 2003, Int. J. Cancer"		2	accepted	6723	Rare Germline	2023-01-09 21:46:59 UTC	https://civicdb.org/links/evidence_items/6723	https://civicdb.org/links/molecular_profiles/2361	FALSE	VHL	7428	*214G (c.640T>G)		chr3	10149963	10149963	T	G	ENST00000256474.2	75		stop_lost	"ENST00000256474.2:c.640T>G,NM_000551.3:c.640T>G,NP_000542.1:p.Ter214Gly,ENSP00000256474.2:p.Ter214Gly"	2023-01-27 17:17:03 UTC	CA351756720	NONE FOUND	"X214G,TER214GLY,C.640T>G,X > GLY + 14AA"	FALSE
VHL *214C (c.641_642insC)	2362	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	N/A	C	N/A	A female of unknown age (Patient 8) from Europe presented with a unilateral adrenal pheochromocytoma. Genetic testing confirmed a germline frameshift mutation found at c.641insC in the VHL gene. Family history and patient demographic is unknown. This patient underwent surgical resection.	12673678	PubMed		"Dannenberg et al., 2003, Int. J. Cancer"		2	accepted	6724	Rare Germline	2023-01-09 21:46:59 UTC	https://civicdb.org/links/evidence_items/6724	https://civicdb.org/links/molecular_profiles/2362	FALSE	VHL	7428	*214C (c.641_642insC)		chr3	10149964	10149965		C	ENST00000256474.2	75		stop_lost	"ENST00000256474.2:c.641_642insC,NC_000003.11:g.10191648_10191649insC,NM_000551.3:c.641_642insC,NP_000542.1:p.Ter214CysextTer?"	2023-01-27 17:17:04 UTC	CA913189243	NONE FOUND	"X214C,TER214CYS,C.641INSC"	FALSE
VHL S65L (c.194C>T)	1664	Von Hippel-Lindau Disease	14175	Clear cell renal cell carcinoma			Predisposing	Supports	C	Uncertain Significance	"240 ccRCC specimens were genetically analyzed. 3 specimens (ccRCC-58, ccRCC-154, ccRCC-238) from 3 different patients were confirmed to carry the p.Ser65Leu; c.194C>T mutation. The mutation was found to be germline in one male patient, age 27, who had contralateral kidney cancer. Family history and patient demographics are unknown. This patient was the source of ccRCC-238. This evidence supports AMCG code 'PM2' - Absent from controls (i.e. gnomAD)."	23797736	PubMed		"Sato et al., 2013, Nat. Genet."		2	accepted	6728	Rare Germline	2023-01-09 21:46:49 UTC	https://civicdb.org/links/evidence_items/6728	https://civicdb.org/links/molecular_profiles/1664	FALSE	VHL	7428	S65L (c.194C>T)		chr3	10142041	10142041	C	T	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.194C>T,NP_000542.1:p.Ser65Leu,NC_000003.11:g.10183725C>T,ENST00000256474.2:c.194C>T"	2023-01-27 17:12:03 UTC	CA020104	182975	"C.194C>T,SER65LEU,RS5030826"	FALSE
VHL E70K (c.208G>A)	1832	Von Hippel-Lindau Disease	14175	"Hemangioblastoma,Retinal capillary hemangioma"			Predisposing	Supports	C	Uncertain Significance	"Thirteen unrelated Korean subjects and their family members were tested for VHL mutations with direct sequencing and multiplex ligation dependent probe amplification. Clinical manifestations and family histories were recorded for each subject. Genetic testing confirmed a c.208G>A missense mutation in members of family #2,3,4. Family #2; A 25-year-old male Korean proband presented with a central nervous system hemangioblastoma. This patient had no family history of VHL. Family #3; A 46-year-old female Korean proband presented with bilateral retinal hemangioblastomas. The patient's 19-year-old son was found to share her mutation, but did not exhibit and VHL symptoms at the time of the study. The proband had a sister with retinal hemangioblastoma, but she did not receive genetic testing. Family #4; A 20-year-old female Korean proband presented with bilateral retinal hemangioblastomas. The patient has a mother who had received treatment for retinal hemangioblastoma, but refused to undergo genetic analysis. No other VHL symptoms were observed in the proband or her mother. Suggested ACMG Code: 'PP4' because the patient's phenotype or family history is highly specific for a disease with a single genetic etiology."	27439424	PubMed		"Lee et al., 2016, BMC Med. Genet."		3	accepted	6742	Rare Germline	2023-01-09 21:46:53 UTC	https://civicdb.org/links/evidence_items/6742	https://civicdb.org/links/molecular_profiles/1832	FALSE	VHL	7428	E70K (c.208G>A)		chr3	10142055	10142055	G	A	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.208G>A,NP_000542.1:p.Glu70Lys,NC_000003.11:g.10183739G>A,ENST00000256474.2:c.208G>A"	2023-01-27 17:13:46 UTC	CA020108	43598	"C.208G>A,GLU70LYS,RS5030802"	FALSE
VHL S65W (c.194C>G)	1663	Von Hippel-Lindau Disease	14175	"Hemangioblastoma,Pancreatic cysts,Renal cell carcinoma"			Predisposing	Supports	C	Uncertain Significance	"A retrospective cohort study included all the VHL patients diagnosed at Peking University First Hospital (Beijing, China) prior to June 1 2016. A total of 291 patients from 115 different families were included for analysis. The c.194C>G (p.Ser65Trp) variant was found in a 48Y patient with RCC and multiple pancreatic cysts or tumours, and his son who had a CNS hemangioblastoma at 22Y. The patient's mother and brother had CNS hemangioblastomas at age 61 and 33 respectively, although genotypic confirmation was not available.  This variant was also found in an unrelated woman with CNS hemangioblastoma diagnosed at age 34Y, and renal cell carcinoma and multiple pancreatic cysts or tumours diagnosed at age 37Y.  ACMG codes: PM2 -absent from controls in GnomAD; PP4 - patient's phenotype or FHx is highly specific for a disease with a single genetic etiology."	28388566	PubMed		"Peng et al., 2017, Oncotarget"		3	accepted	6789	Rare Germline	2023-01-09 21:46:49 UTC	https://civicdb.org/links/evidence_items/6789	https://civicdb.org/links/molecular_profiles/1663	FALSE	VHL	7428	S65W (c.194C>G)		chr3	10142041	10142041	C	G	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.194C>G,NM_000551.3:c.194C>G,NP_000542.1:p.Ser65Trp,NC_000003.11:g.10183725C>G"	2023-01-27 17:12:02 UTC	CA020099	43597	"C.194C>G,SER65TRP,RS5030826"	FALSE
VHL S65L (c.194C>T)	1664	Von Hippel-Lindau Disease	14175	"Pancreatic cysts,Renal cell carcinoma,Retinal capillary hemangioma,Hemangioblastoma,Pheochromocytoma"			Predisposing	Supports	C	Uncertain Significance	"A retrospective cohort study included all the VHL patients diagnosed at Peking University First Hospital (Beijing, China) prior to June 1 2016. A total of 291 patients from 115 different families were included for analysis. A mutation c.194C>T (p.Ser65Leu) was found in 3 families (#4, #5, #6) with 11 genetically confirmed patients and 13 affected members in total. From family #4: one male patient presented with renal cell carcinoma at 33Y and pancreatic cysts or tumors at 33Y (mutation confirmed). From family #5: male proband with CNS haemangioblastoma at 21Y and multpile pancreatic cysts or tumours at 30Y (mutation confirmed), grandfather with CNS haemangioblastoma at 30Y (mutation status unknown), father with CNS haemangioblastoma at 36Y (mutation status unknown), and uncle with CNS haemangioblastoma at 33Y (mutation status unknown). From family #6: female proband with RCC at 36Y who then developed PCT at 37Y (mutation confirmed); daughter confirmed with the mutation but no manifestations and age unknown; mother with CNS hemangioblastoma diagnosed at 59Y (mutation confirmed); uncle 1 with CNS hemangioblastoma at 45Y, renal cell carcinoma at 59Y, and multiple pancreatic cysts or tumours at 65Y (mutation confirmed); son of uncle 1 with CNS hemangioblastoma at 22Y (mutation status unknown); Uncle 2 with CNS hemangioblastoma at 51Y, renal cell carcinoma at 51Y, and pancreatic cysts or tumours at 51Y (mutation status unknown); 1st son of uncle 2 with CNS hemangioblastoma at 22Y, renal cell carcinoma at 30Y, and pancreatic cysts or tumours at 31Y (mutation confirmed); 2nd son of uncle 2 with mutation confirmed but no manifestations and age unknown; granddaughter of uncle 2 with mutation confirmed but no manifestations and age unknown; Uncle 3 with multiple pancreatic cysts or tumours at 49Y (mutation confirmed); Aunt with CNS hemangioblastoma at 53Y and retinal angioma at 53Y (mutation confirmed). This evidence supports the following ACMG Codes: PP4 - the patient's phenotype and family history are highly specific for a disease with single genetic etiology, PP1- Co-segregation with disease in multiple affected family members (.e. family #6), PM2 - Absent from controls (i.e. gnomAD)"	28388566	PubMed		"Peng et al., 2017, Oncotarget"		3	accepted	6791	Rare Germline	2023-01-09 21:46:49 UTC	https://civicdb.org/links/evidence_items/6791	https://civicdb.org/links/molecular_profiles/1664	FALSE	VHL	7428	S65L (c.194C>T)		chr3	10142041	10142041	C	T	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.194C>T,NP_000542.1:p.Ser65Leu,NC_000003.11:g.10183725C>T,ENST00000256474.2:c.194C>T"	2023-01-27 17:12:03 UTC	CA020104	182975	"C.194C>T,SER65LEU,RS5030826"	FALSE
VHL E70K (c.208G>A)	1832	Von Hippel-Lindau Disease	14175	"Retinal capillary hemangioma,Hemangioblastoma"			Predisposing	Supports	C	Uncertain Significance	"Medical records of 26 patients with germline mutations of the VHL gene who had been diagnosed with VHL disease in Severance Hospital (Seoul, Republic of Korea) and Samsung Medical Center (Seoul, Republic of Korea) between 2003 and 2012 were reviewed. 9 unrelated patients diagnosed with Type 1 VHL disease shared the same VHL germline missense mutation (c.208G>A; p.Glu70Lys). The patients' phenotypes were as follows: 55 year old male with multiple CNS hemangioblastomas (patient 3), 55Y male with multiple CNS hemangioblastomas (Patient 4), 43Y male with multiple CNS hemangioblastomas (other phenotypic data not available, Patient 5), 11Y male with bilateral retinal hemangioblastoma (patient 6), 48Y female with CNS hemangioblastoma (Patient 7) , 64Y female with CNS hemangioblastoma (patient 8), 16Y F with retinal hemangioblastoma (Patient 9), 41Y female with CNS hemangioblastoma (patient 10).  One patient has concurrent missense and splicing mutations (208G>A and IVS1+5G>C). 52 year old male with retinal hemangioblstoma. ACMG codes as follows: PM1 Located in a mutational hot spot and/or critical and well-established functional domain (e.g., active site of an enzyme) without benign variation."	25078357	PubMed		"Hwang et al., 2014, J. Hum. Genet."		3	accepted	6860	Rare Germline	2023-01-09 21:46:53 UTC	https://civicdb.org/links/evidence_items/6860	https://civicdb.org/links/molecular_profiles/1832	FALSE	VHL	7428	E70K (c.208G>A)		chr3	10142055	10142055	G	A	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.208G>A,NP_000542.1:p.Glu70Lys,NC_000003.11:g.10183739G>A,ENST00000256474.2:c.208G>A"	2023-01-27 17:13:46 UTC	CA020108	43598	"C.208G>A,GLU70LYS,RS5030802"	FALSE
VHL F76del (c.224_226delTCT)	1964	Von Hippel-Lindau Disease	14175	"Renal cell carcinoma,Hemangioblastoma"			Predisposing	Supports	C	Uncertain Significance	"Medical records of 26 patients diagnosed with VHL disease in two Korean hospitals between 2003-2012 and harboring germline VHL mutations were retrospectively reviewed. One male patient diagnosed with Type 1 VHL disease at 23Y (Patient 14) presented with renal cell carcinoma, multiple CNS hemangioblastomas and other manifestations. He had a germline inframe deletion in the VHL gene (c.227delTCT) and a negative family history of VHL disease."	25078357	PubMed		"Hwang et al., 2014, J. Hum. Genet."		3	accepted	6862	Rare Germline	2023-01-09 21:46:55 UTC	https://civicdb.org/links/evidence_items/6862	https://civicdb.org/links/molecular_profiles/1964	FALSE	VHL	7428	F76del (c.224_226delTCT)		chr3	10142071	10142073	TCT		ENST00000256474.2	75		inframe_deletion	"NP_000542.1:p.Phe76del,ENST00000256474.2:c.224_226delTCT,NC_000003.11:g.10183758_10183760del,NC_000003.12:g.10142074_10142076del,NM_000551.3:c.227_229del,ENSP00000256474.2:p.Phe76del"	2023-01-27 17:15:01 UTC	CA357012	223166	"PHE76DEL,C.224_226DELTCT,C.226_228DELTTC,C.227_229DELTCT,DELPHE76"	FALSE
VHL S65L (c.194C>T)	1664	Renal Carcinoma	4451	"Sporadic,Clear cell renal cell carcinoma"			Oncogenic	Supports	C	Oncogenicity	"Tumors from 110 patients with sporadic renal carcinoma were analyzed for VHL mutations and loss of heterozygosity. 56 of the 98 samples from sporadic, clear cell renal carcinoma patients were identified with VHL somatic mutations; Loss of heterozygosity was observed in 97% of those samples. This missense mutation was found in one of the clear cell renal carcinoma cell lines (sample UOK164). No phenotype described."	7915601	PubMed		"Gnarra et al., 1994, Nat. Genet."		1	accepted	6890	Somatic	2023-02-03 19:21:31 UTC	https://civicdb.org/links/evidence_items/6890	https://civicdb.org/links/molecular_profiles/1664	FALSE	VHL	7428	S65L (c.194C>T)		chr3	10142041	10142041	C	T	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.194C>T,NP_000542.1:p.Ser65Leu,NC_000003.11:g.10183725C>T,ENST00000256474.2:c.194C>T"	2023-01-27 17:12:03 UTC	CA020104	182975	"C.194C>T,SER65LEU,RS5030826"	FALSE
VHL L118P (c.353T>C)	1674	Clear Cell Renal Cell Carcinoma	4467	Clear cell renal cell carcinoma			Oncogenic	Supports	C	Oncogenicity	"Tumors from 98 patients with sporadic clear cell renal carcinoma (ccRC) were analyzed for VHL mutations and loss of heterozygosity (LOH). Somatic VHL variants were observed in 56 patients, and VHL LOH was observed in 98% of samples with VHL variants. VHL L118P (c.353T>C) was found in a granular ccRC (sample T36, variant location indicated at c.566 because of differences in reference transcript). Authors noted that VHL variants were highly specific to ccRC and not found in the 12 other tumor types examined."	7915601	PubMed		"Gnarra et al., 1994, Nat. Genet."		1	accepted	6905	Somatic	2023-02-03 19:21:41 UTC	https://civicdb.org/links/evidence_items/6905	https://civicdb.org/links/molecular_profiles/1674	FALSE	VHL	7428	L118P (c.353T>C)		chr3	10146526	10146526	T	C	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.353T>C,NM_000551.3:c.353T>C,NP_000542.1:p.Leu118Pro,NC_000003.11:g.10188210T>C"	2023-01-27 17:12:11 UTC	CA70049399	428807	"C.353T>C,LEU118PRO,RS5030830"	FALSE
VHL P138R (c.413C>G)	2313	Clear Cell Renal Cell Carcinoma	4467	Clear cell renal cell carcinoma			Oncogenic	Supports	C	Oncogenicity	"Tumors from 98 patients with sporadic clear cell renal carcinoma (ccRC) were analyzed for VHL mutations and loss of heterozygosity (LOH). Somatic VHL variants were observed in 56 patients, and VHL LOH was observed in 98% of samples with VHL variants. P138R (c.413C>G) was found in a granular ccRC (sample UOK102, variant location indicated at NT 626 because of differences in reference transcript). Authors noted that VHL variants were highly specific to ccRC and not found in the 12 other tumor types examined."	7915601	PubMed		"Gnarra et al., 1994, Nat. Genet."		1	accepted	6915	Somatic	2023-02-03 19:21:56 UTC	https://civicdb.org/links/evidence_items/6915	https://civicdb.org/links/molecular_profiles/2313	FALSE	VHL	7428	P138R (c.413C>G)		chr3	10146586	10146586	C	G	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.413C>G,NC_000003.11:g.10188270C>G,NM_000551.3:c.413C>G,NP_000542.1:p.Pro138Arg"	2023-01-27 17:16:47 UTC	CA351754085	NONE FOUND	"C.413C>G,PRO138ARG"	FALSE
VHL N150fs (c.447del)	2434	Renal Carcinoma	4451	Clear cell renal cell carcinoma			Oncogenic	Supports	C	Oncogenicity	"Tumors from 98 patients with sporadic clear cell renal carcinoma (ccRC) were analyzed for VHL mutations and loss of heterozygosity (LOH). Somatic VHL variants were observed in 56 patients, and VHL LOH was observed in 98% of samples with VHL variants. VHL N150fs (c.447del) was found in a ccRC (sample T683, variant noted as c.659del because of differences in reference transcript). Authors noted that VHL variants were highly specific to ccRC and not found in the 12 other tumor types examined."	7915601	PubMed		"Gnarra et al., 1994, Nat. Genet."		1	accepted	6918	Somatic	2023-02-03 19:22:03 UTC	https://civicdb.org/links/evidence_items/6918	https://civicdb.org/links/molecular_profiles/2434	FALSE	VHL	7428	N150fs (c.447del)		chr3	10146619	10146619	C		ENST00000256474.2	75		"minus_1_frameshift_variant,frameshift_truncation"	"NP_000542.1:p.Asn150IlefsTer9,ENST00000256474.2:c.447del,NC_000003.12:g.10146620del,NC_000003.11:g.10188304del,NM_000551.3:c.447del"	2023-01-27 17:17:32 UTC	CA432421904	NONE FOUND	"C.446DELC,N150IFS*9,A149FS"	FALSE
VHL Q164* (c.490C>T)	1721	Clear Cell Renal Cell Carcinoma	4467	Clear cell renal cell carcinoma			Oncogenic	Supports	C	Oncogenicity	"Tumors from 98 patients with sporadic clear cell renal cell carcinoma (ccRCC) were analyzed for VHL mutations and loss of heterozygosity (LOH). Somatic VHL variants were observed in 56 patients, and VHL LOH was observed in 98% of samples with VHL variants. VHL Q164* (c.490C>T) was found in a granular ccRC (sample UOK161, variant location indicated as c.703 because of differences in reference transcript). Authors noted that VHL variants were highly specific to ccRC and not found in the 12 other tumor types examined."	7915601	PubMed		"Gnarra et al., 1994, Nat. Genet."		1	accepted	6925	Somatic	2023-02-03 19:22:11 UTC	https://civicdb.org/links/evidence_items/6925	https://civicdb.org/links/molecular_profiles/1721	FALSE	VHL	7428	Q164* (c.490C>T)		chr3	10149813	10149813	C	T	ENST00000256474.2	75		stop_gained	"NM_000551.3:c.490C>T,NP_000542.1:p.Gln164Ter,NC_000003.11:g.10191497C>T,ENST00000256474.2:c.490C>T"	2023-01-27 17:12:43 UTC	CA357060	223228	"C.490C>T,Q164X,GLN164TER,RS5030819"	FALSE
NTRK3 ETV6::NTRK3	779	B-lymphoblastic Leukemia/lymphoma	80630	Young adult onset	Larotrectinib		Predictive	Supports	D	Sensitivity/Response	"Both in vivo and in vitro models demonstrated Larotrectinib was an effective treatment against cells harboring ETV6-NTRK3. In YFP-luciferase PDX mice from a 16-year-old with Ph-like B-ALL, flow cytometry indicated the absence of leukemic cells in the bone marrow (p<.0001), peripheral blood (p=.0018), and spleen (p=.0001) after 6 weeks of Larotrectinib (n=10) compared to vehicle treated mice (n=10). Treated mice also had lower splenic weight (p<.001) and the absence of leukemia burden in the bone marrow and central nervous system as determined by histopathology. In 2 mice, leukemic burden increased while Larotrectinib was paused from weeks 6-25. Upon the reintroduction of treatment for 4 weeks, leukemic burden was lowered. Conditional knock-in Etv6-NTRK CD19-Cre cells isolated from bone marrow and cultured ex vivo were highly sensitive to serial dilutions of Larotrectinib. After 48 hours of Larotrectinib exposure, Ba/F3 cells stably expressing ETV6-NTRK3 demonstrated a response with an IC50 of 17.0nM (viability measured by CellTiter blue). Finally, Larotrectinib was 1000x more potent against 3 human cancer cell lines with an NTRK fusion versus the 76 with other alterations. The most sensitive was an AML cell line (M0-91) with an ETV6-NTRK3 fusion."	29880614	PubMed		"Roberts et al., 2018, Blood"		4	accepted	6930	Somatic	2023-01-09 21:46:38 UTC	https://civicdb.org/links/evidence_items/6930	https://civicdb.org/links/molecular_profiles/779	FALSE	NTRK3	4916	ETV6::NTRK3		chr12	11649854	11869969			ENST00000396373.4	75	ENST00000394480.2	transcript_fusion		2023-01-09 21:52:09 UTC		N/A	ETV6-NTRK3	FALSE
TERT Promoter Mutation	220	Glioblastoma	3068				Prognostic	Supports	B	Poor Outcome	"In 50 patients with primary glioblastomas, patients without TERT promoter mutations (N=13, median 27 mo) survived longer than those harboring mutations (N=37, 14 mo; P = 0.01 by the log rank test; HR 0.38, 95% CI [0.18, 0.81])."	23530248	PubMed		"Killela et al., 2013, Proc. Natl. Acad. Sci. U.S.A."		3	accepted	6933	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/6933	https://civicdb.org/links/molecular_profiles/220	FALSE	TERT	7015	Promoter Mutation		chr5	1295046	1295258			ENST00000310581.5	75		regulatory_region_variant		2023-01-09 21:52:05 UTC			"-124C>T,-146C>T"	FALSE
BRAF V600	17	Melanoma	1909		"Trametinib,Dabrafenib"	Combination	Predictive	Supports	B	Sensitivity/Response	"In this Phase III trial (NCT01584648 COMBI-d), 423 previously untreated patients with unresectable stage IIIC or IV BRAF V600E or V600K mutant melanoma received dabrafenib and trametinib or dabrafenib alone with primary endpoint of progression free survival with secondary endpoints including disease response. The hazard ratio for progression or death in the dabrafenibtrametinib group was 0.75 (95% confidence interval, 0.57 to 0.99; P=0.03). Of 210 patients in the dabrafenib + trametinib group, 67% of patients had a response, which was 16 percentage points higher than in the dabrafenib-alone group (95% CI, 6 to 25; P=0.002)."	25265492	PubMed		"Long et al., 2014, N. Engl. J. Med."	NCT01584648	5	accepted	6937	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/6937	https://civicdb.org/links/molecular_profiles/17	FALSE	BRAF	673	V600	Other BRAF V600's	chr7	140753336	140753337			ENST00000288602.6	75		protein_altering_variant		2023-01-09 21:52:04 UTC		"13,961,448,153,762,800,000,000,000,000,000"	VAL600	FALSE
BRAF V600E	12	Melanoma	1909		"Trametinib,Dabrafenib"	Combination	Predictive	Supports	B	Sensitivity/Response	"In this Phase III trial (NCT01584648 COMBI-d), previously untreated patients with unresectable stage IIIC or IV melanoma with BRAF V600E (359 patients) or V600K (61 patients) received dabrafenib and trametinib or dabrafenib alone with primary endpoint of progression free survival and secondary endpoints including disease response. The hazard ratio for progression or death in the V600E group was 0.81 for dabrafenib-trametinib vs dabrafenib-alone. Of 179 V600E patients in the dabrafenib-trametinib group, 68% of patients had a response, which was 15 percentage points higher than in the dabrafenib-alone group (95% CI, 4 to 24; P=0.006)."	25265492	PubMed		"Long et al., 2014, N. Engl. J. Med."	NCT01584648	5	accepted	6938	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/6938	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
BRAF V600E	12	Melanoma	1909		"Dabrafenib,Trametinib"	Combination	Predictive	Supports	B	Sensitivity/Response	"In this Phase I and II study (NCT01072175) patients with metastatic melanoma were given dabrafenib and trametinib combination therapy vs. dabrafenib monotherapy. From V600E patients, 45 received monotherapy and 92 received combination therapy. Hazard ratio for progression or death was 0.43 (95% CI, 0.27-0.71). Both patients with the BRAF V600E and V600K mutation showed significant improvement in progression-free survival."	23020132	PubMed		"Flaherty et al., 2012, N. Engl. J. Med."	NCT01072175	4	accepted	6940	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/6940	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
EZH2 Y646F	2858	Skin Melanoma	8923		JQEZ5		Predictive	Supports	D	Sensitivity/Response	Experiment with immunodeficient mice transplanted with melanoma cell lines indicates EZH2 inhibitor JQEZ5 might be effective in combination with a B-RAF inhibitor in RAF-mutant melanoma.	27135738	PubMed		"Souroullas et al., 2016, Nat. Med."		4	accepted	6952	Somatic	2023-02-03 18:04:38 UTC	https://civicdb.org/links/evidence_items/6952	https://civicdb.org/links/molecular_profiles/2858	FALSE	EZH2	2146	Y646F		chr7	148811635	148811635	T	A	ENST00000320356.7			missense_variant	"ENST00000320356.7:c.1937A>T,NC_000007.14:g.148811635T>A,NC_000007.13:g.148508727T>A,ENSP00000320147.2:p.Tyr646Phe,ENST00000460911.5:c.1922A>T,ENSP00000419711.1:p.Tyr641Phe,NM_004456.5:c.1937A>T,NP_004447.2:p.Tyr646Phe,NM_001203247.2:c.1922A>T,NP_001190176.1:p.Tyr641Phe"	2023-01-27 17:18:07 UTC	CA16602259	76768	"Y641F,TYR641PHE,TYR646PHE"	FALSE
ACVR1 G328V	1594	"Diffuse Midline Glioma, H3 K27M-mutant"	80684				Diagnostic	Supports	B	Positive	"In a study sequencing 61 patients (median age 6.3) with diffuse intrinsic pontine glioma (DIPG), 12 variants affecting ACVR1 were observed. Five patients had G328V within the kinase domain. The ACVR1 G328V mutation was expressed using the pCDH511b vector in immortalized normal human astrocytes (iNHAs) where it activated downstream BMP signaling and enhanced cell growth. Activating ACVR1 mutations are recurrent and support diagnosis of high grade glioma. PEDIATRIC"	24705254	PubMed		"Buczkowicz et al., 2014, Nat. Genet."		3	accepted	6955	Somatic	2023-01-09 21:46:47 UTC	https://civicdb.org/links/evidence_items/6955	https://civicdb.org/links/molecular_profiles/1594	FALSE	ACVR1	90	G328V	ACVR1 kinase domain mutation	chr2	157766004	157766004	C	A	ENST00000434821.1	75		missense_variant	"NM_001105.4:c.983G>T,NP_001096.1:p.Gly328Val,NC_000002.11:g.158622516C>A,ENST00000434821.1:c.983G>T"	2023-01-27 17:11:21 UTC	CA16602802	376363	"GLY328VAL,RS387906589"	FALSE
NRAS Q61	94	Thyroid Gland Follicular Carcinoma	3962				Prognostic	Does Not Support	B	Poor Outcome	"Follicular thyroid cancers harboring RAS mutations have limited aggressiveness in the absence of TERT mutations. 2/2 follicular thyroid cancer patients with co-mutations in NRAS (10 Q61R and 1 Q61K) or HRAS (2 Q61R and 1 Q61K) and TERT promoter mutations had persistent or recurrent disease compared to 1/11 patients with only a RAS mutation (100% vs 8%, P=0.03)."	25448848	PubMed		"Muzza et al., 2015, Mol. Cell. Endocrinol."		2	accepted	6959	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/6959	https://civicdb.org/links/molecular_profiles/94	FALSE	NRAS	4893	Q61		chr1	114713907	114713909			ENST00000369535.4	75		missense_variant		2023-01-09 21:52:04 UTC		"7,305,813,900,375,870,000,000,000,000,000,000,000,000"	GLN61	FALSE
BRAF V600K	559	Melanoma	1909		"Trametinib,Dabrafenib"	Combination	Predictive	Supports	B	Sensitivity/Response	"In this Phase III trial (coBRIM, NCT01689519) of 495 V600 mutant melanoma patients, 56 had V600K mutation. 32 patients were treated with vemurafenib and placebo, and 24 were treated with vemurafenib and cobimetinib and tested for progression free survival. 17 of 32 monotherapy group patients had an event with median progression free survival of 5.3 months. In the combination group 4 of 24 patients had an event with median progression-free survival not met, however, when in combination with other V600 mutations median progression-free survival was 9.9 months with combination treatment. Median time to followup for the whole cohort was 7.3 months. Hazard Ratio for progression or death was 0.27 (0.09-0.81)."	25265494	PubMed		"Larkin et al., 2014, N. Engl. J. Med."	NCT01689519	4	accepted	6965	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/6965	https://civicdb.org/links/molecular_profiles/559	FALSE	BRAF	673	V600K	Other BRAF V600's	chr7	140753336	140753337	AC	TT	ENST00000288602.6	75		missense_variant	"ENST00000288602.6:c.1798_1799delinsAA,NC_000007.13:g.140453136_140453137delinsTT,NM_004333.4:c.1798_1799delGTinsAA,NP_004324.2:p.Val600Lys"	2023-01-27 17:04:21 UTC	CA16602420	375941	"VAL600LYS,RS121913227"	FALSE
BRAF V600	17	Melanoma	1909		"Vemurafenib,Cobimetinib"	Combination	Predictive	Supports	B	Sensitivity/Response	"In this Phase 1b study, 129 patients with unresectable or metastatic melanoma were verified for BRAF V600 mutation using the cobas 4800 mutation test were selected who had progressed on vemurafenib (66 patients) or never received BRAF inhibitor (63 patients). The combination of vemurafenib and cobimetinib was deemed safe and tolerable. Confirmed objective responses were seen in 15% of vemurafenib progressed patients and median progression-free survival was 2.8 months (95% CI 26?4). Confirmed objective responses were seen in 87% of patients who had never received BRAF inhibitor, including 10% with complete response. Median progression-free survival was 13.7 months (95% CI 101?75). The majority of patients had BRAF V600E mutation. Post-hoc sequencing of 94 tumor samples indicated seven tumors with a mutation other than BRAF V600E."	25037139	PubMed		"Ribas et al., 2014, Lancet Oncol."	NCT01271803	3	accepted	6966	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/6966	https://civicdb.org/links/molecular_profiles/17	FALSE	BRAF	673	V600	Other BRAF V600's	chr7	140753336	140753337			ENST00000288602.6	75		protein_altering_variant		2023-01-09 21:52:04 UTC		"13,961,448,153,762,800,000,000,000,000,000"	VAL600	FALSE
ABL1 BCR::ABL F359V	866	Chronic Myeloid Leukemia	8552		"Nilotinib,Imatinib Mesylate"	Substitutes	Predictive	Supports	C	Resistance	"In this open-label, phase II registration trial, patients that were imatinib-resistant or intolerant underwent nilotinib monotherapy. Within 12 months of nilotinib therapy, there was no significant difference in response to nilotinib treatment between patients with mutations in the Abl1 kinase domain versus without. However, the authors identify Y253H, E255K/V, and F359C/V variants as resistant as they had an IC50 of >150nM. In patients with F359C and/or F359V mutations prior to nilotinib treatment, complete hematological responses were achieved in 3 of 10 patients, a major cytogenetic response in 1 of 11 patients, a complete cytogenetic response in 0 of 11 patients, and major molecular response in 0 of 10 patients. After a median follow-up of 15.5 months, 9 of 11 patients with this mutation progressed or died. The F359C mutation was present in 1 patient at baseline and newly emerged in 1 patient at progression. The F359V mutation was present in 4 patients at baseline and newly emerged in 1 patient at progression."	19652056	PubMed		"Hughes et al., 2009, J. Clin. Oncol."		3	accepted	6970	Somatic	2023-01-09 21:46:39 UTC	https://civicdb.org/links/evidence_items/6970	https://civicdb.org/links/molecular_profiles/866	FALSE	ABL1	25	BCR::ABL F359V		chr9	130873027	130873027	T	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.1075T>G,NP_005148.2:p.Phe359Val,NC_000009.11:g.133748414T>G,ENST00000318560.5:c.1075T>G"	2023-01-27 17:06:25 UTC	CA16602557	376096	"RS121913452,BCR-ABL F378V,BCR-ABL PHE359VAL,BCR-ABL1 F359V,BCR-ABL1 PHE359VAL,BCR-ABL F359V"	FALSE
ABL1 BCR::ABL E255V	1147	Chronic Myeloid Leukemia	8552		"Nilotinib,Imatinib Mesylate"	Substitutes	Predictive	Supports	C	Resistance	"In this open-label, phase II registration trial, patients that were imatinib resistant or intolerant underwent nilotinib monotherapy. Within 12 months of nilotinib therapy, there was no significant difference in response to nilotinib treatment between patients with mutations in the Abl1 kinase domain versus without. However, the authors identify Y253H, E255K/V, and F359C/V variants as resistant as they had an IC50 greater than 150 nM. In patients with E255K and/or E255V mutations prior to nilotinib treatment, complete hematological responses were achieved in 5 of 7 patients, major cytogenetic responses in 3 of 7 patients, complete cytogenetic responses in 0 of 7 patients, and a major molecular response in 1 of 7 patients. After a median follow-up of 15.5 months, 6 of 7 patients with this mutation progressed or died. The E255K mutation was present in 6 patients at baseline and newly emerged in 4 patients at progression. The E255V mutation was present in 0 patients at baseline and newly emerged in 3 patients at progression."	19652056	PubMed		"Hughes et al., 2009, J. Clin. Oncol."		3	accepted	6971	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/6971	https://civicdb.org/links/molecular_profiles/1147	FALSE	ABL1	25	BCR::ABL E255V		chr9	130862977	130862977	A	T	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.764A>T,NP_005148.2:p.Glu255Val,NC_000009.11:g.133738364A>T,ENST00000318560.5:c.764A>T"	2023-01-27 17:08:31 UTC	CA16602552	376091	"RS121913449,BCR-ABL E274V,BCR-ABL GLU255VAL,BCR-ABL1 E274V,BCR-ABL1 GLU255VAL,BCR-ABL E255V"	FALSE
BRAF V600E	12	Thyroid Gland Anaplastic Carcinoma	80522		"Trametinib,Dabrafenib"	Combination	Predictive	Supports	B	Sensitivity/Response	"Interim analysis of a basket trial evaluating the combination of dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) in previously treated V600E-mutated patients showed 11/16 patients with anaplastic thyroid carcinoma responded to treatment (overall response rate 69%; 95% CI, 41% to 89%). Seven patients had ongoing responses. Median duration of response, progression-free survival, and overall survival were not reached after 120 weeks."	29072975	PubMed		"Subbiah et al., 2018, J. Clin. Oncol."	NCT02034110	4	accepted	6975	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/6975	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
PDGFRB EBF1::PDGFRB	531	Childhood B-cell Acute Lymphoblastic Leukemia	80146	Young adult onset	Imatinib		Predictive	Supports	C	Sensitivity/Response	"A 16-year-old boy with B-cell acute lymphoblastic leukemia refractory to conventional chemotherapy and harboring an IKZF1 deletion (delta 2-7) and a 5q33 microdeletion resulting in an EBF1-PDGFRB fusion responded to continuous imatinib (400 mg/d) during consolidation. Following consolidation therapy that included dexamethasone, vincristine, etoposide, cytarabine, and high-dose methotrexate, MRD declined to 10^-5 and the patient underwent bone marrow transplant. MRD performed at 105 days post-BMT found no detectable blasts with a sensitivity of 10^-5."	24186319	PubMed		"Lengline et al., 2013, Haematologica"		3	accepted	6976	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/6976	https://civicdb.org/links/molecular_profiles/531	FALSE	PDGFRB	5159	EBF1::PDGFRB		chr5	158707979	159099761			ENST00000517373.1	75	ENST00000261799.4	transcript_fusion		2023-01-09 21:52:07 UTC		N/A	EBF1-PDGFRB	FALSE
PDGFRB EBF1::PDGFRB	531	Childhood B-cell Acute Lymphoblastic Leukemia	80146	Young adult onset	Imatinib		Predictive	Supports	C	Sensitivity/Response	"A 16-year-old boy with B-cell acute lymphoblastic leukemia refractory to conventional chemotherapy and harboring an IKZF1 deletion (delta 2-7) and a 5q33 microdeletion resulting in an EBF1-PDGFRB fusion responded to continuous imatinib (400 mg/d) during consolidation. Following consolidation therapy that included dexamethasone, vincristine, etoposide, cytarabine, and high-dose methotrexate, MRD declined to 10^-5 and the patient underwent bone marrow transplant. MRD performed at 105 days post-BMT found no detectable blasts with a sensitivity of 10^-5."	24186319	PubMed		"Lengline et al., 2013, Haematologica"		3	accepted	6976	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/6976	https://civicdb.org/links/molecular_profiles/531	FALSE	PDGFRB	5159	EBF1::PDGFRB		chr5	150113837	150125577			ENST00000517373.1	75	ENST00000261799.4	transcript_fusion		2023-01-09 21:52:07 UTC		N/A	EBF1-PDGFRB	FALSE
ABL1 BCR::ABL N336S	1548	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	C	Resistance	"In a study of 39 chronic phase CML patients with BCR-ABL variants, N336S was seen in a single imatinib-resistant patient that was also resistant or intolerant to dasatinib and/or nilotinib treatment. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occurring."	22371878	PubMed		"Khoury et al., 2012, Blood"	NCT00261846	1	accepted	6979	Somatic	2023-01-09 21:46:47 UTC	https://civicdb.org/links/evidence_items/6979	https://civicdb.org/links/molecular_profiles/1548	FALSE	ABL1	25	BCR::ABL N336S		chr9	130872959	130872959	A	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"ENST00000318560.5:c.1007A>G,NC_000009.11:g.133748346A>G,NM_005157.5:c.1007A>G,NP_005148.2:p.Asn336Ser"	2023-01-27 17:11:06 UTC	CA375249553	NONE FOUND	"N355S,BCR-ABL1 ASN336SER,BCR-ABL N336S,BCR-ABL1 N336S,BCR-ABL N336S"	FALSE
ABL1 BCR::ABL E453A	1444	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	C	Resistance	"In a study of 39 chronic phase CML patients with BCR-ABL variants, E453A was seen in a single imatinib-resistant patient that was also resistant or intolerant to dasatinib and/or nilotinib treatment. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occurring."	22371878	PubMed		"Khoury et al., 2012, Blood"	NCT00261846	1	accepted	6980	Somatic	2023-01-09 21:46:46 UTC	https://civicdb.org/links/evidence_items/6980	https://civicdb.org/links/molecular_profiles/1444	FALSE	ABL1	25	BCR::ABL E453A		chr9	130878502	130878502	A	C	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"ENST00000318560.5:c.1358A>C,NC_000009.11:g.133753889A>C,NM_005157.5:c.1358A>C,NP_005148.2:p.Glu453Ala"	2023-01-27 17:10:18 UTC	CA375251172	NONE FOUND	"E472A,GLU453ALA,BCR-ABL1 E453A,BCR-ABL1 GLU453ALA,BCR-ABL E453A"	FALSE
ABL1 BCR::ABL L387F	1206	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	C	Resistance	"In a study of 39 chronic phase CML patients with BCR-ABL variants, L387F was seen in a single imatinib-resistant patient that was also resistant or intolerant to dasatinib and/or nilotinib treatment. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occurring."	22371878	PubMed		"Khoury et al., 2012, Blood"	NCT00261846	1	accepted	6981	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/6981	https://civicdb.org/links/molecular_profiles/1206	FALSE	ABL1	25	BCR::ABL L387F		chr9	130874943	130874943	G	C	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"ENST00000318560.5:c.1161G>C,NC_000009.11:g.133750330G>C,NM_005157.5:c.1161G>C,NP_005148.2:p.Leu387Phe"	2023-01-27 17:08:47 UTC	CA375249910	NONE FOUND	"L406F,LEU406PHE,LEU387PHE,BCR-ABL1 L387F,BCR-ABL1 LEU387PHE,BCR-ABL L387F"	FALSE
ABL1 BCR::ABL V299L	1205	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	B	Resistance	"In a study of 39 chronic phase CML patients with BCR-ABL variants, V299L was seen in two imatinib-resistant patients that were also resistant or intolerant to dasatinib and/or nilotinib treatment. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occurring."	22371878	PubMed		"Khoury et al., 2012, Blood"	NCT00261846	1	accepted	6982	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/6982	https://civicdb.org/links/molecular_profiles/1205	FALSE	ABL1	25	BCR::ABL V299L		chr9	130872201	130872201	G	C	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.895G>C,NP_005148.2:p.Val299Leu,NC_000009.11:g.133747588G>C,ENST00000318560.5:c.895G>C"	2023-01-27 17:08:46 UTC	CA16602575	376117	"BCR-ABL VAL299LEU,BCR-ABL V318L,RS1057519771,BCR-ABL1 V299L,BCR-ABL1 VAL299LEU,BCR-ABL V299L"	FALSE
ABL1 BCR::ABL Q300R	1435	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	C	Resistance	"In a study of 39 chronic phase CML patients with BCR-ABL variants, Q300R was seen in a single imatinib-resistant patient that was also resistant or intolerant to dasatinib and/or nilotinib treatment. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occurring."	22371878	PubMed		"Khoury et al., 2012, Blood"	NCT00261846	1	accepted	6983	Somatic	2023-01-09 21:46:45 UTC	https://civicdb.org/links/evidence_items/6983	https://civicdb.org/links/molecular_profiles/1435	FALSE	ABL1	25	BCR::ABL Q300R		chr9	130872205	130872205	A	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"ENST00000318560.5:c.899A>G,NC_000009.11:g.133747592A>G,NM_005157.5:c.899A>G,NP_005148.2:p.Gln300Arg"	2023-01-27 17:10:11 UTC	CA375249312	NONE FOUND	"Q319R,BCR-ABL GLN300ARG,BCR-ABL1 Q300R,BCR-ABL1 GLN300ARG,BCR-ABL Q300R"	FALSE
ABL1 BCR::ABL F359I	1431	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	C	Resistance	"In a study of 39 chronic phase CML patients with BCR-ABL variants, F359I was seen in two imatinib-resistant patients that were also resistant or intolerant to dasatinib and/or nilotinib treatment. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occurring."	22371878	PubMed		"Khoury et al., 2012, Blood"	NCT00261846	1	accepted	6984	Somatic	2023-01-09 21:46:45 UTC	https://civicdb.org/links/evidence_items/6984	https://civicdb.org/links/molecular_profiles/1431	FALSE	ABL1	25	BCR::ABL F359I		chr9	130873027	130873027	T	A	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.1075T>A,NP_005148.2:p.Phe359Ile,NC_000009.11:g.133748414T>A,ENST00000318560.5:c.1075T>A"	2023-01-27 17:10:08 UTC	CA16602580	376122	"RS121913452,F378I,BCR-ABL PHE359ILE,BCR-ABL1 F359I,BCR-ABL1 PHE359ILE,BCR-ABL F359I"	FALSE
ABL1 BCR::ABL F359C	1158	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	C	Resistance	"In a study of 39 chronic phase CML patients with BCR-ABL variants, F359C was seen in two imatinib-resistant patients that were also resistant or intolerant to dasatinib and/or nilotinib treatment. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occurring."	22371878	PubMed		"Khoury et al., 2012, Blood"	NCT00261846	1	accepted	6985	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/6985	https://civicdb.org/links/molecular_profiles/1158	FALSE	ABL1	25	BCR::ABL F359C		chr9	130873028	130873028	T	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.1076T>G,NP_005148.2:p.Phe359Cys,NC_000009.11:g.133748415T>G,ENST00000318560.5:c.1076T>G"	2023-01-27 17:08:36 UTC	CA16602582	376124	"F378C,RS1057519775,BCR-ABL PHE359CYS,BCR-ABL1 F359C,BCR-ABL1 PHE359CYS,BCR-ABL F359C"	FALSE
ABL1 BCR::ABL E255V	1147	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	C	Resistance	"In a study of 39 chronic phase CML patients with BCR-ABL variants, E255V was seen in a single imatinib-resistant patient that was also resistant or intolerant to dasatinib and/or nilotinib treatment. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occurring."	22371878	PubMed		"Khoury et al., 2012, Blood"	NCT00261846	1	accepted	6986	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/6986	https://civicdb.org/links/molecular_profiles/1147	FALSE	ABL1	25	BCR::ABL E255V		chr9	130862977	130862977	A	T	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.764A>T,NP_005148.2:p.Glu255Val,NC_000009.11:g.133738364A>T,ENST00000318560.5:c.764A>T"	2023-01-27 17:08:31 UTC	CA16602552	376091	"RS121913449,BCR-ABL E274V,BCR-ABL GLU255VAL,BCR-ABL1 E274V,BCR-ABL1 GLU255VAL,BCR-ABL E255V"	FALSE
ABL1 BCR::ABL F486S	1126	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	C	Resistance	"In a study of 39 chronic phase CML patients with BCR-ABL variants, F486S was seen in a single imatinib-resistant patient that was also resistant or intolerant to dasatinib and/or nilotinib treatment. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occurring."	22371878	PubMed		"Khoury et al., 2012, Blood"	NCT00261846	1	accepted	6987	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/6987	https://civicdb.org/links/molecular_profiles/1126	FALSE	ABL1	25	BCR::ABL F486S		chr9	130880101	130880101	T	C	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"ENST00000318560.5:c.1457T>C,NC_000009.11:g.133755488T>C,NM_005157.5:c.1457T>C,NP_005148.2:p.Phe486Ser"	2023-01-27 17:08:15 UTC	CA375251598	NONE FOUND	"BCR-ABL F505S,BCR-ABL PHE486SER,BCR-ABL1 PHE486SER,BCR-ABL1 F486S,BCR-ABL F486S"	FALSE
ABL1 BCR::ABL H396R	1004	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	C	Resistance	"In a study of 39 chronic phase CML patients with BCR-ABL variants, H396R was seen in a single imatinib-resistant patient that was also resistant or intolerant to dasatinib and/or nilotinib treatment. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occurring."	22371878	PubMed		"Khoury et al., 2012, Blood"	NCT00261846	1	accepted	6988	Somatic	2023-01-09 21:46:42 UTC	https://civicdb.org/links/evidence_items/6988	https://civicdb.org/links/molecular_profiles/1004	FALSE	ABL1	25	BCR::ABL H396R		chr9	130874969	130874969	A	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.1187A>G,NP_005148.2:p.His396Arg,NC_000009.11:g.133750356A>G,ENST00000318560.5:c.1187A>G"	2023-01-27 17:07:48 UTC	CA16602558	376097	"RS121913454,BCR-ABL HIS415ARG,BCR-ABL HIS396ARG,BCR-ABL H415R,BCR-ABL1 H396R,BCR-ABL1 HIS396ARG,BCR-ABL H396R"	FALSE
ABL1 BCR::ABL M351T	1003	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	C	Resistance	"In a study of 39 chronic phase CML patients with BCR-ABL variants, M351T was seen in a single imatinib-resistant patient that was also resistant or intolerant to dasatinib and/or nilotinib treatment. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occurring."	22371878	PubMed		"Khoury et al., 2012, Blood"	NCT00261846	1	accepted	6989	Somatic	2023-01-09 21:46:42 UTC	https://civicdb.org/links/evidence_items/6989	https://civicdb.org/links/molecular_profiles/1003	FALSE	ABL1	25	BCR::ABL M351T		chr9	130873004	130873004	T	C	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.1052T>C,NP_005148.2:p.Met351Thr,NC_000009.11:g.133748391T>C,ENST00000318560.5:c.1052T>C"	2023-01-27 17:07:48 UTC	CA122590	12629	"RS121913457,BCR-ABL M370T,BCR-ABL MET351THR,BCR-ABL MET370THR,BCR-ABL M351T"	FALSE
ABL1 BCR::ABL Y253H	999	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	C	Resistance	"In a study of 39 chronic phase CML patients with BCR-ABL variants, Y253H was seen in 6 imatinib-resistant patients that were also resistant or intolerant to dasatinib and/or nilotinib treatment. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occurring."	22371878	PubMed		"Khoury et al., 2012, Blood"	NCT00261846	3	accepted	6992	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/6992	https://civicdb.org/links/molecular_profiles/999	FALSE	ABL1	25	BCR::ABL Y253H		chr9	130862970	130862970	T	C	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.757T>C,NP_005148.2:p.Tyr253His,NC_000009.11:g.133738357T>C,ENST00000318560.5:c.757T>C"	2023-01-27 17:07:45 UTC	CA122584	12627	"RS121913461,Y272H,TYR272HIS,BCR-ABL TYR253HIS,BCR-ABL1 Y253H,BCR-ABL1 TYR253HIS,BCR-ABL Y253H"	FALSE
ABL1 BCR::ABL G250E	997	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	C	Resistance	"In a study of 39 chronic phase CML patients with BCR-ABL variants, G250E was seen in 6 imatinib-resistant patients that were also resistant or intolerant to dasatinib and/or nilotinib treatment. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occurring."	22371878	PubMed		"Khoury et al., 2012, Blood"	NCT00261846	3	accepted	6993	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/6993	https://civicdb.org/links/molecular_profiles/997	FALSE	ABL1	25	BCR::ABL G250E		chr9	130862962	130862962	G	A	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.749G>A,NP_005148.2:p.Gly250Glu,NC_000009.11:g.133738349G>A,ENST00000318560.5:c.749G>A"	2023-01-27 17:07:43 UTC	CA16602547	376086	"RS121913453,BCR-ABL G269E,BCR-ABL GLY250GLU,BCR-ABL1 G250E,BCR-ABL1 GLY250GLU,BCR-ABL G250E"	FALSE
ABL1 BCR::ABL M244V	995	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	C	Resistance	"In a study of 39 chronic phase CML patients with BCR-ABL variants, M244V was seen in 3 imatinib-resistant patients that were also resistant or intolerant to dasatinib and/or nilotinib treatment. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occurring."	22371878	PubMed		"Khoury et al., 2012, Blood"	NCT00261846	2	accepted	6994	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/6994	https://civicdb.org/links/molecular_profiles/995	FALSE	ABL1	25	BCR::ABL M244V		chr9	130862943	130862943	A	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.730A>G,NP_005148.2:p.Met244Val,NC_000009.11:g.133738330A>G,ENST00000318560.5:c.730A>G"	2023-01-27 17:07:41 UTC	CA16602545	376084	"RS121913456,M263V,MET263VAL,BCR-ABL MET244VAL,BCR-ABL1 M244V,BCR-ABL1 MET244VAL,BCR-ABL M244V"	FALSE
ABL1 BCR::ABL F359V	866	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	C	Resistance	"In a study of 39 chronic phase CML patients with BCR-ABL variants, C475V was seen in one imatinib-resistant patient that was also resistant or intolerant to dasatinib and/or nilotinib treatment. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occurring."	22371878	PubMed		"Khoury et al., 2012, Blood"	NCT00261846	1	accepted	6995	Somatic	2023-01-09 21:46:39 UTC	https://civicdb.org/links/evidence_items/6995	https://civicdb.org/links/molecular_profiles/866	FALSE	ABL1	25	BCR::ABL F359V		chr9	130873027	130873027	T	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.1075T>G,NP_005148.2:p.Phe359Val,NC_000009.11:g.133748414T>G,ENST00000318560.5:c.1075T>G"	2023-01-27 17:06:25 UTC	CA16602557	376096	"RS121913452,BCR-ABL F378V,BCR-ABL PHE359VAL,BCR-ABL1 F359V,BCR-ABL1 PHE359VAL,BCR-ABL F359V"	FALSE
VHL L178P (c.533T>C)	1624	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	Supports	C	Uncertain Significance	"Patients with ELSTs were identified and included in the International Endolymphatic Sac Tumor Registry. The registry contained 93 patients as of July 2014, and of those, 25 were sporadic, and 68 associated with VHL.  statistics of the VHL subgroup is as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. In the data from this study, only endolymphatic sac tumours can be confirmed as a phenotype for this mutation, which was found in 1 individual from France."	25867206	PubMed		"Bausch et al., 2016, Head Neck"		2	accepted	7004	Rare Germline	2023-01-09 21:46:48 UTC	https://civicdb.org/links/evidence_items/7004	https://civicdb.org/links/molecular_profiles/1624	FALSE	VHL	7428	L178P (c.533T>C)		chr3	10149856	10149856	T	C	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.533T>C,NM_000551.3:c.533T>C,NP_000542.1:p.Leu178Pro,NC_000003.11:g.10191540T>C"	2023-01-27 17:11:36 UTC	CA351756245	428795	"C.533T>C,LEU178PRO,RS5030822"	FALSE
VHL Y175* (c.525C>G)	1845	Von Hippel-Lindau Disease	14175	Endolymphatic sac tumor			Predisposing	Supports	C	Uncertain Significance	"Patients with ELSTs were identified and included in the International Endolymphatic Sac Tumor Registry. The registry contained 93 patients as of July 2014, and of those, 25 were sporadic, and 68 associated with VHL.  statistics of the VHL subgroup is as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, 12% with pancreatic neuroendocrine tumour. In the data from this study, only endolymphatic sac tumours can be confirmed as a phenotype for this mutation, which was found in 1 individual from France."	25867206	PubMed		"Bausch et al., 2016, Head Neck"		2	accepted	7005	Rare Germline	2023-01-09 21:46:53 UTC	https://civicdb.org/links/evidence_items/7005	https://civicdb.org/links/molecular_profiles/1845	FALSE	VHL	7428	Y175* (c.525C>G)		chr3	10149848	10149848	C	G	ENST00000256474.2	75		stop_gained	"ENST00000256474.2:c.525C>G,NC_000003.11:g.10191532C>G,NM_000551.3:c.525C>G,NP_000542.1:p.Tyr175Ter"	2023-01-27 17:13:54 UTC	CA020466	182974	"C.525C>G,Y175X,TYR175TER,RS5030835"	FALSE
PDGFRA FIP1L1::PDGFRA T674I	573	"Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1"	80164		Imatinib		Predictive	Supports	C	Resistance	"One patient with FIP1L1/PDGFRA-positive CEL was identified as developing secondary resistance to imatinib. A PDGFRA T674I mutation was identified in the tyrosine kinase domain. Salvage therapy with nilotinib and sorafenib each failed in this patient, who was eventually transplanted with an HLA-matched sibling donor."	21818111	PubMed		"Metzgeroth et al., 2012, Leukemia"		3	accepted	7020	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/7020	https://civicdb.org/links/molecular_profiles/573	FALSE	PDGFRA	5156	FIP1L1::PDGFRA T674I		chr4	54278380	54278380	C	T	ENST00000257290.5	75		"missense_variant,transcript_fusion"	"NC_000004.11:g.55144547C>T,ENST00000257290.5:c.2021C>T,NM_006206.5:c.2021C>T,NP_006197.1:p.Thr674Ile"	2023-01-27 17:04:23 UTC	CA123215	13550	"THR674ILE,RS121908587,FIP1L1-PDGFRA T674I"	FALSE
EGFR Mutation	438	Lung Non-small Cell Carcinoma	3908		Erlotinib		Predictive	Supports	B	Sensitivity/Response	"In this open-label, randomised, phase 3 trial at 22 centres in China, patients with stage IIIB or IV NSCLC who had exon 19 deletion or exon 21 L858R point mutation, and who had not received previous systemic anticancer therapy, were administered tyrosine kinase inhibitor erlotinib (83 patients) or gemcitabine plus carboplatin (82 patients). Median progression-free survival was found to be significantly longer with erlotinib than in patients on chemotherapy (13.1 [95% CI 10.58?6.53] vs 4.6 [4.21?.42] months; hazard ratio 0.16, 95% CI 0.10?.26; p<0.0001). Chemotherapy was also associated with more grade 3 or 4 toxic effects. Authors conclude that in patients with advanced EGFR mutant NSCLC, erlotinib offers an improved first line treatment option."	21783417	PubMed		"Zhou et al., 2011, Lancet Oncol."	NCT00874419	4	accepted	7024	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/7024	https://civicdb.org/links/molecular_profiles/438	FALSE	EGFR	1956	Mutation		chr7	55019101	55211628			ENST00000275493.2	75		inframe_variant		2023-01-09 21:52:07 UTC		N/A		FALSE
PDGFRB EBF1::PDGFRB	531	Childhood B-cell Acute Lymphoblastic Leukemia	80146		Imatinib		Predictive	Supports	C	Sensitivity/Response	Two patients with EBF1-PDGFRB positive pediatric B-ALL were treated with induction/post-induction therapy and Imatinib. Neither patient experienced disease relapse. One patient died of an undefined encephalopathy at 6 mos post-transplant and the other patient was alive in clinical remission at 10 months after diagnosis.	26872634	PubMed		"Schwab et al., 2016, Blood"		2	accepted	7028	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/7028	https://civicdb.org/links/molecular_profiles/531	FALSE	PDGFRB	5159	EBF1::PDGFRB		chr5	158707979	159099761			ENST00000517373.1	75	ENST00000261799.4	transcript_fusion		2023-01-09 21:52:07 UTC		N/A	EBF1-PDGFRB	FALSE
PDGFRB EBF1::PDGFRB	531	Childhood B-cell Acute Lymphoblastic Leukemia	80146		Imatinib		Predictive	Supports	C	Sensitivity/Response	Two patients with EBF1-PDGFRB positive pediatric B-ALL were treated with induction/post-induction therapy and Imatinib. Neither patient experienced disease relapse. One patient died of an undefined encephalopathy at 6 mos post-transplant and the other patient was alive in clinical remission at 10 months after diagnosis.	26872634	PubMed		"Schwab et al., 2016, Blood"		2	accepted	7028	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/7028	https://civicdb.org/links/molecular_profiles/531	FALSE	PDGFRB	5159	EBF1::PDGFRB		chr5	150113837	150125577			ENST00000517373.1	75	ENST00000261799.4	transcript_fusion		2023-01-09 21:52:07 UTC		N/A	EBF1-PDGFRB	FALSE
ABL1 BCR::ABL L248V	996	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	C	Resistance	"In this phase II multinational study, 60 imatinib-resistantpatients with accelerated phase CML and BCR-ABL fusions were treated with dasatinib monotherapy. 44 (73%) of 60 BCR-ABL mutant patients achieved major hematologic responses (MaHRs) and 18 (30%) of 60 achieved major cytogenetic responses (MCyRs). Of patients with L248V, 3/3 had MaHRs and 1/3 had MCyRs which were comparable to response rates among wild type patients."	17264298	PubMed		"Guilhot et al., 2007, Blood"		1	accepted	7029	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/7029	https://civicdb.org/links/molecular_profiles/996	FALSE	ABL1	25	BCR::ABL L248V		chr9	130862955	130862955	C	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.742C>G,NP_005148.2:p.Leu248Val,NC_000009.11:g.133738342C>G,ENST00000318560.5:c.742C>G"	2023-01-27 17:07:42 UTC	CA16602546	376085	"RS121913455,L267V,LEU248VAL,BCR-ABL L248V"	FALSE
ABL1 BCR::ABL E459K	2243	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	C	Resistance	"In this phase II multinational study, patients with accelerated phase CML and BCR-ABL fusions were treated with dasatinib monotherapy. Response rate among 60 imatinib-resistant patients with BCR-ABL mutations did not differ from the rate of the total population of 100 imatinib-resistant or -intolerant patients. 44 (73%) of 60 BCR-ABL mutant patients achieved major hematologic responses (MaHRs) and 18 (30%) of 60 achieved major cytogenetic responses (MCyRs). Of patients with E459K, 1/3 had MaHRs which was lower than response rates among wild type patients, and 3/3 had MCyRs which was higher than response rates among wild type patients."	17264298	PubMed		"Guilhot et al., 2007, Blood"		1	accepted	7031	Somatic	2023-01-09 21:46:58 UTC	https://civicdb.org/links/evidence_items/7031	https://civicdb.org/links/molecular_profiles/2243	FALSE	ABL1	25	BCR::ABL E459K		chr9	130878519	130878519	G	A	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"ENST00000318560.5:c.1375G>A,NC_000009.11:g.133753906G>A,NM_005157.5:c.1375G>A,NP_005148.2:p.Glu459Lys"	2023-01-27 17:16:31 UTC	CA200648598	NONE FOUND	"BCR-ABL GLU459LYS,RS1064156,BCR-ABL1 E459K,BCR-ABL1 GLU459LYS,BCR-ABL E459K"	FALSE
ABL1 BCR::ABL V379I	1517	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	C	Resistance	"In a phase II study of 60 imatinib-resistant patients with BCR-ABL mutations, 4 had V379I mutations"	17264298	PubMed		"Guilhot et al., 2007, Blood"		3	accepted	7033	Somatic	2023-01-09 21:46:46 UTC	https://civicdb.org/links/evidence_items/7033	https://civicdb.org/links/molecular_profiles/1517	FALSE	ABL1	25	BCR::ABL V379I		chr9	130874917	130874917	G	A	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"ENST00000318560.5:c.1135G>A,NC_000009.11:g.133750304G>A,NM_005157.5:c.1135G>A,NP_005148.2:p.Val379Ile"	2023-01-27 17:10:50 UTC	CA375249852	NONE FOUND	"V398I,BCR-ABL VAL379ILE,BCR-ABL1 V379I,BCR-ABL1 VAL379ILE,BCR-ABL V379I"	FALSE
ABL1 BCR::ABL A397P	1520	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	C	Resistance	"In a phase II study of 60 imatinib-resistant patients with BCR-ABL mutations, 2 had A397P mutations. Both patients with A397P mutation achieved major hematologic response, and one also had major cytogenetic response."	17264298	PubMed		"Guilhot et al., 2007, Blood"		1	accepted	7034	Somatic	2023-01-09 21:46:46 UTC	https://civicdb.org/links/evidence_items/7034	https://civicdb.org/links/molecular_profiles/1520	FALSE	ABL1	25	BCR::ABL A397P		chr9	130874971	130874971	G	C	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"ENST00000318560.5:c.1189G>C,NC_000009.11:g.133750358G>C,NM_005157.5:c.1189G>C,NP_005148.2:p.Ala397Pro"	2023-01-27 17:10:52 UTC	CA375249974	NONE FOUND	"A416P,ALA397PRO,BCR-ABL1 A397P,BCR-ABL A397P"	FALSE
ABL1 BCR::ABL F359C	1158	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	C	Resistance	"In a phase II study of 60 imatinib-resistant patients with BCR-ABL mutations, 2 had F359C mutations"	17264298	PubMed		"Guilhot et al., 2007, Blood"		1	accepted	7035	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/7035	https://civicdb.org/links/molecular_profiles/1158	FALSE	ABL1	25	BCR::ABL F359C		chr9	130873028	130873028	T	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.1076T>G,NP_005148.2:p.Phe359Cys,NC_000009.11:g.133748415T>G,ENST00000318560.5:c.1076T>G"	2023-01-27 17:08:36 UTC	CA16602582	376124	"F378C,RS1057519775,BCR-ABL PHE359CYS,BCR-ABL1 F359C,BCR-ABL1 PHE359CYS,BCR-ABL F359C"	FALSE
ABL1 BCR::ABL E355G	1395	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	C	Resistance	"In a phase II study of 60 imatinib-resistant patients with BCR-ABL mutations, 4 had E355G mutations"	17264298	PubMed		"Guilhot et al., 2007, Blood"		1	accepted	7036	Somatic	2023-01-09 21:46:45 UTC	https://civicdb.org/links/evidence_items/7036	https://civicdb.org/links/molecular_profiles/1395	FALSE	ABL1	25	BCR::ABL E355G		chr9	130873016	130873016	A	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.1064A>G,NP_005148.2:p.Glu355Gly,NC_000009.11:g.133748403A>G,ENST00000318560.5:c.1064A>G"	2023-01-27 17:09:47 UTC	CA16602556	376095	"RS121913450,BCR-ABL GLU355GLY,BCR-ABL1 E355G,BCR-ABL1 GLU355GLY,BCR-ABL E355G"	FALSE
ABL1 BCR::ABL M351T	1003	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	C	Resistance	"In a phase II study of 60 imatinib-resistant patients with BCR-ABL mutations, 6 had M351T mutations"	17264298	PubMed		"Guilhot et al., 2007, Blood"		1	accepted	7037	Somatic	2023-01-09 21:46:42 UTC	https://civicdb.org/links/evidence_items/7037	https://civicdb.org/links/molecular_profiles/1003	FALSE	ABL1	25	BCR::ABL M351T		chr9	130873004	130873004	T	C	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.1052T>C,NP_005148.2:p.Met351Thr,NC_000009.11:g.133748391T>C,ENST00000318560.5:c.1052T>C"	2023-01-27 17:07:48 UTC	CA122590	12629	"RS121913457,BCR-ABL M370T,BCR-ABL MET351THR,BCR-ABL MET370THR,BCR-ABL M351T"	FALSE
ABL1 BCR::ABL Y253H	999	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	B	Resistance	"In a phase II study of 60 imatinib-resistant patients with BCR-ABL mutations, 6 had Y253H mutations"	17264298	PubMed		"Guilhot et al., 2007, Blood"		1	accepted	7040	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/7040	https://civicdb.org/links/molecular_profiles/999	FALSE	ABL1	25	BCR::ABL Y253H		chr9	130862970	130862970	T	C	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.757T>C,NP_005148.2:p.Tyr253His,NC_000009.11:g.133738357T>C,ENST00000318560.5:c.757T>C"	2023-01-27 17:07:45 UTC	CA122584	12627	"RS121913461,Y272H,TYR272HIS,BCR-ABL TYR253HIS,BCR-ABL1 Y253H,BCR-ABL1 TYR253HIS,BCR-ABL Y253H"	FALSE
ABL1 BCR::ABL G250E	997	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	B	Resistance	"In a phase II study of 60 imatinib-resistant patients with BCR-ABL mutations, 9 had G250E mutations"	17264298	PubMed		"Guilhot et al., 2007, Blood"		1	accepted	7041	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/7041	https://civicdb.org/links/molecular_profiles/997	FALSE	ABL1	25	BCR::ABL G250E		chr9	130862962	130862962	G	A	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.749G>A,NP_005148.2:p.Gly250Glu,NC_000009.11:g.133738349G>A,ENST00000318560.5:c.749G>A"	2023-01-27 17:07:43 UTC	CA16602547	376086	"RS121913453,BCR-ABL G269E,BCR-ABL GLY250GLU,BCR-ABL1 G250E,BCR-ABL1 GLY250GLU,BCR-ABL G250E"	FALSE
ABL1 BCR::ABL M244V	995	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	C	Resistance	"In a phase II study of 60 imatinib-resistant patients with BCR-ABL mutations, 5 had M244V mutations"	17264298	PubMed		"Guilhot et al., 2007, Blood"		1	accepted	7042	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/7042	https://civicdb.org/links/molecular_profiles/995	FALSE	ABL1	25	BCR::ABL M244V		chr9	130862943	130862943	A	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.730A>G,NP_005148.2:p.Met244Val,NC_000009.11:g.133738330A>G,ENST00000318560.5:c.730A>G"	2023-01-27 17:07:41 UTC	CA16602545	376084	"RS121913456,M263V,MET263VAL,BCR-ABL MET244VAL,BCR-ABL1 M244V,BCR-ABL1 MET244VAL,BCR-ABL M244V"	FALSE
ABL1 BCR::ABL F359V	866	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	C	Resistance	"In a phase II study of 60 imatinib-resistant patients with BCR-ABL mutations, 7 had F359V mutations"	17264298	PubMed		"Guilhot et al., 2007, Blood"		1	accepted	7043	Somatic	2023-01-09 21:46:39 UTC	https://civicdb.org/links/evidence_items/7043	https://civicdb.org/links/molecular_profiles/866	FALSE	ABL1	25	BCR::ABL F359V		chr9	130873027	130873027	T	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.1075T>G,NP_005148.2:p.Phe359Val,NC_000009.11:g.133748414T>G,ENST00000318560.5:c.1075T>G"	2023-01-27 17:06:25 UTC	CA16602557	376096	"RS121913452,BCR-ABL F378V,BCR-ABL PHE359VAL,BCR-ABL1 F359V,BCR-ABL1 PHE359VAL,BCR-ABL F359V"	FALSE
ABL1 BCR::ABL L248V	996	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	C	Resistance	"In a phase II study of 60 imatinib-resistant patients with BCR-ABL mutations, 3 had L248V mutations"	17264298	PubMed		"Guilhot et al., 2007, Blood"		1	accepted	7044	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/7044	https://civicdb.org/links/molecular_profiles/996	FALSE	ABL1	25	BCR::ABL L248V		chr9	130862955	130862955	C	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.742C>G,NP_005148.2:p.Leu248Val,NC_000009.11:g.133738342C>G,ENST00000318560.5:c.742C>G"	2023-01-27 17:07:42 UTC	CA16602546	376085	"RS121913455,L267V,LEU248VAL,BCR-ABL L248V"	FALSE
ABL1 BCR::ABL E459K	2243	Chronic Myeloid Leukemia	8552		Imatinib Mesylate		Predictive	Supports	C	Resistance	"In a phase II study of 60 imatinib-resistant patients with BCR-ABL mutations, 3 had E459K mutations"	17264298	PubMed		"Guilhot et al., 2007, Blood"		1	accepted	7046	Somatic	2023-01-09 21:46:58 UTC	https://civicdb.org/links/evidence_items/7046	https://civicdb.org/links/molecular_profiles/2243	FALSE	ABL1	25	BCR::ABL E459K		chr9	130878519	130878519	G	A	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"ENST00000318560.5:c.1375G>A,NC_000009.11:g.133753906G>A,NM_005157.5:c.1375G>A,NP_005148.2:p.Glu459Lys"	2023-01-27 17:16:31 UTC	CA200648598	NONE FOUND	"BCR-ABL GLU459LYS,RS1064156,BCR-ABL1 E459K,BCR-ABL1 GLU459LYS,BCR-ABL E459K"	FALSE
RET Overexpression	593	Lung Adenocarcinoma	3910				Prognostic	Supports	B	Poor Outcome	"ASCL1 and RET mRNA levels were examined by microarray analysis in lung cancer samples. High expression of RET (RET-high) correlated with shorter overall survival compared to the RET-low group in patients with ASCL1 expression in stage I (P=0.007, N=15 vs 38) and all adenocarcinoma (P=0.037, N=31 vs 58). However, expression of RET did not affect survival in the ASCL1- tumors."	24037524	PubMed		"Kosari et al., 2014, Oncogene"		3	accepted	7056	N/A	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/7056	https://civicdb.org/links/molecular_profiles/593	FALSE	RET	5979	Overexpression		chr10	43077027	43130351			ENST00000355710.3	75		N/A		2023-01-09 21:52:08 UTC		N/A		FALSE
EGFR V441F	2486	Colorectal Cancer	9256		"Panitumumab,Cetuximab"	Substitutes	Predictive	Supports	E	Resistance	"Next-generation sequencing data of cfDNA from 1,397 patients with colorectal cancer identified a novel cluster of extracellular domain (ECD). EGFR V441G/D/F mutations were found in 19% (n=8) of patients with EGFR ECD domain III (location of cetuximab and panitumumab binding epitope) mutations. V441D and V441G were more common than V441F. Resistance of V441G to cetuximab was modeled in silico, and authors predicted that it destroys a critical hydrophobic node. In vitro, V441G/D transduced NIH3T3 cells had significantly reduced binding to panitumumab and cetuximab compared to EGFR wt NH3T3 cells (p<0.01 for all comparisons to wt). Authors inferred that EGFR domain III (ECD) mutations, including V441F, may be responsible for secondary resistance to EGFR blockade."	29196463	PubMed		"Strickler et al., 2018, Cancer Discov"		2	accepted	7096	Somatic	2023-01-09 21:47:00 UTC	https://civicdb.org/links/evidence_items/7096	https://civicdb.org/links/molecular_profiles/2486	FALSE	EGFR	1956	V441F	EGFR ECD MUTATION	chr7	55160161	55160161	G	T	ENST00000275493.2	75		missense_variant		2023-01-27 17:17:47 UTC	CA367579353	NONE FOUND	VAL441PHE	FALSE
PDGFRB EBF1::PDGFRB	531	Childhood B-cell Acute Lymphoblastic Leukemia	80146		"Imatinib,Dasatinib"	Substitutes	Predictive	Supports	C	Sensitivity/Response	"The EBF1-PDGFRB fusion was detected in leukemia cells of a 7 year old Latino boy who presented with B-ALL and initial WBC of 600,000. He failed to enter remission with 4 drug induction (90% blasts at day 23), and showed testicular involvement. SNP array showed deletion of IKZF1 deletion and gains in 5q32 and 5q33.3 that interrupted the PDGFRB and EBF1 loci, respectively. FISH studies demonstrated an extra PDGFRB signal with suspect EBF1-PDGFRB that needs molecular confirmation. Imatinib, cyclophosphamide and etoposide were commenced with MRD 4.3% after 1 month. Imatinib dose was increased with MRD 0.44% after additional month of treatment. MRD was 0.0226% after two months of dasatinib treatment, and the patient proceeded to matched unrelated donor hematopoietic stem cell transplantation."	25207766	PubMed		"Roberts et al., 2014, N. Engl. J. Med."		2	accepted	7128	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/7128	https://civicdb.org/links/molecular_profiles/531	FALSE	PDGFRB	5159	EBF1::PDGFRB		chr5	158707979	159099761			ENST00000517373.1	75	ENST00000261799.4	transcript_fusion		2023-01-09 21:52:07 UTC		N/A	EBF1-PDGFRB	FALSE
PDGFRB EBF1::PDGFRB	531	Childhood B-cell Acute Lymphoblastic Leukemia	80146		"Imatinib,Dasatinib"	Substitutes	Predictive	Supports	C	Sensitivity/Response	"The EBF1-PDGFRB fusion was detected in leukemia cells of a 7 year old Latino boy who presented with B-ALL and initial WBC of 600,000. He failed to enter remission with 4 drug induction (90% blasts at day 23), and showed testicular involvement. SNP array showed deletion of IKZF1 deletion and gains in 5q32 and 5q33.3 that interrupted the PDGFRB and EBF1 loci, respectively. FISH studies demonstrated an extra PDGFRB signal with suspect EBF1-PDGFRB that needs molecular confirmation. Imatinib, cyclophosphamide and etoposide were commenced with MRD 4.3% after 1 month. Imatinib dose was increased with MRD 0.44% after additional month of treatment. MRD was 0.0226% after two months of dasatinib treatment, and the patient proceeded to matched unrelated donor hematopoietic stem cell transplantation."	25207766	PubMed		"Roberts et al., 2014, N. Engl. J. Med."		2	accepted	7128	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/7128	https://civicdb.org/links/molecular_profiles/531	FALSE	PDGFRB	5159	EBF1::PDGFRB		chr5	150113837	150125577			ENST00000517373.1	75	ENST00000261799.4	transcript_fusion		2023-01-09 21:52:07 UTC		N/A	EBF1-PDGFRB	FALSE
VHL G104V (c.311G>T)	2301	Von Hippel-Lindau Disease	14175	"Hypertension,Paraganglioma,Hemangioblastoma"			Predisposing	N/A	C	N/A	"A healthy 21 year old woman presented with high blood pressure. She noted palpitations ongoing for 6 months prior. Her adrenal galnds were found to be normal via CT scan. A 2cm x 1.8cm x 1.5cm lesion close to costovertebral angle of third right thoracic vertebra was found via PET scan were histological findings found this to be consistent with paraganglioma. Blood samples for genomic DNA analysis were taken and screening for mutations in SDHA, SDHB, SDHC, SDHD, RET, SDHAF2, TMEM127, MAX, NF1, FH, MDH2, and EPAS1 genes was negative but she was positive for a heterozygous mutation in the VHL gene, c.311G > T (p.Gly104Val). This same variant was found in her 17 year-old sister and her mother but not in her father. Her mother refused a complete staging. The probands sister presented with a small retinal hemangioblastoma at this time. ACMG evidence codes: 'PM2' since this variant is absent from controls (gnomAD), 'PP1' since there is cosegregation with disease in multiple affected family members, 'PP2' since we have a missense variant in a gene where missense variants are a common mechanism of disease, 'PP4' since the patient presents phenotypes highly specific for a disease with a single genetic etiology."	29789510	PubMed		"Bahougne et al., 2018, J Clin Med"		3	accepted	7134	Rare Germline	2023-01-09 21:46:59 UTC	https://civicdb.org/links/evidence_items/7134	https://civicdb.org/links/molecular_profiles/2301	FALSE	VHL	7428	G104V (c.311G>T)		chr3	10142158	10142158	G	T	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.311G>T,NM_000551.3:c.311G>T,NP_000542.1:p.Gly104Val,NC_000003.11:g.10183842G>T"	2023-01-27 17:16:44 UTC	CA357033	223183	"C.311G>T,GLY104VAL,RS869025630"	FALSE
VHL R161Q (c.482G>A)	1622	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	N/A	C	N/A	"A 12 year old Japanese female confirmed with the germline VHL mutation (c.482G>A) presented with pheochromocytoma. It was found that neither of her parents harboured this variation, confirming that she had a de novo mutation. The paper concluded that weight loss could be indicative of pheochromocytoma."	29662268	PubMed		"Igaki et al., 2018, Clin Pediatr Endocrinol"		3	accepted	7141	Rare Germline	2023-01-09 21:46:48 UTC	https://civicdb.org/links/evidence_items/7141	https://civicdb.org/links/molecular_profiles/1622	FALSE	VHL	7428	R161Q (c.482G>A)		chr3	10149805	10149805	G	A	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.482G>A,NP_000542.1:p.Arg161Gln,NC_000003.11:g.10191489G>A,ENST00000256474.2:c.482G>A"	2023-01-27 17:11:34 UTC	CA020413	182983	"C.482G>A,ARG161GLN,RS730882035"	FALSE
BRAF KIAA1549::BRAF	614	Pilocytic Astrocytoma	4851				Diagnostic	Supports	B	Positive	"Genetic alterations in pilocytic astrocytoma (PA) were evaluated. Whole-genome sequencing of normal (blood) and tumor samples (n=96) was performed along with corresponding RNA-Seq (n=73) and mate-pair (MP) sequencing (n=68).  Several known events activating the MAPK pathway were identified with KIAA1549-BRAF fusion being the most frequent variants (70 of 96 cases, 73%). Importantly, all but one of the cerebellar PA harbored a BRAF fusion (47 of 48 samples, 98%) with this one exception having a KRAS alteration."	23817572	PubMed		"Jones et al., 2013, Nat. Genet."		5	accepted	7148	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/7148	https://civicdb.org/links/molecular_profiles/614	FALSE	BRAF	673	KIAA1549::BRAF	BRAF Fusions	chr7	138861139	138981318			ENST00000440172.1	75	ENST00000288602.6	transcript_fusion		2023-01-09 21:52:08 UTC		N/A	KIAA1549-BRAF	FALSE
BRAF KIAA1549::BRAF	614	Pilocytic Astrocytoma	4851				Diagnostic	Supports	B	Positive	"Genetic alterations in pilocytic astrocytoma (PA) were evaluated. Whole-genome sequencing of normal (blood) and tumor samples (n=96) was performed along with corresponding RNA-Seq (n=73) and mate-pair (MP) sequencing (n=68).  Several known events activating the MAPK pathway were identified with KIAA1549-BRAF fusion being the most frequent variants (70 of 96 cases, 73%). Importantly, all but one of the cerebellar PA harbored a BRAF fusion (47 of 48 samples, 98%) with this one exception having a KRAS alteration."	23817572	PubMed		"Jones et al., 2013, Nat. Genet."		5	accepted	7148	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/7148	https://civicdb.org/links/molecular_profiles/614	FALSE	BRAF	673	KIAA1549::BRAF	BRAF Fusions	chr7	140734479	140787584			ENST00000440172.1	75	ENST00000288602.6	transcript_fusion		2023-01-09 21:52:08 UTC		N/A	KIAA1549-BRAF	FALSE
BRAF V600E	12	Colorectal Cancer	9256				Prognostic	Supports	B	Poor Outcome	"Patients with completely resected colorectal adenocarcinoma (Stage II-III) were treated with fluorouracil and leucovorin +/- ironotecan. Of the 1,307 FFPE samples tested, V600E was observed in 31 Stage II samples (7.6%) and 72 Stage III samples (7.9%). V600E was prognostic for overall survival, but not for relapse-free survival, in patients with stages II and III combined, and in stage III alone. For all MSI low and stable tumors, BRAF V600E positive samples had a hazard ratio (HR) of 2.19 (95% CI, 1.43 to 3.37, P=0.00034). For all samples in the cohort (MSI-H and MSI-L) BRAF V600E positive samples had a 1.66 HR (95% CI, 1.15 to 2.40, P=0.0069). The authors note prognostic value for BRAF V600E, especially in non-MSI high tumors."	20008640	PubMed		"Roth et al., 2010, J. Clin. Oncol."		4	accepted	7156	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/7156	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
BRAF V600E	12	Colorectal Cancer	9256				Prognostic	Supports	B	Poor Outcome	"The CRYSTAL Phase III Trial evaluated efficacy of irinotecan, fluorouracil, and leucovorin (FOLFIRI) with or without Cetuximab for colorectal cancer patients who presented with unresectable metastatic disease. BRAF mutation status (V600E) was analyzed via LightMix BRAF V600E Kit. V600E mutations were detected in 60/999 tumor samples (6%), 59 of which were wild-type for KRAS. When comparing patients with wildtype KRAS (n=625), BRAF V600E tumors had worse outcomes relative to BRAF wildtype. For patients with BRAF V600E tumors (n=566), median overall survival (OS) was 25.1 months with cetuximab and 21.6 months without cetuximab. For patients with wildtype BRAF (n=59), median OS was 14.1 months with cetuximab and 10.3 months without cetuximab."	21502544	PubMed		"Van Cutsem et al., 2011, J. Clin. Oncol."		4	accepted	7157	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/7157	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
BRAF Mutation	395	Colorectal Cancer	9256				Prognostic	Supports	B	Poor Outcome	"In the Medical Research Council (MRC) COIN trial, ISRCTN27286448, patients who presented with advanced colorectal cancer were randomly assigned to chemotherapy (oxaliplatin and fluoropyrimidine; arm A), or chemotherapy plus cetuximab (arm B). Median overall survival was found to differ by mutation, regardless of treatment. Median overall survival was 8.8 months (IQR 4.5-27) for patients with BRAF variants, 14.4 months (IQR 8.5-24.0) for patients with KRAS variants, and 20.1 months (IQR 11.5-31.7) for wildtype patients. BRAF mutations were found in 102/1291 samples (7.90%), and of these, 12 were D594G and 90 V600E."	21641636	PubMed		"Maughan et al., 2011, Lancet"		4	accepted	7158	Somatic	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/7158	https://civicdb.org/links/molecular_profiles/395	FALSE	BRAF	673	Mutation		chr7	140753336	140781603			ENST00000288602.6	75		"gene_variant,gain_of_function_variant"		2023-01-09 21:52:06 UTC				FALSE
BRAF Mutation	395	Colorectal Cancer	9256				Prognostic	Supports	B	Poor Outcome	"A meta analysis was performed using data from 21 published studies (n = 9885 patients) to assess prognostic value of BRAF mutations in colorectal cancer. When evaluating 14 studies (n = 7778 patients), the odds ratio (OR) of a proximal lesion, which is associated with greater mortality in colon cancer, was increased for patients with BRAF mutations (OR 5.222, 95% CI 3.801?.174, P < 0.001). When evaluating 4 studies (n = 1526 patients), the odds ratio of T4 tumors, which indicates tumor growth past bowel lining, was increased for patients with BRAF mutations (OR 1.761, 95% CI 1.164?.663, P = 0.007). When evaluating 8 studies (n = 2786 patients), the odds ratio of poor tumor differentiation was increased in patients with BRAF mutations (OR 3.816, 95% CI 2.714?.365, P < 0.001). These results support that BRAF mutations indicate poor prognosis for patients with colorectal cancer."	24112392	PubMed		"Clancy et al., 2013, Colorectal Dis"		4	accepted	7159	Somatic	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/7159	https://civicdb.org/links/molecular_profiles/395	FALSE	BRAF	673	Mutation		chr7	140753336	140781603			ENST00000288602.6	75		"gene_variant,gain_of_function_variant"		2023-01-09 21:52:06 UTC				FALSE
TP53 R248Q	117	Lymphoma	60058				Predisposing	Supports	D	Likely Pathogenic	"In mouse models, the R248Q variant had accelerated onset of all tumor types and accelerated death rate. Endogenous R248Q proteins are devoid of several important wildtype tp53 tumor-suppressor functions including transcription of cell cycle arrest genes, replicative senescence and irradiation-induced apoptosis. Patients with germline R248Q/+ genotype showed a drastically younger median age until first tumor onset compared with patients with a null/+ genotype (19.5 vs 30 years, P=0.023)."	23538418	PubMed		"Hanel et al., 2013, Cell Death Differ."		4	accepted	7161	Rare Germline	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/7161	https://civicdb.org/links/molecular_profiles/117	FALSE	TP53	7157	R248Q		chr17	7674220	7674220	C	T	ENST00000269305.4	75		missense_variant	"NM_000546.5:c.743G>A,NP_000537.3:p.Arg248Gln,NC_000017.10:g.7577538C>T,ENST00000269305.4:c.743G>A"	2023-01-27 17:02:44 UTC	CA000387	12356	"ARG248GLN,RS11540652"	FALSE
TP53 C238Y	2517	Breast Cancer	1612				Prognostic	Supports	E	Poor Outcome	Cys-238 was directly bound to zinc molecule. Patients with missense mutations affecting amino acids directly involved in DNA or zinc binding displayed a very aggressive clinical phenotype.	11051239	PubMed		"Alsner et al., 2000, Clin. Cancer Res."		3	accepted	7173	Somatic	2023-01-09 21:47:01 UTC	https://civicdb.org/links/evidence_items/7173	https://civicdb.org/links/molecular_profiles/2517	FALSE	TP53	7157	C238Y		chr17	7674250	7674250	C	T	ENST00000269305.4	75		missense_variant	"NC_000017.10:g.7577568C>T,NM_000546.5:c.713G>A,NP_000537.3:p.Cys238Tyr,ENST00000269305.4:c.713G>A"	2023-01-27 17:17:50 UTC	CA000351	182935	CYS238TYR	FALSE
PIK3CA Mutation	307	Head And Neck Squamous Cell Carcinoma	5520		"Celecoxib,Sulindac,Aspirin"	Substitutes	Predictive	Supports	B	Sensitivity/Response	"In this retrospective study, the impact of nonsteroidal anti-inflammatory drugs (NSAID) on survival in PIK3CA-altered HNSCC patients (N=266) was assessed. 37 of 266 (14%) patients harbored a mutation, 29 of 266 (11%) had only amplification, and 9 patients had both. Among patients with a PIK3CA mutation or amplification, regular NSAID use was significantly associated with disease-specific (HR 0.23, p=0.0032) and overall survival (HR 0.31, p=0.0043). These findings were recreated in a panel of six patient-derived xenograft models, where treatment with NSAIDs (sulindac, Celecoxib or Aspirin) significantly reduced growth rates in PIK3CA mutant, but not wild-type models."	30683736	PubMed		"Hedberg et al., 2019, J. Exp. Med."		3	accepted	7185	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/7185	https://civicdb.org/links/molecular_profiles/307	FALSE	PIK3CA	5290	Mutation		chr3	179148523	179240093			ENST00000263967.3	75		"transcript_variant,gain_of_function_variant"		2023-01-09 21:52:06 UTC		N/A		FALSE
PIK3CA Amplification	212	Head And Neck Squamous Cell Carcinoma	5520		"Aspirin,Sulindac,Ibuprofen"	Substitutes	Predictive	Supports	B	Sensitivity/Response	"In this retrospective study, the impact of nonsteroidal anti-inflammatory drugs (NSAID) on survival in PIK3CA-altered HNSCC patients (N=266) was assessed. 37 of 266 (14%) patients harbored a mutation, 29 of 266 (11%) had only amplification, and 9 patients had both. Among patients with a PIK3CA mutation or amplification, regular NSAID use was significantly associated with disease-specific (HR 0.23, p=0.0032) and overall survival (HR 0.31, p=0.0043). These findings were recreated in a panel of six patient-derived xenograft models, where treatment with NSAIDs (sulindac, Celecoxib or Aspirin) significantly reduced growth rates in PIK3CA mutant, but not wild-type models."	30683736	PubMed		"Hedberg et al., 2019, J. Exp. Med."		3	accepted	7186	N/A	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/7186	https://civicdb.org/links/molecular_profiles/212	FALSE	PIK3CA	5290	Amplification		chr3	179148523	179240093			ENST00000263967.3	75		transcript_amplification	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
TERT Promoter Mutation	220	Childhood Low-grade Glioma	80830	"Pediatric onset,Early young adult onset"			Prognostic	Supports	C	Poor Outcome	"The aim of this Chinese study was to identify prognostic biomarkers for pediatric low-grade gliomas (PLGG). Approximately 300 patients were included. Using Sanger sequencing, mutations at TERT promoter (TERTp) regions were identified (C228T: 3/278; C250T: 4/278). The median age of patients with TERTp mutations was 15 years. There were 5 males and 2 females. Six patients had diffuse astrocytoma and one had pilocytic astrocytoma. Tumors were found in the midline of four patients, the hemisphere of two, and the cerebellum of one. Kaplan-Meier survival analysis showed that TERTp mutations were associated with shorter progression-free survival and overall survival [mt (n=6) vs wt (n=205); p<0.0001 for both OS and PFS]. However, the association of TERTp mutations with OS and PFS was no longer statistically significant after adjusting for age, grade, histology, tumor location, and extent of resection in multivariate analysis."	29948154	PubMed		"Yang et al., 2018, Acta Neuropathol."		4	accepted	7188	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/7188	https://civicdb.org/links/molecular_profiles/220	FALSE	TERT	7015	Promoter Mutation		chr5	1295046	1295258			ENST00000310581.5	75		regulatory_region_variant		2023-01-09 21:52:05 UTC			"-124C>T,-146C>T"	FALSE
ATRX Underexpression	644	Childhood Low-grade Glioma	80830	"Early young adult onset,Pediatric onset"			Prognostic	Supports	B	Poor Outcome	"Loss of ATRX was identified in 12 of 247 patients with PLGGs using immunohistochemistry. Survival analysis showed that ATRX loss was associated with adverse overall survival (p<0.0001) and progression-free survival (p=0.0002) [mt (n=10) vs wt (n=175)]. In a multivariate analysis taking into account age, grade, histology, tumour location, and extent of resection, ATRX was still an independent prognosticator of PFS [HR 3.85 (95% CI 1.27?1.65); p = 0.017], and OS [HR 3.53 (95% CI 1.02?2.24); p = 0.047]."	29948154	PubMed		"Yang et al., 2018, Acta Neuropathol."		4	accepted	7190	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/7190	https://civicdb.org/links/molecular_profiles/644	FALSE	ATRX	546	Underexpression		chrX	77504878	77786216			ENST00000373344.5	75		N/A		2023-01-09 21:52:08 UTC		N/A	UNDEREXPRESSION	FALSE
BRAF V600E	12	Childhood Low-grade Glioma	80830	"Pediatric onset,Early young adult onset"			Prognostic	Supports	B	Poor Outcome	"Using Sanger sequencing, BRAFV600E mutations were identified in 21 of 285 patients with PLGGs (7.4%). This mutation was enriched in hemispheric tumors (p<0.007) and was associated with shorter progression-free survival (p=0.011) and overall survival (p=0.032) [mt (n=18) vs wt (n=166)]."	29948154	PubMed		"Yang et al., 2018, Acta Neuropathol."		4	accepted	7191	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/7191	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
BRAF KIAA1549::BRAF	614	Childhood Low-grade Glioma	80830	"Pediatric onset,Early young adult onset"			Prognostic	Supports	B	Better Outcome	KIAA1549-BRAF fusion was identified in 87 of 272 patients with PLGGs using Fluorescence In situ hybridization (FISH) analysis. This mutation was strongly associated with a greater progression-free survival (p=0.0017) and overall survival (p=0.0029) [fusion-positive (n=64) vs fusion-negative (n=141)].	29948154	PubMed		"Yang et al., 2018, Acta Neuropathol."		4	accepted	7193	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/7193	https://civicdb.org/links/molecular_profiles/614	FALSE	BRAF	673	KIAA1549::BRAF	BRAF Fusions	chr7	138861139	138981318			ENST00000440172.1	75	ENST00000288602.6	transcript_fusion		2023-01-09 21:52:08 UTC		N/A	KIAA1549-BRAF	FALSE
BRAF KIAA1549::BRAF	614	Childhood Low-grade Glioma	80830	"Pediatric onset,Early young adult onset"			Prognostic	Supports	B	Better Outcome	KIAA1549-BRAF fusion was identified in 87 of 272 patients with PLGGs using Fluorescence In situ hybridization (FISH) analysis. This mutation was strongly associated with a greater progression-free survival (p=0.0017) and overall survival (p=0.0029) [fusion-positive (n=64) vs fusion-negative (n=141)].	29948154	PubMed		"Yang et al., 2018, Acta Neuropathol."		4	accepted	7193	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/7193	https://civicdb.org/links/molecular_profiles/614	FALSE	BRAF	673	KIAA1549::BRAF	BRAF Fusions	chr7	140734479	140787584			ENST00000440172.1	75	ENST00000288602.6	transcript_fusion		2023-01-09 21:52:08 UTC		N/A	KIAA1549-BRAF	FALSE
BRAF KIAA1549::BRAF	614	Childhood Low-grade Glioma	80830		"Everolimus,Trametinib"	Combination	Predictive	Supports	D	Sensitivity/Response	"This preclinical study proposed to use a combination therapy of an MEK inhibitor (e.g. trametinib) and an mTOR inhibitor (e.g. everolimus) for the treatment of pediatric low-grade gliomas (PLGGs) with BRAF fusions to evade acquired resistance to MEK targeted therapy. The PI3K/Akt/mTOR pathway was identified as a resistance mechanism to MEKi treatment based on RNASeq and GSEA analysis. Using flank xenograft model, mice were injected with NIH3T3 cells expressing KIAA1549-BRAF fusions and treated daily with trametinib, everolimus either alone or combined with each other (n=~10 for each treatment arm). Combination therapy (Trametinib 1mg/kg+ Everolimus 10mg/kg) resulted in better suppression in tumor growth than single-agent treatment. Similarly, combination treatment strongly reduced colony formation as well as pERK and pS6 levels, showing on target effects."	29156677	PubMed		"Jain et al., 2017, Oncotarget"		2	accepted	7199	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/7199	https://civicdb.org/links/molecular_profiles/614	FALSE	BRAF	673	KIAA1549::BRAF	BRAF Fusions	chr7	138861139	138981318			ENST00000440172.1	75	ENST00000288602.6	transcript_fusion		2023-01-09 21:52:08 UTC		N/A	KIAA1549-BRAF	FALSE
BRAF KIAA1549::BRAF	614	Childhood Low-grade Glioma	80830		"Everolimus,Trametinib"	Combination	Predictive	Supports	D	Sensitivity/Response	"This preclinical study proposed to use a combination therapy of an MEK inhibitor (e.g. trametinib) and an mTOR inhibitor (e.g. everolimus) for the treatment of pediatric low-grade gliomas (PLGGs) with BRAF fusions to evade acquired resistance to MEK targeted therapy. The PI3K/Akt/mTOR pathway was identified as a resistance mechanism to MEKi treatment based on RNASeq and GSEA analysis. Using flank xenograft model, mice were injected with NIH3T3 cells expressing KIAA1549-BRAF fusions and treated daily with trametinib, everolimus either alone or combined with each other (n=~10 for each treatment arm). Combination therapy (Trametinib 1mg/kg+ Everolimus 10mg/kg) resulted in better suppression in tumor growth than single-agent treatment. Similarly, combination treatment strongly reduced colony formation as well as pERK and pS6 levels, showing on target effects."	29156677	PubMed		"Jain et al., 2017, Oncotarget"		2	accepted	7199	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/7199	https://civicdb.org/links/molecular_profiles/614	FALSE	BRAF	673	KIAA1549::BRAF	BRAF Fusions	chr7	140734479	140787584			ENST00000440172.1	75	ENST00000288602.6	transcript_fusion		2023-01-09 21:52:08 UTC		N/A	KIAA1549-BRAF	FALSE
BRAF KIAA1549::BRAF	614	Childhood Low-grade Glioma	80830				Prognostic	Supports	B	Better Outcome	"Hawkins et al. (2011) retrospectively studied 70 consecutive patient with incompletely resected pediatric low-grade astrocytomas (PLGA). KIAA1549-BRAF fusion was identified in 60% of cases in this cohort. Multi-variant analysis suggested that KIAA1549-BRAF fusion was the most significant favorable prognosis factor in incompletely resected PLGA and was independent of location, pathology, and age. Five-year PFS of fusion positive and fusion negative patients were 61% +/- 8% and 18% +/- 8% (P=0.0004), respectively. These results suggested that KIAA1549-BRAF fusion confers a less aggressive clinical phenotype on PLGA and may explain their tendency to growth arrest."	21610142	PubMed		"Hawkins et al., 2011, Clin. Cancer Res."		4	accepted	7200	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/7200	https://civicdb.org/links/molecular_profiles/614	FALSE	BRAF	673	KIAA1549::BRAF	BRAF Fusions	chr7	138861139	138981318			ENST00000440172.1	75	ENST00000288602.6	transcript_fusion		2023-01-09 21:52:08 UTC		N/A	KIAA1549-BRAF	FALSE
BRAF KIAA1549::BRAF	614	Childhood Low-grade Glioma	80830				Prognostic	Supports	B	Better Outcome	"Hawkins et al. (2011) retrospectively studied 70 consecutive patient with incompletely resected pediatric low-grade astrocytomas (PLGA). KIAA1549-BRAF fusion was identified in 60% of cases in this cohort. Multi-variant analysis suggested that KIAA1549-BRAF fusion was the most significant favorable prognosis factor in incompletely resected PLGA and was independent of location, pathology, and age. Five-year PFS of fusion positive and fusion negative patients were 61% +/- 8% and 18% +/- 8% (P=0.0004), respectively. These results suggested that KIAA1549-BRAF fusion confers a less aggressive clinical phenotype on PLGA and may explain their tendency to growth arrest."	21610142	PubMed		"Hawkins et al., 2011, Clin. Cancer Res."		4	accepted	7200	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/7200	https://civicdb.org/links/molecular_profiles/614	FALSE	BRAF	673	KIAA1549::BRAF	BRAF Fusions	chr7	140734479	140787584			ENST00000440172.1	75	ENST00000288602.6	transcript_fusion		2023-01-09 21:52:08 UTC		N/A	KIAA1549-BRAF	FALSE
ABL1 NUP214::ABL1	2529	"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like"	80650	Juvenile onset	"Vincristine,Dexamethasone,Dasatinib"	Combination	Predictive	Supports	C	Sensitivity/Response	"A 15-year-old girl with B-cell precursor ALL was placed into the very high risk group after showing corticoid resistance on treatment day 8, and induction failure on day 35 (MRD >0.01). The patient received a successful bone marrow transplant and at day 100 showed a complete remission (CR). The patient relapsed 6 months later, and second line therapy was unsuccessful. During this relapse, SNP microarray was performed on the diagnostic sample and identified amplification of 9q34 flanked by the NUP214 and ABL1 genes. Follow-up molecular studies confirmed a NUP214-ABL1 fusion gene. The patient was then started on dasatinib in combination with vincristine and dexamethasone. The patient achieved a second CR, and continued on dasatinib until her disease relapsed 2 months later."	26681761	PubMed		"Duployez et al., 2016, Haematologica"		2	accepted	7208	Somatic	2023-01-09 21:47:01 UTC	https://civicdb.org/links/evidence_items/7208	https://civicdb.org/links/molecular_profiles/2529	FALSE	ABL1	25	NUP214::ABL1	ABL1 fusions in B-ALL	chr9	131125561	131230769			ENST00000359428.5	75	ENST00000318560.5	transcript_fusion		2023-01-09 21:52:20 UTC			NUP214-ABL1	FALSE
ABL1 NUP214::ABL1	2529	"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like"	80650	Juvenile onset	"Vincristine,Dexamethasone,Dasatinib"	Combination	Predictive	Supports	C	Sensitivity/Response	"A 15-year-old girl with B-cell precursor ALL was placed into the very high risk group after showing corticoid resistance on treatment day 8, and induction failure on day 35 (MRD >0.01). The patient received a successful bone marrow transplant and at day 100 showed a complete remission (CR). The patient relapsed 6 months later, and second line therapy was unsuccessful. During this relapse, SNP microarray was performed on the diagnostic sample and identified amplification of 9q34 flanked by the NUP214 and ABL1 genes. Follow-up molecular studies confirmed a NUP214-ABL1 fusion gene. The patient was then started on dasatinib in combination with vincristine and dexamethasone. The patient achieved a second CR, and continued on dasatinib until her disease relapsed 2 months later."	26681761	PubMed		"Duployez et al., 2016, Haematologica"		2	accepted	7208	Somatic	2023-01-09 21:47:01 UTC	https://civicdb.org/links/evidence_items/7208	https://civicdb.org/links/molecular_profiles/2529	FALSE	ABL1	25	NUP214::ABL1	ABL1 fusions in B-ALL	chr9	130854801	130887675			ENST00000359428.5	75	ENST00000318560.5	transcript_fusion		2023-01-09 21:52:20 UTC			NUP214-ABL1	FALSE
TP53 C238Y	2517						Functional	Supports	D	Dominant Negative	"This study evaluated the dominant negative potential of 103 p53 germline mutations contained in the IRAC database. The C238Y variant was considered severely deficient as cotransformation with empty vector resulted in poor transactivation of luciferase expression in 4 yeast strains compared to the p53 wildtype control vector (mean residual activity <25% of wildtype control). Cotransformation of C238Y and wildtype vectors led to the hinderance of luciferase expression below 90% compared to wildtype alone in all 4 yeast strains, which based on the authors criteria qualified the C238Y variant as dominant negative."	21343334	PubMed		"Monti et al., 2011, Mol. Cancer Res."		2	accepted	7215	Rare Germline	2023-01-09 21:47:01 UTC	https://civicdb.org/links/evidence_items/7215	https://civicdb.org/links/molecular_profiles/2517	FALSE	TP53	7157	C238Y		chr17	7674250	7674250	C	T	ENST00000269305.4	75		missense_variant	"NC_000017.10:g.7577568C>T,NM_000546.5:c.713G>A,NP_000537.3:p.Cys238Tyr,ENST00000269305.4:c.713G>A"	2023-01-27 17:17:50 UTC	CA000351	182935	CYS238TYR	FALSE
ABL1 SNX2::ABL1	2547	B-lymphoblastic Leukemia/lymphoma	80630	Juvenile onset	Dasatinib		Predictive	Supports	C	Resistance	"A 7-yr-old boy with B-cell precursor acute lymphoblastic leukemia was found to harbor the SNX2-ABL1 fusion gene. Gene expression analysis showed enrichment for BCR-ABL1+ ALL using GSEA. After first relapse (15 months after diagnosis) the patient was given imatinib at a dose of 240 mg/m2/d once daily and his disease stabilized for 2 months. The patient received dasatinib (80 mg/m2/d once daily) after an umbilical cord blood transplant and did not respond to treatment. Patient was put back on imatinib at a dose of 600 mg/m2/d once daily which rapidly decreased the number of blast cells. However, 6 months after transplant he had bone marrow relapse and did not again achieve remission by the time of reporting."	24215620	PubMed		"Masuzawa et al., 2014, Eur. J. Haematol."		2	accepted	7241	Somatic	2023-01-09 21:47:01 UTC	https://civicdb.org/links/evidence_items/7241	https://civicdb.org/links/molecular_profiles/2547	FALSE	ABL1	25	SNX2::ABL1	ABL1 fusions in B-ALL	chr5	122774996	122799855			ENST00000379516.2	75	ENST00000372348.2	transcript_fusion		2023-01-09 21:52:21 UTC			SNX2-ABL1	FALSE
ABL1 SNX2::ABL1	2547	B-lymphoblastic Leukemia/lymphoma	80630	Juvenile onset	Dasatinib		Predictive	Supports	C	Resistance	"A 7-yr-old boy with B-cell precursor acute lymphoblastic leukemia was found to harbor the SNX2-ABL1 fusion gene. Gene expression analysis showed enrichment for BCR-ABL1+ ALL using GSEA. After first relapse (15 months after diagnosis) the patient was given imatinib at a dose of 240 mg/m2/d once daily and his disease stabilized for 2 months. The patient received dasatinib (80 mg/m2/d once daily) after an umbilical cord blood transplant and did not respond to treatment. Patient was put back on imatinib at a dose of 600 mg/m2/d once daily which rapidly decreased the number of blast cells. However, 6 months after transplant he had bone marrow relapse and did not again achieve remission by the time of reporting."	24215620	PubMed		"Masuzawa et al., 2014, Eur. J. Haematol."		2	accepted	7241	Somatic	2023-01-09 21:47:01 UTC	https://civicdb.org/links/evidence_items/7241	https://civicdb.org/links/molecular_profiles/2547	FALSE	ABL1	25	SNX2::ABL1	ABL1 fusions in B-ALL	chr9	130862763	130887675			ENST00000379516.2	75	ENST00000372348.2	transcript_fusion		2023-01-09 21:52:21 UTC			SNX2-ABL1	FALSE
FGFR1 Amplification	263	Breast Cancer	1612		Pazopanib		Predictive	Supports	C	Sensitivity/Response	"Case report in a HR positive, Her2/neu negative breast cancer patient harboring an FGFR1 amplification. The patient responded to treatment to Pazopanib - including a near CR of brain metastases. Duration of Treatment or median PFS was not reported at the time of publication."	29223982	PubMed		"Cheng et al., 2017, J Natl Compr Canc Netw"		2	accepted	7246	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/7246	https://civicdb.org/links/molecular_profiles/263	FALSE	FGFR1	2260	Amplification		chr8	38411138	38467845			ENST00000425967.3	75		transcript_amplification	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
ABL1 SNX2::ABL1	2547	B-lymphoblastic Leukemia/lymphoma	80630	Young adult onset	Imatinib		Predictive	Supports	C	Reduced Sensitivity	"In a 29-year-old man with pre B-cell ALL, the t(5;9)(q23;q34) [SNX2-ABL1] was identified. The SNX2-ABL1 fusion, which joins the N-terminal domain of SNX2 without the PX domain to ABL1 exon 4, was detected by RACE PCR and confirmed by RT-PCR and Sanger sequencing. The patient responded to initial chemotherapy, but relapsed early. He then demonstrated a response to hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-C-VAD), but relapsed again. The patient next received imatinib and supportive measures, including hydroxycarbamide, but unfortunately succumbed to his disease approximately one year after diagnosis."	21391972	PubMed		"Ernst et al., 2011, Br. J. Haematol."		1	accepted	7254	Somatic	2023-01-09 21:47:01 UTC	https://civicdb.org/links/evidence_items/7254	https://civicdb.org/links/molecular_profiles/2547	FALSE	ABL1	25	SNX2::ABL1	ABL1 fusions in B-ALL	chr5	122774996	122799855			ENST00000379516.2	75	ENST00000372348.2	transcript_fusion		2023-01-09 21:52:21 UTC			SNX2-ABL1	FALSE
ABL1 SNX2::ABL1	2547	B-lymphoblastic Leukemia/lymphoma	80630	Young adult onset	Imatinib		Predictive	Supports	C	Reduced Sensitivity	"In a 29-year-old man with pre B-cell ALL, the t(5;9)(q23;q34) [SNX2-ABL1] was identified. The SNX2-ABL1 fusion, which joins the N-terminal domain of SNX2 without the PX domain to ABL1 exon 4, was detected by RACE PCR and confirmed by RT-PCR and Sanger sequencing. The patient responded to initial chemotherapy, but relapsed early. He then demonstrated a response to hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-C-VAD), but relapsed again. The patient next received imatinib and supportive measures, including hydroxycarbamide, but unfortunately succumbed to his disease approximately one year after diagnosis."	21391972	PubMed		"Ernst et al., 2011, Br. J. Haematol."		1	accepted	7254	Somatic	2023-01-09 21:47:01 UTC	https://civicdb.org/links/evidence_items/7254	https://civicdb.org/links/molecular_profiles/2547	FALSE	ABL1	25	SNX2::ABL1	ABL1 fusions in B-ALL	chr9	130862763	130887675			ENST00000379516.2	75	ENST00000372348.2	transcript_fusion		2023-01-09 21:52:21 UTC			SNX2-ABL1	FALSE
BRAF V600E	12	Colorectal Cancer	9256		"Cetuximab,Binimetinib,Encorafenib"	Combination	Predictive	Supports	B	Sensitivity/Response	"In a phase III trial, patients with BRAF V600E mutated metastatic colorectal cancer received triplet combination with encorafenib + binimetinib + cetuximab in a second or third-line setting. In the safety-lead in part of this trial, 30 patients were given triplet therapy, of which 29 with V600E mutation were included in the efficacy analysis. The objective response rate was 48% [95%CI: 29.4 - 67.5], median PFS was 8.0 mo [95%CI: 5.6 - 9.3], and median OS was 15.3 mo [95%CI: 9.6 - not reached]. The author concluded that triplet therapy was well tolerated and PFS and OS were substantially improved over historical standard of care."	168986	ASCO	688	"Scott Kopetz, 2019, Gastrointestinal Cancers Symposium, Abstract 688"	NCT02928224	3	accepted	7260	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/7260	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
BRAF V600E	12	Biliary Tract Cancer	4607		"Trametinib,Dabrafenib"	Combination	Predictive	Supports	B	Sensitivity/Response	"In a phase II trial, 33 patients with advanced or metastatic biliary tract cancer (BTC) received dabrafenib (D) and trametinib (T) in a second or higher line therapeutic context. Of the 33 patients, 30 had BRAF V600E mutated tumors, and 32 were evaluable. Objective response rate was 41% (13/32; 95% CI, 24 - 59%). Median PFS was 7.2 months (95% CI, 4.6 - 10.1 months), and median OS was 11.3 months (95% CI, 7.3 - 17.6 months). The author concluded that D+T therapy should be considered for patients with BRAF V600E mutated BTC."	169315	ASCO	187	"Zev A. Wainberg, 2019, Gastrointestinal Cancers Symposium, Abstract 187"	NCT02034110	3	accepted	7264	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/7264	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
MET Exon 14 Skipping Mutation	320	Lung Non-small Cell Carcinoma	3908		Tepotinib		Predictive	Supports	B	Sensitivity/Response	"In a interim analysis of Phase II trial for MET exon 14 skipping NSCLC, 34 patients received MEK selective inhibitor tepotinib. 9/15 (60.0%) evaluable patients had a confirmed PR and 3 (20.0%) had SD."	160289	ASCO	9016	"Enriqueta Felip, 2018, ASCO Annual Meeting, Abstract 9016"	NCT02864992	3	accepted	7272	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/7272	https://civicdb.org/links/molecular_profiles/320	FALSE	MET	4233	Exon 14 Skipping Mutation		chr7	116771849	116771989			ENST00000318493.6	75		exon_loss_variant		2023-01-09 21:52:06 UTC		N/A		FALSE
BRCA1 Mutation	185	Ovarian Cancer	2394		Olaparib		Predictive	Supports	A	Sensitivity/Response	"In the phase 3 SOLO1 trial 390 patients with newly diagnosed advanced ovarian cancer with a mutation in BRCA1 or BRCA2 who had complete or partial response after platinum-based chemotherapy were randomized 2:1 to receive olaparib or placebo. The olaparib arm had 191 patients with BRCA1 mutation, 66 BRCA2, and 3 patients with both BRCA1 and BRCA2, while the placebo arm had 91 BRCA1 and 40 BRCA2 mutant patients. Analysis of PFS by blinded independent review found freedom from disease progression or death at 3 years was 69% in the olaparib arm compared with 35% in the placebo arm (hazard ratio for disease progression or death, 0.28; 95% CI, 0.20 to 0.39; P<0.001)."	30345884	PubMed		"Moore et al., 2018, N. Engl. J. Med."	NCT01844986	5	accepted	7274	Rare Germline	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/7274	https://civicdb.org/links/molecular_profiles/185	FALSE	BRCA1	672	Mutation		chr17	43045629	43125483			ENST00000471181.2	75		"gene_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
BRCA1 Mutation	185	Ovarian Cancer	2394		Olaparib		Predictive	Supports	A	Sensitivity/Response	"In the phase 3 SOLO1 trial 390 patients with newly diagnosed advanced ovarian cancer with a mutation in BRCA1 or BRCA2 who had complete or partial response after platinum-based chemotherapy were randomized 2:1 to receive olaparib or placebo. Two patients were found to have somatic BRCA1/2 mutations. Analysis of PFS by blinded independent review found freedom from disease progression or death at 3 years was 69% in the olaparib arm compared with 35% in the placebo arm (hazard ratio for disease progression or death, 0.28; 95% CI, 0.20 to 0.39; P<0.001)."	30345884	PubMed		"Moore et al., 2018, N. Engl. J. Med."	NCT01844986	1	accepted	7275	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/7275	https://civicdb.org/links/molecular_profiles/185	FALSE	BRCA1	672	Mutation		chr17	43045629	43125483			ENST00000471181.2	75		"gene_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
BRCA2 Mutation	186	Ovarian Cancer	2394		Olaparib		Predictive	Supports	A	Sensitivity/Response	"In the phase 3 SOLO1 trial 390 patients with newly diagnosed advanced ovarian cancer with a mutation in BRCA1 or BRCA2 who had complete or partial response after platinum-based chemotherapy were randomized 2:1 to receive olaparib or placebo. The olaparib arm had 191 patients with BRCA1 mutation, 66 BRCA2, and 3 patients with both BRCA1 and BRCA2, while the placebo arm had 91 BRCA1 and 40 BRCA2 mutant patients. Analysis of PFS by blinded independent review found freedom from disease progression or death at 3 years was 69% in the olaparib arm compared with 35% in the placebo arm (hazard ratio for disease progression or death, 0.28; 95% CI, 0.20 to 0.39; P<0.001)."	30345884	PubMed		"Moore et al., 2018, N. Engl. J. Med."	NCT01844986	5	accepted	7276	Rare Germline	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/7276	https://civicdb.org/links/molecular_profiles/186	FALSE	BRCA2	675	Mutation		chr13	32315474	32399210			ENST00000380152.3	75		"gene_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
IDH1 Mutation	641	Acute Myeloid Leukemia	9119		Ivosidenib		Predictive	Supports	A	Sensitivity/Response	"I phase 1 trial for patients with IDH1-mutated AML, patients who received ivosidenib (AG-120). The rate of complete remission was 21.6%, the over all response rate was 30.4%."	29860938	PubMed		"DiNardo et al., 2018, N. Engl. J. Med."	NCT02074839	3	accepted	7278	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/7278	https://civicdb.org/links/molecular_profiles/641	FALSE	IDH1	3417	Mutation		chr2	208237079	208251551			ENST00000415913.1	75		transcript_variant		2023-01-09 21:52:08 UTC				FALSE
FLT3 Mutation	515	Acute Myeloid Leukemia	9119		Gilteritinib		Predictive	Supports	B	Sensitivity/Response	"In a phase 1/2 trial, patients with refractory or relapsed AML with FLT3 mutation (n=191; ITD n=162, D835 n=13, ITD-D835 n=16) received gilteritinib. 49% (93/191) of patients achieved an overall response, 9% (n=18) complete remission, 5% (n=10) complete remission with incomplete platelet recovery, 22% (n=42) complete remission with incomplete hematological recovery, and 12% (n=23) reached partial remission. The refractory or relapsed AML FLT wildtype group treated with gilteritinib(n=58) had lower overall response rate (12%), complete remission (2%), complete remission with incomplete platelet recovery (0%), complete remission with incomplete hematological recovery (7%), and fewer reached partiral remission (3%). Also, bone marrow myeloblast reduction was greater in FLT3 mutant patients compared to FLT3 wildtype."	28645776	PubMed		"Perl et al., 2017, Lancet Oncol."	NCT02014558	4	accepted	7283	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/7283	https://civicdb.org/links/molecular_profiles/515	FALSE	FLT3	2322	Mutation		chr13	28003274	28100592			ENST00000241453.7	75		"transcript_variant,gain_of_function_variant"		2023-01-09 21:52:07 UTC				FALSE
ALK Fusion	495	Lung Non-small Cell Carcinoma	3908		Alectinib		Predictive	Supports	A	Sensitivity/Response	"In a phase 3 trial, 303 patients with NSCLC with ALK fusion were randomly assigned to alectinib arm (N=152) or crizotinib arm (N=151). PFS was significantly longer with alectinib than with crizotinib (HR for disease progression or death 0.47, 95% CI: 0.34-0.65, p<0.001). Investigator-assessed RR was 82.9% in alectinib arm and 75.5% in crizotinib arm. CNS RR in patients with measurable CNS lesions was 81% and 50% for alectinib and crizotinib, respectively. Eight patients in the alectinib group, in comparison to one patient with crizotinib, had a complete CNS response. Despite longer treatment duration for alectinib, there were fewer grade 3-5 adverse events compared with crizotinib treatment."	28586279	PubMed		"Peters et al., 2017, N. Engl. J. Med."	NCT02075840	5	accepted	7284	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/7284	https://civicdb.org/links/molecular_profiles/495	FALSE	ALK	238	Fusion	ALK Fusion	chr2	29192774	29223528			ENST00000389048.3	75		transcript_fusion		2023-01-09 21:52:07 UTC		N/A	REARRANGEMENT	FALSE
ALK Fusion	495	Lung Non-small Cell Carcinoma	3908		Ceritinib		Predictive	Supports	A	Sensitivity/Response	"In a phase 3 trial, patients with previously treatmented NSCLC with ALK fusion were randomly assigned to ceritinib or chemotherapy. Ceritinib showed a significant improvement in median  PFS compared with chemotherapy (54 months [95% CI 41-69] for ceritinib vs 16 months [14-28] for chemotherapy; hazard ratio 049 [036-067]; p<00001)."	28602779	PubMed		"Shaw et al., 2017, Lancet Oncol."	NCT01828112	5	accepted	7285	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/7285	https://civicdb.org/links/molecular_profiles/495	FALSE	ALK	238	Fusion	ALK Fusion	chr2	29192774	29223528			ENST00000389048.3	75		transcript_fusion		2023-01-09 21:52:07 UTC		N/A	REARRANGEMENT	FALSE
ALK Fusion	495	Lung Non-small Cell Carcinoma	3908		Lorlatinib		Predictive	Supports	B	Sensitivity/Response	"In a phase 2 trial, patients with NSCLC with ALK fusion received lorlatinib. In treatment-naive patients, ORR was 90.0% In patients with at least one previous ALK tyrosine kinase inhibitor, ORR were achieved in 47.0%.In patients who had only received crizotinib ORR was achieved in 69.5%."	30413378	PubMed		"Solomon et al., 2018, Lancet Oncol."	NCT01970865	4	accepted	7286	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/7286	https://civicdb.org/links/molecular_profiles/495	FALSE	ALK	238	Fusion	ALK Fusion	chr2	29192774	29223528			ENST00000389048.3	75		transcript_fusion		2023-01-09 21:52:07 UTC		N/A	REARRANGEMENT	FALSE
BRAF V600	17	Melanoma	1909		"Binimetinib,Encorafenib"	Combination	Predictive	Supports	A	Sensitivity/Response	"In a phase 3 trial, patients with melanoma with BRAF V600E or V600K mutation were randomly assigned to encorafenib plus binimetinib or vemurafenib or encorafenib. mPFS was 149 months (95% CI 110-185) in the encorafenib plus binimetinib group and 73 months (56-82) in the vemurafenib group (hazard ratio [HR] 054, 95% CI 041-071; two-sided p<00001)"	29573941	PubMed		"Dummer et al., 2018, Lancet Oncol."	NCT01909453	5	accepted	7287	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/7287	https://civicdb.org/links/molecular_profiles/17	FALSE	BRAF	673	V600	Other BRAF V600's	chr7	140753336	140753337			ENST00000288602.6	75		protein_altering_variant		2023-01-09 21:52:04 UTC		"13,961,448,153,762,800,000,000,000,000,000"	VAL600	FALSE
KIT K550_K559DEL	2565	Gastrointestinal Stromal Tumor	9253		Sunitinib		Predictive	Does Not Support	C	Resistance	"Patient 78 from a larger cohort of genotyped patients (n= 78) with imatinib resistant or intolerant gastrointestinal stromal tumors (GISTs) harbored a primary (pre-imatinib treatment) KIT K550_V559 deletion. Following failure of imatinib, the GIST was again genotyped, but no secondary mutations were found. The patient started on 50mg sunitinib on a schedule of two weeks on/one weeks off. This patient experienced partial response; time to progression and overall survival were censored at 54 weeks and 84 weeks (Table A1)."	18955458	PubMed		"Heinrich et al., 2008, J. Clin. Oncol."		2	accepted	7289	Somatic	2023-01-09 21:47:01 UTC	https://civicdb.org/links/evidence_items/7289	https://civicdb.org/links/molecular_profiles/2565	FALSE	KIT	3815	K550_K559DEL		chr4	54727416	54727445	AAACCCATGTATGAAGTACAGTGGAAGGTT		ENST00000288135.5	75				2023-01-27 17:17:53 UTC	CA645516734			FALSE
CDKN2A Mutation	2573	Pancreatic Cancer	1793		Palbociclib		Predictive	Does Not Support	B	Sensitivity/Response	"In a phase 2 trial, patients with pancreatic cancer with CDKN2A loss or mutation were received palbociclib. Among 12 patients no overall response or stable disease at 16 weeks were observed."	158598	ASCO	2532	"Tareq Al Baghdadi, 2018, ASCO Annual Meeting, Abstract 2532"	NCT02693535	4	accepted	7299	Somatic	2023-01-09 21:47:01 UTC	https://civicdb.org/links/evidence_items/7299	https://civicdb.org/links/molecular_profiles/2573	FALSE	CDKN2A	1029	Mutation		chr9	21968056	21974866			ENST00000498124.1	75				2023-01-09 21:52:21 UTC		N/A		FALSE
CDKN2A Mutation	2573	Cholangiocarcinoma	4947		Palbociclib		Predictive	Does Not Support	B	Sensitivity/Response	"In a phase 2 trial, patients with gallbladder cancer or bile duct cancer with CDKN2A loss or mutation were received palbociclib. Among 10 patients, no overall response or stable disease at 16 weeks were observed."	158598	ASCO	2532	"Tareq Al Baghdadi, 2018, ASCO Annual Meeting, Abstract 2532"	NCT02693535	4	accepted	7300	Somatic	2023-01-09 21:47:01 UTC	https://civicdb.org/links/evidence_items/7300	https://civicdb.org/links/molecular_profiles/2573	FALSE	CDKN2A	1029	Mutation		chr9	21968056	21974866			ENST00000498124.1	75				2023-01-09 21:52:21 UTC		N/A		FALSE
ERBB2 Amplification	302	Colorectal Cancer	9256		"Pertuzumab,Trastuzumab"	Combination	Predictive	Supports	B	Sensitivity/Response	"In an updated report of a part of the phase 2a MyPathway trial, 57 patients with treatment-refractory, metastatic colorectal cancer with HER2 amplification received pertuzumab and trastuzumab. Objective response rate was 32% (n=18/57). One patient had a complete response, and 17 experienced a partial response. Patients were determined to have HER2 amplification by NGS and/or FISH/CISH. In addition, the authors note that 27/35 patients had HER2 overexpression as determined by IHC, 3 of 47 tested had HER2 mutations, 8 had PIK3CA mutations, and 13 had mutated KRAS. Exploratory analysis found that KRAS wild-type patients had better ORR as compared to KRAS mutated patients (40% vs 8%)."	30857956	PubMed		"Meric-Bernstam et al., 2019, Lancet Oncol."	NCT02091141	3	accepted	7302	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/7302	https://civicdb.org/links/molecular_profiles/302	FALSE	ERBB2	2064	Amplification		chr17	39700080	39728662			ENST00000269571.5	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A	OVEREXPRESSION	FALSE
BRAF KIAA1549::BRAF	614	Spindle Cell Sarcoma	4235		"Bevacizumab,Temsirolimus,Sorafenib"	Combination	Predictive	Supports	C	Sensitivity/Response	A patients with malignant spindle cell tumor treated as as soft tissue sarcoma harboring KIAA1549-BRAF fusion were treated with sorafenib in combination with bevacizumab and temsirolimus.  Tumor of the chest wall showed good response.	26314551	PubMed		"Ross et al., 2016, Int. J. Cancer"		2	accepted	7312	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/7312	https://civicdb.org/links/molecular_profiles/614	FALSE	BRAF	673	KIAA1549::BRAF	BRAF Fusions	chr7	138861139	138981318			ENST00000440172.1	75	ENST00000288602.6	transcript_fusion		2023-01-09 21:52:08 UTC		N/A	KIAA1549-BRAF	FALSE
BRAF KIAA1549::BRAF	614	Spindle Cell Sarcoma	4235		"Bevacizumab,Temsirolimus,Sorafenib"	Combination	Predictive	Supports	C	Sensitivity/Response	A patients with malignant spindle cell tumor treated as as soft tissue sarcoma harboring KIAA1549-BRAF fusion were treated with sorafenib in combination with bevacizumab and temsirolimus.  Tumor of the chest wall showed good response.	26314551	PubMed		"Ross et al., 2016, Int. J. Cancer"		2	accepted	7312	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/7312	https://civicdb.org/links/molecular_profiles/614	FALSE	BRAF	673	KIAA1549::BRAF	BRAF Fusions	chr7	140734479	140787584			ENST00000440172.1	75	ENST00000288602.6	transcript_fusion		2023-01-09 21:52:08 UTC		N/A	KIAA1549-BRAF	FALSE
PIK3CA Mutation	307	Breast Cancer	1612		"Fulvestrant,Alpelisib"	Combination	Predictive	Supports	A	Sensitivity/Response	"In a phase 3 trial, patients with hormone receptor positive, HER2 receptor negative breast were allocated to alpelisib plus fulvestrant or placebo plus fulvestrant. Patients were enrolled into two cohorts on the basis of tumor-tissue PIK3CA mutation status. In the cohort of patients with PIK3CA-mutated cancer (defined by the presence of any PIK3CA mutation in mutation hot spots in the C2, helical, and kinase domains of PI3K corresponding to exons 7, 9, and 20, respectively), PFS was 11 months in the alpelisib-fulvestrant group, as compared with 5.7 months in the placebo-fulvestrant group (HR 0.65, 95% CI, 0.50 to 0.85, p<0.001). In the cohort without PIK3CA-mutated cancer, the HR was 0.85 (95% CI, 0.58 to 1.25). Overall response rate was also greater in the PIK3CA-mutant group (26.6% vs. 12.8%)."	31091374	PubMed		"Andr et al., 2019, N. Engl. J. Med."	NCT02437318	5	accepted	7313	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/7313	https://civicdb.org/links/molecular_profiles/307	FALSE	PIK3CA	5290	Mutation		chr3	179148523	179240093			ENST00000263967.3	75		"transcript_variant,gain_of_function_variant"		2023-01-09 21:52:06 UTC		N/A		FALSE
PIK3CA E542K	103	Breast Cancer	1612		"Fulvestrant,Alpelisib"	Combination	Predictive	Supports	A	Sensitivity/Response	"In a phase 3 trial, 572 patients with hormone receptor positive, HER2 receptor negative advanced breast cancer who previously received endocrine therapy were allocated to alpelisib plus fulvestrant or placebo plus fulvestrant. Patients were enrolled into two cohorts on the basis of tumor-tissue PIK3CA mutation status (N=341). PIK3CA mutation was determined according to the presence or absence of any hot spot mutation in the C2, helical, and kinase domains of PI3K (corresponding to exon 7, 9, and 20, respectively). In the cohort of patients with PIK3CA-mutated cancer, PFS was 11 months in the alpelisib-fulvestrant group, as compared with 5.7 months in the placebo-fulvestrant group (HR 0.65, p<0.001). In the cohort without PIK3CA-mutated cancer, the HR was 0.85. Analyses of PFS according to mutation types showed consistent benefit of treatment with alpelisibfulvestrant across prespecified subgroups, including E542K (N=60, HR 0.60, 95% CI 0.29-1.23), E545X, and H1047X."	31091374	PubMed		"Andr et al., 2019, N. Engl. J. Med."	NCT02437318	3	accepted	7315	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/7315	https://civicdb.org/links/molecular_profiles/103	FALSE	PIK3CA	5290	E542K		chr3	179218294	179218294	G	A	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.1624G>A,NP_006209.2:p.Glu542Lys,ENST00000263967.3:c.1624G>A,NC_000003.11:g.178936082G>A"	2023-01-27 17:02:37 UTC	CA333572	31944	"GLU542LYS,RS121913273"	FALSE
BRAF KIAA1549::BRAF	614	Pilocytic Astrocytoma	4851				Diagnostic	Supports	B	Positive	"This study identified a novel rearrangement event between the uncharacterized gene KIAA-1549 and BRAF in 66% (29 of 44) of pilocytic astrocytoma but not in 244 higher-grade astrocytomas that were evaluated. An in vitro study further showed that this fusion gene lacks the N-terminal BRAF auto-regulatory domain, leading to constitutive activation of BRAF."	18974108	PubMed		"Jones et al., 2008, Cancer Res."		4	accepted	7319	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/7319	https://civicdb.org/links/molecular_profiles/614	FALSE	BRAF	673	KIAA1549::BRAF	BRAF Fusions	chr7	138861139	138981318			ENST00000440172.1	75	ENST00000288602.6	transcript_fusion		2023-01-09 21:52:08 UTC		N/A	KIAA1549-BRAF	FALSE
BRAF KIAA1549::BRAF	614	Pilocytic Astrocytoma	4851				Diagnostic	Supports	B	Positive	"This study identified a novel rearrangement event between the uncharacterized gene KIAA-1549 and BRAF in 66% (29 of 44) of pilocytic astrocytoma but not in 244 higher-grade astrocytomas that were evaluated. An in vitro study further showed that this fusion gene lacks the N-terminal BRAF auto-regulatory domain, leading to constitutive activation of BRAF."	18974108	PubMed		"Jones et al., 2008, Cancer Res."		4	accepted	7319	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/7319	https://civicdb.org/links/molecular_profiles/614	FALSE	BRAF	673	KIAA1549::BRAF	BRAF Fusions	chr7	140734479	140787584			ENST00000440172.1	75	ENST00000288602.6	transcript_fusion		2023-01-09 21:52:08 UTC		N/A	KIAA1549-BRAF	FALSE
BRAF KIAA1549::BRAF	614	Pilocytic Astrocytoma	4851				Oncogenic	Supports	D	Oncogenicity	"This study identified a novel rearrangement event between the uncharacterized gene KIAA-1549 and BRAF in 66% (29 of 44) of pilocytic astrocytomas. The fusion gene was shown to delete the N-terminal BRAF auto-regulatory domain which in vitro assays indicated leads to constitutive activation of BRAF. Cos7 cells were transfected with two isoforms of KIAA1549-BRAF (both exon 16:exon 9), BRAF V600E, or wildtype BRAF and evaluated activity via BRAF kinase assay. Both fusion isoforms showed similar or higher kinase activity than V600E transfected cells. NIH3T3 cells transfected with V600E or the short fusion isoform also demonstrated anchorage-independent growth in soft agarose."	18974108	PubMed		"Jones et al., 2008, Cancer Res."		3	accepted	7337	Somatic	2023-02-03 19:36:14 UTC	https://civicdb.org/links/evidence_items/7337	https://civicdb.org/links/molecular_profiles/614	FALSE	BRAF	673	KIAA1549::BRAF	BRAF Fusions	chr7	138861139	138981318			ENST00000440172.1	75	ENST00000288602.6	transcript_fusion		2023-01-09 21:52:08 UTC		N/A	KIAA1549-BRAF	FALSE
BRAF KIAA1549::BRAF	614	Pilocytic Astrocytoma	4851				Oncogenic	Supports	D	Oncogenicity	"This study identified a novel rearrangement event between the uncharacterized gene KIAA-1549 and BRAF in 66% (29 of 44) of pilocytic astrocytomas. The fusion gene was shown to delete the N-terminal BRAF auto-regulatory domain which in vitro assays indicated leads to constitutive activation of BRAF. Cos7 cells were transfected with two isoforms of KIAA1549-BRAF (both exon 16:exon 9), BRAF V600E, or wildtype BRAF and evaluated activity via BRAF kinase assay. Both fusion isoforms showed similar or higher kinase activity than V600E transfected cells. NIH3T3 cells transfected with V600E or the short fusion isoform also demonstrated anchorage-independent growth in soft agarose."	18974108	PubMed		"Jones et al., 2008, Cancer Res."		3	accepted	7337	Somatic	2023-02-03 19:36:14 UTC	https://civicdb.org/links/evidence_items/7337	https://civicdb.org/links/molecular_profiles/614	FALSE	BRAF	673	KIAA1549::BRAF	BRAF Fusions	chr7	140734479	140787584			ENST00000440172.1	75	ENST00000288602.6	transcript_fusion		2023-01-09 21:52:08 UTC		N/A	KIAA1549-BRAF	FALSE
BRAF V600	17	Colorectal Cancer	9256		"Vemurafenib,Cetuximab,Irinotecan"	Combination	Predictive	Supports	B	Sensitivity/Response	"A randomized clinical trial was done with metastatic colorectal cancer (mCRC) patients (50 in the control group, 49 in the experimental group) with BRAF V600 mutations and RAS wild type that were enrolled from December 2014 to April 2016. The patients were randomized into groups with irinotecan and cetuximab with vemurafenib (VIC group) or without (IC group). The VIC group showed an improvement of progression of free survival (HR 0.42, 95% CI: 0.26 to 0.66, p < 0.001) with a median value of 4.4 months compared to 2.0 months for the IC group. In addition, for the VIC group, there was a 16% drug response rate while the IC group had a 4% drug response rate (p-value = 0.08). Some grade 3/4 adverse events were higher in the experimental arm, and skin toxicity and fatigue showed no increase."	147167	ASCO	3505	"Scott Kopetz, 2017, ASCO Annual Meeting, Abstract 3505"	NCT02164916	3	accepted	7355	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/7355	https://civicdb.org/links/molecular_profiles/17	FALSE	BRAF	673	V600	Other BRAF V600's	chr7	140753336	140753337			ENST00000288602.6	75		protein_altering_variant		2023-01-09 21:52:04 UTC		"13,961,448,153,762,800,000,000,000,000,000"	VAL600	FALSE
EGFR Mutation	438	Lung Non-small Cell Carcinoma	3908		Dacomitinib		Predictive	Supports	B	Sensitivity/Response	"In the ARCHER 1050 Phase 3 Trial (NCT01774721), 452 patients with newly diagnosed stage IIIB/IV or recurrent NSCLC exon 19 deletion or the Leu858Arg mutation, (with or without the T790M) were treated with second generation tyrosine kinase inhibitor (TKI) dacomitinib (227 patients) or first generation TKI gefitinib (225 patients).  Primary endpoint was progression free survival (PFS), and median PFS according to masked independent review was 14.7 months (95% CI 11.1?6.6) with dacomitinib group 9.2 months (9.1?1.0) with gefitinib (HR 059, 95% CI 047?74; p<00001).  Benefit of dacomitinib over gefitinib was lower in non-Asian patient subgroup (n=106) than in Asian group (n=346) although authors note smaller sample size may explain this. Authors state that PFS was significantly improved with first line dacomitinib treatment, and that dacomitinib should be considered for EGFR mutant NSCLC treatment."	28958502	PubMed		"Wu et al., 2017, Lancet Oncol."	NCT01774721	4	accepted	7363	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/7363	https://civicdb.org/links/molecular_profiles/438	FALSE	EGFR	1956	Mutation		chr7	55019101	55211628			ENST00000275493.2	75		inframe_variant		2023-01-09 21:52:07 UTC		N/A		FALSE
FLT3 ITD	55	Acute Myeloid Leukemia	9119		Ponatinib		Predictive	Supports	D	Sensitivity/Response	"In a preclinical trial, multiple experiments testing the effectiveness of ponatinib on the mutation FLT3-ITD in acute myeloid leukemia (AML) were conducted. Ponatinib was very effective in targeting the FLT3-ITD mutation in MV4-11 cell lines (growth inhibition: IC50=2 nmol/L) compared to native FLT3 in RS4;11 cell lines (IC50>100 nmol/L). Additionally, MV4-11 cell lines incubated for 1 hour were shown to have reduced phosphorylation of tyrosine kinases beginning at a ponatinib concentration of 0.3 nmol/L. Ponatinib was shown to induce apoptotic mechanisms measured by caspase-3/7 activity in MV4-cell lines. In mice with the MV4-11 xenograft, ponatinib was very effective in targeting the FLT3-ITD mutation, as dosages of 1-5 mg/kg led to tumor growth inhibition and regression, while dosages of 10 and 25 mg/kg led to complete tumor regression. In primary blast cells from AML patients, Ponatinib was selectively effective in growth inhibition of the FLT3-ITD patient cells (n=1, IC50=4nmol/L) when compared to the native FLT3 patient cells (n=3, IC50>100nmol/L)."	21482694	PubMed		"Gozgit et al., 2011, Mol. Cancer Ther."		5	accepted	7369	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/7369	https://civicdb.org/links/molecular_profiles/55	FALSE	FLT3	2322	ITD		chr13	28034082	28034214			ENST00000241453.7	75		inframe_insertion		2023-01-09 21:52:04 UTC		16270		FALSE
KIT N822K	1237	Acute Myeloid Leukemia	9119		"Sorafenib,Sunitinib"	Substitutes	Predictive	Does Not Support	D	Sensitivity/Response	"In a preclinical trial, the AML cell line Kasumi-1 with the KIT mutation N822K was treated with the tyrosine kinase inhibitors (TKI) ponatinib, sorafenib, and sunitinib. Ponatinib was much more effective in the growth inhibition of cells harboring the KIT mutation (IC50=8 nmol/L) compared to sorafenib (IC50=59 nmol/L) and sunitinib (IC50=56 nmol/L)."	21482694	PubMed		"Gozgit et al., 2011, Mol. Cancer Ther."		3	accepted	7370	Somatic	2023-01-09 21:46:44 UTC	https://civicdb.org/links/evidence_items/7370	https://civicdb.org/links/molecular_profiles/1237	FALSE	KIT	3815	N822K	KIT Exon 17	chr4	54733174	54733174	T	A	ENST00000288135.5	75		missense_variant	"NM_000222.2:c.2466T>A,NP_000213.1:p.Asn822Lys,NC_000004.11:g.55599340T>A,ENST00000288135.5:c.2466T>A"	2023-01-27 17:09:06 UTC	CA16602411	375931	"ASN822LYS,RS121913514"	FALSE
FGFR1 Fusion	565	Acute Myeloid Leukemia	9119		"Sorafenib,Sunitinib"	Substitutes	Predictive	Does Not Support	D	Sensitivity/Response	"In a preclinical trial, the AML cell line KG1 with the FGFR1OP2-FGFR1 fusion mutation was treated with the tyrosine kinase inhibitors (TKI) ponatinib, sorafenib, and sunitinib. Ponatinib was much more effective in the growth inhibition of cells harboring the fusion mutation (IC50=17 nmol/L) compared to sorafenib (IC50>100 nmol/L) and sunitinib (IC50>100 nmol/L)."	21482694	PubMed		"Gozgit et al., 2011, Mol. Cancer Ther."		3	accepted	7375	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/7375	https://civicdb.org/links/molecular_profiles/565	FALSE	FGFR1	2260	Fusion		chr8	38411138	38467845			ENST00000425967.3	75		transcript_fusion	N/A	2023-01-09 21:52:07 UTC		N/A		FALSE
PDGFRA FIP1L1::PDGFRA	570	Acute Myeloid Leukemia	9119		"Sorafenib,Sunitinib"	Substitutes	Predictive	Supports	D	Sensitivity/Response	"In a preclinical trial, the AML cell line EOL1with the FIP1L1-PDGFRa fusion mutation was treated with the tyrosine kinase inhibitors (TKI) ponatinib, sorafenib, and sunitinib. Ponatinib was similarly effective in the growth inhibition of cells harboring the fusion mutation (IC50=0.5 nmol/L) compared to sorafenib (IC50=0.5 nmol/L) and sunitinib (IC50=3 nmol/L)."	21482694	PubMed		"Gozgit et al., 2011, Mol. Cancer Ther."		3	accepted	7378	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/7378	https://civicdb.org/links/molecular_profiles/570	FALSE	PDGFRA	5156	FIP1L1::PDGFRA		chr4	53377645	53428183			ENST00000337488.6	75	ENST00000257290.5	transcript_fusion		2023-01-09 21:52:08 UTC		N/A	FIP1L1-PDGFRA	FALSE
PDGFRA FIP1L1::PDGFRA	570	Acute Myeloid Leukemia	9119		"Sorafenib,Sunitinib"	Substitutes	Predictive	Supports	D	Sensitivity/Response	"In a preclinical trial, the AML cell line EOL1with the FIP1L1-PDGFRa fusion mutation was treated with the tyrosine kinase inhibitors (TKI) ponatinib, sorafenib, and sunitinib. Ponatinib was similarly effective in the growth inhibition of cells harboring the fusion mutation (IC50=0.5 nmol/L) compared to sorafenib (IC50=0.5 nmol/L) and sunitinib (IC50=3 nmol/L)."	21482694	PubMed		"Gozgit et al., 2011, Mol. Cancer Ther."		3	accepted	7378	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/7378	https://civicdb.org/links/molecular_profiles/570	FALSE	PDGFRA	5156	FIP1L1::PDGFRA		chr4	54274841	54298247			ENST00000337488.6	75	ENST00000257290.5	transcript_fusion		2023-01-09 21:52:08 UTC		N/A	FIP1L1-PDGFRA	FALSE
KIT N822K	1237	Acute Myeloid Leukemia	9119		Ponatinib		Predictive	Supports	D	Sensitivity/Response	"In this preclinial trial, the AML cell line Kasumi-1 with c-KIT N822K mutation was treated with Ponatinib. This drug effectively inhibits both KIT phosphorylation and viability for Kasumi-1 cells at IC50 values 20 nmol/L and 8 nmol/L respectively."	21482694	PubMed		"Gozgit et al., 2011, Mol. Cancer Ther."		2	accepted	7379	Somatic	2023-01-09 21:46:44 UTC	https://civicdb.org/links/evidence_items/7379	https://civicdb.org/links/molecular_profiles/1237	FALSE	KIT	3815	N822K	KIT Exon 17	chr4	54733174	54733174	T	A	ENST00000288135.5	75		missense_variant	"NM_000222.2:c.2466T>A,NP_000213.1:p.Asn822Lys,NC_000004.11:g.55599340T>A,ENST00000288135.5:c.2466T>A"	2023-01-27 17:09:06 UTC	CA16602411	375931	"ASN822LYS,RS121913514"	FALSE
FLT3 ITD	55	Leukemia	1240		"Sunitinib,Sorafenib"	Substitutes	Predictive	Supports	D	Sensitivity/Response	"In a preclinical trial, the leukemic cell line MV4-11 with the FLT3-ITD mutation and the leukemic cell line RS4;11 with the native FLT3 gene were treated with the tyrosine kinase inhibitors (TKI) ponatinib, sorafenib, and sunitinib. Ponatinib was similarly effective in the growth inhibition of cells harboring the FLT3-ITD mutation (IC50=2 nmol/L) compared to sorafenib (IC50=4 nmol/L) and sunitinib (IC50=12 nmol/L). Conversely, all three TKIs each were not effective in the growth inhibition of cells with native FLT3 (IC50>100 nmol/L)."	21482694	PubMed		"Gozgit et al., 2011, Mol. Cancer Ther."		4	accepted	7382	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/7382	https://civicdb.org/links/molecular_profiles/55	FALSE	FLT3	2322	ITD		chr13	28034082	28034214			ENST00000241453.7	75		inframe_insertion		2023-01-09 21:52:04 UTC		16270		FALSE
BRCA1 Loss-of-function	131	Pancreatic Adenocarcinoma	4074		Olaparib		Predictive	Supports	A	Sensitivity/Response	"In the phase 3 POLO trial patients who had germline BRCA1/2 mutation and metastatic pancreatic adenocarcinoma that had not progressed during first-line platinum-based chemotherapy were allocated to maintenance olaparib or placebo. BRCA1/2 mutation was determine by the BRAC-Analysis CDx test. Median progression free survival was significantly longer in the olaparib group than in the placebo group (7.4 months vs. 3.8 months; hazard ratio for disease progression or death, 0.53; 95% CI, 0.35 to 0.82; p=0.004). BRCA1 mutations were present in 29/92 patients in the olaparib group and 16/62 patients in the placebo group, while one patient receiving olaparib had both BRCA1 and BRCA2 germline mutations. Responses were seen in 18 (20%) patients in the olaparib group, including two complete responses. The safety profile of olaparib was similar to that observed in other patient populations."	31157963	PubMed		"Golan et al., 2019, N. Engl. J. Med."	NCT02184195	5	accepted	7384	Rare Germline	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/7384	https://civicdb.org/links/molecular_profiles/131	FALSE	BRCA1	672	Loss-of-function	BRCA Germline Variants	chr17	43045629	43125483			ENST00000471181.2	75		"loss_of_heterozygosity,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
BRCA2 Loss-of-function	132	Pancreatic Adenocarcinoma	4074		Olaparib		Predictive	Supports	A	Sensitivity/Response	"In the phase 3 POLO trial patients who had germline BRCA1/2 mutation and metastatic pancreatic adenocarcinoma that had not progressed during first-line platinum-based chemotherapy were allocated to maintenance olaparib or placebo. BRCA1/2 mutation was determine by the BRAC-Analysis CDx test. Median progression free survival was significantly longer in the olaparib group than in the placebo group (7.4 months vs. 3.8 months; hazard ratio for disease progression or death, 0.53; 95% CI, 0.35 to 0.82; p=0.004). BRCA2 mutations were present in 62/92 patients in the olaparib group and 46/62 patients in the placebo group, while one patient receiving olaparib had both BRCA1 and BRCA2 germline mutations. Responses were seen in 18 (20%) patients in the olaparib group, including two complete responses. The safety profile of olaparib was similar to that observed in other patient populations."	31157963	PubMed		"Golan et al., 2019, N. Engl. J. Med."	NCT02184195	5	accepted	7385	Rare Germline	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/7385	https://civicdb.org/links/molecular_profiles/132	FALSE	BRCA2	675	Loss-of-function	BRCA Germline Variants	chr13	32315474	32399210			ENST00000380152.3	75		loss_of_function_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
KIT A502_Y503insAY	1466	Gastrointestinal Stromal Tumor	9253		Sunitinib		Predictive	Supports	D	Sensitivity/Response	"In an in vitro study, an IL3 independant Ba/F3 cell line expressing KIT V560D primary activating mutation demonstrated sensitivity to sunitinib treatment (IC50: 5nmol/L). IC50 was determined by assessing cell viability."	25239608	PubMed		"Garner et al., 2014, Clin. Cancer Res."		2	accepted	7392	Somatic	2023-01-09 21:46:46 UTC	https://civicdb.org/links/evidence_items/7392	https://civicdb.org/links/molecular_profiles/1466	FALSE	KIT	3815	A502_Y503insAY		chr4	54726016	54726017		GCCTAT				inframe_insertion		2023-01-09 21:52:14 UTC	unregistered			FALSE
KIT V560_L576DEL	1458	Gastrointestinal Stromal Tumor	9253		"Ponatinib,Imatinib"	Substitutes	Predictive	Does Not Support	D	Sensitivity/Response	"In the patient-derived cell line GIST430 harboring KIT V560_L576del primary activating mutation implanted in mice, imatinib and ponatinib were shown to reduce KIT phosphorylation compared to the vehicle. In GIST430 cell lines, ponatinib and imatinib reduced phospho-AKT and phospho-ERK levels. A cell line derived from GIST430 patients expressing KIT V560_L576del primary mutation demonstrated sensitivity to imatinib (IC50: 61nmol/L) and ponatinib (IC50: 12nmol/L) treatments. In comparison, the insensitve KIT-independent GIST226 cell line showed IC50 >5000nmol/L and 2807nmol/L for these drugs respectively. IC50 was determined by assessing cell viability."	25239608	PubMed		"Garner et al., 2014, Clin. Cancer Res."		4	accepted	7393	Somatic	2023-01-09 21:46:46 UTC	https://civicdb.org/links/evidence_items/7393	https://civicdb.org/links/molecular_profiles/1458	FALSE	KIT	3815	V560_L576DEL		chr4	54727446	54727496						inframe_deletion		2023-01-09 21:52:14 UTC				FALSE
KIT V560G	946	Gastrointestinal Stromal Tumor	9253		"Ponatinib,Imatinib,Regorafenib"	Substitutes	Predictive	Supports	D	Sensitivity/Response	"In an in vitro kinase study, a KIT V560G primary activating mutant kinase demonstrated sensitivity to imatinib (IC50: 38nmol/L vs. 640nmol/L), regorafenib (IC50: 27nmol/L vs. 533nmol/L), and ponatinib (IC50: 0.3nmol/L vs. 6nmol/L) treatments compared to the wildtype KIT. IC50 was determined by assessing kinase activity."	25239608	PubMed		"Garner et al., 2014, Clin. Cancer Res."		3	accepted	7395	Somatic	2023-01-09 21:46:40 UTC	https://civicdb.org/links/evidence_items/7395	https://civicdb.org/links/molecular_profiles/946	FALSE	KIT	3815	V560G		chr4	54727447	54727447	T	G	ENST00000288135.5	75		missense_variant	"NM_000222.2:c.1679T>G,NP_000213.1:p.Val560Gly,NC_000004.11:g.55593613T>G,ENST00000288135.5:c.1679T>G"	2023-01-27 17:07:14 UTC	CA16602398	"375,916,376,735"	"RS121913521,VAL560GLY"	FALSE
KIT K642E	952	Gastrointestinal Stromal Tumor	9253		"Sunitinib,Ponatinib"	Substitutes	Predictive	Supports	D	Sensitivity/Response	"The GIST882 patient derived cell line expressing KIT K642E mutation demonstrated sensitivity to ponatinib (IC50: 31nmol/L) and sunitinib (IC50: 54nmol/L) treatments. In comparison, the insensitve KIT-independent GIST226 cell line showed IC50 >2807nmol/L and >5000nmol/L for these drugs respectively. IC50 was determined by assessing cell viability. The GIST882 cell line only showed reduced levels of phospho-KIT and phospho-ERK at high concentrations for ponatinib and sunitinib, while phospho-AKT levels were reduced at all concentrations for ponatinib and sunitinib."	25239608	PubMed		"Garner et al., 2014, Clin. Cancer Res."		3	accepted	7397	Somatic	2023-01-09 21:46:40 UTC	https://civicdb.org/links/evidence_items/7397	https://civicdb.org/links/molecular_profiles/952	FALSE	KIT	3815	K642E		chr4	54728055	54728055	A	G	ENST00000288135.5	75		missense_variant	"NM_000222.2:c.1924A>G,NP_000213.1:p.Lys642Glu,NC_000004.11:g.55594221A>G,ENST00000288135.5:c.1924A>G"	2023-01-27 17:07:18 UTC	CA123547	13866	"RS121913512,LYS642GLU"	FALSE
KIT D816E	1467	Gastrointestinal Stromal Tumor	9253		Ponatinib		Predictive	Does Not Support	D	Resistance	"A preclinical study was done in order to test the effects of a tyrosine kinase inhibitor (TKI) on the ponatinib-sensitive KIT-mutant cell line GIST-T1 derived from Gastrointestinal Stromal Tumor (GIST) patients with primary mutation 560-578 deletion and additional secondary mutation D816E. The cells were tested for Ponatinib resistance. GIST-T1/816 cells containing del 560-578 and D816E mutations (IC50: 23 nM) did not show resistance towards Ponatinib compared to GIST-T1 cells with only del 560-578 mutation (IC50: 5 nM). Ponatinib reduced phosphorylation in KIT, AKT, and ERK at higher concentrations. According to the results, the authors suggest that Ponatinib remained highly active in GIST cell lines with secondary mutation D816E."	25239608	PubMed		"Garner et al., 2014, Clin. Cancer Res."		4	accepted	7401	Somatic	2023-01-09 21:46:46 UTC	https://civicdb.org/links/evidence_items/7401	https://civicdb.org/links/molecular_profiles/1467	FALSE	KIT	3815	D816E		chr4	54733156	54733156	C	G	ENST00000288135.5	75		missense_variant	"ENST00000288135.5:c.2448C>G,NC_000004.11:g.55599322C>G,NM_000222.2:c.2448C>G,NP_000213.1:p.Asp816Glu"	2023-01-27 17:10:27 UTC	CA356911882	NONE FOUND	"D812E,ASP816GLU"	FALSE
BRAF KIAA1549::BRAF	614	Childhood Pilocytic Astrocytoma	6812	Infantile onset	"Vemurafenib,Sorafenib"	Substitutes	Predictive	Supports	D	Resistance	A pilocytic astrocytoma (PA) cell line named DKFZ-BT66 was generated from a 2-year old patient with the disease. Expression of KIAA1549-BRAF fusion in this cell line was identified. Treatment with sorafenib or vemurafenib resulted in paradoxical activation of MAPK/ERK as seen by increased pERK in western blots. Authors note that their observation aligns with results from a phase II clinical trial wherein PA patients experienced tumor growth under sorafenib treatment induced by paradoxical MAPK activation.	28002790	PubMed		"Selt et al., 2017, Oncotarget"		2	accepted	7402	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/7402	https://civicdb.org/links/molecular_profiles/614	FALSE	BRAF	673	KIAA1549::BRAF	BRAF Fusions	chr7	138861139	138981318			ENST00000440172.1	75	ENST00000288602.6	transcript_fusion		2023-01-09 21:52:08 UTC		N/A	KIAA1549-BRAF	FALSE
BRAF KIAA1549::BRAF	614	Childhood Pilocytic Astrocytoma	6812	Infantile onset	"Vemurafenib,Sorafenib"	Substitutes	Predictive	Supports	D	Resistance	A pilocytic astrocytoma (PA) cell line named DKFZ-BT66 was generated from a 2-year old patient with the disease. Expression of KIAA1549-BRAF fusion in this cell line was identified. Treatment with sorafenib or vemurafenib resulted in paradoxical activation of MAPK/ERK as seen by increased pERK in western blots. Authors note that their observation aligns with results from a phase II clinical trial wherein PA patients experienced tumor growth under sorafenib treatment induced by paradoxical MAPK activation.	28002790	PubMed		"Selt et al., 2017, Oncotarget"		2	accepted	7402	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/7402	https://civicdb.org/links/molecular_profiles/614	FALSE	BRAF	673	KIAA1549::BRAF	BRAF Fusions	chr7	140734479	140787584			ENST00000440172.1	75	ENST00000288602.6	transcript_fusion		2023-01-09 21:52:08 UTC		N/A	KIAA1549-BRAF	FALSE
KIT A829P	964	Gastrointestinal Stromal Tumor	9253		Ponatinib		Predictive	Does Not Support	D	Resistance	"Ponatinib possesses potent activity against A829P KIT mutant cells in preclinical experiments. A preclinical study tested the effect of a tyrosine kinase inhibitor (TKI) on Ba/F3 cell lines with representative primary ponatinib-sensitizing mutation del 557-558, which induced IL-3 independent growth, and secondary mutation A829P. The cells were tested for Ponatinib resistance. Ba/F3 cells with del 557-558 and A829P mutations (IC50 for growth inhibition: 2 nM) did not show resistance towards Ponatinib compared to Ba/F3 cells with the del 557-558 mutation alone (IC50: 3 nM).  Ponatinib was shown to inhibit KIT phosphorylation in moderate concentrations. Similarly, GIST-T1/829 cells with 560-578 deletion/A829P mutations (IC50 = 16 nM) were not resistant to Ponatinib compared to GIST T1 cells with 560-578 deletion alone (IC50 = 5 nM). Ponatinib inhibited phosphorylation in KIT, ERK, and AKT at moderate to high concentrations in GIST-T1/829 cells."	25239608	PubMed		"Garner et al., 2014, Clin. Cancer Res."		4	accepted	7413	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/7413	https://civicdb.org/links/molecular_profiles/964	FALSE	KIT	3815	A829P		chr4	54736498	54736498	G	C				missense_variant	"NC_000004.11:g.55602664G>C,NM_000222.2:c.2485G>C,NP_000213.1:p.Ala829Pro"	2023-01-27 17:07:26 UTC	CA16602413	375933	"RS1057519713,ALA829PRO"	FALSE
KIT N822K	1237	Gastrointestinal Stromal Tumor	9253		"Imatinib,Sunitinib"	Substitutes	Predictive	Supports	D	Resistance	"Several preclinical studies tested the effects of various tyrosine kinase inhibitors (TKIs) on Ba/F3 cell lines with primary TKI-sensitizing del 557-558 mutation, which induced IL-3 independent growth, and secondary mutation N822K. The cells were tested for Sunitinib and Imatinib resistances. Ba/F3 cells with del 557-558 and N822K mutations (Sunitinib IC50 for growth inhibition: 225 +- 19 nM, Imatinib IC50: 483 +- 24 nM) did show resistance towards Sunitinib and Imatinib compared to Ba/F3 cells with the del 557-558 alone (Sunitinib IC50: 7 +- 2 nM, Imatinib IC50: 27 +- 8 nM).  Sunitinib and Imatinib did not completely inhibit KIT phosphorylation at 1000 nM, which was the highest concentration tested. Additionally, Ba/F3 cells were mutagenized with N-ethyl-N-nitrosourea and incubated with varying concentrations of Sunitinib and Imatinib separately. From these results, N822K mutations were the most frequent KIT mutation observed in resistant Ba/F3 cell populations incubated in Sunitinib. In Imatinib incubated cells, N822K mutations were seen in approximately 10% of resistant Ba/F3 cell clones."	25239608	PubMed		"Garner et al., 2014, Clin. Cancer Res."		4	accepted	7414	Somatic	2023-01-09 21:46:44 UTC	https://civicdb.org/links/evidence_items/7414	https://civicdb.org/links/molecular_profiles/1237	FALSE	KIT	3815	N822K	KIT Exon 17	chr4	54733174	54733174	T	A	ENST00000288135.5	75		missense_variant	"NM_000222.2:c.2466T>A,NP_000213.1:p.Asn822Lys,NC_000004.11:g.55599340T>A,ENST00000288135.5:c.2466T>A"	2023-01-27 17:09:06 UTC	CA16602411	375931	"ASN822LYS,RS121913514"	FALSE
KIT A829P	964	Gastrointestinal Stromal Tumor	9253		"Imatinib,Sunitinib"	Substitutes	Predictive	Supports	D	Resistance	"Several preclinical studies tested the effects of various tyrosine kinase inhibitors (TKIs) on Ba/F3 cell lines with representative primary sunitinib and imatinib sensitizing mutation del 557-558, which induced IL-3 independent growth, and secondary mutation A829P. The cells were tested for Sunitinib and Imatinib resistances. Ba/F3 cells with del 557-558 and A829P mutations did show resistance towards Sunitinib and Imatinib (Sunitinib IC50 for growth inhibition: 319 +- 88 nM and Imatinib IC50: 179 +- 27 nM) compared to Ba/F3 cells with the del 557-558 mutation (Sunitinib IC50: 7 +- 2 nM and Imatinib IC50:  27 +- 8 nM). Imatinib and Sunitinib were shown to not reduce p-KIT at all in Ba/F3 cells with del 557-558/ A829P mutations.  Patient-derived GIST-T1/829 cells with 560-578 deletion/A829P mutations (Sunitinib IC50: 1168 nM and Imatinib IC50:1201 nM) did show resistance towards Sunitinib and Imatinib compared to GIST-T1 cells with 560-578 deletion alone (Sunitinib IC50: 15 nM and Imatinib IC50: 30 nM). Sunitinib and Imatinib did not inhibit p-KIT, p-ERK, and p-AKT in GIST-T1/829 cells."	25239608	PubMed		"Garner et al., 2014, Clin. Cancer Res."		4	accepted	7415	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/7415	https://civicdb.org/links/molecular_profiles/964	FALSE	KIT	3815	A829P		chr4	54736498	54736498	G	C				missense_variant	"NC_000004.11:g.55602664G>C,NM_000222.2:c.2485G>C,NP_000213.1:p.Ala829Pro"	2023-01-27 17:07:26 UTC	CA16602413	375933	"RS1057519713,ALA829PRO"	FALSE
KIT T670I	1241	Gastrointestinal Stromal Tumor	9253		Imatinib		Predictive	Supports	D	Resistance	"A preclinical study tested the effects of a tyrosine kinase inhibitor (TKI) on Ba/F3 cell lines with representative primary imatinib-sensitizing mutation del 557-558, which induced IL-3 independent growth, and secondary mutation T670I. The cells were tested for Imatinib resistance. Ba/F3 cells with del 557-558/T670I mutations (IC50 = >10000 nM) showed resistance towards Imatinib compared to Ba/F3 cells with del 557-558 alone (IC50 = 27 +- 8 nM). Similarly, patient-derived GIST-T1/670 cells with 560-578 deletion/T670I mutations (IC50 > 5000 nM) did show resistance towards Imatinib compared to GIST-T1 cells with 560-578 deletion (IC50 = 30 nM). Del 557-558/T670I cells were implanted into mice and treated with Imatinib. Imatinib was not effective in treating the del 557-558/T670I cells in mice as tumor volume progressively increased. In addition, Ba/F3 cells were mutagenized with N-ethyl-N-nitrosourea and incubated with varying concentrations of Imatinib. In Imatinib incubated cells, T670I mutations were seen in approximately 80% of the resistant cell populations."	25239608	PubMed		"Garner et al., 2014, Clin. Cancer Res."		5	accepted	7416	Somatic	2023-01-09 21:46:44 UTC	https://civicdb.org/links/evidence_items/7416	https://civicdb.org/links/molecular_profiles/1241	FALSE	KIT	3815	T670I		chr4	54729353	54729353	C	T	ENST00000288135.5	75		missense_variant	"NM_000222.2:c.2009C>T,NP_000213.1:p.Thr670Ile,NC_000004.11:g.55595519C>T,ENST00000288135.5:c.2009C>T"	2023-01-27 17:09:09 UTC	CA16602525	376058	"THR670ILE,RS121913516"	FALSE
KIT T670I	1241	Gastrointestinal Stromal Tumor	9253		"Ponatinib,Sunitinib"	Substitutes	Predictive	Does Not Support	D	Resistance	"Several preclinical studies tested the effects of various tyrosine kinase inhibitors (TKIs) on Ba/F3 cell lines with representative primary ponatinib and sunitinib sensitizing mutation del 557-558, which induced IL-3 independent growth, and secondary mutation T670I. The cells were tested for Ponatinib and Sunitinib resistances. Ba/F3 cells with del 557-558/T670I mutations (Ponatinib IC50 = 15 +/- 1 nM, Sunitinib IC50 = 12 +/- 2 nM) did not show resistance towards Ponatinib and Sunitinib compared to Ba/F3 cells with del 557-558 alone (Ponatinib IC50 = 3 +/- 0, Sunitinib IC50 = 7  +/- 2 nM). Similarly, patient-derived GIST-T1/670 cells with 560-578 deletion/T670I mutations (Ponatinib IC50 = 8 nM, Sunitinib IC50 = 15 nM) showed no resistance towards Ponatinib and Sunitinib compared to GIST-T1 cells with 560-578 deletion (Ponatinib IC50 = 5 nM, Sunitinib IC50 = 48 nM). Additionally, del 557-558/T670I cells was implanted into mice and treated with Ponatinib or Sunitinib. Ponatinib or Sunitinib were shown to be effective in treating the Ba/F3 mutant cells as tumor volume progressively decreased to zero at around 14 days."	25239608	PubMed		"Garner et al., 2014, Clin. Cancer Res."		5	accepted	7417	Somatic	2023-01-09 21:46:44 UTC	https://civicdb.org/links/evidence_items/7417	https://civicdb.org/links/molecular_profiles/1241	FALSE	KIT	3815	T670I		chr4	54729353	54729353	C	T	ENST00000288135.5	75		missense_variant	"NM_000222.2:c.2009C>T,NP_000213.1:p.Thr670Ile,NC_000004.11:g.55595519C>T,ENST00000288135.5:c.2009C>T"	2023-01-27 17:09:09 UTC	CA16602525	376058	"THR670ILE,RS121913516"	FALSE
NTRK3 ETV6::NTRK3	779	Congenital Fibrosarcoma	8418		Larotrectinib		Predictive	Supports	C	Sensitivity/Response	"In a pediatric phase 1 trial (NCT02637687) after initial chemotherapy failure, two ETV6-NTRK3 positive children (2 year old and 5 month old) were treated with Larotrectinib, resulting in reduced tumor burden (4 cycles showed ~50% reduction). Treatment was followed up by surgical resection resulting in a disease-free status at the time of last follow-up (>1 year)."	30204247	PubMed		"DuBois et al., 2018, Cancer"	NCT02637687	3	accepted	7418	Somatic	2023-01-09 21:46:38 UTC	https://civicdb.org/links/evidence_items/7418	https://civicdb.org/links/molecular_profiles/779	FALSE	NTRK3	4916	ETV6::NTRK3		chr12	11649854	11869969			ENST00000396373.4	75	ENST00000394480.2	transcript_fusion		2023-01-09 21:52:09 UTC		N/A	ETV6-NTRK3	FALSE
FGFR3 Mutation	805	Transitional Cell Carcinoma	2671		Erdafitinib		Predictive	Supports	A	Sensitivity/Response	"In a phase 2 trial, patients with locally advanced and unresectable or metastatic urothelial carcinoma harboring FGFR3 mutation or FGFR2/3 fusion were treated with Erdafitinib. All the patients had a history of disease progression during or after at least one course of chemotherapy. The response rate in patients receiving continuous daily 8 or 9mg Erdafitinib treatment was 40% (40/99). Within this treatment group, the response rate of patients with FGFR3 mutation was 49% (36/74). FGFR3 mutations included G370C, R248C, S249C, and Y373C."	31340094	PubMed		"Loriot et al., 2019, N. Engl. J. Med."	NCT02365597	4	accepted	7422	Somatic	2023-01-09 21:46:38 UTC	https://civicdb.org/links/evidence_items/7422	https://civicdb.org/links/molecular_profiles/805	FALSE	FGFR3	2261	Mutation		chr4	1793312	1808872			ENST00000340107.4	75				2023-01-09 21:52:09 UTC				FALSE
TP53 R273H	122	Osteosarcoma	3347		"Doxorubicin,Methotrexate"	Substitutes	Predictive	Supports	D	Resistance	"Several preclinical studies were testing drug resistance mechanisms of TP53-R273H variant. Saos-2 cells were transfected with TP53-R273H mutation and these cells were used in the study. Using a western blot, Saos-2/TP53-R273H cells were shown to have a 0.6-fold down-regulation (compared to the Control) for Procaspase-3 protein expression. In addition, Saos-2/TP53-R273H cells were shown to be more resistant to methotrexate and doxorubicin. Reduced levels of drug-induced apoptosis were seen in Saos-2/TP53-R273H cells treated with doxorubicin (0.05 uM and 0.10 uM) and methotrexate (25 nM and 50 nM) in DNA fragmentation assays. According to the results, TP53-R273H induces drug resistance when procaspase-3 is down-regulated."	17363498	PubMed		"Wong et al., 2007, Mol. Cancer Ther."		3	accepted	7430	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/7430	https://civicdb.org/links/molecular_profiles/122	FALSE	TP53	7157	R273H		chr17	7673802	7673802	C	T	ENST00000269305.4	75		missense_variant	"NM_000546.5:c.818G>A,NP_000537.3:p.Arg273His,NC_000017.10:g.7577120C>T,ENST00000269305.4:c.818G>A"	2023-01-27 17:02:48 UTC	CA000434	12366	"ARG273HIS,RS28934576"	FALSE
CDKN2A Loss	550	Lung Non-small Cell Carcinoma	3908		Palbociclib		Predictive	Does Not Support	B	Resistance	"TAPUR, a phase II basket trial, included a cohort of patients with advanced non-small lung cell carcinoma (NSCLC) harboring with CDKN2A loss or mutation and no RB mutations. Twenty-nine patients were treated with CDK4/6 inhibitor palbociclib; one experienced a partial response and 6 experienced stable disease lasting longer than 16 weeks (disease control rate: 29%). Median PFS was 7.9 weeks and median OS was 20.6 weeks. Authors concluded that palbociclib is worthy of further study in advanced NSCLC when standard treatment options aren't available."	174591	ASCO	9041	"Eugene R Ahn, 2019, ASCO Annual Meeting, Abstract 9041"	NCT02693535	2	accepted	7444	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/7444	https://civicdb.org/links/molecular_profiles/550	FALSE	CDKN2A	1029	Loss		chr9	21967753	21994624			ENST00000579755.1	75		loss_of_function_variant		2023-01-09 21:52:07 UTC		N/A		FALSE
IDH1 Mutation	641	Cholangiocarcinoma	4947		Ivosidenib		Predictive	Supports	B	Sensitivity/Response	"In a phase1 trial, 73 patients with cholangiocarcinoma harboring IDH1 mutations were treated with mutant IDH1 inhibitor ivosidenib. The response rate was 5%, median progression free survival was 3.8 months, and median overall survival was 13.8 months."	31300360	PubMed		"Lowery et al., 2019, Lancet Gastroenterol Hepatol"	NCT02073994	3	accepted	7447	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/7447	https://civicdb.org/links/molecular_profiles/641	FALSE	IDH1	3417	Mutation		chr2	208237079	208251551			ENST00000415913.1	75		transcript_variant		2023-01-09 21:52:08 UTC				FALSE
RICTOR Amplification	569	Lung Small Cell Carcinoma	5409		Vistusertib		Predictive	Does Not Support	C	Sensitivity/Response	"In a phase 2 basket trial, patients with small-cell lung carcinoma (SLC) who failed platinum-based chemotherapy and harbored RICTOR amplification were treated with mTOR 1/2 inhibitor vistusertib (AZD2014). Among 4 patients enrolled in this study, no patients showed tumor response or disease control. Progression free survival was 1.25 months, and three patients experienced adverse effects grade 3 or greater. Authors conclude that further development of the tested AZD2014 regimen is not warranted."	173496	ASCO	8514	"Sehhoon Park, 2019, ASCO Annual Meeting, Abstract 8514"	"NCT02593019, NCT03106155, NCT03366675"	3	accepted	7449	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/7449	https://civicdb.org/links/molecular_profiles/569	FALSE	RICTOR	253260	Amplification		chr5	38937919	39074408			ENST00000357387.3	75		transcript_amplification	N/A	2023-01-09 21:52:08 UTC		N/A		FALSE
STAG2 MUTATION	665	Acute Myeloid Leukemia	9119				Prognostic	Does Not Support	B	Poor Outcome	"In a retrospective cohort study of 389 uniformly treated acute myeloid leukemia (AML) patients, 23 patients harbored mutations in genes of the cohesin complex including 5 who harbored mutations in STAG2. Mutation in the cohesin complex was not associated with worse overall survival (OS) or relapse free survival (RFS) compared to wildtype patients. The presence of STAG2 mutations had no influence on OS or RFS compared to wildtype (OS HR: 1.53, p = 0.4; RFS HR: 1.26, P = 0.7), though the authors note that the analysis was limited by the small number of patients. Authors speculate that co-occurring mutations in NPM1 may mask prognostic effects of STAG2 mutations."	24335498	PubMed		"Thol et al., 2014, Blood"	NCT00209833	2	accepted	7451	Somatic	2023-01-09 21:46:37 UTC	https://civicdb.org/links/evidence_items/7451	https://civicdb.org/links/molecular_profiles/665	FALSE	STAG2	10735	MUTATION		chrX	124042568	124083458			ENST00000218089.9	75		protein_altering_variant		2023-01-09 21:52:08 UTC		N/A		FALSE
KIT S628N	1567	Melanoma	1909		Imatinib		Predictive	Does Not Support	C	Sensitivity/Response	"A melanoma patient harboring the KIT S628N activating mutation underwent second-line imatinib therapy following lung metastatic progression that appeared after an eighth cycle of chemotherapy. The S628N mutation was not present in the blood, which confirmed that it was a somatic mutation. After 3 months of imatinib treatment (300 mg/d for first three weeks, then 400 mg/d), the patient exhibited disease progression and increased tumor size, and after an additional three months of imatinib treatment (400 mg/d), the patient developed multiple supratentorial brain metastases in addition to increased lung metastases and died 5 days later. The authors reported preclinical data which indicated variant sensitivity to imatinib. although this outcome did not coroberate the preclinical result, the authors still concluded the variant may be sensitive."	25317746	PubMed		"Vita et al., 2014, JAMA Dermatol"		3	accepted	7463	Somatic	2023-01-09 21:46:47 UTC	https://civicdb.org/links/evidence_items/7463	https://civicdb.org/links/molecular_profiles/1567	FALSE	KIT	3815	S628N		chr4	54728014	54728014	G	A				missense_variant		2023-01-27 17:11:12 UTC	CA356908374		S624N	FALSE
KIT D816V	65	Cancer	162		"Dasatinib,Imatinib"	Substitutes	Predictive	Supports	C	Resistance	"In an in vitro study, COS-7 cells expressing KIT D816V activating mutation demonstrated resistance to 1uM dasatinib treatment. In a separate in vitro study, TF-1 cells expressing KIT D816V activating mutation demonstrated resistance to 1 and 10 uM imatinib treatment. Sensitivity was determined by assessing reduced mutant KIT auto-phosphorylation with addition of inhibitors. No reduction in D816V autophosphorylation was observed with inhibitor treatment."	25317746	PubMed		"Vita et al., 2014, JAMA Dermatol"		2	accepted	7465	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/7465	https://civicdb.org/links/molecular_profiles/65	FALSE	KIT	3815	D816V	KIT Exon 17	chr4	54733155	54733155	A	T	ENST00000288135.5	75		missense_variant	"NM_000222.2:c.2447A>T,NP_000213.1:p.Asp816Val,ENST00000288135.5:c.2447A>T,NC_000004.11:g.55599321A>T"	2023-01-27 17:02:23 UTC	CA123513	13852	"ASP816VAL,RS121913507"	FALSE
NF1 Mutation	583	Childhood Low-grade Glioma	80830		Selumetinib		Predictive	Supports	B	Sensitivity/Response	"In a phase 2 trial, patients with pediatric low-grade glioma after at least one standard therapy were treated with MEK1/2 inhibitor selumetinib. In stratum 1, nine patients with WHO grade I pilocytic astrocytoma harboring KIAA1549-BRAF fusion or BRAF V600E mutation showed tumor response. The response rate was 36% (9/25). In stratum 3, ten patients with neurofibromatosis type 1 associated pediatric low-grade glioma showed tumor response. The response rate was 40% (10/25)."	31151904	PubMed		"Fangusaro et al., 2019, Lancet Oncol."	NCT01089101	3	accepted	7487	Rare Germline	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/7487	https://civicdb.org/links/molecular_profiles/583	FALSE	NF1	4763	Mutation		chr17	31094927	31377677			ENST00000358273.4	75		"protein_altering_variant,loss_of_function_variant"		2023-01-09 21:52:08 UTC		N/A		FALSE
FGFR1 Amplification	263	Breast Cancer	1612		Lucitanib		Predictive	Supports	B	Sensitivity/Response	"In a phase 1 trial, patients with advanced solid tumors were treated with FGFR1/2, VEGFR1/2/3, and PDGFR inhibitor lucitanib. Among 12 patients with breast cancer harboring FGFR alterations (8 FGFR1 amplification, 4 11q amplification), 6 patients showed tumor response. The response rate was 50% and the duration of response was 48.7 weeks. Among the 8 patients with FGFR1 amplification, 4 showed a partial response and 4 achieved stable disease."	25193991	PubMed		"Soria et al., 2014, Ann. Oncol."		3	accepted	7488	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/7488	https://civicdb.org/links/molecular_profiles/263	FALSE	FGFR1	2260	Amplification		chr8	38411138	38467845			ENST00000425967.3	75		transcript_amplification	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
NTRK3 ETV6::NTRK3	779	Solid Tumor			Larotrectinib		Predictive	Supports	A	Sensitivity/Response	"In this phase 1 dose-escalation study seventy patients with metastatic solid tumours were enrolled. Eight patient tumours were found to harbour NTRK gene fusions, six of which were ETV6-NTRK3. Treatment with larotrectinib resulted in reduced tumour burden for all patients with NTRK fusions. The average time on treatment was 28.4 months for patients with NTRK fusion cancer, compared to 1.8 months for those without an NTRK fusion."	30624546	PubMed		"Hong et al., 2019, Ann. Oncol."	NCT02122913	3	accepted	7496	Somatic	2023-01-09 21:46:38 UTC	https://civicdb.org/links/evidence_items/7496	https://civicdb.org/links/molecular_profiles/779	FALSE	NTRK3	4916	ETV6::NTRK3		chr12	11649854	11869969			ENST00000396373.4	75	ENST00000394480.2	transcript_fusion		2023-01-09 21:52:09 UTC		N/A	ETV6-NTRK3	FALSE
MET R1004G	2643	Head And Neck Cancer	11934		Crizotinib		Predictive	Supports	C	Sensitivity/Response	A patient with platinum-refractory oral cavity head and neck squamous carcinoma underwent comprehensive genomic profiling that identified an activating MET R1004G mutation. The patient showed a rapid response to the treatment of crizotinib.	31391294	PubMed		"Chu et al., 2019, Oncologist"		3	accepted	7498	Somatic	2023-01-09 21:47:02 UTC	https://civicdb.org/links/evidence_items/7498	https://civicdb.org/links/molecular_profiles/2643	FALSE	MET	4233	R1004G		chr7	116771971	116771971	C	G	ENST00000397752.8			missense_variant	"NC_000007.14:g.116771971C>G,NC_000007.13:g.116412025C>G,ENST00000397752.8:c.3010C>G,ENSP00000380860.3:p.Arg1004Gly,NM_000245.4:c.3010C>G,NP_000236.2:p.Arg1004Gly"	2023-01-27 17:17:55 UTC	CA368987455	NONE FOUND	ARG1004GLY	FALSE
TP53 R248Q	117						Functional	Supports	D	Dominant Negative	"CRISPR-Cas9 editing was used to create five isogenic MOLM13-TP53 AML cell lines with combinations of wild-type, mutant, and null TP53 alleles at the endogenous locus: p53+/+, p53+/-, p53-/-, R248Q/+, and R248Q/-. Cells were treated with and without DNA damaging agent and p53 inducing agent Daunorubicin and western blot used to assess p21 induction. p21 was induced in +/+ and +/-, but not -/-, R248Q/+, and R248Q/- cells. Daunorubicin treatment caused less cell death in +/- than in +/+ cells, but induced significantly less death in -/-, R248Q/+, and R248Q/-, where these three conditions were not statistically different. A similar result was seen with p53 activating agent Nutlin-3a, where p53-/-, R248Q/+, and R248Q/- cells grouped together with equivalent resistance to the agent in comparison to +/+ and +/- cells. The grouping in results of  -/-, R248Q/+, and R248Q/- suggest that R248Q inactivates the wt p53 copy, which does not occur in the +/- condition."	31395785	PubMed		"Boettcher et al., 2019, Science"		4	accepted	7525	Unknown	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/7525	https://civicdb.org/links/molecular_profiles/117	FALSE	TP53	7157	R248Q		chr17	7674220	7674220	C	T	ENST00000269305.4	75		missense_variant	"NM_000546.5:c.743G>A,NP_000537.3:p.Arg248Gln,NC_000017.10:g.7577538C>T,ENST00000269305.4:c.743G>A"	2023-01-27 17:02:44 UTC	CA000387	12356	"ARG248GLN,RS11540652"	FALSE
TP53 Y220C	896						Functional	Does Not Support	D	Neomorphic	"The Y220C mutation was used to create isogenic AML cell lines using MOLM13 and K526 lines. Y220C/- cells showed resistance to chemotherapeutic agents and failure to induce p21, indicating disruption of p53 function. ChIP assays demonstrated reduced p53 occupation across the genome for most p53 variants tested, including Y220C. RNAseq studies determined that a novel gene expression program was not induced in Y220C cells at baseline or with DNA damage induced p53 signal activation, and that the signature of gene expression was most similar to that of p53 loss, indicating that Y220C mutation does not induce a neomophic p53 function."	31395785	PubMed		"Boettcher et al., 2019, Science"		4	accepted	7527	Unknown	2023-01-09 21:46:40 UTC	https://civicdb.org/links/evidence_items/7527	https://civicdb.org/links/molecular_profiles/896	FALSE	TP53	7157	Y220C		chr17	7674872	7674872	T	C	ENST00000269305.4	75		missense_variant	"NM_000546.5:c.659A>G,NP_000537.3:p.Tyr220Cys,NC_000017.10:g.7578190T>C,ENST00000269305.4:c.659A>G"	2023-01-27 17:06:41 UTC	CA000315	127819	"RS121912666,TYR220CYS"	FALSE
TP53 M237I	1040						Functional	Does Not Support	D	Neomorphic	"The M237I mutation was used to create isogenic AML cell lines using MOLM13 and K526 lines. M237I/- cells showed resistance to chemotherapeutic agents and failure to induce p21, indicating disruption of p53 function. ChIP assays demonstrated reduced p53 occupation across the genome for most p53 variants tested, including M237I. RNAseq studies determined that a novel gene expression program was not induced in M237I cells at baseline or with DNA damage induced p53 signal activation, and that the signature of gene expression was most similar to that of p53 loss, indicating that M237I mutation does not induce a neomophic p53 function."	31395785	PubMed		"Boettcher et al., 2019, Science"		4	accepted	7528	Unknown	2023-01-09 21:46:42 UTC	https://civicdb.org/links/evidence_items/7528	https://civicdb.org/links/molecular_profiles/1040	FALSE	TP53	7157	M237I		chr17	7674252	7674252	C	A	ENST00000269305.4	75		missense_variant	ENST00000269305.4:c.711G>T	2023-01-27 17:07:55 UTC	CA287488024	NONE FOUND	MET237ILE	FALSE
TP53 R248Q	117						Functional	Does Not Support	D	Neomorphic	"The R248Q mutation was used to create isogenic AML cell lines using MOLM13 and K526 lines. R248Q/- cells showed resistance to chemotherapeutic agents and failure to induce p21, indicating disruption of p53 function. ChIP assays demonstrated reduced p53 occupation across the genome for most p53 variants tested, including R248Q. RNAseq studies determined that a novel gene expression program was not induced in R248Q cells at baseline or with DNA damage induced p53 signal activation, and that the signature of gene expression was most similar to that of p53 loss, indicating that R248Q mutation does not induce a neomophic p53 function."	31395785	PubMed		"Boettcher et al., 2019, Science"		4	accepted	7529	Unknown	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/7529	https://civicdb.org/links/molecular_profiles/117	FALSE	TP53	7157	R248Q		chr17	7674220	7674220	C	T	ENST00000269305.4	75		missense_variant	"NM_000546.5:c.743G>A,NP_000537.3:p.Arg248Gln,NC_000017.10:g.7577538C>T,ENST00000269305.4:c.743G>A"	2023-01-27 17:02:44 UTC	CA000387	12356	"ARG248GLN,RS11540652"	FALSE
TP53 R273H	122						Functional	Does Not Support	D	Neomorphic	"The R273H mutation was used to create isogenic AML cell lines using MOLM13 and K526 lines. R273H/- cells showed resistance to chemotherapeutic agents and failure to induce p21, indicating disruption of p53 function. ChIP assays demonstrated reduced p53 occupation across the genome for most p53 variants tested, including R273H. RNAseq studies determined that a novel gene expression program was not induced in R273H cells at baseline or with DNA damage induced p53 signal activation, and that the signature of gene expression was most similar to that of p53 loss, indicating that R273H mutation does not induce a neomophic p53 function."	31395785	PubMed		"Boettcher et al., 2019, Science"		4	accepted	7530	Unknown	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/7530	https://civicdb.org/links/molecular_profiles/122	FALSE	TP53	7157	R273H		chr17	7673802	7673802	C	T	ENST00000269305.4	75		missense_variant	"NM_000546.5:c.818G>A,NP_000537.3:p.Arg273His,NC_000017.10:g.7577120C>T,ENST00000269305.4:c.818G>A"	2023-01-27 17:02:48 UTC	CA000434	12366	"ARG273HIS,RS28934576"	FALSE
BRAF G466V	2098	Colorectal Cancer	9256		"Panitumumab,Irinotecan"	Combination	Predictive	Supports	D	Sensitivity/Response	"In the study with a tumor from a patient with metastatic colorectal cancer BRAF (G466V) and wild-type RAS and NF1. Treament with Panitumumab and irinotecan cause tumor regression. And in tumor cells of patient-derived xenograft generated from this patient, ERK signaling was sensitive to cetuximab and resistant to vemurafenib."	28783719	PubMed		"Yao et al., 2017, Nature"		3	accepted	7552	Somatic	2023-01-09 21:46:57 UTC	https://civicdb.org/links/evidence_items/7552	https://civicdb.org/links/molecular_profiles/2098	FALSE	BRAF	673	G466V		chr7	140781611	140781611	C	A	ENST00000288602.6	75		missense_variant	"NC_000007.13:g.140481411C>A,NM_004333.4:c.1397G>T,NP_004324.2:p.Gly466Val,ENST00000288602.6:c.1397G>T"	2023-01-27 17:15:52 UTC	CA123647	13967	"GLY466VAL,RS121913351"	FALSE
BRAF G466V	2098	Colorectal Cancer	9256		Vemurafenib		Predictive	Does Not Support	D	Sensitivity/Response	"In the study with a tumor from a patient with metastatic colorectal cancer BRAF (G466V) and wild-type RAS and NF1. Treatment with Panitumumab and irinotecan cause tumor regression. And in tumor cells of patient-derived xenograft generated from this patient, ERK signaling was sensitive to cetuximab and resistant to vemurafenib."	28783719	PubMed		"Yao et al., 2017, Nature"		3	accepted	7553	Somatic	2023-01-09 21:46:57 UTC	https://civicdb.org/links/evidence_items/7553	https://civicdb.org/links/molecular_profiles/2098	FALSE	BRAF	673	G466V		chr7	140781611	140781611	C	A	ENST00000288602.6	75		missense_variant	"NC_000007.13:g.140481411C>A,NM_004333.4:c.1397G>T,NP_004324.2:p.Gly466Val,ENST00000288602.6:c.1397G>T"	2023-01-27 17:15:52 UTC	CA123647	13967	"GLY466VAL,RS121913351"	FALSE
BRAF G466V	2098	Solid Tumor			Vemurafenib		Predictive	Does Not Support	D	Sensitivity/Response	"RAF inhibitor vemurafenib failed to inhibit ERK signaling in tumor cells and NIH3T3 that express class 3 BRAF mutations (G466V, G466E,  D594G, D594N, and G596R)."	28783719	PubMed		"Yao et al., 2017, Nature"		3	accepted	7554	Somatic	2023-01-09 21:46:57 UTC	https://civicdb.org/links/evidence_items/7554	https://civicdb.org/links/molecular_profiles/2098	FALSE	BRAF	673	G466V		chr7	140781611	140781611	C	A	ENST00000288602.6	75		missense_variant	"NC_000007.13:g.140481411C>A,NM_004333.4:c.1397G>T,NP_004324.2:p.Gly466Val,ENST00000288602.6:c.1397G>T"	2023-01-27 17:15:52 UTC	CA123647	13967	"GLY466VAL,RS121913351"	FALSE
BRAF D594G	607	Cancer	162		Vemurafenib		Predictive	Does Not Support	D	Sensitivity/Response	"RAF inhibitor vemurafenib failed to inhibit ERK signaling in tumor cells and NIH3T3 that express class 3 BRAF mutations (G466V, G466E, D594G, D594N, and G596R)."	28783719	PubMed		"Yao et al., 2017, Nature"		3	accepted	7556	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/7556	https://civicdb.org/links/molecular_profiles/607	FALSE	BRAF	673	D594G		chr7	140753354	140753354	T	C	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1781A>G,NP_004324.2:p.Asp594Gly,NC_000007.13:g.140453154T>C,ENST00000288602.6:c.1781A>G"	2023-01-27 17:04:35 UTC	CA123657	13972	"ASP594GLY,RS121913338"	FALSE
FGFR3 Mutation	805	Urinary Bladder Cancer	11054		"Cisplatin,Gemcitabine"	Combination	Predictive	Supports	B	Sensitivity/Response	"In this study, 52 patients with Muscle Invasive Bladder Cancer (MIBC) were randomly selected and administered neoadjuvant cisplatin and gemcitabine chemotherapy. 39 out of 52 patients showed pathological response (partial & complete) and 13 patients were resistant to neoadjuvant chemotherapy.35.9% (14/39) patients that responded to neoadjuvant chemotherapy had the following FGFR3 somatic mutations - p.S249C,p.V372C, p.G299S, p.V411M. FGFR3 somatic mutations exclusively occurred in the responder group.The somatic FGFR3 mutation frequency in the responder group was also compared with three unselected bladder cancer populations from TCGA, Kim et al.study and Guo et al. studies.This analysis revealed that FGFR3 somatic mutations were significantly enriched in the responder cohort compared with the unselected bladder cancer cohorts."	29941343	PubMed		"Yang et al., 2018, EBioMedicine"		3	accepted	7566	Somatic	2023-01-09 21:46:38 UTC	https://civicdb.org/links/evidence_items/7566	https://civicdb.org/links/molecular_profiles/805	FALSE	FGFR3	2261	Mutation		chr4	1793312	1808872			ENST00000340107.4	75				2023-01-09 21:52:09 UTC				FALSE
BRAF V600E	12	Langerhans Cell Sarcoma	7146		Vemurafenib		Predictive	Supports	B	Sensitivity/Response	"Off-label use of vemurafenib to treat BRAF V600E mutation-positive, refractory, childhood Langerhans cell histiocytosis (LCH) was evaluated. Fifty-four patients from 12 countries were treated with vemurafenib 20 mg/kg/day. Because LCH is a heterogeneous systemic disease, the quantitative Disease Activity Score (DAS), which reflects overall LCH extension, was used as an evaluation criterion. At 8 weeks, 38 patients had CRs (non-active disease) and 16 had PRs (active disease better). DAS decreased from a median value of 7 to 0 between VMF initiation and day 60 (P < 0.001)."	31513482	PubMed		"Donadieu et al., 2019, J. Clin. Oncol."		4	accepted	7583	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/7583	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
EGFR Exon 19 Deletion	133	Lung Non-small Cell Carcinoma	3908		Anti-PD1 Monoclonal Antibody		Predictive	Supports	B	Resistance	"In a multicenter retrospective study, the relationship between EGFR status in 171 patients with non-small cell lung carcinoma and response to immune checkpoint blockade was examined. Immune checkpoint inhibitor included PD-1 inhibitor alone, PD-L1 inhibitor alone or PD-(L)1 inhibitor / CTLA-4 inhibitor combination. These patients were compared to 212 previously published EGFR wild type patient outcomes. The response rate in patients with EGFR wild type, EGFR L858R mutation, and EGFR exon 19 deletions were 22, 16, and 7% respectively."	31086949	PubMed		"Hastings et al., 2019, Ann. Oncol."		4	accepted	7586	Somatic	2023-04-14 16:58:45 UTC	https://civicdb.org/links/evidence_items/7586	https://civicdb.org/links/molecular_profiles/133	FALSE	EGFR	1956	Exon 19 Deletion		chr7	55174722	55174820			ENST00000275493.2	75		inframe_deletion	ENST00000275493.2:c.2185_2283del	2023-01-09 21:52:05 UTC		N/A		FALSE
EGFR Exon 19 Deletion	133	Lung Non-small Cell Carcinoma	3908		Anti-PD-L1 Monoclonal Antibody		Predictive	Supports	B	Resistance	"In a multicenter retrospective study, the relationship between EGFR status in 171 patients with non-small cell lung carcinoma and response to immune checkpoint blockade was examined. Immune checkpoint inhibitor included PD-1 inhibitor alone, PD-L1 inhibitor alone or PD-(L)1 inhibitor / CTLA-4 inhibitor combination. These patients were compared to 212 previously published EGFR wild type patient outcomes. The response rate in patients with EGFR wild type, EGFR L858R mutation, and EGFR exon 19 deletions were 22, 16, and 7% respectively."	31086949	PubMed		"Hastings et al., 2019, Ann. Oncol."		4	accepted	7587	Somatic	2023-04-14 16:57:37 UTC	https://civicdb.org/links/evidence_items/7587	https://civicdb.org/links/molecular_profiles/133	FALSE	EGFR	1956	Exon 19 Deletion		chr7	55174722	55174820			ENST00000275493.2	75		inframe_deletion	ENST00000275493.2:c.2185_2283del	2023-01-09 21:52:05 UTC		N/A		FALSE
H3-3A K28M	2289	Glioma			Akt/ERK Inhibitor ONC201		Predictive	Supports	B	Sensitivity/Response	"In a phase 2 trial, patients with H3 K27M mutant glioma have been treated with DRD2 antagonist ONC201. Among 29 patients, 1 patient experienced complete clinical regression lasting >14 months, and 3 patients experienced durable partial response by RANO. 10 patients had a best response of stable disease by RANO, with a few of these patients showing substantial tumor regression in some lesions. Author concluded that ONC201 is well tolerated and has clinical activity against K27M-mutated glioma."	172409	ASCO	3005	"Isabel Arrillaga, 2019, ASCO Annual Meeting, Abstract 3005"	NCT03295396; NCT02525692	4	accepted	7601	Somatic	2023-01-09 21:46:58 UTC	https://civicdb.org/links/evidence_items/7601	https://civicdb.org/links/molecular_profiles/2289	FALSE	H3-3A	3020	K28M		chr1	225876734	225876734	A	T	ENST00000366813.1	105		non_conservative_missense_variant	"ENST00000366813.1:c.83A>T,ENSP00000355778.1:p.Lys28Met"	2023-01-27 17:16:41 UTC	CA16602870	376435	K27M	FALSE
EGFR Exon 20 Insertion	707	Lung Non-small Cell Carcinoma	3908		Osimertinib		Predictive	Supports	B	Sensitivity/Response	Retrospective study of six Chinese patients with EGFR exon 20 insertion mutant stage IV non-small cell lung carcinoma treated with osimertinib. Four of the patients experienced partial response (67.7%) and two had stable disease during treatment. Two patients had sustained disease control and remained on treatment. The median progression-free survival was 6.2 months (95% CI 5.0-12.9 months).	31208370	PubMed		"Fang et al., 2019, BMC Cancer"		2	accepted	7610	Somatic	2023-02-02 21:25:19 UTC	https://civicdb.org/links/evidence_items/7610	https://civicdb.org/links/molecular_profiles/707	FALSE	EGFR	1956	Exon 20 Insertion		chr7	55181298	55181329			ENST00000275493.2	75		inframe_insertion		2023-01-09 21:52:08 UTC				FALSE
BRAF V600E	12	Colorectal Cancer	9256		"Cetuximab,Binimetinib,Encorafenib"	Combination	Predictive	Supports	B	Sensitivity/Response	"665 patients with BRAF V600E-mutated metastatic CRC were enrolled In this open-label, phase 3 trial. Patients were randomly assigned in a 1:1:1 ratio to receive encorafenib, binimetinib, and cetuximab (triplet-therapy group); encorafenib and cetuximab (doublet-therapy group); or the investigators?choice of either cetuximab and irinotecan or cetuximab and FOLFIRI. The median overall survival was 9.0 months in the triplet-therapy group and 5.4 months in the control group (hazard ratio for death, 0.52; 95% confidence interval [CI], 0.39 to 0.70; P<0.001). The confirmed response rate was 26% (95% CI, 18 to 35) in the triplet-therapy group and 2% (95% CI, 0 to 7) in the control group (triplet group vs. control P<0.001). The median progression-free survival in the triplet-therapy group was 4.3 months (95% CI, 4.1 to 5.2) and 1.5 months (95% CI, 1.5 to 1.7) in the control group (hazard ratio for disease progression or death, 0.38; 95% CI, 0.29 to 0.49; P<0.001)."	31566309	PubMed		"Kopetz et al., 2019, N. Engl. J. Med."	NCT02928224	5	accepted	7612	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/7612	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
BRAF A728V	1172						Functional	Supports	D	Gain of Function	"The BRAF mutation A728V (also known as A727V) resulted in elevated kinase activity relative to wild-type BRAF in vitro, as well as increased phosphorylation of ERK1/2 in COS cells. B-RAF activity was determined using kinase dead MEK as a substrate. A727V activity was 14 times higher than basal WT BRAF. The authors classified A727V activity as intermediate, since its kinase activity was between basal WT BRAF and G12V RAS-activated WT B-RAF cells. In comparison, some BRAF variants displayed high kinase activity above the G12V RAS-activated WT BRAF cells."	15035987	PubMed		"Wan et al., 2004, Cell"		2	accepted	7614	Unknown	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/7614	https://civicdb.org/links/molecular_profiles/1172	FALSE	BRAF	673	A728V		chr7	140734715	140734715	G	A				missense_variant		2023-01-27 17:08:40 UTC	CA369537269		A336V	FALSE
BRAF V600D	11	Melanoma	1909		BRAF Inhibitor		Predictive	Supports	C	Sensitivity/Response	"In a retrospective study from 20 institutes in 4 countries, the efficacy of BRAF inhibitor and/or MEK inhibitor in patients with melanoma harboring BRAF nonV600E/K mutations were evaluated. Treated with BRAF inhibitor monotherapy, response rate were 27%(4/15) for V600R, 100%(2/2) for V600D, 0% (0/2) for V600_K601>E, 0% (0/1) for V600G, 0% (0/1) for V600L, 0% (0/9) for V600_S602>DT, 0% (0/5) for L597, 0% (0/6) for K601E, 0% (0/2) for G469, 0% (0/1) for G593D,and 0% (0/1) for T599_V600insT Treated with MEK inhibitor monotherapy, response rate were 100% (1/1) for L597, and 0% (0/1) for K601E. Treated with BRAF inhibitor and MEK inhibitor combination thearpy, response rate were 55% (16/29) for V600R, 67% (2/3) for V600D, 50% (1/2) for V600_K601>E, 50% (1/2) for V600M, 22% (2/9) for L597,25% (1/4) for K601E, 67% (2/3) for G469, and 0% (0/1) for A598V."	31580757	PubMed		"Menzer et al., 2019, J. Clin. Oncol."		3	accepted	7616	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/7616	https://civicdb.org/links/molecular_profiles/11	FALSE	BRAF	673	V600D	Other BRAF V600's	chr7	140753335	140753336	CA	AT	ENST00000288602.6	75		missense_variant	"NC_000007.13:g.140453135_140453136delinsAT,NM_004333.4:c.1799_1800delTGinsAT,NP_004324.2:p.Val600Asp,ENST00000288602.6:c.1799_1800delTGinsAT"	2023-01-27 17:02:01 UTC	CA16602419	375939	"RS121913377,VAL600ASP"	FALSE
BRAF V600D	11	Melanoma	1909		"BRAF Inhibitor,Mitogen-Activated Protein Kinase Kinase Inhibitor"	Combination	Predictive	Supports	C	Sensitivity/Response	"In a retrospective study from 20 institutes in 4 countries, the efficacy of BRAF inhibitor and/or MEK inhibitor in patients with melanoma harboring BRAF nonV600E/K mutations were evaluated. Treated with BRAF inhibitor monotherapy, response rate were 27%(4/15) for V600R, 100%(2/2) for V600D, 0% (0/2) for V600_K601>E, 0% (0/1) for V600G, 0% (0/1) for V600L, 0% (0/1) for V600_S602>DT, 0% (0/5) for L597, 0% (0/6) for K601E, 0% (0/2) for G469, 0% (0/1) for G593D,and 0% (0/1) for T599_V600insT Treated with MEK inhibitor monotherapy, response rate were 100% (1/1) for L597, and 0% (0/1) for K601E. Treated with BRAF inhibitor and MEK inhibitor combination thearpy, response rate were 55% (16/29) for V600R, 67% (2/3) for V600D, 50% (1/2) for V600_K601>E, 50% (1/2) for V600M, 22% (2/9) for L597,25% (1/4) for K601E, 67% (2/3) for G469, and 0% (0/1) for A598V."	31580757	PubMed		"Menzer et al., 2019, J. Clin. Oncol."		3	accepted	7629	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/7629	https://civicdb.org/links/molecular_profiles/11	FALSE	BRAF	673	V600D	Other BRAF V600's	chr7	140753335	140753336	CA	AT	ENST00000288602.6	75		missense_variant	"NC_000007.13:g.140453135_140453136delinsAT,NM_004333.4:c.1799_1800delTGinsAT,NP_004324.2:p.Val600Asp,ENST00000288602.6:c.1799_1800delTGinsAT"	2023-01-27 17:02:01 UTC	CA16602419	375939	"RS121913377,VAL600ASP"	FALSE
BRAF A598V	2695	Melanoma	1909		"BRAF Inhibitor,Mitogen-Activated Protein Kinase Kinase Inhibitor"	Combination	Predictive	Does Not Support	C	Sensitivity/Response	"In a retrospective study from 20 institutes in 4 countries, the efficacy of BRAF inhibitor and/or MEK inhibitor in patients with melanoma harboring BRAF nonV600E/K mutations were evaluated. Treated with BRAF inhibitor monotherapy, response rate were 27%(4/15) for V600R, 100%(2/2) for V600D, 0% (0/2) for V600_K601>E, 0% (0/1) for V600G, 0% (0/1) for V600L, 0% (0/1) for V600_S602>DT, 0% (0/5) for L597, 0% (0/6) for K601E, 0% (0/2) for G469, 0% (0/1) for G593D,and 0% (0/1) for T599_V600insT Treated with MEK inhibitor monotherapy, response rate were 100% (1/1) for L597, and 0% (0/1) for K601E. Treated with BRAF inhibitor and MEK inhibitor combination thearpy, response rate were 55% (16/29) for V600R, 67% (2/3) for V600D, 50% (1/2) for V600_K601>E, 50% (1/2) for V600M, 22% (2/9) for L597,25% (1/4) for K601E, 67% (2/3) for G469, and 0% (0/1) for A598V."	31580757	PubMed		"Menzer et al., 2019, J. Clin. Oncol."		3	accepted	7635	Somatic	2023-01-09 21:47:02 UTC	https://civicdb.org/links/evidence_items/7635	https://civicdb.org/links/molecular_profiles/2695	FALSE	BRAF	673	A598V		chr7	140753342	140753342	G	A	ENST00000288602.6	75		missense_variant		2023-01-27 17:17:59 UTC	CA369543099	NONE FOUND	ALA598VAL	FALSE
ERBB2 Amplification	302	Cholangiocarcinoma	4947		"Pertuzumab,Trastuzumab"	Combination	Predictive	Supports	C	Sensitivity/Response	A patient with cholangiocarcinoma harboring with ERBB2 amplification (3+) detected by circulating tumor DNA testing and confirmed by tissue-based testing was treated with trastuzumab and pertuzumab. This treatment showed a tumor response and continued over 12 months.	31453370	PubMed		"Yarlagadda et al., 2019, NPJ Precis Oncol"		3	accepted	7638	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/7638	https://civicdb.org/links/molecular_profiles/302	FALSE	ERBB2	2064	Amplification		chr17	39700080	39728662			ENST00000269571.5	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A	OVEREXPRESSION	FALSE
MET Exon 14 Skipping Mutation	320	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	B	Sensitivity/Response	"Pts with MET exon 14-altered NSCLC were enrolled into an expansion cohort of the phase I PROFILE 1001 study (NCT00585195) and received crizotinib. Responses were assessed. By data-cut off 18 pts with MET exon 14-altered NSCLC had enrolled and 17 received treatment (15 response-evaluable). Antitumor activity per RECIST was documented in 10/15 pts: 5 with confirmed PRs and 5 with unconfirmed PRs. Median PFS could not be calculated, with no deaths or PD by the data cut-off. Treatment-related AEs were generally tolerable, and were most commonly edema, nausea, vision disorder, bradycardia, and vomiting. AEs were mostly grade 1 or 2, with one grade 3 edema, and no grade 4/5 AEs."	123413	ASCO	108	"Alexander E. Drilon, 2016, ASCO Annual Meeting, Abstract 108"	NCT00585195	1	accepted	7642	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/7642	https://civicdb.org/links/molecular_profiles/320	FALSE	MET	4233	Exon 14 Skipping Mutation		chr7	116771849	116771989			ENST00000318493.6	75		exon_loss_variant		2023-01-09 21:52:06 UTC		N/A		FALSE
MET Exon 14 Skipping Mutation	320	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	C	Sensitivity/Response	"In this case Report, a 67-year old female patient with a lung adenocarcinoma displaying a MET exon 14 donor splice site mutation (D1028N) detected using next generation sequencing. Within 5 weeks of crizotinib therapy, a partial response was observed."	26892698	PubMed		"Mahjoubi et al., 2016, Invest New Drugs"		2	accepted	7643	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/7643	https://civicdb.org/links/molecular_profiles/320	FALSE	MET	4233	Exon 14 Skipping Mutation		chr7	116771849	116771989			ENST00000318493.6	75		exon_loss_variant		2023-01-09 21:52:06 UTC		N/A		FALSE
VHL Y98H (c.292T>C)	1617	Von Hippel-Lindau Disease	14175	"Cerebellar hemangioblastoma,Retinal capillary hemangioma,Pheochromocytoma"			Predisposing	N/A	B	N/A	"Peripheral blood from 116 VHL-affected patients in an interrelated group of 14 German and 2 American families with common ancestry was tested for mutations of the VHL gene, revealing a c.292T>C mutation leading to a p.Tyr89His missense protein change. Among these 116 affected patients, 116 retinal angiomas, 17 CNS hemangioblastomas, 73 pheochromocytomas, and 4 renal cell carcinomas were noted. ACMG evidence codes: 'PP1', with the allele significant cosegregation with the disease in family members for a gene known to cause the described syndrome, and 'PP4' because the patients' phenotypes or family histories are highly specific for a disease with a single genetic etiology."	7759077	PubMed		"Brauch et al., 1995, Hum. Genet."		4	accepted	7645	Rare Germline	2023-01-09 21:46:48 UTC	https://civicdb.org/links/evidence_items/7645	https://civicdb.org/links/molecular_profiles/1617	FALSE	VHL	7428	Y98H (c.292T>C)		chr3	10142139	10142139	T	C	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.292T>C,NP_000542.1:p.Tyr98His,NC_000003.11:g.10183823T>C,ENST00000256474.2:c.292T>C"	2023-01-27 17:11:30 UTC	CA020246	2223	"C.292T>C,TYR98HIS,RS5030809"	FALSE
ERBB2 Amplification	302	Stomach Cancer	10534		Trastuzumab Deruxtecan		Predictive	Supports	B	Sensitivity/Response	"In a phase 1 trial, 44 patients with HER2-positive gastric or gastroesophageal junction cancer previously treated with trastuzumab were treated with Trastuzumab Deruxtecan (DS-8201a). The response rate was 43.2% (19/44). All patients had at least one treatment-emergent adverse event (AE). A serious AE was recorded in 11 patients but without a drug-related death."	31047804	PubMed		"Shitara et al., 2019, Lancet Oncol."	NCT02564900	3	accepted	7647	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/7647	https://civicdb.org/links/molecular_profiles/302	FALSE	ERBB2	2064	Amplification		chr17	39700080	39728662			ENST00000269571.5	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A	OVEREXPRESSION	FALSE
ABL1 SNX2::ABL1	2547	B-lymphoblastic Leukemia/lymphoma	80630		"Imatinib,Dasatinib"	Substitutes	Predictive	Supports	D	Resistance	"SNX2-ABL1 protein (SNX2 exon 3 to ABL1 exon 4) was transfected in murine Ba/F3 cells and proliferation rates in the presence of IL-3, and tyrosine kinase inhibitors, imatinib and dasatinib was compared to BCR-ABL1 p190 and p210 transfected Ba/F3 cells. Cell proliferation assays showed that SNX2-ABL1 transfected cells had over 20% and 50% of cell survival after 24-hr incubation with imatinib (2M) and dasatinib (10nM). SNX2-ABL1 transfected cells continued to proliferate again 48 hr after treatment with dasatinib (10nM). This data was further supported by apoptosis (annexin V-propidium iodide) studies. In addition, newer tyrosine kinase inhibitors including nilotinib (500nM), bafetinib (500nM), rebastinib (500nM), and ponatinib (100nM), were examined and SNX2-ABL1 cells showed a better response, but still some resistance to these compounds. Further examination of downstream phosphorylation of SNX2-ABL1 cells showed only partial inhibition with imatinib and dasatinib."	24367893	PubMed		"Tomita et al., 2014, Leuk. Res."		3	accepted	7655	Somatic	2023-01-09 21:47:01 UTC	https://civicdb.org/links/evidence_items/7655	https://civicdb.org/links/molecular_profiles/2547	FALSE	ABL1	25	SNX2::ABL1	ABL1 fusions in B-ALL	chr5	122774996	122799855			ENST00000379516.2	75	ENST00000372348.2	transcript_fusion		2023-01-09 21:52:21 UTC			SNX2-ABL1	FALSE
ABL1 SNX2::ABL1	2547	B-lymphoblastic Leukemia/lymphoma	80630		"Imatinib,Dasatinib"	Substitutes	Predictive	Supports	D	Resistance	"SNX2-ABL1 protein (SNX2 exon 3 to ABL1 exon 4) was transfected in murine Ba/F3 cells and proliferation rates in the presence of IL-3, and tyrosine kinase inhibitors, imatinib and dasatinib was compared to BCR-ABL1 p190 and p210 transfected Ba/F3 cells. Cell proliferation assays showed that SNX2-ABL1 transfected cells had over 20% and 50% of cell survival after 24-hr incubation with imatinib (2M) and dasatinib (10nM). SNX2-ABL1 transfected cells continued to proliferate again 48 hr after treatment with dasatinib (10nM). This data was further supported by apoptosis (annexin V-propidium iodide) studies. In addition, newer tyrosine kinase inhibitors including nilotinib (500nM), bafetinib (500nM), rebastinib (500nM), and ponatinib (100nM), were examined and SNX2-ABL1 cells showed a better response, but still some resistance to these compounds. Further examination of downstream phosphorylation of SNX2-ABL1 cells showed only partial inhibition with imatinib and dasatinib."	24367893	PubMed		"Tomita et al., 2014, Leuk. Res."		3	accepted	7655	Somatic	2023-01-09 21:47:01 UTC	https://civicdb.org/links/evidence_items/7655	https://civicdb.org/links/molecular_profiles/2547	FALSE	ABL1	25	SNX2::ABL1	ABL1 fusions in B-ALL	chr9	130862763	130887675			ENST00000379516.2	75	ENST00000372348.2	transcript_fusion		2023-01-09 21:52:21 UTC			SNX2-ABL1	FALSE
BRAF Amplification	1243	Melanoma	1909		"Trametinib,Dabrafenib"	Combination	Predictive	Supports	C	Resistance	"In a retrospective study, authors analyzed BRAF V600 mutated melanoma metastases derived from 10 patients treated with the combination of dabrafenib and trametinib for resistance mechanisms and genetic correlates of response. An acquired resistance mechanism activating the MAPK pathway was identified in 9 tumors; BRAF amplification (n=4), MEK1/2 mutation (n=3), NRAS mutations (n=3). Among them, mutual exclusive alterations were BRAF amplification (n=4), MEK2 C125S (n=1), and NRAS Q61K (n=2)."	25452114	PubMed		"Long et al., 2014, Nat Commun"		4	accepted	7677	Somatic	2023-01-09 21:46:44 UTC	https://civicdb.org/links/evidence_items/7677	https://civicdb.org/links/molecular_profiles/1243	FALSE	BRAF	673	Amplification		chr7	140734479	140924764			ENST00000288602.6	75		transcript_amplification	N/A	2023-01-09 21:52:12 UTC		N/A		FALSE
ABL1 SNX2::ABL1	2547	B-lymphoblastic Leukemia/lymphoma	80630	Young adult onset			Prognostic	Supports	C	Poor Outcome	"A 16 yr-old male with precursor B-ALL was found to have the t(5;9)(q23;q34) in his peripheral blasts. Fluorescence in situ hybridization (FISH), RT-PCR, and sequencing of the product confirmed a SNX2-ABL1 fusion gene (SNX2 exon 3 fused in frame to ABL1 exon 4) was present. The patient also was found to carry an IKZF1 deletion (exons 2-8) and amplification of PAX5. The patient was treated with vindesine, idarubicin, and dexamethasone (VDP) and VDCP (plus cyclophosphamide) regimens. He received two bone marrow transplants, but eventually died of disease. The patient did not receive tyrosine-kinase inhibitors."	28278724	PubMed		"Mu et al., 2017, Leuk. Lymphoma"		1	accepted	7694	Somatic	2023-01-09 21:47:01 UTC	https://civicdb.org/links/evidence_items/7694	https://civicdb.org/links/molecular_profiles/2547	FALSE	ABL1	25	SNX2::ABL1	ABL1 fusions in B-ALL	chr5	122774996	122799855			ENST00000379516.2	75	ENST00000372348.2	transcript_fusion		2023-01-09 21:52:21 UTC			SNX2-ABL1	FALSE
ABL1 SNX2::ABL1	2547	B-lymphoblastic Leukemia/lymphoma	80630	Young adult onset			Prognostic	Supports	C	Poor Outcome	"A 16 yr-old male with precursor B-ALL was found to have the t(5;9)(q23;q34) in his peripheral blasts. Fluorescence in situ hybridization (FISH), RT-PCR, and sequencing of the product confirmed a SNX2-ABL1 fusion gene (SNX2 exon 3 fused in frame to ABL1 exon 4) was present. The patient also was found to carry an IKZF1 deletion (exons 2-8) and amplification of PAX5. The patient was treated with vindesine, idarubicin, and dexamethasone (VDP) and VDCP (plus cyclophosphamide) regimens. He received two bone marrow transplants, but eventually died of disease. The patient did not receive tyrosine-kinase inhibitors."	28278724	PubMed		"Mu et al., 2017, Leuk. Lymphoma"		1	accepted	7694	Somatic	2023-01-09 21:47:01 UTC	https://civicdb.org/links/evidence_items/7694	https://civicdb.org/links/molecular_profiles/2547	FALSE	ABL1	25	SNX2::ABL1	ABL1 fusions in B-ALL	chr9	130862763	130887675			ENST00000379516.2	75	ENST00000372348.2	transcript_fusion		2023-01-09 21:52:21 UTC			SNX2-ABL1	FALSE
RET M918T	113	Thyroid Gland Medullary Carcinoma	3973		Cabozantinib		Predictive	Supports	B	Sensitivity/Response	"In this retrospective analysis of a phase 3 trial of cabozantinib or placebo in 330 patients. Among those, 51.2% were RET mutation-positive (38.2% with RET M918T), 34.8% were RET mutation-unknown, and 13.9% were RET mutation-negative. Sixteen patients were RAS mutation-positive. Cabozantinib appeared to prolong PFS versus the placebo in the RET mutation-positive subgroup (hazard ratio [HR], 0.23; 95% confidence interval [CI], 0.14-0.38; P??0001).  Patients in a RET mutation-negative population showed relatively smaller benefits from cabozantinib (HR 0.53). The RET M918T subgroup achieved the greatest observed PFS benefit from cabozantinib versus the placebo (HR 0.15)."	27525386	PubMed		"Sherman et al., 2016, Cancer"		4	accepted	7710	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/7710	https://civicdb.org/links/molecular_profiles/113	FALSE	RET	5979	M918T	RET Motesanib Resistance	chr10	43121968	43121968	T	C	ENST00000355710.3	75		missense_variant	"NM_020975.4:c.2753T>C,NP_065681.1:p.Met918Thr,ENST00000355710.3:c.2753T>C,NC_000010.10:g.43617416T>C"	2023-01-27 17:02:41 UTC	CA009082	13919	"MET918THR,RS74799832"	FALSE
IDH1 Mutation	641	Chondrosarcoma	3371				Prognostic	Supports	B	Better Outcome	"In a retrospective study, the authors evaluated the association between IDH1/IDH2 mutation and prognosis in patients with high-grade central chondrosarcoma. Although no association was discovered between IDH mutation status and the patient's overall survival, IDH1/IDH2 mutation was found to be associated with longer relapse free and metastasis free survival in high-grade chondrosarcomas."	31615936	PubMed		"Zhu et al., 2020, Clin. Cancer Res."		4	accepted	7725	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/7725	https://civicdb.org/links/molecular_profiles/641	FALSE	IDH1	3417	Mutation		chr2	208237079	208251551			ENST00000415913.1	75		transcript_variant		2023-01-09 21:52:08 UTC				FALSE
IDH2 Mutation	566	Chondrosarcoma	3371				Prognostic	Supports	B	Better Outcome	"In a retrospective study, the authors evaluated the association between IDH1/IDH2 mutation and prognosis in patients with high-grade central chondrosarcoma. Although no association was discovered between IDH mutation status and the patient's overall survival, IDH1/IDH2 mutation was found to be associated with longer relapse free and metastasis free survival in high-grade chondrosarcomas."	31615936	PubMed		"Zhu et al., 2020, Clin. Cancer Res."		4	accepted	7726	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/7726	https://civicdb.org/links/molecular_profiles/566	FALSE	IDH2	3418	Mutation		chr15	90083045	90102504			ENST00000330062.3	75		protein_altering_variant		2023-01-09 21:52:07 UTC		N/A		FALSE
FLT3 Mutation	515	Acute Myeloid Leukemia	9119		Gilteritinib		Predictive	Supports	B	Sensitivity/Response	"In this phase 3 trial (ADMIRAL), 371 patients with relapsed or refractory FLT3-mutated AML (required to have FLT3 ITD or TKD D835 or I836 mutations) were randomly assigned in a 2:1 ratio to receive either gilteritinib (n=247, at a dose of 120 mg per day) or salvage chemotherapy (n=124). Median overall survival in the gilteritinib group was significantly longer than in the chemotherapy group (9.3 months vs. 5.6 months; hazard ratio for death, 0.64; 95% confidence interval [CI], 0.49 to 0.83; P<0.001). Median event-free survival was 2.8 months in the gilteritinib group and 0.7 months in the chemotherapy group (hazard ratio for treatment failure or death, 0.79; 95% CI, 0.58 to 1.09). The complete remission rate with full or partial hematologic recovery was 34.0% in the gilteritinib group and 15.3% in the chemotherapy group (risk difference, 18.6 percentage points; 95% CI, 9.8 to 27.4); the percentages with complete remission were 21.1% and 10.5%, respectively (risk difference, 10.6 percentage points; 95% CI, 2.8 to 18.4). Notably, gilteritinib treatment resulted in similar median overall survival (9.3 months vs. 8.0 months) and percentage of complete remission (20.5% vs. 19.0%) in patients with ITD mutations and patients with TKD mutations. The authors concluded gilteritinib therapy in relapsed or refractory FLT3-mutated AML patients resulted longer survival and improved response versus salvage chemotherapy."	31665578	PubMed		"Perl et al., 2019, N. Engl. J. Med."	NCT02421939	5	accepted	7728	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/7728	https://civicdb.org/links/molecular_profiles/515	FALSE	FLT3	2322	Mutation		chr13	28003274	28100592			ENST00000241453.7	75		"transcript_variant,gain_of_function_variant"		2023-01-09 21:52:07 UTC				FALSE
ABL1 SNX2::ABL1	2547	B-lymphoblastic Leukemia/lymphoma	80630	Juvenile onset			Prognostic	Supports	C	Poor Outcome	"This case report describes a 7-year old boy with B-ALL who presented with high white blood count (115.4x109 /L). Karyotype analysis showed a t(5;9)(q22;q34), resulting in a SNX2-ABL1 fusion. The patient was treated based on the ALL-BFM95 regimen; although he received remission, he relapsed during maintenance, 15 months after the initial diagnosis. He could not achieve the second remission using chemotherapy, but was treated at this time with imatinib (dose of 240 mg/m2 /d once daily); this allowed to achieve disease control and proceed with an umbilical cord blood transplant. However, at 6 months from transplantation, the patient developed bone marrow relapse again. He never achieved a remission after the second relapse (despite salvage chemotherapies and therapy with both imatinib and dasatinib). The patient died of progressive disease."	24215620	PubMed		"Masuzawa et al., 2014, Eur. J. Haematol."		1	accepted	7744	Somatic	2023-01-09 21:47:01 UTC	https://civicdb.org/links/evidence_items/7744	https://civicdb.org/links/molecular_profiles/2547	FALSE	ABL1	25	SNX2::ABL1	ABL1 fusions in B-ALL	chr5	122774996	122799855			ENST00000379516.2	75	ENST00000372348.2	transcript_fusion		2023-01-09 21:52:21 UTC			SNX2-ABL1	FALSE
ABL1 SNX2::ABL1	2547	B-lymphoblastic Leukemia/lymphoma	80630	Juvenile onset			Prognostic	Supports	C	Poor Outcome	"This case report describes a 7-year old boy with B-ALL who presented with high white blood count (115.4x109 /L). Karyotype analysis showed a t(5;9)(q22;q34), resulting in a SNX2-ABL1 fusion. The patient was treated based on the ALL-BFM95 regimen; although he received remission, he relapsed during maintenance, 15 months after the initial diagnosis. He could not achieve the second remission using chemotherapy, but was treated at this time with imatinib (dose of 240 mg/m2 /d once daily); this allowed to achieve disease control and proceed with an umbilical cord blood transplant. However, at 6 months from transplantation, the patient developed bone marrow relapse again. He never achieved a remission after the second relapse (despite salvage chemotherapies and therapy with both imatinib and dasatinib). The patient died of progressive disease."	24215620	PubMed		"Masuzawa et al., 2014, Eur. J. Haematol."		1	accepted	7744	Somatic	2023-01-09 21:47:01 UTC	https://civicdb.org/links/evidence_items/7744	https://civicdb.org/links/molecular_profiles/2547	FALSE	ABL1	25	SNX2::ABL1	ABL1 fusions in B-ALL	chr9	130862763	130887675			ENST00000379516.2	75	ENST00000372348.2	transcript_fusion		2023-01-09 21:52:21 UTC			SNX2-ABL1	FALSE
BRAF D594G	607	Cancer	162		Trametinib		Predictive	Supports	D	Sensitivity/Response	"In a BRAF-mutation inducible model in the NIH3T3 cell line, class 3 BRAF mutations (G466V, G466E, D594G, D594N, and G596R) were resistant to vemurafenib but sensitive to MEK-inhibitor trametinib."	28783719	PubMed		"Yao et al., 2017, Nature"		2	accepted	7760	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/7760	https://civicdb.org/links/molecular_profiles/607	FALSE	BRAF	673	D594G		chr7	140753354	140753354	T	C	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1781A>G,NP_004324.2:p.Asp594Gly,NC_000007.13:g.140453154T>C,ENST00000288602.6:c.1781A>G"	2023-01-27 17:04:35 UTC	CA123657	13972	"ASP594GLY,RS121913338"	FALSE
ABL1 BCR::ABL V299L	1205	Chronic Myeloid Leukemia	8552		Axitinib		Predictive	Supports	D	Sensitivity/Response	"In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed decreased incorporation when harboring fusions with the V299L variant of ABL1 compared to fusions with wildtype ABL1 (IC50 of 188nM vs. 823 nM), indicating V299L induces sensitivity compared to BCR-ABL1 without secondary variants."	25686603	PubMed		"Pemovska et al., 2015, Nature"		2	accepted	7767	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/7767	https://civicdb.org/links/molecular_profiles/1205	FALSE	ABL1	25	BCR::ABL V299L		chr9	130872201	130872201	G	C	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.895G>C,NP_005148.2:p.Val299Leu,NC_000009.11:g.133747588G>C,ENST00000318560.5:c.895G>C"	2023-01-27 17:08:46 UTC	CA16602575	376117	"BCR-ABL VAL299LEU,BCR-ABL V318L,RS1057519771,BCR-ABL1 V299L,BCR-ABL1 VAL299LEU,BCR-ABL V299L"	FALSE
ABL1 BCR::ABL T315A	2208	Chronic Myeloid Leukemia	8552		Axitinib		Predictive	Supports	D	Sensitivity/Response	"In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed decreased incorporation when harboring fusions with the T315A variant of ABL1 compared to fusions with wildtype ABL1 (IC50 of 389nM vs. 823 nM), indicating T315A induces sensitivity compared to BCR-ABL1 without secondary variants."	25686603	PubMed		"Pemovska et al., 2015, Nature"		2	accepted	7768	Somatic	2023-01-09 21:46:58 UTC	https://civicdb.org/links/evidence_items/7768	https://civicdb.org/links/molecular_profiles/2208	FALSE	ABL1	25	BCR::ABL T315A		chr9	130872895	130872895	A	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.943A>G,NP_005148.2:p.Thr315Ala,NC_000009.11:g.133748282A>G,ENST00000318560.5:c.943A>G"	2023-01-27 17:16:25 UTC	CA16602576	376118	"THR315ALA,T334A,RS1057519772,BCR-ABL T315A"	FALSE
ABL1 BCR::ABL M351T	1003	Chronic Myeloid Leukemia	8552		Axitinib		Predictive	Does Not Support	D	Resistance	"In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed decreased incorporation when harboring fusions with the M351T variant of ABL1 compared to those with wildtype ABL1 (IC50 of 553nM vs. 823 nM), indicating the M351T variant induces sensitivity compared to BCR-ABL1 without secondary variants."	25686603	PubMed		"Pemovska et al., 2015, Nature"		2	accepted	7769	Somatic	2023-01-09 21:46:42 UTC	https://civicdb.org/links/evidence_items/7769	https://civicdb.org/links/molecular_profiles/1003	FALSE	ABL1	25	BCR::ABL M351T		chr9	130873004	130873004	T	C	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.1052T>C,NP_005148.2:p.Met351Thr,NC_000009.11:g.133748391T>C,ENST00000318560.5:c.1052T>C"	2023-01-27 17:07:48 UTC	CA122590	12629	"RS121913457,BCR-ABL M370T,BCR-ABL MET351THR,BCR-ABL MET370THR,BCR-ABL M351T"	FALSE
ABL1 BCR::ABL H396P	1439	Chronic Myeloid Leukemia	8552		Axitinib		Predictive	Does Not Support	D	Resistance	"In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed lower incorporation when harboring fusions with the H396P variant of ABL1 compared to those with wildtype ABL1 (IC50 of 683nM vs. 823 nM), indicating the H396P variant induces sensitivity compared to BCR-ABL1 without secondary variants."	25686603	PubMed		"Pemovska et al., 2015, Nature"		2	accepted	7770	Somatic	2023-01-09 21:46:45 UTC	https://civicdb.org/links/evidence_items/7770	https://civicdb.org/links/molecular_profiles/1439	FALSE	ABL1	25	BCR::ABL H396P		chr9	130874969	130874969	A	C	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"ENST00000318560.5:c.1187A>C,NC_000009.11:g.133750356A>C,NM_005157.5:c.1187A>C,NP_005148.2:p.His396Pro"	2023-01-27 17:10:14 UTC	CA375249969	NONE FOUND	"BCR-ABL HIS396PRO,BCR-ABL1 H396P,BCR-ABL1 HIS396PRO,BCR-ABL H396P"	FALSE
ABL1 BCR::ABL M244V	995	Chronic Myeloid Leukemia	8552		Axitinib		Predictive	Does Not Support	D	Resistance	"In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed similar incorporation when harboring fusions with the M244V variant of ABL1 compared to those with wildtype ABL1 (IC50 of 690nM vs. 823 nM), indicating that the M244V variant does not induce resistance."	25686603	PubMed		"Pemovska et al., 2015, Nature"		2	accepted	7771	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/7771	https://civicdb.org/links/molecular_profiles/995	FALSE	ABL1	25	BCR::ABL M244V		chr9	130862943	130862943	A	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.730A>G,NP_005148.2:p.Met244Val,NC_000009.11:g.133738330A>G,ENST00000318560.5:c.730A>G"	2023-01-27 17:07:41 UTC	CA16602545	376084	"RS121913456,M263V,MET263VAL,BCR-ABL MET244VAL,BCR-ABL1 M244V,BCR-ABL1 MET244VAL,BCR-ABL M244V"	FALSE
ABL1 BCR::ABL E279K	2755	Chronic Myeloid Leukemia	8552		Axitinib		Predictive	Supports	D	Sensitivity/Response	"In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed similar incorporation when harboring fusions with the E279K variant of ABL1 compared to those with wildtype ABL1 (IC50 of 778nM vs. 823 nM), indicating that the E279K variant does not induce resistance."	25686603	PubMed		"Pemovska et al., 2015, Nature"		2	accepted	7772	Somatic	2023-01-09 21:47:03 UTC	https://civicdb.org/links/evidence_items/7772	https://civicdb.org/links/molecular_profiles/2755	FALSE	ABL1	25	BCR::ABL E279K		chr9	130872141	130872141	G	A	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"ENST00000318560.5:c.835G>A,NC_000009.11:g.133747528G>A,NM_005157.5:c.835G>A,NP_005148.2:p.Glu279Lys"	2023-01-27 17:10:10 UTC	CA375249162	NONE FOUND	"BCR-ABL1 E279K,BCR-ABL GLU279LYS,BCR-ABL1 GLU279LYS,BCR-ABL E298K,BCR-ABL E279K"	FALSE
ABL1 BCR::ABL L248R	2213	Chronic Myeloid Leukemia	8552		Axitinib		Predictive	Supports	D	Resistance	"In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed increased incorporation when harboring fusions with the L248R variant of ABL1 compared to those with wildtype ABL1 (IC50 of 1399nM vs. 823 nM), indicating resistance."	25686603	PubMed		"Pemovska et al., 2015, Nature"		2	accepted	7776	Somatic	2023-01-09 21:46:58 UTC	https://civicdb.org/links/evidence_items/7776	https://civicdb.org/links/molecular_profiles/2213	FALSE	ABL1	25	BCR::ABL L248R		chr9	130862956	130862956	T	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"ENST00000318560.5:c.743T>G,NC_000009.11:g.133738343T>G,NM_005157.6:c.743T>G,NP_005148.2:p.Leu248Arg"	2023-01-27 17:16:26 UTC	CA375263224	NONE FOUND	"LEU248ARG,BCR-ABL L248R"	FALSE
CTNNB1 Exon 3 Mutation	2761	Desmoid Tumor	80366				Prognostic	Does Not Support	B	Poor Outcome	"This study illustrates the prevalence of CTNNB1 mutations in sporadic desmoid tumors, and examines whether the presence of CTNNB1 mutations correlates with the disease outcome. CTNNB1 mutations (including specific exon 3 mutations T41A, S45F, S45P, and S45C) were found in 106 out of 145 desmoid tumor specimens, and in 86 out of 115 specimens from patients who had undergone complete surgical resection. At a median follow-up of 31 months, the 5-year recurrence free survival rate of patients with the beta-catenin mutated tumors was worse than that of the patients with wild-type tumors (58% vs 74%), however, the difference was not statistically significant (p = 0.285). Thus, the study shows that there is no statistically significant correlation between the CTNNB1 mutation and the recurrence risk of sporadic desmoid tumors, even though specific exon 3 CTNNB1 mutations are commonly identified in these tumors."	23960186	PubMed		"Mullen et al., 2013, Oncologist"		4	accepted	7784	Somatic	2023-05-04 23:01:49 UTC	https://civicdb.org/links/evidence_items/7784	https://civicdb.org/links/molecular_profiles/2761	FALSE	CTNNB1	1499	Exon 3 Mutation		chr3	41224526	41224753			ENST00000349496.5	75				2023-01-09 21:52:22 UTC				FALSE
DPYD EXON 11-19 DELETION	2762	Head And Neck Squamous Cell Carcinoma	5520		"Leucovorin,Fluorouracil"	Combination	Predictive	Supports	C	Sensitivity/Response	"A 69 year old patient diagnosed with HNSCC presented with an unresectable neck mass three months after surgery and adjuvant radiation therapy. A biopsy was taken for whole genome and transcriptome analysis and the patient was started on systemic therapy. After showing resistance to the systemic therapy treatment with 5-FU and leucovorin was initiated based on the discovery of a somatic exon 11-19 in frame deletion in DPYD, which was hypothesized to increase sensitivity to 5-FU in the tumour. A dramatic clinical and radiographic response was sustained for 17 weeks, but following a 3 week treatment break a new nodule appeared. This recurrence showed resistance to re-initiation of treatment with capecitabine (oral 5-FU), and analysis of an additional biopsy provided no evidence as to the mechanism of resistance."	31871216	PubMed		"Majounie et al., 2019, Cold Spring Harb Mol Case Stud"		4	accepted	7787	Somatic	2023-01-09 21:47:03 UTC	https://civicdb.org/links/evidence_items/7787	https://civicdb.org/links/molecular_profiles/2762	FALSE	DPYD	1806	EXON 11-19 DELETION		chr1	97234852	97573970			ENST00000370192.3	75		inframe_deletion		2023-01-09 21:52:22 UTC				FALSE
MET Exon 14 Skipping Mutation	320	Histiocytic And Dendritic Cell Cancer	5621		Crizotinib		Predictive	Supports	C	Sensitivity/Response	"An 84 year old never-smoker with an upper chest mass was found to have stage 3 histiocytic sarcoma. Genomic profiling discovered a MET exon 14 variant c.2888-5_2944del62, as well as TP53 p.R175H and ZMYM3 c.3008-1G>A. After four months of crizotinib treatment tumour volume had decreased by >60%, however the patient showed progression at 11 months."	25971938	PubMed		"Frampton et al., 2015, Cancer Discov"		3	accepted	7796	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/7796	https://civicdb.org/links/molecular_profiles/320	FALSE	MET	4233	Exon 14 Skipping Mutation		chr7	116771849	116771989			ENST00000318493.6	75		exon_loss_variant		2023-01-09 21:52:06 UTC		N/A		FALSE
MET Exon 14 Skipping Mutation	320	Cancer	162		Capmatinib		Predictive	Supports	D	Sensitivity/Response	"MET exon 14 skipping was modelled in vitro by expressing human MET cDNA with exon 14 deletion in HEK293 cells and mouse MET with homologous exon 15 deletion in NIH3T3 cells. NIH3T3 cells expressing MET with exon 15 deletion showed dose dependent inhibition of cell proliferation upon treatment with capmatinib, with significantly lower cell survival compared to control cells. In addition, HEK293 cells expressing MET with exon 14 deletion had increased ERK phosphorylation, while NIH3T3 cells expressing mouse MET with exon 15 deletion had increased MET phosphorylation and increased anchorage-independent colony formation compared to wt MET."	25971938	PubMed		"Frampton et al., 2015, Cancer Discov"		3	accepted	7797	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/7797	https://civicdb.org/links/molecular_profiles/320	FALSE	MET	4233	Exon 14 Skipping Mutation		chr7	116771849	116771989			ENST00000318493.6	75		exon_loss_variant		2023-01-09 21:52:06 UTC		N/A		FALSE
CDK4 EXPRESSION	25	Childhood B-cell Acute Lymphoblastic Leukemia	80146		"Dexamethasone,Ribociclib"	Combination	Predictive	Supports	D	Sensitivity/Response	"CDK4 was found to be significantly overexpressed in the bone marrow of MLL-rearranged B-ALL patients (n=70) compared to normal bone marrow (n=74, p<.001). Combination treatment with dexamethasone (glucocorticoid) and Ribociclib (a highly selective CDK4 / CDK6 inhibitor) of both glucocorticoid sensitive (Rs4;11 & NALM6) and glucocorticoid resistant (RCH-ACV & SEM) B-ALL cell lines synergistically reduced cell viability of all four lines greater than individual drug exposures. Combination therapy also synergistically reduced the cell viability of 5 primary B-ALL lines derived from diagnosis bone marrow compared to individual treatment. (Note: Expression of CDK4 was not quantitatively measured in the derived and primary B-ALL lines used). Further investigation in RCH-ACV and SEM lines revealed dexamethasone and Ribociclib combined increased apoptosis (annexin-V) and increased G1 arrest along with increased p16 (a CDK4 & CDK6 inhibitor) and decreased phosphorylation of downstream G1 to S cell cycle progression markers compared to single treatments. Combination treatment also led to the increase of NR3C1 expression. Knockdown of CDK4 and CDK6 by siRNAs in RCH-ACV sensitized these cells to dexamethasone treatment and increased NR3C1 expression."	29408328	PubMed		"Bortolozzi et al., 2018, Biochem. Pharmacol."		2	accepted	7798	N/A	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/7798	https://civicdb.org/links/molecular_profiles/25	FALSE	CDK4	1019	EXPRESSION		chr12	57747727	57752521			ENST00000257904.6	75		N/A		2023-01-09 21:52:04 UTC		N/A		FALSE
CDK6 Overexpression	598	Glioblastoma Proneural Subtype	50804		Palbociclib		Predictive	Supports	D	Sensitivity/Response	"In this study twelve GBM cell lines and normal human astrocytes (NHA) were treated with the CDK4/6 inhibitor palbociclib. NHA and several GBM cell lines were resistant to palbociclib with IC50 values greater than 1000 nM, while six of seven proneural subtype GBM lines were highly sensitive (IC50 9-210 nM). Palbociclib treatment induced cell accumulation in G1 phase in 3 sensitive proneural lines, but not in 3 resistant lines. Treatment with vehicle versus oral palbociclib (150 mg/kg/day) was compared in mice with intracranial implantation of proneural GBM stem cell-like G448 cells, which are shown to have higher than normal expression of CDK6. Mice receiving palbociclib had significantly longer survival time (p=0.038)."	28903422	PubMed		"Li et al., 2017, Oncotarget"		2	accepted	7800	N/A	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/7800	https://civicdb.org/links/molecular_profiles/598	FALSE	CDK6	1021	Overexpression		chr7	92604921	92833917			ENST00000265734.4	75		N/A		2023-01-09 21:52:08 UTC		N/A		FALSE
ERBB2 Amplification	302	Colorectal Cancer	9256		Afatinib		Predictive	Supports	D	Sensitivity/Response	Afatinib monotherapy was tested in patient-derived colorectal cancer (M051) mouse xenografts and gastric cancer cell-line (NCI-N87) mouse xenografts.  Tumor shrinkage was observed and tumor volume was significantly decreased compared to treatment with vehicle or lapatinib monotherapy (p<0.0001 (M051 Afatinib vs. Lapatinib) and p=0.0003 (NCI-N87 Afatinib vs. Lapatinib).	26296355	PubMed		"Leto et al., 2015, Clin. Cancer Res."		3	accepted	7807	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/7807	https://civicdb.org/links/molecular_profiles/302	FALSE	ERBB2	2064	Amplification		chr17	39700080	39728662			ENST00000269571.5	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A	OVEREXPRESSION	FALSE
FGFR1 Amplification	263	Adenosquamous Lung Carcinoma	4829		Pazopanib		Predictive	Supports	C	Sensitivity/Response	"Patient diagnosed with metastatic squamous cell lung cancer had high-level amplification of FGFR1 and high expression of MYC.  Patient was treated with 400 mg pazopanib twice a day.  CT taken four and eight weeks after start of pazopanib showed tumor regression and cavitation.   Due to side effects, patient stopped taking pazopanib after 6 months.  No clinical or radiologic signs of tumor progression were present at that time."	24302556	PubMed		"Malchers et al., 2014, Cancer Discov"		3	accepted	7811	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/7811	https://civicdb.org/links/molecular_profiles/263	FALSE	FGFR1	2260	Amplification		chr8	38411138	38467845			ENST00000425967.3	75		transcript_amplification	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
NT5C2 R367Q	234	Childhood Acute Lymphocytic Leukemia	80144		"Thioguanine,Mercaptopurine"	Substitutes	Predictive	Supports	C	Resistance	"71 Childhood B-cell acute lymphocytic leukemia relapse patients had their diagnosis and relapse samples sequenced for NT5C2 mutations. Sequencing revealed an early relapse case with NT5C2 R367Q enriched to a variant allele frequency (VAF) of 25% at relapse and only a VAF of .02% at diagnosis. R367Q could drive clonal outgrowth through the promotion of drug resistance, specifically to thiopurines, which are a staple of ALL maintenance therapy that are administered daily."	23377183	PubMed		"Meyer et al., 2013, Nat. Genet."		2	accepted	7812	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/7812	https://civicdb.org/links/molecular_profiles/234	FALSE	NT5C2	22978	R367Q		chr10	103093198	103093198	C	T	ENST00000343289.5	75		missense_variant	NC_000010.10:g.104852955C>T	2023-01-27 17:03:06 UTC	CA16602791	376349	ARG367GLN	FALSE
NT5C2 R238W	2765	Childhood Acute Lymphocytic Leukemia	80144		"Mercaptopurine,Thioguanine"	Substitutes	Predictive	Supports	D	Resistance	"Lentiviral-mediated overexpression of NT5C2 R238W in Reh cells resulted in significant resistance against thiopurines (mercaptopurine and thioguanine) versus wildtype and GFP controls, as indicated by reduced apoptosis. Compared to controls, overexpression cells also displayed reduced intercellular thioguanoside nucleotides after 24 hours of drug exposure, as measured by HPLC. Additionally, recombinant protein expression of R238W led to increased 5?nucleotidase activity."	23377183	PubMed		"Meyer et al., 2013, Nat. Genet."		4	accepted	7813	Somatic	2023-01-09 21:47:03 UTC	https://civicdb.org/links/evidence_items/7813	https://civicdb.org/links/molecular_profiles/2765	FALSE	NT5C2	22978	R238W		chr10	103097350	103097350	G	A	ENST00000343289.5	75				2023-01-27 17:18:05 UTC	CA377975023			FALSE
NT5C2 S445F	2766	Childhood Acute Lymphocytic Leukemia	80144		"Thioguanine,Mercaptopurine"	Substitutes	Predictive	Supports	D	Resistance	"Lentiviral-mediated overexpression of NT5C2 S445F in Reh cells resulted in significant resistance against thiopurines (mercaptopurine and thioguanine) versus wildtype and GFP controls, as indicated by reduced apoptosis.  Compared to controls, overexpression cells also displayed reduced intercellular thioguanoside nucleotides after 24 hours of drug exposure, as measured by HPLC. Additionally, recombinant protein expression of S445F led to increased 5?nucleotidase activity."	23377183	PubMed		"Meyer et al., 2013, Nat. Genet."		4	accepted	7814	Somatic	2023-01-09 21:47:03 UTC	https://civicdb.org/links/evidence_items/7814	https://civicdb.org/links/molecular_profiles/2766	FALSE	NT5C2	22978	S445F		chr10	103090726	103090726	G	A	ENST00000343289.5	75		"missense_variant,gain_of_function_variant"		2023-01-27 17:18:06 UTC	CA377969059	NONE FOUND		FALSE
NT5C2 R367Q	234	Childhood Acute Lymphocytic Leukemia	80144		"Cytarabine,Gemcitabine,Prednisolone,Doxorubicin"	Substitutes	Predictive	Does Not Support	D	Resistance	"Lentiviral mediated overexpression of NT5C2 R367Q in Reh cells resulted in no change in apoptosis after exposure to cytarabine, gemcitabine, doxorubicin, or prednisolone compared to wildtype NT5C2 overexpression and GFP control lines."	23377183	PubMed		"Meyer et al., 2013, Nat. Genet."		4	accepted	7815	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/7815	https://civicdb.org/links/molecular_profiles/234	FALSE	NT5C2	22978	R367Q		chr10	103093198	103093198	C	T	ENST00000343289.5	75		missense_variant	NC_000010.10:g.104852955C>T	2023-01-27 17:03:06 UTC	CA16602791	376349	ARG367GLN	FALSE
NT5C2 R238W	2765	Childhood Acute Lymphocytic Leukemia	80144		"Prednisolone,Cytarabine,Gemcitabine,Doxorubicin"	Substitutes	Predictive	Does Not Support	D	Resistance	"Overexpression of NT5C2 R238W in Reh cells resulted in no change in response to cytarabine, gemcitabine, doxorubicin or prednisolone versus wildtype or GFP controls as indicated by similar apoptosis."	23377183	PubMed		"Meyer et al., 2013, Nat. Genet."		4	accepted	7816	Somatic	2023-01-09 21:47:03 UTC	https://civicdb.org/links/evidence_items/7816	https://civicdb.org/links/molecular_profiles/2765	FALSE	NT5C2	22978	R238W		chr10	103097350	103097350	G	A	ENST00000343289.5	75				2023-01-27 17:18:05 UTC	CA377975023			FALSE
NT5C2 S445F	2766	Childhood Acute Lymphocytic Leukemia	80144		"Cytarabine,Prednisolone,Doxorubicin,Gemcitabine"	Substitutes	Predictive	Does Not Support	D	Resistance	"Overexpression of NT5C2 S445F in Reh cells resulted in no change in response to cytarabine, gemcitabine, doxorubicin or prednisolone versus wildtype or GFP controls as indicated by similar apoptosis."	23377183	PubMed		"Meyer et al., 2013, Nat. Genet."		4	accepted	7817	Somatic	2023-01-09 21:47:03 UTC	https://civicdb.org/links/evidence_items/7817	https://civicdb.org/links/molecular_profiles/2766	FALSE	NT5C2	22978	S445F		chr10	103090726	103090726	G	A	ENST00000343289.5	75		"missense_variant,gain_of_function_variant"		2023-01-27 17:18:06 UTC	CA377969059	NONE FOUND		FALSE
ABL1 BCR::ABL H396R	1004	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	C	Resistance	"Prior to dasatinib treatment, one imatinib-resistant patient with chronic myeloid leukemia in chronic phase had the BCR-ABL1 fusion with H396R and E355G variants in 9/11 and 1/11 clones, respectively. Clones were generated using peripheral blood RNA. The patient had no best cytogenetic and complete best hematologic responses to dasatinib which were comparable to responses in patients with unmutated BCR-ABL1."	16775234	PubMed		"Talpaz et al., 2006, N. Engl. J. Med."	NCT00064233	3	accepted	7823	Somatic	2023-01-09 21:46:42 UTC	https://civicdb.org/links/evidence_items/7823	https://civicdb.org/links/molecular_profiles/1004	FALSE	ABL1	25	BCR::ABL H396R		chr9	130874969	130874969	A	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.1187A>G,NP_005148.2:p.His396Arg,NC_000009.11:g.133750356A>G,ENST00000318560.5:c.1187A>G"	2023-01-27 17:07:48 UTC	CA16602558	376097	"RS121913454,BCR-ABL HIS415ARG,BCR-ABL HIS396ARG,BCR-ABL H415R,BCR-ABL1 H396R,BCR-ABL1 HIS396ARG,BCR-ABL H396R"	FALSE
ABL1 BCR::ABL M244V	995	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	C	Resistance	One chronic myeloid leukemia patient in chronic phase had no response to imatinib. Bacterial clones generated using peripheral blood RNA later revealed the BCR-ABL1 fusion with the M244V secondary variant in 12/12 clones.	16775234	PubMed		"Talpaz et al., 2006, N. Engl. J. Med."	NCT00064233	1	accepted	7825	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/7825	https://civicdb.org/links/molecular_profiles/995	FALSE	ABL1	25	BCR::ABL M244V		chr9	130862943	130862943	A	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.730A>G,NP_005148.2:p.Met244Val,NC_000009.11:g.133738330A>G,ENST00000318560.5:c.730A>G"	2023-01-27 17:07:41 UTC	CA16602545	376084	"RS121913456,M263V,MET263VAL,BCR-ABL MET244VAL,BCR-ABL1 M244V,BCR-ABL1 MET244VAL,BCR-ABL M244V"	FALSE
ABL1 BCR::ABL	1	Chronic Myeloid Leukemia	8552		"Dasatinib,Bafetinib,Nilotinib"	Substitutes	Predictive	Supports	D	Sensitivity/Response	"In an in vitro study, six CML cell lines expressing the BCR-ABL1 fusion protein showed sensitivity to nilotinib (IC50: 24.3-84.5 nM), dasatinib (IC50: 1.5-10.9 nM), and bafetinib (IC50: 11.8-87.7 nM). When comparing potency of these treatments against the 6 CML cell lines, dasatinib, nilotinib and bafetinib were on average 98.6, 9.85 and 16.4 times more potent than imatinib. Sensitivity was determined by assessing cell proliferation using the MTT assay."	18191450	PubMed		"Deguchi et al., 2008, Leuk. Res."		3	accepted	7838	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/7838	https://civicdb.org/links/molecular_profiles/1	FALSE	ABL1	25	BCR::ABL	ABL1 fusions in B-ALL	chr22	23180210	23290413			ENST00000305877.8	75	ENST00000318560.5	transcript_fusion	N/A	2023-01-09 21:52:04 UTC		N/A	"T(9;22)(Q34;Q11),BCR-ABL1,BCR-ABL"	FALSE
ABL1 BCR::ABL	1	Chronic Myeloid Leukemia	8552		"Dasatinib,Bafetinib,Nilotinib"	Substitutes	Predictive	Supports	D	Sensitivity/Response	"In an in vitro study, six CML cell lines expressing the BCR-ABL1 fusion protein showed sensitivity to nilotinib (IC50: 24.3-84.5 nM), dasatinib (IC50: 1.5-10.9 nM), and bafetinib (IC50: 11.8-87.7 nM). When comparing potency of these treatments against the 6 CML cell lines, dasatinib, nilotinib and bafetinib were on average 98.6, 9.85 and 16.4 times more potent than imatinib. Sensitivity was determined by assessing cell proliferation using the MTT assay."	18191450	PubMed		"Deguchi et al., 2008, Leuk. Res."		3	accepted	7838	Somatic	2023-01-09 21:46:24 UTC	https://civicdb.org/links/evidence_items/7838	https://civicdb.org/links/molecular_profiles/1	FALSE	ABL1	25	BCR::ABL	ABL1 fusions in B-ALL	chr9	130854064	130887676			ENST00000305877.8	75	ENST00000318560.5	transcript_fusion	N/A	2023-01-09 21:52:04 UTC		N/A	"T(9;22)(Q34;Q11),BCR-ABL1,BCR-ABL"	FALSE
ABL1 BCR::ABL M351T	1003	Cancer	162		Imatinib		Predictive	Supports	D	Resistance	"In an in vitro study, a Ba/F3 cell line stably expressing the M351T mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to imatinib treatment (IC50: >2000.0 nM) as compared to wild-type BCR-ABL1 expressing Ba/F3 cells (IC50: 1712 nM). Sensitivity was determined by assessing cell proliferation using the MTT assay."	18191450	PubMed		"Deguchi et al., 2008, Leuk. Res."		3	accepted	7841	Somatic	2023-01-09 21:46:42 UTC	https://civicdb.org/links/evidence_items/7841	https://civicdb.org/links/molecular_profiles/1003	FALSE	ABL1	25	BCR::ABL M351T		chr9	130873004	130873004	T	C	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.1052T>C,NP_005148.2:p.Met351Thr,NC_000009.11:g.133748391T>C,ENST00000318560.5:c.1052T>C"	2023-01-27 17:07:48 UTC	CA122590	12629	"RS121913457,BCR-ABL M370T,BCR-ABL MET351THR,BCR-ABL MET370THR,BCR-ABL M351T"	FALSE
ABL1 BCR::ABL T315A	2208	Cancer	162		"Nilotinib,Bafetinib"	Substitutes	Predictive	Does Not Support	D	Resistance	"In an in vitro study, a Ba/F3 cell line stably expressing the dasatinib-resistance variant T315A in the ABL1 portion of the BCR-ABL1 fusion protein was associated with similar sensitivity to nilotinib and bafetinib (INNO-406) treatment (IC50: 949.2 nM, 422.5 nM) as compared to wild-type BCR-ABL1 expressing Ba/F3 cells (IC50: 642.3 nM and 152.9 nM). Sensitivity was determined by assessing cell proliferation using the MTT assay."	18191450	PubMed		"Deguchi et al., 2008, Leuk. Res."		3	accepted	7842	Somatic	2023-01-09 21:46:58 UTC	https://civicdb.org/links/evidence_items/7842	https://civicdb.org/links/molecular_profiles/2208	FALSE	ABL1	25	BCR::ABL T315A		chr9	130872895	130872895	A	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.943A>G,NP_005148.2:p.Thr315Ala,NC_000009.11:g.133748282A>G,ENST00000318560.5:c.943A>G"	2023-01-27 17:16:25 UTC	CA16602576	376118	"THR315ALA,T334A,RS1057519772,BCR-ABL T315A"	FALSE
ABL1 BCR::ABL T315A	2208	Cancer	162		"Dasatinib,Imatinib"	Substitutes	Predictive	Supports	D	Resistance	"In an in vitro study, a Ba/F3 cell line stably expressing T315A in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to imatinib and dasatinib treatment (IC50: >2000.0 nM) as compared to wild-type BCR-ABL1 expressing Ba/F3 cells (IC50: 1712 nM and 87.6 nM). Sensitivity was determined by assessing cell proliferation. The authors examined X-ray crystal structure of dasatinib/ABL to determine why dasatinib was ineffective against mutations at amino acid 315, and found that T315A causes decreased steric and hydrogen-bonding interactions with dasatinib."	18191450	PubMed		"Deguchi et al., 2008, Leuk. Res."		3	accepted	7844	Somatic	2023-01-09 21:46:58 UTC	https://civicdb.org/links/evidence_items/7844	https://civicdb.org/links/molecular_profiles/2208	FALSE	ABL1	25	BCR::ABL T315A		chr9	130872895	130872895	A	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.943A>G,NP_005148.2:p.Thr315Ala,NC_000009.11:g.133748282A>G,ENST00000318560.5:c.943A>G"	2023-01-27 17:16:25 UTC	CA16602576	376118	"THR315ALA,T334A,RS1057519772,BCR-ABL T315A"	FALSE
ABL1 BCR::ABL H396P	1439	Cancer	162		"Nilotinib,Bafetinib"	Substitutes	Predictive	Does Not Support	D	Resistance	"In an in vitro study, a Ba/F3 cell line stably expressing H396P in the ABL1 portion of the BCR-ABL1 fusion protein was associated with similar sensitivity to nilotinib and bafetinib (INNO-406) treatment (IC50: 986.9 nM and 280.1 nM) as compared to wild-type BCR-ABL1 expressing Ba/F3 cells (IC50: 642.3 nM and 152.9 nM). Sensitivity was determined by assessing cell proliferation using the MTT assay."	18191450	PubMed		"Deguchi et al., 2008, Leuk. Res."		3	accepted	7846	Somatic	2023-01-09 21:46:45 UTC	https://civicdb.org/links/evidence_items/7846	https://civicdb.org/links/molecular_profiles/1439	FALSE	ABL1	25	BCR::ABL H396P		chr9	130874969	130874969	A	C	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"ENST00000318560.5:c.1187A>C,NC_000009.11:g.133750356A>C,NM_005157.5:c.1187A>C,NP_005148.2:p.His396Pro"	2023-01-27 17:10:14 UTC	CA375249969	NONE FOUND	"BCR-ABL HIS396PRO,BCR-ABL1 H396P,BCR-ABL1 HIS396PRO,BCR-ABL H396P"	FALSE
ABL1 BCR::ABL H396P	1439	Cancer	162		Imatinib		Predictive	Supports	D	Resistance	"In an in vitro study, a Ba/F3 cell line stably expressing H396P in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to imatinib treatment (IC50: >2000.0 nM) as compared to wild-type BCR-ABL1 expressing Ba/F3 cells (IC50: 1712 nM). Sensitivity was determined by assessing cell proliferation using the MTT assay."	18191450	PubMed		"Deguchi et al., 2008, Leuk. Res."		3	accepted	7847	Somatic	2023-01-09 21:46:45 UTC	https://civicdb.org/links/evidence_items/7847	https://civicdb.org/links/molecular_profiles/1439	FALSE	ABL1	25	BCR::ABL H396P		chr9	130874969	130874969	A	C	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"ENST00000318560.5:c.1187A>C,NC_000009.11:g.133750356A>C,NM_005157.5:c.1187A>C,NP_005148.2:p.His396Pro"	2023-01-27 17:10:14 UTC	CA375249969	NONE FOUND	"BCR-ABL HIS396PRO,BCR-ABL1 H396P,BCR-ABL1 HIS396PRO,BCR-ABL H396P"	FALSE
ABL1 BCR::ABL Y253F	2778	Cancer	162		Imatinib		Predictive	Supports	D	Resistance	"In an in vitro study, a Ba/F3 cell line stably expressing the Y253F mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to imatinib treatment (IC50: > 2000.0 nM) as compared to wild-type BCR-ABL1 expressing Ba/F3 cells (IC50: 1712 nM). Sensitivity was determined by assessing cell proliferation using the MTT assay."	18191450	PubMed		"Deguchi et al., 2008, Leuk. Res."		3	accepted	7848	Somatic	2023-01-09 21:47:03 UTC	https://civicdb.org/links/evidence_items/7848	https://civicdb.org/links/molecular_profiles/2778	FALSE	ABL1	25	BCR::ABL Y253F		chr9	130862971	130862971	A	T	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"ENST00000318560.5:c.758A>T,NM_005157.5:c.758A>T,NP_005148.2:p.Tyr253Phe,NC_000009.11:g.133738358A>T"	2023-01-27 17:07:45 UTC	CA16602550	376089	"RS121913460,Y272F,TYR253PHE,TYR272PHE,BCR-ABL Y253F"	FALSE
ABL1 BCR::ABL Q252H	998	Cancer	162		"Bafetinib,Imatinib"	Substitutes	Predictive	Supports	D	Resistance	"In an in vitro study, a Ba/F3 cell line stably expressing the Q252H mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to imatinib and bafetinib (INNO-406) treatment (IC50: > 2000.0 nM and 888.1 nM) as compared to wild-type BCR-ABL1 expressing Ba/F3 cells (IC50: 1712 nM and 152.9 nM). Sensitivity was determined by assessing cell proliferation using the MTT assay."	18191450	PubMed		"Deguchi et al., 2008, Leuk. Res."		3	accepted	7849	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/7849	https://civicdb.org/links/molecular_profiles/998	FALSE	ABL1	25	BCR::ABL Q252H		chr9	130862969	130862969	G	C	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.756G>C,NP_005148.2:p.Gln252His,NC_000009.11:g.133738356G>C,ENST00000318560.5:c.756G>C"	2023-01-27 17:07:44 UTC	CA16602548	376087	"RS121913458,BCR-ABL Q271H,BCR-ABL1 Q252H,BCR-ABL1 GLN252HIS,BCR-ABL Q252H"	FALSE
ABL1 BCR::ABL M244V	995	Cancer	162		"Imatinib,Bafetinib"	Substitutes	Predictive	Supports	D	Resistance	"In an in vitro study, a Ba/F3 cell line stably expressing the M244V mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to imatinib and bafetinib (INNO-406) treatment (IC50: > 2000.0 nM and 874.2 nM) as compared to wild-type BCR-ABL1 expressing Ba/F3 cells (IC50: 1712 nM and 152.9 nM). Sensitivity was determined by assessing cell proliferation using the MTT assay."	18191450	PubMed		"Deguchi et al., 2008, Leuk. Res."		3	accepted	7850	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/7850	https://civicdb.org/links/molecular_profiles/995	FALSE	ABL1	25	BCR::ABL M244V		chr9	130862943	130862943	A	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.730A>G,NP_005148.2:p.Met244Val,NC_000009.11:g.133738330A>G,ENST00000318560.5:c.730A>G"	2023-01-27 17:07:41 UTC	CA16602545	376084	"RS121913456,M263V,MET263VAL,BCR-ABL MET244VAL,BCR-ABL1 M244V,BCR-ABL1 MET244VAL,BCR-ABL M244V"	FALSE
JAK1 OVEREXPRESSION	392	Sarcoma	1115		Ruxolitinib		Predictive	Supports	C	Sensitivity/Response	"Sequencing of an 8-year old patient diagnosed with a left tentorial-based CNS sarcoma discovered an EWSR1-ATF fusion and IL6 and JAK1 overexpression. Patient was treated with ruxolitinib based on overexpression of JAK1. Stable disease per RECIST and improvement of Lansky score from 60 to 90-100 was observed for 5 months. After ruxolitinib discontinuation, the patient's symptoms worsened and lung lesions progressed. Ruxolitinib was started again per family request and patient again had stable disease and improvement in body weight and Lansky score. Dose reduction was required because of myelosuppression and patient death occurred 23 months after relapse."	31372595	PubMed		"Newton et al., 2018, JCO Precis Oncol"		3	accepted	7852	N/A	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/7852	https://civicdb.org/links/molecular_profiles/392	FALSE	JAK1	3716	OVEREXPRESSION		chr1	64833229	64966504			ENST00000342505.4	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
ABL1 BCR::ABL G250E	997	Cancer	162		"Imatinib,Bafetinib"	Substitutes	Predictive	Supports	D	Resistance	"In an in vitro study, a Ba/F3 cell line stably expressing the G250E mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to imatinib and bafetinib (INNO-406) treatment (IC50: > 2000.0 nM and 852 nM) as compared to wild-type BCR-ABL1 expressing Ba/F3 cells (IC50: 1712 nM and 152.9 nM). Sensitivity was determined by assessing cell proliferation using the MTT assay."	18191450	PubMed		"Deguchi et al., 2008, Leuk. Res."		3	accepted	7853	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/7853	https://civicdb.org/links/molecular_profiles/997	FALSE	ABL1	25	BCR::ABL G250E		chr9	130862962	130862962	G	A	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.749G>A,NP_005148.2:p.Gly250Glu,NC_000009.11:g.133738349G>A,ENST00000318560.5:c.749G>A"	2023-01-27 17:07:43 UTC	CA16602547	376086	"RS121913453,BCR-ABL G269E,BCR-ABL GLY250GLU,BCR-ABL1 G250E,BCR-ABL1 GLY250GLU,BCR-ABL G250E"	FALSE
NT5C2 R367Q	234	Childhood Acute Lymphocytic Leukemia	80144		"Thioguanine,Mercaptopurine"	Substitutes	Predictive	Supports	D	Resistance	"Lentiviral-mediated overexpression of NT5C2 R367Q in Reh cells resulted in significant resistance against thiopurines (mercaptopurine and thioguanine) versus wildtype and GFP controls, as indicated by reduced apoptosis. Compared to controls, overexpression cells also displayed reduced intercellular thioguanoside nucleotides after 24 hours of drug exposure, as measured by HPLC. Additionally, recombinant protein expression of R367Q led to increased 5?nucleotidase activity."	23377183	PubMed		"Meyer et al., 2013, Nat. Genet."		4	accepted	7862	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/7862	https://civicdb.org/links/molecular_profiles/234	FALSE	NT5C2	22978	R367Q		chr10	103093198	103093198	C	T	ENST00000343289.5	75		missense_variant	NC_000010.10:g.104852955C>T	2023-01-27 17:03:06 UTC	CA16602791	376349	ARG367GLN	FALSE
NT5C2 R238W	2765	Childhood Acute Lymphocytic Leukemia	80144	Pediatric onset			Prognostic	Supports	C	Poor Outcome	"71 Childhood B-cell acute lymphocytic leukemia relapse patients had their diagnosis and relapse samples sequenced for NT5C2 mutations. Sequencing revealed 3 early relapse cases with NT5C2 R238W enriched at relapse at variant allele frequencies (VAF) of 27%, 18%, and 31% and only a VAF of .01%, 0%, and 0% at diagnosis. R238W could drive clonal outgrowth through the promotion of drug resistance, specifically to thiopurines, which are a staple of ALL maintenance therapy that are administered daily."	23377183	PubMed		"Meyer et al., 2013, Nat. Genet."		2	accepted	7863	Somatic	2023-01-09 21:47:03 UTC	https://civicdb.org/links/evidence_items/7863	https://civicdb.org/links/molecular_profiles/2765	FALSE	NT5C2	22978	R238W		chr10	103097350	103097350	G	A	ENST00000343289.5	75				2023-01-27 17:18:05 UTC	CA377975023			FALSE
NT5C2 S445F	2766	Childhood Acute Lymphocytic Leukemia	80144				Prognostic	Supports	C	Poor Outcome	"71 Childhood B-cell acute lymphocytic leukemia relapse patients had their diagnosis and relapse samples sequenced for NT5C2 mutations. Sequencing revealed an early relapse case with NT5C2 S445F enriched to a variant allele frequency (VAF) of 25% at relapse and was undetected at diagnosis. S445F could drive clonal outgrowth through the promotion of drug resistance, specifically to thiopurines, which are a staple of ALL maintenance therapy that are administered daily."	23377183	PubMed		"Meyer et al., 2013, Nat. Genet."		2	accepted	7864	Somatic	2023-01-09 21:47:03 UTC	https://civicdb.org/links/evidence_items/7864	https://civicdb.org/links/molecular_profiles/2766	FALSE	NT5C2	22978	S445F		chr10	103090726	103090726	G	A	ENST00000343289.5	75		"missense_variant,gain_of_function_variant"		2023-01-27 17:18:06 UTC	CA377969059	NONE FOUND		FALSE
VHL L188V (c.562C>G)	1712	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	N/A	C	N/A	"36 VHL-related pheochromocytomas (from 21 patients) and 10 VHL-related CNS hemangioblastomas (from 6 patients) were studied using comparative genomic hybridization (CGH) to detect genetic imbalances. The study identified selective loss of chromosome 11 in pheochromocytomas associated with VHL.  Patient XVI, XX and XXI in VHL-associated pheochromocytoma were found with germline missense mutation (c.562C>G) in the VHL gene. ACMG evidence codes:  'PP4' because the patients' phenotypes are highly specific for a disease with single genetic etiology."	11850829	PubMed		"Lui et al., 2002, Oncogene"		3	accepted	7889	Rare Germline	2023-01-09 21:46:51 UTC	https://civicdb.org/links/evidence_items/7889	https://civicdb.org/links/molecular_profiles/1712	FALSE	VHL	7428	L188V (c.562C>G)		chr3	10149885	10149885	C	G	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.562C>G,NP_000542.1:p.Leu188Val,NC_000003.11:g.10191569C>G,ENST00000256474.2:c.562C>G"	2023-01-27 17:12:38 UTC	CA020488	2225	"C.562C>G,LEU188VAL,RS5030824"	FALSE
VHL L178Q (c.533T>A)	1873	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	N/A	C	N/A	36 VHL-related pheochromocytomas (from 21 patients) and 10 VHL-related CNS hemangioblastomas (from 6 patients) were studied using comparative genomic hybridization (CGH) to detect genetic imbalances. The study identified selective loss of chromosome 11 in pheochromocytomas associated with VHL. Patient XVII and XVIII in VHL-associated pheochromocytoma were found with a germline missense mutation (c.533T>A) in the VHL gene. ACMG evidence codes: 'PP4' because the patients' phenotypes are highly specific for a disease with single genetic etiology.	11850829	PubMed		"Lui et al., 2002, Oncogene"		3	accepted	7890	Rare Germline	2023-01-09 21:46:54 UTC	https://civicdb.org/links/evidence_items/7890	https://civicdb.org/links/molecular_profiles/1873	FALSE	VHL	7428	L178Q (c.533T>A)		chr3	10149856	10149856	T	A	ENST00000256474.2	75		missense_variant	"NC_000003.11:g.10191540T>A,NM_000551.3:c.533T>A,NP_000542.1:p.Leu178Gln,ENST00000256474.2:c.533T>A"	2023-01-27 17:14:05 UTC	CA70052370	625260	"C.533T>A,LEU178GLN,RS5030822"	FALSE
VHL R161Q (c.482G>A)	1622	Von Hippel-Lindau Disease	14175	Pheochromocytoma			Predisposing	N/A	C	N/A	36 VHL-related pheochromocytomas (from 21 patients) and 10 VHL-related CNS hemangioblastomas (from 6 patients) were studied using comparative genomic hybridization (CGH) to detect genetic imbalances. The study identified selective loss of chromosome 11 in pheochromocytomas associated with VHL. Patient XIX with VHL-associated pheochromocytoma was found with a germline missense mutation (c.482G>A) in the VHL gene. ACMG evidence codes: 'PP4' because the patients' phenotypes are highly specific for a disease with single genetic etiology.	11850829	PubMed		"Lui et al., 2002, Oncogene"		3	accepted	7891	Rare Germline	2023-01-09 21:46:48 UTC	https://civicdb.org/links/evidence_items/7891	https://civicdb.org/links/molecular_profiles/1622	FALSE	VHL	7428	R161Q (c.482G>A)		chr3	10149805	10149805	G	A	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.482G>A,NP_000542.1:p.Arg161Gln,NC_000003.11:g.10191489G>A,ENST00000256474.2:c.482G>A"	2023-01-27 17:11:34 UTC	CA020413	182983	"C.482G>A,ARG161GLN,RS730882035"	FALSE
VHL N78S (c.233A>G)	1631	Von Hippel-Lindau Disease	14175	Hemangioblastoma			Predisposing	N/A	C	N/A	36 VHL-related pheochromocytomas (from 21 patients) and 10 VHL-related CNS hemangioblastomas (from 6 patients) were studied using comparative genomic hybridization (CGH) to detect genetic imbalances. Patient II in VHL-Associated hemangioblastoma was found with germline missense mutation (c.233A>G) in the VHL gene. ACMG evidence codes: 'PP4' because the patients' phenotypes are highly specific for a disease with single genetic etiology.	11850829	PubMed		"Lui et al., 2002, Oncogene"		3	accepted	7893	Rare Germline	2023-01-09 21:46:48 UTC	https://civicdb.org/links/evidence_items/7893	https://civicdb.org/links/molecular_profiles/1631	FALSE	VHL	7428	N78S (c.233A>G)		chr3	10142080	10142080	A	G	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.233A>G,NP_000542.1:p.Asn78Ser,NC_000003.11:g.10183764A>G,ENST00000256474.2:c.233A>G"	2023-01-27 17:11:40 UTC	CA020131	93326	"C.233A>G,ASN78SER,RS5030804"	FALSE
VHL C77_N78insL (c.230_231insTCT)	2965	Von Hippel-Lindau Disease	14175	Hemangioblastoma			Predisposing	N/A	C	N/A	36 VHL-related pheochromocytomas (from 21 patients) and 10 VHL-related CNS hemangioblastomas (from 6 patients) were studied using comparative genomic hybridization (CGH) to detect genetic imbalances. Patient III in VHL-Associated hemangioblastoma was found with germline insertion mutation (c.230insTCT) in the VHL gene. ACMG evidence codes: 'PP4' because the patients' phenotypes are highly specific for a disease with single genetic etiology.	11850829	PubMed		"Lui et al., 2002, Oncogene"		3	accepted	7894	Rare Germline	2023-01-09 21:47:05 UTC	https://civicdb.org/links/evidence_items/7894	https://civicdb.org/links/molecular_profiles/2965	FALSE	VHL	7428	C77_N78insL (c.230_231insTCT)		chr3	10142077	10142078		TCT	ENST00000256474.2	75		disruptive_inframe_insertion	"NC_000003.12:g.10142077_10142078insTCT,NC_000003.11:g.10183761_10183762insTCT,NM_000551.3:c.230_231insTCT,NP_000542.1:p.Cys77_Asn78insLeu"	2023-01-27 17:18:21 UTC	CA2499214029	NONE FOUND	77INSL	FALSE
VHL C162W (c.486C>G)	1650	Von Hippel-Lindau Disease	14175	Hemangioblastoma			Predisposing	N/A	C	N/A	36 VHL-related pheochromocytomas (from 21 patients) and 10 VHL-related CNS hemangioblastomas (from 6 patients) were studied using comparative genomic hybridization (CGH) to detect genetic imbalances. Patient IV with VHL-Associated hemangioblastoma was found with a germline missense mutation (c.486C>G) in the VHL gene. ACMG evidence codes: 'PP4' because the patients' phenotypes are highly specific for a disease with single genetic etiology.	11850829	PubMed		"Lui et al., 2002, Oncogene"		3	accepted	7895	Rare Germline	2023-01-09 21:46:49 UTC	https://civicdb.org/links/evidence_items/7895	https://civicdb.org/links/molecular_profiles/1650	FALSE	VHL	7428	C162W (c.486C>G)		chr3	10149809	10149809	C	G	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.486C>G,NP_000542.1:p.Cys162Trp,NC_000003.11:g.10191493C>G,ENST00000256474.2:c.486C>G"	2023-01-27 17:11:53 UTC	CA357016	223227	"C.486C>G,CYS162TRP,RS869025662"	FALSE
ROS1 Rearrangement	265	Lung Non-small Cell Carcinoma	3908		Crizotinib		Predictive	Supports	A	Sensitivity/Response	"A phase 2 clinical trial studied the efficacy of Crizotinib in East Asian NSCLC patients positive for ROS1 rearrangements (detected by RT-PCR AmoyDx assay) and negative for ALK1 rearrangements. Of the 127 patients enrolled, 17 achieved complete response and 74 achieved partial response. Overall response rate by independent radiology review was 71.7% (95% CI 63-79.3%) Time to response was rapid (median 1.9 months) and durable (Duration of response median 19.7 months). Median progression free survival was 15.9 months. Crizotinib was clinically beneficial regardless of demographics and prior therapy. Based on these results, Crizotinib was approved for the treatment of ROS1 positive NSCLC in 2017 in Japan, Taiwan, China, and Korea."	29596029	PubMed		"Wu et al., 2018, J. Clin. Oncol."	NCT01945021	4	accepted	7933	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/7933	https://civicdb.org/links/molecular_profiles/265	FALSE	ROS1	6098	Rearrangement		chr6	117288300	117425855			ENST00000368508.3	75		transcript_fusion		2023-01-09 21:52:06 UTC		N/A		FALSE
KRAS R164Q	1181	Cancer	162				Oncogenic	Does Not Support	D	Oncogenicity	"NIH3T3 cells were transfected with control or KRAS R164Q plasmid and focus formation assays were performed. R164Q cells formed 0 foci > 5mm diameter per well, which was the same as wt cells. In contrast, known gain of function mutations KRAS G12V and G12D formed over 70 foci > 5mm diameter average per well. In conclusion, these data suggest that R164Q does not promote oncogenic transformation of NIH3T3 cells by loss of contact inhibition, and gives support for ClinGen/CGC/VICC Oncogenicity Code SBS2."	20147967	PubMed		"Smith et al., 2010, Br. J. Cancer"		3	accepted	7935	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/7935	https://civicdb.org/links/molecular_profiles/1181	FALSE	KRAS	3845	R164Q		chr12	25215520	25215520	C	T	ENST00000256078.4	75		missense_variant	"NC_000012.11:g.25368454C>T,NC_000012.12:g.25215520C>T,NP_203524.1:p.Arg164Gln,NM_033360.4:c.491G>A"	2023-01-27 17:08:42 UTC	CA6486860	NONE FOUND	"ARG164GLN,RS758575947"	FALSE
KRAS Q61H	881	Cancer	162				Oncogenic	Supports	D	Oncogenicity	"NIH3T3 cells were transfected with control or KRAS Q61H plasmid and focus formation assays were performed. Q61H cells formed approximately 50 foci > 5mm diameter per well, where wt cells formed none, demonstrating Q61H promotes loss of contact inhibition suggestive of oncogenic transformation of NIH3T3 cells. This evidence provides support for the OS2 ClinGen/CGC/VICC evidence code for in vitro functional assays suggesting variant oncogenicity."	20147967	PubMed		"Smith et al., 2010, Br. J. Cancer"		3	accepted	7936	Somatic	2023-01-09 21:46:39 UTC	https://civicdb.org/links/evidence_items/7936	https://civicdb.org/links/molecular_profiles/881	FALSE	KRAS	3845	Q61H		chr12	25227341	25227341	T	G	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.183A>C,NP_004976.2:p.Gln61His,NC_000012.11:g.25380275T>G,ENST00000256078.4:c.183A>C"	2023-01-27 17:06:35 UTC	CA180922	177881	"RS17851045,GLN61HIS"	FALSE
FGFR3 S249C	624	Lung Squamous Cell Carcinoma	3907	Squamous cell lung carcinoma			Oncogenic	Supports	D	Oncogenicity	"NIH-3T3 cells with the FGFR3 S249C extracellular domain mutation demonstrated an increase in colony formation compared to wild-type in an anchorage-independence assay, which was counteracted by the treatment with AP24534 or BGJ398. Xenograft assays showed similar results with all transforming FGFR3 mutations leading to increased tumor growth compared to wild-type."	23786770	PubMed		"Liao et al., 2013, Cancer Res."		3	accepted	7941	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/7941	https://civicdb.org/links/molecular_profiles/624	FALSE	FGFR3	2261	S249C		chr4	1801841	1801841	C	G	ENST00000340107.4	75		missense_variant	"NC_000004.11:g.1803568C>G,NM_000142.4:c.746C>G,NP_000133.1:p.Ser249Cys,ENST00000340107.4c.746C>G"	2023-01-27 17:04:39 UTC	CA126380	16339	"SER249CYS,RS121913483"	FALSE
ABL1 BCR::ABL Y253H	999	Acute Lymphoblastic Leukemia	9952		Dasatinib		Predictive	Does Not Support	C	Resistance	"Prior to dasatinib treatment, one imatinib-resistant patient with acute lymphoblastic leukemia had the BCR-ABL1 fusion with Y253H and Y253H/Q252R variants in 9/10 and 1/10 clones, respectively. Clones were generated using peripheral blood RNA. The patient had complete response as best cytogenetic response and complete response as best hematologic response to dasatinib which were improved compared to responses in a patient with unmutated BCR-ABL1."	16775234	PubMed		"Talpaz et al., 2006, N. Engl. J. Med."	NCT00064233	3	accepted	7947	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/7947	https://civicdb.org/links/molecular_profiles/999	FALSE	ABL1	25	BCR::ABL Y253H		chr9	130862970	130862970	T	C	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.757T>C,NP_005148.2:p.Tyr253His,NC_000009.11:g.133738357T>C,ENST00000318560.5:c.757T>C"	2023-01-27 17:07:45 UTC	CA122584	12627	"RS121913461,Y272H,TYR272HIS,BCR-ABL TYR253HIS,BCR-ABL1 Y253H,BCR-ABL1 TYR253HIS,BCR-ABL Y253H"	FALSE
ABL1 BCR::ABL Y253H	999	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	C	Resistance	"Prior to dasatinib treatment, one imatinib-resistant patient with chronic myeloid leukemia in chronic phase had the BCR-ABL1 fusion with Y253H, M388L, and M388L/M244V variants in 4/10, 5/10, and 1/10 clones, respectively. Clones were generated using peripheral blood RNA. The patient had no response as best cytogenetic response and complete response as best hematologic response to dasatinib which were comparable to responses in patients with unmutated BCR-ABL1."	16775234	PubMed		"Talpaz et al., 2006, N. Engl. J. Med."	NCT00064233	3	accepted	7949	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/7949	https://civicdb.org/links/molecular_profiles/999	FALSE	ABL1	25	BCR::ABL Y253H		chr9	130862970	130862970	T	C	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.757T>C,NP_005148.2:p.Tyr253His,NC_000009.11:g.133738357T>C,ENST00000318560.5:c.757T>C"	2023-01-27 17:07:45 UTC	CA122584	12627	"RS121913461,Y272H,TYR272HIS,BCR-ABL TYR253HIS,BCR-ABL1 Y253H,BCR-ABL1 TYR253HIS,BCR-ABL Y253H"	FALSE
CTNNB1 Exon 3 Mutation	2761	Childhood Medulloblastoma	3869	Juvenile onset			Diagnostic	Supports	B	Positive	"A series of 72 pediatric medulloblastomas were evaluated for CTNNB1 mutations (by direct sequencing), copy number alterations (by array-comparative genomic hybridization), and beta-catenin protein expression (by immunohistochemistry). CTNNB1 mutations were detected in all six cases with extensive (>50% of the tumor cells) nuclear staining of beta-catenin. Remarkably, five out of these six tumors demonstrated a loss of chromosome 6, a cytogenetic event that is absent in CTNNB1-wildtype tumors (p <0.0001, Fishers exact test)."	19197950	PubMed		"Fattet et al., 2009, J. Pathol."		3	accepted	7965	Somatic	2023-01-09 21:47:03 UTC	https://civicdb.org/links/evidence_items/7965	https://civicdb.org/links/molecular_profiles/2761	FALSE	CTNNB1	1499	Exon 3 Mutation		chr3	41224526	41224753			ENST00000349496.5	75				2023-01-09 21:52:22 UTC				FALSE
CTNNB1 Exon 3 Mutation	2761	Childhood Medulloblastoma	3869	Juvenile onset			Diagnostic	Supports	B	Positive	"A total of 51 medulloblastomas from two independent cohorts (19 and 32 cases) were assessed for evidence of Wnt/Wg pathway activation, alongside a genome-wide analysis of associated copy-number aberrations. Cases displaying evidence of Wnt/Wg activation (CTNNB1 mutation and/or beta-catenin nuclear stabilization) were exclusively associated with a distinct genomic signature involving loss of an entire copy of chromosome 6 but few other aberrations. Loss of chromosome 6 was exclusively observed in Wnt/Wg-activated medulloblastoma, as evidenced by 3 of 3 cases with nuclear immune-positivity for b-catenin in the first cohort (19 cases). In the second cohort (32 cases), loss of chromosome 6 is observed in Wnt/Wg-active tumors and absence in Wnt/Wg-negative cases (8/13 vs. 0/19; p=0.0001)."	17172831	PubMed		"Clifford et al., 2006, Cell Cycle"		4	accepted	7967	Somatic	2023-01-09 21:47:03 UTC	https://civicdb.org/links/evidence_items/7967	https://civicdb.org/links/molecular_profiles/2761	FALSE	CTNNB1	1499	Exon 3 Mutation		chr3	41224526	41224753			ENST00000349496.5	75				2023-01-09 21:52:22 UTC				FALSE
CDKN2A Loss	550	Acute Lymphoblastic Leukemia	9952				Prognostic	Supports	B	Poor Outcome	"A total of thirteen studies including 2857 patients were combined in a meta-analysis. Combined HRs suggested that CDKN2A/B deletions were poor prognostic factors for both overall survival (OS) (HR = 2.15, 95% CI 1.82-2.54) and event-free survival (EFS)/disease-free survival (DFS)/relapse-free survival (RFS) (HR = 2.16, 95% CI 1.73-2.69)."	30592434	PubMed		"Zhang et al., 2019, Ann. Med."		4	accepted	7986	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/7986	https://civicdb.org/links/molecular_profiles/550	FALSE	CDKN2A	1029	Loss		chr9	21967753	21994624			ENST00000579755.1	75		loss_of_function_variant		2023-01-09 21:52:07 UTC		N/A		FALSE
NTRK3 ETV6::NTRK3	779	B-lymphoblastic Leukemia/lymphoma	80630	Late onset	Larotrectinib		Predictive	Supports	C	Sensitivity/Response	"Case report of a 61-year-old man with B-ALL. An initial analysis detected the ETV6-NTRK3 fusion and a NRASGly12Asp mutation. Initial therapies included chemotherapy and CAR-T infusion. Relapse 6 weeks after initial complete response to these therapies found a large increase in fusion transcripts and NTRK3 rearrangements were detectable by FISH in 50/50 blast nuclei whereas NRAS mutations were no longer detectable. The patient was treated with oral monotherapy larotrectinib (100mg twice per day). After 4 days on treatment peripheral blood blasts became undetectable; after 6 days on treatment lymphadenopathy and leukemia cutis resolved and a biopsy revealed an ablated bone marrow with only a few scattered blasts. The patient experienced clinical benefit with no apparent side effects during 42 days of larotrectinib treatment, however, patient eventually succumbed to multifocal angioinvasive aspergillosis because of insufficient recovery of normal hematopoiesis. Later sequencing of the NTRK3 kinase domain did not detect any larotrectinib resistance mutations (p.G623R, p.G696A)."	31905241	PubMed		"Nardi et al., 2020, Blood Adv"		3	accepted	7993	Somatic	2023-01-09 21:46:38 UTC	https://civicdb.org/links/evidence_items/7993	https://civicdb.org/links/molecular_profiles/779	FALSE	NTRK3	4916	ETV6::NTRK3		chr12	11649854	11869969			ENST00000396373.4	75	ENST00000394480.2	transcript_fusion		2023-01-09 21:52:09 UTC		N/A	ETV6-NTRK3	FALSE
NTRK3 ETV6::NTRK3	779	Acute Myeloid Leukemia	9119		Entrectinib		Predictive	Supports	D	Sensitivity/Response	"Two AML cell lines, IMS-M2 and M0-91, with the ETV6-NTRK3 fusion were treated with entrectinib.  Sequencing of these cell lines found no other driver mutations in 265 other cancer genes suggesting the ETV6-NTRK3 fusion is the oncogenic driver.  The IC50 for the IMS-M2 and M0-91 cell lines was 0.47 and 0.65 nmol/L, respectively.  Mouse xenografts treated with entrectinib at 10 or 30 mg/kg had complete remission while treatment with 3 mg/kg caused significant reduction in tumor growth.  Testing of the bone marrow of IMS-M2 xenografts after 3 weeks of treatment found no human CD45-positive cells in the 3, 10, and 30 mg/kg treatment groups; all vehicle treated mice had some human CD45-positive cells in their bone marrow.  Zebrafish xenotransplantation of M0-91 cells were sensitive to entrectinib treatment."	29237803	PubMed		"Smith et al., 2018, Mol. Cancer Ther."		3	accepted	7994	Somatic	2023-01-09 21:46:38 UTC	https://civicdb.org/links/evidence_items/7994	https://civicdb.org/links/molecular_profiles/779	FALSE	NTRK3	4916	ETV6::NTRK3		chr12	11649854	11869969			ENST00000396373.4	75	ENST00000394480.2	transcript_fusion		2023-01-09 21:52:09 UTC		N/A	ETV6-NTRK3	FALSE
ABL1 BCR::ABL F359V	866	Chronic Myeloid Leukemia	8552		Dasatinib		Predictive	Does Not Support	C	Resistance	"Prior to dasatinib treatment, one imatinib-resistant patients with chronic myeloid leukemia (CML) in myeloid blast crisis had the BCR-ABL1 fusion with F359V, F359V/Q252R, and L273M secondary variants in 9/12, 1/12, and 2/12 clones, respectively. Clones were generated using peripheral blood RNA. The patient had complete best cytogenetic and no evidence of leukemia best hematologic responses to dasatinib which were better outcomes in comparison to those seen in patients with unmutated BCR-ABL in this phase."	16775234	PubMed		"Talpaz et al., 2006, N. Engl. J. Med."	NCT00064233	1	accepted	8002	Somatic	2023-01-09 21:46:39 UTC	https://civicdb.org/links/evidence_items/8002	https://civicdb.org/links/molecular_profiles/866	FALSE	ABL1	25	BCR::ABL F359V		chr9	130873027	130873027	T	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.1075T>G,NP_005148.2:p.Phe359Val,NC_000009.11:g.133748414T>G,ENST00000318560.5:c.1075T>G"	2023-01-27 17:06:25 UTC	CA16602557	376096	"RS121913452,BCR-ABL F378V,BCR-ABL PHE359VAL,BCR-ABL1 F359V,BCR-ABL1 PHE359VAL,BCR-ABL F359V"	FALSE
PIK3CA E542K	103	Breast Cancer	1612		PI-103		Predictive	Supports	D	Resistance	"As part of a preclinical study, the efficacy of PI-103 was evaluated for several cell lines of breast cancer. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. KPL1 is a luminal-like breast cancer cell line harboring PIK3CA E542K, and it had an IC50 of 7.62uM."	20453058	PubMed		"O'Brien et al., 2010, Clin. Cancer Res."		1	accepted	8007	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/8007	https://civicdb.org/links/molecular_profiles/103	FALSE	PIK3CA	5290	E542K		chr3	179218294	179218294	G	A	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.1624G>A,NP_006209.2:p.Glu542Lys,ENST00000263967.3:c.1624G>A,NC_000003.11:g.178936082G>A"	2023-01-27 17:02:37 UTC	CA333572	31944	"GLU542LYS,RS121913273"	FALSE
PIK3CA E545K	104	Breast Cancer	1612		PI-103		Predictive	Supports	D	Resistance	"As part of a preclinical study, the efficacy of PI-103 was evaluated for several cell lines of breast cancer. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. MCF7 is a luminal-like breast cancer cell line harboring PIK3CA E545K, and it had an IC50 of 1.53uM."	20453058	PubMed		"O'Brien et al., 2010, Clin. Cancer Res."		1	accepted	8008	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/8008	https://civicdb.org/links/molecular_profiles/104	FALSE	PIK3CA	5290	E545K		chr3	179218303	179218303	G	A	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.1633G>A,NP_006209.2:p.Glu545Lys,ENST00000263967.3:c.1633G>A,NC_000003.11:g.178936091G>A"	2023-01-27 17:02:37 UTC	CA123334	13655	"GLU545LYS,RS104886003"	FALSE
PIK3CA H1047L	1125	Breast Cancer	1612		PI-103		Predictive	Supports	D	Sensitivity/Response	"As part of a preclinical study, the efficacy of PI-103 was evaluated for several cell lines of breast cancer. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. EFM-19 is a luminal-like breast cancer cell line harboring PIK3CA H1047L, and it had an IC50 of 0.16uM."	20453058	PubMed		"O'Brien et al., 2010, Clin. Cancer Res."		1	accepted	8009	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/8009	https://civicdb.org/links/molecular_profiles/1125	FALSE	PIK3CA	5290	H1047L		chr3	179234297	179234297	A	T	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.3140A>T,NP_006209.2:p.His1047Leu,NC_000003.11:g.178952085A>T,ENST00000263967.3:c.3140A>T"	2023-01-27 17:08:14 UTC	CA123328	13653	"RS121913279,HIS1047LEU"	FALSE
PIK3CA K111N	1208	Her2-receptor Positive Breast Cancer	60079		PI-103		Predictive	Supports	D	Sensitivity/Response	"As part of a preclinical study, the efficacy of PI-103 was evaluated for several cell lines of breast cancer. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. BT-474 is a HER2 receptor amplified breast cancer cell line harboring PIK3CA K111N, and it had an IC50 of 0.60uM."	20453058	PubMed		"O'Brien et al., 2010, Clin. Cancer Res."		1	accepted	8011	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/8011	https://civicdb.org/links/molecular_profiles/1208	FALSE	PIK3CA	5290	K111N		chr3	179199158	179199158	G	C	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.333G>C,NP_006209.2:p.Lys111Asn,NC_000003.11:g.178916946G>C,ENST00000263967.3:c.333G>C"	2023-01-27 17:08:48 UTC	CA16602917	376483	"LYS111ASN,RS1057519934"	FALSE
PTEN Loss	214	Her2-receptor Positive Breast Cancer	60079		PI-103		Predictive	Supports	D	Sensitivity/Response	"As part of a preclinical study, the efficacy of PI-103 was evaluated for several cell lines of breast cancer. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. HCC-1569 is a HER2 receptor amplified breast cancer cell line harboring PTEN Loss, and it had an IC50 of 0.40uM."	20453058	PubMed		"O'Brien et al., 2010, Clin. Cancer Res."		1	accepted	8012	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/8012	https://civicdb.org/links/molecular_profiles/214	FALSE	PTEN	5728	Loss		chr10	87863113	87971930			ENST00000371953.3	75		loss_of_function_variant	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
PIK3CA E542K	103	Her2-receptor Positive Breast Cancer	60079		PI3Ka/Di		Predictive	Supports	D	Sensitivity/Response	"As part of a preclinical study, the efficacy of PI3KA/Dia selective inhibitor for the  and  subunits of class I PI3Kwas evaluated for several cell lines of breast cancer. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. HCC-202 is a HER2 receptor amplified breast cancer cell line harboring PIK3CA E542K and it had an IC50 of 0.62uM."	20453058	PubMed		"O'Brien et al., 2010, Clin. Cancer Res."		1	accepted	8013	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/8013	https://civicdb.org/links/molecular_profiles/103	FALSE	PIK3CA	5290	E542K		chr3	179218294	179218294	G	A	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.1624G>A,NP_006209.2:p.Glu542Lys,ENST00000263967.3:c.1624G>A,NC_000003.11:g.178936082G>A"	2023-01-27 17:02:37 UTC	CA333572	31944	"GLU542LYS,RS121913273"	FALSE
PIK3CA E542K	103	Breast Cancer	1612		PI3Ka/Di		Predictive	Supports	D	Sensitivity/Response	"As part of a preclinical study, the efficacy of PI3KA/Dia selective inhibitor for the  (IC50 for p100: 3nM) and  (IC50 for p100: 20nM) subunits of class I PI3Kwas evaluated for several cell lines of breast cancer. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. KPL-1 is a luminal-type breast cancer cell line harboring PIK3CA E542K and it had an IC50 of 0.55uM."	20453058	PubMed		"O'Brien et al., 2010, Clin. Cancer Res."		1	accepted	8016	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/8016	https://civicdb.org/links/molecular_profiles/103	FALSE	PIK3CA	5290	E542K		chr3	179218294	179218294	G	A	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.1624G>A,NP_006209.2:p.Glu542Lys,ENST00000263967.3:c.1624G>A,NC_000003.11:g.178936082G>A"	2023-01-27 17:02:37 UTC	CA333572	31944	"GLU542LYS,RS121913273"	FALSE
PIK3CA E545K	104	Her2-receptor Positive Breast Cancer	60079		PI3Ka/Di		Predictive	Supports	D	Sensitivity/Response	"As part of a preclinical study, the efficacy of PI3KA/Dia selective inhibitor for the  (IC50 for p100: 3nM) and  (IC50 for p100: 20nM) subunits of class I PI3Kwas evaluated for several cell lines of breast cancer. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. MDA-MB-361 is a HER2 amplified breast cancer cell line harboring PIK3CA E545K and it had an IC50 of 0.16uM."	20453058	PubMed		"O'Brien et al., 2010, Clin. Cancer Res."		1	accepted	8017	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/8017	https://civicdb.org/links/molecular_profiles/104	FALSE	PIK3CA	5290	E545K		chr3	179218303	179218303	G	A	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.1633G>A,NP_006209.2:p.Glu545Lys,ENST00000263967.3:c.1633G>A,NC_000003.11:g.178936091G>A"	2023-01-27 17:02:37 UTC	CA123334	13655	"GLU545LYS,RS104886003"	FALSE
PIK3CA E545K	104	Breast Cancer	1612		PI3Ka/Di		Predictive	Supports	D	Sensitivity/Response	"As part of a preclinical study, the efficacy of PI3KA/Dia selective inhibitor for the  (IC50 for p100: 3nM) and  (IC50 for p100: 20nM) subunits of class I PI3Kwas evaluated for several cell lines of breast cancer. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. MCF7 is a luminal-type breast cancer cell line harboring PIK3CA E545K and it had an IC50 of 0.84uM."	20453058	PubMed		"O'Brien et al., 2010, Clin. Cancer Res."		1	accepted	8018	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/8018	https://civicdb.org/links/molecular_profiles/104	FALSE	PIK3CA	5290	E545K		chr3	179218303	179218303	G	A	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.1633G>A,NP_006209.2:p.Glu545Lys,ENST00000263967.3:c.1633G>A,NC_000003.11:g.178936091G>A"	2023-01-27 17:02:37 UTC	CA123334	13655	"GLU545LYS,RS104886003"	FALSE
PIK3CA H1047L	1125	Breast Cancer	1612		PI3Ka/Di		Predictive	Supports	D	Sensitivity/Response	"As part of a preclinical study, the efficacy of PI3KA/Dia selective inhibitor for the  and  subunits of class I PI3Kwas evaluated for several cell lines of breast cancer. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. EFM-19 is a luminal-type breast cancer cell line harboring PIK3CA H1047L and it had an IC50 of 0.17uM."	20453058	PubMed		"O'Brien et al., 2010, Clin. Cancer Res."		1	accepted	8019	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/8019	https://civicdb.org/links/molecular_profiles/1125	FALSE	PIK3CA	5290	H1047L		chr3	179234297	179234297	A	T	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.3140A>T,NP_006209.2:p.His1047Leu,NC_000003.11:g.178952085A>T,ENST00000263967.3:c.3140A>T"	2023-01-27 17:08:14 UTC	CA123328	13653	"RS121913279,HIS1047LEU"	FALSE
PIK3CA K111N	1208	Her2-receptor Positive Breast Cancer	60079		PI3Ka/Di		Predictive	Supports	D	Sensitivity/Response	"As part of a preclinical study, the efficacy of PI3KA/Dia selective inhibitor for the  and  subunits of class I PI3Kwas evaluated for several cell lines of breast cancer. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. BT-474 is a HER2 amplified breast cancer cell line harboring PIK3CA K111N and it had an IC50 of 0.52uM."	20453058	PubMed		"O'Brien et al., 2010, Clin. Cancer Res."		1	accepted	8020	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/8020	https://civicdb.org/links/molecular_profiles/1208	FALSE	PIK3CA	5290	K111N		chr3	179199158	179199158	G	C	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.333G>C,NP_006209.2:p.Lys111Asn,NC_000003.11:g.178916946G>C,ENST00000263967.3:c.333G>C"	2023-01-27 17:08:48 UTC	CA16602917	376483	"LYS111ASN,RS1057519934"	FALSE
PTEN Loss	214	Her2-receptor Positive Breast Cancer	60079		PI3Ka/Di		Predictive	Supports	D	Resistance	"As part of a preclinical study, the efficacy of PI3KA/Dia selective inhibitor for the  and  subunits of class I PI3Kwas evaluated for several cell lines of breast cancer. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. HCC-1569 is a HER2 amplified breast cancer cell line harboring PTEN loss and it had an IC50 of 2.82uM."	20453058	PubMed		"O'Brien et al., 2010, Clin. Cancer Res."		1	accepted	8022	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/8022	https://civicdb.org/links/molecular_profiles/214	FALSE	PTEN	5728	Loss		chr10	87863113	87971930			ENST00000371953.3	75		loss_of_function_variant	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
PIK3CA V955I	2870	Colorectal Cancer	9256		Cetuximab		Predictive	Supports	C	Resistance	"Among 32 colorectal cancer patients with acquired resistance (PFS > 12 weeks) to cetuximab, one was determined to have V955I mutation. V995I allelic fractions low at start of treatment but increased in frequency during treatment. PolyPhen-2 and SIFT functional predict folding changes to activation-loop domain. DiFi cells transfected with PIK3CA V955I plasmid assayed with western blot for pAKT (phosphorylated AKT) and pERK showed increased phosphorylation, which was not affected by the addition of cetuximab. PIK3CA V955I transfected cells also promoted cell viability in the presence of cetuximab."	28424201	PubMed		"Xu et al., 2017, Clin. Cancer Res."		4	accepted	8063	Somatic	2023-01-09 21:47:04 UTC	https://civicdb.org/links/evidence_items/8063	https://civicdb.org/links/molecular_profiles/2870	FALSE	PIK3CA	5290	V955I		chr3	179230303	179230303	G	A	ENST00000263967.3	75		missense_variant	"NC_000003.11:g.178948091G>A,NM_006218.2:c.2863G>A,ENST00000263967.3:c.2863G>A,NP_006209.2:p.Val955Ile"	2023-01-27 17:18:08 UTC	CA355281422	NONE FOUND	VAL955ILE	FALSE
ABL1 BCR::ABL E355G	1395	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	C	Resistance	"In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. An acute-phase patient achieved complete hematologic response but progressed to chronic phase with detection of the E355G mutation and then to accelerated phase. After allograft, this patient relapsed into chronic phase and the E355G mutation was again detected in 100% of transcripts."	12623848	PubMed		"Branford et al., 2003, Blood"		3	accepted	8090	Somatic	2023-01-09 21:46:45 UTC	https://civicdb.org/links/evidence_items/8090	https://civicdb.org/links/molecular_profiles/1395	FALSE	ABL1	25	BCR::ABL E355G		chr9	130873016	130873016	A	G	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.1064A>G,NP_005148.2:p.Glu355Gly,NC_000009.11:g.133748403A>G,ENST00000318560.5:c.1064A>G"	2023-01-27 17:09:47 UTC	CA16602556	376095	"RS121913450,BCR-ABL GLU355GLY,BCR-ABL1 E355G,BCR-ABL1 GLU355GLY,BCR-ABL E355G"	FALSE
ABL1 BCR::ABL F486S	1126	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	C	Resistance	"In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. An accelerate-phase patient had a complete cytogenetic response until progressing to major cytogenetic response (MCyR) at month 17 and then losing MCyR at month 24 despite dose escalation. At month 9, the F486S variant was found in ~25% of transcripts increasing to ~50% at month 16 and then remaining at a stable proportion."	12623848	PubMed		"Branford et al., 2003, Blood"		2	accepted	8091	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/8091	https://civicdb.org/links/molecular_profiles/1126	FALSE	ABL1	25	BCR::ABL F486S		chr9	130880101	130880101	T	C	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"ENST00000318560.5:c.1457T>C,NC_000009.11:g.133755488T>C,NM_005157.5:c.1457T>C,NP_005148.2:p.Phe486Ser"	2023-01-27 17:08:15 UTC	CA375251598	NONE FOUND	"BCR-ABL F505S,BCR-ABL PHE486SER,BCR-ABL1 PHE486SER,BCR-ABL1 F486S,BCR-ABL F486S"	FALSE
ABL1 BCR::ABL E459K	2243	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	C	Resistance	"In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. A late-chronic phase (CP) patient had a complete hematologic response but acquired resistance 7 months after treatment initiation. At month 11, the L248V, G250E, S417Y, and E459K variants were present in approximately 25, 25, 25, and 50% of transcripts, respectively. The patient died in accelerated phase at month 14."	12623848	PubMed		"Branford et al., 2003, Blood"		2	accepted	8092	Somatic	2023-01-09 21:46:58 UTC	https://civicdb.org/links/evidence_items/8092	https://civicdb.org/links/molecular_profiles/2243	FALSE	ABL1	25	BCR::ABL E459K		chr9	130878519	130878519	G	A	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"ENST00000318560.5:c.1375G>A,NC_000009.11:g.133753906G>A,NM_005157.5:c.1375G>A,NP_005148.2:p.Glu459Lys"	2023-01-27 17:16:31 UTC	CA200648598	NONE FOUND	"BCR-ABL GLU459LYS,RS1064156,BCR-ABL1 E459K,BCR-ABL1 GLU459LYS,BCR-ABL E459K"	FALSE
PIK3CA E545K	104	Cervical Cancer	4362		"Cisplatin,Radiation Ionizing Radiotherapy"	Sequential	Predictive	Supports	D	Resistance	Cervical cancer cell lines were treated with 1uM cisplatin followed by 1-6Gy ionizing radiation (IR). CaSki cells with PIK3CA E545K mutation show resistance to cisplatin plus IR when compared with HeLa or SiHa cells that express only wild-type PIK3CA. Transfection of HeLa cells with PIK3CA E545K resulted in resistance to cisplatin plus IR compared to cells expressing only wild-type PIK3CA or with PIK3CA depleted.	27489350	PubMed		"Arjumand et al., 2016, Oncotarget"		3	accepted	8112	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/8112	https://civicdb.org/links/molecular_profiles/104	FALSE	PIK3CA	5290	E545K		chr3	179218303	179218303	G	A	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.1633G>A,NP_006209.2:p.Glu545Lys,ENST00000263967.3:c.1633G>A,NC_000003.11:g.178936091G>A"	2023-01-27 17:02:37 UTC	CA123334	13655	"GLU545LYS,RS104886003"	FALSE
CCND1 Overexpression	20	Childhood B-cell Acute Lymphoblastic Leukemia	80146				Prognostic	Supports	B	Poor Outcome	"Reverse phase protein array (RPPA) revealed upregulation of CCND1 at diagnosis in B-ALL relapse patients (n=27) versus patients that did not relapse (n=86, p>.01). 5-year cumulative incidence of relapse analysis showed B-ALL patients within this cohort with CCND1 expression at diagnosis above the 75th percentile had a higher incidence of relapse versus those below the 75th percentile. CCND1 upregulation appears to impact relapse 500 days post initial diagnosis."	29408328	PubMed		"Bortolozzi et al., 2018, Biochem. Pharmacol."		2	accepted	8115	N/A	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/8115	https://civicdb.org/links/molecular_profiles/20	FALSE	CCND1	595	Overexpression		chr11	69641087	69654474			ENST00000227507.2	75		N/A	N/A	2023-01-09 21:52:04 UTC		N/A		FALSE
PML PML::RARA A216V	458	Acute Promyelocytic Leukemia	60318		Arsenic Trioxide		Predictive	Supports	B	Resistance	"Five point mutations were identified in the PML B2 domain of PML-RARA transcripts in 9 patients diagnosed with APL and resistant to arsenic. DNA from these 9 patients was cloned into flag-tagged pCag expression vectors. Immunoblotting analyses demonstrated that after the addition of arsenic, the A216V, S214L, and A216T mutants experienced no change in expression or degradation when compared to wild type cells, indicating that these mutants were not inhibited by arsenic and demonstrate resistance. Immunofluorescent measurements indicated arsenic treatment did not alter the nuclear localization pattern of mutants A216V, S214L, or A216T, but had an effect on the localization of other mutants as well as wild type cells."	26537301	PubMed		"Liu et al., 2016, Blood"		4	accepted	8177	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/8177	https://civicdb.org/links/molecular_profiles/458	FALSE	PML	5371	PML::RARA A216V	PML-RARa B2 Domain	chr15	74022872	74022872	C	T	ENST00000268058.3	75		"missense_variant,transcript_fusion"	NC_000015.9:g.74315213C>T	2023-01-27 17:03:52 UTC	CA393121894	NONE FOUND	PML-RARA A216V	FALSE
PIK3CA K111N	1208	Her2-receptor Positive Breast Cancer	60079		"Trastuzumab,Lapatinib,Dactolisib"	Substitutes	Predictive	Does Not Support	D	Resistance	"The BT-474 HER2 positive human breast cancer cell line, which is heterozygous for the PIK3CA K111N mutation, demonstrated strongly reduced colony formation when treated with lapatinib, trastuzumab or dactolisib alone or in combination, suggesting that K111N does not induce resistance to these drugs."	19010894	PubMed		"Eichhorn et al., 2008, Cancer Res."		2	accepted	8183	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/8183	https://civicdb.org/links/molecular_profiles/1208	FALSE	PIK3CA	5290	K111N		chr3	179199158	179199158	G	C	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.333G>C,NP_006209.2:p.Lys111Asn,NC_000003.11:g.178916946G>C,ENST00000263967.3:c.333G>C"	2023-01-27 17:08:48 UTC	CA16602917	376483	"LYS111ASN,RS1057519934"	FALSE
BCL2 G101V	2829	Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma	6354		Venetoclax		Predictive	Supports	C	Resistance	The effective cohort in this study was 11 CLL patients who were first treated with ibrutinib and then on progression treated with venetoclax until progression. Patient samples were sequenced before and after progression on venetoclax. The previously described BCL2 G101V mutation was observed in 1 patient at progression	32232486	PubMed		"Lucas et al., 2020, Blood"		2	accepted	8185	Somatic	2023-01-09 21:47:04 UTC	https://civicdb.org/links/evidence_items/8185	https://civicdb.org/links/molecular_profiles/2829	FALSE	BCL2	596	G101V		chr18	63318365	63318365	C	A	ENST00000398117.1	75		missense_variant	ENST00000398117.1:c.302G>T	2023-01-27 17:18:06 UTC	CA402632336	NONE FOUND	GLY101VAL	FALSE
MYOD1 L122R	2901	Spindle Cell Rhabdomyosarcoma	3260				Diagnostic	Supports	B	Positive	"This study evaluated forty-nine cases of rhabdomyosarcoma (RMS) (17 cases of alveolar RMS, 10 of embryonal RMS, 21 of spindle cell and sclerosing RMS, and a single case of a pleomorphic RMS) for MYOD1 (L122R), PIK3CA (H1047), and PIK3CA (E542/E545) variants. All 10 cases that were positive for the MYOD1 (L122R) variant were either the spindle cell (3/12) or the sclerosing (7/9) subtypes of RMS, while all 10 cases of the embryonal subtype of RMS were negative for the MYOD1 (L122R) variant. The study suggests that the MYOD1 L122R variant is specific for spindle cell and sclerosing subtype of RMS (where it was detected in 10/21 cases or 48%). The study also confirmed the positive relationship between the spindle cell and the sclerosing subtypes of RMS, which both can have the same molecular abnormality (MYOD1 L122R variant) and are now considered to be the same subtype. Finally, the study confirmed the negative correlation between the aforementioned subtypes with the embryonal subtype of rhabdomyosarcoma."	27562493	PubMed		"Rekhi et al., 2016, Mod. Pathol."		4	accepted	8193	Somatic	2023-01-09 21:47:05 UTC	https://civicdb.org/links/evidence_items/8193	https://civicdb.org/links/molecular_profiles/2901	FALSE	MYOD1	4654	L122R		chr11	17720147	17720147	T	G	ENST00000250003.3	75		missense_variant		2023-01-27 17:18:14 UTC	CA379790889	NONE FOUND	LEU122ARG	FALSE
MYOD1 L122R	2901	Spindle Cell Rhabdomyosarcoma	3260				Prognostic	Supports	B	Poor Outcome	"This study evaluated forty-nine cases of rhabdomyosarcoma (RMS) (17 cases of alveolar RMS, 10 of embryonal RMS, 21 of spindle cell and sclerosing RMS, and a single case of a pleomorphic RMS) for MYOD1 (L122R), PIK3CA (H1047), and PIK3CA (E542/E545) mutations. 10/49 cases were positive for the MYOD1 (L122R) variant, and all the positive cases belonged to either spindle cell or sclerosing RMS subtype. None of the embryonal RMS cases was positive for the MYOD1 L122R variant. All cases were treated with surgical resection and either adjuvant chemotherapy, adjuvant radiotherapy, or both. On patient follow-up, the alive-with-disease ratio was higher in the adult than in the pediatric population. Furthermore, the patients positive for MYOD1 mutation showed a higher number of disease-positive states on follow-up, while the patients negative for MYOD1 mutation showed a higher number of disease-free states on follow-up. This suggests that the MYOD1 L122R variant is associated with a more aggressive clinical course, although the difference did not reach statistical significance (P=0.34)."	27562493	PubMed		"Rekhi et al., 2016, Mod. Pathol."		2	accepted	8194	Somatic	2023-01-09 21:47:05 UTC	https://civicdb.org/links/evidence_items/8194	https://civicdb.org/links/molecular_profiles/2901	FALSE	MYOD1	4654	L122R		chr11	17720147	17720147	T	G	ENST00000250003.3	75		missense_variant		2023-01-27 17:18:14 UTC	CA379790889	NONE FOUND	LEU122ARG	FALSE
VHL Splice Site (c.340+1G>A)	1990	Von Hippel-Lindau Disease	14175	Retinal capillary hemangioma			Predisposing	N/A	C	N/A	"41 non-related patients with retinal capillary hemangioma presenting in the Benjamin Franklin University Eye Clinic between 1988 to 1999 Germany were evaluated for the presence of other VHL lesions. VHL disease was diagnosed in 33 patients based on the presence of other severe VHL lesions (spinal hemangioblastoma, cerebellar hemangioblastoma, renal cysts, pancreatic cyst, renal carcinoma, and pheochromocytoma), molecular genetic testing, and/or family history. VHL germline mutations were identified in 27 out of 29 VHL families screened with molecular genetics. One patient with VHL-related retinal angiomatosis was found to have germline splicing (c.340+1G>A) mutation in the VHL gene. The other VHL lesions harbored by this patient were not specified. ACMG evidence codes: 'PP4' because the patient's phenotype is highly specific for a disease with single genetic etiology."	11148816	PubMed		"Kreusel et al., 2000, Graefes Arch. Clin. Exp. Ophthalmol."		3	accepted	8215	Rare Germline	2023-01-09 21:46:55 UTC	https://civicdb.org/links/evidence_items/8215	https://civicdb.org/links/molecular_profiles/1990	FALSE	VHL	7428	Splice Site (c.340+1G>A)		chr3	10142188	10142188	G	A	ENST00000256474.2	75		splice_donor_variant	"NM_000551.3:c.340+1G>A,NC_000003.11:g.10183872G>A,ENST00000256474.2:c.340+1G>A"	2023-01-27 17:15:13 UTC	CA357042	223190	"C.340+1G>A,C.553+1G>A"	FALSE
VHL Q132P (c.395A>C)	2001	Von Hippel-Lindau Disease	14175	Retinal capillary hemangioma			Predisposing	N/A	C	N/A	"41 non-related patients with retinal capillary hemangioma presenting in the Benjamin Franklin University Eye Clinic between 1988 to 1999 Germany were evaluated for the presence of other VHL lesions. VHL disease was diagnosed in 33 patients based on the presence of other severe VHL lesions (spinal hemangioblastoma, cerebellar hemangioblastoma, renal cysts, pancreatic cyst, renal carcinoma, and pheochromocytoma), molecular genetic testing, and/or family history. VHL germline mutations were identified in 27 out of 29 VHL families screened with molecular genetics. One patient with VHL-related retinal capillary hemangioma was found to have germline missense VHL Q132P (c.395A>C). 3 other affected relatives were also evaluated. It's unclear which other VHL-related lesions were identified in this patient. ACMG evidence codes: 'PP4' because the patients' phenotypes and family history are highly specific for a disease with single genetic etiology."	11148816	PubMed		"Kreusel et al., 2000, Graefes Arch. Clin. Exp. Ophthalmol."		3	accepted	8218	Rare Germline	2023-01-09 21:46:55 UTC	https://civicdb.org/links/evidence_items/8218	https://civicdb.org/links/molecular_profiles/2001	FALSE	VHL	7428	Q132P (c.395A>C)		chr3	10146568	10146568	A	C	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.395A>C,NC_000003.11:g.10188252A>C,NM_000551.3:c.395A>C,NP_000542.1:p.Gln132Pro"	2023-01-27 17:15:20 UTC	CA351753958	496063	"C.395A>C,GLN132PRO,RS1347416980"	FALSE
VHL R161* (c.481C>T)	1680	Von Hippel-Lindau Disease	14175	Retinal capillary hemangioma			Predisposing	N/A	C	N/A	"41 non-related patients with retinal capillary hemangioma presenting in the Benjamin Franklin University Eye Clinic between 1988 to 1999 Germany were evaluated for the presence of other VHL lesions. VHL disease was diagnosed in 33 patients based on the presence of other severe VHL lesions (spinal hemangioblastoma, cerebellar hemangioblastoma, renal cysts, pancreatic cyst, renal carcinoma, and pheochromocytoma), molecular genetic testing, and/or family history. VHL germline mutations were identified in 27 out of 29 VHL families screened with molecular genetics. Two patients with VHL-related retinal capillary hemangioma were found to have germline missense VHL R161* (c.481C>T). 1 other affected relative was also evaluated for one of the patients. Other VHL lesions harbored by the patients were not specified. ACMG evidence codes: 'PP4' because the patients' phenotypes and family history are highly specific for a disease with single genetic etiology."	11148816	PubMed		"Kreusel et al., 2000, Graefes Arch. Clin. Exp. Ophthalmol."		3	accepted	8222	Rare Germline	2023-01-09 21:46:50 UTC	https://civicdb.org/links/evidence_items/8222	https://civicdb.org/links/molecular_profiles/1680	FALSE	VHL	7428	R161* (c.481C>T)		chr3	10149804	10149804	C	T	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.481C>T,NP_000542.1:p.Arg161Ter,NC_000003.11:g.10191488C>T,ENST00000256474.2:c.481C>T"	2023-01-27 17:12:16 UTC	CA020408	2217	"C.481C>T,R161X,ARG161TER,RS5030818"	FALSE
PDGFRB EBF1::PDGFRB	531	"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like"	80650		"Imatinib,Chemotherapy"	Combination	Predictive	Supports	C	Sensitivity/Response	"A 9 year old girl with B-lymphoblastic leukemia/ lymphoma (2016 WHO) relapsed 15 months post-maintenance chemotherapy. FISH and genomic analysis detected the EBF1-PDGFRB fusion (exon 11 with Exon14). The patient was treated with induction [fludarabine, idarubicin and cytarabine] therapy followed by additional chemotherapy (cyclophosphamide, adriamycin, vincristine, and dexamethasone followed by high-dose methotrexate and cytarabine) plus tyrosine kinase inhibitor (TKI, imatinib). Imatinib was stopped 10 days before cord blood transplant (CBT) with reduced intensity conditional and re-initiated on day 47 until 12 months post-transplant. The EBF1-PDGFRB transcript level measured using reverse-transcriptase polymerase chain reaction remained below detection limit (<2.5x102 copies/ microgram RNA) for 36 months post CBT. Furthermore, the patient maintained molecular remission during the 24 months post-CBT and the 12 months following completion of TKI administration, based on minimal residual disease (MRD) testing conducted every 6 months."	32068648	PubMed		"Sakurai et al., 2020, J. Pediatr. Hematol. Oncol."		3	accepted	8260	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/8260	https://civicdb.org/links/molecular_profiles/531	FALSE	PDGFRB	5159	EBF1::PDGFRB		chr5	158707979	159099761			ENST00000517373.1	75	ENST00000261799.4	transcript_fusion		2023-01-09 21:52:07 UTC		N/A	EBF1-PDGFRB	FALSE
PDGFRB EBF1::PDGFRB	531	"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like"	80650		"Imatinib,Chemotherapy"	Combination	Predictive	Supports	C	Sensitivity/Response	"A 9 year old girl with B-lymphoblastic leukemia/ lymphoma (2016 WHO) relapsed 15 months post-maintenance chemotherapy. FISH and genomic analysis detected the EBF1-PDGFRB fusion (exon 11 with Exon14). The patient was treated with induction [fludarabine, idarubicin and cytarabine] therapy followed by additional chemotherapy (cyclophosphamide, adriamycin, vincristine, and dexamethasone followed by high-dose methotrexate and cytarabine) plus tyrosine kinase inhibitor (TKI, imatinib). Imatinib was stopped 10 days before cord blood transplant (CBT) with reduced intensity conditional and re-initiated on day 47 until 12 months post-transplant. The EBF1-PDGFRB transcript level measured using reverse-transcriptase polymerase chain reaction remained below detection limit (<2.5x102 copies/ microgram RNA) for 36 months post CBT. Furthermore, the patient maintained molecular remission during the 24 months post-CBT and the 12 months following completion of TKI administration, based on minimal residual disease (MRD) testing conducted every 6 months."	32068648	PubMed		"Sakurai et al., 2020, J. Pediatr. Hematol. Oncol."		3	accepted	8260	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/8260	https://civicdb.org/links/molecular_profiles/531	FALSE	PDGFRB	5159	EBF1::PDGFRB		chr5	150113837	150125577			ENST00000517373.1	75	ENST00000261799.4	transcript_fusion		2023-01-09 21:52:07 UTC		N/A	EBF1-PDGFRB	FALSE
PIK3CA Amplification	212	Her2-receptor Positive Breast Cancer	60079		Trastuzumab		Predictive	Supports	D	Resistance	HER2-positive breast cancer cell line BT-474 (heterozygous for PIK3CA K111N) was retrovirally transduced with wildtype PIK3CA and treated with trastuzumab. PIK3CA amplification diminished the growth inhibitory effects of trastuzumab monotherapy in comparison to the inhibition of controls without PIK3CA overexpression.	19010894	PubMed		"Eichhorn et al., 2008, Cancer Res."		2	accepted	8267	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/8267	https://civicdb.org/links/molecular_profiles/212	FALSE	PIK3CA	5290	Amplification		chr3	179148523	179240093			ENST00000263967.3	75		transcript_amplification	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
PIK3CA Amplification	212	Her2-receptor Positive Breast Cancer	60079		"Lapatinib,Dactolisib"	Substitutes	Predictive	Supports	D	Sensitivity/Response	"This preclinical study tested the sensitivity of HER2-positive breast cancer cell line BT-474 (heterozygous for PIK3CA K111N) retrovirally transduced with wildtype PIK3CA to NVP-BEZ235 (dactolisib; a dual PI3K/mTOR inhibitor), lapatinib and trastuzumab. The study found that dactolisib and lapatinib were effective in inhibiting outgrowth of PIK3CA amplified cells as monotherapies. Combination therapy produced similar abrogation of growth for PIK3CA amplified cells. Additionally, growth of untransduced BT-474 control cells was prevented by treatment with any monotherapy or combination of lapatinib or dactolisib."	19010894	PubMed		"Eichhorn et al., 2008, Cancer Res."		2	accepted	8271	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/8271	https://civicdb.org/links/molecular_profiles/212	FALSE	PIK3CA	5290	Amplification		chr3	179148523	179240093			ENST00000263967.3	75		transcript_amplification	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
PTEN Loss	214	Her2-receptor Positive Breast Cancer	60079		Trastuzumab		Predictive	Supports	D	Resistance	"In a preclinical study, efficacy of trastuzumab monotherapy was evaluated in vitro against HER2 amplified human breast cancer cell line BT474 (heterozygous for PIK3CA K111N) with shRNA-induced PTEN expression loss. Authors found that loss of PTEN expression induced resistance to trastuzumab as assessed by colony formation assay compared to PTEN expressing control cells. Among trastuzumab treated cells, concentration of phosphorylated AKT (S473 and T308) was higher in PTEN knockdown cells compared to PTEN expression cells, by western blot."	19010894	PubMed		"Eichhorn et al., 2008, Cancer Res."		2	accepted	8274	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/8274	https://civicdb.org/links/molecular_profiles/214	FALSE	PTEN	5728	Loss		chr10	87863113	87971930			ENST00000371953.3	75		loss_of_function_variant	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
PTEN Loss	214	Her2-receptor Positive Breast Cancer	60079		Lapatinib		Predictive	Supports	D	Resistance	"In a preclinical study, efficacy of trastuzumab monotherapy was evaluated in vitro against HER2 amplified human breast cancer cell line BT474 (heterozygous for PIK3CA K111N) with shRNA-induced PTEN expression loss. Authors found that loss of PTEN expression induced resistance to lapatinib as assessed by colony formation assay compared to PTEN expressing control cells. Among lapatinib treated cells, concentration of phosphorylated AKT and ERK was substantially higher in cells with PTEN loss compared to PTEN expressing cells, by western blot. Furthermore, athymic nude mice injected with PTEN non-expressing BT474 cells had significantly higher mean tumor volume following lapatinib monotherapy compared to mice injected with PTEN expressing BT474. Authors conclude that loss of PTEN expression confers resistance to lapatinib in HER2 positive breast cancer cells."	19010894	PubMed		"Eichhorn et al., 2008, Cancer Res."		4	accepted	8275	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/8275	https://civicdb.org/links/molecular_profiles/214	FALSE	PTEN	5728	Loss		chr10	87863113	87971930			ENST00000371953.3	75		loss_of_function_variant	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
PTEN Loss	214	Her2-receptor Positive Breast Cancer	60079		Dactolisib		Predictive	Supports	D	Resistance	"In a preclinical study, efficacy of dactolisib monotherapy was evaluated in vitro against HER2 amplified human breast cancer cell line BT474 (heterozygous for PIK3CA K111N) with shRNA-induced PTEN expression loss. PTEN loss resulted in partial rescue from the strong dactolisib induced reduction of colony formation that was seen in BT474 cells with unperturbed PTEN. Among cells treated with dactolisib (100nmol/L), those lacking PTEN expression demonstrated higher concentrations of phosphorylated AKT (S473) and phosphorylated ERK compared to PTEN expressing cells."	19010894	PubMed		"Eichhorn et al., 2008, Cancer Res."		2	accepted	8276	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/8276	https://civicdb.org/links/molecular_profiles/214	FALSE	PTEN	5728	Loss		chr10	87863113	87971930			ENST00000371953.3	75		loss_of_function_variant	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
PTEN Loss	214	Her2-receptor Positive Breast Cancer	60079		"Lapatinib,Dactolisib"	Combination	Predictive	Does Not Support	D	Resistance	"In a preclinical study, efficacy of NVP-BEZ235 (dactolisib; a dual PI3K/mTOR inhibitor) and lapatinib combination therapy was evaluated in vitro against HER2 amplified breast cancer cell line BT474 (heterozygous for PIK3CA K111N) with shRNA-induced PTEN expression loss. Authors found that while PTEN loss induced resistance to lapatinib, combination with dactolisib produced an additive anti-proliferation effect. Western blot analysis of lapatinib and dactolisib combination treated cells showed a decrease in phosphorylated AKT and S6 relative to untreated and lapatinib treated control cells. Authors concluded that addition of dactolisib to lapatinib overcame PTEN loss induced lapatinib resistance in HER-2 positive breast cancer cells."	19010894	PubMed		"Eichhorn et al., 2008, Cancer Res."		2	accepted	8278	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/8278	https://civicdb.org/links/molecular_profiles/214	FALSE	PTEN	5728	Loss		chr10	87863113	87971930			ENST00000371953.3	75		loss_of_function_variant	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
PTEN Loss	214	Her2-receptor Positive Breast Cancer	60079		"Dactolisib,Trastuzumab"	Combination	Predictive	Does Not Support	D	Resistance	"In a preclinical study, efficacy of NVP-BEZ235 (dactolisib; a dual PI3K/mTOR inhibitor) and trastuzumab combination therapy was evaluated in vitro against HER2 amplified human breast cancer cell line BT474 (heterozygous for PIK3CA K111N) with shRNA-induced PTEN expression loss. Authors found that while PTEN loss induced resistance to trastuzumab, combination with dactolisib produced an additive anti-proliferation effect."	19010894	PubMed		"Eichhorn et al., 2008, Cancer Res."		2	accepted	8279	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/8279	https://civicdb.org/links/molecular_profiles/214	FALSE	PTEN	5728	Loss		chr10	87863113	87971930			ENST00000371953.3	75		loss_of_function_variant	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
MYOD1 L122R	2901	Spindle Cell Rhabdomyosarcoma	3260				Prognostic	Supports	B	Poor Outcome	"This study examined 17 cases of spindle cell/sclerosing rhabdomyosarcoma (SC/SRMS) for the presence of MYOD1 variants. 12 cases harbored a MYOD-1 mutation, of which 8 cases were homozygous for p.L122R, 3 were heterozygous for p.L122R, and 1 was heterozygous for a novel p.E118K variant. There was one case of predominantly spindle cell rhabdomyosarcoma with the MYOD-1 mutation that also contained a PIK3CA mutation. The case with both MYOD-1 and PIK3CA mutations consisted histologically of lipoblasts within focally myxoid stroma, thus demonstrating that the PIK3CA mutation was a secondary aberration while MYOD-1 was the primary neomorphic mutation. On clinical follow-up, seven of the MYOD-1 variant cases experienced local recurrences and/or metastatic disease. In a median of a 13.5 month follow-up, there was 1 patient who passed away, 8 patients who were alive with the disease, and 3 patients who were alive without the disease; there was no correlation with the type of treatment that the patients had received. This supports aggressive clinical course for SC/SRMS positive for MYOD-1 variants, regardless of the presence of a concurrent PIK3CA mutation."	30604891	PubMed		"Tsai et al., 2019, Histopathology"		3	accepted	8313	Somatic	2023-01-09 21:47:05 UTC	https://civicdb.org/links/evidence_items/8313	https://civicdb.org/links/molecular_profiles/2901	FALSE	MYOD1	4654	L122R		chr11	17720147	17720147	T	G	ENST00000250003.3	75		missense_variant		2023-01-27 17:18:14 UTC	CA379790889	NONE FOUND	LEU122ARG	FALSE
FGFR3 R248C	2276	Cancer	162		R3Mab		Predictive	Does Not Support	D	Resistance	"In this preclinical study, R3Mab (a monoclonal antibody specific to FGFR3) inhibited ligand-independent proliferation in Ba/F3 cells expressing common bladder carcinoma variant: FGFR3 R248C. Authors note that R3Mab similarly inhibited proliferation of FGF1 stimulated Ba/F3 cells expressing wildtype FGFR3 and bladder carcinoma cell lines expressing wildtype FGFR3 (RT112 and RT4). They conclude that R3Mab inhibits wildtype and mutant FGFR3 by inhibiting receptor dimerization."	19381019	PubMed		"Qing et al., 2009, J. Clin. Invest."		3	accepted	8321	Somatic	2023-01-09 21:46:58 UTC	https://civicdb.org/links/evidence_items/8321	https://civicdb.org/links/molecular_profiles/2276	FALSE	FGFR3	2261	R248C		chr4	1801837	1801837	C	T	ENST00000340107.4	75		missense_variant	"NC_000004.11:g.1803564C>T,NM_000142.4:c.742C>T,NP_000133.1:p.Arg248Cys,ENST00000340107.4:c.742C>T"	2023-01-27 17:16:36 UTC	CA126378	16332	"RS121913482,ARG248CYS"	FALSE
NTRK3 ETV6::NTRK3	779	Congenital Fibrosarcoma	8418				Diagnostic	Supports	A	Positive	"This is the first study showing the ETV6-NTRK3 gene fusion in congenital fibrosarcoma (CFS). Using cytogenetic and FISH analyses, a novel t(12;15)(p13;q25) rearrangement was identified in CFS cases (3 of 4, including 1 case likely presenting overgrowth of normal fibroblasts). Mapping of breakpoints and mRNA analysis revealed that the translocation gives rise to the ETV6-NTRK3 fusion transcript, consisting of the HLH dimerization domain of ETV6 fused to the kinase domain of NTRK3. This aberration was absent in adult-type fibrosarcoma (ATFS, 2 cases) and infantile fibromatosis (IFB, 15 cases). This is the first study describing the involvement of NTRK proteins in human oncogenesis and ETV6 gene fusion in solid tumors and proposing ETV6-NTRK3 as a diagnostic biomarker for CFS."	9462753	PubMed		"Knezevich et al., 1998, Nat. Genet."		4	accepted	8332	Somatic	2023-01-09 21:46:38 UTC	https://civicdb.org/links/evidence_items/8332	https://civicdb.org/links/molecular_profiles/779	FALSE	NTRK3	4916	ETV6::NTRK3		chr12	11649854	11869969			ENST00000396373.4	75	ENST00000394480.2	transcript_fusion		2023-01-09 21:52:09 UTC		N/A	ETV6-NTRK3	FALSE
TP53 Mutation	222	Medulloblastoma SHH Activated	80703				Prognostic	Supports	B	Poor Outcome	"In the childhood (?.3 years) SHH-MB subgroup, TP53 mutations (n=13) are associated with shorter progression-free survival (PFS) compared to the no mutation group (n=35) (HR, 3.47; 95% CI, 1.29 to 9.3; p<0.014)."	28545823	PubMed		"Schwalbe et al., 2017, Lancet Oncol."		5	accepted	8347	N/A	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/8347	https://civicdb.org/links/molecular_profiles/222	FALSE	TP53	7157	Mutation		chr17	7668402	7687538			ENST00000269305.4	75		protein_altering_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
PIK3CA H1047R	107	Colorectal Cancer	9256		"Akt Inhibitor MK2206,Vemurafenib"	Combination	Predictive	Supports	D	Sensitivity/Response	"Resistance of RKO cells, which harbor BRAF V600E (a known vemurafenib sensitizing mutation) and PIK3CA H1047R, to vemurafenib monotherapy was abrogated by the addition of pan-AKT inhibitor MK-2206 in vitro and in vivo. In vitro, vemurafenib and MK-2206 combination treatment of RKO cells resulted in substantially greater proliferation inhibition than either agent in isolation or untreated control cells (combination index score = 0.691 at EC50). Synergistic effects of vemurafenib and MK-2206 on RKO cells was confirmed in vivo via xenografts on an athymic mouse model, where mice treated with vemurafenib monotherapy experienced minimal tumor growth inhibition (25%), mice treated with MK-2206 monotherapy experienced modest tumor growth inhibition (37%), and mice treated with both achieved 87% tumor growth inhibition compared to vehicle treated control mice (P <0.001)."	22180495	PubMed		"Yang et al., 2012, Cancer Res."		3	accepted	8364	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/8364	https://civicdb.org/links/molecular_profiles/107	FALSE	PIK3CA	5290	H1047R		chr3	179234297	179234297	A	G	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.3140A>G,NP_006209.2:p.His1047Arg,ENST00000263967.3:c.3140A>G,NC_000003.11:g.178952085A>G"	2023-01-27 17:02:38 UTC	CA123326	13652	"HIS1047ARG,RS121913279"	FALSE
KRAS Exon 2 Mutation	75	Colorectal Cancer	9256		Vemurafenib		Predictive	Does Not Support	D	Sensitivity/Response	"This preclinical study examined vemurafenib efficacy on various colorectal cancer cell lines and in vivo via mouse xenograft experiments. Three cell lines harbored KRAS exon 2 mutations and wt BRAF: HCT 116 (KRAS G13D), SW620 (KRAS G12V), LOVO (KRAS G13D). Cell lines with KRAS exon 2 mutations were insensitive to vemurafenib compare those with wt KRAS and BRAF V600E (a known vemurafenib sensitizing mutation; HT29, Colo205, Colo471, LS411N; IC50s >10uM vs 0.025-0.35 uM). Nude, athymic mice with HCT116 or LoVo xenografts did not experience tumor inhibition when treated with vemurafenib."	22180495	PubMed		"Yang et al., 2012, Cancer Res."		3	accepted	8367	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/8367	https://civicdb.org/links/molecular_profiles/75	FALSE	KRAS	3845	Exon 2 Mutation		chr12	25245274	25245395			ENST00000256078.4	75		missense_variant		2023-01-09 21:52:04 UTC				FALSE
BCL2 F104I	2951	Follicular Lymphoma	50873		Venetoclax		Predictive	Supports	C	Resistance	This study identified BCL2 F104I mutation in one Follicular Lymphoma patient who developed resistance to venetoclax. Codon 104 is located at the venetoclax binding site of BCL2.	31234236	PubMed		"Blombery et al., 2019, Br. J. Haematol."		2	accepted	8375	Somatic	2023-01-09 21:47:05 UTC	https://civicdb.org/links/evidence_items/8375	https://civicdb.org/links/molecular_profiles/2951	FALSE	BCL2	596	F104I		chr18	63318357	63318357	A	T	ENST00000398117.1	75		missense_variant	"NC_000018.10:g.63318357A>T,NC_000018.9:g.60985590A>T,NM_000633.3:c.310T>A,NP_000624.2:p.Phe104Ile"	2023-01-27 17:18:21 UTC	CA402632320	NONE FOUND	PHE104ILE	FALSE
BCL2 F104I	2951	Follicular Lymphoma	50873		Venetoclax		Predictive	Supports	D	Resistance	Rs4;11 cells overexpressing BCL2 F104I exhibited >40-fold greater resistance to venetoclax after 24-hour treatment (IC50 not reached) than Rs4;11 overexpressing BCL2 WT cells as determined by cell titer glo measured cytotoxicity assays. Plasmon resonance protein binding assays demonstrated marked impairment (300 fold) of venetoclax binding to F104I (Ki=5.9 nM) veresus WT (Ki=.018nM). The authors pointed out reduction in binding was a similar magnitude as that observed previously with the BCL2 G101V and F104L.	31234236	PubMed		"Blombery et al., 2019, Br. J. Haematol."		3	accepted	8376	Somatic	2023-01-09 21:47:05 UTC	https://civicdb.org/links/evidence_items/8376	https://civicdb.org/links/molecular_profiles/2951	FALSE	BCL2	596	F104I		chr18	63318357	63318357	A	T	ENST00000398117.1	75		missense_variant	"NC_000018.10:g.63318357A>T,NC_000018.9:g.60985590A>T,NM_000633.3:c.310T>A,NP_000624.2:p.Phe104Ile"	2023-01-27 17:18:21 UTC	CA402632320	NONE FOUND	PHE104ILE	FALSE
VHL R167W (c.499C>T)	1623	Von Hippel-Lindau Disease	14175	Neoplasm of the adrenal gland			Predisposing	N/A	C	N/A	"The 10 1/2 year old patient was diagnosed with adrenal incidentaloma. He had intermittent abdominal pain for 6 months. His blood pressure was normal. A CT scan showed a left adrenal solid tumor (3x3cm) with no calcifications and I-MIBG scintiography was normal. He underwent an adrenalectomy. He was found to have a point mutation in exon 3 (Arg167Trp) but neither parent had this mutation. Brain and spinal cord MRI, ophthalmoscopy, whole body CT scan and ultrasonography of the testes, showed no abnormalities. ACMG evidence codes: 'PS2' since both parents are tested and do not present with the variant (de novo), 'PP4' since the patient presents phenotypes highly specific for a disease with a single genetic etiology."	16042317	PubMed		"Pozo et al., 2005, J. Pediatr. Endocrinol. Metab."		3	accepted	8469	Rare Germline	2023-01-09 21:46:48 UTC	https://civicdb.org/links/evidence_items/8469	https://civicdb.org/links/molecular_profiles/1623	FALSE	VHL	7428	R167W (c.499C>T)		chr3	10149822	10149822	C	T	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.499C>T,NP_000542.1:p.Arg167Trp,NC_000003.11:g.10191506C>T,ENST00000256474.2:c.499C>T"	2023-01-27 17:11:35 UTC	CA020450	2218	"C.499C>T,ARG167TRP,R126W,RS5030820"	FALSE
VHL L184P (c.551T>C)	1652	Von Hippel-Lindau Disease	14175	"Retinal vascular proliferation,Morphological central nervous system abnormality,Retinal capillary hemangioma,Abnormality of the pancreas,Abnormal renal morphology"			Predisposing	N/A	C	N/A	"Of 14 patients with retinal vascular proliferation and known family history of VHL disease, 12 patients were enrolled in an approved study protocol at the National Cancer Institute. 11 of these patients underwent genetic testing and were found to have mutations in the VHL gene. Patient 1 presented with retinal capillary hemangioblastoma (RCH) in her left eye at age the age of 13, which was treated with radiation. At age 62 years, this eye had good visual acuity (20/20) without any RCHs. As of her last visit, patient 1 also presented with abnormalities in the CNS, pancreas and kidney. She was found to have the L184P (c.551T>C) mutation. Her last known age was 69 years old. ACMG evidence codes: 'PP4' since the patient presents phenotypes highly specific for a disease with a single genetic etiology."	18474773	PubMed		"Wong et al., 2008, Arch. Ophthalmol."		3	accepted	8491	Rare Germline	2023-01-09 21:46:49 UTC	https://civicdb.org/links/evidence_items/8491	https://civicdb.org/links/molecular_profiles/1652	FALSE	VHL	7428	L184P (c.551T>C)		chr3	10149874	10149874	T	C	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.551T>C,NP_000542.1:p.Leu184Pro,NC_000003.11:g.10191558T>C,ENST00000256474.2:c.551T>C"	2023-01-27 17:11:54 UTC	CA16617792	419447	"C.551T>C,LEU184PRO,RS1064793878"	FALSE
ATM Mutation	178	Prostate Carcinoma	10286		Olaparib		Predictive	Supports	A	Sensitivity/Response	"This study (PMID 32343890) by de Bono et al, is a randomized, open-label, phase 3 trial evaluating the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving a new hormonal agent (e.g., enzalutamide or abiraterone).The study found that in men with mCRPC who had disease progression while receiving enzalutamide or abiraterone and who had somatic or germline deleterious alterations (irrespective of zygosity) in any of the following HRR genes (BRCA1, BRCA2, ATM, BRIP1, BARD1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, and RAD54L), olaparib was associated with longer progression-free survival and better measures of response and patient- reported end points than either enzalutamide or abiraterone (PFS HR 0.49 [0.38, 0.63]). For patients with ATM mutations specifically, PFS HR 1.04 [0.61-1.87]. Based on the results of this study, On May 19, 2020, the Food and Drug Administration approved olaparib (LYNPARZA) for adult patients with deleterious or suspected deleterious germline or somatic HRR gene-mutated mCRPC, who have progressed following prior treatment with enzalutamide or abiraterone."	32343890	PubMed		"de Bono et al., 2020, N. Engl. J. Med."	NCT02987543	4	accepted	8505	Unknown	2023-04-19 20:53:52 UTC	https://civicdb.org/links/evidence_items/8505	https://civicdb.org/links/molecular_profiles/178	FALSE	ATM	472	Mutation		chr11	108222832	108369099			ENST00000278616.4	75		"transcription_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
BRAF V600E	12	Colorectal Cancer	9256		"Vemurafenib,Cetuximab,Irinotecan"	Combination	Predictive	Supports	D	Sensitivity/Response	"This in vivo study examined the efficacy of various treatments on athymic nude mice xenografted with colorectal cancer HT29 cells, which harbor BRAF V600E. The authors sought to understand whether the addition of vemurafenib (a BRAF V600E inhibitor) to agents approved for the treatment of metastatic colorectal cancer increased therapeutic efficacy, and which combinations worked best. Irinotecan, cetuximab and vemurafenib combination therapy resulted in >100% tumor growth inhibition (TGI) and 250% increased lifespan (ILS) compared to vehicle treated controls. Of the ten treated mice, nine experienced partial response and one experienced a complete response. Compared to all doublet and single agent combinations of vemurafenib, irinotecan, and cetuximab, triplet therapy produced the best TGI and ILS (p<0.05, p <0.0001 for all comparisons)."	22180495	PubMed		"Yang et al., 2012, Cancer Res."		3	accepted	8506	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/8506	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
BRAF V600E	12	Colorectal Cancer	9256		"Erlotinib,Vemurafenib"	Combination	Predictive	Supports	D	Sensitivity/Response	"This in vivo study examined the efficacy of various treatments on athymic nude mice xenografted with colorectal cancer HT29 cells, which harbor BRAF V600E. The authors sought to understand whether the addition of vemurafenib (a BRAF V600E inhibitor) to agents approved for the treatment of metastatic colorectal cancer increased therapeutic efficacy, and which combinations worked best. Erlotinib and vemurafenib combination therapy resulted in >100% tumor growth inhibition (TGI) and 142% increased lifespan (ILS) compared to vehicle treated controls. Of ten treated mice, 9 experienced partial response. Doublet therapy produced a greater increase in TGI and ILS than either agent in isolation."	22180495	PubMed		"Yang et al., 2012, Cancer Res."		3	accepted	8507	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/8507	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
ABL1 BCR::ABL Y253F	2778	Chronic Myeloid Leukemia	8552		Imatinib		Predictive	Supports	C	Resistance	"In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. An AP patient had a complete hematologic response. After 9 months of therapy, the patient progressed returning to chronic phase. Concurrently, the Y253F and E255V variants were found in ~50% and ~50% of BCR-ABL1 transcripts, respectively. Imatinib was withdrawn at 10 months and the patient died 14 months after treatment initiation."	12623848	PubMed		"Branford et al., 2003, Blood"		3	accepted	8508	Somatic	2023-01-09 21:47:03 UTC	https://civicdb.org/links/evidence_items/8508	https://civicdb.org/links/molecular_profiles/2778	FALSE	ABL1	25	BCR::ABL Y253F		chr9	130862971	130862971	A	T	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"ENST00000318560.5:c.758A>T,NM_005157.5:c.758A>T,NP_005148.2:p.Tyr253Phe,NC_000009.11:g.133738358A>T"	2023-01-27 17:07:45 UTC	CA16602550	376089	"RS121913460,Y272F,TYR253PHE,TYR272PHE,BCR-ABL Y253F"	FALSE
FLT3 D835H	608	Acute Myeloid Leukemia	9119		Gilteritinib		Predictive	Supports	D	Sensitivity/Response	"Ba/F3 cells were transfected to express FLT3-ITD or FLT3 tyrosine kinase domain mutations. Immunoblots revealed gilteritinib IC50s of 2nM, 1.6nM, and 5nM for D835H, FLT3-ITD, and wildtype (cell line: SEMK2) cells, respectively."	27908881	PubMed		"Lee et al., 2017, Blood"		2	accepted	8517	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/8517	https://civicdb.org/links/molecular_profiles/608	FALSE	FLT3	2322	D835H		chr13	28018505	28018505	C	G	ENST00000241453.7	75		missense_variant	"NM_004119.2:c.2503G>C,NP_004110.2:p.Asp835His,ENST00000241453.7:c.2503G>C,NC_000013.10:g.28592642C>G"	2023-01-27 17:04:35 UTC	CA280208	16273	"ASP835HIS,RS121913488"	FALSE
FLT3 D835V	1276	Acute Myeloid Leukemia	9119		Gilteritinib		Predictive	Supports	D	Sensitivity/Response	"Ba/F3 cells were transfected to express FLT3-ITD or FLT3 tyrosine kinase domain mutations. Immunoblots revealed gilteritinib IC50s of 0.7nM, 1.6nM, and 5nM for D835H, FLT3-ITD, and wildtype (cell line: SEMK2) cells, respectively."	27908881	PubMed		"Lee et al., 2017, Blood"		2	accepted	8518	Somatic	2023-01-09 21:46:44 UTC	https://civicdb.org/links/evidence_items/8518	https://civicdb.org/links/molecular_profiles/1276	FALSE	FLT3	2322	D835V		chr13	28018504	28018504	T	A	ENST00000241453.7	75		missense_variant	"ENST00000241453.7:c.2504A>T,NM_004119.2:c.2504A>T,NP_004110.2:p.Asp835Val,NC_000013.10:g.28592641T>A"	2023-01-27 17:09:21 UTC	CA126344	16272	"RS121909646,ASP835VAL"	FALSE
PIK3CA Mutation	307	Her2-receptor Positive Breast Cancer	60079		Trastuzumab Emtansine		Predictive	Does Not Support	B	Resistance	"In a phase 3 clinical trial (NCT00829166), metastatic HER-2 amplified breast cancer patients whose tumors harbored PIK3CA mutations treated with ado-trastuzumab emtansine (T-DM1; n=40) were associated with similar median progression free survival (PFS), overall response rate (ORR), and overall survival (OS) compared to patients whose tumors harbored wild-type PIK3CA (n=93; PFS: 10.9 vs. 9.8 months, ORR: 50% vs 47.4%, OS not reached for either group). Of PIK3CA mutant HER2 patients, those treated with T-DM1 experienced a greater decrease in disease progression than those treated with standard of care capecitabine + lapatinib. In vitro, HER2 amplified cell lines with various PIK3CA mutations were associated with similar sensitivity to T-DM1 as PIK3CA wild-type cell line SK-BR-3. In mouse xenograft models of various PIK3CA mutations (H1047R, E545K, or K111N), tumor regression or complete tumor suppression >20 days was seen following a single dose >10mg/kg for all models."	26920887	PubMed		"Baselga et al., 2016, Clin. Cancer Res."		3	accepted	8536	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/8536	https://civicdb.org/links/molecular_profiles/307	FALSE	PIK3CA	5290	Mutation		chr3	179148523	179240093			ENST00000263967.3	75		"transcript_variant,gain_of_function_variant"		2023-01-09 21:52:06 UTC		N/A		FALSE
PIK3CA E545K	104	Her2-receptor Positive Breast Cancer	60079		Trastuzumab		Predictive	Supports	D	Resistance	"As part of a pre-clinical experiment, the efficacy of trastuzumab was evaluated against various HER2 positive cell lines. MCF7-neo/HER2 cell line harboring PIK3CA E545K was associated with resistance to trastuzumab compared to PIK3CA wild-type cell line SK-BR-3, at all concentrations tested (0-10 ug/mL)."	26920887	PubMed		"Baselga et al., 2016, Clin. Cancer Res."		2	accepted	8547	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/8547	https://civicdb.org/links/molecular_profiles/104	FALSE	PIK3CA	5290	E545K		chr3	179218303	179218303	G	A	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.1633G>A,NP_006209.2:p.Glu545Lys,ENST00000263967.3:c.1633G>A,NC_000003.11:g.178936091G>A"	2023-01-27 17:02:37 UTC	CA123334	13655	"GLU545LYS,RS104886003"	FALSE
PIK3CA H1047R	107	Her2-receptor Positive Breast Cancer	60079		Trastuzumab		Predictive	Supports	D	Resistance	"As part of a pre-clinical experiment, the efficacy of trastuzumab was evaluated against various HER2 positive cell lines. CC1954 and KPL-4 cell lines expressing PIK3CA H1047R were associated with resistance to trastuzumab compared to PIK3CA wild-type cell line SK-BR-3, at all concentrations tested (0-10 ug/mL)."	26920887	PubMed		"Baselga et al., 2016, Clin. Cancer Res."		2	accepted	8548	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/8548	https://civicdb.org/links/molecular_profiles/107	FALSE	PIK3CA	5290	H1047R		chr3	179234297	179234297	A	G	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.3140A>G,NP_006209.2:p.His1047Arg,ENST00000263967.3:c.3140A>G,NC_000003.11:g.178952085A>G"	2023-01-27 17:02:38 UTC	CA123326	13652	"HIS1047ARG,RS121913279"	FALSE
PIK3CA C420R	905	Her2-receptor Positive Breast Cancer	60079		Trastuzumab		Predictive	Supports	D	Resistance	"As part of a pre-clinical experiment, the efficacy of trastuzumab was evaluated against various HER2 positive cell lines. EFM-192A cell line expressing PIK3CA C420R was associated with resistance to trastuzumab compared to PIK3CA wild-type cell line SK-BR-3, at all concentrations tested (0-10 ug/mL)."	26920887	PubMed		"Baselga et al., 2016, Clin. Cancer Res."		2	accepted	8549	Somatic	2023-01-09 21:46:40 UTC	https://civicdb.org/links/evidence_items/8549	https://civicdb.org/links/molecular_profiles/905	FALSE	PIK3CA	5290	C420R		chr3	179210192	179210192	T	C	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.1258T>C,NP_006209.2:p.Cys420Arg,NC_000003.11:g.178927980T>C,ENST00000263967.3:c.1258T>C"	2023-01-27 17:06:45 UTC	CA180900	31945	"RS121913272,CYS420ARG"	FALSE
FGFR3 S249C	624	Transitional Cell Carcinoma	2671		Cisplatin		Predictive	Supports	D	Resistance	"Bladder cancer cell line 97-7 expressing endogenous FGFR3 S249C (IC50 44.6ug/ml) was resistant to cisplatin compared to two FGFR3 wild-type cell lines, 5637 (IC50 2.07ug/ml) and T24 (IC50 1.58ug/ml) as shown by a CCK-8 colorimetric cytotoxicity. Western blot revealed the ratio of phosphorylated-Akt/total Akt was higher in the 97-7 cells than in the wild-type cells, which was reversed by siRNA knockdown of FGFR3. Inhibition of Akt signaling by treatment with GDC0068 or LY294002 increased the cisplatin sensitivity of 97-7 cells (IC50 4.17ug/ml & 8.91ug/ml respectively)."	31316618	PubMed		"Xie et al., 2019, Exp Ther Med"		3	accepted	8642	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/8642	https://civicdb.org/links/molecular_profiles/624	FALSE	FGFR3	2261	S249C		chr4	1801841	1801841	C	G	ENST00000340107.4	75		missense_variant	"NC_000004.11:g.1803568C>G,NM_000142.4:c.746C>G,NP_000133.1:p.Ser249Cys,ENST00000340107.4c.746C>G"	2023-01-27 17:04:39 UTC	CA126380	16339	"SER249CYS,RS121913483"	FALSE
ALK Fusion	495	Lung Non-small Cell Carcinoma	3908		Alectinib		Predictive	Supports	A	Sensitivity/Response	"A randomized phase 3 trial (J-ALEX) of 207 Japanese ALK-positive NSCLC patients compared the efficacy and safety of alectinib (300mg twice daily) and crizotinib (250mg twice daily) in the first-line setting. When used as a first line treatment the median progression-free survival of the alectinib group was unreached (95% CI 17.5not estimated) versus 10.2 months (95% CI 8.3?3.9) in the crizotinib group (HR 0.31; 95% CI 0.17?57). In the overall intent to treat population, Alectinib showed improved median PFS (HR 0.34; 99.7% CI 0.17-0.71; stratified log-rank p<00001) with an unreached PFS (95% CI 20.3-not estimated) compared to 10.2 months (95% CI 8.2-12.0) for crizotinib. The safety profile of alectinib was favorable relative to crizotinib with fewer dose interruptions (29% vs 74%) and fewer grade 3-4 adverse events (26% vs 52%)."	28501140	PubMed		"Hida et al., 2017, Lancet"		5	accepted	8657	Somatic	2023-01-09 21:46:34 UTC	https://civicdb.org/links/evidence_items/8657	https://civicdb.org/links/molecular_profiles/495	FALSE	ALK	238	Fusion	ALK Fusion	chr2	29192774	29223528			ENST00000389048.3	75		transcript_fusion		2023-01-09 21:52:07 UTC		N/A	REARRANGEMENT	FALSE
PIK3CA K111N	1208	Her2-receptor Positive Breast Cancer	60079		Trastuzumab		Predictive	Does Not Support	D	Resistance	"As part of a pre-clinical experiment, the efficacy of trastuzumab was evaluated against various HER2 positive cell lines in cell viability assays. BT-474 cell line expressing PIK3CA K111N was associated with similar sensitivity to trastuzumab as PIK3CA wild-type cell line SK-BR-3, at all concentrations tested (0-10 ug/mL)."	26920887	PubMed		"Baselga et al., 2016, Clin. Cancer Res."		2	accepted	8662	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/8662	https://civicdb.org/links/molecular_profiles/1208	FALSE	PIK3CA	5290	K111N		chr3	179199158	179199158	G	C	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.333G>C,NP_006209.2:p.Lys111Asn,NC_000003.11:g.178916946G>C,ENST00000263967.3:c.333G>C"	2023-01-27 17:08:48 UTC	CA16602917	376483	"LYS111ASN,RS1057519934"	FALSE
PIK3CA I391M	1209	Her2-receptor Positive Breast Cancer	60079		Trastuzumab		Predictive	Does Not Support	D	Resistance	"As part of a pre-clinical experiment, the efficacy of trastuzumab was evaluated against various HER2 positive cell lines using cell viability assays. ZR-75-30 cell line expressing PIK3CA I391M was associated with similar sensitivity to trastuzumab compared to PIK3CA wild-type cell line SK-BR-3, at all concentrations tested (0-10 ug/mL)."	26920887	PubMed		"Baselga et al., 2016, Clin. Cancer Res."		2	accepted	8663	Somatic	2023-01-09 21:46:43 UTC	https://civicdb.org/links/evidence_items/8663	https://civicdb.org/links/molecular_profiles/1209	FALSE	PIK3CA	5290	I391M		chr3	179209622	179209622	A	G	ENST00000263967.3	75		missense_variant	"NM_006218.3:c.1173A>G,NP_006209.2:p.Ile391Met,NC_000003.11:g.178927410A>G,ENST00000263967.3:c.1173A>G"	2023-01-27 17:08:49 UTC	CA161490	135038	"ILE391MET,RS2230461"	FALSE
PIK3CA Mutation	307	Her2-receptor Positive Breast Cancer	60079		"Lapatinib,Capecitabine"	Combination	Predictive	Supports	B	Resistance	"In a phase 3 clinical trial (NCT00829166), metastatic HER-2 amplified breast cancer patients whose tumors harbored PIK3CA mutations treated with standard of care capecitabine and lapatinib combination chemotherapy (n=39) were associated with lower median progression free survival (PFS), overall response rate (ORR), and overall survival (OS) compared to patients whose tumors harbored wild-type PIK3CA (n=87; PFS: 4.3 vs. 6.4 months, ORR: 17.1% vs 39.7%, OS 17.3 vs 27.8 mo)."	26920887	PubMed		"Baselga et al., 2016, Clin. Cancer Res."		3	accepted	8705	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/8705	https://civicdb.org/links/molecular_profiles/307	FALSE	PIK3CA	5290	Mutation		chr3	179148523	179240093			ENST00000263967.3	75		"transcript_variant,gain_of_function_variant"		2023-01-09 21:52:06 UTC		N/A		FALSE
PTEN Loss	214	Her2-receptor Positive Breast Cancer	60079		Trastuzumab Emtansine		Predictive	Does Not Support	B	Resistance	"In a phase 3 clinical trial (NCT00829166), metastatic HER-2 amplified breast cancer patients whose tumors had decreased, slightly decreased, or absent PTEN expression (assessed by IHC) treated with ado-trastuzumab emtansine (T-DM1; n= 113) were associated with similar median progression free survival (PFS) compared to patients whose tumors expressed PTEN normally or greater (n=21; 8.4 vs. 9.9 months). In HER2 patients with decreased or absent PTEN expression, T-DM1 was a more effective treatment than standard of care capecitabine + lapatinib as measured by PFS, although no difference in OS was seen."	26920887	PubMed		"Baselga et al., 2016, Clin. Cancer Res."		3	accepted	8706	Somatic	2023-01-09 21:46:30 UTC	https://civicdb.org/links/evidence_items/8706	https://civicdb.org/links/molecular_profiles/214	FALSE	PTEN	5728	Loss		chr10	87863113	87971930			ENST00000371953.3	75		loss_of_function_variant	N/A	2023-01-09 21:52:05 UTC		N/A		FALSE
ERBB3 Overexpression	285	Her2-receptor Positive Breast Cancer	60079		Trastuzumab Emtansine		Predictive	Does Not Support	B	Resistance	"In a phase 3 clinical trial (NCT00829166), metastatic HER-2 amplified breast cancer patients whose tumors harbored higher than median levels of ERBB3 mRNA treated with ado-trastuzumab emtansine (T-DM1; n=210) were associated with similar median progression free survival (PFS) compared to patients whose tumors harbored the median or lower levels of ERBB3 mRNA (n=214; PFS: 9.8 vs. 9.3 months)."	26920887	PubMed		"Baselga et al., 2016, Clin. Cancer Res."		2	accepted	8707	N/A	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/8707	https://civicdb.org/links/molecular_profiles/285	FALSE	ERBB3	2065	Overexpression		chr12	56079861	56103505			ENST00000267101.3	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
VHL P86S (c.256C>T)	1778	Von Hippel-Lindau Disease	14175	"Renal cell carcinoma,Pheochromocytoma,Pancreatic endocrine tumor"			Predisposing	N/A	C	N/A	"Among patients prospectively followed by the members of the French VHL Study Group, 35 consecutive patients with well-documented endocrine pancreatic tumour (20 women and 15 men; median age,37 [21Y-57] years) were included. All 35 patients had VHL germline mutations and were assessed for the presence of pheochromocytoma and renal carcinoma in addition to pancreatic tumours. The presence of other phenotypes was not described. DNA was isolated from peripheral blood lymphocytes and mutations were detected using direct sequencing of the 3 exons of VHL and/or southern blot analysis. A germline missense mutation (c.256C>T) was found in 3 patients, 2 of which were related. Patient No 7 from family 503 presented with pancreatic endocrine tumour, pheochromocytoma, and renal carcinoma and patient No 15 from family 503 presented with pancreatic endocrine tumour. Their familial relation was not described. Patient No. 27 from family 11 also had the same mutation and presented with pancreatic endocrine tumour, pheochromocytoma, and renal carcinoma. The patients' phenotypes are highly specific to VHL disease (ACMG PP4)."	18580449	PubMed		"Corcos et al., 2008, Pancreas"		3	accepted	8771	Rare Germline	2023-01-09 21:46:52 UTC	https://civicdb.org/links/evidence_items/8771	https://civicdb.org/links/molecular_profiles/1778	FALSE	VHL	7428	P86S (c.256C>T)		chr3	10142103	10142103	C	T	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.256C>T,NP_000542.1:p.Pro86Ser,NC_000003.11:g.10183787C>T,ENST00000256474.2:c.256C>T"	2023-01-27 17:13:14 UTC	CA020180	178692	"C.256C>T,PRO86SER,RS398123481"	FALSE
KRAS Mutation	332	Ovary Serous Adenocarcinoma	5744		Binimetinib		Predictive	Supports	B	Sensitivity/Response	"Post hoc analysis of a randomized phase 3 trial (MILO/ENGOT-ov11) suggests a possible association between KRAS mutation and response to binimetinib in patients with pretreated (1-3 lines of prior chemotherapy) recurrent or persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum. Of 133 binimetinib-treated patients with individual response and molecular data, 46 harbored KRAS mutations. KRAS mutation status was significantly associated with local best response (P=0.004); 44% of patients with KRAS mutation versus 19% of patients with KRAS WT had CR or PR in the binimetinib arm. KRAS mutation was also associated with prolonged PFS in patients treated with binimetinib (median PFS: KRAS mutant: 17.7 months; KRAS wild-type (WT): 10.8 months; P = .006), but not in patients receiving standard chemotherapy (physicians' choice, median PFS: KRAS mutant: 14.6 months; KRAS WT: 11.5 months; P=.502)."	32822286	PubMed		"Monk et al., 2020, J Clin Oncol"	NCT01849874	3	accepted	8773	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/8773	https://civicdb.org/links/molecular_profiles/332	FALSE	KRAS	3845	Mutation		chr12	25209431	25250803			ENST00000256078.4	75		protein_altering_variant		2023-01-09 21:52:06 UTC		N/A		FALSE
KRAS Wildtype	3069	Colorectal Cancer	9256		Regorafenib		Predictive	Does Not Support	D	Resistance	"In an in vitro study, a human colon adenocarcinoma SW48 cell line expressing KRAS wildtype did not demonstrate resistance to regorafenib treatment (IC50: 114.28 nM) compared to SW48 cells expressing various common KRAS G12/G13 mutations. Resistance was determined by assessing cell viability. In vivo, SW48 cells were injected into NOD/SCID mice. Treatment with regorafenib did not lead to a significant delay of tumor growth, although KRAS wt mice trended toward better response than KRAS G12C expressing mice. IHC analysis of mouse tissue revealed more pronounced changes in markers of proliferation (Ki67), angiogenesis (CD31), and apoptosis (TUNEL) in KRAS wt mice treated with regorafenib compared to KRAS G12C mice whose tumors did not display changes in these markers. Authors concluded that KRAS wildtype was not resistant to regorafenib compared to other common KRAS G12/G13 mutations."	26161928	PubMed		"Camaj et al., 2015, Future Oncol"		2	accepted	8840	Somatic	2023-01-09 21:47:06 UTC	https://civicdb.org/links/evidence_items/8840	https://civicdb.org/links/molecular_profiles/3069	TRUE	KRAS	3845	Wildtype		chr12	25209431	25250803			ENST00000256078.4	75		wild_type		2023-01-09 21:52:24 UTC				FALSE
BCL2 G101V	2829	Chronic Lymphocytic Leukemia	1040		Venetoclax		Predictive	Supports	D	Resistance	"This study described the similar crystal structures of BCL-2 wild-type and G101V when bound to venetoclax. Steady state competition surface plasmon resonance experiments demonstrated a ~177 fold decrease in venetoclax affinity for G101V (Ki=3.2nM) versus WT (Ki=.018nM). Resistance is acquired by a knock-on effect in the P2 pocket of V101 on an adjacent residue, E152 as affinity for venetoclax was restored in BCL2 G101V through the introduction of an E152A mutation (Ki =.002nM). Additionally, BCL2 G101V maintains similar affinity for apoptotic BH3 peptides, which assists in the prevention of apoptosis."	31160589	PubMed		"Birkinshaw et al., 2019, Nat Commun"		3	accepted	8841	Somatic	2023-01-09 21:47:04 UTC	https://civicdb.org/links/evidence_items/8841	https://civicdb.org/links/molecular_profiles/2829	FALSE	BCL2	596	G101V		chr18	63318365	63318365	C	A	ENST00000398117.1	75		missense_variant	ENST00000398117.1:c.302G>T	2023-01-27 17:18:06 UTC	CA402632336	NONE FOUND	GLY101VAL	FALSE
BRCA2 Mutation	186	Prostate Cancer	10283		Olaparib		Predictive	Supports	A	Sensitivity/Response	"In phase 3 trial of 387 patients comparing olaparib and new hormonal agent (enzalutamide or abiraterone) therapy for patients with metastatic castration-resistant prostate cancer harboring homologous recombinant repair-related gene mutation detected from a tumor sample, olaparib showed significant PFS benefit in an ITT population (HR [95%CI] 0.49 [0.38, 0.63]). But in subgroup analysis, the treatment effect differed in each mutated genes. Among them, patients with BRCA2 mutations (olaparib: n=92, control: n=53) showed a prominent benefit of olaparib (PFS HR [95%CI] 0.21 [0.13, 0.32])."	32343890	PubMed		"de Bono et al., 2020, N. Engl. J. Med."	NCT02987543	5	accepted	8842	Unknown	2023-04-20 18:26:45 UTC	https://civicdb.org/links/evidence_items/8842	https://civicdb.org/links/molecular_profiles/186	FALSE	BRCA2	675	Mutation		chr13	32315474	32399210			ENST00000380152.3	75		"gene_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
MET Exon 14 Skipping Mutation	320	Lung Non-small Cell Carcinoma	3908		Capmatinib		Predictive	Supports	A	Sensitivity/Response	"In a phase 2 trial, a total of 364 patients with non-small cell lung cancer and MET alterations were assigned to cohorts based on prior treatment and type of MET alteration. A total of 97 patients, from cohorts 4 (pretreated) and 5b (no previous treatment), had MET exon 14 skipping mutations. Among pretreated (1-2 lines of therapy) patients with NSCLC with a MET exon 14 skipping mutation, overall response was observed in 41% (95% confidence interval [CI], 29 to 53) of 69 patients. Overall response rate was 68% (95% CI, 48 to 84) of 28 patients who had not received treatment previously. The median duration of response was 9.7 months (95% CI, 5.6 to 13.0) for cohort 4 and 12.6 months (95% CI, 5.6 to could not be estimated) for cohort 5b."	32877583	PubMed		"Wolf et al., 2020, N Engl J Med"	NCT02414139	4	accepted	8847	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/8847	https://civicdb.org/links/molecular_profiles/320	FALSE	MET	4233	Exon 14 Skipping Mutation		chr7	116771849	116771989			ENST00000318493.6	75		exon_loss_variant		2023-01-09 21:52:06 UTC		N/A		FALSE
FGFR3 S249C	624	Bladder Urothelial Carcinoma	4006				Oncogenic	Supports	D	Oncogenicity	"In contrast to controls (empty vector and FGFR3 wildtype overexpression NIH-3T3 cell lines), the stable transfection of NIH-3T3 cells with FGFR3b-S249C led to ligand-independent phosphorylation of FGFR3 and the acquisition of elongated, refractile spindle-shaped morphology like transformed cells. Using a thymidine incorporation assay, S249C expressing cells were shown to lose contact inhibition and grew 3x to 4x more rapidly than controls. Soft agar assays demonstrated increased colony formation and anchorage independent growth in S249C expressing cells versus controls. All nude mice subcutaneously injected with S249C cells rapidly formed tumors, but no tumors were observed in empty vector injected mice. The authors conclude mutated FGFR3b-S249C has transforming properties attributed to oncogenes."	16338952	PubMed		"Bernard-Pierrot et al., 2006, Carcinogenesis"		4	accepted	8853	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/8853	https://civicdb.org/links/molecular_profiles/624	FALSE	FGFR3	2261	S249C		chr4	1801841	1801841	C	G	ENST00000340107.4	75		missense_variant	"NC_000004.11:g.1803568C>G,NM_000142.4:c.746C>G,NP_000133.1:p.Ser249Cys,ENST00000340107.4c.746C>G"	2023-01-27 17:04:39 UTC	CA126380	16339	"SER249CYS,RS121913483"	FALSE
FGFR3 S249C	624						Functional	Supports	D	Gain of Function	"Forster Resonance Energy Transfer (FRET)-based technique acquired quantitative measurement of the effect of S249C on unliganded mutant FGFR3 dimer stability and structure in plasma membrane vesicles from CHO cells. Dimer stability was modestly increased by S249C (-3.7 kcal/mol) versus wildtype FGFR3 (-3.4 kcal/mol). Intrinsic FRET demonstrated S249C dimers were significantly closer together (45 A) than the wildtype dimer (53 A). The substitution of cysteine was expected to lead to strong covalent bonds, but the authors conclude their data demonstrates S249C does not induce constitutive FGFR3 dimerization, but induces dimer structural modifications."	25606676	PubMed		"Del Piccolo et al., 2015, Biophys J"		3	accepted	8854	N/A	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/8854	https://civicdb.org/links/molecular_profiles/624	FALSE	FGFR3	2261	S249C		chr4	1801841	1801841	C	G	ENST00000340107.4	75		missense_variant	"NC_000004.11:g.1803568C>G,NM_000142.4:c.746C>G,NP_000133.1:p.Ser249Cys,ENST00000340107.4c.746C>G"	2023-01-27 17:04:39 UTC	CA126380	16339	"SER249CYS,RS121913483"	FALSE
IDH1 Mutation	641	Acute Myeloid Leukemia	9119		Venetoclax		Predictive	Supports	C	Sensitivity/Response	"In this case series, 7 elderly patients with secondary AML (sAML) not eligible for intensive chemotherapy and refractory to HMA (including 1 patient with antecedent myeloproliferative neoplasm) were treated with venetoclax monotherapy. Three of 7 patients showed response. Of these: 2 patients achieved complete remission (1 of which was mutated for IDH2). One patient with IDH1 mutation showed PB blast clearance (derived anti-leukemic benefit) but BM was not performed to evaluate response. Venetoclax responders had high BCL? and/or BIM expression levels in myeloblasts, and the response was significantly associated with OS. BCL-2 and BIM expression levels can potentially identifer venetoclax responders."	30725494	PubMed		"Huemer et al., 2019, Eur J Haematol"		3	accepted	8856	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/8856	https://civicdb.org/links/molecular_profiles/641	FALSE	IDH1	3417	Mutation		chr2	208237079	208251551			ENST00000415913.1	75		transcript_variant		2023-01-09 21:52:08 UTC				FALSE
IDH2 Mutation	566	Acute Myeloid Leukemia	9119		Venetoclax		Predictive	Supports	C	Sensitivity/Response	"In this case series, 7 elderly patients with secondary AML (sAML) not eligible for intensive chemotherapy and refractory to HMA (including 1 patient with antecedent myeloproliferative neoplasm) were treated with venetoclax monotherapy. Three of 7 patients showed response. Of these: 2 patients achieved complete remission (1 of which was mutated for IDH2). One patient with IDH1 mutation showed PB blast clearance (derived anti-leukemic benefit) but BM was not performed to evaluate response. Venetoclax responders had high BCL? and/or BIM expression levels in myeloblasts, and the response was significantly associated with OS. BCL-2 and BIM expression levels can potentially identifer venetoclax responders."	30725494	PubMed		"Huemer et al., 2019, Eur J Haematol"		3	accepted	8857	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/8857	https://civicdb.org/links/molecular_profiles/566	FALSE	IDH2	3418	Mutation		chr15	90083045	90102504			ENST00000330062.3	75		protein_altering_variant		2023-01-09 21:52:07 UTC		N/A		FALSE
SMARCB1 Loss	3071	Atypical Teratoid Rhabdoid Tumor	2129				Diagnostic	Supports	B	Positive	"53 pediatric tumors consisting of 20 AT/RT, 10 PNET, and 23 other central nervous system tumors were classified using microscopic diagnosis, and then tested for expression of the SMARCB1 gene product INI1. In the 20 cases of AT/RT, expression of INI1 was not detected in tumor cells using the BAF47/SNF5 monoclonal INI1 antibody. Expression of INI1 was detected in 31 out of the 33 remaining tumors, with one Oligodendroglioma showing no expression, and one pituitary adenoma showing weak expression. The authors conclude that immunohistochemical staining with an INI1 antibody may be useful in confirming histologic diagnosis of AT/RT."	15105654	PubMed		"Judkins et al., 2004, Am J Surg Pathol"		4	accepted	8862	Somatic	2023-01-09 21:47:06 UTC	https://civicdb.org/links/evidence_items/8862	https://civicdb.org/links/molecular_profiles/3071	FALSE	SMARCB1	6598	Loss		chr22	23786963	23834516			ENST00000344921.6	75		loss_of_function_variant		2023-02-06 15:28:11 UTC		N/A		FALSE
ATRX Mutation	3072	Malignant Astrocytoma	3069	"Glioma,Brain neoplasm"			Diagnostic	Supports	B	Positive	"Whole exome sequencing of 4 low grade gliomas (LGGs) and targeted sequencing of 28 LGGs revealed ATRX variants are found exclusively in a subset of IDH1-mutant, 1p/19q intact LGGs. Paired blood samples were sequenced in all cases and mutations were confirmed by Sanger. IDH1mutation was found in 28/32 LGGs and of these 12 possessed an ATRX mutation (~43%). In all 12 ATRX mutated cases 1p/19q was intact (correlation p=0.0003), and ATRX variants were not observed in the 12 1p/19q codeleted cases. Additionally, multiplex mRNA profiling of 28 astrocytic tumors with subclasses assigned based on 75 gene signatures demonstrated ATRX mutations were associated (p=.0044) with the early progenitor-like subclass (EPL) (11/13 EPL cases harbored ATRX mutants)."	23104868	PubMed		"Kannan et al., 2012, Oncotarget"		3	accepted	8868	Somatic	2023-01-09 21:47:06 UTC	https://civicdb.org/links/evidence_items/8868	https://civicdb.org/links/molecular_profiles/3072	FALSE	ATRX	546	Mutation		chrX	77504878	77786216			ENST00000373344.5	75				2023-01-09 21:52:24 UTC		N/A		FALSE
FGFR3 Y373C	2277	Urinary Bladder Cancer	11054				Oncogenic	Supports	D	Oncogenicity	"The authors identified a bladder cancer cell line (MGH-U3) with a homozygous Y373C mutation. With immunoprecipitation (IP), and immunoblotting (IB) experiments, they demonstrated constitutional phosphorylation of FGFR3 Y373C protein. Then with SU5492 (an FGFR3 TKI) and FGFR3 siRNA, they also demonstrate that constitutional phosphorylation of the FGFR3 Y373C can be inhibited. Furthermore, cells treated with SU5492 (for inhibition) and FGFR3 siRNA (for depletion) of the mutant FGFR3 Y373C protein show inhibition of cell proliferation and anchorage independent growth. These studies suggest potentially oncogenic properties for the Y373C mutation."	16338952	PubMed		"Bernard-Pierrot et al., 2006, Carcinogenesis"		3	accepted	8881	Somatic	2023-01-11 21:00:40 UTC	https://civicdb.org/links/evidence_items/8881	https://civicdb.org/links/molecular_profiles/2277	FALSE	FGFR3	2261	Y373C		chr4	1804372	1804372	A	G	ENST00000440486.2	75		missense_variant	"NC_000004.11:g.1806099A>G,NM_001163213.1:c.1124A>G,NP_000133.1:p.Tyr373Cys,NM_000142.5:c.1118A>G,NC_000004.12:g.1804372A>G"	2023-01-27 17:16:37 UTC	CA341413	16342	"TYR375CYS,RS121913485,Y375C,TYR373CYS"	FALSE
NTRK1 LMNA::NTRK1 e11-e10	3094	Colorectal Cancer	9256		Entrectinib		Predictive	Supports	C	Sensitivity/Response	"After disease progression with no objective response to therapy, a 75-year-old with metastatic colorectal cancer that spread to the liver displayed elevated NTRK1 expression in both primary tumor and liver metastasis as measured by immunohistochemistry. FISH of the tumor and patient derived xenograft indicated NTRK1 involvement. 5RACE PCR discovered a novel LMNA-NTRK1 fusion (exon 11 & exon 10), which resulted in the expression of two different fusion splice transcripts (exons 1-10 with exons 10-16 and exons 1-11 with exons 10-16). Fusion expression of both transcripts was confirmed by western blot, and Sanger sequencing revealed the fusion to be in-frame with the kinase domain intact. After 4 weeks of treatment with Entrectinib, CT scan revealed the patient showed a partial response with a 30% reduction of target lesions. This response was maintained for 5 months."	26563355	PubMed		"Sartore-Bianchi et al., 2016, J Natl Cancer Inst"		4	accepted	8900	Somatic	2023-01-09 21:47:07 UTC	https://civicdb.org/links/evidence_items/8900	https://civicdb.org/links/molecular_profiles/3094	FALSE	NTRK1	4914	LMNA::NTRK1 e11-e10		chr1	156114707	156138757			ENST00000368300.4	75	ENST00000524377.1	transcript_fusion		2023-01-09 21:52:24 UTC			LMNA-NTRK1 E11-E10	FALSE
NTRK1 LMNA::NTRK1 e11-e10	3094	Colorectal Cancer	9256		Entrectinib		Predictive	Supports	C	Sensitivity/Response	"After disease progression with no objective response to therapy, a 75-year-old with metastatic colorectal cancer that spread to the liver displayed elevated NTRK1 expression in both primary tumor and liver metastasis as measured by immunohistochemistry. FISH of the tumor and patient derived xenograft indicated NTRK1 involvement. 5RACE PCR discovered a novel LMNA-NTRK1 fusion (exon 11 & exon 10), which resulted in the expression of two different fusion splice transcripts (exons 1-10 with exons 10-16 and exons 1-11 with exons 10-16). Fusion expression of both transcripts was confirmed by western blot, and Sanger sequencing revealed the fusion to be in-frame with the kinase domain intact. After 4 weeks of treatment with Entrectinib, CT scan revealed the patient showed a partial response with a 30% reduction of target lesions. This response was maintained for 5 months."	26563355	PubMed		"Sartore-Bianchi et al., 2016, J Natl Cancer Inst"		4	accepted	8900	Somatic	2023-01-09 21:47:07 UTC	https://civicdb.org/links/evidence_items/8900	https://civicdb.org/links/molecular_profiles/3094	FALSE	NTRK1	4914	LMNA::NTRK1 e11-e10		chr1	156874571	156881642			ENST00000368300.4	75	ENST00000524377.1	transcript_fusion		2023-01-09 21:52:24 UTC			LMNA-NTRK1 E11-E10	FALSE
NTRK1 LMNA::NTRK1 e11-e10	3094	Colorectal Cancer	9256				Oncogenic	Supports	D	Oncogenicity	"FISH of the tumor and patient derived xenograft of a 75-year-old with metastatic colorectal cancer that spread to the liver indicated NTRK1 involvement. 5RACE PCR discovered a novel LMNA-NTRK1 fusion (exon 10 & exon 10), which resulted in the expression of two different fusion splice transcripts (exons 1-10 with exons 10-16 and exons 1-11 with exons 10-16). Expression was confirmed by Western and Sanger sequencing revealed the fusion to be in-frame with the kinase domain intact. Western blot of the tumor also indicated constitutive activation of the fusion based on phosphorylation of the fusion. Additionally, downstream kinase targets (PLC1, AKT, and MAPK) were also phosphorylated in the tumor, similar to levels observed in the TPM3-NTRK1 containing KM12 colorectal cancer cell line."	26563355	PubMed		"Sartore-Bianchi et al., 2016, J Natl Cancer Inst"		1	accepted	8901	Somatic	2023-01-09 21:47:07 UTC	https://civicdb.org/links/evidence_items/8901	https://civicdb.org/links/molecular_profiles/3094	FALSE	NTRK1	4914	LMNA::NTRK1 e11-e10		chr1	156114707	156138757			ENST00000368300.4	75	ENST00000524377.1	transcript_fusion		2023-01-09 21:52:24 UTC			LMNA-NTRK1 E11-E10	FALSE
NTRK1 LMNA::NTRK1 e11-e10	3094	Colorectal Cancer	9256				Oncogenic	Supports	D	Oncogenicity	"FISH of the tumor and patient derived xenograft of a 75-year-old with metastatic colorectal cancer that spread to the liver indicated NTRK1 involvement. 5RACE PCR discovered a novel LMNA-NTRK1 fusion (exon 10 & exon 10), which resulted in the expression of two different fusion splice transcripts (exons 1-10 with exons 10-16 and exons 1-11 with exons 10-16). Expression was confirmed by Western and Sanger sequencing revealed the fusion to be in-frame with the kinase domain intact. Western blot of the tumor also indicated constitutive activation of the fusion based on phosphorylation of the fusion. Additionally, downstream kinase targets (PLC1, AKT, and MAPK) were also phosphorylated in the tumor, similar to levels observed in the TPM3-NTRK1 containing KM12 colorectal cancer cell line."	26563355	PubMed		"Sartore-Bianchi et al., 2016, J Natl Cancer Inst"		1	accepted	8901	Somatic	2023-01-09 21:47:07 UTC	https://civicdb.org/links/evidence_items/8901	https://civicdb.org/links/molecular_profiles/3094	FALSE	NTRK1	4914	LMNA::NTRK1 e11-e10		chr1	156874571	156881642			ENST00000368300.4	75	ENST00000524377.1	transcript_fusion		2023-01-09 21:52:24 UTC			LMNA-NTRK1 E11-E10	FALSE
NTRK3 ETV6::NTRK3	779	B-lymphoblastic Leukemia/lymphoma	80630	Juvenile onset	"Etoposide,Larotrectinib,Methotrexate"	Combination	Predictive	Supports	C	Sensitivity/Response	"All lines of conventional therapy (including allogeneic HSCT, blinatumomab, and CAR T cells) were inefficient for a 6-year-old boy with B-cell ALL and CNS infiltration (National Cancer Institute high risk). Conventional cytogenetics, FISH, and an Abbott break-apart probe of a peripheral blood sample collected at diagnosis revealed an unbalance translocation of the ETV6 locus. The patient relapsed twice and RNA sequencing of the initial diagnosis sample revealed a cytogenetically cryptic ETV6-NTRK3 fusion. Treatment with larotrectinib was initiated in combination with etoposide and methotrexate resulted in molecular remission in 66 days in bone marrow and CNS. A third relapse occurred 45 days after Larotrectinib was paused for CAR-T infusions. Larotrectinib was resumed with a dosage increase and again achieved sustained undetectable minimal residual disease after 66 days, and displayed molecular remission through 39 days. The authors suggest larotrectinib as a potential effective treatment for B-cell ALL patients harboring ETV6-NTRK3, including those with CNS infiltration."	31725893	PubMed		"Schewe et al., 2019, Blood Adv"		4	accepted	8917	Somatic	2023-01-09 21:46:38 UTC	https://civicdb.org/links/evidence_items/8917	https://civicdb.org/links/molecular_profiles/779	FALSE	NTRK3	4916	ETV6::NTRK3		chr12	11649854	11869969			ENST00000396373.4	75	ENST00000394480.2	transcript_fusion		2023-01-09 21:52:09 UTC		N/A	ETV6-NTRK3	FALSE
FLT3 ITD	55	Acute Myeloid Leukemia	9119		Gilteritinib		Predictive	Supports	D	Sensitivity/Response	"This study was designed to test the efficacy of FLT3 inhibitors in vitro against FLT3-ITD and other TKD variants clinically observed. IC50s were determined from immunoblots quantifying FLT3 phosphorylation in endogenous (Molm14) or ectopic expression FLT3-ITD cell lines (TF-1, Ba/F3) and the endogenous wildtype FLT3 SEMK2 cell line after gilteritinib treatment. IC50 values ranged from 1.4 to 1.8 nM in the three FLT3-ITD lines compared to 5nM in wildtype cells, suggesting increased sensitivity to the inhibitor. As measured by MTT assay, primary cultures from two AML patients with high allelic FLT3-ITD showed cytotoxic response to gilteritinib. Additionally, plasma taken from 3 patients receiving 120mg of gilteritinib daily was able to inhibit FLT3 phosphorylation in Molm14 cells."	27908881	PubMed		"Lee et al., 2017, Blood"		3	accepted	8923	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/8923	https://civicdb.org/links/molecular_profiles/55	FALSE	FLT3	2322	ITD		chr13	28034082	28034214			ENST00000241453.7	75		inframe_insertion		2023-01-09 21:52:04 UTC		16270		FALSE
FLT3 ITD	55	Acute Myeloid Leukemia	9119		Gilteritinib		Predictive	Supports	D	Sensitivity/Response	"In vitro gilteritinib treatment of MV4-11 and MOLM-13 cells, which endogenously express FLT3-ITD, showed growth suppression based on CellTiter GLO cytotoxicity assays with IC50 values of 0.92 nM (95% CI: 0.23?.6 nM) and 2.9 nM (95% CI: 1.4?.8 nM), respectively. Phosphorylation of FLT3 and its downstream targets were rapidly inhibited in MV4-11 cells relative to control treatment (DMSO). In a mouse xenograft model using MV4-11 cells, increasing doses of gilteritinib further reduced tumor size and growth and inhibited phosphorylation of both FLT3 and STAT5 (N=6, p<0.05 at lowest dose). Gilteritinib inhibited growth in vitro of Ba/F3 cells expressing FLT3-ITD (IC50 1.8nM; 95% CI: 1.0-3.0 nM) and in vivo as tumor maintenance or shrinkage was also significant in mice xenografted with Ba/F3 FLT3-ITD cells (N=5, p<0.001). Mice receiving an intra-bone marrow injection of MV4-11 cells labelled with luciferase began gilteritinib treatment on day 15. Gilteritinib treated mice showed significantly less widespread disease at day 42 than control counterparts (N=10, p<0.001) and significantly improved survival (log-rank, p<0.001)."	28516360	PubMed		"Mori et al., 2017, Invest New Drugs"		4	accepted	8924	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/8924	https://civicdb.org/links/molecular_profiles/55	FALSE	FLT3	2322	ITD		chr13	28034082	28034214			ENST00000241453.7	75		inframe_insertion		2023-01-09 21:52:04 UTC		16270		FALSE
NTRK3 ETV6::NTRK3	779	B-lymphoblastic Leukemia/lymphoma	80630	Juvenile onset	Larotrectinib		Predictive	Supports	D	Sensitivity/Response	"Conventional cytogenetics, FISH, and an Abbott break-apart probe of a peripheral blood sample collected at diagnosis of a 6-year-old boy with B-cell ALL and CNS infiltration (National Cancer Institute high risk) revealed an unbalance translocation of the ETV6 locus. RNA sequencing of detected a cytogenetically cryptic ETV6-NTRK3 fusion. Larotrectinib therapy achieved remission of the patients two separate relapses. Patient derived xenografts injected into mice and treated with Larotrectinib demonstrated significant reductions in spleen volume, blasts in spleen, and blast in bone marrow (p < .0001) compared to controls 25 days after injection. Larotrectinib treatment was effective regardless of the day of initiation post xenograft injection (1 day or 8 days after)."	31725893	PubMed		"Schewe et al., 2019, Blood Adv"		3	accepted	8930	Somatic	2023-01-09 21:46:38 UTC	https://civicdb.org/links/evidence_items/8930	https://civicdb.org/links/molecular_profiles/779	FALSE	NTRK3	4916	ETV6::NTRK3		chr12	11649854	11869969			ENST00000396373.4	75	ENST00000394480.2	transcript_fusion		2023-01-09 21:52:09 UTC		N/A	ETV6-NTRK3	FALSE
NTRK3 ETV6::NTRK3	779	B-lymphoblastic Leukemia/lymphoma	80630				Oncogenic	Supports	D	Oncogenicity	"The tyrosine kinase domain of NTRK3 was inserted into exon 6 of Etv6 to create conditional knock-in Etv6-NTRK3 mice . Expression was induced in pre-b cells during lymphoid development by CD19-Cre. Fusion expression in the bone marrow was confirmed by RT-PCR. Etv6-NTRK3/+ CD19-Cre mice developed aggressive lymphoid leukemia. Compared to controls (Etv6-NTRK3/+; n=28), Etv6-NTRK3/+ CD19-Cre mice (n=27) displayed worse overall survival (p<.0001), decreased body weight (p<.0001), increased spleen weights (p<.05), and increased circulating CD19+/B220+ cells (p=.0008). Over 60% of Etv6-NTRK3 CD19-Cre mice demonstrated extramedullary tumors and over 50% presented with central nervous system infiltration. RNA-sequencing indicated upregulation of the AP1 complex in the Etv6-NTRK3 CD19-Cre mice. The authors conclude this ETV6-NTRK3 Cre-19 mouse model mimics human B-ALL."	29880614	PubMed		"Roberts et al., 2018, Blood"		4	accepted	8931	Somatic	2023-01-09 21:46:38 UTC	https://civicdb.org/links/evidence_items/8931	https://civicdb.org/links/molecular_profiles/779	FALSE	NTRK3	4916	ETV6::NTRK3		chr12	11649854	11869969			ENST00000396373.4	75	ENST00000394480.2	transcript_fusion		2023-01-09 21:52:09 UTC		N/A	ETV6-NTRK3	FALSE
NRAS Q61K	423	Ovary Serous Adenocarcinoma	5744		Trametinib		Predictive	Supports	C	Sensitivity/Response	"One 56 year old female with advanced recurrent low grade serous ovarian cancer with NRAS Q61K mutation had a partial response to trametinib, with short follow-up."	30809568	PubMed		"Champer et al., 2019, Gynecol Oncol Rep"		2	accepted	8933	Somatic	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/8933	https://civicdb.org/links/molecular_profiles/423	FALSE	NRAS	4893	Q61K		chr1	114713909	114713909	G	T	ENST00000369535.4	75		missense_variant	"NM_002524.4:c.181C>A,NP_002515.1:p.Gln61Lys,NC_000001.10:g.115256530G>T,ENST00000369535.4:c.181C>A"	2023-01-27 17:03:41 UTC	CA151263	73058	"GLN61LYS,RS121913254"	FALSE
BRAF KIAA1549::BRAF	614	Childhood Pilocytic Astrocytoma	6812	Childhood onset	Selumetinib		Predictive	Supports	D	Sensitivity/Response	"In this preclinical experiment, a pediatric pilocytic astrocytoma cell line (DKFZ-BT66) harboring KIAA1549:BRAF fusion was generated from a two year old patient. Treatment with selumetinib resulted in a significant decrease in viable cell count at concentrations of 10M. Treatment with selumetinib fully abrogated ERK activation at concentrations of 0.1M for as long as 120 hours. Authors note that inhibitory effects were more pronounced in cells treated with trametinib than cells treated with selumetinib."	28002790	PubMed		"Selt et al., 2017, Oncotarget"		2	accepted	8943	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/8943	https://civicdb.org/links/molecular_profiles/614	FALSE	BRAF	673	KIAA1549::BRAF	BRAF Fusions	chr7	138861139	138981318			ENST00000440172.1	75	ENST00000288602.6	transcript_fusion		2023-01-09 21:52:08 UTC		N/A	KIAA1549-BRAF	FALSE
BRAF KIAA1549::BRAF	614	Childhood Pilocytic Astrocytoma	6812	Childhood onset	Selumetinib		Predictive	Supports	D	Sensitivity/Response	"In this preclinical experiment, a pediatric pilocytic astrocytoma cell line (DKFZ-BT66) harboring KIAA1549:BRAF fusion was generated from a two year old patient. Treatment with selumetinib resulted in a significant decrease in viable cell count at concentrations of 10M. Treatment with selumetinib fully abrogated ERK activation at concentrations of 0.1M for as long as 120 hours. Authors note that inhibitory effects were more pronounced in cells treated with trametinib than cells treated with selumetinib."	28002790	PubMed		"Selt et al., 2017, Oncotarget"		2	accepted	8943	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/8943	https://civicdb.org/links/molecular_profiles/614	FALSE	BRAF	673	KIAA1549::BRAF	BRAF Fusions	chr7	140734479	140787584			ENST00000440172.1	75	ENST00000288602.6	transcript_fusion		2023-01-09 21:52:08 UTC		N/A	KIAA1549-BRAF	FALSE
BRAF KIAA1549::BRAF	614	Childhood Pilocytic Astrocytoma	6812	Infantile onset	Trametinib		Predictive	Supports	D	Sensitivity/Response	"In this preclinical experiment, a pediatric pilocytic astrocytoma cell line (DKFZ-BT66) harboring KIAA1549:BRAF fusion was generated from a two year old patient. Treatment with trametinib resulted in a significant decrease in viable cell count at concentrations of 100nM and above. Trametinib also fully abrogated ERK activation at concentrations of 0.1M for as long as 120 hours. Authors note that inhibitory effects were more pronounced in cells treated with trametinib than cells treated with selumetinib."	28002790	PubMed		"Selt et al., 2017, Oncotarget"		3	accepted	8944	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/8944	https://civicdb.org/links/molecular_profiles/614	FALSE	BRAF	673	KIAA1549::BRAF	BRAF Fusions	chr7	138861139	138981318			ENST00000440172.1	75	ENST00000288602.6	transcript_fusion		2023-01-09 21:52:08 UTC		N/A	KIAA1549-BRAF	FALSE
BRAF KIAA1549::BRAF	614	Childhood Pilocytic Astrocytoma	6812	Infantile onset	Trametinib		Predictive	Supports	D	Sensitivity/Response	"In this preclinical experiment, a pediatric pilocytic astrocytoma cell line (DKFZ-BT66) harboring KIAA1549:BRAF fusion was generated from a two year old patient. Treatment with trametinib resulted in a significant decrease in viable cell count at concentrations of 100nM and above. Trametinib also fully abrogated ERK activation at concentrations of 0.1M for as long as 120 hours. Authors note that inhibitory effects were more pronounced in cells treated with trametinib than cells treated with selumetinib."	28002790	PubMed		"Selt et al., 2017, Oncotarget"		3	accepted	8944	Somatic	2023-01-09 21:46:36 UTC	https://civicdb.org/links/evidence_items/8944	https://civicdb.org/links/molecular_profiles/614	FALSE	BRAF	673	KIAA1549::BRAF	BRAF Fusions	chr7	140734479	140787584			ENST00000440172.1	75	ENST00000288602.6	transcript_fusion		2023-01-09 21:52:08 UTC		N/A	KIAA1549-BRAF	FALSE
TP53 Overexpression	1280	Renal Wilms' Tumor	5176				Prognostic	Supports	B	Poor Outcome	"44 archival FFPE samples from confirmed cases of Wilms tumor with mean age 3 years 2 months, and taken from the most histologically aggressive parts of each tumor, were stained with p53 monoclonal antibody and the corresponding patient clinical data was analyzed. 24 samples were p53 positive, and did not correlate with age or sex. All tumors with unfavorable histology were p53 positive, in contrast to 13 of 33 tumors with favorable histology, with weak-moderate p53 signal (p<0.001). 2 year overall survival rate was 89.2% in p53 negative, and 55.7% for p53 positive cases (P = .01), and mean survival was 46 months in p53 negative and 26 months in p53 positive cases (P = .02). Compared with p53 negative, tumors with week to moderate p53 signal had HR 3.75 (P = .05), and high signal had HR 8.61 (P = .01). No significant correlation was seen between tumor clinicopathological stage and p53 expression."	21525573	PubMed		"Jadali et al., 2011, Iran J Kidney Dis"		3	accepted	8945	N/A	2023-01-09 21:46:44 UTC	https://civicdb.org/links/evidence_items/8945	https://civicdb.org/links/molecular_profiles/1280	FALSE	TP53	7157	Overexpression		chr17	7668402	7687538			ENST00000269305.4	75		N/A		2023-01-09 21:52:12 UTC		N/A		FALSE
FGFR3 R248C	2276						Functional	Supports	D	Gain of Function	"In BaF3 cells, the R248C mutant was shown to fully activate FGFR3 with complete independence of the ligand presence. Ligand independent activation was determined by proliferation, phosphorylation, and dimerization assays (via the formation of an intermolecular disulfide bond)."	8640234	PubMed		"Naski et al., 1996, Nat Genet"		5	accepted	8946	Rare Germline	2023-01-09 21:46:58 UTC	https://civicdb.org/links/evidence_items/8946	https://civicdb.org/links/molecular_profiles/2276	FALSE	FGFR3	2261	R248C		chr4	1801837	1801837	C	T	ENST00000340107.4	75		missense_variant	"NC_000004.11:g.1803564C>T,NM_000142.4:c.742C>T,NP_000133.1:p.Arg248Cys,ENST00000340107.4:c.742C>T"	2023-01-27 17:16:36 UTC	CA126378	16332	"RS121913482,ARG248CYS"	FALSE
VHL R167W (c.499C>T)	1623	Von Hippel-Lindau Disease	14175	"Meningioma,Pheochromocytoma,Paraganglioma"			Predisposing	N/A	C	N/A	"Patients' records in a tertiary care university hospital were reviewed. Fifty-four Black patients presenting with phaeochromocytoma between 1980 and 2009 were included. Two patients had VHL syndrome (submitted for publication). The second diagnosis of VHL syndrome was made in the pregnant woman (Case 9) who had bilateral adrenal phaeochromocytomas. There were no clinical features of VHL syndrome; however, MRI showed a haemangioblastoma in the cervical spine. Genetic testing revealed a missense mutation (c.499C>T) in the VHL gene, located on chromosome 3p26-p25. Her 6-year-old daughter screened positive for the mutation; her 8-year-old son was negative. Both mother and daughter will be investigated further and monitored long-term. ACMG PP4"	21382250	PubMed		"Huddle, 2011, S Afr Med J"		3	accepted	8968	Rare Germline	2023-01-09 21:46:48 UTC	https://civicdb.org/links/evidence_items/8968	https://civicdb.org/links/molecular_profiles/1623	FALSE	VHL	7428	R167W (c.499C>T)		chr3	10149822	10149822	C	T	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.499C>T,NP_000542.1:p.Arg167Trp,NC_000003.11:g.10191506C>T,ENST00000256474.2:c.499C>T"	2023-01-27 17:11:35 UTC	CA020450	2218	"C.499C>T,ARG167TRP,R126W,RS5030820"	FALSE
VHL N78S (c.233A>G)	1631	Von Hippel-Lindau Disease	14175	"Hemangioblastoma,Retinal capillary hemangioma"			Predisposing	Supports	C	Predisposition	"Germline mutations in 45 unrelated Japanese VHL patients were determined from blood samples using PCR-SSCP or Southern blot analyses. The authors used the 284 codon ORF previously described by Latif et al., 1993 and this notation was converted to NP_000542. PCR-SSCP or Southern blot analyses of the DNA from family members showed that mutations were segregated with disease phenotype in VHL families, although this data was not shown. Data on the presence of retinal angioma, CNS hemangioblastoma (Hb) renal cell carcinoma (RCC), and pheochromocytoma was available. Case 9 had p.Asn78Ser (c.233A>G) mutation. Three members were affected, and all had retinal capillary hemangioma and CNS hemangioblastoma. Other demographics of the members were not described. ACMG PP4"	8634692	PubMed		"1995, Hum Mol Genet"		3	accepted	8970	Rare Germline	2023-02-18 21:12:24 UTC	https://civicdb.org/links/evidence_items/8970	https://civicdb.org/links/molecular_profiles/1631	FALSE	VHL	7428	N78S (c.233A>G)		chr3	10142080	10142080	A	G	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.233A>G,NP_000542.1:p.Asn78Ser,NC_000003.11:g.10183764A>G,ENST00000256474.2:c.233A>G"	2023-01-27 17:11:40 UTC	CA020131	93326	"C.233A>G,ASN78SER,RS5030804"	FALSE
VHL P81S (c.241C>T)	1713	Von Hippel-Lindau Disease	14175	Hemangioblastoma			Predisposing	Supports	C	Predisposition	"Germline mutations in 45 unrelated Japanese VHL patients were determined from blood samples using PCR-SSCP or Southern blot analyses. The authors used the 284 codon ORF previously described by Latif et al., 1993 and this notation was converted to NP_000542. PCR-SSCP or Southern blot analyses of the DNA from family members showed that mutations were segregared with disease phenotype in VHL families, although this data was not shown. Data on the presence of retinal angioma, CNS Hb, RCC, and Pheo was available. Case 37 had p.Pro81Ser mutation. One member was affected with hemangioblastoma. Other demographics of the members were not described. ACMG PP4"	8634692	PubMed		"1995, Hum Mol Genet"		3	accepted	8971	Rare Germline	2023-02-18 21:12:58 UTC	https://civicdb.org/links/evidence_items/8971	https://civicdb.org/links/molecular_profiles/1713	FALSE	VHL	7428	P81S (c.241C>T)		chr3	10142088	10142088	C	T	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.241C>T,NP_000542.1:p.Pro81Ser,NC_000003.11:g.10183772C>T,ENST00000256474.2:c.241C>T"	2023-01-27 17:12:39 UTC	CA020148	2233	"C.241C>T,PRO81SER,RS104893829"	FALSE
VHL P86S (c.256C>T)	1778	Von Hippel-Lindau Disease	14175	"Renal cell carcinoma,Hemangioblastoma,Retinal capillary hemangioma"			Predisposing	Supports	C	Predisposition	"Germline mutations in 45 unrelated Japanese VHL patients were determined from blood samples using PCR-SSCP or Southern blot analyses. The authors used the 284 codon ORF previously described by Latif et al., 1993 and this notation was converted to NP_000542. PCR-SSCP or Southern blot analyses of the DNA from family members showed that mutations were segregated with disease phenotype in VHL families, although this data was not shown. Data on the presence of retinal angioma, CNS hemangioblastoma (Hb) renal cell carcinoma (RCC), and pheochromocytoma was available. Case 42 had p.Pro86Ser (c.256C>T) mutation. One member was affected with hemangioblastoma, retinal angioma, and RCC. Other demographics of the members were not described. ACMG PP4"	8634692	PubMed		"1995, Hum Mol Genet"		3	accepted	8972	Rare Germline	2023-02-18 21:13:53 UTC	https://civicdb.org/links/evidence_items/8972	https://civicdb.org/links/molecular_profiles/1778	FALSE	VHL	7428	P86S (c.256C>T)		chr3	10142103	10142103	C	T	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.256C>T,NP_000542.1:p.Pro86Ser,NC_000003.11:g.10183787C>T,ENST00000256474.2:c.256C>T"	2023-01-27 17:13:14 UTC	CA020180	178692	"C.256C>T,PRO86SER,RS398123481"	FALSE
VHL P86L (c.257C>T)	1636	Von Hippel-Lindau Disease	14175	Retinal capillary hemangioma			Predisposing	Supports	C	Predisposition	"Germline mutations in 45 unrelated Japanese VHL patients were determined from blood samples using PCR-SSCP or Southern blot analyses. The authors used the 284 codon ORF previously described by Latif et al., 1993 and this notation was converted to NP_000542. PCR-SSCP or Southern blot analyses of the DNA from family members showed that mutations were segregated with disease phenotype in VHL families, although this data was not shown. Data on the presence of retinal angioma, CNS hemangioblastoma, renal cell carcinoma, and pheochromocytoma was available. Case 39 had p.Pro86Leu (c.257C>T) mutation. One member was affected with retinal angioma. Other demographics of the members were not described. ACMG PP4"	8634692	PubMed		"1995, Hum Mol Genet"		3	accepted	8973	Rare Germline	2023-02-18 21:14:12 UTC	https://civicdb.org/links/evidence_items/8973	https://civicdb.org/links/molecular_profiles/1636	FALSE	VHL	7428	P86L (c.257C>T)		chr3	10142104	10142104	C	T	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.257C>T,NP_000542.1:p.Pro86Leu,NC_000003.11:g.10183788C>T,ENST00000256474.2:c.257C>T"	2023-01-27 17:11:44 UTC	CA020186	182977	"C.257C>T,PRO86LEU,RS730882034"	FALSE
VHL W88S (c.263G>C)	1842	Von Hippel-Lindau Disease	14175	Renal cell carcinoma			Predisposing	Supports	C	Predisposition	"Germline mutations in 45 unrelated Japanese VHL patients were determined from blood samples using PCR-SSCP or Southern blot analyses. The authors used the 284 codon ORF previously described by Latif et al., 1993 and this notation was converted to NP_000542. PCR-SSCP or Southern blot analyses of the DNA from family members showed that mutations were segregared with disease phenotype in VHL families, although this data was not shown. Data on the presence of retinal angioma, CNS Hb, RCC, and Pheo was available. Case 8 had p.Trp88Ser mutation. 5 members were affected with renal cell carcinoma. Other demographics of the members were not described. ACMG PP4"	8634692	PubMed		"1995, Hum Mol Genet"		3	accepted	8985	Rare Germline	2023-02-18 21:16:21 UTC	https://civicdb.org/links/evidence_items/8985	https://civicdb.org/links/molecular_profiles/1842	FALSE	VHL	7428	W88S (c.263G>C)		chr3	10142110	10142110	G	C	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.263G>C,NP_000542.1:p.Trp88Ser,NC_000003.11:g.10183794G>C,ENST00000256474.2:c.263G>C"	2023-01-27 17:13:51 UTC	CA020202	2220	"C.263G>C,TRP88SER,RS119103277"	FALSE
VHL T157I (c.470C>T)	1621	Von Hippel-Lindau Disease	14175	"Renal cell carcinoma,Pheochromocytoma"			Predisposing	Supports	C	Predisposition	"Germline mutations in 45 unrelated Japanese VHL patients were determined from blood samples using PCR-SSCP or Southern blot analyses. The authors used the 284 codon ORF previously described by Latif et al., 1993 and this notation was converted to NP_000542. PCR-SSCP or Southern blot analyses of the DNA from family members showed that mutations were segregated with disease phenotype in VHL families, although this data was not shown. Data on the presence of retinal angioma, CNS hemangioblastoma, renal cell carcinoma (RCC), and pheochromocytoma was available. Case 45 had a p.Thr157Ile (c.470C>T) mutation. 2 members were affected: one had RCC and the other had RCC and pheochromocytoma (ACMG PP4). Other demographics of the members were not described."	8634692	PubMed		"1995, Hum Mol Genet"		3	accepted	8988	Rare Germline	2023-02-18 21:17:56 UTC	https://civicdb.org/links/evidence_items/8988	https://civicdb.org/links/molecular_profiles/1621	FALSE	VHL	7428	T157I (c.470C>T)		chr3	10149793	10149793	C	T	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.470C>T,NP_000542.1:p.Thr157Ile,NC_000003.11:g.10191477C>T,ENST00000256474.2:c.470C>T"	2023-01-27 17:11:33 UTC	CA357133	223223	"C.470C>T,THR157ILE,RS869025660"	FALSE
VHL C162R (c.484T>C)	1648	Von Hippel-Lindau Disease	14175	"Renal cell carcinoma,Retinal capillary hemangioma,Hemangioblastoma"			Predisposing	Supports	C	Predisposition	"Germline mutations in 45 unrelated Japanese VHL patients were determined from blood samples using PCR-SSCP or Southern blot analyses. The authors used the 284 codon ORF previously described by Latif et al., 1993 and this notation was converted to NP_000542. PCR-SSCP or Southern blot analyses of the DNA from family members showed that mutations were segregated with disease phenotype in VHL families, although this data was not shown. Data on the presence of retinal angioma, CNS hemangioblastoma (Hb) renal cell carcinoma (RCC), and pheochromocytoma was available. Case 4 had a C162R (c.484T>C) mutation. 2 members were affected: both had RCC, 1 had retinal angioma, and 1 had CNS Hb (ACMG PP4). We were not able to determine which member had more than one phenotype. Other demographics of the members were not described."	8634692	PubMed		"1995, Hum Mol Genet"		3	accepted	8989	Rare Germline	2023-02-18 21:18:11 UTC	https://civicdb.org/links/evidence_items/8989	https://civicdb.org/links/molecular_profiles/1648	FALSE	VHL	7428	C162R (c.484T>C)		chr3	10149807	10149807	T	C	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.484T>C,NM_000551.3:c.484T>C,NC_000003.11:g.10191491T>C,NP_000542.1:p.Cys162Arg"	2023-01-27 17:11:51 UTC	CA351756117	496067	"RS1553620313,C.484T>C,CYS162ARG"	FALSE
VHL C162Y (c.485G>A)	1700	Von Hippel-Lindau Disease	14175	Hemangioblastoma			Predisposing	Supports	C	Predisposition	"Germline mutations in 45 unrelated Japanese VHL patients were determined from blood samples using PCR-SSCP or Southern blot analyses. The authors used the 284 codon ORF previously described by Latif et al., 1993 and this notation was converted to NP_000542. PCR-SSCP or Southern blot analyses of the DNA from family members showed that mutations were segregated with disease phenotype in VHL families, although this data was not shown. Data on the presence of retinal angioma, CNS hemangioblastoma (Hb), renal cell carcinoma (RCC), and pheochromocytoma was available. Case 11 had a p.Cys162Tyr (c.485G>A) mutation. 4 members were affected with CNS Hb (ACMG PP4). Other demographics of the members were not described."	8634692	PubMed		"1995, Hum Mol Genet"		3	accepted	8990	Rare Germline	2023-02-18 21:18:31 UTC	https://civicdb.org/links/evidence_items/8990	https://civicdb.org/links/molecular_profiles/1700	FALSE	VHL	7428	C162Y (c.485G>A)		chr3	10149808	10149808	G	A	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.485G>A,NP_000542.1:p.Cys162Tyr,NC_000003.11:g.10191492G>A,ENST00000256474.2:c.485G>A"	2023-01-27 17:12:31 UTC	CA357010	223225	"C.485G>A,CYS162TYR,RS397516444"	FALSE
VHL R167W (c.499C>T)	1623	Von Hippel-Lindau Disease	14175	"Pheochromocytoma,Hemangioblastoma,Retinal capillary hemangioma,Renal cell carcinoma"			Predisposing	Supports	C	Predisposition	"Germline mutations in 45 unrelated Japanese VHL patients were determined from blood samples using PCR-SSCP or Southern blot analyses. The authors used the 284 codon ORF previously described by Latif et al., 1993 and this notation was converted to NP_000542. PCR-SSCP or Southern blot analyses of the DNA from family members showed that mutations were segregated with disease phenotype in VHL families, although this data was not shown. Data on the presence of retinal angioma, CNS hemangioblastoma (Hb) renal cell carcinoma (RCC), and pheochromocytoma was available. Case 19 had an R167W (c.499C>T) mutation. 1 member was affected with RCC, pheochromocytoma, CNS Hb, and retinal hemangioma (ACMG PP4). Other demographics of the members were not described."	8634692	PubMed		"1995, Hum Mol Genet"		3	accepted	8991	Rare Germline	2023-02-18 21:19:13 UTC	https://civicdb.org/links/evidence_items/8991	https://civicdb.org/links/molecular_profiles/1623	FALSE	VHL	7428	R167W (c.499C>T)		chr3	10149822	10149822	C	T	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.499C>T,NP_000542.1:p.Arg167Trp,NC_000003.11:g.10191506C>T,ENST00000256474.2:c.499C>T"	2023-01-27 17:11:35 UTC	CA020450	2218	"C.499C>T,ARG167TRP,R126W,RS5030820"	FALSE
VHL R167Q (c.500G>A)	1615	Von Hippel-Lindau Disease	14175	"Hemangioblastoma,Renal cell carcinoma,Retinal capillary hemangioma"			Predisposing	Supports	C	Predisposition	"Germline mutations in 45 unrelated Japanese VHL patients were determined from blood samples using PCR-SSCP or Southern blot analyses. The authors used the 284 codon ORF previously described by Latif et al., 1993 and this notation was converted to NP_000542. PCR-SSCP or Southern blot analyses of the DNA from family members showed that mutations were segregated with disease phenotype in VHL families, although this data was not shown. Data on the presence of retinal angioma, CNS hemangioblastoma (Hb), renal cell carcinoma (RCC), and pheochromocytoma was available. Case 5 had an R167Q (c.500G>A) mutation. 2 members were affected: 1 had RCC, CNS Hb, and retinal hemangioma. The other had CNS Hb and retinal hemangioma. (ACMG PP4) Other demographics of the members were not described."	8634692	PubMed		"1995, Hum Mol Genet"		3	accepted	8992	Rare Germline	2023-02-18 21:19:33 UTC	https://civicdb.org/links/evidence_items/8992	https://civicdb.org/links/molecular_profiles/1615	FALSE	VHL	7428	R167Q (c.500G>A)		chr3	10149823	10149823	G	A	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.500G>A,NP_000542.1:p.Arg167Gln,NC_000003.11:g.10191507G>A,ENST00000256474.2:c.500G>A"	2023-01-27 17:11:29 UTC	CA020454	2216	"C.500G>A,ARG167GLN,RS5030821"	FALSE
VHL L178P (c.533T>C)	1624	Von Hippel-Lindau Disease	14175	"Renal cell carcinoma,Retinal capillary hemangioma,Hemangioblastoma"			Predisposing	Supports	C	Predisposition	"Germline mutations in 45 unrelated Japanese VHL patients were determined from blood samples using PCR-SSCP or Southern blot analyses. The authors used the 284 codon ORF previously described by Latif et al., 1993 and this notation was converted to NP_000542. PCR-SSCP or Southern blot analyses of the DNA from family members showed that mutations were segregared with disease phenotype in VHL families, although this data was not shown. Data on the presence of retinal angioma, CNS Hb, RCC, and Pheo was available. Case 34 had an c.533T>C mutation. 1 member was affected with RCC, CNS Hb, and retinal hemangioma (ACMG PP4). Other demographics of the members were not described."	8634692	PubMed		"1995, Hum Mol Genet"		3	accepted	8993	Rare Germline	2023-02-18 21:20:10 UTC	https://civicdb.org/links/evidence_items/8993	https://civicdb.org/links/molecular_profiles/1624	FALSE	VHL	7428	L178P (c.533T>C)		chr3	10149856	10149856	T	C	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.533T>C,NM_000551.3:c.533T>C,NP_000542.1:p.Leu178Pro,NC_000003.11:g.10191540T>C"	2023-01-27 17:11:36 UTC	CA351756245	428795	"C.533T>C,LEU178PRO,RS5030822"	FALSE
VHL R120fs (c.358_359insAC)	3113	Von Hippel-Lindau Disease	14175	Renal cell carcinoma			Predisposing	Supports	C	Predisposition	"Germline mutations in 45 unrelated Japanese VHL patients were determined from blood samples using PCR-SSCP or Southern blot analyses. The authors used the 284 codon ORF previously described by Latif et al., 1993 and this notation was converted to NP_000542. PCR-SSCP or Southern blot analyses of the DNA from family members showed that mutations were segregated with disease phenotype in VHL families, although this data was not shown. Data on the presence of retinal angioma, CNS hemangioblastoma (Hb) renal cell carcinoma (RCC), and pheochromocytoma was available. Case 14 had p.Arg120fs ( c.358insAC) mutation. 2 members were affected with renal cell carcinoma (ACMG PP4). Other demographics of the members were not described."	8634692	PubMed		"1995, Hum Mol Genet"		3	accepted	8995	Rare Germline	2023-02-18 21:21:25 UTC	https://civicdb.org/links/evidence_items/8995	https://civicdb.org/links/molecular_profiles/3113	FALSE	VHL	7428	R120fs (c.358_359insAC)		chr3	10146531	10146532		AC	ENST00000256474.2	75		"frameshift_truncation,plus_2_frameshift_variant"	"NC_000003.12:g.10146531_10146532insAC,NC_000003.11:g.10188215_10188216insAC,NM_000551.3:c.358_359insAC,NP_000542.1:p.Arg120AsnfsTer?"	2023-01-27 17:18:35 UTC	CA2573106245	NONE FOUND	R120NFS*40	FALSE
VHL S80fs (c.239del)	2384	Von Hippel-Lindau Disease	14175	"Hemangioblastoma,Retinal capillary hemangioma"			Predisposing	Supports	C	Predisposition	"Germline mutations in 45 unrelated Japanese VHL patients were determined from blood samples using PCR-SSCP or Southern blot analyses. The authors used the 284 codon ORF previously described by Latif et al., 1993 and this notation was converted to NP_000542. PCR-SSCP or Southern blot analyses of the DNA from family members showed that mutations were segregated with disease phenotype in VHL families, although this data was not shown. Data on the presence of retinal angioma, CNS hemangioblastoma (Hb) renal cell carcinoma (RCC), and pheochromocytoma was available. Case 22 had p.Ser80fs (c.239del) mutation. One member was affected with retinal capillary hemangioma and hemangioblastoma (ACMG PP4). Other demographics of the members were not described."	8634692	PubMed		"1995, Hum Mol Genet"		3	accepted	8996	Rare Germline	2023-02-18 21:21:56 UTC	https://civicdb.org/links/evidence_items/8996	https://civicdb.org/links/molecular_profiles/2384	FALSE	VHL	7428	S80fs (c.239del)		chr3	10142086	10142086	G		ENST00000256474.2	75		"minus_1_frameshift_variant,frameshift_truncation"	"NP_000542.1:p.Ser80IlefsTer,ENST00000256474.2:c.239del,NC_000003.11:g.10183770del,NM_000551.3:c.239del"	2023-01-27 17:17:13 UTC	CA913189245	NONE FOUND	"C.239DELG,SER80ILEFS*79,S80IFS*79 (C.239DELG)"	FALSE
VHL L118P (c.353T>C)	1674	Von Hippel-Lindau Disease	14175	Renal cell carcinoma			Predisposing	Supports	C	Predisposition	"Germline mutations in 45 unrelated Japanese VHL patients were determined from blood samples using PCR-SSCP or Southern blot analyses. The authors reported a nucleotide deletion (i.e. 566T>C) which coincides with legacy variant nomenclature (AF010238.1) and was mapped to c.353T>C (NM_000551.3). PCR-SSCP or Southern blot analyses of the DNA from family members showed that mutations were segregated with disease phenotype in VHL families, although this data was not shown. Data on the presence of retinal angioma, CNS hemangioblastoma, renal cell carcinoma (RCC), and pheochromocytoma was available. Case 46 had p.Leu117Pro (c.353T>C) mutation. 1 member was affected with RCC. Other demographics of the members were not described."	8634692	PubMed		"1995, Hum Mol Genet"		3	accepted	8998	Rare Germline	2023-02-18 21:25:24 UTC	https://civicdb.org/links/evidence_items/8998	https://civicdb.org/links/molecular_profiles/1674	FALSE	VHL	7428	L118P (c.353T>C)		chr3	10146526	10146526	T	C	ENST00000256474.2	75		missense_variant	"ENST00000256474.2:c.353T>C,NM_000551.3:c.353T>C,NP_000542.1:p.Leu118Pro,NC_000003.11:g.10188210T>C"	2023-01-27 17:12:11 UTC	CA70049399	428807	"C.353T>C,LEU118PRO,RS5030830"	FALSE
VHL Q96_P97delinsH (c.288_290del)	3115	Von Hippel-Lindau Disease	14175	"Renal cell carcinoma,Retinal capillary hemangioma"			Predisposing	Supports	C	Predisposition	"Germline mutations in 45 unrelated Japanese VHL patients were determined from blood samples using PCR-SSCP or Southern blot analyses. The authors used the 284 codon ORF previously described by Latif et al., 1993 and this notation was converted to NP_000542. PCR-SSCP or Southern blot analyses of the DNA from family members showed that mutations were segregated with disease phenotype in VHL families, although this data was not shown. Data on the presence of retinal angioma, CNS hemangioblastoma, renal cell carcinoma (RCC), and pheochromocytoma was available. Case 25 had c.288delGCC mutation resulting in the replacement of Q96 and P97 with H. 1 member was affected with retinal angioma and RCC (ACMG PP4). Other demographics of the members were not described."	8634692	PubMed		"1995, Hum Mol Genet"		3	accepted	8999	Rare Germline	2023-02-18 21:29:52 UTC	https://civicdb.org/links/evidence_items/8999	https://civicdb.org/links/molecular_profiles/3115	FALSE	VHL	7428	Q96_P97delinsH (c.288_290del)		chr3	10142135	10142137	GCC		ENST00000256474.2	75		disruptive_inframe_deletion	"NC_000003.12:g.10142135_10142137del,NC_000003.11:g.10183819_10183821del,NM_000551.3:c.288_290del,NP_000542.1:p.Gln96_Pro97delinsHis"	2023-01-27 17:18:35 UTC	CA2573106244	NONE FOUND	"C.288DELGCC,C.288_290DELGCC"	FALSE
VHL G144fs (c.429_439del)	3116	Von Hippel-Lindau Disease	14175	"Hemangioblastoma,Retinal capillary hemangioma,Renal cell carcinoma"			Predisposing	Supports	C	Predisposition	"Germline mutations in 45 unrelated Japanese VHL patients were determined from blood samples using PCR-SSCP or Southern blot analyses. The authors used the 284 codon ORF previously described by Latif et al., 1993 and this notation was converted to NP_000542. PCR-SSCP or Southern blot analyses of the DNA from family members showed that mutations were segregated with disease phenotype in VHL families, although this data was not shown. Data on the presence of retinal angioma, CNS hemangioblastoma (Hb) renal cell carcinoma (RCC), and pheochromocytoma was available. Case 26 had a G144fs (c.429_439del) frameshift mutation. 1 member was affected with retinal angioma, CNS hemangioblastoma, and renal cell carcinoma (ACMG PP4). Other demographics of the members were not described."	8634692	PubMed		"1995, Hum Mol Genet"		3	accepted	9000	Rare Germline	2023-02-18 21:30:32 UTC	https://civicdb.org/links/evidence_items/9000	https://civicdb.org/links/molecular_profiles/3116	FALSE	VHL	7428	G144fs (c.429_439del)		chr3	10146601	10146611	ACGGACAGCCT		ENST00000256474.2	75		"frameshift_truncation,minus_2_frameshift_variant"	"NC_000003.12:g.10146602_10146612del,NC_000003.11:g.10188286_10188296del,NM_000551.3:c.429_439del,NP_000542.1:p.Gly144PhefsTer26"	2023-01-27 17:18:36 UTC	CA2573106247	NONE FOUND	"G144FFS*26,C.428_438DEL"	FALSE
BRAF V600E	12	Thyroid Gland Papillary Carcinoma	3969		Vemurafenib		Predictive	Supports	B	Sensitivity/Response	"Open label phase 2 (Clinical Level B) trial including patients from across the globe (USA, Italy, and the Netherlands) investigating sensitivity to Vemurafenib in patients that have BRAF V600E-positive papillary thyroid cancer that have become resistant to radioactive iodine (the standard treatment). There were 116 patients identified for this trial, 51 of which met the conditions to be included. These 51 patients were split into two cohorts: 1) patients that had never been treated with a multikinase inhibitor targeting VEGFR and 2) patients that have previously been treated with a VEGFR multikinase inhibitor. In cohort 1, ten of 26 patients had best overall response. Best overall response was defined as the proportion of patients with a complete or partial response, however these ten patients were all partial response. In the same cohort 1, nine had achieved stable disease control for at least six months; therefore, 19 patients achieved disease control (73% of total cohort 1, 95% CI 52-88). In cohort 2, of 23 eligible patients, six had a partial response as best overall response and six had stable disease control for at least six months; therefore, 12 patients achieved disease control. (55% of total cohort 2, 95% CI 32-76). The authors conclude that vemurafenib is a potential treatment option for late-stage BRAF V600E-positive papillary thyroid cancer for treatment in patients nave to a multikinase inhibitor (Cohort 1) and to patients that have been previously treated with a multikinase inhibitor (Cohort 2)."	27460442	PubMed		"Brose et al., 2016, Lancet Oncol."	NCT01286753	4	accepted	9018	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/9018	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
ABL1 NUP214::ABL1	2529	"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like"	80650	"Young adult onset,Juvenile onset"			Diagnostic	Supports	C	Positive	"Transcriptome and whole genome sequencing were performed on 15 cases of B-lymphoblastic leukemia/lymphoma (B-ALL) that were previously shown to have a BCR-ABL1-like (Ph-like) expression signature. Two cases were positive for the NUP214-ABL1 fusion, identified by RNA-seq analysis. In both cases the fusion was generated by a small copy number gain (duplication) in 9q34, with the breakpoints in the two partner genes. Considering the previously shown Ph-like expression signature in the studied cases, the results suggest association of the NUP214-ABL1 fusion in B-ALL with the Ph-like genetic subtype of the disease."	22897847	PubMed		"Roberts et al., 2012, Cancer Cell"		2	accepted	9074	Somatic	2023-01-09 21:47:01 UTC	https://civicdb.org/links/evidence_items/9074	https://civicdb.org/links/molecular_profiles/2529	FALSE	ABL1	25	NUP214::ABL1	ABL1 fusions in B-ALL	chr9	131125561	131230769			ENST00000359428.5	75	ENST00000318560.5	transcript_fusion		2023-01-09 21:52:20 UTC			NUP214-ABL1	FALSE
ABL1 NUP214::ABL1	2529	"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like"	80650	"Young adult onset,Juvenile onset"			Diagnostic	Supports	C	Positive	"Transcriptome and whole genome sequencing were performed on 15 cases of B-lymphoblastic leukemia/lymphoma (B-ALL) that were previously shown to have a BCR-ABL1-like (Ph-like) expression signature. Two cases were positive for the NUP214-ABL1 fusion, identified by RNA-seq analysis. In both cases the fusion was generated by a small copy number gain (duplication) in 9q34, with the breakpoints in the two partner genes. Considering the previously shown Ph-like expression signature in the studied cases, the results suggest association of the NUP214-ABL1 fusion in B-ALL with the Ph-like genetic subtype of the disease."	22897847	PubMed		"Roberts et al., 2012, Cancer Cell"		2	accepted	9074	Somatic	2023-01-09 21:47:01 UTC	https://civicdb.org/links/evidence_items/9074	https://civicdb.org/links/molecular_profiles/2529	FALSE	ABL1	25	NUP214::ABL1	ABL1 fusions in B-ALL	chr9	130854801	130887675			ENST00000359428.5	75	ENST00000318560.5	transcript_fusion		2023-01-09 21:52:20 UTC			NUP214-ABL1	FALSE
ABL1 RANBP2::ABL1	3137	"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like"	80650	"Young adult onset,Juvenile onset"			Diagnostic	Supports	C	Positive	"This study included 1389 cases of high-risk pediatric B-ALL, of which 284 were identified by TaqMan Low Density Array to have a Ph-like gene expression signature. RT-PCR or RNAseq performed on Ph-like, CRLF2 negative patients revealed 17 cases with ABL1 fusions with 8 different partner genes. There were three cases with the RANBP2-ABL1 fusion. Considering the previously confirmed Ph-like expression signature in the tested cases, the results suggest that the presence of the RANBP2-ABL1 fusion in B-ALL indicates the BCR-ABL1-like (Ph-like) subtype of the disease."	28408464	PubMed		"Reshmi et al., 2017, Blood"		2	accepted	9076	Somatic	2023-01-09 21:47:07 UTC	https://civicdb.org/links/evidence_items/9076	https://civicdb.org/links/molecular_profiles/3137	FALSE	ABL1	25	RANBP2::ABL1	ABL1 fusions in B-ALL	chr2	108719607	108758548			ENST00000283195	75	ENST00000372348.2	transcript_fusion		2023-01-09 21:52:24 UTC			RANBP2-ABL1	FALSE
ABL1 RANBP2::ABL1	3137	"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like"	80650	"Young adult onset,Juvenile onset"			Diagnostic	Supports	C	Positive	"This study included 1389 cases of high-risk pediatric B-ALL, of which 284 were identified by TaqMan Low Density Array to have a Ph-like gene expression signature. RT-PCR or RNAseq performed on Ph-like, CRLF2 negative patients revealed 17 cases with ABL1 fusions with 8 different partner genes. There were three cases with the RANBP2-ABL1 fusion. Considering the previously confirmed Ph-like expression signature in the tested cases, the results suggest that the presence of the RANBP2-ABL1 fusion in B-ALL indicates the BCR-ABL1-like (Ph-like) subtype of the disease."	28408464	PubMed		"Reshmi et al., 2017, Blood"		2	accepted	9076	Somatic	2023-01-09 21:47:07 UTC	https://civicdb.org/links/evidence_items/9076	https://civicdb.org/links/molecular_profiles/3137	FALSE	ABL1	25	RANBP2::ABL1	ABL1 fusions in B-ALL	chr9	130854064	130887675			ENST00000283195	75	ENST00000372348.2	transcript_fusion		2023-01-09 21:52:24 UTC			RANBP2-ABL1	FALSE
ABL1 ZMIZ1::ABL1	3138	"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like"	80650	"Juvenile onset,Young adult onset"			Diagnostic	Supports	C	Positive	"This study included 1389 cases of high-risk pediatric B-ALL, of which 284 were identified by TaqMan Low Density Array to have a BCR-ABL1-like (Ph-like) gene expression signature. RT-PCR or RNAseq performed on Ph-like, CRLF2 negative patients revealed 17 cases with ABL1 fusions with 8 different partner genes. There were three cases with the ZMIZ1-ABL1 fusion. Considering the previously confirmed Ph-like expression signature in the tested cases, the results suggest that the presence of the ZMIZ1-ABL1 fusion in B-ALL indicates the BCR-ABL1-like (Ph-like) subtype of the disease."	28408464	PubMed		"Reshmi et al., 2017, Blood"		2	accepted	9077	Somatic	2023-01-09 21:47:07 UTC	https://civicdb.org/links/evidence_items/9077	https://civicdb.org/links/molecular_profiles/3138	FALSE	ABL1	25	ZMIZ1::ABL1	ABL1 fusions in B-ALL	chr10	79069035	79302212			ENST00000334512.5	75	ENST00000318560.5	transcript_fusion		2023-01-09 21:52:24 UTC			ZMIZ1-ABL1	FALSE
ABL1 ZMIZ1::ABL1	3138	"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like"	80650	"Juvenile onset,Young adult onset"			Diagnostic	Supports	C	Positive	"This study included 1389 cases of high-risk pediatric B-ALL, of which 284 were identified by TaqMan Low Density Array to have a BCR-ABL1-like (Ph-like) gene expression signature. RT-PCR or RNAseq performed on Ph-like, CRLF2 negative patients revealed 17 cases with ABL1 fusions with 8 different partner genes. There were three cases with the ZMIZ1-ABL1 fusion. Considering the previously confirmed Ph-like expression signature in the tested cases, the results suggest that the presence of the ZMIZ1-ABL1 fusion in B-ALL indicates the BCR-ABL1-like (Ph-like) subtype of the disease."	28408464	PubMed		"Reshmi et al., 2017, Blood"		2	accepted	9077	Somatic	2023-01-09 21:47:07 UTC	https://civicdb.org/links/evidence_items/9077	https://civicdb.org/links/molecular_profiles/3138	FALSE	ABL1	25	ZMIZ1::ABL1	ABL1 fusions in B-ALL	chr9	130854064	130887675			ENST00000334512.5	75	ENST00000318560.5	transcript_fusion		2023-01-09 21:52:24 UTC			ZMIZ1-ABL1	FALSE
ABL1 BCR::ABL G250E	997	Cancer	162		Dasatinib		Predictive	Supports	D	Sensitivity/Response	"In an in vitro study, a Ba/F3 cell line stably expressing the G250E mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with increased sensitivity to dasatinib treatment (IC50: 27.2 nM) as compared to wild-type BCR-ABL1 expressing Ba/F3 cells (IC50: 87.6 nM). Sensitivity was determined by assessing cell proliferation using the MTT assay."	18191450	PubMed		"Deguchi et al., 2008, Leuk. Res."		3	accepted	9083	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/9083	https://civicdb.org/links/molecular_profiles/997	FALSE	ABL1	25	BCR::ABL G250E		chr9	130862962	130862962	G	A	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"NM_005157.5:c.749G>A,NP_005148.2:p.Gly250Glu,NC_000009.11:g.133738349G>A,ENST00000318560.5:c.749G>A"	2023-01-27 17:07:43 UTC	CA16602547	376086	"RS121913453,BCR-ABL G269E,BCR-ABL GLY250GLU,BCR-ABL1 G250E,BCR-ABL1 GLY250GLU,BCR-ABL G250E"	FALSE
ABL1 BCR::ABL H396P	1439	Cancer	162		Dasatinib		Predictive	Supports	D	Sensitivity/Response	"In an in vitro study, a Ba/F3 cell line stably expressing H396P in the ABL1 portion of the BCR-ABL1 fusion protein was associated with increased sensitivity to dasatinib treatment (IC50: 8.9 nM) as compared to wild-type BCR-ABL1 expressing Ba/F3 cells (IC50: 87.6 nM). Sensitivity was determined by assessing cell proliferation using the MTT assay."	18191450	PubMed		"Deguchi et al., 2008, Leuk. Res."		3	accepted	9084	Somatic	2023-01-09 21:46:45 UTC	https://civicdb.org/links/evidence_items/9084	https://civicdb.org/links/molecular_profiles/1439	FALSE	ABL1	25	BCR::ABL H396P		chr9	130874969	130874969	A	C	ENST00000318560.5	75		"missense_variant,transcript_fusion"	"ENST00000318560.5:c.1187A>C,NC_000009.11:g.133750356A>C,NM_005157.5:c.1187A>C,NP_005148.2:p.His396Pro"	2023-01-27 17:10:14 UTC	CA375249969	NONE FOUND	"BCR-ABL HIS396PRO,BCR-ABL1 H396P,BCR-ABL1 HIS396PRO,BCR-ABL H396P"	FALSE
ABL1 NUP214::ABL1	2529	"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like"	80650	"Pediatric onset,Juvenile onset"			Prognostic	Supports	B	Better Outcome	"A multicenter, retrospective, cohort study that included 122 pediatric patients (aged 1-18 years) with newly diagnosed ABL-class fusion B-cell acute lymphocytic leukemia who had not received tyrosine-kinase inhibitor treatment as a first-line therapy. ABL-class genes included ABL1, ABL2, CSF1R and PDGFRB. There were 33% of patients (40/122) that harbored an ABL1 fusion, including 7 with a NUP214-ABL1 fusion. For patients that were ABL1 fusion positive the 5-year event-free survival was 68.6% (54.5-86.3), the 5-year overall survival was 82.9% (71.2-96.4) and the 5-year cumulative incidence of relapse was 29.6% (15.0-45.9). Additionally ABL1 fusion positive patients had the lowest levels of MRD at the end of induction therapy (20/29 evaluable patients had less than 10^-2). Of patients with NUP214-ABL1, 4/7 had MRD <10^-2 at the end of induction."	33357483	PubMed		"den Boer et al., 2021, Lancet Haematol"		3	accepted	9148	Somatic	2023-01-09 21:47:01 UTC	https://civicdb.org/links/evidence_items/9148	https://civicdb.org/links/molecular_profiles/2529	FALSE	ABL1	25	NUP214::ABL1	ABL1 fusions in B-ALL	chr9	131125561	131230769			ENST00000359428.5	75	ENST00000318560.5	transcript_fusion		2023-01-09 21:52:20 UTC			NUP214-ABL1	FALSE
ABL1 NUP214::ABL1	2529	"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like"	80650	"Pediatric onset,Juvenile onset"			Prognostic	Supports	B	Better Outcome	"A multicenter, retrospective, cohort study that included 122 pediatric patients (aged 1-18 years) with newly diagnosed ABL-class fusion B-cell acute lymphocytic leukemia who had not received tyrosine-kinase inhibitor treatment as a first-line therapy. ABL-class genes included ABL1, ABL2, CSF1R and PDGFRB. There were 33% of patients (40/122) that harbored an ABL1 fusion, including 7 with a NUP214-ABL1 fusion. For patients that were ABL1 fusion positive the 5-year event-free survival was 68.6% (54.5-86.3), the 5-year overall survival was 82.9% (71.2-96.4) and the 5-year cumulative incidence of relapse was 29.6% (15.0-45.9). Additionally ABL1 fusion positive patients had the lowest levels of MRD at the end of induction therapy (20/29 evaluable patients had less than 10^-2). Of patients with NUP214-ABL1, 4/7 had MRD <10^-2 at the end of induction."	33357483	PubMed		"den Boer et al., 2021, Lancet Haematol"		3	accepted	9148	Somatic	2023-01-09 21:47:01 UTC	https://civicdb.org/links/evidence_items/9148	https://civicdb.org/links/molecular_profiles/2529	FALSE	ABL1	25	NUP214::ABL1	ABL1 fusions in B-ALL	chr9	130854801	130887675			ENST00000359428.5	75	ENST00000318560.5	transcript_fusion		2023-01-09 21:52:20 UTC			NUP214-ABL1	FALSE
ABL1 ZMIZ1::ABL1	3138	"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like"	80650	"Young adult onset,Pediatric onset"			Prognostic	Supports	B	Better Outcome	"A multicenter, retrospective, cohort study that included 122 paediatric patients (aged 1-18 years) with newly diagnosed ABL-class fusion B-cell acute lymphocytic leukemia who had not received tyrosine-kinase inhibitor treatment as a first-line therapy. ABL-class genes included ABL1, ABL2, CSF1R and PDGFRB. There were 33% of patients (40/122) that harbored an ABL1 fusion, including 16 with a ZMIZ1-ABL1 fusion. For patients that were ABL1 fusion positive the 5-year event-free survival was 68.6% (54.5-86.3), the 5-year overall survival was 82.9% (71.2-96.4) and the 5-year cumulative incidence of relapse was 29.6% (15.0-45.9). Additionally ABL1 fusion positive patients had the lowest levels of MRD at the end of induction therapy. Patients with ZMIZ1-ABL1 had a median MRD between 10^-3 and <10^4 at the end of induction, but between fusion parters, MRD did not differ significantly."	33357483	PubMed		"den Boer et al., 2021, Lancet Haematol"		4	accepted	9149	Somatic	2023-01-09 21:47:07 UTC	https://civicdb.org/links/evidence_items/9149	https://civicdb.org/links/molecular_profiles/3138	FALSE	ABL1	25	ZMIZ1::ABL1	ABL1 fusions in B-ALL	chr10	79069035	79302212			ENST00000334512.5	75	ENST00000318560.5	transcript_fusion		2023-01-09 21:52:24 UTC			ZMIZ1-ABL1	FALSE
ABL1 ZMIZ1::ABL1	3138	"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like"	80650	"Young adult onset,Pediatric onset"			Prognostic	Supports	B	Better Outcome	"A multicenter, retrospective, cohort study that included 122 paediatric patients (aged 1-18 years) with newly diagnosed ABL-class fusion B-cell acute lymphocytic leukemia who had not received tyrosine-kinase inhibitor treatment as a first-line therapy. ABL-class genes included ABL1, ABL2, CSF1R and PDGFRB. There were 33% of patients (40/122) that harbored an ABL1 fusion, including 16 with a ZMIZ1-ABL1 fusion. For patients that were ABL1 fusion positive the 5-year event-free survival was 68.6% (54.5-86.3), the 5-year overall survival was 82.9% (71.2-96.4) and the 5-year cumulative incidence of relapse was 29.6% (15.0-45.9). Additionally ABL1 fusion positive patients had the lowest levels of MRD at the end of induction therapy. Patients with ZMIZ1-ABL1 had a median MRD between 10^-3 and <10^4 at the end of induction, but between fusion parters, MRD did not differ significantly."	33357483	PubMed		"den Boer et al., 2021, Lancet Haematol"		4	accepted	9149	Somatic	2023-01-09 21:47:07 UTC	https://civicdb.org/links/evidence_items/9149	https://civicdb.org/links/molecular_profiles/3138	FALSE	ABL1	25	ZMIZ1::ABL1	ABL1 fusions in B-ALL	chr9	130854064	130887675			ENST00000334512.5	75	ENST00000318560.5	transcript_fusion		2023-01-09 21:52:24 UTC			ZMIZ1-ABL1	FALSE
ABL1 NUP214::ABL1	2529	B-lymphoblastic Leukemia/lymphoma	80630	Young adult onset	"Nilotinib,Dasatinib,Imatinib,Ponatinib"	Substitutes	Predictive	Does Not Support	D	Sensitivity/Response	"A 22-year-old male with B-cell acute lymphoblastic leukemia was treated with induction therapy. FISH using a BCR-ABL1 probe demonstrated 50-80 extrachromosomal copies of ABL1; FISH using probes to the 3' regions of ABL1 and NUP214 confirmed NUP214-ABL1 amplification in ~99% of cells. The NUP214-ABL1 amplification was also confirmed by MLPA and SNP6.0 analysis. Additionally, this patient harbored a focal deletion of IKZF1 (exons 2-7) and CDKN2A/B (exons 1-2). Day 29 marrow showed complete morphological remission; however PCR-based IgVH MRD rearrangement studies revealed clonal IgVH rearrangement (1 in 10^4 cells). Patient underwent sibling donor allogenic stem cell transplant, and at 4 months is in complete remission. NUP214-ABL1 positive patient primary cells were cultured with various tyrosine kinase inhibitors (imatinib, dasatinib, nilotinib, and ponatinib). After 72-hour culture there was no significant reduction in viable cell numbers or increase in apoptosis, when compared to the no drug control. The in vitro sensitivity to TKIs may be attributed to variable NUP214-ABL1 copy number and/or focal deletions of IKZF1 and CDKN2A/B."	23175662	PubMed		"Eyre et al., 2012, Blood"		2	accepted	9150	Somatic	2023-01-09 21:47:01 UTC	https://civicdb.org/links/evidence_items/9150	https://civicdb.org/links/molecular_profiles/2529	FALSE	ABL1	25	NUP214::ABL1	ABL1 fusions in B-ALL	chr9	131125561	131230769			ENST00000359428.5	75	ENST00000318560.5	transcript_fusion		2023-01-09 21:52:20 UTC			NUP214-ABL1	FALSE
ABL1 NUP214::ABL1	2529	B-lymphoblastic Leukemia/lymphoma	80630	Young adult onset	"Nilotinib,Dasatinib,Imatinib,Ponatinib"	Substitutes	Predictive	Does Not Support	D	Sensitivity/Response	"A 22-year-old male with B-cell acute lymphoblastic leukemia was treated with induction therapy. FISH using a BCR-ABL1 probe demonstrated 50-80 extrachromosomal copies of ABL1; FISH using probes to the 3' regions of ABL1 and NUP214 confirmed NUP214-ABL1 amplification in ~99% of cells. The NUP214-ABL1 amplification was also confirmed by MLPA and SNP6.0 analysis. Additionally, this patient harbored a focal deletion of IKZF1 (exons 2-7) and CDKN2A/B (exons 1-2). Day 29 marrow showed complete morphological remission; however PCR-based IgVH MRD rearrangement studies revealed clonal IgVH rearrangement (1 in 10^4 cells). Patient underwent sibling donor allogenic stem cell transplant, and at 4 months is in complete remission. NUP214-ABL1 positive patient primary cells were cultured with various tyrosine kinase inhibitors (imatinib, dasatinib, nilotinib, and ponatinib). After 72-hour culture there was no significant reduction in viable cell numbers or increase in apoptosis, when compared to the no drug control. The in vitro sensitivity to TKIs may be attributed to variable NUP214-ABL1 copy number and/or focal deletions of IKZF1 and CDKN2A/B."	23175662	PubMed		"Eyre et al., 2012, Blood"		2	accepted	9150	Somatic	2023-01-09 21:47:01 UTC	https://civicdb.org/links/evidence_items/9150	https://civicdb.org/links/molecular_profiles/2529	FALSE	ABL1	25	NUP214::ABL1	ABL1 fusions in B-ALL	chr9	130854801	130887675			ENST00000359428.5	75	ENST00000318560.5	transcript_fusion		2023-01-09 21:52:20 UTC			NUP214-ABL1	FALSE
ABL1 ZMIZ1::ABL1	3138	B-lymphoblastic Leukemia/lymphoma	80630	Childhood onset			Oncogenic	Supports	C	Oncogenicity	"A 18-month-old female with B-cell acute lymphoblastic leukemia. Chromosome and FISH analysis using a BCR-ABL1 probe confirmed the involvement of ABL1 in a t(9;10)(q34;q22.3) translocation. Follow-up molecular analysis using RT-PCR confirmed the presence of a ZMIZ1-ABL1 fusion transcript (ZMIZ1 exon 14 and ABL1 exon 2). Patient was treated according to standard risk protocol without kinase inhibitors and is in first complete remission. Authors note that The ZMIZ1-ABL1 fusion transcript predicts the the synthesis of ZMIZ1-ABL fusion protein, which contains one of the proline-rich domains of ZMIZ1 and ABL tyrosine kinase domain. Similar to other oncogenic fusion proteins, the proline-rich domain of ZMIZ1 is involved in protein-protein interactions, and therefore the fusion may encode a constitutively activated tyrosine kinase that promotes cellular transformation. The authors further note that patients with t(9;10) would be eligible for imatinib treatment."	18007576	PubMed		"Soler et al., 2008, Leukemia"		1	accepted	9151	Somatic	2023-02-03 19:55:10 UTC	https://civicdb.org/links/evidence_items/9151	https://civicdb.org/links/molecular_profiles/3138	FALSE	ABL1	25	ZMIZ1::ABL1	ABL1 fusions in B-ALL	chr10	79069035	79302212			ENST00000334512.5	75	ENST00000318560.5	transcript_fusion		2023-01-09 21:52:24 UTC			ZMIZ1-ABL1	FALSE
ABL1 ZMIZ1::ABL1	3138	B-lymphoblastic Leukemia/lymphoma	80630	Childhood onset			Oncogenic	Supports	C	Oncogenicity	"A 18-month-old female with B-cell acute lymphoblastic leukemia. Chromosome and FISH analysis using a BCR-ABL1 probe confirmed the involvement of ABL1 in a t(9;10)(q34;q22.3) translocation. Follow-up molecular analysis using RT-PCR confirmed the presence of a ZMIZ1-ABL1 fusion transcript (ZMIZ1 exon 14 and ABL1 exon 2). Patient was treated according to standard risk protocol without kinase inhibitors and is in first complete remission. Authors note that The ZMIZ1-ABL1 fusion transcript predicts the the synthesis of ZMIZ1-ABL fusion protein, which contains one of the proline-rich domains of ZMIZ1 and ABL tyrosine kinase domain. Similar to other oncogenic fusion proteins, the proline-rich domain of ZMIZ1 is involved in protein-protein interactions, and therefore the fusion may encode a constitutively activated tyrosine kinase that promotes cellular transformation. The authors further note that patients with t(9;10) would be eligible for imatinib treatment."	18007576	PubMed		"Soler et al., 2008, Leukemia"		1	accepted	9151	Somatic	2023-02-03 19:55:10 UTC	https://civicdb.org/links/evidence_items/9151	https://civicdb.org/links/molecular_profiles/3138	FALSE	ABL1	25	ZMIZ1::ABL1	ABL1 fusions in B-ALL	chr9	130854064	130887675			ENST00000334512.5	75	ENST00000318560.5	transcript_fusion		2023-01-09 21:52:24 UTC			ZMIZ1-ABL1	FALSE
ABL1 ZMIZ1::ABL1	3138	"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like"	80650	Pediatric onset			Diagnostic	Supports	C	Positive	"Study comprised 574 children with newly diagnosed B-cell precursor acute lymphoblastic leukemia (BCP-ALL) and focused on B-other/BCR-ABL-like which were identified by hierarchical clustering of gene expression data. RT-PCR followed by Sanger sequencing for detection of tyrosine kinase fusions was performed for 153 cases. There were 14 fusions found among the BCR-ABL-like cases (14/77=18%), which included one case with a ZMIZ1-ABL1 (exon 18 and exon 2). ZMIZ1-AML1 fusion was among a group of nine fusions found, and characterized by the authors as predictive for activated ABL signaling. The 8-year cumulative incidence of relapse for the fusion-positive BCR-ABL1-like group (35%) was comparable to the fusion-negative BCR-ABL1-like group (35%), and worse than non-BCR-ABL1-like B-other group (17%, p=0.07)."	27894077	PubMed		"Boer et al., 2017, Oncotarget"		2	accepted	9152	Somatic	2023-01-09 21:47:07 UTC	https://civicdb.org/links/evidence_items/9152	https://civicdb.org/links/molecular_profiles/3138	FALSE	ABL1	25	ZMIZ1::ABL1	ABL1 fusions in B-ALL	chr10	79069035	79302212			ENST00000334512.5	75	ENST00000318560.5	transcript_fusion		2023-01-09 21:52:24 UTC			ZMIZ1-ABL1	FALSE
ABL1 ZMIZ1::ABL1	3138	"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like"	80650	Pediatric onset			Diagnostic	Supports	C	Positive	"Study comprised 574 children with newly diagnosed B-cell precursor acute lymphoblastic leukemia (BCP-ALL) and focused on B-other/BCR-ABL-like which were identified by hierarchical clustering of gene expression data. RT-PCR followed by Sanger sequencing for detection of tyrosine kinase fusions was performed for 153 cases. There were 14 fusions found among the BCR-ABL-like cases (14/77=18%), which included one case with a ZMIZ1-ABL1 (exon 18 and exon 2). ZMIZ1-AML1 fusion was among a group of nine fusions found, and characterized by the authors as predictive for activated ABL signaling. The 8-year cumulative incidence of relapse for the fusion-positive BCR-ABL1-like group (35%) was comparable to the fusion-negative BCR-ABL1-like group (35%), and worse than non-BCR-ABL1-like B-other group (17%, p=0.07)."	27894077	PubMed		"Boer et al., 2017, Oncotarget"		2	accepted	9152	Somatic	2023-01-09 21:47:07 UTC	https://civicdb.org/links/evidence_items/9152	https://civicdb.org/links/molecular_profiles/3138	FALSE	ABL1	25	ZMIZ1::ABL1	ABL1 fusions in B-ALL	chr9	130854064	130887675			ENST00000334512.5	75	ENST00000318560.5	transcript_fusion		2023-01-09 21:52:24 UTC			ZMIZ1-ABL1	FALSE
BRAF V600E	12	Thyroid Gland Papillary Carcinoma	3969				Prognostic	Supports	B	Poor Outcome	"Clinical study including 219 patients with papillary thyroid cancer (PTC) to determine a correlation between the BRAF V600E mutation and poor oncological outcome. This study found that 107 of the 219 (49%) patients had this mutation signifying that the BRAF V600E mutation is one of the most commonly occurring among PTC patients. This cohort was split into two groupsBRAF+ and BRAF-. Of the 107 patients that were BRAF+, 25% had tumor reoccurrence compared with 9% in the BRAF- group (P=0.004). Multivariate analysis was performed to assess BRAF correlation independent of known contributing factors to cancer such as age, gender, and multifocality. The results showed that the BRAF mutation is indicative/contributes to lymph node metastasis, associated with tumor reoccurrence, stage, and that recurrent disease was more extensive and required more aggressive treatments in BRAF+ patients compared with BRAF- patients. The authors conclude that PTC patients with the BRAF V600E mutation have worse clinicopathological outcomes, and that the BRAF mutation can be used to assess risk stratification in patients with PTC."	16174717	PubMed		"Xing et al., 2005, J Clin Endocrinol Metab"		4	accepted	9170	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/9170	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
ABL1 SNX2::ABL1	2547	"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like"	80650	Juvenile onset			Diagnostic	Supports	C	Positive	"This retrospective study intended to clarify clinical characteristics of patients with B-lymphoblastic leukemia/lymphoma (B-ALL) and kinase fusions that are not well described (excluding ETV6-RUNX1, E2A-PBX1, MLL rearrangements and BCR-ABL). The SNX2-ABL1 fusion is rare; in this study investigating 373 high risk pediatric B-ALL patients of which 29 demonstrated uncommon kinase gene fusions, only one case with SNX2-ABL1 (exon 3-exon 4) was observed. Gene expression profiles were compared to Ph-positive B-ALL and reportedly all fusion-containing samples (except P2RY8-CRLF2) were similar to BCR-ABL1-positive patients. This patient did not respond to tyrosine kinase inhibitors administered in combination with chemotherapy at the first or second relapses."	27176795	PubMed		"Imamura et al., 2016, Blood Cancer J"		3	accepted	9177	Somatic	2023-01-09 21:47:01 UTC	https://civicdb.org/links/evidence_items/9177	https://civicdb.org/links/molecular_profiles/2547	FALSE	ABL1	25	SNX2::ABL1	ABL1 fusions in B-ALL	chr5	122774996	122799855			ENST00000379516.2	75	ENST00000372348.2	transcript_fusion		2023-01-09 21:52:21 UTC			SNX2-ABL1	FALSE
ABL1 SNX2::ABL1	2547	"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like"	80650	Juvenile onset			Diagnostic	Supports	C	Positive	"This retrospective study intended to clarify clinical characteristics of patients with B-lymphoblastic leukemia/lymphoma (B-ALL) and kinase fusions that are not well described (excluding ETV6-RUNX1, E2A-PBX1, MLL rearrangements and BCR-ABL). The SNX2-ABL1 fusion is rare; in this study investigating 373 high risk pediatric B-ALL patients of which 29 demonstrated uncommon kinase gene fusions, only one case with SNX2-ABL1 (exon 3-exon 4) was observed. Gene expression profiles were compared to Ph-positive B-ALL and reportedly all fusion-containing samples (except P2RY8-CRLF2) were similar to BCR-ABL1-positive patients. This patient did not respond to tyrosine kinase inhibitors administered in combination with chemotherapy at the first or second relapses."	27176795	PubMed		"Imamura et al., 2016, Blood Cancer J"		3	accepted	9177	Somatic	2023-01-09 21:47:01 UTC	https://civicdb.org/links/evidence_items/9177	https://civicdb.org/links/molecular_profiles/2547	FALSE	ABL1	25	SNX2::ABL1	ABL1 fusions in B-ALL	chr9	130862763	130887675			ENST00000379516.2	75	ENST00000372348.2	transcript_fusion		2023-01-09 21:52:21 UTC			SNX2-ABL1	FALSE
ABL1 SNX2::ABL1	2547	"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like"	80650	Juvenile onset			Diagnostic	Supports	C	Positive	"In the study involving 1725 B-ALL patients, 264 were identified by microarray-based algorithm to have a Ph-like expression signature. Next generation sequencing (RNAseq, WGS, and/or WES) performed on 154 Ph-like patients revealed 91% possessed genomic alterations activating kinase signaling with 96 (62%) involving rearrangements. In one adolescent male, an in-frame SNX2-ABL1 fusion (exon 3 and exon 4) with the ABL1 tyrosine kinase domain intact was identified and confirmed by RT-PCR and Sanger. This patient, evaluated by WES and RNA-seq, also harbored IKZF1, EBF1, and VPREB deletions, and was designated Ph-like non CRLF2."	25207766	PubMed		"Roberts et al., 2014, N. Engl. J. Med."		3	accepted	9178	Somatic	2023-01-09 21:47:01 UTC	https://civicdb.org/links/evidence_items/9178	https://civicdb.org/links/molecular_profiles/2547	FALSE	ABL1	25	SNX2::ABL1	ABL1 fusions in B-ALL	chr5	122774996	122799855			ENST00000379516.2	75	ENST00000372348.2	transcript_fusion		2023-01-09 21:52:21 UTC			SNX2-ABL1	FALSE
ABL1 SNX2::ABL1	2547	"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like"	80650	Juvenile onset			Diagnostic	Supports	C	Positive	"In the study involving 1725 B-ALL patients, 264 were identified by microarray-based algorithm to have a Ph-like expression signature. Next generation sequencing (RNAseq, WGS, and/or WES) performed on 154 Ph-like patients revealed 91% possessed genomic alterations activating kinase signaling with 96 (62%) involving rearrangements. In one adolescent male, an in-frame SNX2-ABL1 fusion (exon 3 and exon 4) with the ABL1 tyrosine kinase domain intact was identified and confirmed by RT-PCR and Sanger. This patient, evaluated by WES and RNA-seq, also harbored IKZF1, EBF1, and VPREB deletions, and was designated Ph-like non CRLF2."	25207766	PubMed		"Roberts et al., 2014, N. Engl. J. Med."		3	accepted	9178	Somatic	2023-01-09 21:47:01 UTC	https://civicdb.org/links/evidence_items/9178	https://civicdb.org/links/molecular_profiles/2547	FALSE	ABL1	25	SNX2::ABL1	ABL1 fusions in B-ALL	chr9	130862763	130887675			ENST00000379516.2	75	ENST00000372348.2	transcript_fusion		2023-01-09 21:52:21 UTC			SNX2-ABL1	FALSE
ABL1 RANBP2::ABL1	3137	"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like"	80650	Young adult onset	Dasatinib		Predictive	Supports	C	Sensitivity/Response	"This retrospective study reported the outcome of 24 patients with Ph-like acute lymphoblastic leukemia (Ph-like ALL) harboring ABL-class fusions, who were treated with a combination of tyrosine kinase inhibitors (TKIs) and chemotherapy. Of the 24 patients reported, 12 had fusions involving ABL1; in 7/12 patients the ABL1 fusion was detected at diagnosis, and in 5/12 it was identified at relapse. One relapse patient was found to have a RANBP2-ABL1 fusion. This patient was a 20 year old female. An IKZF1 intragenic deletion was detected in her leukemia in addition to the RANBP2-ABL1 fusion. She had good initial prednisone response and reached complete remission (CR) after treatment on the GRAALL2005R trial. However, she relapsed with refractory disease. The RANBP2-ABL1 fusion was detected at relapse, and dasatinib (140 mg daily) was added to chemotherapy; this resulted in a brief response even though her leukemia was previously refractory to several lines of salvage treatment (best MRD level 8x10-3). However, the patient experienced another relapse and died of progressive disease. The case illustrates partial response to TKIs in combination with chemotherapy in a relapsed Ph-like B-ALL with RANBP2-ABL1 fusion."	31434701	PubMed		"Tanasi et al., 2019, Blood"		2	accepted	9211	Somatic	2023-01-09 21:47:07 UTC	https://civicdb.org/links/evidence_items/9211	https://civicdb.org/links/molecular_profiles/3137	FALSE	ABL1	25	RANBP2::ABL1	ABL1 fusions in B-ALL	chr2	108719607	108758548			ENST00000283195	75	ENST00000372348.2	transcript_fusion		2023-01-09 21:52:24 UTC			RANBP2-ABL1	FALSE
ABL1 RANBP2::ABL1	3137	"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like"	80650	Young adult onset	Dasatinib		Predictive	Supports	C	Sensitivity/Response	"This retrospective study reported the outcome of 24 patients with Ph-like acute lymphoblastic leukemia (Ph-like ALL) harboring ABL-class fusions, who were treated with a combination of tyrosine kinase inhibitors (TKIs) and chemotherapy. Of the 24 patients reported, 12 had fusions involving ABL1; in 7/12 patients the ABL1 fusion was detected at diagnosis, and in 5/12 it was identified at relapse. One relapse patient was found to have a RANBP2-ABL1 fusion. This patient was a 20 year old female. An IKZF1 intragenic deletion was detected in her leukemia in addition to the RANBP2-ABL1 fusion. She had good initial prednisone response and reached complete remission (CR) after treatment on the GRAALL2005R trial. However, she relapsed with refractory disease. The RANBP2-ABL1 fusion was detected at relapse, and dasatinib (140 mg daily) was added to chemotherapy; this resulted in a brief response even though her leukemia was previously refractory to several lines of salvage treatment (best MRD level 8x10-3). However, the patient experienced another relapse and died of progressive disease. The case illustrates partial response to TKIs in combination with chemotherapy in a relapsed Ph-like B-ALL with RANBP2-ABL1 fusion."	31434701	PubMed		"Tanasi et al., 2019, Blood"		2	accepted	9211	Somatic	2023-01-09 21:47:07 UTC	https://civicdb.org/links/evidence_items/9211	https://civicdb.org/links/molecular_profiles/3137	FALSE	ABL1	25	RANBP2::ABL1	ABL1 fusions in B-ALL	chr9	130854064	130887675			ENST00000283195	75	ENST00000372348.2	transcript_fusion		2023-01-09 21:52:24 UTC			RANBP2-ABL1	FALSE
EGFR A767_V769dupASV	1487	Lung Non-small Cell Carcinoma	3908		Osimertinib		Predictive	Supports	C	Sensitivity/Response	"In a retrospective study of 2316 Chinese patients with stage IV non-small cell lung carcinoma, a 63 year old female with the EGFR exon 20 insertion A767_V769dupASV received osimertinib as first-line treatment. The patient achieved a partial response with greater than 30% reduction in tumour size, and progression-free survival of 6.0 months."	31208370	PubMed		"Fang et al., 2019, BMC Cancer"		3	accepted	9220	Somatic	2023-01-09 21:46:46 UTC	https://civicdb.org/links/evidence_items/9220	https://civicdb.org/links/molecular_profiles/1487	FALSE	EGFR	1956	A767_V769dupASV		chr7	55181307	55181308		GCCAGCGTG	ENST00000275493.2			inframe_insertion		2023-01-27 17:10:35 UTC	CA180588			FALSE
EGFR D770_N771insG	1420	Lung Non-small Cell Carcinoma	3908		Osimertinib		Predictive	Supports	C	Sensitivity/Response	"In a retrospective study of 2316 Chinese patients with stage IV non-small cell lung carcinoma, a 63 year old female with the EGFR exon 20 insertion D770_N771insG received osimertinib as second-line treatment. The patient had clinical improvement and achieved partial response with nearly 50% reduction in tumour size. Progression-free survival was 6.4 months."	31208370	PubMed		"Fang et al., 2019, BMC Cancer"		3	accepted	9223	Somatic	2023-02-02 21:30:01 UTC	https://civicdb.org/links/evidence_items/9223	https://civicdb.org/links/molecular_profiles/1420	FALSE	EGFR	1956	D770_N771insG		chr7	55181319	55181320		GGT	ENST00000275493.2			inframe_insertion	"NC_000007.14:g.55181319_55181320insGGT,NC_000007.13:g.55249012_55249013insGGT,ENST00000275493.7:c.2310_2311insGGT,ENSP00000275493.2:p.Asp770_Asn771insGly,NM_005228.5:c.2310_2311insGGT,NP_005219.2:p.Asp770_Asn771insGly"	2023-01-27 17:10:01 UTC	CA645561591	NONE FOUND	ASP770_ASN771INSGLY	FALSE
EGFR A763_Y764insFQEA	1423	Lung Non-small Cell Carcinoma	3908		Osimertinib		Predictive	Supports	C	Sensitivity/Response	"In a retrospective study of 2316 Chinese patients with stage IV non-small cell lung carcinoma, a 65 year old female with the EGFR exon 20 insertion A763_Y764insFQEA received osimertinib as second-line treatment. The patient achieved a partial response with greater than 50% reduction in tumour size, and progression-free survival of 5.1 months. The patient had previously achieved partial response on gefinitib, but experienced disease progression after 9.0 months at which point a rebiopsy was found to harbor a T790M mutation."	31208370	PubMed		"Fang et al., 2019, BMC Cancer"		2	accepted	9225	Somatic	2023-01-09 21:46:45 UTC	https://civicdb.org/links/evidence_items/9225	https://civicdb.org/links/molecular_profiles/1423	FALSE	EGFR	1956	A763_Y764insFQEA		chr7	55181299	55181300		TCCAGGAAGCCT	ENST00000275493.2			inframe_insertion	"NP_001333827.1:p.Ala763_Tyr764insPheGlnGluAla,NC_000007.13:g.55248992_55248993insTCCAGGAAGCCT,NM_001346898.1:c.2290_2291insTCCAGGAAGCCT"	2023-01-27 17:10:04 UTC	CA135833	NONE FOUND	RS397517106	FALSE
ALK EML4::ALK	5	Malignant Pleural Mesothelioma	7474		Alectinib		Predictive	Supports	C	Sensitivity/Response	"A 33 year old M non-smoker with no cancer family history and no known exposure to asbestos showed weakness, chest pain, and plural effusion (PE) accumulation. Mass in right lung was seen under enhanced CT. Patient was diagnosed with stage IIIB (cT4N2M0) malignant pleural mesothelioma (MPM) using National Comprehensive Cancer Network (NCCN) guidelines on MPM staging (v.1.2018).   Patient was given palliative chemotherapy for two cycles, which reduced the PE and improved physical mobility. Targeted NGS panel with 520 genes of PE showed EML4::ALK variant 3 (allelic fraction 24.21%). After 1 month symptoms were alleviated and NGS showed reduced EML4::ALK abundance (allelic fraction 8.22%). After 2 months CT showed tumor shrinkage. This was evaluated as partial response."	32600123	PubMed		"Hu et al., 2020, Ther Adv Respir Dis"		4	accepted	9228	Somatic	2023-02-16 01:13:35 UTC	https://civicdb.org/links/evidence_items/9228	https://civicdb.org/links/molecular_profiles/5	FALSE	ALK	238	EML4::ALK	ALK Fusion	chr2	42169350	42295516			ENST00000318522.5	75	ENST00000389048.3	transcript_fusion		2023-01-09 21:52:04 UTC		N/A	EML4-ALK	FALSE
ALK EML4::ALK	5	Malignant Pleural Mesothelioma	7474		Alectinib		Predictive	Supports	C	Sensitivity/Response	"A 33 year old M non-smoker with no cancer family history and no known exposure to asbestos showed weakness, chest pain, and plural effusion (PE) accumulation. Mass in right lung was seen under enhanced CT. Patient was diagnosed with stage IIIB (cT4N2M0) malignant pleural mesothelioma (MPM) using National Comprehensive Cancer Network (NCCN) guidelines on MPM staging (v.1.2018).   Patient was given palliative chemotherapy for two cycles, which reduced the PE and improved physical mobility. Targeted NGS panel with 520 genes of PE showed EML4::ALK variant 3 (allelic fraction 24.21%). After 1 month symptoms were alleviated and NGS showed reduced EML4::ALK abundance (allelic fraction 8.22%). After 2 months CT showed tumor shrinkage. This was evaluated as partial response."	32600123	PubMed		"Hu et al., 2020, Ther Adv Respir Dis"		4	accepted	9228	Somatic	2023-02-16 01:13:35 UTC	https://civicdb.org/links/evidence_items/9228	https://civicdb.org/links/molecular_profiles/5	FALSE	ALK	238	EML4::ALK	ALK Fusion	chr2	29192774	29223528			ENST00000318522.5	75	ENST00000389048.3	transcript_fusion		2023-01-09 21:52:04 UTC		N/A	EML4-ALK	FALSE
ATRX Deletion	3177	Cancer	162		"Fluorouracil,Cisplatin"	Substitutes	Predictive	Supports	D	Sensitivity/Response	"Transgenic mice were generated with conditional knockouts affecting exon 18 of the mouse ATRX gene, previously shown to be an equivalent of a loss of function. Macrophages derived from the knockout mice were significantly more sensitive to 5-FU (P<0.05) compared to macrophages derived from wild-type mice, as demonstrated by reduced survival by TUNEL assays. Re-introduction of ATRX rescued cells from 5-FU treatment. Similar significant (P<0.05) increases in TUNEL-positive cells were seen for ATRX-deficient neurons treated with 5-FU, as well as myoblasts and embryonic fibroblasts treated with 5-FU or cisplatin. The authors conclude that ATRX loss leads to sensitivity to DNA damaging agents."	23284920	PubMed		"Conte et al., 2012, PLoS One"		3	accepted	9239	N/A	2023-01-09 21:47:07 UTC	https://civicdb.org/links/evidence_items/9239	https://civicdb.org/links/molecular_profiles/3177	FALSE	ATRX	546	Deletion		chrX	77504878	77786216			ENST00000373344.5	75		deletion		2023-01-09 21:52:24 UTC				FALSE
TP53 A161T	1088						Functional	Supports	D	Loss of Function	"The TP53 A161T variant was identified in a chronic lymphocytic leukemia (CLL) cohort. In vitro work identified the A161T mutation as temperature sensitive, displaying the mutant loss-of-function phenotype (red yeast colonies) at 35 C and the wild type phenotype (white yeast colonies) at 25 . Protein activity was assessed via FASAY (functional analysis of separated alleles in yeast)."	21232794	PubMed		"Pekova et al., 2011, Leuk Res"		3	accepted	9286	Somatic	2023-01-09 21:46:42 UTC	https://civicdb.org/links/evidence_items/9286	https://civicdb.org/links/molecular_profiles/1088	FALSE	TP53	7157	A161T		chr17	7675131	7675131	C	T				missense_variant		2023-01-27 17:08:06 UTC	CA000234			FALSE
EGFR R222C	3212						Functional	Supports	D	Gain of Function	"A moderate throughput platform was used to functionally characterize 1000 somatic cancer variants. The platform found EGFR R222C to be an activating mutation based on in vitro screening in two growth-factordependent cell models using reverse-phase protein arrays for assessment. This was also the consensus from 5 other tools as well: HotSpot3D, HotMAPS, VEST, CanDrA, and Mutation Assessor (supplemental figure S5)."	29533785	PubMed		"Ng et al., 2018, Cancer Cell"		2	accepted	9333	Somatic	2023-01-09 21:47:08 UTC	https://civicdb.org/links/evidence_items/9333	https://civicdb.org/links/molecular_profiles/3212	FALSE	EGFR	1956	R222C		chr7	55152581	55152581	C	T	ENST00000275493.2	75		missense_variant		2023-01-27 17:18:38 UTC	CA367577392	1000203	ARG222CYS	FALSE
CSF1R MEF2D::CSF1R	30	"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like"	80650	Young adult onset	Imatinib		Predictive	Supports	C	Sensitivity/Response	"This study describes a cohort of 24 patients with BCR-ABL1-like B-ALL and ABL-class kinase rearrangement exposed to TKI frontline or at relapse, who showed favorable MRD response and outcome. Specifically, one 34-year-old man with MEF2D-CSF1R identified by RNAseq was prescribed an unspecified dose of imatinib as adjuvant to his frontline chemotherapy (protocol GRAALL-2014). His initial MRD analysis at 94 days remained positive for blasts (1 x 10^-4), but was consistent with continuous complete remission at day 147."	31434701	PubMed		"Tanasi et al., 2019, Blood"		3	accepted	9360	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/9360	https://civicdb.org/links/molecular_profiles/30	FALSE	CSF1R	1436	MEF2D::CSF1R		chr1	156477012	156500828			ENST00000348159.4	75	ENST00000286301.3	transcript_fusion		2023-01-09 21:52:04 UTC		N/A	MEF2D-CSF1R	FALSE
CSF1R MEF2D::CSF1R	30	"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like"	80650	Young adult onset	Imatinib		Predictive	Supports	C	Sensitivity/Response	"This study describes a cohort of 24 patients with BCR-ABL1-like B-ALL and ABL-class kinase rearrangement exposed to TKI frontline or at relapse, who showed favorable MRD response and outcome. Specifically, one 34-year-old man with MEF2D-CSF1R identified by RNAseq was prescribed an unspecified dose of imatinib as adjuvant to his frontline chemotherapy (protocol GRAALL-2014). His initial MRD analysis at 94 days remained positive for blasts (1 x 10^-4), but was consistent with continuous complete remission at day 147."	31434701	PubMed		"Tanasi et al., 2019, Blood"		3	accepted	9360	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/9360	https://civicdb.org/links/molecular_profiles/30	FALSE	CSF1R	1436	MEF2D::CSF1R		chr5	150054224	150061849			ENST00000348159.4	75	ENST00000286301.3	transcript_fusion		2023-01-09 21:52:04 UTC		N/A	MEF2D-CSF1R	FALSE
EZH2 Y646H	3232	Diffuse Large B-cell Lymphoma	50745		Tazemetostat		Predictive	Supports	C	Sensitivity/Response	"A phase I safety and dose-escalation study (NCT01897571) was completed for tazemetostat in relapsed or refractory B-cell non-Hodgkin lymphoma or advanced solid tumors. Durable objective responses, including complete responses, were observed in eight (38%) of 21 patients with B-cell non-Hodgkin lymphoma and two (5%) of 43 patients with solid tumours. EZH2 mutation status was assessed retrospectively. Two DLBCL patients had mutations. One of these (with a Y646H mutation) had a durable partial response before disease progression after 16 months on study. The variant in the second patient was not reported and the duration of therapy for this patient that did not respond was among the shortest in the trial."	29650362	PubMed		"Italiano et al., 2018, Lancet Oncol."	NCT01897571	2	accepted	9377	Somatic	2023-01-09 21:47:08 UTC	https://civicdb.org/links/evidence_items/9377	https://civicdb.org/links/molecular_profiles/3232	FALSE	EZH2	2146	Y646H		chr7	148811636	148811636	A	G	ENST00000320356.7			missense_variant	"ENST00000320356.7:c.1936T>C,NC_000007.14:g.148811636A>G,NC_000007.13:g.148508728A>G,ENSP00000320147.2:p.Tyr646His,ENST00000460911.5:c.1921T>C,ENSP00000419711.1:p.Tyr641His,NM_004456.5:c.1936T>C,NP_004447.2:p.Tyr646His,NM_001203247.2:c.1921T>C,NP_001190176.1:p.Tyr641His"	2023-01-27 17:18:39 UTC	CA16602260	76769	"Y641H,TYR641HIS,TYR646HIS"	FALSE
EZH2 Y646	165						Functional	Supports	D	Gain of Function	"Using a baculovirus expression system, wild-type EZH2 or Y641 (Y641F, Y641H, Y641N, Y641S) mutants were coexpressed with the PRC2 complex in Spodoptera frugiperda cells. Methyltransferase activity assays showed that the Y641 mutants were more effective than the wildtype in catalyzing dimethyl to trimethyl reactions. In comparison to the wildtype, the enzyme turnover and catalytic efficiency for the mutants was lower for the non methylated and monomethylated substrates, and higher for dimethylated substrates. Western blots of patient derived lymphoma cell lines (one homozygous wildtype and four heterozygous Y641 mutant lines) supported steady state enzyme kinetic predictions where the homozygous wildtype line demonstrated increased me1 and me2, but decreased 3me at H3K27. Alternatively, the heterozygous lines displayed increased 3me but decreased me1 and me2 at H3K27. These results suggest both the wildtype and Y641 mutants contribute to trimethylation and therefore the altered expression signature."	21078963	PubMed		"Sneeringer et al., 2010, Proc Natl Acad Sci U S A"		3	accepted	9412	Somatic	2023-01-09 21:46:29 UTC	https://civicdb.org/links/evidence_items/9412	https://civicdb.org/links/molecular_profiles/165	FALSE	EZH2	2146	Y646		chr7	148811634	148811636			ENST00000320356.2	75		protein_altering_variant		2023-01-09 21:52:05 UTC		"3,762,187,676,837,620,000,000"	"Y641,TYR646"	FALSE
KRAS G12C	78	Lung Non-small Cell Carcinoma	3908		Sotorasib		Predictive	Supports	A	Sensitivity/Response	"The phase II cohort of the CodeBreaK 100 study (NCT03600883) investigated the activity of the KRAS G12C inhibitor sotorasib in previously treated patients with KRAS G12C-mutated non-small cell lung cancer. A total of 124 patients had measurable disease and were evaluated for response by independent central review. Complete response was seen in four patients and partial response in 42 patients, for an objective response rate of 37.1% (95% CI, 28.6 to 46.2). The median progression-free survival and overall survival were 6.8 (95% CI, 5.1 to 8.2) months and 12.5 months (95% CI, 10.0 to could not be evaluated), respectively."	34096690	PubMed		"Skoulidis et al., 2021, N Engl J Med"	NCT03600883	5	accepted	9431	Somatic	2023-01-09 21:46:27 UTC	https://civicdb.org/links/evidence_items/9431	https://civicdb.org/links/molecular_profiles/78	FALSE	KRAS	3845	G12C	EGFR TKI Resistance	chr12	25245351	25245351	C	A	ENST00000256078.4	75		missense_variant	"NM_004985.4:c.34G>T,NP_004976.2:p.Gly12Cys,NC_000012.11:g.25398285C>A,ENST00000256078.4:c.34G>T"	2023-01-27 17:02:26 UTC	CA122528	12578	"GLY12CYS,RS121913530"	FALSE
EZH2 Y646F	2858						Functional	Supports	D	Gain of Function	"H3K27me3 (histone H3 Lys-27specific trimethylation) level was higher in EZH2 (Y641F) bearing germinal center B-cell type DLBCL derived lymphoma cell lines and tumors than in wild-type cells. There was no difference of H3K27Me2 and H3K9Me3 levels between Y641F/N and WT, indicating specificity in a gain of function of Y641F/N. Expression of Y641F mutation in HEK293T cells with wild-type EZH2 led to an increase in H3K27me3. Primary murine B-cell lines with Y641F mutation also showed an increase of H3K27me3. Structural modeling indicated that Y641F/N helped push the equilibrium to favor trimethylated products. A 3H methyl incorporation assay was used to study the activity of the PRC2 complex containing Y641F mutation in vitro. PRC2 complexes containing Y641F showed nearly two times higher activity with H3K27me2 substrates than PRC complexes with wild-type EZH2. This study indicates that EZH2 (Y641F) increases H3K27 trimethylation."	21190999	PubMed		"Yap et al., 2011, Blood"		3	accepted	9517	Somatic	2023-01-09 21:47:04 UTC	https://civicdb.org/links/evidence_items/9517	https://civicdb.org/links/molecular_profiles/2858	FALSE	EZH2	2146	Y646F		chr7	148811635	148811635	T	A	ENST00000320356.7			missense_variant	"ENST00000320356.7:c.1937A>T,NC_000007.14:g.148811635T>A,NC_000007.13:g.148508727T>A,ENSP00000320147.2:p.Tyr646Phe,ENST00000460911.5:c.1922A>T,ENSP00000419711.1:p.Tyr641Phe,NM_004456.5:c.1937A>T,NP_004447.2:p.Tyr646Phe,NM_001203247.2:c.1922A>T,NP_001190176.1:p.Tyr641Phe"	2023-01-27 17:18:07 UTC	CA16602259	76768	"Y641F,TYR641PHE,TYR646PHE"	FALSE
EZH2 Y646N	3958						Functional	Supports	D	Gain of Function	"H3K27me3 (histone H3 Lys-27specific trimethylation) level was higher in EZH2 (Y641N) bearing germinal center B-cell type DLBCL derived lymphoma cell lines and tumors than in wild-type cells. There was no difference of H3K27Me2 and H3K9Me3 levels between Y641F/N and WT, indicating specificity in a gain of function of Y641F/N. Expression of Y641N mutation in HEK293T cells with wild-type EZH2 led to an increase in H3K27me3. Structural modeling indicated that Y641F/N helped push the equilibrium to favor trimethylated products. A 3H methyl incorporation assay was used to study the activity of the PRC2 complex containing Y641N mutation in vitro. PRC2 complexes containing Y641N showed nearly two times higher activity with H3K27me2 substrates than PRC complexes with wild-type EZH2. This study indicates that EZH2 (Y641N) increases H3K27 trimethylation."	21190999	PubMed		"Yap et al., 2011, Blood"		3	accepted	9518	Somatic	2023-01-09 21:47:14 UTC	https://civicdb.org/links/evidence_items/9518	https://civicdb.org/links/molecular_profiles/3958	FALSE	EZH2	2146	Y646N		chr7	148811636	148811636	A	T	ENST00000320356.7			missense_variant	"NC_000007.14:g.148811636A>T,NC_000007.13:g.148508728A>T,ENST00000320356.7:c.1936T>A,ENSP00000320147.2:p.Tyr646Asn,NM_004456.5:c.1936T>A,NP_004447.2:p.Tyr646Asn,NM_001203247.2:c.1921T>A,NP_001190176.1:p.Tyr641Asn,ENST00000460911.5:c.1921T>A,ENSP00000419711.1:p.Tyr641Asn"	2023-01-27 17:19:37 UTC	CA16602670	376217	"Y641N,TYR646ASN,TYR641ASN"	FALSE
EZH2 Y646F	2858						Functional	Supports	D	Loss of Function	A 3H methyl incorporation assay tested the function of EZH2 Y641F containing PRC2 complexes in vitro. It showed that Y641F/N PRC2 complexes had significantly decreased enzyme activity on unmethylated and monomethylated H3 mimicking peptide substrates compared with wild-type.	21190999	PubMed		"Yap et al., 2011, Blood"		3	accepted	9519	Somatic	2023-01-09 21:47:04 UTC	https://civicdb.org/links/evidence_items/9519	https://civicdb.org/links/molecular_profiles/2858	FALSE	EZH2	2146	Y646F		chr7	148811635	148811635	T	A	ENST00000320356.7			missense_variant	"ENST00000320356.7:c.1937A>T,NC_000007.14:g.148811635T>A,NC_000007.13:g.148508727T>A,ENSP00000320147.2:p.Tyr646Phe,ENST00000460911.5:c.1922A>T,ENSP00000419711.1:p.Tyr641Phe,NM_004456.5:c.1937A>T,NP_004447.2:p.Tyr646Phe,NM_001203247.2:c.1922A>T,NP_001190176.1:p.Tyr641Phe"	2023-01-27 17:18:07 UTC	CA16602259	76768	"Y641F,TYR641PHE,TYR646PHE"	FALSE
EZH2 Y646N	3958						Functional	Supports	D	Loss of Function	A 3H methyl incorporation assay tested the function of EZH2 Y641N containing PRC2 complexes in vitro. It showed that Y641F/N PRC2 complexes had significantly decreased enzyme activity on unmethylated and monomethylated H3 mimicking peptide substrates compared with wild-type.	21190999	PubMed		"Yap et al., 2011, Blood"		3	accepted	9520	Somatic	2023-01-09 21:47:14 UTC	https://civicdb.org/links/evidence_items/9520	https://civicdb.org/links/molecular_profiles/3958	FALSE	EZH2	2146	Y646N		chr7	148811636	148811636	A	T	ENST00000320356.7			missense_variant	"NC_000007.14:g.148811636A>T,NC_000007.13:g.148508728A>T,ENST00000320356.7:c.1936T>A,ENSP00000320147.2:p.Tyr646Asn,NM_004456.5:c.1936T>A,NP_004447.2:p.Tyr646Asn,NM_001203247.2:c.1921T>A,NP_001190176.1:p.Tyr641Asn,ENST00000460911.5:c.1921T>A,ENSP00000419711.1:p.Tyr641Asn"	2023-01-27 17:19:37 UTC	CA16602670	376217	"Y641N,TYR646ASN,TYR641ASN"	FALSE
EZH2 Y646H	3232						Functional	Supports	D	Gain of Function	Whole-cell lysates from frozen GCB-derived lymphoma sections with EZH2 Y641H showed a higher level of H3K27me3 (histone H3 Lys-27specific trimethylation) compared with those from tumor with wild-type EZH2 in western blots using an antibody specific for H3K27me3 (sample number 178).	21190999	PubMed		"Yap et al., 2011, Blood"		3	accepted	9521	Somatic	2023-01-09 21:47:08 UTC	https://civicdb.org/links/evidence_items/9521	https://civicdb.org/links/molecular_profiles/3232	FALSE	EZH2	2146	Y646H		chr7	148811636	148811636	A	G	ENST00000320356.7			missense_variant	"ENST00000320356.7:c.1936T>C,NC_000007.14:g.148811636A>G,NC_000007.13:g.148508728A>G,ENSP00000320147.2:p.Tyr646His,ENST00000460911.5:c.1921T>C,ENSP00000419711.1:p.Tyr641His,NM_004456.5:c.1936T>C,NP_004447.2:p.Tyr646His,NM_001203247.2:c.1921T>C,NP_001190176.1:p.Tyr641His"	2023-01-27 17:18:39 UTC	CA16602260	76769	"Y641H,TYR641HIS,TYR646HIS"	FALSE
EZH2 Y646S	2535						Functional	Supports	D	Gain of Function	Whole-cell lysates from frozen GCB-derived lymphoma sections with EZH2 Y641H showed a higher level of H3K27me3 (histone H3 Lys-27specific trimethylation) compared with those from tumor with wild-type EZH2 in western blots using an antibody specific for H3K27me3 (sample number 353).	21190999	PubMed		"Yap et al., 2011, Blood"		3	accepted	9522	Somatic	2023-01-09 21:47:01 UTC	https://civicdb.org/links/evidence_items/9522	https://civicdb.org/links/molecular_profiles/2535	FALSE	EZH2	2146	Y646S		chr7	148811635	148811635	T	G	ENST00000320356.7			missense_variant	"NC_000007.14:g.148811635,NC_000007.13:g.148508727,ENST00000320356.7:c.1937A>C,ENSP00000320147.2:p.Tyr646Ser,NM_004456.5:c.1937A>C,NP_004447.2:p.Tyr646Ser"	2023-01-27 17:17:51 UTC	CA16602671	376218	"Y641S,TYR641SER,TYR646SER"	FALSE
MYOD1 L122R	2901	Rhabdomyosarcoma	3247	"Young adult onset,Pediatric onset"			Prognostic	Supports	B	Poor Outcome	"This study evaluated 641 cases of rhabdomyosarcoma (RMS), enrolled on Childrens Oncology Group trials (1998-2017) and UK malignant mesenchymal tumor and RMS2005 trials (1995-2016), for mutations in 39 genes previously implicated in RMS. The analysis was done using a custom-capture sequencing assay. MYOD1 L122R variant was identified in 17 cases (3%) and was not restricted to spindle-cell histology, but was also observed in association with other histologic patterns (including cases with densely packed cells that mimicked embryonal rhabdomyosarcoma (ERMS) or RMS not otherwise specified ). MYOD1 mutation showed association with older age, head and neck primary site, and a dismal survival. In both COG and UK patient cohorts, patients with the MYOD1 L122R mutation had rapid disease progression and significantly worse event free survival as compared to the patients with wild-type MYOD1."	34166060	PubMed		"Shern et al., 2021, J Clin Oncol"		4	accepted	9532	Somatic	2023-01-09 21:47:05 UTC	https://civicdb.org/links/evidence_items/9532	https://civicdb.org/links/molecular_profiles/2901	FALSE	MYOD1	4654	L122R		chr11	17720147	17720147	T	G	ENST00000250003.3	75		missense_variant		2023-01-27 17:18:14 UTC	CA379790889	NONE FOUND	LEU122ARG	FALSE
VHL L158P (c.473T>C)	1614	Von Hippel-Lindau Disease	14175	Retinal capillary hemangioma			Predisposing	Supports	C	Predisposition	"A study of 103 patients with VHL retinal manifestations and 108 patients without VHL retinal manifestations revealed that the number of hemangioblastomas appeared higher in patients who had a substitution when compared with patients with a truncated protein. Detected by PCR and SSCP, the missense mutation (c.473T>C (p.Leu158Pro)) was found in a single patient with a VHL retinal hemangioma manifestation."	12202531	PubMed		"Dollfus et al., 2002, Invest. Ophthalmol. Vis. Sci."		3	accepted	9537	Rare Germline	2023-02-03 20:12:03 UTC	https://civicdb.org/links/evidence_items/9537	https://civicdb.org/links/molecular_profiles/1614	FALSE	VHL	7428	L158P (c.473T>C)		chr3	10149796	10149796	T	C	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.473T>C,NP_000542.1:p.Leu158Pro,NC_000003.11:g.10191480T>C,ENST00000256474.2:c.473T>C"	2023-01-27 17:11:28 UTC	CA020399	182980	"C.473T>C,LEU158PRO,RS121913346"	FALSE
VHL R167Q (c.500G>A)	1615	Von Hippel-Lindau Disease	14175	Retinal capillary hemangioma			Predisposing	Supports	C	Predisposition	"A study of 103 patients with VHL retinal manifestations and 108 patients without VHL retinal manifestations revealed that the number of hemangioblastomas appeared higher in patients who had a substitution when compared with patients with a truncated protein. Detected by PCR and SSCP, the missense mutation (c.500G>A (p.Arg167Gln)) was found in 10 patients total - 3 of which are stated to have retinal HBs and 7 are said to not. Other manifestations are possible but not clear."	12202531	PubMed		"Dollfus et al., 2002, Invest. Ophthalmol. Vis. Sci."		3	accepted	9538	Rare Germline	2023-02-03 20:31:51 UTC	https://civicdb.org/links/evidence_items/9538	https://civicdb.org/links/molecular_profiles/1615	FALSE	VHL	7428	R167Q (c.500G>A)		chr3	10149823	10149823	G	A	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.500G>A,NP_000542.1:p.Arg167Gln,NC_000003.11:g.10191507G>A,ENST00000256474.2:c.500G>A"	2023-01-27 17:11:29 UTC	CA020454	2216	"C.500G>A,ARG167GLN,RS5030821"	FALSE
VHL N78S (c.233A>G)	1631	Von Hippel-Lindau Disease	14175	Retinal capillary hemangioma			Predisposing	Supports	C	Predisposition	"A study of 103 patients with VHL retinal manifestations and 108 patients without VHL retinal manifestations revealed that the number of hemangioblastomas appeared higher in patients who had a substitution when compared with patients with a truncated protein. Detected by PCR and SSCP, the missense mutation (c.233A>G (p.Asn78Ser)) was found in 2 patients total - 1 of which is stated to have retinal HBs and the other is said to not. Other manifestations are possible but not clear."	12202531	PubMed		"Dollfus et al., 2002, Invest. Ophthalmol. Vis. Sci."		3	accepted	9539	Rare Germline	2023-02-03 20:32:44 UTC	https://civicdb.org/links/evidence_items/9539	https://civicdb.org/links/molecular_profiles/1631	FALSE	VHL	7428	N78S (c.233A>G)		chr3	10142080	10142080	A	G	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.233A>G,NP_000542.1:p.Asn78Ser,NC_000003.11:g.10183764A>G,ENST00000256474.2:c.233A>G"	2023-01-27 17:11:40 UTC	CA020131	93326	"C.233A>G,ASN78SER,RS5030804"	FALSE
VHL R161* (c.481C>T)	1680	Von Hippel-Lindau Disease	14175	Retinal capillary hemangioma			Predisposing	Supports	C	Predisposition	"A study of 103 patients with VHL retinal manifestations and 108 patients without VHL retinal manifestations revealed that the number of hemangioblastomas appeared higher in patients who had a substitution when compared with patients with a truncated protein. Detected by PCR and SSCP, the missense mutation (c.481C>T (p.Arg161Ter)) was found in 8 patients total - 3 of which are stated to have retinal HBs and 5 are said to not. Other manifestations are possible but not clear."	12202531	PubMed		"Dollfus et al., 2002, Invest. Ophthalmol. Vis. Sci."		3	accepted	9540	Rare Germline	2023-02-03 20:36:26 UTC	https://civicdb.org/links/evidence_items/9540	https://civicdb.org/links/molecular_profiles/1680	FALSE	VHL	7428	R161* (c.481C>T)		chr3	10149804	10149804	C	T	ENST00000256474.2	75		missense_variant	"NM_000551.3:c.481C>T,NP_000542.1:p.Arg161Ter,NC_000003.11:g.10191488C>T,ENST00000256474.2:c.481C>T"	2023-01-27 17:12:16 UTC	CA020408	2217	"C.481C>T,R161X,ARG161TER,RS5030818"	FALSE
VHL R113* (c.337C>T)	1672	Von Hippel-Lindau Disease	14175	Retinal capillary hemangioma			Predisposing	Supports	C	Predisposition	"A study of 103 patients with VHL retinal manifestations and 108 patients without VHL retinal manifestations revealed that the number of hemangioblastomas appeared higher in patients who had a substitution when compared with patients with a truncated protein. Detected by PCR and SSCP, the missense mutation (c.337C>T (p.Arg113Ter)) was found in 2 patients stated to have retinal HBs. Other manifestations are possible but not clear."	12202531	PubMed		"Dollfus et al., 2002, Invest. Ophthalmol. Vis. Sci."		3	accepted	9541	Rare Germline	2023-02-03 20:38:06 UTC	https://civicdb.org/links/evidence_items/9541	https://civicdb.org/links/molecular_profiles/1672	FALSE	VHL	7428	R113* (c.337C>T)		chr3	10142184	10142184	C	T	ENST00000256474.2	75		stop_gained	"NM_000551.3:c.337C>T,NP_000542.1:p.Arg113Ter,NC_000003.11:g.10183868C>T,ENST00000256474.2:c.337C>T"	2023-01-27 17:12:09 UTC	CA348491	220414	"C.337C>T,R113X,ARG113TER,RS5030810"	FALSE
VHL Y175* (c.525C>G)	1845	Von Hippel-Lindau Disease	14175	Retinal capillary hemangioma			Predisposing	Supports	C	Predisposition	"A study of 103 patients with VHL retinal manifestations and 108 patients without VHL retinal manifestations extracted from the French VHL database meeting diagnostic criteria of VHL disease revealed that the number of hemangioblastomas appeared higher in patients who had a substitution when compared with patients with a truncated protein. Detected by PCR and SSCP, the missense mutation (c.525C>G (p.Tyr175Ter)) was found in 7 patients total - 3 of which are stated to have retinal HBs and 4 are said to not. Other manifestations are possible but not clear."	12202531	PubMed		"Dollfus et al., 2002, Invest. Ophthalmol. Vis. Sci."		4	accepted	9542	Rare Germline	2023-02-03 21:07:38 UTC	https://civicdb.org/links/evidence_items/9542	https://civicdb.org/links/molecular_profiles/1845	FALSE	VHL	7428	Y175* (c.525C>G)		chr3	10149848	10149848	C	G	ENST00000256474.2	75		stop_gained	"ENST00000256474.2:c.525C>G,NC_000003.11:g.10191532C>G,NM_000551.3:c.525C>G,NP_000542.1:p.Tyr175Ter"	2023-01-27 17:13:54 UTC	CA020466	182974	"C.525C>G,Y175X,TYR175TER,RS5030835"	FALSE
TP53 ALTERATION	1281	Rhabdomyosarcoma	3247	"Young adult onset,Pediatric onset"			Prognostic	Supports	B	Poor Outcome	"This study evaluated 641 cases of rhabdomyosarcoma (RMS) that were enrolled in the Childrens Oncology Group (COG) trials from 1998 to 2017 and the UK malignant mesenchymal tumor and RMS2005 trails from 1995 to 2016. Molecular testing included 39 genes which had been implicated in the past with regards to RMS. The analysis was performed with a custom-capture sequencing assay. Altered TP53 was noted in 69 out of 515 FOXO1 fusion-negative RMS cases (13%), with the most frequent mutations at codons G245S (6 cases), R248Q or W (6 cases), R175H (4 cases), and P72A (4 cases). These cases displayed a worse event free survival. In FOXO1 fusion-positive RMS subtype, there was a small number of cases with altered TP53 (3 and 2 cases in the COG and UK patient cohorts, respectively), but they were universally fatal. Due to lack of a matched germline sample, it could not be determined whether the TP53 abnormalities were of somatic or germline origin. Nevertheless, both cohorts show that mutations in TP53 are associated with a poor prognosis in both fusion-negative and fusion-positive RMS, with a particularly bleak outcome in fusion-positive RMS."	34166060	PubMed		"Shern et al., 2021, J Clin Oncol"		4	accepted	9594	Somatic	2023-01-09 21:46:44 UTC	https://civicdb.org/links/evidence_items/9594	https://civicdb.org/links/molecular_profiles/1281	FALSE	TP53	7157	ALTERATION		chr17	7668402	7687538			ENST00000269305.4	75				2023-01-09 21:52:12 UTC		N/A		FALSE
HRAS Mutation	271	Bladder Urothelial Carcinoma	4006		Tipifarnib		Predictive	Supports	B	Sensitivity/Response	4 of 16 patients with urothelial carcinoma harboring HRAS hotspot point mutations and 1 patient with an HRAS frameshift insertion had a partial response to the farnesyltransferase inhibitor tipifarnib while none of the 6 patients with wild-type HRAS responded.	32636318	PubMed		"Lee et al., 2020, Clin Cancer Res"		2	accepted	9632	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/9632	https://civicdb.org/links/molecular_profiles/271	FALSE	HRAS	3265	Mutation		chr11	533873	534289			ENST00000451590.1	75		coding_transcript_variant		2023-01-09 21:52:06 UTC		"376,033,126,131,260,000,000,000,000,000,000"		FALSE
HRAS Mutation	271	Head And Neck Squamous Cell Carcinoma	5520		Tipifarnib		Predictive	Supports	B	Sensitivity/Response	"In a phase II HNSCC trial, an objective response rate of 55% was seen in HRAS-mutant patients (11 of 20) treated with the farnesyltransferase inhibitor tipifarnib with a PFS of 5.6 months and an OS of 15.6 months (providing the allele fraction was at least 20%)."	33750196	PubMed		"Ho et al., 2021, J Clin Oncol"	NCT02383927	2	accepted	9633	Somatic	2023-01-09 21:46:31 UTC	https://civicdb.org/links/evidence_items/9633	https://civicdb.org/links/molecular_profiles/271	FALSE	HRAS	3265	Mutation		chr11	533873	534289			ENST00000451590.1	75		coding_transcript_variant		2023-01-09 21:52:06 UTC		"376,033,126,131,260,000,000,000,000,000,000"		FALSE
ERBB2 Amplification	302	Childhood Ependymoma	5509		Lapatinib		Predictive	Supports	B	Sensitivity/Response	"From a phase one clinical trial, pediatric patients with refractory CNS malignancies were administered 300-1150 mg/m2 twice daily of ERBB2 and EGFR inhibitor lapatinib. The maximum-tolerated dose was established at 900 mg/m2 twice daily, regardless of steroid use. From the 59 patients, 12 patients, including 5 diagnosed with ependymoma, demonstrated a prolonged stable disease in response to lapatinib. In comparison to other CNS tumors, pretrial samples from patients with ependymoma tumors displayed high expression of ERBB2 and activation of ERBB2 signaling. Due to the high expression of ERBB2 receptors, targeting ERBB2 may be a viable treatment for patients with ependymoma tumors and other high expressing ERBB2 brain tumors."	20713864	PubMed		"Fouladi et al., 2010, J Clin Oncol"		1	accepted	9778	N/A	2023-02-03 15:55:46 UTC	https://civicdb.org/links/evidence_items/9778	https://civicdb.org/links/molecular_profiles/302	FALSE	ERBB2	2064	Amplification		chr17	39700080	39728662			ENST00000269571.5	75		transcript_amplification	N/A	2023-01-09 21:52:06 UTC		N/A	OVEREXPRESSION	FALSE
CTNNB1 S45F	1260	Desmoid Tumor	80366				Prognostic	Supports	B	Poor Outcome	"This was a multi-institutional retrospective cohort study which looked at the prognostic value of CTNNB1 gene mutations in aggressive fibromatosis (also known as desmoid tumor). The study analyzed 101 patients who had undergone surgical resection of confirmed primary extra-abdominal or abdominal wall aggressive fibromatosis. Specimens were reviewed for the presence of T41A, S45F, and 45P mutations on the CTNNB1 gene. Mutations were found in 76 patients, with T41A being most common (n = 49), followed by S45F (n = 18), and 45P (n = 3). The 5-year cumulative risk of recurrence was 22.8%. Further analysis revealed that patients with an S45F mutation had a 5-year recurrence risk of 63.8% and an 8.5-fold higher risk of recurrence compared to patients with wild type tumors (P=0.006)."	25341748	PubMed		"van Broekhoven et al., 2015, Ann Surg Oncol"		4	accepted	9788	Somatic	2023-01-09 21:46:44 UTC	https://civicdb.org/links/evidence_items/9788	https://civicdb.org/links/molecular_profiles/1260	FALSE	CTNNB1	1499	S45F		chr3	41224646	41224646	C	T	ENST00000349496.5	75		missense_variant	"NM_001904.3:c.134C>T,NP_001895.1:p.Ser45Phe,NC_000003.11:g.41266137C>T,ENST00000349496.5:c.134C>T"	2023-01-27 17:09:14 UTC	CA127283	17588	"SER45PHE,RS121913409"	FALSE
BRAF V600E	12	Colorectal Cancer	9256		"Encorafenib,Cetuximab"	Combination	Predictive	Supports	A	Sensitivity/Response	"The open-label phase 3 BEACON CRC trial included 665 patients with BRAF V600E-mutated metastatic CRC. Patients were randomly assigned in a 1:1:1 ratio to receive encorafenib, binimetinib, and cetuximab (triplet-therapy group); encorafenib and cetuximab (doublet-therapy group); or the investigators?choice of either cetuximab and irinotecan or cetuximab and FOLFIRI. The median overall survival was 8.4 months (95% CI, 7.5 to 11.0) in the doublet-therapy group and 5.4 months (95% CI, 4.8 to 6.6) in the control group, with a significantly lower risk of death compared to the control group (hazard ratio for death doublet-group vs. control, 0.60; 95% CI, 0.45 to 0.79; P<0.001). The confirmed response rate was 26% (95% CI, 18 to 35) in the triplet-therapy group, 20% in the doublet-therapy group (95% CI 13 to 29) and 2% (95% CI, 0 to 7) in the control group (doublet group vs. control P<0.001). Median PFS was 4.2 months (95% CI, 3.7 to 5.4) in the doublet-therapy group, and 1.5 months (95% CI, 1.5 to 1.7) in the control group (hazard ratio for disease progression doublet-group vs control, 0.40; 95% CI, 0.31 to 0.52, P<0.001)."	31566309	PubMed		"Kopetz et al., 2019, N. Engl. J. Med."	NCT02928224	5	accepted	9851	Somatic	2023-01-09 21:46:25 UTC	https://civicdb.org/links/evidence_items/9851	https://civicdb.org/links/molecular_profiles/12	FALSE	BRAF	673	V600E		chr7	140753336	140753336	A	T	ENST00000288602.6	75		missense_variant	"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A"	2023-01-27 17:02:02 UTC	CA123643	"13,961,376,069"	"RS113488022,VAL600GLU,V640E,VAL640GLU"	FALSE
EZH2 Y646C	3475						Functional	Supports	D	Loss of Function	"EZH2 mutations were identified in a screen of 614 patients with myeloid malignancies. Several mutations in the highly conserved CXC-SET domains were expressed in Sf9 insect cells along with polycomb repressive complex 2 components EED and SUZ12. Complexes were immunoprecipitated and assayed in vitro for H3K27M methyltransferase activity. EZH2 Y646C resulted in reduced methyltransferase activity, similar to the negative control (SET domain deletion). In addition, the SKM-1 cell line expressing EZH2 Y646C showed reduced H3K27M methyltransferase activity compared to EZH2-unmutated SKK-1 and MOLM-13 cell lines."	20601953	PubMed		"Ernst et al., 2010, Nat Genet"		2	accepted	9868	Unknown	2023-01-09 21:47:10 UTC	https://civicdb.org/links/evidence_items/9868	https://civicdb.org/links/molecular_profiles/3475	FALSE	EZH2	2146	Y646C		chr7	148811635	148811635	T	C	ENST00000320356.7			missense_variant	"NC_000007.14:g.148811635T>C,NC_000007.13:g.148508727T>C,ENST00000320356.7:c.1937A>G,ENSP00000320147.2:p.Tyr646Cys,NM_004456.5:c.1937A>G,NP_004447.2:p.Tyr646Cys"	2023-01-27 17:18:49 UTC	CA369713035	NONE FOUND	TYR646CYS	FALSE
ACVR1 G328V	1594	"Diffuse Midline Glioma, H3 K27M-mutant"	80684				Diagnostic	Supports	C	Positive	"It has been reported that recurrent activating somatic mutations (R206H, R258G, G328E/V/W, G356D) in the ACVR1 gene, which encodes a type I activin receptor serine/threonine kinase, are in 21% (11/52) of DIPG samples. The mutations were highly specific to DIPG, with an overall frequency of 0.3% in other tumors present in the Catalogue of Somatic Mutations in Cancer database. Data was collected from whole genome sequencing on 20 pre-treated biopsy samples of DIPG as well as whole exome sequencing from 1 biopsy sample and five samples obtained at autopsy. An additional 26 DIPG biopsy samples were screened via Sanger sequencing and identified the variant (G328W). DIPG cases with somatic mutations of ACVR1 (R206H, R258G, G328E/V/W, G356D) had longer overall survival (n=11 versus 41; median of 14.9 versus 10.9 months; p=0.05, log-rank test)."	24705252	PubMed		"Taylor et al., 2014, Nat. Genet."		2	accepted	10011	Somatic	2023-01-09 21:46:47 UTC	https://civicdb.org/links/evidence_items/10011	https://civicdb.org/links/molecular_profiles/1594	FALSE	ACVR1	90	G328V	ACVR1 kinase domain mutation	chr2	157766004	157766004	C	A	ENST00000434821.1	75		missense_variant	"NM_001105.4:c.983G>T,NP_001096.1:p.Gly328Val,NC_000002.11:g.158622516C>A,ENST00000434821.1:c.983G>T"	2023-01-27 17:11:21 UTC	CA16602802	376363	"GLY328VAL,RS387906589"	FALSE
ACVR1 G328W	2156	"Diffuse Midline Glioma, H3 K27M-mutant"	80684				Diagnostic	Supports	C	Positive	"It has been reported that recurrent activating somatic mutations (R206H, R258G, G328E/V/W, G356D) in the ACVR1 gene, which encodes a type I activin receptor serine/threonine kinase, are in 21% (11/52) of DIPG samples. The mutations were highly specific to DIPG, with an overall frequency of 0.3% in other tumors present in the Catalogue of Somatic Mutations in Cancer database. Data was collected from whole genome sequencing on 20 pre-treated biopsy samples of DIPG as well as whole exome sequencing from 1 biopsy sample and five samples obtained at autopsy. An additional 26 DIPG biopsy samples were screened via Sanger sequencing and identified the variant (G328W). DIPG cases with somatic mutations of ACVR1 (R206H, R258G, G328E/V/W, G356D) had longer overall survival (n=11 versus 41; median of 14.9 versus 10.9 months; p=0.05, log-rank test)."	24705252	PubMed		"Taylor et al., 2014, Nat. Genet."		2	accepted	10013	Somatic	2023-01-09 21:46:57 UTC	https://civicdb.org/links/evidence_items/10013	https://civicdb.org/links/molecular_profiles/2156	FALSE	ACVR1	90	G328W	ACVR1 kinase domain mutation	chr2	157766005	157766005	C	A	ENST00000263640.3	75		missense_variant	"NM_001105.4:c.982G>T,NP_001096.1:p.Gly328Trp,NC_000002.11:g.158622517C>A,ENST00000263640.3:c.982G>T"	2023-01-27 17:16:08 UTC	CA128481	29594	GLY328TRP	FALSE
EGFR G598V	971	Cancer	162		Erlotinib		Predictive	Supports	D	Sensitivity/Response	"In an in vitro study, a Ba/F3 cell line expressing EGFR G598V demonstrated increased sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing EGFR wild-type. Variant function was assessed by EGFR auto-phosphorylation. Sensitivity was assessed by cell viability assay using stable transfection of each variant and increasing concentrations of erlotinib (0?0 uM)."	17177598	PubMed		"Lee et al., 2006, PLoS Med."		3	accepted	10066	Somatic	2023-01-09 21:46:41 UTC	https://civicdb.org/links/evidence_items/10066	https://civicdb.org/links/molecular_profiles/971	FALSE	EGFR	1956	G598V		chr7	55165350	55165350	G	T	ENST00000275493.2	75		missense_variant	"NC_000007.13:g.55233043G>T,NM_001346898.2:c.1793G>T,NP_001333827.1:p.Gly598Val"	2023-01-27 17:07:32 UTC	CA4265696	376210	RS139236063	FALSE
PTPRB Loss-of-function	797	Angiosarcoma	1816				Diagnostic	Supports	B	Positive	A cohort of angiosarcomas (n=36) was sequenced and revealed to contain recurrent mutations in PTPRB (10/36) which were predominantly truncating or splice variants which impact the tyrosine phosphotase domain. Loss of function variants in PTPRB are rare in other cancer types suggesting this is specfic to angiosarcomas.	24633157	PubMed		"Behjati et al., 2014, Nat. Genet."		3	accepted	10079	Somatic	2023-01-09 21:46:38 UTC	https://civicdb.org/links/evidence_items/10079	https://civicdb.org/links/molecular_profiles/797	FALSE	PTPRB	5787	Loss-of-function		chr12	70516850	70637440			ENST00000334414.6	75		loss_of_function_variant		2023-01-09 21:52:09 UTC		N/A		FALSE
NTRK1 LMNA::NTRK1	1252	Cancer	162		Entrectinib		Predictive	Supports	D	Sensitivity/Response	"BaF3 cells were transduced with a number of NTRK fusions. IC50 values were measured following treatment with entrectinib: TPM3-NTRK1 (2.5nM), LMNA-NTRK1 (1.4nM), ETV6-NTRK1 (2.5nM), VCL-NTRK2 (4.3nM), AFAP1-NTRK2 (2.7nM), ETV6-NTRK2 (4.5nM), ETV6-NTRK3 (3.8nM), and control (>1000nM)."	26884591	PubMed		"Drilon et al., 2016, Ann. Oncol."	NCT02097810	3	accepted	10095	N/A	2023-02-04 19:59:09 UTC	https://civicdb.org/links/evidence_items/10095	https://civicdb.org/links/molecular_profiles/1252	FALSE	NTRK1	4914	LMNA::NTRK1	NTRK1 Fusions	chr1	156114707	156138757			ENST00000368300.4	75	ENST00000524377.1	transcript_fusion		2023-01-09 21:52:12 UTC		N/A	LMNA-NTRK1	FALSE
NTRK1 LMNA::NTRK1	1252	Cancer	162		Entrectinib		Predictive	Supports	D	Sensitivity/Response	"BaF3 cells were transduced with a number of NTRK fusions. IC50 values were measured following treatment with entrectinib: TPM3-NTRK1 (2.5nM), LMNA-NTRK1 (1.4nM), ETV6-NTRK1 (2.5nM), VCL-NTRK2 (4.3nM), AFAP1-NTRK2 (2.7nM), ETV6-NTRK2 (4.5nM), ETV6-NTRK3 (3.8nM), and control (>1000nM)."	26884591	PubMed		"Drilon et al., 2016, Ann. Oncol."	NCT02097810	3	accepted	10095	N/A	2023-02-04 19:59:09 UTC	https://civicdb.org/links/evidence_items/10095	https://civicdb.org/links/molecular_profiles/1252	FALSE	NTRK1	4914	LMNA::NTRK1	NTRK1 Fusions	chr1	156874571	156881642			ENST00000368300.4	75	ENST00000524377.1	transcript_fusion		2023-01-09 21:52:12 UTC		N/A	LMNA-NTRK1	FALSE
FLCN c.1285dupC	3595	Renal Cell Carcinoma	4450	"Fibrofolliculoma,Pulmonary cyst,Spontaneous pneumothorax"	Everolimus		Predictive	Supports	C	Sensitivity/Response	"A case study showed that the mTOR inhibitor everolimus exhibited a relatively long-term effect in a patient with renal cell carcinoma and a FLCN germline mutation (c. 1285dupC, likely loss of function)."	23995526	PubMed		"Nakamura et al., 2013, Hinyokika Kiyo"		1	accepted	10137	Rare Germline	2023-01-09 21:47:11 UTC	https://civicdb.org/links/evidence_items/10137	https://civicdb.org/links/molecular_profiles/3595	FALSE	FLCN	201163	c.1285dupC		chr17	17216394	17216395		G	ENST00000285071.9	75			"NM_144997.7:c.1285dup,NP_659434.2:p.His429fs"	2023-01-27 17:18:57 UTC	CA090951	3363	HIS429FS	FALSE
SF3B1 K700E	561	Leukemia	1240		"Olaparib,Etoposide"	Substitutes	Predictive	Supports	D	Sensitivity/Response	"The cancer-associated SF3B1-K700E mutation compromises homologous recombination repair and increases the sensitivity to ionising radiation and DNA damaging agents, such as etoposide or small molecule inhibitors including olaparib in isogenic K562 cell line. The SF3B1-WT and SF3B1-K700E cell lines were also engrafted subcutaneously into immunocompromised mice, and the mice were treated with etoposide, olaparib or a vehicle control and monitored tumour growth for 28 days. Treatment with either etoposide or olaparib significantly reduced the volume of the SF3B1-K700E mutant tumours, but had little effect on the volume of SF3B1-WT tumours."	35027467	PubMed		"Lappin et al., 2022, Cancer Res"		3	accepted	10139	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/10139	https://civicdb.org/links/molecular_profiles/561	FALSE	SF3B1	23451	K700E	SF3B1 HEAT domain mutation	chr2	197402110	197402110	T	C	ENST00000335508.6	75		missense_variant	"NM_012433.3:c.2098A>G,NP_036565.2:p.Lys700Glu,ENST00000335508.6:c.2098A>G,NC_000002.11:g.198266834T>C"	2023-01-27 17:04:22 UTC	CA2042597	376004	"LYS700GLU,RS559063155"	FALSE
ERCC1 Underexpression	2282	Lung Non-small Cell Carcinoma	3908		"Gemcitabine,Carboplatin"	Combination	Predictive	Supports	B	Sensitivity/Response	"As part of a randomized phase III trial (USO-03012) in advanced NSCLC of gemcitabine vs. combination gemcitabine and carboplatin, protein expression levels for RRM1 (n=69) and ERCC1 (n=65) were evaluated using fluorescence-based IHC. RRM1 levels were significantly inversely correlated with response (r = ?.41; P = .001, n=58), as were ERCC1 levels (r = ?.39; P = .003, n=55). RRM1 and ERCC1 levels were correlated with each other (r = 0.36; P = .003, n=65). There was no significant interaction with treatment arm (P = .64 for RRM1; P = .79 for ERCC1). The authors conclude that RRM1 and ERCC1 expression levels are predictive of response to gemcitabine, and gemcitabine and carboplatin."	19884554	PubMed		"Reynolds et al., 2009, J Clin Oncol"		3	accepted	10142	N/A	2023-01-09 21:46:58 UTC	https://civicdb.org/links/evidence_items/10142	https://civicdb.org/links/molecular_profiles/2282	FALSE	ERCC1	2067	Underexpression		chr19	45413434	45423566			ENST00000013807.5	75		N/A		2023-01-09 21:52:19 UTC		N/A		FALSE
RRM1 Underexpression	1231	Lung Non-small Cell Carcinoma	3908		"Gemcitabine,Carboplatin"	Combination	Predictive	Supports	B	Sensitivity/Response	"As part of a randomized phase III trial (USO-03012) in advanced NSCLC of gemcitabine vs. combination gemcitabine and carboplatin, protein expression levels for RRM1 (n=69) and ERCC1 (n=65) were evaluated using fluorescence-based IHC. RRM1 levels were significantly inversely correlated with response (r = ?.41; P = .001, n=58), as were ERCC1 levels (r = ?.39; P = .003, n=55). RRM1 and ERCC1 levels were correlated with each other (r = 0.36; P = .003, n=65). There was no significant interaction with treatment arm (P = .64 for RRM1; P = .79 for ERCC1). The authors conclude that RRM1 and ERCC1 expression levels are predictive of response to gemcitabine, and gemcitabine and carboplatin."	19884554	PubMed		"Reynolds et al., 2009, J Clin Oncol"		3	accepted	10143	N/A	2023-01-09 21:46:44 UTC	https://civicdb.org/links/evidence_items/10143	https://civicdb.org/links/molecular_profiles/1231	FALSE	RRM1	6240	Underexpression		chr11	4094809	4138876			ENST00000300738.5	75		N/A		2023-01-09 21:52:12 UTC		N/A		FALSE
IDH1 R132C	59	Cancer	162		Olaparib		Predictive	Supports	D	Sensitivity/Response	"IDH1 R132C mutation confers a switch of function mutation where the mutated protein produces 2-hydroxyglutarate (2HG), rather than -ketoglutarate (KG). The novel metabolite induces a homologous recombination (HR) defect that sensitizes the tumor cells to poly (ADP-ribose) polymerase (PARP) inhibitors. PARP inhibitor sensititivity was tested in vivo in HeLa cells where the R132C mutation was create with CRISPR, the HCT116 colon cancer cell line where R132C mutation was created with recombinant adeno-associated virus (rAAV), and the HT1080 human sarcoma cell line which already has R132C. The results were then duplicated in non-commercial glioma cell lines: 6 IDH1 R132 mutant; 4 IDH1 wt."	28148839	PubMed		"Sulkowski et al., 2017, Sci Transl Med"		3	accepted	10144	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/10144	https://civicdb.org/links/molecular_profiles/59	FALSE	IDH1	3417	R132C		chr2	208248389	208248389	G	A	ENST00000415913.1	75		missense_variant	"NM_005896.3:c.394C>T,NP_005887.2:p.Arg132Cys,NC_000002.11:g.209113113G>A,ENST00000415913.1:c.394C>T"	2023-01-27 17:02:19 UTC	CA16602374	375891	"RS121913499,ARG132CYS"	FALSE
ERCC1 Underexpression	2282	Ovary Epithelial Cancer	2152		Platinum Compound		Predictive	Supports	B	Sensitivity/Response	"Ovarian epithelial tumours (n=235) were used to create TMAs and IHC results were scored for ERCC1 (n=114 low, n=121 high). For platinum sensitive patients (n=250 in supplementary table, but not all have ERCC1 levels available), low ERCC1 was associated with better PFS (p = 0.034, HR 1.9, 95% CI 1.1-3.6). For platinum resistant patients (n=26 in supplementary table, but not all have ERCC1 levels available), there was no significant association (p = 0.550, HR 0.5, 95% CI 0.1-4.3)."	30797591	PubMed		"Mesquita et al., 2019, Gynecol Oncol"		3	accepted	10146	N/A	2023-01-09 21:46:58 UTC	https://civicdb.org/links/evidence_items/10146	https://civicdb.org/links/molecular_profiles/2282	FALSE	ERCC1	2067	Underexpression		chr19	45413434	45423566			ENST00000013807.5	75		N/A		2023-01-09 21:52:19 UTC		N/A		FALSE
NTRK1 Amplification	1254	Solid Tumor			Larotrectinib		Predictive	Supports	C	Sensitivity/Response	"In a phase I study of larotrectinib in 67 patients with solid tumours, 8 patients were recorded as having objective response. 7 of these harboured NTRK fusions, and one had a NTRK1 amplification. This patient's tumour had a size reduction measured as 45% and a response duration of 3.7 months. It is not stated in the publication whether a survey of amplification status in other patients in the study was done."	30624546	PubMed		"Hong et al., 2019, Ann. Oncol."	NCT02122913	2	accepted	10170	Somatic	2023-01-09 21:46:44 UTC	https://civicdb.org/links/evidence_items/10170	https://civicdb.org/links/molecular_profiles/1254	FALSE	NTRK1	4914	Amplification		chr1	156860894	156881642			ENST00000524377.1	75		transcript_amplification		2023-01-09 21:52:12 UTC		N/A		FALSE
KIT EXPRESSION	425	Glioblastoma	3068		Sunitinib		Predictive	Supports	B	Sensitivity/Response	"Phase II trial of sunitinib in 40 patients with first recurrence of primary glioblastoma. Median PFS 2.2 mo, median OS 9.2 mo, 5 stable disease >=6 months, no objective responses, so primary study endpoint was not met. However, IHC of multiple receptor kinases was performed, and protein expression of KIT in vascular endothelial cells was associated with longer PFS (P = .017; HR, 2.564; 95% CI, 1.180?.570). All 5 with stable disease were KIT+ in vascular endothelial cells. Note KIT staining was not observed in tumour cells. No association with OS."	24311637	PubMed		"Hutterer et al., 2014, Neuro Oncol"	NCT00535379	3	accepted	10180	Somatic	2023-01-09 21:46:33 UTC	https://civicdb.org/links/evidence_items/10180	https://civicdb.org/links/molecular_profiles/425	FALSE	KIT	3815	EXPRESSION		chr4	54657918	54740715			ENST00000288135.5	75		N/A		2023-01-09 21:52:07 UTC		N/A		FALSE
TP53 A276V	1024						Functional	Does Not Support	D	Dominant Negative	A set of previously characterized p53 mutants was tested in the yeast assay to understand their transdominant potential (dominant negative). Each mutant was expressed equally with the wild-type p53. The authors used the RGC sequence as a p53 binding site. TP53 variant A276V was classified as recessive for RGC and a hotspot for mutation (P < 0.01) by the authors.	11896595	PubMed		"Monti et al., 2002, Oncogene"		3	accepted	10232	Somatic	2023-01-09 21:46:42 UTC	https://civicdb.org/links/evidence_items/10232	https://civicdb.org/links/molecular_profiles/1024	FALSE	TP53	7157	A276V		chr17	7673793	7673793	G	A	ENST00000269305.4	75		missense_variant	ENST00000269305.4:c.827C>T	2023-01-27 17:07:52 UTC	CA397836916	N/A	ALA276VAL	FALSE
TP53 R158H	1603						Functional	Does Not Support	D	Dominant Negative	"A set of previously characterized p53 mutants was tested in the yeast assay to understand their transdominant potential (dominant negative). Each mutant was expressed equally with the wild-type p53. The authors used the p21, bax, and PIG3 sequences as p53 binding sites. TP53 variant R158H was classified as recessive for p21, bax, and PIG3. In addition, R158H was classified as a hotspot for mutation (P < 0.001) by the authors."	11896595	PubMed		"Monti et al., 2002, Oncogene"		3	accepted	10237	Somatic	2023-01-09 21:46:47 UTC	https://civicdb.org/links/evidence_items/10237	https://civicdb.org/links/molecular_profiles/1603	FALSE	TP53	7157	R158H		chr17	7675139	7675139	C	T	ENST00000269305.4	75		missense_variant	ENST00000269305.4:c.473G>A	2023-01-27 17:11:23 UTC	CA000227	141963	ARG158HIS	FALSE
TP53 C242Y	1038						Functional	Supports	D	Dominant Negative	"A set of previously characterized p53 mutants was tested in the yeast assay to understand their transdominant potential (dominant negative). Each mutant was expressed equally with the wild-type p53. The authors used the RGC, p21, bax, and PIG3 sequences as p53 binding sites. TP53 variant C242Y was classified as dominant negative for RGC, p21, bax, and PIG3. In addition, C242Y was classified as a hotspot for mutation (P < 0.001) by the authors. The authors proposed a hierarchy of dominance of p53 variants for p21, PIG3, and bax sequences. They observed p53 variants that are dominant negative for p21 are also dominant for PIG3 and bax, and p53 variants that are dominant negative for PIG3 are also dominant for bax. The authors suggested lack of transactivation ability is necessary but not sufficient to predict dominance."	11896595	PubMed		"Monti et al., 2002, Oncogene"		3	accepted	10251	Somatic	2023-01-09 21:46:42 UTC	https://civicdb.org/links/evidence_items/10251	https://civicdb.org/links/molecular_profiles/1038	FALSE	TP53	7157	C242Y		chr17	7674238	7674238	C	T	ENST00000269305.4	75		missense_variant	"NM_000546.5:c.725G>A,NP_000537.3:p.Cys242Tyr,NC_000017.10:g.7577556C>T,ENST00000269305.4:c.725G>A"	2023-01-27 17:07:54 UTC	CA000361	12354	RS121912655	FALSE
TP53 G245S	853						Functional	Supports	D	Dominant Negative	"A set of previously characterized p53 mutants was tested in the yeast assay to understand their transdominant potential (dominant negative). Each mutant was expressed equally with the wild-type p53. The authors used the RGC, p21, bax, and PIG3 sequences as p53 binding sites. TP53 variant G245S was classified as dominant negative for RGC, p21, bax, and PIG3. In addition, G245S was classified as a hotspot for mutation (P < 0.001) by the authors. The authors proposed a hierarchy of dominance of p53 variants for p21, PIG3, and bax sequences. They observed p53 variants that are dominant negative for p21 are also dominant for PIG3 and bax, and p53 variants that are dominant negative for PIG3 are also dominant for bax. The authors suggested lack of transactivation ability is necessary but not sufficient to predict dominance."	11896595	PubMed		"Monti et al., 2002, Oncogene"		3	accepted	10253	Somatic	2023-01-09 21:46:39 UTC	https://civicdb.org/links/evidence_items/10253	https://civicdb.org/links/molecular_profiles/853	FALSE	TP53	7157	G245S		chr17	7674230	7674230	C	T	ENST00000269305.4	75		missense_variant	"NC_000017.10:g.7577548C>T,NM_000546.5:c.733G>A,NP_000537.3:p.Gly245Ser,ENST00000269305.4:c.733G>A"	2023-01-27 17:06:17 UTC	CA000367	12365	RS28934575	FALSE
TP53 R273C	121						Functional	Supports	D	Dominant Negative	"A set of previously characterized p53 mutants was tested in the yeast assay to understand their transdominant potential (dominant negative). Each mutant was expressed equally with the wild-type p53. The authors used the RGC, p21, bax, and PIG3 sequences as p53 binding sites. TP53 variant R273C was classified as dominant negative for RGC, p21, bax, and PIG3. In addition, R273C was classified as a hotspot for mutation (P < 0.001) by the authors. The authors proposed a hierarchy of dominance of p53 variants for p21, PIG3, and bax sequences. They observed p53 variants that are dominant negative for p21 are also dominant for PIG3 and bax, and p53 variants that are dominant negative for PIG3 are also dominant for bax. The authors suggested lack of transactivation ability is necessary but not sufficient to predict dominance."	11896595	PubMed		"Monti et al., 2002, Oncogene"		3	accepted	10256	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/10256	https://civicdb.org/links/molecular_profiles/121	FALSE	TP53	7157	R273C		chr17	7673803	7673803	G	A	ENST00000269305.4	75		missense_variant	"NM_000546.5:c.817C>T,NP_000537.3:p.Arg273Cys,NC_000017.10:g.7577121G>A,ENST00000269305.4:c.817C>T"	2023-01-27 17:02:47 UTC	CA000432	43594	"ARG273CYS,RS121913343"	FALSE
TP53 R248W	118						Functional	Supports	D	Dominant Negative	"A set of previously characterized p53 mutants was tested in the yeast assay to understand their transdominant potential (dominant negative). Each mutant was expressed equally with the wild-type p53. The authors used the p21, bax, and PIG3 sequences as p53 binding sites. TP53 variant R248W was classified as dominant negative for p21, bax, and PIG3. In addition, R248W was classified as a hotspot for mutation (P < 0.001) by the authors. The authors proposed a hierarchy of dominance of p53 variants for p21, PIG3, and bax sequences. They observed p53 variants that are dominant negative for p21 are also dominant for PIG3 and bax, and p53 variants that are dominant negative for PIG3 are also dominant for bax. The authors suggested lack of transactivation ability is necessary but not sufficient to predict dominance."	11896595	PubMed		"Monti et al., 2002, Oncogene"		3	accepted	10261	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/10261	https://civicdb.org/links/molecular_profiles/118	FALSE	TP53	7157	R248W		chr17	7674221	7674221	G	A	ENST00000269305.4	75		missense_variant	"NM_000546.5:c.742C>T,NP_000537.3:p.Arg248Trp,NC_000017.10:g.7577539G>A,ENST00000269305.4:c.742C>T"	2023-01-27 17:02:45 UTC	CA000382	12347	"ARG248TRP,RS121912651"	FALSE
FGFR1 N546K	511	Pilocytic Astrocytoma	4851		Pemigatinib		Predictive	Supports	C	Sensitivity/Response	Case report of a 32-year old male patient with pilocytic astrocytoma. Genomic profiling (FoundationOne) revealed a FGFR1 N546K mutation. The patient was enrolled in a phase I/II trial of pemigatinib and achieved a partial response lasting 18 months.	35507888	PubMed		"Capone et al., 2022, JCO Precis Oncol"		3	accepted	10325	Somatic	2023-01-09 21:46:35 UTC	https://civicdb.org/links/evidence_items/10325	https://civicdb.org/links/molecular_profiles/511	FALSE	FGFR1	2260	N546K		chr8	38417331	38417331	G	T	ENST00000341462.5	75		missense_variant	"NM_023110.2:c.1638C>A,NP_075598.2:p.Asn546Lys,ENST00000341462.5:c.1638C>A,NC_000008.10:g.38274849G>T"	2023-01-27 17:04:05 UTC	CA357830	224896	"ASN546LYS,RS779707422"	FALSE
FGFR3 Overexpression	321	Cancer	162		R3Mab		Predictive	Supports	D	Sensitivity/Response	Pro-B Ba/F3 cells transfected with wild type FGFR3 resulted in Il-3 independence with FGF1 dependence for growth.  Monoclonal antibody R3Mab treatment in addition to FGF1 resulted in suppression of proliferation of Ba/F3 cells with wild type FGFR3.	19381019	PubMed		"Qing et al., 2009, J. Clin. Invest."		3	accepted	10352	Somatic	2023-01-09 21:46:32 UTC	https://civicdb.org/links/evidence_items/10352	https://civicdb.org/links/molecular_profiles/321	FALSE	FGFR3	2261	Overexpression		chr4	1793312	1808872			ENST00000440486.2	75		N/A		2023-01-09 21:52:06 UTC		N/A		FALSE
FGFR3 G370C	2279	Cancer	162		R3Mab		Predictive	Does Not Support	D	Resistance	"Ba/F3 cells transfected with wild type FGFR3 or common bladder carcinoma variant FGFR3 G372C both resulted in IL-3 independence with FGF1 dependence for growth. Monoclonal antibody R3Mab treatment with FGF1 suppressed proliferation of Ba/F3 FGFR3 G372C cells. Wildtype FGFR3 overexpression in Ba/F3 cells as well as bladder cancer cell lines RT112 and RT4 (who both have normal levels of endogenously expressed wildtype FGFR3), were similarly sensitive to R3Mab treatment, therefore mutation G372C did not change that responsiveness."	19381019	PubMed		"Qing et al., 2009, J. Clin. Invest."		3	accepted	10353	Somatic	2023-01-09 21:46:58 UTC	https://civicdb.org/links/evidence_items/10353	https://civicdb.org/links/molecular_profiles/2279	FALSE	FGFR3	2261	G370C		chr4	1804362	1804362	G	T	ENST00000440486.8	75		missense_variant	"NC_000004.11:g.1806089G>T,NC_000004.12:g.1804362G>T,NM_000142.5:c.1108G>T,NP_000133.1:p.Gly370Cys,NP_001156685.1:p.Gly372Cys"	2023-01-27 17:16:39 UTC	CA129946	16359	"GLY370CYS,G372C,GLY372CYS"	FALSE
FGFR3 Y373C	2277	Cancer	162		R3Mab		Predictive	Does Not Support	D	Resistance	"Pro-B Ba/F3 cells transfected with wild type FGFR3 resulted in IL-3 independence with FGF1 dependence for growth. Cell transfected FGFR3 with mutation Y375C also resulted in IL-3 independence and FGF1 dependence. Monoclonal antibody R3Mab treatment along with FGF1 resulted in suppression of proliferation of Ba/F3 cells with FGFR3 Y375C. Wild type FGFR3 overexpression in Ba/F3 cells with FGF1 was sensitive to monoclonal antibody R3Mab treatment, and mutation Y375C did not change that responsiveness."	19381019	PubMed		"Qing et al., 2009, J. Clin. Invest."		3	accepted	10354	Somatic	2023-01-09 21:46:58 UTC	https://civicdb.org/links/evidence_items/10354	https://civicdb.org/links/molecular_profiles/2277	FALSE	FGFR3	2261	Y373C		chr4	1804372	1804372	A	G	ENST00000440486.2	75		missense_variant	"NC_000004.11:g.1806099A>G,NM_001163213.1:c.1124A>G,NP_000133.1:p.Tyr373Cys,NM_000142.5:c.1118A>G,NC_000004.12:g.1804372A>G"	2023-01-27 17:16:37 UTC	CA341413	16342	"TYR375CYS,RS121913485,Y375C,TYR373CYS"	FALSE
FGFR3 K650E	1308	Cancer	162		R3Mab		Predictive	Does Not Support	D	Resistance	"Ba/F3 cells transfected with wildtype FGFR3 resulted in IL-3 independence with FGF1 dependence for growth, whereas cells transfected with common bladder carcinoma variant FGFR3 K652E resulted in IL-3 independence, weak ligand-independent proliferation and a strong growth response to FGF1. Monoclonal antibody R3Mab treatment with FGF1 suppressed proliferation of Ba/F3 FGFR3 K652E cells. Wildtype FGFR3 overexpression in Ba/F3 cells as well as bladder cancer cell lines RT112 and RT4 (who both have normal levels of endogenously expressed wildtype FGFR3), were similarly sensitive to R3Mab treatment, therefore mutation K652E did not change that responsiveness."	19381019	PubMed		"Qing et al., 2009, J. Clin. Invest."		3	accepted	10355	Somatic	2023-01-09 21:46:44 UTC	https://civicdb.org/links/evidence_items/10355	https://civicdb.org/links/molecular_profiles/1308	FALSE	FGFR3	2261	K650E		chr4	1806162	1806162	A	G	ENST00000340107.4	75		missense_variant	"NC_000004.11:g.1807889A>G,NC_000004.12:g.1806162A>G,NM_000142.5:c.1948A>G,NP_000133.1:p.Lys650Glu"	2023-01-27 17:09:30 UTC	CA126376	16331	"RS78311289,LYS650GLU,K652E,LYS652GLU,TDII"	FALSE
FGFR3 K650N	3563						Functional	Supports	D	Gain of Function	"Five patients from four families suffering from skeletal dysplasia were found to harbor a novel heterozygous K650N variant in FGFR3. The variant cosegregated in two patients from one family (a father and his daughter), whereas it occurred sporadically in the others. NIH3T3 cells were transfected with the variant construct followed by kinase activity assay that showed increased activity by ~ 4 folds compared to the wild type. The authors suggest that this variant, although showing lower activation levels than other known variants responsible for severe skeletal dysplasia forms, is responsible for the milder skeletal dysplasia form seen in those patients (mild hypochondroplasia phenotype), and they further highlight the significance of Lys650 site in the active domain loop of the receptor."	11055896	PubMed		"Bellus et al., 2000, Am J Hum Genet"		2	accepted	10377	N/A	2023-01-09 21:47:11 UTC	https://civicdb.org/links/evidence_items/10377	https://civicdb.org/links/molecular_profiles/3563	FALSE	FGFR3	2261	K650N		chr4	1806164	1806164	G	C	ENST00000440486.8			missense_variant	"NC_000004.12:g.1806164G>C,NC_000004.11:g.1807891G>C,ENST00000440486.8:c.1950G>C,NM_000142.5:c.1950G>C,ENSP00000414914.2:p.Lys650Asn,NP_000133.1:p.Lys650Asn"	2023-01-27 17:18:53 UTC	CA280221	"1,634,716,346"	LYS650ASN	FALSE
FGFR3 K650Q	3887						Functional	Supports	D	Gain of Function	"A patient suffering from skeletal dysplasia was found to harbor a novel heterozygous K650Q variant in FGFR3. NIH3T3 cells were transfected with the variant construct followed by kinase activity assay that showed increased activity by 5 folds compared to the wild type. The authors suggest that this variant, although showed lower activation levels than other known variants responsible for severe skeletal dysplasia forms, is responsible for the milder skeletal dysplasia form seen in those patients (mild hypochondroplasia phenotype), and they further highlight the significance of Lys650 site in the active domain loop of the receptor."	11055896	PubMed		"Bellus et al., 2000, Am J Hum Genet"		2	accepted	10378	Somatic	2023-01-09 21:47:13 UTC	https://civicdb.org/links/evidence_items/10378	https://civicdb.org/links/molecular_profiles/3887	FALSE	FGFR3	2261	K650Q		chr4	1806162	1806162	A	C	ENST00000440486.8			missense_variant	"NC_000004.12:g.1806162A>C,NC_000004.11:g.1807889A>C,ENST00000440486.8:c.1948A>C,NM_000142.5:c.1948A>C,ENSP00000414914.2:p.Lys650Gln ,NP_000133.1:p.Lys650Gln"	2023-01-27 17:18:59 UTC	CA170755	16348	"LYS650GLN,LYS652GLN,LYS538GLN,LYS651GLN,K652Q,K538Q,K651Q"	FALSE
FGFR3 K650M	3881						Functional	Supports	D	Gain of Function	The K650M variant in FGFR3 is known to be responsible for the severe skeletal dysplasia forms seen in TDI/SADDAN. The mutant receptor was tested for comparison between other variants discussed in this paper. FGFR3 cDNA construct with the K650M variant was synthesized and transfected into NIH3T3 cells. The K650M variant receptor had 18- fold greater kinase activity compared to the wild type receptor.	11055896	PubMed		"Bellus et al., 2000, Am J Hum Genet"		1	accepted	10380	N/A	2023-01-09 21:47:13 UTC	https://civicdb.org/links/evidence_items/10380	https://civicdb.org/links/molecular_profiles/3881	FALSE	FGFR3	2261	K650M		chr4	1806163	1806163	A	T	ENST00000440486.8			missense_variant	"NC_000004.12:g.1806163A>T,NC_000004.11:g.1807890A>T,ENST00000440486.8:c.1949A>T,ENSP00000414914.2:p.Lys650Met,NM_000142.5:c.1949A>T,NP_000133.1:p.Lys650Met"	2023-01-27 17:18:58 UTC	CA126382	16341	LYS650MET	FALSE
FGFR3 K650E	1308						Functional	Supports	D	Gain of Function	NIH 3T3 cells were transfected with wild-type and mutant K650E FGFR3. Immunoprecipitation measuring kinase activity showed FGFR3 K650E had 100-fold greater autophosphorylation than wildtype. The authors concluded that the position and charge of K650E lead to its constitutive activation.	8754806	PubMed		"Webster et al., 1996, Mol Cell Biol"		3	accepted	10393	Common Germline	2023-01-09 21:46:44 UTC	https://civicdb.org/links/evidence_items/10393	https://civicdb.org/links/molecular_profiles/1308	FALSE	FGFR3	2261	K650E		chr4	1806162	1806162	A	G	ENST00000340107.4	75		missense_variant	"NC_000004.11:g.1807889A>G,NC_000004.12:g.1806162A>G,NM_000142.5:c.1948A>G,NP_000133.1:p.Lys650Glu"	2023-01-27 17:09:30 UTC	CA126376	16331	"RS78311289,LYS650GLU,K652E,LYS652GLU,TDII"	FALSE
EZH2 Y646F	2858	B-cell Lymphoma	707				Oncogenic	Supports	D	Oncogenicity	"Ezh2 Y641F (EZH2 Y641F) was conditionally expressed in mouse B-cells and caused high-penetrance lymphoma that was further accelerated by Bcl2 overexpression or p53 loss (but not c-Myc overexpression). Expression of Ezh2 Y641F increased global abundance of H3K27 trimethylation (H3K27me3) and also caused widespread redistribution of H3K27me3 leading to widespread transciptional changes. Overall, these results suggest that Ezh2 Y641F induces B-cell lymphoma through widespread reorganization of chromatin structure."	27135738	PubMed		"Souroullas et al., 2016, Nat. Med."		4	accepted	10394	Somatic	2023-01-09 21:47:04 UTC	https://civicdb.org/links/evidence_items/10394	https://civicdb.org/links/molecular_profiles/2858	FALSE	EZH2	2146	Y646F		chr7	148811635	148811635	T	A	ENST00000320356.7			missense_variant	"ENST00000320356.7:c.1937A>T,NC_000007.14:g.148811635T>A,NC_000007.13:g.148508727T>A,ENSP00000320147.2:p.Tyr646Phe,ENST00000460911.5:c.1922A>T,ENSP00000419711.1:p.Tyr641Phe,NM_004456.5:c.1937A>T,NP_004447.2:p.Tyr646Phe,NM_001203247.2:c.1922A>T,NP_001190176.1:p.Tyr641Phe"	2023-01-27 17:18:07 UTC	CA16602259	76768	"Y641F,TYR641PHE,TYR646PHE"	FALSE
FGFR3 K650D	3892						Functional	Supports	D	Gain of Function	"NIH 3T3 cells were transfected with wild-type and mutant FGFR3 K650D. Immunoprecipitation measuring kinase activity showed FGFR3 K650D had similar autophosphorylation through constitutive action to FGFR3 K650E, which had 100-fold greater autophosphorylation than wildtype. The authors concluded that for constitutive FGFR3 activation, an acidic residue at position 650 is beneficial but not required."	8754806	PubMed		"Webster et al., 1996, Mol Cell Biol"		3	accepted	10400	Somatic	2023-01-09 21:47:13 UTC	https://civicdb.org/links/evidence_items/10400	https://civicdb.org/links/molecular_profiles/3892	FALSE	FGFR3	2261	K650D		chr4	1806162	1806164	GAC	AAG	ENST00000440486.8			delins	"NC_000004.12:g.1806162_1806164delinsGAC,NC_000004.11:g.1807889_1807891delinsGAC,ENST00000440486.8:c.1948_1950delinsGAC,ENSP00000414914.2:p.Lys650Asp ,NM_000142.5:c.1948_1950delinsGAC,NP_000133.1:p.Lys650Asp"	2023-01-09 21:52:29 UTC	unregistered	NONE FOUND	LYS650ASP	FALSE
FGFR3 K650Q	3887						Functional	Supports	D	Gain of Function	"NIH 3T3 cells were transfected with wild-type and mutant FGFR3 K650Q. Immunoprecipitation measuring kinase activity showed FGFR3 K650Q had much lower autophosphorylation to FGFR3 K650E, which had 100-fold greater autophosphorylation than wildtype, but that FGFR K650Q still had higher autophosphorylation driven by constitutive action than wildtype. The authors concluded that for constitutive FGFR3 activation, an acidic residue at position 650 is beneficial but not required."	8754806	PubMed		"Webster et al., 1996, Mol Cell Biol"		2	accepted	10401	Somatic	2023-01-09 21:47:13 UTC	https://civicdb.org/links/evidence_items/10401	https://civicdb.org/links/molecular_profiles/3887	FALSE	FGFR3	2261	K650Q		chr4	1806162	1806162	A	C	ENST00000440486.8			missense_variant	"NC_000004.12:g.1806162A>C,NC_000004.11:g.1807889A>C,ENST00000440486.8:c.1948A>C,NM_000142.5:c.1948A>C,ENSP00000414914.2:p.Lys650Gln ,NP_000133.1:p.Lys650Gln"	2023-01-27 17:18:59 UTC	CA170755	16348	"LYS650GLN,LYS652GLN,LYS538GLN,LYS651GLN,K652Q,K538Q,K651Q"	FALSE
FGFR3 K650L	3893						Functional	Supports	D	Gain of Function	"NIH 3T3 cells were transfected with wild-type and mutant FGFR3 K650L. Immunoprecipitation measuring kinase activity showed FGFR3 K650L had much lower autophosphorylation than FGFR3 K650E, which had 100-fold greater autophosphorylation than wildtype but had higher autophosphorylation driven by constitutive action than wildtype. The authors concluded that for constitutive FGFR3 activation, an acidic residue at position 650 is beneficial but not required."	8754806	PubMed		"Webster et al., 1996, Mol Cell Biol"		2	accepted	10402	Somatic	2023-01-09 21:47:13 UTC	https://civicdb.org/links/evidence_items/10402	https://civicdb.org/links/molecular_profiles/3893	FALSE	FGFR3	2261	K650L		chr4	1806162	1806163	AA	CT	ENST00000440486.8				"NC_000004.12:g.1806162_1806163delinsCT,NC_000004.11:g.1807889_1807890delinsCT,ENST00000440486.8:c.1948_1949delinsCT,ENSP00000414914.2:p.Lys650Leu,NM_000142.5:c.1948_1949delinsCT,NP_000133.1:p.Lys650Leu"	2023-01-27 17:19:03 UTC	CA2573130207	NONE FOUND	LYS650LEU	FALSE
FGFR3 G380R	2278						Functional	Supports	D	Gain of Function	"Achondroplasia  associated FGFR3 mutant G380R (ACH), K650E (TDII), and wildtype (WT) FGFR3 constructs were cloned and transfected into NIH3T3 cells, and immunopercipitated with anti-FGFR3. In vitro kinase assays were performed and G380R was found to have activity between WT and K650E, which had approximately 100 fold increase over WT."	8754806	PubMed		"Webster et al., 1996, Mol Cell Biol"		2	accepted	10416	Unknown	2023-01-09 21:46:58 UTC	https://civicdb.org/links/evidence_items/10416	https://civicdb.org/links/molecular_profiles/2278	FALSE	FGFR3	2261	G380R		chr4	1804392	1804392	G	C	ENST00000340107.4	75		missense_variant	"NC_000004.11:g.1806119G>C,NC_000004.12:g.1804392G>C,NM_000142.5:c.1138G>C,NP_000133.1:p.Gly380Arg,NP_001156685.1:p.Gly382Arg,NM_001163213.1:c.1144G>C"	2023-01-27 17:16:38 UTC	CA280218	16328	"GLY380ARG,G382R,GLY382ARG"	FALSE
FGFR3 K650E	1308						Functional	Supports	D	Gain of Function	"A construct of PDGF and FGFR3 was created as a chimeric receptor to study the effect of the K650E variant on downstream signaling pathways. Transfecting PC12 cells showed continuous ligand-independent activity of the chimeric mutant receptor with the presence of an inducer alone (zinc) but not the ligand; PDFG. Upon addition of PDGF, further activation was also observed. Conversely, control cells showed activity only with the addition of both ligand and zinc. Gene expression profiling showed P21 gene was expressed at a higher level (1.7 folds) in mutant receptor cells, providing evidence of ERK1/2 and STAT1/3 activation. The mutant receptor produced a highly sustained ERK1/2 activation even after 1 hour of PDGF treatment, whereas wild-type expressing cells showed a decrease in ERK1/2 activity. Lastly, cells only expressing the variant K650E receptor were able to phosphorylate tyrosine in STAT1, and tyrosine, along with serine, in a ligand-independent manner in STAT3. Authors confirm that mutant FGFR3 activates ERK1/2 and STAT1/3 in a ligand-independent manner and maintains this activation over longer periods of time when treated with ligand than does the wild-type receptor."	15843401	PubMed		"Nowroozi et al., 2005, Hum Mol Genet"		3	accepted	10493	N/A	2023-01-09 21:46:44 UTC	https://civicdb.org/links/evidence_items/10493	https://civicdb.org/links/molecular_profiles/1308	FALSE	FGFR3	2261	K650E		chr4	1806162	1806162	A	G	ENST00000340107.4	75		missense_variant	"NC_000004.11:g.1807889A>G,NC_000004.12:g.1806162A>G,NM_000142.5:c.1948A>G,NP_000133.1:p.Lys650Glu"	2023-01-27 17:09:30 UTC	CA126376	16331	"RS78311289,LYS650GLU,K652E,LYS652GLU,TDII"	FALSE
FGFR3 A391E	3891						Functional	Supports	D	Gain of Function	"FRET was used to compare the structural changes in FGFR dimers when FGF1 and FGF2 bind, and found that FGF2 bound dimers were much closer to each other than FGF1. The authors also looked at FGFR3 phosphorylation using western blot analysis and found that FGF2-bound dimers had increased FGFR3 phosphorylation. Therefore it was concluded that the FGF1 bound dimer is the inactive state, while the FGF2 bound dimer is the active state. Common bladder cancer and Crouzon syndrome with acanthosis nigricans variant FGFR3 A391E dimerization and phosphorylation were measured via FRET and western blot assays respectively. The A391E substitution was shown to activate FGFR3 through ligand-independent dimerization similar to the FGF2 bound state. Thus the authors concluded that the A391E mutation traps FGF3R in its most active state."	26725515	PubMed		"Sarabipour et al., 2016, Nat Commun"		4	accepted	10513	Somatic	2023-01-09 21:47:13 UTC	https://civicdb.org/links/evidence_items/10513	https://civicdb.org/links/molecular_profiles/3891	FALSE	FGFR3	2261	A391E		chr4	1804426	1804426	C	A	ENST00000440486.8			missense_variant	"NC_000004.11:g.1806153C>A,NC_000004.12:g.1804426C>A,NM_000142.5:c.1172C>A,ENST00000440486.8:c.1172C>A,ENSP00000414914.2:p.Ala391Glu,NP_000133.1:p.Ala391Glu "	2023-01-27 17:19:01 UTC	CA249860	16329	"ALA391GLU,ALA393GLU,A393E"	FALSE
TP53 R175H	116						Functional	Supports	D	Dominant Negative	"Yeast strain yIG397 was cultured to express both wild-type (WT) and mutant R175H originally identified in anaplastic astrocytoma. Should the mutant be dominant-negative (DN), TP53 will not bind and transactivate the ADE2 protein, resulting in red/pink colonies. If the mutant is recessive, then WT function is not blocked and ADE2 protein is expressed through TP53 transactivation, resulting in white colonies. Western blot analysis showed that yeast lysates showed expression of both WT and mutant alleles. Yeast expressing p53 variant and WT p53 produced red/pink colonies, demonstrating that R175H displays transdominance. Authors reported that all of the DN mutants affected the amino acids essential to the upkeep of DNA binding surfaces according to crystallographic structure."	10519380	PubMed		"Marutani et al., 1999, Cancer Res"		3	accepted	10527	Somatic	2023-01-09 21:46:28 UTC	https://civicdb.org/links/evidence_items/10527	https://civicdb.org/links/molecular_profiles/116	FALSE	TP53	7157	R175H		chr17	7675088	7675088	C	T	ENST00000269305.4	75		missense_variant	"NM_000546.5:c.524G>A,NP_000537.3:p.Arg175His,NC_000017.10:g.7578406C>T,ENST00000269305.4:c.524G>A"	2023-01-27 17:02:43 UTC	CA000251	12374	"ARG175HIS,RS28934578,R43H,R136H"	FALSE
TP53 G245S	853						Functional	Supports	D	Dominant Negative	"Yeast strain yIG397 was cultured to express both wild-type (WT) and mutant G245S originally identified in an oral lesion. Should the mutant be dominant-negative (DN), TP53 will not bind and transactivate the ADE2 protein, resulting in red/pink colonies. If the mutant is recessive, then WT function is not blocked and ADE2 protein is expressed through TP53 transactivation, resulting in white colonies. Western blot analysis showed that yeast lysates showed expression of both WT and mutant alleles. Yeast expressing p53 variant and WT p53 produced red/pink colonies, demonstrating that G245S displays transdominance. Authors reported that all of the DN mutants affected the amino acids essential to the upkeep of DNA binding surfaces according to crystallographic structure."	10519380	PubMed		"Marutani et al., 1999, Cancer Res"		3	accepted	10532	Somatic	2023-01-09 21:46:39 UTC	https://civicdb.org/links/evidence_items/10532	https://civicdb.org/links/molecular_profiles/853	FALSE	TP53	7157	G245S		chr17	7674230	7674230	C	T	ENST00000269305.4	75		missense_variant	"NC_000017.10:g.7577548C>T,NM_000546.5:c.733G>A,NP_000537.3:p.Gly245Ser,ENST00000269305.4:c.733G>A"	2023-01-27 17:06:17 UTC	CA000367	12365	RS28934575	FALSE
TP53 C135W	898						Functional	Does Not Support	D	Dominant Negative	"Yeast strain yIG397 was cultured to express both wild-type (WT) and mutant C135W originally identified in glioblastoma. Should the mutant be dominant-negative (DN), TP53 will not bind and transactivate the ADE2 protein, resulting in red/pink colonies. If the mutant is recessive, then WT function is not blocked and ADE2 protein is expressed through TP53 transactivation, resulting in white colonies. Western blot analysis showed that yeast lysates showed expression of both WT and mutant alleles. Yeast expressing C135W and WT p53 produced white colonies, indicating that C135W is not DN."	10519380	PubMed		"Marutani et al., 1999, Cancer Res"		3	accepted	10557	Somatic	2023-01-09 21:46:40 UTC	https://civicdb.org/links/evidence_items/10557	https://civicdb.org/links/molecular_profiles/898	FALSE	TP53	7157	C135W		chr17	7675207	7675207	G	C	ENST00000269305.4	75		missense_variant	"NM_000546.5:c.405C>G,NP_000537.3:p.Cys135Trp,NC_000017.10:g.7578525G>C,ENST00000269305.4:c.405C>G"	2023-01-27 17:06:41 UTC	CA16602987	376561	"CYS135TRP,C3W,C96W"	FALSE
TP53 R158H	1603						Functional	Does Not Support	D	Dominant Negative	"Yeast strain yIG397 was cultured to express both wild-type (WT) and mutant R158H originally identified in glioblastoma. Should the mutant be dominant-negative (DN), TP53 will not bind and transactivate the ADE2 protein, resulting in red/pink colonies. If the mutant is recessive, then WT function is not blocked and ADE2 protein is expressed through TP53 transactivation, resulting in white colonies. Western blot analysis showed that yeast lysates showed expression of both WT and mutant alleles. Yeast expressing R158H and WT p53 produced white colonies, indicating that R158H is not DN."	10519380	PubMed		"Marutani et al., 1999, Cancer Res"		3	accepted	10561	Somatic	2023-01-09 21:46:47 UTC	https://civicdb.org/links/evidence_items/10561	https://civicdb.org/links/molecular_profiles/1603	FALSE	TP53	7157	R158H		chr17	7675139	7675139	C	T	ENST00000269305.4	75		missense_variant	ENST00000269305.4:c.473G>A	2023-01-27 17:11:23 UTC	CA000227	141963	ARG158HIS	FALSE
NTRK3 ETV6::NTRK3	779	Congenital Mesoblastic Nephroma					Diagnostic	Supports	B	Positive	"A frequent genetic alteration is the translocation t(12;15) resulting in a fusion of the ETV6 gene on 12p13 and the NTRK3 gene on 15p15 that occurs almost exclusively in cellular MN.  In a group of 111 mesoblastic nephroma (MN) samples, 79 were were evaluable by FISH, which consisted of 38 classical MN, 29 cellular MN, and 12 mixed MN samples. 16 of 29 cellular type MN had ETV6::NTRK3 via break apart FISH, while 0/38 classical and 0/12 mixed types were positive."	29286563	PubMed		"Vokuhl et al., 2018, Pediatr Blood Cancer"		3	accepted	10841	Somatic	2023-05-09 02:32:11 UTC	https://civicdb.org/links/evidence_items/10841	https://civicdb.org/links/molecular_profiles/779	TRUE	NTRK3	4916	ETV6::NTRK3		chr12	11649854	11869969			ENST00000396373.4	75	ENST00000394480.2	transcript_fusion		2023-01-09 21:52:09 UTC		N/A	ETV6-NTRK3	FALSE
IDH1 R132	58	Cholangiocarcinoma	4947		Ivosidenib		Predictive	Supports	A	Sensitivity/Response	"The multicenter randomized double-blind phase 3 study included patients with IDH1-mutant cholangiocarcinoma who had progressed on previous therapy. Patients were randomly assigned to Ivosidenib or placebo. Placebo to Ivosidenib crossover was permitted on radiological progression. The primary endpoint was progression-free survival by independent central review. Progression-free survival was significantly improved with Ivosidenib compared with the placebo (median 2.7, vs 1.4 months; hazard ratio 0.37; 95% CI 0.25-0.54; one-side p<0.0001). Median overall survival was 10.8 months for the Ivosidenib group versus 9.7 months for the placebo group (HR 0.69 [95% CI 0.44-1.10]; p=0.060) in which 35 patients were crossover from the placebo group. In a prespecified exploratory analysis, the rank-preserving structural failure time (RPSFT) method was used to reconstruct the survival curve for patients receiving a placebo as if crossover had never occurred. RPSFT assumes that the treatment effect is the same for all patients, regardless of when the treatment is given. The RPSFT-adjusted median overall survival was 6.0 months for the placebo group (HR 0.46 [95% CI 0.28-0.75]; p=0.0008)."	32416072	PubMed		"Abou-Alfa et al., 2020, Lancet Oncol."	NCT02989857	5	accepted	10886	Somatic	2023-01-09 21:46:26 UTC	https://civicdb.org/links/evidence_items/10886	https://civicdb.org/links/molecular_profiles/58	FALSE	IDH1	3417	R132		chr2	208248387	208248389			ENST00000415913.1	75		protein_altering_variant	"NC_000002.11:g.209113113G>A,NC_000002.11:g.209113112C>T,NC_000002.11:g.209113113G>C,NC_000002.11:g.209113112C>A,NC_000002.11:g.209113113G>T,NC_000002.11:g.209113112C>G"	2023-01-09 21:52:04 UTC		"156,444,375,891,375,000,000,000,000,000,000,000"	ARG132	FALSE
SRSF2 P95L	4179	Myeloid Neoplasm	70004		CTX-712		Predictive	Supports	D	Sensitivity/Response	"Several splicing factors known to drive myeloid neoplasms (including SRSF2) require phosphorylation by CLK family kinases for nuclear translocation.  The authors describe development of an inhibiter of a CLK family kinase called CTX-712 and evaluate its efficacy in cell line and murine models. CTX-712 efficacy was confirmed in MDS/AML-derived xenografts (PDX).  One PDX model with an SRSF2 P95L variant exhibited significant reduction in tumor volume 2 weeks after CTX-712 high dose treatment compared to vehicle (P=0.0162, N=6). CTX-712 treatment also improved survival in the SRSF2 P95L-mutated model (P=0.0030, N=6 mice)."	10.1182/blood-2021-148205	ASH		"Yoda et al., 2021, Blood"		3	accepted	11027	Somatic	2023-01-12 23:23:48 UTC	https://civicdb.org/links/evidence_items/11027	https://civicdb.org/links/molecular_profiles/4179	FALSE	SRSF2	6427	P95L		chr17	76736877	76736877	G	A	ENST00000359995.10:c.284C>T			missense_variant	"NC_000017.11:g.76736877G>A,NC_000017.10:g.74732959G>A,ENST00000359995.10:c.284C>T,ENSP00000353089.5:p.Pro95Leu,NM_001195427.2:c.284C>T,NP_001182356.1:p.Pro95Leu"	2023-01-27 17:19:39 UTC	CA8790423	NONE FOUND	PRO95LEU	FALSE
SRSF2 P95H	4180	Myeloid Neoplasm	70004		CTX-712		Predictive	Supports	D	Sensitivity/Response	Several splicing factors known to drive myeloid neoplasms (including SRSF2) require phosphorylation by CLK family kinases for nuclear translocation. The authors describe development of an inhibiter of a CLK family kinase called CTX-712 and evaluate its efficacy in cell line and murine models. CTX-712 efficacy was confirmed in MDS/AML-derived xenografts (PDX). One PDX model with an SRSF2 P95H variant showed a significant response to CTX-712 in a dose-dependent manner. 4 out of 5 mice receiving a high dose protocol achieved complete remission. CLK inhibition also induced aberrant splicing events including skipped exons and this effect was more prevalent in the SRSF2-mutated model.	10.1182/blood-2021-148205	ASH		"Yoda et al., 2021, Blood"		3	accepted	11028	Somatic	2023-01-12 23:25:09 UTC	https://civicdb.org/links/evidence_items/11028	https://civicdb.org/links/molecular_profiles/4180	FALSE	SRSF2	6427	P95H		chr17	76736877	76736877	G	T	ENST00000359995.10			missense_variant	"NC_000017.11:g.76736877G>T,NC_000017.10:g.74732959G>T,ENST00000359995.10:c.284C>A,ENSP00000353089.5:p.Pro95His,NM_001195427.2:c.284C>A,NP_001182356.1:p.Pro95His"	2023-01-27 17:19:40 UTC	CA8790422	NONE FOUND	PRO95HIS	FALSE
RAF1 R391W	1588						Functional	Supports	D	Gain of Function	"RAF1 (CRAF) R391W was observed in a melanoma patient from which cell line M375 was derived (wild-type for BRAF and NRAS). RAF1 R391W expressed in 293T cells showed increased phosphorylation of MEK and ERK compared to wild-type, including when treated with vemurafenib. Measuring cleaved PARP also indicated that exogenous expression of CRAF R391W prevented induction of apoptosis by vemurafenib in M238 cells. A soft-agar transformation assay showed an increase in colonies in R391W compared to wild-type indicating increased anchorage-independent growth."	27273450	PubMed		"Atefi et al., 2016, Sci Rep"		3	accepted	11044	Somatic	2023-02-01 18:38:15 UTC	https://civicdb.org/links/evidence_items/11044	https://civicdb.org/links/molecular_profiles/1588	FALSE	RAF1	5894	R391W		chr3	12591730	12591730	T	A	ENST00000251849.4	75		missense_variant	ENST00000251849.4:c.1171A>T	2023-02-28 22:34:08 UTC	CA2259575	NONE FOUND	"R176W,R270W,R310W,R411W"	FALSE
ALK Fusion	495	Lung Non-small Cell Carcinoma	3908		Brigatinib		Predictive	Supports	A	Sensitivity/Response	"The phase III ALTA-1L open-label randomized trial examined 275 NSCLC patients given brigatinib (137 patients) vs crizotinib (138 patients).  Patients were ALK fusion positive by an FDA-approved diagnostic test and had not previously received ALK inhibitors. Brigatinib showed superior PFS compared to crizotinib (HR 0.49 [95% CI, 0.35 to 0.68]; log-rank P < .0001; median, 24.0 v 11.0 months). Initial results from this trial were previously reported in 2018 (PMID: 30280657)."	32780660	PubMed		"Camidge et al., 2020, J. Clin. Oncol."	NCT02737501	5	accepted	11121	Somatic	2023-03-03 20:20:57 UTC	https://civicdb.org/links/evidence_items/11121	https://civicdb.org/links/molecular_profiles/495	FALSE	ALK	238	Fusion	ALK Fusion	chr2	29192774	29223528			ENST00000389048.3	75		transcript_fusion		2023-01-09 21:52:07 UTC		N/A	REARRANGEMENT	FALSE
NTRK1 Fusion	415	Solid Tumor			Entrectinib		Predictive	Supports	A	Sensitivity/Response	"Describes a meta-analysis of three separate phase I or II trials: ALKA-372-001, STARTRK-1, and STARTRK-2. All of these evaluate entrectinib in NTRK fusion-positive solid tumours. 31/54 had objective response (57%; 95% CI 432?08), including 4 CR and 27 PR. 9 had SD. Response by NTRK gene type: 13/22 NTRK1 fusions [59%; 95% CI 364?93], 18/31 NTRK3 fusions [58%; 391?55], and 0/1 NTRK2 fusion. Most frequent tumour types were sarcoma, NSCLC, salivary, breast, thyroid, colorectal. Most common fusions were ETV6-NTRK3 (25), TPM3-NTRK1 (4) and TPR-NTRK1 (4)."	31838007	PubMed		"Doebele et al., 2020, Lancet Oncol"	"NCT02568267,NCT02097810,NCT02650401"	5	accepted	11124	Somatic	2023-05-09 21:03:43 UTC	https://civicdb.org/links/evidence_items/11124	https://civicdb.org/links/molecular_profiles/415	FALSE	NTRK1	4914	Fusion	NTRK1 Fusions	chr1	156874383	156881642			ENST00000524377.1	75		transcript_fusion		2023-01-09 21:52:06 UTC		N/A		FALSE
ARAF S214C	10	Lung Cancer	1324				Oncogenic	Supports	D	Oncogenicity	"194 somatic mutations seen in primary lung cancers were functionally evaluated using three approaches: (1) differences in pattern or extent of changes in gene expression in A549 cells induced by transduction of lentiviral vectors containing mutant vs. wild-type genes; (2) xenograft assay based on human lung epithelial cells harbouring the variant introduced in mice and subsequent measurement of tumour size; (3) evaluation of resistance to erlotinib, afatinib, lapatinib, sofarenib and trametinib in PC9 isogenic lines expressing mutant alleles. ARAF S214C mutations showed differences in gene expression from wild-type, induced tumour formation, and in the presence of erlotinib rescued cell viability."	27478040	PubMed		"Berger et al., 2016, Cancer Cell"		3	accepted	11147	Somatic	2023-03-09 18:08:12 UTC	https://civicdb.org/links/evidence_items/11147	https://civicdb.org/links/molecular_profiles/10	FALSE	ARAF	369	S214C		chrX	47566722	47566722	C	G	ENST00000377045.4	75		missense_variant	"NC_000023.10:g.47426121C>G,NM_001654.4:c.641C>G,NP_001645.1:p.Ser214Cys,ENST00000377045.4:c.641C>G"	2023-01-27 17:02:00 UTC	CA16602595	376137	"SER214CYS,RS1057519786"	FALSE
BRCA1 Loss-of-function	131	Her2-receptor Negative Breast Cancer	60080		Olaparib		Predictive	Supports	A	Sensitivity/Response	"Report of OlympiA (NCT02032823), a randomized, double-blind, placebo-controlled study of 1836 patients with HER2-negative breast cancer with germline pathogenic or likely pathogenic mutations in BRCA1 or BRCA2. Patients were early stage but had completed chemotherapy; ER/PR+ patients could also have concurrent hormone therapy. 82% of patients were triple negative. 72% of patients had BRCA1 germline mutations, 27% had BRCA2, and 0.4% both. 921 patients received olaparib and 915 placebo.  Invasive disease-free survival (IDFS) showed improvement with olaparib treatment (86% vs 77%, HR 0.58 [0.41 to 0.82], P<0.001). For overall survival, deaths in the olaparib arm were lower (59 vs 86, HR 0.68 [0.44 to 1.05], P=0.02). The IDFS benefit was independent of whether mutation was in BRCA1 (HR=0.52, 0.39-0.70) or BRCA2 (HR 0.52, 0.30-0.86)."	34081848	PubMed		"Tutt et al., 2021, N Engl J Med"	NCT02032823	5	accepted	11201	Rare Germline	2023-04-18 23:03:56 UTC	https://civicdb.org/links/evidence_items/11201	https://civicdb.org/links/molecular_profiles/131	FALSE	BRCA1	672	Loss-of-function	BRCA Germline Variants	chr17	43045629	43125483			ENST00000471181.2	75		"loss_of_heterozygosity,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
BRCA2 Loss-of-function	132	Her2-receptor Negative Breast Cancer	60080		Olaparib		Predictive	Supports	A	Sensitivity/Response	"Report of OlympiA (NCT02032823), a randomized, double-blind, placebo-controlled study of 1836 patients with HER2-negative breast cancer with germline pathogenic or likely pathogenic mutations in BRCA1 or BRCA2. Patients were early stage but had completed chemotherapy; ER/PR+ patients could also have concurrent hormone therapy. 82% of patients were triple negative. 72% of patients had BRCA1 germline mutations, 27% had BRCA2, and 0.4% both. 921 patients received olaparib and 915 placebo.  Invasive disease-free survival (IDFS) showed improvement with olaparib treatment (86% vs 77%, HR 0.58 [0.41 to 0.82], P<0.001). For overall survival, deaths in the olaparib arm were lower (59 vs 86, HR 0.68 [0.44 to 1.05], P=0.02). The IDFS benefit was independent of whether mutation was in BRCA1 (HR=0.52, 0.39-0.70) or BRCA2 (HR 0.52, 0.30-0.86)."	34081848	PubMed		"Tutt et al., 2021, N Engl J Med"	NCT02032823	5	accepted	11202	Rare Germline	2023-04-18 22:39:26 UTC	https://civicdb.org/links/evidence_items/11202	https://civicdb.org/links/molecular_profiles/132	FALSE	BRCA2	675	Loss-of-function	BRCA Germline Variants	chr13	32315474	32399210			ENST00000380152.3	75		loss_of_function_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
BRCA1 Mutation	185	Prostate Carcinoma	10286		Olaparib		Predictive	Supports	A	Sensitivity/Response	"This randomized, open-label, phase 3 trial evaluated the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving a new hormonal agent (e.g., enzalutamide or abiraterone). The study found that in men with mCRPC who had somatic or germline deleterious alterations (irrespective of zygosity) in any of the following HRR genes (BRCA1, BRCA2, ATM, BRIP1, BARD1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, and RAD54L), olaparib was associated with longer progression-free survival and better measures of response and patient-reported end points than either enzalutamide or abiraterone (PFS HR 0.49 [0.38, 0.63]). For 15 patients with BRCA1 mutations specifically, PFS HR 0.41 [0.13-1.39]. . Based on the results of this study, on May 19, 2020, the Food and Drug Administration approved olaparib (LYNPARZA) for adult patients with deleterious or suspected deleterious germline or somatic HRR gene-mutated mCRPC, who have progressed following prior treatment with enzalutamide or abiraterone."	32343890	PubMed		"de Bono et al., 2020, N. Engl. J. Med."	NCT02987543	4	accepted	11203	Unknown	2023-04-19 19:43:54 UTC	https://civicdb.org/links/evidence_items/11203	https://civicdb.org/links/molecular_profiles/185	FALSE	BRCA1	672	Mutation		chr17	43045629	43125483			ENST00000471181.2	75		"gene_variant,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
BRCA1 Loss-of-function	131	Triple-receptor Negative Breast Cancer	60081		Olaparib		Predictive	Supports	A	Sensitivity/Response	"Report of OlympiA (NCT02032823), a randomized, double-blind, placebo-controlled study of 1836 patients with HER2-negative breast cancer with germline pathogenic or likely pathogenic mutations in BRCA1 or BRCA2. Patients were early stage but had completed chemotherapy; ER/PR+ patients could also have concurrent hormone therapy. 82% of patients were triple negative. 72% of patients had BRCA1 germline mutations, 27% had BRCA2, and 0.4% both. 921 patients received olaparib and 915 placebo. Invasive disease-free survival (IDFS) showed improvement with olaparib treatment (86% vs 77%, HR 0.58 [0.41 to 0.82], P<0.001). For overall survival, deaths in the olaparib arm were lower (59 vs 86, HR 0.68 [0.44 to 1.05], P=0.02). The IDFS benefit was independent of whether mutation was in BRCA1 (HR=0.52, 0.39-0.70) or BRCA2 (HR 0.52, 0.30-0.86)."	34081848	PubMed		"Tutt et al., 2021, N Engl J Med"	NCT02032823	5	accepted	11216	Rare Germline	2023-04-22 00:54:56 UTC	https://civicdb.org/links/evidence_items/11216	https://civicdb.org/links/molecular_profiles/131	FALSE	BRCA1	672	Loss-of-function	BRCA Germline Variants	chr17	43045629	43125483			ENST00000471181.2	75		"loss_of_heterozygosity,loss_of_function_variant"		2023-01-09 21:52:05 UTC		N/A		FALSE
BRCA2 Loss-of-function	132	Triple-receptor Negative Breast Cancer	60081		Olaparib		Predictive	Supports	A	Sensitivity/Response	"Report of OlympiA (NCT02032823), a randomized, double-blind, placebo-controlled study of 1836 patients with HER2-negative breast cancer with germline pathogenic or likely pathogenic mutations in BRCA1 or BRCA2. Patients were early stage but had completed chemotherapy; ER/PR+ patients could also have concurrent hormone therapy. 82% of patients were triple negative. 72% of patients had BRCA1 germline mutations, 27% had BRCA2, and 0.4% both. 921 patients received olaparib and 915 placebo. Invasive disease-free survival (IDFS) showed improvement with olaparib treatment (86% vs 77%, HR 0.58 [0.41 to 0.82], P<0.001). For overall survival, deaths in the olaparib arm were lower (59 vs 86, HR 0.68 [0.44 to 1.05], P=0.02). The IDFS benefit was independent of whether mutation was in BRCA1 (HR=0.52, 0.39-0.70) or BRCA2 (HR 0.52, 0.30-0.86)."	34081848	PubMed		"Tutt et al., 2021, N Engl J Med"	NCT02032823	5	accepted	11217	Rare Germline	2023-04-22 00:55:28 UTC	https://civicdb.org/links/evidence_items/11217	https://civicdb.org/links/molecular_profiles/132	FALSE	BRCA2	675	Loss-of-function	BRCA Germline Variants	chr13	32315474	32399210			ENST00000380152.3	75		loss_of_function_variant		2023-01-09 21:52:05 UTC		N/A		FALSE
NTRK3 ETV6::NTRK3	779	Congenital Fibrosarcoma	8418	Infantile onset			Diagnostic	Supports	B	Positive	"In this study, a collection of pediatric spindle cell tumors were screened for the ETV6::NTRK3 fusion by RT-PCR.  10 of 11 (91%) cases diagnosed as congenital fibrosarcoma were found to harbor the ETV6::NTRK3 fusion while none of the 51 other malignant or benign spindle cell tumors (including adult-type fibrosarcoma, infantile fibromatosis, myofibromatosis, and more aggressive malignant spindle cell tumors) were positive for this fusion.  The authors conclude ETV6::NTRK3 RT-PCR analysis is a reliable and specific modality to aid in the diagnosis of this disease."	10895816	PubMed		"Bourgeois et al., 2000, Am J Surg Pathol"		3	accepted	11276	Somatic	2023-05-08 15:14:31 UTC	https://civicdb.org/links/evidence_items/11276	https://civicdb.org/links/molecular_profiles/779	FALSE	NTRK3	4916	ETV6::NTRK3		chr12	11649854	11869969			ENST00000396373.4	75	ENST00000394480.2	transcript_fusion		2023-01-09 21:52:09 UTC		N/A	ETV6-NTRK3	FALSE
NTRK3 ETV6::NTRK3	779	Congenital Fibrosarcoma	8418				Diagnostic	Supports	B	Positive	"In this study, the ETV6::NTRK3fusion was detected in 7 of 10 (70%) of congenital fibrosarcomas by RT-PCR but absent in 38 other control spindle cell tumors,  including adult-type fibrosarcomas, leiomyosarcomas, malignant fibrous histiocytomas,  synovial sarcomas, MPNST, dermatofibrosarcoma protuberans,  schwannomas, fibromatosis cases, and nodular fasciitis cases.  This demonstrates utility of ETV6::NTRK3 fusion  detection in diagnosis of this disease."	11242790	PubMed		"Sheng et al., 2001, Am J Clin Pathol"		3	accepted	11277	Somatic	2023-05-08 15:29:50 UTC	https://civicdb.org/links/evidence_items/11277	https://civicdb.org/links/molecular_profiles/779	FALSE	NTRK3	4916	ETV6::NTRK3		chr12	11649854	11869969			ENST00000396373.4	75	ENST00000394480.2	transcript_fusion		2023-01-09 21:52:09 UTC		N/A	ETV6-NTRK3	FALSE
NTRK3 ETV6::NTRK3	779	Congenital Mesoblastic Nephroma					Diagnostic	Supports	B	Positive	"In an analysis of 19 cases of mesoblastic nephroma, the ETV6::NTRK3 fusion was detected in 0 of 5 of the classic mesoblastic nephroma, 8 of 8 (100%) of the cellular mesoblastic nephroma and 5 of 6 (83%) of the mixed mesoblastic nephroma cohorts."	27020209	PubMed		"El Demellawy et al., 2016, Pathology"		3	accepted	11279	Somatic	2023-05-09 02:36:08 UTC	https://civicdb.org/links/evidence_items/11279	https://civicdb.org/links/molecular_profiles/779	FALSE	NTRK3	4916	ETV6::NTRK3		chr12	11649854	11869969			ENST00000396373.4	75	ENST00000394480.2	transcript_fusion		2023-01-09 21:52:09 UTC		N/A	ETV6-NTRK3	FALSE
NTRK3 ETV6::NTRK3	779	Congenital Mesoblastic Nephroma					Diagnostic	Supports	B	Positive	"In an analysis of 22 cases of mesoblastic nephroma, 4 of 5 (80%) cellular mesoblastic nephromas harbored ETV6::NTRK3, 1 of 5 cellular mesoblastic nephromas harbored a KLHL7::BRAF fusion, 12 of 12 (100%) classic mesoblastic nephromas harbored EGFR ITD, 4 of 5 of mixed histology had EGFR ITD, and 1 of 5 of mixed histology had the  ETV6::NTRK3 fusion."	32590884	PubMed		"Zhao et al., 2020, Histopathology"		2	accepted	11280	Somatic	2023-05-09 02:40:15 UTC	https://civicdb.org/links/evidence_items/11280	https://civicdb.org/links/molecular_profiles/779	FALSE	NTRK3	4916	ETV6::NTRK3		chr12	11649854	11869969			ENST00000396373.4	75	ENST00000394480.2	transcript_fusion		2023-01-09 21:52:09 UTC		N/A	ETV6-NTRK3	FALSE
